https://www.medthority.com/news/2025/10/optitrop-lung04-improves-egfrm-nsclc-outcomes/transcript-the-optitrop-lung04-trial/2025-11-10T10:56:06+00:00weekly0.5https://www.medthority.com/news/2025/10/optitrop-lung04-improves-egfrm-nsclc-outcomes/transcript-esmo-congress-2025-key-takeaways/2025-11-10T11:01:48+00:00weekly0.5https://www.medthority.com/news/2021/11/livtencity-is-approved-by-the--fda-as-the-first-and-only-treatment-for-people-ages-12-and-older-with-post-transplant-cytomegalovirus--refractory-with-or-without-genotypic-resistance-to-conventional-antiviral-therapies.-takeda2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/johnson--johnson-covid-19-vaccine-fully-approved-by-health-canada-to-prevent-covid-19-in-individuals-18-years-and-older.-2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/aadi-bioscience-announces-fda-approval-of-its-first-product-fyarro-for-patients-with-locally-advanced-unresectable-or-metastatic-malignant-perivascular-epithelioid-cell-tumor-pecoma/2024-11-14T14:10:21+00:00weekly0.6https://www.medthority.com/news/2021/11/amryt-provides-an-update-on-fda-review-process-for-oleogel-s10-a-treatment-for-epidermolysis-bullosa/2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/chmp-recommends-approval-of-comirnaty-for-children-5-to-under-12-years--with-covid-19.--pfizer--biontech-se2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/eu-approves-trodelvy-for-metastatic-triple-negative-breast-cancer.--gilead-sciences2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/merck-inc.-and-ridgeback-biotherapeutics-provide-update-on-results-from-the-move-out-study-of-molnupiravir-an-oral-antiviral-in-at-risk-adults-with-mild-to-moderate-covid-192022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/moderna-announces-strategy-to-address-omicron-b.1.1.529-sars-cov-2-variant.-2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-approves-lenvima--keytruda-to-treat-endometrial-carcinoma.--eisai--merck-inc2024-11-14T14:10:33+00:00weekly0.6https://www.medthority.com/news/2021/11/fennec-pharma-expects-a-complete-response-letter-from-the-fda--for-pedmark-which-is-intended-to-prevent-ototoxicity-associated-with-cisplatin-chemotherapy/2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-accepts-nda-for-bms-986165-and-ema-validates-maa-for-moderate-to-severe-plaque-psoriasis.--bms2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/11/the-phase-iii-gem-3-trial-of-vyjuvek-meets-primary-endpoint-in-dystrophic-epidermolysis-bullosa.--krystal-biotech-2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/11/uk-medical-device-company-acurable-receives-fda--510k-clearance-for-its-home-sleep-apnoea-testing-device-acupebble-sa100/2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/12/lynparza-granted-priority-review-in-the-us-for-brca-mutated-her2-negative-high-risk-early-breast-cancer-.-astrazeneca--merck-inc2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/12/artesunate-amivas-granted-eu-approval--for-treatment-of-severe-malaria.-amivas2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/12/pivotal-soraya-trial-of-imgn-853-shows-efficacy-in-ovarian-cancer.--immunogen2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/12/ema-validates-filing-of-tab-cel-for-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease.--atara-biotherapeutics2024-11-14T14:10:49+00:00weekly0.6https://www.medthority.com/news/2021/12/cti-biopharma-announces-extension-of-fda-review-period-for-pacritinib-in-myelofibrosis-with-severe-thrombocytopenia/2024-11-14T14:11:00+00:00weekly0.6https://www.medthority.com/news/2021/12/merck-inc.and-ridgeback-statement-on-positive-fda-advisory-committee-vote-for-investigational-oral-antiviral-molnupiravir-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/completion-of-enrolment-in-dissolve-phase-iii-study-evaluating-sel-212-for-chronic-refractory-gout.--sobi--selecta-biosciences-inc2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/deciphera-pharmaceuticals-announces-restructuring-to-prioritize-clinical-development-programs-and-streamline-commercial-operations/2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/adamis-pharmaceuticals-updates-comparative-pharmacology-model-data-supporting-the-higher-5-mg-intramuscular-dose-of-naloxone-in-zimhi/2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/the-phase-iii-discreet-trial-of-otezla-achieves-meaningful-improvements-in-moderate-to-severe-genital-psoriasis-and-moderate-to-severe-plaque-psoriasis.--amgen2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/publication-of-results-from-pivotal-phase-iii-study-protect-of-vbis-prophylactic-3-antigen-hepatitis-b-vaccine-candidate-in-the-lancet-infectious-diseases.--vbi-vaccines-inc2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-expands-approval-of-kyprolis--to-include-combination-with-darzalex-faspro-and-dexamethasone-for--relapsed-or-refractory-multiple-myeloma.--amgen2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/omeros-sells-omidria-ophthalmic-franchise-to-rayner-surgical/2024-11-14T14:11:12+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-open-label-shoreline-study-of-sage-217-shows-no-new-findings-in-major-depressive-disorder.--sage-therapeutics2024-11-14T14:11:21+00:00weekly0.6https://www.medthority.com/news/2021/12/mhra-uk-grants-conditional-marketing-authorisation-for-covid-19-treatment-xevudy.-glaxosmithkine2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/sanofi-to-acquire-origimm-biotechnology-and-with-it-novel-therapeutic-vaccine-ori-001-for-acne-vulgaris.-2022-02-08T07:46:23+00:00weekly0.6https://www.medthority.com/news/2021/12/preclinical-data-demonstrate-xevudy-sotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant.-glaxosmithkline2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/fda--issues-a-complete-response-letter-for-plinabulin-for-prevention-of-chemotherapy-induced-neutropenia.-beyondspring2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-ii-attract-22-study-shows-benefits-for-lung-injury-with-c-21-in-covid-19.--vicore-pharma2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-cytalux-for-patients-with-ovarian-cancer-to-identify-malignant-lesions-.--on-target-laboratories-inc2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/bamlanivimab-with-etesevimab--is-fda-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12.--eli-lilly2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-use-in-infants-and-children.--merck-inc2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/-fda-approves-keytruda-as-adjuvant-treatment-for-adult-and-pediatric-12-years-and-older-patients-with-stage-iib-or-iic-melanoma-following-complete-resection.--merck-inc2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-accepts-for-priority-review-sbla--for-reblozyl-in-adults-with-non-transfusion-dependent-ntd-beta-thalassemia.-bms--merck-inc2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/mpa-approval-in-china-of-sylvant-for-idiopathic-multicentric-castleman-disease.-beigene--eusa-pharma2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/advent-bid-to-acquire-sobi-fails/2025-10-16T11:36:14+00:00weekly0.6https://www.medthority.com/news/2021/11/completion-of-clinical-trials-for-sb-12-a--eculizumab-biosimilar.--samsung-bioepis2022-02-08T07:46:22+00:00weekly0.6https://www.medthority.com/news/2021/12/ema-validate-filing-of-at-gaa-for-pompe-disease.--amicus-therapeutics2022-02-08T07:46:24+00:00weekly0.6https://www.medthority.com/news/2021/12/recordati-acquires-eusa-pharma-uk-ltd/2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/abbvie-provides-update-on-rinvoq--for-the-treatment-of-rheumatoid-arthritis-in-the-u.s2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/spectrum-pharmaceuticals-submits-nda-for-poziotinib-to-treat-advanced-or-metastatic-nsclc-with-her2-exon-20-insertion-mutations/2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/merck-inc.-announces-pause-in-enrollment-for-two-phase-iii-clinical-trials-of-once-monthly-oral-islatravir-for-pre-exposure-prophylaxis-of-hiv-1-infection2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/nature-medicine-publishes-results-from-two-registration-studies-of-ayvakit-showing-sustained-benefits-in-patients-with-advanced-systemic-mastocytosis.--blueprint-medicine-corporation2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/astrazeneca-and-ionis-sign-deal-to-develop-and-commercialise-eplontersen-formerly-known-as-ionis-ttr-lrx/2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/medicago-and-gsk-announce-positive-phase-iii-efficacy-and-safety-results-for-adjuvanted-plant-based-covid-19-vaccine-candidate/2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/booster-of-covid-19-vaccine-ad26.cov2.s-administered-six-months-after-two-dose-regimen-of-bnt162b2-shows-substantial-increase-in-antibody-and-t-cell-responses.--johnson--johnson2022-02-08T07:46:25+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-phase-iii-data-for-kinect-hd-study-of-valbenazine-for-chorea-associated-with-huntington-disease.--neurocrine-bioscience2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/mhra-uk-approves-skyrizi-to-treat-psoriatic-arthritis.-abbvie2024-11-14T14:11:36+00:00weekly0.6https://www.medthority.com/news/2021/12/new-kisqali-data-shows-consistent-overall-survival-benefit-across-genomic-and-clinical-subtypes-of-interest-in-hrher2--metastatic-breast-cancer.--novartis2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/study-indicates-bnt-162b2-helps-neutralise-covid-19-omicron-variant.--pfizer-and-biontech2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/evusheld-formerly-azd-7442-long-acting-antibody-combination-fda-authorised-for-emergency-use-for-pre-exposure-prophylaxis-prevention-of-covid-19.--astrazeneca2021-12-20T17:31:24+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-foundationonecdx-as-companion-diagnostic-for-melanoma.--foundation-medicine2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/updated-results-from-pivotal-her2climb-trial-evaluating-tukysa-in-patients-with-her2-positive-breast-cancer-with-brain-metastases.-seagen-inc2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/new-england-journal-of-medicine-publishes-positive-phase-iii-dupixent--results-in-children-with-moderate-to-severe-asthma.--regeneron--sanofi2024-11-14T14:12:07+00:00weekly0.6https://www.medthority.com/news/2021/11/alzheimers-disease-and-p.-gingivalis-infection-in-phase-iiiii-gain-trial-additional-top-line-data-with-atuzaginstat-presented-at-ctad-2021.-cortexyme-inc2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-approves-ronapreve-to-treat-of-non-hospitalized-patients-outpatients-with-confirmed-covid-19-who-do-not-require-oxygen-supplementation/2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/positive-chmp-recommendation-for-use-of-tavneos-in-anca-vasculitis.--chemocentryx-inc2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/new-real-world-data-show-high-rate-of-patient-adherence-to-tepezza--for-thyroid-eye-disease-ted.--horizon-therapeutics-plc2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/lumykras-receives-positive-chmp--opinion-for-treatment-of-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer.-amgen2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/chmp-positive-opinion-for-regdanvimab--as-one-of-the-first-monoclonal-antibodies-recommended-by-the-chmp-as-a-treatment-for-covid-19-.--celltrion2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/horizon-therapeutics-plc-receives-chmp-positive-opinion-for-uplizna-as-a-monotherapy-for-the-treatment-of-adult-patients-with-neuromyelitis-optica-spectrum-disorder/2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/health-canada-approves-nypozi-biosimilar-to-neupogen-to-treat-neutropenia.-tanvex-biopharma-inc2021-11-14T13:35:21+00:00weekly0.6https://www.medthority.com/news/2021/11/norse-two-phase-iii-trial-of-ons-5010-meets-primary-and-secondary-endpoints-in-wet-age-related-macular-degeneration.--outlook-therapeutics2024-11-14T13:21:01+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-approves-besremi-for-polycythemia-vera.--pharmaessentia-corp2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/mallinckrodt-presents-results-from-two-retrospective-studies-on-real-world-characteristics-and-outcomes-of-patients-with-hepatorenal-syndrome-type-1-hrs-1-at-the-liver-meeting-digital-experience/2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/positive-chmp-opinion-for-transcon-hgh-for-patients-with-pediatric-growth-hormone-deficiency.--ascendispharma-as2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/chmp-recommends-voraxaze-to-reduce-toxic-plasma-methotrexate-concentration.--serb-sas2024-11-14T13:21:19+00:00weekly0.6https://www.medthority.com/news/2021/11/comet-tail-phase-iii-trial-of-xevudy--meets-endpoint-in-covid-19.--gsk--vir-biotechnology-2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/chmp-recommends-vyepti-for-the-preventive-treatment-of-migraine.-h.lundbeck-as2022-02-08T07:46:16+00:00weekly0.6https://www.medthority.com/news/2021/11/eton-pharmaceuticals-announces-co-promotion-agreement-with-tolmar-pharmaceuticals-for-alkindi-sprinkle/2024-11-14T14:07:04+00:00weekly0.6https://www.medthority.com/news/2021/11/bms-launches-could-it-be-hcm-campaign-to-increase-awareness-of-hypertrophic-cardiomyopathy/2024-11-14T14:07:13+00:00weekly0.6https://www.medthority.com/news/2021/11/nucala--is-the-first-and-only-anti-il-5-add-on-treatment-approved-in-canada-that-targets-eosinophilic-inflammation-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps.--gsk-2022-02-08T07:46:17+00:00weekly0.6https://www.medthority.com/news/2021/11/new-phase-iii-study-to-investigate-expanded-use-of-vericiguat-in-patients-with-chronic-heart-failure-with-reduced-ejection-fraction.-bayer-healthcare--merck-inc2022-02-08T07:46:17+00:00weekly0.6https://www.medthority.com/news/2021/11/bayer-extends-clinical-development-program-for-finerenone-with-phase-iii-study-in-children-and-adolescents-with-chronic-kidney-disease/2022-02-08T07:46:17+00:00weekly0.6https://www.medthority.com/news/2021/11/sanofi-announces-results-of-chmp-re-examination-of-the-new-active-substance-status-for-avalglucosidase-alfa-a-potential-new-standard-of-care-for-the-treatment-of-pompe-disease/2022-02-08T07:46:17+00:00weekly0.6https://www.medthority.com/news/2021/11/orexo-announces-positive-results-from-pivotal-trial-for-its-leading-pharmaceutical-pipeline-asset-ox-124/2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-grants-marketing-authorization-for-vumerity-as-an-oral-treatment-for-relapsing-remitting-multiple-sclerosis/2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/jyseleca-approved-in-the-european-union-for-the-treatment-of-ulcerative-colitis.--galapagos-nv2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/phase-iii-reverse-it-study-of-pb-2452-meets-primary-endpoint-in-life-threatening-bleeding.--phasebio-pharma2024-11-14T14:07:28+00:00weekly0.6https://www.medthority.com/news/2021/11/eu-approves-regkirona-for-covid-19.--celltrion2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/phase-iii-activ-3-study-of-mp-0420-has-failed-to-meet-endpoint-in-covid-19.--molecular-partners2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/paxlovid-filed-for-eua-with-fda-for-covid-19.--pfizer2022-02-08T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-accepts-supplemental-nda-and-grants-priority-review-for-jardiance-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction.--eli-lilly--boehringer2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/zai-lab-announces-first-patient-dosed-in-greater-china-in-global-registrational-adhere-clinical-trial-of-efgartigimod-in-chronic-inflammatory-demyelinating-polyneuropathy.-zai-lab--argenx2024-11-14T14:09:56+00:00weekly0.6https://www.medthority.com/news/2021/11/eisai-presents-late-breaker-updates-on-lecanemab-data-from-phase-iib-study-core-and-ole-extension-across-five-years-of-clinical-trials-on-alzheimers-disease-ctad-conference.-2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/first-patient-dosed-in-greater-china-in-global-registrational-clinical-trial-of-efgartigimod-in-primary-immune-thrombocytopenia.--zai-lab--argenx2024-11-14T13:20:43+00:00weekly0.6https://www.medthority.com/news/2021/11/chmp-recommends-eu-approval-of-casirivimab-and-imdevimab-antibody-cocktail-to-treat-and-prevent-covid-19-infection.-regeneron-pharma--roche2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/wegovy-recommended-for-approval-for-the-treatment-of-obesity-by-the-chmp.--novo-nordisk2022-02-08T07:46:15+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-approves-skyrizi-to-treat-psoriatic-arthritis.-abbvie2024-11-14T14:10:09+00:00weekly0.6https://www.medthority.com/news/2021/11/novavax-inc.confirms-european-medicines-agency-review-of-covid-19-vaccine-nuvaxovid-filed-for-conditional-marketing-authorization2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/update-on-regulatory-review-of-aducanumab-a-proposed-treatment-for-alzheimers-disease-in-the-european-union/2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/new-analyses-of-two-azd-7442-covid-19-phase-iii-trials-provent-and-tackle-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention-of-covid-19.-astrazeneca2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/emgality-versus-nurtec-odt-head-to-head-migraine-preventive-treatment-study-now-enrolling-patients.--eli-lilly-and-company2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/cassava-sciences-initiates-a-second-phase-iii-study-of-simufilam-for-the-treatment-of-patients-with-alzheimers-disease/2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/expanded-fda-emergency-use-authorization-of-covid-19-vaccine-booster-to-include-individuals-18-and-older.--pfizer--biontech-se2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/moderna-announces-fda-authorization-of-booster-dose-of-covid-19-vaccine-in-the-u.s.-for-adults-18-years-and-older2022-02-08T07:46:19+00:00weekly0.6https://www.medthority.com/news/2021/11/510k-clearance--from-fda-for-pillcam-small-bowel-3-home-endoscopy-procedure.--medtronic2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-approves-gavreto--for-the-treatment-of-adults-with-ret-fusion-positive-advanced-non-small-cell-lung-cancer.---roche2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/phase-iii-cosmic-312-trial-of-cabometyx-and-tecentriq-meets-primary-endpoint-in-hepatocellular-carcinoma.--exelixis2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/gilead-sciences-exercises-options-to-three-arcus-biosciences-clinical-stage-programs-and-adds-research-collaboration/2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/xeljanz-receives-marketing-authorisation-from-the-european-commission-for-the-treatment-of-active-ankylosing-spondylitis.-pfizer2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/eu-approves-qinlock-for-advanced-gastrointestinal-stromal-tumor.--deciphera-pharma2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/new-analysis-published-in-multiple-sclerosis-and-related-disorders-supports-the-efficacy-of-uplizna--in-patients-previously-treated-with-rituximab-for-neuromyelitis-optica-spectrum-disorder.-horizon-therapeutics-2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-priority-review-of-bla-for-beti-cel-gene-therapy-for-patients-with-beta-thalassemia-who-require-regular-red-blood-cell-transfusions.--bluebird-bio2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/santhera-and-reveragen-announce-positive-topline-results-with-vamorolone-after-completion-of-the-vision-dmd-study-for-duchenne-muscular-dystrophy.-2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/health-canada-has-authorized-the-emergency-use-of-leronlimab-for-the-treatment-of-a-patient-with-metastatic-triple-negative-breast-cancer.--cytodyn-inc2022-02-08T07:46:20+00:00weekly0.6https://www.medthority.com/news/2021/11/eu-approves-zeposia-for-ulcerative-colitis.--bms2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/european-commission-approval-of-brukinsa-for-treatment-of-adults-with-waldenstroms-macroglobulinemia.--beigene2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/11/apollomics-inc.doses-first-patient-in-phase-iii-clinical-trial-in-china-of-glycomimetics-uproleselan-for-the-treatment-of-aml2022-02-08T07:46:21+00:00weekly0.6https://www.medthority.com/news/2021/12/uniqure-and-csl-behring-announce-primary-endpoint-achieved-in-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-gene-therapy-in-patients-with-hemophilia-b/2022-02-08T07:46:28+00:00weekly0.6https://www.medthority.com/news/2021/12/novartis-data-highlight-efficacy-of-piqray-in-hrher2--metastatic-breast-cancer-with-a-pik3ca-driver-mutation-immediately-post-cdk46-inhibition/2022-02-08T07:46:28+00:00weekly0.6https://www.medthority.com/news/2021/12/beigene-presents-results-from-phase-iii-trial-of-tislelizumab-in-nasopharyngeal-cancer-at-esmo-immuno-oncology-congress-2021/2022-02-08T07:46:28+00:00weekly0.6https://www.medthority.com/news/2021/12/actemraroactemra-approved-by-the-european-commission-to-treat-patients-with-severe-covid-19.--roche2022-02-08T07:46:28+00:00weekly0.6https://www.medthority.com/news/2021/12/pivotal-phase-iii-pivotal-transform-of-breyanzi-shows-improved-survival-in-large-b-cell-lymphoma.--bms2022-02-08T07:46:29+00:00weekly0.6https://www.medthority.com/news/2021/12/eu-gives-conditional-approval-for-rybrevant-in-non-small-cell-lung-cancer.--janssen-pharmaceuticals2022-02-08T07:46:29+00:00weekly0.6https://www.medthority.com/news/2021/12/scemblix-demonstrates-sustained-response-rate-in-48-week-follow-up-in-patients-with-chronic-myeloid-leukemia.--novartis2024-11-14T14:12:19+00:00weekly0.6https://www.medthority.com/news/2021/12/real-world-evidence-results-from-re-mind2-study-of-monjuvi--revlimid-for-diffuse-large-b-cell-lymphoma.-morphosys.-2022-02-08T07:46:29+00:00weekly0.6https://www.medthority.com/news/2021/12/kymriah-demonstrates-strong-responses-in-high-risk-patients-with-relapsed-or-refractory-follicular-lymphoma-in-extended-study-follow-up-of-elara-trial.--novartis2022-02-08T07:46:29+00:00weekly0.6https://www.medthority.com/news/2021/12/new-data-published-in-nejm-further-demonstrates-beti-cel-as-a-potentially-curative-one-time-gene-therapy-for-beta-thalassemia-patients-.-bluebird-bio-inc2022-02-08T07:46:29+00:00weekly0.6https://www.medthority.com/news/2021/12/radius-health-announces-results-from-the-wearable-trial-evaluating-abaloparatide-transdermal-system-in-postmenopausal-women-with-osteoporosis/2024-11-14T14:12:31+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-emerald-trial-results-for-elacestrant-to-treat-erher2--advanced-breast-cancer-presented-at-san-antonio-breast-cancer-symposium-2021.--radius-health--menarini2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/elevate-rr-head-to-head-trial-data--presented-at-ash-showed-patients-on-ibrutinib-experienced-a-37-higher-burden-of-adverse-events-of-any-grade-while-on-treatment-vs.-patients-on-calquence.--astrazeneca2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/interim-data-from-phase-iii-haven-6-study-demonstrate-favorable-safety-and-efficacy-profile-of-hemlibra-in-people-with-moderate-or-mild-hemophilia-a.--genentechroche2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-phase-iii-dupixent-data-in-children-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-featured-in-rad-2021-late-breaking-session.-regeneron--sanofi2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/the-lancet-respiratory-medicine-publishes-peer-reviewed-paper-and-independent-expert-commentary-on-positive-live-air-phase-iii-lenzilumab-results.--humanigen-inc2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/destiny-breast03-data-showed-enhertu-demonstrated-a-similar-benefit-in-patient-subgroups-including-those-with-stable-brain-metastases-when-compared-to-t-dm1.--astrazeneca--daiichi-sankyo2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-kestrel-study-of-beovu-confirms-benefits-in-diabetic-macular-edema.--novartis2022-02-08T07:46:26+00:00weekly0.6https://www.medthority.com/news/2021/12/confide-study-reveals-underappreciation-of-bowel-urgency-as-a-symptom-of-ulcerative-colitis-and-highlights-communication-gap-between-healthcare-providers-and-patients.--eli-lilly2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/highly-significant-positive-top-line-results-from-a-phase-iii--pivotal-trial-for-sp-102-to-treat-sciatica.--scilex-holding-company2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/vbi-vaccines-announces-filing-of-nds-for-3-antigen-hepatitis-b-vaccine-to-health-canada/2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/intercept-pharma-withdraws-its-maa-for-obeticholic-acid-for-the-treatment-of-liver-fibrosis-due-to-nash/2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-advisory-committee-meeting-is-negative-for-bardoxolone-as-a-treatment-of-chronic-kidney-disease-caused-by-alport-syndrome.-reata-pharma2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/ucb-announces-positive-phase-iii-results-for-rozanolixizumab-in-generalized-myasthenia-gravis/2022-02-08T07:46:27+00:00weekly0.6https://www.medthority.com/news/2021/12/beigene-presents-results-from-sequoia-trial-of-brukinsa--venclexta-in-first-line-chronic-lymphocytic-leukemia-at-the-63rd-ash-annual-meeting/2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/alnylam-submits-regulatory-applications-to-the-fda-and-ema-to-support-label-expansion-for-oxlumo-for-the-treatment-of-advanced-primary-hyperoxaluria-type-1/2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-topline-results-from-the-global-phase-iii-pivotal-restore-trial-of-once-weekly-rezafungin-for-the-treatment-of-candidemia-and-invasive-candidiasis.--cidara-therapeutics---mundipharma2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/merck-inc.-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/yescarta-zuma-12-study-demonstrates-78-complete-response-rate-as-part-of-first-line-treatment-in-newly-diagnosed-high-risk-large-b-cell-lymphoma.--kitegilead-sciences2022-02-08T07:46:30+00:00weekly0.6https://www.medthority.com/news/2021/12/breyanzi-shows-superiority-over-20-year-standard-of-care-in-second-line-rr-large-b-cell-lymphoma-based-on-transform-study-results.-bms2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/two-phase-iii-studies-of-aln-at3-show-significant-improvements-in-hemophilia-a-or-b.--sanofi2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-choice-01-study-of-tuoyi-showed-improved-survival-in-non-small-cell-lung-cancer.--shanghai-junshi-biosciences--coherus-biosciences2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-xeljanzxeljanz-xr-for-ankylosing-spondylitis.--pfizer2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/mirikizumab-demonstrates-superiority-over-placebo-in-phase-iii-maintenance-study-in-ulcerative-colitis-supporting-regulatory-submissions-in-2022.--eli-lilly2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/polivy-combination-r-chp-reduced-the-risk-of-disease-worsening-or-death-by-27-in-people-with-previously--untreated-diffuse-large-b-cell-lymphoma.-genentechroche2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/additional-phase-iiiii-study-results-confirm-robust-efficacy-of-novel-oral-antiviral-paxlovid--ritonavir-treatment-of-covid-19-in-reducing-risk-of-hospitalisation-or-death.--pfizer2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/european-commission-approves-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-individuals-18-years-of-age-and-older.--merck-inc2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/apellis-and-sobi-announce-eu-approval-of-aspaveli-for-treatment-of-paroxysmal-nocturnal-hemoglobinuria/2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/mhra-united-kingdom-approves--brukinsa-for-the-treatment-of-adultswith-waldenstroms-macroglobulinemia.--beigene-.-2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/braeburn-receives-new-complete-response-letter-for-brixadi--for-treatment-of-opioid-use-disorder-in-the-us.--camurus-ab--braeburn2022-02-08T07:46:31+00:00weekly0.6https://www.medthority.com/news/2021/12/pfizer-to-acquire-arena-pharma-and-with-it-etrasimod/2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/kineret-anakinra-receives-positive-opinion-from-the-chmp-for-treatment-of-patients-with-covid-19-pneumonia.--swedish-orphan-biovitrum.sobi2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.-astrazeneca2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-accepts-snda-for-ruxolitinib-cream-as-a-treatment-for-patients-with-vitiligo.-incyte-corporation2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/china-nmpa-approves-nuzyra-as-a-category-1-innovative-drug-for-the-treatment-of-patients-with-community-acquired-bacterial-pneumonia-cabp-and-acute-bacterial-skin-and-skin-structure-infections-absssi--zai-lab/2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/update-on-the-phase-iv-confirmatory-study-of-aduhelm-for-alzheimers-disease.---biogen--eisai2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-top-line-results-for-bimzelx-in-phase-iii-be-mobile-2-study-to-treat-ankylosing-spondyloarthritis.--ucb2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/eu-approves-avt-02-as-biosimilar-to-humira.--alvotech2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-grants-priority-review-to-spesolimab-for-pustular-psoriasis.--boehringer2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-orencia-in-combination-with-a-calcineurin-inhibitor-and-methotrexate-for-the-prevention-of-acute-graft-versus-host-disease.--bms-2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/vaxart-to-test-cross-reactivity-of-its-covid-19-oral-tablet-against-omicron-variant/2022-02-08T07:46:32+00:00weekly0.6https://www.medthority.com/news/2021/12/rinvoq-receives-fda-approval-to-treat-active-psoriatic-arthritis.--abbvie2024-11-14T14:15:12+00:00weekly0.6https://www.medthority.com/news/2021/12/publication-of-phase-iii-study-of-molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-in-the-new-england-journal-of-medicine.--merck-inc.--ridgeback-biotherapeutics2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-preliminary-booster-data-for-covid-19-vaccine-candidate-and-continuation-of-phase-iii-trial-per-independent-monitoring-board-recommendation.--sanofi--gsk2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-chmp-opinion-for-a-booster-shot-of-jnj-78436735-covid-19-vaccine.--johnson--johnson2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/velys-robotic-assisted-solution-paves-the-way-for-next-generation-knee-replacement-surgery-in-australia.--depuy-synthesjj.-2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-positive-recommendation-for---somatrogon-a-long-acting-treatment-for-pediatric-growth-hormone-deficiency.--pfizer--opko-health2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-issues-positive-opinion-for-20-valent-pneumococcal-conjugate-vaccine-for-the-prevention-of-vaccine-type-pneumococcal-pneumonia-in-adults--pfizer/2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-negative-on-maa-for-aduhelm-for-alzheimers-disease.--biogen--eisai2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-positive-opinion-for-once-daily-oral-tepmetko-to-treat-nsclc-with-met-exon-14-skipping-mutations.--merck-kgaa2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-positive-recommendation-for-keytruda-for-the-adjuvant-treatment-of-adults-with-renal-cell-carcinoma.--merck-inc2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/eu-approves-xevudy-for-covid-19.--gsk--vir-biotechnology2022-02-08T07:46:33+00:00weekly0.6https://www.medthority.com/news/2021/12/tezspire-approved-in-the-us-for-severe-asthma.--astrazeneca--amgen2024-11-14T14:16:51+00:00weekly0.6https://www.medthority.com/news/2021/12/immatics-and-bms-enter-into-global-exclusive-license-for-immatics-tcr-bispecific-program-ima-401/2022-02-08T07:46:34+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-priority-review-of-bla-for-eli-cel-gene-therapy-for-cerebral-adrenoleukodystrophy-cald-in-patients-without-a-matched-sibling-donor.--bluebird-bio2022-02-08T07:46:34+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approval-of-vyvgart-efgartigimod-alfa-fcabin-generalized-myasthenia-gravis-.--zai-lab-and-argenx2022-02-08T07:46:34+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-opinion--positive-for-lorviqua--as-first-line-treatment-for-alk-positive-advanced-nsclc.--pfizer-inc2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-grants-accelerated-approval-for-tarpeyo--to-reduce-proteinuria-in-iga-nephropathy.-calliditas-therapeutics--ab2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/primary-endpoint-met-statistical-significance-in-corrected-topline-efficacy-data-of-phase-iii-roman-trial-of-avasopasem---galera-therapeutics/2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/ipsen-and-genfit-enter-into-exclusive-licensing-agreement-for-elafibranor-a-phase-iii-asset-evaluated-in-primary-biliary-cholangitis-as-part-of-a-long-term-global-partnership/2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/a-panel-of-us-experts-has-voted-unanimously-to-recommend-the-pfizer-and-moderna-covid-19-vaccines-over-johnson--johnsons-which-has-been-linked-to-deadly-side-effects/2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/novartis-provides-an-update-on-phase-iii-ligelizumab-studies-in-chronic-spontaneous-urticaria-csu.-2024-11-14T14:17:12+00:00weekly0.6https://www.medthority.com/news/2021/12/eisai-enters-an--agreement-with-gilead-sciences-to-commercialise-filgotinib-in-asia/2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/saphnelo-recommended-for-approval-by-chmp-for-the-treatment-of-patients-with-systemic-lupus-erythematosus.-astrazeneca2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/ema-issues-advice-on-use-of-paxlovid-pf-07321332-and-ritonavir-for-the-treatment-of-covid-19.--pfizer2022-02-08T07:47:00+00:00weekly0.6https://www.medthority.com/news/2021/12/moderna-announces-preliminary-booster-data-and-updates-strategy-to-address-omicron-variant-of-covid-19/2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-otezla-for-the-treatment-of-patients-with-plaque-psoriasis-regardless-of-severity-level.--amgen.-2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/sandoz-submits-bla-for-proposed-biosimilar-trastuzumab-to-fda/2024-11-14T14:17:22+00:00weekly0.6https://www.medthority.com/news/2021/12/intercept-pharma-provides-update-on-phase-iii-reverse-trial-of-oca-for-compensated--cirrhosis-due-to-nash/2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/lebrikizumab--topical-corticosteroids-demonstrated-in-a-third-phase-iii-study-significant-skin-improvement-and-itch-relief-in-people-with-atopic-dermatitis.--eli-lilly--almirall2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/aldeyra-therapeutics-announces-top-line-results-from-the-phase-iii-tranquility-trial-of-0.25-reproxalap-in-dry-eye-disease2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/ultomiris-regulatory-submission-accepted-under-fda-priority-review-in-the-us-for-adults-with-generalised-myasthenia-gravis.--alexionastrazeneca2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-trial-of-tavalisse-meets-primary-endpoint-in-chronic-immune-thrombocytopenia.--rigel-pharma2024-11-14T14:17:37+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-yusimry-as-humira-biosimilar.--coherus-biosciences2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-data-from-post-hoc-study-of-vyndaqel-in-transthyretin-amyloid-cardiomyopathy-published-in-circulation-heart-failure.--pfizer2022-02-08T07:47:01+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-apretude-for-hiv.--viiv-healthcare2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/2021/12/eu-approves-variation-for-veklury-in-covid-19-patients.--gilead-sciences2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/2021/12/sandoz-submits-maa-for-proposed-biosimilar-trastuzumab-to-ema/2024-11-14T14:18:20+00:00weekly0.6https://www.medthority.com/news/news-trends/migraine/anti-cgrp-treatments-for-migraine/2026-01-26T16:14:33+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approval-of-caplyta-for-the-treatment-of-bipolar-depression-in-adults.-intra-cellular-therapies2021-12-23T11:00:11+00:00weekly0.6https://www.medthority.com/news/2021/12/tki-258-filed-with-fda-for-renal-cell-carcinoma.--allarity-therapeutics2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/2021/12/phase-iii-trial-results-show-ak-002-fails-to-meet-primary-endpoint-in-eosinophilic-esophagitis.--allakos2024-11-14T14:18:29+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-provides-complete-response-letter-for-tak-721-in-eosinophilic-esophagitis.--takeda2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-leqvio-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year.--novartis2024-11-14T14:18:39+00:00weekly0.6https://www.medthority.com/news/2021/12/sanofi-to-acquire-amunix-and-with-it-amx-818a-masked-her2-directed-transformative-t-cell-engager/2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/2021/12/novartis-acquires-gyroscope-therapeutics-and-with-it-gt-005-a-proposed-treatment-for-geographic-atrophy/2022-02-08T07:47:02+00:00weekly0.6https://www.medthority.com/news/news-trends/migraine/managing-migraine-over-time/2026-01-26T16:12:04+00:00weekly0.6https://www.medthority.com/news/2021/12/cosentyx-receives-fda-approval-for-the-treatment-of-children-and-adolescents-with-enthesitis-related-arthritis-and-psoriatic-arthritis.-novartis-------2024-11-14T14:18:48+00:00weekly0.6https://www.medthority.com/news/2021/12/vaxzevria-significantly-boosted-antibody-levels-against-omicron-variant-of-covid-19-astrazeneca/2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-studies-from-oxford-and-washington-universities.--astrazeneca2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/aquestive-therapeutics-receives-notification-from-the-fda-that-it-will-not-be-ready-to-take-action-by-december-23-2021-for-the-nda-for-libervant-buccal-film/2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/molnupiravir-receives-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19.--merck-inc.--ridgeback-biotherapeutics2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/spesolimab-significantly-improved-signs-and-symptoms-of-flares-in-rare-life-threatening-skin-disease-generalized-pustular-psoriasis.--boehringer2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/mhra-approves-piqray--fulvestrant-for-patients-with-pik3ca-mutation-in-her--her2-breast-cancer--novartis-/2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/lecanemab-granted-fast-track-designation-by-the-fda-to-treat-alzheimers-disease.-eisai--biogen2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-emergency-use-authorization-is-granted-for-paxlovid-for-the-treatment-of-mild-to-moderate-covid-19-.--pfizer2022-02-08T07:47:03+00:00weekly0.6https://www.medthority.com/news/2021/12/pfizer-and-biontech-se-submit-updated-longer-term-follow-up-data-of-comirnaty-for-covid-19-in-adolescents-12-through-15-years-of-age-to-ema-and-fda/2026-02-18T22:18:06+00:00weekly0.6https://www.medthority.com/news/2021/12/gilead-announces-publication-of-data-demonstrating-veklury-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19/2026-02-18T22:17:13+00:00weekly0.6https://www.medthority.com/news/2021/12/molnupiravir-an-investigational-oral-antiviral-covid-19-treatment-receives-special-approval-for-emergency-in-japan.--merck-inc.--ridgeback-biotherapeutics2026-02-18T22:17:38+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-xarelto-to-treat-venous-thromboembolism-vte-and-to-prevent-vte-in-children.-bayer-healthcare2026-02-18T22:16:37+00:00weekly0.6https://www.medthority.com/news/2021/12/chmp-opinion-for-finerenone-as-a-new-treatment-for-adult-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes.--bayer-healthcare2026-02-18T22:15:50+00:00weekly0.6https://www.medthority.com/news/2021/12/pfizer-and-biontech-submit-updated-longer-term-follow-up-data-of-comirnaty-in-adolescents-12-through-15-years-of-age-to-ema/2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/covid-19-at-home-test-granted-fda-emergency-use-authorization-to-expand-access-to-rapid-self-testing-solutions-in-the-united-states.--roche2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-nurowns-phase-iii-study-for-als-in-muscle-and-nerve-journal/2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/european-commission-grants-conditional-marketing-authorization-for-nuvaxovid-covid-19-vaccine.-novavax-inc2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/oxbryta-receives-positive-chmp-opinion-for-the-treatment-of-hemolytic-anemia-in-patients-with-sickle-cell-disease-aged-12-rears-and-older.-global-blood-therapeutics-inc2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-chmp-opinion-for-padcev--in-locally-advanced-or-metastatic-urothelial-cancer.-astellas--seagen2024-11-14T14:21:22+00:00weekly0.6https://www.medthority.com/news/2021/12/positive-chmp-opinion-for-linzagolix-an-oral-gnrh-antagonist-for-the-treatment-of-uterine-fibroids.-obseva-sa2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/takeda-receives-positive-chmp-opinion-for-vedolizumab-iv-for-the-treatment-of-active-chronic-pouchitis/2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/merck-kgaa-acquires-chord-therapeutics-and-with-it-crd-1-cladribine-for-new-indications/2025-10-16T11:24:20+00:00weekly0.6https://www.medthority.com/news/2021/12/mhra-uk-approves-qinlock-in-the-united-kingdom-for-the-treatment-of-fourth-line-gastrointestinal-stromal-tumor.---deciphera-pharmaceuticals2022-02-08T07:47:04+00:00weekly0.6https://www.medthority.com/news/2021/12/covistix-covid-19-virus-rapid-antigen-detection-test-detects-the-omicron-variant.--sorrento-therapeutics2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2021/12/astrazeneca-and-ionis-close-agreement-to-develop-and-commercialise-eplontersen/2024-11-14T14:21:31+00:00weekly0.6https://www.medthority.com/news/2021/12/summit-therapeutics-announces-topline-results-for-phase-iii-ri-codify-study-for-c.-difficile-infection2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2021/12/poyphor-ag-and-enbiotix-inc.-merge-and-will-trade-as-spexis-ag2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2022/1/zynquista-filed-with-fda-for-type-2-diabetes-plus-heart-failure-risk.--lexicon-pharmaceuticals2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approves-recorlev-for-cushings-syndrome.--xeris-biopharma2024-11-14T14:21:43+00:00weekly0.6https://www.medthority.com/news/2022/1/phase-iiib-sisonke-study-of-ad26.cov2.s-shows-85-effectiveness-against-covid-19.--johnson--johnson2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2022/1/novavax-submits-final-data-packages-to-fda-as-prerequisite-to-emergency-use-authorization-application-request-for-covid-19-vaccine/2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/bridgebio-pharma-reports-month-12-topline-results-from-phase-iii-attribute-cm-study-for-acoramidis-to-treat-attr-cm.-2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/european-medicines-agencys-accepts-maa-for-infigratinib-for-patients-with-cholangiocarcinoma-with-fibroblast-growth-factor-receptor-2-fusions-or-rearrangement.-helsinn--bridgebio-pharma2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/oral-covid-19-antiviral-paxlovid-is--approved-by-mhra-uk.--pfizer2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/kiniksa-announces-results-from-phase-iii-trial-of-mavrilimumab-in-covid-19-related-ards/2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/allarity-therapeutics-and-oncoheroes-biosciences-sign-agreements-to-advance-pediatric-cancer-development-of-dovitinib-and-stenoparib/2024-11-14T14:21:54+00:00weekly0.6https://www.medthority.com/news/2022/1/novartis-announces-u.s.-court-of-appeals-for-the-federal-circuit--upholds-validity-of-gilenya-dosage-regimen-patent2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/quidel-to-acquire-ortho-clinical-diagnostics/2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/the-lancet-diabetes--endocrinology-publishes-positive-results-for-the-mpowered-phase-iii-trial-for-mycapssa-in-acromegaly-patients.--amryt-2022-02-08T07:47:06+00:00weekly0.6https://www.medthority.com/news/2022/1/aldeyra-therapeutics-completes-enrollment-in-part-1-of-the-phase-iii-guard-trial-of-adx-2191-in-proliferative-vitreoretinopathy.-2024-11-14T14:22:06+00:00weekly0.6https://www.medthority.com/news/2022/1/daiichi-sankyo-obtains-approval-in-japan-for-efient-to-prevent--recurrence-of-ischemic-cerebrovascular-disease.-2024-11-14T14:22:18+00:00weekly0.6https://www.medthority.com/news/2022/1/santhera-enters-into-exclusive-license-agreement-with-sperogenix-therapeutics-for-vamorolone-in-rare-diseases-in-the-greater-china-region/2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/avrobio-reprioritizes-pipeline-programs-for-avr-rd-01-in-fabry-disease/2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/corbevax-gets-dcgi-india-approval-to-prevent-covid-19.-biological-e-limited2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/amx-0035-filed-with-eu-for-amyotrophic-lateral-sclerosis.--amylyx-pharma2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/nice-does-not-recommend-olaparib-to-treat-prostate-cancer.-astrazeneca--merck-inc.-msd-2024-11-14T14:22:27+00:00weekly0.6https://www.medthority.com/news/2022/1/nmpa-china-approves-tislelizumab-as-second--or-third-line-treatment-for-locally-advanced-or-metastatic-nsclc.--beigene2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/supplemental-approval-of-opdivo-for-expanded-use-for-treatment-of-cancer-of-unknown-primary-in-japan.--ono--bms2024-11-14T14:22:38+00:00weekly0.6https://www.medthority.com/news/2022/1/positive-phase-iii-data-for-xywav-is-published-in-the-lancet-neurology--jazz-pharma/2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/zai-lab-announces-nda-acceptance-of-margetuximab-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer-in-china-by-the-nmpa/2022-02-08T07:47:07+00:00weekly0.6https://www.medthority.com/news/2022/1/inflarx-initiates-phase-iii-clinical-program-with-vilobelimab-in-hidradenitis-suppurativa/2024-11-14T14:25:54+00:00weekly0.6https://www.medthority.com/news/2022/1/abbvie-submits-applications-for-rinvoq-in-non-radiographic-axial-spondyloarthritis-to-fda-and-european-medicines-agency.-2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/dermavant-to-present-new-data-from-phase-iii-psoaring-program-for--tapinarof-cream-at-the-2022-winter-clinical-dermatology-conference/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/cara-therapeutics-announces-korsuva-injection-achieves-positive-topline-results-in-phase-iii-clinical-study-in-japan-for-the-treatment-of-pruritus-in-hemodialysis-patients/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/medtronic-announces-approval-of-the-evolut-pro-tavr-system-in-china-to-treat-severe-aortic-stenosis/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/arrowhead-pharmaceuticals-initiates-phase-iii-palisade-study-of-aro-apoc3-for-treatment-of-familial-chylomicronemia-syndrome/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/zai-lab-announces-first-patient-treated-in-greater-china-in-panova-3-phase-iii-pivotal-trial-of-tumor-treating-fields-in-pancreatic-cancer/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/new-vaxzevria-data-further-support-its-use-as-third-dose-booster.--astrazeneca2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/publication-of-new-aveed-data-in--journal-of-clinical-pharmacology-data-evaluates-dosing-flexibility-in-men-with-hypogonadism.--endo-international2024-11-14T14:26:03+00:00weekly0.6https://www.medthority.com/news/2022/1/roche-launches-the-cobas-pulse-system-an-industry-first-professional-blood-glucose-management-solution-with-mobile-digital-health-capabilities-to-improve-patient-care/2022-02-08T07:47:08+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approval-for--cibinqo-to-treat-adults-living-with-refractory-moderate-to-severe-atopic-dermatitis.--pfizer-2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/positive-top-line-results-of-pfizers-phase-iii-study-exploring-co-administration-of-prevnar-20-with-pfizer-biontech-covid-19-vaccine-in-older-adults-released/2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/medtronic-announces-results-showing-meaningful-pain-relief-using-dtm-spinal-cord-stimulation-endurance-therapy/2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/enhertu-granted-priority-review-in-the-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen.--astrazeneca--daichi-sankyo2022-01-18T14:26:56+00:00weekly0.6https://www.medthority.com/news/2022/1/ascendis-pharma-as-receives-european-approval-for-transcon-hgh-for-pediatric-growth-hormone-deficiency/2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/-nmpa-approval-of-antifungal-cresemba-for-invasive-aspergillosis-in-china.-pfizer--basilea2024-11-14T14:26:14+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approves-rinvoq-for-atopic-dermatitis-patients-aged-12-and-upwards.--abbvie--2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/cansinobio-announces-approval-for-its-mcv4-meningococcal-vaccine-menhycia-in-china/2024-11-14T14:27:02+00:00weekly0.6https://www.medthority.com/news/2022/1/health-canada-approves-paxlovid-to-treat-mild-to-moderate-covid-19-infection--pfizer/2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/positive-top-line-results-for-bimzelx-in-phase-iii-non-radiographic-axial-spondyloarthritis-study--ucb/2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/imfinzi--tremelimumab-demonstrated-unprecedented-survival-in-1st-line-unresectable-liver-cancer-with-31-of-patients-alive-at-three-years.--astrazeneca2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer.-astrazeneca2022-02-08T07:47:09+00:00weekly0.6https://www.medthority.com/news/2022/1/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-phase-ii-clinical-trial-of-covi-msc-in-covid-19-patients-with-persistent-pulmonary-compromise-after-recovery-long-hauler/2024-11-14T14:27:12+00:00weekly0.6https://www.medthority.com/news/2022/1/positive-long-term-safety-and-efficacy-data-confirm-the-role-of-mycapssa-in-the-management-of-acromegaly-patients.--amryt2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/ucb-acquires-zogenix-inc.-and-with-it-fintepla2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-accepts-for-review-libtayo---chemotherapy-for-first-line-treatment-of-advanced-nsclc.--regeneron2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/data-from-phase-iii-studiesgemstone-301-and-gemstone-302-of-sugemalimab-for-nsclc-were-published-in-the-lancet-oncology.--eqrx-inc.-and-cstone-pharmaceuticals2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/pfizer-shares-in-vitro-efficacy-of-novel-covid-19-oral-treatment-paxlovid-against-omicron-variant/2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/phase-iii-trial-of-dupixent-meets-primary-and-secondary-endpoints-in-prurigo-nodularis.--sanofi2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/phase-iii-keynote-394-trial-final-results-for-keytruda-show-benefits-in-hepatocellular-carcinoma.--merck-inc2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/ema-approves-tavneos-for-anca-associated-vasculitis.--vifor-fresenius-medical-care-renal-pharma2022-02-08T07:47:10+00:00weekly0.6https://www.medthority.com/news/2022/1/beigene-announces-acceptance-of-a-sbla-in-china-for-brukinsa-for-waldenstroms-macroglobulinemia/2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/lumakras-receives-approval-in-japan-for-patients-with-kras-g12c-mutated-advanced-nsclc.--amgen2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/sorrento-therapeutics-announces-covishield-a-broad-spectrum-neutralising-antibody-potently-neutralises-omicron-and-omicron--r346k-variants-of-sars-cov-2/2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/zealand-pharma-completes-enrollment-in-ease-sbs-1-phase-iii-trial-assessing-glepaglutide-in-patients-with-short-bowel-syndrome/2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/bms-receives-approval-for-abecma--the-first-car-t-therapy-approved-for-the-treatment-of-multiple-myeloma-in-japan/2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/omeros-submits-response-to-fda-relating-to-narsoplimab-to-treat-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-hsct-tma/2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/jyseleca-approved-for-treatment-of-adult-patients-with-moderate-to-severe-ulcerative-colitis-in-united-kingdom.--galapagos-nv-and-gilead-sciences2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/results-from-pivotal-phase-iii-keynote-775study-309-trial-of-keytruda-and-lenvima-in-advanced-endometrial-carcinoma-published-in-the-new-england-journal-of-medicine/2024-11-14T14:28:37+00:00weekly0.6https://www.medthority.com/news/2022/1/positive-top-line-rrsults-for-bimzelx-in-second-phase-iii-be-complete-study-for-psoriatic-arthritis.--ucb2022-02-08T07:47:11+00:00weekly0.6https://www.medthority.com/news/2022/1/helios-a-phase-iii-study-of-aln-ttrsc02-meets-all-secondary-endpoints-in-hattr-amyloidosis-with-polyneuropathy.--alnylam-pharma2024-11-14T14:28:48+00:00weekly0.6https://www.medthority.com/news/2022/1/final-spectra-phase-iiiii-clinical-trial-efficacy-data--for-scb-2019-is-published-in-the-lancet.--clover-biopharmaceuticals2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approves-veklury-for-the-treatment-of-non-hospitalized-patients-at-high-risk-for-covid-19-disease-progression.-gilead-sciences2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/mhlw-japan-approves-ngenla-a-new-long-acting-treatment-for-pediatric-growth-hormone.--pfizer--opkpo-health2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/complete-response-letter-for-somatrogon-for-the-treatment-of--growth-hormone-deficiency.--pfizer--opko-health2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/gamida-cell-to-initiate-rolling-submission-to-fda-for-omidubicel-to-treat-patients-with-blood-cancers-in-need-of-stem-cell-transplant/2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2021/12/blueprint-medicines-acquires-lengo-therapeutics-and-with-it-lng-451--a-therapy-for-treatment-of-nsclc-in-patients-with-egfr-exon-20-insertion-mutations/2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2021/12/jnj-64007957-filed-with-fda-for-multiple-myeloma.--janssen-pharma2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2021/12/fda-approves-adbry-for-atopic-dermatitis.--leo-pharma2022-02-08T07:47:05+00:00weekly0.6https://www.medthority.com/news/2022/1/bimzelx-is-approved-in-japan-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-psoriatic-erythroderma.--ucb2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/sputnik-v-demonstrates-strong-protection-against-omicron-variant.-gamaleya-center2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/fourth-covid-vaccine-partially-effective-against-omicron-israeli-study/2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/two-papers-in-the-lancet-highlight-one-year-results-from-roches-phase-iii-trials-evaluating-faricimab-in-neovascular-or-wet-age-related-macular-namd-and-diabetic-macular-edema-dme/2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/complete-response-letter-for-gefapixant-a-non-narcotic-orally-administered-selective-p2x3-receptor-antagonist-under-development-for-the-treatment-of-refractory-chronic-cough.-merck-inc2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/mhlw-japan-approves-lyfnua-gefapixant-to-treat-refractory-or-unexplained-cough.--merck-inc2022-02-08T07:47:12+00:00weekly0.6https://www.medthority.com/news/2022/1/european-commission-approves-vyepti-for-the-preventive-treatment-of-migraine-in-adults.-lundbeck-as2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/beigene-announces-positive-findings-from-phase-iii-trial-of-tislelizumab--chemotherapy-in-first-line-gastric-or-gastroesophageal-junction-adenocarcinoma/2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/idorsia-receives-pmda-japan-approval-of-pivlaz-clazosentan-sodium-150-mg-to-treat-cerebral-vasospasm/2025-08-20T14:38:18+00:00weekly0.6https://www.medthority.com/news/2022/1/japans-ministry-of-health-labour-and-welfare-mhlw-has-approved-vyvgart-intravenous-infusion-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-gmg.--argenx2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/tga-australia-approves-zejula-for-ovarian-cancer-providing-another-option-for-newly-diagnosed-women-with-this-deadly-disease.--gsk2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/mhlw-japan-approves-abcema-to-treat-rr-multiple-myeloma.--bms2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/pfizer--biontech-initiate-study-to-evaluate-omicron-based-covid-19-vaccine-in-adults-18-to-55-years-of-age/2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/evrysdi-is-granted-fda-priority-review-for-treatment-of-pre-symptomatic-babies-under-2-months-of-age-with-spinal-muscular-atrophy.---genentechroche2022-02-08T07:47:13+00:00weekly0.6https://www.medthority.com/news/2022/1/merck-kgaa-announces-out-licensing-agreement-with--trialsparkhigh-line-bio-for--sprifermin-for-osteoarthritis.-2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/a-newly-published-network-meta-analysis-nma-found-tremfya-ranked-highest-for-overall-level-of-skin-clearance-and-provided-positive-joint-efficacy-among-active-psoriatic-arthritis-therapies.-janssen-pharma2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approves-kimmtrak-for-metastatic-uveal-melanoma.--immunocore-2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/moderna-inc.-announced-that-the-first-participant-has-been-dosed-in-the-phase-ii-study-of-the-companys-omicron-specific-booster-candidate-mrna-1273.5292022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/incyte-provides-update-on-parsaclisib-and-mcla-145/2024-11-14T14:29:05+00:00weekly0.6https://www.medthority.com/news/2022/1/pfizer-receives-chmp-positive-opinion-for-paxlovid-a-novel-covid-19-oral-treatment/2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/eu-approves-keytruda-in-renal-cell-carcinoma.--merck-inc2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/update-on-the-phase-iv-envision-confirmatory-study-of-aduhelm.--biogen--eisai-2022-02-08T07:47:14+00:00weekly0.6https://www.medthority.com/news/2022/1/biogen-agrees-with-samsung-biologics-to-sell-its-equity-stake-in-their-biosimilar-joint-venture-for-up-to-$2.3-billion2024-11-14T14:37:00+00:00weekly0.6https://www.medthority.com/news/2022/1/trevena-announces-submission-of-nda-in-china-for-olinvyk-by-its-partner-jiangsu-nhwa-pharmaceutical-for-management-of-acute-pain/2024-11-14T14:37:02+00:00weekly0.6https://www.medthority.com/news/2022/1/beigene-announces-acceptance-of-sdna-in-china-for-brukinsa-in-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-/2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/update-on-olumiant-phase-iii-lupus-program-and-status-of-atopic-dermatitis-snda.--eli-lilly--incyte2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/chmp-recommends-approval-of-breyanzi-for-diffuse-large-b-cell-lymphoma-mediastinal-large-b-cell-lymphoma-and-follicular-lymphoma-grade-3b.--bms-2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/chmp-recommends-change-to-authorisation-for-vimpat-in-partial-onset-seizures.--ucb2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/chmp-recommends-change-to-authorisation-for-briviact-in-partial-onset-seizures.--ucb2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/chmp-recommends-approval-of-teriparatide-biosimilar-sondelbay-for-osteoporosis.--accord-healthcare2022-02-08T07:47:15+00:00weekly0.6https://www.medthority.com/news/2022/1/chmp-recommends-extension-to-authorisation-for-jardiance-in-type-2-diabetes.--boehringer2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/ayvakyt-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis--blueprint-medicines/2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/regeneron-and-sanofi-withdraw-libtayo--sbla-from-fda-to-treat-advanced-cervical-cancer/2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-to-treat-wet-or-neovascular-age-related-macular-degeneration-amd-and-diabetic-macular-edema-dme.genentechroche2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/cortexyme-announces-clinical-hold-on-atuzaginstats-investigational-new-drug-application-for-alzheimers-disease/2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/sierra-oncology-announces-momelotinib-achieved-statistically-significant-benefit-on-symptoms-anemia-and-splenic-size-in-the-pivotal-momentum-study-for-myelofibrosis/2024-11-14T14:37:09+00:00weekly0.6https://www.medthority.com/news/2022/1/eu-grants-approval-of-lorviqua-in-alk-positive-advanced-non-small-cell-lung-cancer.--pfizer2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/1/fda-approval-of-spinal-cord-stimulation-therapy-intellis-rechargeable-neurostimulator-for-treating-chronic-pain-resulting-from-diabetic-peripheral-neuropathy.--medtronic2024-11-14T14:37:19+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-approval-of-dupixent-for-children-aged-6-to-10-years-with-severe-asthma-and-type-2-inflammation.---regeneron--sanofi2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/2/-fda-approves-new-label-update-for-car-t-cell-therapy-yescarta-showing-prophylactic-steroid-use-improves-management-of-cytokine-release-syndrome/2022-02-08T07:47:16+00:00weekly0.6https://www.medthority.com/news/2022/2/modernainc.-announced-the-fda-has-approved-the-bla-for-spikevax-covid-19-vaccine-mrna-to-prevent-covid-19-in-individuals-18-years-of-age-and-older2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/novavax-submits-request-to-the-fda-for-emergency-use-authorization-of-covid-19-vaccine/2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/pf-07285557-discontinued-for-cv-risk-reduction-and-hypertriglyceridemia.--pfizerionis-pharma2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-prophylaxis-with-vonvendi-in-type-3-von-willebrand-disease.--takeda2024-11-14T14:37:21+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-maestro-nafld-1-study-of-mgl-3196-shows-it-to-be-safe-and-well-tolerated-in-non-alcoholic-fatty-liver-disease.--madrigal-pharma2024-11-14T14:38:29+00:00weekly0.6https://www.medthority.com/news/2022/2/jnj-64007957-filed-with-ema-for-multiple-myeloma.--janssen-pharma2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/reata-pharma-starts-rolling-submission-with-fda-for-omaveloxolone-in-friedreichs-ataxia/2024-11-14T14:40:13+00:00weekly0.6https://www.medthority.com/news/2022/2/mhra-uk-approves-xevudy-to-reduce-the-risk-of-hospitalisation-and-death---in-people-with-mild-to-moderate-covid-19.---gsk--vir-biotechnology2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/uk-rolls-out-new-drug-approval-pathway/2022-02-08T07:47:17+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-avatar-trial-of-anavex-2-73-shows-significant-improvement-in-rett-syndrome.--anavex-life-sciences2024-11-14T14:38:34+00:00weekly0.6https://www.medthority.com/news/2022/2/mhra-uk-approves-tecentriq-for-early-stage-nsclc-with-pd-l1-mutation-post-surgery-and-chemo.--roche2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-expands-label-approval-of-cabenuva--rilpivirine-in-hiv.--viiv-healthcare2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/provention-bio-to-resubmit-bla-for--delay-of-clinical-type-1-diabetes-in-at-risk-patients/2024-11-14T14:40:00+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-for-health-and-care-excellence-nice-uk-recommends-keytruda-for-adjuvant-treatment-of-completely-resected-stage-3-melanoma-with-lymph-node-involvement.--merck-inc2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-of-health-and-care-excellence-nice-uk-recommends-ponvory-to-treat-multiple-sclerosis.-actelionjohnson--johnson2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-of--health-and-care-excellence-niceuk-recommends-palforzia-for-treating-peanut-allergy-in-children.-aimmunenestle2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-of-care-and-health-excellence-nice-uk-recommends-darzalex--combination-for-treatment-for-multiple-myeloma-when-a-stem-cell-transplant-is-suitable.--genmab--janssen-biotech2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-for-health--care-excellence-nice-uk-recommends-rinvoq-to-treat-psoriatic-arthritis--abbvie/2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/pfizer-and-biontech-initiate-rolling-submission-for-emergency-use-authorization-of-their-covid-19-vaccine-in-children-6-months-through-4-years-of-age-following-request-from--fda/2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-clearance-of-omnipod-5-automated-insulin-delivery-system-first-tubeless-system-with-smartphone-control--insulet/2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-for-health-and-care-excellence--niceuk-recommends-fremanezumab-to-prevent-migraine.-teva2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/adcetris-combination-significantly-improves-overall-survival-in-newly-diagnosed-patients-with-advanced-hodgkin-lymphoma.--seagen-inc2022-02-08T07:47:18+00:00weekly0.6https://www.medthority.com/news/2022/2/tlando-resubmitted-to-fda-for-testosterone-replacement-therapy.--antares-pharma2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/nice-uk-recommends-venetoclax-with-azacitidine-for-untreated-acute-myeloid-leukaemia-when-intensive-chemotherapy-is-unsuitable.-abbvie2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-skyrizi-to-treat-psoriatic-arthritis.--abbvie2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/oral-opaganib-reduces-mortality-by-70-given-on-top-of-remdesivir-and-corticosteroids-in-severe-covid-19--redhill-biopharma-ltd/2022-02-10T11:38:45+00:00weekly0.6https://www.medthority.com/news/2022/2/pivotal-phase-iii-data-for-keytruda--in-high-risk-early-stage-triple-negative-breast-cancer-is-published-in-the-new-england-journal-of-medicine.--merck-inc2022-02-10T11:33:03+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-accepts-dupixent-for-priority-review-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis.--regeneron--sanofi2022-02-10T11:27:23+00:00weekly0.6https://www.medthority.com/news/2022/2/plan-to-limit-medicare-coverage-of-aduhelm-to-patients-who-are-enrolled-in-clinical-trials-is-needlessly-restrictive.-2022-02-11T14:44:08+00:00weekly0.6https://www.medthority.com/news/2022/2/mp-0420-filed-with-fda-for-eua-in-covid-19.--molecular-partners2022-02-11T15:23:00+00:00weekly0.6https://www.medthority.com/news/2022/2/national-institute-for-health-and-care-excellence-uk-recommends-keytruda-with-carboplatin-and-paclitaxel-for-metastatic-squamous-non-small-cell-lung-cancer.--merck-inc2025-01-31T11:16:39+00:00weekly0.6https://www.medthority.com/news/2022/2/eisai-submits-formal-comments--to-centers-for-medicare-and-medicaid-services-proposed-national-coverage-determination-for-monoclonal-antibodies-for-treatment-of-alzheimers-disease/2022-02-11T15:37:11+00:00weekly0.6https://www.medthority.com/news/2022/2/new-two-year-data-for-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-two-causes-of-vision-loss.--genentechroche2022-02-11T13:30:08+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-prebla-meeting-completed-with-fda-for-omburtamab-in-neuroblastoma.-y-mabs-therapeutics-2022-02-12T17:01:20+00:00weekly0.6https://www.medthority.com/news/2022/2/bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19.--eli-lilly2022-02-12T17:05:35+00:00weekly0.6https://www.medthority.com/news/2022/2/encouraging-phase-ii-results-for-high-dose-eylea-8-mg-in-wet-age-related-macular-degeneration-presented-at-angiogenesis-meeting.--regeneron2022-02-13T14:43:13+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iiiii-interim-data-evaluating-the-safety-tolerability-and-clinical-outcomes-of-veklury-in-pediatric-patients-with-covid-19-presented-at-croi-2022.--gilead-sciences2022-02-14T08:13:49+00:00weekly0.6https://www.medthority.com/news/2022/2/biktarvy-demonstrates-high-efficacy-and-durable-viral-suppression-at-five-years-in-treatment-naive-adults-with-hiv.--gilead-sciences2022-02-14T08:10:57+00:00weekly0.6https://www.medthority.com/news/2022/2/nmpa-china-approves-benlysta-to-treat-active-lupus-nephritis.--gsk2022-02-14T08:09:01+00:00weekly0.6https://www.medthority.com/news/2022/2/baclofen-oral-suspension-is-fda-approved-for-treatment-of-spasticity-in-multiple-sclerosis.-azurity-pharma2022-02-14T08:05:44+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approval-for-prefilled-syringe-presentation-of-takhzyro-for-use-as-a-preventive-treatment-for-hereditary-angioedema-attacks.--takeda2022-02-13T14:34:02+00:00weekly0.6https://www.medthority.com/news/2022/2/update-on-rolling-submission-for-emergency-use-authorization-of-covid-19-vaccine-in-children-6-months-through-4-years-of-age.--pfizer--biontech-se2022-02-14T14:50:31+00:00weekly0.6https://www.medthority.com/news/2022/2/gamida-cell-initiates-rolling-submission-of-bla-for-omidubicel-for-patients-with-blood-cancers-in-need-of-stem-cell-transplant/2022-02-14T11:51:51+00:00weekly0.6https://www.medthority.com/news/2022/2/pivotal-phase-iiiii-illuminate-trial-of-sepofarsen-for-the-treatment-of-cep290-mediated-leber-congenital-amaurosis-10--did-not-meet-its-primary-endpoint-of-best-corrected-visual-acuity-at-month-12.--proqr-therapeutics2022-02-15T13:50:37+00:00weekly0.6https://www.medthority.com/news/2022/2/independent-data-monitoring-committee-for-the-phase-iii-sabizabulin-covid-19-clinical-study-recommends-continuing-study-as-planned.--veru-inc2022-02-15T13:50:19+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-clinical-trial-of-nurtec-odt-meets-co-primary-endpoints-in-migraine.--biohaven-pharmaceutical-and-pfizer2022-02-15T13:44:44+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iiiii-clinical-trial-results-phase-iia-part-for-the-covid-19-therapeutic-drug-s-217622.--shionogi2022-02-15T15:54:55+00:00weekly0.6https://www.medthority.com/news/2022/2/lynparza-plus-abiraterone-reduced-risk-of-disease-progression-by-34-vs.-standard-of-care-in-1st-line-metastatic-castration-resistant-prostate-cancer.-astrazeneca--merck-inc2022-02-15T13:29:28+00:00weekly0.6https://www.medthority.com/news/2022/2/collegium-pharma-acquires-biodelivery-sciences-international-inc.-and-with-it-belbuca--symproic-and-elyxyb2022-02-15T15:42:03+00:00weekly0.6https://www.medthority.com/news/2022/2/topline-results-from-meteoric-hf-phase-iii-study-of-omecamtiv-mecarbil-in-heart-failure-patients-showed-no-change-on-the-primary-endpoint--cytokinetics-inc/2022-02-16T11:52:18+00:00weekly0.6https://www.medthority.com/news/2022/2/enrollment-completed-in-phase-iii-trial-of-dasiglucagon-in-children-with-congenital-hyperinsulinism.--zealand-pharma-as2022-02-16T11:47:51+00:00weekly0.6https://www.medthority.com/news/2022/2/outcome-of-fda-advisory-committee-meeting-on-iv-tramadol--avenue-therapeutics/2022-02-16T11:44:14+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-accepts-nda-for-adagrasib-as-a-treatment-of-previously-treated-krasg12c-mutated-non-small-cell-lung-cancer.--mirati-therapeutics2025-01-31T11:16:22+00:00weekly0.6https://www.medthority.com/news/2022/2/new-post-marketing-safety-analysis-shows-rate-of-hearing-related-events-associated-with-tepezza.--horizon-therapeutics-2022-02-16T11:22:47+00:00weekly0.6https://www.medthority.com/news/2022/2/olipudase-alfa-shown-to-provide-sustained-improvement-across-multiple-clinical-manifestations-of-asmdniemann-pick-disease.--sanofi2022-02-17T13:25:20+00:00weekly0.6https://www.medthority.com/news/2022/2/nexviazyme-shows-sustained-improvements-in-respiratory-function-and-mobility-in-patients-with-pompe-disease.--sanofi2022-02-17T13:20:13+00:00weekly0.6https://www.medthority.com/news/2022/2/saphnelo-approved-in-the-eu-for-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus.-astrazeneca2022-02-17T13:15:22+00:00weekly0.6https://www.medthority.com/news/2022/2/ema-approves-20-valent-pneumococcal-conjugate-vaccine-against-invasive-pneumococcal-disease-and-pneumonia-in-adults.-pfizer2022-02-17T13:10:03+00:00weekly0.6https://www.medthority.com/news/2022/2/n-momentum-phase-iiiii-pivotal-trial-of-uplinza-demonstrates-reduced-severity-of-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-02-17T12:53:48+00:00weekly0.6https://www.medthority.com/news/2022/2/valor-hcm-phase-iii-trial-of-myk-461-meets-primary-endpoint-in-symptomatic-obstructive-hypertrophic-cardiomyopathy.--bms2022-02-17T12:50:45+00:00weekly0.6https://www.medthority.com/news/2022/2/eu-approves-ngenla-in-growth-hormone-deficient-children.--pfizer--opko-health2022-02-17T12:47:31+00:00weekly0.6https://www.medthority.com/news/2022/2/eu-approves-oxbryta-for-hemolytic-anemia-due-to-sickle-cell-disease.--global-blood-therapeutics2022-02-17T12:44:44+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-coral-study-of-sage-217-meets-trial-objectives-in-depression.--sage-therapeutics-and-biogen2025-01-31T11:14:40+00:00weekly0.6https://www.medthority.com/news/2022/2/tga-in-australia-has-granted-provisional-registration-for-spikevax--covid-19-vaccine-for-children-aged-6-11-years-old.--moderna2022-02-17T12:30:40+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-advisory-committee-requires-additional-trials-for-tyvyt-to-show-applicability-to-usa-for-nsclc.--eli-lilly--innovent-biologics2025-01-31T11:12:48+00:00weekly0.6https://www.medthority.com/news/2022/2/ucb-announces-positive-data-in-myasthenia-gravis-with-zilucoplan-phase-iii-raise-study-results/2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/viatris-is-first-to-receive-fda-approval-of-generic-restasis-cyclosporine-ophthalmic-emulsion-0.05-to-treat-dry-eye-disease2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/mhra-uk-grants-conditional-approval-for-nuvaxovid-vaccine-to-prevent-covid-19.--novavax-inc2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/cytokinetics-announces-fda-acceptance-of-an-nda-for-omecamtiv-mecarbil--for-the-treatment-of-heart-failure-with-reduced-ejection-fraction.-2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-gener8-1-study-safety-update-of-roctavian-in-haemophilia-a.--biomarin-pharma2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/health-canada-approves-ontruzant-biosimilar-to-treat-breast-cancer-and-gastric-cancer.--samsung-bioepis2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/jazz-pharmaceuticals-completes-fda-supplemental-bla-for-rylaze-for-mondaywednesdayfriday-dosing-schedule/2022-02-08T12:44:24+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-enjaymo-for-cold-agglutinin-disease.--bioverativ-inc.sanofi2022-02-08T07:47:19+00:00weekly0.6https://www.medthority.com/news/2022/2/landmark-reduce-lap-hf-ii-trial-demonstrates-clinical-benefit-of-corvia-atrial-shunt-in-large-segment-of-heart-failure-patients.--corvia-medical2022-02-08T07:47:20+00:00weekly0.6https://www.medthority.com/news/2022/2/vanda-pharmaceuticals-reports--results-from-the-phase-iii--study-of-tradipitant-in-gastroparesis/2022-02-08T12:42:31+00:00weekly0.6https://www.medthority.com/news/2022/2/ema-grants-conditional-marketing-approval-for-paxlovid-to-treat-covid-19-infection.-pfizer2022-02-08T07:47:20+00:00weekly0.6https://www.medthority.com/news/2022/2/actemra-approved-for-additional-indication-of-sars-cov-2-pneumonia-in-japan--chugai/2022-02-08T07:47:20+00:00weekly0.6https://www.medthority.com/news/2022/2/ultra-fast-endoscope-drying-and-storage-solution--the-plasma-typhoon-is-launched-in-the-uk.--pentax-medical2022-02-09T12:06:51+00:00weekly0.6https://www.medthority.com/news/2022/2/healx-and-ovid-therapeutics-to-enter-strategic-partnership-for-gaboxadol/2022-02-09T12:04:47+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-juvderm-volbella-xc-for-undereye-hollows/2022-02-09T12:01:39+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-siendoengot-en5gog-3055-study-of-xpovio-meets-primary-endpoint-in-endometrial-cancer.--karyopharm-therapeutics2022-02-09T11:57:32+00:00weekly0.6https://www.medthority.com/news/2022/2/positive-type-a-meeting-with-fda-for-mydcombi-nda-resubmission-for-mydriasis---eyenovia-inc/2022-02-09T11:54:07+00:00weekly0.6https://www.medthority.com/news/2022/2/enrollment-update-of-subjects-in-phase-iiiii-study-of-tempol-for-the-treatment-of-covid-19.--adamis-pharma2022-02-09T11:49:41+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iia-trial-of-ibezapolstat-is-published-in-clinical-infectious-diseases-as-a-treatment-for-clostridium-difficile-infection.--acurx2022-02-18T12:37:45+00:00weekly0.6https://www.medthority.com/news/2022/2/nirsevimab-ema-regulatory-submission-accepted-under-accelerated-assessment-for-respiratory-syncytial-virus-rsv-protection-in-all-infants.--astrazeneca--sanofi2022-02-18T12:34:23+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-accepts-supplemental-bla-for-breyanzi-in-large-b-cell-lymphoma--after-failure-of-first-line-therapy.--bms2022-02-18T12:22:23+00:00weekly0.6https://www.medthority.com/news/2022/2/sandoz-launches-generic-lenalidomide-in-19-countries-across-europe/2022-02-18T12:12:57+00:00weekly0.6https://www.medthority.com/news/2022/2/update-on-ongoing-dupixent-chronic-spontaneous-urticaria-phase-iii-program.-regeneron--sanofi2025-01-31T11:12:14+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-lucent-1-study-of-ly-3074828-achieved-statistical-significant-improvements-in-ulcerative-colitis.--eli-lilly2022-02-19T12:46:55+00:00weekly0.6https://www.medthority.com/news/2022/2/interim-data-from-inspire-study-of-alofisel-shows-clinical-remission-rate-in-crohns-disease.--takeda2022-02-19T12:44:29+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-pyrukynd-for-hemolytic-anemia-in-adults-with-pyruvate-kinase--deficiency.--agios-pharma2022-02-19T12:45:13+00:00weekly0.6https://www.medthority.com/news/2022/2/eu-approves-tepmetko-as-monotherapy-in-nsclc-with-metex14-mutations.--merck-kgaa2022-02-19T12:45:52+00:00weekly0.6https://www.medthority.com/news/2022/2/refusal-to-file-from-fda-for--dovitinib-and-its-accompanying--application-for-the-drp-dovitinib-companion-diagnostic.-allerity-therapeutics2022-02-20T13:45:05+00:00weekly0.6https://www.medthority.com/news/2022/2/medtronic-receives-fda-expanded-approval-for-cardiac-cryoablation-catheters-for-pediatric-treatment-of-a-common-heart-rhythm-condition/2022-02-20T13:43:41+00:00weekly0.6https://www.medthority.com/news/2022/2/gsk-provides-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme/2022-02-22T12:31:39+00:00weekly0.6https://www.medthority.com/news/2022/2/resubmission-of-snda-to-fda-for-nuplazid-to-treat-alzheimers-disease-psychosis.--acadia-pharma2022-02-22T12:21:26+00:00weekly0.6https://www.medthority.com/news/2022/2/kerendia-approved-in-eu-for-adult-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes.--bayer-healthcare2022-02-22T12:09:12+00:00weekly0.6https://www.medthority.com/news/2022/2/nmpa-china-approves-paxlovid-conditionally-to-treat-covid-19.--pfizer2022-02-23T13:07:34+00:00weekly0.6https://www.medthority.com/news/2022/2/complete-response-letter-for-terlipressin-a-proposed-treatment-for-hepato-renal-syndrome/2025-01-31T11:10:01+00:00weekly0.6https://www.medthority.com/news/2022/2/the-european-commission-has-authorised-the-marketing-of-okedi-to-treat-schizophrenia-in-adults-for-whom-tolerability-and-effectiveness-has-been-established-with-oral-risperidone.-laboratorios-rovi2022-02-23T12:56:21+00:00weekly0.6https://www.medthority.com/news/2022/2/health-canada-approves-nuvaxovid-a-vaccine-to-protect-against-covid-19-infection.-novavax2022-02-23T12:50:17+00:00weekly0.6https://www.medthority.com/news/2022/2/the-data-and-safety-monitoring-board-for-the-rsv-program-has-endorsed-the-start-of-the-phase-iii-portion-of-the-pivotal-clinical-study-of-mrna-1345-the--moderna-respiratory-syncytial-virus-vaccine/2022-02-23T12:46:41+00:00weekly0.6https://www.medthority.com/news/2022/2/topline-results-from-phase-iii-sprinter-trial-of-sng-001-a-proposed-treatment-for-covid-19-infection.--synairgen-plc2022-02-23T12:38:54+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-accepts-snda-for-brukinsa-to-treat-chronic-lymphocytic--leukemiasmall-lymphocytic-leukemia.-beigene2022-02-23T12:35:52+00:00weekly0.6https://www.medthority.com/news/2022/2/supplemental-new-drug-application-submitted--to-fda-for-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder.--abbvie2025-01-31T11:10:39+00:00weekly0.6https://www.medthority.com/news/2022/2/panbela-therapeutics-to-acquire-cancer-prevention-pharmaceuticals-inc/2025-10-16T11:24:03+00:00weekly0.6https://www.medthority.com/news/2022/2/combination-of-niraparib--abiraterone-acetate--prednisone-significantly-improved-radiographic-progression-free-survival-as-a-first-line-therapy-in-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.--janssen2022-02-24T12:01:10+00:00weekly0.6https://www.medthority.com/news/2022/2/erleada-analysis-demonstrates-rapid-deep-prostate-specific-antigen-psa-response-in-metastatic-castration-sensitive-prostate-cancer.--janssen-pharma2022-02-24T11:52:50+00:00weekly0.6https://www.medthority.com/news/2022/2/nice-recommends-odevixibat-for-treating-progressive-familial-intrahepatic-cholestasis.--albireo2022-02-24T11:42:19+00:00weekly0.6https://www.medthority.com/news/2022/2/initiation-of-phase-iii-clinical-trial-optic-j-in-japan-evaluating-teprotumumab-for-the-treatment-of-active-thyroid-eye-disease-ted.--horizon-therapeutics2022-02-24T11:39:29+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-sequoia-hcm-trial-commences-enrollment-of-aficamten-for-hypertrophic-cardiomyopathy.--cyokinetics-inc2022-02-24T11:36:48+00:00weekly0.6https://www.medthority.com/news/2022/2/health-canada-approves-bimzelx-to-treat-plaque-psoriasis.--ucb2025-06-03T09:06:15+00:00weekly0.6https://www.medthority.com/news/2022/2/nice-recommends-pembrolizumab-for-treating-relapsed-or-refractory-classical-hodgkin-lymphoma-after-stem-cell-transplant-or-at-least-2-previous-therapies.--merck-inc2022-02-24T11:23:54+00:00weekly0.6https://www.medthority.com/news/2022/2/sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/2022-02-25T12:34:39+00:00weekly0.6https://www.medthority.com/news/2022/2/mavenclad-data-at-actrims-forum-2022-shows-favourable-efficacy-outcomes-versus-other-oral-dmts-and-lower-occurrence-of-further-relapses-in-rr-multiple-sclerosis.-merck-kgaa2022-02-25T12:30:37+00:00weekly0.6https://www.medthority.com/news/2022/2/prx-102-filed-with-ema-for-fabry-disease.--protalix-biotherapeutics-and-chiesi2022-02-25T12:21:49+00:00weekly0.6https://www.medthority.com/news/2022/2/health-canada-approves-covifenz-for-covid-19.--medicago-and-glaxosmithkline2022-02-25T12:18:29+00:00weekly0.6https://www.medthority.com/news/2022/2/fda-approves-jardiance-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction.-boehringer--eli-lilly2022-02-25T12:16:35+00:00weekly0.6https://www.medthority.com/news/2022/2/lenvima--keytruda-is-approved-in-japan-for-radically-unresectable-or-metastatic-renal-cell-carcinoma.--eisai--merck-inc2022-02-25T12:02:50+00:00weekly0.6https://www.medthority.com/news/2022/2/gamifant-recommended-for-approval-in-china-for-treatment-of-primary-haemophagocytic-lymphohistiocytosis.--sobi-2022-02-26T13:36:46+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-prehevbri-hepatitis-b-vaccine.-vbi-vaccines-inc2022-02-26T13:35:19+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-orgovyx-to-treat-advanced-hormone-sensitive-prostate-cancer.-myovant-sciences2022-02-26T13:33:41+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-positive-for-kapruvia-to-treat-pruritus-associated-with-chronic-kidney-disease-in-hemodialysis-patients.---vifor-fresenius--cara-therapeutics2022-02-26T13:32:13+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-opdivo--yervoy-for-first-line-treatment-of-metastatic-esophageal-squamous-cell-carcinoma.--bms2022-02-26T13:30:44+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-opdivo-for-the-adjuvant-treatment-of-adults-with-muscle-invasive-urothelial-carcinoma.--bms2022-02-26T13:29:22+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-approval-of-beovu-for-visual-impairment-in-diabetic-macular-oedema.--novartis-2022-02-26T13:27:46+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-change-to-authorisation-for-delstrigo-in-hiv.--merck-inc2022-02-26T13:25:32+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-change-of-indication-of-verzenios-in-breast-cancer.--eli-lilly2022-02-26T13:24:08+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-approval-of-quviviq-for-insomnia.--idorsia-pharmaceuticals2022-02-26T13:22:28+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-approval-of-kimmtrak-for-uveal-melanoma.--immunocore2022-02-26T13:18:29+00:00weekly0.6https://www.medthority.com/news/2022/2/chmp-recommends-approval-of-vydura-for-migraine.--biohaven-pharma2022-02-26T13:16:49+00:00weekly0.6https://www.medthority.com/news/2022/2/positive-early-access-decision-by-french-haute-autorite-de-sante-to-use-idefirix-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients.--hansa-biopharma-ab2022-02-27T16:11:07+00:00weekly0.6https://www.medthority.com/news/2022/2/s-217622-a-therapeutic-drug-for-covid-19-is-filed-with-pmda-in-japan.-shionogi2022-02-27T16:09:24+00:00weekly0.6https://www.medthority.com/news/2022/2/convidecia-is-approved-as-a-heterologous-booster-for-covid-19-in-china.--cansino-biologics2022-02-27T16:08:14+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-trial-of-dupixent-shows-efficacy-in-chronic-spontaneous-urticaria.--regeneron--sanofi2022-02-27T16:06:57+00:00weekly0.6https://www.medthority.com/news/2022/2/phase-iii-trial-of-dupixent-shows-improvement-in-eosinophilic-esophagitis.--sanofi--regeneron2022-02-27T16:05:29+00:00weekly0.6https://www.medthority.com/news/2022/2/pakirovid-nirmatrelvir--ritonavir-approved-in-japan-for-covid-19.--pfizer2022-02-21T12:18:52+00:00weekly0.6https://www.medthority.com/news/2022/2/sanofi-files-nda-for-acquired-thrombotic-thrombocytopenic-purpura-in-japan/2022-02-21T12:15:19+00:00weekly0.6https://www.medthority.com/news/2022/2/complete-response-letter-from-the-fda-for-bardoxolone-for-the-treatment-of-patients-with-chronic-kidney-disease-caused-by-alport-syndrome.--reata-pharma2022-02-28T12:48:23+00:00weekly0.6https://www.medthority.com/news/2022/2/new-data-reinforces-efficacy-of-tezspire-in-a-broad-population-of-severe-asthma-patients.--amgen2022-02-28T12:38:14+00:00weekly0.6https://www.medthority.com/news/2022/3/complete-response-letter-for-oleogel-s10-for-epidermolysis-bullosa.--amyrt2022-03-01T12:42:07+00:00weekly0.6https://www.medthority.com/news/2022/3/chmp-confirms-positive-opinion-for-padcev-in-locally-advanced-or-metastatic-urothelial-cancer.-astellas--seagen-inc2022-03-01T12:39:13+00:00weekly0.6https://www.medthority.com/news/2022/3/mn-166-identified-as-potential-beneficial-pharmacotherapy-for-treatment-of-degenerative-cervical-myelopathy-in-global-spine-journal.--medicinova-inc2022-03-01T12:37:04+00:00weekly0.6https://www.medthority.com/news/2022/3/late-breaking-study-results-reinforce-positive-real-world-outcomes-with-the-watchman-flx-laac-device.---boston-scientific2024-03-28T10:24:39+00:00weekly0.6https://www.medthority.com/news/2022/3/update-on-regulatory-review-of-arimoclomol-in-the-european-union-for-treatment-of-niemann-pick-disease-type-c.-orphazyme-as2022-03-01T12:29:50+00:00weekly0.6https://www.medthority.com/news/2022/3/approval-of-can-108-for-rare-liver-disease-alagille-syndrome-under-the-early-and-pilot-implementation-policy-in-boao-lecheng-international-medical-tourism-pilot-zone-china.-canbridgepharma2022-03-01T12:27:22+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-accepts-sbla-for-opdivo--chemotherapy-for-nsclc.--bms-2025-01-31T11:09:35+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iv-empower-study-of-takhzyro-shows-efficacy-and-safety-in-hereditary-angioedema.--takeda2022-03-01T12:20:00+00:00weekly0.6https://www.medthority.com/news/2022/3/publication-of-roluperidone-phase-iii-study-results-for-treatment-of-negative-symptoms-of-schizophrenia-in-schizophrenia-bulletin.--minerva-neurosciences2022-03-01T12:17:12+00:00weekly0.6https://www.medthority.com/news/2022/3/extended-durability-of-protection-against-infection-and-disease-is-shown-in-united-kingdom-covid-19-vaccine-phase-iii-clinical-trial.--novavax-inc2022-03-03T12:50:50+00:00weekly0.6https://www.medthority.com/news/2022/3/update-regarding-skyrizi-for-the-treatment-of-moderate-to-severe-crohns-disease-in-the-u.s.--abbvie--boehringer2022-03-03T12:46:06+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-clover-trial-for--clostridioides-difficile-vaccine-indicates-strong-potential-effect-in-reducing-duration-and-severity-of-disease-based-on-secondary-endpoints.--pfizer2022-03-03T12:41:45+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-accepts-for-review-supplemental-application-for-abrilada--interchangeability.---pfizer2022-03-03T12:37:21+00:00weekly0.6https://www.medthority.com/news/2022/3/european-medicines-agency-ema-accepts-marketing-authorisation-application-for-daprodustat-to-treat-anaemia-of-chronic-kidney-disease.--gsk2022-03-03T12:34:19+00:00weekly0.6https://www.medthority.com/news/2022/3/abbvie-to-acquire-syndesi-therapeutics-and-its-neuroscience-portfolio-including-sdi-118/2022-03-04T17:56:15+00:00weekly0.6https://www.medthority.com/news/2022/3/nirsevimab-significantly-protected-infants-against-rsv-disease-in-phase-iii-melody-trial--sanofi--astrazeneca/2022-03-04T17:55:26+00:00weekly0.6https://www.medthority.com/news/2022/3/health-canada-approval-for-brukinsa--in-relapsed-or-refractory-marginal-zone-lymphoma.--beigene2022-03-04T17:54:05+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-phase-iii-data-analysis-for-ampion-targeting-severe-osteoarthritis-of-the-knee--ampio/2022-03-04T17:53:25+00:00weekly0.6https://www.medthority.com/news/2022/3/medtronic-introduces-nuvent-balloon-to-treat-eustachian-tube-dysfunction/2022-03-04T17:49:00+00:00weekly0.6https://www.medthority.com/news/2022/3/reach-a-phase-iii-clinical-trial-of-losmapimod-is-initiated-in-facioscapulohumeral-muscular-dystrophy.---fulcrum-therapeutics2022-03-04T17:48:13+00:00weekly0.6https://www.medthority.com/news/2022/3/biocon-biologics-to-acquire-viatris-biosimilars-assets-for-up-to-$3.335-billion-in-stock-and-cash2022-03-04T17:47:24+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-regulatory-update-on-selinexor-in-advanced-or-recurrent-endometrial-cancer.--karyopharm2022-03-04T17:46:33+00:00weekly0.6https://www.medthority.com/news/2022/3/roche-and-three-leading-research-institutions-combine-expertise-on-new-skyline-alzheimers-prevention-trial-of-gantenerumab/2022-03-04T17:45:54+00:00weekly0.6https://www.medthority.com/news/2022/3/submission-of-data-under-prior-assessment-consultation-procedure-in-japan-for-lecanemab-for-alzheimers-disease--eisai/2022-03-04T17:45:02+00:00weekly0.6https://www.medthority.com/news/2022/3/change-of-indication-for-g-lasta-for-the-mobilization-of-hematopoietic-stem-cells-into-peripheral-blood-in-allogeneic-blood-stem-cell-transplantation-in-japan.--kyowa-kirin2022-03-05T14:45:47+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-opdivo-with-chemotherapy-as-neoadjuvant-treatment-for-certain-adult-patients-with-resectable-non-small-cell-lung-cancer.-bms2022-03-08T07:36:23+00:00weekly0.6https://www.medthority.com/news/2022/3/update-on-phase-iii-trial-of-cp-101-in-recurrent-c.-difficile-infection.-finch-therapeutics-group2022-03-06T14:08:15+00:00weekly0.6https://www.medthority.com/news/news-trends/migraine/selecting-migraine-treatments-for-your-patient/2026-01-26T16:11:52+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-bla-for-releuko-biosimilar-to-neupogen.--amneal-pharma2022-03-07T11:00:20+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-data-for-poziotinib-in-first-line-nsclc-patients-with-her2-exon-20-insertion-mutations.-spectrum-pharma2022-03-08T13:11:58+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-tropics-02-study-met-the-primary-endpoint-of-progression-free-survival-in-late-line-hrher2--metastatic-breast-cancer.--gilead-sciences2022-03-08T13:10:23+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-reopen1-trial-of-xhance-meets-co-primary-endpoints-in-chronic-sinusitis.--optinose-2022-03-08T13:05:04+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-naloxone-auto-injector-10-mg-for-the-treatment-of-known-or-potential-exposure-to-ultra-potent-weaponized-opioids.--kaleo2022-03-08T13:01:00+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-grants-priority-review-of-the--sbla-for-the-concomitant-use-of-krystexxa--methotrexate-for-people-living-with-uncontrolled-gout--horizon-therapeutics/2022-03-08T12:57:20+00:00weekly0.6https://www.medthority.com/news/2022/3/initiation-of-kvd-900-phase-iii-konfident-clinical-trial-of-oral-treatment-for-hereditary-angioedema--attacks.--kalvista-pharma2022-03-08T12:55:11+00:00weekly0.6https://www.medthority.com/news/2022/3/publication-of-data-from-phase-ii-study-of-fostamatinib-for-the-treatment-of-warm-antibody-autoimmune-hemolytic-anemia-in-the-american-journal-of-hematology.--rigel-pharma2022-03-09T14:28:29+00:00weekly0.6https://www.medthority.com/news/2022/3/jardiance-becomes-the-first-and-only-approved-treatment-in-europe-for-adults-with-symptomatic-chronic-heart-failure-regardless-of-ejection-fraction.-boehringer--eli-lilly2022-03-09T14:27:39+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-tropics-02-study-of-trodelvy-meets-primary-endpoint-in-hrher2--metastatic-breast-cancer.--gilead-sciences2022-03-09T14:26:49+00:00weekly0.6https://www.medthority.com/news/2022/3/daxi-bla-refiled-with-fda-for-glabellar-lines-after-complete-response.--revance-therapeutics2022-03-09T14:25:43+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-study-of-vla-1553-completed-and-meets-endpoints-in-chikungunya-fever.--valneva-se-2022-03-09T14:24:52+00:00weekly0.6https://www.medthority.com/news/2022/3/additional-findings-based-on-review-of-brilacidin-phase-ii-covid-19-trial-results.--innovation-pharma-2022-03-09T14:23:59+00:00weekly0.6https://www.medthority.com/news/2022/3/efanesoctocog-alfa-met-primary-and-key-secondary-endpoints-in-pivotal-study-in-haemophilia-a-showing-superiority-to-prior-factor-prophylaxis-treatment--sobi--sanofi/2022-03-10T13:25:46+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-skylight-4-trial-of-esn-364-meets-the-primary-endpoint-in-menopause-symptoms.--astellas-pharma--2022-03-10T13:24:48+00:00weekly0.6https://www.medthority.com/news/2022/3/bayer-submits-applications-in-the-u.s.-and-eu-for-additional-indication-of-nubeqa-for-metastatic-hormone-sensitive-prostate-cancer2022-03-10T13:24:02+00:00weekly0.6https://www.medthority.com/news/2022/3/key-data-demonstrating-the-potential-of-imlifidase-to-significantly-alter-course-of-anti-gbm-disease-published-in-jasn.--hansa-biopharma-ab2022-03-10T13:23:21+00:00weekly0.6https://www.medthority.com/news/2022/3/abbvie-resolves-humira-u.s.-patent-litigation-with-alvotech2022-03-10T13:22:20+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iiiii-study-of-novel-covid-19-oral-treatment-paxlovid-is-initiated-in-pediatric-participants.--pfizer2022-03-10T13:21:24+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-phase-iii-progress-trial-of-atogepant-positive-for-the-preventive-treatment-of-chronic-migraine.-abbvie2022-03-11T13:22:41+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-monaleesa-2-trial-for-kisqali-in-hrher2--breast-cancer-published-in-nejm.--novartis2022-03-11T13:00:55+00:00weekly0.6https://www.medthority.com/news/2022/3/application-submitted-to-mhlw-for-additional-indication-of-nubeqa-in-japan.--bayer2022-03-11T12:59:38+00:00weekly0.6https://www.medthority.com/news/2022/3/nmpa-china-conditionally-approves-tislelizumab-for-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-solid-tumours.--beigene2022-03-12T13:12:41+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-study-of-cefepime-taniborbactam-meets-the-primary-efficacy-endpoint-in-urinary-tract-infections.--venatorx-pharma2022-03-12T13:11:35+00:00weekly0.6https://www.medthority.com/news/2022/3/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.--astrazeneca--merck-inc2022-03-12T13:10:44+00:00weekly0.6https://www.medthority.com/news/2022/3/novan-to-acquire-dermatology-company-epi-health/2022-03-12T13:09:53+00:00weekly0.6https://www.medthority.com/news/2022/3/august-4-2022--is-pdufa-date-for-resubmitted-snda-for-nuplazid--for-the-treatment-of-alzheimers-disease-psychosis.--acadia-pharma2022-03-13T13:37:04+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-bracanalysis-cdx-test-as-companion-diagnostic-for-lynparza-for-breast-cancer.--myriad-genetics2022-03-13T13:35:47+00:00weekly0.6https://www.medthority.com/news/2022/3/farxiga-is-recommended-by-nice-uk-to-treat-chronic-kidney-disease.--astrazeneca2022-03-13T13:34:34+00:00weekly0.6https://www.medthority.com/news/2022/3/nice-uk-positive-for-jardiance-for-treating-chronic-heart-failure-with-reduced-ejection-fraction.--eli-lilly--boehringer2022-03-13T13:33:32+00:00weekly0.6https://www.medthority.com/news/2022/3/wakix-is-not-nice-recommended--to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adults-with-obstructive-sleep-apnoea.--bioproject-pharma2022-03-13T13:32:30+00:00weekly0.6https://www.medthority.com/news/2022/3/novartis-data-again-demonstrate-age-appropriate-development-when-zolgensma-is-used-presymptomatically-and-post-hoc-data-reveal-sma-type-1-patients-could-speak-swallow-and-maintain-airway-protection/2022-03-14T13:57:04+00:00weekly0.6https://www.medthority.com/news/2022/3/mhra-uk-approves-kerendia-to-treat-chronic-kidney-disease-associated-with-type-2-diabetes-in-adults.--bayer2022-03-14T13:56:07+00:00weekly0.6https://www.medthority.com/news/2022/3/empagliflozin-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-empulse-phase-iii-trial.-boehringer--eli-lilly2022-03-02T11:29:35+00:00weekly0.6https://www.medthority.com/news/2022/3/complete-response-letter-from-fda-for-investigational-lenacapavir-due-to-vial-compatibility-issues.--gilead-sciences-inc2022-03-02T11:21:17+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-carvykti-to-treat-rr-multiple-myeloma-following-four-lines-of-therapy.--janssen-pharma2022-03-02T11:15:02+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-accepts-snda-for-oxlumo-for-the-treatment-of-advanced-primary-hyperoxaluria-type-1.--alnylam-pharma2022-03-02T11:11:35+00:00weekly0.6https://www.medthority.com/news/2022/3/filing-of-patent-infringement-suit--by-ono-pharma-against-astrazeneca-k.k.-relating-to-imfinzi.-2025-01-31T12:00:19+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-accelerated-approval-of-vonjo--for-the-treatment-of-adult-patients-with-myelofibrosis-and-thrombocytopenia.--cti-biopharma-corp2022-03-02T11:03:25+00:00weekly0.6https://www.medthority.com/news/2022/3/complete-response-letter-for-fasenra--sbla-to-treat-chronic-rhinosinusitis-with-nasal-polyps.-astrazeneca.-2022-03-15T11:51:06+00:00weekly0.6https://www.medthority.com/news/2022/3/bms-and-nektar-announce-update-on-phase-iii-pivot-io-001-trial-of-bempegaldesleukin--opdivo--in-previously-untreated-unresectable-or-metastatic-melanoma/2022-03-15T11:50:12+00:00weekly0.6https://www.medthority.com/news/2022/3/xpovio-approved-by-tga-australia-to-treat-multiple-myeloma.--antengene-corporation2022-03-15T11:49:23+00:00weekly0.6https://www.medthority.com/news/2022/3/oral-edaravone-is-filed-in-japan-to-treat-amyotropic-lateral-sclerosis.--mitsubishi-tanabe2022-03-17T14:08:35+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-pathway-trial-of-transcon-pth-in-adults-with-hypoparathyroidism-met-primary-and-all-key-secondary-endpoints.--ascendis-as2022-03-17T14:07:28+00:00weekly0.6https://www.medthority.com/news/2022/3/keylynk-010-trial-evaluating-keytruda--lynparza-in--metastatic-castration-resistant-prostate-cancer-to-stop-for-futility.--merck-inc.--astrazeneca2022-03-17T14:06:35+00:00weekly0.6https://www.medthority.com/news/2022/3/update-on-phase-ii-study-evaluating-amcenestrant-in-erher2--advanced-or-metastatic-breast-cancer.--sanofi2022-03-17T14:05:39+00:00weekly0.6https://www.medthority.com/news/2022/3/jardiance-phase-iii-empa-kidney-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease.--boehringer--eli-lilly2022-03-17T14:03:33+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-extends-review-period-for-imcrivree-to-treat-patients--with-bardet-biedl-syndrome-or-alstrom-syndrome.--rhythm-pharmaceuticals2022-03-17T14:02:39+00:00weekly0.6https://www.medthority.com/news/2022/3/vonoprazan-filed-with-fda-for-erosive-oesophagitis.--phathom-pharma2022-03-17T14:02:03+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-trials-of-aduhelm-show-benefits-in-alzheimers-disease-pathology-at-week-132.--biogen-2022-03-17T13:58:40+00:00weekly0.6https://www.medthority.com/news/2022/3/olympia-phase-iii-trial-of-lynparza-shows-improvement-in-os-in-her2--breast-cancer.--astrazeneca2022-03-17T13:53:30+00:00weekly0.6https://www.medthority.com/news/2022/3/rinvoq-is-filed-in-japan-to-treat-non-radiographic-axial-spondyloarthritis-.--abbvie2022-03-17T13:50:38+00:00weekly0.6https://www.medthority.com/news/2022/3/astrazeneca-reaches-settlement-agreement-resolving-patent-litigation-related-to-ultomiris/2022-03-18T11:00:10+00:00weekly0.6https://www.medthority.com/news/2022/3/mhra-uk-approves-evusheld-to-prevent-covid-19.-astrazeneca2022-03-18T11:00:12+00:00weekly0.6https://www.medthority.com/news/2022/3/nice-uk-recommends-dostarlimib-for-use-in-the-cancer-drugs-fund-to-treat-endometrial-cancer-with-high-microsatellite-instability-or-mismatch-repair-deficiency.--gsk2022-03-18T11:00:12+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-derby-and-oaks-studies-of-empaveli-show-favourable-safety-profile-in-geographic-atrophy.--apellis-pharma2022-03-18T12:52:38+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-rinvoq-for-ulcerative-colitis.--abbvie2022-03-18T12:51:20+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-keynote-091-trial-of-keytruda-improved-survival-in-non-small-cell-lung-cancer.--merck-inc2022-03-18T12:50:32+00:00weekly0.6https://www.medthority.com/news/2022/3/publication-in-nejm-of-one-year-results-from-phase-iii-pivotal-trial-with-valoctocogese-roxaparvovec-gene-therapy-in-severe-hemophilia-a.--biomarin2022-03-18T12:49:33+00:00weekly0.6https://www.medthority.com/news/2022/3/moderna-requests-amendment-to-the-emergency-use-authorization-for-an-additional-booster-dose-of-its-covid-19-vaccine-in-the-u.s2022-03-18T12:46:02+00:00weekly0.6https://www.medthority.com/news/2022/3/pfizer-and-biontech-submit-for-u.s.-emergency-use-authorization-of-an-additional-booster-dose-of-their-covid-19-vaccine-for-older-adults2022-03-19T17:30:49+00:00weekly0.6https://www.medthority.com/news/2022/3/nmpa-china-approves-gamifant-for--primary-haemophagocytic-lymphohistiocytosis--sobi-/2022-03-19T17:29:03+00:00weekly0.6https://www.medthority.com/news/2022/3/application-is-submitted-in-the-eu--to-extend-the-indication-of-finerenone-to-include-early-stages-of-ckd-associated-with-type-2-diabetes--bayer/2022-03-19T17:27:46+00:00weekly0.6https://www.medthority.com/news/2022/3/health-canada-approves-spikevax-in-covid-19-for-children-age-6-11.--moderna2022-03-19T17:26:42+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-first-lag-3-blocking-antibody-combination-opdualag-nivolumab-and-relatlimab-rmbw-as-treatment-for-unresectable-or-metastatic-melanoma.-bms2022-03-19T17:24:58+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-ztalmy-for-cyclin-dependent-kinase-like-5-deficiency-disorder.--marinus-pharma2022-03-20T11:36:18+00:00weekly0.6https://www.medthority.com/news/2022/3/final-results-for-sp-102-from-its-pivotal-phase-iii-clinical-trial-program-for-sciatica-pain-management.--scilexsorrento-therapeutics2022-03-20T11:35:07+00:00weekly0.6https://www.medthority.com/news/2022/3/single-dose-peginterferon-lambda-for-covid-19-reduced-risk-of-hospitalization-or-er-visits-by-50--in-phase-iii-together-study.--eiger-biopharma2022-03-20T11:30:49+00:00weekly0.6https://www.medthority.com/news/2022/3/accruferferaccru-filed-in-canada-to-treat-to-treat-iron-deficiency-anaemia-.-shield-therapeutics--kye-pharma2022-03-22T12:13:04+00:00weekly0.6https://www.medthority.com/news/2022/3/nda-filed-for-sparsentan-for-the-treatment-of-iga-nephropathy.-travere-therapeutics2022-03-22T12:09:14+00:00weekly0.6https://www.medthority.com/news/2022/3/heartinsight-a-remote-heart-failure-hf-management-solution-received-ce-mark.--biotronik2022-03-22T12:07:34+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-bright-trial-of-prx-102-shows-drug-well-tolerated-in-fabry-disease.--biotherapeutics-and-chiesi2022-03-22T12:05:08+00:00weekly0.6https://www.medthority.com/news/2022/3/recro-announces-name-change-to-societal-cdmo-to-reflect-corporate-expansion-and-transformation/2022-03-22T12:00:42+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-results-from-phase-iii-prime-study-of-zejula-at-society-of-gynecologic-oncology-meeting.-zai-lab--gsk2025-01-31T11:59:33+00:00weekly0.6https://www.medthority.com/news/2022/3/systematic-review-and-meta-analysis-of-real-world-observational-studies-provide-additional-evidence-of-effectiveness-of-prevymis-in-preventing-cytomegalovirus-infection-and-disease-in-adults-undergoing-allogeneic-hct.--merck-inc2022-03-23T12:56:21+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-adapt-sc-of-subcutaneous-efgartigimod-meets-primary-endpoint-in-myasthenia-gravis.--argenx-se2022-03-23T12:49:34+00:00weekly0.6https://www.medthority.com/news/2022/3/uk-mhra-grants-conditional-approval-for-exkivity-in-egfr-exon20ins-nsclc.--takeda2025-01-31T11:59:05+00:00weekly0.6https://www.medthority.com/news/2022/3/uk-nice-recommends-use-of-vimizim-in-mucopolysaccharidosis-type-4a.--biomarin2022-03-23T12:43:09+00:00weekly0.6https://www.medthority.com/news/2022/3/libtayo-filed-in-japan-to-treat-patients-with-cervical-cancer.--sanofi2025-01-31T11:59:18+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-keytruda-for-patients-with-msi-hdmmr-advanced-endometrial-carcinoma-who-have-disease-progression-following-prior-systemic-therapy.--merck-inc2022-03-23T12:36:32+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approval-of-adalarity-transdermal-system-for-treatment-of-patients-with-alzheimers-disease.--corium-inc2022-03-23T12:32:47+00:00weekly0.6https://www.medthority.com/news/2022/3/latest-findings-on-lecanemab--clinical-efficacy-aria-rates-biomarkers-relationship-to-clinical-outcomes-and-dosing-regimens-presented-at-adpd-annual-meeting.--eisai--biogen-2022-03-23T12:29:10+00:00weekly0.6https://www.medthority.com/news/2022/3/nmpa-china-approval-of-gavreto--for-the-treatment-of-advanced-or-metastatic-ret-mutant-medullary-thyroid-cancer-and-ret-fusion-positive-thyroid-cancer.--cstone-pharma2022-03-25T13:59:50+00:00weekly0.6https://www.medthority.com/news/2022/3/approval-of-zynrelef-by-health-canada-for-the-management-of-postoperative-pain.--heron-therapeutics2022-03-25T13:58:52+00:00weekly0.6https://www.medthority.com/news/2022/3/covid-19-vaccine-phase-iiiii-kidcove-trial-in-children-6-months-to-under-6-years-has-successfully-met-its-endpoint.--moderna2022-03-25T13:57:39+00:00weekly0.6https://www.medthority.com/news/2022/3/health-canada-authorizes-spikevax-covid-19-vaccine-in-children-6-11-years.-moderna-inc2022-03-25T13:56:39+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-study-of-apd-334-meets-primary-endpoint-in-ulcerative-colitis.--pfizer2022-03-25T13:55:43+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-pivotal-innovate-3-study-of-optune--paclitaxel-given-approval-to-continue-by-idmc-in-ovarian-cancer.--novocure2022-03-25T13:54:46+00:00weekly0.6https://www.medthority.com/news/2022/3/pluvicto-approved-by-fda-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-psma-positive-metastatic-castration-resistant-prostate-cancer.--novartis2022-03-25T13:52:45+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-topline-phase-iii-data-from-adapt-sc-study-evaluating-subcutaneous-efgartigimod-for-generalized-myasthenia-gravis.--argenx-se2022-03-25T13:50:08+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-eu-chmp-opinion-for-keytruda-for-patients-with-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-tumors-in-five-different-types-of-cancer.-merck-inc2022-03-26T14:41:56+00:00weekly0.6https://www.medthority.com/news/2022/3/eu-chmp-recommends-approval-of-kymriah-for-relapsed-or-refractory--follicular-lymphoma.--novartis2022-03-26T14:40:53+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-extends-the-pdufa-date-for-sbla-of-reblozyl-in-beta-thalassemia.--bms2022-03-26T14:39:38+00:00weekly0.6https://www.medthority.com/news/2022/3/eu-chmp-recommends-approval-of-cabometyx-for-differentiated-thyroid-carcinoma.--exelixixipsen2022-03-26T14:38:24+00:00weekly0.6https://www.medthority.com/news/2022/3/eu-chmp-recommends-approval-of-cilta-cel-for-multiple-myeloma.--janssen-pharma2022-03-26T14:36:37+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-ecztend-long-term-study-of-adbry-shows-consistency-with-other-studies-in-atopic-dermatitis.--leo-pharma2022-03-26T14:30:39+00:00weekly0.6https://www.medthority.com/news/2022/3/chmp-recommends-approval-of-jakavi-for-acute-graft-versus-host-disease-or-chronic-graft-versus-host-disease.--incyte2022-03-26T14:29:24+00:00weekly0.6https://www.medthority.com/news/2022/3/chmp-recommends-keytruda--chemotherapy-to-treat-metastatic-cervical-cancer.-merck-inc2022-03-27T11:45:36+00:00weekly0.6https://www.medthority.com/news/2022/3/chmp-recommends-eu-approval-of--polivy-combination-mabthera--r-chp-for-previously-untreated-diffuse-large-b-cell-lymphoma.--roche2022-03-27T11:44:40+00:00weekly0.6https://www.medthority.com/news/2022/3/new-long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis-presented-at-the-2022-aad-annual-meeting.--ucb2022-03-27T11:43:28+00:00weekly0.6https://www.medthority.com/news/2022/3/chmp-recommends-camcevi-to-treat-hormone-dependent-prostate-cancer.--accord-biopharma2022-03-27T11:42:37+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-data-at-aad-2022-show-dupixent-significantly-improved-signs-and-symptoms-of-prurigo-nodularis--regeneron--sanofi/2022-03-27T11:41:38+00:00weekly0.6https://www.medthority.com/news/2022/3/pooled-analysis-extending-phase-iii-brave-aa1-and-brave-aa2-trials-of-olumiant-demonstrates-benefits-in-alopecia-areata-and-is-presented-at-aad-2022-and-published-in-nejm.--eli-lilly2022-03-27T11:40:39+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-true-v-trial-of-opzelura-showed-improvement-in-nonsegmental-vitiligo.--incyte2022-03-27T11:39:48+00:00weekly0.6https://www.medthority.com/news/2022/3/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-coverage-at-52-weeks-in-pivotal-phase-iii-studies.--eli-lilly2022-03-27T11:38:25+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-gem-3-study-of-b-vec-shows-continued-benefits-in-dystrophic-epidermolysis-bullosa.--krystal-biotech2022-03-28T11:22:47+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-accepts-snda-for--breyanzi-to-treat-large-b-cell-lymphoma.-bms-k.k2022-03-28T11:20:11+00:00weekly0.6https://www.medthority.com/news/2022/3/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-pre-exposure-prophylaxis-prevention-of-covid-19-in-a-broad-population.-astrazeneca.-2022-03-28T11:18:32+00:00weekly0.6https://www.medthority.com/news/2022/3/nice-recommends-atidarsagene-autotemcel-to-treat-metachromatic-leukodystrophy.-orchard-therapeutics2022-03-29T11:58:22+00:00weekly0.6https://www.medthority.com/news/2022/3/positive-results-from-lebrikizumab-monotherapy-in-the-advocate-program-to-treat-moderate-to-severe-atopic-dermatitis.--eli-lilly--almirall2022-03-29T11:55:51+00:00weekly0.6https://www.medthority.com/news/2022/3/nmpa-china-approves-gavreto-to-treat-metastatic-rearranged-ret-fusion-positive-nsclc.--cstone-pharma2022-03-29T11:53:25+00:00weekly0.6https://www.medthority.com/news/2022/3/regulatory-approval-of-dysval-for-the-treatment-of-tardive-dyskinesia-in-japan.-mitsubishi-tanabe--neurocrine-biosciences2022-03-29T11:50:46+00:00weekly0.6https://www.medthority.com/news/2022/3/jyseleca-approved-in-japan-for-ulcerative-colitis.---gilead--eisai--ea-pharmaeisai2022-03-29T11:48:28+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-regulatory-approval-for-mitchga-the-first-antibody-targeting-il-31-for-itching-associated-with-atopic-dermatitis.--maruho2022-03-29T11:43:53+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-approves-vabysmo-the-first-bispecific-antibody-in-ophthalmology-for-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema.--chugai2022-03-29T11:42:18+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-approves-takhzyro-to-prevent-acute-attacks-of-hereditary-angioedema.-takeda2022-03-29T11:39:14+00:00weekly0.6https://www.medthority.com/news/2022/3/ondexxya-approved-in-japan-for-patients-treated-with-the-factor-xa-inhibitors-apixaban-rivaroxaban-or-edoxaban-when-reversal-of-anticoagulation-is-needed.-astrazeneca2022-03-29T11:36:27+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-cosmic-312-trial-of-cabometyx-does-not-show-clear-benefits-in-liver-cancer.--exelixis2022-03-16T13:57:36+00:00weekly0.6https://www.medthority.com/news/2022/3/abbv-951-is-filed-in-japan-to-treat-parkinsons-disease.-abbvie2022-03-16T13:56:04+00:00weekly0.6https://www.medthority.com/news/2022/3/new-data-for-evrysdi-demonstrate-long-term-efficacy-and-safety-in-a-broad-population-of-people-with-spinal-muscular-atrophy.-genentechroche-2022-03-16T13:54:32+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-approves-xenpozyme-to-treat-non-cns-manifestations-of-acid-sphingomyelinase-deficiency--niemann-pick-disease--sanofi/2022-03-30T11:39:35+00:00weekly0.6https://www.medthority.com/news/2022/3/ema-validates-application-for-opdivo-with-chemotherapy-as-neoadjuvant-treatment-for-resectable-nsclc--bms/2022-03-30T11:36:10+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-fintepla-oral-solution-for-treatment-of-seizures-associated-with-lennox-gastaut-syndrome.--ucb2022-03-30T11:33:42+00:00weekly0.6https://www.medthority.com/news/2022/3/health-canada-approves-skyrizi-to-treat-psoriatic-arthritis.--abbvie2022-03-30T11:29:28+00:00weekly0.6https://www.medthority.com/news/2022/3/nmpachina-approves-ensartinib-to-treat-first-line-alk-positive-nsclc.--xcovery-holdings--betta-pharma-2022-03-30T11:26:00+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approval-for-emergency-use-authorization-of-second--booster-dose-of-covid-19-vaccine-mrna-1273.--moderna2022-03-30T11:23:12+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-revises-emergency-use-authorization-for-sotrovimab-due-to-omicron-ba.2-subvariant-of-covid-19.--gsk--vir-biotechnology2022-03-30T11:20:11+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-tlando-an-oral-testosterone-deficiency-treatment--antares-pharma/2022-03-30T11:16:59+00:00weekly0.6https://www.medthority.com/news/2022/3/eagle-pharmaceuticals-acquires-acacia-pharma-group/2022-03-30T11:15:02+00:00weekly0.6https://www.medthority.com/news/2022/4/request-to-expand-conditional-marketing-authorization-of-nuvaxovid--the-covid-19-vaccine-in-the-european-union-to-adolescents-ages-12-17--novavax/2022-04-01T11:38:54+00:00weekly0.6https://www.medthority.com/news/2022/4/supplemental-approval-from-pmda-japan-for-vonvendi-to-treat-von-willebrand-disease.-takeda2022-04-01T11:38:01+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-approves-triumeq-pd-formulation-for-pediatric-treatment-of-hiv-plus-a-supplemental-approval-for-triumeg.--viiv-healthcare2022-04-01T11:37:18+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-beovu-for-diabetic-macular-edema.--novartis2022-04-01T11:36:01+00:00weekly0.6https://www.medthority.com/news/2022/4/ons-5010-filed-with-fda-for-wet-age-related-macular-degeneration.--outlook-therapeutics2022-04-01T11:35:17+00:00weekly0.6https://www.medthority.com/news/2022/4/post-hoc-analysis-from-n-momentum-phase-iii-trial-of-uplizna-shows-effectiveness-in-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-04-01T11:34:20+00:00weekly0.6https://www.medthority.com/news/2022/4/update-on-fda-review-of-sbla-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-infants-and-children.--merck-inc2022-04-03T18:20:43+00:00weekly0.6https://www.medthority.com/news/2022/4/omburtamab-resubmitted-with-the-fda-for-cnsleptomeningeal-metastasis-from-neuroblastoma.--y-mabs-therapeutics2022-04-03T18:19:47+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-athena-mono-trial-of-rubraca-meets-primary-endpoint-in-ovarian-cancer.--clovis-oncology2022-04-03T18:18:55+00:00weekly0.6https://www.medthority.com/news/2022/4/data-from-new-voyager-pad-analyses-at-acc.22-reinforce-benefit-of-xarelto---aspirin-in-patients-with-peripheral-artery-disease-and-co-morbid-conditions.-janssen-pharma-companies2024-09-30T12:11:51+00:00weekly0.6https://www.medthority.com/news/2022/4/data-demonstrates-that-treatment-with-lagevrio-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo.--merck-inc.--ridgeback-biotherapeutics2022-04-03T18:17:01+00:00weekly0.6https://www.medthority.com/news/2022/4/yescarta-receives-fda-approval-as-first-car-t-cell-therapy-for-initial-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma-.--kitegilead-sciences2022-04-03T18:16:01+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-advisory-committee-meeting-on-amx-0035-for-the-treatment-of-als-gives-a-negative-decision.--amylyx-pharma2022-04-03T18:15:04+00:00weekly0.6https://www.medthority.com/news/2022/4/positive-top-line-results-from-yearlong-phase-iii-trial-of-etrasimod-in-ulcerative-colitis-underscoring-best-in-class-potential.---pfizer2022-04-03T18:14:00+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-scored-trial-of-zynquista-shows-improvements-in-patients-with-type-2-diabetes-and-chronic-kidney-disease.--lexicon-pharma2022-04-03T18:12:55+00:00weekly0.6https://www.medthority.com/news/2022/4/mavacamten-demonstrated-significant-reduction-in-need-for-septal-reduction-therapy-in-symptomatic-obstructive-hcm-patients-in-phase-iii-valor-trial--bms/2022-04-03T18:11:51+00:00weekly0.6https://www.medthority.com/news/2022/4/results-from-cohort-3-of-redwood-hcm-study-were-presented-at-american-college-of-cardiology-annual-scientific-session.--cytokinetics-inc.-2022-04-03T18:10:29+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-data-for-kinect-hd-study-evaluating-valbenazine-for-chorea-associated-with-huntington-disease-is-presented-at-aan-2022.--neurocrine-biosciences2022-04-03T18:09:19+00:00weekly0.6https://www.medthority.com/news/2022/4/draft-nice-guidance-does-not-recommend-piqray--fulvestrant-for-metastatic-breast-cancer-with-pik3ca-mutation.--novartis2022-04-04T12:07:23+00:00weekly0.6https://www.medthority.com/news/2022/4/alnylam-announces-3-month-extension-of-review-period-for-new-drug-application-for-vutrisiran-to-treat-attr-amyloidosis/2022-04-05T13:48:47+00:00weekly0.6https://www.medthority.com/news/2022/4/data-from-explorer-lte-demonstrates-sustained-improvements-in-cardiovascular-outcomes-at-weeks-48-and-84-with-mavacamten-in-symptomatic-obstructive-hypertrophic-cardiomyopathy-.--bms2022-04-05T13:49:52+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-accepts-sbla-for-dupixent-for-priority-review-in-eosinophilic-esophagitis.--regeneron-pharma2022-04-05T11:41:24+00:00weekly0.6https://www.medthority.com/news/2022/4/spyral-htn-on-med-trial-demonstrates-long-term-improvements-in-patients-using-symplicity-spyral-renal-denervation-system-for-hypertension.--medtronic2022-04-05T13:53:08+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-consonance-study-data-of-ocrevus-shows-benefits-in-1-year-analysis-with-multiple-sclerosis-patients.--genentechroche2025-01-31T11:58:51+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-accepts-sbla-for-actemra-and-grants-priority-review-in-hospitalised-covid-19-patients.--genentechroche2022-04-05T11:50:14+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-opdivo-as-adjuvant-treatment-for-urothelial-carcinoma.--bms2022-04-06T11:46:26+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-opdivo-plus-chemotherapy-for-oesophageal-squamous-cell-carcinoma.--bms2022-04-06T11:47:46+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-opdivo---yervoy-for-oesophageal-squamous-cell-carcinoma.--bms2022-04-06T11:49:03+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-breyanzi-for-diffuse-large-b-cell-lymphoma.--bms2022-04-06T11:50:57+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-kimmtrak-for-unresectable-or-metastatic-uveal-melanoma.--immunocore2022-04-06T11:54:27+00:00weekly0.6https://www.medthority.com/news/2022/4/sumitomo-dainippon-changes-its-name-to-sumitomo-pharma/2022-04-06T11:59:18+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-approval-for-sembrix-the-first-drug-for-chronic-myelogenous-leukemia-in-japan-that-has-a-new-mechanism-of-action-and-stamp-inhibitory-effect.-novartis2022-03-31T11:30:27+00:00weekly0.6https://www.medthority.com/news/2022/3/biogen-submits-study-protocol-for-confirmatory-phase-iv-envision-trial-of-aduhelm-to-treat-early-alzheimers-disease/2022-03-31T11:29:20+00:00weekly0.6https://www.medthority.com/news/2022/3/expanded-u.s.-emergency-use-authorization-for-an-additional-covid-19-vaccine-booster-in-individuals-aged-50-years-and-older.--pfizer--biontech2022-03-31T11:28:12+00:00weekly0.6https://www.medthority.com/news/2022/3/phase-iii-skyscraper-02-study-of-rg-6058--tecentriq-fails-to-meet-primary-endpoint-in-extensive-stage-small-cell-lung-cancer.--genentechroche2022-03-31T11:27:20+00:00weekly0.6https://www.medthority.com/news/2022/3/complete-response-for-vadadustat-to-treat-anemia-due-to-chronic-kidney-disease.--akebia-therapeutics2022-03-31T11:24:37+00:00weekly0.6https://www.medthority.com/news/2022/3/mhlw-japan-approves-kerendia-to-treat-chronic-kidney-disease-and-type-2-diabetes-excluding-patients-with-end-stage-renal-disease-or-on-dialysis.-bayer-healthcare2022-03-31T11:23:46+00:00weekly0.6https://www.medthority.com/news/2022/3/new-analysis-shows-that-kesimpta-treated-adults-with-relapsing-remitting-multiple-sclerosis-are-not-at-increased-risk-of-severe-covid-19-infections.--novartis2022-03-31T11:22:54+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-grants-accelerated-approval-for-vijoice-in-pik3ca-related-overgrowth-spectrum.--novartis2022-04-07T11:03:47+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-validates-filing-of-tislelizumab-in-non-small-cell-lung-cancer.--novartis2025-01-31T11:58:34+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-validates-filing-of-tislelizumab-in-oesophageal-squamous-cell-carcinoma.--novartis2022-04-07T11:16:04+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-rest-on-trial-of-ft218-in-narcolepsy-published-in-cns-drugs-journal.--avadel-pharma2022-04-07T11:21:31+00:00weekly0.6https://www.medthority.com/news/2022/4/sotrovimab-is-no-longer-authorised-to-treat-covid-19-in-any-us-region--gsk--vir-biotechnology/2022-04-07T11:22:53+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-approves-igalmi-for-agitation-associated-with-schizophrenia-or-bipolar-i-or-ii-disorder.--bioxcel-therapeutics2022-04-07T11:26:20+00:00weekly0.6https://www.medthority.com/news/2022/4/ultomiris-demonstrated-sustained-improvements-in-functional-activities-and-quality-of-life-with-generalised-myasthenia-gravis-through-60-weeks.--alexionastrazeneca2022-04-07T11:27:43+00:00weekly0.6https://www.medthority.com/news/2022/4/dupixent-approved-by-european-commission-for-children-aged-6-to-11-years-with-severe-asthma-with-type-2-inflammation--regeneron-sanofi/2022-04-08T11:11:50+00:00weekly0.6https://www.medthority.com/news/2022/4/update-from-type-c-meeting-with-fda--for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia--minerva-neurosciences/2022-04-08T11:19:02+00:00weekly0.6https://www.medthority.com/news/2022/4/nice-uk-reverses-decision-against-bavencio-to-treat-urothelial-carcinoma-bladder-cancer--merck-kgaa-and-pfizer/2022-04-08T11:20:58+00:00weekly0.6https://www.medthority.com/news/2022/4/long-term-breeze-safety-study-of-tyvaso-dpi-in-pulmonary-arterial-hypertension-published-in--pulmonary-circulation-journal.--united-therapeutics2022-04-08T11:23:19+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-trial-of-iontak-shows-consistent-results-to-previously-marketed-form-in-cutaneous-t-cell-lymphoma.--citius-pharmaceuticals2022-04-08T11:26:33+00:00weekly0.6https://www.medthority.com/news/2022/4/pfizer-to-acquire-reviral-ltd-and-promising-candidates-for-respiratory-syncytial-virus/2022-04-08T11:27:55+00:00weekly0.6https://www.medthority.com/news/2022/4/jardiance-now-approved-by-pmda-in-japan-for-use-in-patients-with-chronic-heart-failure-with-preserved-ejection-fraction-hfpef--nippon-boehringer--eli-lilly/2022-04-09T11:59:57+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-crown-trial-of-lorbrena-shows-continued-benefit-at-3-years-in-non-small-cell-lung-cancer.--pfizer2022-04-09T11:58:46+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-jupiter-02-trial-of-tuoyi-shows-improved-pfs-in-nasopharyngeal-carcinoma.--shanghai-junshi-biosciences-and-coherus-biosciences2022-04-09T11:55:34+00:00weekly0.6https://www.medthority.com/news/2022/4/seagen-announces-jury-award-in-patent-infringement-case-concerning-enhertu-against-daiichi-sankyo/2022-04-10T12:40:30+00:00weekly0.6https://www.medthority.com/news/2022/4/vortioxetine-demonstrates-advantage-on-daily-and-social-functioning-vs.-desvenlafaxine-in-a-large-head-to-head-vivre-study.--lundbeck-as2025-01-31T11:57:58+00:00weekly0.6https://www.medthority.com/news/2022/4/brukinsa-demonstrates-superior-overall-response-rate-versus-ibrutinib-in-final-response-analysis-of-alpine-trial-in-chronic-lymphocytic-leukemia.-beigene2022-04-12T11:34:41+00:00weekly0.6https://www.medthority.com/news/2022/4/positive-topline-phase-iii-results-evaluating-investigational-twice-daily-administration-of-vuity-in-adults-with-age-related-blurry-near-vision-presbyopia.--allerganabbvie2022-04-12T11:28:54+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-accepts-bla-resubmission-for-eflapegrastim-to-treat-febrile-neutropenia.--spectrum-pharma2022-04-12T11:24:52+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-checkmate--816-trial-of-neoadjuvant-treatment-opdivo-shows-benefits-in-non-small-cell-lung-cancer.--bms2025-01-31T11:58:18+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-covid-19-trial-evaluating-oral-veru-111-halted-early-by-idsm-for-efficacy-in-covid-19-ards.--veru2022-04-12T11:14:52+00:00weekly0.6https://www.medthority.com/news/2022/4/nmpa-china-approval-of-pemazyre-for-the-treatment-of-adults-with-locally-advanced-or-metastatic-cholangiocarcinoma.--incyte--innovent-biologics2022-04-12T11:09:32+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-adhere-trial-of-rg-3637-shows-improvement-in-atopic-dermatitis-at-16-weeks.--eli-lilly2022-04-12T11:06:56+00:00weekly0.6https://www.medthority.com/news/2022/4/update-on-snda-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis.--myovant-sciences---pfizer2022-04-13T11:46:39+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-shp643-301-study-of-takhzyro-meets-objectives-in-hereditary-angioedema.--takeda2022-04-13T11:44:35+00:00weekly0.6https://www.medthority.com/news/2022/4/new-data-for-finerenone-on-the-risk-reduction-of-cardiovascular-and-renal-outcomes-in-patients-with-a-combination-of-atherosclerotic-cardiovascular-disease-chronic-kidney-disease-and-type-2-diabetes.--bayer2022-08-25T13:46:06+00:00weekly0.6https://www.medthority.com/news/2022/4/xareno-study-revealed-xarelto-was-associated-with-net-clinical-benefit-and-a-reduced-risk-of-kidney-failure-compared-to-vitamin-k-antagonists.--bayer2022-04-13T11:38:57+00:00weekly0.6https://www.medthority.com/news/2022/4/health-canada-approval-of-rybrevant-the-first-and-only-targeted-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.--janssen2025-01-31T11:56:59+00:00weekly0.6https://www.medthority.com/news/2022/4/lumakras-codebreak-100-study-shows-two-year-overall-survival-of-32.5-in-kras-g12c-mutated-nsclc.--amgen2025-01-31T11:57:23+00:00weekly0.6https://www.medthority.com/news/2022/4/tepotinib-is-recommended-by-nice-to-treat-advanced-non-small-cell-lung-cancer-with-metex14-skipping-alterations-in-adults.--merck-kgaa2022-04-15T15:49:31+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-extends-review-of-bla-for-regen-cov-casirivimab-and-imdevimab-for-treatment-and-prophylaxis-of-covid-19.-regeneron2022-04-15T15:48:11+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-activate-study-of-pyrukynd-in-pyruvate-kinase-deficiency-published-in-nejm.--agios-pharma2022-04-15T15:46:51+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-marigold-trial-of-ztalmy-in-cdkl5-deficiency-disorder--published-in-the-lancet-neurology.---marinus-pharma2022-04-15T15:45:01+00:00weekly0.6https://www.medthority.com/news/2022/4/update-on-clinical-development-program-for-bempegaldesleukin----opdivo.--bms--nektar2022-04-15T15:42:12+00:00weekly0.6https://www.medthority.com/news/2022/4/data-demonstrates-a-high-immune-response-following-a-booster-dose-of-the-pfizer-biontech-covid-19-vaccine-in-children-5-through-11-years-of-age.--pfizer--biontech2022-04-15T15:39:03+00:00weekly0.6https://www.medthority.com/news/2022/4/gsk-acquires-sierra-oncology-and-with-it-momelotinib-a-new-treatment-in-phase-iii-development-for-anemia/2022-04-15T15:36:34+00:00weekly0.6https://www.medthority.com/news/2022/4/nmpa-china-approves-tislelizumab-as-a-treatment-for-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma.-beigene2022-04-16T13:55:03+00:00weekly0.6https://www.medthority.com/news/2022/4/mhra-uk-approves-update-for-approval-of-the-moderna-covid-19-vaccine-spikevax-for-6-to-11-year-olds.--moderna2022-04-16T13:53:37+00:00weekly0.6https://www.medthority.com/news/2022/4/positive-topline-data-for-repotrectinib-across-all-ros1-positive-nsclc-cohorts-of-phase-1ii-trident-1-study.--turning-point-therapeutics2022-04-17T16:55:19+00:00weekly0.6https://www.medthority.com/news/2022/4/nmpa-china-approves-vitrakvi-to-treat-advanced-solid-tumors-that-harbour-a-ntrk-gene-fusion.-bayer2022-04-17T16:54:18+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-approves-alymsys-a-bevacizumab-biosimilar.--amneal-pharma2022-04-19T12:04:44+00:00weekly0.6https://www.medthority.com/news/2022/4/health-canada-approves-evusheld-for-pre-exposure-prophylaxis-of-covid-19-in-canada.-astrazeneca2022-04-18T13:21:45+00:00weekly0.6https://www.medthority.com/news/2022/4/tg-therapeutics-announces-voluntary-withdrawal-of-the-blasnda-for-ublituximab-and-ukoniq-combination-to-treat-patients-with-cll-and-sll/2022-04-19T12:02:23+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-grants-emergency-use-authorisation-for-inspectir-covid-19-breathalyzer.--insepct-ir-systems-llc2022-04-19T11:56:45+00:00weekly0.6https://www.medthority.com/news/2022/4/publication-of-real-world-data-from-a-retrospective-study-on-the-use-of-inomax-in-hospitalized-covid-19-patients-with-ards---mallinckrodt-plc/2022-04-19T11:54:46+00:00weekly0.6https://www.medthority.com/news/2022/4/positive-phase-iii-study-of-abp-654a-ustekinumab-biosimilar.-amgen2025-05-06T13:33:27+00:00weekly0.6https://www.medthority.com/news/2022/4/halozyme-therapeutics-acquires-antares-pharma/2022-04-19T11:44:05+00:00weekly0.6https://www.medthority.com/news/2022/3/update-on-calla-phase-iii-trial-of-concurrent-use-of-imfinzi-and-chemoradiotherapy-in-locally-advanced-cervical-cancer.-astrazeneca2022-03-25T13:49:15+00:00weekly0.6https://www.medthority.com/news/2022/3/uk-nice-recommends-opdivo-and-yervoy-for-use-within-the-nhs-in-renal-cell-carcinoma.--bms2022-03-25T13:48:26+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-provides-complete-response-to-filing-of-sintilimab-in-non-small-cell-lung-cancer.--eli-lilly2022-03-25T13:47:27+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-expanded-indication-for-smoflipid-lipid-injectable-emulsion-for-parenteral-nutrition.--fresenius-kabi2022-03-25T13:46:35+00:00weekly0.6https://www.medthority.com/news/2022/3/fda-approves-label-update-for-cabenuva-in-hiv-treatment.--viiv-healthcare2022-03-25T12:38:51+00:00weekly0.6https://www.medthority.com/news/2022/3/evusheld-long-acting-antibody-combination-recommended--by-chmp-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-of-covid-19.--astrazeneca2022-03-25T12:36:30+00:00weekly0.6https://www.medthority.com/news/2022/4/safer-technologies-programmedical-devices-fda-designation-for-pear-010-to-treat-acute-and-chronic-pain.---pear-therapeutics2022-04-20T12:22:04+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-accepts-sbla-and-grants-priority-review-of-enhertu-to-treat-nsclc-with-her2-erbb2-mutation.-daiichi-sankyo-and-astrazeneca2025-01-31T11:56:24+00:00weekly0.6https://www.medthority.com/news/2022/4/updated-results-from-phase-iii-rationale-309-trial-of-pd-1-inhibitor-tislelizumab-in-first-line-rm-npcnasopharyngeal-cancer-in-virtual-asco-plenary-series.--beigene2022-04-20T12:06:22+00:00weekly0.6https://www.medthority.com/news/2022/4/clinical-update-on-bivalent-covid-19-booster-platform.--moderna-inc2022-04-20T11:30:03+00:00weekly0.6https://www.medthority.com/news/2022/4/mhlw-japan-approves-nuvaxovid-covid-19-vaccine-for-primary-and-booster-immunization-in-japan.--novavax-inc.--takeda2022-04-20T11:27:35+00:00weekly0.6https://www.medthority.com/news/2022/4/regeneron-to-acquire-checkmate-pharma-and-with-it-vidutolimod-a-tlr-9-agonist/2022-04-20T11:09:14+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-extends-the-pdufa-date-for-tenapanor-for-the-control-of-serum-phosphorus-in-patients-with-ckd-on-dialysis.-ardelyx-inc2024-10-24T14:22:04+00:00weekly0.6https://www.medthority.com/news/2021/5/farxiga-approved-in-the-us-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes.--astrazeneca2021-12-20T17:33:05+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-beovu-data-in-kestrel-and-kite-studies-show-potential-for-fluid-resolution-in-more-diabetic-macular-edema-patients-with-fewer-injections-versus-aflibercept.--novartis2024-11-07T15:42:49+00:00weekly0.6https://www.medthority.com/news/2021/5/reproxalap-ophthalmic-solution-achieves-statistical-significance-for-primary-and-all-secondary-endpoints-in-phase-iii-invigorate-clinical-trial-in-allergic-conjunctivitis----aldeyra-therapeutics/2024-11-12T09:39:22+00:00weekly0.6https://www.medthority.com/news/2021/5/update-on-tofersen-clinical-program-to-treat-als--biogen/2024-10-24T14:22:17+00:00weekly0.6https://www.medthority.com/news/2021/5/adverum-biotechnologies-provides-update-on-the-infinity-trial-evaluating-advm-022-in-patients-with-diabetic-macular-edema/2024-11-12T11:21:37+00:00weekly0.6https://www.medthority.com/news/2021/5/sandoz-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2024-11-07T15:37:40+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-issues-complete-response-letter-for-tralokinumab-for-thetreatment-of-adults-with-moderate-to-severe-atopic-dermatitis.--leo-pharma2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/cdsco-in-india-grants-emergency-use-approval-for-baricitinib--remdesivir-to-treat-covid-19.-natco2021-12-20T17:33:05+00:00weekly0.6https://www.medthority.com/news/2021/5/yondelis-approved-by-tga-in-australia-to-treat-unresectable-or-metastatic-liposarcoma-lps-or-leiomyosarcoma.--specialised-therapeutics2024-10-24T14:21:25+00:00weekly0.6https://www.medthority.com/news/2021/5/mhra-approves-ogluo-to-treat-severe-hypoglycaemia-in-patients-with-diabetes-mellitus.--xeris-pharma2024-10-24T14:20:16+00:00weekly0.6https://www.medthority.com/news/2021/5/apabetalone-demonstrates-a-positive-effect-on-major-cv-events-in-patients-with-chronic-kidney-disease.--resverlogix-corporation2024-11-12T11:00:44+00:00weekly0.6https://www.medthority.com/news/2021/5/merck-inc.at-organon-investor-day-outlines-the-vision-and-plans-for-the-new-company2024-11-12T14:12:29+00:00weekly0.6https://www.medthority.com/news/2021/5/european-commission-approves-benlysta-for-adult-patients-with-active-lupus-nephritis.--gsk2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-accepts-for-review-snda-for-otezla-to-treat-mild-to-moderate-plaque-psoriasis-patients-who-are-candidates-for-phototherapy-or-systemic-therapy.-amgen2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/versius-surgical-robot-begins-first-gynaecological-procedures-in-nhs-hospital.--cmr-surgical2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/adagio-therapeutics-announces-adg-20-phase-1-data-and-initiation-of-globalphase-iiiii-clinical-trial-of-adg-20-for-the-prevention-of-covid-19/2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/pfizer-and-biontech-receive-health-canada-authorization-of-covid-19-vaccine-in-adolescents/2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/amryt-to-acquire-chiasma-inc-and-with-it-mycapssa/2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-accepts-filing-and-grants-priority-review-for-keytruda--lenvima-in-renal-cell-carcinoma.--merck-inc--eisai2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-grants-priority-review-to-keytruda--lenvima-for-advanced-endometrial-carcinoma.--merck-inc--eisai2024-11-12T14:43:29+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-keytruda--herceptin-in-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma.--merck-inc2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/imfinzi--tremelimumab---chemotherapy-demonstrated-overall-survival-benefit-in-poseidon-trial-for-1st-line-stage-iv-non-small-cell-lung-cancer.--astrazeneca2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-advisory-committee-votes-on-recommending-ccx-168-for-approval-in-vasculitis.--chemocentryx-2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/ema-starts-rolling-review-of-vir-7831-in-covid-19.--gskvir-biotechnology2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-orarials-01-trial-of-arimoclomol-fails-to-meet-endpoints-in-amyotrophic-lateral-sclerosis.--orphazyme-2022-02-08T07:45:00+00:00weekly0.6https://www.medthority.com/news/2021/5/china-national-medical-products-administration-grants-conditional-approval-for-pamiparib-to-treat-gbrca-ovarian-cancer.--beigene2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/new-analysis-of-uplizna--for-neuromyelitis-optica-spectrum-disorder-is-published-in-neurology-neuroimmunology--neuroinflammation.--horizon-therapeutics2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/use-of-the-astrazeneca-covid-19-azd1222-vaccine-updated-joint-committee-on-vaccination-and-immunisation-uk-statement/2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/auris-medical-provides-update-on-bentrio-program-in-allergy/2024-11-12T14:14:13+00:00weekly0.6https://www.medthority.com/news/2021/5/broad-efficacy-and-improved-safety-profile-of-hybryte-presented-at-society-for-investigative-dermatology-virtual-meeting.--soligenix-inc2024-11-12T14:14:23+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-results-from-genesis-phase-iii-trial-of-motixafortide-in-stem-cell-mobilization-for-autologous-bone-marrow-transplantation-in-multiple-myeloma-.biolinerx-ltd2024-11-12T14:14:47+00:00weekly0.6https://www.medthority.com/news/2021/5/viiv-healthcare-initiates-rolling-submission-of-new-drug-application-with-fda-for-long-acting-cabotegravir-for-prevention-of-hiv/2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/-eli-lilly-accelerating-baricitinibs-availability-in-india-following--permission-for-restricted-emergency-use-as-a-covid-19-therapy/2022-02-08T07:44:59+00:00weekly0.6https://www.medthority.com/news/2021/5/aurinia-announces-publication-of-aurora-1-phase-iii-study-results-with-lupkynis-for-the-treatment-of-lupus-nephritis-in-the-lancet/2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/tezepelumab-bla-is-submitted-to-the-fda-to-treat-severe-asthma.-amgen--astrazeneca2024-11-12T14:15:01+00:00weekly0.6https://www.medthority.com/news/2021/5/cassava-sciences-announces-initiation-of-simufilam-in-patients-with-alzheimers-disease-in-a-phase-iii-cognition-maintenance-study.-2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approval-of-ferriprox-for-treatment-of-transfusional-iron-overload-due-to-sickle-cell--disease.--chiesi-global-rare-diseases2022-02-08T07:45:01+00:00weekly0.6https://www.medthority.com/news/2021/5/european-commission-grants--extended-approval-for-xtandi-to-treat-metastatic-castration-sensitive-prostate-cancer.--astellas2025-01-31T11:18:08+00:00weekly0.6https://www.medthority.com/news/2021/5/tecentriq-approved-by-european-commission-as-a-first-line-monotherapy-treatment-for-people-with-a-type-of-metastatic-nsclc.--roche2022-02-08T07:45:02+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-figaro-dkd-study-of-bay-94-8862-meets-primary-endpoint-in-patients-with-chronic-kidney-disease-and-type-2-diabetes.--bayer-healthcare-2022-02-08T07:45:02+00:00weekly0.6https://www.medthority.com/news/2021/5/debut-trial-of-buvidal-opioid-dependence-treatment-is-published-in-jama-open-network.--camurus-ab-2022-02-08T07:45:02+00:00weekly0.6https://www.medthority.com/news/2021/5/athenex-acquires-kuur-therapeutics-inc/2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/inovio-announces-positive-data-from-phase-ii-segment-of-clinical-trial-evaluating-ino-4800-its-covid-19-dna-vaccine/2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-expands-approval-of-comirnaty-for-young-people-with-covid-19.--pfizer-and-biontech2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/efficacy-0f-repatha-across-high-risk-patient-populations-reinforced-at-acc.212024-11-12T14:15:26+00:00weekly0.6https://www.medthority.com/news/2021/5/minerva-neurosciences-announces-the-results-of-the-phase-iii-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia-following--completion-of-the-40-week-open-label-extension/2024-11-12T14:15:36+00:00weekly0.6https://www.medthority.com/news/2021/5/biogen-exercises-option-to-acquire-tms-007-for-acute-ischemic-stroke-based-on-positive-phase-iia-data/2024-11-12T14:15:48+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-trial-of-libtayo-shows-benefits-in-efficacy-in-cervical-cancer.--regeneron-pharma2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/allerganabbvie-acquires-soliton-and-with-it-resonic-a-rapid-acoustic-pulse-device-for-treatment-of-tattoo-removal-and-cellulite/2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/merck-kgaa-out-licenses--m-1095-to-moonlake-immunotherapeutics-ag.-a-proposed-treatment-for-psoriasis2022-02-08T07:45:03+00:00weekly0.6https://www.medthority.com/news/2021/5/merck-inc.-announces-phase-iii-keynote-522-trial-met-dual-primary-endpoint-of-event-free-survival-efs-in-patients-with-high-risk-early-stage-triple-negative-breast-cancer2022-02-08T07:45:04+00:00weekly0.6https://www.medthority.com/news/2021/5/heron-therapeutics-announces-fda-approval-of-zynrelef-for-the-management-of-postoperative-pain-for-up-to-72-hours/2024-11-12T14:15:58+00:00weekly0.6https://www.medthority.com/news/2021/5/biogen-announces-topline-results-from-phase-iiiii-gene-therapy-study-of-biib-112-for-x-linked-retinitis-pigmentosa/2024-11-12T14:16:13+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-empaveli-to-treat-paroxysmal-nocturnal-hemoglobinuria.-apellis-pharmaceuticals2022-02-08T07:45:04+00:00weekly0.6https://www.medthority.com/news/2021/5/late-breaking-phase-iii-data-demonstrating-health-status-benefits-of-mavacamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy.--bms-2024-11-12T14:16:29+00:00weekly0.6https://www.medthority.com/news/2021/5/additional-analysis-of-phase-iii-arise-3-trial-of-rgn-259-shows-efficacy-in-dry-eye-disease.--regentree2022-02-08T07:45:04+00:00weekly0.6https://www.medthority.com/news/2021/5/reduce-it-hf-analyses-show-vascepa-driven-serum-epa-levels-that-suggest-potential-benefits-in-new-heart-failure---amarin-corp-/2024-11-12T14:17:11+00:00weekly0.6https://www.medthority.com/news/2021/5/data-from-phase-iii-senscis-on-study-of-ofev-shows-safety-profile-in-systemic-sclerosis-associated-interstitial-lung-disease.--boehringer2024-11-12T14:17:25+00:00weekly0.6https://www.medthority.com/news/2021/5/real-world-data-from-biosolve-iv-registry-confirms-long-term-safety-and-efficacy-of-magmaris-resorbable-magnesium-scaffold--biotronik/2024-09-30T14:02:15+00:00weekly0.6https://www.medthority.com/news/2021/5/eli-lilly-licenses-baricitinib-to---natco-pharma-for-covid-19-and-grants--six-voluntary-licence-agreements-with-indian-pharma-companies-for-the-drug.-2022-02-08T07:45:05+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-extends-review-of-avalglucosidase-alfa-next-generation-enzyme-replacement-therapy--for-pompe-disease-to-18-august-2021/2022-02-08T07:45:05+00:00weekly0.6https://www.medthority.com/news/2021/5/real-world-study-of-sapien-3-and-sapien-3-ultra-transcatheter-aortic-valve-replacement-shows-positive-outcomes-in-aortic-stenosis.--edwards-lifesciences2024-11-12T14:17:42+00:00weekly0.6https://www.medthority.com/news/2021/5/real-world-study-of-halaven-in-breast-cancer-published-in-advances-in-therapy.--eisai2024-11-12T14:17:56+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-accepts-filing-of-tyvyt--alimta-for-non-small-cell-lung-cancer.--innovent-biologics-and-eli-lilly2022-02-08T07:45:05+00:00weekly0.6https://www.medthority.com/news/2021/5/xarelto--aspirin-significantly-reduced-total-ischemic-events-in-peripheral-artery-disease-patients-after-lower-extremity-revascularization.--janssen-pharmaceutical-companies2024-11-12T14:21:00+00:00weekly0.6https://www.medthority.com/news/2021/5/aegis-h2h-study-results-published-in-inflammatory-bowel-diseases-demonstrates-long-term-effectiveness-of-ferric-maltol-compared-to-intravenous-iron.--shield-therapeutics-2024-11-12T14:21:07+00:00weekly0.6https://www.medthority.com/news/2021/5/medicago-and-gsk-announce-positive-interim-phase-ii-results-for-adjuvanted-covid-19-vaccine-candidate/2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/pivotal-phase-iii-impower010-study-data-show-tecentriq-helps-certain-people-with-early-lung-cancer-live-significantly-longer-without-their-disease-returning--genentechroche/2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/tirzepatide-achieves-all-primary-and-key-secondary-study-outcomes-against-insulin-glargine-in-adults-with-type-2-diabetes-and-increased-cardiovascular-risk-in-surpass-4-trial.--eli-lilly2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/merck-announces-positive-topline-results-from-pneu-direction-v114-027-and-pneu-plan-v114-024-phase-iii-pediatric-studies-for-v114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine/2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-opdivo-as-adjuvant-treatment-in-oesophageal-or-gastroesophageal-junction-cancer.--bms2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/incyte-announces-positive-results-from-phase-iii-true-v-program-evaluating-ruxolitinib-cream-in-patients-with-vitiligo/2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/early-use-of-anakinra-reduces-risk-of-mortality-for-patients-with-covid-19-pneumonia-reduces-icu-admission-and-increases-likelihood-of-full-recovery.--swedish-orphan-biovitrum2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan/2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/beigene-announces-fda-acceptance-and-priority-review-of-supplemental-nda-for-brukinsa--in-marginal-zone-lymphoma/2024-11-12T14:21:13+00:00weekly0.6https://www.medthority.com/news/2021/5/chmp-issues-positive-opinion-for-jardiance-for-the-treatment-of-adults-with-heart-failure-with-reduced-ejection-fraction.---boehringer--eli-lilly2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/chmp-recommends-approval-of-skysona-for-cerebral-adrenoleukodystrophy.--bluebird-bio2022-02-08T07:45:06+00:00weekly0.6https://www.medthority.com/news/2021/5/chmp-recommends-approval-of-klisyri-for-actinic-keratosis.--almirall2024-11-12T14:21:43+00:00weekly0.6https://www.medthority.com/news/2021/5/myovant-sciences-receives-positive-chmp-opinion-for-ryeqo-relugolix-combination-tablet-for-the-treatment-of-women-with-uterine-fibroids/2024-11-12T14:22:05+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-topline-results-from-phase-iii-trial-of-tislelizumab--chemotherapy-as-first-line-treatment-for-recurrent-or-metastatic-nasopharyngeal-cancer.---beigene2022-02-08T07:45:07+00:00weekly0.6https://www.medthority.com/news/2021/5/-chmp-opinion-recommends-opdivo---yervoy--for-treatment-of-mismatch-repair-deficient-or-microsatellite-instabilityhigh-metastatic-colorectal-cancer-after-prior-chemotherapy.--bms2024-11-12T14:22:16+00:00weekly0.6https://www.medthority.com/news/2021/5/rybrevant-receives-fda-accelerated-approval-as-the-first-targeted-treatment-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.--janssen--genmab-as2022-02-08T07:45:07+00:00weekly0.6https://www.medthority.com/news/2021/5/complete-trial-results-manuscript-of-novavax-covid-19-investigational-vaccine-posted-to-preprint-server-medrxiv/2022-02-08T07:45:07+00:00weekly0.6https://www.medthority.com/news/2021/5/aumolertinib-significantly-prolongs-progression-free-survival-pfs-with-fewer-side-effects-in--first-line-treatment--of-advanced-egfr-mutated-nsclc.-eqrx--hansoh-pharma-2022-02-08T07:45:07+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-opdivo-as-adjuvant-treatment-of-completely-resected-esophageal-or-gastroesophageal-junction-cancer-in-patients-who-have-received-neoadjuvant-chemoradiotherapy.--bms2022-02-08T07:45:07+00:00weekly0.6https://www.medthority.com/news/2021/5/lag-3-blocking-antibody-relatlimab-and-nivolumab-fixed-dose-combination-significantly-improves-progression-free-survival-vs.-opdivo-in-patients-with-previously-untreated-metastatic-or-unresectable-melanoma.--bms2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/omeros-announces-extension-for-fda-review-of-narsolimab-to-treat-hsct-tma/2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-ecospor-iii-study-of-ser-109-shows-efficacy-to-24-weeks-in-c.-difficile-infection.--seres-therapeutics2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-punch-cd3-trial-of-rbx-2660-meets-primary-endpoint-in-c.-difficile-infection.--ferring-pharmaceuticals-and-rebiotix2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/european-commission-approves-estelle-oral-contraceptive.--mithra2024-11-12T14:22:31+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-grants-priority-review-of-maribavir-to-treat-post-transplant-recipients-with-cytomegalovirus-infection-.--takeda2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/potential-impact-of-takedas-dengue-vaccine-candidate-tak-003-reinforced-by-long-term-safety-and-efficacy-results.--takeda2024-11-12T14:22:40+00:00weekly0.6https://www.medthority.com/news/2021/5/rhythm-pharmaceuticals-receives-positive-chmp-opinion-for-setmelanotide-for-treatment-of-obesity-and-control-of-hunger-associated-with-pomc-pcsk1-and-lepr-deficiency/2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/ngm-bio-reports-topline-results-from-24-week-phase-iib-alpine-23-study-of-aldafermin-in-nash/2022-02-08T07:45:08+00:00weekly0.6https://www.medthority.com/news/2021/5/chmp-recommends-ozawade-for-the-treatment-of-excessive-daytime-sleepiness-in-obstructive-sleep-apnoea.--bioproject-pharma2024-11-12T14:22:49+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-chmp-opinion-for-symptomatic-chronic-heart-failure-treatment-vericiguat.--bayer2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/albireo-receives-positive-chmp-opinion-for-bylvay-for-treatment-of-progressive-familial-intrahepatic-cholestasis-pfic/2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-chmp-opinion-for-keytruda--chemotherapy-as-first-line-treatment-for-esophageal-cancer-or-her2-negative-gastroesophageal-junction-adenocarcinoma.--merck-inc2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/libtayo-receives-positive-chmp-opinion-for-the-treatment-in-europe-of-two-advanced-cancers-namely-nsclc-and-basal-cell-carcinoma.-regeneron--sanofi-2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/moderna-announces-teencove-study-of-its-covid-19-vaccine--mrna-1273-in-adolescents-meets-primary-endpoint--/2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/myovant-sciences-and-pfizer-receive-fda-approval-for-myfembree-the-first-once-daily-treatment-for-heavy-menstrual-bleeding-associated-with-uterine-fibroids/2024-11-12T14:25:20+00:00weekly0.6https://www.medthority.com/news/2021/5/novartis-and-molecular-partners-announce-start-of-empathy-clinical-trial-for-ensovibep-for-the-treatment-of-covid-19/2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-top-line-results-from-the-phase-iii-prince-study-of-pegcetacoplan-in-treatment-naive-patients-with-paroxysmal-nocturnal-haemoglobinuria.-sobi--apellis2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/positive-topline-results-from-vision-1-phase-iii-study-of-microline-for-the-treatment-of-presbyopia.-eyenovia2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/european-commission-approval-for-venclyxto--a-hypomethylating-agent-for-newly-diagnosed-acute-myeloid-leukemia-.-abbvie---2024-11-12T14:22:59+00:00weekly0.6https://www.medthority.com/news/2021/5/the-lancet-publishes-results-from--phase-iii-program-evaluating-rinvoq--in-atopic-dermatitis.---abbvie2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/larotrectinib--to-treat-advanced-solid-tumors-that-display-a-neurotrophic-tyrosine-receptor-kinase-ntrk-gene-fusion-is-submitted-for-marketing-authorization-in-china.--bayer2024-11-12T13:25:41+00:00weekly0.6https://www.medthority.com/news/2021/5/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnologys-sotrovimab-for-the-early-treatment-of-covid-19/2022-02-08T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/5/horizon-therapeutics-plc-initiates-advance-trial-evaluating-krystexxa--with-methotrexate-for-people-who-previously-developed-anti-drug-antibodies-on-krystexxa-monotherapy/2024-11-12T14:25:29+00:00weekly0.6https://www.medthority.com/news/2021/5/sanofi-and-gsk-initiate-global-phase-iii-clinical-efficacy-study-of-covid-19-vaccine-candidate/2022-02-08T07:45:10+00:00weekly0.6https://www.medthority.com/news/2021/5/intercept-pharmaceuticals-inc.-announces-updates-to-ocaliva-prescribing-information-for-primary-biliary-cholangitis2022-02-08T07:45:10+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-zeposia-to-treat-moderately-to-severely-active-ulcerative-colitis.--bms2022-02-08T07:45:10+00:00weekly0.6https://www.medthority.com/news/2021/5/sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-fda-for-treatment-of-mild-to-moderate-covid-19-in-high-risk-adults-and-paediatric-patients.--gsk--vir-biotechnology-inc2022-02-08T07:45:10+00:00weekly0.6https://www.medthority.com/news/2021/5/tagrisso-approved-in-the-eu-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer.--astrazeneca2022-02-08T07:45:10+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-andromeda-study-of-subcutaneous-darzalex-shows-long-term-positive-response-in-light-chain-amyloidosis.--janssen-pharma2024-11-12T14:25:38+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-advisory-committee-recommends-approval-of-mga-031-for-type-1-diabetes.--provention-bio2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/phase-iii-gemstone-301-study-of-sugemalimab-meets-primary-endpoint-in-non-small-cell-lung-cancer.--cstone-pharma2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/european-commission-approves-ponvory--a-once-daily-oral-therapy-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis.janssen2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/mhra-approves-ad26.cov2-s-recombinant-for-active-immunisation-against-covid-19-within-the-united-kingdom---janssen2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-approves-lumakras-the-first-and-only-targeted-treatment-for-kras-g12c-mutated-locally-advanced-or-metastatic-nsclc.-amgen2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/long-term-erleada-patient-reported-outcomes-data-in-metastatic-castration-sensitive-prostate-cancer-shows--maintenance-of-health-related-quality-of-life-for-patients.--janssen-pharmaceutical-companies2025-01-31T11:41:58+00:00weekly0.6https://www.medthority.com/news/2021/5/janssen-presents-results-of-first-head-to-head-study-of-biologic-therapies-in-patients-with-moderate-to-severe-crohns-disease/2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-accepts-filing-of-palovarotene-for-fibrodysplasia-ossificans-progressiva.--ipsen2024-11-12T14:25:48+00:00weekly0.6https://www.medthority.com/news/2021/5/novartis-reports-one-year-results-of-phase-iii-merlin-study-evaluating-beovu-every-four-week-dosing-and-provides-update-on-beovu-clinical-program/2024-11-12T14:25:55+00:00weekly0.6https://www.medthority.com/news/2021/5/omeros-announces-preliminary-results-from-additionally-critically-ill-covid-19-patients-treated-with-narsoplimab/2022-02-08T07:45:11+00:00weekly0.6https://www.medthority.com/news/2021/5/eton-pharmaceuticals-receives-complete-response-letter-from-fda-for-dehydrated-alcohol-injection-for-the-treatment-of-methanol-poisoning/2024-11-12T14:26:08+00:00weekly0.6https://www.medthority.com/news/2021/5/lantheus-receives-fda-approval-of-pylarify-injection-the-first-and-only-commercially-available-psma-pet-imaging-agent-for-prostate-cancer/2024-11-12T14:26:20+00:00weekly0.6https://www.medthority.com/news/2021/5/nefecon-filed-with-ema-for-primary-iga-nephropathy.-calliditas-therapeutics2022-02-08T07:45:12+00:00weekly0.6https://www.medthority.com/news/2021/5/kb-003-filed-with-fda-requesting-eua-for-covid-19.--humanigen-2022-02-08T07:45:12+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-pylarify-the-first-and-only-commercially-available-psma-pet-imaging-agent-for-prostate-cancer--lantheus-holdings/2024-11-12T14:26:37+00:00weekly0.6https://www.medthority.com/news/2021/6/health-canada-approves-abecma-for-multiple-myeloma.--bms2022-02-08T07:45:12+00:00weekly0.6https://www.medthority.com/news/2021/6/cti-biopharma-announces-fda-acceptance-of-nda-granted-with-priority-review-of-pacritinib-for-treatment-of-patients-with-myelofibrosis/2024-11-12T14:26:46+00:00weekly0.6https://www.medthority.com/news/2021/6/zyesami-filed-with-fda-for-emergency-use-authorization-in-covid-19.--nrx-pharmaceuticals2022-02-08T07:45:12+00:00weekly0.6https://www.medthority.com/news/2021/6/vt-1161-filed-with-fda-for-vulvovaginal-candidiasis.--mycovia-pharmaceuticals2024-11-12T14:27:03+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-lybalvi-for-schizophrenia-and-bipolar-i-disorder.--alkermes2024-11-12T14:27:11+00:00weekly0.6https://www.medthority.com/news/2021/6/interim-analysis-of-the-phase-iii-alpine-trial-comparing-brukinsa-to-ibrutinib-in-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-to-be-reported-at-eha-2021-virtual-congress.-beigene2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/biogen-and-bio-thera-announce-positive-results-from-phase-iii-study-of-bat-1806-a-proposed-biosimilar-referencing-actemra-/2024-11-12T12:21:05+00:00weekly0.6https://www.medthority.com/news/2021/6/taltz-showed-consistent-long-term-improvement-in-key-signs-and-symptoms-of-axial-spondyloarthritis-through-two-years-in-phase-iii-study.--eli-lilly2024-11-12T14:27:25+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-presents-positive-phase-iii-results-from-junipera-study-supporting-cosentyx-as-a-potential-treatment-in-a-jia-population-at-eular-2021.--2024-11-12T14:27:39+00:00weekly0.6https://www.medthority.com/news/2021/6/anifrolumab-showed-benefit-across-different-measures-of-skin-and-joint-disease-activity-in-patients-with-systemic-lupus-erythematosus.--astrazeneca2024-11-12T14:27:49+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-cosentyx-receives-fda-approval-for-treatment-of-children-and-adolescents-with-moderate-to-severe-plaque-psoriasis/2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/olumiant-improved-pain-physical-function-and-morning-joint-stiffness-in-rheumatoid-arthritis-in-phase-iii-post-hoc-analyses.-eli-lilly2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/bausch-health-and-clearside--biomedical-announce-fda-re-filing-acceptance-for-xipere-to-treat-macular-edema-associated-with-uveitis.-2024-11-12T14:27:58+00:00weekly0.6https://www.medthority.com/news/2021/6/bms-receives-european-commission-approval-for-opdivo--yervoy--as-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma/2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-kisqali-reports-longest-median-overall-survival-in-postmenopausal-hrher2--metastatic-breast-cancer-patients/2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/amryt-announces-fda-acceptance-of--nda-for-oleogel-s10-for-the-treatment-of-epidermolysis-bullosa/2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/travere-therapeutics-completes-enrollment-in-pivotal-phase-iii-protect-study-of-sparsentan-in-iga-nephropathy/2022-02-08T07:45:13+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-fortify-study-of-skyrizi-meets-endpoints-in-crohns-disease.--abbvie2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-kymriah-pivotal-elara-trial-demonstrates-strong-response-rates-and-a-remarkable-safety-profile-in-relapsed-or-refractory-follicular-lymphoma/2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/ab-science-announces-a-voluntary-hold-on-the-clinical-studies-of-masitinib-worldwide/2024-11-12T14:28:07+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-grants-priority-review-for-nda-for-oleogel-s10-to-treat-epidermolysis-bullosa.--amryt2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/morphosys-will-acquire-constellation-pharma-and-with-it-cpi-0619-pelabresib-a-bet-inhibitor-and-cpi-0209-a-second-generation-ezh2-inhibitor/2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/scynexis-announces-fda-approval-of-brexafemme-as-the-first-and-only-oral-non-azole-treatment-for-vaginal-yeast-infections/2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/organon-launches-as-new-global-womens-health-company/2024-11-12T14:28:22+00:00weekly0.6https://www.medthority.com/news/2021/6/sanofi-provides-update-on-venglustat-clinical-program/2024-11-12T14:28:30+00:00weekly0.6https://www.medthority.com/news/2021/6/seagen-announces-long-term-results-from-tukysa-pivotal-trial-for-her2-positive-breast-cancer-during-the--2021-asco-annual-meeting/2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/fda--grants-accelerated-approval-for-truseltiq-to-treat-metastatic-cholangiocarcinoma-with-an-fgfr2-fusion---bridgebio-pharma-qed-therapeutics-and-helsinn-group.-2022-02-08T07:45:14+00:00weekly0.6https://www.medthority.com/news/2021/6/liminal-biosciences-provides-an-update-on-currently-planned-clinical-activities-for-fezagepras/2024-11-12T14:28:39+00:00weekly0.6https://www.medthority.com/news/2021/6/lynparza-reduced-the-risk-of-cancer-recurrence-by-42-in-the-adjuvant-treatment-of-patients-with-germline-brca-mutated-high-risk-early-breast-cancer-in-olympia-phase-iii-trial.-astrazeneca--merck-inc2022-02-08T07:45:15+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-reports-clinically-relevant-improvement-in-median-overall-survival-data-in-final-analysis-of-pivotal-netter-1-study-with-targeted-radioligand-therapy-lutathera/2024-11-12T14:28:48+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-177lu-psma-617-significantly-improves-overall-survival-and-radiographic-progression-free-survival-for-men-with-metastatic-castration-resistant-prostate-cancer-in-phase-iii-vision-study.-2024-11-12T14:29:13+00:00weekly0.6https://www.medthority.com/news/2021/6/long-term-data-from-pacific-phase-iii-trial-at-asco-showed-33-of-nsclc-patients-remained-progression-free-at-five-years.-astrazeneca2022-02-08T07:45:15+00:00weekly0.6https://www.medthority.com/news/2021/6/-eli-lilly-reveals-critical-barriers-to-optimal-migraine-care-and-insights-from-novel-clinical-and-patient-centric-real-world-evidence-supporting-lillys-preventive-and-acute-treatment-portfolio-at-ahs-2021/2022-02-08T07:45:15+00:00weekly0.6https://www.medthority.com/news/2021/6/selection-study-on-filgotinib-in-ulcerative-colitis-is-published-in-the-lancet.-galapagos-nv2022-02-08T07:45:15+00:00weekly0.6https://www.medthority.com/news/2021/6/keynote-564-evaluating-keytruda-is-the-first-phase-iii-study-to-show-positive-results-for-adjuvant-immunotherapy-in-renal-cellcarcinoma.--merck-inc2022-02-08T07:45:15+00:00weekly0.6https://www.medthority.com/news/2021/6/liminal-biosciences-announces-fda-approval-for-its-bla-of-ryplazim-to-treat-patients-with-plasminogen-deficiency-type-1/2024-11-12T14:29:23+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-investigational-checkpoint-inhibitor-tislelizumab-met-primary-endpoint-of-overall-survival-in-pivotal-phase-iii-trial-of-esophageal-cancer-after-systemic-therapy/2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/novartis-announces-tabrecta-first-published-overall-survival-and-updated-overall-response-data-in-patients-with-metex14-metastatic-nsclc/2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/results-from-phase-ii-codebreak-100-show-lumakras-is-the-first-and-only-kras-g12c-inhibitor-with-overall-survival-data-for-nsclc.-amgen2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/tecartus-demonstrates-high-response-rate-in-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia.--kitegilead2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/wegovy-semaglutide-2.4-mg-the-first-and-only-once-weekly-glp-1-therapy-for-weight-management-approved-in-the-us.-novo-nordisk2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/new-data-from-phase-iii-monarche-trial-for-verzenio-in-high-risk-early-breast-cancer-and-phase-ia-data-for-ly-3484356.--eli-lilly2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/trodelvy-demonstrates-superior-outcomes-to-standard-of-care-in-second-line-treatment-of-metastatic-triple-negative-breast-cancer-in-phase-iii-ascent-study--gilead-sciences/2022-02-08T07:45:16+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-trial-data-for-riavax-shows-extended-survival-in-pancreatic-cancer.--samsung-pharm-co2024-11-12T14:29:33+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-nuzyra-oral-only-dosing-regimen-for-the-treatment-of-community-acquired-bacterial-pneumonia-cabp.--paratek-pharma2024-11-12T14:31:31+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-tembexa-for-smallpox.--chimerix2024-11-12T14:31:22+00:00weekly0.6https://www.medthority.com/news/2021/6/calquence-demonstrated-fewer-incidences-of-atrial-fibrillation-versus-ibrutinib-in-previously-treated-patients-with-chronic-lymphocytic-leukaemia-and-sustained-patient-benefit-at-four-years-in-the-front-line-setting.-astrazeneca2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/european-commission-approves--opdivo---yervoy-as-first-line-treatment-for-unresectable-malignant-pleural-mesothelioma.--bms2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/new-data-on-lenvima--keytruda--versus-sunitinib-from-phase-iii-keynote-581-study-in-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma.-eisai--merck-inc.-2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iiib-open-label-study-of-onpattro-shows-benefit-in-hereditary-attr-amyloidosis.--alnylam-pharmaceuticals-2024-11-12T14:32:24+00:00weekly0.6https://www.medthority.com/news/2021/6/beigene-announces-acceptance-of-a-sbla-in-china-for-tislelizumab-in-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors/2024-11-12T14:32:38+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-grants-accelerated-approval-for-aduhelm-to-treat-alzheimers-disease.-biogen--eisai2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-ultomiris-for-children-and-adolescents-with-paroxysmal-nocturnal-hemoglobinuria.--alexion-pharmaceuticals2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/results-from-imbruvica-resonate-2-study-provide-up-to-seven-years-of-progression-free-and-overall-survival-data-in-first-line-chronic-lymphocytic-leukemia.-abbvie2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/aurinia-announces-additional-analysis-of-its-aurora-1-phase-iii-study-data--for-lupus-nephritis-presented-at-era-edta-2021-congress/2022-02-08T07:45:17+00:00weekly0.6https://www.medthority.com/news/2021/6/captivate-study-shows-an-imbruvica--venclexta-combination-has-potential-for-remission-in-cllsll-patients.--abbvie2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-prevnar-20-a-pneumococcal-20-valent-conjugate-vaccine-for-adults-aged-18-years-and-older.--pfizer2024-11-12T14:32:55+00:00weekly0.6https://www.medthority.com/news/2021/6/medtronic-stops-distribution-of-heartware-hvad-system-in-united-states/2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/incyte-announces-the-fda-has-extended-the-snda-review-period-for-ruxolitinib-in-chronic-graft-versus-host-disease-gvhd/2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approval-for-trikafta-in-children-with-cystic-fibrosis-ages-6-through-11-with-a-certain-mutation.--vertex2024-11-12T14:33:08+00:00weekly0.6https://www.medthority.com/news/2021/6/u.s.-government-commits-to-purchase-approximately-1.7-million-courses-of-molnupiravir-upon-issuance-of-emergency-use-authorization-or-approval-by-the-fda.--merck-inc2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/zimhi-resubmitted-nda-is-accepted-by--the-fda-for-the-treatment-of-opioid-overdose.-adamis-pharmaceuticals2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/sanofi-partnering-with-leading-academic-groups-to-study-amcenestrant-in-the-adjuvant-setting-for-patients-with-er-breast-cancer/2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-transform-study-of-breyanzi-meets-primary-endpoint-in-large-b-cell-lymphoma.--bms2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/genentech-announces-data-at-eha-2021-reinforcing-efficacy-of-venclexta-combinations-in-chronic-lymphocytic-leukemia-and-acute-myeloid-leukemia/2022-02-08T07:45:18+00:00weekly0.6https://www.medthority.com/news/2021/6/new-genentech-data-for-evrysdi-show-improved-motor-function-in-pre-symptomatic-babies-after-one-year-and-confirm-safety-profile-in-previously-treated-people-with-spinal-muscular-atrophy.-2024-11-12T14:33:26+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-new-formulation-of-epclusa-for-children-ages-3-and-older-with-hcv.--gilead-sciences-2024-11-12T14:33:50+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-delays-pdufa-action-date-for-jakavi-in-atopic-dermatitis.--incyte2022-02-08T07:45:19+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-cadenza-study-of-bivv-009-shows-safety-and-efficacy-in-cold-agglutinin-disease.--bioverativ-inc.sanofi2024-11-12T14:34:05+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves--vanta-a-recharge-free-implantable-neurostimulator--for-chronic-pain.--medtronic2024-11-12T14:34:16+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-glow-study-of-imbruvica--venclexta-meets-primary-endpoint-in-cllsll.--abbvie2022-02-08T07:45:19+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-maia-study-of-darzalex--revlimid--dexamethasone-shows-survival-benefits-in-multiple-myeloma.--janssen-biotech2022-02-08T07:45:19+00:00weekly0.6https://www.medthority.com/news/2021/6/cassiopeia-phase-iii-study-of-darzalex--velcade--thalomid--dexamthasone-shows-efficacy-in-multiple-myeloma.--genmab2022-02-08T07:45:19+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-sensight-directional-lead-system-used-for-deep-brain-stimulation-therapy--medtronic/2024-09-30T09:37:44+00:00weekly0.6https://www.medthority.com/news/2021/6/ema-approves-alluzience-for-glabellar-lines.--galderma2022-02-08T07:45:19+00:00weekly0.6https://www.medthority.com/news/2021/6/longer-term-data-for-yescarta-in-rr-follicular-lymphoma-demonstrates-substantial-survival-improvement-over-current-therapies-.--kitegilead-sciences2024-11-12T14:34:29+00:00weekly0.6https://www.medthority.com/news/2021/6/detailed-results-from-phase-iii-cosmic-311-pivotal-trial-of-cabozantinib-in-for-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer---ipsen--exelixis-inc/2024-11-12T14:34:38+00:00weekly0.6https://www.medthority.com/news/2021/6/new-data-from-public-health-england--demonstrated-covid-19-vaccine-astrazeneca-offers-high-levels-of-protection-against-the-delta-variant-b.1.617.2-formerly-the-indian-variant.-astrazeneca2022-02-08T07:45:20+00:00weekly0.6https://www.medthority.com/news/2021/6/update-on-storm-chaser-trial-assessing-azd-7442-in-post-exposure-prevention-of-symptomatic-covid-19.--astrazeneca2022-02-08T07:45:20+00:00weekly0.6https://www.medthority.com/news/2021/6/eli-lilly-announces-head-to-head-study-comparing-once-monthly-emgality-with-every-other-day-nurtec-odt-for-the-preventive-treatment-of-migraine/2022-02-08T07:45:20+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-rezipres-for-the-treatment-of-clinically-important-hypotension-occurring-in-the-setting-of-anesthesia.-eton-pharma2024-11-12T14:34:49+00:00weekly0.6https://www.medthority.com/news/2021/6/pivotal-phase-iii-sierra-trial-data-showing-100-bone-marrow-transplant-engraftment-in-patients-treated-with-iomab-b-presented-at-the-2021-virtual-snmmi-conference.--actinium-pharmaceuticals2024-11-12T14:43:40+00:00weekly0.6https://www.medthority.com/news/2021/6/vbl-therapeutics-provides-update-on-oval-a-phase-iii-registration-enabling-study-of-vb-111-in-ovarian-cancer/2022-02-08T07:45:20+00:00weekly0.6https://www.medthority.com/news/2021/6/positive-pivotal-phase-iii-results-for-zuranolone-an-investigational-two-week-once-daily-therapeutic-for-major-depressive-disorder.---sage-therapeutics--biogen2024-11-12T14:55:13+00:00weekly0.6https://www.medthority.com/news/2021/6/regen-cov--phase-iii-recovery-trial-meets-primary-outcome-improving-survival-in-hospitalized-covid-19-patients-lacking-an-immune-response-to-sars-cov-2.-regeneron-pharmaroche2022-02-08T07:45:20+00:00weekly0.6https://www.medthority.com/news/2021/6/mallinckrodt-announces-fda-approval-of-stratagraft-to-treat-thermal-burns/2024-11-12T14:56:14+00:00weekly0.6https://www.medthority.com/news/2021/6/pivotal-trial-data-for-narsolimab-to-treat-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-hsct-tma.--omeros-corporation2022-02-08T07:45:21+00:00weekly0.6https://www.medthority.com/news/2021/6/health-canada-approves-rinvoq-for-the-treatment-of-adults-with-active-psoriatic-arthritis--abbvie-canada/2024-11-12T14:56:25+00:00weekly0.6https://www.medthority.com/news/2021/6/entresto-approved-in-china-to-treat-essential-hypertension.---novartis2024-11-12T14:56:39+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-approves-ayvakit-to-treat-advanced-systemic-mastocytosis.-blueprint-medicines-corpn2022-02-08T07:45:21+00:00weekly0.6https://www.medthority.com/news/2021/6/topline-results-from-phase-ii-study-of-gosuranemab-an-anti-tau-antibody-for-alzheimers-disease.-biogen2022-02-08T07:45:21+00:00weekly0.6https://www.medthority.com/news/2021/6/paladin-labs-inc.-announces-approval-of-wakix-in-canada-for-the-treatment-of-excessive-daytime-sleepiness--or-cataplexy2024-11-12T14:56:53+00:00weekly0.6https://www.medthority.com/news/2021/6/first-patient-dosed-in-phase-iii-topaz-1-study-to-treat-systemic-lupus-erythematosus---biogen-inc/2024-11-12T14:57:03+00:00weekly0.6https://www.medthority.com/news/2021/6/first-patient-dosed-in-apolloe4-phase-iii-trial-of-oral-alz-801-in-patients-with-early-alzheimersdisease.-alzheon-inc2022-02-08T07:45:21+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-ap-003-c-trial-of-ampion-shows-efficacy-out-to-12-weeks-in-osteoarthritis-of-the-knee.--ampio-pharma2022-02-08T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/6/beigene-announces-first-patient-dosed-in-phase-iii-trial-of-anti-tigit-antibody-ociperlimab--tislelizumab-in-nsclc/2022-02-08T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/6/curevac-provides-update-on-phase-iibiii-herald-study-of-first-generation-covid-19-candidatecvncov/2022-02-08T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-accepts-alymsys-filing-for-metastatic-colorectal-cancer.--amneal-pharma2024-11-12T14:57:25+00:00weekly0.6https://www.medthority.com/news/2021/6/complete-response-letter-for--arimoclomol-a-heat-shock-protein-amplifier-intended-for-the-treatment-of-niemann-pick-disease-type-c.--orphazyme-as2024-11-12T14:57:43+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-spr1nt-and-str1ve-eu-trials-show-efficacy-in-spinal-muscular-atrophy.--novartis2024-11-12T14:57:57+00:00weekly0.6https://www.medthority.com/news/2021/6/ema-approves-onureg-for-acute-myeloid-leukemia.--bms2024-11-12T14:58:08+00:00weekly0.6https://www.medthority.com/news/2021/6/nmpa-china-gives-conditional-approval-for-brukinsa-to-treat--adult-patients-with-waldenstroms-macroglobulinemia-.--beigene-ltd2024-10-22T08:14:22+00:00weekly0.6https://www.medthority.com/news/2021/6/health-canada-approves-trikafta-for-cystic-fibrosis-patients-ages-12-and-older-who-have-at-least-one-f508del-mutation.-vertex-pharma2024-11-12T14:58:18+00:00weekly0.6https://www.medthority.com/news/2021/6/avenue-therapeutics-receives-complete-response-letter-from-the-fda-for-iv-tramadol/2022-02-08T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/6/novavax-nvx-cov2373-vaccine-demonstrates-90-overall-efficacy-and-100-protection-against-moderate-and-severe-covid-19-disease-in-prevent-19-phase-iii-trial/2022-02-08T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/6/eu-approves-extended-approval-of-aubagio-for-pediatric-patients-with-relapsing-remitting-multiple-sclerosis.--sanofigenzyme2022-02-08T07:45:23+00:00weekly0.6https://www.medthority.com/news/2021/6/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab-for-covid-19/2022-02-08T07:45:23+00:00weekly0.6https://www.medthority.com/news/2021/6/gileads-veklury-is-associated-with-a-reduction-in-mortality-rate-in-hospitalized-patients-with-covid-19-across-three-analyses-of-large-retrospective-real-world-data-sets/2022-02-08T07:45:23+00:00weekly0.6https://www.medthority.com/news/2021/6/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.---astrazeneca--merck-inc2024-11-12T14:50:03+00:00weekly0.6https://www.medthority.com/news/2021/6/agios-submits-nda-to-the-fda-for-mitapivat-for-treatment-of-adults-with-pyruvate-kinase-deficiency/2024-11-12T14:50:13+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-accepts-nda-for-vutrisiran-for-the-treatment-of-the-polyneuropathy-of-hereditary-attr-amyloidosis.-alnylam-pharma2024-11-12T14:51:21+00:00weekly0.6https://www.medthority.com/news/2021/6/fda-end-of-phase-ii-meeting-leaves-inrhythm-on-track-for-phase-iii-trials-and-filing-in-atrial-fibrillation.--incarda-therapeutics2024-11-12T14:51:39+00:00weekly0.6https://www.medthority.com/news/2021/6/phase-iii-orient-15-study-of-tyvyt--chemotherapy-meets-primary-endpoint-in-oesophageal-squamous-cell-carcinoma.--innovent-biologics2022-02-08T07:45:23+00:00weekly0.6https://www.medthority.com/news/2021/6/tga-australia-approves-covid-19-vaccine-janssen-to-prevent-covid-19.--janssen-cilag-pty.-ltd2022-02-08T07:45:23+00:00weekly0.6https://www.medthority.com/news/2021/6/tga-australia-grants-provisional-approval-to-covid-19-vaccine-elasomeran-to-prevent-covid-19--moderna-australia-pty.-ltd.-2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/chmp-recommends-approval-of-rinvoq--for-the-treatment-of-atopic-dermatitis.--abbvie2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/lillys-surpass-1-results-published-in-the-lancet-show-tirzepatides-superior-a1c-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes/2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/investigational-2.0-mg-dose-of-once-weekly-ozempic-demonstrates-superior-reductions-in-blood-sugar-vs-ozempic-1.0-mg-in-type-ii-diabetes.-novo-nordisk2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/tarsus-pharmaceuticals-inc.-announces-positive-results-of-saturn-1-pivotal-trial-of-tp-03-for-the-treatment-of-demodex-blepharitis2024-11-12T14:51:55+00:00weekly0.6https://www.medthority.com/news/2021/6/boston-scientific-acquires-farapulse-inc.-and--its-pulsed-field-ablation-system2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/first-covid-19-variant-vaccine-azd-2816-phase-iiiii-trial-participants-vaccinated.--astrazeneca2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/aurinia-announces-licensing-partner-otsuka-filed-initial-marketing-authorization-application-maa-for-voclosporin-with-the-european-medicines-agency-ema-for-lupus-nephritis/2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/nirsevimab-medley-phase-iiiii-trial-demonstrated-favourable-safety-and-tolerability-profile-in-infants-at-high-risk-of-respiratory-syncytial-virus.--astrazeneca--sanofi2022-02-08T07:45:24+00:00weekly0.6https://www.medthority.com/news/2021/6/forxiga-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-patients-with-chronic-kidney-disease.--astrazeneca2022-02-08T07:45:25+00:00weekly0.6https://www.medthority.com/news/2021/6/polyphor-provides-update-on-the-phase-iii-fortress-study-of-balixafortide-in-patients-with-advanced-her2-negative-breast-cancer/2022-02-08T07:45:25+00:00weekly0.6https://www.medthority.com/news/2021/6/dupixent-product-characteristics-updated-with-long-term-data-reinforcing-well-established-safety-profile-in-adults-with-moderate-to-severe-atopic-dermatitis.-regeneron--sanofi2022-02-08T07:45:25+00:00weekly0.6https://www.medthority.com/news/2021/7/phase-iii-study-of-rinvoq-meets-primary-and-secondary-endpoints-in-ulcerative-colitis.--abbvie2024-11-12T14:52:09+00:00weekly0.6https://www.medthority.com/news/2021/7/eu-approves-enspryng-for-neuromyelitis-optica-spectrum-disorder.--roche2022-02-08T07:45:25+00:00weekly0.6https://www.medthority.com/news/2021/7/mediwound-receives-complete-response-letter-from-the-fda-for-nexobrid-bla-for-for-eschar-removal-debridement-in-adults-with-thermal-burns/2024-11-12T14:52:17+00:00weekly0.6https://www.medthority.com/news/2021/7/maa-for-fyb-201-biosimilar-to-lucentis-is-filed-at-ema-.--formycon-ag--bioeq-ag2024-11-12T14:52:26+00:00weekly0.6https://www.medthority.com/news/2021/7/new-soliqua-data-shows-improved-blood-sugar-control-without-weight-gain-versus-premixed-insulin.--sanofi2022-02-08T07:45:25+00:00weekly0.6https://www.medthority.com/news/2021/7/sc-pharmaceuticals-inc.-announces-receipt-of-written-minutes-from-type-c-meeting-with-the-fda-regarding-development-of-furoscix-for-the-treatment-of-heart-failure2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/additional-analyses-from-phase-iii-galactic-hf-study-of-amg-423-showed-impact-in-atrial-fibrillation.--cytokinetics2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/arcutis-provides-update-on-phase-iia-clinical-trial-for--arq-252-cream-as-a-treatment-for-vitiligo/2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/reflect-phase-iii-clinical-trial-for-lumevoq-shows-benefits-for-bilateral-treatment-in-leber-hereditary-optic-neuropathy.--gensight-biologics2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/fda-approves-rylaze-for-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma.--jazz-pharma2024-11-12T14:52:36+00:00weekly0.6https://www.medthority.com/news/2021/7/seres-therapeutics-and-nestle-health-science-to-jointly-commercialise-ser-109-oral-microbiome-in-united-states-and-canada/2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/merck--inc.-provides-update-on-keytruda-indication-in-third-line-gastric-cancer-in-the-us2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/philips-announces-first-patient-treated-with-its-new-real-time-3d-intracardiac-echocardiography-catheter--verisight-pro/2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/at-527-an-oral-antiviral--reduces-viral-replication-in-hospitalized-patients-with-covid-19-in-phase-ii-interim-analysis.-atea--roche2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/phase-iii-trial-of-covaxin-meets-primary-endpoint-in-covid-19-phase-iii-study.--ocugenbharat-biotech2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/gsk-and-alector-announce-global-collaboration-in-immuno-neurology-for-two-clinical-stage-first-in-class-monoclonal-antibodies-for-neurodegenerative-diseases.-2022-02-08T07:45:26+00:00weekly0.6https://www.medthority.com/news/2021/7/positive-new-data-for-johnson--johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response/2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/uk-mhra-approval-for-byfavo-for-procedural-sedation.--paion-ag2024-11-12T14:52:48+00:00weekly0.6https://www.medthority.com/news/2021/7/fda-approves-expanded-label-for-keytruda-for-locally-advanced-cutaneous-squamous-cell-carcinoma--that-is-not-curable-by-surgery-or-radiation.--merck-inc2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/breakthrough-results-for-jardiance-confirm-emperor-preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction.-eli-lilly--boehringer2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/amendment-filed-to-fda-for-ccx-168-in-vasculitis-and-pudfa-goal-date-delayed.--chemocentryx2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/fda-issues-complete-response-for-prv-031-in-type-1-diabetes.--provention-bio2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/advaxis-inc-and-biosight-ltd.-to-merge-and-trade-as-biosight-therapeutics2022-02-08T07:45:27+00:00weekly0.6https://www.medthority.com/news/2021/7/health-canada-approves-vyxeos-the-first-chemotherapy-advance-in-over-40-years-for-adults-with-high-risk-acute-myeloid-leukemia-.--jazz-pharmaceuticals2024-11-12T14:52:57+00:00weekly0.6https://www.medthority.com/news/2021/7/nmpa-accepts-sbla-in-china-for-tislelizumab-to-treat-esophageal-squamous-cell-carcinoma--beigene-ltd.-2022-02-08T07:45:28+00:00weekly0.6https://www.medthority.com/news/2021/7/tezepelumab-regulatory-submission-accepted-and-granted-fda-priority-review-for-the-treatment-of-patients-with-asthma.-astrazeneca--amgen2024-11-12T14:53:05+00:00weekly0.6https://www.medthority.com/news/2021/7/mirikizumab-up-regulates-genes-associated-with-mucosal-healing-in-ulcerative-colitis-for-up-to-one-year-in-phase-ii-study.--eli-lilly2022-02-08T07:45:28+00:00weekly0.6https://www.medthority.com/news/2021/7/bluebird-bio-announces-positive-recommendation-by-eu-prac-committee-regarding-safety-referral-review-of-zynteglo--for-transfusion-dependent-beta-thalassemia-and-marketing-to-resume-in-eu/2022-02-08T07:45:28+00:00weekly0.6https://www.medthority.com/news/2021/7/new-phase-iii-data-support-the-sustained-long-acting-efficacy-of-lenacapavir-an-investigational-hiv-1-capsid-inhibitor.--gilead-sciences2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/four-year-biktarvy-data-presented-at-ias-2021-demonstrate-high-efficacy-and-durable-viral-suppression-in-treatment-naive-adults-with-hiv.-gilead-sciences2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/new-data-for-genentechs-hemlibra-reinforce-safety-profile-in-people-with-hemophilia-a/2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/ema-validates-maa-for-valoctocogene-roxaparvovec-the-first-potential-gene-therapy-in-europe-to-treat-severe-haemophilia-a.---biomarin2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/fibrogen-announces-outcome-of-fda-advisory-committee-review-of-roxadustat-for-treatment-of-anemia-of-chronic-kidney-disease/2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/alexion-announces-positive-topline-results-from-phase-iii-study-of-ultomiris-for-generalized-myasthenia-gravis.-2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/japan-is-the-first-country-to-approve-casirivimab--imdevimab-combination--for-the-treatment-of-mild-to-moderate-covid-19/2022-02-08T07:45:29+00:00weekly0.6https://www.medthority.com/news/2021/7/bylvay-is-european-commission-approved-to-treat-progressive-familial-intrahepatic-cholestasis-.--albireo-pharma2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/fda-approval-for-bylvay-the-first-drug-treatment-for-patients-with-progressive-familial-intrahepatic-cholestasis.--albireo-pharma-inc2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/topline-results-from-the-phase-iib-eco-reset-study-evaluating-ser-287-in-patients-with-mild-to-moderate-ulcerative-colitis.--seres-therapeutics2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/fda-approves-fexinidazole-as-the-first-all-oral-treatment-for-sleeping-sickness.-sanofi--dndi2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/kyowa-kirin-provides-update-on-application-for-istradefylline-in-europe-for-the-treatment-of-off-episodes-in-people-livingwith-parkinsons/2024-11-12T14:53:16+00:00weekly0.6https://www.medthority.com/news/2021/7/chmp-recommends-nexviadyme-a-treatment-for--for-glycogen-storage-disease-type-ii-pompe-disease--genzymesanofi/2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/vaxzevria-and-mrna-covid-19-vaccines-showed-similar-and-favourable-safety-profiles-in-a-population-based-cohort-study-of-over-a-million-people.-astrazeneca2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/vaxzevria-showed-no-increased-incidence-of-thrombosis-with-thrombocytopenia-after-second-dose-for-covid-19.--astrazeneca2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/-eli-lilly-releases-donanemab-data-from-the-phase-ii-trailblazer-alz-study-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline/2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/merck-inc.-announced-positive-overall-survival-results-from-the--pivotal-phase-iii-keynote-355-trial-evaluating-keytruda--chemotherapy-for-the-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/7/complete-response-letter-from-fda-for-nda-for-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis.--ardelyx2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/8/arvinas-inc.-and-pfizer-inc.-announce-a-global-collaboration-to-develop-and-commercialize-protac---protein-degrader-arv-471.-2022-02-08T07:45:30+00:00weekly0.6https://www.medthority.com/news/2021/8/european-commission-approves-opdivo--as-adjuvant-treatment-for-esophageal-or-gastroesophageal-junction-cancer-patients-with-residual-pathologic-disease-following-chemoradiotherapy.--bms2022-02-08T07:45:31+00:00weekly0.6https://www.medthority.com/news/2021/8/opdivo--indication-for-hepatocellular-carcinoma-liver-cancer-withdrawn-from-fda.--bms2024-11-12T11:26:57+00:00weekly0.6https://www.medthority.com/news/2021/8/biocon-biologics-and-viatris-inc.-receive-fda-approval-for-first-interchangeable-biosimilar-semglee--for-the-treatment-of-diabetes2022-02-08T07:45:31+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-expanded-botox--label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity.-allerganabbvie2024-11-12T14:53:29+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-uptravi-iv-for-pulmonary-arterial-hypertension.--jj2022-02-08T07:45:31+00:00weekly0.6https://www.medthority.com/news/2021/8/illuminate-c-phase-iii-open-label-study-of-oxlumo-shows-efficacy-in-primary-hyperoxaluria-type-1.--alnylam-pharma2022-02-08T07:45:31+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-iii-ab09004-study-of-masican-shows-efficacy-and-safety-in-mild-to-moderate-alzheimers-disease.--ab-science2022-02-08T07:45:31+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-twyneo-to-treat-acne-vulgaris.--galderma--sol-gen-technologies2024-11-12T14:53:40+00:00weekly0.6https://www.medthority.com/news/2021/8/baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invasive-mechanical-ventilation.--eli-lilly--incyte2022-02-08T07:45:32+00:00weekly0.6https://www.medthority.com/news/2021/8/novartis-announces-lift-of-partial-clinical-trial-hold-and-plans-to-initiate-a-new-pivotal-phase-iii-study-of-intrathecal-oav-101-in-older-patients-with-sma/2024-11-12T14:53:47+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-grants-tecentriq-slba-priority-review-in-non-small-cell-lung-cancer.--genentechroche2022-02-08T07:45:32+00:00weekly0.6https://www.medthority.com/news/2021/8/health-canada-approves-arazlo-lotion-0.045-first-such-lotion-treatment-for-acne-vulgaris.-bausch-healthcanada2024-11-12T14:53:55+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-iii-trial-of-regen-cov-meets-primary-endpoint-in-covid-19-and-is-published-in-nejm.--regeneron-pharma2022-02-08T07:45:32+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-iii-trial-of-libtayo-halted-early-after-meeting-endpoint-in-nsclc.--sanofiregeneron2022-02-08T07:45:32+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-accepts-sbla-for-keytruda-in-high-risk-stage-ii-melanoma.--merck-inc2022-02-08T07:45:32+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-accepts-sbla-for-cabometyx-in-thyroid-cancer.--exelixis-2024-11-12T14:54:11+00:00weekly0.6https://www.medthority.com/news/2021/8/novavax--serum-institute-of-india-file-regulatory-submissions-to-the-drugs-controller-general-of-india-and-to-regulatory-agencies-in-indonesia-and-philippines--covid-19-vaccine/2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-nexviazyme-for-pompe-disease.--genzymesanofi2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-ii-data-shows-nvx-cov2373-booster-provides-improved-antibody-response-for-covid-19.--novavax2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-qiareach-sars-cov-2-antigen-test-with-emergency-use-authorisation-for-covid-19-diagnostics.--qiagen2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/penpulimab-monoclonal-antibody-pd-1-obtains-marketing-approval-in-china.--akeso-inc2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/fyb-201a-biosimilar-to-lucentis-is-filed-at-the-fda.-formycon-ag--bioeq-ag2024-11-12T14:54:21+00:00weekly0.6https://www.medthority.com/news/2021/8/bavencio-is-approved-by-the-scottish-medicines-consortium-for-use-via-nhs-scotland-as-a-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma-.-merck-kgaa--pfizer2024-11-12T14:58:50+00:00weekly0.6https://www.medthority.com/news/2021/8/alnylam-completes-enrollment-in-helios-b-phase-iii-study-of-vutrisiran-in-patients-with-transthyretin-mediated-amyloidosis-with-cardiomyopathy/2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/bluebird-bio-reports-second-quarter-financial-results-and-provides-operational-update/2022-02-08T07:45:33+00:00weekly0.6https://www.medthority.com/news/2021/8/eu-approves-forxiga-for-chronic-kidney-disease-with-and-without-type-2-diabetes.--astrazeneca2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/exploratory-analysis-shows-olinvyk-treated-patients-are-~50-less-likely-to-experience-an-ae-compared-to-morphine-patients-at-equivalent-levels-of-analgesia/2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-grants-priority-review-to-sbla-for-keytruda--as-adjuvant-therapy-in-certain-patients-with-renal-cell-carcinoma-following-surgery.--merck-inc2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/boston-scientific-receives-fda-clearance-for-exalt-model-b-single-use-bronchoscope/2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-new-berinert--administration-kit-for-increased-patient-convenience-in-treatment-for--acute-hereditary-angioedema.-csl-behring-2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/amicus-therapeutics-announces-european-commission-approval-of-galafold-for-adolescents-with-fabry-disease/2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/tga-australia-grants-provisional-approval-to--covid-19-vaccine-moderna-to-prevent-covid-19.--moderna-inc2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/fibrogen-receives-complete-response-letter-from-the-fda-for-roxadustat-for-anemia-of-chronic-kidney-disease.--fibrogen--astrazeneca2024-11-12T14:59:05+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-keytruda--lenvima--combination-for-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma-.merck-inc.--eisai2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-raises-deficiencies-in-the-nda-for-axs-05-a-proposed-treatment-for-major-depressive-disorder.-axsome-therapeutics2024-11-12T15:02:58+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-ticovac-for-tick-borne-encephalitis.--pfizer2022-02-08T07:45:34+00:00weekly0.6https://www.medthority.com/news/2021/8/rolling-review-of-mk-4482-for-covid-19-begins-in-canada.--merck-inc-2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/gw-pharmaceuticals-receives-approval-for-epidyolex--from-the-mhra-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex/2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-.--eli-lilly2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/vectura-group-is-acquired-by-philip-morris/2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/worlds-first-surgery-using-virtual-incisions-mira-miniature-robotic-system-performed-at-bryan-medical-center-in-lincoln-nebraska/2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/oramed-pharma-announces-publication-of-oral-insulin-study-of-ormd-0801-in-peer-reviewed-journal-diabetes-obesity-and-metabolism-.-----2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-amplatzer-amulet-device-to-treat-people-with-atrial-fibrillation-at-risk-of-stroke.--abbott2022-02-08T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/8/pdufa-date-for-et-101-from-azurity-pharma-to-treat-epilepsy-is-now-extended-to-6-november-2021/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/pfizer-and-biontech-announce-submission-of-initial-data-to-fda-to-support-booster-dose-of-covid-19-vaccine/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/i-mab-reports-positive-interim-analysis-from-phase-iiiii-study-of-its-gm-csf-antibody-plonmarlimab-tjm2-to-treat-patients-with-severe-covid-19/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-jardiance-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction.-boehringer-ingelheim--eli-lilly2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/gsk-receives-fda-accelerated-approval-for-jemperli-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/miravo-healthcare-announces-receipt-of-health-canada-notice-of-compliance-for-the-pediatric-use-of-blexten/2024-11-12T14:59:36+00:00weekly0.6https://www.medthority.com/news/2021/8/second-generation-mrna-covid-19-vaccine-candidate-cv2cov-demonstrates-improved-immune-response-and-protection-in-preclinical-study.--curevac-nv-and-gsk2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/lilly-announces-the-formation-of-neuroscience-and-immunology-business-units/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/zimmer-biomet-receives-fda-clearance-for-rosa-hip-system-for-robotically-assisted-direct-anterior-total-hip-arthroplasty/2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/first-dose-administration-of--glepaglutide-in-phase-iii-ease-sbs-4-trial-to-treat-short-bowel-syndrome.-zealand-pharma2022-02-08T07:45:36+00:00weekly0.6https://www.medthority.com/news/2021/8/bavarian-nordic-initiates-phase-ii-clinical-trial-of-abncov2-a--covid-19-booster-vaccine/2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/pfizer--biontech-covid-19-vaccine-comirnaty-receives-full-fda-approval-for-individuals-16-years-and-older-to-prevent-covid-19/2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-accepts-sbla-for-orencia-in-severe-acute-graft-versus-host-disease.--bms2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/india-gives-emergency-use-authorisation-for-needle-free-vaccine-zycov-d-in-covid-19.--zydus-cadila2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/vla-2001-begins-rolling-submission-process-with-uk-mhra-in-covid-19.--valneva-se2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approval-of-korsuva-injection-for-the-treatment-of-moderate-to-severe-pruritus-associated-with-ckd-in-hemodialysis-patients.--cara-therapeutics--vifor-pharma2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/kymriah-did-not-meet-endpoint--of-event-free-survival-in-belinda-study-in-aggressive-b-cell-non-hodgkin-lymphoma-.novartis2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/top-line-results-from-phase-iib-dose-finding-induction-study-of-izencitinib-for-patients-with-ulcerative-colitis.--theravance-biopharma--janssen2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/european-commission-approves-bimzelx-for-the-treatment-of-moderate-to-severe-plaque-psoriasis.-ucb2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/pfizer-to-acquire-trillium-therapeutics-and-with-it-two-lead-molecules-tti-622-and-tti-621/2022-02-08T07:45:37+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-evolut-fx-tavr-system-for-severe-aortic-stenosis.--medtronic2024-11-12T15:00:00+00:00weekly0.6https://www.medthority.com/news/2021/8/health-canada-approves-minjuvi--lenalidomide-for-diffuse-large-b-cell-lymphoma.--incyte2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-gives-expanded-approval-for-xarelto-in-peripheral-artery-disease.--janssen-pharma2024-11-12T15:00:24+00:00weekly0.6https://www.medthority.com/news/2021/8/cassava-sciences-announces-agreement-with-fda-on-special-protocol-assessments--for-its-phase-iii-studies-of-simufilam-for-the-treatment-of-alzheimers-disease/2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/european-commission-approves-evrenzoto-treat-adult-patients-with---symptomatic-anemia-associated-with-chronic-kidney-disease.-astellas--fibrogen-inc2024-11-12T15:00:47+00:00weekly0.6https://www.medthority.com/news/2021/8/novavax-to-participate-in-octave-duo-study-to-evaluate--third-dose-of-nvx-cov2373-vaccine-in--covid-19-participants-with-impaired-immune-systems/2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/arcutis-enrolls-first-patient-in-phase-iii-trial-of-topical-roflumilast-foam-as-a-potential-treatment-for-scalp-and-body-psoriasis/2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/merck-inc.-announces-vaxneuvance-met-key-immunogenicity-and-safety-endpoints-in-phase-iii--pneu-ped-pivotal-trial-evaluating-use-in-infants2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/pfizer-and-biontech-file-sbla-with-fda-for-comirnaty-as-booster-dose-for-16-years-and-up-in-covid-19/2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/merck-kgaa-has--decided-to-discontinue--phase-ii-intrpid-btc-055-trial-of-bintrafusp-alfa-for-metastatic-biliary-tract-cancer.-2022-02-08T07:45:38+00:00weekly0.6https://www.medthority.com/news/2021/8/eu-approves-rinvoq-for-atopic-dermatitis.--abbvie2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/forxiga-approved-in-japan-for-the-treatment-of-chronic-kidney-disease-in-patients-with-and-without-type-2-diabetes/2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/alxn-1840-demonstrated-approximately-three-times-greater-copper-mobilisation-from-tissues-than-standard-of-care-treatments.-astrazeneca.-2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-iii-activ-2-trial-interim-data-for-brii-196--brii-198-shows-benefits-for-high-risk-outpatients-with-covid-19.--brii-biosciences2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/fda-approves-skytrofa-for-pediatric-growth-hormone-deficiency.--ascendis-pharma2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/new-data-at-esc-congress-2021-shows-repatha-improves-features-of-plaque-stability-in-patients-with--acute-coronary-syndrome.--amgen-2024-09-30T14:00:54+00:00weekly0.6https://www.medthority.com/news/2021/8/european-commission-grants-conditional-approval-for-minjuvi-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.-incyte--morphosys-ag2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/european-commission-approves-voxzogo-to-treat-achondroplasia.--biomarin2024-11-12T15:01:08+00:00weekly0.6https://www.medthority.com/news/2021/8/emperor-preserved-trial-demonstrates-jardiance-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction.--eli-lilly--boehringer2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/amneal-pharma-announces-positive-topline-results-from-pivotal-phase-iii-rise-pd-clinical-trial-of-ipx-203-in-patients-with-parkinsons-disease-who-experience-motor-fluctuations/2024-11-12T15:05:47+00:00weekly0.6https://www.medthority.com/news/2021/8/genentechroche-will-voluntarily-withdraw-the-fda-accelerated-approval-for-tecentriq--chemo--to-treat-triple-negative-breast-cancer/2022-02-08T07:45:39+00:00weekly0.6https://www.medthority.com/news/2021/8/keytruda-is-approved-in-japan-by-pmda-for-her2--negative-inoperable-breast-cancer-and-for-patients-with-unresectable-advanced-or-recurrent-high-microsatellite-instability-msi-h-colorectal-cancer.--merck-inc2022-02-08T07:45:40+00:00weekly0.6https://www.medthority.com/news/2021/8/new-data-on-finerenone-for-the-protection-of-patients-with-chronic-kidney-disease-and-type-2-diabetes-from-cardiovascular-events-and-kidney-disease-progression-is-published-in-nejm.--bayer2022-02-08T07:45:40+00:00weekly0.6https://www.medthority.com/news/2021/8/guide-hf-study-data-shows-cardio-mems-system--can-improve-care-for-patients-with-heart-failure.-abbott2022-02-08T07:45:40+00:00weekly0.6https://www.medthority.com/news/2021/8/dupixent--pivotal-trial-meets-all-endpoints-becoming-first-biologic-medicine-to-significantly-reduce-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-children-as-young-as-6-months.--regeneron--sanofi2022-02-08T07:45:40+00:00weekly0.6https://www.medthority.com/news/2021/8/dupixent--pivotal-trial-meets-all-endpoints-becoming-first-biologic-medicine-to-significantly-reduce-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-children-as-young-as-6-months2.--regeneron--sanofi2022-02-08T07:45:40+00:00weekly0.6https://www.medthority.com/news/2021/8/phase-iii-jta-004-study-of-jta-004-fails-to-meet-endpoints-in-knee-osteoarthritis.--bone-therapeutics2022-02-08T07:45:41+00:00weekly0.6https://www.medthority.com/news/2021/9/cassiopea-spa-and-sun-pharma-announce--that-sun-pharma-will-commercialise-winlevi-a-treatment-for-acne-in-the-us-and-canada/2024-11-12T15:06:03+00:00weekly0.6https://www.medthority.com/news/2021/9/health-canada-approves-sunosi--for-excessive-daytime-sleepiness-associated-with-narcolepsy-or-obstructive-sleep-apnea.-jazz-pharma2022-02-08T07:45:41+00:00weekly0.6https://www.medthority.com/news/2021/9/incyte-announces-health-canada-approval-of-minjuviin-combination-with-lenalidomide-for-the-treatment-of-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.-2022-02-08T07:45:41+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-jade-dare-trial-of-pf-04965842-meets-primary-endpoint-in-atopic-dermatitis-and-shows-superiority-over-dupilumab.--pfizer2022-02-08T07:45:41+00:00weekly0.6https://www.medthority.com/news/2021/9/data-from-nihnhlbi-sponsored-phase-ii-trial-of-fostamatinib-in-hospitalized-covid-19-patients-is-published-in-clinical-infectious-diseases-journal.-rigel-pharma2022-02-08T07:45:41+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-updates-approval-label-of-keytruda-from-accelerated-to-full-approval-in-urothelial-carcinoma-bladder-cancer.--merck-inc2024-11-12T15:06:12+00:00weekly0.6https://www.medthority.com/news/2021/9/bayer-starts-phase-iii-clinical-development-program-oasis-with-elinzanetant/2024-11-08T09:02:06+00:00weekly0.6https://www.medthority.com/news/2021/9/merck-inc.-and-ridgeback-biotherapeutics-announce-initiation-of-pivotal-phase-iii-move-ahead-study-evaluating-molnupiravir-for-post-exposure-prophylaxis-of-covid-19-infection2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/fda--approves-brukinsa--for-treatment-of-waldenstroms-macroglobulinemia.--beigene-ltd2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/statement-by-the-board-of-directors-of-swedish-orphan-biovitrum-ab-in-relation-to-the-public-cash-offer-by-advent-and-gic/2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/adamis-pharmaceuticals-doses-first-patients-in-phase-iiiii-clinical-trial-for-tempol-in-the-treatment-of-covid-19/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2021/9/rolling-submission-for-tuoyi-to-fda-completed-for-nasopharyngeal-carcinoma.--shanghai-junshi-biosciencescoherus-biosciences2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-panther-trial-of-tak-924--vidaza-failed-to-meet-primary-endpoint-in-myelodysplastic-syndromes.--takeda2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/moderna-announces-submission-of-initial-data-to-the-fda-for-mrna-1273-at-the-50-g-dose-level/2024-10-22T09:20:30+00:00weekly0.6https://www.medthority.com/news/2021/9/ultomiris-has-been-approved-in-the-european-union-for-expanded-use-to-include-children--adolescents-with-paroxysmal-nocturnal-haemoglobinuria.--alexionastrazeneca-2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/nature-medicine-publishes-phase-iii-anakinra-study-results-in-patients-with-covid-19-pneumonia.--swedish-orphan-biovitrium-sobi2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-requires-warnings-about-increased-risk-of-serious-heart-related-events-cancer-blood-clots-and-death-for-jak-inhibitors-that-treat-certain-chronic-inflammatory-conditions/2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-trudhesa--nasal-spray-for-the-treatment-of--acute--migraine.--impel-neuropharma2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/the-bristol-myers-squibb-pfizer-alliance-welcomes-the-decision-by-the-u.s.-court-of-appeals-for-the-federal-circuit-upholding-the-eliquis-patents2022-02-08T07:45:42+00:00weekly0.6https://www.medthority.com/news/2021/9/moderna-files-cma-to-ema-for-mrna-1273-booster-dose-in-covid-19/2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-de-novo-approval-for-the-tibial-extension-of-persona-iq-for-total-knee-replacement-surgery.-zimmer-biomet--canary-medical2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/pfizer-announces-start-of-phase-iii-trial-in-adults-for-its-vaccine-rsvpref-against-respiratory-syncytial-virus.-2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/new-tezepelumab-data-shows-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps.-amgen--astrazeneca2024-11-12T15:06:20+00:00weekly0.6https://www.medthority.com/news/2021/9/china-nmpa-approves-carteyva-for-large-b-cell-lymphoma.--jw-therapeutics-2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/novartis-announced-that-following-an-interim-analysis-of-data-from-the-cirrus-1-study-it-will-discontinue-the-trial-for-organ-rejection-in-patients-receiving-a-kidney-transplant/2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/bavarian-nordic-reports-positive-results-from-human-challenge-trial-of-mva-bn-rsv-a-rsv-vaccine-candidate/2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves--invega-hayfera6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia.--janssen-pharmaceuticals2024-11-12T15:03:58+00:00weekly0.6https://www.medthority.com/news/2021/9/sk-bioscience-and-gsk-start-phase-iii-trial-of-gbp-510-and-an-adjuvanted-covid-19-vaccine-candidate/2022-02-08T07:45:43+00:00weekly0.6https://www.medthority.com/news/2021/9/medtronic-announces-navablate-study-results-with-the-emprint-ablation-catheter-kit-for-bronchoscopic-ablation-at-the-european-respiratory-society-international-congress-2021/2024-11-12T15:04:12+00:00weekly0.6https://www.medthority.com/news/2021/9/keytruda--is-approved-in-china-in-combination-with-chemotherapy-for-first-line-treatment-of--locally-advanced-unresectable-or-metastatic-esophageal-or-gastroesophageal-junction-carcinoma/2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/sanofi-to-acquire-kadmon-holdings-adding-rezurock-to-its-transplant-portfolio/2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/sandoz-acquires-us-eu-and-canadian-rights-to-bevacizumab-biosimilar-from-bio-thera-solutions-ltd/2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/servier-and-neurochlore-announce-the-results-of-two-phase-iii-clinical-trials-assessing-bumetanide-for-autism-spectrum-disorder.-2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/horizon-therapeutics-plc-initiates-randomized-controlled-clinical-trial-evaluating-tepezza-for-the-treatment-of-chronic-inactive-thyroid-eye-disease/2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/travere-therapeutics-announces-successful-outcome-from-type-a-meeting-with-fda-for-sparsentan-in-focal-segmental-glomerulosclerosis/2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/idmc-recommends-that-phase-iii-salamander-trial-of-rex-001-continues-in-chronic-limb-threatening-ischemia.--ixaka2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/sophia-phase-iii-study-of-margenza-announces-final-os-data-in-her2-positive-breast-cancer-patients.--macrogenics2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/mhra-approves-bylvay-for-progressive-familial-intrahepatic-cholestasis.--albireo-pharma2022-02-08T07:45:44+00:00weekly0.6https://www.medthority.com/news/2021/9/immunocore-announces-uk--mhra-accepts-maa-for-tebentafusp-in-metastatic-uveal-melanoma/2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/biodelivery-sciences-international-completes-acquisition-of-elyxyb-for-acute-migraine-treatment-in-the-u.s.-and-canada2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/pds-biotech-completes-enrollment-of-lead-in-safety-cohort-in-versatile-002-phase-ii-combination-trial-of-pds-0101--keytruda-in-recurrent-or-metastatic-head-and-neck-cancer.-2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/sanofi-provides-update-on-phase-iii-study-evaluating-rilzabrutinib-for-the-treatment-of-pemphigus/2024-11-12T15:04:23+00:00weekly0.6https://www.medthority.com/news/2021/9/imfinzi--tremelimumab---chemotherapy-improved-progression-free-survival-and-overall-survival--in-poseidon-phase-iii-trial-in-1st-line-stage-iv-nsclc.--astrazeneca2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/gensight-biologics-announces-publication-analyzing-visual-parameters-of-nd4-lhon-subjects-before-lumevoq-treatment-in-phase-iii-trials/2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/ardelyx-announces-publication-of-52-week-phase-iii-phreedom-trial-in-kidney-360-journal-of-tenapanor-for-the-control-of-serum-phosphorus-in-the-management-of-hyperphosphatemia/2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/mhra-approves-lumykras-for-patients-with-previously-treated-metastatic-nsclc-with-kras-g12c-mutation-and-early-access-is-granted--to-the-nhs.-amgen-2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-derby-and-oaks-studies-of-empaveli-show-mixed-results-in-geographic-atrophy.--apellis-pharma2022-02-08T07:45:45+00:00weekly0.6https://www.medthority.com/news/2021/9/bristol-myers-squibb-shares-research-supporting-correlation-between-new-york-heart-association-functional-class-nyha-class-and-mortality-in-obstructive-hypertrophic-cardiomyopathy/2024-11-12T15:04:37+00:00weekly0.6https://www.medthority.com/news/2021/9/top-line-results-for-avt-02-shows-no-difference-in-switching-with-humira.--alvotech2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/polyphor-to-merge-with-enbiotix/2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-grants-brukinsa-accelerated-approval-in-relapsed-or-refractory-marginal-zone-lymphoma.---beigene2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/travere-therapeutics-and-vifor-pharma-announce-licensing-agreement-for-the-commercialization-of-sparsentan-in-europe-australia-and-new-zealand/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/sk-bioscience-and-gsk-start-phase-iii-trial-of-adjuvanted-covid-19-vaccine-candidate/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-accepts-supplemental-nda-for-myfembree-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis.-pfizer--myovant-sciences2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/ebola-vaccine-regimen-demonstrated-robust-and-durable-immune-response-in-adults-and-children-in-data-published-in-the-lancet-infectious-diseases.--johnson--johnson2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/erleada-oral-presentations-at-aua-meeting-demonstrate-importance-of-prostate-specific-antigen-psa-as-key-efficacy-indicator-and-show-strong-patient-adherence-rates--janssen-pharmaceuticals/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-declines-to-grant-emergency-use-authorization-of-lenzilumab-to-treat-newly-hospitalized-covid-19-patients.-humanigen2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/soleno-therapeutics-announces-positive-data-showing-continued-significant-improvements-in-symptoms-of-prader-willi-syndrome-following-one-year-treatment-with-dccr/2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-checkmate--214-trial-of-opdivo--yervoy-shows-os-at-67-months-in-renal-cell-carcinoma.--bms2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/rinvoq-filed-with-fda-and-ema-for-ulcerative-colitis.--abbvie2024-11-12T15:05:00+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-exkivity-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.--takeda2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/emergency-use-authorization-for--bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-covid-19.--eli-lilly2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/novavax-inc.-to-participate-with-nvx-cov2373-in-university-of-oxford-com-cov3-study-comparing-mixed-covid-19-vaccine-schedule-in-adolescents2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/analyses-published-in-nejm-of-a-third-booster-shot-of-the-comirnaty-messenger-rna-vaccine-from-pfizer/2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/lumakras---vectibix-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12c-mutated-colorectal-cancer.--amgen2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/novavax-to-participate-with--in-university-of-oxford-com-cov3-study-comparing-mixed-covid-19-vaccine-schedule-in-adolescents/2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/novartis-reports-positive-health-related-quality-of-life-data-for-177lu-psma-617-radioligand-therapy-in-patients-with-advanced-prostate-cancer-at-esmo-2021/2025-01-31T11:17:26+00:00weekly0.6https://www.medthority.com/news/2021/9/moderna-announces-health-canada-approves-spikevax-its-covid-19-vaccine/2022-02-08T07:45:48+00:00weekly0.6https://www.medthority.com/news/2021/9/moderna-highlights-new-clinical-data-on-spikevax-its-covid-19-vaccine/2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-vumerity-to-treat-relapsing-remitting-multiple-sclerosis.--biogen2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-qinlock-to-treat--adult-patients-with-advanced-gastrointestinal-stromal-tumor.-deciphera-pharmaceuticals2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/efficacy-and-safety-results-of-destiny-gastric02-trial-of-enhertu-are-consistent-with-registrational-destiny-gastric01-study-and-will-support-ongoing-discussions-with-global-health-authorities.--daiichi-sankyo--astrazeneca2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-advisory-committee-votes-unanimously-for-comirnaty--booster-dose-for-emergency-use-in-people-65-and-older-and-certain-high-risk-populations.--pfizer--biontech-se-2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-keytruda--chemo-for-the-treatment-of-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer.-merck-inc2021-12-20T17:32:38+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-jyseleca-to-treat--moderately-to-severely-active-ulcerative-colitis.-galapagos-nv.-2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/discovery-trial-of-verklury-concluded-there-was-no-clinical-benefit-in--hospitalised-patients-with-covid-19.-gilead-sciences2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/beigene-receives-positive-chmp-opinion-for-brukinsa-for-the-treatment-of-adults-with-waldenstroms-macroglobulinemia/2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/enhertu-demonstrated-robust-and-durable-tumour-response-of-54.9-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer.-astrazeneca--daiichi-sankyo2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/enhertu-reduced-the-risk-of-disease-progression-or-death-by-72-vs.-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer.--astrazeneca--daiichi-sankyo2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian-phase-iii-trial-in-extensive-stage-small-cell-lung-cancer.--astrazeneca2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/keytruda--chemotherapy-with-or-without-bevacizumab-reduced-risk-of-death-by-one-third-versus-chemotherapy-with-or-without-bevacizumab-as-first-line-treatment-for-persistent-recurrent-or-metastatic-cervical-cancer.--merck-inc2022-02-08T07:45:49+00:00weekly0.6https://www.medthority.com/news/2021/9/keytruda-demonstrated-superior-recurrence-free-survival-in-patients-with-resected-high-risk-stage-ii-melanoma-compared-to-placebo-in-the-adjuvant-setting.--merck-inc2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/keytruda--chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-whose-tumors-expressed-pd-l1-.--merck-inc2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/novartis-presents-new-kisqali-data--from-phase-iii-monaleesa-2-study-showing-longest-median-overall-survival-ever-reported-in-hrher2--advanced-breast-cancer/2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/esmo-late-breaking-data-show-libtayo--and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc.--regeneron-pharmaceuticals--sanofi2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/genmab--seagen-present-interim-results-from-the-innovatv-205-study-for-tisotumab-vedotin-combination-therapy-treatment-of-recurrent-or-metastatic-cervical-cancer-at-esmo-virtual-congress-2021/2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/alnylam-submits-maa-to-the-european-medicines-agency-for-investigational-vutrisiran-for-the-treatment-of-hereditary-attr-amyloidosis-with-polyneuropathy/2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/teleflex-announces-large-scale-analysis-of-real-world-healthcare-claims-data-for-enlarged-prostate-procedures-at-the-american-urological-association-2021-annual-meeting/2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/opdivo--yervoy-demonstrates-durable-overall-survival-at-three-years-compared-to-chemotherapy-in-first-line-unresectable-malignant-pleural-mesothelioma.--bms2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/ultragenyx-canada-announces-health-canada-approval-of--crysvita-for-the-treatment-of-tumour-induced-osteomalacia-in-adults/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/uk-mhra-grants-marketing-authorisation-for-cibinqo-for-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis.--pfizer2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/curevac-streamlines-european-network-for-mrna-product-manufacturing/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/azurrx-acquires-first-wave-bio-and-with-it-niclosamide-an-oral-small-molecule-drug-with-antiviral-an-anti-inflammatory-properties/2022-02-08T07:45:47+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-biooviz-a-lucentis-biosimilar.--samsung-bioepis--biogen2022-02-08T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/9/mirati-therapeutics-announces-positive-phase-ii-topline-results-for-adagrasib-in-patients-with-kras-g12c-mutated-advanced-non-small-cell-lung-cancer/2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-accepts-bms-986016--opdivo-for-priority-review-in-metastatic-melanoma.--bms2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-impower010-study-of-tecentriq-consistent-with-previous-studies-in-nsclc-and-published-in-the-lancet.--genentechroche2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/skyrizi-filed-with-fda-for-moderate-to-severe-crohns-disease.--abbvie2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iiiii-trial-data-for-comirnaty-shows-favourable-safety-profile-in-5-11-year-olds-in-study-for-covid-19.--pfizer-and-biontech2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/mirati-therapeutics-presents-positive-clinical-data-with--adagrasib-as-monotherapy-and--cetuximab-in-kras-g12c-mutated-colorectal-cancer-patients/2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/fda--grants-accelerated-approval-to-tivdak-for-the-treatment-of-metastatic-cervical-cancer.-seagen-inc.-genmab-as2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-gavreto-to-treat-ret-fusion-positive-advanced-non-small-lung-cancer.-roche2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-qinlock-to-treat-advanced-gastrointestinal-stromal-tumor.-deciphera-pharmaceuticals2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-negative-for-approval-of-raylumis-as-a-proposed--treatment-for-pain-associated-with-osteoarthritis.-pfizer2022-02-08T07:45:51+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-artesunate-amivas-for-the-initial-treatment-of-severe-malaria.--amivas2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/chmp-recommends-hukyndra-a-biosimilar-to-humira-for-infammatory-and-autoimmune-disorders.-stada-arzneimittel-ag2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/alvotech-provides-update-on-fda-action-regarding-avt-02-proposed-high-concentration-biosimilar-to-humira/2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/johnson--johnson-announces-real-world-evidence-and-phase-iii-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u.s2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-opzelura-cream-for-mild-to-moderate-atopic-dermatitis.--incyte2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/bluebird-bio-completes-rolling-submission-to-fda-for-beti-cel-in-beta-thalassemia/2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/veklury-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19.--gilead-sciences2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/cassava-sciences-announces-top-line-results-of-12-month-interim-analysis-from-open-label-study-evaluating-simufilam-in-alzheimers-disease/2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/rhythm-pharmaceuticals-announces-marketing-authorisation-of-imcivree--in-great-britain/2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/incyte-announces-fda-approval-of-jakafi-for-treatment-of-chronic-graft-versus-host-disease.-2022-02-08T07:45:52+00:00weekly0.6https://www.medthority.com/news/2021/9/pfizer-and-biontech-receive-first--fda-emergency-use-authorization-of-a-covid-19-vaccine-booster/2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/novartis-acquires--arctos-medical-and-its-optogenetics-based-gene-therapy-programs/2021-10-12T14:15:16+00:00weekly0.6https://www.medthority.com/news/2021/9/bayer-initiates-phase-iii-find-ckd-study-for-finerenone-in-patients-with-non-diabetic-ckd/2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/roche-presents-new-data-for-evrysdi-at-world-muscle-society-wms-2021-highlighting-new-advances-for-people-living-with-rare-neuromuscular-disorders/2024-11-14T13:06:14+00:00weekly0.6https://www.medthority.com/news/2021/9/lynparza-in-combination-with-abiraterone-significantly-delayed-disease-progression-in-all-comers-in-propel-phase-iii-trial-in-1st-line-metastatic-castration-resistant-prostate-cancer.-astrazeneca--merck-inc2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/results-from-nanoflu-influenza-vaccine-phase-iii-clinical-trial-published-in-the-lancet-infectious-diseases.--novavax-inc2024-11-14T13:09:09+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-accepts-bla-for-tislelizumab--to-treat--esophageal-squamous-cell-carcinoma.--beigene2024-11-12T15:04:49+00:00weekly0.6https://www.medthority.com/news/2021/9/abbvie-and-regenxbio-announce-eye-care-collaboration-for-rgx-314--a-one-time-gene-therapy/2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/nhs-launches-world-first-trial-for--for-new-galleri-test-to-detect-cancer/2022-02-08T07:45:46+00:00weekly0.6https://www.medthority.com/news/2021/9/horizon-therapeutics-plc-announces-data-showing-uplinza-produces-rapid-and-sustained-b-cell-depletion-in-african-americans-with-neuromyelitis-optica-spectrum-disorder/2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/verrica-pharmaceuticals-receives-complete-response-letter-from-the-fda-identifying-deficiencies-at-a-manufacturing-facility-for-vp-102-for-the-treatment-of-molluscum-contagiosum/2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-repatha-for-the-treatment-of-pediatric-patients-with--heterozygous-familial-hypercholesterolemia-.-amgen2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/nucala-is-approved-in-canada-to-treat-hypereosinophilic-syndrome.-gsk-2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/tga-australia-approves-zepzelca-to-treat-patients-with-small-cell-lung-cancer.--specialised-therapeutics2022-02-08T07:45:53+00:00weekly0.6https://www.medthority.com/news/2021/9/chemocentryx-announces-approval-in-japan-of-tavneos-for-the-treatment-of-anca-associated-vasculitis/2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-accepts-bmss-applications-for-opdivo--yervoy-and-opdivo--chemotherapy-for-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma/2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/latest-analyses-of-vitrakvi--reaffirm-powerful-efficacy-and-tolerability-profile-for-both-adult-and-pediatric-patients-with-trk-fusion-cancer.-bayer-healthcare-2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-keynote-394-trial-of-keytruda-meets-primary-endpoint-in-hepatocellular-carcinoma.--merck-inc2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/health-canada-approves-trodelvy-for-locally-advanced-or-metastatic-triple-negative-breast-cancer.--gilead-sciences2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/pfizer-and-opko-health-announce-the-extension-of-the-pdufa-date-for-review-of-somatrogon-for-pediatric-growth-hormone-deficiency/2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/pfizer-starts-global-phase-iiiii-epic-pep-study-of-novel-covid-19-antiviral-pf-07321332-for-post-exposure-prophylaxis/2024-11-14T13:09:31+00:00weekly0.6https://www.medthority.com/news/2021/9/saphnelo-approved-in-japan-for-systemic-lupus-erythematosus.-astrazeneca2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-expands-erbutix-label-with--braftovi-for-braf-v600e-mutation-positive-metastatic-colorectal-cancer--after-prior-therapy.-eli-lilly--pfizer2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/biohaven-provides-update-on-phase-iii-trial-of-verdiperstat-for-multiple-system-atrophy/2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-tango-study-of-dovato-shows-efficacy-in-hiv-1-at-three-years.--viiv-healthcare2022-02-08T07:45:54+00:00weekly0.6https://www.medthority.com/news/2021/9/phase-iii-furi-study-of-ibrexafungerp-shows-positive-clinical-results-in-multiple-fungal-infections.--scynexis-2022-02-08T07:45:55+00:00weekly0.6https://www.medthority.com/news/2021/9/health-canada-approves-truseltiq-for-cholangiocarcinoma-under-project-orbis.--helsinn--bridgebio-pharma2022-02-08T07:45:55+00:00weekly0.6https://www.medthority.com/news/2021/9/new-bimzelx-two-year-data-in-moderate-to-severe-plaque-psoriasis-presented-at-the-eadv-2021-congress.--ucb2022-02-08T07:45:55+00:00weekly0.6https://www.medthority.com/news/2021/9/fda-approves-livmarli--as-the-first-and-only-approved-medication-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-one-year-of-age-and-older.--mirum-pharma2024-11-14T13:09:51+00:00weekly0.6https://www.medthority.com/news/2021/9/astrazenecaalexion-acquires-caelum-biosciences-and-cael-101-a-potential-treatment-for-light-chain--amyloidosis/2022-02-08T07:45:55+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-surpass-3-trial-of-ly-3298176-meets-primary-endpoints-in-type-2-diabetes.--eli-lilly2022-02-08T07:45:55+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-brave-aa1-and-brave-aa2-trials-of-olumiant-shows-superiority-to-placebo-at-at-24-weeks-in-alopecia.--eli-lilly-and-incyte2024-11-14T13:10:22+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-trial-of-regen-cov-in-covid-19-published-in-nejm-.-regeneron-pharma2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iiiii-trial-of-regen-cov-meets-primary-endpoint-in-covid-19.--regeneron-pharma2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/mhra-uk-approves-tepmetko-to-treatmetex14-skipping-mutated-nsclc.--merck-inc2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/arcutis-submits-topical-roflumilast-cream-nda-to-the-fda-for-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis/2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/n-momentum-phase-iiiii-pivotal-trial-of-uplizna-in-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/viiv-healthcare-submits-extended-approval-request-for-tablet-formulation-of-triumeq-for-hiv-to-fda/2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-data-results-for-skyriziin-keepsake-1-and-keepsake-2-trials-for-active-psoriatic-arthritis.--abbvie2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-qulipta-for-prevention-of-migraine.--abbvie2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/azd-7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us.--astrazeneca2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/pharmamar-announces-the-approval-of-zepzelca-for-the-treatment-of-relapsed-stage-iii-or-metastatic-small-cell-lung-cancer-in-canada.--jazz-pharma2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-selection-trial-data-for-jyseleca-demonstrates-clinical-benefits-in-ulcerative-colitis.--galapagos2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/data-presented-at-ectrims-highlights-long-term-efficacy-of-enspryng-in-neuromyelitis-optica-spectrum-disorder.--genentechroche2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/chmp-recommends-approval-of-comirnaty-as-booster-dose-for-covid-19.--pfizer--biontech-se2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/humanigen-submits-all-planned-modules-of-lenzilumab-for-potential-conditional-marketing-authorization--in-hospitalized-covid-19-patients-to-the-uks-mhra/2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/more-than-a-dozen-studies-of-ocrevus-for-multiple-sclerosis-presented-at-ectrims.--genentechroche2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/positive-late-breaking-clinical-trial-data-for-the-ekosonic-endovascular-system-presented-at-viva21-meeting.-boston-scientific2024-11-14T13:11:49+00:00weekly0.6https://www.medthority.com/news/2021/10/ranger-ii-sfa-trial-of-ranger-drug-coated-balloon-shows-safety-and-efficacy-for-peripheral-artery-disease.--boston-scientific2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/ema-approves-extended-filing-for-spikevax-as-booster-for-covid-19.--moderna2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/niceuk-recommends-adakveo-as-a-treatment-for-preventing-recurrent-sickle-cell-crises.--novartis2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/submission-of-emergency-use-authorization-amendment-to-the-fda-to-support-booster-of-its-single-shot-covid-19-vaccine.--johnson--johnson2022-02-08T07:45:58+00:00weekly0.6https://www.medthority.com/news/2021/10/safety-analysis-of-biologics-and-highlighting-vaccine-hesitancy-real-world-data-shines-a-light-on-the-impact-of-covid-19-on-psoriasis-patients/2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-dtg-for-children-living-with-hiv.-viiv-healthcare2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-tavneos-for-vasculitis.--chemocentryx-2021-12-20T17:30:11+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-advisory-committee-recommends-approval-of-tak-620-for-cytomegalovirus-infection.--takeda2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/brii-196--brii-198-combination-filed-with-fda-for--emergency-use-authorization-in-covid-19.--brii-biosciences2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-rethymic--for-pediatric-congenital-athymia.--enzyvant2024-10-24T14:20:02+00:00weekly0.6https://www.medthority.com/news/2021/10/gantenerumab-granted-fda-breakthrough-therapy-designation-in-alzheimers-disease-and-reports-significant-reduction-of-amyloid-plaque.-genentechroche2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/beigene-announces-brukinsa-approved-in-australia-for-treatment-of-patients-with-mantle-cell-lymphoma--beigene/2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/azd-7442-reduced-risk-of-developing-severe-covid-19-or-death-in-tackle-phase-iii-outpatient-treatment-trial.--astrazeneca2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/merck-kgaa-announces-mutual-decision-to-end-bintrafusp-alfa-agreement-with-gsk/2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-accepts-filing-and-gives-priority-review-for-177-lu-psma-617-in-prostate-cancer.--novartis2024-11-14T13:10:58+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-reports-issues-with-filing-review-of-oms-721-for-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy.--omeros2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/ema-validates-filing-of-bms-986016--opdivo-for-advanced-melanoma.--bms2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderate-covid-19.-merck-inc.--ridgeback-biotherapeutics2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/merck-inc.-acquires-acceleron-pharma2025-10-16T11:24:39+00:00weekly0.6https://www.medthority.com/news/2021/10/european-medicines-agency-validates-maa-for-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy.--bms2024-11-14T13:11:20+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-tecartus-for-b-cell-precursor-acute-lymphoblastic-leukemia.--kite2022-02-08T07:45:56+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-true-v-trial-of-opzelura-shows-improvements-in-nonsegmental-vitiligo.--incyte2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-ecospor-iii-study-of-ser-109-shows-efficacy-in-c.-difficile-infection.--seres-therapeutics2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/two-studies-of-remsima-sc-shows-switching-to-subcutaneous-therapy-has-no-impact-on-treatment-for-inflammatory-bowel-disease.--celltrion-healthcare2022-02-08T07:45:57+00:00weekly0.6https://www.medthority.com/news/2021/10/cosmos-pharma-nv-makes-takeover-offer-for-cassiopea-s.p.a2025-10-16T11:35:28+00:00weekly0.6https://www.medthority.com/news/2021/10/bms-provides-update-on-phase-ii-study-of-deucravacitinib-in-patients-with-moderate-to-severe-ulcerative-colitis/2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/opdivo--yervoy-combination-could-be-an-alternative-to-extreme-chemotherapy-in-some-head-and-neck-cancers.--bms2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/rinvoq-met-primary-and-all-ranked-secondary-endpoints-in-select-axis-2-a-phase-iii-study-in-ankylosing-spondylitis.--abbvie2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/rinvoq-met-primary-and-most-ranked-secondary-endpoints-in-select-axis-2-a-phase-iii-study-for-non-radiographic-axial-spondyloarthritis.--abbvie2024-11-14T13:12:19+00:00weekly0.6https://www.medthority.com/news/2021/10/janssen-submits-application-seeking-fda-approval-of-stelara-for-the-treatment-of-pediatric-patients-with-juvenile-psoriatic-arthritis/2024-11-14T13:12:36+00:00weekly0.6https://www.medthority.com/news/2021/10/supernus-pharma-to-acquire-adamas-pharma-and-with-it-gocovri-which-is-fda-approved-for-parkinsons-disease/2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/new-real-world-mavenclad-data-show-sustained-effectiveness-and-benefit-on-quality-of-life-measures-in-relapsing-multiple-sclerosis-patients.---merck-kgaa2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/five-years-of-data-from-long-term-daybreak-study-reinforcing-efficacy-and-safety-profile-of-zeposia--in-patients-with-relapsing-forms-of-multiple-sclerosis.-bms2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-trials-of-ocrevus-show-efficacy-and-safety-in-multiple-sclerosis.--genentechroche2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-verzenio-as-the-first-and-only-cdk46-inhibitor-for-certain-people-with-hr-her2--high-risk-early-breast-cancer.--eli-lilly2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/new-long-term-data-reinforcing-promising-safety-and-efficacy-profile-of-brain-penetrant-tolebrutinib-presented-at-ectrims-2021--sanofi/2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-keytruda-plus-chemotherapy-for-cervical-cancer.--merck-inc2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/new-data-reinforce-the-relationship-between-b-cell-depletion-and-improved-outcomes-in-people-receiving-uplizna--for-neuromyelitis-optica-spectrum-disorder-nmosd.-horizon-therapeutics2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/new-4-year-data-show-enspryng-significantly-reduces-debilitating-relapses-in-people-with-aqp4-igg-seropositive-neuromyelitis-optica-spectrum-disorder.--genentechroche2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/chmp-recommends-eu-approval-of-zeposia-for-ulcerative-colitis.--bms2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/cibinqo-recommended-for-approval-by-chmp-for-atopic-dermatitis.--pfizer2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves--tecentriq-as-adjuvant-treatment-for-certain-people-with-early-non-small-cell-lung-cancer.--genentechroche2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-advisory-committee-unanimously-votes-in-support-of-emergency-use-for-a-booster-dose-of-modernas-covid-19-vaccine-in-the-u.s2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/avadel-pharmaceuticals-announces-ongoing-fda-review-of-nda-for-ft-218-for-patients-with-narcolepsy/2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-ultimate-i--ii-trials-of-tg-1101-shows-improvement-for-multiple-sclerosis.--tg-therapeutics-2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/top-line-results-from-ap-013-phase-iii-trial-of-ampion-in-adult-patients-with-severe-osteoarthritis-of-the-knee.--ampio-pharma2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/aspaveli--receives-positive-chmp-opinion-for-treatment-of-paroxysmal-nocturnal-haemoglobinuria.--sobi--apellis-pharma2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/opsynvi--becomes-the-first-and-only-health-canada-approved-once-daily-fixed-dose-combination-treatment-for-pulmonary-arterial-hypertension.--janssen-pharmaceuticals2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/johnson--johnson-covid-19-vaccine-booster-shot-unanimously-recommended-for-emergency-use-authorization-by--fda-advisory-committee/2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/chmp-recommends-rybrevant-to-treat-nsclc-with-activating-epidermal-growth-factor-receptor-egfr-exon-20-insertion-mutations.-janssen-international-n.v2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-supplemental-application-for-cyltezo-as-interchangeable-biosimilar-for-humira.--boehringer2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/chmp-recommends-sacituzumab-govitecan-as-monotherapy-for-adult-patients-with-unresectable-or-metastatic-triple-negative-breast-cancer.--gilead-sciences2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-individuals-18-years-of-age-and-older.--merck-inc2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/merck-and-eisai-receive-positive-eu-chmp-opinions-for-keytruda--plus-lenvima-in-advanced--renal-cell-carcinoma-and-endometrial-carcinoma.-2022-02-08T07:46:03+00:00weekly0.6https://www.medthority.com/news/2021/10/abbvie-receives-chmp-positive-opinion-for-skyrizi-for-the-treatment-of-adults-with-active-psoriatic-arthritis-in-the-european-union/2024-11-14T13:17:39+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-accepts-regen-cov-for-priority-review-for-treatment-and-prophylaxis-of-covid-19.--regeneron-pharma2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-monarche-trial-of-verzenio-in-breast-cancer-published-in-annals-of-oncology.--eli-lilly2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/ema-approves-new-shorter-infusion-time-for-gazyvaro-in-follicular-lymphoma.--roche2022-02-08T07:46:01+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-studies-of-kesimpta-shows-safety-in-multiple-sclerosis.--novartis2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/altamira-therapeutics-receives-fda-acceptance-for-bentrio-510k-application/2024-11-12T14:02:46+00:00weekly0.6https://www.medthority.com/news/2021/10/new-data-presented-at-ectrims-show-evobrutinib-is-first-btk-inhibitor-to-demonstrate-a-significant-reduction-in-slowly-expanding-lesions-sel-in-patients-with-relapsing-multiple-sclerosis.-merck-kgaa2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/imfinzi--tremelimumab-significantly-improved-overall-survival-in-himalaya-phase-iii-trial-in-1st-line-unresectable-liver-cancer.-astrazeneca2022-02-08T07:46:02+00:00weekly0.6https://www.medthority.com/news/2021/10/hugo-robotic-assisted-surgery-system-receives-european-ce-mark-approval.-medtronic2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/merck-inc.-and-ridgeback-announce-submission-of-emergency-use-authorization-application-to-the-fda-for-molnupiravir-an--oral-antiviral-medicine-for-the-treatment-of-mild-to-moderate-covid-19-in-at-risk-adults2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-modify-study-of-lucerastat-fails-to-meet-primary-endpoint-in-fabry-disease.--idorsia2022-02-08T07:45:59+00:00weekly0.6https://www.medthority.com/news/2021/10/pacira-biosciences-inc.-acquires-flexion-therapeutics-inc.-and-with-it-zilretta-a-treatment-for-oa-knee-pain2022-02-08T07:46:00+00:00weekly0.6https://www.medthority.com/news/2021/10/complete-response-letter--for-daxibotulinumtoxina-for-injection-to-treat-severe-glabellar-frown-lines.--revance-therapeutics2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/nice-recommends-the-use-of-opdivo-in-resected-oesophageal-or-gastro-oesophageal-junction-cancer.--bms2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/sarepta-therapeutics-srp-9001-shows-sustained-functional-improvements-in-multiple-studies-of-patients-with-duchenne/2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/biogen-announces-topline-results-from-the-tofersen-phase-iii--valor-study-and-its-open-label-extension-in-sod1-als-study/2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/update-on-fda-review-of-biologics-license-application-bla-for-bimekizumab-to-treat-psoriasis.-ucb2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/nrx-pharma-announced-publication-in-journal-of-infectious-diseases-and-treatment-of-aviptadil-for-the-treatment-of-respiratory-failure-in-patients-with-critical-covid-19-/2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-provides-a-complete-response-letter-for-oms-721-in-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy.--omeros2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-orient-31-trial-of-tyvyt--byvasda-meets-primary-endpoint-in-non-small-cell-lung-cancer.--innovent-biologics2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-atom-trial-of-tymlos-shows-positive-results-in-osteoporosis.--radius-health2024-11-14T13:18:07+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-phalcon-ee-trial-of-takecab-meets-its-primary-and-key-secondary-endpoints-in-erosive-oesophagitis.--phathom-pharmaceuticals2022-02-08T07:46:04+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approval-for-sbla-for-dextenza-for-intracanalicular-use-for-treatment-of-ocular-itching-associated-with-conjunctivitis.--ocular-therapeutix-inc2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/adamis-receives-fda-approval-for-zimhi-a-new-high-dose-naloxone-product-for-the-treatment-of-opioid-overdose/2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/sage-therapeutics--biogen-plan-to-submit-an-nda-for-zuranolone-for-major-depressive-disorder-and-post-partum-depression-in-the-second-half-of-2022-with-rolling-submission-expected-to-start-in-early-2022/2024-11-14T13:18:19+00:00weekly0.6https://www.medthority.com/news/2021/10/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-type-2-diabetes-with-increased-cardiovascular-risk.--eli-lilly2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/novavax-statement-on-initial-com-cov2-phase-ii-clinical-trial-results-presented-at-world-vaccine-congress-europe/2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/atea-pharmaceuticals-provides-update-and-topline-results-for-phase-ii-moonsong-trial-evaluating-at-527-in-the-outpatient-setting-of-covid-19-patients/2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/oyster-point-pharma-announces-fda-approval-of-tyrvaya-nasal-spray-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2022-02-08T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/10/zai-lab--entasis-therapeutics-announce-positive-topline-results-for-sulbactam-durlobactam-sul-dur-from-phase-iii-attack-trial-in-patients-with-infections-caused-by-acinetobacter-baumannii/2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/valneva-reports-positive-phase-iii-results-for-inactivated-adjuvanted-covid-19-vaccine-candidate-vla-2001/2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/eu-approves-opdivo-and-chemo-for-her2-negative-gastric-gastroesophageal-junction-or-oesophageal-adenocarcinoma.--bms2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-trial-of-comirnaty-shows-efficacy-as-booster-for-covid-19.--pfizerbiontech2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-dupixent-as-add-on-treatment-for-moderate-to-severe-asthma.--sanofi--regeneron2024-11-14T13:18:32+00:00weekly0.6https://www.medthority.com/news/2021/10/positive-pivotal-phase-iii-prime2-trial-reports-on-dupixent-in-adults-with-uncontrolled-prurigo-nodularis-a-chronic-type-2-inflammatory-skin-disease-that-causes-extreme-itch.--regeneron--sanofi-2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/baxter-and-biomerieux-announce-ce-mark-for-nephroclear-ccl14-test-to-predict-persistent-severe-acute-kidney-injury/2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/two-phase-iii-studies-of-xiaflex-show-efficacy-in-peyronies-disease.--endo-international2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/eu-approves-keytruda-plus-chemo-for-metastatic-triple-negative-breast-cancer.--merck-inc2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-ecztra-6-trial-of-adtralza-meets-its-primary-endpoints-at-16-weeks-for-atopic-dermatitis.--leo-pharma2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-solstice-trial-of-lonsurf-fails-to-meet-primary-endpoint-in--colorectal-cancer.--servier2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-ventana-pd-l1-sp263-assay-for-non-small-cell-lung-cancer-detection.--roche2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-issues-emergency-use-authorization-for-a-booster-dose-of-the-jnj-78436735-covid-19-vaccine-for-adults-aged-18-and-older.--johnson--johnson2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-susvimo-for-age-related-macular-degeneration.--genentechroche2024-11-14T13:18:47+00:00weekly0.6https://www.medthority.com/news/2021/10/pepaxto-withdrawn-from-market-in-us.--oncopeptides-2022-02-08T07:46:07+00:00weekly0.6https://www.medthority.com/news/2021/10/azurity-pharma-acquires-arbor-pharma/2025-10-16T11:05:06+00:00weekly0.6https://www.medthority.com/news/2021/10/bluebird-bio-to-withdraw-marketing-of-skysona-gene-therapy-in-europe/2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/galera-therapeutics-announces-results-of-phase-iii-roman-trial-of-avasopasem-for-radiotherapy-induced-severe-oral-mucositis/2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/novartis-presents-top-line-results-for-canopy-1-phase-iii-study-support-further-evaluation-of-canakinumab-in-lung-cancer/2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/imfinzi-plus-chemotherapy-significantly-improved-overall-survival-in-1st-line-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial-at-interim-analysis.--astrazeneca2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/moderna-announces-positive-top-line-data-from-phase-iiiii-study-of-covid-19-vaccine-in-children-6-to-11-years-of-age/2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-trial-of-dupixent-shows-efficacy-in-eosinophilic-esophagitis.--sanofiregeneron-pharma2022-02-08T07:46:08+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-mirror-trial-of-krystexxa-meets-primary-endpoint-in-chronic-gout.--horizon-therapeutics2024-11-14T13:19:03+00:00weekly0.6https://www.medthority.com/news/2021/10/retrospective-chart-review-study-of-variquel-shows-bleed-control-in-esophageal-variceal-hemorrhage.--mallinckrodt-2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/pivotal-phase-iii-trials-of-mk-8591--pifeltro-meet-endpoints-in-hiv.--merck-inc2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-trybeca-1-trial-of-graspa-fails-to-meet-primary-endpoint-in-pancreatic-cancer.--erytech-pharma2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/tirzepatide-is-filed-at-fda-and-at-ema-to-treat-type-2-diabetes.--eli-lilly2024-10-24T09:33:53+00:00weekly0.6https://www.medthority.com/news/2021/10/eli-lilly-and-pfizer-discontinue-the-global-clinical-development-program-for-tanezumab-an-investigational-nerve-growth-factor-inhibitor/2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/dsmb-supports-continuation-of-phase-iii-trial-of-bucillamine-in-covid-19.--revive-therapeutics2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/cortexyme-inc.-reports-gain-trial-data-of-atuzaginstat-demonstrated-relationship-between-reduction-of-p.-gingivalis-infection-and-slowing-of-alzheimers-disease-progression2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/alkermes-initiates-artistry-7-phase-iii-trial-of-nemvaleukin-alfa-in-patients-with-platinum-resistant-ovarian-cancer/2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/the-medicines-patent-pool-and-merck-inc.-enter-into-a-license-agreement-for-molnupiravir-an-investigational-oral-antiviral-covid-19-medicine-to-increase-broad-access-in-low--and-middle-income-countries2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-advisory-committee-votes-in-favour-of-granting-emergency--use-authorization-for--pfizer-biontech-se-covid-19-vaccine-in-children-aged-5-to-less-than-12-years/2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/positive-topline-18-month-results-from-helios-a-phase-iii-study-of-vutrisiran-in-patients-with-hattr-amyloidosis-with-polyneuropathy.-alnylam-pharma2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/sorrento-therapeutics-announces-encouraging-results-from-two-phase-ii-studies-of-abivertinib-for-treatment-of-hospitalized-severe-covid-19-patients/2022-02-08T07:46:09+00:00weekly0.6https://www.medthority.com/news/2021/10/novavax-files-for-authorization-of-its-covid-19-vaccine-nvx-cov2373-in-the-united-kingdom/2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/ema-and-fda-accept-filing-of-kymriah-for-follicular-lymphoma.--novartis2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-carisel-study-of-vocabria--rekambys-shows-long-acting-regimen-is-achievable-in-hiv.--viiv-healthcare2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-accepts-updated-rolling-review-timetable-for-leronlimab-as-a-combination-therapy-for-hiv-patients.--cytodyn2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/angion-biomedica-and-vifor-pharma-report-topline-results-from-phase-iii-trial-of-ang-3777-in-kidney-transplant-patients-at-risk-of-delayed-graft-function/2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/incyte-announces-the-ema--validation-of-the-maa-for-ruxolitinib-cream-as-a-potential-treatment-for-vitiligo/2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/a-post-acute-ocular-tolerability-comparison-of-topical-reproxalap-0.25-and-lifitegrast-5-in-patients-with-dry-eye-disease.-aldeyra-therapeutics-inc2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/additional-overall-survival-data-for--verzenio-phase-iii-monarche-trial--published-in-the-annals-of-oncology.--eli-lilly2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda-in-a-complete-response-letter/2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/spesolimab-filed-with-eu-for-pustular-psoriasis.--boehringer2021-12-20T17:31:01+00:00weekly0.6https://www.medthority.com/news/2021/10/zynlonta-filed-with-eu-in-diffuse-large-b-cell-lymphoma.--adc-therapeutics2022-02-08T07:46:10+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-studies-3111-301-001-and--3111-302-001-of-vraylar-show-statistically-significant-change-in-major-depressive-disorder.--abbvie2024-11-14T13:19:29+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-scemblix-with-novel-mechanism-of-action-for-the-treatment-of-chronic-myeloid-leukemia.-novartis2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/10/merck-announces-withdrawal-and-refiling-under-the-hart-scott-rodino-act-and-extension-of-tender-offer-to-acquire-acceleron-pharma-inc/2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/10/moderna-announces-first-participant-dosed-in-phase-iii-pivotal-registration-study-of-its-mrna-cytomegalovirus-cmv-vaccine/2024-10-24T09:34:06+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-vuity-for-presbyopia.--allerganabbvie2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/10/bluebird-bio-inc.-to-spin-off-its-oncology-programs-to-2seventy-bio-as--a-publicly-traded-company-in-early-november-20212022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/sorrento-announces-that-covistix-covid-19-virus-rapid-antigen-detection-test-has-received-a-ce-mark-and-registration-of-the-device/2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/fda-approves-expanded-indication-of-biktarvy-for-treatment-of-hiv-1-in-pediatric-populations.--gilead-sciences2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/phase-iii-emerald-study-of-rad-1901-meets-primary-endpoints-in-erher2--breast-cancer.--menarini-group--radius-health2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/10/ferriprox-approved-in-canada-for-treatment-of-iron-overload-in-patients-with-sickle-cell-disease.--chiesi-global-rare-diseases.-2022-02-08T07:46:06+00:00weekly0.6https://www.medthority.com/news/2021/11/pfizer-and-biontech-receive-first-usa-emergency-use-authorization-of-a-covid-19-vaccine-for-children-ages-5-through-11-years/2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/merck-inc.-announced-new-data-from-studies-evaluating-keytruda-mercks-anti-pd-1-therapy-at-the-society-for-melanoma-research-smr-2021-congress2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/rafael-pharmaceuticals-provides-update-on-pivotal-phase-iii-clinical-trial-in-patients-with-metastatic-adenocarcinoma-of-the-pancreas/2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/astrazeneca-to-transfer-global-rights-for-eklira-and-duaklir-to-covis-pharma/2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/moderna-provides-update-on-timing-of-u.s.-emergency-use-authorization-of-its-covid-19-vaccine-for-adolescents2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/updated-interim-results-from-the-aurora-2-continuation-study-of-lupkynis-for-the-treatment-of-lupus-nephritis.--aurinia-pharma2022-02-08T07:46:11+00:00weekly0.6https://www.medthority.com/news/2021/11/incyte-announces-acceptance-by-fda-of-nda-for-parsaclisib-for-three-types-of-relapsed-or-refractory-non-hodgkin-lymphomas/2024-11-14T13:19:44+00:00weekly0.6https://www.medthority.com/news/2021/11/novavax-files-for-covid-19-vaccine-authorization-with-health-canada-and-completes-submission-for-rolling-review-to-european-medicines-agency/2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/amylyx-pharmaceuticals-submits-nda-for-amx-0035-to-the-fda-for-the-treatment-of-amyotrophic-lateral-sclerosis/2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/janssen-announces-extension-of--fda-pdufa-date-for-bcma-car-t-ciltacabtagene-autoleucel-formultiple-myeloma/2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/idorsia-to-advance-cenerimod-into-phase-iii-development-for-treatment-of-patients-with-systemic-lupus-erythematosus/2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/new-comprehensive-phase-iii-data-show-first-in-class-tremfya--provided-durable-improvements-in-measures-of-psoriatic-arthritis-through-two-years.-johnson--johnson2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/-the-uk-medicines-and-healthcare-products-regulatory-agency-mhra-authorizes-lageviro-for-the-treatment-of-mild-to-moderate-covid-19-in-adults-with-a-positive-sars-cov-2-diagnostic-test.merck-inc.--ridgeback-biotherapeutics2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/abbv-951-showed-improvement-in-controlling-motor-fluctuations-compared-to-oral-levodopacarbidopa-medication-in-pivotal-phase-iii-trial-in--advanced-parkinsons-disease.-abbvie2024-11-14T13:20:04+00:00weekly0.6https://www.medthority.com/news/2021/11/eli-lilly-to-cease-supplying-etesevimab--bamlanivimab-combination-in-the-eu-and-withdraw-its-application--for-full-authorization/2022-02-08T07:46:12+00:00weekly0.6https://www.medthority.com/news/2021/11/emperor-preserved-phase-iii-trial-of-jardiance-shows-efficacy-in-heart-failure.--eli-lilly--boehringer2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/intrigue-phase-iii-study-of-qinlock-fails-to-meet-primary-endpoint-in-gastrointestinal-stromal-tumor.--deciphera-pharmaceuticals2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/illuminate-c-phase-iii-open-label-study-of-oxlumo-shows-efficacy-in-primary-hyperoxaluria-type-1.--alnylam-pharmaceuticals2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/paxlovid-significantly-reduced-hospitalization-and-death-based-on-an-interim-analysis-of-the-phase-iiiii-epic-hr-study-of-non-hospitalized-adult-patients-with-covid-19--pfizer/2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/covaxin-filed-with-fda-for-emergency-use-authorization-in-covid-19.--ocugen2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/phase-iii-ascend-studies-of-duvroq-meet-their-primary-endpoints-in-anaemia-due-to-chronic-kidney-disease.--glaxosmithkline2024-11-14T13:20:25+00:00weekly0.6https://www.medthority.com/news/2021/11/medtronics-intrepid-transfemoral-tmvr-system-evaluated-in-early-feasibility-study.----2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/wegovy-demonstrated-significant-and-sustained-weight-loss-in-two-year-study-in-adults-with-obesity.--novo-nordisk2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/baxter-highlights-new-data-indicating-sharesource-digital-health-platform-for-home-dialysis-may-improve-survival-and-reduce-hospitalizations/2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/weill-cornell-medicine-and-new-york-presbyterian-hospital-join-boehringer-ingelheim-to-study-the-incidence-of-progressive-interstitial-lung-disease-in-covid-19-patients/2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/eton-pharmaceuticals-and-azurity-pharmaceuticals-inc.-announce-fda-approval-of-eprontia-oral-solution-for-epilepsy-and-migraine2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-grants-tentative-approval-for-yutrepia-to-treat-pulmonary-arterial-hypertension.---liquidia-corpn2022-02-08T07:46:13+00:00weekly0.6https://www.medthority.com/news/2021/11/neoadjuvant-opdivo-plus-chemotherapy-significantly-improves-event-free-survival-in-patients-with-resectable-non-small-cell-lung-cancer-in-phase-iii-checkmate--816-trial.--bms2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/first-head-to-head-study-comparing-aimovig-an-anti-cgrp-pathway-therapy-to-topiramate-for-episodic-and-chronic-migraine-is-published-in-cephalalgia.-amgen--novartis2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/new-phase-iii-analyses-show-that-a-single-dose-of-regen-cov-provides-long-term-protection-against-covid-19.-regeneron--roche-2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/health-canada-approves-opdivo-for-her2-negative-gastric-gastroesophageal-junction-or-esophageal-adenocarcinoma-cancers-and-as-monotherapy-for-the-adjuvant-treatment-for-resected-esophageal-or-gastroesophageal-junction-cancers.-bms-2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/fda-approves-cortrophin-gel-for-acute-flare-ups-in-multiple-sclerosis-and-other-autoimmune-conditions.-ani-pharma2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/olumiant-long-term-safety-profile-established-up-to-9.3-years-in-integrated-analysis-of-more-than-3700-patients-with-rheumatoid-arthritis.--eli-lilly--incyte2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/biohaven-and-pfizer-enter-strategic-collaboration-for-the-commercialization-of-rimegepant-outside-of-the-usa/2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/kalvista-pharmaceuticals-provides-progress-update-on-kvd-900-for-oral-on-demand-treatment-of-hereditary-angioedema/2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/moderna-files-to-expand-the-conditional-marketing-authorization-for-its-covid-19-vaccine-in-the-european-union-to-include-children-ages-6-11-years/2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/abbvie-presents-new-efficacy-data-on-rinvoq-in-people-with-active-psoriatic-arthritis-and-axial-involvement-at-acr-convergence-2021/2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2021/11/phase-iib-registrational-study-of-sacituzumab-govitecan-conducted-in-china-for-metastatic-triple-negative-breast-cancer-meets-primary-overall-response-rate-endpoint.-gilead-sciences---everest-medicines2022-02-08T07:46:14+00:00weekly0.6https://www.medthority.com/news/2020/06/new-data-from-hgb-206-study-show-near-elimination-of-sickle-cell-disease-related-vaso-occlusive-crises-by-lentiglobin-gene-therapy-and-plans-to-file-at-fda-in-2021-.--bluebird-bio.-2024-11-12T13:44:50+00:00weekly0.6https://www.medthority.com/news/2020/06/pivotal-trial-of-oms-721-shows-good-response-rate-in-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy.--omeros-corp2024-10-21T15:02:02+00:00weekly0.6https://www.medthority.com/news/2020/06/nice-draft-guidance-does-not-recommend-use-of-cablivi-in-thrombotic-thrombocytopenic-purpura.--sanofi2024-10-24T14:58:01+00:00weekly0.6https://www.medthority.com/news/2020/06/nice-draft-guidance-rejects-the-use-of-sarclisa-combination-therapy-for-multiple-myeloma.--sanofi2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-trial-with-ninlaro-meets-primary-endpoint-as-first-line-maintenance-treatment-of-multiple-myeloma.--takeda2021-12-20T17:32:29+00:00weekly0.6https://www.medthority.com/news/2020/06/novo-nordisk-acquires-corvidia-therapeutics-and-with-it-ziltivekimab/2021-09-24T07:11:27+00:00weekly0.6https://www.medthority.com/news/2020/06/sobi-acquires-rights-outside-china-to-sel-212-a-proposed-treatment-for-gout-from-selecta-biosciences/2024-10-21T15:02:20+00:00weekly0.6https://www.medthority.com/news/2020/06/positive-phase-iii-results-for-venclexta-combination-in-acute-myeloid-leukemia-presented-at-eha-2020.-genentechroche2024-11-08T11:39:32+00:00weekly0.6https://www.medthority.com/news/2020/06/genentech-announces-2-year-risdiplam-data-from-sunfish-and-new-data-from-jewelfish-in-infants-children-and-adults-with-spinal-muscular-atrophy-sma/2024-11-12T09:17:29+00:00weekly0.6https://www.medthority.com/news/2020/06/real-world-study-of-trulicity-shows-improved-adherence-and-persistence-in-type-2-diabetes.--eli-lilly2024-10-21T15:02:27+00:00weekly0.6https://www.medthority.com/news/2020/06/real-world-studies-of-ozempic-show-efficacy-and-weight-reduction-in-type-2-diabetes.--novo-nordisk-2024-10-22T07:35:58+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-study-of-subcutaneous-daratumumab-combination-treatment-shows-positive-response-in-light-chain-al-amyloidosis.--janssen-rd2024-11-08T09:33:31+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-resurface-12-extension-studies-showed-ilumya-offers-sustained-and-improved-results-in--plaque-psoriasis.--sun-pharma2021-12-20T17:32:29+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-expands-approval-for-gardasil-9-to-include-oropharyngeal-and-other-head-and-neck-cancers.--meck-inc2024-11-08T11:39:26+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-pegasus-study-of-apl-2-shows-consistent-impact-in-paroxysmal-nocturnal-hemoglobinuria.--apellis-pharma2024-11-08T09:33:48+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-pso-long-trial-of-enstilar-meets-primary-endpoint-in-plaque-psoriasis.--leo-pharma2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-clinical-data-from-be-vivid-and-be-ready--studies-of-bimekizumab-presented-at-aad-for-treatment-of-psoriasis.--ucb2024-10-22T07:37:09+00:00weekly0.6https://www.medthority.com/news/2020/06/soleno-therapeutics-announces-top-line-results-from-phase-iii-trial-of-dccr-for-treatment-of-prader-willi-syndrome/2024-10-22T09:43:51+00:00weekly0.6https://www.medthority.com/news/2020/06/immerge-phase-iiib-data-shows-superior-rates-of-skin-clearance-for-skyrizi-in-psoriasis.--abbvie2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/envision-phase-iii-study-results-of-givlaari-to-treat-acute-hepatic-porphyria--were-published-online-in-the-nejm.--alnylam-pharma2024-10-21T15:01:26+00:00weekly0.6https://www.medthority.com/news/2020/06/johnson--johnson-initiates-phase-iiia-trial-of-ad26.cov2-s-recombinant-to-treat-covid-192021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/real-world-data-of-terlipressin-in-hospitalized-patients-in-the-u.k.-with-hepatorenal-syndrome-type-1--is-published-in-alimentary-pharmacology-and-therapeutics.--mallinckrodt2024-10-22T11:53:27+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-study-of-mrna-1273-for-prevention-of-symptomatic-covid-19-disease-is-expected-to-begin-in-july-2020-.--moderna-inc2024-10-21T15:01:37+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-trials-show-efficacy-of-eb-1020-in-attention-deficit-hyperactivity-disorder.--otsuka-pharmaceutical2024-10-21T15:01:50+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approval-of-uplizna-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder---viela-bio/2024-10-25T08:53:40+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-best-trial-of-thr-1442-shows-efficacy-in-type-2-diabetes-with-cv-risk.--theracos2024-11-12T09:17:08+00:00weekly0.6https://www.medthority.com/news/2020/06/results-from-phase-ii-ace-cl-001-trial-and-phase-iii-ascend-trials-shows-long-term-efficacy-of-calquence-in-chronic-lymphocytic-leukaemia.--astrazeneca2024-10-25T08:53:52+00:00weekly0.6https://www.medthority.com/news/2020/06/freestyle-libre-system-associated-with-reduction-in-hba1c-levels-for--type-2-diabetes.--abbott2024-11-12T09:16:33+00:00weekly0.6https://www.medthority.com/news/2020/06/zealand-pharma-presents-clinical-and-non-clinical-evidence-for-dasiglucagon-rescue-therapy-at-the-80th-scientific-sessions-of-the-american-diabetes-association/2024-10-22T07:39:06+00:00weekly0.6https://www.medthority.com/news/2020/06/lilly-begins-a-phase-iii-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients/2021-12-20T17:32:24+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-semglee-an-insulin-glargine-injection-biosimilar-for-types-1-and-2-diabetes.--mylan--biocon2024-10-25T08:54:11+00:00weekly0.6https://www.medthority.com/news/2020/06/-fda-gives-accelerated-approval-to-zepzelca-for-the-treatment-of-metastatic-small-cell-lung-cancer.jazz-pharma--pharmamar2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/06/verzenio--significantly-reduced-the-risk-of-cancer-returning-in-people-with-high-risk-hr-her2--early-breast-cancer.--eli-lilly2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/06/sanofis-avalglucosidase-alfa-shows-clinically-meaningful-improvement-in-critical-manifestations-of-late-onset-pompe-disease/2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-vertis-cv-trial-with--steglatro-meets-endpoint-in-type-2-diabetes--cv.--merck-inc-and-pfizer2024-10-22T11:44:23+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-lyumjev-insulin-lispro-aabc-injection-a-new-rapid-acting-insulin.--eli-lilly2024-10-22T07:39:24+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-cosentyx-to-treat-active-non-radiographic-axial-spondyloarthritis.--novartis2024-11-08T11:39:15+00:00weekly0.6https://www.medthority.com/news/2020/06/overcome-study-reveals-less-than-30-percent-of-people-living-with-migraine-take-recommended-prescription-medications.-eli-lilly2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19.--generic2024-10-22T11:44:46+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-linc-4-study-of-isturisa--for-the-treatment-of-patients-with-cushings-disease.--recordati2024-11-12T14:08:51+00:00weekly0.6https://www.medthority.com/news/2020/06/additional-data-from-4-year-update-of-ongoing-phase-1ii-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a-presented-at-world-federation-of-hemophilia-virtual-summit.--biomarin2024-10-22T07:40:54+00:00weekly0.6https://www.medthority.com/news/2020/06/emgality-demonstrates-reduction-in-frequency-duration-and-pain-severity-in-patients-with-episodic-and-chronic-migraine.--eli-lilly2024-10-22T11:45:04+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-endeavorrx--a-prescription-treatment-for-children-with-adhd.--akili2024-11-08T09:46:20+00:00weekly0.6https://www.medthority.com/news/2020/06/keytruda-is-now-approved-for-adult-and-pediatric-patients-with-unresectable-or-metastatic-tumor-mutational-burden-high-tmb-h-mutationsmegabase-solid-tumors.--merck-inc2024-10-22T07:42:31+00:00weekly0.6https://www.medthority.com/news/2020/06/brukinsa-maa-validated-by-ema-to-treat-waldenstroms-macroglobulinemia-.--beigene2024-10-22T11:45:23+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-crysvita-for-the-treatment-of-fibroblast-growth-factor-23--related-hypophosphatemia-in-tumor-induced-osteomalacia-tio--ultragenyx--kyowa-kirin-co.-ltd2024-10-22T11:45:44+00:00weekly0.6https://www.medthority.com/news/2020/06/mylan-announces-court-decision-that-biogens-tecfidera-patent-is-invalid/2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-ipatential150-study-with-rg-7440-plus-zytiga-meets-co-primary-endpoint-in-prostate-cancer.--genentechroche2025-01-31T11:05:56+00:00weekly0.6https://www.medthority.com/news/2020/06/emperial-reduced-and-emperial-preserved-trials-of-jardiance-shows-efficacy-in-chronic-heart-failure.--boehringer---eli-lilly2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/initiation-of-phase-i-trial-of-covid-19-s-trimer-vaccine-scb-2019.--clover-biopharmaceuticals--gsk2024-10-22T11:46:06+00:00weekly0.6https://www.medthority.com/news/2020/06/first-participants-dosed-in-phase-i-trial-of-scb-2019-vaccine---tlt-9-for-covid-19.-dynavax--clover-biopharmaceuticals2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/ridgeback-biotherapeutics-announces-the-launch-of-two-phase-ii-clinical-trials-to-test-the-efficacy-of-eidd-2801-as-an-anti-viral-treatment-for-covid-19.merck-inc2024-10-22T07:43:16+00:00weekly0.6https://www.medthority.com/news/2020/06/positive-results-from-randomized-controlled-trial-of-cp1-01-an-oral-microbiome-drug-for-the-prevention-of-recurrent-c.-difficile-infection.-finch-therapeutics-group2024-10-22T07:43:44+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-cobas-ezh2-mutation-test-as-companion-diagnostic-for-tazverik-in-follicular-lymphoma.--roche2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-provides-complete-response-letter-for-resubmission-of-contepo-in-complicated-urinary-tract-infections.--nabriva-therapeutics2024-10-24T14:57:37+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-gimoti-to-treat-gastroparesis--evoke-pharma-inc/2024-10-24T14:57:49+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-grants-accelerated-approval-for-tazverik-to-treat-follicular-lymphoma.-epizyme-inc2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/indian-government-approves-fabiflu-for-mild-to-moderate-covid-19-patients.--glenmark-pharma--2024-10-22T07:44:31+00:00weekly0.6https://www.medthority.com/news/2020/06/health-canada-approves-qinlock-for-advanced-gastrointestinal-stromal-tumor.--deciphera-pharma2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-accepts-nda-for-oral-relugolix-for-treatment-of-advanced-prostate-cancer.--myovant-sciences2025-01-31T11:40:11+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-studies-of-v-114-meet-objectives-in-pneumococcal-disease.--merck-inc2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/publication-of-early-patient-experience-with-the-urolift-system-as-a-superior-treatment-to-rezum-steam-injection-in-patients-with-enlarged-prostate.teleflex-incorporated2025-01-31T11:06:56+00:00weekly0.6https://www.medthority.com/news/2020/06/first-patient-enrolled-in-sanofis-phase-iii-trial-of-sar-442168-in-relapsing-multiple-sclerosis.--sanofi2024-10-22T11:46:56+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-grants-accelerated-approval-for-xpovio-to-treat-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-dlbcl.-karyopharmtherapeutics2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/fulcrum-therapeutics-initiates-phase-iii-trial-of-losmapimod-to-treat-covid-19/2024-10-22T07:43:57+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-grants-emergency-use-authorisation-for-genepro-sars-cov-2-test-as-diagnostic-for-covid-19.--gencurix2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-recover-analysis-of-sublocade-shows-two-year-outcome-in-opioid-use-disorder.--indivior-2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/breztri-aerosphere-significantly-reduced-rate-of-moderate-or-severe-copd-exacerbations-in-phase-iii-ethos-trial.--astrazeneca2024-10-22T11:47:35+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-keytruda-to-treat-cutaneous-squamous-cell-carcinoma-that-is-not-curable-by-surgery-or-radiation.--merck-inc2024-10-22T07:44:18+00:00weekly0.6https://www.medthority.com/news/2020/06/la-jolla-pharmaceutical-company-acquires-tetraphase-pharmaceuticals-and-with-it-xerava/2021-09-24T07:11:23+00:00weekly0.6https://www.medthority.com/news/2020/06/positive-results-from-second-phase-iii-study-evaluating-once-daily-relugolix-combination-therapy-in-women-with-endometriosis.--myovantsciences2024-11-07T16:08:11+00:00weekly0.6https://www.medthority.com/news/2020/06/adial-pharmaceuticals-commences-onward-trial-of-ad-04-as-a-therapeutic-agent-for-the-treatment-of-alcohol-use-disorder/2024-10-22T12:47:15+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-fintepla-to-treat-dravet-syndrome.--zogenix2024-10-24T15:26:13+00:00weekly0.6https://www.medthority.com/news/2020/06/elocta-gains-increased-access-for-people-with-haemophilia-a-in-the-uk.--sobi2021-12-20T17:31:45+00:00weekly0.6https://www.medthority.com/news/2020/06/european-commission-approves-reblozyl-to-treat-myelodysplastic-syndromes-and-transfusion-dependent-anemia-associated-with-beta-thalassemia.--bms--acceleron-pharma2021-12-20T17:31:45+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-xolair-an-add-on-therapy-with-intranasal-corticosteroids-for-the-treatment-of-adults-with-severe-chronic-rhinosinusitis-with-nasal-polyps.--novartis-2024-11-12T10:51:29+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-positive-for-treatment-of--plaque-psoriasis-with-cosentyx-in-children-and-adolescents-aged-6-to-18-years.--novartis2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-grants-positive-opinion-for-kaftrio-ivacaftortezacaftorelexacaftor-in-combination-with-kalydeco-ivacaftor-in-people-ages-12-and-older-with-cystic-fibrosis-with-the-most-common-genotypes.--vertex2024-10-24T09:49:01+00:00weekly0.6https://www.medthority.com/news/2020/06/operation-warp-speed-to-test-first-oral-covid-19-vaccine-in-non-human-primates.--vaxart2021-12-20T17:31:45+00:00weekly0.6https://www.medthority.com/news/2020/06/complete-response-for-abicipar-pegol-to-treat--neovascular-wet-age-related-macular-degeneration.-allerganabbvie--molecular-partners-2024-11-12T14:02:57+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-idefirix-for-the-desensitization-treatment-of-highly-sensitized-adult-kidney-transplant-patients-with-a-positive-crossmatch-against-an-available-deceased-donor..-hansa-biopharma2024-11-12T10:51:40+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-aybintio-a-bevacizumab-biosimilar.-samsung-bioepis--merck-inc2021-12-20T17:33:02+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-livogiva-a-teriparatide-biosimilar-for-the-treatment-of-osteoporosis.-alvogen2024-10-24T09:49:31+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-negative-for-turalio-a-medicine-intended-for-the-treatment-of-tenosynovial-giant-cell-tumour.--plexxikondaiichi-sankyo2024-11-07T16:08:49+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-approval-of-veklury-for-covid-19-novel-coronavirus.--gilead-sciences2021-12-20T17:33:03+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-approval-of-qutavina-teriparatide-biosimilar-for-osteoporosis.--eurogenerics-holdings2024-10-25T10:59:02+00:00weekly0.6https://www.medthority.com/news/2020/06/eu-recommends-change-to-marketing-authorisation-for-epclusa-in-chronic-hepatitis-c-virus-infection.--gilead-sciences2024-11-07T16:09:00+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-extending-the-indication-for-remsima-sc-to-include-crohns-disease-ulcerative-colitis-ankylosing-spondylitis-psoriatic-arthritis-and-psoriasis.--celltrion-healthcare2024-11-07T16:09:15+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-mycapssa-for-long-term-maintenance-treatment-in-acromegaly-patients.--chiasma-inc2024-11-12T10:53:45+00:00weekly0.6https://www.medthority.com/news/2020/06/csl-behring-to-acquire-global-license-rights-to-adeno-associated-virus-gene-therapy-program-amt-061-for-hemophilia-b-from-uniqure/2024-11-12T10:54:11+00:00weekly0.6https://www.medthority.com/news/2020/06/abbotts-optical-coherence-tomography-imaging-changed-treatment-decisions-in-88-of-artery-blockages/2024-11-07T16:09:28+00:00weekly0.6https://www.medthority.com/news/2020/06/chmp-recommends-gencebok-for-the-treatment-of-primary-apnoea-of-premature-newborns.--gennisium-pharma2024-10-24T09:50:01+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-lotus-study-of-stelara-in-systemic-lupus-erythematosus-discontinued.--janssen-pharma2024-10-22T12:46:55+00:00weekly0.6https://www.medthority.com/news/2020/07/scpharmaceuticals-inc.-has-resubmitted-its-nda-to-the-fda-for-furoscix-for-the-treatment-of-congestion-in-patients-with-heart-failure2021-09-24T07:11:42+00:00weekly0.6https://www.medthority.com/news/2020/07/rm-493-filed-with-maa-for-pro-opiomelanocortin-pomc-deficiency-obesity-and-leptin-receptor-lepr-deficiency-obesity.--rhythm-pharma2024-11-08T08:54:12+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-bavencio-as-first-line--maintenance-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma/2024-11-12T10:20:47+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-has-granted-marketing-authorization-for-mvabea---zabdeno--vaccine-regimen-for-treatment-of-ebola.--janssen-vaccines--bavarian-nordic2024-11-12T10:21:05+00:00weekly0.6https://www.medthority.com/news/2020/07/preliminary-data-shows-that-bnt-162b1-is-safe-and-immunologically-active-in-covid-19.--pfizer-and-biontech2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/07/udenafil-filed-with-fda-for-single-ventricle-heart-disease.--mezzion-pharma2024-11-08T08:55:41+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-trial-of-sb-393-plus-vidaza-in-acute-myeloid-leukaemia-discontinued.--helsinn--mei-pharma2024-10-24T15:26:26+00:00weekly0.6https://www.medthority.com/news/2020/07/hansa-biopharma-licences-sarepta--to-develop-imlifidase-as-a-potential-pre-treatment-prior-to-the-administration-of-gene-therapy-for-muscular-dystrophy-patients/2024-10-24T09:35:21+00:00weekly0.6https://www.medthority.com/news/2020/07/kevzara--phase-iii-u.s.-trial-in-covid-19-patients-does-not-meet-endpoints.-sanofi--regeneron2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-dojolvi-for-the-treatment-of-pediatric-and-adult-patients-with-molecularly-confirmed-long-chain-fatty-acid-oxidation-disorders.-_ultragenyx2024-11-08T08:56:35+00:00weekly0.6https://www.medthority.com/news/2020/07/favourable-topline-results-reported--from-innovatv-204-trial-of-tisotumab-vedotin-for-cervical-cancer.--seattle-genetics--genmab-as2021-09-24T07:11:41+00:00weekly0.6https://www.medthority.com/news/2020/07/nhs-to-reimburse-kaftrio-triple-therapy-to-treat-cystic-fibrosis.---vertex2024-11-12T10:21:17+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-rukobia-for-hiv.--viiv-healthcare2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-byfavo-for-procedural-sedation-in-adults.--acacia-pharma2024-10-25T10:59:16+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-approves-veklury-a-treatment-for-covid-19-infection.--gilead-sciences2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/07/cardiovascular-and-renal-safety-profile-of-linagliptin-demonstrated-in-asian-adults-with-type-2-diabetes--boehringer--eli-lilly/2024-11-12T10:48:13+00:00weekly0.6https://www.medthority.com/news/2020/07/idelvion-becomes-first-and-only-factor-ix-therapy-with-21-day-prophylactic-dosing-for-treating-haemophilia-b.-csl-behring2024-11-12T10:48:26+00:00weekly0.6https://www.medthority.com/news/2020/07/myovant-sciences-presents-additional-data-on-relugolix-combination-therapy-from-phase-iii-liberty-studies-in-women-with-uterine-fibroids-and-from-ovulation-inhibition-study/2024-11-08T08:56:49+00:00weekly0.6https://www.medthority.com/news/2020/07/bd-launches-portable-rapid-point-of-care-antigen-test-to-detect-sars-cov-2-in-15-minutes-dramatically-expanding-access-to-covid-19-testing/2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/07/viiv-healthcare-presents-positive-data-from-first-ever-implementation-research-study-on-how-best-to-integrate-an-investigational-once-monthly-injectable-hiv-treatment-in-us-healthcare-practices/2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/07/regeneron-initiates-phase-iii-trial--of-regn-cov2-to-treat-and-prevent-covid-19-/2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves--next-generation-gallan-implantable-cardioverter-defibrillator-icd-and-cardiac-resynchronization-therapy-defibrillator-crt-d-devices.--abbott2024-09-30T10:58:57+00:00weekly0.6https://www.medthority.com/news/2020/07/approval-of-vadadustat-as-vafseo-in-japan-for-the-treatment-of-anemia-due-to-chronic-kidney-disease.--mitsubishi-tanabe--akebia2024-11-08T08:57:04+00:00weekly0.6https://www.medthority.com/news/2020/06/idmc-reports-phase-iii-pallas-trial-of-ibrutinib-unlikely-to-meet-endpoint-in-early-breast-cancer.--pfizer2024-10-24T09:19:16+00:00weekly0.6https://www.medthority.com/news/2020/06/biomarin-provides-highlights-of-4-years-of-clinical-data-from-ongoing-phase-1ii-study-of-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a/2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/06/brilinta-approved-by-fda-to-reduce-the-risk-of-a-first-heart-attack-or-stroke-in-high-risk-patients-with-coronary-artery-disease-.-astrazeneca2024-10-24T09:19:28+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-supplemental-bla-for-taltz-for-the-treatment-of-active-non-radiographic-axial-spondyloarthritis.--eli-lilly2024-10-24T14:33:09+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-ii-destiny-crc01-trial-of--enhertuenhurtu-demonstrated-meaningful-activity-in-patients-with-her2-positive-unresectable-andor-metastatic-colorectal-cancer.--daiichi-sankyo--astrazeneca2024-10-25T08:53:19+00:00weekly0.6https://www.medthority.com/news/2020/06/gilead-announces-results-from-phase-iii-trial-of-remdesivir-in-patients-with-moderate-covid-19.--gilead-sciences2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/06/sure-2-phase-iii-clinical-trial-of--sulopenem-fails-to-meet-endpoint-in-complicated-urinary-tract-infection.--iterum-therapeutics2024-10-24T09:19:43+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-accepts-refiling-of-fotivda-for-renal-cell-carcinoma.--aveo-oncology2024-10-22T11:43:38+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-ii-destinylung01-trial-positive-for-enhertuenhurtu-in-her2-mutant-nsclc.--daiichi-sankyo-and-astrazeneca2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/06/vbl-presents-positive-interim-data-from-the-oval-phase-iii-pivotal-study-of-vb-111-in-ovarian-cancer-at-the-asco-meeting-showing-58-or-higher-objective-response-rate/2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/06/myovant-sciences-has-submitted-an-nda-to-the-fda-for-its-once-daily-relugolix-for-the-treatment-of-women-with-heavy-menstrual-bleeding-associated-with-uterine-fibroids/2025-01-31T11:37:34+00:00weekly0.6https://www.medthority.com/news/2020/06/zeposia-met-primary-and-secondary--endpoints-in-true-north-phase-iii-study-for-adult-patients-with-moderate-to-severe-ulcerative-colitis.--bms2021-12-20T17:29:54+00:00weekly0.6https://www.medthority.com/news/2020/06/recent-publication-of-two-papers-concerning-oral-feraccruaccrufer-treatment-for-iron-deficiency.--shield-therapeutics2024-10-21T14:55:05+00:00weekly0.6https://www.medthority.com/news/2020/06/new-data-reinforces-improved-and-durable-responses-of-orencia-in-moderate-to-severe-early-rheumatoid-arthritis-patients-with-autoantibodies-linked-to-more-severe-disease.---bms2024-11-12T09:34:18+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iiibiv-spirit-h2h-study-of-taltz-shows-efficacy-in-psoriatic-arthritis.--eli-lilly2024-10-22T11:53:09+00:00weekly0.6https://www.medthority.com/news/2020/06/eular-2020-lilly-shares-new-data-for-olumiant-in-rheumatoid-arthritis-and-systemic-lupus-erythematosus/2024-11-08T09:29:23+00:00weekly0.6https://www.medthority.com/news/2020/06/ce-mark-for-opti-sars-cov-2-rt-pcr-laboratory-test-kit-for-the-detection-of-sars-cov-2.--opti-medical-systems2021-12-20T17:32:14+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-dolomites-study-of-roxadustat-versus-darbepoetin-alfa-to-treat-anemia-in-non-dialysis-dependent-adult-patients-with-chronic-kidney-disease.--astellas2024-10-21T15:01:13+00:00weekly0.6https://www.medthority.com/news/2020/06/regulatory-applications-for-vericiguat-to-treat-symptomatic-chronic-heart-failure-are-filed-in-the-eu-and-japan.--bayer-healthcare--merck-inc2021-12-20T17:32:33+00:00weekly0.6https://www.medthority.com/news/2020/06/gilead-sciences-files--maa-for-remdesivir-at-the--ema-to-treat-covid-19.-2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/06/ucb-pharma-acquires-engage-therapeutics-and-with-it-staccato-alprazolam-a-treatment-for-termination-of-epileptic-seizure/2021-09-24T07:11:27+00:00weekly0.6https://www.medthority.com/news/2020/06/tirzepatide-enters-surpass-cvot-the-phase-iii-cardiovascular-outcomes-trial--eli-lilly/2024-11-08T09:29:37+00:00weekly0.6https://www.medthority.com/news/2020/06/stratatechmallinckrodt-has-completed-its-rolling-submission-of--its-bla-to-the-fda-for-stratagraft-for-the-treatment--deep-partial-thickness-thermal-burns/2024-10-22T11:49:02+00:00weekly0.6https://www.medthority.com/news/2020/06/health-canada-approves-ziextenzo-pegfilgrastim-reference-biologic-drug-neulasta-and-riximyo-rituximab-reference-biologic-drug-rituxan-for-marketing-in-canada.-sandoz-canada2024-10-22T11:49:22+00:00weekly0.6https://www.medthority.com/news/2020/06/celyad-sa-is-now-celyad-oncology/2021-09-24T07:11:27+00:00weekly0.6https://www.medthority.com/news/2020/06/fulcrum-therapeutics-to-evaluate-losmapimod-in-phase-iii-trial-as-a-potential-treatment-for-covid-19/2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2020/05/jnj-4528-showed-early-deep-and-durable-responses-in-heavily-pretreated-patients-with-multiple-myeloma.janssen-pharmaceutical-companies2024-10-22T12:55:27+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-lynparza-to-treat-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer.-astrazeneca--merck-inc2024-10-24T14:03:57+00:00weekly0.6https://www.medthority.com/news/2020/05/journal-of-clinical-psychiatry-publishes-data-from-alkermes-alpine-study-in-patients-with-schizophrenia.--alkermes-plc2024-10-24T14:04:12+00:00weekly0.6https://www.medthority.com/news/2020/05/data-from-a-phase-iii-trial-of-cabotegravir-for-hiv-prevention-has-been-stopped-early-because-of-high-efficacy-.--viiv-health-care2024-10-22T12:52:02+00:00weekly0.6https://www.medthority.com/news/2020/05/health-canada-approves-rozlytrek-for-ros1-positive-non-small-cell-lung-cancer.--roche-canada2024-10-24T11:00:37+00:00weekly0.6https://www.medthority.com/news/2020/05/results-of-phase-iibiii-trial-of-filgotinib-in-moderately-to-severely-active-ulcerative-colitis.-gilead-sciences--galapagos-nv2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/ema-validates-maa-for-tafasitamab-lenalidomide-to-treat-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-.-incyte--morphosys-ag2024-10-22T12:52:28+00:00weekly0.6https://www.medthority.com/news/2020/05/ema-accepts-maa-for-for-roxadustat-for-the-treatment-of-anemia-in-adult-patients-with-chronic-kidney-disease.--astellas--fibrogen-inc.-2024-10-22T12:52:41+00:00weekly0.6https://www.medthority.com/news/2020/04/new-longer-term-data-reinforce-safety-of-genentechs-satralizumab-in-adults-and-adolescents-with-neuromyelitis-optica-spectrum-disorder-nmosd/2024-11-08T11:32:38+00:00weekly0.6https://www.medthority.com/news/2020/05/abbott-announces-contract-to-supply-millions-of-igg-lab-based-antibody-tests-to-the-uk-government/2021-12-20T17:31:03+00:00weekly0.6https://www.medthority.com/news/2020/05/eu-gives-ce-mark-approval-for--ultragene-combo2screen-sars-cov-2-assay-as-a-diagnostic-for-covid-19.--advanced-biological-laboratories2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2020/05/nice-reverses-decision-and-now-recommends-use-of-tecentriq-plus-abraxane-in-metastatic-triple-negative-breast-cancer.--roche2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/05/ema-validates-maa-for-both-idecabtagene-vicleucel-ide-cel-bb2121-for-multiple-myeloma-and-cc-486-for-the-maintenance-treatment-of-patients-with-acute-myeloid-leukemia-aml.--bms--bluebird-bio-inc2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/05/architect-sars-cov-2-igg-test-is-authorized-by-health-canada--abbott/2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approval-for-kynmobi-for-the-acute-intermittent-treatment-of-off-episodes-in-patients-with-parkinsons-disease.-sunovion-pharma2024-11-12T09:25:13+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-phexxi--the-first-and-only-non-hormonal-prescription-gel-for-the-prevention-of-pregnancy.-evofem-biosciences-inc2024-10-24T14:22:28+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-trial-of-dupixent-meets-endpoints-in-eosinophilic-esophagitis.--sanofiregeneron-pharma2024-11-08T09:28:29+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-accepts-filing-of-hypopal-rescue-pen-for-hypoglycemia-in-people-with-diabetes.--zealand-pharma2024-11-08T09:26:09+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-alunbrig-for-alk-metastatic-non-small-cell-lung-cancer.--takeda2024-11-12T09:24:21+00:00weekly0.6https://www.medthority.com/news/2020/05/ole-study-of-onpattro-shows-benefits-for-polyneuropathy-of-hattr-amyloidosis.--alnylam-pharma2024-10-24T14:22:40+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-trial-of-entinostat-exemestane-in-her-her2--breast-cancer-fails-to-meet-primary-endpoint.--syndax-pharmaceuticals-inc2024-10-24T14:22:53+00:00weekly0.6https://www.medthority.com/news/2020/05/positive-results-from-pivotal-rockstar-trial-of-belumosudil-to-treat-chronic-graft-versus-host-disease.--kadmon-holdings-inc2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/05/study-of-veklury-remdesivir-for-covid-19-shows-the-drug-is-chiefly-helpful-to-patients-on-supplemental-oxygen.-gilead-sciences2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2020/05/study-of-hydroxychloroquine-for-covid-19-showing-increased-risk-in-patients-is-published-in-the-lancet/2021-12-20T17:29:54+00:00weekly0.6https://www.medthority.com/news/2020/05/couldnt-make-it-to-ean-2020-heres-what-you-missed/2025-05-06T14:58:27+00:00weekly0.6https://www.medthority.com/news/2020/05/couldnt-make-it-to-asco-2020-heres-what-you-missed/2024-11-12T14:08:36+00:00weekly0.6https://www.medthority.com/news/2020/05/novartis-kisqali-shows-overall-survival-benefit-in-hrher2--advanced-breast-cancer-with-consistent-findings-in-patients-with-more-aggressive-disease/2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/05/merck-inc.-and-ridgeback-bio-collaborate-to-advance-development-of-novel-antiviral-candidate-eidd-2801-to-treat-covid-19-2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/05/european-commission-approves-zeposia-to-treat-relapsing-remitting-multiple-sclerosis.--bms2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/05/hansa-biopharma-submits-responses-to-outstanding-questions-from-ema-for-imlifidase-application-in-kidney-transplantation/2024-11-12T09:24:57+00:00weekly0.6https://www.medthority.com/news/2020/05/aurinia-pharmaceuticals-inc.has--completed-the-rolling-submission-to-the-fda-for-voclosporin-as-a-potential-treatment-for-lupus-nephritis.-2024-10-24T09:08:07+00:00weekly0.6https://www.medthority.com/news/2020/05/novartis-announces-at-ean-new-data-for-ofatumumab-demonstrating-robust-efficacy-and-safety-in-the-treatment-of-relapsing-forms-of-multiple-sclerosis-rms/2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-opdivo---yervoy--combined-with-limited-chemotherapy-as-first-line-treatment-of-metastatic-or-recurrent-non-small-cell-lung-cancer.--bms-2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-archway-study-of-lucentis-port-delivery-system-meets-primary-endpoint-in-age-related-macular-degeneration.--genentechroche2024-10-22T09:27:49+00:00weekly0.6https://www.medthority.com/news/2020/05/iavi-and-merck-inc.-collaborate-to-develop-vaccine-against-sars-cov-2.-2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-dupixent-to-treat-children-with-atopic-dermatitis.-sanofi--regeneron2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2020/05/genentechroche---gilead-sciences-initiate-phase-iii-trial-of-actemra--remdesivirin-hospitalized-patients-with-severe-covid-19-pneumonia/2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2020/05/remdesivir-granted-early-access-in-the-uk-by-mhra-for-covid-19-treatment.--gilead-sciences2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-adaura-trial-showed-treatment-with-tagrisso-after-surgery-with-curative-intent-reduced-the-risk-of-disease-recurrence-or-death-by--80.--astrazeneca2024-11-12T09:16:18+00:00weekly0.6https://www.medthority.com/news/2018/06/successful-phase-iii-a16-study-of-flortaucipir-f-18--a-pet-agent-to-predict-alzheimers-disease-diagnosis.---eli-lilly2024-11-08T09:26:21+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-tauvida-radioactive-diagnostic-agent-for-pet-imaging-to-evaluate-alzheimers-disease.-eli-lilly2024-11-12T09:23:51+00:00weekly0.6https://www.medthority.com/news/2020/05/santhera-provides-update-on-the-ongoing-regulatory-review-of-puldysa-by-the-chmp-in-duchenne-muscular-dystrophy.-2024-10-24T14:23:06+00:00weekly0.6https://www.medthority.com/news/2020/05/minerva-neurosciences-announces-results-from-phase-iii-trial-of-roluperidone-min-101-for-treatment-of-negative-symptoms-in-schizophrenia/2024-10-24T09:08:27+00:00weekly0.6https://www.medthority.com/news/2020/05/novartis-announces-long-term-relapse-free-survival-benefit-for-high-risk-stage-iii-melanoma-patients-treated-with-tafinlar--mekinist-following-surgery/2024-11-08T09:26:36+00:00weekly0.6https://www.medthority.com/news/2020/05/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer-in-phase-ii-destiny-gastric01-trial-.--astrazeneca--daiichi-sankyo2024-10-24T14:23:19+00:00weekly0.6https://www.medthority.com/news/2020/05/imfinzi-showed-a-sustained-overall-survival-benefit-in-1st-line-extensive-stage-small-cell-lung-cancer-in-the-phase-iii-caspian-trial.---astrazeneca2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-zilxi-for-rosacea.--menlo-therapeutics2024-10-24T09:08:40+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-hero-study-of-tak-385-for-prostate-cancer-published-in-new-england-journal-of-medicine.--myovant-sciences2024-10-24T09:08:53+00:00weekly0.6https://www.medthority.com/news/2020/05/final-phase-iii-prosper-trial-data-of-xtandi-shows-benefits-in-non-metastatic-castration-resistant-prostate-cancer.--pfizer-and-astellas2024-11-08T09:26:48+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-tecentriq--avastin--for-people-with-unresectable-or-metastatic-hepatocellular-carcinoma-.-genentechroche2024-10-24T14:23:32+00:00weekly0.6https://www.medthority.com/news/2020/05/piqray--fulvestrant-receives-positive-chmp-opinion-to-treat-hrher2--advanced-breast-cancer-with-a-pik3ca-mutation.--novartis2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-zabdeno--mvabea-for-ebola.--janssen-cilag-international2024-11-08T09:28:45+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-hepcludex-for-chronic-hepatitis-delta-virus.--myr2022-01-10T10:22:58+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-rozlytrek-in-ntrk-fusion-positive-solid-tumours.--roche2024-11-12T09:26:08+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-rozlytrek-for-ros1-positive-advanced-non-small-cell-lung-cancer.--roche2024-10-24T14:23:45+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-xenleta-for-community-acquired-pneumonia.--nabriva-therapeutics2024-11-08T09:28:58+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-zercepac-for-treating-breast-or-gastric-cancer.--accord-healthcare2024-10-24T09:17:49+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-lynparza-for-metastatic-adenocarcinoma-of-the-pancreas.--astrazeneca2024-10-24T14:24:02+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-aspen-trial-of-brukinsa-in-waldenstroms-macroglobulinemia-shows-positive-follow-up-data.--beigene-2024-10-22T11:35:08+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-cyramza--erlotinib-for-first-line-treatment-of-metastatic-nsclc-with--egfr-exon-19-deletions-or-exon-21-l858r-mutations.--eli-lilly2024-10-24T14:32:51+00:00weekly0.6https://www.medthority.com/news/2020/06/novartis-prevent-data-shows-cosentyx-helps-patients-realize-early-and-lasting-relief-in-axial-spondyloarthritis/2024-10-22T09:28:12+00:00weekly0.6https://www.medthority.com/news/2020/06/eu-approves-darzalex-subcutaneous-formulation-for-multiple-myeloma.--janssen-2021-12-20T17:32:14+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-monotherapy-study-jade-mono-2-of-pf-04965842-in-atopic-dermatitis-published-in-jama-dermatol.--pfizer-inc2021-12-20T17:32:14+00:00weekly0.6https://www.medthority.com/news/2020/06/hydroxychloroquine-does-not-offer-covid-19-protection-after-exposure-according-to-university-of-minnesota-study.-2024-10-22T09:28:32+00:00weekly0.6https://www.medthority.com/news/2020/06/tetraphase-will-now-merge-with-melinta-therapeutics/2026-02-02T17:02:58+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-finch-1-and-finch-3-studies-of-glpg-0634-show-52-week-efficacy-in-rheumatoid-arthritis.--gilead-sciencesgalapagos2024-10-21T14:55:19+00:00weekly0.6https://www.medthority.com/news/2020/06/inovio-and-ivi-partner-with-seoul-national-university-hospital-to-start-phase-1ii-clinical-rial-of-inovios-covid-19-dna-vaccine-ino-4800-in-south-korea/2021-12-20T17:32:14+00:00weekly0.6https://www.medthority.com/news/2020/06/novartis-phase-iiib-argon-study-meets-primary-endpoint-in-a-comparison-of-enerzair-breezhaler-qvm149-versus-a-free-combination-of-two-existing-inhaled-treatments-in-uncontrolled-asthma/2024-11-12T09:18:10+00:00weekly0.6https://www.medthority.com/news/2020/06/roches-elecsys-il-6-test-receives-fda-emergency-use-authorisation-to-help-in-identifying-patients-at-high-risk-of-severe-inflammatory-response/2024-10-22T09:28:45+00:00weekly0.6https://www.medthority.com/news/2020/06/aurinia-presents-aurora-pivotal-trial-subgroup-analysis-of--voclosporin-for-lupus-nephritis-at-the-eular-2020-e-congress/2024-10-22T09:28:58+00:00weekly0.6https://www.medthority.com/news/2020/06/calquence-showed-promising-clinical-improvement-in-majority-of-19-hospitalised-covid-19-patients-.--astrazeneca2024-10-21T15:00:41+00:00weekly0.6https://www.medthority.com/news/2020/06/new-analyses-of-phase-ii-equator-clinical-program-support-durable-efficacy-of-filgotinib-in-psoriatic-arthritis.--gilead-sciences-inc.--galapagos-nv2024-11-12T09:17:54+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-select-choice-trial-of-rinvoq-meets-primary-endpoint-in-rheumatoid-arthritis.--abbvie2024-11-12T09:24:40+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-apex-2-and-apex-s-trials-of-bcx-7353-show-improvements-in-hereditary-angioedema.--biocryst-pharma2024-10-21T15:01:00+00:00weekly0.6https://www.medthority.com/news/2020/06/interim-data-from-phase-iii-help-ole-study-of-takhzyro-shows-efficacy-in-hereditary-angioedema.--takeda2021-12-20T17:32:14+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-recarbrio-in-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia.--merck-inc2024-11-08T09:33:15+00:00weekly0.6https://www.medthority.com/news/2020/06/recovery-trial-shows-no-benefit-from-hydroxycholoroquine-as-treatmant-for-covid-19.--novartis2021-12-20T17:32:30+00:00weekly0.6https://www.medthority.com/news/2020/06/aln-go1-filed-with-ema-and-fda-for-primary-hyperoxaluria-type-1.--alnylam-pharma2024-11-12T09:24:07+00:00weekly0.6https://www.medthority.com/news/2020/04/biontech-ag-and-pfizer-inc.-initiate-a-phase-1ii-trial-of-bnt-162-vaccine-to-prevent-covid-19-infection2021-12-20T17:29:29+00:00weekly0.6https://www.medthority.com/news/2020/04/biontech-ag-and-pfizer-inc2.-initiate-a-phase-1ii-trial-of-bnt-162-vaccine-to-prevent-covid-19-infection2024-10-22T11:29:52+00:00weekly0.6https://www.medthority.com/news/2020/04/livanova-bi-flow-cannula-receives-ce-mark-for-extracorporeal-membrane-oxygenation-ecmo-applications/2024-10-24T14:02:41+00:00weekly0.6https://www.medthority.com/news/2020/04/mateon-pharma-submits-ind-to-the-fda-to-approve-new-phase-ii-study-of-ot-101-for-the-treatment-of-covid-19-pandemic/2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-ongentys--an-add-on-treatment-to-levodopacarbidopa-in-patients-with-parkinsons-disease-experiencing-off-episodes.--neurocrine-biosciences2024-10-22T11:30:13+00:00weekly0.6https://www.medthority.com/news/2020/04/phase-iii-trial-of-libtayo--as-monotherapy-for-first-line-advanced-nsclc-stopped-early-due-to-highly-significant-improvement-in-overall-survival.--sanofi--regeneron2021-12-20T17:29:29+00:00weekly0.6https://www.medthority.com/news/2020/04/myovant-sciences-announces-publication-of-abstracts-detailing--efficacy-and-safety-from-phase-iii-liberty-studies-in-uterine-fibroids-in-obstetrics--gynecology-journal/2024-10-22T11:30:37+00:00weekly0.6https://www.medthority.com/news/2020/04/sanofi-and-regeneron-provide-update-on-u.s.-phase-iiiii-adaptive-designed-trial-in-hospitalized-covid-19-patients2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/04/axsome-therapeutics-announces-axs-05-achieves-primary-endpoint-in-the-advance-1-pivotal-phase-iiiii-trial-in-alzheimers-disease-agitation/2024-10-24T14:05:04+00:00weekly0.6https://www.medthority.com/news/2020/01/moderate-to-severe-psoriasis-treatment-young-women/2024-08-21T12:55:58+00:00weekly0.6https://www.medthority.com/news/2019/12/moderate-to-severe-psoriasis-the-disease-burden-and-unmet-needs-in-different-patient-groups/2024-08-21T14:57:54+00:00weekly0.6https://www.medthority.com/news/2020/02/biologic-efficacy-for-complications-associated-with-moderate-to-severe-psoriasis/2024-08-21T12:56:13+00:00weekly0.6https://www.medthority.com/news/2017/11/how-close-are-we-to-a-disease-modifying-treatment-for-alzheimers/2024-08-21T14:57:20+00:00weekly0.6https://www.medthority.com/news/2020/04/improving-non-alcoholic-steatohepatitis-care/2024-11-15T08:46:29+00:00weekly0.6https://www.medthority.com/news/2020/04/traumakine-to-participate-in-world-health-organizations-who-solidarity-trial--investigating-potential-covid-19-treatments.-faron-pharma2021-12-20T17:30:49+00:00weekly0.6https://www.medthority.com/news/2020/04/first-patient-dosed-in-avdoralimab-phase-ii-clinical-trial-in-covid-19-patients-with-severe-pneumonia.--innate-pharma-sa2024-10-24T08:57:49+00:00weekly0.6https://www.medthority.com/news/2020/04/health-canada-approves-rozlytrek-for-ntrk-fusion-positive-locally-advanced-or-metastatic-solid-tumors.--roche2024-10-24T08:58:05+00:00weekly0.6https://www.medthority.com/news/2017/06/left-ventricular-assist-devices--a-viable-therapeutic-option-for-heart-failure/2024-11-14T16:08:18+00:00weekly0.6https://www.medthority.com/news/2017/04/cancer-immunotherapies/2024-08-22T09:49:02+00:00weekly0.6https://www.medthority.com/news/2020/04/antibody-drug-conjugates-adcs/2024-08-22T09:48:50+00:00weekly0.6https://www.medthority.com/news/2020/04/european-commission--approves-cosentyx--for-the-treatment-of--patients-with-active-non-radiographic-axial-spondyloarthritis-nr-axspa.--novartis2024-10-22T11:32:15+00:00weekly0.6https://www.medthority.com/news/2020/04/topline-results-from-the-open-label-phase-iii-simple-trial-evaluating-5-day-and-10-day-dosing-durations-of-remdesivir--in-hospitalized-patients-with-severe-manifestations-of-covid-19-disease.-gilead-sciences2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/05/new-6-year-data-for--ocrevus--shows-earlier-treatment-initiation-nearly-halves-risk-of-needing-walking-aid-in-relapsing-multiple-sclerosis--genentechroche-/2021-12-20T17:29:30+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-supplemental-nda-for-zejula-in-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer.--glaxosmithkline2021-12-20T17:29:30+00:00weekly0.6https://www.medthority.com/news/2020/05/eu-chmp-recommends-approval-of-subcutaneous-darzalex-for-multiple-myeloma.--genmab2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-gives-emergency-use-authorization-to-sars-cov-2-total-ab-test-for-covid-19-diagnostics.--bio-rad-labs2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-reblozyl-for-transfusion-dependent-anemia-due-to-very-low--low--and-intermediate-risk-myelodysplastic-syndromes-and-transfusion-dependent-anemia-associated-with-beta-thalassemia.--bms--acceleron2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/05/niaid-adaptive-clinical-trial-shows-remdesivir-accelerates-recovery-from-advanced-covid-19/2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-flash-trial-of-sgx-301-shows-increased-efficacy-in-t-cell-lymphoma.--soligenix2024-10-24T08:58:34+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-guidance-for-phase-iii-b-simple-4-trial-of-sb-206-to-treat-molluscum-contagiosum.--novan-inc2024-10-24T14:05:18+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-enerzair-breezhaler-as-a-maintenance-treatment-of-asthma-in-adult-patients-not-adequately-controlled-with-a-combination-of-a-long-acting-beta2-agonist-laba-and-a-high-dose-of-an-inhaled-corticosteroid.--novartis2024-10-24T14:05:46+00:00weekly0.6https://www.medthority.com/news/2020/05/cc-486-has-nda-accepted-by-fda-for-maintenance-treatment-of-adult-patients-in-remission-with-acute-myeloid-leukemia.--bms2024-10-24T08:58:50+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-ultomiris-for-atypical-hemolytic-uremic-syndrome.--alexion-pharma2024-10-24T08:59:03+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-darzalex-faspro-subcutaneous-formulation-for-multiple-myeloma.--genmabjanssen-biotech2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/eu-gives-ce-mark-approval-to-sars-cov-2-covid-19-antibody-microarray-test-as-a-diagnostic-for-covid-19.--quotient-2021-12-20T17:30:49+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-daurismo-intended-for-the-treatment-of-acute-myeloid-leukaemia-.--pfizer2024-10-22T11:32:59+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends--insulin-aspart-sanofi-a-biosimilar-product-intended-for-the-treatment-of-diabetes-mellitus.--sanofi2024-10-22T11:33:30+00:00weekly0.6https://www.medthority.com/news/2020/04/nice-recommends-vitrakvi-to-treat-neurotrophic-tyrosine-receptor-kinase-ntrk-fusion-positive-solid-tumors.-bayer-healthcare2024-10-24T12:45:36+00:00weekly0.6https://www.medthority.com/news/2020/04/positive-results-from-phase-iii-spirit-2-study--of-once-daily-relugolix-combination-therapy-in-women-with-endometriosis-and-from-ovulation-inhibition-study.--myovantsciences-2024-11-12T11:29:42+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-grants-trodelvy-accelerated-approval-for-triple-negative-breast-cancer.--immunomedics-2024-10-22T09:32:05+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-gives-emergency-use-authorisation-for-allplex-2019-ncov-assay-a-real-time-rt-pcr-test-for-sars-cov-2.--seegene2024-10-22T09:32:17+00:00weekly0.6https://www.medthority.com/news/2020/04/novartis-announces-data-showing-jakavi-ruxolitinib-more-effective-than-best-available-therapy-in-acute-graft-versus-host-disease/2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/04/sanofi-brain-penetrant-btk-inhibitor--sar-442168-significantly-reduced-disease-activity-in-phase-iib-trial-in-relapsing-multiple-sclerosis.--2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/04/ease-study-of-ap-101-update-of-patient-enrollment-in-phase-iii-trial--for-epidermolysis-bullosa..-amryt-pharma2021-12-20T17:31:04+00:00weekly0.6https://www.medthority.com/news/2019/12/update-on-ap-101-trial--as-a-potential-treatment-for-epidermolysis-bullosa.--amryt2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/04/astrazeneca--saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients/2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/04/the-population-health-research-institute-phri--bayer-canada-inc.-announced-plans-to-launch-a-major-clinical-research-program-aimed-at-identifying-potential-covid-19-treatments2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/04/lynparza-demonstrated-overall-survival-benefit-in-phase-iii-profound-trial-for-brca12-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-.--astrazeneca--merck-inc2024-10-24T13:08:25+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-menquadfi-the-latest-innovation-in-meningococcal-menacwy-vaccination-.--sanofi2024-11-12T11:29:55+00:00weekly0.6https://www.medthority.com/news/2020/04/siemens-healthlineers-has-developed-a-laboratory-based-total-antibody-test-to-detect-the-presence-of-sars-cov-2-antibodies-in-blood/2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/04/supplemental-applications-for-simponi-aria-filed-with-fda-for-polyarticular-juvenile-idiopathic-arthritis-and-juvenile-psoriatic-arthritis.--janssen-biotech2024-11-12T09:25:32+00:00weekly0.6https://www.medthority.com/news/2020/04/virokey-sars-cov-2-rt-pcr-test-receives-the-ce-mark-for-in-vitro-diagnostic-test-for-covd-19.--vela-diagnostics2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/04/novartis-to-sponsor-large-clinical-trial-of-hydroxychloroquine-in-hospitalized-covid-19-patients-/2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/04/opdivo--yervoy-improved-overall-survival-in-checkmate--743-trial-for-patients-with-malignant-pleural-mesothelioma.-bms2024-11-12T11:29:20+00:00weekly0.6https://www.medthority.com/news/2020/04/ultomiris-to-initiate-a-phase-iii-study-to-treat-covid-19.-alexion-pharma2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/04/positive-topline-results-from-pivotal-phase-iii-checkmate--9er-trial-of-cabometyx-v.-sunitinib-for-advanced-renal-cell-carcinoma.-bms--exelixis2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/04/new-mayzent-data-published-in-neurology-shows-sustained-effect-in-delaying-disability-for-up-to-five-years-in--secondary-progressive-multiple-sclerosis-.--novartis2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/04/study-of-hizentra-meets-primary-endpoint-in-primary-immunodeficiency-.--csl-behring2024-10-24T12:44:59+00:00weekly0.6https://www.medthority.com/news/2020/04/cobas-hpv-test-approved-for-use-on-cobas-68008800-system.--roche2024-10-22T11:36:12+00:00weekly0.6https://www.medthority.com/news/2020/04/myovant-sciences-submits-nda-to-the-fda-for-once-daily-oral-relugolix-for-the-treatment-of-men-with-advanced-prostate-cancer/2024-10-22T11:42:51+00:00weekly0.6https://www.medthority.com/news/2020/04/kalm-2-pivotal-phase-iii-trial-of-korsuva-shows-efficacy-in--chronic-kidney-disease-associated-pruritus.--cara-therapeuticsvifor-fresenius-2024-10-24T12:45:16+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-cabazitaxel-accord-for-metastatic-prostate-cancer.--accord-healthcare2024-10-22T11:43:22+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-approval-of-extension-to-indication-of-cablivi-for-thrombotic-thrombocytopenic-purpura.--ablynx2024-11-12T11:29:02+00:00weekly0.6https://www.medthority.com/news/2020/05/health-canada-approves-ibsrela-to-treat-irritable-bowel-syndrome-with-constipation.--knight-therapeutics2024-10-24T14:06:13+00:00weekly0.6https://www.medthority.com/news/2020/05/topline-data-for-libtayo-to-treat-advanced-basal-cell-carcinoma.--sanofi--regeneron2024-10-22T11:44:08+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-grants-emergency-use-authorization-for-its-elecsys-anti-sars-cov-2-antibody-test-which-is-also-available-in-markets-accepting-the-ce-mark/2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/05/university-of-louisville-division-of-infectious-diseases-group-b-streptococcus-infections-study-results-announced-by-pfizer/2024-10-24T12:40:01+00:00weekly0.6https://www.medthority.com/news/2020/05/inno2vate-phase-iii-program-of-akb-6548-meets-primary-and-secondary-endpoints-in-anaemia-due-to-chronic-kidney-disease.--akebia-therapeutics2024-10-24T11:13:48+00:00weekly0.6https://www.medthority.com/news/2020/05/farxiga-approved-in-the-us-for-the-treatment-of-heart-failure-in-patients-with-heart-failure-with-reduced-ejection-fraction.--astrazeneca2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2020/05/alexion-pharma-acquires-portola-pharma--and-with-it-andexxa/2021-09-24T07:11:19+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-extends-pdufa-date-for-liso-cel-to-treat-large-b-cell-lymphoma.---bms2021-12-20T17:30:47+00:00weekly0.6https://www.medthority.com/news/2020/05/first-participants-dosed-in-phase-iii-trial-of--bnt-162-vaccine-to-prevent-covid-19.-pfizer--biontech-se2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-elyxyb-for-acute-treatment-of-migraine.--dr.-reddys-labs2021-12-20T17:30:34+00:00weekly0.6https://www.medthority.com/news/2020/05/positive-top-line-results-from-otezla-phase-iii-advance-study-in-mild-to-moderate-plaque-psoriasis--amgen/2024-10-24T08:08:19+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves--met-inhibitor-tabrecta-for-metastatic-non-small-cell-lung-cancer-with-metex14-skipping-mutation.--novartis2024-10-22T13:00:38+00:00weekly0.6https://www.medthority.com/news/2020/05/tavo--keytruda-demonstrated-41-overall-response-rate-and-36-complete-response-in-a-late-stage-metastatic-melanoma-study-featured-in-clinical-cancer-research.--oncosec-medical2024-10-24T11:13:35+00:00weekly0.6https://www.medthority.com/news/2020/05/health-canada-approves-real-time-fluorescent-rt-pcr-kit-for-detecting-sars-cov-2.--bgi-genomics2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/rebiotix--ferring-announce--first-with-positive-preliminary-pivotal-phase-iii-data-for-investigational-microbiome-based-therapy-rbx2660/2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/positive-topline-results-from-the-unity-cll-phase-iii-study-of-the-combination-of-umbralisib-and-ublituximab-u2-for-the-treatment-of-chronic-lymphocytic-leukemia.--tg-therapeutics2024-10-22T13:01:15+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-gives-emergency-use-authorisation-for-sars-cov-2-igg-test-for-covid-19-diagnostics.--abbott-2021-12-20T17:30:49+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-bridge-trial-of-prx-102-met-main-objectives-for-safety-and-efficacy-in-fabry-disease.--protalix-biotherapeutics2024-10-24T11:00:04+00:00weekly0.6https://www.medthority.com/news/2020/05/lynparza-approved-by-the-fda-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.---astrazeneca--merck-inc2021-12-20T17:30:32+00:00weekly0.6https://www.medthority.com/news/2020/05/vital-patch-secures-fda-emergency-use-authorization-for-cardiac-monitoring-in-covid--19-patients.--vitalconnect2024-10-24T13:50:29+00:00weekly0.6https://www.medthority.com/news/2020/05/results-from-interim-analysis-of-resolve-it-phase-iii-trial-of-elafibranor-in-adults-with-nash-and-fibrosis.-genfit2024-11-12T11:28:31+00:00weekly0.6https://www.medthority.com/news/2020/05/sarclisa--carfilzomib--dexamethasone-phase-iii-ikema-trial-meets-primary-endpoint-early-in-patients-with-relapsed-multiple-myeloma.--sanofi2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/adamis-pharmaceuticals-announces-new-commercialization-agreement-in-the-us-for-symjepi-and-zimhi-products/2024-10-24T11:01:21+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-explorer-hcm-trial-of-myk-461-meets-all-endpoints-in-hypertrophic-cardiomyopathy.--myokardia-2024-10-24T11:01:34+00:00weekly0.6https://www.medthority.com/news/2020/05/nih-clinical-trial-testing-antiviral-remdesivir-plus-anti-inflammatory--baricitinib-for-covid-19-begins/2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-braftovi--cetuximabfor-the-treatment-of-adult-patients-with-metastatic-colorectal-cancer-crc-with-a-braf-v600e-mutation.--pierre-fabre2024-11-12T09:26:24+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-grants-emergency-use-authorization-of-remdesivir-to-treatcovid-19/2021-12-20T17:30:50+00:00weekly0.6https://www.medthority.com/news/2020/05/rolling-submission-at-ema-for-remdesivir-to-treat-coronavirus-disease.--gilead-sciences2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/picato-to-treat-actinic-keratosis-is-withdrawn-from-eu.--leo-pharma2024-10-24T14:06:00+00:00weekly0.6https://www.medthority.com/news/2020/05/ayvakit-fails-to-meet-primary-endpoint-in-phase-iii-voyager-trial-versus-regorafenib-for-gastrointestinal-stromal-tumor.--blueprint-medicines-corpn2021-12-20T17:31:05+00:00weekly0.6https://www.medthority.com/news/2020/05/chmp-recommends-kalydeco-for-children-and-adolescents-with-cystic-fibrosis--ages-6-months-and-older-to-treat-cystic-fibrosis-cftr-gene.--vertex-pharma2024-10-22T11:35:48+00:00weekly0.6https://www.medthority.com/news/2020/05/results-of-phase-iii-trial-of-the-efficacy-and-safety-of--recarbrio-v.--piperacillin-and-tazobactam-in-adult-patients-with-habpvabp-.--merck-inc2024-10-24T11:01:46+00:00weekly0.6https://www.medthority.com/news/2020/05/fulphia--a-pegfilgrastim-biosimilar-is-launched-in-canada.mylan--bgp-pharma-ulc--biocon2024-10-24T14:04:40+00:00weekly0.6https://www.medthority.com/news/2020/05/pinnacle-flx-trial-of-watchman-flx-laac-meets-endpoints-in-stroke-risk-reduction.--boston-scientific2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-clinical-data-of-fexuprazan-shows-efficacy-in-gastroesophageal-reflux-disease.--daewoong-pharma2024-10-22T12:58:18+00:00weekly0.6https://www.medthority.com/news/2020/05/eu-approves-entyvio-subcutaneous-formulation-for-active-ulcerative-colitis-or-crohns-disease.--takeda2024-10-22T12:58:43+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-keytruda--for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-for-all-approved-adult-indications.-merck-inc2024-10-24T14:04:51+00:00weekly0.6https://www.medthority.com/news/2020/05/higher-investigational-doses-of-trulicity-meaningfully-reduced-a1c-and-body-weight-in-people-with-type-2-diabetes.--eli-lilly2024-10-22T12:57:15+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-retevmo-for-metastatic-ret-fusion-positive-nsclc-and-ret-mutant-medullary-thyroid-cancer.-eli-lilly2024-10-24T11:02:19+00:00weekly0.6https://www.medthority.com/news/2020/05/la-jolla-pharmaceutical-company-to-provide-giapreza-angiotensin-ii-for-emergency-medical-program-in-patients-with-septic-shock-due-to-covid-19-at-chirec-delta-hospital-brussels-belgium/2024-10-24T11:14:29+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-grants-emergency-use-authorization-to-the-zero-contact-covid-19-test-kit-as-a-saliva-based-diagnostic-for-at-home-use-to-detect-covid-19.--vitagene-2021-12-20T17:30:49+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-grants-emergency-use-authorisation-for-sofia-2-sars-antigen-test-for-covid-19-detection.--quidel-corp2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/menarini-group-to-acquire-stemline-therapeutics-in-transaction-valued-at-up-to-$677-million-and-with-it-elzonris/2021-09-24T07:11:17+00:00weekly0.6https://www.medthority.com/news/2020/05/positive-topline-data-from-phase-iii--study-of-omidubicel-in-patients-with-high-risk-hematologic-malignancies-gamida-cell/2024-11-12T11:28:42+00:00weekly0.6https://www.medthority.com/news/2020/05/refusal-to-file-letter-for-idecabtagene-vicleucel-for-patients-with-heavily-pre-treated-relapsed-and-refractory-multiple-myeloma.-bms--bluebird-bio2024-10-22T12:59:38+00:00weekly0.6https://www.medthority.com/news/2020/05/health-canada-approves-first-covid-19-serological-test-for-use-in-the-country-to-detect-covid-19-antibodies.-diasorin2024-10-22T13:00:02+00:00weekly0.6https://www.medthority.com/news/2020/05/vanda-pharmaceuticals-agrees-with-the--fda-on-resubmission-of-the-application-for-hetlioz-for-the-treatment-of-patients-with-smith-magenis-syndrome/2024-10-24T13:50:43+00:00weekly0.6https://www.medthority.com/news/2020/05/three-year-data-from-checkmate--227-confirms-durable-long-term-survival-benefit-for-opdivo--yervoy--in-metastatic-first-line-non-small-cell-lung-cancer-.--bms2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/opdivo--yervoy--with-limited-chemotherapy-significantly-improves-overall-survival-vs.-chemotherapy-alone-for-first-line-metastatic-non-small-cell-lung-cancer-in-checkmate--9la-study.--bms-2024-10-22T13:00:13+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-grants-priority-review-of-sutimlimab-potential-first-approved-treatment-of-hemolysis--for-cold-agglutinin-disease.--sanofi-2024-10-24T11:00:14+00:00weekly0.6https://www.medthority.com/news/2020/05/hd-lifesciences-gains-510k-clearance-for-its-hive-alif-standalone-lumbar-interbody-fusion-system-an-adjustable-spinal-implant/2024-10-22T12:53:20+00:00weekly0.6https://www.medthority.com/news/2020/05/-adcetris-receives-european-commission-approval-for-treatment-of-adult-patients-with-previously-untreated-systemic-anaplastic-large-cell-lymphoma.--takeda--seattle-genetics2024-11-12T11:28:52+00:00weekly0.6https://www.medthority.com/news/2020/05/pfizer-announces-positive-top-line-results-from-phase-iii-lot-consistency-study-of-20-valent-pneumococcal-conjugate-vaccine-in-pneumococcal-vaccine-naive-adults-18-through-49-years-of-age/2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-pomalyst-to-treat-aids-related-kaposi-sarcoma.-bms2024-10-22T12:53:32+00:00weekly0.6https://www.medthority.com/news/2020/05/pti-125-did-not-meet-its-primary-endpoint-in-a-phase-iib-study-for-alzheimers-disease.--cassava-sciences2024-10-22T12:55:38+00:00weekly0.6https://www.medthority.com/news/2020/05/phase-iii-seer-1-trial-of-rgn-259-shows-efficacy-in-neurotrophic-keratopathy.--regentree--regenerx-biopharma2024-10-24T13:50:57+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-provide-complete-response-letter-for-ayvakit-in-fourth-line-gastrointestinal-stromal-tumor.--blueprint-medicines2021-12-20T17:33:10+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-rubraca-for-metastatic-castration-resistant-prostate-cancer.--clovis-oncology2024-10-24T13:51:11+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-opdivo--yervoy-for--first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer-nsclc-whose-tumors-express-pd-l.--bms2024-10-22T12:55:51+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approves-qinlock-for-adults-with-advanced-gastrointestinal-stromal-tumor.--deciphera-pharma2024-10-22T12:56:17+00:00weekly0.6https://www.medthority.com/news/2020/05/pascal-transcatheter-valve-repair-system-receives-european-approval-for-tricuspid-repair.--edwards-life-sciences2021-12-20T17:30:32+00:00weekly0.6https://www.medthority.com/news/2020/05/teleflex-announces-positive-data-showing-that-the-urolift-system--treating-lower-urinary-tract-symptoms-due-to-benign-prostatic-hyperplasia-relieves-enlarged-prostate-symptoms-while-preserving-patients-sexual-function/2024-10-22T12:56:28+00:00weekly0.6https://www.medthority.com/news/2020/05/new-spinraza-data-reinforce-sustained-efficacy-and-longer-term-safety-across-a-broad-range-of-spinal-muscular-atrophy-patients-.-biogen-inc2024-11-12T11:28:20+00:00weekly0.6https://www.medthority.com/news/2020/05/adamis-pharmaceuticals-resubmits-nda-for-zimhi--for-the-treatment-of-opioid-overdose/2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/moderna-announces-positive-interim-phase-1-data-for-its-mrna-vaccine-mrna-1273-against-novel-coronavirus/2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2020/05/nubeqa-significantly-improved-overall-survival-with-a-favorable-safety-profile-in-men-with-non-metastatic-prostate-cancer.--bayer-healthcare2024-10-24T11:13:23+00:00weekly0.6https://www.medthority.com/news/2020/05/avexisnovartis-receives-ec-approval-and-activates-day-one-access-program-for-zolgensma-the-only-gene-therapy-for-spinal-muscular-atrophy-sma/2024-10-24T14:04:24+00:00weekly0.6https://www.medthority.com/news/2020/05/-phase-iii-clinical-study-of-jta-004--commences-to-reduceosteoarthritis-pain-in-the-knee.--bone-therapeutics2021-12-20T17:33:09+00:00weekly0.6https://www.medthority.com/news/2020/05/fda-approvestecentriq-as-a-first-line-monotherapy-for-certain-people-with-metastatic-non-small-cell-lung-cancer.--genentechroche2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2020/05/agios-announces-publication-of-tibsovo-phase-iii-data-in-the-lancet-oncology-demonstrating-significant-improvement-in-progression-free-survival-in-previously-treated-idh1-mutant-cholangiocarcinoma-patients/2024-10-22T12:57:03+00:00weekly0.6https://www.medthority.com/news/2020/05/results-of-geras-us-study-shows-societal-cost-burden-for--early-stages-of-alzheimers-disease.--eli-lilly2024-10-24T14:03:45+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-combination-opdivo---yervoy-to-treat-intermediate--and-poor-risk-advanced-renal-cell-carcinoma---bms-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2019/02/clinigen-group-acquires-us-rights-to-proleukin-from-novartis-/2021-09-24T07:17:11+00:00weekly0.6https://www.medthority.com/news/2011/09/glow-1-and-glow-3-studies-to-support-seebribreezhaler-application-/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2019/09/scpharmaceuticals-inc--provides-furoscix-update-on-heart-failure-re-submission-/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2012/03/abbvie-is-the-new-abbott-research-based-pharma-company/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-trial-of-ogx-011--custirsen--in-non-small-cell-lung-cancer-fails-to-meet-primary-endpoint--oncogenex-pharmaceuticals/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2015/06/actavis-changes-its-name-to-allergan/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2019/03/success-with-phase-ii-study-of-trofinetide-for-rett-syndrome---acadia-pharma---neuren-pharma/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-generic-plavix/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2019/06/new-trial-required-by-fda-for-iclaprim--for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections---motif-bio-plc/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-iii-results-for-arikace--insmed--v--tobi-in-cystic-fibrosis-infections/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2013/08/tradjenta-successful-in-elderly-type-2-diabetes-patients/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2013/08/mirvaso-is-fda-approved-for-rosacea/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2014/09/nice-does-not-recommend-remicade--humira-and-simponi-as-treatments-for-ulcerative-colitis---merck-inc----abbvie/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2018/01/raynauds-awareness-month-2018/2022-02-08T07:44:53+00:00weekly0.6https://www.medthority.com/news/2018/09/iqwig--oncotype-dx-assay-effective-for-breast-cancer---genomic-health-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2012/06/aubagio---genzyme-sanofi-reports-results-of-tower-trial-in-multiple-sclerosis/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2014/07/astrazeneca-and-qiagen-collaborate-to-develop-diagnostic-test-for-iressa-in-nsclc---/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2016/11/positive-topline-results-for-dextenza--dexamethasone-insert--in-post-surgical-ocular-inflammation-and-pain--ocular-therapeutix/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-label-update-for-kyprolis---dexamethasone-for-multiple-myeloma---amgen/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2012/03/omega-3-fatty-acids-study-and-brain-aging/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2011/11/chmp-recommends-nevanac-alcon-novartis--for-diabetic-macular-oedema-following-cataract-surgery/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-viekira-pak-treatment-for-hepatitis-c--abbvie/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2016/09/liletta--levonorgestrel-releasing-intrauterine-system--52-mg-iud-single-handed-inserter-for-contraception-launched-in-us--allergan---medicines360/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-clinical-trial-of-sb-1518--pacritinib--meets-one-co-endpoint-in-myelofibrosis---cti-biopharma/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2014/06/merck-inc--to-acquire-idenix-pharma-for--3-85-billion-and-with-it-hepatitis-c-drug-developments/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2018/05/eli-lilly-acquires-armo-biosciences-and-with-it-pegilodecakin-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2018/12/aradigm-announces-results-of-third-party-evaluation-of-phase-iii--clinical-trials-for-apulmiq--formerly-linhaliq--to-treat-bronchiectasis--/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-gives-510-k--approval-to-signosrt-bladder-ultrasound-imaging-system-signostics/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-trial-of-dwp-450-meets-primary-endpoint-in-glabellar-lines-study---evolus-/2021-09-24T07:05:54+00:00weekly0.6https://www.medthority.com/news/2015/03/samsung-bioepis---biogen-file-sb-2-infliximab-biosimilar-at-ema-/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2015/10/xeomin--incobotulinumtoxina--filed-with-fda-for-treatment-of-upper-limb-spasticity--merz/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2018/04/parkinson-s-awareness-week-2018/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-study-of-sym-1219--secnidazole--met-endpoints-for-bacterial-vaginosis--symbiomix-/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-gives-510-k--approval-for-the-accula-rsv-test-for-diagnosing-respiratory-syncytial-virus---mesa-biotech-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-advisory-committee-rejects-cangrelor-for-pci---the-medicines-company/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-parsabiv--etelcalcetide--for-the-treatment-of-secondary-hyperparathyroidism---amgen/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-vabomere-to-treat-infections--namely-ciai--cuti--hap-vap--bacteraemia-and-aerobic-gram-negative-infections---melinta-therapeutics/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2014/12/jazz-pharma-initiates-rolling-submission-to-fda-for-defibrotide-for-hepatic-veno-occlusive-disease/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2014/09/shire-files-snda-at-fda-for-vyvanse-to-manage-binge-eating-disorder/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2012/01/gammagard-liquid10---baxter--in-second-alzheimers-disease-phase-iii-trial/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2019/04/additional-results-from-long-term-open-label-safety-study-of-lumateperone-to-treat-schizophrenia----intra--cellular-therapies/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2012/09/breo-gsk-theravance-combination-filed-at-fda-for-copd/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2016/08/janssen-biotech-files-supplemental-biologics-license-application--sbla--at-fda-for-daratumumab--darzalex-for-use-with-lenalidomide-and-dexamethasone-or-bortezomib-and-dexamethasone-for-multiple-myeloma-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2016/01/merck-inc-completes-enrollment-in-phase-iii-trial-for-mk-8931--verubecestat-as-a-treatment-for-alzheimers-disease-/2024-02-19T14:36:33+00:00weekly0.6https://www.medthority.com/news/2012/04/ampio-pharma-to-discuss-filing-with-fda-of-zertane-for-premature-ejaculation-treatment/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2015/02/results-of-phase-iii-engage-trial-for-cerdelga--eliglustat--for-gaucher-disease-published-in-jama-sanofi/2024-02-19T14:39:40+00:00weekly0.6https://www.medthority.com/news/2019/10/herzuma-and-truxima-biosimilars-to-be-distributed-in-australia-by-celltrion-and-to-hospitals-by-juno-pharmaceuticals-/2024-10-15T07:23:25+00:00weekly0.6https://www.medthority.com/news/2019/06/abbvie-to-acquire-allergan-for--63-billion/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2019/08/complete-response-letter--for-golodirsen--nda-for-the-treatment-of-duchenne-muscular-dystrophy--dmd--in-patients-with-a-confirmed-mutation-amenable-to-exon-53-skipping---sarepta-therapeutics/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-abilify-maintena-for-schizophrenia--lundbeck-otsuka/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2017/10/lymphoma---myeloma-2017--an-international-congress-on-haematologic-malignancies/2024-02-19T14:40:30+00:00weekly0.6https://www.medthority.com/news/2017/02/clinical-trial-initiated-to-assess-the-potential-of-faims--field-asymmetric-ion-mobility-spectrometer--technology-in-the-early-detection-of-colorectal-cancer---owlstone-medical/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2017/03/vertex-pharmaceuticals-to-acquire-ctp-656--a-proposed-treatment-for-cystic-fibrosis-from-concert-pharmaceuticals-/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-extend-approval-of-alimta--eli-lilly--for-maintenance-treatment-in-nsclc/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2016/08/roche--launches-accu-check-guide-diabetes-monitoring-system-/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2019/02/interim-analysis-of-phase-iii-furi-study-of-ibrexafungerp-shows-positive-results-in-fungal-infections---scynexis/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2020/02/enrollment-for-phase-iii-recovery-study-of-tonmya-in-ptsd-halted-due-to-futility---tonix-pharma/2021-09-24T07:12:00+00:00weekly0.6https://www.medthority.com/news/2012/11/abraxane--celgene--success-in-phase-iii-study-of-pancreatic-cancer/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2013/09/ideglira-success-in-phase-iii-trial-for-type-2-diabetes/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2014/03/baxter-to-divide-into-two-companies/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-awards-ce-mark-approval-for-vergenixfg-in-chronic-and-acute-wound-healing--collplant/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2017/12/eu-treat-study-shows-benefits-of-switching-to-tresiba-for-type-1-and-2-diabetes-patients---/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-provenge-for-prostate-cancer/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2014/10/hp802-247-fails-phase-iii-trial-for-treatment-of-venous-leg-ulcers-smith---nephew/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2015/06/razumab--ranibizumab-biosimilar--is-launched-in-india-for-degenerative-conditions-of-the-eye--intas-pharma/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/03/findings-from-the-phase-iii-resurface-1-and-resurface-2-studies-show-sustained-response-by-patients--and-ilumya-was-well-tolerated--sun-pharma---almirall-s-a-/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2014/09/results-of-phase-iiib-trial-for-ryzodeg-offers-successful-glycaemic-control-and--with-fewer-injections-than-a-basal-bolus-regimen--novo-nordisk/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2018/03/-ibs-awareness-month-2018/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2013/01/feiba-nf-success-in-phase-iii-trial-for-hemophilia-a-and-b/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2016/05/uk-nice-does-not-recommend-perjeta--pertuzumab--plus-herceptin--trastuzumab--for-her2-positive-breast-cancer--roche/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2013/12/sobi--will-sell-orfadin-in-us-canada-and-latin-america/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2015/04/mylan-to-acquire-perrigo-company-plc/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-nivestym-bisimilar-for--neutropenia--chemotherapy-infections-and-nonmyeloid-malignancies--as-neupogen---pfizer-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2013/05/biogen-files-plegridy-at-fda-for-treatment-of-relapsing-multiple-sclerosis/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2018/04/ce-mark-for-coap-pro-device-for-treatment-of-mitral-valve-repair---heartstitch/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-duo-trial-of-copiktra--in-cll---sll-is-published-in-blood---verastem-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-accepts-filing-and-grants-priority-review-for-car-t-therapy--ctl-019--tisagenlecleucel-t--to-treat--b-cell-acute-lymphoblastic-leukemia--novartis/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2018/12/study-of-endopredict-test-shows-influence-on-outcome-in-breast-cancer---myriad-genetics-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-future-1-study-for-cosentyx-shows-continued-impact-on-psoriatic-arthritis-at-5-years---novartis-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-of-sufentanil-nanotab-pca-system--acelrx-pharmaceuticals--shows-superiority-to-morphine-for-pain-relief/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2018/10/tour-study-of-vibativ-reports-use-in-s--aureus-infections-in-real-world-setting---theravance-biopharma-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2014/12/actelion-files-maa-at-ema-for-uptravi--selexipag--for-treatment-of-pah/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2014/09/nice-recommends-tafinlar-as-a-treatment-for-metastatic-melanoma-patients-with-braf-v600-mutation--gsk/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-data-for-revlimid-for-multiple-myeloma--celgene/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-javelin-gastric-100-study-of-bavencio-fails-to-meet-endpoint-in-gastroesophageal-junction--gej--cancer---merck-pfizer/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2013/02/study-shows-prebiotic-bimuno--clasado--shows-some-benefits-to-gastrointestinal-health/2021-09-24T07:15:33+00:00weekly0.6https://www.medthority.com/news/2018/01/abraxane---gemcitabine-positive-results-from-lapact-trial-for-locally-advanced-pancreatic-cancer---celgene-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-afinitor-disperz--novartis--for-sega-tumours-------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-chmp-recommends-broadening-approval-of-darzalex--daratumumab--for-multiple-myeloma--janssen-cilaq/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-eliquis--bms-pfizer--to-reduce-the-risk-of--stroke-and-systemic-embolism/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2018/09/ers-2018---pollution-linked-to-new-dangers-for-unborn-babies/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-filing-of-lynparza--olaparib--to-treat-germline-brca-mutated--gbrcam---her2-negative-metastatic-breast-cancer-----astrazeneca---merck-inc-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2011/12/ocriplasmin--thrombogenics--filed-at-fda-for-vitreomacular-adhesion-/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2019/03/celgene-submits-maa-to-ema-for-ozanimod-to-treat-relapsing-remitting-multiple-sclerosis--/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-analysis-of-xtampza-er--oxycodone-extended-release-capsules--for-chronic-pain-published-in-current-medical-research-and-opinion--collegium-pharmaceutical/2024-02-19T14:48:41+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-praluent-for-heart-attack-and-stroke-prevention---regeneron/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2019/05/cirrhosis-related-deaths-expected-to-treble-by-2030/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2019/06/bluebird-bio-announced-new-data-from-patients-in-group-c-of-its-ongoing-phase-i-ii-hgb-206-study-of--lentiglobin-for-sickle-cell-disease--scd--at-the-24th-european-hematology-association--eha--congress-/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-entresto---sacubitril-valsartan--for-treatment-of-heart-failure--novartis/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2017/08/repatha--evolocumab--economic-analysis-published-in-the-journal-of-the-american-medical-association--jama--cardiology---amgen/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2016/09/eu-approves-expanded-indication-for--xultophy--insulin-degludec---liraglutide--in-type-2-diabetes-with-moderate-renal-impairment--novo-nordisk/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2012/08/phase-iii-trials-commence-for-oms-103hp-for-arthroscopic-surgery/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2012/05/revlimid--celgene--prolongs-disease-control-for-multiple-myeloma-patients/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-daklinza---daclatasvir--for-hepatitis-c--bms/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-odyssey-outcomes-trial-of-praluent-shows-fewer-deaths-from-cv-events----sanofi---regeneron-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2018/08/alnylam-receives-approval-of-onpattrotm--patisiran--in-europe/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-saril-ra-monarch-trial-of-sar-153191--sarilumab--meets-primary-endpoint-and-is-superior-to-humira--adalimumab--for-rheumatoid-arthritis--sanofi-regeneron/2024-02-19T14:48:57+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approval-for-hetlioz--tasimelteon--to-treat-non-24-hour-sleep-wake-disorder--vanda-pharma/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2016/04/gilead-sciences--acquires-nimbus-apollo-inc-from-nimbus-therapeutics-and-with-it-ndi-010976/2021-09-24T07:10:47+00:00weekly0.6https://www.medthority.com/news/2019/03/new-phase-3-data-on-stelara--ustekinumab--in-ulcerative-coliti/2024-06-27T14:18:07+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-requires-warnings-for-use-of-sovaldi---sofosbuvir--or-harvoni--sofosbuvir-plus-ledipasvir--with-amiodarone--gilead/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2014/02/amg-145-meets-endpoint-in-phase-iii-trial-for-hefh-amgen/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2014/04/votrient-application-to-ema-for-ovarian-cancer-withdrawn---glaxo-smith-kline/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2013/06/nice-recommends-forxiga--bms-astrazeneca--for--combination-in-type-2-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2013/08/gsk-files-votrient-at-ema-for-ovarian-cancer/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-tremfya-one-press-for-plaque-psoriasis---janssen/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2018/02/successful-results-for-erleada-in-spartan-trial-for-non-metastatic-castration-resistant-prostate-cancer--johnson---johnson/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2012/06/acz-885--novartis--success-in-phase-ii-trial-for-traps/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2017/05/ibalizumab-filed-with-fda-for-multidrug-resistant-human-immunodeficiency-virus-1---theratechnologies-/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2016/04/positive-results-from-paloma-2-trial-of-ibrance--palbociclib----letrozole-for-estrogen-receptor-positive--human-epidermal-growth-factor-receptor-2-negative--er---her2---advanced-or-metastatic-breast-cancer--pfizer/2024-02-19T14:49:16+00:00weekly0.6https://www.medthority.com/news/2019/01/cara-therapeutics-reports--completion-of-enrollment-of-kalm-1-trial-of-korsuva-for-hemodialysis-patients-with-moderate-to-severe-chronic-kidney-disease-associated-pruritus-/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2018/03/veloxis-a-s-reports-publication-of--asertaa-trial-in--american-journal-of-kidney-diseases-of-envarsus-xr-in-afroamerican-renal-translant-patients-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2014/03/intuniv-is-filed-in-eu-for-adhd---shire/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2012/05/sar-236553-success-in-phase-ii-study-for-hefh/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-recommends-xarelto--bayer--for-stroke-prevention/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-data-on-xtandi-in-prostate-cancer-published-in-lancet-oncology-astellas/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-gallium-trial-shows-gazyva--obinutuzumab--improves-progression-free-survival-versus-rituxan-in-follicular-lymphoma--genentech-roche/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-gives-accelerated-approval-to-keytruda-for-previously-treated-hepatocellular-carcinoma---merck-inc-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2014/04/post-hoc-analysis-of-xiaflex-xiapex-for-peyronie-s-disease-reported---auxilium/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-talzenna-for-patients-with-deleterious-or-suspected-deleterious-germline-brca-mutated--gbrcam---her2-negative-locally-advanced-or-metastatic-breast-cancer---pfizer/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2012/05/fdfa-advisory-committee-recommends-quad--gilead--for-hiv-treatment/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2019/10/lilly-announces-phase-iii-sequoia-study-of-pegilodecakin---folfox-in-patients-with-metastatic-pancreatic-cancer-did-not-meet-primary-endpoint-of-overall-survival-/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-requires-labelling-changes-for-fluoroquinolones--including-an-updated-boxed-warning-/2021-09-24T07:09:30+00:00weekly0.6https://www.medthority.com/news/2020/06/complete-response-letter-for-htx--011-as-a-treatment-for-postoperative-pain.--heron-therapeutics2024-11-07T16:09:40+00:00weekly0.6https://www.medthority.com/news/2020/06/complete-response-letter-for--obeticholic-acid-for-the-treatment-of-fibrosis-due-to-nonalcoholic-steatohepatitis-nash.--intercept-pharmaceuticals2024-10-24T09:50:22+00:00weekly0.6https://www.medthority.com/news/2020/06/eu-approves-ultomiris-for-patients-with-atypical-hemolytic-uremic-syndrome.--alexion-pharma2024-11-12T10:54:22+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-phesgo-for-her2-positive-breast-cancer.--genentechroche2021-12-20T17:33:03+00:00weekly0.6https://www.medthority.com/news/2020/06/fabolus-faster-phase-iv-trial-of-aggrastat-in-acute-coronary-syndrome-published-in-circulation.--medicure2024-11-12T13:42:58+00:00weekly0.6https://www.medthority.com/news/2020/06/phase-iii-rhapsody-trial-of-rilonacept-meets-endpoints-in-pericarditis.--kiniksa-pharma2024-10-24T09:50:35+00:00weekly0.6https://www.medthority.com/news/2020/06/cpp-1xsul-filed-with-fda-and-maa-for-treatment-of-adults-with-familial-adenomatous-polyposis.--cancer-prevention-pharma2024-11-12T10:58:34+00:00weekly0.6https://www.medthority.com/news/2020/06/in-phase-iii-sure-1-trial-sulopenem-meets-endpoint-for-uncomplicated-urinary-tract-infections.--iterum-therapeutics2024-11-12T10:58:47+00:00weekly0.6https://www.medthority.com/news/2020/06/rauora-phase-iii-trial-of-cytisinicline-shows-non-inferiority-to-chantix-in-smoking-cessation.--achieve-life-sciences2024-10-24T09:51:03+00:00weekly0.6https://www.medthority.com/news/2020/06/uk-approves-phase-iiiii-study-evaluating-yeliva-in-patients-hospitalized-with-severe-sars-cov-2-infection.--redhill-biopharma2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/07/ibsrela-filed-with-fda-for-hyperphosphatemia-in-adult-patients-with-chronic-kidney-disease-on-dialysis.--ardelyx2024-11-12T09:09:56+00:00weekly0.6https://www.medthority.com/news/2020/07/two-phase-i-studies-of-ino-4800-report-safety-in-covid-19.--inovio2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/07/eu-approves-daurismo-for-acute-myeloid-leukemia.--pfizer2024-11-08T08:52:51+00:00weekly0.6https://www.medthority.com/news/2020/07/connect-fx-study-of-zygel-fails-to-meet-endpoints-in-fragile-x-syndrome.--zynerba-pharma2024-11-08T08:53:55+00:00weekly0.6https://www.medthority.com/news/2020/06/health-canada-approves-kynmobi-for-the-acute-intermittent-treatment-of-off-episodes-in-patients-with-parkinsons-disease-.--sunovion2024-10-22T11:47:23+00:00weekly0.6https://www.medthority.com/news/2020/06/fda-approves-ilaris-to-treatadult-onset-stills-disease---novartis/2024-10-22T07:42:44+00:00weekly0.6https://www.medthority.com/news/2020/06/gilead-sciences-gains-an-interest-in-pionyr-immunotherapeutics/2021-09-24T07:11:23+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-approves-invokana-to-treat-diabetic-kidney-disease-dkd-in-type-2-diabetes.---mundipharma2024-11-08T09:02:42+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-approves--enerzair-breezhaler-as-a-maintenance-treatment-of-asthma.-novartis2024-11-08T09:02:56+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-qwo-collagenase-clostridium-histolyticum-aaes-to-treat-cellulite-in-adult-women.-endo-international2024-10-24T09:35:36+00:00weekly0.6https://www.medthority.com/news/2020/07/advisory-committee-to-meet-to-review-data-for-terlipressin-to-treat-hepatorenal-syndrome.--mallinckrodt2024-11-12T10:34:59+00:00weekly0.6https://www.medthority.com/news/2020/07/aldeyra-therapeutics-development-plans-for-an-nda--for-reproxalap-in-dry-eye-disease.-2024-10-24T09:35:51+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-approves-lynparza-to-treat-germline-brca-mutated-gbrcam-metastatic-pancreatic-cancer.--astrazeneca--merck-inc2024-10-25T10:59:33+00:00weekly0.6https://www.medthority.com/news/2020/07/new-findings-on--biktarvy-presented-at-aids-2020-virtual-include-positive-switch-data-in-older-adults.--gilead-sciences2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/biib-037-filed-with-fda-for-alzheimers-disease.--biogen2024-11-08T09:03:16+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-altapore-shape-bioactive-bone-graft.-baxter-international2024-10-25T10:59:52+00:00weekly0.6https://www.medthority.com/news/2020/07/chemocentryx-inc.-has-submitted-a--nda-to-the-fda-for-avacopan-for-the-treatment-of-patients-with-anca-associated-vasculitis2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/complete-response-from-fda-for-keytruda--lenvima-combination-to-treat-hepatocellular-carcinoma--liver-cancer--merck-inc.--eisai2024-10-24T09:37:14+00:00weekly0.6https://www.medthority.com/news/2020/07/eisai-co.-ltd.-has-submitted-a-marketing-authorization-application-in-japan-for-the-ezh2-inhibitor-tazemetostat-hydrobromide-for-ezh2-gene-mutation-positive-follicular-lymphoma2021-12-20T17:31:51+00:00weekly0.6https://www.medthority.com/news/2020/07/ferring-to-market-the-prefilled-syringe-formulation--of-cimzia-in-the-us-for-the-treatment-of-crohns-disease.-ucb--ferring2024-11-08T09:02:27+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-hulio-for-ra-jia-pa-as-cd-uc-and-pp.--mylan2024-10-24T09:37:31+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-grants-priority-review-to-keytruda-in-hodgkin-lymphoma.--merck-inc2024-10-24T09:37:44+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-accepts-an-snda-for-brilinta--for-the-reduction-of-subsequent-stroke-in-patients-who-experienced-an-acute-ischemic-stroke-or-transient-ischemic-attack.-astrazeneca-2024-10-24T08:23:09+00:00weekly0.6https://www.medthority.com/news/2020/07/positive-results-from--primrose-1-and-primrose-2-studies-of-yselty-to-treat--heavy-menstrual-bleeding-due-to-uterine-fibroids.--obseva-sa--kissei2024-10-24T08:23:23+00:00weekly0.6https://www.medthority.com/news/2020/07/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19/2024-10-24T08:23:38+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-study-fidelio-dkd-of-bay-94-8862-meets-primary-endpoint-in-diabetic-kidney-disease.--bayer-2024-11-08T11:38:55+00:00weekly0.6https://www.medthority.com/news/2020/07/results-of-phase-iii-iridium-study-of-enerzair-breezhaler-in-asthma-published-in-lancet-respiratory-medicine.--novartis2024-11-12T09:14:12+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-sbla-for-botox-in-pediatric-patients-with-lower-limb-spasticity-caused-by-cerebral-palsy.--allerganabbvie2024-11-08T09:03:29+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-upneeq-to-treat-blepharoptosis.---osmotica-pharma2024-11-08T09:04:14+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-ascent-study-of-trodelvy--met-its-primary-endpoint-of-progression-free-survival-for-triple-negative-breast-cancer.--immunomedics-inc2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-letter-sent-to-verrica-pharma--notes-deficiencies-in-the-nda-for-vp-102-to-treat-molluscum-contagiosum/2024-11-08T09:08:01+00:00weekly0.6https://www.medthority.com/news/2020/07/hologic-launches-in-the-us-the-supersonic-mach-40-ultrasound-system/2024-11-08T09:04:33+00:00weekly0.6https://www.medthority.com/news/2020/07/leo-pharma-files-at-fda-a-bla-fortralokinumab-to-treat-moderate-to-severe-atopic-dermatitis/2021-12-20T17:31:51+00:00weekly0.6https://www.medthority.com/news/news-trends/transplant-organ-rejection/challenges-in-transplant-organ-rejection/2024-09-16T14:00:36+00:00weekly0.6https://www.medthority.com/news/news-trends/transplant-organ-rejection/treating-rejection-in-organ-transplants/2024-09-09T09:54:17+00:00weekly0.6https://www.medthority.com/news/2020/07/positive-effect-of-reltecimod-on-resolution-of-organ-dysfunction-in-phase-iii-accute-trial-for-patients-with-necrotizing-soft-tissue-infection-.--atox-bio2024-11-08T09:05:30+00:00weekly0.6https://www.medthority.com/news/2020/07/idorsia-ltd-announces-positive-results-in-the-second-phase-iii-study-of-daridorexant-in-patients-with-insomnia/2024-11-08T09:05:55+00:00weekly0.6https://www.medthority.com/news/2020/07/global-survey-of-copd-in-younger-and-older-patients-is-published-in-copd-journal-of-chronic-obstructive-pulmonary-disease.--boehringer2024-11-12T09:15:29+00:00weekly0.6https://www.medthority.com/news/2020/07/successful-trial-of-itolizumab-which-significantly-reduced-mortality-in-patients-hospitalized-with-covid-19.--equillium--biocon2024-10-25T11:00:04+00:00weekly0.6https://www.medthority.com/news/2020/07/genentech-update-on-phase-iii-study-of-tecentriq--avastin-in-women-with-advanced-stage-ovarian-cancer/2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/07/angelini-s.p.a.will--commercialise-ov-101-in-europe-turkey-and-russia-for-the-treatment-of-angelman-syndrome.--ovid-therapeutics2024-11-08T11:39:10+00:00weekly0.6https://www.medthority.com/news/2020/07/united-kingdoms-mhra-grants-early-access-to-lumasiran-a-treatment-forprimary-hyperoxaluria-type-1-.-alnylam-pharma2024-11-12T09:15:50+00:00weekly0.6https://www.medthority.com/news/2020/07/new-data-from-phase-iiib-stasey-study-reinforces-safety-profile-of--hemlibra-in-people-with-hemophilia-a.--genentechroche2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/07/eiasi-initiates-a-new-phase-iii-clinical-study-ahead-3-45-of-ban-2401-for-individuals-with-preclinical-alzheimers-disease2/2024-10-25T11:01:25+00:00weekly0.6https://www.medthority.com/news/2020/07/initiation-of-an-investigator-sponsored-trial-by-imperial-college-london-to-evaluate-the-efficacy-of-fostamatinib-for-the-treatment-of-covid-19-pneumonia.-rigel-pharma2024-11-08T09:06:11+00:00weekly0.6https://www.medthority.com/news/2020/07/european-commission-approves-nintedanib-in-adults-for-the-treatment-of-other-chronic-fibrosing-interstitial-lung-diseases-ilds-with-a-progressive-phenotype-beyond-idiopathic-pulmonary-fibrosis.--boehringer2024-10-25T11:01:38+00:00weekly0.6https://www.medthority.com/news/2020/07/publication-in-the-new-england-journal-of-medicine-of-interim-results-from-phase-1-study-of-the-mrna-vaccine-against-covid-19-mrna-1273.--moderna-inc2021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/07/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in-patients-who-had-an-acute-ischaemic-stroke-or-tia-in-the-phase-iii-thales-trial.--astrazeneca2024-11-08T09:20:50+00:00weekly0.6https://www.medthority.com/news/2020/07/advisory-committee-meeting--recommends-terlipressin-to-treat-adults-with-hepatorenal-syndrome-type-1.--mallinckrodt2024-11-08T09:06:22+00:00weekly0.6https://www.medthority.com/news/2020/07/the-new-england-journal-of-medicine-publishes-positive-phase-iib-trial-of--topical-roflumilast-cream-for-chronic-plaque-psoriasis.--arcutis-biotherapeutics2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves--konect-resilia-aortic-valved-conduit--the-first-ready-to-implant-solution-for-bio-bentall-procedures-for-aortic-surgery.-edwards-life-sciences-2024-10-24T09:37:57+00:00weekly0.6https://www.medthority.com/news/2020/07/-fda-advisory-committee-recommends-belantamab-mafodotin-to-treat-relapsed-or-refractory-multiple-myeloma.--gsk2021-12-20T17:32:09+00:00weekly0.6https://www.medthority.com/news/2020/07/perceval-plus-sutureless-surgical-aortic-heart-valve-is-now-available-for-commercial-release-in-europe.--livanova2024-10-24T09:38:26+00:00weekly0.6https://www.medthority.com/news/2020/07/pt-20-iron-based-phosphate-binder-study-is-published-in--nephrology-dialysis-transplantation.-shield-therapeutics2024-11-08T09:12:17+00:00weekly0.6https://www.medthority.com/news/2020/07/bay-1021189-filed-with-fda-for-heart-failure.--merck-inc-2021-12-20T17:31:50+00:00weekly0.6https://www.medthority.com/news/2020/07/biogen-plans-to-initiate-a-phase-iv-study-evaluating-spinraza-in-patients-with-spinal-muscular-atrophy-and-treated-with-zolgensma/2024-10-24T09:38:46+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-xywav-to-treat--cataplexy-or-excessive-daytime-sleepiness-in-patients-with-narcolepsy.--jazz-pharma-2024-11-08T08:59:14+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-accepts-filing-of-snda-for-nuplazid-to-treat-hallucinations-and-delusions-associated-with-dementia-related-psychosis.acadia-pharma2024-11-08T08:59:23+00:00weekly0.6https://www.medthority.com/news/2020/07/top-line-results-from-the-phase-iii-clarity-study-evaluating-pimavanserin-for-the-adjunctive-treatment-of-major-depressive-disorder.-acadia-pharmaceuticals2024-10-24T09:39:02+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-six-months-between-treatments-for-neovascular-age-related-macular-degeneration.-genentechroche2024-11-12T09:14:49+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-reach3-study-of-jakafi-meets-primary-endpoint-in-chronic-graft-versus-host-disease.--incyte2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/07/g1-therapeutics-inc-announces-a-license-agreement-for-lerociclib-to-eqrx/2024-11-08T08:59:32+00:00weekly0.6https://www.medthority.com/news/2020/07/biomarin-files-maa-at-ema-for-vosoritide-to-treat-children-with-achondroplasia/2024-11-08T08:59:41+00:00weekly0.6https://www.medthority.com/news/2020/07/clinical-trials-for-seladelpar--in-nash-pbc-and-psc-may-resume--cymabay-therapeutics/2024-11-12T09:15:01+00:00weekly0.6https://www.medthority.com/news/2020/07/bimekizumab-superior-to-cosentyx-in-achieving-complete-psoriasis-skin-clearance.-ucb2021-12-20T17:32:22+00:00weekly0.6https://www.medthority.com/news/2020/07/breztri-aerosphere-approved-in-the-us-for-the-maintenance-treatment-of-copd.--astrazeneca-2024-11-08T08:59:50+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-jyseleca-a-once-daily-treatment-for-rheumatoid-arthritis.--gilead-sciences--galapagos-nv2024-11-07T15:43:42+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-arikayce-for-non-tuberculous-mycobacterial-lung-infections.--insmed-2024-11-07T15:38:43+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-gsk-2857916-in-multiple-myeloma.--glaxosmithkline2021-12-20T17:32:22+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-car-t-cell-therapy-tecartus-for-mantle-cell-lymphoma.--kite-pharmagilead-sciences2024-11-08T11:39:04+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-imbruvica--rituxan-for-chronic-lymphocytic-leukaemia.--janssen2024-11-07T15:43:54+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-crysvita-for-x-linked-hypophosphataemia.--kyowa-kirin-2024-10-24T08:39:34+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-negative-recommendation-foremapalumab-for-the-treatment-of-primary-haemophagocytic-lymphohistiocytosis.--swedish-orphan-biovitrium2024-10-24T09:40:14+00:00weekly0.6https://www.medthority.com/news/2020/07/adakveo-receives-positive-chmp-opinion-for-the-prevention-of-recurrent-vaso-occlusive-crises-in-patients-with-sickle-cell-disease.--novartis2024-10-24T09:40:25+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-results-show-antiviral-treatment-favipiravir-demonstrated-a-28.6-faster-viral-clearance-of-covid-19-compared-to-placebo.---glenmark-pharma2021-12-20T17:32:33+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-ayvakyt-in-gastrointestinal-stromal-tumours.--blueprint-medicines2021-12-20T17:31:27+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-calquence-for-chronic-lymphocytic-leukaemia--astrazeneca/2024-11-12T09:15:15+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-zynrelef-for-post-surgical-pain.--heron-therapeutics2024-10-24T09:40:40+00:00weekly0.6https://www.medthority.com/news/2020/07/chmp-recommends-approval-of-equidacent-as-biosimilar-for-avastin-in-a-range-of-cancers.--centus-biotherapeutics-2024-11-07T15:44:14+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-trial-of-mrna-1273-in-coronavirus-expanded-in-us.--moderna2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/07/imfinzi-recommended-for-approval-by-chmp-for-extensive-stage-small-cell-lung-cancer.-astrazeneca2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/pds-0203-vaccine-elicits-immuno-response-in-early-trials-for-covid-19.--pds-biotechnology-corp2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/07/post-hoc-analysis-of-tavalisse-in-chronic-immune-thrombocytopenia-published-in-british-journal-of-haematology.--rigel-pharma2024-10-24T09:34:58+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-accepts-for-review--nda-for-furoscix-to-treat-congestive-heart-failure.--scpharmaceuticals2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/07/results-from-phase-iii-dapa-ckd-trial-of-farxiga-met-primary-and-secondary-endpoints-to-treat-chronic-kidney-disease---astrazeneca/2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/07/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against-covid-19-and-commence-pivotal-phase-iiiii-global-study/2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/07/health-canada-approves-velkury-to--treat-pneumonia-associated-with-covid-19.--gilead-sciences2024-10-24T08:36:19+00:00weekly0.6https://www.medthority.com/news/2020/07/study-of-p-tau217-diagnostic-aid-in-alzheimers-disease-published-in-jama.--eli-lilly2024-10-24T08:36:32+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-ad-up-trial-of-rinvoq-meets-endpoints-in-atopic-dermatitis.--abbvie2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-refals-trial-of-simdax-fails-to-meet-endpoints-in-amyotrophic-lateral-sclerosis.--orion2024-11-12T10:20:33+00:00weekly0.6https://www.medthority.com/news/2020/07/eu-approves-xenleta-in-community-acquired-pneumonia.--nabriva-therapeutics2024-11-07T15:38:18+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-topical-wynzora-cream-to-treat-plaque-psoriasis.--mc2-therapeutics2021-12-20T17:31:27+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-advance-trial-of-atogepant-meets-primary-endpoint-in-migraine.--abbvie2024-10-24T08:36:49+00:00weekly0.6https://www.medthority.com/news/2020/07/txa-127-to-enter-phase-ii-trials-for-covid-19.--constant-therapeutics2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/eu-approves-piqray-for-hrher2--locally-advanced-or-metastatic-breast-cancer.--novartis2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-ventana-her2-dual-ish-dna-probe-cocktail-assay-for-detection-her2-breast-cancer.--roche2021-12-20T17:31:27+00:00weekly0.6https://www.medthority.com/news/2020/07/actemra-does-not-meet-endpoints-in-phase-iii-covacta-study-for-severe-covid-19-associated-pneumonia.--genentechroche2024-10-24T08:37:13+00:00weekly0.6https://www.medthority.com/news/2020/07/idecabtagene-vicleucel--is-re-filed-at-fda-to-treat-relapsed-and-refractory-multiple-myeloma.-bms--bluebird-bio-inc2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/positive-results-from-phase-iib-trial-of-nirsevimab-to-treat-infants-with-respiratory-syncytial-virus.sanofi--astrazeneca2024-10-24T08:37:30+00:00weekly0.6https://www.medthority.com/news/2020/07/sorrento-therapeutics-inc.-has-licensed-from--columbia-university--the-rights-to-a-rapid-one-step-diagnostic-test-that-detects-sars-cov-2-virus-in-as-little-as-30-minutes-from-a-sample-of-saliva2024-10-24T08:37:47+00:00weekly0.6https://www.medthority.com/news/2020/07/emperor-reduced-phase-iii-trial-positive-for-jardiance-as-a-treatment-for-heart-failure.--boehringer-ingelheim--eli-lilly2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/07/nice-recommends-bavencio----axitinib-for-the-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma/2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/07/ad26.cov2-s-vector-based-vaccine-protected-against-infection-with-sars-cov-2--in-a-pre-clinical-study-which-is-published-in-nature.--johnson--johnson2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-tecentriq--cotellic-zelboraf--to-treat-of-braf-v600-mutation-positive-advanced-melanoma-patients.--genentechroche2024-11-07T15:43:01+00:00weekly0.6https://www.medthority.com/news/2020/08/et-104-zonisamide-oral-suspension-is-filed-at-the--fda-to-treat-partial-seizures-in-patients-with-epilepsy.--eton-pharma2021-12-20T17:31:27+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-expanded-indication-for-stelara-in-pediatric-plaque-psoriasis.--janssen-pharma2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/08/new-topline-tepezza-data-confirms-its-efficacy-in-longer-disease-duration-long-term-durability-and-potential-for-retreatment-in-people-living-with-thyroid-eye-disease-ted.horizon-therapeutics2024-10-24T09:35:10+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-apollo-study-of-darzalex--pomalyst--dexamethasone-meets-primary-endpoint-in-multiple-myeloma.--janssen-biotech2024-10-24T08:38:42+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-epidiolex--oral-solution-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex.--gw-pharma--greenwich-biosciences2024-10-24T08:39:22+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-grants-accelerated-approval-for-monjuvi--lenalidomide-to-treat-diffuse-large-b-cell-lymphoma-dlbcl.--morphosys-ag--incyte2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/pfizer-and-biontech-announce-early-positive-update-from-german-phase-1ii-covid-19-vaccine-study-of-bnt-162-mrna-based-vaccine-including-first-t-cell-response-data/2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-phase-ii-trial-of-ac-0010ma-in-covid-19.--sorrento-therapeutics2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/07/trial-results-with-caldolor-in-pain-treatment-published-in-journal-of-orthopedic-trauma.--cumberland-pharma2022-01-10T10:16:56+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-grants-emergency-use-authorisation-for-xmap-sars-cov-2-multi-antigen-igg-assay-in-coronavirus.--luminex-corp2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-cov001-trial-of-azd-1222-shows-vaccine-well-tolerated-in-sars-cov-2-virus.--astrazeneca2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2020/07/trial-of-sng-001-shows-positive-results-in-covid-19-patients.--synairgen2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/07/phase-iii-trial-of-bxcl-501-meets-endpoints-in-patients-with-agitation-and-schizophrenia-and-bipolar-disorder.--bioxcel-therapeutics2024-11-12T13:43:37+00:00weekly0.6https://www.medthority.com/news/2020/07/bellerophon-therapeutics-announces-publication-of-cohort-1-of-ino-pf-phase-iiiii-study-in-the-chest-journal-and-participation-in-webinar-to-discuss-clinical-results/2024-11-08T11:38:59+00:00weekly0.6https://www.medthority.com/news/news-trends/transplant-organ-rejection/complications-of-stem-cell-transplants/2024-09-16T14:17:53+00:00weekly0.6https://www.medthority.com/news/news-trends/transplant-organ-rejection/the-future-of-organ-transplantation/2024-09-09T11:21:38+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-accepts-filing-of-nda-for-voclosporin-as-a-treatment-for-lupus-nephritis.--aurinia-pharma2024-11-12T09:14:29+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-watchman-flx-left-atrial-appendage-closure-laac-device-to-reduce-the-risk-of-stroke.--boston-scientific2021-12-20T17:32:22+00:00weekly0.6https://www.medthority.com/news/2020/07/gilead-sciences-acquires-minority-interest-in-tizona-therapeutics-inc/2021-09-24T07:11:35+00:00weekly0.6https://www.medthority.com/news/2020/08/european-commission-approves-cosentyx-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-children-and-adolescents.--novartis2021-12-20T17:32:22+00:00weekly0.6https://www.medthority.com/news/2020/08/eli-lilly-initiates-phase-iii-trial-of-ly-cov555-for-prevention-of-covid-19-at-long-term-care-facilities-in-partnership-with-niaid/2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-accepts-vandas-applications-for-hetlioz-in-the-treatment-of-smith-magenis-syndrome/2024-11-08T09:06:37+00:00weekly0.6https://www.medthority.com/news/2020/08/novartis-announces-kymriah-meets-primary-endpoint-at-interim-analysis-of-pivotal-study-in-follicular-lymphoma/2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/08/complete-response-from-fda-for-viaskin--peanut-patch-to-treat-peanut-allergies-in-children-ages-4-to-11-years.-dbv-technologies2024-11-08T09:06:56+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-accepts-snda-submission--for-exparel-postsurgical-analgesia-in-children.--pacira-biosciences2024-11-08T11:35:55+00:00weekly0.6https://www.medthority.com/news/2020/08/nejm-publishes-phase-iii-asclepios-trials-demonstrating-superior-efficacy-of-ofatumumab-in-patients-with-relapsing-multiple-sclerosis.--novartis2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/08/aegis-h2h-study-reanalysis-shows-that-feraccruaccrufer-is-a-credible-alternative-to-iv-therapy-for-iron-deficiency-anaemia.--shield-therapeutics2024-11-08T11:35:39+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-grants-accelerated-approval-for-blenrep-to-treat-relapsed-or-refractory-multiple-myeloma-for-those-who-have-received-at-least-four-prior-therapies-.--gsk2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/08/genentechroche-provides-update-on-phase-iii-study-of-tecentriq-in-combination-with-paclitaxel-for-people-with-metastatic-triple-negative-breast-cancer/2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/08/bausch-will-spin-off-its-eye-care-business-into--a-separate-publicly-traded-company/2021-09-24T07:12:31+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-somatom-on.site-a-mobile-head-computed-tomography-ct-scanner-from-siemens-healthineers2024-11-08T11:35:29+00:00weekly0.6https://www.medthority.com/news/2020/08/pacira-announces-publication-of-phase-iv-study-of-exparel-in-cesarean-section-procedures-in-anesthesia--analgesia/2024-10-24T09:40:50+00:00weekly0.6https://www.medthority.com/news/2020/08/cimzia-is-the-first-and-only-biologic-approved-in-europe-with-the-option-for-a-reduced-maintenance-dose-for-patients-across-the-full-axial-spondyloarthritis-spectrum--ucb/2024-10-25T11:01:49+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves--evrysdi-risdiplam-for-treatment-of-spinal-muscular-atrophy-sma-in-adults-and-children-2-months-and-older.-genentechroche2024-10-25T11:01:59+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-supplemental-indication-of-spravato-for-major-depressive-disorder--with-acute-suicidal-ideation-or-behavior.-johnson--johnson2024-10-24T09:41:01+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-accepts-bla-from-eisai-and-biogen-for-aducanumab-a-proposed-treatment-for-alzheimers-disease/2024-10-24T09:41:13+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-orient-11-trial-of-tyvyt-plus-alimta-shows-efficacy-in-nsclc.--innovent-biologics--eli-lilly2021-12-20T17:31:52+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-olinvyk-for-management-of-acute-pain.--trevena2024-10-24T08:31:01+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-checkmate--743-trial-of-opdivo--yervoy-shows-efficacy-in-malignant-pleural-mesothelioma.--bms2024-11-12T09:16:05+00:00weekly0.6https://www.medthority.com/news/2020/08/vaxart-announces-that--its-covid-19-investigational-new-drug-ind-application-for-an-oral-vaccine-has-been-filed-with-the-fda/2021-12-20T17:32:23+00:00weekly0.6https://www.medthority.com/news/2020/08/omeros-corporation-reports-recovery-and-survival-of-all-patients-in-a-study-evaluating--narsoplimab-with-acute-respiratory-distress-syndrome-associated-with-covid-19/2024-10-24T08:35:07+00:00weekly0.6https://www.medthority.com/news/2020/08/gilead-sciences-files-nda-at-fda-veklury-an-investigational-antiviral-for-the-treatment-of-patients-with-covid-19/2024-10-24T08:35:44+00:00weekly0.6https://www.medthority.com/news/2020/08/-the-fda-has-accepted-for-review-the-bla-for-stratagraft-an-investigational-regenerative-skin-tissue-therapy-in-development-for-the-treatment-of-deep-partial-thickness-thermal-burns.--mallinckrodt2024-11-08T09:08:08+00:00weekly0.6https://www.medthority.com/news/2020/08/mixed-results-from-phase-iii-trial-of-rg-7413-in-ulcerative-colitis.--genentechroche2021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-ecospor-iii-study-of-ser-109-shows-efficacy-in-c.-difficile-infection.--seres-therapeutics2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/08/no-fda-decision-yet-on-em-100-treatment-for-ocular-itching.--eton-pharma--bausch--lomb2024-10-24T08:23:56+00:00weekly0.6https://www.medthority.com/news/2020/08/-china-national-medical-products-administration-nmpa-approves-truvada-for-pre-exposure-prophylaxis-prep.-gilead-sciences2024-10-25T11:02:17+00:00weekly0.6https://www.medthority.com/news/2020/08/checkmate--577-a-phase-iii-trial-evaluating-opdivo-as-adjuvant-therapy-for-resected-esophageal-or-gastroesophageal-junction-cancer-meets-primary-endpoint-of-disease-free-survival.--bms2021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/08/health-canada-approves-opdivo--yervoy-with-chemo-for-metastatic-non-small-cell-lung-cancer.--bms2021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-trial-of-nt-300-starts-for-mild-or-moderate-covid-19.--romark2024-10-24T08:24:10+00:00weekly0.6https://www.medthority.com/news/2020/08/checkmate--649-a-phase-iii-trial-of-opdivo--chemotherapy-vs.-chemotherapy-meets-primary-endpoints-of-superior-overall-survival-and-progression-free-survival-in-first-line-treatment-of-gastric-and-esophageal-cancers.-bms2024-11-08T09:08:19+00:00weekly0.6https://www.medthority.com/news/2020/08/european-commission-approves-xolair-as-an-add-on-therapy-with-intranasal-corticosteroids-for-the-treatment-of-severe-chronic-rhinosinusitis-with-nasal-polyps.---novartis2024-10-24T08:27:18+00:00weekly0.6https://www.medthority.com/news/2020/08/australia-joins-u.s.-switzerland-canada-and-singapore-in-approval-of-tukysa-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-her2-positive-breast-cancer---seattle-genetics2021-12-20T17:31:18+00:00weekly0.6https://www.medthority.com/news/2020/08/guardant360-cdx-first-fda-approved-liquid-biopsy-for-comprehensive-tumor-mutation-profiling-across-all-solid-cancers.-guardant-health-inc2024-10-24T08:31:09+00:00weekly0.6https://www.medthority.com/news/2020/08/vbl-therapeutics-announces-second-successful-pre-planned-interim-analysis-with-a-positive-data-safety-monitoring-committee-review-looking-at-os---the-primary-endpoint-of-the-oval-phase-iii-potential-registration-study-of-vb-111-in-ovarian-cancer/2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/08/complete-response-letter-for-pedmark-for-the-prevention-of-ototoxicity-associated-with-cisplatin-chemotherapy-in-pediatric-patients--with-localized-non-metastatic-solid-tumors.-fennec-pharma2024-11-08T09:08:32+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-viltepso-for-duchenne-muscular-dystrophy.--ns-pharmanippon-shinyaku2024-10-24T08:31:21+00:00weekly0.6https://www.medthority.com/news/2020/08/regn-1500-filed-with-the-fda-for-homozygous-familial-hypercholesterolemia.--regeneron-pharmaceuticals2024-10-24T08:33:33+00:00weekly0.6https://www.medthority.com/news/2020/08/tyvyt-filed-in-china-for-squamous-non-small-cell-lung-cancer.--innovent-biologics--eli-lilly2021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/08/bayer-healthcare-acquires-kandy-therapeutics-and-with-it-nt-814-to-treat-menopause/2021-09-24T07:12:28+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-accepts-application-for-xolair--prefilled-syringe-for-self-administration-across-all-indications.-novartis2024-11-12T14:03:32+00:00weekly0.6https://www.medthority.com/news/2020/08/results-from-the-phase-iii-viale-a-clinical-study-of-venclexta-with-vidaza-in-acute-myeloid-leukemia-aml-in-nejm.--abbvie2024-11-08T09:12:30+00:00weekly0.6https://www.medthority.com/news/2020/08/thermo-fisher-acquisition-of-qiagen-will-not-proceed/2021-09-24T07:12:28+00:00weekly0.6https://www.medthority.com/news/2020/08/anvisa-has-granted-permission-to-commence-a-phase-iii-study-of-lenzilumab-in-patients-with-covid-19-in-brazil.--humanigen2024-10-24T08:33:50+00:00weekly0.6https://www.medthority.com/news/2020/08/ema-validates-maa-for-vosoritide-to-treat-children-with-achondroplasia.--biomarin2024-11-08T09:12:40+00:00weekly0.6https://www.medthority.com/news/2020/08/fibrogen-initiates-phase-iii--lelantos-trial-for-pamrevlumab--in-combination-with-corticosteroids-in-patients-with-non-ambulatory-duchenne-muscular-dystrophy/2024-11-08T09:19:09+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-enspryng-to-treat-neuromyelitis-optica-spectrum-disorder.--genentechroche2024-10-24T08:34:33+00:00weekly0.6https://www.medthority.com/news/2020/08/moletest-scotland-ltd-offers-nomela-the-first-and-only--rule-out-screening-test-for-skin-lesions-suspected-of-melanoma/2024-10-24T08:34:51+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-clinical-trial-of-solosec-shows-efficacy-in-trichomoniasis-sti.--lupin-pharma2024-11-08T09:20:35+00:00weekly0.6https://www.medthority.com/news/2020/07/heron-therapeutics-announces-initiation-of-phase-ii-clinical-study-of-cinvanti-for-the-treatment-of-covid-19/2021-12-20T17:32:09+00:00weekly0.6https://www.medthority.com/news/2020/07/mirikizumab-superior-to-cosentyx-in-a-phase-iii-study-for-patients-with-moderate-to-severe-plaque-psoriasis.--eli-lilly2021-12-20T17:30:14+00:00weekly0.6https://www.medthority.com/news/2020/07/european-medicines-agency-validates-application-for-car-t-cell-therapy-lisocabtagene-maraleucel-liso-cel.--bms2021-12-20T17:31:50+00:00weekly0.6https://www.medthority.com/news/2020/07/fda-approves-tremfya-to-treat-psoriatic-arthritis.-janssen-pharma2024-11-08T08:57:18+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-advisory-committee-recommendsryoncil-to-treat-pediatric-patients-with-steroid-refractory-acute-graft-versus-host-disease.--mesoblast-ltd2024-10-24T08:36:02+00:00weekly0.6https://www.medthority.com/news/2020/08/complete-response-letter-for-ryanodex-to-treat-exertional-heat-stroke.--eagle--pharma2024-11-07T15:38:00+00:00weekly0.6https://www.medthority.com/news/2020/08/ligand-acquires-pfenex-inc/2021-09-24T07:12:27+00:00weekly0.6https://www.medthority.com/news/2020/08/missed-the-digital-ilc-2020-heres-a-look-back-at-the-highlights/2025-02-03T14:40:40+00:00weekly0.6https://www.medthority.com/news/2020/08/novavax-inc.-commences-phase-iib-trial-of-nvx-cov2373-in-south-africa-to-treat-covid-192021-12-20T17:32:10+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-accepts-filing-snda-for-tyvaso-inhaled-solution-for-the-treatment-of-pulmonary-hypertension-associated-with-interstitial-lung-disease-.--united-therapeutics2024-11-12T09:42:06+00:00weekly0.6https://www.medthority.com/news/2020/08/redhill-biopharma-licenses-european-rights-to-movantik-and-rhb-204-to-cosmo-pharma/2024-11-12T09:42:20+00:00weekly0.6https://www.medthority.com/news/2020/08/nda-for-once-daily-oral-relugolix-combination-tablet-for-the-treatment-of-women-with-heavy-menstrual-bleeding-associated-with-uterine-fibroids-accepted-for-review-by-the-fda.--myovant-sciences2025-01-31T11:37:48+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-enlighten-2-trial-of-alks-3831-in-schizophrenia-published-in-american-journal-of-psychiatry.--alkermes-2024-11-08T09:21:26+00:00weekly0.6https://www.medthority.com/news/2020/08/deciphera-announces-publication-of-qinlock-phase-1-study-results-in-patients-with-gastrointestinal-stromal-tumor-in-journal-of-clinical-oncology/2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/08/sanofi-acquires-principia-biopharma-inc/2021-09-24T07:12:27+00:00weekly0.6https://www.medthority.com/news/2020/08/the-fda-has-accepted-the-sbla-for-imfinzi-and-granted-priority-review-in-the-us-for-a-new-four-week-fixed-dose-regimen-for-nsclc-and-bladder-cancer-astrazeneca/2021-12-20T17:30:15+00:00weekly0.6https://www.medthority.com/news/2020/08/vanda-pharma-reports-interim-analysis-that-tradipitant-may-accelerate-clinical-improvement-in-sars-cov-2-covid-19-pneumonia-in-the-odyssey-study/2024-11-07T15:44:50+00:00weekly0.6https://www.medthority.com/news/2020/08/chiasma-optimal-phase-iii-trial-of-mycapssa-in-acromegaly-published-in-journal-of-clinical-endocrinology--metabolism.--chiasma2024-11-07T15:45:03+00:00weekly0.6https://www.medthority.com/news/2020/08/gilead-sciences-and-galapagos-nv-receive-complete-response-letter-from-fda--for-filgotinib-an-investigational-treatment-for-moderately-to-severely-active-rheumatoid-arthritis/2024-10-24T09:42:17+00:00weekly0.6https://www.medthority.com/news/2020/08/genentechroche-to-collaborate-with-regeneron-for-the-development-and-distribution-of-regn-cov2-worldwide/2021-12-20T17:32:42+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-issues-complete-response-letterfor-valoctocogene-roxaparvovec-gene-therapy-for-severe-hemophilia-a.-biomarin2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/08/tecentriq--avastin-approved-by-health-canada-for-unresectable-or-metastatic-hepatocellular-carcinoma.--genentechroche2024-11-08T09:21:42+00:00weekly0.6https://www.medthority.com/news/2020/08/mylan-launches-generic-tecfidera-in-the-us-to-treat-multiple-sclerosis/2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-programme--of-subcutaneous-concizumab-prophylaxis-treatment-in-haemophilia-a-and-b-patients-regardless-of-inhibitor-status-is-resumed.---novo-nordisk2024-11-12T12:00:53+00:00weekly0.6https://www.medthority.com/news/news-trends/liver/the-latest-treatments-in-nash/2024-09-09T11:13:31+00:00weekly0.6https://www.medthority.com/news/news-trends/liver/the-next-global-epidemic/2024-09-09T11:13:16+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-trial-of-regn-1500-in-homozygous-familial-hypercholesterolemia-published-in-nejm.--regeneron-pharma2024-10-24T09:42:31+00:00weekly0.6https://www.medthority.com/news/2020/08/biomarin-submits-nda-to-fda-for-vosoritide-to-treat--children-with-achondroplasia/2024-10-24T09:42:50+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-kesimpta-to-treat-multiple-sclerosis.--novartis2021-12-20T17:33:15+00:00weekly0.6https://www.medthority.com/news/2020/08/one-year-follow-up-on-etna-af-europe-registry-with-lixiana-shows-efficacy-in-non-valvular-atrial-fibrillation.--daiichi-sankyo-2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/08/eu-approves-aybintio-for-carcinoma-of-the-colon-or-rectum-breast-cancer-non-small-cell-lung-cancer-renal-cell-cancer-epithelial-ovarian-fallopian-tube-and-peritoneal-cancer-and-cervical-cancer.--samsung-bioepis2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-kyprolis--darzalex--dexamethasone-combination-to-treat-multiple-myeloma--amgen/2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2020/08/momenta-pharma-is-acquired-by-johnson--johnson-and-with-it-nipocalimab/2021-09-24T07:12:25+00:00weekly0.6https://www.medthority.com/news/2020/08/nmpa-china-approves-zercepac-to-treat-breast-cancer-and-gastric-cancer--shanghai-henlius-biotech/2024-10-24T11:18:34+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-ii-trial-starts-for-nvx-cov2373-in-covid-19.--novavax-2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-study-of-estybon-fails-to-meet-primary-endpoint-in-higher-risk-myelodysplastic-syndromes.--onconova-therapeutics2024-10-24T09:43:24+00:00weekly0.6https://www.medthority.com/news/2020/08/first-participants-dosed-in-trial-of-azd-7442-to-assess-the-combination-of-two-monoclonal-antibodies-against-covid-19.-astrazeneca2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/08/yumanity-therapeutics-and-proteostasis-therapeutics-to-merge-and-operate-as-yumanity-therapeutics/2021-09-24T07:12:24+00:00weekly0.6https://www.medthority.com/news/2020/08/bms-acquires-forbius-and-its-potent-inhibitors-of-tgf-beta-1--3/2021-09-24T07:12:24+00:00weekly0.6https://www.medthority.com/news/2020/08/bavarian-nordic-as--announced-topline-results-from-the-pivotal-phase-iii-study-of-the-freeze-dried-formulation-of-its-mva-bn-smallpox-vaccine/2024-10-24T09:51:16+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-cystadrops-to-treat-cystinosis.--recordati2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/08/idhifa-did-not-meet-the-primary-endpoint-of-overall-survival-in-the-idhentify-study-to-treat-acute-myeloid-leukemia--with-an-isocitrate-dehydrogenase-2-idh2-mutation.--bms-2024-10-24T09:51:42+00:00weekly0.6https://www.medthority.com/news/2020/08/sarepta-completes-filing-of-casimersen-to-treat-patients-with-duchenne-muscular-dystrophy-who-have-genetic-mutations-that-are-amenable-to-skipping-exon-45-of-the-duchenne-gene/2024-10-24T11:18:46+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-grants-priority-review-for-tepotinib-for-the-treatment-of--metastatic-nsclc-with-tumors-with-a-mutation-that-leads-to-mesenchymal-epithelial-transition-exon-14-metex14-skipping.--merck-kgaa2021-12-20T17:30:34+00:00weekly0.6https://www.medthority.com/news/2020/08/rinvoq-filed-with-fda-and-maa-for-active-ankylosing-spondylitis.--abbvie2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/08/novartis-investigational-novel-stamp-inhibitor-asciminib--meets-primary-endpoint-of-phase-iii-chronic-myeloid-leukemia-study/2024-11-12T09:38:51+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approval-for-foundationone-liquid-cdxa-comprehensive-pan-tumor-liquid-biopsy-test-foundation-medicineroche/2025-01-31T11:37:03+00:00weekly0.6https://www.medthority.com/news/2020/08/positive-phase-ii-study-of--seladelpar-in-patients-with-primary-biliary-cholangitis.-cymabay-therapeutics2024-10-24T11:20:02+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-needs-more-time-to-review-tlando-to-treat-testosterone-deficiency.--lipocine-inc2024-10-24T09:51:55+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-expands-indication-for-veklury-to-treat-all-hospitalized-patients-with-covid-19-in-addition-to-the-previous-authorization-for-patients-hospitalized-with-severe-covid-19.-gilead-sciences2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/08/full-results-of-emperor-reduced-phase-iii-study-of-empagliflozin-in-heart-failure.-eli-lilly--boehringer2021-09-24T07:12:22+00:00weekly0.6https://www.medthority.com/news/2020/08/outlook-therapeutics-reports-topline-results-and-positive-proof-of-concept-for-ons-5010--lytenava-from-norse-1-trial-to-treat-wet-amd/2024-11-12T12:07:18+00:00weekly0.6https://www.medthority.com/news/2020/08/odonate-therapeutics-announces-positive-top-line-results-from-contessa-a-phase-iii-study-of-tesetaxel-in-patients-with-metastatic-breast-cancer/2021-12-20T17:30:36+00:00weekly0.6https://www.medthority.com/news/2020/08/new-analysis-of-orion-10-and-orion-11-trials-shows-high-consistency-in-lowering-ldl-c-in-individual-response-with-investigational-inclisiran.--novartis2024-10-24T09:02:50+00:00weekly0.6https://www.medthority.com/news/2020/08/bluebird-bio-presents-new-results-from-elivaldogene-autotemcel-eli-cel-lenti-d-gene-therapy-for-cerebral-adrenoleukodystrophy.-cald2021-12-20T17:29:46+00:00weekly0.6https://www.medthority.com/news/2020/08/positive-results-from-phase-iii-dapa-ckd-trial-of-farxiga-to-treat-chronic-kidney-disease.-astrazeneca2024-11-12T11:40:18+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-explorer-hcm-trial-of-myk-461-in-obstructive-hypertrophic-cardiomyopathy-published-in-the-lancet.--myokardia-2024-10-24T11:20:15+00:00weekly0.6https://www.medthority.com/news/2020/08/hauser-rct-phase-iiib-study-of-repatha-in-heterozygous-familial-hypercholesterolemia-published-in-nejm.--amgen2024-11-08T11:30:47+00:00weekly0.6https://www.medthority.com/news/2020/09/results-from-evaporate-trial-of-vascepa-in-coronary-atherosclerosis-published-in-european-heart-journal.--hls-therapeutics2024-11-08T11:30:54+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iiiii-comet-ice-trial-of-vir-7831-in-covid-19-doses-first-patient.--vir-biotechnology--glaxosmithkline2021-12-20T17:29:46+00:00weekly0.6https://www.medthority.com/news/2020/09/novan-inc.-initiates-b-simple4-pivotal-phase-iii-study-of-sb-206-for-treatment-of-molluscum-contagiosum2024-11-12T09:34:54+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-data-on-vimpat-in-primary-generalized-tonic-clonic-seizures-published-in-journal-of-neurology-neurosurgery--psychiatry.--ucb2021-12-20T17:31:27+00:00weekly0.6https://www.medthority.com/news/2020/09/irb-approves-phase-iii-trial-of-bucillamine-in-covid-19.--revive-therapeutics2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/09/positive-headline-results-from-the-vyepti-relief-study-for-preventive--migraine-therapy.--lundbeck2021-12-20T17:32:21+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-trial-enrolling-up-to-30000-adults-aged-18-years-or-over-to-assess-safety-efficacy-and-immunogenicity-of-azd-1222-for-the-prevention-of-covid-19.-astrazeneca2021-12-20T17:29:47+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-trial-of-kevzara-did-not-meet-its-primary-or-secondary-endpoints-in-hospitalised-patients-with-covid-19.--sanofi2021-12-20T17:29:47+00:00weekly0.6https://www.medthority.com/news/2020/09/european-commission-approves-imfinzi-to-treat-extensive-small-cell-lung-cancer.-astra-zeneca2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/09/nestle-acquires-aimmune-therapeutics-inc/2021-09-24T07:12:42+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-onureg-for-the-continued-treatment-of-adult-patients-with-acute-myeloid-leukemia.---bms2024-11-08T11:38:50+00:00weekly0.6https://www.medthority.com/news/2020/09/preliminary-study-of-t-705-shows-efficacy-in-covid-19-with-data-is-published-in-the-lancet.--fujifilm2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-cobas-hiv-1hiv-2-qualitative-test-for-hiv-diagnosis.--roche2021-12-20T17:32:33+00:00weekly0.6https://www.medthority.com/news/2020/09/ionis-pharmaceuticals-to-acquire-remaining-stake-in-akcea-therapeutics/2021-09-24T07:12:41+00:00weekly0.6https://www.medthority.com/news/news-trends/liver/phase-ii-trials-and-stem-cell-therapies/2024-09-09T11:48:36+00:00weekly0.6https://www.medthority.com/news/news-trends/liver/over-the-horizon-early-stage-trials-for-nash/2024-09-16T15:34:06+00:00weekly0.6https://www.medthority.com/news/2020/09/final-analysis-of-the-observational-giotag-study-of-sequential-afatinib-and-osimertinib-in-patients-with-egfr-mutation-positive-non-small-cell-lung-cancer.--boehringer2024-11-12T09:41:26+00:00weekly0.6https://www.medthority.com/news/2020/08/european--commission-approves-kaftrio-to-treat-cystic-fibrosis-in-people-ages-12-years-and-older.--vertex-pharma2024-11-07T15:44:34+00:00weekly0.6https://www.medthority.com/news/2020/08/virtual-fda-advisory-committee-meeting-to-review-nda--for-alks-3831-for-treatment-of-schizophrenia-and-bipolar-i-disorder-tentatively-scheduled-for-9-october-2020.--alkermes-plc2024-11-12T09:34:43+00:00weekly0.6https://www.medthority.com/news/2020/08/keytruda--chemotherapy-significantly-improved-overall-survival-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or-first-line-metastatic-esophageal-cancer.-merck-inc2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-combi-i-study-of-pdr-001--tafinlar--mekinist-fails-to-meet-primary-endpoint-in-melanoma.--novartis2024-10-24T09:43:04+00:00weekly0.6https://www.medthority.com/news/2020/08/phase-iii-psoaring-1-and-psoaring-2-trials-of-gsk-2894512-meets-primary-endpoints-in-both-trials-for-plaque-psoriasis.--dermavant-sciences2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-awards-emergency-use-authorization-for-advanta-dx-sars-cov-2-rt-pcr-assay-in-covid-19-detection.--fluidigm-corp2021-12-20T17:30:34+00:00weekly0.6https://www.medthority.com/news/2020/08/eu-approves-blenrep-for-multiple-myeloma.--glaxosmithkline2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/08/eu-commission-grants-conditional-approval-for-idefirix-in-highly-sensitized-kidney-transplant-patients-in-the-european-union.--hansa-biopharma2024-11-12T09:10:22+00:00weekly0.6https://www.medthority.com/news/2020/08/fda-approves-winlevi-to-treat-acne.--cassiopea-spa2024-11-08T11:38:38+00:00weekly0.6https://www.medthority.com/news/2020/08/new-england-journal-of-medicine-publishes-phase-1ii-data-for-retevmo-in-advanced-ret-driven-lung-and-thyroid-cancers.--eli-lilly2024-10-24T11:18:24+00:00weekly0.6https://www.medthority.com/news/2020/09/sanofi-and-gsk-initiate-phase-1ii-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/09/new-analysis-of-covid-19-studies-shows-mortality-benefit-of-inexpensive-steroids/2021-12-20T17:31:28+00:00weekly0.6https://www.medthority.com/news/2020/09/amylyx-pharmaceuticals-announces-new-england-journal-of-medicine-publication-of-pivotal-amx-0035-data-demonstrating-statistically-significant-benefit-in-people-with-als/2024-11-12T09:41:37+00:00weekly0.6https://www.medthority.com/news/2020/09/akebia-therapeutics-announces-top-line-results-from-its-pro2tect-global-phase-iii-program-of-vadadustat-for-treatment-of-anemia-due-to-chronic-kidney-disease-in-adult-patients-not-on-dialysis/2024-10-24T09:34:44+00:00weekly0.6https://www.medthority.com/news/2020/09/bavencio-from-merck-kgaa-and-pfizer-is-available-under-the-early-access-to-medicines-scheme-eams-as-first-line-maintenance-treatment-for-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma/2024-11-12T10:20:18+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-additional-doses-of-trulicity-for-the-treatment-of-type-2-diabetes.--eli-lilly2026-02-02T16:51:45+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approval-of-gavreto-to-treat-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-as-detected-by-an-fda-approved-test.--blueprint-medicines--genentechroche2021-12-20T17:32:21+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-accepts-for-review-nda-forpralsetinib--to-treat-patients-with-advanced-or-metastatic-ret-mutant-medullary-thyroid-cancer-mtc-and-ret-fusion-positive-thyroid-cancer.--blueprint-medicines--genentechroche2024-10-24T11:21:11+00:00weekly0.6https://www.medthority.com/news/2020/09/emas-safety-committee-prac-recommended-revocation-of-the-marketing-authorisations-of-5-mg-ulipristal-acetate-to-treat-symptoms-of-uterine-fibroids.--abbvie--gedeon-richter2024-11-12T11:44:53+00:00weekly0.6https://www.medthority.com/news/2020/09/supplemental-bla-filed-with-fda-for-yescarta-in-relapsed-or-refractory-indolent-non-hodgkin-lymphoma.--kite-pharmagilead-sciences2024-11-12T13:47:05+00:00weekly0.6https://www.medthority.com/news/2020/09/acasti-pharma-reports-topline-results-from-phase-iii-trilogy-2-study-of-capre-in-patients-with-severe-hypertriglyceridemia/2024-10-24T09:04:31+00:00weekly0.6https://www.medthority.com/news/2020/09/fasenra-success-in-phase-iii-ostro--trial-for-treatment-of-nasal-polyps.-astrazeneca2024-10-24T11:20:38+00:00weekly0.6https://www.medthority.com/news/2020/09/janssen-biotech-files-sbla-at-fda-for-darzalex-faspro--to-treat-light-chain-al-amyloidosis/2024-11-12T10:19:38+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-trelegy-ellipta-to-treat-asthma.-gsk2024-11-12T10:19:51+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-sakurastar-and-sakurasky-trials-of-enspryng-shows-efficacy-in-neuromyelitis-optica-spectrum-disorder.--genentechroche-2024-10-24T11:19:12+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-study-study-3-of-fintepla-meets-primary-objective-in-dravet-syndrome.--zogenix-2024-10-24T11:19:00+00:00weekly0.6https://www.medthority.com/news/2020/09/new-data-reinforce-ocrevus-as-a-highly-effective-treatment-for-people-with-multiple-sclerosis.--genentechroche2021-12-20T17:33:04+00:00weekly0.6https://www.medthority.com/news/2020/09/reyvow-showed-significant-therapeutic-gains-of-17-21-for-pain-freedom-at-2-hours-and-met-all-18-gated-endpoints.-eli-lilly2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/09/novartis-presents-data-at-actrims-ectrims-for-kesimpta-in-newly-diagnosed-treatment-naive-adults-with-relapsing-multiple-sclerosis/2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/09/neurocrine-biosciences-presents-new-data-analyses-demonstrating-efficacy-of-once-daily-ongentys--in-patients-with-parkinsons-disease-at-the-mds-virtual-congress-2020/2024-11-12T10:19:12+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iiib-exchange-and-expand-trials-show-mayzent-as-safe-in-multiple-sclerosis.--novartis2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-fap-310-trial-of-cpp-1xsul-in-familial-adenomatous-polyposis-published-in-nejm.--cancer-prevention-pharma2024-11-12T13:22:35+00:00weekly0.6https://www.medthority.com/news/2020/09/nih-activ-initiative-launches-adaptive-clinical-trials-of-blood-clotting-treatments-for-covid-19.--bms--pfizer2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/09/covid-19-vaccine-azd-1222-clinical-trials-resumed-in-the-uk.--astrazeneca2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/09/study-402-positive-results--evaluating-lumateperone-as-adjunctive-therapy-to-lithium-or-valproate-in-the-treatment-of-major-depressive-episodes-associated-with-bipolar-i-or-bipolar-ii-disorder.-intra-cellular-therapies2024-11-12T10:19:23+00:00weekly0.6https://www.medthority.com/news/2020/09/positive-results-from-pedfic-1-trial-of-odevixibat-to-treat-progressive-familial-intrahepatic-cholestasis.--albireo-pharma-inc2024-11-12T12:09:49+00:00weekly0.6https://www.medthority.com/news/2020/09/negative-results-from-phase-iii-resolve-1-study-of-lenabasum-in-patients-with-diffuse-cutaneous-systemic-sclerosis-.--corbus-pharmaceutical-holdings-inc2024-11-12T12:14:50+00:00weekly0.6https://www.medthority.com/news/2020/09/satsuma-pharmaceuticals-announces-topline-results-from-emerge-phase-iii-trial-of-sts-101--nasal-powder-for-the-acute-treatment-of-migraine/2021-12-20T17:30:13+00:00weekly0.6https://www.medthority.com/news/2020/09/novartis-reports-positive-topline-results-from-the-first-phase-iii-trial-of-beovu-versus-aflibercept-in-patients-with-diabetic-macular-edema-dme/2024-11-12T09:13:49+00:00weekly0.6https://www.medthority.com/news/2020/09/orexo-commences-patent-infringement-litigation-against-sun-pharmaceutical/2021-12-20T17:29:47+00:00weekly0.6https://www.medthority.com/news/2020/09/recovery-in-hospitalized-patients-with-covid-19-in-niaid-sponsored-actt-2-trial-of-baricitinib-plus-remdesivir/2021-12-20T17:29:52+00:00weekly0.6https://www.medthority.com/news/2020/09/alexion-and-caelum-biosciences-announce-start-of-phase-iii-studies-of-cael-101-in-al-amyloidosis/2024-10-24T11:20:49+00:00weekly0.6https://www.medthority.com/news/2020/09/complete-response-letter-for-terlipressin-to-treat-hepatorenal-syndrome-type-1.--mallinckrodt2024-10-24T11:21:00+00:00weekly0.6https://www.medthority.com/news/2020/09/seattle-genetics-and-merck-inc.-announce-two-strategic-oncology-collaborations-affecting-ladiratuzumab-vedotin-and-tucatinib2021-12-20T17:29:52+00:00weekly0.6https://www.medthority.com/news/2020/09/gemini-phase-iii-trial-of-axs-05-shows-improved-outcomes-in-depression.--axsome-therapeutics2024-11-12T14:09:13+00:00weekly0.6https://www.medthority.com/news/2020/09/vertex-pharmaceuticals-applies-at-ema-for-expanded-indication-of-kaftrio-to-treat-cystic-fibrosis-in-patients-ages-12-years-and-older.-2024-11-12T12:16:53+00:00weekly0.6https://www.medthority.com/news/2020/09/myovant-sciences-presents-additional-data-on-bone-mineral-density-in-women-with-uterine-fibroidsfrom-phase-iii-liberty-program-of-relugolix-combination-therapy.-2024-11-12T12:17:03+00:00weekly0.6https://www.medthority.com/news/2020/09/gilead-sciences-acquires-immunomedics-and-with-it-trodelvya-treatment-for--triple-negative-breast-cancer/2021-09-24T07:12:37+00:00weekly0.6https://www.medthority.com/news/2020/09/study-of-ajovy-in-migraine-published-in-neurology-journal.--teva-pharma2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2020/09/eu-submission-complete-for-opdivo--yervoy-application-to-treat-untreated-unresectable-malignant-pleural-mesothelioma.---bms2024-11-12T12:16:35+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-expands-approval-of-cintec-plus-cytology-test-in-hpv-positive-patients.--roche2021-12-20T17:30:36+00:00weekly0.6https://www.medthority.com/news/2020/09/novartis-tafinlar--mekinist-demonstrates-long-term-relapse-free-survival-benefit-for-high-risk-stage-iii-melanoma-patients-in-study-published-in-nejm.--novartis2024-11-08T09:23:59+00:00weekly0.6https://www.medthority.com/news/2020/09/mirror-open-label-trial-data-published-in-journal-of-rheumatology-shows-79-percent-of--gout-patients-achieved-a-complete-response-using-krystexxa-with-methotrexate.--horizon-therapeutics2024-11-08T09:24:18+00:00weekly0.6https://www.medthority.com/news/2020/09/health-canada-approves-tremfya-to-treat-psoriatic-arthritis.--janssen-pharma2024-10-24T11:21:23+00:00weekly0.6https://www.medthority.com/news/2020/09/chemocentryx-announces-fda-acceptance-of-the-avacopan-nda-for-the-treatment-of-anca-associated-vasculitis/2021-12-20T17:30:53+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-checkmate--214-trial-of-yervoy--opdivo-shows-sustained-benefits-and-four-year-survival-rate-in-advanced-renal-cell-carcinoma.--bms2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/09/real-world-study-of-nerivio-migra-in-migraine-published-in-pain-medicine.--theranica-2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/09/genentechs-phase-iii-empacta-study-showed-actemra-reduced-the-likelihood-of-needing-mechanical-ventilation-in-hospitalized-patients-with-covid-19-associated-pneumonia.--genentechroche2021-12-20T17:33:17+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-ibii-trial-of-pcm-075-shows-efficacy-in-metastatic-kras-colorectal-cancer.--cardiff-oncology2024-11-12T12:18:31+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-positive-for-olumiant-to-treat-atopic-dermatitis.-eli-lilly2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2020/09/pacific-phase-iii-trial-data-at-esmo--showed-an-estimated-35-of-non-smallcell-lung-cancer-patients-treated-with-imfinzi-had-not-progressed-after-four-years.--astrazeneca2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/09/five-year-data-from-the-solo-1-phase-iii-trial-is-the-longest-follow-upanalysis-for-any-parp-inhibitor-in-the-1st-line-maintenance-setting-to-treat-advanced-brca-mutated--ovarian-cancer.-astrazeneca--merck-inc2021-12-20T17:30:53+00:00weekly0.6https://www.medthority.com/news/2020/09/orfadin-receives-positive-opinion-from-chmp-for-treatment-of-alkaptonuria.--swedish-orphan-biovitrum2024-10-24T14:18:03+00:00weekly0.6https://www.medthority.com/news/2020/09/beigene-presents-data-at-esmo-virtual-congress-2020-on-phase-iii-trial-of-tislelizumab-in-first-line-non-squamous-non-small-cell-lung-cancer.-2021-12-20T17:33:16+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-approval-of-exparel-in-post-surgical-pain.--pacira-biosciences2024-10-24T09:43:41+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-trial-of-padcev-meets-primary-endpoint-in-urothelial-cancer.--astellas-pharma-and-seattle-genetics2024-11-12T12:17:28+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-approval-of-zejula-for-ovarian-cancer.--glaxosmithkline2021-12-20T17:33:16+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-approval-of--tecentriq-plus-avastin-for-unresectable-hepatocellular-carcinoma.--roche2024-11-12T12:17:52+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-javelin-bladder-100-study-of-bavencio-in-urothelial-carcinoma-published-in-nejm.--emd-serono--pfizer2024-11-08T09:22:00+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-menquadfi-for-prophylaxis-against-invasive-meningococcal-disease-.--sanofi-pasteur2024-11-08T09:22:13+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-obiltoxaximab-sfl-to-treat-anthrax.--sfl-pharmaceuticals-deutschland-gmbh2024-11-12T12:18:11+00:00weekly0.6https://www.medthority.com/news/2020/09/lilly-announces-proof-of-concept-data-for-neutralizing-antibody-ly-cov555-in-the-covid-19-outpatient-setting/2021-12-20T17:30:53+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-eortc1325keynote-054-trial-of-keytruda-meets-secondary-endpoint-in-melanoma.--merck-inc2024-10-24T14:19:14+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-solar-1-trial-of-piqray-shows-efficacy-in-advanced-pik3ca-breast-cancer.--novartis2021-12-20T17:32:11+00:00weekly0.6https://www.medthority.com/news/2020/09/deciphera-presents-data-from-qinlock--program-in-patients-with-gastrointestinal-stromal-tumor-at-the-esmo-virtual-congress-2020/2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-ascent-study-of-trodelvy-shows-improved-survival-in-triple-negative-breast-cancer.--immunomedics2021-12-20T17:33:17+00:00weekly0.6https://www.medthority.com/news/2020/09/genentech-presents-new-data-from-multiple-phase-iii-studies-of-tecentriq-in-triple-negative-breast-cancer-at-esmo-virtual-congress-2020.--genentechroche2021-12-20T17:30:53+00:00weekly0.6https://www.medthority.com/news/2020/09/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-of-spartalizumab-pdr-001-with-tafinlar-and-mekinist-in-advanced-melanoma/2024-10-24T14:19:26+00:00weekly0.6https://www.medthority.com/news/2020/09/tagrisso-reduced-the-risk-of-disease-recurrence-in-the-brain-by-82-in-the-adjuvant-treatment-of-early-stage-egfr-mutated-lung-cancer.--astrazeneca2024-11-08T09:22:28+00:00weekly0.6https://www.medthority.com/news/2020/09/nice-rejects-spravato-a-second-time-as-an-adjunctive-treatment-for-depression.--janssen2024-11-12T12:15:01+00:00weekly0.6https://www.medthority.com/news/2020/09/post-hoc-analysis-of-enerzair-breezhaler-shows-reduction-in-exacerbation-rates-of-asthma.--novartis2024-10-24T09:34:32+00:00weekly0.6https://www.medthority.com/news/2020/09/eu-approves-variation-to-maa-for-imbruvica-plus-rituxan-in-chronic-lymphocytic-leukaemia.--janssen2024-11-12T10:20:04+00:00weekly0.6https://www.medthority.com/news/2020/09/scottish-medicines-consortium-smc--accepts-iluvien-intravitreal-implant--for-prevention-of-relapse-in-recurrent-non-infectious-uveitis.--alimera-sciences2024-11-12T12:15:17+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-liberty-asthma-quest-study--of-dupilumab-shows-a-reduction-in-severe-asthma-attacks.--sanofi--regeneron2024-10-24T11:19:38+00:00weekly0.6https://www.medthority.com/news/2020/09/biotroniks-passeo-35-xeo-pta-balloon-catheter-is-now-available-in-europe/2024-10-24T09:04:45+00:00weekly0.6https://www.medthority.com/news/2020/09/-biogen-data-presented-at-ms-virtual-2020-actrimsectrims-meeting-advances--understanding-of-clinical-and-health-disparities-in-multiple-sclerosis-/2021-12-20T17:32:58+00:00weekly0.6https://www.medthority.com/news/2020/09/redhill-biopharmas-opaganib-demonstrates-completeinhibition-of-sars-cov-2/2021-12-20T17:33:15+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-cough-1-and-cough-2-trials-of-mk-7264-shows-mixed-results-in-chronic-cough.--merck-inc2024-11-12T12:16:13+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-adapt-po-trial-of-spr-994-shows-efficacy-in-complicated-urinary-tract-infection.--spero-therapeutics2024-10-24T11:19:26+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-pedfic-1-trial-of-a-4250-meets-primary-endpoints-in-progressive-familial-intrahepatic-cholestasis.--albireo2024-11-12T10:18:50+00:00weekly0.6https://www.medthority.com/news/2020/09/liminal-biosciences-announces-resubmission-of-bla-to-fda-for-ryplazim-to-treat-congenital-plasminogen-deficiency/2024-11-12T10:47:55+00:00weekly0.6https://www.medthority.com/news/2020/09/the-lancet-publishes-detailed-vosoritide-phase-iii-data-demonstrating-statistically-significant-increase-in-annualized-growth-velocity-agv-over-52-weeks-in-children-with-achondroplasia.--biomarin2024-10-24T11:19:51+00:00weekly0.6https://www.medthority.com/news/2020/09/successful-phase-iii--trial-of-filsuvez-to-treat-epidermolysis-bullosa.--amryt2021-12-20T17:33:15+00:00weekly0.6https://www.medthority.com/news/2020/09/genentechroche-initiates-phase-iii-trial-programme-for-fenebrutinib-in-multiple-sclerosis/2021-12-20T17:30:35+00:00weekly0.6https://www.medthority.com/news/2020/09/brukinsa-filed-with-health-canada-to-treat-waldenstroms-macroglobulinemia.-beigene-ltd2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/09/transcon-hgh-filed-with-ema-for-pediatric-growth-hormone-deficiency.--ascendis-pharma-2024-10-24T09:34:19+00:00weekly0.6https://www.medthority.com/news/2020/09/merck-inc.-announces-positive-topline-results-from-two-phase-iii-adult-studies-evaluating-v114-an-investigational-15-valent-pneumococcal-conjugate-vaccine-including-pivotal-trial2021-12-20T17:33:15+00:00weekly0.6https://www.medthority.com/news/2020/09/genentechroche-announced--a-higher-dose-phase-iii-clinical-trial-program-for-ocrevus-and-a-distinct-ocrevus-trial-specifically-to-support-african-american-and-hispanic--and-latin-american-patients-with-multiple-sclerosis/2021-12-20T17:33:15+00:00weekly0.6https://www.medthority.com/news/2020/09/azd-1222-vaccine--phase-iii-trial-for-coronavirus-19-is-paused.-astrazeneca2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/09/new-england-journal-of-medicine-publishes-positive-final-results-from-phase-1iia-study-of-bivv001-in-people-with-severe-haemophilia-a.sanofi--sobi2021-12-20T17:32:59+00:00weekly0.6https://www.medthority.com/news/2020/09/grifols-acquires-alkahest-inc/2021-09-24T07:12:40+00:00weekly0.6https://www.medthority.com/news/2020/09/lynparza-reduced-the-risk-of-death-by-31-in-brca12-or-atm-mutated-metastatic-castration-resistant-prostate-cancer-in-phase-iii-profound-trial.-astrazeneca--merck-inc2024-11-15T11:03:41+00:00weekly0.6https://www.medthority.com/news/2020/09/verzenio-significantly-reduced-the-risk-of-cancer-recurrence-by-25-for-people-with-hr-her2--high-risk-early-breast-cancer.--eli-lilly2021-12-20T17:29:53+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-a-new-100-mgml-intravenous-iv-advanced-formulation-of-ultomiris.--alexion-pharma2024-11-12T12:17:16+00:00weekly0.6https://www.medthority.com/news/2020/09/late-breaking-esmo-presentation-shows-libtayo-monotherapy-increases-overall-survival-in-first-line-advanced-non-small-cell-lung-cancer-with-pd-l1-expression-of-greater-than-50.--regeneron--sanofi2021-12-20T17:29:52+00:00weekly0.6https://www.medthority.com/news/2020/09/abbott-receives-ce-mark-for-next-generation-mitraclip-heart-valve-repair-device-to-treat-mitral-regurgitation/2024-11-08T09:24:37+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-nyvepria--pegfilgrastim-biosimilar.--pfizer2024-10-24T14:10:21+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-lynparza-to-treat-metastatic-castration-resistant-prostate-cancer-with-breast-cancer-susceptibility-gene-12-brca12-mutations.--astrazeneca--merck-inc2024-11-15T11:15:10+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-lynparza-for-the-1st-line-maintenance-treatment-with-bevacizumab-of-patients-with-homologous-recombination-deficient--positive-advanced-ovarian-cancer.-astrazeneca--merck-inc2026-02-02T15:39:24+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-new-formulations-of-clinimix-and-clinimix-e-to-support-parenteral-nutrition--baxter/2026-01-29T11:00:08+00:00weekly0.6https://www.medthority.com/news/2020/09/johnson--johnson-initiates-pivotal-global-phase-iii-clinical-trial-of--jnj-78436735-janssens-covid-19-vaccine-candidate/2021-12-20T17:32:42+00:00weekly0.6https://www.medthority.com/news/2020/09/first-patient-randomised-in-the-phase-iii-dissolve-clinical-programme-of-se-l212-for-chronic-refractory-gout.--sobi--selecta-biosciences2024-10-24T09:05:00+00:00weekly0.6https://www.medthority.com/news/2020/09/semorinemabanti-tau-antibody-in-early-alzheimers-disease-fails-in-phase-ii-trial.--ac-immune--genentech-roche2024-10-24T09:06:04+00:00weekly0.6https://www.medthority.com/news/2020/09/worlds-largest-study-of-cardiovascular-disease-in-type-2-diabetes-shows-need-for-improved-knowledge/2024-11-12T13:22:36+00:00weekly0.6https://www.medthority.com/news/2020/09/-keytruda--plus-chemotherapy-reduced-risk-of-death-by-27-versus-chemotherapy-as-first-line-treatment-for-locally-advanced-or-metastatic-esophageal-cancer.--merck-inc2026-01-29T10:58:40+00:00weekly0.6https://www.medthority.com/news/2020/09/in-an-interim-analysis-opdivo-in-checkmate--274-met-primary-endpoints-of-disease-free-survival-in-both-all-randomized-patients-and-in-patients-whose-tumors-express-pd-l1-in-at-least-1-of-cells.--bms2024-10-24T14:19:37+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-times-2-and-3-trials-of-imeglimin-meet-primary-endpoints-in-type-2-diabetes.--poxel2024-10-24T09:06:16+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-alaway-to-treat-ocular-itching.-bausch--lomb-2022-01-10T09:59:14+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-kalydeco-as-first-and-only-cftr-modulator-to-treat-eligible-infants-with-cf-as-early-as-four-months-of-age.--vertex2024-11-12T12:19:14+00:00weekly0.6https://www.medthority.com/news/2020/09/european-commission-approves-jyseleca--to-treat-adults-with-moderate-to-severe-rheumatoid-arthritis.--gilead-sciences--galapagos-nv2024-11-12T12:20:49+00:00weekly0.6https://www.medthority.com/news/2020/09/novavax-initiates-phase-iii-efficacy-trial-of-covid-19-vaccine-nvx-cov2373-in-the-united-kingdom/2021-12-20T17:33:17+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-issues-complete-response-letter-for-libervant-to-treat-seizure-clusters.--aquestive-therapeutics2021-12-20T17:29:53+00:00weekly0.6https://www.medthority.com/news/2020/09/eu-approves-ayvakyt-for-metastatic-gastrointestinal-stromal-tumors.--blueprint-medicines-corp2021-12-20T17:29:53+00:00weekly0.6https://www.medthority.com/news/2020/09/johnson--johnson-posts-interim-results-from-phase-1iia-clinical-trial-of-jnj-78436735-to-treat-covid-19/2021-12-20T17:33:17+00:00weekly0.6https://www.medthority.com/news/2020/09/inovio-reports-fda-partial-clinical-hold-for-planned-phase-ii-iii-trial-of-covid-19-vaccine-candidate-ino-4800/2021-12-20T17:32:12+00:00weekly0.6https://www.medthority.com/news/2020/09/ce-mark-for-freestyle-3--system-of-glucose-monitoring-and-control.--abbott2024-11-08T09:24:53+00:00weekly0.6https://www.medthority.com/news/2020/09/boston-scientific-launches-acurate-neo2-aortic-valve-system-in-europe/2024-11-12T09:42:55+00:00weekly0.6https://www.medthority.com/news/2020/09/the-addition-of-ipatasertib-to-paclitaxel-in-patients-with-pik3caakt1pten-altered-hormone-receptorpositive-her2-negative-advanced-breast-cancer-did-not-improve-survival.--genentechroche2021-12-20T17:33:16+00:00weekly0.6https://www.medthority.com/news/2020/09/phase-iii-checkmate-577-trial-of-opdivo-shows-benefits-in-oesophageal-cancer.--bms2021-12-20T17:32:12+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-gives-priority-review-for-bb-2121-for-multiple-myeloma.--bms2021-12-20T17:29:52+00:00weekly0.6https://www.medthority.com/news/2020/09/chmp-recommends-extension-of-fycompaindication--to-children-with-partial-onset-seizures.--eisai2021-12-20T17:32:12+00:00weekly0.6https://www.medthority.com/news/2020/09/novartis-provides-update-on-avxs-101-intrathecal-clinical-development-program-for-spinal-muscular-atrophy/2024-10-24T11:20:26+00:00weekly0.6https://www.medthority.com/news/2020/09/illumina-acquires-grail-and-with-it-galleri--a-cancer-screening-test/2021-09-24T07:12:34+00:00weekly0.6https://www.medthority.com/news/2020/09/roche-acquires-inflazome-and-its-early-stage-nlrp3-inhibitors/2021-09-24T07:12:33+00:00weekly0.6https://www.medthority.com/news/2020/09/ironwood-to-discontinue-iw-3718-development-program-of-iw-3718-in-refractory-gastroesophageal-reflux-disease-following-results-from-planned-efficacy-assessment/2024-11-12T09:42:35+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-alkindi-sprinkle-oral-granules-as-replacement-therapy-for-adrenocortical-insufficiency.--eton-pharma2024-10-24T09:06:36+00:00weekly0.6https://www.medthority.com/news/2020/09/fda-approves-nucala-to-treat-hypereosinophilic-syndrome.---gsk2024-11-08T09:25:07+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-trial-of-azd-1222--vaccine-to-treat-covid-19-is-to-resume.-astrazeneca2021-12-20T17:32:12+00:00weekly0.6https://www.medthority.com/news/2020/10/ema-accepts-maa-for-elivaldogene-autotemcel-eli-cel-lenti-d-gene-therapy-for-cerebral-adrenoleukodystrophy-.-bluebird-bio-inc2024-10-22T09:19:15+00:00weekly0.6https://www.medthority.com/news/2020/10/cytokinetics-announces-publication--of-omecamtiv-mecarbil-in-the-galactic-hf-trial-in-european-journal-of-heart-failure/2024-10-22T09:19:31+00:00weekly0.6https://www.medthority.com/news/2020/10/bms-announces-update-on-checkmate--915-evaluating-opdivo--yervoy-versus-opdivo-in-resected-high-risk-melanoma-patients/2024-11-08T09:25:32+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-opdivo--yervoy--as-the-first-and-only-immunotherapy-treatment-for-previously-untreated-unresectable-malignant-pleural-mesothelioma.--bms2026-01-29T10:43:34+00:00weekly0.6https://www.medthority.com/news/2020/10/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and-improved-symptoms-in-non-hospitalised-covid-19-patients/2021-12-20T17:32:42+00:00weekly0.6https://www.medthority.com/news/2020/10/amgen-announces-five-year-data-that-reinforce-the-safety-and-efficacy--of-aimovig-in-adult-patients-with-episodic-migraine/2021-12-20T17:32:42+00:00weekly0.6https://www.medthority.com/news/2020/10/gilead-sciences-update-on-supply-and-distribution-of-veklury-in-the-united-states/2021-12-20T17:29:53+00:00weekly0.6https://www.medthority.com/news/2020/10/mesoblast-receives-a-complete-response-letter-from-the-fda--for-its-bla-for-treatment-of-steroid-refractory-acute-graft-versus-host-disease-in-children/2021-12-20T17:32:12+00:00weekly0.6https://www.medthority.com/news/2020/10/iterum-therapeutics-announces-positive-pre-nda-meeting-with-fda-for-sulopenem-for-treatment-of-uncomplicated-urinary-tract-infections/2024-10-22T09:19:55+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-xeljanz-to-treat-polyarticular-course-juvenile-idiopathic-arthritis-.--pfizer2024-11-12T09:43:30+00:00weekly0.6https://www.medthority.com/news/2020/10/alnylam-reports-positive-topline-results-from-illuminate-b-phase-iii-study-of-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-in-children-under-the-age-of-six/2024-10-24T09:07:35+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-accepts-snda-for-xalkori-for-the-treatment-of-pediatric-patients-with-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma.---pfizer2024-10-24T09:07:53+00:00weekly0.6https://www.medthority.com/news/2020/10/zolgensma-data-including-patients-with-more-severe-spinal-muscular-atrophy-at-baseline-further-demonstrate-therapeutic-benefits.--novartis2024-10-22T09:20:11+00:00weekly0.6https://www.medthority.com/news/2020/10/sobi-and-selecta-biosciences-announce-topline-data-of-sel-212-from-the-phase-ii-compare-study-supporting-the-potential-for-important-clinical-improvement-in-patients-with-chronic-refractory-gout/2024-10-24T09:06:54+00:00weekly0.6https://www.medthority.com/news/2020/10/ema-accepts-regulatory-submission-for-avalglucosidase-alfa-an-enzyme-replacement-therapy-for-pompe-disease.--genzymesanofi2021-12-20T17:29:53+00:00weekly0.6https://www.medthority.com/news/2020/10/santhera-to-discontinue-phase-iii-sideros-study-and-development-of-puldysa-in-duchenne-muscular-dystrophy-dmd-and-focus-on-vamorolone/2024-11-12T09:43:20+00:00weekly0.6https://www.medthority.com/news/2020/10/bms-to-acquire-myokardia-and-with-it-mavacamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy/2021-09-24T07:11:05+00:00weekly0.6https://www.medthority.com/news/2020/10/cytokinetics-announces-data-from-two-presentations-of-omecamtiv-mecarbil-at-heart-failure-society-of-america-virtual-meeting.-2021-12-20T17:30:54+00:00weekly0.6https://www.medthority.com/news/2020/10/sb-11-filed-with-ema-for-retinal-vascular-disorders.--samsung-bioepis--biogen2024-11-08T09:25:45+00:00weekly0.6https://www.medthority.com/news/2020/10/gilead-presents-biktarvy-findings-from-switch-studies--analysis-of-real-world-bicstar-study-at-hiv-glasgow-2020/2021-12-20T17:32:13+00:00weekly0.6https://www.medthority.com/news/2020/10/reyvow-c-v-demonstrated-superior-pain-freedom-at-2-hours-in-at-least-2-of-3-migraine-attacks-in-new-phase-iii-centurion-consistency-of-effect-study.--eli-lilly2021-12-20T17:30:54+00:00weekly0.6https://www.medthority.com/news/2020/10/vir-biotechnology--gsk-announce-global-expansion-to-phase-iii-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/2021-12-20T17:30:54+00:00weekly0.6https://www.medthority.com/news/2020/10/madrigal-pharmaceuticals-announces-three-abstracts-to-be-presented-at-the-liver-meeting-digital-experience-in-november-2020-including-phase-iii-maestro-nafld-1-trial/2024-11-12T10:12:25+00:00weekly0.6https://www.medthority.com/news/2020/10/lilly-provides-comprehensive-update-on-progress-of-sars-cov-2-neutralizing-antibody-programs-including-interim-data-on-combination-therapy/2021-12-20T17:30:54+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-label-expansion-to-allow-maximum-dose-of-60-mg-for-palynziq-injection-for-treatment-of-adults-with-pku.--biomarin2024-11-12T09:43:08+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-checkmate--816-trial-of-opdivo-meets-primary-endpoint-in-nsclc.--bms2021-12-20T17:32:42+00:00weekly0.6https://www.medthority.com/news/2020/10/post-authorisation-study-of-id-now-covid-19-eua-test-confirms-results-submitted-to-fda.--abbott2021-12-20T17:32:56+00:00weekly0.6https://www.medthority.com/news/2020/10/pfizer-and-sangamo-dose-first-participant-in-phase-iii-study-of-giroctocogene-fitelparvovec-for-hemophilia-a-gene-therapy-treatment/2021-12-20T17:32:56+00:00weekly0.6https://www.medthority.com/news/2020/10/seattle-genetics-changes-its-name-to-seagen-inc/2021-09-24T07:11:03+00:00weekly0.6https://www.medthority.com/news/2020/10/baricitinib-has-significant-effect-on-recovery-time-and-is-most-impactful-in-covid-19-patients-requiring-oxygen.--eli-lilly2021-12-20T17:30:26+00:00weekly0.6https://www.medthority.com/news/2020/10/first-patient-enrolled-in-nih-phase-iii-trial-to-evaluate-potential-covid-19-hyperimmune-medicine.-takeda--csl-behring2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/10/final-results-of-niaids-actt-1-trial-published-in-nejm-expands-clinical-benefits-of-veklury-for-the-treatment-of-covid-19.--gilead-sciences2021-12-20T17:30:53+00:00weekly0.6https://www.medthority.com/news/2020/10/sobi-announces-topline-phase-iii-data-of-avatrombopag-for-the-treatment-of-chemotherapy-induced-thrombocytopenia/2024-10-24T10:40:14+00:00weekly0.6https://www.medthority.com/news/2020/10/lillys-overcome-study-reveals-nearly-80-of-people-reported-improvement-in-their-migraine-since-starting-a-cgrp-monoclonal-antibody-for-preventive-treatment/2021-12-20T17:30:27+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-c0311002-study-of-somatrogon-shows-efficacy-in-growth-hormone-deficiency.--pfizer--opko-health2024-11-12T09:23:33+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-stop-301-study-of-inp-104-shows-benefit-in-migraine.--impel-neuropharma2021-12-20T17:31:03+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-advisory-committee-votes-in-support-of-alks-3831-for-the-treatment-of-schizophrenia-and-bipolar-i-disorder.--alkermes2024-11-12T10:12:12+00:00weekly0.6https://www.medthority.com/news/2020/10/two-trials-of-azd-7442-combination-will-enrol-over-6000-adults-for-the-prevention-of-covid-19-with-additional-trials-enrolling--approximately-4000-adults-for-the-treatment-of-sars-cov-2-infections.--astrazeneca2021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2020/10/penelope-b-trial-of-ibrance--in-early-breast-cancer-did-not-meet-primary-endpoint--pfizer/2021-12-20T17:32:31+00:00weekly0.6https://www.medthority.com/news/2020/10/bnt-162b2-vaccine-begins-rolling-submission-with-health-canada-for-covid-19.--pfizer-canada-and-biontech-se2021-12-20T17:31:03+00:00weekly0.6https://www.medthority.com/news/2020/10/bridgebio-acquires--the-shares-of-eidos-therapeutics/2021-09-24T07:11:02+00:00weekly0.6https://www.medthority.com/news/2020/10/eton-pharmaceuticals-submits-nda-to-the-fda-for-orphan-drug-dehydrated-alcohol-injection-ds-100/2024-11-12T11:28:09+00:00weekly0.6https://www.medthority.com/news/2020/10/bms-presents-at-ueg-week-positive-late-breaking-data-from-phase-iii-true-north-trial-evaluating-zeposia-in-adult-patients-with-moderate-to-severe-ulcerative-colitis/2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/10/xenon-pharmaceuticals-receives-fda-feedback-and-plans--to-initiate-xen-496-phase-iii-clinical-trial-for-the-treatment-of-kcnq2-dee-before-year-end/2024-11-08T11:39:38+00:00weekly0.6https://www.medthority.com/news/2020/10/cti-biopharma-initiates-rolling-submission-of-nda-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia/2024-10-22T10:06:16+00:00weekly0.6https://www.medthority.com/news/2020/10/johnson--johnson-temporarily-pauses-all-dosing-in-janssen-covid-19-vaccine-candidate-clinical-trials/2024-10-22T10:06:28+00:00weekly0.6https://www.medthority.com/news/2020/10/rolling-submission-of-mrna-1273-initiated-for-covid-19-with-health-canada.--moderna2024-10-22T10:06:41+00:00weekly0.6https://www.medthority.com/news/2020/10/eli-lilly-statement-on-the-niaid-decision-to-pause-enrollment-in-activ-3-clinical-trial-of-bamlanivimab-as-a-treatment-for-covid-19-in-hospitalized-patients/2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/10/real-world-study-of-gilotrif-shows-second-line-treatment-efficacy-in-squamous-cell-carcinoma-of-the-lung.--boehringer2024-10-24T08:42:18+00:00weekly0.6https://www.medthority.com/news/2020/10/real-world-analysis-of-provenge-in-prostate-cancer-shows-reduction-in-risk-of-death-and-prolonged-os.--dendreon-pharmaceuticals2024-11-15T11:14:31+00:00weekly0.6https://www.medthority.com/news/2020/10/tepezza--data-from-the-phase-ii-clinical-trial-evaluates--longer-term-responses-in-people-living-with-thyroid-eye-disease-ted.--horizon-therapeutics2024-11-07T15:55:45+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-expanded-use-of-wakix-for-cataplexy-in-patients-with-narcolepsy.---harmony-biosciences2024-11-12T11:30:23+00:00weekly0.6https://www.medthority.com/news/2020/10/safety-and-efficacy-of-subcutaneous-entyvio-sustained-during-long-term-maintenance-therapy-in-adults-with-moderately-to-severely-active-ulcerative-colitis.--takeda2021-12-20T17:29:23+00:00weekly0.6https://www.medthority.com/news/2020/10/complete-response-letter-for--tramadol-i.v.-for-the-management-of-moderate-to-moderately-severe-pain.--avenue-therapeutics2024-10-22T10:07:02+00:00weekly0.6https://www.medthority.com/news/2020/10/bavencio--axitinib-combination-accepted-for-use-within-nhs-scotland-for-the-first-line-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma.-merck-kgaa--pfizer2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iibiii-selection-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis.--galapagos-nv--gilead-sciences2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2020/10/dupixent-significantly-reduced-severe-asthma-attacks-in-children/2024-11-12T14:09:25+00:00weekly0.6https://www.medthority.com/news/2020/10/mallinckrodt-secures-broad-consensus-with-key-stakeholders-on-comprehensive-chapter-11-restructuring/2021-09-24T07:11:01+00:00weekly0.6https://www.medthority.com/news/2020/10/-fda-510k-clearance-on-the-smart-correction-external-fixation-system-for-use-in-pediatric-orthopaedic-surgery.-wishbone-medical-inc2024-10-24T11:18:12+00:00weekly0.6https://www.medthority.com/news/2020/10/revance-reports-positive-results-from-aspen-1-phase-iii-trial-of-daxibotulinumtoxina-for-injection-in-cervical-dystonia/2024-11-12T11:30:06+00:00weekly0.6https://www.medthority.com/news/2020/10/ce-mark-for-precisionone--a-device-that-provides-automated-glucose-control-and-real-time-blood-chemistry-analyses-for-critical-care-patients.-admetsys2024-11-07T15:55:33+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-accepts-nda-for-zonisamide-oral-suspension-to-treat-partial-seizures.--eton-pharma-2024-10-24T08:22:54+00:00weekly0.6https://www.medthority.com/news/2020/10/eli-lilly-acquires-disarm-therapeutics-and-gains-access-to-sarmi-inhibitors-to-treat-axonal-degeneration/2021-09-24T07:11:00+00:00weekly0.6https://www.medthority.com/news/2020/10/astellas-acquires-iota--biosciences-and-access-to-neural-dust/2021-09-24T07:11:00+00:00weekly0.6https://www.medthority.com/news/2020/10/novartis-receives-positive-chmp-opinion-for-leqvio-a-potential-first-in-class-sirna-for-the-treatment-of-high-cholesterol/2024-10-24T08:19:20+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-approval-of-opdivo-in-recurrent-or-metastatic-oesophageal-squamous-cell-carcinoma.--bms2021-12-20T17:31:36+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-extended-approval-for-dupixent-in-severe-atopic-dermatitis-in-children.--sanofi2021-12-20T17:31:20+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-approval-of-vocabria--in-hiv.---viiv-healthcare2024-10-24T08:19:49+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-expanded-label-for-keytruda-in-relapsed-or-refractory-classical-hodgkin-lymphoma.--merck-inc2024-10-24T08:20:37+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-approval-of-tremfya-in-active-psoriatic-arthritis.--janssen-pharma2024-11-12T11:30:50+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-approval-of-kte-x19-in-mantle-cell-lymphoma.--kitegilead2024-10-25T11:04:13+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-approval-of-oxlumo-for-primary-hyperoxaluria-type-1.--alnylam-pharmaceuticals2024-10-24T08:21:09+00:00weekly0.6https://www.medthority.com/news/2020/10/emapalumabs-efficacy-for-primary-hlh-is-confirmed-by-sensitivity-analysis-presented-at-esid2020.--swedish-orphan-biovitrium2024-11-12T11:31:02+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-fintepla-for-the-treatment-of-seizures-associated-with-dravet-syndrome.--zogenix2024-10-25T11:10:46+00:00weekly0.6https://www.medthority.com/news/2020/10/orchard-therapeutics-receives-positive-chmp-opinion-for-libmeldy-for-the-treatment-of-early-onset-metachromatic-leukodystrophy-mld/2024-10-24T11:18:00+00:00weekly0.6https://www.medthority.com/news/2020/10/new-long-term-data-from-keynote-021-cohort-g-reinforce-use-of-keytruda-in-certain-patients-with-advanced-nonsquamous-nsclc.--merck-inc2024-10-24T08:21:28+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-venclexta----azacitidinedecitabine-or-low-dose-cytarabine-for-the-treatment-of-newly-diagnosed-acute-myeloid-leukemia-.-abbvie--genentechroche2024-10-24T08:21:48+00:00weekly0.6https://www.medthority.com/news/2020/10/solidarity-therapeutics-trial-produces-conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19.-who2021-12-20T17:33:11+00:00weekly0.6https://www.medthority.com/news/2020/10/trial-finds-olumiant--veklury-cuts-time-to-recovery-for-patients-with-covid-19.--eli-lilly-and-incyte2021-12-20T17:33:12+00:00weekly0.6https://www.medthority.com/news/2020/10/aimmune-receives-positive-chmp-opinion-on-palforzia-for-the-treatment-of-peanut-allergy-in-europe/2024-10-24T11:17:50+00:00weekly0.6https://www.medthority.com/news/2020/10/gilead-ceo-statement-on-remdesivir--final-report-for-the-actt-1-study-group-for-treatment-of-covid-19/2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-forxiga-to-treat-heart-failure-in-patients-with-or-without-diabetes.--astrazeneca2021-12-20T17:29:25+00:00weekly0.6https://www.medthority.com/news/2020/10/chmp-recommends-trixeo-aerospherefor-maintenance-treatment-in-adult-patients-with-moderate-to-severe-copd.--astrazeneca-2024-10-25T11:13:13+00:00weekly0.6https://www.medthority.com/news/2020/10/hangzhou-zhongmei-huadong-pharmaceutical-co.-ltd.-will-commercialise-mirvetuximab-soravtansine-in-mainland-china-hong-kong-macau-and-taiwan.--immunogen2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-accepts-for-priority-review-applications-for-opdivo-in-combination-with-cabometyx--in-advanced-renal-cell-carcinoma.--bms--exelixis2024-10-22T10:10:30+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-grants-priority-review--for--tagrisso-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer.--astrazeneca2024-10-22T10:17:16+00:00weekly0.6https://www.medthority.com/news/2020/10/endo-acquires-biospecifics-technologies-and-access-to-xiaflex-and-qwo/2021-09-24T07:10:57+00:00weekly0.6https://www.medthority.com/news/2020/10/cobitolimod-for-moderate-to-severe-left-sided-ulcerative-colitis-conduct-a-phase-iib--dose-ranging-induction-trial.-index-pharma-and-merck-kgaa-2024-11-12T14:10:25+00:00weekly0.6https://www.medthority.com/news/2020/10/moderna-completes-enrollment-of-phase-iii-cove-study-of-mrna-vaccine-against-covid-19-mrna-1273/2022-02-08T07:44:56+00:00weekly0.6https://www.medthority.com/news/2020/10/roche-announces-collaboration-with-atea-pharmaceuticals-to-develop-at-527-a-potential-oral-treatment-for-covid-19-patients/2022-02-08T07:44:56+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-antiviral-veklury--for-treatment-of-covid-19.--gilead-sciences2022-02-08T07:44:56+00:00weekly0.6https://www.medthority.com/news/2020/10/pivotal-trial-of-oms-721-shows-efficacy-in-hsct-tma.--omeros-corp2022-02-08T07:44:56+00:00weekly0.6https://www.medthority.com/news/2020/10/alnylam-presents-positive-results-from-illuminate-b-phase-iii-study-of--lumasiran-in-pediatric-patients-with-primary-hyperoxaluria-type-1-at-the-american-society-of-nephrology-kidney-week/2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/allarity-therapeutics-provides-update-on-dovitinib-program-for-renal-cell-carcinoma/2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/first-patient-dosed-in-phase-iii-clinical-trial-of-monalizumab--cetuximab-in-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck--innate-pharma--astrazeneca.-2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/farxiga-dapa-ckd-phase-iii-trial-reduced-worsening-of-kidney-function-risk-of-cardiovascular-or-renal-death-in-patients-with-chronic-kidney-disease-irrespective-of-underlying-cause.--astrazeneca2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/new-sub-analysis-of-the-emperor-reduced-phase-iii-trial-of-jardiance-showed-improved-cardio-renal-outcomes-in-adults-with-heart-failure-with-reduced-ejection-fraction-regardless-of-chronic-kidney-disease-status.--boehringer--eli-lilly2024-10-22T10:32:46+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-authorises-restart-of-the-covid-19-azd-1222-vaccine-us-phase-iii-trial.--astrazeneca2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-fidelio-dkd-study-of-bay-94-8862-shows-benefits-in-chronic-kidney-disease--t2d.--bayer2024-11-12T13:26:25+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-pivotal-trial-of-m-001-vaccine-fails-to-meet-primary-endpoints-in-influenza.--biondvax-pharma2024-11-07T15:55:58+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-pro2tect-study-of-vafseo-meets-primary-endpoints-in-anemia-due-to-chronic-kidney-disease.--akebia-therapeutics2024-10-22T10:34:27+00:00weekly0.6https://www.medthority.com/news/2020/10/ultragenyx-and-solid-biosciences-announce-strategic-collaboration-to-develop-and-commercialize-new-gene-therapies-for-duchenne-muscular-dystrophy/2021-09-24T07:10:55+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-dapa-ckd-trial-of-farxiga-shows-efficacy-in-chronic-kidney-disease.--astrazeneca2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/10/amylyx-pharmaceuticals-announces-publication-of-centaur-survival-data-in-muscle-and-nerve-journal-demonstrating-a-significant-survival-benefit-from-amx-0035-in-als-patients/2024-10-22T10:17:28+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-510k-approval-for-immersiveview-surgical-plan-a-digital-surgery-platform..-immersivetouch2024-11-12T11:31:17+00:00weekly0.6https://www.medthority.com/news/2020/10/two-phase-iii-trials-of-v-114-show-efficacy-of-vaccine-in-pneumococcal-disease.--merck-inc2021-12-20T17:33:12+00:00weekly0.6https://www.medthority.com/news/2020/10/merck-announces-positive-topline-results-from-two-additional-phase-iii-adult-studies-evaluating-v-114-mercks-investigational-15-valent-pneumococcal-conjugate-vaccine/2021-12-20T17:33:12+00:00weekly0.6https://www.medthority.com/news/2020/10/jazz-pharmaceuticals-announces-sleep-publication-of-phase-iii-xywav-oral-solution-study-in-cataplexy-or-excessive-daytime-sleepiness-in-patients-with-narcolepsy/2024-10-25T11:13:28+00:00weekly0.6https://www.medthority.com/news/2020/10/health-canada-approves-keytruda--as-first-line-treatment-formetastatic-or-unresectable-recurrent-head-and-neck-squamous-cellcarcinoma/2024-10-22T10:27:26+00:00weekly0.6https://www.medthority.com/news/2020/10/health-canada-approves-first-ever-gene-replacement-therapy-luxturna--a-one-time-treatment-for-vision-loss-due-to-inherited-retinal-dystrophy-with--biallelic-rpe65-mutations.-novartis2024-11-12T13:41:58+00:00weekly0.6https://www.medthority.com/news/2020/10/-fda-approves-a-new-formulation-of-ultomiris-with-significantly-reduced-infusion-time-for-for-patients-with-ahus-and-pnh.--alexion-pharma2024-11-12T11:31:37+00:00weekly0.6https://www.medthority.com/news/2020/10/antibody-cocktail-regn-eb3-inmazeb-is-the-first-fda-approved-treatment-for-ebola.-regeneron2024-10-25T11:13:49+00:00weekly0.6https://www.medthority.com/news/2020/10/biogen-submits-maa-at-ema-for-aducanumab-an-investigational-treatment-for-alzheimers-disease/2024-10-24T08:44:15+00:00weekly0.6https://www.medthority.com/news/2020/10/spectrum-pharmaceuticals-announces-that-the-fda-is-deferring-its-action-on-the-bla-for-rolontis-to-treat-neutropenia/2024-10-25T11:14:06+00:00weekly0.6https://www.medthority.com/news/2020/10/dupixent-late-breaking-pivotal-data-showing-significant-improvement-in-eosinophilic-esophagitis-signs-and-symptoms-presented-at-acg-and-ueg-meetings--sanofi.-2024-11-07T15:33:03+00:00weekly0.6https://www.medthority.com/news/2020/10/bayer-acquires-asklepios-biopharmaceutical-inc.-askbio-a-gene-therapy-company2025-10-16T11:22:24+00:00weekly0.6https://www.medthority.com/news/2020/10/new-analysis-presented-at-eadv-congress-reveals-long-hauler-covid-19-patients-with-prolonged-skin-symptoms.-2024-10-22T10:36:31+00:00weekly0.6https://www.medthority.com/news/2020/10/long-term-and-post-hoc-analyses-of-taltz-shows-efficacy-in-psoriasis.--eli-lilly2021-12-20T17:31:36+00:00weekly0.6https://www.medthority.com/news/2020/10/spirit-studies-of-taltz-show-sustained-efficacy-in-psoriatic-arthritis.--eli-lilly2024-11-07T15:57:23+00:00weekly0.6https://www.medthority.com/news/2020/10/blaze-1-phase-ii-trial-of-ly-cov555-in-covid-19-published-in-nejm.--eli-lilly2021-12-20T17:31:36+00:00weekly0.6https://www.medthority.com/news/2020/10/libtayo-filed-with-fda-and-maa-for-metastatic-non-small-cell-lung-cancer-with-minimum-50-pd-l1.--regeneronsanofi2021-12-20T17:29:25+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-measure-up-1-and-measure-up-2-studies-support-applications-to-fda-and-maa-for-rinvoq-in-atopic-dermatitis.--abbvie2024-10-22T10:37:04+00:00weekly0.6https://www.medthority.com/news/2020/10/european-patent-office-rules-in-favor-of-sanofi-and-regeneron-concerning-praluent/2024-11-12T13:26:36+00:00weekly0.6https://www.medthority.com/news/2020/10/pooled-data-from-phase-iii-studies-true-ad1-and-true-ad2-of-jakavi-shows-itch-reduction-in-atopic-dermatitis.--incyte2021-12-20T17:31:36+00:00weekly0.6https://www.medthority.com/news/2020/10/novartis-acquires-vedere-bio-and-photoreceptor-protein-based-optogenetic-therapies/2021-09-24T07:10:53+00:00weekly0.6https://www.medthority.com/news/2020/10/fall-clinical-dermatology-2020-lilly--incyte-provide-positive-new-data-for-baricitinib-in-adult-patients-with-alopecia-areata/2024-10-22T10:37:24+00:00weekly0.6https://www.medthority.com/news/2020/10/ema-accepts-for-review-maa-for-aducanumab-treatment-for-mild--alzheimers-disease.-eisai--biogen2022-02-08T07:44:57+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-approves-eysuvis-for-short-term-treatment-of-dry-eye-disease.--kala-pharma2024-11-12T13:26:46+00:00weekly0.6https://www.medthority.com/news/2020/10/dmc-rules-genesis-phase-iii-trial-of-bl-8040-enrollment-complete-in-multiple-myeloma-patients.--biolinerx2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-grants-expanded-approval-for-cobas-egfr-mutation-test-v2-in-non-small-cell-lung-cancer.--roche2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/10/fasenra-eliminated-oral-corticosteroid-use-in-a-majority-of-ocs-dependent-patients-with-asthma-in-ponente-phase-iiib-trial.--astrazeneca2022-01-11T20:30:00+00:00weekly0.6https://www.medthority.com/news/2020/10/idmc-recommends-changes-to-trials-of-regn-cov2-in-covid-19.--regeneron-pharma2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/10/global-coalition-for-adaptive-research-amgen-and-eisaiannounce-first-patient-enrolled-in-remap-covid-trial-involving-apremilast-and-eritoran/2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/10/fda-grants-510k-clearance-for--a-cardiopulmonary-bypass-system-called-the-abiomed-breethe-oxy-1-system.-abiomed2024-10-22T10:38:35+00:00weekly0.6https://www.medthority.com/news/2020/10/nih-sponsored-activ-3-trial-closes-ly-cov555-sub-study.-eli-lilly2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/10/xarelto-filed-with-fda-for-a-supplemental-approval-in-peripheral-artery-disease.--janssen2024-10-24T08:45:02+00:00weekly0.6https://www.medthority.com/news/2020/10/pf-04965842-filed-with-maa-and-fda-for-atopic-dermatitis.--pfizer2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/10/sobi-and-apellis-collaborate-on-the-development-and-commercialisation-of-pegcetacoplan/2024-11-12T13:27:31+00:00weekly0.6https://www.medthority.com/news/2020/10/novavax-provides-phase-iii-nvx-cov2373-covid-19-vaccine-clinical-development-update/2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/10/molecular-partners-announces-collaboration-with-novartis-to-develop-two-darpin-therapies-designed-for-potential-use-against-covid-19/2021-12-20T17:29:25+00:00weekly0.6https://www.medthority.com/news/2020/10/insmeds-arikayce-receives-marketing-authorization-for-treatment-of-mycobacterial-lung-infections-/2024-10-22T10:34:39+00:00weekly0.6https://www.medthority.com/news/2020/10/new-evidence-shows-psoriasis-can-be-treated-with-a-microbe-derived-from-gut-bacteria.-evelo-biosciences2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/10/neovasc-announces-fda-advisory-panel-result-on-neovasc-reducer-medical-device-for-the-treatment-of-refractory-angina/2024-11-12T13:27:45+00:00weekly0.6https://www.medthority.com/news/2020/10/enhertu-granted-priority-review-in-the-us-for-the-treatment-of-her2-positive-metastatic-gastric-cancer.--astrazeneca--daiichi-sankyo2024-10-22T10:34:51+00:00weekly0.6https://www.medthority.com/news/2020/10/phase-iii-gemini-1-and-2-clinical-trials-of-agn-190584-meet-primary-endpoints-in-presbyopia.--allerganabbvie2024-10-22T10:35:06+00:00weekly0.6https://www.medthority.com/news/2020/11/bimekizumab-phase-iii-data-shows-superior-skin-clearance-over-humira-in-moderate-to-severe-psoriasis-patients.--ucb2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-breeze-ad3-trial-of-olumiant-shows-long-term-efficacy-in-atopic-dermatitis.--eli-lilly-and-incyte2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/11/two-pivotal-phase-iii-studies-evaluating-rm-493-in-pomc-and-lepr-published-in-the-lancet-diabetes--endocrinology.--rhythm-pharma2024-10-22T10:37:48+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-expands-keytruda-approval-for-classical-hodgkin-lymphoma-indication-based-on-results-from-keynote-204-trial.--merck-inc2024-10-24T08:44:27+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-resurface-extension-studies-of-ilumya-shows-consistent-benefit-in-plaque-psoriasis.--sun-pharma2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/11/novartis-announces-positive-results-from-a-phase-iv-study-showing-superior-tolerability-and-efficacy-of-aimovig-compared-with-topiramate-in-migraine-prevention-.----2021-12-20T17:31:21+00:00weekly0.6https://www.medthority.com/news/2020/11/boston-scientific--announced-it-has-received-fda-approval-of-the-ranger-drug-coated-balloon-developed-for-the-treatment-of-patients-with-peripheral-artery-disease.-2024-10-22T10:38:01+00:00weekly0.6https://www.medthority.com/news/2020/11/pp-6m-filed-with-fda-for-schizophrenia.--janssen-pharma2024-10-24T08:44:49+00:00weekly0.6https://www.medthority.com/news/2020/11/european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-ulcerative-colitis.--gilead-sciences--galapagos-nv2021-12-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2020/11/aurinia-announces-outcome-of-audrey-clinical-trial--evaluating-voclosporin-ophthalmic-solution-in-dry-eye-syndrome/2024-11-12T13:27:56+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-accepts-biomarins-nda--for-vosoritide-to-treat-children-with-achondroplasia/2024-11-12T13:28:10+00:00weekly0.6https://www.medthority.com/news/2020/11/chemocentryx-and-vfmcrp-announce-european-medicines-agency-has-accepted-to-review-the-aa-for-avacopan-to-treat-anca--associated-vasculitis/2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-poetyk-pso-1-trial-of-bms-986165-meets-endpoints-in-plaque-psoriasis.--bms2024-10-22T10:38:50+00:00weekly0.6https://www.medthority.com/news/2020/11/nice-recommends-approval-of-saxenda-in-obesity.--novo-nordisk2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2020/11/higher-response-rates-in-recipe-randomized-controlled-trial-for-gout-treatment-by-krystexxa--with-mycophenolate-mofetil.--horizontherapeutics2024-10-24T10:54:26+00:00weekly0.6https://www.medthority.com/news/2020/11/sanofi-to-acquire-kiadis-nv-and-its-innovative-k-nk-cell-platform/2021-09-24T07:12:50+00:00weekly0.6https://www.medthority.com/news/2020/11/adial-pharmaceuticals-provides-an-update-on-its-onward--pivotal-phase-iii-trial-of-ad-04-for-treatment-of-alcohol-use-disorder/2024-11-12T13:28:22+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-warns-of-covid-19-antigen-test-false-positives-as-report-refers-to-quidel-on-accuracy/2021-12-20T17:29:26+00:00weekly0.6https://www.medthority.com/news/2020/11/acr-2020-lilly-and-incyte-highlight-positive-data-for-olumiant-in-rheumatoid-arthritis/2024-10-22T10:39:37+00:00weekly0.6https://www.medthority.com/news/2020/11/cosentyx-shows-early-synovitis-reduction-in-patients-with-psoriatic-arthritis-in-first-of-its-kind-study.--novartis-2024-10-24T10:54:40+00:00weekly0.6https://www.medthority.com/news/2020/11/novartis-provides-update-on-can---covid-trial-of-canakinumab--in-hospitalized-patients-with-covid-19-pneumonia-and-cytokine-release-syndrome/2024-10-22T10:39:52+00:00weekly0.6https://www.medthority.com/news/2020/11/brilinta-approved-in-the-us-to-reduce-the-risk-of-stroke-in-patients-with-an-acute-ischaemic-stroke-or-high-risk-transient-ischaemic-attack.--astrazeneca2024-10-22T10:40:08+00:00weekly0.6https://www.medthority.com/news/2020/11/bms-receives-european-commission-approval-for-opdivo--yervoy-with-two-cycles-of-chemotherapy-for-first-line-treatment-of-metastatic-nsclc/2021-12-20T17:33:25+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-discover-1--discover-2-trials-of-tremfya-show-improved-fatigue-in-psoriatic-arthritis.--janssen-pharma2024-11-12T13:29:02+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-study-of-xeljanz-meets-endpoints-in--ankylosing-spondylitis.--pfizer2024-10-22T10:40:22+00:00weekly0.6https://www.medthority.com/news/2020/11/merck-inc-acquires-velosbio-and-with-it-vls-101/2021-09-24T07:12:48+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-advisory-committee-negative-towards-aducanumab-treatment-for-mild-alzheimers-disease-.-biogen--eisai2024-10-22T10:40:34+00:00weekly0.6https://www.medthority.com/news/2020/11/regeneron-provides-update-on-the-garetosmab-phase-ii-lumina-1-trial-in-fibrodysplasia-ossificans-progressiva-/2024-10-24T10:56:26+00:00weekly0.6https://www.medthority.com/news/2020/11/australian-tga-approves-scenesse-to-prevent-phototoxicity-in-adult-patients-with-erythropoietic-protoporphyria--clinuvel-pharmaceuticals/2024-10-24T08:51:49+00:00weekly0.6https://www.medthority.com/news/2020/11/forxiga-approved-in-the-eu-for-heart-failure.--astrazeneca2021-12-20T17:29:27+00:00weekly0.6https://www.medthority.com/news/2010/11/lynparza-approved-in-the-eu-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer.--astrazeneca--merck-inc2024-10-24T10:57:13+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-step-3-trial-of-ozempic-shows-weight-loss-in-obesity.--novo-nordisk2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2020/11/lynparza-approved-in-the-eu-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.-astrazeneca--merck-inc2021-12-20T17:29:27+00:00weekly0.6https://www.medthority.com/news/2020/11/new-analysis-supports-long-term-treatment-with-nintedanib-in-patients-with-systemic-sclerosis-associated-interstitial-lung-disease-.--boehringer2024-10-24T08:52:04+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-advises-lipocine-that-it-is-working-towards-action-on-the-nda-for-tlando-to-treat-hypogonadism-on-or-about-30-november-2020/2024-10-24T10:57:26+00:00weekly0.6https://www.medthority.com/news/2020/11/calquence-approved-in-the-eu-for-the-treatment-of-chronic-lymphocytic-leukaemia.--astrazeneca2024-11-12T13:29:14+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-extends-pdufa-date-for-review-ofryplazim--for-the-treatment-of--congenital-plasminogen-deficiency.--liminal-biosciences2024-11-12T13:29:25+00:00weekly0.6https://www.medthority.com/news/2020/11/bnt-162b2-vaccine-interim-analysis-demonstrates-efficacy-against-covid--19.--pfizer--biontech2021-12-20T17:29:27+00:00weekly0.6https://www.medthority.com/news/2020/11/viiv-healthcare-announces-investigational-injectable-cabotegravir-is-superior-to-oral-standard-of-care-for-hiv-prevention-in-women/2024-10-22T10:40:47+00:00weekly0.6https://www.medthority.com/news/2020/11/update-on-calavi-phase-ii-trials-for-calquence-in-patients-hospitalised-with-respiratory-symptoms-of-covid-19.--astrazeneca2021-12-20T17:29:27+00:00weekly0.6https://www.medthority.com/news/2020/11/supernus-announces-a-complete-response-letter-for-spn-812-a-treatment-for-adhd/2024-10-24T08:52:37+00:00weekly0.6https://www.medthority.com/news/2020/11/supernus-pharma-announces-receipt-from-the-fda-of-a---refusal-to-file-letter-for-spn-830-a-proposed-treatment-for-parkinsons-disease/2024-10-24T10:57:50+00:00weekly0.6https://www.medthority.com/news/2020/11/darzalex-faspro--darzalex-sc-filed-with-fda-and-ema-for-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy.--halozyme-therapeutics2021-12-20T17:30:29+00:00weekly0.6https://www.medthority.com/news/2020/11/nice-recommends-approval-of-cablivi-for-thrombotic-thrombocytopenic-purpura.--sanofi2024-10-24T08:52:51+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-jade-regimen-study-of-pf-04965842-meets-endpoints-in-atopic-dermatitis.--pfizer2024-10-22T10:46:13+00:00weekly0.6https://www.medthority.com/news/2020/11/data-from-phase-iii-cove-study-of-mrna-1273-prepared-for-submission-to-dsmb-in-covid-19.--moderna2024-10-22T10:46:29+00:00weekly0.6https://www.medthority.com/news/2020/11/retrophin-completes-acquisition-of-orphan-technologies-and-with-it-ot-58-for-the-treatment-of-classical-homocystinuria-/2021-09-24T07:12:47+00:00weekly0.6https://www.medthority.com/news/2020/11/chmp-gives-negative-opinion-for-emapalumab-to-treat-primary-haemophagocytic-lymphohistiocytosis.-swedish-orphan-biovitrum2024-10-24T08:53:09+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-orion-9--10-and--11-trials-of-leqvio-show-efficacy-in-atherosclerotic-cardiovascular-disease-and-heterozygous-familial-hypercholesterolemia.--novartis2024-11-12T13:29:36+00:00weekly0.6https://www.medthority.com/news/2020/11/optic-phase-iii-trial-of-tepezza-shows-benefits-in-less-severe-thyroid-eye-disease.--horizon-therapeutics2024-11-12T13:29:45+00:00weekly0.6https://www.medthority.com/news/2020/11/chmp-recommends-approval-of-elzonris-for-blastic-plasmacytoid-dendritic-cell-neoplasm.--menarini-group2024-10-22T10:46:49+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-galactic-hf-trial-of-amg-423-meets-primary-endpoints-but-not-secodnary-ones-in-heart-failure.--cytokinetics-2021-12-20T17:29:28+00:00weekly0.6https://www.medthority.com/news/2020/11/apex-2-phase-iii-trial-data-abstracts-of-bcx-7353-show-efficacy-in-hereditary-angioedema.--biocryst-pharma2021-12-20T17:30:29+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-issues-complete-response-letter-for-sutimlimab-an-investigational-treatment-for-hemolysis-in-adults-with-cold-agglutinin-disease-.--sanofi--2024-10-24T10:58:01+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-approves-pd-l1-ihc-22c3-pharmdx-as-aid-in-identifying--triple-negative-breast-cancer.--agilent-technologies-2021-12-20T17:29:28+00:00weekly0.6https://www.medthority.com/news/2020/11/sumitomo-biopharma-acquires-control-of-urovant-and-with-it-vibegron-a-proposed-treatment-for-overactive-bladder/2021-09-24T07:12:47+00:00weekly0.6https://www.medthority.com/news/2020/11/abbott-announces-the-u.s.-launch-of-the-ionicrf-generator-for-use-in-patients-living-with-chronic-pain2024-10-24T10:57:38+00:00weekly0.6https://www.medthority.com/news/2020/11/european-commission-approves-lynparza--avastin-as-first-line-maintenance-treatment-of-ovarian-cancer.--astrazeneca--merck-inc2021-12-20T17:29:27+00:00weekly0.6https://www.medthority.com/news/2020/11/tezepelumab-in-navigator-phase-iii-trial-met-primary-endpoint-of-a--reduction-in-exacerbations-in--patients-with-severe-asthma.---astrazeneca--amgen2024-10-24T08:52:18+00:00weekly0.6https://www.medthority.com/news/2020/11/real-world-study-of-brilinta-shows-non-superiority-over-plavix-in-percutaneous-coronary-intervention.--astrazeneca2024-11-12T11:31:50+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-alpheus-study-of-in-percutaneous-coronary-intervention-published-in-the-lancet.--astrazeneca2024-10-24T10:58:13+00:00weekly0.6https://www.medthority.com/news/2020/11/eisai-receives-european-commission-approval-for-extended-indication-of-fycompa-for-pediatric-patients-with-epilepsy/2024-10-22T10:51:18+00:00weekly0.6https://www.medthority.com/news/2020/11/adamis-pharmaceuticals-receives-a-complete-response-letter-from-the-fda-regarding-zimhi-for-the-treatment-of-opioid-overdose/2021-12-20T17:30:29+00:00weekly0.6https://www.medthority.com/news/2020/11/studies-of-ocaliva-show-importance-of-non-invasive-tests-in-diagnosis-nash.--intercept-pharma2024-10-22T10:52:24+00:00weekly0.6https://www.medthority.com/news/2020/11/modernas-covid-19-vaccine-candidate-mrna-1273-meets-its-primary-efficacy-endpoint-in-the-first-interim-analysis-of-the-phase-iii-cove-study/2024-10-22T10:52:40+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-advises-bms-that-it-cannot-complete-its-review-of-liso-cel-to-treat-large-b-cell-lymphoma-by-the-pdufa-action-date-of-16-november-2020/2021-12-20T17:30:29+00:00weekly0.6https://www.medthority.com/news/2020/11/alkermes-receives-fda-complete-response-letter-related-to-alks-3831-a-proposed-treatment-for-schizophrenia-and-bipolar-1-disorder/2024-11-12T11:31:57+00:00weekly0.6https://www.medthority.com/news/2020/11/cymabay-therapeutics-announces-oral-late-breaking-presentation-of-positive-results-from-the-enhance-global-phase-iii-study--of-seladelpar-for-primary-biliary-cholangitis-at-the-liver-meeting-2020/2024-10-24T10:58:28+00:00weekly0.6https://www.medthority.com/news/2020/11/ema-starts-rolling-review-of-mrna-1273-for-covid-19.--moderna2024-10-22T10:47:06+00:00weekly0.6https://www.medthority.com/news/2020/11/fidelio-dkd-phase-iii-study-of-bay-94-8862-in-ckd--t2d-published-in-circulation.--bayer2024-10-22T10:47:22+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-expands-approval-of-vimpat-as-adjunctive-therapy-to-children-in-primary-generalized-tonic-clonic-seizures.--ucb2021-12-20T17:30:29+00:00weekly0.6https://www.medthority.com/news/2020/11/beigene-announces-that-rationale-303-trial-of-tislelizumab-in-non-small-cell-lung-cancer-met-the-primary-endpoint-of-overall-survival-at-interim-analysis/2021-12-20T17:33:12+00:00weekly0.6https://www.medthority.com/news/2020/11/once-weekly-semaglutide-2.0-mg-demonstrates-superior-reduction-in-hba1c-vs-once-weekly-semaglutide-1.0-mg-in-people-with-type-2-diabetes-in-the-sustain-forte-trial--novo-nordisk2024-10-24T08:53:24+00:00weekly0.6https://www.medthority.com/news/2020/11/brainstorm-therapeutics-announces-topline-results-from-nurown-phase-iii-als-study/2024-10-22T10:47:38+00:00weekly0.6https://www.medthority.com/news/2020/11/rethrophon-name-change-to-travere-therapeutics/2021-09-24T07:12:46+00:00weekly0.6https://www.medthority.com/news/2020/11/eu-approves-exparel-for-post-operative-pain-in-adults.--pacira-biosciences2024-10-24T10:58:40+00:00weekly0.6https://www.medthority.com/news/2020/11/omeros-corporation-submits-its-bla-to-the-fda-for-narsoplimab-for-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy/2021-12-20T17:29:28+00:00weekly0.6https://www.medthority.com/news/2020/11/nice-recommends-use-of-emgality-in-migraine-in-adults-with-episodic-and-chronic-migraine.--eli-lilly2024-10-22T10:47:59+00:00weekly0.6https://www.medthority.com/news/2020/11/european-commission-approves-supemtek-quadrivalent-recombinant-influenza-vaccine-for-the-prevention-of-influenza---sanofi/2024-11-12T11:39:50+00:00weekly0.6https://www.medthority.com/news/2020/11/sb-11-biosimilar-filed-with-fda-for-retinal-vascular-disorders.--samsung-bioepis--biogen2024-10-24T10:59:16+00:00weekly0.6https://www.medthority.com/news/2020/11/neogaa-filed-with-fda-for-pompe-disease.--sanofi2021-12-20T17:29:28+00:00weekly0.6https://www.medthority.com/news/2020/11/jardiance-reduced-the-risk-of-first-plus-recurrent-cardiovascular-events-in-type-2-diabetes-and-cv-disease-in-a-new-analysis-from-the-empa-reg-outcome-trial.--eli-lilly2024-10-24T08:53:40+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-authorizes-first-prescription-at-home-molecular-test-for-covid-19-thatprovides-lab-quality-results-in-30-minutes-or-less-from-home.-lucira-health2021-12-20T17:29:28+00:00weekly0.6https://www.medthority.com/news/2020/11/pfizer-and-biontech-conclude-phase-iii-study-of-bnt162b2-vaccine-for-covid-19-meeting-all-primary-endpoints/2021-12-20T17:33:25+00:00weekly0.6https://www.medthority.com/news/2020/11/hologic-announces-ce-mark-of-the-genius-digital-diagnostics-system-for-cervical-cancer-screening/2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/mmi-spa-launches-breakthrough-technology-advancing-robotic-microsurgery-with-the-worlds-smallest-wristed-surgical-instruments/2024-10-24T08:54:23+00:00weekly0.6https://www.medthority.com/news/2020/11/european-commission-approves--oxlumo-an-rnai-therapeutic-to-treat-primary-hyperoxaluria-type-1.--alnylam-pharma2024-10-22T10:48:14+00:00weekly0.6https://www.medthority.com/news/2020/11/chmp-positive-for-phesgo-to-treat-her2-positive-breast-cancer.-roche2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/11/results-from-phase-iii-crown-trial-of-lorbrena--for-previously-untreated-alk--lung-cancer-is-published-in-nejm.--pfizer-2024-11-12T13:30:49+00:00weekly0.6https://www.medthority.com/news/2020/11/chmp-positive-for-xofluza-intended-for-the-treatment-and-post-exposure-prophylaxis-of-uncomplicated-influenza.--roche.-2024-10-24T10:59:27+00:00weekly0.6https://www.medthority.com/news/2020/11/the-fda-has-granted-accelerated-approval-for-keytruda--chemotherapy-to-treat-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer-whose-tumors-express-pd-l1.--merck-inc2024-10-22T10:48:30+00:00weekly0.6https://www.medthority.com/news/2020/11/johnson--johnson-initiates-second-phase-iii-clinical-trial-ensemble-2-of-jnj-78436735-covid-19-vaccine.-2024-10-22T10:50:24+00:00weekly0.6https://www.medthority.com/news/2020/11/chmp-positive-for-roclanda-for-the-reduction-of-elevated-intraocular-pressure--with-primary-open-angle-glaucoma-or-ocular-hypertension--aerie-pharma/2024-11-12T13:30:59+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-issues-emergency-use-authorization-for-baricitinib--remdesivir-in-hospitalized-patients-with-covid-19.--eli-lilly2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/11/four-week-dosing-now-approved-in-all-imfinzi-indications-reducing-medical-visits-and-improving-patient-convenience.--astrazeneca2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-edpc003r01-trial-of-vascepa-meets-primary-endpoint-in-patients-with-very-high-triglycerides.--amarin-corp2024-10-22T10:50:49+00:00weekly0.6https://www.medthority.com/news/2020/11/eu-approves-new-iv-formulation-of-ultomiris-for-paroxysmal-nocturnal-hemoglobinuria-and-atypical-hemolytic-uremic-syndrome.--alexion-pharma2024-10-24T08:55:35+00:00weekly0.6https://www.medthority.com/news/2020/11/bamlanivimab-ly-cov555-receives-interim-authorization-from-health-canada-as-a-treatment-for-covid-19.--eli-lilly2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-accepts--bla-and-grants-priority-review-for-loncastuximab-tesirine-for-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.--adc-therapeutics2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-approves-zokinvy-for-progeria.--eiger-biopharmaceuticals2024-10-22T10:51:00+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-seal-study-of-xpovio-shows-efficacy-in-liposarcoma.--karyopharm-therapeutics-2024-10-24T08:56:47+00:00weekly0.6https://www.medthority.com/news/2020/11/pfizer-and-biontech-se-submit-emergency-use--authorisation-request-to-the-fda-for-their-vaccine--bnt-162b2--for-covid-19-/2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/11/mesoblast-enters-collaboration-with-novartis-for-remestemcel-l-for--acute-respiratory-distress-syndrome-ards-including-covid-19-associated-ards/2024-11-12T13:31:09+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-grants-emergency-use-authorisation-for-regn-cov2-in-covid-19.--regeneron-pharma2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/11/azd-1222-vaccine-met-primary-efficacy-endpoint-in-preventing-covid-19.--astrazeneca2021-12-20T17:31:22+00:00weekly0.6https://www.medthority.com/news/2020/11/european-commission-approves-menquadfi-the-latest-innovation-in-meningococcal-menacwy-vaccination-for-individuals-12-months-of-age-and-older.--sanofi-2024-10-22T10:53:17+00:00weekly0.6https://www.medthority.com/news/2020/11/rigel-and-medison-announce-health-canada-approval-of-tavalisse-an-oral-medication-for-the-treatment-of--chronic-immune-thrombocytopenia/2024-10-22T10:53:31+00:00weekly0.6https://www.medthority.com/news/2020/11/baxter-announces-fda-510k-approval-for-clearance-of-homechoice-claria-peritoneal-dialysis-system-with-sharesource/2024-11-07T15:33:19+00:00weekly0.6https://www.medthority.com/news/2020/11/cytokinetics-regains-rights-to-to--omecamtiv-mecarbil-a-proposed-treatment-for-heart-failure-and-to-amg-594-from-amgen.-2021-12-20T17:31:22+00:00weekly0.6https://www.medthority.com/news/2020/11/-eli-lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-covid-19/2024-10-22T10:45:20+00:00weekly0.6https://www.medthority.com/news/2020/11/-keytruda--lenvima-demonstrated-statistically-significant-improvement-in-progression-free-survival--overall-survival-and-objective-response-rate-versus-sunitinib-as-first-line-treatment-for-renal-cell-carcinoma.--merck-inc.--eisai2024-10-22T10:45:38+00:00weekly0.6https://www.medthority.com/news/2020/11/merck-announces-keynote-598-trial-evaluating-keytruda-plus-ipilimumab-versus-keytruda-monotherapy-for--metastatic-non-small-cell-lung-cancer-to-stop-for-futility-and-patients-to-discontinue/2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/european-commission-approves-opdivofor-the-treatment-of-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma.-bms-2021-12-20T17:31:22+00:00weekly0.6https://www.medthority.com/news/2020/11/genentech-announces-fda-approval-of-xofluza-for-the-prevention-of-influenza-following-contact-with-an-infected-person/2024-11-12T13:31:19+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-approval-of-oxlumo-the-first-and-only-treatment-approved-for-primary-hyperoxaluria-type-1-to-lower-urinary-oxalate-levels-in-pediatric-and-adult-patients.---alnylam-pharma2024-10-22T10:54:02+00:00weekly0.6https://www.medthority.com/news/2020/11/hls-therapeutics-announces-health-canada-approval-of-perseris-extended-release-for-the-treatment-of-schizophrenia/2024-10-22T10:56:20+00:00weekly0.6https://www.medthority.com/news/2020/11/bausch-health-initiates-second-phase-iii-study-for-nov0-3--treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2024-11-07T15:33:31+00:00weekly0.6https://www.medthority.com/news/2020/11/merck-inc.-acquires-oncoimmune-inc.-and-with--itcd24fc-for-the-treatment-of-covid-192021-09-24T07:12:43+00:00weekly0.6https://www.medthority.com/news/2020/11/uniqure-announces-positive-top-line-data-from-the-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-gene-therapy-in-patients-with-hemophilia-b/2024-11-12T13:31:29+00:00weekly0.6https://www.medthority.com/news/2020/11/phase-iii-imcgp100-202-study-of-imcgp100-shows-statistical-improvement-in-metastatic-uveal-melanoma.--immunocore2024-10-24T08:57:10+00:00weekly0.6https://www.medthority.com/news/2020/11/eu-approves-tremfya-in-active-psoriatic-arthritis.--janssen-pharma2024-10-22T11:28:59+00:00weekly0.6https://www.medthority.com/news/2020/11/bio-thera-solutions--has-submitted-a-maa-for-bat-1706-a-proposed-biosimilar-to-avastin--to-ema/2024-11-12T13:31:41+00:00weekly0.6https://www.medthority.com/news/2020/11/liquidia-receives-complete-response-letter-from-fda-for-liq-861-inhalation-powder-for-the-treatment-of-pulmonary-arterial-hypertension/2021-12-20T17:31:22+00:00weekly0.6https://www.medthority.com/news/2020/11/merck-inc.-submits-applications-for-licensure-of-v-114-an-investigational-15-valent-pneumococcal-conjugate-vaccine--to-the-fda-and-ema2021-12-20T17:29:29+00:00weekly0.6https://www.medthority.com/news/2020/11/who-solidarity-trial-and-who-recommendations-find-no-evidence-to-support-remdesivir-and-other-re-purposed-drugs-to-improve-covid-19-outcomes/2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/efficacy-reports-of-sputnik-v-vaccine-for-covid-19-show-91.4-efficacy-from-a-second-interim-analysis-of-more-than-18000-people.--gamaleya-national-center-of-epidemiology-and-microbiology2021-12-20T17:33:26+00:00weekly0.6https://www.medthority.com/news/2020/11/nice-recommends-use-of-sarclisa-plus-pomalidomide-and-dexamethasone-for-multiple-myeloma-.--sanofi2021-12-20T17:31:22+00:00weekly0.6https://www.medthority.com/news/2020/11/european-medicines-agency-validates-application-for-tepotinib-for-the-treatment-of-advanced-nsclc-with-metex14-skipping-alterations.--merck-kgaa2021-12-20T17:29:29+00:00weekly0.6https://www.medthority.com/news/2020/11/eu-approves-symkevi--kalydeco-for-eligible-children-with-cystic-fibrosis.--vertex2024-11-07T15:33:46+00:00weekly0.6https://www.medthority.com/news/2020/11/nice-does-not-recommend-nhs-use-of-adakveo-in-sickle-cell-disease.--novartis2024-10-24T08:57:23+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-approves-imcivree-for-obesity-due-to-pomc-pcsk1-or-leptin-receptor-lepr-deficiencies-confirmed-by-genetic-testing.--rhythm-pharmaceuticals2024-10-24T08:57:37+00:00weekly0.6https://www.medthority.com/news/2020/11/grail-and-uk-government-to-make-galleri-multi-cancer-early-detection-blood-test-available-in-the-uk.--grail-inc2024-11-12T13:31:51+00:00weekly0.6https://www.medthority.com/news/2020/11/fda-extends-pdufa-date-for-prx-102-in-fabry-disease.--protalix-biotherapeutics-and-chiesi2024-11-12T13:32:00+00:00weekly0.6https://www.medthority.com/news/2020/12/european-commission-approves-dupixent-as-first-and-only-biologic-medicine-for-children-with-severe-atopic-dermatitis.-sanofi--regeneron2021-12-20T17:33:27+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-grants-accelerated-approval-fordanyelza-to-treat-with-gm-csf-pediatric-patients-with-high-risk-neuroblastoma.-y-mabs-therapeutics-inc2024-10-22T11:30:57+00:00weekly0.6https://www.medthority.com/news/2020/12/novavax-announces-covid-19-vaccine-clinical-development-progress-ofnvx-cov2373/2021-12-20T17:29:29+00:00weekly0.6https://www.medthority.com/news/2020/12/moderna-announces-primary-efficacy-analysis-in-phase-iii-cove-study-for-mrna-1273-vaccine-candidate-and-filing-today-with-the-fda-for-emergency-use-authorization/2021-12-20T17:33:27+00:00weekly0.6https://www.medthority.com/news/2020/12/forxiga-approved-in-japan-for-heart-failure-in-patients-with-reduced-ejection-fraction.--astrazeneca2021-12-20T17:33:27+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-intercept-blood-system-for-control-of-bleeding.--cerus-corp2024-10-22T11:31:52+00:00weekly0.6https://www.medthority.com/news/2020/12/minerva-neurosciences-announces-outcome-of-type-c-meeting-with-fda-and-next-steps-in-the-development-of-roluperidone-for-treatment-of-negative-symptoms-in-schizophrenia/2024-10-22T11:32:00+00:00weekly0.6https://www.medthority.com/news/2020/12/boston-scientific-corporation-sells-its-btg-specialty-pharmaceuticals-business-to-serb-sa/2024-10-24T08:58:20+00:00weekly0.6https://www.medthority.com/news/2020/12/genentech-announces-fda-approval-of-supplemental-bla-of-xolair-for-add-on-maintenance-treatment-of-nasal-polyps.-2024-11-07T15:34:34+00:00weekly0.6https://www.medthority.com/news/2020/12/accelerated-fda-approval-for-gavreto-to-treat-ret-mutant-medullary-thyroid-cancer-.--genentech2024-11-12T13:32:11+00:00weekly0.6https://www.medthority.com/news/2020/12/jazz-pharmaceuticals--pharmamar-announce-results-of-atlantis-phase--iii-study-of-zepzelca---doxorubicin-for-small-cell-lung-cancer/2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/12/genmab-announces-that-janssen-has-submitted-a-bla-to-the-fda-for-amivantamab-in-non-small-cell-lung-cancer/2024-11-12T13:38:46+00:00weekly0.6https://www.medthority.com/news/2020/12/protective-2-phase-iii-study-of-plinabulin--pegfilgrastim-met-the-primary-endpoint-in-neutropenia.--beyondspring2024-11-12T13:39:19+00:00weekly0.6https://www.medthority.com/news/2020/12/biocryst-announces-fda-approval-of-orladeyo-the-first-oral-once-daily-therapy-to-prevent-attacks-in-hereditary-angioedema-patients/2021-12-20T17:33:27+00:00weekly0.6https://www.medthority.com/news/2020/12/european-commission-approves-obiltoxaximab-for-the-treatment-of-inhalation-anthrax.--elusys-therapeutics2024-11-12T09:33:29+00:00weekly0.6https://www.medthority.com/news/2020/12/-eli-lilly-and-united-health-group-partner-on-pragmatic-study-of-neutralizing-antibody-bamlanivimab-ly-cov555-for-covid-19/2021-12-20T17:29:30+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-reach3-study-of-jakavi-improved-outcome-in-chronic-graft-versus-host-disease.--novartis2021-12-20T17:33:25+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-trial-of-instiladrin-shows-efficacy-for-invasive-bladder-cancer.--fergene-inc2024-11-07T15:35:11+00:00weekly0.6https://www.medthority.com/news/2020/12/livanova-plc-sells-its-heart-valve-business-to-gyrus-capital-and-with-it-the-perceval-sutureless-aortic-valve/2021-09-24T07:13:00+00:00weekly0.6https://www.medthority.com/news/2020/12/new-data-for-tecartus-demonstrates-durable-responses-at-one-year-in-zuma-2-trial-follow-up-in-relapsed-or-refractory-mantle-cell-lymphoma-kitegilead/2024-10-22T11:32:31+00:00weekly0.6https://www.medthority.com/news/2020/12/new-four-year-data-show-long-term-survival-in-patients-with-large-b-cell-lymphoma-treated-with-yescarta-in-zuma-1-trial.-kitegilead2021-12-20T17:29:30+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-analyses-confirm-benefit-of-kymriah-with-rates-of-complete-response-seen-in-patients-with-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma/2021-12-20T17:33:25+00:00weekly0.6https://www.medthority.com/news/2020/12/freestyle-libre-2-has-received-approval-by-health-canada-for-adults-and-children-4-and-older-with-diabetes.-abbott2024-10-24T09:01:35+00:00weekly0.6https://www.medthority.com/news/2020/12/pfizer-and-biontech-achieve-first-authorisation-in-the-world-from-mhra--in-the-uk-for-bnt-162b2-mrna-vaccine-against-covid-19/2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-hetlioz-for-the-treatment-of-adults-and-children-respectively-with-nighttime-sleep-disturbances-associated-with-smith-magenis-syndrome.--vanda-pharma2024-11-12T14:30:50+00:00weekly0.6https://www.medthority.com/news/2020/12/ovid-therapeutics-announces-phase-iii-neptune-clinical-trial-of-ov-101-for-the-treatment-of-angelman-syndrome-did-not-meet-primary-endpoint/2024-11-07T15:34:49+00:00weekly0.6https://www.medthority.com/news/2020/12/reach3-study-shows-jakavi-significantly-improves-outcomes-in-patients-with-steroid-refractorydependent-chronic-graft-versus-host-disease.-incyte--novartis2024-10-22T11:32:45+00:00weekly0.6https://www.medthority.com/news/2020/12/ace-ly-004-phase-ii-trial-results-substantiate-established-efficacy-and-safety-profile-of-calquence-in-mantle-cell-lymphoma.--astrazeneca.-2024-10-24T08:59:36+00:00weekly0.6https://www.medthority.com/news/2020/12/long-term-data-for-betibeglogene-autotemcel-shows-patients-achieve-transfusion-independence-and-remain-free-from-transfusions-up-to-six-years.--bluebird-bio-inc2021-12-20T17:31:23+00:00weekly0.6https://www.medthority.com/news/2020/12/bms-and-bluebird-bio-present-data-highlighting-anti-bcma-car-t-cell-therapy-ide-cel-in-relapsed-and-refractory-multiple-myeloma-at-ash-2020/2021-12-20T17:33:25+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-mavoric-trial-analyses-of-poteligeo-shows-impact-of-therapy-in--t-cell-lymphoma.--kyowa-kirin2024-10-24T08:59:55+00:00weekly0.6https://www.medthority.com/news/2020/12/genentech-announces-new-data-reinforcing-the-long-term-benefit-of-venclexta-based-combinations-for--relapsed-or-refractory-chronic-lymphocytic-leukemia/2024-10-24T09:00:10+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-aims-for-tlando-decision-for-testosterone-replacement-therapy-in-week-of-7-december-2020.--lipocine2024-11-12T09:33:40+00:00weekly0.6https://www.medthority.com/news/2020/12/less-than-1-of-patients-treated-with-calquence-discontinued-treatment-due-to-cardiac-adverse-events-in-pooled-analysis-of-chronic-lymphocytic-leukaemia-patients.--astrazeneca2024-10-24T09:00:25+00:00weekly0.6https://www.medthority.com/news/2020/12/bms-presents-data-evaluating-potential-of-liso-cel-across-leukemia-and-lymphomas-at-ash-2020/2024-11-12T13:29:59+00:00weekly0.6https://www.medthority.com/news/2020/12/lentiglobin-gene-therapy-for-sickle-cell-disease--results-in-complete-elimination-of-scd-related-severe-vaso-occlusive-events-in-group-c-of-phase-1ii-hgb-206-clinical-study-.--bluebird-bio-inc2024-11-12T13:45:31+00:00weekly0.6https://www.medthority.com/news/2020/12/bms-announced-data-at-ash-meeting-from-transcend-nhl-001-study--evaluating-liso-cel-in-relapsed-or-refractory-mantle-cell-lymphoma/2024-11-12T09:26:41+00:00weekly0.6https://www.medthority.com/news/2020/12/bms-presents-analyses-from-pivotal-quazar-aml-001-study-of-onureg--in-adults-with-acute-myeloid-leukemia-in-first-remission/2024-11-07T15:35:34+00:00weekly0.6https://www.medthority.com/news/2020/12/aldeyra-announces-first-patient-enrolled-in-the-phase-iii-tranquility-trial-of-reproxalap-for-the-treatment-of-dry-eye-disease/2024-11-12T13:30:10+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-galactic-hf-trial-of-amg-423-shows-impact-of-treatment-in-heart-failure.--cytokinetics2021-12-20T17:31:23+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-accepts-filing-of-nucala-in-chronic-rhinosinusitis-with-nasal-polyps.--gsk2024-10-24T09:00:42+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-investigational-stamp-inhibitor-asciminib-shows-superior-major-molecular-response-rate-to-bosulif-in-chronic-myeloid-leukemia-trial/2024-10-24T09:01:01+00:00weekly0.6https://www.medthority.com/news/2020/12/safety-and-efficacy-of-the-chadox1-ncov-19-vaccine-azd-1222-against-sars-cov-2-an-interim-analysis-offour-randomised-controlled-trials-in-brazil-south-africa-and-the-uk.-astrazeneca2021-12-20T17:31:23+00:00weekly0.6https://www.medthority.com/news/2020/12/enhertu-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer.--astrazeneca--daiichi-sankyo2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/12/sobi-files-maa-in-china-for-emapalumab-for-treatment-of-adult-and-paediatric-newborn-and-older-patients-with-primary-hemophagocytic-lymphohistiocytosis/2024-11-07T15:36:11+00:00weekly0.6https://www.medthority.com/news/2020/12/ema-accepts-maa-for-maralixibat-for-the-treatment-of-patients-with-progressive-familial-intrahepatic-cholestasis-type-2-.-mirum-pharma2024-11-07T15:36:31+00:00weekly0.6https://www.medthority.com/news/2020/12/albireo-submits-nda-to-fda-and-maa-to-ema-seeking-approval-of-odevixibat-for-the-treatment-of-patients-with-progressive-familial-intrahepatic-cholestasis-/2024-11-12T13:30:27+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iiib-trial-of-rinvoq-shows-superiority-to-dupilumab-in-atopic-dermatitis.--abbvie2021-12-20T17:29:32+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-trial-of-bnt-162b2-in-covid-19-published-in-nejm.--pfizer--biontech2021-12-20T17:32:32+00:00weekly0.6https://www.medthority.com/news/2020/12/mycovia-pharmaceuticals-announces-publication-of-positive-study-results-ofoteseconazole-for-the-treatment-of-acute-vulvovaginal-candidiasis/2024-11-07T15:37:00+00:00weekly0.6https://www.medthority.com/news/2020/12/sobi-and-apellis-report-positive-top-line-results-at-48-weeks-from-the-phase-iii-pegasus-study-of-pegcetacoplan-in-paroxysmal-nocturnal-haemoglobinuria/2024-11-12T13:30:39+00:00weekly0.6https://www.medthority.com/news/2020/12/purnovate-llc-is-acquired-by-adial-pharma-and-with-it-ad-04-a-proposed-treatment-for-alcohol-dependence/2021-09-24T07:12:58+00:00weekly0.6https://www.medthority.com/news/2020/12/aytu-bioscience-inc.-to-acquire-neos-therapeutics2021-09-24T07:12:58+00:00weekly0.6https://www.medthority.com/news/2020/12/gilead-sciences-acquires-myr-gmbh-and-with-it--hepcludex-a-eu-approved-treatment-for-hepatitis-d/2021-09-24T07:12:58+00:00weekly0.6https://www.medthority.com/news/2020/12/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-program-to-improve-immune-response-in-the-elderly/2024-10-22T11:33:46+00:00weekly0.6https://www.medthority.com/news/2020/12/pfizer--biontech-receive-fda-advisory-committee-vote-supporting-potential-first-emergency-use-authorization-for-vaccine-bnt162b2-to-combat-covid-19-in-the-u.s2021-12-20T17:31:23+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-adopts-positive-opinion-for-doptelet-to-treat-primary-chronic-immune-thrombocytopenia--in-adult-patients-who-are-refractory-to-other-treatment.--dova-pharmasobi2024-11-07T15:42:35+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-recommends-approval-of-inrebic-to-treat--disease-related-splenomegaly-enlarged-spleen-or-symptoms-of-myelofibrosis.--bms2024-10-22T11:34:01+00:00weekly0.6https://www.medthority.com/news/2020/12/gilead-advances-new-data-from-phase-iii-ascent-trial-of-trodelvy-in-metastatic-triple-negative-breast-cancer/2021-12-20T17:29:32+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-heplisav-b-for-the-active-immunization-against-hepatitis-b-virus-infection.--dynavax-technologies2021-12-20T17:33:27+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-under-exceptional-circumstances-for-lumoxiti-for-the-treatment-of-relapsed-or-refractory-hairy-cell-leukaemia.-astrazeneca2024-11-07T15:37:20+00:00weekly0.6https://www.medthority.com/news/2020/12/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca/2024-11-12T13:39:52+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-tukysa--trastuzumab--capecitabine-to-treat-her2-positive-locally-advanced-or-metastatic-breast-cancer.--seagen-inc2024-10-22T11:34:24+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-sibnayal-for-treatment-of-distal-renal-tubular-acidosis.---advicenne2024-10-24T09:02:24+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-rukobia-for-the-treatment-of-hiv-1-infection.--viiv-healthcare2021-12-20T17:31:24+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-conditional-approval-for-retsevmo-for-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-ret-fusion-positive-thyroid-cancer-and-ret-mutant-medullary-thyroid-cancer.--eli-lilly2024-10-24T10:59:36+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-recommends-approval-of-rinvoq-for-psoriatic-arthritis-and-ankylosing-spondylitis.--abbvie2024-10-22T11:34:44+00:00weekly0.6https://www.medthority.com/news/2020/12/pfizer-and-biontech-announce--first-authorization-in-the-u.s.-of--bnt162b2-vaccine-to-prevent-covid-192021-12-20T17:32:30+00:00weekly0.6https://www.medthority.com/news/2020/12/boehringer-acquires-nbe-therapeutics-and-with-it-nbe-002-in-studies-for-triple-negative-breast-cancer/2021-09-24T07:12:57+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-enhurtu-to-treat-metastatic-her2-positive-breast-cancer.---astrazeneca--daichi-sankyo2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-yuflyma-an-adalimumab-biosimilar.--celltrion2024-11-12T10:39:16+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-provides-tentative-approval-of-tlando-to-treat-testosterone-deficiency.--lipocine-inc2024-11-12T09:18:21+00:00weekly0.6https://www.medthority.com/news/2020/12/results-of-phase-iii-trial-of--olumiant--veklury-in-covid-19-published-in-nejm.--eli-lilly-and-incyte2021-12-20T17:32:30+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-contessa-study-of-tesetaxel-meets-primary-endpoint-in--metastatic-breast-cancer.--odonate-therapeutics2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-recommends--a-change-to-the-marketing-authorisation-for-veklury-a-treatment-for-covid--19.---gilead-sciences2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/12/astrazeneca-to-acquire-alexion/2021-09-24T07:12:56+00:00weekly0.6https://www.medthority.com/news/2020/12/lilly-presents-positive-primary-outcome-data-from-monarche-trial-that-builds-on-previous-definitive-analysis-for-verzenio--endocrine-therapy/2021-12-20T17:29:31+00:00weekly0.6https://www.medthority.com/news/2020/12/kisqali-data-demonstrate-superior-benefit-across-main-intrinsic-subtypes-in-metastatic-breast-cancer.--novartis2021-12-20T17:29:31+00:00weekly0.6https://www.medthority.com/news/2020/12/kisqali--endocrine-therapy-demonstrates-nearly-five-years-median-overall-survival-in-metastatic-her2--breast-cancer.--novartis2021-12-20T17:29:32+00:00weekly0.6https://www.medthority.com/news/2020/12/combined-data-from-phase-iii-studies-of-imbruvica-shows-efficacy-and-safety-in-high-risk-previously-untreated-chronic-lymphocytic-leukemia-and-real-world-data-indicating-low-biomarker-testing-rates-.-abbvie2024-11-07T15:35:53+00:00weekly0.6https://www.medthority.com/news/2020/12/chimerix-announces-fda-acceptance-of-an-nda-for-brincidofovir-as-a-medical-countermeasure-for-smallpox/2024-10-24T09:19:55+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-issues-complete-response-letter-for-furoscix--a-treatment-for-edema-or-fluid-overload-in-patients-with-heart-failure.-sc-pharmaceuticals2021-09-24T07:12:56+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-bavencio-to-treat--locally-advanced-or-metastatic-urothelial-carcinoma-bladder-cancer.-merck-kgaa--pfizer2024-11-12T09:18:34+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-provides-update-on-ruxcovid-study-of-ruxolitinib-for-hospitalized-patients-with-covid-19/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2020/12/trixeo-aerosphere-approved-in-the-eu-for-maintenance-treatment-of-copd.-astrazeneca2024-10-24T09:20:10+00:00weekly0.6https://www.medthority.com/news/2020/12/nice-reverses-final-decision-now-recommending-use-of-aimovig-for-migraine-treatment.--novartis2021-12-20T17:32:30+00:00weekly0.6https://www.medthority.com/news/2020/12/eu-approves-leqvio-for-hypercholesterolemia.--novartis2024-11-12T09:22:59+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-ocrevus-shorter-2-hour-infusion-for-relapsing-and-primary-progressive-multiple-sclerosis---genentechroche/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2020/12/allarity-therapeutics-as-expands-its-stenoparib-license-rights-to-include-anti-viral-uses/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto-to-treat-patients-with-hfpef/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2020/12/european-commission-grants-conditional-approval-to-tecartus-for-relapsed-or-refractory-mantle-cell-lymphoma.-kitegilead2024-11-12T13:26:12+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-positive-for-keytruda--as-first-line-treatment-in-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-colorectal-cancer.--merck-inc2024-10-24T13:14:46+00:00weekly0.6https://www.medthority.com/news/2020/12/lenvima--keytruda-demonstrated-in-keynote-755-phase-iii-study-statistically-significant-improvement-in-os-pfs-and-orr-v.-chemotherapy-inadvanced-endometrial-cancer.-merck-inc.--eisai-2024-11-12T10:07:20+00:00weekly0.6https://www.medthority.com/news/2020/12/novo-nordisk-to-enter-phase-iii-development-in-alzheimers-disease-with-oral-semaglutide/2024-11-12T10:07:32+00:00weekly0.6https://www.medthority.com/news/2020/12/eyenovia-inc.-announces-first-patient-enrolled-in-phase-iii-study-of-microline-for-presbyopia2024-10-24T09:23:01+00:00weekly0.6https://www.medthority.com/news/2020/12/curevac-n.v.-commences-global-pivotal-phase-iibiii-trial-for-covid-19-vaccine-candidate-cvncov2021-12-20T17:33:21+00:00weekly0.6https://www.medthority.com/news/2020/12/amgen-submits-sotorasib-nda-to-the-fda-for-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation/2021-12-20T17:30:45+00:00weekly0.6https://www.medthority.com/news/2020/12/topiramate-oral-solution-is-accepted-for-filing-by-the-fda-for-seizures-and-for-migraine--prevention/2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2020/12/blueprint-medicines-submits-supplemental-nda-to-the-fda-for-ayvakit-for-the-treatment-of-advanced-systemic-mastocytosis/2024-10-24T13:15:02+00:00weekly0.6https://www.medthority.com/news/2020/12/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca/2024-10-24T09:22:47+00:00weekly0.6https://www.medthority.com/news/2020/12/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer/2021-12-20T17:30:06+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-benlysta-for-lupus-nephritis.--glaxosmithkline2024-10-24T13:15:28+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-labeling-update-for-abbotts-heartmate-3-heart-pump-for-use-in-pediatric-patients/2021-12-20T17:30:48+00:00weekly0.6https://www.medthority.com/news/2020/12/ultragenyx-and-mereo-biopharma-announce-collaboration-and-license-agreement-for-setrusumab-in-osteogenesis-imperfecta/2022-01-10T09:53:48+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-amgens-riabni-rituximab-arrx-a-biosimilar-to-rituxan/2024-11-12T13:25:58+00:00weekly0.6https://www.medthority.com/news/2020/12/moderna-receives-fda-advisory-committee-vote-supporting-emergency-use-for-modernas-vaccine-mrna-1273-against-covid-19-in-the-united-states/2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-reports-positive-topline-results-from-second-phase-iii-trial-of-beovu-in-patients-with-diabetic-macular-edema.----2024-10-24T09:20:26+00:00weekly0.6https://www.medthority.com/news/2020/12/imfinzi-recommended-for-approval-by-chmp-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer.--astrazeneca2021-12-20T17:30:47+00:00weekly0.6https://www.medthority.com/news/2020/12/dream-hf-phase-iii-trial-of-revascor-shows-impact-on-mortality-in-chronic-heart-failure.--mesoblast2021-12-20T17:30:45+00:00weekly0.6https://www.medthority.com/news/2020/12/chmp-recommends-approval-of-additional-indication-for-plavix-in-ischemic-attack.--sanofi2024-10-24T09:20:43+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-accepts-filing-of-tak-721-for-eosinophilic-esophagitis.--takeda2024-10-24T09:22:36+00:00weekly0.6https://www.medthority.com/news/2020/12/lilly-announces-agreement-to-acquire-prevail-therapeutics-and-its-gene-therapies/2021-09-24T07:12:56+00:00weekly0.6https://www.medthority.com/news/2020/12/gensight-biologics-announces-publication-of-results-from-lumevoq-reverse-pivotal-phase-iii-trial-in-science-translational-medicine/2024-11-12T10:39:29+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-orgovyx-for-prostate-cancer.--myovant-sciences2025-01-31T11:37:18+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-approves-xpovio-plus-velcade-for-multiple-myeloma.--karyopharm-therapeutics2021-12-20T17:30:46+00:00weekly0.6https://www.medthority.com/news/2020/12/eusa-pharma-announces-first-patient-enrolled-in-phase-iii-trial-investigating-siltuximab-in-hospitalised-patients-with-covid-19--or-acute-respiratory-distress-syndrome-ards/2024-11-12T09:44:00+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-issues-complete-response-to-filing-of-leqvio-for-hyperlipidemia.--novartis2024-10-24T10:59:45+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-grants-emergency-use-authorisation-for-mrna-1273-for-covid-19.--moderna2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-grants-supplemental-approval-for-iclusig-in-cp-chronic-myeloid-leukemia.--takeda2024-11-12T13:42:45+00:00weekly0.6https://www.medthority.com/news/2020/12/lilly-to-begin-pragmatic-study-of-neutralizing-antibody-bamlanivimab-ly-cov555-for-covid-19-in-new-mexico/2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/12/novartis-acquires-cadent-therapeutics-and-two-new-clinical-stage-neuroscience-programs/2021-09-24T07:12:54+00:00weekly0.6https://www.medthority.com/news/2020/12/tagrisso-approved-in-the-us-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer.--astrazeneca2024-10-24T13:16:03+00:00weekly0.6https://www.medthority.com/news/2020/12/faricimab-meets-primary-endpoint-and-shows-strong-durability-across-two--phase-iii-studies-yosemite-and-rhine-for-diabetic-macular-edema.--genentechroche2024-10-24T10:59:54+00:00weekly0.6https://www.medthority.com/news/2020/12/viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-vocabria--rekambys--edurant-in-europe/2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/12/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/2021-12-20T17:32:52+00:00weekly0.6https://www.medthority.com/news/2020/12/application-submission-for-jzp-458-for-the-treatment-of-acute-lymphoblastic-leukemia-or-lymphoblastic-lymphoma.--jazzpharmaceuticals2024-11-12T09:44:16+00:00weekly0.6https://www.medthority.com/news/2020/12/eu-approves-new-intramuscular-injection-of-plegridy-for-multiple-sclerosis.--biogen2021-12-20T17:30:30+00:00weekly0.6https://www.medthority.com/news/2020/12/eu-chmp-recommends-approval-of-bnt-162b2-for-covid-19.--pfizer--biontech-2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-data-for-epidiolex-in-tuberous-sclerosis-complex-published-in-jama-neurology.--gw-pharma2024-11-12T09:44:45+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-recovery-study-of-tnx-102-sl-fails-to-meet-significance-in-ptsd.--tonix-pharma2024-11-12T09:54:50+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-ariel4-study-of-rubraca-meets-primary-endpoint-in-relapsed-ovarian-cancer.--clovis-oncology2021-12-20T17:30:46+00:00weekly0.6https://www.medthority.com/news/2020/12/update-on-source-phase-iii-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroid-dependent-asthma.--astrazeneca--amgen2024-11-12T09:55:02+00:00weekly0.6https://www.medthority.com/news/2020/12/chemocentryx-and-vfmcrp-provide-results-from-accolade-trial-of-avacopan-in-c3-glomerulopathy-including-improved-estimated-glomerular-filtration-rate-egfr/2022-01-10T10:30:49+00:00weekly0.6https://www.medthority.com/news/2020/12/amgen-submits-sotorasib-maa-to-the-european-medicines-agency-for-treatment-of-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-nsclc/2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2020/12/health-canada-approves-micra-av-pacemaker-for-av-block.--medtronic2024-11-12T09:55:12+00:00weekly0.6https://www.medthority.com/news/2020/12/study-of-nerivio-in-adolescents-with-migraine-published-in-headache-journal.--theranica2021-12-20T17:30:46+00:00weekly0.6https://www.medthority.com/news/2020/12/health-canada-approves-ragwitek-for-ragweed-pollen-allergies.--alk2024-11-12T11:33:49+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iii-dom-innate-trial-of-sgx-942-fails-to-meet-primary-endpoint-in-head-and-neck-cancer.--soligenix2024-11-12T13:46:35+00:00weekly0.6https://www.medthority.com/news/2020/12/ridgeback-biotherapeutics-lp-announces-the-approval-of-ebanga-for-ebola/2024-10-24T13:16:16+00:00weekly0.6https://www.medthority.com/news/2020/12/vertex-announces-fda-approvals-of-trikafta-symdeko--and-kalydeco--for-use-in-people-with-cystic-fibrosis-with-certain-rare-mutations/2024-10-24T13:16:30+00:00weekly0.6https://www.medthority.com/news/2020/12/uniqure-announces-clinical-update-on-hemophilia-b-gene-therapy-program-involving-phase-iii-hope-b-study-of-etranacogene-dezaparvovec-/2024-11-12T09:55:23+00:00weekly0.6https://www.medthority.com/news/2020/12/agios-to-focus-on-developing-and-commercializing-innovative-treatments-for-genetically-defined-diseases-and-sell-its-oncology-business-to-servier-for-up-to-$2-billion-plus-royalties/2021-09-24T07:12:53+00:00weekly0.6https://www.medthority.com/news/2020/12/sorrento-announces-emergency-use-authorization--application-to-the-fda-for-covi-stix-rapid-test-for-the-detection-of-sars-cov-2-viral-antigen/2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/12/keytruda--chemotherapy-filed-at-fda-supplemental-sbla-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-esophageal-and-gastroesophageal-junction-cancer/2021-12-20T17:32:52+00:00weekly0.6https://www.medthority.com/news/2020/12/bms-announces-update-on-phase-iii-checkmate-548-trial-evaluating-patients-with-newly-diagnosed-mgmt-methylated-glioblastoma-multiforme/2024-11-12T09:55:34+00:00weekly0.6https://www.medthority.com/news/2020/12/urovant-sciences-announces--fda-approval-of-gemtesa-75-mg-tablets-for-the-treatment-of-overactive-bladder.-2024-11-12T09:55:47+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-i-trial-results-with-ino-4800-in-covid-19-published-in-eclinicalmedicine.--inovio-2021-12-20T17:32:52+00:00weekly0.6https://www.medthority.com/news/2020/12/im-immunotech-announces-availability-of-the-mecfs-clinical-trial-of--ampligen-for-enrollment-to-covid-19-long-haulers/2021-12-20T17:30:07+00:00weekly0.6https://www.medthority.com/news/2020/12/rhythm-pharmaceuticals-announces-positive-topline-results-from-pivotal-phase-iii--trial-evaluating-setmelanotide-in-bardet-biedl-and-alstrom-syndromes/2022-01-11T20:44:07+00:00weekly0.6https://www.medthority.com/news/2020/12/spectrum-provides-poziotinib-update-after-successful-pre-nda-meeting-with-the-fda/2024-10-24T09:33:13+00:00weekly0.6https://www.medthority.com/news/2020/12/ce-mark-for-micromatrix-cytal-wound-matrix-and-cytal-burn-matrix-devices-for-burn-and-wound-management--acell-inc/2024-10-24T13:17:53+00:00weekly0.6https://www.medthority.com/news/2020/12/fibrogen-initiates-phase-iii-zephyrus-2--trial-of-pamrevlumab-for-the-treatment-of-idiopathic-pulmonary-fibrosis/2024-10-24T13:18:22+00:00weekly0.6https://www.medthority.com/news/2020/12/eu-approves-phesgo-for-her2-positive-breast-cancer.--roche2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/12/astellas-reports-xospata---azacitidine-did-not-meet-the-endpoint-of-overall-survival-in-newly-diagnosed-flt3-mutation-positive-acute-myeloid-leukemia/2024-11-12T11:34:06+00:00weekly0.6https://www.medthority.com/news/2020/12/ce-mark-for-blastx-antimicrobial--wound-gel.--next-science2024-10-24T13:48:18+00:00weekly0.6https://www.medthority.com/news/2020/12/athenex-announces-fda-approval-of-klisyri-for-the-treatment-of-actinic-keratosis-on-the-face-or-scalp/2024-11-12T09:56:24+00:00weekly0.6https://www.medthority.com/news/2020/12/health-canada-authorizes-moderna-covid-19-vaccine-mrna-1273-in-canada/2021-12-20T17:30:07+00:00weekly0.6https://www.medthority.com/news/2020/12/viatris-a-new-kind-of-healthcare-company/2021-09-24T07:12:52+00:00weekly0.6https://www.medthority.com/news/2020/12/lynparza-approved-in-japan-for-the-treatment-of-advanced-ovarian-prostate-and-pancreatic-cancers.--astrazeneca--merck-inc2024-11-12T10:06:37+00:00weekly0.6https://www.medthority.com/news/2020/12/korsuva-filed-with-fda-for-treating-moderate-to-severe-pruritus-in-hemodialysis-patients.--cara-therapeutics2024-10-24T13:48:34+00:00weekly0.6https://www.medthority.com/news/2020/12/ema-validates-filing-of-zeposia-for-ulcerative-colitis.--bristol-myers-squibb2021-09-24T07:12:52+00:00weekly0.6https://www.medthority.com/news/2020/12/health-canada-gives-trikafta-priority-review-for-cystic-fibrosis-in-people-ages-12-years-and-older.--vertex-pharma2024-11-12T10:48:36+00:00weekly0.6https://www.medthority.com/news/2020/12/jnj-6372-filed-with-ema-for-metastatic-egfr-non-small-cell-lung-cancer.--janssen2024-11-12T10:48:50+00:00weekly0.6https://www.medthority.com/news/2020/12/albireo-initiates-global-phase-iii-clinical-trial-of-odevixibat-in-alagille-syndrome/2024-11-12T10:06:52+00:00weekly0.6https://www.medthority.com/news/2020/12/new-england-journal-of-medicine-publishes-positive-initial-regeneron-antibody-cocktail-results-casirivimab-and-imdevimab-in--non-hospitalised-patients-with-covid-19/2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2020/12/novavax-announces-initiation-of-prevent-19-pivotal-phase-iii-efficacy-trial-of-covid-19-vaccine-nvx-cov2373-in-the-united-states-and-mexico/2021-12-20T17:30:07+00:00weekly0.6https://www.medthority.com/news/2020/12/myovant-sciences--pfizer-announce-collaboration-to-develop-and-commercialize-relugolix-in-oncology-and-womens-health/2021-09-24T07:12:51+00:00weekly0.6https://www.medthority.com/news/2020/12/update-on-remestemcel-l-in-ventilator-dependent-patients-with-moderate-to-severe-acute-respiratory-distress-syndrome-due-to-covid-19-infection-.-mesoblast--novartis2024-10-24T13:50:09+00:00weekly0.6https://www.medthority.com/news/2020/12/fda-accepts-alkermes-resubmission-of-nda-for-alks-3831-to-treat-adults-with-schizophrenia-and-adults-with-bipolar-i-disorder/2024-11-12T10:07:04+00:00weekly0.6https://www.medthority.com/news/2020/12/novo-nordisk-files-for-eu-regulatory-approval-of-once-weekly-semaglutide-2.0-mg-for-the-treatment-of-type-2-diabetes2024-11-12T10:49:02+00:00weekly0.6https://www.medthority.com/news/2020/12/osmotica-pharmaceuticals-plc-receives-complete-response-letter-from-fda-for-arbaclofen-er-tablets-to-treat-spasticity-resulting-from-multiple-sclerosis/2021-12-20T17:30:07+00:00weekly0.6https://www.medthority.com/news/2020/12/astrazenecas-covid-19-vaccineazd-1222-is-authorised-for-emergency-supply-in-the-uk/2021-12-20T17:30:46+00:00weekly0.6https://www.medthority.com/news/2020/12/bristol-myers-squibb-bms-statement-on-opdivo-small-cell-lung-cancer-u.s.-indication2021-12-20T17:30:47+00:00weekly0.6https://www.medthority.com/news/2020/12/vbl-therapeutics-announces-first-patient-enrolled--in-europe-in-the-oval-trial-of-vb-iii-to-treat-platinum-resistant-ovarian-cancer/2021-09-24T07:12:51+00:00weekly0.6https://www.medthority.com/news/2020/12/bridge-phase-iii-trial-of-prx-102-shows-benefit-in-renal-function-in-fabry-disease.--protalix-biotherapeutics-and-chiesi2024-11-12T10:49:13+00:00weekly0.6https://www.medthority.com/news/2020/12/phase-iiiiii-clinical-trial-of-regn-cov2-passed-futility-trial-in-covid-19.--regeneron-pharma2021-12-20T17:33:02+00:00weekly0.6https://www.medthority.com/news/2020/12/imbruvica-u.s.-prescribing-information-updated-to-include-long-term-data-for-waldenstroms-macroglobulinemia.-abbvie2021-12-20T17:30:47+00:00weekly0.6https://www.medthority.com/news/2021/1/the-chinese-government-has-approved-a-coronavirus-vaccine-from-sinopharm-/2021-12-20T17:30:07+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-grants-supplemental-approval-for-kineret-to-treat-deficiency-of-il-1-receptor-antagonist.-swedish-orphan-biovitrium2024-10-24T09:33:28+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-trial-of-mrna-1273-in-covid-19-published-in-nejm.--moderna2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2020/01/aprea-therapeutics-announces-results-of-phase-iii-trial-of-eprenetapopt--azacitidine-in-tp53-mutant-myelodysplastic-syndromes.-2024-10-24T14:02:52+00:00weekly0.6https://www.medthority.com/news/2021/1/bristol-myers-squibb-statement-on-status-of-liso-cel-application-to-fdafor-large-b-cell-lymphoma/2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2021/1/opdivo-filing-at-ema-is-validated-for-combination-with-chemotherapy-for-first-line-treatment-of-gastric-cancer-gastroesophageal-junction-cancer-or-esophageal-adenocarcinoma.--2024-11-12T10:07:48+00:00weekly0.6https://www.medthority.com/news/2021/1/sinopharm-receives-first-covid-19-vaccine-coronavac-conditional-approval-from-china-national-regulators/2021-12-20T17:30:06+00:00weekly0.6https://www.medthority.com/news/2021/1/genmab-announces-phase-iii-innovatv-301-trial-of-tisotumab-vedotin-in-recurrent-or-metastatic-cervical-cancer/2021-12-20T17:33:23+00:00weekly0.6https://www.medthority.com/news/2021/1/angelini-pharma-to-acquire-arvelle-therapeutics-and-with-it-cenobamate/2021-09-24T07:01:21+00:00weekly0.6https://www.medthority.com/news/2021/1/farxiga-granted-priority-review-in-the-us-for-the-treatment-of-patients-with-chronic-kidney-disease.--astrazeneca2021-12-20T17:30:45+00:00weekly0.6https://www.medthority.com/news/2021/1/china-regulator-approval-for-sulanda-in-non-pancreatic-extra-pancreatic-neuroendocrine-tumours-epnet-hutchison-china-meditech/2024-11-12T13:24:18+00:00weekly0.6https://www.medthority.com/news/2021/1/health-canada-grants-approval-of-cytosorb-for-treatment-of-covid-19.--cytosorbent2021-12-20T17:30:06+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-ultraviolet-clinical-trial-for-vt-1161-meets-primary-endpoints-for-vulvovaginal-candidiasis.--mycovia-pharma2024-10-24T13:15:45+00:00weekly0.6https://www.medthority.com/news/2021/1/skyrizi-phase-iii-results-demonstrate-improvements-in-disease-activity-across-joint-and-skin-symptoms-among-psoriatic-arthritis-patients.--abbvie2024-11-12T09:43:46+00:00weekly0.6https://www.medthority.com/news/2021/1/helios-a-phase-iii-study-of-vutrisiran-positive-for--for-the-treatment-of-transthyretin-mediated-attr-amyloidosis-with-polyneuropathy.-alnylam-pharma2024-11-12T13:23:37+00:00weekly0.6https://www.medthority.com/news/2021/1/european-commission-has-granted-a-conditional-marketing-authorization--for-covid-19-vaccine-moderna.--moderna-inc2021-12-20T17:30:48+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-advance-and-motivate-studies-of-skyrizi-show-efficacy-in-crohns-disease.--abbvie2024-10-24T14:03:04+00:00weekly0.6https://www.medthority.com/news/2021/1/aldeyra-therapeutics-inc.--announced-positive-top-line-symptom-redness-and-schirmers-test-results-from-the-run-in-cohort-of-the-phase-iii-tranquility-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease2024-10-24T14:03:17+00:00weekly0.6https://www.medthority.com/news/2021/1/nice-has-announced-it-does-not-recommend-use-of-opdivo-for-head-and-neck-cancer.--bms2021-12-20T17:32:53+00:00weekly0.6https://www.medthority.com/news/2021/1/uk-mhra-approves-temporary-use-of-covid-19-vaccine-for-use-in-the-uk.--moderna2021-12-20T17:30:48+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-snda-to-add-additional-prescribing-data-on-nubeqa-in-treatment-for-prostate-cancer.--bayer2025-01-31T11:36:37+00:00weekly0.6https://www.medthority.com/news/2021/1/neurana-pharmaceuticals-announces-first-patient-enrolled-in-phase-iii--resume-1-study-of-of-tolperisone-for--muscle-spasms-of-the-back/2024-11-12T11:00:04+00:00weekly0.6https://www.medthority.com/news/2021/1/chimerix-acquires-oncoceutics-inc.and-with-it-onc-201-currently-in-a-registrational-trial-to-treat-h3-k27m-mutant-glioma2021-09-24T07:01:20+00:00weekly0.6https://www.medthority.com/news/2021/1/-biogen-announces-first-patient-treated-in-respond-phase-iv-study-evaluating-spinraza-in-patients-treated-with-zolgensma-for-spinal-muscular-atrophy/2024-10-24T14:03:30+00:00weekly0.6https://www.medthority.com/news/2021/1/immunitybio-to-merge-with-nantkwest-inc/2021-09-24T07:01:20+00:00weekly0.6https://www.medthority.com/news/2021/1/biomarin-announces-positive-phase-iii--gener8-1-study-results-of-valoctocogene-roxaparvovec--gene-therapy-in-adults-with-severe-hemophilia-a/2021-12-20T17:30:46+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-accepts-supplemental-nda-for-jardiance-for-adults-with-heart-failure-with-reduced-ejection-fraction.--eli-lilly--boehringer2021-12-20T17:33:04+00:00weekly0.6https://www.medthority.com/news/2021/1/lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-ii-trial/2024-10-24T09:23:13+00:00weekly0.6https://www.medthority.com/news/2021/1/eu-approves-xofluza-for-influenza-in-patients-aged-12-years-and-above.--roche2024-11-12T11:00:24+00:00weekly0.6https://www.medthority.com/news/2021/1/bluebird-bio-to-separate-oncology-business-into-independent-company/2021-09-24T07:01:20+00:00weekly0.6https://www.medthority.com/news/2021/1/sanofi-to-acquire-kymab-adding-ky-1005-to-its-pipeline/2021-09-24T07:01:20+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-resp-system-external-device-for-remote-monitoring-and-analysing-lung-diseases.--strados-labs2024-11-12T11:00:14+00:00weekly0.6https://www.medthority.com/news/2021/1/ema-validates-maa-for-opdivo--as-adjuvant-treatment-for-resected-esophageal-or-gastroesophageal-junction-cancer-following-chemoradiotherapy.--bms2021-12-20T17:33:04+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-accepts-for-priority-review-the-bla-for-v114-investigational-15-valent-pneumococcal-conjugate-vaccine-for-use-in-adults-18-years-of-age-and-older.---merck-inc2021-12-20T17:30:06+00:00weekly0.6https://www.medthority.com/news/2021/1/roche-to-present-updated-data-confirming-tecentriq-in-combination-with-avastin-substantially-improves-overall-survival-in-people-with-the-most-common-form-of-liver-cancer/2024-11-12T09:41:12+00:00weekly0.6https://www.medthority.com/news/2021/1/in-vitro-study-shows-pfizer-biontech-se-covid-19-vaccine-elicits-antibodies-that-neutralise-covid-19-with-a-mutation-associated-with-rapid-transmission/2021-12-20T17:32:51+00:00weekly0.6https://www.medthority.com/news/2021/1/arcutis-initiates-pivotal-phase-iii-clinical-trials-for-topical-roflumilast-cream-arq-151-as-a-potential-treatment-for-atopic-dermatitis/2021-12-20T17:32:51+00:00weekly0.6https://www.medthority.com/news/2021/1/allergan-aesthetics-has-option-to-acquire-cypris-medical-and-xact-surgical-device/2021-09-24T07:01:20+00:00weekly0.6https://www.medthority.com/news/2021/1/china-national-medical-products-administration-approves-tislelizumab-in-combination-with-chemotherapy-in-first-line-advanced-squamous-non-small-cell-lung-cancer.--beigene-ltd2024-10-22T11:47:58+00:00weekly0.6https://www.medthority.com/news/2021/1/biomericas--covid-19-iggigm-rapid-test-receives-ce-mark-and-provides-results-in-15-minutes/2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-grants-priority-review-to-nda--for-finerenone-to-treat-patients-with-chronic-kidney-disease-and-type-2-diabetes.--bayer-healthcare2021-09-24T07:01:19+00:00weekly0.6https://www.medthority.com/news/2021/1/enrollment-halted-in-global-phase-iii-trial-of-ultomiris-in-covid-19.--alexion-pharmaceuticals2024-10-22T11:48:24+00:00weekly0.6https://www.medthority.com/news/2021/1/eu-gives-extended-approval-for-formulation-of-tivicay-for-paediatric-patients-with-hiv.--viiv-healthcare2024-10-22T11:48:37+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-indicates-phase-iii-marigold-study-of-oral-ganaxolone-supports-filing-in-cdkl5-deficiency-disorder.--marinus-pharma2024-11-08T11:00:31+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-clinical-trial-of-lumevoq-in-leber-hereditary-optic-neuropathy-published-in-ophthalmology-journal.--gensight-biologics2024-10-22T08:00:37+00:00weekly0.6https://www.medthority.com/news/2021/1/nida-funded-study-evaluating-extended-release-injectable-naltrexone--bupropion-for-the-treatment-of-methamphetamine-use-disorder--is-published-in-nejm.--alkermes2024-11-12T09:34:32+00:00weekly0.6https://www.medthority.com/news/2021/1/boston-scientific-launches-wavewriter-alpha-spinal-cord-stimulator-systems-in-the-us-to-manage--chronic-intractable-pain/2024-10-22T11:48:50+00:00weekly0.6https://www.medthority.com/news/2021/1/curevac-and-bayer-join-forces-on-covid-19-vaccine-candidate-cvncov/2021-12-20T17:31:06+00:00weekly0.6https://www.medthority.com/news/2021/1/imfinzi-approved-in-the-eu-and-uk-for-less-frequent-fixed-dose-use-in-unresectable-non-small-cell-lung-cancer.--astrazeneca2021-12-20T17:32:15+00:00weekly0.6https://www.medthority.com/news/2021/1/united-therapeutics-announces-nejm-publication-of-the-increase-study-for-tyvaso-in-pulmonary-hypertension-associated-with-interstitial-lung-disease/2024-11-12T13:42:07+00:00weekly0.6https://www.medthority.com/news/2021/1/xalkori-approved-by-the-fda-for-treatment-of-pediatric-and-young-adults-with-relapsedrefractory-alk-positive-anaplastic-large-cell-lymphoma.--pfizer2024-10-24T15:25:50+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-gives-regulatory-feedback-for-phase-iii-soloist-and-scored-trials-of-zynquista-in-cv-risk-with-type-2-diabetes.--lexicon-pharma2024-11-07T15:32:20+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-darzalex-faspro-combination-treatment-for--light-chain-al-amyloidosis.--janssen-biotech2024-10-24T09:43:58+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-expansion-of-indication-for-enhertu-in-metastatic-her2-positive-gastric-or-gastroesophageal--adenocarcinoma.--astrazenecadaiichi-sankyo2024-10-24T09:44:18+00:00weekly0.6https://www.medthority.com/news/2021/1/mateon-announces-positive-interim-results-from-arti-19-clinical-trial-evaluating-artiveda-as-a-covid-19-therapeutic/2021-12-20T17:30:16+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-grants-advaite-emergency-use-authorization-for-rapcov-rapid-covid-19-test/2021-12-20T17:31:15+00:00weekly0.6https://www.medthority.com/news/2021/1/novartis-expands-oncology-pipeline-with-in-licensing-of-tislelizumab-from-beigene/2024-11-12T11:00:34+00:00weekly0.6https://www.medthority.com/news/2021/1/inventiva-announces-design-of-phase-iii-clinical-trial-withlanifibranor-in-nash/2024-10-25T10:58:21+00:00weekly0.6https://www.medthority.com/news/2021/1/agios-presents-final-data-from-phase-iii--claridhy-study-of-tibsovo-in-patients-with-previously-treated-idh1-mutant-cholangiocarcinoma/2024-10-22T12:04:07+00:00weekly0.6https://www.medthority.com/news/2021/1/dbv-technologies-provides-update-oninvestigational-viaskin-peanut-for-children-ages-4-11-years/2024-10-24T09:45:07+00:00weekly0.6https://www.medthority.com/news/2021/1/biohaven-provides-an-update-on-phase-iiiii-trial-of-troriluzole-as-a-symptomatic-treatment-in-mild-to-moderate-alzheimers-disease.-2024-11-08T11:09:31+00:00weekly0.6https://www.medthority.com/news/2021/1/interim-results-of-a-phase-1iia-trial-of-jnj-78436735-covid-19-vaccine-published-in-nejm.--johnson--johnson2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/enhertu-approved-in-the-eu-for-the-treatment-of-her2-positive-metastatic-breast-cancer/2021-12-20T17:30:17+00:00weekly0.6https://www.medthority.com/news/2021/1/amryt-receives-reimbursement-approval-from-nice-for-myalepta-as-an-adjunct-to-diet-as-replacement-therapy-for-the-treatment-of-leptin-deficiency/2024-10-24T09:44:38+00:00weekly0.6https://www.medthority.com/news/2021/1/zydus-cadila-receives-approvals-from-the-dcgi-to-startphase-iii-clinical-trial-of-zycov-d---a-fully-indigenously-developed-vaccine/2024-10-22T12:03:16+00:00weekly0.6https://www.medthority.com/news/2021/1/doptelet-avatrombopag-approved-in-the-eu-for-treatment-of-primary-chronic-immune-thrombocytopenia--swedish-orphan-biovitrium/2024-10-22T12:03:31+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-accepts-sbla-for-opdivo--combined-with-chemotherapy-for-treatment-of-gastric-cancer-gastroesophageal-junction-cancer-and-esophageal-adenocarcinoma.--bms2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/novo-nordisk-files-for-fda-approval-of-once-weekly-semaglutide-2.0-mg-for-the-treatment-of-type-2-diabetes2024-10-24T09:44:54+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-grants-priority-review-to-genentechs-esbriet-for-unclassifiable-interstitial-lung-disease/2024-10-22T12:03:42+00:00weekly0.6https://www.medthority.com/news/2021/1/adding-tocilizumab-to-standard-care-does-not-improve-clinical-outcomes-for-people-with-severe-or-critical-covid-19-and-may-increase-mortality-risk.--genentechroche2021-12-20T17:32:16+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-accepts-sbla-for-opdivo-to-treatpatients-with-resected-esophageal-or-gastroesophageal-junction-gej-cancer-in-the-adjuvant-setting.---bms-2021-12-20T17:32:16+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-verquvo-for-heart-failure.--merck-inc2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/-eli-lillys-neutralizing-antibody-bamlanivimab-ly-cov555-prevented-covid-19-at-nursing-homes-in-the-blaze-2-trial-reducing-risk-by-up-to-80-percent-for-residents/2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/positive-results-from-benefit-study-for-monarch-platform-diagnostic-and-therapeutic-bronchoscopic-procedures.-auris-healthethiconjj2024-11-12T13:41:44+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-accepts-bla-for-retifanlimab-to-treat-squamous-cell-carcinoma-of-the-anal-canal-.--incyte2024-11-08T11:09:20+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-cabenuva-for-hiv.--viiv-healthcare2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-vercise-genus-deep-brain-stimulation-dbs-system-for-parkinsons-disease.--boston-scientific2024-11-07T15:32:45+00:00weekly0.6https://www.medthority.com/news/2021/1/japan-approves-hunterase-icv-for-mucopolysaccharidosis-type-ii-hunter-syndrome.--gc-pharma2024-11-08T11:09:47+00:00weekly0.6https://www.medthority.com/news/2021/1/eu-approves-elzonris-for-blastic-plasmacytoid-dendritic-cell-neoplasm.--menarini-group2024-11-08T11:10:01+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-lupkynis-to-treat-lupus-nephritis.--aurinia-pharmaceuticals-inc2024-10-22T12:03:54+00:00weekly0.6https://www.medthority.com/news/2021/1/fda-approves-opdivo-in-combination-with-cabometyx-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma.--bms2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/1/calquence-approved-in-japan-to-treatrelapsed-or-refractory-chronic-lymphocytic-leukaemia--including-small-lymphocytic-lymphoma-astrazeneca-/2024-10-25T10:58:33+00:00weekly0.6https://www.medthority.com/news/2021/1/calquence-met-primary-efficacy-endpoint-in-head-to-head-trial-against-ibrutinib-in-chronic-lymphocytic-leukaemia.--astrazeneca2024-11-08T11:10:12+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-tenaya-and-lucerne-studies-of-rg-7716-meet-primary-endpoints-in-age-related-macular-degeneration.--genentechroche2024-10-24T09:46:32+00:00weekly0.6https://www.medthority.com/news/2021/1/eu-approves-bavencio-for-locally-advanced-or-metastatic-urothelial-carcinoma.--merck-kgaa--pfizer2024-10-25T09:08:38+00:00weekly0.6https://www.medthority.com/news/2021/1/european-commission-approves-rinvoq-to-treat-active-psoriatic-arthritis-psa-and-active-ankylosing-spondylitis.--abbvie2024-10-22T12:04:23+00:00weekly0.6https://www.medthority.com/news/2021/1/marketing-approval-received-in-japan-for-alunbrig-in-the-treatment-of-alk-fusion-gene-positive-unresectable-advanced-or-recurrent-non-small-cell-lung-cancer.--takeda2024-10-24T09:46:43+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-blaze-1-trial-of-ly-cov555-and-ly-cov016-meets-primary-endpoint-in-covid-19.--eli-lilly2024-10-22T12:05:54+00:00weekly0.6https://www.medthority.com/news/2021/1/eu-approves-keytruda-for-metastatic-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-colorectal-cancer.--merck-inc2024-10-22T12:06:08+00:00weekly0.6https://www.medthority.com/news/2021/1/myovant-sciences-and-pfizer-announce-positive-one-year-data-from-phase-iii-spirit-extension-study-of-once-daily-relugolix-combination-therapy-in-women-with-endometriosis/2024-11-08T11:10:30+00:00weekly0.6https://www.medthority.com/news/2021/1/favourable-results-for-elocta-when-evaluating-treatment-options-for-haemophilia-a.--sobi2021-12-20T17:30:17+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-trial-of-regen-cov--shows-positive-data-in-prevention-of-covid-19.--regeneron-pharma2021-12-20T17:32:16+00:00weekly0.6https://www.medthority.com/news/2021/1/carbaglu-receives-fda-approval-for-a-new-indication-to-treat-acute-hyperammonemia-associated-with-propionic-acidemia-andmethylmalonic-acidemia.-recordati2024-10-24T15:06:54+00:00weekly0.6https://www.medthority.com/news/2021/1/oxbryta-filed-and-validated-by-maa-for-sickle-cell-disease.--global-blood-therapeutics2024-11-12T13:44:29+00:00weekly0.6https://www.medthority.com/news/2021/1/vaxart-announces-publication-of-a-peer-reviewed-journal-article-showing-the-potential-clinical-and-economic-value-of-a-norovirus-vaccine/2024-10-24T15:07:03+00:00weekly0.6https://www.medthority.com/news/2021/1/oral-surveillance-post-marketing-safety-study-of-xeljanz-fails-to-meet-endpoints-in-rheumatoid-arthritis.--pfizer2024-10-22T12:04:37+00:00weekly0.6https://www.medthority.com/news/2021/1/vertex-announces-fda-acceptance-of-supplemental-nda-for-trikafta-in-children-with-cystic-fibrosis-ages-6-through-11-with-certain-mutations/2024-11-08T11:10:38+00:00weekly0.6https://www.medthority.com/news/2021/1/agios-announces-phase-iii-activate-t-trial-of-mitapivat-achieved-primary-endpoint-for-pyruvate-kinase-deficiency-patients-who-are-regularly-transfused/2024-10-24T09:46:54+00:00weekly0.6https://www.medthority.com/news/2021/1/beigene-announces-positive-topline-results-for-global-phase-iii-trial-of-tislelizumab-in-esophageal-squamous-cell-carcinoma/2024-10-22T12:04:59+00:00weekly0.6https://www.medthority.com/news/2021/1/bat-1706-bevacizumab-biosimilar-filed-with-fda-for-colorectal-cancer-non-small-cell-lung-cancer-glioblastoma-renal-cell-carcinoma-and-cervical-cancer.--bio-thera-solutions2024-10-24T09:47:05+00:00weekly0.6https://www.medthority.com/news/2021/1/nda-submitted-to-pmda-in-japan-for-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency.--opko-health--pfizer-japan2024-11-08T11:32:54+00:00weekly0.6https://www.medthority.com/news/2021/1/novavax-covid-19-vaccine-nvx-cov2373-demonstrates-89.3-efficacy-in-uk-phase-iii-trial2021-12-20T17:31:10+00:00weekly0.6https://www.medthority.com/news/2021/1/tagrisso-data-from--adaura-phase-iii-trial-presented-at-wclc-showed-patients-with-epidermal-growth-factor-receptor-mutated-nsclc-egfr-maintained-their-quality-of-life-based-on-patient-reported-outcomes.-astrazeneca-2024-10-25T09:08:54+00:00weekly0.6https://www.medthority.com/news/2021/1/covid-19-vaccine-astrazeneca-formerly-azd-1222-recommended-for-use-in-the-eu.--astrazeneca2024-10-22T12:05:13+00:00weekly0.6https://www.medthority.com/news/2021/1/novartis-receives-positive-chmp-opinion-for-kesimpta-a-self-administered-treatment-for-adult-patients-with-relapsing-multiple-sclerosis/2021-12-20T17:30:17+00:00weekly0.6https://www.medthority.com/news/2021/1/recordati-licence-obtained-from-tolmar-international-for-eligard--treatment-of-advanced-prostate-cancer-in-eu-russia-and-turkey/2024-11-15T11:14:43+00:00weekly0.6https://www.medthority.com/news/2021/1/johnson--johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-iii-ensemble-trial/2021-12-20T17:31:10+00:00weekly0.6https://www.medthority.com/news/2021/1/chmp-recommends-once-weekly-sogroya--to-treat-growth-hormone-deficiency.--novo-nordisk2024-10-25T09:09:09+00:00weekly0.6https://www.medthority.com/news/2021/1/phase-iii-keynote-598-study-finds-keytruda--yervoy-inferior-to-keytruda-monotherapy-in-nsclc.--merck-inc2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/1/positive-chmp-opinion-for-pemigatinib-to-treat-unresectable-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fibroblast-growth-factor-receptor-2-fgfr2-fusion-or-rearrangement.--incyte2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/1/chmp-recommends-approval-of-ontozry-for-focal-onset-partial-onset-seizures.--sk-biopharmaceuticals2024-10-22T12:05:28+00:00weekly0.6https://www.medthority.com/news/2021/1/chmp-recommends-approval-of-nexpovio-for-multiple-myeloma.--karyopharm-therapeutics--2024-10-22T12:05:41+00:00weekly0.6https://www.medthority.com/news/2021/1/chmp-recommends-approval-of-vazkepa-for-the-risk-of-cardiovascular-events.--amarin-corp2024-10-24T09:47:29+00:00weekly0.6https://www.medthority.com/news/2021/2/sanofi-covid-19-vaccine-development-update/2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/2/merck-inc.-cancels-its-sars-cov-2covid-19-vaccine-candidates-v-590-and-v-591-and-focuses-on-mk-7110-and-mk-44822021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/biogen-and-eisai-co.-ltd.-announced-that-the-fda-has-extended-the-review-period-by-three-months-for-the-bla-for-aducanumab-an-investigational-treatment-for-alzheimers-disease.-2024-10-25T09:28:09+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-intramuscular-injection-route-of-administration-of-plegridy-for-multiple-sclerosis.--biogen2021-12-20T17:32:24+00:00weekly0.6https://www.medthority.com/news/2021/2/arcutis-announces-positive-topline-results-from-pivotal-dermis-1-and--2-phase-iii-trials-of-topical-roflumilast-cream-arq-151-in-plaque-psoriasis/2021-12-20T17:31:09+00:00weekly0.6https://www.medthority.com/news/2021/2/ema-starts-rolling-review-of-regn-cov2-combination-to-treat-and-prevent-covid-19.-regeneron--roche2024-10-22T12:06:23+00:00weekly0.6https://www.medthority.com/news/2021/2/chmp-recommends-byfavo-for-procedural-sedation-.--paion-ag2024-10-24T09:48:05+00:00weekly0.6https://www.medthority.com/news/2021/2/chmp-recommends-alymsys-a-bevacizumab-biosimilar.-mabxience-research-sl2024-11-08T11:39:21+00:00weekly0.6https://www.medthority.com/news/2021/2/chmp-recommends-oyavas-a-bevacizumab-biosimilar.--stada2024-10-22T12:23:15+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-accepts-snda-for-zeposia-in-ulcerative-colitis.--bms2021-12-20T17:31:09+00:00weekly0.6https://www.medthority.com/news/2021/2/horizon-therapeutics-acquires-viela-bio-inc/2021-09-24T07:01:15+00:00weekly0.6https://www.medthority.com/news/2021/2/travere-therapeutics-announces-achievement-of-interim-proteinuria-endpoint-in-the-phase-iii-duplex-study-of-sparsentan-for-focal-segmental-glomerulosclerosis/2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/2/durect-corporation-announces--fda-approval-of-posimir-for-post-surgical-pain-reduction-for-up-to-72-hours-following-arthroscopic-subacromial-decompression/2024-10-22T12:24:09+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-trimbow-for-asthma.--chiesi2024-10-24T09:47:40+00:00weekly0.6https://www.medthority.com/news/2021/2/bms-announces-positive-topline-results-from-second-pivotal-phase-iii-poetyk-pso-2-psoriasis-study-showing-superiority-of-deucravacitinib-over-placebo-and-otezla-/2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2021/2/merck-inc.-receives-positive-chmp-opinion-for-expanded-approval-of-keytruda-in-certain-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma2024-10-25T09:28:25+00:00weekly0.6https://www.medthority.com/news/2021/2/covid-19-vaccine-astrazeneca-confirms-100-protection-against-severe-disease-hospitalisation-and-death-in-the-primary-analysis-of-phase-iii-trials.-2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2021/2/clover--biopharmaceuticals-plans-to-initiate-a-global-phase-iiiii-efficacy-trial-of-its-protein-based-s-trimer-covid-19-vaccine-candidate-adjuvanted-with-dynavaxs-cpg-1018-plus-alum-in-the-first-half-of-2021/2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-supplemental-approval-for-gocovri-as-an-adjunctive-treatment-to-levodopacarbidopa-in-parkinsons-disease-patients-experiencing-off-episodes.-adamas-pharma2024-11-08T11:11:36+00:00weekly0.6https://www.medthority.com/news/2021/2/novavax-announces-start-of-rolling-review-by-multiple-regulatory-authorities-for--nvx-cov2373-its-covid-19-vaccine-/2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2021/2/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2021/2/johnson--johnson-submits-application-to-the-fda-for-emergency-use-authorization-of-its-single-shot-janssen-covid-19-vaccine-candidate/2021-12-20T17:32:24+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-tepmetko-to-treat-nsclc-with-mesenchymal-epithelial-transition-met-exon-14-skipping-alterations.-merck-kgaa2021-12-20T17:32:24+00:00weekly0.6https://www.medthority.com/news/2021/2/jazz-pharma-to-acquire-gw-pharma-its-proprietary-cannabinoid-product-platform/2021-09-24T07:01:14+00:00weekly0.6https://www.medthority.com/news/2021/2/the-wits-vaccines-and-infectious-diseases-analytics-research-unit-which-runs-the-chadox1-ncov-19-vaccine-trial-in-south-africa-has-announced-results/2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-breyanzi-to-treat--large-b-cell-lymphoma-including-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapy.--bms-2024-11-12T09:16:51+00:00weekly0.6https://www.medthority.com/news/2021/2/european-commission-approves-inrebic-to-treat-myelofibrosis.-bms2024-10-24T15:14:19+00:00weekly0.6https://www.medthority.com/news/2021/2/eton-pharmaceuticals--sells-its-neurology-portfolio-to-azurity--pharmaceuticals-namely-et-101-et-104-and-et-105-which-are-all-under-fda-review/2021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-expanded-use-of-spravato-in-depression.--janssen-pharma2024-10-24T09:47:53+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-rukobia-for-hiv-1-infection.--viiv-healthcare2021-12-20T17:32:24+00:00weekly0.6https://www.medthority.com/news/2021/2/opdivo-in-combination-with-cabometyx-shows-sustained-survival-and-response-rate-benefits-as-first-line-treatment-for-advanced-renal-cell-carcinoma-in-the-phase-iii-checkmate--9er-trial--bms--exelixis-inc/2024-10-22T12:39:13+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-breyanzi-lisocabtagene-maraleucel-a-new-car-t-cell-therapy-for-relapsed-or-refractory-large-b-cell-lymphoma.--bms2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/2/update-on-kestrel-phase-iii-trial-of-imfinzi-with-or-without-tremelimumab-in-the-1st-line-treatment-of-recurrent-or-metastatic-head-and-neck-cancer.--astrazeneca2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/2/boston-scientific-recalls-emblem-s-icd-subcutaneous-electrode-model-3501-due-to-risk-of-fractures/2024-10-22T12:24:39+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-ukoniq-to-treat-marginal-zone-lymphoma-and-follicular-lymphoma.---tg-therapeutics2024-10-22T12:38:52+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-data-update-for-coronavac-in-covid-19.--sinovac-biotech2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2021/2/adjuvant-treatment-with-opdivo-shows-statistically-significant-and-clinically-meaningful-improvement-in-disease-free-survival--for--muscle-invasive-urothelial-carcinoma-in-phase-iii-checkmate--274-trial.--bms2024-11-07T15:45:15+00:00weekly0.6https://www.medthority.com/news/2021/2/lineage-enters-into-exclusive-agreement-with-neurgain-technologies-to-evaluate-novel-delivery-system-for-opc-1-to-treat-spinal-cord-injury.-neurgain2024-10-22T07:44:56+00:00weekly0.6https://www.medthority.com/news/2021/2/sanofi-presents-at-eahad-amended-protocols-for-fitusiran-clinical-studies-for-haemophilia-a--b/2024-10-25T10:50:03+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-acis-study-of-erleada--and-zytiga-meets-primary-endpoint-in-prostate-cancer.--janssen-pharma2025-01-31T11:38:09+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-canstem303c-study-of-bbi-608--folfiri-fails-to-meet-endpoints-in-colorectal-cancer.--sumitomo-dainippon2024-10-22T07:45:09+00:00weekly0.6https://www.medthority.com/news/2021/2/-eli-lillys-bamlanivimab--administered-with-etesevimab-receives-fda-emergency-use-authorization-for-covid-19/2024-10-22T07:45:22+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-libtayo-as-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma.--sanofi2024-09-30T15:17:05+00:00weekly0.6https://www.medthority.com/news/2021/2/galapagos-and-gilead-discontinue-isabela-phase-iii-trials-of-ziritaxestat-in-ipf/2024-10-22T12:41:32+00:00weekly0.6https://www.medthority.com/news/2021/2/seagen--genmab-as-submit-tisotumab-vedotin-bla-to-the-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer/2024-10-22T12:39:24+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-advisory-committee-defers--decision-on-keytruda--to-treat-early-stage-neoadjuvant-triple-negative-breast-cancer.--merck-inc2021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-trial-of-revascor-shows-safety-and-efficacy-in-chronic-low-back-pain.--mesoblast2024-11-07T15:45:33+00:00weekly0.6https://www.medthority.com/news/2021/2/kitegilead-announces-new-zuma-1-cohort-analysis-of-prophylactic-corticosteroid-use-with-yescarta--for-relapsed-or-refractory-large-b-cell-lymphoma/2024-11-07T15:45:50+00:00weekly0.6https://www.medthority.com/news/2021/2/tocilizumab-reduces-deaths-in-patients-hospitalised-with-covid-19.--roche2021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/sandoz-announces-agreement-to-acquire-gsks-cephalosporin-antibiotics-business.-2021-09-24T07:01:12+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-evkeeza-to-treat-homozygous-familial-hypercholesterolemia.--regeneron2024-10-22T12:40:06+00:00weekly0.6https://www.medthority.com/news/2021/2/detailed-data-from-phase-iii-trials-of-rg-7716-shows-efficacy-in-dme-and-namd.--genentechroche2024-11-07T15:49:39+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-ogluo-for-hypoglycaemiadiabetes.--xeris-pharmaceuticals2024-10-22T07:45:35+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-tak-620-303-solstice-trial-of-tak-620-meets-primary-endpoint-in--cytomegalovirus-infection.--takeda-2024-10-22T12:40:19+00:00weekly0.6https://www.medthority.com/news/2021/2/cvncov-filed-with-eu-for-rolling-submission-in-covid-19.--curevac2021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/the-lancet-publishes-pivotal-libtayo-data-showing-extended-overall-survival-in-patients-with-first-line-advanced-nsclc-with-pd-l1-expression-of-greater-than-50.--sanofi--regeneron2021-12-20T17:31:32+00:00weekly0.6https://www.medthority.com/news/2021/2/us-federal-circuit-court-of-appeals-rules-in-favour-of-regeneron--sanofi-in-praluent-patent-litigation/2024-11-07T15:50:47+00:00weekly0.6https://www.medthority.com/news/2021/2/european-commission-approves-tukysa--trastuzumab-and-capecitabine-to-treat-her2-positive-locally-advanced-or-metastatic-breast-cancer.--seagen-inc.-2024-10-22T12:40:33+00:00weekly0.6https://www.medthority.com/news/2021/2/seagen--astellas-announce-padcev--pivotal-ev-201-trial-for-previously-treated-advanced-urothelial-cancer-for-those--ineligible-for-cisplatin-chemotherapy/2024-10-22T12:40:47+00:00weekly0.6https://www.medthority.com/news/2021/2/gamida-cell-presents-efficacy-and-safety-results-of-phase-iii-study-of-omidubicel-for-hematologic-malignancies-at-the-2021-tct-meetings-of-astct-and-cibmtr/2024-10-22T07:45:50+00:00weekly0.6https://www.medthority.com/news/2021/2/who-gives-covid-19-vaccine-astrazeneca-emergency-use-listing-for-covid-19.--astrazeneca2021-12-20T17:31:11+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-kixelle-for-type-2-diabetes.--biocon-biologics2024-10-25T10:50:19+00:00weekly0.6https://www.medthority.com/news/2021/2/eu-approves-yuflyma-for-multiple-chronic-inflammatory-diseases.--celltrion-healthcare2024-11-07T15:51:13+00:00weekly0.6https://www.medthority.com/news/2021/2/germany-europes-medtech-powerhouse-installs-first-versius-system.--cmr-surgical2024-10-25T10:52:55+00:00weekly0.6https://www.medthority.com/news/2021/2/jazz-pharmaceuticals-completes-rolling-submission-of-supplemental-nda-for-xywav-oral-solution-for-idiopathic-hypersomnia/2024-10-25T10:53:08+00:00weekly0.6https://www.medthority.com/news/2021/2/bluebird-bio-announces-temporary-suspension-on-phase-1ii-and-phase-iii-studies-of-lentiglobin-gene-therapy-for-sickle-cell-disease-bb1111/2024-11-12T13:43:52+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-grants-expanded-approval-for-entresto-in-heart-failure.--novartis2022-02-08T07:44:58+00:00weekly0.6https://www.medthority.com/news/2021/2/health-canada-approves-assure-tech-ecotest-covid-19-serological-rapid-test-for-covid-19.--verify-diagnostics2024-10-22T12:43:56+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-grants-sotorasib-priority-review--to-treat-patients-with-kras-g12c-metastatic-nsclc.--amgen2024-10-22T12:44:15+00:00weekly0.6https://www.medthority.com/news/2021/2/ultragenyx-announces--canadian-approval-of-dojolvi--to-treat-long-chain-fatty-acid-oxidation-disorders-in-adults-and-children/2024-10-24T15:14:44+00:00weekly0.6https://www.medthority.com/news/2021/2/olympia-phase-iii-trial-of-lynparza-for-the-treatment-of-brca-mutated-high-risk-her2-negative-early-breast-cancer-will-reported-early.--astrazeneca--merck-inc2024-10-22T07:48:22+00:00weekly0.6https://www.medthority.com/news/2021/2/beigene-announces-fda-acceptance-of-supplemental-nda-for-brukinsa-for-waldenstroms-macroglobulinemia/2024-10-22T07:48:51+00:00weekly0.6https://www.medthority.com/news/2021/2/sandoz-launches-hyrimoz-biosimilar-in-canada/2024-10-22T07:49:19+00:00weekly0.6https://www.medthority.com/news/2021/2/tirzepatide-significantly-reduced-a1c-and-body-weight-in-type-2-diabetes-in-two-phase-iii-trials-from-the-surpass-program.--eli-lilly2024-11-07T15:51:54+00:00weekly0.6https://www.medthority.com/news/2021/2/lilly-and-rigel-enter-strategic-collaboration-to-develop-ripk1-inhibitors-for-the--treatment-of-immunological-and-neurodegenerative-diseases/2024-10-22T12:44:29+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-liberty-1-and-liberty-2-studies-of-orgovyx-in-uterine-fibroids-published-in-nejm.--sumitovant-biopharma2024-10-22T12:45:22+00:00weekly0.6https://www.medthority.com/news/2021/2/pivotal-phase-iii-advocate-study-of-ccx-168-in-vasculitis-published-in-nejm.--chemocentryx2024-10-22T07:49:36+00:00weekly0.6https://www.medthority.com/news/2021/2/voluntary-withdrawal-of-imfinzi-indication-in-advanced-bladder-cancer-in-the-us.--astrazeneca2024-10-25T10:53:52+00:00weekly0.6https://www.medthority.com/news/2021/2/nmpa-regulatory-agency-for-china-granted-conditional-approval-for-toripalimab-to-treat-recurrent-or-metastatic-nasopharyngeal-carcinoma.--shanghai-junishi-biosciences2021-12-20T17:31:33+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-libtayo-to-treat-non-small-cell-lung-cancer.-regeneron--sanofi2021-12-20T17:31:33+00:00weekly0.6https://www.medthority.com/news/2021/2/sanofi-and-gsk-announced-the-initiation-of-a-new-phase-ii-study--to-select-the-most-appropriate-antigen-dosage-for-phase-iii-evaluation-of-their-adjuvanted-recombinant-protein-covid-19-vaccine/2021-12-20T17:31:16+00:00weekly0.6https://www.medthority.com/news/2021/2/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-lifecontinues-well-beyond-acute-disease-into-chronic-phase.--horizon-therapeutics2024-10-22T12:45:41+00:00weekly0.6https://www.medthority.com/news/2021/2/amgen-submits-supplemental-nda-for-otezla--for-adults-with-mild-to-moderate-plaque-psoriasis.-2024-10-22T07:46:56+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-u-accomplish-study-of-rinvoq-meets-primary-endpoint-in-ulcerative-colitus.--abbvie-2024-10-22T07:47:10+00:00weekly0.6https://www.medthority.com/news/2021/2/scpharmaceuticals-inc.-announces-results-of-type-a-end-of-review-meeting-with-fda-regarding-furoscix--a-treatment-for-edema-in-patients-with-heart-failure2024-10-22T12:45:56+00:00weekly0.6https://www.medthority.com/news/2021/2/otonomy-announces-top-line-results-for-the-phase-iii-clinical-trial-of-otividex-in-patients-with-menieres-disease/2024-10-24T15:26:00+00:00weekly0.6https://www.medthority.com/news/2021/2/incyte-announces-acceptance-and-priority-review-of-snda-for-jakafi-as-a-treatment-for-patients-with-chronic-graft-versus-host-disease/2024-10-22T07:47:27+00:00weekly0.6https://www.medthority.com/news/2021/2/adial-pharma-to-file-at-fda-for-fast-track-review--for-ad-04-a-treatment-of-alcohol-use-disorder.--2024-10-22T07:47:40+00:00weekly0.6https://www.medthority.com/news/2021/2/cassava-sciences-announces-positive-end-of-phase-ii-meeting-with-fda-and-outlines-pivotal-phase-iii-program-for-simufilam-in-alzheimers-disease/2024-10-25T10:58:50+00:00weekly0.6https://www.medthority.com/news/2021/2/mhra-uk-approves-tukysa-for-the-treatment-of-advanced-her2-positive-breast-cancer.--seagen2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2021/2/health-canada-approves-reblozyl-to-treat-transfusion-dependent-anemia-resulting-from--lowintermediate--risk-myelodysplastic-syndromes.---bms2024-10-22T07:48:10+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-accepts-nda-and-priority-review-for-jakavi-in-atopic-dermatitis.--incyte2024-10-22T07:46:05+00:00weekly0.6https://www.medthority.com/news/2021/2/phase-iii-pivotal-skylight-1-and-skylight-2-trials-of-esn-364-meet-endpoints-in-menopause.--astellas-pharma2024-10-25T10:53:22+00:00weekly0.6https://www.medthority.com/news/2021/2/cortexyme-provides-regulatory-update-on-development-program-for-atuzaginstat-in-alzheimers-disease/2024-10-25T10:53:38+00:00weekly0.6https://www.medthority.com/news/2021/2/pfizer-and-biontech-submit-covid-19-vaccine-stability-data-at-standard-freezer-temperature-to-the-fda/2024-10-22T07:46:18+00:00weekly0.6https://www.medthority.com/news/2021/2/medtronic-announces-voluntary-recall-of-unused-valiant-navion-thoracic-stent-graft-system/2024-10-24T15:15:03+00:00weekly0.6https://www.medthority.com/news/2021/2/clean3---first-of-its-kind-randomized-clinical-trial-published-in-the-lancet-infectious-diseases.--bd-becton-dickinson-and-company2024-11-07T15:51:25+00:00weekly0.6https://www.medthority.com/news/2021/1/gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-solid-cancers-at-asco-gastrointestinal-cancers-symposium/2024-11-07T15:32:33+00:00weekly0.6https://www.medthority.com/news/2021/2/pfizer-inc.--biontech-se-announced-that-the-first-participants-have-been-dosed-in-a-global-phase-iiiii-study--to--evaluate--the-pfizer-biontech-covid-19-vaccine-in-preventing-covid-19-in-pregnant-women-18-years-of-age-and-older-2021-12-20T17:31:17+00:00weekly0.6https://www.medthority.com/news/2021/2/ticovac-filed-with-fda-for-tick-borne-encephalitis.--pfizer2024-10-22T12:46:37+00:00weekly0.6https://www.medthority.com/news/2021/2/results-from-pivotal-phase-ii-karmma-study-of-idecabtagene-vicleucel-to-treat--refractory-multiple-myeloma-were-published-in-nejm.---bluebird-bio--bms2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/2/moderna-announces-it-has-shipped-variant-specific-vaccine-candidate-mrna-1273.351-to-nih-for-clinical-study2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/2/pfizer-and-biontech--se-initiate-a-study-as-part-of-broad-development-plan-to-evaluate-covid-19-booster-and-new-vaccine-variants/2021-12-20T17:31:14+00:00weekly0.6https://www.medthority.com/news/2021/2/merck-inc.-to-acquire-pandion-therapeutics-including-pt-101--for-the-potential-treatment-of-ulcerative-colitis-and-other-autoimmune-diseases2021-09-24T07:01:10+00:00weekly0.6https://www.medthority.com/news/2021/2/new-data-presented-at-actrims-forum-2021-indicate-mavenclad-treated---relapsing-multiple-sclerosis-patients-mount-protective-antibody-response-to-common-vaccines.-merck-kgaa2021-12-20T17:31:33+00:00weekly0.6https://www.medthority.com/news/2021/2/cosentyx-gains-eu-label-update-for-first-of-its-kind-maximise-data-in-axial-manifestations-of-psoriatic-arthritis.--novartis2024-10-22T07:57:31+00:00weekly0.6https://www.medthority.com/news/2021/2/positive-chmp-opinion-for-opdivo----cabometyx-as-first-line-treatment--advanced-renal-cell-carcinoma.--bms2024-10-22T09:49:39+00:00weekly0.6https://www.medthority.com/news/2021/2/chmp-positive-recommendation-for-dostarlimab-for-women-with-recurrent-or-advanced-endometrial-cancer.--gsk2024-10-24T15:16:31+00:00weekly0.6https://www.medthority.com/news/2021/2/gsk-announces-results--for-its-monoclonal-antibody-otilimab-for-the-treatment-of-hospitalised-adult-patients-with-covid-19/2021-12-20T17:31:33+00:00weekly0.6https://www.medthority.com/news/2021/2/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-a-broad-population-of-severe-asthma-patients.--astrazeneca--amgen2024-11-07T15:52:06+00:00weekly0.6https://www.medthority.com/news/2021/2/nice-recommends-kisqali-plus-fulvestrant--to-treat-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-her2-negative--breast-cancer.-novartis2024-10-22T10:04:34+00:00weekly0.6https://www.medthority.com/news/2021/2/sarepta-therapeutics-announces-fda-approval-of-amondys-45--injection-for-the-treatment-of-duchenne-muscular-dystrophy-in-patients-amenable-to-skipping-exon-45/2024-10-22T10:04:49+00:00weekly0.6https://www.medthority.com/news/2021/2/ema-validates-filing-of-incmga-0012-for-anal-carcinoma.--incyte2024-10-22T07:57:54+00:00weekly0.6https://www.medthority.com/news/2021/2/chmp-recommends-approval-of-orladeyo--in-hereditary-angioedema.--biocryst-pharmaceuticals2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/2/ema-accepts-filing-of-20vpnc-for-pneumococcal-disease.--pfizer2021-12-20T17:31:14+00:00weekly0.6https://www.medthority.com/news/2021/2/ema-validates-filing-of-somatrogon-to-treat-growth-hormone-deficiency.--pfizer2024-10-25T10:56:52+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-approves-nulibry-for-molybdenum-cofactor-deficiency-type-a.--origin-biosciences--bridge-bio2024-11-07T15:52:22+00:00weekly0.6https://www.medthority.com/news/2021/3/johnson--johnson-announces-first-single-shot-vaccine-for-covid-19-is-authorized-by-the-fda-for-emergency-use-/2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/brainstorm-announces-high-level-fda-feedback-on-nurown-als-clinical-development-program/2024-10-22T10:04:59+00:00weekly0.6https://www.medthority.com/news/2021/3/tricida-provides-update-on-fda-interactions-regarding-an-appeal-denied-letter-relating-to-veverimer--and--metabolic--acidosis/2024-10-22T10:05:10+00:00weekly0.6https://www.medthority.com/news/2021/3/cormedix-receives--a-complete-response-letter-from-the-fda--for-defencath/2024-10-22T10:05:27+00:00weekly0.6https://www.medthority.com/news/2021/3/athenex-receives-complete-response-letter--for-oral-paclitaxel--encequidar-for-the-treatment-of-metastatic-breast-cancer.--athenex-inc2024-10-24T15:19:15+00:00weekly0.6https://www.medthority.com/news/2021/3/the-fda-will-convene--an-advisory-committee-meeting-to-review--the-nda-for-roxadustat-to-treat-anemia-of-ckd.---astrazeneca--fibrogen-inc2024-11-12T10:08:59+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-pepaxto-for-patients-with-relapsed-or-refractory-multiple-myeloma.--oncopeptides-ab2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-azstarys-to-treat-attention-deficit-hyperactivity-disorder.---kem-pharma-inc2024-10-22T10:06:04+00:00weekly0.6https://www.medthority.com/news/2021/3/allarity-therapeutics-initiates-phase-ii-trial-of-ixempra-in-europe-for-the-treatment-of-metastatic-breast-cancer/2024-11-07T15:52:57+00:00weekly0.6https://www.medthority.com/news/2021/3/tirzepatide-achieved-superior-a1c-and-body-weight-reductions-across-all-three-doses-compared-to-injectable-semaglutide-in-adults-with-type-2-diabetes.--eli-lilly2024-11-12T10:08:35+00:00weekly0.6https://www.medthority.com/news/2021/3/bellicum-announces-first-reported-use-of-caspacide-safety-switch-to-mitigate-car-t-cell-toxicity/2024-10-24T15:25:17+00:00weekly0.6https://www.medthority.com/news/2021/3/vbl-therapeutics-announces-peer-reviewed-publication-of-positive-results-of-pre-specified-interim-analysis-of-oval-a-phase-iii-registration-enabling-study-of-vb-111-in-ovarian-cancer/2024-10-22T11:53:40+00:00weekly0.6https://www.medthority.com/news/2021/3/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/allergan-an-abbvie-company-submits-nda-for-investigational-agn-190584-for-the-treatment-of-presbyopia/2024-11-07T15:53:10+00:00weekly0.6https://www.medthority.com/news/2021/3/mallinckrodt-announces-new-england-journal-of-medicine-publication-of-results-from-its-hase-iii-confirm-study-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-hrs-1/2024-10-22T11:53:54+00:00weekly0.6https://www.medthority.com/news/2021/3/amgen-acquires-five-prime-therapeutics-and-with-it-bemarituzumab-a-proposed-treatment-for-gastric-cancer/2021-09-24T07:00:47+00:00weekly0.6https://www.medthority.com/news/2021/3/us-district-court-decision-favours-symbicort-in-patent-litigation.--astrazeneca2024-10-22T10:05:41+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-positive-for-evrysdi-for-the-treatment-of-5q-spinal-muscular-atrophy.--roche2024-10-22T07:59:32+00:00weekly0.6https://www.medthority.com/news/2021/3/biocryst-submits-maa-for-uk-approval-of-orladeyo-an-oral-once-daily-therapy-to-prevent-attacks-in-patients-with-hereditaryangioedema.--biocryst-pharma2024-10-22T07:59:53+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-abevmy-a-bevacizumab-biosimilar-to-treat-the-indications-of-avastinits-originator-drug-.-mylanviatris2024-10-22T10:05:52+00:00weekly0.6https://www.medthority.com/news/2021/3/baricitinib-is-first-jak-inhibitor-to-demonstrate-hair-regrowth-in-phase-iii-alopecia-areata-aa-trial--eli-lilly/2024-10-24T15:24:43+00:00weekly0.6https://www.medthority.com/news/2021/3/gw-pharmaceuticals-receives-positive-chmp-opinion-for-epidyolex-for-use-as-treatment-of-seizures-associated-with-tuberous-sclerosis-complex/2024-11-07T15:52:35+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-study-of-blincyto-in-acute-lymphoblastic-leukemia-published-in-journal-of-the-american-medical-association.--amgen2024-11-12T10:08:03+00:00weekly0.6https://www.medthority.com/news/2021/3/toripalimab-filed-with-fda-in-rolling-submission-for-nasopharyngeal-carcinoma.--junshi-biosciences-and-coherus-biosciences2021-12-20T17:31:14+00:00weekly0.6https://www.medthority.com/news/2021/3/daridorexant-filed-with-eu-for-insomnia.--idorsia2024-10-24T15:25:03+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-study-of-covaxin-reports-efficacy-of-80.6-in-covid-19.--ocugenbharat-biotech2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-expands-approval-of-lorbrena-as-first-line-treatment-of-metastatic-nsclc.--pfizer2024-11-12T10:08:21+00:00weekly0.6https://www.medthority.com/news/2021/3/merck-inc.-to-help-manufacture-johnson--johnsons-covid-19-vaccine.--2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/actemra-is-fda-approved-by-the-fda-for-slowing-the-rate-of-decline-in-pulmonary-function-in-adults-with-systemic-sclerosis-associated-interstitial-lung-disease/2024-11-07T15:53:22+00:00weekly0.6https://www.medthority.com/news/2021/3/bharat-biotech-announces-phase-iii-results-of-covaxin-indias-first-covid-19-vaccine-demonstrates-interim-clinical-efficacy-of-81/2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/takeda-secures-global-rights-tosoticlestat-for-the-treatment-of-developmental-and-epileptic-encephalopathies-including-dravet-syndrome-ds-and-lennox-gastaut-syndrome-/2024-10-22T11:54:21+00:00weekly0.6https://www.medthority.com/news/2021/3/beigene-announces-acceptance-of-a-supplemental-biologics-license-application-in-china-for-tislelizumab-in-second--or-third-line-nsclc/2021-12-20T17:31:15+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-approval-of-ly-cov555-and-ly-cov555--ly-cov016-in-covid-19.--eli-illy2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/biktarvy-shows--high-efficacy-and-durable-viral-suppression-in-treatment-naive-adults-with-hiv-1-in-four-year-data-presented-at-croi.--gilead-sciences2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-issues-emergency-use-authorisation-for-t-detect-covid-test-diagnostic-in-covid-19.--adaptive-biotechnologies2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iiib-atlas-2m-study-of-cabenuva--edurant-shows-continued-efficacy-to-week-96-in-hiv.--viiv-healthcare2024-10-22T11:54:36+00:00weekly0.6https://www.medthority.com/news/2021/3/health-canada-approves-brukinsa-to-treat-waldenstroms-macroglobulinemia.-beigene2021-12-20T17:31:14+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-reveal-1-trial-of-vgx-3100-meets-endpoint-in-hpv-1618-associated-cervical-squamous-intraepithelial-lesions.--inovio2024-10-22T07:58:38+00:00weekly0.6https://www.medthority.com/news/2021/3/merck-announced-the-withdrawal-of-the-u.s.-indication-for-keytruda--for-the-treatment-of-patients-with-metastatic-small-cell-lung-cancer2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/merck-kgaa-acquires-worldwide-rights-from-debiopharm-for-phase-iii-stage-xevinapant-to-treat-carcinoma-of-the-head-and-neck/2024-10-22T07:59:04+00:00weekly0.6https://www.medthority.com/news/2021/3/roche-announces-results-from-evrysdi--study-in-infants-with-type-1-spinal-muscular-atrophy-sma-published-in-nejm/2024-10-22T12:01:46+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-yescarta-to-treat-relapsed-or-refractory-follicular-lymphoma-after-two-lines-of-systemic-therapy.-kitegilead-sciences2024-10-24T15:25:29+00:00weekly0.6https://www.medthority.com/news/2021/3/opthea-finalizes-study-designs--for-the-phase-iii-shore-and-coast-pivotal-clinical-trials-of-opt-302-in-wet-age-related-macular-degeneration/2024-10-22T11:55:00+00:00weekly0.6https://www.medthority.com/news/2021/3/abbott-introduces-neurosphere-virtual-clinic-first-of-its-kind-remote-neuromodulation-patient-care-technology-in-the-u.s2024-10-22T11:55:15+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-accelerated-approval-for-tecentriq-voluntarily-withdrawn-in-metastatic-urothelial-carcinoma-.--genentechroche2024-11-12T10:09:16+00:00weekly0.6https://www.medthority.com/news/2021/3/vicineum-filed-with-eu-for-non-muscle-invasive-bladder-cancer.--sesen-bio2024-11-07T15:53:37+00:00weekly0.6https://www.medthority.com/news/2021/3/amryt-and-medison-pharma-ltd-sign-distribution-agreement-for-myalept-in-canada/2024-11-12T10:09:30+00:00weekly0.6https://www.medthority.com/news/2021/3/korsuva-filed-with-fda-and-given-priority-review-in-pruritus-in-hemodialysis-patients.--vifor-pharma-and-cara-therapeutics2024-10-22T11:55:25+00:00weekly0.6https://www.medthority.com/news/2021/3/novartis-provides-update-on-phase-iii-study-evaluating-canakinumab-as-second-or-third-line-treatment-in-combination-with-chemotherapy-in-nsclc/2021-12-20T17:32:33+00:00weekly0.6https://www.medthority.com/news/2021/3/gileads-lenacapavir-demonstrates-sustained-long-acting-efficacy-for-in-heavily-treated-people-with-multi-drug-resistant-hiv-1-infection/2021-12-20T17:31:34+00:00weekly0.6https://www.medthority.com/news/2021/3/ventana-alk-d5f3-cdx-assay-is-fda-approved--as-a-companion-diagnostic-for-nsclc-treatment-with-lorbrena.-roche2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-accepts-filing-of-daridorexant-for-insomnia.--idorsia2024-10-24T15:25:40+00:00weekly0.6https://www.medthority.com/news/2021/3/bluebird-bio-provides-updated-findings-from-reported-case-of-aml-in-lentiglobin-for-sickle-cell-disease-gene-therapy-program/2024-11-12T13:46:09+00:00weekly0.6https://www.medthority.com/news/2021/3/lupin-will-partner-with-endoceutics-to-commercialise-intrarosa-for-postmenopausal-vulvovaginal-atrophy-in-canada/2024-11-12T10:09:42+00:00weekly0.6https://www.medthority.com/news/2021/3/lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-iii-blaze-1-trial-for-early-covid-19/2021-12-20T17:31:20+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-requires-soleno-to-conduct-another-phase-iii-study-evaluating-dccr-in-prader-willi-syndrome.-2024-10-25T11:03:29+00:00weekly0.6https://www.medthority.com/news/2021/3/tga-approves-feraccru-to-treat-iron-deficiency-in-australia.--shield-therapeutics--norgine2024-10-22T11:55:40+00:00weekly0.6https://www.medthority.com/news/2021/3/acadia-pharmaceuticals-provides-regulatory-update-on-snda-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-dementia-related-psychosis/2024-10-22T12:01:33+00:00weekly0.6https://www.medthority.com/news/2021/3/takeda-to-acquire-maverick-therapeutics-and-with-it-mvc-101-for-the-treatment-of-egfr-expressing-solid-tumors/2021-09-24T07:00:46+00:00weekly0.6https://www.medthority.com/news/2021/3/vir-biotechnology--gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/2021-12-20T17:31:20+00:00weekly0.6https://www.medthority.com/news/2021/3/bristol-myers-squibb-statement-on-opdivo-for-hepatocellular-carcinoma-liver-cancer-u.s.-indication2024-10-25T11:03:43+00:00weekly0.6https://www.medthority.com/news/2021/3/novavax-confirms-high-levels-of-efficacy--of-nvx-cov2373-against-original-and-variant-covid-19-strains-in-united-kingdom-and-south-africa-trials/2021-12-20T17:31:20+00:00weekly0.6https://www.medthority.com/news/2021/3/first-patient-dosed-in-phase-iii-study-with--doptelet-for-treatment-of-itp-in-children.-sobi2024-11-12T10:09:55+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-gives-expanded-access-approval-for-lomecel-b-in-hypoplastic-left-heart-syndrome.--longeveron-inc2024-10-25T11:03:56+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-fotivda-for-advanced-renal-cell-carcinoma.--aveo-oncology2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/eu-grants-conditional-approval-for-single-dose-covid-19-vaccine-jnj-78436735.--johnson--johnson2024-10-22T12:02:05+00:00weekly0.6https://www.medthority.com/news/2021/3/aveo-oncology-announces-collaboration-with-bms-to-evaluate-fotivda--opdivo--in-pivotal-phase-iii-tinivo-2-trial-relapsed-renal-cell-carcinoma/2021-12-20T17:31:15+00:00weekly0.6https://www.medthority.com/news/2021/3/donanemab-slowed-alzheimers-disease-progression-in-phase-ii-trial-full-data-presented-at-adpd-2021-and-published-in-nejm.-eli-lilly2024-11-07T15:54:39+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-extends-review-date-for-belumosudil-for-the-treatment-of-chronic-graft-versus-host-disease.--kadmon-holdings2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/update-on-the-safety-of-covid-19-vaccine-astrazeneca/2024-10-22T12:02:27+00:00weekly0.6https://www.medthority.com/news/2021/3/roche-provides-update-on-the-phase-iii-remdacta-trial-of-actemraroactemra-plus-veklury-in-patients-with-severe-covid-19-pneumonia/2021-12-20T17:31:15+00:00weekly0.6https://www.medthority.com/news/2021/3/health-canada-approves--covid-19-astrazeneca-vaccine-to-prevent-covid-19/2024-10-22T12:02:40+00:00weekly0.6https://www.medthority.com/news/2021/3/gilead---merck-announce-agreement-to-jointly-develop-and-commercialize-long-acting-investigational-treatment-combinations-of-lenacapavir-and-islatravir-in-hiv/2024-10-24T08:39:59+00:00weekly0.6https://www.medthority.com/news/2021/3/superiority-of-orsiro-des-over-xience-des-confirmed-in-stemi-patients--according-to-new-follow-up-data-from-the-biostemi-trial.--biotronik2024-09-30T14:02:49+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-spr1nt-and-restore-study-data-on-zolgensma-shows-efficacy-and-safety-in-spinal-muscular-atrophy.--novartis2024-10-22T12:02:54+00:00weekly0.6https://www.medthority.com/news/2021/3/nefecon-filed-for-accelerated-approval-with-fda-for-primary-iga-nephropathy.--calliditas-therapeutics2024-11-07T15:54:51+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-trial-of-libtayo-halted-early-in-cervical-cancer-after-positive-report-from-idmc.--regeneron-pharmasanofi2024-10-24T08:41:21+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-kimyrsa-for-faster-infusion-against-acute-bacterial-skin-and-skin-structure-infections.--melinta-therapeutics2024-11-07T15:29:59+00:00weekly0.6https://www.medthority.com/news/2021/3/abbvie-announces-extension-of-review-for-supplemental-nda-of-upadacitinib-to-treat-psoriatic-arthritis/2024-10-25T09:03:50+00:00weekly0.6https://www.medthority.com/news/2021/3/keytruda-monotherapy-is-eu-approved-for-adult-and-pediatric-patients-aged-3-years-and-older-with--relapsed-or-refractory-classical-hodgkin-lymphoma.--merck-inc.-2024-10-25T09:07:57+00:00weekly0.6https://www.medthority.com/news/2021/3/merck-announces-filing-of-form-10-registration-statement-in-connection-with-planned-spinoff-of-organon--co/2024-10-22T09:47:04+00:00weekly0.6https://www.medthority.com/news/2021/3/interim-sagewho-recommendation-supporting-the-use-of-the-johnson--johnson-covid-19-vaccine/2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-edaravone-post-hoc-analysis-of-radicut-shows-risk-reduction-in-amyotrophic-lateral-sclerosis.--mitsubishi-tanabe2024-10-24T08:41:33+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-arise-3-trial-of-rgn-259-fails-to-meet-endpoint-in-dry-eye-syndrome.--regenerx-biopharma2024-10-22T09:47:20+00:00weekly0.6https://www.medthority.com/news/2021/3/real-world-evidence--from-israeli-ministry-of-health-analysis-confirms-high-effectiveness-of-the-pfizer-biontech-covid-19-vaccine/2024-10-22T09:48:19+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-discover-2a-study-of-tremfya-shows-efficacy-and-safety-at-two-years-in-psoriatic-arthritis.--janssen-pharma2024-10-25T09:08:17+00:00weekly0.6https://www.medthority.com/news/2021/3/uk-and-eu-regulatory-agencies-confirm-covid-19-vaccine-astrazeneca-is-safe-and-effective.-2024-10-24T08:41:45+00:00weekly0.6https://www.medthority.com/news/2021/3/ucb-gains-ce-mark-for-ava-connect-a-first-in-class-electromechanical-device-for-use-with-biologic-treatment-in-rheumatology-and-dermatology/2024-10-24T14:58:56+00:00weekly0.6https://www.medthority.com/news/2021/3/incyte-announces-results-from-the-phase-iii-devent-study-of-jakafi-for-covid-19-associated-acute-respiratory-distress-syndrome--patients-on-mechanical-ventilation/2024-10-25T10:54:38+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-accepts-nda-for-mavacamten--to-treat--symptomatic-obstructive-hypertrophic-cardiomyopathy.--bms-2024-10-24T08:42:02+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-keynote-775study-309-trial--of-keytruda--lenvima-meets-endpoints-in-endometrial-cancer.--merck-inc-and-eisai2024-11-07T15:55:04+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-illuminate-301-trial-of-imo-2125--yervoy-fails-to-meet-primary-endpoint-in-melanoma.--idera-pharma2024-10-25T10:55:30+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-arcalyst-for-recurrent-pericarditis.--kiniksa-pharma2024-10-24T15:15:41+00:00weekly0.6https://www.medthority.com/news/2021/3/srp-9003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2e-shows-sustained-expression-and-functional-improvements-2-years-after-administration.--sarepta2024-11-12T10:10:15+00:00weekly0.6https://www.medthority.com/news/2021/3/-jazz-pharmaceuticals-and-hypersomnia-foundation-launch-campaign-to-increase-understanding-and-awareness-of-idiopathic-hypersomnia/2024-11-12T10:10:30+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-ponvory-for-multiple-sclerosis.--janssen-pharma2024-10-22T09:48:31+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-study-of-bmn-111-shows-efficacy-maintained-in-2-years-of-treatment-for-achondroplasia.--biomarin-pharma2024-10-22T09:48:45+00:00weekly0.6https://www.medthority.com/news/2021/3/multi-centre-study-of-jatenzo-shows-treatment-is-effective-in-long-term-use-in-testosterone-deficiency.--clarus-therapeutics2024-11-12T10:10:41+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-ariel4-study-of-rubraca-shows-benefits-in-pfs-for-ovarian-cancer.--clovis-oncology2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/mirikizumab-met-the-primary-and-all-key-secondary-endpoints-in-lucent-1-phase-iii-induction-study-to-evaluate-the-efficacy-and-safety-of-mirikizumab-for--moderate-to-severe-ulcerative-colitis-/2024-10-22T09:42:54+00:00weekly0.6https://www.medthority.com/news/2021/3/fibrogen-initiates-second-phase-iii-study-of-pamrevlumab-to-treat--duchenne-muscular-dystrophy-/2024-10-22T09:46:44+00:00weekly0.6https://www.medthority.com/news/2021/3/lilly-presents-patient-reported-outcomes-from-the-positive-phase-iii-monarche-trial-for-verzenio-at-st.-gallen-virtual-congress-20212021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-kimyrsa-to-treat-acute-bacterial-skin-and-skin-structure-infections-absssi.--melinta-therapeutics2024-11-12T10:11:15+00:00weekly0.6https://www.medthority.com/news/2021/3/the-nejm-publishes-phase-iii-pegasus-study-results-comparing-pegcetacoplan-to-eculizumab-for-pnh.--sobi2024-10-22T09:43:26+00:00weekly0.6https://www.medthority.com/news/2021/3/bluebird-bio-presents-long-term-data-for-elivaldogene-autotemcel-eli-cel-lenti-d-gene-therapy-for-cerebral-adrenoleukodystrophy-cald/2024-10-22T09:43:38+00:00weekly0.6https://www.medthority.com/news/2021/3/mpowered-phase-iii-trial-of-mycapssa-shows-benefits-in-acromegaly.--chiasma-2024-11-07T15:55:20+00:00weekly0.6https://www.medthority.com/news/2021/3/azd-1222-us-phase-iii-trial-met-primary-efficacy-endpoint-in-preventing-covid-19-at-interim-analysis.--astrazeneca2021-12-20T17:31:14+00:00weekly0.6https://www.medthority.com/news/2021/3/odonate-therapeutics-announces-discontinuation-of-development-of-tesetaxel/2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-impower010-study-of-tecentriq-meets-primary-end-point-in-early-stage-nsclc.--genentechroche2021-12-20T17:31:35+00:00weekly0.6https://www.medthority.com/news/2021/3/novartis-announces-positive-result-of-phase-iii-study-with-radioligand-therapy-177lu-psma-617-in-patients-with-advanced-prostate-cancer.-2024-11-15T11:15:37+00:00weekly0.6https://www.medthority.com/news/2021/3/amryt-receives-positive-feedback-from-the-fda-on-the-path-forward-for-myalept-indication-for-partial-lipodystrophy/2024-10-22T09:48:56+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-supplemental-nda--for-exparel-for-postsurgical-local-analgesia-in-pediatric-patients.-pacira-biosciences2024-10-24T10:35:30+00:00weekly0.6https://www.medthority.com/news/2021/3/phase-iii-outcomes-trial-of-regen-cov-meets-primary-and-secondary-endpoints-in-covid-19.--regeneron-pharma2021-12-20T17:32:54+00:00weekly0.6https://www.medthority.com/news/2021/3/idmc-recommends-phase-iii-generation-hd1-study-of-ionis-httrx-halted-in-huntingtons-disease.--ionis-pharma2024-10-24T15:16:08+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-zegalogue-for-severe-hypoglycemia-in-pediatric-and-adult-patients-with-diabetes.--zealand-pharma2024-10-22T09:49:15+00:00weekly0.6https://www.medthority.com/news/2021/3/eyenovia-and-eversana-announce-partnership-to-support-the-launch-in-the-us-of-mydcombi-a-treatment-for-mydriasis-/2024-10-24T10:36:07+00:00weekly0.6https://www.medthority.com/news/2021/3/remitoro-intravenous-drip-infusion-is-approved-in-japan-for-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma.-eisai2024-10-24T10:36:22+00:00weekly0.6https://www.medthority.com/news/2021/3/incyte-announces-approval-of-pemazyre-in-japan-for-the-treatment--unresectable-biliary-tract-cancer-btc-with-a-fibroblast-growth-factor-receptor-2-fgfr2-fusion-gene.-2024-10-22T09:49:26+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-issues-refusal-to-file-for-label-expansion-of-once-weekly-ozempic-for-the-treatment-of-type-2-diabetes.--novo-nordisk2024-10-25T10:55:49+00:00weekly0.6https://www.medthority.com/news/2021/3/lenvima-approved-for-additional-indication-of-thymic-carcinoma-in-japan.-eisai2024-10-25T10:56:06+00:00weekly0.6https://www.medthority.com/news/2021/3/positive-results-from-phase-iii-linc-4-study-reinforce-the-efficacy-and-safety-of-isturisa-in-cushings-disease.--recordati2024-11-12T10:11:02+00:00weekly0.6https://www.medthority.com/news/2021/3/adults-with-obesity-treated-with-semaglutide-2.4-mg-achieved-and-maintained-a-significant-amount-of-weight-loss-in-a-68-week-trial.-novo-nordisk2021-12-20T17:30:26+00:00weekly0.6https://www.medthority.com/news/2021/3/insulets-omnipod-5-automated-insulin-delivery-system-improves-clinical-outcomes-in-type-1-diabetes2/2024-10-25T10:56:37+00:00weekly0.6https://www.medthority.com/news/2021/3/azd-1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy-for-prevention-of-covid-19.astrazeneca2021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2021/3/tga-approves-use-of-trikafta-to-treat-cystic-fibrosis--f508del-mutation-in-australia.---vertex2024-10-24T10:36:35+00:00weekly0.6https://www.medthority.com/news/2021/3/health-canada-approves-kesimpta-to-treat-relapsing-remitting-multiple-sclerosis.-novartis2021-12-20T17:31:33+00:00weekly0.6https://www.medthority.com/news/2021/3/ema-validates-maa-for-trodelvy-under-accelerated-review-in-triple-negative-breast-cancer.--gilead-sciences-2024-10-22T09:44:21+00:00weekly0.6https://www.medthority.com/news/2021/3/japans-mhlw-approves-breyanzi-a-new-car-t-cell-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-and-follicular-lymphoma.--bms-kk2024-10-22T09:44:32+00:00weekly0.6https://www.medthority.com/news/2021/3/european-medicines-agency-accepts-maa-for-enfortumab-vedotin--to-treat-locally-advanced-or-metastatic-urothelial-cancer.--astellas--seagen2024-10-22T07:53:20+00:00weekly0.6https://www.medthority.com/news/2021/3/sorrento-announces-updated-positive-results-of-phase-1b-study-of-covi-msc-for-treatment-of-icu-covid-19-ard-patients/2024-10-22T07:53:40+00:00weekly0.6https://www.medthority.com/news/2021/3/agios-shareholders-approve-sale-of-oncology-business-to-servier/2021-09-24T07:00:40+00:00weekly0.6https://www.medthority.com/news/2021/3/primary-results-of-phase-iiiii-relativity-047--trial-evaluating-the-fixed-dose--of-relatlimab-and-opdivo-for-metastatic-melanoma.--bms-2024-10-22T09:44:44+00:00weekly0.6https://www.medthority.com/news/2021/3/joint-fda-advisory-committee-votes-against-application-for-tanezumab-for-the-treatment-of-osteoarthritis-pain.--eli-lilly--pfizer2024-10-22T09:44:56+00:00weekly0.6https://www.medthority.com/news/2021/3/update-on-covid-19-variants-and-impact-on-bamlanivimab-distribution/2024-10-22T07:54:01+00:00weekly0.6https://www.medthority.com/news/2020/6/ferric-maltol-real-world-effectiveness-study-in-hospital-practice-fresh-is-published-in-bmj-open-gastro.--shield-therapeutics2024-10-22T09:45:48+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-copiktra-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukaemia--and-refractory-follicular-lymphoma/2024-10-25T09:03:35+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-richter-drovelis-a-new-combined-contraceptive.-gedeon-richter2024-11-07T15:50:59+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-ponvory-for-the-treatment-of-adult-patients-with-relapsing-multiple-sclerosis.-janssen-pharma2024-10-22T07:49:53+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-benlysta-to-treat-lupus-nephritis--glaxo-smith-kline/2024-10-22T09:46:02+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-abecma-the-first-anti-bcma-car-t-cell-therapy-for-relapsed-or-refractory-multiple-myeloma.--bms--bluebird-bio2024-10-22T09:46:16+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-approval-of-buvidal-slow-release-injection-for-opioid-dependence.--camurus2024-10-22T07:50:11+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-expanded-approval-for-saxenda-in-obesity.--novo-nordisk2024-10-22T07:50:59+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-recommends-extended-approval-of-tecentriq-for-metastatic-non-small-cell-lung-cancer-without-egfr-or-alk.--roche2024-10-22T09:46:32+00:00weekly0.6https://www.medthority.com/news/2021/3/fda-approves-harmony-transcatheter-pulmonary-valve-for-congenital-heart-disease.--medtronic2024-10-22T09:32:34+00:00weekly0.6https://www.medthority.com/news/2021/3/chmp-issues-advice-on-the-use-of-celltrions-regdanvimab-ct-p59-for-covid-19-patients-in-the-european-union/2024-10-22T07:51:28+00:00weekly0.6https://www.medthority.com/news/2021/3/ema-validates-maa-for-relugolix-for-the-treatment-of-advanced-prostate-cancer.--myovant-sciences2025-01-31T11:40:35+00:00weekly0.6https://www.medthority.com/news/2021/3/amryt-files-maa-at-ema-for-oleogel-s10-a-treatment-of-cutaneous-manifestations-of-junctional-and-dystrophic-epidermolysis-bullosa-/2021-12-20T17:30:26+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-accepts-abbvies-nda--for-atogepant-for-the-preventive-treatment-of-migraine.--abbvie2021-12-20T17:30:26+00:00weekly0.6https://www.medthority.com/news/2021/4/merck-inc.-receives-positive-chmp-opinion-for-updated-label-of-keytruda-to-include-results-of-phase-iii-keynote-361-trial-in-certain-adult-patients-with-locally-advanced-or-metastatic-urothelial--cancer.bladder-cancer2024-11-12T10:11:26+00:00weekly0.6https://www.medthority.com/news/2021/4/complete-response-letter-for-sbla-for-keytruda-in-high-risk-early-stage-triple-negative-breast-cancer-tnbc.--merck-inc2021-12-20T17:30:34+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-keytruda--platinum--and-fluoropyrimidine-based-chemotherapy-to-treat-locally-advanced-or-metastatic-esophageal-or-gastroesophageal-junction-carcinoma.--merck-inc2024-10-24T08:18:36+00:00weekly0.6https://www.medthority.com/news/2021/3/merckorganon-to-acquire-alydia-health-and-with-it-jade-system-for-prevention-of-post-partum-bleeding/2021-09-24T07:00:39+00:00weekly0.6https://www.medthority.com/news/2021/4/xience-stent-receives-european-ce-mark-for-one-month-dual-anti-platelet-therapy-dapt-for-high-bleeding-risk-patients.---abbott2024-09-30T14:03:37+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-extends-pdufa-date-for--review-of-rinvoq-in-the-treatment--of-atopic-dermatitis.--abbvie2024-10-22T12:56:07+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-extends-pdufa-date-for-review-of-baricitinib-for-the-treatment-of-atopic-dermatitis.---eli-lilly--incyte2021-12-20T17:30:32+00:00weekly0.6https://www.medthority.com/news/2021/4/fibrogen-announces-fda-advisory-committee-to-review-roxadustat-nda-tentatively-scheduled-for-july-15-2021-for-the-treatment-of-anemia-of-chronic-kidney-disease.--fibrogen2024-10-24T10:36:46+00:00weekly0.6https://www.medthority.com/news/2021/4/fibrogen-provides-additional-information-on-roxadustat-to-the-fda-relating-to-u.s.-primary-cardiovascular-safety-analyses2024-11-12T10:11:59+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approval-of-additional-indication-for-vyxeos-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients.--jazz-pharma2024-11-12T11:27:11+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-praluent-for-homozygous-familial-hypercholesterolemia.--regeneron2024-10-24T10:37:29+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-ii-trial-data-for-krystexxa-in-gout-published-in-arthritis--rheumatology-journal.--horizon-therapeutics2024-10-24T11:01:09+00:00weekly0.6https://www.medthority.com/news/2021/4/eu-approves-sc-version-of-tysabri-for-multiple-sclerosis.--biogen2024-10-22T12:56:39+00:00weekly0.6https://www.medthority.com/news/2021/4/skyrizi-filed-with-fda-and-eu-for-psoriatic-arthritis.--abbvie2024-11-12T11:27:23+00:00weekly0.6https://www.medthority.com/news/2021/4/delcath-systems-inc.-announces-positive-preliminary-results-from-phase-iii-focus-trial-of-hepzato-in-patients-with-metastatic-ocular-melanoma2024-11-12T11:27:35+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival.--gilead-sciences2024-10-22T12:56:51+00:00weekly0.6https://www.medthority.com/news/2021/4/nih--sponsored-trial-finds-eylea-reduced-vision-threatening-complications-by-68-after-two-years-in-diabetic-retinopathy-patients-.--regeneron--bayer2024-10-24T11:01:57+00:00weekly0.6https://www.medthority.com/news/2021/4/astrazenecas-covid-19-vaccine-ema-finds-possible-link-to-very-rare-cases-of-unusual-blood-clots-with-low-blood-platelets/2021-12-20T17:33:07+00:00weekly0.6https://www.medthority.com/news/2021/4/lilly-and-incyte-announce-results-from-the-phase-iii-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients/2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iii-checkmate--648-trial-of-opdivo-shows-survival-benefits-in-oesophageal-squamous-cell-carcinoma.--bms2021-12-20T17:33:07+00:00weekly0.6https://www.medthority.com/news/2021/4/keytruda-demonstrated-superior-disease-free-survival-in-keynote-564-compared-with-placebo-as-adjuvant-therapy-in-patients-with-renal-cell-carcinoma-following-surgery/2021-12-20T17:33:07+00:00weekly0.6https://www.medthority.com/news/2021/4/seagen--genmab-announce-fda-filing-acceptance-for-priority-review-of-tisotumab-vedotin-bla-for-patients-with-recurrent-or-metastatic-cervical-cancer/2021-12-20T17:33:07+00:00weekly0.6https://www.medthority.com/news/2021/4/pfizer-announces-extension-of-review-of-nda-for-abrocitinib-for-treatment-of-atopic-dermatitis-and-for-xeljanz-for-ankylosing-spondylitis/2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2021/4/new-real-world-observational-analysis-of-uptravi-underscores-the-importance-of-risk-assessment-for-treating-pulmonary-arterial-hypertension-patients.-johnson--johnson2024-10-22T12:57:28+00:00weekly0.6https://www.medthority.com/news/2021/4/positive-results-from-the-sutimlimab-pivotal-trial-for-people-with-cold-agglutinin-disease-published-in-new-england-journal-of-medicine.--sanofi2024-11-12T11:27:47+00:00weekly0.6https://www.medthority.com/news/2021/4/scilex-holding-sorrento-therapeutics-has-received-a-snda-approval-from-the-fda-for-ztlido-to-make-efficacy-labeling-change-with-clinical-data-for-post-herpetic-neuralgia/2024-11-12T11:27:58+00:00weekly0.6https://www.medthority.com/news/2021/4/provention-bio-provides-regulatory-update-on-bla-for--teplizumab-for-delay-or-prevention-of-type-1-diabetes-in-at-risk-individuals/2024-10-24T11:02:07+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iii-checkmate--816-study-of-opdivo--chemo-shows-positive-response-in-nsclc.--bms2024-10-22T12:57:42+00:00weekly0.6https://www.medthority.com/news/2021/4/hypothesis-for-rare-side-effect-linked-to-astrazeneca-vaccine/2024-10-22T12:58:29+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iii-chronos-3-trial-of-aliqopa-and-rituxan-in-non-hodgkins-lymphoma-published-in-the-lancet-oncology.--bayer-healthcare2024-11-12T13:46:51+00:00weekly0.6https://www.medthority.com/news/2021/4/update-on-the-dare-19-phase-iii-trial-for-farxiga-in-covid-19.--astrazeneca2021-12-20T17:30:32+00:00weekly0.6https://www.medthority.com/news/2021/4/adamis-pharmaceuticals-provides-an-update-on-zimhi-high-dose-naloxone-injection-product-intended-for-the-treatment-of-opioid-overdose/2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-accepts-snda-for-xywav-to-treat-with-idiopathic-hypersomnia-with-pdufa-date-on-12-august-2021--jazz-pharma/2024-10-24T11:14:00+00:00weekly0.6https://www.medthority.com/news/2021/4/arcutis-initiates-phase-iii-clinical-trial-of-topical-roflumilast-cream-arq-151-as-a-potential-treatment-for-atopic-dermatitis-in-pediatric-patients-between-the-ages-of-two-and-five-years/2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2021/4/beigene-presents-interim-analysis-results-of-rationale-303-trial-of-tislelizumab-in-second--or-third-line-non-small-cell-lung-cancer-at-the-aacr-annual-meeting-/2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-xolair-prefilled-syringe-for-self-injection-across-all-indications-genentech--novartis/2024-10-24T10:54:11+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iii-regn-cov-2069-trial-of-regn-cov2-meets-endpoints-in-covid-19.--roche2024-10-22T13:00:27+00:00weekly0.6https://www.medthority.com/news/2021/4/myovant-sciences-and-pfizer-announce-first-participant-dosed-in-phase-iii-serene-study-of-relugolix-combination-tablet-for-contraception/2024-10-22T13:00:50+00:00weekly0.6https://www.medthority.com/news/2021/4/positive-topline-data-shows-fostamatinib-meets-primary-endpoint-of-safety-in-phase-ii-patients-with-covid-19.--rigel-pharma2024-10-22T13:01:02+00:00weekly0.6https://www.medthority.com/news/2021/4/first-patient-dosed-in-phase-iii-xtend-kids-study-with-efanesoctocog-alfa-in-children-with-haemophilia-a.--swedish-orphan-biovitrum2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2021/4/endo-announces-publication-of-phase-iii-qwo-collagenase-clostridium-histolyticum-aaes-data-in-peer-reviewed-dermatologic-surgery-journal/2024-11-12T10:15:48+00:00weekly0.6https://www.medthority.com/news/2021/4/johnson--johnson-statement-on-covid-19-vaccine--jnj-78436735.updated2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-grants-accelerated-approval-to-trodelvy-for-the-treatment-of-metastatic-urothelial-cancer--gilead-sciences/2024-10-24T11:14:13+00:00weekly0.6https://www.medthority.com/news/2021/4/novavax-to-participate-in-university-of-oxford-com-cov2-study-comparing-mixed-covid-19-vaccine-combination/2024-10-22T13:01:27+00:00weekly0.6https://www.medthority.com/news/2021/4/genentechs-evrysdi-continues-to-improve-motor-function-and-survival-in-babies-with-type-1-spinal-muscular-atrophy-/2024-11-12T10:17:37+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iii-select-psa-1-trial-of-rinvoq-in-psoriatic-arthritis-published-in-nejm.--abbvie2024-10-24T11:17:36+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-tyvaso-for-pulmonary-hypertension-associated-with-interstitial-lung-disease.--united-therapeutics2024-10-24T10:37:40+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-sarclisa--carfilzomib--dexamethasone-for-multiple-myeloma.--sanofi2021-12-20T17:30:26+00:00weekly0.6https://www.medthority.com/news/2021/4/kite-submits-sbla-to-fda-for-tecartus-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia/2024-10-24T11:00:47+00:00weekly0.6https://www.medthority.com/news/2021/4/high-efficacy-and-no-serious-safety-concerns-through-up-to-six-months-following-second-dose-in-updated-topline-analysis-of-landmark-covid-19-vaccine-study.-pfizer--biontech-se2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2021/4/paion-ag-receives-european-commission-approval-for-byfavo-for-procedural-sedation/2024-10-24T10:37:50+00:00weekly0.6https://www.medthority.com/news/2021/4/evrysdi-approved-by-european-commission-as-first-and-only-at-home-treatment-for-spinal-muscular-atrophy.--roche2024-10-24T10:39:44+00:00weekly0.6https://www.medthority.com/news/2021/4/novartis-receives-eu-approval-for-kesimpta-the-first-and-only-self-administered-targeted-b-cell-therapy-for-adult-patients-with-relapsing-multiple-sclerosis/2024-10-22T12:52:16+00:00weekly0.6https://www.medthority.com/news/2021/4/stada-introduces-bevacizumab-biosimilar-in-germany-and-the-netherlands-upon-regulatory-approval-with-several-more-countries-to-follow-soon/2024-10-24T11:13:12+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-approves-pemazyre-to-treat-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion-or-rearrangement.--incyte2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2021/4/amarin-receives-european-commission-approval-for-vazkepa-to-reduce-cardiovascular-events/2024-10-24T10:40:03+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-grants-conditional-approval-for-nexpovio-to-treat-multiple-myeloma--karyopharm-therapeutics/2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2021/4/nejm-publishes-phase-iii--illuminate-a--trial-of-lumasiran-to-treat-primary-hyperoxaluria-type-1.--alnylam-pharma2024-10-24T11:00:24+00:00weekly0.6https://www.medthority.com/news/2021/4/emergent-biosolutions-announces-topline-data-from-niaid-phase-iii-itac-trial-insight-013-of-immunoglobulins-as-a-treatment-for-hospitalized-patients-with-covid-19/2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2021/4/health-canada-approves-taltz-for-pediatric-patients-with-plaque-psoriasis.--eli-lilly2021-12-20T17:33:08+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-qelbree-for-attention-deficit-hyperactivity-disorder-in-pediatric-patients.--supernus-pharmaceuticals2024-10-22T12:53:09+00:00weekly0.6https://www.medthority.com/news/2021/4/humanigen-reports-positive-phase-iii-results-demonstrating-that-lenzilumab-improves-survival-without-need-for-mechanical-ventilation-in-hospitalized-patients-with-covid-19/2021-12-20T17:30:31+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-supplies-complete-response-for-nuplazid-in-dementia-related-psychosis.--acadia-pharma2024-10-24T11:00:58+00:00weekly0.6https://www.medthority.com/news/2021/4/sorrento-therapeutics-acquires-acea-therapeutics-and-with-it-abivertinib/2021-09-24T07:00:37+00:00weekly0.6https://www.medthority.com/news/2021/4/cti-biopharma-completes-rolling-submission-of-nda-for-pacritinib-in-myelofibrosis-patients-with-severe-thrombocytopenia/2024-11-12T10:11:37+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iiiii-trial-evaluating-arimoclomol-for-the-treatment-of-inclusion-body-myositis-did-not-meet-its-endpoints.--orphazyme-as2024-11-12T10:11:48+00:00weekly0.6https://www.medthority.com/news/2021/4/eu-approves-alymsys-for-colon-or-rectum-breast-cancer-non-small-cell-lung-cancer-renal-cell-cancer-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-and-carcinoma-of-the-cervix.--mabxience2024-10-22T13:01:37+00:00weekly0.6https://www.medthority.com/news/2021/4/promore-pharma-comments-on-media-reports-about-ensereptide-a-proposed-treatment-for-skin-scarring/2024-10-24T08:15:44+00:00weekly0.6https://www.medthority.com/news/2021/4/pfizer-biontech-announce-positive-topline-results-of-pivotal-covid-19-vaccine-study-in-adolescents/2021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2021/4/eu-approves-cabometyx--opdivo-for-advanced-renal-cell-carcinoma.--ipsen2021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2021/3/helius-medical-inc-receives-fda-marketing--authorization-for-the-pons-device-to-treat-gait-deficit-for-ms-patients/2021-12-20T17:32:55+00:00weekly0.6https://www.medthority.com/news/2021/3/topline-data-announced-from-phase-ii-blaze-4-study-of-bamlanivimab-vir-7831-gsk-4182136-which-reduced-viral-load-by-70-in-covid-19-patients.-eli-lillygskvir-biotech2021-12-20T17:30:33+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-nextstellis-for-contraception.--mayne-pharma2024-11-12T10:13:42+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-de-novo-approval-for-gi-genius-intelligent-endoscopy-module.--medtronic2024-11-12T10:13:59+00:00weekly0.6https://www.medthority.com/news/2021/4/novocure-announces-update-on-phase-iii-pivotal-lunar-trial-of-tumor-treating-fields-in-non-small-cell-lung-cancer/2021-12-20T17:29:24+00:00weekly0.6https://www.medthority.com/news/2021/4/covid-19-vaccine-astrazeneca-has-been-given-authorisation-for-temporary-supply-by-the-uk-department-of-health-and-mhra/2024-10-22T10:07:14+00:00weekly0.6https://www.medthority.com/news/2021/4/united-therapeutics-submits-tyvaso-dpi-nda-to-fda--for-pulmonary-arterial-hypertension-and-for-pulmonary-hypertension-interstitial-lung-disease.-2022-02-08T07:44:58+00:00weekly0.6https://www.medthority.com/news/2021/4/eu-approves-sarclisa-with-kyprolis--dexamethasone-for-relapsed-multiple-myeloma.--sanofi2021-12-20T17:32:56+00:00weekly0.6https://www.medthority.com/news/2021/4/ovid-provides-update-on-ov-101-program-and-the-prioritization-of-its-resources/2024-10-22T12:58:55+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-expands-approval-of-ragwitek-for-young-people-age-5-and-above-in-ragweed-pollen-induced-allergic-rhinitis.--alk-abello2024-10-22T12:59:08+00:00weekly0.6https://www.medthority.com/news/2021/4/two-sblas-filed-with-fda-for-padcev-in-urothelial-cancer.--astellas-pharma--seagen2024-10-24T10:40:50+00:00weekly0.6https://www.medthority.com/news/2021/4/helios-a-phase-iii-study-of-aln-ttrsc02-meets-primary-and-secondary-endpoints-in-attr-hattr-amyloidosis-with-polyneuropathy.--alnylam-pharma2024-10-24T10:40:59+00:00weekly0.6https://www.medthority.com/news/2021/4/18-month-pre-specified-analysis-showing-consistent-reduction-in-clinical-outcome-measures-from-a-lecanemab-ban-2401-phase-iib-clinical-trial-in-early-alzheimers-disease.--eisai--biogen2024-10-22T12:59:20+00:00weekly0.6https://www.medthority.com/news/2021/4/merck-to-discontinue-development-of-mk-7110-for-covid-19/2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/avenue-therapeutics-announces-that-the-fda-is-still-reviewing-its-nda-resubmission-for-iv-tramadol/2024-10-24T08:42:52+00:00weekly0.6https://www.medthority.com/news/2021/4/merck-inc.--ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-antiviral-for-the-treatment-of-mild-to-moderate-covid-192024-10-22T10:07:26+00:00weekly0.6https://www.medthority.com/news/2021/4/-eli-lilly-requests-revocation-of-emergency-use-authorization-for-bamlanivimab-alone-to-complete-transition-to-bamlanivimab-and-etesevimab-together-for-treatment-of-covid-19-in-the-u.s2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/geneuro-will-study-whether-its-monoclonal-antibody-temelimab-can-prevent-long-covid.-2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/phase-iiib-ensemble-study-of-ocrevus-shows-efficacy-and-low-relapse-rate-in-multiple-sclerosis.--genentechroche2021-12-20T17:29:24+00:00weekly0.6https://www.medthority.com/news/2021/4/melflufen-filed-with-ema-for-multiple-myeloma.--oncopeptides-ab2024-10-22T10:08:25+00:00weekly0.6https://www.medthority.com/news/2021/4/new-long-term-data-for-uplizna-in-people-living-with-neuromyelitis-optica-spectrum-disorder.-viela-biohorizon-therapeutics2024-10-24T10:53:56+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-opdivo-in-combination-with-chemotherapy-for-patients-with-advanced-or-metastatic-gastric-cancer-gastroesophageal-junction-cancer-and-esophageal-adenocarcinoma.--bms2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/new-integrated-data-and-follow-up-outcomes-from-two-tepezza-pivotal-trials-published-in-the-lancet-diabetes--endocrinology.--horizon-therapeutics2024-10-24T08:43:06+00:00weekly0.6https://www.medthority.com/news/2021/4/dcgi-india-approves-sputnik-v-covid-19-vaccine-for-emergency-use-in-india.--dr-reddys-laboratories2024-10-22T10:08:37+00:00weekly0.6https://www.medthority.com/news/2021/4/bd-announces-510k-clearance-of-pristine-long-term-hemodialysis-catheter/2024-11-12T10:13:03+00:00weekly0.6https://www.medthority.com/news/2021/4/after-data-from-phase-iii-acis-study-erleada--zytiga-combination-will-not-be-pursued-for-prostate-cancer.--janssen-pharma2025-01-31T11:40:22+00:00weekly0.6https://www.medthority.com/news/2021/4/eli-lilly--incytes-baricitinib-improved-hair-regrowth-for-alopecia-areata-patients-in-second-phase-iii-study/2024-10-24T08:43:19+00:00weekly0.6https://www.medthority.com/news/2021/4/alkermes-presents-new-data-from-psychiatry-portfolio-at-virtual-2021-congress-of-the-schizophrenia-international-research-society/2024-11-12T13:43:11+00:00weekly0.6https://www.medthority.com/news/2021/4/bluebird-bio-provides-update-on-severe-genetic-disease-programs-and-business-operations/2024-11-12T13:44:10+00:00weekly0.6https://www.medthority.com/news/2021/4/oncotelic-therapeutics-inc.-announces-positive-top-line-data-from-arti-19-clinical-trial-evaluating-pulmoheal-for-covid-19..-2024-10-22T10:09:01+00:00weekly0.6https://www.medthority.com/news/2021/4/five-year-patient-level-meta-analysis-of-illumenate-eu-rct-and-pivotal-study-results-confirms-safety-profile-of-philips-stellarex-.035-low-dose-drug-coated-balloon2024-10-22T10:09:18+00:00weekly0.6https://www.medthority.com/news/2021/4/covis-pharma-group-announces-top-line-safety-and-efficacy-data-from-a-phase-iii-placebo-controlled-covid-19-study-using-inhaled-corticosteroid-ciclesonide/2024-10-22T10:09:28+00:00weekly0.6https://www.medthority.com/news/2021/4/romark-announces-initial-results-of-phase-iii-trial-of-nt-300-tablets-for-the-treatment-of-covid-19.-2021-12-20T17:29:24+00:00weekly0.6https://www.medthority.com/news/2021/4/johnson--johnson-single-shot-covid-19-vaccine-phase-iii-data-published-in-new-england-journal-of-medicine/2024-10-22T10:09:48+00:00weekly0.6https://www.medthority.com/news/2021/4/johnson--johnson-covid-19-vaccine-roll-out-to-resume-in-europe-following-european-medicines-agency-review/2021-12-20T17:32:56+00:00weekly0.6https://www.medthority.com/news/2021/4/trevena-announces-trv-027-selected-for-study-in-global-remap-cap-trial-in-covid-19-patients/2024-11-12T10:13:21+00:00weekly0.6https://www.medthority.com/news/2021/4/gsk---vir-biotechnology-announce-ema-review-of-dual-action-monoclonal-antibody-vir-7831-for-the-early-treatment-of-covid-19/2024-10-22T10:09:59+00:00weekly0.6https://www.medthority.com/news/2021/4/medtronic-receives.-fda-approval-for-pipeline-flex-embolization-device-with-shield-technology2024-10-24T08:43:34+00:00weekly0.6https://www.medthority.com/news/2021/4/in.pact-av-drug-coated-balloon-is-first-and-only-to-show-superior-and-sustained-results-through-two-years-compared-to-pta-in-treating-arteriovenous-fistulae-lesions2024-10-24T10:41:09+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-grants-accelerated-approval-for-jemperli-in-endometrial-cancer.--glaxosmithkline2024-11-12T10:13:31+00:00weekly0.6https://www.medthority.com/news/2021/4/eu-chmp-recommends-approval-of-onureg-for-acute-myeloid-leukemia.--bristol-myers-squibb2024-10-24T08:43:47+00:00weekly0.6https://www.medthority.com/news/2021/4/uk-mhra-approves-vazkepa-to-reduce-the-risk-of-cardiovascular-events.--amarin-corp2024-11-12T14:10:42+00:00weekly0.6https://www.medthority.com/news/2021/4/health-canada-starts-rolling-review-of-covlp--pandemic-adjuvant-system-for-covid-19.--medicago2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-approval-of-opdivo--yervoy-in-malignant-pleural-mesothelioma.--bristol-myers-squibb2024-11-12T11:39:39+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-ec-decision-reliance-procedure-for-determination-of-a-maa-by-mhra/2024-11-12T14:11:22+00:00weekly0.6https://www.medthority.com/news/2021/4/taltz-delivers-more-cumulative-days-with-completely-clear-skin-for-adults-with-psoriasis-compared-to-seven-other-biologics-in-novel-network-meta-analysis.--eli-lilly2024-10-22T10:10:08+00:00weekly0.6https://www.medthority.com/news/2021/4/otezla-significantly-improved-measures-of-disease-severity-in-adults-with-mild-to-moderate-plaque-psoriasis.--amgen2024-10-22T10:10:18+00:00weekly0.6https://www.medthority.com/news/2021/4/arcutis-biotherapeutics-showcases-new-roflumilast-data-in-psoriasis-and-seborrheic-dermatitis-at-american-academy-of-dermatology-aad-virtual-meeting-experience-vmx-2021/2024-10-24T10:41:21+00:00weekly0.6https://www.medthority.com/news/2021/4/bms-presents-positive-data-from-two-pivotal-phase-iii-psoriasis-studies-demonstrating-superiority-of-deucravacitinib-compared-to-placebo-and-otezla.-2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-announce-that-vaccinations-with-jnj-78436735-for-covid-19-can-restart.--johnson--johnson2021-12-20T17:29:24+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-approval-of-enspryng--for-neuromyelitis-optica-spectrum-disorder.--roche2024-10-24T08:44:01+00:00weekly0.6https://www.medthority.com/news/2021/4/new-analyses-of-breeze-ad5-phase-iii-clinical-trial-data-and-an-extended-safety-analysis-for-olumiant-across-multiple-trials-for-atopic-dermatitis/2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/the-new-england-journal-of-medicine-publishes-results-from-two-bimekizumab-phase-iii-studies-in-moderate-to-severe-plaque-psoriasis--ucb/2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/adc-therapeutics-announces-fda-approval-of-zynlonta--in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-10-24T10:41:32+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-approval-of-adtralza-in-atopic-dermatitis.--leo-pharma2021-12-20T17:32:57+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-approves-zylonta-for-large-b-cell-lymphoma.--adc-therapeutics2021-12-20T17:30:28+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-extended-approval-of-venclyxto-for-acute-myeloid-leukemia.--abbvie2024-11-12T09:40:44+00:00weekly0.6https://www.medthority.com/news/2021/4/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer-.-astrazeneca2024-11-12T09:41:01+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-approves-abevmy-a--bevacizumab-biosimilar-to-treat-the-same-indications-as-the-originator-drug-.--biocom-biologics2024-11-12T09:38:39+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-evkeeza-to-treatadult-and-adolescent-patients-aged-12-years-and-older-with-homozygous-familial-hypercholesterolaemia.--regeneron2024-11-12T09:39:50+00:00weekly0.6https://www.medthority.com/news/2021/4/chmp-recommends-conditional-approval-for-koselugo-to--treat-paediatric-patients-with-neurofibromatosis-type-1-nf1-plexiform-neurofibromas-.--astrazeneca2024-11-12T11:33:00+00:00weekly0.6https://www.medthority.com/news/2021/4/health-canada-approves-humira-for-inducing-and-maintaining-clinical-remission-in-pediatric-patients--ulcerative-colitis.---abbvie2022-02-08T07:44:58+00:00weekly0.6https://www.medthority.com/news/2021/4/health-canada-approves-darzalex--bortezomib--cyclophosphamide--dexamethasone-to-treat-light-chain-amyloidosis.--janssen-biotech2024-10-22T09:17:40+00:00weekly0.6https://www.medthority.com/news/2021/4/mhra-uk-approves-roclanda--for-the-reduction-of-elevated-intraocular-pressure-in-adult-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension.-aerie-pharma2024-10-22T09:18:02+00:00weekly0.6https://www.medthority.com/news/2021/4/sol-gel-technologies-provides-update-on-delayed-fda-review-of-epsolay-a-proposed--treatment-for-rosacea/2024-11-12T09:40:03+00:00weekly0.6https://www.medthority.com/news/2021/4/nirsevimab-melody-phase-iii-trial-met-primary-endpoint-of-reducing-lower-respiratory-tract-infections-due-to-rsv-in-healthy-infants.-sanofi-astrazeneca2024-11-12T11:33:13+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-approves--epidyolex-for-the-treatment-of-seizures-associated-with-tuberous-sclerosis-complex.--gw-pharmajazz-pharma2024-11-12T11:33:28+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-has-set-a-pdufa-date-for-review-of-bimekizumab-to-treat-psoriasis-on-15-october-2021.--ucb2024-10-22T09:18:41+00:00weekly0.6https://www.medthority.com/news/2021/4/dcgi-india-grants--emergency-use-approval-for-pegylated-interferon-alpha-2b-virafin-in-treating-moderate-covid-19infection-in-adults.--zydus-cadilla2021-12-20T17:32:39+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-approves-conditionally-jemperli-for-use-in-women-with-mismatch-repair-deficient-dmmrmicrosatellite-instability-high-recurrent-or-advanced-endometrial-cancer.-gsk2024-10-22T09:18:58+00:00weekly0.6https://www.medthority.com/news/2021/4/optimize-pro-clinical-study-shows-promising-early-outcomes-for-patients-implanted-with-the-evolut-pro-tavr-system.--medtronic2024-10-24T10:40:39+00:00weekly0.6https://www.medthority.com/news/2021/4/merck--inc.-announces-voluntary-licensing-agreements-with-five-indian-generics-manufacturers-to-accelerate-access-to-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-covid-192021-12-20T17:33:12+00:00weekly0.6https://www.medthority.com/news/2021/4/a-single-dose-of-either-the-pfizerbiontech-or-the-astrazenecaoxford-covid-19-vaccines-reduced-household-transmission-by-up-to-a-half/2021-12-20T17:30:27+00:00weekly0.6https://www.medthority.com/news/2021/4/european-commission-approval-for-kaftrio-in-combination-with-ivacaftor-to-treat-cystic-fibrosis-patients-12-years-and-older-with-at-least-one-f508del-mutation-in-the-cftr-gene.--vertex2024-11-12T09:40:20+00:00weekly0.6https://www.medthority.com/news/2021/4/omburtamab-filed-with-maa-for-pediatric-patients-with-cnsleptomeningeal-metastasis-from-neuroblastoma.--y-mabs-therapeutics2024-11-12T09:40:31+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-oncologic-drugs-advisory-committee-voted-in-favor-of-maintaining-accelerated-approval-of-tecentriq--abraxane-for-the-treatment-of-unresectable-locally-advanced-or-metastatic-triple-negative-breast-cancer.-genentechroche-2021-12-20T17:30:27+00:00weekly0.6https://www.medthority.com/news/2021/4/pfizer-acquires-amplyx-pharma-and-with-it-fosmanogepix-a-novel-proposed-treatment-for-fungal-infections/2021-09-24T07:00:27+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-issues-complete-response-letter-for-tysabri-supplemental-filing-in-sc-form-for-multiple-sclerosis.--biogen2021-12-20T17:31:01+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-oncological-drugs-advisory-committee-votes-in-support-of-tecentriq-in-bladder-cancer.--genentechroche2024-11-12T11:32:47+00:00weekly0.6https://www.medthority.com/news/2021/4/fda-issues-a-complete-response-letter-relating-to-the-bla-for-prx-102-for-the-proposed-treatment-of-fabry-disease.--protalix-biotherapeutics2024-10-24T10:40:27+00:00weekly0.6https://www.medthority.com/news/2021/5/fda-advisory-committee-meeting-negative-on-opdivo-post-sorafenib-for-hepatocellular-carcinoma-u.s.-accelerated-approval.bms2024-10-24T14:20:28+00:00weekly0.6https://www.medthority.com/news/2022/5/publication-of-pivotal-ascend-phase-ii-trial-of-axs-05-in-major-depressive-disorder-in-the-american-journal-of-psychiatry.--axsome-therapeutics2022-05-27T11:42:03+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-grants-conditional-approval-of-carvykti--for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma.--janssen-biotech2022-05-27T11:38:31+00:00weekly0.6https://www.medthority.com/news/2022/5/new-pivotal-data-demonstrate-clinical-benefit-of-glofitamab-a-potential-first-in-class-bispecific-antibody-for-people-with-aggressive-lymphoma.--roche-2022-05-27T11:34:27+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-accepts-nda-for-daprodustat-to-treat-anaemia-of-chronic-kidney-disease.--gsk2022-04-21T13:52:43+00:00weekly0.6https://www.medthority.com/news/2022/4/first-patient-dosed-in-pivotal-phase-iiiii-orbit-clinical-study-of-setrusumab-for-the-treatment-of-osteogenesis-imperfecta.--ultragenyx--pharma2022-04-21T13:50:01+00:00weekly0.6https://www.medthority.com/news/2022/4/journal-of-clinical-oncology-publication-of-pivotal-clinical-trial-results-for-narsolimab-in-hsct-tma.--omeros-corporation.-2022-04-21T13:40:34+00:00weekly0.6https://www.medthority.com/news/2022/4/results-from-respiratory-physiology-study-of-head-to-head-comparison-of-olinvyk-and-iv-morphine-in-elderlyoverweight-subjects.--trevena2022-04-21T13:37:44+00:00weekly0.6https://www.medthority.com/news/2022/4/initiation-of-a-phase-iii-clinical-trial-of-mva-bn-rsv-vaccine-in-older-adults.--bavarian-nordic-as2025-01-31T11:46:27+00:00weekly0.6https://www.medthority.com/news/2022/4/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations.-astrazeneca2022-04-21T12:23:48+00:00weekly0.6https://www.medthority.com/news/2022/4/health-canada-approves-expanded-use-of-trikafta-to-treat-children-with-cystic-fibrosis-with-f508del-mutation/2022-04-21T12:08:32+00:00weekly0.6https://www.medthority.com/news/2022/4/asahi-kasei-agrees-to-acquire-bionova-scientific-llc/2022-04-21T11:37:09+00:00weekly0.6https://www.medthority.com/news/2022/4/submission-of-application-in-china-for-additional-indication-of-darolutamide--docetaxel-for-prostate-cancer.-bayer2022-04-23T14:45:58+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-approval-of-yselty-for-uterine-fibroids.--obseva2022-04-23T14:45:10+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-approval-of-novoseven-in-haemophilia.--novo-nordisk2022-04-23T14:44:23+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-approval-of-lunsumio-for-follicular-lymphoma.--roche2022-04-23T14:43:38+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-change-of-approval-of-keytruda-in-triple-negative-breast-cancer.--msd2022-04-23T14:42:46+00:00weekly0.6https://www.medthority.com/news/2022/4/update-on-regulatory-submission-for-aducanumab-to-treat-early-alzheimers-disease-in-the-european-union.--biogen2022-04-23T14:41:55+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-tabrecta-to-treat-non-small-cell-lung-cancer-with-met-exon14-skipping.---novartis2022-04-23T14:41:03+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-filsuvez-to-treat-wounds-associated-with-epidermolysis-bullosa.--amryt2022-04-23T14:39:59+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-a-change-to-indication-for-tecentriq-in-nsclc.--genentechroche2022-04-23T14:37:00+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-change-of-indication-for-retsevmo-in-ret-fusion-positive-non-small-cell-lung-cancer.--eli-lilly2022-04-23T14:36:06+00:00weekly0.6https://www.medthority.com/news/2022/4/chmp-recommends-change-to-terms-of-approval-for-yescarta-for-follicular-lymphoma.--kitegilead-sciences2022-04-23T14:35:18+00:00weekly0.6https://www.medthority.com/news/2022/4/novavax-initiates-booster-dose-trial-for-nvx-cov2373-vaccine-for-covid-19/2022-04-24T12:38:43+00:00weekly0.6https://www.medthority.com/news/2022/4/positive-long-term-safety-and-efficacy-data-for-mycapssa-from-the-2nd-year-of-optimal-open-label-extension-study-in-acromegaly-patients.--amryt-2022-04-14T11:28:33+00:00weekly0.6https://www.medthority.com/news/2022/4/european-commission-approves-padcev--for-locally-advanced-or-metastatic-urothelial-cancer.--astellas--seagen.-2022-04-14T11:20:44+00:00weekly0.6https://www.medthority.com/news/2022/4/aeb-1102-filed-with-fda-for-arginase-1-deficiency.--aeglea-biotherapeutics2022-04-14T11:17:52+00:00weekly0.6https://www.medthority.com/news/2022/4/rezurock-patient-reported-outcomes-correlated-with-clinical-response-in-chronic-graft-versus-host-disease.--sanofi2022-04-22T12:05:25+00:00weekly0.6https://www.medthority.com/news/2022/4/health-sciences-councils-subcommittee-chair-negative-on--s-217622-vaccine-for-covid-19----shionogi/2022-04-25T12:53:18+00:00weekly0.6https://www.medthority.com/news/2022/4/imfinzi--tremelimumab-stride-regimen-bla-is-accepted-by-fda-for-treatment-of-unresectable-liver-cancer-.-astrazeneca2022-04-26T11:15:42+00:00weekly0.6https://www.medthority.com/news/2022/4/several-new-studies-presented-at-eccmic-2022-confirm-veklury-activity-in-treating-covid-19.--gilead-sciences2022-04-26T11:12:44+00:00weekly0.6https://www.medthority.com/news/2022/4/interim-analysis-of-japan-trial-for-s-268019-vaccine-for-covid-19-confirms-no-major-safety-concerns-increase-in-antibody-titers.--shionogi2022-04-26T11:09:54+00:00weekly0.6https://www.medthority.com/news/2022/4/equillium-announces-two-oral-presentations-at-the-annual-meeting-of-the-european-society-for-blood-and-marrow-transplantation/2022-04-26T11:06:19+00:00weekly0.6https://www.medthority.com/news/2022/4/tislelizumab-plus-chemotherapy-significantly-improved-overall-survival-as-first-line-treatment-for-advanced-esophageal-cancer-in-phase-iii-study.--novartis--beigene2022-04-28T15:28:36+00:00weekly0.6https://www.medthority.com/news/2022/4/top-line-results-from-two-open-label-extension-studies-of-repatha-over-five-years-for-atherosclerotic-cardiovascular-disease.--amgen2022-04-28T15:27:40+00:00weekly0.6https://www.medthority.com/news/2022/4/casirivimab--imdevimab-removed-from--nhs-commissioning-policy-as-omicron-variant-is-not-susceptible-to-the-combination.--regeneron--roche2022-04-28T15:26:03+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-orca-2-trial-of-cytisinicline-shows-benefits-in-smoking-cessation.--achieve-life-sciences2022-04-28T15:25:19+00:00weekly0.6https://www.medthority.com/news/2022/4/nice-recommends-tucatinib--trastuzumab--capecitabine-to-treather-2-positive-breast-cancer.--seagen2022-04-28T15:24:36+00:00weekly0.6https://www.medthority.com/news/2022/4/nice-recommends-niraparib-for-maintenance-treatment-of-platinum-sensitive-ovarian-fallopian-tube-and-peritoneal-cancer.--gsk2022-04-28T15:23:54+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-vydura-for-migraine.--pfizer--biohaven-pharma2022-04-28T15:23:12+00:00weekly0.6https://www.medthority.com/news/2022/4/nmpa-china-approves-tegoprazan-to-treat-erosive-esophagitis.-shandong-luoxin-pharmaceutical-group2022-04-28T15:22:23+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-approves-snda-for-veklury-to-treat-pediatric-patients-who-are-older-than-28-days-and-exposed-to-covid-19.--gilead-sciences2022-04-27T12:24:54+00:00weekly0.6https://www.medthority.com/news/2022/4/long-term-health-outcomes-using-stimulation-model-of-lecanemab-in-patients-with-early-alzheimers-disease-published-in-neurology-and-therapy.--eisai2022-04-27T12:27:04+00:00weekly0.6https://www.medthority.com/news/2022/4/pafsc-committee-japan-approves-comirnaty-and-spikevax-for-booster-use-limited-to-high-risk-people-with-covid-19/2022-04-27T12:28:56+00:00weekly0.6https://www.medthority.com/news/2022/4/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis-.alexionastrazeneca2022-04-30T19:30:05+00:00weekly0.6https://www.medthority.com/news/2022/4/phase-iii-surmount-1-clinical-trial-of-ly-3298176-meets-co-primary-endpoints-in-obesity.--eli-lilly2022-04-30T19:30:16+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-kapruvia-in-pruritus-associated-with-chronic-kidney-disease-in-hemodialysis-patients.--vifor-fresenius-medical-care-renal-pharma-and-cara-therapeutics2022-04-30T19:33:01+00:00weekly0.6https://www.medthority.com/news/2022/4/zejula-plus-zytiga-and-prednisolone-filed-with-eu-for-prostate-cancer.--janssen-pharma2022-04-30T19:38:46+00:00weekly0.6https://www.medthority.com/news/2022/4/results-of-onwards-2-trial-ofinsulin-icodec-vs-insulin-degludec-in-type-2-diabetes.--novo-nordisk2022-04-30T19:38:36+00:00weekly0.6https://www.medthority.com/news/2022/4/fda-approves-camzyos-to-treat-obstructive-hypertrophic-cardiomyopathy.-bms2022-04-30T19:38:28+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approval-of-qelbree-for-the-treatment-of-adhd-in-adults.--supernus2022-05-01T12:20:34+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-rinvoq-to-treat-ankylosing-spondylitis.--abbvie2022-05-01T12:20:51+00:00weekly0.6https://www.medthority.com/news/2022/5/top-line-results-from-phase-iiiii-epic-pep-study-of-paxlovid-for-post-exposure-prophylactic-use-were-not-statistically-significant.--pfizer2022-05-01T12:20:05+00:00weekly0.6https://www.medthority.com/news/2022/5/bms-and-nektar-end-collaboration-for-bempegaldesleukin--opdivo/2022-05-01T12:25:15+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-accepts-nda-resubmission-for-pedmark-for-prevention-of-platinum-induced-ototoxicity-in-solid-tumors.-fennec-pharma2022-05-02T13:03:02+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-vivjoa-for-the-treatment-of-recurrent-vulvovaginal-candidiasis-chronic-yeast-infection--mycovia-pharma/2022-05-02T13:05:06+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-epsolay-cream-for-the-treatment-of-rosacea.--sol-gel-technologies--galderma2022-05-02T13:07:48+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-approval-of-uplizna-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-05-03T11:31:00+00:00weekly0.6https://www.medthority.com/news/2022/5/rolling-submission-is-initiated--of-nda-to-the-fda-for-zuranolone-for-the-potential-treatment-of-major-depressive-disorder.-sage-therapeutics--biogen2025-01-31T11:46:10+00:00weekly0.6https://www.medthority.com/news/2022/5/complete-response-letter-for-toripalimab--gemcitabine--cisplatin-and-as-monotherapy-for-metastatic-nasopharyngeal-carcinoma.--shanghai-junshi-biosciences--coherus-biosciences2022-05-03T11:23:43+00:00weekly0.6https://www.medthority.com/news/2022/5/complete-response-letter-from-the--fda-for-surufatinib-for-the-treatment-of-advanced-neuroendocrine-tumors.-hutchmed2022-05-03T11:21:03+00:00weekly0.6https://www.medthority.com/news/2022/5/oramed-completes-patient-enrollment-in-pivotal-phase-iii-oral-insulin-study-ora-d-013-1-of-ormd-0801-in-type-2-diabetes.--oramed-pharma--2025-01-31T11:45:24+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-accepts-nda-and-grants-priority-review-for-darolutamide-in-combination-with-docetaxel-for-metastatic-hormone-sensitive-prostate-cancer.--bayer2022-05-04T12:19:49+00:00weekly0.6https://www.medthority.com/news/2022/5/eu-approves-cabometyx-in-thyroid-carcinoma.--exelixis2025-01-31T11:45:56+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-voquezna-triple-pack-andvoquezna-dual-pack-to-treat-helicobacter-pylori-infection.-phathom-pharma-us--takeda2022-05-04T12:10:29+00:00weekly0.6https://www.medthority.com/news/2022/5/imfinzi-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer-based-on-topaz-1-phase-iii-trial.--astrazeneca2022-05-04T12:04:43+00:00weekly0.6https://www.medthority.com/news/2022/5/new-data-demonstrates-only-kisqali-offers-more-life-in-the-first-line-setting-for-postmenopausal-hrher2--advanced-breast-cancer-patients.--novartis2022-05-05T11:20:01+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-identifies-deficiencies-in-nda-for-tebipenem-hbr-and-adapt-po-trial.--spero-therapeutics2022-05-05T11:18:06+00:00weekly0.6https://www.medthority.com/news/2022/5/enhertu-approved-fully-by-fda-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen.--astrazeneca--daiichi-sankyo2022-05-05T11:15:29+00:00weekly0.6https://www.medthority.com/news/2022/5/farxiga-met-primary-endpoint-in-deliver-phase-iii-trial-reducing-risk-of-cardiovascular-death-or-worsening-heart-failure-in-patients-with-preserved-ejection-fraction.--astrazeneca2022-05-05T11:07:52+00:00weekly0.6https://www.medthority.com/news/2022/5/ultomiris-met-primary-endpoint-in-champion-nmosd-phase-iii-trial-in-adults-with-neuromyelitis-optica-spectrum-disorder.-astrazeneca2022-05-05T11:06:15+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-approval-of-jakavi-as-the-first-post-steroid-treatment-for-acute-and-chronic-graft-versus-host-disease.--novartis--incyte2022-05-06T12:42:22+00:00weekly0.6https://www.medthority.com/news/2022/5/brickell-biotech-announces-sale-of-sofpironium-bromide-gel-to-botanix-pharmaceuticals/2022-05-06T12:39:07+00:00weekly0.6https://www.medthority.com/news/2022/5/phase-iii-advance-trial-of-vyvgart-meets-primary-endpoint-in-primary-immune-thrombocytopenia.--argenx-se2022-05-06T12:30:26+00:00weekly0.6https://www.medthority.com/news/2022/5/publication-of-phase-iii-covid-19-vaccine-study-results-of-covifenz-in-new-england-journal-of-medicine.-medicago--gsk2022-05-06T12:28:25+00:00weekly0.6https://www.medthority.com/news/2022/5/pivotal-phase-iii-sp-102-semdexa-data-presentation-at-the-american-society-of-interventional-pain-asipp-2022-annual-meeting.--scilex-holding-companysorrento2022-05-06T12:26:20+00:00weekly0.6https://www.medthority.com/news/2022/4/moderna-files-to-expand-conditional-marketing-authorization-for-its-covid-19-vaccine-to-include-children-six-months-to-under-six-years-in-the-european-union/2022-04-30T19:40:33+00:00weekly0.6https://www.medthority.com/news/2022/4/three-year-data-from-firefish-study-of-evrysdi-shows-efficacy-and-safety-in-spinal-muscular-atrophy.--genentechroche2022-04-30T19:41:51+00:00weekly0.6https://www.medthority.com/news/2022/4/skycovione-filed-in-south-korea-for-covid-19.--sk-bioscience-and-gsk2022-04-30T19:43:25+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-keytruda-cervical-cancer-in-adults-whose-tumors-express-pd-l1.--merck-inc2022-04-30T19:44:45+00:00weekly0.6https://www.medthority.com/news/2022/4/eu-approves-keytruda-for-microsatellite-instability-high-or-deficient-mismatch-repair-tumors-in-5-cancers.--merck-inc2022-04-30T19:46:34+00:00weekly0.6https://www.medthority.com/news/2022/4/european-commission-approval-for-orgovyx-for-the-treatment-of-advanced-hormone-sensitive-prostate-cancer.--myovant-sciences2022-04-30T19:48:04+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-extends-pdufa-date-for-myfembree-to-manage-moderate-to-severe-pain-associated-with-endometriosis-.-myovant-sciences--pfizer2022-05-07T12:05:11+00:00weekly0.6https://www.medthority.com/news/2022/5/novartis-provides-update-on-production-of-radioligand-therapy-medicines/2022-05-07T12:04:19+00:00weekly0.6https://www.medthority.com/news/2022/5/johnson--johnson-updates-u.s.-covid-19-vaccine-fact-sheet2022-05-07T12:03:25+00:00weekly0.6https://www.medthority.com/news/2022/5/variations-to-expand-australian-and-new-zealand-provisional-approval-of-nuvaxovid-covid-19-vaccine-to-adolescents-aged-12-through-17-years.--novavax2022-05-07T12:02:46+00:00weekly0.6https://www.medthority.com/news/2022/5/nmpa-china-approves-conditionally-blincyto-for-pediatric-patients-with-relapsed-or-refractory-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia-.-beigene--amgen2022-05-08T16:18:02+00:00weekly0.6https://www.medthority.com/news/2022/5/mhlw-japan-approves-use-of-comirnaty-and-spikevax-boosters-to-people-60-years-of-age-or-older-and-those-aged-18-with-pre-existing-medical-conditions.-pfizer--moderna-2022-05-09T11:39:28+00:00weekly0.6https://www.medthority.com/news/2022/5/pharmaessentia-japan-submits-an-nda-in-japan-for-the-polycythemia-vera-pv-treatment-ropeginterferon-alfa-2b.-2022-05-09T11:35:09+00:00weekly0.6https://www.medthority.com/news/2022/5/s-217622-improves-respiratory-and-feverish-symptoms-associated-with-covid-19.--shionogi2022-05-09T11:27:46+00:00weekly0.6https://www.medthority.com/news/2022/5/-following-fda-meeting-a-new-phase-iii-trial-is-planned-for-vicineum-for-the-treatment-of-nmibc-non-muscle-invasive-bladder-cancer.--sesen-bio-inc2022-05-09T11:17:40+00:00weekly0.6https://www.medthority.com/news/2022/5/myovant-sciences-and-accord-healthcare-ltd.-enter-into-exclusive-license-agreement-to-commercialize-orgovyx-for-advanced-hormone-sensitive-prostate-cancer-in-europe2022-05-10T12:23:45+00:00weekly0.6https://www.medthority.com/news/2022/5/efficacy-and-safety-results-for-zilucoplan-and-rozanolixizumab-in-generalized-myasthenia-gravis-presented-at-mgfa-conference.--ucb2022-05-10T12:12:41+00:00weekly0.6https://www.medthority.com/news/2022/5/rolling-submission-to-the-fda-of-bla-for-lecanemab-for-early-alzheimers-disease-is-completed-under-accelerated-approval-pathway.-eisai--biogen2022-05-10T12:00:41+00:00weekly0.6https://www.medthority.com/news/2022/5/eisai-initiates-nda-in-japan-for-ultrahigh-dose-mecobalamin-based-on-results-of-jetals-clinical-trial-for-amyotrophic-lateral-sclerosis/2022-05-10T11:42:14+00:00weekly0.6https://www.medthority.com/news/2022/5/quviviq-is-granted-eu-approval-to-improve-both-nighttime-symptoms-and-daytime-functioning-in-adults-with-chronic-insomnia-disorder.--idorsia-ltd2022-05-11T12:02:20+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-marketing-authorisation-for-prehevbri-a-3-antigen-adult-hepatitis-b-vaccine.-vbi-vaccines2022-05-11T12:01:01+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-approval-of-kymriah-as-first-car-t-cell-therapy-for-adults-with-relapsed-or-refractory-follicular-lymphoma.--novartis2022-05-11T11:59:03+00:00weekly0.6https://www.medthority.com/news/2022/5/incyte-and-maruho-announce-strategic-alliance-agreement-for-ruxolitinib-cream-in-japan/2022-05-11T11:57:26+00:00weekly0.6https://www.medthority.com/news/2022/5/phase-iii-furi-study-of-ibrexafungerp-shows-positive-outcomes-in-vulvovaginal-candidiasis.--scynexis2022-05-11T11:55:42+00:00weekly0.6https://www.medthority.com/news/2022/5/interim-results-for-phase-iii-skyscraper-01-study-in-pd-l1-high-metastatic-non-small-cell-lung-cancer.--genentechroche2022-05-11T11:53:29+00:00weekly0.6https://www.medthority.com/news/2022/5/phase-iii-momentum-study-of-cyt-387-in-myelofibrosis-presented-at-2022-annual-meeting-of-the-european-hematology-association.--sierra-oncology2022-05-13T12:04:18+00:00weekly0.6https://www.medthority.com/news/2022/5/rinvoq-achieved-clinical-remission-and-endoscopic-response-at-one-year-in-phase-iii-maintenance-study-in-patients-with-crohns-disease---abbvie/2022-05-13T11:59:51+00:00weekly0.6https://www.medthority.com/news/2022/5/symplicity-spyral-rnd-system-demonstrates-significant-blood-pressure-reduction-through-three-years.--medtronic2022-05-13T11:57:16+00:00weekly0.6https://www.medthority.com/news/2022/5/complete-response-letter-for--bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis.--ucb2025-05-06T13:39:26+00:00weekly0.6https://www.medthority.com/news/2022/5/u.s-commercial-launch-of-the-urolift--2-system-and-urolift-atc-advanced-tissue-control-system-to-manage-benign-prostatic-hyperplasia.--teleflex-inc2022-05-14T14:34:08+00:00weekly0.6https://www.medthority.com/news/2022/5/nvx-cov2373-vaccine-is-filed-for-emergency-use-authorization--to-prevent-covid-19-in-taiwan.-novavax2022-05-14T14:32:45+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approval-for-onyx-frontier--the-latest-generation-drug-eluting-coronary-stent-system.--medtronic2024-09-30T13:58:59+00:00weekly0.6https://www.medthority.com/news/2022/5/new-two-year-deucravacitinib-data-reinforce-durable-efficacy-and-consistent-safety-profile-in-moderate-to-severe-plaque-psoriasis.---bms2022-05-14T14:31:25+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-mounjaro-injection-the-first-and-only-once-weekly-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes.---eli-lilly2022-05-14T14:30:28+00:00weekly0.6https://www.medthority.com/news/2022/5/national-institute-for-health-and-care-excellence-nice-recommends-relugolix-combination-therapy-to-treat-uterine-fibroids.--gedeon-richter2022-05-14T14:29:22+00:00weekly0.6https://www.medthority.com/news/2022/5/nice-uk-recommends-selumetinib-for-treating-symptomatic-and-inoperable-plexiform-neurofibromas-associated-with-type-1-neurofibromatosis.--astrazeneca--merck-inc2022-05-15T11:51:12+00:00weekly0.6https://www.medthority.com/news/2022/5/nmpa-china-approves-verkazia-to-treat-vernal-keratoconjunctivitis-vkc-in-children-and-adolescents.--santen2022-05-15T11:49:58+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-radicava-ors-oral-suspension-to-treat-amyotrophic-lateral-sclerosis.--mitsubishi-tanabe2022-05-15T11:48:49+00:00weekly0.6https://www.medthority.com/news/2022/5/taiho-acquires-cullinan-pearl-and-rights-to-cln-081tas-6417/2022-05-16T12:09:33+00:00weekly0.6https://www.medthority.com/news/2022/5/nmpa-china-approves-tuoyi-to-treat-unresectable-locally-advanced-recurrent-or-distant-metastatic-esophageal-squamous-cell-carcinoma-.-shanghai-junishi-biosciences-co2022-05-17T11:42:17+00:00weekly0.6https://www.medthority.com/news/2022/5/results-from-a-pylarify-ai-study-presented-at-the-american-urological-association-aua-annual-meeting.-lantheus-holdings-inc2022-05-17T11:38:54+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-lifts-clinical-hold-on-investigational-lenacapavir-for-the-treatment-and-prevention-of-hiv.--gilead-sciences2025-01-31T11:44:54+00:00weekly0.6https://www.medthority.com/news/2022/5/update-on-checkmate--901-trial-evaluating-opdivo--yervoy-as-first-line-treatment-for-unresectable-or-metastatic-urothelial-carcinoma-bladder-cancer.--bms2022-05-17T11:10:32+00:00weekly0.6https://www.medthority.com/news/2022/5/zealand-pharma-agrees-to-sell-v-go-insulin-delivery-device-to-mannkind-corporation.-2022-05-18T12:01:44+00:00weekly0.6https://www.medthority.com/news/2022/5/sarclisa-combination-provides-unprecedented-median-progression-free-survival-in-patients-with-relapsed-multiple-myeloma-receiving-a-proteasome-inhibitor-therapy.--sanofi2022-05-18T12:00:10+00:00weekly0.6https://www.medthority.com/news/2022/5/u.s.-emergency-use-authorization-for-booster-dose-of-the-pfizer-biontech-covid-19-vaccine-in-children-5-through-11-years-of-age2022-05-18T11:57:23+00:00weekly0.6https://www.medthority.com/news/2022/5/phase-ii-data-for-bi-1015550-a-novel-investigational-phosphodiesterase-4b-inhibitor--was-published-in-the-new-england-journal-of-medicine-nejm.--boehringer2022-05-18T11:55:47+00:00weekly0.6https://www.medthority.com/news/2022/5/shionogi-acquires-rights-to-olorofim-from-f2g-ltd.-for-invasive-fungal-infections-in-europe-and-asia2022-05-18T11:54:13+00:00weekly0.6https://www.medthority.com/news/2022/5/aim-immunotech-provides-update-on-ampligen-long-covid-development-program/2022-05-19T12:05:56+00:00weekly0.6https://www.medthority.com/news/2022/5/post-hoc-analysis-using-computer-automated-grading-of-phase-iii-tranquility-trial-digital-photography-demonstrated-statistical-significance-in-favor-of-reproxalap-over-vehicle-for-primary-endpoint-of-ocular-redness.-aldeyra-therapeutics2022-05-19T11:55:11+00:00weekly0.6https://www.medthority.com/news/2022/5/announcement-of-termination-of-global-license-agreements-by-otsuka-with-akebia-therapeutics-inc.-for-vadadustat-to-treat-renal-anemia.-2022-05-19T11:51:36+00:00weekly0.6https://www.medthority.com/news/2022/5/clinical-data-for-berdazimer-gel-10.3-sb-206-to-treat-molluscum-contagiosum-to-be-presented-at-the-annual-meeting-of-the-society-for-investigative-dermatology.--novan-inc2022-05-20T11:16:39+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-cosentyx--in-the-juvenile-idiopathic-arthritis-jia-categories-of-enthesitis-related-arthritis-era-and-juvenile-psoriatic-arthritis-jpsa-in-patients-6-years-and-older.--novartis2022-05-21T12:53:40+00:00weekly0.6https://www.medthority.com/news/2022/5/mrtx-849-filed-with-eu-for-non-small-cell-lung-cancer-with-the-krasg12c-mutation.--mirati-therapeutics2022-05-21T12:52:41+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-olumiant-for-the-treatment-of-adults-with-severe-alopecia-areata.-eli-lilly2022-05-21T12:51:58+00:00weekly0.6https://www.medthority.com/news/2022/5/eu-chmp-recommends-approval-of-keytruda-for-adjuvant-treatment-of-stage-iib-or-iic-melanoma.--merck-inc2022-05-21T12:51:12+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-dupixent-to-treat-patients-with-eosinophilic-esophagitis.--regeneron--sanofi2022-05-21T12:50:19+00:00weekly0.6https://www.medthority.com/news/2022/5/nuvaxovid-covid-19-vaccine-is-filed-in-the-european-union-for-expanded-conditional-marketing-authorization.--novavax2022-05-21T12:47:12+00:00weekly0.6https://www.medthority.com/news/2022/5/positive-full-results-of-mandala-phase-iii-trial-of-pt-027-in-asthma-patients-are-published-in-nejm.--avillion--astrazeneca2022-05-21T12:46:23+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-upstaza--for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency.--ptc-therapeutics2022-05-22T12:03:29+00:00weekly0.6https://www.medthority.com/news/2022/5/nda-filed-at-fda-for-investigational-abbv-951-for-the-treatment-of-motor-fluctuations-in-advanced-parkinsons-disease.-abbvie2022-05-22T12:02:41+00:00weekly0.6https://www.medthority.com/news/2022/5/ultragenyx-acquires-global-rights-to-aav-gene-therapy-abo-102-for-sanfilippo-syndrome-type-a-mps-iiia-from-abeona-therapeutics/2022-05-22T12:01:52+00:00weekly0.6https://www.medthority.com/news/2022/5/evkeeza-phase-iii-trial-demonstrates-48-ldl-c-reduction-in-children-with-ultra-rare-form-of-high-cholesterol.-regeneron2022-05-22T12:00:58+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-olumiant-for-covid-19.--eli-lilly2022-05-12T12:14:33+00:00weekly0.6https://www.medthority.com/news/2022/5/phase-iii-melody-and-phase-iib--trials-of-medi-8897-shows-efficacy-in-rsv.--sanofi-and-astrazeneca2025-01-31T11:45:07+00:00weekly0.6https://www.medthority.com/news/2022/5/mhlw-japan-in-its-covid-care-guide-cites-reduced-efficiency-of-xevudy-against-ba-2-omicron-subvariant-of-covid-19.--gsk2022-05-12T12:07:12+00:00weekly0.6https://www.medthority.com/news/2022/5/pfizer-to-acquire-biohaven-and-with-it-nurtec-odt-a-treatment-for-migraine/2022-05-12T12:04:43+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-xenpozyme-for-the-treatment-of-non-central-nervous-system-non-cns-manifestations-of-acid-sphingomyelinase-deficiency-asmd.--sanofi2022-05-23T11:23:25+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-cevenfacta-to-control-bleeding-episodes-in-patients-with-congenital-haemophilia.--lfb2022-05-23T11:21:56+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-opinion-positive-for-zokinvy-as-a-treatment-for-hutchinson-gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies.--eiger-biopharma2022-05-23T11:20:13+00:00weekly0.6https://www.medthority.com/news/2022/5/vaxzevria-is-approved-in-the-eu-as-third-dose-booster-against-covid-19.--astrazeneca2022-05-23T11:18:09+00:00weekly0.6https://www.medthority.com/news/2022/5/chmp-recommends-kinpeygo-for-the-treatment-of-primary-immunoglobulin-a-iga-nephropathy.--calliditas--stada-arzneimittel-ag2022-05-23T11:16:31+00:00weekly0.6https://www.medthority.com/news/2022/5/positive-chmp-opinion-for-nexpovio--velcade--dexamethasone-for-the-treatment-of-patients-with-refractory-multiple-myeloma.--karyopharm--menarini2022-05-24T11:00:20+00:00weekly0.6https://www.medthority.com/news/2022/5/chmprecommends-rinvoq-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-.--abbvie2022-05-24T11:00:21+00:00weekly0.6https://www.medthority.com/news/2022/5/new-18-month-results-from-exploratory-cardiac-endpoints-in-helios-a-phase-iii-study-of-vutrisiran-for-treatment-of-attr-amyloidosis-alnylam/2022-05-24T11:47:55+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-accepts-for-review-an-nda-for-intranasal-zavegepant-for-the-acute-treatment-of-migraine.--biohaven-pfizer2022-05-24T11:35:14+00:00weekly0.6https://www.medthority.com/news/2022/5/positive-data-from-phase-iii-study-of-vraylar-for-the-adjunctive-treatment-of-major-depressive-disorder-is-presented-at--2022-apa-annual-meeting.-abbvie2022-05-24T11:29:18+00:00weekly0.6https://www.medthority.com/news/2022/5/innovia-inc.-to-acquire-enstasis-and-with-it-leading-asset-sul-dur2022-05-24T11:21:37+00:00weekly0.6https://www.medthority.com/news/2022/5/vv-116-tablet-meets-primary---endpoint-in-phase-iii-trial-versus-paxlovid-for-early-treatment-of-mild-to-moderate-covid-19/2022-06-06T14:45:31+00:00weekly0.6https://www.medthority.com/news/2022/5/fifty-percent-of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-phase-iii-lucent-2-study.--eli-lilly2022-05-25T11:42:55+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-vtama-topical-cream-to-treat-psoriasis.--dermavant-sciences2022-05-25T11:40:38+00:00weekly0.6https://www.medthority.com/news/2022/5/update-on-phase-iii-clinical-trial-evaluating-troriluzole--for-spinocerebellar-ataxia.-biohaven2022-05-25T11:37:13+00:00weekly0.6https://www.medthority.com/news/2022/5/elevate-uc-pivotal-findings-demonstrate-etrasimods-potentially-best-in-class-profile-in-ulcerative-colitis.--pfizer2022-05-25T11:33:33+00:00weekly0.6https://www.medthority.com/news/2022/5/european-commission-approves-keytruda-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-triple-negative-breast-cancer-at-high-risk-of-recurrence.---merck-inc2022-05-25T11:29:39+00:00weekly0.6https://www.medthority.com/news/2022/5/new-data-support-renal-and-cardiovascular-benefits-of-kerendia-in-patients-with-and-without-history-of-left-ventricular-hypertrophy-and-chronic-kidney-disease-and-type-2-diabetes.--bayer2023-07-24T15:19:13+00:00weekly0.6https://www.medthority.com/news/2022/5/two-large-xarelto-studies-support-effectiveness-of-dual-pathway-inhibition-in-patients-with-coronary-artery-disease-andor-peripheral-artery-disease.--bayer2022-08-25T13:43:58+00:00weekly0.6https://www.medthority.com/news/2022/5/complete-response-letter-for-vp-102-for-the-treatment-of-molluscum-contagiosum.--verrica-pharma2022-05-25T11:23:33+00:00weekly0.6https://www.medthority.com/news/2022/5/positive-phase-iii-study-with-aprocitentan-demonstrates-significant-antihypertensive-efficacy-in-patients-with-resistant-hypertension.-janssed-biotech--id2022-05-26T11:56:04+00:00weekly0.6https://www.medthority.com/news/2022/5/athersys-announces-that-its-partner-healios-k.k.-reported-topline-data-from-the-treasure-multistem-ischemic-stroke-study2022-05-26T11:51:36+00:00weekly0.6https://www.medthority.com/news/2022/5/nirogacestat-achieved-primary-and-all-key-secondary-endpoints-in-phase-iii-defi-trial-in-adult-patients-with-progressing-desmoid-tumors.-springworks-therapeutics2022-05-26T11:48:38+00:00weekly0.6https://www.medthority.com/news/2022/5/polivy--r-chp-approved-by-european-commission-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma.--roche2022-05-26T11:46:26+00:00weekly0.6https://www.medthority.com/news/2022/5/nice-uk-recommends-romosozumab-to-treat-severe-osteoporosis-after-menopause-in-people-at-risk-of-fracture.--ucb--amgen2022-05-26T11:42:41+00:00weekly0.6https://www.medthority.com/news/2022/8/elecsys-igra-sars-cov-2-test-a-new-diagnostic-test-for-the-better-understanding-of-immune-response-to-sars-cov-2.--roche2022-08-16T11:25:08+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-tropics-02-study-evaluating-trodelvy-shows-significant-results-in-hrher2--metastatic-breast-cancer.--gilead-sciences-2022-08-16T11:23:21+00:00weekly0.6https://www.medthority.com/news/2022/8/mhra-approves-spikevax-bivalent-originalomicron-booster-that-targets-two-covid-19-variants.--moderna2022-08-16T11:21:11+00:00weekly0.6https://www.medthority.com/news/2022/8/gilead-to-acquire-remaining-worldwide-rights-of-trodelv-from-everest-medicines/2022-08-16T11:19:03+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-accepts-supplemental-biologics-license-application-for-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma.---genentechroche2022-08-16T11:17:36+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-grants-emergency-use-authorization-of-omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-booster-for-ages-12-years-and-older.--pfizer--biontech-se2022-09-01T11:19:54+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-authorisation-for-emergency-use-of-omicron-targeting-bivalent-covid-19-booster-vaccine-for-adults-18-years-and-older.--moderna2022-09-01T11:23:14+00:00weekly0.6https://www.medthority.com/news/2022/9/topline-data-for-lumakras-phase-iii-codebreak-200-trial-in-nsclc.-amgen2025-02-03T11:00:54+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-xenpozyme-for-acid-sphingomyelinase-deficiency.--sanofi2022-09-01T11:34:41+00:00weekly0.6https://www.medthority.com/news/2022/9/jama-neurology-publishes-positive-pivotal-clinical-trial--vision-dmd-with-vamorolone-in-duchenne-muscular-dystrophy.--santhera-pharma2022-09-01T11:37:15+00:00weekly0.6https://www.medthority.com/news/2022/9/new-clinical-data-demonstrates-100-survival-at-30-days-following-use-of-aquadex-flexflow-system-of-ultrafiltration-in-high-risk-post-operative-coronary-artery-bypass-grafting-cabg-patients.-nuwellis-inc2022-09-01T11:39:27+00:00weekly0.6https://www.medthority.com/news/2022/9/united-therapeutics-prevails-in-dry-powder-inhaler-patent-litigation-against-liquidia-technologies/2022-09-01T11:42:15+00:00weekly0.6https://www.medthority.com/news/2022/9/ons-5010-refiled-with-fda-for-wet-age-related-macular-degeneration.--outlook-therapeutic2022-09-01T11:46:21+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-spevigo-as-the-first-treatment-option-for-generalized-pustular-psoriasis-flares-in-adults.--boehringer2022-09-02T11:17:59+00:00weekly0.6https://www.medthority.com/news/2022/9/novo-nordisk-to-acquire-forma-therapeutics-and-with-it-etavopivat-a-proposed-treatment-for-sickle-cell-disease/2022-09-02T11:13:07+00:00weekly0.6https://www.medthority.com/news/2022/9/nuvaxovid-covid-19-vaccine-recommended-by-chmp-as-a-booster-for-covid-caused-by-acute-severe-respiratory-distress-syndrome--novavax/2022-09-03T14:23:21+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-eu-approval-of-bivalent-covid-19-vaccine.--pfizer-and-biontech-se2022-09-03T14:22:35+00:00weekly0.6https://www.medthority.com/news/2022/9/kerendia-receives-updated-label-from-the-fda--to-include-findings-from-phase-iii-figaro-dkd-cardiovascular-outcomes-study.-bayer2022-09-03T14:21:55+00:00weekly0.6https://www.medthority.com/news/2022/9/msb-11456-tocilizumab-biosimilar-is-filed-at-emain-both-intravenous-and-subcutaneous-routes-of-administration-.--fresenius-kabi2022-09-03T14:21:16+00:00weekly0.6https://www.medthority.com/news/2022/9/top-line-results-of-phase-iii-shield-i-trial-of-d-plex-100-for-the-prevention-of-surgical-site-infections-in-abdominal-surgery.--polypid-ltd2022-09-03T14:20:34+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approval-for-orkambi-in-children-with-cystic-fibrosis-ages-12-to-24-months.--vertex2022-09-03T14:19:52+00:00weekly0.6https://www.medthority.com/news/2022/9/forxiga-approved-in-china-for-the-treatment-of-chronic-kidney-disease-in-patients-at-risk-of-progression-with-and-without-type-2-diabetes.--astrazeneca2022-09-05T12:40:32+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-imfinzi-for-the-treatment-of-adult-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer-in-combination-with-chemotherapy-.--astrazeneca2022-09-05T12:43:34+00:00weekly0.6https://www.medthority.com/news/2022/9/new-data-from-a-post-hoc-subgroup-analysis-from-the-phase-iii-tropics-02-study-evaluating-trodelvy-in-patients-with-hrher2--metastatic-breast-cancer/2022-09-05T12:45:23+00:00weekly0.6https://www.medthority.com/news/2022/9/results-from-phase-iii-open-label-extension-trial-of-dupixent-for-children-aged-6-to-11-years-with-moderate-to-severe-asthma.--regeneron--sanofi2022-09-06T10:43:14+00:00weekly0.6https://www.medthority.com/news/2022/9/new-data--for-nintedanib-in-children-and-adolescents-with-fibrosing-interstitial-lung-disease.--boehringer2022-09-06T11:49:14+00:00weekly0.6https://www.medthority.com/news/2022/9/adapt-study-results-published-in-the-lancet-diabetes--endocrinology-show-improved-glycemic-control-and-treatment-satisfaction-among-those-using-minimed-780g-system-compared-to-insulin-injections.--medtronic2022-09-07T11:50:50+00:00weekly0.6https://www.medthority.com/news/2022/9/nice-uk-recommends-avalglucosidase-alfa-to-treat-pompe-disease--sanofi/2022-09-07T11:39:49+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-removes-clinical-hold-on-phase-ii-momentum-trial-of-srp-5051-in-duchenne-muscular-dystrophy.--sarepta-therapeutics2022-09-07T11:31:55+00:00weekly0.6https://www.medthority.com/news/2022/9/advisory-committee-meeting-to-be-held-to-review-nda-for-daprodustat-to-treat-anaemia-due-to-chronic-kidney-disease-.---glaxo-smith-kline2022-09-07T11:15:38+00:00weekly0.6https://www.medthority.com/news/2022/9/zealand-pharma-as--has-entered-into-a-global-license-agreement-with-novo-nordisk-as-to-commercialize-zegalogue-for-the-treatment-of-severe-hypoglycemia-in-pediatric-and-adult-patients-with-diabetes/2022-09-07T11:13:40+00:00weekly0.6https://www.medthority.com/news/2022/9/new-three-year-bimzelx-data-reinforce-long-term-maintenance-of-complete-skin-clearance-in-moderate-to-severe-plaque-psoriasis--ucb/2025-05-06T13:41:08+00:00weekly0.6https://www.medthority.com/news/2022/9/data-from-mpowered-phase-iii-trial-of-mycapssa--to-be-presented-at-enea-2022--amryt/2022-09-08T11:33:49+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-topline-data-from-phase-iii-study-of-exparel-as-a-single-dose-femoral-nerve-block-in-the-adductor-canal-for-total-knee-arthroplasty.-pacira-biosciences2022-09-08T11:39:59+00:00weekly0.6https://www.medthority.com/news/2022/9/ser-109-rolling-submission-completed-at-fda-for-the-prevention-of-recurrent-c.-difficile-infection--seres-therapeutics-2022-09-08T11:43:36+00:00weekly0.6https://www.medthority.com/news/2022/9/valneva-and-vbi-vaccines-announce-european-partnership-for-marketing-and-distribution-of-prehevbi-for-hepatitis-b/2022-09-08T11:45:28+00:00weekly0.6https://www.medthority.com/news/2022/9/imara-inc.to-sell-imr-687-to-cadurion-pharma2022-09-08T11:47:20+00:00weekly0.6https://www.medthority.com/news/2022/9/equillium-inc.-acquires-metacrine-inc2022-09-08T11:48:45+00:00weekly0.6https://www.medthority.com/news/2022/9/notice-of-opportunity-for-an-fda-hearing-on-the-snda-for-hetlioz-in-jet-lag-disorder.--vanda-pharma2022-09-09T11:47:46+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-authorizes-proprietary-monkeypox-test-for-emergency-use.--quest-diagnostics2022-09-09T11:51:26+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-update-from-european-medicine-agency-on-ntcd-m3-phase-iii-development-plans-to-prevent-cdifficile.---destiny-pharma2022-09-09T11:53:26+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approval-of-daxxify-for-injection-the-first-and-only-peptide-formulated-neuromodulator-with-long-lasting-results-for-glabellar-lines.--revance2022-09-09T11:58:33+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-advisory-committee-supports-approval-of-amx-0035-for-the-treatment-of-amyotrophic-lateral-sclerosis-.--amylyx-pharma2022-09-09T12:02:26+00:00weekly0.6https://www.medthority.com/news/2022/9/aflibercept-8-mg-meets-primary-endpoints-in-two-global-pivotal-trials-for-dme-and-wamd-with-a-vast-majority-of-patients-maintained-on-12--and-16-week-dosing-intervals.--regeneron--bayer2022-09-09T12:04:28+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-topline-outcomes-for-both-phase-iii-pivotal-trials-of-idose-tr-that-achieved-efficacy-endpoints-and-demonstrated-favorable-tolerability-and-safety-profiles.--glaukos-corpn2022-09-09T12:08:44+00:00weekly0.6https://www.medthority.com/news/2022/9/three-year-data-on-the-amplatzer-piccolo-occluder-the-worlds-smallest-heart-device-to-treat-patent-ductus-arteriosus.--abbott2022-09-09T12:10:57+00:00weekly0.6https://www.medthority.com/news/2022/9/lebrikizumab-dosed-every-four-weeks-maintained-durable-skin-clearance-in--phase-iii-monotherapy-atopic-dermatitis-trials.--eli-lilly--almirall2022-09-09T12:12:40+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-results-from-the-apollo-b-phase-iii-study-of-patisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy.--alnylam2022-09-09T12:15:44+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-new-data-from-otezla-studies-sprout-for-pediatric-plaque-psoriasis-and-discreet-for-genital-psoriasis.--amgeb2025-05-06T13:58:26+00:00weekly0.6https://www.medthority.com/news/2022/9/kisqali-adds-one-more-year-of-survival-benefit-for-broadest-set-of-patients-including-those-with-aggressive-hrher2--advanced-breast-cancer-.-novartis2025-02-03T11:05:51+00:00weekly0.6https://www.medthority.com/news/2022/9/3d-modelling-of-hip-dxa-scans-in-postmenopausal-women-with-osteoporosis-reveals-superior-improvements-in-bone-density-of-romosozumab-versus-controls.--ucb--amgen2022-09-09T12:29:22+00:00weekly0.6https://www.medthority.com/news/2022/9/new-data-from-stratum-pivotal-phase-iii-trial-of-roflumilast-foam-0.3-in-seborrheic-dermatitis-presented-at-european-academy-of-dermatology-and-venereology-congress.--arcutis-biotherapeutics2022-09-10T13:34:46+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approval-for-rolvedon--injection-for-management-of-severe-chemotherapy--induced-neutropenia.--spectrum-pharma2022-09-10T13:34:01+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-sotyktu--oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis.--bms2022-09-10T13:29:32+00:00weekly0.6https://www.medthority.com/news/2022/9/lynparza---bevacizumab-and-as-monotherapy-demonstrates-clinically-meaningful-long-term-survival-in-certain-patients-with-first-line-advanced-ovarian-cancer-in-two-phase-iii-trials.--astrazeneca--merck-inc2022-09-10T13:28:45+00:00weekly0.6https://www.medthority.com/news/2022/9/cosentyx-shows-clinically-meaningful-symptom-improvements-in-patients-with-hidradenitis-suppurativa-in-pivotal-phase-iii-trials.--novartis2024-11-14T15:02:52+00:00weekly0.6https://www.medthority.com/news/2022/9/results-from-phase-iii-trials-of-skyrizi-evaluating-long-term-effect-on-skin-and-joint-symptoms-in-patients-with-psoriatic-arthritis-at-week-100.--abbvie2022-09-11T15:31:06+00:00weekly0.6https://www.medthority.com/news/2022/9/measure-ad-analyses-evaluate-clinical-psychosocial-and-economic-burdens-in-atopic-dermatitis-patients.-abbvie2022-09-11T15:30:19+00:00weekly0.6https://www.medthority.com/news/2022/9/results-from-phase-iii-leap-002-trial-evaluating-keytruda--lenvima--versus-lenvima--monotherapy-in-patients-with-unresectable-hepatocellular-carcinoma-liver-cancer--merck-inc.-eisai2022-09-11T15:29:31+00:00weekly0.6https://www.medthority.com/news/2022/9/zejula-shows-durable-and-sustained-long-term-progression-free-survival-benefit-in-the-prima-study-of-first-line-platinum-responsive-advanced-ovarian-cancer.-glaxo-smith-kline2022-09-11T15:25:48+00:00weekly0.6https://www.medthority.com/news/2022/9/tagrisso-demonstrated-5.5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.--astrazeneca2022-09-11T15:24:57+00:00weekly0.6https://www.medthority.com/news/2022/9/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer-nearly-doubling-the-number-of-patients-alive-after-three-years-vs.-chemotherapy.--astrazeneca2025-02-03T11:06:08+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-study-of-shr-1210--aitan-shows-prolonged-survival-in-hepatocellular-carcinoma.--jiangsu-hengrui-pharma2022-09-12T12:50:33+00:00weekly0.6https://www.medthority.com/news/2022/9/imfinzi-plus-chemotherapy-further-improved-overall-survival-benefit-in-advanced-biliary-tract-cancer-in-the-topaz-1-phase-iii-trial-reducing-the-risk-of-death-by-24-in-additional-follow-up.-astrazeneca2022-09-12T12:48:14+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-neoadjuvant-libtayo-monotherapy-data-in-resectable-cutaneous-squamous-cell-carcinoma-presented-at-esmo-and-published-in-nejm.-regeneron-pharma2022-09-13T11:33:04+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-codebreak-200-trial-of-lumakras-shows-improved-pfs-and-orr-in-kras-g12c-mutated-non-small-cell-lung-cancer-.-amgen2025-02-03T14:03:18+00:00weekly0.6https://www.medthority.com/news/2022/9/eodyssey-24-week-phase-iii-trial-of-ak-002-meets-co-primary-endpoint-in-eosinophilic-duodenitis.--allakos2022-09-13T11:25:55+00:00weekly0.6https://www.medthority.com/news/2022/9/imcivree-approved-by-european-commission-for-treatment-of-obesity-and-control-of-hunger-in-bardet-biedl-syndrome.--rhythm-pharma2022-09-13T11:22:56+00:00weekly0.6https://www.medthority.com/news/2022/9/tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia.--kitegilead2022-09-13T11:20:11+00:00weekly0.6https://www.medthority.com/news/2022/9/marketing-approval-and-orphan-drug-designation-for-filsuvez-in-great-britain-to-treatepidermolysis-bullosa-.-amryt2022-09-13T11:17:20+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-terlivaz-to-treat-hepato-renal-syndrome--mallinckrodt/2022-09-16T11:11:44+00:00weekly0.6https://www.medthority.com/news/2022/9/epi-health-a-novan-company-and-mc2-therapeutics-present-wynzora-cream-0.0050.064-subgroup-data-analysis-at-skin-of-color-update-2022-conference2022-09-16T11:15:45+00:00weekly0.6https://www.medthority.com/news/2022/9/new-post-hoc-analysis-of-ongentys--capsules-effect-on-comt-activity-at-the-2022-mds-international-congress---neurocrine-biosciences/2022-09-16T11:18:24+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-checkmate--76k-trial-of-opdivo-in-adjuvant-setting-meets-primary-endpoint-in-melanoma.--bms2022-09-16T11:20:33+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-trial-of-menabcwy-pentavalent-meningococcal-vaccine-meets-primary-endpoints-and-is-set-for-bla.--pfizer2022-09-16T11:22:33+00:00weekly0.6https://www.medthority.com/news/2022/9/narsoplimab-treatment-results-in-critically-ill-covid-19-patients-in-i-spy-covid-trial.-omeros2022-09-16T11:31:47+00:00weekly0.6https://www.medthority.com/news/2022/9/roctavian-is-assessed-to-provide-substantial-cost-savings-per-hemophilia-a-patient-in-a-preliminary-independent-report.-biomarin-pharma2022-09-16T11:34:03+00:00weekly0.6https://www.medthority.com/news/2022/9/beyfortus--recommended-for-approval-in-the-eu-by-chmp-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.-astrazeneca--sanofi.-2025-02-03T14:02:56+00:00weekly0.6https://www.medthority.com/news/2022/9/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-treatment-of-covid-19.--astrazeneca2022-09-16T11:43:14+00:00weekly0.6https://www.medthority.com/news/2022/9/loncastuximab-tesirine-receives-positive-chmp-opinion-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.--sobi---adc-therapeutics2022-09-17T11:10:41+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-extending-the-indication-for-biktarvy-to-include-children-with-hiv.--gilead-sciences2022-09-17T11:13:03+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-chmp-opinion-for-conversion-of-comirnaty-conditional-marketing-authorization-to-full-marketing-authorization-in-the-european-union-and-third-booster-dose-for-children.--pfizer--biontech-se2022-09-17T11:14:27+00:00weekly0.6https://www.medthority.com/news/2022/9/car-t-cell-therapy-yescarta-first-in-europe-to-receive-positive-chmp-opinion-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma.--kitegilead2022-09-17T11:15:57+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-chmp-opinion-for-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-in-infants-and-children.--merck-inc2022-09-17T11:17:20+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-expanded-approval--for-veklury-to-treat-pediatric-patients-with-covid-19.--gilead-sciences2022-09-17T11:19:34+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-approval-of-enjaymo--first-and-only-approved-treatment-for-hemolytic-anemia-in-adult-patients-with-cold-agglutinin-disease.--sanofi2022-09-17T11:23:04+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-chmp-opinion-for-maribavir-for-the-treatment-of-adults-with-post-transplant-cytomegalovirus-refractory-with-or-without-resistance-to-prior-therapies.--takeda2022-09-17T11:24:55+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-adopts-positive-opinion-for-mycapssa-for-the-treatment-of-acromegaly.-amryt2022-09-18T11:00:20+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-pyrukynd--for-the-treatment-of-pyruvate-kinase--deficiency-in-adult-patients--agios-pharma/2022-09-18T13:08:22+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-accelerated-approval-granted--for-skysona-gene-therapy-for-early-active-cerebral-adrenoleukodystrophy.---bluebirdbio2022-09-18T13:07:03+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approval-of-aponvie-htx-019-for-the-prevention-of-postoperative-nausea-and-vomiting-ponv--heron-therapeutics/2022-09-18T13:05:35+00:00weekly0.6https://www.medthority.com/news/2022/9/stada-and-xbrane-welcome-chmp-positive-opinion-for-ranibizumab-biosimilar-candidate--ximluci/2022-09-18T13:04:32+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-alpha-trial-of-alxn-2040-meets-primary-endpoint-in-paroxysmal-nocturnal-haemoglobinuria.--astrazeneca--alexion-pharma2022-09-18T13:03:31+00:00weekly0.6https://www.medthority.com/news/2022/9/eu-approves-opdualag-for-advanced-unresectable-or-metastatic-melanoma.--bms2022-09-18T13:02:20+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-approval-for-adtralza--in-moderate-to-severe-atopic-dermatitis.--leo-pharma2022-09-18T13:01:03+00:00weekly0.6https://www.medthority.com/news/2022/9/six-months-data-from-clasp-iid-trial-of-pascal-system-confirming-teer-as-safe-and-effective-for-degenerative-mitral-regurgitation-dmr-in-first-head-to-head-trial-.-edwards-lifesciences2022-09-18T12:59:39+00:00weekly0.6https://www.medthority.com/news/2022/9/new-data-reinforce-the-safety-and-effectiveness-of-mitraclip-for-treating-mitral-regurgitation.--abbott2022-09-18T12:58:29+00:00weekly0.6https://www.medthority.com/news/2022/9/results-presented-at-tct-meeting-demonstrate-the-benefits-of-triclip-for-tricuspid-regurgitation.--abbott2022-09-20T09:17:16+00:00weekly0.6https://www.medthority.com/news/2022/9/three-year-outcomes-from-amulet-ide-study-of-amplatzer-amulet-laa-occluder-presented-at-tct-meeting.-abbott2022-09-20T07:01:02+00:00weekly0.6https://www.medthority.com/news/2022/9/results-from-protected-tavr-study-evaluating-sentinel-cerebral-protection-system-for-removal-of-embolic-debris-from-tavr-are-presented-at-tct-meeting.--boston-scientific2022-09-20T06:59:25+00:00weekly0.6https://www.medthority.com/news/2022/9/data-from-phase-iii-trial-of-dasiglucagon-in-congenital-hyperinsulinism-are-presented-at-the-60th-annual-espe-meeting.--zealand-pharma2022-09-20T06:57:14+00:00weekly0.6https://www.medthority.com/news/2022/8/kymriah-is-approved-in-japan-to-treatrelapsed-or-refractory-follicular-lymphoma.-novartis-2022-08-31T11:41:09+00:00weekly0.6https://www.medthority.com/news/2022/8/mhlw-japan-approves-evusheld-for-treatment-and-prevention-of-symptomatic-covid-19.--astra-zeneca2022-08-31T11:37:55+00:00weekly0.6https://www.medthority.com/news/2022/8/initiation-of-recruitment-for--phase-iii-clinical-trial-investigating-abelacimab-to-treat-thrombosis-in-patients-diagnosed-with-gigu-cancers.--anthos-therapeutics2022-08-31T11:34:39+00:00weekly0.6https://www.medthority.com/news/2022/8/final-analysis-of-phase-ii-griffin-study-presented-for-darzalex-daratumumab-based-investigational-quadruplet-regimen-in-patients-with-newly-diagnosed-transplant-eligible-multiple-myeloma.-janssen2022-08-31T11:29:47+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-scemblix-for-chronic-myeloid-leukemia-ph-cml-cp.--novartis2022-08-31T11:25:28+00:00weekly0.6https://www.medthority.com/news/2022/8/otsuka-canada--announces-health-canada-approval-of-korsuva-for-the-treatment-of-moderate-to-severe-pruritus-associated-with-chronic-kidney-disease-in-adult-hemodialysis-patients.--cara-therapeutics2022-08-31T11:22:00+00:00weekly0.6https://www.medthority.com/news/2022/8/quizartinib-supplemental-new-drug-application-submitted-in-japan-for-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia.--daichi-sankyo-2022-08-31T11:18:05+00:00weekly0.6https://www.medthority.com/news/2022/8/initiation-of-pivotal-phase-iii-clinical-trial-of-lbs-008-in-stargardt-disease-in-the-u.s.--belite-bio-inc2024-11-14T15:03:13+00:00weekly0.6https://www.medthority.com/news/2022/8/evusheld-vaccine-to-be-submitted-to-nice-for-appraisal.--astrazeneca2022-08-24T11:41:37+00:00weekly0.6https://www.medthority.com/news/2022/8/restore-ef-study-shows-heart-function-symptom-improvements-for-high-risk-pci-patients-supported-by-impella.--abiomed2022-08-24T11:48:14+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-top-line-results-from-phase-iii-study-of-abp-959-biosimilar-to-soliris.--amgen2022-08-24T12:03:17+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-new-proclaim-plus-spinal-cord-stimulation-device-which-provides-tailored-relief-to-multiple-pain-areas-.--abbott2022-08-24T12:05:46+00:00weekly0.6https://www.medthority.com/news/2022/8/moderna-completes-application-to-fda-for-emergency-use-authorization-of-omicron-targeting-bivalent-covid-19-booster-vaccine-mrna-1273.2222022-08-24T12:07:12+00:00weekly0.6https://www.medthority.com/news/2022/8/alcon-to-acquire-aerie-pharmaceuticals/2022-08-24T12:14:45+00:00weekly0.6https://www.medthority.com/news/2022/8/teleflex-to-acquire-standard-bariatrics-inc.-and-with-it-titan-sgs-stapler2022-08-24T12:16:06+00:00weekly0.6https://www.medthority.com/news/2022/8/european-commission-approves-conditionally-roctavian-the-first-gene-therapy-for-adults-with-severe-hemophilia-a.--biomarin-2022-08-25T12:27:23+00:00weekly0.6https://www.medthority.com/news/2022/8/ultomiris-approved-in-japan-for-the-treatment-of-adults-with-generalised-myasthenia-gravis.-alexionastrazeneca-2022-08-25T12:30:45+00:00weekly0.6https://www.medthority.com/news/2022/8/tagrisso-approved-in-japan-for-the-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer--astrazeneca-/2025-02-03T10:59:52+00:00weekly0.6https://www.medthority.com/news/2022/8/novartis-to-spin-off-sandoz/2022-08-25T12:09:01+00:00weekly0.6https://www.medthority.com/news/2022/8/lynparza-approved-in-japan-as-adjuvant-treatment-for-patients-with-brca-mutated-her2-negative-high-risk-early-breast-cancer--astrazeneca--merck-inc/2025-02-03T11:00:10+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-resilient-trial-of-onivyde-fails-to-meet-primary-endpoint-in-small-cell-lung-cancer.--ipsen-biopharma2022-08-26T11:45:48+00:00weekly0.6https://www.medthority.com/news/2022/8/imbruvica-is-fda-approved-to-treat-children-with-chronic-graft-versus-host-disease-.--abbvie2022-08-26T11:59:18+00:00weekly0.6https://www.medthority.com/news/2022/8/first-approval-worldwide-for-tecvayli-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-multiple-myeloma.--janssen2022-08-26T12:01:18+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-top-line-data-from-phase-iii-renoir-trial-of-rsvpref-in-older-adults-for-respiratory-syncytial-virus.--pfizer--2022-08-26T12:04:24+00:00weekly0.6https://www.medthority.com/news/2022/8/updated-covid-19-vaccine-data-supporting-efficacy-in-children-6-months-through-4-years-of-age/2022-08-26T12:10:32+00:00weekly0.6https://www.medthority.com/news/2022/8/erytech-provides-regulatory-update-on-graspa-for-hypersensitive-acute-lymphoblastic-leukemia/2022-08-26T12:12:02+00:00weekly0.6https://www.medthority.com/news/2022/8/moderna-sues-pfizer-and-biontech-for-infringing-patents-central-to-modernas-innovative-mrna-technology-platform/2022-08-27T12:43:19+00:00weekly0.6https://www.medthority.com/news/2022/8/iovance-biotherapeutics-initiates-rolling-submission-with-fda-for-contego-in-advanced-unresectable-or-metastatic-melanoma/2022-08-27T12:42:11+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-pemazyre-for-relapsed-or-refractory-myeloidlymphoid-neoplasms.--incyte2022-08-27T12:40:56+00:00weekly0.6https://www.medthority.com/news/2022/8/mhlw-grants-additional-approval--for-onoact-for-tachyarrhythmia--in-pediatric-patients.--ono-pharma2024-09-30T10:51:10+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-deliver-trial-results-for-farxiga-showing-benefits-in-heart-failure-published-in-nejm.--astrazeneca2022-08-28T12:14:52+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-ranivisio-for-serious-retinal-diseases.--formycon-polpharma-biologics-and-bioeq2022-08-28T12:14:03+00:00weekly0.6https://www.medthority.com/news/2022/8/ritlecitinib-filed-in-japan-for-alopecia-areata-treatment-.--pfizer2022-08-28T12:13:11+00:00weekly0.6https://www.medthority.com/news/2022/8/polivy-is-approved-by-mhlw-in-japan--to-treat-previously-untreated-diffuse-large-b-cell-lymphoma-dlbcl.--chugairoche2022-08-29T11:22:10+00:00weekly0.6https://www.medthority.com/news/2022/8/extravascular-icd-ev-icd-system-meets-global-pivotal-clinical-trials-safety-and-effectiveness-endpoints.-medtronic2024-09-30T10:44:55+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-pivotal-trial-results-as-assessed-by-an-irc-with-matured-long-term-follow-up-of-abivertinib-for-advanced-non-small-cell-lung-cancer.--sorrento-therapeutics2025-02-03T11:00:36+00:00weekly0.6https://www.medthority.com/news/2022/8/new-data-indicate-positive-effects-of-kerendia-on-mortality-in-patients-with-chronic-kidney-disease-and-type-2-diabetes.--bayer2022-08-30T12:49:29+00:00weekly0.6https://www.medthority.com/news/2022/8/new-data-show--heartmate-3-heart-pump-extends-life-beyond-five-years-for-advanced-heart-failure-patients.--abbott2022-08-30T12:47:51+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-study-results-for-vla-2001-show-positive-immunogenicity-and-booster-data-in-covid-19.--valneva-se2022-08-30T12:45:42+00:00weekly0.6https://www.medthority.com/news/2022/8/quizartinib-maa-validated-by-ema-for-treatment-of-adult-patients-with-newly-diagnosed-flt3itd-positive-acute-myeloid-leukemia.--daiichi-sankyo2022-08-30T12:44:16+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-grants-priority-review-to-efanesoctocog-alfa-for-people-with-haemophilia-a-and-provides-pdufa-date.---sobi--sanofi2022-08-30T12:42:49+00:00weekly0.6https://www.medthority.com/news/2022/8/bayer-initiates-landmark-phase-iii-study-program-to-investigate-oral-fxia-inhibitor-asundexian/2022-08-30T12:41:20+00:00weekly0.6https://www.medthority.com/news/2022/8/new-data-presented-at-esc-2022--show-long-term-data-of-ldl-c-lowering-with-repatha-which-was-well-tolerated-over-eight-years.-amgen2022-08-30T12:39:17+00:00weekly0.6https://www.medthority.com/news/2022/8/therapeutic-goods-administration-provisionally-approves-omicron-containing-bivalent-booster-vaccine-mrna-1273.214-for-australia.--moderna2022-08-30T12:30:40+00:00weekly0.6https://www.medthority.com/news/2022/8/supplementary-nda-is-submitted-in-japan-for-antiepileptic-drug-fycompa-injection-formulation-as-a-new-route-of-administration.--eisai2022-08-30T12:29:01+00:00weekly0.6https://www.medthority.com/news/2022/8/boston-scientific-acquires-obsidio-inc.-and-with-it-gel-embolic-material-technology2022-08-30T12:24:45+00:00weekly0.6https://www.medthority.com/news/2022/8/enhertu-significantly-delayed-disease-progression-in-destiny-breast02-phase-iii-trial-vs.-physicians-choice-of-treatment-in-patients-with-her2-positive-metastatic-breast-cancer.--daiichi-sankyo--astrazeneca2022-08-15T11:18:11+00:00weekly0.6https://www.medthority.com/news/2022/8/update-on-phase-iii-canopy-a-study-evaluating-canakinumab-as-adjuvant-treatment-in-non-small-cell-lung-cancer-.--novartis2022-08-15T11:13:12+00:00weekly0.6https://www.medthority.com/news/2022/8/lynparza-in-combination-with-abiraterone-granted-priority-review-in-the-us-for-patients-with-metastatic-castration-resistant-prostate-cancer.--astrazeneca--merck-inc2022-08-17T11:39:12+00:00weekly0.6https://www.medthority.com/news/2022/8/application-to-the-fda-for-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-as-a-booster-in-adults-aged-18-and-older.--novavax2022-08-17T11:37:02+00:00weekly0.6https://www.medthority.com/news/2022/8/nice-uk-recommends-tremfya-guselkumab-to-treat-psoriatic-arthritis.--eli-lilly2022-08-17T11:35:20+00:00weekly0.6https://www.medthority.com/news/2022/8/endo-enters-into-restructuring-support-agreement-with-senior-secured-debtholders-to-strengthen-financial-position.-2022-08-17T11:33:20+00:00weekly0.6https://www.medthority.com/news/2022/8/edirols-tablet-form-approved-in-japan-for-osteoporosis.-towa-responsible-for-distribution.--chugai--towa2022-08-18T11:57:19+00:00weekly0.6https://www.medthority.com/news/2022/8/scilex-holding-company-announces-exclusive-product-distribution-agreement-with-ch-trading-group-llc-to-commercialise-ztlido-across-certain-designated-territories-including-middle-east-and-north-africa--scilex-holding-company/2022-08-18T11:44:41+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-top-line-results-from-pioneer-trial-of-ayvakit--in-patients-with-non-advanced-systemic-mastocytosis-achieved-primary-and-all-key-secondary-endpoints-.--blueprint-medicines2022-08-18T11:41:01+00:00weekly0.6https://www.medthority.com/news/2022/8/sanofi-halts-development-of-amcenestrant-for-breast-cancer/2022-08-18T11:38:37+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-hadlima-high-concentration-form-as-biosimilar-for-humira.--samsung-bioepis-and-organon2022-08-18T11:36:13+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-zynteglo-to-treat-beta-thalassemia.-bluebird-bio2022-08-18T11:34:09+00:00weekly0.6https://www.medthority.com/news/2022/8/ce-mark-for-pascal-precision-transcatheter-valve-repair-system-for-the-treatment-of-mitral-and-tricuspid-regurgitation.--edwards-lifesciences2022-08-18T11:05:15+00:00weekly0.6https://www.medthority.com/news/2022/8/first-patient-enrolled-and-dosed-in-pivotal-phase-iii-study-evaluating-lb-1148-for-post--operative-return-of-bowel-function.--palisade-bio2022-08-18T11:02:48+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-results-for-csl-312-meet-primary-and-secondary-objectives-in-hereditary-angioedema.--csl-behring2022-08-19T12:20:51+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-pepaxti-in-multiple-myeloma-with-at-least-three-prior-lines-of-therapies.--oncopeptides2022-08-19T12:19:13+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-accepts-filing-for-cyt-387-in-myelofibrosis.--gsk2022-08-19T11:57:35+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-accepts-nda-for-esn-364-in-vasomotor-symptoms-with-menopause.--astellas-pharma2022-08-19T11:52:25+00:00weekly0.6https://www.medthority.com/news/2022/8/health-canada-grants-accelerated-approval-for-lynparza-for-the-adjuvant-treatment-of-deleterious-germline-brca--mutated-g-brca-m-human-epidermal-growth-factor-receptor-2-her2-negative-high-risk-early-breast-cancer.---astrazeneca--merck-inc2022-08-19T11:50:37+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-rolling-submission-of-vla-1553-vaccine-begins-for-chikungunya-fever.--valneva-se2022-08-19T11:47:54+00:00weekly0.6https://www.medthority.com/news/2022/8/ema-accepts-filing-for-aeb-1102-in-arginase-1-deficiency.--immedica-pharma2022-08-19T11:46:09+00:00weekly0.6https://www.medthority.com/news/2022/8/mirena-approved-in-the-us-for-extended-duration-of-use-in-contraception.--bayer2022-08-19T11:43:27+00:00weekly0.6https://www.medthority.com/news/2022/8/nice-positive-recommendation-for-opdivo--yervoy-to-treat-malignant-pleural-mesothelioma.--bms2022-08-19T11:41:48+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-vegzelma-for-breast-cancer-non-small-cell-lung-cancer-renal-cell-cancer-carcinoma-of-the-colon-or-rectum-ovarian-cancer-and-cervical-cancer.--celltrion-healthcare2022-08-20T11:09:52+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approval-of-auvelity-the-first-and-only-oral-nmda-receptor-antagonist-for-the-treatment-of-major-depressive-disorder-in-adults.--axsome-therapeutics2022-08-20T11:15:18+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-crysvita-for-fgf23-related-hypophosphataemia-in-tumour-induced-osteomalacia.--kyowa-kirin2022-08-20T11:17:35+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-it-matters-trial-of-multikine-in-head-and-neck-cancer-announces-10-year-results-for-fda-submission.--cel-sci-corp2022-08-21T12:16:04+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-activate-t-study-of-pyrukynd-in-pyruvate-kinase-deficiency-published-in-the-lancet-haematology.--agios-pharma2022-08-21T12:14:06+00:00weekly0.6https://www.medthority.com/news/2022/8/cel-sci-corpn-to-commence-phase-iii-trial-of-multikine-in-head-and-neck-cancer/2022-08-22T11:45:38+00:00weekly0.6https://www.medthority.com/news/2022/8/european-commission-approves--sunlenca-the-only-twice-yearly-hiv-treatment-option.--gilead-sciences2022-08-22T11:26:22+00:00weekly0.6https://www.medthority.com/news/2022/8/application-is-submitted-to-fda-for-emergency-use-authorization-of-omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine.--pfizer--biontech-se2022-08-23T12:25:46+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccine-adjuvanted-for-adolescents-aged-12-through-17.--novavax2022-08-23T12:24:11+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-accepts-filing-of-rezafungin-for-invasive-candidiasis.--mundipharma-2022-08-23T12:21:09+00:00weekly0.6https://www.medthority.com/news/2022/8/roche-launches--digital-lightcycler-system-a-digital-pcr-system-a-powerful-new-diagnostics-platform-in-the-fight-against-cancer-and-other-diseases/2022-08-23T12:17:33+00:00weekly0.6https://www.medthority.com/news/2022/8/nda-submitted-to-fda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia.--minerva-neurosciences2022-08-23T11:53:10+00:00weekly0.6https://www.medthority.com/news/2022/7/headline-results-announced-from-the-onwards-3-and-onwards-4-phase-iiia-trials-with-once-weekly-insulin-icodec-in-adults-with-type-2-diabetes.--novo-nordisk2022-07-30T12:25:51+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-approves-zoryve-cream-0.3-for-the-treatment-of-plaque-psoriasis.--arcutis-biotherapeutics-inc2022-07-30T12:25:05+00:00weekly0.6https://www.medthority.com/news/2022/7/eu-approves-rinvoq-in-non-radiographic-axial-spondyloarthritis.--abbvie2022-07-31T14:17:39+00:00weekly0.6https://www.medthority.com/news/2022/7/new-drug-application-of-fgfr-inhibitor-futibatinib-filed-with-mhlw-japan-for-biliary-tract-cancer.--taiho2022-07-31T14:16:54+00:00weekly0.6https://www.medthority.com/news/2022/7/sarepta-therapeutics-announces-intent-to-submit-an-accelerated-approval-bla-for-its-gene-therapy-srp-9001-to-treat-duchenne-muscular-dystrophy/2022-07-31T14:16:10+00:00weekly0.6https://www.medthority.com/news/2022/7/update-on-checkmate--914-trial-evaluating-opdivo--yervoy-as-adjuvant-treatment-of-localized-renal-cell-carcinoma.--bms2022-07-31T14:15:23+00:00weekly0.6https://www.medthority.com/news/2022/7/health-canada-approves-rinvoq-to--treat-active-ankylosing-spondylitis.--abbvie2022-07-25T12:53:54+00:00weekly0.6https://www.medthority.com/news/2022/7/european-approval-for-zokinvy-for-hutchinson-gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies.--eiger-biopharmceuticals2022-07-25T12:53:07+00:00weekly0.6https://www.medthority.com/news/2022/7/european-commission-approves-kinpeygo-for-adults-with-primary-iga-nephropathy.---calliditas-therapeutics-ab--stada-arzneimittel-ag2022-07-25T12:49:59+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-accepts-bla-for-first-of-a-kind-biosimilar-natalizumab-to-treat-indications-covered-by-tysabri.--sandoz2022-07-25T12:49:08+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-tezspire-the-first-and-only-biologic-recommended-for-eu-approval-in-patients-with-severe-asthma-with-no-phenotype-or-biomarker-limitations---astrazeneca/2022-07-25T12:48:11+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-ultomiris-to-treat-patients-with-generalised-myasthenia-gravis-who-are-anti-acetylcholine-receptor-achr-antibody-positive.--astrazeneca2022-07-25T12:47:25+00:00weekly0.6https://www.medthority.com/news/2022/7/topline-results-for-onward-phase-iii-trial-for-ad-04-in-patients-with-alcohol-use-disorder.--adial-pharmaceuticals2022-07-27T11:49:03+00:00weekly0.6https://www.medthority.com/news/2022/7/mhra-will-support-expedited-review-ofsabizabulin-treatment-in-hospitalized-covid-19-patients-at-high-risk-for-acute-respiratory-distress-syndrome.--veru-inc2022-07-27T11:46:26+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-trial-of-bucillamine-under-analysis-and-setting-new-end-points-in-covid-19.--revive-therapeutics2022-07-27T11:42:47+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-study-of-oral-paclitaxel--encequidar-in-breast-cancer-published-in-journal-of-clinical-oncology.--athenex-2022-07-27T11:41:22+00:00weekly0.6https://www.medthority.com/news/2022/7/eu-approves-bypassing-agent-cevenfacta-for-haemophilia-a-or-b-.--lfb2022-07-27T11:38:28+00:00weekly0.6https://www.medthority.com/news/2022/7/enhertu-granted-priority-review-by-the-fda-for-patients-with-her2-low-metastatic-breast-cancer.--daiichi-sankyo--astrazeneca2022-07-27T11:36:36+00:00weekly0.6https://www.medthority.com/news/2022/7/npma-china-conditionally--approves-azvudine-first-oral-antiviral-made-in-china-to-treat-covid-19--genuine-biotech/2022-07-27T11:34:59+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-accepts-nda-for-tofersen-to-treat-for-superoxide-dismutase-1-amyotrophic-lateral-sclerosis-.--biogenimnc2022-07-27T11:31:57+00:00weekly0.6https://www.medthority.com/news/2022/7/mhlw-japan--provides-supplemental-approval-for-nuvaxovid-to-prevent-covid-19-in-adolescents-caused-by-severe-acute-respiratory-syndrome-.--novavax2022-07-27T11:29:48+00:00weekly0.6https://www.medthority.com/news/2022/7/tga-australia--grants-expended-approval-for-nuvaxovid-to-prevent-covid-19-caused-by-severe-acute-respiratory-syndrome-in-adolescents--novavax/2022-07-27T11:28:03+00:00weekly0.6https://www.medthority.com/news/2022/7/peer-reviewed-publication-of--phase-iii-clinical-trials-on-novel-nitric-oxide-nasal-spray-for-covid-19-in-lancet-journal.-sanotize-research--development-corp--glenmark-pharma2022-07-27T11:26:28+00:00weekly0.6https://www.medthority.com/news/2022/7/eu-approves-rinvoq-for-active-ulcerative-colitis.--abbvie2022-07-27T11:23:06+00:00weekly0.6https://www.medthority.com/news/2022/7/paladin-phase-iv-study-confirms-safety-of-iluvien-in-diabetic-macular-oedema.--alimera-sciences2022-07-27T11:20:45+00:00weekly0.6https://www.medthority.com/news/2022/7/uk-mhra-approves-oxbryta-for-hemolytic-anemia-due-to-sickle-cell-disease.--global-blood-therapeutics2022-07-27T11:19:02+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-data-evaluating-vivjoa-in-recurrent-vulvovaginal-candidiasis-published-in-nejm-evidence.--mycovia-pharma2022-07-27T11:16:34+00:00weekly0.6https://www.medthority.com/news/2022/7/aurinia-pharmaceuticals-notification-regarding-inter-partes-patent-review-for-lupkynis/2022-07-27T11:13:43+00:00weekly0.6https://www.medthority.com/news/2022/8/update-on-astrazeneca-sponsored-interlink-1-phase-iii-study-of-monalizumab--cetuximab-for-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-.--innate-pharma-sa2022-08-01T11:33:04+00:00weekly0.6https://www.medthority.com/news/2022/8/chmp-recommends-restricting-third-line-rucaparib-use-in-brca-ovarian-cancer.--clovis-oncology2025-02-03T14:08:52+00:00weekly0.6https://www.medthority.com/news/2022/8/jeil-pharmaceutical-secures-rights-to-cefiderocol--a-siderophore-cephalosporin-antibacterial-drug-in-south-korea.--shionogi2022-08-02T11:35:39+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-accepts-snda-and-gives-priority-review-to-brexafemme-in-vulvovaginal-candidiasis.--scynexis-2022-08-02T11:39:55+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-thrive-aa2-trial-of-ctp-543-meets-endpoints-in-alopecia-areata.--concert-pharma2022-08-02T11:42:34+00:00weekly0.6https://www.medthority.com/news/2022/8/regulatory-applications-to-fda-and-ema-for-upadacitinib-in-crohns-disease-submitted--abbvie/2022-08-02T11:45:59+00:00weekly0.6https://www.medthority.com/news/2022/8/stelara-approved-by-the-fda-to-treat-pediatric-patients-with-active-psoriatic-arthritis.--janssen2022-08-02T11:48:23+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-benlysta-for-children-with-lupus-nephritis.---gsk2022-08-03T11:05:31+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-imscin001-study-of-subcutaneous-tecentriq-meets-primary-endpoint-in-nsclc.--genentechroche2025-02-03T10:55:04+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-accepts-re-submitted--nda-for-acer-001-to-treat-patients-with-urea-cycle-disorders.--acer-therapeutics--relief-therapeutics2022-07-29T11:04:36+00:00weekly0.6https://www.medthority.com/news/2022/7/biktarvy-demonstrates-high-efficacy-for-a-broad-range-of-people-initiating-treatment-for-hiv-including-those-with-hbv-coinfection.--gilead-sciences2022-07-29T11:05:44+00:00weekly0.6https://www.medthority.com/news/2022/7/bausch-health-provides-update-following-oral-order-in-xifaxan-patent-litigation/2022-07-29T11:06:49+00:00weekly0.6https://www.medthority.com/news/2022/7/positive-phase-ii-data-on-litifilimab-biib059-in-cutaneous-lupus-erythematosus-published-in-nejm.--biogen-inc2022-07-29T11:08:10+00:00weekly0.6https://www.medthority.com/news/2022/7/roflumilast-cream-0.3-is-filed-with-health-canada-to-treat-plaque-psoriasis.-arcutis-biotherapeutics-inc2022-07-29T11:09:21+00:00weekly0.6https://www.medthority.com/news/2022/7/cidara-therapeutics-submits-nda-for-rezafungin-and-announces-license-agreement-with-melinta-therapeutics-for-commercialization-of-rezafungin-in-the-usa/2022-07-28T12:16:19+00:00weekly0.6https://www.medthority.com/news/2022/8/rain-therapeutics-announces-completion-of-enrollment-in-phase-iii-mantra-trial-for-milademetan-in-liposarcoma/2022-08-05T12:08:33+00:00weekly0.6https://www.medthority.com/news/2022/8/lynparza-approved-in-the-eu-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.--astrazeneca--merck-inc2025-02-03T10:56:25+00:00weekly0.6https://www.medthority.com/news/2022/8/amgen-to-acquire-chemocentryx-and-with-it-tavneos-a-treatment-for-anca-associated-vasculitis/2022-08-05T12:05:46+00:00weekly0.6https://www.medthority.com/news/2022/8/lnitiation-of-phase-iibiii-hummingbird-global-clinical-trial-for-the-novavax-covid-19-vaccine-in-children-aged-six-months-through-11-years.--novavax2022-08-06T13:30:25+00:00weekly0.6https://www.medthority.com/news/2022/8/brilacidin-a-defensin-mimetic-drug-candidate-exhibiting-broad-spectrum-antiviral-properties-is-to-be-evaluated-for-its-treatment-potential-against-the-monkeypox-virus.--innovation-pharma2022-08-06T13:28:46+00:00weekly0.6https://www.medthority.com/news/2022/8/calquence-tablet-formulation-approved-in-the-us-across-current-indications--astrazeneca/2022-08-06T13:27:20+00:00weekly0.6https://www.medthority.com/news/2022/8/complete-response-letter-from-fda-for-snda-for-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheimers-disease-psychosis.-acadia-pharma2022-08-06T13:25:20+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-lifts-partial-hold-on-trials-with-bcx-9930-in-paroxysmal-nocturnal-hemoglobinuria.--biocryst-pharma-2022-08-06T13:23:07+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-keynote-921-trial-of-keytruda--chemotherapy-failed-to-meet-dual-primary-endpoints-in-metastatic-castration-resistant-prostate-cancer.--merck-inc2022-08-06T13:21:08+00:00weekly0.6https://www.medthority.com/news/2022/8/pfizer-to-discontinue-development-program-for-pf-07265803-for-lmna-related-dilated-cardiomyopathy/2022-08-06T13:19:40+00:00weekly0.6https://www.medthority.com/news/2022/8/enhertu-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.--daiichi-sankyo--astrazeneca2022-08-06T13:18:15+00:00weekly0.6https://www.medthority.com/news/2022/8/-fda-approval-of-myfembree-a-once-daily-treatment-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis.--pfizer--myovant-sciences-2022-08-06T13:16:18+00:00weekly0.6https://www.medthority.com/news/2022/8/-fda-approval-of-myfembree-a-once-daily-treatment-for-the-management-of-moderate-to-severe-pain-associated-with-endometriosis2.--pfizer--myovant-sciences-2022-08-06T13:13:57+00:00weekly0.6https://www.medthority.com/news/2022/8/gilead-sciences-to-acquire-mirobio-and-with-it-mb-272/2022-08-06T13:11:31+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-an-snda-for-nubeqa-plus-docetaxol-in-metastatic-hormone-sensitive-prostate-cancer.--bayer2022-08-07T15:22:40+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-xalkori-to-treat--anaplastic-lymphoma-kinase-alk-positive-myofibroblastic-tumors.--pfizer2022-08-08T11:17:08+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-emergent-2-trial-of-karxt-meets-primary-endpoint-in-adults-with-schizophrenia.--zai-labkaruna-therapeutics2022-08-09T11:50:44+00:00weekly0.6https://www.medthority.com/news/2022/8/eli-lilly-and-company-announced--the-availability-of-a-new-citrate-free-formulation-of-taltz/2022-08-09T11:43:56+00:00weekly0.6https://www.medthority.com/news/2022/8/tagrisso--savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-with-high-levels-of-met-overexpression-andor-amplification-in-savannah-phase-ii-trial.--astrazeneca--hutchmed2022-08-09T11:41:49+00:00weekly0.6https://www.medthority.com/news/2022/8/pfizer-acquires-global-blood-therapeutics-and-with-it-oxbryta/2022-08-09T11:37:48+00:00weekly0.6https://www.medthority.com/news/2022/8/japan-approves-km-biologics-smallpox-vaccine-for-monkeypox.--km-biologics2022-08-04T11:52:06+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approves-cimerli-as-the-first-and-only-interchangeable-biosimilar-to-lucentis-for-all-five-indications-with-12-months-of-interchangeability-exclusivity.--coherus-biosciences2022-08-04T11:50:40+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-topline-results-reported-from-apollo-b-phase-iii-study-of-patisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy.--alnylam-pharma2022-08-04T11:49:27+00:00weekly0.6https://www.medthority.com/news/2022/8/positive-phase-iii-trial-results-for-pd-1-inhibitor-tislelizumab-in-first-line-unresectable-hepatocellular-cancer-liver-cancer--beigene--novartis/2022-08-11T11:31:10+00:00weekly0.6https://www.medthority.com/news/2022/8/ensifentrine-meets-primary-endpoint-in-phase-iii-enhance-2-trial-for-copd.--verona-pharma-plc2022-08-11T11:28:58+00:00weekly0.6https://www.medthority.com/news/2022/8/wall-street-journal-reports-that-endo-international-plc-faces-imminent-bankruptcy/2022-08-11T11:32:17+00:00weekly0.6https://www.medthority.com/news/2022/8/topline-results-from-karmma-3-trial-showing-abecma-significantly-improves-progression-free-survival-versus-standard-regimens-in-rr-multiple-myeloma.--bms--2seventy-bio-inc2022-08-11T11:18:28+00:00weekly0.6https://www.medthority.com/news/2022/8/biora-therapeutics-announces-successful-completion-of-device-performance-study-in-ulcerative-colitis-patients-for-its-targeted-therapeutics-platform/2022-08-11T11:16:18+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-ii-tuxedo-1-trial-of-enhertu-in-breast-cancer-with-brain-metastases-published-in-nature-medicine.--daiichi-sankyo--astrazeneca2022-08-11T11:14:33+00:00weekly0.6https://www.medthority.com/news/2022/8/publication-of-phase-iii-intrigue-clinical-study-result-of-qinlock-in-journal-of-clinical-oncology.--deciphera-pharma2022-08-11T11:11:35+00:00weekly0.6https://www.medthority.com/news/2022/8/new-study-shows-i-stat-tbi-plasma-test-for-concussion-could-predict-outcomes-from-brain-injury-and-inform-treatment-interventions.--abbott2022-08-12T12:24:33+00:00weekly0.6https://www.medthority.com/news/2022/8/eu-approves-vyvgart-for-generalized-myasthenia-gravis.--argenx2022-08-12T12:19:34+00:00weekly0.6https://www.medthority.com/news/2022/8/enrollment-complete-in-phase-iii-explorer-cn-study-of-mavacamten-in-chinese-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy.--lianbio2022-08-12T12:10:07+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-accepts-nda-for-elacestrant-to-treat-patients-with-erher2--advanced-or-metastatic-breast-cancer.-menarini2022-08-12T12:08:44+00:00weekly0.6https://www.medthority.com/news/2022/8/publication-of-phase-ii-data-in-the-lancet-demonstrating-safety-and-efficacy-of-pyrukynd-in-non-transfusion-dependent-alfa--and-beta-thalassemia.--agios-pharma2022-08-12T12:03:53+00:00weekly0.6https://www.medthority.com/news/2022/8/fda-approval-of-xofluza-to-treat-influenza-in-children-aged-five-years-and-older.--roche2022-08-12T12:02:03+00:00weekly0.6https://www.medthority.com/news/2022/8/enhertu-approved-by-the-fda-as-the-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-non-small-cell-lung-cancer-.--astrazeneca--daiichi-sankyo2022-08-12T11:59:28+00:00weekly0.6https://www.medthority.com/news/2022/8/pfizer-and-valneva-initiate-phase-iii-study-of-lyme-disease-vaccine-candidate-vla-15/2022-08-10T12:46:25+00:00weekly0.6https://www.medthority.com/news/2022/8/cormedix-receives-a-second-complete-response-letter-from-the-fda-for-defencath/2022-08-10T12:44:27+00:00weekly0.6https://www.medthority.com/news/2022/8/phase-iii-covid-19-study-of-veru-111-halted-for-clear-demonstration-of-efficacy-in-covid-19-ards.--veru-inc-2022-08-10T12:40:19+00:00weekly0.6https://www.medthority.com/news/2022/8/bone-therapeutics-to-merge-with-medsenic/2022-08-10T12:34:09+00:00weekly0.6https://www.medthority.com/news/2022/8/european-commission-approves-imbruvika-in-a-fixed-duration-combination-regimen-for-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia.-janssen2022-08-13T14:39:10+00:00weekly0.6https://www.medthority.com/news/2022/8/pivotal-phase-iii-study-of-20vpnc-vaccine-meets-2-co-primary-objectives-in-invasive-pneumococcal-disease.--pfizer2022-08-13T14:38:06+00:00weekly0.6https://www.medthority.com/news/2022/8/two-deaths-of-children-reported-from-zolgensma-treatment-for-spinal-muscular-atrophy.--novartis2022-08-14T13:34:59+00:00weekly0.6https://www.medthority.com/news/2022/8/mhra-grants-marketing-authorisation-for--radioligand-therapy-pluvicto-lutetium-177-lu-vipivotide-tetraxetan-in-advanced-prostate-cancer-in-great-britain.-novartis--advanced-accelerator-applications2022-08-14T13:34:13+00:00weekly0.6https://www.medthority.com/news/2022/8/valneva-suspends-manufacturing-of-vla-2001-vaccine-for-covid-19/2022-08-14T13:33:02+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-lynk-003-trial-of-lynparza-for-colorectal-cancer-is-stopped-for-futility.--merck-inc.--astrazeneca2022-07-22T12:30:09+00:00weekly0.6https://www.medthority.com/news/2022/7/eu-issues-full-approval-of-nexpovio-in-multiple-myeloma.--karyopharm-therapeutics2022-07-22T12:28:38+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-advance-1-trial-of-hyqvia-meets-primary-endpoint-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy.--takeda2022-07-22T12:26:54+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-imvanex--to-protect-people-with-monkeypox.-bavarian-nordic2022-07-22T11:24:56+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-positive-recommendation-for-lupkynis-to-treat-lupus-nephritis.--otsuka--aurinia-pharma2022-07-23T11:39:33+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-vabysmo-to-treat-neovascular-or-wet-age-related-macular-degeneration-and-visual-impairment-due-to-diabetic-macular-edema-.--roche2022-07-23T11:42:10+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-veklury--for-a-marketing-authorization--that-is-no-longer-subject-to-specific-obligations.--gilead-sciences2022-07-23T11:45:19+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-amuvttra-to-treat-hereditary-transthyretin-mediated-hattr-amyloidosis.--alnylam-pharma2022-07-23T11:47:21+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-mounjaro-to-treat-type-2-diabetes.--eli-lilly2022-07-23T11:49:05+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-tecartus-to-treat-relapsed-or-refractory-rr-b-cell-precursor-acute-lymphoblastic-leukemia-all.-kitegilead2022-07-23T11:52:41+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-approval-of-opdualag-in-unresectable-or-metastatic-melanoma.--bms2022-07-23T11:54:40+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-approval-of-tecvayli-in-multiple-myeloma.--janssen-cilag-international2022-07-23T11:56:36+00:00weekly0.6https://www.medthority.com/news/2022/7/chmp-recommends-imcrivee-for-the-treatment-of-obesity-and-control-of-hunger-in-adult-and-pediatric-patients-6-years-of-age-and-older-with-genetically-confirmed-bardet-biedl-syndrome.--rhythm-pharma2022-07-23T11:59:21+00:00weekly0.6https://www.medthority.com/news/2022/7/topline-results-announced-from-palisade-1-phase-iii-clinical-trial-for-investigational-drug-ph-94b.--vistagen2022-07-23T12:02:19+00:00weekly0.6https://www.medthority.com/news/2022/7/marketing-authorization-application-to-ema-submitted-for-atogepant-for-the-preventive-treatment-of-migraine.--abbvie2022-07-24T11:35:43+00:00weekly0.6https://www.medthority.com/news/2022/7/abbvie-and-istar-medical-announce-strategic-alliance-for-the-treatment-of-glaucoma.-abbvie-2022-07-24T11:37:08+00:00weekly0.6https://www.medthority.com/news/2022/7/ars-pharma-and-silverback-therapeutics-will-merge-and-operate-in-future-as-ars-pharma/2022-07-25T12:54:23+00:00weekly0.6https://www.medthority.com/news/2022/7/top-line-data-reported-for-phase-iii-oval-trial-of-vb-iii-ofra-vec-in-patients-with-platinum--resistant-ovarian-cancer.--vbl-therapeutics2022-07-21T12:49:49+00:00weekly0.6https://www.medthority.com/news/2022/7/phase-iii-keynote-412-trial-of-keytruda-fails-to-meet-primary-endpoint-in-head-and-neck-cancer.--merck-inc2022-07-21T12:48:20+00:00weekly0.6https://www.medthority.com/news/2022/7/eu-approves-upstaza-for-aromatic-l-amino-acid-decarboxylase-aadc-deficiency.--ptc-therapeutics2022-07-21T12:38:45+00:00weekly0.6https://www.medthority.com/news/2022/7/sbla-accepted-by-fda-for-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation---sandoz/2022-07-21T12:35:41+00:00weekly0.6https://www.medthority.com/news/2022/7/data-from-restore-study-shows-lumevoq-improves-vision-in-leber-hereditary-optical-neuropathy.--gensight-biologics-2022-07-21T12:13:03+00:00weekly0.6https://www.medthority.com/news/2022/7/mhra-approves-tecovirimat-to-prevent-smallpox-monkeypox-cowpox-and-vaccinia-complications.--siga-technologies2022-07-19T12:01:33+00:00weekly0.6https://www.medthority.com/news/2022/7/nmpa-china-approves-cosela--to-decrease-the-incidence-of-chemotherapy-induced-myelosuppression---for-extensive-stage-small-cell-lung-cancer.-g1-therapeutics--simcere-pharma2022-07-19T11:58:10+00:00weekly0.6https://www.medthority.com/news/2022/7/health-canada-authorises-covid-19-vaccine-spikevax-in-young-children-6-months-to-5-years.---moderna-inc2022-07-19T11:54:47+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-approval-of-zonisade-to-control-partial-seizures-convulsions-in-the-treatment-of-epilepsy.---eton-pharma--azurity-pharma2022-07-19T11:52:27+00:00weekly0.6https://www.medthority.com/news/2022/7/resubmission-of-nda-for-acer-001-for-treatment-of-urea-cycle-disorders.-acer-therapeutics2022-07-19T11:50:10+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-approves-opzelura-1.5-cream-for-the-topical-treatment-of-nonsegmental-vitiligo-in-adult-and-pediatric-patients-12-years-of-age-and-older.--incyte2022-07-19T11:46:38+00:00weekly0.6https://www.medthority.com/news/2022/7/enhertu-approved-in-the-eu-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens.---daiichi-sankyo--astrazeneca2025-02-03T14:08:10+00:00weekly0.6https://www.medthority.com/news/2022/7/tga-australiagrants-provisional-approval-for-modernas-covid-19-vaccine-in-children-aged-six-months-to-five-years/2022-07-19T11:34:49+00:00weekly0.6https://www.medthority.com/news/2022/7/ultragenyx-to-acquire-genetx-and-with-it-gtx-102-a-potential-treatment-for-angelman-syndrome/2022-07-19T11:32:18+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-accepts-and-grants-priority-review-of-the-nda-for-pegcetacoplan-for-the-treatment-of-geographic-atrophy-secondary-to-amd.--apellis-pharma2022-07-20T11:21:54+00:00weekly0.6https://www.medthority.com/news/2022/7/launch-of-the-elecsys-hcv-duo-immunoassay-in-countries-that-accept-the-ce-mark.--roche2022-07-18T11:07:05+00:00weekly0.6https://www.medthority.com/news/2022/7/takhzryo--demonstrated-positive-results-in-the-prevention-of-hae-attacks-in-first-and-only-open-label-phase-iii-trial-in-children-ages-2-to-less-than-12-years.--takeda2022-07-04T11:22:59+00:00weekly0.6https://www.medthority.com/news/2022/7/novo-nordisk-pharma--has-submitted-an-application-in-japan-seeking-a-label-expansion-sogroya-subcutaneous-injection-for-the-treatment-of-short-stature-due-to-growth-hormone-deficiency-without-epiphyseal-closure/2022-07-05T12:22:01+00:00weekly0.6https://www.medthority.com/news/2022/7/reproxalap-ophthalmic-solution-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial.-aldeyra-therapeutics2022-07-13T11:32:11+00:00weekly0.6https://www.medthority.com/news/2022/7/vertex-pharma-acquires-viacyte-to-complement-internal-work-on-vx-880/2022-07-13T11:29:16+00:00weekly0.6https://www.medthority.com/news/2022/7/publication-of-positive-results-from-pivotal-phase-iii-study-of-berdazimer-gel-10.3-sb-206-in-patients-with-molluscum-contagiosum-in-jama-dermatology.--novan-inc2022-07-14T12:00:21+00:00weekly0.6https://www.medthority.com/news/2022/7/exclusive-license-agreement--by-adc-therapeutics-for--sobi-to-develop-and-commercialize-zynlonta-in-europe-and-select-international-territories/2022-07-14T11:48:32+00:00weekly0.6https://www.medthority.com/news/2022/7/dupixent-phase-iii-trial-shows-positive-results-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis---regeneron--sanofi/2022-07-14T11:42:45+00:00weekly0.6https://www.medthority.com/news/2022/7/bayer-to-sell-mens-health-product-nebido-to-grunenthal/2022-07-14T11:31:17+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-grants-emergency-use-authorization-for-novavaxcovid-19-vaccine-adjuvanted-nvx-cov2373-.-novavax2022-07-15T11:23:50+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-piqray--fulvestrant-for-the-treatment-of-postmenopausal-women-and-men-with-hr-and-her2--locally-advanced-or-metastatic-breast-cancer-with-a-pik3ca-mutation.--novartis2025-02-03T14:06:58+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-roxadustat-to-treat-symptomatic-anaemia-associated-with-chronic-kidney-disease.--astellas2022-07-16T12:40:52+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-trodelvy-to-treat-triple-negative-breast-cancer.---immunomedicsgilead2025-02-03T14:05:05+00:00weekly0.6https://www.medthority.com/news/2022/7/pdufa-date-for-tislelizumab---as-a-second-line-treatment-for-patients-with-unresectable-or-metastatic-esophageal-squamous-cell-carcinoma-escc-is-deferred.-beigene---novartis2022-07-16T12:38:11+00:00weekly0.6https://www.medthority.com/news/2022/7/eight-year-data-from-aphinity-study-show-roches-perjeta-based-regimen-continues-to-reduce-the-risk-of-disease-returning-for-people-with-her2-positive-early-breast-cancer.--roche2022-07-16T12:37:27+00:00weekly0.6https://www.medthority.com/news/2022/7/new-two-year-data-confirm-vabysmo-improves-vision-with-fewer-treatments-for-people-with-neovascular-age-related-macular-degeneration.--roche2022-07-16T12:36:51+00:00weekly0.6https://www.medthority.com/news/2022/7/novavax-covid-19-vaccine-to-be-reviewed-at-u.s.-centers-for-disease-control-and-preventions-advisory-committee-on-immunization-practices-meeting-on-july-19-20222022-07-17T11:56:20+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-510k-clearance-for-next-generation-unid-spine-analyzer-with-degenerative-spine-surgery-predictive-model.-medtronic2022-07-17T11:55:10+00:00weekly0.6https://www.medthority.com/news/2022/7/medtronic-announces-co-promotion-agreement-with-cathworks-for-ffrangio-system-with-potential-toward-acquisition/2022-07-17T11:53:39+00:00weekly0.6https://www.medthority.com/news/2022/7/independent-dsmb-recommends-exebacase-phase-iii-trial-be-stopped-for-futility-following-interim-analysis.--contrafect-corporation2022-07-17T11:08:29+00:00weekly0.6https://www.medthority.com/news/2022/7/humanigen-receives-preliminary-topline-data-from-nihniaid-study-of-lenzilumab-in-activ-5bet-b-trial/2022-07-17T11:07:24+00:00weekly0.6https://www.medthority.com/news/2022/7/nuvaxovid-covid-19-vaccine-conditionally-authorized-in-the-european-union-for-adolescents-aged-12-through-17-years.--novavax-inc2022-07-06T11:32:47+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-grants-priority-review-to-mosunetuzumab-for-people-with-relapsed-or-refractory-follicular-lymphoma.---genentechroche2022-07-06T11:41:37+00:00weekly0.6https://www.medthority.com/news/2022/7/astrazeneca-acquires-teneo-two-and-with-it-tbn-486/2022-07-06T11:45:33+00:00weekly0.6https://www.medthority.com/news/2022/7/pivotal-data-from-xtend-1-phase-iii-study-demonstrates-once-weekly-efanesoctocog-alfa-provides-superior-bleed-protection-compared-to-prior-factor-prophylaxis.-sanofi--sobi2022-07-11T11:11:45+00:00weekly0.6https://www.medthority.com/news/2022/7/shionogi-starts-document-submission-for-s-217622-to-treat-covid-19-in-china/2022-07-11T11:13:25+00:00weekly0.6https://www.medthority.com/news/2022/7/data-presented-at-isth-meeting-show-a-reduction-in-treated-spontaneous-and-traumatic-bleeds-and-mean-annualised-bleeding-rate-abr-of-1.7-with-concizumab.--novo-nordisk2022-07-11T11:16:05+00:00weekly0.6https://www.medthority.com/news/2022/7/new-data-from-phase-iii-haven-6-study-reinforce-favourable-safety-and-efficacy-profile-of-hemlibra-in-people-with-moderate-or-mild-haemophilia-a.--rochechugaigenentech2022-07-12T11:30:25+00:00weekly0.6https://www.medthority.com/news/2022/7/omicron-containing-bivalent-booster-candidate-mrna-1273.214-demonstrates-significantly-higher-neutralizing-antibody-response-against-omicron-subvariants-ba.45-compared-to-currently-authorized-booster.--moderna2022-07-12T11:32:12+00:00weekly0.6https://www.medthority.com/news/2022/7/first-patient-treated-in-the-post-authorization-efficacy-study-paes-of-idefirix-imlifidase-in-highly-sensitized-kidney-transplant-patients.--hansa-biopharma-ab2022-07-12T11:34:14+00:00weekly0.6https://www.medthority.com/news/2022/7/fitusiran-prophylaxis-reduced-bleeds-by-61-in-people-with-hemophilia-a-or-b-with-or-without-inhibitors-compared-to-prior-factor-or-bypassing-agent-prophylaxis.--sanofi2022-07-12T11:38:28+00:00weekly0.6https://www.medthority.com/news/2022/7/submission-of-a-variation-to-ema-for-the-vaccination-of-children-6-months-to-less-than-5-years-with-comirnaty.-pfizer--biontech-se2022-07-12T11:43:30+00:00weekly0.6https://www.medthority.com/news/2022/7/new-data-at-linc-2022-confirm-passeo-18-lux-drug-coated-balloon-is-a-safe-and-effective-treatment-in-challenging-patient-groups-following-suboptimal-angioplasty-and-femoropopliteal-lesions.---biotronik2024-09-30T12:14:45+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-accepts-and-grants-priority-review-for-bla-of-lecanemab-for-early-alzheimers-disease-under-the-accelerated-approval-pathway.--biogen--eisai2022-07-07T12:22:15+00:00weekly0.6https://www.medthority.com/news/2022/7/resubmission-of-bla-application-of-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma.--coherus-biosciences--shanghai-junshi-biosciences.-2022-07-07T12:24:37+00:00weekly0.6https://www.medthority.com/news/2022/7/new-england-journal-of-medicine-evidence-publication-of-phase-iii-clinical-trial-results-demonstrating-that-sabizabulin-treatment-significantly-reduced-deaths-in-high-risk-hospitalized-covid-19-patients.-veru-inc2022-07-07T12:27:44+00:00weekly0.6https://www.medthority.com/news/2022/7/syros-pharma-and-tyme-technologies-to-merge/2022-07-07T12:29:45+00:00weekly0.6https://www.medthority.com/news/2022/7/expanded-access-to-paxlovid-with-pharmacist-prescribing-in-the-us.---pfizer2022-07-08T11:15:55+00:00weekly0.6https://www.medthority.com/news/2022/7/urovant-sciences--pierre-fabre-medicament-enter-into-exclusive-license-agreement-for-vibegron-for-the-treatment-of-overactive-bladder-in-the-european-economic-area-uk-and-switzerland/2022-07-08T11:19:33+00:00weekly0.6https://www.medthority.com/news/2022/7/intercept-after-new-analysis-will-resubmit-obeticholic-acid-for-fda-approval-to-treat-liver-fibrosis-due-to-nash--intercept-pharma/2022-07-08T11:23:25+00:00weekly0.6https://www.medthority.com/news/2022/7/sobi-to-license-loncastuximab-tesirine-from-adc-therapeutics/2022-07-08T11:25:35+00:00weekly0.6https://www.medthority.com/news/2022/7/scilex-holding-company-acquires-ancora-medical-and-with-it-ancora-nerve-block-catheter-set/2022-07-08T11:27:57+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-approves-krystexxa-injection-co-administered-with-methotrexate--to-help-more-people-with-uncontrolled-gout-achieve-a-complete-response-to-therapy.--2022-07-09T11:37:57+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-fintepla-for-treatment-of-dravet-syndrome.--zogenix2022-07-09T11:37:14+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-setmelanotide-to-treat-obesity-and-controlling-hunger-caused-by-pro-opiomelanocortin-pomc-deficiency-including-proprotein-convertase-subtilisinkexin-type-1-or-leptin-receptor-lepr-deficiency.--rhythm-pharma2022-07-09T11:34:29+00:00weekly0.6https://www.medthority.com/news/2022/7/darolutamide--androgen-deprivation-therapy--docetaxel-demonstrates-consistent-overall-survival-benefits-across-various-patient-segments-in-metastatic-hormone-sensitive-prostate-cancer.--bayer2022-07-09T11:33:48+00:00weekly0.6https://www.medthority.com/news/2022/7/fda-approval-of-covid-19-vaccine-comirnaty-for-adolescents-12-through-15-years-of-age.-pfizer--biontech-se2022-07-10T15:03:29+00:00weekly0.6https://www.medthority.com/news/2022/7/variation-submitted-to-ema-for-the-vaccination-of-children-6-months-to-less-than-5-years-with-comirnaty--pfizer--biontech-se/2022-07-10T15:02:49+00:00weekly0.6https://www.medthority.com/news/2022/7/new-phase-iii-study-of-sb-12-eculizuma-biosimilar-showed-equivalence-to-soliris-at-the-european-hematology-association-eha-congress-2022.--samsung-bioepis2022-07-11T06:39:14+00:00weekly0.6https://www.medthority.com/news/2022/7/wall-street-journal-reports-that-merck-inc.-is-close-to-acquisition-of-seagen2022-07-10T14:56:51+00:00weekly0.6https://www.medthority.com/news/2022/7/new-phase-iii-data-from-rationale-306--trial-shows-tislelizumab--chemotherapy-significantly-extended-median-overall-survival-by-more-than-6-months-in-first-line-advanced-esophageal-cancer.---novartis--beigene2022-07-01T11:00:21+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-cemiplimab-to-treat-cutaneous-squamous-cell-carcinoma.--regeneron2022-07-05T12:24:32+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-teduglutide-for-treating-short-bowel-syndrome.--takeda2022-07-05T12:29:12+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-faricimab-to-treat-diabetic-macular-oedema.--genentechroche2022-07-05T12:33:00+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-ukrecommends-faricimab-to-treat-wet-age-related-macular-degeneration.--genentechroche2022-07-05T12:38:39+00:00weekly0.6https://www.medthority.com/news/2022/7/gemcovac-19-mrna-vaccine-has-emergency-use-authorisation-in-india-against-covid-19.--gennova-biopharma.--2022-07-05T12:41:12+00:00weekly0.6https://www.medthority.com/news/2022/7/nice-uk-recommends-pembrolizumab-to-treat-triple-negative-locally-recurrent-unresectable-or-metastatic-breast-cancer.--merck-inc2022-07-05T12:44:34+00:00weekly0.6https://www.medthority.com/news/2022/7/patient-enrollment-of-phase-iii-tolebrutinib-trials-for-multiple-sclerosis--myasthenia-gravis-paused-in-the-u.s.--sanofi2022-07-02T14:19:18+00:00weekly0.6https://www.medthority.com/news/2022/7/nmpa-china-approves-cadonilimab-injection-for-the-treatment-of-relapsed-or-metastatic-cervical-cancer.-akeso-inc2022-07-02T14:18:12+00:00weekly0.6https://www.medthority.com/news/2022/7/positive-results-of-phase-iii-eradicate-study-with-ceftobiprole-in-staphylococcus-aureus-bacteremia-sab.--basilea-pharmaceutica2022-07-02T14:16:45+00:00weekly0.6https://www.medthority.com/news/2022/7/novavax-statement-on-prototype-vaccines-broad-immune-responses-and-accelerated-focus-on-omicron-ba.45-as-recommended-by-the-fda2022-07-02T14:15:56+00:00weekly0.6https://www.medthority.com/news/2022/7/submission-of-nda-to-the-fda-for-paxlovid-full-approval.--pfizer2022-07-02T14:15:17+00:00weekly0.6https://www.medthority.com/news/2022/7/apex-2-and-apex-s-trials-of-orladeyo-shows-reductions-in-attack-and-quality-of-life-benefits-in-hereditary-angioedema.--biocryst-pharma2022-07-02T14:14:11+00:00weekly0.6https://www.medthority.com/news/2022/7/nmpa-china-approves-kerendia-to-treat-chronic-kidney-disease-associated-with-type-2-diabetes.--bayer2022-07-02T14:13:15+00:00weekly0.6https://www.medthority.com/news/2022/7/sanofi-gsk-first-to-report-a-successful-efficacy-study-against-omicron-with-covid-19b-beta-containing-vaccine/2022-07-02T14:12:39+00:00weekly0.6https://www.medthority.com/news/2022/7/mhlw-japan-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older.--gsk2022-07-03T11:55:40+00:00weekly0.6https://www.medthority.com/news/2022/7/mhra-uk-approves-yselty-to-treat-symptoms-of-uterine-fibroids.--obseva-sa2022-07-03T11:54:58+00:00weekly0.6https://www.medthority.com/news/2022/7/cosentyx-receives-expanded-approvals-in-eu-for-use-in-childhood-arthritic-conditions.-novartis2022-07-03T11:50:29+00:00weekly0.6https://www.medthority.com/news/2022/7/nmpa-china-approves-tyvyt--chemotherapy-to-treat-first-line-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma.---innovent-biologics---eli-lilly2022-07-03T11:49:48+00:00weekly0.6https://www.medthority.com/news/2022/7/nmpa-china-approves-cresemba-to-treat-invasive-aspergillosis-and-invasive-mucormycosis.--pfizer--basilea-pharmaceutica2022-07-03T11:49:05+00:00weekly0.6https://www.medthority.com/news/2022/7/results-from-pivotal-mountaineer-trial-demonstrating-clinically-meaningful-antitumor-activity-of-tukysa--trastuzumab-in-previously-treated-her2-positive-metastatic-colorectal-cancer.-seagen-inc.--merck-inc2022-07-03T11:48:21+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-issues-complete-response-for-spr-994-in-complicated-urinary-tract-infection.--spero-therapeutics2022-06-29T15:44:27+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-nexviadyme-for-pompe-disease.--sanofi2022-06-29T15:43:40+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-xenpozyme-for-niemann-pick-disease.--sanofi2022-06-29T15:42:47+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-yescarta-for-relapsed-or-refractory-follicular-lymphoma.--kite-pharma2022-06-29T15:41:32+00:00weekly0.6https://www.medthority.com/news/2022/6/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing-registrational-studies-for-oral-brepocitinib-in-dermatomyositis-and-lupus/2022-06-29T15:40:43+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-lungfit-ph-for-persistent-pulmonary-hypertension-of-the-newborn.--beyond-air2022-06-30T13:10:50+00:00weekly0.6https://www.medthority.com/news/2022/6/eylea-injection-sbla-for-every-16-week-dosing-regimen-in-patients-with-diabetic-retinopathy-accepted-for-fda-review.--regeneron2022-06-30T13:10:09+00:00weekly0.6https://www.medthority.com/news/2022/6/updates-on-ongoing-nda-submission-for-vamorolone-in-duchenne-muscular-dystrophy.--santhera-pharma2022-06-30T13:08:29+00:00weekly0.6https://www.medthority.com/news/2022/6/new-long-term-follow-up-clinical-data-for-3-antigen-adult-hepatitis-b-vaccine-presented-at-easl-2022.-vbi-vaccines-inc2022-06-30T13:07:42+00:00weekly0.6https://www.medthority.com/news/2022/6/imfinzi-plus-chemotherapy-before-surgery-significantly-improved-pathologic-complete-response-in-aegean-phase-iii-trial-in-resectable-non-small-cell-lung-cancer.--astrazeneca2022-06-30T13:06:45+00:00weekly0.6https://www.medthority.com/news/2022/6/mhlw-japan-approves-jcovden--formerly-ad26.cov2.-s-vaccine-for-covid-19.--janssen-pharmaceuticals-kk-2022-06-29T15:52:12+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-issues-a-positive-opinion-recommending-full-approval-of--pepaxti-in-eu-for-patients-with-triple-class-refractory-multiple-myeloma.--oncopeptides-ab2022-06-29T15:52:52+00:00weekly0.6https://www.medthority.com/news/2022/6/investigational-sunlenca-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv.--gilead-sciences2022-06-29T15:50:57+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-positive-for-vyvgart-for-treatment-of-anti-acetylcholine-receptor-achr-antibody-positive-generalised-myasthenia-gravis.-agenx2022-06-29T15:50:12+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-ranivisioranibizumab-biosimilar-for-treatment-of-the-same-indications-as-lucentis.--teva-pharma2022-06-29T15:49:19+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-vegzelma-bevacizumab-biosimilar.--celltrion2022-06-29T15:48:31+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-rayvow--a-serotonin-5-ht-1f-receptor-agonist-to-treat-migraine.--eli-lilly2022-06-29T15:47:35+00:00weekly0.6https://www.medthority.com/news/2022/6/new-drug-application-re-submitted--to-fda-for-lenacapavir-an-investigational-long-acting-hiv-1-capsid-inhibitor.---gilead-sciences2022-06-29T15:46:52+00:00weekly0.6https://www.medthority.com/news/2022/6/altamira-therapeutics-receives-fda-510k-clearance-for-bentrio-to-treat-allergic-rhinitis/2022-06-29T15:46:09+00:00weekly0.6https://www.medthority.com/news/2022/6/ipsen-acquires-epizyme-and-with-it-tazverik/2022-06-29T15:45:24+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-epidys-trial-with-itf-2357-meets-primary-endpoint-in-duchenne-muscular-dystrophy.--italfarmaco2022-06-27T11:48:25+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-results-showing-reduced-agitation-in-patients-with-alzheimers-dementia-treated-with-brexpiprazole.--otsuka--lundbeck2022-06-27T11:47:33+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-lynparza-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.-astrazeneca--merck-inc2022-06-27T11:46:52+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-enhertu-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen.--daiichi-sankyo--astrazeneca2022-06-27T11:45:59+00:00weekly0.6https://www.medthority.com/news/2022/6/new-drug-application-submitted-to-the--fda-for-elacestran-to-treat-erher2--advanced-or-metastatic-breast-cancer.--menarini--radius-health2022-06-27T11:45:13+00:00weekly0.6https://www.medthority.com/news/2022/6/nice-ukrecommends-venetoclax-for-treatment-of-chronic-lymphocytic-leukemia.-abbvie2022-06-20T11:32:48+00:00weekly0.6https://www.medthority.com/news/2022/6/covid-pill-ensitrelvir-is--for-pharmaceutical-affairs-and-food-sanitation-council-pafsc-review-for-first-emergency-approval.--shionogi2022-06-20T11:29:38+00:00weekly0.6https://www.medthority.com/news/2022/6/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-car-t-therapies/2022-06-23T11:40:37+00:00weekly0.6https://www.medthority.com/news/2022/6/tafinlar--mekinist-receives-fda-approval-for-first-tumor-agnostic-indication-for-braf-v600e-solid-tumors.--novartis2022-06-23T11:45:52+00:00weekly0.6https://www.medthority.com/news/2022/6/initiation-of-the-stellar-303-phase-iii-pivotal-trial-evaluating-xl-092--atezolizumab-in-patients-with-metastatic-colorectal-cancer--exelixis/2022-06-23T11:49:22+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-supplemental-indication-for-vaxneuvance-to-include-children-6-weeks-through-17-years-of-age-to-prevent-invasive-disease-caused-by-streptococcus-pneumoniae-.-merck-inc2022-06-23T11:54:02+00:00weekly0.6https://www.medthority.com/news/2022/6/brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers.--innovation-pharma2022-06-24T11:49:59+00:00weekly0.6https://www.medthority.com/news/2022/6/supplemental-nda-submitted-to-the-fda-for-quilpta-to-support-label-expansion-for-the-preventive-treatment-of-migraine.--abbvie2022-06-24T11:46:05+00:00weekly0.6https://www.medthority.com/news/2022/6/mhlw-japan-approves-xarelto--aspirin-to-treat-peripheral-artery-disease.--bayer-yakunin2024-09-30T12:14:18+00:00weekly0.6https://www.medthority.com/news/2022/6/alxn-1840-shows-rapid-and-sustained-improvement-in-copper-mobilisation-from-tissues-potentially-closing-treatment-gaps-for-wilson-disease-community.---alexionastrazeneca2022-06-24T11:39:57+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-olympia-2-trial-of-cim-331-shows-benefits-in-prurigo-nodularis.--galderma2022-06-24T11:35:49+00:00weekly0.6https://www.medthority.com/news/2022/6/b-vec-filed-with-fda-for-dystrophic-epidermolysis-bullosa.--krystal-biotech2022-06-24T11:31:52+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-approval-of-vla-2001-for-covid-19.--valneva-se2022-06-24T11:28:49+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-results-in-two-phase-iii-studies-for-a-novel-liquid-formulation-botulinumtoxin-a-relabotulinumtoxin-a-for-the-treatment-of-glabellar-lines-frown-and-lateral-canthal-lines-crows-feet.-galderma2022-06-24T11:25:10+00:00weekly0.6https://www.medthority.com/news/2022/6/sanofi-gsk-next-generation-covid-19-booster-delivers-strong-immune-response-against-variants-of-concern-including-omicron.--sanofi2022-06-24T11:20:09+00:00weekly0.6https://www.medthority.com/news/2022/6/ema-starts-rolling-review-for-spikevax-version-to-target-two-strains-of-sars-cov-2.--moderna2022-06-24T11:17:34+00:00weekly0.6https://www.medthority.com/news/2022/6/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-patients-with-her2-low-metastatic-breast-cancer-with-hr-positive-and-hr-negative-disease-.--daiichi-sankyo--astrazeneca2022-06-25T16:28:08+00:00weekly0.6https://www.medthority.com/news/2022/6/chmp-recommends-roctavian-to-treat-haemophilia-a--biomarin/2022-06-25T16:27:09+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-chmp-opinion-for-scemblix-a-novel-treatment-for-adult-patients-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase-.--novartis2022-06-25T16:26:14+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-showing-effect-of-early-zeposia-use-demonstrated-cognitive-benefits-in-people-with-relapsing-multiple-sclerosis.--bms-2022-06-25T16:25:24+00:00weekly0.6https://www.medthority.com/news/2022/6/new-analysis-finds-uplizna-effective-among-european-populations-with-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-06-25T16:24:28+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-keytruda-as-adjuvant-treatment-in-stage-iib-or-iic-melanoma.--merck-inc2022-06-25T16:23:27+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-trial-of-hepcludex-shows-efficacy-in-chronic-hepatitis-delta-virus-infection.--gilead-sciences2022-06-25T16:22:36+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy.---bms2022-06-25T16:21:50+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-highlight-immune-response-to-covid-19-vaccines-in-individuals-with-relapsing-forms-of-multiple-sclerosis-treated-with-zeposia.--bms-2022-06-25T16:20:25+00:00weekly0.6https://www.medthority.com/news/2022/6/european-commission-approves-filsuvez-for-the-treatment-of-dystrophic-and-junctional-epidermolysis-bullosa-.--amryt-2022-06-26T14:30:44+00:00weekly0.6https://www.medthority.com/news/2022/6/european-commission-approval-for-tabrecta-for-the-treatment-of-metex14-skipping-advanced-non-small-cell-lung-cancer.--novartis2022-06-26T14:29:56+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-vla-2001-vaccine-for-covid-19.-valneva-se-2022-06-26T14:29:09+00:00weekly0.6https://www.medthority.com/news/2022/6/data-from-the-phase-iii-maestro-nafld-1-study-of-resmetirom-in-nafld-presented-at-international-liver-congress-easl-2022.--madrigal-pharmaceuticals2022-06-26T14:28:27+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-maestro-nafld-1-study-of-mgl-3196-in-nash-presented-at-international-liver-congress-easl-2022.--madrigal-pharmaceuticals2022-06-26T14:27:31+00:00weekly0.6https://www.medthority.com/news/2022/6/canaglu-approved-by-mhlw-japan-for-treatment-of-chronic-kidney-disease-complicated-by-type-2-diabetes.---mitsubishi-tanabe2022-06-26T14:26:24+00:00weekly0.6https://www.medthority.com/news/2022/6/mhlw-japan-approves-darvias-injection-to-treat-peripheral-t-cell-lymphoma.-solasia-pharma-and-nippon-kayaku2022-06-26T14:25:25+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-japan-approval-for-yutiq-for-the-treatment-of-chronic-non-infectious-uveitis-affecting-the-posterior-segment-of-the-eye---eyepoint-pharma--ocumension-therapeutics/2022-06-26T14:24:18+00:00weekly0.6https://www.medthority.com/news/2022/6/santen-receives-manufacturing-and-marketing-approval-for-the-dry-eye-treatment-diquas-lx-ophthalmic-solution-3-in-japan-/2022-06-26T14:22:54+00:00weekly0.6https://www.medthority.com/news/2022/6/complete-response-letter-from-fda-review-of-nda-for-acer-001-for-urea-cycle-disorders.--acer-therapeutics2022-06-23T11:15:29+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-china-accepts-sbla-for-tislelizumab--chemotherapy-as-a-first-line-treatment-for-patients-with-advanced-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma.--beigene-2022-06-23T11:20:15+00:00weekly0.6https://www.medthority.com/news/2022/6/results-from-phase-iii-propel-trial-of-lynparza---abiraterone-in-first-line-metastatic-castration-resistant-prostate-cancer-published-in-nejm-evidence.--astrazeneca--merck-inc2022-06-23T11:23:25+00:00weekly0.6https://www.medthority.com/news/2022/6/mhlw-in-japan-granted-approval-for-vozxogo-for-injection-for-the-treatment-of-children-with-achondroplasia-whose-growth-plates-are-not-closed.--biomarin2022-06-23T11:25:57+00:00weekly0.6https://www.medthority.com/news/2022/6/novartis-plans-to-petition-the-u.s.-court-of-appeals-for-the-federal-circuit-for-further-review-to-uphold-validity-of-the-gilenya-dosing-regimen-patent.-2022-06-23T11:30:01+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-china-approves-the--snda-for-tyvyt--cisplatin--paclitaxel-or-cisplatin--5-fluorouracil-chemotherapy-for-the-first-line--metastatic-esophageal-squamous-cell-carcinoma.--innovent-biologics--eli-lilly2022-06-23T11:35:49+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-accepts-resubmission-for-omidenepag-isopropyl-a-proposed-treatment-for-glaucoma-and-ocular-hypertension.---santen--ube-industries2022-06-15T11:46:47+00:00weekly0.6https://www.medthority.com/news/2022/6/mhra-uk-accepts-marketing-authorization-application-for-aumolertinib-for-egfr-mutated-non-small-cell-lung-cancer.--eqrx-inc2025-01-31T12:07:13+00:00weekly0.6https://www.medthority.com/news/2022/6/first-patient-dosed-in-tropion-breast02-phase-iii-trial-of-dato-dxd-for-metastatic-triple-negative-breast-cancer.--daiichi-sankyo--astrazeneca2025-01-31T12:08:39+00:00weekly0.6https://www.medthority.com/news/2022/6/quizartinib--chemotherapy-significantly-improved-overall-survival-compared-to-chemotherapy-in-patients-with-newly-diagnosed-flt3-itd-positive-acute-myeloid-leukemia.-daiichi-sankyo2022-06-16T11:24:18+00:00weekly0.6https://www.medthority.com/news/2022/6/additional-data-from-epic-sr-study-for-paxlovid-to-support-upcoming--nda-submission-to-fda.--pfizer2022-06-16T11:21:44+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-eua-for-cobas-sars-cov-2-duo-the-first-pcr-test-to-simultaneously-detects-covid-19-and-quantitatively-measures-viral-load-levels-of-covid-19.--roche2022-06-16T11:17:34+00:00weekly0.6https://www.medthority.com/news/2022/6/negative-results-from-phase-ii-study-of-lyt-100-cov-in-post-acute-long-covid-with-respiratory-complications.--puretech-health2022-06-16T11:13:26+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-presented-at-cure-sma-reveal-residual-unmet-needs-in-young-sma-patients-treated-with-gene-therapy-and-suggest-further-potential-of-using-spinraza.--biogen2022-06-16T11:11:15+00:00weekly0.6https://www.medthority.com/news/2022/6/update-on-alzheimers-prevention-initiative-study-evaluating-crenezumab-in-autosomal-dominant-alzheimers-disease.-genentechroche2025-02-03T11:07:16+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-interim-results-from-registration-enabling-trial-of-cosibelimab-in-locally-advanced-cutaneous-squamous-cell-carcinoma.--checkpoint-therapeutics2022-06-21T11:39:40+00:00weekly0.6https://www.medthority.com/news/2022/6/european-medicines-agency-validates--application-for-car-t-cell-therapy-breyanzi-in-relapsed-or-refractory-large-b-cell-lymphoma-after-first-line-therapy--bms/2022-06-21T11:37:47+00:00weekly0.6https://www.medthority.com/news/2022/6/data-from-np30179-study-of-glofitamab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-submitted-to-ema.-genentechroche2022-06-21T11:34:52+00:00weekly0.6https://www.medthority.com/news/2022/6/continuation-pv-study-of-besremi-shows-survival-benefits-in-polycythaemia-vera.--aop-health2022-06-21T11:27:41+00:00weekly0.6https://www.medthority.com/news/2022/6/eplontersen-met-co-primary-and-secondary-endpoints-in-interim-analysis-of-the-neuro-ttransform-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn.-astrazeneca--ionis2022-06-21T11:15:14+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-grants-emergency-use-authorisation-of-mrna-1273-vaccine-for-children-6-months-and-older.-moderna-inc2022-06-21T11:12:26+00:00weekly0.6https://www.medthority.com/news/2022/6/nuvaxovid-a--covid-19-vaccine-is-provisionally-registered-in-australia-as-a-booster-in-individuals-aged-18-and-over.--novavax-inc2022-06-15T12:23:41+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-china-approves-tislelizumab-for-recurrent-or-metastatic-nasopharyngeal-cancer.--beigene2022-06-15T12:17:36+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-accepts-sbla-for-keytruda--as-adjuvant-therapy-for-stage-ib--greater-than-4-centimeters-following-complete-surgical-resection.--merck-inc2025-01-31T12:06:54+00:00weekly0.6https://www.medthority.com/news/2022/6/the-phase-iii-real-4-of-sogroya-shows-efficacy-in-growth-hormone-deficiency.--novo-nordisk2022-06-15T12:10:36+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-reopen2-trial-of-xhance-shows-significant-benefits-in-chronic-sinusitis.--optinose2022-06-15T12:02:42+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-olumiant--as-first-and-only-systemic-medicine-for-adults-with-severe-alopecia-areata.--eli-lilly--incyte2022-06-15T12:00:02+00:00weekly0.6https://www.medthority.com/news/2022/6/data-for-mycapssa-from-optimal-and-mpowered-phase-iii-trials-presented-at-endo-2022.--amryt2022-06-15T11:57:35+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approval-of-amvuttra-an-rnai-therapeutic-for-the-treatment-of-the-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-in-adults.--alnylam-pharma2022-06-15T11:54:38+00:00weekly0.6https://www.medthority.com/news/2022/6/favorable-results-from-global-phase-ii-study-of-voxzogo-for-injection-in-infants-and-young-children-with-achondroplasia-are-presented-at-the-endocrine-society-annual-meeting.--biomarin2022-06-15T11:50:36+00:00weekly0.6https://www.medthority.com/news/2022/6/nice-uk-recommends-use-of-idefirix--as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients.--hansa-biopharma2025-02-03T14:04:16+00:00weekly0.6https://www.medthority.com/news/2022/6/results-from-the-deliver-study-with-vyepti-have-been-published-in-the-lancet-neurology.--lundbeck2022-06-17T11:38:12+00:00weekly0.6https://www.medthority.com/news/2022/6/launch-in-countries-accepting-the-ce-mark-of-human-papillomavirus-hpv-self-sampling-solution-expanding-cervical-cancer-screening-options.-roche2022-06-17T11:33:03+00:00weekly0.6https://www.medthority.com/news/2022/6/start-of-open-label-extension-study-courage-als-ole-for-als-patients-completing-courage-als-study.-cytokinetics-incorporated2022-06-17T11:29:52+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-from-long-term-extension-trial-evaluating-setmelanotide-in--pomc-or-lepr-deficiency-obesity-at-endo-2022.--rhythm-pharmaceuticals-inc2022-06-17T11:26:33+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-from-long-term-extension-trial-evaluating-setmelanotide-in-bardet-biedl-syndrome-is-presented-at--at-endo-2022.-rhythm-pharmaceuticals-inc2022-06-17T11:22:49+00:00weekly0.6https://www.medthority.com/news/2022/6/health-canada-conditionally-approves-albrioza-for-the-treatment-of-amyotrophic-lateral-sclerosis-.--amylyx-pharma2022-06-17T11:18:10+00:00weekly0.6https://www.medthority.com/news/2022/6/sandoz-application-for-proposed-biosimilar-adalimumabs-high-concentration-formulation-accepted-by-ema/2025-02-03T14:19:36+00:00weekly0.6https://www.medthority.com/news/2022/6/boehringer-acquires-trutino-biosciences/2022-06-18T17:57:13+00:00weekly0.6https://www.medthority.com/news/2022/6/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use-authorization-for-children-6-months-through-4-years-of-age/2022-06-18T17:56:22+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-skyrizi-for-crohns-disease.--abbvie2022-06-18T17:55:30+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-imcivree-in-bardet-biedl-syndrome.--rhythm-pharma2022-06-18T17:54:27+00:00weekly0.6https://www.medthority.com/news/2022/6/cyt-387-filed-with-fda-for-myelofibrosis.--sierra-oncology2022-06-18T17:53:32+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-approves-yselty-for-uterine-fibroids.--obseva2022-06-18T17:52:41+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-spirit-1-and-spirit-2-studies-of-relugolix-combination-therapy-in-endometriosis-pain-published-in-the-lancet.--myovant-sciences-and-pfizer2022-06-18T17:51:47+00:00weekly0.6https://www.medthority.com/news/2022/6/addex-pharma-reports-success-in-phase-iia-trial-for-dipraglurant-for-parkinsons-disease-/2022-06-18T17:50:38+00:00weekly0.6https://www.medthority.com/news/2022/6/cytokinetics-provides-regulatory-update-for-omecamtiv-mecarbil-for-heart-failure/2022-06-18T17:49:49+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-c601-and-c602-trials-show-dccr-demonstrates-positive-impact-in-prader-willi-syndrome.--soleno-therapeutics-2022-06-19T14:21:56+00:00weekly0.6https://www.medthority.com/news/2022/6/approval-of-trodelvy-in-china-for-second-line-metastatic-triple-negative-breast-cancer.--everest-medicines--immumomedics-gilead-2022-06-19T14:20:51+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-advisory-committee-does-not-support-pimavanserin-for-the-treatment-of-hallucinations-and-delusions-associated-with-alzheimers-disease-psychosis.--acadia-pharma2022-06-19T14:19:53+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approval-of-priorix-for-the-prevention-of-measles-mumps-and-rubella-in-individuals-12-months-of-age-and-older.--gsk2022-06-11T13:22:57+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-pivotal-phase-iii-data-for-respiratory-syncytial-virus-rsv-vaccine-candidate-for-older-adults.--gsk2022-06-11T13:21:57+00:00weekly0.6https://www.medthority.com/news/2022/6/new-teclistamab-data-presented-at-the-2022-asco-annual-meeting-report-longer-follow-up-from-phase-1ii-majestec-1-study-evaluating-the-bcmaxcd3-bispecific-antibody-including-progression-free-survival-and-subgroup-analyses.--janssen-pharma2022-06-11T13:21:10+00:00weekly0.6https://www.medthority.com/news/2022/6/first-data-from-planned-interim-analysis-of-pivotal-phase-ii-magnetismm-3-trial-of-bcma-cd3-bispecific-antibody-elranatamab-for-relapsedrefractory-multiple-myeloma.--pfizer2022-06-11T13:20:18+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-reinforce-robust-efficacy-and-safety-profile-of-aspaveliempaveli--for-paroxysmal-nocturnal-haemoglobinuria-at-the-eha2022-congress.--sobi--apellis2022-06-11T13:19:35+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-advisory-committee-unanimously-supports-beti-cel-gene-therapy-for-people-with-beta-thalassemia-who-require-regular-red-blood-cell-transfusions.--bluebird-bio2022-06-11T13:18:43+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-advisory-committee-unanimously-recommends-eli-cel-an-investigational-lvv-gene-therapy-for-the-treatment-of-cerebral-adrenoleukodystrophy.--bluebird-bio2022-06-11T13:17:55+00:00weekly0.6https://www.medthority.com/news/2022/6/primary-results-from-the-phase-iii-shine-study-demonstrated-that-once-daily-oral-imbruvica--plus-bendamustine-rituximab-br-and-rituximab-maintenance-significantly-reduced-the-risk-of-disease-progression-in-mantle-cell-lymphoma.--janssen-biotech2022-06-11T13:17:08+00:00weekly0.6https://www.medthority.com/news/2022/6/overall-survival-results-from-phase-iii-paloma-2-trial-of-ibrance--for-the-first-line-treatment-of-er-her2--metastatic-breast-cancer.--pfizer2022-06-11T13:16:14+00:00weekly0.6https://www.medthority.com/news/2022/6/new-imbruvica-data-in-fixed-duration-combination-regimen---venetoclax-presented-at-eha-2022-shows-deep-durable-response-at-three-years-in-untreated-chronic-lymphocytic-leukemia.--janssen2022-06-11T13:15:18+00:00weekly0.6https://www.medthority.com/news/2022/6/health-canada-conditionally-approves-tabrecta-for-locally-advanced-unresectable-or-metastatic-non-small-cell-lung-cancer.--novartis2022-06-12T12:41:41+00:00weekly0.6https://www.medthority.com/news/2022/6/health-canada-approves-orladeyo--the-only-oral-treatment-for-the-prevention-of-hereditary-angioedema-attacks.--biocryst2022-06-12T12:40:38+00:00weekly0.6https://www.medthority.com/news/2022/6/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-in-children-and-young-adults-with-advanced-b-cell-all.--novartis-2022-06-20T10:35:47+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-china-grants-supplemental-approval-for-cejemly-to-treat-unresectable-stage-iii-non-small-cell-lung-cancer-.-c-stone-pharma---pfizer2022-06-13T11:45:18+00:00weekly0.6https://www.medthority.com/news/2022/6/the-mhra-uk-tga-australia-and-health-canada-approve-kimmtrak--for-the-treatment-of-unresectable-or-metastatic-uveal-melanoma.-immunocore2022-06-13T11:44:29+00:00weekly0.6https://www.medthority.com/news/2022/6/continued-progress-presented-at-aha-congress-of-ayvakit-toward--transforming-treatment-of-systemic-mastocytosis.--blueprint-medicines2022-06-10T11:39:02+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-foundationone-cdx-as-companion-diagnostic-for-rozlytrek-in-solid-tumours.--rochefoundation-medicine2022-06-10T11:33:02+00:00weekly0.6https://www.medthority.com/news/2022/6/eu-gives-positive-opinion-on-dysport-in-urinary-incontinence.--ipsen2022-06-10T11:30:03+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-demonstrates-venclyxtovenclexta-combination-sustained-progression-free-survival-in-chronic-lymphocytic-leukemia-after-four-years-of-treatment.--abbvie2022-06-10T11:27:50+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iiib-retrospective-study-of-ajovy-shows-efficacy-in-migraine.--teva-pharma2022-06-10T11:19:51+00:00weekly0.6https://www.medthority.com/news/2022/6/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial--astrazeneca-/2022-06-09T11:57:52+00:00weekly0.6https://www.medthority.com/news/2022/6/top-line-results-from-forward-phase-iii-clinical-trial-of-fostamatinib-in-patients-with-warm-autoimmune-hemolytic-anemia.--rigel-pharma2022-06-09T11:54:58+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-stratum-study-results-positive-for-roflumilast-foam-for-treatment-of-seborrheic-dermatitis.--arcutis-inc2022-06-09T11:52:40+00:00weekly0.6https://www.medthority.com/news/2022/6/primary-endpoint-in-phase-iii-tranquility-2-trial-in-dry-eye-disease-is-achieved-and-plans-are-to-submit-a-nda-for-symptoms-and-three-sign-endpoints-of-dry-eye-disease.-aldeyra-therapeutics2022-06-09T11:51:03+00:00weekly0.6https://www.medthority.com/news/2022/6/uk-mhra-marketing-authorisation-for-prehevbri-a-3-antigen-adult-hepatitis-b-vaccine.--vbi-vaccines-inc2022-06-09T11:47:54+00:00weekly0.6https://www.medthority.com/news/2022/6/brexafemme-filed-with-supplemental-nda-to-the-fda-for-recurrent-vulvovaginal-candidiasis.--scynexis-2022-06-09T11:46:07+00:00weekly0.6https://www.medthority.com/news/2022/6/european-commission-approves-tecentriq-as-adjuvant-treatment-for-a-subset-of-people-with-early-stage-non-small-cell-lung-cancer.--roche2022-06-09T11:33:51+00:00weekly0.6https://www.medthority.com/news/2022/6/omicron-containing-bivalent-booster-candidate-mrna-1273.214-demonstrates-superior-antibody-response-against-omicron-variant.-moderna2022-06-09T11:31:45+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-top-line-results-from-phase-ii-clinical-trial-of-mn-166-in-hospitalized-covid-19-patients-at-risk-for-acute-respiratory-distress-syndrome.--medicinova-inc2022-06-09T11:29:48+00:00weekly0.6https://www.medthority.com/news/2022/6/regeneron-acquires-sanofis-stake-in-libtayo/2022-06-06T12:23:13+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-paradigm-trial-of-vectibix-shows-superiority-over-bevacizumab-in-colorectal-cancer.--amgen--takeda2022-06-06T12:21:00+00:00weekly0.6https://www.medthority.com/news/2022/6/the-pivotal-destiny-breast04-phase-iii-trial-of-enhertu-shows-efficacy-in-her2-low-breast-cancer.--astrazeneca-and-daiichi-sankyo2025-01-31T11:44:43+00:00weekly0.6https://www.medthority.com/news/2022/6/trodelvy-improved-progression-free-survival-by-34-in-heavily-pre-treated-hrher2--metastatic-breast-cancer-patients.--gilead-sciences2025-01-31T11:44:32+00:00weekly0.6https://www.medthority.com/news/2022/6/jardiance-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-dpp-4-inhibitors-and-by-30-versus-glp-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-evidence-study.--boehringer--eli-lilly2022-06-06T12:19:30+00:00weekly0.6https://www.medthority.com/news/2022/6/significant--clinically-meaningful-improvement-in-distant-metastasis-free-survival-with-keytruda-in-patients-with-resected-stage-iib-or-iic-melanoma-in-phase-iii-keynote-716-trial.--merck-inc2022-06-06T11:51:10+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-accepts-supplemental-new-drug-application-for-myfembree.--myovant-sciences--pfizer2022-06-06T11:46:06+00:00weekly0.6https://www.medthority.com/news/2022/6/three-year-data-from-phase-iii-checkmate-9la-trial-demonstrates-long-term-durable-survival-outcomes-of-opdivo--yervoy-with-two-cycles-of-chemotherapy-for-patients-with-metastatic-non-small-cell-lung-cancer.---bms2025-02-03T11:18:51+00:00weekly0.6https://www.medthority.com/news/2022/6/landmark-five-year-data-from-phase-iii-checkmate--227-trial-demonstrates-long-term-durable-survival-outcomes-with-opdivo--yervoy-in-first-line-treatment-of-patients-with-metastatic-non-small-cell-lung-cancer.--bms2025-01-31T12:09:02+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-has-delayed-the-pre-submission-meeting-regarding-the-marketing-application-for-ocaliva-in-nonalcoholic-steatohepatitis.-intercept-pharma2022-06-07T11:50:08+00:00weekly0.6https://www.medthority.com/news/2022/6/presentation-of-final-positive-phase-1bii-clinical-trial-results-for-sabizabulin-in-metastatic-castration-resistant-prostate-cancer-at-the-2022-american-society-of-clinical-oncology-annual-meeting.--veru-inc2022-06-07T11:48:29+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-riabni-a-rituximab-biosimilar-for-moderate-to-severe--rheumatoid-arthritis.--amgen2022-06-07T11:46:31+00:00weekly0.6https://www.medthority.com/news/2022/6/tafinlar--mekinist-demonstrates-unprecedented-efficacy-in-pediatric-patients-with-braf-v600-low-grade-gliomas-in-phase-iiiii-study.---novartis2022-06-07T11:43:56+00:00weekly0.6https://www.medthority.com/news/2022/6/final-data-from-phase-iii-ascent-study-demonstrates-trodelvy-extends-overall-survival-over-chemotherapy-in-second-line-metastatic-triple-negative-breast-cancer.--gilead-sciences2022-06-07T11:40:35+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-phase-iii-results-for-awcorna-mrna-vaccine-for-prevention-of-covid-19.--abogen-biosciences2022-06-07T11:36:05+00:00weekly0.6https://www.medthority.com/news/2022/6/new-analyses-of-mounjaro-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-american-diabetes-associations-82nd-scientific-sessions.--eli-lilly2022-06-07T11:33:21+00:00weekly0.6https://www.medthority.com/news/2022/6/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lebrikizumab-atopic-dermatitis-monotherapy-trials.--eli-lilly2022-07-19T20:44:40+00:00weekly0.6https://www.medthority.com/news/2022/6/negative-results-from-prax-113-phase-iiiii-monotherapy-aria-study-in-major-depressive-disorder.-praxis-precision-medicines-inc2022-06-07T11:19:11+00:00weekly0.6https://www.medthority.com/news/2022/6/yumanity-therapeutics-to-sell-ytx-7738an-inhibitor-of-stearoyl-coa-desaturase-to-janssen-pharmaceutica-nv/2022-06-07T11:13:45+00:00weekly0.6https://www.medthority.com/news/2022/6/emergency-use-authorization-application-to-fda-for-sabizabulin--for-hospitalized-covid-19-patients-at-high-risk-for-ards.-veru-inc2022-06-08T11:33:48+00:00weekly0.6https://www.medthority.com/news/2022/6/new-data-for-lagevrio-from-phase-iii-move-out-study-in-covid-19.--merck-inc.--ridgeback-biotherapeutics2022-06-08T11:31:45+00:00weekly0.6https://www.medthority.com/news/2022/6/first-patient-dosed-in-the-valiant-phase-iii-study-of-pegcetacoplan-for-ic-mpgn-and-c3g-rare-kidney-diseases-with-high-unmet-medical-need.--sobi--apellis2022-06-08T11:28:27+00:00weekly0.6https://www.medthority.com/news/2022/6/scemblix-with-novel-mechanism-of-action-shows-superior-long-term-efficacy-and-consistent-tolerability-in-96-week-follow-up-of-phase-iii-ascembl-trial-for-chronic-myeloid-leukemia-.--novartis2022-06-08T11:23:27+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-dupixent-as-first-biologic-medicine-for-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis.--sanofi--regeneron2022-07-19T20:40:06+00:00weekly0.6https://www.medthority.com/news/2022/6/european-commission-approves-first-in-class-bispecific-antibody-lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma.-roche--2022-06-08T11:18:17+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-advisory-committee-recommends-emergency-use-authorisation-for-novavax-covid-19-vaccine-for-individuals-18-years-and-older.--novavax2022-06-08T11:13:25+00:00weekly0.6https://www.medthority.com/news/2022/6/yumanity-therapeutics-acquires-kineta-inc.-and-with-it-kva12.1--a-potential-best-in-class-vista-blocking-immunotherapy2022-06-08T11:10:57+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-ivosidenib--azacitidine-for-newly-diagnosed-idh1-mutated-aml.--servier2022-05-30T11:30:33+00:00weekly0.6https://www.medthority.com/news/2022/5/complete-response-letter-for-lamotrigine-liquid-oral-tablet-for-epilepsy.--azurity-pharma2022-05-30T11:26:09+00:00weekly0.6https://www.medthority.com/news/2022/5/bavarian-nordic-enters-first-larger-vaccine-contract-with-government-in-response-to-monkey-pox-outbreak/2022-05-31T11:29:19+00:00weekly0.6https://www.medthority.com/news/2022/5/verquvo-is-approved-in-china-by-nmpa-to-treat-patients-with-chronic-heart-failure-and-reduced-ejection-fraction.--bayer--merck-inc2022-05-31T11:26:51+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-tyvaso-dpi--for-the-treatment-of-pulmonary-arterial-hypertension-and-pulmonary-hypertension-associated-with-interstitial-lung-disease.--united-therapeutics-2022-05-31T11:24:20+00:00weekly0.6https://www.medthority.com/news/2022/5/two-combination-treatments-of-opdivo--yervoy-and-opdivo--chemotherapy-approved-in-japan-for-first-line-treatment-of-unresectable-advanced-or-recurrent-esophageal-cancer.--bms--ono-pharma2022-05-31T11:20:52+00:00weekly0.6https://www.medthority.com/news/2022/6/tecentriq-obtains-regulatory-approval-from-mhlw-as-the-first-immunotherapy-in-japan-for-adjuvant-treatment-of-non-small-cell-lung-cancer.--chugai2022-06-02T16:19:51+00:00weekly0.6https://www.medthority.com/news/2022/6/new-analysis-shows-that-freestyle-libre-system-provides-similar-and-sustained-reductions-in-glucose-levels-for-people-with-both-type-1-and-type-2-diabetes.--abbott2022-06-02T16:18:33+00:00weekly0.6https://www.medthority.com/news/2022/6/zai-lab-to-present-new-prime-subgroup-analysis-for-niraparib-in-ovarian-cancer-at-2022-asco-annual-conference/2022-06-02T16:17:22+00:00weekly0.6https://www.medthority.com/news/2022/6/dupixent-given-priority-review-for-prurigo-nodularis-by-fda.--regeneron--sanofi2022-06-02T16:15:56+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-accepts-omblastys-for-priority-review-in-pediatric-patients-with-cnsleptomeningeal-metastasis-from-neuroblastoma.--y-mabs-therapeutics2022-06-02T16:14:50+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-approves-label-extension-for-evrysdi-to-include-babies-under-two-months-old-with-spinal-muscular-atrophy.--genentechroche2022-06-02T16:13:24+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-pivotal-trial-of-uplizna-shows-genetic-screening-impact-in-treating-neuromyelitis-optica-spectrum-disorder.--horizon-therapeutics2022-06-02T16:12:11+00:00weekly0.6https://www.medthority.com/news/2022/6/mhlw-japan-approval-for-vocabria-in-combination-with-rekambys-to-treat-hiv-in-japan.-viiv-healthcare--janssen-therapeutics2022-06-02T16:10:54+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-mirror-trial-of-krystexxa-shows-response-in-uncontrolled-gout.-horizon-therapeutics-2022-06-02T16:09:30+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-skylark-study-of-sage-217-meets-all-endpoints-in-postpartum-depression.--biogen-and-sage-therapeutics2022-06-02T16:08:05+00:00weekly0.6https://www.medthority.com/news/2022/6/the-lancet-publishes-results-from-phase-iii-induction-and-maintenance-programs-evaluating-rinvoq-in-ulcerative-colitis.--abbvie2022-06-02T16:06:50+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-results-from-phase-iii-select-axis-2-trials-of-rinvoq-in-patients-with-axial-spondyloarthritis-presented-at-eular-2022-abbvie/2022-06-02T16:05:40+00:00weekly0.6https://www.medthority.com/news/2022/6/nice-uk-recommends-filgotinib-to-treat-moderate-to-severe-ulcerative-colitis.--galapagos-nv--elsai2022-06-02T16:04:21+00:00weekly0.6https://www.medthority.com/news/2022/6/nmpa-china-approves-two-dose-schedule-for-hpv-vaccine-cervarix-for-prevention-of-cervical-cancer.--gsk2022-06-02T16:02:46+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-accepts-bla-for-etranacogene-dezaparvovec-for-priority-review-for-treatment-of-hemophilia-b.--csl-behring2022-06-02T16:01:32+00:00weekly0.6https://www.medthority.com/news/2022/6/gsk-acquires-affinivax-inc.-and-its-next-generation-pneumococcal-vaccines2022-06-02T15:59:51+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-results-from-phase-iii-select-axis-2-trials-of-rinvoq-in-patients-with-axial-spondyloarthritis-presented-at-eular-2022.--abbvie2022-06-03T16:44:33+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-valor-study-data-for-biib-067-shows-earlier-initiation-benefit-in-amyotrophic-lateral-sclerosis.--biogen2022-06-04T13:22:55+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-activ-1-trial-of-orencia-shows-recovery-time-improvement-in-covid-19.--bms2022-06-04T13:21:04+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-iii-onwards-1-and-6-trials-of-weekly-insulin-icodec-met-primary-endpoints-in-type-2-diabetes.--novo-nordisk2022-06-04T13:19:16+00:00weekly0.6https://www.medthority.com/news/2022/6/phase-ii-aura-lv-and-phase-iii-aurora-1-studies-of-lupkynis-shows-efficacy-in-lupus-nephritis.--aurinia-pharmaceuticals2022-06-04T13:17:16+00:00weekly0.6https://www.medthority.com/news/2022/6/fda-extends-pdufa-date-for-amx-0035-a-proposed-treatment-for-amyotrophic-lateral-sclerosis-.--amylyx-pharma2022-06-04T13:16:09+00:00weekly0.6https://www.medthority.com/news/2022/6/positive-phase-iii-data-for-tocilizumab-biosimilar-presented-at-the-annual-european-congress-of-rheumatology-eular-2022.--biogen--bio-thera-solutions-ltd2022-06-04T13:14:49+00:00weekly0.6https://www.medthority.com/news/2022/6/withdrawal-of-supplemental-sbla-for-reblozyl-for-non-transfusion-dependent-beta-thalassemia.--bms2022-06-05T13:15:41+00:00weekly0.6https://www.medthority.com/news/2022/6/award-peds-trial-investigating-use-of-trulicity--in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-a1c-reduction-vs-placebo.--eli-lilly2022-06-05T13:14:31+00:00weekly0.6https://www.medthority.com/news/2022/6/surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16.0-and-22.5-weight-loss-in-adults-with-obesity-or-overweight.--eli-lilly2022-06-05T13:07:39+00:00weekly0.6https://www.medthority.com/news/2022/6/elevate-tn-phase-iii-trial-of-calquence--gazyva-shows-pfs-benefit-in-chronic-lymphocytic-leukaemia.--astrazeneca2022-06-05T13:06:27+00:00weekly0.6https://www.medthority.com/news/2022/6/tecartus-a-car-t-cell-therapy-demonstrates-strong-overall-survival-rates-and-continued-durable-responses-in-long-term-follow-p-of-two-pivotal-studies-including-longest-ever-follow-up-of-a-car-t-cell-therapy-in-mantle-cell-lymphoma.-kitegilead2022-06-05T13:04:53+00:00weekly0.6https://www.medthority.com/news/2022/6/sub-analyses-of-zuma-7-trial-reinforce-yescarta-car-t-cell-therapy-superiority-over-standard-of-care--as-initial-treatment-for-patients-with-relapsed-or-refractory-large-b-cell-lymphoma.--kitegilead2022-06-05T13:03:23+00:00weekly0.6https://www.medthority.com/news/2022/6/bms-to-acquire-turning-point-therapeutics-and-with-it-repotrectinib-/2022-06-05T13:01:51+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-510k-clearance-for-the-use-of-renuvion-cosmetic-technology-in-dermal-resurfacing-procedures.--apyx-medical-corporation2022-05-28T13:03:58+00:00weekly0.6https://www.medthority.com/news/2022/5/mhra-uk-approves-ongavia-a--biosimilar-to-lucentis-for-neovascular-wet-age-related-macular-degeneration.--teva-pharma2022-05-28T13:03:10+00:00weekly0.6https://www.medthority.com/news/2022/5/takeda-and-seagen-to-highlight-at-asco-meeting-adcetris-combination-data-showing-statistically-significant-improvement-in-overall-survival-os-for-advanced-hodgkin-lymphoma/2022-05-28T13:02:23+00:00weekly0.6https://www.medthority.com/news/2022/5/data-safety-monitoring-board-update-on-u.s.-national-institutes-of-health-nih-study-of-zyesami-in-covid-19-respiratory-failure.--nrx-pharma2022-05-28T13:01:37+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-fylnetra-pegfilgrastim-biosimilar-in-neutropenia.--amneal-pharma2022-05-28T13:00:34+00:00weekly0.6https://www.medthority.com/news/2022/5/adagrasib-delivers-positive-results-in-registration-enabling-study-of-patients-with-krasg12c-mutated-advanced-non-small-cell-lung-cancer.-mirati-therapeutics2022-05-28T13:00:43+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-kymriah-car-t-cell-therapy-for-adult-patients-with-relapsed-or-refractory-follicular-lymphoma-.--novartis2022-05-28T13:00:51+00:00weekly0.6https://www.medthority.com/news/2022/5/fda-approves-two-opdivo--based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-esophageal-squamous-cell-carcinoma--bms/2022-05-29T12:55:59+00:00weekly0.6https://www.medthority.com/news/2022/5/mhlw-japanapproved-rinvoq-to-treat-ankylosing-spondylitis.--abbvie2022-05-29T12:55:12+00:00weekly0.6https://www.medthority.com/news/2022/5/the-lancet-publishes-results-from-phase-iii-induction-and-maintenance-programs-evaluating-risankizumab-in-crohns-disease.--abbvie2022-05-29T12:53:44+00:00weekly0.6https://www.medthority.com/news/2022/5/mhra-uk-grants-early-access-to-medicines-scheme-availability-for-efgartigimod-to-treat-generalised-myasthenia-gravis.--argenx2022-05-29T12:52:59+00:00weekly0.6https://www.medthority.com/news/2022/5/presentation-of-efficacy-and-safety-data-from-versatile-002-phase-ii-clinical-trial-in-recurrent-or-metastatic-head-and-neck-cancer-at-asco-2022.--pds-biotechnology2022-05-29T12:52:07+00:00weekly0.6https://www.medthority.com/news/2022/12/the-lancet-publishes-results-from-two-bimekizumab-phase-iii-studies-in-psoriatic-arthritis.--ucb2022-12-08T12:26:37+00:00weekly0.6https://www.medthority.com/news/2022/12/enhertu-achieved-statistically-significant-overall-survival-reducing-the-risk-of-death-by-36-vs.-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer-in-destiny-breast03.--daiichi-sankyo--astrazeneca2022-12-08T12:29:23+00:00weekly0.6https://www.medthority.com/news/2022/12/dinamo-phase-iii-trial-demonstrated-jardiance-is-the-first-sglt2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes.--eli-lilly--boehringer2022-12-08T12:39:45+00:00weekly0.6https://www.medthority.com/news/2022/12/novartis-investigational-iptacopan-provides-clinically-meaningful-increases-in-hemoglobin-levels-in-complement-inhibitor-naive-patients-with-pnh/2022-12-08T12:41:22+00:00weekly0.6https://www.medthority.com/news/2022/12/kisqali-prolonged-pfs-benefit-for-pre--and-perimenopausal-patients-with-aggressive-hrher2--metastatic-breast-cancer-compared-to-chemotherapy.--novartis2022-12-08T12:44:31+00:00weekly0.6https://www.medthority.com/news/2022/12/acoziborole-investigational-single-dose-oral-treatment-raises-hope-for-elimination-of-sleeping-sickness-in-africa.--sanofi--drugs-for-neglected-diseases-initiative2022-12-07T12:17:49+00:00weekly0.6https://www.medthority.com/news/2022/12/data-from-phase-iii-monarche-trial-of-adjuvant-verzenio-plus-et-showing-deepening-benefit-in-early-breast-cancer-published-in-the-lancet-oncology.--eli-lilly2022-12-07T12:16:44+00:00weekly0.6https://www.medthority.com/news/2022/12/prx-102-resubmitted-to-fda-for-fabry-disease.--protalix-biotherapeutics2022-12-07T12:14:19+00:00weekly0.6https://www.medthority.com/news/2022/12/rolling-submission-for-sage-217-in-major-depressive-disorder-mdd-and-postpartum-depression-completed.--sage-therapeutics-and-biogen2022-12-07T12:12:07+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-delta-1-trial-of-corectim-0.5-ointment-meets-primary-endpoint-in-chronic-hand-eczema.--leo-pharma2022-12-07T12:08:40+00:00weekly0.6https://www.medthority.com/news/2022/12/european-medicines-agency-accepts-tofersen-maa-to-treat-superoxide-dismutase-1-sod1-amyotrophic-lateral-sclerosis.--biogen-inc.-2022-12-07T12:06:38+00:00weekly0.6https://www.medthority.com/news/2022/12/early-completion-of-enrollment-in-phase-ii-altitude-nash-liver-function-trial-of-rencofilstat-.-hepion-pharma2022-12-06T12:17:15+00:00weekly0.6https://www.medthority.com/news/2022/12/-jazz-pharmaceuticals-presents-new-findings-from-caregiver-survey-on-outcomes-of-epidiolex-for-adult-and-pediatric-patients-with-severe-childhood-onset-epilepsies/2022-12-06T12:19:36+00:00weekly0.6https://www.medthority.com/news/2022/12/omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-filed-with-fda-for-emergency-use-authorisation-as-third-3-microgram-dose-in-covid-19.--pfizer2022-12-06T12:21:08+00:00weekly0.6https://www.medthority.com/news/2022/12/antibody-persistence-trial-vla1553-303-shows-twelve-months-antibody-persistence-for-vla-1553-in-chikungunya.--valneva-se2022-12-06T12:36:37+00:00weekly0.6https://www.medthority.com/news/2022/11/eli-lilly-and-company-has-announced-the-launch-of-ramiven-abemaciclib-following-approval-from-the-dcgi-india--endocrine-therapy-for-adjuvant-treatment-in-hr-positive-her2-negative-early-breast-cancer-.-2022-11-29T12:57:12+00:00weekly0.6https://www.medthority.com/news/2022/11/restore-phase-iii-trial-of-rezafungin-in-candidaemia-and-invasive-candidiasis-published-in-the-lancet.--cidara-therapeutics-2022-11-29T13:00:05+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-connect-fx-study-of-zygel-in-fragile-x-syndrome-published-in-journal-of-neurodevelopmental-disorders.--zynerba-pharma2022-11-29T13:02:58+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-510k-premarket-clearance-for-painshield-plus-to-treat-chronic-pain.-nanovibronix-inc2022-11-30T12:42:39+00:00weekly0.6https://www.medthority.com/news/2022/11/first-patient-dosed-in-sunrise-3-phase-iii-registrational-trial-of-bemnifosbuvir-an-investigational-oral-antiviral-for-the-treatment-of-covid-19.--atea-pharma2022-11-30T12:44:58+00:00weekly0.6https://www.medthority.com/news/2022/11/european-approval-for-use-of-biktarvy-in-children-with-hiv.--gilead-sciences2022-11-30T12:46:59+00:00weekly0.6https://www.medthority.com/news/2022/11/nda-presented-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease.--aldeyra-therapeutics.-2022-11-30T12:48:43+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-4whim-trial-of-x4p-001-rd-meets-primary-endpoint-in-whim-syndrome.--x4-pharma2022-11-30T12:51:14+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-accord-trial-of-axs-05-meets-primary-endpoint-in-alzheimers-disease-agitation.--axsome-therapeutics2022-11-30T12:52:45+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accepts-filing-for-srp-9001-and-gives-it-priority-review-for-duchenne-muscular-dystrophy.--sarepta-therapeutics2022-11-30T12:54:39+00:00weekly0.6https://www.medthority.com/news/2022/11/nordic-nanovector-to-merge-with-apim-therapeutics/2022-11-30T12:56:20+00:00weekly0.6https://www.medthority.com/news/2022/11/apollo-endosurgery-acquired-by-boston-scientific-corpn/2022-11-30T12:57:51+00:00weekly0.6https://www.medthority.com/news/2022/11/astrazeneca-to-acquire-neogene-therapeutics-and-with-it-access-to-next-generation-t-cell-receptor-therapies.-2022-11-30T12:39:51+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-510k-premarket-clearance-for-painshield-plus-to-treat-chronic-pain2.-nanovibronix-inc2022-11-30T12:38:24+00:00weekly0.6https://www.medthority.com/news/2022/11/first-patient-dosed-in-sunrise-3-phase-iii-registrational-trial-of-bemnifosbuvir-an-investigational-oral-antiviral-for-the-treatment-of-covid-192.--atea-pharma2022-11-30T12:36:30+00:00weekly0.6https://www.medthority.com/news/2022/11/european-approval-for-use-of-biktarvy-in-children-with-hiv2.--gilead-sciences2022-11-30T12:34:27+00:00weekly0.6https://www.medthority.com/news/2022/11/nda-presented-to-the-fda-for-reproxalap-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease.--aldeyra-therapeutics2.-2022-11-30T12:32:04+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-4whim-trial-of-x4p-001-rd-meets-primary-endpoint-in-whim-syndrome2.--x4-pharma2022-11-30T12:30:48+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-accord-trial-of-axs-05-meets-primary-endpoint-in-alzheimers-disease-agitation2.--axsome-therapeutics2022-11-30T12:21:34+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accepts-filing-for-srp-9001-and-gives-it-priority-review-for-duchenne-muscular-dystrophy2.--sarepta-therapeutics2022-11-30T12:18:56+00:00weekly0.6https://www.medthority.com/news/2022/11/nordic-nanovector-to-merge-with-apim-therapeutics2/2022-11-30T12:17:03+00:00weekly0.6https://www.medthority.com/news/2022/11/apollo-endosurgery-acquired-by-boston-scientific-corpn2/2022-11-30T12:14:39+00:00weekly0.6https://www.medthority.com/news/2022/11/astrazeneca-to-acquire-neogene-therapeutics-and-with-it-access-to-next-generation-t-cell-receptor-therapies2.-2022-11-30T12:12:49+00:00weekly0.6https://www.medthority.com/news/2022/12/full-results-of-lecanemab-phase-iii-confirmatory-clarity-ad-study-for-early-alzheimers-disease--presented-at-clinical-trials-on-alzheimers-disease-ctad-conference2.-eisai--biogen2022-12-01T12:34:32+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-has-accepted-for-priority-review-the-supplemental-biologics-license-application-for-evkeeza-in-homozygous-familial-hypercholesterolemia2.--regeneronpharma2022-12-01T12:30:48+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-emerald-study-of-rad-1901-in-breast-cancer-presented-at-san-antonio-breast-cancer-symposium2.--menarini-group2022-12-01T12:28:06+00:00weekly0.6https://www.medthority.com/news/2022/12/donanemab-data-in-first-active-comparator-studytrailblazer-alz-4-in-early-symptomatic-alzheimers-disease2.-eli-lilly2022-12-01T12:24:47+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approval-of-second-indication-for-brexafemme-for-reduction-in-incidence-of-recurrent-vulvovaginal-candidiasis.--scynexis-inc2022-12-02T12:26:06+00:00weekly0.6https://www.medthority.com/news/2022/12/azheimers-lift-ad-trial-of-fosgonimeton-is-recommended-to-continue-by-monitoring-committee.-athira-pharma2022-12-02T12:27:53+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approval-of-rezlidhia-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-with-a-susceptible-idh1-mutation.--rigel-pharma2022-12-04T11:06:32+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approval-for-rebyota--a-novel-first-in-class-microbiota-based-live-biotherapeutic-for-the-prevention-of-recurrence-of-clostridioides-difficile-infection.--ferring-pharma2022-12-04T11:05:44+00:00weekly0.6https://www.medthority.com/news/2022/12/acceptance-of-maa-by-the-european-medicines-agency-for-aumolertinib-in-egfr-mutated-non-small-cell-lung-cancer.-eqrx-inc2022-12-04T11:04:50+00:00weekly0.6https://www.medthority.com/news/2022/12/rubyengot-en6gog3031nsgo-phase-iii-trial-investigating-jemperli-meets-primary-endpoint-in-endometrial-cancer.--gsk2022-12-04T11:03:52+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-issues-complete-response-letter-for-omburtamab-in-cnsleptomeningeal-metastasis-from-neuroblastoma.--y-mabs-therapeutics-2022-12-04T11:02:53+00:00weekly0.6https://www.medthority.com/news/2022/12/ema-validates-filing-of-momelotinib-for-myelofibrosis.--gsk2022-12-04T11:00:50+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-trial-of-ub-612-as-booster-meets-endpoints-in-covid-19.--vaxxinity2022-12-04T10:59:38+00:00weekly0.6https://www.medthority.com/news/2022/12/anavax2-73-in-phase-iibiii-study-met-primary-endpoints-for-the-treatment-of-mild-cognitive-impairment-due-to-alzheimers-disease.--anavex-life-sciences2022-12-04T11:01:58+00:00weekly0.6https://www.medthority.com/news/2022/12/next-gen-evolut-fx-tavr-system-shows-significant-improvement-in-commissure-alignment-in-real-world-setting.--medtronic2022-12-05T12:21:05+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-accepts-bla-of-denileukin-diftitox-reformulation-for-persistent-or-recurrent-cutaneous-t-cell-lymphoma.--eisai--citius-pharma2022-12-05T12:25:17+00:00weekly0.6https://www.medthority.com/news/2022/12/merck-kgaa-announces-positive-phase-iii-results-for-arpraziquantel-as-part-of-its-schistosomiasis-elimination-program/2022-12-05T12:26:43+00:00weekly0.6https://www.medthority.com/news/2022/12/pluvicto-shows-statistically-significant-and-clinically-meaningful-radiographic-progression-free-survival-benefit-in-patients-with-psmapositive-metastatic-castration-resistant-prostate-cancer.--novartis2022-12-05T12:29:09+00:00weekly0.6https://www.medthority.com/news/2022/11/xocova-tablets-125mg-approved-in-japan-for-the-treatment-of-sars-cov-2-infection-under-the-emergency-regulatory-approval-system.--shionogi2022-11-25T12:31:13+00:00weekly0.6https://www.medthority.com/news/2022/11/spravato-data-from-the-phase-iiib-escape-trd-study-demonstrate-superior-efficacy-compared-to-quetiapine-extended-release-in-treatment-resistant-major-depressive-disorder.--janssen-pharma2022-11-26T15:10:11+00:00weekly0.6https://www.medthority.com/news/2022/11/mhra-uk-approves-upstaza-to-treataromatic-l-amino-acid-decarboxylase-aadc-deficiency.--ptc-therapeutics2022-11-26T15:09:24+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-issues-crl-for-poziotinib-in-non-small-cell-lung-cancer-and-company-announces-drug-deprioritisation.--spectrum-pharma2022-11-26T15:08:39+00:00weekly0.6https://www.medthority.com/news/2022/11/sezaby-is-approved-by-the-fda-for-the-treatment-of-neonatal-seizures-.--sun-pharma2022-11-27T16:26:36+00:00weekly0.6https://www.medthority.com/news/2022/11/one-year-data-on-evoque--transcatheter-tricuspid-valve-replacement.--edwards-lifesciences2022-11-28T12:39:25+00:00weekly0.6https://www.medthority.com/news/2022/11/first-results-from-acurate-neo-2--aortic-valve-system-post-market-clinical-follow-up-study.---boston-scientific2022-11-28T12:38:14+00:00weekly0.6https://www.medthority.com/news/2022/11/bimekizumab-demonstrated-at-acr-convergence-2022-sustained-clinical-responses-to-week-52-in-phase-iii-studies-in-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis.--ucb2022-11-11T12:24:21+00:00weekly0.6https://www.medthority.com/news/2022/11/bimekizumab-demonstrated-at-acr-convergence-2022-sustained-clinical-responses-to-week-52-in-phase-iii-studies-in-psoriatic-arthritis.--ucb2022-11-11T12:28:44+00:00weekly0.6https://www.medthority.com/news/2022/11/late-breaking-data-at-aha-from-pivotal-phase-iii-precision-study-demonstrates-significant-and-sustained-effect-of-aprocitentan-on-lowering-blood-pressure-for-patients-with-difficult-to-control-hypertension.--janssen--idorsia-ltd2025-02-03T11:30:11+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-grants--emergency-use-authorisation--for-kineret-for-treatment-of-covid-19-patients-with-pneumonia.--sobi2022-11-11T12:39:35+00:00weekly0.6https://www.medthority.com/news/2022/11/chmp-opinion-for-omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-booster-for-children-5-through-11-years-of-age-in-european-union.--pfizer--biontech-se2022-11-11T12:42:56+00:00weekly0.6https://www.medthority.com/news/2022/11/european-commission-approves--vidprevtyn-beta-as-a-booster-to--prevent-covid-19.--sanofi--gsk2022-11-11T12:45:09+00:00weekly0.6https://www.medthority.com/news/2022/11/chmp-recommends-lynparza--abiraterone--prednisone-or-prednisolone-for-the-treatment-of-adult-patients-with-mcrpc-in-whom-chemotherapy-is-not-clinically-indicated.--astrazeneca--merck-inc2022-11-14T08:09:59+00:00weekly0.6https://www.medthority.com/news/2022/11/pt-027-recommended-by-fda-advisory-committee-as-a-new-rescue-treatment-for-asthma-in-people-aged-18-years-and-older.--astrazeneca--avillion-2022-11-10T12:12:58+00:00weekly0.6https://www.medthority.com/news/2022/11/strong-hf-study-results-demonstrate-clear-benefits-for-acute-heart-failure-patients-with-utilisation-of-the--elecsys-nt-probnp-biomarker.--roche2022-11-10T12:40:20+00:00weekly0.6https://www.medthority.com/news/2022/11/onivyde-regimen-demonstrated-statistically-significant-improvement-in-overall-survival-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma.--ipsen2022-11-10T12:43:55+00:00weekly0.6https://www.medthority.com/news/2022/11/libtayo--chemotherapy-is-fda-approved-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer.--regeneron-2025-02-03T13:47:27+00:00weekly0.6https://www.medthority.com/news/2022/11/publication-of-positive-data-from-phase-1biia-clinical-study-of-efzofitimod-for-the-treatment-of-pulmonary-sarcoidosis-in-the-journal-chest.--atyr-pharma2022-11-10T12:53:34+00:00weekly0.6https://www.medthority.com/news/2022/11/update-on-fda-advisory-committee-meeting-regarding-emergency-use-authorization-of-sabizabulin-to-treat-hospitalized-covid-19-patients-at-high-risk-for-acute-respiratory-distress-syndrome.--veru-inc2022-11-10T12:55:51+00:00weekly0.6https://www.medthority.com/news/2022/11/reductions-in-certain-types-of-hpv-related-cervical-and-non-cervical-diseases-in-women-and-men-observed-with-real-world-use-of-gardasil-in-systematic-literature-review-of-138-studies.--merck-inc2022-11-10T13:00:50+00:00weekly0.6https://www.medthority.com/news/2022/11/full-marketing-authorisation-granted-from-european-commission-based-on-totality-of-efficacy-and-safety-data-confirming-the-benefits-of-vaxzevria.--astrazeneca-2022-11-02T12:14:52+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accepts-nda-for-transcon-pth-to-treat-hypoparathyroidism.--ascendis-pharma2022-11-02T12:16:44+00:00weekly0.6https://www.medthority.com/news/2022/11/focus-phase-iii-clinical-trial-of-tavalisse-fails-to-meet-statistical-significance-in-covid-19.--rigel-pharma2022-11-02T12:20:45+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-matisse-trial-of-rsvpref-vaccine-meets-one-primary-endpoint-in-respiratory-syncytial-virus.--pfizer-2025-02-03T13:58:00+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-cingal-19-01-study-demonstrates-superiority-in-knee-osteoarthritis-pain-relief.--anika-therapeutics2022-11-02T12:31:45+00:00weekly0.6https://www.medthority.com/news/2022/11/disrupt-pad-iii-observational-study-of-lithoplasty-balloon-catheter-ivl-in-pad-presented-at-viva22.--shockwave-medical2024-09-30T12:12:27+00:00weekly0.6https://www.medthority.com/news/2022/11/sonics-study-of-recorlev-in-cushings-syndrome-published-in-european-journal-of-endocrinology.--xeris-biopharma2022-11-03T12:02:05+00:00weekly0.6https://www.medthority.com/news/2022/11/johnson--johnson-to-acquire-abiomed/2022-11-02T12:37:01+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-vemlidy-for-treatment-of-chronic-hepatitis-b-virus-infection-in-pediatric-patients.--gilead-sciences2022-11-03T13:00:12+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-clinical-trials-with-nt-501-ect-showed-statistical-significance-for-the-primary-endpoint-in-macular-telangiectasia-type-2.--neurotech-pharma2022-11-03T12:59:48+00:00weekly0.6https://www.medthority.com/news/2022/11/european-commission-approves-brukinsa-to-treat-marginal-zone-lymphoma.--beibene2022-11-03T13:02:45+00:00weekly0.6https://www.medthority.com/news/2022/11/alkermes-plc-announces-intent-to-separate-oncology-business/2022-11-03T13:04:22+00:00weekly0.6https://www.medthority.com/news/2022/11/results-from-cytosorb-therapy-in-covid-19-ctc-registry-presented-at-35th-annual-congress-of-the-european-society-of-intensive-care-medicine.--cytosorbents-corp2022-11-04T12:45:56+00:00weekly0.6https://www.medthority.com/news/2022/11/eagle-2-and-eagle-3-phase-iii-trials-for-gepotidacin-stopped-early-for-efficacy-following-pre-planned-interim-analysis-by-independent-data-monitoring-committee.--gsk-plc2022-11-04T12:56:33+00:00weekly0.6https://www.medthority.com/news/2022/11/pooled-analysis-of-two-phase-iii-studies-of-ibrexafungerp-in-vulvovaginal-candidiasis-published-in-the-journal-of-womens-health.--scynexis2022-11-04T13:00:21+00:00weekly0.6https://www.medthority.com/news/2022/11/eu-approves-beyfortus-for-respiratory-syncytial-virus.--astrazeneca--sanofi2022-11-05T15:19:30+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-viital-study-of-eb-101-meets-2-primary-endpoints-in-recessive-dystrophic-epidermolysis-bullosa.--abeona-therapeutics2022-11-05T15:18:45+00:00weekly0.6https://www.medthority.com/news/2022/11/rolling-review-of-zimura-submitted-to-fda-for-geographic-atrophy.--iveric-bio2022-11-05T15:17:54+00:00weekly0.6https://www.medthority.com/news/2022/11/empa-kidney-phase-iii-clinical-trial--of-jardiance-meets-primary-endpoint-in-chronic-kidney-disease-with-results-announced-at-kidney-week-and-published-in-nejm.--eli-lilly--boehringer2022-11-05T15:16:59+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-kinect-hd-study-of-valbenazine-updates-dosing-and-adverse-events-in-huntington-disease-presented-at-29th-annual-meeting-of-the-huntington-study-group.--neurocrine-biosciences2022-11-05T15:16:08+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-cotellic-for-the-treatment-of-adult-patients-with-histiocytic-neoplasms.--genentechroche--exelixis2022-11-07T12:04:58+00:00weekly0.6https://www.medthority.com/news/2022/11/gsk-seeks-approval-in-japan-of-gsk-3389245a-a-rsv-vaccine/2025-02-03T13:58:17+00:00weekly0.6https://www.medthority.com/news/2022/11/european-commission-expands-vaxneuvance-vaccine-indication-to-include-infants-children-and-adolescents.-merck-inc2022-11-01T14:34:31+00:00weekly0.6https://www.medthority.com/news/2022/11/positive-phase-1-data-for-orally-disintegrating-tablet-formulation-of-sebetralstat-for-use-in-hereditary-angioedema.-kalvista2022-11-01T14:39:01+00:00weekly0.6https://www.medthority.com/news/2022/11/top-line-data-from-the-expedite-study-of-remodulin-induction-prior-to-orenitram-therapy-for-pulmonary-arterial-hypertension----united-therapeutics/2022-11-01T14:41:11+00:00weekly0.6https://www.medthority.com/news/2022/11/plan-announced-to-submit-application-for-partial-change-to-label-for-dosage-and-admnistration-of-aricept174-for-treatment-of-dementia-with-lewy-bodies.--eisai2022-11-01T14:44:37+00:00weekly0.6https://www.medthority.com/news/2022/11/european-medicines-agency-validates--maa-for-vamorolone-in-duchenne-muscular-dystrophy.--santhera-pharma2022-11-01T14:50:38+00:00weekly0.6https://www.medthority.com/news/2022/11/positive-topline-results-of-phase-iii-commands-trial-in-the-first-line-treatment-by-reblozyl-of-adult-patients-with-very-low-low--or-intermediate-risk-myelodysplastic-syndromes-who-require-rbc-transfusions.--bms2022-11-01T14:54:14+00:00weekly0.6https://www.medthority.com/news/2022/11/positive-top-line-results-from-pivotal-phase-iii-sierra-trial-of-iomab-b-in-patients-with-active-relapsed-or-refractory-acute-myeloid-leukemia.--actinium-pharma2022-11-01T14:56:57+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-announces-priority-review-to-transcon-pth-in-hypoparathyroidism.--ascendis-pharma2022-11-01T15:10:31+00:00weekly0.6https://www.medthority.com/news/2022/11/takeda-and-shionogi-to-cancel-copromotion-for-intuniv-and--vyvanse-products-for-adhd-in-2023/2022-11-08T12:24:00+00:00weekly0.6https://www.medthority.com/news/2022/11/tenapanor-is-filed-in-japan-for-the-improvement-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-undergoing-dialysis.--kyowa-kirin--ardelyx2025-02-03T13:47:51+00:00weekly0.6https://www.medthority.com/news/2022/11/farxiga-improved-symptom-burden-and-health-related-quality-of-life-in-patients-with-mildly-reduced-or-preserved-ejection-fraction-in-deliver-phase-iii-trial.--astrazeneca2022-11-08T12:41:32+00:00weekly0.6https://www.medthority.com/news/2022/11/lilly-to-begin-rollout-of-tempo-personalized-diabetes-management-platform/2025-02-03T13:57:45+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-credit-1-study-of-ibi-306-in-non-familial-hypercholesterolemia-presented-at-the-american-heart-association-aha-scientific-sessions.--innovent-biologics2022-11-08T13:02:35+00:00weekly0.6https://www.medthority.com/news/2022/11/new-long-term-leqvio-phase-ii-orion-3-trial-data-show-sustained-efficacy-and-safety--low-density-lipoprotein-cholesterol-ldl-c-reduction-over-four-years.--novartis2022-11-08T13:09:37+00:00weekly0.6https://www.medthority.com/news/2022/11/health-canada-authorises-mrna-1273.222-as-an-omicrom-targeted-bivalent-booster.--moderna-inc2022-11-08T13:12:19+00:00weekly0.6https://www.medthority.com/news/2022/11/nmpa-china-approves-hansizhuang--chemotherapy-for-first-line-treatment-of--squamous-non-small-cell-lung-cancer.---shanghai-henlius-biotech2025-02-03T13:48:21+00:00weekly0.6https://www.medthority.com/news/2022/11/biomarin-announces-incremental-progress-on-bla-review-for-valoctocogene-roxaparvovec-aav-gene-therapy-for-adults-with-severe-hemophilia-a-/2022-11-09T12:24:11+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-ii-oceana-dose-trial-results-in-adults-with-elevated-lipoprotein-levels-and-atherosclerotic-cardiovascular-disease.--amgen2025-02-03T14:19:00+00:00weekly0.6https://www.medthority.com/news/2022/11/update-on-dreamm-3-phase-iii-trial-for-blenrep-in-relapsedrefractory-multiple-myeloma.--gsk-plc2022-11-09T12:34:10+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-covid-19-omicron-trial-supports-the-continued-and-future-use-of-novavax-prototype-vaccine-as-a-booster.--novavax2022-11-09T12:37:32+00:00weekly0.6https://www.medthority.com/news/2022/11/avenue-therapeutics-completes-acquisition-of-baergic-bio-inc-and-with-it-baer-101/2022-11-09T12:41:14+00:00weekly0.6https://www.medthority.com/news/2022/11/uks-mhra-approves-beyfortus-to-prevent-respiratory-syncytial-virus-in-infants.--sanofi2022-11-16T13:29:31+00:00weekly0.6https://www.medthority.com/news/2022/11/topline-results-from-summit-phase-iii-trial-of-sts-101-for-the-acute-treatment-of-migraine.--satsuma-pharma2022-11-16T13:26:24+00:00weekly0.6https://www.medthority.com/news/2022/11/update-on-phase-iii-graduate-programme-evaluating-gantenerumab-in-early-alzheimers-disease.--roche2022-11-16T13:24:03+00:00weekly0.6https://www.medthority.com/news/2022/11/toripalimab-filed-with-eu-for-nasopharyngeal-carcinoma.--shanghai-junshi-biosciences2022-11-16T13:21:52+00:00weekly0.6https://www.medthority.com/news/2022/11/toripalimab-filed-with-eu-for-oesophageal-squamous-cell-carcinoma.--shanghai-junshi-biosciences-2022-11-16T13:05:11+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-regal-study-of-galinpepimut-s-shows-extended-benefits-in-acute-myeloid-leukemia.--sellas-life-sciences2022-11-16T13:02:41+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-frutiga-study-of-hmpl-013--taxol-meets-one-primary-endpoint-in-gastric-cancer.--hutchmed-2022-11-16T13:00:32+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-elahere-for-the-treatment-of-adult-patients-with-folate-receptor-alpha-positive-platinum-resistant-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer.--immunogen-inc2022-11-16T12:52:01+00:00weekly0.6https://www.medthority.com/news/2022/11/invidior-to-acquire-opiant-pharma-and-with-it-opnt-003-an-investigational-opioid-overdose-reversal-agent/2022-11-16T12:46:28+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-grants-emergency-use-authorization-for-cobas-mpxv--high-throughput-test-to-detect-monkeypox-virus.--roche2022-11-17T12:10:40+00:00weekly0.6https://www.medthority.com/news/2022/11/pfizer-and-biontech-advance-next-generation-covid-19-vaccine-strategy-with-study-start-of--bnt162b4-aimed-at-enhancing-breadth-of-t-cell-responses-and-duration-of-protection/2022-11-17T12:16:16+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-advisory-committee-votes-that-the-benefits-of-xphozah-outweigh-its-risks-for-the-control-of-serum-phosphorus-in-adult-patients-with-chronic-kidney-disease-on-dialysis.--ardelyx-inc2022-11-17T12:19:18+00:00weekly0.6https://www.medthority.com/news/2022/11/gsk-provides-an-update-on-zejula--us-prescribing-information-for-ovarian-cancer/2022-11-18T12:11:56+00:00weekly0.6https://www.medthority.com/news/2022/11/european-commission-approval-for-brukinsa-for-the-treatment-of-adults-with-chronic-lymphocytic-leukemia--beigene-/2022-11-18T12:22:18+00:00weekly0.6https://www.medthority.com/news/2022/11/510k-clearance-for-extracorporeal-membrane-oxygenation-for-lifesparc-the-next-generation-advanced-circulatory-support-system.-livanova-plc2022-11-18T12:28:27+00:00weekly0.6https://www.medthority.com/news/2022/11/tzield-is-approved-by-the-fda-as-the-first-and-only-treatment-indicated-to-delay-the-onset-of-stage-3-type-1-diabetes-t1d-in-adult-and-pediatric-patients-aged-8-years-and-older-with-stage-2-t1d.--provention-bio--sanofi2022-11-18T12:46:01+00:00weekly0.6https://www.medthority.com/news/2022/11/nuvaxovid-covid-19-vaccine-receives-expanded-authorization-in-canada-.--novavax2022-11-19T11:36:54+00:00weekly0.6https://www.medthority.com/news/2022/11/new-data-on-omicron-ba.4ba.5-adapted-bivalent-booster-demonstrating-improved-immune-response-against-emerging-omicron-sublineages.pfizer--biontech-se2022-11-19T11:36:12+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accepts-nda-amendment-and-new-pdufa-date-of-february-26-2023-for-pegcetacoplan-for-geographic-atrophy.--apellis-2022-11-20T11:05:15+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-mondaywednesdayfriday-intramuscular-dosing-schedule-for-rylaze-to-treat-all-and-lbl.-jazz-pharma2022-11-20T11:04:23+00:00weekly0.6https://www.medthority.com/news/2022/11/yimmugo-approved-in-germany-for-replacement-therapy-in-primary-antibody-deficiency-syndromes-and-secondary-immune-deficiency.--biotest-ag2022-11-20T11:03:37+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-liletta-52-mg-to-prevent-pregnancy-for-up-to-eight-years.--medicines-3602022-11-20T11:02:42+00:00weekly0.6https://www.medthority.com/news/2022/11/european-commission-approves-enjaymo-for-treatment-of-hemolytic-anemia-in-adult-patients-with-cold-agglutinin-disease.--sanofi2022-11-20T11:01:54+00:00weekly0.6https://www.medthority.com/news/2022/11/tgaaustralia-approves-vazkepa-to-reduce-the-risk-of-cardiovascular-events-in-adult-statin--treated-patients.--amarin-corpn2022-11-20T11:01:08+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-trial-of-dcvax-l-meets-both-endpoints-in-glioblastoma.--northwest-biotherapeutics2022-11-20T11:00:24+00:00weekly0.6https://www.medthority.com/news/2022/11/full-findings-from-lecanemab--confirmatory-phase-iii-trial-clarity-ad-will-be-presented-at-alzheimers-disease-conference.-eisai2022-11-22T12:29:11+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accepts-for-priority-review-bla-for-epcoritamab-for-the-treatment-of-relapsedrefractory-large-b-cell-lymphoma-.--genmab--abbvie2022-11-22T12:23:59+00:00weekly0.6https://www.medthority.com/news/2022/11/uk-mhra-approves-expanded-marketing-authorisation-of-imcivree-in-bardet-biedl-syndrome.--rhythm-pharmaceuticals2022-11-22T12:19:15+00:00weekly0.6https://www.medthority.com/news/2022/11/presentation-of-deuruxolitinib--thrive-aa1-phase-iii-study-results-in-alopecia-areata-at-world-congress-for-hair-research.---concert-pharma2022-11-22T12:15:10+00:00weekly0.6https://www.medthority.com/news/2022/11/merck-inc.-to-acquire-imago-biosciences-and-with-it-img-7289-treatment-for-essential--thrombocythemia-myelofibrosis-and-polycythemia-vera2022-11-22T12:12:01+00:00weekly0.6https://www.medthority.com/news/2022/11/pyrukynd-is-eu-approved-as-the-first-and-only-disease-modifying-therapy-for-pyruvate-kinase-deficiency-.--agios-pharma2022-11-15T12:16:25+00:00weekly0.6https://www.medthority.com/news/2022/11/modernas-ba.4ba.5-targeting-bivalent-booster-mrna-1273.222-meets-primary-endpoint-of-superiority-against-omicron-variants-compared-to-booster-dose-of-mrna-1273-in-phase-iiiii-clinical-trial2022-11-15T12:20:35+00:00weekly0.6https://www.medthority.com/news/2022/11/health-canada-authorisation-of-radicava-oral-suspension-for-the-treatment-of-amyotrophic-lateral-sclerosis.---mitsubishi-tanabe2022-11-15T12:22:09+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approval-of-new-indication-for-adcetris--chemotherapy-for-children-with-previously-untreated-high-risk-hodgkin-lymphoma--seagen-inc/2022-11-15T12:24:27+00:00weekly0.6https://www.medthority.com/news/2022/11/nuvaxovid-covid-19-vaccine-authorized-in-the-united-kingdom-as-a-booster-to-prevent-coronavirus-disease-caused-by--severe-acute-respiratory-syndrome--in-adults.--novavax-inc2025-02-03T11:29:40+00:00weekly0.6https://www.medthority.com/news/2022/11/phase-iii-keynote-859-trial-met-primary-endpoint-of-overall-survival-in-patients-with-her2-negative-gastric-or-gastroesophageal-junction--adenocarcinoma.--merck-inc2022-11-23T12:16:20+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-gives-priority-review-to-efgartigimod-ph20-for-myasthenia-gravis.--argenx-se2022-11-23T12:21:20+00:00weekly0.6https://www.medthority.com/news/2022/11/eu-approves-libtayo-for-cervical-cancer.--regeneron-pharma2022-11-23T12:23:29+00:00weekly0.6https://www.medthority.com/news/2022/11/update-on-blenrep-us-marketing-authorisation-for-relapsed-or-refractory-multiple-myeloma-.--gsk-plc2022-11-23T12:25:12+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-approves-hemgenix-the-first-gene-therapy-for-hemophilia-b.--csl2022-11-23T12:27:33+00:00weekly0.6https://www.medthority.com/news/2022/11/obseva-announces-sale-of-ebopiprant-license-agreement-to-xoma-for-up-to-$113-million/2022-11-25T12:06:14+00:00weekly0.6https://www.medthority.com/news/2022/11/submission-of-supplemental-nda-to-fda-for-ayvakit-for-the-treatment-of-indolent-systemic-mastocytosis.--blueprint-medicines-corpn2022-11-25T12:22:01+00:00weekly0.6https://www.medthority.com/news/2022/11/eu-approves-skyrizi-for-crohns-disease.--abbvie2022-11-25T12:23:33+00:00weekly0.6https://www.medthority.com/news/2022/11/fda-accept-filing-for-tak-003-and-grant-priority-review-for-dengue.--takeda2022-11-25T12:25:18+00:00weekly0.6https://www.medthority.com/news/2022/11/ganaplacidelumefantrine-formulation-moves-into-phase-iii-trials-for-malaria.--novartis-and-mmv2022-11-25T12:27:36+00:00weekly0.6https://www.medthority.com/news/2022/11/graybug-vision-and-calcimedica-to-merge-and-focus-on-the-development-of-auxora/2022-11-25T12:29:30+00:00weekly0.6https://www.medthority.com/news/2022/10/90-day-analysis-shows-moderna-omicron-ba.1-targeting-bivalent-vaccinemrna--1273-214-demonstrates-superior-antibody-respose-as-booster-compared-to-spikevax-prototype2022-10-20T11:26:09+00:00weekly0.6https://www.medthority.com/news/2022/10/positive-chmp-opinion-for-comirnaty--vaccine-in-children-6-months-to-less-than-5-years-in-the-european-union.-pfizer--biontech-se2022-10-20T11:29:57+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-zoster-049-extension-study-shows-that-shingrix-provides-10-years-of-protection-in-shingles.--glaxosmithkline2022-10-20T11:34:23+00:00weekly0.6https://www.medthority.com/news/2022/10/database-lock-for-pivotal-phase-iii-viital-study-of-eb-101-in-patients-with-recessive-dystrophic-epidermolysis-bullosa.---abeona-therapeutics-2022-10-20T11:39:31+00:00weekly0.6https://www.medthority.com/news/2022/10/data-from-checkmate-76k-shows-opdivo--reduced-the-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma.--bms2022-10-20T11:42:40+00:00weekly0.6https://www.medthority.com/news/2022/10/positive-results-from-phase-iii-rapid-clinical-trial-of-etripamil-nasal-spray-in-patients-with-paroxysmal-supraventricular-tachycardia.--milestone-pharma2022-10-20T11:44:50+00:00weekly0.6https://www.medthority.com/news/2022/10/ayala-pharma-to-merge-with-advaxis-inc/2022-10-20T11:47:11+00:00weekly0.6https://www.medthority.com/news/2022/10/committee-for-medicinal-products-for-human-use-adopts-positive-opinion-recommending-authorization-of--omicron-ba.4-ba.5-targeting-bivalent-covid-19-vaccine-in-the-european-union.--moderna2022-10-21T13:10:08+00:00weekly0.6https://www.medthority.com/news/2022/10/philips-advances-mrcat-head-and-neck-radiotherapy-imaging-and-simulation-for-head-and-neck-cancers/2022-10-21T13:12:51+00:00weekly0.6https://www.medthority.com/news/2022/10/committee-for-medicinal-products-for-human-use-recommends-authorization-for-the-use-of-spikevax-mrna-1273-in-children-6-months---5-years-in-the-european-union.--moderna-inc2022-10-21T13:14:47+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-grants-emergency-use-authorization-for-novavax-covid-19-vaccinenvx-cov2373-adjuvanted-as-a-booster-for-adults.--novavax2022-10-21T13:18:41+00:00weekly0.6https://www.medthority.com/news/2022/10/eu-approves-adtralza-for-moderate-to-severe-atopic-dermatitis.--leo-pharma2022-10-21T13:21:47+00:00weekly0.6https://www.medthority.com/news/2022/10/dmc-rules-phase-iii-freedom-1-study-of-fcr-001-in-kidney-transplant-may-continue-after-reported-death.--talaris-therapeutics2022-10-21T13:24:49+00:00weekly0.6https://www.medthority.com/news/2022/10/positive-results-from-visio-2-phase-iii-trial-of-microline-as-a-potential-on-demand-treatment-for-presbyopia.-eyenovia-inc2022-10-21T13:27:11+00:00weekly0.6https://www.medthority.com/news/2022/10/nefigard-part-a-pivotal-phase-iii-trial-of-tarpeyo-in-iga-nephropathy-published-in-kidney-international-journal.--calliditas-therapeutics2022-10-21T13:30:12+00:00weekly0.6https://www.medthority.com/news/2022/10/abbvie-acquires-djs-antibodies-and-with-it-preclinical-djs-002/2022-10-21T13:32:51+00:00weekly0.6https://www.medthority.com/news/2022/10/data-from--a-survey-conducted-by-national-psoriasis-foundation-is-presented-at-42nd-annual-fall-clinical-dermatology-conference.--novan-inc.-epi-health-a-novan-company-and-mc2-therapeutics2022-10-22T12:34:35+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-has-granted-pediatric-exclusivity-for-eylea.-this-grant-extends-the-period-of-u.s.-market-exclusivity-for-eylea-by-an-additional-six-months-through-may-17-2024.--regeneron2022-10-22T12:33:55+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-accepts-snda-for-camyzos-for-an-expanded-indication-to-reduce-the-need-for-septal-reduction-therapy-.--bms2022-10-22T12:33:06+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-has-approved-rinvoq-once-daily-an-oral-therapy-for-the-treatment-of-adults-with-active-non-radiographic-axial-spondyloarthritis-nr-axspa.--abbvie-2022-10-22T12:31:07+00:00weekly0.6https://www.medthority.com/news/2022/10/prevymis-demonstrates-efficacy-in-phase-iii-study-for-prevention-of-cytomegalovirus-disease-in-adults-after-kidney-transplantation.--merck-inc2022-10-23T12:17:41+00:00weekly0.6https://www.medthority.com/news/2022/10/new-real-world-analysis-of-tepezza-use-indicates-a-small-percentage-of-people-receive-a-second-course-of-treatment-for-thyroid-eye-disease.--horizon-therapeutics2022-10-23T12:18:47+00:00weekly0.6https://www.medthority.com/news/2022/10/investigational-oral-monotherapy-iptacopan-demonstrates-clinically-meaningful-superiority-over-anti-c5-treatment-in-phase-iii-apply-pnh-study-in-paroxysmal-nocturnal-hemoglobinuria.-novartis2022-10-25T06:36:05+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-clearance-for-covid-19-pcr-test-for-use-on-cobas-68008800-systems-to-detect-sars-cov-2.---roche-diagnostics2022-10-24T11:15:56+00:00weekly0.6https://www.medthority.com/news/2022/10/imjudo-tremelimumab-in-combination-with-imfinzi-approved-in-the-us-for-patients-with-unresectable-liver-cancer.--astrazeneca2022-10-24T11:13:22+00:00weekly0.6https://www.medthority.com/news/2022/10/real-world-evidence-reinforces-the-use-of-biktarvy-for-the-treatment-of-people-living-with-hiv-with-a-range-of-comorbidities.--gilead-sciences2022-10-24T11:11:40+00:00weekly0.6https://www.medthority.com/news/2022/10/cyclasol-filed-with-fda-and-accepted-for-dry-eye-disease.--novaliq2022-10-25T12:55:00+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-march-study-evaluating-livmarli-shows-benefits-in-progressive-familial-intrahepatic-cholestasis.--mirum-pharma2022-10-25T13:00:46+00:00weekly0.6https://www.medthority.com/news/2022/10/evusheld-receives-health-canada-approval-for-treatment-of-mild-to-moderate-covid-19.--astrazeneca2022-10-25T13:03:03+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-furi-study-of-ibrexafungerp--in-refractory-candidiasis-presented-at-idweek-2022.--scynexis2022-10-25T13:04:55+00:00weekly0.6https://www.medthority.com/news/2022/10/abiomed-successfully-completes-all-impella-post-approval-studies-for-high-risk-pci-cardiogenic-shock-post-cardiotomy-cardiogenic-shock-and-right-heart-failure/2022-10-25T13:08:17+00:00weekly0.6https://www.medthority.com/news/2022/10/poster-presentation-at-the-anesthesiology-2022-annual-meeting-compares-oliceridine-and-morphine-on-ventilation-in-an-elderly-population.--trevena-inc2022-10-25T13:11:20+00:00weekly0.6https://www.medthority.com/news/2022/10/data-from-landmark-phase-iii-attack-trial-presented-at-idweek-2022-for-sulbactam-durlobactam-v.-colistin-therapy-in-acinetobacter-baumannii-calcoaceticus-complex-infections.--entasis-therapeuticsinnovia-inc2022-10-25T13:14:37+00:00weekly0.6https://www.medthority.com/news/2022/10/quizartinib-filed-with-fda-and-given-priority-review-for-acute-myeloid-leukemia.--daiichi-sankyo2022-10-25T13:16:20+00:00weekly0.6https://www.medthority.com/news/2022/10/bone-therapeutics-completes-the-acquisition-of-medsenic-and-changes-its--name-to-biosenic/2022-10-25T13:17:52+00:00weekly0.6https://www.medthority.com/news/2022/10/the-british-journal-of-dermatology-publishes-results-from-ease-phase-iii-trial-of-of-filsuvez-in-epidermolysis-bullosa.--amryt2022-10-26T13:59:37+00:00weekly0.6https://www.medthority.com/news/2022/10/full-enrollment-in-the-registrational-phase-iii-arise-hf-trial-of-at-001-in-diabetic-cardiomyopathy.--applied-therapeutics2022-10-26T14:00:56+00:00weekly0.6https://www.medthority.com/news/2022/10/messina-phase-iii-trial-of-fasenra-fails-to-meet-one-of-dual-primary-endpoints-in-eosinophilic-esophagitis.--astrazeneca2022-10-26T14:02:23+00:00weekly0.6https://www.medthority.com/news/2022/10/avant-phase-iii-trial-for-duaklir--and-eklira-achieved-statistical-significance-in-chronic-obstructive-pulmonary-disease.--covis-pharma2022-10-26T14:04:23+00:00weekly0.6https://www.medthority.com/news/2022/10/capivasertib-a-potential-first-in-class-akt-inhibitor--faslodex-shows-positive-results-in-capitello-291-phase-iii-trial-for-hr-positive-breast-cancer.--astrazeneca2022-10-26T14:05:50+00:00weekly0.6https://www.medthority.com/news/2022/10/camizestrant-significantly-improved-progression-free-survival-vs.-faslodex-in-serena-2-phase-ii-trial-in-advanced-er-positive-breast-cancer.--astrazeneca2022-10-26T14:07:07+00:00weekly0.6https://www.medthority.com/news/2022/10/sumitomo-pharma-co.-ltd-and-sumitovant-biopharma-acquire-myovant-sciences2022-10-26T14:08:34+00:00weekly0.6https://www.medthority.com/news/2022/10/ultomiris-from-astrazeneca-showed-zero-relapses-in-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-with-median-treatment-duration-of-73-weeks.-2022-10-29T12:47:04+00:00weekly0.6https://www.medthority.com/news/2022/10/contrast-phase-iii-programme-for-gsk-3196165-meets-primary-endpoint-in-rheumatoid-arthritis.--gsk2022-10-29T12:46:11+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-crdac-supports-benefits-of-daprodustat-in-anaemia-of-chronic-kidney-disease.--gsk2022-10-29T12:45:32+00:00weekly0.6https://www.medthority.com/news/2022/10/last-patient-enrolled-in-pivotal-study-evaluating-the-efficacy-of-modia-in-combination-with-sublingual-buprenorphine-naloxone-for-the-treatment-of-opioid-use-disorder.--orexo-ab2022-10-29T12:44:48+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-defers-pdufa-action-on-filing-for-at-gaa-in-late-onset-pompe-disease.-amicus-therapeutics2022-10-29T12:43:59+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-advisory-committee-rejects-omburtamab-application-to-treat-cnsleptomeningeal-metastasis-from-neuroblastoma.--y-mabs-therapeutics-inc2022-10-30T14:06:18+00:00weekly0.6https://www.medthority.com/news/2022/10/eu-validates-filing-of-cabotegravir-long-acting-injectable-for-hiv.--viiv-healthcare2022-10-30T14:04:14+00:00weekly0.6https://www.medthority.com/news/2022/10/subcutaneous-duobody-filed-with-fda-for-large-b-cell-lymphoma-and-for-diffuse-large-b-cell-lymphoma-with-the-eu.--genmababbvie2022-10-30T14:02:23+00:00weekly0.6https://www.medthority.com/news/2022/10/retrospective-pooled-analysis-of-imgn-853-in-ovarian-cancer-presented-at-23rd-congress-of-the-european-society-of-gynaecological-oncology.--immunogen2022-10-30T14:00:40+00:00weekly0.6https://www.medthority.com/news/2022/10/bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy/2022-10-18T11:37:06+00:00weekly0.6https://www.medthority.com/news/2022/10/nintedanib-expanded-access-program--is-announced--for-children-and-adolescents-with-fibrosing-interstitial-lung-disease.--boehrniger-ingelheim2022-10-18T11:39:33+00:00weekly0.6https://www.medthority.com/news/2022/10/supernus-provides-regulatory-update-on-spn-830-for-parkinsons-disease/2022-10-17T07:27:50+00:00weekly0.6https://www.medthority.com/news/2022/10/yescarta-first-car-t-cell-therapy-to-receive-european-marketing-authorization-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma.-kitegilead-science2022-10-19T11:39:02+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iiiii-lift-ad-clinical-study-of-fosgonimeton-in-mild-to-moderate-alzheimers-patients-advances-following-independent-unblinded-interim-analysis.--athira-pharfma2022-10-19T11:41:11+00:00weekly0.6https://www.medthority.com/news/2022/10/ultomiris-reduced-the-risk-of-relapse-in-a-late-stage-trial-for-the-neuromyelitis-optica-spectrum-disorder.--alexionastrazeneca2022-10-19T11:44:18+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approves-menveo-in-a-new-single-vial-presentation-to-help-prevent-disease-caused-by-meningococcal-bacteria-serogroups-a-c-y-and-w.--gsk-plc2022-10-19T11:49:30+00:00weekly0.6https://www.medthority.com/news/2022/10/health-canada-approves-keytruda-as-monotherapy-for-the-adjuvant-treatment-of-adults-with-renal-cell-carcinoma-at-intermediate-high-or-high-risk-of-recurrence-following-nephrectomy-or-following-nephrectomy-and-resection-of-metastatic-lesions.-merck-inc2022-10-19T11:55:46+00:00weekly0.6https://www.medthority.com/news/2022/10/lg-chem-to-acquire-aveo-oncology-and-with-it-fotivda/2022-10-19T11:58:37+00:00weekly0.6https://www.medthority.com/news/2022/10/eli-lilly--acquires-akouos-and-with-it-ak-otof-a-gene-therapy-for-hearing-loss/2022-10-19T11:59:50+00:00weekly0.6https://www.medthority.com/news/2022/10/novartis-ordered--by-us-district-court-to-pay-$177.8-million-to-daiichi-sankyo-for-tafinlar-patent-violation2022-10-10T11:59:17+00:00weekly0.6https://www.medthority.com/news/2022/10/positive-top-line-results-from-pivotal-phase-iii-stellar-trial-evaluating-sotatercept-for-the-treatment-of-adults-with-pulmonary-arterial-hypertension.---merck-inc2022-10-11T11:43:38+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approval-of-furoscix-the-first-and-only-self-administered-subcutaneous-loop-diuretic-for-the-at-home-treatment-of-congestion-in-chronic-heart-failure.--sc-pharmaceuticals.-2022-10-11T11:41:10+00:00weekly0.6https://www.medthority.com/news/2022/10/-dme-recommends-continuation-of-courage-als-trial-of-reldesemtiv-following-first-interim-analysis-.--cytokinetics2022-10-11T11:38:50+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approves-boostrix-for-tetanus-toxoid-reduced-diphtheria-toxoid-and-acellular-pertussis-vaccine-adsorbed-in-third-trimester-of-pregnancy.--glaxosmithkline2022-10-11T11:37:16+00:00weekly0.6https://www.medthority.com/news/2022/10/switzerlands-federal-office-of-public-health-recommended-nuvaxovid-nvx-cov2373-as-a-heterologous-and-homologous-booster-for-immunization-to-prevent-covid--19-caused-by-severe-acute-respiratory-syndrome.--novavax-2022-10-11T11:35:03+00:00weekly0.6https://www.medthority.com/news/2022/10/nmpa-china-approves-cyramza-to-treat-liver-cancer--hepatocellular-cancer-in-china.--eli-lilly---innovent-biologics.-2022-10-11T11:32:31+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-comorbidities.--eli-lilly2022-10-07T11:32:16+00:00weekly0.6https://www.medthority.com/news/2022/10/new-study-published-in-the-new-england-journal-of-medicine-demonstrates--freestyle-libre-2-system-has-positive-impacts-on-glucose-levels-and-quality-of-life.--abbott2022-10-07T11:40:02+00:00weekly0.6https://www.medthority.com/news/2022/10/costar-lung-trial-of-cobolimab--dostarlimab-advances-into-phase-iii-to-treat-patients-with-advanced-nsclc-who-have-progressed-on-prior-anti-pd-l1-therapy.---gsk2025-02-03T13:58:31+00:00weekly0.6https://www.medthority.com/news/2022/10/kalvista-pharma-terminates-komplete-phase-ii-clinical-trial-for-kvd-824-for-the-prevention-of-attacks-in-people-with-hereditary-angioedema-/2022-10-07T11:46:42+00:00weekly0.6https://www.medthority.com/news/2022/10/provention-bio-enters-co-promotion-agreement-with-sanofi-for-the-us-launch-of-teplizumab-to-treat-type-1-diabetes/2022-10-07T11:49:21+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approval-of-supplemental-new-drug-application-for-oxlumo--in-advanced-primary-hyperoxaluria-type-1.--alnylam-pharma2022-10-07T11:50:47+00:00weekly0.6https://www.medthority.com/news/2022/10/update-on-new-clinical-and-non-clinical-studies-of-lagevrio-.--merck-inc.---ridgeback-biotherapeutics2022-10-07T11:53:35+00:00weekly0.6https://www.medthority.com/news/2022/10/bone-therapeutics-regains-world-rights-to-allob-bone-cell-therapy/2022-10-07T11:55:38+00:00weekly0.6https://www.medthority.com/news/2022/10/omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-booster-receives-health-canada-authorization-for-individuals-12-years-of-age-and-older.--pfizer--biontech-se-2022-10-08T11:36:55+00:00weekly0.6https://www.medthority.com/news/2022/10/hugel-aesthetics-resubmits-botulax-to-fda-for-glabellar-lines/2022-10-08T11:24:54+00:00weekly0.6https://www.medthority.com/news/2022/10/stn-1013001-is-accepted-for-review-in-europe-for-lowering-of-intraocular-pressure-in-open-angle-glaucoma-and-ocular-hypertension.--santen2022-10-09T14:36:14+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-trial-of-nurown-shows-evidence-of-mechanism-of-action-in-amyotrophic-lateral-sclerosis.--brainstorm-cell-therapeutics2022-10-09T14:34:58+00:00weekly0.6https://www.medthority.com/news/2022/10/final-phase-iii-allium-data-in-is-published-in-jama--cefepimeenmetazobactam-met-criteria-for-superiority.--allecra-therapeutics-2022-10-09T14:33:46+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-vote-from-fda-advisory-committee-for-rbx-2660-to-reduce-the-recurrence-of-c.difficile.--ferring-pharma2022-09-24T12:36:58+00:00weekly0.6https://www.medthority.com/news/2022/9/eu-approves-ultomiris-for-generalised-myasthenia-gravis.--alexion-pharmaastrazeneca2022-09-24T12:40:35+00:00weekly0.6https://www.medthority.com/news/2022/9/regulatory-update-for-iv-tramadol-including-receipt-of-type-a-meeting-minutes-from-the-fda.-avenue-therapeutics2022-09-24T12:42:28+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-affine-study-of-giroctocogene-fitelparvovec-for-hemophilia-a-has-re-opened-recruitment.--pfizer--sangamo2022-09-24T12:44:26+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-top-line-results-from-phase-iii-study-in-20-valert-pneumococcal-conjugate-vaccine-in-infants-in-the-european-union.--pfizer2022-09-24T12:46:34+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-the-onyx-frontier-drug-eluting-stent-des-and-the-resolute-onyx-des-to-treat-bifurcation-percutaneous-coronary-intervention.--medtronic.-2022-09-25T11:59:48+00:00weekly0.6https://www.medthority.com/news/2022/9/symplicity-htn-3-trial-data-show-sustained-long-term-blood-pressure-reductions-with-symplicity-renal-denervation-procedure.--medtronic2022-09-26T11:21:53+00:00weekly0.6https://www.medthority.com/news/2022/9/duvelisib-loses-support-for-cllsll-indication-following-advisory-committee-odac-meeting---secura-bio/2022-09-26T11:26:04+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-panel-opposes-continued-approval-of-melphalan-flufenamide-in-relapsedrefractory-multiple-myeloma.--oncopeptides2022-09-26T11:28:50+00:00weekly0.6https://www.medthority.com/news/2022/9/application-to-fda-for-emergency-use-authorization-of-omicron-ba.4ba.5-adapted-bivalent-vaccine-booster-in-children-5-through-11-years-of-age.--pfizer--biontech-se2022-09-27T11:21:28+00:00weekly0.6https://www.medthority.com/news/2022/9/arrector-phase-iii-trial-evaluating-roflumilast-foam-meets-co-primary-endpoints-in-psoriasis.--arcutis-biotherapeutics2025-05-06T13:59:24+00:00weekly0.6https://www.medthority.com/news/2022/9/omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-filed-with-fda-for-emergency-use-authorisation-in-children-with-covid-19.-pfizer-and-biontech-se-2022-09-27T11:40:28+00:00weekly0.6https://www.medthority.com/news/2022/9/fintpla-is-approved--by-mhlw-to-treatseizures-in-japan-associated-with-dravet-syndrome-.--zogenixucb-2022-09-27T11:42:48+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-has-granted-traditional-approval-for-retevmo-in-adult-patients-with-locally-advanced-or-metastatic-nsclc-with-a-ret-gene-fusion-as-detected-by-an-fda-approved-test.--eli-lilly.-2025-02-03T13:59:02+00:00weekly0.6https://www.medthority.com/news/2022/9/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas-in-neurofibromatosis-type-1.--astrazeneca2022-09-27T11:50:09+00:00weekly0.6https://www.medthority.com/news/2022/9/mhlw-japan-approves-tezspire-for-the-treatmant-of-severe-asthma--astrazeneca/2022-09-28T12:24:58+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-supplemental-approval-for-diacomit-to-treat-dravet-syndrome-seizures-in-children-as-young-as-6-months.--biocodex-inc2022-09-28T12:27:42+00:00weekly0.6https://www.medthority.com/news/2022/9/nmpachina-approves-tuoyi--chemotherapy-to-treat-nsclc-without-egfr-mutations-or-alk-fusions.--shanghai-junishi-biosciences2022-09-28T12:29:21+00:00weekly0.6https://www.medthority.com/news/2022/9/the-european-commission-has-granted-marketing-authorization-for-nulibry-for-injection-as-the-first-therapy-for-the-treatment-of-patients-with-molybdenum-cofactor-deficiency.-bridgebio--sentynltherapeuticszydus2022-09-28T12:31:32+00:00weekly0.6https://www.medthority.com/news/2022/9/japanese-mhlw-approves-ezharmia--for-relapsed-or-refractory-adult-t-cell-leukemialymphoma.--daiichi-sankyo2022-09-28T12:33:26+00:00weekly0.6https://www.medthority.com/news/2022/9/keytruda-receives-mhlw-japan-approval-for-adjuvant-treatment-of-renal-cell-carcinoma-following-nepphrectomy.-merck-inc2022-09-28T12:35:02+00:00weekly0.6https://www.medthority.com/news/2022/9/mhlw-japan-approves-keytruda--chemotherapy-with-or-without-bevacizumab-to-treat-advanced-cervical-cancer-.--merck-inc2022-09-29T11:46:44+00:00weekly0.6https://www.medthority.com/news/2022/9/mlhw-japan-approves-keytruda--chemotherapy-to-treat-triple-negative-breast-cancer.--merck-inc2022-09-29T11:43:06+00:00weekly0.6https://www.medthority.com/news/2022/9/iontak-filed-with-fda-for-cutaneous-t-cell-lymphoma.--citius-pharma2022-09-29T11:40:47+00:00weekly0.6https://www.medthority.com/news/2022/9/cdz-173-given-priority-review-by-fda-for-activated-phosphoinositide-3-kinase-delta-syndrome.--pharming2022-09-29T11:38:35+00:00weekly0.6https://www.medthority.com/news/2022/9/korsuva-injection-filed-in-japan-for-pruritus-in-hemodialysis-patients.--cara-therapeutics2022-09-29T11:36:32+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-vegzelma-biosimilar-for-avastin-in-six-types-of-cancer.--celltrion2022-09-29T11:24:43+00:00weekly0.6https://www.medthority.com/news/2022/9/mlhw-japan-approves-keytruda-for-adjuvant-treatment-of-stage-iib-and-stage-iic-melanoma-afer-complete-resection--merck-inc/2022-09-29T11:22:53+00:00weekly0.6https://www.medthority.com/news/2022/9/lecanemab-confirmatory-phase-iii-trial-clarity-ad-study-met-primary-endpoint-showing-a-reduction-of-clinical-decline-in-early-alzheimers-disease.-eisai--biogen2022-09-29T11:21:24+00:00weekly0.6https://www.medthority.com/news/2022/9/eu-approves-expanded-conditional-marketing-for-nuvaxovid-in-covid-19.--novavax-2022-09-14T12:28:27+00:00weekly0.6https://www.medthority.com/news/2022/9/bl--8040-filed-with-fda-for-stem-cell-mobilization-for-autologous-bone-marrow-transplantation-for-multiple-myeloma.--biolinerx2022-09-14T12:13:54+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-comfort-study-data-for-cf-101-in-psoriasis-presented-at-european-academy-of-dermatology-and-venerology-eadv-congress.-can-fite-biopharma-2025-05-06T13:59:11+00:00weekly0.6https://www.medthority.com/news/2022/9/eu-approves-amvuttra-for-hereditary-transthyretin-mediated-hattr-amyloidosis.--alnylam-pharmaceuticals2022-09-22T11:28:38+00:00weekly0.6https://www.medthority.com/news/2022/9/eu-grants-approval-for-lupkynis-in-lupus-nephritis.--aurinia-pharmaceuticals2022-09-22T11:30:05+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-retevmo-the-first-and-only-ret-inhibitor-for-adults-with-advanced-or-metastatic-solid-tumors-with-a-ret-gene-fusion-regardless-of-type.--eli-lilly2022-09-22T11:31:48+00:00weekly0.6https://www.medthority.com/news/2022/9/lynparza-approved-in-china-as-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer.-astrazeneca--merck-inc2022-09-26T07:27:51+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-study-of-exparel-meets-endpoint-in-bunionectomy-surgery.--pacira-biosciences2022-09-22T11:35:03+00:00weekly0.6https://www.medthority.com/news/2022/9/subcutaneous-efgartigimod-ph20-filed-with-fda-for-myasthenia-gravis.--argenx-se2022-09-22T11:37:41+00:00weekly0.6https://www.medthority.com/news/2022/9/release-of-positive-results-for-denosumab-biosimilar-integrated-phase-iiii-clinical-trial.--sandoz--2022-09-20T11:54:47+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-chmp-opinion-for-brukinsa-for-the-treatment-of-adults-with-marginal-zone-lymphoma.--beigene2022-09-20T11:57:10+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-chmp-opinion-for-skyrizi-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease.--abbvie2022-09-20T11:59:02+00:00weekly0.6https://www.medthority.com/news/2022/9/tukysa--trastuzumab-granted-priority-review-by-fda-for-previously-treated-her2-positive-metastatic-colorectal-cancer.--seagen-inc.--merck-inc2022-09-20T12:02:03+00:00weekly0.6https://www.medthority.com/news/2022/9/health-canada-approves-keytruda-for-adjuvant-treatment-of-stage-iib-or-iic-melanoma-following-complete-resection.--merck-inc2022-09-20T12:05:14+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-recommends-the-expanded-approval-of-xalkori-for-two-more-uses-i.-to-treat-certain-children-with-anaplastic-large-cell-lymphoma-alcl-and-ii.-inflammatory-myofibroblastic-tumor-imt.--pfizer2022-09-20T12:08:10+00:00weekly0.6https://www.medthority.com/news/2022/9/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19.--astrazeneca2022-09-21T14:59:21+00:00weekly0.6https://www.medthority.com/news/2022/9/european-medicine-agency-accepts-maas-for-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis--ucb/2022-09-21T14:57:52+00:00weekly0.6https://www.medthority.com/news/2022/9/nice-recommends-brukinsa-for-patients-with-waldenstroms-macroglobulinemia-who-have-had-at-least-one-treatment.--beigene2022-09-21T14:56:19+00:00weekly0.6https://www.medthority.com/news/2022/9/analysis-of-the-impact-of-timing-for-zejula-maintenance-treatment-in-newly-diagnosed-advanced-ovarian-cancer-is-presented-at-the-2022-international-gynecologic-cancer-society-meeting.-zai-lab-limited2022-09-21T11:45:14+00:00weekly0.6https://www.medthority.com/news/2022/9/chmp-posigive-for-expanded-indication-of-exparel-to-include-children-as-a-field-block-for-treatment-of-somatic-post-operative-pain-from-small--to-medium-sized-surgical-wounds.--pacira2022-09-21T11:47:12+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-clearance-for-expanded-indication-of-linq-ii-insertable-cardiac-monitor-for-use-in-pediatric-patients-ages-2-and-older.--medtronic2024-09-30T10:48:09+00:00weekly0.6https://www.medthority.com/news/2022/9/novartis-plans-to-petition-the-u.s.-supreme-court-to-uphold-validity-of-the-gilenya-dosing-regimen-patent.-------------2022-09-21T11:53:27+00:00weekly0.6https://www.medthority.com/news/2022/9/positive-dupixent-phase-iii-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-atopic-dermatitis-is-published-in-the-lancet.--regeneron--sanofi2022-09-21T11:55:51+00:00weekly0.6https://www.medthority.com/news/2022/9/european-commission-approves-tezspire-for-the-treatment-of-severe-asthma.-astrazeneca2022-09-21T11:57:39+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approves-pedmark-to-reduce-the-risk-of-ototoxicity-associated-with-cisplatin-in-pediatric-patients-1-month-and-older-with-localized-non-metastatic-solid-tumors..--fennec-pharma2022-09-21T11:59:58+00:00weekly0.6https://www.medthority.com/news/2022/9/eylea-approved-in-japan-for-treatment-of-preterm-infants-with-retinopathy-of-prematurity.--bayer2022-09-30T11:39:29+00:00weekly0.6https://www.medthority.com/news/2022/9/submission-to-european-medicines-agency-for-omicron-ba.4ba.5-adapted-bivalent-vaccine-booster-in-children-5-through-11-years-of-age.-pfizer--biontech-se2022-09-30T11:37:55+00:00weekly0.6https://www.medthority.com/news/2022/9/bla-submitted-for-srp-9001-for-the-treatment-of-ambulant-patients-with-duchenne-muscular-dystrophy.--sareptatherapeutics2022-09-30T11:33:36+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-part-of-asian-trial-of-s-217622-meets-primary-endpoint-in-covid-19.--shionogi-2022-09-30T11:31:53+00:00weekly0.6https://www.medthority.com/news/2022/9/re-submission-of-bla-for-valoctocogene-roxaparvovec-for-adults-with-severe-hemophilia-a.--biomarin-pharma2022-09-30T11:29:44+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-approval-of-relyvrio-for-the-treatment-of-amyotrophic-lateral-sclerosis.--amylyx-pharma2022-09-30T11:27:26+00:00weekly0.6https://www.medthority.com/news/2022/9/nice-recomends-tecentriq-for-use-within-the-cancer-drugs-fund-as-an-option-for-adjuvant-treatment-after-complete-tumour-resection-in-adults-with-stage-2-to-3a-non-small-cell-lung-cancer.---genentechroche2025-02-03T13:58:46+00:00weekly0.6https://www.medthority.com/news/2022/9/nice-uk-recommends-upadacitinib-as-an-option-for-treating-active-ankylosing-spondylitis-that-is-not-controlled-well-enough-with-conventional-therapy-in-adults.-abbvie2022-09-30T11:18:15+00:00weekly0.6https://www.medthority.com/news/2022/9/phase-iii-trial-of-ga-depot-meets-primary-endpoint-in-multiple-sclerosis.--mapi-pharma-and-viatris-2022-09-23T11:48:46+00:00weekly0.6https://www.medthority.com/news/2022/9/european-commission-approves-vabysmo-to-treat-neovascular-or-wet-age-related-macular-degeneration-namd-and-visual-impairment-due-to-diabetic-macular-edema-dme.--roche2022-09-23T11:45:39+00:00weekly0.6https://www.medthority.com/news/2022/9/fda-to-convene-odac-to-review-engot-ov16nova-phase-iii-clinical-trial-of-zejula-in-ovarian-cancer.--tesarogsk2022-09-23T11:40:00+00:00weekly0.6https://www.medthority.com/news/2022/9/presentation-at-easd-meeting-of-new-cardiorenal-data-for-kerendia-across-a-broad-range-of-patients-with-early-to-late-stage-chronic-kidney-disease-and-type-2-diabetes.--bayer2022-09-23T11:38:30+00:00weekly0.6https://www.medthority.com/news/2022/9/new-phase-iii-clinical-program-with-lower-dose-of-daily-oral-islatravir-in-combination-with-doravirine-for-treatment-of-people-with-hiv-1-infection.--merck-inc2025-02-03T13:59:19+00:00weekly0.6https://www.medthority.com/news/2022/9/oncologic-drugs-advisory-committee-meeting-negative-on-poziotinib-for-the-treatment-of-patients-with-non-small-cell-lung-cancer-harboring-her2-exon-20-insertion-mutations.--spectrum-pharma2025-02-03T13:59:33+00:00weekly0.6https://www.medthority.com/news/2022/9/gsk-and-spero-therapeutics-announce-exclusive-license-agreement-for-late-stage-antibiotic-tebipenem-hbr.-gsk-spero-pharma2022-09-23T11:28:15+00:00weekly0.6https://www.medthority.com/news/2022/10/emergency-use-authorization-eua-application-for-peginterferon-lambda-will-not-be-submitted-to-the-fda-for-covid-19.--eiger-biopharma2022-10-06T11:33:11+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-accepts-supplemental-bla-for-takhzyro-in-hereditary-angioedema.--takeda2022-10-06T11:49:10+00:00weekly0.6https://www.medthority.com/news/2022/10/ryaltris-approved-in-canada-for-the-symptomatic-treatment-of-moderate-to-severe-seasonal-allergic-rhinitis--bausch-health-companies-inc/2022-10-06T11:50:33+00:00weekly0.6https://www.medthority.com/news/2022/10/pivotal-101-multicenter-study-of-omblastys-in-neuroblastoma-presented-at-international-society-of-pediatric-oncology-annual-congress.--y-mabs-therapeutics2022-10-05T11:11:37+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approval-of-supplemental-nda-for-firdapse-expanding-patient-population-to-include-pediatric-patients-with-lambert-eaton-myasthenic-syndrome.--catalyst-pharma2022-10-05T11:14:14+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-talapro-2-study-of-talzenna-with-xtandi-meets-primary-endpoint-in-prostate-cancer.--pfizer2022-10-05T11:16:48+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-triton3-trial-of-rubraca-meets-primary-endpoint-in-prostate-cancer.--clovis-oncology2022-10-05T11:19:06+00:00weekly0.6https://www.medthority.com/news/2022/10/onwards-5-phase-iii-trial-of-once-weekly-insulin-icodec-meets-primary-endpoint-in-type-2-diabetes.--novo-nordisk2022-10-05T11:21:39+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approval-of-iheezo-chloroprocaine-hydrochloride-oophthalmic-gel-3-for-ocular-surface-anesthesia.--harrow-health2022-10-05T11:24:18+00:00weekly0.6https://www.medthority.com/news/2022/10/european-commission-approves-mounjaroan-adjunct-to-diet-and-exercise-for-the-treatment-of-adults-with-insufficiently-controlled-type-2-diabetes-mellitus.--eli-lilly2022-10-05T11:26:11+00:00weekly0.6https://www.medthority.com/news/2022/10/additional-results-from-the-apollo-b-phase-iii-study-of-patisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy-are-presented-at-heart-failure-society-of-america-annual-meeting.--alnylan-pharma2022-10-05T11:28:51+00:00weekly0.6https://www.medthority.com/news/2022/10/incyte-to-acquire-villaris-therapeutics-and-with-it-auremolimab-a-proposed-treatment-for-vitiligo/2022-10-05T11:31:24+00:00weekly0.6https://www.medthority.com/news/2022/9/results-of-phase-iii-mirror-trial-of-krystexxa-in-gout-published-in-arthritis--rheumatology.--horizon-therapeutics2022-09-15T11:30:00+00:00weekly0.6https://www.medthority.com/news/2022/10/universal-covid-19-booster-vaccine-scb-2019-candidate-demonstrates-superior-neutralization-of-omicron-ba.5--subvariant-compared-to-inactivated-vaccine.-clover-biopharmaceuticals2022-10-01T12:23:44+00:00weekly0.6https://www.medthority.com/news/2022/10/phase-iii-trial-of-zp-1848-shows-positive-results-in-short-bowel-syndrome.--zealand-pharma2022-10-02T11:33:00+00:00weekly0.6https://www.medthority.com/news/2022/10/reverse-phase-iii-study-of-obeticholic-acid-in-compensated-cirrhosis-due-to-nash-did-not-meet-its-endpoint.--intercept-pharma2022-10-02T11:34:42+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approves-lytgobi--for-intrahepatic-cholangiocarcinoma--harboring-fibroblast-growth-factor-receptor-2-fgfr2-gene-fusions-or-other-rearrangements.--taiho-pharmaceutical2022-10-02T11:36:16+00:00weekly0.6https://www.medthority.com/news/2022/10/24-month-phase-iii-oaks-study-of-empaveli-shows-positive-trends-in-geographic-atrophy-ga-secondary-to-age-related-macular-degeneration.--apellis-pharma2022-10-02T11:38:21+00:00weekly0.6https://www.medthority.com/news/2022/10/rolling-review-for-exagamglogene-autotemcel-for-the-potential-treatment-of-sickle-cell-disease--and-transfusion-dependent-beta-thalassemia.--vertex--crispr-therapeutics-2022-10-02T11:39:58+00:00weekly0.6https://www.medthority.com/news/2022/10/new-analysis-of-soloist-whf-phase-iii-outcomes-trial-underscores-sotagliflozins-effect-on-reducing-recurrent-heart-failure-events.--lexicon-pharma2022-10-03T11:34:52+00:00weekly0.6https://www.medthority.com/news/2022/10/maa-submitted-to-ema-for-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy-.-santhera-pharma2022-10-03T11:38:31+00:00weekly0.6https://www.medthority.com/news/2022/10/initiation-of-the-phase-iii-lighthouse-study-of-biib-122-in-parkinsons-disease-associated-with-lrrk2-pathogenic-mutations.--biogen--denali-therapeutics2022-10-04T11:17:22+00:00weekly0.6https://www.medthority.com/news/2022/10/fda-approval-for-first-companion-diagnostic-to-identify-patients-with-her2-low-metastatic-breast-cancer-eligible-for-enhertu.--roche2022-10-04T11:14:34+00:00weekly0.6https://www.medthority.com/news/2022/10/topline-results-demonstrating-survival-signal-for-cnm-au8-in-healey-als-platform-trial-foramyotrophic-lateral-sclerosis.--clene-inc2022-10-04T11:11:30+00:00weekly0.6https://www.medthority.com/news/2022/10/astrazeneca-rare-diseases--alexion-to-acquire-logic-bio/2022-10-04T11:09:04+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-filing-of-a-supplemental-bla-and-grants-priority-review-for-traditional-approval-of-leqembi-to-treat-alzheimers-disease.-eisai2023-03-10T13:50:50+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-clears-freestyle-libre-2-and-freestyle-libre-3-sensors-for-integration-with-automated-insulin-delivery-systems.--abbott2023-03-10T13:50:12+00:00weekly0.6https://www.medthority.com/news/2023/3/new-data-presented-at-acc-related-to-lifetime-managemnent-of-aortic-stenosis.---edwards-lifesciences2023-03-10T13:49:35+00:00weekly0.6https://www.medthority.com/news/2023/3/pulse-select-pfa-system-demonstrates-impressive-results-in-landmark-pulsed-af-global-ide-trial--medtronic/2024-09-30T12:00:43+00:00weekly0.6https://www.medthority.com/news/2023/3/sotatercept-improved-six-minute-walk-distance-by-40.8-meters-at-week-24-versus-placebo-in-adults-with-pulmonary-arterial-hypertension-on-background-therapy.--merck-inc2023-03-10T13:48:13+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-nda-for-berdazimer-gel-10.3-for-the-treatment-of-molluscum-contagiosum-with-a-pdufa-goal-date-of-5-january-2024--novan-inc2023-03-10T13:47:25+00:00weekly0.6https://www.medthority.com/news/2023/3/update-on-interim-analysis-of-phase-iii-limber-304-study-of-parsaclisib--ruxolitinib-in-patients-with-myelofibrosis.--incyte2023-03-10T13:46:32+00:00weekly0.6https://www.medthority.com/news/2023/3/dupixent-sbla-for-treatment-of-chronic-spontaneous-urticaria--in-adults-and-adolescents-accepted-for-fda-review.-regeneron--sanofi2023-03-10T13:45:13+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-trial-of-hbm-9161-meets-primary-endpoint-in-myasthenia-gravis.--hanall-biopharmaharbour-biomed2023-03-10T13:44:25+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-snda-to-expand-use-of-voxzogo-for-injection-to-treat-children-with-achondroplasia-under-the-age-of-5.--biomarin2023-03-10T13:43:31+00:00weekly0.6https://www.medthority.com/news/2023/3/landmark-clear-outcomes-study-demonstrates-nexletol-tablet-is-the-only-ldl-c-lowering-therapy-since-statins-to-reduce-hard-ischemic-events-in-both-primary-and-secondary-prevention-patients.--esperion--daiichi-sankyo2023-03-10T13:42:53+00:00weekly0.6https://www.medthority.com/news/2023/3/avian-influenza-a-virus-real-time-pcr-test-kit-available-in-eu.-virax-biolabs-group2023-03-10T13:42:05+00:00weekly0.6https://www.medthority.com/news/2023/3/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimers-disease/2023-03-10T13:41:29+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-snda-for-jardiance-for-children-10-years-and-older-with-type-2-diabetes.--boehringer--eli-lilly2023-03-10T13:40:46+00:00weekly0.6https://www.medthority.com/news/2023/3/new-real-world-study-data-on-reduced-risk-of-adverse-kidney-outcomes-for-xarelto-compared-to-vitamin-k-antagonists.--bayer2023-03-10T13:40:05+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-nda-for-ionis-ttr-lrx-in-hereditary-transthyretin-mediated-amyloid-polyneuropathy.--ionis-pharma2023-03-10T13:39:26+00:00weekly0.6https://www.medthority.com/news/2023/3/tagrisso-demonstrated-strong-overall-survival-benefit-in-the-adaura-phase-iii-trial-for-adjuvant-treatment-of-patients-with-early-stage-egfr-mutated-lung-cancer.--astrazeneca2023-03-10T13:38:49+00:00weekly0.6https://www.medthority.com/news/2023/3/imfinzi-significantly-improved-event-free-survival-in-aegean-phase-iii-trial-for-patients-with-resectable-non-small-cell-lung-cancer.--astrazeneca2023-03-10T13:38:00+00:00weekly0.6https://www.medthority.com/news/2023/3/request-for-eua-for-sabizabulin--to-treat-hospitalized-covid-19-patients-at-high-risk-for-ards-is-not-accepted-by-fda---veru-inc/2023-03-04T14:05:08+00:00weekly0.6https://www.medthority.com/news/2023/3/eu-grants-approval-of-reblozyl-for-anemia-in-non-transfusion-dependent-ntd-beta-thalassemia.--bms2023-03-04T14:04:27+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-broadens-indication-for-verzenio-in-hr-her2--node-positive-high-risk-early-breast-cancer.--eli-lilly2023-03-04T14:03:44+00:00weekly0.6https://www.medthority.com/news/2023/3/data-from-a-clinical-study-shows-bentrio-nasal-sprays-residence-time--and-rheological-properties-superior-to-saline-control.-altamira-therapetics2023-03-04T14:03:07+00:00weekly0.6https://www.medthority.com/news/2023/3/data-on-improvements-over-time-with-long-term-use-of-ingrezza-capsules-in-older-and-elderly-patients-were-presented-at-the-american-association-for-geriatric-psychiatry-2023-annual-meeting.--neurocrine-biossciences2023-03-04T14:02:23+00:00weekly0.6https://www.medthority.com/news/2023/3/independent-data-monitoring-committee-recommends-continuation-of-ringside-phase-iiiii-study-of-al-102-in-desmoid-tumors.--ayala-pharma-2023-03-04T14:01:27+00:00weekly0.6https://www.medthority.com/news/2023/3/new-data-show-superiority-of-triclip-device-compared-to-medical-therapy-for-tricuspid-regurgitation.--abbott2023-03-05T12:57:26+00:00weekly0.6https://www.medthority.com/news/2023/3/five-year-results-from-the-landmark-coapt-trial-show-mitraclip-can-cut-the-rate-of-hospitalizations-while-improving-survival-for-heart-failure-patients-.-abbott2023-03-06T14:31:53+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-results-from-cohort-4-of-redwood-hcm-study-of-aficamten-in--non-obstrauctive-cardiomyopathy-and-long-term-results-from-forest-hcm-study.-cytokinetics2023-03-06T14:30:58+00:00weekly0.6https://www.medthority.com/news/2023/3/enhertu-met-prespecified-criteria-in-the-destiny-pantumor02-trial-in-locally-advanced-previously-treated-her2-expressing-solid-tumours.----astrazeneca--daiichi-sankyo2023-03-06T14:29:59+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-data-demonstrating-long-acting-injectable-cabenuva-is-as-effective-as-daily-oral-biktarvy-for-the-treatment-of-hiv-1.-viiv-healthcare2023-02-28T12:59:48+00:00weekly0.6https://www.medthority.com/news/2023/2/approval-in-japan-for-precedex-for-sedation-and-tests-in-non-inturbated-children.--pfizer2023-02-28T12:41:06+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-acceptance-and-priority-review-of-nda-for-nirogacestat-to-treat-adults-with-desmoid-tumors.--springworks-therapeutics2023-02-28T12:31:26+00:00weekly0.6https://www.medthority.com/news/2023/2/nubeqa-approved--by-mhlw-in-japan-for-additional-indication-of-metastatic-prostate-cancer.---bayer2023-02-28T12:28:43+00:00weekly0.6https://www.medthority.com/news/2023/2/rinvoq-is-mhlw-approved-in-japan-to-treat-non-radiographic-axial-spondyloarthritis.--abbvie2023-02-28T12:23:48+00:00weekly0.6https://www.medthority.com/news/2023/2/talazoparib-is-filed-in-japan-for-treatment-of-brca-mutated-her2-negative-inoperable-or-recurrent-breast-cancer.-pfizer2023-02-28T12:19:40+00:00weekly0.6https://www.medthority.com/news/2023/2/data-from-phase-iii-vanguard-clinical-trial-of-csl-312-showing-reduced-attack-rate-in-hereditary-angioedema-presented-at-aaaai-meeting.--csl2023-02-28T12:16:49+00:00weekly0.6https://www.medthority.com/news/2023/2/full-marketing-authorization-from-the-mhra-uk-for-nexpovio--bortezomib--dexamethasone-for-the-treatment-of-adult-patients-with-multiple-myeloma-who-have-received-at-least-one-prior-therapy.--stemline-therapeuticsmenarini2023-02-28T11:00:26+00:00weekly0.6https://www.medthority.com/news/2023/2/lucira--health-files-for-protection-under-chapter-11-of-the-us-bankrupcy-code/2023-02-28T12:09:02+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-top-line-results-from-12-month-safety-clinical-trial-of-reproxalap-in-patients-with-dry-eye-disease.--aldeyra-therapeutics2023-03-01T12:21:38+00:00weekly0.6https://www.medthority.com/news/2023/3/merck-inc.-provides-update-on-phase-iii-trial-keynote-789-in-combination-with-pemetrexed-plus-platinum-based-chemotherapy-for-metastatic-nonsquamous-non-small-cell-lung-cancer2023-03-01T12:23:39+00:00weekly0.6https://www.medthority.com/news/2023/3/merck-inc.-provides-update-on-phase-iii-trial-keynote-641-of-pembrolizumab-and-enzalutamide-to-treat-metastatic-castration-resistant-prostate-cancer.-2023-03-01T12:27:26+00:00weekly0.6https://www.medthority.com/news/2023/3/late-breaking-data-reinforce-benefits-of-navitor-transcatheter-aortic-valve-implantation-tavi-system-and-amplatzer-amulet-left-atrial-appendage-laa-occluder.-abbott2023-03-01T12:31:12+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approval-of-skyclarys-the-first-and-only-drug-indicated-for-patients-with-friedreichs-atxia.--reata-pharmaceuticlas2023-03-01T12:34:10+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-issues-a-complete-respose-letter-for-omecamtiv-mecarbil-for-the-treatment-of-heart-failure.--cytokinetics2023-03-01T12:35:52+00:00weekly0.6https://www.medthority.com/news/2023/3/aflibercept-8-mg-filed-for-marketing-authorization-in-japan.--bayer2023-03-02T12:47:25+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approval-for-kevzara-to-treat-polymyalgia-rheumatica.--regeneron--sanofi2023-03-02T12:45:41+00:00weekly0.6https://www.medthority.com/news/2023/3/recor-medical-announces-two-concurrent-jama-network-publications-of-study-results-on-the-paradise-ultrasound-renal-denervation-system-for-the-treatment-of-hypertension/2023-03-02T12:42:24+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-topline-results-from-pivotal-xtend-kids-phase-iii-study-of-efanesoctocog-alfa-in-children-under-12-years-of-age-with-haemophilia-a.--sobi--sanofi2023-03-02T12:35:50+00:00weekly0.6https://www.medthority.com/news/2023/3/maa-submitted-to-the-uk-mhra-for-vamorolone-in-duchenne-muscular-dystrophy.--santhera2023-03-03T12:43:35+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-priority-review-for-adx-2191-nda-to-treat-primary-vitreoretinal-lymphoma.-aldeyra-therapeutics-inc2023-03-03T12:41:14+00:00weekly0.6https://www.medthority.com/news/2023/3/bms--janssen-collaboration-launches-pivotal-phase-iii-librexia-clinical-trial-program-evaluating-milvexian-an-investigational-oral-factor-xia-inhibitor/2023-03-03T12:38:50+00:00weekly0.6https://www.medthority.com/news/2023/3/update-on-us-regulatory-review-of-lynparza-in-combination-with-abiraterone-for-metastatic-castration-resistant-prostate-cancer.--astrazeneca--merck-inc2023-03-03T12:35:17+00:00weekly0.6https://www.medthority.com/news/2023/3/interim-analysis-of-phase-iii-ace-breast-02-study-shows-arx-788-meets-pre-specified-interim-primary-endpoint-in-breast-cancer.--ambrx-biopharma2023-03-03T12:30:52+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-keynote-671-trial-of-keytruda-meets-one-of-primary-endpoints-as-perioperative-treatment-in-non-small-cell-lung-cancer.--merck-inc2023-03-03T12:27:58+00:00weekly0.6https://www.medthority.com/news/2023/3/eu-approves-nubeqa-for-hormone-sensitive-prostate-cancer.--bayer-and-orion-corp2023-03-03T12:25:27+00:00weekly0.6https://www.medthority.com/news/2023/3/santhera-pharmaceuticals-files-vbp-15-for-duchenne-muscular-dystrophy-with-uk-mhra-and-applying-to-eams/2023-03-03T12:23:26+00:00weekly0.6https://www.medthority.com/news/2023/3/update-on-phase-iii-contact-03-trial-evaluating-cabozantinib--atezolizumab-in-patients-with-previously-treated-advanced-renal-cell-carcinoma.--exelixis2023-03-03T12:21:04+00:00weekly0.6https://www.medthority.com/news/2023/3/novavax-comments-from-financial-report-2022/2023-03-03T12:18:31+00:00weekly0.6https://www.medthority.com/news/2023/2/refusal-to-file-letter-from-fda-for-hybryte-nda-in-the-treatment-of-cutaneous-t-cell-lymphoma.--soligenix-inc2023-02-15T12:02:00+00:00weekly0.6https://www.medthority.com/news/2023/2/publication-of-olinvyk-respiratory-physiology-study-in-anesthesiology-journal.--trevena-inc2023-02-15T12:05:19+00:00weekly0.6https://www.medthority.com/news/2023/2/sorrento-therapeutics-inc.-and-its-wholly-owned-direct-subsidiary-scintilla-pharmaceuticals-inc.-commenced-voluntary-bankrupcy-proceedings-2023-02-15T12:07:06+00:00weekly0.6https://www.medthority.com/news/2023/2/update-on-progress-of-sebetralstat-development-in-hereditary-angioedema..--kalvista-pharmaceuticals2023-02-16T11:57:55+00:00weekly0.6https://www.medthority.com/news/2023/2/bavarian-nordic-to-acquire-portfolio-of-travel-vaccines-from-emergent-biosolutions/2023-02-16T12:01:47+00:00weekly0.6https://www.medthority.com/news/2023/2/independent-data-monitoring-committee-recommends-continuation-of-phase-iii-study-of-uproleselan-in-rr-aml.-glycomimetics-inc2023-02-16T12:04:59+00:00weekly0.6https://www.medthority.com/news/2023/2/livmarli-filed-with-fda-for-snda-in-cholestatic-pruritus-in-patients-two-months-of-age-and-older-with-progressive-familial-intrahepatic-cholestasis.--mirum-pharma2023-02-16T12:08:09+00:00weekly0.6https://www.medthority.com/news/2023/2/hepzato-kit-melphalanhds-is-resubmitted-to-fda-for-hepatic-dominant-metastatic-ocular-melanoma.--delcath-systems2023-02-16T12:10:25+00:00weekly0.6https://www.medthority.com/news/2023/2/topline-results-for-phase-iib-study-of-fx-322-for-the-treatment-of-sensorineural-hearing-loss.--frequency-therapeutics2023-02-16T12:12:47+00:00weekly0.6https://www.medthority.com/news/2023/2/phase-iii-jupiter-02-study-shows-positive-results-for-toripalimab-in-nasopharyngeal-carcinoma.--shanghai-junshi-biosciences-and-coherus-biosciences2023-02-16T11:54:42+00:00weekly0.6https://www.medthority.com/news/2023/2/-the-lancet-neurology-has-published-phase-iii-data-for-zavegepant-for-the-acute-treatment-of-migraine-in-adults.--pfizer2023-02-17T12:34:02+00:00weekly0.6https://www.medthority.com/news/2023/2/final-results-of-key-secondary-overall-survival-endpoint-from-phase-iii-propel-trial-presented-at-asco-gu-cancers-symposium.--astrazeneca--merck-inc2023-02-17T12:29:19+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-talzenna--xtandi-combination-data-from-phase-iii-talapro-2-study-in-men-with-metastatic-castration-resistant-prostate-cancer.--pfizer2023-02-17T12:24:26+00:00weekly0.6https://www.medthority.com/news/2023/2/updated-data-demonstrating-improved-outcomes-from-the-use-of-niraparib--abiraterone-acetate--prednisone-as-a-first-line-therapy-in-patients-with-brca-positive-metastatic-castration-resistant-prostate-cancer.--janssen-pharma2023-02-17T12:21:16+00:00weekly0.6https://www.medthority.com/news/2023/2/new-data-presented-at-asco-gu-confirm-survival-benefits-and-favorable-safety-profile-of-darolutamide-across-different-subgroups-of-patients-with-metastatic-hormone-sensitive-prostate-cancer.--bayer2023-02-17T12:15:00+00:00weekly0.6https://www.medthority.com/news/2023/2/sequencing-treatment-with-lutetium-177-177lu-psma-617-after-radium-223-was-safe-and-well-tolerated-and-demonstrated-similar-overall-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-.--novartis2023-02-18T14:10:29+00:00weekly0.6https://www.medthority.com/news/2023/2/ce-mark-for-the-aurora-ev-icd-mri-surescan-extravascular-implantable-cardioverter-defibrillator-and-epsila-ev-mri-surescan-defibrillation-lead.--medtronic-2023-02-18T14:09:12+00:00weekly0.6https://www.medthority.com/news/2023/2/results-of-phase-iii-keynote-859-trial-of-keytruda-plus-chemo-showing-improved-os-in-gastric-or-gastroesophageal-junction-adenocarcinoma-presented-at-esmo.--merck-inc2023-02-18T14:08:07+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-lamzede-for-alpha-mannosidosis.--chiesi-farmaceutici2023-02-18T14:06:55+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-nda-for-zimura-in-geographic-atrophy-and-sets-pdufa-date.--iveric-bio2023-02-18T14:05:49+00:00weekly0.6https://www.medthority.com/news/2023/2/interim-results-of-phase-iii-trial-of-mrna-1010-shows-mixed-results-in-influenza.--moderna2023-02-18T14:04:30+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accelerated-approval-of-filspari--the-first-and-only-non-immunosuppressive-therapy-for-the-reduction-of-proteihuria-in-iga-nephropathy.--travere-therapeutics2023-02-18T14:03:03+00:00weekly0.6https://www.medthority.com/news/2023/2/health-canada-approves-covid-19-booster-vaccine-mrna-1273.214--for-use-in-children-and-adolescents.--moderna-inc2023-02-18T14:01:54+00:00weekly0.6https://www.medthority.com/news/2023/2/adjuvant-opdivo-continues-to-provide-significant-durable-clinical-benefits-for-radically-resected-high-risk-muscle-invasive-urothelial-carcinoma-after-three-years-in-checkmate--274-trial.--bms2023-02-18T14:00:50+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-for-priority-review-the-supplemental-nda-for-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-kidney-transplant-recipients-at-high-risk.-merck-inc2023-02-18T13:59:39+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-notifies-3-month-extension-of-bla-pdufa-date-and-regulatory-update-for-b-vec-to-treat-patients-with-dystrophic-epidermolysis-bullosa-krystal-biotech-inc.-2023-02-18T13:58:24+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-syfovre-as-the-first-and-only-treatment-for-geographic-atrophy-a-leading-cause-of-blindness.--apellis-pharmaceuticals2023-02-19T14:04:45+00:00weekly0.6https://www.medthority.com/news/2023/2/pembrolizumab-produces-high-dfs-rates-in-bcg-unresponsive-high-risk-nonmuscle-invasive-bladder-cancer.--merck-inc2023-02-19T14:03:57+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-full-data-results-from-the-pivotal-phase-iii-sierra-trial-of-iomab-b-in-patients-with-active-relapsed-or-refractory-acute-myeloid-leukemia.--actinium-pharmaceuticals-2023-02-19T14:03:22+00:00weekly0.6https://www.medthority.com/news/2023/2/longitudinal-immune-reconstitution-profiling-suggests-anti-viral-protection-after-transplantation-with-omidubicel-a-phase-iii-sub-study.-gamida-cell-ltd2023-02-21T12:46:19+00:00weekly0.6https://www.medthority.com/news/2023/2/ponatinib--reduced-intensity-chemotherapy-outperformed-imatinib-for-the-treatment-of-newly-diagnosed-philadelphia-chromosome-ph-positive-acute-lymphoblastic-leukemia-all.--takeda--incyte2023-02-21T12:45:53+00:00weekly0.6https://www.medthority.com/news/2023/2/phase-iii-graphite-study-of-entyvio-meets-primary-endpoint-in-acute-graft-versus-host-disease-and-data-is-presented-at-2023-tandem-meetings.--takeda2023-02-21T12:48:23+00:00weekly0.6https://www.medthority.com/news/2023/2/toripalimab--chemotherapy-for-treatment-of-advanced-triple-negative-breast-cancer-met-its-primary--endpoint-in-phase-iii-torchlight-study.---shanghai-junishi-biosciences2023-02-21T12:53:08+00:00weekly0.6https://www.medthority.com/news/2023/2/topical-roflumilast-foam-0.3-nda-submitted--to-the-fda-for-the-treatment-of-seborrheic-dermatitis-in-adults-and-adolescents.--arcutis-biotherapeutics-inc2023-02-22T12:49:01+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-snda-for-onpattro-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis.--alnylam-pharma2023-02-22T12:50:44+00:00weekly0.6https://www.medthority.com/news/2023/2/update-on-phase-iii-move-ahead-trial-evaluating-lagevrio-for-post-exposure-prophylaxis-for-prevention-of-covid-19.--merck-inc2023-02-22T12:52:30+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-priority-review-of-pozelimab-for-chaple-disease.--regeneron2023-02-22T12:54:47+00:00weekly0.6https://www.medthority.com/news/2023/2/eu-approves-hemgenix-for-hemophilia-b.--csl2023-02-22T13:04:39+00:00weekly0.6https://www.medthority.com/news/2023/2/imfinzi--imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.--astrazeneca2023-02-22T13:07:08+00:00weekly0.6https://www.medthority.com/news/2023/2/calquence-tablet-formulation-approved-in-the-eu-for-patients-with-chronic-lymphocytic-leukaemia.--astrazeneca2023-02-22T13:12:19+00:00weekly0.6https://www.medthority.com/news/2023/2/amgen-announces-cardiovascular-study-to-evaluate-the-association-between-lipoprotein-a-and-cardiovascular-disease-in-african-americans/2023-02-23T12:01:06+00:00weekly0.6https://www.medthority.com/news/2023/2/landmark-new-england-journal-of-medicine-publication-reinforces-potential-of-respiratory-syncytial-virus-older-adult-vaccine-candidate.--gsk-plc2025-02-03T11:26:46+00:00weekly0.6https://www.medthority.com/news/2023/2/roche-launches-two-new-antibodies-idh1-r132h-mrq-67-rabbit-monoclonal-primary-antibody-and-the-atrx-rabbit-polyclonal-antibody--to-identify-key-clinical-mutations-in-patients-with-brain-cancer/2023-02-23T12:09:38+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-breakthrough-designation-formrna-4157v940--keytruda-for-the-adjuvant-treatment-of-patients-with-high-risk-melanoma-following-complete-resection-.--merck-inc.--moderna--2023-02-23T12:15:08+00:00weekly0.6https://www.medthority.com/news/2023/2/sorrento-therapeutics-inc.-receives-court-approval-for-$75-million-financing-in-chapter-11-case2023-02-23T12:19:29+00:00weekly0.6https://www.medthority.com/news/2023/2/new-data-suggest-uplizna-for-neuromyelitis-optica-spectrum-disorder-did-not-increase-the-risk-of-covid-19-infection-or-reduce-antibody-levels-from-childhood-vaccines-horizon-therapeutics-plc-/2023-02-24T12:24:24+00:00weekly0.6https://www.medthority.com/news/2023/2/blueprint-medicines-to-regain-global-rights-to-gavreto-from-roche/2023-02-24T12:21:51+00:00weekly0.6https://www.medthority.com/news/2023/2/highlights-of-new-four-year-efficacy-and-safety-data-for-btk-inhibitor-evobrutinib-in-relapsing-multiple-sclerosis.--merck-kgaa2023-02-24T12:19:06+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-once-weekly-efanesoctocog-alfa-a-new-class-of-high-sustained-factor-viii-therapy-for-haemophilia-a.--sobi--sanofi2023-02-24T12:07:59+00:00weekly0.6https://www.medthority.com/news/2023/2/aflibercept-8-mg-bla-for-treatment-of-wet-age-related-macular-degeneration-and-diabetic-macular-edema-is-accepted-for-fda-priority-review--regeneron-pharma--bayer/2023-02-24T12:03:49+00:00weekly0.6https://www.medthority.com/news/2023/2/vbl-therapeutics-and-notable-labs-to-merge/2023-02-24T12:01:36+00:00weekly0.6https://www.medthority.com/news/2023/2/nmpa-china-approves-enhertu-to-treat--adult-patients-with-unresectable-or-metastatic-her2-positive-breast-cancer-who-have-received-one-or-more-prior-anti-her2-based-regimens.-astrazeneca--daiichi-sankyo2023-02-25T12:46:52+00:00weekly0.6https://www.medthority.com/news/2023/2/libtayo--chemotherapy-receives-positive-chmp-opinion-for-the-treatment-of-advanced-pd-l1-positive-non-small-cell-lung-cancer.--regeneron2023-02-25T12:46:15+00:00weekly0.6https://www.medthority.com/news/2023/2/minimed-780g-system-demonstrates-superiority-over-multiple-daily-injections-with-cgm-for-type-1-diabetes-management-at-one-year-in-adapt-study.-medtronic2023-02-25T12:43:47+00:00weekly0.6https://www.medthority.com/news/2023/2/chmp-negative-recommendation-for-lagevrio-for-the-treatment-of-patients-with-covid-19.---merck-inc.--ridgeback-biotherapeutics2023-02-25T12:43:06+00:00weekly0.6https://www.medthority.com/news/2023/2/mei-pharma-and-infinity-to-merge/2023-02-25T12:42:25+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-chmp-opinion-for-akeega---prednisone-or-prednisolone-for-the-treatment-of-adult-patients-with-brca12-gene-mutated-metastatic-castration-resistant-prostate-cancer.--janssen2023-02-26T11:35:09+00:00weekly0.6https://www.medthority.com/news/2023/2/chmp-positive-for-hyftor-or-the-treatment-of-facial-angiofibroma-associated-with-tuberous-sclerosis-complex.--plusultra--pharmanobel2023-02-26T11:34:30+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-chmp-opinion-for-opzelura-for-the-treatment-of-non-segmental-vitiligo-in-adults-and-adolescents.--incyte2023-02-26T11:33:49+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-chmp-opinion-for-tibsovo-in-idh1-mutated-acute-myeloid-leukemia--and-cholangiocarcinoma-patients.-servier.-2023-02-26T11:32:59+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-chmp-opinion-for-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease.---chiesi-global-rare-diseases--protalix-biotherapeutics-inc2023-02-26T11:32:04+00:00weekly0.6https://www.medthority.com/news/2023/2/chmp-positive-decision-for-bekemv-the-first--eculizumab-biosimilar-to-treat-paroxysmal-nocturnal-haemoglobinuria.---amgen2023-02-26T11:31:16+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-chmp-opinion-in-europe-for-vafseo-for-the-treatment-of-symptomatic-anaemia-associated-with-chronic-kidney-disease-in-adults-on-chronic-maintenance-dialysis.-akebia-therapeutics2023-02-26T11:21:58+00:00weekly0.6https://www.medthority.com/news/2023/2/libtayo--chemotherapy-has-a-chmp-recommendation--for-the-treatment-of-advanced-pd-l1-positive-non-small-cell-cancer.--regeneron2023-02-26T11:21:18+00:00weekly0.6https://www.medthority.com/news/2023/2/chmp-recommends-rinvoq-to-treat-crohns-disease.--abbvie2023-02-26T11:20:40+00:00weekly0.6https://www.medthority.com/news/2023/2/abbvie-and-capsida-biotherapeutics-expand-their-collaboration-to-develop-genetic-medicines-for-eye-diseases/2023-02-26T11:19:56+00:00weekly0.6https://www.medthority.com/news/2023/2/sbla-submitted--for-fda-approval-of-omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-for-ages-12-years-and-older-as-primary-series-or-booster-for-covid-19.--pfizer--biontech-se2023-02-27T12:39:16+00:00weekly0.6https://www.medthority.com/news/2023/2/elranatamab-receives-fda-priority-review-and-ema-prime-scheme-to-treatrr-multiple-myeloma.--pfizer2023-02-27T12:43:08+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-bla-for-respiratory-syncytial-virus-maternal-vaccine-candidate-for-priority-review.--pfizer2023-02-27T12:45:20+00:00weekly0.6https://www.medthority.com/news/2023/2/new-phase-iii-data-presented-at-world-symposium-reinforce-nexviazyme-as-potential-new-standard-of-care-for-all-people-living-with-late-onset-pompe-disease.--sanofi2023-02-27T12:52:05+00:00weekly0.6https://www.medthority.com/news/2023/2/results-of-react-a-phase-iii-study-of-clazosentan-in-patients-following-aneurysmal-subarachnoid-hemorrhage.-idorsia-ltd2023-02-08T13:21:00+00:00weekly0.6https://www.medthority.com/news/2023/2/fintepla-oral-solution-approved-in-the-eu-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome.---ucb2023-02-08T13:16:26+00:00weekly0.6https://www.medthority.com/news/2023/2/investigational-pulsed-field-ablation-platform-presented-at-af-symposium-2023.--biosense-websterjj-2024-09-30T11:56:23+00:00weekly0.6https://www.medthority.com/news/2023/2/paxlovid-shelf-life-extended-in-japan--pfizer/2023-02-14T12:41:09+00:00weekly0.6https://www.medthority.com/news/2023/2/nyxol-filed-with-fda-for-mydriasis.--ocuphire-pharma2023-02-14T12:39:38+00:00weekly0.6https://www.medthority.com/news/2023/2/phase-iii-preserve-1-trial-of-trilaciclib-discontinued-due-to-inferiority-to-placebo-in-severe-neutropenia-in-colorectal-cancer.--g1-therapeutics2023-02-14T12:37:59+00:00weekly0.6https://www.medthority.com/news/2023/2/acceleration-of-phase-iii-clinial-trial-of-nomacopan-to--treat-pediatric-hsct-tma-into-pivotal-part-b-and-addition-of-new-pipeline-programme.--akari-therapeutics2023-02-14T12:36:14+00:00weekly0.6https://www.medthority.com/news/2023/2/opdivo--cabometyx-shows-durable-survival-with-over-three-years-of-follow-up-in-the-checkmate--9er-trial-in-first-line-advanced-renal-cell-carcinoma.--bms--exelixis-inc2023-02-14T12:33:13+00:00weekly0.6https://www.medthority.com/news/2023/2/new-analyses-reinforce-survival-benefit-of-bavencio-first-line-maintenance-treatment-in-patients-with-advanced-urothelial-carcinoma.--merck-kgaa2023-02-14T12:27:13+00:00weekly0.6https://www.medthority.com/news/2023/2/eylea-injection-approved-as-the-first-pharmacologic-treatment-for-preterm-infants-with-retinopathy-of-prematurity-by-the-fda.-regeneron-2023-02-09T12:20:54+00:00weekly0.6https://www.medthority.com/news/2023/2/patient-enrollment-update-for-phase-iii-studies-of-simufilam-for-the-treatment-of-alzheimers-disease.-cassava-sciences2023-02-09T12:16:50+00:00weekly0.6https://www.medthority.com/news/2023/2/topline-results-from-phase-iii-diversity-trial-of-filgotinib-in-crohns-disease.--galapagos-nv2023-02-09T12:15:10+00:00weekly0.6https://www.medthority.com/news/2023/2/abbott-to-acquire-cardiovascular-systems-inc/2023-02-09T12:12:34+00:00weekly0.6https://www.medthority.com/news/2023/2/results-from-the-komfort-phase-ii-trial-of-oral-difelikefalin-for-the-treatment-of-pruritus-in-notalgia-paresthetica--is-published-in-the-new-england-journal-of-medicine.--cara-therapeutics2023-02-10T12:03:39+00:00weekly0.6https://www.medthority.com/news/2023/2/phase-iii-data-show-vabysmo-rapidly-improved-vision-and-reduced-retinal-fluid-in-people-with-retinal-vein-occlusion-rvo.--genentechroche2023-02-10T12:00:41+00:00weekly0.6https://www.medthority.com/news/2023/2/tecartus-car-t-cell-therapy-demonstrates-overall-survival-benefit-in-three-year-follow-up-of-pivotal-zuma-3-trial-in-rr-b-cell-acute-lymphoblastic-leukemia.--kitegilead-sciences2023-02-10T11:51:27+00:00weekly0.6https://www.medthority.com/news/2023/2/linq-insertable-cardiac-monitor-detects-10-times-more-atrial-fibrillation-in-ischemic-stroke-patients-at-three-years-compared-to-standard-of-care.-medronic2024-09-30T10:49:11+00:00weekly0.6https://www.medthority.com/news/2023/2/phathom-pharmaceuticals-provides-regulatory-updates-for-for-its-approved-products-voquezna-triple-pak-and-voquezna-dual-pak/2023-02-10T11:41:50+00:00weekly0.6https://www.medthority.com/news/2023/2/eliem-therapeutics-provides-strategic-update.-2023-02-10T11:36:57+00:00weekly0.6https://www.medthority.com/news/2023/2/kerendia-is-granted-expanded-indication-in-the-eu-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.--bayer-2023-02-11T13:33:56+00:00weekly0.6https://www.medthority.com/news/2023/2/abecma-reduced-the-risk-of-disease-progression-or-death-by-51-versus-standard-regimens-in-earlier-lines-of-therapy-in-karmma-3-study-for-rr-multiple-myeloma.-bms.-2023-02-11T13:33:09+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-jemperli-for-mismatch-repair-deficient-endometrial-cancer.--glaxosmithkline2023-02-11T13:32:03+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-supplemental-new-drug-application-for-cibinqo-in-atopic-dermatitis.--pfizer2023-02-11T13:31:00+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-data-from-delgocitinib-cream-delta-2-trial-for-chronic-hand-eczema.--leo-pharma2023-02-11T13:29:52+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-as-a-potential-treatment-for-mismatch-repair-deficientmicrosatellite-instability-high-locally-advanced-rectal-cancer.--glaxo-smith-kline2023-02-11T13:28:58+00:00weekly0.6https://www.medthority.com/news/2023/2/globus-medical-to-merge-with-nuvasive-to-advance-in-the-musculoskeletal-technology/2023-02-12T13:55:24+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-topline-phase-ii-results-for-nipocalimab-in-pregnant-individuals-at-high-risk-for-severe-hemolytic-disease-of-the-fetus-and-newborn-hdfn--janssen-pharma/2023-02-07T12:10:34+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-accepts-filing-of-sage-217-for-major-depressive-disorder-and-postpartum-depression.--biogen-and-sage-therapeutics2023-02-07T12:08:15+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-data-from-global-phase-iii-commodore-2-study-for-crovalimab-in--paroxysmal-nocturnal-haemoglobinuria-a-rare-life-threatening-blood-condition.--roche2023-02-07T12:03:00+00:00weekly0.6https://www.medthority.com/news/2023/2/forxiga-approved-in-the-eu-for-the-treatment-of-symptomatic-chronic-heart-failure-.-astrazeneca2023-02-07T11:56:43+00:00weekly0.6https://www.medthority.com/news/2023/2/lantheus-holdings-to-acquire-cerveau-technologies-and-with-it-mk-6240-a-pet-imaging-agent-that-targets-tau-tangles-in-alzheimers-disease/2023-02-08T13:20:39+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-trodelvy-in-pre-treated-hrher2--metastatic-breast-cancer.--gilead-sciences2023-02-04T14:38:43+00:00weekly0.6https://www.medthority.com/news/2023/2/keytruda--chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma.--merck-inc2023-02-04T14:38:06+00:00weekly0.6https://www.medthority.com/news/2023/2/update-on-fda-nda-for-maat-013-in-patients-with-acute-graft-versus-host-disease.--maat-pharma2023-02-04T14:37:22+00:00weekly0.6https://www.medthority.com/news/2023/2/magenta-therapeutics-completes-review-of-its-business/2023-02-04T14:35:47+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-sbla-for-takhzyro-in-pediatric-patients-with-hereditary-angioedema.--takeda2023-02-05T14:43:56+00:00weekly0.6https://www.medthority.com/news/2023/2/resubmission-of-bla-to-fda-for-remestemcel-l-in-children-with-steroid-refractory-acute-graft-versus-host-disease.--mesoblast-ltd2023-02-06T13:53:25+00:00weekly0.6https://www.medthority.com/news/2023/2/license-application-for-proposed-biosimilar-denosumab-to-treat-osteoporosis-and-related-conditions-is-accepted-by-fda.--sandoz-2023-02-06T13:52:34+00:00weekly0.6https://www.medthority.com/news/2023/2/tga-australia-approval-for-nuceiva-to-treat-glabellar-lines-in-australia.--evolus-inc2023-02-01T12:18:53+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-odactra--to-treat-house-dust-mite-hdm-induced-allergic-rhinitis.--alk-abello2023-02-01T12:20:14+00:00weekly0.6https://www.medthority.com/news/2023/2/fda-approves-brenzavvy-treat-type-2-diabetes.--theracosbio-2023-02-01T12:21:29+00:00weekly0.6https://www.medthority.com/news/2023/2/act-132577-filed-with-eu-for-resistant-hypertension.--idorsia2023-02-01T12:29:17+00:00weekly0.6https://www.medthority.com/news/2023/2/european-commission-approves-label-expansion-of-hemlibra-to-include-people-with-moderate-haemophilia-a-in-the-eu.---genentechroche2023-02-01T12:41:10+00:00weekly0.6https://www.medthority.com/news/2023/2/hillstream-biopharma-signs-an-exclusive-option-agreement-to-advance-next-generation-anti-muc1-c-agents-for-drug-resistant-cancers/2023-02-01T12:56:27+00:00weekly0.6https://www.medthority.com/news/2023/2/jardiance-filed-in-japan-for-chronic-kidney-disease.--nippon-boehringer--eli-lilly-japan2023-02-02T12:21:24+00:00weekly0.6https://www.medthority.com/news/2023/2/gsk-3228836-enters-2-phase-iii-b-well-trials-for-hepatitis-b.--ionis-pharmaceuticals2023-02-02T12:18:50+00:00weekly0.6https://www.medthority.com/news/2023/1/nmpa-china-approves-mindewei-formerly-vv-116--to-treat-mild-to-moderate-covid--19.--shanghai-junishi-biosciences2023-01-31T12:11:49+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-orserdu-for-er-her2--esr1-mutated-breast-cancer.--menarini-group2025-02-03T14:59:23+00:00weekly0.6https://www.medthority.com/news/2023/1/the-first-patient-has-been-dosed-in-the-global-randomized-tropion-lung07-phase-iii-trial-evaluating-datopotamab-deruxtecan--pembrolizumab-in-patients-with-previously-untreated-metastatic-nsclc.--daiichi-sankyo-astrazeneca2025-02-03T11:27:31+00:00weekly0.6https://www.medthority.com/news/2023/1/spesolimab-meets-primary-and-key-secondary-endpoint-for-prevention-of-generalized-pustular-psoriasis-flares.--boehringer2025-05-06T14:00:08+00:00weekly0.6https://www.medthority.com/news/2023/2/tezspire-approved-for-self-administration-in-the-uswith-a-new-pre-filled-pen.-amgen--astrazeneca2023-02-03T13:20:36+00:00weekly0.6https://www.medthority.com/news/2023/2/jesduvroq-approved-by-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis.--gsk-plc2023-02-03T13:19:52+00:00weekly0.6https://www.medthority.com/news/2023/2/positive-final-results-from-phase-ii--iii-cova-study-of-sarconeos-bio-101-in-treatment--of-covid-19-related-respiratory-failure.--biophytis-sa2023-02-03T13:18:46+00:00weekly0.6https://www.medthority.com/news/2023/2/nda-submitted-to-fda-for-ox-124-a-high-dose-rescue-medication-for-opioid-overdose.--orexo-ab2023-02-03T13:17:56+00:00weekly0.6https://www.medthority.com/news/2023/2/celyad-oncpology-change-in-strategy-and-prorities/2023-02-03T13:15:25+00:00weekly0.6https://www.medthority.com/news/2023/1/leqembi-filed-in-japan-for-mild-cognitive-impairment-due-to-alzheimers-disease-and-mild-ad-dementia.--eisai-and-biogen2023-01-17T12:18:45+00:00weekly0.6https://www.medthority.com/news/2023/1/biosimilar-ustekinumab-demonstrates-therapeutic-equivalance-to-stelara-for-treatment-of-psoriasis.--meiji-seika2023-01-24T12:50:00+00:00weekly0.6https://www.medthority.com/news/2023/1/ranibizumab-bs-intravitreal-injection-kit-biosimilar-secures-additional-indication-in-japan-for-diabetic-macular-edema.--senju--kidswell-bio2023-01-24T12:51:20+00:00weekly0.6https://www.medthority.com/news/2023/1/new-terlivaz-for-injection-data--on-hepatorenal-syndrome-reversal-is-presented-at--the-society-of-critical-care-medicine-2023-critical-care-congress.--mallinckrodt-plc2023-01-24T12:53:03+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-acceptance-of-snda-for-ayvakit-for-the-treatment-of-indolent-systemic-mastocytosis.--blueprint-medicines-corpn2023-01-24T12:54:25+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-rykindo-for-the-treatment-of-schizophrenia-and-bipolar-1-disorder.--luye-pharma2023-01-24T12:56:14+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-adacel-vaccine-during-pregnancy-to-protect-infants-against-pertussis.-sanofi-2023-01-24T12:58:07+00:00weekly0.6https://www.medthority.com/news/2023/1/update-on--fda-emergency-use-authorisation-of-evusheld--astrazeneca/2023-01-27T13:03:25+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves--proclaim-xr-spinal-cord-stimulation-for--painful-diabetic-peripheral-neuropathy--abbott/2023-01-27T13:05:29+00:00weekly0.6https://www.medthority.com/news/2023/1/transcend-cll-004-trial-of-breyanzi-met-primary-endpoint-of-complete-response-rate-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia/2023-01-27T13:08:30+00:00weekly0.6https://www.medthority.com/news/2023/1/dupixent-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.--sanofi--regeneron2023-01-27T13:11:32+00:00weekly0.6https://www.medthority.com/news/2023/1/novavax-announces-a-plan-to-deliver-updated-protein-based-vaccine-consistent-with-fda-recommendations-for-20232024-vaccination-season-at-vrbpac-meeting/2023-01-28T14:49:53+00:00weekly0.6https://www.medthority.com/news/2023/1/chmp-recommends-darolutamide-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.--bayer2023-01-28T14:49:08+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-chmp-opinion-for-reblozyl--for-adult-patients-with-anemia-associated-non-transfusion-dependentntd-beta-thalassemia.--bms2023-01-28T14:48:14+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-appproves-keytruda-for-adjuvant-treatment-following-surgical-resection-and-chemotherapy-for-nsclc.--merck-inc2023-01-28T14:47:29+00:00weekly0.6https://www.medthority.com/news/2023/1/chmp-recommends-approval-of-sotyktu-in-plaque-psoriasis.--bristol-myers-squibb2023-01-28T14:46:45+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-ar-301-002-study-of-ar-301-shows-improved-clinical-cure-rate-in-pneumonia-infection.--aridis-pharma2023-01-28T14:46:06+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-cartitude-4-study-of-carvykti-meets-primary-endpoint-in-multiple-myeloma.--legend-biotech-corp2023-01-28T14:45:23+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-jaypirca--the-first-and-only-non-covalent-reversible-btk-inhibitor-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-after-at-least-two-lines-of-systemic-therapy-including-a-btk-inhibitor.--loxolillyeli-lilly2023-01-28T14:44:41+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-stand-study-of-crizanlizumab-shows-no-significant-difference-between-doses-for-treating-sickle-cell-disease-pain-crises.--novartis2023-01-29T13:56:41+00:00weekly0.6https://www.medthority.com/news/2023/1/tecentriq--avastin-is-the-first-treatment-combination-to-reduce-the-risk-of-cancer-returning-in-people-with-certain-types-of-early-stage-liver-cancer-in-a-phase-iii-imbrave050-trial.--roche2023-01-30T11:25:57+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-chmp-opinion-for-citrate-free-high-concentration-formulation-of-adalimumab-biosimilar.-sandoz2023-01-30T11:28:16+00:00weekly0.6https://www.medthority.com/news/2023/1/dupixent-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis-in-the-european-union.--regeneron--sanofi2023-01-30T11:34:29+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approval-for-navitor-a-next-generation-tavi-system-designed-to-treat-aortic-stenosis.--abbott2023-01-18T12:24:30+00:00weekly0.6https://www.medthority.com/news/2023/1/nmpa-approves-hansizhuang-for-extensive-stage-small-cell-lung-cancer.--shanghai-henlius-biotech2023-01-18T12:20:22+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-sunlight-trial-of-lonsurf-meets-primary-endpoint-in-colorectal-cancer.--servier-and-taiho-oncology2023-01-18T12:16:32+00:00weekly0.6https://www.medthority.com/news/2023/1/innovation-passport-designation-by-the-mhra-uk-for-nemvaleukin-alfa-for-the-treatment-of-mucosal-melanoma.--alkermes-plc2023-01-18T12:11:06+00:00weekly0.6https://www.medthority.com/news/2023/1/topline-results-from-rose2-study-of-obicetrapib--ezetimibe-as-adjunct-to-high-intensity-statin-therapy.--new-amsterdam-pharma2023-01-19T12:42:18+00:00weekly0.6https://www.medthority.com/news/2023/1/health-canada-approves-qulipta-for-the-prevention-of-episodic-migraine.--abbvie2023-01-19T12:37:45+00:00weekly0.6https://www.medthority.com/news/2023/1/tecentriq--avastin-is-the-first-treatment-combination-to-reduce-the-risk-of-cancer-returning-in-certain-types-of-early-stage-liver-cancer-in-a-phase-iii-trial.--genentechroche2023-01-19T12:32:24+00:00weekly0.6https://www.medthority.com/news/2023/1/mesdopetam-phase-iib-top-line-data-as-a-treatment-for-parkinsons-disease-levodopa-induced-dyskinesias.--irlab-therapeutics2023-01-20T13:12:51+00:00weekly0.6https://www.medthority.com/news/2023/1/mrna-1345-an-investigational-respiratory-syncytial-virus-vaccine-has-met-primary-endpoints-in-a-phase-iii-trial-in-older-adults.--moderna2023-01-20T13:10:19+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-accepts-nda-for-obeticholic-acid--seeking-accelerated-approval-for-treatment-of-patients-with-pre-cirrhotic-liver-fibrosis-due-to-nash.-intercept-pharma2023-01-20T13:07:32+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-recommends-exkivity-to-treat-egfr-exon-20-insertion-gene-mutation-positive-advanced-non-small-cell-lung-cancer-.--takeda2025-02-03T11:28:24+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-mosaico-study-of-ad26.mos4.hiv-discontinued-for-hiv-patients.--janssen-pharma2023-01-20T12:56:46+00:00weekly0.6https://www.medthority.com/news/2023/1/mhra-approves-brukinsa-for-chronic-lymphocytic-leukemia-and-marginal-zone-lymphoma.--beigene2023-01-20T12:51:27+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-recommends-lenvima-and-keytruda-for-renal-cell-carcinoma-for-intermediate-and-poor-risk-patients.--merck-inc.--eisai2023-01-20T12:47:53+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-issues-complete-response-letter-for-accelerated--approval-of-donanemab-for-treatment-of-early-symptomatic-alzheimers-disease.--eli-lilly2023-01-20T12:43:18+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-accelerated-approval-of-tukysa-in-combination-with-trastuzumab-for--previously-treated-ras-wild-type-her2-positive-metastatic-colorectal-cancer.--seagen--merck-inc2023-01-20T12:41:03+00:00weekly0.6https://www.medthority.com/news/2023/1/aim-immunotech-enters-collaborative-research-agreement-with-erasmus-mc-and-astrazeneca/2023-01-20T12:38:43+00:00weekly0.6https://www.medthority.com/news/2023/1/update-on-nda-review-of-vonoprazan-for-erosive-esophagitis.--phathom-pharma2023-01-21T15:02:53+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-topline-results-from-phase-iii-phalcon-nerd-301-trial-evaluating-daily-dosing-of-vonoprazan-for-symptomatic-non-erosive-gastroesophageal-reflux-disease-nerd--phathom-pharma/2023-01-21T15:02:08+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-accepts-supplemental-nda-for-jardiance-for-adults-with-chronic-kidney-disease.--boehringer--eli-lilly2023-01-21T15:01:30+00:00weekly0.6https://www.medthority.com/news/2023/1/brukinsa-approved-in-the-u.s.-for-chronic-lymphocytic-leukemia.-beigene2023-01-21T15:00:52+00:00weekly0.6https://www.medthority.com/news/2023/1/concert-pharma-is-acquuired-by-sun-pharma-and-with-it-deuruxolitinib-a-proposed-treatment-for-alopecia-areata/2023-01-21T14:59:56+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-napoli-3-trial-of-onivyde-reports-improved-os-and-pfs-in-metastatic-pancreatic-ductal-adenocarcinoma-at-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium.--ipsen2023-01-22T15:24:41+00:00weekly0.6https://www.medthority.com/news/2023/1/dr.-reddys-successfully-completes-full-set-of-clinical-studies-of-its-rituximab-biosimilar-for-filing-in-the-u.s.-and-europe-2023-01-23T12:56:27+00:00weekly0.6https://www.medthority.com/news/2023/1/health-canada-approves-ultomiris-for-achr-positive-generalized-myasthenia-gravis.--astrazeneca2023-01-25T12:17:46+00:00weekly0.6https://www.medthority.com/news/2023/1/finch-therapeutics-announces-decision-to-discontinue-phase-iii-trial-of-cp-101--for-recurrent-c.-difficile-infection-and-focus-on-realizing-the-value-of-its-intellectual-property-estate.-2023-01-25T12:20:00+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-top-line-clinical-results-in-phase-ii-study-evaluating-simufilam-in-alzheimers-disease.-cassava-sciences-inc2023-01-25T12:24:49+00:00weekly0.6https://www.medthority.com/news/2023/1/takeda-to-acquire-exclusive-worldwide-ex-china-license-of-hutchmeds-fruquintinib/2023-01-25T12:27:00+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-brenzavvy-in-type-2-diabetes.--theracosbio2023-01-25T12:29:12+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-regulatory-update-on-d-plex100-for-abdominal-colorectal-surgical-site-infections.--polupid2023-01-25T12:37:22+00:00weekly0.6https://www.medthority.com/news/2023/1/hsr-clearance-for-expansion-of-innate-pharma-collaboration-with-sanofi-on-nk-cell-engagers/2023-01-25T12:39:30+00:00weekly0.6https://www.medthority.com/news/2023/1/update-on-nasar-clinical-trial-with-bentrio-for--seasonal-allergic-rhinitis.--altamira-therapeutics2023-01-26T12:46:02+00:00weekly0.6https://www.medthority.com/news/2023/1/update-on-covamid-trial-with-bentrio-for-acute-covid-19.--altamira-therapeutics2023-01-26T12:49:46+00:00weekly0.6https://www.medthority.com/news/2023/1/keynote-991-trial-evaluating-keytruda--enzalutamide-and-androgen-deprivation-therapy-for-metastatic-hormone-sensitive-prostate-cancer-to-stop-for-futility.--merck-inc2023-01-26T12:52:37+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-advisory-committee-recommends-approval-of-rezafungin-for-the-treatment-of-candidemia-and-invasive-candidiasis.--cidara-therapeutics--melinta-therapeutics2023-01-26T12:57:35+00:00weekly0.6https://www.medthority.com/news/2023/1/ultravist-now-approved-for-contrast-enhanced-mammography-in-eu.--bayer-healthcare2023-01-26T13:04:38+00:00weekly0.6https://www.medthority.com/news/2023/1/keytruda--chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-in--first-line-advanced-or-unresectable-biliary-tract-cancer-in-keynote-966-trial.--merck-inc2023-01-26T12:41:21+00:00weekly0.6https://www.medthority.com/news/2023/1/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer-.--astrazeneca--daiichi-sankyo2023-01-26T12:36:07+00:00weekly0.6https://www.medthority.com/news/2023/1/nejm-publishes-once-weekly-efanesoctocog-alfa-phase-iii-data-demonstrating-its-potential-to-transform-the-treatment-landscape-for-people-with-hemophilia-a.--sanofi--sobi2023-01-26T12:33:09+00:00weekly0.6https://www.medthority.com/news/2022/12/ayvakit-data-showed-high-durable-response-rates-and-prolonged-overall-survival-os-in-patients-with-advanced-systemic-mastocytosis.--blueprint-medicines-corpn.-2022-12-13T12:14:39+00:00weekly0.6https://www.medthority.com/news/2022/12/post-hoc-analysis-of-phase-iii-vital-study-shows-neod-001-provides-consistent-benefits-to-9-months-in-al-amyloidosis.--prothena-corp2022-12-13T12:16:39+00:00weekly0.6https://www.medthority.com/news/2022/12/amgen-inc-to-acquire-horizon-therapeutics-/2022-12-13T12:18:42+00:00weekly0.6https://www.medthority.com/news/2022/12/enhertu-approved-in-the-eu-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer.--daiichi-sankyo--astrazeneca2022-12-20T12:08:21+00:00weekly0.6https://www.medthority.com/news/2022/12/update-on-pearl-phase-iii-trial-of-imfinzi-monotherapy-in-stage-iv-non-small-cell-lung-cancer.--astrazeneca2022-12-20T12:10:03+00:00weekly0.6https://www.medthority.com/news/2022/12/uks-mhra-accepts-maa-for-sugemalimab-in-metastatic-non-small-cell-lung-cancer.--eqrx-inc2022-12-20T12:11:40+00:00weekly0.6https://www.medthority.com/news/2022/12/abbott-launches-freestyle-librelink-app-with-novo-nordisks-smart-connected-insulin-pens-in-the-uk/2022-12-20T12:13:48+00:00weekly0.6https://www.medthority.com/news/2022/12/bylvay-filed-with-fda-and-ema-for-alagille-syndrome.--albireo-pharma2022-12-20T12:15:55+00:00weekly0.6https://www.medthority.com/news/2022/12/zoryve-filed-with-snda-to-fda-for--plaque-psoriasis-in-children-ages-2-to-11.--arcutis-biotherapeutics2022-12-20T12:17:55+00:00weekly0.6https://www.medthority.com/news/2022/12/positive-topline-results-from-the-pivotal-phase-iii-maestro-nash-clinical-trial-of-resmetirom-for-the-treatment-of-nash-and-liver-fibrosis.--madrigal-pharma2022-12-20T12:21:41+00:00weekly0.6https://www.medthority.com/news/2022/12/eisai-to-divest-rights-to-anti-epileptic-fycompa-in-the-us-to-catalyst-pharmaceuticals/2022-12-21T12:15:37+00:00weekly0.6https://www.medthority.com/news/2022/12/car-t-cell-therapy-breyanzi-approved-as-relapsed-or-refractory-large-b-cell-lymphoma-second-line-therapy-in-japan.-bms2022-12-21T12:17:40+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-gives-padcev--ketruda-combination-priority-review-sbla-in-metastatic-urothelial-cancer.---astellas-pharma-seagen-inc.-and-merck-2022-12-21T12:19:54+00:00weekly0.6https://www.medthority.com/news/2022/12/eu-approves-ebvallo-in-refractory-epsteinbarr-virus-positive-posttransplant-lymphoproliferative-disease.--atara-biotherapeutics-and-pierre-fabre2022-12-21T12:22:28+00:00weekly0.6https://www.medthority.com/news/2022/12/final-part-of-rolling-submission-of-zimura-to-fda-in-geographic-atrophy-completed.--iveric-bio2022-12-21T12:25:26+00:00weekly0.6https://www.medthority.com/news/2022/12/act-132577-filed-with-fda-for-difficult-to-control-hypertension.--idorsia2022-12-21T12:28:14+00:00weekly0.6https://www.medthority.com/news/2022/12/gilead-sciences-to-acquire-imunity-therapeutics/2022-12-21T12:29:59+00:00weekly0.6https://www.medthority.com/news/2022/12/imfinzi-plus-chemotherapy-approved-in-the-eu-as-first-immunotherapy-regimen-for-patients-with-advanced-biliary-tract-cancer.--astrazeneca2022-12-22T11:32:29+00:00weekly0.6https://www.medthority.com/news/2022/12/lynparza-in-combination-with-abiraterone-approved-in-the-eu-as-1st-line-treatment-for-patients-with-metastatic-castration-resistant-prostate-cancer.--astra-zeneca2022-12-22T11:31:53+00:00weekly0.6https://www.medthority.com/news/2022/12/zynlonta-approved-in-the-eu-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.-sobi--adc-therapeutics2022-12-22T11:31:13+00:00weekly0.6https://www.medthority.com/news/2022/12/ensifentrine-meets-primary-and-key-secondary-endpoints-in-phase-iii-enhance-1-trial-for-copd.--verona-pharma-plc2022-12-22T11:30:18+00:00weekly0.6https://www.medthority.com/news/2022/12/positive-topline-data-in-the-pivotal-herizon-btc-01-trial-of-zanidatamab-for-her2-amplified-biliary-tract-cancer.--zymeworks2022-12-22T11:29:34+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-and-eu-accept-filing-of-apd-334-for-ulcerative-colitis.--pfizer2022-12-22T11:28:48+00:00weekly0.6https://www.medthority.com/news/2022/12/vidprevtyn-beta-covid-19-booster-approved-in-uk.--gsk2022-12-22T11:26:33+00:00weekly0.6https://www.medthority.com/news/2022/12/adx-2191-filed-with-fda-for-primary-vitreoretinal-lymphoma.--aldeyra-therapeutics-2022-12-22T11:25:45+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-actemra-for-the-treatment-of-covid-19-in-hospitalised-adults.--roche-2022-12-22T11:25:06+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-tymlos-for-men-with-osteoporosis.--radius-health2022-12-22T11:24:28+00:00weekly0.6https://www.medthority.com/news/2022/12/duobody-cd3xcd20-filed-with-mhlw-japan-to-treat-large-b-cell-lymphoma.--genmab2022-12-22T11:23:43+00:00weekly0.6https://www.medthority.com/news/2022/12/shield-therapeutics-and-viatris-sign-collaborative-sales-agreement-for-accrufer-in-the-united-states/2022-12-14T12:16:21+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-e1910-trial-of-blincyto-showing-benefits-over-standard-care-in-b-lineage-acute-lymphoblastic-leukemia-b-all-presented-at-ash.--amgen2022-12-14T12:19:22+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-grants-accelerated-approval-of-krazatiin-kras-g12c-non-small-cell-lung-cancer.--mirati-therapeutics2025-02-03T11:29:09+00:00weekly0.6https://www.medthority.com/news/2022/12/eu-approves-livmarli-for-cholestatic-pruritus-in-patients-with-alagille-syndrome.--mirum-pharma2022-12-14T12:29:22+00:00weekly0.6https://www.medthority.com/news/2022/12/brukinsa-demonstrated-superior-progression-free-survival-over-imbruvica-in-chronic-lymphocytic-leukemia-in-late-breaker-at-ash.--beigene2022-12-14T12:31:25+00:00weekly0.6https://www.medthority.com/news/2022/12/pivotal-phase-iii-apply-pnh-data-at-ash-demonstrates-investigational-oral-monotherapy-iptacopan-superiority-over-anti-c5-patients-with-paroxysmal-nocturnal-hemoglobinuria-.--novartis------------2022-12-14T12:33:28+00:00weekly0.6https://www.medthority.com/news/2022/12/novavax-incannounced-that-health-canada-has-approved-a-snds-for-nuvaxovid-covid-19-vaccine-to-prevent-coronavirus-caused-by-the-severe-acute-respiratory-syndrome-as-a-primary-series-of-two-doses-in-adolescents-aged-12-through-17/2022-12-14T12:35:25+00:00weekly0.6https://www.medthority.com/news/2022/12/health-canada-approval-for-prehevbrio-for-the-prevention-of-hepatitis-b-in-adults.--vbi-vaccines2022-12-14T12:39:03+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-advisory-committee-negative-for--omecamtiv-mecarbil-for-treatment-ofheart-failure-with-reduced-ejection-fraction..--cytokinetics-inc2022-12-14T12:42:35+00:00weekly0.6https://www.medthority.com/news/2022/12/dupixent-approved-by-european-commission-as-the-first-and-only-targeted-medicine-indicated-for-prurigo-nodularis.--regenereon--sanofi2022-12-15T11:35:56+00:00weekly0.6https://www.medthority.com/news/2022/12/sio-gene-therapies-to-liquidate/2022-12-15T11:38:08+00:00weekly0.6https://www.medthority.com/news/2022/12/mrna-4157v940-a-personalised-mrna-cancer-vaccine--keytruda-met-primary-efficacy-endpoint-in-phase-iib-keynote-942-trial-to-treat-melanoma.--moderna--merck-inc2022-12-16T12:34:04+00:00weekly0.6https://www.medthority.com/news/2022/12/update-on-us-regulatory-review-of-lynparza--abiraterone--prednisone-or-prednisolone-as-treatment-of-metastatic-castration-resistant-prostate-cancer.--merck-inc2022-12-16T12:31:19+00:00weekly0.6https://www.medthority.com/news/2022/12/first-patient-enrolled-in-u.s.-clinical-trial-for-hugo-robotic-assisted-surgery-system.--medtronic2022-12-16T12:25:08+00:00weekly0.6https://www.medthority.com/news/2022/12/real-world-study-shows-patients-treated-with-imbruvica-were-less-likely-to-initiate-a-next-line-treatment-than-patients-on-acalabrutinib-in-first-line-chronic-lymphocytic-leukemia--janssenjj/2022-12-16T12:21:48+00:00weekly0.6https://www.medthority.com/news/2022/12/eu-approves-pluvicto--adt-in-prostate-cancer.--novartis2022-12-16T12:17:38+00:00weekly0.6https://www.medthority.com/news/2022/12/bcx-9930-will-discontinued-in-development-programme.--biocryst-pharma2022-12-16T12:11:34+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-oa-7-long-trm-extension-trial-of-lorecivivint-shows-safety-and-efficacy-in-knee-osteoarthritis-pain.--biosplice-therapeutics2022-12-16T12:28:45+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-expansion-of-eu-label-for-hemlibra-to-include-people-with-moderate-haemophilia-a.--roche2022-12-17T18:42:00+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-vraylar-as-an-adjunctive-treatment-for-major-depressive-disorder.--abbvie--gedeon-richter2022-12-17T18:41:17+00:00weekly0.6https://www.medthority.com/news/2022/12/finerenone-receives-positive-chmp-opinion-for-eu-label-extension-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.-bayer-healthcare--2022-12-17T18:39:49+00:00weekly0.6https://www.medthority.com/news/2022/12/chmprecommends-the-use-of-ba.1-targeting-bivalent-covid-19-booster-mrna-1273.214-in-children-6-11-years-in-the-european-union.--moderna2022-12-17T18:39:07+00:00weekly0.6https://www.medthority.com/news/2022/12/dupixent-is-recommended-for-eu-approval-by-the-chmp-for-the-treatment-of-eosinophilic-esophagitis.--regeneron--pharma--sanofi2022-12-17T18:37:47+00:00weekly0.6https://www.medthority.com/news/2022/12/submission-of-snda-to-fda-to-support-new-indication-of-linzess-for-functional-constipation-in-children-and-adolescents-6-to-17-years-of-age.--abbvie--ironwood-pharma2022-12-18T13:24:31+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-cipaglucosidase-alfa--miglustat-to-treat-late-stage-pompe-disease.--amicus2022-12-18T13:23:17+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-imjudo--imfinzi-combination-to-treat-liver-cancer--astrazeneca/2022-12-18T13:21:56+00:00weekly0.6https://www.medthority.com/news/2022/12/positive-chmp-opinion-for-etranacogene-dezaparvovec--gene-therapy-for-adults-with-hemophilia-b.--csl-behring2022-12-18T13:20:16+00:00weekly0.6https://www.medthority.com/news/2022/12/ema-has-recommended-refusal-of-marketing-authorisation-for-omblastys-for-the-treatment-of-neurobastoma/2022-12-18T13:19:10+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-enhertu-to-treat-her2-low-breast-cancer.--daiichi-sankyo--astrazeneca2022-12-19T12:54:36+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-extension-of-fintepla-indication-to-include-lennox-gastaut-syndrome.-zogenixucb2022-12-19T12:56:24+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-imfinzi--imjudo--chemotherapy-for-first-line-treatment--of-nsclc-with-no-sensitising-egfr-or-alk-positive-mutations.-astrazeneca2022-12-19T12:58:03+00:00weekly0.6https://www.medthority.com/news/2022/12/chmp-recommends-a-label-extension-for-kerendia-to-include-results-of-phase-iii-figaro-dkd-study.--bayer2022-12-19T13:01:25+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-adstiladrin-for-bladder-cancer.--ferring-pharma2022-12-19T13:03:07+00:00weekly0.6https://www.medthority.com/news/2022/12/intravitreal-pegcetacoplan-filed-with-eu-for-geographic-atrophy.--apellis-pharma2022-12-19T13:04:51+00:00weekly0.6https://www.medthority.com/news/2022/12/kitegilead-sciences-and-daiichi-sankyo-announce-changes-to-yescarta-car-t-cell-therapy-licensing-agreement-in-japan/2022-12-09T13:01:40+00:00weekly0.6https://www.medthority.com/news/2022/12/lupkynis-is-approved-by-the-uk--mhra-to-treat-active-lupus-nephritis-.-aurinia-pharma2022-12-09T13:00:22+00:00weekly0.6https://www.medthority.com/news/2022/12/alzheimers-disease-cerebrospinal-fluid-csf-assays-receive-fda-clearance-supporting-more-accurate-and-timely-diagnosis.roche-2022-12-09T12:57:21+00:00weekly0.6https://www.medthority.com/news/2022/12/sotyktu--an-oral-treatment-for-adults-with-moderate-to-severe-plaque-psoriasis-is-approved-in-canada.---bms2022-12-09T12:55:40+00:00weekly0.6https://www.medthority.com/news/2022/12/camizestrant-significantly-delayed-disease-progression-in-advanced-er-positive-breast-cancer-adding-at-least-3.5-months-benefit-versus-faslodex-in-serena-2-study.-astrazeneca2022-12-09T12:54:02+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-emergency-use-authorization-for-omicron-ba.4ba.5-adapted-bivalent-covid-19-vaccine-in-children-under-5-years.--pfizer--biontech-se2022-12-09T12:52:05+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-emergency-use-authorization-for-omicron-targeting-bivalent-covid-19-booster-vaccine-in-cchildren-6-months-through-5-years-of-age.--moderna2022-12-09T12:49:54+00:00weekly0.6https://www.medthority.com/news/2022/12/eu-approves-qdenga-vaccine-for-dengue-fever.--takeda2022-12-09T12:46:44+00:00weekly0.6https://www.medthority.com/news/2022/12/health-canada-approves-prehevbrio-for-hepatitis-b.--vbi-vaccines2022-12-09T12:44:22+00:00weekly0.6https://www.medthority.com/news/2022/12/capivasertib--faslodex-reduced-the-risk-of-disease-progression-or-death-by-40-versus-faslodex-in-advanced-hr-positive-breast-cancer.--astrazeneca-2022-12-09T12:39:53+00:00weekly0.6https://www.medthority.com/news/2022/12/snda-submitted-to-the-fda-for-onpattro-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis..--alnylam-pharma2022-12-09T12:21:48+00:00weekly0.6https://www.medthority.com/news/2022/12/first-results-for-datopotamab-deruxtecan-are-reported-from-tropion-pantumor01-phase-i-trial-for-heavily-pretreated-hormone-receptor-hr-positive-her2-low-breast-cancer.--daiichi-sankyo--astrazeneca2022-12-09T12:16:06+00:00weekly0.6https://www.medthority.com/news/2022/12/independent-data-monitoring-committee-recommends-galinpepimut-s-regal-trial-to-continue-as-planned--sellas-life-sciences/2022-12-10T13:16:16+00:00weekly0.6https://www.medthority.com/news/2022/12/jnj-64407564-filed-with-fda-for-multiple-myeloma.--janssen-pharma2022-12-10T13:15:13+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-be-heard-i-and-ii-studies-of-bimzelx-meet-primary-endpoint-in-hidradenitis-suppurativa.--ucb2024-11-14T15:27:14+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-accepts-nda-on-re-submission-for-brixadi-extended-release-weekly-and-monthly-subcutaneous-injections-for-moderate-to-severe-opioid-use-disorder.--braeburn2022-12-10T13:13:54+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-contact-01-trial-of-cabometyx---tecentriq-fails-to-meet-primary-endpoint-in-metastatic-non-small-cell-lung-cancer.--exelixis2022-12-10T13:13:03+00:00weekly0.6https://www.medthority.com/news/2022/12/datopotamab-deruxtecan-showed-an-encouraging-objective-response-rate-of-32-and-a-manageable-safety-profile-in-patients-with-metastatic-tnbc-in-tropion-pantumor01-phase-i-trial.--daiichi-sankyo--astrazeneca2022-12-10T13:12:00+00:00weekly0.6https://www.medthority.com/news/2022/12/datopotamab-deruxtecan-plus-imfinzi-showed-73.6-orr-in-1st-line-treatment-of-metastatic-tnbc.--daiichi-sankyo--astrazeneca2022-12-10T13:11:14+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-accepts-for-priority-review-the-bla-for-pf-06928316-or-rsvpref-to-prevent-respiratory-syncytial-virus-in-older-adults.--pfizer2022-12-10T13:10:08+00:00weekly0.6https://www.medthority.com/news/2022/12/bivalent-covid-19-booster-vaccine-approved-by-mhra-uk--pfizer--biontech-se/2022-12-11T17:34:33+00:00weekly0.6https://www.medthority.com/news/2022/12/new-data-from-lovotibeglogene-autotemcel-gene-therapy-for-sickle-cell-disease-presented-at-64th-ash-annual-meeting.--bluebird-bio2022-12-11T17:33:15+00:00weekly0.6https://www.medthority.com/news/2022/12/new-data-from-gene-therapy-betibeglogene-autotemcel-beti-cel-for-transfusion-dependent-beta-thalassemia-is-presented-at-64th-ash-annual-meeting.--bluebird-bio2022-12-11T17:32:04+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-hope-b-study-of-hemgenix-showing-long-term-benefits-in-haemophilia-b-presented-at-the-64th-ash-annual-meeting.--csl2022-12-11T17:30:55+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-glow-study-of-imbruvica--venclexta-shows-benefits-in-chronic-lymphocytic-leukaemia-at-4-years-follow-up.--janssen-pharma2022-12-11T17:29:18+00:00weekly0.6https://www.medthority.com/news/2022/12/updated-favorable-elranatamab-data-from-pivotal-phase-ii-magnetismm-3-trial-is-presented-at-ash.--pfizer2022-12-11T17:28:11+00:00weekly0.6https://www.medthority.com/news/2022/12/interim-data-from-phase-iii-study-presented-at-ash-2022-show-hemlibra--achieved-meaningful-bleed-control-in-infants-from-birth.-genentechroche2022-12-12T12:44:06+00:00weekly0.6https://www.medthority.com/news/2022/12/subcutaneous-crovalimab-given-every-four-weeks-achieves-disease-control-in-phase-iii-commodore-3-study-for-people-with-pnh-a-life-threatening-blood-condition.--roche2022-12-12T12:46:25+00:00weekly0.6https://www.medthority.com/news/2022/12/updated-pyrukynd-data-of-long-term-safety-profile-and-durable-improvement-in-hemoglobin-and-markers-of-hemolysis-and-ineffective-erythropoiesis-in-non-transfusion-dependent-alpha--and-beta-thalassemia-.--agios-pharma2022-12-12T12:48:01+00:00weekly0.6https://www.medthority.com/news/2022/12/updated-interim-data-for-zilovertamab--ibrutinib-for-cllmclmzl-at-ash-2022.--oncternal-therapeutics-inc2022-12-12T12:49:46+00:00weekly0.6https://www.medthority.com/news/2022/12/discontinuation-is-announced-of-zandelisib-development-for-b-cell-malignancies-outside-of-japan-following-fda-meeting.--mei-pharma--kyowa-kirin-co.-ltd2022-12-12T12:52:13+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-polarix-study-of-polivy--r-chp-showing-3-year-improvement-in-diffuse-large-b-cell-lymphoma-presented-at-ash.--genentechroche2022-12-12T12:54:13+00:00weekly0.6https://www.medthority.com/news/2022/12/updated-pyrukynd-long-term-extension-data-demonstrating-sustained-clinical-benefits-in-adults-with-pyruvate-kinase-pk-deficiency-presented-at-64th-ash-annual-meeting-and-exposition.--agios-pharma2022-12-12T12:58:23+00:00weekly0.6https://www.medthority.com/news/2022/12/tislelizumab-filing-for-liver-cancer-in-china-is-accepted-by-nmpa--beigene-/2023-01-01T13:03:15+00:00weekly0.6https://www.medthority.com/news/2022/12/radicut-oral-suspension-2.1-approved-in-japan-to-treat-amyotrophic-lateral-sclerosis.--mitsubishi-tanabe-pharma-corporation2023-01-01T13:02:10+00:00weekly0.6https://www.medthority.com/news/2022/12/mhlw-japan-approves-tavalisse-to-treat-chronic-idiopathic-thrombocytopenic-purpura.--kissei2023-01-01T13:01:09+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-recommends-cabozantinib-to-treat-hepatocellular-carcinoma-liver-cancer--ipsen/2023-01-01T13:00:06+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-recommends-avatrombopag-to-treat-primary-chronic-immune-thrombocytopenia-itp-refractory-to-other-treatments.--sobi2023-01-01T12:58:58+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-negative-recommendation-foramivantamab-to-treat-nsclc-with-egfr-exon-20-insertion-mutations.--janssen-cilag-ltd2023-01-01T12:57:44+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-negative-recommendation-for-esketamine-nasal-spray-for-treatment-resistant-depression.-janssen-pharma2023-01-01T12:56:40+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-briumvi-to-treat-multiple-sclerosis.--tg-therapeutics2023-01-01T12:55:42+00:00weekly0.6https://www.medthority.com/news/2023/1/nice-uk-recommends-trifluridinetipiracil-combination-to-treat-metastatic-gastric-cancer-or-gastro-oesophageal-junction-adenocarcinoma.-servier--taiho-oncology2023-01-01T12:54:28+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-nexobrid--for-the-removal-of-eschar-in-adults-with-deep-partial-thickness-andor-full-thickness-thermal-burns.-vericel--mediwound-ltdteva2023-01-02T16:41:35+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approves-xenoview-for-use-with-mri-for-the-evaluation-of-lung-ventilation.--polarean-imaging-plc2023-01-04T13:29:01+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-approval-for-adalimumab-biosimilar-idacio.---fresenius-kabi2023-01-04T13:30:46+00:00weekly0.6https://www.medthority.com/news/2023/1/npma-china-grants-conditional-approval-for-molnupiravir-to-be-used-in-adult-patients-who-have-mild-to-medium-covid-infection-and-a-high-risk-of-progressing-to-severe-cases.--merck-inc2023-01-04T13:31:54+00:00weekly0.6https://www.medthority.com/news/2023/1/mersana-therapeutics-announces-research-collaboration-and-commercial-license-agreement-with-merck-kgaa-darmstadt-germany-to-develop-novel-immunosynthen-antibody-drug-conjugates/2023-01-04T13:33:36+00:00weekly0.6https://www.medthority.com/news/2022/12/bavarian-nordic-completes-enrollment-in-global-phase-iii-trial-of-mva-bn-rsv-vaccine-for-respiratory-syncytial-virus/2022-12-23T11:13:36+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-trial-of-dupixent-for-eosinophilic-esophagitis-published-in-new-england-journal-of-medicine.--sanofi-2022-12-23T11:19:38+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-sunlenca--for-hiv-1-infection.--gilead-sciences2022-12-23T11:25:42+00:00weekly0.6https://www.medthority.com/news/2022/12/eu-validates-filing-of-lytenava-for-wet-age-related-macular-degeneration.--outlook-therapeutics2022-12-23T11:34:28+00:00weekly0.6https://www.medthority.com/news/2022/12/biontech-and-fosun-pharma-announce-full-regulatory-approval-of-their-mono-and-bivalent-covid-19-vaccine-comiraty-in-individuals-12-years-and-older-in-hong-kong/2022-12-25T10:18:39+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-grants-accelerated-approval-for-lunsumio-a-first-in-class-bispecific-antibody-to-treat-people-with-relapsed-or-refractory-follicular-lymphoma.--genentechroche2022-12-25T10:17:06+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-trial-initiated-for-encaleret-in-autosomal-dominant-hypocalcemia-type-1.--bridgebio-pharma2022-12-25T10:16:05+00:00weekly0.6https://www.medthority.com/news/2022/12/ocaliva-resubmitted-to-fda-for-nash.--intercept-pharma-2022-12-25T10:15:04+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-lifts-partial-clinical-hold-on-phase-iii-vitesse-trial-of-viaskin-peanut-250-microg-patch-for-peanut-allergy.--dbv-technologies2022-12-25T10:14:07+00:00weekly0.6https://www.medthority.com/news/2022/12/japanese-mhlw-approves-cresemba-for-aspergillosis-mucormycosis-and-cryptococcosis.--basilea-pharmaceutica2022-12-25T10:13:06+00:00weekly0.6https://www.medthority.com/news/2022/12/japanese-mhlw-approves-adtralza-for-atopic-dermatitis.--leo-pharma2022-12-25T10:11:56+00:00weekly0.6https://www.medthority.com/news/2022/12/libtayo-approved-in-japan-for-advanced-or-recurrent-cervical-cancer.--regeneron-pharma2022-12-25T10:10:55+00:00weekly0.6https://www.medthority.com/news/2022/12/update-on-the-fda-review-of-the-bla-for-toripalimab-as-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma.-junishi-biosciences--coherus-biosciences2022-12-26T09:16:35+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-issues-complete-response-to-application-for-sohonos-in-fibrodysplasia-ossificans-progressiva.--clementia-pharmaceuticals2022-12-26T09:15:00+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approval-for-additional-indication-for-pemfexy--pembrolizumab-and-platinum-chemotherapy.--eagle-pharma2022-12-26T15:09:51+00:00weekly0.6https://www.medthority.com/news/2022/12/breyanzi-approved-as-relapsed-or-refractory-large-b-cell-lymphoma-second-line-therapy-in-japan.--bms-k.k2022-12-26T15:08:21+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-approves-olpruva-to-treat--certain-patients-living-with-urea-cycle-disorders.-acer-therapeutics2022-12-28T12:35:43+00:00weekly0.6https://www.medthority.com/news/2022/12/calquence-granted-extension-of-approval-by-mhlw-in-japan-for-treatment-naive-chronic-lymphocytic-leukaemia-including-small-lymphocytic-lymphoma--astrazeneca/2022-12-29T14:56:05+00:00weekly0.6https://www.medthority.com/news/2022/12/imfinzi--imjudo-approved-in-japan-for-advanced-liver-and-non-small-cell-lung-cancers-and-imfinzi-approved-for-unresectable-biliary-tract-and-liver-cancers.--astrazeneca2022-12-29T15:00:08+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-confirms-issue-of-refusal-to-file-letter-for-roluperidone-nda-for-negative-symptoms-in-patients-with-schizophrenia.--minerva-neurosciences2022-12-29T15:06:48+00:00weekly0.6https://www.medthority.com/news/2022/12/submission-of-nda-to-fda-completed-for-pf-03084014-in-desmoid-tumors.--springworks-therapeutics2022-12-30T12:03:13+00:00weekly0.6https://www.medthority.com/news/2022/12/fda-accepts-application-for-bla-for-menabcwy-vaccine-for-meningococcal-disease.--pfizer2022-12-30T12:01:47+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-benegene-2-study-of-pf-06838435-meets-primary-endpoint-in-haemophilia-b.--pfizer2022-12-30T11:57:59+00:00weekly0.6https://www.medthority.com/news/2022/12/phase-iii-trial-of-vv-116-in-covid-19-published-in-nejm.--shanghai-junshi-biosciences2022-12-30T11:55:19+00:00weekly0.6https://www.medthority.com/news/2022/12/rain-therapeutics-becomes-rain-oncology/2022-12-30T11:52:57+00:00weekly0.6https://www.medthority.com/news/2023/1/ema-validates-maa-for-trodelvy--for-pre-treated-hrher2--metastatic-breast-cancer.--gilead-sciences-inc2023-01-04T13:35:07+00:00weekly0.6https://www.medthority.com/news/2023/1/niceuk-recommends-keytruda--chemotherapy-for-neoadjuvant-treatment-and-then-as-monotherapy-after-surgery-for-triple-negative-breast-cancer.--merck-nc2023-01-04T13:37:07+00:00weekly0.6https://www.medthority.com/news/2023/1/ema-validates-application-for-extension-of-indication-for-voxzogo--for-injection-to-treat-children-with-achondroplasia-under-the-age-of-2.--biomarin-pharma2023-01-04T13:38:23+00:00weekly0.6https://www.medthority.com/news/2023/1/jnj-64407564-filed-with-eu-for-multiple-myeloma.--janssen-pharma2023-01-04T13:39:37+00:00weekly0.6https://www.medthority.com/news/2023/1/first-patient-enrolled-in-phase-iii-trial-evaluating-abelacimab-in-high-risk-patients-with-atrial-fibrillation-deemed-unsuitable-for-current-anticoagulants.--anthos-therapeutics2023-01-04T13:41:14+00:00weekly0.6https://www.medthority.com/news/2023/1/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies/2023-01-04T13:45:48+00:00weekly0.6https://www.medthority.com/news/2023/1/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies2/2023-01-04T13:50:14+00:00weekly0.6https://www.medthority.com/news/2023/1/ck-301-filed-with-fda-for-cutaneous-squamous-cell-carcinoma.--checkpoint-therapeutics2023-01-05T12:23:14+00:00weekly0.6https://www.medthority.com/news/2023/1/results-from-phase-iii-gobi-trial-for-nov-03-in-dry-eye-disease-published-in-opthalmology.--bausch--lomb-corp-and-novaliq2023-01-05T12:25:28+00:00weekly0.6https://www.medthority.com/news/2023/1/ema-validates-type-ii-variation-application-for-enhertu-in-non-small-cell-lung-cancer.--daiichi-sankyo2023-01-05T12:27:22+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-interim-results-from-mitazalimab-optimize-1-phase-ii-trial-in-pancreatic-cancer-exceeding-50-objective-response-rate.---alligator-bioscience2023-01-05T12:28:43+00:00weekly0.6https://www.medthority.com/news/2023/1/alligator-bioscience-and-orion-corporation-announce-the-initiation-of-the-second-program----of-their-immuno-oncology-research-collaboration-relating-to-bispecific-antibodies/2023-01-05T12:21:55+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-grants-priority-review-for--glofitamab-to-treat-large-b-cell-lymphoma-and-pdufa-date-is-expected-on-1-july-2023--genentechroche/2023-01-07T13:39:30+00:00weekly0.6https://www.medthority.com/news/2023/1/nda-submitted-to-the-fda-for-berdazimer-gel-10.3-for-the-treatment-of-molluscum-contagiosum.--novan-inc2023-01-07T13:38:51+00:00weekly0.6https://www.medthority.com/news/2023/1/inventiva-announces-changes-to-the-clinical-development-of-lanifibranor-including-plans-for-a-new-phase-iii-trial-in-patients-with-nash-and-compensated-cirrhosis/2023-01-07T13:37:54+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-gives-priority-review-to-sbla-for-20vpnc-in-pneumococcal-disease.--pfizer2023-01-07T13:37:10+00:00weekly0.6https://www.medthority.com/news/2023/1/accelerated-approval-from-fda-for-leqembi-to-treat-alzheimers-disease.--eisai--biogen2023-01-07T13:36:22+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-grants-accelerated-approval-for-lecanemab-irm-for-the-treatment-of-alzheimers-disease.--eisai--biogen-inc2023-01-07T13:35:39+00:00weekly0.6https://www.medthority.com/news/2023/1/new-data-from-phase-iii-maestro-nash-biopsy-clinical-trial-of-mgl-3196-in-nash-with-liver-fibrosis-presented-at-nash-tag-conference.--madrigal-pharma2023-01-07T13:34:57+00:00weekly0.6https://www.medthority.com/news/2023/1/eisai-submits-sbla-to-the-fda-for-traditional-approval-of-leqembi-for-the-treatment-of-alzheimers-disease/2023-01-08T12:45:10+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-acceptance-and-priority-review-of-snda-for-brexpiprazole-for-the-treatment-of-agitation-associated-with-alzheimers-dementia.--lundbeck--otsuka-pharma2023-01-08T12:43:54+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-reviewing-sbla-for-daxxify-in-cervical-dystonia.--revance-therapeutics2023-01-08T12:43:05+00:00weekly0.6https://www.medthority.com/news/2023/1/cytomx-and-moderna-announce-strategic-research-collaboration-for-mrna-based-conditionally-activated-therapeutics/2025-10-17T09:13:43+00:00weekly0.6https://www.medthority.com/news/2023/1/eiasis-approach-to-us-pricing-for-leqembi-a-treatment-for-early-alzheimers-disease/2025-02-03T14:18:07+00:00weekly0.6https://www.medthority.com/news/2023/1/forxiga-label-update-from-mhlw-japan-to-allow-use-for-chronic-heart-failure-irrespective-of-left-ventricular-ejection-fraction.-astrazeneca--ono-pharma2023-01-12T11:17:12+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-acceptance-of-nda-response-for-dehydrated-alcohol-injection-to-treatmethanol-poisoning.--eton-pharma2023-01-12T11:15:51+00:00weekly0.6https://www.medthority.com/news/2023/1/airsupra-pt-027-approved-in-the-us-for-asthma.--astrazeneca2023-01-12T11:13:32+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability.--glaukos-corporation2023-01-12T11:11:08+00:00weekly0.6https://www.medthority.com/news/2023/1/european-commission-approval-of-xofluza-for-the-treatment-and-prevention-of-influenza-in-children-aged-one-year-and-above.--roche-2023-01-12T11:08:57+00:00weekly0.6https://www.medthority.com/news/2023/1/top-line-negative-results-from-phase-iii-trial-of--ormd-0801-for-the-treatment-of-type-2-diabetes.--oramed-pharma2023-01-12T11:04:47+00:00weekly0.6https://www.medthority.com/news/2023/1/market-registration-plans-submitted-to-ema-for-cf-101-in-psoriasis.--can-fite-biopharma2023-01-11T11:36:51+00:00weekly0.6https://www.medthority.com/news/2023/1/maa-submitted-to-ema-for-lecanemab-as-a-treatment-for-early-alzheimers-disease.--eisai--biogen2023-01-11T11:33:47+00:00weekly0.6https://www.medthority.com/news/2023/1/chiesi-farmaceutici-s.p.a-to-acquire-amryt-pharma-and-with-it-filsuvez2023-01-11T11:28:55+00:00weekly0.6https://www.medthority.com/news/2023/1/helsinn-publishes-results-from-a-secondary-analysis-of-a-phase-iii-trial-of-oral-or-i.v.-nepa-in-patients-with-cinv-in-the-oncologist2023-01-07T13:45:33+00:00weekly0.6https://www.medthority.com/news/2023/1/nirsevimab-regulatory-submission-accepted-by-fda-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants-and-children-up-to-age-24-months-.--astrazeneca--sanofi2023-01-07T13:44:42+00:00weekly0.6https://www.medthority.com/news/2023/1/positive-top-line-results-from-phase-iii-pediatric-trial-of-lomitapide-in-hofh.--amryt2023-01-07T13:43:52+00:00weekly0.6https://www.medthority.com/news/2023/1/new-harris-poll-reveals-significant-gaps-in-womens-knowledge-about-cervical-cancer.--bd-becton-dickinson-and-company2023-01-07T13:42:59+00:00weekly0.6https://www.medthority.com/news/2023/1/tuv-sud-issues-the-first-ivdr--certificate-for-an-ivdr-companion-diagnostic-cdx-from-roche-diagnostics/2023-01-07T13:42:06+00:00weekly0.6https://www.medthority.com/news/2023/1/phase-iii-study-of-tak-755-shows-efficacy-and-safety-in-congenital-thrombotic-thrombocytopenic-purpura.--takeda2023-01-07T13:41:14+00:00weekly0.6https://www.medthority.com/news/2023/1/pivotal-lunar-study-of-tumor-treating-fields-in-non-small-cell-lung-cancer-met-primary-overall-survival-endpoint.--zai-lab--novocure-inc2023-01-07T13:40:24+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-accepts-nda-for-vamorolone-in-duchenne-muscular-dystrophy.--santhera-pharmaceuticals--reveragen-biopharma-inc2023-01-11T12:12:02+00:00weekly0.6https://www.medthority.com/news/2023/1/ipsen-to-acquire-albireo-and-with-it-bylvay/2023-01-11T12:09:55+00:00weekly0.6https://www.medthority.com/news/2023/1/abbvie-and-immunome-anounce-strategic-collaboration-to-discover-multiple-novel--oncology-targets/2023-01-11T12:07:36+00:00weekly0.6https://www.medthority.com/news/2023/1/neurocrine-biosciences-and-voyager-therapeutics-collaborate-to-advance-multiple-gene-therapies-for-the-treatment-of-neurological-diseases/2023-01-11T11:56:42+00:00weekly0.6https://www.medthority.com/news/2023/1/askbio-announces-strategic-collaboration-with-recode-therapeutics-to-explore-single-vector-gene-editing-platform/2023-01-11T11:46:39+00:00weekly0.6https://www.medthority.com/news/2023/1/astrazeneca-to-acquire-cincor-pharma-inc.and-with-it-baxdrostat-for-resistant-hypertension2023-01-11T11:44:09+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-accepts-nda-for-mydcombi-ophthalmic-spray-for-in-office-pupil-dilation-mydriasis.--eyenovia2023-01-13T12:33:51+00:00weekly0.6https://www.medthority.com/news/2023/1/new-administration-option-for--tezspire-first-and-only-severe-asthma-biologic-approved-in-theeu-with-no-phenotype-or-biomarker-limitations.--astrazeneca-2023-01-14T13:45:37+00:00weekly0.6https://www.medthority.com/news/2023/1/astrazeneca-to-discontinue-selling-lumoxiti-in-the-us-due-to-low-clinical-uptake/2023-01-14T13:44:41+00:00weekly0.6https://www.medthority.com/news/2023/1/fda-updates-label-for-rybelsus-for-type-2-diabetes-patients.--novo-nordisk2023-01-14T13:43:52+00:00weekly0.6https://www.medthority.com/news/2023/1/new-phase-ii-long-term-data-showing-sustained-efficacy-and-clearance-for-a-median-of-10-months-with-roflumilast-cream-in-adults-with-chronic-plaque-psoriasis.--arcutis-biotherapeutics2023-01-15T12:13:39+00:00weekly0.6https://www.medthority.com/news/2023/1/results-of-phase-ib-equate-study-of-alzumab-in-acute-graft-versus-host-disease-presented-at-transplantation--cellular-therapy-meeting.--equillium-2023-01-16T12:26:39+00:00weekly0.6https://www.medthority.com/news/2024/6/alvotech-and-stada-add-to-strategic-alliance-through-denosumab-partnership/2024-06-12T12:19:57+00:00weekly0.6https://www.medthority.com/news/2024/6/kevzara--sarilumab-approved-by-fda-for-the-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis-pjia.--regeneron--sanofi2024-06-12T12:21:42+00:00weekly0.6https://www.medthority.com/news/2024/6/moderna-announces-positive-phase-iii-data-for-combination-vaccine-against-influenza-and-covid-19/2024-06-12T12:23:15+00:00weekly0.6https://www.medthority.com/news/2024/6/first-presentations-of-bimzelx-bimekizumab-two-year-data-in-axial-spondyloarthritis-and-psoriatic-arthritis-at-eular-2024.--ucb2024-06-12T12:24:59+00:00weekly0.6https://www.medthority.com/news/2024/6/merck-inc.-update-to-oncology-pipeline2024-06-12T12:07:19+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-accepts-filing-of-leqembi-lecanemab-irmb-supplemental-biologics-license-application-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimerdisease-.eisai--biogen2024-06-11T11:35:43+00:00weekly0.6https://www.medthority.com/news/2024/6/safety-and-efficacy-profile-of-lupkynis-voclosporin-for-people-with-lupus-nephritis-presented-at-europeanalliance-of-associations-for-rheumatology-congress-eular.-aurinia-pharma2024-06-11T11:38:24+00:00weekly0.6https://www.medthority.com/news/2024/6/iqirvo-elafibranor-receives-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis.-ipsen2024-06-11T11:40:25+00:00weekly0.6https://www.medthority.com/news/2024/6/sarclisa-is-first-anti-cd38-to-significantly-improve-progression-free-survival-in-combination-with-vrd-for-newly-diagnosed-transplant-ineligible-multiple-myeloma-in-phase-iii--sanofi/2024-06-11T11:43:05+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-advisory-committee-recommended-that--anti-amyloid-donanemab-is-effective-for-the-treatment-of-patients-with-early-symptomatic-alzheimers-disease.--eli-lilly2024-06-11T11:45:00+00:00weekly0.6https://www.medthority.com/news/2024/6/complete-response-letter-for-nd-0612--for-treatment-of-motor-fluctuations-in-people-with-parkinsons-disease.--mitsubishi-tanabe--neuroderm-ltd.-2024-06-14T11:28:05+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-augtyro-repotrectinib-a-next-generation-tyrosine-kinase-inhibitor-tki-for-the-treatment-of-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumors.--bms2024-06-14T11:31:40+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-phase-iii-efficacy-data-for-mrna-1283-the-next-generation-covid-19-vaccine.--moderna2024-06-14T11:34:15+00:00weekly0.6https://www.medthority.com/news/2024/6/ultragenyx-announces-plans-to-file-for-accelerated-approval-of-ux-111gene-therapy-for-the-treatment-of-sanfilippo-syndrome-type-a-mps-iiia/2024-06-14T11:38:22+00:00weekly0.6https://www.medthority.com/news/2024/6/abbvie-licences-fg-m701-from-futuregen-biopharmaceutical-beijingco.-ltd2024-06-14T11:41:47+00:00weekly0.6https://www.medthority.com/news/2024/6/vanda-receives-offer-from-future-pak-llc/2024-06-14T11:46:53+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-blincyto-blinatumomab-for-treatment-of-adult-and-pediatric-patients-one-month-or-older-with-cd19-positive-philadelphia-chromosome-negative-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-in-the-consolidation-phase.--amgen2024-06-15T12:19:19+00:00weekly0.6https://www.medthority.com/news/2024/6/findings-from-landmark-resonate-2-study-confirm-sustained-survival-benefit-of-imbruvica-ibrutinib-for-first-line-chronic-lymphocytic-leukaemia-treatment-with-up-to-10-years-follow-up.-janssen-cilag-jj2024-06-16T14:28:16+00:00weekly0.6https://www.medthority.com/news/2024/6/510k-fda-clearance-of-the-velys-robotic-assisted-solution-for-use-in-unicompartmental-knee-athroplasty-procedures--depuy-synthes-jj/2024-06-16T14:27:12+00:00weekly0.6https://www.medthority.com/news/2024/6/phase-ii-starglo-study-demonstrates-columvi-glofitamab-significantly-extends-survival-in-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.--roche2024-06-16T14:26:20+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-results-from-phase-iii-energize-study-of-mitapivat-in-non-transfusion-dependent-thalassemia-in-plenary-session-at-the-european-hematology-association-2024-hybrid-congress.--agios-pharma2024-06-16T14:23:44+00:00weekly0.6https://www.medthority.com/news/2024/6/calquence--chemoimmunotherapy-reduced-the-risk-of-disease-progression-or-death-by-27-vs.-standard-of-care-in-patients-with-untreated-mantle-cell-lymphoma-in-echo-phase-iii-trial.--astrazeneca2024-06-17T11:12:01+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-grants-full--approval-to-selpercatinib-for-ret-thyroid-cancer--eli-lilly/2024-06-17T11:13:43+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-infinzi-durvalumab--chemotherapy-to-treat-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer-that-is-mismatch-repair-deficient--astrazeneca/2024-06-18T11:50:42+00:00weekly0.6https://www.medthority.com/news/2024/6/poster-of-tonmya-sublingual-cyclobenzaprine-hcl-for-the-management-of-fibromyalgia-presented-at-the-annual-european-congress-of-rheumatology-eular-2024.--tonix-pharma2025-08-20T12:10:51+00:00weekly0.6https://www.medthority.com/news/2024/6/completion-of-bla-rolling-submission-to-fda-for-chikv-vlp-vaccine-candidate-for-immunization-against-chikungunya-virus-infection.--bavarian-nordic2024-06-18T11:46:23+00:00weekly0.6https://www.medthority.com/news/2024/6/phase-iii-topline-results-for-soticlestat-tak-935-in-patients-with-dravet-syndrome-and-lennox-gastaut-syndrome.-takeda2024-06-18T11:44:41+00:00weekly0.6https://www.medthority.com/news/2024/6/subcutaneous-amivantamab-bla-submitted-to--fda-for-patients-with-egfr-mutated-non-small-cell-lung-cancer.-johnson--johnson2024-06-18T11:42:52+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves--keytruda-pembrolizumab-plus-carboplatin-and-paclitaxel-as-treatment-for-adult-patients-with-primary-advanced-or-recurrent-endometrial-carcinoma.--merck-inc2024-06-18T11:39:14+00:00weekly0.6https://www.medthority.com/news/2024/6/long-term-data-reported-from-phase-iii-monuental-1-study--of-talvey-talquetamab-in-rr-multiple-myeloma---johnson--johnson/2024-06-18T11:37:24+00:00weekly0.6https://www.medthority.com/news/2024/6/new-clinical-research-and-real-world-evidence-for-yescarta-axicabtagene-ciloleucel-axi-cel-demonstrate-benefit-from-earlier-lines-of-treatment.--kitegilead2024-06-18T11:34:56+00:00weekly0.6https://www.medthority.com/news/2024/6/update-on-the-capitello-290-phase-iii-trial-for-truqap--chemotherapy-in-advanced-or-metastatic-triple-negative-breast-cancer.--astrazeneca2024-06-18T11:28:35+00:00weekly0.6https://www.medthority.com/news/2024/6/elahere-mirvetuximab-soravtansine-meets-primary-end-point-of-piccolo-trial-in-fr-alpha-high-platinum-sensitive-ovarian-cancer--abbvie/2024-06-10T11:26:22+00:00weekly0.6https://www.medthority.com/news/2024/6/roche-four-in-one-molecular-test-for-sars-cov-2-influenza-ab-viruses-and-rsv-receives--fda-emergency-use-authorization.--roche2024-06-10T11:28:02+00:00weekly0.6https://www.medthority.com/news/2024/6/global-experts-release-new-guidelines-on-prevention-of-progression-of-epileptic-seizures-addressing-critical-treatment-gaps.--ucb2024-06-10T11:29:30+00:00weekly0.6https://www.medthority.com/news/2024/6/european-commission-approves-alecensa-alectinib-as-the-first-and-only-targeted-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cancer.--roche.-2024-06-10T11:31:23+00:00weekly0.6https://www.medthority.com/news/2024/6/santhera-announces-launch-of-early-access-program-in-china-for-agamree-by-its-partner-sperogenix/2024-06-10T11:33:43+00:00weekly0.6https://www.medthority.com/news/2024/6/tagrisso-granted-priority-review-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer.---astrazeneca2024-06-10T11:35:47+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-klisyri-tirbanibulin-for-the-treatment-of-actinic-keratosis-on-expanded-area-of-face-or-scalp-up-to-100-cm.--almirall2024-06-10T11:39:09+00:00weekly0.6https://www.medthority.com/news/2024/5/datopotamab-deruxtecan-showed-clinically-meaningful-overall-survival-improvement-vs.-chemotherapy-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial.-daichi-sankyo--astrazeneca2024-05-28T11:46:47+00:00weekly0.6https://www.medthority.com/news/2024/5/atrasentan-phase-iii-data-show-clinically-meaningful-proteinuria-reduction-further-advancing-companys-iga-nephropathy-igan-portfolio.--novartis2024-05-28T11:45:46+00:00weekly0.6https://www.medthority.com/news/2024/5/phase-iii-fabhalta-iptacopan-data-in-c3-glomerulopathy-c3g-showing-clinically-meaningful-and-statistically-significant-35.1-proteinuria-reduction-vs.-placebo--novartis2024-05-28T11:44:56+00:00weekly0.6https://www.medthority.com/news/2024/5/viltolarsen-ns-065ncnp-01-for-the-treatment-of-duchenne-muscular-dystrophy.-preliminary-results-of-the-analysis-of-the-phase-iii-trial-racer53-study.-nipppon-shinyaku2024-05-28T11:44:01+00:00weekly0.6https://www.medthority.com/news/2024/5/initiation-of-a-rolling-submission-of-nda-to-fda-seeking-accelerated-approval-of-avutometinib-and-defactinib-combination-for-the-treatment-of-adult-patients-with-recurrent-kras-mutant-low-grade-serous-ovarian-cancer.--verastem-oncology.-2024-05-29T12:53:36+00:00weekly0.6https://www.medthority.com/news/2024/5/first-in-class-cholesterol-lowering-treatment-nilemdo-nexletol-in-the-u.s.-and-its-combination-with-ezetimibe-nustendi-nexlizet-in-the-u.s.-approved-in-europe-to-treat-hypercholesterolemia-and-reduce-cardiovascular-risk.--daiichi-sankyo--esperion-2024-05-29T12:57:38+00:00weekly0.6https://www.medthority.com/news/2024/5/positive-topline-results-from-landmark-aspen-study-of-brensocatib-in-patients-with-bronchiectasis..--insmed-inc2024-05-29T13:00:25+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-grants-priority-review-to--inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation.-genentechroche-2024-05-29T13:03:08+00:00weekly0.6https://www.medthority.com/news/2024/5/johnson--johnson-acquires-from-numab-therapeutics-nm-26-a-bispecific-antibody-to-treat-atopic-dermatitis/2024-05-29T13:05:41+00:00weekly0.6https://www.medthority.com/news/2024/5/primary-endpoint-met-in-pivotal-phase-iii-grace-trial-of-relacorilant-in-patients-with-hypercortisolism-cushings-syndrome.--corcept-therapeutics2024-05-30T14:35:19+00:00weekly0.6https://www.medthority.com/news/2024/5/pivotal-study-of-seltorexant-shows-statistically-significant-and-clinically-meaningful-improvement-in-depressive-symptoms-and-sleep-disturbance-outcomes.--jj2024-05-30T14:37:01+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approves-bkemv-the-first-interchangeable-biosimilar-to-soliris-eculizumab-to-treat-certain-rare-diseases.--amgen2024-05-30T14:38:19+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-grants-priority-review-to-application-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-of-patients-with-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma.-merck-inc2024-05-30T14:48:46+00:00weekly0.6https://www.medthority.com/news/2024/5/merck-inc.-to-acquire-eye-bio-and-with-it-restoret-eye-102-to-treat-retinal-vascular-leakage2024-05-30T14:50:17+00:00weekly0.6https://www.medthority.com/news/2024/5/asahi-kasei-will-acquire-calliditas-therapeutics-and-with-it-tarpeyo--a-treatment-for-primary-immunoglobulin-a-nephropathy/2024-05-30T14:51:03+00:00weekly0.6https://www.medthority.com/news/2024/5/the-fda-has-approved-onyda-xr-clonidine-hydrochloride-a-once-a-day-extended-release-oral-suspension-with-nighttime-dosing-for-the-treatment-of-adhd-.--tris-pharma2024-05-31T13:36:50+00:00weekly0.6https://www.medthority.com/news/2024/5/chmp-recommends-dupixent-dupilumab--to-treat-uncontrolled-chronic-obstructive-pulmonary-disease-copd-.--regeneron--sanofi2024-05-31T13:39:37+00:00weekly0.6https://www.medthority.com/news/2024/5/update-on-fda-priority-review-of-dupixent-dupilumab-for-the-treatment-of-copd-patients-with-type-2-inflammation.--regeneron--sanofi2024-05-31T13:42:52+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive--opinion-for-two-320-mg-device-presentations-of-bimzelx-bimekizumab.--ucb2024-06-01T14:48:21+00:00weekly0.6https://www.medthority.com/news/2024/6/ivonescimab-monotherapy-decisively-beats-pembrolizumab-monotherapy-head-to-head-achieves-statistically-significant-superiority-in-pfs-in-first-line-treatment-of-patients-with-pd-l1-positive-nsclc-in-china-.-summit-therapeutics---akeso2024-06-01T14:47:20+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-breyanzi-lisocabtagene-maraleucel-liso-cel-as-a-new-car-t-cell-therapy-for-relapsed-or-refractory-mantle-cell-lymphoma.--bms2024-06-01T14:46:13+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-opinion-for-livmarli-maralixibat-oral-solution-for-the-treatment-of-progressive-familial-intrahepatic-cholestasis-in-patients-three-months-of-age-and-older--mirum-pharma/2024-06-01T14:45:03+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-results-from-oasis-hae-and-oasisplus-studies-of-investigational-medicine-donidalorsen-in-patients-with-hereditary-angioedema.--ionis-pharma2024-06-01T14:43:09+00:00weekly0.6https://www.medthority.com/news/2024/6/lorbrena-lorlatinib-crown-study-shows-majority-of-patients-with-alk-positive-advanced-lung-cancer-living-beyond-five-years-without-disease-progression.--pfizer2024-06-01T14:36:17+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-mresvia-mrna-1345-an-mrna-respiratory-syncytial-virus-rsv-vaccine-to-protect-adults-aged-60-years-and-older-from-lower-respiratory-tract-disease-caused-by-rsv-infection.--moderna-inc2024-06-01T14:35:30+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for--akantior-polihexanide-for-the-treatment-of-acanthamoeba-keratitis.--sifi-spa2024-06-02T14:53:15+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-cejemly-sugemalimab--chemotherapy-for-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-nsclc.--sfl-pharmaceuticals-deutschland-gmbh.-2024-06-02T14:50:43+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-durveqtix-fidanacogene-elaparvovec-to-treat-haemophilia-b.--pfizer2024-06-02T14:49:16+00:00weekly0.6https://www.medthority.com/news/2024/6/first-results-from-late-breaking-phase-iii-paloma-3-study-show-five-fold-reduction-in-infusion-related-reactions-with-five-minute-subcutaneous-amivantamab-administration..--johnson--johnson2024-06-02T14:47:07+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-grants-accelerated-approval-to-selpercatinib-for-pediatric-patients-two-years-and-older-with-ret-altered-metastatic-thyroid-cancer-or-solid-tumors.--eli-lilly2024-06-02T14:45:46+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-galliapharm-a-radionuclide-generator.--eckert--ziegler-radiopharm-gmbh2024-06-02T14:44:13+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-ixchiq-a-chikungunya-vaccine.-valneva-se2024-06-02T14:41:17+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation--for-dasiglucagon-for-treatment-of-severe-hypoglycemia-in-diabetes-.--zealand-pharma-as--novo-nordisk2024-06-02T14:39:29+00:00weekly0.6https://www.medthority.com/news/2024/6/krazati-adagrasib-demonstrated-statistically-significant-improvement-in-progression-free-survival-in-patients-with-pretreated-locally-advanced-or-metastatic-krasg12c-mutated-non-small-cell-lung-cancer.--bms2024-06-02T14:37:47+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-avzivi--bevacizumab-biosimilar.--fgk-representative-service2024-06-04T10:58:58+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation-for-eliquis-apixaban-to-treat-venous-thromboembolism-vte-and-prevention-of-recurrent-vte-in-children.--bms--pfizer2024-09-30T12:08:32+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation--for-kinpeygo-budesonide-enteric-formulation-for-the-treatment-of-adults-with-primary-immunoglobulin-a-nephropathy-igan.--calliditas--stada-arzneimittel-ag2024-06-04T11:04:34+00:00weekly0.6https://www.medthority.com/news/2024/6/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial-reducing-the-risk-of-death-by-27-vs.-placebo.--astrazeneca2024-06-04T11:09:34+00:00weekly0.6https://www.medthority.com/news/2024/6/destiny-breast06-results-show-enhertu-trastuzumab-deruxtecan-is-the-first-her2-directed-medicine-and-adc-to-demonstrate-clinically-meaningful-benefit-for-patients-in-with-hr-positive-her2-low-metastatic-breast-cancer-.--daiichi-sankyo--astrazeneca2024-06-04T11:13:36+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-recommendation--for-skyrizi-risankizumab-to-treat-ulcerative-colitis-.--abbvie2024-06-04T11:16:13+00:00weekly0.6https://www.medthority.com/news/2024/6/preliminary-analysis-of-data-evaluating-investigational-epcoritamab-duobody-cd3xcd20-combination-demonstrates-95-overall-response-rate-in-patients-with-previously-untreated-follicular-lymphoma.--genmab-as--abbvie2024-06-04T11:18:03+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-tagrisso--osimertinib--chemotherapy-for-1st-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-egfrm--non-small-cell-lung-cancer--whose-tumours-have-exon-19-deletions-or-exon-21-mutations.--astrazeneca2024-06-04T11:20:28+00:00weekly0.6https://www.medthority.com/news/2024/6/anti-tigit-domvanalimab---zimberelimab-and-chemotherapy-exceeded-one-year-of-median-progression-free-survival-as-a-first-line-treatment-for-upper-gi-cancers.--gilead--arcus-biosciences2024-06-04T11:22:45+00:00weekly0.6https://www.medthority.com/news/2024/6/tagrisso-osimertinib-reduced-the-risk-of-disease-progression-or-death-by-84-in-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer-vs.-placebo-in-laura-phase-iii-trial.--astrazeneca2024-06-04T11:24:27+00:00weekly0.6https://www.medthority.com/news/2024/6/blenrep--belantamab-mafodotin-combination-reduced-the-risk-of-disease-progression-or-death-by-nearly-50-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma.-2024-06-04T11:26:27+00:00weekly0.6https://www.medthority.com/news/2024/6/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results-with-no-evidence-of-disease-in-100-of-patients-with-locally-advanced-mismatch-repair-deficient-dmmr-rectal-cancer.--gsk2024-06-04T11:31:09+00:00weekly0.6https://www.medthority.com/news/2024/6/supplementary-approval-for-firdapse-amifampridine-for-the-treatment-of-lambert-eaton-myasthenic-syndrome-.--catalyst-pharma2024-06-05T11:08:53+00:00weekly0.6https://www.medthority.com/news/2024/6/european-commission-approves-qalsodytofersen-to-treat-adults-with-amyotrophic-lateral-sclerosis-at-adults-with-amyotrophic-lateral-sclerosis-als-linked-to-a-mutation-in-the-superoxide-dismutase-1-gene-sod1-als..biogen2024-06-05T11:11:37+00:00weekly0.6https://www.medthority.com/news/2024/6/european-commission-approves--opdivo-nivolumab-in-combination-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma-.-bms2024-06-05T11:13:47+00:00weekly0.6https://www.medthority.com/news/2024/6/austedo-xrdeutetrabenazine-extended-release-tablets-are-fda-approved-as-a-one-pill-once-daily-treatment-option-for-clinically-therapeutic-doses-2448-mgday.--teva2024-06-05T11:18:44+00:00weekly0.6https://www.medthority.com/news/2024/6/european-commission--authorization-for-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd.--outlook-therapeutics2024-06-05T11:00:24+00:00weekly0.6https://www.medthority.com/news/2024/6/update-on-fda-advisory-committee-meeting-for-investigational-mdma-assisted-therapy-for-ptsd--lykos-therapeutics/2024-06-05T11:23:13+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-topline-results-from-pivotal-phase-iii-trial-for-first-in-class-c1q-blocking-antibody-anx-005-in-guillain--barre-syndrome.--annexon-inc2024-06-05T11:26:35+00:00weekly0.6https://www.medthority.com/news/2024/6/opdivo-nivolumab--yervoy-ipilimumab-significantly-improved-overall-survival-compared-to-lenvatinib-or-sorafenib-as-first-line-treatment-for-patients-with-advanced-hepatocellular-carcinoma-in-checkmate--9dw-trial.--bms2024-06-05T11:29:21+00:00weekly0.6https://www.medthority.com/news/2024/6/breyanzi-lisocabtagene-maraleucel-liso-cel-demonstrates-clinically-meaningful-outcomes-across-a-broad-range-of-b-cell-malignancies-in-new-data-presented-at-2024-asco-annual-meeting.--bms2024-06-05T11:31:48+00:00weekly0.6https://www.medthority.com/news/2024/6/spexis-ag-appeals-against-trading-suspension/2024-06-05T11:40:42+00:00weekly0.6https://www.medthority.com/news/2024/6/seladelpar-demonstrated-a-sustained-and-consistent-long-term-efficacy-and-safety-profile-in-primary-biliary-cholangitis.--gilead-sciences2024-06-06T13:07:42+00:00weekly0.6https://www.medthority.com/news/2024/6/johnson--johnson-submits-new-drug-application-to-fda-seeking-expand-pediatric-indication-for-hiv-1-therapy-prezcobix/2024-06-06T13:02:29+00:00weekly0.6https://www.medthority.com/news/2024/6/carvykti-ciltacabtagene-autoleucel-significantly-improved-progression-free-survival-and-deepened-responses-versus-two-standard-therapies-for-patients-with-functional-high-risk-multiple-myeloma.--johnson--johnson-2024-06-06T13:03:48+00:00weekly0.6https://www.medthority.com/news/2024/6/start-of-multiple-myeloma-phase-iii--clinical-trial-for-investigational-asset-abbv-383.--abbvie2024-06-06T13:05:34+00:00weekly0.6https://www.medthority.com/news/2024/6/moderna--merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-showed--sustained-improvement-in-recurrence-free-survival-versus-keytruda-in--high-risk-stage-iiiiv-melanoma-following-complete-resection/2024-06-06T13:07:07+00:00weekly0.6https://www.medthority.com/news/2024/6/seres-therapeutics-sells--microbiome-pill-vowst-to-nestle-health-science/2024-06-07T12:06:02+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-topline-phase-iii-results-for-uplizna-inebilizumab-cdon-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd.--amgen2024-06-07T12:05:39+00:00weekly0.6https://www.medthority.com/news/2024/6/gsk-acquires-elsie-biotechnologies/2024-06-07T12:07:19+00:00weekly0.6https://www.medthority.com/news/2024/6/unsolicited-offer-for-vanda-from-cycle-group-holdings/2024-06-07T12:08:46+00:00weekly0.6https://www.medthority.com/news/2024/6/survodutide-shows-breakthrough-improvement-in-liver-fibrosis-with-no-worsening-of-mash-in-64.5-of-patients-with-f2-and-f3-fibrosis.--boehringer--zealand--pharma2024-06-08T12:18:34+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approval-of-rytelo-imetelstat-a-first-in-class-telomerase-inhibitor-for-the-treatment-of-adult-patients-with-lower-risk-mds-with-transfusion-dependent-anemia.--geron-corporation2024-06-08T12:17:43+00:00weekly0.6https://www.medthority.com/news/2024/6/-ce-mark-for-aveir-dr--the-worlds-fist-dual-chamber-leadless-pacemaker-system.--abbott2024-09-30T10:40:21+00:00weekly0.6https://www.medthority.com/news/2024/6/new-data-at-the-european-cystic-fibrosis-conference-demonstrating-significant-benefits-of-treatment-with-trikaftaelexacaftortezacaftorivacaftor-and-ivacaftor.--vertex2024-06-09T12:29:52+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-expanded-age-indication-for-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk--gsk/2024-06-09T12:24:02+00:00weekly0.6https://www.medthority.com/news/2024/6/five-year-data-for-evrysdi-risdiplam-show-the-majority-of-treated-children-with-a-severe-form-of-spinal-muscular-atrophy-sma-achieved-or-maintained-the-ability-to-sit-stand-or-walk.-genentechroche2024-06-09T12:23:19+00:00weekly0.6https://www.medthority.com/news/2024/6/moderna-files-fda-application-for-the-jn.1-targeting-covid-19-vaccine2024-06-09T12:22:00+00:00weekly0.6https://www.medthority.com/news/2024/5/nmpa-china-approval-for-xacduro-sulbactam-durlobactam-or-sul-dur-for-hospital-acquired-and-ventilator-associated-pneumonia-caused-by-acinetobacter-baumannii-calcoaceticus-complex-in-china.---zai-lab--innoviva2024-05-21T12:45:30+00:00weekly0.6https://www.medthority.com/news/2024/5/new-data-presented-at-ats-2024-show-the-potential-of-tezspire--tezepelumab-ekko-to-help-patients-living-with-copd.--amgen--astrazeneca2024-05-21T12:43:19+00:00weekly0.6https://www.medthority.com/news/2024/5/simlandi-adalimumab-ryvk-is-available-in-the-usa--as-an-interchangeable-biosimilar-to-humira.teva--alvotech2024-05-21T12:43:47+00:00weekly0.6https://www.medthority.com/news/2024/5/tremfya-guselkumab-quasar-maintenance-study-in-uc-met-its-primary-endpoint-and-all-major-secondary-endpoints-including-highly-statistically-significant-rates-of-endoscopic-remission.--johnson--johnson2024-05-21T12:38:08+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-grants-breakthrough-therapy-designation-to-inavolisib-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation.--genentechroche2024-05-21T12:35:24+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approves-trastuzumab-strf-for-her2-overexpressing-breast-and-gastricgej-cancer.--accord-pharmaintas--shanghai-henlius-biotech2024-06-24T09:36:43+00:00weekly0.6https://www.medthority.com/news/2024/5/completion-of-enrollment-in-phase-iii-orbit-and-cosmic-studies-evaluating-setrusumab-ux-143-for-the-treatment-of-osteogenesis-imperfecta-oi.---ultragenyx-pharma2024-05-07T10:31:13+00:00weekly0.6https://www.medthority.com/news/2024/5/astrazeneca-completes-equity-investment-in-cellectis/2024-05-07T10:28:43+00:00weekly0.6https://www.medthority.com/news/2024/5/lilly-statement-on-fda-advisory-committee-meeting-on-donanemab-for-early-symptomatic-alzheimers-disease/2025-07-01T09:00:36+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-advisory-committee-meeting-to-review-investigational-mdma-assisted-therapy-for-ptsd.--lykos-therapeutics2024-05-08T11:42:05+00:00weekly0.6https://www.medthority.com/news/2024/5/ucb-presents-final-open-label-extension-fenfluramine-data-at-international-child-neurology-congress-icnc-annual-meeting/2024-05-08T11:44:11+00:00weekly0.6https://www.medthority.com/news/2024/5/updated-action-date-by-the-fda-for-subcutaneous-nivolumab-nivolumab--hyaluronidase.--bms2024-05-22T11:00:20+00:00weekly0.6https://www.medthority.com/news/2024/5/more-than-one-half-of-patients-with-crohns-disease-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-including-patients-with-previous-biologic-failure.--eli-lilly2024-05-22T11:00:21+00:00weekly0.6https://www.medthority.com/news/2024/5/european-commission-approves-wyost---denosumab-and-jubbonti-denosumab-which-are-the-first-and-only-biosimilars-of-denosumab-in-europe-.-sandoz2024-05-22T11:00:22+00:00weekly0.6https://www.medthority.com/news/2024/5/positive-results-from-phase-iii-severe-asthma-trials-swift-1-and-swift-2-of-depemokimab.--gsk2024-05-22T11:49:26+00:00weekly0.6https://www.medthority.com/news/2024/5/gsk-to-become-a-founding-partner-of-fleming-initiative-to-fight-antimicrobial-resistance-amr/2024-05-22T11:39:36+00:00weekly0.6https://www.medthority.com/news/2024/5/affera-mapping-and-ablation-system-with-sphere-9-catheter-achieves-endpoints-for-safety-and-efficacy-providing-promising-evidence-for-the-future-of-atrial-fibrillation-treatment.--medtronic2024-09-30T11:36:08+00:00weekly0.6https://www.medthority.com/news/2024/5/dupixent-dupilumab-late-breaking-data-from-notus-confirmatory-phase-iii-trial-for-uncontrolled-copd-is--presented-at-ats-and-published-in-nejm.--regeneron--sanofi2024-05-23T11:40:30+00:00weekly0.6https://www.medthority.com/news/2024/5/dupixent--dupilumab-sbla-accepted-by-fda-for-priority-review-for-treatment-of-adolescents-with-chronic-rhinosinusitis-with-nasal-polyposis.--regeneron--sanofi2024-05-23T11:44:36+00:00weekly0.6https://www.medthority.com/news/2024/5/otsuka-to-terminate-development-of-avp-786--as-a-potential-treatment-for-agitation-associated-with-dementia-due-to-alzheimers-disease/2024-05-23T11:47:02+00:00weekly0.6https://www.medthority.com/news/2024/5/publication-in-the-lancet-is-announced-of-phase-iii-bimekizumab-trials-in-moderate-to-severe-hidradenitis-suppurativa.--ucb2024-09-30T14:56:05+00:00weekly0.6https://www.medthority.com/news/2024/5/complete-response-letter-for-camrelizumab--rivoceranib-in-unresectable-liver-cancer.---jiangsu-hengrui-pharmaceuticals--elevar-therapeutics2024-05-24T11:48:45+00:00weekly0.6https://www.medthority.com/news/2024/5/tremfya-guselkumab-demonstrates-superiority-versus-steklara-ustekinumab-in-phase-iii-crohns-disease-program.--jj2024-05-24T11:52:21+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approval-of-one-of-the-first-hpv-self-collection-solutions-in-the-u.s.-expanding-access-and-screening-options-to-help-eliminate-cervical-cancer.-roche2024-05-25T14:56:27+00:00weekly0.6https://www.medthority.com/news/2024/5/positive-data-from-phase-ii-noble-study-of-pegcetacoplan-presented-as-late-breaker-at-era-congress.--sobi--apellis-pharma2024-05-25T14:55:42+00:00weekly0.6https://www.medthority.com/news/2024/5/eclipse-study-data-demonstrating-efficacy-of-shield-blood-based-test-for-colorectal-cancer-screening-to-be-published-in-the-new-england-journal-of-medicine.-guardanthealth-inc2024-05-25T14:52:56+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-advisory-committee-panel-strongly-recommends-approval-of-shield-blood-test-for-colorectal-cancer-screening-as-a-primary-non-invasive-screening-option.--guardant-health2024-05-25T14:52:14+00:00weekly0.6https://www.medthority.com/news/2024/5/ozempic-semaglutide-injection-cut-risk-of-death-in-diabetes-patients-with-chronic-kidney-disease--reported-in-nejm.-novo-nordisk2024-05-25T14:51:08+00:00weekly0.6https://www.medthority.com/news/2024/5/european-commission-returns-translarna-opinion-to-chmp-for-re-evaluation.--ptc-therapeutics2024-05-26T16:12:22+00:00weekly0.6https://www.medthority.com/news/2024/5/calquence-acalabrutinibcombination-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-1st-line-mantle-cell-lymphoma-in-echo-phase-iii-trial--astrazeneca/2024-05-03T12:20:38+00:00weekly0.6https://www.medthority.com/news/2024/5/stenoparib-shows-clear-clinical-benefit-and-achieves-significant-milestone-with-early-conclusion-of-phase-ii-trial-in-advanced-ovarian-cancer.--allarity-therapeutics2024-05-03T12:23:25+00:00weekly0.6https://www.medthority.com/news/2024/5/positive-data-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults.--merck-inc2024-05-03T12:27:40+00:00weekly0.6https://www.medthority.com/news/2024/5/emergent-biosolutions-to-reduce-workforce/2024-05-03T12:29:29+00:00weekly0.6https://www.medthority.com/news/2024/5/phase-iii-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--merck-inc2024-05-06T09:42:31+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approves-updated-lupkynis-voclosporin-label-to-include-long-term-data-from-the-aurora-clinical-program.----aurinia-pharmaceuticals2024-05-06T09:41:33+00:00weekly0.6https://www.medthority.com/news/2024/5/cretostimogene-monotherapy-demonstrated-75.2-complete-response-rate-in-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer.-cg-oncology2024-05-06T09:40:37+00:00weekly0.6https://www.medthority.com/news/2024/5/mariana-oncology-is-acquired-by-novartis-and-with-it--mc-339-a-novel-radioligand-therapy-rlt-designed-to-target-small-cell-lung-cancer/2024-05-06T09:39:43+00:00weekly0.6https://www.medthority.com/news/2024/5/safety-of-switching-from-a-vitamin-k-antagonist-to-a-nonvitamin-k-antagonist-oral-anticoagulant-in-frail-older-patients-with-atrial-fibrillation/2024-05-06T09:38:56+00:00weekly0.6https://www.medthority.com/news/2024/5/phase-iii-keynote-811-trial-met-dual-primary-endpoint-of-overall-survival-os-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma2.--merck-inc2024-05-08T11:19:12+00:00weekly0.6https://www.medthority.com/news/2024/5/results-of-pivotal-phase-iii-study-of-uproleselan-in-relapsedrefractory-rr-acute-myeloid-leukemia-.--glycomimetics-inc2024-05-08T11:20:50+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-accepts-application-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidasesubcutaneous-nivolumab.--bms2024-05-08T11:23:06+00:00weekly0.6https://www.medthority.com/news/2024/5/publication-of-cytisinicline-vaping-cessation-trial--orca-v1results-in-jama-internal-medicine.--achieve-life-sciences2024-05-08T11:24:42+00:00weekly0.6https://www.medthority.com/news/2024/5/publication-of-torrey-phase-ii-results-in-the-lancet-respiratory-medicine/2024-05-08T11:27:57+00:00weekly0.6https://www.medthority.com/news/2024/5/gossamer-bio-and-chiesi-group-announce-transformative-global-collaboration-to-develop-and-commercialize-seralutinib-in-pah-ph-ild--other-indication/2024-05-08T11:30:08+00:00weekly0.6https://www.medthority.com/news/2024/5/neurocrine-bioscienes--supports-tardive-dyskinesia-awareness-week/2024-05-08T11:31:36+00:00weekly0.6https://www.medthority.com/news/2024/5/bayer-to-collaborate-with-evotec-to-develop-innovative-precision-treatments--for-cardiovascular-disease/2024-05-08T11:33:46+00:00weekly0.6https://www.medthority.com/news/2024/5/european-commission-approves-an-indication-extension-for-aspaveli-pegcetacoplan-for-treatment-of-adult-patients-with-paroxysmal-nocturnal-haemoglobinuria-pnh-who-have-haemolytic-anaemia.--sobi2024-05-09T13:11:04+00:00weekly0.6https://www.medthority.com/news/2024/5/nmpa-china-approves-symplicity-spyral-renal-denervation-rdn-system--medtronic/2024-05-09T13:13:16+00:00weekly0.6https://www.medthority.com/news/2024/5/positive-phase-iii-efficacy-results-from-solaris-trial-evaluating-tev-749-olanzapine-as-a-once-monthly-subcutaneous-long-acting-injectable-in-adults-with-schizophrenia.-teva--medincell2024-05-09T13:15:20+00:00weekly0.6https://www.medthority.com/news/2024/5/launch-of-sapien-3-ultra-resilia-valve-in-europe-with-technology-to-enhance-durability.--edwards-lifesciences2024-05-09T13:16:39+00:00weekly0.6https://www.medthority.com/news/2024/5/publication-of-results-from-phase-iib-clinical-trial-of-losmapimod-in-facioscapulohumeral-muscular-dystrophy-redux4-in-the-lancet-neurology.--fulcrum-therapeutics2024-05-10T11:17:39+00:00weekly0.6https://www.medthority.com/news/2024/5/aldeyra-therapeutics-enrolls-first-patient-in-phase-iii-clinical-trial-designed-to-enable-potential-resubmission-of-new-drug-application-of-reproxalap-in-dry-eye-disease/2024-05-10T11:19:23+00:00weekly0.6https://www.medthority.com/news/2024/5/annovis-announces-unblinding-of-the-buntenetap-phase-iii-data-in-parkinsons-disease/2024-05-10T11:21:14+00:00weekly0.6https://www.medthority.com/news/2024/5/update-on-phase-iii-keynote-b21-trial-evaluating-keytruda-pembrolizumab---chemotherapy-with-or-without-radiotherapy-for-patients-with-newly-diagnosed-high-risk-endometrial-cancer-after-surgery-with-curative-intent.--merck-inc2024-05-10T11:25:18+00:00weekly0.6https://www.medthority.com/news/2024/5/commencement-of-cedar-hcm-a-clinical-trial-of-aficamten-in-a-pediatric-population-with-symptomatic-obstructive-hypertrophic-cardiomyopathy--cytokinetics-inc/2024-05-10T11:29:22+00:00weekly0.6https://www.medthority.com/news/2024/5/elamipretide-for-barth-syndrome-receives-priority-review-designation.-stealth-biotherapeutics2024-05-11T16:33:35+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approval-for-myhibbin-mycophenolate-mofetil-oral-suspension-to-protect-a-donated-organ-from-being-rejected-from-the-bodys-immune-response.--azurity-pharma2024-05-11T16:30:51+00:00weekly0.6https://www.medthority.com/news/2024/5/national-approvals-in-all-eu-countries-for-mob-15-to-treat-mild-to-moderate-fungal-infections-of-the-nails.-moberg-pharma2024-05-11T16:30:07+00:00weekly0.6https://www.medthority.com/news/2024/5/phase-iii-checkmate--73l-trial-did-not-meet-its-primary-endpoint-in---stage-iii-non-small-cell-lung-cancer-nsclc.-bms2024-05-11T16:29:00+00:00weekly0.6https://www.medthority.com/news/2024/5/novavax-and-sanofi-announce-co-exclusive-licensing-agreement-to-co-commercialize-covid-19-vaccine-and-develop-novel-covid-19-influenza-combination-vaccines/2024-05-12T15:19:43+00:00weekly0.6https://www.medthority.com/news/2024/5/aspaveli-pegcetacoplan-approved-in-europe-for-use-among-treatment-naive-adult-patients-with-pnh.-sobi2024-05-12T15:19:07+00:00weekly0.6https://www.medthority.com/news/2024/5/head-to-head-superiority-to-high-dose-dulaglutide-first-phase-iii-clinical-trial-of-mazdutide-in-chinese-patients-with-type-2-diabetes-met-study-endpoints.--innovent-biologics--eli-lilly2024-05-13T11:38:57+00:00weekly0.6https://www.medthority.com/news/2024/5/fycompa-perampanel-hydrate-is-approved-in-china-for-adjunctive-treatment-of-primary-generalised-tonic-clonic-seizures--eisai-/2024-05-13T11:42:05+00:00weekly0.6https://www.medthority.com/news/2024/5/approval-of-augtyro-repotrectinib-for-patients-with-ros1-positive-nsclc-by-chinas-nmpa.--zai-lab2025-05-06T14:26:44+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approves-colosense---a--noninvasive-multi-target-stool-rna-mt-srna-colorectal-cancer-screening-test.--geneoscopy-inc2024-05-13T11:54:41+00:00weekly0.6https://www.medthority.com/news/2024/5/update-on-phase-iii-keyvibe-010-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-as-adjuvant-treatment-for-patients-with-resected-high-risk-melanoma.--merck-inc2024-05-14T11:17:16+00:00weekly0.6https://www.medthority.com/news/2024/5/updates-from-scorpio-hr-a-global-phase-iii-study-of-ensitrelvir-for-non-hospitalized-participants-with-covid-19.--shionogi2024-05-14T11:19:37+00:00weekly0.6https://www.medthority.com/news/2024/5/primary-results-from-sequoia-hcm-presented-in-late-breaking-clinical-trial-session-at-the-european-society-of-cardiology-heart-failure-2024-congress-and-published-in-the-new-england-journal-of-medicine.--cytokinetics-inc2024-05-14T11:23:27+00:00weekly0.6https://www.medthority.com/news/2024/5/headline-results-announced--for-pivotal-phase-iiia-trial-of-once-weekly-and-once-monthly-subcutaneous-mim8-in-haemophilia-a.--novocnordisk2024-05-14T11:25:24+00:00weekly0.6https://www.medthority.com/news/2024/5/boehringer-ingelheim-announced-an-agreement-with-quallent-pharmaceuticals-a-private-label-pharmaceutical-distributor-to-help-expand-patient-access-to-citrate-free-adalimumab-adbm/2024-05-14T11:31:15+00:00weekly0.6https://www.medthority.com/news/2024/5/ac-immune-sa-and-takeda-collaboration-on-aci-24.060-for-the-treatment-of-azheimers-disease2025-07-01T09:10:47+00:00weekly0.6https://www.medthority.com/news/2024/5/regulatory-update-on-sbla-for-four-dose-heplisav-b-regimen-for-adults-on-hemodialysis-in-the-us.--dynavax-technologies-2024-05-15T11:30:13+00:00weekly0.6https://www.medthority.com/news/2024/5/extension-of-fda-review-period-for-transcon-pth-for-adults-with-hypoparathyroidism---ascendis-pharma/2024-05-15T11:31:49+00:00weekly0.6https://www.medthority.com/news/2024/5/four-year-data-for-wegovy-semaglutide-in-obesity-presented-at-eco-meeting-and-published-in-nature.--novo-nprdisk2024-05-15T11:40:31+00:00weekly0.6https://www.medthority.com/news/2024/5/eisai-initiates-rolling-biologics-license-application-to-fda-for-leqembi-lecanemab-irmb--for-subcutaneous-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-under-the-fast-track-status/2025-07-01T09:41:27+00:00weekly0.6https://www.medthority.com/news/2024/5/landmark-trial-highlights-the-safety-and-effectiveness-of-the-myval-transcatheter-heart-valve-series.--meril-life-sciences2024-05-16T11:41:55+00:00weekly0.6https://www.medthority.com/news/2024/5/phase-iii-enlighten-cirrhosis-trial-of-pegozafermin-is-initiated-in-metabolic-dysfunction-associated-steatohepatitis-mash-patients-with-compensated-cirrhosis.--89bio.-inc2024-05-16T11:40:05+00:00weekly0.6https://www.medthority.com/news/2024/5/breyanzi-lisocabtagene-maraleucel-approved-by-the-fda-for-relapsed-or-refractory-follicular-lymphoma.--bms2024-05-16T11:34:09+00:00weekly0.6https://www.medthority.com/news/2024/5/supernova-phase-iii-trial-of-sipavibart-long-acting-antibody-met-primary-endpoints-in-preventing-covid-19-in-immunocompromised-patient-population.--astrazeneca-2024-05-17T11:47:17+00:00weekly0.6https://www.medthority.com/news/2024/5/new-four-year-sotyktu-deucravacitinib-data-demonstrates-durable-response-rates-and-consistent-safety-in-moderate-to-severe-plaque-psoriasis--bms/2024-05-17T11:49:01+00:00weekly0.6https://www.medthority.com/news/2024/5/fda--approves-imdelltra-taralatamab--dllethe-first-and-only-t-cell-engager-therapy-to-treatextensive-stage-small-cell-lung-cancer.--amgen2024-05-17T11:50:36+00:00weekly0.6https://www.medthority.com/news/2024/5/once-a-week-dosing-insulin-efsitora-alfa-delivers-a1c-reduction-and-safety-profile-consistent-with-daily-insulin--eli-lilly/2024-05-17T11:52:19+00:00weekly0.6https://www.medthority.com/news/2024/5/first-wave-biopharma-changes-its-name-to-entero-therapeutics/2024-05-17T11:54:03+00:00weekly0.6https://www.medthority.com/news/2024/5/elinzanetant-significantly-reduces-frequency-and-severity-of-moderate-to-severe-hot-flashes-associated-with-menopause.--bayer2024-05-18T17:17:10+00:00weekly0.6https://www.medthority.com/news/2024/5/late-breaking-data-show-reliable-performance-of-small-diameter-defibrillation-lead-the-omniasecure.---medtronic2024-09-30T10:48:58+00:00weekly0.6https://www.medthority.com/news/2024/5/abbvie-and-gilgamesh-pharma-to-develop-novel-neuroplastogens-to-address-mental-health-disorders/2024-05-18T17:12:36+00:00weekly0.6https://www.medthority.com/news/2024/5/johnson--johnson-to-acquire-proteologix-inc-and-with-it-px-128-and-px-130/2024-05-19T12:26:03+00:00weekly0.6https://www.medthority.com/news/2024/5/seladelpar-demonstrates-significant-improvements-in-liver-disease-progression-and-reduced-itching-in-primary-biliary-cholangitis.-gilead-sciences2024-05-20T11:27:57+00:00weekly0.6https://www.medthority.com/news/2024/5/sumitomo-reports-loss-in-fy2023-and-loss-of-exclusivity-for-latuda-lurasidone/2024-05-20T11:29:11+00:00weekly0.6https://www.medthority.com/news/2024/6/hutchmed-highlights-publication-of-phase-iii-eslim-01-results-in-the-lancet-haematology/2024-06-19T12:12:49+00:00weekly0.6https://www.medthority.com/news/2024/6/long-term-data-from-phase-iii-advance-cidp-3-clinical-trial-of-hyqvia-immune-globulin-infusion-10-human-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-at-pns-annual-meeting.-takeda2024-06-19T12:09:48+00:00weekly0.6https://www.medthority.com/news/2024/6/topline-results-from-phase-iii-raise-trial-of-i.v.-ganaxolone-in-refractory-status-epilepticus.--marinus-pharma2024-06-19T12:07:40+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults.--merck-inc2024-06-19T12:02:40+00:00weekly0.6https://www.medthority.com/news/2024/6/cytokinetics-announces-initiation-of-phase-1-study-of-aficamten-in-healthy-japanese-participants/2024-06-19T12:00:38+00:00weekly0.6https://www.medthority.com/news/2024/6/european-commission-grants-marketing-authorisation-for-altuvoct-efanesoctocog-alfa-for-treatment-of-haemophilia-a.--sobi2024-06-19T11:58:00+00:00weekly0.6https://www.medthority.com/news/2024/6/boston-scientific-acquires-silk-road-medical/2024-06-19T11:55:53+00:00weekly0.6https://www.medthority.com/news/2024/6/update-on-phase--iii-study-of-fordadistrogene-movaparvovec-for-ambulatory-boys-with-duchenne-muscular-dystrophy.--pfizer2024-06-13T11:35:48+00:00weekly0.6https://www.medthority.com/news/2024/6/farxiga-dapagliflozin-approved-in-the-us-for-the-treatment-of-paediatric-type-2-diabetes.--astrazeneca2024-06-13T11:38:18+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-expands-approval-of-elevidys-to-duchenne-muscular-dystrophy-patients.-the-fda-grants-traditional-approval-to-elevidys-for-ambulatory-duchenne-patients-and-accelerated-approval-for-non-ambulatory-duchenne-patients.-sarepta-therapeutics2024-06-22T13:52:47+00:00weekly0.6https://www.medthority.com/news/2024/6/twice-yearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-emtricitabine-200mg-and-tenofovir-disoproxil-fumarate-300mg-ftdf--for-hiv-prevention.---gilead-sciences2024-06-22T13:49:19+00:00weekly0.6https://www.medthority.com/news/2024/6/cc-42344-inhibits-activity-in-the-highly-pathogenic-avian-influenza-a-h5n1-pb2-protein-recently-identified-in-infected-dairy-cattle.--cocrystal-pharma2024-06-22T13:35:28+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-results-for-nipocalimab--in-clinessdaia-score-versus-placebo-at-24-weeks-compared-to-baseline-primary-endpoint-in-the-phase-ii-dahlias-dose-ranging-study.--johnson--johnson2024-06-22T13:34:41+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-grants-accelerated-approval-of-krazati-adagrasib-in-combination-with-cetuximab-for-adult-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer.--bms-2024-06-22T13:33:51+00:00weekly0.6https://www.medthority.com/news/2024/6/european-medicines-agency-validates-bristol-myers-squibbs-application-for-subcutaneous-nivolumab/2024-06-22T13:33:04+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approval-of-vyvgart-hytrulo-efgartigimod-alfa-and-hyaluronidase-qvfc-for-chronic-inflammatory-demyelinating-polyneuropathy.-argenx-2024-06-22T13:31:55+00:00weekly0.6https://www.medthority.com/news/2024/6/tirzepatide-reduced-obstructive-sleep-apnea-osa-severity-with-up-to-51.5-of-participants-meeting-the-criteria-for-disease-resolution.--eli-lilly2024-06-23T11:07:13+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-long-term-data-on-casgevy-exagamglogene-autotemcel-presented-at-the-2024-annual-european-hematology-association-eha-congress.--vertex-pharma2024-06-23T11:06:20+00:00weekly0.6https://www.medthority.com/news/2024/6/mim8-demonstrated-superior-reductions-in-annualised-bleeding-rate-compared-to-on-demand-and-prior-prophylaxis-treatment-in-people-with-haemophilia-a.--novo-nordisk2024-06-23T11:05:21+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-sofpironium-sofdra-as-first-and-only-chemical-entity-for-primary-axillary-hyperhidrosis.--botanix-pharma2024-06-24T11:36:10+00:00weekly0.6https://www.medthority.com/news/2024/6/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma.--dizal2024-06-25T11:46:51+00:00weekly0.6https://www.medthority.com/news/2024/6/chinas-nmpa-gives-approval-to-toripalimab-plus-chemotherapy-in-first-line-es-extensive-stagesmall-cell-lung-cancer.-junshi-biosciences2024-06-25T11:44:49+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approval-for-innovative-immunoglobulin-yimmugo-for-the-treatment-of-patients-with-primary-immunodeficiencies.--biotest-ag2024-06-25T11:43:24+00:00weekly0.6https://www.medthority.com/news/2024/6/merck-kgaa-provides-update-on-xevinapant-program-in-locally-advanced-head-and-neck-cancer/2024-06-25T11:42:12+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approval-for-wakix-pitolisant-in-pediatric-patients-with-narcolepsy.--harmony-biosciences.-2024-06-25T11:40:57+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-topline-results-from-helios-b-phase-iii-study-of-vutrisiran-achieves-statistical-significance-on-primary-and-all-secondary-endpoints-in-both-overall-and-monotherapy-populations.--alnylam-pharma2024-06-25T11:39:13+00:00weekly0.6https://www.medthority.com/news/2024/6/tagrisso-with-the-addition-of-chemotherapy-is-approved-in-japan-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer-.--astrazeneca2024-06-25T11:36:34+00:00weekly0.6https://www.medthority.com/news/2024/6/update-on-adjuvant-br.31-phase-iii-trial-of-imfinzi-durvalumab-in-non-small-cell-lung-cancer-.--astrazeneca2024-06-25T11:35:02+00:00weekly0.6https://www.medthority.com/news/2024/6/imfinzi-durvalumab-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-event-free-survival-and-overall-survival-for-muscle-invasive-bladder-cancer-in-niagara-phase-iii-trial.--astrazeneca2024-06-25T11:32:30+00:00weekly0.6https://www.medthority.com/news/2024/6/biocon-biologics-obtains-fda-approval-for-biosimilar-aflibercept-for-yesafili-and-enters-u.s.-ophthalmology-market2024-06-20T11:20:03+00:00weekly0.6https://www.medthority.com/news/2024/6/post-hoc-analysis-of-phase-iii-study-for-epysqli-sb-12-eculizumab-biosimilar-at-the-european-hematology-association-eha-congress-2024.--samsung-bioepis2024-06-20T11:23:59+00:00weekly0.6https://www.medthority.com/news/2024/6/truqap-capivasertib--faslodex--fulvestrant-combination-is-approved-in-the-eu-for-patients-with-advanced-er-positive-breast-cancer.--astrazeneca2024-06-20T11:33:27+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-skyrizi-risankizumab-rzaa-for-ulcerative-colitis-expanding-abbvies-portfolio-across-inflammatory-bowel-disease/2024-06-21T11:31:40+00:00weekly0.6https://www.medthority.com/news/2024/6/application-submitted-to-fda-seeking-approval-of-tremfya-guselkumab-for-the-treatment-of-moderately-to-severely-active-crohns-disease.-johnson--johnson2024-06-21T11:34:01+00:00weekly0.6https://www.medthority.com/news/2024/6/johnson--johnson-medtech-releases--the-polyphonic-digital-ecosystem-for-a-more-connected-surgical-experience/2024-06-21T11:36:36+00:00weekly0.6https://www.medthority.com/news/2024/6/wegovy-semaglutide-is-approved-by-nmpa-china-for-long-term-weight-management-for-overweight-and-obese-people.-novo-nordisk2024-06-26T12:04:06+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-update-on-abbv-951-foscarbidopaffoslevodopa-for-the-treatment-of-motor-fluctuations-in-adults-with-advanced-parkinsons-disease.--abbvie2024-06-26T11:59:54+00:00weekly0.6https://www.medthority.com/news/2024/6/ezharmia-approved-in-japan-as-first-dual-ezh1-and-ezh2-inhibitor-therapy-for-patients-with-peripheral-t-cell-lymphoma.--daiichi-sankyo2024-06-26T11:57:54+00:00weekly0.6https://www.medthority.com/news/2024/6/nmpa-china-approves-tecvayli-teclistamab-for-the-treatment-of-adults-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-three-prior-lines-of-treatment.-johnson--johnson2024-06-26T11:55:08+00:00weekly0.6https://www.medthority.com/news/2024/6/nmpa-china-approves-tagrisso-osimertinib--chemotherapy-for-the-1st-line-treatment-of-patients-with-epidermal-growth-factor-receptor-mutated-nsclc-whose-tumours-have-exon-19-deletions-or-exon-21-l858r-mutations.--astrazeneca2024-06-26T11:52:07+00:00weekly0.6https://www.medthority.com/news/2024/6/mhlw-japan-approves-briviact-brivaracetam-as-monotherapy-and-adjunctive-therapy-in-the-treatment-of-partial-onset-seizures.--ucb2024-06-26T11:50:22+00:00weekly0.6https://www.medthority.com/news/2024/6/lilly-collaborates-with-openai-to-discover-novel-medicines-to-treat-drug-resistant-bacteria/2024-06-26T11:47:56+00:00weekly0.6https://www.medthority.com/news/2024/6/bavarian-nordic-submits-marketing-authorization-application-for-its-chikungunya-vaccine-candidate-to-ema/2024-06-27T12:40:10+00:00weekly0.6https://www.medthority.com/news/2024/6/novo-nordisk-stops-the-ocedurenone-clarion-ckd-trial-and-recognises-impairment-loss/2024-06-27T12:38:18+00:00weekly0.6https://www.medthority.com/news/2024/6/mhlw-japan-approved-omjjara-momelotinib-for-the-treatment-of-myelofibrosis.--gsk2024-06-27T12:37:13+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-approves-ohtuvayre-ensifentrine-for-the-maintenance-treatment-of-chronic-obstructive-pulmonary-disease-copd-in-adult-patients.-verona-pharma2024-06-27T12:36:07+00:00weekly0.6https://www.medthority.com/news/2024/6/complete-response-letter-for-patritumab-deruxtecan-her3-dxd-for-the-treatment-of-adult-patients-with-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer.--daiichi-sankyo--merck-inc2024-06-27T12:33:17+00:00weekly0.6https://www.medthority.com/news/2024/6/altimmune-presents-data-on-the-effect-of-pemvidutide-on-cardioinflammatory-lipids-during-oral-presentation-at-american-diabetes-associations-84th-annual-scientific-sessions.-2024-06-29T14:11:35+00:00weekly0.6https://www.medthority.com/news/2024/6/elrexfio--elranatamab-bcmm-shows-median-overall-survival-of-more-than-two-years-in-people-with-relapsed-or-refractory-multiple-myeloma/2024-06-29T14:10:39+00:00weekly0.6https://www.medthority.com/news/2024/6/fda-grants-approval-for-epkinly-epcoritamab-bysp-to-treat-patients-with-relapsed-or-refractory-follicular-lymphoma.--abbvie2024-06-29T14:09:41+00:00weekly0.6https://www.medthority.com/news/2024/6/abbvie-to-acquire-celsius-therapeutics-and-with-it-cel-383-a-first-in-class-anti-trem1-antibody-/2024-06-29T14:08:38+00:00weekly0.6https://www.medthority.com/news/2024/6/dupixent-positive-phase-iii-data-in-children-one-to-11-years-of-age-with-eosinophilic-esophagitis-published-in-nejm-.--sanofi2024-06-29T14:07:45+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-balversa-erdafitinib-to-treat--urothelial-carcinoma--bladder-cancerharbouring-susceptible-fgfr3-genetic-alterations-janssen-cilag-jj/2024-06-29T14:06:59+00:00weekly0.6https://www.medthority.com/news/2024/6/eurneffy-adrenaline-nasal-spray-recommended-for-approval-by-chmp-for-emergency-treatment-of-allergic-reactions-anaphylaxis.-ars-pharma2024-06-29T14:06:10+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-mresvia-intended-for-the-prevention-of-lower-respiratory-tract-disease--caused-by-respiratory-syncytial-virusrsv.--moderna-biotech2024-06-29T14:04:57+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-recommends-approval-of--piasky-crovalimab-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria.--roche2024-06-29T14:03:18+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-tauvid-flortaucipir-f-18-intended-for-the-diagnosis-of-alzheimers-disease--eli-lilly/2024-06-29T13:51:35+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-conditional-marketing-authorization-of-odronextamab-to-treat-adults-with-relapsedrefractory-follicular-lymphoma-fl-or-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapy.--regeneron-pharma2024-06-29T13:50:27+00:00weekly0.6https://www.medthority.com/news/2024/6/positive-chmp-opinion-for-winrevair-sotatercept-in-pulmonary-arterial-hypertension-pah.--merck-inc2024-06-29T13:49:44+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-steqeyma-ustekinumab-biosimilar-to-treat-adults-and-children-with-plaque-psoriasis-and-adults-with-psoriatic-arthritis-or-crohns-disease.--celltrion2024-06-29T13:48:24+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-will-not-renew-the-conditional-marketing-authorisation-for-translarna-ataluren-for--duchenne-muscular-dystrophy-.-ptc-therapeutics2024-06-30T17:45:23+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-combination-lynparza-olaparib-with-durvalumab--for-the-maintenance-treatment-of-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer-that-is-mismatch-repair-proficient.--astrazeneca--merck-inc2024-06-30T17:43:55+00:00weekly0.6https://www.medthority.com/news/2024/6/coherus-biosciences-divests-yusimry-adalimumab-aqvh-to-hong-kong-king-friend-industrial-co.-ltd.-for-up-front-all-cash-consideration-of-$40-million-2024-06-30T17:42:54+00:00weekly0.6https://www.medthority.com/news/2024/6/regulatory-update-on-kresladi-marnetegragene-autotemcel-marne-cel--to-treat-severe-leukocyte-adhesion-deficiency-i.--rocket-pharma2024-06-30T17:40:01+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-vabysmo-faricimab-marketing-authorisation-to-include-the-treatment-of-visual-impairment-due-to-macular-edema-secondary-to-retinal-vein-occlusion-rvo.--roche2024-06-30T17:38:53+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-positive-for-conditional-marketing-authorization-of-epcoritamab-tepkinly-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-rr-follicular-lymphoma-fl.--abbvie2024-06-30T17:37:17+00:00weekly0.6https://www.medthority.com/news/2024/6/chmp-recommends-that--ocaliva-obeticholic-acid--marketing-authorisation-be-revoked-because-its-benefits-are-no-longer-considered-to-outweigh-its-risks.-advanz-pharma2024-06-30T17:35:53+00:00weekly0.6https://www.medthority.com/news/2024/6/maa-submitted-to-european-medicines-agency-for-lifileucel-to-treat--advanced-melanoma.--iovance-biotherapeutics2024-06-30T17:33:22+00:00weekly0.6https://www.medthority.com/news/2024/7/mirum-submits-nda-to-the-fda-for-chenodiol-for-the-treatment-of-cerebrotendinous-xanthomatosis-ctx/2024-07-02T11:43:43+00:00weekly0.6https://www.medthority.com/news/2024/7/sipavibart-ema-regulatory-submission-accepted-under-accelerated-assessment-for-covid-19-prevention.--astrazeneca2024-07-02T11:45:40+00:00weekly0.6https://www.medthority.com/news/2024/7/sandoz---samsung-bioepis-pyzchivaustekinumab-ttwe-a-biosimilar-to-stelara-has-gained-fda-approval/2024-07-02T11:47:49+00:00weekly0.6https://www.medthority.com/news/2024/7/tepylute-sh-105-gains-fda-approval-for-breast-and-ovarian-cancers.--shorla-oncology2024-07-02T11:52:23+00:00weekly0.6https://www.medthority.com/news/2024/7/european-commission-approves-obgemsa-vibegron-for-the-symptomatic-treatment-of-overactive-bladder-syndrome-in-adults.--pierre-fabre2024-07-02T11:55:37+00:00weekly0.6https://www.medthority.com/news/2024/3/update-on-bla-for-odronextamab-in-relapsedrefractory--follicular-lymphoma--and-in-diffuse-large-b-cell-lymphoma-.--regeneron2024-03-26T13:29:11+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-grants-full-approval-for-elahere-mirvetuximab-soravtansine-gynx-for-certain-ovarian-cancer-patients.-abbvie2024-03-26T13:28:24+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-once-daily-tryvio-aprocitentan--the-first-and-only-endothelin-receptor-antagonist-for-the-treatment-of-high-blood-pressure-not-adequately-controlled-in-combination-with-other-antihypertensives.--idorsia-ltd2024-03-26T13:27:10+00:00weekly0.6https://www.medthority.com/news/2024/3/abbvie-to-acquire-landos-biopharma-and-nx-13-for-ulcerative-colitis-and-crohns-disease/2024-03-26T13:26:30+00:00weekly0.6https://www.medthority.com/news/2024/3/novo-nordisk-to-acquire-cardior-pharma-and--with-it-cdr-132l-a-potential-treatment-for-heart-failure/2024-03-26T13:25:22+00:00weekly0.6https://www.medthority.com/news/2024/3/novo-nordisk-to-acquire-cardior-pharma-and--with-it-cdr-132l-a-potential-treatment-for-heart-failure2/2024-03-26T13:24:42+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-oncologic-drugs-advisory-committee-recommends-carvykti--ciltacabtagene-autoleucel-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma.--johnson--johnson2024-03-19T11:59:41+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-accepts-nda-for-ensartinib-x-396-for-the-treatment-of-adult-patients-with-metastatic-alk-positive-nonsmall-cell-lung-cancer.--xcovery-holdings2024-03-19T12:01:20+00:00weekly0.6https://www.medthority.com/news/2024/3/lynparza-olaparib-and-imfinzi-durvalumabdemonstrated-strong-clinical-benefit-and-more-than-doubled-median-duration-of-response-vs.-chemotherapy-in-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer.-astrazeneca-2024-03-19T12:03:43+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-for-lenmeldy--atidarsagene-autotemcel-to-treat-early-onsetmetachromatic-leukodystrophy.--orchard-therapeutics2024-03-19T12:05:43+00:00weekly0.6https://www.medthority.com/news/2024/3/astrazeneca-to-acquire-fusion-pharmaceuticals-and-with-it-fpi-2265-a-new--treatment-for-prostate-cancer/2024-03-19T12:13:36+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-topline-results-from-phase-iii-long-term-study-oasis-3-support-submissions-for-marketing-authorization-of-elinzanetant.---bayer2024-03-20T12:07:41+00:00weekly0.6https://www.medthority.com/news/2024/3/boehringer-ingelheim-announced-that-the-fda-has-approved-spevigo-spesolimab-sbzo-injection-for-the-treatment-of-generalized-pustular-psoriasis-gpp-in-adults-and-pediatric-patients-aged-12-and-above-weighing--greater-than-40-kg/2024-03-20T12:12:34+00:00weekly0.6https://www.medthority.com/news/2024/3/ferinject--ferric-carboxymaltose-approved-by-health-canada-for-the-treatment-of-iron-deficiency-anemia-in-adult-and-pediatric-patients-and-iron-deficiency-in-adult-patients-with-heart-failure.--csl-vifor2024-03-20T12:20:15+00:00weekly0.6https://www.medthority.com/news/2024/3/once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in-phase-iii-pathindr-2-study-in-acromegaly-patients.-crinetics-pharma2024-03-20T12:23:45+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-data-on-v-116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-demonstrated-immune-responses-in-adults.--merck-inc2024-03-20T12:26:59+00:00weekly0.6https://www.medthority.com/news/2024/3/orchard-therapeutics-outlines-u.s.-launch-plans-for-lenmeldy-atidarsagene-autotemcel-the-only-approved-therapy-for-children-with-early-onset-metachromatic-leukodystrophy2024-03-23T19:10:29+00:00weekly0.6https://www.medthority.com/news/2024/3/checkmate--9dw-trial-evaluating-opdivo-nivolumab---yervoy-ipilimumab-meets-primary-endpoint-of-overall-survival-for-the-first-line-treatment-of-advanced-hepatocellular-liver-carcinoma.-bms2024-03-23T19:11:21+00:00weekly0.6https://www.medthority.com/news/2024/3/abecma-idecabtagene-vicleucel-becomes-first-car-t-cell--therapy-approved-in-the-european-union-in-earlier-lines-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma.--bms2024-03-23T19:12:39+00:00weekly0.6https://www.medthority.com/news/2024/3/update-on-phase-iii-keylynk-006-trial-evaluating-keytruda-pembrolizumab----maintenance-lynparza-olaparib-for-certain-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer.-merck-inc.--astrazeneca2024-03-23T19:14:03+00:00weekly0.6https://www.medthority.com/news/2024/3/results-from--phase-iii-luminesce-study-of-enspryng-satralizumab-a-treatment-for-generalized-myasthenia-gravis.-chugai-pharma2024-03-23T19:14:51+00:00weekly0.6https://www.medthority.com/news/2024/3/tagrisso-osimertinib-with-the-addition-of-chemotherapy-showed-favourable-trend-in-overall-survival-in-egfr-mutated-advanced-lung-cancer-with-further-follow-up-in-flaura2-phase-iii-trial.---astrazeneca2024-03-23T19:15:33+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer.--gsk-plc2024-03-23T19:16:13+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-edurant-ped-rilpivirine-for-certain-pediatric-patients-living-with-hiv-1.--johnson--johnson2024-03-23T19:17:34+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-awiqli-once-weekly-basal-insulin-icodec-for-treatment-of-diabetes-in-adults.--novo-nordisk2024-03-23T19:18:27+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-bimzelx-bimekizumab-for-the-treatment-of-active-moderate-to-severe-hidradenitis-suppurativa.--ucb2024-09-30T14:20:43+00:00weekly0.6https://www.medthority.com/news/2024/3/anti-trust-clearance-given-to-acquisition-of-morphosys-by-novartis/2024-03-23T19:07:37+00:00weekly0.6https://www.medthority.com/news/2024/3/harris-poll-survey-finds-people-receiving-treatment-for-cidp-are-interested-in-exploring-more-convenient-treatment-options.-csl-behring2024-03-23T19:07:06+00:00weekly0.6https://www.medthority.com/news/2024/3/fabhalta-iptacopan-receives-positive-chmp-opinion-as-first-oral-monotherapy-for-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria---novartis/2024-03-23T19:02:21+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-duvyzat-givinostat-to-treat--patients-6-years-or-older-with-duchenne-muscular-dystrophy---italfarmaco-s.p.a2024-03-23T19:01:36+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-emblaveo-aztreonam--avibactam-for-the-treatment-of-complicated-intra-abdominal-and-urinary-tract-infections-hospital-acquired-pneumonia-and-infections-due-to-aerobic-gram-negative-organisms.-pfizer2024-03-23T19:00:26+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-lytenva-bevacizumab-gamma-for-the-treatment-of-wet-age-related-macular-degeneration-wet-amd-in-the-eu-.--outlook-therapeutics-inc2024-03-23T18:59:45+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive--for-jubbonti-a-denosumab-prolia-biosimilar.--sandoz2024-03-23T18:59:00+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-omlyclo-omalizumab-biosimilar-to-treat-asthma-rhinosinusitis-and-urticaria.--celltrion2024-03-23T18:58:19+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-wyost-denosumab-biosimilar-for-the-prevention-of-bone-complications-in-adults-with-advanced-cancer-involving-bone-and-for-the-treatment-of-adults-and-skeletally-mature-adolescents-with-giant-cell-tumour-of-bone.--sandoz2024-03-23T18:57:39+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-issues-emergency-use-authorisation-of-pemgarda-pemivibart-formerly-vyd-222-for-pre-exposure-prophylaxis-of-covid-19--invivyd-inc/2024-03-23T18:56:55+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-neoatricon-intended-for-treatment-of-hypotension-in-neonates-infants-and-children-under-18-years-of-age.-brepco-biopharma-limited2024-03-24T13:41:39+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-agilus-intended-for-the-treatment-of-malignant-hyperthermia-.--norgine-bv2024-03-24T13:41:00+00:00weekly0.6https://www.medthority.com/news/2024/3/deliberations-at-chmp--regarding-maa-for-lecanemab-have-been-rescheduled-due-to-procedural-reasons-at-european-medicines-agency.--eisai2024-03-24T13:40:20+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-opinion-on-variation-to-marketing-authorisation-for-nilemdo-bempedoic-acid.--daiichi-sankyo2024-03-24T13:39:00+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-opinion-on-variation-to-marketing-authorisation-of-nustendi-bempedoic-acid--ezetimibe--daiichi-sankyo/2024-03-24T13:39:40+00:00weekly0.6https://www.medthority.com/news/2024/3/chmp-positive-for-onivyde-pegylated-liposomal--chemotherapy-for-metastatic-adenocarcinoma-of-the-pancreas--servier/2024-03-25T13:57:47+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-chmp-opinion-for-xtandi--enzaltamidein-additional-recurrent-early-prostate-cancer-treatment-setting.--astellas2025-01-23T14:05:05+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-of-supplemental-nda-for-for-iclusig-ponatinb-in-adult-patients-with-newly-diagnosed-ph-all.--takeda2024-03-25T13:56:22+00:00weekly0.6https://www.medthority.com/news/2024/3/ultomiris-approved-in-the-us-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd.--astrazeneca2024-03-25T13:53:53+00:00weekly0.6https://www.medthority.com/news/2024/3/sobi-announces-positive-results-from-phase-iii-study-of-doptelet-avatrombopag-for-treatment-of-children-and-adolescents-with-immune-thrombocytopenia-/2024-03-25T13:51:55+00:00weekly0.6https://www.medthority.com/news/2024/3/ce-approval-for-complete-conduction-system-pacing-system-for-left-bundle-branch-area-pacing.---biotronik2024-03-15T12:50:21+00:00weekly0.6https://www.medthority.com/news/2024/3/mandara-phase-iii-data-published-in-new-england-journal-of-medicine-shows-remission-is-an-achievable-goal-in-eosinophilic-granulomatosis-with-polyangiitis-egpa-with-fasenra-benralizumab.-astrazeneca2024-03-15T12:52:47+00:00weekly0.6https://www.medthority.com/news/2024/3/the-phase-iii-tharros-trial-will-evaluate-the-effect-of-triple-combination-inhaled-therapy-breztri-budesonide--glycopyrronium--formoterol-fumarate--on-the-reduction-of-cardiopulmonary-events-in-copd-patients.--astrazeneca2024-03-15T12:54:28+00:00weekly0.6https://www.medthority.com/news/2024/3/application-is-submitted-to-the-fda-for-approval-of-tremfya-guselkumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis.--johnson--johnson2024-03-15T12:56:18+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-breyanzi-lisocabtagene-maraleucel-liso-cel-as-the-first-and-only-car-t-cell-therapy-for-adults-with-rr-chronic-lymphocytic-leukemia-cll-or-small-lymphocytic-lymphoma-sll.--bms2024-03-15T12:58:05+00:00weekly0.6https://www.medthority.com/news/2024/3/novartis-acquires-ifm-due-and-its-cgas-sting-program-/2024-03-15T13:01:12+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-oncologic-drugs-advisory-committee-votes-in-favor-of-the-clinical-benefitrisk-profile-of-imetelstat-for-the-treatment-of-transfusion-dependent-anemia-in-patients-with-lower-risk-mds.--geron-corporation2024-03-16T12:00:34+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-for-tevimbra-for-the-treatment-of-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-after-prior-chemotherapy.--beigene.-2024-03-16T11:59:46+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-of-rezdiffra-resmetirom-for-noncirrhotic-nash-with-moderate-to-advanced-liver-fibrosis-consistent-with-stages-f2-to-f3-fibrosis-.--madrigal-pharmaceuticals-inc2024-03-16T11:59:02+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-advisory-committee-positive-for--abecma-idecabtagene-vicleucel-for-triple-class-exposed-multiple-myeloma-in-earlier-lines-of-therapy.--bms--2seventy-bio-inc2024-03-16T11:57:42+00:00weekly0.6https://www.medthority.com/news/2024/3/keytruda-pembrolizumab--chemoradiotherapy-crt-significantly-improved-overall-survival-versus-crt-alone-in-patients-with-newly-diagnosed-high-risk-locally-advanced-cervical-cancer.--merck-inc2024-03-17T16:46:54+00:00weekly0.6https://www.medthority.com/news/2024/3/novabay-pharmaceuticals-and-eyenovia-collaborate-to-co-promote-ophthalmic-products-in-the-usa/2024-03-17T16:46:12+00:00weekly0.6https://www.medthority.com/news/2024/3/xhance-fluticasone-propionate-is-approved-by-the-fda-as-first-and-only-medication-indicated-for-treatment-of-adults-with-chronic-rhinosinusitis-without-nasal-polyps.--optinose2024-03-17T16:45:24+00:00weekly0.6https://www.medthority.com/news/2024/3/first-wave-biopharma-inc.-acquires-immunogenx-and-with-it-latiglutenase-to-treat-celiac-disease2024-03-17T16:44:35+00:00weekly0.6https://www.medthority.com/news/2024/3/sugemalimab-approved-in--china-as-first-line-treatment-for-gastric-cancer.-cstone-pharmaceuticals2024-03-27T12:50:09+00:00weekly0.6https://www.medthority.com/news/2024/3/health-canada-approves-bimzelx-bimekizumab-injection-for-the-treatment-of-adults-with-axial-spondyloarthritis-axspa.--ucb2024-03-27T12:49:19+00:00weekly0.6https://www.medthority.com/news/2024/3/update-on-verify-patient-enrollment-and-timing-of-top-line-data-for-rusfertide-in-polycythemia-vera-.--protagonist-therapeutics2024-03-27T12:47:02+00:00weekly0.6https://www.medthority.com/news/2024/3/nmpa-china-approves-hl-085-tunlametinib-to-treat-neuroblastoma-ras-viral-oncogene-homolog-nras-mutated-advanced-melanoma.-shanghai-kechow-pharma2024-03-27T12:46:11+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-winrevair-sotatercept-csrk-a-first-in-class-treatment-for-adults-with-pulmonary-arterial-hypertension-pah-who-group-1.--merck-inc2024-03-27T12:45:31+00:00weekly0.6https://www.medthority.com/news/2024/3/mhra-uk-extends-indication-of-mavenclad-cladribine-tablets-for-relapsing-forms-of-multiple-sclerosis.--merck-kgaa2024-03-27T12:44:28+00:00weekly0.6https://www.medthority.com/news/2024/3/truqap-capivasertib--faslodex--fulvestrant-approved-in-japan-for-patients-with-advanced-hr-positive-breast-cancer.--astrazeneca2024-03-27T12:43:41+00:00weekly0.6https://www.medthority.com/news/2024/3/mhlw-japan-approves-beyfortus-nirsevimab-in-japan-for-the-prevention-of-rsv-disease-in-infants.--astrazeneca2024-03-28T16:23:28+00:00weekly0.6https://www.medthority.com/news/2024/3/-mhlw-approval-for-piasky-340-mg-for-paroxysmal-nocturnal-hemoglobinuria-in-japan.--chugairoche2024-03-28T16:22:01+00:00weekly0.6https://www.medthority.com/news/2024/3/mhlw-japan-approval-for--vyloy-zolbetuximab-to-treat-cldn18.2-positive-unresectable-advanced-or-recurrent-gastric-cancer.-astellas2024-03-28T16:20:43+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-vafseo--vadadustat-tablets--for-the-treatment-of-anemia-due-to-chronic-kidney-disease-ckd-in-adults-who-have-been-receiving-dialysis-for-at-least-three-months.-csl-vifor2024-03-29T20:53:54+00:00weekly0.6https://www.medthority.com/news/2024/3/sosei-group-to-change-its-name-to-nxera-pharma/2024-03-29T20:56:01+00:00weekly0.6https://www.medthority.com/news/2024/3/abilify-maintena-960-mg-aripiprazole-approved-in-the-eu-as-the-first-once-every-two-months-long-acting-injectable-for-the-maintenance-treatment-of-schizophrenia.---otsuka-and--h.lundbeck-as2024-03-29T20:58:06+00:00weekly0.6https://www.medthority.com/news/2024/3/health-canada-approval-for-wakik-pitolisant-hydrochloride-tablets-for-the-treatment-of-excessive-daytime-sleepiness-eds-or-cataplexy-in-pediatric-patients.-paladin-labs-inc2024-03-31T16:42:14+00:00weekly0.6https://www.medthority.com/news/2024/3/update-on-the-first-phase-iii-yellowstone-trial-evaluating-oral-zeposia-ozanimod-in-patients-with-moderate-to-severe-active-crohns-disease.-bms2024-03-31T16:43:21+00:00weekly0.6https://www.medthority.com/news/2024/3/pivotal-krystal-12-confirmatory-trial-evaluating-krazati-adagrasib-meets-primary-endpoint-of-progression-free-survival-for-patients-with-pretreated-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer--bms/2024-03-31T16:44:52+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-update-on-pdufa-target-action-date-for-govorestat-for-the-treatment-of-classic-glactosemia.--applied-therapeutics2024-03-31T16:46:27+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-priority-review-of-nda-for-revumenib-for-the-treatment-of-rr--kmt2ar-acute-leukemia.-syndax2024-04-01T17:13:39+00:00weekly0.6https://www.medthority.com/news/2024/4/submission-of-leqembi-lecanemab-irmb-supplemental-biologics-license-application-for-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-to-the-fda.--eisai--biogen2024-04-02T12:11:12+00:00weekly0.6https://www.medthority.com/news/2024/4/voydeya-approved-in-the-us-as-add-on-therapy-to-ravulizumab-or-eculizumab-for-treatment-of-extravascular-haemolysis-in-adults-with-the-rare-disease-pnh.-astrazeneca2024-04-01T17:15:27+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-broad-new-labels-for-nexletol--bempedoic-acid-and-nexlizet-bempedoic-acid-and-ezetimibe-to-prevent-heart-attacks-and-cardiovascular-procedures-in-both-primary-and-secondary-prevention-patients-regardless-of-statin-use.-esperion2024-04-02T11:59:49+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-clearance-of-rejoyn-the-first-prescription-digital-therapeutic-authorized-in-the-u.s.-for-the-treatment-of-major-depressive-disorder-.-otsuka2024-04-02T11:55:54+00:00weekly0.6https://www.medthority.com/news/2024/4/datopotamab-deruxtecan-bla-is-accepted-in-the-us-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer.--daiichi-sankyo--astra-zeneca2024-04-02T11:51:12+00:00weekly0.6https://www.medthority.com/news/2024/4/preliminary-progression-free-survival-and-long-term-circulating-tumor-dna-ctdna-data-from-phase-ii-portion-of-ongoing-phase-iiiii-study-of--granite-vaccine-in-front-line-metastatic-microsatellite-stable-colorectal-cancer--gritstone-bio/2024-04-03T13:09:09+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-expands-approval-of-reblozyl-luspatercept-to-include-first-line-treatment-of-transfusion-dependent-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes.-bms-2024-04-03T13:09:57+00:00weekly0.6https://www.medthority.com/news/2024/4/acorda-therapeutics-files-for-voluntary-bankruptcy/2024-04-03T13:05:35+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-accepts-sblas-for-bimzelx-bimekizumab-bkzx-for-moderate-to-severe-hidradenitis-suppurativa-and-additional-2ml-device-presentations--ucb/2024-09-30T14:24:16+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approves-keytruda-pembrolizumab--chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-resectable-non-small-cell-lung-cancer-nsclc-at-high-risk-of-recurrence-in-adults.--merck-inc2024-04-05T11:14:36+00:00weekly0.6https://www.medthority.com/news/2024/4/rejoice-ovarian01-phase-iiiii-trial-of-raludotatug-deruxtecan-initiated-in-patients-with-platinum-resistant-ovarian-cancer.--daiichi-sankyo--merck-inc2024-04-05T11:13:17+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approves-exblifep---cefepime-and-enmetazobactam-to-treat-complicated-urinary-tract-infections-pyelonephritis-hospital-acquired-pneumonia-and-ventilator-associated-pneumonia.--advanz-pharma2024-04-05T11:11:27+00:00weekly0.6https://www.medthority.com/news/2024/4/phase-iii-clinical-trial-is-initiated-of-mk-1084-an-investigational-oral-kras-g12c-inhibitor-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-certain-patients-with-metastatic-non-small-cell-lung-cancer.--merck-inc2024-04-05T11:10:45+00:00weekly0.6https://www.medthority.com/news/2024/4/imfinzi-durvalumab-significantly-improved-overall-survival-and-progression-free-survival-for-patients-with-limited-stage-small-cell-lung-cancer-in-adriatic-phase-iii-trial.--astrazeneca-2024-04-05T11:10:03+00:00weekly0.6https://www.medthority.com/news/2024/4/genmab-as-to-acquire-profoundbio-and-with-itrina-s-an-fralpha-adc-to-treat-ovarian-cancer/2024-04-05T11:09:09+00:00weekly0.6https://www.medthority.com/news/2024/4/criticism-of-fda-approval-decision-of-the-avertd-test-to-assess-the-elevated-risk-of-developing-opioid-use-disorder.--autogenomicssolvd-health2024-04-06T22:04:37+00:00weekly0.6https://www.medthority.com/news/2024/4/enhertu-trastuzumab-deruxtecan--approved-in-the-us-as-first-tumour-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumours.-daiichi-sankyo--astrazeneca2024-04-06T22:04:50+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-carvykti-ciltacabtagene-autoleucel-cilta-cel-as-the-first-and-only-bcma-targeted-treatment--for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy.--johnson--johnson2024-04-06T22:04:52+00:00weekly0.6https://www.medthority.com/news/2024/4/boehringer-lays-off-or-relocates--sales-staff--for-its-humira-biosimilar-cyltezo-adalimumab-biosimilar/2024-04-06T22:04:54+00:00weekly0.6https://www.medthority.com/news/2024/4/johnson--johnson-acquires-shockwave-medical/2024-04-06T22:04:57+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-abecma-idecabtagene-vicleucel-ide-cel-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma-after-two-prior-lines-of-therapy.-bms--2seventy-bio-inc2024-04-07T11:00:22+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-de-novo-approval-for-sepsis-immunoscore-an-artificial-intelligencemachine-learning-software-as-a-medical-device-ai-samd-to-guide-rapid-diagnosis-and-prediction-of-sepsis.-prenosis-inc2024-04-07T11:00:26+00:00weekly0.6https://www.medthority.com/news/2024/4/additional-48-week-data-from-forest-hcm-the-open-label-extension-clinical-study-of-aficamten-presented--at-the-american-college-of-cardiology-73rd-annual-scientific-session.--cytokinetics-inc2024-04-07T11:00:27+00:00weekly0.6https://www.medthority.com/news/2024/4/topline-results-of-phase-ii-kickstart-trial-of-tomivosertib--pembrolizumab-in-non-small-cell-carcinoma.--effector-therapeutics-inc2024-04-08T14:18:16+00:00weekly0.6https://www.medthority.com/news/2024/4/new-data-shows-early-addition-of-twice-yearly-leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-ldl-c-in-ascvd-patients-in-real-world-setting.--novartis2024-04-08T14:16:49+00:00weekly0.6https://www.medthority.com/news/2024/4/boston-scientific-initiates-navigate-pf-study-of-the-farawave-nav-pulsed-field-ablation-catheter-and-faraview-software-module-for-treatment-of-paroxysmal-and-persistent-atrial-fibrillation/2024-09-30T11:36:52+00:00weekly0.6https://www.medthority.com/news/2024/4/krazati-adagrasib--cetuximab-demonstrates-clinically-meaningful-activity-as-a-targeted-treatment--for-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer--bms/2024-04-09T14:30:39+00:00weekly0.6https://www.medthority.com/news/2024/4/relyvrioalbrioza-sodium-phenylbutyrate-and-taurursodiol-also-known-as-ursodoxicoltaurine-also-known-as-amx0035-for-als-will-be-removed-from-the-market-in-the-us-and-canada.-amylyx-pharma2024-04-09T14:33:52+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-issues-complete-response-letter-for-spn-830-apomorphine-infusion--for--treatment-of-motor-fluctuations-off-episodes-in-parkinsons-disease.--supernus-pharma2024-04-09T14:36:12+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-accepts-filing--nda-for-elamipretide-for-the-treatment-of-barth-syndrome.--stealth-biotherapeutics2024-04-09T14:38:27+00:00weekly0.6https://www.medthority.com/news/2024/4/wegovy-semaglutide-improved-symptoms-and-physical-function-in-patients-with-obesitydiabetes-and-a-common-type-of-heart-failure.--novo-nordisk-2024-04-09T14:40:21+00:00weekly0.6https://www.medthority.com/news/2024/4/eyenovia-inc.to-accelerate-development-of-micropine-and-explore-alternatives-to-maximize-shareholder-value2024-04-09T14:42:15+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-zevtera-ceftobiprole-medocaril-sodium-for-injection-to-treat-staphylococcus-aureus-bloodstream-infectionsendocarditis-absssi-and-cabp-infections.--basilea-pharmaceutica.ltd2024-04-10T11:11:50+00:00weekly0.6https://www.medthority.com/news/2024/4/approval-in-japan-for-sargramostin-to-treat-apap-autoimmune-pulmonary-alveolar-proteinosis-.--partner-therapeutics--nobelpharma2024-04-10T11:09:44+00:00weekly0.6https://www.medthority.com/news/2024/4/risvan-risperidone-ism--receives-fda-approval-as-a-treatment-for-schizophrenia.--laboratorios-farmaceuticos-rovi-s.a2024-04-10T11:08:04+00:00weekly0.6https://www.medthority.com/news/2024/4/positive-top-line-results-from-phase-iii-study-of-abrysvo-in-adults-aged-18-to-59-at-increased-risk-for-rsv-disease.--pfizer2024-04-11T11:35:23+00:00weekly0.6https://www.medthority.com/news/2024/4/vertex-acquires-alpine-immune-sciences-and-with-it-povetacicept-a-potential-treatment-for-kidney-disease/2024-04-11T11:19:50+00:00weekly0.6https://www.medthority.com/news/2024/4/peer-reviewed-publication-highlighting-promising-safety-data-and-high-patient-compliance-in-a-clinical-trial-of-ad-04-as-a-potential-treatment-for-alcohol-use-disorder.--adial-pharma2024-04-12T12:02:37+00:00weekly0.6https://www.medthority.com/news/2024/4/snda-is-filed-for-fda-review-of-brexpiprazole-and-sertraline-combination-as-potential-treatment-for-ptsd.-lundbeck--otsuka2024-04-12T11:59:41+00:00weekly0.6https://www.medthority.com/news/2024/4/inaxaplin-vx-147--advances-into-phase-iii-portion-of-adaptive-phase-iiiii-clinical-trial-for-the-treatment-of-apol1-mediated-kidney-disease.--vertex-pharma2024-04-12T11:47:52+00:00weekly0.6https://www.medthority.com/news/2024/4/key-milestone-is-achieved-in-the-development-of-pax-101-and-an--update-is-provided-on-potential-nda-submission-for-the-treatment-of-stage-1-human-african-trypanosomiasis.-paxmedica2024-04-12T11:44:24+00:00weekly0.6https://www.medthority.com/news/2024/4/saruparib-shows-favorable-activity-safety-in-mutant-advanced-solid-tumors.--astrazeneca2024-04-14T18:27:28+00:00weekly0.6https://www.medthority.com/news/2024/4/latest-real-world-evidence-presented-at-wco-iof-esceo-assesses-how-evenity-romosozumab-can-help-to-close-the-treatment-gap-in-osteoporosis.--ucb2024-04-14T18:22:07+00:00weekly0.6https://www.medthority.com/news/2024/4/eliem--acquires-tenet-medicines-and-with-it-tnt-119-a-potential-treatment-for-sle/2024-04-14T18:21:08+00:00weekly0.6https://www.medthority.com/news/2024/4/late-breaking-data-presented-at-aan-supporting-long-term-safety-and-efficacy-of-atogepant-qulipta-for-preventive-treatment-of-migraine---abbvie/2024-04-14T18:18:57+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approval-for-fanapt-iloperidone-tablets-to-treat--manic-or-mixed-episodes-associated-with-bipolar-i-disorder-in-adults.--vanda-pharma2024-04-05T11:17:11+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-triclip-first-of-its-kind-device-to-treat-tricuspid-regurgitation-tr-or-a-leaky-tricuspid-valve.--abbott2024-04-05T11:16:28+00:00weekly0.6https://www.medthority.com/news/2024/4/new-pooled-interim-long-term-safety-and-metabolic-outcomes-data-from-the-emergent-program-evaluating-karxt-in-schizophrenia-presented-at-the-2024-annual-congress-of-the-schizophrenia-international-research-society.--bms2024-04-08T13:51:14+00:00weekly0.6https://www.medthority.com/news/2024/4/toripalimab--axitinib-combination--approved-in-china-for-frontline-renal-cell-carcinoma---shanghai-junshi-biosciences-co.-ltd2024-04-15T11:32:35+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-accepts-nda-for-sh-201--the-first-palatable-oral-liquid-of-the-related-chemotherapeutic-agent-for-the-treatment-of-certain-forms-of-leukemia-and-other-cancers.---shorla-oncology2024-04-15T11:35:33+00:00weekly0.6https://www.medthority.com/news/2024/4/sphere-360-pulse-field-ablation-catheter-a-new-paradigm-in-single-shot-ablation-demonstrates-impressive-results-in-treating-paroxysmal-atrial-fibrillation.--medtronic2024-09-30T12:01:50+00:00weekly0.6https://www.medthority.com/news/2024/4/columvi-glofitamab--chemotherapy-meets-primary-endpoint-of-overall-survival-in-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-phase-iii-starglo-study.--roche--genentechroche2024-04-16T11:45:30+00:00weekly0.6https://www.medthority.com/news/2024/4/fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-of-38.3-versus-placebo-for-patients-with-iga-nephropathy.--novartis2024-04-16T11:48:11+00:00weekly0.6https://www.medthority.com/news/2024/4/update-on-the-phase-iii-raise-trial-for-intravenous-ganaxolone-for-the-treatment-of-refractory-status-epilepticus.--marinus-pharma2024-04-16T11:50:26+00:00weekly0.6https://www.medthority.com/news/2024/4/imfinzi-durvalumab--plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.-astrazeneca2024-04-16T12:20:42+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approval-of-dovato-dolutegravirlamivudine-for-adolescents-living-with-hiv.--viiv-healthcare2024-04-16T12:11:10+00:00weekly0.6https://www.medthority.com/news/2024/4/positive-phase-iii-topline-results-from-study-501-evaluating-lumateperone-as-adjunctive-therapy-in-patients-with-major-depressive-disorder.--intra--cellular-therapies-inc2024-04-17T11:34:55+00:00weekly0.6https://www.medthority.com/news/2024/4/kesimpta-ofatumumab-six-year-efficacy-data-show-substantial-benefits-in-recently-diagnosed-treatment--naive-people-with-relapsing-multiple-sclerosis.--novartis2024-04-17T11:37:58+00:00weekly0.6https://www.medthority.com/news/2024/4/tirzepatide-reduced-sleep-apnea-severity-by-up-to-nearly-two-thirds-in-adults-with-obstructive-sleep-apnea-osa-and-obesity.--eli-lilly2024-04-18T13:56:42+00:00weekly0.6https://www.medthority.com/news/2024/4/topline-results-from-phase-ii-precedent-study-of-dalzanemdor-sage-718-in-the-treatment-of-mild-cognitive-impairment-in-parkinsons-disease.--sage-therapeutics2024-04-18T13:54:45+00:00weekly0.6https://www.medthority.com/news/2024/4/positive-topline-results-for-tavapadon-in-phase-iii-adjunctive-trial-for-people-living-with-parkinsons-disease.--cerevel-therapeuticsabbvie2024-04-19T11:58:36+00:00weekly0.6https://www.medthority.com/news/2024/4/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-urogenital-gonorrhoea-gc-amid-growing-resistance-to-existing-treatments.--gsk2024-04-19T11:54:18+00:00weekly0.6https://www.medthority.com/news/2024/4/tranquility-in-care-pivotal-phase-iii-trial-plan-with-bxcl-501-for-agitation-associated-with-alzheimers-dementia.--bioxcel-therapeutics-inc2024-04-19T11:52:15+00:00weekly0.6https://www.medthority.com/news/2024/4/fda--has-granted-a-rolling-new-drug-application-nda-submission-for-suzetrigine-vx-548-in-moderate-to-severe-acute-pain.--vertex-pharma2024-04-19T11:50:43+00:00weekly0.6https://www.medthority.com/news/2024/4/iomab-b--apamistamab-to-overcome-high-risk-tp53-mutation-resulting-in-significant-improvement-in-overall-survival-in-patients-with-active-relapsed-refractory-aml-at-the-european-bone-marrow-transplant-annual-meeting.--actinium-pharmaceuticals-inc2024-04-19T11:49:01+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-selarsdi-ustekinumab-biosimilar-to-treat-plaque-psoriasis-and-active-psoriatic-arthritis.--teva--alvotech2024-04-19T11:45:52+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-alecensa-alectinib-as-the-first-adjuvant-treatment-for-people-with-alk-positive-early-stage-lung-cancer.--genentechroche2024-04-19T11:42:04+00:00weekly0.6https://www.medthority.com/news/2024/4/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-iib-ascend-nash-trial/2024-04-20T11:44:18+00:00weekly0.6https://www.medthority.com/news/2024/4/health-canada-approves-biosimilar--niopeg-a-pegylated-form-of-filgrastim-in-canada.--nora-pharma2024-04-20T11:42:05+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-grants-clearance-for-first-ever-digital-bone-marrow-aspirate-application--scopio-labs/2024-04-21T12:45:03+00:00weekly0.6https://www.medthority.com/news/2024/4/phase-iii-select-gca-study-of-upadacitinib-rinvoq-showed-positive-results-in-patients-with-giant-cell-arteritis.--abbvie2024-04-21T12:44:08+00:00weekly0.6https://www.medthority.com/news/2024/4/health-canada-approves-new-indication-for-prevymis-letermovir-for-prevention-of-cytomegalovirus-cmv-disease-in-high-risk-adult-kidney-transplant-recipients.--merck-inc2024-04-21T12:43:16+00:00weekly0.6https://www.medthority.com/news/2024/4/health-canada-approves-keytruda--chemotherapy-as-a-first-line-treatment-for-adult-patients-with-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--merck-inc.-2024-04-21T12:41:47+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-lumisight-and-lumicell-dvs-for-residual-breast-cancer-detection.--lumicell-inc2024-04-22T12:25:19+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-requires-boxed-warning-for-risk-of-t-cell-malignancies-with-approved-car-t-cell-therapies/2024-04-22T12:23:28+00:00weekly0.6https://www.medthority.com/news/2024/4/abbottthoratec-corp.-recalls-heartmate-ii-and-heartmate-3-left-ventricular-assist-system-lvas-due-to-long-term-buildup-causing-an-obstruction2024-04-22T12:16:26+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-subcutaneous-administration-of--entyvio--vedolizumab-for-maintenance-therapy-in-moderately-to-severely-active-crohns-disease.--takeda2024-04-23T11:15:04+00:00weekly0.6https://www.medthority.com/news/2024/4/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade.--gsk2025-05-06T13:27:11+00:00weekly0.6https://www.medthority.com/news/2024/4/gsks-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-the-fda/2024-04-22T11:57:02+00:00weekly0.6https://www.medthority.com/news/2024/4/bruker-to-acquire-assets-of-nanostring/2024-04-22T11:55:19+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approval-of-pyzchiva-ustekinumab-biosimilar-further-strengthening-immunology-offering.--sandoz2025-07-01T09:00:01+00:00weekly0.6https://www.medthority.com/news/2024/4/mhra-approves-nulibry-fosdenopterin-to-treat-molybdenum-cofactor-deficiency-mocd-type-a.--sentynl-therapeuticszydus2024-04-23T11:56:59+00:00weekly0.6https://www.medthority.com/news/2024/4/subcutaneous-ocrevus-one-year-data-from-ocarina-ii-study-demonstrates-near-complete-suppression-of-clinical-relapses-and-brain-lesions-in-patients-with-progressive-and-relapsing-forms-of-ms.--roche2024-04-23T11:59:38+00:00weekly0.6https://www.medthority.com/news/2024/4/voydeya-approved-in-the-eu-as-add-on-treatment-to-ravulizumab-or-eculizumab-for-adults-with-the-rare-disease-pnh-who-have-residual-haemolytic-anaemia.--alexion-astrazeneca-2024-04-23T12:01:01+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approves-bimzelx-bimekizumab-for-the-treatment-of-active-moderate-to-severe-hidradenitis-suppurativa.-ucb2024-09-30T14:23:42+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approval-for-tislelizumab-as-treatment-for-non-small-cell-lung-cancer.--beigene2025-05-06T14:20:44+00:00weekly0.6https://www.medthority.com/news/2024/4/abeona-therapeutics-provides-regulatory-update-on-pz-cel-prademagene-zamikeracefor-the-treatment-of-patients-with-recessive-dystrophic-epidermolysis-bullosa/2024-04-24T12:09:51+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approves-emblaveo--aztreonam-avibactam-for-patients-with-multidrug-resistant-infections-and-limited-treatment-options.--pfizer2024-04-24T12:05:36+00:00weekly0.6https://www.medthority.com/news/2024/4/novartis-and-medicines-for-malaria-venture-announce-positive-efficacy-and-safety-data-for-a-novel-treatment-for-babies-5-kg-with-malaria/2024-04-24T12:03:06+00:00weekly0.6https://www.medthority.com/news/2024/4/ojemda-tovorafenib-receives-fda-accelerated-approval-for-relapsed-or-refractory-braf-altered-pediatric-low-grade-glioma-plgg-the-most-common-form-of-childhood-brain-tumor.--day-one-biopharmaceuticals-inc2024-04-24T12:01:04+00:00weekly0.6https://www.medthority.com/news/2024/4/lutathera-is-fda-approved-as-first-medicine-specifically-for-pediatric-patients-with-gastro-enteropancreatic-neuroendocrine-tumors-.--novartis2024-04-24T11:58:22+00:00weekly0.6https://www.medthority.com/news/2024/4/treefrog-therapeutics-licenses-c-stem-technology-to-vertex-pharma-to-optimise-type-1-diabetes-development-/2024-04-24T11:53:40+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-conditionally-approves-filspari-sparsentan-for-the-treatment-of-iga-nephropathy.--csl-vifor---travere-therapeutics2024-04-25T12:18:46+00:00weekly0.6https://www.medthority.com/news/2024/4/topline-results-from-a-confirmatory-clinical-study-for-avt-05-a-proposed-biosimilar-for-simponi-golimumab.--alvotech2024-04-25T12:13:28+00:00weekly0.6https://www.medthority.com/news/2024/4/fintepla-fenfluramine-oral-solution-approved-in-japan-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs.--ucb2024-04-25T12:11:05+00:00weekly0.6https://www.medthority.com/news/2024/4/cidara-therapeutics-announces-the-divestiture-of-rezafungin-rights-to-mundipharma.-2024-04-25T12:09:26+00:00weekly0.6https://www.medthority.com/news/2024/4/cidara-therapeutics-reacquires-global-development-and-commercial-rights-to-cd-388-from-johnson--johnson.-2024-04-25T12:05:30+00:00weekly0.6https://www.medthority.com/news/2024/4/antibe-therapeutics-has-receiver-appointed/2024-04-25T12:00:01+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-for-opdivo-nivolumab--cisplatin--gemcitabine-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma.--bms2024-04-27T15:02:55+00:00weekly0.6https://www.medthority.com/news/2024/4/amgen-to-submit-maa-to-ema-for-teprotumumab-to-treat--moderate-to-severe-thyroid-eye-disease-ted/2024-04-27T15:02:01+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-beqvezfidanacogene--elaparvovec-dzkt-a-one-time-gene-therapy-for-adults-with-hemophilia-b.--pfizer2024-04-27T14:50:25+00:00weekly0.6https://www.medthority.com/news/2024/4/sobi-receives-positive-chmp-opinion-recommending-approval-of-altuvoct-efanesoctocog-alfa-for-once-weekly-treatment-of-haemophilia-a/2024-04-27T14:49:30+00:00weekly0.6https://www.medthority.com/news/2024/4/positive-chmp--recommendation-for-fruzaqla-fruquintinib-in-previously-treated-metastatic-colorectal-cancer.--takeda2024-04-27T14:48:20+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive--for-jeraygo-aprocitentan-for-the-treatment-of-resistant-hypertension-in-adult-patients-in-combination-with-at-least-three-antihypertensive-medicinal-products.--idorsia-ltd2024-04-27T14:46:35+00:00weekly0.6https://www.medthority.com/news/2024/4/novavax-is-prepared-to-deliver-protein-based-non-mrna-jn.1-covid-19-vaccine-in-line-with-who-recommendation-this-fall2024-04-27T14:45:31+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approval-for-kalydeco-to-treat-infants-with-cystic-fibrosis-ages-1-month-and-older.--vertex2024-04-27T14:44:23+00:00weekly0.6https://www.medthority.com/news/2024/4/xoma-corporation-announces-completion-of-acquisition-of-shares-of-kinnate-biopharma-inc/2024-04-27T14:40:53+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation--for-capivasertib-truqap-for-the-treatment-of-locally-advanced-or-metastatic-breast-cancer-with-one-or-more-specific-genetic-mutations-pik3ca-akt1-or-pten.--astrazeneca2024-04-28T12:10:21+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-for-obgemsa-vibegron-intended-for-the-symptomatic-treatment-of-adults-with-overactive-bladder-oab-syndrome.-pierre-fabre2024-04-28T12:09:28+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-for-wezenla-ustekinumab-biosimilar-intended-for-the-treatment-of-plaque-psoriasis-including-paediatric-plaque-psoriasis-psoriatic-arthritis-and-crohns-disease-in-adults.--amgen2024-04-28T12:08:36+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-to-change-the-marketing-authorisation-for-rozlytrek-entrectinib---roche--/2024-04-28T12:07:45+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-for-rybrevant-amivantamab-in-combination-with-chemotherapy-for-first-line-treatment-of--non-small-cell-lung-cancer-with-activating-epidermal-growth-factor-receptor-egfr-exon-20-insertion-mutations.--janssen-cilag-jj2024-04-28T12:06:10+00:00weekly0.6https://www.medthority.com/news/2024/4/complete-response-letter-for-nda--for-ketarx-ketamine-for-the-treatment-for-levodopa-induced-dyskinesia-in-parkinsons-disease.---pharmather-holdings2024-04-28T12:05:16+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-to-change-the-marketing-authorisation-of-sirturo-bedaquiline-in-patients-with-pulmonary-tuberculosis.--jansssen--cilag-jj2024-04-28T12:04:08+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-to-change-to-marketing-authorisation-of-triumeq-abacavir-sulfate--dolutegravir-sodium--lamivudine-to-treat-hiv-infections.-viiv-healthcare2024-04-28T12:03:18+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-to-extend-the-marketing-authorisation-of-alecensa-alectinib-hydrochloride.--roche2024-04-28T12:01:49+00:00weekly0.6https://www.medthority.com/news/2024/4/results-from-phase-iv-study-of-mydcombi-phenylephrine--tropicamide-to-characterize-the-lowest-deliverable-dose-for-mydriasis.--eyenovia2024-04-26T11:36:08+00:00weekly0.6https://www.medthority.com/news/2024/4/european-commission-approves-label-extension-for-xtandi-enzalutamidefor-the-treatment-of-adult-men-with-high-risk-biochemical-recurrent-bcr-non-metastatic-hormone-sensitive-prostate-cancer-.---astellas--pfizer2025-01-23T14:04:40+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-pivya-pivmecillinam-tablets-for-the-treatment-of-female-adults-with-uncomplicated-urinary-tract-infections.--utility-therapeutics2024-04-26T11:27:17+00:00weekly0.6https://www.medthority.com/news/2024/4/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-dupilumab-across-primary-and-all-secondary-endpoints-in-an-open-label-head-to-head-atopic-dermatitis-study.--abbvie2024-04-26T11:23:40+00:00weekly0.6https://www.medthority.com/news/2024/4/chmp-positive-recommendation-for-tofidence-tocilizumab-biosimilar--biogen-inc/2024-04-26T11:17:54+00:00weekly0.6https://www.medthority.com/news/2024/4/regeneron-pharma-and-mammoth-biosciences-collaborate-on-crispr-based-gene-editing-therapies/2024-04-26T11:14:20+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-anktivan-803-or-nogapendekin-alfa-inbakicept-pmln-first-in-class-il-15-receptor-agonist-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer.-immunitybio-inc2024-04-29T15:44:32+00:00weekly0.6https://www.medthority.com/news/2024/4/enhertu-in-destiny-breast06-phase-111-trial-demonstrated-a-clinicallymeaningful-progression-free-survival-improvement-in-patients-with-her2-ultralow-expression.-astrazeneca--daiichi-sankyo2024-04-29T15:43:03+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approval-of-xolremdi-mavorixafor-capsules-first-drug-indicated-in-patients-with-whim-syndrome.--x4-pharmaceuticals2024-04-30T11:51:27+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approval-and-market-access-for-libervant-diazepam-buccal-film-in-pediatric-patients-ages-2-to-5-and-provides-update-on-anaphylm-epinephrine-sublingual-film.--aquestive-therapeutics2024-04-30T11:48:31+00:00weekly0.6https://www.medthority.com/news/2024/4/sandoz-reaches-agreement-with-amgen-resolving-all-patent-litigation-related-to-its-us-denosumab-biosimilars/2024-04-30T11:45:53+00:00weekly0.6https://www.medthority.com/news/2024/4/mhra-approves-yorvipath-palopegteriparatide-to-treat-chronic-hypoparathyroidism-.--ascendis-pharma2024-04-30T11:44:29+00:00weekly0.6https://www.medthority.com/news/2024/4/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv.--gilead-sciences2024-04-30T11:42:39+00:00weekly0.6https://www.medthority.com/news/2024/4/positive-overall-survival-results-of-anktiva-combined-with-checkpoint-inhibitors-in-non-small-cell-lung-cancer-meeting-scheduled-with-fda-to-discuss-registration-path-for-anktiva-in-lung-cancer.--immunitybio2024-04-30T11:40:18+00:00weekly0.6https://www.medthority.com/news/2024/4/ono-pharma-to-acquire-deciphera-pharma/2024-04-30T11:33:43+00:00weekly0.6https://www.medthority.com/news/2024/5/european-commission-approves-carvykti-ciltacabtagene-autoleucel-cilta-cel-to-treat--rr-multiple-myeloma.janssen---cilag-jj2024-05-01T11:31:46+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-grants-full-approval-for-tivdak-tisotumab-vedotin-tftv-to-treat-recurrent-or-metastatic-cervical-cancer.---genmab-as--pfizer2025-02-03T14:46:02+00:00weekly0.6https://www.medthority.com/news/2024/5/-fda-approval-of-ingrezza-sprinkle-valbenazine-capsules-for-the-treatment-of-adults-with-tardive-dyskinesia-and-chorea-associated-with-huntingtons-disease.--neurocrine-biosciences2024-05-01T11:20:55+00:00weekly0.6https://www.medthority.com/news/2024/5/promising-findings-in-phase-iibiii-clinical-trial-of-nrx-101-vs.-lurasidone-for-treatment-of-suicidal-bipolar-depression.--nrx-pharmaceuticals2024-05-01T11:18:08+00:00weekly0.6https://www.medthority.com/news/2024/5/the-fda-has-approved-the-esprit-btk-everolimus-eluting-resorbable-scaffold-system-esprit-btk-system-a-breakthrough-innovation-for-people-with-chronic-limb-threatening-ischemia-below-the-knee.--abbott-2024-09-30T12:16:03+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approval-for-inceptiv-closed-loop-spinal-cord-stimulator--stimulator-scsfor-the-treatment-of-chronic-pain.---medtronic2024-05-02T11:50:44+00:00weekly0.6https://www.medthority.com/news/2024/5/fda-approves-high-concentration-citrate-free-formulation-of-cyltezo-adalimumab-adbm-injection-interchangeable-biosimilar-to-humira.--boehringer2024-05-02T11:47:17+00:00weekly0.6https://www.medthority.com/news/2024/3/supplemental-nda-submitted-to-the-fda-seeking-full-approval-of-filspari-sparsentan-for-the-treatment-of-iga-nephropathy-.--travere-therapeutics2024-03-12T12:18:02+00:00weekly0.6https://www.medthority.com/news/2024/3/large-real-world-studies-demonstrate-continued-excellent-outcomes-from-patients-receiving-sapien-tavr.--edwards-lifesciences2024-03-12T12:21:26+00:00weekly0.6https://www.medthority.com/news/2024/3/advisory-committee-positive-forlumisight-an-optical-imaging-agent-used-in-combination-with-the-lumicell-direct-visualization-system--for-use-in-patients-with-breast-cancer.--lumicell-inc2024-03-12T12:24:10+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-grants-accelerated-approval-to-zanubrutinib-brukinsa--grayva-obinutuzumab-for-relapsed-or-refractory-follicular-lymphoma.--beigene2024-03-13T12:30:23+00:00weekly0.6https://www.medthority.com/news/2024/3/ce-mark-for-varipulse-platform-for-the-treatment-of-symptomatic-drug-refractory-recurrent-paroxysmal-atrial-fibrillation.--biosense-webster-jj2024-09-30T11:38:37+00:00weekly0.6https://www.medthority.com/news/2024/3/publication-of-long-term-efficacy-and-safety-data-further-support-fyarro-nab-sirolimus-for-the-treatment-of-malignant-pecoma.--aadi-bioscience2024-03-04T12:36:16+00:00weekly0.6https://www.medthority.com/news/2024/3/new-data-is-presented-at-mda-meeting-of-zolgensma-onasemnogene-abeparvovec--from-the-smart-study-for-the-treatment-of-spinal-muscular-atrophy.--novartis2024-03-04T12:37:53+00:00weekly0.6https://www.medthority.com/news/2024/3/two-datopotamab-deruxtecan-applications-validated-in-the-eu-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-or-hr-positive-her2-negative-breast-cancer-.--daiichi-sankyo--astrazeneca2024-03-04T12:39:42+00:00weekly0.6https://www.medthority.com/news/2024/3/bayer-strengthens-pharma-portfolio-with-acquisition-of-eu-rights-to-new-cardiology-drug-acoramidis-for-the-treatment-of-patients-suffering-from-attr-cm/2024-03-04T12:41:56+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-label-expansion-for-oral-ibrutinib-suspension-in-all-current-indications--abbvie--jansen-biotech/2024-03-05T12:10:44+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-of-definity-perflutren-lipid-microsphere-for-pediatric-patients-with-suboptimal-echocardiograms.-2024-03-05T12:18:12+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-app-13007-clobetasol-propionate-ophthalmic-suspension-0.05-for-post-operative-inflammation-and-pain-following-ocular-surgery.--eyenovia-2024-03-05T12:21:27+00:00weekly0.6https://www.medthority.com/news/2024/3/ucb-strategic-equity-investment-in-imidomics/2024-03-05T12:24:07+00:00weekly0.6https://www.medthority.com/news/2024/3/semaglutide-1.0-mg-demonstrates-24-reduction-in-the-risk-of-kidney-disease-related-events-in-people-with-type-2-diabetes-and-chronic-kidney-disease-in-the-flow-trial.--novo-nordisk2024-03-06T12:37:51+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-aoc-1001-long-term-data-showing-reversal-of-disease-progression-in-people-living-with-myotonic-dystrophy-type-1-across-multiple-endpoints-same-key-endpoints-agreed-for-phase-iii-harbor-trial.--avidity--biosciences2024-03-06T12:40:03+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-for-first-and-only-denosumab-biosimilars.--sandoz2024-03-06T12:41:51+00:00weekly0.6https://www.medthority.com/news/2024/3/mhlw-japan--grants-full-approval-for-xocova--ensitrelvir-to-treatsars-cov-2-infection-in-japan.--shionogi2024-03-07T12:34:57+00:00weekly0.6https://www.medthority.com/news/2024/3/new-data-from-three-real-world-retrospective-studies-of-veklury-remdesivir-are-presented-at-the-31st-conference-on-retroviruses-and-opportunistic-infections-croi.--gilead-sciences2024-03-07T12:36:14+00:00weekly0.6https://www.medthority.com/news/2024/3/real-world-data-show-freestyle-libre-systems-and-glp-1-medicines-work-better-together-for-people-with-type-2-diabetes.---abbott2024-03-07T12:38:19+00:00weekly0.6https://www.medthority.com/news/2024/3/complete-response-letter-for-hetlioztasimelteon-for-insomnia-characterised-by-difficulty-with-sleep-initiation.--vanda-pharma2024-03-07T12:41:30+00:00weekly0.6https://www.medthority.com/news/2024/3/gilead-and-merus-announcec-collaboration-to-discover-novel-antibody-based-trispecific-t-cell-engagers/2024-03-07T12:43:16+00:00weekly0.6https://www.medthority.com/news/2024/3/merck-kgaa-stops-its-evobrutinib--programme-following-failure-in-phase-iii-trial-for-multiple-sclerosis/2024-03-09T17:10:26+00:00weekly0.6https://www.medthority.com/news/2024/3/publication-in-psychiatry-research-showing-activity-of-bedtime-tnx-102-sl-on-ptsd-symptoms-and-sleep-quality-in-military-related-ptsd-at-four-weeks-of-therapy.--tonix-pharma2024-03-09T17:09:44+00:00weekly0.6https://www.medthority.com/news/2024/3/juvederm-voluma-xc-is-fda-approved-for-temple-hollows.---allergan-aestheticsabbvie2024-03-09T17:08:31+00:00weekly0.6https://www.medthority.com/news/2024/3/dupixent-provides-late-breaking-results-showing-reduced-airway-inflammation-and-mucus-plugging-in-adults-with-uncontrolled-moderate-to-severe-asthma--sanofi--regeneron/2024-03-09T17:07:46+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-belantamab-mafodotin--versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma.--gsk-plc2024-03-09T17:06:50+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-topline-results-from-the-phase-ii-kardia-2-study-in-people-with-hypertension-demonstrating-clinically-significant-blood-pressure-reductions-with-zilebesiran-when-added-to-standard-of-care.--alnylam--roche.-2024-03-09T17:05:26+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-to-convene-advisory-committee-meeting-to-discuss-the-trailblazer-alz-2-study-of-donanemab.--eli-lilly2024-03-09T17:02:53+00:00weekly0.6https://www.medthority.com/news/2024/3/aflibercept-8-mg-clinical-study-data-now-published-in-the-lancet.-bayer--regeneron2024-03-09T17:02:01+00:00weekly0.6https://www.medthority.com/news/2024/3/topline-results-from-global-phase-iii-phoenix-trial-of-amx-0035-in-amyotrophic-lateral-sclerosis.--amylyx-pharma2024-03-09T17:01:19+00:00weekly0.6https://www.medthority.com/news/2024/3/wegovy-approved-in-the-us-for-cardiovascular-risk-reduction-in-people-with-overweight-or-obesity-and-established-cardiovascular-disease.--novo-nordisk2024-03-09T16:59:44+00:00weekly0.6https://www.medthority.com/news/2024/3/inventiva-announces-that-screening-in-the-nativ3-phase-iii-clinical-trial-evaluating-lanifibranor-in-nash-has-resumed/2024-03-09T16:58:42+00:00weekly0.6https://www.medthority.com/news/2024/3/publication-of-phase-iib-symmetry-cohort-d-study-in-clinical-gastroenterology-and-hepatology--akero-therapeutics-inc/2024-03-10T17:01:53+00:00weekly0.6https://www.medthority.com/news/2024/3/new-research-reveals-genomic-profile-of-seborrheic-dermatitis-and-answers-key-questions-on-immune-response-and-skin-barrier-dysfunction.-arcutis-biotherapeutics-inc2024-03-10T17:01:11+00:00weekly0.6https://www.medthority.com/news/2024/3/first-presentation-at-aad-meeting--of-four-year-bimzelx-bimekizumab-bkzx-data-showed-long-term-maintenance-of-complete-skin-clearance-in-moderate-to-severe-plaque-psoriasis.--ucb2024-03-10T17:00:24+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-topline-cgm-accuracy-data-of-accu-chek-at-the-17th-international-conference-on-advanced-technologies-and-treatments-for-diabetes.-roche2024-03-11T11:30:03+00:00weekly0.6https://www.medthority.com/news/2024/3/late-breaking-data-presented-from-integument-ped-phase-iii-trial-of-roflumilast-cream-0.05-in-atopic-dermatitis-in-children-ages-2-to-5-at-the-aad-meeting.--arcutis-biotherapeutics-inc2024-03-11T11:27:09+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-opdivo--nivolumab-plus-cisplatin-and-gemcitabine-for-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma.--bms2024-03-11T11:22:07+00:00weekly0.6https://www.medthority.com/news/2024/3/top-line-results-from--phase-iii-advance-2-trial--of-pimavanserin-for-the-treatment-of-negative-symptoms-of-schizophrenia.-acadia-pharma2024-03-13T12:34:37+00:00weekly0.6https://www.medthority.com/news/2024/3/complete-response-letter-for-ga-depot-to-treat-multiple-sclerosis.--viatris-inc.-and-mapi-pharma2024-03-13T12:36:51+00:00weekly0.6https://www.medthority.com/news/2024/3/new-phase-iib-results-for-amlitelimab-presented-at-aad-meeting--support-potential-for-best-in-class-maintenance-of-response-in-atopic-dermatitis.--sanofi2024-03-13T12:38:25+00:00weekly0.6https://www.medthority.com/news/2024/3/abbott-recalls-heartmate-touch-communication-system-for-unintentional-pump-start-and-stop/2024-03-13T12:40:08+00:00weekly0.6https://www.medthority.com/news/2024/3/galderma--presents-new-data-at-aad-meeting-that-demonstrate-the-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-atopic-dermatitis/2024-03-13T12:41:15+00:00weekly0.6https://www.medthority.com/news/2024/3/groundbreaking-safe-mcs-study-of--early-bird-bleed-monitoring-system-is-presented-at-crt-meeting.--saranas-inc2024-03-13T12:42:38+00:00weekly0.6https://www.medthority.com/news/2024/3/merck-inc-announces-plans-to-conduct-clinical-trials-of-a-novel-investigational-multi-valent-human-papillomavirus-hpv-vaccine-and-single-dose-regimen-for-gardasil-9/2024-03-13T12:45:09+00:00weekly0.6https://www.medthority.com/news/2024/3/long-term-follow-up-data-for-maat-013-in-early-access-program-for-patients-with-agvhd--to-be-presented-at-the-upcoming-ebmt-conference.--maat-pharma2024-03-13T12:47:06+00:00weekly0.6https://www.medthority.com/news/2024/3/boehringer-and-sosei-corporation-agree-a-collaboration-for-sosei-heptares-gpr52-agonists-including-htl-0048149/2024-03-13T12:48:38+00:00weekly0.6https://www.medthority.com/news/2024/3/eu-approval-for-prevnar-20--formerly-apexxnar-to-help-protect-infants-and-children-against-pneumococcal-disease.--pfizer2024-03-14T11:44:54+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-overall-survival-in-phase-iii-trial-of-adcetris-regimen-in-patients-with-relapsedrefractory-diffuse-large-b-cell-lymphoma-dlbcl.--seagen-pfizer2024-03-14T11:46:21+00:00weekly0.6https://www.medthority.com/news/2024/3/almirall-s.a-acquires-global-rights-to-zkn-013-from-eloxx-pharma-for-the-use-in-orphan-dermatological-diseases2024-03-14T11:48:35+00:00weekly0.6https://www.medthority.com/news/2024/3/santheras-partner-catalyst-pharmaceuticals-launches-agamree-vamorolone-in-the-united-states-to-treat-duchenne-muscular-dystrophy/2024-03-14T11:49:43+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approves-livmarli-maralixibat-for-the-treatment-of-cholestatic-pruritus-in-patients-five-years-of-age-and-older-with-progressive-familial-intrahepatic-cholestasis.---mirum-pharma2024-03-14T11:50:50+00:00weekly0.6https://www.medthority.com/news/2024/3/astrazeneca-to-acquire-amolyt-pharma-and-with-it-eneboparatide-a-treatment-for-hypoparathyroidism/2024-03-14T11:52:12+00:00weekly0.6https://www.medthority.com/news/2024/3/hepatology-publishes-six-year-data-demonstrating-improved-clinical-outcomes-in-patients-with-alagille-syndrome-treated-with-livmarli-maralixibat--mirum-pharma/2024-03-01T12:18:36+00:00weekly0.6https://www.medthority.com/news/2024/3/new-efficacy-analysis-comparing-brukinsa-vs-acalabrutinib-in-relapsed-or-refractory-chronic-lymphocytic-leukemia.--beigene-ltd2024-03-01T12:16:21+00:00weekly0.6https://www.medthority.com/news/2024/3/positive-topline-results-from-global-phase-iii-trial-of-once-weekly-apraglutide-in-adults-with-short-bowel-syndrome-with-intestinal-failure-sbs-if-ironwood-pharmaceuticals/2024-03-01T12:13:45+00:00weekly0.6https://www.medthority.com/news/2024/3/european-medicines-agency-validation-for-maa-of-nirogacestat-for-the-treatment-of-adults-with-desmoid-tumors.--springworks-therapeutics2024-03-01T12:10:22+00:00weekly0.6https://www.medthority.com/news/2024/3/new-data-from-the-long-term-daybreak-study-reinforces-efficacy-and-safety-of-zeposia-ozanimod-in-patients-with-relapsing-forms-of-multiple-sclerosis.--bms2024-03-02T14:16:32+00:00weekly0.6https://www.medthority.com/news/2024/3/boston-scientific-to-acquire-axonics-including-r20-and-f15-neuromodulation-systems/2024-03-02T14:15:22+00:00weekly0.6https://www.medthority.com/news/2024/3/fda-approval-for-the-agent-drug-coated-balloon-to-treat-coronary-in-stent-restenosis-in-patients-with-coronary-artery-disease-.--boston-scientific2024-09-30T13:59:34+00:00weekly0.6https://www.medthority.com/news/2024/3/rybrevant-amivantamab-vmjw-in-combination-with-chemotherapy-is-the-first-fda-approved-therapy-for-first-line-treatment-of-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations---johnson--johnson/2024-03-04T10:31:40+00:00weekly0.6https://www.medthority.com/news/2024/2/fibrogen-regains-all-rights-to-roxadustat-from-astrazeneca-in-the-united-states-and-other-astrazeneca-territories-except-china-and-south-korea/2024-02-28T12:29:49+00:00weekly0.6https://www.medthority.com/news/2024/2/complete-response-letter-from-fda-for-nda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-patients-with-schizophrenia.--minervaneurosciences-inc2024-02-28T12:31:40+00:00weekly0.6https://www.medthority.com/news/2024/2/sar443820dnl788-misses-endpoint-in-phase-ii-himalaya-trial-to-treat-amyotropic-lateral-sclerosis-als.-sanofi--denali-2024-02-29T13:05:15+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-acceptance-and-priority-review-of-nda-for-govorestat-for-the-treatment-of-classic-galactosemia.--applied-therapeutics2024-02-29T13:06:36+00:00weekly0.6https://www.medthority.com/news/2024/2/positive-results-from-clinical-pharmacokinetic-bridging-study-of-tonmya-cyclobenzaprine-low-dose-to-support-development-and-partnering-in-japan-and-china.--tonix-pharma--2024-02-29T13:08:28+00:00weekly0.6https://www.medthority.com/news/2024/2/bla-application-for-tevimbra-tislelizumab-for-first-line-gastric-or-gastroesophageal-junction-cancers-accepted-by-fda.--beigene-ltd2024-02-29T13:10:21+00:00weekly0.6https://www.medthority.com/news/2024/2/milestone-pharmaceuticals-announces-plan-to-resubmit-nda-for-etripamil-for-the-treatment-of-paroxysmal-supraventricular-tachycardia.-2024-02-29T13:11:27+00:00weekly0.6https://www.medthority.com/news/2024/2/arcutis-and-sato-announce-strategic-collaboration-and-licensing-agreement-for-topical-roflumilast-in-japan/2024-02-29T13:13:12+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-grants-humanitarian-device-exemption-approval-to-selective-cytopheretic-device-for-pediatric-acute-kidney-injury.--seastar-medical-holding-corporation.-2024-02-23T12:14:31+00:00weekly0.6https://www.medthority.com/news/2024/2/rigel-pharmaceuticals-acquires-u.s.-rights-to-gavreto-pralsetinib-from-blueprint-medicines-corporation2024-02-25T10:21:33+00:00weekly0.6https://www.medthority.com/news/2024/2/dupixent-dupilumab-sbla--is-accepted-for-fda-priority-review-for-treatment-of-copd-with-type-2-inflammation.--regeneron--sanofi2024-02-25T10:21:13+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-opinion-for-kalydeco-for-the-treatment-of-infants-with-cystic-fibrosis-ages-1-month-and-older.-vertex-pharma2024-02-25T10:20:20+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-qalsody-tofersen-to-treat-adults-with-amyotrophic-lateral-sclerosis-als-associated-with-a-mutation-in-the-superoxide-dismutase-1-sod1-gene.--biogen-inc2024-02-25T10:19:33+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-opinion-for-filsparisparsentan-for-the-treatment-of-iga-nephropathy.-travere-therapeutics-inc.--csl-vifor2024-02-25T10:18:46+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-tizvenitislelizumab-to-treat-locally-advanced--or-metastatic-non-small-lung-cancer.-beigene2024-02-25T10:17:56+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-voydeya-danicopanas-add-on-therapy-to-ravulizumab-or-eculizumab-for-the-treatment-of-residual-haemolytic-anaemia-in-adult-patients-with-paroxysmal-nocturnal-haemoglobinuria.-alexionastrazeneca-2024-02-25T10:17:11+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-zynyz-retifanlimab-intended-for-the-treatment-of-merkel-cell-carcinoma.--incyte-biosciences2024-02-25T10:16:26+00:00weekly0.6https://www.medthority.com/news/2024/2/two-abstracts-for-sb-17-a-proposed-biosimilar-to-stelara-ustekinumab--are-presented--at-the-19th-annual-congress-of-european-crohns-and-colitis-organisation-ecco.--samsung-bioepis--sandoz2024-02-25T10:15:34+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-pyzchiva-ustekinumab-biosimilar-to-treat-psoriasis-psoriatic-arthritis-ulcerative-colitis-and-crohns-disease.---samsung-bioepis--sandoz2024-02-25T10:14:46+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-celldemic-vaccine--intended-for-active-immunisation-against-the-h5n1-subtype-of-influenza-a-virus-in-adults-and-infants-.seqiruscsl2024-02-25T10:13:50+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-incellipan-an-active-immunisation-against-influenza-in-an-officially-declared-pandemic-.--seqiruscsl2024-02-26T08:05:11+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-extension-of-indication-of-keytruda-pembrolizumabto-include-the-pre--and-post-operative-treatment-of-adults-whose-nsclc-can-be-removed-by-surgery-and-who-are-at-high-risk-of-recurrence.--merck-inc2024-02-26T08:04:21+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-extension-of-indication-of-reblozyl-luspatercept-aamtfor-i.-transfusion-dependent-anaemia-due-to-low-and-intermediate-risk-myelodysplastic-syndromes.-ii.-anaemia-with-transfusion-dependent-beta-thalassaemia.--bms2024-02-26T08:03:30+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-recommends-a-change-to-the-indication-of-xromi-hydroxycarbamide-to-include-prevention-of-sickle-cell-disease-complications.--nova-laboratories2024-02-26T08:02:41+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approval-of-simlandi-adalimumab-ryvk-injection-the-first-interchangeable-high-concentration-citrate-free-biosimilar-to-humira.-alvotech--teva2024-02-26T08:01:56+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-zynyz-retifanlimab-for-the-treatment-of-merkel-cell-carcinoma.--incyte-biosciences2024-02-26T08:01:07+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-extension-of-indication-for-carvykti-ciltacabtagene-autoleucel-to-include-patients-with-rr-multiple-myeloma-who-have-received-at-least-one-prior-therapy.--janssen--cilag2024-02-26T08:00:20+00:00weekly0.6https://www.medthority.com/news/2024/2/chmp-positive-for-extension-of-indication-of-cibingo-abrocitinib-to-include-treatment-of-adolescents-aged-12-years-and-older-with-atopic-dermatitis.--pfizer2024-02-26T07:59:39+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-issues-complete-response-letter-for-cefepime-taniborbactam-application.--venatorx-pharma--melinta-therapeutic2024-02-26T12:21:37+00:00weekly0.6https://www.medthority.com/news/2024/2/alvotech-announces-expected-global-market-entry-dates-for-avt-04-biosimilar-to-stelara-ustekinumab/2024-02-26T12:19:58+00:00weekly0.6https://www.medthority.com/news/2024/2/abbvie-and-tentarix-announce-collaboration-to-develop-conditionally-active-multi-specific-biologics-for-oncology-and-immunology/2024-02-26T12:15:44+00:00weekly0.6https://www.medthority.com/news/2024/2/tecvayli-teclistamab-cqyv-biweekly-dosing-approved-by-the-fda-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma.--johnson--johnson2024-02-27T12:06:17+00:00weekly0.6https://www.medthority.com/news/2024/2/new-england-journal-of-medicine-publishes-phase-iii-data-showing-xolair-omalizumab-significantly-reduced-allergic-reactions-across-multiple-foods-in-people-with-food-allergies.--genentechroche2024-02-27T12:04:55+00:00weekly0.6https://www.medthority.com/news/2024/2/actinium-announces-iomab-b-markedly-increases-long-term-survival-in-patients-65-years-or-older-with-active-rr-aml-in-the-phase-iii-sierra-trial-at-the-2024-tandem-meetings-/2024-02-27T12:02:54+00:00weekly0.6https://www.medthority.com/news/2024/2/positive-headline-results-from-eagle-1-phase-iii-trial-for-gepotidacin-in-uncomplicated-urogenital-gonorrhoea-gc.--gsk-plc2024-02-27T12:01:13+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-for-priority-review-the-supplemental-bla--for-epcoritamab-epkinly-for-difficult-to-treat-relapsed-or-refractory-follicular-lymphoma.--genmab-as--abbvie2024-02-27T11:56:46+00:00weekly0.6https://www.medthority.com/news/2024/2/the-fda-has-approved-an-expanded-indication-of-the-wavewriter-scs-systems-for-the-treatment-of-chronic-low-back-and-leg-pain.--boston-scientific2024-02-13T13:37:06+00:00weekly0.6https://www.medthority.com/news/2024/2/top-line-results-from-the-phase-iii-aegis-ii-trial-evaluating--csl-112-apolipoprotein-a-i-human-following-an-acute-myocardial-infarction-.--csl2024-09-30T09:59:42+00:00weekly0.6https://www.medthority.com/news/2024/2/shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over-is-accepted-for-review-by-china-national-medical-products-administration--gsk-plc/2024-02-13T13:42:16+00:00weekly0.6https://www.medthority.com/news/2024/2/new-data-demonstrate-clinical-safety-benefit-and-durability-of-nexviazyme-avalglucosidase-alfa-across-a-wide-range-of-pompe-disease-patient-groups.--sanofi2024-02-13T13:46:25+00:00weekly0.6https://www.medthority.com/news/2024/2/european-commission-approves-skyclarys-omaveloxolone-to-treat-friedreichs-ataxia.--biogen2024-02-13T13:48:25+00:00weekly0.6https://www.medthority.com/news/2024/2/european-union-approves-first-crisprcas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.--vertex-pharma2024-02-13T13:50:10+00:00weekly0.6https://www.medthority.com/news/2024/2/gilead-acquires-cymabay-and-with-it-seladelpar-for-the-treatment-of-primary-biliary-cholangitis/2024-02-13T13:51:49+00:00weekly0.6https://www.medthority.com/news/2024/2/pivotal-phase-iii-trial-of-trilaciclib-in-metastatic--triple-negative-breast-cancer-recommended-to-proceed-by-independent-data-monitoring-committee.--g1-therapeutics.-2024-02-14T12:36:01+00:00weekly0.6https://www.medthority.com/news/2024/2/mhlw-japan-approves-jardiance-empagliflozin-for-the-treatment-of-chronic-kidney-disease-ckd.--nippon-boehringer-ingelheim2024-02-14T12:30:15+00:00weekly0.6https://www.medthority.com/news/2024/2/phase-iii-konfident-trial-meets-all-endpoints-for-sebetralstat-as-first-oral-on-demand-therapy-for-hereditary-angioedema.-kalvista-pharmaceuticals.-2024-02-14T12:28:07+00:00weekly0.6https://www.medthority.com/news/2024/2/onivyde-regimen-a-potential-new-standard-of-care-first-line-therapy-in-metastatic-pancreatic-adenocarcinoma-approved-by-fda-.--ipsen2024-02-14T12:24:59+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approves-eohilia-budesonide-oral-suspension-the-first-and-only-oral-treatment-in-the-u.s.-for-eosinophilic-esophagitis.--takeda2024-02-14T12:22:25+00:00weekly0.6https://www.medthority.com/news/2024/2/publication-of-efficacy-safety-and-tolerability-data-with-vamorolone-agamree-in-patients-with-duchenne-muscular-dystrophy-in-neurology-journal.--santhera2024-02-15T11:57:21+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-for-priority-review--application-for-augtyro-repotrectinib-for-the-treatment-of-patients-with-ntrk-positive-locally-advanced-or-metastatic-solid-tumors.--bms2024-02-15T12:00:16+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-advisory-committee-votes-in-favour-of-first-of-its-kind-triclipsystem-to-treat-people-with-a-leaky-tricuspid-valve..--abbott2024-02-15T12:02:27+00:00weekly0.6https://www.medthority.com/news/2024/2/topline-results--reported-from-phase-iii-trial-of-fibrinogen-concentrate--bt-524-as-a-treatment-for-acquired-fibrinogen-deficiency-.--grifols-2024-02-15T12:04:27+00:00weekly0.6https://www.medthority.com/news/2024/2/lianbio-to-wind-down/2024-02-15T12:06:21+00:00weekly0.6https://www.medthority.com/news/2024/2/metoject-subcutaneous-injection-pen-methotrexate-pen--type-autoinjector-approved-in-japan.--eisai-2024-02-16T12:38:43+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-bla-for-ustekinumab-biosimilar.--alvotech2024-02-16T12:31:50+00:00weekly0.6https://www.medthority.com/news/2024/2/japan-first-in-the-world-to-approve-dupixent-dupilumab-for-chronic-spontaneous-urticaria-csu.-regeneron--sanofi2024-02-16T12:27:22+00:00weekly0.6https://www.medthority.com/news/2024/2/invitae-files-for-voluntary-chapter-11-protection/2024-02-16T12:24:42+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approves-xolair-as-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-allergies.-genentechroche--novartis2024-02-18T14:00:22+00:00weekly0.6https://www.medthority.com/news/2024/2/phase-iii-topline-results-of-avp-786-announced-for-the-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-disease.-otsuka2024-02-18T13:59:38+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approves-tagrisso-osimertinib--chemotherapy-to-treat-metastatic-epidermal-growth-factor-receptor-mutated-egfrm-non-small-cell-lung-cancer-.--astrazeneca2024-02-18T13:58:50+00:00weekly0.6https://www.medthority.com/news/2024/2/amtagvi-lifileucel-receives-fda-accelerated-approval-for-advanced-melanoma.--iovance-biotherapeutics-inc2024-02-18T13:58:02+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-grants-regular-approval-for-tepmetko-tepotinib-for-metastatic-nsclc-harboring-met-exon-14-skipping-alterations.--merck-kgaa2024-02-19T11:15:02+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-resubmission-of-dasyno-dasatinib-formulation-to-treat-hronic-myeloid-leukemia-cml--xspray-pharma-ab/2024-02-19T11:18:29+00:00weekly0.6https://www.medthority.com/news/2024/2/tagrisso-osimertinib-is-the-first-egfr-inhibitor-and-targeted-treatment-to-demonstrate-progression-free-survival-benefit-in-stage-iii-setting-of-non-small-cell-lung-cancer.--astrazeneca2024-02-21T14:30:42+00:00weekly0.6https://www.medthority.com/news/2024/2/health-canada-approves-rexulti-brexpiprazole-for-agitation-associated-with-alzheimers-disease-related-dementia-.--otsuka--lundbeck2024-02-21T14:33:09+00:00weekly0.6https://www.medthority.com/news/2024/2/datopotamab-deruxtecan-bla-is-accepted-in-the-us-for-patients-with-previously-treated-advanced-nonsquamous-non-small-cell-lung-cancer-.-astrazeneca--daiichi-sankyo2024-02-21T14:34:51+00:00weekly0.6https://www.medthority.com/news/2024/2/bla-resubmitted-to-fda-for-denileukin-diftitox-in-relapsedrefractory-cutaneous-t-cell-lymphoma.--citius-pharmaceuticals2024-02-21T14:37:14+00:00weekly0.6https://www.medthority.com/news/2024/2/evusheld-tixagevimab--cilgavimab--failed-to-improve-outcomes-in-a-phase-iii-trial-involving-hospitalised-covid-19-patients--astrazeneca/2024-02-21T14:38:45+00:00weekly0.6https://www.medthority.com/news/2024/2/tenax-therapeutics-announces-global-license-amendment-that-significantly-expands-rights-to-levosimendan.-2024-02-21T14:40:23+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-supplemental-nda--for-krazati-adagrasib--cetuximab-to-treat-patients-with-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-colorectal-cancer.--bms-2024-02-21T14:49:37+00:00weekly0.6https://www.medthority.com/news/2024/2/clinical-hold-on-studies-of-zelnecirnon-rpt193-in-atopic-dermatitis-and-asthma.--rapt-therapeutics2024-02-21T14:51:39+00:00weekly0.6https://www.medthority.com/news/2024/2/linvoseltamab-bla-for-treatment-of-relapsedrefractory-multiple-myeloma-accepted-for-fda-priority-review.--regeneron-pharma2024-02-22T12:48:59+00:00weekly0.6https://www.medthority.com/news/2024/2/new-england-journal-of-medicine-publishes-results-of-positive-randomized-phase-ii-revive-trial-of-rusfertide-in-treatment-of-polycythemia-vera.--protagonist-therapeutics-inc.--takeda2024-02-22T12:51:46+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-sbla-for-keytruda-pembrolizumab--chemotherapy-to-treat--primary-advanced-or-recurrent-endometrial-carcinoma.--merck-inc2024-02-22T12:54:11+00:00weekly0.6https://www.medthority.com/news/2024/2/phase-ii-data-published-in-nejm-show-potential-of-frexalimab-as-high-efficacy-therapy-in-relapsing-multiple-sclerosis.--sanofi2024-02-22T12:55:55+00:00weekly0.6https://www.medthority.com/news/2024/2/update-on-fda-oncologic-drugs-advisory-committee-meeting-for-abecma-in-triple-class-exposed-multiple-myeloma-based-on-karmma-3-study.--bms--2seventy-bio-inc2024-02-07T08:27:47+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-update-for-supplemental-nda-for-hetlioz-tasimelteonin-the-treatment-of-insomnia.--vanda-pharma2024-02-07T08:27:00+00:00weekly0.6https://www.medthority.com/news/2024/2/first-patient-randomized-in-registrational-trial-of-otl-203-for-mps-i-hurler-syndrome.-orchard-therapeutics2024-02-07T08:25:50+00:00weekly0.6https://www.medthority.com/news/2024/2/late-breaking-data-from-inspire-and-admire-clinical-trials-for-varipulse-platform-presented-at-af-symposium.-biosense-webster-jj2024-09-30T11:57:47+00:00weekly0.6https://www.medthority.com/news/2024/2/novartis-to-acquire-morphosys-ag/2024-02-07T08:23:58+00:00weekly0.6https://www.medthority.com/news/2024/2/the-stimulus-mds2-trial-of-sabatolimab--azacitidine-did-not-meet-its-primary-endpoint--for-subjects-with-intermediate-high-or-very-high-risk-myelodysplastic-syndromes.--novartis2024-02-02T12:46:20+00:00weekly0.6https://www.medthority.com/news/2024/2/enhertu-famtrastuzumab-deruxtecan-nxki-is--granted-priority-review-in-the-u.s.-for-patients-with-metastatic-her2-positive-solid-tumors-.-daiichi-sankyo--astrazeneca2024-02-02T12:48:13+00:00weekly0.6https://www.medthority.com/news/2024/2/tonix-pharmaceuticals-announces-research-indicating-pre-existing-fibromyalgia-type-symptoms-may-increase-the-risk-of-developing-long-covid/2024-02-02T12:55:00+00:00weekly0.6https://www.medthority.com/news/2024/2/kiora-pharmaceuticals--has-entered-into-an-agreement-with-thea-open-innovation-sas-concerning-the-kio-301-molecular-photoswitch-product/2024-02-02T12:56:41+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approves-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-t-cell-therapy.-kitegilead-sciences2024-02-02T12:58:02+00:00weekly0.6https://www.medthority.com/news/2024/2/results-from-open-label-phase-iii-trial-for-transthyretin-mediated-amyloid-cardiomyopathy-to-support-acoramidis-local-regulatory-submission-in-japan.-alexion-astrazeneca-rare-disease2024-02-02T12:59:49+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approval-for-evoque-tricuspid-valve-replacement-system-for-the-treatment-of-tricuspid-regurgitation.--edwards-lifesciences-corporation2024-02-03T17:33:32+00:00weekly0.6https://www.medthority.com/news/2024/2/tisotumab-vedotin-marketing-authorization-application-validated-by-ema-for-treatment-of-recurrent-metastatic-cervical-cancer.--genmab-as--pfizer-inc2024-02-03T17:32:40+00:00weekly0.6https://www.medthority.com/news/2024/2/linvoseltamab-receives-ema-filing-acceptance-for-treatment-of-relapsedrefractory-multiple-myeloma/2024-02-04T14:02:38+00:00weekly0.6https://www.medthority.com/news/2024/2/study-supports-low-and-zero-fluoroscopy-workflow-as-safe-effective-alternative-to-conventional-catheter-ablation--biosense-websterjj/2024-09-30T12:02:36+00:00weekly0.6https://www.medthority.com/news/2024/2/submission-of-a-supplemental-bla-to-the-fda-seeking-approval-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-for-the-treatment-of-patients-with-transplant-eligible-newly-diagnosed-multiple-myeloma.--johnson--johnson2024-02-05T14:29:07+00:00weekly0.6https://www.medthority.com/news/2024/2/regulatory-applications-accepted-in-the-u.s.-and-japan-for-breyanzi-lisocabtagene-maraleucel-in-relapsed-or-refractory-follicular-lymphoma-and-relapsed-or-refractory-mantle-cell-lymphoma-.--bms2024-02-05T14:31:52+00:00weekly0.6https://www.medthority.com/news/2024/2/mini-tee-ultrasound-transducer-has-fda-510-k-approval-to-improve-cardiac-care-for-more-patients.--royal-philips2024-02-07T12:43:23+00:00weekly0.6https://www.medthority.com/news/2024/2/immunome-inc.-to-acquire-al-102-a-phase-iii-asset-for-the-treatment-of-desmoid-tumors-from-ayala-pharmaceuticals2024-02-07T12:42:36+00:00weekly0.6https://www.medthority.com/news/2024/2/jazz-pharmaceuticals-to-acquire-a-kras-inhibitor-program-from-redx/2024-02-07T12:41:30+00:00weekly0.6https://www.medthority.com/news/2024/2/no-decline-in-cognition-scores-in-patients-with-mild-alzheimers-disease-who-received-simufilam-continuously-for-24-months.--cassava-sciences2024-02-08T11:41:21+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-acceptance-of-u.s.-and-eu-regulatory-filings-for-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-opdivo-in-resectable-non-small-cell-lung-cancer.--bms2024-02-08T11:44:26+00:00weekly0.6https://www.medthority.com/news/2024/2/first-patient-in-phase-iii-level-study-evaluating-tnx-103-oral-levosimendan-for-the-treatment-of-pulmonary-hypertension-in-heart-failure-with-preserved-ejection-fraction-ph-hfpef.--tenax-therapeutics-inc2024-02-08T11:46:44+00:00weekly0.6https://www.medthority.com/news/2024/2/gilead-sciences-terminates-development-of-magrolimab-in-blood-cancers/2024-02-08T11:50:12+00:00weekly0.6https://www.medthority.com/news/2024/2/new-england-journal-of-medicine-publishes-efficacy-and-safety-data-of-targeted-oral-peptide-jnj-2113-in-a-phase-iib-moderate-to-severe-plaque-psoriasis-study.--protagonist-therapeutics-inc2024-02-12T09:08:22+00:00weekly0.6https://www.medthority.com/news/2024/2/arexvy-is--accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk.--gsk2024-02-09T11:23:54+00:00weekly0.6https://www.medthority.com/news/2024/2/latest-analyses-of-bimekizumab-phase-iii-studies-in-moderate-to-severe-hidradenitis-suppurativa-presented-at-ehsf-2024--ucb/2024-09-30T14:31:19+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-accepts-filing-of-nda-for--acoramidis-for-the-treatment-of-attr-cm.--bridgebio-pharma-inc.-2024-02-12T11:38:21+00:00weekly0.6https://www.medthority.com/news/2024/2/takeda-intends-to-rapidly-initiate-the-first-global-phase-iii-trials-of-tak-861-an-oral-orexin-agonist-in-narcolepsy-type-1-in-first-half-of-fiscal-year-2024/2024-02-12T11:41:37+00:00weekly0.6https://www.medthority.com/news/2024/2/synlogic-announces-decision-to-discontinue-synpheny-3-study-of-labafenogene-marselecobac-and-provides-corporate-update/2024-02-12T11:43:05+00:00weekly0.6https://www.medthority.com/news/2024/2/positive-topline-results-from-phase-ii-study-evaluating-ampligen-rinatatolimod-for-the-treatment-of-post-covid-conditions.--aim-immunotech-inc2024-02-12T11:44:20+00:00weekly0.6https://www.medthority.com/news/2024/2/vyalev-foslevodopafoscarbidopa-solution-available-for-the-treatment-of-advanced-parkinsons-disease-in-canada.--abbvie2024-02-12T11:45:29+00:00weekly0.6https://www.medthority.com/news/2024/2/ce-mark-approval-of-omnipod-5-integration-with-abbott-freestyle-libre-2-plus-sensor.--insulet-corpn2024-02-12T11:47:36+00:00weekly0.6https://www.medthority.com/news/2024/2/belantamab-mafodotin--vd-more-than-doubles-pfs-in-relapsedrefractory-multiple-myeloma.--gsk2024-02-12T11:49:16+00:00weekly0.6https://www.medthority.com/news/2024/2/second-line-fruquintinib--paclitaxel-significantly-improves-pfs-but-not-os-in-advanced-gastric-or-gej-adenocarcinoma.--eli-lilly2024-02-12T11:50:52+00:00weekly0.6https://www.medthority.com/news/2024/1/boston-scientific-presents-key-data-at-the-2024-north-american-neuromodulation-society-meeting/2024-01-23T11:00:20+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-acceptance-of-the-pma-application-for-ttfields-therapy-for-non-small-cell-lung-cancer.--novocure2024-01-23T12:41:41+00:00weekly0.6https://www.medthority.com/news/2024/1/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-iiib-study--johnson--johnson/2024-01-23T12:45:57+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-grants-full-approval-for-balversa-erdafitinib-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations.--johnson--johnson2024-01-23T12:48:32+00:00weekly0.6https://www.medthority.com/news/2024/1/update-on-phase-iii-evoke-01-study-of-trodelvy-sacituzumab-govitecan-hziy-for-nsclc.--gilead-sciences2025-02-03T14:59:52+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-topline-results-from-phase-iii-oasis-hae-study-of-investigational-donidalorsen-in-patients-with-hereditary-angioedema.--ionis-pharma2024-01-23T12:53:57+00:00weekly0.6https://www.medthority.com/news/2024/1/multiple-new-analyses-reinforce-the-role-of-bavencio-avelumab-as-a-standard-of-care-for-locally-advanced-or-metastatic-urothelial-carcinoma.merck-kgaa2024-01-23T12:57:00+00:00weekly0.6https://www.medthority.com/news/2024/1/eight-year-data-for-opdivo-nivolumab--yervoy-ipilimumab-continue-to-demonstrate-longest-survival-benefit-vs.-sunitinib-reported-in-patients-with-previously-untreated-advanced-or-metastatic-renal-cell-carcinoma.--bms2024-01-23T13:00:19+00:00weekly0.6https://www.medthority.com/news/2024/1/opdivo-nivolumab--cabometyx-cabozantinib-demonstrates-long-term-survival-benefits-after-four-years-of-follow-up-in-the-checkmate--9er-trial-in-first-line-advanced-renal-cell-carcinoma.--bms2024-01-24T12:44:19+00:00weekly0.6https://www.medthority.com/news/2024/1/sanofi-to-buy-inhibrx-inc.-and-inbrx-101-an-optimized-recombinant-alpha-1-antitrypsin-aat-augmentation-therapy-2024-01-24T12:41:50+00:00weekly0.6https://www.medthority.com/news/2024/1/initiation-of-pivotal-phase-iii-trial-of-antibody-drug-conjugate-candidate-bnt323db-1303-in-metastatic-breast-cancer--biontech-se--duality-biologics/2024-01-24T12:38:42+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-updates-for-car-t-therapies-regarding-risk-of-blood-cancer/2024-01-25T12:46:50+00:00weekly0.6https://www.medthority.com/news/2024/1/ce-mark-for-da-vinci-single-port-sp-surgical-system-.--intuitive2024-01-25T12:48:38+00:00weekly0.6https://www.medthority.com/news/2024/1/complete-response-letter-for-the-f8-formulation-of-tesamorelin-for-hiv-associated-lipodystrophy.--theratechnologies-inc2024-01-25T12:50:47+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approval-of-zynrelef-indication-expansion-to-include-additional-orthopedic-and-soft-tissue-procedures.--heron-therapeutics-inc2024-01-25T12:52:05+00:00weekly0.6https://www.medthority.com/news/2024/1/new-data-at-cmr-2024-from-forest-hcm-the-open-label-extension-clinical-trial-of-aficamten-in-hypertrophic-cardiomyopathy.--cytokinetics-inc2024-01-26T12:55:20+00:00weekly0.6https://www.medthority.com/news/2024/1/orchard-therapeutics-announces-agreement-with-the-beneluxa-consortium-enabling-reimbursed-access-to-libmeldy-atidarsagene-autotemcel-for-early-onset-metachromatic-leukodystrophy/2024-01-26T13:35:22+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approval-for-liberta-rc-dbs-system-to-treat-movement-disorders.--abbott2024-01-26T13:37:55+00:00weekly0.6https://www.medthority.com/news/2024/1/detailed-results-of-phase-iii-contact-02-pivotal-trial-evaluating-cabozantinib--atezolizumab-in-metastatic-castration-resistant-prostate-cancer-presented-at-asco-gu-2024.-exelixis-inc2025-01-23T14:05:17+00:00weekly0.6https://www.medthority.com/news/2024/1/liquidia-corporation-provides-update-on-nda-for-yutrepia-treprostinil-inhalation-powder/2024-01-26T13:45:34+00:00weekly0.6https://www.medthority.com/news/2024/1/new-long-term-data-for-vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion-rvo.--genentechroche2024-01-26T13:55:31+00:00weekly0.6https://www.medthority.com/news/2024/1/nda-submitted-in-japan-for-mecobalamin-ultra-high-dose-formulation-to-treat-amyotrophic-lateral-sclerosis.--eisai2024-01-26T13:57:59+00:00weekly0.6https://www.medthority.com/news/2024/1/dupixent-dupilumab-is-fda-approved-as-the-first-and-only-treatment-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis.--regeneron--sanofi2024-01-26T14:00:20+00:00weekly0.6https://www.medthority.com/news/2024/1/european-medicines-agency-validates-type-ii-variation-application-for-padcev-enfortumab-vedotin-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer.--astellas--pfizer2024-01-27T14:09:05+00:00weekly0.6https://www.medthority.com/news/2024/1/keytruda-pembrolizumab-significantly-improved-disease-free-survival-dfs-as-adjuvant-therapy-versus-observation-in-high-risk-patients-with-localized-muscle-invasive-and-locally-advanced-urothelial-carcinoma-after-surgery.--merck-inc2024-01-27T14:08:26+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-chmp-opinion-for-car-t-cell-therapy-abecma-idecabtagene-vicleucelin-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-and-refractory-multiple-myeloma.--bms2024-01-27T14:07:42+00:00weekly0.6https://www.medthority.com/news/2024/1/advanz-pharma-receives-positive-chmp-opinion-for-exblifep-cefepimeenmetazobactam-to-treatcomplicated-urinary-tract-infections/2024-01-27T14:07:01+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-ryzneuta-efbemalenograstim-alpha-to-reduce-the-duration-of-neutropenia-and-the-incidence-of-febrile-neutropenia-due-to-chemotherapy.-evive-biotecnology2024-01-27T14:06:19+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-refusal-of-approval-for-nezglyal-leriglitazone-to-treat-cerebral-adrenoleukodystrophy.--minoryx-therapeutics-s.l.-2024-01-28T15:29:05+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-refusal-of-approval-for-syfovre-pegcetacoplan-to-treatgeographic-atrophy-caused-by-age-related-macular-degeneration.-apellis-pharma2024-01-28T15:28:25+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-variation--of-the-indication-of-abcema-idecabtagene-vicleucel-for-rr-multiple-myeloma-bms/2024-01-29T12:02:01+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-variation-of-the-indication-for-aspaveli-pegcetacoplan-to-include-patients-with-paroxysmal-nocturnal-haemoglobinuria-who-have-haemolytic-anaemia-and-have-not-had-previous-treatment-with-a-c5-inhibitor.--sobi2024-01-29T12:00:44+00:00weekly0.6https://www.medthority.com/news/2024/1/chmp-recommends-variation-to-indication-of-retsevmo-selpercatinib--to-include-treatment-of-adults-and-adolescents-with-ret-fusion-positive-thyroid-cancer-that-is-radioactive-iodine-refractory.eli-lilly2024-01-29T11:59:19+00:00weekly0.6https://www.medthority.com/news/2024/1/keytruda-pembrolizumab-reduced-the-risk-of-death-by-38-versus-placebo-as-adjuvant-therapy-for-patients-with-renal-cell-carcinoma-rcc-at-an-increased-risk-of-recurrence-following-nephrectomy.--merck-inc2024-01-29T11:53:57+00:00weekly0.6https://www.medthority.com/news/2024/1/obecabtagene-autoleucel-bla--accepted-for-rr-b-all-and-under-fda-review.--autolus-therapeutics2024-01-29T11:51:13+00:00weekly0.6https://www.medthority.com/news/2024/1/adagrasib-approved-conditionally-in-europe-for-pretreated-kras-g12c-advanced-nsclc.-mirati-therapeutics2025-02-03T14:13:21+00:00weekly0.6https://www.medthority.com/news/2024/1/lantheus-announces-fda-acceptance-of-its-first-to-file-anda-for-generic-lutathera-lutetium-lu-177-dotatate/2024-01-12T12:08:16+00:00weekly0.6https://www.medthority.com/news/2024/1/tivdak-tisotumab-vedotin-tftv-supplemental-biologics-license-application-accepted-by-the-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer.-genmab-as--pfizer2024-01-12T12:12:31+00:00weekly0.6https://www.medthority.com/news/2024/1/publication-of-positive-results-from-phase-iii-attribute-cm-study-of-acoramidis-for-patients-with-transthyretin-amyloid-cardiomyopathy-attr-cm-in-the-new-england-journal-of-medicine.--bridgebio-pharma2024-01-12T12:14:58+00:00weekly0.6https://www.medthority.com/news/2024/1/mhra-approval-for-agamree-vamorolone-to-treat-duchenne-muscular-dystrophy.--santhera-pharma2024-01-14T18:17:32+00:00weekly0.6https://www.medthority.com/news/2024/1/the-new-england-journal-of-medicine-publication-demonstrating-durable-clinical-activity-of-repotrectinib-in-patients-with-advanced-ros1-fusion-positive-nsclc.--zai-labs2024-01-14T18:16:46+00:00weekly0.6https://www.medthority.com/news/2024/1/complete-response-for-zolbetuximab-to-treat-locally-advanced-unresectable-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--astellas2024-01-14T18:16:02+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approves-keytruda-pembrolizumab--chemoradiotherapy-as-a-treatment-for-patients-with-figo-2014-stage-iii-iva-cervical-cancer--merck-inc/2024-01-14T18:15:18+00:00weekly0.6https://www.medthority.com/news/2024/1/european-commission-approves-talzenna-talazoparib-xtandi-enzalutamide-for-adult-patients-with-metastatic-castration-resistant-prostate-cancer.--pfizer2025-01-23T14:06:23+00:00weekly0.6https://www.medthority.com/news/2024/1/tandem-diabetes-cares-tslim-x2-insulin-pump-is-the-first-automated-insulin-delivery-system-to-integrate-with-abbotts-new-freestyle-libre-2-plus-sensor/2024-01-14T18:14:03+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approves-percept-rc-deep-brain-stimulation-dbs-system-with-exclusive-brainsense-technology.-medtronic2024-01-14T18:13:11+00:00weekly0.6https://www.medthority.com/news/2024/1/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype.--gsk-plc2024-01-14T18:12:27+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-filing-acceptance-of-nda-for-novel-formulation--of-sh-105-to-treat-breast-cancer-and-ovarian-cancer.--shorla-oncology2024-06-24T09:37:32+00:00weekly0.6https://www.medthority.com/news/2024/1/spexis-ag-agrees-with-basilea-pharmaceutica-to-provide-a-preclinical-program-of-antibiotics-targeting-gram--negative--bacteria/2024-01-15T12:25:23+00:00weekly0.6https://www.medthority.com/news/2024/1/comparison-of-the-efficacy-in-clinical-trials-versus-effectiveness-in-the-real-world-of-treatments-for-multiple-myeloma-a-population-based-cohort-study/2024-01-20T14:10:52+00:00weekly0.6https://www.medthority.com/news/2024/1/alvotech-provides-update-on-status-of-blas-for-avt-02-and-avt-04-by-february-24-2024-and-april-16-2024-their-respective-goal-dates/2024-01-20T14:10:10+00:00weekly0.6https://www.medthority.com/news/2024/1/long-term-follow-up-results-from-intrigue-phase-iii-clinical-study-in-second-line-gist-patients-at-the-2024-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium--deciphera-pharmaceuticals-inc/2024-01-20T14:09:25+00:00weekly0.6https://www.medthority.com/news/2024/1/voydeya-danicopan-has-been-approved-in-japan-for-the-treatment-of-paroxysmal-nocturnal-haemoglobinuria-pnh.--astrazeneca2024-01-20T14:08:44+00:00weekly0.6https://www.medthority.com/news/2024/1/lutathera-significantly-reduced-risk-of-disease-progression-or-death-by-72-as-first-line-treatment-for-patients-with-advanced-gastroentero-pancreatic-neuroendocrine-tumors.--novartis2024-01-20T14:07:59+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-results-from-emerald-1-phase-iii-trial-showed-infinzi-durvalumab--tace--bevacizumab-for-liver-cancer-presented-at-asco-gi-meeting.--astrazeneca2024-01-20T14:07:19+00:00weekly0.6https://www.medthority.com/news/2024/1/opdivo-nivolumab--yervoy-ipilimumab-reduced-the-risk-of-disease-progression-or-death-by-79-versus-chemotherapy-in-patients-with-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer-in-checkmate--8hw-trial.--bms2024-01-21T16:09:02+00:00weekly0.6https://www.medthority.com/news/2024/1/halozyme-therapeutics-announced-that-argenx-received-approval-from-mhlw-japan-for-vyvdura-injection-co-formulated-with-halozymes-enhanze-drug-delivery-technology.--halozyme--argenx2024-01-21T16:08:13+00:00weekly0.6https://www.medthority.com/news/2024/1/sbla-for-trogarzo-intramuscular-im-method-of-administration-for-hiv-infection-is-submitted-to-fda.-theratechnologies-inc2024-01-22T12:29:18+00:00weekly0.6https://www.medthority.com/news/2024/1/sandoz-acquires-cimerli-biosimilar-ranibizumab-eqrn-business-from-coherus-biosciences/2024-01-22T12:30:39+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-top-line-results-frpm-pk-study-of-avt-03-a-denosumab-biosimilar.--alvotech2024-01-30T13:27:35+00:00weekly0.6https://www.medthority.com/news/2024/1/aripiprazole-once-every-two-months-long-acting-injectable-recommended-for-approval-by-the-chmp-for-the-maintenance-treatment-of-schizophrenia-in-adult-patients-stabilised-with-aripiprazole.--otsuka---h.lundbeck2024-01-30T13:28:59+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-accepts-sbla-for-enhertu-trastuzumab-deruxtecan-to-treat-unresectable-or-metastatic-her2-positive-immunohistochemistry-ihc-3-solid-tumours.--astrazeneca--daiichi-sankyo-2024-01-30T13:36:03+00:00weekly0.6https://www.medthority.com/news/2024/1/journal-of-the-american-academy-of-dermatology-publishes-zorvye-roflumilast-foam-0.3-results-for-seborrheic-dermatitis-from-pivotal-phase-iii-trial.--arcutis-biotherapeutics-inc2024-01-30T13:38:23+00:00weekly0.6https://www.medthority.com/news/2024/1/nmpa-china-accepted-a-submission-for-aflibercept-8-mg-for-the-treatment-of-neovascular-wet-age-related-macular-degeneration.---bayer2024-01-30T13:39:15+00:00weekly0.6https://www.medthority.com/news/2024/1/european-commission-approves-omjjara-momelotinib-indicated-for-treating-splenomegaly-enlarged-spleen-or-symptoms-in-adult-myelofibrosis-patients-with-moderate-to-severe-anaemia.--gsk2024-01-30T13:40:23+00:00weekly0.6https://www.medthority.com/news/2024/1/subcutaneous-nivolumab-nivolumab-and-hyaluronidase-shows-noninferiority-compared-to-intravenous-opdivo-nivolumab-in-advanced-or-metastatic-clear-cell-renal-cell-carcinoma-in-checkmate--67t-trial.-bms2024-01-30T13:41:24+00:00weekly0.6https://www.medthority.com/news/2024/1/court-orders-fda-to-resolve-vanda-pharmaceuticals-jet-lag-hearing-request-by-march-5-2024/2024-01-30T13:42:40+00:00weekly0.6https://www.medthority.com/news/2024/1/mhra-uk-approval-of-rezzayo-rezafungin-acetate-for-the-treatment-of-invasive-candidiasis-in-adults.--cidara-therapeutics-and-mundipharma2024-01-31T11:00:20+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-results-from-the-vx-548-phase-iii-program-for-the-treatment-of-moderate-to-severe-acute-pain.-vertex2024-01-31T12:27:44+00:00weekly0.6https://www.medthority.com/news/2024/1/sandoz-launches-first-and-only-biosimilar-for-multiple-sclerosis-tyruko-natalizumab-in-germany.-2024-01-31T12:29:50+00:00weekly0.6https://www.medthority.com/news/2024/1/regeneron-to-form-regeneron-cell-medicines-and-acquire-from-2seventy-bio-inc.all-rights-to-its-novel-immune-cell-therapies2024-01-31T12:31:19+00:00weekly0.6https://www.medthority.com/news/2024/1/mhlw-approves-fycompa--perampanel-in-japan-as-an-alternative-epilepsy-therapy-when-oral-administration-is-temporarily-not-possible.--eisai2024-01-19T12:21:49+00:00weekly0.6https://www.medthority.com/news/2024/1/first-global-procedures-in-a-clinical-trial-of-the-volt-pulsed-field-ablation-system-to-treat-patients-with-abnormal-heart-rhythms.--abbott2024-09-30T11:42:48+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approval-for-farapulse-pulsed-field-ablation-system.--boston-scientific2024-09-30T11:40:30+00:00weekly0.6https://www.medthority.com/news/2024/2/biogen-will-terminate-aduhelm-aducanumab-avwa-evision-study-for-alzheimers-disease-and-reprioritize-its-resources/2024-02-01T13:16:46+00:00weekly0.6https://www.medthority.com/news/2024/2/european-commission-ec-approved-hyqvia-immune-globulin-infusion-10-human-with-recombinant-human-hyaluronidase-as-maintenance-therapy-in-patients-of-all-ages-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp.--takeda2024-02-01T13:18:52+00:00weekly0.6https://www.medthority.com/news/2024/2/fda-approves-gammagard-liquid-immune-globulin-infusion-human-10-solution-to-improve-neuromuscular-disability-and-impairment-in-chronic-inflammatory-demyelinating-polyneuropathy-cidp.--takeda2024-02-01T13:20:34+00:00weekly0.6https://www.medthority.com/news/2024/2/takeda-and-protagonist-therapeutics-inc.-enter-into-a-worldwide-license--for-rusfertide-currently-in-phase-iii-for-polycythemia-vera.-2024-02-01T13:22:03+00:00weekly0.6https://www.medthority.com/news/2024/2/avrobio-inc.-to-merge-with-tectonic-therapeutic-inc2024-02-01T13:23:50+00:00weekly0.6https://www.medthority.com/news/2023/4/data-on-terlivaz-for-injection-in-adult-patients-with-hepatorenal-syndrome--to-be-presented-at-the-national-kidney-foundation-nkf-2023-spring-clinical-meeting-scm.--mallinckrodt-plc2023-04-11T11:55:27+00:00weekly0.6https://www.medthority.com/news/2023/4/analysis-of-clinical-studies-with-betahistine-in-treatment-of-most-common-cause-of-vertigo--altamira-therapeutics/2023-04-11T11:57:02+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iv-clinical-trial-of-tepezza-confirms-efficacy-in-thyroid-eye-disease.--horizon-therapeutics2023-04-11T11:59:53+00:00weekly0.6https://www.medthority.com/news/2023/4/erleada-first-and-only-next-generation-androgen-receptor-inhibitor-with-once-daily-single-tablet-option-now-available-in-the-u.s..--janssen-pharma2023-04-11T12:03:23+00:00weekly0.6https://www.medthority.com/news/2023/4/pear-therapeutic-files-for-bankrupcy/2023-04-11T12:06:39+00:00weekly0.6https://www.medthority.com/news/2023/4/mrna-4157v940-an-investigational-personalized-mrna-cancer-vaccine---keytruda-receives-prime-scheme-designation-from-the-ema-for-adjuvant-treatment-of-patients-with-high-risk-stage-iiiiv-melanoma-following-complete-resection--moderna--merck-inc/2023-04-08T15:05:12+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-leap-003-trial-of-keytruda--lenvima-is-discontinued-after-no-improvement-in-survival-in-melanoma.--merck-inc-and-eisai2023-04-08T15:10:39+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-leap-017-trial-of-keytruda--lenvima-fails-to-meet-primary-endpoint-in-colorectal-cancer.--merck-inc--eisai2023-04-09T16:52:53+00:00weekly0.6https://www.medthority.com/news/2023/4/abbvie-to-withdraw-in-the-u.s.-accelerated-imbruvica-approvals-for-patients-with-the-blood-cancers-mantle-cell-lymphoma-mcl-and-marginal-zone-lymphoma-mzl.--abbvie2023-04-08T15:11:48+00:00weekly0.6https://www.medthority.com/news/2023/4/jcr-pharmaceuticals-co.-ltd-and-sumitomo-pharma-co.-ltd.-announced--that-they-have-concluded-a-co-promotion-agreement-for-izcargo-i.v.-infusion-10-mg.-in-japan2023-04-09T16:56:05+00:00weekly0.6https://www.medthority.com/news/2023/4/clovis-agrees-to-sell-oncology-drug-rubraca-to-pharma-schwiez/2023-04-09T16:59:07+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-withdraws-preterm-birth-drug-makena-and-its-generics-from-us-market-after-12-years.--covis-pharma2023-04-09T17:04:08+00:00weekly0.6https://www.medthority.com/news/2023/4/sobi-to-streamline-nirsevimab-contractual-arrangements/2023-04-10T11:17:51+00:00weekly0.6https://www.medthority.com/news/2023/4/mhlw-japan-approves-wegovy-from-novo-nordisk-to-treat-obesity/2023-04-10T11:14:58+00:00weekly0.6https://www.medthority.com/news/2023/4/mhlw-japan-approval-for--entyvio-subcutaneous-injection--for-the-maintenance-treatment-of-moderate-to-severe-ulcerative-colitis.--takeda2023-04-10T11:13:21+00:00weekly0.6https://www.medthority.com/news/2023/4/reduced-hospitalizations-for-covid-19-patients-with-use-of-bemnifosbuvir-shown-at-2023-european-congress-of-clinical-microbiology--infectious-diseases.--atea-pharma2023-04-13T11:25:02+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-clinical-flames-study-of-js-109-completes-interim-analysis-in-ovarian-cancer-and-meets-efficacy-target.--shanghai-junshi-biosciences2023-04-13T11:21:11+00:00weekly0.6https://www.medthority.com/news/2023/4/results-from-phase-iii-essence-2-trial-for-cyclasol-in-dry-eye-disease-published-in-jama-ophthalmol.--novaliq2023-04-13T11:19:50+00:00weekly0.6https://www.medthority.com/news/2023/4/fibromyalgia-and-chronic-migraine-programs-expedited-for-tnx-102-sl-and-tnx-1900-respectively.--tonix-pharma-2023-04-14T11:42:39+00:00weekly0.6https://www.medthority.com/news/2023/4/initiation-of-new-patients-on-evobrutinib-paused-in-the-u.s.-fully-enrolled-phase-iii-evobrutinib-studies-continue.--merck-kgaa2023-04-14T11:44:11+00:00weekly0.6https://www.medthority.com/news/2023/4/enrollment-completed-in-phase-iii-invigorate-2-clinical-trial-in-allergic-conjunctivitis.--aldeyra-therapeutics2023-04-14T11:45:34+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-accepts-filing-of-keytruda-plus-chemo-for-gastric-or-gastroesophageal-junction-adenocarcinoma.--merck-inc2023-04-14T11:47:11+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-emergency-use-authorization-for-gohibic-for-treatment-of-critically-ill-covid-19-patients.--inflarx-n.v2023-04-14T11:49:01+00:00weekly0.6https://www.medthority.com/news/2023/4/complete-response-letter-for-mirikizumab-to-treat-ulcerative-colitis.--eli-lilly2023-04-14T11:51:23+00:00weekly0.6https://www.medthority.com/news/2023/4/advisory-committee-meeting-for-srp-9001-for-duchene-muscular-dystrophy-will-be-may-12-2023.-sarepta-therapeutics2023-04-14T11:53:26+00:00weekly0.6https://www.medthority.com/news/2023/4/biogen-will-acquire-antibody-transport-vehicle-program-targeting-amyloid-beta-from-denali2/2023-04-14T11:56:16+00:00weekly0.6https://www.medthority.com/news/2023/4/complete-response-letter-for-avt-02-a-high-concentration-biosimilar-candidate-for-humira.--alvotech2023-04-15T14:42:37+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-requires-additional-trial-for-review-of-hybryte-a-proposed-treatment-for-early-stage-cutaneous-t-cell-lymphoma-.--soligenix-inc2023-04-15T14:41:48+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approval-of-an-update-to-the-indication-language-for-tepezza-to-specify-its-use-in-thyroid-eye-disease-patients-regardless-of-disease-activity-or-duration--horizon-therapeutics/2023-04-15T14:40:58+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-spotlight-trial-of-imab-362-in-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-published-in-the-lancet.--astellas-pharma2023-04-16T11:17:18+00:00weekly0.6https://www.medthority.com/news/2023/4/eagle-2-and-eagle-3-phase-iii-trials-for-gsk-2140944-in-urinary-tract-infections-demonstrated-non-inferiority-and-were-halted-early-and-presented-at-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid.--gsk2023-04-16T11:16:16+00:00weekly0.6https://www.medthority.com/news/2023/4/tecentriq--avastin-reduced-the-risk-of-cancer-returning-in-people-with-certain-types-of-adjuvant-liver-cancer-in-a-phase-iii-study--genentechroche/2023-04-17T12:06:30+00:00weekly0.6https://www.medthority.com/news/2023/4/results-presented-at-aacr-2023-found-that-four-times-as-many-patients-treated-with-imfinzi-plus-chemotherapy-before-surgery-achieved-pathologic-complete-response-versus-those-treated-with-neoadjuvant-chemotherapy-alone.-astrazeneca2023-04-17T12:08:06+00:00weekly0.6https://www.medthority.com/news/2023/4/keytruda--chemotherapy-significantly-improved-overall-survival-compared-to-chemotherapy-alone-in-patients-with-advanced-or-unresectable-biliary-tract-cancer.-merck-inc2023-04-17T12:09:50+00:00weekly0.6https://www.medthority.com/news/2023/4/additional-detailed-analyses-from-phase-ii-study-201-of-lecanemab-published-as-three-papers-in-peer-reviewed-journals.--eisai--biogen2023-04-01T16:51:17+00:00weekly0.6https://www.medthority.com/news/2023/4/entresto-receives-positive-chmp-opinion-for-pediatric-heart-failure.--novartis2023-04-01T16:49:40+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-epysqli-in-paroxysmal-nocturnal-haemoglobinuria.--samsung-bioepis2023-04-01T16:48:31+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-extension-to-marketing-terms-for-tenkasi-in-acute-bacterial-skin-and-skin-structure-infections.--menarini2023-04-01T16:47:15+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-change-to-marketing-terms-for-ultomiris-for-paroxysmal-nocturnal-haemoglobinuria-and-atypical-haemolytic-uremic-syndrome.--alexion-europe2023-04-01T16:46:11+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-extension-to-marketing-terms-for-wegovy-in-weight-management.--novo-nordisk2023-04-01T16:45:01+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-briumvi-to-treat-relapsing-forms-of-multiple-sclerosis.--propharma-group-the-netherlands-b.v.--tg-therapeutics2023-04-01T16:43:40+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-omvoh-in-ulcerative-colitis.--eli-lilly2023-04-02T13:46:38+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-of-pedmarqsi-in-prevention-of-ototoxicity-induced-by-cisplatin-chemotherapy-in-children-with-solid-tumours.--fennec-pharma2023-04-02T13:45:57+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-protect-study-evaluating-filspari-in-iga-nephropathy-presented-at-world-congress-of-nephrology-2023-and-published-in-the-lancet.--travere-therapeutics2023-04-02T13:45:11+00:00weekly0.6https://www.medthority.com/news/2023/4/merck-kgaa-secures-exclusive-worldwide-rights-to-anti-pd-l1-antibody-bavencio/2023-04-02T13:44:21+00:00weekly0.6https://www.medthority.com/news/2023/4/the-janssen-pharmaceutical-companies-of-johnson--johnson-disclosed-its-exit-from-the-investigational-rsv-adult-vaccine-program/2023-04-02T13:43:29+00:00weekly0.6https://www.medthority.com/news/2023/4/the-data-monitoring-committee-reviewed-unblinded-data-from-courage-als-trial-of-reldesemtiv-to-treat-als--and-recommended-the-discontinuation-of-the-clinical-trial-due-to-futility.--cytokinetics2023-04-02T13:42:40+00:00weekly0.6https://www.medthority.com/news/2023/4/medtronic-plc-and-davita-inc.-announce-the-launch-of-mozarc-medical2023-04-02T13:41:57+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-ultomiris-to-treat--neuromyelitis-optica-spectrum-disorder-patients-who-are-anti-aquaporin-4-aqp4-antibody-positive.--astrazeneca2023-04-04T11:30:01+00:00weekly0.6https://www.medthority.com/news/2023/4/rolling-blas-to-the-fda-for-exa-cel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia-are-completed--vertex--crispr-therapeutics/2023-04-04T11:28:15+00:00weekly0.6https://www.medthority.com/news/2023/4/the-european-commission-approves--hyrimoz-adalimumab-biosimilar-high-concentration-formulation.--sandoz2023-04-04T11:26:14+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-keytruda---padcev-for-first-line-treatment-of-certain-patients-with-locally-advanced-or-metastatic-urothelial-bladder-cancer.--merck-inc2023-04-04T11:23:48+00:00weekly0.6https://www.medthority.com/news/2023/4/european-commission-approval-for-pombiliti--in-patients-with-late-onset-pompe-disease.---amicus-therapeutics2023-04-04T11:21:34+00:00weekly0.6https://www.medthority.com/news/2023/4/baxter-launches-zosyn-premix-in-us-for-the-treatment-of-multiple-infections-caused-by-susceptible-bacteria/2023-04-05T11:16:23+00:00weekly0.6https://www.medthority.com/news/2023/4/update-on-fda-regulatory-reviews-of-transconpth-in-hypoparathyroidism--ascendis-pharma-as/2023-04-05T11:14:43+00:00weekly0.6https://www.medthority.com/news/2023/4/lynparza---imfinzi-combination-improved-progression-free-survival-in-newly-diagnosed-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-duo-o-phase-iii-trial.-astrazeneca-2023-04-05T11:12:57+00:00weekly0.6https://www.medthority.com/news/2023/4/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise--brexafemme-a-novel-first-in-class-medicine-to-treat-fungal-infection.-2023-04-06T12:00:51+00:00weekly0.6https://www.medthority.com/news/2023/4/two-fitusiran-phase-iii-studies-published-in-the-lancet-and-the-lancet-haematology-highlight-potential-to-address-unmet-needs-across-all-types-of-hemophilia.--sanofi--genzyme2023-04-06T11:58:40+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-accepts-snda-for-braftovi--mektovi-to-treat-metastatic-non-small-cell-lung-cancer--with-a-braf-v600e-mutation.--pfizer2023-04-06T11:56:26+00:00weekly0.6https://www.medthority.com/news/2023/4/fixed-duration-imbruvica--venclexta-combination-is-approved--in-canada-for-previously-untreated-cllsll.--abbvie--janssen2023-04-07T11:08:59+00:00weekly0.6https://www.medthority.com/news/2023/4/mhlw-japan-approval-of-pemazyre--for-the-treatment-of-patients-with-myeloidlymphoid-neoplasms.-incyte2023-04-07T11:06:59+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-first-in-class-evkeeza-for-young-children-with-homozygous-familial-hypercholesterolemia.---regeneron-pharma2023-03-23T12:24:16+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-zynyz-for-merkel-cell-carcinoma.--incyte2023-03-23T12:23:58+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-study-of-ph-94b-shows-safety-and-functional-improvements-in-social-anxiety-disorder.--vistagen2023-03-23T12:23:34+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-rezzayo-for-candidemia-and-invasive-candidiasis.--cidara-therapeutics-and-melinta-therapeutics2023-03-23T12:20:11+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-glow-trial-of-imab-362-in-gastric-or-gastroesophageal-junction-adenocarcinoma-presented-at-asco.--astellas-pharma2023-03-23T12:23:02+00:00weekly0.6https://www.medthority.com/news/2023/3/calquence-granted-first-regulatory-approval-in-china-for-adults-with-previously-treated-mantle-cell-lymphoma.--astrazeneca-2023-03-23T12:21:16+00:00weekly0.6https://www.medthority.com/news/2023/3/dupixent-demonstrates-potential-to-become-first-biologic-to-treat-copd-by-showing-significant-reduction-in-exacerbations-in-pivotal-trial--regeneron--sanofi/2023-03-23T12:20:40+00:00weekly0.6https://www.medthority.com/news/news-trends/clinical-trials/how-can-flaws-in-clinical-trial-design-conduct-and-reporting-impact-clinical-decision-making/2024-08-19T14:54:53+00:00weekly0.6https://www.medthority.com/news/news-trends/clinical-trials/interpreting-clinical-trial-results-through-a-frame-of-reference-why-take-the-time/2024-08-19T14:55:11+00:00weekly0.6https://www.medthority.com/news/2023/3/update-on-fda-advisory-committee-meeting-on-tofersen-for-sod1-als.--biogen2023-03-24T12:03:05+00:00weekly0.6https://www.medthority.com/news/2023/3/expansion-of-global-clinical-program-for-darolutamide-in-prostate-cancer.--orion--bayer2023-03-24T12:02:32+00:00weekly0.6https://www.medthority.com/news/2023/3/journal-of-clinical-psychiatry-publishes-data-from--enlighten-early-study-of-lybalvi-in-young-adults-early-in-their-illness.--alkermes-plc2023-03-24T12:00:57+00:00weekly0.6https://www.medthority.com/news/2023/3/upadacitinib-advances-to-phase-iii-clinical-trials-in-systemic-lupus-erythematosus.--abbvie2023-03-24T12:00:16+00:00weekly0.6https://www.medthority.com/news/2023/3/regulatory-update-on-ruxolitinib-extended-release-tablets.--incyte2023-03-24T11:59:31+00:00weekly0.6https://www.medthority.com/news/2023/3/oral-semaglutide-25-mg-and-50-mg-demonstrate-superior-reductions-in-hba1c-and-body-weight-versus-14-mg-in-people-with-type-2-diabetes-in-the-pioneer-plus-phase-iii-trial--novo-nordisk/2023-03-26T10:55:25+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approval-of-joenja-asthe-first-and-only-treatment-indicated-for-activated-phosphoinositide-3-kinase-delta--syndrome.--pharming-nv2023-03-26T10:54:42+00:00weekly0.6https://www.medthority.com/news/2023/3/completion-of-bla-application--submission-for-lifileucel-in-advanced-melanoma.--iovance-biotherapeutics-inc2023-03-26T10:53:57+00:00weekly0.6https://www.medthority.com/news/news-trends/clinical-trials/looking-under-the-surface-of-clinical-trials-are-the-findings-valid-and-relevant-to-your-patients/2024-08-19T14:55:30+00:00weekly0.6https://www.medthority.com/news/2023/3/kisqali-phase-iii-natalee-trial-meets-primary-endpoint-at-interim-analysis-demonstrating-clinically-meaningful-benefit-in-broad-population-of-patients-with-early-breast-cancer.--novartis2023-03-27T13:55:27+00:00weekly0.6https://www.medthority.com/news/2023/3/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-through-66-weeks.--astrazeneca--ionis-2023-03-27T13:57:01+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-scape-trd-study-of-spravato-shows-improved-remission-in-major-depressive-disorder.--janssen-pharma2023-03-28T12:16:42+00:00weekly0.6https://www.medthority.com/news/2023/3/result-of-interim-analysis-of-phase-iibiii-voice-trial-evaluating-validive-for-severe-oral-mucositis.-monopar-therapeutics2023-03-28T12:10:30+00:00weekly0.6https://www.medthority.com/news/2023/3/keytruda--chemotherapy-significantly-improved-progression-free-survival-compared-to-chemotherapy-alone-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma-regardless-of-mismatch-repair-status.--merck-inc2023-03-28T12:09:16+00:00weekly0.6https://www.medthority.com/news/2023/3/mhlw-japan-approves-enhertu-for-the-treatment-of-adult-patients-with-her2-low-unresectable-or-recurrent-breast-cancer-after-prior-chemotherapy.--daiichi-sankyo2023-03-30T07:12:20+00:00weekly0.6https://www.medthority.com/news/2023/3/vanda-prevails-in-jet-lag-litigation-against-the-fda/2023-03-30T07:11:07+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli--chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer-versus-chemotherapy-alone.--gsk2023-03-31T11:29:08+00:00weekly0.6https://www.medthority.com/news/2023/3/eu-approves-libtayo-plus-chemo-for-non-small-cell-lung-cancer.--regeneron-pharma2023-03-31T11:27:44+00:00weekly0.6https://www.medthority.com/news/2023/3/eu-approves-sotyktu-for-plaque-psoriasis.--bms2023-03-31T11:26:03+00:00weekly0.6https://www.medthority.com/news/2023/3/rybrevant-data-showed-long-term-clinical-response-and-safety-in--advanced-nsclc-with-egfr-exon-20-insertion-mutations-in-patients-who-have-failed-prior-platinum-based-chemotherapy.--janssen-2023-03-31T11:24:26+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-over-the-counter-designation-for--narcan-nasal-spray-for-the-opioid-overdose-emergency-treatment.--emergent-biosolutions2023-03-31T11:22:09+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-converts-to-full-approval-indication-for-keytruda-for-certain-adult-and-pediatric-patients-with-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors--merck-inc/2023-03-31T11:20:38+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-efficacy-and-safety-data-from-phase-iii-relief-study-of-tnx-102-sl-for-the-management-of-fibromyalgia-at-the-congress-on-controversies-in-fibromyalgia.-tonix-pharma2023-03-31T11:19:19+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-checkmate--816-trial-of-neoadjuvant-opdivo--chemo-shows-sustained-benefits-in-nsclc-at-3-year-follow-up-as-presented-at-elcc.--bms2023-03-31T11:18:13+00:00weekly0.6https://www.medthority.com/news/2023/3/eu-chmp-recommends-approval-of-bimervax-vaccine-for-covid-19.--hipra-human-health2023-03-31T11:16:56+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iv-earnest-study-of-entyvio-in-chronic-pouchitis-published-in-nejm.--takeda2023-03-31T11:14:45+00:00weekly0.6https://www.medthority.com/news/2023/3/initial-topline-olinvyk-data-from-patient-real-world-clinical-outcomes-study.--treveva-inc2023-03-31T11:15:06+00:00weekly0.6https://www.medthority.com/news/2023/3/eisai-presented-new-analyses-of-aria-and-qol-on-lecanemab-in-clarity-ad-study-at-the-adpd-2023-meeting.--2023-03-31T11:15:23+00:00weekly0.6https://www.medthority.com/news/2023/3/topline-results-from-acer-801--phase-iia-trial-for-moderate-to-severe-vasomotor-symptoms--associated-with-menopause.--acer-therapeutics-2023-03-18T15:22:14+00:00weekly0.6https://www.medthority.com/news/2023/3/nmpa-approves-bat-1806-in-china-a-biosimilar-to-actemra.--bio-thera-solutions2023-03-18T15:21:31+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-ecztra-6-and-ecztend-trials-of-adbry-in-atopic-dermatitis-reported-at-aad-2023-annual-meeting.--leo-pharma2023-03-18T15:20:49+00:00weekly0.6https://www.medthority.com/news/2023/3/integument-1-and-integument-2-pivotal-phase-iii-studies-of-zoryve-meet-primary-endpoints-in-atopic-dermatitis.--arcutis-biotherapeutics2023-03-19T16:57:12+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-delta-1-trial-of-delgocitinib-cream-shows-improvements-in-primary-and-key-secondary-endpoints-for-severe-chronic-hand-eczema-with-data-presented-at-american-academy-of-dermatology-2023-annual-meeting.--leo-pharma2023-03-19T16:56:22+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-olympia-2-trial-of-cim-331-meets-all-primary-endpoints-in-prurigo-nodularis-and-data-is-presented-at-2023-american-academy-of-dermatology-annual-meeting.--galderma2023-03-19T16:55:45+00:00weekly0.6https://www.medthority.com/news/2023/3/bimekizumab-phase-iii-data-in-hidradenitis-suppurativa-show-clinically-meaningful-deep-and-maintained-response-over-48-weeks.--ucb2024-09-30T14:20:07+00:00weekly0.6https://www.medthority.com/news/2023/3/patient-recruitment-completed-for-stage-1-of-phase-iii-diamond-study-for-ocs-01--in-diabetic-macular-edema.--oculis-sa2023-03-19T16:54:24+00:00weekly0.6https://www.medthority.com/news/2023/3/results-of-study-evaluating-52-week-efficacy-and-safety-of-skyrizi--in-psoriasis-patients-with-a-prior-suboptimal-response-to-il-17-a-inhibitor-therapy.--abbvie-2023-03-19T16:53:42+00:00weekly0.6https://www.medthority.com/news/2023/3/dupixent-data-at-aad-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis.--regeneron--sanofi2023-03-19T16:52:58+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-thrive-aa2-trial-of-ctp-543-in-alopecia-areata-presented-at-the-american-academy-of-dermatologys-aad-2023-annual-meeting.--concert-pharma2023-03-20T13:27:40+00:00weekly0.6https://www.medthority.com/news/2023/3/postitive-topline-results-from-the-phase-iii-embark-trial-evaluating-xtandi-in-men-with-non-metastatic-hormone-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence-.--pfizer--astellas2023-03-20T13:27:02+00:00weekly0.6https://www.medthority.com/news/2023/3/zolgensma-long-term-data-demonstrates-sustained-durability-up-to-7.5-years-post-dosing-100-achievement-of-all-assessed-milestones-in-children-treated-prior-to-sma-symptom-onset.--novartis2023-03-20T13:25:56+00:00weekly0.6https://www.medthority.com/news/2023/3/nubeqa-approved-for-metastatic-hormone-sensitive-prostate-cancer--in-china.---orion-corporation--bayer2023-03-20T13:25:13+00:00weekly0.6https://www.medthority.com/news/2023/3/new-four-year-data-for-evrysdi-reinforce-long-term-efficacy-and-safety-profile-in-some-of-the-most-severely-affected-people-with-types-2-and-3-spinal-muscular-atrophy-.--genentechroche2023-03-21T12:01:50+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-results-from-phase-iii-emergent-3-trial-of-karxt-in-schizophrenia.--karuna-therapeuticws-inc2023-03-21T12:01:10+00:00weekly0.6https://www.medthority.com/news/2023/3/dupixent-is-approved-by-the--european-commission-as-first-and-only-targeted-medicine-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.--regeneron--sanofi2023-03-21T11:58:58+00:00weekly0.6https://www.medthority.com/news/2023/3/mhrauk-approves-vyvgart-as-an-add-on-to-standard-therapy-for-the-treatment-of-adult-patients-with-generalised-myasthenia-gravis-who-are-achr-antibody-positive.--argenx2023-03-21T11:57:56+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-expanded-indication-for-illuccix-to-include-patient-selection-for-psma-directed-radioligand-therapy-for-prostate-cancer.--telix-pharma2023-03-21T11:57:09+00:00weekly0.6https://www.medthority.com/news/2023/3/graybug-vision-to-change-its-name-to-calcimedica-and-merge-with-calcimedica-inc.inc-2023-03-21T11:56:24+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-grants-label-expansion-for-livmarli-to-include-infants-three-months-of-age-and-older-for-cholestatic-pruritus-with-alagille-syndrome.--mirum-pharma2023-03-22T12:40:08+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approval-for-biosimilar-hyrimoz--high-concentration-formulation.-sandoz2023-03-22T12:39:30+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-zuma-7-study-of-yescarta-shows-improvement-in-os-for-large-b-cell-lymphoma-patients.--kitegilead-sciences2023-03-22T12:38:49+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-dissolve-i--ii-studies-of-sel-212-meets-primary-endpoint-in-gout.--selecta-biosciences-and-sobi2023-03-22T12:38:07+00:00weekly0.6https://www.medthority.com/news/2023/3/roche-announces-collaboration-with-lilly-to-enhance-early-diagnosis-of-alzheimers-disease/2023-03-22T12:37:25+00:00weekly0.6https://www.medthority.com/news/2023/3/evofem-biosciences-announces-cost-reduction-measures/2023-03-22T12:36:43+00:00weekly0.6https://www.medthority.com/news/2023/3/covis-pharma-group-has-requested-an-orderly-wind-down-in-an-effort-to-voluntarily-withdraw-makena-the-only-fda-approved-treatment-to-reduce-the-risk-of-preterm-birth/2023-03-10T13:37:14+00:00weekly0.6https://www.medthority.com/news/2023/3/review-article-on-lumevoq-in-5-clinical-trials-for-nd4-lhon-published-in-american-journal-of-ophthalmology.--gensight-biologics2023-03-10T13:36:31+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-advisory-committee-positive-vote-for-polivy-combination-r-chpfor--previously-untreated-diffuse-large-b-cell-lymphoma.--genentechroche2023-03-10T13:35:52+00:00weekly0.6https://www.medthority.com/news/2023/3/topline-data-announced-from-pivotal-inspire-2.0-study-of-neuro-spinal-scaffold-for-acute-spinal-cord-injury.-invivo-therapeutics2023-03-10T13:35:08+00:00weekly0.6https://www.medthority.com/news/2023/3/chinas-nmpa-accepts-bla-for-enfortumab-vedotin-in-certain-patients-with-locally-advanced-or-metastatic-urothelial-bladder-cancer.--seagen--astellas2023-03-10T13:34:20+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-510k-clearance-for-essenz-heart-lung-machine-for-cardiopulmonary-bypass-procedures.--livanova-plc2023-03-10T13:33:37+00:00weekly0.6https://www.medthority.com/news/2023/3/keytruda--chemotherapy-significantly-improved-overall-survival-versus-chemotherapy-alone-as-first-line-treatment-for-advanced-malignant-pleural-mesothelioma.--merck-inc2023-03-11T13:34:45+00:00weekly0.6https://www.medthority.com/news/2023/3/topline-results-from-phase-iii-morpho-trial-of-gilteritinib-as-maintenance-treatmant-following--allogeneic-hematopoietic-stem-cell-transplantation.--astellas2023-03-11T13:34:04+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-zavzpret-for-migraine-with-or-without-aura.--pfizer2023-03-11T13:33:30+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-roman-results-for-gc-4419-in-head-and-neck-cancer-presented-at-european-congress-on-head-and-neck-oncology.--galera-therapeutics2023-03-11T13:32:56+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-advisory-committee-date-for-obeticholic-acid-as-a-treatment-for-pre-cirrhotic-liver-fibrosis-due-to-nash.--intercept--pharma2023-03-11T13:32:14+00:00weekly0.6https://www.medthority.com/news/2023/3/invox-pharmasino-biopharma-acquires-f-star-therapeutics/2023-03-12T13:34:44+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-a-due-data-show-single-tablet-combination-therapy-of-macitentan-and-tadalafil-significantly-improves-pulmonary-hemodynamics-versus-monotherapy-in--pulmonary-arterial-hypertension---janssen-pharmaceuticals-/2023-03-13T13:21:49+00:00weekly0.6https://www.medthority.com/news/2023/3/new-voyager-pad-analysis-confirms-consistent-benefit-of-xarelto-plus-aspirin-following-lower-extremity-revascularization.--janssen-pharmaceuticals-2024-09-30T12:15:21+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-accepts-for-priority-review-adx-2191-nda-for-the-treatment-of-primary-vitreoretinal-lymphoma.--aldeyra-pharma2023-03-14T12:27:24+00:00weekly0.6https://www.medthority.com/news/2023/3/real-world-experience-shows-tepezza-was-effective-in-treating-people-with-dysthyroid-optic-neuropathy-don.--horizon-therapeutics-plc2023-03-14T12:26:41+00:00weekly0.6https://www.medthority.com/news/2023/3/reflect-phase-iii-clinical-trial-with-lumevoq-shows-efficacy-and-safety-in-leber-hereditary-optic-neuropathy.---gensight2023-03-14T12:25:42+00:00weekly0.6https://www.medthority.com/news/2023/3/sanofi-to-acquire-provention-bio.inc.-and-with-it-tzield-for-type-1-diabetes2023-03-14T12:25:02+00:00weekly0.6https://www.medthority.com/news/2023/3/pfizer-acquires-seagen-and-with-it-adcetris/2023-03-14T12:24:01+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-approves-dayblue-to-treat-rett-syndrome.--acadia-pharmaceuticals-inc2023-03-15T12:49:36+00:00weekly0.6https://www.medthority.com/news/2023/3/updated-data-presented-at-2023-acmg-meeting-demonstrates-commitment-to-understanding-long-term-benefit-of-voxzogo-in-children-with-achondroplasia.--biomarin-pharma-2023-03-15T12:48:44+00:00weekly0.6https://www.medthority.com/news/2023/3/new-data-shows-favorable-profile-of-bemnifosbuvir-for-treatment-of-covid-19-and-hepatitis-c-presented-at-2023-international-conference-on-antiviral-research.--atea-pharma2023-03-15T12:48:02+00:00weekly0.6https://www.medthority.com/news/2023/3/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-neuromyelitis-optica-spectrum-disorder.--horizon-therapeuticsamgen2023-03-15T12:47:13+00:00weekly0.6https://www.medthority.com/news/2023/3/primary-endpoint-successfully-met-in-phase-iii-nefigard-trial-evaluating-nefeconin-iga-nephropathy.--calliditas-therapeutics-ab2023-03-15T12:46:27+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-indigo-clinical-trial-of-ag-881-meets-primary-and-secondary-endpoints-in-glioma.--servier2023-03-16T13:56:48+00:00weekly0.6https://www.medthority.com/news/2023/3/phase-iii-trial-of-menabcwy-pentavalent-vaccine-meets-all-primary-endpoints-in-meningococcal-disease.--gsk2023-03-16T13:56:10+00:00weekly0.6https://www.medthority.com/news/2023/3/ce-mark-approval-for-affera-mapping-and-ablation-system-to-treat-atrial-arrhythmias.--medtronic-inc2024-09-30T11:37:23+00:00weekly0.6https://www.medthority.com/news/2023/3/jounce-therapeutics-confirms-receipt-of-unsolicited-proposal-from-concentra-biosciences/2023-03-16T13:54:40+00:00weekly0.6https://www.medthority.com/news/2023/3/positive-topline-results-from-adoring-2-atopic-dermatitis-phase-iii-trial-of-vtama-cream-1-once-daily-in-adults-and-children-as-young-as-2-years-old.--dermavant-sciences2023-03-17T14:14:26+00:00weekly0.6https://www.medthority.com/news/2023/3/new-data-from-biomag-1-study-highlights-promising-angiographic-and-safety-profile-of-third-generation-resorbable-magnesium-scaffold.--biotronik2024-09-30T14:01:42+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-510k-clearance-for-first-of-its-kind-high-throughput-diagnostic-test-for-infectious-vaginitis.-bd-becton-dickinson-and-company2023-03-17T14:13:02+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-amdac-votes-to-support-paxlovid-for-use-in-covid-19.--pfizer2023-03-17T14:12:18+00:00weekly0.6https://www.medthority.com/news/2023/3/tafinlar--mekinist-approved-by-fda-for-pediatric-patients-with-braf-v600e-low-grade-glioma-the-most-common-pediatric-brain-cancer.--novartis2023-03-17T14:11:34+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-issue-pdufa-date-after-palovarotene-is-refiled-to-treat-fibrodysplasia-ossificans-progressiva.--ipsen2023-03-17T14:10:53+00:00weekly0.6https://www.medthority.com/news/2023/3/publication-in-new-england-journal-of-medicine-of-results-from-phase-ii-study-of-inaxaplin-for-focal-segmental-glomerulosclerosis.--vertex2023-03-17T14:10:04+00:00weekly0.6https://www.medthority.com/news/2023/3/update-from-open-label-arm-of-phase-ii-keyvibe-002-trial-of-mk-7684a-a-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small-cell-lung-cancer.--merck-inc.-2023-03-17T14:09:08+00:00weekly0.6https://www.medthority.com/news/2023/3/fda-advisory-committee-meeting-to-be-held-for-srp-9001-a-gene-therapy-for-duchenne-muscular-dystrophy.--sarpeta-therapeutics2023-03-17T14:08:20+00:00weekly0.6https://www.medthority.com/news/2023/5/real-world-outcomes-from-the-eu-poria-registry-of-the-farapulse-pulsed-field-ablation-pfa-system.--boston-scientific2024-09-30T12:01:23+00:00weekly0.6https://www.medthority.com/news/2023/5/primary-results-of-the-frozen-af-ide-trial-with-the-polarx-cryoablation-system.--boston-scientific2024-09-30T12:00:13+00:00weekly0.6https://www.medthority.com/news/2023/5/dupixent-phase-iii-copd-results-presented-at-ats-meeting-and-simultanously-published-in-nejm.--regeneron--sanofi2023-05-22T11:22:50+00:00weekly0.6https://www.medthority.com/news/2023/5/effects-of-emblem-mri-subcutaneous-implantable-defibrillator-s-icd-on-tricuspid-regurgitation-and-hybrid-strategy-for-secondary-prevention-of-cardiac-death.-boston-scientific2023-05-22T11:26:16+00:00weekly0.6https://www.medthority.com/news/2023/5/notable-developments-for-the-watchman-flx-laac-device.--boston-scientific2023-05-22T11:28:39+00:00weekly0.6https://www.medthority.com/news/2023/5/mhra-uk-approves-sotyktu-to-treat-moderate-to-severe-plaque-psoriasis.--bms.-2023-05-19T16:32:30+00:00weekly0.6https://www.medthority.com/news/2023/5/skinvive-by-juvederm-receives-fda-approval.-allergan-aesthetics2023-05-19T16:31:47+00:00weekly0.6https://www.medthority.com/news/2023/5/kerendia-granted-expanded-indication-in-china-to-include-results-on-cardiovascular-cv-outcomes-from-the-phase-iii-figaro-dkd-study.--bayer2023-05-19T16:31:05+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-resubmission-of-nda-for-xphozah-for-the-control-of-serum-phosphate-in-adult-patients-with-chronic-kidney-disease.--ardelyx2023-05-19T16:30:22+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-bla-for-tak-755--an-enzyme-replacement-therapy-for-the-treatment-of-congenital-thrombotic-thrombocytopenic-purpura.--takeda2023-05-19T16:29:30+00:00weekly0.6https://www.medthority.com/news/2023/5/lecanemab-accepted-for-review-by-canadian-authorities-to-treat-early-alzheimers-disease.--eisaibiogen2023-05-19T16:28:48+00:00weekly0.6https://www.medthority.com/news/2023/5/peresolimab-phase-iia-rheumatoid-arthritis-trial-published-in-the-new-england-journal-of-medicine.--eli-lilly2023-05-19T16:28:01+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-clearance-for-assert-iq-insertable-cardiac-monitor-to-help-doctors-monitor-heart-rhythms-long-term.--abbott2024-09-30T10:45:56+00:00weekly0.6https://www.medthority.com/news/2023/5/ema-validates-marketing-authorisation-application-for-efanesoctocog-alfa-for-treatment-of-haemophilia-a--sobi--sanofi/2023-05-19T16:26:38+00:00weekly0.6https://www.medthority.com/news/2023/5/eyepoint-pharmaceuticals-announces-sale-of-yutiq-to-alimera-sciences-inc.-for-$82.5-million-cash-plus-royalties2023-05-19T16:25:52+00:00weekly0.6https://www.medthority.com/news/2023/5/biodexa-pharmaceuticals-intention-to-acquire-varian-biopharmaceuticals/2023-05-19T16:24:59+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-tactiflex-ablation-catheter-for-treatment-of-abnormal-heart-rhythm.-abbott2024-09-30T11:41:40+00:00weekly0.6https://www.medthority.com/news/2023/5/aphenity-trial-of-sepiapterin-achieved-primary-endpoint-in-pku-patients.--ptc-therapeutics-inc2023-05-20T17:06:54+00:00weekly0.6https://www.medthority.com/news/2023/5/publication-of-full-kinect-hd-phase-iii-study-results-of-valbenazine-for-the-treatment-of-chorea-associated-with-huntingtons-disease-in-the-lancet-neurology.--neurocrine-biosciences2023-05-20T17:06:09+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-advisory-committee-negative-decision-for-obeticholic-acid-as-a-treatment-for-pre-cirrhotic-fibrosis-due-to-nash--intercept-pharma/2023-05-20T17:05:10+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-the-first-ever-redosable-gene-therapy-vyjuvek-for-the-treatment-of-dystrophic-epidermolysis-bullosa.--krystal-biotech2023-05-21T13:00:56+00:00weekly0.6https://www.medthority.com/news/2023/5/phase-iii-velos-3-trial-of-tanfanercept-fails-to-meet-primary-endpoints-in-dry-eye-disease.--hanall-biopharma2023-05-21T13:00:11+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-epkinly-for-diffuse-large-b-cell-lymphoma.--genmababbvie2023-05-21T12:59:17+00:00weekly0.6https://www.medthority.com/news/2023/5/apollo-b-phase-iii-study-of-onpattro-backs-positive-impact-in-transthyretin-mediated-attr-amyloidosis-with-cardiomyopathy.--alnylam-pharma2023-05-21T12:58:20+00:00weekly0.6https://www.medthority.com/news/2023/5/extravascular-icd-global-clinical-trial-designed-to-treat-dangerously-fast-heart-rhythms-that-can-lead-to-sudden-cardiac-arrest-provides-results-reinforce-device-safety-and-effectiveness.--medtronic2024-09-30T10:45:22+00:00weekly0.6https://www.medthority.com/news/2023/5/results-announced-from-oasis-1-a-phase-iiia-trial-comparing-once-daily-oral-semaglutide-50-mg-for-weight-management-to-placebo-in-667-adults-with-obesity.-novo-nordisk2023-05-23T11:25:54+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-cyltezo-pen-a-new-autoinjector-option-for-patients-living-with-chronic-inflammatory-diseases.--boehringer2023-05-23T11:27:54+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-of-opvee-nasal-spray-an-opioid-overdose-rescue-medicine-for-natural-and-synthetic-opioids-like-fentanyl--opiant-pharmainvidior/2023-05-23T11:29:40+00:00weekly0.6https://www.medthority.com/news/2023/5/supplemental-fda-approval-for-ayvakit-to-treat-indolent-systemic-mastocytosis.--blueprint-medicines2023-05-23T11:34:22+00:00weekly0.6https://www.medthority.com/news/2023/5/vezoah-is-approved-by-the-fda-for-treatment-of-vasomotor-symptoms-due-to-menopause.--astellas2023-05-24T11:41:02+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-of-miebo-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease.--bausch--lomb-and-novaliq2023-05-24T11:44:28+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-rinvoq-as-a-once-daily-pill-for-moderately-to-severely-active-crohns-disease-in-adults--abbvie/2023-05-24T11:47:59+00:00weekly0.6https://www.medthority.com/news/2023/5/caldolor-now-fda-approved-for-treatment-of-fever-and-pain-in-infants.--cumberland-pharma-2023-05-24T11:39:18+00:00weekly0.6https://www.medthority.com/news/2023/5/topline-results-from-vatiquinone-move-fa-registration-directed-trial.--ptc-therapeutics2023-05-24T11:37:24+00:00weekly0.6https://www.medthority.com/news/2023/5/ironwood-pharma-acquires-vectivbio/2023-05-24T11:33:01+00:00weekly0.6https://www.medthority.com/news/2023/5/cohbar-inc.and-morphogenesis-inc.-to-merge2023-05-24T11:29:30+00:00weekly0.6https://www.medthority.com/news/2023/5/european-study-finds-the-cardiomems-sensor-results-in-improved-quality-of-life-and-44-reduction-in-heart-failure-hospitalizations.--abbott2023-05-25T12:12:08+00:00weekly0.6https://www.medthority.com/news/2023/5/sarepta-therapeutics-announces-update-on-fda-regulatory-review-of-srp-9001/2023-05-25T12:15:32+00:00weekly0.6https://www.medthority.com/news/2023/5/nejm-evidence-publishes-results-from-registrational-pioneer-trial-demonstrating-significant-clinical-benefits-of-ayvakit--in-indolent-systemic-mastocytosis.--blueprint-medicines2023-05-25T12:18:15+00:00weekly0.6https://www.medthority.com/news/2023/5/kerendia-granted-expanded-indication-in-china-for-broad-range-of-patients-with-chronic-kidney-disease-and-type-2-diabetes.--bayer2023-05-25T12:19:57+00:00weekly0.6https://www.medthority.com/news/2023/5/marketing-authorization-applications-for-proposed-biosimilar-denosumab-accepted-by-ema.--sandoz2023-05-25T12:21:24+00:00weekly0.6https://www.medthority.com/news/2023/5/mirati-therapeutics-provides-update-on-the-phase-iii-sapphire-study-evaluating-sitravatinib-in-combination-with-opdivo-in-nsclc/2025-02-03T11:26:19+00:00weekly0.6https://www.medthority.com/news/2023/5/pyxis-oncology-to-acquire-apexigen-and-with-it-sotigalimab/2023-05-25T12:28:19+00:00weekly0.6https://www.medthority.com/news/2023/5/chmp-positive-opinion-recommending-once-weekly-sogroya-for-replacement-of-endogenous-growth-hormone-gh-in-children-aged-three-years-and-above-and-adolescents-with-growth-failure-due-to-growth-hormone-deficiency.--novo-nordisk2023-05-27T11:14:23+00:00weekly0.6https://www.medthority.com/news/2023/5/new-england-journal-of-medicine-publishes-results-from-phase-iii-induction-and-maintenance-programs-evaluating-rinvoq-in-crohns-disease.--abbvie2023-05-27T11:13:35+00:00weekly0.6https://www.medthority.com/news/2023/5/bms-receives-positive-chmp-opinion-recommending-approval-for-opdivo--with-chemotherapy-as-neoadjuvant-treatment-of-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence.-2023-05-27T11:12:29+00:00weekly0.6https://www.medthority.com/news/2023/5/paxlovid-receives-fda-approval-for-adult-patients-at-high-risk-of-progression-to-severe-covid-19.--pfizer2023-05-27T11:11:39+00:00weekly0.6https://www.medthority.com/news/2023/5/presentation-of-additional-data-from-phase-iii-defi-trial-of-nirogacestat-in-adults-with-desmoid-tumors-at-the-2023-asco-annual-meeting.--springworks-therapeutics2023-05-27T11:10:50+00:00weekly0.6https://www.medthority.com/news/2023/5/phase-iii-commands-study-of-reblozyl-in-myelodysplastic-syndromes-reported-at-asco-and-eha-meetings.--bms2023-05-27T11:09:36+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-yuflyma-biosimilar-for-rheumatoid-arthritis-juvenile-idiopathic-arthritis-psoriatic-arthritis-ankylosing-spondylitis-crohns-disease-ulcerative-colitis-plaque-psoriasis-and-hidradenitis-suppurativa.--celltrion-usa2023-05-27T11:08:38+00:00weekly0.6https://www.medthority.com/news/2023/5/chmp-recommends-revocation-of-marketing-authorisation-for-adakveo-in-pain-crises-in-sickle-cell-disease.--novartis2023-05-27T11:07:47+00:00weekly0.6https://www.medthority.com/news/2023/5/chmp-recommends-approval-of-ztalmy--in-cdkl5-deficiency-disorder.--marinus-pharma2023-05-27T11:06:50+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-inpefa-to-treat-heart-failure.-lexicon-pharma2023-05-28T14:47:00+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-of-the-ilet-bionic-pancreas.--beta-bionics2023-05-28T14:46:19+00:00weekly0.6https://www.medthority.com/news/2023/5/updated-data-from-part-a-of--ramp-201-trial-show-an-orr-of-45-in-patients-with-recurrent-low-grade-serous-ovarian-cancer-treated-with-avutometinib-and-defactinib.--verastem-oncology2023-05-29T14:52:00+00:00weekly0.6https://www.medthority.com/news/2023/5/ribociclibfulvestrant-combination-generates-pfs-improvement-in-metastatic-breast-cancer.--novartis2023-05-29T14:50:58+00:00weekly0.6https://www.medthority.com/news/2023/5/nirsevimab-delivers-83-reduction-in-rsv-infant-hospitalizations-in-a-real-world-clinical-trial-setting.-sanofi2023-05-13T11:46:15+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-advisory-committee-votes-in-support-of-favorable-bnefit-risk-profile-for-neffy-intranasal-for-the-treatment-of-allergic-reactions-type-1-including-anaphylaxis.--ars-pharmaceuticals-inc2023-05-14T12:31:59+00:00weekly0.6https://www.medthority.com/news/2023/5/pivotal-data-is-presented-at-espid-confirming-effectiveness-of-the-5-in-1-meningococcal-abcwy-vaccine-candidate-with-demonstrated-coverage-against-a-panel-of-110-menb-strains--gsk/2023-05-15T12:38:04+00:00weekly0.6https://www.medthority.com/news/2023/5/janssen-enters-worldwide-collaboration-and-license-agreement-with-cellular-biomedicine--group-to-develop-next-generation-car-t-therapies/2023-05-15T12:37:16+00:00weekly0.6https://www.medthority.com/news/2023/5/bayer-and-bicycle-therapeutics-enter-strategic-collaboration-to-develop-novel-radionuclide-therapies-in-oncology/2023-05-15T12:36:31+00:00weekly0.6https://www.medthority.com/news/2023/5/eqrx-resets-to-focus-on-clinically-differentiated-medicines/2023-05-15T12:35:50+00:00weekly0.6https://www.medthority.com/news/2023/5/initiation-of-rolling-submission-for-bla-of-otl-200-for-metachromatic-leukodystrophy-to-fda.--orchard-therapeutics2023-05-16T13:22:38+00:00weekly0.6https://www.medthority.com/news/2023/5/oramed-announces-that-its-chinese-partner-htit-has-successfully-completed-a-phase-iii-oral-insulin-clinical-trial-and-submitted-a-maa-in-china/2023-05-16T13:15:51+00:00weekly0.6https://www.medthority.com/news/2023/5/positive-vote-from-fda-advisory-committee-meeting-for-srp-9001-gene-therapy-to-treat-duchenne-muscular-dystrophy--sarepta-therapeutics/2023-05-16T13:15:05+00:00weekly0.6https://www.medthority.com/news/2023/5/kyowa-kirin-announces-discontinuation-of-developmentof-bardoxolone-methyl-in-japan-/2023-05-16T13:14:15+00:00weekly0.6https://www.medthority.com/news/2023/5/phase-iii-tremfya-data-in-inflammatory-bowel-disease-show-positive-induction-results-among-patients-with-moderately-to-severely-active-ulcerative-colitis.--eli-lilly2023-05-16T13:13:20+00:00weekly0.6https://www.medthority.com/news/2023/5/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation/2023-05-16T13:11:53+00:00weekly0.6https://www.medthority.com/news/2023/5/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation2/2023-05-17T13:05:23+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-the-burstdr-scs-technology-to-treat-chronic-back-pain-in-people-who-have-limited-surgical-options.--abbott2023-05-17T13:05:09+00:00weekly0.6https://www.medthority.com/news/2023/5/enrollment-completed-for-phase-iii-palisade-clinical-trial-evaluating-aro-apoc3-for-treatment-of-familial-chylomicronemia-syndrome.---arrowhead-pharma2023-05-17T13:04:09+00:00weekly0.6https://www.medthority.com/news/2023/5/phase-iii-adoring-1-trial-of-vtama-meets-primary-endpoint-in-atopic-dermatitis.--dermavant-sciences2023-05-17T13:03:02+00:00weekly0.6https://www.medthority.com/news/2023/5/tagrisso-plus-chemotherapy-demonstrated-strong-improvement-in-progression-free-survival-for-patients-with-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial.--astrazeneca2023-05-17T13:01:15+00:00weekly0.6https://www.medthority.com/news/2023/5/fenebrutinib-significantly-reduced-brain-lesions-in-people-with-relapsing-forms-of-multiple-sclerosis.--roche2023-05-17T12:59:09+00:00weekly0.6https://www.medthority.com/news/2023/5/health-canada-approves-empaveli-for-the-treatment-of-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria--sobi/2023-05-06T13:13:12+00:00weekly0.6https://www.medthority.com/news/2023/5/eu-approves-prx-102-for-fabry-disease.--chiesi-and-protalix-biotherapeutics2023-05-07T12:11:10+00:00weekly0.6https://www.medthority.com/news/2023/5/phase-iii-matterhorn-study-of-evrenzo-fails-to-meet-primary-endpoint-in-anaemia-and-myelodysplastic-syndromes/2023-05-07T12:10:15+00:00weekly0.6https://www.medthority.com/news/2023/5/new-approvals-for-brukinsa-in-china.--beigene2023-05-07T12:09:28+00:00weekly0.6https://www.medthority.com/news/2023/5/nmpa-china-approves-koselugo-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas-.-astrazeneca--merck-inc2023-05-08T13:25:13+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-acceptance-of-bla-resubmission-for-subcutaneous-administration-of-entyvio-for-maintenance-therapy-in-moderately-to-severely-active-ulcerative-colitis.--takeda2023-05-08T13:24:06+00:00weekly0.6https://www.medthority.com/news/2023/5/nmpa-china-approves-olinvyk-to-treat-acute-pain.--trevena-inc2023-05-09T11:11:07+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-mydcombi-for-inducing-mydriasis-for-diagnostic-eye--procedures.-eyenovia-inc2023-05-09T11:10:17+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-application-for-vabysmo-for-the-treatment-of-retinal-vein-occlusion.--genentechroche-2023-05-09T11:09:27+00:00weekly0.6https://www.medthority.com/news/2023/5/farxiga-extended--by-the--fda-to-reduce-risk-of-cardiovascular-death-and-hospitalisation-for-heart-failure-to-a-broader-range-of-patients.--astrazeneca2023-05-09T11:08:29+00:00weekly0.6https://www.medthority.com/news/2023/5/first-in-class-interim-phase-ii-data-in-pediatric-patients-and-new-analysis-from-phase-iii-program-in-adult-patients-for-mirikizumab-in-ulcerative-colitis.-eli-lilly2023-05-12T15:12:42+00:00weekly0.6https://www.medthority.com/news/2023/5/gilead-science-acquires-xin-thera/2023-05-12T15:11:52+00:00weekly0.6https://www.medthority.com/news/2023/5/ultomiris-approved-in-eu-to-treat-anti-aquaporin-4-aqp4-antibody-positive-ab-neuromyelitis-optica-spectrum-disorder-.--astrazeneca2023-05-12T15:11:03+00:00weekly0.6https://www.medthority.com/news/2023/5/update-on-nda-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia.--minerva-neurosciences-inc2023-05-12T15:10:19+00:00weekly0.6https://www.medthority.com/news/2023/5/bayer-initiates-phase-iii-study-to-investigate-aflibercept-8-mg-in-retinal-vein-occlusion.--bayer--regeneron2023-05-12T15:09:31+00:00weekly0.6https://www.medthority.com/news/2023/5/sobi-to-acquire-cti-biopharma-corp.-and-with-it-vonjo-2023-05-12T15:08:39+00:00weekly0.6https://www.medthority.com/news/2023/5/completion-of-patient-dosing-in-a-randomized-controlled-trial-of-simufilam-in-alzheimers-disease.-cassava-sciences-inc2023-05-12T15:07:55+00:00weekly0.6https://www.medthority.com/news/2023/5/final-fda-approval-of-lumryz-for-extended-release-oral-suspension-as-the-first-and-only-once-at-bedtime-oxybate-for-cataplexy-or-excessive-daytime-sleepiness-in-adults-with-narcolepsy--avadel-pharma/2023-05-12T15:07:06+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-kalydeco-to-treat-eligible-infants-with-cystic-fibrosis-ages-1-month-and-older.-vertex-pharma2023-05-12T15:06:14+00:00weekly0.6https://www.medthority.com/news/2023/5/health-canada-approves-quviviq--for-the-management-of-adult-patients-with-insomnia.--idorsia-ltd2023-05-12T15:05:25+00:00weekly0.6https://www.medthority.com/news/2023/5/first-line-libtayo-plus-chemotherapy-receives--approval-in-canada-for-advanced-nsclc.--regeneron2023-05-12T15:04:33+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-of-snda-for-rexulti--for-the-treatment-of-agitation-associated-with-dementia-due-to-alzheimers-disease.-lundbeck--otsuka2023-05-12T15:03:44+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-appoint-pnh-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-to-near-normal-levels-leading-to-transfusion-independence-in-all-treatment-naive-pnh-patients.-novartis2023-04-27T11:29:10+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-grants-accelerated-approval-for-qalsody-for-sod1-als-a-major-scientific-advancement-as-the-first-treatment-to-target-a-genetic-cause-of-als.--biogen-inc2023-04-27T11:31:42+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-eu-approval-of--fixed-duration-columvi--for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.-roche.-2023-04-27T11:35:07+00:00weekly0.6https://www.medthority.com/news/2023/4/cosentyx-gains-positive-chmp-opinion-for-hidradenitis-suppurativa-novartis/2024-09-30T14:21:27+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommendations-for-bimekizumab-for-the-treatment-of-adults-with-psoriatic-arthritis-and-axial-spondyloarthritis-in-the-european-union.--ucb2023-04-27T11:40:57+00:00weekly0.6https://www.medthority.com/news/2023/4/lilly-to-divest-baqsimi-nasally-administered-glucagon-to-amphastar-pharma/2023-04-25T11:29:19+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-lifts-clinical-hold-on-phase-iii-investigational-nda-for-maat-013-in-patients-with-acute-graft-versus-host-disease.--maat-pharma2023-04-25T11:35:05+00:00weekly0.6https://www.medthority.com/news/2023/4/bla-is-submitted-to-the-fda-for-lovotibeglogene-autotemcel-for-patients-with-sickle-cell-disease-12-years-and-older-with-a-history-of-vaso-occlusive-events.--bluebird-bio-inc2023-04-25T11:38:14+00:00weekly0.6https://www.medthority.com/news/2023/4/clinical-benefit-of-govorestat-in-action-galactosemia-kids-trial-company-plans-to-meet-with-fda-regarding-potential-nda-submission.-applied-therapeutics2023-04-26T11:38:30+00:00weekly0.6https://www.medthority.com/news/2023/4/vamorolone-nda-mid-cycle-review-meeting-for-duchenne-muscular-dystrophy-by-fda-completed.--santhera-pharma2023-04-26T11:54:31+00:00weekly0.6https://www.medthority.com/news/2023/4/shockwave-medical-to-acquire-neovasc-and-with-it-the-neovasc-reducer-system-for-treatment-of-refractory-angina/2023-04-26T11:56:09+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approval-for-hizentra-20-liquid-50ml10gm-prefilled-syringe-to-treat-primary-immunodeficiency-and-chronic-inflammatory-demyelinating-polyneuropathy.-csl-behring2023-04-26T11:58:07+00:00weekly0.6https://www.medthority.com/news/2023/4/quizartinib-nda-review-for-patients-with-newly-diagnosed-flt3-itd-positive-aml-is-extended-by-fda-to-24-july-2023.--daiichi-sankyo2023-04-26T12:01:51+00:00weekly0.6https://www.medthority.com/news/2023/4/ema-validates-filing-of-jemperli--chemo-for-dmmrmsi-h-endometrial-cancer.--gsk2023-04-26T12:04:04+00:00weekly0.6https://www.medthority.com/news/2023/4/initial-fda-feedback-on-proposed-imc-1-phase-iii-program-for-treatment-of-fibromyalgia.--virios-therapeutics-inc2023-04-26T12:06:52+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-proof-hd-clinical-study-of-pridopidine-reported-on-huntingtons-disease.--prilenia-therapeutics2023-04-26T12:09:19+00:00weekly0.6https://www.medthority.com/news/2023/4/assertio-holding-to-acquire-spectrum-pharma-and-with-it-roveldon/2023-04-26T12:11:43+00:00weekly0.6https://www.medthority.com/news/2023/4/tirzepatide-achieved-up-to-15.7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-surmount-2-study--eli-lilly2023-04-28T11:34:28+00:00weekly0.6https://www.medthority.com/news/2023/4/publication-of-psoriasis-patient-data-demonstrating-need-for-rapid-symptom-improvement.--novan2023-04-28T11:36:59+00:00weekly0.6https://www.medthority.com/news/2023/4/prevent-19-adolescent-data-published-in-the-journal-of-the-american-medical-association-network-open.---novavax2023-04-28T11:38:27+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-vowst-microbiome-to-prevent-recurrence-of-c.-difficile-infection.--seres-therapeutics--nestle-2023-04-28T11:40:28+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-approval-for-camzyos-for-the-treatment-of-symptomatic-obstructive-hypertrophic-cardiomyopathy.--bms2023-04-28T11:46:13+00:00weekly0.6https://www.medthority.com/news/2023/4/gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-chmp-opinion/2023-04-28T11:48:16+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-lytgobi--to-treat-locally-advanced-or-metastatic-cholangiocarcinoma.--taiho-pharma2023-04-28T11:49:51+00:00weekly0.6https://www.medthority.com/news/2023/4/interim-analysis-of-the-renotorch-study-of-toripalimab-plus-axitinib-meets-predefined-boundary-in-renal-cell-carcinoma.--shanghai-junshi-biosciences2023-04-28T11:51:19+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-prevnar-20-for-pneumococcal-disease.--pfizer2023-04-28T11:53:25+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-miglustat-the-enzyme-stabilizer-component-for-pombiliti-for-pompe--disease.--amicus-therapeutics2023-04-28T11:54:46+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-expanded-use-of-trikafta-in-children-with-cystic-fibrosis.--vertex-pharma2023-04-28T11:56:30+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-recommends-jaypirca-to-treat-relapsed-or-refractory-mantle-cell-lymphoma.--eli-lilly-2023-04-28T11:59:04+00:00weekly0.6https://www.medthority.com/news/2023/4/chmp-positive-opinion-for-orkambi-lumacaftorivacaftor-in-children-with-cystic-fibrosis-ages-1-to-2-years-old.--vertex-pharma2023-04-28T12:01:02+00:00weekly0.6https://www.medthority.com/news/2023/4/first-approval-worldwide-for-akeega--with-ec-authorization-for-metastatic-castration-resistant-prostate-cancer-with-brca12-mutations.--janssen2023-04-29T14:11:43+00:00weekly0.6https://www.medthority.com/news/2023/4/update-on-fda-advisory-committee-vote-on-lynparza-plus-abiraterone-for-metastatic-castration-resistant-prostate-cancer.--astra-zeneca--merck-inc.-2023-04-29T14:10:54+00:00weekly0.6https://www.medthority.com/news/2023/4/health-canada-approves-zoryve-to-treat-psoriasis.--arcutis-biotherapeutics-inc2023-04-30T11:21:42+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-embark-trial-of-xtandi-plus-leuprolide-in-prostate-cancer-presented-at-2023-american-urological-association-annual-meeting.--astellas-pharma-and-pfizer2023-04-30T11:20:51+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-uzedy-extended-release-sc-in-schizophrenia.--teva-pharma--medincell2023-04-30T11:19:40+00:00weekly0.6https://www.medthority.com/news/2023/5/nda-filing-for-roluperidone-for-the-treatment-of-negative-symptoms-in-schizophrenia.--minerva-neurosciences2023-05-02T12:20:47+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-for-priority-review-sbla-and-ema-validates-application-for-reblozyl-as-first-line-treatment-of-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes.--bms2023-05-02T12:22:52+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approval-for-next-generation-micra-leadless-pacing-systems.--medtronic2024-09-30T10:45:38+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-nda-for-idp-126-gel-triple-therapy-to-treat-acne.-bausch-health-2023-05-02T12:27:53+00:00weekly0.6https://www.medthority.com/news/2023/5/initiation-of-phase-iii-trial-in-japan-evaluating-tepezza-in-adults-with-chroniclow-clinical-activity-score-cas-thyroid-eye-disease--horizon-therapeutics/2023-05-02T12:30:04+00:00weekly0.6https://www.medthority.com/news/2023/5/csl-seqirus-mrna-covid-vaccine-for-the-prevention-of-covid-19--is-filed-by-meiji-holdings-in-japan/2023-05-02T12:31:25+00:00weekly0.6https://www.medthority.com/news/2023/5/astellas-acquires-iveric-bio-and-with-it-avacincaptad-pegol-an-important-program-for-geographic-atrophy/2023-05-02T12:32:48+00:00weekly0.6https://www.medthority.com/news/2023/5/topline-results-from-two-year-primary-efficacy-endpoint-in-pivotal-phase-iii-duplex-study-of-sparsentan-in-focal-segmental-glomerulosclerosis.--travere-therapeutics2023-05-03T11:33:08+00:00weekly0.6https://www.medthority.com/news/2023/5/enrollment-in-integument-ped-pivotal-phase-iii-trial-of-roflumilast-cream-0.05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5.--arcutis-biotherapeutics-inc2023-05-03T11:30:22+00:00weekly0.6https://www.medthority.com/news/2023/5/publication-of-an-expert-article-in-jcc-on-obefazimod-as-promising-therapeutic-management-option-for-ulcerative-colitis-patients.--abivax-sa2023-05-03T11:27:50+00:00weekly0.6https://www.medthority.com/news/2023/5/donanemab-significantly-slowed-cognitive-and-functional-decline-in-phase-iii-study-of-early-alzheimers-disease.--eli-lilly2023-05-05T08:53:09+00:00weekly0.6https://www.medthority.com/news/2023/5/european-commission-approval-for-car-t-cell-therapy-breyanzi-for-relapsed-or-refractory-large-b-cell-lymphoma-after-one-prior-therapy.--bms2023-05-05T08:52:18+00:00weekly0.6https://www.medthority.com/news/2023/5/elahere-demonstrates-overall-survival-benefit-in-the-phase-iii-mirasol-trial-in-patients-with-fralpha-positive-platinum-resistant-ovarian-cancer.--immunogen-inc2023-05-05T08:51:20+00:00weekly0.6https://www.medthority.com/news/2023/5/positive-clinical-results-from-compatibility-study-of-hybryte-in-the-treatment-of-cutaneous-t-cell-lymphoma.--soligenix-inc2023-05-05T11:10:17+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-arexvy-the-worlds-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults.-gsk-plc2023-05-05T11:09:25+00:00weekly0.6https://www.medthority.com/news/2023/5/magenta-therapeutics-to-merge-with-dianthus-therapeutics-and-advance-dnth-103-complement-inhibitor/2023-05-06T13:14:11+00:00weekly0.6https://www.medthority.com/news/2023/4/eu-approves-rinvoq-in-crohns-disease.--abbvie2023-04-18T11:24:42+00:00weekly0.6https://www.medthority.com/news/2023/4/merck-inc.to-acquire-prometheus-biosciences-and-with-it-pra-0232023-04-18T11:23:25+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approval-to-expand-the-use-of-hyqvia-to-treat-primary-immunodeficiency-in-children.--takeda2023-04-19T11:21:37+00:00weekly0.6https://www.medthority.com/news/2023/4/health-canada-expands-orkambi-label-for-the-treatment-of-cystic-fibrosis--for-children-ages-between-one-and-two.--vertex2023-04-19T11:20:03+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-accepts-nda-for-roflumilast-foam-0.3-for-the-treatment-of-seborrheic-dermatitis.--arcutis-biotherapeutics2023-04-19T11:17:50+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-expands-approval-of-qulipta-for-migraine.--abbvieallergan2023-04-19T11:14:46+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-omisirge-for-allogeneic-stem-cell-transplant-therapy.--gamida-cell2023-04-19T11:13:19+00:00weekly0.6https://www.medthority.com/news/2023/4/rexulti-supported-by-fda-advisory-committees-for-alzheimers-agitation.--otsuka--lundbeck2023-04-19T11:10:38+00:00weekly0.6https://www.medthority.com/news/2023/4/gsk-acquires-bellus-health-and-with-it-camlipixant--a-potential-treatment-for-chronic-cough/2023-04-19T11:08:25+00:00weekly0.6https://www.medthority.com/news/2023/4/alkermes-to-separate-its-oncology-and--neurology-business-into-individual-companies/2023-04-19T11:06:55+00:00weekly0.6https://www.medthority.com/news/2023/4/new-five-year-data-on-disability-outcomes-and-safety-of-kesimpta--in-people-living-with-relapsing-multiple-sclerosis.--novartis2023-04-20T11:26:19+00:00weekly0.6https://www.medthority.com/news/2023/4/amgen-wins-patent-appeal-on-otezla/2023-04-20T11:24:40+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-polivy--r-chp-for-people-with-certain-types-of-previously-untreated-diffuse-large-b-cell-lymphoma.--genentechroche2023-04-20T11:23:30+00:00weekly0.6https://www.medthority.com/news/2023/4/positive-phase-iii-tislelizumab-trial-in-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma.--beigene2023-04-21T11:24:59+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-accepts-for-priority-reviewsnda-for-the-use-of-lonsurf--bevacizumab-forrefractory-metastatic-colorectal-cancer-.--taiho-pharma2023-04-21T11:27:19+00:00weekly0.6https://www.medthority.com/news/2023/4/eu-approves-opzelura-for-non-segmental-vitiligo.--incyte2023-04-21T11:23:17+00:00weekly0.6https://www.medthority.com/news/2023/4/phase-iii-pivotal-brio-i-trial-of-brimochol-pf-in-presbyopia.--visus-therapeutics2023-04-21T11:21:45+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approves-rizafilm-versafilm-an-orally-disintegrating-film-formulation-for-the-acute-treatment-of-migraine.--intelgenxgensco2023-04-21T11:20:04+00:00weekly0.6https://www.medthority.com/news/2023/4/dermata-announces-receipt-of-type-c-meeting-response-from-the-fda-and-plans-to-initiate-a-phase-iii-program-for-acne-for-dmt-310/2023-04-21T11:16:59+00:00weekly0.6https://www.medthority.com/news/2023/4/veru-inc.-sells-entadfi-to-blue-water-vaccines---2023-04-21T11:12:48+00:00weekly0.6https://www.medthority.com/news/2023/4/enhance-phase-iii-study-evaluating-mbx-8025-in-primary-biliary-cholangitis-published-in-hepatology.--cymabay-therapeutics-2023-04-22T11:50:09+00:00weekly0.6https://www.medthority.com/news/2023/4/fda-approval-for-minimed-780g-system-the-worlds-first-insulin-pump-with-meal-detection-technology-featuring-5-minute-auto-corrections.-medtronic2023-04-22T11:49:09+00:00weekly0.6https://www.medthority.com/news/2023/4/gensight-biologics-to-withdraw-application-to-ema-for-lumevoq-as-data-is-insufficient-to-support-a-chmp-opinion-for-lhon/2023-04-23T16:10:00+00:00weekly0.6https://www.medthority.com/news/2023/4/late-breaking-results-from-phase-iii-trial-of-qulipta-for-the-preventive-treatment-of-episodic-migraine-presented-at-the-2023-aan-annual-meeting.-abbvie2023-04-23T16:08:23+00:00weekly0.6https://www.medthority.com/news/2023/7/janssen-submits-supplemental-new-drug-application-to-fda-seeking-expanded-pediatric-indication-for-hiv-1-therapy-edurant/2023-07-31T12:35:36+00:00weekly0.6https://www.medthority.com/news/2023/7/santhera-completes-divestment-of-raxoneidebenone-business-to-chiesi-group/2023-07-31T12:33:57+00:00weekly0.6https://www.medthority.com/news/2023/7/pafsc-advisory-committee-in-japan-recommends-jakavi-for-post-transplant-graft-versus-host-disease.--novartis2023-07-26T11:27:04+00:00weekly0.6https://www.medthority.com/news/2023/8/first-line-rivoceranib-plus-camrelizumab-improves-survival-in-unresectable-hepatocellular-carcinoma-liver-cancer.--elevar-therapeutics2023-08-01T11:12:40+00:00weekly0.6https://www.medthority.com/news/2023/8/jemperli--chemotherapy-approved-by-the-fda-as-the-first-new-frontline-treatment-option-in-decades-for-dmmrmsi-h-primary-advanced-or-recurrent-endometrial-cancer.-gsk-plc2023-08-01T11:15:21+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-type-c-meeting-feedback-from-fda-on-potential-heart-failure-class-iv-indication-expansion-of-furoscix.-scpharmaceuticals-inc.-2023-08-02T12:51:48+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-clearance-for-expanded-indication-for-quikclot-control--hemostatic-device-usage-in-cardiac-surgical-procedures--teleflex-inc/2023-08-02T12:57:28+00:00weekly0.6https://www.medthority.com/news/2023/8/jardiance-approved-in-the-eu-for-the-treatment-of-adults-with-chronic-kidney-disease-.--boehringer--eli-lilly2023-08-02T13:00:26+00:00weekly0.6https://www.medthority.com/news/2023/8/livmarli-receives-health-canada-authorization-for-alagille-syndrome.--mirum-pharmaceuticals2023-08-02T13:02:14+00:00weekly0.6https://www.medthority.com/news/2023/8/health-canada-approves-rinvoq-for-adults-with-moderately-to-severely-active-ulcerative-colitis.--abbvie2025-07-01T08:47:22+00:00weekly0.6https://www.medthority.com/news/2023/8/sumitomo-pharma-and-otsuka-announce-topline-results-fromphase-iii-diamond-1-and-diamond-2-clinical-studiesevaluating-ulotaront-in-schizophrenia/2023-08-02T13:13:44+00:00weekly0.6https://www.medthority.com/news/2023/7/abbott-recalls-amplatzer-steerable-delivery-sheath-used-to-deliver-the-amplatzer-amulet-left-atrial-appendage-occluder.--abbott2023-07-29T12:03:08+00:00weekly0.6https://www.medthority.com/news/2023/7/positive-topline-results-from-the-pivotal-agave-201-trial-of-axatilimab-in-chronic-graft-versus-host-disease.--syndax-pharma--incyte-2023-07-29T12:02:28+00:00weekly0.6https://www.medthority.com/news/2023/7/biogen-to-acquire-reata-pharma-and-with-it-skyclaris-the-first-treatment-for-friedreichs-ataxia/2023-07-29T12:01:27+00:00weekly0.6https://www.medthority.com/news/2023/7/phase-iii-keynote-756-trial-of-keytruda--chemotherapy-as-neoadjuvant-meets-primary-endpoint-in-breast-cancer-erher2-.--merck-inc2023-07-30T17:20:35+00:00weekly0.6https://www.medthority.com/news/2023/7/first-patient-enrolled-in-pivotal-phase-iii-beyond-study-of-zigakibart-for-patients-with-iga-nephrology.--chinook-therapeutics2023-07-30T17:19:29+00:00weekly0.6https://www.medthority.com/news/2023/7/aflibercept-8-mg-two-year-results-from-pivotal-photon-trial-in-diabetic-macular-edema-presented-at-asrs--regeneron--bayer/2023-07-30T17:18:27+00:00weekly0.6https://www.medthority.com/news/2023/7/soliris-has-european-commission-extended-approval-to-treat-refractory-generalised-myasthenia-gravis-gmg-in-children-and-adolescents.--astrazeneca2023-07-28T11:34:07+00:00weekly0.6https://www.medthority.com/news/2023/7/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies.-eli-lilly2023-07-28T11:38:11+00:00weekly0.6https://www.medthority.com/news/2023/7/v-116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults-met-key-immunogenicity-and-safety-endpoints-in-two-phase-iii-trials.-merck-inc2023-07-28T11:40:20+00:00weekly0.6https://www.medthority.com/news/2023/7/vyalev-a-continuous-subcutaneousinfusion-for-parkinsons-disease-is-now-launched-in-japan.-abbvie2023-07-28T11:41:37+00:00weekly0.6https://www.medthority.com/news/2023/7/european-commission-approves-trodelvy-to-treat-unresectable-or-metastatic-hormone-receptor-hr-positive-her2-negative-breast-cancer-patients-who-have-received-endocrine-based-therapy.--gilead-sciences2023-07-28T11:43:38+00:00weekly0.6https://www.medthority.com/news/2023/7/homology-medicines-completes-strategic-review/2023-07-28T11:45:06+00:00weekly0.6https://www.medthority.com/news/2023/7/alexionastrazeneca-rare-disease-to-acquire-from-pfizer-a-portfolio-of-preclinical-gene-therapy-programmes/2023-07-28T11:46:50+00:00weekly0.6https://www.medthority.com/news/2023/8/mhra-approves-bimervax-as-a-booster-for-covid-19-patients.---hipra2023-08-03T11:51:51+00:00weekly0.6https://www.medthority.com/news/2023/8/european-commission-approves-lonsurf-in-combination-with-bevacizumab-for-the-third-line-treatment-of-metastatic-colorectal-cancer.--servier--taiho2023-08-03T11:54:28+00:00weekly0.6https://www.medthority.com/news/2023/8/top-line-results-from-phase-iii-axlerate-oc-study-of-batiraxcept-in-platinum-resistant-ovarian-cancer.-aravive-inc2023-08-03T12:01:59+00:00weekly0.6https://www.medthority.com/news/2023/8/apellis-provides-update-on-review-of-rare-safety-events-with-syfovre-for-geographic-atrophy/2023-08-03T12:09:20+00:00weekly0.6https://www.medthority.com/news/2023/8/european-commission-adopts-decision-endorsing-chmp-recommendation-to-revoke-the-conditional-marketing-authorization-for-adakveo.--novartis2023-08-06T00:14:13+00:00weekly0.6https://www.medthority.com/news/2023/8/analysis-of-cost-effectiveness-of-besremi-in-polycythemia-vera-published-in-journal-of-comparative-effectiveness-research.--pharmaessentia2023-08-06T00:15:55+00:00weekly0.6https://www.medthority.com/news/2023/8/retevmo-is-the-first-targeted-therapy-to-demonstrate-superior-progression-free-survival-compared-to-a-pd-1-inhibitor-for-newly-diagnosed-advanced-ret-fusion-positive-non-small-cell-lung-cancer.--eli-lilly2023-08-06T00:19:08+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-zurzuvae-the-first-and-only-oral-treatment-for-postpartum-depression-and-issues-a-complete-response-letter-for-major-depressive-disorder.--sage-therapeutics--biogen2023-08-06T00:19:57+00:00weekly0.6https://www.medthority.com/news/2023/8/galapagos-to-review-future-of-jyseleca/2023-08-06T19:36:18+00:00weekly0.6https://www.medthority.com/news/2023/8/complete-response-for-remestemcel-l-for-the-treatment-of-pediatric-steroid-refractory-acute-graft-versus-host-disease-.--mesoblast-limited2023-08-06T19:39:02+00:00weekly0.6https://www.medthority.com/news/2023/8/abbott-initiates-us-market-withdrawal-of-trifecta-family-of-heart-valves/2023-08-06T19:40:20+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-results-from-phase-iii-codebreak-300-study-evaluating-lumakras--vectibix-vs-current-standard-of-care-in-chemo-refractory-metastatic-kras-g12c-mutated-colorectal-cancer.--amgen2023-08-06T19:41:04+00:00weekly0.6https://www.medthority.com/news/2023/8/supplemental-nda-for-lumakras-accepted-by-fda-for-full-approval-to-treat-previously-treated-locally-advanced-or-metastatic-kras-g12c-mutated-non-small-cell-lung-cancer.-amgen.-2023-08-06T19:41:42+00:00weekly0.6https://www.medthority.com/news/2023/7/topline-results-from-phase-iii-studies-of-tarcocimab-tedromer-in-neovascular-age-related-macular-degeneration-and-diabetic-macular-edema-and--update-on-tarcocimab-development-program.--kodiak-sciences-inc2023-07-27T11:07:02+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-xdemvy-to-treat-demodex-blepharitis.-tarsus-pharma2023-07-27T11:09:24+00:00weekly0.6https://www.medthority.com/news/2023/7/skyrizi-achieved-superiority-versus-apremilast-for-co-primary-endpoints-among-adult-patients-with-moderate-plaque-psoriasis-in-phase-iv-head-to-head-study.-abbvie2023-07-27T11:13:14+00:00weekly0.6https://www.medthority.com/news/2023/7/biosense-webster-launches-the-optrell-mapping-catheter-with-trueref-technology-for-mapping-of-complex-cardiac-arrhythmias/2024-09-30T10:44:18+00:00weekly0.6https://www.medthority.com/news/2023/7/phase-iii-study-evaluating-v-940--keyruda--is-initiated-for-adjuvant-treatment-of-patients-with-resected-high-risk-stage-iib-iv-melanoma.--merck-inc.--moderna-inc2023-07-27T11:19:22+00:00weekly0.6https://www.medthority.com/news/2023/7/first-patient-dosed-in-global-phase-iii-trial-of-rinvoq-in-hidradenitis-suppurativa.--abbvie2024-09-30T14:29:50+00:00weekly0.6https://www.medthority.com/news/2023/7/biogen-announces-cost-saving-programme/2023-07-27T11:24:29+00:00weekly0.6https://www.medthority.com/news/2023/7/results-from-landmark-phase-iii-trial-of-donanemab-are-presented-at-alzheimers-association-conference-and-published-in-jama.--eli-lilly2023-07-18T11:24:41+00:00weekly0.6https://www.medthority.com/news/2023/7/eu-regulatory-filing-for-bimekizumab-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa-.-ucb2024-09-30T14:22:15+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-beyfortus-for-the-prevention-of-rsv-lower-respiratory-tract-disease-in-infants.--astrazeneca--sanofi2023-07-18T11:29:11+00:00weekly0.6https://www.medthority.com/news/2023/7/positive-results-from-clinical-trial-with-bentrio-in-house-dust-mite-allergy-is-published-in-clinical-and-translational-allergy.--altamira-2023-07-18T11:31:04+00:00weekly0.6https://www.medthority.com/news/2023/7/novan-enters-into-agreement-to-sell-substantially-all-of-its-assets-including-berdazimer-gel-10.3-and-files-for-chapter-11-protection2023-07-18T11:33:40+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-supplemental-nda-for-velkury-in-covid-19-patients-with-severe-renal-impairment.--gilead-sciences2023-07-16T13:32:07+00:00weekly0.6https://www.medthority.com/news/2023/7/first-patient-treated-in-mainland-china-for-the-global-phase-iii-fortitude-101-study-of-bemarituzumab-in-first-line-gastric-cancer.--zai-lab2023-07-16T13:31:33+00:00weekly0.6https://www.medthority.com/news/2023/7/nanobiotix-announces-a-license-agreement-with-janssen-pharmaceutica-for-worldwide-co-development-and-commercialization-of-potential-first-in-class-radioenhancer-nbtx-r3/2023-07-16T13:30:40+00:00weekly0.6https://www.medthority.com/news/2023/7/eu-accepts-filing-of-imab-362-for-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--astellas-pharma2023-07-16T13:29:56+00:00weekly0.6https://www.medthority.com/news/2023/7/eli-lilly-to-acquire-versanis-bio-and-with-it-bimagrumab-which-is-in--trials-for-treatment-of-cardiometabolic-disorders/2023-07-17T11:48:27+00:00weekly0.6https://www.medthority.com/news/2023/7/novartis-terminates-its-option-agreement-with-beigene-relating-to-ociperlimab-an-investigational-tigit-inhibitor/2023-07-16T13:28:41+00:00weekly0.6https://www.medthority.com/news/2023/7/first-line-opdivo-plus-chemotherapy-provides-survival-benefit-in-metastatic-urothelial-carcinoma-bladder-cancer.-bms2023-07-17T11:49:58+00:00weekly0.6https://www.medthority.com/news/2023/7/equecabtagene-autoleucel-approved-in-china-for-relapsedrefractory-multiple-myeloma.--innovent-biologics2023-07-17T11:51:26+00:00weekly0.6https://www.medthority.com/news/2023/7/acceptance-by-chinas-nmpa-of-the-bla-for-efgartigimod-alfa-injection-subcutaneous-injection-for-patients-with-generalized-myasthenia-gravis.--zai-lab2023-07-11T11:24:54+00:00weekly0.6https://www.medthority.com/news/2023/7/european-commission-approves-fixed-duration-columvi-glofitamab-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--roche/2023-07-11T11:28:10+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-authorization-for-aspyrerx-to-treat-adults-with-type-2-diabetes--better-therapeutics-inc/2023-07-11T11:30:40+00:00weekly0.6https://www.medthority.com/news/2023/7/global-regulatory-submissions-made-for-mrna-1345-a-respiratory-syncytial-virus-vaccine--from-moderna-inc/2023-07-11T11:32:26+00:00weekly0.6https://www.medthority.com/news/2023/7/late-breaking-study-data-at-europrc-meeting--orsiro-des-outperforms-other-ultrathin-strut-drug-eluting-stent.--biotronik2024-09-30T14:00:12+00:00weekly0.6https://www.medthority.com/news/2023/7/mhrauk-approves-arexvy-for-prevention-of-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virus-in-adults-60-years-of-age-and-older.--gsk2023-07-12T13:41:31+00:00weekly0.6https://www.medthority.com/news/2023/7/enhertu-approved-in-china-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer.--daiichi-sankyo--astrazeneca-2023-07-13T12:07:00+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-accepts-snda-for-brukinsa--obinutuzumab-indication-for-rr-follicular-lymphoma-after-two-prior-therapies---beigene/2023-07-13T12:08:56+00:00weekly0.6https://www.medthority.com/news/2023/7/phase-iii-true-ad3-study-of-opzelura-meets-primary-endpoint-in-atopic-dermatitis.--incyte2023-07-13T11:30:21+00:00weekly0.6https://www.medthority.com/news/2023/7/positive-phase-iii-results-for--ocrevus-twice-a-year-10-minute-subcutaneous-injection-in-patients-with-multiple-sclerosis.--genentechroche2023-07-13T11:29:17+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-reviews-drl_ri-rituximab-biosimilar-for-approval.--dr.-reddys-lab2023-07-13T11:27:59+00:00weekly0.6https://www.medthority.com/news/2023/7/avrobio-to-explore-strategic-alternatives/2023-07-13T11:26:36+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-optilume-bph-catheter-system-for-the-treatment-of-lower-urinary-tract-symptoms-luts-secondary-to-bph.--urotronic-inc2023-07-14T12:13:08+00:00weekly0.6https://www.medthority.com/news/2023/7/topline-results-from-the-phase-iii-mvor-1-and-mvor-2-trials-comparing-dfd-29-against-galdermas-oracea-in-papulopustular-rosacea.--journey-medical2023-07-14T12:10:52+00:00weekly0.6https://www.medthority.com/news/2023/7/biopact-rct-subgroup-analyses-show-consistent-results-for-passeo-18-lux-drug-coated-balloon.--biotronik2024-09-30T12:11:13+00:00weekly0.6https://www.medthority.com/news/2023/7/ema-statement-on-ongoing-review-of-glp-1-receptor-agonists/2023-07-14T12:04:27+00:00weekly0.6https://www.medthority.com/news/2023/7/treatment-with-rybrevant---chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-egfr-exon-20-insertion-mutation-positive-nsclc.--johnson--johnson2023-07-20T11:40:21+00:00weekly0.6https://www.medthority.com/news/2023/7/nmpa-china-accepts-a-new-drug-application-for-toripalimab--etoposide-to-treat-extensive-stage-small-cell-lung-cancer.--shanghai-junishi-biosciences-2023-07-20T11:42:20+00:00weekly0.6https://www.medthority.com/news/2023/7/long-term-phase-iii-data-published-in-arthritis--rheumatology-shows-lupkynis-preserved-kidney-function-up-to-three-years-in-lupus-nephritis-patients-with-no-new-or-unexpected-adverse-events.-aurinia-pharma2023-07-20T11:43:47+00:00weekly0.6https://www.medthority.com/news/2023/7/new-clinical-and-real-world-data-for-vabysmo-at-asrs-reveal-improved-outcomes-for-people-with-wet-or-neovascular-age-related-macular-degeneration-amd-and-diabetic-macular-edema-dme.-genentechroche2023-07-20T11:45:50+00:00weekly0.6https://www.medthority.com/news/2023/7/latest-analysis-of-lecanemabs-effect-on-biomarker-changes-andsubcutaneous-dosing-presented-at-the-alzheimers-association-international-conference-aaic-2023.--eisai--biogen2023-07-20T11:48:21+00:00weekly0.6https://www.medthority.com/news/2023/7/pieris-pharmaceuticals-to-restructure/2023-07-20T11:52:34+00:00weekly0.6https://www.medthority.com/news/2023/7/medtronic-recalls-nearly-350000-defibrillators-for-risk-of-reduced-shock/2024-09-30T10:49:31+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-label-update-for-leqvio-to-enable-to-enable-earlier-use-in-patients-with-elevated-ldl-c-who-have-an-increased-risk-of-heart-disease.--novartis2023-07-21T11:07:41+00:00weekly0.6https://www.medthority.com/news/2023/7/biophytis-has-requested-a-pre-submission-meeting-with-the-fda-for-an-emergency-use-authorization-for-sarconeos-for-the-treatment-of-covid-19/2023-07-21T11:05:52+00:00weekly0.6https://www.medthority.com/news/2023/7/amarin-to-restructure/2023-07-21T11:04:40+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-positive-for-extension-of-the-evrysdi-marketing-authorisation-to-include-infants--with-genetically-confirmed-diagnosis-of-sma-type-1-type-2-or-type-3-.-roche2023-07-22T13:33:57+00:00weekly0.6https://www.medthority.com/news/2023/7/new-england-journal-of-medicine-publication-on-group-b-streptococcus-gbs-maternal-vaccine-candidate/2023-07-22T13:33:16+00:00weekly0.6https://www.medthority.com/news/2023/7/gilead-to-discontinue-phase-iii-enhance-study-of-magrolimab--azacitidine-in-higher-risk-mds/2023-07-22T13:32:38+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-ycanth-to-treat-molluscum-contagiosum.--verrica-pharma2023-07-22T13:31:46+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-abrysvo-the-first-rsv-vaccine-to-protect-infants-up-to-6-months-of-age-and-older-adults.-pfizer2023-07-23T13:50:08+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-cyfendus-anthrax-vaccine-for-post-exposure-prophylaxis-of-disease.--emergent-biosolutions2023-07-23T13:49:34+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-apretude-for-prevention-of-sexually-acquired-hiv-1-in-combination-with-safer-sex-practices.--viiv-healthcare2023-07-23T13:48:39+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-jzp-458-as--a-component--for-the-treatment-of-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma.-jazz-pharma2023-07-23T13:48:01+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-inaqovi-for-the-treatment-of-acute-myeloid-leukaemia.--taihootsuka2023-07-23T13:47:14+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-litfulo-an-oral-treatment-for-alopecia-areata.--pfizer2023-07-23T13:46:38+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-lyfnua-as-a-treatment-for-refractory-or-unexplained-chronic-cough.--merck-inc2024-10-01T12:20:59+00:00weekly0.6https://www.medthority.com/news/2023/7/a-phase-iii-clinical-trial-of-mva-bn-rsv-a-respiratory-syncytial-virus-rsv-vaccine-candidate-for-adults--over-60-years-of-age-did-not-meet-all-the-primary-endpoints-of-preventing-lower-respiratory-tract-disease.--bavarian-nordic2023-07-23T13:45:24+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-orserdu-to-treat-patients-with-er-her2--locally-advanced-or-metastatic-breast-cancerwith-an-activating-esr1-mutation.--menarini--stemline-therapeutics2023-07-23T13:44:50+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-approval-of-keytruda-plus-herceptin-in-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinoma.--merck-inc2023-07-24T11:13:57+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-talvey-to-treat-relapsed-and-refractory-multiple-myeloma-rrmm-in-patients--who-have-received-at-least-three-prior-therapies.--janssen-pharma2023-07-24T11:15:35+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-tepkinly-as-a-monotherapy-for-the-treatment-of--patients-with-rr-diffuse-large-b-cell-lymphoma-dlbcl-after-two-or-more-lines-of-systemic-therapy.-abbvie2023-07-24T11:17:31+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-tevimbra-to-treat-oesophageal-squamous-cell-carcinoma.--novartis2023-07-24T11:19:45+00:00weekly0.6https://www.medthority.com/news/2023/7/settlement-of-cabometyx-patent-litigation-with-teva-pharmaceuticals-development-inc.-and-teva-pharmaceuticals-usa-inc.--exelixis2023-07-24T11:21:48+00:00weekly0.6https://www.medthority.com/news/2023/7/tocilizumab-biosimilar-candidate-msb-11456-receives-positive-chmp-opinion.--fresenius-kabi2023-07-24T11:24:27+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-approval-for-tyruko-a-multiple-sclerosis-biosimilar-natalizumab---sandoz/2023-07-24T11:25:51+00:00weekly0.6https://www.medthority.com/news/2023/7/chmp-recommends-yesafili-an-aflibercept-biosimilar.--biocon-biologics2023-07-24T11:27:35+00:00weekly0.6https://www.medthority.com/news/2023/7/chmprefuses-recommendation-for-krazati-as-a-treatment-of-advanced-non-small-cell-lung-cancer-with-a-kras-g12c-mutation.-mirati-therapeutics2023-07-24T11:29:58+00:00weekly0.6https://www.medthority.com/news/2023/7/alnylam-announces-partnership-with-roche-to-co-develop-and-co-commercialize-zilebesiran-an-investigational-rnai-therapeutic-for-the-treatment-of-hypertension-in-patients-with-high-cardiovascular-risk/2023-07-25T11:13:20+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-vanflyta--chemotherapy-to-treat-newly-diagnosed-acute-myeloid-leukemia-aml-that-is-flt3-itd-positive.--daiichi-sankyo2023-07-25T11:16:51+00:00weekly0.6https://www.medthority.com/news/2023/7/update-on-e.u.-marketing-authorization-application-for-bylvay-for-cholestatic-pruritus-in-patients-with-alagille-syndrome.--ipsen2023-07-25T11:18:16+00:00weekly0.6https://www.medthority.com/news/2023/7/twice-yearly-lenacapavir-demonstrates-sustained-impact-on-health-related-quality-of-life-in-people-with-hiv.--gilead-sciences2023-07-25T11:20:19+00:00weekly0.6https://www.medthority.com/news/2023/7/label-updated-by-pdma-in-japan-for-viivs-4-hiv-products-to-change-caution-for-patients-with-renal-dysfunction/2023-07-25T11:21:38+00:00weekly0.6https://www.medthority.com/news/2023/7/dsmb-recommendation-to-pause-new-enrollment-in-phase-iii-pivotal-cardiamp-cell-therapy-heart-failure-trial-while-additional-blinded-data-is-collected.-biocardia-inc2023-07-25T11:10:36+00:00weekly0.6https://www.medthority.com/news/2023/7/immunogen-to-collaborate-with-immunobiochem-on-antibody-drug-conjugates/2023-07-25T11:06:20+00:00weekly0.6https://www.medthority.com/news/2023/7/alvotech-and-teva-expand-their-biosimilar-collaboration/2023-07-25T11:04:37+00:00weekly0.6https://www.medthority.com/news/2023/7/long-term-data-from-the-mirror-randomized-controlled-trial-of-krystexxa-injection-with-methotrexate-published-in-acr-open-rheumatology.--horizon-therapeutics2023-07-10T12:18:08+00:00weekly0.6https://www.medthority.com/news/2023/7/susoctocog-alfa-filed-in-japan-for-the-control-of-bleeding-episodes-in-patients-with-acquired-hemophilia-a-aha.--takeda2023-07-04T11:14:42+00:00weekly0.6https://www.medthority.com/news/2023/7/mulpleta-approved-in-china-to-treatthrombocytopenia-in-adult-patients-with-chronic-liver-disease-.--eddingpharm2023-07-04T11:17:36+00:00weekly0.6https://www.medthority.com/news/2023/7/omicron-xbb.1.5-adapted-monovalent-covid-19-vaccine-for-individuals-6-months-of-age-and-older-is-filed-at-fda.-pfizer--biontech-se2023-07-04T11:19:47+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-ngenla-to-treat-human-growth-hormone-analog-indicated-for-treatment-of-pediatric-patients-aged-three-years-and-older-who-have-growth-failure-due-to-inadequate-secretion-of-endogenous-growth-hormone.-pfizer--opko-health2023-07-04T11:22:04+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-lantidra-the-first-allogeneic-donor-pancreatic-islet-cellular-therapy-made-from-deceased-donor-pancreatic-cells-for-the-treatment-of-type-1-diabetes.--cell-trans2023-07-04T11:23:03+00:00weekly0.6https://www.medthority.com/news/2023/7/european-commission-approves-camzyosfor-the-treatment-of-symptomatic-new-york-heart-association-nyha-class-ii-iii-obstructive-hypertrophic-cardiomyopathy.--bms2023-07-04T11:24:40+00:00weekly0.6https://www.medthority.com/news/2023/7/absorica-ld-approved-in-canada-to-treat-acne.--sun-pharma-canada-inc2023-07-05T11:48:09+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-accepts-bla-for-hemophilia-b-gene-therapy-fidanacogene-elaparvovec.--pfizer2023-07-05T11:50:32+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-approves-litfulo-for-adults-and-adolescents-with-severe-alopecia-areata.--pfizer2023-07-05T11:52:26+00:00weekly0.6https://www.medthority.com/news/2023/7/spesolimab-prevented-generalized-pustular-psoriasis-flares-in-effisayil-2-trial.--boehringer2023-07-05T11:57:45+00:00weekly0.6https://www.medthority.com/news/2023/7/european-commission-approves-orkambi-for-the-treatment-of-children-with-cystic-fibrosis-ages-1-to-less-than-2-years-old.--vertex-pharma2023-07-06T11:46:37+00:00weekly0.6https://www.medthority.com/news/2023/7/initial-data-from-phase-ii-trial-of-ixempra-indicates-potential-for-improved-clinical-benet-indrp-selected-metastatic-breast-cancer-patients.--allarity-therapeutics2023-07-06T11:44:15+00:00weekly0.6https://www.medthority.com/news/2023/7/abbott-receives-fda-approval-for-worlds-first-dual-chamber-leadless-pacemaker/2024-09-30T10:42:50+00:00weekly0.6https://www.medthority.com/news/2023/7/intercept-pharma-to-restructure/2023-07-06T11:40:57+00:00weekly0.6https://www.medthority.com/news/2023/7/nuvaxovid-receives-full-marketing-authorization-in-the-eu-for-the-prevention-of-covid.--novavax-inc2023-07-07T11:39:42+00:00weekly0.6https://www.medthority.com/news/2023/7/first-patients-dosed-in-phase-iii-program-evaluating-setrusumab--for-the-treatment-of-osteogenesis-imperfecta.--ultragenyx--mereo-biopharma2023-07-07T11:36:17+00:00weekly0.6https://www.medthority.com/news/2023/7/biotronik-receives-fda-approval-for-next-generation-family-of-pacemakers/2024-09-30T10:44:33+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-grants-full-approval-for-leqembi-to-treat-early-alzheimers-disease.--biogen--eisai2023-07-07T11:23:25+00:00weekly0.6https://www.medthority.com/news/2023/7/the-positive-study-of-ilumetri-significantly-improved-wellbeing-in-patients-with-moderate-to-severe-plaque-psoriasis.---almirall-sa2023-07-10T07:03:03+00:00weekly0.6https://www.medthority.com/news/2023/7/european-commission-grants-conditional-approval-for-lytgobi-to--treat-cholangiocarcinoma-.--taiho-oncology-europe2023-07-10T07:02:05+00:00weekly0.6https://www.medthority.com/news/2023/7/mhra-uk-approves-opzelura-cream-to-treat-non-segmental-vitiligo.-incyte-biosciences2023-07-10T07:01:02+00:00weekly0.6https://www.medthority.com/news/2023/7/novartis-will-appeal-to-u.s.-court-of-appeals-to-uphold-validity-of-entresto-combination-patent2023-07-10T06:59:47+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-grants-de-novo-marketing-authorization-for-kidneyintelx.dkd-to-assess-risk-of-progressive-kidney-function-decline-in-adults-with-diabetes-and-early-stage-kidney-disease.--renalytix-plc2023-07-10T06:59:06+00:00weekly0.6https://www.medthority.com/news/2023/7/complete-response-letter-for-ipx-203-for-treatment-of-parkinsons-disease.-amneal-pharma2023-07-10T06:58:25+00:00weekly0.6https://www.medthority.com/news/2023/7/sorrento-announces-positive-phase-iia-study-results-of-abivertinib-for-the-treatment-of-rr-marginal-zone-lymphoma-and-its-plan-for-a-pivotal-phase-iii-study/2023-07-10T06:57:35+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-issues-complete-response-lette-for-nda-for-dehydrated-alcohol-injection-for-the-treatment-of-methanol-poisoning.--eton-pharma2023-06-29T13:09:49+00:00weekly0.6https://www.medthority.com/news/2023/6/complete-response-letter-for-avt-02-biosimilar-candidate-for-humira.--alvotech2023-06-29T13:07:32+00:00weekly0.6https://www.medthority.com/news/2023/6/maa-submitted-to-the-european-medicines-agency-for-approval-of-single-tablet-combination-therapy--of-macitentan-and-tadalafil-for-treatment-of-pulmonary-arterial-hypertension.--jansen-pharmaceuticals2023-06-29T13:05:31+00:00weekly0.6https://www.medthority.com/news/2023/6/imfinzi--imjudo-demonstrated-sustained-overall-survival-benefit-in-advanced-liver-cancer-with-an-unprecedented-one-in-four-patients-alive-at-four-years-in-himalaya-phase-iii-trial.--astrazeneca2023-06-30T11:23:46+00:00weekly0.6https://www.medthority.com/news/2023/6/european-commission-approves-opdivo--chemotherapy-for-neoadjuvant-treatment-of-resectable-non-small-cell-lung-cancer-at-high-risk-of-recurrence-in-adult-patients-with-tumor-cell-pd-l1-expression-greater-than-1..--bms2023-06-30T11:25:35+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-roctavian-the-first-and-only-gene-therapy-for-adults-with-severe-hemophilia-a.--biomarin-pharma2023-06-30T11:27:08+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-topline-results-from-tranquility-ii-phase-iii-trial-of-bxcl-501-for-acute-treatment-of-alzheimers-disease-related-agitation.--bioxcel-therapeutics2023-06-30T11:29:46+00:00weekly0.6https://www.medthority.com/news/2023/6/cyclo-therapeutics-announces-publication-of-positive-data-from-phase-ii-clinical-study-of-trappsol-cyclo-for-the-treatment-of-niemann-pick-disease-type-c1/2023-06-30T11:33:26+00:00weekly0.6https://www.medthority.com/news/2023/6/sangamo-therapeutics-and-voyager-therapeutics-enter-licence-agreement-for-epigenetic--regulation-treatment-of-prion-disease/2023-06-30T11:35:29+00:00weekly0.6https://www.medthority.com/news/2023/6/eli-lilly-to-acquire-sigilon-therapeutics-and-with-it-sig-002-for-the-treatment-of-type-1-diabetes/2023-06-30T11:38:45+00:00weekly0.6https://www.medthority.com/news/2023/7/novartis-divests-front-of-eye-ophthalmology-assets-to-bausch--lomb/2023-07-01T15:16:46+00:00weekly0.6https://www.medthority.com/news/2023/7/positive-outcome-of-fda-advisory-committee-on-investigational-palovarotene-for-fibrodysplasia-ossificans-progressiva--ipsen/2023-07-01T15:15:56+00:00weekly0.6https://www.medthority.com/news/2023/7/phase-iiib-trial-of-fezolinetant-shows-positive-topline-resultsfor-treatment-of-vasomotor-symptoms.--due-to-menopause.--astellas2023-07-01T15:14:28+00:00weekly0.6https://www.medthority.com/news/2023/7/new-analysis-of-mri-findings-shows-uplizna-reduced-the-formation-of-subclinical-spinal-cord-lesions-in-people-with-neuromyelitis-optica-spectrum-disorder-.---horizon-therapeutics2023-07-01T15:13:40+00:00weekly0.6https://www.medthority.com/news/2023/7/submission-of-nda-to-the-fda-of-dasiglucagon-for-the-prevention-and-treatment-of--hypoglycemia-in-pediatric-patients.--zealand-pharma-as2023-07-01T15:12:51+00:00weekly0.6https://www.medthority.com/news/2023/7/new-data-at-cure-sma-highlight-potential-benefit-of-spinraza-in-infants-and-toddlers-with-unmet-clinical-needs-after-gene-therapy-for-spinal-muscular-atrophy.--biogen2023-07-01T15:11:48+00:00weekly0.6https://www.medthority.com/news/2023/7/sandoz-to-launch-hyrimoz-high-concentration-formulation-marking-sandoz-entrance-into-us-immunology-space/2023-07-01T15:09:39+00:00weekly0.6https://www.medthority.com/news/2023/7/four-year-follow-up-data-for-evrysdi-show-continued-increase-in-number-of-children-with-a-severe-form-of-spinal-muscular-atrophy-able-to-sit-stand-and-walk-genentechroche/2023-07-01T15:10:59+00:00weekly0.6https://www.medthority.com/news/2023/7/mlhw-japan-approves-updated-indication-for-shingrix-for-the-prevention-of-shingles.--gsk2023-07-02T13:35:30+00:00weekly0.6https://www.medthority.com/news/2023/7/jcr-receives-an-approval-from-mhlw-japan-for-expanded-indication-of-growject-in-short-stature-due-to-shox-deficiency/2023-07-02T13:34:46+00:00weekly0.6https://www.medthority.com/news/2023/7/cyltezo--an-adalimumab-biosimilar-is-now-available-in-usa.--boehringer2023-07-02T13:33:50+00:00weekly0.6https://www.medthority.com/news/2023/7/fda-action-for-bla-for-bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis-is-now-shifted-to-q3-2023.-ucb2023-07-02T13:33:12+00:00weekly0.6https://www.medthority.com/news/2023/7/date-is-set-for-the-planned-fda-advisory-committee-meeting-for-onpattro-for-the-treatment-of-cardiomyopathy-of-attr-amyloidosis.-alnylam2023-07-03T11:22:50+00:00weekly0.6https://www.medthority.com/news/2023/7/moderna-submits-regulatory-application-to-the-european-medicines-agency-for-its-updated-covid-19-vaccine--for-the-xbb.1.5-sublineage-of-sars-cov-22023-07-03T11:24:18+00:00weekly0.6https://www.medthority.com/news/2023/7/the-japan-pharmaceutical-and-medical-devices-agency-pmda-has-approved--luxturna-for-the-treatment-of-inherited-retinal-dystrophies-irds-caused-by-biallelic-rpe65-mutations--novartis/2023-07-03T11:26:10+00:00weekly0.6https://www.medthority.com/news/2023/7/positive-results-from-the-tropion-lung01-phase-iii-trial-of-datopotamab-deruxtecan--demonstrated-a-statistically-significant-improvement-in-pfs-compared-to-chemotherapy.-astrazenca---daiichi-sankyo2023-07-03T11:29:09+00:00weekly0.6https://www.medthority.com/news/2023/6/bavarian-nordic-as-reported-topline-results-from-a-phase-iii-non-inferiority-clinical-trial-of-abncov2-a-vlp-based-non-adjuvanted-covid-19-booster-vaccine-candidate/2023-06-28T11:51:56+00:00weekly0.6https://www.medthority.com/news/2023/6/two-year-results-for-aflibercept-8-mg-from-pivotal-photon-trial-demonstrates-durable-vision-gains-at-extended-dosing-intervals-in-diabetic-macular-edema--regeneron/2023-06-28T11:47:53+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-issues-complete-response-letter-for-bla-for-aflibercept-8-mg.--regeneron--bayer2023-06-28T11:45:55+00:00weekly0.6https://www.medthority.com/news/2023/6/topline-results-from-phase-iii-zephyrus-1-study-of-pamrevlumab-for-the-treatment-of-idiopathic-pulmonary-fibrosis.--fibrogen2023-06-27T11:49:57+00:00weekly0.6https://www.medthority.com/news/2023/6/new-topline-olinvyk-data-highlighting-reduced-cost-per-admission-from-artemis-real-world-outcomes-study.--trevena-inc2023-06-27T11:51:52+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-results-from-phase-ii-portion-of-rise-up-pivotal-study-in-sickle-cell-disease-with-both-mitapivat-dose-arms-achieving-statistically-significant-hemoglobin-response.--agios-pharma2023-06-27T11:54:36+00:00weekly0.6https://www.medthority.com/news/2023/6/zenyaku-kogyo-acquires-exclusive-rights-in-japan-to-eblasakimab-from-aslan-pharma-for-the-treatment-of-atopic-dermatitis/2023-06-27T11:56:21+00:00weekly0.6https://www.medthority.com/news/2023/6/surmount-2-results-published-in-the-lancet-show-tirzepatide-achieved-a-mean-weight-reduction-of-15.7-at-the-highest-dose-15-mg-in-adults-with-obesity-or-overweight-and-type-2-diabetes.--eli-lilly2023-06-27T11:59:48+00:00weekly0.6https://www.medthority.com/news/2023/6/late-breaking-efanesoctocog-alfa-data-presented-at-isth-demonstrates-highly-effective-bleed-protection-in-children-with-severe-haemophilia-a-with-once-weekly-dosing.-sobi--sanofi2023-06-27T12:02:09+00:00weekly0.6https://www.medthority.com/news/2023/6/xigduo-xr-approved-in-china-for-adults-with-type-2-diabetes.--astrazeneca2023-06-27T12:04:37+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approval-of-rystiggo--for-the-treatment-of-adults-with-generalized-myasthenia-gravis.--ucb2023-06-27T11:46:58+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-topline-data-from-phase-iii-clinical-trial-optic-j-in-japan-evaluating-tepezza-for-the-treatment-of-active-thyroid-eye-disease-.--horizon-therapeutics2023-06-23T13:51:53+00:00weekly0.6https://www.medthority.com/news/2023/6/intercept-pharma-ends-investment-in-development-of-obeticholic-acid-for-nonalcoholic-steatohepatitis-nash/2023-06-23T13:51:10+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approval-of-elevidys-the-first-gene-therapy-to-treat-duchenne-muscular-dystrophy.--sarepta-therapeutics2023-06-23T13:50:27+00:00weekly0.6https://www.medthority.com/news/2023/6/hepcludex-demonstrates-sustained-efficacy-and-safety-profile-in-people-with-chronic-hepatitis-delta-virus-at-96-weeks.--gilead-sciences2023-06-24T11:51:05+00:00weekly0.6https://www.medthority.com/news/2023/6/moderna-files-for-fda-authorization-of-its-updated-covid-19-vaccine-containing-spike-proteins-for-the-xbb.1.5-sublineage-of-sars-cov-2-mrna-1273.8152023-06-24T11:50:20+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-positive-opinion-for-trodelvy-in-pre-treated-hrher2--metastatic-breast-cancer--gilead-sciences/2023-06-24T11:49:35+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-chmp-opinion-for-atogepant-for-the-preventive-treatment-of-adults-with-migraine.--abbvie2023-06-24T11:48:56+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-positive-for-jesduvroq-to-treat-symptomatic-anemia-in-adults-with-chronic-kidney-disease-who-are-on-dialysis--gsk/2023-06-24T11:48:14+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-negative-opinion-for-albrioza--for-the-treatment-of-adults-with-amyotrophic-lateral-sclerosis.--amylyx-pharma2023-06-24T11:47:38+00:00weekly0.6https://www.medthority.com/news/2023/6/jardiance-recommended-for-the-treatment-of-adults-with-chronic-kidney-disease-in-the-eu.--boehringer--eli-lilly2023-06-24T11:46:59+00:00weekly0.6https://www.medthority.com/news/2023/6/talaris-therapeutics-to-merge-with-tourmaline-bio/2023-06-24T11:46:18+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-positive-for-lonsurf--bevacizumab-for-the-treatment-of-adult-patients-with-metastatic-colorectal-cancer-crc-who-have-received-two-prior-anticancer-treatment-regimens-.--servier2023-06-25T12:34:11+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-positive-for-mircera--to-treat-paediatric-patients-with-anaemia-associated-with-ckd.--roche2023-06-25T12:33:28+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-extends-existing-indication-of-generalised-myasthenia-gravis-to-patients-aged-6-years-and-above.--alexionastrazeneca2023-06-25T12:32:42+00:00weekly0.6https://www.medthority.com/news/2023/6/chmp-extends-the-indication-of--refixia-to-prophylaxis-of-bleeding-in-patients-12-years-and-above-with-haemophilia-b.--novo-nordisk2023-06-26T11:41:48+00:00weekly0.6https://www.medthority.com/news/2023/6/new-data-show-once-weekly-insulin-icodec-met-additional-endpoints-in-adults-with-type-2-diabetes.--novo-nordisk-2023-06-26T11:40:50+00:00weekly0.6https://www.medthority.com/news/2023/6/maa-submitted-to-the-european-medicines-agency-for-dasiglucagon-for-treatment-of-severe-hypoglycemia-in-diabetes.--novo-nordisk--zealand-pharma2023-06-26T11:39:23+00:00weekly0.6https://www.medthority.com/news/2023/6/data-shows-nearly-19-weight-loss-in-people-with-overweight-or-obesity-in-phase-ii-trial-with-survodutide-bi-456906--boehringer--zealand-pharma-as/2023-06-26T11:36:56+00:00weekly0.6https://www.medthority.com/news/2023/6/publication-of-phase-iii-fresco-2-results-evaluating-fruquintinib-in-patients-with-previously-treated-colorectal-cancer-in-the-lancet.--takeda-and-hutchmed2023-06-20T13:24:24+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-bylvay-for-patients-living-with-cholestatic-pruritus-due-to-alagille-syndrome.--ipsen2023-06-20T13:27:27+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-accepts-snda-for-onivyde--chemotherapy-to-treat-metastatic-pancreatic-ductal-adenocarcinoma.--ipsen2023-06-20T13:29:10+00:00weekly0.6https://www.medthority.com/news/2023/6/santhera-grants-exclusive-north-america-license-for-vamorolone-to-catalyst-pharmaceuticals-in-deal-valued-at-up-to-$231-million-plus-royalties/2023-06-20T13:19:43+00:00weekly0.6https://www.medthority.com/news/2023/6/new-data-from-tepezza-clinical-trials-and-real-world-analyses-shed-light-on-link-between-thyroid-autoimmunity-and-hearing-risks.--horizon-therapeutics2023-06-22T07:19:54+00:00weekly0.6https://www.medthority.com/news/2023/6/amneal-receives-505b2-nda-approval-from-fda-for-pemrydi-rtu-a-ready-to-use-oncology-injectable/2023-06-22T07:19:01+00:00weekly0.6https://www.medthority.com/news/2023/6/health-canada-approves-xcopri-to-treat-partial-offset-seizures.-paladin-labs2023-06-22T07:18:09+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approval-for-surveil-drug-coated-balloon-for-percutaneous-transluminal-angioplasty.--abbott2023-06-22T07:17:31+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-week-36-efficacy-and-safety-results-of-phase-iib-origin-clinical-trial-of-atacicept-in-igan--presented-at-60th-european-renal-association-era-congress.--vera-therapeutics2023-06-22T07:16:26+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-under-the-skin-injection-vyvgart-for-the-treatment-of-a-muscle-weakening-genetic-disease-called-generalized-myasthenia-gravis.---argenx2023-06-22T07:21:46+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-trial-of-adcetris-with-modified-chemo-regimen-shows-non-inferiority-with-unprecedented-3-year-progression-free-survival-of-94.9-vs-less-tolerable-international-standard-of-care-in-advanced-classical-hodgkin-lymphoma.-seagen--takeda2023-06-22T07:13:27+00:00weekly0.6https://www.medthority.com/news/2023/6/eli-lilly-to-acquire-dice-therapeutics-and-with-it-oral-il-17-inhibitors-dc-806-and-dc-853/2023-06-22T07:12:06+00:00weekly0.6https://www.medthority.com/news/2023/6/complete-response-letter-for-adx-2191-a-proposed-treatment-for-primary-vitreoretinal-lymphoma.--aldeyra2023-06-23T13:54:38+00:00weekly0.6https://www.medthority.com/news/2023/6/fda--grants-full-supplemental-approval-for-blincyto-to-treat-minimal-residual-disease-b-cell-precursor--acute-lymphoblastic-leukemia.--amgen--2023-06-23T13:53:53+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-jardiance-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older.--boehringer-ingelheim--eli-lilly2023-06-23T13:53:16+00:00weekly0.6https://www.medthority.com/news/2023/6/bayer-to-start-phase-iii-study-with-finerenone-in-adults-with-chronic-kidney-disease-and-type-1-diabetes/2023-06-23T13:52:38+00:00weekly0.6https://www.medthority.com/news/2023/6/n-momentum-clinical-trial-of-uplizna-shows-role-of-assessment-accuracy-in-neuromyelitis-optica-spectrum-disorder-and-is-published-in-multiple-sclerosis-journal.--horizon-therapeutics2023-06-13T12:03:02+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-sierra-trial-of-iomab-b-in-aml-presented-at-eha-congress.--actinium-pharma2023-06-13T12:04:44+00:00weekly0.6https://www.medthority.com/news/2023/6/sintilimab--chemoradiotherapy-improves-efs-in-locally-advanced-nasopharyngeal-carcinoma.--eli-lilly--innovent-biologics2023-06-08T12:04:08+00:00weekly0.6https://www.medthority.com/news/2023/6/fianlimab--cemiplimab-demonstrates-early-clinical-activity-and-safety-in-advanced-melanoma.--regeneron2023-06-08T11:59:14+00:00weekly0.6https://www.medthority.com/news/2023/6/eu-approves-arexvy-for-respiratory-syncytial-virus.--gsk2023-06-08T11:55:53+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-accepts-filing-for-jemperli---chemotherapy-for-the-treatment-of-dmmrmsi-h-primary-advanced-or-recurrent-endometrial-cancer.--gsk2023-06-09T11:44:42+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-accepts-application-for-keytruda---chemotherapy-as-treatment-for-advanced-or-unresectable-biliary-tract-cancer.--merck-inc2023-06-09T11:46:36+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approval-of-vevye-0.1-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease.---novaliq2023-06-09T11:48:26+00:00weekly0.6https://www.medthority.com/news/2023/6/topline-results-from-lelantos-1-phase-iii-clinical-study-of-pamrevlumab-in-non-ambulatory-patients-with-duchenne-muscular-dystrophy--fibrogen/2023-06-09T11:50:49+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-lavender-trial-of-daybue-in-rett-syndrome-published-in-nature-medicine.--acadia-pharmaceuticals2023-06-09T11:53:02+00:00weekly0.6https://www.medthority.com/news/2023/6/danicopan-as-add-on-to-ultomiris-or-soliris-improved-haemoglobin-levels-and-maintained-disease-control-in-patients-with-pnh-experiencing-signs-or-symptoms-of-clinically-significant-extravascular-haemolysis-astrazeneca/2023-06-11T13:00:33+00:00weekly0.6https://www.medthority.com/news/2023/6/new-data-show-subcutaneously-administered-crovalimab-achieved-disease-control-and-was-well-tolerated-in-people-with-paroxysmal-nocturnal-hemoglobinuria-.-genentechroche2023-06-11T12:59:21+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-advisory-committee-recommends-approval-of-nirsevimab-for-respiratory-syncytial-virus.--astrazeneca-and-sanofi2023-06-11T12:57:34+00:00weekly0.6https://www.medthority.com/news/2023/6/climb-111-and-climb-121-phase-iii-trials-of-exa-cel-meet-their-primary-endpoint-in-beta-thalassemia-or-severe-sickle-cell-disease.--vertex-pharma2023-06-10T11:00:27+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-advisory-committee-votes-unanimously-to-confirm-the-clinical-benefit-of-leqembi-for-the-treatment-of-alzheimers-disease.--eisai--biogen2023-06-11T12:55:41+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-accepts-blas-for-exagamglogene-autotemcel-for-severe-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.--vertex-pharma--crispr-therapeutics2023-06-11T12:54:26+00:00weekly0.6https://www.medthority.com/news/2023/6/astrazeneca-announces-agreement-with-quell-therapeuticsto-develop-manufacture-and-commercialise-engineeredt-regulatory-cell-therapies-for-autoimmune-diseases/2023-06-11T12:53:39+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-injectafer-to-treat-iron-deficiency-and-heart-failure.--daiichi-sankyo--american-regent-inc2023-06-12T12:06:56+00:00weekly0.6https://www.medthority.com/news/2023/6/european-commission-approval-for-pedmarqsi-to-reduce-the-risk-of-hearing-loss-in-paediatric-oncology-patients.--fennec-pharma2023-06-12T12:08:26+00:00weekly0.6https://www.medthority.com/news/2023/6/mhra-uk-expands-approval-for-xeomin-to-treat-focal-spasticity-of-the-lower-limbs-affecting-the-ankle-joint.--merz-therapeutics-2023-06-12T12:10:22+00:00weekly0.6https://www.medthority.com/news/2023/6/novartis-to-acquire-chinook-therapeutics-and-with-it-atrasentan-and-zigakibart/2023-06-12T12:12:54+00:00weekly0.6https://www.medthority.com/news/2023/6/seagen-announces-adcetris--novel-immunotherapy-combination-delivers-98-overall-response-rate-and-93-complete-response-rate-in-early-stage-classical-hodgkin-lymphoma/2023-06-14T11:07:21+00:00weekly0.6https://www.medthority.com/news/2023/6/publication-of-chikungunya-vaccine-candidate--vla-1553-phase-iii-data-in-the-lancet.--valneva-se2023-06-14T11:11:58+00:00weekly0.6https://www.medthority.com/news/2023/6/soliris-approved-in-china-for-the-treatment-of-adults-with-refractory-generalised-myasthenia-gravis.--astrazeneca2023-06-14T11:13:36+00:00weekly0.6https://www.medthority.com/news/2023/6/venclyxtovenclexta-continues-to-show-sustained-progression-free-survival-pfs-in-chronic-lymphocytic-leukemia-cll-patients.--abbvie2023-06-14T11:16:25+00:00weekly0.6https://www.medthority.com/news/2023/6/panbela-therapeutics-enters-research-agreement-university-of-texas-md-anderson-cancer-center-to-evaluate-polyamine-metabolic-inhibitor-therapies-to-augment-car-t-mediated-cytotoxicity-against-c19-large-b-cell-lymphoma-cell-lines/2023-06-14T11:18:35+00:00weekly0.6https://www.medthority.com/news/2023/6/sbla-submitted-to-the-fda-seeking-approval-for-carvykti-for-the-earlier-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma.-janssen2023-06-15T14:42:57+00:00weekly0.6https://www.medthority.com/news/2023/6/bayer-starts-phase-iiiii-study-with-vericiguat-in-children-with-heart-failure.-2023-06-15T14:44:38+00:00weekly0.6https://www.medthority.com/news/2023/6/sandoz-introduces-act4biosimilars-action-plan-to-accelerate-patient-access-to-biosimilar-medicines-----/2023-06-15T14:46:30+00:00weekly0.6https://www.medthority.com/news/2023/6/randomized-phase-iii-trial-of-io102-io103-dual-antigen-immunotherapeutic-plus-pembrolizumab-versus-pembrolizumab-alone-in-unresectable-or-metastatic-advanced-melanoma.-io-biotech2023-06-16T11:56:07+00:00weekly0.6https://www.medthority.com/news/2023/6/publication-of-results-from-phase-iii-relief-trial-of-tnx-102-sl-for-the-management-of-fibromyalgia.-tonix-pharma-holding-corp2023-06-16T11:57:59+00:00weekly0.6https://www.medthority.com/news/2023/6/vbi-vaccines-announces-prehevbri-is-now-available-in-the-united-kingdom-for-the-prevention-of-hepatitis-b-in-adults/2023-06-16T12:00:58+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-columvi-the-first-and-only-bispecific-antibody-with-a-fixed-duration-treatment-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.--roche-2023-06-16T12:04:16+00:00weekly0.6https://www.medthority.com/news/2023/6/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episodic-migraine-prevention.--eli-lilly2023-06-18T09:14:22+00:00weekly0.6https://www.medthority.com/news/2023/6/verve-establishes-global-collaboration-with-lilly-to-advance-verves-in-vivo-gene-editing-program-targeting-lpa-for-the-treatment-of-atherosclerotic-cardiovascular-disease/2023-06-18T09:13:28+00:00weekly0.6https://www.medthority.com/news/2023/6/skyrizi-met-primary-and-key-secondary-endpoints-in-52-week-phase-iii-maintenance-study-in-ulcerative-colitis-patients--abbvie/2023-06-18T14:04:07+00:00weekly0.6https://www.medthority.com/news/2023/6/keytruda--trastuzumab---chemotherapy-met-primary-endpoint-of-progression-free-survival-as-first-line-treatment-of-her2-positive-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--merck-inc2023-06-18T14:03:21+00:00weekly0.6https://www.medthority.com/news/2023/6/gsk-announces-extension-of-fda-review-period-for-momelotinib-to-treat-myelofibrosis/2023-06-18T14:02:32+00:00weekly0.6https://www.medthority.com/news/2023/6/coherus-biosciences-acquires-surface-oncology-and-with-it-srf-388-for-lung-and-liver-cancer-and-sfr-114-for-solid-tumours/2023-06-18T14:01:42+00:00weekly0.6https://www.medthority.com/news/2023/6/additional-data-from-phase-iv-tepezza-clinical-trial-presented-at-the-endocrine-society-annual-meeting-reinforces-efficacy-in-people-with-thyroid-eye-disease-ted-regardless-of-disease-activity-or-duration.-horizon-therapeuticsamgen2023-06-19T11:26:27+00:00weekly0.6https://www.medthority.com/news/2023/6/150th-bipolar-depression-patient-randomized-in-recover-clinical-study-of-vns-therapy--liva-nova-/2023-06-19T11:23:54+00:00weekly0.6https://www.medthority.com/news/2023/6/breyanzi-delivers-deep-and-durable-responses-in-relapsed-or-refractory-follicular-lymphoma-and-mantle-cell-lymphoma-in-transcend-clinical-trials-presented-at-icml-2023.--bms2023-06-19T11:22:18+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-addition-of-positive-data-from-phase-iii-valor-hcm-study-to-camzyos-label-showing-reduction-of--the-composite-endpoint-of-guideline-based-eligibility-for-septal-reduction-therapy.--bms2023-06-19T11:19:28+00:00weekly0.6https://www.medthority.com/news/2023/5/new-drug-application-for-fruquintinib-for-treatment-of-previously-treated-metastatic-colorectal-cancer-granted-priority-review.--hutchmed--takeda2023-05-30T11:04:01+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-approves-xacduro-for-habp-and-vabp-caused-by-acinetobacter-infection.--entasisinnovia2023-05-30T11:05:48+00:00weekly0.6https://www.medthority.com/news/2023/5/promising-topline-results-from-part-1-of-pivotal-serenity-iii-trial-of-bxcl-501-for-at-home-use-in-acute-treatment-of-agitation-in-bipolar-disorders-or-schizophrenia.--bioxcel-therapeutics-inc2023-05-30T11:10:47+00:00weekly0.6https://www.medthority.com/news/2023/5/first-patient-dosed-with-imlifidase-in-a-global-pivotal-phase-iii-trial-in-anti-glomerular-basement-membrane-anti-gbm-disease.--hansa-biopharma2023-05-30T11:12:41+00:00weekly0.6https://www.medthority.com/news/2023/5/nuvaxovid-receives-positive-chmp-opinion-for-full-marketing-authorization-for-the-prevention-of-covid-19-in-the-eu.--novavax2023-05-30T11:15:11+00:00weekly0.6https://www.medthority.com/news/2023/5/results-from-a-phase-iii-study-of-tradipitant-in-motion-sickness.--vanda-pharma2023-05-26T11:32:32+00:00weekly0.6https://www.medthority.com/news/2023/5/apellis-reports-top-line-results-from-phase-ii-meridian-study-of-pegcetacoplan-in-als/2023-05-26T11:30:40+00:00weekly0.6https://www.medthority.com/news/2023/5/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-to-treat-covid-19-in-people-with-severe-renal-impairment-including-those-on-dialysis.--gilead-sciences2023-05-26T11:27:01+00:00weekly0.6https://www.medthority.com/news/2023/5/lenvima--keytruda-demonstrateslong-term-durable-survival-benefit-versus-sunitinib-as-first-line-treatment-for-advanced-renal-cell-carcinoma.--eisai--merck-inc2023-05-26T11:23:40+00:00weekly0.6https://www.medthority.com/news/2023/5/interim-data-demonstrates-12-month-survival-rate-of-87-with-pds-0101-in-combination-with-keytruda--for-head-and-neck-cancer-patients.-pds-biotechnology-corporation2023-05-26T11:21:45+00:00weekly0.6https://www.medthority.com/news/2023/5/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-neuromyelitis-optica-spectrum-disorder-.--astrazeneca2023-05-26T11:19:38+00:00weekly0.6https://www.medthority.com/news/2023/5/imfinzi--lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-advanced-endometrial-cancer-when-added-to-chemotherapy.--astrazeneca2023-05-26T11:18:05+00:00weekly0.6https://www.medthority.com/news/2023/6/new-analyses-of-the-mirror-randomized-controlled-trial-in-uncontrolled-gout-presented-at-the-2023-eular-european-congress-of-rheumatology.--horizon-therapeutics2023-06-01T13:30:48+00:00weekly0.6https://www.medthority.com/news/2023/6/positive-phase-ii-data-of-novel-investigational-anti-cd40l-antibody-frexalimab-show-significantly-reduced-disease-activity-in-relapsing-multiple-sclerosis.--sanofi2023-06-01T13:33:00+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-agrees-to-a-single-confirmatory-phase-iii-study-of-ar-301-and-the-clinical-study-design.--aridis-pharmaceuticals2023-06-01T13:35:58+00:00weekly0.6https://www.medthority.com/news/2023/6/update-on-brazikumab-development-programme.--astrazeneca2023-06-01T13:39:17+00:00weekly0.6https://www.medthority.com/news/2023/6/lynparza--abiraterone-approved-in-the-us-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer.-astrazeneca--merck-inc2025-05-06T14:01:20+00:00weekly0.6https://www.medthority.com/news/2023/6/sandoz-ag-to-move-to-new-offices-in-basel/2023-06-01T13:56:49+00:00weekly0.6https://www.medthority.com/news/2023/6/troriluzole-filed-at-fda-to-treat-spinocerebellar-ataxia-type-3.--biohaven2023-06-02T12:04:20+00:00weekly0.6https://www.medthority.com/news/2023/6/lupkynis-achieved-significantly-higher-renal-response-in-lupus-nephritis-patients-with-high-proteinuria-compared-to-patients-treated-with-mmf-and-low-dose-steroids-alone.---aurinia2023-06-02T12:01:41+00:00weekly0.6https://www.medthority.com/news/2023/6/biomarker-analysis-publication-highlights-key-signals-of-disability-worsening-associatedw-ith-neuromyelitis-optica-spectrum-disorder-nmosd-attacks-illustrates-efficacy-of-uplizna/2025-02-03T11:25:00+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-approves-abrysvo-vaccine-for-the-prevention-of-respiratory-syncytial-virus-rsv-in-older-adults.--pfizer2025-02-03T11:25:46+00:00weekly0.6https://www.medthority.com/news/2023/6/lilly-highlights-verzenio-data-for-hr-and-her2--breast-cancer-at-asco-annual-meeting-2023/2023-06-03T13:59:58+00:00weekly0.6https://www.medthority.com/news/2023/6/kisqali-significantly-reduced-the-risk-of-recurrence-by-25-across-a-broad-population-of-patients-with-early-breast-cancer-clinically-meaningful-benefit-was-consistent-.across-subgroups.--novartis2023-06-03T13:59:16+00:00weekly0.6https://www.medthority.com/news/2023/6/sub-group-analyses-of-3-vitrakvi-post-hoc-studies-in-trk-fusion-cancer-presented-at-asco.--bayer2023-06-03T13:58:26+00:00weekly0.6https://www.medthority.com/news/2023/6/eu-approves-briumvi-in-adults-with-relapsing-multiple-sclerosis.--tg-therapeutics2023-06-03T13:57:45+00:00weekly0.6https://www.medthority.com/news/2023/6/presentation-of-ingezza-capsules-data-on-tardive-dyskinesia-improvement-regardless-of-baseline-antipsychotic-use-at-2023-psych-congress-elevate.--neurocrine-biosciences2023-06-03T13:57:03+00:00weekly0.6https://www.medthority.com/news/2023/6/updated-data-from-the-phase-1ii-bruin-trial-of-jaypirca-in-patients-with-covalent-btk-inhibitor-pre-treated-rr-mantle-cell-lymphoma-continue-to-demonstrate-durable-efficacy--eli-lilly-/2023-06-03T13:56:16+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-revisit-and-assemble-studies-of-atm-avi-show-the-combination-is-effective-in-gram-negative-bacterial-infections.--pfizer2023-06-03T13:55:30+00:00weekly0.6https://www.medthority.com/news/2023/6/imerge-phase-iii-trial-of-grn-163l-in-myelodysplastic-syndromes-patients-meets-primary-endpoint.--geron-corp-2023-06-03T13:54:48+00:00weekly0.6https://www.medthority.com/news/2023/6/lynparza--imfinzi-combination-reduced-risk-of-disease-progression-or-death-by-37-vs.-chemotherapy-and-bevacizumab-in-advanced-ovarian-cancer-without-tumour-brca-mutations-in-the-duo-o-phase-iii-trial--astrazeneca2023-06-04T13:40:38+00:00weekly0.6https://www.medthority.com/news/2023/6/grail-and-university-of-oxford-present-results-from-first-prospective-study-of-multi-cancer-early-detection-in-a-symptomatic-patient-population-at-2023-asco-annual-meeting/2023-06-04T13:39:46+00:00weekly0.6https://www.medthority.com/news/2023/6/tagrisso-achieved-unprecedented-survival-in-early-stage-egfr-mutated-lung-cancer-with-88-of-patients-alive-at-five-years-in-adaura-phase-iii-trial.--astrazeneca2023-06-05T11:06:35+00:00weekly0.6https://www.medthority.com/news/2023/6/four-year-outcomes-from-phase-iii-checkmate-9la-trial-show-durable-long-term-survival-with-opdivo---yervoy-with-two-cycles-of-chemotherapy-for-metastatic-non-small-cell-lung-cancer.--bms2023-06-05T11:08:34+00:00weekly0.6https://www.medthority.com/news/2023/6/keytruda--chemotherapy-significantly-improved-overall-survival-v.-chemotherapy-alone-as-first-line-treatment-for-unresectable-advanced-pleural-mesothelioma.--merck-inc2023-06-05T11:11:20+00:00weekly0.6https://www.medthority.com/news/2023/6/presentation-of-new-lumakras-codebreak-200-cns-data-at-asco-2023meeting.--amgen2023-06-05T11:14:33+00:00weekly0.6https://www.medthority.com/news/2023/6/elahere-demonstrates-35-reduction-in-the-risk-of-disease-progression-or-death-v.chemotherapy-in-fralpha-positive-platinum-resistant-ovarian-cancer.-immunogen2023-06-05T11:18:41+00:00weekly0.6https://www.medthority.com/news/2023/6/keytruda--chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-reduced-the-risk-of-event-free-survival-events-by-42-versus-pre-operative-chemotherapy-in-resectable-stage-ii-iiia-or-iiib-nsclc.--merck-inc2023-06-05T11:21:01+00:00weekly0.6https://www.medthority.com/news/2023/6/andexxa-phase-iv-trial-stopped-early-after-achieving-pre-specified-criteria-on-haemostatic-efficacy-versus-usual-care.--astrazenca2023-06-05T11:24:30+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-accepts-for-priority-review--application-for-repotrectinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-ros1-positive-nsclc.--bms2023-06-05T11:26:47+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-acceptance-of-the-bla-of-lifileucel-for-the-treatment-of-advanced-melanoma.--iovance-biotherapeutics2023-06-05T11:31:39+00:00weekly0.6https://www.medthority.com/news/2023/5/health-canada-approves-brukinsa-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia.--beigene2023-05-31T11:22:17+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-accepts-nda-for-repotrectinib-for-the-treatment-of-patients-with-ros1-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer.--bms2023-05-31T11:24:46+00:00weekly0.6https://www.medthority.com/news/2023/5/positive-marstacimab-results-from-pivotal-phase-iii-hemophilia-a-and-b-trial--pfizer/2023-05-31T11:28:24+00:00weekly0.6https://www.medthority.com/news/2023/5/fda-provides-akebia-therapeutics-a-path-forward-for-vadadustat-for-the-treatment-of-anemia-due-to-chronic-kidney-disease/2023-05-31T11:30:23+00:00weekly0.6https://www.medthority.com/news/2023/5/new-long-term-data-on-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis-presented-at-eular-2023.-ucb2023-05-31T11:34:14+00:00weekly0.6https://www.medthority.com/news/2023/5/new-research-on-otezla-in-psoriatic-arthritis-presented-at-eular-2023.-amgen2023-05-31T11:37:09+00:00weekly0.6https://www.medthority.com/news/2023/5/brixadi-extended-release-subcutaneous-injection-receives-fda-approval-for-moderate-to-severe-opioid-use-disorder.--braeburn-2023-05-31T11:38:36+00:00weekly0.6https://www.medthority.com/news/2023/5/atea-pharmaceuticals-board-of-directors-unanimously-rejects-unsolicited-proposal-from-tang-capital-partners-affiliate-concentra-bioscience/2023-05-31T11:40:09+00:00weekly0.6https://www.medthority.com/news/2023/6/springworks-therapeutics-announces-pdufa-date-extension-for-nirogacestat-nda-to-treat-desmoid-tumour/2023-06-06T14:03:05+00:00weekly0.6https://www.medthority.com/news/2023/6/datopotamab-deruxtecan-combinations-showed-encouraging-tumour-responses-in-patients-with-advanced-non-small-cell-lung-cancer-in-tropion-lung02-phase-ib-trial.-astrazeneca--daiichi-sankyo2025-02-03T14:17:17+00:00weekly0.6https://www.medthority.com/news/2023/6/enhertu-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing-advanced-solid-tumours.--astrazeneca--daiichi-sankyo2023-06-06T13:39:24+00:00weekly0.6https://www.medthority.com/news/2023/6/mrna-4157-v940--keytruda--demonstrated-a-statistically-significant-and-clinically-meaningful-improvement-in-distant-metastasis-free-survival-in-patients-with-high-risk-stage-iiiiv-melanoma-following-complete-resection.--moderna-inc.--merck-inc2023-06-06T13:34:02+00:00weekly0.6https://www.medthority.com/news/2023/6/results-from-the-pivotal-phase-iii-indigo-trial-show-that-vorasidenib-was-associated-with-a-significant-delay-in-time-to-disease-progression-when-compared-with-placebo.--servier2023-06-06T13:30:39+00:00weekly0.6https://www.medthority.com/news/2023/6/autolus-therapeutics-presents-positive-results-from-pivotal-phase-ii-felix-study-in-adult-rr-b-all-at-asco/2023-06-06T13:28:07+00:00weekly0.6https://www.medthority.com/news/2023/6/yescarta-car-t-cell-therapy-demonstrates-significantly-longer-overall-survival-versus-standard-of-care-as-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma.--kitegilead2023-06-06T13:24:19+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-tropics-02-study-of-trodelvy-shows-improved-os-in-hrher2--metastatic-breast-cancer.--gilead-sciences2025-02-03T14:17:38+00:00weekly0.6https://www.medthority.com/news/2023/6/phase-iii-cartitude-4-study-of-cilta-cel-shows-a-reduced-risk-of-death-or-disease-progression-by-74-in-multiple-myeloma.--legend-biotech-corp2023-06-06T13:03:57+00:00weekly0.6https://www.medthority.com/news/2023/6/braftovi--mektovi-significantly-improves-objective-response-rates-in-metastatic-non-small-cell-lung-cancer-pfizer/2025-02-03T14:17:53+00:00weekly0.6https://www.medthority.com/news/2023/6/tremfya-provides-sustained-improvements-across-all-minimal-disease-activity-domains-for-adults--with-active-psoriatic-arthritis-in-phase-iiib-trial.--janssen2023-06-06T12:51:03+00:00weekly0.6https://www.medthority.com/news/2023/6/janssen-biotech-to-collaborate-with-cellular-biomedicine-group-to-develop-and-commercialise-the-next-generation-of-car-t-cell-therapies/2023-06-06T12:42:46+00:00weekly0.6https://www.medthority.com/news/2023/6/presentation-of-longer-term-data-for-tecvayli-showing-a-duration-of-response-of-22-months-in-patients-with-rr-multiple-myeloma.-janssen2023-06-07T11:41:20+00:00weekly0.6https://www.medthority.com/news/2023/6/tecartus-car-t-cell-therapy-demonstrates-78-complete-response-rate-and-90-overall-response-rate-in-largest-real-world-evidence-analysis-for-rr-mantle-cell-lymphoma.--kitegilead2023-06-07T11:57:02+00:00weekly0.6https://www.medthority.com/news/2023/6/lunar-phase-iii-clinical-trial-demonstrates-statistically-significant-and-clinically-meaningful-extension-in-overall-survival-for-patients-with-metastatic-non-small-cell-lung-cancer-after-platinum-based-therapies--zai-lab--novocure/2023-06-07T12:08:57+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-advisory-committee-meeting-to-review-nurown-bla-scheduled-for-september-27-2023.--brainstorm-cell-therapeutics2023-06-07T12:10:35+00:00weekly0.6https://www.medthority.com/news/2023/6/fda-grants-supplemental-approval-for-prevymis-for-prophylaxis-of-cytomegalovirus-disease-in-adult-kidney-transplant-recipients-at-high-risk.---merck-inc.-2023-06-07T12:12:40+00:00weekly0.6https://www.medthority.com/news/2023/6/balversa-improved-overall-survival-versus-chemotherapy-in-patients-with-metastatic-or-unresectable-urothelial-carcinoma-and-selected-fibroblast-growth-factor-receptor-gene-alterations-after-prior-anti-pd-l1-treatment.--janssen2023-06-07T12:21:50+00:00weekly0.6https://www.medthority.com/news/2023/6/european-commission-approval-for-cosentyx-as-first-and-only-il-17a-inhibitor-for-hidradenitis-suppurativa.--novartis2024-09-30T14:22:55+00:00weekly0.6https://www.medthority.com/news/2023/6/european-commission-approvals-for-bimzelx-for-the-treatment-of-psoriatic-arthritis-and-axial-spondyloarthritis-including-non-radiographic-axspa-and-ankylosing-spondylitis.--ucb2023-06-07T12:24:59+00:00weekly0.6https://www.medthority.com/news/2023/6/liso-cel-leads-to-rapid-responses-high-undetectable-mrd-rates-in-relapsedrefractory-cllsll.--bms2023-06-07T12:27:11+00:00weekly0.6https://www.medthority.com/news/2023/6/paratek-pharma-is-acquired-by-gurney-point-and-novo-holdings-as/2023-06-07T12:29:11+00:00weekly0.6https://www.medthority.com/news/2024/1/additional-data-highlighting-the-favorable-tolerability-and-differentiated-side-effect-profile-of-tnx-102-sl-in-second-positive-phase-iii-clinical-trial-for-the-management-of-fibromyalgia.--tonix-pharma2024-01-16T12:17:46+00:00weekly0.6https://www.medthority.com/news/2024/1/completion-of--enrollment-of-phase-iiiii-lift-ad-clinical-trial-of-fosgonimeton-in-mild-to-moderate-alzheimers-disease.-athira-pharma2024-01-16T12:19:27+00:00weekly0.6https://www.medthority.com/news/2024/1/zoryve-roflumilast-topical-foam-0.3-clears-seborrheic-dermatitis-in-individuals-who-previously-reported-an-inadequate-response-to-topical-steroids.--arcutis-biotherapeutics2024-01-16T12:22:31+00:00weekly0.6https://www.medthority.com/news/2024/1/majority-of-individuals-with-atopic-dermatitis-improved-with-roflumilast-cream-0.15-according-to-new-data-from-phase-iii-program--arcutis-biotherapeutics2024-01-16T12:13:20+00:00weekly0.6https://www.medthority.com/news/2024/1/european-commission-approves-tecentriq-scatezolizumab-the-eus-first-pd-l1-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types.--roche2025-02-03T15:00:12+00:00weekly0.6https://www.medthority.com/news/2024/1/allakos-reports-on-trials-of-lirentelimab-for-atopic-dermatitis-and-chronic-spontaneous-urticaria-/2024-01-17T12:40:15+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approval-of-casgevy-exagamglogene-autotemcel-for-the-treatment-of-transfusion-dependent-beta-thalassemia.--vertex--crispr-therapeutics2024-01-17T12:42:09+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approval-for-dupixent-dupilumab-in-atopic-dermatitis-adding-efficacy-and-safety-data-for-patients-aged-12-years-and-older-with-atopic-dermatitis-with-uncontrolled-moderate-to-severe-hand-andor-foot-involvement.--sanofi--regeneron2024-01-18T11:57:04+00:00weekly0.6https://www.medthority.com/news/2024/1/mhlw-approval-of-varipulse-pulsed-field-ablation-pfa-platform-in-japan.--biosense-webster-jj2024-09-30T11:59:32+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approves-hyqvia-as-maintenance-therapy-in-adults-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp.--takeda2024-01-18T12:00:53+00:00weekly0.6https://www.medthority.com/news/2024/1/screening-is-initiated-in-emergene-a-phase-iii-clinical-study-of-srp-9003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2er4.--sarepta-therapeutics2024-01-18T12:02:32+00:00weekly0.6https://www.medthority.com/news/2024/1/mhlw-approves-eylea-8-mg-aflibercept-8-mg-for-the-treatment-of-neovascular-wet-age-related-macular-degeneration-and-diabetic-macular-edema-.-regeneron--bayer2024-01-18T12:04:22+00:00weekly0.6https://www.medthority.com/news/2024/1/new-eylea-8-mg-approved-in-eu-for--neovascular-wet-age-related-macular-degeneration-namd-and-visual-impairment-due-to-diabetic-macular-edema-dme.--bayer2024-01-10T12:14:31+00:00weekly0.6https://www.medthority.com/news/2024/1/combine-3-phase-iiia-trial-successfully-completed-with-once-weekly-icosema-demonstrating-non-inferior-reduction-in-hba1c-versus-daily-basal-bolus-treatment-insulin-glargine-u100-and-insulin-aspart-in-people-with-type-2-diabetes.--novo-nordisk2024-01-10T12:16:22+00:00weekly0.6https://www.medthority.com/news/2024/1/medtronic-diabetes-announces-worlds-first-approval-for-minimed-780g-system-with-simplera-sync-disposable-all-in-one-sensor/2024-01-09T11:00:24+00:00weekly0.6https://www.medthority.com/news/2024/1/merck-inc.-to-acquire-harpoon-therapeutics-and-with-it-hpn-3282024-01-10T12:25:50+00:00weekly0.6https://www.medthority.com/news/2024/1/boston-scientific-to-acquire-axonics-inc-which-has-interests-in-urinary-and-bowel-dysfunction/2024-01-10T12:29:25+00:00weekly0.6https://www.medthority.com/news/2024/1/johnson--johnson-to-acquire-ambrx-biopharma-and-its-platform-to-develop-next-generation-antibody-drug-conjugates/2024-01-10T12:32:05+00:00weekly0.6https://www.medthority.com/news/2024/1/top-line-results-from-phase-iii-oasis-1-and-oasis-2-studies-of-elinzanetant-for-moderate-to-severe-vasomotor-symptoms-._-bayer2024-01-10T12:34:28+00:00weekly0.6https://www.medthority.com/news/2024/1/nmpa-china-approves-leqembi-as-a-treatment-of-mild-cognitive-impairment-mci-due-to-alzheimers-disease.--eisai-and-biogen2025-02-03T14:14:37+00:00weekly0.6https://www.medthority.com/news/2024/1/lantheus-expands-radiopharmaceutical-oncology-pipeline-via-strategic-agreements-with-perspective-therapeutics/2024-01-10T12:42:16+00:00weekly0.6https://www.medthority.com/news/2024/1/gsk-acquires-aiolos-bio-and-with-it-aio-001-a-long-acting-antithymic-stromal-lymphopoietin-tslp-monoclonal-antibody/2024-01-10T12:44:13+00:00weekly0.6https://www.medthority.com/news/2024/1/boehringer-licenses-a-novel-first-class-treatment-for-fibro-inflammatory-diseases-from-kyowa-kirin/2024-01-10T12:45:55+00:00weekly0.6https://www.medthority.com/news/2024/1/complete-response-letter-for-zolbetuximab-to-treat-unresectable-or-metastatic-human-epidermal-growth-factor-receptor-2-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-whose-tumors-are-claudin-cldn-18.2-positive.--astellas2024-01-11T11:58:48+00:00weekly0.6https://www.medthority.com/news/2024/1/european-commission-approves-uzpruvo-avt04-a-ustekinumab-biosimilar.--alvotech--stada2024-01-11T12:00:18+00:00weekly0.6https://www.medthority.com/news/2024/1/positive-topline-results-from-phase-iii-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye.--alcon2024-01-11T11:56:23+00:00weekly0.6https://www.medthority.com/news/2024/1/scientific-advisory-group-sag-will-convene-to-discuss-the-marketing-authorization-application-maa-of-lecanemab-under-review-by-the-european-medicines-agency--eisai--biogen/2024-01-11T11:54:12+00:00weekly0.6https://www.medthority.com/news/2023/12/hyftor-sirolimus-2-mgg-gel-is-launched-in-europe-to-treat-facial-angiofibroma-associated-with-tuberous-sclerosis-complex.--plusultra-pharma-gmbh-2023-12-29T11:18:47+00:00weekly0.6https://www.medthority.com/news/2023/12/initiation-of-avant-guard-clinical-trial-to-evaluate-farapulse-pulsed-field-ablation-system-as-first-line-treatment-for-persistent-atrial-fibrillation--boston-scientific/2024-09-30T11:54:36+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approval-of--udenyca-onbodypegfilgrastim-cbqv-a-novel-and-proprietary-state-of--the-art-delivery-system-for-management-of-febrile-neutropenia.--coherus-biosciences-inc2023-12-30T12:28:42+00:00weekly0.6https://www.medthority.com/news/2023/12/sanofi-announces-end-of-program-evaluating-tusamitamab-ravtansine-after-a-nsclc-phase-iii-trial-did-not-meet-a-primary-endpoint/2023-12-30T12:27:54+00:00weekly0.6https://www.medthority.com/news/2024/1/galapagos-signs-agreement-to-transfer-jyseleca-business-to-alfasigma/2024-01-04T13:22:58+00:00weekly0.6https://www.medthority.com/news/2024/1/nmpa-china-approves-beyfortus-nirsevimab-for-the-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-infection.-sanofi--astrazeneca2024-01-04T13:24:36+00:00weekly0.6https://www.medthority.com/news/2024/1/european-medicines-agency-validates--application-for-repotrectinib-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-and-ntrk-positive-solid-tumors.--bms2024-01-04T13:26:21+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approval-for-filsuvez-birch-triterpenes-topical-gel-for-the-treatment-of-epidermolysis-bullosa--chiesi-global-rare-diseases/2024-01-04T13:27:27+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-approves-alygo-immune-globulin-intravenous-human-stwk-10-liquid-to-treat--primary-humoral-immunodeficiency.-gc-biopharma2024-01-04T13:29:44+00:00weekly0.6https://www.medthority.com/news/2024/1/clinical-study-results-demonstrate-therapeutic-equivalence-between-biosimilar-candidate-avt-06-and-reference-product-eylea-aflibercept.-alvotech2024-01-04T13:30:59+00:00weekly0.6https://www.medthority.com/news/2024/1/maa-validation-and-nda-submission-of-govorestat-at-007-for-treatment-of-classic-galactosemia.-applied-therapeutics2024-01-04T13:33:12+00:00weekly0.6https://www.medthority.com/news/2024/1/topline-results-from-long-term-open-label-safety-and-duralility-of-treatment-effect-study-of-lybalvi-olanzapine-and-samidorphan-in-patients-with-schizophrenia-schizophreniform-disorder-or-bipolar-i-disorder-.--alkermes-plc2024-01-04T13:37:53+00:00weekly0.6https://www.medthority.com/news/2024/1/patient-enrollment-completed-in-study-008a-of-evenamide-in-patients-suffering-from-schizophrenia.--newron-pharma2024-01-04T13:39:39+00:00weekly0.6https://www.medthority.com/news/2024/1/seastar-medical-updates-subject-enrollment-in-its-pivotal-trial-with-the-selective-cytopheretic-device-in-adults-with-acute-kidney-injury/2024-01-01T16:03:48+00:00weekly0.6https://www.medthority.com/news/2024/1/avenue-therapeutics-reaches-final-agreement-with-the--fda-for-the-phase-iii-safety-study-for-iv-tramadol/2024-01-05T12:23:39+00:00weekly0.6https://www.medthority.com/news/2024/1/merck-kgaa-expands-colorectal-cancer-portfolio-through-licensing-agreement-with-inspirna/2024-01-05T12:26:48+00:00weekly0.6https://www.medthority.com/news/2024/1/topline-results-from-the-arise-hf-phase-iii-study-of-at-001-in-diabetic-cardiomyopathy.--applied-therapeutics2024-01-05T12:28:53+00:00weekly0.6https://www.medthority.com/news/2024/1/medtronic-receives-ce-mark-for-its-next-generation--micra-av2-and-micra-vr2-leadless-pacing-systems/2024-09-30T10:50:43+00:00weekly0.6https://www.medthority.com/news/2024/1/nature-medicine-publication-of-results-from-exploratory-ctdna-analysis-from-intrigue-phase-iii-study-demonstrates-substantial-clinical-benefit-of-qinlock-ripretinib-in-2l-gist-patients-with-mutations-in-kit-exon-11-and-1718.--deciphera-pharmaceuticals2024-01-07T14:20:54+00:00weekly0.6https://www.medthority.com/news/2024/1/results-from-phase-iv-yupelri--revefenacin-pifr-2-study-in-patients-with-severe-to-very-severe-chronic-obstructive-pulmonary-disease----theravance-biopharma/2024-01-07T14:20:06+00:00weekly0.6https://www.medthority.com/news/2024/1/fda-has-approved-zelsuvmi-berdazimer-topical-gel10.3-for-the-treatment-of-molluscum-contagiosum-in-adults-and-pediatric-patients-one-year-of-age-and-older.--ligand-pharma2024-01-07T14:19:26+00:00weekly0.6https://www.medthority.com/news/2024/1/merck-inc-announced-the-initiation-of-pivotal-phase-iii-trials-for-four-of-its-investigational-candidates-from-its-diverse-pipeline-in-hematologic-malignancies-and-solid-tumors/2024-01-07T14:18:38+00:00weekly0.6https://www.medthority.com/news/2024/1/nmpa-china-approves-cejemly-sugemalimab-with-chemotherapy-for-use-in-the-frontline-treatment-of-patients-with-unresectable-locally-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma.--cstone-pharmaceuticals2024-01-08T11:44:40+00:00weekly0.6https://www.medthority.com/news/2024/1/scemblix-shows-superior-major-molecular-response-mmr-rates-vs.-standard-of-care-tkis-in-phase-iii-trial-for-newly-diagnosed-patients-with-chronic-myeloid-leukemia.--novartis2024-01-08T11:49:22+00:00weekly0.6https://www.medthority.com/news/2024/1/european-commission-approval-of-rystiggo-rozanolixizumab-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-in-europe.--ucb2024-01-08T11:52:04+00:00weekly0.6https://www.medthority.com/news/2023/12/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-therapy-regimen-shows-significant-improvement-in-outcomes-for-patients-with-transplant-eligible-newly-diagnosed-multiple-myeloma.--johnson--johnson2023-12-19T12:55:56+00:00weekly0.6https://www.medthority.com/news/2023/12/mhra-approves-veoza-fezolinetant-to-treat-vasomotor-symptoms-associated-with-menopause.-astellas2023-12-19T12:53:52+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-iwilfineflornithine-to-reduce-the-risk-of-relapse-in-adult-and-pediatric-patients-with-high-risk-neuroblastoma.--us-world-meds2023-12-19T12:51:58+00:00weekly0.6https://www.medthority.com/news/2023/12/for-the-first-time-paediatric-patients-aged-5-11-years-with-hofh-in-the-eu-have-access-to-a-first-in-class-medicine-evkeeza-evinacumab-to-treat-an-ultrarare-inherited-form-of-high-cholesterol.--ultragenyx-pharma2023-12-19T12:49:58+00:00weekly0.6https://www.medthority.com/news/2023/12/outcome-from-dose-finding-part-a-of-kind-1-study-evaluating-oral-difelikefalin-for-moderate-to-severe-pruritus-in-patients-with-atopic-dermatitis.--cara-therapeutics2023-12-19T12:40:52+00:00weekly0.6https://www.medthority.com/news/2023/12/complete-response-letter-for-cosibelimab-for-the-treatment-of-patients-with-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma.--checkpoint-therapeutics.-2023-12-26T16:34:38+00:00weekly0.6https://www.medthority.com/news/2023/12/bimzelx-bimekizumab-receives-approval-in-japan-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis.--ucb2023-12-27T12:16:26+00:00weekly0.6https://www.medthority.com/news/2023/12/regulatory-update-on-status-of-lumakras-sotorasib.-amgen2023-12-27T12:18:02+00:00weekly0.6https://www.medthority.com/news/2023/12/astrazeneca-to-acquire-gracell-biotechnologies-and-with-it-gc0-12f/2023-12-28T12:28:03+00:00weekly0.6https://www.medthority.com/news/2023/12/bms-acquires-rayzebio/2023-12-27T12:14:56+00:00weekly0.6https://www.medthority.com/news/2023/12/positive-results-from-sequoia-hcm-the-pivotal-phase-iii-clinical-trial-of-aficamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy.-cytokinetics-incorporated2023-12-28T12:26:26+00:00weekly0.6https://www.medthority.com/news/2023/12/iovance-biotherapeutics-announces-clinical-program-update-for-ln-145.-in-non-small-cell-lung-cancer2023-12-28T12:22:04+00:00weekly0.6https://www.medthority.com/news/2023/12/application-filed-in-japan-for-an-additional-indication-for-treprost-inhalation-solution-for-pulmonary-hypertension-associated-with-interstitial-lung-disease-or-combined-pulmonary-fibrosis-and-emphysema.-mochida2023-12-28T12:20:16+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-grants-priority-review-to-new-bla-for-v-116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults.--merck-inc2023-12-20T12:32:29+00:00weekly0.6https://www.medthority.com/news/2023/12/european-commission-approves-keytruda-pembrolizumab--chemotherapy-as-first-line-treatment-of-locally-advanced-unresectable-or-metastatic-biliary-tract-carcinoma-btc-in-adults..--merck-inc2023-12-20T12:30:36+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-avert-d-test-to-identify-an-elevated-risk-of-developing-opioid-use-disorder.--autogenomics2023-12-21T11:37:22+00:00weekly0.6https://www.medthority.com/news/2023/12/argenx-reports-topline-results-from-address-study-of-efgartigimod-sc-in-pemphigus.-2023-12-21T11:41:54+00:00weekly0.6https://www.medthority.com/news/2023/12/complete-response-letter-for-gefapixant-an-investigational-non-narcotic-oral-selective-p2x3-receptor-antagonist-under-development-for-the-treatment-of-refractory-chronic-cough-.merck-inc2024-10-01T11:00:55+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-full-approval-of-tarpeyo-budesonide-delayed-release-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function.--calliditas-ab2023-12-21T11:45:41+00:00weekly0.6https://www.medthority.com/news/2023/12/atara-biotherapeutics-announces-closing-of-expanded-global-tab-cel-partnership-with-pierre-fabre-labs/2023-12-21T11:47:24+00:00weekly0.6https://www.medthority.com/news/2023/12/highly-statistically-significant-and-clinically-meaningful-topline-results-in-second-positive-phase-iii-clinical-trial-of-tnx-102-sl-for-the-management-of-fibromyalgia.-tonix-pharma2023-12-22T12:42:47+00:00weekly0.6https://www.medthority.com/news/2023/12/dmk-pharmaceuticals-regains-full-rights-to-commercialize-zimhi-naloxone/2023-12-22T12:36:18+00:00weekly0.6https://www.medthority.com/news/2023/12/dmk-pharmaceuticals-regains-full-rights-from-us-worldmeds-for-symjepi-epinephrine-injection-and-provides-corporate-update/2023-12-22T12:32:50+00:00weekly0.6https://www.medthority.com/news/2023/12/maa-is-submitted-to-ema-seeking-approval-of-lazertinib---rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer.--janssen-pharmaceutical-companies-jj2023-12-22T12:30:43+00:00weekly0.6https://www.medthority.com/news/2023/12/end-of-program-evaluating-tusamitamab-ravtansine-is-announced-after-a-2l-nsclc-phase-iii-trial-did-not-meet-a-primary-endpoint.--sanofi2023-12-22T12:28:42+00:00weekly0.6https://www.medthority.com/news/2023/12/wainua-eplontersen-granted-first-ever-regulatory-approval-in-the-us-for-the-treatment-of-adults-with-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis.--astrazeneca--ionis2023-12-22T12:26:00+00:00weekly0.6https://www.medthority.com/news/2023/12/zealand-pharma-submits-nda-to-the--fda-for-glepaglutide-a-long-acting-glp-2-analog-in-short-bowel-syndrome/2023-12-26T16:54:08+00:00weekly0.6https://www.medthority.com/news/2023/12/patritumab-deruxtecan-granted-priority-review-in-the-u.s.-for-certain-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer.--daiichi-sankyo--merck-inc2023-12-26T16:52:31+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-label-update-for-brukinsa-zanubrutinib-in-chronic-lymphocytic-leukemia.---beigene-ltd2023-12-26T16:51:09+00:00weekly0.6https://www.medthority.com/news/2023/12/allovir-provides-updates-on-phase-iii-clinical-development-program-for-posoleucel-an-allogeneic-virus-specific-t-cell-therapy/2023-12-26T16:49:51+00:00weekly0.6https://www.medthority.com/news/2023/12/european-approval-of-rezzayo-rezafungin-for-the-treatment-of-invasive-candidiasis-in-adults.--cidara-therapeutics--mundipharma2023-12-26T16:44:51+00:00weekly0.6https://www.medthority.com/news/2023/12/bristol-myers-squibb-acquires-karuna-therapeutics-and-with-it-karxt-an-antipsychotic-with-a-novel-mechanism-of-action/2023-12-26T16:43:18+00:00weekly0.6https://www.medthority.com/news/2023/12/complete-response-for-dasiglucagon-to-provide-prevention-and-treatment-of-hypoglycemia-in-pediatric-patients.-novo-nordisk--zealand-pharma-as2023-12-26T16:41:22+00:00weekly0.6https://www.medthority.com/news/2023/12/clene-inc.-provides-update-on-als-clinical-development-meeting-with-fda-to-discuss-cnm-au82023-12-26T16:39:59+00:00weekly0.6https://www.medthority.com/news/2023/12/r21matrix-malaria-vaccine-granted-prequalification-by-world-health-organization.-novavax2023-12-26T16:38:36+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-label-update-for-yescarta-car-t-cell-therapy-to-include-overall-survival-data-for-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-.--kitegilead2023-12-26T16:37:06+00:00weekly0.6https://www.medthority.com/news/2023/12/theseus-pharmaceuticals-is-acquired-by-concentra-biosciences/2023-12-26T16:35:53+00:00weekly0.6https://www.medthority.com/news/2023/12/new-data-for-columvi-and-lunsumio-presented-at-ash-2023-support-continued-benefit-for-people-with-lymphoma.--roche-2023-12-12T14:58:10+00:00weekly0.6https://www.medthority.com/news/2023/12/iomab-b-produces-high-response-rates-and-significant-improvement-in-overall-survival-in-relapsed-or-refractory-aml-patients-with-active-disease-overcoming-tp53-mutation.-actinium-pharma2023-12-12T14:57:30+00:00weekly0.6https://www.medthority.com/news/2023/12/zepbound-tirzepatide-achieved-additional-6.7-weight-loss-following-a-36-week-open-label-lead-in-period-for-a-total-mean-weight-loss-of-26.0-from-study-entry-over-88-weeks.--eli-lilly2023-12-12T14:56:41+00:00weekly0.6https://www.medthority.com/news/2023/12/latest-odronextamab-data-in-relapsedrefractory-follicular-lymphoma-showed-compelling-responses-and-overall-maintenance-of-patient-reported-outcomes.--regeneron-pharma2023-12-12T14:56:01+00:00weekly0.6https://www.medthority.com/news/2023/12/interpath-002-a-phase-iii-study-evaluating-v-940-mrna-4157---keytruda-pembrolizumab-for-adjuvant-treatment-of-patients-with-certain-types-of-resected-non-small-cell-lung-cancer--merck-inc.--moderna-inc2023-12-12T14:55:11+00:00weekly0.6https://www.medthority.com/news/2023/12/updated-data-from-the-bruin-phase-1ii-study-of-jaypirca-pirtobrutinib-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-presented-at-the-2023-ash-annual-meeting.-loxolilly--eli-lilly2023-12-12T14:54:28+00:00weekly0.6https://www.medthority.com/news/2023/12/astrazeneca-to-acquire-icosavax-inc.-and-with-it-ivx-a12-a-potential-first-in-class-phase-iii-ready-vaccine2023-12-12T14:53:08+00:00weekly0.6https://www.medthority.com/news/2023/12/findings-from-phase-ii-keyvibe-002-trial-evaluating-an-investigational-coformulation-of-vibostolimab-and-pembrolizumab-in-previously-treated-patients-with-metastatic-non-small-cell-lung-cancer-nsclc.--merck-inc2023-12-08T12:30:37+00:00weekly0.6https://www.medthority.com/news/2023/12/keylynk-008-trial-evaluating-keytruda-pembrolizumab--lynparza-olaparib-for-metastatic-squamous-non-small-cell-lung-cancer-to-stop-for-futility.--merck-inc2023-12-08T12:37:05+00:00weekly0.6https://www.medthority.com/news/2023/12/phase-iii-checkmate--8hw-trial-evaluating-opdivo-nivolumab--yervoy-ipilimumab-compared-to-chemotherapy-in-microsatellite-instabilityhigh-or-mismatch-repair-deficient-metastatic-colorectal-cancer-meets-primary-endpoint.--bms2023-12-08T12:44:20+00:00weekly0.6https://www.medthority.com/news/2023/12/ce-mark-for-for-the-percept-rc-rechargeable-dbs-neurostimulator-with-brainsense-technology.--medtronic2023-12-08T12:45:36+00:00weekly0.6https://www.medthority.com/news/2023/12/vanda-pharmaceuticals-acquires-u.s.-and-canadian-rights-to-ponvory-ponesimod-a-selective-s1p1r-modulator-approved-for-patients-with-relapsing-multiple-sclerosis2023-12-11T12:29:57+00:00weekly0.6https://www.medthority.com/news/2023/12/update-on-phase-iii-leap-001-trial-evaluating-keytruda-pembrolizumab--lenvima-lenvatinib-as-first-line-treatment-for-advanced-or-recurrent-endometrial-carcinoma.--merck-inc.--eisai2023-12-11T12:29:21+00:00weekly0.6https://www.medthority.com/news/2023/12/kisqali-ribociclib-natalee-analysis-reinforces-25-reduction-in-risk-of-recurrence-across-broad-population-of-patients-with-early-breast-cancer-supports-regulatory-submissions.--novartis2023-12-11T12:28:39+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approval-for-casgevy--exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-in-patients-12-years-of-age-and-older-with-recurrent-vaso-occlusive-crises.--crispr-therapeutics2023-12-11T12:27:57+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approval-of-lyfgenia-lovotibeglogene-autotemcel-for-treatment-of-patients-ages-12-and-older-with-sickle-cell-disease-and-a-history-of-vaso-occlusive-events.--bluebird-bio2023-12-11T12:27:12+00:00weekly0.6https://www.medthority.com/news/2023/12/bluebird-bio-details-plans-for-the-commercial-launch-of-lyfgenia-gene-therapy-for-patients-ages-12-and-older-with-sickle-cell-disease-and-a-history-of-vaso-occlusive-events.-2023-12-11T12:26:26+00:00weekly0.6https://www.medthority.com/news/2023/12/new-pivotal-data-for-bispecific-antibody-epcoritamab-duobody-cd3xcd20-demonstrates-high-overall-and-complete-responses-in-patients-with-hard-to-treat-relapsedrefractory-follicular-lymphoma-.--genmab--abbvie2023-12-11T12:25:40+00:00weekly0.6https://www.medthority.com/news/2023/12/new-data-reinforce-the-benefit-of-early-preventative-treatment-with--hemlibra-emicizumab-kxwh-for-babies-with-severe-hemophilia-a.--genentechroche2023-12-11T12:24:53+00:00weekly0.6https://www.medthority.com/news/2023/12/primary-efficacy-and-safety-analysis-of-the-phase-iii-commands-trial-of-reblozyl-luspatercept-aamt-for-treatment-of-anemia-in-erythropoiesis-stimulating-agent-naive-patients-with-lower-risk-myelodysplastic-syndromes-presented-at-ash-2023.--bms2023-12-11T12:23:56+00:00weekly0.6https://www.medthority.com/news/2023/12/long-term-alpha-phase-iii-trial-data-showed-danicopan-as-add-on-to-ultomiris-or-soliris-sustained-clinical-improvements-in-subset-of-patients-with-pnh-experiencing-clinically-significant-extravascular-haemolysis-.--astrazeneca2023-12-11T12:23:05+00:00weekly0.6https://www.medthority.com/news/2023/12/investigational-iptacopan-phase-iii-study-demonstrates-clinically-meaningful-and-statistically-significant-proteinuria-reduction-in-patients-with-c3-glomerulopathy-c3g.--novartis2023-12-11T12:22:08+00:00weekly0.6https://www.medthority.com/news/2023/12/pelabresib-improves-all-four-hallmarks-of-myelofibrosis-in-phase-iii-manifest-2-study.-morphosys-ag2023-12-11T12:21:14+00:00weekly0.6https://www.medthority.com/news/2023/12/update-on-crystalize-evidence-trials-for-lokelma-sodium-zirconium-cyclosilicate-for-hyperkalaemia-.--astrazeneca2023-12-01T12:38:15+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-grants-priority-review-to-sbla-for-keytruda-pembrolizumab---padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of--locally-advanced-or-metastatic-urothelial-cancer.--merck-inc2023-12-01T12:35:50+00:00weekly0.6https://www.medthority.com/news/2023/12/positive-topline-results-from-momentum-48-week-phase-ii-obesity-trial-of-pemvidutide.--altiimmune-inc2023-12-01T12:32:14+00:00weekly0.6https://www.medthority.com/news/2023/12/abbvie-to-acquire-immunogen-and-with-it-elahere/2023-12-01T12:29:38+00:00weekly0.6https://www.medthority.com/news/2023/12/johnson--johnson-medtech--acquires-laminar-inc.-a-company-focused-on-eliminating-the-left--atrial-appendage2023-12-01T12:27:52+00:00weekly0.6https://www.medthority.com/news/2023/12/results-from-phase-iiib-trials-demonstrate-rapid-and-long-lasting-effect-of-relabotulinumtoxina-on-crows-feet-and-frown-lines.--galderma2023-12-02T17:17:28+00:00weekly0.6https://www.medthority.com/news/2023/12/jaypirca-pirtobrutinib-has-accelerated-approval-from-the-fda--for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-therapy.----eli-lilly2023-12-02T17:16:45+00:00weekly0.6https://www.medthority.com/news/2023/12/topline-phase-iib-results-of-oral-glp-1r-agonist-danuglipron-in-adults-with-obesity.---pfizer2023-12-02T17:16:00+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-investigating-serious-risk-of-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous-chimeric-antigen-receptor-car-t-cell-immunotherapies/2023-12-04T09:24:38+00:00weekly0.6https://www.medthority.com/news/2023/12/european-commission-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis.--ucb2023-12-04T12:20:41+00:00weekly0.6https://www.medthority.com/news/2023/12/roche-to-acquire-carmot-therapeutics-and-with-it-incretins-with-best-in-class-potential-to-treat-obesity/2023-12-04T12:20:19+00:00weekly0.6https://www.medthority.com/news/2023/12/merck-kgaa-enters-licence-agreement-with-abbisko-therapeutics-for-phase-iii--absk-021-pimicotinib-for-the-treatment-of-tenosynovial-giant-cell-tumor/2023-12-05T13:32:21+00:00weekly0.6https://www.medthority.com/news/2023/12/initiation-of-the-stellar-305-phase-iiiii-pivotal-trial-evaluating-zanzalintinib--pembrolizumab-in-patients-with-previously-untreated-recurrent-or-metastatic-head-and-neck-cancer--exelixis-inc/2023-12-05T13:29:58+00:00weekly0.6https://www.medthority.com/news/2023/12/positive-phase-iii-results-for-inavolisib-combination-in--advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation--genentechroche/2023-12-05T13:27:24+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-accepts-nda-for-tradipitant-for-the-treatment-of-gastroparesis.--vanda-pharma2023-12-05T13:22:06+00:00weekly0.6https://www.medthority.com/news/2023/12/final-overall-survival-analysis-from-the-monarch-3-study-of-verzenio-abemaciclib-presented-at-the-2023-san-antonio-breast-cancer-symposium.--eli-lilly2023-12-06T11:51:53+00:00weekly0.6https://www.medthority.com/news/2023/12/data-presentations-for-lumateperone-and-preclinical--iti-1549-at-the-american-college-of-neuropsychopharmacology-annual-meeting.--intra-cellular-therapies2023-12-06T11:55:39+00:00weekly0.6https://www.medthority.com/news/2023/12/merck-kgaa-provides-update-on-phase-iii-results-for-evobrutinib-in-relapsing-multiple-sclerosis/2023-12-06T12:11:01+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh.--novartis2023-12-06T12:14:01+00:00weekly0.6https://www.medthority.com/news/2023/12/health-canada-approves-expanded-authorization-for-nuvaxovid-xbb.1.5-vaccine-recombinant-protein-adjuvanted-nvx-cov2601-for-active-immunization-to-prevent-covid-19-caused-by-sars-cov-2-in-individuals-aged-12-and-older.--novavax2023-12-07T13:23:30+00:00weekly0.6https://www.medthority.com/news/2023/12/mounjaro-versus-wegovy-in-treatment-of-obesity.--eli-lilly2023-12-07T13:21:01+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-accepts-for-priority-review-sbla-for-opdivo-nivolumab-in-combination-with-cisplatin-based-chemotherapy-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma-bladder-cancer--bms/2023-12-07T13:19:06+00:00weekly0.6https://www.medthority.com/news/2023/12/tukysa-tucatinib-in-combination-with-antibody-drug-conjugate-ado-trastuzumab-emtansine-improves-progression-free-survival-in-previously-treated-her2-positive-metastatic-breast-cancer.--seagenpfizer2023-12-07T12:29:45+00:00weekly0.6https://www.medthority.com/news/2023/12/abecma-is-the-first-car-t-approved-for-use-in-earlier-lines-of-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma-in-japan.--bms2023-12-07T12:27:44+00:00weekly0.6https://www.medthority.com/news/2023/12/abbvie-to-acquire-cerevel-therapeutics-and-with-itemraclidinea-potential-best-in-class-next-generation-antipsychotic-to-treat-schizophrenia/2023-12-07T12:14:03+00:00weekly0.6https://www.medthority.com/news/2023/12/analyses-of--yescarta-car-t-cell-therapy-support-curative-potential-in-patients-with-non-hodgkin-lymphomas.-kitegilead-sciences2023-12-14T08:38:58+00:00weekly0.6https://www.medthority.com/news/2023/12/positive-results-from-pivotal-trials-of-casgevy-exagamglogene-autotemcel-highlighted-in-oral-presentations-at-the-american-society-of-hematology-ash-annual-meeting.-vertex--crispr-therapeutics.-2023-12-14T09:12:18+00:00weekly0.6https://www.medthority.com/news/2023/12/ayvakyt-avapritinib-receives-european-commission-approval-as-the-first-and-only-treatment-for-indolent-systemic-mastocytosis.--blueprint-medicines-corpn2023-12-14T09:15:27+00:00weekly0.6https://www.medthority.com/news/2023/12/report-of-2-year-follow-up-data-from-rusfertide-revive-study-at-the-ash-annual-meeting-showing-durable-efficacy-and-no-new-safety-signals.--protagonist-therapeutics2023-12-14T09:23:40+00:00weekly0.6https://www.medthority.com/news/2023/12/united-therapeutics-to-acquire-miromatrix-medical/2023-12-14T09:27:10+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-grants-expanded-approval-to-wilate-as-the-first-vwf-concentrate-for-prophylaxis-in-all-types-of-von-willebrand-disease.--octapharma2023-12-14T12:55:40+00:00weekly0.6https://www.medthority.com/news/2023/12/european-commission-approves-veoza-fezolinetant-to-treat-vasomotor-symptoms-associated-with-menopause.-astellas2023-12-14T12:56:54+00:00weekly0.6https://www.medthority.com/news/2023/12/pxt-3003-fails-in-phase-iii-trial-forcharcot-marie-tooth-disease-type-1a-due-to-placebo-effect.-pharnext-sa2023-12-14T13:00:14+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approval-for-pulseselect-pulsed-field-ablation-pfa-system-for-the-treatment-of-both-paroxysmal-and-persistent-atrial-fibrillation-.--medtronic-plc2024-09-30T11:41:01+00:00weekly0.6https://www.medthority.com/news/2023/12/japans-ministry-of-health-labour-and-welfare-accepts-arexvy-rsv-vaccine-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59-at-increased-risk.-gsk-plc2023-12-14T12:51:35+00:00weekly0.6https://www.medthority.com/news/2023/12/jemperli-dostarlimab-plus-chemotherapy-is-eu-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union-for-dmmrmsi-h-primary-advanced-or-recurrent-endometrial-cancer.--gsk-plc2023-12-14T12:49:37+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-grants-priority-review-to-tarlatamab-application-to-treat-advanced-small-cell-lung-cancer.--amgen2023-12-15T12:39:54+00:00weekly0.6https://www.medthority.com/news/2023/12/mrna-4157-v940---keytruda-pembrolizumab-demonstrated-continued-improvement-in-recurrence-free-survival-and-distant-metastasis-free-survival-in-high-risk-stage-iiiiv-melanoma-following-complete-resection-at-three-years.--moderna-inc.--merck-inc2023-12-15T12:34:58+00:00weekly0.6https://www.medthority.com/news/2023/12/initiation-of-pivotal-phase-iii-clinical-trial-of-pegtibatinase-for-the-treatment-of-classical-homocystinuria-hcu----travere-therapeutics/2023-12-15T12:31:48+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-welireg-belzutifan-for-the-treatment-of-advanced-renal-cell-carcinoma-following-a-pd-1-or-pd-l1-inhibitor-and-a-vegf-tki.--merck-inc2023-12-15T12:28:49+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-updates-ldl-c-lowering-indication-for-nexletol-bempedoic-acid-tablet-and-nexlizet-bempedoic-acid-and-ezetimibe-tablet.--esperion2023-12-18T10:14:53+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approval-of-idosetr-travoprost-intracameral-implant-single-administration-per-eye-to-reduce-intraocular-pressure-in-patients-with-ocular-hypertension-or-open-angle-glaucoma-.--glaukos-corpn2023-12-18T10:14:14+00:00weekly0.6https://www.medthority.com/news/2023/12/chmp-issues-positive-opinion-for-skyclarys-omaveloxolone-the-first-therapy-to-treat-friedreichs-ataxia-a-rare-neurodegenerative-disease.--biogen-inc2023-12-18T10:13:33+00:00weekly0.6https://www.medthority.com/news/2023/12/positive-scientific-opinion-from-ema-for-arpraziquantel-to-treat-schistosomiasis-in-preschool-aged-children.--merck-kgaa2023-12-18T10:12:52+00:00weekly0.6https://www.medthority.com/news/2023/12/chmp-positive-opinion-for-the-first-crisprcas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.---vertex-pharma2023-12-18T10:12:13+00:00weekly0.6https://www.medthority.com/news/2023/12/moderna-announces-new-england-journal-of-medicine-publication-of-pivotal-phase-iii-clinical-safety-and-efficacy-data-for-mrna-1345-the-investigational-respiratory-syncytial-virus-rsv-vaccine/2023-12-18T10:11:36+00:00weekly0.6https://www.medthority.com/news/2023/12/chmp-recommends-velsipityetrasimod-for-the-treatment-of-ulcerative-colitis.-pfizer2023-12-18T10:10:59+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-zoryve--roflumilast-topical-foam-0.3-for-the-treatment-of-seborrheic-dermatitis.--arcutis-biotherapeutics-inc2023-12-18T10:10:15+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-expanded-indication-for-keytruda-pembrolizumab---padcev-enfortumab-vedotin-ejfv-for-the-first-line-treatment-of-adult-patients-with-locally-advanced-or-metastatic-urothelial-cancer.--merck-inc.--pfizer2023-12-18T10:09:19+00:00weekly0.6https://www.medthority.com/news/2023/12/bms-provides-update-on-relativity-123-trial-evaluating-the-fixed-dose-combination-of-nivolumab-and-relatlimab-in-patients-with-previously-treated-metastatic-microsatellite-stable-mss-colorectal-cancer/2023-12-18T10:08:32+00:00weekly0.6https://www.medthority.com/news/2023/12/sarclisa-isatuximab-plus-krd-significantly-improved-rate-of-minimal-residual-disease-negativity-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-versus-krd-alone.--sanofi2023-12-18T10:07:49+00:00weekly0.6https://www.medthority.com/news/2023/12/pfizer-announces-cost-cutting-programme/2023-12-18T10:07:06+00:00weekly0.6https://www.medthority.com/news/2023/12/sarclisa-isatuximab-phase-iii-trial-met-the-primary-endpoint-of-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-not-eligible-for-transplant.--sanofi2023-12-18T12:17:59+00:00weekly0.6https://www.medthority.com/news/2023/12/fda-approves-trogarzo-90-second-intravenous-iv-push-loading-dose-for-the-treatment-of-hiv-infection.-theratechnologies-inc2023-12-18T12:14:31+00:00weekly0.6https://www.medthority.com/news/2023/12/european-commission-approves-agamree-vamorolone-to-treat-duchenne-muscular-dystrophy.---santhera-pharma2023-12-18T12:12:19+00:00weekly0.6https://www.medthority.com/news/2023/12/marketing-application-submitted-in-japan-for-tasurgratinib-to-treat-biliary-tract-cancer-with-fgfr2-gene-fusion.--eisai2023-12-18T12:10:16+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approves-kaftrio-in-combination-with-ivacaftor-for-the-treatment-of-children-with-cystic-fibrosis-ages-2-through-5years.--vertex-pharma2023-11-24T12:30:25+00:00weekly0.6https://www.medthority.com/news/2023/11/fgfr-inhibitor-erdafitinib-for-urothelial-cancer-is-filed-in-japan.--janssen-pharmaceutical2023-11-24T12:33:08+00:00weekly0.6https://www.medthority.com/news/2023/11/the-national-medical-products-administration-of-china-nmpa-has-granted-priority-review-designation-to-the-nda-for-ibi-351-to-treat-advanced-non-small-cell-lung-cancer--harboring-kras-g12c-mutation.-innovent2023-11-24T12:35:38+00:00weekly0.6https://www.medthority.com/news/2023/11/index-pharmaceuticals-discontinues-cobitolimod-phase-iii-program-for-ulcerative-colitis/2023-11-24T12:38:36+00:00weekly0.6https://www.medthority.com/news/2023/11/beigene-to-acquire-from-ensem-therapeutics-an-investigational-new-drug-ind-application-ready-oral-cyclin-dependent-kinase-2-cdk2-inhibitor/2023-11-24T12:40:34+00:00weekly0.6https://www.medthority.com/news/2023/11/freeline-therapeutics-is-acquired-by-syncona-ltd/2023-11-24T12:43:08+00:00weekly0.6https://www.medthority.com/news/2023/11/evelo-biosciences-is-shutting-down-according-to-a-regulatory-filing/2023-11-24T12:44:49+00:00weekly0.6https://www.medthority.com/news/2023/11/aldeyra-therapeutics-enters-into-exclusive-option-agreement-with-abbvie-for-license-to-develop-and-commercialize-reproxalap/2023-11-25T16:20:11+00:00weekly0.6https://www.medthority.com/news/2023/11/sbla-is-submitted-to-the-fda-seeking-approval-of-rybrevant-amivantamab-vmjw--chemotherapy-to-treat-egfr-mutated-non-small-cell-lung-cancer-which-progressed-on-or-after-osimertinib.--janssen-pharmaceutical-companies2023-11-25T16:19:19+00:00weekly0.6https://www.medthority.com/news/2023/11/final-results-for-vv116-mindeudesivir-hydrobromide-shows-efficacy-in-covid-19-trial--junishi-biosciences/2023-11-25T16:18:23+00:00weekly0.6https://www.medthority.com/news/2023/11/nmpa-china-approves-xenleta-lefamulin-in-china-for-the-treatment-of-community-acquired-pneumonia-in-adults-.--sumitomo-pharma2023-11-26T17:26:28+00:00weekly0.6https://www.medthority.com/news/2023/11/ce-mark-for-pulseselect-pulsed-field-ablation-pfa-system-and-the-nitron-cryoconsole.--medtronic2024-09-30T11:37:54+00:00weekly0.6https://www.medthority.com/news/2023/11/astrazeneca-launches-evinova-a-provider-of-digital-health-solutions/2023-11-26T17:25:02+00:00weekly0.6https://www.medthority.com/news/2023/11/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2023-11-26T17:24:18+00:00weekly0.6https://www.medthority.com/news/2023/11/rucaparib-receives-ec-approval-for-advanced-ovarian-cancer.--pharma-schwiez2023-11-27T12:42:14+00:00weekly0.6https://www.medthority.com/news/2023/11/dupixent-dupilumab-significantly-reduced-copd-exacerbations-in-second-positive-phase-iii-notus-trial--confirming-potential-to-become-first-approved-biologic-for-this-serious-disease.-regeneron--sanofi2023-11-27T12:39:06+00:00weekly0.6https://www.medthority.com/news/2023/11/roche-expands-hepatitis-diagnostics-portfolio-to-help-clinicians-diagnose-and-monitor-patients-with-acute-or-chronic-hepatitis-b-infection/2023-11-27T12:27:24+00:00weekly0.6https://www.medthority.com/news/2023/11/bms-and-2seventy-bio-provide-update-on-fda-review-of-sbla-for-abecma-idecabtagene-vicleucel-in-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma/2023-11-21T12:49:14+00:00weekly0.6https://www.medthority.com/news/2023/11/national-psoriasis-foundation-releases-consensus-statement-on-management-of-generalized-pustular-psoriasis.-gpp2023-11-21T12:51:30+00:00weekly0.6https://www.medthority.com/news/2023/11/phase-iii--manfest--2-study-of-pelabresib-in-myelofibrosis-demonstrates-statistically-significant-improvement-in-spleen-volume-reduction-and-strong-positive-rend-in-symptom-reduction.--morphosys-ag2023-11-21T12:55:35+00:00weekly0.6https://www.medthority.com/news/2023/11/hyrimoz-hcf-adalimumab-biosimilar--high-concentration-formulation-is-launched-in-europe-aiming-to-improve-patient-care--sandoz/2023-11-21T12:59:51+00:00weekly0.6https://www.medthority.com/news/2023/11/two-year-biopact-randomised-controlled-trial--analysis-demonstrates-persistent-excellence-for-low-profile-passeo-18-lux-dcb.--biotronik2024-09-30T12:19:07+00:00weekly0.6https://www.medthority.com/news/2023/11/protagonist-therapeutics-inc.-announced-phase-iii-studies-iconic-advance-1-and-iconic-advance-2-for-jnj-2113-in-head-to-head-comparisons-against-deucravacitinib--in-patients-with-moderate-to-severe-psoriasis2023-11-28T12:14:44+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approves-of-ogsiveo-nirogacestat-as-the-first-and-only-treatment-for-adults-with-desmoid-tumors.--springworks-therapeutics2023-11-28T12:13:33+00:00weekly0.6https://www.medthority.com/news/2023/11/v-116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults-demonstrated-superior-immunogenicity-for-10-of-11-unique-serotypes-compared-to-pcv20-in-adults-50-years-of-age-and-older.--merck-inc2023-11-29T12:16:44+00:00weekly0.6https://www.medthority.com/news/2023/11/positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep-belantamab-mafodotin-in-relapsedrefractory-multiple-myeloma.--gsk2023-11-29T12:18:41+00:00weekly0.6https://www.medthority.com/news/2023/11/medtronic-launches-penditure-laa-exclusion-system-in-the-united-states/2024-09-30T11:58:28+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approves-takhzyro-lanadelumab-to-include-children-with-hereditary-angioedema-hae-as-young-as-2-years-of-age.--takeda2023-11-29T12:22:14+00:00weekly0.6https://www.medthority.com/news/2023/11/spexis-provides-update-regarding-debt--restructuring-moratorium/2023-11-29T12:24:19+00:00weekly0.6https://www.medthority.com/news/2023/11/bms-to-collaborate-with-avidity-to-develop-antibody-oligonucleotide-conjugates/2023-11-29T12:26:09+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approves-yorvipath-palopegteriparatide-as-replacement-therapy-indicated-for-the-treatment-of-adults-with-chronic-hypoparathyroidism.-ascendis-pharma2023-11-30T12:47:14+00:00weekly0.6https://www.medthority.com/news/2023/11/topline-results-from-the-advance-sc-study-evaluating-vyvgart-hytrulo-efgartigimod-alfa-and-hyaluronidase-qvfc-in-adults-with-primary-immune-thrombocytopenia-itp.--argenx-se2023-11-30T12:48:58+00:00weekly0.6https://www.medthority.com/news/2023/11/vivos-therapeutics-receives-first-ever-fda-510k-clearance-for-oral-device-treatment-of-severe-obstructive-sleep-apnea/2023-11-30T12:53:40+00:00weekly0.6https://www.medthority.com/news/2023/11/efficacy-data-is-announced-from-phase-iii-trial-of-ne-3107-in-patients-with-mild-to-moderate-alzheimers-disease.--biovie-2023-11-30T12:55:09+00:00weekly0.6https://www.medthority.com/news/2023/11/results-published-in-the-lancet-show-ubrelvy-ubrogepant-reduces-the-headache-phase-of-a-migraine-attack-when-dosed-during-the-prodrome-of-migraine.--abbvie2023-11-20T12:37:55+00:00weekly0.6https://www.medthority.com/news/2023/11/oceanic-af-study--of-asundexian-stopped-early-due-to-lack-of-efficacy.--bayer2023-11-20T12:35:48+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approves-catiolanze-cationic-emulsion-of-latanoprost-50ugml-to-treat-open-angle-glaucoma-and-ocular-hypertension.--santen2023-11-22T12:42:24+00:00weekly0.6https://www.medthority.com/news/2023/11/rybrevant-amivantamab--chemotherapy-is-filed-in-japan-to-treat-nsclcegfr--janssen-pharma/2023-11-22T12:44:18+00:00weekly0.6https://www.medthority.com/news/2023/11/amgen-presents-new-cardiovascular-research-at-aha-meeting/2023-11-22T12:46:29+00:00weekly0.6https://www.medthority.com/news/2023/11/gsk-announces-major-step-towards-sustainability-ambitions-with-advancement-of-low-carbon-ventolin-programme-to-phase-iii-trials/2023-11-22T12:48:13+00:00weekly0.6https://www.medthority.com/news/2023/11/merck-inc.-to-acquire-caraway-therapeutics2023-11-22T12:50:49+00:00weekly0.6https://www.medthority.com/news/2023/11/oxurion-has-decided-to-file-for-bankruptcy-following-failure-of-thr-149-in-diabetic-macular-edema-study/2023-11-23T12:39:51+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission--approved-sc-injectable-vyvgart.-efgartigimod-alfa-as-an-add-on-to-standard-therapy-for-the-treatment-of-generalized-myasthenia-gravis.-argenx-se2023-11-23T12:42:20+00:00weekly0.6https://www.medthority.com/news/2023/11/health-canada-approves-bylvay-odevixibat-to-treat-pruritus-in-patients-aged-6-months-or-older-with-progressive-familial-intrahepatic-cholestasis.--ipsen--medison2023-11-23T12:44:45+00:00weekly0.6https://www.medthority.com/news/2023/11/mhlw-japan-orders-label-revisions-to-five-anticoagulants-to-advise-the-risk-of-kidney-injury/2023-11-23T12:47:42+00:00weekly0.6https://www.medthority.com/news/2023/11/update-on-fda-review-of-sbla-for-abecma-idecabtagene-vicleucel-in-earlier-lines-of-therapy-for-triple-class-exposed-relapsed-or-refractory-multiple-myeloma.-bms--2seventy-bio.inc2023-11-23T12:49:50+00:00weekly0.6https://www.medthority.com/news/2023/11/boehringer-acquires-t3-pharma-ag/2023-11-23T12:51:38+00:00weekly0.6https://www.medthority.com/news/2023/11/3m-spins-off-solventum-as-an-independent-healthcare-company/2023-11-23T12:54:57+00:00weekly0.6https://www.medthority.com/news/2023/11/development-of-tnx-601-er1a-once-daily-formulation-of-tianeptine-for-depression-is-ended-following--phase-ii-trial-results.--tonix-pharma2023-11-03T12:03:36+00:00weekly0.6https://www.medthority.com/news/2023/11/ingrezza-valbenazine-capsules-interim-data-demonstrating-sustained-improvements-in-chorea-associated-with-huntingtons-disease-presented-at-huntington-study-group-2023.--neurocrine-biosciences-inc2023-11-03T12:05:05+00:00weekly0.6https://www.medthority.com/news/2023/11/approval-from-the-mhra-for-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation.--mirati-therapeutics2023-11-04T16:19:32+00:00weekly0.6https://www.medthority.com/news/2023/11/new-late-breaking-data-demonstrate--indigo-aspiration-system-with-lightning-for-pulmonary-embolism-improved-patient-outcomes.--penumbra-inc2023-11-04T16:18:40+00:00weekly0.6https://www.medthority.com/news/2023/11/amgen-presents-new-data-that-show-blood-decreases-for-adults-treated-with-krystexxa-pegloticase.-2023-11-04T16:17:49+00:00weekly0.6https://www.medthority.com/news/2023/11/cook-medical-sells-maternal-fetal-medicine-products-to-cooper-companies/2023-11-04T16:17:02+00:00weekly0.6https://www.medthority.com/news/2023/11/novel-ai-driven-model-validated-to-predict-risk-of-chronic-kidney-disease-progression-in-large-u.s.-study.-_-boehringer2023-11-05T14:20:00+00:00weekly0.6https://www.medthority.com/news/2023/11/bi-690517-an-aldosterone-synthase-inhibitor-on-top-of-empagliflozin-showed-a-significant-reduction-of-albuminuriaa-marker-of-kidney-damage-in-phase-ii-trial.---boehringer2023-11-05T14:18:53+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-for-keytruda-pembrolizumab--chemotherapy-for-the-treatment-of-patients-with-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer.--merck-inc.--2023-11-07T13:08:12+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-validates-submission-for-approval-of--encorafenib-braftovi-and-binimetinib-mektovi-for-the-treatment-of-adult-patients-with-braf-v600mutant-advanced-nonsmall-cell-lung-cancer.--pierre-fabre2023-11-07T13:06:37+00:00weekly0.6https://www.medthority.com/news/2023/11/new-clinical-data-on-rayaldee-er-calcifediol-presented-at-kidney-week-2023.--opko-health-inc2023-11-07T13:05:00+00:00weekly0.6https://www.medthority.com/news/2023/11/new-asundexian-phase-iii-study-to-include-patients-with-atrial-fibrillation-ineligible-for-oral-anticoagulant-treatment.--bayer2023-11-07T13:02:40+00:00weekly0.6https://www.medthority.com/news/2023/11/zibotentan--dapagliflozin-combination-demonstrated-significant-albuminuria-reduction-in-patients-with-chronic-kidney-disease-and-proteinuria-in-zenith-ckd-phase-iib-trial.--astrazeneca2023-11-07T12:54:42+00:00weekly0.6https://www.medthority.com/news/2023/11/zora-real-world-evidence-demonstrates-that-lokelma-substantially-increases-cardiorenal-patients-chances-of-maintaining-lifesaving-raasi-therapy-in-hyperkalaemia-patients.-astrazeneca2023-11-07T12:52:53+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approves-ryeqo-relugolix-40-mg-estradiol-1.0-mg-and-norethisterone-acetate-0.5-mg-to-treat-endometriosis.--gedeon-richter2023-11-07T12:50:09+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-of-voqenza-vonoprazan-tablets-for-the-treatment-of-erosive-gerd-and-relief-of-heartburn-associated-with-erosive-gerd-in-adults.--phathom-pharma2023-11-07T12:47:13+00:00weekly0.6https://www.medthority.com/news/2023/11/health-canada-approves-hemgenix-etranacogene-dezaparvovec-for-treating-adults-with-hemophilia-b-who-rely-on-routine-prophylactic-therapies-to-prevent-or-reduce-bleeding-episodes.-csl-behring2023-11-08T12:35:19+00:00weekly0.6https://www.medthority.com/news/2023/11/data-from-aurora-clinical-programunderscores-value-of-lupkynis-voclosporin-for-patients-with--lupus-nephritis-at-acr-2023-meeting--aurinia-pharma/2023-11-08T12:39:23+00:00weekly0.6https://www.medthority.com/news/2023/11/national-medical-products-administration-has--approved-for-vocabria-cabotegravir-in-combination-with-rekambys-rilpivirine-the-first-and-only-complete-long-acting-hiv-1-injectable-treatment.--viiv-healthcare2023-11-08T12:44:01+00:00weekly0.6https://www.medthority.com/news/2023/11/phase-iii-ruby-trial-of-jemperli-dostarlimab-plus-chemotherapy-meets-endpoint-of-overall-survival-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer2.--gsk2023-11-08T12:49:38+00:00weekly0.6https://www.medthority.com/news/2023/11/jazz-pharmaceuticals-and-md-anderson-announce-five-year-collaboration-to-evaluate-zanidatamab-in-her2-expressing-cancers/2023-11-08T12:51:40+00:00weekly0.6https://www.medthority.com/news/2023/10/evolut-tavr-platform-outperforms-surgery-with-sustained-valve-performance-for-low-risk-patients-at-four-years.---medtronic2023-10-26T11:16:38+00:00weekly0.6https://www.medthority.com/news/2023/10/detailed-results-from-phase-iii-cabinet-pivotal-trial-evaluating-cabozantinib-in-advanced-neuroendocrine-tumors-presented-at-esmo-2023--exelixis/2023-10-26T11:13:55+00:00weekly0.6https://www.medthority.com/news/2023/10/keytruda-pembrolizumab--padcev-enfortumab-vedotin-ejfv-reduced-risk-of-death-by-more-than-half-versus-chemotherapy-in-patients-with-previously-untreated-locally-advanced-or-metastatic-urothelial-cancer.--merck-inc.seagenpfizer--astellas2023-10-26T11:12:02+00:00weekly0.6https://www.medthority.com/news/2023/10/new-lumakras-sotorasib--vectibixpanitumumab-in-kras-g12c-mutated-metastatic-colorectal-cancer.--amgen2023-10-26T11:08:47+00:00weekly0.6https://www.medthority.com/news/2023/10/five-year-data-from-partner-3-trial-demonstrates-excellent-survival-for-patients-receiving-sapien-3-valve.-edwards-lifesciences2023-10-26T11:07:09+00:00weekly0.6https://www.medthority.com/news/2023/10/worlds-first-expert-recommendations-on-remote-management-of-spinal-cord-stimulation-systems-published--biotronik/2023-10-27T11:22:32+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-penbraya-the-first-and-only-vaccine-for-the-prevention-of-the-five-most-common-serogroups-causing-meningococcal-disease-in-adolescents.--pfizer2023-10-27T11:24:46+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-tibsovo-ivosidenib-for-myelodysplastic-syndromes.--servier-pharma2023-10-27T11:26:55+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves--omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis.--eli-lilly2023-10-27T11:28:58+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-outcome-following-dsmb-review-reinforcing-confidence-in-phase-iii-on-going-trial-in-acute-graft-v.-host-disease-with-maat0-13-maat-pharma2023-10-27T11:31:51+00:00weekly0.6https://www.medthority.com/news/2023/10/leqembi-lecanemab-irmbsubcutaneous-formulation-interim-study-results-and-clinical-improvement-in-earlier-stages-of-alzheimers-disease-from-clarity-ad-trials.-eisai--biogen2023-10-27T11:35:57+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approval-of-agamree-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy.--santhera-pharma2023-10-29T15:42:41+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-accepts--bla-re-submission-of-n-803-as-complete-and-sets-new-pdufa-date.--immmunitybio-inc2023-10-29T15:41:16+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approval-of-loqtorzi-toripalimab-tpzi-in-all-lines-of-treatment-for-recurrent-or-metastatic-nasopharyngeal-carcinoma-npc.--coherus-bioscience--shanghai-junishi2023-10-29T15:39:56+00:00weekly0.6https://www.medthority.com/news/2023/10/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based-chemotherapy.-merck-inc2023-10-29T15:38:27+00:00weekly0.6https://www.medthority.com/news/2023/10/european-medicines-agency-acceptance-of-maa-for-mirvetuximab-soravtansine-elahere-in-platinum-resistant-ovarian-cancer.--immunogen-inc2023-10-29T15:37:12+00:00weekly0.6https://www.medthority.com/news/2023/10/repotrectinib-filed-in-japan-for-ros1-positive-nsclc.--bms2023-10-29T15:35:49+00:00weekly0.6https://www.medthority.com/news/2023/10/clasp-iid-one-year-data-confirms-safety-and-efficacy-of-pascal-system-for-degenerative-mitral-regurgitation.-edwards-life-sciences2023-10-31T12:44:25+00:00weekly0.6https://www.medthority.com/news/2023/10/atrasentan-phase-iii-study-demonstrates-clinically-meaningful-and-highly-statistically-significant-proteinuria-reduction-in-patients-with-iga-nephropathy-igan.--novartis2023-10-31T12:47:53+00:00weekly0.6https://www.medthority.com/news/2023/10/phase-iii-mariposa-2-study-shows-rybrevant-amivantamab-vmjw--chemotherapy-given-with-or-without-lazertinib-reduced-risk-of-disease-progresion-or-death-in-egfr-mutated--nsclc--who-progressed-on-or-after-osimertinib--janssen-pharma/2023-10-31T12:55:11+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-topline-results-from-global-pivotal-phase-iii-recover-trial-of-brilaroxazine-in-schizophrenia.--reviva-pharma2023-10-31T12:58:00+00:00weekly0.6https://www.medthority.com/news/2023/10/topline-results-from-embark-a-global-pivotal-study-of-elevidys-gene-therapy-for-duchenne-muscular-dystrophy.--sarepta-therapeutics2023-10-31T13:00:28+00:00weekly0.6https://www.medthority.com/news/2023/10/galapagos-concludes-strategic-evaluation-and-signs-letter-of-intent-to-transfer-jyseleca-business-to-alfasigma/2023-10-31T13:02:30+00:00weekly0.6https://www.medthority.com/news/2023/10/lianbio-announces-topline-results-from-phase-iii-libra-trial-of-tp-03-in-chinese-patients-with-demodex-blepharitis/2023-10-31T13:04:41+00:00weekly0.6https://www.medthority.com/news/2023/10/merck-kgaa-and-jiangsu-hengrui-collaboration/2025-10-16T11:05:55+00:00weekly0.6https://www.medthority.com/news/2023/11/phase-iii-ruby-trial-of-jemperli-dostarlimab-plus-chemotherapy-meets-endpoint-of-overall-survival-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer.--gsk2023-11-01T12:54:43+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approves--cosentyx--secukinumab-as-the-first-new-biologic-treatment-option-for-hidradenitis-suppurativa-patients-in-nearly-a-decade.--novartis2024-09-30T14:29:08+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-issues-approvable-letter-for--selective-cytopheretic-device-for-pediatric-patients.--seastar-medical2023-11-01T12:51:11+00:00weekly0.6https://www.medthority.com/news/2023/11/kite-and-epicrispr-biotechnologies-collaboration/2023-11-01T12:47:35+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-advisory-committee-concludes-review-on-exagamglogene-autotemcel-exa-cel-for-the-treatment-of-sickle-cell-disease.--crispr-therapeutics--vertex-pharma2023-11-02T12:19:16+00:00weekly0.6https://www.medthority.com/news/2023/11/protagonist-announces-achievement-of-$50-million-milestone-event-after-third-patient-is-dosed-in-phase-iii-study-of-jnj-2113-in-moderate-to-severe-psoriasis/2023-11-02T12:23:26+00:00weekly0.6https://www.medthority.com/news/2023/11/rexulti-brexpiprazole-is-filed--in--japan-for-alzheimers-associated-agitation-.--otsuka2023-11-02T12:25:12+00:00weekly0.6https://www.medthority.com/news/2023/11/astra-zeneca-collaboration-with-cellectis-inc.-to-accelerate-cell-therapy-and-genomic-medicine-ambitions-2023-11-02T12:28:06+00:00weekly0.6https://www.medthority.com/news/2023/11/keytruda-pembrolizumab-significantly-improved-overall-survival-versus-placebo-as-adjuvant-therapy-for-certain-patients-with-renal-cell-carcinoma-following-nephrectomy.--merck-inc2023-11-09T12:56:24+00:00weekly0.6https://www.medthority.com/news/2023/11/gilead-and-arcus-announce-new-data-showing-encouraging-clinical-activity-of-anti-tigit-domvanalimab-containing-regimen-as-first-line-treatment-for-upper-gi-cancers.--gilead-sciences2023-11-15T10:02:21+00:00weekly0.6https://www.medthority.com/news/2023/11/interactive-digital-tool-called-discover-td--is-launched-for-use-by-healthcare-providers-to-help-expand-education-on-identifying-and-diagnosing-tardive-dyskinesia.--neurocrine-biosciences2023-11-09T13:01:23+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-for-zepbound--tirzepatide-injection-the-first-and-only-obesity-treatment-of-its-kind-that-activates-both-gip-glucose-dependent-insulinotropic-polypeptide-and-glp-1-glucagon-like-peptide-1-hormone-receptors.--eli-lilly2023-11-09T13:03:50+00:00weekly0.6https://www.medthority.com/news/2023/11/imfinzi---transarterial-chemoembolisation-bevacizumab-met-primary-endpoint-for-progression-free-survival-in-liver-cancer-eligible-for-embolisation-in-emerald-1-phase-iii-trial-.--astrazeneca2023-11-10T12:45:39+00:00weekly0.6https://www.medthority.com/news/2023/11/new-real--world-data-show-tremfya-guselkumab-was-associated-with-clinically-meaningful-improvements-in-patient-reported-outcomes-for-adults-living-with-active-psoriatic-arthritis.--eli-lilly2023-11-10T12:48:43+00:00weekly0.6https://www.medthority.com/news/2023/11/submission-of-phase-iii-study-data-on-pulmonary-tuberculosis-to-the-european-medicines-agency-and-fda--for-sirturo-bedaquiline.--janssen-pharma2023-11-10T12:50:30+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-recommends-rozanolixizumab--to-treat--generalized-myasthenia-gravis-.--ucb2023-11-12T14:54:02+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-omjjara-momelotinibto-treat-myelofibrosis.-gsk2023-11-12T14:53:20+00:00weekly0.6https://www.medthority.com/news/2023/11/positive-chmp-opinion-for-uzpruvo-europes-first-ustekinumab-biosimilar-to-stelara.-stada--alvotech2023-11-12T14:52:39+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-rystiggo-rozanolixizumab-to-treat-generalized-myasthenia-gravis-gmg-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-or-anti-muscle-specific-tyrosine-kinase-musk-antibody-positive.---ucb2023-11-12T14:51:44+00:00weekly0.6https://www.medthority.com/news/2023/11/post-hoc-analysis-showed-meaningful-efficacy-of-certolizumab-pegol-for-ra-patients-with-high-rheumatoid-factor-rf-levels.--ucb2023-11-12T14:51:06+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-ayvakyt-avapritinib-to-treat-indolent-systemic-mastocytosis-.-blueprint-medicines2023-11-12T14:50:18+00:00weekly0.6https://www.medthority.com/news/2023/11/primary-results-of-select-phase-iii-cardiovascular-outcomes-trial-of-once-weekly-semaglutide-2.4-mg-wegovy-in-adults-with-established-cardiovascular-disease--and-overweight-or-obesity-without-diabetes-are-presented-at-aha-meeting.--novo-nordisk2023-11-12T14:49:36+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-krazati-adagrasibto-treat-krasg12c--mutated-advanced-non-small-cell-lung-cancer-.--mirati-therapeutics2023-11-12T14:48:42+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-opinion-for-keytruda-pembrolizumab---gemcitabine--cisplatin-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-biliary-tract-cancer--merck-inc/2023-11-12T14:48:05+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-recommends-approval-of-rimmyrah-ranibizumab-biosimilar.--qilu-pharma2023-11-12T14:47:25+00:00weekly0.6https://www.medthority.com/news/2023/11/phase-iii-konfident-trial-milestone-achieved-for-sebetralstat-for-hereditary-angioedema..--kalvista-2023-11-14T13:02:52+00:00weekly0.6https://www.medthority.com/news/2023/11/new-drug-application-is-filed-in-japan-for-lupkynis-voclosporin--to-treat-lupus-nephritis--otsuka--aurinia-pharma/2023-11-14T13:09:02+00:00weekly0.6https://www.medthority.com/news/2023/11/health-canada-approves-doptelet-avatrombopag-to-treat-chronic-immune-thrombocytopenia.--sobi2023-11-14T13:12:09+00:00weekly0.6https://www.medthority.com/news/2023/11/aflibercept-8-mg-recommended-by-chmp-for-approval-in-the-eu.--bayer2023-11-14T13:14:39+00:00weekly0.6https://www.medthority.com/news/2023/11/update-on-pacific-2-phase-iii-trial-of-imfinzi-concurrently-administered-with-platinum-based-chemoradiotherapy-in-unresectable-stage-iii-non-small-cell-lung-cancer.-astrazeneca2023-11-14T13:17:02+00:00weekly0.6https://www.medthority.com/news/2023/11/imfinzi--chemotherapy-approved-in-china-as-first-immunotherapy-regimen-for-patients-with-locally-advanced-or-metastatic-biliary-tract-cancer.--astrazeneca2023-11-14T13:19:56+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-recommends-subcutaneous-injection-of-tecentriq-for-multiple-cancer-types.--roche2023-11-14T13:21:47+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-talzenna--xtandi-talazoparib--enzalutamide-to-treatmetastatic-castration-resistant-prostate-cancer.--pfizer2025-01-23T14:11:31+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-accepts-for-priority-review-application-for-breyanzi-lisocabtagene-maraleucelfor-relapsed-or-refractory-chronic-lymphocytic-leukemia--or-small-lymphocytic-lymphoma.--bms-2023-11-13T12:36:24+00:00weekly0.6https://www.medthority.com/news/2023/11/chmp-positive-for-mounjaro-tirzepatide-for-the-treatment-of-obesity.--eli-lilly2023-11-13T12:33:43+00:00weekly0.6https://www.medthority.com/news/2023/11/health-canada-approves-avt-04-a-biosimilar-to-stelara-ustekinumab.--alvotech--jamp-pharma2023-11-15T13:07:40+00:00weekly0.6https://www.medthority.com/news/2023/11/selecta-biosciences-merges-with-cartesian-therapeutics/2023-11-15T13:09:49+00:00weekly0.6https://www.medthority.com/news/2023/11/mallinckrodt-emerges-from-chapter-11-proceedings/2023-11-15T13:12:20+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-of-expanded-approval-for-expanded-exparel-label-to-include-two-additional--nerve-block-indications.--pacira-biosciences.-2023-11-16T12:58:19+00:00weekly0.6https://www.medthority.com/news/2023/11/rheumacensus-experts-unite-and-call-for-essential-psoriatic-arthritis-and-axial-spondyloarthritis-care-improvements.--ucb2023-11-16T12:59:45+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approves-augtyro-repotrectinib-a-next-generation-tyrosine-kinase-inhibitor-for-the-treatment-of-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer-nsclc--bms/2023-11-16T13:01:10+00:00weekly0.6https://www.medthority.com/news/2023/11/mhra-uk-authorises-the-first-crisprcas9-gene-edited-therapy-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia.--vertex--crispr-therapeutics2023-11-16T13:02:45+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-of-worlds-first-chikungunya-vaccine-ixchiq.--valneva-se2023-11-16T13:04:02+00:00weekly0.6https://www.medthority.com/news/2023/11/truqap-capivasertib--faslodex-approved-in-the-us-for-patients-with-advanced-hr-positive-breast-cancer.-astrazeneca2023-11-17T12:18:04+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approves-keytruda-pembrolizumab--chemotherapy-as-first-line-treatment-for-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--merck-inc2023-11-17T12:20:24+00:00weekly0.6https://www.medthority.com/news/2023/11/alkermes-completes-transfer-of-its-oncology-business-to-mural-oncology/2023-11-17T12:26:07+00:00weekly0.6https://www.medthority.com/news/2023/11/boston-scientific-closes-acquisition-of-relievant-medsystems-inc.-and-with-it-intracept-intraosseous-nerve-ablation-system2023-11-18T17:33:02+00:00weekly0.6https://www.medthority.com/news/2023/11/european-commission-approval-for-brukinsa-zanubrutinib-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma.--beigene2023-11-18T17:32:21+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approves-symplicity-spyral-renal-denervation-rdn-system-for-treatment-of-hypertension.--medtronic2023-11-18T17:31:31+00:00weekly0.6https://www.medthority.com/news/2023/11/fda-approval-for-defencath-taurolidine-and-heparin-catheter-lock-solution-to-reduce-the-incidence-of-catheter-related-bloodstream-infections.--cormedix-2023-11-18T17:30:52+00:00weekly0.6https://www.medthority.com/news/2023/11/astellas-to-acquire-propella-therapeutics-and-with-it-prl-02-a-next-generation-androgen-biosynthesis-inhibitor-to-treat-prostate-cancer/2023-11-18T17:29:55+00:00weekly0.6https://www.medthority.com/news/2023/11/enrollment-of-patients-in-dmt-310-phase-iii-acne-clinical-program-to-begin-in-december-2023-based-on-agreement-with-fda-on-the-phase-iii-protocols.-dermata-therapeutics2023-11-19T15:54:41+00:00weekly0.6https://www.medthority.com/news/2023/11/altamira-therapeutics-announces-partial-spin-off-of-bentrio-business/2023-11-20T12:39:03+00:00weekly0.6https://www.medthority.com/news/2023/10/health-canada-approves-myfembree-to-manage-moderate-to-severe-pain-associated-with-endometriosis.--sumitomo-pharma-canada--pfizer-canada2023-10-24T11:34:16+00:00weekly0.6https://www.medthority.com/news/2023/10/datopotamab-deruxtecan-improved-progression-free-survival-vs.-chemotherapy-in-patients-with-previously-treated-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial.--astrazeneca2025-02-03T14:15:16+00:00weekly0.6https://www.medthority.com/news/2023/10/pluvicto-shows-clinically-meaningful-and-highly-statistically-significant-rpfs-benefit-in-patients-with-psma-positive-metastatic-castration-resistant-prostate-cancer-in-the-pre-taxane-setting.--novartis2025-01-23T14:11:37+00:00weekly0.6https://www.medthority.com/news/2023/10/kisqali-natalee-analysis-reinforces-consistent-reduction-in-risk-of-recurrence-across-key-subgroups-of-patients-with-early-breast-cancer.--novartis2023-10-24T11:55:22+00:00weekly0.6https://www.medthority.com/news/2023/10/novartis-statement-of-strategy/2023-10-24T11:57:11+00:00weekly0.6https://www.medthority.com/news/2023/10/new-data-on-hae-attacks-in-patients-receiving-long-term-prophylaxis--presented-at-the-asia-pacific-association-of-allergy-asthma-and-clinical-immunology-2023-international-conference.---kalvista-pharma2023-10-25T11:13:23+00:00weekly0.6https://www.medthority.com/news/2023/10/moderna-announces-first--participant-dosed-in-phase-iii-study-of-mrna-1083-a-combination-vaccine-against-influenza-and-covid-19/2023-10-25T11:15:23+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-accepts-for-review-supplemental-biologics-license-application-for-self-administration-of-flumist-quadrivalent.--astrazeneca2023-10-25T11:18:35+00:00weekly0.6https://www.medthority.com/news/2023/10/5-year-head--neck-cancer-survival-increased-from-45-to-73-in-cel-scis-target-population-with-multikine-cutting-risk-of-death-in-half-as-presented-at-leading-cancer-conference-esmo-2023/2023-10-25T11:20:15+00:00weekly0.6https://www.medthority.com/news/2023/10/late-breaking-data-showcase-the-benefits-of-abbotts-minimally-invasive-devices-for-people-with-leaky-heart-valves/2023-10-25T11:21:48+00:00weekly0.6https://www.medthority.com/news/2023/10/bla-resubmission-for-n-803-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer-carcinoma-in-situ.--immunitybio-inc2023-10-25T11:24:10+00:00weekly0.6https://www.medthority.com/news/2023/10/real-pe-study-demonstrates-statistically-significant-lower-major-bleeding-rates-with-the-ekos-endovascular-system-compared-to-mechanical-thrombectomy-device-for-treatment-of-pulmonary-embolism.--boston-scientific2023-10-25T11:29:17+00:00weekly0.6https://www.medthority.com/news/2023/10/lianbio-enters-into-agreement-with-bms-for-mavacamten-in-china-and-other-asian-markets/2023-10-25T11:31:10+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-phase-ii2-noble-results-of-pegcetacoplan-in-post-transplant-recurrence-of-primary-ic-mpgn-and-c3g.--sobi--apellis2023-10-19T12:42:49+00:00weekly0.6https://www.medthority.com/news/2023/10/chmp-positive-for-prevymis-letermovir-for-prophylaxis-of-cytomegalovirus-disease-in-adult-kidney-transplant-recipients-at-high-risk.--merck-inc2023-10-19T12:42:07+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases.--novartis2023-10-19T12:41:30+00:00weekly0.6https://www.medthority.com/news/2023/10/alecensa-reduces-the-risk-of-disease-recurrence-or-death-by-an-unprecedented-76-in-people-with-alk-positive-early-stage-non-small-cell-lung-cancer.--genentechroche2023-10-19T12:40:54+00:00weekly0.6https://www.medthority.com/news/2023/10/elecsys-il-6-immunoassay-is-the-first-immunoassay-approved-to-aid-sepsis-diagnosis-in-newborns.-roche2023-10-19T12:40:11+00:00weekly0.6https://www.medthority.com/news/2023/10/bimzelx--bimekizumab-bkzx-approved-by-the-fda-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis.--ucb2023-10-19T12:39:36+00:00weekly0.6https://www.medthority.com/news/2023/10/phase-iii-rationale-315-trial-met-primary-endpoints-of-major-pathological-response-rate-and-event-free-survival-for-tislelizumab-plus-chemotherapy-in-patients-with-resectable-non-small-cell-lung-cancer---beigene/2023-10-19T12:38:46+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approval-of-zilbrysq-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis.--ucb2023-10-19T12:38:03+00:00weekly0.6https://www.medthority.com/news/2023/10/late-breaking-data-at-esmo-showing-tislelizumab-plus-chemotherapy-significantly-improved-overall-survival-at-final-analysis-in-first-line-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma.--beigene2023-10-19T12:37:16+00:00weekly0.6https://www.medthority.com/news/2023/10/soliris-approved-in-china-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder.-alexion-pharmaastrazeneca2023-10-19T12:36:30+00:00weekly0.6https://www.medthority.com/news/2023/10/full-marketing-authorization-granted-by-mhra--for-prototype-covid-19-vaccine-nuvaxovid-in-united-kingdom--novavax-inc/2023-10-19T12:35:48+00:00weekly0.6https://www.medthority.com/news/2023/10/tzield-phase-iii-data-presented-at-ispad-shows-potential-to-slow-the-progression-of-stage-3-type-1-diabetes-in-newly-diagnosed-children-and-adolescents-full-data-simultaneously-published-in-the-nejm.-sanofi2023-10-19T12:28:06+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-xphozah-tenapanor-a-first-in-class-phosphate-absorption-inhibitor-to-treat-hyperphosphatemia--ardelyx-inc/2023-10-19T12:27:26+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-clearance-of-investigational-new-drug-ind-application-to-initiate-a-pivotal-phase-iii-trial-of-ntla-2001-for-the-treatment-of-transthyretin-attr-amyloidosis-with-cardiomyopathy.--intellia--regeneron2023-10-19T12:26:21+00:00weekly0.6https://www.medthority.com/news/2023/10/evoque-transcatheter-tricuspid-replacement-system-receives-ce-mark.--edwards-life-sciences-2023-10-21T13:22:31+00:00weekly0.6https://www.medthority.com/news/2023/10/phase-iii-checkmate--67t-trial-of-subcutaneous-nivolumab-nivolumab-and-hyaluronidase-meets-co-primary-endpoints-in-advanced-or-metastatic-clear-cell-renal-cell-carcinoma.-bms2023-10-21T13:21:46+00:00weekly0.6https://www.medthority.com/news/2023/10/daiichi-sankyo-and-merck-announce-global-development-and-commercialization-collaboration-for-three-daiichi-sankyo-dxd-adcs/2023-10-21T13:20:59+00:00weekly0.6https://www.medthority.com/news/2023/10/takeda-announces-topline-results-of-phase-iii-admire-cd-ii-trial-of-alofisel-darvadstrocel-in-complex-crohns-perianal-fistulas/2023-10-21T13:21:02+00:00weekly0.6https://www.medthority.com/news/2023/10/keytruda-pembrolizumab--concurrent-chemoradiotherapy-significantly-improved-progression-free-survival-versus-concurrent-chemoradiotherapy-alone-in-newly-diagnosed-high-risk-locally-advanced-cervical-cancer--merck-inc/2023-10-21T13:19:11+00:00weekly0.6https://www.medthority.com/news/2023/10/update-on-dupixent-dupilumab-sbla-for-chronic-spontaneous-urticaria.--regeneron--sanofi2023-10-21T13:18:20+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia.--biomarin2023-10-21T13:17:39+00:00weekly0.6https://www.medthority.com/news/2023/10/tagrisso-plus-chemotherapy-reduced-the-risk-of-disease-progression-in-the-brain-by-42-in-patients-with-egfr-mutated-advanced-lung-cancer-and-brain-metastases-at-baseline.--astrazeneca2023-10-21T13:16:59+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-cabtreo-clindamycin-phosphate-adapalene-and-benzoyl-peroxide-topical-gel-for-the-treatment-of-patients-12-year-and-older.--bausch-health-companies2023-10-22T11:52:45+00:00weekly0.6https://www.medthority.com/news/2023/10/imfinzidurvalumab-plus-lynparza-olaparib-reduced-the-risk-of-disease-progression-or-death-by-45-vs.-chemotherapy-in-advanced-or-recurrent-endometrial-cancer.--astrazeneca2023-10-22T11:52:04+00:00weekly0.6https://www.medthority.com/news/2023/10/retevmo-selpercatinib-phase-iii-results-in-ret-fusion-positive-nsclc--and-ret-mutant-medullary-thyroid-cancer--are-both-published-in-the-new-england-journal-of-medicine-and-presented-in-a-presidential-symposium-at-esmo-congress-2023.--eli-lilly2023-10-22T11:51:13+00:00weekly0.6https://www.medthority.com/news/2023/10/landmark-5-year-monarche-outcome-data-demonstrate-verzenio-abemaciclibs-long-term-impact-on-cancer-recurrence-in-high-risk-early-breast-cancer--eli-lilly/2023-10-22T11:50:21+00:00weekly0.6https://www.medthority.com/news/2023/10/libtayo-cemiplimab-neoadjuvant-treatment-demonstrates-encouraging-event-free-survival-in-patients-with-resectable-cutaneous-squamous-cell-carcinoma-.--regeneron-pharma2023-10-22T11:49:40+00:00weekly0.6https://www.medthority.com/news/2023/10/welireg-belzutifan-significantly-improved-progression-free-survival-and-objective-response-rates-versus-everolimus-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma.---merck-inc.-2023-10-23T12:33:01+00:00weekly0.6https://www.medthority.com/news/2023/10/datopotamab-deruxtecan-plus-imfinzi-demonstrated-robust-and-durable-tumour-responses-in-1st-line-treatment-of-patients-with-metastatic-triple-negative-breast-cancer-in-begonia-phase-ibii-trial.--astra-zeneca--daiichi-sankyo2023-10-23T12:32:18+00:00weekly0.6https://www.medthority.com/news/2023/10/european-commission-approves-adcetris-brentuximab-vedotin-for-the-treatment-of-adult-patients-with-previously-untreated-cd30-stage-iii-hodgkin-lymphoma-in-combination-with-avd-chemotherapy.---takeda2023-10-23T12:31:32+00:00weekly0.6https://www.medthority.com/news/2023/10/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-lebrikizumab-monthly-maintenance-dosing-at-two-years.--eli-lilly2023-10-23T12:30:52+00:00weekly0.6https://www.medthority.com/news/2023/10/enhertu-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.--astrazeneca--daiichi-sankyo2023-10-23T12:30:13+00:00weekly0.6https://www.medthority.com/news/2023/10/roche-to-acquire-telavant-holdings-inc.-and-with-it-rvt-3101-a-promising-new-therapy-for-inflammatory-bowel-disease2023-10-23T12:29:28+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-clearance-for-trileap-lower-extremity-anatomic-plating-system---depuy-synthesjj/2023-10-17T11:37:44+00:00weekly0.6https://www.medthority.com/news/2023/10/arcutis-presents-positive-patient-reported-outcome-data-from-the-pivotal-arrector-phase-iii-trial-in-scalp-and-body-psoriasis-at-european-academy-of-dermatology-and-venereology-congress/2023-10-17T11:37:07+00:00weekly0.6https://www.medthority.com/news/2023/10/chmp-recommends-elrexfio-elranatamaba-bispecific-monoclonal-antibody-to-treat-rr-multiple-myeloma.--pfizer2023-10-17T11:36:25+00:00weekly0.6https://www.medthority.com/news/2023/10/chmp-positive-for-elucirem-gadopiclenol-in-the-european-union-eu-for-use-in-adults-and-children-aged-2-years-and-over-for-mri-with-contrast-enhancement.--guerbet-s.a.-bracco2023-10-17T11:35:51+00:00weekly0.6https://www.medthority.com/news/2023/10/loargys-pegzilarginase-receives-positive-opinion-by-the-chmp-for-treatment-of-arginase-1-deficiency.-immedica-pharma2023-10-17T11:35:15+00:00weekly0.6https://www.medthority.com/news/2023/10/chmp-positive-for-vezoa-fezolinetant-to-treat-vasomotor--symptoms-associated-with-menopause.-astellas-pharma2023-10-17T11:34:41+00:00weekly0.6https://www.medthority.com/news/2023/10/withdrawal-of-the-marketing-authorisation-from-ema-of--jivadco-trastuzumab-duocarmazine-for-the-treatment-of-her2-positive-breast-cancer.-medac-gmbh2023-10-17T11:33:58+00:00weekly0.6https://www.medthority.com/news/2023/10/imlifidase-demonstrated-90-patient-survival-and-82-graft-survival-at-five-years-in-extended-pooled-analysis-with-data-from-17-hmedides-14-study-in-kidney-transplant-patients.--hansa-biopharma2023-10-17T11:33:25+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-resectable-t-greater-than-4-cm-or-n-nsclc-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued-as-a-single-agent-as-adjuvant-treatment-after-surgery.--merck-inc2023-10-17T11:32:43+00:00weekly0.6https://www.medthority.com/news/2023/10/highlights-of-the-latest-research-for-tremfya-guselkumab-and-investigational-targeted-oral-peptide-jnj-2113-in-moderate-to-severe-plaque-psoriasis-at-the-european-academy-of-dermatology-and-venereology-eadv-congress--janssen-pharmaceuticals/2023-10-16T07:12:06+00:00weekly0.6https://www.medthority.com/news/2023/10/phase-iii-data-analysis-presented-at-eadv-2023-showed-bimekizumab-achieved-high-thresholds-of-clinical-response-in-hidradenitis-suppurativa.--ucb2024-09-30T14:55:31+00:00weekly0.6https://www.medthority.com/news/2023/10/cidara-therapeutics-and-mundipharma-receive-positive-chmp-opinion-for-rezafungin-for-the-treatment-of-invasive-candidiasis-in-adults.-2023-10-16T07:10:45+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-chmp-opinion-for-brukinsa-zanubrutinib-in-relapsed-or-refractory-follicular-lymphoma--beigene/2023-10-16T07:09:55+00:00weekly0.6https://www.medthority.com/news/2023/10/late-breaking-data-for-btk-inhibitor-fenebrutinib-show-brain-penetration-and-significant-reduction-in-lesions-in-patients-with-relapsing-multiple-sclerosis.--genentechroche2023-10-16T07:09:11+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-eu-chmp-opinion-for-keytruda-pembrolizumab-plus-chemotherapy-as-first-line-treatment-for-her2-negative-advanced-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-expressing-pd-l1.--merck-inc.-2023-10-16T07:08:25+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-opdivo-nivolumab-as-adjuvant-treatment-for-eligible-patients-with-completely-resected-stage-iib-or-stage-iic-melanoma.--bms2023-10-16T07:07:40+00:00weekly0.6https://www.medthority.com/news/2023/10/lebrikizumab-improves-signs-and-symptoms-of-moderate-to-severe-atopic-dermatitis-in-patients-inadequately-controlled-with-or-ineligible-for-cyclosporine.--almirall-s.a2023-10-16T07:06:26+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves--velsipity-for-adults-with-moderately-to-severely-active-ulcerative-colitis-.--pfizer2023-10-16T07:05:45+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-braftovi--mektovi-for-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer.--pfizer2023-10-16T07:04:32+00:00weekly0.6https://www.medthority.com/news/2023/10/interim-phase-ii-data-from-phase-iiiii-orbit-study-demonstrate-setrusumab-ux143-significantly-reduced-fracture-rates-in-patients-with-osteogenesis-imperfecta.-ultragenyx-pharmaceutical--mereo-biopharma2023-10-16T07:03:44+00:00weekly0.6https://www.medthority.com/news/2023/10/spravato-esketamine-demonstrates-superior-efficacy-compared-to-quetiapine-extended-release-in-treatment-resistant-major-depressive-disorder.-johnson--johnson2023-10-16T14:30:07+00:00weekly0.6https://www.medthority.com/news/2023/10/tirzepatide-shows-additional-21.1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention-for-a-total-mean-weight-loss-of-26.6-from-study-entry-over-84-weeks--eli-lilly-2023-10-16T14:31:04+00:00weekly0.6https://www.medthority.com/news/2023/10/tagrisso-plus-chemotherapy-granted-priority-review-in-the-us-for-patients-with-egfr-mutated-advanced-lung-cancer.--astrazeneca2023-10-16T14:33:21+00:00weekly0.6https://www.medthority.com/news/2023/10/pivotal-keynote-671-trial-meets-dual-primary-endpoint-of-overall-survival-os-in-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer.---merck-inc2023-10-11T12:27:06+00:00weekly0.6https://www.medthority.com/news/2023/10/publication-of-results-from-xen-1101-phase-iib-x-tole-clinical-trial-in-peer-reviewed-journal-article-in-jama-neurology.--xenon-pharma2023-10-11T12:28:25+00:00weekly0.6https://www.medthority.com/news/2023/10/abbvie-showcases-breadth-and-depth-of-research-in-crohns-disease-and-ulcerative-colitis-at-ueg-week-2023/2023-10-11T12:33:17+00:00weekly0.6https://www.medthority.com/news/2023/10/novo-nordisk-will-stop-the-once-weekly-injectable-semaglutide-kidney-outcomes-trial-flow-based-on-interim-analysis/2023-10-11T12:34:03+00:00weekly0.6https://www.medthority.com/news/2023/10/alexion-data-at-9th-joint-ectrims-actrims-meeting-msmilan2023-showcase-impact-of-c5-inhibition-in-neuromyelitis-optica-spectrum-disorder.--alexionastrazeneca2023-10-11T12:35:40+00:00weekly0.6https://www.medthority.com/news/2023/10/first-ever-clinical-trial-exclusively-in-black-and-hispanic--latinx-people-living-with-multiple-sclerosis-shows-ocrevus-effectively-manages-disease-activity.--genentechroche2023-10-11T12:36:43+00:00weekly0.6https://www.medthority.com/news/2023/10/update-on-confides-phase-iii-trial-of-imlifidase-in-highly-sensitized-kidney-transplant-patients.--hansa-biopharma2023-10-12T12:35:46+00:00weekly0.6https://www.medthority.com/news/2023/10/merck-kgaa-presents-new-five-year-evobrutinib-data-for-relapsing-multiple-sclerosis-at-the-9th-joint-ectrims-actrims-congress-in-milan/2023-10-12T12:35:03+00:00weekly0.6https://www.medthority.com/news/2023/10/ilumetri-tildrakizumab-significantly-improves-wellbeing-for-patients-and-their-relatives-in-moderate-to-severe-plaque-psoriasis.--almirall-s.a2023-10-12T12:33:47+00:00weekly0.6https://www.medthority.com/news/2023/10/ocrevus-twice-yearly-10-minute-subcutaneous-injection-was-non-inferior-to-intravenous-infusion-and-provided-near-complete-suppression-of-brain-lesions.--genentechroche2023-10-12T12:34:06+00:00weekly0.6https://www.medthority.com/news/2023/10/new-data-for-ocrevus-show-that-after-10-years-of-treatment-77-of-people-with-relapsing-multiple-sclerosis-were-free-from-disability-progression-and-92-continue-to-walk-unaided.--roche2023-10-12T12:34:23+00:00weekly0.6https://www.medthority.com/news/2023/10/resubmission-to-the-fda-of-bla-supplement-for-udenyca-onbody-the--on-body-injector-presentation-of-udenyca.--coherus2023-10-10T13:22:33+00:00weekly0.6https://www.medthority.com/news/2023/10/keytruda-pembrolizumab-met-a-primary-endpoint-of-disease-free-survival-in-certain-patients-with-muscle-invasive-urothelial-carcinoma-after-surgery.--merck-inc2023-10-10T13:25:34+00:00weekly0.6https://www.medthority.com/news/2023/10/complete-response-letter-from-fda-for-supplemental-new-drug-application-for-patisiran-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis.-alnylam-pharma2023-10-10T13:30:46+00:00weekly0.6https://www.medthority.com/news/2023/10/vabysmo-maintained-vision-improvements-with-extended-treatment-intervals-up-to-four-months-for-people-with-retinal-vein-occlusion-rvo-in-phase-iii-trials.-genentechroche2023-10-10T13:31:54+00:00weekly0.6https://www.medthority.com/news/2023/10/merck-kgaa-presents-new-mavenclad-data-at-the-9th-joint-ectrims-actrims-congress-in-milan/2023-10-10T13:33:29+00:00weekly0.6https://www.medthority.com/news/2023/10/the-fda-has-issued-a-complete-response-letter-for-avt-04-a-biosimilar-candidate-to-stelara-ustekinumab--alvotech--teva/2023-10-13T13:40:01+00:00weekly0.6https://www.medthority.com/news/2023/10/sotyktu-deucravacitinib-long-term-data-demonstrate-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-psoriasis.--bms2023-10-13T13:40:57+00:00weekly0.6https://www.medthority.com/news/2023/10/mirikizumab-helped-patients-with-crohns-disease-achieve-long-term-remission-in--vivid-1-phase-iii-trial.--eli-lilly2023-10-13T13:42:06+00:00weekly0.6https://www.medthority.com/news/2023/10/chmp-grants-positive-opinion-recommending-approval-of-agamree-vamorolone-for-the-treatment-of-duchenne-muscular-dystrophy.--santhera-pharmaceuticals2023-10-13T13:43:02+00:00weekly0.6https://www.medthority.com/news/2023/10/rybrevantamivantamab-in-combination-with-chemotherapy-is-submitted-to-ema-for-the-first-line-treatment-of-advanced-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.-janssen-companies2023-10-13T13:44:07+00:00weekly0.6https://www.medthority.com/news/2023/10/promore-pharma-ab-enters-voluntary-liquidation/2023-10-13T13:44:55+00:00weekly0.6https://www.medthority.com/news/2023/10/epimab-biotherapeutics-and-almirall-announce-bispecific-antibody-license-agreement/2023-10-16T07:12:42+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-issues-complete-response-letter-for-lebrikizumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis.--eli-lilly--2023-10-03T11:14:53+00:00weekly0.6https://www.medthority.com/news/2023/10/beigene-announces-positive-regulatory-updates-in-europe-and-the-u.s.-after-recently-regaining-global-rights-for-tevimbra-tislelizumab2023-10-03T11:16:50+00:00weekly0.6https://www.medthority.com/news/2023/10/synaptogenix-announces-peer-reviewed-publication-of-nih-sponsored-phase-ii-clinical-trial-results-demonstrating--persistent-benefits-of-bryostatin-1-in-advanced-alzheimers-disease.--2023-10-03T11:18:56+00:00weekly0.6https://www.medthority.com/news/2023/10/r21matrix-m-malaria-vaccine-with-novavaxs-adjuvant-technology-receives-who-recommendation/2023-10-03T11:20:48+00:00weekly0.6https://www.medthority.com/news/2023/10/syros-announces-planned-ceo-leadership-transition-and-strategic-reorganization/2023-10-03T11:23:02+00:00weekly0.6https://www.medthority.com/news/2023/10/european-commission-approval-of-tepkinly-epcoritamab-for-adults-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.--abbvie2023-10-01T11:00:21+00:00weekly0.6https://www.medthority.com/news/2023/10/bayer-to-present-latest-real-world-evidence-of-menopausal-symptoms-and-their-treatment/2023-10-02T06:51:27+00:00weekly0.6https://www.medthority.com/news/2023/10/results--presented-from-phase-iii-canova-study-of-venetoclax-in-patients-with-rr-multiple-myeloma--abbvue/2023-10-02T06:53:25+00:00weekly0.6https://www.medthority.com/news/2023/10/once-weekly-altuviiio-efanesoctocog-alfa-is-approved-in-japan-as-a-new-class-of-factor-viii-therapy-for-hemophilia-a.-sanofi--sobi2023-10-02T06:56:52+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-bosulif-bosutinib-for-pediatric-ph-cp-cml.--pfizer2023-10-02T11:09:32+00:00weekly0.6https://www.medthority.com/news/2023/10/phase-iii-enhance-2-trial-of-magrolimab--azacitidine-in-tp53-mutant-aml-is-discontinued.--gilead-sciences2023-10-02T11:15:04+00:00weekly0.6https://www.medthority.com/news/2023/10/positive-top-line-results-announced-from-the-interim-analysis-of-the-phase-iii-applause-igan-study-of-iptacopan-for-iga-nephropathy.-novartis2023-10-02T11:19:08+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-statistically-significant--top-line-results-from-randomised-withdrawal-period-of-study-c602-of-dccr-for-prader-willi-syndrome/2023-09-28T13:32:12+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-has-accepted-the-nda-filing-for-ensifentrine-for-the-maintenance-treatment-of-copd.--verona-pharma2023-09-28T13:33:37+00:00weekly0.6https://www.medthority.com/news/2023/9/ionis-announces-positive-olezarsen-topline-results-from-phase-iii-study-in-people-with-familial-chylomicronemia-syndrome.--ionis-pharma2023-09-28T13:37:31+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approval-of-ryzumvi-phentolamine-ophthalmic-solution-0.75-eye-drops-for-the-treatment-of-pharmacologically-induced-mydriasis-produced-by-adrenergic-agonists--or-parasympatholytic-agents.--ocuphire-pharma--viatris-2023-09-28T13:38:54+00:00weekly0.6https://www.medthority.com/news/2023/9/elahere-shows-overall-and-progression-free-survival-benefit-regardless-of-prior-parpi-exposure-or-prior-lines-of-therapy-in-fr-apha-positive-platinum-resistant-ovarian-cancer.--immunogen-inc2023-09-29T13:09:07+00:00weekly0.6https://www.medthority.com/news/2023/9/health-canada-authorization-for-xbb.1.5-adapted-monovalent-covid-19-vaccine.--pfizer--biontech-se2023-09-29T13:10:41+00:00weekly0.6https://www.medthority.com/news/2023/9/update-on-fda-advisory-committee-meeting-to-review-nurown-for-the-treatment-of-als.--brainstorm--cell-therapeutics-inc2023-09-29T13:12:53+00:00weekly0.6https://www.medthority.com/news/2023/9/priority-review-from-fda-for-new-bla-for-sotatercept-an-activin-signaling-inhibitor-to-treat-adults-with-pulmonary-arterial-hypertension-.--merck-inc2023-09-29T13:15:06+00:00weekly0.6https://www.medthority.com/news/2023/9/new-drug-application-submitted-to-fda-for-karxt-for-the-treatment-of-schizophrenia.--karuna-therapeutics2023-09-29T13:17:07+00:00weekly0.6https://www.medthority.com/news/2023/9/novartis-completes-divestment-of-front-of-eye-ophthalmology-assets/2023-10-23T16:16:08+00:00weekly0.6https://www.medthority.com/news/2023/9/new-analysis-highlights-importance-of-adhering-to-uninterrupted-full-course-of-treatment-with-tepezza-teprotumumab-trbw-to-support-thyroid-eye-disease-patient-outcome.-horizon-therapeutics2023-10-02T06:42:56+00:00weekly0.6https://www.medthority.com/news/2023/9/odronextamab-bla-for-treatment-of-rr-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma--accepted-for-fda-priority-review.-regeneron-pharma2023-10-02T06:44:10+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approves--tofidence-tocilizumab-bavi-a-biosimilar-referencing-actemra.--biogen2023-10-02T06:45:50+00:00weekly0.6https://www.medthority.com/news/2023/10/takeda-provides-update-on-exkivity-mobocertinibfor-epidermal-growth-factor-receptor-egfr-exon20-insertion-mutation-positive-nsclc/2023-10-04T11:29:07+00:00weekly0.6https://www.medthority.com/news/2023/10/pivotal-augment-101-trial-of-revumenib-in-rr-kmt2ar-acute-leukemia-meets-primary-endpoint-and--is-stopped-early-for-efficacy.--syndax-pharma2023-10-04T11:30:59+00:00weekly0.6https://www.medthority.com/news/2023/10/novavax-2023-2024-covid-19-vaccine-now--fda-authorized-and-recommended-for-use-in-the-u.s2023-10-04T11:33:51+00:00weekly0.6https://www.medthority.com/news/2023/10/majority-of-newborn-babies-with-spinal-muscular-atrophy-sma-treated-with-evrysdi-risdiplam-are-able-to-sit-independently-after-1-year-of-treatment.-roche2023-10-04T11:36:13+00:00weekly0.6https://www.medthority.com/news/2023/10/invitaes-common-hereditary-cancers-panel-receives-fda-market-authorization/2023-10-04T11:38:36+00:00weekly0.6https://www.medthority.com/news/2023/10/seastar-medical-provides-regulatory-update-regarding-selective-cytopheretic-device-use-in-pediatric-acute-kidney-injury-under-a-humanitarian-device-exemption/2023-10-04T11:41:00+00:00weekly0.6https://www.medthority.com/news/2023/10/regeneron-and-intellia-collaborate-on-in-vivo-crispr-based-gene-editing-for-neurological-and--muscular-diseases/2023-10-04T11:43:02+00:00weekly0.6https://www.medthority.com/news/2023/10/eli-lilly-to-acquire-point--biopharma-global-and-with-it--pnt-20021--a-prostate-specific-membrane-antigen-/2023-10-04T11:45:18+00:00weekly0.6https://www.medthority.com/news/2023/10/analyses-of-valtoco--diazepam-nasal-spray-to-be-presented-at-child-neurology-society-meeting.--neurelis2023-10-05T11:56:26+00:00weekly0.6https://www.medthority.com/news/2023/10/novartis-to-present-new-oncology-data-at-esmo-2023-demonstrating-practice-changing-innovation-in-advanced-prostate-and-early-breast-cancer.-------------2024-12-17T13:18:08+00:00weekly0.6https://www.medthority.com/news/2023/10/janssen-pharma-to-collaborate-with-sanofi-in-janssens-extraintestinal-pathogenic-escherichia-coli-vaccine-programme/2023-10-05T12:00:51+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-limflow-system-in-patients-with-chronic-limb---threating-ischemia.---limflow-s.a2023-10-06T12:13:34+00:00weekly0.6https://www.medthority.com/news/2023/10/innate-pharma-provides-update-on-lacutamab-clinical-program/2023-10-06T12:15:02+00:00weekly0.6https://www.medthority.com/news/2023/10/abbvie-acquires-mitokinin-and-disease-modifying-treatment-for-parkinsons-disease-/2023-10-06T12:18:53+00:00weekly0.6https://www.medthority.com/news/2023/10/kyowa-kirin-acquires-orchard-therapeutics/2023-10-06T12:27:35+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-zoryve--roflumilast-cream-0.3-for-treatment-of-psoriasis-in-children-ages-6-to-11--arcutis-biotherapeutics2023-10-08T13:55:52+00:00weekly0.6https://www.medthority.com/news/2023/10/alnylam-to-present-additional-data-for-patisiran-in-patients-with-the-cardiomyopathy-of-attr-amyloidosis-including-24-month-results-from-the-apollo-b-phase-iii-study-at-the-heart-failure-society-of-america-annual-scientific-meeting-2023/2023-10-08T13:55:04+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-approves-pombiliti--opfolda-combination-to-treat-late-stage-pompe-disease--amicus-therapeutics/2023-10-08T13:54:03+00:00weekly0.6https://www.medthority.com/news/2023/10/uniqure-to-restructure/2023-10-08T13:53:06+00:00weekly0.6https://www.medthority.com/news/2023/10/mhra-uk-approves-jemperli-dostarlimab-a-treatment-for-some-types-of-endometrial-cancer-in-adults.--gsk2023-10-08T13:52:17+00:00weekly0.6https://www.medthority.com/news/2023/10/ucb-to-present-new-bimekizumab-data-in-hidradenitis-suppurativa-psoriasis-and-psoriatic-arthritis-at-eadv-2023/2024-09-30T14:56:38+00:00weekly0.6https://www.medthority.com/news/2023/10/fda-panel-votes-that-phase-iii-pfs-data-for-sotorasib-in-kras-g12c-advanced-nsclc-cannot-be-reliably-interpreted.--amgen2023-10-09T11:14:38+00:00weekly0.6https://www.medthority.com/news/2023/10/cytokinetics-presents-baseline-characteristics-from-sequoia-hcm--the-pivotal-phase-iii-clinical-trial-of-aficamten-at-the-hcm-society-scientific-sessions/2023-10-09T11:17:49+00:00weekly0.6https://www.medthority.com/news/2023/10/bms-to-acquire-mirati-therapeutics-and-with-it-krazati-an-important-lung-cancer--franchise/2023-10-09T11:20:15+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-approves-inaqovidecitabine-and-cedazuridine-to-treat-acute-myeloid-leukemia-.--otsuka-pharma2023-09-21T14:18:31+00:00weekly0.6https://www.medthority.com/news/2023/9/japan-tobacco--torii-submit-tapinarof-cream-to-treat-atopic-dermatitis-and-psoriasis-in-japan/2023-09-21T14:20:08+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-grants-priority-review-to-application-for-keytruda---concurrent-chemoradiotherapy--as-treatment-for-newly-diagnosed-high-risk-locally-advanced-cervical-cancer.--merck-inc2023-09-21T14:21:03+00:00weekly0.6https://www.medthority.com/news/2023/9/complete-response-letter-for-neffyepinephrine-nasal-spray-to-treat-allergic-reactions-and-anaphylaxis.--ars-pharma2023-09-21T14:21:53+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-accepts-bla-for-avt-02-adalimumab-biosimilar-from-alvotech/2023-09-21T14:22:38+00:00weekly0.6https://www.medthority.com/news/2023/9/boston-scientific-acquires-relievant-medsysytems-and-with-it-the-intracept-intraosseous-nerve-ablation-system/2023-09-21T14:23:22+00:00weekly0.6https://www.medthority.com/news/2023/9/alexion-astrazeneca-rare-disease-has-completed-a-definitive-purchase-and-licence-agreement-for-a-portfolio-of-preclinical-rare-disease-gene-therapy-programmes--from-pfizer/2023-09-21T14:24:05+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-approves-litfulo-ritlecitinib-to-treat-adults-and-adolescents-12-years-of-age-and-older-with-severe-alopecia-areata.--pfizer2023-09-22T12:10:27+00:00weekly0.6https://www.medthority.com/news/2023/9/datopotamab-deruxtecan-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-benefit-in-patients-with-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial.--astrazeneca--daiichi-sankyo2023-09-22T12:13:13+00:00weekly0.6https://www.medthority.com/news/2023/9/confirmatory-data-from-the-phase-iii-protect-study-of-filspari-demonstrates-long-term-kidney-function-preservation-in-iga-nephropathy-narrowly-missing-egfr-total-slope-endpoint-versus-active-control-irbesartan.--travere-therapeutics2023-09-23T11:34:48+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-approval-for-enrylaze-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma.--jazz-pharma2023-09-23T11:37:05+00:00weekly0.6https://www.medthority.com/news/2023/9/padcev-enfortumab-vedotin-ejfv-and-keytruda-pembrolizumab-significantly-improve-overall-survival-and-progression-free-survival-in-previously-untreated-advanced-bladder-cancer-in-pivotal-phase-iii-ev-302-trial.-seagen--astellas2023-09-23T11:39:35+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approves-jardiance-empagliflozinfor-the-treatment-of-adults-with-chronic-kidney-disease.-boehringer--eli-lilly2023-09-23T11:41:07+00:00weekly0.6https://www.medthority.com/news/2023/9/perioperative-regimen-of-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-adjuvant-opdivo-significantly-improves-event-free-survival-in-patients-with-resectable-non-small-cell-lung-cancer--bms/2023-09-23T11:42:59+00:00weekly0.6https://www.medthority.com/news/2023/9/update-on-two-phase-iii-trials-evaluating-lenvima-lenvatinib-plus-keytruda-pembrolizumab-in-patients-with-certain-types-of-metastatic-non-small-cell-lung-cancer.--merck-inc.--eisai2023-09-23T11:45:31+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-acceptance-of-nda-resubmission-of-tak-721-budesonide-oral-suspension-for-the-short-term-treatment-of-eosinophilic-esophagitis.--takeda2023-09-23T11:46:56+00:00weekly0.6https://www.medthority.com/news/2023/9/united-therapeutics-announces-recent-milestones-for-its-heart-and-kidney-xenotransplantation-programs/2023-09-23T11:49:03+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-advisory-committee-voted-unanimously-to-reject-an-appeal-for-intarcia-therapeutics-type-2-diabetes-drug-device-combination-treatment-citing-continued-safety-concerns.-2023-09-24T11:56:55+00:00weekly0.6https://www.medthority.com/news/2023/9/evaluation-begins-of-large-tip-focal-pulsed-field-omnypulse-catheter-in-omny-ire-clinical-trial-in-europe.-biosense-webster-inc.jj2024-09-30T11:39:13+00:00weekly0.6https://www.medthority.com/news/2023/9/leqembi-intravenous-infusion-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-japan.--eisai--biogen2023-09-25T11:30:13+00:00weekly0.6https://www.medthority.com/news/2023/9/lutathera-demonstrated-statistically-significant-and-clinically-meaningful-progression-free-survival-in-first-line-advanced-gastroenteropancreatic-neuroendocrine-tumors-gep-nets.--novartis2023-09-25T11:31:33+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approval-sought-for-frontline-tevimbra-tislelizumab-in-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma.--beigene2023-09-25T11:33:31+00:00weekly0.6https://www.medthority.com/news/2023/9/bayer-and-hologic-collaborate-to-deliver-contrast-enhanced-mammography-solutions-to-improve-the-detection-of-breast-cancer-/2023-09-25T11:39:15+00:00weekly0.6https://www.medthority.com/news/2023/9/novartis-confirms-sandoz-spin-off-for-october-4-2023/2023-09-25T11:40:51+00:00weekly0.6https://www.medthority.com/news/2023/9/new-data-at-ers-showed-xenpozyme-olipudase-alfa-improved-respiratory-functions-in-adults-with-asmd.--sanofi2023-09-26T11:07:00+00:00weekly0.6https://www.medthority.com/news/2023/9/mhlw-japan-approves-avt-04-asa-ustekinumab-biosimilar.--fuji-pharma--alvotech2023-09-26T11:08:50+00:00weekly0.6https://www.medthority.com/news/2023/9/new-campaign-from-arcutis-aims-to-educate-raise-awareness-and-provide-encouragement-for-those-living-with-seborrheic-dermatitis/2023-09-26T11:11:15+00:00weekly0.6https://www.medthority.com/news/2023/9/ce-mark-for-simplera-continuous-glucose-monitor-cgm-featuring-a-simple-two-step-insertion-process.--medtronic2025-02-03T14:15:44+00:00weekly0.6https://www.medthority.com/news/2023/9/mhlw-japan-approves-rystiggo-rozanolixizumab-and-zilbrysq-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients-only-for-patients-who-inadequately-respond-to-steroids-or-other-immunosuppressants.-ucb2023-09-26T11:41:48+00:00weekly0.6https://www.medthority.com/news/2023/9/industry-leading-biomarker-brain-preservation-and-clinical-benefits-following-24-months-of-treatment-in-phase-ii-trial-of-oral-alz-801-valiltramiprosate-in-patients-with-early-alzheimers-disease.-alzheon-inc2023-09-26T11:43:59+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-approves-tyruko-natalizumab-biosimilar-first-and-only-biosimilar-for-multiple-sclerosis-in-europe--sandoz/2023-09-26T11:45:28+00:00weekly0.6https://www.medthority.com/news/2023/9/dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1-to-11-years-accepted-for-fda-priority-review--regeneron--sanofi/2023-09-26T11:47:10+00:00weekly0.6https://www.medthority.com/news/2023/9/leqvio-inclisiran-is-approved-by-mhlw-for-familial-and-non-familial-hypercholesterolemia-and-for-patients-who-are-at-a-high-risk-of-developing-cardiovascular-events.--novartis2023-09-27T11:53:50+00:00weekly0.6https://www.medthority.com/news/2023/9/epkinly-epcoritamab-is-approved-by-mhlw-japan-as-the-first-bispecific-antibody-to-treat-adults-patients-with-certain-types-of-relapsed-or-refractory-rr-large-b-cell-lymphoma.--genmab-as--abbvie2023-09-27T11:55:26+00:00weekly0.6https://www.medthority.com/news/2023/9/veru-inc.-reaches-agreement-with-fda-on-a-new-phase-iii-clinical-trial-for-sabizabulin-for-broader-indication-hospitalized-adult-patients-with-any-type-of-viral-acute-respiratory-distress-syndrome-ards2023-09-27T11:57:42+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-approves--orserdu-elacestrant-for-the-treatment-of-patients-with-er-her2--locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation.-menarini--stemline2023-09-27T12:00:00+00:00weekly0.6https://www.medthority.com/news/2023/9/vyvgart-is-the-first-and-only-neonatal-fc-receptorfcrn-blocker-authorized-for-sale-in-canada-for-for-the-treatment-of-generalized-myasthenia-gravis.-argenx-se2023-09-27T12:01:51+00:00weekly0.6https://www.medthority.com/news/2023/9/mhlw-japan-approves-arexvy-respiratory-syncytial-virus-vaccine-recombinant-adjuvanted-for-the-prevention-of-rsv-respiratory-syncytial-virus-disease.--gsk2023-09-27T12:04:29+00:00weekly0.6https://www.medthority.com/news/2023/9/mhlw-japan-approval-for-phesgo-the-fixed-dose-subcutaneous-combination-of-perjeta-and-herceptin-for-her2-positive-breast-and-colorectal-cancer.---chugai2023-09-27T12:06:29+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approves-likmez-metronidazole-oral-suspensionto-treat-parasitic-and-anaerobic-bacterial-infections.--saptalis-pharmaceuticals2023-09-27T12:08:30+00:00weekly0.6https://www.medthority.com/news/2023/9/alfasigma-s.p.a--to-acquire-intercept-pharmaceuticals-inc.-and-with-it-ocaliva2023-09-27T12:10:14+00:00weekly0.6https://www.medthority.com/news/2023/9/pfizer-and-biontech-receive-fda-approval-for-2023-2024-covid-19-vaccine/2023-09-13T11:33:14+00:00weekly0.6https://www.medthority.com/news/2023/9/once-daily-oral-paltusotine-achieved-primary-and-all-secondary-endpoints-in-phase-iii-pathfinder-1-study-in-acromegaly.--crinetics-pharma2023-09-13T11:35:33+00:00weekly0.6https://www.medthority.com/news/2023/9/momelotinib-filed-in-japan-to-treatmyelofibrosis.--gsk2023-09-13T11:31:12+00:00weekly0.6https://www.medthority.com/news/2023/9/maa-is-submitted-to-the-european-medicines-agency-seeking-approval-of-erdafitinib-for-the-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-cancer-with-susceptible-fgfr-alterations.--janssen-pharmaceutical2023-09-11T11:32:54+00:00weekly0.6https://www.medthority.com/news/2023/9/sandoz-announces-exclusive-deal-to-commercialize-biosimilar-ustekinumab-further-reinforcing-growing-pipeline-and-immunology-patient-offering/2023-09-11T11:30:25+00:00weekly0.6https://www.medthority.com/news/2023/9/tagrisso-plus-chemotherapy-extended-median-progression-free-survival-by-nearly-9-months-in-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial.--astrazeneca2023-09-11T11:28:06+00:00weekly0.6https://www.medthority.com/news/2023/9/science-publication-that-confirms-mechanism-of-action-of-simufilam-a-novel-drug-candidate-for-alzheimers-disease.--cassava-sciences2023-09-12T11:52:35+00:00weekly0.6https://www.medthority.com/news/2023/9/fasenra-met-the-primary-endpoint-in-the-mandara-phase-iii-trial-in-eosinophilic-granulomatosis-with-polyangiitis-egpa.--astrazeneca2023-09-12T11:58:06+00:00weekly0.6https://www.medthority.com/news/2023/9/new-analyses-supporting-the-potential-of-sotatercept-an-investigational-medicine-for-adults-with-pulmonary-arterial-hypertension-presented-at-ers-meeting.--merck-inc2023-09-12T12:03:10+00:00weekly0.6https://www.medthority.com/news/2023/9/moderna-receives-fda-approval-for-updated-covid-19-vaccine/2023-09-12T12:05:26+00:00weekly0.6https://www.medthority.com/news/2023/9/otsuka-and-shape-therapeutics-shapetx-collaborate-to-develop-intravitreally-delivered-adeno-associated-viruses-aavs-for-ocular-diseases/2023-09-12T12:07:04+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approval-of-an-investigational-nda--for-phase-iibiii-impact-clinical-trial-of-s-pindolol-benzoate-to-treat-cancer-cachexia.--actimed-therapeutics2023-09-09T14:46:11+00:00weekly0.6https://www.medthority.com/news/2023/9/keytruda-filed-in-japan-in-nsclc-neoadjuvantadjuvant-setting.-merck-inc2023-09-09T14:47:50+00:00weekly0.6https://www.medthority.com/news/2023/9/topline-results-announced-from-two-phase-iii-trials-of-brexpiprazole-as-combination-therapy-with-sertraline-for-the-treatment-of-post-traumatic-stress-disorder-in-adults.--otsuka--lundbeck2023-09-09T14:50:51+00:00weekly0.6https://www.medthority.com/news/2023/9/adamis-pharmaceuticals-changes-its-name-to-dmk-pharmaceuticals-corporation/2023-09-09T14:52:43+00:00weekly0.6https://www.medthority.com/news/2023/9/ds-5670-an-omicron-xbb.1.5-adapted-covid-19-vaccine-is-filed-in-japan-as-a-supplemental-new-drug-application.--daiichi-sankyo-2023-09-09T14:54:22+00:00weekly0.6https://www.medthority.com/news/2023/9/new-data-at-ers-showcases-sanofis-scientific-leadership-in-addressing-unmet-needs-across-a-variety-of-respiratory-conditions-/2023-09-10T12:05:54+00:00weekly0.6https://www.medthority.com/news/2023/9/two-year-follow-up-data-from-krystal-1-study-demonstrates-durable-response-and-long-term-overall-survival-and-is-presented-at-2023-world-conference-on-lung-cancer.--mirati-therapeutics2023-09-10T12:07:36+00:00weekly0.6https://www.medthority.com/news/2023/9/bms-986278-reduces-rate-of-lung-function-decline-in-progressive-pulmonary-fibrosis-cohort-of-phase-ii-study.--bms2023-09-10T12:09:36+00:00weekly0.6https://www.medthority.com/news/2023/9/successful-pre-nda-meeting-with-the-fda-and-plan-to-submit-nda-for-govorestat-at-007-for-treatment-of-classic-galactosemia-to-fda-in-q4-2023.---applied-therapeutics-inc2023-09-07T11:09:52+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-long-term-results-of-roflumilast-cream-0.15-showing-durable-and-improved-efficacy-over-time-and-favorable-safety-profile-in-treatment-of-mild-to-moderate-atopic-dermatitis-ad.--arcutis-bio2023-09-08T11:46:24+00:00weekly0.6https://www.medthority.com/news/2023/9/completion-of-enrollment-in-the-phase-iii-reach-clinical-trial-of-losmapimod-in-facioscapulohumeralmuscular-dystrophy-.--fulcrum-therapeutics-inc2023-09-08T11:47:56+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-expands-ervebo-ebola-zaire-vaccine-rvsvg-zebov-gp-live-indication-to-include-children-1-year-of-age-and-older.--merck-inc2023-09-08T11:50:28+00:00weekly0.6https://www.medthority.com/news/2023/9/zenas-biopharma-announces-strategic-license-and-cbollaboration-agreement-to-develop-and-commercialize-obexelimab-with-bms/2023-09-08T11:54:56+00:00weekly0.6https://www.medthority.com/news/2023/9/seladelpar-achieves-high-statistical-significance-for-the-primary-and-key-secondary-endpoints-in-the-phase-iii-response-trial-in-primary-biliary-cholangitis.-cymabay-therapeutics2023-09-08T11:57:55+00:00weekly0.6https://www.medthority.com/news/2023/9/nurix-therapeutics-and-seagen-collaboration-combining-targeted-protein-degradation-and-antibody-drug-conjugation-/2023-09-08T12:04:51+00:00weekly0.6https://www.medthority.com/news/2023/9/xtandi-accepted-for-ema-review-for-earlier-type-of-prostate-cancer.--astellas2025-07-01T09:48:17+00:00weekly0.6https://www.medthority.com/news/2023/9/pfizer-japan-files-20-valent-pneumococcal-vaccine-for-older-adults-and-individuals-at-high-risk-of-contracting-an-infectious-disease-caused-by-pneumococcus/2023-09-15T12:52:13+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-accepts-nda-for-ingrezza-oral-granules-sprinkle-formulation.-neurocrine-biosciences2023-09-15T12:54:33+00:00weekly0.6https://www.medthority.com/news/2023/9/additional-significant-efficacy-outcomes-announced-from-bentrio-clinical-trial-in-seasonal-allergic-rhinitis--altamira-therapeutics-ltd/2023-09-15T12:39:10+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-updates-pdufa-action-date-for-lifileucel-for-the-treatment-of-advanced-melanoma.--iovance-biotherapeutics-inc2023-09-15T12:30:20+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-spikevax-the-updated-covid-19-vaccine-containing-spike-proteins-for-the-xbb.1.5-sublineage-of-sars-cov-2-for-active-immunization-to-prevent-covid-19-caused-by-sars-cov-2-in-individuals-six-months-of-age-and-older.-moderna2023-09-15T12:25:56+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-ebglyss-for-the-treatment-of-adult-and-adolescent-patients-with-moderate-to-severe-atopic-dermatitis-who-are-candidates-for-systemic-therapy.--almirall-sa2023-09-16T21:15:05+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-chmp-opinion-in-europe-to-expand-use-of-voxzogo-to-treat-children-aged-4-months-and-older-with-achondroplasia.--biomarin-pharma2023-09-16T21:16:02+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-finlee--trametinib-for-the-treatment-of-low-and-high-grade-glioma-.--novartis2023-09-16T21:18:13+00:00weekly0.6https://www.medthority.com/news/2023/9/enhertu-recommended-for-approval-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer.--astrazeneca--daichi-sankyo2023-09-16T21:19:51+00:00weekly0.6https://www.medthority.com/news/2023/9/ojjaara-momelotinib-approved-by-fda-to-treat-intermediate-or-high-risk-myelofibrosis.--gsk2023-09-16T21:21:44+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-negative-decision-on-the-conversion-of-the-conditional-marketing-authorization-to-full-marketing-authorization-of-translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchennemuscular-dystrophy-.--ptc-therapeutics2023-09-17T12:44:07+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-zilucoplan-as-add-on-to-standard-therapy-for-generalized-myasthenia-gravis-in-adult-patients-who-are-anti-acetylcholine-receptor-achr-antibody-positive.--ucb2023-09-17T12:44:53+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-chmp-opinion-for-transcon-pth-palopegteriparatide-for-adults-with-chronic-hypoparathyroidism.-ascendis-pharma-as2023-09-17T12:46:11+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-herwenda-a-biosimilar-intended-for-the-treatment-of-her2-positive-breast-and-gastric-cancer.---sandoz2023-09-17T12:49:39+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-recommends-a-paediatric-use-marketing-authorisation-for-aqumeldi-intended-for-the-treatment-of-heart-failure-in-children.-proveca-pharma2023-09-17T12:53:24+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-recommends-catiolanze-for-the-reduction-of-elevated-intraocular-pressure-iop-in-patients-with-open-angle-glaucoma-or-ocular-hypertension.santen2023-09-17T12:57:34+00:00weekly0.6https://www.medthority.com/news/2023/9/quizartinib-recommended-for-approval-in-eu-by-chmp-for-patientswith-newly-diagnosed-flt3-itd-positive-aml-.-daiichi-sankyo2023-09-17T13:00:09+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for-kaftrio-for-the-treatment-of-children-with-cystic-fibrosis-cf-ages-2-through-5-years-old-who-have-at-least-one-f508del-mutation.--vertex2023-09-17T13:04:14+00:00weekly0.6https://www.medthority.com/news/2023/9/chmp-positive-for--zoonotic-influenza-vaccine-seqirus-against-h5n1-subtype-of-influenza-a-virus.--seqiruscsl2023-09-17T13:05:02+00:00weekly0.6https://www.medthority.com/news/2023/9/abbbott-to-acquire-bigfooot-biomedical-and-with-it-bigfoot-unity-smart-insulin-management-system/2023-09-17T13:05:53+00:00weekly0.6https://www.medthority.com/news/2023/9/johnson--johnson-makes-name-changes-to-its-pharmaceutical-and-medtech-businesses/2023-09-17T13:06:34+00:00weekly0.6https://www.medthority.com/news/2023/9/aphexda--filgrastim-fda-approved-to-mobilize-hematopoietic-stem-cells-for-collection-and-subsequent-autologous-transplantation-in-patients-with-multiple-myeloma--biolinerx-ltd/2023-09-14T11:57:39+00:00weekly0.6https://www.medthority.com/news/2023/9/avalo-therapeutics-enters-into-an-agreement-with-aug-therapeutics-to-sell-avtx-800-series/2023-09-14T11:59:09+00:00weekly0.6https://www.medthority.com/news/2023/9/skyrizi-met-all-primary-and-secondary-endpoints-versus-stelara-in-head-to-head-study-in-crohns-disease.--abbvie2023-09-14T11:55:36+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-outcome-of-fda-advisory-committee-meeting-on-patisiran-for-the-treatment-of-the-cardiomyopathy-of-attr-amyloidosis.--alnylam-pharma2023-09-14T11:53:50+00:00weekly0.6https://www.medthority.com/news/2023/9/madrigal-pharmaceuticals-announces-nda-acceptance-and-priority-review-of-the-nda-for-resmetirom-for-the-treatment-of-nash-with-liver-fibrosis/2023-09-14T11:42:02+00:00weekly0.6https://www.medthority.com/news/2023/9/nda-submitted-to-fda-for-ox-124-a-high-dose-rescue-medication-for-opioid-overdose.--orexo-ab2023-09-19T12:36:22+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-approves-new-and-updated-indications-for-temozolomide-in-anaplastic-astrocytoma---merck-inc/2023-09-19T12:37:17+00:00weekly0.6https://www.medthority.com/news/2023/9/dsmb-recommends-the-phase-iii-trials-of-simufilam-continue-as-planned-without-modification.--cassava-sciences-inc2023-09-19T12:38:17+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-accepts-bla-for-otl-200-in--metachromatic-leukodystrophy-and-grants-priority-review.-orchard-therapeutics2023-09-19T12:39:56+00:00weekly0.6https://www.medthority.com/news/2023/9/yescarta-demonstrates-high-response-rate-and-durable-remission-in-alycante-study-as-initial-treatment-for-transplant-ineligible-patients-with-rr-large-b-cell-lymphoma.--gilead-sciences2023-09-19T12:42:14+00:00weekly0.6https://www.medthority.com/news/2023/9/completion-of-rolling-nda-submission-to-fda-for-tovorafenib-to-treat--relapsed-or-progressive-pediatric-low-grade-glioma.--day-one-biopharma2023-09-19T12:43:54+00:00weekly0.6https://www.medthority.com/news/2023/9/point-biopharma-collaborates-with-athebio-ag-to-develop-darpin-targeted-radioligands/2023-09-19T12:44:55+00:00weekly0.6https://www.medthority.com/news/2023/9/positive-topline-results-from-second-phase-iii-study-of-onabotulinumtoxina-botox-cosmetic-for-the-treatment-of-platysma-prominence.--allergan-aestheticsabbvie2023-09-20T12:42:44+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-accepts-for-priority-review--snda-for-welireg-belzutifan-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma.--merck-inc2023-09-20T12:45:02+00:00weekly0.6https://www.medthority.com/news/2023/9/european-commission-authorises-apretude-cabotegravir-long-acting-and-tablets-for-hiv-prevention.--viiv-healthcare2023-09-20T12:45:53+00:00weekly0.6https://www.medthority.com/news/2023/9/beigene-regains-full-rights-from-novartis-for-anti-pd-1-antibody-tevimbra-tislelizumab/2023-09-20T12:48:26+00:00weekly0.6https://www.medthority.com/news/2023/9/histogen-enters-voluntary-liquidation/2023-09-20T12:49:24+00:00weekly0.6https://www.medthority.com/news/2023/9/mhra-uk-approves-bimzelx-for-patients-with-active-psoriatic-arthritis-and-adult-patients-with-active-axial-spondyloarthritis.--ucb2023-09-06T12:58:40+00:00weekly0.6https://www.medthority.com/news/2023/9/brixadi-extended-release-injection-for-subcutaneous-use-is-now-available-in-the-u.s.-for-the-treatment-of-moderate-to-severe-opioid-use-disorder.--braeburn2023-09-06T12:55:59+00:00weekly0.6https://www.medthority.com/news/2023/9/travere-therapeutics-completes-sale-of-bile-acid-product-portfolio-to-mirum-pharmaceuticals/2023-09-06T12:52:45+00:00weekly0.6https://www.medthority.com/news/2023/9/mhra-approves-hyftor-for-the-treatment-of-facial-angiofibroma-associated-with-tuberous-sclerosis-complex-.--nobelpharma--plusultra-pharma2023-09-06T12:50:20+00:00weekly0.6https://www.medthority.com/news/2023/9/long-term-follow-up-data-on-sustained-immunogenicity-and-safety-for-gardasil-9-published-in-pediatrics.--merck-inc2023-09-06T12:44:32+00:00weekly0.6https://www.medthority.com/news/2023/9/fda-accepts-bla-for-crovalimab-for-the-treatment-of-paroxysmal-nocturnal-hemoglobinuria-a-rare-life-threatening-blood-condition.--genentechroche2023-09-06T12:41:52+00:00weekly0.6https://www.medthority.com/news/2023/9/mhlw-japan-accepts-for-review-application-for-nucala-to-treat-chronic-rhinosinusitis-with-nasal-polyps.--gsk-2023-09-06T12:39:42+00:00weekly0.6https://www.medthority.com/news/2023/9/complete-response-for-regulatory-review-of-ultomiris-in-the-treatment-of-adult-patients-with-neuromyelitis-optica-spectrum-disorder.--astrazeneca2023-09-06T12:37:12+00:00weekly0.6https://www.medthority.com/news/2023/9/new-post-hoc-analysis-showed-substantial-improvement-in-observed-estimated-glomerular-filtration-rate-egfr-in-transcon-pth-treated-adults-with-hypoparathyroidism--ascendis-pharma-as/2023-09-06T12:35:08+00:00weekly0.6https://www.medthority.com/news/2023/9/biocardia-announces-interim-efficacy-results-in-phase-iii-pivotal-cardiamp-cell-therapy-heart-failure-trial/2023-09-06T12:33:33+00:00weekly0.6https://www.medthority.com/news/2023/9/tivdak-improved-overall-survival-in-patients-with-recurrent-or-metastatic-cervical-cancer-compared-with-chemotherapy-alone.--seagen--genmab2023-09-05T11:29:20+00:00weekly0.6https://www.medthority.com/news/2023/9/calquence-approved-in-china-for-chronic-lymphocytic-leukaemia.--astrazeneca-2023-09-04T13:34:33+00:00weekly0.6https://www.medthority.com/news/2023/8/data-at-mds-international-congress-of-parkinsons-disease-and-movement-disorders-demonstrates-comparable-improvement-over-time-in-tardive--dyskinesia-severity-and-impact-following-treatment-with-ingrezza.--neurocrine-biosciences-inc2023-08-30T12:53:07+00:00weekly0.6https://www.medthority.com/news/2023/8/european-commission-approves-keytruda--trastuzumab--chemotherapy-as-first-line-treatment-for-her2-positive-advanced-gastric-or-gastroesophageal-junction--adenocarcinoma-expressing-pd-l1-.-_-merck-inc2023-08-30T12:52:28+00:00weekly0.6https://www.medthority.com/news/2023/8/tecentriq-becomes-the-first-subcutaneous-anti-pd-l1-cancer-immunotherapy-available-to-patients-in-great-britain-reducing-treatment-time-to-just-minutes.--roche2023-08-30T12:51:47+00:00weekly0.6https://www.medthority.com/news/2023/8/zealand-pharma-announces-designation-of-priority-review-by-the-fda-for-dasiglucagon-in-congenital-hyperinsulinism/2023-08-30T12:51:09+00:00weekly0.6https://www.medthority.com/news/2023/8/topline-results-from-lelantos-2-a-phase-iii-clinical-study-of-pamrevlumab-in-ambulatory-duchenne-muscular-dystrophy.-2023-08-30T12:50:34+00:00weekly0.6https://www.medthority.com/news/2023/8/northwest-biotherapeutics-announces-completion-of-prerequisites-and-plans-for-submission-of-maa-to-mhra-for-approval-of-dcvax-l-treatment-of-glioblastoma/2023-08-30T12:49:56+00:00weekly0.6https://www.medthority.com/news/2023/8/complete-response-letter-for--lytenava--bevacizumab-biosimilar-to-treat-wet-age-related-macular-degeneration.-outlook-therapeutics2023-08-31T11:42:26+00:00weekly0.6https://www.medthority.com/news/2023/8/chmp-recommends-approval-of-omicron-xbb.1.5-adapted-monovalent-covid-19-vaccine-for-coronavirus.--pfizer-and-biontech-se2023-08-31T11:37:50+00:00weekly0.6https://www.medthority.com/news/2023/8/biomarin-announces-first-person-treated-commercially-with-roctavian--for-severe-hemophilia-a-in-europe.-2023-08-31T11:35:15+00:00weekly0.6https://www.medthority.com/news/2023/8/livanova-unveils-essenz-in-line-blood-monitor-with-fda-510k-clearance-and-ce-mark/2023-08-31T11:29:15+00:00weekly0.6https://www.medthority.com/news/2023/9/presentation-of-data-comprising-the-clinical-package-for-the-otl-200-bla-in-metachromatic-leukodystrophy-at-the-ssiem-annual-symposium-2023.--orchard-therapeutics2023-09-01T11:17:15+00:00weekly0.6https://www.medthority.com/news/2023/9/phase-iii-ctj101pghd301-study-of-gx-h9-meets-primary-endpoint-in-growth-hormone-deficiency.--genexine2024-05-13T10:45:19+00:00weekly0.6https://www.medthority.com/news/2023/9/alecensa-delivers-unprecedented-phase-iii-results-for-people-with-alk-positive-early-stage-lung-cancer.-roche2025-02-03T14:16:03+00:00weekly0.6https://www.medthority.com/news/2023/9/zevra-therapeutics-to-acquire-acer-therapeutics/2023-09-01T11:44:20+00:00weekly0.6https://www.medthority.com/news/2023/9/sage-therapeutics-implements-strategic-reorganization-to-support-plans-for-zurzuvaecommercial-launch-and-pipeline-advancement/2023-09-01T11:51:13+00:00weekly0.6https://www.medthority.com/news/2023/9/regulatory-applications-submitted--to-fda-and-ema-for-skyrizi-in-ulcerative-colitis.--abbvie2023-09-03T15:06:12+00:00weekly0.6https://www.medthority.com/news/2023/9/journal-of-cosmetic-dermatology-publishes-data-demonstrating-patient-satisfaction-with-natural-looking-outcomes-following-treatment-with-botox-cosmetic.--allergan-aesthetics2023-09-03T15:05:19+00:00weekly0.6https://www.medthority.com/news/2023/9/biomag-i-study-optical-coherence-tomography-analysis-confirmed-that-dreams-3g-resorbable-magnesium-scaffold-resorbed-at-12-months.--biotronik2024-09-30T13:57:52+00:00weekly0.6https://www.medthority.com/news/2023/9/otsuka-to-acquire-mindset-pharma-inc/2023-09-03T15:03:17+00:00weekly0.6https://www.medthority.com/news/2023/9/bavarian-nordic-provides-update-on-covid-19-booster-vaccine-program/2023-09-03T15:02:18+00:00weekly0.6https://www.medthority.com/news/2023/9/apellis-pharma-to-restructure/2025-10-16T11:22:44+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-results-from-phase-iii-cabinet-pivotal-trial-evaluating-cabozantinib-in-advanced-pancreatic-and-extra-pancreatic-neuroendocrine-tumors.--exelixis2023-08-25T11:43:12+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-advisory-committee-recommends-paradise--ultrasound-renal-denervation-rdn-system-indicated-to-reduce-blood-pressure-in-patients-with-hypertension.--recor-medical-inc--otsuka2023-08-25T11:45:07+00:00weekly0.6https://www.medthority.com/news/2023/8/eu-approves-abrysvo-for-respiratory-syncytial-virus.--pfizer2023-08-25T11:47:00+00:00weekly0.6https://www.medthority.com/news/2023/8/results-of-phase-iv-trial-zoster-076-of-shingrix-shows-efficacy-and-safety-in-herpes-zoster.--gsk-2023-08-25T11:48:57+00:00weekly0.6https://www.medthority.com/news/2023/8/phase-iii-results-from-rise-pd-clinical-study-of-ipx-203-in-parkinsons-disease-published-in-jama-neurology.--amneal-pharmaceuticals2023-08-25T11:50:10+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-tyruko-first-and-only-fda-approved-biosimilar-for-relapsing-forms-of-multiple-sclerosis.--sandoz2023-08-25T11:52:16+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-veklury-to-treat-covid-19-in-people-with-mild-to-severe-hepatic-impairment-with-no-dose-adjustment-gilead-sciences/2023-08-25T11:54:40+00:00weekly0.6https://www.medthority.com/news/2023/8/mhlw-approval-of-lumicef-forpalmoplantar-pustulosis-in-japan.--kyowa-kirin-co.-ltd2023-08-26T14:55:01+00:00weekly0.6https://www.medthority.com/news/2023/8/inceptiv-spinal-cord-stimulator-with-closed-loop-sensing-to-treat-chronic-pain-receives-ce-mark.--medtronic-plc2023-08-26T14:54:19+00:00weekly0.6https://www.medthority.com/news/2023/8/merck-inc.-initiates-phase-iii-clinical-program-for-oral-pcsk9-inhibitor-candidate-mk-0616-for-the-treatment-of-hypercholesterolemia2023-08-26T14:53:33+00:00weekly0.6https://www.medthority.com/news/2023/8/retrospective-observational-study-assessing-real-world-clinical-impact-of-switching-or-continuing-eliquis-or-rivaroxaban-presented-at-the-european-society-of-cardiology-esc-congress-2023.--bms--pfizer2023-08-26T14:52:48+00:00weekly0.6https://www.medthority.com/news/2023/8/update-on-phase-iii-leap-010-trial-evaluating-keytruda--lenvima-in-patients-with-certain-types-of-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma.--merck-inc.--eisai2023-08-26T14:52:06+00:00weekly0.6https://www.medthority.com/news/2023/8/results-from-the-phase-iii-step-hfpef-trial-showing-that-compared-with-placebo-once-weekly-semaglutide-2.4-mg-led-to-large-reductions-in-heart-failure-related-symptoms.--novo-nordisk2023-08-26T14:50:52+00:00weekly0.6https://www.medthority.com/news/2023/8/late-breaking-phase-ii-olpasiran-data-from-oceana-dose-study-is-presented-at-european-society-of-cardiology-annual-meeting.--amgen2023-08-28T12:01:39+00:00weekly0.6https://www.medthority.com/news/2023/8/expanded-approval-request-filed-with-fda-for-rybrevant-in-non-small-cell-lung-cancer-egfr.--janssen-pharma2023-08-28T12:00:58+00:00weekly0.6https://www.medthority.com/news/2023/8/phase-iii-clear-study-of-nexletol-supports-long-term-use-in-patients-at-high-risk-of-cardiovascular-events-and-in-those-with-diabetes-with-data-presented-at-esc-2023.--daiichi-sankyo2023-08-28T12:00:20+00:00weekly0.6https://www.medthority.com/news/2023/8/results-from-phase-iii-heart-fid-trial-of-injectafer-in-iron-deficiency-plus-hfref-fail-to-meet-endpoint-and-presented-at-esc-2023-and-published-in-nejm.--american-regentdaiichi-sankyo2023-08-28T11:59:42+00:00weekly0.6https://www.medthority.com/news/2023/8/additional-studies-with-finerenone-across-a-wide-range-of-heart-failure-patients-initiated.--bayer2023-08-28T11:59:03+00:00weekly0.6https://www.medthority.com/news/2023/8/farapulse-pulsed-field-ablation-system-meets-primary-efficacy-and-safety-endpoints-in-advent-clinical-trial--boston-scientific/2024-09-30T11:40:02+00:00weekly0.6https://www.medthority.com/news/2023/8/pafsc-in-japan-endorses-lecanemab-for-slowing-the-progression-of-mild-cognitive-impairment-due-to-alzheimers-disease.-eisai2023-08-28T11:57:28+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-grants-priority-review-for-xtandi-in-non-metastatic-castration-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence.-astellas--pfizer2023-08-28T11:56:49+00:00weekly0.6https://www.medthority.com/news/2023/8/mallinckrodt-initiates-chapter-11-bankruptcy-proceedings/2023-08-28T11:56:11+00:00weekly0.6https://www.medthority.com/news/2023/8/new-long-term-leqvio-data-from-orion-8-study-presented-at-esc-congress-demonstrates-consistent-efficacy-and-safety-beyond-six-years.-novartis2023-08-29T12:39:00+00:00weekly0.6https://www.medthority.com/news/2023/8/phase-iii-engot-ov50--gog-3029--innovate-3-clinical-trial-of-tumor-treating-fields-fails-to-meet-endpoint-in-ovarian-cancer.--novocure2023-08-29T12:38:19+00:00weekly0.6https://www.medthority.com/news/2023/8/long-term-follow-up-data-from-two-phase-iii-studies-of-camzyos--demonstrate-consistent-and-durable-response-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-.--bms2023-08-29T12:37:36+00:00weekly0.6https://www.medthority.com/news/2023/8/european-commission-approves-evrysdi-for-babies-under-two-months-old-with-spinal-muscular-atrophy-sma.--roche2023-08-29T12:36:56+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-reblozyl-as-first-line-treatment-of-anemia-in-adults-with-lower-risk-myelodysplastic-syndromes-who-may-require-transfusions.-bms2023-08-29T12:36:14+00:00weekly0.6https://www.medthority.com/news/2023/8/ema-accepts-maa-for-avacincaptad-pegol-for-the-treatment-of-geographic-atrophy-ga-secondary-to-age-related-macular-degeneration.-astellas-2023-08-22T11:53:21+00:00weekly0.6https://www.medthority.com/news/2023/8/ema-accepts-marketing-authorization-application-for-delgocitinib-cream-in-chronic-hand-eczema.--leo-pharma2023-08-22T12:02:17+00:00weekly0.6https://www.medthority.com/news/2023/8/amgen-to-discuss-application-for-full-approval-for-lumakras-to-treat-kras-g12c-positive-nsclc-at-fda-advisory-committee-meeting-/2023-08-22T12:03:54+00:00weekly0.6https://www.medthority.com/news/2023/8/leo-pharma-to-acquire-timber-pharmaceuticals--and-with-it-tmb-001-for-congenital-ichthyosis/2023-08-22T12:05:27+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-abrysvo-vaccine-for-the-prevention-of-respiratory-syncytial-virus-rsv-in-infants-though-active-immunization-of-pregnant-individuals-32-36-weeks-of-gestational-age.-pfizer2023-08-23T11:25:08+00:00weekly0.6https://www.medthority.com/news/2023/8/eu-conditionally-approves-talvey-in-relapsed-and-refractory-multiple-myeloma.--janssen-pharma2023-08-23T11:21:01+00:00weekly0.6https://www.medthority.com/news/2023/8/eu-approves-opdivo-monotherapy-as-adjuvant-treatment-for-stage-iib-or-iic-melanoma.--bms2023-08-23T11:19:07+00:00weekly0.6https://www.medthority.com/news/2023/8/mhra-approval-of-pombiliti--opfolda-to-treat-late--onset-pompe-disease--in-the-united-kingdom.--amicus-therapeutics2023-08-23T11:16:22+00:00weekly0.6https://www.medthority.com/news/2023/8/retevmo-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer.--eli-lilly2023-08-23T11:14:13+00:00weekly0.6https://www.medthority.com/news/2023/8/roche-provides-update-on-phase-iii-skyscraper-01-study-in-pd-l1-high-metastatic-non-small-cell-lung-cancer/2025-02-03T14:16:21+00:00weekly0.6https://www.medthority.com/news/2023/8/pdufa-date-announced-for-imetelstat-nda-in-lower-risk-myelodysplastic-syndromes.--geron-corporation2023-08-24T11:24:16+00:00weekly0.6https://www.medthority.com/news/2023/8/apellis-provides-updates-on-injection-kits-and-rare-safety-events-with-synfovre-/2023-08-24T11:26:26+00:00weekly0.6https://www.medthority.com/news/2023/8/lynparza--abiraterone-approved-in-japan-for-the-treatment-of-brca-mutated-metastatic-castration-resistant-prostate-cancer-.--astrazeneca--merck-inc2023-08-24T11:30:12+00:00weekly0.6https://www.medthority.com/news/2023/8/soliris-approved-in-japan-for-paediatric-patients-with-generalised-myasthenia-gravis-gmg-.--astrazeneca2023-08-24T11:33:41+00:00weekly0.6https://www.medthority.com/news/2023/8/medtronic-issues-statement-on-the-fda-circulatory-systems-devices-advisory-panel-vote-for-the-symplicity-spyral-renal-denervation-system/2023-08-24T11:37:25+00:00weekly0.6https://www.medthority.com/news/2023/8/mallinckrodt-to-enter-restructuring-support-scheme-and-chapter-11-proceedings/2023-08-24T11:40:55+00:00weekly0.6https://www.medthority.com/news/2023/8/survodutide-to-advance-into-three-global-phase-iii-studies-in-obesity.--boehringer2023-08-18T11:22:10+00:00weekly0.6https://www.medthority.com/news/2023/8/first-implant-of-amvia-sky-in-europe-the-worlds-first-pacemaker-approved-for-left-bundle-branch-area-pacing--biotronik/2024-09-30T10:48:21+00:00weekly0.6https://www.medthority.com/news/2023/8/precision-biosciences-completes-strategic-transaction-with-imugene-for-azer-cel-in-cancer/2023-08-18T11:27:25+00:00weekly0.6https://www.medthority.com/news/2023/8/chinas-nmpa-approves-sintbilo-for-primary-hypercholesterolemia-and-dyslipidemia.--innovent-biologics2023-08-18T11:29:45+00:00weekly0.6https://www.medthority.com/news/2023/8/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsedrefractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma.--regeneron2023-08-18T11:31:34+00:00weekly0.6https://www.medthority.com/news/2023/8/eu-approves-aquipta-for-prophylaxis-of-migraine.--abbvie2025-02-03T14:16:41+00:00weekly0.6https://www.medthority.com/news/2023/8/forxiga-approved-in-china-to-reduce-the-risk-of-cardiovascular-death-and-hospitalisation-in-adult-patients-with-symptomatic-chronic-heart-failure-.--astrazeneca2023-08-18T11:40:06+00:00weekly0.6https://www.medthority.com/news/2023/8/trial-data-confirms-updated-covid-19-vaccine-generates-robust-immune-response-in-humans-against-widely-circulating-variants.--moderna-inc2023-08-18T11:41:54+00:00weekly0.6https://www.medthority.com/news/2023/8/gilead-and-tentarix-to-discover-and-develop-novel-therapies-to-address-unmet-medical--needs-across-cancer-and-inflammation/2023-08-18T11:44:05+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-first-therapeutic-indication-for-daxxify-for-injection-for-the-treatment-of-cervical-dystonia.--revance-therapeutics2023-08-21T07:09:53+00:00weekly0.6https://www.medthority.com/news/2023/8/welireg-phase-iii-litespark-005-trial-met-primary-endpoint-of-progression-free-survival-in-certain-previously-treated-patients-with-advanced-renal-cell-carcinoma.-merck-inc2023-08-21T07:09:11+00:00weekly0.6https://www.medthority.com/news/2023/8/congenital-thrombotic-thrombocytopenic-purpura-therapy-adamts-13-tak-755-is-filed--in-japan.--takeda2023-08-21T07:08:29+00:00weekly0.6https://www.medthority.com/news/2023/8/eu-grants-type-ii-variation-approval-for-tecvayli-in-multiple-myeloma.--janssen-pharma2023-08-21T07:07:47+00:00weekly0.6https://www.medthority.com/news/2023/8/nice-recommends-pombiliti-for-treatment-of-pompe-disease-in-adults.--amicus-therapeutics2023-08-21T07:07:09+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approval-for-eylea-hd-to-treat-wet-age-related-macular-degeneration-wamd-diabetic-macular-edema-dme-and-diabetic-retinopathy-.--regeneron2023-08-21T07:06:33+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approval-for-ingrezza-capsules-for-the-treatment-of-chorea-associated-with-huntingtons-disease.--neurocrine-biosciences-inc2023-08-21T07:05:43+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-veopoz-as-the-first-treatment-for-children-and-adults-with-chaple-disease.-regeneron2023-08-21T07:04:59+00:00weekly0.6https://www.medthority.com/news/2023/8/health-canada-approves-arexvy-to-prevent-respiratory-syncytial-virus-rsv-related-lower-respiratory-tract-disease-lrtd-in-people-aged-60-years-and-above.--gsk2023-08-21T07:04:14+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-results-are-announced-from-phase-iii-contact-02-pivotal-trial-evaluating-cabozantinib--atezolizumab-in-metastatic-castration-resistant-prostate-cancer.-exelixis--ipsen2025-05-06T14:07:19+00:00weekly0.6https://www.medthority.com/news/2023/8/updated-results-from-on-going-potentially-pivotal-study-of-berubicin-in-adult-patients-with-recurrent-glioblastoma-multiforme-after-failure-of-standard-first-line-therapy.--cns-pharma2023-08-16T12:12:46+00:00weekly0.6https://www.medthority.com/news/2023/8/harmony-biosciences-to-acquire-zynerba-pharma-and-with-it-zygel-which-is-in-phase-iii-for-fragile-x-syndrome/2023-08-16T12:15:36+00:00weekly0.6https://www.medthority.com/news/2023/8/updated-data-from-trident-1-trial--show-durable-efficacy-benefits-with-repotrectinib-for-patients-with-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer.--bms2025-02-03T14:16:56+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-has-communicated-that-an-advisory-committee-meeting-will-not-be-scheduled-for-lovotibeglogene-autotemcel-for-treatment-of-sickle-cell-disease.-bluebird-bio2023-08-17T11:14:52+00:00weekly0.6https://www.medthority.com/news/2023/8/pdufa-date-extension-for-vla-1553-chikungunya-virus-vaccine-candidate.-valneva-se2023-08-17T11:16:25+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-sohonos-capsules-the-first-and-only-treatment-for-people-with-fibrodysplasia-ossificans-progressiva.--ipsen2023-08-17T11:20:09+00:00weekly0.6https://www.medthority.com/news/2023/8/elrexfio-receives-fda-accelerated-approval-for-relapsed-or-refractory-multiple-myeloma.-pfizer2023-08-17T11:23:22+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-results-from-mylight-phase-lll-study-for-biosimilar-aflibercept.--sandoz2023-08-15T11:51:28+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approval-of-hepzato-kit-for-the-treatment-of-adult-patients-with-unresectable-hepatic-dominant-metastatic-uveal-melanoma.--delcath-systems2023-08-15T11:53:45+00:00weekly0.6https://www.medthority.com/news/2023/8/publication-of-vx-548-positive-phase-ii-proof-of-concept-results-in-new-england-journal-of-medicine.--vertex2023-08-05T22:45:58+00:00weekly0.6https://www.medthority.com/news/2023/8/rolling-submission-of-otl-200-to-fda--completed-for-metachromatic-leukodystrophy.--orchard-therapeutics2023-08-05T22:46:23+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-lonsurf-plus-bevacizumab--for-metastatic-colorectal-cancer.--taiho-oncology-and-taiho-pharma2023-08-06T00:08:41+00:00weekly0.6https://www.medthority.com/news/2023/8/us-cdc-recommends-beyfortus-for-prevention-of-respiratory-syncytial-virus.--sanofi-and-astrazeneca2023-08-06T00:12:38+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-expanded-indication-for-ervebo-in-zaire-ebolavirus.--merck-inc2023-08-06T00:13:12+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-izervay-for-geographic-atrophy.--astellasiveric2023-08-07T12:02:13+00:00weekly0.6https://www.medthority.com/news/2023/8/sunlenca-approved-in-japan-for-the-treatment-of-multi-drug-resistant-hiv-1-infection.--gilead-sciences2023-08-07T12:03:55+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-results-from-phase-iii-trial-of-virus-like-particle-vlp-based-chikungunya-virus-vaccine-candidate-chikv-vlp-.--bavarian-nordic2023-08-08T11:50:55+00:00weekly0.6https://www.medthority.com/news/2023/8/european-commission-approves-ztamly-for-the-adjunctive-treatment-of-epileptic-seizures-associated-with-cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder.--marinus-pharma2023-08-08T11:48:20+00:00weekly0.6https://www.medthority.com/news/2023/8/positive-top-line-results-from-phase-iii-palisade-2-trial-of-fasedienol--nasal-spray-in-social-anxiety-disorder.--vistagen2023-08-09T11:36:15+00:00weekly0.6https://www.medthority.com/news/2023/8/wegovy-reduces-the-risk-of-major-adverse-cardiovascular-events-by-20-in-adults-with-overweight-or-obesity-in-the-select-trial-novo-nordisk/2023-08-09T11:34:14+00:00weekly0.6https://www.medthority.com/news/2023/8/remibrutinib-phase-iii-trials-met-their-primary-endpoints-and-showed-rapid-symptom-control-in-chronic-spontaneous-urticaria---novartis/2023-08-09T11:31:27+00:00weekly0.6https://www.medthority.com/news/2023/8/bristol-myers-squibb-launches-clear-understanding-campaign-to-reveal-the-plain-truth-about-living-with-moderate-to-severe-plaque-psoriasis/2023-08-10T11:12:00+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approval-for-the-polarx-cryoablation-system--for-the-treatment-of-patients-with-paroxysmal-atrial-fibrillation-.--boston-scientific2024-09-30T11:42:09+00:00weekly0.6https://www.medthority.com/news/2023/8/complete-response-from-fda-for-avasopasem-manganese-in-radiotherapy-induced-severe-oral-mucositis-.-galera-therapeutics2023-08-10T11:16:55+00:00weekly0.6https://www.medthority.com/news/2023/8/regeneron-pharma-acquires-decibel-therapeutics-and-with-it-db-oto/2023-08-10T11:19:53+00:00weekly0.6https://www.medthority.com/news/2023/8/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years.--bayer2023-08-12T21:02:46+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-talvey-a-first-in-class-bispecific-therapy-for-the-treatment-of-patients-with-heavily-pretreated-multiple-myeloma.-janssen-pharma2023-08-12T21:03:13+00:00weekly0.6https://www.medthority.com/news/2023/8/arcutis-and-huadong-announce-strategic-collaboration-and-licensing-agreement-for-topical-roflumilast-in-greater-china-and-southeast-asia/2023-08-12T21:03:58+00:00weekly0.6https://www.medthority.com/news/2023/8/novo-nordisk-acquires-inversago-and-with-it-inv-202/2023-08-12T21:04:38+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-approves-akeega-the-first-and-only-dual-action-tablet-for-the-treatment-of-patients-with-brca-positive-metastatic-castration-resistant-prostate-cancer.--janssen2023-08-14T11:30:25+00:00weekly0.6https://www.medthority.com/news/2023/8/fda-grants-regular-approval-to-gavreto-for-adult-patients-with-metastatic-ret-fusionpositive-nonsmall-cell-lung-cancer-as-detected-by-an-fda-approved-test.--blueprint-medicines--genentechroche2023-08-14T11:29:06+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-update-of-the--product-label-for-zilretta-for-treatment-of-osteoarthritis-knee-pain.--flexion-therapeutics2021-12-20T17:31:41+00:00weekly0.6https://www.medthority.com/news/2019/12/results-of-phase-iii-sunrise-1-study-of-dayvigo-in-insomnia-published-in-jama-network-open-journal.--eisai2024-10-24T12:41:17+00:00weekly0.6https://www.medthority.com/news/2019/12/johnson--johnson-acquires-taris-biomedical-specialist-in-drug-delivery-technology-for-bladder-diseases-and-with-lead-product-tar-200/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-lynparza-for-the-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-adenocarcinoma--astrazeneca--merck-inc/2024-11-12T14:03:39+00:00weekly0.6https://www.medthority.com/news/2020/01/eli-lilly-initiates-libretto-531-phase-iii-clinical-trial-for-loxo-292-to-treat-ret-mutant-medullary-thyroid-cancer/2024-10-24T11:21:34+00:00weekly0.6https://www.medthority.com/news/2020/01/lumoxiti-filed-maa-at-ema-to-treathairy-cell-leukemia.-innate-pharma2024-10-24T12:41:26+00:00weekly0.6https://www.medthority.com/news/2020/01/neovasc-inc.-files-premarket-approval-application--to-fda-for--neovasc-reducer-medical-device-for-the-treatment-of-refractory-angina2024-11-07T16:10:03+00:00weekly0.6https://www.medthority.com/news/2020/01/top-line-results-from-phase-iii-b-simple-program-of-sb-206-for-the-treatment-of-molluscum-contagiosum.--novan-inc2024-11-08T08:42:31+00:00weekly0.6https://www.medthority.com/news/2020/01/itacitinib-fails-to-meet-primary-endpoint-in-phase-iii-gravitas-301-study-to-treatgraft-versus-host-disease.--incyte-corpn2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/01/the-national-institute-for-health-and-care-excellence-nice-recommends-that--tecentriq-in-combination-with-carboplatin-and-etoposide-should-not-be-made-available-for-untreated-extensive-stage-small-cell-lung-cancer-in-adults.--genentechroche2021-12-20T17:30:40+00:00weekly0.6https://www.medthority.com/news/2020/01/melinta-therapeutics-enters-voluntary-bankrupcy2/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2020/01/the-national-institute-for-health-and-care-excellence--refuses-recommendation-for-waylivra-to-treat-familial-chylomicronaemia-syndrome.--akcea-therapeutics2024-10-24T11:21:43+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-tobacco-products-scientific-advisory-committee-will-conduct-a-public-hearing-regarding-22nd-century-groups-modified-risk-tobacco-product-application-for-its-vln-cigarettes/2024-11-08T08:42:44+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-vascepa-to-reduce-the-risk-of-cv-events.--hls-therapeutics2024-10-24T12:41:40+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-javelin-bladder-100-study-met-its-primary-endpoint-to-treaturothelial-carcinoma-.--merck-kgaa--pfizer2024-10-24T12:42:05+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-snda-for-farxiga-to-reduce-the-risk-of-cardiovascular-cv-death-or-the-worsening-of-heart-failure-.-astrazeneca2021-12-20T17:30:40+00:00weekly0.6https://www.medthority.com/news/2020/01/ema-validates-maa-for-pemigatinib-in-patients-with-cholangiocarcinoma.--incyte-2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-keynote-604-trial-of-keytruda-plus-chemo-meets-primary-endpoint-in-small-cell-lung-cancer.--merck-inc2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/01/exparel-achieves-primary-and-key-secondary-endpoints-in-phase-iv-choice-study-in-cesarean-section-patients.--pacira-biosciences-inc2024-11-08T08:41:38+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-expanded-indication-for-the-use-of-the-urolift-system-to-treat-larger-prostates-between-80cc-and-100cc.-teleflex-incorporated2024-10-24T12:42:24+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-rinvoq-for-treatment-of-rheumatoid-arthritis-patients-who-have-had-an-inadequate-response-or-intolerance-to-methotrexate-mtx.--abbvie2024-10-24T13:10:40+00:00weekly0.6https://www.medthority.com/news/2020/01/apellis-reports-positive-top-line-results-from-phase-iii-pegasus-head-to-head-study-of-pegcetacoplan-compared-to-eculizumab-for-paroxysmal-nocturnal-hemoglobinuria/2024-10-24T13:11:00+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-less-invasive-surgical-approach-for-abbotts-heartmate-3-to-help-patients-avoid-open-heart-surgery.--abbott2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/01/galecto-to-merge-with-pharmakcea-inc/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2020/01/completion-of-patient-screening-in-phase-iii-trial-of-roluperidone-to-treat-negative-symptoms-in-schizophrenia.--minerva-neurosciences2024-10-24T12:42:36+00:00weekly0.6https://www.medthority.com/news/2020/01/accelerated-enrollment-of--phase-iii-pegasus-pivotal-trial-of-prn-1008-to-treat-pemphigus-vulgaris.---principia-biopharma-inc2024-11-08T08:44:14+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-keytruda-to-treat--bacillus-calmette-guerin-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ---merck-inc/2022-01-11T20:49:00+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-snda-for-mycamine-in-candidemia-acute-disseminated-candidiasis-candida-peritonitis-and-abscesses-for-pediatric-patients.--astellas2024-11-08T08:41:53+00:00weekly0.6https://www.medthority.com/news/2020/01/abbvie-creates-allergan-aesthetics-for-development-and-marketing-of-aesthetic-products2/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2020/01/nejm-publishes-medalist-study-results-for-reblozyl-to-treat--anemia-in-myelodysplastic-syndromes.-bms--acceleration-pharma-2024-11-08T08:42:11+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-ayvakit-to-treat--unresectable-or-metastatic-gastrointestinal-stromal-tumor.--blueprint-medicines2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/01/eli-lilly-to-acquire-dermira-and-with-it-lebrikizumab-a-treatment-for-atopic-dermatitis/2021-09-24T07:11:53+00:00weekly0.6https://www.medthority.com/news/2020/01/alnylam-pharmaceuticals-initiates-a-rolling-submission-to-the-fda-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-/2024-10-24T13:11:18+00:00weekly0.6https://www.medthority.com/news/2020/01/morphosys-and-incyte-sign-global-collaboration-and-license-agreement-for-tafasitamab/2024-10-24T12:42:45+00:00weekly0.6https://www.medthority.com/news/2020/01/lynparza-filed-sbla-at-fda-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer.-astrazeneca--merck-inc2021-12-20T17:30:39+00:00weekly0.6https://www.medthority.com/news/2020/01/tyvyt--alimta----platinum-met-primary-endpoint-in-phase-iii-orient-11-study-as-first-line-therapy-in-nonsquamous-nsclc.-eli-lilly--innovent-biologics2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/01/mirror-open-label-study-of-krystexxa-shows-response-in-gout.--horizon-therapeutics2024-11-08T08:44:31+00:00weekly0.6https://www.medthority.com/news/2020/01/crysvita-submitted-to-fda-in-sbla-for-hypophosphatemia-associated-with-phosphaturic-mesenchymal-tumors.--ultragenyx-pharmaceutical-and-kyowa-kirin2024-10-24T12:38:31+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-valtoco-for-frequent-seizure-activity-in-epilepsy.--neurelis-2021-12-20T17:30:39+00:00weekly0.6https://www.medthority.com/news/2020/01/independent-data-monitoring-committee-has-recommended-to-discontinue-the-strength--trial-as-epanova-is-unlikely-to-demonstrate-a-benefit.---astrazeneca2024-11-08T08:44:44+00:00weekly0.6https://www.medthority.com/news/2020/01/tazarotene-0.045-lotion-positive-for-the-once-daily-treatment-of-moderate-to-severe-acne-vulgaris-in-adult-males.--bausch-health--ortho-dermatologics2024-11-08T08:45:04+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-trial-of-skyrizi-meets-all-endpoints-in-plaque-psoriasis.--abbvie2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/01/abbott-to-initiate-repair-mr-trial--of-mitraclip-for-people-with-primary-mitral-regurgitation-eligible-for-open-heart-surgery/2024-10-24T12:38:41+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-advisory-committee-does-not-recommend-oxycodegol--nktr-181-as-a-treatment-for-chronic-pain-and-the-drug-is-withdrawn.--nektar-therapeutics2024-10-24T12:39:39+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-filing-of-opdivo--yervoy-combination-to-treat--first-line--metastatic-or-recurrent-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations.--bms2021-12-20T17:30:41+00:00weekly0.6https://www.medthority.com/news/2020/01/acasti-pharma-inc-reports-results-for-trilogy-1-phase-iii-trial-of-capre-for-the-treatment-of-severe-hypertriglyceridemia-/2024-11-08T08:46:54+00:00weekly0.6https://www.medthority.com/news/2020/01/biontech-acquires-neon-therapeutics-and-neo-ptc-01-a-personalised-neoantigen-targeted-t-cell-therapy/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-keytruda-as-a-treatment-of-head-and-neck-cancer.-merck-inc2021-12-20T17:30:39+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-xospata-to-treat-aml-with-flt3-mutations--astellas2/2024-10-24T12:39:47+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-recommends-lynparza-for-maintenance-treatment-of-relapsed-platinum-sensitive-high-grade-epithelial-ovarian-fallopian-tube-or-peritoneal-cancer-if-they-have-a-brca1-or-brca2-mutation-brcam.--astrazeneca--merck-inc2021-12-20T17:30:39+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-ozempic-for-type-2-diabetes--cv-risks.--novo-nordisk2024-10-24T13:11:37+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-label-extension--for-ozempic-for-reduction-of-risk-of-major---adverse-cardiovascular-events-in-type-2-diabetes.--novo-nordisk2024-10-24T13:11:50+00:00weekly0.6https://www.medthority.com/news/2020/01/the-pdufa-date-for-fda-review-of-ocaliva-to-treat-nash-is-extended-to-26-june-2020.--intercept-pharma2024-10-24T14:06:23+00:00weekly0.6https://www.medthority.com/news/2020/01/durect-corporation-announces-the-outcome-of--the-fda-advisory-committee-meeting-for-posimir-which-resulted-in-a-split-vote-on-the-treatment-of-post-surgical-pain-/2024-11-07T16:12:05+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approval-for-isturisa-for-the-treatment-of-people-with-endogenous-cushings-syndrome.--recordati2024-10-24T13:12:02+00:00weekly0.6https://www.medthority.com/news/2020/01/fda--advisory-committees-again-reject-aximris-xr-for-the-management-of-pain.---intellipharmaceutics-international-inc2024-10-24T13:12:15+00:00weekly0.6https://www.medthority.com/news/2020/01/aquestive-therapeutics-receives-fda-response-to-citizens-petitionthat-the-fda-stay-approval-of-a-nda--for-valtoco--diazepam-nasal-spray-submitted-by-neurelis-inc/2021-12-20T17:31:49+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-vitrakvi-to-treat-neurotrophic-tyrosine-receptor-kinase-fusion-positive-solid-tumours.--bayer-healthcare2024-10-24T12:42:58+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approval-for-mayzent-to-treat-secondary-progressive-multiple-sclerosis.--novartis2021-12-20T17:31:46+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approves-sunosito-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adults-with-narcolepsy-jazz-pharma/2024-10-24T13:12:29+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-filing-of-nda-for-lynparzafor-patients-with-metastatic-castration-resistant-prostate-cancer-.-astrazeneca--merck-inc2024-10-24T13:12:40+00:00weekly0.6https://www.medthority.com/news/2020/01/leo-pharma-withdraws-picato-a-treatmemt-for-actinic-keratosis-in-the-eu/2024-11-07T16:12:13+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-approves-darzalex--velcade--thalomid--dexamethasone-in-newly-diagnosed-multiple-myeloma.--genmab2021-12-20T17:31:46+00:00weekly0.6https://www.medthority.com/news/2020/01/idmc-recommends-early-halt-of-phase-iii-sanet-p-study-of-hmpl-012-in-neuroendocrine-tumors--pancreatic.--hutchison-china-meditech2024-10-24T13:12:50+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-grants-conditional-approval-of-polivy--mabthera--bendamustine-for-diffuse-large-b-cell-lymphoma.--roche2021-12-20T17:31:49+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-priority-review-to-gsk-2857916-in-relapsed-or-refractory-multiple-myeloma.--glaxosmithkline2021-12-20T17:30:42+00:00weekly0.6https://www.medthority.com/news/2020/01/positive-interim-results-from-phase-iii-trial-of-tislelizumab-in-patients-with-first-line-squamous-nsclc.--beigene2021-12-20T17:31:46+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-tepezza-to-treat-thyroid-eye-disease.--horizon-therapeutics2024-10-24T12:43:59+00:00weekly0.6https://www.medthority.com/news/2020/01/jzp-258-filed-with-fda-for-cataplexy-and-excessive-daytime-sleepiness.--jazz-pharma2024-10-24T12:44:24+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-tagrisso-in-first-line-non-small-cell-lung-cancer---astrazeneca2/2024-11-08T08:47:17+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-does-not-recommend-stelara-to-treat-ulcerative-colitis.--janssen2021-12-20T17:31:49+00:00weekly0.6https://www.medthority.com/news/2020/01/dayvigo-is-approved-in-japan-to-treat-insomnia.-eisai2024-10-24T12:44:37+00:00weekly0.6https://www.medthority.com/news/2020/01/additional-indications-in-japan-for-fycompa-for-partial-onset-seizures.-eisai2021-12-20T17:30:40+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-optic-clinical-trial-evaluating-tepezza-for-thyroid-eye-disease-is-published-in-nejm.--horizon-therapeutics2024-11-07T16:12:30+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-accelerated-approval-for-tazervik--to-treat-metastatic-or-locally-advanced-epithelioid-sarcoma-.--epizyme-inc2024-10-24T13:13:02+00:00weekly0.6https://www.medthority.com/news/2020/01/tecentriq-fails-in-phase-iii-imvigor010-study-as-an-adjuvant-after-surgery-monotherapy-compared-to-observation-in-people-with-muscle-invasive-urothelial-cancer-.-genentechroche2024-11-08T08:47:43+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-akp01-study-of-akvano-shows-efficacy-in-plaque-psoriasis.--lipidor2021-12-20T17:31:42+00:00weekly0.6https://www.medthority.com/news/2020/01/new-indication-approved-for-infinity-deep-brain-stimulation-dbs-system-to-improve-symptoms-of-parkinsons-disease.--abbott2024-10-24T14:06:31+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-refiling-of-intravenous-iv-meloxicam-for-the-management-of-moderate-to-severe-pain.--baudax-bio2024-11-07T16:12:42+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-does-not-recommend-saxenda-as-a-treatment-for-obesity.---novo-nordisk2021-12-20T17:30:50+00:00weekly0.6https://www.medthority.com/news/2020/01/ipsen-to-pause-dosing-patients-in-the-global-phase-iii-pvo-1a-301-study-to-evaluate-the-efficacy-and-safety-of-palovarotene-in-patients-with-fibrodysplasia-ossificans-progressiva/2024-11-07T16:05:55+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approval-for-micra-av-the-worlds-smallest-pacemaker-to-treat-av-block.--medtronic2024-11-07T16:06:10+00:00weekly0.6https://www.medthority.com/news/2020/01/astrazeneca-recovers-rights-to-brazikumab-from-allergan/2021-12-20T17:31:46+00:00weekly0.6https://www.medthority.com/news/2020/01/brilinta-meets-primary-endpoint-in-phase-iii-thales-trial-in-stroke.--astrazeneca2024-11-07T16:12:52+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-ii-registrational-trial-ofenhertu-to-treat-her2-positive-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-cancer-.-astrazeneca--daiichi-sankyo2024-10-24T14:06:38+00:00weekly0.6https://www.medthority.com/news/2020/01/top-line-results-from-phase-iii-study-breeze-ad4-of-baricitinib-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-controlled-with-cyclosporine.--eli-lilly2021-12-20T17:31:42+00:00weekly0.6https://www.medthority.com/news/2012/08/phase-iii-phoenix-1-study-of-stelara-jj-janssen-cilag-shows-consistent-results-for--plaque-psoriasis-/2021-12-20T17:30:42+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approves-use-of-stelara-in-paediatric-patients-with-plaque-psoriasis.-johnson--johnson2021-12-20T17:30:42+00:00weekly0.6https://www.medthority.com/news/2020/01/kissei-announces-the-publication-of-the-results-of-phase-iii--trials-of-rovatirelin-for-the-treatment-of-spinocerebellar-degeneration-in-the-journal-of-neurology-neurosurgery-and-psychiatry/2024-10-24T14:06:48+00:00weekly0.6https://www.medthority.com/news/2020/01/vibegron-filed-with-fda-for-overactive-bladder.--urovant-sciences2024-11-07T16:13:05+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-times-2-trial-of-imeglimin-shows-positive-results-in-type-2-diabetes.--poxelsumitomo-dainippon-pharma2024-10-24T11:22:01+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-mmpower-3-trial-of-ocuvia-fails-to-meet-endpoint-in-primary-mitochondrial-myopathy.--stealth-biotherapeutics-2024-11-07T16:06:26+00:00weekly0.6https://www.medthority.com/news/2020/01/sorrento-therapeutics-rejects-takeover-offer/2025-10-16T11:15:12+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-dificid-for-oral-suspension-and-for-children-aged-6-months-and-over-to-treat-clostridioides-formerly-clostridium-difficile-associated-diarrhea.-merck-inc.-astellas2021-12-20T17:31:47+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-sbla-for-dupixent-as-an-add-on-maintenance-treatment-for-children-with-moderate-to-severe-atopic-dermatitis.-sanofi--regeneron2021-12-20T17:30:50+00:00weekly0.6https://www.medthority.com/news/2020/01/-fda-approves-the--only-triple-combination-tablet-with-trijardy-xr-for-adults-with-type-2-diabetes.--eli-lilly--boehringer2024-10-24T11:22:08+00:00weekly0.6https://www.medthority.com/news/2020/01/true-ad2-pivotal-trial-of-ruxolitinib-cream-met-its-primary-endpoint-in-patients-with-atopic-dermatitis.--incyte-corpn2021-12-20T17:31:42+00:00weekly0.6https://www.medthority.com/news/2020/01/bausch-health--clearside-biomedical-announce-publication-ofpivotal-phase-iii-data-on-xipere--in-ophthalmology-journal/2024-11-07T16:06:39+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-nda-for-alks-3831-for-treatment-of-schizophrenia-and-bipolar-i-disorder.--alkermes2024-10-24T14:06:58+00:00weekly0.6https://www.medthority.com/news/2020/01/opdivo-did-not-improve-overall-survival-in-ono-4538-23-study-for-recurrent-ovarian-cancer.--ono--bms2021-12-20T17:30:50+00:00weekly0.6https://www.medthority.com/news/2020/01/illumenate-pivotal-trial-of-stellarex-confirms-safety-profile-in-peripheral-arterial-disease.--royal-philips2024-11-07T16:13:18+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-monoferric-for-iron-deficiency-anemia.--pharmacosmos-therapeutics2024-10-24T11:22:16+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-approves-expanded-indication-for-erleada-in-metastatic-hormone-sensitive-prostate-cancer.--janssen-pharma2024-10-24T11:22:25+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-invokana-to-reduce-the-risks-associated-with-diabetic-kidney-disease-in-patients-with-type-2-diabetes.-janssen-pharma2024-10-24T11:22:39+00:00weekly0.6https://www.medthority.com/news/2020/01/conatus-pharma-to-merge-with-histogen-inc-and-trade-as-histogen-inc/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2020/01/ce-mark-for-tendyne-transcatheter-mitral-valve-implantation-tmvi-system.--abbott2024-10-24T14:07:07+00:00weekly0.6https://www.medthority.com/news/2020/01/positive-top-line-results-from-the-breeze-ad5-phase-iii-study-of--baricitinib-for-moderate-to-severe-atopic-dermatitis.-eli-lilly--incyte-corpn2021-12-20T17:31:47+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iiiii-ascend-study-of-gz-402665-meets-first-endpoint-in-niemann-pick-disease.--sanofi2024-10-24T11:22:49+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-givlaari-to-treatacute-hepatic-porphyria.--alnylam-pharma2024-11-12T10:12:33+00:00weekly0.6https://www.medthority.com/news/2020/03/ema-validates-maa-for-kte-x19for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.-kitegilead2024-11-07T16:13:30+00:00weekly0.6https://www.medthority.com/news/2020/03/mavoric-trial-of-poteligeo-consistent-with-safety-data-in-cutaneous-t-cell-lymphoma.--kyowa-kirin2024-11-07T16:13:49+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-approval-of-change-of-indication-for-maviret-in-chronic-hepatitis-c-genotype-3.--abbvie2024-11-12T10:12:44+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-approval-of-venclyxto---gazyvaro-in-chronic-lymphocytic-leukemia.--abbvie2024-10-24T11:22:57+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-approval-of-vaxchora-vaccine-for-cholera.--emergent-biosolutions2024-10-24T14:07:15+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-approval-of-nubeqa-in-non-metastatic-castration-resistant-prostate-cancer.--orion-corporation-and-bayer2024-11-07T16:14:01+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-approval-of-rybelsus-in-type-2-diabetes.--novo-nordisk2024-10-25T08:51:42+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-lillys-new-fast-acting-mealtime-insulin-liumjev-to-improve-glycemic-control-in-adults-with-diabetes/2024-11-12T10:12:51+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-palforzia-to-treat-peanut-allergy.--aimmune-therapeutics2024-11-12T10:17:39+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-ruxience-a-biosimilar-to-mabthera.-pfizer2024-10-24T14:07:26+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-staquis-to-treatatopic-dermatitis.--pfizer2021-12-20T17:30:51+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-nilemdo-bempedoic-acid-to-treat-treatment-of-hypercholesterolemia-and-mixed-dyslipidemia.--daiichi-sankyo--esperion2024-11-12T10:17:45+00:00weekly0.6https://www.medthority.com/news/2020/03/bms-withdraws-its-application-in-the-eu-for-opdivo--yervoy-combination--for-the-treatment-of-advanced-nsclc.-2021-12-20T17:32:58+00:00weekly0.6https://www.medthority.com/news/2020/03/nice-recommends-rinvoq-to-treat-severe-rheumatoid-arthritis.--abbvie2024-11-12T10:17:49+00:00weekly0.6https://www.medthority.com/news/2020/02/ce-mark-for-cobalt-and-crome-portfolio-of-implantable-cardioverter-defibrillators--and-cardiac-resynchronization-therapy-defibrillators.--medtronic2024-09-30T10:57:40+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-audenz-for-influenza-a-h5n1.--seqirus2024-10-25T08:52:53+00:00weekly0.6https://www.medthority.com/news/2020/02/ema-approves-accelerated-process-of-assessment-for-gsk-2857916-in-relapsed-or-refractory-multiple-myeloma.--glaxosmithkline2021-12-20T17:31:47+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-accepts-snda-for-recarbrio-in-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia.--merck-inc2024-10-24T11:24:32+00:00weekly0.6https://www.medthority.com/news/2020/02/epidiolex-filed-with-fda-for--tuberous-sclerosis-complex.--gw-pharma2024-10-24T11:24:41+00:00weekly0.6https://www.medthority.com/news/2020/02/cti-has-reached-agreement-with-the-fda--on-an-accelerated-approval-pathway-for-pacritinib-for-the-treatment-of-myelofibrosis-patients-with-severe-thrombocytopenia/2024-11-07T16:14:19+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-510kapproval-fortjf-q190v-duodenoscope.--olympus-medical2024-11-07T16:14:30+00:00weekly0.6https://www.medthority.com/news/2020/02/the-national-institute-of-allergy-and-infectious-diseases-stops-administration-of-vaccinations-in--hvtn-702-trial-of-an-investigational-hiv-vaccine/2024-11-12T10:18:07+00:00weekly0.6https://www.medthority.com/news/2020/02/cerecor-acquires-avei-genomic-medicine2/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2020/02/ema-validates-maa-for-tucatinib---trastuzumab--capecitabine-to-treat--locally-advanced-unresectable-or-metastatic-her2-positive-breast-cancer-including-brain-metastases.-seattle-genetics2021-12-20T17:32:58+00:00weekly0.6https://www.medthority.com/news/2020/02/final-overall-survival-analysis-of-phase-iii-aramis-trial-of-nubeqa-for-non-metastatic-castration-resistant-prostate-cancer.-bayer-healthcare2024-10-24T14:09:04+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-bulkamid-device-for-the-treatment-of-stress-urinary-incontinence.---contura2024-10-24T14:09:53+00:00weekly0.6https://www.medthority.com/news/2020/02/merck-inc.to-spin-off-products-from-its-womens-health-trusted-legacy-brands-and-biosimilars-businesses-into-a-new-yet-to-be-named-independent-publicly-traded-company2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2020/02/genentechroche-presents-one-year-data-from-part-2-of-sunfish-study-of-risdiplam-to-treat-spinal-muscular-atrophy/2024-10-24T11:24:50+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-issues-emergency-authorisation-for-ncov-real-time-rt-pcr-diagnostic-panela-diagnostic-test-for--coronavirus/2024-10-24T11:24:59+00:00weekly0.6https://www.medthority.com/news/2020/02/cytokinetics-announced-the-publication-to-the-design-of-galactic-hf-cardiovascular-outcomes-clinical-trial-of-omecamtiv-mecarbil-in-the-journal-of-american-college-of-cardiology-heart-failure/2021-12-20T17:30:51+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-studies-fx2016-11-and-fx2016-12-of-fmx-103-for-rosacea-published-in-journal-of-the-american-academy-of-dermatology.--foamix-pharma2024-10-24T14:10:04+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-select-psa-1-study-of-rinvoq-shows-positive-top-line-results-in-psoriatic-arthritis.--abbvie2024-11-12T10:18:16+00:00weekly0.6https://www.medthority.com/news/2020/02/enrollment-for-phase-iii-recovery-study-of-tonmya-in-ptsd-halted-due-to-futility.--tonix-pharma2024-10-24T11:25:08+00:00weekly0.6https://www.medthority.com/news/2020/02/coherus-biosciences--acquires-licence-to-commercialise-ibi-305--bevacizumab-biosimilar-in-us-and-canada-from-innovent-biologics/2021-12-20T17:30:37+00:00weekly0.6https://www.medthority.com/news/2020/02/positive-top-line-results-from--pivotal-phase-iii-trial-of-fintepla--to-treat-lennox-gastaut-syndrome.--zogenix2024-11-07T16:14:43+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-panorama-trial-of-eylea-shows-positive-results-in-diabetic-retinopathy.--regeneron-pharma2024-11-07T16:14:55+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-liberty-study-of-tak-385-shows-positive-results-for-uterine-fibroids.--myovant-sciences2024-10-24T13:13:16+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-gives-final-approval-for-pemfexy-in-non-small-cell-lung-cancer--and-pleural-mesothelioma.--eagle-pharma2021-12-20T17:30:42+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-trial-of-troriluzole-fails-to-meet-endpoint-in--generalized-anxiety-disorder.--biohaven-pharma2024-10-24T11:25:17+00:00weekly0.6https://www.medthority.com/news/2020/02/analysis-of-dian-tu-study-showed-that-solanezumab-did-not-meet-the-primary-endpoint-for-alzheimers-disease--eli-lilly/2024-11-07T16:15:06+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-to--kte-x-19-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma.-kitegilead2024-10-22T08:30:39+00:00weekly0.6https://www.medthority.com/news/2020/02/trevena-resubmits-new-drug-application-for-oliceridine-for-the-management-of-moderate-to-severe-acute-pain/2024-10-22T08:31:01+00:00weekly0.6https://www.medthority.com/news/2020/02/zealand-pharma-as-acquires-valeritas-holdings/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2020/02/fda--has-granted-priority-review-to-capmatinibs-nda--to-treat-locally-advanced-or-metastatic-met-exon-14-skipping-metex14-mutated-nsclc.--novartis2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/02/final-overall-survival-data-for-phase-iii-prosper-trial-of-xtandi-shows-significant-improvement-in-prostate-cancer.--astellas-pharma--pfizer-2024-11-12T10:18:33+00:00weekly0.6https://www.medthority.com/news/2020/02/pedmark-filed-with-eu-and-rolling-submission-completed-with-fda-for-hearing-loss.--fennec-pharma2024-10-22T08:34:08+00:00weekly0.6https://www.medthority.com/news/2020/02/health-canada-approves-taltz-to-treatadult-patients-with-active-ankylosing-spondylitis-.--eli-lilly2021-12-20T17:31:47+00:00weekly0.6https://www.medthority.com/news/2020/02/ce-mark-for-orsiro-mission-drug-eluting-stent-system.--biotronik2024-09-30T13:58:24+00:00weekly0.6https://www.medthority.com/news/2020/02/keytruda-met-one-of-its-primary-endpoints-in-phase-iii-keynote-355-trial--chemotherapy-for-metastatic-triple-negative-breast-cancer.--merck-inc.-2021-12-20T17:32:58+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-to-liso-cel-for-treatment-of-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma.--bms2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-for-tucatinib---trastuzumab--capecitabine-to-treat-locally-advanced-unresectable-or-metastatic-her2-positive-breast-cancer-including-patients-with-brain-metastases.-seattle-genetics2021-12-20T17:31:48+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-requires-belviq-to-be--withdrawn-from-its-us-market-due-to-cancer-risks.-eisai2024-10-22T08:35:14+00:00weekly0.6https://www.medthority.com/news/2020/02/tazverik-filed-with-fda-and-given-accelerated-approval-for-follicular-lymphoma.--epizyme-2021-12-20T17:31:19+00:00weekly0.6https://www.medthority.com/news/2020/02/nice-in-draft-guidance-does-not-recommend-the-combination-of-keytruda--inlyta-to-treat-renal-cell-carcinoma.-merck-inc.-pfizer2021-12-20T17:31:44+00:00weekly0.6https://www.medthority.com/news/2020/02/interim-data-from-phase-iiib-stardust-study-of-stelara-shows-clinical-response-in-crohns-disease.--jj-janssen-cilag2024-11-07T16:15:17+00:00weekly0.6https://www.medthority.com/news/2020/02/long-term-data-for-epsolay-confirms-safety-profile-in-rosacea.--sol-gel-technologies2024-11-07T16:15:33+00:00weekly0.6https://www.medthority.com/news/2020/02/gantenerumab-arm-of-the-phase-iiiii-dian-tu-001-study-did-not-meet-its-primary-endpoint-for-early--onset-alzheimers-disease.--roche2024-10-22T08:36:13+00:00weekly0.6https://www.medthority.com/news/2020/02/chiesi-establishes-boston-unit-to-support-treatments-for--rare-lysosomal-storage-hematological-and-ophthalmological-disorders-in-the-us/2024-11-07T16:06:54+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-twirla-weekly-application-contraceptive-patch.-agile-therapeutics2024-11-07T16:07:14+00:00weekly0.6https://www.medthority.com/news/2020/02/updated-positive-results-for-phase-iii-checkmate-214-study-of-opdivo--yervoy-versus-sunitinib-to-treat-metastatic-renal-cell-carcinoma.---bms-2024-10-22T09:17:21+00:00weekly0.6https://www.medthority.com/news/2020/02/five-year-positive-follow-up-of-checkmate-025-study-of-opdivo-versus-everolimus-for-metastatic-renal-cell-carcinoma-.--bms2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/02/positive-results-from-phase-iii-visible-2-trial-of-subcutaneous-entyvio-to-treat-moderate-to-severe-crohns-disease.--takeda2024-11-08T11:33:04+00:00weekly0.6https://www.medthority.com/news/2020/02/health-canada-approves-transfer-of-otezla-from-celgene-corporation-to-amgen-canada/2021-12-20T17:32:17+00:00weekly0.6https://www.medthority.com/news/2020/02/european-commission-approves-beovu-to-treat-wet-age-related-macular-degeneration.-novartis-2024-11-12T14:03:56+00:00weekly0.6https://www.medthority.com/news/2020/02/pharmamar-files-nda-at-fda-for-lurbinectedin-for-the-treatment-of-patients-with-small-cell-lung-cancer-/2021-12-20T17:31:44+00:00weekly0.6https://www.medthority.com/news/2019/02/eu-approves-vyndaqel-for-hereditary-transthyretin-amyloidosis-with-cardiomyopathy.--pfizer2024-11-07T16:07:23+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-clinical-trials-for-fmx-103-show-benefits-in-papulopustular-rosacea.--foamix-pharma2024-11-08T11:11:57+00:00weekly0.6https://www.medthority.com/news/2019/02/alnylam-completes-enrollment-of-helios-a-phase-iii-study-of-vutrisiran-for-the-treatment-of-hattr-amyloidosis-with-polyneuropathy/2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/02/fdas-tobacco-product-scientific-advisory-committee-likely-to-make--a-decision-on-reduced-nicotine-content-cigarettes-by-q2-2020.-22nd-century-group2024-11-08T11:12:11+00:00weekly0.6https://www.medthority.com/news/2020/02/updated-results-from-phase-1bii-ev-103-trial-of-padcev-with-pembrolizumab-for-first-line-treatment-for-advanced-urothelial-cancer.-seattle-genetics--astellas2024-10-25T11:02:29+00:00weekly0.6https://www.medthority.com/news/2020/02/primary-and-secondary-endpoints-met-in-both-true-ad1-and-true-ad2-trials-for-ruxolitinib-cream--to-treat-atopic-dermatitis.--incyte2021-12-20T17:31:44+00:00weekly0.6https://www.medthority.com/news/2020/02/merck-kgaa-sells-allergopharma-to-dermapharm/2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2020/02/aytu-bioscience-acquires-innnovus-pharma/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-grants-priority-review-for-sbla-of-tecentriq-in-nsclc--efgr--alk-pd-l1.--roche2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2021/2/fda-accepts-bla-for-valoctocogene-roxaparvovec-for-adults-with-hemophilia-a.-pdufa-action-date-is-august-21-2020.--biomarin2021-12-20T17:30:21+00:00weekly0.6https://www.medthority.com/news/2020/02/intra-cellular-therapies-inc.---announced-the-publication-in-jama-psychiatry-of--caplyta-trial-iti-007-301-in-adult-patients-with-schizophrenia2024-11-08T11:31:05+00:00weekly0.6https://www.medthority.com/news/2020/02/teva-pharmaceutical-industries-ltd.-announced-deutetrabenazine-failed-to-meet-the-endpoint-inin-phase-iiiii-trials-to-treat-tics-in-pediatric-patients-with--tourette-syndrome2024-11-07T16:07:39+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-escape-na1-study-of-nerinetide-suggests-potential-to-treat-stroke.--nono-inc2024-10-25T11:03:00+00:00weekly0.6https://www.medthority.com/news/2020/02/tocagen-and-forte-biosciences-to-merge/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-vyepti-for-migraine-prevention.--lundbeck2021-12-20T17:30:21+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-anjeso-to-treat-moderate-to-severe-pain.--baudax-bio2024-10-24T09:52:09+00:00weekly0.6https://www.medthority.com/news/2020/02/interim-data-from-the-sierra-trial-of-iomab-b-shows-side-effect-differences-in-acute-myeloid-leukemia-patients.--actinium-pharma2024-11-08T11:13:16+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-trulicity-to-reduce--major-adverse-cardiovascular-events-in-type-2-diabetes-patients--eli-lilly/2024-10-24T09:52:22+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-nexletol--to-treat-heterozygous-familial-hypercholesterolemia-hefh-or-established-atherosclerotic-cardiovascular-disease---esperion/2024-10-25T11:03:15+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-accepts-nda-for-libervant-buccal-film-for-the-treatment-of-seizure-clusters.--aquestive-therapeutics2021-12-20T17:31:44+00:00weekly0.6https://www.medthority.com/news/2020/02/fda--and-ema-accept-filings-of-subcutaneous-ofatumumab-for-the-treatment-of-relapsing-multiple-sclerosis.--genmab-as--novartis-2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-increase-study-of-tyvaso-meets-primary-endpoint-in-pulmonary-hypertension-with-interstitial-lung-disease.--united-therapeutics-2024-10-24T09:52:42+00:00weekly0.6https://www.medthority.com/news/2020/02/astrazeneca-licenses-rights-to-movantik-to-redhill-biopharma-a-treatment-for-opioid-induced-constipation/2024-10-24T09:52:53+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-510k-approval-for-novalung-to-treat-long-term--acute-respiratorycardiopulmonary-failure.-xenios-ag-fresenius2024-11-12T10:58:55+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-new-dosage-form-for-procysbi-to-treat-nephropathic-cystinosis.--horizon-therapeutics2024-11-12T10:59:05+00:00weekly0.6https://www.medthority.com/news/2020/02/vanda-reports-results-from-the-epione-study-of-tradipitant-in-the-treatment-of-pruritus-in-atopic-dermatitis/2022-01-11T20:48:17+00:00weekly0.6https://www.medthority.com/news/2020/02/data-monitoring-committee-recommends-phase-iii-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure-continue-without-changes.-amgen--cytokinetic-s-servier2021-12-20T17:30:21+00:00weekly0.6https://www.medthority.com/news/2020/02/co-diagnostics-secures-ce-mark--for-its-logix--smart-covid-19-coronavirus-pcr-test/2024-11-08T11:13:31+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-barhemsys-to-treat-post-operative-nausea-and-vomiting-ponv-in-a-hospital-setting--acacia-pharma/2024-11-12T10:59:13+00:00weekly0.6https://www.medthority.com/news/2020/02/gilead-sciences-initiates-phase-iii-studies-of-remdesivir-to-treat--covid-19-novel-coronavirus/2024-10-24T11:25:26+00:00weekly0.6https://www.medthority.com/news/2020/02/nice-rejects-polivy--bendamustine--rituximab-combination-to-treat-diffuse-large-b-cell-lymphoma.-roche2021-12-20T17:33:03+00:00weekly0.6https://www.medthority.com/news/2020/02/ce-mark-for-gallant-implantable-cardioverter-defibrillator--and-cardiac-resynchronization-therapy-defibrillator-devices.--abbott2024-09-30T10:58:37+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-accepts-bla-for-fixed-dose-combination--of-perjeta---herceptin-with-hyaluronidase-by-subcutaneous--injection-in-combination-with-i.v.--chemotherapy-for-the-treatment-of---her2-positive-breast-cancer.-genentechroche2021-12-20T17:32:18+00:00weekly0.6https://www.medthority.com/news/2020/02/takeda-acquires-pvp-biologics-and-with-it-tak-062-to-treat-celiac-disease/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-nintedanib-in-systemic-sclerosis-associated-interstitial-lung-disease.--boehringer2024-10-24T11:25:33+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-entyvio-for-ulcerative-colitis-or-crohns-disease.--takeda-pharma2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/03/viale-c-trial-of-venclexta--low-dose-cytarabine-versus-ldac--placebo-did-not-meet-its-primary-endpoint--for-patients-with-acute-myeloid-leukemia.-abbvie2024-11-12T10:59:22+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-nurtec-odt-to-treat-acute-migraine.---biohaven2021-12-20T17:33:03+00:00weekly0.6https://www.medthority.com/news/2020/03/trelegy-ellipta-filed-with-eu-for-asthma.--glaxosmithkline--innoviva2024-11-08T11:13:41+00:00weekly0.6https://www.medthority.com/news/2020/03/ce-mark-for--cad-eye-to-support-real-time-detection-of-colonic-polyps-during-colonoscopy-utilizing-ai-technology.--fujifilm2024-11-08T11:31:33+00:00weekly0.6https://www.medthority.com/news/2020/03/keytruda-significantly-improved-pfs-compared-with-brentuximab-vedotin-in--relapsed-or-refractory-classical-hodgkin-lymphoma.---merck-inc2024-10-24T11:25:41+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-sarclisa-for-multiple-myeloma.--sanofi2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/03/variquel-starts-rolling-submission-process-with-fda-for-hepatorenal-syndrome-type-1.--mallinckrodt2024-10-24T09:53:05+00:00weekly0.6https://www.medthority.com/news/2020/03/pivotal-trial-of-oms-721-shows-efficacy-in-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy.--omeros2021-12-20T17:32:18+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-gwpcare2-trial-of-epidiolex-in-dravet-syndrome-published-in-jama-neurology.--gw-pharma2024-11-12T10:59:31+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-trial-of-yutiq-shows-positive-topline-results-in-uveitis.--eyepoint-pharma--2024-11-12T10:59:40+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-boston-study-of-xpovio---velcade---low-dose-dexamethasone-meets-primary-endpoint-with-a-significant-increase-in-progression-free-survival-in--multiple-myeloma.--karyopharm2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/03/gilead-science-acquires-forty-seven-inc.-and-with-it-magrolimab2021-09-24T07:12:19+00:00weekly0.6https://www.medthority.com/news/2020/03/ema-approves-givlaari-to-treat--acute-hepatic-porphyria.--alnylam2024-10-24T09:53:18+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-fetcroja-intended-for-the-treatment-of-infections-due-to-aerobic-gram-negative-organisms-.--shionogi2024-11-08T11:13:53+00:00weekly0.6https://www.medthority.com/news/2020/03/ponesimod-filed-with-eu-for-relapsing-multiple-sclerosis.--janssen2021-12-20T17:30:21+00:00weekly0.6https://www.medthority.com/news/2020/03/thermo-fisher-acquires-qiagen-n.v.a-provider-of-molecular-diagnostics2021-09-24T07:12:18+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-durysta-to-treat-open-angle-glaucoma-or-ocular-hypertension-.--allergan2024-11-12T11:34:13+00:00weekly0.6https://www.medthority.com/news/2020/03/510k-approval-for-steerable-plateau-ti-system.--life-spine2024-11-08T11:14:07+00:00weekly0.6https://www.medthority.com/news/2020/03/alkermes-plc-announced-the-publication-of-phase-iii-enlighten-1-trial-of-alks-3831-in-the-journal-of-clinical-psychiatry-/2022-01-07T09:54:00+00:00weekly0.6https://www.medthority.com/news/2020/03/imfinzi--tremelimumab-did-not-meet-endpoints-in-phase-iii-danube-trial-for-stage-iv-bladder-cancer.-astrazeneca2024-10-24T09:53:31+00:00weekly0.6https://www.medthority.com/news/2020/03/vorvida-is-filed-at-fda-by-orexo--ab-to-treat-alcohol-use-disorder-/2024-11-12T11:39:59+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-accepts-abla-for-avastin--biosimilar-myl-14020.-mylan--2024-10-24T12:37:25+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-fluad-quadrivalent-adjuvanted-seasonal-influenza-vaccine.--seqiruscsl2024-11-12T11:40:08+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-approves-change-to-authorization-of-maviret-in-hepatitis-c-genotype-3.--abbvie2024-11-08T11:14:16+00:00weekly0.6https://www.medthority.com/news/2020/03/amgen-acquires-all-the-shares-of-amgen-astellas-biopharma/2021-09-24T07:12:18+00:00weekly0.6https://www.medthority.com/news/2020/03/new-data-on-acthar-gel--in-rheumatoid-arthritis-sle-and-dermatomyositispolymyositis-published-in-open-access-rheumatology-research-and-reviews.--mallinckrodt2024-10-24T09:53:44+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-isturisa-for-cushings-disease.--recordati2024-10-24T10:06:50+00:00weekly0.6https://www.medthority.com/news/2020/03/urovant-sciences-announces-publication-in-the-journal-of-urology-of-the-phase-iii-empowur-trial-of-vibegron-for-overactive-bladder-/2024-10-24T10:07:07+00:00weekly0.6https://www.medthority.com/news/2020/03/urovant-sciences-announces-fda-acceptance-of-nda-for-vibegron-for-the-treatment-of-overactive-bladder.-2024-11-12T10:59:47+00:00weekly0.6https://www.medthority.com/news/2020/03/primary-results-of-eloquent-1-study-of-empliciti--revlimid---dexamethasone-in-patients-with-newly-diagnosed-untreated-multiple-myeloma.-bms2021-12-20T17:30:38+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-ofev-for-chronic-fibrosing-interstitial-lung-diseases.--boehringer2024-10-24T12:37:37+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-flair-study-of-cabotegravir--rilpivirine-shows-efficacy-in-hiv.--viiv-healthcare2021-12-20T17:32:18+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-atlas-2m-study-of-cabotegravir-and-rilpivirine-meets-primary-endpoint-at-48-weeks-in-hiv.--viiv-healthcare2021-12-20T17:30:21+00:00weekly0.6https://www.medthority.com/news/2020/03/stride-3-phase-iii-trial-of-eysuvis-meets-endpoints-in-dry-eye-disease.--kala-pharma2024-10-24T10:20:30+00:00weekly0.6https://www.medthority.com/news/2020/03/quest-diagnostics-to-launch-coronavirus-disease-2019-covid-19-test/2024-10-24T12:37:50+00:00weekly0.6https://www.medthority.com/news/2020/03/ce-mark-for-symmetry-vagus-nerve-stimulation-therapy-to-treat-depression.---livanova-plc2024-10-24T12:38:05+00:00weekly0.6https://www.medthority.com/news/2020/03/takeda-provides-update-on-tourmaline-mm2-phase-iii-trial-ofixazomib--lenalidomide--dexamethasone-to-treat-transplantation-ineligible-multiplemyeloma-patients/2021-12-20T17:30:39+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-spi2-trial-of-md-1003-fails-to-meet-endpoints-in-multiple-sclerosis.--medday-pharma2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/acceleron-announces-topline-results-from-the-phase-ii-trial-of-ace-083-in-patients-with-charcot-marie-tooth-disease/2024-10-24T10:20:58+00:00weekly0.6https://www.medthority.com/news/2020/03/discover-trial-of-descovy-shows-efficacy-in-hiv-pre-exposure-prophylaxis.--gilead-sciences2024-11-08T11:31:43+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-opdivo--yervoy-to-treat-hepatocellular-cancer-liver-cancer-.--bms2024-11-12T10:59:53+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-delivers-second-complete-response-letter-to-intarcia-for-itca-650-implanta-small-osmotic-pump-to-treat-type-2-diabetes/2024-11-12T11:45:00+00:00weekly0.6https://www.medthority.com/news/2020/03/update-on-phase-iii-gy004-trial-for-cediranib--lynparza-in-platinum-sensitive-relapsed-ovarian-cancer.--astrazeneca--merck-inc2021-12-20T17:33:14+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-approves-venclyxto--gazyva-for-chronic-lymphocytic-leukemia.--abbvie2024-10-24T10:21:27+00:00weekly0.6https://www.medthority.com/news/2020/03/nice-recommends-ajovy-for-prevention-of-migraine.--teva2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/nice-rejects-dupixent-as-a-treatment-for-severe-asthma-with-type-2-inflammation.--sanofi--regeneron2024-11-08T11:33:13+00:00weekly0.6https://www.medthority.com/news/2020/03/mayzent-is-approved-in-canada-to-treat-secondary-progressive-multiple-sclerosis.--novartis2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/-merck-kgaa-and-pfizer-agree-to-terminate-the-javelin-head-and-neck-100-trial-of-bavencio--as-unlikely-to-show-a-statistically-significant-improvement-in-progression-free-survival/2021-12-20T17:32:19+00:00weekly0.6https://www.medthority.com/news/2020/03/cobas-sars-cov-2-test-issued-an-emergency-authorisation-by-fda-for-covid-19-disease.--roche2024-11-12T11:52:41+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approval-of-cintec-plus-cytology-as-the-first-biomarker-based-triage-test-for-women-whose-primary-cervical-cancer-screening-results-are-positive-for-hpv-using-the-cobas-4800-hpv-test.--roche2021-12-20T17:30:42+00:00weekly0.6https://www.medthority.com/news/2020/03/padsevonil-in-arise-phase-iib-trial-does-not-meet-statistical-significance-for-treatment-of-focal-onset-seizures-.-ucb2021-12-20T17:33:14+00:00weekly0.6https://www.medthority.com/news/2020/03/two-phase-iii-and-one-phase-ii-trials-of-concizumab-in-haemophilia-a-and-b-have-been-halted.--novo-nordisk2024-11-08T11:33:24+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-grants-rolling-submission-to-luveniq-for-lupus-nephritis.--aurinia-pharmaceuticals2024-11-08T11:33:33+00:00weekly0.6https://www.medthority.com/news/2020/03/final-results-from-phase-iii-caspian-study-of-imfinzi-shows-meaningful-overall-survival--benefit--to-treat-small-cell-lung-cancer.--astrazeneca2021-12-20T17:33:14+00:00weekly0.6https://www.medthority.com/news/2020/03/-mallinckrodt-plc-completed-its-rolling-submission-of-a-nda-to-the-fda-for-terlipressin-for-the-treatment-of-hepatorenal-syndrome-type-1/2024-10-24T13:13:36+00:00weekly0.6https://www.medthority.com/news/2020/03/sage-therapeutics-announces-development-plan-for-zuranolone--following--meeting-with-the-fda/2024-10-24T13:13:52+00:00weekly0.6https://www.medthority.com/news/2016/11/results-of-inclisiranaln-pcssc-from-orion-1-phase-ii-trial-positive-for-the-treatment-of-hypercholesterolemia.---the-medicines-company--alnylam-pharma2024-10-24T10:23:27+00:00weekly0.6https://www.medthority.com/news/2020/03/novartis-announces-nejm-publication-of-three-pivotal-trials-showing-efficacy-of-inclisiran-an-investigational-first-in-class-sirna-cholesterol-lowering-therapy/2024-10-24T10:23:38+00:00weekly0.6https://www.medthority.com/news/2020/03/genentech-initiates-phase-iii--clinical-trial-of-actemra-in-hospitalized-patients-with-severe-covid-19-pneumonia/2024-11-08T11:33:46+00:00weekly0.6https://www.medthority.com/news/2020/03/transenterix-receives-fda-510k-clearance-for-first-machine-vision-system-in-robotic-surgery/2024-11-12T11:52:48+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-flash-trial-of-sgx-301--shows-statistical-significant-response-in-cutaneous-t-cell-lymphoma.--soligenix2024-11-12T11:55:22+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-issues-emergency-use-authorisation-for-realtime-sars-cov-2-eua-test-as-diagnostic-for-coronavirus.--abbott2024-11-12T12:00:02+00:00weekly0.6https://www.medthority.com/news/2020/03/real-time-fluorescent-rt-pcr-sars-cov-2-test-launched-in-us-after-application-for-emergency-use-authorization.--bgi-genomics2024-11-12T12:00:13+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-results-for-20vpnc-vaccine-for-pneumococcal-disease.--pfizer2021-12-20T17:32:19+00:00weekly0.6https://www.medthority.com/news/2020/03/health-canada-approves-cabenuva-for-hiv.--viiv-healthcare2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-grants-emergency-use-authorisation-to-eplex-sars-cov-2-test-for-coronavirus-detection.--genmark-diagnostics2024-10-24T10:27:23+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-issues-complete-response-letter-to-eli-lilly-and-boehringer-for-empagliflozin-to-treat-type-1-diabetes/2024-10-24T13:14:04+00:00weekly0.6https://www.medthority.com/news/2020/03/oncology-venture-reports-results-of-fda-meeting-for-dovitinib-as-a-treatment-for-renal-cell-carcinoma/2021-12-20T17:30:43+00:00weekly0.6https://www.medthority.com/news/2020/03/favipiravir-positive-studies-in-china--to-treat-coronavirus.-zhejiang-hisun-pharma2024-11-12T12:00:21+00:00weekly0.6https://www.medthority.com/news/2020/03/global-phase-iiiii-trial-of-kevzara-in-patients-hospitalized-with-severe-covid-19-infection-.--regeneron--sanofi2024-10-24T10:27:51+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-grants-emergency-use-authorisation-for-xpert-xpress-sars-cov-2-test-for-coronavirus.--cepheid2024-11-08T11:14:26+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-approves-akynzeo-iv-formulation-for-treating-nausea.--helsinn2024-10-24T10:28:02+00:00weekly0.6https://www.medthority.com/news/2020/03/venclexta--chemotherapy-improved-overall-survival-in-viale-a-study--with-patients-with-previously-untreated-acute-myeloid-leukemia.---genentech-roche2024-10-24T10:28:11+00:00weekly0.6https://www.medthority.com/news/2020/03/the-lancet-publishes-papers-from-two-studies-of--tak-003-dengue-vaccine-candidate.--takeda2024-11-12T12:00:31+00:00weekly0.6https://www.medthority.com/news/2020/03/top-line-results-from-phase-iii-trials-evaluating-gefapixant-mk-7624-a-treatment-for-refractory-or-unexplained-chronic-cough.--merck-inc2024-10-24T13:14:19+00:00weekly0.6https://www.medthority.com/news/2020/03/-fda-approves-expanded-indication-of-eucrisa-ointment-2-in-children-as-young-as-3-months-of-age-with-mild-to-moderate-atopic-dermatitis.--pfizer2021-12-20T17:32:19+00:00weekly0.6https://www.medthority.com/news/2020/03/zolgensma-data-shows-rapid-significant-clinically-meaningful-benefit-in-sma-including-prolonged-event-free-survival-motor-milestone-achievement-and-durability-now-up-to-5-years-post-dosing.---novartis2024-10-24T10:28:47+00:00weekly0.6https://www.medthority.com/news/2020/03/nanoflu-seasonal-influenza-vaccine--achieves-all-primary-endpoints-in-phase-iii-clinical-trial.-novavax-inc2024-11-08T11:33:55+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iv-trial-data-with-rayaldee-shows-efficacy-in-chronic-kidney-disease.--opko-health2024-10-24T13:14:31+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-awards-ce-mark-approval-to-ebx-041-sars-cov2-diagnostic-test-for-coronavirus.--eurobio-scientific2021-12-20T17:30:43+00:00weekly0.6https://www.medthority.com/news/2020/03/tepmetko-is-approved-in-japan-for-the-treatment-of-patients-with-unresectable-advanced-or-recurrent-non-small-cell-lung-cancer-with-met-exon-14-metex14-skipping-alterations.--merck-kgaa2021-12-20T17:33:14+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-accepts-for-filing-nda-for--jzp-258-for-the-treatment-of-cataplexy-or-excessive-daytime-sleepiness--in-patients-7-years-of-age-and-older-with-narcolepsy.-jazz-pharma2024-11-07T16:07:51+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-zeposia-to-treat--relapsing-forms-of-multiple-sclerosis-including-clinically-isolated-syndrome-relapsing-remitting-disease-and-active-secondary-progressive-disease.-bms2021-12-20T17:32:19+00:00weekly0.6https://www.medthority.com/news/2020/03/new-england-journal-of-medicine-publishes-results-from-pivotal-phase-iii-believe-trial-of-reblozyl--in-adult-patients-with-beta-thalassemia--bms/2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/data-from-two-phase-iii-trials-in-adult-and-pediatric-patients-for-mm-36-showed-statistically-significant-improvements-in--atopic-dermatitis.--medimetriks-pharmaceuticals2021-12-20T17:30:22+00:00weekly0.6https://www.medthority.com/news/2020/03/synairgen-plc-initiates-phase-ii-trial-of-sng-001-to-treat-covid-19-patients-/2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-gives-ce-mark-approval-to-sars-cov-2-test-for-coronavirus.--thermo-fisher2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2020/03/interim-analysis-in-phase-iii-oval-study-of-vb-111-shows-positive-outcome-in-ovarian-cancer.--vbl-therapeutics2021-12-20T17:30:18+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-accepts-genentechs-nda-for-xofluza-for-the-treatment-of-influenza-in-children--genentechroche/2024-10-24T09:48:17+00:00weekly0.6https://www.medthority.com/news/2020/03/sanofi-receives-positive-chmp-opinion-for-sarclisa-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma/2021-12-20T17:30:23+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-zolgensma-for-the-treatment-of-patients-with-5q-spinal-muscular-atrophy-.---novartis2024-10-24T10:30:57+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-zeposia-to-treat-adult-patients-with-relapsing-remitting-multiple-sclerosis.--bms2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/03/chinas-national-medical-products-administration--has-accepted-an-application-for-the-approval-of-denosumab-copy-biological-hlx-14.--shanghai-henlius-biotech2024-10-24T09:48:47+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-cosentyx--for-the-treatment-of-adult-patients-with-active-non-radiographic-axial-spondyloarthritis.--novartis2024-11-07T16:08:34+00:00weekly0.6https://www.medthority.com/news/2020/03/complete-response-for-rizaport-versafilm-to-treat-migraine.--intelgenx-technologies2021-12-20T17:30:19+00:00weekly0.6https://www.medthority.com/news/2020/03/cytodyn-files-fda-suggested-modifications-to-ind-and-protocol-for-phase-ii-clinical-trial-for-covid-19-patients-with-mild-to-moderate-indications-/2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/03/pooled-data-from-three-phase-iii-studies-of-inclisiran-shows-durable-repsonse-in-hyperlipidemia.--novartis2024-10-24T10:31:07+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-voyager-pad-study-of-xarelto-meets-primary-endpoints-in-symptomatic-peripheral-artery-disease.--janssen2024-10-24T10:31:19+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-grants-emergency-use-authorisation-for-id-now-covid-19-eua-test-for-coronavirus.--abbott2021-12-20T17:30:23+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-grants-emergency-use-authorisation-for-nxtag-cov-extended-panel-test-for-coronavirus.--luminex-corp2021-12-20T17:31:45+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-dapa-hf-trial-of-farxiga-shows-efficacy-in-heart-failure.--astrazeneca2021-12-20T17:31:45+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-beijerinck-trial-of-repatha-shows-reduction-of-ldl-c-in-hiv-patients-with-dyslipidaemia.--amgen-2024-10-24T09:49:12+00:00weekly0.6https://www.medthority.com/news/2020/03/topline-results-from-first-of-its-kind-phase-iii-node-301-trial-of-etripamil-for-at-home-acute-supraventricular-tachycardia-treatment.--milestone-pharma2024-10-24T09:49:46+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-extending-indication-of-ruconest-to-children-with-hereditary-angioedema.--pharming2021-12-20T17:30:23+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-victoria-study-of-bay-1021189-shows-reduced-risk-of-hospitalisation-or-death-in-heart-failure.--merck-inc--bayer-healthcare2021-12-20T17:30:23+00:00weekly0.6https://www.medthority.com/news/2020/03/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.-astrazeneca2022-02-08T07:44:48+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-imfinzi-as-first-line-treatment-for--extensive-stage-small-cell-lung-cancer.--astrazeneca2022-02-08T07:44:48+00:00weekly0.6https://www.medthority.com/news/2020/03/dapa-ckd-trial-for-farxiga-is-stopped-early-in-patients-with-chronic-kidney-disease-due-to-overwhelming-efficacy.--astrazeneca2022-02-08T07:44:49+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-elipse-hofh-trial-results-of-regn-1500-met-primary-endpoint-in-homozygous-familial-hypercholesterolemia.--regeneron-pharma2024-11-12T14:04:02+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-odyssey-hofh-trial-of-praluent-meets-primary-endpoint-in-homozygous-familial-hypercholesterolemia.--regeneron-pharma2024-11-12T14:04:09+00:00weekly0.6https://www.medthority.com/news/2020/03/eu-approves-nubeqa-for-castration-resistant-prostate-cancer-.--orion--bayer2024-11-12T14:04:13+00:00weekly0.6https://www.medthority.com/news/2020/03/stride-1-phase-iii-trial-of-axs-05-meets-key-secondary-endpoints-in-depression.--axsome-therapeutics2024-11-12T14:04:16+00:00weekly0.6https://www.medthority.com/news/2020/03/fda-approves-supplemental-sbla-for-taltz-to-treat--pediatric-patients--with-moderate-to-severe-plaque-psoriasis-who-are-candidates-for-systemic-therapy-or-phototherapy.--eli-lilly2022-02-08T07:44:49+00:00weekly0.6https://www.medthority.com/news/2020/03/brilinta--monotherapy-reduced-the-risk-of-clinically-relevant-bleeding-compared-to-aspirin--brilinta-in-high-risk-coronary-patients-according-to--phase-iv-independent-twilight-trial.-astrazeneca2024-11-12T14:04:21+00:00weekly0.6https://www.medthority.com/news/2020/03/chmp-recommends-extending-indication-of-ruconest-to-children-with-hereditary-angioedema2.--pharming2021-12-20T17:30:23+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-victoria-study-of-bay-1021189-shows-reduced-risk-of-hospitalisation-or-death-in-heart-failure2.--merck-inc--bayer-healthcare2021-12-20T17:33:13+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-elipse-hofh-trial-results-of-regn-1500-met-primary-endpoint-in-homozygous-familial-hypercholesterolemia2.--regeneron-pharma2024-10-24T10:31:26+00:00weekly0.6https://www.medthority.com/news/2020/03/phase-iii-odyssey-hofh-trial-of-praluent-meets-primary-endpoint-in-homozygous-familial-hypercholesterolemia2.--regeneron-pharma2024-10-24T10:31:33+00:00weekly0.6https://www.medthority.com/news/2020/03/dapa-ckd-trial-for-farxiga-is-stopped-early-in-patients-with-chronic-kidney-disease-due-to-overwhelming-efficacy3.--astrazeneca2024-10-24T10:31:52+00:00weekly0.6https://www.medthority.com/news/2020/04/bms--bluebird-bio-file-bla-at-fda-for-idecabtagene-vicleucel-to-treatmultiple-myeloma-patients-who-have-received-at-least-three-prior-therapies/2021-12-20T17:30:19+00:00weekly0.6https://www.medthority.com/news/2020/04/chmp-recommends-approval-for-pretomanid-fgk-intended-for-the-treatment-of-tuberculosis-in-combination-with-bedaquiline-and-linezolid.--tb-alliance2024-11-08T11:34:06+00:00weekly0.6https://www.medthority.com/news/2020/04/phase-ii-and-iii-clinical-trials-of-tepezza-shows-reduction-in-proptosis-in-thyroid-eye-disease.--horizon-therapeutics2024-11-12T11:33:36+00:00weekly0.6https://www.medthority.com/news/2020/04/phase-iii-study-of-saxenda-in-adolescent-obesity-published-in-new-england-journal-of-medicine.--novo-nordisk-2021-12-20T17:33:00+00:00weekly0.6https://www.medthority.com/news/2020/04/retrospective-study-of-velphoro-in-hyperphosphataemia-published-in-kidney-medicine-journal.--fresenius-medical2024-11-12T09:09:45+00:00weekly0.6https://www.medthority.com/news/2020/04/chmp-recommends-extension-of-approval-for-adcetris-plus-chp-in-anaplastic-large-cell-lymphoma.--takeda-pharma2024-10-24T09:50:48+00:00weekly0.6https://www.medthority.com/news/2020/04/chmp-recommends-approval-of-fluad-tetra-adjuvanted-quadrivalent-influenza-vaccine.--seqirus2024-11-12T10:35:02+00:00weekly0.6https://www.medthority.com/news/2020/04/chmp-recommends-nepexto-a-etanercept-biosimilar.--mylan2024-11-12T10:35:13+00:00weekly0.6https://www.medthority.com/news/2020/04/mallinckrodt-and-novoteris-receive-clearance-from-health-canada-to-start--a-pilot-trial-of-high-dose-inhaled-nitric-oxide-therapy-for-covid-19-infection-and-associated-complications.--mallinckrodt--novoteris-llc2021-12-20T17:32:19+00:00weekly0.6https://www.medthority.com/news/2020/04/interima-analysis-of-phase-iii-atalante-1-trial-of-tedopi-meets-endpoint-in-nsclc-but-trial-on-temporary-hold.--ose-immunotherapeutics2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/04/rivaroxaban-significantly-reduced-risk-of-major-venous-thromboembolism-following-non-major-orthopaedic-surgery.-bayer-healthcare--janssen-pharma2024-10-24T10:32:08+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-reblozyl-to-treat-anemia-associated-with-lower-risk-myelodysplastic-syndromes.-bms--acceleron2024-10-24T10:32:21+00:00weekly0.6https://www.medthority.com/news/2020/04/eu-approves-rybelsus-for-type-2-diabetes.--novo-nordisk2024-11-12T09:10:07+00:00weekly0.6https://www.medthority.com/news/2020/04/case-study-in-wuhan-china-shows-positive-effect-of-actemra-as-a-treatment-for-covid-19-and-is-published-in-blood-advances.--roche2021-12-20T17:30:20+00:00weekly0.6https://www.medthority.com/news/2020/04/kiniksa-announces-early-evidence-of-treatment-response-with-mavrilimumab-in-6-patients-with-severe-covid-19-pneumonia-and-hyperinflammation/2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/04/reata-pharmaceuticals-closes--catalyst-study-of-bardoxolone-methyl-for-connective-tissue-disease-associated-pulmonary-arterial-hypertension-/2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/04/the-covid-19-pandemic-will-not-have-a-significant-impact-on-completion-of-the-phase-iii-cardinal-trial-of--bardoxolone-for-ckd-caused-by-alport-syndrome.--reata-pharma2024-11-12T10:36:19+00:00weekly0.6https://www.medthority.com/news/2020/04/phase-iii-falcon-study-of-bardoxolone-in-patients-with-autosomal-dominant-polycystic-kidney-disease-is-paused.--reata-pharma2024-11-12T10:37:52+00:00weekly0.6https://www.medthority.com/news/2020/04/stratatechmallinckrodt-initiates-a-rolling-submission--to-the-fda-of-stratagraft-a-regenerative-skin-tissue-therapy-for-the-treatment-of-burns/2024-11-12T09:12:19+00:00weekly0.6https://www.medthority.com/news/2020/04/mateon-achieves-milestone-in-development-of-ot-101-a-phase-iii-clinical-drug-candidate-against-covid-19/2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/04/university-of-wisconsinmadison-flugen-and-bharat-biotech-to-develop-coroflu-a-coronavirus-vaccine/2021-12-20T17:30:24+00:00weekly0.6https://www.medthority.com/news/2020/04/biomarin-plans-regulatory-submissions-in-q3-2020-at-fda-and-ema-for-vosoritide-to-treat-children-with-achondroplasia.-2024-10-24T10:32:33+00:00weekly0.6https://www.medthority.com/news/2020/04/alnylam-completes-rolling-submission-of-nda-to-the-fda-and-submits-maa-to-the-european-medicines-agency-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1/2024-10-24T09:51:29+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-extends-pdufa-date-for-review-ofrisdiplam-to-treat-spinal-muscular-atrophy.--genetechroche2024-11-12T09:12:36+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-braftovi--cetuximab-for-the-treatment-of-brafv600e-mutant-metastatic-colorectal-cancer-crc-after-prior-therapy.--pfizer2024-10-24T10:33:13+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-and-ema-filings-for-opdivo---yervoy-with-limited-chemotherapy-are-accepted-in-first-line-lung-cancer/2021-12-20T17:30:24+00:00weekly0.6https://www.medthority.com/news/2020/04/abbotts-freestyle-libre-14-day-system-now-available-in-the-u.s.-for-hospitalized-patients-with-diabetes-during-covid-19-pandemic.-2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/04/medicinova-plans-to-initiate-a-clinical-trial-of-mn-166--for-covid-19-acute-respiratory-distress-syndrome-ards/2024-11-12T09:12:53+00:00weekly0.6https://www.medthority.com/news/2020/04/merck-kgaa--pfizer--submit-application-for-bavencio-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma/2024-11-12T10:38:12+00:00weekly0.6https://www.medthority.com/news/2020/04/health-canada-approves-descovy-for-pre-exposure-prophylaxis-prep-to-reduce-the-risk-of-sexually-acquired-hiv-1-infection.--gilead-sciences2024-11-12T10:38:22+00:00weekly0.6https://www.medthority.com/news/2020/04/adial-pharmaceuticals-provides-update-on-phase-iii-onward-trial-of-ad-04-to-treat-alcohol-use-disorder/2024-11-08T11:15:50+00:00weekly0.6https://www.medthority.com/news/2020/04/lfb-announces-fda-approval-for-sevenfact-a-new-recombinant-coagulation-factor-viiia-for-for-the-treatment-of-hemophilia-a-or-b-with-inhibitors/2024-11-08T11:15:56+00:00weekly0.6https://www.medthority.com/news/2020/04/adaura-is-the-first-phase-iii-trial-for-tagrisso-to-show-statisticallysignificant-benefit-in-adjuvant-treatment-of-egfrm--nsclc.--astrazeneca2024-10-24T10:33:27+00:00weekly0.6https://www.medthority.com/news/2020/04/data-on-53-patients-treated-with--remdesivir-through-the-compassionate-use-program-is-published-in-new-england-journal-of-medicine.--gilead-sciences2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/04/china-national-medical-products-administration-approves-tislelizumab-to-treat-metastatic-urothelial-carcinoma--with-pd-l1-high-expression-.--beigene-ltd2024-10-24T09:02:37+00:00weekly0.6https://www.medthority.com/news/2020/04/immunomedics-announces-phase-iii-ascent-study-of-sacituzumab-govitecan-to-treat-metastatic-triple-negative-breast-cancer-to-be-stopped-for-compelling-efficacy/2021-12-20T17:32:20+00:00weekly0.6https://www.medthority.com/news/2020/04/novartis-completes-safety-review-and-initiates-update-to-the-beovu-prescribing-information-worldwide/2024-10-24T10:33:47+00:00weekly0.6https://www.medthority.com/news/2020/04/keytruda-filed-at-fda-to-treatpatients-with-unresectable-or-metastatic-solid-tumors-with-tissue-tumor-mutational-burden-high.--merck-inc2024-10-24T10:34:51+00:00weekly0.6https://www.medthority.com/news/2020/04/studies-mti-105-and-mti-106-oforal-serlopitant-did-not-meet-their-respective-primary-endpoint-of-reduction-of-pruritus.-menlo-therapeutics2024-10-24T09:03:03+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-koselugo-to-treat--paediatric-patients-two-years-of-age-and-older-with-neurofibromatosis-type-1-nf1.---astrazeneca--merck-inc2024-10-24T09:04:00+00:00weekly0.6https://www.medthority.com/news/2020/04/ema-approves-nilemdo-for-primary-hypercholesterolaemia-heterozygous-familial-and-non-familial-or-mixed-dyslipidaemia.--daiichi-sankyo--esperion2024-11-12T10:38:33+00:00weekly0.6https://www.medthority.com/news/2020/04/ema-approves-nustendi-for--primary-hypercholesterolaemia-heterozygous-familial-and-non-familial-or-mixed-dyslipidaemia.--daiichi-sankyo--esperion2024-10-24T10:35:03+00:00weekly0.6https://www.medthority.com/news/2020/04/health-canada-approves-spartan-cube--covid-19-test.---spartan-bioscience2024-11-12T10:38:45+00:00weekly0.6https://www.medthority.com/news/2020/04/astrazeneca-initiates-calavi-study-of-calquence-to-treat--cytokine-storm-associated-with-covid-19-infection/2021-12-20T17:30:24+00:00weekly0.6https://www.medthority.com/news/2020/04/health-canada-approves-rybelsus-to-treat-type-2-diabetes.--novo-nordisk2024-10-24T10:35:19+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-grants-fast-track-designation-for-vutrisiran-to-treat-the-polyneuropathy-of-hereditary-transthyretin-mediated-hattr-amyloidosis.--alnylam-pharma2021-12-20T17:32:21+00:00weekly0.6https://www.medthority.com/news/2020/04/bausch-health-initiates-trial-program-of-virazole-to-treat-hospitalised-patients-with-covid-19/2024-11-08T11:38:44+00:00weekly0.6https://www.medthority.com/news/2020/04/phase-iii-trial-of-tislelizumab---pemetrexed--for-first-line-nsclc-met-the-primary-endpoint-of-progression-free-survival-at-interim-analysis--beigene/2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/04/ontruzant-biosimilar-to-reference-product-herceptin-is-launched-in-the-us--merck-inc/2024-10-24T09:04:18+00:00weekly0.6https://www.medthority.com/news/2020/04/zealand-pharma-presents-positive-clinical-and-health-economic-outcome-data-with-use-of-regular-human-insulin-delivered-by-the-v-go-in-adults-with-type-2-diabetes/2024-11-12T10:38:55+00:00weekly0.6https://www.medthority.com/news/2020/04/novartis-announces-data-in-neurology-reinforcing-the-real-world-and-long-term-effectiveness-and-safety-of-aimovig-as-a-preventive-treatment-across-the-full-spectrum-of-migraine/2021-12-20T17:30:24+00:00weekly0.6https://www.medthority.com/news/2020/04/abbott-launches-antibody-test-for-covid-19/2021-12-20T17:32:21+00:00weekly0.6https://www.medthority.com/news/2019/05/axs-07-eliminated-migraine-pain-and-substantially-and-significantly-prevented-progression-of-migraine-pain-in-the-intercept-phase-iii-trial-in-the-early-treatment-of-migraine.--axsome-therapeutics2021-12-20T17:29:47+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-tukysa---trastuzumab--capecitabine-to-treat-unresectable-or-metastatic-her2-positive-breast-cancer-including-patients-with-brain-metastases.--seattle-genetics2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-pemazyre-to-treat-cholangiocarcinoma-with-a-fibroblast-growth-factor-receptor-2-fgfr2-fusion.--incyte-corpn2021-12-20T17:33:01+00:00weekly0.6https://www.medthority.com/news/2020/04/incyte-announces-initiation-of-phase-iii-ruxcovid-study-for-jakafi-as-a-treatment-for-patients-with-covid-19-associated-cytokine-storm/2021-12-20T17:32:21+00:00weekly0.6https://www.medthority.com/news/2020/04/fda-approves-jelmyto-to-treat-low-grade-upper-tract-urothelial-cancer-urogen-pharma/2024-11-12T09:13:34+00:00weekly0.6https://www.medthority.com/news/2019/09/superiority-of-orsiro-stent-over-xience-demonstrated-in-stemi-patients--late-breaking-data-at-esc---biotronik/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2013/04/revance-therapeutics-to-initiate-phase-iii-trial-for-rt-001-for-treatment-of-facial-wrinkles/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2017/06/alder-biopharmaceuticals-announces-results-of-phase-iii-promise-study-of-eptinezumab-for-migraine-prevention-/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2020/01/abbott-to-initiate-repair-mr-trial--of-mitraclip-for-people-with-primary-mitral-regurgitation-eligible-for-open-heart-surgery-/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2016/04/trial-of-victoza--liraglutide--shows-superiority-to-sitagliptin-in-type-2-diabetes--novo-nordisk/2024-02-22T13:12:16+00:00weekly0.6https://www.medthority.com/news/2013/11/study-of-remsima-inflectra--hospira--shows-equivalence-to-remicade-in-ra/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-accepts-filing-and-grants-priority-review-for-lucentis--ranibizumab-injection--in-treatment-of-myopic-choroidal-neovascularization--genentech-roche/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-510-k--approval-for-speedboat-rs2-device-and-the-croma-platform-to-treat-bowel-lesions---creo-medical-group-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-rasuvo-sc-for-rheumatoid-arthritis---medac-pharma/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-advisory-committee-rejects-melblez-kit--delcath--for-ocular-melanioma-metastatic-to-the-liver-/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-510-k--approval-for-dilumen-is-endolumenal-interventional-scissors--a-device-to-support-endoscopic-procedures--lumendi-llc-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2011/10/trial-of-omega-platinum-chromium-coronary-stent-system-now-enrolling-patients/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2014/11/interim-phase-iii-data-for-arzerra-in-cll-meets-primary-endpoint---genmab/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2015/07/astrazeneca-licenses-non-us-rights-to-entocort--budesonide--to-tillots-pharma-ag-for-crohns-disease-and-colitis-/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-data-on-kovaltry--recombinant-factor-viii--in-haemophilia-published-online--bayer-healthcare/2024-02-22T13:27:36+00:00weekly0.6https://www.medthority.com/news/2015/11/amg-416--etelcalcetide--non-inferior-to-oral-cinacalcet-in-treatment-of-secondary-hyperparathyroidism--amgen/2024-02-22T13:27:50+00:00weekly0.6https://www.medthority.com/news/2011/11/chantix--pfizer--raises-suicide-risk-and-is-unsuitable-for-treating-first-line-nicotine-addiction-/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2014/12/gilenya-and-primary-progressive-multiple-sclerosis-novartis/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2016/03/xenoport-sells-us-rights-to-xp-23829-treatment-for-psoriasis-to-dr-reddy--/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-does-not-recommend-opdivo--nivolumab--as-a-treatment-for-squamous-nsclc--bms/2024-02-22T13:27:59+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-sbla-for-dupixent-to-treat-severe-chronic-rhinosinusitis-with-nasal-polyps--crswnp---sanofi---regeneron/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2018/07/boston-scientific-to-acquire-cryterion-medical--inc-and-its-cryoablation-platform-for-the-treatment-of-atrial-fibrillation-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2015/12/pristiq--desvenlafaxine-succinate-sustained-release--fails-again-in-second-phase-iii-trial-for-depression--pfizer/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-advisers-recommmend-cv-trial-for-vascepa--amarin-/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2018/11/exparel-achieves-significant-reductions-in-opioid-use--hospital-stay-and-total-hospitalization-costs-following-knee-replacement-surgery--pacira-pharma/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2015/03/cardinal-health-to-buy-cordis-from-johnson---johnson/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-phase-iii-trial-of-vonvendi--von-willebrand-factor--recombinant---to-treat-bleeds-in-elective-surgical-settings-for-adults-with-severe-von-willebrand-disease--vwd----shire-plc-/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-grant-510-k--approval-for-dario-blood-glucose-monitoring-system-in-type-2-diabetes--labstyle-innovations/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-gives-positive-opinion-on-mosquirix--rts-s--vaccine-for-malaria--glaxo-smith-kline/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2015/05/study-shows-positive-benefits-of-sapien-3-transcatheter-aortic-valve-in-avs-patients-edwards-lifesciences/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2020/01/durect-corporation-announces-the-outcome-of--the-fda-advisory-committee-meeting-for-posimir-which-resulted-in-a-split-vote-on-the-treatment-of-post-surgical-pain--/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2018/09/positive-interim-analysis-from-envision-study-of-givosiran-to-treat-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2014/03/n8-gp-long-acting-factor--viii-completes-phase-iii-trial-for-haemophilia-a---novo-nordisk/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2016/06/cubicin--daptomycin--patents-declared-invalid-by-supreme-court--cubist-pharma-merck-inc-/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2016/11/shingrix-vaccine-for-herpes-zoster-filed-with-ema--glaxosmithkline/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2018/07/the-lancet-has-published-key-early-stage-data-regarding-an-investigational-mosaic-based-preventive-vaccine-regimen-against-hiv-1-infection----janssen-pharmaceutical-companies-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-odefsey--emtricitabine-200-mg-rilpivirine-25-mg-tenofovir-alafenamide-25-mg--to-treat-hiv-1-infection--gilead-sciences/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-follow-up-with-htx-011-shows-effective-pain-management-post-hernia-operation---heron-therapeutics/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-arazlo-for-the-topical-treatment-of-acne--ortho-dermatologics-bausch/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2016/08/mallinckrodt-sells-its-nuclear-imaging-business-to-iba-molecular-for--690-million-/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-snda-for-xtandi-to-expand-its-indication-to-include-men-with-non-metastatic-castration-resistant-prostate-cancer----pfizer---astellas-pharma-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---novel-therapies-slow-ckd-progression-in-patients-with-diabetes/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2015/11/results-from-study-of-inspire-upper-airway-stimulation--uas--system-in-obstructive-sleep-apnea-published-in-otolaryngol-head-neck-surg-journal--inspire-medical-systems/2024-02-22T13:28:17+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-nda-for-alks-3831-for-treatment-of-schizophrenia-and-bipolar-i-disorder---alkermes/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2018/08/prelude-feasibility-study-of-caisson-transcatheter-mitral-valve-replacement--tmvr--system-concludes-positively---livanova-plc-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2015/05/takeda-withdraws-from-collaboration-with-sumitomo-dainippon-for-marketing-latuda--lurasidone-hydrochloride--/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-adds-to-recall-warning-over-zilver-ptx-stent--cook-medical--for-pad/2021-09-24T07:16:20+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-xofigo--bayer--for-prostate-cancer/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2018/05/positive-results-of-select-sunrise-study-for-upadacitinib-for-treatment-of-rheumatoid-arthritis--abbvie-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2016/06/cat-spire--cat-allergy-t-cell-vaccine-fails-in-phase-iii-study---circassia-pharma-/2021-09-24T07:09:59+00:00weekly0.6https://www.medthority.com/news/2012/02/phase-i-iii-study-of-rviii-singlechain--csl-behring--for-haemophilia-a-begins/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2015/02/valeant-pharma-to-acquire-salix-pharma-for--14-5-billion/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-advance-study-of-long-acting-rolontis-shows-non-inferiority-to-pegfilgrastim-in-treatment-of-neutropenia---spectrum-pharmaceuticals-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-besremi-for-polycythaemia-vera---pharmaessentia-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-approves-xolair-for-urticaria---novartis---genentech/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-success-for-m-923--adalimumab-biosimilar--baxalta---momenta-pharma/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2017/08/sanofi-brings-patent-infringement-case-in-new-york-against-merck-inc--in-relation-to-insulin-glargine-biosimilar-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2012/02/enrollment-complete-for-phase-iii-carfilzomib--onyx-pharmaceuticals--trial-for-multiple-myeloma/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-ii-success-for-arzerra--gsk-genmab--for-ms/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2014/02/complete-response-letter-from-fda-for-versafilm-for-migraine--intelgenx/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-incruse-ellipta-for-treatment-of-copd--gsk/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2015/11/livermultiscan-imaging-device-receives-fda-510-k--clearance-for-detecting-early-liver-disease--perspectum-diagnostics/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-rewalk-system-for-patients-with-lower-body-paralysis--rewalk-robotics/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2012/02/rp-g28-success-in-phase-ii-trial-fro-lactose-intolerance/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2019/09/mundipharma-will-distribute-rezafungin-for-the-treatment-and-prevention-of-invasive-fungal-infections-in-all-markets-save-for-japan-and-usa--cidara-therapeutics/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2018/07/european-commission-approves-dzuveo-to-manage-acute-moderate-to-severe-pain-in-medically-monitored-settings---acelrx-pharmaceuticals-inc-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-does-not-recommend-besponsa---inotuzumab-ozogamicin--to-treat-relapsed-or-refractory-cd22-positive-b-cell-precursor-acute-lymphoblastic-leukaemia---pfizer/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2011/09/qnexa-to-be-re-filed-at-fda-for-obesity/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2014/11/revolade-variation-filed-with-ema-for-severe-aplastic-anaemia-gsk/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-javelin-ovarian-200-trial-of-avelumab-did-not-meet-endpoint-in-patients-with-refractory-ovarian-cancer--merck-kgaa---pfizer-its/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-accepts-sbla-for-tecentriq-plus-nab-paclitaxel-for-first-line--treatment-of-triple-negative-breast-cancer---genentech--roche/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2014/05/theravance-to-divide-into-two-companies/2025-10-16T11:15:54+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-nexavar--bayer-healthcare--meets-primary-endpoint-in-patients-with-thyroid-cancer/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-radium-ra-223-dichloride-for-prostate-cancer/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2016/05/hyper-acute-pancreas--algenpantucel-l--fails-to-meet-primary-endpoint-in-phase-iii-impress-trial-for-pancreatic-cancer--newlink-genetics/2024-02-22T13:28:30+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-robin-study-of-sage-217-meets-primary-endpoints-in-postpartum-depression---sage-therapeutics-/2024-10-21T14:53:23+00:00weekly0.6https://www.medthority.com/news/2019/03/data-from-phase-iii-trial-of-sublocade-in-opioid-use-disorder-published-in-journal-of-addiction-medicine---indivior/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2015/05/baxter-acquires-rights-to-oncaspar--pegaspargase--from-sigma-tau-/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2017/03/european-commission-approves-ledaga--chlormethine-gel--to-treat-mycosis-fungoides-type-cutaneous-t-cell-lymphoma---actelion-/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2018/03/results-from-three-studies-of-natpara--rhpth-1-84---in-chronic-hypoparathyroidism-presented-at-endo---shire-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-provenge---dendreon--for-treatment-of-prostate-cancer/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-two-indications-for-keytruda--pembrolizumab--to-treat-locally-advanced-or-metastatic-urothelial-carcinoma---merck-inc-/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-advisory-committee-does-not-approve-exparel-to-treat-regional-analgesia---pacira-pharma-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2014/05/merck-inc---sells-ophthamology-products-to-santen/2025-10-16T11:15:38+00:00weekly0.6https://www.medthority.com/news/2013/01/study-finds-cholestoff--nature-made--reduces-cholesterol-levels-in-patients-with-cv-risk/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2018/10/alliqua-merges-with-adynxx-to-create-a-new-company-to-promote-brivoligide-for-the-reduction-of-long-term-pain-relief-and-the-reduction-of-opioids-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2014/09/success-for-combination-zelboraf---cobimetinib-in-advanced-melanoma---genentech-roche-/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-freestyle-libre-pro-system-professional-diagnostic-for-type-1-and-2-diabetes--abbott/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2015/09/sony-olympus-medical-solutions-announces-planned-launch-of-4k-technology-endoscopy-system-called-visera-4k-uhd/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2018/10/new-analyses-from-pivotal-phase-iii-trials-of-oral-ozanimod-for-relapsing-multiple-sclerosis---celgene/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2016/04/recharge-study-of-vbloc-neurometabolic-therapy-successful-for-obesity---enteromedics-inc-/2024-02-22T13:29:04+00:00weekly0.6https://www.medthority.com/news/2013/05/two-analyses-show-fycompa--eisai--effective-for-epilepsy/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-announce-study-of-lartruvo-fails-to-meet-endpoint-in-soft-tissue-sarcoma---eli-lilly/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-issues-complete-response-letter-for-tx-004hr--an--applicator-free-vaginal-estradiol-softgel-drug-candidate-for-the-treatment-of-moderate-to-severe-dyspareunia---therapeutics-md-inc--/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2018/06/versartis-acquires-aravive-biologics-and-with-it-avb-56-500-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2019/12/generic-afinitor-is-launched-in-us-by-par-pharma--endo-/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2019/08/adma-biologics--inc--announces-the-commercial-relaunch-and-its-first-commercial-sales-of-bivigam-for-primary-humoral-immunodeficiency-/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-phase-iii--prevent-trial-of-cosentyx-to-treat-non-radiographic-axial-spondyloarthritis--novartis/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-perjeta-for-neoadjuvant--breast-cancer-/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2019/11/precision-focused-immunology-leadership-from-bms-with-new-data-on-orencia-in-early-ra--acpa-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2013/03/crlx-101--cerulean-pharma--fails-in-phase-ii-trial-for-nsclc-/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2012/05/menarini-acquires-rights-to-priligy-for-premature-ejaculation-treatment/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2017/07/mylan-n-v--and-biocon-ltd--announced-that-the-fda-oncologic-drugs-advisory-committee--odac--recommended-approval-of-the-companies--proposed-biosimilar-trastuzumab-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2014/09/mnk-155-meets-primary-endpoint-in-phase-iii-pain-study-mallinckrodt/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2012/12/precision-spectra-spinal-cord-stimulator--boston-scientific--receives-ce-mark/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-now-finds-firmagon--degarelix--to-be-not-cost-effective-as-a-prostate-cancer-treatment--ferring/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2013/02/fission-and-neutrino-studies-success-for-gs-7977--gilead-sciences--for-hepatitis-c/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2018/11/seattle-genetics-files-sbla-at-fda-for-adcetris-to-treat-cd30-expressing-peripheral-t-cell-lymphoma--ptcl--/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-study-results-for-tecentriq---cotellic----zelboraf-for-previously-untreated-braf-v600-mutation-positive-advanced-melanoma--genentech-roche/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2014/01/xtandi-success-in-phase-iii-prevail-study-for--prostate-cancer-astellas-medivation/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2019/11/fourier-outcomes-phase-iii-study-of-repatha-shows-effectiveness-in-myocardial-infarction---amgen/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommendation-for-nuwiq--for-treatment-of-haemophilia---octapharma-ag/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2016/09/study-of-relvar-ellipta--fluticasone-furoate--vilanterol--in-chronic-obstructive-pulmonary-disease-published-in-new-england-journal-of-medicine--glaxosmithkline---innoviva/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2013/06/positive-top-line-results-from-myrror-trial-of-eylea--regeneron-bayer-healthcare--for-choroidal-neovascularization/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2016/01/heplisav-b-superior-to-engerix-b-in-phase-iii-trial-for-treatment-of-hepatitis-b--dynavax/2024-02-22T14:52:32+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-issues-complete-response--letter-for-tlando--a-proposed-testosterone-replacement-therapy----lipocine-inc-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2016/10/setpoint-medical-implant-study-modulates-the-inflammatory-reflex-via-vagus-nerve-to-treat-crohn-s-disease-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-accepts-for-review-vascepa-to-reduce-residual-cardiovascular-risk-in-patients-with-statin-managed-ldl-c-cholesterol--amarin/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-argus-ii-retinal-prosthesis-system-for-retinitis-pigmentosa/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2018/02/vertex-pharma-initiates-phase-iii-study-for-vx-659---tezacaftor---ivacaftor-to-treat-f508del-mutation-cystic-fibrosis-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2017/09/medtronic-launches-intellis-spinal-cord-neurostimulation-platform--which-includes-the-world-s-smallest-fully-implantable-spinal-cord-neurostimulator-to-treat-pain-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2017/03/myovant-initiates-phase-iii-hero-trial-of-relugolix-to-treat-advanced-prostate-cancer-/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2014/08/r-348-fails-phase-ii-trial-for-dry-eye-disease---rigel/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-panel-recommends-cimzia-for-axial-spondyloarthritis/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2019/11/lilly-presents-52-week-head-to-head--spirit-h2h--data-from-taltz--v--humira-trial-in-psoriatic-arthritis-/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2016/10/study-of-tri-moxi-vanc-dropless-therapy--triamcinolone-acetonide---moxifloxacin---vancomycin--after-cataract-surgery-published-in-current-opinion-in-ophthalmology--imprimis-pharmaceuticals/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-defitelio--gentium--for-veno-occlusive-disease/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2012/08/phase-iii-programme-of-gsk-573719-plus-vilanterol--glaxo-smith-kline-theravance--for-copd-completed---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-eylea-for-treatment-of-diabetic-macular-edema---regeneron/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-trial-of-hpam4-cide--90y-labelled-clivatuzumab-tetraxetan--in-pancreatic-cancer-terminated-early-due-to-low-efficacy--immunomedics-/2024-02-22T14:54:39+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-advisory-committee-recommends-probuphine-to-treat-opioid-dependence--titan-pharmaceuticals/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2019/09/toca-5-phase-iii-trial-with-toca-511---toca-fc-fails-to-meet-endpoint-in-glioma---tocagen/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-advisory-committee-recommends-once-weekly-semaglutide--for-type-2-diabetes----novo-nordisk-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2015/12/results-of-accurate-study-show-advantage-of-axium-neurostimulator-system-in-pain-relief--st-jude-medical/2024-02-23T10:58:26+00:00weekly0.6https://www.medthority.com/news/2015/06/amgen-completes-enrollment--for-fourier-trial-of-repatha--evolocumab-in-combination-with-a-statin-for-reduction-of-cv-risk-/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-aliqopa--copanlisib--to-treat-patents-with-relapsed-follicular-lymphoma---bayerhealthcare-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-linzess--linaclotide--for-ibs-c-meets-all-endpoints--actavis-ironwood-pharma/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-a-new-420-mg-single-dose-delivery-option-for-repatha--evolocumab-for-eliminating--bad--cholesterol--low-density-lipoprotein-cholesterol-or-ldl-c----amgen/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2018/05/novel-test-for-antibiotic-associated-kidney-damage-in-children-with-cystic-fibrosis-identified/2021-12-01T13:15:42+00:00weekly0.6https://www.medthority.com/news/2017/12/at-ash-meeting-seattle-genetics-updates-results-of-alcanza-trial-of-adcetrisfor-cutaneous-anaplastic-large-cell-lymphoma-/2024-02-22T14:54:21+00:00weekly0.6https://www.medthority.com/news/2013/12/lbh-589-success-in-phase-iii-multiple-myeloma-trial-novartis/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-accepts-filing-of-fixed-ratio-lixisenatide---basal-insulin-glargine--lixilan--to-treat-type-2-diabetes-sanofi/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2019/10/ra-pharmaceuticals-announces-dosing-of-first-patient-in--phase-iii-pivotal-study-of-zilucoplan-for-generalized-myasthenia-gravis-/2021-09-24T07:17:25+00:00weekly0.6https://www.medthority.com/news/2013/02/st-jude-medical-initiates-trial-of-enlightn-system-for-cv-risk-reduction---------------/2021-09-24T07:15:33+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-deep-brain-stimulation-for-epilepsy--medtronic/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2019/05/nektar-therapeutics-announces-formation-of-inheris-biopharma-inc---a-cns-focused-company-/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2017/11/ionis-ttrrx-filed-with-ema-for-hereditary-ttr-amyloidosis---ionis-pharma-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-recommends-ezetrol--ezetimibe--for-treating-primary-hypercholesterolaemia--merck-inc/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2016/12/sienna-biopharmaceuticals--inc--buys-creabilis-plc-and-with-it-sna-120--formerly-ct327-and-sna-125--formerly-ct340-/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2018/03/regular-monitoring-rather-than-immediate-treatment-justified-for-some-cervical-lesions/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2012/08/oral-start-trial-success-for-tofacitinib--pfizer--in-ra/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-betaconnect-electronic-autoinjector-for-multiple-sclerosis--bayer-healthcare/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-recommends-conditional-use-of-esbriet-in-specific-population-with-idiopathic-pulmonary-fibrosis---roche-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2016/01/astrazeneca--medimmune--and-moderna-therapeutics-to-collaborate-on-mrna-therapy/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-vivasight--etview-medical--for-use-in-lung-surgery/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2019/03/even-younger-nightshift-workers-shown-to-need-to-pee-more--worsening-quality-of-life-/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-avastin---chemotherapy-for-resistant-ovarian-cancer--roche/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2012/06/insulin-degludec-novo-nordisk--success-in-nocturnal-hypoglycaemia/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2015/03/idarucizumab-filed-with-ema-and-health-canada-as-antidote-for-dabigatran-boehringer/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2015/03/bms-files-yervoy--ipilimumab--for-supplemental-approval-for-stage-3-melanoma-recurrence-/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2013/10/bms-945429--bms--shows-promising-efficacy-in-ra/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2019/09/pdufa-date-for-av-001-a-treatment-for-narcolepsy--is-extended-to-15-december-2019----avadel-pharma/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2019/10/partner-3-trial-of-sapien-3-valve-for-aortic-stenosis-published-in-journal-of-american-college-of-cardiology---edwards-lifesciences/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2013/06/xgeva--amgen--is-fda-approved-to-treat-giant-cell-tumor-of-bone/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2014/08/halaven-fails-phase-iii-study-in-non-small-cell-lung-cancer---eisai/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2018/05/interim-analysis-of-phase-iii-olympus-trial-of-mitogel-shows-positive-results-in-urothelial-cancer---urogen-pharma-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2018/04/glembatumumab-vedotin-fails-phase-ii-trial-for-triple-negative-breast-cancer---celldex-therapeutics-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-uceris--santarus--for-mild-to-moderate-ulcerative-colitis/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-accepts-sdna-for-promacta-for-first-line-treatment-of-severe-aplastic-anemia---novartis-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2014/05/pfizer-final-offer-to-astra-zeneca/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2014/08/nicox-s-a--to-co-promote-latanoprostene-bunod-in-us-with-bausch---lomb-for-glaucoma---ocular-hypertension-/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2013/01/positive-results-in-phase-iii-trial-of-xeljanz--pfizer--in-patients-with-rheumatoid-arthritis-/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2014/04/janssen-files-darunavir-cobicistat-for-hiv-with-the-fda/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2012/10/phase-iii-success-for-eliglustat-tartrate--sanofi-genzyme--in-gaucher-disease----------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2011/04/phase-ii-data-for-bi-201335-for-hepatitis-c/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2018/03/real-world-notion-trial-shows-corevalve-tavr-offers-improved-quality-of-life-in-aortic-stenosis---medtronic-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2016/08/vertex-update-on-vx-661---kalydeco---ivacaftor--phase-iii-studies-for-cystic-fibrosis--f508del-mutation-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2015/03/interim-analysis-of-light-study-of-contrave--naltrexone-hcl-bupropion--in-cv-risk-with-obese-patients--orexigen-takeda/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2017/04/the-fda-has-accepted-the-resubmission-of-the-biologics-license-application-for-kevzara---sarilumab--for-the-treatment-of-rheumatoid-arthritis---sanofi---regeneron/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2017/03/data-from-absorb-iii-study-showed-that-absorb-bioresorbable-vascular-stent-was-comparable-in-efficacy-to--the-xience-metallic-drug-eluting-stent-abbott/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-trial-of-triple-therapy-is-initiated-for-vx-445--tezacaftor-and-ivacaftor-to-treat-f508del-mutation-cystic-fibrosis---vertex--pharma-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-prezcobix-for-hiv-aids---janssen-therapeutics/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-expands-sprycel-indication-to-include-children-with--philadelphia-chromosome-positive--ph---chronic-myeloid-leukemia---bms/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-apealea-to-treat-ovarian-cancer---oasmia-pharma/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2017/08/eu-approves-mavenclad--cladribine--for-relapsing-multiple-sclerosis--merck-kgaa-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2013/12/lower-rates-of-hypoglycaemia-with-ryzodeg-compared-to-insulin-aspart-novo-nordisk/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2015/03/phase-iii-results-with-invega-sustenna-xeplion--paliperidone-palmitate--in-schizophrenia-published-in-jama--janssen/2024-02-22T14:56:22+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-praluent--alirocumab--for-limited-use-in-hypercholesterolemia---sanofi---regeneron/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2019/03/study-suggests-personality-tests-may-improve-care-for-prostate-cancer-patients/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2016/05/study-shows-oncotype-dx-breast-diagnostic-test-accurately-predicts-recurrence-risk-of-breast-cancer--genomic-health/2024-02-22T14:56:41+00:00weekly0.6https://www.medthority.com/news/2013/02/pa-21--galencia--is-filed-at-fda-and-ema-for-treatment-of-hyperphosphataemia--in-ckd-patients/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2019/06/results-from-polo-trial-of-lynparza-as-monotherapy-for-maintenance-for-brca-mutated-pancreatic-cancer--astra-zeneca---merck-inc-/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2013/10/auxilium-pharma-to-market-stendra-for-erectile-dysfunction-in-the-us-and-canada/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2015/07/allergan-buys-oculeve-for--125-million/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-trial-of-kadcyla-shows-benefits-in-breast-cancer/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/06/new-xerava-data-presented-at-annual-surgical-infection-society-meeting-for-treatment-of-complicated-intra-abdominal-infections--tetraphase/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2018/02/placebo-pills-prescribed-help-cancer-survivors-manage-symptoms/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2016/06/long-term-survival-data-for-opdivo--nivolumab--in-treatment-of-renal-cell-carcinoma---bms/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2019/04/interim-data-from-emricasan-phase-iii-trial--for-nash-cirrhosis-and-portal-hypertension---conatus---novartis/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2015/07/horizon-pharma-plc-to-acquire-depomed-inc--for--3-billion/2025-10-16T11:01:41+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-avastin-for-treatment-of-ovarian-cancer---genentech-roche/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2016/05/lynparza--olaparib--plus-paclitaxel-fails-to-meet-endpoint-in-phase-iii-gold-trial-for-advanced-gastric-cancer--astrazeneca/2024-02-22T14:58:09+00:00weekly0.6https://www.medthority.com/news/2013/02/tasimelteon--vanda--fails-trial-for-treatment-of-depression-/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2019/08/epoch-2-phase-iii-study-of-htx-011-in-pain-control-published-in-hernia-journal---heron-therapeutics/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-results-with-gocovri-in-parkinson-s-disease-published-in-movement-disorders-clinical-practice---adamas-pharmaceuticals-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2012/06/study-shows-viramune-viramune-xr--boehringer--halves-risk-of-hiv-infection-in-newborns/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2013/09/atx-101-meets-phase-iii-endpoints-for-submental-fat--double-chin-/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2012/06/exelixis-reports-results-for-xl-184-in-thyroid-cancer/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-credence-study-of-invokana-finds-benefits-for-kidney-function-in--diabetic-nephropathy---janssen-pharma/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-activa-dbs-system-for-parkinsons-of-at-least-4-years-duration--medtronic/2024-02-22T14:58:28+00:00weekly0.6https://www.medthority.com/news/2018/10/empa-reg-outcome-trial-of-jardiance-in-t2d---cv-published-in-circulation---boehringer---eli-lilly-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2018/12/new-analysis-of-mystic-trial--of--imfinzi-monotherapy-or-imfinzi---tremelimumab-was-presented-at-the-esmo-immuno-oncology-congress--astrazeneca/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-probuphine--buprenorphine-implant-to-treat--opioid-dependence---titian-pharma/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2017/06/body-fat-and-waist-size-linked-to-increased-risk-of-developing-rheumatoid-arthritis-in-women/2021-11-30T10:24:22+00:00weekly0.6https://www.medthority.com/news/2012/05/nice-to-recommend-botox--allergan--for-migraine/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2020/01/kissei-announces-the-publication-of-the-results-of-phase-iii--trials-of-rovatirelin-for-the-treatment-of-spinocerebellar-degeneration-in-the-journal-of-neurology--neurosurgery--and-psychiatry-/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2019/07/amgen--novartis-and-banner-alzheimer-s-institute-discontinue-clinical-research-program-with-cnp-520-for-alzheimer-s-prevention-/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-srt-100-radiotherapy-system--sensus-healthcare--to-treat-keloids/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2018/06/dexcom-g6-continuous-glucose-monitor-for-diabetes-receives-ce-mark---dexcom-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2019/05/breast-cancer-in-young-women--good-outcomes-with-advised-therapy-/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-opdivo--nivolumab--to-treat-advanced-renal-cell-carcinoma--bms---ono-pharma-/2024-02-22T14:58:39+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-kengreal--cangrelor-as-adjunctive-therapy-in-pci-the-medicines-company-/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-opdivo--nivolumab---yervoy--ipilimumab--for-treatment-of-advanced-melanoma-in-adults--bms/2024-02-22T14:59:25+00:00weekly0.6https://www.medthority.com/news/2016/11/allergan-acquires-motus-therapeutics-and-with-it--relamorelin--rm-131--for-the-treatment--of-gastroparesis/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-expands-indication-for-aczone-for-patients-age-9---11-with-acne---almirall/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-approval-for-nexavar-for-treatment-of-thyroid-cancer---bayer-healthcare/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2012/12/botox--allergan--approved-in-ireland-for-treating-overactive-bladder--the-first-step-towards-eu-wide-approval/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2017/04/ema-expands-approval-of-acarizax-house-dust-mite-sublingual-allergy-immunotherapy--slit--tablet-for-adolescent-patients--alk/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2014/12/new-phase-iii-results-for-revlimid-in-myelodysplastic-syndromes-celgene/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-mepsevii-to-treat-non-neurological-manifestations-of-mucopolysaccharidosis-vii--mps-vii--sly-syndrome----ultragenyx-pharma-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2019/05/genentech-presents-pivotal-firefish-and-sunfish-studies-in-spinal-muscular-atrophy-/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-accepts-sbla-for-praluent-to-reduce-cv-events--regeneron/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2015/11/iqwig-assessment-suggests-nulojix--belatacept--offers-considerable-added-benefit-after-kidney-transplant-bms/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2013/08/lux-lung-trial-data-for-nsclc-published-in-jo-clinical-oncology/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2015/03/nice-gives-final-recomendation-to-gazyvaro--obinutuzumab---for-cll--genentech--roche/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2019/07/results-from-solace-trial-of--reproxalap-to-treat-noninfectious-anterior-uveitis/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2016/02/data-from-phase-iii-energito-study-of-stiolto-respimat--olodaterol---tiotropium--published-in-journal-of-chronic-obstructive-pulmonary-disease--boehringer/2024-02-22T14:57:05+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-grants-iclusig--ponatinib--full-approval-for-chronic-myeloid-leukemia-or-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia--for-t315i-positive-cml-or-t315i-positive-ph--all--ariad-pharma/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-trial-success-for-pci-32765--janssen-biotech--in-cll-treatment/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2014/06/nivolumab---ipilimumab-success-in-phase-1b-study-for-advanced-melanoma--bms/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2016/07/results-from-the-pivot-phase-iii-trial-of-ampion-show-safety-and-efficacy-in-osteoarthritis-of-the-knee--ampio-pharma/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2018/04/dupixent-is-filed-at-ema-as-add-on-maintenance-treatment-in-certain-adults-and-adolescents--12-years-of-age-and-older--with-inadequately-controlled-moderate-to-severe-asthma--sanofi-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2012/02/zelboraf--roche--for-metastatic-melanoma-nearly-doubles-median-survival/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2019/03/ema-approves-hemlibra-for-routine-prophylaxis-in-haemophilia-a---roche/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-gives-tentative-approval-for-dolutegravir----emtricitabine---tenofovir-alafenamide-in-hiv-aids---mylan-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---new-connection-found-between-non-alcoholic-fatty-liver-disease-and-rare-pregnancy-complication/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2014/09/basal-insulin-peglispro-superior-to-lantus-in-type-1-diabetes--eli-lilly/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2019/08/positive-top-line-results-from-comparative-study-of-abp-798--biosimilar-to-rituxan---allergan---amgen/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2014/08/insys-therapeutics-files-nda-at-fda-for-dronabinol-oral-solution-for-anorexia-and-nausea-/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2019/02/positive-phase-iii-polo-trial-of-lynparza-in-germline-brca-mutated-metastatic-pancreatic-cancer--astrazeneca---merck-inc-/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2012/04/phase-iia-results-for-miravirsen--santaris-pharma--show-prolonged-antiviral-activity-in-hepatitis-c-patients/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2012/04/chmp-recommends-rienso--takeda--for-iron-deficiency-anaemia/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-libtayo-to-treat--metastatic-cutaneous-squamous-cell-carcinoma----regeneron---sanofi/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-restylane-lyft-as-dermal-filler-for-the-back-of-the-hands---galderma-nestle-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2019/10/complete-response-letter-for-injectable-formulation-of-long-acting-cosyntropin--treatment-for-adrenocortical-insufficiency---assertio-therapeutics/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2019/06/study-supports-glucocorticoid-tapering-in-patients-achieving-disease-control-on-tocilizumab/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-refusal-of-application-for-adlumiz--anamorelin--for-anorexia--cachexia-or-unintended-weight-loss-in-patients-with-non-small-cell-lung-cancer--helsinn-birex-pharmaceuticals/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2019/07/janssen-reports-positive-top-line-phase-iii-results-for-ponesimod-in-adults-with-relapsing-multiple-sclerosis/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2014/10/ce-mark-for-accolade-pacemakers-from-boston-scientific/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2016/10/zubsolv--buprenorphine-and-naloxone--sublingual-tablet-filed-with-eu-for-treatment-of-opioid-dependence--mundipharma-and-orexo/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-customflex-artificial-iris-to-treat-congenital-aniridia--human-optics-ag-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-trial-of-gene-therapy-valoctocogene-roxaparvovec--is-initiated-to-treat-haemoplilia-a---biomarin-/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2017/02/kids-b-long-phase-iii-clinical-trial-for-alprolix--eftrenonacog-alfa--as-a-treatment-of-haemophilia-b-is-published-in-the-lancet-haematology---sobi---bioverativ-inc-/2021-09-24T07:13:16+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-grants-section-510-k--clearance-to-calypso-soft-tissue-beacon-transponder---varian-medical/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2011/11/trial-comparing-xience-v--abbott--with-endeavor-resolute--metronic--shows-non-inferiority-for-pci-patients/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-approves-single-site-instrumentation-for-da-vinci-si-surgical-system--intuitive-surgical-/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2015/06/eu-approves-synjardy---empagliflozin-plus-metformin---for-treatment-of-type-2-diabetes-boehringer/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2018/02/purdue-pharma-to-cease-marketing-oxycontin-and-opioid-drugs-in-the-us-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-extends-review-date-of-uplyso--pfizer-for-gauchers-disease-until-1-may-2012/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2017/12/four-year-data-confirms-efficacy-and-safety-of-jakafi-in-polycythemia-vera---incyte-/2021-09-24T07:13:41+00:00weekly0.6https://www.medthority.com/news/2019/11/halo-301-phase-iii-study-of-pegph-20---abraxane---gemcitabine-fails-to-meet-endpoint-in-pancreatic-cancer---halozyme-therapeutics/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2016/04/cariprazine-filed-at-ema-for-treatment-of-schizophrenia---gedeon-richter/2021-09-24T07:10:45+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-darzalex--daratumumab--as-a-treatment-for--relapsed-and-refractory-multiple-myeloma--janssen-cilag/2024-02-22T15:00:05+00:00weekly0.6https://www.medthority.com/news/2015/12/ono-7643--anamorelin-hci--filed-with-eu-for-unintended-weight-loss-in-non-small-cell-lung-cancer--helsinn/2024-02-22T15:00:17+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-intandem1-study-of-lx-4211--sotagliflozin--meets-secondary-endpoints-in-type-1-diabetes--lexicon-pharmaceuticals/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-visia-implantable-cardioverter-defibrillators-for-atrial-fibrillation-medtronic/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-yupelri-to-treat-copd---theravance-bipoharma---mylan/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-juxtapid--aegerion-pharma--for-patients-with-homozygous-familial-hypercholesterolemia/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2015/01/shire-acquires-nps-pharma-for--5-2-billion-including--gattex-revestive-and-natpara/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-dalvance-injection-for-absssi---durata-therapeutics/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-ebi-005--isunakinra--for-allergic-conjunctivitis-fails-to-meet-endpoint--eleven-biotherapeutics/2024-02-22T15:00:35+00:00weekly0.6https://www.medthority.com/news/2018/12/long-term-study-of-eloctate-confirms-safety-and-efficacy-in-haemophilia-a---orphan-biovitrum-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2019/07/topline-results-reported-from-phase-iii-paragon-hf-study-of-sacubitril-valsartan-in-hfpef--a-form-of-heart-failure---novartis/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---melanoma-diagnosis--first-data-from-artificial-intelligence-/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2013/08/nejm-study-shows-votrient-s-benefits-in-kidney-cancer/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2015/01/sativex-fails-phase-iii-trial-to-treat-cancer-pain--gw-pharma/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2020/01/janssen-seeks-expanded-use-of-spravato----esketamine--nasal-spray-in-europe-as-a-treatment-for-depressive-symptoms-in-adults-with-major-depressive-disorder-who-have-current-suicidal-ideation-with-intent/2024-07-26T10:58:48+00:00weekly0.6https://www.medthority.com/news/2018/08/ozempic-reduced-the-risk-of-major-cardiovascular-events-across-type-2-diabetes-populations-at-high-cv-risk-regardless-of-prior-cv-events-at-baseline---novo-nordisk-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2017/10/smartphone-compatible-cardiac-monitor-clears-fda-approval/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2014/05/new-data-shows-survival-benefits-of-gilotrif-for-nsclc---boehringer/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2016/12/adynovate--recombinant-factor-viii--approved-by-fda-for-hemophilia-a--in-pediatric-patients-under-12-years-of-age-and-in-surgical-settings--shire/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2013/05/nice-recommends-betmiga--astellas--for-patients-with-overactive-bladder/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2015/07/medtronic-acquires-rf-surgical-systems/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-edarbi-ipreziv-for-hypertension/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2019/05/clinical-data-with-symplicity-renal-denervation-system-shows-efficacy-in--uncontrolled-hypertension/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2011/10/us-cdc-recommend-hpv-vaccine-against-human-papalloma-virus-for-11-or-12-year-old-boys/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-neuviz-prime-128-slice-ct-scanner---neusoft-medical-/2021-09-24T07:14:41+00:00weekly0.6https://www.medthority.com/news/2012/10/complete-response-letter-from-fda-for-levadex--map-pharma--for-migraine-1/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2017/04/cytrx-corporation-agrees-on-preparations-for-a-new-drug-application--nda--submission-for-aldoxorubicin-in-soft-tissue-sarcomas--sts--/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2015/01/roche-acquires-trophos-s-a/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2014/07/genentech-reports-success-in-cobrim-trial-with-cobimetinib---zelboraf-combination-for-metastatic-melanoma/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-removes-hold-on-phase-iii-trial-of-evp-6124--encenicline--in-cognitive-impairment-in-schizophrenia--forum-pharma/2024-02-22T15:00:47+00:00weekly0.6https://www.medthority.com/news/2016/03/encenicline--frm-6124--fails-in-two-phase-iii-trials-to-treat-cognitive-impairment-with-schizophrenia--forum-pharma/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2016/08/darzalex--daratumumab--plus-bortezomib-and-dexamethasone-filed-with-eu-for-multiple-myeloma--genmab--janssen/2021-09-24T07:09:38+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-spravato-for-resistant-depression---janssen-pharma/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2017/03/eu-extends-label-of-cinryze--c1-inhibitor--human---for-children-with-hereditary-angiodema--hae---shire-plc/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2011/12/chmp-recommends-esmya--preglem--for--pre-operative-treatment-of-uterine-fibroids/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2013/02/tavaborole--anacor-pharma--success-in-phase-iii-for-onychomycosis-/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-rinvoq-to-treat-moderately-to-severely-active-rheumatoid-arthritis---abbvie-/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2016/04/successful-opal-broaden-phase-iii--trial-for-xeljanz--tofacitinib--to-treat-psoriatic-arthritis--pfizer/2024-02-22T15:01:07+00:00weekly0.6https://www.medthority.com/news/2015/07/allergan-acquires-oral-cgrp-receptor-antagonists-from-merck-inc--including-mk-1602-and-mk-8031/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2018/01/court-of-appeals-for-the-federal-circuit-lifts-preliminary-injunction-on-generic--buprenorphine-and-naloxone--sublingual-film---indivior-plc-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-extension-of-indication-of-zytiga--abiraterone--in-prostate-cancer---janssen-cilag-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2018/07/ce-mark-for-the-sacral-neuromodulation-external-trial-system-to-treat-urinary-dysfunction---axonics-modulation-technologies--inc-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2017/05/tecentriq--atezolizumab--fails-phase-iii-trial-for-locally-advanced-or-metastatic-urothelial-cancer-after-treatment-with-a-platinum-based-chemotherapy-----genentech---roche/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2013/06/sir-spheres-microspheres--sirtex--benefit-both-elderly-and-younger-patients-with-liver-cancer/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-study-of-crysvita-meets-primary-endpoint-in-x-linked-hypophosphatemia---ultragenyx-pharma-kyowa-hakko-kirin-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-study-of-elagolix-shows-significant-improvements-in-endometriosis--abbvie-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-accepts-bla-application-for-seg-101--for-the-prevention-of-vaso-occlusive-crises--in-patients-with-sickle-cell-disease---novartis/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-data-shows-faster-acting-insulin-aspart-reduces-hba1c-in-type-1-diabetes-versus-novorapid--insulin-aspart----novo-nordisk/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2020/01/positive-interim-results-from-phase-iii-trial-of-tislelizumab-in--patients-with-first-line-squamous-nsclc---beigene/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2018/01/updated-nice-guidelines-announced-for-vegf--treatment-of--wet--age-related-macular-degeneration--bayer---regeneron/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-recommends-entyvio--vedolizumab--from-takeda-to-treat-ulcerative-colitis/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2018/06/relevance-phase-iii-trial-of-revlimid---fails-to-meet-endpoint-in-follicular-lymphoma---celgene-corp-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2014/03/ldk-378-trial-for-alk---nsclc-patients-published-in-nejm---novartis/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-rejects-afinitor--everolimus--from-the-cancer-drugs-fund-as-a-treatment-for-breast-cancer--novartis/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2012/07/eeva-system--auxogyn--shows-positive-results-in-trial-for-ivf/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2018/09/paradigms-study-of-gilenya-for-pediatric-multiple-sclerosis-patients-is-published-in-nejm---novartis/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2019/10/completion-of-interim-statistical-assessment-and-small-increase-in-target-enrollment-for-kalm-2-phase-iii-trial-of-korsuva-injection/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-issues-2nd-draft-guidance-on-pixuvri--cell-therapeutics-/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2016/10/auvi-q--epinephrine-injection--auto-injector-for-anaphylaxis-to-be-reintroduced-to-the-us-market--kal-o/2024-10-21T14:41:53+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-chmp-recommends-approval-of-zalviso--sufentanil-sublingual-tablets--for-post-operative-pain--grunenthal/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-tryton-side-branch-stent-for-the-treatment-of-coronary-bifurcation-lesions--tryton-medical--inc-/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-extension-studies-show-advantages-of-botox--onabotulinumtoxina--in-urinary-incontinence--allergan/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2014/12/gsk-submits-snda-for-promacta-in-thrombocytopenia--gsk/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2015/12/egalet-files-arymo--morphine-sulfate-extended-release-tablets--at-fda-to-treat-severe-pain/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2016/06/sensitivity-analysis-shows-probuphine--subdermal-buprenorphine-implant--superiority-to-sublingual-buprenorphine-in-opioid-dependence--braeburn-pharmaceuticals/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2019/12/reblozyl-studies-evaluating-treatment-of-anemia-in-myelofibrosis-associated-anemia--presented-at-american-society-of-hematology--ash--meeting--bms---acceleron-pharma/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2013/08/vogelxo-fda-approval-for-testosterone-deficiency/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2017/07/nice-recommends-cabometyx--cabozantinib--to-treat-renal-cell-carcinoma---ipsen-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-jivi-a-prophylactic-treatment-for-hemophilia-a---bayer-healthcare-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-pradaxa--dabigatran-etexilate-mesylate--for-deep-venous-thrombosis-and-pulmonary-embolism--boehringer-ingelheim/2024-02-22T15:01:28+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-study-of-ultomiris-shows-efficacy-and-safety-in-paroxysmal-nocturnal-hemoglobinuria---alexion-pharma/2021-09-24T07:16:55+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-sep360-321-trial-of-dasotraline-meets-primary-endpoint-in-binge-eating-disorder---sunovion-pharma-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-advisory-committee-recommends-mirabegron-astellas-for-treatment-of-overactive-bladder/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-s-clinical-hold-on-all-trials-of-sb-1518--pacritinib--for-patients-with-myelofibrosis-now-removed--cti-biopharma/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-somo-v-automated-breast-ultra-sound-system-for-dense-breast-imaging------------------------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2019/10/be-vivid-phase-iii-study-of-ucb-4940-meets-co-primary-endpoints-in-chronic-plaque-psoriasis---ucb/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-kalm-1-trial-of-korsuva-for-chronic-kidney-disease-associated-pruritus-published-in-nejm---cara-therapeutics/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2019/04/nejm-has-published-a-successful-phase-i-ii--trial-of-a-lentiviral-gene-therapy-for-the-treatment-of-infants-with-xscid---bubble-boy-disease/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2012/10/oral-treprostinal--united-therapeutics--attracts-complete-response-letter-from-fda/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approves-sunosi-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adults-with-narcolepsy--jazz-pharma/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-juvederm-ultra-xc-for-lip-augmentation--allergan/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2019/11/bms-and-pfizer-announce-randomized--controlled-trial-to-evaluate-the-effect-of-atrial-fibrillation-screening-on-health-outcomes-in-older-individuals-/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-namzaric-for-alzheimers-actavis-adamas-pharma/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-panorama-trial-of-eylea-meets-endpoints-in-non-proliferative-diabetic-retinopathy---regeneron-pharma-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2016/11/pfizer-cancels-program-for-bococizumab-its-proposed-treatment-for-dyslipidaemia-/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2019/07/innovation-pharma-licences-brilacidin-to-alfasigma-for-the-treatment-of-ulcerative-proctitis-ulcerative-proctosigmoiditis-/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-iii-study-of-revlimid--celgene--meets-primary-endpoint-for-multiple-myeloma/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2019/03/biosolve-iv-one-year-data-underline-the-benefit-of-the-magmaris-resorbable-magnesium-scaffold-for-patients-with-de-novo-coronary-artery-lesions---biotronik/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2019/09/biogen-announces-a-new-trial-devote-to-evaluate-a-higher-dose-of-spinraza-for-patients-with-spinal-muscular-atrophy-/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-triple-therapy-fluticasone-furoate-umeclidinium-vilanterol--ff-umec-vi---as-trelegy-ellipta--for-the-long-term--once-daily--maintenance-treatment-of-patients-with-copd--gsk---innoviva-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2016/03/genable-technologies-is-acquired-by-spark-therapeutics-and-with-it-rhonova/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2015/07/baxalta-announces-publication-of-phase-ii-iii-results-for-bax-855--adynovate--for-hemophilia-a/2024-02-22T15:02:11+00:00weekly0.6https://www.medthority.com/news/2017/01/eu-amends-marketing-authorisation-for-ruconest--recombinant-human-c1-esterase-inhibitor--to-include-self-administration-in-acute-hereditary-angioedema--pharming-group/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2014/09/ambrisentan-and-tadalafil-combination-success-in-ambition-study-for-pah---gilead-gsk/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-approves-baha-4-attract-for-hearing-loss--cochlear/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2017/06/gilead-sciences-has-filed-a-nda-for-a-once-daily-single-tablet-containing-bictegravir--50-mg---a-novel-integrase-strand-transfer-inhibitor-and-emtricitabine-tenofovir-alafenamide--200-25-mg---ftc-taf--to-treat-hiv-1-infection-/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2019/03/celgene-submits-nda-to-fda-for-ozanimod-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis-/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2013/06/final-results-for-bolero-3-trial-of-afinitor-in-breast-cancer/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-verigene-gp-blood-culture-nucleic-acid-test--nanosphere--for-identifying-bacterial-infections/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2017/09/zytiga--abiraterone--in-combination-with-prednisone-and-adt-filed-with-fda-for-supplemental-new-drug-application-in-metastatic-hormone-na-ve-prostate-cancer-or-newly-diagnosed--high-risk-metastatic-hormone-sensitive-prostate-cancer---janssen-biotech-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2018/04/study-of-vercise-dbs-system-at-one-year-meets-endpoint-in-parkinsons-disease---boston-scientific-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-lynparza-for-her2--negative-metastatic-breast-cancer---astrazeneca---merck-inc-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2014/06/positive-results-from-novottf-therapy-registry-data-treating-brain-cancer---novocure/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-reviewing-marketing-application-for-dupixent-in-moderate-to-severe-asthma---regeneron-pharma---sanofi-/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2015/10/new-phase-iii-trial-results-for-vargatef-ofev--nintedanib--in-idiopathic-pulmonary-fibrosis-boehringer/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2015/10/update-on-liberate-study-of-otezla--apremilast--as-a-treatment-for-severe-plaque-psoriasis--celgene/2024-02-22T15:02:23+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-ii-trial-of-toleromune--circassia--shows-benefits-for-cat-allergy-two-years-after-treatment/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2013/01/nice-now-recommends-colobreathe---forest-labs-for-cystic-fibrosis-infections-/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2018/07/nice-in-final-guidance-does-not-recommend-orkambi-for-cystic-fibrosis---in-people-with-two-copies-of-the-f508del-mutation--vertex-pharma-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-ultomiris-to-treat-atypical-hemolytic-uremic-syndrome---alexion-pharma/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2018/10/enrollment-completed-in-hero-trial-of-relugolix-for-the-treatment-of-men-with-advanced-prostate-cancer---myovant-sciences/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2014/11/simponi-filed-with-ema-for-axial-spondyloarthritis-janssen/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2019/02/eu-approves-mulpleta-for-severe-thrombocytopaenia---shionogi/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2016/11/opal-broaden-and-beyond-trials-of-xeljanz--tofacitinib-citrate--for-psoriatic-arthritis-presented-at-acd-arhp-meeting-by-pfizer-/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2018/07/abbott-to-initiate-study-in-the-u-s--of-its-tendyne-transcatheter-mitral-valve-replacement--tmvr--system-for-the-treatment-of-mitral-regurgitation-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2018/08/bayer-files--maa-at-ema-for-larotrectinib-to-treat--locally-advanced-or-metastatic-solid-tumors-with-ntrk-gene-fusion---loxo-oncology---bayer-healthcare-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2017/04/eu-approves-tafinlar--dabrafenib-----mekinist--trametinib--for-the-treatment-of-patients-with-braf-v600-positive-advanced-or-metastatic-non-small-cell-lung-cancer---novartis/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-inspiring-interim-analysis-shows-tivicay-effective-and-well-tolerated-in-hiv-patients-with-tuberculosis---viiv-healthcare-/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2019/09/successful-results-from-evolve-short-dapt-clinical-trial-shows-low-rates-of-adverse-events--boston-scientific/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-trial-of-ingrezza-shows-drug-well-tolerated-in-tardive-dyskinesia---neurocrine-biosciences-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-captain-study-of-trelegy-ellipta-meets-primary-endpoint-in-asthma---gsk---innoviva/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-emend--aprepitant--for-paediatric-patients-to-treat-acute-and-delayed-nausea-and-vomiting--merck-inc-/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2012/03/purocin-protein-technology--avidbiotics--offers-rapid-response-to-e-coli-infection/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-rejects-erbitux--cetuximab--in-draft-guidance-as-a-treatment-for-head-and-neck-cancer---merck-kgaa/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-picosure-laser-for-treating-wrinkles-cynosure/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-opdivo--nivolumab--for-treatment-of-nsclc--bms/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2014/12/pxvx-0200-vaccine-meets-goals-in-phase-iii-trial-for-cholera-paxvax/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2012/10/actelion-files-opsumit-at-fda-for-treatment-of-pah/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2016/02/launch-of-new-chronic-lymphocytic-leukaemia-cme/2021-11-26T11:04:48+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-advisory-committee-recommends-approval-of-grastek-for-allergy-merck/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-issues-a-complete-response-letter-to-evolus-for-dwp-450-a-proposed-treatment-for-glabellar-lines-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2017/09/helsinn-to-co-promote-zykadia--ceritinib-in-usa-for-patients-with-alk-positive-metastatic-non-small-cell-lung-cancer---novartis-/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2019/03/astrazeneca-and-daiichi-sankyo-collaborate-on-trastuzumab-deruxtecan--a-potential-new-targeted-medicine-for-cancer-/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2017/01/nu-q-screening-triage-test-receives-ce-mark-approval-in-the-eu-for-colorectal-cancer-diagnostics--volitionrx/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-ilaris--canakinumab-to-treat-three-rare-and-distinct-types-of-periodic-fever-syndromes--novartis/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-katherine-study-of-kadcyla-meets-primary-endpoint-in-her2--breast-cancer---genentech-roche-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2018/07/sangamo-therapeutics-acquires-txcell-s-a--and-access-to-regulatory-t-cell--treg--development-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2017/04/the-76th-annual-meeting-of-the-society-for-investigative-dermatologists-is-underway-in-portland--oregon--usa/2024-02-13T10:56:09+00:00weekly0.6https://www.medthority.com/news/2018/06/post-hoc-analysis-of-ignite1-and-ignite4-trials-of-eravacycline-met-endpoints-in-complicated-intra-abdominal-infections---tetraphase-pharma-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2018/03/pdufa-date-for-fda-review-of-ulipristal-acetate-for-treatment-of-uterine-fibroids-is-extended-to-august-2018----allergan/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-and-health-canada-approval-for-machine-vision-image-guided-surgery--migs--system-for-spinal-surgery---7d-surgical/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2017/11/pledox-enters-phase-iii-trials-to-treat-neuropathy-consequent-upon-chemotherapy-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-admiral-trial-data-for-xospata-in-acute-myeloid-leukemia-published-in-nejm---astellas/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-stelara-for-psoriatic-arthritis-in-adults/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-provides-complete-response-letter-for-dsuvia--sufentanil-sublingual-tablet--in-acute-pain---acelrx-pharmaceuticals-/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-vosevi--an-investigational--once-daily--single-tablet-regimen-of-sofosbuvir-400-mg--velpatasvir-100-mg--and-voxilaprevir-100-mg--sof-vel-vox--for-the-treatment-of-chronic-hepatitis-c-virus---gilead-sciences/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2012/04/omadacycline--paratek-pharma--special-protocol-with-fda-is-agreed-for-phase-iii-study-for-absssi-and-cabp/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2015/04/keytruda--pembrolizumab--filed-with-fda-for-marketing-approval-in-nsclc-merck-inc/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2017/07/nice-recommends-olumiant--baricitinib--to-treat-rheumatoid-arthritis---eli-lilly/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2017/03/ptc-therapeutics--inc---acquires-emflaza--deflazacort--from-marathon-pharmaceuticals--llc--to-treat-duchenne-muscular-dystrophy-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-approves-ingrezza--valbenazine--capsules-for-the-treatment-of-adults-with-tardive-dyskinesia---neurocrine-biosciences--inc-/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2019/06/full-patient-enrollment-achieved-in-illuminate-a-phase-iii-study-of-lumasiran-to-treat-primary-hyperoxaluria-type-1---alnylam-pharma-/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-trial-of-new-loteprednol-etabonate-formulation-shows-benefits-in-ocular-surgery---bausch---lomb/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2019/09/purdue-pharma-files-for-bankrupcy/2025-10-17T09:17:19+00:00weekly0.6https://www.medthority.com/news/2018/01/zepsyre-fails-in-phase-iii-trial-for-ovarian-cancer---pharma-mar--s-a-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2019/08/novartis-stands-behind-zolgensma--for-the-treatment-of-children-less-than-2-years-of-age-with-spinal-muscular-atrophy-/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-approves-imlygic--talimogene-laherparepvec--for-metastatic-melanoma--amgen/2024-02-13T10:56:21+00:00weekly0.6https://www.medthority.com/news/2017/05/positive-results-from-phase-iii-trial-of-kpi-121-1--for-the-treatment-of-inflammation-and-pain-in-cataract-surgery-patients----kala-pharmaceuticals/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2019/10/genentech-s-tecentriq--improves-overall-survival-as-a-first-line-monotherapy-in-certain-people-with-advanced-non-small-cell-lung-cancer-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2016/11/aerie-pharma-reports-positive-results-from-rocket-4-phase-iii-trial-of-rhopressa--netarsudil-ophthalmic-solution--for-glaucoma-and-ocular-hypertension-/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-ravicti--glycerol-phenylbutyrate--oral-liquid-for-chronic-management-of-adult-and-paediatric-patients-greater-than-two-months-of-age-with-urea-cycle-disorders--horizon-pharma/2021-09-24T07:03:42+00:00weekly0.6https://www.medthority.com/news/2011/09/eu-commission-approves-dexdor-for-sedation-of-patients-in-intensive-care/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2013/09/olaparib-moves-to-phase-iii-for-ovarian-cancer/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-of-usl-255---upsher-smith-labs--shows-success-for-epilepsy-treatment/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2017/04/eu-chmp-recommends-approval-of-besponsa--inotuzumab-ozogamicin--for-treating-acute-lymphoblastic-leukaemia--pfizer/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2018/05/galcanezumab-met-its-primary-endpoint-in-a-phase-iii-study-of-patients-with-episodic-cluster-headache---eli-lilly-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2019/04/biotronik-launches-pk-papyrus-covered-coronary-stent-system-for-use-in-the-emergency-treatment-of-acute-coronary-perforations-/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2018/03/horizon-files-snda-to-extend-the-indication-of-ravicti-to-include-infants-younger-than-two-months-of-age-living-with-urea-cycle-disorders-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2019/06/northstar-2-and-3-phase-iii-trials-of-lentiglobin-show-efficacy-to-month-16-in-beta-thalassemia---bluebird-bio/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-for-humira--abbott--for-pediatric-patients-with-crohn-s-disease/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-foundationfocus-cdxbrca-companion-diagnostic-for-use-with-rubraca-in-treating-ovarian-cancer--foundation-medicine/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2017/05/high-implant-success-rate-for--watchman-laac-device-derived-from-ewolution-registry-evaluation---boston-scientific/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2019/12/bms---acceleron-announced-that-an-fda-advisory-committee-will-review-reblozyl-for-use-in-patients-with-myelodysplastic-syndromes-/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-tresiba-for-children-adolescents-with-diabetes--novo-nordisk/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2013/10/lotus-aortic-valve--boston-scientific--receives-ce-mark/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2019/12/zafgen-inc--and-chondrial-therapeutics--inc--merge-to-form-larimar-therapeutics-inc-/2025-10-16T11:27:03+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-kogenate-fs-for-haemophilia-a-prophylaxis---bayer-healthcare/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2017/09/european-commission-approves-fotivda--tivozanib--for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma--aveo-oncology---eusa-pharma-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2019/07/greater-awareness-needed-of-stomach-cancer-risk-in-under-40s--especially-in-latin-america/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2017/05/pfizer-acquires-rights-to-early-stage-sb-525--a-proposed-treatment-for-haemophilia-a-from-sangamo-therapeutics-/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2011/10/rts-s-anti-malaria-vaccine-success-in-large-african-study/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2018/04/shire-plc-sells-its-oncology-business-to-servier/2025-10-16T11:20:41+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-positive-for-pyramax-shin-poong-pharma--a-new-treatment-for-malaria/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2016/04/epidiolex--cannabidiol-or-cbd--commences-phase-iii-study-to-treat-tuberous-sclerosis-complex--gw-pharma/2021-09-24T07:10:44+00:00weekly0.6https://www.medthority.com/news/2015/04/boston-scientific-acquires-xlumena-inc-and-with-it-axios-stents-for-transgastric-endoscopic-drainage/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2011/11/takeda-re-files-nesina-at-the-fda-for-type-2-diabetes/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2014/03/phase-iii-tesla-trial-success-for-evolocumab---amgen/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2014/08/nice-rejects-iressa-for-nsclc-patients-who-have-failed-previous-treatments-but-recommends-tarceva---astrazeneca-roche/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2016/11/results-of-inclisiran-aln-pcssc--from-orion-1-phase-ii-trial-positive-for-the-treatment-of-hypercholesterolemia----the-medicines-company---alnylam-pharma-/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-humira-for-crohns-in-patients-6-years-and-older---abbvie/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2018/04/new-analyses-from-expand-study-of-siponimod-for-multiple-sclerosis-shows-reduced-risk-of-disability-progression---novartis/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2011/09/bolero-2-study-of-afinitor-in-er-her-2-advanced-breast-cancer-is-presented-at-emcc-congress-1/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2011/12/generic-caduet--pfizer--launched-in-usa-by-ranbaxy/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2019/07/results-from-skyrizi--phase-iii-immvent-study-in-moderate-to-severe-plaque-psoriasis-published-in-the-lancet--abbvie/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-new-snda-for-sorilux--stiefel-gsk--to-treat-plaque-psoriasis-of-the-scalp/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-baremsis--amisulpride--demonstrates-efficacy-in-post-operative-nausea---vomiting--acacia-pharma-/2024-02-13T10:57:18+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-data-from-phase-iii-study-of-abraxane--celgene-oncology--for-nsclc-patients/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-approves-brilique--ticagrelor--for-patients-at-risk-of-atherothrombotic-events--astrazeneca/2024-02-13T10:57:32+00:00weekly0.6https://www.medthority.com/news/2019/07/the-european-commission-has-approved-ultomiris-for-the-treatment-of-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2019/12/european-commission-approves--spravato-nasal-spray-to-treat-treatment-resistant-major-depressive-disorder---janssen/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2019/12/chmp-recommends-approval-of-beovu-in-age-related-macular-degeneration---novartis/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-accepts-new-drug-application-for-ux-007-for-treatment-of-long-chain-fatty-acid-oxidation-disorders---ultragenyx-pharmaceutical/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2014/07/stryker-acquires-small-bone-innovations-and-star-ankle-system/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-savaysa-to-treat-stroke-risk-in-patients-with-atrial-fibrillation-and-for-dvt-and-pulmonary-embolism--daiichi-sankyo/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2014/09/lbh-589---bortezomib---dexamethasone-positive-for-multiple-myeloma--data-published-in-lancet-oncology--novartis/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2019/09/intra-cellular-therapies-provides-lumateperone-regulatory-update--for-the-treatment-of-schizophrenia-/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-advisory-committee-recommends-tresiba-and-ryzodeg-for-types-1-and-2-diabetes---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2015/11/allergan-and-pfizer-to-merge/2025-10-16T11:10:10+00:00weekly0.6https://www.medthority.com/news/2019/01/nice-approves-xeljanz-for-ulcerative-colitis---pfizer-/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2019/12/aldeyra-therapeutics--inc--announced-enrollment-of-the-first-patient-into-the-phase-iii-guard-trial-of-adx-2191--for-the-prevention-of-proliferative-vitreoretinopathy-/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2013/10/xtandi--medivation-astellas--success-as-pre-chemotherapy-treatment-for-prostate-cancer/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2015/10/interim-results-reported-for-neurx-diaphragm-pacing-system-in-diaphragm-dysfunction--synapse-biomedical/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2014/01/merck-inc-files--rolling-submission--to-fda-for-mk-3475-for-advanced-melanoma-/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-provides-guidance-to-auris-medical-holding-ag-for-further-phase-iii-trial-of-am-iii-to--treat--sudden-sensorineural-hearing-loss-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2014/09/new-data-for-vargatef-in-pulmonary-fibrosis-boehringer/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-stivarga--bayer-onyx-pharma--for-metastatic-colorectal-cancer/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2014/06/promacta-revolade-in-new-phase-iii-trial-for-cytopenias-gsk/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-of-sufentanil-nanotab-pca-system--acelrx-pharmaceuticals--meets-primary-endpoint-for-pain-relief/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-diamond-study-of-symtuza-shows-rapid-initiation-benefits-in-hiv-patients---janssen-pharma/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2018/06/positive-comparison-study-of-jakavi-and-best-available-therapy-for-polycythemia-vera---novartis-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2017/11/acorda-therapeutics-discontinues-development-program-for-tozadenant-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2019/10/smile-hf-trial-of-reds-shows-reduction-in-readmission-for-heart-failure---medicure/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2017/11/are-people-in-relationships-less-at-risk-of-dementia-/2024-02-13T10:57:58+00:00weekly0.6https://www.medthority.com/news/2019/03/cosentyx-shows-superior-improvements-in-psoriasis-patients--quality-of-life-versus-stelara--novartis/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2012/10/aquacell-ag---convatec--surgical-cover-success-reported-in-jama---------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-the-iassist-knee--zimmer--for-knee-replacement-surgery/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-flublok-vaccine---protein-sciences--for-influenza/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2013/08/vedolizumab-phase-iii-results-from-gemini-ii-study-in-crohns-disease/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-data-from-advance-trial-of-ventricular-assist-device--heartware--for-heart-failure-patients/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2013/10/inclusig--ariad--negative-events-in-pace-trial-for-cml/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2019/11/update-on-checkmate--915-for-opdivo----yervoy-v--opdivo-alone-in-patients-with-resected-high-risk-melanoma-and-pd-l1--1----bms/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2014/03/puritan-bennett-980-ventilator-receives-ce-mark-and-510--k--approval---covidien/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2019/12/ascertain-phase-iii-trial-of-astx-727-meets-primary-endpoint-in-myelodysplastic-syndromes---astex-pharma/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2013/05/freestyle-insulinx-blood-glucose-monitoring-system--abbott--is-recalled-in-the-usa/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2013/09/abor-pharma-to-market-edarbi-and-edarbyclor-in-usa/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-grants-accelerated-approval-for-keytruda-to-treat-merkel-call-carcinoma--merck-inc-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2012/05/mri-guided-radiation-therapy-system--viewray--for-cancer-treatment-receives-fda-510-k--approval/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-lume-colon-1-trial-data-on-vargatef--nintedanib--shows-improved-progression-free-survival-but-not-overall-survival-in-metastatic-colorectal-cancer--boehringer/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2015/10/exablate-neuro-system-mri-guided-ultrasound-filed-with-fda-for-essential-tremor--insightec/2021-09-24T07:03:13+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-trials-of-mk-8835--ertugliflozin--meet-primary-endpoint-in-type-2-diabetes--merck-inc-and-pfizer/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-chmp-recommends-approval-of-brilique--ticagrelor--for-atherothrombosis--astrazeneca-/2024-02-13T10:58:18+00:00weekly0.6https://www.medthority.com/news/2016/03/aralez-pharma-re-submits-yosprala--pa32540-pa8140--to-fda-as-a-treatment-for-secondary-prevention-of-cv-disease-in-patients-at-risk-for-aspirin-induced-gastric-ulcers-/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2015/07/mallinckrodt-sells-contrast-media-and-delivery-systems-business-to-guerbet-for--270-million-/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2016/05/trumenba--vaccine--filed-with-ema-for-meningococcal-group-b--pfizer-/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2019/09/alnylam-pharma-provides-perspective-on-positive-results-from-orion-11-phase-iii-study-of-inclisiran-/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2014/07/respimat-soft-mist-inhaler-filed-with-eu-for-copd-boehringer/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2016/08/mallinckrodt-announced-merger-agreement-with-stratatech-corporation/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-issues-recall-for-sapien-3-ultra-delivery-system-in-aortic-stenosis---edwards-lifesciences/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2016/05/allergan-secures-fda-approval-and-launches-generic-crestor--rosuvastatin--/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-qsymia--vivus-inc---treatment-for-obesity/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-butterfly-iq-a-smart-phone-ultrasound---butterfly-network-/2021-09-24T07:13:20+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-combination-xigduo-xr-for-treatment-of-type-2-diabetes-astrazeneca/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-soliris--eculizumab--to-include-the-treatment-of-refractory-generalized-myasthenia-gravis--gmg--in-patients-who-are-anti-acetylcholine-receptor--achr--antibody-positive--alexion-pharma/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2012/09/merck-returns-all-rights-to-vernakalant-to-cardiome-pharma-for-atrial-fibrillation/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2014/04/resistance-to-sovaldi-as-a-treatment-for-hepatitis-c-from-heath-benefit-insurers/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2017/04/eu-chmp-recommends-approval-of-opdivo--nivolumab--in-bladder-cancer--bms/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-recommends-use-of-eylea--aflibercept--for-visual-impairment-due-to-branch-retinal-vein-occlusion--bayer-healthcare/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2019/02/ongoing-study-shows-durable-benefit-of-brineura-for-three-years-for--neuronal-ceroid-lipofuscinosis-type-2--batten-disease---biomarin/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-advisory-committee-does-not-recommend-buprenorphine-sublingual-spray-as-a-treatment-for-moderate-to-severe-acute-pain---insys-therapeutics-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-pedicle-screw-fixations--depuy--for-adolescent-scoliosis-patients---------------/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2012/09/levomilnacipran--forest-labs-pierre-fabre--filed-at-fda-for-major-depressive-disorder---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2015/01/sanofi--regeneron-file-maa-for-praluent-at-ema-to-treat-hypercholesterolemia-/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2014/04/new-phase-iii-study-of-lixiana-in-stroke-prevention--af----daiichi-sankyo/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2018/05/post-hoc-analysis-of-mavenclad-in-multiple-sclerosis-published-in-multiple-sclerosis-journal---merck-kgaa-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-approves-kengrexal-for-pci---the-medicines-co/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2018/10/for-children-and-adolescents-with-type-1-diabetes--fiasp-could-be-an-option-to-better-manage-their-blood-sugar-levels---novo-nordisk/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-jentadueto-xr--linagliptin---metformin--extended-release--for-type-2-diabetes--boehringer-ingelheim-and-eli-lilly/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2015/06/data-from-three-phase-iii-trials-of-ly-2605541--basal-insulin-peglispro--show-benefit-in-type-2-diabetes/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2015/04/long-term-safety-of-s-icd-system-defibrillatior-published-in-jo-american-college-of-cardiology-boston-scientific/2024-02-13T10:58:32+00:00weekly0.6https://www.medthority.com/news/2018/02/eliana-study-updated-results-of-kymriah-for-b-cell-acute-lymphoblastic-leukemia-is-published-in-nejm---novartis-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2018/01/complete-response-for-cam-2038-a-proposed-treatment-for-opioid-use-disorder---braeburn-pharmaceuticals-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2012/01/novel-antibacterial-ozenoxacin--ferrer--enters-phase-iii-for-treatment-for-impetigo/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2013/06/nice-now-recommends-iluvien--alimera-sciences--for-dme/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2015/06/biomarin-pharma-submits--maa-to-ema-for-drisapersen-for-the-treatment-of--duchenne-muscular-dystrophy--amenable-to-single-exon-skipping-/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2016/06/pb-272--neratinib--filed-with-eu-for-breast-cancer--puma-biotechnology/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2014/05/novartis-acquires-non-us-rights-to-fovista-from-ophthotech-for-wet-age-related-macular-degeneration/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-study-success-of-quizartinib--astellas-ambit-bioscience--in-aml/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2019/11/post-hoc-analysis-of-phase-iii-trial-of-zilretta-shows-significant-pain-relief-post-osteoarthritis-knee-surgery---flexion-therapeutics/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-kadcyla--genentech-roche--for-her2-positive-metastatic-breast-cancer-patients/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-melafind--mela-sciences--for-spotting-skin-lesions-and-melanoma/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-recommends-zydelig--idelalisib----rituximab-for-treatment-of-cll--gilead/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2019/11/obseva-announces-that-nolasiban-implant-4-study-did-not-meet-primary-endpoint-in-women-undergoing-embryo-transfer-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2012/07/chmp-recommends-glybera--uniqure--gene-therapy-for-lpld/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2016/12/the-ensite-precision-cardiac-mapping-system-is-fda-approved--to-provide-automation--flexibility-and-precision-in-cardiac-mapping-during-the-treatment-of-patients-with-abnormal-heart-rhythms---st-jude-medical-/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2019/12/eli-lilly-initiates-libretto-531-phase-iii-clinical-trial-for-loxo-292-to-treat-ret-mutant-medullary-thyroid-cancer-/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-approves-trulicity--a-glp-1-agonist-for-treatment-of-type-2-diabetes-eli-lilly/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-lenvima-for-unresectable-hepatocellular-carcinoma---eisai-and-merck-inc-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-interim-analysis-of-blisibimod--anthera-pharma--clinical-trial-for-sle/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2019/03/biotronik-launches-the-world-s-smallest-icd-and-crt-d--devices-acticor-and-rivacor-to-treat-atrial-fibrillation-/2024-10-21T14:45:39+00:00weekly0.6https://www.medthority.com/news/2017/03/mylan-and-genentech-roche-agree-global-settlement-to-market-trastuzumab-biosimilar--------/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2017/06/the-eu--chmp-will-review-its-negative-opinion-of--human-igg1-monoclonal-antibody-specific-for-human-interleukin-1-alpha-xbiotech--intended-to-treat-symptoms-of-advanced-colorectal-cancer--xbiotech/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2013/01/plecanatide--synergy-pharma--success-in-phase-iii-trial-for-constipation/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2012/01/sycrest-lundbeck--is-launched-for-bipolar-disorder-in-uk-1/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2014/05/shire-acquires-lumena-pharmaceuticals-for--260-million-plus-milestone-payments/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2016/08/cariprazine-fails-in-phase-iii-trial-for-depression---allergan---gedeon-richter/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2012/04/benefits-of-avastin--roche--for-older-patients-with-nsclc-are-not-clear/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2020/02/epidiolex-filed-with-fda-for--tuberous-sclerosis-complex---gw-pharma/2021-09-24T07:12:00+00:00weekly0.6https://www.medthority.com/news/2013/10/avastin-success-in-ovarian-cancer-trial/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2014/01/phase-ii-trial-of-avastin-shows-benefits-for-cervical-cancer-genentech/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2012/04/endurant-aaa-stent-graft-system-medtronic--two-year-results/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-provides-accelerated-approval-for-yervoy---opdivo-combination-to-treat-microsatellite-instability-high-or-mismatch-repair-deficient-metastatic-colorectal-cancer-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-advisory-committee-recommends-shingrix-vaccine-for-the-prevention-of-herpes-zoster--shingles--in-adults-ages-50-and-over---gsk-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2017/06/gout-hospitalisation-exacerbated-by-failure-to-prescribe-recommended-urate-lowering-treatment-/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-dexcom-g5-mobile-cgm-system-that-can-be-used-to-make-daily-diabetes-treatment-decisions-without-finger-pricking--dexcom-inc-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-amplify-trial-of-duaklir-genuair--aclidinium-bromide-formoterol--positive-as-a-treatment-for-copd---astrazeneca---circassia-pharma-/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-grants-accelerated-approval-to-lartruvo--olaratumab--with-doxorubicin-for-soft-tissue-sarcoma--eli-lilly/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2015/08/eu-approves-pfizer-s-acquisition-of-hospira/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2019/05/adynxx-inc--merges-with-alliqua-biomedical-inc-/2025-10-17T09:16:48+00:00weekly0.6https://www.medthority.com/news/2011/04/novartis-discontinues-tasigna-trial-in-gist/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2016/11/post-marketing-trial-of-omidria--phenylephrine---ketorolac-injection--finds-therapy-safe-in-pediatric-cataract-surgery--omeros-corporation/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-accepts-snda-for-pediatric-use-of-teflaro--ceftaroline-fosamil--in-absssi-and-cabp--allergan/2024-02-22T15:01:49+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-lenvima-to-treat-hepatocellular-carcinoma--liver-cancer---eisai---merck-inc-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2014/02/ven-307-fails-phase-iii-study-for-treatment-of-anal-fissure-pain--ventrus/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2019/06/chmp-recommends-approval-of-giapreza-for-refractory-hypotension/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2016/06/nice-recommends-use-of-eylea--aflibercept--in-branch-retinal-vein-occlusion-only-after-laser-photocoagulation-therapy--bayer-healthcare/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-botox--onabotulinumtoxina--extended-indication-for-upper-limb-spasticity--allergan-actavis/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2015/01/trial-of-brilinta-in-acs-meets-primary-endpoint-astrazeneca/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-tucatinib-her2climb-trial-results-in-locally-advanced-or-metastatic-her2-positive-breast-cancer--published-in-the-nejm-seattle-genetics/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-accepts-sbla-for-dupixent-in-adolescent-patients-12-to-17-years-of-age-with-moderate-to-severe-atopic-dermatitis----sanofi---regeneron/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-zulresso-to-treat-postpartum-depression/2024-10-21T14:48:50+00:00weekly0.6https://www.medthority.com/news/2014/04/new-phase-iii-trial-of-xofigo-in-metastatic-prostate-cancer---bayer-healthcare/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2013/12/the-medicines-company-to-co-promote-promus-premier-cardiac-stent-in-us-boston-scientific/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2015/06/new-study-on-apligraf-in-diabetic-foot-ulcer-healing-is-published--novartis/2024-02-13T10:55:26+00:00weekly0.6https://www.medthority.com/news/2018/08/tafamidis-phase-iii-trial-positive-results-for-treatment-of--transthyretin-amyloid-cardiomyopathy----pfizer/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2011/03/long-term-data-for-prolia-in-freedom-extension-trial/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2016/05/flucelvax-quadrivalent--vaccine--is-approved-by-fda-as-a-seasonal-influenza-vaccine-for-people-aged-four-years-and-older--seqirus-csl/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2015/10/positive-data-from-study-of-valiant-thoracic-stent-graft-system-for-aortic-aneurysms--medtronic/2024-02-13T10:58:44+00:00weekly0.6https://www.medthority.com/news/2015/06/vertex-acquires-rights-to-parion-sciences-drugs-for-cystic-fibrosis-and-pulmonary-diseases/2025-10-16T11:21:20+00:00weekly0.6https://www.medthority.com/news/2018/06/roche-and-foundation-medicine-agree-to-merger-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2018/10/post-hoc-analysis-of-switch-1-and-switch-2-trials-in-types-i---2-diabetes-show-lower-risk-of-hypoglycaemia-with-tresiba---novo-nordisk/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-invocell-system-for-patients-diagnosed-with-infertility--invo-bioscience/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-data-for-halaven--eribulin--in-soft-tissue-sarcoma-used-for-submission-to-eu-for-extended-indication--eisai/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-izba-for-ocular-hypertension-glaucoma-alcon/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2019/09/bd-announces-publication-of-an-independent-analysis-of-drug-coated-balloon-safety-data-for-lutonix-for-femoropopliteal-peripheral-arterial-disease---bd--becton-dickinson-/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-koning-breast-ct-imaging-system-koning-corp/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2018/04/keytruda---alimta---chemotherapy--extends-os-and-reduces-death-risk-in-keynote-189-study-for-first-line-nsclc-patients---merck-inc-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-extended-indication-for-avycaz-in-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia---allergan-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2019/03/results-of-prepare-trial-of-resvax-vaccine-for-respiratory-syncytial-virus-disease---novavax-inc-/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2014/04/two-new-phase-iii-trials-of-tmc-435-gs-7977-for-hepatitis-c-janssen/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2015/05/price-cutting-of-biosimilar-infliximab-drugs-in-norway--hospira-and-orion-oyj-/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-and-ema-accept-for-review-ozanimod-for-the-treatment-relapsing-remitting-multiple-sclerosis--celgene-bms/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-ovation-ix-abdominal-stent-graft-system-for-abdominal-aortic-aneurysm--trivascular-technologies/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2017/08/suptavumab--regn-2222--fails-phase-iii-trial-to-prevent-medically-attended-rsv-infections-in-infants---regeneron-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2012/11/two-year-results-of-certican--novartis---in-liver-transplant-rejection-confirm-superiority-over-tacrolimus---------------/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-simbrinza--alcon-novartis--for-glaucoma-and-ocular-hypertension-treatment/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2016/10/fkb-327--an-adalimumab-biosimilar--is-equivalent-to-humira-its-reference-drug-for-treatment-of-ra--fujifilm-kyowa-kirin-biologics-co-ltd-/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2013/01/chmp-recommends-bosutinib--pfizer--for-ph-cml/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2015/06/new-phase-iii-analysis-of-adcetris--brentuximab-vedotin--in-hodgkin-lymphoma--seattle-genetics/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-issues-complete-response-letter-for-cl-108--hydrocodone--acetaminophen--promethazine---an-investigational-treatment-for-the-management-of-pain--charleston-labs---daiichi-sankyo-/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2016/12/shire-plc--presents-at-ash-40-years-of-real-world-experience-with-the-bypassing-agent-feiba--anti-inhibitor-coagulant-complex---a-treatment-for-hemophilia-a-/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-intandem1-study-for-lx-4211-published-in-diabetes-care-journal---lexicon-pharmaceuticals-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-advisory-committee-rejects-lixivaptan---------------/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2014/03/tracleer-fails-phase-iv-study-evaluating-mortality-in-pah-patients---actelion--/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2015/12/roche-collaboration-with-pieris-pharmaceuticals/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2018/01/tesaro-reports-anaphylaxis--anaphylactic-shock-and-other-hypersensitivity-reactions-with-treatment-by-varubi-injectable-emulsion-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2018/03/orexigen-files-for-bankruptcy-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2013/10/cqr-1-stem-cell--cardio3biosciences--to-begin-phase-iii-heart-failure-trial/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-aristada-initio-for-use-as-therapy-with-aristada-in-schizophrenia---alkermes-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2012/03/amg-145-success-in-phase-1b-trial-for-high-cholesterol/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2012/03/da-vinci-surgical-system-a-benefit-for-hpv-related-oral-cancer/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-recommends-remicade-for-ulcerative-colitis-merck-inc-/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2018/02/new-data-for-scalp-psoriasis-and-effect-of-cosentyx---novartis-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2016/03/austri-study-of-advair-diskus---laba--salmeterol-and-fluticasone-propionate--in-asthma-published-in-new-england-journal-of-medicine--glaxosmithkline/2024-02-13T10:59:46+00:00weekly0.6https://www.medthority.com/news/2013/04/picato-leo-pharma--fails-iqwig-assessment-for-actinic-keratosis-in-germany/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-grants-label-extension-to-trokendi-xr--topiramate-extended-release--in-prophylaxis-of-migraine-headache--supernus-pharmaceuticals/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-alethia-cmv-assay-test-system-for-diagnosing-cytomegalovirus---meridian-bioscience-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-of-mekinist---taflinar-for-metastatic-melanoma-halted-early---gsk/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-refuses-to-recommend-approval-to-uplyso-pfizer-for-gaucher-disease/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2018/05/successful-phase-iii-c-axspand-study-of-cimzia-to-treat-axial-spondyloarthritis---ucb-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-javelin-bladder-100-study-met-its-primary-endpoint-to-treat-urothelial-carcinoma----merck-kgaa---pfizer/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2016/07/fda-approves-xpert-carba-r-assay-diagnostic-for-carbapenem-resistant-enterobacteriaceae-infection--cepheid/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2016/10/vyxeos--cytarabine-and-daunorubicin-liposome-injection--in-a-rolling-submission-to-fda-for-acute-myeloid-leukemia--jazz-pharma/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-priority-review-to-gsk-2857916-in-relapsed-or-refractory-multiple-myeloma---glaxosmithkline/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-rejects-serelaxin-again-for-heart-failure---novartis/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-approval-for-anoro-ellipta-for-chronic-obstructive-pulmonary-disease--gsk-theravance/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2011/10/mabcampath-campath-plus-fludarabine-offers-improved-treatment-for-cll/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2018/04/acorda-therapeutics-files-maa-with-ema--for-inbrija-for-symptoms-of-off-periods-in-people-with-parkinson-s-disease-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2016/11/more-than-70-percent-of-patients-on-simponi-aria--golimumab--meet-primary-endpoint-in-phase-iii-ankylosing-spondylitis-study--janssen/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-re-verse-ad-study-of-bi-655075--idarucizumab--meets-endpoint-as-antidote-boehringer/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2011/12/phase-iii-study-of-menerba--bionovo-inc-commences-for-menopausal-hot-flashes-/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2013/09/gelrinc-shows-positive-recovery-rates-for-knee-cartilage-damage/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-trial-of-zp-4207-meets-primary-endpoint-in-severe-hypoglycemia-in-diabetes---zealand-pharma-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-keytruda-to-treat--bacillus-calmette-guerin--bcg--unresponsive--high-risk--non-muscle-invasive-bladder-cancer-with-carcinoma-in-situ----merck-inc-/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2011/10/transit-study-of-stelara-in-psoriasis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-zimmer-psi-shoulder-system/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2014/03/cd-5024-meets-endpoints-in-phase-iii-trials-for-rosacea---galderma/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2014/09/baxalta-will-be-the-name-of-new-baxter-company-to-be-launched-in-2015/2025-10-16T11:17:53+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-wakix-for-excessive-daytime-sleepiness-in-narcolepsy---harmony-biosciences/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-sapien-transcatheter-heart-valve-edwards-lifesciences--for-patients-with-inoperable-aortic-valve-disease/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-trial-shows-floraglo-lutein--kemin--fails-to-protect-against-amd/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2017/05/keytruda--pembrolizumab--is-filed-at-fda-to-treat-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma---merck-inc-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-praluent--alirocumab--meets-endpoint-for-dyslipidaemia-in-odyssey-japan-trial---regeneron-sanofi/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-approves-orenitram-for-pah-united-therapeutics/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iv-ixora-r-study-of-taltz-meets-primary-endpoint-in-plaque-psoriasis---eli-lilly/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-dolab-study-for-docosahexaenoic-acid-shows-improvement-in-reading-and-behaviour-in-underperforming-children----------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/03/myaln-and-revance-to--collaborate-to-develop-biosimilar-botox-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2016/03/positive-phase-iii-results-for-vyxeos--cytarabine---daunorubicin--liposome-for-injection-to-treat-acute-myeloid-leukaemia--celator-pharma/2024-02-13T10:59:57+00:00weekly0.6https://www.medthority.com/news/2019/10/european-commission-approves-opdivo-four-week-dosing-schedule-for-the-adjuvant-treatment-of-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection--bms/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2018/09/salix-pharma-will-co-promote-doptelet-for-thrombocytopenia-in-the-us-with-dova-pharma-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-announces-guidance-for-licensing-zertane--ampio-pharma--for-premature-ejaculation/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2014/12/veloxis-pharma-files-action-against-fda-over-envarsus-for-kidney-transplant-patients/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-to-review-re-submitted-intermezzo-in-november-2011-for-insomnia/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2014/09/medtronic-re-thinking-covidien-acquisition/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-talicia-for-helicobacter-pylori--h--pylori--infection---redhill-biopharma/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2017/01/neurorx-has-fda-clearance-to-commence-phase-ii-iii-trial-of-nrx-101-to-treat-acute-suicidal-ideation-and-behavior-in-bipolar-depression--asib--and-depression-/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2014/04/valeant-pharma-international-makes-offer-for-allergan/2025-10-16T10:56:52+00:00weekly0.6https://www.medthority.com/news/2020/01/acasti-pharma-inc-reports-results-for-trilogy-1-phase-iii-trial-of-capre-for-the-treatment-of-severe-hypertriglyceridemia--/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2014/11/bosatria-filed-with-fda-and-ema-for-eosinophilic-asthma-gsk/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2019/02/adamis-receives-a-refusal-to-sign-letter-from-fda-for-sublingual-tadalafil-to-treat-erectile-dysfunction-/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2012/09/vercise-dbs-system-receives-ce-mark-for-parkinsons-disease---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2013/03/nice-now-recommends-xolair--novartis--for-allergic-asthma/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-trial-of-stelara--ustekinumab--meets-primary-endpoint-in-crohn-s-disease--janssen/2024-02-13T11:00:09+00:00weekly0.6https://www.medthority.com/news/2018/11/real-world-evidence-on-patients-aged-80-and-older-presented-from-aristophanes-study-evaluating-oral-anticoagulants-among-patients-with-non-valvular-atrial-fibrillation--bms---pfizer/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2012/10/new-global-study-to-assess-3-drugs-to-prevent-early-onset-alzheimer-s-disease/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2015/02/eu-approves-velcade-for-mcl---janssen-cilag/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2015/04/complement-1-study-of-arzerra--ofatumumab---chlorambucil-positive-results-published-in-the-lancet-novartis/2024-02-13T11:01:22+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-results-with-galafold--migalastat--in-fabry-disease-published-in-new-england-journal-of-medicine--amicus-therapeutics/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-does-not-recommend-cyramza--ramucirumab--for-gi-cancer--eli-lilly-/2024-02-13T11:01:35+00:00weekly0.6https://www.medthority.com/news/2014/06/nice-recommends-yervoy-for-malignant-melanoma-and-zelboraf-for-metastatic-melanoma---bms-roche/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2019/08/nice-does-not-recommend-epidyolex-as-a-treatment-with-clobazam-for-dravet-and-lennox-gastaut-syndromes---gw-pharma/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-epidiolex--cannabidiol--for-seizures-associated-with-lennox-gastaut-syndrome-meets-primary-endpoint--gw-pharmaceuticals/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/02/vitaros-apricus-bioscience--for-erectile-dysfunction-rights-update/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2016/12/the-fda-has-extended-the-prescription-drug-user-fee-act--pdufa--date-for-its-review-of-the-biologics-license-application--bla--of-ocrevus--ocrelizumab--to-treat-multiple-sclerosis-to-28-march-2017---genetech---roche/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2015/06/-positive-data-for-micra-transcatheter-pacing-system-presented-at-ehra-europace-cardiostim-meeting--medtronic/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-i-trials-of-biib-037--aducanumab--shows-promise-in-alzheimers-disease--biogen/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-q-pan-h5n1-vaccine-for-influenza-glaxo-smith-kline/2021-09-24T07:16:28+00:00weekly0.6https://www.medthority.com/news/2013/08/biodelivery-sciences-files-bunavail-at-fda-for-opioid-dependence/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2019/08/auris-medical-develops-protocol-for-new-phase-ii-iii-trial-of-keyzilen-to-treat-acute-tinnitus-following-traumatic-cochlear-injury-/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-extends-label-data-for-gazyva-for-chronic-lymphocytic-leukemia--genentech-roche/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2015/02/remicade-patent-rejected-by-patent---trademark-office---johnson---johnson/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2018/11/nda-filed-at-fda-for-lasmiditan-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults---eli-lilly/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-ryzodeg-novo-nordisk--for-treatment-of-diabetes-mellitus-/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2012/03/us-court-rules-that-seroquel-xr-patent--astrazeneca--is-valid/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2014/01/eu-approves-tivicay-for-hiv-treatment-viiv-healthcare/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2016/10/pfizer-intends-to-launch-inflectra---infliximab-biosimilar--in-the-us-in-november-2016-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2013/03/nejm-publishes-respect-study-of-amplatzer-pfo-occluder--st-jude-medical--effect-in-stroke-prevention/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-gives-510-k--approval-for-the-hydrasolve-autologous-fat-transfer-system--andrew-technologies--for-lipoplasty/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2012/04/nbi-98854--neurocrine-biosciences--moves-into-phase-iib-for-tardive-dyskinesia/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2015/10/results-of-harmony-study-of-botox-cosmetic--onabotulinumtoxina--in-glabellar-lines-and--crow-s-feet--lines--allergan/2024-02-13T11:01:48+00:00weekly0.6https://www.medthority.com/news/2016/05/source-3-registry-studies-use-of-edwards-sapien-3-valve-for-patients-with-aortic-stenosis-/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2014/06/positive-results-with-azd-9291-in-nsclc-presented-at-asco---astrazeneca/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-sprycel-for-pediatric-patients-one-year-of-age-and-older-with-newly-diagnosed-philadelphia-chromosome-positive--ph---acute-lymphoblastic-leukemia--all-----bms/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2019/08/esmo-2019---learn-more/2024-02-22T15:07:29+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-rejects-again-nerventra-for-treatment-of-multiple-sclerosis---teva/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2015/11/one-year-results-for-sb4--etanercept-biosimilar--are-comparable-to-enbrel-in-rheumatoid-arthritis--samsung-bioepis/2021-09-24T07:04:24+00:00weekly0.6https://www.medthority.com/news/2014/07/bms-and-ono-pharma-extend-their-collaboration-on-opdivo--nivolumab----bms---ono-pharma/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2017/02/uk-nice-rejects-the-use-of-kanuma--sebelipase-alfa--to-treat-lysosomal-acid-lipase-deficiency--alexion/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-vargatef---docetaxel-for-treatment-of-non-small-cell-lung-cancer---boehringer/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2012/01/ipsen-returns-row-rights-to-fipamezole-to-santhera-pharma/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-approval-of-biktarvy-for-hiv-1-infection---gilead-sciences-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2015/12/adynovate--recombinant-factor-viii--meets-primary-endpoint-in-phase-iii-trial-for-haemophilia--baxalta-/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-extension-of-prevnar-13-vaccine-indication-/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2014/04/t-vec-fails-to-meet-os-endpoint-in-phase-iii-trial-for-metastatic-melanoma---amgen/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2016/11/bavarian-nordic-announced-the-completion-of-enrollment-of-a-phase-iii-clinical-study-for-its-smallpox-vaccine--imvamune--/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-korlym--corcept-therapeutics--for-cushings-syndrome/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2018/03/new-analyses-from-canvas-program-of-invokana-show-reductions-in-cv-death-risk-or-hospitalisation-for-heart-failure-in-type-2-diabetes-patients---janssen/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-study-of-chs-1420--adalimumab-humira-biosimilar--meets-primary-endpoint-in-psoriasis--coherus-biosciences/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-xerava-to-treat-ciai-infections--tetraphase/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2018/05/united-therapeutics-acquires-steadymed-ltd--and-with-it-trevyent-a-treatment-for-pulmonary-arterial-hypertension-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iiib-eliminate-af-study-of-lixiana-shows-safety-and-efficacy-in-bleeding-events---daiichi-sankyo/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2018/10/emerald-study-for-symtuza-for-hiv--shows-high-virologic-suppression--and-low-virologic-failure---janssen-pharma-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-luzu--valeant-pharma--for-fungal-infections/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-sbla-for-opdivo---low-dose-yervoy-for-the-treatment-of-first-line-nsclc--in-patients-with-tumor-mutational-burden----bms-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2011/11/reolysin--oncolytics--success-in-head-and-neck-cancer/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2018/05/radiance-htn-solo-study-with-paradise-renal-denervation-system-meets-primary-endpoint-in-hypertension---recor-medical-/2024-07-26T09:49:36+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-post-hoc-analysis-of-emgality-shows-reduction-in-migraine-frequency---eli-lilly-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-trial-of-stivarga--regorafenib--for-hepatocellular-carcinoma-meets-primary-endpoint--bayer-healthcare/2024-02-13T13:44:43+00:00weekly0.6https://www.medthority.com/news/2019/11/novartis-prevent-data-show-cosentyx-delivers-early-relief-in-axial-spondyloarthritis-/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2013/08/eu-approval-for-ilaris-for-sjia/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2019/04/tecentriq-and-cotellic-combination-fails-phase-iii-trial-to-treat-microsatellite-stable-colorectal-cancer--genentech-roche/2024-02-22T15:11:56+00:00weekly0.6https://www.medthority.com/news/2014/03/phase-iii-success-for-jakafi-jakavi-for-polycythemia-vera---incyte--novartis/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2013/04/ema-pharmacovigilance-risk--assessment-committee-recommends-restrictions-on-protelos--servier--as-a-treatment-for-osteoporosis/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2018/07/luspatercept-achieved-primary-and-key-secondary-endpoints-in-phase-iii--medalist--study-in-patients-with-low-to-intermediate-risk-myelodysplastic-syndromes--celgene---acceleron-pharma-/2024-07-30T14:57:41+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-cobas-egfr-mutation-test-v2-for-use-with-plasma-samples--as-a-companion-diagnostic-for-non-small-cell-lung-cancer-therapy--roche/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---more-patients-with-severe-alcoholic-hepatitis-receiving-liver-transplants/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2014/03/amitiza-fails-phase-iii-trial-for-ci-constipation---sucampo-takeda/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2018/06/titian-pharma-regains-rights-from-braebrun-pharma-to-probuphine-which-is-approved-in-the-us-and-canada-for-maintenance-treatment-of-opioid-dependence-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-arrival-data-on-kalydeco--in-cystic-fibrosis-published-in-the-lancet-respiratory-medicine---vertex-pharma-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2017/11/ema-validates-application-for--opdivo-plus-yervoy-to-treat-advanced-renal-cell-carcinoma----bms-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2013/03/eu-approves-selincro--biotie-lundbeck--for-treatment-of-alcohol-dependence/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-morab-003-004-trial-data-of-morab-003--farletuzumab--fails-to-meet-pfs-endpoints-in-ovarian-cancer--morphotek/2024-02-13T13:45:45+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-ii-study-of-xgeva--amgen--for-giant-cell-tumour-of--bone-published-in-lancet-oncology/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-trial-of-dcvax-l-shows-continued-benefits-in-brain-cancer---northwest-biotherapeutics-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2014/11/dendreon-files-for-bankrupcy/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2014/02/stretta-rf-therapy-meets-endpoints-for-gerd---mederi/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-authorisation-of-lanadelumab-for-the-prevention-of-hae-attacks---shire-plc/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-does-not-recommend-gazyvaro-for-cll---roche-genentech/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-duo-study-of-ipi-145--duvelisib--shows-superiority-to-standard-care-in-progression-free-survival-for-chronic-lymphocytic-leukemia--small-lymphocytic-lymphoma---verastem-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-praxbind--idarucizumab--as-antidote-to-pradaxa-in-uncontrolled-bleeding--boehringer-ingelheim/2024-02-13T13:46:02+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-grants-accelerated-approval-to-arikayce-to-treat-mycobacterium-avium-complex-lung-disease--insmed/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2018/05/studies-reported-for-esketamine-nasal-spray-in-patients-with-treatment-resistant-depression---janssen-pharma-/2024-10-21T14:51:40+00:00weekly0.6https://www.medthority.com/news/2016/01/publication-in-nejm-of-phase-iii-trials-for-viberzi--eluxadoline--for-treatment-of-ibs-with-diarrhea--allergan/2024-02-13T13:46:48+00:00weekly0.6https://www.medthority.com/news/2018/11/oral-semaglutide-demonstrates-favourable-cardiovascular-safety-profile-in-type-2-diabetes-patients-in-pioneer-6-trial---novo-nordisk/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---dickkopf-related-protein-3--dkk3--predicts-aki/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2015/10/chmp-recommends-cosentyx--secukinumab--to-treat-psoriatic-arthritis-and-ankylosing-spondylitis--novartis/2021-09-24T07:03:13+00:00weekly0.6https://www.medthority.com/news/2013/11/new-aha-guidelines-may-favour-crestor--astrazeneca-/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2014/01/mma-for-urea-cycle-disorders-filed-in-eu-cytonet/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2012/01/inferanserin--ventrus-biosciences--in-phase-iii-for-treatment-of-haemorrhoids/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2013/10/vessix-denervation-system--boston-scientific--effective-for-resistant-hypertension/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---fewer-medical-tests---timely-listing-for-transplantation/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2015/07/eribulin-for-soft-tissue-sarcoma-filed-in-us--eu-and-japan--eisai/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-votubia--novartis--for--renal-angiomyolipoma---------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2015/08/nt-0202--extended-release--odt--amphetamine-polistirex--refiled-with-fda-for-adhd-neos-therapeutics/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2015/07/selumetinib-fails-phase-iii-trial-for-metastatic-uveal-melanoma---astrazeneca/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-announces-actions-to-manage-the-risks-of-using-essure--a-device-to-control-fertility--bayer/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-approves-label-variation-for-adcetris--brentuximab-vedotin--in-hodgkin-lymphoma-and-systemic-anaplastic-large-cell-lymphoma--salcl---takeda/2024-02-13T13:47:55+00:00weekly0.6https://www.medthority.com/news/2012/04/cell-therapeutics-acquires-world-rights-to-pancritinib-for-myelofibrosis-/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iii-study-of-dasotraline-shows-significant-improvement-in-children-with-adhd--sunovion-pharma-/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2018/09/european-approval-for-ozalin-as-premedication-before-procedures-in-children---primex-pharma/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-actemra-for-systemic-juvenile-idiopathic-arthritis---genentech-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-promus-premier-stent-for-cad-boston-scientific/2021-09-24T07:16:28+00:00weekly0.6https://www.medthority.com/news/2014/06/novartis-files-bexsero-at-fda-for-meningococcal-disease/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2018/01/boston-scientific-corporation-takes-option-to-acquire-millipede--inc---and-with-it-the-iris-transcatheter-annuloplasty-ring-system-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2014/06/adaptivcrt-algorithm-in-viva-crt-d-and-crt-p-defibrillators-saves-hospital-costs--medtronic/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2017/07/spark-therapeutics-announced-the-lancet--has-published-phase-iii-clinical-trial-data-of-voretigene-neparvovec--for-the-treatment-of-patients-with-vision-loss-due-to-confirmed-biallelic-rpe65-mediated-inherited-retinal-disease-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2016/10/combi-v-study-of-tafinlar--dabrafenib----mekinist--trametinib--success-in-braf-v600-mutation-positive-advanced-melanoma--novartis/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2017/05/boston-scientific-closes-acquisition-of-symetis-sa--a-heart-company-focused-on-minimally-invasive-transcatheter-aortic-valve-implantation-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2018/11/tch-003-study-of-nerivio-migra-meets-primary-endpoint-in-migraine-control---theranica-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2013/12/brintellix-succesful-focus-study-in-cognition-and-depression--lundbeck/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2019/11/positive-results-in-phase-iii-trial-for-toujeo-in-children-and-adolescents-with-type-1-diabetes---sanofi/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2014/02/nice-requests-more-data-from-biogen-idec-for-tecfidera-assessment-in-multiple-sclerosis/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-grants-extended-approval-for-trisenox-to-treat-acute-promyelocytic-leukemia--teva/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2014/08/mylan-files-in-fda-for-generic-copaxone-for-multiple-sclerosis-/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/09/nuplazid--pimavanserin--filed-with-fda-for-psychosis-in-parkinson-s-disease--acadia-pharma/2024-02-13T13:48:07+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-advisory-committee-recommends-approval-of-spravato-for-depression--janssen-pharma/2024-10-21T14:52:26+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-melody-tpv-for-heart-surgery-medtronic/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2017/04/hdm-spire--t-cell-vaccine--fails-to-improve-on-placebo-in-dust-mite-allergy-immunotherapy-phase-iib-field-study---circassia-pharmaceuticals/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-botox-for-canthal-lines/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/05/cara-therapeutics-licenses-worldwide-rights-to-korsuva-to-vifor-fresenius-medical-care-renal-pharma-ltd-except-for-usa--japan-and-south-korea-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2013/06/two-phase-iii-studies-of-roactemra-actemra--genetech-roche--show-long-term-efficacy-and-early-treatment-benefits-in-ra-patients/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-results-in-phase-iii-study-of-isis-ttrrx-in-fap-isis-pharma/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2016/09/ema-validates-application-for-opdivo--nivolumab--to-treat-metastatic-urothelial-carcinoma--muc---bladder-cancer---bms/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2011/10/surfaxin-is-re-filed-at-fda-for-respiratory-distress-syndrome/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2014/07/shire-acquires-rights-to-agt-182-for-potential-treatment-of-hunter-syndrome---armagen---shire/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2017/05/analyses-of-flame-trial-show-ultibro-breezhaler-superior-to-seretide-for-copd-regardless-of-eosinophil-count---novartis/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2014/11/pooled-analysis-of-halaven-in-breast-cancer-published---eisai/2024-02-13T13:58:35+00:00weekly0.6https://www.medthority.com/news/2017/06/merck-inc--has-accepted-the-external-data-monitoring-committee-recommendation-to-pause-new-enrollment-on-keynote-183-and-keynote-185---studies-exploring-keytruda-treatment-in-combination-with-other-therapies-in-multiple-myeloma-/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2013/09/tresiba-study-for-2-5-years-type-2-diabetes/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-solana-rsv---hmpv-assay-as-a-diagnostic-for-infectious-disease---quidel-corp-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2018/08/reduce-study-of-neovasc-reducer-for-refractory-angina-published-in-the-international-journal-of-cardiology---neovasc-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2014/06/tykerb-tyverb-trastuzumab-fails-to-meet-primary-endpoint-in-phase-iii-breast-cancer-trial---gsk/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-stivarga--bayer-healthcare--in-patients-with-gist/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-and-bluebird-bio-announce-positive-top-line-results-from-the-pivotal-phase-ii-karmma-study-of-ide-cel-in-relapsed-and-refractory-multiple-myeloma/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2016/01/-phase-iib-trial-initiated-for-aerosurf--aerosolized-kl4-surfactant--to-treat-respiratory-distress-syndrome--discovery-laboratories/2024-02-13T13:58:48+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-plegridy-for-relapsing-multiple-sclerosis---biogen-idec/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-ii-tortuga-study-of-filgotinib-to-treat-ankylosing-spondyliti-is-published-in-the-lancet---gilead---galapagos/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2018/12/twelve-month-data-of-medlift-study-in-patients-with-benign-prostatic-hyperplasia---neotract/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/10/world-psoriasis-day-2017/2021-11-30T11:36:09+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-advisory-committee-recommends-probuphine-to-treat-opiod-dependence/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2017/07/johnson---johnson--announced--the-first-in-human-clinical-trial-results-for-the-investigational-human-immunodeficiency-virus--hiv-1--preventive-vaccine--/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/04/europrevent-2018--exercise-after-a-heart-attack--it-could-save-your-life-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2019/08/ema-approves-soliris-to-treat-neuromyelitis-optica-spectrum-disorder----alexion-pharma/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2015/07/baxalta-commences-business/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2011/10/ceftazidime-avibactam-from-forest-astrazeneca-enters-phase-iii-trials/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2013/01/study-shows-anti-vegf-treatments-could-cause-harmful-side-effects-in-the-eye/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2011/10/astrazeneca-to-present-positive-health-economics-data-on-brilique-brilinta-at-ispor-meeting-in-november/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2013/07/iclusig--ariad-pharma--eu-approved-for--cml-and-ph-all-/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2012/04/actelion-discointinues-setipiprant-in-asthma-and-allergic-rhinitis/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2017/01/johnson---johnson-to-acquire-actelion-ltd/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-omidria-for-cataract-surgery---omeros/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-humira--adalimumab--for-hidradenitis-suppurativa-abbvie/2025-01-31T11:41:42+00:00weekly0.6https://www.medthority.com/news/2012/12/eu-commission-approves-exjade--novartis--for-treatment-of-iron-overload-with-thalassemia-syndromes/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-faslodex--fulvestrant--500mg-as-expanded-use--for-postmenopausal-women-with-hr--her2--advanced-breast-cancer--astrazeneca-1/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-xofluza-for-people-at-high-risk-of-developing-influenza-related-complications---genentech-roche/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2015/12/post-hoc-studies-of-zebinix--eslicarbazepine-acetate--show-benefits-in-epilepsy--bial/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2015/08/langford-ic-systems-inc--launches-lic-instrument-processor-cleaning-system-to-reduce-infections-from-endoscopes/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2016/12/sovaldi---gs-5816---gs-9857--sofosbuvir---velpatasvir---voxilaprevir--filed-with-fda-for-chronic-hepatitis-c-virus--gilead-sciences/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-tags-data-for-lonsurf-consistent-with-earlier-studies-in-gastric-cancer---taiho-oncology---servier/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2018/01/clarity-study-shows-superiority-of-cosentyx-over-stelara-in-patients-with-plaque-psoriasis---novartis-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2019/08/novan-s-phase-iii-molluscum-pivotal-program-completes-enrollment-of-b-simple-trials-for-sb-206-/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-keynote-062-trial-of-keytruda-meets-endpoint-as-monotherapy-but-not-for-combination-therapy-in-gastic-cancer---merck-inc/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2013/07/safety-analysis-shows-zonegran--eisai--well-tolerated-by-elderly-epilepsy-patients----------------/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2018/10/nice-recommends-use-of-mylotarg-in-cd33-positive-acute-myeloid-leukaemia---pfizer-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2016/11/results-for-saril-ra-monarch--a-phase-iii-study-of-sarilumab-versus-humira--adalimumab--in-the-treatment-of-ra----sanofi---regeneron/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2018/06/six-monthly-update-for-transcend-study-of-jcar-017-investigational-cd19-directed-car-t-cell-therapy--in-patients-with-r-r-aggressive-b-cell-non-hodgkin-lymphoma--nhl-----celgene-/2024-07-26T09:48:35+00:00weekly0.6https://www.medthority.com/news/2014/10/arzerra-enters-phase-iii-study-for-pemphigus-vulgaris--stiefel-gsk/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2014/04/gsk-and-amgen-amend-prolia-marketing-agreement/2025-10-16T10:51:36+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-committee-recommends-approval-of-savaysa-for-stroke-prevention--af--daiichi-sankyo/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-gives-accelerated-approval-to-keytruda--pembrolizumab--in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma--merck-inc/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-truxima--rituximab-bioimilar--to-treat-originator-drug--mabthera-indications---celltrion/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2018/05/yonsa-approved-by-the-fda-for-metastatic-castration-resistant-prostate-cancer---sun-pharma-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-gives-ce-mark-approval-to-i-cor-synchronized-cardiac-assist-system-for-heart-failure--xenios/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2019/06/aaic-2019---preview/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/06/five-year-phase-iii-data-for-taltz-treatment-of-plaque-psoriasis----eli-lilly-/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2019/09/lynparza-added-to-bevacizumab-reduced-the-risk-of-disease-progression-or-death-by-41--in-the-overall-paola-1-trial-population-in-advanced-ovarian-cancer---astrazeneca---merck-inc-/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2011/10/vivus-re-submiots-qnexa-to-the-fda-for-obesity-treatment/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-emerald-study-of-symtuza--darunavir---cobicistat---emtricitabine---tenofovir-alafenamide--in-hiv-published-in-the-lancet-hiv---janssen-pharma-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-on-incruse-ellipta-plus-breo-ellipta-show-benefits-in-copd---gsk-theravance/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2016/10/-fda-advisory-committee-recommends-ser-120---low-dose-nasal-formulation-of-desmopressin--for-patients-with-nocturnal-polyuria----allergan/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2014/10/abbvvie-and-shire-terminate-merger-proposals/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2012/05/study-shows-corpath-200-robotic-pci-surgery-system--corindus-inc--is-safe-and-practical/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2012/09/orexo-files-zubsolv-at-fda-for-treatment-of-opioid-dependence/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2018/11/eu-approves-venclyxto---mabthera-for-chronic-lymphocytic-leukaemia---roche-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-palynziq-to-reduce-blood-phenylalanine--phe--concentrations-in-patients-with-phenylketonuria--pku----biomarin/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2011/12/toviaz-pfizer--success-in-overactive-bladder-in-older-patients/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2014/08/-tralokinumab-enters-phase-iii-trials-for-severe-asthma--astrazeneca---medimmune/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2018/04/rocapuldencel-t---sunitinib-combination-fails-phase-iii-adapt-trial-to-treat-renal-cell-carcinoma--argos-therapeutics-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2017/11/jardiance-reduces-risk-of-cv-death-in-patients-with-type-2-diabetes-and-peripheral-artery-disease--/2024-07-26T09:48:06+00:00weekly0.6https://www.medthority.com/news/2015/04/chmp-recommends-opdivo--nivolumab--for-metastatic-melanoma--bms/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2018/10/reverse-phase-iii-trial-of-gs-010-shows-efficacy-at-72-weeks-for--leber-hereditary-optic-neuropathy---gensight-biologics-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2019/12/bluebird-bio-presents-new-data-on-long-term-transfusion-independence-and-safety-for-lentiglobin-gene-therapy-for-beta-thalassemia-at-ash-meeting-/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-the-somatom-perspective--siemens--ct-scanner/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2018/08/sierra-oncology--inc--announces-it-has-acquired-momelotinib-from-gilead-sciences--for-the-treatment-of-myelofibrosis-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-icaria-mm-trial-of-sar-650984-meets-primary-endpoint-in-multiple-myeloma---sanofi/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2019/05/new-data-for--larotrectinib-to-treat-children-with-trk-fusion-cancer/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2018/07/evenity-re-filed--bla--with-fda-for-osteoporosis---amgen---ucb-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2012/11/lambda-plus-daclatasvir--bms--combination-success-in-phase-iib-trial-for-hepatitis-c/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2013/11/-fda-issues-complete-response-letter-for-cariprazine--forest-gedeon-richter--for-schizophrenia/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-frame-study-of-romosozumab-in-treatment-of-postmenopausal-women-with-osteoporosis--amgen---ucb/2024-02-13T13:59:13+00:00weekly0.6https://www.medthority.com/news/2013/10/astra-zeneca-to-co-promote-zytiga-in-japan-for-prostate-cancer/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-grants-accelerated-approval-for-keytruda--pembrolizumab-for-the-treatment-of-adult-and-pediatric-patients-with-unresectable-or-metastatic--microsatellite-instability-high--msi-h--or-mismatch-repair-deficient-solid-tumors---merck-inc-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-eliquis-for-prophylaxis-of-deep-vein-thrombosis---bms-pfizer/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2017/11/real-world-database-study-of-patients-in-germany-prescribed-entresto-for-heart-failure---novartis/2024-07-26T09:47:27+00:00weekly0.6https://www.medthority.com/news/2017/05/zoptrex--zoptarelin-doxorubicin--fails-to-meet-primary-endpoint-in-endometrial-cancer--aeterna-zentaris/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2018/02/ecco-congress-2018/2024-02-13T13:59:35+00:00weekly0.6https://www.medthority.com/news/2013/01/iqwig-review-of-inlyta-pfizer--nexavar--bayer-and-afinitor--novartis--as-treatments-for-renal-cell-carcinoma/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2015/11/success-for-qutenza--capsaicin-8--patch--in-comparison-trial-with-pregabalin-capsules-for-treament-of-peripheral-neuropathic-pain---astellas/2024-02-13T14:00:04+00:00weekly0.6https://www.medthority.com/news/2019/12/sanofi-----regeneron-announce-their-intention-to-restructure-antibody-collaboration-for-kevzara-and-praluent-/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2015/08/novartis-completes-sale-of-its-influenza-vaccines-to-csl/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-data-on-fp-001--leuprolide-mesylate-injectable-suspension--in-prostate-cancer--foresee-pharmaceuticals/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-balversa-to-treat-bladder-cancer--janssen-r-d/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2018/03/biotime-inc---submits-renevia-for-ce-mark-for-treatment-of-facial-lipoatrophy-in-hiv-patients-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2013/03/early-start-late-start-laquinimod--teva--in-allergo-extension-trial-for-ms/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2017/01/amgen-announces-three-phase-iii-trials-published-in-jama-for-parsabiv--etelcalcetide---to-treat-hyperparathyroidism--/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2018/02/european-society-of-radiology-annual-meeting-2018--esr-2018-/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-in-phase-iii-study-of-mdv-3100--medivation-inc--in-prostate-cancer-patients/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-scale-trial-of-saxenda--liraglutide-shows-benefits-in-obesityy--novo-nordisk/2024-02-13T14:01:25+00:00weekly0.6https://www.medthority.com/news/2019/07/ortho-receives-ce-mark-for-enhanced-vitros-immunodiagnostic-products-nt-probnp-ii-assay--an-aid-in-diagnosing-and-assessing-heart-failure-/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2016/07/decline-in-efficacy-of-mosquirix-vaccine-for-malaria-after-seven-years---gsk/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2011/10/brilinta-brilique-is--reviewed-for-acs-by-iqwig-the-german-health-quality-institute/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2013/02/two-trials-demonstrate-benefits-of-pradaxa-rendix--boehringer--for-patients-with-vte/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2016/06/compliance-data-for-baxter-sigma-spectrum-infusion-system-shows-enhanced-patient-safety--baxter/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2013/11/xiaflex--auxilium--benefits-multiple-dupuytren-s-contractures-/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-xofluza-to-treat--acute--uncomplicated-influenza--genentech-roche/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-anti-hbc-igm-assay--roche--for-hepatitis-b-testing/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2017/11/improved-joint-health-in--haemophilia-a-patients-treated-prophylactically-with-elocta--eloctate---sobi---bioverativ-/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-extension-for-cyramza-in-gastric-cancer---eli-lilly/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-reverses-earlier-decision-and-recommends-approval-of-nerlynx-in-breast-cancer---puma-biotech-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2018/11/safety-and-efficacy-data-of-emapalumab-in-pediatric-patients-with-primary-hemophagocytic-lymphohistiocytosis--to-be-presented-at-ash---swedish-orphan-biovitrium/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-admiral-trial-of-xospata-shows-improved-survival-in-aml---astellas/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-procysbi--raptor-pharma--to-treat-nephropathic-cystinosis-/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-xarelto---aspirin-to-prevent-atherothrombotic-events---bayer-healthcare---janssen-pharma-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2015/09/vercise-primary-cell--pc--deep-brain-stimulation-system-receives-ce-mark-approval-in-the-eu-for-parkinsons-disease--dystonia-and-essential-tremor--boston-scientific/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2015/04/teva-to-acquire-generics-manufacturer-mylan/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2012/03/phase-iii-trial-begins-of-arx-01-system--acelrx-pharmaceuticals--for-treatment-of-post-operative-pain/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2011/11/actos-improves-efficacy-of-radioiodine-therapy-in-metastatic-thyroid-cancer/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2012/03/kynamro---genzyme-sanofi-is-filed-at-fda-for-homozygous-familial-hypercholesterolaemia/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-advisory-committee-postpones-decision-on-eteplirsen-as-a-treatment-for-duchenne-muscular-dystrophy--sarepta/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2016/03/new-data-from-cou-aa-302-trial-of-zytiga--abiraterone-acetate--shows-increased-overall-survival-versus-prednisone-alone-for-prostate-cancer--janssen-biotech/2024-02-13T14:01:37+00:00weekly0.6https://www.medthority.com/news/2014/12/bax-855-is-filed-at-fda-for-treatment-of-haemophilia-a--baxter/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2018/02/tinnitus-week-2018/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2013/08/resure-sealant-filed-at-fda/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2016/10/alimta--pemetrexed--plus-carboplatin-in-combination-with-keytruda--pembrolizumab--shows-efficacy-in-non-small-cell-lung-cancer--eli-lilly-merck/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2018/03/waist-size-bigger-heart-attack-risk-in-women--report-says/2024-11-15T09:14:01+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-keytruda-for-metastatic-melanoma-merck/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2019/01/breakthrough-therapy-designation--for-crizanlizumab-to-treat-sickle-cell-disease---novartis/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2011/11/generic-lipitor-is-launched-in-usa-by-ranbaxy/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for--mogamulizumab-for-treatment-of-patients-with-mycosis-fungoides-or-s-zary-syndrome---kyowa-hakko-kirin/2024-10-21T14:38:27+00:00weekly0.6https://www.medthority.com/news/2019/04/tenecteplase-enters-phase-iii-timeless-trial-to-treat-acute-ischemic-stroke---genentech-roche/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2019/01/daiichi-sankyo-to-market-bempedoic-acid-and-the-bempedoic-acid---ezetimibe-combination-pill-in-the-european-economic-area-and-switzerland--esperion-therapeutics/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2018/01/spectra-wavewriter-spinal-cord-stimulator--scs--system-is-fda-approved-to-treat-chronic-pain---boston-scientific/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2018/03/linhaliq-filed-with-the-eu-for-non-cystic-fibrosis-bronchiectasis---aradigm-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2016/04/priority-review-designation-at-fda-for-atezolizumab--mpdl-3280a--for-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer--genentech-roche/2021-09-24T07:10:44+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-recommends-stelara--ustekinumab--for-psoriatic-arthritis--johnson---johnson/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2015/09/mylan-commences-hostile-bid-for-perrigo/2025-10-16T11:08:39+00:00weekly0.6https://www.medthority.com/news/2012/07/pfizer-files-aprela-at-ema-for-oestrogen--deficiency-symptoms/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2012/08/dutch-regulatory-authority-rejects-cortiment--cosmo-ferring--for-ulcerative-colitis/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-eviplera-triple-therapy-for-hiv-1-infection/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves--annovera-first-one-year-contraceptive---the-population-council---therapeuticsmd-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2018/02/ovarian-cancer-awareness-month-2018/2024-07-26T09:46:09+00:00weekly0.6https://www.medthority.com/news/2015/10/valeant-pharma-international-terminates-relationship-with-philidor-rx-services/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2012/03/cem-101--cempra--success-in-phase-ii-trial-for-cabp/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-trial-of-xiaflex-finds-benefits-for-dupuytren-s-contracture-/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2018/05/chs-1701-refiled-with-fda-for-neutropenia---coherus-biosciences-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2013/07/varisolve--btg--data-for-varicose-veins-published/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2012/03/crtx-080--cornerstone--is-filed-at-fda-for-hyponatraemia-/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2019/05/breakthrough-therapy-designation-for-pomalyst-to-treat--hiv--positive-kaposi-sarcoma/2021-09-24T07:17:37+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-gives-510-k--approval-of-the-microthermx-microwave-ablation-system-for--laparoscopic-ablation-perseon-corp/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2014/01/phase-iii-generx-trial-for-myocardial-ischemia-on-track-cardium-therapeutics/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2013/11/positive-results-from-trials-of-pradaxa-in-af-boehringer/2021-09-24T07:16:28+00:00weekly0.6https://www.medthority.com/news/2019/10/eadv-2019--full-details-announced-for-medthority-com-symposium-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2019/06/positive-overall-survival-results-for-imfinzi-for-first-line-small-cell-lung-cancer/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-extends-review-period-of-tecentriq---avastin---chemo-to-treat-non-squamous-nsclc-to-5-december-2018----genentech-roche/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-data-from-study-of-amigal-in-fabry-disease-amicus-therapeutics/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2014/09/boston-scientific-initiates-reprise-iii-trial-of-lotus-valve-system-for-aortic-stenosis-to-support-us-approval/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2014/03/afinitor--aromasin-combination-fails-bolero-2-study-in-breast-cancer---novartis---pfizer/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2016/12/abt-493--glecaprevir--plus-abt-530--pibrentasvir--filed-with-fda-for-chronic-hcv--enanta-abbvie/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2012/06/phase-iii-grid-study-of-bay-73-4506--bayer-healthcare--for-gist-meets-primary-endpoint/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2017/07/study-suggests-reminyl-xl-razadyne--galantamine-hydrobromide--provides-benefits-in-metabolic-syndrome--janssen-pharma/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2012/03/phase-iii-study-of-zytiga--janssen--for-prostate-cancer-unblinded/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-accepts-avycaz-snda--to-include-the-treatment-of-complicated-urinary-tract-infections-and-complicated-intra-abdominal-infections-in-pediatric-patients---allergan-/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-restricts-use-of-pletal-otsuka-and-ekistol-lacer--to-treat-intermittant-claudication/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2012/03/relovair--gsk-theravance-programme-is-now-complete-for-copd-and-asthma/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2018/06/positive-results-from-cgp-md-01--a-phase-iib-iii-trial-evaluating-orally-administered-atogepant-in-patients-with-episodic-migraine--allergan-/2024-07-26T09:43:49+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-midayis--mixed-salts-of-a-single-entity-amphetamine-product-a-once-daily-treatment-for-adhd---shire-plc-/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-advisory-committee-recommends-approval-of--epidiolex-for-the-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome--and-dravet-syndrome----gw-pharma-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2015/10/translarna--ataluren--filed-in-eu-for-nonsense-mutation-cystic-fibrosis--ptc-therapeutics/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2015/09/sanofi-and-eli-lilly-agree-terms-which-will-enable-biosimilar-basaglar-to-enter-us-market-for-diabetes-after-15-december-2016/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2016/11/results-from-phase-iii-studies-simplify-1-and-simplify-2-for-momelotinib-to-treat-myelofibrosis---gilead-sciences/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2011/12/eu-approval-is-given-for-intravenous-formulation-of-remodulin--united-therapeutics-/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2018/03/ehra-2018--apixaban-is-a-safe-alternative-to-warfarin-during-catheter-ablation-of-atrial-fibrillation/2024-02-13T14:02:04+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-chmp-recommends-extension-to-indication-for-cubicin--daptomycin--to-include-complicated-skin-and-soft-tissue-infections-cubist-pharma/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2017/06/nice-grants-limited-recommendation-for-esbriet--pirfenidone--as-a-treatment-for-idiopathic-pulmonary-fibrosis--roche/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2019/09/abbott-s-triclip-device-in-the-triluminate-feasibility-study-met-both-the-primary-safety-and-performance-endpoints-for-reduction-of-tricuspid-regurgitation-/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2014/09/ain-457-meets-endpoints-in-phase-iii-trials-for-psoriatic-arthritis---novartis/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-gives-complete-response-to-filing-of-ryanodex--dantrolene-sodium--for-exertional-heat-stroke--eagle-pharmaceuticals/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2014/06/lp2086-filed-with-the-fda-for-meningococcal-disease-pfizer/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-extends-use-of-zonegran--eisai--as-monotherapy-for-epilepsy-/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-trial-of-lampit-meets-primary-endpoint-in-study-of-chagas-disease---bayer-healthcare/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-angelmed-guardian-system-to-detect-acute-coronary-syndrome-events---angel-medical-systems-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2017/07/study-of-pci-patients-with-impella-2-5-heart-pump-published-in-journal-of-interventional-cardiology--abiomed/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-results-for-soliris-in-ahus-alexion-pharma/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-label-update-for-sprycel--dasatinib--in-ph--chronic-myeloid-leukemia--bms-otsuka/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2012/07/final-results-from-trial-of-truvada--gilead-sciences--for-hiv-prevention/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2015/06/cefaly-technology-publishes-study--in-neurological-sciences-of-cefaly-nerve-stimulation-for-migraine-/2024-02-13T14:20:19+00:00weekly0.6https://www.medthority.com/news/2013/12/norway-to-fund-biosimilar-trials-starting-with-inflectra-hospira/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2014/06/minimed-duo-insulin-pump-receives-ce-mark-approval---medtronic/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-issues-complete-response-letter-for-rayaldee--calcifediol--as-a-treatment-for-secondary-hyperparathyroidism---opko-health-inc-/2021-09-24T07:10:51+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-inspire-uas-therapy-for-obstructive-sleep-apnea-inspire-medical/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2014/07/alectinib-is-approved-in-japan-for-treatment-of-alk--non-small-cell-lung-cancer-roche/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-iii-trial-shows-benefits-of-resolute-zes--medtronic--in-cad-patients-with-diabetes/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2013/12/ec-approves-2-dose-cervarix-vaccine-for-cervical-cancer-gsk/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iv-data-for-gilenya--fingolimod--shows-high-patient-retention-rate-in-multiple-sclerosis--novartis/2024-02-13T14:20:36+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-expanded-indication-for-hizentra-in-pi-csl-behring/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-pivotal-study-sunrise-1-of-e-2006-meets-primary-endpoint-in-multiple-sleep-disorders---eisai---purdue-pharma-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2017/07/phase-iii-giacta-study-of-actemra--tocilizumab--in-giant-cell-arteritis--is-published-in-the-new-england-journal-of-medicine---genentech-roche-/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2017/01/quantiferon-tb-gold-plus-filed-with-fda-as-test-for-tuberculosis--qiagen-/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2016/03/sbla-filed-with-fda-for-xolair--omalizumab--in-allergic-asthma-for-paediatric-patients--genentech-roche/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2018/06/teva-discontinues-the-enforce-trial-of-fremanezumab-for-chronic-cluster-headache-but-the-episodic-cluster-headache-part-of-the-study-continues-as-planned-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2016/03/sanofi-pasteur-and-merck-inc--to--end-their-joint-venture--sanofi-pasteur-msd--in-vaccines-in-europe/2021-09-24T07:10:26+00:00weekly0.6https://www.medthority.com/news/2012/10/map-pharma-re-submits-levadex-to-the-fda-for-treatment-of-migraine-/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2013/04/chmp-recommends-xtandi--enzalutamide--as-a-treatment-for-prostate-cancer/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-phase-iii--emilia-study-data-for-t-dm1--genentech-roche--in-breast-cancer-patients-confirmed/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2015/07/eyegate-pharma-licences-world-rights-for-egp-437-to-valeant-pharmaceuticals-international/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2019/10/submission-to-ema-for-nuzyra-in-absssi-and-cabp-withdrawn---paratek-pharma/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-issues-warning-concerning-canagliflozin-from-janssen-pharmaceuticals-/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-kalydeco--ivacaftor--for-cystic-fibrosis-in-children-with-the-cftr-gene--vertex/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-rejects-masiviera-for-pancreatic-cancer--ab-science/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2015/11/smith---nephew-acquires-blue-belt-for--275-million/2025-10-16T11:01:14+00:00weekly0.6https://www.medthority.com/news/2015/02/astrazeneca-acquires-actavis-branded-respiratory-franchise-in-us-and-canada-for--600-million/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-targiniq-er-an-opioid-analgesic-for-treatment-of-severe-pain---purdue-pharma/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2013/03/shire-acquires-sarcode-bioscience-and-phase-iii-lifitegrast-for-dry-eye-disease/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2016/03/tivozanib-is-filed-at-ema-for-the-first-line-treatment-of-advanced-renal-cell-carcinoma--eusa-pharma---aveo-oncology/2024-02-13T14:21:53+00:00weekly0.6https://www.medthority.com/news/2018/09/mulpleta-is-now-available-in-the-us-for-the-treatment-of-thrombocytopenia---shionogi-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2016/02/chmp-recommends-opdivo--nivolumab--to-treat--metastatic-non-small-cell-lung-cancer--nsclc--after-prior-chemotherapy--and-adults-with-advanced-renal-cell-carcinoma---bms-/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2016/06/deflazacort-is-filed--nda--at-fda-to-treat-duchenne--muscular-dystrophy----marathon-pharma--/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-extension-of-opdivo--nivolumab--to-include-metastatic-nsclc-where-disease-has-progressed-after-platinum-chemotherapy--bms/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-application-withdrawn-for-balimek-in-nras-mutant-melanoma-pierre-fabre-medicament/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-recommends-xofigo-for-treatment-of-prostate-cancer-bayer-healthcare/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2018/08/complete-response-letter-for-stannsoporfin--to-treat-newborns-at-risk-of-developing-severe-jaundice--mallinckrodt-plc-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-data-shows-abt-450-r--abt-267--abt-333--abbvie--successful-in-patients-with-hepatitis-c-/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-nucala-as-adjunctive-treatment-for-severe-refractory-eosinophilic-asthma-in-children-aged-6-to-17-years----gsk-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-study--482--published-in-the-lancet-oncology-for-xgeva-for-prevention-of-skeletal-related-events-in-multiple-myeloma-patients---amgen-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-recomends-iclusig--ariad-pharma--for-cml-and-ph-all/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2011/12/cobicistat--gilead-sciences--success-in-study-114-as--booster--in-aids-treatment/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2011/12/bi-201335--boehringer-ingelheim--phase-iii-trial-completes-recruitment/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2016/09/new-analyses-from-three-trials-of-ocrevus--ocrelizumab--in-primary-progressive-ms-and-relapsing-ms--genentech---roche/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-zontivity-to-reduce-the-risk-of-heart-attack--stroke--cardiovascular-death--merck---company-inc-/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2017/11/canvas-study-shows-invokana-improves-outcomes-in-type-2-diabetes-with-cv-risk---janssen-r-d-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-rejects-yondelis--trabectedin--as-a-treatment-for--ovarian-cancer--pharma-mar/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2017/07/eisai-files-at-fda-and-ema-applications-for-lenvatinib-for-the-treatment-of-hepatocellular-carcinoma-/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-iluvien-for-dmo---alimera-sciences/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2015/01/asfotase-alfa-submission-to-fda-for-hypophosphatasia-is-completed-alexion-pharma/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2016/09/emtricitabine-tenofovir-disoproxil-zentiva-recommended-by-ema-chmp-as-generic-for-truvada-in-hiv-treatment--zentiva/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2019/06/horizon-therapeutics-initiates--trial-for-krystexxa--pegloticase-injection--plus-methotrexate-to-increase-durability-of-response-for-patients-living-with-chronic-gout-/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-extends-approval-of-total-artificial-heart--syncardia-to-be-used-in-destination-therapy/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-fenix-continence-restoration-system-to-treat-faecal-incontinence--torax-medical/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2016/11/studies-presented-by-janssen-biotech-at-the-2016-acr-arhp-annual-meeting-reveal-higher-discontinuation-rates-in-patients-newly-beginning-or-switching-to-treatment-with-remsima-inflectra--ct-p13--/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2018/03/endometriosis-awareness-week-2018/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2015/01/phase-iii-trials-of-dysport-show-response-in-spasticity-ipsen/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2013/05/barrx-rf-ablation-system-success-in-barrett-s-oesophagus/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2012/04/ib-1001--inspiration-bio--filed-at-fda-for-haemophilia-b/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2017/10/nice-funding-rejected-for-lenvima-and-nexavar-in-thyroid-cancer/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-commission-approves-strimvelis-to-treat-rare-disease--ada-scid--severe-combined-immunodeficiency-due-to-adenosine-deaminase-deficiency---gsk/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2018/01/research-to-investigate-the-links-between-brain-haemorrhage-and-stroke-/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2017/07/amryt-pharma--announced-the-publication-of-a-long-term-extension-study-evaluating-the-benefits-of-lojuxta--lomitapide--in-the-treatment-of-homozygous-familial-hypercholesterolaemia-/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-rejects-faslodex-for-metastatic-oestrogen-receptor-positive-breast-cancer-in-postmenopausal-women-who-have-not-had-endocrine-therapy--astrazeneca-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2018/10/five-years-data-in-relapsing-and-primary-progressive-multiple-sclerosis-with-ocrevus--genentech-roche/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-eclipse-study-of-tremfya-demonstrates-superiority-to-cosentyx-in-plaque-psoriasis---janssen-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2018/10/510-k--approval-for-b-laser-atherectomy-system-to-treat-peripheral-artery-disease---eximo-medical/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2011/03/fda-advisory-committee-recommends-novo-ttf-100a-for-glioblastoma/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2019/08/baxter-healthcare-launches-finomel-in-the-european-union-to-provide-parenteral-nutrition-/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2013/08/-fda-advisory-committee-recommends-riociguat-for-pah-and-cteph/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2018/10/ri-002--formerly-bivigam--establishes-a-new--pdufa-date-of-2-april-2019---adma-biologics--inc/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2014/09/first-european-launch-in-denmark-of-brintellix-for-major-depressive-episodes--lundbeck-/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2014/08/genentcch-roche-files-lucentis-at-fda-for-treatment-of-diabetic-retinopathy-/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2011/10/crestor-patent-challenged-by-generic-companies/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-recommends-lynparza-for-maintenance-treatment-of-relapsed--platinum-sensitive-high-grade-epithelial-ovarian--fallopian-tube-or-peritoneal-cancer-if-they-have-a-brca1-or-brca2-mutation--brcam----astrazeneca---merck-inc-/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-gives-ce-mark-for-triguard-cerebral-protection-device/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-warns-of-priapism-effect-with-certain-adhd-drugs/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2020/01/janssen-responds-to-the-national-institute-for-health-and-care-excellence--nice--draft-guidance-for-its-novel-antidepressant-spravato----esketamine--nasal-spray-in-treatment-resistant-major-depressive-disorder/2024-02-13T11:08:49+00:00weekly0.6https://www.medthority.com/news/2012/11/suvorexant-is-filed-at-fda-by-merck-inc---for-sleep-disorder/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-lymphoseek-to-detect-head-and-neck-tumours---navidea-biopharmaceuticals/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2011/09/afinitor-success-in-phase-iii-study-with-angiomyolipomas--associated-with-tuberous-sclerosis-complex--/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2011/09/incivek-treatment-still-effective-when-course-is-half-as-long-in-treatment-of-hepatitis-c-genotype-1/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2013/10/tdcs--soterix-medical--in-phase-iii-trial-for-depression/2024-10-21T14:51:48+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-ii-iii-study-of-nurelin--adamas-pharmaceuticals--meets-primary-endpoint-in-parkinsons-disease-patients/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2017/01/nice-publishes-final-guidelines-recommending-imbruvica--ibrutinib--for-patients-with-17p-deletion-or-tp53-mutation-chronic-lymphocytic-leukaemia--janssen/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2013/03/lundbeck-and-otsuka-collaborate-on-lu-ae-58054-as-a-treatment-for-alzheimers-disease/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2019/03/three-phase-iii-studies-of-glyx-13-fail-to-meet-primary-endpoints-in-major-depressive-disorder---allergan/2024-10-21T14:54:41+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-chmp-recommends-approval-of-nucala--mepolizumab--for-eosinophilic-asthma--glaxosmithkline/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2014/07/opc-34712-filed-with-fda-for-schizophrenia-and-mdd-otsuka-lundbeck/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2018/05/interim-phase-iii-analysis-of-dcvax-l-in-glioblastoma-published-in-journal-of-translational-medicine---northwest-biotherapeutics-/2024-02-13T11:09:22+00:00weekly0.6https://www.medthority.com/news/2011/09/illluminate-trial-of-incivek-is-published-in-nejm/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-study-of-n-1539--intravenous-meloxicam--meets-endpoint-in-acute-postoperative-pain--recro-pharma/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2018/04/novartis-to-acquire-avexis-inc--and-with-it-avxs-101-a-gene-therapy-to-treat-spinal-muscular-atrophy-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2011/11/thrombosis-risk-in-early-drug-eluting-stents/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2015/09/new-subset-analysis-results-with-fycompa--perampanel--show-benefits-in-epilepsy--eisai/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2015/06/zs-9-is-filed-at-fda-to-treat-hyperkalaemia--zs-pharma/2023-07-24T15:14:36+00:00weekly0.6https://www.medthority.com/news/2017/05/successful-phase-iii-trial-of-roclatan--netarsudil-latanoprost-ophthalmic-solution--to-treat-glaucoma-or-ocular-hypertension----aerie-pharmaceuticals-inc-/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-now-recommends-zydelig--idelalisib--to-treat-cll--gilead-sciences/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-olympus-trial-of-ugn-101-shows-positive-response-in-urothelial-cancer---urogen-pharma-/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2018/05/retrospective-effectiveness-study--positive-for-saxenda-in-weight-reduction---novo-nordisk-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2018/10/european-commission-approves-hulio---adalimumab-biosimilar-for-all-indications-of-the-reference-drug---mylan---fujifilm-kyowa-kirin-biologics-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-noxafil-dr-for-fungal-infections--merck/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2014/02/merck-files-v-503-at-fda-for-9-valent-human-papillomavirus-virus--hpv--vaccine/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/06/-results-of-follow-up-study-suggest-early-and-intensive-treatment-of-rheumatoid-arthritis-has-long-term-benefits/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-filing-of-galcanezumab-for-the-prevention-of-migraine----eli-lilly-/2024-02-13T11:09:35+00:00weekly0.6https://www.medthority.com/news/2016/09/egalet-corporation-announces-oxaydo--oxycodone-oral-hcl-tablets--bioequivalence-study-for-treatment-of-acute-and-chronic-pain-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-approval-of-kalydeco-in-cystic-fibrosis-cftr-gene-mutation---vertex-pharma/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-trial-of-abbv-066-meets-primary-endpoints-in-plaque-psoriasis---abbvie-/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2019/05/nice-recommends-spinraza-for-the-treatment-of-spinal-muscular-atrophy/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2015/12/bionor-announces-that-the-hiv--shock---kill--trial-reduc-with-vacc-4x-and-romidepsin-meets-its-primary-endpoint-by-significantly-reducing-latent-hiv-reservoir-and-demonstrates-control-of-viral-load--/2024-02-13T11:09:47+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-entresto--sacubitril-valsartan--to-treat-symptomatic-chronic-heart-failure-and-reduced-ejection-fraction-novartis/2024-02-13T11:10:13+00:00weekly0.6https://www.medthority.com/news/2019/11/acthar-gel-therapy-in-symptomatic-sarcoidosis-is-published-in-therapeutic-advances-in-respiratory-disease---mallinckrodt/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2018/05/results-of-two-phase-iii-trials-of-hemlibra-in-haemophilia-a-show-effectiveness-of-therapy-without-inhibitors---chugai-pharma-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-clears-new-indications-for-existing-lyme-disease-tests-that-may-help-streamline-diagnoses/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2016/09/aralez-pharmaceuticals-acquires-us-and-canadian-rights-to-zontivity--vorapaxar--from-merck-inc-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-510-k--approval-for-digitaldiagnost-c90--radiography-system---royal-philips/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2012/07/canagliflozin-filed-by-janssen-cilag-in-eu-for-type-2-diabetes/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2013/11/sofosbuvir--gilead--success-in-genotype-2-and-3-hepatitis-c-trial/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-reviews-snda-of-vyvanse--shire--as-maintenenace-treatment-for-young-patients-with-adhd---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2015/06/xultophy--ideglira----metformin-superior-to-insulin-glargine---metformin-in-reduction-of-hba1c-in-type-2-diabetes--novo-nordisk/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-otezla-for-treatment-of-plaque-psoriasis--celgene/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-grants-510-k--approval-for--solana-c--difficile-assay----quidel-corporation/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-clinical-trial-of-mek-162--binimetinib--meets-primary-endpoint-in-nras-mutant-melanoma--array-biopharma/2024-02-13T11:10:23+00:00weekly0.6https://www.medthority.com/news/2012/09/janssen-biotech-submit-application-to-fda-for-simponi-as-treatment-for-adults-with-active-rheumatoid-arthritis/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2014/04/eu-approves-incruse-ellipta-for-copd-gsk/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2015/03/santen-files-opsiria---intravitreal-sirolimus--at-ema-to-treat-noninfectious-uveitis-/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2012/08/ocriplasmin-novartis-thrombogenics--studies-for-vitreomacular-adhesion-published-in-nejm/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-sbla-for-imfinzi--durvalumab--for-the-treatment-of-patients-with-locally-advanced--stage-iii--unresectable-nsclc---astrazeneca-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2019/07/gsk-initiates-phase-iii-programme-for-otilimab--for-patients-with-moderate-to-severe-rheumatoid-arthritis-/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-grants-510-k--approval-for-zeus-borrelia-modified-two-tiered-testing--mttt--algorithm-to-diagnose-lyme-disease--zeus-scientific/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2017/05/flex-robotic-system-is-fda-approved-for-colorectal-procedures-in-the-united-states---medrobotics-corp---/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-snda-of-cinvanti-for-nausea-and-vomiting-from-chemotherapy---heron-therapeutics/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-snda-for-gilotrif--afatinib--in-metastatic-non-small-cell-lung-cancer-with-egfr--exon-21--l861q---g719x-or-s768i-substitution-mutations---boehringer-/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves-mobilett-mira-mobile-x-ray-unit-/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2016/09/cnto-136--sirukumab--filed-with-fda-for-rheumatoid-arthritis---janssen/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2015/08/shire-s-offer-to-combine-baxalta-and-shire-into-one-global-company-is-rejected-by-the-baxalta-board-of-directors/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2018/12/european-commission-approves-bevespi-aerosphere-as-a-maintenance-dual-bronchodilator-treatment-to-relieve-symptoms-in-adult-patients-with-copd---astrazeneca/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-catasyn-advanced-technology-wound-hydrogel-to-treat-burns-and-wounds---synedgen-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2018/06/complete-response-letter-from-fda-for--biosimilar-trastuzumab----amgen-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-xilonix--monoclonal-antibody--reports-reduction-in-serious-adverse-events-in-colorectal-cancer-patients--xbiotech-/2024-02-13T11:10:35+00:00weekly0.6https://www.medthority.com/news/2018/05/ema-validates-application-for-opdivo---yervoy-to-treat-nsclc-patients-who-have-tumor-mutational-burden---bms-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-pandemic-live-attenuated-influenza-vaccine--p-laiv--for-prevention-of-influenza--astrazeneca---medimmune/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2013/12/kcentra-superior-to-plasma-in-surgery-csl-behring/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iv-study-shows-eucrisa-well-tolerated-in-young-patients-with-atopic-dermatitis/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2017/05/oncologic-drugs-advisory-committee-recommends-endari--l-glutamine--to-treat-sickle-cell-disease--emmaus-life-sciences-inc-/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2018/11/edge-therapeutics-will-merge-with-pds-biotechnology-corporation-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-oak-study-of-tecentriq--atezolizumab--shows-improved-overall-survival-in-non-small-cell-lung-cancer--genentech-roche/2024-07-26T09:51:48+00:00weekly0.6https://www.medthority.com/news/2017/11/3rd-global-summit-on-heart-diseases/2024-02-20T13:53:08+00:00weekly0.6https://www.medthority.com/news/2018/10/pfizer-and-novartis-to-combine-tropifexor-and-one-or-more-pfizer-compounds-to-treat-nash-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2017/02/chmp-recommends-tafinlar--dabrafenib--in-combination-with-mekinist--trametinib-to-treat-metastatic-non-small-cell-lung-cancer--novartis/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-now-recommends-imbruvica-to-treat-mantle-cell-lymphoma----janssen-biotech-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2015/03/opdivo--nivolumab--filed-at-fda-for-treatment-of-nsclc--bms/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2014/04/almirall---forest-report-feedback-from-fda-for-aclidinium-bromide---formoterol-fumarate-combination-for-copd/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-study-success-for-bevacizumab-biosimilar-abp-215-in-nsclc--allergan---amgen/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-trial-of-rbp-6000--buprenorphine-monthly-depot--for-adults-with-moderate-to-severe-opioid-use-disorder--meets-primary-endpoint--indivior/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2013/12/pooled-safety-data-for-pradaxa-in-dvt-published-boehringer/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-of-dysport--abobotulinumtoxina--in-brain-injury-patients-with-spasticity-published-in-the-lancet-neurology--ipsen/2024-02-13T11:10:49+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-galafold--migalastat---to-treat-fabry-disease--amicus-therapeutics/2021-09-24T07:10:48+00:00weekly0.6https://www.medthority.com/news/2013/12/rolapitant-phase-iii-results-for-cinv--nausea---tesaro/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-fycompa--perampanel-hydrate--to-treat-generalized-tonic-clonic-seizures--eisai/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/11/all-haemophilia-a-patients-in-republic-of-ireland-get-continued-access-to-sobi-s-extended-half-life-factor-replacement-therapy-/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2016/11/cnto-1959--guselkumab--filed-with-ema-for-moderate-to-severe-plaque-psoriasis--janssen/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2012/03/gsk-files-at-fda-for--h5n1-subtype--influenza-vaccine/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-solitaire-iv--trial-of-oral-solithromycin-has-success-in-treatment-of-community-acquired-bacterial-pneumonia--cempra/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-alere-i-strep-test-for-group-a-streptococcus-infectious-diseases--alere-/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2012/09/phase-ii-success-for-resminostat--4sc--in-liver-cancer/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/10/global-resolution-of-patent-issues-between-sandoz-and-abbvie-relating-to--hyrimoz--adalimumab-biosimilar--/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2013/12/forest-acquires-us-rights-to-saphris-from-merck-inc/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2017/09/eu-approves-bavencio--avelumab--to-treat--metastatic-merkel-cell-carcinoma---merck-kgaa---pfizer-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2014/06/odm-201-to-be-marketed-by-bayer-for-prostate-cancer--orion---bayer/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approves-viekirax---exviera--for-treatment-of-hepatitis-c--abbvie/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2018/06/cam-2038-is-resubmitted-by-braeburn-pharma-to-the-fda-for-the-treatment-of-opioid-use-disorder-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2019/03/mental-health-state-associated-with-higher-death-rates-for-prostate-and-other-urological-cancers/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-kadcyla--roche--for-her2-positive-breast-cancer/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-prevymis-for-prophylaxis-of-cytomegalovirus-infection---merck-inc-/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2015/06/trulicity--dulaglutide---superior-to-victoza--liraglutide--in-japanese-trial-in-type-2-diabetes-eli-lilly/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2012/05/gsk-to-co-pomote-testim--auxilium-pharma--in-usa/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-snda-for-farxiga-to-reduce-the-risk-of-cardiovascular--cv--death-or-the-worsening-of-heart-failure---astrazeneca/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2019/07/seattle-genetics---astellas-submit-a-bla-to-the-fda-for-accelerated-approval-for-enfortumab-vedotin-for-metastatic-urothelial-cancer-/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2018/02/intercept-pharma-initiates-reverse-trial-of-obeticholic-acid-for-patients-with-compensated-cirrhosis-due-to-nash-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-activa-deep-brain-stimulation-neurostimulators-for-full-body-mri-scans--medtronic/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approve-resolute-integrity--medtronic-inc--drug-eluting-stent-/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2016/03/results-of-ontime-phase-iii-trial-of-estybon--rigosertib--in-myelodysplastic-syndromes-published-in-lancet-oncology--onconova/2024-02-13T11:11:15+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-afinitor-for-treatment-of-renal-angiomyolipomas/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2019/05/acceleration-of-the-timeline-for-topline-results-from-the-momentum-phase-iii-trial-of-axs-07-for-the-acute-treatment-of-migraine--axsome-therapeutics-/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2014/09/lemtrada-low-relapse-rates-in-multiple-sclerosis-sustained-over-two-years-sanofi/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-trial-shows-zonegran-for-epilepsy-well-tolerated-in-young-patients---eisai/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-cholib--abbott-healthcare--to-treat-dyslipidaemia/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approval-for-micra-av-the-world-s-smallest-pacemaker-to-treat-av-block---medtronic-/2024-10-21T14:43:54+00:00weekly0.6https://www.medthority.com/news/2011/12/eisai-re-submits-perampanel-to-fda-for-epilepsy/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-data-from-trial-of-brilinta--ticagrelor--in-acs-patients-astrazeneca/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2019/08/rova-t-failed-meru-trial-for-small-cell-lung-cancer-and-the------programme-has-been-terminated--abbvie/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-recommends-incivo--j-j-janssen-cilag--for-genotype-1-chronic-hepatitis-c-patients/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2018/05/eli-lilly-to-acquire-aurka-pharma-and-ak-01--an-aurora-kinase-a-inhibitor--in-early-trials-for-solid-tumours-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2014/02/vyvanse-fails-phase-iii-trials-for-depression---shire/2024-10-21T14:51:55+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-briviact-brivaracetam--as-adjunctive-therapy-for-partial-onset-seizures--ucb/2024-02-13T11:12:17+00:00weekly0.6https://www.medthority.com/news/2013/08/afrezza-success-in-type-2-diabetes-trial/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2018/10/adalimumab-biosimilars-launches-in-europe-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2011/11/vytorin-recommended-for-reduction-of-cv-risk-in-ckd-patients/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2013/10/stada-to-market-gastrofil-for-neutropenia-in-eu/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-progesterone-receptor-1e2-image-analysis-system--ventana-medical-systems--for-breast-cancer/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-recommends-change-to-authorisation-for-relvar-ellipta-in-asthma---glaxo-group-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2017/06/merck-inc--announces-positive-outcomes-of-reveal-study-of-anacetrapib--mk-0859--showing-a-reduction-of-coronary-events-/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-expanded-indication-for-osteocool-rf-ablation-system-for-palliative-treatment-of-metastases-in-all-bony-anatomy--medtronic--/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2017/05/kalydeco-is-fda-approved-for-use-in--cystic-fibrosis-patients-ages-2-and-older-who-have-one-of-23-residual-function-mutations-in-the-cftr--gene---vertex-pharma/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2012/03/biotie-lundbeck-report-results-of-phase-iii-studies-for-selincro-for-alcohol-dependence/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-afinitor--novartis--for--hr---her2-neu-negative-advanced-breast-cancer/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2012/06/origin-trial-of-lantus-sanofi-shows-no-cv-effect-or-cancer-risk/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-i-iii-affinity-trial-of-rviii-singlechain--csl-behring--shows-good-safety-and-efficacy-for-haemophilia-a/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2019/06/ema-validates-maa-for-exparel-for-post-surgical-analgesia--pacira-pharma/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2016/12/amgen---allergan-file-maa-at-ema-for-abp-215--a-biosimilar-candidate-to-avastin---bevacizumab-----amgen-and-allergan-plc--/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-labelling-change-for-exablate-neuro-system-mri-guided-ultrasound-in-uterine-fibroids--insightec/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-requires-belviq-to-be--withdrawn-from-its-us-market-due-to-cancer-risks--eisai/2021-09-24T07:12:03+00:00weekly0.6https://www.medthority.com/news/2014/12/bay-81-8973-filed-at-ema-for-treatment-of-haemophilia-a-in-children-and-adults--bayerhealthcare/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2013/07/eliquis--bms-pfizer--success-in-vte-trial-amplify/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-xultophy-100-3-6--insulin-degludec-plus-liraglutide--to-treat-type-2-diabetes--novo-nordisk/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2013/09/risk-of-haemophilia-found-with-plavix-association/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2017/10/mereo-biopharma-group-licenses-azd-9668-from-astrazeneca-to-treat-alpha-1-antitrypsin-deficiency-/2021-09-24T07:13:20+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-snda-for-tivicay--dolutegravir---changing-weight-limit-in-hiv-treatment--viiv-healthcare/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2014/09/new-safety-analysis-of-nerventra-in-ms-teva-active-biotech/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-approval-of-rinvoq-for-severe-active-rheumatoid-arthritis---abbvie/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2015/06/new-analyses-from-phase-iii-studies-for-xolair--omalizumab--for-chronic-spontaneous-urticaria-novartis/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-converts-accelerated-approval-for-perjeta-treatment-for-breast-cancer-to-full-approval-and-approves-perjeta---herceptin-adjuvant--treatment---genentech-/2021-09-24T07:13:34+00:00weekly0.6https://www.medthority.com/news/2017/03/chmp-recommends-approval-of-keytruda--pembrolizumab---for-relapsed-or-refractory-classical-hodgkin-lymphoma--merck-inc/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2014/03/novartis-launches-pre-filled-syringe-version-of-lucentis---novartis/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2018/10/merck---co-inc---and-samsung-bioepis--have-jointly-terminated-development-of-lusdarna-a-diabetes-insulin-treatment-biosimilar-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2011/11/adapt-des-registry-data-for-acs-patients-shows-risk-of-stent-thrombosis/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-mrdx-bcr-abl-test-as-a-companion-diagnostic-to-tasigna-in-chronic-myeloid-leukemia-ph----molecularmd-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2018/08/association-of-insecticide-levels-in-pregnant-women-may-provide-biomarker-evidence-of-a-cause-of-autism-according-to--a-new-study-published-in-the-american-journal-of-psychiatry-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2019/05/vertex--has-selected-the-triple-combination-of-vx-445--elexacaftor---tezacaftor-and-ivacaftor-to-submit-for-potential-regulatory-approvals-for-people-ages-12-and-older-with-cystic-fibrosis-/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-advisory-committee-negative-for--brinavess-for-the-rapid-conversion-of-recent-onset-atrial-fibrillation---correvio-pharma-corp-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2018/09/sandoz-novartis-sells-us-dermatology-business-to-aurobindo/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2014/07/interim-data-on-phase-iv-trial-of-nuedexta-in-pba---avanir-pharma/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2012/10/levadex-is-filed-at-the-fda-for-migraine-/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2018/01/positive-phase-iii-celestial-study-of-cabometyx-in-hepatocellular-carcinoma--liver-cancer---exelixis-inc---ipsen-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2016/10/symphonx-is-launched-in-the-us-by-fortimedix-surgical-for-use-in-minimally-invasive-abdominal-laparoscopic-surgery--/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-tafinlar---mekinist-for-anaplastic-thyroid-cancer---novartis-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-venclyxto----gazyvaro-in-chronic-lymphocytic-leukemia---abbvie/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2011/11/tofacitinib--pfizer--is-filed-at-ema-for-rheumatoid-arthritis/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2013/10/baxter-launches-hemopatch-in-eu-for-haemostasis/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2018/02/american-academy-of-dermatology-annual-meeting--aad-2018---san-diego--ca/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-cranial-bone-void-filler-repair-system/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2014/03/nice-rejects-revlimid-for-multiple-myeloma-post-velcade---celgene/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2015/06/success-in-phase-iii-study-of-sd-809-for-tardive-dyskinesia--servier/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2015/09/supplemental-nda-for-imbruvica--ibrutinib--in-front-line-treatment-of-chronic-lymphocytic-leukemia-submitted-to-fda--janssen-biotech/2024-02-13T11:12:40+00:00weekly0.6https://www.medthority.com/news/2013/04/air-band--maquet-cardiovascular--given-fda-510-k--and-eu-ce-mark-approval-for-use-in-surgery/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2017/11/nice-does-not-recommend-halaven-as-second-line-treatment-for-breast-cancer---eisai-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-presents-additional-data-at-ash-for-liso-cel-from-transcend-cll-004--study-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-simplexa-hsv-1-2-direct-test-for-herpes-simplex---focus-diagnostics/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2019/05/data-reported-from-neuro-ttr-study-of-tegsedi-in-patients-with-hereditary-attr-amyloidosis/2021-09-24T07:17:37+00:00weekly0.6https://www.medthority.com/news/2015/08/positive-phase-iii-results-for-plecanatide-as-treatment-for-chronic-idiopathic-constipation--synergy-pharmaceuticals/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2016/03/flutiform-k-haler--fluticasone-plus-formoterol--filed-in-uk-for-adults-and-adolescents-with-asthma--mundipharma/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-approval-of-namuscla-in-myotonic-disorders---lupin-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/05/dabrafenib--gsk--impressive-in-metastatic-melanoma/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2012/02/vedolizumab--takeda--meets-endpoints-in-phase-iii-ulcerative-colitis-trial/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-cuvitru--immune-globulin-subcutaneous--human---20--solution-to-treat-primary-immunodeficiency---shire-plc/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2018/01/prosper-study-design-reported-in-hepatology-medicine-and-policy-of-rifaximin-alpha-a-proposed-treatment-for--hepatic-encephalopathy---norgine-b-v-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2012/08/eu-approves-zinforo--astrazeneca--for-cssti-and-cap-infections---------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2016/05/ema-approves-opdivo---yervoy--nivolumab---ipilimumab--for-advanced-melanoma--bms/2024-02-13T11:12:52+00:00weekly0.6https://www.medthority.com/news/2015/01/phase-iii-study-shows-prt-4445-meets-endpoint-as-antidote-portola-pharma-/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-and-ema-accept-filing-of-siponimod-for-the-treatment-of-secondary-progressive-multiple-sclerosis---novartis/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2019/08/leo-pharma-a-s-acquires-rights-to-develop-and-market-kyntheum-for-moderate-to-severe-psoriasis-outside-of-europe-/2021-09-24T07:17:47+00:00weekly0.6https://www.medthority.com/news/2015/06/national-cancer-institute-initiates-nci-match-study-of-targeted-therapy-in-cancer-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-integra-dermal-regeneration-template--now-omnigraft-for-the-treatment-of-diabetic-foot-ulcers--integra-lifesciences-/2024-02-13T11:13:01+00:00weekly0.6https://www.medthority.com/news/2012/09/results-show-benefits-of-rx-herculink-elite-stent--abbott-vascular--in-patients-with-renal-artery-stenosis/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2017/10/earlier-initiation-of-treatment-with-spinraza--nusinersen--may-improve-outcomes-in-children-with-spinal-muscular-atrophy---biogen-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2015/12/merck-kgaa-and-pfizer-initiate-phase-iii-trials-for-avelumab-to-treat-gastric-gastro-esophageal-junction--gej--cancers-/2024-02-23T14:36:15+00:00weekly0.6https://www.medthority.com/news/2016/09/allergan-acquires-vitae-pharma-and-with-it-vtp-43742-and-vtp-38543-/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2013/02/sobi-and-savient-pharma-to-co--promote-kineret-in-usa---------------/2021-09-24T07:15:33+00:00weekly0.6https://www.medthority.com/news/2014/05/conditional-ema-approval-given-for-translarna-for-duchenne-muscular-dystrophy---ptc-therapeutics/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2013/11/phase-iii-study-shows-sar-153191-effective-in-ra-sanofi-regeneron/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-olympus-and-rockies-trials-for-roxadustat-each-met-their-primary-efficacy-endpoints-for-the-treatment-of-patients-with-anaemia-in-chronic-kidney-disease---astrazeneca---fibrogen/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2011/10/intensity-study-of-onbrez-breezhaler-and-spiriva-in-copd-reported-in-european-respiratory-journal/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2017/06/complete-response-letter-delays-approval-for-retacrit--epoetin-alfa-biosimilar----hospira-pfizer/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2015/10/shiga-toxin-direct-test-diagnostic-filed-with-fda-for-shiga-toxin-producing-e--coli--great-basin-scientific/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-approves-darzalex--daratumumab--plus-lenalidomide-and-dexamethasone-for-multiple-myeloma--genmab/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2016/10/eu-approves-onivyde--pegylated-liposomal-irinotecan-hydrochloride-trihydrate--to-treat-adenocarcinoma-of-the-pancreas--shire-plc-/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2017/09/fda--grants-accelerated-approval-for-opdivo--nivolumab--to-treat-hepatocellular-carcinoma--liver-cancer----bms-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2011/10/merck-inc--files-ridaforolimus-at-fda-for-metastatic-sarcomas/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2015/11/scale-phase-iiia-trial-for-saxenda--liraglutide--results-in-three-year-weight-loss--novo-nordisk--/2024-02-13T11:13:12+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-advisory-committee-recommends-anoro-ellipta-for-copd/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2017/05/-eu-chmp-recommends-blitzima--rituximab-biosimilar--to-treat-nhl--cll--granulomatosis-with-polyangiitis-and-microscopic-polyangiitis----celltrion/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2017/04/nice-recommends-blincyto--blinatumomab---for-treating--philadelphia-chromosome-negative--ph---relapsed-or-refractory-b-precursor-acute-lymphoblastic-leukaemia-amgen/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2019/11/european-commission-approves-qtrilmet-to-improve-glycaemic-control-in-adults-with-type-2-diabetes---astrazeneca/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2017/11/real-world-analysis-of-invokana-in-type-2-diabetes-published-in-circulation---janssen-pharma-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-glivec--novartis--to-treat-ph--all/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2011/12/dificlir--astellas-optimer-pharma--is-eu-approved-for-clostridium-difficile-/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iv-augustus-trial-of-eliquis-shows-superiority-in-non-valvular-atrial-fibrillation---bms---pfizer/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-advisory-committee-recommends-approval-for-alo-02--oxycodone-hydrochloride-and-naltrexone-hydrochloride-extended-release--to-manage-severe-pain---pfizer/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-accepts-filing-of-opdivo--nivolumab--for-previously-untreated-patients-with-metastatic-melanoma--bms/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2015/11/interim-results-show-efficacy-of-zs-9--sodium-zirconium-cyclosilicate--in-hyperkalemia--zs-pharma/2024-02-13T11:13:22+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-does-not-recommend-saxenda-as-a-treatment-for-obesity----novo-nordisk/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2015/11/watchman-flx-left-atrial-appendage-closure--laac--device-receives-ce-mark-approval-in-the-eu-for-stroke-prevention--boston-scientific/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-trial-of-tookad--padeliporfin-di-potassium--meets-endpoint-in-prostate-cancer-and-receives-approval-in-mexico-steba-biotech/2024-02-13T11:13:30+00:00weekly0.6https://www.medthority.com/news/2017/11/mixed-results-from-healos-phase-iii--trial-of-am-111-to-treat-profound-sudden-deafness---auris-medical-/2021-09-24T07:14:35+00:00weekly0.6https://www.medthority.com/news/2017/11/the-medicines-company-sells-its-infectious-diseases-business-to-melinta-therapeutics-which-includes-vabomere-orbactiv-and-minocin-iv-/2025-10-16T11:14:14+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-velphoro-for-hyperphosphataemia-in-ckd--vifor-fresenius/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-ideglira--now-xultophy--for-treatment-of-type-2-diabetes---novo-nordisk/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2016/02/ema-makes-new-recommendations-for-treatment-of-multiple-sclerosis-using-tysabri--natalizumab---biogen/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---blue-dye-tablet-helps-identify-polyps-during-colonoscopy/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2016/10/ema-s-chmp-recommends-a-change-in-authorisation-for-lucentis--ranibizumab--in-choroidal-neovascularisation--novartis/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2018/03/ipscs-cancer-vaccine/2025-01-31T12:01:08+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-rejects-both-erbitux--cetuximab--from-merck-serono-and-vectibix--panitumumab--from-amgen-as-first-line-treatments-for-colorectal-cancer-/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2015/09/encore-study-of-vitaria-autonomic-regulation-therapy-device-shows-benefits-in-heart-failure--cyberonics/2021-09-24T07:03:41+00:00weekly0.6https://www.medthority.com/news/2018/10/abbvie-acquires-all-cystic-fibrosis-compounds-of-galapagos-nv-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-accepts-filing-of-nda-application-for-bimatoprost-sustained-release-for-reduction-of-intraocular-pressure-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension--allergan-abbvie/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-identifies-deficiencies-in-supplemental-new-drug-application--for-hetlioz-to-treat-jet-lag-disorder/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2011/12/meta-analysis-supports-no-increased-risk-of-cancer-by-use-of-lantus--sanofi-aventis-/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-priority-review-for-tafinlar-mekinist-for-melanoma/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2018/07/research-could-prompt-changes-in-cancer-treatment/2024-02-13T11:14:13+00:00weekly0.6https://www.medthority.com/news/2012/01/spectrum-pharma-acquires-world-rights-to-zevalin-for-nhl/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2015/01/depomed-acquires-nucynta--tapentadol--us-rights-from-janssen-pharmaceuticals-for--1-05-billion/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2019/07/chmp-recommends-lucentis-to-treat-preterm-infants-with-retinopathy-of-prematurity---novartis-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2011/10/transdermal-iqp-0410-patch-shows-promise-for-hiv-patients/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-glucogorx-glucose-monitoring-test-kit-from-innovus-pharmaceuticals--inc-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-focused-cold-therapy--myoscience--for-patients-with-peripheral-nerve-pain/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2019/07/alexion-receives-positive-chmp-opinion-for-soliris-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2017/11/two-phase-iii-trials-of-rth-258-show-reduced-eye-damage-in-age-related-macular-degeneration---novartis-/2021-09-24T07:14:42+00:00weekly0.6https://www.medthority.com/news/2018/04/results-for-two-phase-iii-clinical-trials--bhv3000--301-and-bhv3000-302--of-rimegepant-a-proposed-treatment-for-migraine---biohaven-pharma-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-simponi-aria--janssen-biotech--infusion-for-rheumatoid-arthritis/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2016/04/ema-approves-lonsurf--trifluridine-tipiracil--for--metastatic-colorectal-cancer--taiho-pharmaceutical-servier/2024-02-13T11:14:26+00:00weekly0.6https://www.medthority.com/news/2014/10/results-from-phase-iii-trials-of-belviq-for-obesity-published-eisai-arena-pharma/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-bavencio---inlyta-to-treat-renal-cell-carcinoma/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-rejects-onivyde-as-a-cost-effective-treatment-for-metastatic-adenocarcinoma-of-the-pancreas----shire-plc-/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2017/12/mallinckrodt-plc-to-acquire-sucampo-pharma-and-with-it-amitiza-and-rescula-/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-altreno-lotion-to-treat-acne----ortho-dermatologics-bausch-health-companies-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2019/03/secura-bio-inc--acquires-global-rights-to-farydak-from-novartis-/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-credence-trial-of-invokana-halted-early-after-efficacy-criteria-reached-in-chronic-kidney-disease-and-type-2-diabetes---janssen-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2018/12/european-commission-approval-for-self-administration-of-xolair-across-all-indications---novartis/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-data-with-lumigan-shows-potential-in-glaucoma-or-ocular-hypertension---allergan-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2018/07/boston-scientific-to-acquire-claret-medical-and-with-it-sentinel-cerebral-embolic-protection-system/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2012/08/quartette--teva--is-fda-filed-for-contraception---------------/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-accepts-bla-for-rhucin-as-a-treatment-for-hae/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/03/healthcare-science-week-2018/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-soliris-to-treat-neuromyelitis-optica-spectrum-disorder/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-aproves-clinolipid--baxter--for-parenteral-nutrition/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2013/08/avanir-pharma-to-promote-januvia-janumet-in--usa/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2014/03/forest-files-at-fda-combination-memantine---donepezil-for-alzheimers-disease/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-halaven--eribulin-mesylate---for-liposarcoma--eisai/2024-02-13T13:35:18+00:00weekly0.6https://www.medthority.com/news/2015/07/gi-dynamics-discontinues-endo-trial-of-endobarrier-therapy-for-obese-patients-with-type-2-diabetes/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2012/10/allergan-to-co-market-levadex-in-usa/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2012/03/oral-powder-formulation-of-fosrenal--shire--approved-in-eu/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-iv-trial-of-triumeq--abacavir-dolutegravir-lamivudine--in-hiv-meets-primary-endpoint--viiv-healthcare-/2024-02-22T15:11:09+00:00weekly0.6https://www.medthority.com/news/2018/06/antidepressant-use-may-be-linked-to-increased-risk-of-weight-gain--study-finds-/2024-02-13T13:38:48+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-relvar-ellipta--gsk--for-asthma-and-copd/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2015/07/ema-validates-application-from-bms-for-combination-opdivo--nivolumab----yervoy--ipilimumab--to-treat-advanced--unresectable-or-metastatic--melanoma--/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2017/11/nice-now-supports-tecentriq-to-treat-bladder-cancer--roche-/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-paediatric-indication-for-oxycontin--oxycodone--to-treat-severe-pain--purdue-pharma-/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-nuceiva-in-glabellar-lines---evolvus/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-monarch-3-study-of-verzenio--abemaciclib--to-treat--postmenopausal-women-with-advanced-breast-cancer-is-published-in-jo-clinical-oncology---eli-lilly-/2024-02-13T13:44:00+00:00weekly0.6https://www.medthority.com/news/2014/08/phase-iii-study-of-lcz-696-meets-endpoint-for-heart-failure---novartis/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-data-from-evolve-trial-of-synergy-cardiac-stent-system--boston-scientific-/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2014/02/delafloxacin-enters-phase-iii-study-for-gonorrhea--melinta-therapeutics/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2018/02/nejm-publishes-clinical-details-of-larotrectinib--a-treatment-for-trk-fusion--cancers--loxo-oncology---bayer-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2015/02/mini-med-530-g-retrospective-analysis-shows-reduction-of-hypoglycemia-published-in-diabetes-technology---therapeutics--medtronic/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2018/08/laekna-inc-agrees-with-novartis-pharma-ag-for-exclusive-global-rights-to-develop-and-commercialize-afuresertib--asb-183--and-uprosertib--upb-795--/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2015/08/nice-recommends-lixiana--edoxaban--for-prevention-of-recurrent-deep-vein-thrombosis-and-pulmonary-embolism--daiichi-sankyo/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-zejula--niraparib--for-late-line-treatment-for-women-with-recurrent-ovarian-cancer--gsk/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2011/12/tekturna--novartis--fails-altitude-study-in-diabetic-hypertensive-patients-with-renal-impairment/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves--juvisync-combination-for-type-2-diabetes-and-elevated-cholesterol/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2013/08/-eu-approves-longuex-for-chemotherapy-induced-neutropenia/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-in-two-phase-iii-studies-of-fycompa--eisai--for-epilepsy---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2018/11/european-commission-approves-label-extension-for-kalydeco-to-treat-children-with-cystic-fibrosis--vertex/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2014/11/elvitegravir--cobicistat--emtricitabine-and-tenofovir-alafenamide-filed-with-fda-for-hiv-gilead-sciences/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2017/09/adaccess-phase-iii-study-of-gp-2017--biosimilar-adalimumab--matches-the-originator-medicine-to-treat-plaque-psoriasis---sandoz-/2024-07-26T09:51:18+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-grants-priority-review-for-revlimid---rituximab-for-treatment-of-previously-treated-follicular-and-marginal-zone-lymphoma---celgene/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-endari--l-glutamine-oral-powder--in-sickle-cell-disease--emmaus-life-sciences/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-tafinlar-in-combination-with-mekinist--for-the-adjuvant-treatment-of-stage-iii-patients-with-braf-v600-mutation-positive-melanoma-after-complete-surgical-resection---novartis-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2011/10/eu-approves-alimta-as-continuation-maintenance-therapy-in-non-squamous-nsclc/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2015/10/vernalis-acquires-moxatag--amoxicillin-extended-release--from-pragma-pharma-to-treat-tonsillitis-and-or-pharyngitis/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-activextend-trial-shows-tymlos-plus-alendronate-benefits-in-osteoporosis---radius-health-/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-approval-of-otezla-for-psoriatic-arthritis-celgene/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-study-of-mg01ci-for-adhd-shows-significant-improvement---alcobra/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2013/06/nice-recommends-eylea--bayer-healthcare--for-wet-age-related-macular-degeneration/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2018/09/lenvima-approved-in-china-for-liver-cancer---eisai-merck-inc-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2011/12/exemestane-plus-afinitor--novartis--increased-progression-free-survival-for-breast-cancer-patients/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2013/08/eu-approves-imvanex-vaccine-for-smallpox/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2012/03/plex-id-assay-from-abbott-has-ce-mark-for-detection-of-infectious-diseases/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-vraylar-for-the-maintenance-treatment-of-schizophrenia---allergan-/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-onzetra-xsail--sumatriptan-nasal-powder--for-migraine--avanir-pharmaceuticals/2024-02-13T13:44:14+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-ii-data-shows-cnv-1014802--convergence-pharmaceuticals--provides-benefits-for-patients-with-trigeminal-neuralgia/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-approves-trumenba--meningococcal-group-b-vaccine--for-the-prevention-of-invasive-meningococcal-disease--pfizer/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2013/06/cherish-trial-of-roactemra-actemra--genetech-roche--shows-sustained-benefits-for-polyarticular-juvenile-idiopathic-arthritis-/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2018/12/abbvie-stops-enrollment-in-tahoe-trial-of-rova-t-to-treat-small-cell-lung-cancer-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2017/04/ce-mark-for-mirabilis-system-of-therapeutic-ultrasound-technology-to-treat-uterine-fibroids---mirabilis-medical-inc-/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2017/08/data-shows-reduced-intervention-after-use-of-pleuraflow-active-clearance-technology-in-cardiac-surgery--clearflow/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2015/10/boston-scientific-funds-mvalve-technologies-and-its-percutaneous-mitral-valve-replacement-system/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-advisory-committee-recommends-lucentis--genentech--for-treatment-of-diabetic-macular-edema/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2016/06/aegerion-pharma-and-qlt-inc--to-merge-and-be-succeeded-by-novelion-therapeutics--inc-/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2017/08/positive-results-from--checkmate--214-trial-for-opdivo--nivolumab--plus-yervoy--ipilimumab--versus-sunitinib-as-a--treatment-for-renal-cell-carcinoma----bms/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2012/02/eu-approves-esmya--preglem--for-moderate-to-severe-symptoms-of-uterine-fibroids/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2018/12/results-of-phase-iii-trials-northstar-2-and-northstar-3--of-lentiglobin-gene-therapy-to-treat-transfusion-dependent-beta-thalassemia--bluebirdbio-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2014/09/t2candida-and-t2dx-receive-fda-approval-to-detect-candida---t2-biosystems/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2014/09/endo-launches-generic-fortesta-gel-in-us-for-hypogonadism-/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2019/11/adamis-statement-on-pdufa-date-for-zimhi-/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-nda-for-iclaprim-to-treat-absssi---motif-bio-plc-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2014/08/ta-8995--dez-001--positive-in-phase-iib-trial-for-treatment-of-dyslipidaemia---dezima-pharma/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-victoria-study-of-vericiguat-for-chronic-heart-failure-is-initiated---bayer-healthcare-and--merck-inc-/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2016/12/momenta-pharma-completes-confirmatory-phase-iii-trial-for--m-923--adalimumab-biosimilar--for-plaque-psoriasis-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2011/05/selumetinib-success-in-phase-ii-biliary-cancer-trial-/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-ziextenzo-a-biosimilar-pegfilgrastim----sandoz/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2018/03/sub-analyses-of-cantos-trial-of-canakinumab-announced-as-a-treatment-for-cv-risk----novartis-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-imbruvica-for-waldenstrom-s-macroglobulinemia---pharmacyclics/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2013/03/iqwig-rejects-eylea-for-treatment-of--wet--age-related-macular-degeneration/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-advisory-committee-recommends-qnexa-vivus-inc---for-treatment-of-obesity/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-select-compare-clinical-trial-of-abt-494-in-rheumatoid-arthritis-published-in-arthritis-and-rheumatology-journal---abbvie/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-aim2cerv-trial-of-axal-in-cervical-cancer-placed-on-hold-by-fda---advaxis/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2019/12/gsk-3684934-filed-with-fda-for-hiv-1-infection---viiv-healthcare/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2016/04/nice-recommends-entresto--sacubitril---valsartan--to-treat-chronic-heart-failure--novartis/2024-02-13T14:22:54+00:00weekly0.6https://www.medthority.com/news/2016/12/clonidine-topical-gel-fails-trial-to-treat-painful-diabetic-neuropathy-and-programme-is-discontinued---biodelivery-sciences-international-/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2017/06/successful-phase-i-trial-of-blu-285-for-gastrointestinal-stromal-tumors-is-basis-for-initiating-phase-iii-trial-in-2018---blueprint-medicines/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2012/04/new-europe-focused-phase-iii-trial-of-therasphere--nordion--for-liver-cancer/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2017/02/uk-nice-recommends-use-of-iclusig--ponatinib--in-chronic-myeloid-leukaemia--incyte/2021-09-24T07:13:16+00:00weekly0.6https://www.medthority.com/news/2015/06/eloquent-2-study-interim-results-of-elotuzumab---lenalidomide---dexamethasone-in-multiple-myeloma--bms--abbvie/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-does-not-recommend-zytiga--abiraterone--for-treatment-of-prostate-cancer-before-chemotherapy--janssen/2024-02-13T14:23:05+00:00weekly0.6https://www.medthority.com/news/2018/01/amarin-corporation-reports-progress-of-reduce-it-cardiovascular-outcomes-study-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2017/11/mouth-cancer-action-month/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2019/05/esa-2019---learn-more/2024-02-13T14:23:25+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-grants-accelerated-approval-to-padcev--for-the-treatment-of--locally-advanced-or-metastatic-urothelial-cancer--seattle-genetics---astellas/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-proclaim-elite-spinal-cord-stimulation-system-for-chronic-pain--st-jude-medical/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2016/04/oncobeam-ras-crc-test-awarded-ce-mark-approval-in-the-eu-as-a-diagnostic-for-metastatic-colorectal-cancer---sysmex-corps/2021-09-24T07:10:47+00:00weekly0.6https://www.medthority.com/news/2016/04/in-final-guidance--uk-nice-now-recommends-jevtana--cabazitaxel--for-some-prostate-cancer-patients--sanofi-/2021-09-24T07:10:40+00:00weekly0.6https://www.medthority.com/news/2015/09/post-hoc-analysis-of-scale-obesity-and-prediabetes-and-scale-diabetes-trials-for-saxenda--liraglutide--novo-nordisk/2024-02-13T14:23:37+00:00weekly0.6https://www.medthority.com/news/2017/08/the-fda-has-found-the-resubmitted-biologics-license-application--bla--from-portola-pharmaceuticals-inc--relating-to-andexxa--andexanet-alfa--to-be-acceptable-for-review-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-issues-complete-response-letter-for-kangio--bivalirudin-injection--for-pci--eagle-pharma/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-active-trial-of-ba-058--abaloparatide--in-osteoporosis-published-in-jama--radius-health/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2018/09/instage-trial-data-on-ofev-in-ipf-published-in-nejm---boehringer-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2014/12/roche-terminates-scarlet-road--study-of-gantenerumab--in-alzheimers-disease/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-requests-additional-data-in-complete-response-letter-for-shp-606--lifitegrast--in-dry-eye-disease--shire/2024-02-13T14:23:52+00:00weekly0.6https://www.medthority.com/news/2019/08/bsaci-annual-meeting-2019---learn-more/2024-02-13T14:25:09+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-in-preliminary-guidance-rejects-strensiq--asfotase-alfa--as-a-treatment-for-hypophosphatasia--alexion-pharma/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-extension-of-use-of-promacta--eltrombopag--to-children-for-thrombocytopenia--novartis/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-sculptor-robotic-guidance-arm--stanmore-implants--for-surgery/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-progression-free-survival--results-for-imfinzi-and-tremelimumab--when-added-to-chemotherapy--from-the-phase-iii-poseidon-trial-in-previously-untreated-stage-iv--metastatic--nsclc---astrazeneca-/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2012/12/antares-pharma-files-otrexup-at-fda-for-rheumatoid-arthritis/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2016/01/study-shows-pfat-software-with-sorin-xtra-autotransfusion-system-removes-fat-particles-during-autotransfusion--livanova/2024-02-13T14:26:47+00:00weekly0.6https://www.medthority.com/news/2014/02/mirvaso-is-eu-approved-for-rosacea---gladerma/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2018/05/ce-mark-for-cardioband-tricuspid-valve-reconstruction-system-for-the-treatment-of-tricuspid-regurgitation---edwards-lifesciences-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-bunavail-for-opioid-dependence---biodelivery-sciences/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2013/10/galvus--novartis--fails-german-g-ba-review-for-diabetes-/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2017/11/national-pathology-week-2017/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-extends-pdufa-date-for-andexxa-for-reversal-of-coagulation---portola-pharma/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-approves-label-addition-for-victoza--liraglutide--in-type-ii-diabetes--novo-nordisk/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2018/12/bracanalysis-cdx-test-for-ovarian-cancer-with-gbrcam-approved-by-fda-for-use-with-lynparza---myriad-genetics-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-extends-harvoni--ledipasvir-sofosbuvir--indicationsor-use-in-chronic-hepatitis-c-patients-with-advanced-liver-disease--gilead-sciences--/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2017/12/janssen-biotech-to-market-aprocitentan-a-proposed-treatment-for-resistant-hypertension-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2016/02/merck-inc--to-market-lixiana--edoxaban-in-nordic-and-eastern-european-countries--daiichi-sankyo/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-rejects-defitelio--gentium-sobi-for-hepatic-veno--occlusive-disease/2021-09-24T07:15:41+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-has-accepted-for-nda-review-relistor--methylnaltrexone-bromide--for-tablets-to-treat-opioid-induced-constipation--oic--with-chronic-non-cancer-pain--valeant/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2019/06/positive-results-for-taltz-vs--humira--in-a-head-to-head--spirit-h2h--superiority-study-in-active-psoriatic-arthritis-----eli-lilly/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-riptide-aspiration-system-to-treat-acute-ischemic-stroke--_-medtronic-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2017/06/pooled-analyses-of-eight-olumiant--baricitinib--clinical-trials-and-long-term-extension-study-in-moderate-to-severe-rheumatoid-arthritis-presented-at-eular---eli-lilly-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/09/eon-mini-neurostimulator--st-jude-medical---receives-ce-mark-for-migraine/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2012/05/neurostar-tms-therapy--neuronetics--success-in-depression/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2013/06/further-complete-response-letter-for-aveed--endo-pharma-/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-of-isturisa-for-use-in-cushing-s-syndrome---recordati/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2015/10/analysis-of-long-term-effect-of-gilenya--fingolimod--in-patients-with-relapsing-ms--novartis/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-juvederm-volbella-xc-as-dermal-filler--allergan/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2015/10/ganetespib-fails-phase-iii-trial-for-treatment-of-nsclc--synta-pharma/2025-02-03T14:54:26+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-dotarem--gadoterate-meglumine--for-imaging-in-pediatric-patients-under-two-years-old---guerbet-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2013/08/vercirnon-fails-phase-iii-trial-for-crohn-s-disease/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2011/01/eu-approves-tasigna-for-newly-diagnosed-ph-cml/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2012/05/tivozanib--astellas--success-in-tivo-1-study-for-renal-cell-carcinoma-/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-phoenix-trial-of-imbruvica---r-chop-fails-to-meet-primary-endpoint-in-non-germinal-center-b-cell-subtype-of-dlbcl---janssen-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-select-monotherapy-trial-of-abt-494-shows-benefits-at-14-weeks-in-rheumatoid-arthritis---abbvie-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2012/04/eoquin--spectrum-allergan--phase-iii-results-in-bladder-cancer/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2017/07/celgene-and-beigene-ltd-collaborate-to-licence--bgb-a317-an-advanced-pd-i-inhibitor-to-celgene-and-to-licence-certain-celgene-products-to-beigene-in-china-/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2016/09/espouse-study-of-springtms-in-migraine-meets-primary-endpoint--eneura/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2016/06/transmission-free-remission-of--philadelphia-chromosome-positive--ph---cml-patients-undergoing-tasigna--nilotinib--treatment--novartis/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2019/12/pharmamar-submits-nda-to-fda-for-lurbinectedin-for-the-treatment-of-patients-with-small-cell-lung-cancer--and-licenses-us-rights-to-jazz-pharma-/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-empliciti--elotuzumab--plus-revlimid--lenalidomide--and-dexamethasone-for-multiple-myeloma--bms-abbvie/2024-02-13T09:37:11+00:00weekly0.6https://www.medthority.com/news/2014/03/triferic-filed-at-fda-for-treatment-of-iron-deficiency-in-ckd/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2018/04/very-low-protein-diet-can-delay-the-need-for-dialysis-in-patients-with-chronic-kidney-disease--ckd--/2024-02-13T09:38:14+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-trial-of-inflectra--infliximab-ct-p13--meets-endpoint-in-crohn-s-disease--pfizer-and-celltrion-healthcare/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2013/07/mallinckrodt-files-mnk-795-at-fda-for-pain/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-approves-gore-viabahn-balloon-expandable-endoprosthesis--vbx-stent-graft---to-treat-iliac-artery-lesions-/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-vyzulta-to-treat-open-angle-glaucoma-or-ocular-hypertension--bausch---lomb-and-nicox-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2014/10/amag-pharma-to-buy-lumara-health-for--675-million-inlluding-makena-treatment-for-pre-term-birth-risk/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2013/08/eteplirsen-success-in-phase-iii-for-duchenne-muscular-dystrophy/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2018/02/claim-study-of-ultibro-breezhaler-shows-reduction-of-lung-hyperinflation-in-copd-patients--novartis-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approves-xiapex-for-peyronie-s-disease--swedish-orphan-biovitrium/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-voncento--csl-behring--for-haemophilia-a-von-willebrand-disease/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-recommends-maviret-to-treat-all-genotypes-hepatitis-c--abbvie/2021-09-24T07:13:42+00:00weekly0.6https://www.medthority.com/news/2015/09/heartware-international-to-acquire-valtech-cardio/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2013/03/nice-rejects-afinitor--novartis--for-her-2-negative--hormone-receptor-positive-breast-cancer/2021-09-24T07:15:41+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-extends-pdufa-date-for-selinexor-to-treat-multiple-myeloma-to-6-july-2019---karyopharm-therapeutics/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2018/09/initial-results-from-zenith-1-trial-of-bcx-7353-or-both-prophylactic-and-acute-treatment-of-hae-attacks---biocryst-pharma-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-trial-of-chs-1420---adalimumab-biosimilar--meets-primary-endpoint-in-psoriasis--coherus-biosciences/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2018/04/blueberries-could-be-used-to-fight-alzheimer-s--researchers-suggest/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2018/04/norgine-reports-rifaximin-study-shows-improved-outcomes-on-the-waiting-list-with-a-significant-reduction-in-all-cause-hospital-admissions-and-episodes-of-sepsis---norgine--/2024-10-21T14:48:12+00:00weekly0.6https://www.medthority.com/news/2015/05/talimogene-laherparepvec-phase-iii-optim-study-results-in-metastatic-melanoma-published-in-journal-of-clinical-oncology--amgen/2024-02-13T09:38:34+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approval-for-mako-total-knee-with-triathlon-tritanium---stryker-/2021-09-24T07:13:23+00:00weekly0.6https://www.medthority.com/news/2017/06/nice-recommends-xiapex--clostridial-collagenase-for-injection---for-treatment-of-moderate-forms-of-dupuytren-s-contracture--swedish-orphan-biovitrium/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2015/10/new-results-from-phase-iii-study-of-dysport--abobotulinumtoxina--in-spastic-equinus-foot--ipsen-biopharmaceuticals/2024-02-13T09:38:48+00:00weekly0.6https://www.medthority.com/news/2013/01/positive-results-in-study-of-metanx--pamlab--for-diabetic-peripheral-neuropathy/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2018/09/pooled-data-from-amagine-2-and-amagine-3-studies-showed-kyntheum-cleared-psoriasis-more-effectively--than-ustekinumab--leo-pharma/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2018/07/ptc-therapeutics-inc--acquires-agilis-biotherapeutics-and-with-it-gt-aadc-a-treatment-for-aromatic-l-amino-acid-decarboxylase-deficiency-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-ascend-trial-of-calquence-shows-pfs-improvement-in-chronic-lymphocytic-leukaemia---astrazeneca/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2012/04/minophagen-extends-marketing-rights-to-bexarotene-for-t-cell-lymphoma/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-supplemental-indication-for-somatuline-depot--lanreotide--in-carcinoid-syndrome---ipsen-/2021-09-24T07:13:51+00:00weekly0.6https://www.medthority.com/news/2016/01/results-from-study-of-grafalon--anti-human-t-lymphocyte-globulin--in-graft-versus-host-disease-published-in-nejm-neovii/2024-02-13T09:39:03+00:00weekly0.6https://www.medthority.com/news/2011/10/higher-radiation-dose-plus-erbitux-not-beneficial-for-lung-cancer-patients/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2019/05/astrazeneca-reports-data-from-novel-start-trial-of-symbicort-turbuhaler-to-relieve-inflammation-in-mild-asthma-/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-eclipse-system-for-fecal-incontinence-pelvalon/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-panel-recommends-approval-for-kxl-system---combined-riboflavin--for-corneal-ectasia-and-ketatoconus--avedro/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2011/10/aubagio-reduces-significant-relapses-in-patients-with-multiple-sclerosis/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approves-opdivo--nivolumab--for-squamous-nsclc--bms---ono/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2018/06/ema-recommendations-for-esmya-in-relation-to-liver-injury-risk----allergan--gedeon-richter-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-brisdelle--noven-pharma--to-treat-hot-flushes-associated-with-menopause/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2017/06/updated-results-from-phase-iii-studies-of-p-1101--ropeginterferon-alfa-2b--for-patients-with-polycythemia-vera--aop-orphan-pharmaceuticals-and-pharmaessentia/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2019/07/zambon-acquires-breath-therapeutics-and-with-it-l-csa-i-a-novel-proprietary-liposomal-formulation-of-cyclosporine-a-for-bronchiolitis-obliterans-syndrome-/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-xw-100-automated-hematology-analyzer-blood-cell-test---sysmex-america--inc-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-study-of-emgality-shows-significant-reduction-in-episodic-cluster-headache---eli-lilly-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2011/10/velcade-withdrawn-from-combination-treatment-of-follicular-lymphoma/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2018/08/updated-results-from-beacon-crc-trial-of-braftovi---mektovi---cetuximab-for---patients-with-brafv600e-mutant-metastatic-colorectal-cancer--array-biopharma-/2024-07-26T09:43:17+00:00weekly0.6https://www.medthority.com/news/2013/01/latanoprostene-bunod--bausch---lomb--enters-phase-iii-for-glaucoma-and-ocular-hypertension/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2013/11/vyvanse--shire--success-in-binge-eating-disorder-studies/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2016/03/new-data-from-clear-study-shows-cosentyx--secukinumab--remains-superior-to-stelara--ustekinumab--in-achieving-sustained-skin-clearance-in-psoriasis-patients--novartis/2024-02-13T09:39:13+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-inomax--ikaria-inc--for-compatibility-with-3-additional-devices/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2019/03/legal-dispute-between-novartis-and--amgen-relating-to-migraine-collaboration-/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2013/01/eu-approves-appy1-test--venaxis--for-patients-at-low-risk-for-acute-appendicitis/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-study-of-cx601--stem-cell-implementation--in-crohn-s-meets-primary-endpoint--tigenix/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2018/03/how-exercise-in-old-age-prevents-the-immune-system-from-declining/2024-07-26T09:09:24+00:00weekly0.6https://www.medthority.com/news/2018/04/rigel-pharma-corrects-information-concerning-pdufa-date-for-fostamatinib-for-adult-patients-with-chronic-immune-thrombocytopenia-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2014/03/mistent-ses-shows-benefits-for-cad---micell-tech/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2013/12/nepa-superior-for-cinv-prevention-helsin-eisai/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2015/12/galapagos-nv-and-gilead-sciences-to-collaborate-on-phase-iii-development-and-commercialisation-of-filgotinib-for-inflammatory-disease-indications-/2024-02-13T09:56:24+00:00weekly0.6https://www.medthority.com/news/2017/05/-time-to-take-action--on-world-bedwetting-day/2021-11-30T10:22:46+00:00weekly0.6https://www.medthority.com/news/2015/04/merck-inc--secures-fda-breakthrough-therapy-designation-for-grazoprevir-elbasvir-for-hepatitis-c-genotype-4-and-genotype-1-in-patients-with-end-stage-renal-disease-on-hemodialysis/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-safety-study-of-brixadi-in-opioid-use-disorder-published-in-addiction-journal---braeburn/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2018/05/international-day-of-the-midwife-2018/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-gives-final-approval-for-subcutaneous-herceptin/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-cablivi--to-treat-acquired-thrombotic-thrombocytopenic-purpura--attp---sanofi/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-approves-lucentis--ranibizumab--for-visual-impairment-due-to-choroidal-neovascularization-associated-with-causes-other-than-neovascular-age-related-macular-degeneration-or-secondary-to-pathologic-myopia--novartis/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2019/11/two-phase-iii-trials-of-akb-6548-meet-primary-endpoints-in-anemia-due-to-chronic-kidney-disease---akebia-therapeutics/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2013/06/spedra--vivus-inc---receives-eu-approval-as-a-treatment-for-erectile-dysfunction/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2016/10/data-from-phase-iii-sculpture-trial-shows-efficacy-of-cosentyx--secukinumab--to-four-years-in-plaque-psoriasis--novartis/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2011/11/lexapro-cipralex--forest-labs-lundbeck--reduces-pain-in-opiod-dependent-patients/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2014/02/symbicort-faces-generic-rival-from-teva-with-chmp-recommendation-for-duoresp-spiromax-and-biresp-spiromax-for-asthma-and-copd---astrazeneca/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/06/novartis-announced--the-publication-of-global-clear-about-psoriasis-survey-data-in-the-journal-of-the-european-academy-of-dermatology-and-venereology-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2017/06/education-for-people-with-rheumatic-and-musculoskeletal-diseases-and-employers-can-improve-ability-to-work-/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-teva-s-generic-form-of-axert--almotriptan-malate--for-migraine--janssen/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2014/06/hetlioz-is-filed-at-ema-for-non-24-hour-sleep-wake-disorder---vanda-pharma/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2018/08/nice-rejects-yescarta-as-not-cost-effective-treatment-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-or-primary-mediastinal-large-b-cell-lymphoma---kite-gilead-sciences-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-myalept-for-lipodystrophy-astrazeneca/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2016/03/results-of-phase-iii-apex-study-of-betrixaban-for-venous-thromboembolism--portola-pharma-/2024-02-13T09:56:35+00:00weekly0.6https://www.medthority.com/news/2011/10/afssaps-refers-protelos-to-ema-for-re-evaluation-as-a-treatment-for-post-menopausal-osteoporosis/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-510-k-approval-for-tjf-q190v-duodenoscope---olympus-medical/2021-09-24T07:12:02+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-paediatric-version-of-proair-respiclick--albuterol-sulfate--to-treat-obstructive-airway-disease-and-for-prevention-of-exercise-induced-bronchospasm--teva/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-heartware-hvad-system-as-a-destination-therapy-for-patients-with-advanced-heart-failure---medtronic-/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2019/03/alcon-acquires-power-vision-inc---provider-of--fluid-based-intraocular-lens-implants/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-relvar-ellipta-for-copd-and-asthma/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2018/03/world-glaucoma-week-2018/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2015/06/novocure-announces-results-of-phase-iii-trial-of-tumor-treating-fields---temozolomide-for-glioblastoma-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-amjevita--adalimumab-atto---biosimilar--for-all-indications-of-the-originator-drug-humira--adalimumab---amgen/2021-09-24T07:09:14+00:00weekly0.6https://www.medthority.com/news/2018/11/sandoz-will-not-pursue-its-submission-for-biosimilar-rituximab-in-the-us-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2014/01/dacomitinib-fails-two-phase-iii-trials-for-nsclc--pfizer/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2016/10/eu-chmp-recommends-a-change-in-authorisation-for-trisenox--arsenic-trioxide-injection--in-acute-promyelocytic-leukaemia--teva/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2012/06/tivantinib--daiichi-sankyo---in-phase-ii-study--of-hepatocellular-carcinoma--/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2015/01/novartis-files-nda-at-fda-for--seebri-breezhaler--nva-237-for-copd/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-sunbeam-trial-shows-ozanimod-superior-in-efficacy-and-safety-to--avonex-for-treatment-of-multiple-sclerosis---celgene-/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-lyrica--pfizer--for-management-of-pain-associated-with-spinal-cord-injury/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-actifuse-flow-bone-graft-substitute--for-use-in-orthopedic-surgical-procedures---baxter-international-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2012/06/lyxumia-sanofi--reduces-hba1c-glycated-hemoglobin-in-type-2-diabetes/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2012/09/baxter-files-bax-326-at-fda-for-management-of-haemophilia-b/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2014/06/shire-rejects-bid-from-abbvie/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2016/08/selumetinib-fails-phase-iii-trial-in-patients-with-kras-mutation-positive--krasm--locally-advanced-or-metastatic-nsclc---astrazeneca/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2016/01/study-of-cesium-131-brachytherapy-published-in-journal-of-neuro-oncology--isoray/2024-02-13T09:56:50+00:00weekly0.6https://www.medthority.com/news/2019/01/eu-approves-erleada-for-prostate-cancer---janssen-pharma/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2013/06/u-300-sanofi--success-in-edition-i-and-edition-ii-trials-in-type-2-diabetes/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/01/ema-accepts-application-of-avacopan-for-the-treatment-of-patients-with--vasculitis--vifor-fresenius-medical-care-renal-pharma---chemocentryx-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-javelin-lung-200-trial-results-comparing-bavencio-to-docetaxel-in-patients-with-unresectable--recurrent-or-metastatic-nsclc----merck-kgaa---pfizer-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2018/10/two-phase-iii-extension-studies-of-lemtrada-shows-drug-impacts-multiple-sclerosis-through-8-years---sanofi-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2015/09/infraredx--inc-is-acquired-by-nipro-corporation-and-with-it-the-tvc-imaging-system/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2015/04/astrazeneca--medimmune-and-celgene-collaborate-on-development-and-commercialisation-of-medi4736-in-blood-cancers-/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-trial-for-omalizumab-biosimilar-to-treat-allergic-asthma--sorrento-therapeutics/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-2--pennsaid-for-osteoarthritis-pain-mallinckrodt/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-leap-1-trial-of-bc-3781--lefamulin--meets-primary-endpoint-in-community-acquired-bacterial-pneumonia---nabriva-therapeutics-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2015/03/updated-phase-iii-data-for-xtandi--enzalutamide--in-prostate-cancer-astellas/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-precision-spectra-spinal-cord-stimulator-system--boston-scientific--for-treating-chronic-pain/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2018/01/25th-international-symposium-on-pancreatic-biliary-endoscopy-ispbe-2018/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2011/09/provenge-sales-for-prostate-cancer--disappoint-dendreon-and-lead-to-staff-reduction-/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-sangia-total-prostate-specific-antigen--psa--diagnostic-test-for-prostate-cancer---opko-health/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2015/05/new-data-from-meta-analysis-of-livalo--pitavastatin--in-patients-with-dyslipidaemia-kowa-pharmaceuticals-/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2014/06/sobi-files-xiapex-at-eu-to-treat-peyronie-s-disease-/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-extension-for-vimpat-for-partial-onset-seizures-in-pediatric-patients---ucb-/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2019/08/ontario-provides-access-to-biktarvy-for-the-treatment-of-hiv/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2017/09/pathway-phase-ii-trial-of--tezepelumab-shows-reduction-in-annual-asthma-exacerbation-rate-and-is-published-in-nejm---medimmune-astrazeneca---amgen-/2024-07-26T08:57:58+00:00weekly0.6https://www.medthority.com/news/2017/08/fovista--pegpleranib-in-combination-with-eylea--aflibercept--or-avastin--bevacizumab-is-not-superior-to-eylea-or-avastin-monotherapy-for-the-treatment-of-wet-age-related-macular-degeneration--ophthotech-corporation-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-warning-letter-to-duodenoscope-manufacturers-related-to-spread-of-infections/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2019/12/european-commission-approves-revlimid---rituxan-for-follicular-lymphoma---celgene-bms/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2018/02/castle-af-study-comparison-of-catheter-ablation-versus-pharmacological-therapy-for-heart-failure-with-atrial-fibrillation---biotronik/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-accepts-for-review-eliquis--bms-pfizer--for-stroke-prevention-associated-with-atrial-fibrillation/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2019/11/announcing-a-new-symposium-on-prostate-cancer-being-held-at-the-11th-european-multidisciplinary-congress-on-urological-cancers/2024-02-22T15:13:36+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-sustain-4-trial-shows-improvements-with-nn-9535--semaglutide--in-type-2-diabetes--novo-nordisk/2024-02-13T09:58:20+00:00weekly0.6https://www.medthority.com/news/2017/11/chmp-recommends-extension-of-nplate-indication-to-children-for-thrombocytopenic-purpura---amgen-/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2014/03/aveed-is-fda-approved-for-testosterone-deficiency--endo-pharma/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2012/04/florbetaben-imaging-tracer-is-sold-by-bayer-to-piramel-imaging-sa/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2011/10/gantenerumab-reduces-amyloid-levels-in-patients-with-alzheimer-s-disease/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-with-trulicity--dulaglutide--shows-superiority-in-type-2-diabetes--eli-lilly/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-seysara-for-the-treatment-of-moderate-to-severe-acne---paratek-pharma---almirall/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-advisory-committee-rejects-rextoro-as-a-treatment-for-testosterone-deficiency---clarus-therapeutics/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2017/06/ema-validates-maa-application-from-shire-for-veyvondi-to-prevent-bleeding-in-patients-with--von-willebrand-disease-/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-eylea--aflibercept-solution-for-injection-into-the-eye--to-treat-myopic-choroidal-neovascularisation--bayer-healthcare/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-results-in-move2-study-of-sativex--almirall--for-patients-with-multiple-sclerosis-spasticity/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-aspireassist-aspiration-therapy-system-for-obesity--aspire-bariatrics/2024-02-13T09:58:31+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-xtandi-astellas-medivation-to-treat-castration--resistant-prostate-cancer---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2014/12/azd-3293--ly-3314814--enters-phase-ii-iii-trial-for-alzheimers-disease--astrazeneca---eli-lilly/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2014/05/astrazeneca-rejects-pfizer-final-offer/2025-10-16T10:51:01+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-data-for-orencia--abatacept--in-rheumatoid-arthritis-offers-insights-into-treatment-bms/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2014/04/eu-gives-ce-mark-approval-to-evera-mri-surescan-icd-for-arrhythmias-medtronic/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2018/05/opsumit-filed-with-fda-for-chronic-thromboembolic-pulmonary-hypertension---actelion-pharma-/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2014/03/positive-analysis-of-talimogene-laherparepvec-for-metastatic-melanoma---amgen/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2013/03/orbit-artherectomy-system--cardiovascular-systems--filed-at-fda-to-treat-calcified-arteries/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2018/12/updated-results-for-legend-2-phase-1-ii-study-of-lcar-b38m-to-treat-multiple-myeloma--janssen-pharma---legend-biotech-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2019/10/biogen-plans-regulatory-filing-at-fda-for-aducanumab-in-alzheimer-s-disease-based-on-new-phase-iii-analyses-/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2017/07/data-from-phase-iii-haven-i-study-of-subcutaneous-emicizumab-prophylaxis--preventative--treatment-in-adults-and-adolescents-with-hemophilia-a-with-inhibitors-is-published-in-nejm---genentech/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2019/09/pooled-analysis-shows--keytruda----chemotherapy-improved-overall-survival-v--chemotherapy-alone-as-first-line-treatment-for-advanced-nsclc-where-tumors-do-not-express-pd-l1---merck-inc-/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2016/02/nice-recommends-tnf-alpha-inhibitors-for-ankylosing-spondylitis/2021-09-24T07:09:03+00:00weekly0.6https://www.medthority.com/news/2016/02/refusal-to-file-letter-from-fda-to-catalyst-pharma-relating-to-firdapse--amifampridine-phosphate--as-a-treatment-for-lambert-eaton-myasthenic-syndrome/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-advisory-committee-recommends-qnexa-vivus-inc---for-treatment-of-obesity-1/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2015/09/qlt-inc-to-acquire-insite-vision-and-its-ophthalmic-products/2024-02-13T09:58:40+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-trial-data-on-perceval-valve-in-avd-sorin/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2015/11/cobas-hiv-1-assay-is-ce-mark-approved-in-the-eu-for-cobas-4800-system--roche/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-interim-results-for-embrace-advanced-scar-therapy--neodyne-biosciences-/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-omontys-affymax-takeda-for-anaemia-for-patients-on-dialysis/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-xenleta-to-treat-community-acquired-bacterial-pneumonia----nabriva-therapeutics/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-gives-510-k--approval-for-the-microdose-si-spect-imaging-system--philips-/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-alinity-ssystem-for-blood-and-plasma-screening---abbott-/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2019/10/dovato-filed-with-fda-in-snda-for-adults-with-hiv-1-infection---viiv-healthcare/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2015/12/faster-acting-insulin-aspart-filed-with-fda-for-type-1-and-type-2-diabetes--novo-nordisk/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-approval-of-change-of-indication-for-cubicin--daptomycin--in-infection---merck-inc-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2018/10/novartis-acquires-endocyte-and-with-it-177-lu-psma-617-for-the-treatment-of-prostate-cancer/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2018/04/settlement-of-litigation-between-samsung-bioepis-and-abbvie-relating-to-adalimumab-biosimilar-imraldi-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2015/02/study-shows-benefits-of-advagraf-in-transplant-rejection-astellas/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-visumax-femtosecond-laser-for-the-small-incision-lenticule-extraction--smile--procedure-to-reduce-or-eliminate-nearsightedness---zeiss/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-nda-for-ulipristal-acetate--a-drug-for-the-treatment-of-abnormal-uterine-bleeding-in-women-with-uterine-fibroids---allergan-/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2017/12/checkmate--078-trial-of-opdivo-for-non-small-cell-lung-cancer-in-chinese-patients-meets-endpoint----bms/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2015/11/medrobotics-launches-flex-robotic-system-in-us-to-access-and-visualise-oropharynx--hypopharynx-and-larynx/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2019/11/tecentriq-in-combination-with-avastin-improves-overall-survival-in-people-with-the-most-common-form-of-liver-cancer--genentech-roche/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2016/03/chmp-recommends-idelvion--albutrepenonacog-alfa--for-prophylaxis-of-bleeding-in-haemophilia-b-patients--csl-behring/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2015/04/teva-acquires-auspex-pharma-for--3-2-billion-and-with-it-sd-809--deutetrabenazine--/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2019/03/publication-of-sustain-9-trial-of-ozempic---sglt-2-inhibitor-for-type--diabetes---novo-nordisk/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approval-for-vacutainer-ultratouch-push-button-blood-collection-set-for-blood-collection--becton--dickinson-and-company/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2015/06/nejm-publishes-results-of-improve-it-trial-of-vytorin-in-acs--merck-inc-/2024-02-13T09:59:07+00:00weekly0.6https://www.medthority.com/news/2013/04/overstitch-endoscopic-suturing--system-gets-ce-mark/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2017/09/freestyle-libre-system-is-now-available-for-reimbursement-in-the-united-kingdom---abbott/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2017/05/results-from-ampact1--trial-of--keyzilen--esketamine-hydrochloride-a-proposed-treatment-for-peripheral-tinnitus---auris-medical-holding-ag/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2018/01/taltz-is-eu-approved-to-treat-psoriatic-arthritis--eli-lilly-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2017/03/data-analysis-of-solitaire-u-phase-iii-study-of-oral-solithromycin-to-treat-gonorrhea--cempra-inc-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2015/07/us-court-of-appeal-requires-180-day-wait-from-fda-approval-for-zarxio--filgrastim-biosimilar--before-launch-in-us--sandoz/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2019/04/real-world-study-finds-significant-reductions-in-the-number-and-length-of-hospitalisations-with-xifaxan-for-hepatic-encephalopathy----norgine/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2015/09/first-drug-sensor-combination---abilify-plus-proteus-ingestible-sensor--filed-with-fda-for-monitoring-health-digitally-otsuka-proteus-digital-health/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2017/05/bioverativ-acquires-true-north-therapeutics-and-with-it-tnt-009-an-innovative-treatment-for-cold-agglutinin-disease-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2016/04/iw-9179-does-not-reduce-symptoms-for-diabetic-gastroparesis-and-development-for-this-indication-is-discontinued--ironwood-pharma/2021-09-24T07:10:47+00:00weekly0.6https://www.medthority.com/news/2018/04/impella-cp-heart-pump-with-smartassist-is-fda-approved-for-ventricular-support---abiomed-inc-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-accofil-for-treatment-of-neutropenia--a-biosimilar-version-of-neupogen-accord-healthcare/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2013/09/study-of-xarelto-for-dvt-and-pe-published-in-thrombosis/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2014/09/vercise-deep-brain-stimulation--dbs-receives-ce-mark-for-treatment-of-essential-tremor---boston-scientific/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-tafinlar---mekinist-for-metastatic-melanoma-gsk-/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress--eau-2018--first-accurate-data-showing-that-male-to-female-transgender-surgery-can-lead-to-a-better-life/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2015/02/successful-phase-iii--ra-build-study-for-baricitinib-in-rheumatoid-arthritis--eli-lilly/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2019/08/glaukos-corporation-to-merge-with-avedro-inc-/2025-10-16T11:31:57+00:00weekly0.6https://www.medthority.com/news/2016/06/marlina-t2d-trial-demonstrates-tradjenta--linagliptin--offers-benefits-in-blood-glucose-for-type-2-diabetes--boehringer-eli-lilly/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2016/03/amra-enters-an-agreement-with-ge-healthcare-for-amra-profiler-protocol-on-mri-scanners/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-trial-of-pf-4383119-meets-all-co-primary-endpoints-in-osteoarthritis-pain---pfizer---eli-lilly-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2014/07/teva-files-albuterol-multi--dose-dry-powder-inhaler-at-fda-to-treat-bronchospasm-/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2019/05/htx-011-has-complete-response-letter-from-fda-for-management-of-postoperative-pain---heron-therapeutics/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2013/04/lymphoseek--navidea--success-in-head-and-neck-cancer-trial/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-trogarzo-for-adults-with-hiv---theratechnologies-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2012/11/nice--will-not-recommend-xolair--novartis--on-re-appraisal-for-allergic-asthma---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2017/02/zosano-announces-successful-results-of-pivotal-zotrip-trial-for-m-207--zolmitriptan-coated-microneedle-patch--as-a-treatment-for-migraine-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2015/10/endologix-and-trivascular-technologies-to-merge-companies-and-endovascular-abdominal-aortic-aneurysm-treatments/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-eylea-for-early-extension-of-the-injection-interval-for-patients-with-neovascular-age-related-macular-degeneration--bayer---regeneron-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-medtronic-cardiac-rhythm-and-heart-failure-devices-and-leads-to-be-scanned-in-both-3-and-1-5-tesla-magnetic-resonance-imaging--mri--machines-/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-success-in-hallmark-dual-study-of-daclatasvir---asunaprevir-in-hepatitis-c--bms/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-vistogard--uridine-triacetate--as-antidote-to-5-fluorouracil--wellstat-therapeutics/2021-09-24T07:04:30+00:00weekly0.6https://www.medthority.com/news/2015/12/the-medicines-company-sells-three-drugs--recothrom--preveleak-and-raplixa--to-mallinckrodt/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-study-of-nucala--mepolizumab--in-eosinophilic-granulomatosis-with-polyangiitis-published-in-nejm--glaxosmithkline/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-expands-indication-of-pillcam-colon-2-for-detection-of-polyps-in-patients-at-risk-of-gi-bleed--medtronic/2021-09-24T07:10:51+00:00weekly0.6https://www.medthority.com/news/2016/03/ova1-test-for-ovarian-cancer-risk-is-510-k--approved-in-usa--vermillion-inc-/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-spravato-nasal-spray-for-adults-with-treatment-resistant-major-depressive-disorder---janssen-cilag/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2013/09/rlx-030-serelaxin-analysis-in-acute-heart-failure/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-issues-complete-response-for-olinvo-in-acute-pain---trevena-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2013/06/ce-mark-for-redux-plier--medtronic--for-use-in-osteotomies/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2019/03/ubrogepant-filed-with-fda-for-migraine---allergan/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-trial-of-imbruvica---chemo-fails-to-meet-endpoint-in-pancreatic-cancer---abbvie/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2017/06/rydapt--midostaurin--phase-iii-ratify--calgb-10603--alliance---data-in-acute-myeloid-leukemia-published-in-the-new-england-journal-of-medicine--novartis/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2019/12/first-patient-is-enrolled-in--phase-iv--multi-center--multiple-dose--open-label-study-to-assess-the-effects-of-acthar-gel-as-a-therapy-option-in-patients-with-severe-keratitis---mallinckrodt/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2014/04/once-daily-onbrez-breezhaler-non-inferior-to-twice-daily-seretide-for-copd---novartis/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2018/04/viral-meningitis-week-2018/2024-07-26T08:58:56+00:00weekly0.6https://www.medthority.com/news/2017/01/review-period-for-olumiant--baricitinib--nda-in-rheumatoid-arthritis-extended-by-us-fda---eli-lilly/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/03/astrazeneca-discontinues-development-of--tc-5214-for-major-depreeive-disorder/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2015/10/two-year-data-shows-in-pact-admiral-drug-coated-balloon-gives-benefits-in-peripheral-arterial-disease--medtronic/2024-10-22T08:16:35+00:00weekly0.6https://www.medthority.com/news/2016/09/abbott-sells-medical-optics-unit-to-johnson---johnson/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2011/12/nice--does-not-recommend-gilenya-novartis--for-relapsing-remitting-multiple-sclerosis/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-expands-label-of-alimta---keytruda--for-the-first-line-treatment-of-metastatic-nonsquamous-nsclc---eli-lilly---merck-inc-/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-for-beovu-for-wet-age-related-macular-degeneration--with-three-month-dosing-intervals---novartis/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2018/04/results-of-phase-iii-arctic-trial-of-durvalumab-plus-tremelimumab-for-nsclc---astrazeneca/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2016/02/s-297995--naldemedine--phase-iii-data-shows-significant-improvement-for-patients-with-opioid-induced-constipation--shionogi-/2024-02-13T10:20:13+00:00weekly0.6https://www.medthority.com/news/2015/12/meta-analysis-of-victoza--liraglutide--trials-demonstrates-efficacy-in-type-2-diabetes--novo-nordisk/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-opdivo--nivolumab--to-treat-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck--bms/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2012/05/bi-1744-cl--boehringer--shows-positive-results-in-phase-ii-copd-trial/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-aspen-trial-of-brukinsa-did-not-reach-statistical-significance-in-waldenstrom-s-macroglobulinemia---beigene/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2019/05/first-patient-enrolled-in-phase-iii-clinical-trial-of-fostamatinib/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-yondelis--trabectedin-to-treat-soft-tissue-sarcomas--janssen-biotech---pharmamar/2024-02-13T10:20:23+00:00weekly0.6https://www.medthority.com/news/2015/04/astrazeneca--medimmune-and-innate-pharma-to-combine-medi4736-and-iph-2201-in-cancer-treatments--/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2016/04/real-world-study-of-reveal-linq-insertable-cardiac-monitor-to-detect-atrial-fibrillation---medtronic/2021-09-24T07:10:40+00:00weekly0.6https://www.medthority.com/news/2015/03/retrophin-acquires-cholbam--cholic-acid--from-asklepion-pharmaceuticals-following-fda-approval-for--treatment-for-bile-acid-disorders-/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-priority-review-and-ema-accelerated-assessment-for-kymriah-to-treat-diffuse-large-b-cell-lymphoma--dlbcl----novartis/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2017/06/19th-june-marks-world-sickle-cell-awareness-day/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-issues-complete-response-letter-relating-to-xarelto--bayer-janssen-pharma--for-acute-coronary-syndrome/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2016/05/salford-lung-study-of-relvar-ellipta--fluticasone-furoate-vilanterol--in--chronic-obstructive-pulmonary-disease-shows-treatment-superior-to-standard-care--glaxosmithkline-and-innoviva/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2013/03/vanda-pharmaceuticals-withdraws-eu-mma-for-fanaptum-to-treat-schizophrenia/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2018/02/update-on-ema-marketing-review-of-rucaparib-for-advanced-ovarian-cancer-with-brca-mutation--clovis-oncology-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2018/03/pivotal-phase-iii-study-of-alxn-1210-shows-non-inferiority-in-paroxysmal-nocturnal-hemoglobinuria---alexion-pharma-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-revised-labelling-for-boston-scientific-defibrillators/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-s-oncologic-drugs-advisory-committee-voted-17-0-to-recommend-approval-for-abp-215--a-biosimilar-for-bevacizumab--avastin---amgen---allergan/2024-10-21T14:43:11+00:00weekly0.6https://www.medthority.com/news/2016/11/janssen-biotech-submits-bla-to-fda-for-guselkumab-as-a-treatment-for-moderate-to-severe-plaque-psoriasis-/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2015/04/prt-4445--andexanet-alfa--meets-endpoints-in-second-phase-iii-trial-as-an-antidote--portola-pharma/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2013/06/sanofi-terminates-development-of-otamixaban-in-acs/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-change-of-approval-for-bydureon--exenatide-extended-release--in-type-2-diabetes---astrazeneca-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2017/09/otividex--dexamethasone-sustained-release--fails-in-phase-iii-trial-to-treat-meniere-s-disease--otonomy-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-complete-response-letter-to-xgeva-application-to-treat-high-risk-prostate-cancer-bone-metastases/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-ionsys-transdermal-system---fentanyl-for-acute-moderate-to-severe--post-operative-pain-in-adult-patients--the-medicines-company/2021-09-24T07:03:41+00:00weekly0.6https://www.medthority.com/news/2012/07/brilinta-brilique-astrazeneca--study-in-peripheral-vascular-disease/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2014/12/data-indicates-benefits-of-precision-spectra-scs-in-back-pain-boston-scientific/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-genvoya--elvitegravir-150-mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-alafenamide--taf--10-mg--to-treat-hiv-infection--gilead/2021-09-24T07:03:41+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-xeomin--incobotulinumtoxina--for-upper-limb-spasticity--merz-pharma/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2018/03/nice-draft-guidance-recommends-use-of-bavencio-in-merkel-cell-carcinoma---merck-kgaa-and-pfizer-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2011/10/mechlorethamine-hydrochloride-gel-is-filed-at-fda-for-mycosis-fungoides-/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2017/07/positive-interim-results-from-enlighten-1-study-of-alks-3831-for-the-treatment-of-schizophrenia-alkermes/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommends-variation-of-approval-for-arzerra-in-cll---gsk/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2017/10/european-congress-of-neurosurgery-to-conclude-in-venice-1/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2012/09/merck-serono-withdraws-ema-application-for-treatment-of-non-small-cell-lung-cancer/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-advisory-committee-recommends-prucalopride-as-a-treatment-for-chronic-idiopathic-constipation-----shire-takeda/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-issues-refusal-to-file-letter-for-ozanimod-a-proposed-treatment-for-multiple-sclerosis---clegene-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2019/03/european-commission-approves-forxiga-for-use-in-type-1-diabetes---astrazeneca/2021-09-24T07:18:50+00:00weekly0.6https://www.medthority.com/news/2018/02/dbv-remains-on-track-to-submit-its-bla-for--viaskin-peanut-for-the-treatment-of-peanut-allergy-in-the-second-half-of-2018---p-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2015/12/bms-sells-hiv-medicines-to-viiv-healthcare-and-with-them-fostemsavir-and-bms-955176/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-opdivo-and-yervoy--nivolumab---ipilimumab--for-braf-v600-wild-type-and-braf-v600-mutation-positive-unresectable-or-metastatic-melanoma--bms/2024-02-13T10:20:36+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-recommends-sancuso--prostraken--for-nausea/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2011/09/acz-885-positive-in-phase-iii-juvenile-idiopathic-arthritis-trial/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-farydak--panobinostat--in-combination-with-bortezomib-and-dexamethasone-to-treat-refractory-multiple-myeloma---novartis/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-probeam-proton-therapy-system-varian/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2012/12/nice-recommends-yervoy--bms--and-zelboraf--roche--for-melanoma/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-advisory-committee-considers-that-onglyza--saxagliptin--has-an-acceptable-cv-risk-profile--astrazeneca/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2015/03/new-data-from-phase-iii-extension-study-of-maci--autologous-chondrocyte-implant--in-tissue-repair--vericel-corp/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2013/07/bms-pfizer-file-eliquis-as-a-prophylaxis-treatment-for-dvt/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2014/05/valeant-pharmaceuticals-international-sells-dermatology-products-rights-to-galderma-nestle/2025-10-16T11:12:07+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-biothrax--vaccine-subcutaneous--to-prevent-anthrax-following-suspected-or-confirmed-exposure-to-bacillus-anthracis--emergent-biodefense-operations/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-update-to-erbitux-indication-for-mcrc-merck-serono/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2011/09/zonegran-shows-potential-for-partial-epilepsy-in-paediatric-patients/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2018/06/the-fda-has-approved-nocdurna--for-the-treatment-of-nocturia-due-to-nocturnal-polyuria----ferring-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2013/12/bromsite-success-in-phase-iii-trial-for-cataract-insite-vision/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2012/03/merck-inc-withdraws-from-oral-vernakalant-collaboration/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2017/01/rapivab--peramivir--filed-with-ema-for-influenza-in-adults-18-years--and-older--biocryst-pharma/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2018/09/snda-filed-at-the--fda-for-doptelet-seeking-approval-for-the-treatment-of-patients-with-immune-thrombocytopenia--itp--who-have-had-an-insufficient-response--dova-pharma-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-responds-to-takeda-s-ndas-for-type-2-diabetes-therapies-nesina-and-combination-nesina-and-actos/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2012/04/etc-1002--esperion-therapeutics--positive-in-phase-ii-trial-for-dyslipidaemia/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-lucentis-as-treatment-of-visual-impairment-due-to-choroidal-neovascularization/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2016/05/chmp-recommends-afinitor--everolimus--to-treat-neuroendocrine-tumors--net--of-gastrointestinal--gi--or-lung-origin--novartis/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2016/09/eu-approves-epiduo-0-3----2-5--gel--adapalene--benzoyl-peroxide--for-acne--galderma-/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/08/sirukumab--janssen-gsk--to-enter-phase-iii-for-ra/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-approves-portrazza--necitumumab--to-treat-squamous-egfr-expressing-nsclc---eli-lilly/2024-02-13T10:20:45+00:00weekly0.6https://www.medthority.com/news/2012/03/wheat-bran--brana-vita-fugeia-nv--positive-in-gut-trial-/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-ayvakit-to-treat--unresectable-or-metastatic-gastrointestinal-stromal-tumor---blueprint-medicines/2021-09-24T07:11:53+00:00weekly0.6https://www.medthority.com/news/2013/04/study-shows-ostinol--zycal-bioceuticals--improves-pain-and-stiffness-in-osteoarthritis/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approve-exablate--insightec--to-treat-pain-from-bone-metastases---------------/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2017/12/a-post-hoc-subgroup-analysis-of-the-phase-ii-sustain-study-show-that-crizanlizumab---delayed-the-time-to-first-sickle-cell-pain-crisis---selexys---novartis-/2024-02-13T10:20:58+00:00weekly0.6https://www.medthority.com/news/2015/05/phase-iii-trial-of-ebi-005-fails-to-meet-endpoints-in-dry-eye-disease-eleven-biotherapeutics/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2018/04/common-running-injuries--consultant-surgeon-assesses-the-damage-for-london-marathon-2018/2024-07-26T08:59:56+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-eticovo-for-ra-aspond-pps-psa-pjia---samsung-bioepis/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2012/03/tc-6987--targacept--success-in-phase-ii-asthma-study/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-trial--study-115--of-zydelig--idelalisib--is-unblinded-early-and-shows-benefit-in-cll--gilead/2024-02-13T10:21:07+00:00weekly0.6https://www.medthority.com/news/2012/07/positive-results-from-phase-iii-study-of-isentress--merck-inc--for-hiv-1-patients/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2019/06/biomonitor-iii-cardiac-monitor-is-launched-in-europe-with-ce-mark---biotronik/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-burst-dr-spinal-cord-stimulation-to-treat-chronic-pain---st-jude-medical/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2015/10/alks-8700-advances-comparison-studies-with-tecfidera--dimethyl-fumarate--in-ms--alkermes/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2018/05/novasight-hybrid-imaging-system-receives-510-k--fda-approval---conavi-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2018/03/cannabis-compound-may-help-curb-frequency-of-epileptic-seizures/2024-02-13T10:21:25+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-apadaz-for-the-short-term--no-more-than-14-days--management-of-acute-pain---kempharm-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2017/07/nice-recommends-gazyvaro--obinutuzumab--plus-bendamustine-chemotherapy-to-treat-follicular-lymphoma---roche/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2017/12/five-year-survival-results-for-adcetris-for-mature-t-cell-lymphoma----seattle-genetics-/2024-02-13T08:55:22+00:00weekly0.6https://www.medthority.com/news/2014/03/controversy-over-jama-paper-that-highlighted-cv-risk-and-testosterone-therapy/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-otelza--for-the-treatment-of-oral-ulcers-associated-with-beh-et-s-disease-/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-provides-complete-response-for-application-for-cem-101--solithromycin--in-community-acquired-bacterial-pneumonia--cempra/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2015/08/ema-accepts-maa-for-cinquil--reslizumab--for-the-treatment-of-inadequately-controlled-asthma-in-adult-patients-with-elevated-blood-eosinophils--teva/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-requests-that-endo-pharma-withdraw-opana-er-pain-therapy-from-the-us-market-/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-lojuxta--aegerion-pharmaceuticals--for-hofh/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2016/06/two-phase-iii-trials-show-tresiba--insulin-degludec-injection-u-100--reduces-hypoglycaemia-versus-insulin-glargine-u-100-in-type-2-diabetes--novo-nordisk-/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2012/06/nice-does-not-recommend-zelboraf-roche--for-metastatic-melanoma/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-tags-trial-of-lonsurf-meets-primary-endpoint-in-gastric-cancer---taiho-oncology-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2015/05/new-data-for-envarsus-xr--tacrolimus-extended-release--in-african-american-transplant-patients--veloxis-pharma/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2017/09/apollo-phase-iii-study-of-aln-ttr02--patisiran--in-hereditary-attr-amyloidosis-with-polyneuropathy-meets-primary-endpoints---sanofi-genzyme---alnylam-pharmaceuticals-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2015/03/nice-recommends-harvoni--ledipasvir---sofosbuvir--for-treatment-of-hepatitis-c-genotypes-1-and-4--gilead/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2018/02/seattle-genetics-acquires-cascadian-therapeutics-and-with-it-tucatinib-a-tyrosine-kinase-inhibitor-to-treat-breast-cancer/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-incresync-for-type-2-diabetes/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2017/08/castle-af-study-results-show-a-38-percent-reduction-in-the-composite-of-all-cause-mortality-and-hospitalization-for-worsening-heart-failure--when-heart-failure-patients-with-atrial-fibrillation--af--are-treated-with-catheter-ablation---biotronik/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-tavalisse-to-treat-chronic-immune-thrombocytopenia---rigel-pharma-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2017/06/cognitive-behaviour-therapy-cbt-significantly-reduced-depression-and-anxiety-in-chronic-pain-patients/2024-07-01T12:23:46+00:00weekly0.6https://www.medthority.com/news/2013/06/vantage-study-shows-vercise-dbs--boston-scientific--demonstrates-motor-function-benefits-in-parkinson-s-disease-/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2012/08/xience-xpedition-everolimus-stent--abbott-vascular--receives-ce-mark/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2016/03/meta-analysis-of-nucala--mepolizumab--shows-efficacy-in-asthma-patients--glaxosmithkline-/2024-02-13T09:02:44+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-keytruda---either-paclitaxel-or-nab-paclitaxel--for-the-first-line-treatment-of-patients-with-metastatic-squamous-nsclc--merck-inc-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2013/11/find-ckd-study-results-for-ferinject--vifor-pharma--for-ckd--iron-deficiency/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-tecentriq---chemotherapy--abraxane-and-carboplatin--to-treat-metastatic-non-squamous-non-small-cell-lung-cancer---genentech-roche/2021-09-24T07:18:38+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-liptruzet--merck-inc--for-dyslipidaemia/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2017/01/bristol-myers-squibb-and-ono-pharmaceutical-settle-patent-dispute-with-merck-inc-over-keytruda--pembrolizumab-/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-gives-full-approval-for-keytruda-in-head-and-neck-squamous-cell-carcinoma---merck-inc/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2018/08/corbus-pharmaceuticals-to-commence-phase-iii-study-of-lenabasum-for-the-treatment-of-rare-autoimmune-disease-dermatomyositis-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-bio-rad-bioplex-2200-hiv-ag-ab-assay--bio-rad-laboratories/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2013/02/obinutuzumab--genentech--success-in-phase-iii-trial-for-cll/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2012/07/phase-iii-trial-for-odanacatib-merck-inc---in-osteoporosis-closes-early/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-v920-ebola-zaire-vaccine---ervebo--to-protect-against-ebola-virus-disease---merck-inc-/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---anti-gbm-disease--a-model-for-autoimmune-kidney-diseases/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2018/03/first-steps-taken-for-vaccine-pills/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2012/05/-fda-issues-complete-response-letter-to-alexza-pharma-for-adasuve/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-approves-tretten-for-congenital-factor-xiii-deficiency-novo-nordisk/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-committee-recommends-ocaliva--obeticholic-acid--for-primary-biliary-cholangitis--intercept-pharmaceuticals/2024-02-13T09:03:05+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-results-from-study-of-genesis-neurostimulator--st-jude-medical--in-patients-with-migraine/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2014/12/red-hill-biopharma-files-bekinda--rbh-102--with-mhra-for-european-approval-for-treatment-of-chemotherapy-nausea-and-vomiting/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2012/03/optiscanner--optiscan-biomedical--study-shows-clinical-accuracy-in-monitoring-blood-glucose-in-critically-ill-icu-patients-/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-expansion-of-trulicity-label-to-include-results-from-rewind-cardiovascular-and-diabetes-outcomes-trial---eli-lilly/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---indigestion-remedy-significantly-slows-kidney-function-decline-and-improves-survival-in-late-stage-ckd/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2013/03/german-federal-joint-committee-decides-additional-benefit-of-fycompa--eisai--unproven-as-a-treatment-for-epilepsy-/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii--reset--pivotal-study-of-rivipansel-did-not-meet-its-primary-or-key-secondary-efficacy-endpoints-in-patients-with-sickle-cell-disease/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2014/08/covidien-plc-acquires-sapheon--inc--and-its-venaseal-system-for-varicose-veins-/2025-10-16T11:12:41+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-mora-trial-of-plenvu-in-bowel-preparation-published-in-endoscopy---norgine-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-tuzistra-xr--codeine-polistirex-and-chlorpheniramine-polistirex-for-chronic-cough--vernalis/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-oralair-for-grass-pollen-induced-allergic-rhinitis---stallergenes---greer-labs-/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2012/12/positive-data-from-phase-iii-study-of-eliquis--bms-pfizer--for-vte-prevention/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-approves-snda-for-avycaz--ceftazidime-and-avibactam--in-complicated-urinary-tract-infections--cuti---including-pyelonephritis--allergan/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-biosimilar-truxima-to-treat-three-indications-of-rituxan---celltrion---teva/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2016/09/newron-re-files-xadago--safinamide--at-fda-as-a-treatment-for-parkinsons-disease-/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2018/03/prostate-test--breakthrough--in-nhs-trial/2024-07-26T10:51:16+00:00weekly0.6https://www.medthority.com/news/2018/09/nice-guidance-rejects-the-use-of-respreeza-for-alpha-1-antitrypsin-deficiency---csl-behring-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2019/10/pfenex-receives-fda-approval-for-pf-708--teriparatide-injection-biosimilar--to-treat-osteoporosis-/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2012/02/ct-colonography-shown-to-be-comparable-to-standard-colonoscopy/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2012/05/lumax-740-defibrillator--biotronik--is-fda-approved/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-sierra-study-of-iomab-b-shows-efficacy-in-acute-myeloid-leukemia---actinium-pharma/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2017/09/idp-118--halobetasol-propionate-and-tazarotene--filed-with-the-fda-for-the-treatment-of-plaque-psoriasis---ortho-dermatologics-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2017/11/orsiro1-drug-eluting-stent-shows-long-term-safety-and-performance-in-bioflow-trials---biotronik-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2013/09/evolve-ii-trial-proceeds-for-synergy-cardiac-stent-system-/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-grants-expanded-indication-for-use-of-trevo-retriever-clot-removal-device-for-use-within-24-hours---stryker/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2015/08/daratumumab-monotherapy-phase-i-ii-trial-for--refractory-multiple-myeloma-published-in-nejm--genmab---janssen-biotech/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2018/04/premature-hearts-less-able-to-cope-with-exercise/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2016/08/prometic-life-sciences-inc--acquires-telesta-and-with-it-mcna--a-possible-treatment-for-bladder-cancer-/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2013/12/nepa-is-filed-at-fda-by-helsinn-eisai-for-nausea/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-darzalex---velcade---melphalan---prednisone-combination-to-treat-newly-diagnosed-multiple-myeloma---janssen-pharma-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-gives-supplemental-approval-of-alunbrig--brigatinib--180-mg-tablets-for-alk--metastatic-non-small-cell-lung-cancer---takeda-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-approves-alprolix--rfixfc--for-the-treatment-of-haemophilia-b--swedish-orphan-biovitrum-biogen/2024-02-13T09:49:34+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-raxone---idebenone---to-treat-visual-impairment-in-adolescent-and-adult-patients-with-leber-s-hereditary-optic-neuropathy--lhon---santhera-pharma/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2014/12/astrazeneca-re-files-nda-for-iressa-at-fda-for-egfrm-non-small-cell-lung-cancer/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2012/08/ema-accepts-filing-for-heplisav--dynavax-technologies---a-vaccine-for-hepatitis-b-----------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-rexulti-as-a-treatment-for-schizophrenia---otsuka---lundbeck-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2013/07/omthera-pharma-files-epanova-with-the-fda-for-treating-hypertriglyceridemia/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2013/06/avastin--genentech-roche--effective-in-gog-240-trial-for-cervical-cancer-/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2019/11/rinvoq--meets-primary-and-all--secondary-endpoints-in-phase-iii-study-in-psoriatic-arthritis--abbvie/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-advisory-committee-recommends-approval-of-dsuvia-to-treat-moderate-to-severe-acute-pain---acelrx-pharmaceuticals/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2019/09/alnylam-pharma-initiates-apollo-b-phase-iii-trial-of-onpattro-to-treat--transthyretin-amyloidosis-with-cardiomyopathy-/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2012/05/cardiovascular-safety-concerns-over-smoking-cessation-drug-chantix--pfizer--misleading/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2016/09/visco360-viscosurgical-system-given-eu-ce-mark-approval-for-use-in-glaucoma--sight-sciences/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-recommends-xofigo--radium-ra-223-dichloride--for-treatment-of-hormone-relapsed-metastatic-prostate-cancer--bayer-healthcare/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2015/05/circassia-acquires-aerocrine-ab-and-prosonix-ltd-and-with-them-diagnostic-devices-niox-vero-and-niox-mino-and-soon-to-be-launched-psx-1002/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2018/09/perjeta---herceptin-fails-in-jacob-trial-to-treat-her2-positive-metastatic-gastric-or-gastro-oesophageal-junction-cancer-roche/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2019/12/eu-approves-extension-of-approval-of-kalydeco-to-infants-with-cftr-cystic-fibrosis---vertex-pharma/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2011/09/ema-confirms-risk-benefit-of-multaq-1/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2011/04/novottf-100a-system-is-fda-approved-for-glioblastoma/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2017/05/evenity--romosozumab--arch-phase-iii-study-meets-primary-and-key-secondary-endpoints-in-osteoporosis--amgen-ucb/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-approves-ocrevus-for-relapsing-forms-of-multiple-sclerosis-and-early-primary-progressive-multiple-sclerosis----roche-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2017/06/amg-334--erenumab--filed-in-eu-for-the-prevention-of-migraine--novartis/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-cinqair--reslizumab--to-treat-eosinophilic-asthma--teva/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-shows-efficacy-of-generx-in-myocardial-ischemia--taxus-cardium-pharma/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2019/12/protect-viii-extension-study-of-jivi-in-haemophilia-a-published-in-haemophilia-journal---bayer/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2016/08/complete-response-letter-from-fda-for-parsabiv--etelcalcetide----a-proposed-treatment-for-secondary-hyperparathyroidism--amgen/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-grants-priority-review-for-elagolix--for-the-management-of-endometriosis-and-pain---abbvie---neurocrine-biosciences-/2021-09-24T07:13:20+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-samurai-and-spartan-studies-of-lasmiditan-show-efficacy-in-migraine---eli-lilly/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-trevicta--paliperidone-palmitate-a-3-monthly-injection--to-treat-schizophrenia--janssen-cilag/2021-09-24T07:10:48+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-advisory-commmittee-recommends-baricitinib-2-mg-dose-to-treat-rheumatoid-arthritis-but-not-4-mg-dose---eli-lilly---incyte-corpn-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-grants-premarket-approval-for--hospital-wearable-defibrillator-from-zoll-medical-asahi-kasei-/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2019/08/ectrims-2019---learn-more/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2013/07/celgene-terminates-revlimid--origin-trial-for-cll/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2017/11/chmp-recommends-benralizumab-as-add-on-maintenance-therapy-for-severe-eosinophilic-asthma--astrazeneca-/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2015/02/chmp-recommends-zycadia---ceritinib-to-treat-alk---nsclc--novartis/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-utibron-neohaler--indacaterol-glycopyrrolate--for-chronic-obstructive-pulmonary-disease--novartis/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2018/04/ema-accepts-for-review-cemiplimab-maa-for-the-treatment-of-patients-with-metastatic-cutaneous-squamous-cell-carcinoma--sanofi---regeneron/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/04/successful-coast-x-phase-iii-study-of-taltz-for-the-treatment-of-non-radiographic-axial-spondyloarthritis/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2011/11/eu-approvbes-plenadren--duocort-pharma--for-adrenal-insufficiency/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2020/01/galecto-to-merge-with-pharmakcea-inc-/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2013/09/merck-pulls-plug-on-juvisync-for-dyslipidaemia/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2018/06/china-national-drug-administration-approves-opdivo-to-treat-nsclc--bms/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2018/05/takeda-acquires-shire-plc/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2019/10/adamis-pharmaceuticals-announces-commercial-partnership-with-emerge-health-for-symjepi-in-australia-and-new-zealand-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2018/06/eular-annual-european-congress-of-rheumatology-2018/2021-12-01T13:55:18+00:00weekly0.6https://www.medthority.com/news/2017/10/lupin-acquires-symbiomix-therapeutics--llc-and-solosec-franchise-/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-generic-atomoxetine-to-treat-adhd-/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2011/10/somaxon-may-head-for-otc-status-in-usa-for-insomnia-/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-trial-of-spk-rpe65--gene-therapy-product--in-retinal-dystrophies-meets-primary-endpoint--spark-therapeutics/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-trazimera---trastuzumab-biosimilar---to-treat--her-2-breast-cancer-and-gastric-cancer---pfizer-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2012/08/gsk-files-trametinib-at-the-fda-for-metastatic-melanoma/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-eliquis-for--dvt-and-pe--vte----bms---pfizer/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2016/10/boston-scientific-launches-resolution-360--clip-for-use-in-endoscopy-procedures-of-the-upper-and-lower-gastrointestinal--gi--tract-/2024-10-21T14:42:02+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-treximet--sumatriptan-and-naproxen-sodium--formulation-to-treat-migraine-in-children--pernix-therapeutics/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2017/11/xiii-world-congress-of-intensive-and-critical-care-medicine---xxii-brazilian-congress-of-intensive-care-medicine/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2015/11/ema-finds-no-link-between-hpv-vaccines-and-syndrome-reports/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2011/11/onyx-pharma-files-carfilzomib-at-the-fda-for-multiple-myeloma/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2018/07/two-phase-iii-trials--sequoia-and--cedar-for-abicipar-both-the-8-week-and-12-week-treatment-regimens-met-the-pre-specified-primary-endpoint-of-non-inferiority-to-ranibizumab---allergan---molecular-partners/2024-07-26T09:08:20+00:00weekly0.6https://www.medthority.com/news/2015/09/cti-biopharma-plans-to-submit-nda-to-fda-for-pacritinib-for-treatment-of-myelofibrosis/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2013/02/treprostinil-diolamine-extended-release-tablets--united-therapeutics--re-filed-at-fda-for-treatment-of-pah/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2015/10/nice-recommends-brintellix--vortioxetine--for-major-depressive-disorder--lundbeck/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-advisory-committee-recommends-sugammadex-to-reverse-rocuronium-or-vecuronium-during-surgery--merck/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-harvoni--ledipasvir---sofosbuvir--for-hepatitis-c-with-liver-disease--gilead-sciences/2024-02-13T09:50:08+00:00weekly0.6https://www.medthority.com/news/2017/09/essure-contraceptive-device-is-withdrawn-in-the-eu---bayer/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2016/12/ascend--study-of-zykadia--ceritinib--successful-for--alk---advanced-non-small-cell-lung-cancer--nsclc---novartis-/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2012/07/study-shows-cinryze--viro-pharma--effective-for-long-term-treatment-of-hereditary-angio-oedema/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-bevespi-aerosphere--glycopyrrolate-and-formoterol-fumarate--to-treat-copd--astrazeneca/2021-09-24T07:10:38+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-change-to-indication-for-simponi-in-juvenile-idiopathic-arthritis---janssen-biologics-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2011/11/lemtrada-genzyme-sanofi--superior-to-rebif-in-care-ms-ii-multiple-sclerosis-study/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/09/sanofi-and-abbott-partner-to-integrate-glucose-sensing-and-insulin-delivery-technologies-to-help-change-the-way-diabetes-is-managed-/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2017/05/novartis-exercises-its--option-to-acquire-emricasan--a-treatment-for-liver-disease--from-conatus-pharmaceuticals-inc--/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2012/05/keryx-biopharma-returns-north-american-rights-to-aeterna-zentaris-for-perifosine/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-expands-approval-of-zykadia--ceritinib--to-include-patients-with-metastatic-non-small-cell-lung-cancer-whose-tumors-are-anaplastic-lymphoma-kinase--alk--positive--novartis/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2014/05/medi-4736-enters-phase-iii-for--unresectable-nsclc--astrazeneca/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-issues-complete-response-letter--for-kyndrisa--drisapersen--to-treat--duchenne-muscular-dystrophy--biomarin/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-approves-new-pergoveris-pen--a-ready-to-use-fertility-combination-treatment-option-for-women-with-severe-follicle-stimulating-hormone-and-luteinizing-hormone-deficiency---merck-kgaa/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-study-of-favorite--activaero--shows-superiority-over-conventional-asthma-treatment/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-dotarem--guerbet-sa--for-mri-imaging/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-endolucinbeta--no-carrier-added-nca-lutetium-177--for-radiation-therapy--itg-isotope-technologies-garching/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-accepts-filing-of-lodotra--horizon-pharma--for-rheumatoid-arthritis/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-study-shows-inovelon--rufinamide--well-tolerated-in-lennox-gastaut-syndrome--eisai/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2016/04/heplisav-b-review-date-at-fda-for-hepatitis-b-is-extended-to-15-december-2016/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2011/12/gilenya--novartis--shows-reduction-in-relapse-rates-in-phase-iii-multiple-sclerosis-study-2309-/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-tags-trial-of-lonsurf-in-gastric-cancer-published-in-the-lancet-oncology---taiho-oncology-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2017/08/european-commission-approves-imraldi--a-biosimilar-referencing-humira--adalimumab--to-treat-the-originator-drug-indications--biogen-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2016/01/study-of-istent-trabecular-micro-bypass-stent-in-glaucoma-published-in-journal-of-cataract-and-refractive-surgery--glaukos-corp/2024-02-13T09:50:26+00:00weekly0.6https://www.medthority.com/news/2016/02/snda-filed-with-fda-for-xtandi--enzalutamide--in-prostate-cancer---astellas-and-medivation/2024-02-13T09:50:38+00:00weekly0.6https://www.medthority.com/news/2019/03/vascepa-reduce-it-study/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2017/05/ampio-pharmaceuticals-initiates-a-single-injection-study-to-meet-the--unmet-medical-need--of-treating-the-severe-pain-and-loss-of-function-associated-with-kellgren-lawrence--kl--grade-4-osteoarthritis-of-the-knee-/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2018/10/jardiance-met-the-primary-efficacy-endpoint-in--the-ease-programme-to-treat-type-i-diabetes--eli-lilly---boehringer/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2013/01/merck-inc---withdraws-tredaptive-treatment-for-dyslipidaemia/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-revised-labelling-for-wilate--von-willebrand-factor-coagulation-factor-viii-complex--for-von-willebrand-disease--octapharma/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2012/03/byetta--amylin--is-eu-approved-for-use-with-basal-insulin-in-type-2-diabetes-patients/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2019/08/nhs-england-will-reimburse-hemlibra-for-prevention-of-bleeding-episodes---in--hemophilia-a-patients-who-have-factor-viii-inhibitors--roche/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2015/07/ema-validates-for-review-empliciti--elotuzumab--to-treat-multiple-myeloma--bms/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-topline-results-for-sar-1118--sarcode--for-treating-dry-eye-disease/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2014/05/pernix-therapeutics-acquires-us-rights-to-treximet-for-migraine-from-gsk/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2019/06/lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer---astrazeneca---merck-inc-/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2012/10/botox--allergan--approved-by-mhra-in-uk-for-urinary-incontinence---------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2017/06/excess-risk-of-cardiovascular-events-in-rheumatoid-arthritis-patients-decreased-since-start-of-21st-century-/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-recommends-xarelto--bayer--for-prevention-of-atherosclerotic-events-after-acs/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-approves-vosevi--sofosbuvir---velpatasvir---voxilaprevir--for-the-treatment-of-adults-with-genotype-1-6-chronic-hepatitis-c-virus--gilead-sciences/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-advisory-committee-recommends-tofacitinib-for-the-treatment-of-adult-patients-with-active-psoriatic-arthritis----pfizer/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-trazimera--biosimilar-trastuzumab-for-her2-overexpressing-breast-and-gastric-cancer---pfizer/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2014/06/interim-results-with-sd-809-in-huntingdon-s-disease-auspex-pharma/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-study-of-ionis-ttrx-shows-qol-benefits-in-hereditary-attr-amyloidosis---ionis-pharma-/2021-09-24T07:06:25+00:00weekly0.6https://www.medthority.com/news/2018/02/lorlatinib-is-filed-at-fda--ema-and-in-japan-for-the-treatment-of-patients-with-alk-positive-metastatic-nsclc---pfizer/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-ii-data-for-once-daily--ribavirin-free--pan-genotypic-regimen-of-abt-493-and-abt-530-for-hepatitis-c-genotypes-1-6-in-surveyor-i-and-ii-studies--abbvie/2024-02-13T09:56:06+00:00weekly0.6https://www.medthority.com/news/2016/09/successful-second-phase-iii-aim-td---trial-for-sd-809---deutetrabenazine--for-tardive-dyskinesia----teva/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---addressing-cardiovascular-risk-factors-can-help-to-improve-access-to--and-outcomes-of--kidney-transplantation/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2015/02/rapamune-filed-with-fda-for-lymphangioleiomyomatosis---pfizer/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2014/09/mk-0822-meets-primary-endpoint-in-phase-iii-trial-for-osteoporosis-merck/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2018/03/driver-of-ckd/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-provides-complete-response-letter-to-application-for-remoxy-er--oxycodone--extended-release-capsules-in-pain-treatment--pain-therapeutics/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2017/10/us-appeals-court-orders-new-trial-in-patent-infringement-issue-relating-to-praluent--alirocumab---sanofi---regeneron/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-freestyle-libre-pro-system--a-continuous-glucose-monitoring--cgm--system-abbott/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2013/12/kalydeco-fails-to-meet-primary-endpoint-in-cystic-fibrosis-trial-vertex/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2011/05/hematide-analyse-of-emerald-studies/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-gardasil-9-for-nine-types-of-human-papillomavirus--hpv---merck-inc-/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2018/04/nice-rejects--dupixent-for-atopic-dermatitis-in-a-preliminary-decision----sanofi-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2012/10/phase-iii-results-for-alo-02--pfizer--for-moderate-to-severe-pain/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2014/06/alkermes-initiates-phase-iii-studies-for-alks-5461-for-major-depressive-disorder-/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-statement-related-to-investigational-use-of-keytruda--pembrolizumab--in-multiple-myeloma--merck-inc-/2021-09-24T07:14:01+00:00weekly0.6https://www.medthority.com/news/2013/05/aspecct-study-of-vectibix--amgen--compared-to-erbitux-in-treatment-of-colorectal-cancer/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2013/12/results-from-phase-ii-trial-of-pb-272-for-neoadjuvant-breast-cancer--puma-biotechnology/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-plans-advisory-committee-meeting-for-plazomicin-for-the-treatment-of-complicated-urinary-tract-infections----achaogen--inc-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-data-show-cem-101--cempra-inc--useful-against-urogenital-infections-and-multidrug-resistant-pathogens/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-accepts-for-filing-filgrastim--grastofil---a-biosimilar-version-of--neupogen--apotex/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-prevenar-13--pneumococcal-polysaccharide-conjugate-vaccine--13---valent--adsorbed---four-dose-vial--pfizer/2024-10-21T14:42:44+00:00weekly0.6https://www.medthority.com/news/2015/04/leo-pharma-files-enstilar--calcipotriol-betamethasone-dipropionate---a-cutaneous-foam---in-eu-for-treatment-of-psoriasis/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2019/10/spectrum-pharmaceuticals-re-submits-bla-to-the-fda-for-rolontis-for-the-treatment-of-neutropenia-due-to-myelosuppressive-chemotherapy-/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2015/07/single-tablet-emtricitabine---tenofovir-alafenamide---rilpivirine-submitted-to-fda-for-hiv-aids-gilead-sciences-janssen/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2018/08/novo-nordisk-acquires-ziylo-and-its-glucose-binding-molecule-platform-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-for-exjade--novartis--in-patients-with-iron-overload/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2017/08/positive-data-announced-from-pivotal-phase-iii-intandem2-study-of-lx-4211--sotagliflozin--in-type-1-diabetes--lexicon-pharma/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2012/08/phase-ii-trials-show-improved-survival-with-caprelsa--astrazeneca--for-medullary-thyroid-cancer/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-success-for-reslizumab-in-treatment-of-asthma-teva/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-data-from-trial-of-spiriva-handihaler-plus-striverdi-respimat-for-copd-boehringer/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2017/08/ce-mark-for-7-tesla-magnetic-resonance--mr--scanner-magnetom-terra--siemens-healthineers/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-gala-phase-iii-trial-of-copaxone--teva--for-multiple-sclerosis-patients/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-infliximab-biosimilar-across-gastroenterology--rheumatology-and-dermatology--sandoz-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2018/08/emergent-biosolutions-acquires-adapt-pharma-and-with-it-narcan-a-nasal-form-of-naloxone-indicated-for-the-emergency-treatment-of--opioid-overdose-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-ii-trial-of-wt1-cancer-vaccine-doubles-progression-free-survival-in-malignant-pleural-mesothelioma--sellas-life-sciences-/2024-02-13T14:27:02+00:00weekly0.6https://www.medthority.com/news/2016/09/study-shows-bexsero-vaccine-effective-against-meningococcal-disease--glaxosmithkline/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-trial-of-dupixent-improved---symptoms-of-atopic-dermatitis-in-adolescents--regeneron---sanofi/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-ads-5102--amantadine-hcl--in-parkinsons-disease-meets-primary-endpoint--adamas-pharmaceuticals/2024-02-13T14:27:14+00:00weekly0.6https://www.medthority.com/news/2015/02/gsk-initiates-triple-therapy-fulfil-study-for-copd-compared-to-budesonide-formoterol/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2017/01/the-fda-and-ema-accept-for-review-bi-695501--adalimumab-biosimilar--as-a-biosimilar-to-humira----boehringer/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2017/08/nejm-publishes-results-of-cognitive-function-trial--ebbinghaus-of-repatha--evolocumab--a-treatment-for-atherosclerotic-cardiovascular-disease---amgen-/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2011/09/incivo-will-launch-in-germany-first-for-hepatitis-c/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2017/12/daily-pill-could-reduce-blood-clot-risk-in-cancer-patients/2024-02-13T14:33:53+00:00weekly0.6https://www.medthority.com/news/2017/09/post-hoc-analysis-of-xultophy--insulin-degludec-liraglutide--shows-drug-reduces-risk-factors-for-cardiovascular-disease-in-patients-with-type-2-diabetes---novo-nordisk-/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2017/10/international-stammering-awareness-day-2017/2021-11-30T11:29:15+00:00weekly0.6https://www.medthority.com/news/2018/07/bd--becton--dickinson-and-company--announced-it-has-completed-the-acquisition-of-tva-medical--inc--and-with-it-everlinq-endoavf-system-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-for-humira--abbott--in-one-of-longest-trials-in-patients-with-rheumatoid-arthritis/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2018/07/interim-data-from-phase-iii-alta-1l-trial-of-alunbrig-meets-primary-endpoint-in-non-small-cell-lung-cancer---takeda-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2011/11/trial-of-cre8-polymer-free-stent--cid--shows-promising-results-for-patients-with-coronary-artery-lesions/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/09/astrazeneca-announced-detailed-results-from-the-phase-iii-dapa-hf-trial-that-showed-farxiga-plus--standard-of-care-reduced-both-the-incidence-of-cardiovascular-death-and-the-worsening-of-heart-failure-/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2014/10/janssen-files-stelara-for-pediatric-plaque-psoriasis-with-ema-janssen/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-expanded-approval-of-opdivo-to-include-adjuvant-treatment-of-adults-with-melanoma-in-lymph-nodes-or-metastases-who-have-undergone-complete-resection---bms-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-forxiga-to-treat-type-1-diabetes---astra-zeneca/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-warnings-of-heart-failure--with-use-of-saxagliptin-and-alogliptin--astra-zeneca-and-takeda/2021-09-24T07:10:45+00:00weekly0.6https://www.medthority.com/news/2015/06/two-phase-iii-trials-of-plecanatide-meet-endpoint-in-chronic-idiopathic-constipation--synergy-pharmaceuticals/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-study-of-alecensa--alectinib--in-non-small-cell-lung-cancer-meets-endpoint-and-halted-early--chugai-pharmaceutical-/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-arzerra-combination-therapy-for-cll---gsk-genmab/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-results-for-inclisiran-in-orion-10-study-to-treat-atherosclerotic-cardiovascular-disease--the-medicines-company/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2013/10/allergan-sells-obesity-business-to-apollo-endosurgery/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2015/12/brincidofovir-fails-in-phase-iii-trial-to-prevent-cytomegalovirus--chimerix/2024-02-13T14:34:06+00:00weekly0.6https://www.medthority.com/news/2019/09/lexicon-pharmaceuticals-announced-the-termination-of-its-alliance-with-sanofi-for-the-development-and-commercialization-of-zynquista-in-both-type-1-and-type-2-diabetes-/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-pradaxa-for-vte---boehringer/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2012/01/new-device-is-fda--filed-by-genentech-to-extend-period-of-release-of-lucentis-/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2014/06/palace-4-trial-success-for-otezla-for-psoriatic-arthritis---celgene/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2019/01/positive-phase-iii-inspire-study-of-liq-861-to-treat-pulmonary-arterial-hypertension--liquidia-technologies/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2019/04/motif-bio-plc-announced-new-iclaprim-data-are-presented-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-diseases-meeting-/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2019/07/european-commission-approves-libtayo-to-treat-advanced-cutaneous-squamous-cell-carcinoma/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2020/01/eli-lilly-to-acquire-dermira-and-with-it-lebrikizumab--a-treatment-for-atopic-dermatitis/2021-09-24T07:11:53+00:00weekly0.6https://www.medthority.com/news/2018/01/brevera-breast-biopsy-system-with-corlumina--imaging-technology-gains-ce-mark---hologic-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iiib-trial-of-xarelto--rivaroxaban--shows-reduced-risk-of-bleeding-in-non-valvular-atrial-fibrillation--janssen/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2015/04/tasq--tasquinimod--discontinued-for-prostate-cancer-active-biotech-ipsen/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trials-of-mk-1293--insulin-glargine-biosimilar--meet-endpoints-in-type-1-and-2-diabetes--merck-inc/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2010/11/nplate-compared-to-standard-of-care-therapy-in-itp-patients/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-zerbaxa-to-treat--hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia--merck-inc-/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-trial-of-gvoke-hypopen-showed-efficacy-in-type-1-diabetes---xeris-pharma/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2018/12/amgen-files-sbla-for-nplate-in-adult-itp---amgen-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-spinraza--nusinersen--for-the-treatment-of-spinal-muscular-atrophy--sma--in-pediatric-and-adult-patients---biogen/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2018/03/study-1844-phase-iii-results-show-biktarvy-efficacy-in-patients-with-hiv---gilead-sciences-/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-of-juluca-for-hiv-type-1---janssen---viiv-healthcare-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2019/05/medtronic-launches-telescope-guide-extension-catheter-to-deliver-interventional-devices-during-angioplasty-procedures-/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-phase-iii-top-line-results-from-chiasma-optimal-trial-of-mycapssa-for-the-maintenance-treatment-of-adults-with-acromegaly---chiasma-inc-/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-confirms-recommendation-for-xofigo--radium-223--for-treatment-of-prostate-cancer--bayer-health-care/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2016/05/medtronic-buys-smith---nephew-s--gynecology--gyn--business-including-truclear-system-to-remove-abnormal-uterine-tissue-such-as-polyps-and-fibroids-/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-data-for-eylea-in-diabetic-macular-oedema---regeneron-pharma/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-subcutaneous-formulation-of-actemra--genentech-roche-/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2015/04/novartis-presents-data-from-freedoms-and-freedoms-ii-trials-showing-effect-of-gilenya--fingolimod--in-neda4-measures-of-multiple-sclerosis-/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-libtayo-for-cutaneous-squamous-cell-carcinoma---sanofi---regeneron/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-accepts-bla-from-spark-therapeutics-for-voretigene-neparvovec--an-investigational--potential-one-time-gene-therapy-candidate-for-the-treatment-of-patients-with-vision-loss-due-to-confirmed-biallelic-rpe65-mediated-inherited-retinal-disease-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-convert-study-of-amikacin-liposome-suspension-in-nontuberculous-mycobacterial-lung-disease-published-in-ajrccm---insmed-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2017/06/analysis-confirms--pfs-efficacy-of-endpoint-results-of-phase-ii-cabosun-trial-of-cabozantinib--versus-sunitinib-for-renal-cell-carcinoma-and-sdna-application-for-first-line-treatment---exelixis-inc-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---caffeine-consumption-might-extend-life-expectancy-in-ckd-patients/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2014/04/nice-rejects-kadcyla-for-her-2-positive-breast-cancer---roche/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-repatha--evolocumab--for-high-cholesterol-amgen/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-phase-iii-sustain-6-trial-of-semaglutide-shows-reduction-in-cv-risk-for-type-2-diabetes-patients--novo-nordisk/2024-02-13T09:05:43+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-recommends-expanding-approval-of-blincyto-in-acute-lymphoblastic-leukemia---amgen-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-trial-of-aranesp--amgen--in-anemic-heart-failure-patients-shows-drug-offers-no-real-benefit/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-actemra--tocilizumab--subcutaneous-injection-for-the-treatment-of-giant-cell-arteritis---genentech-roche/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-novoeight-for--treatment-of-haemophilia/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-maci--autologous-cultured-chondrocytes-on-porcine-collagen-membrane--for-knee-cartilage-repair--vericel-corporation/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-eylea-for-treatment-of-diabetic-macular-edema--regeneron---bayer/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-trial-of-quickshot-auto-injector--testosterone-enanthate--shows-efficacy-in-testosterone-deficient-adults--antares-pharma/2024-02-13T09:07:33+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-study-of-esmya-shows-reduced-bleeding-of-uterine-fibroids---allergan-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-reach-2-study-of-cyramza-to-treat-afp-high-liver-cancer-is-published-in-the-lancet-oncology----eli-lilly/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2012/05/seebri-breezhaler--novartis--success-in-glow-3-trial-for-copd/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-extends-approval-of-vectibix-plus-folfiri-in-wild-type-ras-mcrc-amgen/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-grants-510-k--approval-for--vanguard-iep-peripheral-balloon-angioplasty-system---contego-medical/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2011/10/early-stage-breast-cancer-benefit-from-herceptin-and-chemotherapy/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2013/08/vedolizumab-success-in-gemini-1-trial-for-ulcerative-colitis/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-results-for-ner-1006--1-litre-peg-and-ascorbate--meets-primary-endpoints-in-bowel-preparation--norgine-/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2011/12/enest-studies-of-tasgina--novartis-show-superiority-to-glivec-in-ph-cml/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-i-lipo--chromogenex--for-fat-reduction-therapy-/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2012/05/janssen-files-xarelto-at-fda-for-venous-thromboembolism-and-acs--/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2018/03/guideline-recommends-xolair-to-treat-chronic-urticaria---novartis-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-trazimera-biosimilar-to-herceptin-to-treat-breast-and-gastric-cancers--pfizer/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2015/04/pfizer-terminates-agreement-with-catalyst-biosciences/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2017/11/combination-of-eylea-and-nesvacumab-will-not-proceed-for-diabetic-macular-edema-and-wet-amd---regeneron---bayer-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2018/07/enzyvant-initiated-its-rolling-submission-to-the-fda-of-a-bla-for-rvt-802-to-treat-complete-digeorge-anomaly--effects-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-expansion-of-indication-for-kalydeco--ivacaftor--in-cystic-fibrosis---r117h-mutation--ages-18-and-older--vertex-pharmaceuticals/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-phase-iii-data-for-emgality-for-episodic-cluster-headache-is-published-in-nejm--eli-lilly-/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-to-review-isatuximab-as-a-potential-treatment-for-relapsed-refractory-multiple-myeloma---sanofi/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-grants-accelerated-approval-to-pomalyst--celgene--to-treat-multiple-myeloma/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2011/11/erbitux--merck-serono-bms--effective-in-nsclc-patients-with-egfr-mutation/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-tourmaline-mm1-results-for-ninlaro--ixazomib--in-multiple-myeloma-published-in-nejm--takeda/2024-02-13T09:08:22+00:00weekly0.6https://www.medthority.com/news/2019/07/gilead-reports-discussions-with-fda-relating-to-filing-of--filgotinib-for-rheumatoid-arthritis-/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-updates-label-safety-warning-for-multaq--sanofi-aventis-/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2014/06/medtronic-to-acquire-covidien/2025-10-16T10:55:12+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-rejects-adagio-study-results-as-showing-azilect-delays-progression-of-parkinsons-disease/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2017/10/the-european-medicines-agency--ema--has-accepted-a-marketing-authorisation-application--maa--for-imfinzi--durvalumab--for-the-treatment-of-patients-with-nsclc---astrazeneca-/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2017/01/eli-lilly-acquires-colucid-pharmaceuticals-and-its-migraine-treatment-lasmiditan/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2016/07/phase-iii-tailor-study-of-erbitux--cetuximab--plus-folfox-shows-significant-improvement-in-outcomes-for-ras-wild-type-metastatic-colorectal-cancer--merck/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2015/12/xalia-trial-of-xarelto--rivaroxaban--has-success-in-real-world-study-for-dvt---bayer---janssen/2024-02-13T09:08:36+00:00weekly0.6https://www.medthority.com/news/2019/07/ema-accepts-maa-for-review-for---sb-8--a-bevacizumab-biosimilar---samsung-bioepis---merck-inc-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2015/06/ibrance---fulvestrant-paloma-3-study--results-for-breast-cancer-announced-at-asco--pfizer/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2018/10/rise-in-the-use-of-innovative-drugs-matched-to-dna-mutations-in-tumours-in-a-community-setting/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2013/11/bi-201335--boehringer--phase-iii-trials-success-in-hep-c--/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-issues-complete-response-letter-for-optinose-bds-for-migraine-avanir-pharma/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2012/08/study-shows-potential-benefits-of-cocoa-for-blood-pressure---------------/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-to-review-tofacitinib-pfizer--for-rheumatoid-arthritis-in-august-2012/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2018/02/rare-disease-day-2018/2021-11-30T14:26:09+00:00weekly0.6https://www.medthority.com/news/2018/04/ce-mark-for-vagus-nerve-stimulation-therapy-system---livanova/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-recommends-update-to-indication-for-ravicti-in-urea-cycle-disorders---horizon-pharma-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2013/08/-eu-approval-for-imnovid-for-multiple-myeloma/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2012/05/spiriva--boehringer--in-phase-iii-for-asthma/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-tafinlar---mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma---novartis-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-study-of-perifosine--aeterna-zentaris--for-multiple-myeloma--discontinued/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2017/03/janssen-reports-voyage-2-and-navigate-phase-iii-studies-of-guselkumab--cnto-1959--for-treatment-of-moderate-to-severe-psoriasis-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-committee-rejects-xarelto-for-acute-coronary-syndrome/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2016/04/abbvie-announces-data-from-magellan-1-study-of-abt-493--abt-530-for-treatment-of-hepatitis-c/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2017/12/efficacy-of-dysport-to-treat-lower-limb-spasticity-demonstrated-in--phase-iii-trial-and-extension---ipsen-/2024-02-13T09:08:56+00:00weekly0.6https://www.medthority.com/news/2019/02/european-commission-approves-adcetris-with-avd-chemotherapy-for-untreated-cd30--stage-iv-classical-hodgkin-lymphoma----takeda---seattle-genetics/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2012/11/european-commission-approves-constella-almirall-ironwood--for-irritable-bowel-syndrome-with-constipation/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2011/11/vivitrol--alkermes-inc--shows-sustained-efficacy-in-opioid-dependence-study/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2013/08/eylea-success-in-dme-trials/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-study-of-sar-153191--sarilumab--meets-endpoints-in-rheumatoid-arthritis--sanofi-regeneron-pharma/2024-02-13T09:09:11+00:00weekly0.6https://www.medthority.com/news/2018/02/rolontis-is-non-inferior-to-pegfilgrastim-for--mamagement-of-severe-chemotherapy--induced-neutropenia---spectrum-pharma/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2015/01/intercept-rbc-system-meets-endpoint-in-phase-iii-trial-for-anaemia-cerus-corp/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2019/08/zogenix-acquires-modis-therapeutics-and-with-it-mt-1621-a-treatment-for--thymidine-kinase-2-deficiency-/2025-10-16T11:13:59+00:00weekly0.6https://www.medthority.com/news/2017/09/esmo-2017-press-release--study-in-early-stage-breast-cancer-shows-that-even-small-tumours-can-be-aggressive/2024-02-13T09:09:51+00:00weekly0.6https://www.medthority.com/news/2017/08/amgen-submits-sbla-to-fda-for-prolia--denosumab--for-the-treatment-of-patients-with-glucocorticoid-induced-osteoporosis-/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-inbuild-trial-of-ofev-meets-endpoint-in-interstitial-lung-diseases---boehringer/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2019/09/six-year-ocrevus-data-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis---genentech-roche/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-cinvanti-for-prevention-of-nausea-and-vomiting-associated-with-chemotherapy---heron-therapeutics-/2021-09-24T07:14:42+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-gore-tigris-vascular-stent---w--l--gore---associates-/2021-09-24T07:09:38+00:00weekly0.6https://www.medthority.com/news/2015/09/significant-cv-benefits-shown-for-jardiance--empagliflozin--in-type-2-diabetes-patients-boehringer-eli-lilly/2024-02-13T09:10:36+00:00weekly0.6https://www.medthority.com/news/2012/11/relax-af-trial-positive-for-serelaxin--novartis--for-acute-heart-failure---------------/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2016/04/post-marketing-study-of-xarelto--rivaroxaban--confirms-bleeding-rates-in-patients-with-atrial-fibrillation--bayer-healthcare-janssen/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-advisory-committee-does-not-recommend-oxycodegol---nktr-181--as-a-treatment-for-chronic-pain-and-the-drug-is-withdrawn---nektar-therapeutics/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-snda-for-xofluza-for-the-treatment-of-influenza-in-people-at-high-risk-of-complications---genentech-roche/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2017/11/eu-approves-trelegy-ellipta-triple-therapy-to-treat-copd---gsk/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-trial-of-f-627-meets-primary-endpoint-in-chemotherapy-induced-neutropenia---generon-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-shows-benefits-with-amg-145-in-hofh---amgen/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2013/01/positive-results-from-study-of-symphony-tcgm-system--echo-therapeutics--in-critically-ill-patients/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-first-generic-advair-diskus-to-treat-asthma-and-copd---mylan/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2012/10/mk-3103--merck-inc---success-in-phase-iib-study-for-type-2-diabetes/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2018/04/two-year-overall-survival-data-from-checkmate-141-trial-of-opdivo-for-treatment-of-head-and-neck-cancer---bms/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2019/04/stellar-3-phase-iii-study-of-gs-4997-fails-to-meet-endpoint-in-nash/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2015/04/celgene-fulfills-fda-accelerated-approval-requirements-for-pomalyst-imnovid--pomalidomide-for-multiple-myeloma-/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-the-dexcom-g5-mobile-continuous-glucose-monitoring-system-for-diabetes--dexcom/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-510--k--approval-for-velocity-cancer-imaging-software-for-y90-selective-internal-radiation-therapy--sirt--dosimetry-analysis---varian-medical-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2011/10/resection-with-erbitux-boosts-survival-in-colorectal-cancer-patients-with-liver-metastases/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-eradicate-hp-trial-of-rhb-105-in-helicobacter-pylori-bacterial-infection-meets-endpoint--redhill-biopharma/2024-02-13T09:10:47+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-therascreen-kras-rgq-pcr-kit--qiagen--for-use-with-colorectal-cancer-patients------------------------------/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2018/09/boehringer-acquires-viratherapeutics-and-with-it-vsv-gp/2025-10-16T11:27:25+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-grants-priority-review-to-jakafi-which-is-filed-for-acute-graft-versus-host-disease---incyte-corp-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-supplemental-new-drug-application-for-spiriva-respimat--tiotropium-bromide--in-asthma-in-people-age-6-and-older--boehringer-/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-advisory-committee-rejects-serelaxin-for-acute-heart-failure---novartis/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-data-from-phase-iii-study-of-dificid-dificlir--optimer-pharma--for-patients-with-cdad/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2017/12/positive-phase-iii-innovate-trial-for--imbruvica---rituximab-for-waldenstr-m-s-macroglobulinemia---abbvie-/2021-09-24T07:13:41+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-and-eu-accept-submissions-from-biogen-idec-for-plegridy-to-treat-multiple-sclerosis/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2011/10/flutiform-delays-in-eu-for-treatment-approval-for-asthma/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-committee-supports-hyq-via-for-primary-immune-deficiency---baxter/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2014/02/abbvie-reports-completion-of-triple-therapy-combination-programme-for-hepatitis-c/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-accepts-filing--sbla--of-opdivo--nivolumab-to-treat-metastatic-urothelial-carcinoma--bladder-cancer---bms-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-pre-market-approval-for-stellarex--drug-coated-balloon--dcb---to-restore-and-maintain-blood-flow-to-the-superficial-femoral-and-popliteal-arteries-in-patients-with-peripheral-arterial-disease---spectranetics-corporation/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2016/02/european-commission-approves-tagrisso-to-treat-metastatic-epidermal-growth-factor-receptor--egfr--t790m-mutation-positive-nsclc--astrazeneca/2024-02-13T09:11:00+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-beacon-data-on-nktr-102-in-breast-cancer-nektar-therapeutics/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2019/05/novartis-presents-first-of-its-kind-algorithm-based-tool-to-help-evaluate-early-signs-of-progression-to-secondary-progressive-ms/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2019/07/the-new-horizons-of-dermatology/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2015/10/ux-001--aceneuramic-acid-prolonged-release--filed-with-eu-for-hereditary-inclusion-body-myopathy--ultragenyx-pharmaceutical/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-prestalia-for-hypertension-symplmed-pharma/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2014/06/gsk-pays-fines-in-us-for-illegal-promotion/2025-10-17T09:15:46+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-harvoni-for-hcv-in-adults-gilead-sciences/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2013/10/study-of-anti-fungal-isavuconazole-meets-primary-endpoint/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2018/08/advisory-committee-positive-for--omadacycline-for-absssi-and-cabp---paratek-pharmaceuticals-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2015/09/england-high-court-approves-merger-between-sorin-and-cyberonics/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2016/04/sanofi-seeks-to-acquire-medivation-/2025-10-16T11:03:29+00:00weekly0.6https://www.medthority.com/news/2014/12/sandoz-announced-phase-iii-data-for-biosimilar-filgrastim--and-filing-at-fda--for-treatment-of-neutropenia/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-myobloc-for-sialorrhea---us-world-meds/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2019/01/updated-results-from-phase-iii-beacon-crc-trial-evaluating-braftovi---mektovi---erbitux-for-brafv600e-mutant-colorectal-cancer---array-biopharma/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-trial-of-rhb-105-meets-primary-endpoint-for-helicobacter-pylori-bacterial-infection--redhill-biopharma/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2014/06/data-from-phase-iii-trials-of-empagliflozin-and-linagliptin-combo-for-t2d---boehringer-eli-lilly/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2012/12/bayerhealthcare-submits-alpharadin-to-ema-for-treatment-of-castration-resistant-prostate-cancer/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2015/03/post-hoc-analysis-of-examine-trial-for-nesina--alogliptin--showed-no-increased-risk-of-heart-failure-risk--takeda/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2012/05/tasgina-updates-of-enest-programme-in-ph-cml-presented-at-asco-meeting/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-aimovig-for-prevention-of-migraine---novartis---amgen-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2016/10/astellas-acquires-ganymed-ag-and-with-it-imab-362-a-therapy-for-gastroesophageal-cancer/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2014/07/european-commission-approves-gazyvaro-for-treatment-of-cll---roche/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2011/10/xarelto-shows-benefit-for-acs-patients/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2013/11/dual-dose-cervarix--gsk--beneficial-for-cervical-cancer/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-cotempla-xr-odt---methylphenidate-extended-release-orally-disintegrating-tablet--to-treat-adhd---neos-therapeutics/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2015/10/advanced-accelerator-applications-announces-phase-iii-positive-results-for-lutathera--177lu-dotatate--to-treat-neuroendocrine-tumours/2024-02-13T09:14:33+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-trial-of-darzalex--daratumumab-----revlimid---dexamethasone-meets-primary-pfs-endpoint-in-multiple-myeloma--genmab/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2015/09/interim-analysis-supports-phase-iii-data-for-ofev--nintedanib--in-idiopathic-pulmonary-fibrosis--boehringer-ingelheim/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2018/06/nejm-publishes-data-from-cemiplimab-trials-in-advanced-cutaneous-squamous-cell-carcinoma----sanofi---regeneron-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2018/03/eu-approves-alofisel-for-crohns-disease--the-first-allogeneic-stem-cell-therapy-centrally-approved-in-eu---tigenix---takeda-/2024-07-26T09:00:32+00:00weekly0.6https://www.medthority.com/news/2015/11/final-results-of-cobrim-study-with-cotellic--cobimetinib----zelboraf--vemurafenib--show-survival-benefits-in-metastatic-melanoma--genentech-roche/2024-02-13T09:14:42+00:00weekly0.6https://www.medthority.com/news/2013/10/apremilast--celgene--phase-iii-success-for-enthesitis-and-dactylitis-patients-/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2019/05/sandoz-licences-eg-12014--trastuzumab-biosimilar--from-eirgenix--/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2017/12/ash-2017---which-trainees-are-being-recognised-this-year-/2021-09-24T07:13:43+00:00weekly0.6https://www.medthority.com/news/2019/12/aurora-phase-iii-trial-of-luveniq-meets-primary-endpoint-in-lupus-nephritis---aurinia-pharma/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-chmp-recommends-approval-of-fexeric--ferric-citrate-coordination-complex--in-hyperphosphatemia--keryx/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2013/08/ly-801221--eli-lilly--meets-end-point-in-nsclc-trial/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2016/01/rolling-submission-to-fda-for-translarna--ataluren--completed-for-duchenne-muscular-dystrophy-indication--ptc-therapeutics/2024-02-13T09:14:54+00:00weekly0.6https://www.medthority.com/news/2017/03/-482-phase-iii-study-shows-xgeva--denosumab--non-inferior-to-zoledronic-acid-in-the-prevention-of-bone-complications-in-patients-with-newly-diagnosed-multiple-myeloma--amgen/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2012/10/xalkori--pfizer--is-eu-approved-conditionally-for-non-small-cell-lung-cancer/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2015/11/pegfilgrastim-biosimilar-filed-with-fda-for-neutropenia--sandoz/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2015/10/valeant-pharma-establishes-ad-hoc-board-committee-to-investigate-and-clarify-its-relationship-with-philidor/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2016/11/platinum-study-of-the-promus-premier-everolimus-eluting-platinum-chromium-coronary-stent-finds-little-difference-in-outcomes-between-patients-groups-in-coronary-artery-disease--boston-scientific/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2014/07/genentech-acquires-seragon-pharmaceuticals-for--725-million/2025-10-16T10:56:25+00:00weekly0.6https://www.medthority.com/news/2018/01/in-a-human-abuse-potential-study--nasal-administration-remoxy-resulted-in-significantly-lower-abuse-potential-compared-to-immediate-release--ir--oxycodone--pain-therapeutics-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-gives-accelerated-approval-to-lorbrena-for-alk-positive-metastatic-non-small-cell-lung-cancer---pfizer-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-accepts-filing-of-zynquista-for-type-1-diabetes---sanofi-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-accepts-elexacaftor--tezacaftor-and-ivacaftor--triple-therapy--to-treat-cystic-fibrosis-and-assigned-a-pdufa-date-of-19-march-2020--vertex-pharma/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-recommends-keytruda-pembrolizumab-for-use-in-advanced-melanoma/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2016/06/amg-334--erenumab--trial-success-in-chronic-migraine-prevention--novartis---amgen/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-two-year-results-in-study-of-promus-element-cardiac-stent--boston-scientific-/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-issues-warning-of-cv-risk-with-testosterone-products/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-trials-show-dysport-offers-benefits-in-cervical-dystonia-ipsen-pharma/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-lgx-818-and-mek-162--encorafenib---binimetinib--in-metastatic-melanoma-meets-primary-endpoint--array-biopharma-and-pierre-fabre/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2015/12/trial-results-for-zephyr-ebv-therapy-in-severe-emphysema-published-in-new-england-journal-of-medicine--pulmonx-/2024-02-13T09:15:20+00:00weekly0.6https://www.medthority.com/news/2018/07/eli-lilly-announced-initiation-of-the-observational-survey-of-the-epidemiology--treatment-and-care-of-migraine--overcome--study-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/04/gsk-recalls-flulaval-quadrivalent-influenza-vaccine-in-the-us-/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2015/04/chmp-recommends-lixiana--edoxaban---for-non-valvular-af--and-deep-vein-thrombosis-and-pulmonary-embolism-daiichi-sankyo/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2016/09/flutiform--fluticasone-plus-formoterol--fails-phase-iii-trial-for-treatment-of-copd---vectura---mundi/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2016/10/s-trac-phase-iii-data-on-sutent--sunitinib--as-adjuvant-therapy-in-renal-cell-carcinoma-shows-extension-in-disease-free-survival--pfizer/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-give-510-k--approval-for-turbo-tandem-elite-isr-for-pad---spectranetics-/2021-09-24T07:08:48+00:00weekly0.6https://www.medthority.com/news/2019/02/bayer-acquires-global-rights-to-vitrakvi-and-loxo-195-/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2018/06/tresiba-demonstrated-significantly-improved-blood-sugar-control-and-lower-rates-of-hypoglycaemia-versus-insulin-glargine-u300-in-confirm-real-world-evidence-study---novo-nordisk-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-recommends-aubagio--sanofi-genzyme--for-multiple-sclerosis/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2013/03/champion-phoenix-phase-iii-trial-of-cangrelor--medicines-company--success-in-pci/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-jetrea--thrombogenics-nv--for-the-treatment-of-vitreomacular-adhesion-/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-accepts-bla-for-tildrakizumab--a-proposed-treatment-for-psoriasis---sun-pharma-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2018/10/interim-results-from-nurture--an-ongoing-efficacy-and-safety-study--of-spinraza--in-25-presymptomatic-infants-with-sma--biogen/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2013/04/remedee-study-of-combo-dual-therapy-stent--orbus-neich--meets-primary-endpoint/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2019/04/mesoblast-ltd-makes-rolling-submission-to-fda-for-remestemcel-l-in-children-with-steroid-refractory-acute-graft-versus-host-disease-/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2019/08/complete-response-letter-for-hetlioz-for-the-treatment-of-jet-lag-disorder--vanda-pharma/2021-09-24T07:17:47+00:00weekly0.6https://www.medthority.com/news/2014/07/paratek-pharma-acquires-transcept-pharma/2025-10-16T11:34:35+00:00weekly0.6https://www.medthority.com/news/2016/05/falcon--phase-iii-trial-shows--faslodex--fulvestrant--superior-toarimidex--anastrozole--for-the-treatment-of-metastatic-breast-cancer-astrazeneca/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2018/09/tecentriq---chemotherapy-improved-overall-survival-in-impower133-study--for-first-line-sclc---roche/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-resonate-family-of-implantable-cardioverter-defibrillator-and-cardiac-resynchronization-therapy-defibrillator-systems-with-longer-life-batteries---boston-scientific/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2016/06/complete-response-letter-for-apadaz---benzhydrocodone-and-acetaminophen-for-acute-pain--kempharm/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2014/05/ceftolozane-tazobactam-positive-data-for-uti-and-ciai-infections---cubist/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-results-for-nn-9535--semaglutide-subcutaneous--meets-objectives-and-shows-superiority-over-exenatide-for-type-2-diabetes--novo-nordisk/2024-02-13T09:15:34+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-again-rejects-nexavar---sorafenib--as-a-treatment-for-liver-cancer--bayer/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2017/05/nice-rejects-mysimba--bupropion-and-naltrexone--as-a-treatment-for-obesity---orexigen/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-recommends-comtriq-from-ipsen--nexavar-from-bayer-and-lenvima-from-eisai-as-treatments-for-thyroid-cancer-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-kyprolis--carfilzomib---revlimid--lenalidomide----dexamethasone-to-treat-multiple-myeloma--amgen-/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2019/10/opdivo---low-dose-yervoy--in-checkmate--9la--trial--for-the-first-line-treatment-of-advanced-non-small-cell-lung-cancer-met-its-primary-endpoint-of-superior-overall-survival----bms/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-extends-pdufa--date-for-probuphine--buprenorphine-implant-for-maintenance-treatment-of-opioid-addiction-to-27-may-2016---titian-pharma---braeburn-pharma/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2015/09/topline-results-in-four-phase-iii-trials-of-sovaldi---gs-5816--sofosbuvir---velpatasvir--in-hepatitis-c--gilead-sciences/2024-02-13T09:18:15+00:00weekly0.6https://www.medthority.com/news/2014/03/corevalve-system-meets-endpoint-in-study-of-aortic-stenosis---medtronic/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-eperzan-albiglutide--for-type-2-diabetes-gsk/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-ease-lid-2-study-of-gocovri-shows-drug-well-tolerated-in-parkinson-s-disease---adamas-pharma-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2015/11/study-demonstrates-cost-effectiveness-of-in-pact-admiral-drug-eluting-balloon-in-peripheral-artery-disease--medtronic/2024-10-22T08:17:44+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-results-for-jardiance-in-type-2-diabetes-boehringer-eli-lilly/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-exjade--novartis--to-treat--non-transfusion-dependent-thalassemia-/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2014/04/bax-111-completes-successful-phase-iii-trial-for-von-willebrand-disease---baxter/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2019/04/post-hoc-analyses-of-phase-iii-trial-of-buvidal-consistent-with-primary-endpoint-in-opioid-use-disorder---camurus/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-trial-shows-once-daily-isentress--raltegravir--non-inferior-to-twice-daily-formulation-for-hiv--merck-inc/2024-02-13T09:18:26+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-expands-indication-of-medtronic-pacemakers-and-defribillators/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-raises-doubts-on--eteplirsen--sarepta-for-duchenne-muscular-dystrophy/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-wilate-for-haemophilia-a---octapharma/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2015/04/mallinckrodt-acquires-ikaria-inc--for--2-3-billion-and-with-it-inomax--inhaled-nitric-oxide--/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2019/08/ema-accepts-maa-for-filgotinib-to-treat-rheumatoid-arthritis----gilead-sciences---galapagos-nv/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-trial-of-vectibix--panitumumab--meets-endpoint-in-colorectal-cancer-amgen/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2019/04/soligenix-reports-enrollment--stage-for-its-pivotal-phase-iii-trial-of-sgx-942--for--oral-mucositis-in-head-and-neck-cancer/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approvals-for-spiolto-respimat--tiotropium-olodaterol--for-treatment-of-copd--boehringer/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2018/01/ec-approves-adcetris-for-cd30-positive-cutaneous-t-cell-lymphoma---takeda-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-results-for-phase-iii-reach-2-study-of-cyramza-a-treatment-for-liver-cancer---eli-lilly-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2014/11/alirocumab-more-effective-than-zetia-in-odyssey-alternative-trial-for-ldl-c----regeneron---sanofi/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-warning-on-incretin-mimetic-drugs-for-type-2-diabetes-/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2015/03/nice-rejects-imnovid-for-multiple-myeloma-in-final-guidance-celgene/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-beacon-trial-with-erbitux---lgx-818---mek-162-shows-8-month-pfs-in-colorectal-cancer---array-biopharma---pierre-fabre/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2016/02/abbott-laboratories-acquires-kalila-medical-and-with-it-the-vado-steerable-sheath/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2012/02/nice-rejects-herceptin--roche--as-first-line-treatment-for-post-menopausal-breast-cancer/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-expended-indication-for-stelara--ustekinumab--in-moderate-to-severe-plaque-psoriasis---janssen-biotech-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2014/10/new-eeg-electrode-set-for-fast-and-easy-measurement-of-brain-function-abnormalities/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-chmp-recommends-approval-of-segluromet-for-type-2-diabetes---merck-inc-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2011/10/combination-vfend-plus-eraxis-fails-phase-iii-trial-for-aspergillosis/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2015/10/shire-announces-phase-iii-trial-for-cinryze--c1-esterase-inhibitor-human--to-treat-antibody-mediated-rejection-in-kidney-transplant-patients/2024-02-13T09:18:40+00:00weekly0.6https://www.medthority.com/news/2017/11/world-copd-day-2017/2024-10-22T08:06:46+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-zecuity--nupathe--migraine-patch/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2019/10/fevipiprant--zeal-1-and-2-phase-iii-trials--did-not-meet-the-primary-efficacy-endpoint-of-fev1-improvement-in-moderate-asthmatic-patients--novartis/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2012/03/dr-reddy-has-fda-approval-for-generic-seroquel-/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2017/04/amgen--files-sbla-with-fda-and-application-for-variation-of-maa-with-ema-for-xgeva--denosumab--to-prevent--skeletal-related-events--sres--in-solid-tumors-to-include-patients-with-multiple-myeloma--amgen/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2018/11/astrazeneca-to-divest-us-rights-to-synagis-to-sobi-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2016/08/ampligen--rintatolimod--secures-approval-in-argentina-to-treat-severe-myalgic-encephalomyelitis-chronic-fatigue-syndrome----hemispherx-biopharm---gp-pharm-/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2019/01/the-ffrangio-system-enables-non-invasive--objective-functional-evaluation-of-multi-vessel-coronary-artery-disease-and-receives-fda-clearance---cathworks/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2013/05/study-shows-neurostar-tms--neuronetics--successful-for-patients-with-depression-/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2018/03/biogen-and-abbvie-withdraw-zinbryta-a-treatment-for-relapsing-multiple-sclerosis-/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-raxone--idebenone--to-treat-leber-s-hereditary-optic-neuropathy--lhon---santhera/2024-02-20T10:06:48+00:00weekly0.6https://www.medthority.com/news/2014/12/eu-approves-moventig-for-opioid-induced-constipation--astrazeneca/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2020/02/keytruda-met-one-of-its-primary-endpoints-in-phase-iii-keynote-355-trial---chemotherapy-for-metastatic-triple-negative-breast-cancer---merck-inc-/2021-09-24T07:12:05+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-trial-of-promacta-revolade-meets-primary-endpoint-in-thrombocytopenic-purpura---gsk/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2019/01/european-commission-approves-orkambi-for-the-treatment-of-children-with-cystic-fibrosis-aged-2-to-5-years-old-who-have-two-copies-of-the-f508del-mutation----vertex-pharma/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-gintuit--organogenesis--for-mucogingival-conditions/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-gazyva--obinutuzumab---bendamustine-to-treat-follicular-lymphoma--genentech-roche/2024-02-06T15:07:43+00:00weekly0.6https://www.medthority.com/news/2017/02/real-world-analysis-of-pradaxa--dabigatran-etexilate-mesylate--shows-benefits-over-warfarin-in-non-valvular-atrial-fibrillation--boehringer/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2017/04/new-data-for-ocrevus--ocrelizumab--from-phase-ii-and-phase-iii-trials--for-relapsing-or-primary-progressive-forms-of-multiple-sclerosis----genentech-roche/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2019/11/protector-1-phase-iii-study--evaluating-rtb-101-for--symptomatic-respiratory-illness-did-not-meet-its-primary-endpoint----restorbio--inc-/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2016/04/successful-phase-iii-checkmate-041-trial-for-opdivo--nivolumab--for-metastatic-squamous-cell-carcinoma-of-the-head-and-neck--bms-/2024-02-06T15:09:21+00:00weekly0.6https://www.medthority.com/news/2017/01/ardelyx-inc---initiates-phase-iii-trial-of-rdx-7675-to-treat-hyperkalemia-/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-botox-to-treat-pediatric-patients--2-to-17-years-of-age--with-upper-limb-spasticity---allergan-plc-/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2013/01/eu-approves-tresiba-and-ryzodeg--novo-nordisk--for-diabetes/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-corpath-200--corindus-inc--robotic-assisted-system-for-pci/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-amplatzer-piccolo--occluder-to-treat-patent-ductus-arteriosus--abbott/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2018/03/largest-study-of-its-kind-finds-alcohol-use-biggest-risk-factor-for-dementia/2024-02-22T15:17:11+00:00weekly0.6https://www.medthority.com/news/2013/09/analysis-shows-positive-safety-data-for-tradjenta-in-t2d/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-mylotarg-for-previously-untreated--de-novo--cd33-positive-aml-and-bosulif-for--chronic-phase-philadelphia-chromosome-positive-chronic-myelogenous-leukemia---pfizer-/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2018/02/plenvu-superior-to-moviprep-in-mora-study-for-bowel-cleansing-procedures-for-colorectal-cancer---norgine-b-v-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-accepts-supplemental-new-drug-application-for-kalydeco--ivacaftor--in-patients-aged-2-and-older-with-one-of-23-cystic-fibrosis-ctfr-mutations--vertex-pharmaceuticals/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-admire-cd-clinical-trial-of-cx-601--adipose-derived-stem-cells--shows-long-term-remission-in-crohn-s-disease--takeda-tigenix-/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-places-partial-hold-on-vx-135-for-hepatitis-c/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2012/12/tredaptive--merck-inc--fails-in-hps2-thrive-trial/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2019/09/castle-creek-holdings-to-acquire-fibrocell-science-inc-and-with-it-fcx-007-a-propsoed-treatment-for-epidermolysis-bullosa/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2016/10/new-phase-iii-data-for-nusinersen--a-treatment-for-spinal-muscular-atrophy---biogen-/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-pillcam-sb3-for-imaging-in-the-gi-tract/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-approval-of--subcutaneous-mabthera-for-nhl-roche/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2015/12/positive-results-from-sunburst-study-demonstrating-burst-stimulation-for-spinal-cord-pain--st-jude-medical/2024-02-06T15:10:07+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-hyqvia-for-treatment-of-primary-immunodeficiency--baxter/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2019/11/new-analysis-shows-vascepa-is-cost-effective-and-offers-better-outcomes-at-lower-cost-for-high-risk-patients-with-cv-disease---amarin-corporation/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-ventana-pd-l1--sp142--assay-as-diagnostic-for-non-small-cell-lung-cancer--roche/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-sirturo-for-tuberculosis-jansen-cilag/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2015/02/roche-buys-signature-diagnostics-ag/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-lartruvo--olaratumab--to-treat-soft-tissue-sarcoma---eli-lilly/2021-09-24T07:09:50+00:00weekly0.6https://www.medthority.com/news/2018/04/nice-recommends-use-of-tecentriq-in-non-small-cell-lung-cancer---roche-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2018/01/baremsis-is-filed-at-fda-for-post-operative-nausea---vomiting-treatment--acacia-pharma-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-vimizim-for-morquio-a-syndrome---biomarin/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2014/05/tresiba-to-launch-in-german-market-for-type-2-diabetes-subject-to-pricing-agreement---novo-nordisk/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2017/11/cost-effective-analysis-of-tresiba-for-types-1---2-diabetes---novo-nordisk/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2013/10/chmp-recommends-brintellix--lundbeck-takeda--for-depression/2024-10-21T14:50:24+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-sota-empa-study-of-zynquista-meets-primary-and-secondary-endpoints-in-type-2-diabetes---lexicon-pharma/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2016/10/rec-0482--fexapotide--shows-efficacy-in-phase-iii-trial-for-benign-prostatic-hyperplasia---nymox-pharmaceutical/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2011/10/byetta-is-fda-approved-for-use-with-insulin-glargine-in-type-2-diabetes/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-studies-of-seebri-breezhaler--novartis--for-patients-with-copd---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2016/03/nice-does-not-recommend-humira--adalimumab--to-treat-hidradenitis-suppurativa--abbvie/2024-10-22T08:03:08+00:00weekly0.6https://www.medthority.com/news/2017/01/myalept--metreleptin--filed-with-ema-for-leptin-deficiency-in-patients-with-congenital-or-acquired-generalized-lipodystrophy--novelion-therapeutics/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2016/09/cnto-136--sirukumab--filed-with-eu-for-rheumatoid-arthritis--glaxosmithkline---janssen/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2018/09/supernus-pharmaceuticals-acquires-biscayne--neurotherapeutics-and-with-it-spn-817-a-new-drug-for-epilepsy-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2016/03/ec-approves-teva-s-acquisition-of-allergan-s-generics-business/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2015/05/cdi-service-evaluation-study-of-dificlir--fidaxomicin-for--clostridium-difficile-infection--astellas/2026-01-29T10:42:18+00:00weekly0.6https://www.medthority.com/news/2018/03/tecentriq-and-avastin-combination-meets-primary-endpoints-in-phase-iii-impower150-study-for-non-squamous-nsclc---genentech-roche/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-gives-otc-approval-for-celluma-light-therapy-device-biophotas/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-trial-of-lenvima--lenvatinib--meets-primary-endpoint-in-hepatocellular-carcinoma--eisai/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2019/06/ce-mark-for-myval-transcatheter-aortic-heart-valve--meril-life-sciences-/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2018/01/recent-approvals-of-plenvu-bowel-cleansing-preparation----norgine-b-v-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2012/11/amg-134-success-in-gauss-study--in-patients-intolerant-of-statins---------------/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2015/07/lixilan-o-phase-iii-trial-of-insulin-glargine---lixisenatide-met-endpoints-in-type-2-diabetes-sanofi/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2013/12/mendel-2-trial-success-for--evolocumab-in-low-density-lipoprotein-cholesterol-amgen/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2017/07/reflections-b7391003-study---of-biosimilar-pf-06439535-versus-avastin--bevacizumab---met-its-primary-objective-for-treatment-of-nsclc---pfizer/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/09/chinese-regulatory-approval-for-elunate-to-treat-colorectal-cancer---hutchison-china-meditech--/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2018/06/both-ease-trials-of-empagliflozin---insulin-therapy-met-endpoints-in-adults-with-type-1-diabetes---eli-lilly---boehringer-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2013/06/takeda-files-vedolizumab-at-fda-for-crohns-disease-and-ulcerative-colitis/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2017/10/symtuza-found-to-improve-viral-response-rate-in-hiv/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2012/07/benefit-assessment-finds-slight-advantage-of-gilenya--novartis--for-adults-with-multiple-sclerosis/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-results-for-roxadustat-versus-epoetin-alfa-as-treatment-of-anemia-in-incident-dialysis-patients-with-chronic-kidney-disease---fibrogen/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-recommends-approval-of-steglujan-for-type-2-diabetes---merck-inc----pfizer-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2012/07/phase-ii-results-positive-for-prochymal--osiris-therapeutics-following-myocardial-infarction/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2014/10/lancet-publishes-phase-iii-data-for-amg-145-in-fh---amgen/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-axium-neurostimulator-system-for-chronic-lower-limb-pain--st-jude-medical/2024-02-06T15:10:48+00:00weekly0.6https://www.medthority.com/news/2018/05/alnylam-pharmaceuticals-and-the-fda-agree-on-pivotal-study-design-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2015/11/astellas-initiates-phase-iii-trial-for-gilteritinib-in-aml/2024-02-06T15:11:04+00:00weekly0.6https://www.medthority.com/news/2017/06/positive-results-from-phase-iii--482--study-shows-xgeva--denosumab-non-inferior-to-zoledronic-acid-in-delaying-skeletal-related-event-in-patients-with-multiple-myeloma---amgen/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2015/11/astellas-to-acquire-ocata-therapeutics-for--379-million-and-with-it--retinal-pigment-epithelium--rpe--cell-therapies/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-approves-feiba-to-reduce-bleeding-in-haemophilia-patients-with-inhibitors-baxter/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-vargatef--boehringer--meets-primary-endpoint-in-patients-with-nsclc/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-first-cannabis-derived-drug-epidiolex-for--lennox-gastaut-syndrome-and-dravet-syndrome---gw-pharma-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-endear-study-of-spinraza--nusinersen--shows-reduction-in-the-risk-of-death-in-infants-with-spinal-muscular-atrophy--biogen/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-monarch-2-study-shows-ly-2835219--abemaciclib--plus-fulvestrant-improves-survival-in-advanced-breast-cancer--eli-lilly/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-assigns-priority-review-to-combination-ledipasvir---sofosbuvir-for-hepatitis-c--gilead/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-results-for-feraccru-accrufer-in-aegis-h2h-phase-iiib-non-inferiority-study----shield-therapeutics/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-data-on-lcz-696-for-heart-failure-published-in-circulation-novartis/2024-02-13T09:48:42+00:00weekly0.6https://www.medthority.com/news/2012/09/thalomid--celgene--successful-treatment-of-cough-associated-with-ipf/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-veltassa--patiromer-for-oral-suspension--to-treat-hyperkalemia--relypsa/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2019/05/allergenic-products-advisory-committee-to-review-ar-101-to-treat-peanut-allergy/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2018/06/european-commission-approves-tagrisso-as-monotherapy-for-treatment-of--nsclc-with-egfr-mutations---astra-zeneca/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2011/10/carillon-mitral-contour-system-receives-ce-mark-for-cardiac-surgery/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2014/07/ec-approves-envarsus-for-kidney-liver-transplant-rejection-veloxis-pharma/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2016/05/results-from-effortless-registry-study-on-emblem-subcutaneous-implantable-defibrillator-show-efficacy-for-cardiac-arrest--boston-scientific-/2021-09-24T07:09:33+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-sirturo--janssen-therapeutics--for-multi-drug-resistant-tuberculosis-/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2016/02/ptc-therapeutics-receives-refusal-to-file-letter-from-fda-for-translarna--ataluren--to-treat-nonsense-mutation-duchenne-muscular-dystrophy-/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-adzenys-xr-odt--amphetamine-extended-release-oral--for-adhd--neos-therapeutics/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2018/02/drugs--alcohol-and-suicides-contributing-to-alarming-drop-in-us-life-expectancy/2025-02-03T14:53:39+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-advisory-committee-issues-complete-response-letter-for-posidur-and-requires-further-studies---durect-corp/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-accrufer-to-treat-iron-deficiency----shield-therapeutics/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-paediatric-oral-formulation-of-orfadin--nitisinone--for-hereditary-tyrosinaemia-type-1--ht-1---sobi/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-in-phase-iii-study-of-vpriv--shire--for-gaucher-related-bone-disease-/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2015/10/simplexa-flu-a-b---rsv-direct-test--receives-fda-510-k--clearance-for-54-new-virus-strains--focus-diagnostics/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2017/05/successful-phase-iii-trial-of--feraheme--ferumoxytol-shows-non-inferiority-to-injectafer---ferric-carboxymaltose-injection--for-iron-deficienct-anaemia---amag-pharma/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2018/04/ferring-pharma-announces-positive-european-decentralised-procedure-for-testavan-to-treat-hypogonadism-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-grants-510-k--approval-for-xvision-spine-system-an-augmented-reality-guidance-system-for-surgery--augmedics/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-eu-approval-of-jentadueto--boehringer--for-type-2-diabetes/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2015/03/positive-results-from-odyssey-long-term-trial-for-praluent---alirocumab--for-hypercholesterolemia--sanofi---regeneron/2024-07-26T09:42:50+00:00weekly0.6https://www.medthority.com/news/2015/06/study-shows-flublok-quadrivalent-vaccine-effective-against-influenza--protein-sciences-corp/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2015/04/oncurious-nv-formed-to-develop-tb-403-for-the-treatment-of--pediatric-brain-tumors-/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2017/10/paam-2017/2024-07-26T09:42:21+00:00weekly0.6https://www.medthority.com/news/2012/07/autoric--cellaegis--receives-ce-mark-for-ami-patients/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2019/02/two-phase-iii-trials-of-dupixent-show-improvements-in--chronic-rhinosinusitis-with-nasal-polyps---sanofi/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-gilotrif--boehringer----companion-diagnostic-for-nsclc/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2019/03/finch-3-trial-of-filgotinib-achieved-its-primary-endpoint-in-methotrexate-naive-rheumatoid-arthritis-patients---gilead-sciences---galapagos-nv/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2013/12/samsca-filed-with-ema-for-polycystic-kidney-disease-otsuka/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2018/01/genmab-announces-it-is-removing-arzerra-from-the-chronic-lymphocytic-leukaemia-market-outside-the-us---genmab---novartis-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-lotus-edge-aortic-valve-system-to-treat-severe-aortic-stenosis/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2018/01/american-stroke-association-and-american-heart-association-international-stroke-conference-2018/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-approval-of-cialis--eli-lilly--for-benign-prostatic-hyperplasia--/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2016/03/lilly-changes-endpoint-of-expedition3-trial-of-solanezumab-for-alzheimers-disease-/2024-02-13T09:49:10+00:00weekly0.6https://www.medthority.com/news/2015/11/betrixaban-enters-phase-iii-trial-for-prevention-of-vte--portola-pharma/2024-02-13T09:49:19+00:00weekly0.6https://www.medthority.com/news/2018/02/belgian-society-of-medical-oncology-annual-meeting-2018--bsmo-2018-/2021-09-24T07:05:53+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-recommends-use-of-brilique--ticagrelor--at-reduced-dose-of-60-mg-to-reduce-risk-of-heart-attack---astrazeneca/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-application-for-ryplazim--plasminogen-replacement-therapy--in-plasminogen-deficiency---prometic-life-sciences-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-vaxchora-vaccine-for-cholera--paxvax/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2012/06/nice-recommends-xarelto-for-dvt-and-pe/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2020/01/top-line-results-from-phase-iii-b-simple-program-of-sb-206-for-the-treatment-of-molluscum-contagiosum---novan-inc-/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-phase-iii-data-from-two-studies-of-itca-650--exenatide-subcutaneous--in-type-2-diabetes-intarcia-therapeutics/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-austedo--deutetrabenazine--for-the-treatment-of-tardive-dyskinesia-in-adults--teva-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-evista-generic-from-teva/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2016/05/agn-199201--oxymetazoline-hcl-cream--filed-with-the-fda-for-rosacea---allergan/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-advisory-committee-recommends--invokana--canagliflozin---from-janssen-pharma-as-a-treatment-for-type-2-diabetes/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2019/04/united-therapeutics-to-discontinue-development-of-esuberaprost-for-pulmonary-arterial-hypertension-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2013/01/abraxane-celgene--success-in-mpact-trial-for-combination--treatment-of-pancreatic-cancer/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-ongentys--opicapone--for-parkinson-s-disease--bial/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2019/10/vertex-announces-agreement-with-nhs-england-for-access-to-all-licensed-cystic-fibrosis-medicines/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2019/02/roche-acquires-spark-therapeutics-and-with-it-luxturna-for-treatment-of-biallelic-rpe-65-mutation-associated-retinal-dystrophy/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-humira--abbott--for-patients-with-moderately-to-severely-active-ulcerative-colitis-/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-blockstone-study-of-xofluza-meets-primary-endpoint-in-influenza---genentech-roche/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2013/04/roche-diagnostics-launches-elecsys-calcitonin-thyroid-cancer-test/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2015/01/abbvie-reports-success-in-phase-iii-trial--m12-665--of-elagolix-for-endometriosis/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-affinity-pixie-oxygenation-system--medtronic-inc--for-use-in-heart-surgery-on-children---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-results-in-three-studies-of-gilenya--novartis--for-patients-with-multiple-sclerosis/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2011/10/kalydeco-filed-at-fda-for-cystic-fibrosis-treatment/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-gives-priority-review-for-ipi-145-in-relapsed-or-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma---verastem-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-kybella--sodium-deoxycholate--for-submental-fat-reduction--kythera-biopharma/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2012/08/nice-recommends-procoralan--servier--for-treatment-of-chronic-heart-failure/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-trial-of-gene-therapy-valoctocogene-roxaparvovec--is-initiated-to-treat-haemoplilia-a---biomarin--1/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2017/12/engineered-stem-cells-pave-way-for-safer-blood-transfusion-in-sickle-cell-disease/2021-09-24T07:13:39+00:00weekly0.6https://www.medthority.com/news/2017/10/long-term-extend-study-results-for-revolade--eltrombopag--to-treat-immune--idiopathic--thrombocytopenia----novartis-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2016/04/advisory-committee-recommends--nuplazid--pimavanserin--for-the-treatment-of-psychosis-associated-with-parkinson-s-disease--acadia-pharma/2021-09-24T07:10:51+00:00weekly0.6https://www.medthority.com/news/2018/05/successful-phase-iii-vista-trial-of-vicinium-to-treat-high-grade-non-muscle-invasive-bladder-cancer---sesen-bio-inc-/2024-07-26T09:41:38+00:00weekly0.6https://www.medthority.com/news/2015/06/dapagliflozin--saxagliptin-and-metformin--triple-therapy--success-in-phase-iii-trial-for-type-2-diabetes--astrazeneca-/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2013/11/roche-acquires-rights-to-pol-7080-for-pseudomonas-aeruginosa/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2019/07/walking-and-strength-training-may-decrease-the-risk-of-dying-from-liver-disease/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2015/03/successful-pegasus-timi-54-study-for-brilinta-for-prevention-of-atherothrombotic-events---astrazeneca/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-in-pact-dcb-for-treatment-of-peripheral-artery-disease--medtronic/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-micra-transcatheter-pacing-system--first-leadless-heart-pacemaker---medtronic/2021-09-24T07:10:46+00:00weekly0.6https://www.medthority.com/news/2019/04/pfizer-has-begun-enrollment-in-three-phase-iii-trials--evaluating-20-valent-pneumococcal-conjugate-vaccine-in-adults-/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-trial-of-sirolimus-for-uveitis-meet-primary-endpoint---santen/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2017/12/superiority-demonstrated-in-longer-term-results-of-phase-iii-studies-of-hemlibra-in-haemophilia-a---genentech-roche/2021-09-24T07:13:41+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-advisors-recommend-approval-of-ferriprox-for-iron-overload/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2015/01/dermira-and-ucb-initiate-phase-iii-programme-for-cimzia-in-plaque-psoriasis-/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2012/03/humira--abbott--in-2-phase-iii-trials-for-hidradenitis-suppurativa-/2024-10-22T08:01:28+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-approves-use-of-orbactiv--oritavancin--for-absssi--the-medicines-co-/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2012/09/18f-flutemetamol--ge-healthcare--beta-amyloid-studies-positive---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-fasenra-to-treat-severe-asthma-with-eosinophilic-phenotype---astarzeneca/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2017/05/abilify--aripiprazole--embedded-with-a-proteus-ingestible-sensor-is-re-filed-at-fda---otsuka---proteus-digital-health/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2018/01/epidiolex-is-filed--at-eu-for-adjunctive-treatment-for-seizures-associated-with-lennox-gastaut-syndrome-and-dravet-syndrome---gw-pharma/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2019/08/bayer-ag-acquires-bluerock-therapeutics/2025-10-16T11:31:36+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-gleevec--novartis--to-treat-ph-all/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---is-kidney-failure-a-man-s-disease-/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2015/05/mm-398--irinotecan-liposome-injection--is-filed-at-ema-for-treatment-of-adenocarcinoma-of-the-pancreas--baxter---merrimack-pharma/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2014/09/baxter-acquires-ex-us-and-ex-taiwan-rights-to-mm-398-from-merrimack-pharma-for-pancreatic-and-other-cancers-/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2015/09/viekirax--ombitasvir-paritaprevir-ritonavir--approved-for-genotype-1-hepatitis-c-in-japan--abbvie/2024-02-06T15:11:30+00:00weekly0.6https://www.medthority.com/news/2016/02/ce-mark-for-expanded-size-of-resolute-onyx-des-stent-for-cad--medtronic-/2021-09-24T07:09:04+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-approval-of-dzuveo-for-acute-moderate-to-severe-pain---acelrx-pharma-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2019/07/chmp-recommends-larotrectinib-to-treat-solid-tumors-with-a-neurotrophic-tyrosine-receptor-kinase--ntrk--gene-fusion---bayer-healthcare-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-gamifant-to-treat-primary-haemophagocytic-lymphohistiocytosis---swedish-orphan-biovitrium/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2013/06/eu-approves-quadra-assura-mp-crt-d--st-jude-medical--for-heart-failure/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2014/03/nice-recommends-inlyta-for-renal-cell-carcinoma---pfizer/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-palisade-trial-of-ar-101-meets-primary-endpoint-in-patients-with-peanut-allergy---aimmune-therapeutics-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2019/06/a-single-course-of--prv-031-delays-type-1-diabetes-onset-in-high-risk-individuals-by-at-least-two-years---provention-bio-inc-/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2016/01/tenofovir-alafenamide-filed-with-fda-for-hepatitis-b--gilead/2024-02-06T15:11:42+00:00weekly0.6https://www.medthority.com/news/2017/03/eu-approves-xeljanz--tofacitinib-citrate--for-rheumatoid-arthritis--pfizer/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-xen-glaucoma-treatment-system-to-treat-refractory-glaucomas--allergan/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2018/06/sutent-improves-survival-in-renal-cell-carcimoma-patients-who-can-avoid-surgery--pfizer-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-mammomat-revelation-for-breast-biopsies--siemens-healthineers-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-advisory-committee-rejects-nebivolol---valsartan-combination-for-hypertension--forest-actavis/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2017/09/independent-data-monitoring-committee-determines-that-phase-iii-study-of-prostvac-in-prostate-cancer-should-not-continue---bavarian-nordic-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2016/07/study-of-chemosat--melphalan-for-injection--shows-survival-benefit-in-metastatic-uveal-melanoma-patients--delcath-systems/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-gore-cardioform-septal-occluder-to-prevent-recurrent-ischaemic-strokes----w--l--gore---associates--inc-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2016/09/merck-inc--discontinues-development-of-odanacatib--a-proposed-treatment-for-osteoporosis-/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2016/07/new-phase-iii-results-for-aln-ttr02--patisiran--in-hereditary-ttr-mediated-amyloidosis-shows-evidence-for-patient-cardiac-disease--alnylam-pharma/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-reflect-study-of-lenvima-in-hepatocellular-carcinoma-published-in-the-lancet---eisai-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2018/10/momenta-prioritizes-biosimilar-developments-with-mylan-and-restructures-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-results-for-n-1539-in-pain-published-in-clinical-journal-of-pain---recro-pharma-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-olumiant-to-treat-rheumatoid-arthritis----eli-lilly-/2024-07-26T09:01:07+00:00weekly0.6https://www.medthority.com/news/2018/01/best-of-san-antonio-breast-cancer-symposium-san-francisco-2018/2024-10-22T08:23:43+00:00weekly0.6https://www.medthority.com/news/2018/11/ce-mark-for-philips-v60-plus-ventilator-system--royal-philips/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2012/12/jaydress--bayer-levonorgestrel-releasing-intrauterine-contraceptive-is-eu-approved/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2015/06/two-phase-iii-trials-results-for-amg-416-for-secondary-hyperparathyroidism-in-ckd-patients--amgen/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2014/09/analysis-from-shift-study-confirms-role-of-ivabradine-in-reduction-of-risk-in-heart-failure-amgen/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2016/09/baxter-announces-european-launch-of-numeta-g13e-300-ml--the-only-ready-to-use-parenteral--intravenous--nutrition--pn--product-available-to-treat-preterm-infants-/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2019/08/dupixent-success-in-phase-iii-trial-to-treat-children-with-atopic-dermatitis/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-indicates-way-forward-for-ataluren-application-to-treat-duchenne-muscular-dystrophy---translarna-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2015/08/kythera-biopharmaceuticals-files-maa-in-european-union-for-atx-101--deoxycholic-acid--to-reduce-submental-fat--double-chin-/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-provides-complete-response-letter-for-rolapitant-iv-new-drug-application-for-delayed-nausea-and-vomiting--tesaro/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-in-trial-of-solitaire--covidien--for-blood-flow-restoration/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2015/05/opdivo---nivolumab--superior-to-docetaxel-in-nsclc--bms/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2015/06/gardasil-9-vaccine-for-hpv-approved-for-use-in-the-eu-sanofi-pasteur-msd/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2014/09/iqwig-finds-added-benefit-for-olysio-in-certain-hcv-patient-groups-j-j-janssen-cilag/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2017/10/defence-is-the-best-attack--immuno-oncology-breakthroughs-conference-draws-to-a-close/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-yescarta--for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--dlbcl--and-primary-mediastinal-large-b-cell-lymphoma--pmbcl---kite-gilead-sciences-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-approval-of-vokanamet-for-t2d---janssen/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2015/04/pradaxa-snda-filed-with-fda-for-dvt-and-pe-in-patients-after-hip-replacement-boehringer/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-study-of-eg-1962-is-discontinued-for-treatment-of-aneurysmal-subarachnoid-hemorrhage---edge-therapeutics-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2014/10/implanted-miniature-telescope-has-fda-approval-broadened-for-amd--visioncare-ophthalmic-technologies-/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2014/10/updated-results-in-study-of-ampion-for-osteoarthritis-knee--ampio-pharma/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2017/06/biosimilar-concerns-of-rheumatology-patients-being-addressed-by-national-programme-in-denmark-1/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-approves-subcutaneous-formulation-of-mabthera-for-follicular-lymphoma-and-nhl--roche-genentech/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2014/02/results-on-enterovirus-71-for-hfm-disease-published-in-nejm-sinovac-biotech/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2013/01/zerenex--keryc-biophrama--succuss-in-phase-iii-trial-for-hyperphosphatemia/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2019/08/diroximel-fumarate-superior--to-tecfidera-for-gastrointestinal-tolerability-on-evolve-ms-2-study-s-primary-endpoint/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-amplia-mri-quad-crt-d-surescan-and-compia-mri-quad-crt-d-surescan-systems-for-heart-failure--medtronic/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-memo-4d-mitral-annuloplasty-ring-for-treatment-of--mitral-regurgitation---livanova-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-play-study-of-exparel-shows-safety-in-pediatric-post-surgical-pain-treatment---pacira-biosciences/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-supplemental-nda-for-aptiom--eslicarbazepine-acetate--monotherapy-to-treat-partial-onset-seizures--sunovion---eisai/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2015/07/topline-safety-results-from-phase-iii-trial-of-lpcn-1021-in-hypogonadal-men--lipocine/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2017/11/biogen-secures-exclusive-worldwide-licence-from-alkermes-to-market-alks-8700-to-treat-multiple-sclerosis-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2012/03/results-of-study-102-for-quad--gilead--for-hiv/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2015/11/positive-two-year-data-for-cosentyx--secukinumab--from-future-1-study-for-psoriatic-arthritis--novartis/2024-02-06T15:12:05+00:00weekly0.6https://www.medthority.com/news/2015/02/the-medicines-company-buys-annovation-biopharma-and-with-it-abp-700/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2017/11/sub-analysis-of-engage-af-timi-48-trial-showed-lixiana-has-greater-reductions-in-ischaemic-events--compared-to-warfarin---daiichi-sankyo-/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2018/05/positive-follow-up-data-from-phase-iii-alex-study-of-alecensa-shows-reduced-risk-of-disease-progression-or-death-in-alk-positive-nsclc---genentech-roche/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2016/12/plazomicin-meets-objective-of-non-inferiority-in-phase-iii-trials-for-urinary-tract-infections--achaogen-/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2013/06/eu-approves-roactemra--roche--for-polyarticular-juvenile-idiopathic-arthritis/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2017/06/nice-now-recommends--daxas--roflumilast--to-treat-severe-copd---astrazeneca/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2018/02/allergan-to-acquire-elastagen-pty-ltd-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2016/11/intra-cellular-therapies-reports-results-from-its-clinical-development-program-of-iti-007-60-mg-for-schizophrenia-/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2014/08/european-commission-approves-daklinza-for-treatment-of-chronic-hepatitis-c--bms/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-postpones-decision-on-selinexor-to-treat-relapsed-refractory-multiple-myeloma---karyopharm-therapeutics/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2019/02/meteoric-hf-phase-iii-trial-of-omecamtiv-mecarbil-opens-enrollment-for-treatment-of-heart-failure--amgen---cytokinetics---servier/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-aingle-dose-formulation-of-makena--hydroxyprogesterone-caproate-injection--for-preterm-labour--amag-pharmaceuticals/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2019/09/european-commission-approves-keytruda-and-inlyta-combination-for-first-line-treatment-of-renal-cell-carcinoma--merck-inc--/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-restrictions-on-keytruda-and-on-tecentriq-for-bladder-cancer-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2019/09/enrollment-has-been-achieved-in-the-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-for-the-treatment-of-severe-and-moderately-severe-hemophilia-b--uniqure-n-v-/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-data-from-star-study-of-nanoknife-system-in-pancreatic-cancer-angiodynamics/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2017/03/post-hoc-analysis-of-paradigm-hf-study-shows-entresto--sacubitril-valsartan--improves-glycemic-control-in-patients-with-heart-failure--novartis/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2016/11/successful-results-for-erenumab-from-strive-phase-iii-study-for-treatment-of-migraine---amgen---novartis/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2015/11/detailed-results-from-phase-iii-study-ra-beam-of-ly-3009104--baricitinib--shown-superior-to-humira--adalimumab--in-rheumatoid-arthritis--eli-lilly-incyte/2021-11-26T14:49:16+00:00weekly0.6https://www.medthority.com/news/2015/08/astrazeneca-s-medimmune-licenses-therapies-from-inovio-pharma/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2018/02/european-and-canadian-phase-iii-study-shows-dwp-450-non-inferior-to-onabotulinumtoxina-for-treatment-of-glabellar-lines--evolus-inc-/2021-09-24T07:05:54+00:00weekly0.6https://www.medthority.com/news/2017/04/complete-response-letter-for-ccp-07-a-cough-cold-treatment-being-developed-for-vernalis-plc-by-partner-tris-pharma-/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2014/04/study-of-sovaldi-for-retreatment-of-patients-with-hep-c-shows-benefits-gilead/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2018/06/significant-benefits-of-abbott-s-freestyle-libre-system-for-people-living-with-diabetes-presented-at-ada-meeting---abbott-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2017/12/revlimid---rituximab-combination-fails-phase-iii--relevance-study-for-follicular-lymphoma---celgene-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-full-body-magnetic-resonance--mr--conditional-labeling-for-the-proclaim--elite-spinal-cord-stimulation--scs--system--st-jude-medical-/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2014/04/genzyme-plans-re-submission-at-fda-for-lemtrada-for-ms/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-novopen-echo-insulin-delivery-system/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2015/07/heartmate-php--percutaneous-heart-pump--receives-ce-mark-approval--thoratec/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2015/11/in-final-guidance-nice-recommends-harvoni--ledipasvir-sofosbuvir--in-hepatitis-c--gilead-sciences/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2012/09/successful-phase-iii-trial-for-rfixfc--biogen-sobi--for-haemophilia/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2015/06/pooled-analysis-of-otezla--apremilast--in-studies-palace-1-2-and-3-positive-for-treatment-of-enthesitis-and-dactylitis--celgene/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2019/05/mayzent-s-data-shows-a-positive-impact-on-cognitive-processing-speed-in-people-living-with-secondary-progressive-ms---novartis/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2014/07/nexavar---capecitabine-combination-fails-phase-iii-resilience-trial-for-her-2-negative-breast-cancer---bayer---onyx-pharma/2021-09-24T07:08:48+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-grants-de-novo-clearance-for-innovo-device-for-the-treatment-of-stress-urinary-incontinence---atlantic-therapeutics-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2017/02/nice-recommends-heartflow-ffrct-analysis-to-identify-the-cause-of-chest-pain---heartflow-inc-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-amyvid--eli-lilly---for-alzheimers-investigations---------------/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2013/12/pfizer-agreement-with-teva-relating-to-us-marketing-of-viagra/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2012/02/early-results-for-sm101--suppremol--are-encouraging-for-itp/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-iii-cruise-1-study-of-sfp--rockwell-medical--meets-primary-endpoint-for-iron-deficiency/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approves-cosentyx--secukinumab--to-treat-plaque-psoriasis--novartis/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2017/11/ardelyx--to-discontinue-development-of-rdx-7675-for-the-treatment-of-hyperkalemia-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2015/11/iqwig-finds-opdivo--nivolumab--offers-added-benefit-only-in-treatment-naive-patients-with-melanoma-braf-v600-tumour--bms/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2014/07/prostraken-acquires-archimedes-for--230-million-/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2014/06/losmapimod-enters-phase-iii-for-acute-coronary-syndrome---gsk/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-aproval-of-xospata-in-flt3--acute-myeloid-leukemia---astellas-pharma/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2016/05/chmp-recommends-approval-for-zinbryta--daclizumab--intended-for-the-treatment-of-relapsing-forms-of-multiple-sclerosis---biogen---abbvie/2024-02-06T15:12:21+00:00weekly0.6https://www.medthority.com/news/2019/05/updated-data-on-pledge-program-of-relamorelin-to-treat-diabetic-gastroparesis/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2014/05/sigma-spectrum-infusion-pump-has-510-k--clearance-from-fda--baxter/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2015/04/final-results-of-phase-iii-trial-of-rts-s-malaria-vaccine-published-in-the-lancet-glaxo-smith-kline/2024-02-13T09:19:47+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-ascend-trial-showed-calquence--prolonged-the-time-patients-live-without-disease-progression-in-chronic-lymphocytic-leukaemia--cll----astrazeneca/2021-09-24T07:16:55+00:00weekly0.6https://www.medthority.com/news/2014/10/imbruvica-filed-at-fda-to-treat-waldenstroms-macroglobulinemia-pharmacyclics-janssen/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2010/05/cel-sci-corpn-to-commence-phase-iii-trial-of-multikine-in-head-and-neck-cancer/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-gives-htx-011-priority-review-in-filing-for-post-operative-pain---heron-therapeutics-/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-avastin-with-chemotherapy-and-gemcitabine-for-ovarian-cancer/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-cobas-babesia-test-for-use-on-the-cobas-6800-8800-systems-for-individual-blood-donation-testing---roche/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-nda-for-remoxy-er-an-abuse-deterrent-extended-release-formulation-of-oxycodone-for-pain-control--pain-therapeutics-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2018/05/digestive-health-month/2024-07-26T09:01:49+00:00weekly0.6https://www.medthority.com/news/2015/11/monarch-etns-nerve-stimulation-system-receives-eu-ce-mark-approval-for-attention-deficit-hyperactivity-disorder--neurosigma/2024-02-06T15:13:18+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iv-emanate-trial-of-eliquis--apixaban--reports-data-for-patients-with-non-valvular-atrial-fibrillation--nvaf--undergoing-cardioversion-bms---pfizer-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-crl-rejects-macrilen-for-growth-hormone-deficiency-aeterna-zentaris/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2011/11/combo-dual-therapy-stent--orbus-neich--safe-and-effective-in-heart-disease-trial/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-telestar-study-results-with-xermelo-in-carcinoid-syndrome-published-in-clinical-therapeutics---lexicon-pharma-/2024-11-15T08:32:49+00:00weekly0.6https://www.medthority.com/news/2016/01/merck-acquires-iomet/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2018/06/coast-w-phase-iii-study-of-taltz-meets-primary-endpoint-in-ankylosing-spondylitis---eli-lilly-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-thiola-ec-new-formulation-to-treat-cystinuria/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-new-product-labelling-for-oxycontin--controlled-release-purdue-pharma--for-pain-management/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-olysio-for-hepatitis-c-janssen-r-d/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2019/11/uvadex-is-approved-in-australia-for-use-with-the-therakos-cellex-photopheresis-system-for-treatment-of-chronic-graft-versus-host-disease--cgvhd--and-skin-manifestations-of-cutaneous-t-cell-lymphoma-in-adults--mallinckrodt/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2015/05/rolling-fda-submission-for-drisapersen-for-duchenne-muscular-dystrophy-is-completed--biomarin/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-minimed-670g-system-in-patients-with-type-1-diabetes-seven-years-of-age-and-older--medtronic-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-accepts-xgeva--denosumab--sbla--to-expand-the-currently-approved-indication-to-include-patients-with-multiple-myeloma---amgen/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/11/eu-approves-votubia--novartis-for-renal-angiomyolipoma----------------/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/03/valeant-pharma-to-market-mysimba-contrave--naltrexone-hcl---bupropion-hcl-prolonged-release--to-treat-obesity-in-eastern-europe--orexigen-therapeutics/2021-09-24T07:10:23+00:00weekly0.6https://www.medthority.com/news/2017/11/tirasemtiv-development-ended-for-amyotrophic-lateral-sclerosis---cytokinetics-/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-extension-to-indication-for-briviact-in-epilepsy---ucb-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-intrarosa-implant--to-treat-dyspareunia--a-symptom-of-vulvar-and-vaginal-atrophy-due-to-menopause--endoceutics-inc-/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2016/11/uk-nice-reverses-earlier-negative-opinion-on-imbruvica--ibrutinib--in-chronic-lymphocytic-leukaemia-after-price-fall--janssen/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-pivotal-trial-results-for-sb-204--nitric-oxide--in-treatment-of-acne-vulgaris-shows-some-benefits--novan/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2018/09/interconnectivity-between-cardiovascular-and-renal-risks-in-diabetes-to-be-presented-by-astrazeneca-at-easd-meeting-/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2011/09/tradjenta-shows-long-term-benefits-for-type-2-diabetes-patients-1/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2016/06/fd-approves-auris-robotic-endoscopy-system--to-provide-bronchoscopic-visualization-of-patient-airways---auris-surgical-robotics-/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2019/07/intec-pharma-reports-top-line-phase-iii-trial-results-of-accordion-pill-carbidopa-levodopa-in-advanced-parkinson-s-disease-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2013/04/chmp-recommends-spedra--avanafil--as-a-treatment-for-erectile-dysfunction-in-adult-men/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2020/02/coherus-biosciences--acquires-licence-to-commercialise-ibi-305---bevacizumab-biosimilar--in-us-and-canada-from-innovent-biologics-/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2019/09/final-results-from-checkmate--227-part-1-demonstrating-superior-overall-survival-for-opdivo---low-dose-yervoy--vs--chemotherapy-in-advanced-non-small-cell-lung-cancer---bms/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-minimed--670g-system---the-first-hybrid-closed-loop-insulin-delivery-system-to-treat-type-1-diabetes--medtronic/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2012/03/renadyl--kibow-biotech--in-study-for-kidney-failure-patients/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2014/03/ligand-lundbeck-file-carbella-at-fda-for-epilepsy/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2018/11/vr-475-did-not-meet-endpoints-in-phase-iii-for-treatment-of-asthma--vectura/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2015/04/phase-iii-trial-of-md-1003-meets-primary-endpoint-in-multiple-sclerosis-medday/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2016/06/astrazeneca-claims-longer-patent-life-in-us-for-crestor--rosuvastatin--to-treat-dyslipidaemia-/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2012/07/sarepta-therapeutics-success-with-eteplirsen-in-phase-iib-trial-for-duchenne-muscular-dystrophy-/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2017/09/get--heart-healthy--on-world-heart-day/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2020/02/ema-validates-maa-for-kte-x19-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--kite-gilead/2021-09-24T07:12:00+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-results-with-nx-1207--fexapotide--shows-safety-and-efficacy-in-prostate-cancer--nymox-pharmaceutical-corp/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-dignicap-cooling-system-for-use-in-cancer-patients-with-solid-tumors--dignitana/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2012/10/turoctocog-alfa--novo-nordisk--filed-for-haemophilia-in-us-and-eu/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-advisory-committee-decision-limits-scope-of-praluent--alirocumab--to-limit-the-recommended-approval-to-treatment-of-heterozygous-familial-hypercholesterolemia--sanofi---regeneron-/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2013/07/sarepta-to-file-eteplirsen-at-fda-for-duchenne-muscular-dystrophy-in-early-2014/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2015/03/novartis-and-gsk-transfer-of-oncology-products-and-vaccines-completed/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-odefsey--emtricitabine-rilpivirine-tenofovir-alafenamide--for-hiv-aids--gilead-sciences/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-avastin-combined-with-chemo-followed-by-avastin-for-ovarian-cancer---genentech-roche-/2024-07-26T08:53:56+00:00weekly0.6https://www.medthority.com/news/2015/07/roche-revives-development-of-gantenerumab-in-phase-iii-trial-for-mild-alzheimer-s-related-dementia/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-provides-advice-for-amiket--epicept-inc--maa-in-treatment-of-peripheral-neuropathy/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-trial-evaluating-dupixent-in-atopic-dermatitis-meets-primary-endpoint---regeneron-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2018/01/nice-to-reassess-besponsa-for-cd-22-positive-b-cell-precursor-all---pfizer-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-xydalba--dalbavancin--for-absssi--durata-therapeutics-actavis/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-dificlir-for-clostrium-difficile/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-kanuma--sebelipase-alfa--to-treat-lysosomal-acid-lipase-deficiency---alexion-pharma/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-label-extension--for-ozempic-for-reduction-of-risk-of-major---adverse-cardiovascular-events-in-type-2-diabetes---novo-nordisk/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2018/02/data-analysis-shows-higher-rates-of-mucosal-healing-with-entyvio-in-ulcerative-colitis-and-crohn-s-disease---takeda-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2018/12/ef-14-phase-iii-trial-of-optune-in-glioblastoma-published-in-journal-of-neuro-oncology---novocure-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2017/05/nice-in-final-guidance-recommends-cimzia--certolizumab-pegol--from-ucb-and-cosentyx--secukinumab--from-novartis-to-treat-psoriatic-arthritis-/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2013/10/astrazeneca-initiates-phase-iii-for-selumetinib-for-nsclc/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2018/03/shingrix-approved-in-eu-and-japan-for-the-prevention-of-shingles--herpes-zoster--and-post-herpetic-neuralgia----gsk-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-tivicay-for-hiv-infection/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2019/01/bms-withdraws-sbla-for-opdivo---yervoy--low-dose--for-nsclc-patients-with-tumor-mutational-burden-/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-envista-acrylic-intraocular-lens--bausch---lomb-ophthalmic--for-cataract-surgery/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-accepts-sbla-for-tecentriq---abraxane---carboplatin-to-treat-metastatic-nsclc-patients-who-do-not-have-egfr-or-alk-genomic-tumor-aberrations--genentech-roche/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2012/10/tresiba--novo-nordisk--superior-to-lantus-in-lowering-hypoglycaemia-in-type-2-diabetes-patients----------------/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-cobas-egfr-mutation-test-v2-companion-diagnostic-for-tagrisso--osimertinib--for-t790m-mutated-metastatic-epidermal-growth-factor-receptor--egfr--mutation-positive-non-small-cell-lung-cancer--astrazeneca/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2012/08/nice-recommends-xgeva-for--as-a-treatment-for-people-with-bone-metastases-from-most-solid-cancer-tumours-including-breast-cancer/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2019/06/two-phase-iii-studies-of-ultra-rapid-lispro-show-a1c-reductions-in-type-1-2-diabetes---eli-lilly/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2013/10/benralizumab--astrazeneca--moves-into-phase-iii-for-asthma/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-of-afinitor--everolimus--to-treat-neuroendocrine-tumors--net--of-gi-or-lung-origin--novartis/2024-02-06T15:13:59+00:00weekly0.6https://www.medthority.com/news/2019/12/eli-lilly-announces-the-launch-of-triumph--long-term--real-world-evidence-study-of-emgality-in-migraine-/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2014/07/nivolumab-is-approved-in-japan-for-unresectable-melanoma--ono-bms/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-expands-indication-of-ibrance-to-include-her2--breast-cancer-in-males---pfizer/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2014/06/valeant-makes-offer-direct-to-allergan-shareholders-in-hostile-bid/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2011/12/zometa--novartis--shows-clear-benefits-for-premenopausal-er-positive-breast-cancer-patients-/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2019/10/amag-reports-on-fda-advisory-committee-meeting-to-consider-status-of-makena-which-has-been-approved-to-reduce-preterm-birth-/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2019/06/award-11-phase-iii-of-trulicity-meets-endpoints-in-type-2-diabetes---eli-lilly/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2017/10/nice-recommends-opdivo-to-treat-head-and-neck-cancer---bms-/2021-09-24T07:13:23+00:00weekly0.6https://www.medthority.com/news/2018/01/biocryst-pharmaceuticals--inc-and-idera-pharmaceuticals-inc--to-merge-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2018/07/idera-pharma-and-biocryst-merger-is-terminated-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-now-recommends-xalkori--crizotinib-for-first-line-treatment-of-adults-with-alk-positive-advanced-non-small-cell-lung-cancer--pfizer-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2015/10/sativex--nabiximols--does-not-meet-primary-endpoint-in-two-phase-iii-trials-to-treat-cancer-pain--gw-pharma---otsuka-pharma/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-probes-pcsk9-inhibitors-for-adverse-effects/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2018/06/zogenix-intends-to-resubmit-its-nda-for-fintepla-for-the-treatment-of-seizures-associated-with-dravet-syndrome-in-q3-2019-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-trials-success-for-eravacycline-treatment-for-urinary-tract-infections-tetraphase/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2015/06/zydelig--idelalisib----arzerra--ofatumumab-success-in-study-119-for-cll-and-filing-of-snda-at-fda--gilead-sciences/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2016/01/ema-approves-zutectra--subcutaneous-hepatitis-b-immunoglobulin--for-use-after-liver-transplantation--biotest-ag/2024-02-23T14:29:11+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves-anti-helicobacter-pylori-antibody/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2017/06/genes-explain-higher-prevalence-of-cardiovascular-disease-in-chronic-immune-mediated-inflammatory-disease-patients--/2021-11-30T10:31:09+00:00weekly0.6https://www.medthority.com/news/2019/06/combi-d-and-combi-v-phase-iii-trials-of-tafinlar---mekinist-in-melanoma-published-in-nejm---novartis/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iiib-iv-study-of-xeljanz--tofacitinib-citrate--plus-meets-primary-endpoint-in-rheumatoid-arthritis--pfizer/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-trial--pix306--evaluating-pixuvri-plus-rituximab-in-patients-with-aggressive-b-cell-non-hodgkin-lymphoma--nhl--did-not-meet-its-primary-endpoint---cti-biopharma---servier-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2015/12/faster-acting-novorapid--insulin-aspart--filed-with-ema-for-diabetes-type-1-and-2--novo-nordisk/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-geri-the-benchtop-embryo-incubator--merck-kgaa-/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-flublok-quadrivalent-for-influenza--protein-sciences-corporation/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2014/03/dcvax-l-exemption-approval-in-germany-for-glioblastoma---northwest-bio/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2016/09/lotus-edge-valve-system-receives-ce-mark-for-aortic-valve-replacement---boston-scientific-/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2017/06/uk-nice-recommends-use-of-lartruvo--olaratumab--for-adults-with-advanced-soft-tissue-sarcoma--eli-lilly/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2011/10/simoa-psa-test-found-a-reliable-predictor-of-prostate-cancer-recurrence/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2015/12/additional-phase-iii-data-shows-iti-007-improves-symptoms-of-schizophrenia--intra-cellular-therapies/2024-02-09T09:17:16+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-approves-avastin--bevacizumab----tarceva--erlotinib--for-metastatic-or-recurrent-non-squamous-non-small-cell-lung-cancer-with-egfr-mutation--roche/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2019/04/complete-response-letter-for-gimoti-to-treat-diabetic-gastroparesis--evoke-pharma/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-jade-mono-1-study-of-pf-04965842-meets-endpoints-in-atopic-dermatitis---pfizer/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2013/07/eu-gives-extended-ce-mark-approval-to-exablate-system--insightec--for-bone-tumours/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2016/05/uk-nice-recommends-praluent--alirocumab--and-repatha--evolocumab--for-adults-with-primary-hypercholesterolaemia-or-mixed-dyslipidaemia--sanofi-and-amgen/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-fluenz-tetra-for-influenza/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-ultibro-breezhaler--novartis--for-copd/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-esbriet-for-treatment-of-idiopathic-pulmonary-fibrosis---genentech-roche/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2015/10/combination-azd-9291---medi-4736-trials-for-nsclc-are-halted--astrazeneca/2024-02-06T15:14:32+00:00weekly0.6https://www.medthority.com/news/2019/04/application-for-fintepla-in-dravet-syndrome-rejected-by-fda---zogenix/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-trial-of-ykp-3089-reveals-adverse-event-in-epilepsy---sk-life-science-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2017/04/biogen-reports-on-successful-phase-iii-end-of-study-of-spinraza--nusinersen--data-in-children-with-spinal-muscular-atrophy-/2021-09-24T07:14:10+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-optic-oasis-1-trials-of-nuzyra-in-cabp-and-absssi-published-in-new-england-journal-of-medicine---paratek-pharma/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2018/03/real-world-gloria-af-study-confirms-low-major-bleeding-and-stroke-rates-with-pradaxa--dabigatran--for-stroke-prevention-in-atrial-fibrillation---boehringer-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2012/10/sub-analysis-of-eliquis--bms-pfizer-in-aristotle-trial-show-consistent-reductions-in-stroke-and--bleeding-risk---------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2012/03/pycnogenol--horpagh-research--improves-menopausal-transition/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2017/10/uk-nice-recommends-use-of-stivarga--regorafenib--in-adults-with-gastrointestinal-stromal-tumours---bayer-healthcare-/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2015/09/brenzys--etanercept-biosimilar--approved-in-south-korea-for-rheumatoid-arthritis--psoriatic-arthritis--axial-spondyloarthritis--and-psoriasis--merck-and-samsung-bioepis/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2017/12/positive--phase-iii-impower150-study-of-tecentriq---avastin---chemo-for-previously-untreated--advanced-nsclc-presented-at-esmo---genentech-roche-/2021-09-24T07:13:43+00:00weekly0.6https://www.medthority.com/news/2016/06/two-phase-iii-trials-for-baracitinib-as-a-treatment-for-ra-show-significant-improvement-in-quality-of-life--eli-lilly/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2012/07/positive-results-from-phase-iii-trial-of-pa21--vifor-pharma--for-controlling-hyperphosphataemia-/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2017/06/us-idmc-recommends-termination-of-phase-iii-xcite-study-for-xilonix--human-igg1-monoclonal-antibody--in-colorectal-cancer--xbiotech/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2018/01/ce-mark-for-c-scan---an-ingestible-capsule-for-preparation-free--colorectal-cancer-screening---check-cap-ltd-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2013/03/results-from-phase-ii-study-of-chr-2797--cell-therapeutics--for-aml-published-in-the-lancet-oncology/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2015/10/cl-108-meets-endpoints-in-phase-iii-trial-for-moderate-to-severe-pain-after-bunionectomy--charleston-labs---daiichi-sankyo/2024-02-06T15:15:07+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-expands-approval-of-exelon-patch--novartis--to-severe-alzheimers-disease/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-venclexta--plus-a-hypomethylating-agent-or-low-dose-cytarabine--for-the-treatment-of--newly-diagnosed-aml-patients-who-are-age-75-years-or-older-or-ineligible-for-intensive-induction-chemotherapy---genentech-roche/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2012/02/actelion-acquires-rights-to-xiaflex-xiapex-from-auxilium-pharma/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2013/09/amgen-starts-phase-iii-trial-with-biosimilar-abp-501-for-ra/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-banzel-for-lennox-gastaut-syndrome-in-pediatric-patients-eisai/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-results-for-humira--adalimumab--show-benefits-in-youngsters-with-chronic-plaque-psoriasis--abbvie/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2015/06/study-of-endurant-aaa-stent-graft-meets-endpoint-in-aneurysm-treatment-medtronic/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2016/11/intarcia-therapeutics--inc---submitted-its-new-drug-application--nda--to-the-fda-for-itca-650--exenatide-via-an-osmotic-mini-pump---for-the-treatment-of-type-2-diabetes-/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2019/11/biogen-announces-enrollment-completion-of-phase-iii-gene-therapy-study-of-timrepigene-emparvovec-to-treat-choroideremia-/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2017/07/successful-phase-iii-oasis-2--study-of-omadacycline-to-treat-absssi---paratek-pharmaceuticals/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-ilumya-for-moderate-to-severe-plaque-psoriasis---sun-pharma-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2018/01/an-analysis-of-the-seamless-dataset-of-subgroups-of-aml-patients-treated-with-sapacitabine---showed-significant-improvement-in-overall-survival--cyclacel-pharma-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2018/02/ce-mark-for-self-expanding-centera-valve-for-severe--symptomatic-aortic-stenosis---edwards-lifesciences-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-results-for-giotrif--afatinib--in-lung-cancer-published-in-lancet-oncology--boehringer-ingelheim/2024-02-13T09:20:01+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-ii-iii-results-demonstrate-impact-of-pd-l1-expression-on-efficacy-of-keytruda--pembrolizumab--in-non-small-cell-lung-cancer--merck-inc/2024-02-06T15:15:27+00:00weekly0.6https://www.medthority.com/news/2013/03/european-commission-approves-jetrea--alcon-novartis--to-treat-vitreomacular-traction-/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2018/08/positive-study-reports-for-rhopressa-on-aqueous-humor-dynamics-in-patients-with-open-angle-glaucoma-or-ocular-hypertension--aerie-pharmaceuticals-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2014/05/merck-inc---sells-ophthamology-products-in-asia-and-eu-to-santen/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2018/02/rapid-blood-vessel-scan-tolerated-by-claustrophobic-patients-unable-to-stand-longer-tests/2024-02-13T14:44:43+00:00weekly0.6https://www.medthority.com/news/2017/05/safety-and-efficacy-study-of-uceris--budesonide-multimatrix-mmx--in-ulcerative-colitis-published-in-journal-of-crohn-s---colitis--salix-pharmaceuticals/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-chmp-recommends-approval-of-uptravi--selexipag--for-pulmonary-arterial-hypertension--actelion/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2013/07/complete-response-letter-from-fda-to-merck-regarding-suvorexant-as-a-treatment-for-insomnia/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-advisory-committee-recommends-heplisav-b--hepatitis-b-vaccine--recombinant--adjuvanted---for-immunization-against-hepatitis-b---dynavax-technologies-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-advisory-committee-recommends-vimizim--biomarin--for-morquio-a-syndrome/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2016/03/xenon-pharmaceuticals-and-genentech-extend-their-collaboration-focused-on-pain-targets/2021-09-24T07:10:23+00:00weekly0.6https://www.medthority.com/news/2016/01/roche-acquires-tensha-therapeutics-and-with-it-ten-010-cancer-treatment/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2018/07/nabriva-therapeutics-acquires-zavante-therapeutics-and-with-it-contepo---fosfomycin-for-injection-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2019/10/gsk-starts-a-phase-iii-clinical-programme-for-a-potential-first-in-class-antibiotic--gepotidacin-/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-accelerated-approval-for-benznidazole-as-a-treatment-for-chagas-disease--chemo-research-s-l-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2013/12/bi-201335-effective-against-hep-c-variants-boehringer/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2020/02/health-canada-approves-taltz-to-treat-adult-patients-with-active-ankylosing-spondylitis----eli-lilly/2021-09-24T07:12:04+00:00weekly0.6https://www.medthority.com/news/2013/08/allovectin-fails-phase-iii-trial-for-melanoma/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2014/06/sanofi-presents-saril-ra-mobility-study-results-in-ra-for-sarilumab-at-eular-meeting/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-tower-study-shows-blincyto--blinatumomab--offers-two-fold-improvement-in-overall-survival-in-ph--b-cell-precursor-acute-lymphoblastic-leukemia--amgen/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2017/12/cyramza-achieves-progression-free-survival-but-not-overall-survival-in-phase-iii-rainbow-trial-for-gastric-cancer---eli-lilly-/2021-09-24T07:13:41+00:00weekly0.6https://www.medthority.com/news/2014/01/protelos-recommended-for-suspension-in-eu-due-to-blood-clotting-problems-servier/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2018/02/european-society-of-cardiology-issues-stark-warning-on-the-risks-of-sedentary-lifestyle--/2024-02-13T09:20:44+00:00weekly0.6https://www.medthority.com/news/2017/11/3rd-international-paediatric-medical-congress-starts-tomorrow/2024-07-26T09:02:44+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-breakthrough-therapy-designation-for-kisqali-for-pre--or-peri-menopausal-women-with-hr--her2--advanced-or-metastatic-breast-cancer---novartis-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-advisory-committee-recommends-lomitapide--aegerion-pharma--for-hofh---------------/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-flaura-trial-of-tagrisso-meets-endpoint-in-untreated-nsclc-egfr---astrazeneca/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2018/11/glaxosmithkline-files-sbla-to-expand-indication-of-nucala-in-eosinophilic-asthma---gsk-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2016/01/baricitinib-is-filed-at-fda-to-treat-rheumatoid-arthritis--eli-lilly---incyte/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-gammaplex-10---immune-globulin-intravenous--human---10--liquid--for-primary-immunodeficiency-and-chronic-immune-thrombocytopenic-purpura--bio-products-lab/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2018/08/astrazeneca-provides-update-on-aeristo-phase-iiib-trial-for-bevespi-aerosphere-for-copd-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2013/08/phase-iii-results-for-enobosam-effect-on-muscle-wasting-in-nsclc/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-issues-complete-response-letter-for-zynquista-to-treat-type-1-diabetes---sanofi---lexicon/2021-09-24T07:18:50+00:00weekly0.6https://www.medthority.com/news/2015/02/eu-approves-holoclar-for-eye-damage-chiesi/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2015/10/daklinza--daclatasvir--plus-sovaldi--sofosbuvir--filed-with-fda-for-hepatitis-c-patients-with-hiv-co-infection--bms-gilead-sciences/2024-02-06T15:16:30+00:00weekly0.6https://www.medthority.com/news/2011/09/xgeva-success-in-prevention-of-bone-metastases-in-prostate-cancer/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2016/12/restylane--dermal-filler--given-new-approvals-by-fda-for-nasolabial-folds--galderma/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2019/05/three-ongoing-trials-interim-data-from-strong--str1ve-and-sprint-positive-for-zolgensma-to-treat-spinal-muscular-atrophy---avexis-novartis/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-1053-trial-of-cat-8015-meets-primary-endpoint-of-complete-response-in-hairy-cell-leukaemia---astrazeneca---medimmune-/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2018/10/daybreak-phase-iii-study-for-lu-af35700-fails-to-meet-endpoint-in-schizophrenia---lundbeck-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2016/06/soliris-does-not-reach-statistical-significance-in--regain-study-for-refractory-generalized-myasthenia-gravis--alexion-pharma/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2018/03/mundipharma-acquires-european-rights-to-biosimilar-herzuma-for-breast-cancer-and-gastric-cancer---celltrion-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2016/04/synta-merges-with-madrigal-pharma-and-will-focus-on-mgl-3196-for-nash-and-familial-hypercholesterolemia/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-grants-510-k--approval-for-the-spotlight-ct-cardiac-scanner---ge-healthcare-and-arineta-ltd-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2013/12/tivozanib-fails-baton-trial-for-colorectal-cancer--aveo-oncology-astellas/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2016/10/-uk-nice-in-final-guidance-rejects--portrazza--necitumumab--to-treat-metastatic-nsclc---eli-lilly/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2019/06/liso-cel-treatment-for-blood-cancers-in-transcend-cll-004-and-transcend-nhl-001-trials--celgene/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2019/12/results-of-phase-iii-regenerate-study-of-ocaliva-in-nash-published-in-the-lancet---intercept-pharma/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-enliven-study-and-extension-study-of-csf-1r-shows-response-in-tenosynovial-giant-cell-tumor---daiichi-sankyo/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2015/06/pulsar-18-stent-investigator-trial-results-for-femoropopliteal-disease-published-in-clinical-medical-insights--cardiology--biotronik/2024-02-13T09:20:57+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-review-of-flibanserin-for-hypoactive-sexual-desire-disorder-in-pre-menopausal-women---sprout-pharma/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2017/04/24th-april-marks-world-meningitis-day/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2016/11/presentation-of-tolerability--data-for-cuvitru--immune-globulin-subcutaneous--human---20--solution--in-patients-with-primary-immunodeficiency-diseases--shire-plc/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2018/10/opdivo-fails-to-meet-primary-endpoint-in-checkmate-331-study-versus-chemotherapy-for-small-cell-lung-cancer---bms/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-pediatric-lifevest-wearable-cardioverter-defibrillator--zoll-medical-corporation/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-cablivi-for-acquired-thrombotic-thrombocytopenic-purpura---ablynx-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2015/11/lcs-16--levonorgestrel-intrauterine-device--filed-in-eu-and-us-for-contraception--bayer-healthcare/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-imbruvica--ibrutinib--for-the-treatment-of-adult-patients-with-chronic-graft-versus-host-disease--cgvhd----abbvie---janssen-biotech--inc-/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-trial-of-cimzia--certolizumab-pegol--shows-improvement-in-chronic-plaque-psoriasis--ucb-dermira/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2013/01/phase-ii-success-for-at-2220-in-pompe-disease/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2018/04/jama-cardiology-reports-post-hoc-analysis-of-effect-of-entresto-on-social-and-physical-activities-of-heart-failure-patients----novartis-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/09/eu-approves-tecentriq-plus-chemo-approved-for-small-cell-lung-cancer---roche/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2015/01/ucb-files-brivaracetam-at-fda-and-eu-for-treatment-of-partial-onset-seizures-in-patients-with-epilepsy/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-supplemental-nda-for-tradjenta--boehringer-eli-lilly--for-patients-with-type-2-diabetes/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2012/02/avonex-pen--biogen-idec--is-fda-approved-for-relapsing-multiple-sclerosis/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2012/07/gsk-theravance-announce-results-of-four-phase-iii-studies-of-gsk-573719-plus-vilanterol-in-copd/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2017/12/san-antonio-breast-cancer-symposium-2017/2024-10-22T08:10:06+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-skyrizi-to-treat-psoriasis--abbvie/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2016/10/two-studies-show-benefits-of-xarelto--rivaroxaban--in-treating-venous-thromboembolism--janssen-bayer-healthcare/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2013/09/stivarga-filed-at-ema-for-gist/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/10/post-hoc-studies-of-rexulti-demonstrate-efficacy-in-schizophrenia---otsuka-pharma---lundbeck-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-remede-system-implanted-device-for-treating-moderate-to-severe-central-sleep-apnea---respicardia-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2013/04/chmp-rejects-xeljanz--pfizer--as-a-treatment-for-rheumatoid-arthritis/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2012/02/regeneron-files--eylea-vegf-trap-eye--at-fda-for-crvo/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2015/10/zafgen-announces-update-on-trials-for-beloranib-following-death-of-prader-willi-syndrome-patient-in-zaf-311-trial/2025-02-03T14:59:01+00:00weekly0.6https://www.medthority.com/news/2015/01/xultophy-is-approved-in-its-first-market-switzerland--novo-nordisk/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approve-trevo-pro-retriever--stryker--for-clot-removal---------------/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2015/12/programme-developing-th-302-evofosfamide-for-advanced-soft-tissue-sarcoma-and-advanced-pancreatic-adenocarcinoma-cancelled-merck-kgaa-threshold-pharma/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2018/10/tx-001hr-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-due-to-menopause-has-pdufa-date-of-28-october-2018---therapeutics-md/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-cimzia-for-psoriatic-arthritis/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2013/10/study-of-neuroaid--moleac--published-in-stroke/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-vyndaqel-and-vyndamax-for-use-in-patients-with-transthyretin-amyloid-cardiomyopathy---pfizer/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2014/05/rolapitant-final-successful-phase-iii-trial-for-cinv--nausea---tesaro/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2017/06/chmp-recommends-stivarga--regorafenib--for-the-treatment-of-adult-patients-with-hepatocellular-carcinoma----bayer/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2016/01/updated-survival-data-for-onivyde--irinotecan-liposome-injection--in-pancreatic-cancer--merrimack-pharmaceuticals/2024-02-06T15:17:46+00:00weekly0.6https://www.medthority.com/news/2019/04/mateon-therapeutics-and-oncotelic--companies-to-merge-/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-kineret-sobi--for-nomid/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves-cfc-free-combivent-respimat-inhaler-for-copd/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-nda-from-mitsubishi-tanabe-for-edaravone--mci-186--to-treat-amyotrophic-lateral-sclerosis-/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2014/07/abbvie-bid-for-shire-update/2025-10-16T10:55:40+00:00weekly0.6https://www.medthority.com/news/2019/04/achaogen-inc-files-for-bankruptcy/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-safety-and-efficacy-results-for-sb-1518--pacritinib--in-myelofibrosis--cti-biopharma/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2013/10/chmp-recommends-cimzia--ucb--for-psoriatic-arthritis/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2012/05/lipoprotein-2086-vaccine--pfizer--shows-promise-in-protecting-against-meningococcal-infection/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2012/08/campath-mabcampath--sanofi-genzyme--withdraws-marketing-in-eu-and-us-for-oncology-indications-/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-duzallo--lesinurad---allopurinol--to-treat-hyperuricemia-associated-with-gout---ironwood-pharma/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2016/05/combination-of-crs-207-and-gvax-pancreas-fails-phase-iibeclipse-trial-for-pancreatic-cancer--aduro-biotech/2025-02-03T14:57:50+00:00weekly0.6https://www.medthority.com/news/2017/10/successful-phase-iii-t3mpo-2-trial-for-tenapanor-for-irritable-bowel-syndrome-with-constipation--ibs-c----ardelyx-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2018/03/results-of-phase-iii-trial-of-encorafenib-plus-binimetinib-for-braf-mutant-advanced--unresectable-or-metastatic-melanoma-are-published-in-the-lancet-oncology---array-biopharma---pierre-fabre/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2013/03/promus-element-stent--boston-scientific--continues-to-outperform-the-xience-v-stent-at-3-years/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2017/11/two-analyses-show-benefits-of-xarelto-for-patients-with-pad-and-cad---bayer---janssen-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-apex-2-trial-of-bcx-7353-reported--data-for-treatment-of-hereditary-angioedema/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-study-of-cere-120--ceregene--for-parkinsons-fails-to-reach-primary-endpoint/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-qternmet-xr-to-improve-glycaemic-control-in-adults-with-type-2-diabetes---astrazeneca/2024-02-13T09:29:54+00:00weekly0.6https://www.medthority.com/news/2018/10/nice-does-not-recommend-venclyxto-for-use-with-chronic-lymphocytic-leukaemia---abbvie---roche-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2015/11/new-phase-iii-data-for-cotempla-xr-odt--extended-release-methylphenidate--for-children-with-adhd--neos-therapeutics/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2014/09/roche-initiates-phase-iii-trial-for-lampalizumab-for-geographic-atrophy--a-form-of-amd-/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-expended-label-for-promacta-to-include-first-line-treatment-for-adults-and-pediatric-patients-two-years-and-older-with-severe-aplastic-anemia--novartis/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-motegrity-for-chronic-idiopathic-constipation---shire-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2018/12/rolling-submission-underway-to-fda-for-pedmark-in-ototoxicity---fennec-pharma-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2015/10/cell-therapy-plans-a-conditional-authorisation-for-heartcel-for-heart-regeneration/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-reflect-study-shows-lenvima--lenvatinib--delays-in-the-deterioration-of-quality-of-life-scores-in-liver-cancer-compared-to-sorafenib---eisai-/2021-09-24T07:13:56+00:00weekly0.6https://www.medthority.com/news/2012/07/-fda-advisory-committee-recommends-ocriplasmin-thrombogenics--for--treatment-of-vitreomacular-adhesions-/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-tecentriq--atezolizumab--as-a-monotherapy-to-treat-adults-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer--nsclc--after-chemotherapy--roche/2024-07-26T09:03:05+00:00weekly0.6https://www.medthority.com/news/2016/09/review-published-in-the-lancet-concludes-that-lowering-cholesterol-by-statin-therapy-prevents-cardiovascular-events-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-vonvendi--von-willebrand-factor--recombinant---to-treat-von-willebrand-disease--baxalta/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-chmp-recommends-approval-of-oncaspar--pegaspargase--for-acute-lymphoblastic-leukaemia--medac/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-recommends-approval-of-change-of-marketing-of-hizentra-to-include-chronic-inflammatory-demyelinating-polyneuropathy---csl-behring-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-fourier-trial-of-repatha--evolocumab-shows-link-between-ldl-c-levels-and-cv-events-in-atherosclerotic-cardiovascular-disease--amgen-/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-comfort-ii-study-shows-jakafi-jakavi--novartis--improves-overall-survival-in-myelofibrosis-patients/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2012/06/nice-recommends-zytiga--janssen-cilag--for-metastatic-prostate-cancer/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-heartmate-3-left-ventricular-assist-system-for-heart-failure--abbott-/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---professor-raymond-vanholder-and-professor-mehmet-sever-received-the-2019-isn-bywaters-award/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2014/01/rg-1678-fails-to-meet-endpoints-in-phase-iii-trials-for-schizophrenia---roche/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2012/06/treanda-teva-mundipharma-success-in-nhl-study/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-amg-412--epratuzumab--fails-in-systemic-lupus-erythematosus--ucb/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2019/05/updated-phase-iii-columbus-trial-data-of-braftovi---mektovi-presented-at-asco---array-biopharma/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2019/06/findings-from-carolina-trial-show-tradjenta-did-not-increase-cv-risk-in-patients-with-type-2-diabetes---boehringer---eli-lilly/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2015/11/celladon-corporation-is-merged-with-eiger-biopharmaceuticals-/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-brintellix-for-major-depressive-disorder/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-orkambi-to-include-use-in-children-ages-2-through-5-years-with-cystic-fibrosis-who-have-two-copies-of-the-f508del-cftr-mutation---vertex-pharma-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iv-study-of-natesto-shows-benefits-in-hypogonadism-maintained---acerus-pharma/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2016/12/positive-results-from-phase-iii-compass-study-of-volanesorsen-to-treat-severe-hypertriglyceridemia---akcea-therapeutics-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2017/06/nice-in-final-guidance-recommends-routine-use-of-kadcyla--ado-trastuzumab-emtansine--for-women-with-advanced-and-inoperable-her2-positive-breast-cancer---roche/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/04/-truvada--gilead-sciences--given-to-men-at-high-risk-for-hiv-would-be-cost-effective-prophylaxis/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-oncologic-drugs-advisory-committee-approved-the-benefit-risk-of-rituximab-hyaluronidase-for-subcutaneous--under-the-skin--injection-was-favourable-for-certain-blood-cancers---gennetech/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2018/07/more-than-70--of-people-with-liver-disease-in-the-uk-don-t-even-know-they-have-it/2022-02-08T07:44:51+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-issues-complete-response-letter-for-lemtrada-for-multiple-sclerosis--genzyme-sanofi/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2018/11/data-from-the-ongoing-phase-ii-liplacis-study-in-patients-with-metastatic-breast-cancer-shows--50--response-rate--oncology-venture-intends-to-file-on-phase-ii-information-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-cobas-cmv--cytomegalovirus--test--roche/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-gives-510-k--approval-for-shiga-toxin-direct-test-for-shiga-toxin-producing-e--coli--great-basin-scientific/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2015/07/advisory-committee-recommends-necitumumab-to-treat-advanced-squamous-nsclc-eli-lilly/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2016/12/study-of-tasigna--nilotinib--finds-treatment-free-remission-rates-consistent-in-philadelphia-chromosome-positive-chronic-myeloid-leukemia-patients--novartis/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-issues-complete-response-letter-relating-to-abilify-depot--otsuka-lundbeck--for--monthly-treatment-of-schizophrenia/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-foundationonecdx-as-a-companion-diagnostic-for-lynparza/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2012/07/eu-approves-fycompa--eisai--for-treatment-of-epilepsy/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-grants-accelerated-approval-to--tecentriq--atezolizumab--for-metastatic-urothelial-carcinoma--genentech---roche/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-votrient--gsk--to-treat-soft-tissue-sarcoma/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2012/12/trial-of-reminyl-xl-razadyne--janssen-pharmaceuticals--shows-positive-results-in-patients-with-alzheimer-s-disease/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-keytruda-plus-lenvima-combination-treatment-for-atients-with-certain-types-of-endometrial-carcinoma-/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2019/11/tremfya----guselkumab---a-first-in-class-il-23-p19-subunit-inhibitor--meets-primary-endpoints-of-superior-acr20-responses-versus-placebo-at-week-24-in-phase-3-psoriatic-arthritis-studies-/2024-10-22T09:42:37+00:00weekly0.6https://www.medthority.com/news/2018/09/updated-results-for-phase-ii-iii-starbeam-study-of--lenti-d-gene-therapy-in-cerebral-adrenoleukodystrophy---bluebird-bio-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2019/10/efficacy-and-safety-results-of-filgotinib-through-52-weeks-in-finch-1-and-finch-3-studies-in-rheumatoid-arthritis---gilead-sciences---galapagos-nv/2021-09-24T07:17:25+00:00weekly0.6https://www.medthority.com/news/2016/11/novartis-acquires-selexys-pharma-and-with-it-selg1-a-treatment-for-sickle-cell-disease/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-in-pact-av-drug-coated-balloon-to-treat-arteriovenous-fistula-lesions---medtronic/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-grants-de-novo-classification-for-early-bird-bleed-monitoring-system---saranas/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2013/07/study-shows-resveratrol-counteracts-exercise-benefits/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2013/12/eu-approves-opsumit-for-pah-actelion/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2014/04/mallinckrodt-buys-questcor-pharma-for--5-6-billion/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves-generic-zyprexa-to-treat-schizophrenia-and-bipolar-disorder/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-gammagard-liquid-10---baxter--for-multifocal-motor-neuropathy/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-mavyret-for-all-genotypes-of-hepatitis-c---abbvie/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2018/06/ash-to-collaborate-on-clinical-practice-guidelines-on-diagnosis--management-of-von-willebrand-disease/2024-02-13T09:29:18+00:00weekly0.6https://www.medthority.com/news/2015/09/eliquis--apixaban--enters-phase-iv-trial-in-patients-with-nonvalvular-atrial-fibrillation-following-acs-or-pci--pfizer---bms/2024-02-06T15:18:12+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-impress-trial-of-xiaflex--auxilium-pharma--for-peyronie-s-disease/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2015/10/kadcyla--ado-trastuzumab-emtansine--fails-phase-ii-iii-trial-for--her-2---advanced-gastric-cancer--roche-immunogen/2024-02-06T15:18:21+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-change-of-authorisation-for-tasigna--nilotinib--in-philadelphia-chromosome-positive-chronic-myelogenous-leukaemia---novartis-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-advisory-committee-recommends-repatha--evolocumab--for-use-for-homozygous-familial-hypercholesterolaemia-and-heterozygous-familial-hypercholesterolaemia-amgen/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2012/06/aezs-130--aeterna-zentaris--safe-and-effective-in-growth-hormone-deficiency/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-data-from-rgh-md-53-study-of-cariprazine-for-the-treatment-of--bipolar-i-depression-_allergan---gedeon-richter-/2024-10-21T14:49:53+00:00weekly0.6https://www.medthority.com/news/2019/03/european-association-for-the-study-of-the-liver-meeting-10-14-april-2019/2024-02-13T09:30:15+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-of-tomtovok--boehringer--meets-endpoint-for-nsclc/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2014/04/aastrom-bioscience-acquires-sanofi-s-cell-therapy-and-regenerative-medicine-business-for--6-5-million/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2011/11/merck-terminates-early-the-tracer-study-of-vorapaxar-in-acute-coronary-syndrome/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/03/european-commission-approves-tecentriq---avastin-and-chemotherapy-for-the-initial-treatment-of-specific-types-of-metastatic-lung-cancer--roche/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-tagrisso-in-first-line-non-small-cell-lung-cancer---astrazeneca/2021-09-24T07:11:48+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-results-for-rikelta-in-epilepsy-ucb/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2012/09/astellas-submits-nda-for-advagraf-for-prophylaxis-of-organ-rejection----------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2016/06/long-term-safety-of-revolade--eltrombopag--in-adults-with-chronic-immune--idiopathic--thrombocytopenia---novartis/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2013/05/ga-101-success-in-phase-iii-study-for-treatment-of-chronic-lymphocytic-leukemia/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2018/08/new-mallinckrodt-data-analysis-shows-limited-use-of-opioid-free-analgesia-and-underutilization-in-some-patients-more-prone-to-opioid-related-adverse-events-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2016/11/results-for-eb-101--gene-therapy--in-treating-recessive-dystrophic-epidermolysis-bullosa-published-in-jama--abeona-therapeutics/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-extends-pdufa-date-for--ibalizumab--a-proposed-treatment-for-hiv-aids---theratechnologies---taimed-biologics-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2015/02/amg-416-meets-endpoint-in-phase-iii-study-in-hyperparathyroidism-in-ckd-amgen/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-accepts-bla-for-sarilumab-as-a-treatment-for-ra-with-pdufa-date-for-30-october-2016--regeneron---sanofi-/2024-02-13T09:31:10+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-innova-vascular-self-expanding-stent-system-for-pad--boston-scientific/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2016/01/lenvima---afinitor--lenvatinib---everolimus--filed-with-ema-for-renal-cell-carcinoma--eisai/2024-02-22T15:18:01+00:00weekly0.6https://www.medthority.com/news/2018/06/two-extension-studies-confirm-efficacy-and-safety-of-aimovig-in-migraine---novartis-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2013/07/mk-8931--merck-inc---progress-in--alzheimers-disease-early-study/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2012/07/apremilast--celgene--success-in-phase-iii-study-of-psoriatic-arthritis/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2016/07/eu-approves-adcetris--brentuximab-vedotin--for-cd30--hodgkin-lymphoma-at-increased-risk-of-relapse-or-progression-following-autologous-stem-cell-transplant--takeda/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2019/11/boehringer-and-eli-lilly-announce-outcome-of-fda-advisory-committee-meeting-for-empagliflozin-2-5-mg-as-adjunct-to-insulin-for-adults-with-type-1-diabetes-/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2015/07/biofrontera-files-nda-at-fda-for-ameluz---bf-rhodoled-device-to-treat-actinic-keratosis/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-newton-2-study-of-eg-1962-updates-results-in-aneurysmal-subarachnoid-hemorrhage---edge-therapeutics-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2011/11/phase-iii-trial-of-mdv-3100--medivation-astellas--shows-significant-benefits-for-patients-with-advanced-prostate-cancer/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-single-tablet-elvitegravir---cobicistat---emtricitabine---tenofovir-alafenamide-meets-primary-endpoint-in-hiv-aids--gilead-sciences/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2019/11/new-data-on-filgotinib-in-rheumatoid-arthritis-demonstrate-durable-efficacy-and-safety-profile---gilead-sciences---galapagos/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-varubi--rolapitant--for-nausea-and-vomiting-tesaro-inc/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2019/02/ipsen-acquires-clementia-pharma-and-with-it-palovarotene-/2025-10-16T11:25:29+00:00weekly0.6https://www.medthority.com/news/2015/09/valeant-pharma-international-acquires-rights-from-astrazeneca-to-brodalumab--a-potential-treatment-for-psoriasis-and-psoriatic-arthritis/2024-02-13T14:44:55+00:00weekly0.6https://www.medthority.com/news/2016/04/eu-approves-opdivo--nivolumab--to-treat-renal-cell-carcinoma---bms/2024-02-09T09:17:58+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---world-kidney-day---is-this-just-the-tip-of-the-iceberg--/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2019/06/uk-s-mhra-has-renewed-for-a-further-year-the-early-access-to-medicines-scheme--scientific-opinion-for-idebenone-for-patients-with-duchenne-muscular-dystrophy---santhera/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-yescarta-for-diffuse-large-cell-lymphoma-and-primary-mediastinal-b-cell-lymphoma---kite-pharma-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2019/04/ozempic-oral-tablet-filed-with-eu-for-type-2-diabetes---novo-nordisk/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-xuriden--uridine-triacetate--for-hereditary-orotic-aciduria--wellstat-therapeutics/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-blincyto--blinatumomab--for-ph--relapsed-or-refractory-b-precursor-acute-lymphoblastic-leukemia--amgen/2024-02-09T09:18:15+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-diclegis--duchesnay-usa--for-treatment-of-nausea-in-pregnancy/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2015/08/medtronic-to-acquire-twelve/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-kymriah-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-and-diffuse-large-b-cell-lymphoma---novartis-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2016/10/positive-results-for-pollux-study-of-daratumumab-combined-with-lenalidomide-and-dexamethasone-for-treatment-of-multiple-myeloma-published-in-nejm---janssen-biotech/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2018/01/biosimilar-adalimumab-is-filed-at-fda-to-treat-inflammatory-diseases---sandoz-/2024-10-22T08:24:16+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-success-for-vimpat--ucb--as-monotherapy-for-treatment-of-partial-onset-seizures/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2019/10/complete-response-letter-for-pt-101--triple-therapy-for-copd---astra-zeneca/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-data-from-study-of-alpha-ims-in-retinitis-pigmentosa-retina-implant/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2014/09/amgen-files-bla-at-fda-for-blinatumomab-for-treatment-of-acute-lymphoblastic-leukemia-/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-approves-keytruda--pembrolizumab--for-metastatic-non-small-cell-lung-cancer-in-adults-whose-tumors-have-high-pd-l1-expression-with-no-egfr-or-alk-positive-tumor-mutations--merck-inc/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2017/11/gestational-diabetes-world-diabetes-day-2017/2024-02-22T11:58:24+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-approves-excor-pediatric-system--berlin-heart--to-support-heart-failure-patients-until-a-donor-is-found/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2014/02/kaletra-clears-lesions-in-patients-with-hpv---abbvie/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2016/04/sanofi-makes-further-offer-to-medivation/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2015/06/new-results-with-the-argus-ii-retinal-prosthesis-system-in-retinitis-pigmentosa--second-sight-medical/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-edge-radiosurgery-suite--varian-medical-systems--for-radiation-therapy/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2017/06/-solero-microwave-tissue-ablation--mta--system-has-fda-510-k--approval-for-the-ablation-of-soft-tissue-during-open-procedures---angiodynamics/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-baxdela--delafloxacin--as-a-treatment-for-acute-bacterial-skin-and-skin-structure-infections--absssi----melinta-therapeutics/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-recommends-humira--adalimumab--to-treat-hidradenitis-suppurativa--hs---acne-inversa----abbvie/2024-10-22T08:13:47+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-repatha--evolocumab--from-amgen-to-treat-ldl-cholesterol/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2015/01/positive-phase-iii-results-for-qva-149---indacaterol-glycopyrronium-bromide--to-support-nda-for-fda-for-copd--novartis/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2020/02/long-term-data-for-epsolay-confirms-safety-profile-in-rosacea---sol-gel-technologies/2021-09-24T07:12:05+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-minimed-530g-system-for-diabetic-patients/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-accepts-sblas-for-pifeltro-and-delstrigo-for-use-in-hiv-patients-switching-from-a-stable-antiretroviral-regimen--merck-inc-/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2019/08/lynparza--when-added-to-standard-of-care-bevacizumab--significantly-increased-the-time-women-with-ovarian-cancer-lived-without-disease-progression--astrazeneca---merck-inc--/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2017/12/janssen-biotech-acquires-rights-to-car-t-therapy--lcar-b38m--for-multiple-myeloma-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-fluad--mf59-adjuvanted-seasonal-influenza-vaccine--for-influenza--nvs-influenza-vaccines/2024-02-09T09:18:37+00:00weekly0.6https://www.medthority.com/news/2016/11/ce-mark-for-vitalcscan-device-to-detect-and-diagnose-chest-pain--creavo-medical-technologies-/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2015/12/eusa-pharma-buys-renal-cell-carcinoma-rights-to-tivozanib-for-europe--south-america-and-south-africa--aveo-oncology/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2018/04/olita-withdrawn-due-to-fatal-side-effects-as-well-as-stiff-competition-in-non-small-cell-lung-cancer-market---hanmi-pharma-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2016/12/analysis-of-entyvio--vedolizumab--data-in-crohn-s-disease-published-in-inflammatory-bowel-diseases--takeda/2021-09-24T07:10:13+00:00weekly0.6https://www.medthority.com/news/2019/12/johnson---johnson-acquires-taris-biomedical-specialist-in-drug-delivery-technology-for-bladder-diseases-and-with-lead-product-tar-200/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-trial-data-of-xtampza-er--oxycodone-extended-release--in-chronic-low-back-pain-meets-endpoint-and-are-published-in-pain-journal--collegium-pharmaceutical/2024-02-13T14:45:14+00:00weekly0.6https://www.medthority.com/news/2018/09/m72-as01e-vaccine-in-an-ongoing-phase-iib-trial-reduced-the-incidence-of-pulmonary-tuberculosis-disease---gsk/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-award-510-k--clearance-to-springtms-for-migraine---eneura/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2020/01/neovasc-inc--files-premarket-approval-application--to-fda-for--neovasc-reducer-medical-device-for-the-treatment-of-refractory-angina-/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2019/08/mallinckrodt-announces-positive-top-line-results-from-its-pivotal-phase-iii-confirm-trial-of-terlipressin-in-patients-with-hepatorenal-syndrome-type-1-/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2012/01/combining-2-anti-her2-drugs-may-provide-better-preoperative-breast-cancer-treatment/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-chmp-recommends-approval-of-lamzede-for-alpha-mannosidosis---chiesi/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2017/12/treatment-efficacy-versus-quality-of-life---would-you-make-the-trade-off-/2024-10-22T09:53:10+00:00weekly0.6https://www.medthority.com/news/2013/05/takeda-acquires-vaccine-maker-inviragen/2025-10-16T10:57:43+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-label-update-for-lixiana--edoxaban--for-cardioversion-in-patients-with-nvaf--daiichi-sankyo/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-fluzone-quadrivalent--sanofi-pasteur--vaccine-for-influenza/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2019/12/advisory-committee-recommended--lynparza-as-a-1st-line-maintenance-monotherapy-for-patients-with-germline-brca-mutated--metastatic-adenocarcinoma-of-the-pancreas---merck-inc----astrazeneca/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2014/08/st-jude-acquires-neurotherm/2025-10-16T11:07:52+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-expands-zytiga--janssen-biotech--indication-in-prostate-cancer/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2018/05/phae-iii-leap-2-trial-success-for-lefamulin--proposed-treatment-for-moderate-community-acquired-bacterial-pneumonia---nabriva-therapeutics/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2018/03/ehra-stroke-prevention-drugs-may-help-reduce-dementia-risk-for-atrial-fibrillation-patients/2024-02-13T14:48:17+00:00weekly0.6https://www.medthority.com/news/2015/09/stelara--ustekinumab--paediatric-version-launched-in-the-uk-to-treat-psoriasis--janssen-cilag/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2014/11/pooled-data-shows-benefits-of-viva-crt-devices-in-heart-failure-medtronic/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2016/05/new-analyses-of-phase-iii-data-for-ofev--nintedanib--shows-reduction-in-progression-of-idiopathic-pulmonary-fibrosis--boehringer/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2011/09/tradjenta-shows-long-term-benefits-for-type-2-diabetes-patients/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2018/12/complete-response-letter-from-fda-for-bivigam-relating-to-the-drug-substance-pas-submission---adma-biologics/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2012/07/elvitegravir--gilead-sciences--is-filed-at-fda-for-hiv-1-infection-in-treatment-experienced-adults--/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2019/10/gilead-sciences-presents-latest-findings-from-discover-trial-in-a-subset-of-patients-and-on-the-impact-of-hiv-pre-exposure-prophylaxis-in-the-us-/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2014/01/shire-sells-dermagraft-assets-to-organogenesis/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2019/08/amgen-to-acquire-otezla-from-celgene-for--13-4-billion--/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2017/08/kaf-156---lumefantrine-trial-launched-in-mali-to-treat-malaria---novartis/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-rejects-expanded-use-of-esbriet--pirfenidone--for-early-treatment-of-pulmonary-fibrosis--roche/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2016/04/nice-does-not-recommend-vidaza--azacitidine--to-treat-acute-myeloid-leukaemia--celgene/2021-09-24T07:10:45+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-aczone-gel--dapsone--once-a-day-to-treat-acne--allergan/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2016/05/arbor-pharma-acquires-xenoport-and-with-it-horizant/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2017/07/sunovion-divests-us-rights-to-alvesco--ciclesonide---omnaris--ciclesonide--nasal-spray--and-zetonna--ciclesonide-nasal-aerosol-to-covis-n-l/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress-2018--analysis-shows-influential-us-prostate-study-not-representative-of-real-world-/2024-02-13T14:50:13+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-updates-victoza--novo-nordisk--label-to-show-superiority-to-januvia/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-somatom-x-cite-premium-single-source-computed-tomography--ct--scanner--siemens-healthineers/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2011/04/bi-201335-enters-phase-iii-for-hepatitis-c/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2014/07/astrazeneca-acquires-almirall-respiratory-franchise-for-an-initial--875-million/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2015/08/eu-approves-odomzo--sonidegib--formerly-lde225--for-locally-advanced-basal-cell-carcinoma--novartis/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2016/02/pdufa-date-for-fda-review-of-eteplirsen--for-the-treatment-of-duchenne-muscular-dystrophy--dmd--extended-to-26-may-2016--sarepta/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2019/07/new-results-from-nuture-study-of-spinraza-in-pre-symptomatic-infants-with-spinal-muscular-atrophy/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-trial-of-trca-301-meets-primary-endpoint-in-chronic-kidney-disease---tricida-/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-fulphila-biosimilar-to-neulasta--biocon---mylan/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-expands-label-for-fiasp-in-type-1-and-2-diabetes---novo-nordisk/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-announces-hold-on-phase-ii-trial-of-pegph-20-for-pancreatic-cancer---halozyme/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-issues-warning-relating-to-reshape-and-obera-balloon-systems-that-are-associated-with-overinflation-and-acute-pancreatitis--reshape-medical-and-apollo-endo-surgery-/2021-09-24T07:13:16+00:00weekly0.6https://www.medthority.com/news/2015/09/bayer-expands-bay-94-8862--finerenone--phase-iii-programme-in-heart-failure-and-diabetic-kidney-disease/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-issues-complete-response-letters-for-elvitegravir-and-cobicistat--gilead-sciences---/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2012/12/eu-awards-ce-mark-to-revivent-myocardial-anchoring-system--bioventrix--for-heart-failure-patients/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2018/12/abp-710-filed-with-fda-as-biosimilar-to-remicade-in-various-indications---amgen-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-kalydeco-to-treat-infants-with-cftr-gene-cystic-fibrosis---vertex-pharma/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-grants-accelerated-approval-to-ibrance--palbociclib----letrozole-for-er--her2--advanced-breast-cancer--pfizer/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-expands-indication-for-evarrest-fibrin-sealant-patch-for-problematic-bleeding-during-surgery--ethicon/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-give-premarket-approval-for-the-prostate-health-index--beckman-coulter--to-test-for-prostate-cancer/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-recommends-extending-the-approval-of-mozobil-in-lymphoma-or-solid-malignant-tumours---genzyme/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2017/06/ease-lid-clinical-trial-of-ads-5102--amantadine--in-parkinsons-published-in-jama-neurology--adamas-pharmaceuticals/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2019/02/durect-corp-plans-response-to-fda-complete-response-letter-for-posimir-for-treatment-of-post-surgical-pain-/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2015/09/smd-sr90-1-radionuclide-brachytherapy-source-given-510-k--approval-from-fda-for-brachytherapy--salutaris-medical-devices/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2015/11/abp-501--adalimumab-biosimilar--meets-endpoint-in-phase-iii-trial-for-rheumatoid-arthritis--amgen/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2015/04/rhopressa-fails-to-meet-endpoint-in-phase-iii-trial-for-glaucoma-or-ocular-hypertension--aerie-pharmaceuticals/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-staquis-to-treat-atopic-dermatitis---pfizer/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2012/06/humira--abbott--benefits-in-ability-1-study-in-patients-with-active-non-radiographic-axial-spondyloarthritis/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-valchlor-for--cutaneous-t-cell-lymphoma/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-endeavor-trial-results-of-kyprolis--carfilzomib--in-multiple-myeloma-published-in-the-lancet-oncology--amgen/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-camp-1-and-2-trials-of-vp-102-meet-primary-endpoint-in-molluscum-contagiosum---verrica-pharma-/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-commission-approves-kyntheum--brodalumab--of-moderate-to-severe-plaque-psoriasis---leo-pharma/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2013/05/immunoglobulin--baxter---fails-phase-iii-study-for-treatment-of-alzheimers-disease/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-study-of-s-297995--naldemedine--shows-safety-and-low-incidence-of-adverse-effects-in-opioid-induced-constipation--shionogi/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2018/01/celgene-acquires-juno-therapeutics-and-with-it-jcar-017--/2025-10-16T11:20:23+00:00weekly0.6https://www.medthority.com/news/2018/03/bowel-cancer-awareness-month-2018/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-expands-approval-of-opdivo----nivolumab--to-treat-advanced-melanoma--bms/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2011/09/cellnovo-recieves-ce-mark-for-type-1-diabetes-management-system/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2015/10/ocrelizumab-superior-to-interferon-beta-1a--rebif--in-opera-i-and-opera-ii-studies-for-primary-progressive-ms--genentech---roche-/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2014/04/ema-to-investigate-testosterone-medicines-for-link-with-heart-disease/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-expands-approval-for-kardiamobile-to-include-bradycardia-and-tachycardia-detection/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-data-shows-significant-improvements-for-psoriatic-arthritis-patients-on-ly-2439821--ixekizumab---eli-lilly/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2019/07/contravir-pharmaceuticals-inc---changes-its-name-to-hepion-pharmaceuticals--inc-/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-promacta-for-severe-aplastic-anaemia---gsk/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-hetlioz--tasimelteon--for-non-24-hour-sleep-wake-disorder---vanda-pharma/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2019/05/nabriva-therapeutics--has-received-a-complete-response-letter-from-the-fda-for-contepo-a-treatment-of-complicated-urinary-tract-infections-/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2015/03/remsima-inflectra--infliximab-biosimilars--are-launched-in-the-uk--napp-pharma---hospira/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-aramis-trial-of-bay-1841788-meets-primary-endpoint-in-prostate-cancer---orion---bayer-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2015/10/prolia--denosumab--superior-to-zoledronic-acid-in-gains-for-bone-mineral-density-according-to-phase-iv-study-in-postmenopausal-osteoporosis--amgen/2024-02-13T14:50:25+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-trial-of-ogx-011--custirsen--in-metastatic-castrate-resistant-prostate-cancer-fails-to-meet-endpoint--oncogenex-pharmaceuticals-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2014/05/nice-again-rejects-revlimid-for-myelodysplastic-syndromes-treatment---celgene/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-solosec--secnidazole--for-treatment-of-bacterial-vaginosis---symbiomix-therapeutics-/2021-09-24T07:13:51+00:00weekly0.6https://www.medthority.com/news/2017/06/european-society-of-hypertension--esh--annual-congress-underway-in-milan/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2012/12/mk-8931-enters-phase-ii-iii-trial-for-alzheimers-disease/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-sbla-for-nplate-to-treat-pediatric-patients-one-year-of-age-and-older-with-immune-thrombocytopenia--amgen-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/10/7th-joint-ectrims---actrims-meeting/2024-02-13T14:50:47+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-orkambi--lumacaftor-ivacaftor--for-use-in-children-with-cf--f508del-mutation--aged-6-11---vertex/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2016/10/merck-kgaa-announces-launch-of-gavi-oocyte-protocol-and-geri-medium--both-products-to-improve-key-steps-of-assisted-reproductive-treatment--art--/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2013/02/lyrica--pfizer--as-effective-as-keppra--ucb--for-epilepsy-treatment/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2012/06/j-j-janssen-cilag-submits-supplemental-applications-to-extend-use-of-zytiga-in-prostate-cancer/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2015/03/study-of-prevenar-13--pneumococcal-polysaccharide-conjugate-vaccine--in-cap-published-in-nejm--pfizer/2024-02-13T14:51:07+00:00weekly0.6https://www.medthority.com/news/2015/08/the-fda-has-extended-the-review-date-for-the-supplemental-bla-for-opdivo-nivolumab--to-treat-previously-untreated-advanced-melanoma-to-27-november-2015-/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2014/12/cosentyx-is-approved-in-japan-for-treatment-of-psoriasis-and-psoriatic-arthritis--novartis/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2014/01/core-valve-for-aortic-stenosis-is-fda-approved-medtronic/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2018/12/taltz-superior-to-humira-in-head-to-head-phase-iiib-iv-spirit-h2h-study-for-psoriatic-arthritis--eli-lilly/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-grants-510-k--clearance-for-fx-635-laser-device-in-chronic-musculoskeletal-pain/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2019/05/boston-scientific-acquires-vertflex-inc-and-with-it--superion-indirect-decompression-system-for-reduction-of-pain-in-patients-with-lumbar-spinal-stenosis/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-siklos-to-treat-pediatric-patients-with-sickle-cell-disease---addmedica-sas/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2017/01/supplemental-nda-filed-for-liletta--levonorgestrel-releasing-intrauterine-system--with-fda-for-long-term-contraception--allergan/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2017/07/alzheon--inc-makes-presentation-of-data-from-three-studies-of-alz-801--a-proposed-treatment-for-alzheimers-disease-at-the-aaic-meeting-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2012/12/migalastat-amicus-gsk-disappoints-in-phase-iii-trial-for-fabry-disease/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2015/01/analysis-of-peak-and-prime-trials-comparison-of-vectibix-and-avastin-in-colorectal-cancer-amgen/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2017/09/uk-advisory-agency-recommends-treatment-with-alecensa--alectinib--for-alk--non-small-cell-lung-cancer--roche-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2016/01/gsk-withdraws-from-us-development-of-toctino--alitretinoin--for-the-treatment-of-severe-hand-eczema--basilea/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-enbrel--etanercept--sbla-to-treat--pediatric-patients--ages-4-17--with-chronic-moderate-to-severe-plaque-psoriasis---amgen/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-trial-for-n9-gp-novo-nordisk--treatment-for-haemophilia-b/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2014/06/positive-safety-studies-for-nx-1207-for-bph---nymox-pharma/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-accepts-filing-of-vyxeos--cytarabine-and-daunorubicin--liposome-injection-to-treat-acute-myeloid-leukemia----jazz-pharmaceuticals/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2011/09/bolero-2-study-of-afinitor-in-er-her-2-advanced-breast-cancer-is-presented-at-emcc-congress/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-chmp-recommends-approval-of-hemlibra-for-haemophilia-a---roche-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-clinical-study-of-sa-237-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm---chugai-pharma/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2016/09/pharmacyclics-abbvie-files-snda-at-fda-for-imbruvica--ibrutinib--to-treat-patients-with-marginal-zone-lymphoma-/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2011/11/velcade--millennium-janssen-cilag--success-in-multiple-myeloma-trial/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-terra-study-of-lonsurf--trifluridine-and-tipiracil--hydrochloride--meets-primary-endpoint-in-colorectal-cancer--taiho-pharmaceutical/2024-02-13T14:52:12+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-keynote-048-trial-of-keytruda-meets-primary-endpoint-in-head-and-neck-squamous-cell-carcinoma---merck-inc-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-erelzi--etanercept-szzs--biosimilar-for-all-indications-in-the-reference-product---sandoz/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2013/11/lemtrada-sanofi-genzyme--has-advisory-committee-approval-in-us/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2013/02/chelsea-to-re-file-northera-at-fda-for--symptomatic-neurogenic-orthostatic-hypotension/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-phase-iii-results-with-flurpiridaz-f-18-in-pet-imaging-of-cad--lantheus-medical-imaging/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2010/08/sutent-fails-phase-ii-trial-in-nsclc/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2016/12/sandoz-announced-data-from-the-assist-fl-trial-which-shows-gp-2013-met-its-primary-endpoint-of-overall-response-rate--orr---demonstrating-equivalence-with-the-reference-product--mabthera-rituxan-/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2020/01/top-line-results-from-phase-iii-study--breeze-ad4--of-baricitinib-with-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis-not-controlled-with-cyclosporine---eli-lilly/2021-09-24T07:11:46+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-recommends-approval-of-pifeltro-for-hiv---merck-inc-/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2013/01/ema-rejects-raxone-catena--santhera--as-a-treatment-for-leber-s-hereditary-optic-neuropathy-/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2018/06/no-differences-found-in-malignancies-rates-between-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-versus-tnf-inhibitors/2021-12-01T13:58:12+00:00weekly0.6https://www.medthority.com/news/2017/01/gilead-sciences--inc-announced-that-it-s-maa-for-the-once-daily--single-tablet-regimen-of-sofosbuvir---velpatasvir-and-voxilaprevir--sof-vel-vox--for-chronic-hepatitis-c-virus--hcv--has-been-fully-validated-by-ema--/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2017/01/eu-chmp-recommends-approval-of-xeljanz--tofacitinib-citrate--for-rheumatoid-arthritis--pfizer/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2014/03/chmp-recommends-2-dose-schedule-gardasil-for-cervical-cancer---sanofi-pasteur-msd/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2013/05/european-commission-approves-hyqvia-for-treatment-of-primary-and-secondary-immunodeficiencies/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2018/05/world-ms-day-2018/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-chmp-recommends-approval-of-spectrila--asparaginase--for-acute-lymphoblastic-leukaemia--medac/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-results-for-lpcn-1021-for-low-testosterone-treatment---lipocine-inc-/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2016/11/three-year-positive-data-for--cosentyx--secukinumab--as-a-treatment-for-psoriatic-arthritis-presented-at-acr-meeting-by-novartis-/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-accepts-filing-of-uptravi--selexipag--for-treatment-of-pah--actelion/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-clinical-detect-study-of-nexobrid-meets-primary-endpoint-in-burns-treatment---mediwound/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-accepts-nda-for-toujeo-for-diabetes--sanofi-/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2018/01/patent-trial-and-appeal-board-invalidates-zytiga-s-2027-patent-and-opens-the-way-for-generic-competition---johnson---johnson-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2019/01/vyndaqel-filed-with-fda-for-transthyretin-amyloid-cardiomyopathy---pfizer-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-strensiq--asfotase-alfa--to-treat-pediatric-onset-hypophosphatasia--hpp---alexion-pharmaceuticals-inc-/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-clinical-studies-of-spravato-meet-endpoints-in-depression---janssen-pharma/2024-10-21T14:53:05+00:00weekly0.6https://www.medthority.com/news/2013/01/laplace-2-trial-of-evolocumab-plus-statins-success--amgen/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-from-two-phase-iii-trials-of-varisolve--btg--as-varicose-vein-treatment-/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2016/04/new-data-from-phase-iii-bestpws-zaf-311-study-of-zgn-433--beloranib--shows-safety-and-efficacy-in-prader-willi-syndrome--zafgen/2024-02-13T14:52:24+00:00weekly0.6https://www.medthority.com/news/2019/10/cms-001-phase-iii-study-of-firdapse-fails-to-meet-primary-endpoint-in-congenital-myasthenic-syndromes---catalyst-pharma/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2017/04/alecensa--alectinib--superior-to--xalkori--crizotinib--for-treatment-of--alk--positive-advanced-non-small-cell-lung-cancer---genentch-roche/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-dupixent-for-add-on-maintenance-treatment-for-severe-asthma-with-type-2-inflammation---regeneron---sanofi/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends--two-dose-cervarix-cervical-cancer-vaccine/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2019/06/ean-2019---preview/2024-02-22T15:19:02+00:00weekly0.6https://www.medthority.com/news/2014/06/development-of-tak-700-for-prostate-cancer-cancelled-takeda/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2013/06/invokana--janssen-pharmaceuticals--shows-greater-benefit-than-conventional-therapy-for-type-2-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2019/11/stryker-to-acquire-wright-medical/2025-10-16T11:29:22+00:00weekly0.6https://www.medthority.com/news/2019/12/kymriah-demonstrates-consistent-efficacy-and-safety-outcomes-in-us-patients-with-real-world-experience--in-adults-with-r-r-dlbcl---novartis/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-approves-darzalex---velcade---thalomid---dexamethasone-in-newly-diagnosed-multiple-myeloma---genmab/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2015/02/gsk-acquires-glycovaxyn/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2011/09/swift-mri-assists-detection-of-oral-cancer/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-refuses-recommendation-to-approve-exondys-51-for-duchenne-muscular-dystrophy---sarepta-therapeutics-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iv-study-results-for-restylane-dermal-fillers-indicate-benefits-in-facial-expressions--galderma/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2011/11/-bd-max-assay--becton--dickinson-and-company--for-mrsa-detection-is-eu-approved/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2019/11/takeda-s-dengue-vaccine-candidate-demonstrates-protection-in-children-ages-four-to-16-years--regardless-of-previous-dengue-exposure-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-symkevi---kalydeco-to-treat-children-with-cystic-fibrosis--aged-12-and-older---vertex-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-trials-of-ibi-301-meet-primary-endpoints-in-non-hodgkin-lymphoma---innovent-biologics---eli-lilly/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2013/02/new-meta-analysis-shows-benefits-of-xiaflex--auxilium-pharmaceuticals--for-peyronie-s-disease/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2013/05/inotuzumab-ozogamicin--pfizer--fails-phase-iii-trial-for-nhl/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2012/09/ariad-pharma-files-ponatinib-at-ema-for--cml-and-ph-all---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-results-from-the-aegis-h2h-trial-which-compared-feraccru-to-ferinject-for-the-treatment-of-iron-deficiency---norgine---shield-therapeutics/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2017/12/antibiotic-crisis-gives-new-life-to-history-s-diseases/2024-02-22T11:53:19+00:00weekly0.6https://www.medthority.com/news/2015/06/octreolin--octreotide-oral--filed-with-fda-for-acromegaly--chiasma/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-elecsys-hiv-combi-pt-assay-for-hiv-detection--roche/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2018/01/successful-phase-ii-promise-2-trial-for-eptinezumab-for-migraine-prevention--alder-biopharmaceuticals-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-phase-iii-select-compare-study-of-upadacitinib-for-rheumatoid-arthritis--abbvie-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2020/02/zealand-pharma-a-s-acquires-valeritas-holdings-/2021-09-24T07:12:10+00:00weekly0.6https://www.medthority.com/news/2016/05/tlando--lcpn-1021--safety-data-for-treatment-of-testosterone-deficiency-presented-at-111th-annual-scientific-meeting-of-the-american-urological-association--aua----lipocine-inc-/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2018/05/tecentriq---avastin-filed-with-fda-for-nsclc-and-given-priority-review----genentech-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2016/01/allergan-acquires-anterios-and-global-rights-to-ant-1207--a-botulinum-toxin-type-a--formulation/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2015/09/infinity-deep-brain-stimulation-system-ce-mark-approved-in-the-eu-for-parkinsons-and-dystonia--st-jude-medical/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-phase-iii-data-on-e-7080-for-thyroid-cancer-eisai-/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-results-for-xalkori--pfizer--in-treatment-of-patients-with-alk-positive-lung-cancer/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-viteka-for-hiv-1/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2019/05/ece-2019---learn-more/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2014/07/crenezumab-misses-endpoints-in-mid-stage-trial-for-alzheimers-disease---genentech-roche/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2019/02/ce-mark-for-ascyrus-medical-dissection-stent-ascyrus-medical/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-accepts-supplemental-biologics-license-application-for-xolair--for-the-treatment-of-nasal-polyps---genentech-roche/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2014/09/program-for-stimuvax-in-nsclc-discontinued-merck-serono/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2018/11/eu-approves-poteligeo-for-2-forms-of-cutaneous-t-cell-lymphoma---kyowa-hakko-kirin-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-inflectra--biosimilar-infliximab--for-all-remicade--infliximab--indications--pfizer/2021-09-24T07:10:46+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-palforzia-to-treat-peanut-allergy---aimmune-therapeutics/2021-09-24T07:12:02+00:00weekly0.6https://www.medthority.com/news/2015/02/-fda-advisory-committee-to-review-t-vec--talimogene-laherparepvec--for-metastatic-melanoma-on-29-april-2015--amgen/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2014/03/madit-crt-long-term-study-of-crt-defibrillators-demonstrates-reduction-of-risk-in-mild-heart-failure-patients--boston-scientific/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-assurity-and-endurity-pacemakers-for-af-st-jude-medical/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2019/02/cti-biopharma-corp--will-withdraw-its-application--maa--to-ema-for-pacritinib-as-a-treatment-for-myelofibrosis-/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2014/06/epidiolex-preliminary-success-encourages-gw-pharma-to-proceed-to-phase-ii-iii-for-dravet-syndrome/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-expanding-indication-for-hemlibra-in-haemophilia-a---roche/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-approves-latuda-for-schizophrenia---takeda-/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2013/01/biogen-idec-files-rfixfc-at-fda-for-treatment-of-haemophilia-b/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2012/10/european-commission-approves-tradjenta--eli-lilly-boehringer--for-treatment-with-insulin-for-patients-with-type-2-diabetes/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-sbla-for-opdivo---yervoy-to-treat-advanced-renal-cell-carcinoma--bms-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2013/08/iqwig-considers-jetrea-offers-major-benefits-for-vmt/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2016/06/inopulse-delivery-system-enters-phase-iii-trial-to-treat-pulmonary-arterial-hypertension---bellerophon-therapeutics-/2021-09-24T07:09:59+00:00weekly0.6https://www.medthority.com/news/2013/11/nice-rejects-velcade--janssen--as-first-line-therapy-for-mm/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2013/07/eu-grants-provisional-approval-of-erivedge--roche--for-bcc/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2015/04/study-of-heartware-ventricular-assist-system-in-heart-failure-meets-primary-endpoint-heartware/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2016/10/nice-recommends-epclusa--sofosbuvir-velpatasvir--as-a-treatment-option-for-six-genotypes-of-hcv---gilead-sciences/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2012/03/-resolute-des--medtronic--delivers-clinical-benefits-out-to-two-years/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2017/11/tirasemtiv-fails-vitality-als-phase-iii-study-for-amyotrophic-lateral-sclerosis--cytokinetics-inc-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2011/11/vyndaqel-pfizer--is-eu-approved-for--ttr-fap/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-results-in-study-of-diamondback-360-oas-in-cad-patients-cardiovascular-systems/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2012/02/phase-ii-study-of-skl-11197--sk-biopharmaceuticals--for-diabetic-peripheral-neuropathy-initiated-in-us/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-seebri-breezhaler--novartis--for-copd/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-accepts-bla-for-polatuzumab-vedotin----bendamustine---rituxan--for-the-treatment-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--dlbcl---genentech-roche/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-invictus-study-results-positive-for-ripretinib-in-patients-with-fourth-line-and-fourth-line-plus-gastrointestinal-stromal-tumors--deciphera-pharmaceuticals-/2021-09-24T07:17:47+00:00weekly0.6https://www.medthority.com/news/2015/07/enstasis-therapeutics-starts-business-in-anti-bacterials-with-etx-0914/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2015/06/opdivo--nivolumab---yervoy--ipilimumab--and-opdivo-monotherapy-superior-to-yervoy-in-checkmate-067-trial-for-advanced-melanoma---bms/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-now-recommends-combination-farydak---velcade--panobinostat---bortezomib--dexamethasone--to-treat-multiple-myeloma--novartis/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2019/02/selonsertib-fails-stellar-4-study-to-treat-nash---gilead-sciences/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2015/05/three-phase-iii-studies-support-sarilumab-in-ra-sanofi---regeneron/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-of-afinitor--everolimus--shows-benefits-for-tuberous-sclerosis-complex--novartis/2024-02-09T09:19:01+00:00weekly0.6https://www.medthority.com/news/2017/11/6th-ifad-2017/2024-10-22T08:21:18+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-emgality-for-preventive-treatment-of-migraine---eli-lilly/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2013/06/nice-recommends-jetrea--alcon-thrombogenics--to-treat-vitreomacular-traction/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2015/07/celldetect-non-invasive-test-recieves-ce-mark-approval-in-eu-for-bladder-cancer-recurrence--biolight-life-sciences/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2017/01/eisai-acquires-world-rights-to-obesity-therapy-belviq--lorcaserin-hcl-from-arena-pharma-/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2013/09/psd-502-receives-chmp-recommendation-to-treat-premature-ejaculation/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2012/06/study-shows-positive-results-with-heartlight-eas--cardiofocus--for-atrial-fibrillation/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2016/09/successful-phase-iii-trial-of-prolia--denosumab--compared-with-risedronate-in-patients-receiving-glucocorticoid-treatment--amgen-/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2016/06/astrazeneca-grants-exclusive-licence-to-grunenthal-to-market-zurampic-lesinurad-as-a-treatment-for-gout-in-europe-and-latin-america/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2017/03/xermelo--telotristat-ethyl--approved-by-fda-as-orally-administered-therapy-for-the-treatment-of-carcinoid-syndrome-diarrhea-in-combination-with-somatostatin-analog-therapy--lexicon-pharmaceuticals/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2014/02/eu-restricts-use-of-protelos-for-osteoporosis---servier/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2013/12/sanofi-to-market-stendra-in-africa-cis-turkey-and-me-for-erectile-dysfunction/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2019/04/development-of-ajovy-is-discontinued-in-cluster-headaches/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-senshio-as-a-treatment-for-vulvar-and-vaginal-atrophy--shionogi/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2012/11/t-dm1--genentech--is-filed-at-fda-for--her-2-positive-metastatic-breast-cancer/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2018/11/contepo-filed-with-fda-for-complicated-urinary-tract-infections---nabriva-therapeutics-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-recommends-humira-for-ulcerative-colitis-abbvie/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-hope-study-of-gbt-440-met-primary-endpoint-in-sickle-cell-disease---global-blood-therapeutics/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2013/12/edoxaban-effective-in-cancer-patients-with-vte-daiichi-sankyo/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2011/10/higher-hdl-cholesterol-levels-reduces-heart-attack-and-stroke-risk-in-diabetes-patients/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2015/01/kyprolis-is-filed-at-fda-and-ema-to-treat-relapsed-multiple-myeloma--amgen---onyx-pharma/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2012/09/boehringer-files-tomtovok-at-ema-for-nsclc/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-inrebic-to-treat-primary-or-secondary--post-polycythemia-vera-or-post-essential-thrombocythemia--myelofibrosis---celgene/2021-09-24T07:17:47+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-oncologic-drug-advisory-committee-voted-6-in-favor-and-6-against-the-benefit-risk-profile-for-sutent--sunitinib--in-patients-at-high-risk-of-recurrent-renal-cell-carcinoma-after-surgery---pfizer-/2025-02-03T14:58:24+00:00weekly0.6https://www.medthority.com/news/2011/09/new-review-of-cryoballoon-ablation-treatment-for-atrial-fibrillation/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2015/01/stellarex-dcb-has-ce-mark-approval-for-treatment-of-pad-covidien/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-grants-priority-review-to-risdiplam-for-spinal-muscular-atrophy---genentech-roche/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-expands-approval-of-truvada-for-at-risk-adolescents-against-hiv---gilead-sciences-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2018/12/rolling-submission-of-srp-4053-to-fda-for-duchenne-muscular-dystrophy-completed---sarepta-therapeutics-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2014/10/tabalumab-discontinued-for-lupus---eli-lilly/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2018/10/updated-data-for-larotrectinib-in-patients-with-trk-fusion-cancers--loxo-omcology---bayer-ag-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/03/crisaborole-ointment-filed-with-fda-for-atopic-dermatitis--anacor-pharmaceuticals/2021-09-30T12:34:35+00:00weekly0.6https://www.medthority.com/news/2018/03/novel-treatment-target-parkinsons/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2018/04/complete-response-letter-for--trastuzumab-biosimilar---pfizer/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2014/03/gsk-withdraws-mekinist-from-ema-for-metastatic-melanoma-/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2019/03/two-phase-iii-studies-of-kx2-391-ointment-meet-primary-endpoints-in--actinic-keratosis---almirall-and-athenex/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2017/01/update-on-results-of-phase-iii-trial-of-r-788--fostamatinib--in-thrombocytopenic-purpura--rigel-pharma/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2017/11/studies-compare-biosimilar-adalimumab-and-biosimilar-rituximab--with-their-reference-medicines---sandoz/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-panel-rejects-humira--abbvie--for-spondyloarthritis/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2017/01/medtronic-plc-announces-the-ce-mark-and-european-launch-of-the-corevalve-evolut-r-34-mm-valve-the-largest-sized-transcatheter-aortic-valve-implantation--tavi--system-available--/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2019/12/additional-analyses-from-phase-iii-study-with-doptelet-for-the-treatment-of-chronic-immune-thrombocytopenia---dova-pharma-sobi/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2015/09/braeburn-pharma-re-submits-nda-to-fda-for-probuphine--buprenorphine-hcl--subdermal-implant-to-treat-opioid-addiction/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-kymriah-for-the-treatment-of-pediatric-and-young-adult-patients--with-b-cell-acute-lymphoblastic-leukemia-and-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--dlbcl-----novartis-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-reject-taltorvic--merck-inc--for-sarcomas/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-alerts-require-viekira-pak--ombitasvir--paritaprevir--and-ritonavir-tablets--and-technivie--ombitasvir--paritaprevir-and-ritonavir-tablets--label-changes-due-to-hepatic-decompensation-and-liver-failure--abbvie/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2014/10/xtandi---enzalutamide--capsules-receive-positive-chmp-opinion-for-the-treatment-of-men-with-metastatic-castration-resistant-prostate-cancer-who-are-chemotherapy-na-ve/2024-02-22T11:45:30+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-opsumit--actelion--for-pah/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2012/01/isentress--merck--shows-promise-in-treating-young-patients-with-hiv/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2019/11/actelion-pharma-withdraws-filing-of-opsumit-for-cteph/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-updated-indications-for-soliris-in-pnh-alexion/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-spiriva-respimat-for-copd---boehringer/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2016/10/combination-eylea--aflibercept--and-rinucumab-fails-in-phase-ii-capella-study-for-age-related-macular-degeneration---regeneron---bayerhealthcare/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-now-recommends-stelara-for-treatment-of-psoriatic-arthritis--janssen-cilag/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-requires-clinical-trial-hold-for-phase-iii-trial-of-vgx-3100--a-proposed-treatment-for-cervical-cancer---inovio-pharma/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-recommends-cosentyx--secukinumab--to-treat-ankylosing-spondylitis---novartis/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2017/04/study-shows-sir-spheres-y-90-resin-microspheres-in-liver-cancer-reduces-side-effects-versus-sorafenib-with-no-impact-on-survival--sirtex/2021-09-24T07:14:10+00:00weekly0.6https://www.medthority.com/news/2018/07/nejm-publishes-results-of-celestial-trial-of-cabometyx-in-patients-with-previously-treated-advanced-hepatocellular-carcinoma---ipsen---exelixis-/2024-02-09T09:20:03+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-impella-rp-system-for-heart-failure-abiomed/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2017/12/chmp-recommends-approval-of-ozempic--for-type-2-diabetes-novo-nordisk/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-warning-of-rare-cases-of-liver-injury-in-hcv-patients-receiving-mavyret--zepatier-or-vosevi--abbvie-merck-inc--gilead/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-response-2-study-of-jakafi--ruxolitinib--meets-primary-endpoint-in-polycythemia-vera--incyte-corp/2024-02-09T09:20:13+00:00weekly0.6https://www.medthority.com/news/2019/05/pooled-analysis-of-data-from-three-phase-ii-iii-randomized-clinical-trials-on-the-use-of-rescue-medications-with-zilretta/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2017/07/trial-data-with-sir-spheres-microspheres-in-metastatic-colorectal-cancer-shows-improvement-in-overall-survival--sirtex/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-now-recommends-ninlaro-to-treat-multiple-myeloma---takeda-/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2011/11/nice-recommends-pradaxa-for-stroke-prevention-in-non-vavular-atrial-fibrillation-patients/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2019/03/testosterone-slows-prostate-cancer-recurrence-in-low-risk-patients/2021-09-24T07:18:51+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-data-demonstrates-masican--masitinib--superiority-in-severe-mastocytosis--ab-science/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2015/09/merck-announces-initiation-of-two-phase-iii-trials-for-imipenem-cilastatin-relebactam-combination-for-infections/2024-02-13T14:53:40+00:00weekly0.6https://www.medthority.com/news/2013/09/positive-health-outcomes-in-trial-of-ly-2189265-for-t2d/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/05/lundbeck-acquires-abide-therapeutics-and-with-it-abx-1431-/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2019/01/selinexor-filed-at-ema-for-conditional-approval-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma--karyopharm/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2016/06/scenesse--afamelanotide-16mg--has-its-first--launch-in-the-netherlands-to-treat-erythropoietic-protoporphyria---clinuvel-pharmaceuticals/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2016/08/studies-show-repatha--evolocumab--cuts-ldl-c-levels-in-familial-hypercholesterolemia---amgen/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approve-new-dosage-of-suboxone--reckitt-benckiser--for-treating-opioid-dependence/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2015/05/medtronic-evera-mri-surescan-implantable-cardioverter-defibrillator-unaffected-by-mri-scans-medtronic/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-extension-of-isentress-indication-for-hiv/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2018/04/tai-chi-as-good-as-or-better-than-aerobic-exercise-for-managing-chronic-pain/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2013/01/dexpramipexole--biogen-idec--fails-phase-iii-empower-trial-in-als/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-gives-510-k--approval-to-discovery-iq-pet-ct-system-for-imaging-ge-healthcare/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-invokana-to-treat-diabetic-kidney-disease--dkd--and-reduce-the-risk-of-hospitalization-for-heart-failure-in-patients-with-type-2-diabetes-and-dk---janssen-pharma/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2013/04/european-commission-approves-hexyon-hexcima--sanofi-pasteur---six-in-one-vaccine-/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-freestyle-insulinx-blood-glucose-monitoring-system--abbott-/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2019/07/biomarin-plans-regulatory-submissions-for-valoctocogene-roxaparvovec-to-treat-severe-hemophilia-a-in-4q-2019-in-both-u-s--and-europe-/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2015/10/clinical-data-for-corevalve-device-shows-significant-improvement-in-qol-for-aortic-stenosis--medtronic/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2019/11/results-from-phase-iii-olympus-and-rockies-trials-showing-that-roxadustat-significantly-increased-haemoglobin--hb--levels---astrazeneca/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-siliq--brodalumab--to-treat-moderate-to-severe-plaque-psoriasis--valeant-pharma-intl-/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2015/03/shire-files-nda-at-fda-for-lifitegrast-to-treat-dry-eye-disease/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2017/02/nice-rejects-ibrance--palbociclib--in-draft-guidance-as-a-treatment-for-hormone-positive--her-2-negative--breast-cancer---pfizer/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-phase-iii-trials-for-adolescents-and-young-adults-for-trumenba-vaccine-for-meningococcal-b--mnb--disease---pfizer/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-phase-iii-trial-protocol-for-winlevi--cb-03-01--for-treatment-of-acne--cassiopea-spa-/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-snda-for-pifeltro-in-hiv---merck/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2018/01/shocking-figures-reveal-cost-of-non-adherence-in-heart-disease-patients/2024-02-13T14:55:12+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-nouress-for-treating-neonatal-patients-requiring-total-parenteral-nutrition---avadel-pharma/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2019/06/alnylam-completes-rolling-submission-of-nda-to-fda-for-givosiran-for-treatment-of-acute-hepatic-porphyria--/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2013/05/guide-dbs-system--boston-scientific--receives-ce-mark/2021-09-24T07:16:20+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-cll14-study-of-venclexta---gazyva-shows-high-response-rate-in-chronic-lymphocytic-leukemia---genentech-roche/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2019/12/gilead-sciences--inc--has-submitted--an-nda-to-the-fda-for-filgotinib-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis-/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2018/09/positive-data-for-cardiac-assessments-in-the-apollo-phase-iii-study-of-patisiran--alnylam-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-investigation-into-zyprexa-relprevv--olanzapine-pamoate--inconclusive-eli-lilly/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2019/11/ema-prac-recommends-restrictions-on-use-of-lemtrada-in-multiple-sclerosis---sanofi/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2016/06/positive-results-from-trial-of-videssa-breast-diagnostic-system-for-early-stage-breast-cancer--provista-diagnostics/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-expanding-indication-of-the-elecsys-brahms-pct-assay-to-aid-antibiotic-treatment-in-infection---roche-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2014/04/s-icd-10-defibrillator-effortless-registry-results-published-in-european-heart-journal---boston-scientific/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2017/03/ebbinghaus-trial-evaluating-repatha--evolocumab--shows-no-adverse-affect-on-cognitive-function-in-treating-dyslipidaemia--amgen/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-accepts-re-filing-of-nda-for-zs-9--sodium-zirconium-cyclosilicate--to-treat-hyperkalaemia---astrazeneca/2023-07-24T13:13:31+00:00weekly0.6https://www.medthority.com/news/2016/10/results-from-the-phase-iii-falcon-study-show-superior-median-progression-free-survival-for-faslodex--fulvestrant--in-breast-cancer--astrazeneca/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-qtern--10mg-dapagliflozin-and-5mg-saxagliptin--to-treat-type-2-diabetes--astrazeneca/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2013/10/tecfidera--biogen--effective-in-ms-over-the-longterm/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-stelara--ustekinumab--for-moderately-to-severely-active-crohn-s-disease--janssen-cilag/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-raxibacumab--human-genome-sciences-gsk--to-treat-anthrax/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2018/09/ema-validates-filing-of-empliciti---pomalidomide---low-dose-dexamethasone-to-treat-multiple-myeloma--bms/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2015/08/ri-002-filed-with-fda-for-primary-immune-deficiency-disease--adma-biologics/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-pifeltro-and-delstrigo-medicines-for-hiv-1----merck-inc-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-imvigor130-study-of-tecentriq-reduces-the-risk-of-disease-worsening-or-death-in-previously-untreated-locally-advanced-or-metastatic-urothelial-carcinoma/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-approves-cometriq-for-thyroid-cancer---sobi---exelixis/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2017/11/eu-approves-tremfya-for-plaque-psoriasis---janssen-cilag-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2018/11/rewind-trial-shows-significant-reductions-of-cv-events-in-type-2-diabetes-patients-with-trulicity---eli-lilly/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2018/11/palisade-trial-of-ar-101-for-peanut-allergy-is-published-in-nejm--aimmune-therapeutics-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2018/04/ease-lid-2-phase-iii-trial-of-gocovri--shows-benefits-maintained-to-2-years-in-parkinson-s-dyskinesia---adamas-pharmaceuticals-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2012/10/chantix-champix--pfizer--smoking-cessation-study-in-depressed-patients/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2016/12/study-shows-novoseven--rfviia--resolves-majority-of-bleeds-in-haemophilia-a-or-b--novo-nordisk/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2011/12/xareto--j-j-bayer--is-fda-filed-for-acute-coronary-syndrome/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-vumerity-for-relapsing-forms-of-multiple-sclerosis---biogen---alkermes/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2018/05/quantum-r-phase-iii-study-of-single-agent-quizartinib-met-its-primary-endpoint-in-relapsed-refractory-acute-myeloid-leukemia----daiichi-sankyo-/2024-07-26T09:09:49+00:00weekly0.6https://www.medthority.com/news/2016/05/rolling-submission-of-solitaire--solithromycin--to-fda-for-community-acquired-bacterial-pneumonia-now-complete--cempra/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2017/06/urovant-sciences-licenses-vibegron-from-merck-inc--and-will-initiate-a-phase-iii-trial-in-2017-for-overactive-bladder-treatment-/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-procleix-zika-virus-assay-for-detection-of-zika-virus---grifols-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-veyvondi-in-von-willebrand-disease---baxalta-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2018/05/nice-issues-draft-guidance-refusing-the-use-of-lamzede-for-alpha-mannosidosis---chiesi-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2017/11/ra-beam-trial-showed-baricitinib--provides-greater-pain-control-improvements-than-humira-or-placebo-for-ra-patients--eli-lilly---incyte-corporation-/2024-07-26T09:10:32+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-olympiad-trial--overall-survival-results-for-lynparza-in-metastatic-breast-cancer---astrazeneca---merck-inc-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-tresiba--novo-nordisk--for-treatment-of-diabetes/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2015/10/amagine-2-and-amagine-3-studies-of-brodalumab-in-psoriasis-shown-superior-to-stelara--ustekinumab--and-published-in-nejm--valeant-pharma/2024-02-13T14:56:03+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-sbla-for-hemlibra-to-treat-hemophilia-a-without-factor-viii-inhibitors---genentech-roche-/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-approval-of-keytruda-in-head-and-neck-squamous-cell-carcinoma---merck-inc-/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/02/ema-to-review-safety-of-uptravi--selexipag--a-treatment-for-pulmonary-arterial-hypertension---actelion-j-j-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2018/05/faster-walking-heart-patients-are-hospitalised-less/2024-02-13T14:56:34+00:00weekly0.6https://www.medthority.com/news/2015/02/success-for-ixazomib-in-tourmaline-mm1-pivotal-phase-iii-trial-for-multiple-myeloma--takeda/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2016/10/novartis-announces-data-from-ascend-3-phase-ii-study-and-ascend-5-phase-iii-study-for-zykadia--ceritinib-to-treat-alk---non-small-cell-lung-cancer--/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-trial-of-zx-008--low-dose-fenfluramine-hydrochloride--in-dravet-syndrome-meets-primary-endpoints---zogenix-/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2017/08/the-arthritis-advisory-committee-of-the-fda-did-not-recommend-approval-of-sirukumab--proposed-trade-name-plivensia--for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis---janssen-biotech/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2012/03/study-shows-allergy-immunotherapy-tablet--merck--reduces-ragweed-allergy-symptoms-and-medication-use/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2017/12/tisagenlecleucel-in-stubborn-form-of-lymphoma-shows-sustained-responses/2024-02-13T14:57:03+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-approves-prevymis-for-cytomegalovirus-after-haematopoietic-stem-cell-transplant---merck-sharp---dohme-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2015/01/cariprazine-success-in-phase-iii-study-of-relapse-in-schizophrenia--actavis---gedeon-richter/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-latuda--sunovion-pharmaceuticals--for-bipolar-disorder/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/09/olympus-introduces-the-clevercut3v-distal-wireguided--sphincterotome--clevercut3v-dw--for-endoscopic-retrograde-cholangiopancreatography-procedures-/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2017/12/daxibotulinumtoxin-a-in-two-trials-positive-for-alleviating-glabellar-lines----revance-therapeutics-/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2019/12/primary-results-from-phase-ii-zuma-2-trial-of-kte-x19-to-treat-relapsed-or-refractory-mantle-cell-lymphoma--kite-gilead/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-strensiq--asfotase-alfa--for-treatment-of-pediatric-onset-hypophosphatasia--alexion-pharma/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-accepts-sbla-for-coagadex-in-hereditary-factor-x-deficiency---bio-products-lab-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2011/10/vertex-pharma-starts-phase-iiib-trial-in--genoytpe-1-hepatitis-c-patients-who-have--cc--variation-near-the-il28b-gene/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2015/04/success-for-ibrance--palbociclib---fulvestrant-in-paloma-3-trial-for-metastatic-breast-cancer--pfizer/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-conditional-approval-of-waylivra-to-treat-genetically-confirmed-familial-chylomicronemia-syndrome---akcea-therapeutics-and-ionis-pharma/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2016/10/regeneron-and-teva-provide-update-on-progress-of-phase-iib-trial-of-fasinumab-to-treat-chronic-low-back-pain-/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2016/07/belkyra---sodium-deoxycholate-receives-first-european-positive-opinion-via-decentralised-procedure-to-treat-subliminal-fat---allergan/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-announces-label-addition-to-cialis--eli-lilly--for-bph/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2011/11/studies-show-cervarix--glaxosmithkline--protects-against-serious-precursor-to-invasive-cervical-cancer/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/12/viiv-healthcare--received-a-complete-response-letter--from-the-fda-regarding-its-application-for-cabotegravir-and-rilpivirine-long-acting-regimen-for-treatment-of-hiv-1-infection-/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2014/07/baxter-buys-aesrx-and-with-it-aes--103-an--investigational-drug-for-sickle-cell-disease/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2016/01/dexilant-solutab-delayed-release-tablets--dexlansoprazole--approved-by-fda-for-gerd--takeda-/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2016/06/study-results-for-micra-transcatheter-pacing-system-in-arrhythmia-shows-safety-benefits-of-treatment--medtronic-/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2013/06/rely-able-trial-shows-long-term-safety-profile-of-pradaxa--boehringer--in-patients-with-atrial-fibrillation/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-trial-shows-sb2--infliximab-biosimilar--has-similar-safety-profile-to-remicade-in-rheumatoid-arthritis--samsung-bioepis/2024-02-09T09:23:48+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-versa-hd-radiation-therapy-system--elekta-/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2015/07/-urocidin--also-known-as-mcna--mycobacterium-phlei-cell-wall-nucleic-acid-complex--is-filed-at-fda-for-treatment-of-bladder-cancer--telesta-therapeutics/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-lenvima-for-thyroid-cancer-eisai/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2017/12/dual-vii-study-shows-xultophy-manages-type-2-diabetes-better-than--multiple-daily-injections---novo-nordisk/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2017/01/macrilen--macimorelin--fails-phase-iii-trial-for-treatment-of-growth-hormone-deficiency--aeterna-zentaris-inc-/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-study-of-xl-184--exelixis--shows-significant-improvement-in-patients-with-castration-resistant-prostate-cancer/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2016/12/study-of-aspireassist-aspiration-therapy-system-in-obesity-published-in-american-journal-of-gastroenterology--aspire-bariatrics/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2016/09/successful-phase-iii-ascend-4-trial-for-zykadia--ceritinib-for-alk--non-small-cell-lung-cancer-patients--novartis/2021-09-24T07:09:14+00:00weekly0.6https://www.medthority.com/news/2018/10/kidney-transplant-patients-experience-higher-rates-of-uncontrolled-gout-compared-to-other-renal-disease-patients--horizon-pharma/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2014/02/cordis-recieves-ce-mark-for-renlane-renal-denervation-system-for-resistant-hypertension/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-expanded-approval-of-sprycel-to-include-the-treatment-of-pediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive--ph---all---bms/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2014/12/biogen-has-success-with-early-alzheimers-study-for-biib-037-and-moves-to-phase-iii-/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2011/05/bronchitol-gets--negative-trend--vote-at-chmp-for-cystic-fibrosis/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-analyses-of-levodopa-carbidopa-intestinal-gel--abbott--in-patients-with-parkinson-s-disease/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2014/07/pfizer-buys-baxter-vaccines-portfolio-for--635-million/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-radicava--edaravone--for-amyotrophic-lateral-sclerosis--mt-pharma-america/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2013/09/spiriva-respimat-vs-handihaler-copd-study-in-nejm/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-varizig--cangene-corpn--for-chicken-pox-treatment/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2018/04/pf-00299804-filed-with-fda-and-ema-for-advanced-or-metastatic-non-small-cell-lung-cancer---pfizer-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/04/positive-phase-iii-study-of-ph-94b-to-treat-social-anxiety-disorder---vistagen-therapeutics/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2017/03/solo-2-phase-iii-trial-of-lynparza---olaparib--shows-positive-pfs-results-for-gbrca-platinum-sensitive-relapsed-ovarian-cancer-patients--astrazeneca/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2014/02/stivarga-enters-trial-for-treatment-of-colorectal-cancer-after-resection-of-liver-metastases---bayer/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-accepts-nda-for-viekira-pak--ombitasvir---paritaprevir---ritonavir---dasabuvir--in-hepatitis-c--abbvie/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iv-results-with-invocell-fertility-system-published-in-journal-of-assisted-reproduction-and-genetics--invo-bioscience/2024-02-13T14:57:20+00:00weekly0.6https://www.medthority.com/news/2018/01/positive-results-from-keynote-189-trial-for-keytruda---alimta---chemotherapy-combination-for-first-line-nsclc--merck-inc-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-now-recommends-ikervis--ciclosporin--for-severe-keratitis--santen-pharmaceutical/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-advisory-committee-negative-recommendation-for-mepolizumab--as-an-add-on-treatment-for-the-reduction-of-exacerbations-in-patients-with-copd---gsk-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-warning-of-rare-genital-infection-necrotizing-fasciitis--associated-with-sglt2-inhibitors-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2018/02/vx-659-and-vx-445-enter-phase-iii-trials-as-triple-therapies-to-treat-cystic-fibrosis-with-f508del-gene-mutation---vertex/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-tango-study-demonstrates-control-of-hiv-1-with-a-2-drug-regimen-of-dolutegravir-plus-lamivudine-in-virally-suppressed-patients-switching-from-a-3-drug-regimen--viiv-healthcare/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2020/02/ce-mark-for-cobalt-and-crome-portfolio-of-implantable-cardioverter-defibrillators--and-cardiac-resynchronization-therapy-defibrillators---medtronic/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-giotrif--boehringer--for-nsclc/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2017/03/positive-results-from--summit-07-phase-iii-efficacy-study-of-nktr-181--a-first-in-class-opioid-analgesic---nektar-therapeutics/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2013/01/phase-iii-study-of-neulasta--amgen--for-neutropenia-in-colorectal-cancer-meets-primary-endpoint/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2013/10/axiron--eli-lilly--has-german-approval-for-hypogonadism/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2016/12/-a-new-analysis-shows-people-with-cancer-treated-with-xarelto--rivaroxaban--for-blood-clots-had-significantly-fewer-emergency-room--er--visits-and-lower-healthcare-costs--bayer-healthcare---janssen-pharma/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2018/04/neod-001-development-is-discontinued-for-al-amyloidosis--prothena-corpn-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-beacon-crc-trial-of-braftovi-triplet-in-colorectal-cancer-published-in-nejm---pfizer-inc/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2017/10/three-sub-analyses-from-the-phase-iii-oasis-1-study--show-a-consistent-safety-efficacy-profile-of-omadacycline--when-treating--absssi--in-patients-with-comorbid-conditions---paratek-pharmaceuticals-/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-new-treatments-in-chronic-liver-disease/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2018/03/just-a-few-minutes-of-light-intensity-exercise-linked-to-lower-death-risk-in-older-men/2024-10-22T08:28:48+00:00weekly0.6https://www.medthority.com/news/2012/03/allergan-seeks-wider-indication-at-fda-eu-for-botox-for-overactive-bladder/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2012/08/two-new-phase-iii-studies-of-xarelto--bayer-healthcare--initiated-for-af-patients-scheduled-for-surgery---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-combination-zydelig--idelalisib--shows-benefits-in-chronic-lymphocytic-leukemia--gilead-sciences/2024-02-09T09:24:10+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-witouch--hollywog--for-chronic-back-pain---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-discusses-phase-iii-studies-of-arimenda--adamas-pharmaceuticals--for-alzheimers-treatment/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2018/04/ema-validates-maa-from-astrazeneca-and-merck-inc--for-lynparza-to-treat-deleterious-or-suspected-deleterious-brca-mutated--human-epidermal-growth-factor-receptor-2--her2--negative-metastatic-breast-cancer-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/08/hlx-02-trastuzumab-biosimilar-is-filed-at-ema---shanghai-henlius-biotech/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2012/05/bronchitol--pharmaxis--is-filed-at-the-fda-for-the-treatment-of-cystic-fibrosis/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2017/01/supplemental-application-to-fda-for-tecentriq--atezolizumab-for-locally-advanced-urothelial-carcinoma--patients-ineligible-for-cisplatin-chemotherapy---genentech-roche/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-trial-of-translarna-for-cystic-fibrosis-published-in-lancet-resp-med---ptc-therapeutics/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-amglidia-to-treat-neonatal-diabetes--ammtek/2024-07-26T09:10:48+00:00weekly0.6https://www.medthority.com/news/2017/05/biogen-acquires-cirara--intravenous-glyburide--from-remedy-pharma---a-drug-which-is-intended-to-treat-large-hemispheric-infarction--lhi---biogen/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-new-formulation-of-onsolis--fentanyl-buccal-soluble-film--for-pain-treatment-biodelivery-sciences/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-takhzyro-to-prevent-attacks-of-hereditary-angioedema----shire-plc-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2012/04/study-shows-stroke-risk-high-when-xarelto--bayer-healthcare--stopped/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2014/10/cardiorespiratory-fitness-is-often-misdiagnosed/2024-02-13T14:58:29+00:00weekly0.6https://www.medthority.com/news/2016/05/eversense-continuous-glucose-monitoring--cgm--system-receives-ce-mark--senseonics-holdings--inc-/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-advisory-committee-recommends-bedaquiline--janssen-for-treatment-of-tuberculosis-/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-study-of-brabafen-in-dravet-syndrome-published-in-jama-neurology---zogenix/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2012/03/complete-response-letter-for-northera--chelsea-therapeutics--for-neurogenic-orthostatic-hypotension/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-success-for-dapagliflozin-in-type-2-diabetes/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2012/09/lundbeck-files-vortioxetine-at-ema-for-major-depressive-episodes/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2018/05/ironwood-pharmaceuticals-to-separate-into-two-companies-in-2019-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2015/05/light-study-of-cv-risk-in-obese-patients-is-terminated-early-for-contrave--orexigen--takeda/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2018/05/taltz-approved-by-fda-to-treat-psoriasis-involving-the-genital-area---eli-lilly-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-advisory-committee-recommends-inlyta--pfizer--for-renal-cell-carcinoma/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2018/10/hawk-and-harrier-phase-iii-96-week-data-on-rth-258-confirms-superiority-in-age-related-macular-degeneration---novartis-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2013/11/alexion-pharma-announces-four-studies--of-soliris-at-asn-meeting-for-ahus/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2016/10/ema-s-chmp-recommends-approval-of-cystadrops--mercaptamine--for-cystinosis--orphan-europe/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-altapore-bioactive-bone-graft-use-in-posterolateral-spinal-fusion--baxter/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2012/08/cytofab--btg-astrazeneca--fails-sepsis-trial------------------------------/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-review-of-yaz-yasmin--bayer--risk-benefit/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-data-on-solitaire--solithromycin-oral-capsules--in-community-acquired-bacterial-pneumonia--cempra/2024-02-13T14:58:49+00:00weekly0.6https://www.medthority.com/news/2018/06/positive-phase-iii-results-for-alxn-1210-in-patients-with-paroxysmal-nocturnal-hemoglobinuria--pnh--to-be-presented-at-eha-meeting---alexion-pharma-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2012/08/ema-approves-votrient--glaxo-smith-kline--for-patients-with-soft-tissue-sarcoma/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2015/09/eisai-and-purdue-pharma-to-collaborate-on-development-and-marketing-of-e-2006--lemborexant---a-treatment-for-insomnia/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2016/10/successful-phase-ii-study-of-shp-620--maribavir-for-cytomegalovirus--cmv--infection-undergoing-hematopoietic-stem-cell-transplant-or-solid-organ-transplant---shire/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-select-study-of-lenvima--lenvatinib--in-thryoid-cancer-published-in-the-journal-of-clinical-oncology--eisai-/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-accelerated-approval-for-tazervik--to-treat-metastatic-or-locally-advanced-epithelioid-sarcoma----epizyme-inc-/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2015/08/lx-1032--telotristat-etiprate--meets-primary-endpoint-in-cancer-patients-with-carcinoid-syndrome--lexicon-pharmaceuticals/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2017/02/additional-results-of-phase-iii-trial-of-ibalizumab-in-hiv-aids-presented--theratechnologies-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2018/03/method-to-predict-drug-stability-could-lead-to-more-effective-medicines/2021-09-24T07:06:26+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-expands-indication-of-azilect-for-parkinson-s-disease---teva-pharma/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-noctiva--desmopressin-acetate--nasal-spray-to-treat-nocturnal-polyuria--serenity-pharmaceuticals/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2012/04/abt-450-r-plus-abt-333-phase-ii-studies-in-hepatitis-c-announced-by-abbott-labs/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2017/11/study-unlocks-link-between-late-shift-workers-and-increased-instances-of-metabolic-diseases--diabetes-and-obesity/2021-11-30T11:57:22+00:00weekly0.6https://www.medthority.com/news/2014/10/study-of-ciprofloxacin-plus-fluocinolone-acetonide-meets-endpoints-in-otitis-media---lab-salvat/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2011/11/xarelto-bayer-johnson--johnson--success-in-atlas-acs-2-timi-51-study-in-acute-coronary-syndrome-/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-rayaldee--calcifediol--for-secondary-hyperparathyroidism-in-chronic-kidney-disease--opko-health/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/04/post-hoc-analysis-of-phase-iii-trial-of-zilretta-to-treat-osteoarthritis-knee-pain/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2014/06/mk-3475-success-in-study-for-non-small-cell-lung-cancer---merck-inc--/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-grants-accelerated-approval-for-opdivo--nivolumab----yervoy--ipilimumab--combination-to-treat-braf-v600-wild-type-metastatic-melanoma--bms/2024-02-22T15:39:54+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-zirabev---bevacizumab-biosimilar/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-minivelle-for-menopause-osteoporosis---noven-pharma/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2014/01/envarsus-filed-with-fda-for-kidney-transplant-rejection-veloxis-pharma/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2014/08/post-marketing-study-of-actos-shows-no-increased-risk-of-bladder-cancer-in-diabetes-patients-takeda/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2018/10/detailed-results-from-phase-iii-finch-2-trial-of-filgotinib-for-rheumatoid-arthritis---gilead---galapagos/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2019/08/atlas-2m-study-met-its-primary-endpoint-for-cabotegravir-and-rilpivirine-administered-every-eight-weeks-compared-to-four-week-administration--viiv-healthcare/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approve-s-icd--boston-scientific--for-sudden-cardiac-arrest/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2012/09/noven-pharma-files-low-dose-mesylate-salt-of-paroxetine--for-menopause/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-advisory-committee-recommends-natpara-for-treatment-of-hypoparathyroidism--nps-pharma/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2017/10/ueg-week--bacteria-eradication-reduces-gastric-cancer-risk-by-22--in-the-over-60s--new-research-shows/2024-02-22T15:40:56+00:00weekly0.6https://www.medthority.com/news/2011/10/correct-trial-for-regorafenib-success-in-colorectal-cancer/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-mvasi--bevacizumab-awwb--biosimilar-for-non-small-cell-lung-cancer--for-metastatic-colorectal-cancer--glioblastoma--metastatic-renal-cell-carcinoma-and-carcinoma-of-the-cervix---amgen-and-allergan-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2014/08/pfizer-files-bla-at-fda-for-lp2086-vaccine-for-the-prevention-of-invasive-meningococcal-disease-/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2017/01/two-phase-iii-studies-of-fg-4592--roxadustat--in-anemia-meet-primary-endpoints--fibrogen/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2019/04/celgene-and-acceleron-pharma-submit-bla-for-luspatercept-for-the-treatment-of-myelodysplastic-syndromes-associated-anemia-who-have-ring-sideroblasts-and-for-the-treatment-of-patients-with-beta-thalassemia-associated-anemia-who-require-rbc-transfusions-/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2019/06/molmed-suspends-enrollment-in-phase-iii-study-of-zalmoxis-/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2012/01/tradjenta--boehringer--shows-no-added-benefit-in-assessment-for-type-2-diabetes/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2011/10/chmp-recommends-alimta-for-continuation-maintenance-therapy-in-nsclc/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2013/02/sanofi-genzyme-reports-positive-results-from-engage-and-encore-studies-of-eliglustat-for-gaucher-disease-type-1-/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2018/02/positive-results-from-prosper-phase-iii-trial-of-xtandi-to-treat-non-metastatic-castration-resistant-prostate-cancer----astellas---pfizer/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2013/06/tresiba--novo-nordisk--success-in-quality-of-life-study-of-type-2-diabetes/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2016/01/second-trial-failure-of-simtuzumab--in-idiopathic-pulmonary-fibrosis-following-failure--of-the-drug-in-2014-in-pancreatic-cancer--gilead-sciences/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2017/10/international-brain-tumour-awareness-week/2024-03-05T15:07:31+00:00weekly0.6https://www.medthority.com/news/2013/02/eu-approves-lyxumia--sanofi--to-treat-adults-with-type-2-diabetes/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2016/01/supplemental-new-drug-application-for-jardiance--empagliflozin--filed-with-fda-for-cv-risk-reduction--boehringer-eli-lilly/2024-02-22T15:41:09+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-accepts-for-review-nda-for-lixisenatide-to-treat-type-2-diabetes--sanofi/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---psoriasis--increasingly-efficient-therapies-towards-healing/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trial-of-alimta--eli-lilly--fails-to-meet-primary-endpoint-in-nsclc/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-gives-510-k--approval-for-iqon-spectral-ct-imaging-system---philips/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-compass-study-shows-xarelto--rivaroxaban---aspirin-significantly-reduced-major-cv-events---janssen-research-development---bayer-healthcare-/2024-11-15T08:38:36+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-stelara--ustekinumab--for-plaque-psoriasis-in-adolescents--janssen-cilag/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2012/07/early-results-from-phase-ii-study-of-gammagard-liquid-10--baxter--for-alzheimers-disease/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2016/04/spire-ai-phase-iii-trial-success-for-bococizumab-pre--filled-pen-to-treat-dyslipidaemia--pfizer/2024-02-22T15:41:20+00:00weekly0.6https://www.medthority.com/news/2014/08/lesinurad-success-in-clear-1--clear-2-and-crystal-studies-for-gout---astrazeneca/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-maintains-negative-opinion-for-raxonea-poposed-treatmant-for-duchenne-muscular-dystrophy---santhera-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2015/12/pooled-phase-iii-analyses-show-benefits-of-ryzodeg--insulin-degludec-insulin-aspart--in-type-2-diabetes--novo-nordisk/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2018/05/eco-2018/2024-02-22T15:41:53+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-egaten-to-treat-fascioliasis---novartis/2021-09-24T07:17:11+00:00weekly0.6https://www.medthority.com/news/2012/02/phase-iii-success-in-two-studies-for-cariprazine--forest-richter--in-schizophrenia/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2016/05/theranova--dialyse-improves-clearance-of-toxins-by-hemodiafiltration---baxter-international-/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2019/09/tremfya-filed-with-fda-for-psoriatic-arthritis---janssen-pharma/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-extension-study-recorlev-meets-objectives-in-cushing-s-syndrome---strongbridge-biopharma/2024-11-15T11:32:25+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-announces-naloxone-app-competition-to-combat-the-rising-epidemic-of-opioid-overdose-/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-puts-trial-of-zgn-433--beloranib--in-patients-with-prader-willi-syndrome-on-hold--zafgen/2024-02-22T15:42:15+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-single-dose-prefilled-syringes-for-xolair-as-a-new-formulation-for-allergic-asthma-and-urticaria----novartis/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2015/04/ema-report-states-that-glybera--alipogene-tiparvovec--from-uniqurelacks-efficacy-and-has-a-negative-benefit-risk-ratio-for-lld-/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2020/01/bausch-health---clearside-biomedical-announce-publication-of-pivotal-phase-iii-data-on-xipere--in-ophthalmology-journal-/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-advisory-committee-recommends-approval-of-sivextro-for-absssi---cubist/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2013/04/synera--nuvo-research--significantly-improves-pain-in-shoulder-impingement-syndrome/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2016/02/mylan-acquires-meda-ab-for--9-9-billion/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2018/12/duke-clinical-research-institute--is-leading-a-new-clinical-study-coordinate-diabetes-trial--to-optimize-care-for-people-with-type-2-diabetes-and-cardiovascular-disease---eli-lilly---boehringer-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2019/09/rp-g28-fails-to-meet-endpoints-in-its-liberatus-phase-iii-trial-to-treat-lactose-intolerance---ritter-pharma/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-results-using-e-5564--eisai--show-no-significant-benefit-for-sepsis/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-praluent--alirocumab--for-the-treatment-of-hypercholesterolemia---sanofi--regeneron-pharma-/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-ibrance--palbociclib--for-the-treatment-of-women-with-hormone-receptor-positive--human-epidermal-growth-factor-receptor-2-negative--hr--her2---locally-advanced-or-metastatic-breast-cancer----pfizer/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2018/06/complete-response-letter-regarding-the--new-drug-application--nda--for-duobrii---idp-118--lotion-in-the-treatment-of-plaque-psoriasis----ortho-dermatologics-valeant-pharma-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2015/10/astellas-and-immunomic-therapeutics-enter-into-agreement-over-lamp-vax-technology/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-select-psa-1-study-of-rinvoq-shows-positive-top-line-results-in-psoriatic-arthritis---abbvie/2021-09-24T07:12:08+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-intandem3-study-of-lx-4211--sotagliflozin--met-primary-endpoint-in-type-1-diabetes--lexicon-pharmaceuticals/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2018/01/balcoltra--contraceptive--is-fda-approved---avion-pharma/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2015/09/vivagel-bv-receives-eu-approval-for-bacterial-vaginosis-starpharma/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2016/12/uk-nice-recommends-use-of-otezla--apremilast--for-adult-patients-with-psoriatic-arthritis-who-have-had-an-inadequate-response-to-dmards-celgene/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2012/05/cobicistat--gilead-sciences---booster--for-aids-drugs-is-filed-at-ema/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2019/11/naxitamab-filed-with-the-fda-in-a-rolling-submission-for-high-risk-neuroblastoma---y-mabs-therapeutics/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2018/02/imvamune-smallpox-vaccine-is-effective-in-comparison-to-acam2000---bavarian-nordic-a-s-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2017/06/-updated-results-of-devote-phase-iii-trial-of-tresiba--insulin-degludec-injection-100-u-ml-in-type-2-diabetes-patients-with-high-risk-cv-disease--novo-nordisk/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2017/04/the-xii-international-society-of-dermatology-kicks-off-congress-in-buenos-aires--argentina-/2024-07-26T09:12:14+00:00weekly0.6https://www.medthority.com/news/2018/02/a-tipple-a-day/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2015/03/phase-ii--osler-1--and-phase-iii--osler-2--studies-confirm-reduction-of-cv-events-with-rapatha--evolocumab--amgen/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2019/05/eu-approves-lorviqua-for-alk--non-small-cell-lung-cancer---pfizer/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approves-use-of-stelara-in-paediatric-patients-with-plaque-psoriasis--johnson---johnson/2021-09-24T07:11:46+00:00weekly0.6https://www.medthority.com/news/2019/06/exposure-to-inorganic-dust-increases-risk-of-gout-in-women-by-27-/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2016/11/corevalve-evolut-r-system-demonstrates-benefits-for-aortic-stenosis-treatment--medtronic/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-issues-complete-response-letter-to-novartis-for-rlx-030-for-heart-failure-/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2019/07/nice-gives-positive-recommendation-of-skyrizi-for-psoriasis-in-final-guidance---abbvie/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-bromsite--bromfenac-ophthalmic-solution--to-treat-post-operative-inflammation-and-ocular-pain-in-cataract-surgery-patients--sun-ophthalmics-/2021-09-24T07:10:44+00:00weekly0.6https://www.medthority.com/news/2013/06/trebananib--amgen--success-in-phase-iii-trial-for-ovarian-cancer-/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2015/08/trevicta--paliperidone-palmitate--once-every-three-month-injection-filed-with-ema-for-schizophrenia--janssen/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2016/10/nice-recommends-use-of-tagrisso--osimertinib--in-non-small-cell-lung-cancer-in-adults-whose-disease-has-progressed-only-after-first-line-treatment-with-an-egfr-tyrosine-kinase-inhibitor--astrazeneca/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2014/03/successful-trial-for-isentress-compared-to-atazanavir-and-darunavir-for-treatment-naive-hiv----merck-inc-/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2018/07/essure-contraceptive-device-to-be-withdrawn-in-the-us-as-of-31-december-2018--bayer-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2017/01/dextenza--dexamethasone-insert--refiled-with-fda-for-ocular-pain-occurring-after-ophthalmic-surgery--ocular-therapeutix/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2018/04/alexion-pharma-acquires-wilson-therapeutics-and--with-it-wtx-101-a-novel-treatment-for-wilson-disease/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-ultomiris-for-paroxysmal-nocturnal-hemoglobinuria---alexion-pharma-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2015/11/request-to-expand-approval-for-imbruvica--ibrutinib--to-untreated-patients-with-chronic-lymphocytic-leukaemia-submitted-to-ema--janssen/2024-10-22T08:17:15+00:00weekly0.6https://www.medthority.com/news/2014/05/possible-sales-of-older-drugs-by-merck---sanofi-and-abbott-labs/2025-10-16T10:53:32+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-approval-of-airexar-spiromax--salmeterol-xinafoate---fluticasone-propionate--for-treatment-of-severe-asthma-and-chronic-obstructive-pulmonary-disorder---teva/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-cobas-vivodx-mrsa-diagnostic-test-for-detection-of-bacterial-infection---roche/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2018/02/prolia--fails-phase-iii-breast-cancer-trial---amgen---daiichi-sankyo-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-impassion130-study-of-tecentriq-plus-abraxane-meets-co-primary-endpoint-in-triple-negative-breast-cancer---genentech-roche-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2019/05/the-commence-study-shows-that--bioprosthetic-surgical-aortic-valves-with-resilia-tissue-platform-continue-to-demonstrate-favorable-safety-and-hemodynamic-performance-through-four-years-follow-up--edwards-lifesciences-/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2019/10/servier-acquires-world-rights-to-pixuvri-from-cti-biopharma-/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2014/07/shire-board-willing-to-recommend-acceptance-of-new-offer-from-abbvie/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-nucala--an-add-on-treatment-for-severe-refractory-eosinophilic-asthma-in-paediatric-patients-aged-six-up-to-17-years---gsk/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2017/01/rhofade-cream--oxymetazoline-hci-cream-1-0----approved-by-fda-for-persistent-facial-erythema-associated-with-rosacea--allergan-/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2019/06/novartis-announced-new-data-from-the-maximise-trial-evaluating-the-efficacy-and-safety-of-cosentyx-in-the-management-of-axial-manifestations-of-psoriatic-arthritis-/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2015/04/bms-transfers-rights-to-erbitux---cetuximab--in-us--puerto-rico-and-canada-to-eli-lilly-/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-amplatzer-vascular-plug-from-st-jude-medical-/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2016/05/clinical-trial-finds-avastin--bevacizumab--and--lucentis--ranibizumab--perform-equally-well-in-wet-age-related-macular-degeneration--genentech-roche/2024-02-22T15:42:36+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-zanamivir-for-the-treatment-of-complicated-and-life-threatening-influenza-a-or-b-virus-infection-in-adult-and-paediatric-patients---gsk/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2016/01/abt-494-enters-phase-iii-trials-for-ra--abbvie/2024-02-22T15:42:52+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-advisory-committee-recommends-forxiga-for-type-2-diabetes-in-usa-astrazeneca-bms/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-numient--levodopa-carbidopa-modified-release--for-parkinsons-disease--impax/2021-09-24T07:03:41+00:00weekly0.6https://www.medthority.com/news/2016/07/eu-approves-variation-of-authorization-for-kyprolis--carfilzomib----dexamethasone-to-treat-multiple-myeloma--amgen/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iiib-trial--dual-vii--results-with-xultophy--ideglira--positive-for-treatment-of-type-2-diabetes--novo-nordisk-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2013/03/paion-ag-initiates-phase-ii-trial-of-remimazolam-for-anaesthesia/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-updating-indication-for-soliris-in-ahus-alexion/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-grants-510-k--approval-for-propeller-platform-for-use-with-ellipta--inhaler-for-asthma-and-copd---propeller-health---gsk/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2019/07/interim-data-evaluating-elocta-for-immune-tolerance-induction-in-people-with-inhibitors-and-severe-haemophilia-a-shared-at-isth-2019---sobi---sanofi/2021-09-24T07:18:20+00:00weekly0.6https://www.medthority.com/news/2016/03/merck-seeks-royalties-on-sales-of-sovaldi--sofosbuvir--and-harvoni--sofosbuvir---ledipasvir--due-to-alleged-infringement-of-its-patents-by-gilead-sciences/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2016/01/discontinuation-of-higher-doses-in-phase-iii-trials-for-laquinimod-for-ms---teva---active-biotech/2024-02-22T15:43:06+00:00weekly0.6https://www.medthority.com/news/2017/02/the-haemophilia-business-of-biogen-is-transferred-to-bioverativ-inc-/2025-10-16T11:33:34+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-fourier-study-of-repatha--evolocumab--shows-effectiveness-in-reducing-cardiovascular-events--amgen/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2013/02/gsk-initiates-phase-iii-study-of-combination-dabrafenib-and-trametinib-for-melanoma/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2012/03/ulimorelin--tranzyme--fails-in-ulises-007-trial-for-post-operative-ileus/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-inclusion-of-bydureon-bcise-device-with-indication-for-the-drug-in-treating-type-2-diabetes---astrazeneca-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/01/gilead-acquires-farnesoid-x-receptor-agonists-from-phenex-pharma-for-treatment-of-nash/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2012/02/nice-updates-advice-allowing-earlier-use-of-roactemra-actemra--roche--for-rheumatoid-arthritis/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2019/03/aad-congress-2019/2021-12-01T14:02:25+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-kalydeco-for-eight-non-g551d-gating-mutations-in-cystic-fibrosis--vertex/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2018/05/two-phase-iii-trials-for-dupixent-in-asthma-published-in-nejm---sanofi---regeneron-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---familial-primary-distal-renal-tubular-acidosis--results-of-a-multinational-collaboration-study/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-trial-of-arzerra-fails-to-meet-primary-endpoint-in-cll-gsk-genmab/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-lower-dose-of-symjepi--for-the-emergency-treatment-of-allergic-reactions--including-anaphylaxis---admis-pharma/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-chmp-recommend-approval-of-wakix--pitolisant--for-narcolepsy--bioprojet/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-negative-for-re-examination-of-eteplirsen-to-treat-duchenne-muscular-dystrophy---sarepta/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-magnetom-terra-for-mri-imaging---siemens-/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2015/05/g-ba-indicates-translarna--ataluren--offers-benefit-in-duchenne-muscular-dystrophy-ptc-therapeutics/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2019/05/pfizer-to-acquire-therachon-holding-ag-and-with-it-ta-46-for-the-treatment-of-achondroplasia/2025-10-16T11:27:48+00:00weekly0.6https://www.medthority.com/news/2012/05/macitentan-actelion--success-in-phase-iii-for-pah/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2017/09/profile-1014-trial-shows-overall-survival-data-for-xalkori--crizotinib--in-previously-untreated-patients-with-alk-positive-advanced-non-small-cell-lung-cancer---pfizer/2024-07-26T09:22:39+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-clear-wisdom-study-of-etc-1002-shows-safe-profile-in-dyslipidaemia---daiichi-sankyo---esperion/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2016/06/teva-receives-complete-response-letter-from-fda-for-sd-809--deutetrabenazine--as-a-treatment-for-huntington-disease--/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-sustain-results-for-ozempic-show-weight-reductions-in-type-2-diabetes---novo-nordisk-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2011/10/vyvanse-positive-in-european-phase-iii-study-for-adhd/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2012/04/krx-0401--keryx-aeterna-zentaris--fails--x-pect-trial-for-colorectal-cancer/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-expands-approval-of-hawkone-directional-atherectomy-system-for-peripheral-artery-disease--medtronic/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-oxervate-to-treat-neurotrophic-keratitis--dompe-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approve-cimzia--ucb--for-ankylosing-spondylitis/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-synjardy--empagliflozin---metformin--to-treat-type-2-diabetes--boehringer-ingelheim---eli-lilly/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-zynquista-to-treat-type-1-diabetes---sanofi---lexicon/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---traditional-indian-medicines-can-cause-membranous-nephropathy--mn-/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2014/12/farxiga-to-enter-type-1-diabetes-trial-astrazeneca---ono-/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2014/08/nice-requestes-more-information-on-jardiance-for-type-2-diabetes---boehringer/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-spritam-zipdose--levetiracetam--for-epilepsy-aprecia-pharmaceuticals/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-approval-of-aerivio-spiromax--fluticasone-propionate---salmeterol--for-treatment-of-severe-asthma-and-copd-in-adults--teva/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-to-review--vismodegib-genentech--for-basal-cell-carcinoma-/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-accepts-filing-of-zohydro-er-for-chronic-pain-treatment/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2014/09/rayaldee-meets-endpoints-in-phase-iii-trial-for-ckd-opko-health/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2018/02/remoxy-er-is-re-submitted-to-fda-as-an-abuse-deterrent-to-treat--severe-pain---pain-therapeutics-inc-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2013/03/dymista--meda-ab--is-eu-approved-via-decentralised-procedure-for-allergic-rhinitis/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2012/03/eu-approves-vepacel-baxter--vaccine-for-immunisation-against-hsn1-influenza-a/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2014/04/abilify-maintena-reduces-hospitalisation-rates-for-schizophrenia-patients--lundbeck---otsuka/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2016/06/astrazeneca-will-licence-byetta---exenatide--to-teva-permitting-launch-in-us-of-a-generic-in-october-2017-/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2013/09/takeda-launches-latuda--lurasidone--in-switzerland/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2016/12/dupixent--dupilumab--filed-in-the-eu-for-moderate-to-severe-atopic-dermatitis--sanofi-regeneron-pharma/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2014/09/results-of-afinitor-in-radiant---3-trial-for-pancreatic-neuroendocrine-tumor---novartis/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2012/09/no-evidence-for-effect-of-omega-3-fatty-acids-on-cardiovascular-risk---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2017/11/1st-easl-nafld-summit/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2014/09/study-of-cyramza-in-gastric-cancer-published-in-the-lancet-oncology-eli-lilly/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2019/10/nucala-significantly-reduces-exacerbations-in-first-global-prospective-real-world-study-of-a-biologic-in-severe-eosinophilic-asthma---gsk/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2017/03/array-biopharma-inc--withdraws-from-the-fda--binimetinib-monotherapy-for-the-treatment-of-nras-mutant-melanoma-/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2018/01/study-finds-nearly-half-of-all-sudden-death-cases-in-cardiomyopathy-are-genetic-/2024-02-22T15:44:19+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-opdivo--nivolumab--for-metastatic-squamous-nsclc-bms/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2015/04/success-for-ixekizumab-in-spirit-p1-phase-iii-trial-for-psoriatic-arthritis-eli-lilly/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-advisory-committee-to-review-evenity-to-treat-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture--amgen---ucb-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-optic-study-of-ptk-0796-shows-high-response-rate-in-community-acquired-bacterial-pneumonia---paratek-pharma-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-data-of-subcutaneous-cinryze--viro-pharma--with-enhanze--halozyme--delivery-platform-for-hae/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2012/10/successsful-phase-iii-study-of-actimid-in-multiple-myeloma/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2011/11/qnexa--vivus-inc--phase-iii-results-published-in-obesity/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-neba-system--neba-health--for-diagnosing-adhd/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2018/12/positive-phase-iii-results-for-f-627-in-neutropenia-in-breast-cancer---generon-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2013/06/palace-3-study-reported-at-eular-for-apremilast--celgene--for-psoriatic-arthritis/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2014/06/pfizer-files-rlp2086-vaccine-at-fda-for-meningococcal-disease--/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-restricts--sale-of-essure-contraceptive-implant---bayer-healthcare-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2016/09/novartis-to-close-its-cell-and-gene-therapy-unit-/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2012/03/avastin--roche--possible-new-treatment-for-haemorrhagic-telangiectasia/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-trecondi-in-haematopoietic-stem-cell-transplantation---medac-gmbh-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2015/09/alliqua-biomedical--announces-a-poster-at-sawc-meeting-on-alliqua-s-biovance-human-amniotic-membrane-allograft-for-wound-care/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-does-not-recommend-tecentriq-for-patients-who-have-already-received-prior-treatment-for-metastatic-urothelial-cancer--whose-disease-has-progressed-after-platinum-based-chemotherapy---roche-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2016/04/abbvie-to-acquire-stemcentrx--and-with-it-rovalpituzumab-tesirine--rova-t--treatment-for-small-cell-lung-cancer/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-opinion-for-emgality-for-the-prophylaxis-of-migraine--eli-lilly/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2015/02/positive-results-for-eylea-in-head-to-head-study-of-eylea--avastin-and-lucentis-in-dmo-regeneron/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2017/06/chmp-recommends-faslodex--fulvestrant--for-the-first-line-treatment-of-hormone-receptor-positive--hr----locally-advanced-or-metastatic-breast-cancer---astrazeneca/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2019/09/alnylam-presents-results-from-a-proteome-wide-biomarker-analysis-of-samples-from-the-apollo-phase-iii-study-of-onpattro-for-the-treatment-of-the-polyneuropathy-of-hereditary-attr-amyloidosis--/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-advisory-committee-votes-a-qualified-yes-for-watchman-laac-device-for-stroke-prevention---boston-scientific/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-elecsys-hsv-assays--roche--for-detecting-herpes-simplex-virus----------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2016/08/-fda-accepts-an-nda-from-clovis-oncology-for-rucaparib-to-treat-advanced-ovarian-cancer-in-patients-with-deleterious-brca-mutated-tumors--/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-postpones-pdufa-decision-for-duobrii-a-proposed-treatment-for-psoriasis---ortho-dermatologics/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-imlygic--talimogene-laherparepvec--to-treat-unresectable-cutaneous--subcutaneous-and-nodal-lesions-in-patients-with-melanoma--amgen/2024-10-22T08:15:34+00:00weekly0.6https://www.medthority.com/news/2015/05/intercept-pharma-to-initiate-phase-iii-trial-of-oca-for-nash-/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2012/03/phase-ii-success-for-ixekizumab-elililly--in-psoriasis/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-lucemyra-to-mitigate-opioid-withdrawal-symptoms---us-worldmeds/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2019/07/sanofi-provides-update-on-zynquista-type-2-diabetes-phase-iii-program-and-terminates-collaboration-with-lexicon-/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2014/03/metmab-fails-phase-iii-trial-for-nsclc---genentech/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2016/08/buprenorphine-sublingual-spray-meets-primary-endpoint-in-phase-iii-trial-for-moderate-to-severe-postoperative-pain---insys-therapeutics/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-expanded-use-of-impella-2-5--impella-cp-heart-pumps-for-elective-and-urgent-high-risk-percutaneous-coronary-intervention---abiomed-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2014/02/eu-approves-neuraceq-for-pet-imaging-of-amyloid-plaque-piramal-imaging/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2012/09/aveo-files-tivozanib-at-fda-for-treatment-of-renal-cell-carcinoma/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2013/01/eu-approves-betmiga--astellas--for-the-treatment-of-overactive-bladder-/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2011/09/xarelto-reccommended-in-europe-for-dvt--stroke-and-af/2024-10-15T08:02:30+00:00weekly0.6https://www.medthority.com/news/2015/07/results-of-veclose-study-of-venaseal-for-treatment-of-incompetent-greater-saphenous-veins-medtronic/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2013/10/eu-countries-approve-striverdi-respimat--boehringer--for-copd/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2018/04/sunovion-pharma-files-nda-at-fda-for-apomorphine-sublingual-film-to-treat-off-episodes-for-parkinson-s-disease-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2018/09/boston-scientifoc-acquires-augmenix-inc--and-with-it-the-spaceoar-system-for-use-in-prostate-radiotherapy/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2018/04/international-fnd-awareness-day-2018/2024-07-26T09:32:02+00:00weekly0.6https://www.medthority.com/news/2018/11/sandoz-and-pear-therapeutics-launch--reset-for-patients-with-substance-use-disorder-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-accepts-filing--nda--of-ombitasvir--paritaprevir--ritonavir--obv-ptv-r--for-treatment-of-hepatitis-c-genotype-4--abbvie/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trial-shows-plavix--bms-sanofi--plus-aspirin-reduces-risk-of-stroke-by-a-third/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-gazyvaro--obinutuzumab--for-follicular-lymphoma--roche/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2017/06/successful-phase-1-zuma-3-trial-of--kte-c19--axicabtagene-ciloleucel--in-r-r-acute-lymphoblastic-leukemia--kite-pharma/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2013/10/ms-registry-analyses-support-switch-to-gilenya--novartis--for-ms/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2016/09/real-world-evidence-from-global-ms-base-registry-supports-tecfidera--dimethyl-fumarate--efficacy-to-treat-relapsing-remitting-multiple-sclerosis---biogen/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/03/final-results-of-aadvise-study-of-brincidofovir-for-the-treatment-of-adenovirus--adv--infection-in-allogeneic-hematopoietic-cell-transplant--hct--recipients--chimerix-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-recommends-approval-of-xeljanz-for-active-psoriatic-arthritis---pfizer-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-repatha-to-reduce-the-risk-of-heart-attack--stroke-and-coronary-revascularization--amgen-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2016/06/data-shows-reduction-of-risk-of-kidney-disease-with-jardiance--empagliflozin-in-patients-with-type-2-diabetes--boehringer---eli-lilly/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2013/09/yervoy-fails-phase-iii-trial-for-metastatic-prostate-cancer/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2017/04/nice-does-not-recommend-ninlaro---ixazomib--combination---lenalidomide---dexamethasone-as-a-treatment-for-multiple-myeloma--takeda/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2019/06/data-from-ev-201-trial-of-enfortumab-vedotin-for-bladder-cancer--is-presented-at-asco--seattle-genetics-and-astellas/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2011/10/arikase-trials-for-use-in-cystic-fibrosis-are-placed-on-hold-by-fda/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2018/10/two-phase-iii-trials-of-dupixent-in-chronic-rhinosinusitis-meet-primary-endpoints---sanofi-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-siliq--brodalumab--for-patients-with-moderate-to-severe-plaque-psoriasis--leo-pharma/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2015/08/depomed-board-of-directors-rejects-horizon-pharma-offer/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2017/02/uk-nice-rejects-daxas--roflumilast--for-chronic-obstructive-pulmonary-disease--astrazeneca/2021-09-24T07:13:16+00:00weekly0.6https://www.medthority.com/news/2013/10/eli-lilly-and-pfizer-to-collaborate-on-tanezumab-programme-for-osteoarthritis/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2016/03/real-world-study-shows-invokana--canagliflozin--superior-to-dpp-4-inhibitors-in-type-2-diabetes--janssen-pharma/2024-02-22T15:45:09+00:00weekly0.6https://www.medthority.com/news/2011/12/libigel--biosante-pharma--fails-two--phase-iii-trials-for-female-sexual-dysfunction/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2016/09/boston-scientific-acquires-endochoice-and-with-it-full-spectrum-endoscopy--fuse--colonoscope-/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-study-of-probiotics--danone--for-antibiotic-associated-diarrhoea/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2014/12/t-vec---talimogene-laherparepvec--is-filed-at-fda-for-metastatic-melanoma-amgen-/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2016/09/horizon-pharma-acquires-raptor-pharma-and-with-it-procysbi-and-quinsair/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/05/additional-results-reported-from-phase-iii-secure-trial-of-twirla--contraceptive-patch--agile-therapeutics/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-idx-dr-diagnostic-medical-device-for-diabetic-retinopathy---idx-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2019/05/launch-of-confirm-rx-icm-allows-physicians-to-remotely-monitor-arrhythmias/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-yescarta-to-treat--large-b-cell-lymphoma---kite-gilead-sciences-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-phase-iii-results-for-gilotrif-in-scc---boehringer/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2015/01/actavis-and-gedeon-richter-re-file-nda-at-fda-for-rgh-188---cariprazine--for-schizophrenia-and-bipolar-disorder/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2015/01/novartis-files-nda-at-fda-for-ultibro-breezhaler--qva-149--to-treat-copd-/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-gadavist-for-imaging-coronary-artery-disease---bayer/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2013/02/study-of-qsymia--vivus-inc---shows-positive-benefits-for-treatment-of-obesity/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2019/02/novartis-acquires-tqj-230--previously-akcea-apo-a--lrx--from-akcea-therapeutics-for-targeted-cv-therapy-/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2019/11/imbruvica---rituximab-combination-filed-at-fda-to-treat--younger-patients-with-chronic-lymphocytic-leukemia--cll--or-small-lymphocytic-lymphoma--sll---abbvie/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2017/01/keytruda--pembrolizumab---chemotherapy-filed-as-sbla-at-fda-to-treat-first-line-metastatic-or-advanced-non-squamous-non-small-cell-lung-cancer--nsclc--regardless-of-pd-l1-expression-and-with-no-egfr-or-alk-genomic-tumor-aberrations---merck-inc-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-study-of-probuphine--buprenorphine-implant--meets-endpoints-in-opioid-dependence--braeburn-pharmaceuticals/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2018/09/nucala-study-in-eosinophilic-asthma-published-in-jaci---gsk-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-obizur--susoctocog-alfa--for-treatment-of-acquired-haemophilia----baxalta/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2015/08/roche-to-acquire-kapa-biosystems/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2019/06/new-iclaprim-data-were-presented-at-the-american-society-for-microbiology--asm--microbe-2019-meeting--motif-bio/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2015/06/-eu-approval-for-resolor--prucalopride--extended-to-male-patients-with-chronic-constipation-shire-plc/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2019/07/gemphire-therapeutics--to-merge-with-neurobo-pharmaceuticals-/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-nemo-trial-of-mek-162--binimetinib--meets-endpoint-in-nras-mutant-melanoma-patients--array-biopharma/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2012/08/architect-testosterone-assay-abbott--2nd-generation-receives-ce-mark---------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2013/02/eu-approves-promus-premier-stent--boston-scientific--for-treating-cad/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/10/analysis-of-exit-interviews-shows-benefits-of-lx-1032--telotristat-etiprate--in-carcinoid-syndrome--lexicon-pharmaceuticals/2024-02-22T15:45:20+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-results-for-tofacitinib--pfizer--for-psoriasis/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2013/02/ucb-files-cimzia-at-fda-and-ema-for-treatment-of-axial-spondyloarthritis-/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2016/05/uk-nice-final-guidance-recommends-use-of-invokana--canagliflozin---farxiga--dapagliflozin--and-jardiance--empagliflozin--in-type-2-diabetes--janssen-pharmaceuticals---astrazeneca---eli-lilly---boehringer/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2019/08/american-journal-of-ophthalmology--publishes-review-highlighting-lack-of-treatments-for-active-thyroid-eye-disease---horizon-pharma/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-turalio-to-treat--symptomatic-tenosynovial-giant-cell-tumor/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2017/08/pneumonia-or-sepsis-in-adults-associated-with-increased-risk-of-cardiovascular-disease/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-gazyva--genentech--for-cll/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---first-randomized-controlled-trial-of-fecal-transplants-for-obesity-shows-potential-progress/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2019/03/data-from-phase-iii-unifi-study-of-stelara-shows-remission-in-ulcerative-colitis---janssen/2024-07-26T09:32:55+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-symtuza-for-hiv-1---janssen-pharma-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2012/10/clear-benefits-of-transcatheter-aortic-valve-replacement-for-patients-with-aortic-valve-disease/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2014/09/update-on-gardasil-for-cervical-cancer-sanofi/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-ajovy-for-preventative-treatment-of-migraine---teva/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-keytruda-to-treat-cervical-cancer---merck-inc--/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-panorama-1-trial-subgroup-analysis-for-farydak--panobinostat--for-multiple-myeloma--novartis/2024-02-22T15:49:02+00:00weekly0.6https://www.medthority.com/news/2014/07/eu-approves-simbrinza-for-glaucoma-and-ocular-hypertension-alcon-novartis/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2019/04/stryker-launches--in-the-us-its-defibrillation-solution--the-lifepak-cr2-defibrillator-/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2014/06/nice-requires-further-information-from-gilead-before-it-can-recommend-sovaldi-for-hepatitis-c-/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-xerava-to-treat--complicated-intra-abdominal-infections--tetraphase-pharma-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-confirms-rejection-of-abraxane--nab-paclitaxel--for-pancreatic-cancer--celgene/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-shows-halaven-improves-os-in-breast-cancer---eisai/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2018/03/eu-approves-lokelma-to-treat-hyperkalaemia---astrazeneca-/2023-07-24T15:13:31+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-trial-of-stimuvax--merck-serono--fails-to-meet-primary-endpoint-in-patients-with-nsclc/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-zepatier--elbasvir-and-grazoprevir--to-treat-chronic-hepatitis-c-virus-genotype--gt--1-or-gt4-infection--with-or-without-ribavirin--merck-inc-/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2012/04/astrazeneva-and-the-medicines-company-to-co-promote-brilinta-in-usa/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2017/07/two-phase-iii-studies-studies-1489-and-1490-are-positive-for-the-fixed-dose-combination-of-bictegravir-bic-emtricitabine-tenofovir-alafenamide-ftc-taf-for-the-treatment-of-hiv-1-infection-in-treatment-naive-adults-gilead-sciences/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/05/should-the-number-of-gp-s-patient-consultations-be-capped-/2024-02-22T15:49:57+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-data-from-phase-iii-trial-of-serada--depomed-inc--to-manage-menopausal-hot-flashes/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-accepts-nda-for-roxadustat--to-treat-anemia-of-chronic-kidney-disease-in-both-non-dialysis-dependent--and-dialysis-dependent--patients--fibrogen-inc----astrazeneca---astellas/2021-09-24T07:12:01+00:00weekly0.6https://www.medthority.com/news/2016/01/data-validates-decipher-prostate-cancer-classifier-in-diagnosing-the-disease--genomedx-biosciences/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2015/08/ironwood-pharma-to-co-promote-viberzi--eluxadoline--in-the-us-with-allergan-for-irritable-bowel-syndrome/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2015/09/uk-eams-approves-entresto--sacubitril-valsartan--for-heart-failure--novartis/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2018/07/success-for-revlimid---rituxan-combination-in-phase-iii-augment-trial-for-follicular-and-marginal-zone-lymphoma---celgene-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2015/09/results-of-checkmate-025-study-of-opdivo--nivolumab--in-renal-cell-carcinoma-published-in-nejm--bms/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-humulin-r-u-500-kwikpen--insulin-human-injection--for-type-1---2-diabetes--eli-lilly/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2012/09/dalbavancin--durata-therapeutics--qt-study-results------------------------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-data-on-gencaro--arca-biopharma--shows-drug-effective-on-genetic-subset-of-atrial-fibrillation-patients/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2012/04/lower-rates-of-hypoglycaemia-with-insulin-degludec-compared-to-insulin-glargine/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2015/06/data-from-phase-iii-trial-of-alks-9070--aripiprazole-lauroxil--for-schizophrenia-published-in-j-clinical-psychiatry--alkermes/2024-02-22T15:50:19+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-does-not-recommend-cerliponase-alfa-to-treat-ceroid-lipofuscinosis-type-2-disease---biomarin-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2017/04/binaxnow-influenza-a---b-card-2-diagnostic-test-and-reader-get-510-k--clearance-from-fda---alere/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2012/06/phase-iii-psummit-1-study-of-stelara--j-j-janssen-cilag--for-patients-with-active-psoriatic-arthritis-reaches-primary-endpoint/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approve-surgiclear--covalon-technologies--for-wound-healing---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2018/12/retrospective-analysis-shows-significant-reductions-in-postsurgical-pain-and-opioid-requirements-with-exparel-in-cesarean-section-patients---pacira-pharma/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2015/06/humax-cd38--daratumumab--submitted-to-fda-in-rolling-submission-for-multiple-myeloma--janssen-biotech/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-hemangeol-for-infantile-haemangioma---pierre-fabre/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-phase-iii-results-show-xofluza-reduces-risk-of-flu-after-contact-with-an-infected-person-by-86-percent---genenech-roche/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-results-from-phase-iii-study-of-imvamune-vaccine-for-smallpox-bavarian-nordic/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-in-oral-explanation-will-issue-a-negative-opinion-for-raxone--idebenone--in-duchenne-muscular-dystrophy---santhera-pharma-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2015/06/european-commission-approves-opdivo-nivolumab--for-treatment-of-advanced-metastatic-melanoma--bms/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2014/04/new-condition-proposed-as-sluggish-cognitive-tempo---eli-lilly/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2012/04/generx-cardium-therapeutics--enters-phase-iii-for-myocardial-ischaemia/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-data-shows-improvement-in-overall-survival-with-halaven--eribulin--vs-dacarbazine-in-liposarcoma--eisai/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-nda-for-ccp-07as-a-treatment-for-cough-cold---vernalis---tris-pharma/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-rejects-delamanid--otsuka--for-tuberculosis/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2014/06/nice-recommends-use-of-amitiza-for-cic-sucampo-pharma/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-kyprolis--carfilzomib----lenalidomide---dexamethasone-to-treat-multiple-myeloma--amgen/2024-02-22T15:50:32+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-macrilen-for-the-diagnosis-of-patients-with-adult-growth-hormone-deficiency--aeterna-zentaris-inc-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2012/12/positive-european-regulatory-procedure-for-elvanse--shire--for-adhd/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-trailblaze-pharos-rna-based-companion-diagnostic-for-use-with-entrectinib-in-solid-tumours---ignyta-/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2012/07/ag200-15--agile-therapeutics--contraceptive-patch-filed-at-fda/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2013/04/biomarin-files-vimzim-at-ema-for-mucopolysaccharidosis-type-iva-/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2011/10/genetics-and-plavix-iscover--play-role-in-risk-of-post-stent-thrombosis/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2011/11/nomac-e2-is-rejected--by-fda-as-a-contraceptive-1/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-keynote-024-results-for-keytruda--pembrolizumab--show-improved-progression-free-survival-in-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2019/12/spravato----esketamine--nasal-spray-authorised-in-europe-for-adults-with-treatment-resistant-major-depressive-disorder/2024-03-05T15:14:30+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-data-from-pix301-trial-of-pixuvri--cell-therapeutics--for-non-hodgkin-lymphoma/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2015/11/boston-scientific-acquires-celonova-biosciences-and-with-it-embozene-tandem-drug-elutable-microspheres-and-oncozen-and-embozene-microspheres/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2019/04/eado-2019---find-out-more/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2017/06/european-academy-of-neurology--ean--congress-2017/2024-10-11T11:54:09+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-from-phase-iii-study-of-avastin--genentech-roche--in-brain-cancer-patients/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2013/06/reassessment-by-iqwig-finds-xalkori--pfizer--may-offer-considerable-benefit-for-alk--nsclc/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2011/12/herceptin--roche--may-equalise-dfs-for-obese-and-normal-weight-breast-cancer-patients/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-tibsovo-to-treat-aml-with-a-susceptible-isocitrate-dehydrogenase-1--idh1--mutation---agios-pharma-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2015/08/envarsus-xr-receives-orphan-drug-designation--from-fda-for-prophylaxis-of-organ-rejection--veloxis-pharma/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-accepts-nda-for-sd-809--deutetrabenazine--as-a-proposed-treatment-for-tardive-dyskinesia----teva-pharmaceuticals/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2018/02/successful-results-for-nolasiban-from-implant2-trial-for-improving-pregnancy-rate-following-in-vitro-fertilization---obseva-sa/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2016/12/biomarin-initiates-phase-iii-study-of-vosoritide-to-treat-achondroplasia-/2021-09-24T07:10:13+00:00weekly0.6https://www.medthority.com/news/2019/05/gammacore-is-selected-for-innovation-and-technology-payment-program-to-treat-cluster-headache-through-nhs-england---electrocore-inc-/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2017/10/positive-results-from-phase-iii-hercules-study-with-caplacizumab-for-thrombotic-thrombocytopenic-purpura---ablynx-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2016/04/successful-phase-iib-trial-for-cvt-301-for-off-periods-in-parkinson-s-disease--acorda/2024-02-22T15:50:45+00:00weekly0.6https://www.medthority.com/news/2015/06/aveo-pharma-agrees-submission-terms-with-chmp-for-tivozanib-as-a-treatment-for-renal-cell-carcinoma/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-ii-iii-zotrip-study-of-qtrypta-in-migraine-published-in-headache-journal---zosano-pharma/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2017/06/canvas-program-results-for-invokana--canagliflozin-show-improvement-in-cv-outcomes-in-type-2-diabetes-patients---johnson---johnson/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iiia-trial-for-nn-9535--semaglutide-subcutaneous--meets-objective-in-type-2-diabetes--novo-nordisk/2024-02-22T15:51:03+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-elaris-uf-i-study-of-elagolix-meets-primary-endpoint-in-uterine-fibroids---abbvie-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-gocovri--amantadine-extended-release-tablets--to-treat-dyskinesia-in-patients-with-parkinson-s-disease--adamas-pharmaceuticals-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2014/12/rix-fp-filed-with-the-fda-for-hemophilia-b-csl-behring/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2018/06/stryker-may-acquire-boston-scientific-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2016/08/biotronik-launches-enitra-8-hf-t-qp-pacemaker-in-europe-/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2013/06/study-of-kendall-sequential-compression-system--covidien--shows-reduced-risk-of-dvt/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iii-mission-programme-of-two-trials-of-elenbecestat-are--initiated-by-eisai-and-biogen-for-treatment-of-alzheimers-disease/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-rejects-again-xarelto---janssen-bayer--for--treatment-of-acute-coronary-syndrome/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2016/09/sentinel-cerebral-protection-system-filed-with-fda-for-yse-during-tavr---claret-medical/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-purixan-liquid-formulation-for-all--rare-disease-therapeutics/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2016/03/pain-therapeutics-re-files-at-fda--remoxy-an-abuse-deterrent-formulation-of-extended-release-oxycodone-for-long-term-opioid-treatment-of-pain-/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-chmp-recommends-approval-of-episalvan--birch-bark-extract--for-wound-healing--birken-ag/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2014/12/takeda-returns-rights-to-ferumoxytol-to-amag-pharma-/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2019/02/the-phase-iii-keynote-240-trial-evaluating-keytruda-for-advanced-hepatocellular-carcinoma--liver-cancer-did-not-meet-its-co-primary-endpoints-merck-inc--/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2017/09/volanesorsen-is-filed--nda--at-fda-for-the-treatment-of-familial-chylomicronemia-syndrome--akcea-therapeutics-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2017/12/roche-acquires-ignyta-and-with-it-entrectinib--a-cns-active-tyrosine-kinase-inhibitor-directed-to-ros1-or-ntrk-fusion-cancers-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2019/11/roxadustat-phase-iii-programme-pooled-analyses-positive-for-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-ckd---astrazeneca---fibrogen/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2019/10/novartis-positive-52-week-prevent-data-confirm-cosentyx-efficacy-in-addressing-entire-axspa-spectrum-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-data-on-brisdelle-published-in-menopause-noven-pharma/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2019/07/alnylam-pharmaceuticals--inc--submits-a-maa-to-ema-for-givosiran/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2014/06/empagliflozin-is-re-submitted-to-fda-for-type-2-diabetes--eli-lilly-boehringer/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2012/06/mallinckrodt-to-co-market-sumavel-dose-pro-for-migraine-in-us/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2018/03/cosentyx-shows-superior-improvements-in-psoriasis-patients--quality-of-life-versus-stelara---novartis/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iia-study-results-for-benralizumab-in-copd-published-in-the-lancet-respiratory-medicine-astrazeneca/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2012/12/chmp-recommends-selincro--biotie-lundbeck--for-treatment-of-alcohol-dependence/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2013/12/results-of-phase-iii-trial-of-lifitegrast-for-dry-eye-disease-shire/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-advisory-committee-recommends-evenity-to-treat-osteoporosis--amgen---ucb/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-imvexxy-for-treatment-of-moderate-to-severe-dyspareunia---therapeuticsmd-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-issues-complete-response-letter-for-rg-1068--repligen--for-pancreatic-mri-imaging-/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-akynzeo-for-prevention-of-nausea-and-vomiting-for-cancer-chemotherapy-patients-eisai/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2014/01/eu-approves-xigduo-for-type-2-diabetes-astrazeneca/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2015/11/almirall-acquires-rights-to-veltin-and-altabax-from-stiefel-in-exchange-for-its-rights-to-toctino-/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-arnuity-ellipta-for-treatment-of-asthma---gsk/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-chmp-recommends-approval-of-natpar--rhpth-1-84---in-chronic-hypoparathyroidism--shire/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-results-from-studies-of-iprivask-for-dvt---marathon-pharma/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2018/11/pooled-data-from-phase-iii-studies--shows-terlipressin-was-associated-with-improved-overall-and-transplant-free-survival-in-hepatorenal-syndrome-type-1-patients---mallinckrodt/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2018/04/world-parkinson-s-day-2018/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-trimbow--beclometasone-dipropionate---formoterol-fumarate---glycopyrronium--in-copd--chiesi/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-approves-eperzan-for-type-2-diabetes---gsk/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2017/07/auris-medical-holding-ag-announced-that-it-has-completed-patient-enrollment-in-the-phase-iii-healos-clinical-trial--of-am-111-in-idiopathic-sudden-sensorineural-hearing-loss-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2012/07/early-results-for-e-2609--eisai--in-alzheimers-disease/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-help-study-data-on-shp-643-shows-significant-reduction-of-attacks-in-hereditary-angioedema---shire-/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2015/06/eu-approves-oral-orfadin--nitisinone--to-treat-hereditary-tyrosinaemia-type-1--sobi/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2016/09/-bd--becton--dickinson-and-company---has-received-fda-510-k--clearance-for-the-bd-vacutainer-barricor-plasma-blood-collection-tube--bd-barricor--/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-studies--evolve-1--evolve-2-and-regain--of-ly-2951742--galcanezumab--show-decrease-in-number-of-migraine-attacks---eli-lilly/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-negative-opinion-on-ptc-124-for-duchenne-md-ptc-therapeutics/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-innovate-study-of-imbruvica-plus-rituxan-meets-endpoint-in-waldenstroms-macroglobulinemia-abbvie/2024-02-22T11:43:34+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-mpex-209-trial-data-shows-efficacy-of-quinsair--levofloxacin-inhaled-solution--in-cystic-fibrosis--raptor-pharmaceutical/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2018/06/quality-of-life-effect-of-lutathera-in--netter-1-trial-for-neuroendocrine-tumors-is-published-in-journal-of-clinical-oncology---novartis---advanced-accelerator-applications-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2013/12/sprout-pharma-appeals-fda-complete-response-on-flibanserin-for-hypoactive-sexual-desire-syndrome/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2016/11/boston-scientific-announced-results-of-multisense-trial-of-heartlogic-heart-failure-diagnostic-service-to-predict-impending-heart-failure-/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2019/07/teleflex-announces-publication-of-a-large-real-world-study-confirming-results-from-controlled-clinical-studies-of-the-urolift-system-/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2016/08/bioverativ-is-name-of-a-new-biogen-company-to-market-and-develop-treatments-for-hemophilia-and-other-blood-disorders--/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2016/04/post-hoc-analyses-of-phase-iii-trials-of-viekirax--ombitasvir-paritaprevir-ritonavir----exviera--dasabuvir--shows-benefits-in-hepatitis-c-infection--abbvie/2024-02-22T15:51:28+00:00weekly0.6https://www.medthority.com/news/2012/06/xalkori-pfizer-success-in-phase-iii-trial-in-alk-positive-advanced-nsclc-/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2013/02/nice-rejects-extended-use-of-alimta--eli-lilly--in-nsclc/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2014/09/new-labeling-for-anti-smoking-chantix-discards-suicidal-behavior-risk---pfizer/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2017/08/bms-and-clovis-oncology-to-collaborate-with-opdivo--nivolumab--and-rubraca--rucaparib--in-trials-for-ovarian-cancer--triple-negative-breast-cancer-and-prostate-cancer--/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-recommends-vargatef-plus-docetaxel-for-nsclc--adenocarcinoma--boehringer/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-issues-complete-response-letter-for-supplemental-applications-for-januvia--sitagliptin--and-its-combinations-for-treatment-of-type-2-diabetes----merck-inc-/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2018/08/the-first-patient-has-been-enrolled-in--a-phase-iii-study--masters-2--to-evaluate-multistem-cell-therapy-treatment-of-patients-who-have-suffered-an-ischemic-stroke---athersys--inc-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2013/03/tredaptive--merck-inc--fails-to-meet-primary-end-point-in-hps2-thrive-dyslipidaemia-trial/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-triferic-for-ckd-rockwell-medical/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2013/05/astellas-withdraws-from-tivozanib-collaboration-with-aveo-pharma-in-europe/2021-09-24T07:16:20+00:00weekly0.6https://www.medthority.com/news/2017/01/uk-nice-gives-draft-guidance-recommending-use-of-afinitor--everolimus--in-advanced-renal-cell-carcinoma--novartis/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-expanded-indication-for-zomacton-in-adults-with-growth-hormone-deficiency---ferring-pharmaceuticals-/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2015/12/new-phase-iii-safety-data-for-qinprezo--vosaroxin----cpx-351--cytarabine--in-acute-myeloid-leukemia--sunesis-pharmaceuticals/2024-02-09T09:24:40+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-zirabev--bevacizumab-biosimilar--for-metastatic-cancer---pfizer-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/02/ra-beam-study-of-baricitinib--a-treatment-for-moderate-to-severe-rheumatoid-arthritis-is-published-in-nejm---eli-lilly---incyte/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-accepts-sbla-for-soliris-for-treatment-of-neuromyelitis-optica-spectrum-disorder----alexion-pharma/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2018/12/positive-results-from-believe-study-of-luspatercept-for-the-treatment-of-adults-with-beta-thalassemia-associated-anemia--celgene---acceleron-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-trial-of-xgeva--denosumab--meets-primary-endpoint-in-skeletal-related-event-in-patients-with-multiple-myeloma--amgen/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2012/03/dificlir-success-in-reduction-of-recurrence-in-clostridium-difficile/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-trial-of-avp-786-shows-dose-response-in-alzheimer-s-agitation---avanir-pharma/2024-02-22T15:51:50+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-ryzodeg-combination--novo-nordisk--for-treatment-of-diabetes/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2019/10/the-fda--has-placed-a-partial-hold-on-avxs-101-intrathecal-clinical-trials-for-sma-patients-based-on-findings-in-a-small-pre-clinical-animal-study--novartis/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2017/04/uk-nice-gives-final-appraisal-recommending-use-of-cosentyx--secukinumab--in-psoriatic-arthritis--novartis/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2018/03/world-bipolar-day-2018/2024-07-26T09:33:12+00:00weekly0.6https://www.medthority.com/news/2013/10/pooled-analysis-shows-safety-profile-of-pradaxa--boehringer--for-af/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2018/04/results-for-checkmate-227-study-of-opdivo-and-yervoy-combination-for-nsclc-in-patients-with-high-tumor-mutational-burden--bms-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2018/05/analysis-of-orion-1-phase-ii-trial-of-inclisiran-shows-reduction-of-atherogenic-lipoproteins--the-medicines-company-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2017/11/livanova-plc-to-sell-its-cardiac-rhythm--management-business-to-microport-scienrtific-corporation-for--190-million-/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2018/10/single-tablet-dolutegravir-and-lamivudine-filed-with-fda-for-hiv---viiv-healthcare-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-m2-compact-mri--aspect-imaging--for-wrist-imaging/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2018/10/two-chinese-trials-of-roxadustat-positive-to-treat-anemia-associated-with-chronic-kidney-disease---fibrogen/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2017/12/sanofi-discontinues-development-of--clostridium-difficile-vaccine-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-victoza-for-treatment-of-type-2-diabetes-and-renal-impairment--novo-nordisk/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-recommends-approval-of-perjeta-for-her2--breast-cancer/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2015/09/supplemental-nda-submitted-to-fda-for-fanapt--iloperidone--as-maintenance-treatment-for-schizophrenia-vanda-pharma/2024-02-09T09:24:56+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-requests-further-data-in-review-of-relistor--salix--for-opioid-induced-constipation/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2013/10/mistent-sirolimus-eluting-absorbable-coronary-stent-trial-results/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2018/07/sarcoma-awareness-month/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/02/shire-acquires-meritage-pharma-for--70-million/2025-10-16T11:21:47+00:00weekly0.6https://www.medthority.com/news/2019/02/keytruda-and-lynparza-early-findings-for-treatment-of-prostate-cancer---merck-inc-/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2017/06/nucala--mepolizumab--filed-with-fda-as-an-add-on-therapy-to-corticosteroids-for-the-treatment-of-adult-patients-with-eosinophilic-granulomatosis-with-polyangiitis--glaxosmithkline/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2012/04/nice-rejects-avastin-xeloda--roche--combination-for-breast-cancer/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2016/01/second-generation-optune-system-filed-with-fda-for-brain-cancer-novocure-/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2012/11/succesful-trial-of-synflorix-vaccine--glaxo-smith-kline--to-protect-infants-against-pneumococcal-disease-/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2016/05/mederi-therapeutics-announce-new-registry-for-stretta-therapy-to-treat-gastroesophageal-reflux-disease-/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-heartlight-excalibur-balloon-for-the-treatment-of-paroxysmal-atrial-fibrillation---cardiofocus-inc-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2012/06/phase-iii-study-of-edarbyclor--takeda--shows-positive-results-for-hypertension/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2018/05/revive-2-trial-of-iclaprim-to-treat-acute-bacterial-skin-and-skin-structure-infections-is-reported-in-antimicrobial-agents-and-chemotherapy-journal---motif-bio-plc-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2019/09/avexis-novartis-presents-data-continuing-to-show-significant--benefit-of-zolgensma-in-prolonging-event-free-survival-up-to-5-years-of-age-in-spinal-muscular-atrophy--sma-type-i---/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2015/04/phase-iii-data-on-zinforo--ceftaroline-fosamil--in-cap-and-cssti-astrazeneca/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2016/12/st-jude-medical-announces-ce-mark-for-proclaim-elite-scs-system-magnetic-resonance--mri--conditional-labeling-/2021-09-24T07:10:13+00:00weekly0.6https://www.medthority.com/news/2016/11/watchman-left-atrial-appendage-closure--laac--device-procedural-data-shows-a-95-6--implant-success-rate-with-a-median-procedure-time-of-50-minutes---boston-scientific/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2015/06/launch-in-us-of-misago-rx-self-expanding-peripheral-stent-for-treatment-of-peripheral-artery-disease---misago-interventional-systems/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2016/08/merck-inc--withdraws-zontivity--vorapaxar--from-sale-in-the-united-states/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-asceniv-to-treat-primary-humoral-immunodeficiency-disease---adma-biologics/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-fx2016-13-study-of-fmx-103-finds-therapy-generally-safe-in-papulopustular-rosacea---foamix-pharma/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2017/02/medtronic-launches-dxterity-diagnostic-angiography-catheter-line-for-use-in-diagnostic-cardiac-catheterization-procedures-and-percutaneous-coronary-intervention-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2019/01/positive-interim-data-from-phase-iii-vista-trial-of-vicinium-to-treat-bladder-cancer---sesen-bio/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-trial-of-arx-04--sufentanil-sublingual-tablet--shows-efficacy-in-acute-pain--acelrx-pharmaceuticals/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2018/07/positive-phase-ii-results-for-the-first-ever-eye-implant-to-achieve-sustained-delivery-of-a-biologic-medicine--lucentis--to-treat-people-with-wet-age-related-macular-degeneration---genentech-roche---novartis/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2017/06/transfer-of-products-from-actelion-to-idorsia-ltd/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2013/10/studies-confirm-safety-and-efficacy-of-giotrif--boehringer--in-nsclc/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-expanded-indication-for-keytruda--pembrolizumab--as-first-line-treatment-for-melanoma--msd/2024-02-23T11:23:44+00:00weekly0.6https://www.medthority.com/news/2016/06/ema-approves-trevicta---paliperidone-palmitate-a-three-monthly-injection--for-the-maintenance-treatment-of-schizophrenia---janssen-cilag/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2018/03/nda-application-to-fda-of-iclaprim--to-treat-acute-bacterial-skin-and-skin-structure-infections-is-delayed-to-second-quarter-of-2018--motif-bio-plc-/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2017/09/alcobra-ltd-and-arcturus-therapeutics-to-merge-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2014/05/new-phase-iii-data-on-zs-9-for-hyperkalemia---zs-pharma-/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2019/08/data-from-phase-iii-relax-ahf-2-trial-of-reasanz-in-heart-failure-published-in-nejm---novartis/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-gives-510-k--approval-to-the-senographe-pristina-with-self-compression-x-ray-imaging-device--ge-healthcare-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2018/02/pdufa-review-date-extended-to-13-may-2018-for-plenvu-bowel-cleansing-preparation---salix-valeant---norgine-b-v-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-study-of-latuda--lurasidone-hci--shows-statistically-significant-improvement-in-bipolar-disorder--sunovion-pharma/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2016/06/analysis-of-phase-iii-study-shows-efficacy-evidence-for-kyprolis--carfilzomib--plus-lenalidomide-and-dexamethasone-in-multiple-myeloma---amgen/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-provides-positive-opinion-for-biosimilar--grasustek-for-prophylaxis-against-neutropenia-in-patients-treated-with-cytotoxic-chemotherapy---juta-pharma-gmbh/2025-01-31T11:41:05+00:00weekly0.6https://www.medthority.com/news/2019/06/rozlytrek-approved-in-japan-for-ntrk-fusion-solid-tumours---genentech-roche/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2016/11/grunthenthal-acquires-thar-pharmaceuticals-and-with-it-t-121--oral-zoledronic-acid--for-crps/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-shows-adi-peg-20-did-not-meet-primary-endpoint-in-hepatocellular-carcinoma--polaris-group/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-xospata-to-treat-aml-with-flt3-mutations--astellas/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2012/03/jama-publishes-glivec--novartis--follow-up-data-in-gist/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2012/11/actelion-submits-opsumit-to-ema-for-treatment-of-pah/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2019/09/imfinzi-is-first-immunotherapy-to-show-both-significant-survival-benefit-and-improved--durable-responses-in-extensive-stage-small-cell-lung-cancer--astrazeneca/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-advisors-recommend-approval-of-votrient--glaxo-smith-kline--for-soft-tissue-sarcoma/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2018/05/eu-approves-juluca-for-human-immunodeficiency-virus-type-1---viiv-healthcare-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-results-of-liberty-phase-iiib-trial-of-aimovig-in-episodic-migraine-treatmant--novartis/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2016/02/launch-of-chronic-spontaneous-urticaria-cme-activity/2021-11-26T10:46:51+00:00weekly0.6https://www.medthority.com/news/2015/04/celution-system-approved-in-china--cytori-therapeutics/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2013/07/roche-files-with-fda-for-cobas-hpv-test-for-cervical-cancer-primary-screening/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2013/02/analysis-of-two-phase-iii-studies-shows-spiriva--boehringer--provides-benefits-for-asthma-patients/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2013/10/positive-2-year-results-for-simponi-aria--janssen-biotech--in-ra/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2015/09/purdue-pharma-acquires-vm-902a-from-vm-pharma-for-the-treatment-of-chronic-pain/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2014/03/samsca-approved-in-japan-for-polycystic-kidney-diease---otsuka/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2012/07/simponi-janssen-biotech--filed-at-fda-and-ema-for-ulcerative-colitis-treatment/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2019/05/analysis-showed-oral-ozanimod-reduced-brain-volume-loss-across-all-age-subgroups-in-adults-with-relapsing-multiple-sclerosis---celgene/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-advisory-committee-does-not-recommend-expanded-label-for-zetia--ezetimibe---merck/2024-02-23T11:23:55+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-esperoct-in-haemophilia-a---novo-nordisk/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2019/02/results-of-trial-a-392113-of-xeljanz-xr-raises-safety-concerns-with-10-mg-twice-daily-dose--pfizer/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-results-for-benefix-for-prophylaxis-of-haemophilia---pfizer/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2016/06/success-for-actemra--tocilizumab--in-treatment-of-giant-cell-arteritis--genentech---roche/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2012/01/rebif--merck-serono--is-eu-approved-for-early-multiple-sclerosis/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2012/12/eu-award-ce-mark-approval-to-exablate-neuro-system--insightec--for-treatment-of-neurological-disorders-in-the-brain/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2011/10/novartis-cancels-development-of-valdoxan-in-the-usa/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/04/phase-ii-study-of-vyvanse--shire--for-binge-eating-disorder/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-sbla-for-baxdela-to-treat-adult-patients-with-community-acquired-bacterial-pneumonia----melinta-therapeutics/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2015/06/one-year-results-for-cosentyx--secukinumab--for-psoriatic-arthritis-published-in-the-lancet--novartis/2024-02-23T11:24:17+00:00weekly0.6https://www.medthority.com/news/2019/05/success-for-phase-iii-claridhy-trial-of-tibsovo-in-previously-treated-cholangiocarcinoma/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2018/06/long-term-efficacy-data-for-keytruda-from-phase-iii-keynote-006-and-phase-i-keynote-001-studies-in-advanced-melanoma---merck-inc-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2016/11/chmp-positive-opinion-for--biosimilar-teriparatide-to-treat-osteoporosis---stada-arzneimittel-ag---richter-helm-biotec-/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2015/09/generic-exelon-patch--rivastigmine-transdermal-system--for-dementia-in-alzheimers-and-parkinsons-disease-launched-in-us-alvogen-/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-emflaza--deflazacort--to-treat-patients-age-5-years-and-older-with-duchenne-muscular-dystrophy--marathon-pharma/2021-09-24T07:13:16+00:00weekly0.6https://www.medthority.com/news/2013/10/thermodox--celsion--shows-os-benefits-in-liver-cancer-trial/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2017/11/action-study-describes-inadequate-care-in-the-us-of-obesity---the-obesity-society-/2024-02-23T11:24:38+00:00weekly0.6https://www.medthority.com/news/2012/03/tmc-435--medivir--begins-two-new-phase-iii-trials-for-hepatitis-c/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-grants-indication-extension-for-trisenox--arsenic-trioxide--in-acute-promyelocytic-leukemia--teva-pharmaceutical/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2015/01/solitaire-oral-solithromycin-oral--success-in-pivotal-phase-iii-trial-for-cabp--cempra-inc-/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2017/05/study-of-micra-transcatheter-pacing-system-shows-success-rate-in-patients-with-arrhythmias--medtronic/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2012/09/belinostat--topotarget-spectrum--success-in-belief-study-for-ptcl/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-karbinal-er--tris-pharma--for-allergic-rhinitis/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-data-from-trial-of-in-pact-admiral-balloon-in-pad-medtronic/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2019/03/real-world-study-of-xarelto-finds-efficacy-and-cost-saving-in-atrial-fibrillation---janssen/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-sbla-for-blincyto-to-treat-adults-and-children-with-b-cell-precursor-acute-lymphoblastic-leukemia--in-first-or-second-complete-remission-with-minimal-residual-disease---amgen-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2014/05/collaboration-between-merck-inc----and-bayer-healthcare-for-sgc-modulators-in-pulmonary-hypertension-and-heart-failure/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-updates-prescribing-information-for-edurant--tibotec--for-aids-patients/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2013/12/complete-response-letter-from-fda-for-canagilflozin--metformin-janssen/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2015/01/chmp-recommends-ikervis--cyclosporine-ophthalmic-emulsion--for-treatment-of-keratitis-in-dry-eye-disease-santen/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2014/05/forest-labs-to-acquire-furiex-pharma-for--1-1-billion-and-with-it-access-to-eluxadoline/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2011/12/chmp-recommends-vepacel--baxter--influenza-vaccine/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2013/07/study-finds-afinitor--novartis--dramatically-reduces-seizures-in-patients-with-tsc/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2011/11/numeta--baxter--launched-in-eu-for-i-v--nutrition/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2014/09/nice-prepared-to-recommend-soliris-for-treatment-of-hemolytic-uremic-syndrome--alexion/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-advisor-hd-grid-mapping-catheter--sensor-enabled-for-ablation-to-treat-cardiac-arrhythmias--abbott-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2011/12/omnitarg--genentech-roche--success-in-phase-ii-breast-cancer-trial-in-combination-with-herceptin-and-chemotherapy/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-studies-initiated-for-pvc-15-vaccine-for-prevention-of-pneumococcal-disease---merck-inc-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2012/10/nice-recommends-bronchitol--pharmaxis--for-treatment-of-cystic-fibrosis---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2020/01/biontech-acquires-neon-therapeutics-and-neo-ptc-01--a-personalised-neoantigen-targeted-t-cell-therapy/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-cyramza--ramucirumab----folfiri-to-treat-metastatic-colorectal-cancer--eli-lilly/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2012/11/gsk-returns-us-rights-of-horizant-to-xenoport---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2018/04/basilea-licenses-arq-087-from-arqule-inc-for-non-chinese-markets-as-a-treatment-for-biliary-cancer-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-in-phase-iii-study-of-lomitapide--aegerion-pharmaceuticals--for--homozygous-familial-hypercholesterolemia-/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-adopts-negative-opinion-for-its-type-ii-extension-application-for-raxone--idebenone--in-duchenne-muscular-dystrophy----santhera-pharmaceuticals/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2018/11/eu-approves-alunbrig-for-alk--non-small-cell-lung-cancer---takeda-pharmaceutical-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-tpoxx-for-smallpox---siga-technologies-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2010/10/bronchitol-results-in-cystic-fibrosis/2021-09-24T07:01:27+00:00weekly0.6https://www.medthority.com/news/2015/07/sobi-opts-to-extend-its-marketing-territories-for-alprolix--rfixfc--to-treat-haemophilia-b/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-recommends-peginterferon-alfa-plus-ribavirin-for-hepatitis-c-in-children-and-adolescents/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2019/10/updated-analysis-for-larotrectinib-confirms-high-response-rate-and-durable-responses-over-three-years-in-children-and-adults-with-trk-fusion-cancer---bayer-healthcare/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2017/09/summit-07-phase-iii-study-of-nktr-181--a-first-in-class-opioid-analgesic-to-treat-chronic-pain--is-presented-at-the-2017-pain-week---nektar-therapeutics/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2018/03/study-finds--wonder-drug--for-alcohol-use-disorder-ineffective/2022-02-08T07:44:51+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-grants-breakthrough-therapy-to-abt-199--venetoclax--in-chronic-lymphocytic-leukemia--abbvie-and-genentech/2024-02-23T11:24:47+00:00weekly0.6https://www.medthority.com/news/2013/04/nice-recommends-lucentis--novartis--for-macular-oedema-following-rvo/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-injectafer-for-iron-deficiency-anaemia/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-phase-iii-data-published-for-zonegran-in-epilepsy-eisai/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2017/07/fda--advisory-committee-recommends--10-0---approval-of-ctl-019--tisagenlecleucel--car-t-therapy--for-the-treatment-of-relapsed-or-refractory--r-r--pediatric-and-young-adult-patients-with-b-cell-acute-lymphoblastic-leukemia--novartis/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-recommends-xarelto-for-use-in-severe-acute-coronary-syndrome--bayer-healthcare/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2015/05/elotuzumab-in-eloquent-2-trial-for-relapsed-refractory-multiple-myeloma--abbvie---bms/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2014/07/study-of-rapidarc-radiosurgery-published-in-neurosurgery---varian/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/04/ema-committee-reviews-amputation-rates-during-treatment-with-invokana--canagliflozin--in-type-2-diabetes---janssen-pharmaceuticals/2024-02-23T11:25:01+00:00weekly0.6https://www.medthority.com/news/2013/10/abraxane--celgene--data-for-pancreatic-cancer-published-in-nejm/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2019/09/verify-phase-iv-clinical-study-of-vildagliptin-plus-metformin-in-type-2-diabetes-published-in-the-lancet---novartis/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-study-of-rvx-208-fails-to-meet-endpoint-in-post-acs-diabetes---resverlogix/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-inveltys-to-treat-post-operative-inflammation-and-pain-following-ocular-surgery---kala-therapeutics-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2018/11/results-of-acme-trial-of-cefaly-with-migraine-published-in-cephalalgia---stx-medical-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2015/07/st-jude-medical-to-acquire-thoratec/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2012/01/nice-final-guidance-positive-for-eliquis-bms-pfizer-in-vte/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2016/04/clinical-results-presented-for-nellix-endovascular-aneurysm-sealing-system-in-abdominal-aortic-aneurysms--endologix/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2013/12/success-for-u-300-in-edition-ii-study-for-type-2-diabetes-sanofi/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2019/07/dovato-gets-ema-approval-for-hiv-1-infection/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2017/04/-phase-iii-interim-success-for-mpc-150-im-in-patients-with-moderate-to-advanced-chronic-heart-failure--chf---mesoblast/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-vraylar-for-expanded-use-to-treat-depressive-episodes-associated-with-bipolar-i-disorder--bipolar-depression---allergan/2024-10-21T14:52:12+00:00weekly0.6https://www.medthority.com/news/2011/10/why-viread-acts-against-both-hiv-and-hvs-/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2018/04/inlyta-fails-phase-iii-trial-as-adjuvant-therapy-for-patients-at-high-risk-of-recurrent-renal-cell-carcinoma--rcc--after-nephrectomy----pfizer/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-of-mk-3102--omarigliptin--in-type-2-diabetes-meets-endpoint--merck-/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-advisory-committee-negative-for-qapzola--apaziquone--to-treat--non-muscle-invasive-bladder-cancer---spectrum-pharma-/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2017/07/phase-iii-mystic-trial-of-imfinzi--durvalumab--monotherapy-or-imfinzi---tremelimumab-not-meet-the-primary-endpoint-for-stage-iv-nsclc--astrazeneca---medimmune/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-senoclaire-x-ray-imaging-system-ge-healthcare/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2016/06/novartis-to-co-promote-combination-lenvima--lenvatinib--with-afinitor--everolimus--for-renal-cell-carcinoma-in-the-us/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-expanded-indication-for-fycompa-in-pediatric-patients-with-partial-onset-seizures---eisai-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2019/03/lilly-receives-fda-priority-review-designation-for-emgality-for-the-preventive-treatment-of-episodic-cluster-headache-in-adults-/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2014/05/analysis-shows-benefits-of-neurostar-tms-for-depression-neuronetics/2024-10-21T14:48:59+00:00weekly0.6https://www.medthority.com/news/2012/05/passeo-18-lux-balloon-study-success-with-femoropopliteal-lesions/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2011/11/suboxone--reckitt-benckiser--effective-in-large-scale-trial-for-opioid-dependence/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/04/ema-review-of-lemtrada-following-reports-of-immune-related-conditions-and-cardiovascular-problems--sanofi-genzyme/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-for-filing-prolia--denosumab--to-treat-glucocorticoid-induced-osteoporosis--/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2015/12/amgen-to-re-acquire-rights-to-prolia-and-xgeva--denosumab--and-vectibix--panitumumab--from-gsk/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2016/08/aristada--aripiprazole-lauroxil--extended-release-injectable-suspension-filed-with-fda-for-the-treatment-of-schizophrenia--alkermes/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-provides-accelerated-approval-of-imbruvica--ibrutinib--for-marginal-zone-lymphoma--janssen-biotech-and-pharmacyclics/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-data-on-belviq-published-in-obesity---eisai-arena-pharma/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/08/indexxa--andexanet-alfa--maa-is-submitted-to--ema-for-reversal-of-anticoagulation---portola-pharma/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-results-for-htk-011-shows-efficacy-in-postoperative-pain-relief---heron-therapeutics/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2012/04/forest-acquire-canadian-rights-to-savella-and-bystolic/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-iii-trials-of-dsc-127--derma-sciences--start-for-diabetic-foot-ulcers/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-chmp-opinion-for-recarbrio-for-the-treatment-of-infections-due-to-aerobic-gram-negative-organisms-in-adults-with-limited-treatment-options---merck-inc-/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2019/03/envision-phase-iii-study-of-givosiran-met-its-primary-efficacy-endpoint-for-the-treatment-of-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2016/03/successful-phase-iii-study-of-epidiolex--cannabidiol--for-the-treatment-of-dravet-syndrome--gw-pharma/2024-02-23T11:25:58+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-viva-crt-p-pacemaker-for-heart-failure-and-av-block---medtronic/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-label-addition-for--stiolto-respimat--olodaterol---tiotropium--in-copd--boehringer/2024-02-23T11:26:17+00:00weekly0.6https://www.medthority.com/news/2012/10/abraxane--celgene-oncology--success-in-phase-ii-study-for-metastatic-melanoma---------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-cyramza-for-patients-with-hepatocellular-carcinoma-with-an-alpha-fetoprotein/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-admelog--for-diabetes---sanofi-/2021-11-30T13:24:36+00:00weekly0.6https://www.medthority.com/news/2018/08/a-phase-iiia-trial--pioneer-5--reports-with-oral-semaglutide-in-adults-with-type-2-diabetes-and-moderate-renal-impairment---novo-nordisk-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2013/11/gazyva--genentech--pfs-in-cll-11-trial-superior-to-rituximab/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2017/02/long-term-extension-study-of-stelara--ustekinumab--in-adults-with-crohn-s-disease-shows-response-maintained-for-up-to-2-years--janssen-biotech/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-approval-of-mavenclad--cladribine--for-relapsing-forms-of-multiple-sclerosis--merck-kgaa/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2011/11/eviplera-triple-therapy---gilead-sciences--is-eu-approved-for-hiv-1-infection/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2015/08/merck-kgaa-completes-acquisition-of-sigma--aldrich-for--17-0-billion/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2019/03/data-demonstrate-non-inferiority-of-once-daily-descovy-vs--once-daily-truvada-for-prevention-of-hiv-infection--gilead-sciences-/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-ventana-alk--d5f3--cdx-assay-for-nsclc-ventana-medical-systems/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2015/07/arzerra--ofatumumab--filed-in-eu-for-maintenance-in-relapsed-cll--genmab-novartis/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-holocar-for-limbal-stem-cell-deficiency--chiesi/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-lemtrada--sanofi-bayer-to-treat-relapsing-remitting-multiple-sclerosis/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2011/11/kalydeco-phase-iii-strive-study--for-cystic-fibrosis-is-published-in-nejm/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2015/02/study-shows-benefits-of-inflectra-for-ulcerative-colitis-and-crohns-hospira/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2019/03/novo-nordisk-submits-label-updates-for-approval-at-fda-and-ema-for-fiasp-for-children-and-adolescents-with-type-1-diabetes-/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2019/11/adakveo-approved-by-fda-to-reduce-frequency-of-pain-crises-in-individuals-living-with-sickle-cell-disease---novartis/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2018/11/nice-recommends-use-of-vyxeos-in--acute-myeloid-leukemia---jazz-pharma-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-gives-premarket-approval-to-therascreen-pik3ca-kit-as-companion-diagnostic-for-breast-cancer---qiagen/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2015/04/toujeo--insulin-glargine--rdna-origin--injection--is-eu-approved-for-treatment-of-diabetes--sanofi/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2017/05/preliminary-results-from-phase-iii-trial-of-nucala--mepolizumab--in-chronic-obstructive-pulmonary-disease--glaxosmithkline/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2018/08/advisory-committee-recommends-alis--to-treat-nontuberculous-mycobacterial--ntm--lung-disease-caused-by-mycobacterium-avium-complex---insmed-inc-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/08/updated-positive-interim-data-from--a-phase-ii-iii-study-of-subcutaneous--sq--prophylactic-factor-viia--variant-marzeptacog-alfa--activated---marzaa-for-haemophilia-a-or-b---catalyst-biopsciences-inc-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2016/11/solanezumab-did-not-meet-the-primary-endpoint-in-the-expedition-3-clinical-trial-to-treat-moderate-alzheimers-disease---eli-lilly/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-chmp-recommends-extension-of-indication-for-emend--fosaprepitant-dimeglumine--in-treating-nausea--merck/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2012/10/eu-approval-for-seebri-breezhaler--novartis--for-copd---------------/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2014/05/iqwig-assessment-of-sovaldi-for-hepatitis-c---gilead-sciences/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2017/01/advanced-accelerator-applications-s-a--announced-the-new-england-journal-of-medicine-published-the-results-of-the-netter-1-phase-iii-study-evaluating-efficacy-and-safety-of-lutathera--lutetium-177-dotatate--to-treat-midgut-neuroendocrine-tumors-/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2018/09/complete-response-letter-for-dasotraline-to-treat-adhd---sunovion-pharma-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-lutonix-035-dcb-balloon-catheter-for-treatment-of-peripheral-artery-disease--lutonix-inc-/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-deep-transcranial-magnetic-stimulation-system-for-the-treatment-of-major-depressive-disorder---brainsway-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2016/12/novartis-acquires-ziarco-group-ltd-and-with-it-zpl-389--a-potential-first-in-class-oral-treatment-for-moderate-to-severe-eczema--atopic-dermatitis---/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-extension-of-indication-of-gattex-in-short-bowel-syndrome/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2016/09/rhopressa--netarsudil-ophthalmic-solution--filed-with-fda-for-patients-with-glaucoma-or-ocular-hypertension--aerie-pharmaceuticals/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2017/11/emuc-2017/2024-02-23T11:26:52+00:00weekly0.6https://www.medthority.com/news/2019/07/chmp-recommends-empliciti---pomalidomide---low-dose-dexamethasone-to-treat--relapsed-and-refractory-multiple-myeloma----bms/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2019/04/results-of-long-term-study-of--tanezumab-in-patients-with-osteoarthritis/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2014/06/new-phase-iii-data-for-vidaza-in-aml---celgene/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2012/04/bind-014-first-nanomedicine-to-enter-clinical-studies/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2016/04/-nplate--romiplostim--phase-iii-study-in-children-with-symptomatic-immune-thrombocytopenia--amgen/2024-02-23T11:27:10+00:00weekly0.6https://www.medthority.com/news/2016/06/aspen-acquires-rights-to-astrazeneca-anaesthetics-portfolio-outside-the-us-including--diprivan--general-anaesthesia---emla--topical-anaesthetic-and-five-local-anaesthetics-/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-advisory-committee-recommends-mepolizumab-for-treatment-of-severe--eosinophilic-asthma--gsk/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2017/09/elagolix-filed-with-fda-for-management-of-endometriosis-with-associated-pain---abbvie-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2015/03/lyrica-fails-in-phase-iv-study-in-adolescents-with-fibromyalgia--pfizer/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-issues-complete-response-letter-for-hyq--baxter--for-treatment-of-primary-immunodeficiencies/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2013/01/chmp-recommends-extension-of-indication-of-humira-abbvie--in-jia/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-select-monotherapy-trial-of-abt-494-in-rheumatoid-arthritis-meet-endpoints---abbvie-/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-delays-decision-on-vascepa-for-high-triglycerides-and-schedules-a-review---amarin/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-elevate-tn-trial-of-calquence-meets-endpoint-in-chronic-lymphocytic-leukaemia---astrazeneca/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2014/09/daiichi-sankyo-to-buy-ambit-biosciences-for--315-million-including-quizartinib-for-aml/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2015/02/positive-results-from-phase-iii-trials-of-spiriva-respimat-in-asthma-boehringer/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-alprolix-for-bleeding-prevention-in-haemophilia-b---biogen/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2019/07/health-canada-approves-onpattro-to-treat-polyneuropathy-in-adult-patients-with-hereditary-transthyretin-mediated--hattr--amyloidosis---alnylam-pharma-/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2019/01/european-commission-approves-opdivo---yervoy---low-dose--for-first-line-treatment-of-renal-cell-carcinoma---bms/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-trial-of-arx-04-sufentanil-nanotabs--acelrx-pharmaceuticals--meets-endpoint-for-acute-pain/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-assesses-evidence-for-risk-of-thrombosis-with-drospirenone-containing-drugs/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2018/04/successful-phase-ii-data-for-gepotidacin-for-the-treatment-of-uncomplicated-urogenital-gonorrhea---gsk-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2015/07/celgene-acquires-receptos-for--7-2-billion-and-with-it-ozanimod-for-ulcerative-colitis-and-ms/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2016/09/alcon-novartis-launches-ngenuity-3d-visualization-system--a-platform-for-digitally-assisted-vitreoretinal-surgery--/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-label-update-for-imbruvica--ibrutinib--in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma--janssen/2024-02-23T11:27:23+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-vaccine-menhibrix--gsk-for-bacterial-diseases/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-tagrisso-for-first-line-treatment-of-nsclc-with-epidermal-growth-factor-receptor--egfr--mutations---astrazeneca-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-study-of-ns-2330-meets-endpoints-in-obesity---saniona-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---maintaining-work-during-the-final-6-months-prior-to-haemodialysis-was-associated-with-a-better-survival/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2019/09/pivotal-phase-iii-harmony-trial-stopped-early-for-positive-efficacy-of-pimavanserin-in-dementia--related-psychosis---acadia-pharma/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2016/11/merck-inc--announces-publication-in-science-translational-medicine-of-development-of-verubecestat-as-a-potential-treatment-for-alzheimer-s-disease-/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2018/02/new-immunotherapy-combination--effective-in-patients-with-advanced-kidney-cancer/2024-02-23T11:28:15+00:00weekly0.6https://www.medthority.com/news/2012/08/eu-commission-approves-jakavi--novartis--for-myelofibrosis---------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-sustol--granisetron--extended-release-injection-for-the-prevention-of-acute-and-delayed-nausea-and-vomiting---heron-therapeutics/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-imbruvica-for-cll-and-mcl---pharmacyclics/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2014/12/eu-approves-cyramza-for-treatment-of-stomach--gastric-cancer--eli-lilly/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-revlimid---rituxan-for-follicular-lymphoma-or-marginal-zone-lymphoma---celgene/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2012/12/roche-submits-extension-application-to-ema-for-subcutaneous-mabthera/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-data-for-abilify-maintena-in-schizophrenia-otsuka-lundbeck/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-study-of-epidiolex-in-lennox-gastaut-syndrome-published-in-nejm---gw-pharma-/2024-02-23T11:28:33+00:00weekly0.6https://www.medthority.com/news/2012/08/cocoa-flavanols---mars-symbioscience--may-improve-cognition-according-to-italian-study---------------/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2017/11/tagrisso-filed-at-ema-to-treat-cns-metastases-for-the-1st-line-treatment-of-locally-advanced-or-metastatic-nsclc--astrazeneca-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2014/05/positive-phase-iii-study-for-cep-33237-for-treatment-of-chronic-low-back-pain---teva/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-ilaris--novartis--for-treatment-of-systemic-juvenile-idiopathic-arthritis/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-extends-ozurdex-indication-for-diabetic-macular-edema--allergan/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2015/03/success-for-pacritinib-in-persist-1-trial-for-myelofibrosis--cti-biopharma---baxter/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2016/01/lenvatinib-mesylate-is-filed--snda--at-fda-to-treat-renal-cell-carcinoma--eisai/2024-02-23T11:28:41+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-subcutaneous-actemra-as-a-treatment-of-active-polyarticular-juvenile-idiopathic-arthritis---genentech-roche-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-trials-of-setmelanotide-meet-primary-endpoints-in-pomc-and-lepr-deficiency-obesities/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2014/10/success-for-andexanet-alfa-in-trial-reversing-anticoagulation-effect-of-eliquis---portala-pharma/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2018/09/inpulsis-on-trial-data-on-ofev-in-ipf-published-in-the-lancet-respir-med---boehringer-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2015/02/eu-approves-eylea-for-visual-impairment-rvo-regeneron-pharma/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-approval-of-respreeza--alpha1-antitrypsin---for-alpha-1-antitrypsin-deficiency--csl-behring/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-now-recommends-imnovid---pomalidomide--as-a-treatment-for-multiple-myeloma--celgene/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-trial-of-shingrix-vaccine-meets-primary-endpoint-in-shingles--glaxosmithkline/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2016/03/bms-acquires-padlock-therapeutics/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2016/12/novo-nordisk-announces-positive-results-of-devote-cv-outcomes-trial-for-tresiba--insulin-degludec--for-treatment-of-type-2-diabetes-patients-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2012/02/nordic-rights-to-refacto-and-benefix-are-returned-to-pfizer/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress/2024-02-23T11:29:22+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---era-edta-and-the-japanese-society-of-nephrology-build-on-firm-foundations-to-improve-treatment-for-kidney-patients/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2018/01/ionis-ttrrx-filed-with-fda-for-hereditary-ttr-amyloidosis---ionis-pharmaceuticals-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2015/01/leo-pharma-files-nda-at-fda-for-calcipotriene-betamethasone-dipropionate-aerosol-foam-for-psoriasis/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-approves-oncaspar--pegaspargase--as-therapy-for-acute-lymphoblastic-leukaemia--baxalta/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2015/09/transenterix-inc--acquires-robotic-division-of-sofar--s-a--and-telelap-alf-x-for--99-8-million/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2017/10/jnj-927--apalutamide--filed-with-fda-for-non-metastatic-castration-resistant-prostate-cancer---janssen-biotech-/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2012/07/exembol--mitsubishi-tanabe--launched-in-uk-for-hit/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2011/01/dimebon--medivation-pfizer--fails-pivotal-phase--iii-concert-study-in-alzheimers-disease-and-development-terminated-/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2012/09/phase-iii-study-results-for-serelaxin--novartis--for-acute-heart-failure/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2019/01/aeglea-biotherapeutics-initiates-phase-iii-peace-study-for-pegzilarginase-to-treat-arginase-1-deficiency-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-reports-from-poplar-and-birch-studies-for-atezolizumab-in-nsclc--roche/2024-02-23T11:29:33+00:00weekly0.6https://www.medthority.com/news/2012/03/no-proof-of-added-benefit-of-trobalt--glaxo-smith-kline--for-epilepsy/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2013/02/nice-does-not-recommend-krystexxa--savient-pharma--for-treatment-of-severe-gout/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2011/12/nice-recommends-roactemra-roche--for-systemic-idiopathic-juvenile-arthritis/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-accepts-resubmission-nda-of-dextenza-dexamethasone-insert-0-4-mg-for-intracanalicular-use-for-the-treatment-of-ocular-pain-occurring-after-ophthalmic-surgery-ocular-therapeutix-inc/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2014/07/eu-approves-mekinist-for-braf-v600-metastatic-melanoma-gsk/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-eortc1325-keynote-054-data-on-keytruda-in-melanoma-published-in-nejm---merck-inc-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-vipdomet-for-type-2-diabetes-patients/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2015/04/gilead-files-emtricitabine-and-tenofovir-alafenamide-at-fda-for-hiv-/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-recommends-xalkori--crizotinib--as-second-line-therapy-for-nsclc-patients---pfizer/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2016/11/results-of-egality-trial-of-gp-2015--biosimilar-etanercept-published-in-british-journal-of-dermatology---sandoz/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2013/05/fasiglifam--takeda--success-in-phase-iii-trial-for-treatment-of-type-2-diabetes/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2018/08/phase-iii-atlas-study-success-for-two-drug-regimen--namely-cabotegravir-and-rilpivirine--for-the-treatment-of-hiv-compared-with-continuing-a-three-drug-oral-regimen--viiv--healthcare---janssen-therapeutics-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-accepts-nda-for-tasimelton-for-non-24-hour-disorder/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2017/08/mundipharma-acquires-from-cell-act-world-rights-to-cap7-1--a-novel-pro-drug-of-anticancer-agent-etoposide-/2024-02-23T11:29:48+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-vipidia-for-type-2-diabetes-patients/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-chmp-recommends-approval-of-tagrisso--osimertinib--in-non-small-cell-lung-cancer--astrazeneca/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-cequa-to-treat-dry-eye-syndrome---sun-pharma---sun--ophthalmics-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2019/11/clinical-trial-analyses-further-substantiate-that-teprotumumab-significantly-improves-debilitating-effects-of-thyroid-eye-disease---horizon-therapeutics/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2013/07/oritavancin-the-medicines-company--success-iin-solo-11-trial-for-acute-bacterial-skin-and-skin-structure-infections-/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2012/10/eteplirsen--sarepta-therapeutics-success-in-extension-trial-for-duchenne-muscular-dystrophy----------------/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-zaltrap---regeneron-sanofi--for--treatment-of-metastatic-colorectal-cancer/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2017/06/endocrinologic-and-metabolic-drugs-advisory-committee-of-fda-votes-in-favour-of-inclusion-of-cv-outcomes-data-from-leader-trial-in-victoza--liraglutide--label---novo-nordisk-/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-ilesto-7-icd-crt-d--biotronik--for-patients-with-heart-failure/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2018/02/adamis-pharmaceuticals-files-snda-for-symjepi-for-the-emergency-treatment-of-anaphylaxis-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-kitabis-pak-for-cystic-fibrosis-pari/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2018/01/sanofi-to-acquire-bioverativ-inc-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2017/01/alcon-launches-acrysof-iq-panoptix-toric-presbyopia--and-astigmatism-correcting-intraocular-lens-/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2015/09/encenicline-trials-placed-on-clinical-hold-for-alzheimers-disease--forum-pharma/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2016/10/jama-study-shows-that-xarelto---rivaroxaban--from-bayer-healthcare-and-janssen-may-cause-more-bleeds-than-pradaxa--dabigatran--from-boehringer-in-non-valvular-atrial-fibrillation-/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2016/06/european-commission-approves-galafold--migalastat--as-a-treatment-for-fabry-disease---amicus-therapeutics/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-recommends-glivec-for-treatment-of-recurrence-of-gist--novartis/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2016/10/korean-ministry-of-food-and-drug-safety-imposes-conditions-on-the-use-of-olita-tab--olmutinib--for-nsclc----hanmi-pharmaceuticals--/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-onpattro-to-treat-hereditary-transthyretin-mediated-amyloidosis---alnylam-pharma-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-advisory-committee-will-review-abp-501--adalimumab-biosimilar--on-25-september-2016--amgen/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-rejoice-trial-of-tx-004hr--oestradiol--meets-endpoints-in-dyspareunia--therapeuticsmd/2024-02-23T11:30:01+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-ii-iii-trial-of-iv-cr-845-met-statistical-significance-in-patients-undergoing-abdominal-surgeries---cara-therapeutics-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2018/09/following-a-complete-response-letter-recro-pharma-inc--anticipates-resubmitting-the-iv-meloxicam-nda-by-the-end-of-september-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2016/11/abp-215--bevacizumab--biosimilar--filed-with-fda-for-non-small-cell-lung-cancer--amgen-allergan/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2018/02/end-results-for-cherish--study-of-spinraza-for-spinal-muscular-atrophy-are-published-in-nejm---biogen---ionis-pharma-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2017/05/kevzara--sarilumab--is-fda-approved-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis--sanofi---regeneron/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2014/07/further-complete-response-letter-from-fda-for-semprana-for-migraine-allergan/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-ii-study-of-cyt003--cytos-biotechnology--for-allergic-asthma-meets-all-end-points/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-zydelig-for-treatment-of-cll-and-follicular-lymphoma---gilead-sciences-/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2017/01/orthofix-secures-fda-and-ce-mark-approval-to-its--cervicalstim-and-spinalstim-bone-growth-stimulators-/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-edwards-intuity-elite-valve-for-aortic-valve-disease----edwards-lifesciences/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2019/07/coherus-success-in-us--patent-suit-against-amgen-relating-to-udenyca--pegfilgrastim-biosimilar-/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-varubi-i-v--for-the-prevention-of-delayed-nausea--vomiting-associated-with-emetogenic-cancer-chemotherapy--tesaro-/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2018/06/success-for-tecentriq---chemotherapy---abraxane-in-impower130-study-for-treatment-of-squamous-nsclc---genentech-roche/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2012/07/south-korea-approves-first-biosimilar-remsima-from-celltrion-to-compete-with-remicade/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2019/03/venclexta---gazyva-combination-filed-at-fda-for-untreated-chronic-lymphocytic-leukemia--genentech-roche/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2017/08/european-commission-approves-soliris--eculizumab--to-include-the-treatment-of-refractory-generalized-myasthenia-gravis--gmg----alexion-pharmaceuticals-inc-/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2011/11/abilify-depot-otsuka-lundbeck--is-filed-at-fda-for-schizophrenia/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-on-imbruvica-for-cll-sll-published-in-nejm---pharmacyclics/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-impower110-study-of-tecentriq-monotherapy-meets-endpoint-in-nsclc---genentech-roche/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2013/07/trial-finds-hydroeye--sbh--benefits-dry-eye-disease/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2014/04/uk-will-fund-sovaldi-for-patients-with-acute-liver-failure-or-those-awaiting-transplantation---gilead/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2015/03/medtronic-acquires-sophono/2025-10-16T11:09:19+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-studies--ecztra-1-3--of-cat-354-meet-primary-endpoint-in-atopic-dermatitis---leo-pharma/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2015/10/combination-of-sovaldi---gs-5816--sofosbuvir---velpatasvir--filed-with-fda-for-genotype-1-6-hepatitis-c-virus--gilead-sciences/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-extends-invokana-label-to-include-data-from-canvas-study-of-cv-risk-in-diabetic-patients---janssen-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2014/04/first-eu-approvals-for-bufomic-easyhaler-for-asthma-and-copd---orion-pharma/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2017/12/using-data-to-combat-dementia--first-global-monitoring-system-launched/2024-07-26T10:02:12+00:00weekly0.6https://www.medthority.com/news/2016/12/triple-combination-therapy--umeclidinium-bromide-vilanterol--fluticasone--filed-with-ema-for-chronic-obstructive-pulmonary-disease--glaxosmithkline/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-prescription-digital-therapeutic--reset-o-for-patients-with-opioid-use-disorder--sandoz-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2018/04/impact-study-of-trelegy-ellipta-in-copd-published-in-nejm---glaxosmithkline---innoviva-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2013/09/savor-trial-results-of-onglyza-and-cv-risk/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-advisory-committee-recommends-lutonix-dcb-paclitaxel-coated-angioplasty-balloon-for-pad---c-r-bard-inc-/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2015/01/praluent--alirocumab--is-filed-at-the-fda-for-treatment-of-hypercholesterolaemia--sanofi---regeneron/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2015/07/merck-inc-acquires-ccam-biotherapeutuics-and-with-it-checkpoint-inhibitor--cm-24-in-phase-i/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-advisory-committee-votes-14-3-against-approval-of-remoxy-er-for-the-management-of-severe-pain---pain-therapeutics-inc-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-advisory-committee-recommends-northera-chelsea-therapeutics--for-symptomatic-neurogenic-orthostatic-hypotension-/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2016/11/trial-of-abt-493--glecaprevir----abt-530--pibrentasvir--shows-efficacy-in-chronic-hepatitis-c--abbvie/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-lymphoseek--navidea-biopharma--for-intraoperative-lymphatic-mapping/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2016/04/giotrif--afatinib--is-chmp-recommended-for-treatment-of-squamous-nsclc--boehringer/2024-02-23T11:30:13+00:00weekly0.6https://www.medthority.com/news/2019/07/vertex-pharma-files-nda-at-fda-for--elexacaftor--tezacaftor-and-ivacaftor-combination-for-f508del-mutation-cystic-fibrosis-/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2016/12/synergy-pharmaceuticals-inc--announces-phase-iii-data-for-plecanatide-to-treat-irritable-bowel-syndrome-with-constipation-/2021-09-24T07:10:13+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-jynarque-for-autosomal-dominant-polycystic-kidney-disease--otsuka-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2011/09/new-study-of-cervarix-shows-two-doses-are-adequate--against-hpv-types-16-and-18/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2015/11/dsc-127--aclerastide--fails-diabetic-foot-ulcer-healing-trial-and-programme-is-cancelled--derma-sciences-inc-/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2014/12/mr-clean-trial-supports-stent-retriever-with-iv-tpa-use-in-clot-busting-stroke-treatment--stryker-covidien/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2016/01/cometriq--cabozantinib--filed-with-ema-for-renal-cell-carcinoma--exelixis-/2024-02-23T11:30:23+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-study-of-liletta-for-contraception-published-in-american-journal-of-obstetrics---gynecology---medicines360-allergan-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2018/03/surgical-infections-linked-to-drug-resistant-bugs--study-suggests/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2018/11/biotime-inc--and-asterias-biotherapeutics-inc--agree-to-merge-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-uro-v-single-use-diagnostic-cystoscopic-system----uroviu-corporation--/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-crysvita-for-x-linked-hypophosphatemia---ultragenyx-pharma---kyowa-kirin-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-cantos-study-of-acz-885--canakinumab-showed-a-reduction-of-cv-risk-in-patients-with-prior-heart-attack-and-inflammatory-atherosclerosis---novartis/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-label-update-for-avycaz--ceftazidime-and-avibactam--in-combination-with-metronidazole-for-complicated-intra-abdominal-infections--allergan/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-clinical-trials-with-cinquil--reslizumab--show-positive-results-in-asthma--teva-pharma/2021-09-24T07:03:42+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-vitrakvi-to-treat-neurotrophic-tyrosine-receptor-kinase-fusion-positive-solid-tumours---bayer-healthcare/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2016/11/paloma-2-trial-of-ibrance--palbociclib----letrozole-for-breast-cancer-is-published-in-nejm---pfizer/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-ii-study-of-bi-655066-shows-superiority-over-stelara--ustekinumab--for-psoriasis--boehringer-ingelheim/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-follow-up-data-on-imbruvica--ibrutinib--shows-efficacy--in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma--abbvie/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2017/11/new-version-of-gonal-f-prefilled-pen-is-fda-approved-as-a-treatment-for-infertility---merck-kgaa-/2021-09-24T07:14:41+00:00weekly0.6https://www.medthority.com/news/2016/09/aplidin--plitidepsin--filed-with-ema-for-multiple-myeloma----pharmamar/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-erleada-to-treat-non-metastatic-castration-resistant-prostate-cancer---janssen-pharma-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2017/10/amagine-2-phase-iii-extension-study-shows-two-year-positive-results-for-siliq--brodalumab-injection--as-a-treatment-of-psoriasis---ortho-dermatologics-/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2014/11/iqwig-reports-benefits-of-halaven-in-breast-cancer-are-proven---eisai/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2018/10/new-phase-iii-data-for-yupelri-in-copd-presented-at-chest---theravance-biopharma-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2014/11/nice-confirms-recommendation-for-soliris-for-ahus-treatment--alexion/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-envarsus-xr--tacrolimus-extended-release-tablets--for-the-prophylaxis-of-rejection-in-kidney-transplant--veloxis-pharma/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2016/05/zebinix--eslicarbazepine-acetate--filed-with-ema-as-once-daily-monotherapy-for-adults-with-newly-diagnosed-partial-onset-epilepsy--bial/2021-09-24T07:09:30+00:00weekly0.6https://www.medthority.com/news/2015/04/eu-approves-avastin--bevacizumab--for-cervical-cancer-roche/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-bellafill-for-acne-scars-suneva-medical/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-taltz--ixekizumab--to-treat-plaque-psoriasis--eli-lilly/2024-02-23T11:31:09+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-xiapex-for-treatment-of-peyronie-s-disease--swedish-orphan-biovitrium--sobi-/2024-10-21T14:38:48+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-bracanalysis-cdx-as-companion-diagnostic-for-talzenna-in-her2--breast-cancer---myriad-genetics-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2013/04/iqwig-report-on-eliquis--bms-pfizer--for-stroke-prevention-associated-with-atrial-fibrillation-/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-herceptin-hylecta--for-subcutaneous-injection-for-the-treatment-of-certain-people-with-her2-positive-early-breast-cancer---genentech-roche/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2018/06/alcohol-intake-may-be-linked-to-premenstrual-syndrome--pms-/2024-02-23T11:31:31+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-tecfidera--biogen-idec--to-treat-relapsing-multiple-sclerosis/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2013/12/generic-cymbalta-is-fda-approved-eli-lilly/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-does-not-recommend-xtandi--enzalutamide--to-treat-prostate-cancer--astellas/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2017/09/range-study-of-cyramza---ramucirumab----docetaxel-shows-improvement-in-pfs-in-patients-with-urothelial-carcinoma---eli-lilly-/2021-09-24T07:13:56+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-accepts-bla-and-provides-priority-review--for-tecentriq-to-treat-small-cell-lung-cancer--genentech-roche/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/02/national-heart-month-2018-/2024-02-23T11:47:33+00:00weekly0.6https://www.medthority.com/news/2015/06/pristiq--desvenlafaxine-succinate-sustained-release---fails-phase-iii-trial-in-children-for-depression-pfizer/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2012/08/xarelto-bayer-janssen--sub-group-analysis-of-timi-trial-shows-reduction-in-mortality-for-acs-patients---------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-issues-a-complete-response-letter-to-green-cross-corporation-for-ivig-sn--human-normal-immunoglobulin-g-for-intravenous-administration--a-treatment-of-primary-immunodeficiency-diseases-/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2014/10/new-technique-enables-increasingly-accurate-pet-scan-to-detect-cancer-and-heart-conditions/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-gives-510-k--approval-to-corpath-grx-system-in-peripheral-vascular-interventions---corindus-vascular-robotics-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2018/01/starpharma-has-completed-the-vivagel-bv-rolling-submission-to-the-fda-for-treatment-of-bacterial-vaginosis-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2017/10/american-college-of-allergy--asthma-and-immunology-annual-scientific-meeting/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2015/07/european-commission-approves-imbruvica--ibrutinib--to-treat-waldenstrom-s-macroglobulinemia--pharmacyclics-llc--janssen-cilag/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2014/09/mk-3102-meets-endpoints-in-phase-iii-trial-for-t2d-merck/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2016/05/the-sentinel-stroke-national-audit-programme-data--shows-less-than-half-of-patients-admitted-to-hospital-with-a-stroke-were-taking-anticoagulants-/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2013/12/phase-iii-suvvess-for-alprolix-in-haemophilia-b--biogen-sobi/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-insulin-lispro-sanofi--insulin-biosimilar--to-treat-type-1-and-2-diabetes--sanofi/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-sailing-study-of-dolutegravir-viiv--success-in-hiv-1/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2017/06/sommapatch-study-results-similar-to-standard-in-lab-polysomnography-results-in-recording-sleep-patterns---somnarus-sleep-diagnostics-/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2018/12/nice-recommends-opdivo--to-cut-the-risk-of-early-stage-skin-cancer-recurrence-after-surgery--bms/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2012/06/horizon-pharma-licenses-latin-american-rights-to-duexis-to-grunenthal/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-finch-2-trial-of-glpg-0634-success-for-rheumatoid-arthritis---gilead-sciences---galapagos-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-again-negative-on-avastin-for-brain-cancer---roche/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2016/04/abbott-s--architect-stat-high-sensitive-troponin-i--hstnl--test-may-detect-troponin-in-patients-with-stress-induced-ischaemia-/2021-09-24T07:10:47+00:00weekly0.6https://www.medthority.com/news/2018/06/checkmate-238-trial-shows-opdivo-superior-to-yervoy-for-stage-iiib-c-or-stage-iv-high-risk-of-recurrence-melanoma---bms-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2012/06/results-of-ample-study-of-orencia-bms--presented-at-eular/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-advisory-committee-recommends-approval-of-krintafel-for-malaria---glaxosmithkline-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-grant-breakthrough-therapy-designation-to-ga-101--roche--for-cll/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2016/04/results-of-sustain-phase-iii-trial-of-semaglutide-for-type-2-diabetes--novo-nordisk/2024-02-23T11:47:45+00:00weekly0.6https://www.medthority.com/news/2016/05/additional-phase-iii-data-presented-for-plecanatide-in-chronic-idiopathic-constipation--synergy-pharmaceuticals/2024-02-23T11:48:05+00:00weekly0.6https://www.medthority.com/news/2016/02/chmp-recommends-alprolix---rfixfc--for-treatment-of-haemophilia-b--sobi---biogen/2024-02-23T11:48:52+00:00weekly0.6https://www.medthority.com/news/2014/04/tafenoquine-in-two-phase-iii-trials-for-malaria---gsk/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approval-for-visionct--the-first-and-only-fda-approved-clinical-ct-system-dedicated-to-delivering-true-3d-specimen-radiography---faxitron-bioptics-llc-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-delays-approval-of-envarsus-xr-for-transplant-rejection-veloxis/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2014/08/second-phase-iii-trial-of-amg-416-success-for-sec--hyperparathyroidism---amgen/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-revolade--eltrombopag--for-severe-aplastic-anaemia--novartis/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2017/12/does-owning-a-pet-influence-signs-of-ageing/2024-02-23T11:49:37+00:00weekly0.6https://www.medthority.com/news/2019/12/data-from-exploratory-analysis-show--keytruda-improved-overall-survival-as-monotherapy-for-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-regardless-of-kras-mutational-status---merck-inc-/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2016/06/results-of-phase-iii-trial-of-somatuline-depot--lanreotide--in-neuroendocrine-tumour-carcinoid-syndrome-published-in-endocrine-practice--ipsen-biopharmaceuticals/2024-02-23T11:49:56+00:00weekly0.6https://www.medthority.com/news/2018/07/success-for-bardoxolone-in-patients-with-chronic-kidney-disease-due-to-alport-syndrome-shown-in-phase-ii-cardinal-study-and-for-polycystic-kidney-disease-cohort-of-phoenix-study---reata-pharma-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2018/03/keytruda-filed-with-fda-for-advanced-cervical-cancer---merck-inc-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2019/01/uk-nice-recommends-use-of-verzenios-in-breast-cancer---eli-lilly/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2018/10/ce-mark-for-wearable-micropump-for-the-treatment-of-parkinson-s-disease--sensile-medical/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2019/05/stereotaxis-launches-stereotaxis-genesis-rmn-to-advance-robotic-magnetic-navigation-technology-/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-accepts-for-review-nda-for--lumateperone-to-treat-schizophrenia--intra-cellular-therapies/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-of-rubraca--for-ovarian--fallopian-tube--or-primary-peritoneal-cancer---clovis-oncology-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-approves-keytruda--pembrolizumab--in-relapsed-or-refractory-classical-hodgkin-lymphoma--merck-inc/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-cimzia-for-moderate-to-severe-plaque-psoriasis---ucb-/2024-07-26T10:01:42+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-afrezza-to-treat-diabetes-mellitus--mannkind-corporation/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2011/12/insulin-degludec-plus-insulin-aspart--novo-nordisk--in-phase-iii-diabetes-trials/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-grants-market-authorization-of-clearl-lab-reagents--t1--t2--b1--b2--m--to-beckman-coulter--inc-to-aid-in-the-detection-of-leukemias-and-lymphomas-/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2014/08/migalastat-success-in-phase-iii--study-012--for-treatment-of-fabry-disease--amicus-therapeutics-/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-trial-of-zerbaxa-meets-endpoint-in-habp-vabp---merck-inc-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2017/11/alnylam-pharmaceuticals-and-fda-agree-resumption-of-dosing-in-clinical-studies-of-fitusiran-for-hemophilia-a---b-/2021-09-24T07:14:41+00:00weekly0.6https://www.medthority.com/news/2018/06/no-clear-evidence-that-nicotine--preloading--helps-smokers-to-quit/2024-03-05T15:08:25+00:00weekly0.6https://www.medthority.com/news/2017/04/european-association-of-cardiothoracic-anaesthesiology--eacta-2017-/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2012/08/trilogy-acs-study-results-for-efient-effient--daiichi-sankyo-eli-lilly-/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-adempas-for-pah-and-cteph-bayer-healthcare/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2017/06/-don-t-delay--connect-today---initiative-to-encourage-early-diagnosis-of-rheumatic-and-musculoskeletal-diseases-/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2018/10/clementia-pharma-to-file-in-2019--for-palovarotene-based-on-phase-ii-data-for-prevention-of-heterotopic-ossification-in-patients-with-fibrodysplasia-ossificans-progressiva-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2018/11/boston-scientific-acquires-btg-plc-and-with-it-therasphere-y-90-radiotherapy-microspheres-and-galil-cryoablation-system-/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2020/01/tazarotene-0-045--lotion-positive-for-the-once-daily-treatment-of-moderate-to-severe-acne-vulgaris-in-adult-males---bausch-health---ortho-dermatologics/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-extension-of-intercept-blood-system-to-improve-blood-transfusion-safety---cerus-corporation/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-lumicleanse-gel--klox-tech--for-acne/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2017/06/updated-results-from-phase-iii-study-of-keytruda--pembrolizumab--in-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2017/02/health-canada-approves-kevzara--sarilumab-as-a-treatment-for-moderately-to-severely-active-rheumatoid-arthritis---sanofi---regeneron-/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2019/10/swedish-orphan-biovitrium-acquires-dova-pharma-and-with-it-doptelet-/2025-10-16T11:31:20+00:00weekly0.6https://www.medthority.com/news/2019/05/eisai-and-medsir-announce-initiation-of-new-study-investigating-halaven---eribulin--treatment-efficacy-in-metastatic-breast-cancer/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-grants-accelerated-approval-for-keytruda--pembrolizumab--to-treat-squamous-and-non-squamous-nsclc--merck/2024-02-23T11:50:16+00:00weekly0.6https://www.medthority.com/news/2016/04/ema-validates-application-for-opdivo--nivolumab--to-treatclassical-hodgkin-lymphoma---bms/2024-02-23T11:50:32+00:00weekly0.6https://www.medthority.com/news/2014/06/positive-results-for-xtandi-sup----sup--in-phase-iii-prevail-trial/2024-10-21T14:38:39+00:00weekly0.6https://www.medthority.com/news/2014/12/gsk-declines-to-sell-older-brand-drugs/2025-10-16T10:58:40+00:00weekly0.6https://www.medthority.com/news/2012/04/ellipse-cardioverter-defibrillator---st-jude--receives-ce-mark/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-pivotal-study-of-bema-buprenorphine-naloxone--biodelivery-sciences--for-opioid-dependence/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2015/06/janssen-reports-interim-results-from-helios-trial-of-imbruvica---bendamustine---rituximab-in-cll-sll-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2015/09/nhs-in-uk-delists-17-medications-from-cancer-drugs-fund/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-revestive--teduglutide--for-injection-in-paediatric-patients--aged-one-to-17-years--with-short-bowel-syndrome--shire/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2019/05/edwards-lifesciences--describes-transcatheter-mitral-programme-for-pascal-system-to-treat-mitral-regurgitation-/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-humira--abbott--for-paediatric-patients-with-crohn-s-disease/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2019/06/chmp-recommends-approval-of-dupixent-in-adolescents-with-moderate-to-severe-atopic-dermatitis/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2020/02/pedmark-filed-with-eu-and-rolling-submission-completed-with-fda-for-hearing-loss---fennec-pharma/2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-keytruda-to-treat-metastatic-squamous-cell-carcinoma-of-the-esophagus/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2018/09/new-data-reinforces-superior-reduction-of-retinal-fluid--a-key-marker-of-disease-activity-in-age-related-macular-degeneration--novartis/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---chronic-kidney-disease--ckd--a-challenge-for-european-healthcare-systems/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2012/05/catt-trial-comparison-avastin-and-lucentis-for-wet-amd/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-opal-beyond-study-of-xeljanz--tofacitinib-citrate--in-psoriatic-arthritis--meets-primary-endpoint--pfizer/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2017/11/comparative-study-of-anoro-ellipta-meets-primary-endpoint-in-chronic-obstructive-pulmonary-disease---glaxosmithkline---innoviva-/2024-02-23T11:50:57+00:00weekly0.6https://www.medthority.com/news/2015/02/-corevalve--has-advantages-over-cardiac-surgery-in-aortic-stenosis-patients--medtronic/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2013/03/eu-approves-expanded-approval-for-qutenza--astellas--for-neuropathic-pain/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2013/07/bms-astrazeneca-re-file-dapagliflozin-at-fda/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2018/01/successful-phase-ii-trial-keynote--224--of-keytruda-in-patients-with-advanced-liver-cancer---merck-inc-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2012/04/cimzia-success-in-phase-iii-trial-for-axial-spondyloarthritis/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2015/12/eli-lilly-cancels-basal-insulin-peglispro--bil-programme-for-types-1---2-diabetes-/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-sbla-for-blincyto--blinatumomab--to-include-new-data-supporting-the-treatment-of-pediatric-patients-with-philadelphia-chromosome-negative--ph---relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia--all----amgen/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-fycompa--eisai--as-a-treatment-for-epilepsy-/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2012/04/entinostat--syndax-gsk--enetrs-phase-i-ii-trial-for-breast-cancer/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2014/07/oncaspar-filed-with-eu-for-all-sigma-tau-pharma/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2012/04/european-commission-approves-humira-abbott-labs--for-ulcerative--colitis/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2015/10/biomarin-acquires-world-rights-to-kuvan--sapropterin-dihydrochloride---excluding-japan--and-to-pegvaliase-from-merck-serono-as-treatments-for-pku/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2017/12/positive-phase-iii-results-for--vraylar-to-treat-depressive-episodes-associated-with-bipolar-i-disorder---allergan---gedeon-richter-/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-aerospan--acton-pharma--for-asthma/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2013/01/biogen-elan-file-tysabri-at-fda-and-ema-for-first-line-treatment-of-multiple-sclerosis/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-approval-for-benepali--etanercept-biosimilar--to-treat-ra--psa--psoriasis-and-axial-spondyloarthritis--biogen---samsung-bioepis/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-positive-opinion-for-lynparza-as-a-1st-line-maintenance-treatment-of-brca-mutated-advanced-ovarian-cancer----astrazeneca---merck-inc-/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-ofev---nintedanib--for-treatment-of-idiopathic-pulmonary-fibrosis-boehringer/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2017/10/multiple-myeloma-treatment-extends-life-for-relapsed-patients/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2017/09/nice-rejects-again-imbruvica--ibrutinib--to-treat-mantle-cell-lymphoma-but-recommends-the-drug-to-treat-waldenstrom-s-macroglobulinaemia---janssen-biotech-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2015/04/eluvia-drug-eluting-stent-meets-primary-endpoint-in-trial-for-peripheral-artery-disease-boston-scientific/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2014/07/jazz-pharma-acquires-us-rights-to-defitelio-in-us-from-sigma-tau-pharma-/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-recell-system-to-treat-burns---avita-medical/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2017/04/real-world-study-of-zepatier--elbasvir---grazoprevir--shows-benefits-in-hepatitis-c--merck-inc/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2016/08/boston-scientific-receives-fda-approval-for-emblem-mri-subcutaneous-implantable-defibrillator--s-icd--system--an-imageready-mr-conditional-device--which-allows-patients-to-undergo-magnetic-resonance-imaging--mri--safely-/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2015/06/gsk-sells-nimenrix-and-mencevax--meningitis-vaccines-to-pfizer-/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/08/baxter-international-inc--announces--510-k--clearance-of-the-prismax-system-and-integrated-thermax-blood-warmer-for-continuous-renal-replacement-therapy-/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2016/03/socrates-trial-of-brilinta---brilique--ticagrelor--in-stroke-fails-to-meet-endpoint--astrazeneca/2024-02-20T15:53:39+00:00weekly0.6https://www.medthority.com/news/2011/11/kalbitor--dyax-defiante-farma--is-withdrawn-from-ema-for-acute-hereditary-angioedema/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-accepts-mylan-s-bla-for-myl-1401h--a-proposed-biosimilar-to-neulasta---pegfilgrastim----mylan---biocon-ltd/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-checkmate--214-study-of-opdivo-plus-yervoy--nivolumab---ipilimumab--in-untreated-advanced-or-metastatic-renal-cell-carcinoma-meets-endpoint-and-advisory-committee-recommends-halting-study---bms-/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-approval-of-opdivo-flat-dosing-schedule-for-the-adjuvant-treatment-of-adult-patients-with-melanoma---bms/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2016/11/trailblaze-pharos-companion-diagnostic-receives-eu-ce-mark-approval-for-use-with-entrectinib-in-solid-tumours--ignyta/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2012/04/chmp-recommends-jakavi--incyte-novartis-for-myelofibrosis/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2019/01/bms-to-acquire-celgene-for-approximately--74-billion-/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2015/07/analysis-of-expedition-trials-of-solanezumab-in-mild-alzheimers-disease-suggests-benefits--eli-lilly/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2013/10/trasylol--bayer-healthcare--reinstated-for-cardiac-surgery-in-the-eu/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2017/11/nice-recommends-mavanclad-as-a-treatment-for-multiple-sclerosis----merck-kgaa-/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2018/03/use-of-certain-diabetes-drugs-may-be-linked-to-increased-risk-of-inflammatory-bowel-disease/2024-02-22T08:51:02+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-verzenio---an-aromatase-inhibitor-for-hr---her2--advanced-or-metastatic-breast-cancer--eli-lilly-/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2014/08/nice-rejects-kadcyla-as-too-expensive-for-her2-positive-breast-cancer---roche/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-refiling-of-intravenous--iv--meloxicam-for-the-management-of-moderate-to-severe-pain---baudax-bio/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2019/05/european-commission-approves-triplet-therapy--pomalidomide---bortezomib---dexamethasone---for-multiple-myeloma/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2015/06/the-incident-cohort-study-shows-home-hemodialysis-superior-to-peritoneal-dialysis--nxstage-medical/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/01/adcetris---chemotherapy-results-of-echelon-1-trial-for-classical-hodgkin-lymphoma-is-published-in-clinical-cancer-research-/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2018/03/loxo-oncology-completes-rolling-submission-to-fda-for-larotrectinib-for-the-treatment-of-solid-tumors-harboring-an-ntrk-gene-fusion-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-submissions-for-pkc-412--midostaurin--to-treat-aml-patients-with-a-flt3-mutation-and-for-systemic-mastocytosis---novartis/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-filing-of-alxn-1210-to-treat--paroxysmal-nocturnal-hemoglobinuria---alexion-pharma-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2018/04/four-real-world-studies-in-the-use-of-omidria-in-both-routine-and-complex-cataract-surgery-cases---omeros-corpn-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-venclexta--venetoclax---for-patients-with-chronic-lymphocytic-leukemia-17p-deletion--abbvie/2021-09-24T07:10:44+00:00weekly0.6https://www.medthority.com/news/2014/04/baxter-to-acquire-chatham-therapeutics/2025-10-16T11:07:27+00:00weekly0.6https://www.medthority.com/news/2012/07/positive-data-from-phase-iii-summit-trial-of-maci--genzyme-sanofi--for-cartilage-repair/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2019/03/two-phase-iii-studies-of-vx-445--tezacaftor-and-ivacaftor-meet-primary-endpoint-in-cystic-fibrosis---vertex/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2012/02/lactobacillus-reuteri-protectis--biogaia--reduced-diarrhoea-in-children/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-accepts-filing-of-epanova-for-hypertriglyceridaemia/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2013/12/eliquis-filed-at-fda-for-vte-bms-pfizer/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2014/02/avp-825-filed-with-the-fda-for-migraine-optinose/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2012/01/xarelto--bayer-janssen--is-fda-filed-for-acute-coronary-syndrome/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-results-for-ligelizumab-to-treat-chronic-spontaneous-urticaria---novartis/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-positive-results-from-oratorio-trial-of-ocrelizumab-in-primary-progressive-multiple-sclerosis--genentech---roche/2024-02-20T16:02:30+00:00weekly0.6https://www.medthority.com/news/2017/12/hope-for-patients-with-trastuzumab-resistant-breast-cancer/2021-11-30T13:37:11+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-grants-accelerated-approval-for-bexsero-vaccine-for-prevention-of-meningococcal-disease--novartis-/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-does-not-recommend-otezla--apremilast--for-treatment-of-psoriatic-arthritis--celgene/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-phase-iii-for-ibi-10090--dexamethasone-extended-release--in-cataract-surgery-icon-bioscience/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-phase-iii-trial-for-idp-118--halobetasol-propionate-and-tazarotene--to-treat-plaque-psoriasis--valeant-pharma-intl-/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2015/12/zafgen-reports-second-death-in-phase-iii-trial-of-zaf-311--beloranib---a-proposed-treatment-for-prader-willi-syndrome-/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-sleep-system--breathe-technologies--for-obstructive-sleep-apnea/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-brightmatter-guide-neurological-navigation-system-synaptive-medical/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2018/07/juluca--the-first-2-drug-regimen-for-hiv--once-daily--single-pill-regimen--maintains-viral-suppression-through-100-weeks---viiv-healthcare-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2014/11/ftc-approves-medtronic-s-acquisition-of-covidien/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2018/05/results-of-latitude-study-of-filtering-for-emblem-s-icd-system-in-ventricular-arrhythmias-published-in-heart-rhythm-journal---boston-scientific-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-issues-complete-response-letter-for-heplisav-b---hepatitis-b-vaccine--recombinant--adjuvanted---for-immunization-against-hepatitis-b-infection---dynavax-technologies/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2014/09/inhaled-alpha-1-antitrypsin--aat--therapy-fails-endpoints-in-phase-iii-trial-but-has-positive-effects-on-lung-function-kamada/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2013/03/rts-s-malaria-vaccine--gsk--disappoints/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-data-from-24-week-study-of-zubsolv--buprenorphine-naloxone--in-opioid-dependence-orexo/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2011/09/ema-confirms-risk-benefit-of-multaq/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2019/05/opdivo-fails-phase-iii-checkmate--498-trial-to-treat-unmethylated-glioblastoma-multiforme---bms/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2019/06/pioneer-6-trial-demonstrated-non-inferiority-of-major-adverse-cardiovascular-events--mace--with-oral-semaglutide-compared-with-placebo---novo-nordisk/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2016/02/nice-does-not-recommend-praluent---alirocumab--to-treat-high-cholesterol-sanofi/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2017/08/post-market-study-with-rezu-m-radiofrequency-system-in-benign-prostatic-hyperplasia-published-in-research-and-reports-in-urology--nxthera-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2017/04/monarch-3-trial-success-for-abemaciclib---an-aromatase-inhibitor-to-treat-hr--human-epidermal-growth-factor-receptor-2-negative--her2---advanced-breast-cancer---eli-lilly/2021-09-24T07:14:10+00:00weekly0.6https://www.medthority.com/news/2015/07/nice-recommends-entyvio--vedolizumab--for-treatment-of-crohn-s-disease/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2017/08/regenxbio-inc--to-acquire-dimension-therapeutics-inc--and-with-it-dtx-201--dtx-301-and-dtx-401-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2015/04/micra-transcatheter-pacing-system-receives-ce-mark-approval-for-arrhythmias-medtronic/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2012/10/study-shows-second-generation-drug-eluting-stents-are-safe-and-effective---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2015/09/xuriden--uridine-triacetate--filed-with-fda-as-antidote-to-5-fluorouracil-wellstat-therapeutics/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2015/06/pozen-acquires-tribute-pharma--canada--for--146-million-/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2016/09/additional-data-from-delos-study-for-raxone--idebenone-shows-efficacy-on-inspiratory-function-in-patients-with-duchenne-muscular-dystrophy--santhera/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/04/horizons--opinion---insight/2024-07-30T15:22:58+00:00weekly0.6https://www.medthority.com/news/2019/07/orphazyme-a-s--reports-positive-fda-meeting-and-plan-to-submit-nda-for--arimoclomol-for-niemann-pick-disease-/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2017/06/successful-spirit--p1-study-of-taltz--ixekizumab--to-treat-psoriatic-arthritis---eli-lilly/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2016/05/study-published-in-neurology-potentially--links-lyrica--pregabalin-pregabalin-controlled-release--to-birth-defects---pfizer/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2015/09/roche-has-ce-mark-for-cobas-egfr-mutation-test-v2-test-to-identify-mutations-in-the-egfr-gene-for-nsclc/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2012/10/sanofi-pasteur-has-submitted-hexaxim-vaccine-to-ema-for-approval-in-europe---------------/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2012/04/reprise-i-and-ii-trials-to-commence-for-lotus-aortic-valve-system--boston-scientific-/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2018/08/hansa-medical-initiates-follow-up-study-of-patients-treated-with--imlifidase--ides--prior-to-kidney-transplantation-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2013/10/janssen-acquires-gsk-2336805-for-hepatitis-c/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2015/11/invokamet-xr--canagliflozin---metformin-hydrochloride-extended-release--submitted-to-fda-for-type-2-diabetes--janssen/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2015/05/nantpharma-acquires-igdrasol-inc-and-with-it-rights-to-cynviloq--paclitaxel-nanoparticle-polymeric-micelle-/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2019/09/bms-announces-pooled-five-year-survival-results-for-opdivo-in-previously-treated-advanced-nsclc-patients-/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2013/10/-supplemental-application-filed-at-fda-for-kalydeco-in-cystic-fibrosis/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-snda-for-tibsovo-to-treat-newly-diagnosed-patients-with-idh1-mutant-aml-not-eligible-for-intensive-chemotherapy---agios-pharma/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2018/11/ce-mark-for-sapien-3-ultra-system-for-transcatheter-aortic-valve-replacement---edwards-lifesciences--/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2017/12/updated-results-from-juliet-trial-of-kymriah-for-dlbcl--lymphoma---novartis-/2024-02-20T16:03:31+00:00weekly0.6https://www.medthority.com/news/2015/02/gsk-requests-additional-authorisation-in-eu-for-revolade-in-itp---gsk-/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2017/11/subgroup-analysis-of-flaura-data-of-tagrisso-in-nsclc-shows-specific-patient-group-benefits---astrazeneca-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2018/12/initial-data-from-phase-1-11-study-of-liso-cel-for-cll-and-sll-presented-at-ash-2018---juno-celgene/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2014/04/new-phase-iii-trial-of-arc-4558-for-diabetic-neuropathy-pain---biodelivery-sciences/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2013/06/post-hoc-analysis-of-phase-iii-study-with-thermodox--celsion-corp--indicates-benefits-for-liver-cancer/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-biosimilar-adalimumab--to-treat-all-indications-of-the-reference-product---sandoz-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-approves-kovaltry--recombinant-factor-viii--to-treat-haemophilia-a--bayer-healthcare/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2014/10/chmp-recomends-scenesse-for-treatment-of--erythropoietic-protoporphyria---clinuvel/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2016/09/embotrap-ii-revascularization-device-receives-ce-mark-approval-to-treat-acute-ischaemic-stroke---neuravi/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-trial-of-samsca-slows-kidney-function-decline-in-polycystic-kidney-disease---otsuka-/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2016/01/modified-tjf-q180v-duodenoscope-receives-510-k-approval-for-use-in-endoscopic-retrograde-cholangiopancreatography--ercp---olympus-medical/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress--eau-2018---siblings-of-cot-death-victims-have-four-fold-cot-death-risk/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2017/03/mitraclip-system-shows-benefits-in-study-of-transcatheter-mitral-valve-repair--abbott/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-fourth-generation-mitraclip-device--mitraclip-g4-for-treatment-of-mitral-regurgitation--abbott/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2019/11/ema-approves-expanded-approval-of-sapien-3-transcatheter-heart-valve-for-aortic-stenosis---edwards-lifesciences/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2014/10/abp-501-biosimilar-met-endpoints-in-phase-iii-study-comparison-with-humira-for-psoriasis---amgen/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2016/09/ce-mark-for-the-inspiris-resilia-aortic-valve---incorporating-resilia-tissue-to-preserve-tissue-and-improve-anti-calcification---edwards-life-sciences/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2013/03/ranexa-gilead-sciences--success-in-phase-iv-terisa-trial-to-treat-chronic-stable-angina-in-diabetic-patients-/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2015/03/xydalba--dalbavancin--is-eu-approved-for-absssi--actavis---angelini/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-elzonris-for-blastic-plasmacytoid-dendritic-cell-neoplasm---stemline-therapeutics-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2013/12/belinostat-filed-at-fda-for-t-cell-lymphoma-spectrum-pharma/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2019/03/results-from-phase-iii-c-axspand-study-of-cimzia-for-axial-spondyloarthritis-published-in-arthritis---rheumatology---ucb/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-cimzia-for--axial-spondyloarthritis-/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2012/03/oncogenex-teva-initiate-phase-iii-trial-for-custirsen-for-prostate-cancer/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2015/05/otonomy-inc--files-nda-at-fda-for-auripro--ciprofloxacin-sustained-release--to-treat-middle-ear-effusion-in-pediatric-patients--/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2016/01/cti-pharma-and-baxalta-complete-rolling-submission-to-fda-for-pacritinib-as-a-treatment-for-myelofibrosis/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2012/11/-nice-rejects-again-javlor--pierre-fabre--as-a-treatment-for-bladder-cancer/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2019/05/us-district-court-decides-that--vectura-s-us-patent-8303991-was-found-valid-and-infringed-by-us-sales-of-three-of-glaxosmithkline-s--gsk--ellipta-products-/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-panther-testing-system--gen-probe--for-sexually-transmitted-infections/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-supera-peripheral-stent-for-peripheral-artery-disease--abbott-vascular/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2018/06/acrysof-iq-panoptix-intraocular-lens--iol---shows-superior-visual-outcomes-to-the-zeiss-at-lisa-tri-839mp-iol-in-head-to-head-study-of-cataract-patients---alcon-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2018/11/american-college-of-cardiology-recommends-jardiance-as-the-preferred-sglt2-inhibitor-for--reduction-of-the-risk-of-cardiovascular-death-and-cv-disease-in-adults-with-type-2-diabetes---eli-lilly-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2018/09/real-world-studies-of-cosentyx-for-psoriasis-are-presented-at-eadv-meeting---novartis/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2017/11/tralokinumab-fails-in-stratos-2-and-tropos-trials-for-severe-asthma--astrazeneca/2024-07-26T10:01:21+00:00weekly0.6https://www.medthority.com/news/2019/11/alnylam-initiates-illuminate-c-phase-iii-study-of-lumasiran-for-the-treatment-of-advanced-primary-hyperoxaluria-type-1-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2014/05/nda-for-olysio-and-sofosbuvir-submitted-to-fda-for-hcv-janssen/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2015/11/assessment-by-iqwig-of-spiolto-respimat--tiotropium---olodaterol--in-chronic-obstructive-pulmonary-disease-finds-evidence-of-minor-benefits--boehringer-ingelheim/2024-02-20T16:03:44+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-onetouch-veriosync-blood-glucose-monitoring-system--lifescan--for-patients-with-diabetes-types-1---2-/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-votes-to-support-inhaled-powder-form-of-tobramycin--novartis--for-patients-with-cystic-fibrosis---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2017/12/results-from-phase-i-trial-of-bb-2121--a-car-t-cell-therapy--for-multiple-myeloma---celgene---bluebird-bio-/2024-02-20T16:04:01+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-sbla-for-empliciti---pomalidomide---low-dose-dexamethasone-to-treat-relapsed-refractory-multiple-myeloma----bms/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-cosentyx--secukinumab--for-treatment-of-plaque-psoriasis--novartis/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-beacon-trial-of--erbitux--cetuximab----encorafenib-with-or-without-binimetinib-for-colorectal-cancer--merck-kgaa--array-biopharma-and-pierre-fabre/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2015/07/new-phase-iv-results-show-significant-improvement-with-nuedexta--dextromethorphan-and-quinidine-sulphate--in-pseudobulbar-affect--avanir-pharma/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2018/02/trelegy-ellipta-filed-with-ema-for-label-expansion-in-chronic-obstructive-pulmonary-disease---glaxosmithkline---innoviva-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2019/01/nejm-reports-positive-phase-iii-trial-of-cablivi-to-treat-thrombocytopenic-purpura---sanofi/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2011/10/resperate-device-study-shows-benefits-for-heart-failure-patients/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2017/12/opdivo-report-and-effect-on-hiv--bms/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2012/11/nice-rejectes-esbriet--intermune--as-a-treatment-for-pulmonary-fibrosis/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-egranli-for-prophylaxis-of-chemotherapy---induced-neutropenia---teva/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-snda-for-mycamine-in-candidemia--acute-disseminated-candidiasis--candida-peritonitis-and-abscesses-for-pediatric-patients---astellas/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-accepts-nda-for-eravacycline-for-the-treatment-of-complicated-intra-abdominal-infections---tetraphase-pharmaceuticals-/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-trial-of-linzess--linaclotide--in-chronic-constipation-meets-primary-endpoint--astellas-pharma-and-ironwood-pharmaceuticals-/2021-09-24T07:13:02+00:00weekly0.6https://www.medthority.com/news/2018/01/shire-plc-to-operate-as-two-divisions-being-neuroscience-and-rare-diseases-/2021-11-30T14:22:19+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-issues-a-complete-response-letter-to-coherus-biosciences--inc--for-chs-1701--its-pegfilgrastim--neulasta--biosimilar-candidate-/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-epiduo-forte--adapalene-and-benzoyl-peroxide-gel--to-treat-acne--galderma/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2014/08/fluzone-high-dose-vaccine-results-for-influenza-is-published-in-nejm--sanofi-pasteur/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-does-not-support-otezla--apremilast--for-use-in-patients-with-moderate-and-severe-psoriasis--celgene/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-veltassa--patiromer--for-the-treatment-of-hyperkalaemia--vifor-fresenius/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2019/05/msc-100-iv-rolling-submission-for-acute-graft-versus-host-disease-filed-with-fda---mesoblast/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2012/04/cyberknife-vsi-system--accuray--used-in-stereotactic-radiosurgery-/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2014/10/success-for-ain-457-in-two-phase-iii-trials-for-ankylosing-spondylitis--novartis/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2014/07/alirocumab-success-in-odyssey-trials-for-hypercholesterolemia---sanofi---regeneron/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/06/keynote-087-phase-ii-study-of-keytruda--pembrolizumab--relapsed-or-refractory-classical-hodgkin-lymphoma--chl-show-up-to-83--response-rates---merck-inc-/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2014/03/shire-recalls-batch-of-vpriv-in-usa/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2014/06/velcade-filed-with-ema-for-mcl-janssen-cilag/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-requires-new-trial-for-melblez-kit-for-liver-cancer/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2012/05/new-formulation-of-viread--gilead-sciences--makes-gel-safer-for-rectal-use-against-hiv/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2012/05/carbozantinib--exelixis--enters-phase-iii-for-metastatic-castration-resistant-prostate-cancer/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/02/slit-tablet-filed-with-fda-for-house-dust-mite-allergy--merck/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2014/11/cardio3biosciences-acquires-corquest-medical/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2016/03/ema-accepts-for-review-maa-from-pfizer-for-xeljanz--tofacitinib-citrate--to-treat-rheumatoid-arthritis-/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2016/10/pooled-analyses-of-phase-iii-trials--shows-efficacy-of-ofev--nintedanib--in-idiopathic-pulmonary-fibrosis---boehringer/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2016/09/eu-chmp-changes-opinion-on-ninlaro--ixazomib--and-recommends-approval-of-drug-combination-for-multiple-myeloma---takeda/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2017/04/uniqure-n-v--announced-that-it-will-not-pursue-the-renewal-of-the-glybera-alipogene-tiparvovec--marketing-authorization-in-europe-when-it-is-scheduled-to-expire-on-october-25--2017-/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-maintains-clinical-hold-on-proellex--telapristone-acetate----a-treatment-for-uterine-fibroids---repros-therapeutics/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2014/10/johnson---johnson-acquires-alios-biopharma-for--1-75-billion-including-al-8176-/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-otrexup--antares--for-ra--psoriasis-and-pjia/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2018/12/rafael-pharmaceuticals---initiates-a-phase-iii-trial-of-cpi-613-to-treat-metastatic-adenocarcinoma-of-the-pancreas-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-stelara--j-j-janssen-cilag--shows-significant-benefit-at-endpoint-for-active-psoriatic-arthritis-/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2016/09/shire-returns-rights-to-m-923-biosimilar-of-humira--adalimumab--to-momenta-pharmaceuticals-/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2014/12/heartmate-iii-in-trials-for-heart-failure-thoratec/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-data-from-eylea-study-in-dmo-regeneron-pharma/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2019/11/coast-x-phase-iii-trial-of-taltz-meets-primary-and-secondary-endpoints-in-axial-spondyloarthritis---eli-lilly/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2013/03/eu-approves-carotid-embolic-protection-stent--inspiremd--for-stroke-prevention/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2015/10/roche-acquires-adheron-therapeutics-and-with-it-spd-051/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2016/01/abbvie-initiates-phase-iii-trial-of--elagolix---a-gonadotropin-releasing-hormone--gnrh--receptor-antagonist--to-treat-uterine-fibroids-/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2014/03/xtandi-filed-at-fda-for-pre-chemotherapy-prostate-cancer-treatment---astellas---medivation/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2018/01/positive-checkmate--142-trial-for-opdivo-and-yervoy-for-the-treatment-of-patients-with-dna-mismatch-repair-deficient--dmmr--or-microsatellite-instability-high--msi-h--metastatic-colorectal-cancer---bms-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2018/12/results-of-medalist-trial-for-luspatercept--to-treat--patients-with-ring-sideroblast--rs---myelodysplastic-syndromes--mds--associated-anemia---celgene---acceleron/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-label-update-on-maintenance-treatment-of-schizophrenia--lundbeck-otsuka/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/10/study-analyses-role-of-avastin--roche-genentech--in-colorectal-cancer/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-approves-abraxane-for-nsclc-celgene/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2012/01/sycrest-lundbeck--is-launched-for-bipolar-disorder-in-uk/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-treat-trial-showed-that-people-with-type-1-and-type-2-diabetes-saw-a-significant-reduction-in-hba1c-with-tresiba--insulin-degludec----novo-nordisk/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-adreview--ge-healthcare--for-gamma-scintigraphic-assessment-of-heart-failure/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-extends-indication-of-multihance-to-include-imaging-of-pediatric-patients---bracco-diagnostics-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-from-phase-iii-trial-of-ruconest--santarus--in-patients-with-hereditary-angioedema/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2015/08/ftc-clears-pfizer-takeover-of-hospira/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2019/10/rizaport-versafilm-is-re-filed-at-fda-for-the-treatment-of-acute-migraines---intelgenx-corp-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-arch-study-results-with-evenity--romosozumab--for-osteoporosis--published-in-the-new-england-journal-of-medicine---amgen-ucb-/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2018/05/eu-approves-repatha-for-adults-with-established-atherosclerotic-cardiovascular-disease--amgen-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-issues-complete-response-for-sugammadex/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approval-for-dayvigo-to-treat-insomnia-characterized-by-difficulties-with-sleep-onset-and-or-sleep-maintenance--eisai/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2014/09/three-year-data-for-ovation-stent-graft-system-in-abdominal-aortic-aneurysm-trivascular/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-xadago--safinamide--for-parkinsons-disease--zambon/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/03/navidea-appoints-norgine-to-market-lymphoseek-cancer-diagnostic-aid-in-eu/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-keytruda-for-adjuvant-treatment-of-melanoma-with-involvement-of-lymph-node-s--following-complete-resection--merck-inc-/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2019/05/successful-liberty-1-study-of-relugolix-meets-primary-efficacy-endpoint-in-women-with-uterine-fibroids/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2018/03/enrollment-completed-in-biostemi-trial-of-orsiro2-hybrid-drug-eluting-stent-versus-xience-xpedition3-in-stemi-patients----biotronik-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2017/05/successful-results-from-three-phase-iii-trials-of-galcanezumab-for-the-treatment-of-migraine---eli-lilly/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2013/10/apremilast--celgene--success-in-psoriasis/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2019/03/og-217sc-filed-with-the-fda-for-type-2-diabetes/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-yutiq-for-chronic-non-infectious-uveitis---eyepoint-pharma-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2013/01/merck-inc-re-files-sugammadex-at-fda/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2013/12/ce-mark-for-symplicity-spyral-renal-dernervation-system-medtronic/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2017/11/elagolix-demonstrates-sustained-pain-reduction-in-endometriosis---abbvie-/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2014/11/ain-457-success-in-future-studies-for-psoriatic-arthritis--novartis/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-study-for-tezacaftor-ivacaftor-combination-in-cystic-fibrosis-supports-european-medicines-agency-submission---vertex/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2018/05/overall-survival-results-from-pacific-phase-iii-trial-of-imfinzi-in-unresectable-stage-iii-nsclc---astrazeneca-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2012/03/chmp-recommends-tecfidera-biogen-idec--for-treatment-of-multiple-sclerosis/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-results-from-a-trial-of-oncotype-dx-breast-cancer-diagnostics--genomic-health/2024-02-20T16:04:28+00:00weekly0.6https://www.medthority.com/news/2014/02/resolute-integrity-cardiac-stent-non-inferior-to-everolimus-stent---medtronic/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2015/06/study-of-implantable-miniature-telescope-for-patients-with-age-related-macular-degeneration-published-visioncare-/2024-02-20T16:07:59+00:00weekly0.6https://www.medthority.com/news/2015/05/new-data-from-two-studies-of-fycompa--perampanel--for-epilepsy-eisai-/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2015/06/lenvima--lenvatinib-mesylate--is-eu-approved-for-metastatic-differentiated--papillary--follicular--h-rthle-cell--thyroid-carcinoma--dtc---refractory-to-radioactive-iodine--rai---eisai/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2018/09/successful-kronos-phase-iii-trial-of-triple-therapy--pt-010--for-copd--astrazeneca/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommends-translarna-for-duchenne-muscular-dystrophy-ptc-therapeutics/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2013/07/sobi-to-market-xiapex-in-eu-and-other-countries-/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2011/11/smc-021-fails-phase-iii-trial-for-post-menopausal-osteoporosis/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-requires-extended-time-to-review-hyqvia-for-primary-immunodeficiency---baxter/2021-09-24T07:08:08+00:00weekly0.6https://www.medthority.com/news/2016/05/od-01-oculeve-intranasal-tear-neurostimulator-meets-endpoints-in-trial-for-dry-eye-disease--allergan/2024-02-20T16:08:11+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-rozlytrek-to-treat-ros1-positive--metastatic-non-small-cell-lung-cancer-and-ntrk-gene-fusion-positive-solid-tumors--genentech-roche/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-pillcam-colon-for-imaging-given-imaging/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2016/07/phase-iii-napoli-1-data-shows-patients-treated-with-onivyde--irinotecan-liposome-injection--have-similar-quality-of-life-compared-to-other-treatment-regimes-in-pancreatic-cancer--merrimack-pharmaceuticals/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-approves-supplemental-nda-for-synjardy--empagliflozin-metformin-hydrochloride---synjardy-xr--empagliflozin-metformin-hydrochloride-extended-release--and-glyxambi--empagliflozin-linagliptin--in-type-2-diabetes-care--boehringer-and-eli-lilly/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2016/11/trial-of-sentinel-cerebral-protection-system-meets-primary-endpoint-in-tavr--claret-medical/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-generic-singulair-for-asthma/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2016/11/chmp-recommends-vemlidy---tenofovir-alafenamide----taf--as-a-treatment-for-chronic-hepatitis-b-virus-infection---gilead-sciences--/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-ii-data-included-in-nda-for-rucaparib-in-ovarian-cancer-presented-at-european-society-for-medical-oncology-congress--clovis-oncology/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2016/03/uk-nice-issues-draft-guidance-not-recommending-imlygic--talimogene-laherparepvec--for-metastatic-melanoma-that-can-t-be-surgically-removed--amgen/2024-10-21T14:41:18+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-results-for-stelara--ustekinumab--in-crohn-s-disease-published-in-new-england-journal-of-medicine--janssen-research---development/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-resubmision-of-nda-for-cladribine-tablets-as-a-treatment-for--relapsing-forms-of-multiple-sclerosis----merck-kgaa-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2018/02/aviragen-therapeutics-to-merge-with-vaxart-inc-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2018/09/amicus-therapeutics--provides-regulatory-update-on-at-gaa-for-pompe-disease-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2012/04/ranbaxy-launches-indias-first-new-drug-synriam-for-malaria/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-subanalysis-of-zurampic--lesinurad--shows-efficacy-and-safety-in-gout--astrazeneca/2024-02-20T16:08:26+00:00weekly0.6https://www.medthority.com/news/2015/04/attain-study-results-for-plegridy---peginterferon-beta-1a--in-multiple-sclerosis--biogen/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2014/12/paloma-1-trial-results-of-ibrance---palbociclib-for-breast-cancer--published-in-the-lancet-oncology--pfizer/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2015/09/new-data-for-vibativ--telavancin-for-mrsa-and-other-difficult-to-treat-infections--theravance-biopharma/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommend-gazyvaro-for-cll---roche/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2014/06/biosimilar-remsima-inflectra-matches-efficacy-of-remicade-in-ankylosing-spondylitis---hospira/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2015/09/biogen---eisai-initiates-phase-iii-studies--engage-and-emerge-for-aducanumab-to-treat-early-alzheimers-disease/2024-02-20T16:08:41+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-recommends-simponi-for-ulcerative-colitis-merck-/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2012/10/no-significant-evidence-that-cranberry-juice-can-prevent-utis/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-pixuvri-in--non-hodgkin-b-cell-lymphoma---servier/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-trial-shows-tiotropium---olodaterol-benefit-for-copd---boehringer/2021-09-24T07:08:08+00:00weekly0.6https://www.medthority.com/news/2018/08/almirall-acquires-an-allergan-us-portfolio-of-dermatology-products-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2019/02/genentech-roche-file-sbla-with-fda-for-kadcycla-as-adjuvant-treatment-in-her2--breast-cancer/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2014/11/lumiheal-receives-ce-mark-approval-for-wound-healing-klox-tech/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2015/07/astrazeneca-initiates-phase-iia-study-of-azd-9412--inhaled-interferon-beta--for-severe-asthma/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2014/04/herceptin-patents-invalidated-in-uk---roche/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2016/09/fds-warning-on-combined-use-of-opioid-medicines-and-benzodiazepines-/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-gives-510-k--approval-for-cryoform-cryoablation-probe-for-cardiac-arrhythmias--atricure-/2021-09-24T07:10:43+00:00weekly0.6https://www.medthority.com/news/2014/05/results-of-7-year-trial-of-cimzia-in-crohns-ucb/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2020/02/cytokinetics-announced-the-publication-to-the-design-of-galactic-hf-cardiovascular-outcomes-clinical-trial-of-omecamtiv-mecarbil-in-the-journal-of-american-college-of-cardiology--heart-failure-/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2017/06/johnson---johnson-purchase-of-actelion-to-complete-on-16-june-2017-/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2019/07/findings--from-the-from-the-overcome-study-showed-that-nearly-1-in-5-people-with-migraine--19---are-currently-using-opioids-to-treat-their-disease---eli-lilly/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2018/03/ema-accepts-maa-for-pegvaliase-to-treat-phenylketonuria---biomarin-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2019/09/gsk-buys-sitari-pharmaceuticals-a-developer-of-a-novel-treatment-for-celiac-disease-/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-of-repatha--for-established-atherosclerotic-cardiovascular-disease---amgen-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2014/01/bema-buprenorphine-meets-endpoints-in-pain-trial-endo-pharma/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-joint-advisory-panel-recommends-t-vec--talimogene-laherparepvec--for-treatment-of-metastatic-melanoma--amgen/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2015/08/endo-sells-american-medical-systems-men-s-and-prostate-health-businesses-to-boston-scientific/2025-10-16T11:21:01+00:00weekly0.6https://www.medthority.com/news/2016/10/corindus-vascular-robotics-inc--has-received-510-k--clearance-from-the-fda-for-its-corpath-grx-vascular-robotic-system-for-percutaneous-coronary-interventions-/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2019/09/patient-shows-significant-response-in-early-study-of-bria-imt---keytruda-for-breast-cancer---briacell/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-outcome-in-eu-decentralised-procedure-for-copaxone-40-mg--glatiramer-acetate--three-times-a-week-formulation-for-multiple-sclerosis-teva/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-varubi-as-new-option-for-chemotherapy-related-nausea-and-vomiting/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2016/10/esmo-magnitude-of-clinical-benefit-scale--esmo-mcbs--applied-to-checkmate-141-data-for-opdivo---nivolumab--for-head-and-neck-cancer---bms/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2013/03/firmagon--degarelix--shows-lower-cv-risks-in-treatment-of-prostate-cancer/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-accepts-bla-from-bms-for-opdivo--nivolumab--to-treat-hepatocellular-carcinoma---liver-cancer--after-prior-sorafenib-therapy--/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2018/02/results-of-pioneer-study-of-oral-semaglutide-for-type-2-diabetes----novo-nordisk-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-committee-recommends-aproval-of-xtampza-er--oxycodone-extended-release--for-pain-relief-collegium-pharma/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-sofia-study-of-mgah-22-meets-primary-endpoint-in-breast-cancer---macrogenics/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2017/11/european-commission-approves-tasigna-to-treat-pediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive-cml---novartis-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2012/04/-18f-flutemetamol--ge-healthcare--success-in-phase-iii-pet-scan-for-beta-amyloid/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2019/05/global-her2-testing-survey-raises-questions-about-priorities-for-breast-cancer-resources/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2013/12/dual-ii-results-for-ideglira-in-type-2-diabetes-novo-nordisk/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2013/11/latuda--sunovion--success-in-studies-for-bipolar-depression/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2018/02/merck-inc---acquires-viralytics-and-with-it-cavatak--cva-21--investigational-oncolytic-immunotherapy-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2015/12/astrazeneca-enters-into-agreement-to-acquire-the-respiratory-business-of-takeda-including-daliresp-daxas--roflumilast-/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-data-for-everflex-sep-stent-system-in-pad-published--medtronic/2024-02-22T08:52:18+00:00weekly0.6https://www.medthority.com/news/2019/07/early-treatmentis-the-key-to-beating-alzheimer-s-disease-in-later-life/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-lyophilized-oncaspar--pegaspargase---as-a-component-of-antineoplastic-combination-therapy-in-acute-lymphoblastic-leukemia--all--in-pediatric-patients---shire-plc-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2019/09/the-medicines-company-announced-positive-results-for-the-orion-9-phase-iii-clinical-study-of-inclisiran-in-patients-with-heterozygous-familial-hypercholesterolemia-/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2011/09/combination-oladaterol-and-tiotropium-enters-phase-iii-for-copd/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-advisory-committee-recommends-metreleptin-for--lipodystrophy--astrazeneca-bms/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-cyramza-for-gastric-cancer---eli-lilly/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2018/03/eisai---merck-inc---to-collaborate-on-development-and-marketing-of-lenvima-as-monotherapy-and-with-keytruda-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2019/06/soliqua-phase-iii-results-significantly-lowered-blood-sugar-levels-compared-to-glp-1-receptor-agonist-treatments----sanofi/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2016/03/positive-results-in-phase-iii-trial-of-evarrest-fibrin-sealant-patch-in-hemostasis--ethicon-/2024-02-22T08:52:29+00:00weekly0.6https://www.medthority.com/news/2015/06/eu-approves-simponi--golimumab--for-non-radiographic-axial-spondyloarthritis-msd/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2012/08/delay-in-review-of-qt-1571-novartis--for-pah/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-cll14-study-of-venclexta-and-gazyva-meets-endpoint-in-chronic-lymphocytic-leukemia---genentech-roche/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2018/04/orexigen-therapeutics--sells-assets-to-nalpropion-pharmaceuticals--inc--/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2020/01/the-national-institute-for-health-and-care-excellence--refuses-recommendation-for-waylivra-to-treat-familial-chylomicronaemia-syndrome---akcea-therapeutics/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-study-of-pf-4383119-meets-primary-endpoints-in-osteoarthritis-pain---pfizer---eli-lilly-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2012/07/evp-6124--envivo-pharma-success-in--phase-iib-alzheimers-disease-trial/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2014/10/avedro-refiles-kxl-system-for-keratoconus-with-fda---avedro/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2017/02/chmp-recommends-zs-9--sodium-zirconium-cyclosilicate--for-the-treatment-of-hyperkalaemia---astrazeneca-/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2011/09/shotz-study-shows-forteo-more-effective-than-zometa-in-bone-remodelling/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2018/05/pfizer-announces-phase-iii-study-of-lyrica-for-patients-with--pediatric-epilepsy-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2013/05/palace-4-study-confirms-success-of-apremilast--celgene--in-treatment-of-psoriaric-arthritis/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2013/03/tradjenta-in-phase-iii-trial-for-diabetic-nephropathy/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2015/10/medtronic-acquires-lazarus-effect-and-with-it-the-lazarus-cover-device-/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2020/01/alnylam-pharmaceuticals-initiates-a-rolling-submission-to-the-fda-for-lumasiran-for-the-treatment-of-primary-hyperoxaluria-type-1--/2021-09-24T07:11:53+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-skyrizi-for-plaque-psoriasis/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2016/11/successful-phase-iii-study-of-orkambi--lumacaftor-ivacaftor--in-children-who-carry-two-copies-of-f508del-mutation-cystic-fibrosis---vertex-pharma/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2018/08/nice-requests-biogen-to-submit-spinraza-for-single-technology-appraisal-as-a-treatment-for-spinal-muscular-atrophy-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/05/eu-approves-cabometyx-to-treat-intermediate--or-poor--risk-advanced-renal-cell-carcinoma---ipsen---exelixis-inc-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2016/05/sandoz-files-maa-at-eu-for-rituximab-biosimilar-for-same-indications-as-the-reference-product-/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2014/12/revlimid--compared-to-investigators-choice-in-phase-ii-iii-dcl-001-trial-for-diffuse-large-b-cell-lymphoma-celgene/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2019/09/tivo-3-phase-iii-trial-of-fotivda-shows-updated-overall-survival-in-renal-cell-carcinoma---aveo-oncology/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2015/05/zykadia--ceritinib--is-eu-approved-for-anaplastic-lymphoma-kinase--alk--positive-advanced-nsclc--novartis/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2015/06/new-results-from-phase-iii-trials-of-ly-2605541--basal-insulin-peglispro--for-type-1-diabetes--eli-lilly/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2018/11/emprise-study-shows-jardiance-was-associated-with-a-44-percent-relative-risk-reduction-in-hospitalization-for-heart-failure--eli-lilly/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-afstyla---rviii-single-chain--to-treat-haemophilia-a--csl-behring/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-approval-of-vizimpro-for-egfr--non-small-cell-lung-cancer---pfizer/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2016/03/no-cv-benefit-from-contrave--bupropion-and-naltrexone--according-to-jama-study--orexigen/2024-02-22T08:52:55+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-dupixent-to-treat-adolescents-with-atopic-dermatitis---sanofi---regeneron/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-approves-ch14-18-cho--dinutuximab-beta--as-a-treatment-for-high-risk-neuroblastoma-in-children--eusa-pharma/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2012/06/treanda--teva-mundipharma--success-in-nhl-study/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2019/06/suicidal-thoughts-related-to-pain-in-one-in-ten-patients-with-rheumatic-or-musculoskeletal-disease/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-incresync--takeda--for-type-2-diabetes/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2018/07/baloxavir-marboxil-success-in-phase-iii-capstone-2-study-to-treat-influenza---genentech-roche---shionogi-/2024-07-26T09:57:09+00:00weekly0.6https://www.medthority.com/news/2013/05/protect-af-trial-of-watchman-laac--boston-scientific--successful-for-stroke-prevention/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2018/04/moxetumomab-pasudotox-is-filed--bla--at-fda-to-treat-hairy-cell-leukaemia---astrazeneca/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/04/sandoz-resubmits-bla-for-biosimilar-pegfilgrastim-to-the-fda-/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2011/11/arcalyst--regeneron--is-filed-at-fda-for-gout-flares/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2018/05/known-risk-factors-largely-explain-links-between-loneliness-and-first-time-heart-disease-stroke/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2015/07/allergan-to-acquire-naurex-and-with-it--rapastinel--glyx-13--and-nrx-1074-for-depression/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2013/11/vercise--boston-scientific--receives-ce-mark-approval-for-dystonia/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2011/11/amylin-acquires-world-rights-to-byetta-and-bydureon-for-type-2-diabetes-from-eli-lilly/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/04/ellipse-phase-iii-diabetes-trial-of-victoza-meets-endpoints-in-children-and-adolescents-with-type-2-diabetes---novo-nordisk/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2018/10/i-stat-tni-nx--a-point-of-care-diagnostic-test-success-reported-in-jama-cardiology---abbott/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2018/05/arzerra-fails-to-meet-primary-endpoint-in-phase-iii-complement-a-b-study-in-indolent-b-cell-non-hodgkin-s-lymphoma---genmab-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-vital-trial-of-cresemba--isavuconazonium-sulfate--in-invasive-mucormycosis-published-in-the-lancet-infectious-diseases--astellas/2024-02-22T08:53:14+00:00weekly0.6https://www.medthority.com/news/2016/11/study-of-amplatzer-amulet-left-atrial-appendage--laa--occluder-shows-success-rate-in-patients-diagnosed-with-non-valvular-atrial-fibrillation--af---st-jude-medical/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-advisory-committee--unanimously-recommends-ideglira--insulin-degludec---liraglutide--for-treatment-of-type-2-diabetes---novo-nordisk/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-alimta---keytruda-for-nsclc-with-no-egfr--alk-mutations---eli-lilly/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2012/07/ema-approves-axios-stent-system--xlumena--for-gi-surgery/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2019/06/ema-validates-maa-for-puldysa-for--the-treatment-of-respiratory-dysfunction-in-patients-with-duchenne-muscular-dystrophy---santhera/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2014/11/saphris-filed-with-fda-for-pediatric-patients-with-bipolar-disorder-actavis/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-gives-accelerated-approval-to-lynparza-for-ovarian-cancer-with-defective-brca-genes-astrazeneca/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2018/05/tapimmune-inc--to-merge-with-marker-therapeutics-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2012/08/eu-approves-zyclara--meda-ab--for-actinic-keratoses/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2016/04/lx-1032--telotristat-etiprate--filed-with-fda-for-treatment-of-carcinoid-syndrome--lexicon-pharmaceuticals-/2024-02-22T08:53:34+00:00weekly0.6https://www.medthority.com/news/2016/11/bayer-files-applications-in-us---japan-and-europe-for-stivarga--regorafenib-to-treat-unresectable-hepatocellular-carcinoma-/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2014/09/cochrane-collaboration-report-discounts-safety-issues-of-avastin-for-macular-degeneration--novartis---roche-/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-approves-opana-er-from-endo-pharma-for-moderate-to-severe-pain/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-advisory-committee-rejects-rexista---abuse-deterrent-oxycodone-hydrochloride-extended-release---to-treat-moderate-to-severe-pain--intellipharmaceutics-international-inc-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-bydureon-pen-formulation-for-type-2-diabetes---astrazeneca/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2019/10/deciphera-pharmaceuticals-announces--positive-results-from-invictus-pivotal-phase-iii-study-of-ripretinib-in-patients-with-advanced-gastrointestinal-stromal-tumors--/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2015/03/isis-advances-endear-study-of--isis-smnrx-for-infants-with-spinal-muscular-atrophy-isis---biogen-idec-/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2015/04/phase-ii-study-for-opdivo--nivolumab--yervoy--ipilimumab--versus-yervoy-monotherapy-in-untreated-advanced-melanoma--bms/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2011/11/huntexil--neurosearch--trial-suggests-it-is-well-tolerated-and-may-offer-benefits-for-patients-with-huntington-s-disease/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2017/02/studies-104-and-111-of-genvoya---elvitegravir-150-mg--cobicistat-150-mg--emtricitabine-200-mg-and-tenofovir-alafenamide-10-mg--for-treatment-of-hiv-1-show-higher-rates-of-virologic-suppression-compared-to-gilead-s-stribild---gilead-sciences/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2018/02/update-on-forthcoming-chmp-decision-for-betrixaban-as-a-treatment-for-venous-thromboembolism---portola-pharma/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2013/03/merck-inc--files-timothy-grass-pollen--phleum-pratense--allergy--immunotherapy-tablet-at-fda/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-abilify-mycite-to-treat-schizophrenia--depression-and-bipolar-i-disorder----otsuka-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-kyprolis--carfilzomib----revlimid--lenalidomide----dexamethasone-to-treat-multiple-myeloma---amgen/2024-02-22T08:54:04+00:00weekly0.6https://www.medthority.com/news/2015/04/bms-acquires-from-uniqure-n-v--exclusive-rights-to-s100-a1--a-calcium-sensor-in-early-development-for-heart-failure/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-exservan-oral-film--for-the-treatment-of-amyotrophic-lateral-sclerosis---aquestive-therapoeutics/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2017/06/biotronik-has-announced-ce-approval-for-its-new-edora-pacemakers-and-cardiac-resynchronization-therapy-pacemakers--edora-devices-feature-the-company-s-promri-technology--including-the-mri-autodetect-sensor--/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2013/11/migalastat-rights-returned-by-gsk-to-amicus/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-dyanavel-xr--amphetamine-extended-release-oral--for-attention-deficit-hyperactivity-disorder--tris-pharma/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2018/06/pooled-data-from-revive-1-and-revive-2-trials-of-iclaprim-in-absssi-patients-confirms-non-inferiority-to-vancomycin---motif-bio-plc-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2015/02/who-calls-for-action-on-neglected-tropical-diseases/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2012/07/eu-approves-afinitor--novartis-for-the-treatment-of-hormone-receptor-positive--hr----her2-neu-negative--her2---advanced-breast-cancer-/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-bivigam--biotest-pharmaceuticals-corporation--for-primary-humoral-immunodeficiency/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-approves-abasria-for-diabetes-eli-lilly-boehringer/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-clear-wisdom-trial-of-eyc-1002-bempedoic-acid-180-mg--in-atherosclerotic-cv-disease---hfh-published-in-jama---daiichi-sankyo/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2018/06/long-term-treatment-evidence-from-enestop-and-enestfreedom-studies-of-tasigna-for--philadelphia-chromosome-positive--ph---chronic-myeloid-leukemia--cml--in-the-chronic-phase--cp----novartis-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-allergenic-products-advisory-committee-votes-to-support-the-use-of-palforzia--ar101--for-peanut-allergy---aimmune-therapeutics-inc-/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-approves-raplixa--sealant-powder--for-haemostasis--the-medicines-co-/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-accepts-bla-filing-of-opdivo-to-treat-small-cell-lung-cancer----bms-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-grants-510-k--approval-for--arrow-midline-with-chlorag-ard-technology-an-antithrombogenic-and-antimicrobial-peripheral-venous-catheter---teleflex-inc-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2016/06/two-phase-iii-trials-of-nn-9535--semaglutide-subcutaneous--show-improved-glycaemic-control-in-type-2-diabetes--novo-nordisk/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-approves-triumeq-for-hiv-viiv-healthcare/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2019/10/flexion-therapeutics-announces-extended-fda-review-of-supplemental-new-drug-application-for-zilretta-to-treat-osteoarthritis-of-the-knee-/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-slynd-for-contraception---exeltis-usa/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-bay-94-9027-for-treatment-and-prophylaxis-of-bleeding-in-patients-with-haemophilia-a---bayer-/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2018/12/data-presented-at-ash-from-pivotal-phase-ii-iii-trial-of-emapalumab-lzsg-in-primary-haemophagocytic-lymphohistiocytosis---sobi---novimmune/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2016/09/european-commission-approves-xalkori--crizotinib--for-the-treatment-of-adults-with-ros1-positive-advanced-non-small-cell-lung-cancer--nsclc----pfizer/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-stelara-for-psoriatic-arthritis-in-adults/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-investigate-two-deaths-after-treatment-with-schizophrenia-drug-zyprexa-relprevv--eli-lilly-/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-lutathera--lutetium--177lu--oxodotreotide--in-gastroenteropancreatic-neuroendocrine-tumors--advanced-accelerator-applications/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-i-study-of-idhifa--enasidenib-in-patients--with-relapsed--refractory-acute-myeloid-leukemia--and-an-isocitrate-dehydrogenase-2--idh2--mutation---celgene---agios-pharma/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-botox--allergan--as-a-treatment-for-overactive-bladder/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2020/01/independent-data-monitoring-committee-has-recommended-to-discontinue-the-strength--trial-as-epanova-is-unlikely-to-demonstrate-a-benefit----astrazeneca-/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2019/10/calquence-approved-in-canada-to-treat-mantle-cell-lymphoma---astrazeneca/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2015/12/astrazeneca-acquires-majority-stake-in-acerta-pharma-and-with-it-bruton-s-tyrosine-kinase-inhibitor--acalabrutinib--acp-196-/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-trial-of-pcsk9si-meets-all-endpoints-in-cv-disease-and-elevated-ldl-cholesterol---medicines-co/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2018/11/two-phase-iii-trials-of-vx-659--tezacaftor---ivacaftor-meet-primary-endpoint-in-cystic-fibrosis---vertex-pharma-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-requires-two-new-trials-for-iluvien-alimera-sciences--for-diabetic-macular-oedema/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2018/12/pfizer-withdraws-adalimumab-biosimilar-from-ema-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2018/06/samsung-bioepis-and-biogen-announce-pooled-analysis-results-of-anti-tnf-biosimilars--benepali---etanercept---flixabi--infliximab---and-imraldi--adalimumab--at-eular-2018-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2014/11/study-of-zonegran-for-epilepsy-published-in-ejpn-eisai/2024-02-06T15:58:21+00:00weekly0.6https://www.medthority.com/news/2014/09/ivabradine-fails-signify-trial-for-stable-angina-servier/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2018/04/visualase-mri-guided-laser-ablation-system-receives-ce-mark-approval-in-europe-for-neurosurgery---medtronic-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iia-trial-of-afn-1252--affinium-pharma--shows-drug-is-effective-and-safe-against-bacterial-infections/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2012/11/idx-184-and-idx-719-safety-data-presented-by-indenix-/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2018/08/results-of-commander-hf-study-showed-xarelto-to-have-no-significant-benefit-on-death-from-any-cause--heart-attack-or-stroke-compared-to-placebo---bayer-ag---janssen-research---development--llc-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2016/10/auven-therapeutics-sells-ocular-technologies-sarl-to-sun-pharma-and-with-it-seciera-a-drug-in-phase-iii-for-dry-eye-disease/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2018/05/pooled-data-on-ofev-shows-efficacy--safety-and-tolerability-in-idiopathic-pulmonary-fibrosis---boehringer-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approval-for-avance-steerable-introducer--designed-to-introduce-cardiovascular-catheters-into-the-heart/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-solo-1-trial-of-lynparza-in-ovarian-cancer-published-in-nejm---astrazeneca---merck-inc-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2020/02/analysis-of-dian-tu-study-showed-that-solanezumab-did-not-meet-the-primary-endpoint-for-alzheimers-disease--eli-lilly-/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-parsabiv--etelcalcetide--to-treat-secondary-hyperparathyroidism-in-adult-patients-with-chronic-kidney-disease-on-hemodialysis---amgen/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2015/09/rezum-radiofrequency-system-receives-510-k--approval-from-the-fda-for-benign-prostatic-hyperplasia-nxthera/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-persist-2-trial-of-sb-1518-in-myelofibrosis-published-in-jama-oncology---cti-biopharma-corp-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2015/01/phase-iii-data-on-giotrif-in-nsclc-published-in-the-lancet-oncology-boehringer/2024-02-22T08:54:29+00:00weekly0.6https://www.medthority.com/news/2019/09/intercept-pharmaceuticals--has-submitted-an-nda-to-the-fda-for-obeticholic-acid-for-the-treatment-of-patients-with-fibrosis-due-to-nonalcoholic-steatohepatitis--nash--/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2018/12/in-updated-guidance-nice-does-not-recommend-caprelsa-in-medullary-thyroid-cancer---genzyme-sanofi-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/10/olympus-launches-its-4k-3d-video-microscope--orbeye-for-surgical-applications-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-taltz-to-treat-psoriatic-arthritis---eli-lilly/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-expands-approval-of-vonvendi-to-include-perioperative-management-of-bleeding-in-adults-with-von-willebrand-disease---shire-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2015/09/epirus-biopharmaceuticals-acquires-bioceros-holding-b-v-and-with-it-biosimilars-bow-080--bow-090-and-bow-100/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2016/11/global-initiative-for-chronic-obstructive-lung-disease--gold--recommends-the-first-line-use-of-dual-bronchodilators--such-as-ultibro-breezhaler--indacaterol-glycopyrronium-bromide---to-treat-copd----novartis/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-picato--leo-pharma--for-treatment-of-actinic-keratosis/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-optic-clinical-trial-evaluating-tepezza-for-thyroid-eye-disease-is-published-in-nejm---horizon-therapeutics/2021-09-24T07:11:48+00:00weekly0.6https://www.medthority.com/news/2012/10/votrient--gsk--is-non-inferior-to-sutent---pfizer--in-compraz-study-for-renal-cell-carcinoma/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-measure-1-study-for-cosentyx-shows-improvements-in-ankylosing-spondylitis-to-5-years---novartis-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2011/09/daxas-shows-positive-data-on-/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2016/07/eu-chmp-does-not-recommend-accelerated-assessment-of-masican--masitinib--in-amyotrophic-lateral-sclerosis--ab-science/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-trial-of-glyx-13--naurex--shows-positive-results-in-patients-with-depression/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2014/09/new-analyses-of-dualt-trials-of-xultophy-in-type-2-diabetes--novo-nordisk/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2019/01/aldeyra-therapeutics-acquires-helio-vision-and-with-it-adx-2191--intravitreal-methotrexate-to-treat-proliferative-vitreoretinopathy/2025-10-16T11:29:39+00:00weekly0.6https://www.medthority.com/news/2014/06/nivolumab-shows-superior-overall-survival-to-dacarbazine--in-melanoma-trial--bms/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-grants-breakthrough-therapy-designation-for-hemlibra-to-treat-hemophilia-a-patients-without-factor-viii-inhibitors---genentech-roche-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2016/11/new-results-from-phase-iii-trial-for-ocaliva--obeticholic-acid--in-patients-with-primary-biliary-cholangitis--intercept-pharmaceuticals/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-approves-xtandi--astellas-medivation--for-prostate-cancer/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2015/09/sanofi---regeneron-announce-pooled-analysis-from-odyssey-trial-of-hefh-patients-treated-with-praluent--alirocumab-/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2014/03/eu-uk-hold-on-vibativ-is-released-and-clinagen-will-market-in-eu/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2019/06/results-of--potentially-registrational-vision-study-of-tepotinib-to-treat-nsclc--met-exon-14-skipping-mutations----merck-kgaa/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-recommends-entresto--sacubitril---valsartan--to-treat-heart-failure--novartis/2024-02-06T15:58:39+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-expands-revlimid--lenalidomide--indication-to-include-use-for-patients-with-multiple-myeloma-as-maintenance-therapy-following-autologous-hematopoietic-stem-cell-transplant--celgene-/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2013/06/stendra--vivus-inc---success-in-rapid-erectile-dysfunction-effect-in-ta-501-trial-/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/06/banting-study-shows-repatha--lowered-ldl-c--low-density-lipoprotein-cholesterol--and-improved-other-lipid-levels-in-high-risk-patients-with-type-2-diabetes----amgen-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2014/05/shire-acquires-fibrotech-for--75-million-and-access-to-ft-011-a-treatment-for-fibrosis/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2019/10/pooled-phase-iii-data-on-ingrezza-shows-long-term-benefits-in-tardive-dyskinesia---neurocrine-biosciences/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2017/04/data-shows-benefits-of-taking-epidiolex--cannabidiol--in-patients-with-lennox-gastaut-syndrome--gw-pharma/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2017/03/data-on-oncotype-dx-breast-cancer-diagnostic-demonstrates-benefits-for-surgery-assessments--genomic-health-/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-audenz-for-influenza-a--h5n1----seqirus/2021-09-24T07:12:01+00:00weekly0.6https://www.medthority.com/news/2015/01/phase-iii-trial-of-delafloxacin-for-absssi-meets-primary-endpoint-melinta-therapeutics/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-grants-positive-recommendation-for-trelegy---fluticasone-furoate--umeclidinium-vilanterol--ff-umec-vi---as-a-maintenance-treatment-for-copd---gsk-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2017/11/post-hoc-analysis-of-two-trials-of-krystexxa-show-reductions-in-blood-pressure-in-gout-patients---horizon-pharma-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-issues-complete-response-letter-for-mcna--urocidin--or-mycobacterium-phlei-cell-wall-nucleic-acid-complex---in-bladder-cancer--telesta/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-cimzia-for-non-radiographic-axial-spondyloarthritis---ucb/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2017/01/lucentis--ranibizumab-injection--is-fda-approved-to-treat-myopic-choroidal-neovascularization----genentech-roche/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-gauss-3-trial-evaluating-repatha--evolocumab--meets-endpoints-in-cholesterol-reduction--amgen/2024-02-06T15:58:55+00:00weekly0.6https://www.medthority.com/news/2017/11/brainwaves-synchronise-between-adults-and-infants-when-eye-contact-is-made/2024-07-26T09:56:47+00:00weekly0.6https://www.medthority.com/news/2014/08/cubist-pharma-files-ceftolozane-tazobactam-at-ema-for-urinary-tract-and-intra-abdominal-infections-/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2015/09/sandoz-launches-zarxio--filgrastim-sndz--first-biosimilar-fda-approved-in-the-us-to-treat-neutropenia/2024-02-06T15:59:09+00:00weekly0.6https://www.medthority.com/news/2014/12/imbruvica-filed-with-eu-for-waldenstroms-macroglobulinemia-janssen/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves--kedrab--rabies-immune-globulin--human--for-passive--transient-post-exposure-prophylaxis-of-rabies-infection---kedrion-biopharma---kamada-ltd-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2015/11/study-shows-xifaxan-targaxan--rifaximin--cost-effective-versus-lactulose-in-hepatic-encephalopathy-norgine-/2026-01-29T10:41:32+00:00weekly0.6https://www.medthority.com/news/2013/07/medtronic-to-co-promote-prolia--amgen--in-the-us-to-spine-specialists/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2015/10/safety-study-results-for-advair-diskus--salmeterol---fluticasone-propionate--for-asthma--glaxosmithkline/2024-02-06T15:59:20+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-tecentriq---avastin-for-the-initial--first-line--treatment-of-people-with-metastatic-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations--genentech-roche-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2019/12/apl-130277-refiled-with-fda-for-parkinsons-disease---sunovion-pharma/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-reflections-b327-02-study-of-pf-05280014--trastuzumab-biosimilar--met-primary-objective-in-her2-positive-metastatic-breast-cancer---pfizer-/2021-09-24T07:13:56+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-alta-1l-trial-of-alunbrig-shows-benefits-in-nsclc--alk-at-two-years---takeda/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-contrave-for-chronic-weight-management--takeda-orexigen/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-opinion-for-erleada-for-patients-with-non-metastatic-castration-resistant-prostate-cancer--janssen-pharma/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2019/01/upadacitinib-is-filed-at-ema-and-at-fda-to-treat-moderate-to-severe-rheumatoid-arthritis---abbvie/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2012/02/phase-ii-study-of-tak-875--takeda--shows-improved-glycemic-control-in-patients-with-type-2-diabetes/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-rejects-qsiva--vivus-inc----as-a-treatment-for-obesity/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2015/06/carbylan-therapeutics-completes-enrollment-in-phase-iii-pivotal-trial-of-hydros-ta-biodegradable-hydrogel-beads-for-osteoarthritis-pain/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-vitrakvi-to-treat-patients-with-solid-tumors-that-have-a-ntrk-gene-fusion---loxo-oncology---bayer-healthcare/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2016/09/takeda-initiates-tides-study-of-tak-003-vaccine-to-treat-dengue-fever--/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2017/04/zolyd--fosfomycin-for-injection--meets-primary-endpoint-in-pivotal-phase-ii-iii-trial-in-complicated-urinary-tract-infections--zavante-therapeutics/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2017/02/sanofi-and-reneneron-may-continue-marketing-praluent--alirocumab--in-the-us-pending-court-appeal-/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2012/05/phase-iii-study-of-torisel--pfizer--for-renal-cell-carcinoma-does-not-meet-primary-endpoint/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2014/08/roche-buys-santaris-pharma-and-its-locked-nucleic-acid-platform/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2017/09/baxter-international-inc-has-announced--the-publication-of--fish-oil-containing-lipid-emulsions-in-adult-parenteral-nutrition--a-review-of-the-evidence--in-the-journal-of-parenteral-and-enteral-nutrition-/2024-11-15T08:39:19+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-success-for-ultomiris-in-complement-inhibitor-naive-patients-with-atypical-hemolytic-uremic-syndrome---alexion-pharma/2024-10-21T14:46:14+00:00weekly0.6https://www.medthority.com/news/2017/01/the-fda-has-acknowledged-receipt-of-the-class-2-resubmission-of-a-new-drug-application--nda--for-shp-465--a-treatment-for-adhd--shire-plc/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2016/02/new-drug-application-for-sb-1518--pacritinib--for-myelofibrosis-withdrawn-after-fda-announces-clinical-hold-on-trials--cti-biopharma/2024-02-06T15:59:35+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-jardiance-for-t2d---boehringer-eli-lilly/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2019/03/success-for-artemis-trial-in-europe-for-ar-101-for-treatment-of-peanut-allergy--aimmune-therapeutics/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2016/11/pooled-phase-iii-data-reported-for-zurampic--lesinurad--in-hyperuricemia-associated-with-gout--ironwood-pharmaceuticals/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2016/04/european-commission-approves-taltz--ixekizumab--to-treat-moderate-to-severe-plaque-psoriasis-in-adults--eli-lilly-/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2011/09/tradjenta-launch-for-type-2-diabetes-delayed-in-germany/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2011/10/tg-4010-combination-raises-progression-free-survival-in-non-small-cell-lung-cancer-patients-/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2012/05/phase-iii-trial-of-lyrica--pfizer--for-neuropathic-pain-with-hiv-halted/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2014/08/bax-855-success-in-phase-iii-trial-for-haemophilia-a-prophylaxis---baxter/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-fraxel-dual-laser-system--solta-medical--for-skin-pigmentation-treatment/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2017/10/european-congress-of-neurosurgery-to-conclude-in-venice/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2016/03/nice-does-not-recommend-imbruvica--ibrutinib--to-treat-chronic-lymphocytic-leukaemia--janssen/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2016/02/ce-mark-for-eluvia-drug-eluting-vascular-stent-system--boston-scientific/2024-02-06T15:59:50+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-simponi--golimumab--for-non-radiographic-axial-spondyloarthritis-janssen/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2016/04/analysis-of-accelerate-study-of-evacetrapib-provides-a-paradox---eli-lilly/2024-02-06T15:59:59+00:00weekly0.6https://www.medthority.com/news/2017/06/findings-from-cohort-1-of-keynote-059-trial-of-keytruda---pembrolizumab--monotherapy-to-treat-advanced-gastric-cancer---merck-inc-/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-committee-recommends-tofacitinib--pfizer--for-rheumatoid-arthritis/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-positive-opinion-for-kisqali-with-fulvestrant-to-treat-women-with-hr--her2--locally-advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-of-phase-iii-study-of-zytiga--janssen-biotech--in-metastatic-prostate-cancer/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2015/06/updated-results-from-phase-iii-first--mm-020-ifm-07-01--trial-for-revlimid--lenalidomide--in-newly-diagnosed-multiple-myeloma-celgene/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2019/12/intra-cellular-therapies-highlights-lumateperone-presentations-on-bipolar-depression-at-the-58th-annual-meeting-of-the-american-college-of-neuropsychopharmacology-/2024-10-21T14:49:17+00:00weekly0.6https://www.medthority.com/news/2018/02/cosentyx-is-fda-approved-to-treat-scalp-psoriasis---novartis-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-betmiga--astellas--for-patients-with-overactive-bladder/2021-09-24T07:02:15+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-does-not-accept-nda-for-crinone-gel--watson--for-use-in-reducing-risk-of-preterm-birth/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-advisory-committee-does-not-approve-jatenzo-to-treat-hypogonadism-in-adult-males---clarus-therapeutics-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2018/03/calcium-supplements-may-boost-risk-of-abnormal-bowel-growths--polyps-/2021-09-24T07:06:25+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-pro-kinetic-energy-cobalt-chromium--cocr--coronary-stent-system---biotronik/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-recommends-trulign-toric--bausch---lomb--for-cataract-surgery/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2013/12/phase-iii-results-for-ceftolozane-tazobactam-for-intraabdominal-infections-cubist/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-olysio-and-sovaldi-combo-for-hcv-medivir-janssen/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-issues-complete-response-to-sar-153191--sarilumab--filing-for-rheumatoid-arthritis--sanofi-and-regeneron-pharma/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2017/11/positive-phase-iii-realise--study-of-viaskin-peanut-for-treatment-of-peanut-allergic-patients---dbv-technologies-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2017/05/new-ema-ruling-on-use-of-antibiotic-vancomycin-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-aristada--aripiprazole-lauroxil--for-schizophrenia--alkermes/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2019/07/ce-mark-for-profound-ai-for-2d-mammography-software-system-to-analyze-2d-mammography-scans---icad/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2011/11/azasite-and-dexasite--insite-vision--enter-phase-ii-for-blepharitis/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2017/04/kite-pharma-completes-rolling-submission-to-the-fda-for-axicabtagene-ciloleucel--previously-kte-c19--for-patients-with-relapsed-or-refractory-aggressive-non-hodgkin-lymphoma--nhl--who-are-ineligible-for-autologous-stem-cell-transplant-/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2014/01/nice-provides-limited-recommendation-for-pixuvri-for-nhl-cell-therapeutics/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2018/04/data-safety-monitoring-board--positive-recommendation-for-resolve-it-phase-iii-trial-of-elafibranor-to-proced-for-nash---genfit-/2021-09-24T07:05:19+00:00weekly0.6https://www.medthority.com/news/2018/03/success-for-phase-iii-study-of-tafamidis-meglumine-for-the-treatment-of-transthyretin-cardiomyopathy---pfizer-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-gives-510-k--approval-for-gammapod-radiation-treatment-for-breast-cancer---xcision-medical-systems-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2014/10/abbvie-likely-to-withdraw-from-shire-takeover/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2011/11/cangrelor--astrazeneca---maintains-platelet-inhibition-without-major-bleeding-in-acute-coronary-syndrome-patients/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2016/04/ba-058--abaloparatide-sc--filed-with-fda-for-osteoporosis--radius-health/2024-02-22T11:53:37+00:00weekly0.6https://www.medthority.com/news/2018/03/paternal-lineage-ovarian-cancer/2024-02-22T08:57:29+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-revolution-ct-scanner-for-imaging---ge-healthcare/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-firdapse--for-the-treatment-of-adults-with-lambert-eaton-myasthenic-syndrome--lems----catalyst-pharma---biomarin/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2019/07/verastem-oncology-licenses-sanofi-for-commercialization-of-copiktra--in-russia-and-cis--turkey--the-middle-east-and-africa-/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2018/09/taking-diabetes-to-heart-survey-is-presented-by-international-diabetes-federation-and-novo-nordisk-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2015/03/targacept-and-catalyst-biosciences-merge-into-catalyst-biosciences-inc-/2025-10-16T10:58:07+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-advisory-committee-recommends-tissueglu-adhesive-for-surgical-procedures---cohera--medical/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-data-for-prolia-in-osteoporosis-amgen/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2016/11/empa-reg-outcome-trial-of-jardiance--empagliflozin--shows-reduced-risk-of-cv-death-in-type-2-diabetes--boehringer/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-accepts-filing-of-nivolumab-for-treatment-of-non-small-cell-lung-cancer---bms/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2012/03/uk-court-rules-astrazeneca-s-patent-on-seroquel-xr--is-invalid/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2015/02/positive-results-for-alprolix-in-kids-b-long-study-treatment-for-haemophilia-b--sobi--biogen/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2012/09/janssen-submit-maa-to-the-ema-for-tmc-207-as-treatment-for-multi-drug-resistant-tuberculosis---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2015/02/nice-recommends-ozurdex-for-macular-oedema-associated-with-rvo--allergan/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2015/11/in-final-guidance--nice-recommends-viekirax--ombitasvir-paritaprevir-ritonavir--with-or-without-exviera--dasabuvir--in-hepatitis-c--abbvie/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iii-study-of-krn-23--burosumab--in-x-linked-hypophosphatemia--meets-primary-endpoint--ultragenyx-pharmaceutical--kyowa-hakko-kirin/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2012/03/surfaxin--discovery-labs--is-fda-approved-for-respiratory-distress-syndrome/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2019/09/post-market-trial-of-peregrine-system-shows-efficacy-in-resistant-hypertension---ablative-solutions/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-agrees--with-orexigen-the-form-of-cv-risk-trial-for-contrave/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2018/09/eu-approves-imfinzi-for-locally-advanced-unresectable-nsclc---astrazeneca---medimmune-/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2014/10/successful-phase-iii-pioneer-ii-study-of--humira-for-hidradenitis-suppurativa--abbvie/2024-10-22T08:01:42+00:00weekly0.6https://www.medthority.com/news/2013/05/study-of-prolia--amgen-gsk--plus-teriparatide-shows-significant-benefits-in-osteoporosis/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2016/10/alks-5461--samidorphan---olanzapine--meets-primary-end-point-in-phase-iii-trial-for-major-depressive-disorder--alkermes-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-akp01-study-of-akvano-shows-efficacy-in-plaque-psoriasis---lipidor/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-amitiza-sucampo-takeda--for-opioid-induced-constipation/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2012/06/german-iqwig-finds-esbriet--intermune--of--no-proven-added-benefit--for-pulmonary-fibrosis-patients/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-radiesse-dermal-filler-for-hand-augmentation-merz-north-america/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2017/05/pfizer-and-astellas--discontinue-endear-study-of-xtandi--enzalutamide-for-the-treatment-of-triple-negative-breast-cancer-/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-avycaz--ceftazidime-avibactam--to-treat-ciai-and-cuti---actavis/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2012/12/early-study-shows-dantrium--jhp-pharmaceuticals--has-promise-for-treating-duchenne-muscular-dystrophy/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-ellipsys-vascular-access-system-from-avenu-medical--inc---to-make-an-arteriovenous-fistula-for--hemodialysis-patients/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2017/09/european-commission-has-approved-xermelo--telotristat-ethyl--250-mg-as-a-first-and-only-orally-administered-therapy-for-the-treatment-of-carcinoid-syndrome-diarrhea-in-combination-with-somatostatin-analog-therapy---ipsen---lexicon-pharmaceuticals-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2015/05/baxter-files-for-european-approval-for-20-percent-igsc-for-primary-immunodeficiencies-/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-sbla-for-eylea-with-12-week-dosing-schedule-for--wet--age-related-macular-degeneration--regeneron---bayer-healthcare-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-komboglyze-combination-for-type-2-diabetes/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2012/11/two-phase-iii-studies-of-efinaconazole--valeant-pharma--show-positive-results-in-patients-with-onychomycosis/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2014/04/merck-inc---success-with-combination-mk-5172-mk-8742-in-phase-ii-trial-for-hcv-plus-hiv/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2015/10/generic-form-of-spectrum-s-fusilev--levoleucovorin-calcium--launched-in-the-us-for-osteosarcoma--mylan/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2016/12/lume-meso-phase-ii-trial-success-in-patients-with-unresectable-malignant-pleural-mesothelioma-is-followed-by-ongoing-lume-meso-phase-iii-trial---boehringer-/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iiib-dialize-trial-results-of-lokelma-for-hyperkalaemia-in-patients-with-end-stage-renal-disease-on-haemodialysis---astrazeneca/2023-07-24T15:17:18+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-study-of-cotellic--cobimetinib--with-zelboraf--vemurafenib--meets-secondary-endpoint-in-metastatic-melanoma--exelixis-genentech/2024-02-06T15:39:13+00:00weekly0.6https://www.medthority.com/news/2017/06/positive-results-from-haven-1-and-haven-2-studies-for-once-weekly-subcutaneous-emicizumab-prophylaxis-treatment-of-hemophilia-a--genentech-roche/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-recommends-revlimid---bortezomib---dexamethasone--to-treat-multiple-myeloma---celgene/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-tourmaline-mm3-study-of-ninlaro-meets-primary-endpoint-in-multiple-myeloma---takeda-pharma-/2024-07-26T10:22:11+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-lutathera--for-gastroenteropancreatic-neuroendocrine-tumors---advanced-accelerator-applications-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-dengvaxia-for-dengue-disease---sanofi-pasteur/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-ervebo-for-ebola---merck-inc/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-resqcp--system-for-cardiac-arrest-advanced-circulatory--systems-zoll/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2016/12/results-of-two-phase-iii-trials-for-revlimid--lenalidomide--in-multiple-myeloma-presented-at-ash---celgene/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2019/04/initial-results-from-the-emprise-real-world-study-of-empagliflozin-compared-with-dpp-4-inhibitors-for-treatment-of-type-2-diabetes-and-cv-risk--boehringer/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2018/02/improvement-in-impact-of-genital-psoriasis-on-sexual-activity-with-use-of-taltz----eli-lilly-/2021-09-24T07:05:53+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-approval-of-incruse-for-copd---gsk/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2013/06/two-phase-iii-trials-show-tradjenta--boehringer-eli-lilly--improves-glucose-control-in-asian-patients-with-type-2-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-commissioner-on-approval-of-dsuvia--sufentanil-sublingual--/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2020/01/ema-validates-maa-for-pemigatinib-in-patients-with-cholangiocarcinoma---incyte/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2019/10/newlink-genetics-and-lumos-pharma-to-merge-to-develop-lum-201-under-the-name-lumos-pharma-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2016/12/exactvu-micro-ultrasound-system-receives-510-k--clearance-in-us--exact-imaging/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2017/01/immunomedics-announces-new-data-for--sacituzumab-govitecan--immu-132--to-treat-metastatic-triple-negative-breast-cancer-/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2019/03/dabra-laser-system-achieved-94--success-rate-in-patients-with-peripheral-artery-disease---ra-medical-systems/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2012/12/chmp-recommends-perjeta--genentech-roche--for-her2--breast-cancer/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2019/05/four-studies-of-aubagio-show-reduced-risk-of-relapse-in-multiple-sclerosis---sanofi/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2019/08/track-tbi-study-shows-i-stat--alinity-device-identifies-brain-injury--even-if-a--ct-scan-is-normal---abbott/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2015/11/auris-medical-initiates-phase-iii-trial-for-am-111-to-treat-idiopathic-sudden-sensorineural-hearing-loss-/2024-02-06T15:39:23+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-approves-soliris-for-hemolytic-uremic-syndrome/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2012/02/baxter-initiates-phase-iii-stem-cell-therapy-trial-for-chronic-myocardial-ischaemiad/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2018/11/positive-phase-iii-tivo-3-trial-of-tivozanib--to-treat--refractory-advanced-or-metastatic-renal-cell-carcinoma---aveo-oncology-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-in-final-guidance-for-tavalisse-in-chronic-immune-thrombocytopenia---rigel-pharma/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-approval-of-deltyba-for-tuberculosis-otsuka/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2015/05/rbp-7000--risperidone-subcutaneous--meets-endpoints-in-phase-iii-trial-for-schizophrenia--indivior/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2012/12/luveniq--isotechnika--fails-phase-iii-trial-for-treatment-of-uveitis/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2017/08/roche-licenses-lebrikizumab-to-demira-for-atopic-dermatitis-and-all-other-indications---except-for-interstitial-lung-diseases-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-herzuma--trastuzumab-biosimilar--for-breast-cancer---celltrion----teva-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2016/10/betrixaban-filed-with-fda-for-extended-duration-prophylaxis-of-venous-thromboembolism--vte--in-acute-medically-ill-patients--portola-pharmaceuticals/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2014/02/esbriet-meets-endpoints-in-pulmonary-fibrosis-study---intermune/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2014/10/dupilumab-enters-phase-iii-trial-for-treatment-of-atopic-dermatitis--sanofi--regeneron/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2011/09/imatinib-effective-in-pulmonary-arterial-hypertension/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2014/04/eu-approves-duoresp-spiromax-for-asthma-and-copd-teva/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-study-of-riastap--csl-behring--shows-the-drug-has-benefits-in-critical-care-patients/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-trial-of-epidaza--meets-primary-endpoint-in-breast-cancer---shenzhen-chipscreen-biosciences-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2019/08/eu-approves-imbruvica-plus-gazyva-for-untreated-chronic-lymphocytic-leukemia---janssen-biotech/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2014/03/study-shows-benefits-of-latuda-for-schizophrenia---sunovion-takeda/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2012/03/successful-phase-iii-trial-for-levomilnacipran---pierre-fabre-forest-labs--in-major-depressive-disorder/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2016/02/interim-analysis-of-phase-iii-trial-of-arx-04-sufentanil-nanotab-drug-delivery-shows-benefits-in-pain-treatment--acelrx-pharmaceuticals/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-expands-approval-of-imbruvica-for-cll-janssen-biotech-pharmacyclics/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2016/09/study-shows-efficacy-of-aerobika-device-in-chronic-obstructive-pulmonary-disease--trudell-medical/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2018/12/reflections-b328-06-study-of-pf-05280586-meets-primary-endpoint-in-follicular-lymphoma---pfizer-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2015/07/pooled-analysis-of-dengue-vaccination-published-in-nejm--sanofi-pasteur/2024-02-06T16:01:01+00:00weekly0.6https://www.medthority.com/news/2014/03/reactiv8-neurostimulation-for-low-back-pain-trials-commence---mainstay-medical/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-tybost--gilead--for-hiv-treatment/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-change-of-approval-of-alecensa--alectinib--in-non-small-cell-lung-cancer---roche-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2016/03/adynovi--recombinant-factor-viii--filed-with-ema-for-pediatric--adolescent-and-adult-patients-with-hemophilia-a--baxalta/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-places-clinical-hold-on-phase-iii-trial-measure-of-mdx-in-adhd--alcobra/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2019/06/application-for-darzalex---velcade---dexamethasone-in-multiple-myeloma-granted-priority-review-by-fda---janssen-biotech/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-and-eu-approve-sensation-plus--maquet-cardiovascular--for-patients-with-heart-failure/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2013/03/boehringer-and-eli-lilly-submit-nda-to-the-fda-for-empagliflozin-for-treatment-of-type-2-diabetes/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2019/06/being-overweight-linked-to-significantly-higher-disease-severity-in-psoriatic-arthritis/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-nda-for-bremelanotide-a-treatment--for-hypoactive-sexual-desire-disorder--hsdd--in-premenopausal-women---amag-pharma-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-nimodipine-for-subarachnoid-haemorrhage--ani-pharma-sofgen/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2012/09/european-approval-for-revestive-takeda--for-short-bowel-syndrome/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2012/01/nexavar--bayer-healthcare--effective-in-patients-with-non-small-cell-lung-cancer/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-advisory-committee-recommends-modification-to-avandia--gsk--restrictions/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2015/09/bms-files-sbla-at-fda-for-combination-opdivo--nivolumab----yervoy--ipilimumab--to-treat-advanced-melanoma/2024-02-06T15:39:47+00:00weekly0.6https://www.medthority.com/news/2019/06/success-for-rituxan-in-phase-iii-pemphix-trial-to-treat-severe-pemphigus-vulgaris--genentech-roche/2021-09-24T07:16:58+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-nda-for-higher-naloxone-injection-for-the-treatment-of-opioid-overdose--adamis-pharma/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2013/05/new-study-suggests-avandia--glaxo-smith-kline--offers-no--increased-risk-of-heart-attack-in-patients-with-type-2-diabetes/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-chmp-recommends-extension-of-approval-allowing-self-administration-of-ruconest--recombinant-human-c1-esterase-inhibitor--for-acute-hereditary-angioedema--pharming-group/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2015/07/int-747--obeticholic-acid--filed-with-fda-and-ema-for-primary-biliary-cirrhosis--intercept-pharmaceuticals/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-diacomit-to-treat-seizures-associated-with-dravet-syndrome----biocodex-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-vaxchora-vaccine-for-cholera---emergent-biosolutions/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-osseoanchored-prostheses-for-the-rehabilitation-of-amputees--opra--device--integrum-ab/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2012/04/arrow-vps-system-teleflex---received-ce-mark-approval-for-catheter-positioning/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2018/09/e-fit-phase-iii-trial-of-nbt-system-following-stroke-supports-benefits-of-therapy---nexstim-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2012/10/nice-recommends-lucentis--novartis--for-diabetic-macular-oedema/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2015/06/neutral-results-from-phase-iii-trial-of-lyxumia--lixisenatide--for-cardiovascular-risk-in-type-2-diabetes--sanofi/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2018/06/complete-response-letter-for-furoscix--a-proposed-treatment-of--edema-or-fluid-overload-in-patients-with-heart-failure---sc-pharmaceuticals-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-accepts-filing-of-plecanatide-as-a-treatment-for-chronic-idiopathic-constipation-and-fixes-pdufa-date--synergy-pharma/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2015/11/-ema-validates-application-for-opdivo--nivolumab--to-treat-advanced-renal-cell-carcinoma--bms/2024-02-06T16:01:29+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-trial-success-for-brimatoprost-sr-in-reduction-of-intraocular-pressure---allergan/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2013/06/meta-analysis-shows--tradjenta--boehringer-eli-lilly--offers-no-extra-risk-of-cv-events-in-type-2-diabetes-patients/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-tnacity-trial-of-abraxane--paclitaxel-protein-bound-particles-for-injectable-suspension-----carboplatin-for-triple-negative-breast-cancer--celgene/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-trial-results-for-optune-in-glioblastoma-published-in-jama-oncology---novocure-/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-issues-complete-response-letter-for-dapagliflozin--astrazeneca-bms--for-type-2-diabetes/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2018/09/novartis-announces-patient-preference-survey-of-psoriasis-patients-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2016/04/two-phase-iii-trials-of-sun-101-eflow--glycopyrrolate--met-primary-endpoints-in-severe-chronic-obstructive-pulmonary-disease--sunovion/2024-02-06T15:40:09+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-trial-of-chs-0214--etanercept-biosimilar--meets-endpoint-in-plaque-psoriasis--coherus-biosciences-baxalta/2024-02-06T15:40:23+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-ixifi--a-biosimilar-to-remicade--infliximab----for-all-eligible-indications-of-the-reference-product--pfizer-/2021-09-24T07:13:38+00:00weekly0.6https://www.medthority.com/news/2015/04/eu-approves-vectibix---panitumumab--as-first-line-therapy---folfiri--in-wild-type-ras-metastatic-colorectal-cancer--amgen/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2019/02/intravenous--iv--meloxicam-pooled-analysis-is-published-in-regional-anesthesia---pain-medicine---recro-pharma/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2018/11/opdivo---yervoy-combination-fails-to-meet-primary-endpoint-in-checkmate-451-trial-to-treat---small-cell-lung-cancer---bms/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-evenity-to-treat-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture--amgen-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-does-not-recommend-approval-of-quizartinib-for-use-in-acute-myeloid-leukemia---daiichi-sankyo/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2019/07/microbiome--cutaneous-dysbiosis-cause-inflammatory-diseases/2021-09-24T07:18:15+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-new-indication-for-alimta---keytruda-combination-for-initial-treatment-of-patients-with-metastatic-nonsquamous-nsclc--irrespective-of-pd-l1-expression-status---eli-lilly---merck-inc-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2012/12/new-trial-planned-for-solanezumab--eli-lilly--for-mild-alzheimers-disease-treatment/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2018/01/international-prostate-cancer-update-2018-ipcu-28/2024-10-22T08:10:53+00:00weekly0.6https://www.medthority.com/news/2020/02/ema-validates-maa-for-tucatinib-----trastuzumab---capecitabine--to-treat--locally-advanced-unresectable-or-metastatic-her2-positive-breast-cancer--including-brain-metastases--seattle-genetics/2021-09-24T07:12:00+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-approves-zurampic--lesinurad--in-combination-with-a-xanthine-oxidase-inhibitor-to-treat-gout--astrazeneca/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-celestial-trial-of-cabometyx--cabozantinib--meets-primary-endpoint-in-advanced-hepatocellular-carcinoma---ipsen---exelixis-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-revlimid-for-treatment-of-multiple-myeloma-ineligible-for-stem-cell-transplantation--celgene/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2013/09/biomarker-analysis-for-vectibix-in-crc-published-in-nejm/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2014/07/bmj-criticism-of-regulatory-agencies-and-boehringer-regarding-pradaxa---boehringer/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2014/11/analysis-of-pradaxa-for-stroke-prevention--af--boehringer/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-phase-iii-studies-of-ta-7284--janssen-pharmaceuticals--in-patients-with-type-2-diabetes/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2014/06/oral-start-study-confirms-xeljanz-as-monotherapy-in-ra--pfizer/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-study-of-cinqair-did-not-meet-endpoint-in-severe-eosinophilic-asthma---teva-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2014/07/xifaxan-success-in-phase-iii-target-3-trial-for-ibs-diarrhea---salix/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-murano-trial-of-venclexta---rituxan-shows-detection-limits-of-disease-in-chronic-lymphocytic-leukemia---abbvie-roche-genentech-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-slentyo-for-treatment-of-insomnia-in-children-and-adolescents-with-autism-spectrum--disorder-or-smith-magenis-syndrome---rad-neurim-pharma-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-extends-label-of-abilify-maintena--aripiprazole--in-schizophrenia--otsuka/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2013/03/ema-approves-perjeta---roche--for-treatment-of-metastatic-breast-cancer/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2015/06/positive-study-for-inflectra-remsima--infliximab--biosimilar-supporting-switch-from-remicade-in-ra--hospira/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2019/01/eli-lilly-to-acquire-loxo-oncology/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-trial-for-alecensa--alectinib--compared-to-crizotinib-for-nsclc--genentech---roche/2021-09-24T07:09:29+00:00weekly0.6https://www.medthority.com/news/2018/08/first-phase-iii-trial-of-sulopenem---probenecid-versus-ciprofloxacin-to-treat-women-with-uti-infections---iterum-therapeutics-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-data-show-cosentyx--secukinumab--delivered-high-and-long-lasting-skin-clearance-in-patients-with-moderate-to-severe-plaque-psoriasis-at-5-years---novartis/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2012/12/chmp-rejects-kynamro--sanofi--for-treatment-of-homozygous-familial-hypercholesterolemia--/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2011/10/bg-12-results-from-define-study-in-multiple-sclerosis--will-be-presented-by-biogen-at-ectrims-and-actrims-conference/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2015/01/tobira-therapeutics-merges-with-regado-biosciences-/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2014/04/reyataz-and-cobicistat-filed-with-fda-for-hiv---bms-gilead/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2018/02/axalimogene-filolisbac-is-filed-at-ema-to-treat-recurrent-or-metastatic-carcinoma-of-the-cervix---advaxis--inc-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2019/11/gw-pharmaceuticals-receives-positive-nice-recommendation-for-epidyolex-for-the-treatment-of-seizures-in-patients-with-two-rare--severe-forms-of-childhood-onset-epilepsy-/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2011/11/amr-101--amarin-corpn-is-filed-at-the-fda-for-high-triglycerides-/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2018/04/pivotal-trial-data-for-istent-inject-trabecular-micro-bypass-system-meets-primary-endpoint-in-glaucoma-patients-undergoing-cataract-surgery---glaukos-corp-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-odyssey-escape-trial-evaluating-praluent--alirocumab--in-heterozygous-familial-hypercholesterolemia-meets-primary-endpoint--sanofi-regeneron/2024-02-06T15:40:36+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-does-not-accept-nda-application-for-brinavess--vernakalant-hydrochloride--iv--to-treat-atrial-fibrillation---cardiome-pharma/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2015/06/positive-long-term-safety-data-using-rix-fp-for-haemophilia-csl-behring/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-approval-of-seasonique-for-contraception-teva/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-awards-510-k--clearance-to-proxidiagnost-n90-digital-radiography-fluoroscopy-system---royal-philips-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2018/02/sanofi-asks-ema-to-review-fexinidazole-for-the-treatment-of-sleeping-sickness-/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2017/09/new-data-from-multisensor-chronic-evaluation-in-ambulatory-heart-failure-patients--multisense--study--evaluating-the-heartlogic-heart-failure-diagnostic-to-predict-impending-heart-failure--hf--decompensation---boston-scientific-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-presents-overall-survival-and-safety-data-from-pivotal-cc-486-study-quazar-aml-001-in-newly-diagnosed-acute-myeloid-leukemia/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2017/01/stemline-agrees-with-fda-registration-pathway-for-sl-401--stem-cell-therapy--to-treat-blastic-plasmacytoid-dendritic-cell-neoplasm-/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-grants-snda-for-teflaro--ceftaroline-fosamil--in-pediatric-patients-2-months-to-18-years-with-acute-bacterial-skin-and-skin-structure-infections--allergan/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2019/08/european-commission-approves-empliciti---pomalidomide---low-dose-dexamethasone-to-treat-refractory-multiple-myeloma---bms/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-renew-trial-of-adx-102-meets-primary-objective-in-dry-eye-syndrome---aldeyra-therapeutics/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-mirvaso-for-rosacea-galderma/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2014/02/early-treatment-with-avastin-for-gbm-not-recommended---genentech-roche/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/08/data-from-the-mariner-study-showed-that-rivaroxaban-10-mg-once-daily-did-not-significantly-reduce-the-composite-of-symptomatic-venous-thromboembolism--vte--and-vte-related-death-post-hospital-discharge---bayer-ag---janssen-research---development--llc-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2014/06/mm-398-extends-survival-and-pfs-in-patients-with-pancreatic-cancer-merrimack-pharma/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2017/11/eu-approves-10-mg-once-daily-dose-of-xarelto-to-prevent-recurrent-vte---bayer---janssen-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2018/09/global-survey-investigating-perceptions-of-alzheimer-s-disease-novartis---amgen---banner-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-ofev-for-interstitial-lung-disease---boehringer/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-approves-jardiance-for-type-2-diabetes---boehringer-eli-lilly/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2013/06/dapagliflozin--bms-astrazeneca---insulin-study-in-type-1-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-expands-approval-of-fluarix-quadrivalent-to-anyone-6-months-and-older-for-influenza---glaxosmithkline-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-has-accepted-loxo-101-nda-for-treatment-of-solid-tumours-harboring-an-ntrk-gene-fusion---loxo-oncology-inc---bayer-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-recommends-vimizin--elosulfase-alfa--for-mps-iva--biomarin-pharma/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-aphinity-study-showed-adjuvant--after-surgery--treatment-with-the-combination-of-perjeta--pertuzumab---herceptin--trastuzumab--and-chemotherapy-significantly-reduced-the-risk-of-breast-cancer-recurrence-or-death----roche/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2018/03/results-of-phase-iii-murano-trial-of-venclexta----rituxan-in-chronic-lymphocytic-leukaemia-published-in-nejm---abbvie-roche-genentech-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-refuses-to-recommend-semuloparin--sanofi--for-prevention-of-vte/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-committee-recommends-approval-of-sovriad--janssen--for-hepatitis-c/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-kamra-inlay-to-treat-presbyopia--acufocus-inc-/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2016/05/entresto--sacubitril-valsartan--given-class-i-recommendation-for-heart-failure-treatment--novartis/2024-02-06T15:40:47+00:00weekly0.6https://www.medthority.com/news/2015/02/boston-scientific-plan-to-buy-ams-pelvic-device-unit-from-endo-pharma-for--2-billion-/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2015/05/endo-pharma-acquires-generic-drug-company-par-pharma-for--8-05-billion/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-extension-to-indication-of-bosulif-for-newly-diagnosed-chronic-phase-philadelphia-chromosome-positive-cml----pfizer/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2016/06/uk-nice-confirms-it-won-t-recommend-use-of-orkambi--lumacaftor---ivacaftor--for-treating-cystic-fibrosis---vertex-pharmaceuticals-/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2013/11/xiaflex-meets-primary-endpoints-for-peyronie-s---auxilium-pharma/2021-09-24T07:16:28+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-idesign-advanced-wavescan-studioaberrometer-for-lasik-procedures--abbott/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2014/08/amgen-files-procoralan-for-heart-failure-at-fda/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2016/12/heritage-study-of-hertraz--trastuzumab-biosimilar--in-breast-and-gastric-cancer-published-in-jama--mylan-and-biocon/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-halaven--eribulin-mesylate--for-treatment-of-adult-patients-with-unresectable-liposarcomas--eisai-/2024-02-06T15:41:06+00:00weekly0.6https://www.medthority.com/news/2018/12/mereo-biopharma-to-merge-with-oncomed-pharma-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iii-alur-study-of-alecensa--alectinib--significantly-improved-progression-free-survival--in-people-with-alk-positive-advanced--metastatic--non-small-cell-lung-cancer---roche/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-mysimba-for-treatment-of-obesity--orexigen-therapeutics/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2013/07/study-of-gattex--nps-pharma--shows-treatment-offers-relief-in-short-bowel-syndrome/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-advisory-committee-voted-unanimously-for-teprotumumab-to-treat-thyroid-eye-disease----horizon-therapeutics/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-accepts-for-filing--a-supplemental-biologics-license-application-based-on-data-from-the-phase-iii-alcanza-trial-and-two-phase-ii-trials-of-adcetris--brentuximab-vedotin--for-cutaneous-t-cell-lymphoma--ctcl----seattle-genetics---takeda-oncology/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2017/11/nejm-publishes-positive-results-of-strive-trial-of-erenumab-in-the-prevention-of-episodic-migraine----novartis---amgen-/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2017/01/seciera--cyclosporine-a--0-09--ophthalmic-solution--meets-primary-and-key-secondary-endpoints-in-pivotal-phase-iii-trial-for-dry-eye-disease--sun-pharma/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2017/11/acorda-therapeutics-increases-blood-cell-monitoring-in-phase-iii-programme-for-tozadenant-for-parkinson-s-disease-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-advisory-committee-rejects-low-dose-mesylate-salt-of-paroxetine-for-menopause/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2020/01/abbvie-creates-allergan-aesthetics-for-development-and-marketing-of-aesthetic-products/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2016/03/xilonix--monoclonal-antibody--filed-with-ema-for-colorectal-cancer--xbiotech/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trials-of-medi-563--benralizumab--meet-primary-and--secondary-endpoints-for-severe-asthma--medimmune-astrazeneca/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2012/04/medtronic-launches-powerease-system-for-spine-surgery/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-recommends-humira-abbott--for-ulcerative-colitis/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2019/09/new-data-from-ocrevus-trials-provides-insights-into-the-biology-of-relapsing-and-primary-progressive-multiple-sclerosis--genentech-roche/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2012/04/meta-analysis-supports-use-of-soy-isoflavones-to-allieviate-hot-flushes/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-accepts-filing-of-hetlioz-as-a-treatment-for-jet-lag-disorder---vanda-pharma/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2018/03/positive-results-for-recap---in-sepsis-patients-with-acute-kidney-injury---am-pharma--b-v-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-approves-vargatef-with-docetaxel-for-nsclc-boehringer/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2016/01/nuvasive-acquires-ellipse-technologies-and-with-it-the-magec-spinal-bracing-and-distraction-system/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2019/10/evenity-receives-positive-chmp-opinion-for-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture--amgen---ucb/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-to-investigate-plato-trial-for-brilinta/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-data-shows-lyxumia--sanofi--reduces-blood-glucose-levels-in-type-2-diabetes-patients/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-trial-of-darzalex--daratumumab----revlimid---dexamethasone-meets-primary-pfs-endpoint-in-multiple-myeloma--genmab/2024-02-06T15:41:24+00:00weekly0.6https://www.medthority.com/news/2016/12/soliris--eculizumab--fails-phase-ii-iii-protect-study-to-prevent-delayed-graft-function---alexion-pharma/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-release-studies-of-xiaflex-show-improvements-in-cellulite---endo-international-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2012/06/lemtrada--sanofi-genzyme--filed-at-fda-and-ema-for-relapsing-multiple-sclerosis/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-withdraws-approval-of-avastin--genentech--for-breast-cancer-patients/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2018/05/world-ibd-day-2018/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-mayzent-for-the-treatment-of-adults-with-relapsing-forms-of-multiple-sclerosis--novartis/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2017/06/juno-therapeutics-presented---interim-data-from-transcend-trial-of-jcar-017-in-relapsed-and-refractory--r-r--aggressive-b-cell-non-hodgkin-lymphoma--nhl--/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2018/06/idorsia-initiates-precision-phase-iii-trial-of-aprocitentan-for-resistant-hypertension-management--/2024-07-26T10:21:32+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-awards-ce-mark-approval-to-interatrial-shunt-device-for-heart-failure--corvia-medical/2024-02-06T15:41:36+00:00weekly0.6https://www.medthority.com/news/2019/03/darzalex---bortezomib--thalidomide-and-dexamethasone-submitted-to-fda-for-multiple-myeloma---janssen/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2017/08/shire-plc-announces-that-the-uk-as-reference-state-has-validated-the-maa-for-lifitegrast-as-a-treatment-for-dry-eye-disease-/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2015/03/nice-recommends-xolair--omalizumab--as-a-treatment-for-urticaria-novartis/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2018/04/world-health-day-2018/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-tower-study-of-blincyto--blinatumomab--in-philadelphia-chromosome-negative-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia--ends-early-for-efficacy--amgen/2024-02-06T15:41:49+00:00weekly0.6https://www.medthority.com/news/2017/01/results-from-ignite-study-of-contrave--bupropion-and-naltrexone--published-in-obesity---orexigen-therapeutics/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-fixed-dose-akynzeo-iv-for-chemotherapy-induced-nausea-and-vomiting---helsinn-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iiia-study-shows-benefits-of-ideglira-in-t2d---novo-nordisk/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2018/05/fasenra-fails-phase-iii-terranova-trial-for-copd---astrazenaca/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2017/02/amgen-announces-positive-results-of-repatha--evolocumab--in-fourier-cv-outcomes-trial-and-ebbinghaus-cognitive-function-trial--/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2018/12/positive-phase-iii-trial-for-zydis-orally-dissolving-tablet-to-treat-acute-migraine---biohaven-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2019/06/sobi-acquires-gamifant-from-novimmune-/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2018/04/could-an-existing-drug-halt-parkinson-s-disease-/2024-03-05T15:07:56+00:00weekly0.6https://www.medthority.com/news/2012/03/mammaprint-genomic-test--agendia--spares-breast-cancer-patients-chemotherapy-with-no-adverse-effect-on-survival/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2014/12/reversal-of-eliquis-anticoagulation-effect-study-positive-bms---pfizer/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-data-from-phase-iii-aurelia-trial-of-avastin--genentech-roche--for-ovarian-cancer-patients/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2018/04/interim-data-for-lentiglobin-gene-therapy-to-eliminate-or-reduce-chronic-blood-transfusions-in-patients-with-transfusion-dependent-beta-thalassemia-is-published-in-nejm---bluebird-bio-inc-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2011/11/chmp-continues-to-monitor-safety-profile-of-pradaxa--boehringer--for-vte/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-vyxeos--daunorubicin-and-cytarabine--liposome-for-injection-for-the-treatment-of-adults-with-two-types-of-acute-myeloid-leukemia--aml----jazz-pharmaceuticals-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2012/10/updated-results-in-phase-iii-trial-of-abraxane--celgene-oncology--for-patients-with-metastatic-melanoma/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2014/04/study-of-kuvan-meets-primary-endpoint-in-pku-patients---merck-kgaa/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-extend-trial-shows-pixuvri--cell-therapeutics--offers-effective-salvage-therapy-for-non-hodgkin-s-lymphoma/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-reviewers-concerned-over-potential-cv-risks-of-onglyza--saxagliptin--in-t2d-patients-astrazeneca/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2013/03/enobosarm--gtx--is-published-in-the-lancet-oncology/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2014/01/daiichi-sankyo-files-savaysa-at-fda-for-stroke-prevention-and-for-vte/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2018/07/european-commission-approves-aimovig-to-treat-migraine---novartis-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2016/04/eu-extends-indication-of-opdivo--nivolumab--for-locally-advanced-or-metastatic-non-small-cell-lung-cancer--nsclc--after-prior-chemotherapy---bms/2024-02-06T15:42:02+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-sbla-for-opdivo---yervoy-combination-to-treat-advanced-renal-cell-carcinoma---bms-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2016/03/sbla-submitted-to-fda-for-blincyto--blinatumomab--in-pediatric-and-adolescent-patients-with-philadelphia-chromosome-negative--relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia--amgen/2024-02-06T15:42:14+00:00weekly0.6https://www.medthority.com/news/2016/06/efficacy-of-myl-14010-trastuzumab-biosimilar-confirmed-in-heritage-study--biocon---mylan/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-zytiga-for-metastatic-high-risk-castration-sensitive-prostate-cancer---janssen-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2015/11/sanofi-acquires-world-rights-to-sotagliflozin-for-types-1---2-diabetes-with-option-for-lexicon-to-co-promote-in-us-for-type-1-diabetes/2021-09-24T07:04:24+00:00weekly0.6https://www.medthority.com/news/2012/09/f-18-pet-helps-predict-disease-free-survival-for-breast-cancer-patients---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-rapivab-for-treatment-of-influenza--biocryst-pharma/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2019/07/5th-ean-congress--focusing-on-the-role-of-neuroinflammation-in-the-development-of-neurological-diseases/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-results-for-regn-1500-meets-primary-endpoint-in-homozygous-familial-hypercholesterolemia---regeneron-pharma/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2017/06/nurses-crucial-in-improving-uptake-of-potentially-life-saving-vaccine-in-vulnerable-rheumatic-patients/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iiib-iv-propel-trial-of-adynovate-presents-new-data-in-haemophilia-a---takeda/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2017/07/roche-acquires-diabetes-management-company-mysugr-/2025-10-16T11:31:01+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-prouroscan--prourocare-medical--for-elasticity-imaging-of-the-prostate/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-proton-therapy-irradiation-system-sumitomo/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2012/08/ema-401-has-phase-ii-success-for-post-herpetic-neuralgia---------------/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-study-of-bow-015-meets-primary-endpoint-in-rheumatoid-arthritis-epirus-pharma/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2013/02/sanofi-files-lixisenatide-at-fda-for-treatment-of-type-2-diabetes---------------/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-in-final-appraisal-rejects-abraxane-nab-paclitaxel--for-metastatic-pancreatic-cancer-celgene/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2015/02/high-rates-of-diarrhoea-in-phase-iib-study-of-tenapanor-inhyperphosphatemia-in-chronic-kidney-disease--ardelyx--astrazeneca/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2015/03/astra-zeneca-will-co-market--movantik--naloxegol--in-the-us-with-daiichi-sankyo-/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2018/09/novartis-reports-phase-iii-study-of-lucentis-to-treat-retinopathy-of-prematurity-/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2013/04/us-court-removes-age-limits-on-plan-b-one-step-contraceptive/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2012/09/studies-show--onbrez-breezhaler-arcapta-neohaler--novartis--effective-for-patients-with-copd---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2013/01/results-of-reduce-study-show-benefits-from-avodart-avolve--glaxo-smith-kline--for-prostate-cancer-risk/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-delstrigo-for-hiv---merck-inc--/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2013/02/bronchitol--pharmaxis--is-rejected-by-fda-advisory-committee-as-a-treatment-for-cystic-fibrosis-/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-kynamro--genzyme-sanofi--to-treat-homozygous-familial-hypercholesterolemia/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2016/04/nice-recommends-translarna--ataluren--for-children-aged-5-and-over-with-duchenne-muscular-dystrophy--ptc-therapeutics/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2019/12/real-world-data-analysis-of-eliquis-for-the-treatment-of-venous-thromboembolism-in-patients-with-active-cancer---bms---pfizer/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-study-of-ly-3009104--baricitinib--shows-improvement-in-outcomes-for-rheumatoid-arthritis--eli-lilly-and-incyte-corp/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-bd-max-vaginal-panel-diagnostic-for-vaginitis--bd/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2019/10/mallinckrodt-announces-positive-findings-from-its-observational-registry-assessing-relapse-recovery-in-multiple-sclerosis-relapse-patients-treated-with-acthar-gel--repository-corticotropin-injection--/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2015/12/almirall-acquires-poli-group-and-with-it-ciclopoli-a-leading-drug-for-onychomycosis-/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2013/11/study-of-pimavanserin--acadia-pharma--in-pdp-published-in-the-lancet/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2019/05/servier-pharmaceuticals-opens-american-hq-in-boston-/2021-09-24T07:17:37+00:00weekly0.6https://www.medthority.com/news/2014/06/eu-approves-gardasil-to-treat-anal-cancers--sanofi-pasteur-msd/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2018/05/oscar-phase-iv-study-of-epiduo-forte-shows-impact-on-moderate-to-severe-acne---galderma-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2020/02/nice-in-draft-guidance-does-not-recommend-the-combination-of-keytruda---inlyta-to-treat-renal-cell-carcinoma--merck-inc---pfizer/2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-additional-indication-for-kisqali-in-hr--her2--metastatic-breast-cancer---novartis-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2018/07/european-commission-approves-tegsedi-to-treat-stage-1-or-stage-2-polyneuropathy-in-adult-patients-with-hereditary-transthyretin-amyloidosis---akcea-therapeutics---ionis-pharma-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-results-from-checkmate-078-study-of-opdivo-for-nsclc-in-chinese-patients---bms/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2016/08/nejm-publishes-castor-study-of-daratumumab--bortezomib--and-dexamethasone-for-multiple-myeloma--genmab-a-s---janssen-biotech/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2012/04/morab-004--morphotek-eisai--begins-phase-ii-study-in-metastatic-colorectal-cancer/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2012/06/ema-accepts-application-for-elvitegravir-gilead-sciences--for-hiv-1-treatment/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2015/02/success-for-gazyva--obinutuzumab-----bendamustine-in-phase-iii-gadolin-study-for-nhl--genentech--roche/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2018/06/top-line-results-reported-from-cingal-16-02-clinical-trial-in-knee-osteoarthritis---anika-therapeutics-/2024-07-26T10:21:10+00:00weekly0.6https://www.medthority.com/news/2016/04/results-from-study-of-brinavess--vernakalant-iv--shows-benefits-in-atrial-fibrillation--cardiome-pharma-/2024-02-22T08:57:47+00:00weekly0.6https://www.medthority.com/news/2016/11/uk-nice-recommends-reduced-dose-of-brilique--ticagrelor--for-3-years-to-prevent-heart-attack-or-stroke--astrazeneca/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-reshape-integrated-dual-balloon-system--to-treat-obesity--reshape-medical/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2014/07/desmoteplase-fails-dias-3-study-for-acute-ischaemic-stroke--lundbeck/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2014/02/recordati-to-market-vitaros-for-erectile-dysfunction-in-europe-and-africa--apricus-bioscience/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2012/05/nice-draft-guidance-now-approves-zytiga--j-j-janssen-cilag--for-prostate-cancer/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2014/02/the-medicines-company-re-files-oritavancin-at-fda-for-absssi-infections-caused-by-mrsa-/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-extends-approval-in-daklinza--daclatasvir--plus-sovaldi--sofosbuvir--to-genotypes-1-and-3-chronic-hepatitis-c--bms/2024-02-22T09:11:29+00:00weekly0.6https://www.medthority.com/news/2019/06/clinical-practice-data-demonstrates-clinical-effectiveness-and-tolerability-of-zebinix---eslicarbazepine-acetate--as-adjunctive-therapy-in-epilepsy-patients-with-psychiatric-comorbidities/2025-10-16T11:36:33+00:00weekly0.6https://www.medthority.com/news/2019/04/topline-safety-results-from-phase-iii-maple-study-of-abicipar-to-treat-neovascular-macular-degeneration---allergan---molecular-partners/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2018/04/recordati-to-market-cystagon-in-europe-for-nephropathic-cystinosis---mylan/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-extends-label-of-tasigna-to-include-treatment-free-remission-data-for-patients-with-philadelphia-chromosome-positive-cml-in-the-chronic-phase----movartis/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2015/09/european-commission-approves-kanuma--sebelipase-alfa--for-patients-of-all-ages-with-lysosomal-acid-lipase-deficiency--alexion-pharmaceuticals/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2018/02/three-year-survival-data-from-trial-of-kanuma-in-infants-with-lysosomal-acid-lipase-deficiency---alexion-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-in-pact-admiral-drug-coated-balloon-for-superficial-femoral-artery-lesions-in-pad---medtronic-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-safety-notice-relating-to-contamination-of-bronchoscopes/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2015/12/new-analysis-of-phase-iii-data-on-sb-1518--pacritinib--shows-benefits-in-myelofibrosis--cti-biopharma-baxalta/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2016/05/second-phase-iii-trial-of-baxdela--delafloxacin--success-in-treatment-of--acute-bacterial-skin-and-skin-structure-infections---melinta-therapeutics/2024-02-06T15:44:12+00:00weekly0.6https://www.medthority.com/news/2015/09/aduro-biotech-inc--to-acquire-bionovion-holding-b-v-/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2016/01/epinephrine-pre-filled-syringe-for-anaphylaxis-refiled-with-fda--adamis-pharmaceuticals/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-taltz-to-treat-ankylosing-spondylitis---eli-lilly/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2017/05/pooled-data-from-three-phase-iii-studies-of-in-patients-with-high-risk-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma--resonate-resonate-2-and-helios-achieve-higher-survival-rates-with-imbruvica--ibrutinib---abbvie/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-data-from-phase-iii-trial-of-avastin--genentech-roche--for-colorectal-cancer-patients/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2019/05/pooled-cardiovascular--safety-analyses-of-the-global-phase-iii-programme-for-roxadustat/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-avastin--genentech-roche--in-brain-cancer-patients-fails-to-reach-primary-endpoints/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2018/10/hase-iii-flaura-trial-shows-met-amplification-and-egfr-c797s-mutation-among-most-frequent-resistance-mechanisms-to-tagrissoin-nsclc-patients--astrazeneca/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2018/04/allogene-therapeutics-and-servier-collaborate-on-allogeneic-chimeric-antigen-receptor-t-cell--car-t--therapy-and-in-particular-ucart--19-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-flight-trial-shows-transcon-growth-hormone-safe-in-pediatric-growth-hormone-deficiency/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-data-from-phase-iii-study-of-ta-7284--janssen-pharmaceuticals--for-patients-with-type-2-diabetes/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-first-medical-device--monarch-external-trigeminal-nerve-stimulation-system-to-treat-adhd/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2013/12/nice-recommends-aubagio-for-ms--sanofi/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-xience-xpedition-everolimus-eluting-cardiac-stent--abbott-vascular--/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-descovy-for-hiv-pre-exposure-prophylaxis--prep---gilead-sciences/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2014/09/eosinophil-levels-may-predict-response-to-inhaled-corticosteriod-treatment-of-copd--gsk/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2016/03/american-sleep-apnea-association-and-ibm-introduce-sleephealth-app--for-iphone-and-applewatch-to-study-sleep-habits--ibm-watson-health/2021-09-24T07:10:26+00:00weekly0.6https://www.medthority.com/news/2013/04/eu-approves-brio-libra-libraxp-deep-brain-stimulation-systems--st-jude-medical--for-dystonia/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2019/04/gilead-sciences-and-novo-nordisk-to-collaborate-on-combination-therapy-for-nash-/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-vipdomet--takeda--for-type-2-diabetes-/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2015/09/heartmate-3-left-ventricle-assist-device-meets-primary-endpoint-in-ce-mark-trial-for-heart-failure--thoratec-corp/2021-09-24T07:03:41+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-voyage-1-study-of-tremfya-shows-efficacy-in-plaque-psoriasis---janssen/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2018/12/initial-data-from-proof-of-concept-trial-of-jcarh-125-to-treat-r-r-multiple-myeloma---celgene---juno/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2015/06/bayer-ag-sells-diabetes-care-business-to-panasonic-healthcare-for--1022-million/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-data-analyses-show-ocrevus-may-provide-meaningful-disability-benefits-such-as-delay-in-the-need-for-a-wheelchair-for-people-with-primary-progressive-multiple-sclerosis--ppms----genentech-roche-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2014/07/sandoz-files-zarzio-biosimilar-for-neutropenia-at-fda-/2021-09-24T07:08:48+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-stivarga--bayer-healthcare--for-treatment-of-colorectal-cancer/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2016/11/successful-phase-iii-study--gog-0265--of-axalimogene-filolisbac-for-recurrent-metastatic--squamous-or-non-squamous-cell--carcinoma-of-the-cervix---advaxis-inc---/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2019/05/pooled-sub-group-analyses-from--evolve-1-and-evolve-2-studies-of-emgality-for-migraine--eli-lilly/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2012/07/erbitux--merck-serono--fails-expand-trial-for-gastric-cancer/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2015/02/senza-hf-nerve-stimulator-for-pain-approved-in-3t-mri-scanners-nevro/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2015/11/amgen-files-bla-for-abp-501--adalimumab-biosimilar--at-fda-/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-accepts-filing--bla--of-reslizumab--for-eosinophil-elevated-asthma--teva/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2014/05/arzerra-fails-orcharrd-phase-iii-study-for-refractory-diffuse-large-b-cell-lymphoma--dlbcl---gsk/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2018/11/flair-study-meets-primary-endpoint--showing-similar-efficacy-of-a-once-a-month--two-drug-regimen-of-cabotegravir-and-rilpivirine-for-hiv-treatment---compared-to-a-daily--oral-three-drug--integrase-based-regimen--viiv-healthcare/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2018/10/netter-1-data-shows-improved-pfs-with-lutathera-in-neuroendocrine-tumours---novartis-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-study-of-self-administered-galcanezumab-shows-significant-reduction-in-monthly-migraine-headache-days---eli-lilly/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2015/06/uncover-2-and-uncover-3-trials-of-ixekizumab-for-moderate-to-severe-plaque-psoriasis-published-in-the-lancet--eli-lilly/2024-02-22T15:52:08+00:00weekly0.6https://www.medthority.com/news/2015/04/further-data-for-bax-111--highly-purified-recombinant-von-willebrand-factor--from-phase-iii-study-for--von-willebrand-disease-baxter/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2017/06/interim-analysis-of-nci-phase-iii-study-of--yervoy--ipilimumab-in-high-risk-patients-with-stage-iii-or-resectable-stage-iv-melanoma---bms/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2018/12/novartis-announces-results-of-phase-i-start-trial-for-zolgensma-for--spinal-muscular-atrophy-type-1-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-luxturna-to-treat-inherited-retinal-diseases--novartis/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2018/07/data-from-advance-phase-iii-study-of-rolontis-shows-non-inferiority-to-pegfilgrastim-for-management-of-severe-neutropenia----spectrum-pharma-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2017/12/xofigo---abiraterone---prednisone-trial-for-prostate-cancer-is-unblinded-early----bayer-healthcare-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-re-affirms-benefit-risk-profile-of-nuplazid-to-treat-parkinson-s-disease-psychosis---acadia-pharma/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2014/09/two-year-results-for-i-ray-system-in-age-related-macular-degeneration-oraya-/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2018/07/sight-diagnostics-received-a-ce-mark-for-its-point-of-care-blood-diagnostic-device--olo-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2018/11/alcon-to-become-a-stand-alone-company/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2019/12/seattle-genetics----astellas-collaborate-with-merck-inc---to-evaluate-enfortumab-vedotin-in-combination-with-keytruda--to-treat-metastatic-urothelial-cancer-/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2016/09/astrazeneca-withdraws-marketing-application--maa--at-ema-for-cediranib-in-combination-with-platinum-based-chemotherapy-to-treat-ovarian-cancer-/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2013/09/study-of-efient-in-acs-patients-suggests-new-strategies-needed/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2013/08/new-study-of-usl-255--published-in-epilepsia/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2018/04/world-hemophilia-day-2018/2024-02-06T15:22:06+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-issues-revised-approval-for-iclusig-for-cml-ph-all-ariad-pharma/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2013/06/ample-study-results-for-orencia--bms---and-humira--abbvie--comparison-in-ra/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommendation-for-duaklir-genuair-for-treatment-of-copd---astrazeneca--forest-labs-almirall/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2011/12/zometa--novartis--with-endocrine-therapy-improves-survival-in-post-menopausal-breast-cancer-patients/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2019/04/succesful-quarter-for-coherus-biosciences-with-udenyca-a-pegfilgrastim--neulasta--biosimilar---/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2015/10/nice-requires-further-information-on-translarna--ataluren--for-treatment-of-nonsense-mutation-in-duchenne-muscular-dystrophy--ptc-therapeutics/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---kidney-patients-are-the-most-complex-patients/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-asparlas-as-a-component-of-a-multi-agent-chemotherapeutic-regimen-to-treat-acute-lymphoblastic-leukemia---servier/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2013/12/levosimedan-enters-phase-iii-for-low-cardiac-output-syndrome-oxygen-biotherapeutics/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2012/07/ixazomib--takeda-millennium--enters-phase-iii-trials-for-multiple-myeloma/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2013/11/baxter---cti-marketing-of-pacritinib-for-myelofibrosis/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2018/03/national-no-smoking-day-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2015/12/zebinix--eslicarbazepine-acetate--meets-endpoint-in-phase-iii-trial-for-partial-onset-epilepsy--bial/2024-02-06T15:22:33+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-gives-limited-approval-for-oraquick-ebola-rapid-antigen-test--orasure/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2012/03/procoralan--servier--approved-by-european-commission-for-chronic-heart-failure/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-zolgensma-to-treat-spinal-muscular-atrophy----novartis/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-snda-for-giotrif--afatinib--in-advanced-squamous-cell-carcinoma-of-the-lung--boehringer/2024-02-06T15:22:45+00:00weekly0.6https://www.medthority.com/news/2014/05/nice-does-not-recommend-stelara-for-psoriatic-arthritis---janssen/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-accepts-for-review-a-human-anti-rabies-immunoglobulin--igg--therapy-to-treat-rabies---kedrion-biopharma---kamada-ltd/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2015/07/takeda-files-nda-at-fda-for-ixazomib-to-treat-multiple-myeloma/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2019/05/data-from--cs2-cs12--an-open-label-study-of-the-safety-and-tolerability-of-spinraza--published-in-neurology---biogen/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2019/06/eular-2019---preview/2021-12-01T14:21:23+00:00weekly0.6https://www.medthority.com/news/2013/05/seattle-genetics-files-adcetris-at-fda-for-extended-use-in-hodgkin-lymphoma-and-salcl/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2020/01/illumenate-pivotal-trial-of-stellarex-confirms-safety-profile-in-peripheral-arterial-disease---royal-philips/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2011/12/nvc-422--novabay--shows-potential-against-adenoviral-conjuctivitis/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2018/02/new-rare-disease-platform-launched-for-hunter-syndrome/2024-10-22T08:15:06+00:00weekly0.6https://www.medthority.com/news/2012/06/intergard-synergy-vascular-graft--maquet-cardiovascular--receives-ce-mark/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-results-for-phase-iii-study-of-eklira-bretairis--almirall--for-copd/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2015/06/medtronic-acquires-aptus-endosystems/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2017/08/iv-eravacycline-for-the-treatment-of-complicated-intra-abdominal-infections-has-been-submitted-to-and-was-validated-by-the-european-medicines-agency--tetraphase-pharmaceuticals-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2015/01/medimmune-astrazeneca-in-agreement-with-omnis-pharmaceuticals/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-trailblazer-angled-support-catheter-for-use-in-the-peripheral-vascular-system---medtronic/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2018/04/study-of-zalviso-in-moderate-to-severe-pain-published-in-anesthesiology-journal---acelrx-pharma-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-extension-study-shows-cosentyx--secukinumab--efficacy-in-plaque-psoriasis--novartis/2024-02-06T15:34:54+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-estelle-study-of-estelle-meets-primary-endpoint-in-contraception---mithra/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2016/09/frame-study-of-romosozumab-shows-significant-reduction-of-new-vertebral-fractures-in-postmenopausal-women-with-osteoporosis----amgen---ucb/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2012/02/vacc-4x-bionor-pharma--success-in-phase-iib-trial-for--hiv-aids/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-times-2-trial-of-imeglimin-shows-positive-results-in-type-2-diabetes---poxel-sumitomo-dainippon-pharma/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2014/08/ema-accepts-expanded-indication-for-prevenar-13-for-pneumonia---pfizer/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-grants-accelerated-approval-for-synribo---cephalon-teva--for-cml/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-dupixent-to-treat-chronic-rhinosinusitis-with-nasal-polyposis---regeneron---sanofi/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/03/apact-study-of-abraxane---gemcitabine-following-surgical-resection-for-pancreatic-cancer-failed-to-achieve-primary-endpoint---celgene/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2018/08/revisions-to-protocols-of-two-trials-of-xtandi--in-men-with-hormone-sensitive-prostate-cancer-will-accelerate-timelines-for-anticipated-primary-completion---pfizer---astellas-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-quofenix--for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections--absssi----menarini/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2012/07/stem-cells-improve-memory-for-alzheimers-disease/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-xolair-for-urticaria-novartis/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2014/12/giotrif-fails-two-phase-iii-trials-for-breast-cancer--boehringer/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2014/06/response-trial-success-for-jakavi-jakafi-for-polycythemia-vera---incyte---novartis/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2017/09/eu-commission-approves-dupixent--dupilumab--to-treat-in-adults-with-moderate-to-severe-atopic-dermatitis----sanofi---regeneron-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approval-for-hemospray-endoscopic-device-to-treat-gi-bleeding---cook-medical-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2018/11/nice-does-not-recommend-lynparza-as-maintenance-treatment-for--ovarian-cancer--astrazeneca---merck-inc-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-binosto--effrx--for-osteoporosis/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2014/06/eu-approves-extension-of-approval-for-invega-for-schizophrenia---janssen-cilag/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-use-of-tradjenta--boehringer-eli-lilly--with-insulin-in-type-2-diabetes-patients/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2016/08/ema-validates-maa-application-for-neratinib-of-her2-positive-early-stage-breast-cancer-that-has-previously-been-treated-with-trastuzumab---puma-biotechnology-inc-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2019/10/uegw-stelera-data-demonstrates/2024-10-22T11:39:44+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-grants-priority-review-for-bla-for-avelumab-to-treat-merkel-cell-carcinoma---merck-kgaa---pfizer/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2019/11/alkermes-to-acquire-rodin-therapeutics-/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2014/07/ruconest-approved-by-fda-for-treatment-of-hereditary-angioedema---salix-pharma/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2013/12/ce-mark-for-vivia-hemodialysis-system-baxter/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2019/04/federal-grand-jury-indicts-indivior-relating-to-suboxone-marketing-and-indivior-provides-its-response-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-nymalize--arbor-pharmaceuticals--for-sub-arachnoid-haemorrhage/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-prima-trial-of-zejula-meets-primary-endpoint-in-ovarian-cancer---glaxosmithkline/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2014/06/two-phase-iii-trials-of-jardiance-show-benefits-for-t2d-boehringer-eli-lilly/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-opus-3-study-of-lifitegrast-successful-in-treatment-of-dry-eye-disease--shire-plc/2024-02-06T15:35:07+00:00weekly0.6https://www.medthority.com/news/2019/08/biotime-inc--to-change-name-to-lineage-cell-therapeutics-inc-/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-invokamet-for-t2d---janssen-pharma/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2014/08/roche-to-acquire-intermune-inc--for--8-3-billion/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-recommends-pradaxa-for-treatment-of-dte-and-pe--boehringer/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2015/08/botox--onabotulinumtoxin-a--refiled-with-fda-for-adults-with-lower-limb--spasticity--allergan/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2013/10/pivotal-trial-of-v-503--merck--for-hpv-has-met-primary-endpoints/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2014/11/yondelis-filed-with-fda-for-sts---janssen/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-zelboraf-for-erdheim-chester-disease---genentech-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-follow-up-of-abraxane--nab-paclitaxel--in-breast-cancer-shows-benefits-of-reduced-dosage--celgene/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2016/01/european-commission-approves-briviact--brivaracetam--an-adjunctive-therapy-in-the-treatment-of-partial-onset-seizures--ucb/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-advisory-committee-recommends-arymo-er--morphine-sulfate--for-treatment-of-severe-pain---egalet-corporation/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2019/06/abbott-launches-afinion-hba1c-dx-assay-the-first-ever-rapid-point-of-care-hba1c-test-to-aid-in-the-diagnosis-of-diabetes-/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2011/11/erwinase--eusa--is-fda-approved-for-acute-lymphoblastic-leukemia/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2016/12/the-sec-has-declared-effective-the-registration-form-filed-by-bioverativ-inc-as-part-of-the-transfer-of-the-hematology-business-of-biogen-to-bioverativ-which-is-due-to-complete-on-1-february-2017-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2016/06/tafinlar--dabrafenib----mekinist--trametinib--superior-to-tafinlar-monotherapy-in-three-year-analysis--of-braf-mutation-advanced-melanoma---novartis/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2013/08/phase-iii-study-of-conmana-shows-benefits-for-nsclc/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-lucentis--genentech--for-treatment-of-diabetic-macular-edema/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2016/02/chmp-recommends-ixekizumab-to-treatmoderate-to-severe-plaque-psoriasis---elililly/2024-02-06T15:35:30+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-liberty-asthma-quest-study--of-dupilumab-shows-a-reduction-in-severe-asthma-attacks---sanofi---regeneron-/2024-07-26T09:36:50+00:00weekly0.6https://www.medthority.com/news/2012/08/eu-approves-humira--abbott--for-treatment-of-axial-spondyloarthritis----------------/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-simponi--merck--shows-improvements-in-ankylosing-spondylitis-over-5-years-/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2019/10/alkermes-presents-new-health-economics-and-outcomes-research-on-patients-with-schizophrenia-and-bipolar-i-disorder-at-2019-psych-congress-/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2019/05/button-batteries-can-rapidly-damage-stomach-lining-before-symptoms-appear/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2017/05/resolute-onyx-drug-eluting-stent--meets-primary-endpoint-in-coronary-artery-disease--medtronic/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2015/05/tivicay--dolutegravir--edurant-rilpivirine--enter-phase-iii-trial-for-hiv-maintenance-therapy-viiv--janssen/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2018/12/european-commission-approves-split-dosing-regimen-for-darzalex-for-treatment-of-multiple-myeloma--genmab---janssen/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-extends-approval-of-humira-in-jia---abbvie/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2016/06/contravir-pharmaceuticals-merges-with-ciclofilin-pharmaceuticals--acquiring-cpi-431-32-for-hepatitis-b/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-refusal-on-application-of-masipro--masitinib--in-systemic-mastocytosis--ab-science/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2013/05/results-positive-for-afinitor--novartis--in-bolero-3-study-in--her2-positive-breast-cancer/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2016/03/two-year-trial-of-eylea--aflibercept---avastin--bevacizumab--and-lucentis--ranibizumab--in-diabetic-macular-oedema-funded-by-national-eye-institute/2024-02-22T15:52:23+00:00weekly0.6https://www.medthority.com/news/2017/11/chmp-recommends-change-to-approval-of-genvoya-for-hiv---gilead-sciences-/2024-10-21T14:43:28+00:00weekly0.6https://www.medthority.com/news/2016/04/axsome-therapeutics-initiates-phase-iii--coast-1-trial-of-axs-02-for-treatment-of-pain-associated-with-knee-osteoarthritis-/2021-09-24T07:10:44+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-ii-study-of-newmet--elcelyx-therapeutics--offers-improved-treatment-for-type-2-diabetes-patients/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-gives-tentative-approval-to-sincalide-for-injection-for-gallbladder-and-pancreas-disorders---maia-pharmaceuticals-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2013/07/successful-phase-iii-mitra-trial-for-dust-mite-allergy/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2015/08/iqwig-finds-added-benefit-of-exviera-plus-viekirax-in-pretreated-patients-with-genotype-1b-hepatitis-c--abbvie/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2019/11/thermo-fisher-scientific-introduces-first-next-generation-sequencing-platform-that-delivers-specimen-to-report-in-a-single-day-/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-enliven-study-of-csf-1r-shows-efficacy-and-safety-in-tenosynovial-giant-cell-tumor---daiichi-sankyo-/2024-07-26T09:36:30+00:00weekly0.6https://www.medthority.com/news/2019/12/results-from-a-survey-with-patients-with-immune-thrombocytopenia--itp--demonstrates-disease-burden-and-impact-for-patients--dova-pharma--sobi/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2019/07/abbvi-acquires-mavupharma-and-with-it--mavu-104--a-first-in-class--orally-active--small-molecule-inhibitor-of-enpp1--an-enzyme-involved-in-the-regulation-of-the-sting-pathway/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2013/05/enzastaurin--eli-lilly--fails-phase-iii-trial-for-b-cell-lymphoma-/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2012/03/vorapaxar--merck--plus-standard-of-care-significantly-reduces-risk-of-cardiovascular-events/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-510-k--clearance--for-lifesparc-system-advanced-circulatory-support--acs--pump/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2019/03/adv-7103-filed-with-ema-for-distal-renal-tubular-acidosis---advicenne/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2012/05/biochaperone-adocia--success-in-phase-ii-trial-for-diabetic-foot-ulcers/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-bsd-2000--bsd--for-use-with-cervical-cancer-treatment/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-aries-hsv-1-2-assay-for-herpes-simplex-diagnostics--luminex-corp/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-visible-1-trial-of-subcutaneous-entyvio-meets-endpoint-in-ulcerative-colitis---takeda-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-tobi-podhaler--novartis--for-treatment-of-cystic-fibrosis-infections/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-warns-that-leukemia-drug-sprycel-can-lead-to-pah/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2016/04/abbott-to-acquire-st--jude-medical/2025-10-16T10:40:01+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approves-evotaz--atazanavir---cobicistat--to-treat-hiv-1--bms/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2017/09/freestyle-libre-flash-glucose-monitoring-system-is-fda-approved-as-a-replacement-for-blood-glucose-monitoring--abbott-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2015/04/paclical--paclitaxel-water-soluble-formulation--approved-in-russia-for-ovarian-cancer-oasmia-pharma/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2018/08/delay-in-us-for-sbla-for-eylea-for-patients-with-wet-age-related-macular-degeneration--wet-amd--12-week-dosing-schedule---regeneron---bayer/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-recommends-nhs-use-of-vosevi-in-chronic-hepatitis-c---abbvie-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-zinforo-astrazeneca--for-cssti-or-cap-infections/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2019/04/sandoz-to-commercialise-rizmoic-to-treat-opioid-induced-constipation--in-uk--germany-and-the-netherlands---shionogi/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2019/07/subcutaneous-darzalex-filed-with-fda-for-multiple-myeloma---janssen-biotech/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2019/07/genentech-presents-a-broad-range-of-data-for-hemlibra-demonstrating-continued-benefits-for-people-with-hemophilia-a-at-the-isth-2019-congress-/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2018/10/long-term-carmelina-trial-of-tradjenta-reports-on-cv-safety-and-kidney-disease-in-type-2-diabetes--boehringer---eli-lilly/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2018/02/success-for-pomalyst-imnovid-plus-bortezomib-and-low-dose-dexamethasone-by-improving-pfs-in--optimismm-trial-for-multiple-myeloma----celgene-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2014/05/arzerra-fails-orcharrd-phase-iii-study-for-b-cell-lymphoma---gsk/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2013/06/eu-approves-revlimid--celgene--for-transfusion-dependent-anaemia-associated-with-myelodysplastic-syndromes/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2017/09/results-of-phase-iii-intandem3-study-of-lx-4211--sotagliflozin--in-type-1-diabetes-published-in-new-england-journal-of-medicine---lexicon-pharmaceuticals-/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2016/11/seven-year-data-shows-benefits-of-benlysta--belimumab--in-autoantibody-positive-systemic-lupus-erythematosus--glaxosmithkline/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2018/08/phase-iii-trial-of-regn-475-meets-primary-endpoint-in-pain-from-osteoarthritis-of-the-knee-or-hip---regeneron---teva-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2018/09/psoriasis-knowledge-centre-relaunches-on-medthority-com/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2014/04/kids-a-long-study-of-elocate-for-haemophilia-a-success--sobi---biogen/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2011/04/phase-ii-b-emerge-study-of-peg-interferon-lambda-in-hepatitis-c/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2017/10/9th-clinical-dermatology-congress/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2015/09/merck-kgaa-plans-to-re-file-cladribine-tablets-at-ema-for-treatment-of-relapsing-multiple-sclerosis-/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-approves-elipse-gastric-balloon-to-treat-obesity--allurion-technologies/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2015/11/two-year-study-of-opdivo--nivolumab--shows-superiority-in-advanced-melanoma--bms/2024-02-06T15:35:50+00:00weekly0.6https://www.medthority.com/news/2018/06/eu-commission-approves-perjeta---herceptin-for-post-surgery-treatment-of-her2-positive-early-breast-cancer-at-high-risk-of-recurrence----roche-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2020/01/ce-mark-for-tendyne-transcatheter-mitral-valve-implantation--tmvi--system---abbott/2021-09-24T07:11:43+00:00weekly0.6https://www.medthority.com/news/2014/09/eylea-is-approved-in-japan-for-treatment-of--myopic-choroidal-neovascularization--myopic-cnv----bayer-healthcare/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2018/12/european-commission-approves-takhzyro-subcutaneous-injection--for-the-preventive-treatment-of-hereditary-angioedema---shire-takeda/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2013/02/soluble-ferric-pyrophosphate--rockwell-medical--success-in-phase-iii-trial-for-iron-deficiency/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2014/07/breo-ellipta-is-filed-at-fda-for-treatment-of-asthma--gsk---theravance/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-results-of-phase-ii-study-of-immu-132-in-advanced-solid-tumours-immunomedics/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2011/12/aubagio--sanofi-genzyme--results-in-tenere-trial-for-multiple-sclerosis-/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-expands-indication-of-evarrest-fibrin-sealant-patch-to-stop-problematic-bleeding-during-surgery--ethicon-/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-issues-complete-response-letter-to-ap-pharma--relating-to-ap-f-530-for-cinv/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2014/09/trial-of-carillon-mitral-contour-system-in-cadiac-patients-shows-positive-improvements-cardiac-dimensions/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-xtandi-for-non-metastatic-prostate-cancer---astellas---pfizer-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/06/pivotal-phase-iii-trial-results-of-taltz--ixekizumab--in-plaque-psoriasis-published-in-new-england-journal-of-medicine--eli-lilly/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2015/12/successful-phase-iii-trial-for-medidur-to-treat-chronic-noninfectious-uveitis---psivida-corp-/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2016/09/ema-chmp-recommends-approval-of-two-generics-to-procoralan--ivabradine-jensonr-and-ivabradine-zentiva-for-chronic-heart-failure-and-symptomatic-treatment-of-chronic-stable-angina-pectoris---jensonr--and-zentiva/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2012/03/koning-breast-ct-system-secures-ce-mark-approval/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2015/05/phase-iii-results-for-zerbaxa--ceftolozane-tazobactam--in-cuti-and-ciai-published-in-the-lancet-and-clinical-infectious-diseases--merck-inc-/2024-02-22T15:53:00+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-trial-of-skyrizi-meets-all-endpoints-in-plaque-psoriasis---abbvie/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-in-final-guidance-recommends-lixiana--edoxaban-tosylate--to-prevent-stroke-in-patients-with-non-valvular-atrial-fibrilliation--daiichi-sankyo/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2018/08/bristol-myers-squibb-pfizer-alliance-will-present-15-eliquis-posters-at-the-esc-congress-2018-and--new-analyses-from-the-acropolis--apixaban-experience-through-real-world-population-studies--study-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2019/02/bausch-health-companies-acquires-us-rights-from-eton-pharma-to-em-100---an-otc-eyedrop-to-treat-ocular-itching-/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2016/11/mylan-n-v--and-biocon-ltd-file-bla--at-fda-for-myl-1401o-a-proposed-biosimilar-trastuzumab-/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-agrees-to-new-labelling-of-zevalin--spectrum-pharma--to-remove-bioscan-indium-111/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2017/03/reveal-linq-insertable-cardiac-monitor-receives-fda-510-k--clearance-for-diagnostics-in-heart-arrhythmia--medtronic/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-expands-approval-of-harvoni--ledipasvir---sofosbuvir--for-genotype-4--5-and-6-chronic-hepatitis-c--gilead-sciences/2024-02-06T15:36:08+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-provides-510-k--approval-for-aurora-surgiscope-for-neurological-surgery--rebound-therapeutics/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---minimally-invasive-procedure-shows-promise-in-combating-obesity/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2014/01/jakafi-jakavi-enters-phase-iii-for-pancreatic-cancer-incyte---novartis/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2012/07/fluticasone-vilanterol-combination--gsk--is-filed-in-us-for-copd-and-in-the-eu-for-asthma-and-copd/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2019/06/brinavess-refiled-with-fda-for-recent-onset-atrial-fibrillation---correvio-pharma/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-rydapt--midostaurin--for-acute-myeloid-leukemia--flt3-mutation-positive---novartis/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2019/06/surufatinib-in-advanced-neuroendocrine-tumors---extra-pancreatic-met-the-primary-endpoint-of-progression-free-survival--hutchinson-china-meditech-/2024-10-21T14:44:38+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-watchman-laac-device-to-reduce-the-risk-of-thromboembolism--boston-scientific/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2014/06/detailed-data-from-phase-iii-trial-of-tas-102-in-mcrc-taiho-pharma/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2015/10/losmapimod--fails-in-phase-iii-trial--latitude-timi-60--to-treat-acute-coronary-syndrome-gsk/2024-02-06T15:36:20+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-zilretta--triamcinolone-acetonide-extended-release-injectable-suspension--for-osteoarthritis-knee-pain---flexion-therapeutics-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2019/05/new-ocrevus-data-analyses-show-significant-reduction-of-disability-progression-in-relapsing-and-primary-progressive-multiple-sclerosis---genentech-roche/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2015/03/stallergenes-s-a--to-merge-with-greer-laboratories/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-oxbryta-to-treat-sickle-cell-disease---global-blood-therapeutics/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-kcentra--csl-behring-to-reverse-vitamin-k-antagonist-anticoagulation-with-major-bleeding/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-sapien-3-ultra-system-for-transcatheter-aortic-valve-replacement-in-severe-symptomatic-aortic-stenosis-patients--edwards-lifesciences/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2011/12/lyxumia-sanofi-aventis--positive-in-get-goal-duo-study-in-type-2-diabetes-/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2019/08/u-s--district-court-invalidates-amgen-patent-claims-targeting-pcsk9---snofi---regeneron/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2018/03/dynagito-trial-results-of-stiolto-respimat-in-chronic-obstructive-pulmonary-disease-published-in-the-lancet-respiratory-medicine---boehringer-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-accepts-filing-bla-of-myl-1401o---hertraz--biosimilar-trastuzumab--to-treat-her-2-positive-breast-cancer---mylan---biocon/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2016/05/european-commission-approves-uptravi--selexipag--to-treat-pulmonary-arterial-hypertension---actelion/2024-02-06T15:36:35+00:00weekly0.6https://www.medthority.com/news/2013/03/gilenya--novartis--decreases-brain-volume-loss-in-multiple-sclerosis-patients/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2017/12/gw-pharma-re-acquires-us-rights-to-sativex--a-treatment-for-cancer-pain--from-otsuka-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2014/03/bayer-returns-rights-of-atx-101-to-kythera-a-treatment-for-submental-fat/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2012/04/nice-rejects-halaven--eisai--for-breast-cancer/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2017/01/updated-sonablate-high-intensity-focused-ultrasound-receives-510-k--approval-in-us-for-prostate-cancer--sonacare-medical/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2013/08/revlimid-study-for-smoldering-multiple-myeloma/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-advisory-committee-recommends-absorb--bioresorbable-drug-eluting-coronary-stent-to-treat-cad--abbott/2024-02-06T15:36:48+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-accepts-for-priority-review-the-bla-for-pegvaliase--a-pegylated-recombinant-phenylalanine-ammonia-lyase-enzyme-product-to-treat-phenylketonuria---pku---biomarin/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2019/08/prepare-phase-iii-trial-of-res-vax-shows-efficacy-in-respiratory-syncytial-virus---novavax/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-study-of-cqr-1--cardio3biosciences--published-in-journal-of-the-american-college-of-cardiology/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-advisors-vote-against-taltorvic--merck-ariad--for-sarcoma-patients/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2011/10/subcutaneous-herceptin-trial-reveals-benefits-for-breast-cancer-patients/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2016/08/european-commission-approves--cinqaero--reslizumab-as-add-on-therapy-in-adult-patients-with-severe-eosinophilic-asthma--teva-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2016/01/in-pact-admiral-drug-eluting-balloon-receives-ce-mark-approval-for-hemodialysis-access-in-patients-with-end-stage-renal-disease--medtronic/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2018/06/canakinumab-reduces-rate-of-gout-by-half--study-says/2021-12-01T13:52:35+00:00weekly0.6https://www.medthority.com/news/2019/02/expanded--fda-indication-for-pipeline-flex-embolization-device---medtronic/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2014/05/positive-results-from-study-of-invega-sustenna-for-schizophrenia-janssen/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2012/11/european-commission-approves-humira--abbott-labs--for-paediatric-crohn-s-disease/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-lospa-knee-system--corentec-america--for-knee-replacement-surgery/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2018/09/the-tulip-1-phase-iii-trial-for-anifrolumab-in-adult-patients-with-moderate-to-severe-systemic-lupus-erythematosus--sle--did-not-meet-the-primary-endpoint---astrazeneca/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-additional-indication-for-evarrest--fibrin-sealant-patch--for-bleeding-control-during-liver-surgery-ethicon/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2016/03/uk-nice-does-not-recommend-orkambi--lumacaftor-ivacaftor---to-treat-cystic-fibrosis-f508del-mutation--vertex-pharma/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2015/04/swift-prime-and-revascat-trials-confirm-the-addition-of-the-solitaire-stent-thrombectomy-procedure-to-pharmaceutical-treatment-significantly-reduced-disability-in-stroke-patients-medtronic--/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2016/08/pfizer-acquires-medivation-and-with-it-oncology-assets/2021-09-24T07:09:38+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-keynote-042-trial-successful-results-for-keytruda-in-first-line-nsclc---merck-iinc-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2019/12/results-of-phase-iii-sunrise-1-study-of-dayvigo-in-insomnia-published-in-jama-network-open-journal---eisai/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2012/07/review-shows-some-benefit-from-avastin--genentech-roche--for-breast-cancer-patients/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2017/05/-know-your-numbers--on-world-hypertension-day---17th-may-2017/2024-02-22T11:56:48+00:00weekly0.6https://www.medthority.com/news/2019/10/bms--pfizer-alliance-and-fitbit-collaborate-to-address-gaps-in-atrial-fibrillation-detection-to--accelerate-diagnosis-/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-sunrise-study-of-e-2006-shows-improvement-in-insomnia---eisai---purdue-pharma/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2018/06/ce-mark-for-cleancision-wound-retraction-and-protection-system----prescient-surgical-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2020/01/new-indication-approved-for-infinity-deep-brain-stimulation--dbs--system-to-improve-symptoms-of-parkinson-s-disease---abbott/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2016/10/melinta-therapeutics-files-nda-at-fda-for-baxdela--delafloxacin--to-treat-acute-bacterial-skin-and-skin-structure-infections--absssi--/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2017/12/organ-on-a-chip/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-the-light-adjustable-lens-and-light-delivery-device-for-post-cataract-surgery---rx-vision-/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2016/11/ema-validates-maa-for-avelumab-to-treat-merkel-cell-carcinoma---merck-kgaa---pfizer/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2018/11/udencya-approved-by-fda-for-neutropenia---coherus-biosciences-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2016/02/bms-completes-sale-of--hiv-r-d-portfolio-to-viiv-healthcare/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2011/01/fda-refuses-approval-for-new-copaxone-indication/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-onduarp-for-hypertension/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2015/06/trial-results-of-rviii-singlechain-in-haemophilia-shows-benefits--csl-behring/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2015/10/allergan-acquires-aquesys-medical-device-company/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-trial-of-keytruda-meets-primary-endpoint-in-resected-high-risk-melanoma---merck-inc-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-bose-hearing-aid--bose-corporation/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-trial-data-for-auryxia-in-iron-deficiency-anemia-published-in-american-journal-of-hematology---keryx-biopharmaceuticals-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2013/09/successful-pooled-analysis-of-amg-145-in-dyslipidaemia/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-primrose-2-trial-of-klh-2109-shows-benefits-in-uterine-fibroids---obseva-sa/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-ninlaro--ixazomib----lenalidomide---dexamethasone-oral-combination-to-treat-multiple-myeloma--takeda/2024-02-06T15:37:01+00:00weekly0.6https://www.medthority.com/news/2012/04/eu-approves-sancuso-prostraken--for-nausea-treatment/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-evzio-pre-filled-injection-for-opioid-overdose---kaleo/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2012/05/dulaglutide-eli-lilly--positive-for-hypertension-effects/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommends-simbriza-for-ocular-hypertension-and-glaucoma---alcon-novartis/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves--fibroscan-elastography-imaging-system-echosens--for-non-invasive-liver-disease-diagnosis/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-biosimilar-pegfilgrastim-to-treat-same-indications-as-its-reference-medicine--sandoz/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2014/10/firdapse-meets-phase-iii-endpoints-for-lambert-eaton-syndrome---catalyst-pharma/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-opdivo--nivolumab--in-squamous-cell-carcinoma-of-the-head-and-neck-stopped-early--bms/2024-02-06T15:37:12+00:00weekly0.6https://www.medthority.com/news/2015/02/actavis-files-at-fda-for-generic-version-of-uceris---budesonide-extended-release---salix/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2016/11/celltrion-has-south-korean-approval-for-truxima-a-rituximab-biosimilar-to-treat-all-indications-of-the-originator-drug-mabthera-rituxan-/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2015/04/arzerra--ofatumumab--meets-primary-endpoint-in-phase-iii-trial-in-cll--novartis/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-advisory-committee-recommends-kynamro-for-treatment-of-homozygous-familial-hypercholesterolemia-/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2018/12/updated-results-from-zuma-3-trial-of-kte-x19--fomerly-kte-c19--to-treat-r-r-acute-lymphoblastic-leukemia----kite-gilead/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2015/07/genzyme-acquires-caprelsa--vandetanib--from-astrazeneca-/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-first-generics-to-compete-with-duloxetine---eli-lilly/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-rejects-repatha--evolocumab--to-treat-dyslipidaemia--amgen/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-phase-iii-data-for-esbriet-in-pulmonary-fibrosis-intermune/2021-09-24T07:07:49+00:00weekly0.6https://www.medthority.com/news/2015/07/study-of-jardiance--empagliflozin--in-type-1-diabetes--boehringer---eli-lilly/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-trial-with-dysport-shows-benefits-for-patients-with-upper-limb-spasticity---ipsen/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-approves-advate--baxter--for-prophylaxis-of-hemophilia-a/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2012/06/two-papers-and-an-editorial-in-the-new-england-journal-of-medicine-hail-erivedge--roche--as-great-advance-in-bcc/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-lipo-202--salmeterol-xinafoate-for-injection--fails-to-meet-endpoints-in-subcutaneous-fat-reduction--neothetics/2024-02-22T15:53:14+00:00weekly0.6https://www.medthority.com/news/2019/02/rolling-submission-to-the-fda-for-bay-1841788-completed-in-castration-resistant-prostate-cancer---bayer-healthcare/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2018/08/new-switch-data-reinforcing-symtuza-for-treatment-of-hiv-1-regardless-of-prior-regimen-and-for-initiating-the-drug-in-the-newly-diagnosed---janssen-pharma-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-nuzyra-for-cabp-and-absssi---paratek-pharma-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2018/09/studies-show-economic-benefits-of-floseal-hemostatic-matrix-in-spinal-surgeries----baxter/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2016/04/veltassa--patiromer--filed-with-ema-for-hyperkalemia--vifor-fresenius-medical-care-renal-pharma/2024-02-22T15:53:28+00:00weekly0.6https://www.medthority.com/news/2014/12/translarna-filed-on-rolling-submission-with-fda-for-nmdmd-ptc-therapeutics/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2013/09/gilead-sciences-files-idelalisib-at-fda-for-nhl/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/09/nice-recommends-use-of-tafinlar---mekinist-in-braf-v600-mutation-positive-melanoma---novartis-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-approves-remicade-for-pediatric-ulcerative-colitis/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-results-of-prt-4445--andexanet-alfa--as-an-antidote-were-published-in-the-new-england-journal-of-medicine--portola-pharmaceuticals/2024-02-22T15:53:44+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-accepts-bla-from-biogen-for-eloctate-for-treatment-of-haemophilia-a/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-requires-new-phase-iii-trial-for-mirvetuximab-soravtansine-for-patients-with--fr-alpha--positive/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trial-of-votrient--glaxo-smith-kline--shows-significant-pfs-benefits-in-ovarian-cancer/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2013/06/two-studies-of-mitra-clip-system--abbott-vascular--for-mitral-regurgitation-published/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2015/09/amicus-therapeutics-acquires-scioderm/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2013/01/gsk-theravance-file-gsk-573719-plus-vilanterol-at-the-ema-for-copd/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2014/10/zubsolv-filed-with-fda-for-expanded-label-in-opioid-dependence-orexo/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2018/02/blood-thinners-may-raise-stroke-risk-in-over-65s-with-kidney-disease/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2017/04/eu-chmp-recommends-approval-of-brineura--cerliponase-alfa--for-neuronal-ceroid-lipofuscinosis-type-2--cln2--disease--biomarin/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2018/06/rolling-submission-for-elzonris-submitted-to-fda-for-blastic-plasmacytoid-dendritic-cell-neoplasm---stemline-therapeutics-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-issues-letter-relating-to-deficiencies-in-nda-for-furoscix-infusor--a-drug--device-for-heart-failure---sc-pharmaceuticals-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2015/12/ce-approved-aptima-mycoplasma-genitalium-assay-diagnostic-launched-in-the-eu--hologic/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2012/04/ono-4641-success-in-phase-ii-trial-for-multiple-sclerosis/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2017/11/flash-study-confirms-benefit-of-switching-from-seretide-to-ultibro--breezhaler-for-copd-patients----novartis-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-negative-against-sutent-for-the-adjuvant-treatment-of-adult-patients-at-a-high-risk-of-recurrent-renal-cell-carcinoma--rcc--following-nephrectomy---pfizer-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2015/06/daiichi-sankyo-initiates-hokusai-vte-cancer-study-of-edoxaban-for-treatment-of-vte-associated-with-cancer-/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-fycompa--eisai--shows-low-discontinuation-rates-in-epilepsy-treatment/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2013/01/novartis-withdraws-application-at-ema-for-ruvise-treatment-for-pah/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-ii-iii-clinical-trial-in-patients-with-plasminogen-deficiency-has-met-its-primary-and-secondary-endpoints-with-the-intravenous-plasminogen-treatment-from-prometic-life-sciences-inc-/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2019/07/ean2019--near-death-experiences-associated-with-rem-sleep-says-new-research/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2018/06/evotec-ag-to-integrate-sanofi-s-infectious-diseases-unit-into-its-organisation-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2015/04/data-on-invega-sustenna--paliperidone-palmitate--in-schizophrenia-published-in-jcp-janssen-pharmaceuticals/2024-02-23T10:58:49+00:00weekly0.6https://www.medthority.com/news/2018/01/cancer-seek-a-possible-universal-cancer-test---johns-hopkins-university-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-levo-cts-trial-of-levosimendan-failed-to-meet-primary-endpoints-in-low-cardiac-output-syndrome--tenax-therapeutics/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-acepts-sbla-for-keytruda---alimta-and-chemotherapy-to-treat-metastatic-nonsquamous-nsclc---merck-inc-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2019/08/superior-tavr-valve-sapien-3-and-sapien--3-ultra-available-for-all-patients-diagnosed-with-severe--symptomatic-aortic-stenosis--edwards-life-sciences/2021-09-24T07:17:51+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-confirms-rejection-of-xeljanz-for-ra/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2018/05/eu-approves-lynparza-as-a-maintenance-therapy-to-treat-patients-with-platinum-sensitive-relapsed-high-grade--epithelial-ovarian--fallopian-tube--or-primary-peritoneal-cancer---astrazeneca---merck-inc-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-uptravi--selexipag--for-the-treatment-of-pulmonary-arterial-hypertension--actelion/2024-02-22T15:55:42+00:00weekly0.6https://www.medthority.com/news/2018/10/ecog-e3a06--results-positive-for-revlimid-to-treat-smoldering-multiple-myeloma---celgene/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-solo-1-trial-of-lynparza-shows-positive-results-in-ovarian-cancer---astrazeneca-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2014/08/evolocumab-success-in-yukawa-1-trial-for-patients-with-high-cardiovascular-risk-and-high-cholesterol---amgen/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/11/results-from-surveyor-studies-for-abt-493---abt-530-fixed-dose-combination-for-non-cirrhotic-patients-with-hepatitis-c--abbvie/2024-02-09T11:53:18+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-sunrise-1-and-sunrise-2-trials-of-e-2006-show-safety-and-efficacy-in-insomnia---eisai/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2012/02/nice-rejects-botox--allergan--for-migraine-prevention-/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-compass-trial-of-optinose-bi-directional-system-sumatriptan--shows-benefits-in-pain-relief-avanir-pharma/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2012/08/genzyme-receives-refusal-to-file-letter-from-fda-relating-to-lemtrada-application-for-multiple-sclerosis/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2019/10/second-interim-overall-survival-data-from-phase-iii-sophia-study-of-margetuximab-for-her2--positive-metastatic-breast-cancer--macrogenics/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2016/04/allergan-acquires-topokinetherapeutics-and-with-it-xaf-5-for-treatment-of-steatoblepharon/2021-09-24T07:10:40+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-proposal-for-nda-for-ux-007-for-the-treatment-of-long-chain-fatty-acid-oxidation-disorders----ultragenyx-pharmaceutical-inc-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2015/10/uk-nice-recommends-orencia--abatacept---humira--adalimumab---enbrel--etanercept--and-roactemra--tocilizumab--for-juvenile-ideopathic-arthritis/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2019/06/adamis-pharmaceuticals-provides-update-on-its-higher-dose-naloxone-injection-product-/2021-09-24T07:16:58+00:00weekly0.6https://www.medthority.com/news/2019/10/two-year-data-from-cedar-and-sequoia-studies-of-abicipar-pegol-to-treat-neovascular--wet--age-related-macular-degeneration--allergan---molecular-partners-/2021-09-24T07:17:23+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-results-for-nucala--mepolizumab--in-patients-with-relapsing-and-refractory-eosinophilic-granulomatosis-with-polyangiitis--glaxosmithkline/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-results-for-xalkori-in-nsclc-published-in-nejm-pfizer/2024-02-09T09:29:03+00:00weekly0.6https://www.medthority.com/news/2015/06/servier-licenses-tas-102--trifluridine-and-tipiracil-hydrochloride--from-taiho-for-europe-and-other-countries-taiho/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2017/12/esmo-immuno-oncology-congress-2017/2024-02-22T15:56:08+00:00weekly0.6https://www.medthority.com/news/2013/01/gsk-files-albiglutide-at-fda-for-treatment-of-type-2-diabetes/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-update-of-the--product-label-for-zilretta-for-treatment-of-osteoarthritis-knee-pain---flexion-therapeutics/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-prolensa--ista-bausch---lomb--for-postoperative-ocular-inflammation-/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iib-iii-of-emixustat-hydrochloride-fails-to-meet-endpoint-in-geographic-atrophy--acucela/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-ii-study-of-itmsc--stem-cells--in-heart-failure-demonstrates-iv-delivery-is-feasible--cardiocell/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2016/06/-fda-accepts-filing-of-cl-108--promethazine-and-hydrocodone-and-acetaminophen--for-the-relief-of-moderate-to-severe-pain---charleston-laboratories-and-daiichi-sankyo-/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2019/11/orion-9-phase-iii-trial-of-inclisiran-meets-primary-endpoints-in-lowering-ldl-c-in-hefh-patients---the-medicines-co/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-alert-for-zecuity--sumatriptan-iontophoretic-transdermal-system--patch--teva/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2017/09/results-of-fourier-study-shows-repatha--evolocumab--reduces-cardiovascular-events-in-patients-with-and-without-diabetes---amgen-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-seebri-neohaler--glycopyrrolate--for-chronic-obstructive-pulmonary-disease--novartis/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2018/05/european-society-of-cardiology--esc---critical-advice-for-families-to-help-heart-patients---7-9-june-in-dublin--ireland/2022-02-08T07:44:51+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-data-in-studies-of-xiaflex-for-peyronie-s-disease-auxilium-pharma/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-extends-date-for-review-of-keytruda--pembrolizumab-for-previously-treated-patients-with-advanced-microsatellite-instability-high--msi-h--cancer---merck-inc-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iv-study-of-livalo--eli-lilly-kowa-pharmaceuticals--meets-end-point-in-patients-with-dyslipidemia/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2012/05/nexavar--bayer-onyx--fails-to-improve-overall-survival-in-mission-study-for-nsclc/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2016/11/chmp-recommends-ofatumumab--arzerra--in-combination-with-fludarabine-and-cyclophosphamide--fc--for-the-treatment-of-relapsed-chronic-lymphocytic-leukemia--novartis---genmab-a-s/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-extends-indication-for-therascreen-egfr-rgq-pcr-kit-in-non-small-cell-lung-cancer---qiagen-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-trial--ono-4538-12--of-opdivo--nivolumab--success-for-treatment-of-previously-treated-advanced--refractory--gastric-cancer--bms-/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-venus-i-trial-of-esmya--ulipristal-acetate--meets-all-endpoints-in-uterine-fibroids--allergan-gedeon-richter/2024-02-09T09:29:14+00:00weekly0.6https://www.medthority.com/news/2017/06/in-phase-iii-iv-studies--praluent--alirocumab--reaches-endpoints-for-dyslipidaemia--sanofi-and-regeneron-pharma/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2017/05/european-commission-grants-standard-marketing-approval-for-fampyra--prolonged-release-fampridine-tablets---to-improve-walking-for-ms-patients-on-the--basis-of-enhance-study--biogen/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iiib-topaz-ii-study-of-viekira-pak--ombitasvir---paritaprevir---ritonavir---dasabuvir--meets-secondary-endoints-in-hepatitis-c--abbvie/2024-02-09T09:29:24+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-obalon-balloon-system-for-obesity--obalon-therapeutics/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2019/06/iqwig-publishes-positive-report-on-use-of-optune-for-glioblastoma---novocure/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-approval-of-ajovy-in-migraine---teva-pharma/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2014/10/abuse-deterrent-formulation-of-zohydro-filed-at-fda-for-severe-pain-control---zogenix/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2016/02/capsugel-and-pulmatrix-collaborate-on-novel-inhaled-therapeutics-for-pulmonary-diseases/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2019/07/statin-use-reduces-mortality-and-stroke-risk-in-dementia-patients/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-abilify-maintena-as-a-treatment-for-schizophrenia/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-jatenzo-for-testosterone-replacement-therapy---clarus-therapeutics/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2019/03/ilc-2019---find-out-more/2024-02-22T15:56:42+00:00weekly0.6https://www.medthority.com/news/2012/04/pivotal-study-of-e-2087--eisai--shows-positive-results-in-treating-epilepsy/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2018/07/astrazeneca-sells-its-european--rights-to-atacand-and-atacand-plus--to-cheplapharm-arzneimittel-gmbh-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-rydapt--midostaurin--for-systemic-mastocytosis--systemic-mastocytosis-with-associated-hematological-neoplasm-or-mast-cell-leukemia--novartis/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-vectibix--panitumumab--in-metastatic-colorectal-cancer-meets-primary-endpoint--amgen/2024-02-09T09:29:35+00:00weekly0.6https://www.medthority.com/news/2013/03/eu--approves-ilaris--novartis--to-treat-gouty-arthritis/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2011/11/byetta--amylin-and-eli-lilly--for-type-2-diabetes-also-has-rapid-and-powerful-anti-inflammatory-action/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2011/11/successful-phase-iii-trial-for-natpara--nps-pharma--for-hypoparathyroidism/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-releases-restrictions-on-avandia-for-type-2-diabetes--gsk/2021-09-24T07:16:28+00:00weekly0.6https://www.medthority.com/news/2014/07/zerenex-meets-endpoints-in-perfected-study-for-treatment-of-hyperphosphatemia---keryx-biopharma/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2018/02/data-presented-to-us-cdc-shows-fluarix-quadrivalent-efficacy-against-influenza-in-young-children---glaxosmithkline-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2015/05/alexion-pharma-to-acquire-synavega-biopharma/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approve-humira--abbott--for-patients-with-moderately-to-severely-active-ulcerative-colitis-/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2014/07/ranger-paclitaxel-coated-pta-balloon-catheter-has-ce-mark-for--pad--boston-scientific--/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-trial-of-plx-3397---pexidartinib--for-treatment-of-giant-cell-tumor-of-the-tendon-sheath-is-suspended-on-advice-of-dmc--daiichi-sankyo---plexxikon-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2013/08/fibrocaps-phase-iii-success-in-phase-iii-trial-for-haemostasis-/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2016/04/launch-of-lal-deficiency-knowledge-centre/2021-11-26T10:41:36+00:00weekly0.6https://www.medthority.com/news/2011/12/olesoxime-trophos-s-a---fails-phase-iii-trial-for-als/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-sixmo-to-treat-opioid-dependence--molteni-farmaceutici/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2018/06/giapreza-filed-with-ema-for-septic-shock-with-hypotension---la-jolla-pharmaceutical-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2019/07/mdna-life-sciences-plans-launch-of-first-test-for-endometriosis-/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2018/11/astrazeneca-provides-update-on-the-phase-iii-mystic-trial-of-imfinzi-and-tremelimumab-in-stage-iv-nsclc-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2012/11/pregabalin-controlled-release--pfizer--success-in-phase-iii-study-in-fibromyalgia/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-accepts-application-for-the-liquid-frozen-version-of-the-mva-bn-for-active-immunization-against-smallpox-in-adults-age-18-years-and-older--bavarian-nordic/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-vyondys-53-injection-for-the-treatment-of-duchenne-muscular-dystrophy--in-patients-amenable-to-skipping-exon-53----sarepta-therapeutics/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-nexavar-for-thyroid-cancer-bayer-healthcare-onyx-pharma/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2019/05/breast-cancer--integrated-care-ahead-of-innovation/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2019/08/xtandi-snda-filed-with-fda-for-metastatic-hormone-sensitive-prostate-cancer---astellas---pfizer/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-cotellic--cobimetinib----zelboraf--vemurafenib--to-treat-braf-v600e-or-v600k-mutation-positive-unresectable-or-metastatic-melanoma--genentech---roche/2024-02-09T09:29:50+00:00weekly0.6https://www.medthority.com/news/2019/11/asahi-kasei-pharma-makes-an-offer-for-veloxis-a-s/2025-10-16T11:26:03+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-issues-complete-response-for-herzuma--trastuzumab-biosimilar-in-treatment-of-gastric-cancer---celltrion-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2013/05/eu-pharmacovigilance-risk-assessment-committee-clears-diane-35--bayer--for-acne/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2014/09/iressa-label-update-allows-circulating-tumour-dna-to-assess-egfr-mutation-status---astrazeneca/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2013/11/ceftolozane-tazobactam-success-in-phase-iii-for-uti-cubist/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2018/03/new-ehra-practical-guide-on-non-vitamin-k-antagonist-oral-anticoagulants-launched/2024-02-22T15:57:15+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---body-remodeling--scalpel-less-techniques-are-increasingly-in-demand/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2017/07/phase-iii-trial-of-keytruda--pembrolizumab--fails-to-meet-primary-endpoint-in-head-and-neck-cancer--merck-inc/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/07/nice-does-not-recommend-darzalex-plus-chemo-for-second-line-use-in-multiple-myeloma---janssen-biotech-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-olumiant--baricitinib-to-treat-moderate-to-severe-ra---eli-lilly/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-approves-wider-indication-for-fibrin-sealant-tisseel--baxter-/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/04/solo-1-and-2-trials-successful-fordupilumab-to-treat-atopic-dermatitis--sanofi---regeneron/2024-02-22T15:57:31+00:00weekly0.6https://www.medthority.com/news/2014/07/positive-results-of-phase-ii-trial-of-prophage-vaccine-in-brain-cancer-agenus/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2016/01/new-phase-iii-trial-announced-as-part-of-fda-resubmission-for-zalviso--sufentanil-sublingual-tablet-system--in-post-operative-pain--acelrx-pharmaceuticals/2024-02-22T15:57:51+00:00weekly0.6https://www.medthority.com/news/2017/03/boston-scientific-acquires-symetis-s-a--and-with-it-acurate-ta-and-acurate-neo-tf-valve-systems/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2018/09/nice-refuses-to-recommend-kymriah-to-treat-diffuse-large-b-cell-lymphoma---novartis/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2017/09/nice-recommends-against-use-of-faslodex--fulvestrant--to-delay-growth-of-estrogen-receptor-positive-breast-cancer--astrazeneca/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2014/12/dyloject-approved-by-fda-for-pain-hospira/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-accepts-filing-of-sbla-for-actemra--tocilizumab--for-the-treatment-of-giant-cell-arteritis--and-grants-priority-review---genetench-roche/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2012/10/-absorb--the-bioresorbable--vascular-scaffold--abbott-vascular--available-in-eu--latin-america-and-asia/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2017/02/first-patient-dosed-in-phase-iii-aim2cerv-trial-evaluating-axalimogene-filolisbac-as-an-adjuvant-therapy-for-high-risk--locally-advanced--carcinoma-of-the-cervix---advaxis/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-does-not-recommend-arzerra--ofatumumab--as-maintenance-therapy-for-patients-with-relapsed-chronic-lymphocytic-leukemia--genmab/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2015/10/successful-phase-ii-trial--cosmic-hf--of-omecamtiv-mecarbil-in-patients-with-chronic-heart-failure--amgen/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2017/06/update-on-regulatory-pathway-for-inno-206--aldoxorubicin--in-soft-tissue-sarcomas--sts-----cytrx-corporation/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-accepts-supplemental-filing-sbla-for-opdivo--nivolumab-dosing-every-four-weeks-for-all-indications---bms/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-zontivity-for-treatment-of-atherothrombotic-events-in-adult-patients-with-a-history-of-myocardial-infarction---merck-inc-/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-study-of-mk-1439--doravirine--met-primary-endpoint-in-hiv-infection--merck-inc/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2017/12/call-to-update-guidelines-on-fertility-in-breast-cancer-following-successful-trial/2021-09-24T07:13:42+00:00weekly0.6https://www.medthority.com/news/2015/09/graspa-ery-asp--human-erythrocytes-encapsulating-l-asparaginase--filed-with-ema-for-acute-lymphoblastic-leukemia--erytech-pharma--/2024-02-09T09:30:03+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-cancels-advisory-committee-meeting-to-review-androxal--enclomiphene--for-treatment-of-hyopgonadism--repros-therapeutics/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2018/04/nejm-publishes-updated-results-for-brineura-treatment-for-children-with-cln2-disease----biomarin/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2018/08/gemcabene-trial-for-pediatric-patients-with-non-alcoholic-fatty-liver-disease--nafld--is-terminated-due-to-unanticipated-problems---gemphire-therapeutics-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2014/08/phase-i-trial-of-pd-01a-vaccine-for-parkinsons-meets-primary-endpoint---affiris/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-braftovi---mektovi-in--metastatic-melanoma-with-a-brafv600e-or-brafv600k-mutation---array-biopharma---pierre-fabre/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/09/lpcn-1021-filed-with-fda-for-hypogonadism--lipocine/2024-02-09T09:30:15+00:00weekly0.6https://www.medthority.com/news/2020/01/apellis-reports-positive-top-line-results-from-phase-iii-pegasus-head-to-head-study-of-pegcetacoplan-compared-to-eculizumab-for-paroxysmal-nocturnal-hemoglobinuria-/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-priority-review-for-zaltrap--regeneron-sanofi--for-colorectal-cancer/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2018/04/motif-bio-initiates-rolling-submission-at-fda-for-iclaprim-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections--absssi--/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2014/03/otezla-success-in-esteem-2-trial-for-psoriasis---celgene/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2020/01/lumoxiti-filed-maa-at-ema-to-treat-hairy-cell-leukemia--innate-pharma/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2017/09/perceval-sutureless-aortic-valve-meta-analysis-is-reviewed-in-innovations-highlighting-perceval-as-a-safe-aortic-valve-replacement-option---livanova/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2016/04/successful-phase-ii-two-year-results-of-checkmate-069-study-of-opdivo--nivolumab--and-yervoy--ipilimumab--combination-in-advanced-melanoma--bms/2024-02-09T09:30:26+00:00weekly0.6https://www.medthority.com/news/2015/08/second-phase-iii-trial--starts-for--hld-200-for-treatment-of-adhd--highland-therapeutics/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2019/09/five-year-outcomes-for-opdivo---yervoy-demonstrate-benefits-in-patients-with-advanced-melanoma---bms/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2016/02/alcon-novartis-acquires-transcend-medical-and-with-it-cypass-micro-stent-for-glaucoma/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2018/08/positive-top-line-results-reported-from-sonics-study-of-recorlev-to-treat-cushing-s-syndrome---strongbridge-biopharma/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2018/12/results-of-echelon-2-phase-iii-trial-of-adcetris-for-cd30-expressing-peripheral-t-cell-lymphomas-is-presented-at-ash-and-published-in-the-lancet---seattle-genetics---takeda/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-vyvanse--shire--as-maintenance-treatment--of-adhd-for-children-and-adolescents/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-snda-for-delstrigo-in-hiv-patients---merck/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2016/11/new-data-from-reduce-lap-hf-clinical-study-of-its-interatrial-shunt-device-in-heart-failure--corvia-medical/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2016/11/uk-s-nice-recommends-use-of-halaven--eribulin--for-locally-advanced-or-metastatic-breast-cancer--eisai/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-rejects-provenge-as-a-treatment-for-prostate-cancer--dendreon/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2016/06/aries-flu-a-b---rsv-assay-receives-eu-ce-mark-approved-for-influenza-and-rsv--luminex-corp-/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2012/06/avandia-nyracta--glaxo-smith-kline--associated-with-diabetic-macular-oedema-in-type-2-diabetes-patients/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-recommends-semglee-insulin-glargine-biosimilar--for-treatment-of-diabetes-mylan---biocon/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2013/03/study-reveals-mechanism-providing-benefit-of-omega-3-fatty-acids-on-cardiovascular-health/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2019/07/gilead-presents-new-data-on-biktarvy-for-the-treatment-of-hiv-in-women-and-in-virologically-suppressed-patients-with-known-resistance-/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2019/05/biomarin-announced-that--valoctocogene-roxaparvovec--for--severe-hemophilia-a-achieved-pre-specified-clinical-criteria-for-regulatory-review-in-the-u-s--and-europe-/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2016/12/nice-recommends-keytruda--pembrolizumab--for-second-line-treatment-of-nsclc---merck-inc-/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-iii-success-for-cymbalta--eli-lilly--for-peripheral-neuropathy/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2014/06/new-results-from-phase-iii-trial-of-victoza-in-t2d-novo-nordisk/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-approves-opdivo--nivolumab--for-classical-hodgkin-lymphoma--chl----bms/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2012/08/benefit-assessment-finds-no-clear-advantage-of-halaven--eisai--for-breast-cancer-patients/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2019/03/patency-2-phase-iii-trial-of-vonapanitase-fails-to-meet-primary-endpoint-in-chronic-kidney-disease---proteon-therapeutics/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-symdeko-to-treat-cystic-fibrosis-f508del-mutation---vertex-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-perjeta--genentech-roche--for-combination-use-in-metastatic-breast-cancer/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2012/01/intuniv--shire--shows-positive-response-for-children-with-adhd/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2016/01/ivig-sn--immunoglobulin-g-intravenous--filed-with-fda-for-primary-immunodeficiency-diseases--green-cross/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-rn-316--bococizumab--trials-spire-hr-and-spire-fh-meet-endpoints-for-dyslipidaemia--pfizer/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2015/04/success-for-dalvance--dalbavancin--in-dur-001-303-study-for-absssi--actavis/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approval-of-tibsovo-to-treat-aml-is-based-on-study-ag120-c-001--nct02074839---agios-pharma-/2024-07-26T10:15:17+00:00weekly0.6https://www.medthority.com/news/2017/01/amgen-and-immatics-biotechnologies-announce-agreement-to-develop-immunotherapies-for-cancer/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-accepts-bla-for-human-4-factor-prothrombin-complex-concentrate--csl-behring--for-acute-bleeding/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-epidiolex--cannabidiol--meets-primary-endpoint-in-lennox-gastaut-syndrome--gw-pharmaceuticals/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2019/07/eu-label-for-spinraza-updated-in-spinal-muscular-atrophy/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-be-ready-study-of-ucb-4940-met-primary-endpoints-in-plaque-psoriasis---ucb/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2017/05/who-launches-pilot-project-for-prequalifying-biosimilar-medicines-/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-tookad--padeliporfin--for-adenocarcinoma-of-the-prostate---steba-biotech-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2014/12/disappointing-phase-iii-data-for-kadcyla-in-breast-cancer-genentech-roche-/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2014/02/e-7080-meets-primary-endpoint-in-phase-iii-trial-for-thyroid-cancer-eisai/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-committee-recommends-approval-of-dotarem--guerbet-sa--as-mri-contrast-agent/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2015/10/positive-trial-results-for-incruse-ellipta--umeclidinium--in-copd--glaxosmithkline/2024-02-22T15:58:29+00:00weekly0.6https://www.medthority.com/news/2018/11/jama-publishes-results-of-help-trial-of-takhzyro-for-hereditary-angioedema--shire-takeda/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2011/09/alimta-maintenance-therapy-positive-in-elderly-nsclc-patients/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2015/11/astellas-sells-its-global-dermatology-business-to-leo-pharma-for-euros-675-million--the-sale-includes-protopic--except-in-japan-/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2015/03/nice-now-recommends-arzerra--ofatumumab---chlorambucil-for-cll-novartis/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2016/06/positive-results-from-checkmate-205-study-for-opdivo--nivolumab--in-treatment-of-classical-hodgkin-lymphoma--bms/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2019/08/the-medicines-company-reports-on-proposed-release-of-data-from-orion-11--orion-9-and-orion-10-trials-of-inclisiran-to-treat-hypercholesterolemia-/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2014/09/talimogene-laherparepvec-is-filed-at-ema-for-melanoma--amgen/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2019/08/kisqali-significantly-prolongs-life-in-women-with-hr--her2--advanced-breast-cancer/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2013/10/mitraclip--abbott--is-fda-approved-for-mitral-regurgitation/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-signifor-lar-to-treat-acromegaly-where-surgery-is-not-an-option--novartis/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2016/03/ixekizumab-superior-to-etanercept-and-placebo-in-uncover-2-and-uncover-3-phase-iii-trials-for-psoriasis--eli-lilly-/2024-02-22T15:58:46+00:00weekly0.6https://www.medthority.com/news/2018/10/feraccru-filed-with-fda-for-iron-deficiency---shield-therapeutics-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2010/09/menerba-from-bionovo-enters-phase-iii-for-menopause/2021-09-24T07:01:27+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-votubia--everolimus--to-treat-partial-onset-seizures--with-or-without-secondary-generalization-associated-with-tuberous-sclerosis-complex---novartis/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2013/11/talimogene-laherparepvec--amgen--successful-pivotal-trial-for-melanoma/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2016/09/teva-to-acquire-world-rights--ex-asia-to-fasinumab-from-regeneron-to-treat-osteoarthritis-pain-chronic-low-back-pain-/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2014/12/analysis-of-phase-iii-data-for-novoeight-in-haemophilia-a--novo-nordisk/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2017/05/mental-awareness-week-2017-asks--are-you-thriving-or-surviving--/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-krintafel-for-prevention-of-relapse-of-plasmodium-vivax--p--vivax--malaria---gsk----medicines-for-malaria-venture-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2014/11/nice-recommends-approval-of-pradaxa-for-dvt-and-pe-boehringer/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2019/09/entrust-af-pci-study-of-lixiana-shows-non-inferiority-in-atrial-fibrillation--and-is-published-in-the-lancet---daiichi-sankyo/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2019/10/swedish-orphan-biovitrum-ab--publ---sobi--has-entered-into-an-expanded-agreement-with-sanofi-to-exercise-early-opt-in-for-the-development-and-commercialisation-of-bivv-001-for-the-treatment-of-hemophilia-a-/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-trial-of-fmx-101-meets-endpoints-in-acne---foamix-pharma-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2016/02/zilretta--sustained-release-triamcinolone-acetonide--shows-efficacy-in-phase-iii-trial-for-severe-osteoarthritis-knee-pain--flexion-therapeutics/2024-02-09T09:25:06+00:00weekly0.6https://www.medthority.com/news/2018/08/emergent-biosolutions-inc--acquires-paxvax-and-its-vaccines-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2011/11/radiotherapy-combined-with-androgen-deprivation-therapy-improves-survival-in-prostate-cancer-patients/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2014/06/the-lancet-publishes-successful-study-of-nebivolol---valsartan-in-hypertension---forest-labs/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2016/04/benjorna--delayed-release-and-extended-release-methylphenidate-capsules--meets-endpoints-for-adhd-patients-in-phase-iii--hld200--107-trial--highland-therapeutics-/2024-02-09T09:25:19+00:00weekly0.6https://www.medthority.com/news/2012/03/bolero-2-trail-shows-bonbe-improvement-with-afinitor-aromasin-combination-in-breast-cancer/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-phase-iii-trial-of-tookad-soluble--padeliporfin-di-potassium---to-treat-early-localized-prostate-cancer---steba-biotech/2025-02-03T14:57:18+00:00weekly0.6https://www.medthority.com/news/2015/12/updated-phase-iii-results-for-adcetris--brentuximab-vedotin--in-hodgkin-lymphoma-post-transplant--takeda/2024-02-09T09:26:03+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-cometriq-for-thyroid-cancer-exelixis-inc-/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2017/11/five-year-data-from-prevail-study-of-watchman-laac-shows-safety-and-effectiveness-in-stroke-risk-reduction---boston-scientific-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-graspall-trial-of-graspa-in-all-meets-endpoints---erytech/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2018/10/novartis-agrees-licence-of-early-stage-antibiotics-to-boston-pharmaceuticals-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2018/01/european-commission-approves-fasenra-to-treat-adult-patients-with-severe-eosinophilic-asthma----astrazeneca-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-and-iv-study-data-shows-benefits-of-cimzia-in-axial-spondyloarthrtis---ucb/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2018/11/eisai-launches-disease-awareness-campaign-on-advanced-breast-cancer/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2018/10/study-1489-shows-96-week-results-biktarvy--in-adults-new-to-hiv-therapy---gilead-sciences/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2020/01/aquestive-therapeutics-receives-fda-response-to-citizen-s-petition-that-the-fda-stay-approval-of-a-nda--for-valtoco---diazepam-nasal-spray--submitted-by-neurelis--inc-/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-kyprolis--onyx-pharma--for-multiple-myeloma/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2017/11/new-data-from-secure-trial-of-twirla--contraceptive-patch--reported-a-decrease-in-bleeding-and-or-spotting-episodes-----agile-therapeutics-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2016/02/federal-appeals-court-rules-patents-for-oxycontin-are-invalid--purdue-pharma-/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-results-in-phase-iii-analysis-of-cometriq--cabozantinib--in-renal-cell-carcinoma--exelixis/2024-02-09T09:26:18+00:00weekly0.6https://www.medthority.com/news/2015/04/successful-phase-iii-trial-for-kpi-121-for-pain-management-after-cataract-surgery--kala-pharma/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2014/04/meda-ab-rejects-takeover-offer-from-mylan-inc--/2025-10-16T10:56:03+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-c-edge-co-star-trial-of-elbasvir---grazoprevir-shows-success-in-hepatitis-c-patients-who-receive-opioid-agonist-therapy--merck/2024-02-09T09:26:26+00:00weekly0.6https://www.medthority.com/news/2019/11/biomarin-pharma-hassubmitted-a-maa-to-the-european-medicines-agency-for-valoctocogene-roxaparvovec-for-adults-with-severe-hemophilia-a-/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2019/12/merck-inc---to-acquire-arqule-inc--and-with-it-arq-531---oral-bruton-s-tyrosine-kinase-inhibitor-to-treat-b-cell-malignancies/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2013/03/takeda-files-vedolizumab-at-ema-for-crohns-and-ulcerative-colitis/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2017/06/vns-therapy-epilepsy-seizure-devices--aspire-hc-and-aspire-sr--are-fda-approved-for-mri-scans---livanova/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-alecensa--alectinib--to-treat-patients-with-advanced-anaplastic-lymphoma-kinase--alk--positive-non-small-cell-lung-cancer--genentech---roche-/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2011/11/rasitrio--novartis--combination-is-eu-approved-for-hypertension/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-verzenios--in-metastatic-breast-cancer---eli-lilly-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2016/04/kamada-files-maa-at-ema-for-inhaled-alpha-1-antitrypsin--aat--therapy-/2022-09-14T13:29:13+00:00weekly0.6https://www.medthority.com/news/2012/01/gilenya-novartis--patients-with-multiple-sclerosis-to-be-monitored-after-first-dosing/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2015/04/ce-mark-for-eyeart-software-for---automatic-detection-of-diabetic-retinopathy--eyenuk-inc-/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2019/05/kalytera-announces-data--elucidating-cbd-s-mechanisms-of-action-in-prevention-of-gvhd-/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2012/02/first-trial-of-leish---f3---gla-se-for-leishmaniasis/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii--clarity-ad-study-301--of-ban-2401-is-initiated-for-early-alzheimer-s-disease--eisai---biogen-/2024-10-15T08:02:05+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-grants-priority-review-to-sbla-for-keytruda-in-first-line-pd-l1-nsclc---merck-inc-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2018/12/edsivo-filed-with-fda-for-vascular-ehlers-danlos-syndrome---acer-therapeutics-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2015/11/publication-of-cardiomems-hf-system-long-term-effectiveness-in-reducing-heart-failure-hospitalisations-published-in-the-lancet--st-jude-medical/2025-02-03T14:56:50+00:00weekly0.6https://www.medthority.com/news/2012/04/neupro--ucb--fda-approved-for-advanced-parkinsons-and-rls/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2018/11/european-commission-approves-luxturna-to-treat--patients-with-vision-loss-due-to-a-genetic-mutation-in-both-copies-of-the-rpe65-gene---novartis/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2013/06/bms-success-with-nivolumab---ipilimumab-in-melanoma/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2018/12/additional-analysis-of-phase-iii-solar-1-trial-of-byl-719---fulvestrant--pik3ca-mutated--hr--her2--advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iiia-trials-of-oral-semaglutide-show-efficacy-in-type-2-diabetes---novo-nordisk/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-combination-treatment-volibris--ambrisentan--and-adcirca--tadalafil--for-pulmonary-arterial-hypertension--glaxo-smith-kline-gilead-eli-lilly/2024-02-06T15:21:18+00:00weekly0.6https://www.medthority.com/news/2016/08/sanofi-provides-update-to-fda-on-application-for-combination-basal-insulin-glargine-100-units-ml-and-glp-1-receptor-agonist-lixisenatide-to-treat-type-2-diabetes-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-advisory-committee-to-review-sugammadex-again-on-6-november-2015--merck/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2016/06/teva-suspends-sales-of-zecuity--sumatriptan-iontophoretic-transdermal-system--in-us-/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-trulicity-for-treatment-of-type-2-diabetes--eli-lilly/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approves-repatha--evolocumab--to-treat-uncontrolled-cholesterol--amgen/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-prilocaine-lidocaine-plethora-to-treat-premature-ejaculation-plethora/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-accepts-nda-for--zanubrutinib-to-treat-mantle-cell-lymphoma---beigene-ltd-/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-reach2-study-of-jakafi-meets-endpoints-in-acute-graft-versus-host-disease---incyte/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2012/11/phase-iii-trial-of-urocidin--endo-pharma--for-bladder-cancer-is-abandoned/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-announces-at-ash-results-of-pivotal-transcend-nhl-001-study-for--liso-cel-to-treat-large-b-cell-lymphomas-/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2017/06/alecensa--alectinib--significantly-reduced-the-risk-of-disease-worsening-or-death-by-more-than-half--53---compared-to-first-line-treatment-for-people-with-alk-positive-advanced-nsclc--genentech-roche-/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2019/09/naxos-real-world-study-of-eliquis-shows-reduced-bleeding-and-stroke-in-non-valvular-atrial-fibrillation---bms-pfizer/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2015/06/gazyva--obinutuzumab--plus-bendamustine-results-of-phase-iii-gadolin-study-in-non-hodgkin-s-lymphoma--genentech---roche-/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2018/08/complete-response-letter-for-waylivra--a-drug-to-treat-familial-chylomicronemia-syndrome----ionis-pharma---akcea-therapeutics-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2018/12/bc-3781-filed-with-fda-for-community-acquired-bacterial-pneumonia---nabriva-therapeutics-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2015/09/third-phase-iii-trial-of-baricitinib-shows-superiority-to-methotrexate-in-rheumatoid-arthritis--eli-lilly---incyte/2024-02-13T10:55:41+00:00weekly0.6https://www.medthority.com/news/2012/06/actemra--genentech-roche--success-in-adacta-study-in-ra/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2016/11/comparison-of-cimzia--certolizumab-pegol--to-humira--adalimumab--in-adults-with-moderate-to-severe-rheumatoid-arthritis-fails-to-meet-primary-endpoint-for-superiority--ucb/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2015/05/saril-ra-target-study-of-sarilumab-positive-phase-iii-results-for-rheumatoid-arthritis--sanofi---regeneron/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2012/06/syncria--glaxosmithkline--shows-mixed-results-in-phase-iii-studies-of-type-2-diabetes-patients/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2014/12/merck-inc--acquires-cubist-pharma-for--8-4-billion/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---obesity--new-hopes-to-improve-non-alcoholic-fatty-liver-disease--nafld-/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-spirit-extension-study-shows-taltz-improvements-for-psoriatic-arthritis---eli-lilly-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2016/10/final-data-from-progress-study-of-orkambi--lumacaftor---ivacaftor-for-cystic-fibrosis-patients-with-f508del-mutation---vertex/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2012/09/evidence-of-benefit-of-promitor--tate---lyle--for-nutritional-health/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-issues-complete-response-letter-for-rb-103-for-migraine-redhill-biopharma/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2015/01/pfizer-acquires-control-of-redvax/2025-10-16T11:06:18+00:00weekly0.6https://www.medthority.com/news/2015/09/insite-vision-files-nda-for-bromsite--0-075--bromfenac--treatment-of-inflammation-and-prevention-of-ocular-pain-following-post-cataract-surgery/2024-02-13T09:41:37+00:00weekly0.6https://www.medthority.com/news/2014/05/lundbeck-acquires-chelsea-therapeutics-for--658-million-and-with-it-northera-for-neurogenic-orthostatic-hypotension/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2012/12/ptc-therapeutics-submits-ptc-124-to-the-ema-for-treatment-of-patients-with-duchenne-muscular-dystrophy-/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-osmolex-er-for-parkinson-s-disease---osmotica-pharma-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2015/08/eloctate--antihemophilic-factor--recombinant---fc-fusion-protein--showed-low-bleeding-rates-in-aspire-study--biogen---sobi/2024-02-13T09:46:00+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-trial-of-spn-812-meets-primary-endpoint-in-adhd---supernus-pharmaceuticals-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-study--study-1504--for-zx-008-meets-primary-endpoint-in-dravet-syndrome---zogenix-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2018/01/novartis-to-licence-luxturna-from-spark-therapeutics-for-marketing-outside-the-usa-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2014/03/study-of-senza-for-pain-published-in-pain-medicine---nevro-corp/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-draft-guidance-now-approves-xalkori-in-ros1--non-small-cell-lung-cancer---pfizer-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2017/01/ipsen-buys-oncology-therapies-from-merrimack-pharma/2025-10-16T11:29:56+00:00weekly0.6https://www.medthority.com/news/2018/08/gemphire-therapeutics-provides-overview-of-gemcabene-and-its-clinical-trials-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2017/06/positive-phase-ii-trial-of--subcutaneous-semaglutide-to-treat-obesity--novo-nordisk/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2015/03/tas-102-filed-with-fda-for-colorectal-cancer-taiho-pharma/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2014/01/publication-of-trial-of-evk-001-for-diabetic-gastroparesis/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2015/12/roca-blood-test-and-uk-collaborative-trial-of-ovarian-cancer-screening--abcodia-ltd-/2024-02-13T09:46:18+00:00weekly0.6https://www.medthority.com/news/2019/07/icer-report-on-desensitization-treatments-for-peanut-allergy-is-contested-by-aimmune-therapeutics-/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2011/10/eu-approves-prevnar-13-for-pneumococcal-disease-in-adults-aged-50-years-and-older/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2013/10/savor-study-results-for-onglyza-in-t2d/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-eu-approval-of-zyclara--meda--for-actinic-keratoses/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2015/05/successful-pivotal-trial-for--orbera-intragastric-balloon-for-weight-loss--apollo-endosurgery/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-study-of-emend--fosaprepitant-dimeglumine--shows-benefits-in-chemotherapy-induced-nausea-and-vomiting-merck/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2013/11/mesenchymal-precursor-cell-treatment--mesoblast--enters-phase-iii-heart-failure-study/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-interim-results-from-impower132-study-met-its-co-primary-endpoint-of-progression-free-survival-for-advanced-nsclc---roche/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2017/04/eliminate-af-study-will-explore-the-safety-and-efficacy-of-edoxaban---lixiana--savaysa--versus-a-vitamin-k-antagonist-in-patients-with-atrial-fibrillation--af--undergoing-catheter-ablation--daiichi-sankyo/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2019/08/eu-approves-imbruvica-plus-rituxan-for-waldenstr-m-s-macroglobulinemia---janssen-pharma/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-braftovi-plus-mektovi-for-the-treatment-of-adult-patients-with-unresectable-or-metastatic-melanoma-with-a-brafv600-mutation--array-biopharma-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-trikafta-combination-to-treat-cystic-fibrosis-in-people--who-have-at-least-one-f508del-mutation-in-the-cystic-fibrosis-transmembrane-conductance-regulator--cftr--gene----vertex-pharma/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-xyosted-for-testosterone-replacement--antares-pharma/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2020/02/ema-approves-accelerated-process-of-assessment-for-gsk-2857916-in-relapsed-or-refractory-multiple-myeloma---glaxosmithkline/2021-09-24T07:12:00+00:00weekly0.6https://www.medthority.com/news/2019/02/fintepla-filed-with-fda-and-maa-for-dravet-syndrome---zogenix/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2018/06/fourteen-months--results-from-juliet-trial-of-kymriah-for-patients-with-dlbcl---novartis/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-cobas-taqscreen-mpx-test-v2-0-test-for-hiv--hcv-and-hbv/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-expands-use-of-vibativ--theravance--to-treat-gospital-acquired-pneumonia/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2016/12/flamel-technologies-sa-initiates-rest-on-phase-iii-clinical-trial-of-ft-218-to-treat-cataplexy-in-patients-with-narcolepsy-/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2013/05/eu-approves-xarelto--bayer--for-acute-coronary-syndrome/2021-09-24T07:16:20+00:00weekly0.6https://www.medthority.com/news/2018/10/lumoxiti-rights-in-us-and-eu-licensed-to-innate-pharma---astrazeneca/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---pre-dialysis-blood-pressure-measurements-misclassify-hypertension-in-about-1-3-of-hemodialysis-patients/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-kadcyla-for-adjuvant--after-surgery--treatment-of-people-with-her2-positive-early-breast-cancer--genentech-roche/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2018/03/results-from-the-apollo-phase-iii-trial-of-aln-ttr02-in-hereditary-attr--amyloidosis-show-benefits-in-cardiac-system---alnylam-pharma-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2017/06/new-blood-test-detects-stroke-and-heart-attack-risk-in-lupus-patients-with-no-cardiovascular-symptoms/2024-07-01T12:14:24+00:00weekly0.6https://www.medthority.com/news/2018/07/successful-phase-iii-lock-it-100-study-of-neutrolin-to-reduce-the-risk-of-occurrence-of-catheter-related-bloodstream-infections---cormedix-inc-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2013/02/thermodox--celsion--fails-phase-iii-trial-for-liver-cancer/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-committee-votes-against-xarelto-for-acs-janssen-pharma/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2009/04/news355.json_2021-09-24T07:01:27+00:00weekly0.6https://www.medthority.com/news/2016/02/plecanatide-is-filed-nda-at-fda-to-treat-chronic-idiopathic-constipation--cic---synergy-pharma/2021-09-24T07:09:03+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-blum-trial-of-cm-at-shows-symptom-inprovements-in-autism---curemark-llc/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-accepts-snda-for-recarbrio-in-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia---merck-inc/2021-09-24T07:12:01+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-approval-of-cinqaero--reslizumab--as-add-on-treatment-in-adult-patients-with-severe-eosinophilic-asthma--teva/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2015/05/results-using-alpha-ims-subretinal-implant-for-retinitis-pigmentosa-published-in-vision-research-retina-implant/2024-02-09T10:03:18+00:00weekly0.6https://www.medthority.com/news/2011/11/pro-feiba-study-success-in-prophylaxis-in-haemophlia-a-patients/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-eloquent-2-study-of-empliciti--elotuzumab--plus-lenalidomide-dexamethasone-shows-continued-efficacy-in-multiple-myeloma--bristol-myers-squibb/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2019/02/alks-5461-receives-complete-response-letter-for-adjunctive-treatment-of-major-depressive-disorder--alkermes/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2016/08/shire-launches-vonvendi---von-willebrand-factor--recombinant---in-the-us-for-adults-living-with-von-willebrand-disease--/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-remote-programming-via-telemedicine-of--nucleus-cochlear-implant-system---cochlear-corporation-/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-lynparza-as-maintenance-treatment-of-patients-with-brcam-advanced-ovarian-cancer--astrazeneca---merck-inc-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-votubia--novartis--for--renal-angiomyolipoma/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-amzeeq-to-treat-severe-acne---foamix/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2019/02/full-dataset-for-phase-ii-iii-trial-of-arimoclomol-in-niemann--pick-disease---orphazyme-a-s/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2013/07/eu-approval-for-lucentis--novartis--to-treat--choroidal-neovascularization-/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2018/05/new-data-for-brolucizumab-from-hawk-and-harrier-trials-for-neovascular-age-related-macular-degeneration---novartis-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2013/10/zilver-ptx--cook-medical--shows-positive-data-at-4-years-in-pad-trial/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2015/07/nice-recommends-moventig--naloxegol--for-treatment-of-opioid-induced-constipation--astrazeneca/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-eliquis-for-deep-vein-thrombosis-and-pulmonary-embolism--bms---pfizer/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-for-review-nda-for-pb-272--neratinib--to-treat-early-stage-her2-overexpressed-amplified-breast-cancer--puma-biotechnology/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-data-on-cnto-1959--guselkumab--in-plaque-psoriasis-meets-co-primary-endpoints--janssen/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-bydureon-bcise-prolonged-release-suspension-for-injection-in-pre-filled-pen-to-treat-type-2-diabetes---astrazeneca/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2018/09/allergan-to-acquire-bonti-inc--and-with-it-eb-001/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-dupixent-to-treat-adults-with-severe-chronic-rhinosinusitis-with-nasal-polyposis--sanofi/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-initiated-for-imipenem-cilastatin-relebactam--to-treat-intra-abdominal-infections--merck/2024-02-09T10:03:42+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-results-for-vosaroxin-and-cytarabine-in-acute-myeloid-leukemia-published-in-lancet-oncology--sunesis-pharma/2024-02-09T10:04:03+00:00weekly0.6https://www.medthority.com/news/2013/10/proleukin--prometheus-labs--recommended-for-treating-melanoma/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-adcetris---chemotherapy-for-previously-untreated-systemic-anaplastic-large-cell-lymphoma-or-other-cd30-expressing-peripheral-t-cell-lymphomas----seattle-genetics/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2012/06/obesity-drug-lorqess--eisai--shows-positive-trial-results-/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-accepts-submission-to-expand-approval-of-feraheme--ferumoxytol--to-all-adults-with-iron-deficiency-anemia--amag-pharmaceuticals-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-study-of-zx-008-showed-robust-anti-seizure-activity-in-dravet-syndrome---zogenix-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2019/12/follow-up-of-maia-trial-of-darzalex----lenalidomide----dexamethasone-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-ineligible-are-presented-at-ash-meeting----janssen-biotech---genmab-a-s/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-expand-approval-for-healicoil-pk--smith-nephew--for-joint-repairs---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-sakurasky-study-shows-sa-237-cuts-risk-of-relapse-in-neuromyelitis-optica---chugai-pharma-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2015/04/success-for-inotuzumab-ozogamicin-in-phase-iii-ino-vate-all-study-in-all--pfizer/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2015/06/magic-phase-iii-study-success-for-sustol--granisetron-injection--extended-release--for-cinv--heron-therapeutics/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2017/01/results-of-harmony-ctp-phase-iii-trial-of-wakix--pitolisant--in-narcoleptic-patients-published-in-lancet-neurology--bioprojet-pharma/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2015/02/phase-iii-trial-of-octreolin-meets-end-point-in-acromegaly-chiasma/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2017/11/valeant-phama-sells-sprout-pharma-to-its-former-shareholders/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-itca-650---continuous-subcutaneous-exenatide--meets-all-endpoints-versus-januvia-in-type-2-diabetes--intarcia-therapeutics/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2013/03/pegasys--roche--european-indication-expanded-by-ema-in-hepatitis-c-to-include-to-children/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-solo-2-trial-of-lynparza--olaparib--shows-pfs-improvement-in-ovarian-cancer--astrazeneca/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-positive-for-yervoy---opdivo-combination-to-treat-first-line-renal-cell-carcinoma----bms/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2019/09/brilinta-reduced-the-risk-of-cardiovascular-events-in-patients-with-coronary-artery-disease-and-type-2-diabetes-in-phase-iii-themis-trial--astrazeneca/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2015/08/clovis-oncology-files-rociletinib-at-ema-for-the-treatment-of-adult-patients-with-mutant-egfr-nsclc-with--the-egfr-t790m-mutation--/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2015/03/sanofi-announces-elixa-study-results-for-lyxumia--lixisenatide--cardiac-outcomes-study-in-type-2-diabetes-patients/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2013/09/study-shows-no-cv-risk-with-nesina-vipidia-for-type-2d/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2016/03/ema-review-into-direct-acting-antivirals-used-for-treating-chronic--long-term--hepatitis-c---daklinza--exviera--harvoni--olysio--sovaldi-and-viekirax--/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2017/09/thrombogenics-nv-regains-rights-to-jetrea--ocriplasmin---a-treatment-for-vitreomacular-adhesion-and-vitreomacular-traction--from-novartis-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-resorce-trial-of-stivarga--regorafenib--reports-overall-survival-improvements-in-unresectable-hepatocellular-carcinoma--bayer-healthcare-/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2017/12/positive-phase-iv-trial-results-for-tudorza-pressair-in-copd-patients-with-cv-disease---astrazeneca---circassia-pharma/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2014/09/opdivo-has-priority-review-in-us-for-advanced-melanoma-and-breakthrough-designation-and-accelerated-assessment-at-ema--bms---ono-pharma/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2018/06/global-phase-iii-trials-of-lanabecestat-in-alzheimers-disease-discontinued---astrazeneca---eli-lilly-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-freedom-ev-study-of-orenitram-meets-primary-endpoint-in-pulmonary-arterial-hypertension---united-therapeutics/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2016/08/successful-phase-iii-data-for-voretigene-neparvove-for-potential-treatment-of-inherited-retinal-disease---spark-therapeutics-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2015/11/biosense-webster-acquires-coherex-medical-inc-and-with-it-the-coherex-wavecrest-left-atrial-appendage--laa--occlusion-system/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-advisory-committee-recommends-by-14-3-approval-of-vantrela-er--hydrocodone-bitartrate-extended-release--for-the-management-of-severe-pain--teva/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-extension-for-relistor-in-opioid-induced-constipation---salix-pharma/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2013/03/mri-guided-focal-laser-ablation-system--visualase--shows-promise-in-patients-with-prostate-cancer/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-approves-votubia--everolimus--as-adjunctive-treatment-for-partial-onset-seizures-associated-with-tuberous-sclerosis-complex--novartis/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2019/12/chmp-recommends-approval-of-expansion-of-use-of-erleada-in-metastatic-hormone-sensitive-prostate-cancer---janssen-biotech/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2016/06/leader-trial-shows-victoza--liraglutide--significantly-reduced-cv-events-in-type-2-diabetes-patients-and-is-published-in-nejm---novo-nordisk/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2016/04/janssen-discontinues-development-of-fulranumab-in-osteoarthritis-pain-and-returns-rights-to-amgen--/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2015/08/update-to-label-of-brintellix--vortioxetine--for-major-depressive--disorder-filed-with-fda--takeda-lundbeck/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-drugs-advisory-committee-recommends-removal-of-neuropsychiatric-adverse-events-from-boxed-warning-for-chantix--varenicline----pfizer/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2013/01/positive-data-from-phase-ii-trial-of-tolenix--theravida---for-treatment-of-overactive-bladder/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2012/05/nice-recommends-tarceva--roche--for-nsclc/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-lcp-tacro--veloxis-pharma--meets-primary-endpoint-in-kidney-transplant-patients/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2014/04/three-phase-ii-trials-of-sovaldi-for-hcv-report-positive-results---gilead/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-issues-complete-response-letter-relating-to-mycapssa--octreotide--for-maintenance-treatment-of-acromegaly--chiasma/2021-09-24T07:10:41+00:00weekly0.6https://www.medthority.com/news/2013/10/veltuzumab-rights-return-from-takeda-to-immunomedics/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2011/07/fda-supply-complete-response-letter-for-intermezzo/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-advisory-committee-to-review-alis-to-treat-nontuberculous-mycobacterial--lung-disease---insmed-inc-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-octaplas-lg--octapharma--coagulation-factor/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2018/11/in-phase-iii-keynote-181-trial--keytruda-meets-primary-endpoint-in-oesophageal--cancer---merck-inc-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2017/04/4-in-10-men-may-not-be-receiving-adequate-prostate-cancer-treatment-in-england/2024-02-22T16:00:54+00:00weekly0.6https://www.medthority.com/news/2015/11/interim-analysis-shows-benefits-of-pradaxa--dabigatran-etexilate-mesylate--in-reducing-stroke--boehringer-ingelheim/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-accepts-snda-for-gattex-for-pediatric-patients-with-short-bowel-syndrome---shire-plc/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2019/10/eu-approves-dupixent-for-chronic-rhinosinusitis-with-nasal-polyposis---sanofi/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-issues-complete-response-letter-to-sbla-for-opdivo--nivolumab--in-untreated-metastatic-melanoma--bms/2024-02-09T10:04:16+00:00weekly0.6https://www.medthority.com/news/2013/10/lundbeck-otsuka-initiate-phase-iii-trial-for-lu-ae-58054-in-alzheimers-disease/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-genvoya--elvitegravir--cobicistat--emtricitabine--and-tenofovir-alafenamide--for-hiv--gilead-sciences/2024-02-09T10:04:30+00:00weekly0.6https://www.medthority.com/news/2016/08/leader-study-of-victoza--liraglutide--shows-some-risks-for-diabetic-patients-with-heart-failure---novo-nordisk/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2012/12/nice-recommends-revolade--gsk--for--itp/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2014/09/four-phase-iii-trials-of-sar-236553-meet-endpoints-for-hypercholesterolemia-sanofi-regeneron/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2018/01/cmr-1/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2018/04/allergan-does-not-intend-to-make-an-offer-for-shire-plc-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-fexeric--ferric-citrate-coordination-complex--for-hyperphosphatemia--keryx-biopharmaceuticals/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2020/01/the-pdufa-date-for-fda-review-of-ocaliva-to-treat-nash-is-extended-to-26-june-2020---intercept-pharma/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2012/10/novartis-files-qva-149-in-eu-for-copd/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2019/12/bms---acceleron-pharma-provide-update-on-fda-advisory-committee-for-reblozyl-to-treat-myelodysplastic-syndromes-/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2019/11/ferring-launches-new-company--fergene--to-focus-on-development-of-nadofaragene-firadenovec-to-treat--non-muscle-invasive-bladder-cancer-/2024-11-12T13:40:45+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approve-dymista--meda-ab--for-seasonal-allergic-rhinitis/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2018/03/nice-reverses-earlier-decision-to-support-use-of-roactemra-in-giant-cell-arteritis---roche-chugai-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2015/10/new-data-for-tecfidera---dimethyl-fumarate--presented-at-ectrims-showing-reduction-in-relapses-and-reduction-of-inflammation-in-ms-patients-biogen/2024-02-09T10:04:39+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-venclexta---grazyva-to-treat-previously-untreated-chronic-lymphocytic-leukaemia/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2016/03/atlantic-healthcare-plc-initiates-phase-iii-study-of-alicaforsen-enema-to-treat-pouchitis-/2024-02-09T10:04:55+00:00weekly0.6https://www.medthority.com/news/2015/09/bayer-initiates-phase-iii-trial-of-xarelto--rivaroxaban--to-reduce-the-risk-of-major-thrombotic-vascular-events-in-patients-with-symptomatic-peripheral-artery-disease-undergoing-revascularisation/2025-02-03T14:55:12+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-reschedules-review-date-for-sugammadex--merck-inc-/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2013/09/study-of-avp-825-for-migraine-published-in-headache/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2016/11/noqdirna--oral-lyophilisate-desmopressin--launched-in-uk-for-nocturia-due-to-idiopathic-nocturnal-polyuria--ferring-pharma/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2017/02/the-fda-has-accepted-for-review-two-supplemental-biologics-license-applications--sblas--for-keytruda--pembrolizumab---for-treatment-of--patients-with-locally-advanced-or-metastatic-urothelial-cancer---merck-inc-/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2014/06/sovaldi-and-gs-5885-combo-meets-primary-endpoint-in-phase-iii-hcv-study---gilead-sciences-/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-juniper-study-for--verzenio--abemaciclib---as-monotherapy-in-kras-mutated--nsclc-did-not-meet-its-primary-endpoint---eli-lilly-/2024-07-26T10:14:55+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approve-magellan-robotic-system--hansen-medical--for-vascular-surgery/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2014/06/abt-450-r--abt-267--abt-333-combo-for-hepatitis-c-has-priority-review-at-fda---abbvie/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2013/11/mundipharma-to-market-lodotra-for-ra-in-middle-east-and-africa-/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2018/10/enbrel-monotherapy-combination-superior-to-methotrexate-monotherapy-for-treat-psoriatic-arthritis----amgen/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2017/10/ultragenyx-pharmaceutical-inc-acquires-dimension-therapeutics-inc-/2021-09-24T07:13:20+00:00weekly0.6https://www.medthority.com/news/2017/11/seattle-genetics-files-sbla-at-fda-for-adcetris---chemotherapy-for-treatment-of-advanced-classical-hodgkin-lymphoma-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2014/03/nexavar-fails-phase-iii-storm-trial-as-adjuvant-treatment--for-liver-cancer---bayer---onyzx-amgen/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2015/04/study-shows-lemtrada--alemtuzumab--slows-brain-atrophy-in-ms-patients-bayer-genzyme-sanofi/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2013/10/gsk-will-file-based-on-phase-iii-data-for-rts-s-in-malaria/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2018/11/european-commission-approves--biosimilar-ziextenzo-to-treat-neutropenia--sandoz/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2018/03/nice-recommends-keytruda-to-treat-bladder-cancer----merck-inc-/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2014/12/actelion-files-nda-at-fda-for-uptravi--selexipag---as-a-treatment-for-pah/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-phase-iv-study-of-mugard--access-pharma--for-oral-mucositis-/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2019/03/european-medicines-agency-has-validated-the-application-for-bavencio-in-combination-with-inlyta--for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma--merck-gmbh---pfizer/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2019/05/asco-2019-preview/2024-11-15T08:36:47+00:00weekly0.6https://www.medthority.com/news/2014/05/pfizer-to-file-palbociclib-at-fda-for-metastatic-breast-cancer/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-celluma--biophotas--for-treatment-of-acne/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2020/01/brilinta-meets-primary-endpoint-in-phase-iii-thales-trial-in-stroke---astrazeneca/2021-09-24T07:11:46+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-mozart-with-tomospec-for-x-ray-imaging-kubtec/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2018/05/world-hypoparathyroidism-awareness-day/2024-11-14T16:07:18+00:00weekly0.6https://www.medthority.com/news/2018/07/dermavant-sciences-acquires-rights-to-tapinarof-from-gsk--this-is-an-investigational-therapeutic-aryl-hydrocarbon-receptor-modulating-agent-for-the-treatment-of-psoriasis-and-atopic-dermatitis-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2016/03/variation-to-maa-submitted-to-ema-for-arzerra--ofatumumab--combination-treatment-for-relapsed-chronic-lymphocytic-leukemia--novartis/2024-02-09T10:05:24+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-c-edge-co-star-study-of-zepatier--elbasvir-and-grazoprevir--in-hepatitis-c-published-in-annals-of-internal-medicine--merck-inc/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2016/10/gilead-sciences-announces-data-from-phase-iii-studies-of-switching-from-truvada---emtricitabine-and-tenofovir-disoproxil-fumarate-200mg-300mg--ftc-tdf--to-descovy--emtricitabine-and-tenofovir-alafenamide-200mg-25mg--ftc-taf--/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-results-from-phase-iii-trial-of-vargatef--nintedanib--in-nsclc--boehringer-ingelheim/2021-09-24T07:03:42+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-results-from-vbloc-dm2-study-of-vbloc-neurometabolic-therapy-in-obese-patients-with-type-2-diabetes-published--enteromedics-/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2018/07/ce-mark-for-accu-chek-solo-micropump-system-for-diabetes-control---roche-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2013/11/angiox-angiomax--medicines-company--results-from-euromax-trial-for-ami/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2012/07/positive-data-in-study-of-krystexxa--savient-pharma--in-patients-with-gout/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2015/08/mallinckrodt-acquires-therakos-inc--for--1-325-billion-and-with-it-therakos-photopheresis/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-issues-complete-response-letter-for-epinephrine-injection-for-treatment-of-acute-anaphylaxis--adamis-pharma/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2017/08/sub-analysis-of-data-from-the-phase-iii-pegasus-timi-54-trial-of-brilinta-demonstrated-a-29--risk-reduction-in-cv-death---astrazeneca-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-accepts-sbla-to-extend-the-use-of-opdivo--nivolumab--to-patients-with-mismatch-repair-deficient--dmmr--or-microsatellite-instability-high--msi-h--metastatic-colorectal-cancer--crc----bms/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2018/09/nice-does-not-recommend-ocrevus-for-primary-progressive-ms---roche/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2013/04/chmp-recommends-approval-of-nuedexta--avanir-pharma--for-pseudo-bulbar-affect/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-reblozyl-for-the-treatment-of-anemia-in-adults-with-beta--thalassemia-who-require-regular-red-blood-cell-transfusions----celgene---acceleron/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2016/06/meta-analysis-of-overall-survival-in-three-multiple-myeloma-studies-following-revlimid--lenalidomide--maintenance-treatment--celgene-/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2018/06/rubraca-filed-with-eu-for-epithelial-ovarian--fallopian-tube--or-primary-peritoneal-cancer---clovis-oncology-/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2017/11/kisqali-meet-endpoints-in-monaleesa-7-trial-in-advanced-or-metastatic-breast-cancer--novartis-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2019/04/gilead-sciences-submits-sbla-for-descovy-for-pre-exposure-prophylaxis--prep--to-reduce-the-risk-of-sexually-acquired-hiv-1-infection-/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-expands-approval-for-stms-system-in-migraine---eneura/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2012/02/ema--approves-colobreathe--forest-labs--for-cystic-fibrosis-/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2013/02/ucb-files-cimzia-for-psoriatic-arthritis-at-fda-and-ema/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2012/04/alair-bronchial-thermoplasty-system-boston-scientific--has-positive-technology-assessment/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-alunbrig-to-treat--patients-with-anaplastic-lymphoma-kinase-positive--alk----advanced-non-small-cell-lung-cancer---takeda/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2016/09/egalet-corporation-announces-that-oxaydo--oxycodone-hcl-usp-tablets--resist-syringeability-which-could-potentially-deter-abuse-through-the-intravenous-route-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2014/07/gsk-files-rts-s-malaria-vaccine-at-ema-/2021-09-24T07:08:48+00:00weekly0.6https://www.medthority.com/news/2013/01/chmp-recommends-ilaris--novartis--for-treatment-of-acute-gouty-arthritis/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-bridge-trial-of-amg-785--romosozumab--in-osteporosis-meets-primary-endpoints--amgen-ucb/2024-02-09T10:06:27+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-stribild---gilead-sciences--for-treatment-of-hiv-1-infection/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-stiolto-respimat--olodaterol---tiotropium--shows-combination-treatment-benefits-copd--boehringer/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-lyrica--pregabalin--fails-to-meet-endpoint-in-peripheral-neuropathic-pain--pfizer/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-widens-scope-of-guidance-fro-xofigo--radium-ra-223-dichloride-to-apply-to-prostate-patients-unsuitable-for-chemotherapy---bayer-healthcare/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2013/10/alirocumab--sanofi--success-in-phase-iii-trial-for-dyslipidaemia/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-tarceva--genentech-astellas--for-nsclc-as-detected-by-cobas-egfr-mutation-test/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-issues-complete-response-letter-for-eliquis--bms-pfizer--in-stroke-prevention/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2013/07/apceth-approved-to-start-trials-of-mesenchymal-stem-cells-in-gastric-cancer/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2014/11/study-of-mekinist---tafinlar-for-metastatic-melanoma-published-in-nejm---gsk/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2015/09/nuq-diagnostic-assay-has-received-european-ce-mark-approval-for-detection-of-colorectal-cancer--volitionrx/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-study-of-pci-32765--pharmacyclics-inc--shows-some-benefits-in-patients-with-mantle-cell-lymphoma/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2017/11/td-4208-is-filed-at-fda-to-treat-chronic-obstructive-pulmonary-disease---theravance---mylan/2021-09-24T07:14:41+00:00weekly0.6https://www.medthority.com/news/2010/05/genzyme--lumizyme-is-fda-approved-for-pompe-disease/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2016/10/retrospective-analysis-of-vectibix--panitumumab--in-metastatic-colorectal-cancer-shows-overall-survival-improvement-versus-conventional-therapy--amgen/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2015/06/two--phase-ii-studies-of-rucaparib-in-brca-mutant-ovarian-cancer--clovis-oncology/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-phase-iii-alcanza-clinical-trial-evaluating-adcetris--brentuximab-vedotin--in-patients-with-cutaneous-t-cell-lymphoma--ctcl-----takeda-and-seattle-genetics-/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2012/09/novartis-reports-on-phase-ii-study-of-ain-457-in-plaque-psoriasis---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-generic-gleevec--imatinib-mesylate--for-treatment-of-cml---sun-pharma-/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-trial-of-lower-dose-linzess--linaclotide--meets-endpoint-in-chronic-idiopathic-constipation--ironwood-pharma/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2018/10/harmonize-global-phase-iii-trial-results-for-lokelma-presented-at-asn-kidney-week---astrazeneca-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-extends-pdufa-date-for-jakavi-to-treat-acute-graft-versus-host-disease---incyte---novartis/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2017/10/six-years-sustained-efficacy-shown-for--gardasil-9---human-papillomavirus-9-valent-vaccine--recombinant--for-prevention-of-hpv-caused-cancers--warts-and-lesions---merck-inc-/2024-11-15T08:39:59+00:00weekly0.6https://www.medthority.com/news/2014/12/success-for-sd-809-in-phase-iii-trial-for-chorea-associated-with-huntington-s-disease--auspex/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-kalydeco--ivacaftor--for-children-2-to-5-with-cystic-fibrosis--vertex/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-hope-study-of-gbt-440-shows-significant-impact-on-sickle-cell-disease---global-blood-therapeutics-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-pazeo--olopatadine-hydrochloride--for-treatment-of-allergic-conjunctivitis-/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-data-from-phase-iii-trial-of-spiriva--boehringer--in-asthma-patients/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-new-60mg-dose-of-brilinta--ticagrelor--in-patients-with-history-of-heart-attack--astrazeneca/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2017/05/post-market-approval-study-evaluated--the-subcutaneous-implantable-defibrillator--s-icd--system-and-showed-a-high-success-rate-and-a-low-complication-rate---boston-scientific/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-tegsedi-for-hereditary-transthyretin-amyloidosis---ionis-usa-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-initial-rejection-of-cinqaero--reslizumab--from-teva-as-an-add-on-treatment-for-severe-eosinophilic-asthma-/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-ninlaro--ixazomib----lenalidomide---dexamethasone-demonstrates-improved-survival-in-multiple-myeloma--takeda/2024-02-22T16:08:37+00:00weekly0.6https://www.medthority.com/news/2014/03/kiobrina-fails-phase-iii-trial-to-improve-growth-velocity---sobi/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-data-on-zalviso-for-post-operative-pain-published-acelrx-pharma/2024-02-09T10:06:45+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-ozenoxacin-for-impetigo-shows-drug-superiority-over-placebo--ferrer-int/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-advisory-committee-recommends-marqibo-for-ph-all/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-evarrest-sealant-matrix--omrix-biopharm--for-improvement-of-haemostasis/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-tepezza-to-treat-thyroid-eye-disease---horizon-therapeutics/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2019/02/merck-inc---to-acquire-immune-design/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-advisory-committee-rejects-sefelsa-depomed-as-a-treatment-for-menopause/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-of-abp-980-for-breast-cancer-and-gastric-cancer---amgen---allergan-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2016/02/sandoz-files-pegfilgrastim-biosimilar-at-ema-for-the-same-indication-as-the-reference-product-neulasta-/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-data-on-bax-111--recombinant-von-willebrand-factor--published-in-blood--baxalta-/2024-02-09T10:08:19+00:00weekly0.6https://www.medthority.com/news/2015/06/iqwig-does-not-recommend-tresiba--insulin-degludec-for-use-in-children-with-diabetes--novo-nordisk/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-belviq--eisai-arena-pharma--for-obesity/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-horizant--glaxosmithkline-xenoport--for-postherpetic-neuralgia-in-adults/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2012/04/phase-iii-study-of-arikace--insmed--in-cystic-fibrosis-patients-with-pseudomonas-lung-infections-begins-in-europe/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2012/08/idx-184--idenix-trial-for-hepatitis-c-halted-by-fda-for-suspected-cardiotoxicity-/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approved-inbrija-in-parkinson-s-disease---acorda-therapeutics-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2018/10/anixa-biosciences--has-filed-an-ivd-pre-submission-with-the-fda-for-use-of-its-cchek-artificial-intelligence-based-cancer-detection-technology--as-a-prostate-cancer-test-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-results-from-phase-iii-trial-of-jzp-258-for-the-treatment-of-cataplexy-and-excessive-daytime-sleepiness---jazz-pharma/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2011/10/china-s-fda-approves-pcr-kras-assay-for-colorectal-cancer-/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2018/06/topline-results-announced-of-the-phase-ii-iii-act-in-sarc-trial--evaluating-nbtxr-3-in-softtissue-sarcoma--nanobiotix-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-prior-approval-supplement-for-andexxa-generation-2-manufacturing-process---portola-pharma-/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2011/10/lemtrada-success-over-rebif-in-care-ms-1-trial-for-multiple-sclerosis/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iiib-study-of--vyvanse-elvanse--shire--shows-significant-benefits-for-treating-young-patients-with-adhd/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2017/12/can-siri-cope-with-sex-ed--/2024-02-22T16:09:26+00:00weekly0.6https://www.medthority.com/news/2017/09/teva-disposes-of-womens-health-businesses-to-cvc-capital-partners-fund-vi-and-to-foundation-consumer-healthcare-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2018/02/successful-results-for-tecentriq---avastin-versus-sunitinib-in-immotion151-study--for-renal-cell-cancer---genentech-roche-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2018/02/ema-approves-ozempic-once-weekly--treatment-for-type-2-diabetes-novo-nordisk-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2015/07/shire-presents-two-studies-of-vyvanse-for-long-term-maintenance-of--efficacy-in-binge-eating-disorder/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2011/04/zerenex-phase-iii-trials-in-japan-underway/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2013/09/sobi-acquires-all-rights-to-kineret/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/06/opdivo---chemotherapy--and--or-yervoy-shows--improved-pfs-in-checkmate-227-trial-over-chemotherapy-in-first-line-nsclc-with-pd-l1-expression-less-than-1----bms/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-lonquex--teva--for-chemotherapy-induced-neutropenia/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2015/02/launch-in-us-of-long-life-dynagen-el-and-inogen-el--defibrillators--boston-scientific/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2018/03/odyssey-outcomes-trial-success-for-praluent-in-reduction-of-mace-events----sanofi---regeneron-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2013/10/new-phase-iii-data-for-aubagio--sanofi--risk-of-ms-relapse/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2016/08/uk-nice-u-turn-now-recommends-imlygic--talimogene-laherparepvec--for-unresectable--regionally-or-distantly-metastatic--stage-iiib--iiic-or-ivm1a--melanoma--amgen/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2014/07/avastin-is-filed-at-fda-for-treatment-of-ovarian-cancer---genentech-roche/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-paladin-carotid-pta-balloon-system-with-embolic-protection---contego-medical/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2015/03/baxter-acquires-suppremol-gmbh-and-with-it-sm-101/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2016/03/teva-acquires-rimsa-in-mexico/2025-10-16T11:00:15+00:00weekly0.6https://www.medthority.com/news/2020/01/the-national-institute-for-health-and-care-excellence--nice--recommends-that--tecentriq-in-combination-with-carboplatin-and-etoposide-should-not-be-made-available-for-untreated-extensive-stage-small-cell-lung-cancer-in-adults---genentech-roche/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-study-of-ly-3009104--baricitinib--meets-primary-objective-in-rheumatoid-arthritis--eli-lilly-incyte-corp/2024-02-09T10:08:31+00:00weekly0.6https://www.medthority.com/news/2016/05/n9-gp--nonacog-beta-pegol--filed-with-fda-for-haemophilia-b---novo-nordisk/2021-09-24T07:09:30+00:00weekly0.6https://www.medthority.com/news/2015/02/actavis-to-change-name-to-allergan/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-backs-post-approval-cv-safety-trials-of-movantik-for-opioid-constipation---astrazeneca/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2015/07/nice-recommends-viekirax--ombitasvir---paritaprevir---ritonavir----exviera--dasabuvir--for-treatment-of-genotype-1-hepatitis-c--abbvie/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2019/03/santhera-pharma-completes-enrollment-in-phase-iv--leros--study-of-raxone-to-treat-leber-s-hereditary-optic-neuropathy-/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2013/04/nice-confirms-rejection-of-jakavi-novartis--for-myelofibrosis/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-vyxeos-to-treat-acute-myeloid-leukaemia-patients---jazz-pharma/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-fulphila-a-pegfilgrastim-biosimilar-for-treatment-of-febrile-neutropenia----mylan-n-v----biocon-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2014/12/opko-health-licenses-hgh-ctp-human-growth-hormone-worldwide-to-pfizer-/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2015/09/allergan-acquires-aquesys-and-with-it-xen-45-device-for-treatment-of-glaucoma/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2014/12/pomalyst-imnovid-results-in-phase-iiib-stratus-trial-for-multiple-myeloma-celgene/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-zubsolv--buprenorphine-and-naloxone-sublingual-tablet--for-use-in-the-treatment-of-opioid-dependence---mundipharma-and-orexo-ab-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-investigates-longitudinal-failure-of-ion-coronary-stent--boston-scientific-/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2016/06/novartis-enters-a-license-agreement-with-xencor-for-antibody-treatment-for-cancer/2025-10-16T11:25:05+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-approves-nucala--mepolizumab--as-a-treatment-for-severe-refractory-eosinophilic-asthma--gsk/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2013/06/amgen-announced-phase-iii-detailed-results-of-talimogene-laherparepvec-in-melanoma/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2017/09/mundipharma-licensed-by-janssen-pharmaceutica-nv-to-market-invokana--canagliflozin--and-vokanamet---canagliflozin---metformin--for-type-2-diabetes-in-eea-and-switzerland---janssen-pharmaceutica-nv-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2018/03/opdivo---yervoy-filed-sbla-at-fda-to-treat-microsatellite-instability-high--msi-h--or-mismatch-repair-deficient--dmmr--metastatic-colorectal-cancer-----bms-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-does-not-recommend-perjeta---herceptin-combination-to-treat-her2-positive-early-breast-cancer--roche-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2016/06/auris-medical-initiates-assent-phase-iii-trial-of-am-111-to-treat-sudden-deafness-/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2018/04/cancer-genetic-mutations-not-all-treatable--system-to-rank-relevance-of-mutations-needed--esmo-press-statement-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-cosentyx--secukinumab--for-treatment-of-ankylosing-spondylitis--and-psoriatic-arthritis--novartis/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2019/09/ultragenyx-and-kyowa-kirin-co---ltd---announced-plans-to-submit-a-sbla-to-the-fda-for-crysvita-for-the-treatment-of-tumor-induced-osteomalacia-/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2015/04/boston-scientific-initiates-reduce-htn--reinforce-study-of-vessix-v2-renal-denervation-system-for-hypertension--/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2017/06/why-do-ckd-patients-undergo-premature-aging---cdkn2a-p16ink4a-is-associated-with-vascular-progeria-in-the-uremic-milieu/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2015/06/cdc-advisory-committee-on-immunization-in-us-recommends-bexsero--meningococcal-group-b-vaccine--gsk/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-keytruda---alimta----platinum-chemotherapy-to-treat-nonsquamous-nsclc--merck-inc/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2016/05/alexza-pharma-is-acquired-by-grupo-ferrer-internacional--s-a--and-with-it-staccato-alprazolam-and-staccato-zaleplon-as-well-as--approved-adasuve-/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2011/11/ipsen-sells-apokyn-north-america-rights-to-britannia-pharma-/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-sunosi--to-improve-wakefulness-in-adult-patients/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-chmp-recommends-approval-of-briviact--brivaracetam--for-partial-onset-epilepsy-seizures--ucb/2021-09-24T07:04:20+00:00weekly0.6https://www.medthority.com/news/2017/09/botox--onabotulinumtoxina--head-to-head-trial-data-shows-superior-tolerability-profile-than-topamax---topiramate--in-the-treatment-of-migraine---allergan/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2018/07/keytruda-plus-carboplatin-paclitaxel-or-nab-paclitaxel-filed-with-fda-for-metastatic-squamous-non-small-cell-lung-cancer---merck-inc-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2020/02/nice-recommends-rinvoq-to-treat-severe-rheumatoid-arthritis---abbvie/2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2013/09/naloxegol-filed-with-the-fda-for-opioid-constipation/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-zydelig-for-cll--nhl-and-sll---gilead-sciences/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2013/12/ec-extends-indication-of-erbitux-in-crc-merck-serono/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-priftin---nydrazid-for-treatment-of-latent-tuberculosis-infection--sanofi/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-lynparza-to-treat---patients-with-germline-brca1-2-mutations-who-have-her2-negative-locally-advanced-or-metastatic-breast-cancer---astrazeneca---merck-inc-/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2013/02/eu-approves-ilesto-7--biotronik--for-patients-with-heart-failure/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2014/03/mage-a3-fails-to-meet-endpoint-in-phase-iii-trial-for-nsclc---gsk/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-keytruda-pembrolizumab-for-the-first-line-treatment-of-metastatic-nsclc-in-adults-whose-tumors-have-high-pd-l1-expression-with-no-egfr-or-alk-positive-tumor-mutations---merck-inc-/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-syncardia-total-artificial-heart---syncardia-systems/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-filing-of-seysara-for-acne---allergan-/2021-09-24T07:13:34+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-study-of-deflazacort-shows-efficacy-in-duchenne-muscular-dystrophy--marathon-pharmaceuticals/2021-09-24T07:10:41+00:00weekly0.6https://www.medthority.com/news/2016/08/biochaperone-pdgf--bc-pdgf--fails-phase-iii-trial-in-the-treatment-of-diabetic-foot-ulcer---adocia-/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2011/12/avastin--roche-genentech--prevents-spread-of-nasopharyngeal-carcinoma-in-phase-ii-trial/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2012/08/hemispherx-files-response-to-fda-for-ampligen-treatment-of-chronic-fatigue-syndrome/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2011/12/aromasin--pfizer--found-to-lower--good--cholesterol-levels-in-breast-cancer-patients/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2018/06/update-on-phase-iii-trial-programme-evaluating-pxt-3003-for-charcot-marie-tooth-type-1a-disease--pharnext-s-a-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2019/07/verzenio-in-combination-with-fulvestrant-significantly-extended-life-in-women-with-hr---her2--advanced-breast-cancer-in-monarch-2-trial/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-recommends-use-of-selincro-for-alcohol-dedendence---lundbeck/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-expanded-indication-for-adacel-in-tdap---sanofi-pasteur-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2012/02/nice-rejects-tyverb--gsk--as-first-line-treatment-of-post-menopausal-breast-cancer/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2016/09/vasopharm-gmbh-initiates-phase-iii-study--nostra-iii--to-assess-ronopternin--vas-203--for-the-treatment-of-traumatic-brain--tbi--injury-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2015/07/nice-recommendation-for-daklinza--daclatasvir----sofosbuvir-to-treat-hepatitis-c--bms/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2015/05/-chmp-recommends-unituxin--dinutuximab--for-neuroblastoma-in-children-united-therapeutics/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2017/03/myovant-sciences-initiates-phase-iii-trials--liberty-1-and-liberty-2---of-relugolix-to-treat-menstrual-bleeding-associated-with-uterine-fibroids-/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2017/01/first-patient-dosed-in-ignite3-phase-iii-trial-of-intravenous--iv--eravacycline-compared-to-ertapenem-for-urinary-tract-infections---tetraphase-pharma/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-post-hoc-analyses-of-vyndaqel-shows-benefits-in-attr-act---pfizer-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2014/08/meda-ab-acquires-rottapharm-madaus-for-euros-275-million/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2012/08/updated-results-of-tivo-1-study-of-tivozanib-in-renal-cell-carcinoma/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-veraseal-for-use-as-a-sealant-during-surgical-operations-in-adults---instituto-grifols-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-prolia-for-treatment-of-glucocorticoid-induced-osteoporosis----amgen-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2016/06/singulex-inc---and-grifols-partnership-to-develop--singulex--smc-technology-for-the-screening-of-donor-blood-and-plasma-/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2016/05/medi-563--benralizumab--achieves-primary-endpoint-in-two-pivotal-phase-iii-trials-for-asthma-with-eosinophilic-inflammation--astrazeneca/2024-02-09T10:08:44+00:00weekly0.6https://www.medthority.com/news/2012/03/complete-response-letter-from-fda-for-levadex--map-pharma--for-migraine/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-onivyde--irinotecan-liposome-injection----fluorouracil-and-leucovorin-to-treat-metastatic-pancreatic-cancer--merrimack-pharma/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-ingenuity-pet-mri--philips--combined-scanning-system/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2012/10/nice-does-not--recommend-colobreathe--forest-labs--for-treatment-of-cystic-fibrosis-infection---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-approves-kombiglyze-xr-for-type-2-diabetes/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2018/07/mallinckrodt-plc-announced-two-retrospective-analyses-providing-health-economic-insights-on-use-of-ofirmev-for--total-knee-arthroplasty--/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2014/01/study-shows-benefits-with-cefaly-for-migraine-stx-med-/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2017/12/targeted-antibody-demonstrates-significant-improvement-in-pfs-in-patients-with-previously-treated-ctcl/2024-02-09T10:11:19+00:00weekly0.6https://www.medthority.com/news/2015/05/novartis-reports-radiant-4-trial-of-afinitor--everolimus--to-treat-non-functional-neuroendocrine-tumours-of-gi-or-lung-origin-/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2012/04/phase-iib-data-show-svr12-in-hepatitis-c-patients-treated-with-bi-201335--boehringer-ingelheim-/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2015/06/novartis-acquires-spinifex-pharmaceuticals/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2014/10/actavis-acquires-durata-for--675-million-including-dalvance/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2016/10/european-medicines-agency-accepts-for-review-the--maa-for-sb3--a-trastuzumab-biosimilar--to-treat-early-breast-cancer--metastatic-breast-cancer-and-metastatic-gastric-cancer---samsung-bioepis---merck-inc-/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2017/06/supplemental-biologics-license-application-and-variation-to-marketing-authorisation-submitted-to-fda-and-maa-for-repatha--evolocumab--in-dyslipidaemia--amgen/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-approves-erelzi--biosimilar-etanercept--for-rheumatoid-arthritis--axial-spondyloarthritis--plaque-psoriasis--psoriatic-arthritis--juvenile-idiopathic-arthritis-and-pediatric-plaque-psoriasis--sandoz/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2019/12/novartis-provides-update-on-luster-phase-iii-studies--of-fevipiprant-in-patients-with-uncontrolled-gina-4-5-asthma-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2017/09/esmo-2017-press-release--study-highlights-overuse-of-tumour-marker-tests-in-primary-and-secondary-care/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2014/08/arzerra-trial-for-cll-meets-endpoint-in-interim-analysis---gsk-genmab/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2014/02/novel-gene-therapy-success-in-b-cell-acute-lymphoblastic-leukemia---juno-therapeutics/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2014/02/eylea-shows-benefits-in-dmo-trial-regeneron-bayer-healthcare/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2014/12/baxter-files-bla-at-fda-for-bax-111-for-von-willebrand-disease-/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-study-of-atx-101--kythera-biopharmaceuticals--shows-treatment-helps-reduce-submental-fat/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-pivotal-study-of-defibrotide-for-hepatic-veno-occlusive-disease-is-published-in-blood---jazz-pharma/2024-02-09T10:11:43+00:00weekly0.6https://www.medthority.com/news/2015/08/study-results-for-nanostim-leadless-pacemaker-published-in-new-england-journal-of-medicine-st-jude-medical/2024-02-09T10:12:00+00:00weekly0.6https://www.medthority.com/news/2014/06/mitizax-meets-endpoint-in-two-phase-iii-trials-for-dust-mite-allergy---alk/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-coagadex--coagulation-factor-x-human--for-hereditary-factor-x-deficiency--bio-products-lab/2024-02-09T10:12:10+00:00weekly0.6https://www.medthority.com/news/2013/12/analyses-of-comfort-1---2-studies-of-jakavi-for-myelofibrosis-novartis/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2012/02/cyberknife--accuray-inc--relieves-pain-of-trigeminal-neuralgia-facial-nerve-condition/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-phase-iii-study-results-for-one-dose-xofluza-in-children-with-the-flu--genentech-roche/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---the-hidden-epidemic--worldwide--over-850-million-people-suffer-from-kidney-diseases/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2014/06/data-shows-immu-132-stabilises-range-of-solid-cancers-immunomedics/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2019/07/actinium-pharma-highlights-two-presentations-at-the-health-physics-society-annual-meeting-supporting-the-safety-profile-of-iomab-b-for-sierra-trial-caregivers-/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2014/06/vantage-study-of-vercise-dbs-system-shows-benefits-for-parkinson-s-disease---boston-scientific/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2020/01/mirror-open-label-study-of-krystexxa-shows-response-in-gout---horizon-therapeutics/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2013/07/generic-dacogen-launched-in-usa/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2018/09/celltrion-to-advance-remsima-sc--the-subcutaneou-version-of-remsima-biosimilar-for-filing-in-europe-this-year-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-recommends-humira--adalimumab--to-treat-hidradenitis-suppurativa--abbvie-/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-enstilar--calcipotriol-betamethasone-dipropionate--for-plaque-psoriasis--leo-pharma/2024-02-09T10:12:19+00:00weekly0.6https://www.medthority.com/news/2013/10/gsk-files-once-daily-fluticasone-furoate-for-asthma-with-fda/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-phase-iii-achieve-i-trial-results-for-ubrogepant-published-in-nejm---allergan/2021-09-24T07:18:38+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-biosimilar-grastofil-for-neutropenia/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2011/10/nice-refuses-to-recommend-benlysta-for-sle/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2015/12/chmp-recommends-bay-81-8973-for-prophylactic-treatment-of-haemophilia-a--bayer-healthcare---csl-behring/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2012/05/imdx-gbs--intelligentmdx--test-system-for-group-b-streptococcus-receives-ce-mark/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-eylea--bayer--for-macular-oedema-following-crvo/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2012/12/chmp-recommends-adusive--alexza-ferrer-for-control-of-agitation-in-schizophrenia-and-bipolar-patients/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2017/09/rocket-pharmaceuticals-and-inotek-pharmaceuticals-to-merge-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2013/08/new-results-from-study-of-mm-398-in-gastric-cancer/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2012/06/cardinal-health-to-distribute-amyvid-diagnostic-imaging-agent-for-alzheimer-s-disease-/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2016/01/early-results-of-phase-iii-trials-of-lks-5461--samidorphan---olanzapine--in-depression-fail-to-meet-endpoints--alkermes/2024-02-22T16:09:50+00:00weekly0.6https://www.medthority.com/news/2014/04/nice-recommends-use-of-tarceva-for-relapsed-nsclc---roche/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2014/07/topline-data-from-relief-trial-of-jakafi-jakavi-in-polycythemia-vera-fails-to-meet-endpoint---incyte-corp/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2016/08/results-of-phase-iii-poise-trial-of-ocaliva--obeticholic-acid--for-primary-biliary-cholangitis-published-in-new-england-journal-of-medicine--intercept-pharmaceuticals/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-zarxio-biosimilar-for-all-filgrastim-indications--sandoz/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2016/01/nice-recommends-opdivo--nivolumab--to-treat-advanced-melanoma--bms/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2016/07/pain-therapeutics-confirms-pdufa-date-for-remoxy--oxycodone-extended-release--/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-lynparza-as-maintenance-therapy-for-ovarian-cancer-regardless-of-brca-status--astrazeneca----merck-inc-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-jynneos-for-prevention-of-smallpox-and-monkeypox-disease-in-adults-18-years-of-age-and-older-determined-to-be-at-high-risk---bavarian-nordic-a-s/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2017/05/international-nurses-day-2017/2024-02-22T16:10:33+00:00weekly0.6https://www.medthority.com/news/2012/08/ganitumab--amgen--phase-iii-trial-stopped-in-pancreatic-cancer/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-approval-of-fycompa--eisai--for-epilepsy/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2011/09/tak-875-a-new-treatment-for-type-2-diabetes-enters-phase-iii/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2013/07/alpha-ims--retina-implant-ag--receives-ce-mark-approval-in-the-eu-for-retinitis-pigmentosa/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2015/08/european-commission-approves-unituxin--dinutuximab--for-paediatric-neuroblastoma--united-therapeutics/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2017/08/stimwave-llc--has-received-fda-510-k--clearance-for-the-stimq-peripheral-nerve-stimulator--pns--system-which-offers-an-alternative-for-those-who-do-not-want-to-rely-on-invasive-surgical-procedures-or-ongoing-opioid-treatment-for-pain-management-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2012/06/phase-iii-go-further-trial-shows-simponi--janssen-biotech--significantly-improved-rheumatoid-arthritis/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2017/12/ash-2017/2024-10-22T08:08:26+00:00weekly0.6https://www.medthority.com/news/2017/11/study-reveals-evidence-behind-war-zones-and-heightened-risk-low-birthweight-babies/2024-02-22T16:11:02+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-trial-of-lumoxiti-shows-complete-response-rate-in-hairy-cell-leukemia---innate-pharma/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2018/09/pfizer-terminates-phase-ii-trials--of-domagrozumab--pf-06252616--for-the-treatment-of-duchenne-muscular-dystrophy-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2019/10/shionogi-reports-positive-results-from-cefiderocol-phase-iii--study-in-adults-with-pneumonia-caused-by-gram-negative-pathogens-/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2012/11/study-of-pradaxa--boehringer--for-atrial-fibrillation-shows-positive-safety-profile-and-efficacy---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2016/08/hertraz--biosimilar-trastuzumab--filed-with-eu-for-breast-and-gastric-cancers---mylan-and-biocon/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2018/08/ceftobiprole-enters-phase-iii-study-for-the-treatment-of-patients-with-bacteremia--bloodstream-infections--caused-by-staphylococcus-aureus---basilea-pharma-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-iii-data-on-oral-lyn--generex--show-it-is-as-effective-as-human-insulin-in-type-2-diabetes/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-accepts-triferic-for-treatment-of-iron-deficiency-in-ckd-patients--rockwell-medical/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2019/08/eacta-2019---learn-more/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-aimovig-to-prevent-migraine---novartis-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2019/09/mitsubishi-tanabe-initiates-phase-iii-boundless-study-of-nd-0612-to-treat-parkinson-s-disease-/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-giotag-study-with-gilotrif-in-nsclc-published-in-future-oncology---boehringer-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-data-shows-combination-treatment-with-empliciti--elotuzumab--extends-pfs-in-multiple-myeloma--bms/2024-02-09T10:13:16+00:00weekly0.6https://www.medthority.com/news/2014/06/sanofi-files-toujeo---rdna-origin--injection--300-u-ml--at-ema-and-fda-for-diabetes/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-cosentyx-for-treatment-of-plaque-psoriasis--novartis/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2018/11/nejm-publishes-positive-results-from-praluent--cardiovascular-outcomes-trial---sanofi---regeneron/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2013/03/inspra-pfizer--success-in-reminder-trial-for-acute-stemi-patients/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2012/06/plethora-schiele-files-psd-502-at-ema-for-treatment-of-premature-ejaculation/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-invokamet-xr--canagliflozin-and-metformin-hydrochloride-extended-release--for-type-2-diabetes---janssen-pharma/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-kymriah-for-large-b-cell-lymphoma-as-second-indication-for-car-t-therapy---novartis-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-cerdelga-an-oral-therapy-for-gaucher-disease---genzyme-sanofi/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2013/06/ema-approves-xtandi--astellas--to-treat-metastatic-castration-resistant-prostate-cancer/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2017/04/european-commission--ec--has-approved-varuby--oral-rolapitant-tablets--for-the-prevention-of--chemotherapy-induced-nausea-and-vomiting--tesaro/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-refusal-of-application-for-xilonix-human-igg1-monoclonal-antibody-in-colorectal-cancer-xbiotech/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2016/09/subcutaneous-form-of-benlysta--belimumab--filed-in-eu-and-us-for-systemic-lupus-erythematosus---glaxosmithkline/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2019/05/twirla-is-refiled-with-fda-as-contraceptive-patch/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2014/01/phase-iii-trial-of-diapep277-meets-endpoints-in-t1d-andromeda-biotech/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2014/06/eu-approves-pradaxa-for-dvt-and-pulmonary-embolism---boehringer/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-approval-of-nordimet--methotrexate--for--rheumatoid-arthritis--juvenile-idiopathic-arthritis--and-severe-psoriatic-arthritis--nordic-group/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-symdeko-for-use-in-children-with-cystic-fibrosis--who-have-two-copies-of-the-f508del-cftr-mutation-or-who-at-least-one-mutation-in-the-cftr-gene---vertex/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2016/08/sorrento-therapeutics-subsidiary-scintilla-pharma-acquires-semnur-pharma-and-with-it--a-non-opiate-epidural-steroid-injectable-to-treat-chronic-back-pain--/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2013/11/sanofi-cancels-development-of-fedratinib-for-myelofibrosis/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-advisory-committee-does-not-recommend-lbh-589-for-treatment-of-multiple-myeloma---novartis/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2015/08/nxtag-respiratory-pathogen-panel-diagnostic-filed-with-fda-for-510-k--approval--luminex-corp/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2015/12/expansion-to-indication-of-kyprolis--carfilzomib--in-multiple-myeloma-filed-with-ema--amgen/2024-02-09T10:13:39+00:00weekly0.6https://www.medthority.com/news/2019/03/successful-results-from-phase-iii-genesis-trial-of-bl-8040-for-autologous-transplantation-in-multiple-myeloma-patients--biolinerx/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2018/09/keytruda-filed-with-fda-and-granted-priority-review-for-merkel-cell-carcinoma---merck-inc-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2013/03/prevail-trial-of-watchman-laac--boston-scientific--shows-some-benefits-for-af-patients/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2015/05/absorb-gt1--a-fully-dissolving-stent--receives-ce-mark-to-treat-cad-abbott-vascular/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2013/05/metreleptin-sub-analysis-in-paediatric-patients-with-lipodystrophy/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2012/03/pa-32540--pozen--effective-against-gastric-ulcers-in-phase-iii-study/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2018/04/alxn-1210-success-for-patients-switching-from-soliris-for-paroxysmal-nocturnal-hemoglobinuria----alexion-pharma--/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-approval-of-zalmoxis-in-haploidentical-haematopoietic-stem-cell-transplantation--molmed/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-results-from-pivotal-zuma-2-trial-in-relapsed-or-refractory-mantle-cell-lymphoma----kite-gilead/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2012/12/study-shows-benefits-for-bone-growth-in-infants-fed-on-infat--advanced-lipids-/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-issues-complete-response-letter-to-filing-of-canakinumab-for-cardiovascular-risk---novartis-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/04/nicox-files-nda-at-fda-for-ac-170--proprietary-cetirizine-eye-drop-formulation--for-conjunctivitis/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-recommends-pixuvri--cti-life-sciences--for-non-hodgkin-s-b-cell-lymphoma-/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2019/09/sumitomo-dainippon-to-acquire-biopharmaceutical-companies-from-roivant/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-optimizer-smart-system-for-heart-failure/2024-02-09T10:14:19+00:00weekly0.6https://www.medthority.com/news/2019/05/a-subgroup-analysis-of-the-bio-resort--three-year-data-showed-significant-differences-in-efficacy-in-favor-of-ultrathin-strut-orsiror/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2013/10/final-analysis-published-from-mammosite-breast-cancer-study/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2012/09/eu-approve-monarch-etns-system--neurosigma--for-treatment-of-epilepsy/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2016/06/spectral-medicine-submits-modules-to-fda-for-its-pma-application-for-toraymyxin-a-treatment-for-sepsis-/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2019/03/evoke-pharma-receives-fda-review-letter-relating-to-gimoti-to-treat-gastroparesis-/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2012/07/phase-iii-study-of-bapineuzumab--janssen-alzheimer-immunotherapy--for-alzheimers-disease-fails-to-meet-endpoint/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2013/01/nice-draft-guidance-recommends-therapies-for-prevention-of-breast-cancer/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2011/07/afinitor-success-in-bolero-2-study-in-advanced-breast-cancer/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2012/01/epic-nitinol-stent-success-in-orion-trial-for-iliac-artery-disease/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2015/05/morphosys-ag-acquires-lanthio-pharma-b-v--and-its-novel-drug-lp-2/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-vyxeos--cytarabine-daunorubicin--shows-improved-response-rate-in-acute-myeloid-leukemia--celator-pharmaceuticals/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-avsola--infliximab-biosimilar--for-all-indications-of-the-reference-product---amgen/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2017/02/european-patent-office-invalidates-sprycel--dasatinib--composition-of-matter-patent---bms/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2015/11/new-results-of-phase-iii-analysis-of-veltassa--patiromer--for-hyperkalaemia--relypsa/2024-02-09T10:14:32+00:00weekly0.6https://www.medthority.com/news/2018/03/alvogen-s-generic-version-of-suboxone-film-for-opioid-addiction-did-not-infringe-upon-three-patents-held-by-indivior-plc-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2011/09/bydureon-reduces-cardiovascular-risk-factors-in-type-2-diabetes-patients/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2018/12/novartis-withdraws-from-ema-its-application-for-canakinumab-for-the-prevention-of-serious-cv-events-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-grants-priority-review-to-merck-s-sbla-for-keytruda--in-certain-patients-with-high-risk--non-muscle-invasive-bladder-cancer-/2024-10-21T14:47:10+00:00weekly0.6https://www.medthority.com/news/2015/02/eu-approves-xadago-for-parkinsons-newron-pharma/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2015/11/profile-1029-trial-for-xalkori--crizotinib-success-in-prolonging-pfs-for-alk---nsclc---pfizer/2024-02-09T10:14:45+00:00weekly0.6https://www.medthority.com/news/2012/10/arq-197-phase-iii-trial-marquee-for-nsclc-is-stopped/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2013/11/two-trials-with-cyberknife-sbrt--accuray--for-prostate-cancer-published/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-accepts-for-review-the-bla-for-ct-p10-biosimilar-to-rituxan--rituximab----teva---celltrion/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2017/09/bay94-9027-a-long-acting-site-specifically-pegylated-recombinant-human-factor-viii-is-filed-at-fda-for-treatment-of-hemophilia-a--bayer/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2014/04/chmp-recommends-pradaxa-for-dvt-and-pe---boehringer/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2013/03/study-shows-roactemra-actemra--genetech-roche--superior-to-humira-in-achieving-remission-in-rheumatoid-arthritis-patients/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2015/07/rviii-singlechain--recombinant-factor-viii-single-chain--filed-with-fda-for-haemophilia-a--csl-behring/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-study--e1912--of-imbruvica---rituxan-shows-improved-pfs-in-chronic-small-lymphocytic-leukemia---janssen-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-issues-positive-guidance-on-use-of-mri-guided-focused-ultrasound-thalamotomy-for-treatment-resistant-essential-tremor---insightec-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2015/12/kempharm-files-nda-at-fda-for-kp-201-apap-to-treat-acute-pain-/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-gives-ce-mark-approval-to-visia-af-single-chamber-implantable-cardioverter-defibrillators-for-atrial-fibrillation--medtronic/2021-09-24T07:03:14+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-biorphen-to-treat-hypotension-resulting-from-vasodilation-in-the-setting-of-anesthesia---eton-pharma/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2015/02/nice-recommends-targaxan--rifaximin--for-treatment-of--hepatic-encephalopathy--norgine/2026-01-26T16:15:50+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-grants-510-k--approval-for-flowtriever-system-for-treatment-of-pulmonary-embolism---inari-medical-inc-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2012/05/success-for-watchman--laac-device---boston-scientific--in-stroke-prevention/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2019/11/novartis-acquires-the-medicines-company-and-inclisiran/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-gives-pre-market-approval-for-impella-rp-heart-pump-for-right-heart-failure---abiomed-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2012/11/study-shows-benefits-of-high-dose-treatment-with-heartlight--cardiofocus--for-patients-with-af/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2011/09/quad-hiv-drug-more-effective-than-other-therapies/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-ii-study-of-xiaflex--auxilium-pharma--shows-benefits-for-patients-with-adhesive-capsulitis/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2016/05/data-published-in-british-journal-of-cancer-validates-vascular-remodelling-of-halaven--eribulin--in-breast-tumour-tissue--eisai/2024-02-09T10:58:53+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-verity-extremity-scanner--planmed--for-x-ray-imaging/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2016/08/three-post-hoc-analysis-studies-of-vyndaqel--tafamidis-meglumine--in-patients-with-mild-ttr-fap-published-in-amyloid--the-journal-of-protein-folding-disorders---pfizer/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2017/09/new-analysis-of-devote-trial-of-tresiba--insulin-degludec--shows-people-with-type-2-diabetes-who-experience-severe-hypoglycaemia-are-at-greater-risk-of-death---novo-nordisk-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2014/02/estybon-mixed-results-in-phase-iii-trial-for-myelodysplastic-syndromes---oncanova--baxter/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2016/02/launch-of-new-cystic-fibrosis-knowledge-centre/2021-11-26T09:56:09+00:00weekly0.6https://www.medthority.com/news/2019/06/cyclosporine-benefits-patients-through-more-rapid-remission-of-proteinuria-in-lupus-nephritis/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-keynote--024-study-of-keytruda-shows-benefits-for-long-term-overall-survival-in-nsclc---merck/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2015/08/nejm-publishes-ambition-study-of-volibris--ambrisentan----adcirca--tadalafil--for-pah--gsk--gilead---eli-lilly/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2014/04/abt-450-r--abt-267--abt-333-combination-submitted-to-fda-for-hepatitis-c---abbvie/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2018/06/quantum-r-phase-iii-study-of-ac-220-shows-benefits-for-overall-survival-in-acute-myeloid-leukemia---daiichi-sankyo-/2024-07-26T10:10:55+00:00weekly0.6https://www.medthority.com/news/2011/10/onfi-from-lundbeck-is-fda-approved-for-lennox-gaastaut-syndrome-/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/03/s-equol-supplement--pharmavite--success-in-lipids-trial/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-reagila--cariprazine--in-schizophrenia--gedeon-richter/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2019/09/qtrilmet-modified-release-tablets-are-chmp-recommended-for-authorisation-in-the-eu-for-the-treatment-of--type--2-diabetes--astrazeneca/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2019/02/mk-7655---primaxin---cilastatin-filed-with-fda-for-cuti---ciai---merck-inc/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2016/06/trial-results-of-shp-465--mixed-salts-of-a-single-entity-amphetamine--show-benefits-in-attention-deficit-hyperactivity-disorder--shire/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-accepts-bla-for-subcutaneous-formulation-of-herceptin-for-approved-indications---genentech-halozyme-therapeutics-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2019/11/health-canada-approves-adcetris----chemotherapy-in-frontline-cd30-expressing-peripheral-t-cell-lymphoma----seattle-genetics/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2012/11/boston-scientific-acquires-vessix-vascular-and-its-renal-denervation-system-for-hypertension---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2015/11/merck-kgaa-and-pfizer-announce-initiation-of-second-phase-iii-trial-of-avelumab-for-treatment-na-ve-advanced-nsclc-patients/2024-02-09T10:59:10+00:00weekly0.6https://www.medthority.com/news/2013/03/trial-of-stentys-self-apposing-stent--stentys--demonstrates-low-mortality-rates-in-cad-patients-/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2017/10/2nd-international-conference-on-ophthalmology/2021-09-24T07:13:23+00:00weekly0.6https://www.medthority.com/news/2019/05/ats-2019---learn-more/2024-10-22T09:38:21+00:00weekly0.6https://www.medthority.com/news/2017/11/avelumab-did-not-meet-endpoint-in-phase-iii-javelin-gastric-300-trial-for-gastroesophageal-junction-adenocarcinoma----merck-kgaa---pfizer-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2016/04/study-shows-test-can-identify-who-to-target-with-inhaled-corticosteroid---spiriva-handihaler--tiotropium-bromide----laba-in-copd--boehringer/2024-02-09T10:59:34+00:00weekly0.6https://www.medthority.com/news/2016/09/daiichi-sankyo-initiates-phase-iii-trial-for--cs-3150--esaxerenone--as-a-treatment-for-hypertension-/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress---a-quarter-of-penis-cancer-sufferers-don-t-get-recommended-treatment/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends--kisqali--ribociclib--in-combination-with-an-aromatase-inhibitor-for-treatment-of-postmenopausal-women-with--hr--her2--locally-advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-extends-label-for-keytruda-plus-carboplatin-and-either-paclitaxel-or-nab-paclitaxel-to-treat-nsclc--merck-inc-/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-grants-accelerated-approval-for-enhertu-to-treat-unresectable-or-metastatic-her2-positive-breast-cancer--daiichi-sankyo---astrazeneca/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-expands-indication-of-yervoy--ipilimumab--in-metastatic-melanoma--bms/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2015/09/new-data-confirm-tresiba--insulin-degludec--u200-delivers-significantly-lower-rates-of-confirmed-hypoglycaemia-versus-insulin-glargine-u100--novo-nordisk/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2015/07/teva-withdraws-plan-to-acquire-mylan/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2016/04/keytruda--pembrolizumab--filed-with-fda-for-head-and-neck-cancer--merck-inc-/2021-09-24T07:10:43+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trilogy-study-of-extrafine-fixed-triple-combination--formoterol---glycopyrronium---beclomethasone--shows-superior-efficacy-for-chronic-obstructive-pulmonary-disease--chiesi-/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-generic-version-of--diovan-for-hypertension-ranbaxy/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2018/06/baloxavir-marboxil-filed-with-fda-and-given-priority-review-in-influenza---genentech-roche-/2024-07-26T10:07:31+00:00weekly0.6https://www.medthority.com/news/2018/06/diabetes-week-2018--11-15-june---1/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iv-study-of-mu-gard--access-pharma--shows-it-is-effective-for-oral-mucositis/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2017/12/pain-therapeutics-reports-successful-fda-meeting-relating-to-remoxy--a-drug-for-severe-pain-/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-ellipse-and-sjm-assura-icds-and-crt-ds--st-jude-medical--for-heart-failure/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2019/07/sandoz-initiates-rosalia-study-of-denosumab-biosimilar-/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2019/09/vertex-pharmaceuticals-acquires-semma-therapeutics-and-entry-into-type-1-diabetes/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2016/12/quickshot-testosterone-filed-with-fda-for-testosterone-deficiency--antares-pharma/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2016/10/uk-nice-recommends-use-of-cimzia--certolizumab-pegol--in-combination-with-methotrexate--for-active-rheumatoid-arthritis-in-adults-whose-disease-has-responded-inadequately-to--or-who-cannot-tolerate--other-disease-modifying-antirheumatic-drugs--ucb/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-urolift-system-for-bph/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-commission-approves-eylea-for-crvo/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-hizentra-for-chronic-inflammatory-demyelinating-polyneuropathy---csl-behring-/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-valor-trial-of-vosaroxin-in-aml-fails-to-meet-endpoint---sunesis/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2017/12/breast-cancer-patients-undergo-years-of-unnecessary-treatment/2021-11-30T12:55:18+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-advisory-committee-recommends--luxturna--voretigene-neparvovec--gene-therapy--to-treat-vision-loss-due-to--biallelic-rpe65-mediated-inherited-retinal-disease---spark-therapeutics/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-confirms-omeros--schedule-for-rolling-review-of-its-bla-for-narsoplimab-in-the-treatment-of-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-/2024-10-21T14:45:04+00:00weekly0.6https://www.medthority.com/news/2012/04/eu-gives-marketing-approval-for-bronchitol--pharmaxis---to-treat-cystic-fibrosis/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2012/04/phase-iii-study-of-qva-149--novartis--for-copd-meets-primary-endpoint-and-clarifies-timing-of-us-filings/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2016/10/zepatier--elbasvir---grazoprevir--is-recommended-by-uk-nice-for-treating-genotype-1-or-4-chronic-hepatitis-c---merck-inc/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2018/07/camellia-timi-61-outcomes-trial-of-belviq-meets-primary-endpoint-in-obesity---eisai-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2013/11/symplicity-rds-system--medtronic--trial-initiated-for-moderate-hypertension/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2016/11/success-for-phase-iii-cherish-study-of-spinraza--nusinersen--for-treatment-of-spinal-muscular-atrophy---biogen---ionis-pharma/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2017/03/nice-rejects-keytruda--pembrolizumab---as-first-line-therapy-to-treat-metastatic-non-small-cell-lung-cancer---merck-inc-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-bridge-study-of-romosozumab-shows-significant-bone-mineral-density--bmd--gains-in-osteoporotic-men--amgen---ucb/2021-09-24T07:09:50+00:00weekly0.6https://www.medthority.com/news/2011/10/lower-contrast-agent-dose-feasible-in-320-row-ct-angiography/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2015/09/cardioband-mitral-reconstruction-system-receives-ce-mark-approval-in-eu--valtech-cardio/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-rexulti--brexpiprazole--for-adults-with-major-depressive-disorder-and-with-schizophrenia--lundbeck-otsuka/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2015/09/new-analysis-for-esbriet--pirfenidone--in-idiopathic-pulmonary-fibrosis--roche/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---dawn-to-sunset-fasting-suggests-potential-new-treatment-for-obesity-related-conditions/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2019/10/abbvie-receives-fda-approval-of-mavyret-to-shorten-treatment-duration-to-eight-weeks-for-treatment-na-ve-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes-/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2015/07/clovis-oncology-files-nda-at-fda-for-rociletinib-to-treat-non-small-cell-lung-cancer-with-the-egfr-t790m-mutation/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2018/06/alxn-1210-filed-with-rare-disease-priority-at-fda-for-paroxysmal-nocturnal-hemoglobinuria---alexion-pharma-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-extension-to-indication-for-pegasys--peg-interferon-alfa-2a--in-hepatitis-b---roche-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2018/03/supplemental-new-drug-application-filed-with-fda-for-envarsus-xr-for-prophylaxis-of-organ-rejection-in-kidney-transplant-patients---veloxis-pharma-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2015/02/cep-33237-filed-at-fda-for-treatment-for-chronic-pain-teva/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-expanded-label-for-cinryze-to-treat-children-with-hereditary-angioedema----shire-plc-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approval-of-darzalex-split-dosing-regimen--bms/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2012/01/varisolve--btg--success-in-vanish-2-trial-for-varicose-vein-treatment/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-grants-conditional-approval-to-darzalex--daratumumab--in-multiple-myeloma--genmab/2024-02-09T11:02:08+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-study-of-sufentanil-nanotabs--acelrx-pharmaceuticals--shows-non-inferiority-to-morphine-for-acute-pain-/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-study-of-repatha--evolocumab--shows-efficacy-in-patients-with-high-cholesterol--amgen/2024-02-09T11:02:27+00:00weekly0.6https://www.medthority.com/news/2018/08/paion-ag-initiates-phase-iii-trial--for-remimazolam-for-induction-and-maintenance-of-general-anesthesia-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-icaria-mm-trial-of-sar-650984-shows-reduced-risk-in-multiple-myeloma---sanofi/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-kovaltry--recombinant-factor-viii---for-the-treatment-of-hemophilia-a--bayer-health-care/2024-02-09T11:02:55+00:00weekly0.6https://www.medthority.com/news/2015/06/gilead-sciences-files-emtricitabine-and-tenofovir-alafenamide-at-ema-for-hiv-aids-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2018/09/the-fda-has-accepted-a-supplemental-new-drug-application--for-vraylar-to-treat-bipolar-depression---allergan/2024-10-21T14:52:36+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-sword-1-2-studies-of-juluca-shows-efficacy-at-148-weeks-in-hiv---viiv-healthcare/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2016/01/breakthrough-therapy-designation-for-venetoclax-for-treatment-of-patients-with-untreated-treatment-naive-acute-myeloid-leukemia-aml-abbvie/2024-10-21T14:40:34+00:00weekly0.6https://www.medthority.com/news/2014/05/saxagliptin---dapagliflozin---metformin-combination-successful-in-phase-iii-trial-for-type-2-diabetes---astrazeneca/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2019/06/gout-patients-suffer-in-silence-with-low-expectations-of-treatment/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-trial-of-praluent--alirocumab--cut-ldl-c-in-patients-with--heterozygous-familial-hypercholesterolemia--sanofi---regeneron-pharma/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2019/05/bc-3781-file-with-eu-for-community-acquired-pneumonia---nabriva-therapeutics/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2013/10/chmp-recommends-opsumit--actelion--for-pah/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-grants-accelerated-approval-for-tecentriq---abraxane-in-metastatic-triple-negative-breast-cancer---genentech-roche/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-chmp-recommends-approval-of-coagadex--coagulation-factor-x-human--for-hereditary-factor-x-deficiency--bio-products-lab/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-grants-accelerated-approval-for-opdivo-for-patients-with-metastatic-small-cell-lung-cancer---bms-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2017/12/american-society-of-hematology---who-s-in-charge-/2024-02-22T11:54:23+00:00weekly0.6https://www.medthority.com/news/2018/04/the-microbiology-society-annual-conference-2018/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2013/08/lampalizumab-success-in-phase-ii-study-for---dry--amd/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-gives-510-k--approval-to-accula-flu-a-flu-b-test-for-influenza-diagnostics---mesa-biotech-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2018/05/ece-2018---20th-european-congress-of-endocrinology-19---22-may-2018-barcelona--spain/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2016/08/medtronic-completes-acquisition-of-heartware/2021-09-24T07:09:38+00:00weekly0.6https://www.medthority.com/news/2019/07/aries-mrsa-assay-filed-with-the-fda-for-infectious-disease-detection/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-edurant-for-hiv-1-infection/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-bondease-skin-adhesive-for-closure-of-incisions-and-lacerations--optmed-inc-/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2019/02/top-line-results-from-phase-iii-study-of-tanezumab-in-chronic-low-back-pain--eli-lilly---pfizer/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2017/11/kymriah-filed-at-fda-to-treat-relapsed-or-refractory-diffuse-large-b-cell-lymphoma---novartis-/2024-07-26T10:07:14+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-procysbi-for-nephropathic-cystinosis-/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2019/06/novartis-reports-long-term-data-from-the-enestfreedom-and-enestop-trials-of-tasigna-for-ph--chronic-myeloid-leukemia-/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-triumeq-triple-therapy-for-hiv-1-infection---viiv-healthcare/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2017/11/ortus-expandable-posterior-lumbar-interbody-system-receives-510-k--clearance-from-fda---atlas-spine-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2015/02/new-baxter-company-is-baxalta/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2013/11/sofosbuvir--gilead--successful-treatment-of-hcv-and-hiv-patients-/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2016/08/european-commission-grants--a-conditional-approval-for-zalmoxis-as--a-patient-specific-adjunctive-treatment-in-haplo-identical-haematopoietic-stem-cell-transplantation----molmed-s-p-a-/2021-09-24T07:09:38+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-trial-of-yutiq-shows-efficacy-in-uveitis---eyepoint-pharma/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2017/04/nih-study-of-promacta---revolade--eltrombopag-positive-for-treatment-of-severe-aplastic-anemia---novartis/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2012/07/ferring-licenses-elobixibat-from-albireo-for-chronic-constipation-and-ibs-/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-vectibix-plus-folfox-for-first-line-colorectal-cancer-treatment---amgen/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-rfxiii--novo-nordisk--for-fxiii-a-subunit-deficiency/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2014/11/astrazeneca-to-develop-reversal-agent-medi-2452-for-brilinta/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2012/05/f-627--generon--commences-phase-ii-study-for-neutropenia/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2014/01/cevira-update-on-fda-discussions-for--cervical-precancerous-lesions--photocure/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2013/06/norgine-launches-setofilm-in-the-united-kingdom-for--the-prevention-of-nausea/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2011/10/astellas-cancels-its-oral-factor-xa-inhibitor--darexaban/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2014/05/pacira-pharma-submits-snda-to-fda-for-exparel-as-nerve-block-pacira-pharma-/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2016/02/ibrance--palbociclib----fulvestrant-is-fda-approved-for-hr---her2--metastatic-breast-cancer--pfizer/2024-02-22T16:11:20+00:00weekly0.6https://www.medthority.com/news/2016/11/ce-mark-approval-for-quadra-allure-mp-cardiac-resynchronization-therapy-pacemaker--crt-p--with-magnetic-resonance--mr--conditional-labeling---st-jude-medical/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2018/04/nice-gives-final-opinion-approving-use-of-roactemra-in-giant-cell-arteritis---roche-chugai-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2017/06/biological-dmard-guidelines-associated-with-a-reduced-need-for-knee-and-hip-replacements-in-ra-patients/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2018/03/scientists-link-genes-to-brain-anatomy-in-autism/2024-10-22T08:29:12+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-ruzurgi-for-the-treatment-of-lambert-eaton-myasthenic-syndrome--lems--in-patients-6-to-less-than-17-years-of-age----jacobus-pharma/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2014/08/gsk-ends-work-on-gsk-2586184-for-treatment-of-psoriasis-and-ulcerative-colitis/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2013/03/orexo-sells-us-rights-to-abstral-to-galena-biopharma/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-prevymis-for-prophylaxis--prevention--of-cytomegalovirus--merck-inc--/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-s-chmp-recommends-expanding-indication-for-volibris--ambrisentan--as-combination-treatment-for-pulmonary-arterial-hypertension--glaxosmithkline/2024-02-09T11:03:15+00:00weekly0.6https://www.medthority.com/news/2018/01/breakthrough-therapy-designation-to-promacta-for-use-in-the--treatment-of-severe-aplastic-anemia-as-a-first-line-therapy--novartis-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2019/09/european-commission-approves-epidyolix--for-use-as-adjunctive-therapy-of-seizures-associated-with-lennox-gastaut-syndrome-or-dravet-syndrome---gw-pharma/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2013/07/bayer-onyx-file-nexavar-at-fda-and-ema-for-treatment-of-thyroid-cancer/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2018/01/data-on-arymo-er-opioid-treatment-for-severe-pain-published-in--current-medical-research-and-opinion-journal---egalet-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-aemcolo-to-treat-travellers-diarrhea--cosmo-technologies/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-review-clears-olmesartan-of-cv-risk-in-diabetic-patients--daiichi-sankyo/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2019/10/interim-data-from-bridge-phase-iii-study-of-prx-102-shows-efficacy-in-fabry-disease---protalix-biotherapeutics/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-tommorrow-trial-of-pioglitazone-0-8-mg-sr-has-been-terminated-as-a-treatment-for-alzheimers-disease-takeda-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2017/11/successful-phase-iii-trial-of-firdapse-for-the-symptomatic-treatment-of-lambert-eaton--myasthenic-syndrome---catalyst-pharma-/2021-09-24T07:14:35+00:00weekly0.6https://www.medthority.com/news/2018/06/results-of-phase-iii-prosper-trial-in-xtandi-for-prostate-cancer-published-in-new-england-journal-of-medicine---astellas-pharma-/2024-02-09T11:03:46+00:00weekly0.6https://www.medthority.com/news/2019/10/verzenio--abemaciclib--significantly-extends-life-by-a-median-of-9-4-months-for-women-with-hr---her2--advanced-breast-cancer-in-monarch-2-study---eli-lilly/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2015/03/abbvie-to-acquire-pharmacyclics-for--21-billion-and-with-it-imbruvica-/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2012/11/phase-iii-trial-of-stivarga--bayer-healthcare--finds-positive-effect-in-patients-with-gist/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-accepts-filing-of-lifitegrast-for-dry-eye-disease--shire/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2018/10/patients-poorly-informed-about-safety-issues-in-use-of-complementary-alternative-medicines-and-risk-of-interactions-with-anti-cancer-drugs/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2018/09/imperial-trial-reports-positive-12-month-data-for-eluvia-stent-system-in-patients-with-peripheral-artery-disease---boston-scientific/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2016/11/mdco-216--a-cholesterol-efflux-promoter--is-discontinued--the-medicines-company/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2016/10/results-of-study-497-of-relizorb-in-enteral-nutrition-shows-device-improves-nutrition-alcresta-therapeutics/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2017/06/kamada-withdraws-from-ema-its-application--maa--for-its-proprietary-inhaled-alpha-1-antitrypsin--aat--therapy-for-the-treatment-of-alpha-1-antitrypsin-deficiency--aatd--/2022-09-14T13:27:56+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-does-not-recommend-vargetef-for-treatment-of-non-small-cell-lung-cancer--boehringer/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2018/02/poxel-s-a--licenses-us-and-eu-rights-to-imeglimin-a-drug-to-treat-type-2-diabetes-to-roivant-sciences-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-expands-indication-of-xalkori--crizotinib--to-include-previously-untreated-patients-with-alk-positive-nsclc--pfizer/2024-02-09T11:05:18+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-eclipse-study-of-tremfya-showed-superior-long-term-efficacy-in-psoriasis---j-j-janssen-cilag/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2012/03/shire-initiates-phase-iv-trials-to-compare-vyvanse-ands-concerta/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2018/01/ani-pharma-acquires-atacand--atacand-hct--arimidex-and-casodex-us-rights-from-astrazeneca-/2025-10-16T11:14:48+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-lu-ae-58054--idalopirdine--shows-weak-efficacy-in-alzheimer-s-disease--lunbeck/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-bendeka--bendamustine-hydrochloride---a-10-minute-infusion-to-treat-cll--teva/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2014/02/phase-iii-results-for-dysport-next-generation-in-cervical-dystonia-ipsen/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-results-for-etc-1002-in-dyslipidaemia-published-in-nejm---daiichi-sankyo---esperion-therapeutics/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2012/11/freedom-study-finds-that-cabg-has-better-outcomes-than-pci-in-diabetic-patients-with-coronary-disease---------------/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-reyvow-for-migraine---eli-lilly/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2016/09/allergan-acquires-substantially-all-of-the-assets-of-retrosense/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2015/10/shield-1-trial-confirms-benefits-of-heartmate-php-in-percutaneous-coronary-intervention--st-jude-medical/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-zinbryta--daclizumab--to-treat-relapsing-multiple-sclerosis--biogen---abbvie/2024-02-09T11:05:42+00:00weekly0.6https://www.medthority.com/news/2014/05/atx-101-submitted-to-fda-for-submental-fat-reduction-kythera-biopharma/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2016/01/prognosis-study-of-elecsys-sflt-1-plgf-immunoassay-ratio-test-for-pre-eclampsia-published-in-nejm--roche/2024-02-09T11:06:05+00:00weekly0.6https://www.medthority.com/news/2018/01/ubenimex-fails-in-liberty-study-for-pulmonary-arterial-hypertension-and-is-discontinued-for-this-condition---eiger-biopharma-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2019/07/uniqure-announces-36-weeks-of-follow-up-data-from-phase-iib-study-of-amt-061-treated-for-hemophilia-/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-trials-of-tmc-435--medivir-tibotec--show-positive-response-in-patients-with-hepatitis-c/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---listening-to-gut-noises-could-improve-diagnosis-of-irritable-bowel-syndrome/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-approval-of-fotivda--tivozanib--for-patients-with-advanced-renal-cell-carcinoma--eusa-pharma/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iib-report-of-fostamatinib--astrazeneca--oskira-4-trial-for-ra/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2015/07/prism-ii-study-of-nuedexta--dextromethorphan-and-quinidine-sulphate--reports-data-for-treating-pseudobulbar-affect--avanir-pharma/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2012/01/new-fda-drug-labels-for-anaemia-associated-with-chronic-kidney-disease-patients-treated-with-esas/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2014/08/napp-pharma-to-market-remsima-in-uk---celltrion-napp/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/01/chmp-recommends-dutrebis--lamivudine--raltegravir--for-treatment-of-hiv-aids-merck-inc-/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-weekly-drug-albuvirtide-meets-endpoints-in-treating-patients-with-hiv-aids--frontier-biotechnologies/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2012/01/erivedge--genentech-roche-is-fda-approved-for-basal-cell-carcinoma/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-heartlight-endoscopic-ablation-system-for-patients-with-paroxysmal-atrial-fibrillation--cardiofocus/2024-02-09T11:06:14+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-baxdela-for-the-treatment-of-community-acquired-bacterial-pneumonia--cabp----melinta-therapeutics/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2014/06/darbepoetin-alfa-biosimilar-actorise-launched-in-india-for-anaemia-cipla/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2018/02/are-standard-medical-tests-good-enough-to-diagnose-heart-attacks-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2014/11/long-term-results-for-otezla-in-psoriatic-arthritis--celgene/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2017/03/successful-phase-iii-trial--monarch-2-of-abemaciclib-and-fulvestrant-for-hormone-receptor-positive--hr----human-epidermal-growth-factor-receptor-2-negative--her2----advanced-breast-cancer---eli-lilly/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-accepts-filing-of-rituxan--for-pemphigus-vulgaris-and-grants-priority-review---genentech-roche-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2014/05/successful-trials-for-nintedanib-for-idiopathic-pulmonary-fibrosis---boehringer/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2019/07/new-trial-demonstrates-the-efficacy-of-a-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-patients-with-metastatic-colon-cancer----bayer-healthcare/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2016/03/new-intravenous-formulation-of-varubi--rolapitant--for-nausea-filed-with-fda--tesaro-/2024-10-22T08:19:33+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-arches-trial-of-xtandi-meets-primary-endpoint-in-metastatic-prostate-cancer---pfizer-inc--and-astellas/2021-09-24T07:17:11+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-requires-label-changes-to-dermal-filler-products/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2014/04/novartis-reorganises-product-portfolio-in-deals-with-gsk-and-eli-lilly/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2016/10/daiichi-sankyo-collaborates-with-inspirion-delivery-sciences-to-commercialise-morphabond-extended-release-tablets-for-severe-pain-management-in-the-us/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-soliqua-100-33--insulin-glargine---lixisenatide-injection--to-treat-type-2-diabetes---sanofi/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2018/04/world-asthma-day-2018/2021-12-01T12:10:12+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-artis-icono-angiography-systems---siemens-healthineers-/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-bevespi-aerosphere-to-treat-copd---astrazeneca/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2011/07/fda-warns-multaq-increases-risk-of-death--stroke-and-heart-failure-in-patients-with-permanent-atrial-fibrillation/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2019/06/all-primary-and-secondary-outcome-measures-were-met-in-a-phase-iv--study-assessing-acthar-gel-in-patients-with-persistently-active-ra---mallinckrodt/2021-09-24T07:16:58+00:00weekly0.6https://www.medthority.com/news/2015/04/eu-approves-soolantra--ivermectin--via-decentralised-procedure-to-treatrosacea--galderma-/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2019/01/eu-filing-of-ccx-168-for-vasculitis-withdrawn---chemocentryx---vifor-fresenius/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-rapivab---peramivir-injection--extending-its-availability-for-the-treatment-of-acute-uncomplicated-influenza-to-pediatric-patients-2-years-and-older---biocryst-pharmaceuticals-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-approval-of-maviret--glecaprevir-pibrentasvir--for-adults-with-chronic-hepatitis-c-virus--abbvie/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2019/08/epns-2019---congress-preview/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-accepts-filing-nda-from-chiasma-pharma-for-octreotide-capsules--to-treat-acromegaly--roche---genentech/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-grants-accelerated-approval-for-galafold-treatment-of-adults-with-a-confirmed-diagnosis-of-fabry-disease-and-an-amenable-galactosidase-alpha-gene--gla--variant-based-on-in-vitro-assay-data---amicus-therapeutics-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-clears-rotor-gene-q-mdx-instrument-and-compatible-influenza-a-b-assay--qiagen-/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2014/08/cdc-recommends-prevnar-13-to-protect-adults-aged--65-years-and-older-against-pneumococcal-disease--pfizer/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-accepts-for-review-csl-behring-bla-for-csl-627--rviiisinglechain--to-treat-haemophilia-a/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-trials-of-cangrelor-for-pci-confirm-advantages/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2017/11/neos-therapeutics-rejects-offer-from-pdl-biopharma/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2013/01/soliris--alexion-pharma--rejected-by-uk-health-ministers-for-haemolytic-uraemic-syndrome/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2013/03/gsk-files-eperzan--albiglutide--at-ema-for-treatment-of-type-2-diabetes/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-ultresa-and-viokace--aptalis-pharma--for-exocrine-pancreatic-insufficiency/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2012/02/epanova--omthera--has-better-bioavailability-than-lovaza/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2012/05/novottf-100a--novocure--shows-positive-phase-iii-results-for-brain-cancer/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approval-for-adzenys-er--amphetamine--extended-release-oral-suspension-to-treat-adhd---neos-therapeutics-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2012/06/nice-recomends-xgeva--amgen--for-bone-metastases/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-rhythmia-mapping-system-for-arrhythmias/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-accepts-filing-of-opdivo--nivolumab--to-treat--non-squamous-non-small-cell-lung-cancer--bms/2024-02-09T11:06:23+00:00weekly0.6https://www.medthority.com/news/2020/01/astrazeneca-recovers-rights-to-brazikumab-from-allergan-/2021-09-24T07:11:46+00:00weekly0.6https://www.medthority.com/news/2017/11/mallinckrodt-acquires-ocera-therapeutics-and-with-it-ocr-002-a-proposed-treatment-for-hepatic-encephalopathy-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-issues-complete-response-letter-relating-to-kalydeco--ivacaftor--treatment-of-residal-function-mutations-of-cystic-fibrosis-transmembrane-conductance-regulator--cftr----vertex/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2016/12/xydalba--dalbavancin--is-launched-in-the-uk-as-a-treatment-of-acute-bacterial-skin-and-skin-structure-infections---cardiome-pharma/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2013/11/trial-reports-symplicity--medtronic--data-consistent-over-3-year-study/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-javelin-ovarian-100-study-of-bavencio-does-not-meet-endpoint-in-ovarian-cancer---merck-kgaa---pfizer-inc-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iia-trial-showed-significantly-improved-peak-lung-function-when-rpl-554-was-added-to-tiotropium-in-patients-with-moderate-to-severe-copd---verona-pharma/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-study-of--napabucasin----nab-paclitaxel---gemcitabine-for-pancreatic-cancer/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2018/07/successful-phase-iii-study--map-us-study--of-rhb-104-for-treatment-of-crohn-s-disease---redhill-biopharma-ltd-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2018/12/data-analysis-of-monaleesa-trials-shows-efficacy-and-tolerability-of-kisqali-in-hr--her2--advanced-breast-cancer-in-patients-with-difficult-to-treat-visceral-disease--novartis/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-liletta-for-contraception-actavis-medicines360/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-advisory-committee-recommends-gattex--nps-pharma--for-short-bowel-syndrome/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2014/05/abt-450-r--abt-267--abt-333-combo-submitted-to-eu-for-hepatitis-c-abbvie/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2013/03/moxduo--qrx-pharma--resubmitted-to-the-fda-for-approval-for-pain-control/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-extends-review-date-for-the-liquid-frozen-formulation-of-the-mva-bn-smallpox-vaccine---bavarian-nordic-a-s/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-gilenya-to-treat-children-and-adolescents-with-relapsing-remitting-multiple-sclerosis---novartis/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2013/10/chmp-recommend-additional-indication-for-synflorix--gsk--/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-cobas-6800---8800--hiv-test-for-viral-load-diagnostics--roche/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-pentax-medical-video-duodenoscope-ed34-i10t2---dec-duodenoscope----pentax-medical/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2015/12/amgen-to-acquire-catherex--a-subsidiary-of-medigene-ag--developer-of-t-cell-therapy-platforms-and-imlygic--talimogene-laherparepvec--formerly-t-vec-/2024-02-09T11:06:35+00:00weekly0.6https://www.medthority.com/news/2016/05/the-medicines-company-sells-rights-to-cleviprex--clevidipine---kengreal--cangrelor--and-the--rights-to-argatroban-for-injection-to-chiesi-usa--inc-/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2013/03/new-studies-support-the-benefits-of-betmiga-myrbetriq--astellas--for-treating-overactive-bladder/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2012/07/update-recommends-brilinta--astrazeneca--for-heart-attack-patients/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2013/10/orexigen-files-contrave-for-obesity-in-the-eu/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2014/09/two-year-data-for-corevalve-in-aortic-valve-disease-medtronic/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2013/08/further-trials-of-vercimon-in-crohn-s-disease-on-hold/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-impella-2-5--cp--5-0-and-ld-heart-pumps-for-cardiogenic-shock--abiomed/2021-09-24T07:10:45+00:00weekly0.6https://www.medthority.com/news/2015/06/checkmate-017-study-of-opdivo--nivolumab-in-squamous-nsclc-success-over-one-year-bms/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2013/03/reanalysis-of-a-trial-of-lipigesic-m--puramed-bioscience--suggests-treatment-is-effective-for-migraine/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2017/10/european-congress-of-neurosurgery-to-conclude-in-venice-2/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2017/07/biomarin-files-bla-at-fda-for-pegvaliase--a-pegylated-recombinant-phenylalanine-ammonia-lyase-enzyme-product--to-reduce-blood-phenylalanine--phe--levels-in-adult-patients-with-phenylketonuria-/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2014/03/success-in-phase-ii-trial-for-guselkumab-for-psoriasis---janssen/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2014/11/ema-approves-harvoni-combination-to-treat-hepatitis-c-genotype-1-and-4-and-combination-hiv-hcv---gilead-sciences/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2015/04/epidiolex--cannabidiol--cuts-seizures-by-half-in-dravet-and-lg-syndrome-gw-pharma/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-vyvanse--lisdexamfetamine-dimesylate--to-treat-binge-eating-disorder-shire/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2017/12/positive-phase-iii-results-for-burosumab-in-adults-with-x-linked-hypophosphatemia---ultragenyx-pharmaceutical-inc-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2012/05/us-court-rules-against-mylan-that-zetia--merck-inc---patent-is-valid/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2013/07/additional-analysis-reveals-some-benefits-with-gammagard-liquid--baxter--in-alzheimers-disease/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2015/05/ipsen-acquires-octreopharm-sciences/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2019/02/long-term-clinical-accuracy-data-of-onetouch-blood-glucose-test-in-diabetes-published-in-journal-of-diabetes-science-and-technology---j-j-lifescan/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-study-of-shp-643--lanadelumab--meets-primary-endpoint-in-hereditary-angioedema--shire/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2019/09/the-lancet-publishes-results-from-the-pivotal-study-of-inebilizumab-in-patients-with-neuromyelitis-optica-spectrum-disorder---viela-bio/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2016/03/uk-nice-changes-guidance-and-now-recommends-zytiga--abiraterone--for-some-prostate-cancer--janssen-/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2013/05/moxetumomab--medimmune-astrazeneca--moves-into-phase-iii-for-treatment-of-hairy-cell-leukemia/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2012/10/abt-450-r---abt-267---abt-333-combination-in-hepatitis-c/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2012/09/aspirin-clopidogrel-no-better-than-aspirin-alone-for-patients-with-lacunar-stroke/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2019/11/regeneron-update-on-phase-iii-progress-in--two-trials-of-libtayo-to-treat-first-line-nsclc-/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2016/09/eleven-biotherapeutics-acquires-viventia-bio-and-with-it-vicinium-and-proxinium-/2021-09-24T07:09:14+00:00weekly0.6https://www.medthority.com/news/2017/06/late-breaking-clinical-trials-from-era-edta/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2016/04/ironwood-pharma-secures-us-rights-to-market-zurampic--lesinurad--for-the-treatment-of-gout--astrazeneca/2021-09-24T07:10:38+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-label-extension-for-crysvita-in-x-linked-hypophosphatemia---ultragenyx-pharmaceutical-kyowa-kirin/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2018/02/migraine-linked-to-increased-risk-of-cardiovascular-problems/2024-02-23T11:51:24+00:00weekly0.6https://www.medthority.com/news/2011/11/humira--abbott--and-other-tumour-necrosis-factor-antagonists-are-not-linked-to-increased-serious-infection-rate/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2017/12/tecentriq---avastin-meet-endpoints-in-phase-iii-immotion151-study-for-renal-cell-carcinoma--genentech-roche-/2021-09-24T07:13:40+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-cosentyx--secukinumab--for-ankylosing-spondylitis--novartis/2024-02-06T16:02:04+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-issues-warnings-on-avastin/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2012/09/impella-cp-heart-pump--abiomed-inc---receives-510-k--clearance-in-usa/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2014/08/boehringer-files-nda-at-fda-for-olodaterol---tiotropium--for-copd/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2011/10/xience-prime-xience-v-stents-as-alternative-to-cagb-in-excel-trial/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2017/12/new-light-shed-on-how-brain-signals-connect-to-neurons/2024-07-26T10:20:55+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-grants-12-year-exclusivity-to-flublok-influenza-vaccine--protein-sciences/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2017/07/phase-iii-aspire-trial-of-kyprolis--carfilzomib--lenalidomide-and-dexamethasone-in-multiple-myeloma-meets-secondary-endpoint-of-overall-survival--amgen/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2019/04/csf-1r-filed-with-ema-for-symptomatic-tenosynovial-giant-cell-tumor---daiichi-sankyo/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2019/10/fasenra-approved-in-the-us-for-self-administration-in-a-new-pre-filled-auto-injector--the-fasenra-pen---astrazeneca/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2017/07/nice-extends-recommendation-for-strensiq--asfotase-alfa--to-treat-people-with-paediatric-onset-hypophosphatasia---alexion-pharma/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-vizamyl-for-imaging-amyloid-ge-healthcare/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2018/05/ditch-cranberry-juice-for-urine-infections--says-recent-study/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-of-amg-416-meets-endpoints-in-sec--hyperparathyroidism-amgen/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2014/10/itca-650-meets-primary-endpoints-in-phase-iii-trial-for-t2d---intarcia-/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2018/10/additional-data-from-phase-iii-map-us-study-of-rhb-104-confirms-benefits-in-crohn-s---redhill-biopharma-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-issues-complete-response-letter-to-astrazeneca---zs-pharma-relating-to-zs-9--sodium-zirconium-cyclosilicate--a-proposed-treatment-for-hyperkalaemia-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2017/07/plenvu--ner-1006--is-filed-at-fda--to-provide-complete-bowel-cleansing--norgine---salix/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2017/09/sd-101-fails-to-meet-endpoints-in-phase-iii-essence-study-to-treat-epidermolysis-bullosa---amicus-therapeutics-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2016/02/detailed-phase-iii-suppress-data-for-cmx-001--brincidofovir--in-cytomegalovirus--chimerix/2024-02-06T16:02:19+00:00weekly0.6https://www.medthority.com/news/2016/05/bexsero--meningococcal-group-b-vaccine--meets-endpoints-in-phase-iii-study-for-meningococcal-disease--glaxosmithkline/2024-02-06T16:02:32+00:00weekly0.6https://www.medthority.com/news/2018/02/wave-life-sciences-and-takeda-collaborate-on-nucleic-acid-therapies-for-cns-disorders-including-wve-120102-for-huntington-disease-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-approves-anoro-ellipta-for-copd-gsk-theravance/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-jardiance--empagliflozin--to-reduce-the-risk-of-cardiovascular-death-in-adult-patients-with-type-2-diabetes-mellitus-and-cv-disease--boehringer---eli-lilly-/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2018/10/us-label-of-trintellix--is-expanded-to-refer-to-improvement-in-treatment-emergent-sexual-dysfunction-in-depressed-patients---lundbeck---takeda/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-trials-of-bydureon--amylin-and-alkermes-inc--for-type-2-diabetes/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2014/05/catena-success-in-phase-iii-trial-for-duchenne-muscular-dystrophy---santhera/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2017/12/extra-study-data-on-xultophy-in-type-2-diabetes-published-in-diabetes--obesity-and-metabolism---novo-nordisk-/2025-02-03T14:49:51+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-places-hold-on-three-clinical-trials-involving-keytruda--pembrolizumab--plus-pomalidomide-or-lenalidomide-for-multiple-myeloma---merck-inc-/2024-02-22T09:21:58+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-accepts-nda-to-make-procysbi--available-as-oral-granules-in-packets-to-treat-nephropathic-cystinosis/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-nilemdo--bempedoic-acid--to-treat-treatment-of-hypercholesterolemia-and-mixed-dyslipidemia---daiichi-sankyo---esperion/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2019/01/opdivo-success-in-phase-iii-attraction-3-study-to-treat-oesophageal-cancer--bms---ono/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2019/09/kisqali-delivers-consistently-superior-overall-survival---monaleesa-3-trial-demonstrates-more-life-for-postmenopausal-hr--her2--advanced-breast-cancer-patients---novartis/2024-10-21T14:37:04+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-nucletron-s-esteya-brachytherapy-system-for-skin-cancer/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-results-from-ascend-1-study-for-zykadia-in-alk--non-small-cell-lung-cancer---novartis/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2016/03/final-results-of-epos-study-of-aptiom--eslicarbazepine-acetate--in-epilepsy-published-in-acta-neurologica-scandinavica--eisai/2024-02-22T09:23:24+00:00weekly0.6https://www.medthority.com/news/2017/09/application-to-eu-withdrawn-for-fulphila--pegfilgrastim-biosimilar--in-neutropenia---mylan-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2012/06/orexo-ab-regains-us-marketing-rights-to-abstral-/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approval-for-edora-hf-t-qp--an-mr-conditional-cardiac-resynchronization-therapy-pacemaker-with-mri-autodetect-technology---biotronik/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2018/01/nice-gives-limited-approval-for-darzalex-in-multiple-myeloma---janssen-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-study-of-benlysta--belimumab--meets-endpoints-in-systemic-lupus-erythematosus-glaxosmithkline/2021-09-24T07:09:50+00:00weekly0.6https://www.medthority.com/news/2017/05/a-call-to-action-for--better-air--better-breathing--on-world-asthma-day---2nd-may-2017/2021-11-30T10:12:07+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iib-study-of-rvx-208--resverlogix--fails-to-meet-primary-endpoint-in-dyslipidaemia/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2016/05/stryker-acquires-stanmore-implants-for--35-6-million/2025-10-16T11:06:46+00:00weekly0.6https://www.medthority.com/news/2018/04/keytruda---alimta---carboplatin-refiled-with-ema-for-metastatic-nonsquamous-nsclc---merck-inc-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2012/06/three-year-follow-up-data-on-sprycel--otsuka-bms--shows-fast--deep-response-in-cml-patients/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2016/02/nice-issues-draft-guidance-for-kanuma--sebelipase-alfa--for-lysosomal-acid-lipase-deficiency--alexion-pharma/2021-09-24T07:08:59+00:00weekly0.6https://www.medthority.com/news/2017/06/a-post-hoc-analysis-of-victoza--liraglutide--shows-reductions-in-cv-risk-for-patients-with-type-2-diabetes--novo-nordisk/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves--senhance-system--a-new-robotically-assisted-surgical-device---transenterix-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2013/03/study-suggests-omega-3-fish-oil-can-help-protect-against-skin-cancer-/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-study-of-intuniv--guanfacine-hydrochloride-prolonged-release--meets-primary-endpoint-in-adults--with-attention-deficit-hyperactivity-disorder---shire---shionogi-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2017/09/esax-htn-study-phase-iii-pivotal-study-of-non-steroidal--selective-novel-mineralocorticoid-receptor--blocker--esaxerenone--has-success-for-patients-with-essential-hypertension-in-japan----daiichi-sankyo-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2017/10/new-data-show-ocrelizumab-reduces-disease-progression-in-multiple-sclerosis/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-the--only-triple-combination-tablet-with-trijardy-xr-for-adults-with-type-2-diabetes---eli-lilly---boehringer/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2018/06/sandoz-presents-switching-data-from-phase-iii-studies-of-its-biosimilar-zessly--infliximab--and-biosimilar-erelzi--etanercept-showing-the-biosimilars-match-their-reference-biologics-/2024-07-26T10:20:14+00:00weekly0.6https://www.medthority.com/news/2013/11/aezs-130--aeterna-zentaris--filed-with-fda-for-ghd/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2015/04/phase-iii-data-on-hz-su-in-herpes-zoster-published-in-nejm--gsk/2024-02-22T09:23:56+00:00weekly0.6https://www.medthority.com/news/2011/11/nuedexta-is-filed-at-eu-for-pseudobulbar-affect/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2011/10/studies-show-flutiform-benefits-for-asthma-patients/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2018/04/abbv-066-filed-with-fda-for-moderate-to-severe-plaque-psoriasis---abbvie-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2019/05/ddw-2019---learn-more/2024-02-22T09:55:45+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-jakafi--ruxolitinib--shows-treatment-advantages-in-myelofibrosis--novartis/2024-02-06T16:03:01+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-confirms-its-refusal-to-recommend-yondelis--hycamtin-and-gemzar-for-treatment-of-ovarian-cancer-/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2018/10/survey-examines-attitudes-to-brain-atrophy-in-patients-with-multiple-sclerosis---celgene/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-updates-label-of-champix--varenicline--for-nicotine-addiction--pfizer/2024-02-06T16:03:14+00:00weekly0.6https://www.medthority.com/news/2011/10/nice-rejects-yervoy-for-metastatic--malignant-melanoma/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-extension-of-label-for-nerlynx-to-include-safety-information-for-patients-with--her2-positive-early-stage-breast-cancer---puma-biotechnology/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2014/11/birken-ag-files-oleogel-s-10-ointment-for-wound-treatment-at-ema/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2017/01/valeant-pharma-international-sells-its-interest-in-dendreon-pharma-to-sanpower-group-co---ltd-and-with-it--prostate-cancer-vaccine-provenge-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2017/03/eu-chmp-recommends-trumenba---meningococcal-group-b-vaccine--immunization-of-individuals-10-years-and-older-to-prevent-invasive-meningococcal-disease-----pfizer/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2013/09/numeta-g13-e-marketing-suspended-in-the-eu/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2011/11/lower-dose-of-corticosteroids-as-effective-as-higher-dose-for-shoulder-pain/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-invokana-to-reduce-the-risks-associated-with-diabetic-kidney-disease-in-patients-with-type-2-diabetes--janssen-pharma/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-results-for-hetlioz--tasimelteon--in-sleep-disorders-published-in-the-lancet-vanda-pharmaceuticals/2024-02-22T09:57:47+00:00weekly0.6https://www.medthority.com/news/2011/10/ocriplasmin-for-vitromacular-adhesion-is-filed-at-ema/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-illuminate-trial-report-of-imbruvica---gazyva-combination-for-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma---abbvie---janssen-biotech/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2012/11/european-commission-approves-elyea--bayer--for-treatment-of--wet--amd-/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2018/10/ux-007-fails-phase-iii-trial-to-treat-patients-with-glucose-transporter-type-1-deficiency-syndrome--ultragenyx/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-trial-of-hz-su-for-herpes-zoster-meets-primary-endpoint-gsk/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2014/02/sofosbuvir---ledipasvir-combination-for-hepatitis-c-is-filed-at-fda--gilead/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2016/08/publication-of-24-months-results-of-recharge-clinical-study-of-vbloc-neurometabolic-therapy-in-239-patients-with-obesity--enteromedics-inc--/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2012/03/brodalumab--amgen--success-in-psoriasis-phase-ii-study/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2014/09/ferric-citrate-approved-by-fda-for-hyperphosphatemia-keryx-biopharma/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2016/01/shire-resubmits-lifitegrast--shp-605--to-the-fda-for-dry-eye-disease-/2024-02-22T09:58:21+00:00weekly0.6https://www.medthority.com/news/2018/04/ferring-pharma-acquires-rebiotix-inc--and-with-it-microbiome-rbx-2660-for-clostridium-difficile-infection/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2012/11/sobi-files-kineret-at-ema-for-caps-treatment/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2014/07/brivaracetam-success-in-phase-iii-trial-for-partial-onset-seizures---ucb/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2016/08/pivotal-study-of-exablate-neuro-system-for-essential-tremor-published-in-new-england-journal-of-medicine---insightec/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2017/03/study-shows-benefits-of-cardiomems-hf-system-in-heart-failure--abbott/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2013/10/mannkind-corp-resubmits-nda-for-afrezza-for-t1-2d/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-recommends-imnovid---bortezomib---dexamethasone--to-treat-multiple-myeloma--celgene-/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-approves-invokana--janssen--to-treat-type-2-diabetes/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-novoeight--novonordisk--for-haemophilia-a/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2013/04/uk-and-german-approvals-for-fluarix-tetra--gsk--influenza-vaccine/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-cablivi-to-treat-acquired-thrombotic-thrombocytopenic-purpura---ablynx-sanofi/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2016/10/norwegian-government-sponsored-trial-shows--infliximab-biosimilar-is-not-inferior-to-continued-treatment-with--remicade-the-originator-drug--pfizer---celltrion---orion---mundipharma/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-tagrisso-for-1st-line-treatment-of-locally-advanced-or-metastatic-nsclc-with-activating-epidermal-growth-factor-receptor--egfr--mutations---astrazeneca-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-chmp-recommends-lesinurad-with-a-xanthine-oxidase-inhibitor--xoi--for-the-adjunctive-treatment-of-hyperuricaemia-in-adult-gout-patients---astrazeneca/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-and-japan-approve-ultibro-breezhaler-for-copd/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2015/01/biogen-acquires-convergence-pharmaceuticals-for--675-million-/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2012/05/ven-307-success-iin-phase-iii-trial-for-anal-fissure-pain/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-trials-of-e-2609-for-alzheimers-will-be-discontinued---eisai-and-biogen/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2014/09/servier-laboratories-and-cti-agree-collaboration-for-marketing-pixuvri-outside-us-/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2018/10/real-world-registry-data-for-orbactiv-in-absssi-published-in-open-forum-infectious-diseases---melinta-therapeutics-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-advisory-committee-recommends-adasuve--aexza-pharma-l-for-agitation-with-sschizophrenia/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2013/12/contrave-refiled-with-fda-for-obesity-orexigen-therapeutics/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2016/02/flulaval-quadrivalent--influenza-vaccine--filed-with-fda-for-expanded-indication--glaxosmithkline/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2016/07/nice-recommends-firmagon--degarelix--to-treat-men-with-advanced-hormone-dependent-prostate-cancer-who-have-spinal-metastases---ferring/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2015/08/new-results-with-cefaly-in-migraine-pain-published-in-the-journal-of-headache-and-pain--cefaly-technologies/2024-02-22T10:03:48+00:00weekly0.6https://www.medthority.com/news/2018/09/three-year-results-with-the-in-pact-admiral-drug-coated-balloon-shows-positive-results-in-pad---medtronic-/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2018/03/lx-4211-filed-with-ema-for-type-1-diabetes---sanofi-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2011/10/chmp-rejects-glybera-for-lipoprotein-lipase-deficiency/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-iclusig-ariad-pharma--for-cml-and-ph--all/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2014/09/zinbryta-superior-to-avonex-in-phase-iii-decide-trial-for-multiple-sclerosis--biogen---abbvie/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2012/02/new-study-for-architect-tacrolimus-assay--abbott-diagnostics-/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-ocrevus--ocrelizumab--to-treat--relapsing-and-primary-progressive-forms-of-multiple-sclerosis---genentech---roche/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2019/07/ean2019--near-death-experiences-associated-with-rem-sleep-says-new-research-1/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-trial-of-tas-102-for-colorectal-cancer-meets-primary-endpoint---taiho-pharma/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-of-nepa--helsinn-and-eisai--meets-endpoint-in-patients-with-nausea/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-data-shows-gazyva--obinutuzumab--halves-risk-of-death-in-untreated-chronic-lymphocytic-leukemia--genentech/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2012/01/aganocide--novabay-pharma--enters-phase-iib-trial-for-adenoviral-conjunctivitis/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2018/02/analysis-of-pivotal-columbus-trial-of-encorafenib---binimetinib--shows-reduced-risk-of-death-for-patients-with-braf-mutant-melanoma----array-biopharma---pierre-fabre-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2012/08/talactoferrin-fails-fortis-m-trial-for-nsclc/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---exciting-time-in-alopecia--new-tools-of-genetics-to-understand-the-basis-of-the-disease/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2016/05/masican--masitinib--filed-with-ema-for-adults-with-severe-systemic-mastocytosis--ab-science/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-marketing-application-for-xpert-xpress-flu-and-xpert-xpress-flu-rsv-for-influenza-cepheid/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2018/10/kissei-pharma-licenses-tavalisse--for--japan--china--south-korea-nd-taiwan---rigel-pharmaa/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2012/11/acz-885--novartis--success-in-phase-ii-study-for-familial-mediterranean-fever-----------------/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2012/05/enzalutamide-is-filed-at-fda-by-medivation-for-prostate-cancer/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-award-orphan-status-to-a-4250--albireo--for-primary-biliary-cirrhosis-and-pfic---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-ii-trial-of-ad-04-shows-benefits-in-alzheimers---affiris/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2019/02/post-hoc-analysis-of-merit-phase-iii-trial-of-odactra-shows-better-sleep-for-allergic-rhinitis-patients---slit/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-approves-halaven--eribulin--for-adult-patients-with-unresectable-liposarcomas--eisai/2024-02-06T16:03:35+00:00weekly0.6https://www.medthority.com/news/2014/08/celltrion-files-remsima-at-fda-as-biosimilar-version-of-remicade-/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2011/11/xarelto-bayer-johnson---johnson--is-fda-approved-for-stroke-prevention-in-patients-with-non-valvular-atrial-fibrillation/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2012/03/first-patient-treated-in-phase-iii-study-of-riastap--csl-behring--to-control-bleeding-in-aortic-aneurysm-surgery/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-settle-trial-of-safinamide--newron-pharma--shows-significant-improvements-in-parkinson-s-disease-patients/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2014/01/prosensa-provides-postive-subset-analysis-of-drisapersen-for-duchenne-muscular-dystrophy/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2018/01/positive-phase-iiib-liberty-study-for-amg-334-in-patients-with-episodic-migraine--novartis---amgen-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2017/01/sandoz-withdraws-application-at-ema-for-approval-of-zioxtenzo--pegfilgrastim-biosimilar--/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2011/12/addition-of-avastin--genentech--to-conventional-therapy-improves-survival-in-her2-positive-breast-cancer/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2018/08/positive-results-from-solar-1-trial-of-byl-719---fulvestrant-for--hr--her2---pik3ca-mutant-advanced-or-metastatic-breast-cancer----novartis-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-ease-lid-trial-shows-positive-treatment-effect-in-all-age-groups-in-levodopa-induced-dyskinesia-associated-with-parkinson-s-disease--adamas-pharmaceuticals/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2018/08/meta-analysis-published-in-jama-cardiology-supports-a-return-to-ldl-targets-and-lower-mg-dl-leveis-in-high-risk-patients-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2014/06/new-data-from-two-trials-of-zubsolv-for-opioid-dependence-orexo-/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-committee-rejects-arcalyst-regeneron---for-treatment-of-gout-flares/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2018/03/british-science-week-2018/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2014/10/jardiance-plus-metformin-filed-with-fda-for-t2d-eli-lilly-boehringer/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019----sunrays-are-not-evil--but-sun-exposure-must-be-kept-under-control-/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2018/08/amgen-files-snda-for-kyprolis-to-include-a-once-weekly-dosing-option-in-combination-with-dexamethasone--kd--for-patients-with-relapsed-or-refractory-multiple-myeloma-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-issues-complete-response-letter-to-acelrx-pharmaceuticals-for-zalviso-system-for-acute-and-breakthrough-pain/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2013/02/chmp-recommends-hexyon-hexacima-vaccine--sanofi-pasteur--/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2018/08/exact-sciences-and-pfizer-enter-into-u-s--promotion-agreement-for-cologuard-to-diagnose-colorectal-cancer-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2019/01/eu-approves-macrilen-for-growth-hormone-deficiency---aeterna-zentaris/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-snda-for-avycaz-to-include-pediatric-patients-3-months-and-older-for-the-treatment-of-complicated-ciai-in-combination-with-metronidazole-and-for-cuti---allergan/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2017/06/mhra-in-the-uk-grants-raxone--idebenone--a-positive-scientific-opinion-to-treat-duchenne-muscular-dystrophy-under-early-access-to-medicines-scheme---santhera-pharmaceuticals/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2018/06/34th-annual-meeting-of-the-european-society-of-human-reproduction-and-embryology--eshre-2018--/2024-02-22T10:05:00+00:00weekly0.6https://www.medthority.com/news/2019/12/tucatinib---trastuzumab---capecitabine-is-filed-at-fda-for-treatment-of-locally-advanced-unresectable-or-metastatic-her2-positive-breast-cancer--including-patients-with-brain-metastases---seattle-genetics/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-gives-priority-review-to-braftovi-doublet-in-metastatic-colorectal-cancer---pfizer/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2011/10/lipitor-ineffective-for-atherosclerosis-in-pediatric-lupus/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2015/01/topline-results-for-alks-5461-in-depression-alkermes/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2015/10/nice-recommends-samsca--tolvaptan--for-autosomal-dominant-polycystic-kidney-disease--otsuka/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2014/10/novartis-sells-influenza-vaccines-to-csl-ltd-for--275-million-effective-2015/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2016/10/merck---co---inc-announces-phase-iii-trial-results-for-letermovir-to-prevent-clinically-significant-cytomegalovirus--cmv--infection--/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-approves-deltyba-for-treatment-of-mdr-tb--otsuka/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-accepts-snda-for-imbruvica--ibrutinib--in-chronic-graft-versus-host-disease--cgvhd--after-failure-of-one-or-more-lines-of-systemic-therapy----abbvie---janssen-biotech/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2014/01/novo-nordisk-files-liraglutide-at-fda-and-ema-for-treatment-of-obesity/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2017/11/study-of-sun-101-eflow-demostrates-improvement-of-lung-function-for-copd-patients--sunovion-pharma-/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2019/12/chmp-recommends-approval-of-vyndaqel-in-hereditary-transthyretin-amyloidosis---pfizer/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2016/01/chmp-recommends-authorisation-for-revlimid--lenalidomide--in--mantle-cell-lymphoma--celgene/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-trial-of-laquinimod-shows-effect-on-brain-tissue-damage/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2020/01/ecco-2020--a-preview-of-the-scientific-programme-/2024-02-22T10:06:06+00:00weekly0.6https://www.medthority.com/news/2018/03/drm-01-fails-two-phase-iii-trials-for-treatment-of-acne---dermira-inc-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-committee-recommends-approval-of-gs-7977--gilead--ribavirin-for-hep-c/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-lower-dose-angeliq--bayer-healthcare--for-menopause-treatment/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2016/08/pharmacosmos-a-s-initiates--studies-of-monofer--isomaltoside-1000-for-iron-deficiency-anaemia-and-non-dialysis-dependent-kidney-disease-to-support-fda-approval-/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2019/08/celsion-announces-publication-of-results-of-national-institutes-of-health--nih--analysis-of-thermodox-in-journal-of-vascular-and-interventional-radiology-/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2015/02/abp-501-biosimilar-phase-iii-study-equivalent-to-humira-in-ra--amgen/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-data-on-qva-149--novartis--from-three-phase-iii-studies-of-copd----------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2016/11/merck-inc--files-sbla-at-fda-for-keytruda--pembrolizumab--to-treat-advanced-microsatellite-instability-high--msi-h--cancer-/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2011/10/study-backs-findings-that-some-newer-contraceptive-pills-more-likely-to-cause-vte/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2017/11/the-fda-prescription-drug-user-fee-act--pdufa--action-date-for-burosumab-to-treat--x-linked-hypophosphatemia--is-17-april-2018--ultragenyx---kyowa-hakko-kirin-/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2019/06/ecfs-2019-preview---learn-more/2024-02-22T10:22:57+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-approval-of-prolia-for-bone-loss-associated-with-glucocorticoid-therapy---amgen-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-gemini-1-and-gemini-2-studies-of-tivicay---epivir-meet-primary-endpoint-in-hiv-1---viiv-healthcare-/2024-02-06T16:03:53+00:00weekly0.6https://www.medthority.com/news/2012/05/early-success-for-cdx-011--celldex--in-phase-ii-breast-cancer-study/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2012/06/new-results-for-livazo-kyowa-hakko-kirin--in-dyslipidaemia/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2012/02/trial-of-vessix-v2-denervation-system--vessix-vascular--underway-for-hypertension-patients/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2020/01/anssen-responds-to-the-national-institute-for-health-and-care-excellence--nice--draft-guidance-for-stelara---ustekinumab--in-ulcerative-colitis/2024-02-22T12:00:18+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-success-for-idelalisib--gilead--in-cll/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2015/02/nice-recommends-eylea--aflibercept--for-dmo--bayer-healthcare/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2011/09/tarceva-approved-in-eu-as-first-line-treatment-against-nsclc-with-egfr-mutations/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2014/05/irish-medicines-board-recommends-botox-for-spasticity-after-stroke-allergan/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2015/01/gardasil-not-linked-to-multiple-sclerosis-risk--merck--sanofi/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approve-contour-next-ez--bayer-healthcare--for-blood-glucose-monitoring/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2018/09/us-appeal-court-rules-ampyra-patents-invalid-for-multiple-sclerosis---acorda-therapeutics/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2014/12/brexpiprazole-phase-iii-results-in-schizophrenia--otsuka---lundbeck/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-defines-limits-of-aliskiren--novartis--in-hypertension/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2015/02/xeljanz--tofacitinib-citrate--filed-at-fda-for-plaque-psoriasis-treatment-pfizer/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2018/01/rex-001-enters-phase-iii-trials-as-a-treatment-for--critical-limb-ischaemia---rexgenero-ltd-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2017/03/astrazeneca-grants-circassia-pharmaceuticals-marketing-rights-in-the-us-for-tudorza--aclidinium-bromide--and-duaklir--aclidinium-bromide---formoterol--to-treat-copd-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2014/11/alirocumab-success-in-six-phase-iii-trials-to-reduce-ldl-c--regeneron---sanofi/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-trial-of-oms-103hp--omeros-corp--shows-pain-reduction-in-patients-after-arthroscopic-surgery/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2017/06/study-of-toujeo--insulin-glargine--shows-reduced-risk-of-hypoglycemia-in-patients-with-type-2-diabetes--sanofi/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2019/05/eu-approves-dupixent-for-severe-asthma---sanofi/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2015/10/valeant-pharma-international-faces-allegations-over-drug-price-increases/2021-09-24T07:03:14+00:00weekly0.6https://www.medthority.com/news/2019/06/results-of-phase-iii-solo3-trial-of-lynparza-for-patients-with-germline-brca1-2-mutated--gbrcam--advanced-ovarian-cancer--astrazeneca---merck-inc-/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-studies-of-altreno-for-acne-published-in-journal-of-drugs-in-dermatology---bausch-health---ortho-dermatologics-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2014/02/nice-approves-urolift-system-for-bph-neutract/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2019/03/ec-approves-praluent-for-cv-risk-in-adults-with-cv-disease---sanofi---regeneron/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2015/10/chmp-recommends-imlygic--talimogene-laherparepvec--to-treat-unresectable-melanoma--amgen/2024-02-06T16:04:06+00:00weekly0.6https://www.medthority.com/news/2012/06/trametinib-and-dabrafenib-gsk--success-in-break-3-and-metric-studies-for-melanoma/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2017/03/phase-iv-unveil-trial-of-otezla--apremilast--shows-benefits-in-moderate-plaque-psoriasis--celgene/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-imvanex--bavarian-nordic--for-smallpox/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2016/11/sunovion-reports-successful-study-of-latuda--lurasidone-hci--for-treatment-of-schizophrenia-in-adolescents-/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2018/11/european-commission-approves-gilenya-to-treat-children-and-adolescents-with-r-r-multiple-sclerosis----novartis/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-update-to-brintellix--vortioxetine--label-relating-to-cognitive-function-of-patients-with-depression/2024-03-08T14:49:58+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-trial-of-fycompa-meets-primary-endpoint-in-pgtc-epilepsy-eisai/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-trials-of-nx-1207-for-bph-fail-to-meet-endpoints-nymox-pharma/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-phase-iii-monaleesa-2--trial-for-lee-011--ribociclib-----letrozole-for-advanced-breast-cancer--novartis/2024-02-06T16:04:16+00:00weekly0.6https://www.medthority.com/news/2013/07/merck-inc--files-vorapaxar-at-fda-for-prevention-of-cv-risk/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2014/12/three-times-a-week-copaxone-has-positive-decision-from-mhra-and-now-eu-decentralised-approval-for-multiple-sclerosis--teva/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-accepts-snda-for-veltassa-in-hyperkalemia---relypsa-/2021-09-24T07:07:11+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-dovato-in-hiv---viiv-healthcare/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2016/12/amryt-licenses-lojuxta--lomitapide--from-aegerion-pharma-across-the-european-union-and-other-territories--lojuxta-is-used-to-treat-homozygous-familial-hypercholesterolemia--/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2013/05/bexarotene-unlikely-to-have-effect-on-alzheimers-plaque/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2017/09/pfizer-sues-johnson---johnson-alleging-its-anticompetitive-practices-have-denied-u-s--patients-access-to-biosimilar-competitors-including-inflectra--infliximab-dyyb--/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2013/05/early-prediction-of--epileptic-seizures-study-from-neurovista/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2019/07/switching-to-extended-half-life-prophylaxis-impacted-clinical-outcomes-and-improved-quality-of-life-for-people-with-haemophilia-a-or-b---sobi---sanofi/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2015/12/positive-phase-iii-results-from-three-trials-announced-for-sirukumab-for-treatment-of-ra--gsk---janssen-biologics/2024-02-20T08:38:02+00:00weekly0.6https://www.medthority.com/news/2015/08/reply-crt-p-cardiac-resynchronization-therapy-pacemaker-for-heart-failure-launched-sorin-group/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2013/02/avastin--roche---success-in-cervical-cancer-trial/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-c20-invendoscope--invendo-medical-/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approved-abbott-esa-chagas--diagnostic-test-for-chagas-disease/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2014/08/european-commission-extends-approval-of-kalydeco-in-cystic-fibrosis---vertex-pharma/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2019/03/european-lung-cancer-congress-2019/2024-02-22T10:23:24+00:00weekly0.6https://www.medthority.com/news/2015/11/initiation-of-rolling-submission-at-fda-for-pacritinib-to-treat-myelofibrosis--cti-biopharma---baxalta/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2019/07/new-strategies-and-approaches-needed-to-cope-with-growing-burden-of-brain-diseases/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-sapphire-clinical-trial-of-xipere---eylea-fails-to-meet-endpoint-in-retinal-vein-occlusion---clearside-biomedical-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-vimizim-for-mps-iv-a---biomarin/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2013/01/phase-iii-trial-of-morab-003--morphotek-eisai--for-ovarian-cancer-fails-to-meet-primary-endpoint/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2013/08/rigel-pharma-terminates--allergic-asthma-development-of-r-343/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2016/04/results-of-champion-trial-of-cardiomems-hf-systems-in-heart-failure-published-in-jacc-heart-failure--st--jude-medical/2024-02-20T08:40:25+00:00weekly0.6https://www.medthority.com/news/2016/04/auris-surgical-robotics--inc--will-acquire-hansen-medical--inc---for--80-million-and-with-it-the--magellan-robotic-system-/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2014/09/alkermes-plc-files-once-monthly--long-acting-aripiprazole-lauroxil-at-fda-for-schizophrenia/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2015/06/final-results-of-januvia--sitagliptin--study-in-tecos-trial-for-type-2-diabetes-published-in-nejm--merck/2024-11-15T08:42:45+00:00weekly0.6https://www.medthority.com/news/2019/02/nice-now-approves-kymriah-for-treatment-of-diffuse-large-b-cell-lymphoma-on-nhs---novartis/2021-09-24T07:17:15+00:00weekly0.6https://www.medthority.com/news/2012/02/zelboraf--daiichi-sankyo-roche--is-eu-approved-for-brafv600-mutation-metastatic-melanoma/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2016/08/opdivo--nivolumab--as-monotherapy--did-not-meet-its-primary-endpoint-in-patients-with-previously-untreated-advanced-non-small-cell-lung-cancer--nsclc----bms-/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-odomzo--sonidegib--to-treat-basal-cell-carcinoma--novartis/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2018/05/third-phase-iii-study-of-bempedoic-acid-in-high-risk-patients-with-atherosclerotic-cardiovascular-disease--esperion-therapeutics-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2017/06/uk-s-nice-rejects-use-of-zurampic--febuxostat---lesinurad--in-gout---gruenenthal/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-approves-keytruda--pembrolizumab--for-advanced-melanoma--merck/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-givlaari-to-treat-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2014/02/sproutpharma-receives-fda-guidance-on-flibanserin-for-hypoactive-sexual-desire-treatment/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-issues-complete-response-letter-for-daclatasvir-for-treatment-of-hepatitis-c--bms/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2016/04/pfizer-and-allergan-merger-is-terminated-/2025-10-16T11:04:32+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-brighte-study-of-gsk-3684934-shows-positive-results-in-hiv---viiv-healthcare-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2015/05/amgen-terminates-collaboration-with-astrazeneca-for-brodalumab-/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-nda-for-lemborexant-to-treat-insomnia---eisai---imbrium-pharma-purdue/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2014/09/successful-tonado-1-2-studies-for-tiotropium--olodaterol-combination-for-copd--boehringer/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-beacon-crc-trial-positive-for-braftovi---mektovi-and-cetuximab-combination--in-patients-with-brafv600e-mutant-metastatic-colorectal-cancer---array-biopharma---pierre-fabre/2024-07-26T10:19:34+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-pd-l1-ihc-22c3-pharmdx-assay--a-keytruda-companion-diagnostic--for-non-small-cell-lung-cancer-patients--dako/2024-02-20T08:40:35+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-percepta-quad-crt-p-mri-surescan--serena-quad-crt-p-mri-surescan-and-solara-quad-crt-p-mri-surescan-for-patients-with-heart-failure--medtronic/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2019/09/new-clinical-results-for-givosiran-at-the-2019-international-congress-on-porphyrins-and-porphyrias--alnylam-pharma/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2019/07/new-england-journal-of-medicine-publishes-roxadustat-china-phase-iii-results-for-the-treatment-of-anemia-in-chronic-kidney-disease-patients-receiving-dialysis--fibrogen--inc-/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2017/12/ema-review-of-esmya-following-cases-of-liver-injury--allergan---gedeon-richter-/2021-09-24T07:13:45+00:00weekly0.6https://www.medthority.com/news/2018/07/carmelina-trial-reports-on-cv-safety-of-tradjenta-in-diabetes-type-2-patients-with-cv-risk---boehringer---eli-lilly-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2018/02/allergan-and-medicines360-file-snda-to-extend-duration-of-use-of-liletta-contraceptive-to-five-years-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2011/11/tc-5214-fails-first-phase-iii-trial-for--major-depressive-disorder/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2016/08/pm-1183--lurbinectedin--enters-pivotal-phase-iii-trial-for-small-cell-lung-cancer/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-in-draft-guidance-requires-more-information-from-santen-for-ikervis--ciclosporin-eye-drops--to-treat-keratitis/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-unifi-study-of-stelara-positive-for-ulcerative-colitis---janssen-biotech-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2019/02/j-j-via-ethicon-acquires-auris-medical-and-its-robotic-technologies/2025-10-16T11:26:36+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-sbla-for-gardasil-9-for-patients-ages-27-to-45-for-the-prevention-of-certain-cancers-and-diseases-caused-by-nine-human-papillomavirus--hpv--types---merck-inc-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2018/03/33rd-annual-eau-congress--eau-2018--smart-software-can-diagnose-prostate-cancer-as-well-as-a-pathologist/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-approves-numient--levodopa-and-carbidopa--for-adult-patients-with-parkinson-s-disease--impax-labs-/2024-02-20T08:40:50+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-extends-pdufa-date-for-inbrija-to-treat-parkinsons---acorda-therapeutics/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-eu-approval-of-eklira--almirall--for-copd/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/10/nice-recommends-galafold--migalastat--as-a-treatment-for-fabry-disease--amicus-therapeutics/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-now-recommends-gazyvaro-for-treatment-of-cll--roche/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-gives-complete-response-for-nucala-in-copd---gsk-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-calquence-to-treat-chronic-lymphocytic-leukaemia-or-small-lymphocytic-lymphoma---astrazeneca-/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-murano-study-of-venclexta--venetoclax--plus-rituxan--rituximab--in--relapsed-or-refractory-chronic-lymphocytic-leukaemia-meets--primary-endpoint---genentech-roche-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2019/11/canon-medical-systems-usa--inc---introduces-the-cartesion-prime-pet-ct-system--a--digital-pet-ct-scanner-intended-for-more-personalized-care-/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2018/05/traumakine-fails-phase-iii-interest-trial-for-ards---faron-pharma-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-ii-study-of-azd6244--astrazeneca--shows-benefits-for-patients-with-ovarian-cancer/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-viva-and-evera-defibrillators-for-heart-failure/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2014/06/lumacaftor---ivacaftor-combo-success-in-two-phase-iii-trials-for-cystic-fibrosis-vertex/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-recommends-zykadia-to-treat-adults-with-untreated-alk-positive-nsclc--novartis-/2021-09-24T07:13:42+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-approval-for-senstend-for-treatment-of-premature-ejaculation---plethora-solutions/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2018/03/world-autism-awareness-week-2018/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2014/03/amgen-announces-two-phase-iii-studies--gauss-2-and-laplace-2--of-evolocumab-for-high-cholesterol/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2019/07/motif-bio-submits-a-meeting-request-to-the-fda-concerning-its-iclaprim-application-to-treat-absssi-/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-invokana-for-type-2-diabetes-janssen/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2019/05/results-from-untouched-study-of-emblem-defibrillator-for-prevention-of-sudden-cardiac-death/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2016/10/ema-accepts-for-review-maa-for-niraparib-for-the-maintenance-treatment-of-patients-with-platinum-sensitive--recurrent-ovarian-cancer----tesaro-inc-/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-approves-extension-of-azerra--ofatumumab--label-for-the-treatment-of-patients-with-relapsed-chronic-lymphocytic-leukemia---genmab---novartis-/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2011/11/sevikar-hct--daiichi-sankyo--now-available-in-the-uk-/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-expanded-indication-for-xeomin-in-blepharospasm/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-gives-complete-response-for-pa-32540-pa-8140-for-gastric-ulcers---pozen/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2019/01/dextenza-filed-with-fda-for--ocular-inflammation-post-surgery---ocular-therapeutix-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2018/03/quofenix-filed-in-eu-for-infectious-diseases--absssi----melinta-therapeutics-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2014/04/supreme-court-rejects-teva-s-attempt-to-prevent-launch-of-generic-copaxone-/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2018/10/ryzodeg-provides-once-daily-dosing-and-reduced-risk-of-nocturnal-hypoglycaemia-vs-insulin-glargine-u100-plus-insulin-aspart---novo-nordisk/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-advisory-committee-does-not-recommend-approval-for-ac-220-in-acute-myeloid-leukemia/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2012/12/cadazolid--actelion--moves-into-phase-iii-for-clostridium-difficile--/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-prevent-study-of-soliris-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm---alexion-pharma/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-study-of-nucala-meets-primary-endpoint-in-hypereosinophilic-syndrome---gsk/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2011/11/juvenile-idiopathic-arthritis-patients-receiving-enbrel--amgen-pfizer--show-excellent-response/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-cabometyx-for-hepatocellular-carcinoma-in-patients-previously-treated-with-sorafenib--exelixis---ipsen/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2018/09/cidara-therapeutics-initiates-restore-phase-iii-study-of-rezafungin-to-treat-candidiasis--/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2017/07/success-for-tivicay--dolutegravir----2-nrtis-versus-lopinavir-ritonavir-in-dawning-study-for-hiv-adults--viiv-healthcare-/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/03/new-analysis-of-cvd-real-study-of-sglt-2-inhibitors--sglt-2i---including-farxiga-shows-lower-all-cause-death-risk-reduction---astrazeneca/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2014/11/studies-show-benefits-of-cyberknife-sbrt-for-neurological-disease-accuray/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2014/06/nivolumab---ipilimumab-success-in-phase-1b-study-for-advanced-melanoma---bms/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-abilify-maintena--aripiprazole--for-monotherapy-treatment-of-bipolar-i-disorder--lundbeck-and-otsuka/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2013/10/apremilast-celgene-success-in-phase-ii-for-behcets-disease/2024-10-21T14:44:31+00:00weekly0.6https://www.medthority.com/news/2013/06/iqwig-states-that-lyxumia--sanofi-has-no-additional-benefit-over-comparators-in-the-treatment-of-type-2-diabetes/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2016/06/glassia--alpha-antitrypsin-iv--approved-by-fda-for-use-at-home-in-alpha-1-antitrypsin-deficiency--shire-and-kamada/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-rubraca-in-ovarian--fallopian-tube-and-peritoneal-cancer---clovis-oncology-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2011/10/nice-recommends-mepact-for-osteosarcoma/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-trial-of-skyrizi-shows-two-year-skin-clearance-rate-in-psoriasis---abbvie/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2013/08/jakafi-success-in-pancreatic-cancer-phase-ii-trial/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2012/04/renalguard--plc-medical-systems--trial-in-contrast-induced-nephropathy-/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2019/03/gtx-inc-acquired-by-oncternal-therapeutics-/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2015/11/successful-trial-for-micra-transcatheter-pacing-system--a-leadless-pacemaker--medtronic/2024-02-20T08:41:27+00:00weekly0.6https://www.medthority.com/news/2016/06/merck-inc--acquires-afferent-pharmaceuticals-and-with-it-af-201-treatment-for-cough/2025-10-16T11:22:05+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-tremfya--guselkumab--in-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis---janssen-cilag-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2018/08/leo-pharma-to-acquire-dermatology-products-from-bayer/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-zioptan--merck-inc--for-glaucoma-and-ocular-hypertension/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2017/03/successful-phase-iii-fresco-trial-for-fruquintinib-to-treat-metastatic-colorectal-cancer--hutchison-china-meditech-limited--/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2014/07/genentech-files-avastin-at-fda-for-cervical-cancer-and-has-priority-review/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2019/11/ema-prac-recommends-xeljanz-used-with-caution-in-patients-at-high-risk-of-blood-clots---pfizer/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2013/01/3-d-x-ray-mammography-using-hologics-inc-system-improves-diagnosis-of-breast-cancer-/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2012/09/cpl-1001--sorbent-therapeutics--success-in-phase-ii-heart-failure-trial/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/03/rekynda-filed-with-fda-for-hypoactive-sexual-desire-disorder---palatin-technologies-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2018/11/eu-approves-cabometyx-for-liver-cancer---ipsen---exelixis-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2012/09/new-phase-iii-trial-tests-lmtx--taurx-therapeutics--in-patients-with-pick-s-disease---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/02/oncotype-dx-ar-v7-nucleus-detect-test-launched-in-us-for-prostate-cancer-identification---genomic-health-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2016/03/generic-viagra--sildenafil--is-fda-approved-but-teva-agreement-with-pfizer-delays-launch-until-december-2017-/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2018/07/results-of-an-analysis-of-the-xantus-programme-for-xarelto-for-treatment-of--atrial-fibrillation-were-published-in-jo--of--the-american-college-of-cardiology---bayer---janssen-/2024-07-26T10:19:16+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-hemlibra-for-routine-prophylaxis-in-haemophilia-a---roche-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2016/06/biomarin-withdraws-maa-for-kyndrisa--drisapersen--from-ema-as-a-treatment-for-duchenne-muscular-dystrophy---/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2016/02/meta-analysis-published-in-stroke-shows-that-addition-of-solitaire-stent-retriever-to-current-pharmaceutical-treatment--iv-tpa--significantly-improves-functional-outcomes-in-patients-suffering-stroke---medtronic/2024-02-20T08:41:53+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-chmp-recommends-kyprolis-to-include-updated-overall-survival--data-from-the-phase-iii-endeavor-trial-in-patients-with-relapsed-or-refractory-multiple-myeloma---amgen-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2014/05/nice-recommends-lemtrada-for-multiple-sclerosis-treatment---genzyme-sanofi---bayer-health-care/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2016/12/ultibro-breezhaler--indacaterol-glycopyrronium--shows-benefits-in-copd-patients-switching-from-other-treatments--novartis/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2018/08/further-complete-response-letter-for-remoxy-er-for-long-term-abuse-deterrent-treatment-for-pain--pain-therapeutics-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2017/04/prometic-life-sciences-inc--files-bla-at-fda-for-plasminogen-replacement-therapy-/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2012/02/phase-iii-trial-of-mdv-3100--medivation-astellas--in-prostate-cancer-patients-shows-positive-results/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-mepsevii-for-mucopolysaccharidosis-type-vii---ultragenyx-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-supplemental-nda-for-xtandi-in-castration-sensitive-prostate-cancer---pfizer---astellas/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2013/03/new-analysis-shows-gilenya--novartis--offers-significant-benefits-in-multiple-sclerosis-over-four-years-of-treatment/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2015/09/trial-of-stiolto-respimat--tiotropium-olodaterol--in-copd-meets-all-endpoints--boehringer-ingelheim/2024-02-20T08:42:09+00:00weekly0.6https://www.medthority.com/news/2012/03/protelos-servier--indication-for-osteoporosis-to-be-updated-by-ema/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2019/04/empa-reg-outcome-trial-shows-jardiance-can-be-cost-effective-in-type-2-diabetes-patients-with-cv-disease-plus-diabetic-kidney-disease---boehringer---eli-lilly/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-accepts-for-review-nda-for-nktr-181-for-the-treatment-of-chronic-low-back-pain-in-adult-patients-new-to-opioid-therapy---nektar-therapeutics-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-duavee--pfizer--for-menopause/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-recall-of-omontys--affymax-takeda--for-treatment-of-anaemia-in-adult-dialysis-patients/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2014/12/new-results-in-phase-iii-trial-of-abraxane-in-breast-cancer-celgene/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2013/08/sanofi-initiates-phase-iii-studies-for-c-difficile-vaccine/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2019/03/ozempic-filed-with-fda-for-risk-reduction-in-mace/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-expands-indication-for-tasigna-to-include-pediatric-patients-with-philadelphia-chromosome-positive-chronic-myeloid-leukemia---novartis-/2021-09-24T07:06:25+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-somatom-force-ct-imaging-system---siemens/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2012/12/further-positive-results-for-symplicity--medtronic--renal-dernervation-system/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-for-beloranib-successful-to-treat-obesity--complicated-bytype-2-diabetes---zafgen-inc-/2024-02-06T16:04:28+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-trial-for-byetta---basal-insulin-glargine-metformin-as-effective-as-humalog-in-type-2-diabetes---astra-zeneca/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-accepts-bla-for-shp-643-to-treat-hereditary-angioedema/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iii-globe-study-continues-for-ofranergene-obadenovec--vb-111--in-recurrent-glioblastoma--rgbm----vbl-therapeutics/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---no-pain-more-gain--biophotonic-therapy-showing-great-results/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-approves-glatiramer-acetate-injection-a-generic-version-of-copaxone-to-treat-multiple-sclerosis---mylan/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2018/02/reva-medical--inc-has-announced-ce-mark-of-the-2-5-millimeter-diameter-size-and-the-first-implant-of-the-fantom-encore-bioresorbable-scaffold-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2017/10/merck-inc--will-not-submit-regulatory-applications-for-anacetrapib-its-cholesteryl-ester-transfer-protein--cetp--inhibitor-/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-supplies-approval-letter-for-melafind-melanoma-imaging-system/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2015/10/post-hoc-analyses-of-spiolto-respimat--olodaterol---tiotropium---show-improvements-in-copd--boehringer-ingelheim/2024-02-20T08:42:31+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-switch-2-trial-of-insulin-degludec--tresiba--in-type-2-diabetes-meets-primary-endpoint--novo-nordisk/2024-02-06T16:04:42+00:00weekly0.6https://www.medthority.com/news/2018/11/ce-mark-for-valiant-navion-thoracic-stent-graft-system----medtronic/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2019/04/analysis-of-study-of-heartware-hvad-system-shows-efficacy-in-heart-failure---medtronic/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-committee-for-medicinal-products-for-human-use--chmp---recommends--gazyvaro--obinutuzumab--plus-chemotherapy--followed-by-gazyvaro-maintenance-as-a-new-treatment-option-for-previously-untreated-advanced-follicular-lymphoma--roche/2024-07-26T10:18:55+00:00weekly0.6https://www.medthority.com/news/2018/07/the-european-commission--ec--expanded-the-indication-for-sprycel-to-include-the-treatment-of-children-and-adolescents-with-philadelphia-chromosome-positive-cml---bms/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2018/03/eu-approves-label-update-for-relvar-ellipta-in-asthma---glaxosmithkline---innoviva-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2012/08/actos--takeda--us-patent-expires-and-ranbaxy-launches-generic-for-type-2-diabetes-/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2019/01/grifols-to-market-fostamatinib-disodium-hexahydrate-in-all-potential-indications-in-europe-and-turkey--rigel-pharma/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2017/11/gsk-files-at-fda-for-expanded-use-of-trelegy-ellipta-for-maintenance-treatment-of-copd-/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-advisory-committee-recommends-ragwitek-for-ragweed-pollen-allergy-merck-inc-/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2013/09/mage-a3-fails-phase-iii-trial-for-melanoma/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2018/01/post-market-trial-of-wingspan-stent-system-shows-benefits-in-intracranial-atherosclerotic-disease---stryker-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-measure-2-study-data-on-cosentyx-shows-sustained-4-years-response-in-ankylosing-spondylitis---novartis-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-expanded-label-for-tiglutik-in-amyotrophic-lateral-sclerosis---itf-pharma/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-accepts-bla-for-satralizumab-for-neuromyelitis-optica-spectrum-disorder--genentech-roche/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2019/03/early-menopause-in-smokers-linked-to-bladder-cancer/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2019/10/omeros-corporation-initiates-bla--rolling-submission-for-narsoplimab--for-the-treatment-of--hsct-tma-/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2011/09/absorb-bioresorbable-vascular-scaffold-in-critical-limb-ischaemia/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2014/06/biosimilar-remsima-inflectra-shows-comparable-efficacy-to-remicade-in-rheumatoid-arthritis-trial---hospira/2021-09-24T07:07:59+00:00weekly0.6https://www.medthority.com/news/2017/12/deaths-linked-to-flu-on-the-increase/2021-09-24T07:13:38+00:00weekly0.6https://www.medthority.com/news/2016/04/partner-ii-trial-of-sapien-xt-meets-endpoint-in-aortic-stenosis-patients--edwards-lifesciences/2024-02-06T16:04:54+00:00weekly0.6https://www.medthority.com/news/2015/07/veracyte-to-acquire-allegro-diagnostics-corp-for--21-million-and-with-it-bronchogen-lung-cancer-test/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2017/12/unique-drug-targets-fundamental-mechanism-of-sickle-cell-disease-/2021-09-24T07:13:39+00:00weekly0.6https://www.medthority.com/news/2019/12/phreedom-phase-iii-study-of-ibsrela-meets-primary-endpoint-in-hyperphosphatemia-in-patients-with-chronic-kidney-disease---ardelyx/2021-09-24T07:18:38+00:00weekly0.6https://www.medthority.com/news/2016/08/mk-1293--insulin-glargine-biosimilar--filed-with-fda-for-treatment-of-type-1-and-type-2-diabetes--merck-inc/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2014/06/prosensa-plans-to-refile-drisapersen-for-duchenne-md---prosensa/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2018/07/the-label-for-eli-lilly-s-trulicity-is-updated-to-show-its-safety-and-efficacy-in-type-2-diabetes-with--moderate-to-severe-chronic-kidney-disease-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2014/08/kyprolis-interim-data-from-aspire-trial-positive-in-multiple-myeloma---amgen-onyx-pharma/2024-02-06T16:05:17+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-two-new-lengths-of-the-promus-element-stent-system--boston-scientific-/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-data-presented-for-isavuconazole-in-fungal-infection---astellas/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2016/08/keyzilen--am-101--fails-phase-iii-tactt2-trial-in-acute-inner-ear-tinnitus---auris-medical/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2018/11/joint-guidelines-on-managing-cholesterol-from-the-american-heart-association-and-american-college-of-cardiology-released-/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-trials-of-brisdelle-published-in-menopause/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2014/04/aegerion-initiates-phase-iii-trial-of-juxtapid-lojuxta-for-hofh-aegerion-pharma/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-results-for-the-clearway-rx-infusion-catheter--atrium--for-pci-/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-accepts-bla-for-enfortumab-vedotin-to-treat-bladder-cancer---seattle-genetics-/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-oral-rybelsus-for-type-2-diabetes---novo-nordisk/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-ovation-abdominal-stent-graft-system--trivascular--for-abdominal-aortic-aneurysm-patients-/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2011/10/lemtrada-and-aubagio-trials-to-report-at-ectrims-actrims-congress/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2017/12/risk-of-breast-cancer-recurrence-and-death-reduced/2021-11-30T13:48:44+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-reviewers-positive-for-zontivity--vorapaxar--for-reduction-of-cv-events-merck-inc-/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2016/03/elite-pharma-files-nda-at-fda-for-sequestox--eli-200--to-treat-moderate-to-severe-pain-/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2015/09/results-of-phase-iii-trial-of-envarsus-xr--tacrolimus--in-transplant-rejection-published-in-clinical-transplantation--veloxis-pharma/2024-02-23T14:31:14+00:00weekly0.6https://www.medthority.com/news/2017/03/ac-immune-sa---genentech-initiate-a-second-phase-iii-trial-for-crenezumab-to-treat-alzheimers-disease-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2018/04/analysis-of-dysport-demonstrates-consistent-safety-profile-in-lower-limb-spasticity---ipsen-biopharma-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2014/11/new-phase-iii-data-on-orencia-for-rheumatoid-arthritis-bms/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2011/09/xgeva-success-in-trial--147--for-prevention-of-bone-metastases-in-prostate-cancer/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2014/08/eu-commission-approves-velphoro-for-treatment-of-hyperphosphatemia-in-ckd-patients---vifor-fresenius-renal-pharma/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2013/06/prac-recommends-the-same-cardiovascular-precautions-for-diclofenac-as-for-selective-cox-2-inhibitors/2024-11-15T08:40:30+00:00weekly0.6https://www.medthority.com/news/2014/06/valeant-makes-offer-direct-to-allergan-shareholderd-in-hostile-bid/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iii-study-shows-rlx-030--novartis--effective-against-dyspnea-in-heart-failure-patients/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-accepts-opdivo---yervoy--combination-for-patients-with-previously-treated-advanced-hepatocellular-carcinoma--liver-cancer-----bms/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2012/05/pixuvri--cell-therapeutics--approved-in-eu-to-treat-adults-with-non-hodgkin-b-cell-lymphomas/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-liberty-study-of-tak-385-shows-positive-results-for-uterine-fibroids---myovant-sciences/2021-09-24T07:12:07+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-sbla-for-review-of-tagrisso-for-first-line-treatment-of-metastatic-nsclc---astrazeneca/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-data-for-lasmiditan-demonstrates-rapidity-of-action-in-migraine-treatment--colucid-pharma/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-keynote-024-trial-of-keytruda--pembrolizumab--meets-primary-endpoint-in-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-resutls-from-phase-iii-study-of-forxiga--astrazenenca---bms--for-type-2-diabetes-patients/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2014/08/trial-shows-eliquis-reduces-hospitalisation-in-dvt---bms-pfizer/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2016/04/health-economics-data-for-ofirmev--acetaminophen--injection-and-reduced-opioid-use-for-the-treatment-of-acute-surgical-pain--mallinckrodt/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2018/03/five-categories-for-adult-diabetes--not-just-type-1-and-type-2--study-shows/2024-02-20T08:44:19+00:00weekly0.6https://www.medthority.com/news/2019/11/ec-approves-darzalex---lenalidomide---dexamethasone-for-newly-diagnosed-multiple-myeloma---genmab/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-gives-complete-response-to-rizaport-versafilm-for-migraine---intelgenx/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-aproves-elelyso--pfizer---for-type-1-gaucher-disease/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2012/06/acz-885-from-novartis-success-in-systemic-juvenile-idiopathic-arthritis/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-gives-go-ahead-to-restart-phase-iii-trials-of-tanezumab-in-chronic-pain-pfizer-eli-lilly/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2014/09/boehringer-job-cuts-in-germany/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2016/11/mundipharma-submits-maa-to-ema-for-approval-of-nyxoid--intranasal-naloxone-1-8-mg-in-0-1-ml-for-the-emergency-reversal-of-opioid-overdose-/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2014/12/generic-celebrex-launched-in-us-teva-mylan/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-imbruvica-for-cll--janssen-pharmacyclics/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-grants-expanded-indication-for-the-use-of-the-urolift-system-to-treat-larger-prostates--between-80cc-and-100cc--teleflex-incorporated/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-eylea--aflibercept--for-diabetic-retinopathy-in-patients-with-diabetic-macular-oedema-regeneron-pharma/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2014/05/nice-recommends-invokana-for-type-2-diabetes-treatment---janssen/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2011/10/raltegravir-shows-benefits-in-adult-hiv-1-patients/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-constella--almirall--for-for-the-symptomatic-treatment-of-irritable-bowel-syndrome-/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2017/06/post-hoc-phase-iii-trial-of-soliqua-100-33--insulin-glargine---lixisenatide-injection--shows-benefits-in-type-2-diabetes--sanofi/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-now-recommends-otezla--apremilast--to-treat-severe-psoriasis---celgene/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-filing-of-nda-for-solriamfetol-a--treatment-of-excessive-sleepiness-and-provides-pdufa-date-of-20-december-2018----jazz-pharma-/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2018/02/eu-approves-herzuma-for-her2-metastatic-gastric-cancer---celltrion-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2018/07/positive-results-in-pioneer-3-trial-of-oral-semaglutide-versus-sitagliptin-for-type-2-diabetes----novo-nordisk/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-gives-complete-response-for-plumiaz-for-epilepsy-acorda-therapeutics/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2018/02/successful-achieve-i--ubr-md-01--phase-iii-study-of-ubrogepant-to-treat-migraine-attacks---allergan-/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-flucelvax-tetra-----a-quadrivalent-cell-based-influenza-vaccine--seqirus-csl/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-reviews-xiaflex--auxilium-pharmaceuticals--for-patients-with-peyronie-s-disease/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-cnto-136--sirukumab--meets-all-endpoints-in-severely-active-rheumatoid-arthritis--janssen-r-d/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2019/08/wms-2019---congress-preview/2024-02-20T08:53:22+00:00weekly0.6https://www.medthority.com/news/2017/01/vantrela-er--hydrocodone-bitartrate--approved-by-fda-for--management-of-pain--teva/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-rejects-request-from-merck-inc---for-vytorin--ezetimibe----simvastatin--and-zetia--ezetimibe--label-to-include-the-reduction-of-cardiovascular-events-/2024-02-20T08:53:43+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-study-of-barhemsys-as-rescue-treatment-of-post-operative-nausea---vomiting--ponv--has-been-published-in-anesthesiology---acacia-pharma/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2018/12/xipere-filed-in-nda-to-fda-for-uveitis---clearside-biomedical-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-epaned--silvergate-pharm--for-hypertension/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2016/01/breakthrough-therapy-designation--for-lynparza--olaparib-for--brca1-2-or-atm-gene-mutated-metastatic-castration-resistant-prostate-cancer---astrazeneca/2024-02-20T08:54:08+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-imbruvica--ibrutinib--as-a-first-line-treatment-for-patients-with-chronic-lymphocytic-leukaemia--cll---abbvie---janssen-biotech/2024-02-20T08:54:19+00:00weekly0.6https://www.medthority.com/news/2011/12/eu-approves-edarbi--takeda--for-hypertension/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2018/01/successful-phase-iii-kronos-trial-for-pt-010-for-treatment-of-copd---astrazeneca/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-re-submission-of-dsuvia-a-proposed-treatment-for-moderate-to-severe-pain-in-medically-supervised-settings---ace1rx-pharma/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-ryanodex-for-malignant-hyperthermia---eagle-pharma/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2014/07/isavuconazole-filed-with-the-fda-for-fungal-infections-astellas/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2012/03/teva-pharma-launches-generic-seroquel-and-seroquel-xl/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-data-from-phase-iii-study-of-ptc-124--ptc-therapeutics--for-patients-with-nonsense-mutation-cystic-fibrosis/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-abraxane-for-adenocarcinoma-of-the-pancreas-celgene/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2014/07/new-blood-test-from-proteome-sciences-to-identify-alzheimers-disease/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2018/09/philips-launches-ingenia-ambition-x-1-5t-mri-system-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2012/02/european-commission-approves-caprelsa-astrazeneca--for-medullary-thyroid-cancer/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2011/11/potential-role-for-dapagliflozin--bms-astrazeneca-in-cardioprotection/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-tivicay-for-hiv--viiv-healthcare/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-data-with-zebinix--eslicarbazepine-acetate--shows-effectiveness-and-safety-in-epilepsy--bial-/2021-09-24T07:10:41+00:00weekly0.6https://www.medthority.com/news/2019/10/keytruda---chemotherapy-showed-statistically-significant-increase-in-pathological-complete-response-versus-chemotherapy-as-neoadjuvant-therapy-in-early-stage-triple-negative-breast-cancer---merck-inc-/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-combi-v-study-shows-survival-benefits-for-tafinlar--dabrafenib----mekinist--trametinib--in-metastatic-melanoma--novartis/2024-02-20T08:54:28+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-continues-to-show-efficacy-of-tanzeum-eperzan-in-t2d---gsk/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-nuplazid--pimavanserin--for-hallucinations-and-delusions-in-parkinson-s-disease--acadia-pharmaceuticals/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-consensi-for-the-treatment-of-osteoarthritis-pain-and-hypertension---kitov-pharma-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2019/09/successful-phase-iii-study-of-jzp-258--for-the-treatment-of-cataplexy-and-excessive-daytime-sleepiness---jazz-pharma/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2016/11/chmp-recommends-afstyla--lonoctocog-alfa--for-treatment-and-prophylaxis-of-bleeding-in-patients-with-haemophilia-a---csl-behring-/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-ptk-0796--omadacycline--in-absssi-meets-primary-endpoints--paratek-pharmaceuticals/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2018/03/annual-congress-of-the-acute-cardiovascular-care-association--acca--2018/2024-02-20T08:56:29+00:00weekly0.6https://www.medthority.com/news/2013/09/adaptivcrt--success-in-heart-failure-/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-jublia-for-onychomycosis---valeant-pharma/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2017/04/tarextumab--anti-notch2-3--omp-59r5--in-combination-with-etoposide-plus-chemotherapy-fails--in-phase-ii-trialfor-erxtensive-stage-small-cell-lung-cancer---oncomed-pharmaceuticals-/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2016/03/data-from-phase-iii-trials-of-taltz--ixekizumab--in-plaque-psoriasis-published-in-jama-dermatology--eli-lilly/2024-02-20T09:02:48+00:00weekly0.6https://www.medthority.com/news/2017/12/monaleesa-7-trial-demonstrates-significant-outcomes-in-breast-cancer/2024-02-22T11:08:10+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-grants-appeal-for-n-1539-complete-response-for-treatment-of-moderate-to-severe-pain---recro-pharma/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-issues-tentative-approval-for-expanded-label-for-arymo-er-with-abuse-deterrent-properties-for-treatment-of-chronic-pain--eaglet-corporation-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-absorica--ranbaxy--for-severe-acne/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-advisory-committee-rejects-stannsoporfin--a-treatment-of-neonates-at-risk-for-developing-severe-hyperbilirubinemia---mallinckrodt-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-provides-a-refusal-to-file-letter-in-response-to-application-for-inbrija--inhaled-levodopa--in-parkinson-s-disease--acorda-therapeutics-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-echelon-1-trial-of-adcetris--brentuximab-vedotin--met-primary-endpoint-in-untreated-hodgkin-lymphoma--takeda-pharmaceutical-and-seattle-genetics/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-advisory-committee-recommends-kyprolis-onyx--for-multiple-myeloma/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-issues-complete-response-letter-regarding-rytary--impax-pharma--for-parkinsons-disease/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2017/09/onxeo-grants-a-global-exclusive-license-of-validive--clonidine-mucoadhesive-buccal-tablet--developed-to-treat--severe-oral-mucositis-induced-by-radiotherapy-or-chemotherapy-in-patients-suffering-from-head-and-neck-cancer-to-monopar-therapeutics---onxeo-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-eu-approval-of-revestive--nycomed--for-treating-short-bowel-syndrome-/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-orilissa-to-treat-moderate-to-severe-endometriosis-pain---abbvie-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2019/07/roxadustat-china-phase-iii-trial-for-treatment-of-anemia-in-chronic-kidney-disease-patients-not-on-dialysis-published-in-the-nejm--fibrogen/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-issues-complete-response-to-nda-for-edsivo-to-treat-ehlers-danlos-syndrome---acer-therapeutics/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-netspot--gallium-68-dotatate-diagnostic--for-pet-imaging-of-somatostatin-receptor-positive-neuroendocrine-tumors--advanced-accelerator-applications/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-approves-sovaldi--sofosbuvir--to-treat-hepatitis-c-virus--hcv--in-children-ages-12-to-17--gilead-sciences/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2015/10/ce-mark-for-cobas-c-513-analyser-from-roche-to-diagnose-diabetes/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2020/02/merck-inc-to-spin-off-products-from-its-women-s-health--trusted-legacy-brands--and-biosimilars-businesses-into-a-new--yet-to-be-named--independent--publicly-traded-company-/2021-09-24T07:12:06+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-label-change-for-tysabri--biogen-idec--for-multiple-sclerosis-and-approval-of-jcv-antibody-test/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2013/05/vesomni--astellas--approved-in-the-netherlands-for-overactive-bladder/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2012/12/pfizer-files-aprela-at-fda-for--menopausal-symptoms-and-prevention-of-osteoporosis/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2015/06/abilify-maintena-superior-to-invega-sustenna-in-sub-analysis-of-qualify-trial-for-schizophrenia--otsuka---lundbeck/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2019/02/abbvie-to-collaborate-with-teneobio-to-develop-tnb-383b-for-multiple-myeloma-/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2013/09/hyaluronic-acid-shows-benefits-for-knee-osteoarthritis/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2018/03/csl-behring-initiates-phase-iii-aegis-ii-trial-for-post-mi-reduction-of-cv-events-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2018/05/refixia-achieves-greater-total-factor-ix-exposure-in-people-with-haemophilia-b-than-recombinant-factor-ix-fc-fusion-protein---novo-nordisk-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-ogivri-biosimilar-to-herceptin-for-breast-cancer-and-metastatic-stomach-cancer---mylan-biocon-/2024-10-22T08:22:40+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-broadens-label-of-feraheme-to-include-iron-deficiency-anemia--patients-intolerant-to-oral-iron---amag-pharma-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-trial-of-drm-04-shows-significant-improvements-in-hyperhidrosis--dermira/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-abraxane--celgene-oncology--for-nsclc/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2014/05/mguard-meets-primary-endpoint-in-study-of-patients-with-cad-inspiremd/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2019/05/researchers-document-impact-of-coffee-on-bowels/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2013/03/mitraclip-system--abbott-vascular--success-in-everest-ii-trial-for-reatment-of-mitral-regurgitation/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-manta--vascular-closure-device-for-large-bore-femoral-arterial-access-----teleflex/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2011/11/absorb-trial-five-year-and-two-year-results-for--the-bioresorbable-vascular-scaffold-abbott-vascular-/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/03/prolong-trial-evaluating-makena-did-not-meet-endpoint-in-preterm-delivery---amag-pharma/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-sapien-3-transcatheter-heart-valve-to-treat-aortic-stenosis--edwards-lifesciences/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-cyramza-for-treatment-of--metastatic-non-small-cell-lung-cancer--eli-lilly/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2015/05/lotus-valve-system-shows-benefits-in-post-market-study-for-aortic-valve-stenosis--boston-scientific/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-results-with-xeljanz--tofacitinib--in-ulcerative-colitis-published-in-new-england-journal-of-medicine--pfizer/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2016/09/gsk-sells-its-anaesthesia-portfolio--ultiva--nimbex--tracrium--mivacron-and-anectine-to-aspen-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-candor-study-of--kyprolis----darzalex---dexamethasone--meets-primary-endpoint-of-progression-free-survival-for-multiple-myeloma---amgen/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2016/03/shire-launches-intuniv--guanfacine-extended-release--to-treat-adhd-in-the-united-kingdom/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2018/12/subtlepet-diagnostic-device-receives-510-k--clearance-in-us-and-ce-mark-approval-in-the-eu---subtle-medical-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2016/01/baxalta-and-symphogen-collaborate-on-immuno-oncology-/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2012/02/nx-1207--recordati-nymox--starts-phase-iii-trial-for-bph/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2012/08/ingestible-event-marker-pill-is-fda-approved-for-digital-health-feedback/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2014/08/amgen-files-evolocumab-at-fda-for-treatment-of-high-cholesterol/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2012/12/rencarex--wilex--programme-in-renal-cell-carcinoma-is-cancelled/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2020/02/fda--has-granted-priority-review-to-capmatinib-s-nda---to-treat-locally-advanced-or-metastatic-met-exon-14-skipping--metex14--mutated-nsclc---novartis/2024-10-21T14:43:45+00:00weekly0.6https://www.medthority.com/news/2018/05/motor-neurone-awareness-month-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-orbactiv-for-absssi---medicines-co/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2019/08/the-safe-manta-ide-clinical-trial-to-evaluate-the-safety-and-effectiveness-of-the-manta-percutaneous-vascular-closure-device/2021-09-24T07:17:51+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-everlinq-endoavf-system-for-chronic-kidney-disease---tva-medical-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-lonsurf--trifluridine-and-tipiracil--to-treat--advanced-colorectal-cancer--taiho---servier/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2013/06/bi-10773--boehringer-eli-lilly--successful-in-two-phase-iii-trials-for-type-2-diabetes--/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2017/11/eu-approves-ontruzant--trastuzumab--biosimilar--for--breast-cancer-and-metastatic-gastric-cancer---samsung-bioepis-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-rinvoq-for-treatment-of-rheumatoid-arthritis-patients-who-have-had-an-inadequate-response-or-intolerance-to-methotrexate--mtx----abbvie/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2016/12/sun-pharma-acquires-odomzo--sonidegib--an-approved-treatment-for-basal-cell-carcinoma-from-novartis-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2012/10/nice-positive-for-procoralan--servier--for-heart-failure/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-expanded-indication-for-briviact-in-partial-onset-seizures-in-patients-age-four-years-and-older---ucb-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-javelin-ovarian-parp-100-study-is-discontinued/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2012/04/toctino-basilea-pharma--success-in-phase-iii-handel-study-for-chronic-hand-eczema/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2016/12/xtandi--enzalutamide--fails-to-meet-its-primary-endpoint-in-phase-iv-plato-study-to-treat-metastatic-prostate-cancer--pfizer---astellas/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-approves-empliciti--elotuzumab--for-multiple-myeloma--bms-abbvie/2024-02-20T09:02:58+00:00weekly0.6https://www.medthority.com/news/2019/03/eisai-and-biogen-discontinue-phase-iii-trials--engage-and-emerge/2021-09-24T07:18:51+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-kalydeco-to-treat-cystic-fibrosis-in-children-aged-12-to--24-months---vertex-pharma-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2012/03/onglyza--bms-astrazeneca-alerts-for-hypersensitivity-reactions/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2017/11/world-pancreatic-cancer-day-2017/2024-02-22T11:10:03+00:00weekly0.6https://www.medthority.com/news/2019/02/zerbaxa-filed-with-fda-and-given-priority-review-for-nosocomial-pneumonia---merck-inc/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-approval-of-talzenna-in-her2--breast-cancer---pfizer/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-gives-negative-recommendation-to-nerventra-for-multiple-sclerosis-teva/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-clears-phase-iii-trial-of-pol-103a--polynoma--melanoma-vaccine/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-study-compares-pradaxa-to-warfarin---boehringer/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2015/02/phase-iii-data-on-e-7080-in-thyroid-cancer-published-in-nejm-eisai/2024-02-20T09:03:24+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approval-for-isturisa-for-the-treatment-of-people-with-endogenous-cushing-s-syndrome---recordati/2024-10-21T14:44:16+00:00weekly0.6https://www.medthority.com/news/2020/01/accelerated-enrollment-of--phase-iii--pegasus--pivotal-trial-of-prn-1008-to-treat-pemphigus-vulgaris----principia-biopharma-inc-/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2019/05/mtb-rif-inh-test-is-used-to-detect-antibiotic-resistance-mutations-in-the-mycobacterium-tuberculosis/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2015/09/interim-results-of-phase-iii-re-verse-ad-trial-for-bi-655075--idarucizumab--as-antidote--boehringer-ingelheim/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-proair-respiclick---albuterol-sulfate--inhaler-for-treatment-of-asthma-teva/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2019/05/eisai-acquires-us-rights-from-purdue-pharma-to-lemborexant-for-the-treatment-of-multiple-sleep-wake-disorders-/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2019/05/european-commision-approval-for-revlimid----bortezomib---dexamethasone/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-acetylcysteine-injection--app-pharma--generic-version-of-acetadote/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-zubsolv--orexo--for-treatment-of-opioid-dependence/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2016/04/medtronic-launches-barrx-360-express-radiofrequency-ablation--balloon-catheter-to-treat-barrett-s-esophagus-/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2015/05/long-term-data-from-evolve-trial-of-synergy-everolimus-eluting-bioabsorbable-coronary-stent--boston-scientific/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2017/08/gw-pharma--has-statred-a-rolling-submission-at-the-fda-for-epidiolex--cannabidiol--to-treat-dravet-syndrome-and-lennox-gastaut-syndrome-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2015/12/horizon-pharma-acquires-crealta-holdings--for--510-million-and-with-it-krystexxa--a-leading-treatment-for-gout/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2012/08/medtronic-receives-ce-mark-for-viva-and-brava-crt-d-devices-for-heart-failure-patients/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2012/11/study-of-pycnogenol--horphag-research-ltd--shows-positive-results-in-treatment-of-asthma---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2015/06/eli-lilly-reports-results-of-proclaim-trial-for-alimta--pemetrexed--in-non-squamous-nsclc-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-and-ema-accept-filing-of-venetoclax-for-the-treatment-of-chronic-lymphocytic-leukemia--cll----abbvie/2024-02-20T09:03:35+00:00weekly0.6https://www.medthority.com/news/2016/01/shire-and-baxalta-to-merge-in--32-billion-transaction/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2018/04/gsk-transfers-rare-disease-gene-therapies-to-orchard-therapeutics-including-strimvelis-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2019/08/lynparza-met-the-primary-endpoint-of-significantly-increasing-the-time-prostate-cancer-patients-selected-for-brca1-2-or-atm-mutations-live-without-radiographic-disease-progression--astrazeneca---merck-inc-/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2019/09/prometic-life-sciences-inc---to-change-its-name-to-liminal-biosciences-inc-on-3-october-2019/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2012/04/additional-data-from-care-ms-ii-trial-of-lemtrada--genzyme--in-multiple-sclerosis-treatment/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2012/03/genentech-reports-successful-emilia-study-results-for-t-dmi-for-her-2-breast-cancer-/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-augment-trial-positive-results-for-revlimid---rituximab-to-treat-follicular--n-295--and-marginal-zone--n-63--lymphoma---celgene-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2020/02/tazverik-filed-with-fda-and-given-accelerated-approval-for-follicular-lymphoma---epizyme/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-study-of-crysvita-demonstrates-superiority-in-x-linked-hypophosphatemia---ultragenyx-pharma---kyowa-hakko-kirin/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-solvadi-for-chronic-hepatitis-c--gilead-sciences/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2016/11/edwards-lifesciences-corporation-to-acquire-valtech-cardio-ltd-and-with-it-the-cardioband-system-for-repair-of-mitral-and-tricuspid-valves/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2018/03/ehra-more-research-needed-to-see-if-higher-heart-rate-increases-risk-of-heart-rhythm-disorder/2024-02-20T09:04:00+00:00weekly0.6https://www.medthority.com/news/2015/06/baxter-board-approves-separation-of-pharma-business-into-baxalta-inc-/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-commission-approves-intuniv--guanfacine-hydrochloride-prolonged--release--to-treat-adhd--shire/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2018/03/sanofi---regeneron-will-offer-u-s--payers-a-further-reduced-net-price-for-praluent-in-alignment-with-a-new-value-assessment-for-high-risk-patients-from-the-u-s--institute-for-clinical-and-economic-review-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2018/03/insys-therapeutics--inc--announced-initiation-of-a-phase-iii-clinical-trial-to-study-cannabidiol-oral-solution-for-the-treatment-of-infantile-spasms-/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2011/12/exjade--novartis--success-in-thalessaemia-trial/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2016/10/endpoint-met-in-phase-iii-trials-of-mk-3222--tildrakizumab--in-plaque-psoriasis--sun-pharma/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2018/03/full-positive-results-of-expand-study-for-siponimod-in-secondary-progressive-multiple-sclerosis----novartis-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2017/12/reduced-transfusions-for-patients-with-rare-blood-disorder/2021-09-24T07:13:39+00:00weekly0.6https://www.medthority.com/news/2015/02/phase-iii-trial-of-abt-450-r-and-abt-267-in-hcv-meets-endpoint-abbvie/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-prism-2-study-of-pegvaliase-successful-in-treatment-of-pku--phenylketonuria---biomarin-/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2017/01/successful-phase-iii-trial-for-xilonix-therapy-in-colorectal-cancer-is-published-in-the-lancet-oncology--xbiotech-/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2016/11/lee-011--ribociclib----letrozole-filed-with-fda-and-ema-for-hr--her2--metastatic-breast-cancer--novartis/2021-09-24T07:09:55+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-results-for-durasert-confirm-reduction-in-uveitis-recurrence-rate---psivida-/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2014/09/giotrif-meets-endpoints-in-phase-iii-trial-for-head---neck-cancer---boehringer/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2019/04/novartis-acquires-igm-tre-and-its-nlrp3-inhibitors-/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2013/05/merck-inc-files-mk-3641-at-fda-for-treatment-of-ragweed-pollen-allergies/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2016/01/n9-gp--nonacog-beta-pegol--filed-with-eu-for-haemophilia-b--novo-nordisk/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-expanded-indication-for-cinvanti-in-nausea-and-vomiting---heron-therapeutics/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-trial-of-celution-system--cytori-therapeutics--for-cmi-/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2012/02/th-302--threshold-merck-serono--success-in-phase-iib-pancreatic-cancer-trial/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2015/10/five-year-data-of-lemtrada--alemtuzumab--in-care-ms-1-and-care-ms-2-studies-in-ms--sanofi/2024-02-20T09:04:22+00:00weekly0.6https://www.medthority.com/news/2019/03/ecco-congress-2019/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-expands-indication-for-gardasil-9--human-papillomavirus-9-valent-vaccine--recombinant--hpv-vaccine--merck/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-pk-papyrus-covered-coronary-stent-system-to-treat-acute-coronary-artery-perforations---biotronik/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-amagine-1-trial-of-siliq--shows-reduced-anxiety-and-depression-in-plaque-psoriasis---ortho-dermatologics-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-kanjinti-for-breast-cancer-and-gastric-cancer---amgen---allergan/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2016/09/analysis-of-gemini-1-data-of-entyvio--vedolizumab--in-ulcerative-colitis-published-in-clinical-gastroenterology-and-hepatology---takeda-/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-expands-ozurdex-indication-for-dme---allergan/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2019/09/successful-phase-iii-trial-of-a-101-45--topical-solution-to-treat-common-warts---aclaris-therapeutics/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2016/12/onetouch-vibe-plus-insulin-pump-and-continuous-glucose-monitoring--cgm--system-approved-by-fda-and-health-canada-for-monitoring-and-treatment-of-diabetes--animas-corp-j-j/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2012/09/study-finds-link-between-chocolate-consumption-and-stroke-risk---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-keynote-604-trial-of-keytruda-plus-chemo-meets-primary-endpoint-in-small-cell-lung-cancer---merck-inc/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2019/10/polarisdmd-trial-of-edasalonexent-in-duchenne-muscular-dystrophy--completes-enrollment--catabasis-pharma/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-approval-of-darzalex---lenalidomide-and-dexamethasone-in-multiple-myeloma---genmab/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/02/idalopirdine-fails-further-trials--starbeam-and-starbright--as-a-treatment-for-alzheimers-disease--lundbeck---otuska/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2014/04/merck-initiates-phase-iii-trial-of-stimuvax-for-nsclc---merck/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-trial-of-aplidin--plitidepsin--meets-endpoint-in-multiple-myeloma--pharmamar-/2024-02-20T09:04:33+00:00weekly0.6https://www.medthority.com/news/2012/08/ponatinib--ariad-pharma--filed-at-fda-for-cml-and-ph-all------------------------------------------------------------/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2016/05/zambon-finally-launches-xadago--safinamide--in-the-united-kingdom-as-a-treatment-for-idiopathic-parkinson-s-disease-/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2019/03/eu-approves-mabthera-for-pemphigus-vulgaris---roche/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-xalkori--crizotinib--to-treat-nsclc-patients-whose-tumours-are-ros1-positive--pfizer/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2013/12/edivoxetine-fails-phase-iii-trials-for-depression-eli-lilly/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2015/11/cobas-hcv-assay-receives-ce-mark-approval-in-the-eu-for-hepatitis-c--roche/2021-09-24T07:04:24+00:00weekly0.6https://www.medthority.com/news/2018/05/artificial-pancreas-is-a-safe-and-effective-treatment-for-type-1-diabetes/2024-02-20T09:04:59+00:00weekly0.6https://www.medthority.com/news/2019/09/lineage-cell-therapeutics--inc--announced--that-renevia-has-been-granted-a--ce-mark--for-the-treatment-of-facial-lipoatrophy-/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2016/11/xaracoll--bupivacaine-hcl-collagen-matrix-implants--filed-with-fda-for-postsurgical-pain--innocoll/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2017/09/the-fda-has-accepted-for-review-a-biologics-license-application--bla--for-a-biosimilar-candidate--tpi-g-csf--referencing-neupogen--filgrastim----adello-biologics-/2021-09-24T07:13:50+00:00weekly0.6https://www.medthority.com/news/2010/10/novabay-introduces-a-new-class-of-agonacides-with-nvc422/2021-09-24T07:01:27+00:00weekly0.6https://www.medthority.com/news/2015/02/sorin-group-to-merge-with-cyberonics-inc-/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2019/08/endo-ventures-limited-has-entered-into-definitive-agreements-with-helsinn-to-register--commercialize--and-distribute-pracinostat-on-an-exclusive-basis-in-canada-/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-regain-trial-data-of-soliris-in-myasthenia-gravis-published-in-muscle---nerve-journal---alexion-pharma/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-monaleesa-2-study-shows-lee011--ribociclib--plus-letrozole-significantly-extended-progression-free-survival-in-hr--her2--breast-cancer--novartis/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2019/07/acadia-pharmaceuticals-announces-rresults-from-phase-iii-enhance-trial-of-pimavanserin-as-adjunctive-treatment-for-patients-with-schizophrenia-/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2019/07/strive-phase-iii-study-shows-aimovig-provides-benefits-in-migraine/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-tanzeum-for-use-in-type-2-diabetes---glaxosmithkline/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-gives-accelerated-approval-for-exondys-51--eteplirsen--in-duchenne-muscular-dystrophy--sarepta-therapeutics/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2012/02/biogen-idec-files--bg-12-at-fda-for-multiple-sclerosis/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2013/05/results-from-registry-study-of-symplicity--medtronic--confirm-safety-profile/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2017/10/study-of-ampion---aspartyl-alanyl-diketopiperazine--for-pain-in-knee-osteoarthritis-to-be-published-in-orthopedics---ampio-pharma-/2021-09-24T07:13:27+00:00weekly0.6https://www.medthority.com/news/2014/12/eu-approves-lynparza-to-treat-ovarian-cancer--astrazeneca/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2016/11/successful-phase-iii-active-trial-for-otezla--apremilast--for-treatment-of-psoriatic-arthritis---celgene/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2019/06/low-dose-prednisolone-significantly-improves-pain-symptoms-and-function-in-hand-osteoarthritis/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2013/02/bayer-files-riociguat-for-cteph-and-pulmonary-arterial-hypertension-at-fda-and-eu/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2012/04/levodopa-carbidopa-gel--abbott--phase-iii-results/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2018/06/ct-p6-resubmitted-to-fda-as-herceptin-biosimilar---celltrion-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2018/05/engage-af-timi-48-trial-of-lixiana-shows-reduced-rates-of-intracranial-haemorrhage-for-patients-with-atrial-fibrillation---daiichi-sankyo-/2024-07-26T10:05:16+00:00weekly0.6https://www.medthority.com/news/2017/10/world-arthritis-day-2017/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2013/09/examine-study-shows-no-extra-cv-events-with-nesina-in-t2d-/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-trials-of-rexulti-fails-to-meet-primary-endpoint-in-bipolar-disorder---lundbeck----otsuka-pharma/2021-09-24T07:17:11+00:00weekly0.6https://www.medthority.com/news/2011/10/tysabri-shows-benefits-in-multiple-sclerosis-patients/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2019/06/esmo-world-congress-on-gastrointestinal-cancer/2024-02-23T11:10:45+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-data-from-response-2-trial-showed-jakavi--ruxolitinib--support-for-patients-with-polycythemia-vera---novartis/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2012/03/yervoy--bms--in-brain-metastases-study/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-ninlaro--ixazomib--capsules-in-combination-with-lenalidomide-and-dexamethasone-for-adult-patients-with-multiple-myeloma--takeda/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-accepts-bla-for-mk-8237-dust-mite-sublingual-allergy-immunotherapy--slit--tablet--merck/2021-09-24T07:10:43+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-vici-venous-stent-system-for-the-treatment-of-iliofemoral-venous-obstructive-disease---boston-scientific/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-hetlioz-for-non-24-hour-sleep-disorder-vanda/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-gastric-emptying-breath-test--a-non-invasive--test-to-diagnose-gastroparesis--advanced-breath-diagnostics/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2020/01/fda--advisory-committees-again-reject-aximris-xr-for-the-management-of-pain----intellipharmaceutics-international-inc-/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-ii-data-annonuced-for-once-daily--fixed-dose-combination-asthma-treatment/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2019/07/the-brain-s-internal--gps--and-time-tracker-provides-valuable-insight-into-alzheimer-s-disease/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2014/07/success-for-neratinib-in-phase-iii-trial-for-her-2-positive-breast-cancer---puma-biotechnology/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-solution-study-results-of-sollpura--liprotamase--for-exocrine-pancreatic-insufficiency--anthera-pharmaceuticals-/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2013/11/eisai-expands-marketing-regions-for-belviq-for-obesity/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2019/10/510-k--approval-for-low-profile-enteral-feeding-device--peg--from-fidmi-medical-ltd-/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/06/positive-results-from-second-phase-iii-halo-study-of-fremanezumab--tev-48125---an-investigational-treatment-for-the-prevention-of--episodic-migraine---teva/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2015/12/positive-cost-effectiveness-study-of-watchman--laac-for-stroke-reduction--boston-scientific/2024-02-22T16:12:57+00:00weekly0.6https://www.medthority.com/news/2011/09/ostora-oral-calcitonin-safe-and-effective-for-osteoporosis/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2019/02/positive-topline-results-from-pivotal-phase-iii-regenerate-study-of-obeticholic-acid-in-patients-with-liver-fibrosis-due-to-nash---intercept-pharma/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2015/08/allergan-resubmits-application-at-fda-for-botox--onabotulinumtoxin-a--to-treat-lower-limb-spasticity/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2018/07/study-shows-rgn-259-equal-to-or-better-than-competition-in-treating-dry-eye-disease---regenerx-biopharma-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2014/04/xtandi-amendment-submitted-to-eu-for-mcr-prostate-cancer---astellas-medivation/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2016/04/meta-analysis-of-literature-of-efficacy-and-safety-of-exoskeleton-assisted-walking-in-patients-with-spinal-cord-injury---rewalk-robotics-ltd-/2024-02-22T16:13:54+00:00weekly0.6https://www.medthority.com/news/2017/05/ema-widens-scope-of-zebinix--eslicarbazepine-acetate--for-use-as-a-once-daily-monotherapy-to-treat-adults-with-newly-diagnosed-partial-onset-epilepsy----bial---eisai/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-rejects-adcetris--brentuximab-vedotin--as-a-treatment-for-relapsed-or-refractory-hodgkin-lymphoma----takeda-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2014/10/new-patient-led--advance-care-planning--guide-with-tool-could-significantly-reduce-pressure-on-healthcare-professionals/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-of-sbc-102-in-lal-deficiency-meets-primary-endpoint-synageva/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-study-success-for-signifor-lar-for-acromegaly---novartis/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2019/10/janssen-seeks-to-expand-use-of-tremfya----guselkumab--in-the-treatment-of-adults-with-active-psoriatic-arthritis/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2013/11/suspension-of--marketing-iclusig--ariad-pharma--in-us-/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2012/04/iqwig-finds-limited-effect-of-vyndaqel--pfizer-in-ttr-fap/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2018/10/tecentriq---abraxane-success-in--phase-iii-impassion-130-study--to-treat-triple-negative-breast-cancer---genentech-roche/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-arthritis-advisory-committee-recommends-ctp-13--infliximab-biosimilar--for-all-indications-of-the-reference-product---hospira-pfizer/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2017/03/allergan-files-supplemental-snda-at-fda-for-maintenance-of-efficacy-in-adults-with-schizophrenia-with-vraylar--cariprazine--/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-kanuma--sebelipase-alfa--to-treat-lysosomal-acid-lipase-deficiency--alexion-pharma/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-grants-tentative-approval-for-basaglar-for-types-1-and-2-diabetes---eli-lilly---boehringer/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-trials-initiated-by-gsk-for-daprodustat-a-treatment-for--anaemia-associated-with-chronic-kidney-disease--/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2012/12/gsk-theravance-file-gsk-573719-plus-vilanterol-at-the-fda-for-copd/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-xgeva-to-treat-to-treat-skeletal-related-events-in-patients-with-multiple-myeloma--amgen-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-ionsys--fentanyl-iontophoretic-transdermal-system--for-acute-post-operative-pain-the-medicines-company/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2015/10/ats-2015-symposium-materials-added-to-copd-knowledge-centre/2021-11-26T09:33:10+00:00weekly0.6https://www.medthority.com/news/2012/10/european-commission-approves-tradjenta--eli-lilly-boehringer--for-treatment-with-insulin-for-patients-with-type-2-diabetes---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2015/07/allergan-initiates-phase-iii-trial-of-abicipar-pegol-to-treat-wet-age-related-macular-degeneration--molecular-partners/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2016/10/newly-published-phase-iii-trials-of-dupixent--dupilumab--meet-primary-endpoints-in-atopic-dermatitis--sanofi-and-regeneron-pharma/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2011/10/c-11-choline-pet-ct-offers-benefits-for-prostate-cancer-patients/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-erleada-for-the-treatment-of-patients-with-metastatic-castration-sensitive-prostate-cancer--johnson---johnson/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2016/08/three-studies-of-fluad--mf59-adjuvanted-seasonal-trivalent-vaccine--reinforce-safety-and-immunogenicity-profiles-in-influenza-prevention--seqirus-/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-xpert-bcr-abl-ultra-diagnostic-assay-for-chronic-myeloid-leukemia---cepheid/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2015/09/new-phase-iii-data-on-lenvima--lenvatinib--in-thyroid-cancer--eisai/2024-02-22T16:14:05+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-trial-of-vimpat--lacosamide--as-monotherapy-for-patients-with-partial-onset-seizures--ucb/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2018/12/eli-lilly-announces-publication-of-analyses-showing-benefit-of--verzenio-in-multiple-subgroups-of-patients-with-advanced-breast-cancer-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-approval-of-pediatric-formulation-of-mimpara--cinacalcet--in-secondary-hyperparathyroidism--amgen/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2013/06/rhb-103--redhill-biopharma--filed-at-fda-for-treatment-of-acute-migraine/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2018/08/topline-results-from-phase-iii-extension-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids---abbvie---neurocrine-biosciences-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-data-on-shingrix-vaccine-shows-efficacy-for-shingles-in-co-administration-with-flu-vaccine--glaxosmithkline/2024-10-21T14:48:42+00:00weekly0.6https://www.medthority.com/news/2016/12/uk-nice-does-not-recommend-use-of-kadcyla--trastuzumab-emtansine--for-breast-cancer-treatment--roche/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-murano-study-of-venclexta-plus-rituxan-shows-disease-progression-benefits-in-chronic-lymphocytic-leukemia---genentech-roche/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-keynote-045-trial-of-keytruda--pembrolizumab--meets-primary-endpoint-in-advanced-urothelial-cancer--merck-inc/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-symproic--naldemedine---to-treat-opioid-induced-constipation---shionogi---purdue-pharma/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2016/06/impax-laboratories-acquires-generic-drugs-from-teva/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2014/07/european-commission-approves-eliquis-for-deep-vein-thrombosis-and-pulmonary-embolism---bms---pfizer/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2013/09/positive-data-from-study-of-tivicay-in-adults-with-hiv-1/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-recommends-erbitux--cetuximab--plus-platinum-based-chemotherapy-as-a-first-line-therapy-for-patients-with-recurrent-and-or-metastatic--squamous-cell-carcinoma-of-the-head-and-neck--scchn--in-the-oral-cavity----merck-kgaa/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2015/11/european-commission-approves-elocta---rfviiifc--for-the-treatment-of-haemophilia-a--sobi---biogen-/2024-02-23T11:10:58+00:00weekly0.6https://www.medthority.com/news/2012/10/updated-survival-results-of-emilia-study-for-t-dm1-for-metastatic-breast-cancer/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2019/11/santhera-announces-publication-of-long-term-idebenone-data-from-syros-study-in-duchenne-muscular-dystrophy--/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2018/07/european-commission-approves-biktarvy-to-treat-hiv-infection---gilead-sciences-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2019/10/reata-pharmaceuticals-reacquires-rights-from-abbvie-to-develop-and-commercialize-bardoxolone-methyl-and-omaveloxolone-/2021-09-24T07:17:25+00:00weekly0.6https://www.medthority.com/news/2013/05/eu-approves-octava-pink-test--eventus-diagnostics--for-detecting-breast-cancer-/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-vipidia--takeda--for-type-2-diabetes/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-afinitor-disperz-for-tuberous-sclerosis-complex---novartis-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-extends-indication-for-eylea-to-brvo-regeneron-pharma/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2019/07/nice-recommends-onpattro-to-treat-hereditary-transthyretin-mediated-amyloidosis----alnylam/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2013/06/novo-nordisk-files-ideglira-for-eu-approval-for--treatment-of-type-2-diabetes/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2017/04/once-weekly-semaglutide-shows-reductions-in-hba1c-and-body-weight-compared-to-sitagliptin--exenatide-extended-release--er--and-insulin-glargine-u100-in-adults-with-type-2-diabetes---novo-nordisk/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-trial-of-p-1101-demonstrates-superiority-in-polycythemia-vera---aop-orphan-pharmaceuticals---pharmaessentia-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2012/05/pressure-right--pressure-point--device-effective-in-reducing-postoperative-nausea/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2020/02/mavoric-trial-of-poteligeo-consistent-with-safety-data-in-cutaneous-t-cell-lymphoma---kyowa-kirin/2021-09-24T07:12:05+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-warning-of-possible-ketoacidosis-associated-with-sglt2-inhibitor-treatment-of-type-2-diabetes-/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2017/04/trinity-study-of--extrafine-ics-laba-lama-triple-fixed-dose-combination-therapy-for-copd-is-published-in-the-lancet----chiesi/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2017/09/exscel-trial-with-bydureon--exenatide-extended-release--in-patients-with-type-2-diabetes-shows-cv-safety---astrazeneca-/2024-07-26T10:04:48+00:00weekly0.6https://www.medthority.com/news/2017/04/international-society-on-thrombosis-and-hemostasis--isth--announce-upcoming-congress-is-expected-to-be-world-s-largest/2024-10-22T08:20:16+00:00weekly0.6https://www.medthority.com/news/2020/01/melinta-therapeutics-enters-voluntary-bankrupcy/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2011/12/zolinza--merck--shows-good-response-with-aml-patients/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2015/04/medtronic-to-commence-new-programme-for-renal-denervation--in-uncontrolled-hypertension-with-symplicity-spyral-htn-device-/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2019/05/new-data-presented-at-aan-meeting-highlights-clinically-meaningful-benefits-of-spinraza-to-treat--spinal-muscular-atrophy---biogen-inc-/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2018/02/online-kidney-atlas/2024-07-26T10:03:18+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves--fluarix-quadrivalent--gsk--influenza-vaccine/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2019/09/astrazeneca-amends-its-collaboration-agreement-for-linzess-with-ironwood-pharmaceuticals-for-china-mainland--china-hong-kong-and-china-macau-/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-vimpat-monotherapy-in-epilepsy-ucb/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2012/12/new-phase-ii-trial-shows-combination-treatment-with-selumetinib--astrazeneca--has-promise-for-patients-with-nsclc/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-results-with-auryxia-fexeric--ferric-citrate--for-iron-deficiency-anemia-published-in-jasn--keryx-biopharmaceuticals/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/07/new-drug-application-filed-with-fda-for-tmc-207--janssen-pharmaceuticals--for-multi-drug-resistant-tuberculosis------------------------------/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-daklinza--daclatasvir----sovaldi-sofosbuvir--for-use-in--genotype-3-hepatitis-c-patients-without-cirrhosis-over-12-weeks--bms-/2024-02-23T11:19:21+00:00weekly0.6https://www.medthority.com/news/2016/10/infinity-deep-brain-stimulation--dbs--system-is-fda-approved-for-patients-suffering-from-parkinson-s-disease-or-essential-tremor---st-jude-medical-/2024-10-21T14:42:19+00:00weekly0.6https://www.medthority.com/news/2018/05/benevir-biopharm-inc---is-acquired-by-janssen-biotech-inc-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2016/06/gap-trial-of-grazax--sublingual-allergy-immunotherapy-tablet--shows-it-can-prevent-asthma-and-relieve-grass-allergy-symptoms--alk/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2016/11/ascensia-diabetes-care-has-received-510-k--approval-from-the-fda-for-the-contour-next-one-blood-glucose-monitoring-system--/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2015/06/perjeta--pertuzumab--positive-results-from-neosphere-study-in-combination-with-herceptin---docetaxel-in-early-breast-cancer-genentech---roche/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-paradigms-study-positive-topline-results-for-treatment-of-children-and-adolescents--ages-10-to-17--with-multiple-sclerosis---novartis-/2021-09-24T07:13:59+00:00weekly0.6https://www.medthority.com/news/2011/09/vibativ-is-eu-approved-for-nosocomial-pneumonia-caused-by-mnsa/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2019/05/tsolution-one-surgical-system-filed-for-510-k--approval-with-fda-for-knee-replacement---think-surgical/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2016/09/biogen---ionis-have-completed-the-rolling-submission-of-a-new-drug-application--nda--to-the-fda-for-nusinersen--a-treatment-for-spinal-muscular-atrophy--sma--/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2014/08/kyprolis-fails-focus-study-for-multiple-myeloma---amgen-onyx/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2016/01/acorda-therapeutics-acquires-biotie-therapies-and-with-it-tozadenant-and-syn-120-/2021-09-24T07:09:07+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-rejects-ampligen--hemispherx--as-a-treatment-for-chronic-fatigue-syndrome/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2018/07/sandoz-acquires-from-adamis-pharma-us-rights-to-symjepi-for-the-emergency-treatment-of-allergic-reactions-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2016/07/nice-rejects-opdivo--nivolumab--as-a-treatment-for-renal-cell-carcinoma---bms/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-data-on-viekirax--ombitasvir-paritaprevir-ritonavir-tablets----exviera--dasabuvir--shows-response-rates-in-hepatitis-c--abbvie/2021-09-24T07:09:14+00:00weekly0.6https://www.medthority.com/news/2019/08/eu-approves-fiasp--for-the-treatment-of-diabetes-in-adolescents-and-children---novo-nordisk/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-trial-of-amg-827-meets-endpoints-in-plaque-psoriasis-astrazeneca-amgen/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2016/04/nuq-biomarker-assay-shows-significant-detection-rate-for-prostate-cancer--volitionrx/2021-09-24T07:10:40+00:00weekly0.6https://www.medthority.com/news/2019/11/expanded-results-from-allergen-chamber-trial-released-as-well-as--plans-to-initiate-the-phase-iii-invigorate-trial-in-allergic-conjunctivitis---aldeyra-therapeutics/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2014/06/prestalia-filed-with-fda-for-hypertension-symplmed/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2013/10/asteria-1-results-for-omalizumab--genentech-roche--for-uricaria/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-sympazan-for-lennox-gastaut-syndrome---aquestive-therapeutics-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2016/01/two-phase-iii-trials-show-tenofovir-alafenamide-superior-to-viread-in-hepatitis-b--gilead/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2011/12/daclatasvir--bms--and-tme-435-tibotec--combination-for-phase-ii-for-hepatitis-c/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2017/11/european-commission-approves-zytiga-for-the-treatment-of-newly-diagnosed-high-risk-metastatic-hormone-sensitive-prostate-cancer---janssen-cilag-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2015/01/elvanse-adult--lisdexamfetamine-dimesylate--receives-positive-response-from-european-decentralised-procedure-for-adult-use-in-adhd-shire/2021-09-24T07:03:25+00:00weekly0.6https://www.medthority.com/news/2014/12/extention-to-indication-of-volibris-in-pah-filed-with-ema-gsk/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2016/03/gilead-and-merck-in-patent-litigation-over-rights-to-sovaldi--sofosbuvir--and-harvoni--ledipasvir---sofosbuvir-/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-positive-for-solriamfetol-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness-in-adults-with-narcolepsy--with-or-without-cataplexy--or-obstructive-sleep-apnea----jazz-pharma/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-ii-trial-of-ohr-avr118--ohr-pharmaceutical--shows-some-benefits-for-cancer-patients-with-cachexia/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-monaleesa-2-study-reinforces-efficacy-and-safety-of-kisqali--ribociclib--plus-letrozole-in-hr--her2--advanced-or-metastatic-breast-cancer--novartis/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2016/01/auxilium-pharma-endo-pharma-terminates-agreement-to-market-stendra--avanafil--for-erectile-dysfunction-in-the-us-and-canada--vivus/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-fetroja-for-complicated-urinary-tract-infections---shionogi/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2012/07/no-benefit-of-tarceva--genentech-roche--for-patients-with-liver-cancer/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-phase-iii-results-for-two-trials--of-twyneo-to-treat-acne--sol-gel-technologies-ltd-/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2019/02/results-from-phase-iii-lms-003-trial-of-firdapse-in-lambert-eaton-myasthenic-syndrome-published-in-journal-of-clinical-neuromuscular-disease---catalyst-pharma/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2015/02/sante-trial-of-dbs-for-epilepsy--positive-and-published-inneurology--medtronic/2024-02-23T11:19:44+00:00weekly0.6https://www.medthority.com/news/2018/03/xeomin-filed-with-fda-for-sialorrhea-in-parkinsons-disease---merz-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-erbitux--bms-merck-serono--for-metastatic-head-and-neck-cancer-/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2015/10/ner-1006-meets-primary-endpoint-in-phase-iii-trial-for-bowel-cleaning--norgine/2024-02-23T11:19:58+00:00weekly0.6https://www.medthority.com/news/2016/02/alkermes-initiates-enlighten-2-phase-iii-trial-of-alks-3831--samidorphan---olanzapine--for-schizophrenia-/2024-02-23T11:22:25+00:00weekly0.6https://www.medthority.com/news/2014/01/mallinckrodt-terminates-co-promotion-of-sumavel-dose-pro-with-zogenix/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2015/12/isis-pharma-changes-its-name-to-ionis-pharmaceuticals-inc/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2016/01/results-of-trial-of-elecsys-sflt-1-plgf-immunoassay-in--preeclampsia-published-in-nejm--roche/2024-02-23T11:22:43+00:00weekly0.6https://www.medthority.com/news/2013/03/eu-approves-gelrinc--regentis-biomaterials--for-cartilage-repair/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2018/05/complete-response-letter-for-n-1539--i-v-meloxicam--for-acute-post-surgical-pain---recro-pharma-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-ztlido-transdermal-patch-for-post-herpetic-neuralgia---scilex-pharma-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-accepts-bla-for-rolontis-for-the-treatment-of-neutropenia-due-to-myelosuppressive-chemotherapy-and-sets-a-pdufa-date-of-october-24--2020---spectrum-pharma/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2018/10/supplemental-nda-filed-with-fda-for-osphena-to-add-vaginal-dryness-to-dyspareunia---duchesnay-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-ventana-pd-l1--sp263--assay-for--bladder-cancer--roche/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2018/01/novartis-initiates-head-to-head-trials-of-cosentyx-with-biosimilar-adalimumab-in-ankylosing-spondylitis--surpass--and-with-humira-in-psoriatic-arthritis--exceed--/2021-11-30T14:21:07+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approval-for-stelara-to-treat-moderately-to-severely-active-ulcerative-colitis---janssen-pharma/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2016/08/endo-pharma-withdraws-its-supplemental-new-drug-application--snda--relating-to-specific-abuse-deterrent-labeling-for-opana-er-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-label-update-for-teflaro--ceftaroline-fosamil--in-acute-bacterial-skin-and-skin-structure-infections--allergan/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2016/01/shire-plc-close-to-finalising-a-deal-to-acquire-baxalta/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2019/11/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref--/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-recommends-hetlioz--vanda--for-non-24-hour-disorder/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2019/06/savara-announces-results-of-impala--a-phase-iii-study-of-molgradex-for-the-treatment-of-autoimmune-alveolar-pulmonary-proteinosis--/2021-09-24T07:16:58+00:00weekly0.6https://www.medthority.com/news/2019/09/tresiba-showed-an-overall-lower-risk-of-hypoglycaemia-and-significantly-lower-hba1c-compared-to-insulin-glargine-u300-in-type-2-diabetes---novo-nordisk-/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2013/12/mk-8931-in-both-epoch-and-apecs-studies-for-alzheimer-s-disease-merck-inc-/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2015/11/j-j-acquires-novira-therapeutics-and-with-it-nvr-3-778-a-promising-treatment-for-hepatitis-b/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-advisory-committee-to-review-exparel-a-a-nerve-block-for-regional-analgesia---pacira-pharma-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2015/02/positive-results-in-phase-iii-trial-of-ri-002-in-pidd-adma-biologics/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2017/10/ataluren-not-approved-by-fda-for-nonsense-mutation-muscular-dystrophies/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-trial-of-cyltezo-meets-endpoint-in-plaque-psoriasis---boehringer-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2016/05/medivation-rejects-sanofi-offer/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2013/10/studies-show-evidence-of-benefits-of-statins-for-dementia/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-ly-2963016-insulin-glargine-biosimilar-for-types-1---2-diabetes--eli-lilly---boehringer/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2019/09/european-union-approves-stelara-for-moderately-to-severely-active-ulcerative-colitis---janssen-biotech/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2014/01/evolocumab-success-in-gauss-2-study-in-statin-intolerant-patients-amgen/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2011/10/puma-biotechnology-licenses-neratinib-for-breast-cancer-from-pfizer/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2016/09/flame-study-of-ultibro-breezhaler--indacaterol-glycopyrronium-bromide--shows-efficacy-in-patient-sub-groups-in-copd-novartis/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-approves-3d-x--ray-for-breast-cancer/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-onpattro--to-treat-hereditary-transthyretin-mediated--hattr--amyloidosis-in-adults-with-stage-1-or-stage-2-polyneuropathy---alnylam-pharma-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2018/02/slow-eating-speed-may-be-linked-to-weight-loss/2024-02-22T16:01:30+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-g6-continuous-glucose-monitor-for--diabetes-mesurement---dexcom/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2014/07/abbvie-and-shire-to-merge-in--32-billion-deal-/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-trial-of-tak-875-in-t2d-meets-primary-endpoint/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-jadenu--deferasirox-oral-suspension--a-new-formulation-of-deferasirox-to-treat-chronic-iron-overload-novartis/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2013/09/lotus-aortic-valve-system-study-shows-benefits/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2019/05/eu-approves-xeomin-for-sialorrhea-due-to-neurological-conditions---merz/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2014/05/brodalumab-success-in-phase-iii-trial-for-plaque-psoriasis--amgen---astrazeneca/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2012/11/seroquel-xr--astrazeneca--is-declared-invalid-by-german-federal-court/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2014/12/afinitor---herceptin-in-her2--advanced-breast-cancer--novartis/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2018/04/new-findings-from-studies-of-spinraza-for-both-infantile--and-later-onset-spinal-muscular-atrophy---biogen-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2015/09/nice-recommends-ofev--ninedanib--for-treatment-of-idiopathic-pulmonary-fibrosis---boehringer-/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2012/12/updated-survival-results-from-cleopatra-phase-iii-trial-for-perjeta-genentech--in-breast-cancer-treatment/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2014/12/quadra-allure-mp-cardiac-resynchronization-system-receives-ce-mark-for-heart-failure--st-jude-medical/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2016/09/impact-study-of-zephyr-endobronchial-valves-in-emphysema--published-in-american-journal-of-respiratory-and-critical-care-medicine--pulmonx-corp/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2018/11/leo-pharma-and-pellepharm-collaborate-on-the-development-of-patidegib-topical-gel-2---to-treat-gorlin-syndrome-/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-trial-of-aranesp--darbepoetin-alfa--in-anaemia-with-mds-meets-primary-endpoint--amgen/2024-02-09T11:06:47+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-eu-approval-of-kalydeco--vertex--for-cystic-fibrosis/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/01/esperion-therapeutics-initiates-phase-iii-long-term-safety-and-tolerability-study--etc-1002-040--of-bempedoic-acid--etc-1002--in-patients-with-hyperlipidaemia/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-chmp-opinion-for-epidyolex--for-the-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-or-dravet-syndrome---gw-pharmaceuticals/2021-09-24T07:18:04+00:00weekly0.6https://www.medthority.com/news/2016/12/successful-results-of-reflections-b3271002-study-for-pf-05280014-trastuzumab-biosimilar-from-pfizer-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2015/05/five-year-study-shows-lower-hospitalisations-with-remote-cardiac-monitoring-st-jude-medical/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2019/11/complete-response-letter--for-zimhi-high-dose-naloxone-to-treat-opioid-overdose--adamis-pharma/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-magnetom-vida-3-tesla-magnetic-resonance-imaging-system--siemens-healthineers-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2017/06/-the-european-medicines-agency--ema--has-accepted-for-regulatory-review--marketing-authorization-applications-for-biosimilars-to-abbvie-s-humira--adalimumab--and-janssen-s-remicade--infliximab----sandoz/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-poteligeo-for-mycosis-fungoides-or-s-zary-syndrome--the-two-most-common-types-of-cutaneous-t-cell-lymphoma---kyowa-hakko-kirin-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2014/08/vertex-discontinues-sales-of-incivek-for-hepatitis-c-in-us--/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-for-ulipristal-acetate-gedeon-richter-for-the-pre--operative-treatment-of-uterine-fibroids--gedeon-richter-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/04/positive-results-from-boson-phase-iii-study-with-sovaldi--sofosbuvir--in-hcv-gilead/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-study--study-1-or-1002-040--of-bempedoic-acid-as-a-treatment-for-atherosclerotic-cardiovascular-disease---esperion-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2013/02/new-phase-iii-trial-results-of-xolair--genentech-roche-novartis--for-patients-with-urticaria/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/06/qudexy-xr-approval-extended-by-fda-to-patients-two-years-of-age-and-older-who-experience-tonic-clonic-seizures-upsher-smith-labs/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2015/08/eu-approves-omidria--phenylephrine-and-ketorolac-injection--for-use-in-cataract-surgery--omeros-corp/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2018/06/overall-survival-data-from-archer-1050-trial-of-dacomitinib-as-a-first-line-treatment-for-metastatic-nsclc-with-egfr-mutations----pfizer-/2024-02-09T11:08:08+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-cresemba-for-fungal-infections-astellas/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-requires-more-data-for-revlimid--celgene--application-for-maintenance-therapy-in-multiple-myeloma/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-lifts-partial-hold-on-phase-iii-trial-of-dcvax-l--gene-therapy--for-glioblastoma-multiforme-brain-cancer--northwest-biotherapeutics/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2014/02/northera-approved-by-fda-for-symptomatic-neurogenic-orthostatic-hypotension---chelsea-therapeutics/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2018/07/researchers-identify-protein-essential-for-making-stem-cells/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approval-for-aubagio-sanofi-genzyme--as-a-treatment-for-relapsing-multiple-sclerosis---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2019/09/entresto-improved-measures-of-heart-structure-and-function-in-hfref-patients-in-new-novartis-study--additional-data-complement-findings-/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2017/09/ce-mark-granted-for-setalum-sealant--a-bio-inspired-surgical-glue---gecko-medical-/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2019/03/novartis-to-initiate-a-study-of-entresto-to-treat-chagas-cardiomyopathy-/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2019/06/european-commission-approves-doptelet-for-treatment-of-severe-thrombocytopenia----dova-pharma/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-zortress--novartis--for-prophylaxis-of-organ-rejection-in-liver-transplant-patients-/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2017/01/trabodenoson--ino-8875--fails-phase-iii-trial-for-primary-open-angle-glaucoma---inotek-pharmaceuticals-corporation-/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2015/05/phase-iii-data-on-essure-for-contraception-to-be-published--bayer-healthcare/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2012/12/bayerhealthcare-submits-alpharadin-to-fda-for-treatment-of-castration-resistant-prostate-cancer/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2018/12/analyses-of-phase-iii-murano-study-of-venclexta-plus-rituxan-show-continued-benefit-in-chronic-lymphocytic-leukemia---genentech-roche-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-zephyr-endobronchial-valve-in-emphysema---pulmonx-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-study-of-nbi-98854--valbenazine--reports-significant-improvement-in-tardive-dyskinesia--neurocrine-biosciences/2024-02-09T11:08:19+00:00weekly0.6https://www.medthority.com/news/2016/12/endo-international-returns-belbuca---buprenorphine--buccal-film-rights-to-biodelivery-science-international-and-withdraws-from-pain-therapy-development-to-focus-on-xiaflex-/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2013/07/ema-clears-glp-1--diabetes-drugs-of-pancreatitis/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2014/12/faslodex---fulvestrant--significantly-improves-overall-survival-for-women-with-hormone-receptor-positive-breast-cancer-compared-to-arimidex-sup----sup---anastrozole-/2024-02-22T11:49:59+00:00weekly0.6https://www.medthority.com/news/2016/03/tremelimumab-fails-in-phase-iib-trial-for-unresectable-malignant-mesothelioma--astrazeneca/2024-02-09T11:08:30+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-orsiro-drug-eluting-stent--des--system-for-treatment-of-coronary-artery-disease--biotronik/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-data-in-pivotal-trial-of-hematopoietic-stem-cell-transplant--associated-thrombotic--microangiopathy-patients-treated-with-narsoplimab--omeros-corpn-/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2017/03/morphosys-ag-announces-roche-plans-to-initiate-a-phase-iii-programme-with-gantenerumab-in-patients-with-prodromal-to-mild-alzheimer-s-disease-/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2011/11/onglyza--bms-astrazeneca---plus-insulin-is-ema-approved-for-type-2-diabetes/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-for-review-bla-application-for-romosozumab-as-a-treatment-of-osteoporosis-in-postmenopausal-women-at-increased-risk-of-fracture---amgen---ucb/2021-09-24T07:09:11+00:00weekly0.6https://www.medthority.com/news/2019/04/successful-phase-iii-envision-study-for-givosiran-to-treat-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves--ventana-alk--d5f3--cdx-assay-as-companion-diagnostic-for-xalkori--crizotinib--in-non-small-cell-lung-cancer--roche/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-spiriva-respimat--tiotropium-bromide--to-treat-asthma--boehringer/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2018/12/valbenazine-did-not-meet-the-primary-endpoint-in-phase-iib-t-force-gold-study-to-treat-tourette-syndrome---neurocrine-biosciences/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-orbera-intragastric-balloon-for-obesity--apollo-endosurgery/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-acrysof-iq-aspheric-iol-for-patients-undergoing-cataract-surgery--alcon-novartis/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2018/04/impella-5-5-heart-pump-receives-ce-marking-approval-in-europe-for-heart-failure---abiomed-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves--remicade-biosimilar-inflectra/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/08/positive-results-from-proof-of-concept-trial-of-nuq-assay-to-diagnose-prostrate-cancer---volitionrx-ltd-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2016/04/nice-recommends-combination-rezolsta--darunavir---cobicistat--to-treat-hiv-1-virus--janssen/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-stiolto-respimat--tiotropium-bromide-and-olodaterol--for-copd--boehringer/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2012/03/impact-study-for-provenge--dendreon--effect-in-prostate-cancer-questioned-/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2015/09/humax-cd38--daratumumab--filed-with-eu-for-multiple-myeloma-janssen-cilag/2024-02-20T09:05:14+00:00weekly0.6https://www.medthority.com/news/2017/12/breakthrough-treatment-in-genetic-condition/2024-02-20T09:13:37+00:00weekly0.6https://www.medthority.com/news/2014/04/architect-hba1c-test-to-diagnose-diabetes-receives-510-k--approval-in-us---abbott-diagnostics/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2015/01/lesinurad-filed-at-ema-for-treatment-of-hyperuricaemia--gout---astrazeneca/2021-09-24T07:03:25+00:00weekly0.6https://www.medthority.com/news/2015/03/zogenix-inc--sells-zohydo--hydrocodone-bitartrate--to-pernix-therapeutics-for-up-to--283-5-million/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-sbla-for-rituxan-for-the-treatment-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-in-children---genentech-roche/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2016/10/-the-office-of-drug-evaluation-of-the-fda-rejects-an-appeal-from-ptc-therapeutics-against-the-refusal-to-file-letter-from-fda-for-translarna--ataluren--to-treat-duchenne-muscular-dystrophy-/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-senza-ii-scs-for-pain-relief---nevro-corp-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2014/10/teva-conducts-strategic-review-/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-kineret--sobi--for-caps/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-label-update-for-zytiga--abiraterone-acetate--plus-prednisone--in-prostate-cancer--janssen-biotech/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-extends-labelling-for-therascreen-egfr-rgq-pcr-kit-in-non-small-cell-lung-cancer---qiagen-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-kisqali--ribociclib--with-an-aromatase-inhibitor--to-treat-postmenopausal-women-with-hormone-receptor-positive--human-epidermal-growth-factor-receptor-2-negative--hr--her2---advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2011/10/brochitol-has-chmp-recommendation-for-treatment-of-cystic-fibrosis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2015/01/royal-philips-received-section-510--k--approval-for-avalon-cl-fetal-monitoring-solution-/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2018/01/additional-clinical-results-from-healos-trial-of-am-111-for-the-treatment-of-acute-inner-ear-hearing-loss---auris-medical-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2015/09/amgen-submits-application-to-fda-for-repatha--evolocumab--injection-monthly-version-to-treat-dyslipidaemia-/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2016/05/sb-2--infliximab-biosimilar--has-been-accepted-for-review-by-fda----samsung-bioepis---merck-inc-/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2013/01/rp-vita-robotic-solutions-receives-510--k--clearance-by-fda/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2016/08/helsinn-acquires-world-rights-to-pracinostat-a-phase-iii-ready-drug-candidate-for-the-treatment-of-aml--mei-pharma/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2013/05/strato-study-of-lcp-tacro--veloxis-pharmaceuticals--shows-benefits-for-kidney-transplant-patients-/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2016/05/novartis-announces-fortihfy-clinical-trial-programme-for-entresto--sacubitril-valsartan--for-heart-failure-/2024-02-20T09:20:24+00:00weekly0.6https://www.medthority.com/news/2013/11/gs-7977--gilead--success-in-phase-ii-studies-in-hcv/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-recommends-doptelet-to-treat-severe-thrombocytopenia-in-adult-patients-with-chronic-liver-disease----dova-pharma/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2018/04/nice-does-not-recommend-ocrevus-as-a-treatment-for-multiple-sclerosis---roche/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-grants-permaderm--regenicin--for-skin-grafts-orphan-status/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2016/06/bioequivalence-endpoints-met-in-study-of-biosimilar-rituximab---sandoz-/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2017/05/truecoin-meta-analysis-shows-home-monitoring-from-biotronik-saves-lives-by-slowing-heart-failure-progression-/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2015/03/-first-phase-iii-success-for-otx-dp--sustained-release-dexamethasone--for-treatment-of-ocular-inflammation--ocular-therapeutix/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2019/06/ce-mark-for-mallya-device-that-records-key-treatment-information-for-diabetic-patients---biocorp-/2021-09-24T07:16:57+00:00weekly0.6https://www.medthority.com/news/2017/07/faslodex--fulvestrant-approved-as-first-line-treatment-for-oestrogen-receptor-positive--locally-advanced-or-metastatic-breast-cancer-in-postmenopausal-women-/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2013/05/chmp-recommends-revlimid-for-treatment-of-myelodysplastic-syndromes/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-results-for-trulicity--dulaglutide--plus-insulin-glargine-shows-improvement-in-a1c-and-body-weight-in-type-2-diabetes--eli-lilly/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2019/02/pooled-data-from-studies-of-ryaltris-shows-improvements-in-allergic-rhinitis-symptoms---glenmark-pharma/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-results-for-spiolto-respimat--tiotropium-olodaterol--in-copd-published-in-respiratory-medicine--boehringer-ingelheim/2024-02-20T09:21:01+00:00weekly0.6https://www.medthority.com/news/2014/12/gilead-presents-follow-up-data-from-idelalisib--zydelig-q--registrational-studies-in-patients-with-chronic-lymphocytic-leukemia--follicular-lymphoma-and-small-lymphocytic-lymphoma/2024-02-22T11:52:19+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-now-recommends-afinitor--everolimus-----aromasin--exemestane--to-treat-postmenopausal-women-with-her2-negative-hormone-receptor-positive-advanced-breast-cancer---novartis/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2015/09/study-finds-no-higher-risk-of-depression-or-heart-attack-in-patients-using-champix--varenicline--for-smoking-cessation--pfizer/2024-02-20T09:21:27+00:00weekly0.6https://www.medthority.com/news/2014/07/vertex-files-kalydeco-at-fda-for-people-with-cystic-fibrosis-r117h-mutation/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-signifor--novartis--for-treatment-of-cushings-disease/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-advisory-committee-recommends-approval-of-fixed-dose-combination-of-basal-insulin-glargine-plus-lixisenatide-to-treat-type-2-diabetes--sanofi/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2014/10/updated-label-from-fda-for-embeda-for-severe-pain--pfizer/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2012/05/alzheimer-s-drug-ebixa-namenda-xr--lundbeck--fails-to-reduce-significant-agitation/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2015/09/breo-ellipta-relvar-ellipta-fails-to-meet-primary-endpoint-in-summit-study-of-copd-patients-with-risk-of-cv-disease--gsk---theravance/2024-02-20T09:21:41+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-recommends-velcade--bortezomib--from-janssen-cilag-vr-cap-combination-to-treat-mantle-cell-lymphoma--janssen-cilag---takeda-oncology/2024-02-22T10:23:34+00:00weekly0.6https://www.medthority.com/news/2016/10/fda--announced--fda-510-k--clearance-for-xprecia-stride-coagulation-analyzer---siemens-healthcare-diagnostics-/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-delays-review-of-nesina--takeda--for-type-2-diabetes-treatment/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2019/01/mallinckrodt-announced-publication-of-a-retrospective-analysis-of-h-p--acthar-gel--in-kidney-transplant-recipients-with-focal-segmental-glomerular-sclerosis---mallinckrodt/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-trial-of-cpp-1x-sulindac-fails-to-meet-endpoint-in-familial-adenomatous-polyposis---cancer-prevention-pharma/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2017/12/pooled-analysis-shows-best-clinical-outcomes-for-mantle-cell-lymphoma-when-treated-earlier-with-imbruvica----janssen-r-d-/2024-02-20T10:19:24+00:00weekly0.6https://www.medthority.com/news/2012/11/acz-885--novartis--continues-positively-in-phase-ii-trial-for-traps----------------/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2016/09/janssen-cilag-files-maa-at-ema-for-once-daily-darunavir-based-single-tablet-regimen--drv-cobi-ftc---taf--to-treat-hiv-1-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-does-not-recommend-tecentriq--atezolizumab--from-roche-to-treat-urothelial--bladder--cancer-but-suggests-roche-make-a-proposal-to-cancer-drugs-fund-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2015/08/ema-accepts-application--maa--for-ixazomib-to-treat-relapsed-and-or-refractory-multiple-myeloma--takeda/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2016/08/baf-312--siponimod--reports-phase-iii-results-in-treatment-of-secondary-progressive-multiple-sclerosis--novartis/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2018/03/genetic-variant-discovery-to-help-asthma-sufferers/2024-10-22T10:00:07+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-study-of-rec-0482-in-benign-prostate-hyperplasia-published-in-world-journal-of-urology---nymox-pharmaceutical-/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2012/02/ema-accepts-maa-for-hematide--takeda--for-anaemic-adults-on-dialysis/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-approves-cleancision-wound-retraction-and-protection-system-to-protect-and-irrigate-surgical-wounds-prescient-surgical/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-xgeva-for-hypercalcemia-of-malignancy-amgen/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-grants-breakthrough-designation-to-eylea-for-treatment-of-diabetic-retinopathy--regeneron---bayer/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2019/11/interim-results-from-phase-iii-regenerate-study-of-ocaliva-show-improvement-markers-in-nash---intercept-pharma/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-sylvant-for-treatment-of-castleman-s-disease---janssen-biotech/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-of-esmya--ulipristal-acetate--meets-endpoints-in-bleeding-due-to-uterine-fibroids--allergan-and-gedeon-richter/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2018/07/world-hepatitis-day-2018/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2014/09/rixubis-is-fda-approved-to-treat-haemophilia-b-in-children--baxter/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2012/05/early-trial-for-retinitis-pigmentosa-using-microchip-from-retina-implant-ag/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2017/11/uk-heart-failure-incidence-falls-seven-percent/2025-02-03T14:49:02+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-amyvid--eli-lilly--for-beta-amyloid-detection/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-expands-approval-of-complera-in-hiv-gilead-sciences/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2012/06/ema-finds-mabthera--genentech-roche--safe-to-use-/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2012/06/phase-iii-phoenix-1-study-of-stelara--j-j-janssen-cilag--shows-consistent-results-for--plaque-psoriasis-/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2012/03/hyq--baxter-brand-name-to-be-hyqvia-for-immunodeficiency/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-accepts-nda-re-filing-of-remoxy--extended-release-oxycodone--to-treat-severe-pain---pain-therapeutics/2021-09-24T07:10:43+00:00weekly0.6https://www.medthority.com/news/2018/06/diabetes-week-2018--11-15-june--/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2019/06/keytruda-shows-improved-overall-survival-for-metastatic-head-and-neck-squamous-cell-carcinoma-in-final-analysis-of-phase-iii-keynote-048-trial---merck-inc-/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2018/01/chmp-recommends-approval-of-steglatro-for-type-2-diabetes---merck-inc----pfizer-/2021-09-24T07:05:07+00:00weekly0.6https://www.medthority.com/news/2018/04/additional-phase-iii-analysis-shows-consistent-impact-of-rpc-1063-in-relapsing-multiple-sclerosis---celgene-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2013/01/cinryze-viropharma--success-in-paediatric-hereditary-angio-oedema/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---researchers-document-impact-of-coffee-on-bowels/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2013/01/bax-855-enters-phase-ii-iii-study-for-haemophilia/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-cometriq--exelixis-inc---for-treatment-of-thyroid-cancer/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-chs-0214--etanercept-biosimilar--meets-primary-endpoint-in-rheumatoid-arthritis--coherus-biosciences-and-baxalta/2024-02-20T10:19:47+00:00weekly0.6https://www.medthority.com/news/2014/12/bay-81-8973-filed-with-fda-for-haemophilia-a-bayer-healthcare/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2012/01/chmp-recommends-signifor--novartis--for-treatment-of-cushing-s-disease/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2015/04/phase-iii-ally-1-trial-of-sovaldi---daklinza-meets-endpoint-in-hepatitis-c-bms-gilead/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2019/12/assertio-therapeutics-sells-world-rights-of-gralise-to-alvogen-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2013/09/sanofi-withdraws-lixisenatide-application-at-fda-for-type-2-diabetes/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2017/11/combo-dual-therapy-stent-demonstrates-optimal-treatment-in-acute-coronary-syndrome---orbusneich-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2011/10/lyrica-as-monotherapy-is-positive-in-epilepsy-/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2018/03/asparagine-encourages-breast-cancer/2021-11-30T14:47:17+00:00weekly0.6https://www.medthority.com/news/2017/06/new-results-with-cefaly-external-trigeminal-nerve-stimulation-device-for-migraine-published-in-bmc-neurology--stx-med/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2015/05/oto-104-narrowly-misses-endpoints-in-phase-ii-trial-for-m-ni-re-s-disease-but-likely-to-progress-to-phase-iii---otonomy-inc-/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-approves-jentadueta-boehringer-eli-lilly--for-type-2-diabetes/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-recommends-approval-of-zynteglo-for-beta-thalassaemia---bluebird-bio/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2014/08/eu-approves-avastin---chemotherapy-for-recurrent-ovarian-cancer---roche/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2018/12/successful-phase-iii-recover-study-of-rolontis-to-treat-neutropenia-associated-with-chemotherapy-in-breast-cancer-patients---spectrum-pharma-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-evomela--captisol-enabled-melphalan--for-multiple-myeloma--as-conditioning-treatment-prior-to-stem-cell-transplantation-and-as-a-palliative-treatment--spectrum-pharmaceuticals/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2019/10/new-head-to-head-data---phase-iv-ixora-r-study--show-taltz-superiority-versus-tremfya--in-people-with-moderate-to-severe-plaque-psoriasis---eli-lilly/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2015/09/astrazeneca-licenses-starpharma-s-drug-delivery-platform/2025-10-16T11:02:14+00:00weekly0.6https://www.medthority.com/news/2018/06/i-wish-interim-results-report-real-world-impact-of-immune-thrombocytopenia-on-patients---novartis/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-extended-use-of-velcade--janssen--for-multiple-myeloma/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2019/03/scilex-pharma-and-semnur-pharma-merge-to-form-scilex-holding-company--a-potential-global-leader-in-non-opioid-pain-management-/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2013/12/intrabeam-noninferior-for-radiotherapy--carl-zeiss-/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2019/03/ema-recommends-adding-efficacy-data-to-apealea-label-in-ovarian-cancer---oasmia-pharma/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-impower-132-study---chemotherapy-interim-report-for-first-line-nsclc--genentech-roche/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2015/02/overall-survival-data-from-combi-d-trial-of-mekinist---tafinlar-for-metastatic-melanoma--gsk/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2017/06/study-shows-that-sir-spheres-y-90-resin-microspheres-showed-reduced-side-effects-in-liver-cancer--sirtex/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2017/01/cambridge-cognition-announces--510-k--clearance-from-the-fda-to-market-cantab-mobile-as-a-medical-device-designed-to-detect-clinically-relevant-memory-impairment-/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-approves-expanded-indication-for-nimenrix--meningococcal-group-a--c--w-135--and-y-conjugate-vaccine--against-meningococcal-disease--pfizer/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-advisory-committee-rejects-tolvaptan-for-polycystic-kidney-disease/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2011/10/phase-iii-data-for-cariprazine-positive--for-acute-mania-associated-with-bipolar-1-disorder-/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2014/03/nice-requests-explanation-from-alexion-for-price-of-soliris-for-ahus/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2018/08/laquinimod-in-phase-ii-legato-hd-trial-to-treat-huntington-s-disease-did-not-met-its-primary-endpoint---active-biotech---teva-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-the-pentax-ed34-i10t-duodenoscope-for-visualization-and-access-to-the-upper-g-i--tract--with-a-disposable-distal-cap-to--improve-access-for-cleaning-and-reprocessing---pentax-medical-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2019/01/nice-recommends-use-of-fasenra-in-eosinophilic-asthma---astrazeneca-/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-recommends-approval-of-fexinidazole-for-sleeping-sickness---sanofi-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2016/06/european-commission-approves-afinitor--everolimus-to-treat--metastatic--well-differentiated-nonfunctional-neuroendocrine-tumours--net--of-gastrointestinal-or-lung-origin--novartis/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2013/10/pooled-trial-shows-spiriva--boehringer--effective-for-asthma/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2020/01/idmc-recommends-early-halt-of-phase-iii-sanet-p-study-of-hmpl-012-in-neuroendocrine-tumors---pancreatic---hutchison-china-meditech/2024-10-21T14:44:04+00:00weekly0.6https://www.medthority.com/news/2011/11/nice-recommends-eliquis--bms-pfizer--for-venous--thromboembolism-prevention/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2012/09/phase-iii-data-on-kalydeco--vertex--shows-benefits-for-cystic-fibrosis-patients---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2015/06/biogen-submits-maa-for-alprolix--rfixfc--at-ema-for-treatment-of-haemophilia-b--sobi---biogen/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-recommends-lucentis--novartis--for-choroidal-neovascularization/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2012/04/amylin-completes-application-to-fda-for-metreleptin-for-lipidostrophy/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2018/07/new-analyses-from-the-apollo-phase-iii-study-of-patisiran-for-the-treatment-of-hereditary-attr--hattr--amyloidosis-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-deka-arm-system-prosthetic-limb-deka-integrated-solutions--/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-blincyto-for-ph--all-onyx-pharma-amgen/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2016/09/nice-recommends-strensiq--asfotase-alfa-to-treat-perinatal-and-infantile-onset-hypophosphatasia-but-not-for-people-with-hypophosphatasia-that-appears-later-in-childhood-or-in-adults-alexion-pharma/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2016/09/allergan-has-acquired-akarna-therapeutics-including-akn-083-farnesoid-x-receptor--agonist-for-nash/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2016/11/chmp-recommends-suliqua-combination-of-insulin-glargine-and-lixisenatide--intended-for-the-treatment-of-type-2-diabetes---sanofi-/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2019/06/durect-corporation-files-response-to-complete-response-letter-for-treatment-of-post-surgical-pain-/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2015/11/study-suggests-that-combining-aptima-hpv-assay-plus-aptima-hpv-16-18-45-genotype-assay-is-more-effective-and-will-save-money--hologic/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2017/12/22nd-world-cardiology-conference/2024-02-20T10:21:44+00:00weekly0.6https://www.medthority.com/news/2019/04/chmp-positive-for-ultomiris-to-treat-paroxysmal-nocturnal-haemoglobinuria---alexion-pharma/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2014/07/merck-inc--cuts-sales-jobs-in-us/2025-10-16T10:44:17+00:00weekly0.6https://www.medthority.com/news/2015/07/sandoz-to-market-authorised-generic-angiomax-in-usa-for-pci--the-medicines-company/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2012/08/review-finds-insufficient-evidence-for-effectiveness-of-cytotec-pfizer--for-preventing-pph---------------/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2019/07/braveheart-wireless-announces-fda-clearance-of-the-braveheart-life-sensor-cardiac-monitoring-system/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2012/03/repligen-files-secreflo-with-ema-for--detection-of-pancreatic-duct-abnormalities-/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2019/07/aequus-pharmaceuticals-inc-to-dsitribute-evolve-preservative-free-dry-eye-products-within-canada-/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2013/08/grafix-success-in-diabetic-foot-ulcer-trial/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2012/08/array-797--array-biopharma--reports-phase-ii-results-in-osteoarthritis/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2019/09/novartis-announces-positive-results-from-phase-iii-iridium-study-of-inhaled-combination-qvm-149-in-patients-with-uncontrolled-asthma/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2019/06/zejula-snda-submitted-to-fda-for-ovarian--fallopian-tube--or-primary-peritoneal-cancer---tesaro/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2015/08/sanofi-re-submits-nda-to-fda-for-lyxumia--lixisenatide--for-type-2-diabetes/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2018/06/oral-semaglutide-shows-statistically-significantly-greater-reductions-in-hba1c-and-weight-compared-to-victoza-and-sitagliptin-in-the-pioneer-4-and-7-trials---novo-nordisk-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2012/05/seebri-breezhaler-novartis--success-in-glow-2-study-for-copd/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2014/02/eu-approval-for-tecfidera-for-multiple-sclerosis-biogen-idec/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2017/11/marking-lung-cancer-awareness-month--november-2017/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-otezla-for-psoriasis-and-psoriatic-arthritis---celgene/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2012/08/combination-faslosdex-and-arimidex-success-in-breast-cancer-trial/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2016/07/fda-advisory-committee-accepts-evidence-of-positive-cv-effect-of-jardiance--empagliflozin--for-type-2-diabetes-patients---eli-lilly---boehringer/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2011/12/brachytherapy-associated-with-twofold-increased-risk-for-mastectomy/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-advisory-committee-recommends-suvorexant--merck-inc---for-treatment-of-insomnia/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2014/05/successful-phase-iii-scalet-trial-for-liraglutide-for-obesity-treatment---novo-nordisk/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-sbla-for-xiaflex-in-dupuytren-s-contracture-auxilium/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2013/12/cerdelga-filed-at-fda-for-gaucher-disease-type-1-sanofi-genzyme/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-rns-neurostimulation-system--neuropace--for--uncontrolled-seizures/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-extends-indication-of-dymista-in-allergic-rhinitis-meda-ab/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2016/12/-prt-201--vonapanitase--did-not-meet-primary-endpoint-in-phase-iii-trial-to-improve-patency---openness--in-radiocephalic-arteriovenous-fistulae--proteon-therapeutics/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2012/06/ceptaris-therapeutics-receives-complete-response-letter-from-fda-for-mechlorethamine-hydrochloride-treatment-for-mycosis-fungoides/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2017/12/results-of-monaleesa-7-trial-for-kisqali--treatment-for-advanced-breast-cancer--novartis/2021-09-24T07:13:43+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-ii-trial-of-keytruda--pembrolizumab--shows-drug-shrank-tumours-by-30-per-cent-in-patients-with-metastatic-triple-negative-breast-cancer--merck-inc/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2016/01/perceval-sutureless-heart-valve-approved-by-fda-for-replacement-of-diseased-or-damaged-aortic-valves--livanova/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2012/03/addex-pharma-reports-success-in-phase-iia-trial-for-dipraglurant-for-parkinsons-disease-/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2018/12/adamis-pharma-files-nda-at-fda-for-its-fast-dissolving-sublingual-tadalafil-tablet-to-treat-erectile-dysfunction-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2012/05/luae-58054-success-in-phase-ii-study-for-alzheimers-disease/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2011/12/omnitarg--genentech-roche---success-in-cleopatra-trial-in-untreated-her-2-positive-breast-cancer/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2019/07/new-study-reveals-biological-toll-on-brain-function-of-holocaust-survivors/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2018/06/crb-401-phase-i-clinical-study--of-bb-2121-for-multiple-myeloma-led-to-a-median-pfs-of-11-8-months-among-those-patients-who-received-an-active-dose-of-the-cell-therapy----celegene----bluebird-bio-/2024-07-26T10:17:04+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-cellfina-system-for-cellulite-removal--ulthera-inc-/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-braftovi---mektovi-for-metastatic-melanoma-with-a-brafv600-mutation--array-biopharma---pierre-fabre/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2015/03/liberate-study-results-of-otezla--apremilast--in-plaque-psoriasis--celgene/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2017/11/positive-phase-iii-efficacy-data-reported-for-revefenacin-as-a-treatment-of-copd---theravance---mylan-/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2017/12/chmp-recommends-approval-of-alofisel-for-crohn-s-disease/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2013/12/velcade-shows-improved-os-in-multiple-myeloma--takeda/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2019/12/european-commission-approves-evenity-for-severe-osteoporosis---amgen---ucb/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-eliquis--bms-pfizer--for-prevention-of-stroke-and-systemic-embolism-in-nvaf-patients---------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2015/07/catalyst-pharmaceuticals-files-rolling-submission-nda-to-fda-for-firdapse--amifampridine-phosphate--to-treat-lambert-eaton-myasthenic-syndrome--lems--/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-daklinza--daclatasvir-----sofosbuvir-for-cirrhosis-patients--hiv-patients-and-post-liver-transplant-patients-co-infected-with-hepatitis-c---bms/2024-02-09T16:24:56+00:00weekly0.6https://www.medthority.com/news/2018/10/positive-phase-iii-style-study-results-for-otezla-to-treat-scalp-psoriasis---celgene/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-daklinza--daclatasvir----sofosbuvir-to-treat-hepatitis-c-genotype-3--bms/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2017/12/crohn-s-and-colitis-awareness-week-2017/2024-02-22T11:55:30+00:00weekly0.6https://www.medthority.com/news/2016/12/pegpleranib-combination-with-lucentis--ranibizumab-fails-two-phase-iii-trials-to-treat-age-related-macular-degeneration--novartis---ophthotech-/2021-09-24T07:10:13+00:00weekly0.6https://www.medthority.com/news/2012/03/allegro-trial-of-laquinimod-reported-in-nejm/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2015/02/combination-abt-450-r-and-abt-267-filed-in-japan-for-hcv-abbvie/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2016/12/stelara--ustekinumab--filed-with-the-fda-for-the-treatment-of-adolescents--12-to-17-years-of-age--with-moderate-to-severe-plaque-psoriasis--janssen-biotech/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2018/05/nice-approves-use-of-adcetris-for-hodgkin-lymphoma---seattle-genetics-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2017/03/analysis-shows-that-moderate-to-severe-psoriasis-patients-treated-with-cosentyx--secukinumab--rapidly-regain-clear-or-almost-clear-skin--following-relapse-during-a-treatment-pause---novartis/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-advisory-committee-rejects-moxduo-for-moderate-to-severe-pain---qrxpharma/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2015/07/bmj-published-study-linking-birth-defects-with-paxil--paroxetine--and-prozac--fluoxetine--but-not-other-ssris/2024-02-09T16:25:10+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-data-shows-benefits-of-alz-801--tramiprosate-prodrug--in-alzheimer-s--alzheon-/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2019/01/european-commission-approves-blincyto-to-to-include--ph---cd19-positive-b-cell-precursor-all-in-first-or-second-complete-remission-with-minimal-residual-disease--mrd----amgen/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-ra-beacon-trial-of-ly-3009104--baricitinib--in-rheumatoid-arthritis-met-endpoint-and-is-published-in-nejm--li-lilly-incyte/2024-02-09T16:25:29+00:00weekly0.6https://www.medthority.com/news/2018/12/complete-response-letter-for-roxicodone-immediate-release-tablets-for-the-management-of-pain-severe-enough-to-require-an-opioid-analgesic--mallinckrodt---specgx-llc/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2019/01/nice-recommends-venclyxto-plus-rituxan-in-chronic-lymphocytic-leukaemia----abbvie---genentech-roche/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2016/04/boston-scientific-temporarily-stops-sales-of-watchman-flx-laac-for-stroke-prevention-in-europe-due-to-increase-in-rate-of-embolisms-/2021-09-24T07:10:46+00:00weekly0.6https://www.medthority.com/news/2019/04/additional-data-reported-for-phase-iii-regenerate-trial-of-ocaliva-in-nash---intercept-pharma/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2016/06/new-results-demonstrate-efficacy-of-stretta-rf-therapy-in-gerd--mederi-therapeutics/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2014/11/nice-does-not-recommend-use-of-recell-spray-on-skin-for-wound-healing-avita-medical/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---ekha-program-on-transplantation-will-be-hosted-on-eu-commission-s-health-policy-platform/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2018/08/complete-response-letter-for--esmya-for-the-treatment-of-abnormal-uterine-bleeding-in-women-with-uterine-fibroids---allergan-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-accepts-nda-filing-of-avatrombopag-for-the-treatment-of-thrombocytopenia-in-patients-with-chronic-liver-disease---dova-pharma-/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2016/01/lawsuit-filed-against-gilead-sciences-for-hiv-aids-drug-tenofovir/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-genosyl-mv-1000--geno-llc--for-neonates---------------/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2019/10/card-study-of-jevtana-meet-primary-endpoint-in-prostate-cancer-and-is-published-in-nejm---sanofi/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2013/07/self-apposing-stent--stentys--receives-expanded-ce-mark-approval-for-cad-patients-in-eu/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2016/01/vericel-corporation-files-bla-at-fda-for-maci-to-treat-symptomatic-cartilage-defects-of-the-knee/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-kyprolis--carfilzomib----dexamethason-in-adult-patients-with-multiple-myeloma-who-have-received-at-least-one-prior-therapy--amgen/2024-02-09T16:25:41+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-to--kte-x-19--for-the-treatment-of-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma--kite-gilead-/2021-09-24T07:12:03+00:00weekly0.6https://www.medthority.com/news/2018/04/fresenius-terminates-merger-with-akorn-inc-/2025-10-16T11:33:14+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-optimum-study-of-ponesimod-shows-efficacy-in-multiple-sclerosis---janssen/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-voyage-2-trial-results-show-tremfya-maintains-long-term-efficacy-in-plaque-psoriasis---janssen-/2021-09-24T07:05:53+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approve-entyvio-for-ulcerative-colitis-and-crohn-s-disease---takeda/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2019/09/psoriasis-academy-2019/2024-08-21T14:49:04+00:00weekly0.6https://www.medthority.com/news/2016/12/endurant-ii-iis-stent-graft-system-receives-ce-mark-approval-for-expanded-indication-in-abdominal-aortic-aneurysm--medtronic/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-grants-accelerated-approval-to-polivy---bendamustine---rituxan--for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma---genentech--roche/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-does-not-recommend-crysvita-as-a-treatment-for-x-linked-hypophosphatemia--kyowa-hakko-kirin-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2019/04/phosphare-study-program-shows-a-safety-advantage-of-monofer-in-relation-to-hypophosphatemia-and-other-fgf23-mediated-effects---pharmacosmos-a-s/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2018/02/apl-130277-has-complete-response-from-fda-as-a-treatment-for-parkinson-s-disease-sunovion-pharma/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2014/07/bms-to-file-opdivo-at-fda-in-q3-2014-for-advanced-metastatic-melanoma--/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-both-xospata-and-companion-diagnostic-leukostrat-cdx-flt3-mutation-assay-for-aml---astellas---invivoscribe-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-harmony-study-of-nuplazid-meets-primary-endpoint-in-dementia-related-psychosis---acadia-pharma/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-study-of-opdivo--nivolumab--in-squamous-cell-carcinoma-of-the-head-and-neck-shows-improved-quality-of-life-data--bms/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-sprint-endura---single-lead--and-extensa---dual-lead--peripheral-nerve-stimulation--pns--systems---spr-therapeutics-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-data-confirms-previous-studies-of-stivarga--regorafenib--in-metastatic-colorectal-cancer--bayer-healthcare/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2018/08/data-from-phase-iii-toledo-study-of-apo-go-movapo-in-parkinsons-disease-published-in-lancet-neurology---britannia-pharma-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2019/03/dna-of-sperm-taken-directly-from-testicles-of-infertile-men-is--as-good-as-sperm-from-fertile-men-/2024-07-30T15:01:14+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---dna-based-vaccine-treatment-for-colorectal-cancer-to-undergo-first-human-study/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2013/01/peginterferon-beta-1a--biogen--success-in-advance-study-for--ms/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-voltaire-ra1-study-shows--bi-695501--adalimumab-biosimilar--similar-to-humira-in-rheumatoid-arthritis--boehringer/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-supplemental-biologics-licence-application--sbla--for-keytruda--pembrolizumab--as-first-line-treatment-for-nsclc---merck-inc-/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2017/09/urology-week-2017-draws-to-a-close/2021-11-30T11:26:40+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-sophia-study-with-mgah-22-not-yet-statistically-significant-in--metastatic-breast-cancer---macrogenics/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-azure-pacemakers-with-improved-longevity----medtronic-inc-/2021-09-24T07:14:36+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-approves-signifor-for-treatment-of-acromegaly-novartis/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2017/08/reveal-study-of-mk-0859--anacetrapib---a-treatment-for-atherosclerotic-vascular-disease-is-published-in-nejm-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2014/04/sun-pharma-to-acquire-ranbaxy-pharma-for---4-billion/2025-10-16T11:12:26+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-expands-indication-for-sorilux-to-include-adolescents-with-psoriasis/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2019/11/azd-6244-filed-with-fda-for-nf1-and-plexiform-neurofibromas-and-given-priority-review---astrazeneca-and-merck-inc/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-files-bla-at-fda-for-liso-cel-to-treat-large-b-cell-lymphoma--/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2019/04/keytruda-inlyta-approved-by-fda-to-treat-first-line-renal-cell-carcinoma/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-katherine-study-of-kadcyla-meets-primary-endpoint-in-breast-cancer-and-is-published-in-nejm---genentech-roche-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2016/08/galapagos---gilead-initiate-a-three-phase-iii-trial-program-for-filgotinib--once-daily--in-rheumatoid-arthritis--/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2018/03/positive-results-for-triamcinolone-acetonide-scs-for-treatment-of-macular-edema-associated-with-non-infectious-uveitis---clearside-biomedical-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2018/11/district-court-invalidates-all--asserted-claims-of-u-s--patent-no--8-822-438-for-zytiga---johnson---johnson/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2019/05/reverse-phase-iii-trial-of-gs-010-shows-improvement-in-leber-hereditary-optic-neuropathy/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-future-1-study-of-secukinumab-for-psoriatic-arthritis-is-published-in-nejm--novartis/2024-02-09T16:29:59+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-aspire-cristalle-for-mammography-imaging-fujifilm/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-nexobrid-for-treatment-of-burns/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2019/04/flexion-therapeutics-announces-publication-of-independent-data-review--of-pain-relief-by-zilretta-in-the-journal-drugs-/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2017/10/post-hoc-analysis-of-3-phase-iii-trials-of-plenvu-demonstrate-high-quality-cleaning-in-bowel-cleansing---norgine-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2017/11/new-analysis-of-the-phase-iii-cantos-study-shows-31---reduction-in-cv-death-with-canakinumab---novartis/2021-09-24T07:14:40+00:00weekly0.6https://www.medthority.com/news/2011/10/rituxan-mabthera-may-alleviate-chronic-fatigue-syndrome-/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2019/07/nice-recommends-vizimpro-to-treat-non-small-lung-cancer-patients-with-egfr-mutation---pfizer/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2017/03/kyprolis--carfilzomib---dexamethasone-superior-to-velcade--bortezomib----dexamethasone-for--relapsed-or-refractory-multiple-myeloma-according-to--phase-iii--head-to-head-endeavor-trial--amgen/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2016/03/stimwave-launches-stimq-peripheral-nerve-stimulator--pns--system-for-the-relief-of-severe-intractable-chronic-pain-of-peripheral-origin-/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2019/09/one-year-outcomes-study-of-lixiana-shows-efficacy-in-atrial-fibrillation---daiichi-sankyo/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2015/09/two-phase-iii-trials-starting-with-mk-7655-and-imipenem-cilastatin-for-bacterial-infections-after-positive-phase-ii-data--merck-inc/2024-02-09T16:30:15+00:00weekly0.6https://www.medthority.com/news/2019/05/pooled-phase-iii-data-with-xeljanz-shows-changes-that-could-correlate-with-cv-risk-in-psoriatic-arthritis----pfizer/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2016/08/astrazeneca-sells-its-ex-us-antibiotics-business-to-pfizer-which-includes-merrem--zinforo--zavicefta--atm-avi-and-cxl-/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-chmp-recommends-approval-of-cresemba--isavuconazole--for-fungal-infections--basilea-pharma/2024-02-09T16:30:28+00:00weekly0.6https://www.medthority.com/news/2013/05/merck-inc-discontinues-preladenant-for-parkinsons-disease/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2015/08/sd-809--deutetrabenazine--filed-with-the-fda-for-huntington-disease--teva-pharmaceutical/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-artus-cmv-qs-rgq-mdx-test-for-cytomegalovirus-diagnostics--qiagen/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2014/09/survival-results-for-perjeta-in-cleopatra-study-for-metastatic-breast-cancer---genentech-roche/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2013/01/chmp-recommends-pegasys-roche--for-paediatric-use-in-hepatitis-c/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-results-from-two-studies-of-trikafta-for-cystic-fibrosis-published-in-the-new-england-journal-of-medicine-and-the-lancet---vertex-pharma/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2012/12/successful-phase-ii-trial-for-ponesimod--actelion--in-plaque-psoriasis/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-of-alzt-op1-combination-therapy-for-early-alzheimers-disease-commences-in-us--aztherapies/2024-02-09T16:30:48+00:00weekly0.6https://www.medthority.com/news/2019/06/eu-approves-itulazax-for-allergy-to-birch-trees---alk/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2014/06/eloctate-is-fda-approved-for-treatment-of-haemophilia-a---biogen-idec/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-cosentyx--secukinumab--for-psoriatic-arthritis--novartis/2024-02-09T16:31:01+00:00weekly0.6https://www.medthority.com/news/2018/02/world-hearing-day-2018/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-shows-lx-4211--sotagliflozin--met-its-primary-endpoint-in-patients-with-type-1-diabetes--lexicon-pharma/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2020/01/itacitinib-fails-to-meet-primary-endpoint-in-phase-iii-gravitas-301-study-to-treat-graft-versus-host-disease---incyte-corpn-/2021-09-24T07:11:56+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-iii-trial-of-amg-785--romosozumab--in-osteoporosis-meets-primary-endpoint--amgen-ucb/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2018/01/five-year-study-of-nx-1207-shows-cut-in-surgery-or-radiotherapy-for-prostate-cancer-patients---nymox-pharma-/2021-09-24T07:05:10+00:00weekly0.6https://www.medthority.com/news/2019/10/data-from-phase-iii-claridhy-trial-of-tibsovo-demonstrates-significant-improvement-in-progression-free-survival-in-previously-treated-idh1-mutant-cholangiocarcinoma-patients--agios-pharma/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-strensiq--asfotase-alfa--to-treat-hypophosphatasia--alexion/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2017/06/advisory-committee-date-for-review-of-tisagenlecleucel-t--ctl-019--to-treat-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-----novartis/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2016/04/insulin-pump-therapy-versus-multiple-daily-injections--minimed-insulin-pump--opt2mise-study--medtronic/2024-02-09T16:31:27+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-gives-510-k--approval-to-cobas-m-511-analyzer-for-hematology-testing---roche-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2017/06/new-tools-help-early-diagnosis-of-systemic-sclerosis/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2011/12/lipitor--pfizer--may-benefit-alzheimer-s-patients/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2014/10/chmp-recommends-duavive-for-treatment-of-oestrogen-deficiency--pfizer/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2017/10/benefit-risk-data-analysis-for--mavenclad-to-treat-multiple-sclerosis---merck-kgaa-/2021-09-24T07:13:21+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-cancels-advisory-committee-meeting-for-lumateperone-for-the-treatment-of-schizophrenia/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-triumeq-for-hiv-viiv-healthcare/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2020/02/final-overall-survival-analysis-of--phase-iii-aramis-trial-of-nubeqa-for-non-metastatic-castration-resistant-prostate-cancer--bayer-healthcare/2021-09-24T07:12:03+00:00weekly0.6https://www.medthority.com/news/2019/12/doptelet-demonstrates-cost-effectiveness-for-the-treatment-of-thrombocytopenia-in-patients-with-chronic-liver-disease---dova-pharma-sobi/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2019/12/scpharmaceuticals-inc--announces-recent-progress-on-furoscix-a-proposed-treatment-for-heart-failure-/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2018/10/study-of-portico-transcatheter-aortic-heart-valve-in-aortic-stenosis-published-in-journal-of-the-american-college-of-cardiology---abbott-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2018/12/gsk-acquires-tesaro-and-with-it-zejula--a-parp-inhibitor-currently-approved-to-treat-ovarian-cancer/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2017/02/post-hoc-analysis-of-the-clarity-study-of-movectro--cladribine--in-patients-with-relapsing-remitting-multiple-sclerosis-is-published-and-shows-a-reduction-in-brain-atrophy--merck-kgaa-/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2013/04/fostamatinib--astrazeneca---mixed-results-in-oskira-1-trial-for-ra/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2016/12/opera-i-and-opera-ii-studies-in-relapsing-multiple-sclerosis--rms--and-the-oratorio-study-in-primary-progressive-multiple-sclerosis--ppms--are-published-in-nejm---genentech-roche/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2017/09/esmo-2017-press-release--miro-trial--3-year-outcomes-favour-laparoscopic-surgery-for-oesophageal-cancer/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2012/12/early-trial-shows-promising-results-with-simvastatin-in-wound-healing/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2018/04/achieve-ii-phase-iii-trial-of-ubrogepant-shows-dose-dependent-results-in-migraine---allergan-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-studies-mensa-and-sirius-of-mepolizumab-for-asthma--gsk/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-xeljanz-for-adults-with-moderately-to-severely-active-ulcerative-colitis---pfizer-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2012/10/nypta--zeltia-noscira--fails-alzheimers-disease-study/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-510-k--approval-for-signa-premier-mri-system--ge-healthcare/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-simponi-for-ulcerative-colitis-in-adults/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-now-recommends-ocrevus-to-treat-relapsing-remitting-ms-under-specific-conditions---roche-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2018/06/ucb-presents-findings-of-patient-survey--fears-and-misconceptions-of-women-with-chronic-rheumatic-disease-along-their-journey-to-motherhood--at-eular-meeting-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-haven-1-study-evaluating-emicizumab-prophylaxis-reports-progress-in-treating-patients-with-hemophilia-a-and-inhibitors-to-factor-viii---genentech---roche/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-study-of-r-788--fostamatinib--meets-primary-endpoint-in-immune-thrombocytopenia---rigel-pharma/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2011/09/protelos-risk-benefit-profile-in-pmo-questioned/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-kit-302--celecoxib---amlodipine--meets-primary-endpoint-in-pain-relief-in-osteoarthritis--kitov-pharmaceuticals/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-gvoke-injection--a-ready-to-use--room-temperature-stable-liquid-glucagon-for-the-treatment-of-severe-hypoglycemia--xeris-pharma/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2015/10/allergan-and-numedii-form-research-alliance-to-identify-new-psoriasis-treatments/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2019/02/ce-mark-for-determine-hbsag-2-test-for-the-detection-of-hepatitis-b-surface-antigen--abbott/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-trials-of-cnto-136--sirukumab--shows-improvement-versus-humira--adalimumab--monotherapy-in-rheumatoid-arthritis---janssen/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-humira--adalimumab--to-treat-hidradenitis-suppurativa--abbvie/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2013/11/eylea--bayer-regeneron--filed-at-fda-and-eu-for-dme/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-interim-data-for-xilonix-in-cachexia-in-crc-xbiotech-/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2010/09/sycrest-approved-in-eu-for-bipolar-1-disorder-and-fda-extends-indications/2021-09-24T07:01:27+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-accepts-filing-of-snda-for-jakafi-for-treatment-of-polycythemia-vera---incyte-novartis/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2018/12/new-data-demonstrates-iv-meloxicam-s-effect-on-platelet-function---recro-pharma/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2014/02/sub-analysis-of-aristotle-trial-for-eliquis-in-stroke-prevention---bms-pfizer/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2014/09/study-of-zalviso-for-post-op-pain-published-in-pain-practice-acelrx/2024-02-09T16:31:44+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-resurface-trials-of-ilumya-shows-response-was-maintained-for-4-years-in-moderate-to-severe-plaque-psoriasis---sun-pharma/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-advisory-committee-recommends-vorapaxar-for-cv-risk---merck-inc-/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-lucentis-to-treat-diabetic-retinopathy-associated-with-dme--genetech---novartis/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2015/06/benefits-of-victoza--liraglutide--in-type-2-diabetes-during-fasting--novo-nordisk/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2017/09/european-commission-has-approved-actemra-roactemra--tocilizumab--for-the-treatment-of-giant-cell-arteritis---genentech---roche-/2024-07-26T10:25:16+00:00weekly0.6https://www.medthority.com/news/2017/12/results-of-study-of-qarziba-in-high-risk-neuroblastoma-published-in-mabs---apeiron-biologics-/2024-11-15T08:43:24+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-top-line-results-from-epsolay-phase-iii-program-in-papulopustular-rosacea----sol-gel-technologies-ltd-/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2013/11/ema-grants-new-active-substance-to-tecfidera-biogen-idec/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-data-on-optinose-bi-directional-system-for-headache-published-avanir-pharma/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2012/10/novartis-to-discontinue-development-of-long-acting-fanapt-for-schizophrenia/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-impavido-for-treatment-of-leishmaniasis---knight-therapeutics/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---shedding-a-new-light--the-implication-of-micrornas-in-chronic-kidney-disease/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-advisory-committee-recommends-xeljanz-to-treat-ulcerative-colitis---pfizer-/2021-09-24T07:06:32+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-dificid-for-oral-suspension-and-for-children-aged-6-months-and-over-to-treat-clostridioides--formerly-clostridium--difficile-associated-diarrhea--merck-inc---astellas/2021-09-24T07:11:46+00:00weekly0.6https://www.medthority.com/news/2015/05/eagle-pharma-files-rtu-bivalirudin-at-fda-for-percutaneous-coronary-interventions-/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2012/04/januvia-approved-in-uk-for-use-in-renally-impaired-diabetic-patients/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2011/11/janacti--merck-inc---withdrawn-in-europe-for-type-2-diabetes/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2012/01/daclatasvir-plus-asunaprevir-bms--in-phase-ii-hepatitis-c-trial/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-palynziq-to-reduce-blood-phenylalanine-concentrations-in-adult-patients-with-phenylketonuria--pku----biomarin-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-xelprost-for-glaucoma-ocular-hypertension---sun-pharma-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-prosper-trial-of-xtandi--enzalutamide--plus-androgen-deprivation-therapy--adt--versus-adt-alone-for-non-metastatic-castration-resistant-prostate-cancer-met-its-primary-endpoint-of-improved-metastasis-free-survival---pfizer---astellas/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2017/09/first-in-human-trial-of-mobius-hd-implant-to-treat-resistant-hypertension-published-in-the-lancet-vascular-dynamics-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-change-of-indication-for-maviret-in-chronic-hepatitis-c-genotype-3---abbvie/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2014/05/benefits-observed-in-phase-iii-study-of-tak-700-in-prostate-cancer---takeda/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-keynote-407-trial-of-keytruda-meets-primary-endpoint-in-first-line-metastatic-squamous-non-small-cell-lung-cancer---merck-inc-/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2018/01/updates-in-general-internal-medicine-for-specialists-2018/2024-02-20T10:22:44+00:00weekly0.6https://www.medthority.com/news/2016/02/ocrevus--ocrelizumab--receives-breakthrough-therapy-designation-and-plans-submission-to-fda-for-primary-progressive-multiple-sclerosis-in-h1-2016--genentech-roche/2024-02-09T16:32:03+00:00weekly0.6https://www.medthority.com/news/2012/06/delamanid--otsuka--positive-in-phase-iib-trial-for-tuberculosis-/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-12-month-data-for-elightn-rds-in-hypertension-st-jude-medical/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2017/03/gp-2017--adalimumab-biosimilar--in-phase-iii-study-shows-equivalent-efficacy-to-the-reference-medicine--humira---sandoz--/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2019/08/fosmetpantotenate-fails-in-phase-iii-fort-study-to-treat--pantothenate-kinase-associated-neurodegeneration---retrophin-inc-/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-solo-smart-valve-for-aortic-valve-disease-sorin/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2017/08/biocon-withdraws-application-for-trastuzumab-biosimilar-from-ema/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-naviopfs-orthopedic-surgical-system--blue-belt-technologies--for-knee-replacement/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2011/10/ameluz-has-chmp-recommendation-for-actinic-keratosis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-results-for-na-1--nono--in-phase-ii-trial-of-stroke-patients/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-revolade--eltrombopag-to-treat-severe-aplastic-anemia-novartis/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-committees-meet-to-investigate-testosterone-deficiency-therapy/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2015/12/successful-br-002-trial-of-novilase-breast-therapy-as-a-laser-treatment-for-small-breast-cancers--novian-health-/2024-02-05T15:11:14+00:00weekly0.6https://www.medthority.com/news/2015/05/analysis-of-phase-iii-trial-of-movantik--naloxegol--in-opioid-constipation-astrazeneca/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-xeljanz-xr--tofacitinib-citrate--once-daily-to-treat-rheumatoid-arthritis--pfizer/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-accurian-rf-ablation-platform-for-chronic-pain---medtronic/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2017/05/tralokinumab-does-not-meet-endpoint-of-reduction-in-asthma-exacerbation-rate-in-phase-iii-stratos-i-trial---astrazeneca/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2017/01/aptima-hiv-1-quant-assay-receives-fda-approval-as-diagnostic-for-hiv-hologic/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2014/01/eu-approves-solvadi-for-hepatitis-c-gilead-sciences/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2014/10/approval-letter-from-fda-for-augment-bone-graft--wright-medical/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2014/04/chmp-recommends-extending-use-of-nexavar-in-thyroid-cancer-bayer-healthcare/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2014/01/envivo-pharma-initiates-phase-iii-trial-for-encenicline-for-alzheimers/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-marketing-extension-for-stribild--elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate--in-adolescents-with-hiv---gilead-sciences-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-nn-9535--semaglutide-subcutaneous--meets-objective-in-type-2-diabetes-and-demonstrates-superiority-to-sitagliptin--novo-nordisk/2024-02-09T16:32:15+00:00weekly0.6https://www.medthority.com/news/2019/02/new-company-arvelle-therapeutics-secures-eu-rights-to-cenobamate-for-treatment-of-focal--partial-offset--seizures---arvelle---sk-biopharmaceuticals/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-results-for-taltz--in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis---eli-lilly/2021-09-24T07:17:23+00:00weekly0.6https://www.medthority.com/news/2019/03/data-from-radiance-htn-solo-trial-of-paradise-renal-denervation-system-for-hypertension-published-in-circulation---recor-medical/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2018/09/phase-iii-efficacy-study-of-cam-2038-meets-endpoints-in-chronic-low-back-pain---camurus-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2015/09/boston-scientific-launches-captivator-emr-device-for-endoscopic-mucosal-resection-for-management-of-barrett-s-oesophagus/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-study-of-delamanid--otsuka--for-patients-with-mdr-tb---------------/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-kerydin-for-treatment-of-onychomycosis-anacor-pharma/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-new-indication-for-victoza--liraglutide--to-cut-risk-of-cv-events-in-type-2-diabetes--novo-nordisk-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2017/06/successful-go-alive-trial-for-intravenous-simponi-aria---golimumab---to-treat-ankylosing-spondylitis--janssen-biotech/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-data-on-cystoscopy-with-cysview-shows-detection-of-significant-numbers-of-patients-with-recurrence-of-bladder-cancer--photocure-/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2018/09/teva-returns-rights-of-laquinimod-for-multiple-sclerosis-to-active-biotech-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2014/09/final-study-reports-for-dengue-fever-vaccine--sanofi-pasteur-/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2015/12/imbruvica--ibrutinib--prolongs-pfs-and-orr-in-patients-with-mantle-cell-lymphoma-compared-to-temsirolimus---abbvie---janssen-biotech/2024-02-09T16:34:36+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-ii-iii-trial-of-biktarvy-positive-for-children-and-adolescents-with-hiv---gilead-sciences/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2017/05/nejm-publishes-phase-iii-trial-of-epidiolex--cannabidiol--in-children-with-dravet-syndrome----gw-pharma-/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2016/02/ema-validates-maa-for-tenofovir-alafenamide--as-fumarate---taf--as-a-treatment-for-hepatitis-b--gilead/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2018/03/boehringer-and-eli-lilly-expand-heart-failure-program-for-jardiance-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2013/12/success-for-sovaldi--ledipasvir-in-ion-studies-for-hepatitis-c-gilead/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2016/04/european-commission-approves-variation-to-permit-subcutaneous-route-of-administration-in-binocrit-s--epoetin-alfa--nephrology-indication---sandoz/2024-02-09T16:34:50+00:00weekly0.6https://www.medthority.com/news/2018/10/a-new-fourier-analysis--evaluating-the-effects-of-repatha-in-patients-with-established-cardiovascular-disease-by-kidney-function---amgen/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-approves-signifor--novartis--for-treatment-of-cushing-s-disease---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2013/11/baxter-files-rixubis-at-ema-for-haemophilia-b/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-trial-of-dextenza--sustained-release-dexamethasone--meets-primary-endpoint-in-allergic-conjunctivitis--ocular-therapeutix/2024-02-09T16:35:00+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-aorfix--lombard-medical--for-treatment-of-abdominal-aortic-aneurysms----------------/2021-09-24T07:15:33+00:00weekly0.6https://www.medthority.com/news/2017/10/phase-iii-optic-study-of-omadacycline--is-positive-against-community-acquired-bacterial-pneumonia--cabp-----paratek-pharmaceuticals-/2021-09-24T07:13:29+00:00weekly0.6https://www.medthority.com/news/2015/12/final-results-in-keynote-010-study-of-keytruda--pembrolizumab--in-non-small-cell-lung-cancer-published-in-the-lancet--merck-inc/2024-02-09T16:35:21+00:00weekly0.6https://www.medthority.com/news/2016/10/eisai-initiates-phase-iii-trial-of-lenvima--lenvatinib--with-everolimus-or-pembrolizumab-to-treat-advanced-renal-cell-carcinoma-/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2012/01/oraquick-advance-rapid-hiv-112--orasure--compares-to-conventional-blood-test-for-hiv/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-results-for-cc-486-in-phase-iii-quazar-aml-001-trial-for-newly-diagnosed-acute-myeloid-leukemia--celgene-bms/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2019/09/tagrisso-showed-in-flaura-trial-a-52--reduction-in-risk-of-central-nervous-system-disease-progression-or-death---astrazeneca/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2019/03/santhera-update-on-filing-for-conditional-marketing-authorization-in-europe-for-puldysa--idebenone--in-duchenne-muscular-dystrophy-/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-does-not-recommend-lynparza---olaparib--in-preliminary-assessment-for-ovarian-cancer--astrazeneca-/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2019/03/nice-recommends-ilumetri-to-treat-plaque-psoriasis---almirall-s-a-/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2014/01/positive-data-from-trial-of-opc-34712-for-mdd---otsuka-lundbeck/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2012/04/gilenya--novartis--toxicity-problems-issue/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2013/12/3d-regimen-results-in-sapphire-ii-study-for-hepatitis-c-abbvie-/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-advisory-committee-recommends-urocidin-mcna--mycobacterium-phlei-cell-wall-nucleic-acid-complex--for-bladder-cancer--telesta-therapeutics/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2012/12/navidea-biopharma-files-lymphoseek-at-ema-for-intraoperative-lymphatic-mapping/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2014/06/orencia---mtx-shown-by-avert-trial-to-be-superior-to-mtx-alone-for-higher-rates-of-remission-in-ra---bms/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2019/04/eco-2019---find-out-more/2024-02-20T10:29:48+00:00weekly0.6https://www.medthority.com/news/2015/11/european-commission-approves-genvoya---elvitegravir-150-mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-alafenamide-10-mg-or-e-c-f-taf--to-treat-hiv--gilead-sciences/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-give-510-k--approval-for-alluraclarity-x-ray-imaging-system--philips-/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2017/02/bausch---lomb-valeant---nicox-s-a--announced-the-resubmission-of-a-new-drug-application--nda--to-the-fda-for-latanoprostene-bunod-ophthalmic-solution-to-treat-open-angle-glaucoma-or-ocular-hypertension--/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2019/02/darolutamide---adt-extends-metastasis-free-survival--in-non-metastatic-castration-resistant-prostate-cancer--bayer-healthcare/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2015/08/giotrif-gilotrif--afatinib--filed-with-fda-and-ema-for-advanced-squamous-cell-carcinoma-of-lung--boehringer-ingelheim/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2012/11/amg-145--amgen--success-in-rutherford-study-for-hefh---------------/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2015/01/sb4--etanercept-biosimilar--is-filed-at-ema-for-rheumatoid-arthritis--samsung-bioepis---biogen-idec/2021-09-24T07:03:25+00:00weekly0.6https://www.medthority.com/news/2011/11/first-implantable-miniature-telescope--visioncare--used-for-patient-with-amd/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-results-from-phase-iii-liberty-1---2-studies-of-relugolix-combination-therapy-in-women-with-heavy-menstrual-bleeding-associated-with-uterine-fibroids---myovant-sciences/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-study-shows-ly-2963016-equivalent-to-lantus---eli-lilly-boehringer/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-menopur-bravelle-combination-as-fertility-treatment---ferring-pharma-/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-data-from-phase-iii-study-of-xgeva--amgen--in-breast-cancer-patients---------------/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-approves-kevzara--sarilumab--in-combination-with-methotrexate--mtx--for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis--sanofi-and-regeneron-pharmaceuticals/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-recommends-ledaga--chlormethine-gel-to-treat-mycosis-fungoides-type-cutaneous-t-cell-lymphoma--mf-ctcl---actelion-/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2013/01/positive-results-from-phase-iii-trial-of-avastin--genentech-roche--in--elderly-colorectal-cancer-patients/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-simplexa-flu-a-b---rsv-direct-test--focus-diagnostics--to-detect-influenza/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-sbla-for-keytruda-in-resected--high-risk-stage-iii-melanoma---merck-inc-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2018/03/world-tuberculosis-day-2018/2021-09-24T07:06:25+00:00weekly0.6https://www.medthority.com/news/2018/02/sub-analysis-of-pegasus-timi-54-study-shows-risk-reduction-with-use-of-brilinta-in-heart-attack-survivors--astrazeneca/2021-09-24T07:06:01+00:00weekly0.6https://www.medthority.com/news/2017/11/new-positive-long-term-radiographic-data-for-cosentyx-patients-with-anklyosing-spondylitis---novartis/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2016/01/results-of-ablatherm-focal-hifu-study-published-in-prostate-cancer-and-prostatic-diseases--edap/2024-02-20T09:58:51+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-grants-premarket-approval-for--venovo--venous-stent-to-treat-iliofemoral-venous-occlusive-disease--becton--dickinson-and-company/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2018/05/large-scale-body-composition-study-reveals-link-between-specific-fat-distributions-and-metabolic-diseases-and-is-published-in-obesity--amra-medical/2021-09-24T07:07:05+00:00weekly0.6https://www.medthority.com/news/2019/02/court-decision-upholds-amgen-patents-related-to-pcsk9-antibodies-/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2011/10/cox-2-targeted-pet-imaging-agent-offers-view-of-inflammation/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-epoch-study-evaluating-mk-8931--verubecestat--in-people-with-mild-to-moderate-alzheimer-s-disease-halted--merck-inc/2024-10-21T14:42:54+00:00weekly0.6https://www.medthority.com/news/2013/12/rdea-594-meets-primary-endpoint-in-gout-study-astrazeneca/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2018/09/babies-exposed-to-higher-levels-of-organochlorine-compounds-in-the-womb-go-on-to-have-worse-lung-function-in-childhood/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2014/10/-dtap5-ipv-hib-hepb1--six-in-one--vaccine-filed-at-fda--merck-inc----sanofi-pasteur/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-investigates-cv-risk-in-patients-taking-testosterone-therapy/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-study-of-cam-2038-in-opioid-use-disorder-published-in-jama-internal-medicine---braeburn-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-data-shows-imbruvica--ibrutinib--superior-to-chlorambucil-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma---janssen-pharmacyclics/2024-02-20T10:01:05+00:00weekly0.6https://www.medthority.com/news/2017/05/study-of-relvar-ellipta--fluticasone-furoate-vilanterol--reports-improvements-in-asthma-patients-versus-standard-care--gsk-innoviva/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-expands-approval-of-cobas-ampliprep-cobas-taqman-hcv-test-for-hepatitis-c--roche/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2013/03/biogen-idec-files-rfviii-fc-at-fda-for-treatment-of-haemophilia-a/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2015/10/study-of-rns-neurostimulator-device-in-epilepsy-published-in-epilepsia--neuropace/2024-02-20T10:01:37+00:00weekly0.6https://www.medthority.com/news/2019/07/targeted-therapy-combination-improves-survival-in-patients--with-advanced-bowel-cancer/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-intermezzo--transcept-pharmaceuticals--for-use-with-middle-of-the-night-insomnia/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2018/02/update-on-chmp-review-of-andexanet-alfa-for-reversal-of-anticoagulation----portola-pharma-/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-tecentriq--atezolizumab--as-monotherapy-to-treat-metastatic-urothelial-carcinoma---bladder-cancer---roche/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-results-of-vrd--bortezomib---lenalidomide---dexamethasone--in-multiple-myeloma-published-in-the-lancet--j-j-janssen-cilag/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-xyrem--for-the-treatment-of-cataplexy-and-excessive-daytime-sleepiness-in-pediatric-patients-with-narcolepsy---jazz-pharma/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2015/05/interim-phase-iii-data-for-dermapace-in-diabetic-foot-ulcers-does-not-meet-endpoint-sanuwave-health/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2012/01/eloxatin--sanofi--improves-colon-cancer-survival/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2012/04/igaki-tamai-biodegradable-stent--kyoto-medical-planning--safe-for-long-term-treatment-of-coronary-artery-disease/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2018/03/bioequivalence-study-shows-zydis-with-rimegepant-meets-targets-in-migraine---biohaven-pharma-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2012/08/glaxo-smith-kline-files-nda-and-maa-for-dabrafenib-in-metastatic-melanoma-patients---------------/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-gadavist--gadobutrol---for-use-with-magnetic-resonance-angiography-to-evaluate-supra-aortic-or-renal-artery-disease--baterhealthcare/2024-02-20T10:02:23+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-does-not-recommend-approval-of-masican-for-amyotrophic-lateral-sclerosis---ab-science-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2019/12/boehringer-ingelheim---eli-lilly-provide-update-on-jardiance-phase-iii-exercise-ability-studies-in-chronic-heart-failure-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2019/08/european-commission-approves-dupixent-to-treat-adolescents-12-to-17-years-of-age-with-moderate-to-severe-atopic-dermatitis/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-crown-prt-stented-aortic-bioprosthesis-for-aortic-valve-disease--livanova/2021-09-24T07:09:04+00:00weekly0.6https://www.medthority.com/news/2016/03/alder-therapeutics-reports-positive-results-in-phase-iib-study-of-ald-403-to-treat-and-prevent-migraine-/2024-02-20T10:02:38+00:00weekly0.6https://www.medthority.com/news/2019/03/once-weekly-transcon-growth-hormone-superior-to-daily-growth-hormone-in-phase-iii-height-trial-for-pediatric-growth-hormone-deficiency--ascendis-a-s/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2011/11/enbrel--amgen-pfizer--shows-clear-benefits-for-patients-with-moderately-active-rheumatoid-arthritis/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/05/safety-and-efficacy-results-from-two-phase-iii-trials--mist-1-and-mist-2--for-pharmacologic-mydriasis--pupil-dilation/2021-09-24T07:17:37+00:00weekly0.6https://www.medthority.com/news/2015/12/algovita-spinal-cord-stimulation-system--implant-device--received-approval-from-fda-for-chronic-pain-management--greatbatch/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-saphris--asenapine--for-paediatriac-bipolar-1-disorder--actavis/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2016/01/csl-behring-submits-maa-to-ema-for-recombinant-factor-viii-single-chain--rviii-singlechain--to-treat-haemophilia-a/2024-02-20T10:03:05+00:00weekly0.6https://www.medthority.com/news/2017/11/janssen-biotech-files-sbla-with-fda-for-darzalex-combination-in-newly-diagnosed-multiple-myeloma---janssen-biotech-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2014/01/study-202-success-for-eteplirsen-in-duchenne--muscular-dystrophy-sarepta/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2012/03/results-show-protelos--servier--slows-progression-of-osteoarthritis-/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2017/06/interim-results-from-ongoing-northstar-2--hgb-207--phase-iii-clinical-study-of-lentiglobin-drug-product-in-patients-with-transfusion-dependent-beta-thalassemia--tdt--and-non-beta0-beta0-genotypes---bluebird-bio/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2016/10/icu-medical-to-acquire-hospira-infusion-systems-from-pfizer-for--1-billion/2025-10-16T11:17:09+00:00weekly0.6https://www.medthority.com/news/2018/04/post-hoc-analyses-of-phase-iii-studies-of-galcanezumab-shows-50---reduction-of-migraine-headache-days---eli-lilly-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2012/04/chmp-recomends-heart-monitoring-for-gilenya--novartis--patients/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2015/06/negative-impact-of-obesity-on-patients-treated-with-captisol-enabled-delafloxacin-in-treatment-of-absssi--melinta-therapeutics/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2012/04/positive-results-in-phase-iib-study-of-cg100649--crystalgenomics--for-osteoarthritis/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-added-approval-for-stendra-in-erectile-dysfunction-vivus-auxilium/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-study-of-ljpc-501--angiotensin-ii--published-online-by-the-new-england-journal-of-medicine--la-jolla-pharma-/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2016/09/uk-nice-recommend-use-of-zepatier--elbasvir---grazoprevir--for-hepatitis-c--merck-inc/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2019/05/chiesi-farmaceutici-licences-raxone-for-the-treatment-of--leber-s-hereditary-optic-neuropathy-worldwide-except-in-us-and-canada--santhera-pharma/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2018/07/ce-mark-for-panther-fusion-mrsa-assay---hologic-inc-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-gives-510-k--clearance-for-myriad-automated-tissue-removal-technology-in-surgery--nico-corporation/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommends-envarsus-for-organ-transplant-rejection---veloxis-pharma/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2016/03/orexigen-re-acquires-us-rights-to-contrave--naltrexone-hcl---bupropion-hcl-extended-release--to-treat-obesity-in-united-states-from-takeda/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2014/12/lundbeck-discontinues-development-of-desmoteplase-for-ischaemic-stroke/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2017/04/the-first-patient-has-now-been-enrolled-into--ease---the-pivotal-phase-iii-clinical-trial--which-is-evaluating-ap-101-as-a-potential-treatment-for-the-rare--genetic-skin-disorder--epidermolysis-bullosa---amryt-/2021-09-24T07:14:10+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-zurampic-lesinurad--with-a-xanthine-oxidase-inhibitor-to-treat-hyperuricemia-associated-with-gout--astrazeneca-/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2012/11/forest-files-cariprazine-at-fda-for-schizophrenia-and-bipolar-disorder/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-has-recommended-approval-of-ilaris--canakinumab--in-europe-to-treat-three-rare-and-distinct-periodic-fever-syndromes---novartis/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-accepts-protocol-for-wearable-artificial-kidney-trial---blood-purification-technologies-inc-/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-restylane-lyft-for-cheek-augmentation--galderma/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-approves-saxenda--liraglutide-3-mg--for-obesity-novo-nordisk/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2013/10/janssen-files-darunavir-cobicistat-hiv-combo-in-the-eu/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2014/10/zogenix-inc--acquires-brabant-pharma-and-with-it-brabafen-for-dravet-syndrome/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2012/07/chmp-recommends-xalkori--pfizer--for-treatment-of-nsclc/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2014/09/humira-success-in-phase-iii-studies-for-hidradenitis-suppurativa---acne-inversa---abbvie/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2019/07/advaxis-announces-increasing-focus-on-neoantigen-directed-immunotherapies-and-closing-of-its-phase-iii-aim2cerv-study-of-axal-/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2013/12/lyxumia-shows-positive-results-in-phase-iiib-study-of-blood-sugar-lowering-sanofi/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2019/01/e-2006-filed-with-fda-for-insomnia-sleep-wake-disorder---eisai-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2019/07/bms-announces-checkmate--227-part-1a---evaluating-opdivo----low-dose-yervoy-meets-co-primary-endpoint-of-overall-survival-in-first-line-nsclc-/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2012/03/sinergy-cooled-rf-system--kimberly-clark-health-care--shows-benefits-for-patients-with-sacroiliac-joint-pain-in-the-lower-back--/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2015/11/iqwig-assessment-of-lixiana--edoxaban--shows-considerable-added-benefit-in-prevention-of-stroke-and-systemic-embolism--daiichi-sankyo/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2018/03/novel-target-for-toxoplasmosis-malaria-treatment/2024-07-26T10:49:48+00:00weekly0.6https://www.medthority.com/news/2018/08/ortho-dermatologies-re-files-duobrii-at-fda-as-a-proposed-treatment-for-psoriasis-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-praxbind--idarucizumab--for-reversal-of-the-anticoagulant-effects-of-dabigatran--boehringer-ingelheim/2024-02-20T10:03:25+00:00weekly0.6https://www.medthority.com/news/2017/01/amag-pharma-acquires-north-american-rights-from-palatin-technologies-inc--to-rekynda--bremelanotide--to-treat-hypoactive-sexual-desire-disorder-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2018/02/the-effect-of-high-volume-online-haemodiafiltration-on-nutritional-status-and-body-composition--the-protein-stores-preservation--peset--study/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-broadens-the-range-of-anti-hormonal-therapy-that-may-be-administered-with-ibrance--palbociclib--to-treat-breast-cancer---pfizer/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2011/12/european-decentralised-approval-concluded-for-steovess--takeda--for-osteoporosis/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2015/06/grazoprevir-elbasvir-combination-filed-at-fda-to-treat-hepatitis-c--gt--1--4-or-6-infection-merck-inc-/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-entresto-sacubitril-valsartan-for-adults-with-symptomatic-chronic-heart-failure-novartis/2024-02-06T15:52:12+00:00weekly0.6https://www.medthority.com/news/2015/06/rayaldee--vitamin-d-prohormone-is-filed-at-fda-for-secondary-hyperparathyroidism-in-patients-with-ckd--opko-health-/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-success-for-nintedanib-in-nsclc/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2019/06/wcd-2019---learn-more/2021-12-01T14:23:00+00:00weekly0.6https://www.medthority.com/news/2014/08/nice-draft-guidance-on-sovaldi-for-hepatitis-c---gilead-sciences-/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/05/achillion-pharma-and-janssen-pharma-collaborate-on-hepatitis-c-drugs-including-ach-3102--ach-3422-and-sovaprevir/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2012/06/vanda-pharma-announces-non-24-hour-sleep-disorder/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2019/04/european-commission-approves-idacio--an--adalimumab-biosimilar---fresenius-kabi/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-nerlynx--neratinib--to-treat-patients-with-early-stage-her2-overexpressed-amplified-breast-cancer--following-adjuvant-trastuzumab-based-therapy---puma-biotechnology/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2012/11/phase-iii-trial-of-gs-7977-plus-rbv--gilead-sciences--shows-positive-results-in-patients-with-hepatitis-c/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2012/09/eu-approval-for-dacogen--janssen--cilag--for-treatment-of-acute-myeloid-leukemia---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2012/11/european-commission-rejects-uplyso--pfizer-protalix--for-gaucher-disease---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-warning-of-deaths-in-keynote-361-and-imvigor-130-studies-of-patients-with-bladder-cancer-taking-keytruda-or-tecentriq-monotherapy--merck-inc-and-genentech--roche-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-tafinlar-for-braf-v600-metastatic-melanoma/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2013/01/apremilast-celgene--success-in-esteem-1---2-trials-for-psoriasis/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-enroute-tns-to-restore-blood-flow-to-carotid-arteries--silk-road-medical-/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-approval-of-cimzia-for-moderate-to-severe-plaque-psoriasis---ucb-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-omidria--ketorolac-and-phenylephrine--for-cataract-surgery--omeros-corp/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-eylea--bayer-healthcare--for-wet-amd/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2017/11/defining-the-ecash-concept-in-pad-management/2024-08-21T14:55:09+00:00weekly0.6https://www.medthority.com/news/2017/01/sumitomo-dainippon-pharma-acquires-tolero-pharma-and-with-it-six-compounds-and-alvocidib-a-treatment-proposed-for-aml-/2025-10-16T11:14:30+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-expands-approval-of-pd-l1-ihc-22c3-pharmdx-assay-in-nsclc---agilent-hematogenix/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-data-on-eskata-in-seborrheic-keratoses-published-in-journal-of-the-american-academy-of-dermatology---aclaris-therapeutics-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2018/07/successful-phase-iii-study-of-vyxeos-compared-to-standard-of-care-for-aml-is-published-in-the-journal-of-clinical-oncology-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-inflectra-infliximab-biosimilar-hospira--for-rheumatoid-arthritis/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2019/01/eu-approves-rubraca-for-maintenance-treatment-of-ovarian--fallopian-tube--or-primary-peritoneal-cancer---clovis-oncology/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2019/01/adamis-pharma-files-nda-at-fda-for-naloxone-pre-filled-single-dose-syringe-product-to-treat-opioid-overdose-/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2016/09/volitionrx-limited-anticipates-nu-q-triage-colorectal-cancer-screening-test--blood-test--ce-mark-in-2016-/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2014/07/auripro-success-in-two-phase-iii-trials-for-paediatric-middle-ear-effusion-otonomy-inc-/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-rejects-acrescent--lundbeck--balaxur--merz--as-a-treatment-for-alzheimers-disease/2021-09-24T07:02:04+00:00weekly0.6https://www.medthority.com/news/2019/03/invokana-filed-with-fda-for-end-stage-kidney-disease-in-type-2-diabetes---janssen/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2016/08/eu-approves-ongentys--opicapone--to-treat-adult-parkinson-s-disease-patients-with-motor-fluctuations---bial/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-varsity-trial-shows-entyvio-superior-to-humira-in-ulcerative-colitis---takeda/2024-11-14T16:11:32+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-iressa--gefitinib--to-treat-egfr-exon-19-deletions-or-exon-21--l858r--substitution-mutations-in-nsclc/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2012/04/amitiza--sucampo-takeda--success-in-phase-iii-safety-trial-for-obd/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2012/03/zemplar--abbott--shows-positive-results-in-phase-iv-hyperparathyroidism-study/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2018/09/reduce-it-trial-of-vascepa-meets-primary-endpoint-in-elevated-triglycerides-patients---amarin-corp-/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2015/03/mallinckrodt-acquires-ikaria-inc--and-with-itinomax-for-hypoxic-respiratory-failure/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-trial-of-instiladrin-meets-primary-endpoint-in-unresponsive-non-muscle-invasive-bladder-cancer---fergene/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2011/10/z-one-elastography-imaging-helps-determine-treatment-for-crohn-s-disease/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2013/06/xolair--novartis-genentech--success-in-glacier-study-for-chronic-spontaneous-urticaria/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2017/08/kite-pharma-files-maa-at-ema--for-axicabtagene-ciloleucel-as-a-treatment-for-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma--dlbcl---transformed-follicular-lymphoma--tfl---and-primary-mediastinal-b-cell-lymphoma--pmbcl---nhl--/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2012/11/pimavanserin---acadia-biovail--success-in-phase-iii-trial-for-treatment-of-psychosis-in-parkinsons-disease/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2016/02/nice-now-recommends-repatha--evolocumab--for-dyslipidaemia-amgen/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2014/06/sanofi-anounces-results-of-pooled-analysis--edition-iii-and-edition-iv-studies-of-toujeo-in-types-1-and-2-diabetes/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-gilotrif-to-treat-three-additional-egfr-mutations--l861q--g719x-and-s768i-in-nsclc---boehringer-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2015/01/janssen-to-market-taf--tenofovir---emtricitabine-and-cobicistat--and--darunavir-combination-for-hiv-aids/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2013/03/bromsite-insite-vision--success-in-phase-iii-trial-for-cataract-surgery/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2013/11/horizon-pharma-to-market-vimovo-in-the-us-for-inflammatory-conditions/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2019/03/immobility-and-sleep-disruption-in-the-icu---latest-recommendations/2024-08-21T14:55:24+00:00weekly0.6https://www.medthority.com/news/2012/01/bayer-healthcare-plans-to-file-regorafenib-at-the-fda-for-metastatic-colorectal-cancer-in-2012/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-cobas-egfr-mutation-test-v2-for-non-small-cell-lung-cancer-therapies--roche/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2012/08/nktr-102---nektar--update-on-cancer-trials/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2016/10/astrazeneca-has-entered-into-an-agreement-with-aralez-pharmaceuticals-for-rights-to-toprol-xl--metoprolol-succinate-/2025-10-16T11:16:51+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-ondexxya-for-the-reversal-of-the-anticoagulant-effects-of-the-factor-xa-inhibitors-apixaban-or-rivaroxaban---portola-pharma/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2018/02/nice-recommends-kyntheum-as-a-treatment-for-plaque-psoriasis---leo-pharma-/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-blincyto-for-pediatric-patients-aged-one-year-or-older-with-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia----amgen-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2017/10/resolve-ii-study-of-sinuva--a-steroid-releasing-sinus-implant--is-successful-and-fda-sets-pdufa-date---intersect-ent-/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-bijuva-to-treat-moderate-to-severe-vasomotor-symptoms-due-to-menopause--therapeutics-md/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2015/05/phase-iii-results-with-revlimid--lenalidomide--in-non-del-5q-myelodysplastic-syndromes--celgene/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2020/01/jzp-258-filed-with-fda-for-cataplexy-and-excessive-daytime-sleepiness---jazz-pharma/2021-09-24T07:11:48+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-narcan--naloxone-intranasal--for-opioid-overdose--adapt-pharma/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-bruker-maldi-biotyper-ca-system-for-the-identification-of-c--auris-which-can-cause-serious-infections-in-hospitalized-patients--bruker-daltonik-gmbh-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2018/09/nice-now-recommends-crysvita-to-treat-x-linked-hypophosphatemia---kyowa-hakko-kirin---ultragenyx-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2015/11/unituxin--dinutuximab--not-cost-effective-to-treat-neuroblastoma-in-children-according-to-nice--united-therapeutics/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2018/02/champion-trial-is-completed-of-carbetocin-to-prevent-excessive-bleeding-after-childbirth---ferring---merck-inc-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trials-of-ocrelizumab-report-positive-results-in-multiple-sclerosis--genentech/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2014/07/nice-recommends-tecfidera-as-a-treatment-for--multiple-sclerosis-biogen-idec/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2016/07/new-data-on-sir-spheres-y-90-resin-microspheres-shows-benefits-in-patients-with-liver-dominant-metastatic-colorectal-cancer--sirtex/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-snda-for-fluzone-quadrivalent-for-influenza---sanofi/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-data-for-hdm-sublingual-allergy-immunotherapy-tablet-acarizax-for-house-dust-mite-allergy-published-in-journal-of-the-american-medical-association--alk/2024-02-20T10:06:05+00:00weekly0.6https://www.medthority.com/news/2014/08/novel-malaria-drug-kae-609--phase-ii-results-published-in-nejm---novartis/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2015/06/the-lancet-oncology-publishes-reach-study-of-cyramza--ramucirumab--in-liver-cancer--eli-lilly/2024-02-20T10:30:09+00:00weekly0.6https://www.medthority.com/news/2015/04/betaconnect-filed-with-fda-for-multiple-sclerosis-bayer/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-accepts-palbociclib-for-filing-as-treatment-for-er--her2--advanced-breast-cancer--pfizer/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2016/07/phase-ii-study-results-of-response-rate-of-pkc-412--midostaurin--in-systemic-mastocytosis-published-in-new-england-journal-of-medicine--novartis-/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-angiovue-optical-coherence-tomography-angiography-imaging-system-for-age-related-macular-degeneration--optovue/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-iii-results-for-bax-326--baxter--for-haemophilia-b/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2017/08/success-for-semaglutide-in-sustain-7-head-to-head-trial-with-trulicity---dulaglutide--in-treatment-of-type-2-diabetes---novo-nordisk/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2011/05/zyvox---pfizer-effective-for-patients-with-mrsa/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-trial-of-rdz-5792--tenapanor--meets-endpoint-in-treatment-for-hyperphosphatemia--ardelyx-/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2019/09/xiaflex-filed-with-fda-for-cellulite---endo-international/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2014/04/pfizer-makes-offer-for-astrazeneca/2025-10-16T10:46:55+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-accepts-nda-for-telotristat-etiprate-to-treat-carcinoid-syndrome-with-pdufa--target-action-date-of-november-30--2016--lexicon-pharma-/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2011/09/galvus-achieves-significant-improvements-in-type-2-diabetes-study/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-approval-of-nyxoid--intranasal-naloxone--for-treatment-of-opioid-overdose---mundipharma-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---money-or-altruism--what-motivates-people-to-donate-their-poop-to-medicine-/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2013/01/votubia-afinitor-success-in-treatment-of-renal-angiomyolipoma--reported-in-the-lancet/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2016/09/emmaus-life-sciences-inc---files-nda-at-fda-for-l-glutamine-treatment-for-sickle-cell-disease-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2015/06/successful-accurate-study-for-axium-neurostimulator-system-for-chronic-lower-limb-pain-st-jude-medical/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-expanding-approval-of-zykadia--ceritinib--to-include-first-line-treatment-of-patients-with-advanced-non-small-cell-lung-cancer--nsclc--whose-tumors-are-anaplastic-lymphoma-kinase--alk--positive--novartis/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2014/06/pembrolizumab--formerly-lambrolizumab--being-mk-3475-success-in-phase-1b-trial-for-head---neck-cancer/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2018/01/baremsis-filed-with-fda-for-post-operative-nausea---vomiting---acacia-pharma-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2018/09/declare-trial-reports-on-effect-of-farxiga-on-cv-events-in-type-2-diabetes-patients--astrazeneca/2021-09-24T07:06:41+00:00weekly0.6https://www.medthority.com/news/2015/07/nn-9535--semaglutide--meets-endpoints-for-type-2-diabetes-in-phase-iii-trial--novo-nordisk/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2019/03/sub---analysis-of-phase-iii-declare-timi-58-trial-showed-that-farxiga-reduced-the-relative-risk-of-major-adverse-cardiovascular-events---astrazeneca/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-trials-of-fluticasone-propionate-salmeterol-inhalers-meet-primary-endpoints-in-asthma-teva-pharmaceuticals/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2013/09/ultibro-breezhaler-improvements-in-copd-trials/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2017/12/admyre-phase-iii-pivotal-trial-of-aplidin-meets-primary-endpoint-in-multiple-myeloma---pharmamar-/2024-07-26T10:42:27+00:00weekly0.6https://www.medthority.com/news/2017/10/abbott-completes-acquisition-of-alere-inc-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2015/06/-gavi-and-geri-fertility-technologies-secure-ce-mark--merck-kgaa---genea-biomedx/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2014/02/cubist-files-maa-for-tr-701-at-ema-for-infections---cubist-pharma/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2013/06/astrazeneca-ceases-development-of-fostamatinib-/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2015/11/analysis-demonstrates-reinitiation-of-antithrombotic-therapy-after-praxbind--idarucizumab--therapy-in-atrial-fibrillation-patients--boehringer-ingelheim/2024-02-06T15:53:19+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-impower130-study-of-tecentriq---chemo-shows-os-gain-in-nsclc---genentech-roche-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-paradym-defibrillators--sorin--for-patients-at-risk-of-cardiac-arrest/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2016/03/dsmb-recommends-discontinuation-of-phase-iii-study-of-rintega--rindopepimut--in-brain-cancer--celldex-therapeutics-/2024-02-06T15:53:40+00:00weekly0.6https://www.medthority.com/news/2011/11/rheumatoid-arthritis-trial-shows-week-12-response-to-cimzia--ucb--predicts-response-at-1-year--/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/03/eu-gives-ce-mark-approval-for-watchman-flx-left-atrial-appendage-closure-for-stroke-prevention---boston-scientific/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-astagraf-xl--astellas--for-transplant-rejection/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-results-for-blinctyo-in-pediatric-patients-with-high-risk--b-cell-acute-lymphoblastic-leukemia---amgen/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2017/06/chmp-recommends-imraldi--also-known-as-sb5---an-adalimumab-biosimilar-to-treat-humira-the-originator-drug-indications---samsung-bioepis/2021-09-24T07:15:01+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-xarelto-to-prevent-atherothrombotic-events-in-adult-patients-with-coronary-artery-disease-or-symptomatic-peripheral-artery-disease----bayer---janssen-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2019/12/sobi-reports-republic-of-ireland-extends-supply-contract-for-elocta-to-treat-haemophilia-a/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2017/10/positive--results-from-keynote-024-trial-for-keytruda-for-nsclc---merck-inc-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2014/07/dengue-fever-vaccine-phase-iii-results-published-in-the-lancet-sanofi-pasteur/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-hemangiol-for-treatment-of-infantile-haemangioma---pierre-fabre/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2012/12/results-of-phase-iii-studies-show-substantial-benefits-of-acz-885--novartis--in-patients-with-juvenile-idiopathic-arthritis-/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2014/08/nice-recommends-revlimid-for-specific-myelodysplastic-syndromes---celgene/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-lucentis--0-3-mg-prefilled-syringe-as-a-new-method-of-administering-the-medicine-to-treat-all-forms-of-diabetic-retinopathy---genentech-roche-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2019/11/roche-to-acquire-promedior-and-with-it-prm-151-a-proposed-treatmemt-for-fibrotic-diseases/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-phase-iii-top-line-results-for-somatrogon--an-investigational-long-acting-human-growth-hormone-to-treat-children-with-growth-hormone-deficiency---opko-health---pfizer/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2017/11/uesc-2017/2024-02-22T11:06:22+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-accepts-filing-and-grants-priority-review-for-defibrotide-for-treatment-of-hepatic-veno-occlusive--disease--jazz-pharma/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2019/05/positive-results-from-phase-ii-destiny-breast01-trial-of-trastuzumab-deruxtecan-to-treat-her2-positive--unresectable--breast-cancer---daiichi-sankyo---astrazeneca/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2017/08/post-hoc-analysis-of-the-phase-iii--endeavor-trial-shows-kyprolis--carfilzomib--reduces-risk-of-death-in-multiple-myeloma--and-data-submitted-to-fda--amgen-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2013/04/ruconest--santarus-pharming--is-re-filed-with-fda-for-treatment-of-hereditary-angioedema/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2019/05/study-of-signatera-ctdna-assay-in-colorectal-cancer-published-in-jama-oncology/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-tissueglu-adhesive-for-surgical-procedures--cohera-medical/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-issues-complete-response-letter-for-tafamidis--pfizer--for-ttr-fap/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2013/05/genous-stent--orbus-neich--has-lower-restenosis-rate-than-bare-metal-stents-in-acs-treatment/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2014/01/positive-phase-iib-tardive-dyskinesia-study-with-nbi-98854-neurocrine-biosciences/2021-09-24T07:07:37+00:00weekly0.6https://www.medthority.com/news/2013/05/master-trial-shows-mguard--inspiremd--offers-benefits-in-treating-coronary-artery-disease/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-nourianz-for-parkinson-s-disease---kyowa-kirin/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2014/07/3c-study-of-campath-for-transplant-rejection-published-in-the-lancet-sanofi-genzyme/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-epanova-for-treatment-of-hypertriglyceridaemia-astrazeneca/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2017/06/interim-analysis-of-magnify-phase-iiib-study-of-revlimid--lenalidomide--plus-rituximab-in-marginal-zone-lymphoma--celgene-corp/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2016/10/moberg-pharma-ab-initiates-phase-iii-program-for-mob-015-to-treat-onychomycosis-/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2017/03/--successful-phase-iii-trial-of-ameluz--5-aminolevulinic-acid--with-photodynamic-therapy--to-treat-actinic-keratosis---biofrontera-ag/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2019/11/alnylam-announces-new-and-enhanced-framework-for-value-based-agreements-to-accelerate-patient-and-provider-access-to-givlaari-/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2016/09/post-hoc-analysis-of-entresto--sacubitril-valsartan--suggests-quality-of-life-benefits-for-patients-with-heart-failure--novartis/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-kadcyla-for-breast-cancer/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-duobrii-lotion-to-treat-psoriasis/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2014/02/dulaglutide-non-inferior-to-victoza-for-type-2-diabetes---eli-lilly/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-compassionate-use-of-sofosbuvir---ledipasvir-combination-for-hepatitis-c---gilead-sciences/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-tudorza-pressair---forest-pharma--for-copd/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-filing-of-naloxegol-is-accepted/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2017/01/eu-approves-fiasp--rapid-acting-insulin-aspart--for-the-treatment-of-diabetes---novo-nordisk-/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-approves-chocolate-pta-balloon-catheter-trireme-medical--for-pad/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-510-k--approval-for-unity-subcutaneous-delivery-system-for-remodulin--injection-to-treat-pulmonary-arterial-hypertension--united-therapeutics/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2019/11/chemocentryx-and-vfmcrp-announce-positive-data-from---phase-iii--advocate-trial-showing--superiority-of-avacopan-over-standard-of-care-in-anca-associated-vasculitis-/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-advisory-committee-meeting-to-consider-exparel-for-regional-analgesia-is-to-be-held-on-14-15-february-2018---pacira-pharma-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-the-genius-3d-mammography-exam-for-routine-breast-cancer-screening-of-women-with-dense-breasts---hologic/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-quinsair-for-treatment-of-cystic-fibrosis-pseudomonas-aeruginosa-aptalis-actavis/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/09/novo-nordisk-files-nda-at-fda-for-xultophy--combination-of-tresiba--insulin-degludec--and-victoza--liraglutide--to-treat-type-2-diabetes/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2019/05/merck-inc---acquires-peloton-therapeutics-and-with-it-pt-2977---a-novel-oral-hif-2-alpha-inhibitor-to-treat-renal-cell-carcinoma/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2017/05/pivotal-trial-results-for-recell-in-wound-healing-to-be-submitted-to-fda-for-approval--avita-medical/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2012/12/nice-rejects-inlyta-pfizer--for-treatment-of-renal-cell-carcinoma/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-advisory-committee-votes-against-approving-exondys--eteplirsen--for-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping--sarepta-therapeutics/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-capstone-2-study-showed---baloxavir-marboxil-significantly-reduced-time-to-improvement-of-influenza-symptoms---genentech-roche/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2014/05/vintafolide-fails-phase-iii-proceed-trial-for-ovarian-cancer--merck-inc-/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2017/08/sellas-life-sciences-to-acquire-galena-therapeutics-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-im-uniti-study-of-stelara-shows-continued-efficacy-at-3-years-in-crohn-s-disease---j-j-janssen-cilag-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2015/01/chmp-recommends-sivextro--tedizolid-phosphate--treatment-of-absssi--merck-inc--/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2019/12/fibrogen-files-nda-to-fda-for-roxadustat-for-the-treatment-of-anemia-of-chronic-kidney-disease-/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2016/11/astrazeneca-drops-plans-to-file-durvalumab-for-treatment-of-head-and-neck-cancers-/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2018/10/ema-accepts-filing--maa--for-lentiglobin--gene-therapy-to-treat-transfusion-dependent-beta-thalassemia---bluebird-bio/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2017/04/eu-chmp-recommends-approval-of-gp-2013--biosimilar-rituximab--for-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma--chronic-lymphocytic-leukemia--rheumatoid-arthritis--granulomatosis-with-polyangiitis--and-microscopic-polyangiitis--sandoz/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-clinical-data-of-cvt-301--inhaled-levodopa--shows-improvement-in-parkinsons-disease-patients--acorda-therapeutics/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2013/01/iqwig-finds-no-additional-benefit-in-eklira-genuair--almiral--in-copd-treatment/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-chmp-recommends-marketing-authorisation-for-the-lusduna--insulin-glargine-biosimilar--for-diabetes--merck-inc-/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2015/03/bi-655075-filed-with-fda-as-antidote-boehringer/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2017/10/positive-phase-iii-trial-for-relugolix-versus-leuprorelin-for-the-treatment-of-uterine-fibroids-in-japanese-women---myovant---takeda-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2012/05/votrient--glaxo-smith-kline--prolongs-progression-free-survival-in-advanced-soft-tissue-sarcoma/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-chmp-recommends-approval-of-viekirax--ombitasvir-paritaprevir-ritonavir----exviera--dasabuvir--for-eight-week-treatment-of-genotype-1b-patients-with-chronic-hcv-infection--abbvie/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-topline-results-from-study-of-abt-450-r--abt-267--abt-333--abbott--for-hepatitis-c/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-chmp-recommends-lonsurf--trifluridine-tipiracil--for-metastatic-colorectal-cancer--servier/2024-02-06T15:53:58+00:00weekly0.6https://www.medthority.com/news/2018/10/taltz-progress-in--coast-v-and-coast-w-trials-for-ankylosing-spondylitis---eli-lilly/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-cll11-study-of-gazyva-shows--impact-on-survival-in-chronic-lymphocytic-leukaemia---roche-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-expands-use-of-levemir--novo-nordisk--for-type-1-diabetic-children/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-axumin--fluciclovine--18f---for-pet-imaging-of-suspected-recurrent-prostate-cancer---blue-earth-diagnostics-ltd/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2015/04/studies-show-ctdna-test-effective-in-detecting-egfr-nsclc-for-treatment-with-iressa-astrazeneca/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2016/09/takeda-initiates-insight-mm-global--observational-study-of-patients-with-multiple-myeloma-/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2018/03/sollpura-fails-result-phase-iii-study-for-exocrine-pancreatic-insufficiency----anthera-pharma-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2016/12/lundbeck---otsuka-file-snda-at-fda-for-abilify-maintena--aripiprazole-depot--to-treat-bipolar-disorder-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-i-study-of-givosiran-to-treat-acute-hepatic-porphyria-is-published-in-the-new-england-journal-of-medicine---alnylam/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-spartan-study-of-erleada-shows-reduced-risk-of-prostate-cancer---janssen-pharma-/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-accepts-for-review-ibrance--palbociclib----fulvestrant-to-treat-human-epidermal-growth-factor-receptor-2-negative--hr---her2---metastatic-breast-cancer---pfizer/2024-02-06T15:54:19+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-and-ema-report-on-effect-of-incretin-mimetics-on-pancreatitis-and-pancreatic-cancer/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2013/12/heart-mate-ii-device-associated-with-blood-clots-thoratec-corpn-/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2015/06/rociletinib-success-in-tiger-x-study-for-nsclc--clovis-oncology/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2017/02/merck-inc---takes-a--2-9-billion-charge-on-uprifsobuvir--mk-3682--as-the-hepatitis-c-market-diminishes-/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2012/06/abediterol--almirall-forest--superior-to-indacaterol-in-phase-iia-trial-for-copd/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-filmarray-me-panel-for-diagnosis-of-meningitis-and-encephalitis--biofire-diagnostics/2021-09-24T07:03:18+00:00weekly0.6https://www.medthority.com/news/2019/09/nice-rejects-aimovig-as-a-treatment-for-migraine---novartis/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2018/10/esketamine-nasal-spray-filed-with-ema-for-major-depressive-disorder---janssen-pharma-/2024-10-21T14:53:49+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-doptelet-for-thrombocytopenia---dova-pharmaceuticals-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-results-show-abraxane-leads-to-high-disease-free-survival-rates-in-breast-cancer---celgene-/2021-09-24T07:13:41+00:00weekly0.6https://www.medthority.com/news/2014/06/lbh-589-success-in-panorama-study-for-multiple-myeloma---novartis/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2013/04/merck-inc-and-pfizer-to-collaborate-on-ertugliflozin-for-type-2-diabetes/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2015/12/eu-chmp-recommends-approval-of-portrazza--necitumumab--for-non-small-cell-lung-cancer--eli-lilly/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-flumist-quadrivalent--medimmune--for-influenza/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2019/08/u-s--court-of-appeals-ruled-in-favor-of-eli-lilly--confirming-that-the-alimta-vitamin-regimen-patent-would-be-infringed-by-competitors-with-an-alternative-salt-form-of-pemetrexed-prior-to-the-patent-expiry-/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2018/12/new-phase-iii-results-with-fintepla--zx-008--in-dravet-syndrome-presented---zogenix-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-in-draft-guidance-recommends-remsima-and-inflectra-biosimilars-for-ra--napp-pharma--hospira/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-issues-complete-response-letter-relating-to-evomela--captisol-enabled-melphalan--an-intended-treatment-for-multiple-myeloma--spectrum-pharma-/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2016/01/portala-pharma-completes-bla-submission-to-fda-for-andexanet-alfa-to-reverse-the-anticoagulant-activity-of-both-direct-and-indirect-factor-xa-inhibitors/2024-10-22T08:18:32+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-envarsus-xr-for-organ-rejection-in-de-novo-kidney-transplant---veloxis-pharma-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-study-of-stx-209--seaside-therapeutics--for-patients-with-fragile-x-syndrome/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2019/07/mvasi-biosimilar-to-avastin-and-kanjinti-biosimilar-to-herceptin-are-launched-in-us/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2013/03/positive-results-in-three-year-trial-of-absorb-vascular-scaffold--abbott-/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2014/10/chmp-gives-positive-opinion-on-update-for-esbriet-in-ipf-roche/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-advisory-committee-rejects-olaparib-for-ovarian-cancer-astrazeneca/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2017/02/vidas-brahms-pct-assay-receives-510-k-clearance-from-fda-as-diagnostic-for-respiratory-tract-infections-such-as-community-acquired-pneumonia-biomerieux/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2018/11/genetech-roche-acquires-jecure-therapeutics-and-its-preclinical-portfolio-of-nlrp3-inhibitors-a-prospective-treatment-for-nash/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2014/03/ryanodex-filed-at-fda-for-malignant-hyperthermia---eagle-pharma/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approve-aptima-hpv-assay--hologic--for-detecting-human-papillomavirus----------------/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2018/04/post-hoc-analysis-of-paradigm-study-shows-entresto-preserves-kidney-function-and-is-published-in-the-lancet-diabetes---endocrinology---novartis/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2016/08/viiv-healthcare-starts-phase-iii-programme-of-dolutegravir--tivicay--and-lamivudine--epivir--as-a-treatment-for-hiv-1-infection--/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2015/04/checkmate-057-trial-of-opdivo--nivolumab--for-nsclc-meets-endpoint-and-is-stopped-early--bms-/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2011/09/viramine-xr-once-a-day-is-eu-approved-for-hiv-treatment/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2015/06/pfizer-initiates-rivipansel-in-phase-iii-reset-trial-for-vaso-occlusive-crisis-of-sickle-cell-disease/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2018/11/tappas-phase-iii-trial-shows-apostream-effective-in-capturing-tumour-cells-in-angiosarcoma---precision-for-medicine-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-advisory-committees-recommend-addyi--flibanserin--for-treatment-of-hypoactive-sexual-desire-disorder--hsdd--in-premenopausal-women--sprout-pharma/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-results-from-phase-iii-bliss-ln-trial-of-benlysta-to-treat-lupus-nephritis---gsk/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-outcome-to-eu-decentralized-approval-of-iluvien--almeria-sciences--for-dme-/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2014/05/serious-fraud-office-in-uk-to-investigate-gsk-commercial-operations/2025-10-16T10:52:12+00:00weekly0.6https://www.medthority.com/news/2018/05/eu-approves-biosimilar-zessly--to-treat-all-indications-of-infliximab-the-reference-medicine---sandoz-/2024-07-26T10:42:15+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-harvoni-for-for-the-treatment-of-chronic-hepatitis-c---gilead-sciences/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2015/09/aerie-pharma-reports-phase-iii-results-of-rhopressa-for-glaucoma-and-ocular-hypertension/2024-02-06T15:54:38+00:00weekly0.6https://www.medthority.com/news/2016/10/gsk-files-bla-at-fda-for-shingrix-a-vaccine-to-prevent-herpes-zoster--shingles--/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-committee-votes-on-tafamidis--pfizer--for-ttr-fap/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2015/07/continuous-intravascular-glucose-monitoring-system--achieves-ce-mark-glysure-limited/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2018/03/ehra-2018--study-finds-the-heart-can-terminate-atrial-fibrillation-itself-after-local-gene-therapy/2024-02-20T10:07:48+00:00weekly0.6https://www.medthority.com/news/2017/08/regeneron-and-sanofi-to-conclude-antibody-discovery-agreement-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2019/09/first-patient--enrolled-in-the-pivotal-phase-iii-neptune-trial-of-ov-101-for-treatment-of-angelman-syndrome---ovid-therapeutics-/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2012/04/review-shows-botox--allergan--offers-modest-benefit-for-chronic-migraine-and-daily-headaches/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-flutemetamol-f-18--ge-healthcare--for-alzheimers-diagnosis/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2012/10/ramucirumab--eli-lilly--success-in-phase-iii-trial-for-gastric-cancer/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2019/04/euro-cmr-2019-preview/2024-02-20T10:13:12+00:00weekly0.6https://www.medthority.com/news/2015/03/pt-003-positive-in-phase-iii-studies-for-copd--astrazeneca/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-phase-iii-results-for-decapeptyl-in-prostate-cancer-ipsen/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2017/06/new-effective-treatments-for-psoriatic-arthritis-patients/2021-11-30T10:35:26+00:00weekly0.6https://www.medthority.com/news/2016/09/ema-s-chmp-recommends-approval-of-revatio-generic-granpidam--sildenafil--for-pulmonary-arterial-hypertension--accord-healthcare/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2013/11/a-long-study-of-elocate--biogen-sobi--published-in-blood-journal/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2015/09/apricus-re-licenses-rights-to-erectile-dysfunction-drug-vitaros--alprostadil-topical-from-allergan/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2019/03/post-market-study-of-impella-rp-system-reports-survival-rates-in-heart-failure---abiomed/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2017/11/nejm-publishes-results-of-endear-study-of-spinraza--a-new-treatment-for-spinal-muscular-atrophy---biogen---ionis-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2012/08/eu-expanded-indication-for-velcade-in-multiple-myeloma/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-filing-of-nda-for-lynparza-for-patients-with-metastatic-castration-resistant-prostate-cancer---astrazeneca---merck-inc-/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-pemphix-study-shows--rituxan-superior-to-mycophenolate-mofetil-in-patients-with-pemphigus-vulgaris--genentech-roche/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-approves-flulaval-quadrivalent-vaccine/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2016/12/kite-pharma-announces-results-of-zuma-1-trial-of-axicabtagene-ciloleucel--kte-c19-for-chemorefractory-aggressive-non-hodgkin-lymphoma--nhl--/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2019/01/daiichi-sankyo-initiates-destiny-breast-04-trial-of-fam---trastuzumab-deruxtecan--in-patients-with-her2-low--unresectable-and-or-metastatic-breast-cancer-/2021-09-24T07:18:44+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-zorvolex--iroko-pharma--for-mild-to-moderate-pain/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2018/05/tecentriq---cotellic-combination--did-not-meet-primary-endpoint-in--imblaze370-trial-for-colorectal-cancer---genentech-roche/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2012/07/phase-ii-proof-of-concept-trial-for-apg-101--apogenix--is-confirmed-for-glioblastoma-multiforme/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2016/05/three-newly-published-studies-demonstrate-invokana--canagliflozin--produces-improvements-in-type-2-diabetes--janssen-pharmaceuticals/2024-02-19T10:43:59+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-extension-to-indication-for-sprycel-in-ph--chronic-myeloid-leukemia---bms-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-phase-iii-data-for-zytiga--j-j-janssen-cilag--plus-prednisone-for-prostate-cancer/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2019/09/amplify-phase-iii-study-of-rdz-5792-meets-primary-endpoint-in-hyperphosphatemia---ardelyx/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2013/10/imnovid--celgene--may-cause-birth-defects-in-mm-patients/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2017/10/world-mental-health-day-/2024-02-19T10:44:23+00:00weekly0.6https://www.medthority.com/news/2019/11/european-commission-approves-rhokiinsa-to-reduce-elevated-intraocular-pressure-in-adult-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension--aerie-pharma/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2017/08/amgen-and-allergan-plc---announce-the-submission-of-a-biologics-license-application--bla--to-the--fda--for-abp-980--a-biosimilar-candidate-to-herceptin--trastuzumab--/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-advisory-committee-recommends-lesinurad-for-the-treatment-of-hyperuricaemia-associated-with-gout--astrazeneca/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-advisory-committee-recommends-rhopressa--netarsudil-ophthalmic-solution--0-02---to-treat-glaucoma--aerie-pharmaceuticals-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2018/01/nice-recommends-simponi-to-treat-ankylosing-spondylitis---merck-inc-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2014/04/cochrane-collaboration-and-bmj-critical-of-tamifu-studies-for-prevention-of-influenza---roche/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2012/03/mmx-mesalamine--shire--fails-phase-iii-study-for-diverticulitis/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2018/01/honda-walking-assist-device--an-assistive-device-for-use-in-the-rehabilitation-of-walking--secures-ce-mark---honda-motor-co-ltd-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2012/09/novo-nordisk-cancels-further-development-of-vatreptacog-alfa-as-a-treatment-for-diabetes---------------/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2011/10/lb-03002-success-in-treatment-of-growth-hormone-deficiency-/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2019/03/chmp-positive-for-lorviqua-to-treat-patients-with-alk-positive-advanced-non-small-cell-lung-cancer--nsclc----pfizer/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2014/09/break-3-study-of-tafinlar-shows-45--of-patients-still-alive-after-2-years-with-melanoma---gsk/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2017/06/on-world-blood-donor-day---give-blood--give-now--give-often--/2024-07-26T10:59:02+00:00weekly0.6https://www.medthority.com/news/2016/10/opdivo--nivolumab--given-chmp-recommendation-for-approval-in-treatment-for-relapsed-or-refractory-classical-hodgkin-lymphoma--bms/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2014/11/nivolumab-versus-dacarbazine-in-phase-iii-trial-for-melanoma---bms/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-juvderm-voluma-xc--allergan--facial-filler/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2017/01/krn-23--monoclonal-antibody--filed-with-the-eu-for-the-treatment-of-x-linked-hypophosphatemia--ultragenyx-pharmaceutical---kyowa-kirin/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-results-from-phase-iii--essence-study-in-the--casimersen-arm-to-treat-duchenne-muscula-dystrophy--sarepta-therapeutics/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2016/04/bimagrumab--bym-338--fails-phase-iib-iii-trial-to-treatsporadic-inclusion-body-myositis--muscle-wasting----morphosys---novartis/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-announces-at-ash-additional-data-from-pilot-and-outreach-studies-for-liso-cel-for-second-line-patients-with-large-b-cell-non-hodgkin-s-lymphoma/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-low-dosage-nsaid-vivlodex--meloxicam--for-osteoarthritis-pain--iroko-pharma/2024-02-06T15:55:11+00:00weekly0.6https://www.medthority.com/news/2011/12/onduarp--boehringer--is-ema-approved-for-essential-hypertension/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2015/04/repros-therapeutics-files-at-fda-enclomiphene-citrate-for-hypogonadism-in-overweight-men-/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2014/05/astrazeneca-rejects-new-pfizer-proposal-/2025-10-16T11:34:18+00:00weekly0.6https://www.medthority.com/news/2017/06/post-hoc-analyses-of-from-the--ocrevus--ocrelizumab--phase-iii-clinical-trial-program-for--multiple-sclerosis---genentech/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2019/05/amryt-acquires-aegerion-pharmaceuticals--/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2016/01/priority-review-at-fda-for-combination-sovaldi--sofosbuvir---gs-5816--velpatasvir--to-treat-genotype-1-6-hepatitis-c--gilead-sciences/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2013/11/study-confirms-benefits-of-mistent-for-cad-micell-technologies/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2011/10/zometa-prevents-bone-loss-side-effects-of-breast-cancer-medication/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-trial-data-on-pradaxa-in-nvaf-published-in-circulation-boehringer/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2016/06/ema-validates--maa-for-raxone--idebenone--for-duchenne-muscular-dystrophy----santhera-pharma-/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-sbla-for-botox-to-treat-pediatric-patients--2-to-17-years-of-age--with-lower-limb-spasticity--allergan-abbvie/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-norditropin-flexpro-penmate--somatropin-injection--for-growth-hormone-treatment--novo-nordisk/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-biologics-license-application-for-avastin-in-newly-diagnosed-advanced-ovarian-cancer-/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2019/01/update-on-ap-101-trial--as-a-potential-treatment-for-epidermolysis-bullosa---amryt/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2020/02/cti-has-reached-agreement-with-the-fda--on-an-accelerated-approval-pathway-for-pacritinib-for-the-treatment-of-myelofibrosis-patients-with-severe-thrombocytopenia-/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2011/11/contraceptives-containing-beyaz--bayer-healthcare--show-higher-risk-of-blood-clots/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2019/12/reblozyl-study-evaluating-the-treatment-of-anemia-associated-with-beta-thalassemia--was-presented-at--ash-meeting---bms---acceleron-pharma/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2013/03/xarelto-enters-phase-iii-trial-for-heart-failure-and-cad/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-provides-complete-response-letter-for-vitaros-in-erectile-dysfunction---apricus-biosciences-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2011/10/mr-guided-focused-ultrasound-promising-for-treatment-of-essential-tremor/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-accepts-filing-of-beleodaq-for-t-cell-lymphoma--spectrum-pharma/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-generic-xeloda/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-zonda-trial-of-medi-563--benralizumab--meets-primary-endpoint-in-asthma-and-is-published-in-nejm--astrazeneca/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2013/11/phase-iii-trials-of-sovriad--janssen-r-d--show-benefits-in-hep-c/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-expands-approval-of-corifact--csl-behring--to-manage-surgical-bleeding-in-adult-and-pediatric-patients-with-factor-xiii-deficiency/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-glyxambi--empagliflozin-linagliptin--to-treat-type-2-diabetes---eli-lilly---boehringer/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2019/11/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china-/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2014/10/vargatef-in-new-phase-iii-trial-for-colorectal-cancer-boehringer/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2019/11/amphora-refiled-with-fda-for-the-prevention-of-pregnancy--evofem-biosciences/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2012/09/generic-diovan-hct-launched-in-usa/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2018/01/positive-adenoma-trial-for-endocuff-vision-colonscopy-device---norgine-b-v---olympus-medical-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2018/04/journal-of-the-american-academy-of-dermatology--jaad--has-published-positive-two-phase-iii--multicenter--randomized--double-blind-clinical-trials--studies-1-and-2--for-psoriasis--to-assess-the-safety-and-efficacy-of-duobrii---ortho-dermatologics-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2019/10/new-data-shows-improved--muscle-function-and-improved-tolerability-for-vamorolone-v--corticosteroids-treatment-in-duchenne-muscular-dystrophy--santhera-pharma/2021-09-24T07:17:25+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-rezolsta-combination-darunavir---cobicistat-for-hiv-treatment---janssen-cilag/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2018/12/european-commission-approves-dengvaxia-dengue-vaccine---sanofi/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2017/06/zomig--zolmitriptan--rights-outside-japan-are-transferred-by-astrazeneca-to-grunenthal-/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2017/07/sanofi-acquires-protein-sciences-and-with-it-flublok-quadrivalent-influenza-vaccine--qiv-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2017/12/first-successful-gene-therapy-for-haemophilia-a/2024-02-19T10:58:02+00:00weekly0.6https://www.medthority.com/news/2018/09/rdx-5791-filed-with-fda-for-irritable-bowel-syndrome-with-constipation---ardelyx-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2012/10/eu-approves-subcutaneous-formulation-of-orencia--bms--for-moderate-to-severe-rheumatoid-arthritis---------------/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2013/12/ec-approves-fluenz-tetra-vaccine-for-influenza--astrazeneca/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2015/10/valeant-to-respond-to-allegations-in-conference-call-on-26-october/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-lumason-for-ultrasound-imaging-of-the-heart--bracco/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2016/06/ap-26113--brigatinib--filed-with-fda-in-a-rolling-submission-for-alk--non-small-cell-lung-cancer---ariad-pharmaceuticals/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2011/10/bioalliance-files-sitavir-in-the-eu-for-orofacial-herpes/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-requires-more-data-for-arcalyst--regeneron--for-gout-flares-treatment/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-concerns-relating-to-repatha--evolocumab--and-praluent-alirocumab--for-treatment-of-cv-risk--amgen-sanofi-regeneron/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-priority-review-for-gazyva--obinutuzumab--in-combination-with-chemotherapy-followed-by-gazyva-alone-for-people-with-previously-untreated-follicular-lymphoma--genentech-roche/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2012/03/banzel-inovelon-eisai--is-launched-in-germany-for-lgs/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2012/05/viramune--boehringer--patent-expires-on-22-may-2012/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2019/06/positive-phase-iii-ethos-trial-for-triple-combination-therapy-breztri-aerosphere-for-very-severe-chronic-obstructive-pulmonary-disease---astrazeneca/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2016/05/pfizer-and-anacor-pharmaceuticals-to-merge/2021-09-24T07:09:30+00:00weekly0.6https://www.medthority.com/news/2011/09/eliquis-launched-in-uk-for-vte/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2019/02/results-of-phase-iii-iv-annexa-4-study-of-andexxa-for-reversal-of-anticoagulation-published-in-nejm---portola-pharma/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2012/09/repligen-withdraws-application-at-ema-for-secreflo-an-agent-for-pancreatic-imaging---------------/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2012/09/phase-ii-success-for-gsk-961081-gsk-theravance--for-copd/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-iii-study-shows-tr-701--trius-therapeutics--equivalent-to-best-alternative-treatment-for-absssi/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2015/09/swissmedic-approves-entresto---sacubitril-valsartan-to-reduce-cv-risk-in-heart-failure-patients-with-reduced-ejection-fraction--novartis/2024-02-19T10:58:13+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approve-cyltezo--adalimumab-biosimilar--for-treatment-of-rheumatoid-arthritis--juvenile-idiopathic-arthritis--psoriatic-arthritis--ankylosing-spondylitis--crohn-s-disease--ulcerative-colitis-and-plaque-psoriasis--boehringer-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-range-study-of-cyramza--ramucirumab--met-its-primary-endpoint-in-metastatic-urothelial-carcinoma--eli-lilly/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2019/09/new-five-year-disease-stability-data-confirm-the-long-term-efficacy-and-safety-of-mavenclad-as-a-treatment-for-multiple-sclerosis--merck-kgaa-/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-ii-studies-of-indoximod-with-checkpoint-inhibitors-for-advanced-melanoma-and-with-chemotherapy-for-pancreatic-cancer-may-revive-interest-in-ido-pathway-inhibition--newlink-therapeutics-/2021-09-24T07:05:35+00:00weekly0.6https://www.medthority.com/news/2012/06/six-year-follow-up-on-phase-iii-study-of-sprycel--bms---otsuka--shows-positive-results-for-cml-patients/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2017/12/the-best-of-sabsc-2017/2021-11-30T13:57:33+00:00weekly0.6https://www.medthority.com/news/2013/01/chmp-recommends-jetrea--alcon--for-treatment-of-vitreomacular-traction-/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2017/03/new-data-from-novartis-suggests-that--cosentyx--secukinumab--may-modify-the-course-of-moderate-to-severe-psoriasis-leading-to-long-term--treatment-free-skin-clearance-/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-zohydro--zogenix--for-severe-pain-/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2015/12/iqwig-finds--/2024-02-19T10:58:23+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-bla-for-luspatercept-to-treat-myelodysplastic-syndromes-anemia-and-beta-thalassemia-associated-anemia---celgene---acceleron-pharma/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2015/08/novartis-acquires-auto-immune-rights-to-arzerra--ofatumumab--from-gsk/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-haven-3-trial-of-hemlibra-in-hemophilia-a-meets-primary-endpoint---genentech-/2024-07-30T14:57:22+00:00weekly0.6https://www.medthority.com/news/2015/02/pfizer-to-acquire-hospira/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2019/05/european-commission-approves-palynziq-to-treat-phenylketonuria---biomarin-pharma/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2015/01/bms-stops-phase-iii-study-of-opdivo-in-nsclc-as-dmc-asessment-showed-the-drug-had-met-its-endpoint-of-overall-survival-/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-ubrelvy-to-treat-acute-migraine---allergen/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-accepts-nda-for-stannsoporfin-a-treatment-of-neonates-at-risk-for-developing-severe-hyperbilirubinemia---mallinckrodt/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-dupixent-to-treat--moderate-to-severe-asthma--sanofi---regeneron-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/11/first-patients-dosed-with-filgotinib-for-crohn-s-disease-in-phase-iii-diversity-study---gilead---galapagos/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2016/06/novartis-to-present-at-eular--long-term-analyses-of-cosentyx--secukinumab--for-treatment-of-ankylosing-spondylitis--as--and-psoriatic-arthritis-/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2018/09/results-from-alta-il-trial-show-alunbrig-reduced-disease-progression---risk-by-50--compared-to-xalkori-for-alk--nsclc---takeda/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2015/06/bayer-health-care-and-janssen-pharma-to-initiate-studies-of-xarelto--rivaroxaban--for-vte-in-cancer-patients--/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2014/08/trials-show-androxal-superior-in-secondary-hypogonadism---repros-therapeutics/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/09/lixilan--insulin-glargine-plus-lixisenatide--success-in-phase-iiilixilan-o-study-for--type-2-diabetes--sanofi/2024-02-09T16:01:12+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-accepts-bla-for-emicizumab-prophylaxis--preventative--as-a-once-weekly-subcutaneous-treatment-for-adults--adolescents-and-children-with-hemophilia-a-with-factor-viii-inhibitors---genentech-roche/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-daurismo-for-the-treatment-of-newly-diagnosed-aml-in-patients-who-are-75-years-or-older-or-who-have-comorbidities---pfizer-/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2018/01/dova-pharma-to-file-nda-at-fda-in-second-half-of-2018-for--avatrombopag-to-treat-immune-thrombocytopenic-purpura--/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-brukinsa-to-treat-mantle-cell-lymphoma--beigene/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-advisory-panel-does-not-recommend-metal-on-metal-hip-replacement-implants/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2014/03/patients-enrolled-in-a-phase-iii-trial-for-aneamia-treatment-in-ckd-patient-that-could-lead-to-the-removal-of-the-need-for-multiple-injections---astellas-pharma-europe-ltd--/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2014/08/palbociclib-is-filed-at-fda-for-treatment-of-her2-advanced-breast-cancer-with-letrozole---pfizer/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-approves-inlyta--pfizer--for-renal-cell-carcinoma/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2019/06/pfizer-to-acquire-array-biopharma-inc--and-with-it-braftovi-and-mektovi-/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2017/02/nice-rejects-venclexta--venetoclax--as-a-treatment-for-chronic-lymphocytic-leukemia---abbvie---roche/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2018/07/keytruda-filed-and-granted-priority-review-with-fda-for-liver-cancer---merck-inc-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2012/02/c-early-phase-iii-study-of-cimzia--ucb--begins-for-rheumatoid-arthritis-patients/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-invokana-for-type-2-diabetes/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-convert-study-showed-that-the-addition-of-alis--amikacin-liposome-inhalation-suspension--to-guideline-based-therapy-eliminated-evidence-of-nontuberculous-mycobacterial-lung-disease-caused-by-mycobacterium-avium-complex---ismed-/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2016/12/nice-now-recommends-nucala--mepolizumab-as-a-treatment-for-severe-asthma--gsk/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2017/11/european-commission-approves-zubsolv-to-treat-opioid-dependence---orexo-ab---mundipharma-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2015/05/initial-results-of-liletta-in-access-ius-study-published-in-contraception--actavis/2024-02-09T16:01:38+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-data-for-qudexy-xr-for-epilepsy--upsher-smith-labs/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-nubeqa-in-non-metastatic-castration-resistant-prostate-cancer---orion-corporation-and-bayer/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2018/02/viiv--starts-phase-iii-tango-study--switching-patients-from-triple-therapy-to-combination-tivicay-and-epivir-as-a-treatmant-for-hiv-1-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-510-k--clearance-of-the-exalt-model-d-single-use-duodenoscope-for-use-in-endoscopic-retrograde-cholangiopancreatography--ercp--procedures--_-boston-scientific/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-approves-somakit-toc-for-diagnostic-imaging--advanced-accelerator-applications/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2015/07/heron-therapeutics-re-submits-nda-to-fda-for-sustol--granisetron--injection--extended-release--to-treat-cinv-/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2012/04/chmp-recommends-forxiga---astrazeneca-bms--for-type-2-diabetes/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2019/07/interim-data-from-an-ongoing-investigator-sponsored-clinical-trial-led-by-baylor-college-of-medicine-evaluating--multitaa-t-cell-therapy-in-patients-with-pancreatic-adenocarcinoma---marker-therapeutics/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2017/07/complete-response-letter-for-dextenza--dexamethasone-insert--0-4mg-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery---ocular-therapeutix--inc/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2014/01/abt-888-enters-phase-iii-trial-for-breast-cancer-abbvie/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2016/10/ce-mark-awarded-for-papilloplex-hr-hpv-diagnostic-for-cervical-cancer--gene-first-ltd/2021-09-24T07:10:31+00:00weekly0.6https://www.medthority.com/news/2019/02/rescue-phase-iii-trial-of-gs-010-failed-to-meet-primary-endpoint-in-leber-hereditary-optic-neuropathy---gensight-biologics/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-xermelo--telotristat-ethyl--for-carcinoid-syndrome-diarrhea---lexicon-pharmaceuticals/2024-10-07T10:41:33+00:00weekly0.6https://www.medthority.com/news/2015/09/two-phase-iii-trials-of-xeljanz--tofacitinib--meet-endpoints-in-ulcerative-colitis--pfizer/2024-02-09T16:01:58+00:00weekly0.6https://www.medthority.com/news/2014/12/-us-district-court-invalidates-four-patents-for-cubicin---cubist-pharma/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-clarion-trial-of-kyprolis--carfilzomib---melphalan-and-prednisone-fails-to-meet-endpoint-in-multiple-myeloma--amgen-/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-bavencio---axitinib-for-first-line-treatment-of-renal-cell-carcinoma--merck-kgaa---pfizer/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2014/05/results-of-esbriet-for-pulmonary-fibrosis-published-in-nejm---intermune/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2012/08/trial-of-symphony-tcgm-glucose-monitoring-in-critical-care/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-annexa-a-study-of-andexanet-alfa-antidote-for-eliquis--apixaban--achieved-endpoints--portola-pharmaceuticals/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/11/anifrolumab-demonstrated-superiority-across-multiple-efficacy-endpoints-in-patients-with-systemic-lupus-erythematosus-in-phase-iii-tulip-2-trial----astrazeneca/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2014/07/isavuconazole-filed-with-eu-for-fungal-infections-basilea-pharma/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2015/07/cobas-egfr-mutation-test-v2-companion-diagnostic-for-nsclc-filed-with-fda--roche-/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-to-review-xgeva-amgen--potential-to-delay-bone-metastases-in-non-metastatic-prostate-cancer/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2012/12/two-phase-iii-trials-show-benefits-of-tasigna--novartis--for-patients-with-ph--cml-/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-victoria-study-with-vericiguat-in-patients-with-worsening-chronic-heart-failure-meets-primary-endpoint---bayer---merck-inc-/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-sonablate-450-high-intensity-focused-ultrasound-for-prostate-cancer--sonacare-medical/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2016/03/latest-updates-to-the-chronic-spontaneous-urticaria-knowledge-centre/2021-11-26T09:30:10+00:00weekly0.6https://www.medthority.com/news/2016/09/in-phase-iii-study--vertis-sita2---ertugliflozin-meets-endpoints-in-treatment-of-type-2-diabetes----merck-inc-----pfizer-inc--/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2016/04/eu-approves-use-of-revolade--eltrombopag--in-paediatric-patients-for-treatment-of-chronic-immune--idiopathic--thrombocytopenic-purpura----novartis/2021-09-24T07:10:46+00:00weekly0.6https://www.medthority.com/news/2013/12/eu-approves-brintellix-for-major-depressive-disorder-lundbeck/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2016/12/durvalumab-is-filed--bla--at-fda-to-treat-metastatic-urothelial-carcinoma----astrazeneca/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-top-line-results-from--a-phase-iii-trial-of-lumateperone-in-patients-with-bipolar-depression---intra-cellular-therapies/2021-09-24T07:18:20+00:00weekly0.6https://www.medthority.com/news/2013/12/biocryst-files-peramivir-at-fda-for-influenza-/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2020/02/positive-top-line-results-from--pivotal-phase-iii-trial-of-fintepla--to-treat-lennox-gastaut-syndrome---zogenix/2021-09-24T07:12:08+00:00weekly0.6https://www.medthority.com/news/2018/05/complete-response-letter-for-bla-for--biosimilar-rituximab---sandoz-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2019/11/european-commission-approves-remsima-sc-to-treat-rheumatoid-arthritis---celltrion/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2017/12/researchers-discover-resistance-mechanism-to-checkpoint-inhibitors-and-how-to-reverse-it/2021-09-24T07:13:40+00:00weekly0.6https://www.medthority.com/news/2019/12/lonafarnib-filed-with-fda-for-rolling-review-in-progeria---eiger-biopharma/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-panorama-trial-of-eylea-confirms-benefits-in-diabetic-retinopathy---regeneron-pharma/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-vyleesi-to-treat-acquired--generalized-hypoactive-sexual-desire-disorder--hsdd--in-premenopausal-women---amag-pharma/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-elocta--rfviiifc-for-treatment-of-haemophilia-a--biogen---sobi/2024-02-09T16:02:11+00:00weekly0.6https://www.medthority.com/news/2016/01/astrazeneca-and-incyte-corporation-announce-collaboration-on-incb39110-in-non-small-cell-lung-cancer/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2019/11/complete-response-letter-from-fda-to-lipocine-inc---for-tlando-for-testosterone-replacement-therapy-/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-filing-of-opdivo---yervoy-combination-to-treat--first-line--metastatic-or-recurrent-nsclc-with-no-egfr-or-alk-genomic-tumor-aberrations---bms/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-accepts-re-filing-of-nda-for-macrilen--macimorelin--to-treat-growth-hormone-deficiency---aeterna-zentaris-inc-/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2019/02/opdivo---yervoy-success-in--checkmate-650-trial-for-prostate-cancer---bms/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2016/07/bristol-myers-squibb-and-psioxus-therapeutics-announce-collaboration-over-oncolytuc-adenovirus-therapy/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-accepts-sbla-for-bavencio---inlyta-combination-to-treat-renal-cell-carcinoma---pfizer---merck-kgaa-/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-gives-emergency-use-authorization-for-xmap-multiflex-zika-rna-assay-for-zika-virus-detection--luminex-corporation/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2017/03/nice-recommends-zinbryta--daclizumab-high-yield-process--to-treat-relapsing-remitting-multiple-sclerosis---abbvie---biogen-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2020/02/bms-withdraws-its-application-in-the-eu-for-opdivo---yervoy-combination--for-the-treatment-of-advanced-nsclc-/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-comittee-recommends-lorqess--arena-eisai-for--weight-loss/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2014/09/evolocumab-is-filed-at-ema-for-treatment-of-high-cholesterol-amgen/2021-09-24T07:07:52+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-supplemental-application-for-blincyto--blinatumomab--in-philadelphia-chromosome-positive--ph---relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia--amgen/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2017/06/orencia--abatacept-is-chmp-recommended-to-treat-active-psoriatic-arthritis--psa---bms-/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2017/11/data-shows-80--of-infants-with-lysosomal-acid-lipase-deficiency-treated-with-kanuma-survive-beyond-1-year-of-age---alexion-pharma-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2018/02/positive-results-for-semaglutide-versus-dulaglutide-from-sustain-7-trial-for-type-2-diabetes---novo-nordisk-/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-accepts-nda-for-talazoparib-for-patients-with-germline--inherited--brca-mutated--her2-negative-locally-advanced-or-metastatic-breast-cancer---pfizer-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2014/03/phase-iii-trial-of-l-glutamine-meets-endpoints-for-sickle-cell-disease---emmaus/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2014/11/data-from-phase-ii-and-iii-studies-confirms-positive-evolocumab-effect-in-lowering-ldl-c--amgen/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2017/11/csicon-2017/2024-02-19T10:59:12+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-lenvima--lenvatinib-mesylate--in-combination-with-everolimus-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma----eisai/2024-02-09T16:06:03+00:00weekly0.6https://www.medthority.com/news/2016/08/ferring-acquires-exclusive-rights--excluding-japan-to-si-6603--condoliase--from--seikagaku-for-the-treatment-of-radicular-leg-pain--e-g--sciatica--due-to-lumbar-disc-herniation--/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-grants-accelerated-approval-to-calquence--acp-196--to-treat-mantle-cell-lymphoma---astrazeneca/2021-09-24T07:14:48+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-ilumetri-to-treat-psoriasis---almirall/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-checkmate-227-study-of-opdivo---yervoy-meets-primary-endpoint-in-first-line-nsclc-in-patients-with-tumor-mutation-burden----bms-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2019/08/top-line-phase-iii-results-for-oral-jak-inhibitor-baricitinib--plus-topical-corticosteroids-in-patients-with-moderate-to-severe-atopic-dermatitis---eli-lilly/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2014/09/combination-regimen-including-tenofovir-alafenamide-for-hiv-aids-successful---gilead-sciences/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2012/04/study-shows-zostavax--merck-inc---safe-for-shingles/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2016/09/treponema-pallidium-assay-receives-fda-510-k--approval-for-syphilis-diagnostics--roche/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-accepts-nda-for-oral-remodulin--united-therapeutics--for-pah/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-issues-complete-response-letter-to-novo-nordisk-for-tresiba-and-ryzodec-/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2019/04/five-year-study-shows-srt-100-benefits-patients-with-non-melanoma-skin-cancer/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2018/05/delay-at-fda-for-inotersen-to-treat-hereditary-ttr-amyloidosis---akcea-therapeutics/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-idelvion--coagulation-factor-ix--recombinant--for-the-treatment-of-hemophilia-b--csl-behring/2021-09-24T07:10:26+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-keynote-407-trial-of-keytruda-in-metastatic-squamous-non-small-cell-lung-cancer-meets-secondary-endpoint-and-is-filed-with-fda---merck-inc-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2019/07/bms-provides-update-on-part-2-of-checkmate--227-trial-to-treat-first-line-non-squamous-non-small-cell-lung-cancer-regardless-of-pd-l1-status-/2021-09-24T07:18:05+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-topline-results-from-phase-iii-studies-of-avycaz--ceftazidime-avibactam--in-urinary-tract-infections--allergan/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2017/03/the-fda-accepts-for-review-three-new-drug-applications--ndas-for--ertugliflozin--as-monotherapy--in-combination-with-januvia--sitagliptin---and-with-metformin-to-treat-type-2-diabetes---merck-inc----pfizer/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2015/12/nejm-publishes-lyxumia--lixisenatide--results-of-cv-outcomes-trial-in-type-2-diabetes-patients-with-acs--sanofi/2024-02-09T16:06:36+00:00weekly0.6https://www.medthority.com/news/2019/01/significant-reduction-in-total-postsurgical-opioid-consumption-with-exparel-in-patients-with-cesarean-section---pacira-pharma/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-recarbrio-for-treatment-of-complicated-urinary-tract-infections-and--intra-abdominal-infectionsc-/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-grants-510-k--clearance--for-extended-storage-for-trima-accel--blood-collection-system--terumo-bct/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-recommends-esmya--ulipristal-acetate--to-treat-menstrual-bleeding-and-uterine-fibroids---gedeon-richter/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2018/10/two-phase-iii-studies-for--ubrogepant-for-the-acute-treatment-of-migraine-are-completed--allergan-plc/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2015/08/free-haemato-oncology-report-added-to-aikn-ifi-congresses-section/2021-11-26T09:50:46+00:00weekly0.6https://www.medthority.com/news/2016/04/astrazeneca-considers-bid-for-medivation-and-with-it-xtandi/2025-10-17T09:18:33+00:00weekly0.6https://www.medthority.com/news/2012/06/stereotactic-ablative-radiotherapy-effective-in-elderly-patients-with-nsclc/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-imbruvica---gazyva-combination-to-treat-untreated-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma---abbvie---janssen-biotech/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2014/04/chmp-recommends-mekinist-for-metastatic-melanoma---glaxo-smith-kline/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2013/01/dalbavancin--durata-therapeutics--reports-on-discover-1-trial-for-skin-infections/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2019/04/first-patient-enrolled-in-the-renew-phase-iii-clinical-trial--of-reproxalap-for-dry-eye-disease--aldeyra-therapeutics/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-tybost-a--booster--for-hiv-medicines/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-valtoco-for-frequent-seizure-activity-in-epilepsy---neurelis/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2019/06/Disease-remission-associated-with-80--reduction-in-risk-of-cadiovascular-outcomes-in-patients-with-rheumatoid-arthritis/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2013/03/nice-rejects-xalkori--pfizer--for-treatment-of-non-small-cell-lung-cancer/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-issues-refusal-to-file-letter-for-alks-5461-to-treat-major-depressive-disorder--alkermes-plc-/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2017/01/solosec--secnidazole-oral-granules--filed-with-fda-for-bacterial-vaginosis--symbiomix-/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-sbla-for-opdivo-updating-dosing-schedule----bms/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-triggerfish-diagnostic-device-for-monitoring-onset-of-glaucoma--sensimed-/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2015/09/results-from-one-year-study-of-absorb-dissolvable-heart-stent-in-coronary-artery-disease--abbott/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-trials-evaluating-rm-493-show-additional-benefits-in-pomc-and-lepr-deficiency-obesity---rhythm-pharma/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2018/09/analysis-of-three-studies-of-zulresso--brexanolone-injection--in-postpartum-depression-published-in-the-lancet---sage-therapeutics-/2024-10-21T14:53:36+00:00weekly0.6https://www.medthority.com/news/2018/03/who-launches-health-review-after-microplastics-found-in-90--of-bottled-water/2021-09-24T07:06:25+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-phase-iii-flaura-study-of-tagrisso-as-1st-line-therapy-in-patients-with-locally-advanced-or-metastatic-epidermal-growth-factor-receptor-mutation-positive-nsclc---astrazeneca-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2014/12/vimizim-approved-in-japan-for-morquio-a-syndrome-biomarin-pharma/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2011/10/temso-study-for-aubagio-in-multiple-sclerosis-is-published-in-nejm/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2018/12/bausch-health-companies-inc---acquires-asets-of-synergy-pharma-including-trulance-to-treat-chronic-idiopathic-constipation-and-ibs-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/02/kalytera-therapeutics-acquires-talent-biotechs-and-its-programme-for-cannabidiol--pharmaceuticals-/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-study-shows-cialis--eli-lilly--plus-finasteride-provides-benefits-for-benign-prostatic-hyperplasia-/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2017/11/the-phase-iii-impower150-study-showed-that-tecentriq---avastin-reduced-the-risk-of-disease-worsening-for-first-line-nsclc-patients---roche-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-erbitux-eli-lilly-bms-for-first-line-combination-treatment-of-kras-wild-type-egfr-expressing-metastatic-colorectal-cancer-/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2016/03/ema-advice-on-use-of-zydelig--idelalisib--to-include--an-antibiotic---gilead-sciences/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-qvar-redihaler--beclomethasone-dipropionate-hfa--inhalation-aerosol-to-treat-asthma--teva-pharma/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2019/09/three-year-analysis-of-efficacy-data-from-the-phase-iii-checkmate--238-study-evaluating-adjuvant-use-of-opdivo-versus-yervoy-in-patients-with-stage-iii-or-stage-iv-melanoma---bms/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2019/05/novartis-acquires-xiidra--a-treatment-for-dry-eye-disease-from-takeda-/2021-09-24T07:17:39+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-xembify--a-20--subcutaneous-immunoglobulin-to-treat-primary-immunodeficiencies---grifols/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2019/12/darzalex---chemotherapy-in-phase-iii-alcyone-study-shows-overall-survival-benefit-in-patients-with-newly-diagnosed-multiple-myeloma--ineligible-for-transplant--janssen-/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-paloma-3-trial-of-ibrance----fulvestrant-misses-statistical-significance-in-overall-survival-in-metastatic-breast-cancer---pfizer-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2013/08/phase-ii-study-of-mm-398-in-pancreatic-cancer-published/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-extends-approval-of-gammaplex--immune-globulin-intravenous--to-pediatric-patients-with-primary-immunodeficiency--bio-products-lab/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2011/11/-chmp-recommends-extension-of-erbitux--merck-serono--indication-in-colorectal-cancer/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2016/04/study-of-cardiomems-hf-system-shows-benefits-in-heart-failure--st--jude-medical/2021-09-24T07:10:48+00:00weekly0.6https://www.medthority.com/news/2016/02/sandoz-acquires-european-rights-to-pf-06438179--infliximab-biosimilar--frompfizer/2024-02-09T16:06:50+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-expansion-of-indication-for-mitraclip-device-in-mitral-valve-repair---abbott/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2019/02/uvadex-sterile-solution-and-therakos-cellex-photopheresis-system-interim-phase-iii-results-for-graft-versus-host-disease-----mallinckrodt/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-nesina-oseni-and-kazano--takeda--treatments-for-type-2-diabetes/2021-09-24T07:15:49+00:00weekly0.6https://www.medthority.com/news/2017/11/eu-approves-subcutaneous-form-of-benlysta-for-systemic-lupus-erythematosus---glaxosnithkline-/2021-09-24T07:14:41+00:00weekly0.6https://www.medthority.com/news/2013/09/drisapersen-fails-phase-iii-for-duchenne/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-polo-trial-of-lynparza-in-pancreatic-cancer-published-in-nejm---astrazeneca---merck-inc/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-refuses-to-approve-lipid-lowering-combination-of-atorvastatin-and-ezetimibe--merck-/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approve-picosure--cynosure--pulsed-laser-system-for-treating-benign-pigmented-lesions/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2016/05/trv-027-fails-phase-iib-blast-ahf-study-in-acute-heart-failure---trevena/2024-02-09T16:08:06+00:00weekly0.6https://www.medthority.com/news/2017/02/ariad-pharma-files-maa-with-ema-for-brigatinib--an-investigational-oral-anaplastic-lymphoma-kinase--alk--inhibitor--to-treat--alk---non-small-cell-lung-cancer--nsclc--/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2013/05/sar-302503--sanofi--successs-in-jakarta-study-of-myelofibrosis/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2017/11/nice-does-not-recommend-stivarga-as-a-treatment-for-liver-cancer---bayer-healthcare-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2019/03/pfizer-acquires-option-to-buy-vivet-therapeutics-to-develop-gene-therapy-for-inherited-liver-disorders-/2021-09-24T07:18:48+00:00weekly0.6https://www.medthority.com/news/2017/06/new-data-from-sharesource-remote-patient-management-technology-to-improve-peritoneal-dialysis-is-presented-by-baxter-international-at-congress-of-the-european-renal-association-and-european-dialysis-and-transplant-association-/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2014/01/bosulif-enters-phase-iii-for-chronic-phase-philadelphia-chromosome-positive--ph---chronic-myelogenous-leukemia--cml-/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2011/11/lyxumia--sanofi-aventis--is-filed-at-ema-for-type-2-diabetes/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2019/08/esc-2019---learn-more/2024-02-19T11:00:04+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-xience-prime-everolimus-coronary-stent/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2019/05/post-hoc-analysis-of-griphon-study-for-uptravi/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2013/03/-fda-advisory-committee-recommends-mitraclip--abbott-vascular-to-treat-mitral-regurgitation/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2012/08/-fda-advisory-panel-recommends-humira--abbott-labs--for-treatment-of-ulcerative-colitis/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2013/02/positive-topline-results-from-study-of-vxm01--vaximm--for-pancreatic-cancer/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-ii-trial-of-rpc-1063--ozanimod--demonstrates-efficacy-and-safety-in-ulcerative-colitis--celgene-corporation/2024-02-09T16:08:18+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-of-mayzent-in-secondary-progressive-multiple-sclerosis---novartis/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2018/07/study-of-sonablate-high-intensity-focused-ultrasound-shows-equivalence-to-surgery-in-prostate-cancer---sonacare-medical-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-perseris--once-monthly--treatment-of-schizophrenia----indivior-plc-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2014/06/retrospective-study-shows-benefits-of-lantus-vs-detemir-in-t2d---sanofi/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-expands-approval-of-kalydeco--ivacaftor--to-include-nine-gating-mutations-in-the-cystic-fibrosis---cftr--gene--g551d--g1244e--g1349d--g178r--g551s--s1251n--s1255p--s549n-and-s549r---vertex-pharmaceuticals/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-xstat-30-wound-dressing-from-revmedx/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2015/06/us-district-court-rejects-otsuka-submission-to-prevent-generic-competition-for-abilify--aripiprazole----otsuka/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2017/07/canalia-combination-tablets--a-type-2-diabetes-mellitus-treatment-agent-is-approved-in-japan-for--daiichi-sankyo-and-mitsubishi-tanabe-/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2019/04/new-positice-phase-iii-data-from-optic-study-of-teprotumumab-for-the-treatment-of-active-thyroid-eye-disease---horizon-pharma/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2018/01/novo-nordisk-proposes-acquisition-of-ablynx-for-approximately-euros-2-6-billion-which-is-rejected-by-board-of-ablynx/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2019/01/nice-recommends-bravtovi---mektovi-combination-in-melanoma---pierre-fabre---array-biopharma/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-confirm-study-of-variquel-meets-primary-endpoint-in-hepatorenal-syndrome-type-1---mallinckrodt/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-ii-equator-trial-of-filgotinib-to-treat-psoriatic-arthritis-is-published-in-the-lancet---gilead---galapagos-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-novoseven-for-glanzmann-s-thrombasthenia-novo-nordisk/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2015/06/medtronic-acquires-cardioinsight-technologies-and-with-it-ecvue-system-of-cardiac-mapping/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2019/06/european-commission-has-approved-sixmo-for-treatment-of-opioid-dependence/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2011/12/btg-licence-of-rights-to-voraxaze-for-methotrexate-toxicity/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approve-a-labelling-update-for-reyataz--bms--for-hiv-infected-pregnant-women/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2015/07/kyprolis--carfilzomib--filed-with-fda-for-expanded-indication-in-multiple-myeloma--amgen/2024-02-09T16:08:31+00:00weekly0.6https://www.medthority.com/news/2018/05/results-from-spyral-htn-on-med-study-of-symplicity-spyral-rdn-shows-blood-pressure-reductions-in-uncontrolled-hypertension---medtronic-/2024-07-26T10:41:22+00:00weekly0.6https://www.medthority.com/news/2011/11/acz-885-success-in-systemic-juvenile-idiopathic-arthritis/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2012/05/lu-aa-21004-successful-phase-iii-trials-in-depression/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-two-phase-iii-studies-of-tradjenta--boehringer-eli-lilly--in-type-2-diabetes-patients/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2018/05/long-term-study-of-nucala-shows-reduced-exacerbations-in-eosinophilic-asthma---glaxosmithkline-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-dsuvia-for-acute-pain---acelrx-pharmaceuticals-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2013/11/zerenex--keryx-biopharma--success-in-phase-ii-trial-for-ndd-ckd/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-trial-data-support-current-standard-12-month-adjuvant-trastuzumab-for-her2-positive-breast-cancer/2021-11-30T13:44:06+00:00weekly0.6https://www.medthority.com/news/2010/08/hemlibra-results-from-haven-3-trial-for-haemophilia-a-prophylaxis-in-patients-without-factor-viii-inhibitors-was-published-in-nejm---genentech-roche-/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2019/04/oncology-venture-a-s-acquires-option-from-r-pharm-to-the-european-rights-for-ixempra-to-treat-breast-cancer-/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2015/12/abp-501--adalimumab-biosimilar--filed-in-eu-for-moderate-to-severe-plaque-psoriasis-and-moderate-to-severe-rheumatoid-arthritis--amgen/2024-02-09T16:08:46+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-data-on-lixiana-for-vte-published-in-nejm/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2018/01/ani-pharmaceuticals-acquires-us-rights-to-atacand--atacand-hct--arimidex-and-casodex-from-astrazeneca-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-gives-510-k--approval-for-adexusdx-hcg-test-for-pregnancy-nowdiagnostics/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---chronic-kidney-disease--ckd--a-challenge-for-european-healthcare-systems-1/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-approves-trulance-to-treat--irritable-bowel-syndrome-with-constipation---synergy-pharma-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2017/04/phase-iv-ms-mrius-study-shows-effectiveness-of-gilenya--fingolimod--in-four-key-measures-of-ms-disease-activity---novartis/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2015/09/marizev--omarigliptin--approved-in-japan-for-type-2-diabetes--merck/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-veyvondi-to-treat-von-willebrand-disease---shire-/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-tecentriq--atezolizumab--to-treat-nsclc-with-egfr-or-alk-gene-abnormalities----genentech---roche/2024-07-26T10:41:06+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-trial-of-eravacycline-in-complicated-urinary-tract-infections-fails-to-hit-efficacy-endpoints---tetraphase-pharma-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2018/10/full-data-from--liberty-study-of-aimovig-in-episodic-migraine-patients--novartis/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2012/08/vacc-4x--bionor-pharma--in-phase-iii-trial-with-revlimid-celgene-for-hiv-treatment/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-trial-of-zp-4207--dasiglucagon--for-treatment-of-severe-hypoglycemia-in-type-1-diabetes-meets-primary-endpoint---zealand-pharma-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-gives-final-approval-for-pemfexy-in-non-small-cell-lung-cancer--and-pleural-mesothelioma---eagle-pharma/2021-09-24T07:12:02+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-grants-isis-ttrrx--isis-pharmaceuticals--fast-track-designation-for-treating-familial-amyloid-polyneuropathy/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2015/09/allergan-launches-fda-approved-generic-version-of-invega--paliperidone-extended-release--for-treatment-of-schizophrenia/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2018/08/topline-results-for-phase-iii-bempedoic-acid---ezetimibe-combination-pill-study--1002-053--/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-trial-of-troriluzole-fails-to-meet-endpoint-in--generalized-anxiety-disorder---biohaven-pharma/2021-09-24T07:12:08+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-sapien-xt-transcatheter-heart-valve-for-pulmonic-valve-replacement-procedures--edwards-lifesciences/2024-02-09T16:08:56+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-ii-iii-study-of-md-1003--biotin--shows-benefits-and-safety-in-multiple-sclerosis--medday/2024-02-09T16:09:10+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-approval-of-jinarc-in-adpkd-otsuka-pharmaceutical/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2017/04/-fda-advisory-committee-recommends-approval-of-immediate-release-oxycodone-formulation--roxybond---an-abuse-deterrent-oxycodone-tablet-to-treat-chronic-pain---inspirion-delivery-sciences/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2018/08/genetic-screening-before-embryo-transfer-fails-to-improve-the-chance-of-a-baby/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2017/10/eu-approves-lutathera--lutetium-177lu-oxodotreotide--for--gastroenteropancreatic-neuroendocrine-tumors---advanced-accelerator-applications-/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-approval-for-stellaris-elite--vision-enhancement-system-for-the-emulsification-and-removal-of-cataracts--anterior-and-posterior-segment-vitrectomy--bausch---lomb-valeant/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2019/03/emit-af-vte-study-of-lixiana-finds-low-bleeding-rates-in-patients-at-risk-of-stroke-and-vte---daiichi-sankyo/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2017/08/melinta-therapeutics-and-cempra-inc--to-merge-/2025-10-16T11:16:31+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-gemini-1---2-studies-of--a-two-drug-regimen--of-dolutegravir--and-lamivudine-show-non-inferiority-to-three-drug-regimen-in-treatment-na-ve-hiv-i-patients--gsk-/2024-02-09T16:09:43+00:00weekly0.6https://www.medthority.com/news/2014/11/amg-386-fails-in-phase-iii-trial-for-ovarian-cancer---amgen/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-data-from-phase-ii-iii-trial-of-nalbuphine-er-in-uremic-pruritus-trevi-therapeutics/2024-02-09T16:10:53+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-forward-study-of-mirvetuximab-soravtansine-did-not-meet-its-primary-endpoint-to-treat--fr-alfa--positive--platinum-resistant-ovarian-cancer---immunogen-inc-/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-byvalson--nebivolol---valsartan--as-a-treatment-for-hypertension---allergan/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2018/02/bmj-debates-assisted-dying/2024-02-19T14:52:11+00:00weekly0.6https://www.medthority.com/news/2012/12/chmp-rejects-fanaptum--vanda-pharma-for-treatment-of-schizophrenia/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2018/06/stanford-scientists-discover-biomarker-for-flu-susceptibility/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2011/09/chmp-recommends-triple-combination-rasitrio-for-hypertension/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-trial-of-procrit-for-anaemia-in-breast-cancer-fails-janssen-/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-will-review-procysbi--raptor-pharma--in-april-2013/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-accepts-filing-of-snda-to-provide-for-single-dose-dalvance--dalbavancin--for-absssi--skin-infections---allergan/2024-02-09T16:11:17+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends-extension-of-approval-of-lucentis-to-treatment-of--proliferative-diabetic-retinopathy---novartis/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2015/07/nice-recommends-lixiana--edoxaban--for-vte--daiichi-sankyo/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-recommends-approval-of-bi-1744-cl--boehringer--for-copd/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2015/10/clinical-data-confirms-earlier-results-for-mistent-ses-in-coronary-artery-disease--micell-technologies/2024-02-09T16:11:57+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-clinical-trial-with-fluarix-tetra-in-influenza-a-and-b-published-in-the-lancet-child---adolescent-health---glaxosmithkline-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-of-revlimid---rituxan-in-follicular-lymphoma---celgene-corp/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2016/03/eu-gives-ce-mark-approval-of-xpert-mrsa-nxg-for-detecting-mrsa-infections-cepheid/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2017/06/european-commission-approves-refixia-for-the-treatment-of-adolescents-and-adults-with-haemophilia-b---novonordisk/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-trial-of-gs-010--for-treatment-of-leber-hereditary-optic-neuropathy----gensight-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-generic-forms-of-abilify--aripiprazole--to-treat-schizophrenia-and-bipolar-disorder--otsuka-lundbeck/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-vyxeos-in-acute-myeloid-leukaemia-or-aml-with-myelodysplasia-related-changes---jazz-pharma-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2015/06/success-for-cimzia--certolizumab-pegol--with-c-early-study-in-ra--ucb-pharma/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2020/01/the-european-commission-approves-expanded-use-of-janssen-s-stelara---ustekinumab--for-the-treatment-of-paediatric-patients-with-moderate-to-severe-plaque-psoriasis/2025-02-03T14:52:02+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-chmp-recommends-extending-approval-of-edurant--rilpivirine--in-hiv-to-patients-aged-12-and-older--janssen-therapeutics/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2015/10/keynote-010-trial-of-keytruda--pembrolizumab--meets-primary-objective-in-nsclc-merck-inc/2024-02-06T15:55:58+00:00weekly0.6https://www.medthority.com/news/2014/03/nice-rejects-xofigo-for-prostate-cancer---bayer/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-defitelio--defibrotide-sodium--for-hepatic-veno-occlusive-disease--jazz-pharmaceuticals/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2012/05/phase-iii-trial-of-tas-102--taiho--for-colorectal-cancer-begins-in-june/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2015/09/swiss-approval-for-cotellic--cobimetinib----zelboraf--vemurafenib--to-treat-advanced-melanoma--roche/2024-02-09T16:12:08+00:00weekly0.6https://www.medthority.com/news/2019/05/option-trial-initiated-to-compare-watchman-flx-left-atrial-appendage-closure-platform-to-first-line-oral-anticoagulants--boston-scientific/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2016/12/aura3-trial-supports-tagrisso--osimertinib-as-the-new-standard-of-care-for-2nd-line-treatment-of-patients-with-epidermal-growth-factor-receptor--egfr--t790m-mutation-positive-locally-advanced-or-metastatic-nsclc---astrazeneca/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-does-not-accept-keytruda--pembrolizumab--as-a-cost-effective-treatment-for-urothelial--bladder--cancer---merck-inc-/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2012/06/fda-approves-myrbetriq--astellas--for-patients-with-overactive-bladder/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2013/05/taigen-biotechnology-files-nda-for-antibiotic-nemonoxacin-in-taiwan-and-china/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-recommends-adcetris--brentuximab-vedotin--as-a-treatment-for-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma--takeda-oncology-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2016/05/positive-results-from-scale-phase-iii-trials-for-saxenda--liraglutide--in-obesity--novo-nordisk/2024-02-09T16:12:20+00:00weekly0.6https://www.medthority.com/news/2019/09/chmp-recommends--rhokiinsa-for-the-reduction-of-elevated-intraocular-pressure-in--patients-with-primary-open-angle-glaucoma-or-ocular-hypertension---aerie-pharmaceuticals----p-/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2014/07/otezla-results-in-phase-iii-posture-study-for-ankylosing-spondylitis--celgene/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-iii-trial-of-bimatoprost-sr-shows-positive-data-in-glaucoma-or-ocular-hypertension---allergan-/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2015/10/trokendi-xr--topiramate-extended-release--snda-filed-with-fda-for-prophylaxis-of-migraine-headache--supernus-pharmaceuticals/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2013/12/draft-nice-guidance-recommends-firmagon-for-prostate-cancer-ferring-pharma-/2021-09-24T07:15:14+00:00weekly0.6https://www.medthority.com/news/2018/09/european-commission-approves-duzallo-to-treat-gout---grunenthal-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2016/03/cx-601--allogeneic-expanded-adipose-derived-stem-cells--filed-in-eu-for-complex-perianal-fistulas-in-adults-with-crohn-s-disease--tigenix-/2024-02-09T16:12:32+00:00weekly0.6https://www.medthority.com/news/2014/10/pfizer-to-discontinue-commercialisation-of-remoxy-for-pain-pfizer-pain-therapeutics/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-movantik-for-treatment-of-opioid-induced-constipation-in-patients-with-chronic-non-cancer-pain----astrazeneca-/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2015/07/edwards-life-sciences-buys-cardiaq-valve-technologies-to-advance-its-business-in-mitral-valve-replacement/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2017/09/pinnacle-4-phase-iii-trial-success-for-bevespi-aerosphere--glycopyrronium-and-formoterol-fumarate--to-treat-moderate-to-very-severe-copd---astrazeneca-/2021-09-24T07:13:48+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-grants-tentative-approval-for-bryhali-lotion-for-the-topical-treatment-of-psoriasis--ortho-dermatolpgics/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2017/08/luxturna--voretigene-neparvovec--is-filed-at-ema--one-time-gene-therapy-for-the-treatment-vision-loss-due-to-leber-congenital-amaurosis-or-retinitis-pigmentosa-caused-by-confirmed-biallelic-rpe65-mutations----spark-therapeutics-/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2015/12/viberzi--eluxadoline--treatment-for-irritable-bowel-syndrome-with-diarrhea-is-now-launched-in-the-us--allergan/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-duopa--carbidopa---levodopa-suspension--for-advanced-parkinsons-disease-abbvie/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2019/11/alkermes-submits-nda-to-fda-for-alks-3831-for-the-treatment-of-schizophrenia-and-bipolar-i-disorder-/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-advisory-committee-recommends-praluent--alirocumab--for-treatment-of-hypercholesterolemia--sanofi---regeneron/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2016/10/uk-nice-recommends-tagrisso--osimertinib--for-use-in-advanced-or-metastatic-egfr-t790m-mutation-positive-non-small-cell-lung-cancer--astrazeneca/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2019/05/braftovi-triplet-combination-success-in-beacon-crc-trial-in-patients-with-brafv600e-mutant-metastatic-colorectal-cancer/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2014/02/positive-phase-iii-results-in-irritable-bowel-syndrome-for-eluxadoline--furiex-pharma/2021-09-24T07:08:20+00:00weekly0.6https://www.medthority.com/news/2015/10/allergan-acquires-rights-to-almirall-drug-linaclotide/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2013/05/chmp-recommends-erivedge--roche--for-treatment-of-basal-cell-carcinoma/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2015/10/int-747--obeticholic-acid--fails-to-achieve-goals-in-japanese-study-for-non-alcoholic-steatohepatitis--nash---intercept-pharma---sumitomo/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2012/02/brivanib--bms--fails-in-phase-iii-colorectal-cancer-trial/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2014/07/daklinza---sunvepra-combination-approved-in-japan-for-hepatitis-c---bms/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2016/04/results-of-phase-iii-tailor-study-shows-erbitux--cetuximab--plus-folfox-chemotherapy-met-primary-endpoint-in-colorectal-cancer--merck/2024-02-09T16:12:51+00:00weekly0.6https://www.medthority.com/news/2018/05/artificial-pancreas-is-a-safe-and-effective-treatment-for-type-1-diabetes-1/2024-02-09T16:16:10+00:00weekly0.6https://www.medthority.com/news/2019/08/positive-results-for-emgality-from-the-conquer-study-in-patients-who-failed-previous-migraine-preventive-treatments/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-draft-guidance-supports-use-of-cosentyx--secukinumab--in-severe-plaque-psoriasis--novartis/2021-09-24T07:03:38+00:00weekly0.6https://www.medthority.com/news/2017/07/-eliminate-hepatitis-by-2030----the-campaign-for-world-hepatitis-day-/2024-07-26T10:50:14+00:00weekly0.6https://www.medthority.com/news/2015/10/vitalbeam-radiotherapy-platform-receives-fda-510-k--and-eu-ce-mark-approval--varian-/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2017/04/european-commission-grants-full-approval-for-tagrisso--osimertinib---for-the-treatment-of-patients-with-locally-advanced-or-metastatic-epidermal-growth-factor-receptor--egfr--t790m-mutation-positive-non-small-cell-lung-cancer--nsclc----astrazeneca/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-impact-study-of-trelegy-ellipta--fluticasone-furoate-umeclidinium-vilanterol--meets-primary-endpoint-in-chronic-obstructive-pulmonary-disease---glaxosmithkline---innoviva-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-approves-subcutaneous--sc--formulation-of-mabthera--rituximab--for-untreated-and-relapsed-refractory-chronic-lymphocytic-leukaemia--roche-/2024-02-09T16:20:12+00:00weekly0.6https://www.medthority.com/news/2019/01/week-72-analyses-of-reverse-trial-of-gs-010-for-treatment-of-leber-s-hereditary-optic-neuropathy--gensight-biologics-/2024-10-21T14:47:03+00:00weekly0.6https://www.medthority.com/news/2011/09/ampio-pharma-and-zertane-for-premature-ejeculation/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-anturol--watson-pharma--for-overactive-bladder-treatment-----------------------------------------------------------------------------------------------------------------------------------------/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2019/04/edurant---gsk-1265744-filed-with-fda-for-hiv---viiv-healthcare---janssen/2021-09-24T07:16:42+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-issues-complete-response-letter-for-safinamide-as-a-treatment-forparkinson-s-disease--zambon---us-world-meds---newron-pharma/2021-09-24T07:10:50+00:00weekly0.6https://www.medthority.com/news/2013/04/select-study-of-daclizumab-high-yield--biogen--for-ms-published-in-the-lancet/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-biomonitor-2-insertable-cardiac-remote-monitor-to-treat-arrhythmias--biotronik/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-accepts-supplemental-application-to-expand-indication-of-cinryze-to-children-aged-6-years-and-older-with-hereditary-angioedema---shire-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2012/09/epi-743--edison-pharmaceuticals--granted-orphan-status-for-leigh-syndrome-in-eu---------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-palladium-data-on-new-inhaled-dual-combination-qmf-149-show-significant-improvement-across-key-asthma-outcomes-versus-monotherapy---novartis/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2013/11/minerva-study-of--medtronic-pacemakers-and-atrial-fibrillation/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2018/08/alnylam-pharmaceuticals--inc--has-achieved-full-patient-accrual-in-its-envision-phase-iii-study-of-givosiran--for-the-treatment-of-acute-hepatic-porphyrias-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2019/07/nonacog-beta-pegol--n9-gp--is-effective-and-well-tolerated-for-the-prevention-and-treatment-of-bleeding-in-children-with-haemophilia-b---novonordisk/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2017/12/allergan-to-acquire-repros-therapeutics-and-with-it-proellex--a-drug-in-development-for-treatment-of-uterine-fibroids-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2012/12/davunetide--allon-therapeutics--fails-trial-for-supranuclear-palsy/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2014/06/astra-zeneca-acquires-global-rights-to-sgn-001-for-respiratory-tract-viral-infections---synairgen-plc/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2013/12/baxter-files-ob-1-at-fda-for-haemophilia-a/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2016/06/astellas-uk-suspended-from-association-of-the-british-pharmaceutical-industry/2025-10-16T10:45:19+00:00weekly0.6https://www.medthority.com/news/2014/07/merck-inc--files-pembrolizumab-at-ema-for-advanced-melanoma-/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-label-update-for-abilify-maintena-for-schizophrenia-otsuka-lundbeck/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2018/01/topline-results-for-stride-1-and-stride-2-trials-of-kpi-121-for-dry-eye-disease---kala-pharmaceuticals-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-rizmoic-for-opioid-induced-constipation---shionogi-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2019/06/overall-survival-results-for-kisqali-in-combination-with-endocrine-therapy-in-phase-iii-monaleesa-7-trial-for--hr--her2---advanced-or-metastatic-breast-cancer----novartis/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2016/08/-apricus-biosciences---ferring-pharma-announce-approval-in-the-uk-for-vitaros--alprostadil-topical-cream--to-treat-erectile-dysfunction---/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-advisory-committee-rejects-zohydro-for-chronic-pain-treatment/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-results-with-ofev--nintedanib--shows-benefits-in-idiopathic-pulmonary-fibrosis--boehringer/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2012/09/first-clinical-study-using-lonafarnib--merck-inc---for-treatment-of-progeria---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2011/11/eliquis-versus-enoxaparin-in-adopt-study-for-vte-acutely-ill-patients/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-subcutaneous-actemra-for-patients-2-years-and-older-with-systemic-juvenile-idiopathic-arthritis--genentech-roche/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-results-from-phase-iii-trials-of-stiolto-respimat-inhaler--tiotropium-olodaterol-fixed-dose-combination--for-copd-boehringer/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2019/12/intra-cellular-therapies-highlights-lumateperone-presentations-at-the-58th-annual-meeting-of-the-american-college-of-neuropsychopharmacology-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2018/02/the-european-association-for-the-study-of-the-liver-easl-hepatitis-c-virus-hcv-conference-2018/2024-02-19T14:54:21+00:00weekly0.6https://www.medthority.com/news/2016/11/results-from-phase-iii-trials--ra-beam-and-ra-build-of-baricitinib-for-ra-presented-at-acr-meeting---eli-lilly---incyte-corporation/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-trial-of-taigexyn--nemonoxacin--meets-endpoint-in-community-acquired-pneumonia-infection--taigen-biotechnology/2024-02-09T16:20:23+00:00weekly0.6https://www.medthority.com/news/2018/05/success-for-tecentriq---chemotherapy---abraxane-in-impower130-study-for-treatment-of--non-squamous-nsclc---genentech-roche/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2014/10/chmp-recommends-rixubis-for-treatment-of-haemophilia-b--baxter/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-rejects-sanofi-s-caprelsa--vandetanib--and-ipsen-s-cometriq--cabozantinib--as-cost-effective-treatments-for-thyroid-cancer-/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2012/08/mixed-results-from-phase-iii-studies-of-ly-2062430--eli-lilly--in-alzheimer-s-disease-patients/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2014/05/endo-international-acquires-world-rights-to-sumavel-dose-pro-for-migraine-from-zogenix-inc-/2021-09-24T07:08:09+00:00weekly0.6https://www.medthority.com/news/2012/05/abilify-depot-otsuka--maintenance-of-schizophrenia-study-comfirmed/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2012/05/successful-phase-iii-study-for-signifor-for-acromegaly/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-gives-new-approval-for-invokamet--canagliflozin-metformin--in-type-2-diabetes--janssen/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2019/04/moderated-poster-presentation-of-i-v-meloxican-data-for-treatment-of-moderate-to-severe-pain---recro-pharma/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2015/04/otx-dp--sr-dexamethasone--meets-endpoint-in-second-phase-iii-trial-for-ocular-inflammation-ocular-therapeutix/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2016/10/newly-published-phase-iii-data-on-lixiana--edoxaban--shows-efficacy-in-vte--daiichi-sankyo/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2018/08/transition-phase-iii--study-shows-entresto-can-be-initiated-early-and-safely-in-a-wide-range-of-heart-failure-patients-with-reduced-ejection-fraction---novartis-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-vemlidy--tenofovir-alafenamide----taf---a-treatment-for-chronic-hepatitis-b-virus-infection---gilead-sciences/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-ii-study-of-monarch-etns--neurosigma--shows-benefits-for-epilepsy/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-mountain-study-of-sage-217-fails-to-meet-endpoint-in-major-depressive-disorder---sage-therapeutics/2024-10-21T14:54:31+00:00weekly0.6https://www.medthority.com/news/2013/04/fda-approves-quartette--teva--for-contraception-/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-grants-tentative-approval-to-sypmazan-oral-film-to-treat--lennox-gastaut-syndrome-----aquestive-therapeutics--inc-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2012/01/stenting-with-emboshield-pro--abbott-vascular--for-carotid-arteryt-disease-becoming-safer-in-high-risk-patients/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2016/03/once-weekly-benefix-coagulation-factor-ix-for-prophylaxis-versus-on-demand-haemophilia-b-results-published-in-haemophilia---pfizer/2024-02-09T16:20:38+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-label-extension-for-qutenza--capsaicin-8--patch--for-diabetic-patients-with-peripheral-neuropathic-pain-astellas/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-tafinlar--dabrafenib--in-combination-with-mekinist--trametinib--to-treat-patients-with-metastatic-non-small-cell-lung-cancer--nsclc--whose-tumors-express-the-braf-v600e-mutation---novartis/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2013/11/merck-presents-mk-7243-phase-iii-grass-allergy-study-/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2015/11/sophiris-bio-announces-successful-phase-iii-results-for-prx-302-for-treatment-of-benign-prostatic-hyperplasia/2021-09-24T07:04:22+00:00weekly0.6https://www.medthority.com/news/2013/11/bi-201335-filed-with-ema-for-hepatitis-c--boehringer/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-arches-trial-of-xtandi-meets-primary-endpoint-in-prostate-cancer---astellas-pharma---pfizer-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2014/06/daclizumab-high-yield-process-superior-to-interferon-beta-1a-for-relapsing-remitting-ms----biogen-abbvie/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2013/07/ferinject--vifor-luitpold--reduces-need-for-esas-in-chronic-kidney-disease-patients-with-iron-deficiency/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-ibsrela-to-treat-irritable-bowel-syndrome-with-constipation----ardelyx-inc-/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-alur-study-shows-alecensa--alectinib--reduces-risk-of-death-in-anaplastic-lymphoma-kinase--alk--positive-advanced-non-small-cell-lung-cancer---roche-/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2011/12/why-women-with-breast-cancer-quit-aromatase-therapy/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-opdivo--nivolumab--for-classical-hodgkin-lymphoma--chl--after-autologous-stem-cell-transplant--asct---bms/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2012/12/orphan-europe-acquires-european-rights-to-graspa-for-all/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2012/03/ec-906-filed-by-astellas-foe-eu-approval-for--luts-associated-with-bph/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2017/12/chmp-recommends-burosumab-to-treat-x-linked-hypophosphatemia---ultragenyx---kyowa-hakko-kirin-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2014/05/novartis-and-roche-face-investigations-for-alleged-collusion-in-selling-lucentis-for-age-related-macular-degeneration/2025-10-16T11:17:27+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-rocklatan-in-glaucoma-or-ocular-hypertension---aerie-pharma/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-onpattro-for-hereditary-transthyretin-mediated-amyloidosis---alnylam-pharma-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2019/07/alkermes-to-expand--the-proposed-nda-for-alks-3831-to-include-bipolar-1-disorder-as-well-as-schizophrenia--/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2016/10/study-of-nucala--subcutaneous--mepolizumab--in-eosinophilic-asthma-published-in-journal-of-allergy-and-clinical-immunology--glaxosmithkline/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-onexton-gel-for-treatment-of-acne--valeant-pharma-intl-/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2016/02/label-update-for-rexulti--brexpiprazole--filed-with-fda-for-the-maintenance-treatment-of-adults-with-schizophrenia--lundbeck-and-otsuka/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2018/07/otsuka-acquires-visterra-and-its-hierotope-platform-targeting-iga-nephropathy-and-other-kidney-diseases--cancer--chronic-pain-and-infectious-diseases-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2015/07/gevokizumab-fails-phase-iii-trial-for-behcets-uveitis-xoma-servier/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2012/04/ib-1001--inspiration-biopharm--is-filed-at-fda-for-haemophilia-b/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2014/08/eisai-files-lenvatinib-at-fda-and-ema-for-treatment-of-thyroid-cancer/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2013/01/gi-dynamics-initiates-endo-trial-for-treatment-of-type-2-diabetes-and-obesity/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2020/01/tyvyt---alimta-----platinum-met-primary-endpoint-in-phase-iii-orient-11-study-as-first-line-therapy-in-nonsquamous-nsclc--eli-lilly---innovent-biologics/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-rejects-bi-10773-nda-for-type-2-diabetes---boehringer-lilly/2021-09-24T07:08:27+00:00weekly0.6https://www.medthority.com/news/2013/05/nice-recommends-forxiga--bms-astrazeneca--for-treatment-of-type-2-diabetes/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2019/07/chmp-positive-for-self-administration-option-for-fasenra--pen-to-treat-eosinophilic-asthma/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2013/02/nice-rejects-forxiga--bms-astrazeneca--as-a-treatment-for-type-2-diabetes/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2017/02/phase-iii-compass-trial-of-xarelto--rivaroxaban--for-the-prevention-of-major-adverse-cardiac-events-stopped-early--janssen/2021-09-24T07:13:17+00:00weekly0.6https://www.medthority.com/news/2013/11/positive-long-term-results-with-pradaxa--boehringer--in-af/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-evarrest--ethicon-biosurgery--for-problematic-bleeding-during-surgery/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2012/09/bayer-healthcare-submit-nda-for-bay-73-4506-as-treatment-for-gist/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2018/10/xospata-approved-in-japan-to-treat-aml---astellas/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2014/11/positive-results-for-vytorin-in-cardiovascular-risk-merck/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2019/09/plinabulin--shows-superior-quality-of-life-over-pegfilgrastim-in-a-head-to-head-comparison-trial-for-the-prevention-of-neutropenia---beyondspring-inc-/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approval-of-darzalex---bortezomib---thalidomide-and-dexamethasone-for--multiple-myeloma--patients-who-are-eligible-for-autologous-stem-cell-transplant--janssen-biotech/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2016/05/results-of-flame-trial-of-ultibro-breezhaler--indacaterol---glycopyrronium-bromide--in-chronic-obstructive-pulmonary-disease-published-in-new-england-journal-of-medicine--novartis/2024-02-09T16:21:05+00:00weekly0.6https://www.medthority.com/news/2018/06/breast-cancer-test--reduces-need-for-chemotherapy-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2016/09/three-year-data-on-valiant-captivia-thoracic-stent-graft-system-shows-safety-and-efficacy-in-type-b-aortic-dissection--medtronic/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2018/05/alpivab-approved-in-eu-for-uncomplicated-influenza-in-adults-and-children---biocryst-pharma-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2017/11/vyxeos-is-filed-at-eu--treat-adults-with-high-risk-acute-myeloid-leukemia-patients---jazz-pharmaceuticals-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2014/05/real-world-trial-of-dificid-for--em-clostridium-difficile--em--shows-less-infection-recurrence-and-cost-savings---astellas/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-basaglar--insulin-glargine-injection--for-type-1---2-diabetes--eli-lilly---boehringer/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2017/07/two-phase-iii-studies-show-efficacy-and-safety-of-exparel--bupivacaine-liposome-injectable-suspension--in-surgical-procedures--pacira-pharmaceuticals/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-cyltezo--adalimumab-biosimilar--to-treat-multiple-chronic-inflammatory-diseases-based-on-clinical-equivalence-to-humira--adalimumab---the-reference-product---boehringer-/2021-09-24T07:13:50+00:00weekly0.6https://www.medthority.com/news/2013/12/ly-2963016-filed-with-fda-for-type-1--2-diabetes---eli-lilly-boehringer/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2015/08/s-297995--naldemedine--meets-primary-endpoint-in-a-phase-iii-study-for-opioid-induced-constipation--shionogi--/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2017/05/radiance-trial-showed-a-reduction-of-annualised-relapse-rate-of-ms-for-ozanimod-compared-to-avonex-but--in-a-pooled-analysis-of-radiance-and-sunbeam-studies-ozanimod--did-not-reach-a-significant--disability-endpoint---celgene/2021-09-24T07:14:26+00:00weekly0.6https://www.medthority.com/news/2015/02/lcz-696-has-priority-review-at-fda-and-decision-in-august-2015---novartis/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2019/08/nice-recommends-xarelto--to-prevent-atherothrombotic-events-in-adult-patients-with-coronary-artery-disease-or-symptomatic-peripheral-arterial-disease/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2015/10/successful-phase-ii-trial--cosmic-hf--of-omecamtiv-mecarbil-in-patients-with-chronic-heart-failure--amgen-/2024-02-19T11:01:09+00:00weekly0.6https://www.medthority.com/news/2016/08/klas-rates-sigma-spectrum-infusion-system-leader-among-all-large-volume-infusion-pumps-in-drug-library-compliance---baxter/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2017/01/strongbridge-biopharma-acquires-us-rights-to-keveyis--dichlorphenamide--from-taro-pharma-to-treat-primary-periodic-paralysis-/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2015/12/shire-in-takeover-talks-with-baxalta/2021-09-24T07:04:29+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-cabometyx-for-the-expanded-indication-of-patients-with-advanced-renal-cell-carcinoma----exelixis-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2015/07/positive-data-from-study-of-sir-spheres-microspheres-in-colorectal-cancer-sirtex/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2014/11/spiriva-respimat-filed-with-fda-for-asthma-boehringer/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2016/01/almirall-acquires-thermigen-and-with-it-thermirf-and-thermi-250-aesthetic-devices/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2015/04/horizon-pharma-acquires-hyperion-therapeutics-for--1-1-billion-and-with-it-ravicti-and-buphenyl/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2013/05/xience-xpedition-48-everolimus-eluting-coronary-stent-from-abbott-vascular-has-ce-mark/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2015/03/successful-phase-ii-trial-for-rth-258-compared-to-aflibercept-for-age-related-macular-degeneration--alcon/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-issues-complete-response-letter-for--feraheme-for-extended--anaemia-indication--amag-pharma/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-on-qudexy-in-epilepsy-published-in-epilepsia-upsher-smith-labs/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2016/09/european-commission-approves-kisplyx--lenvatinib-mesylate--in-combination-with-everolimus-for-the-treatment-of-adult-patients-with-advanced-renal-cell-carcinoma---eisai-/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-the-ultrashape-system-for-lipoplasty---syneron-medical/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2015/09/expanded-label-application-for-aggrastat--tirofiban-hcl--filed-with-fda-for-st-segment-elevation-myocardial-infarction--medicure/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-three-times-a-week-copaxone-for-ms--teva/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2012/07/two-year-study-of-tradjenta--boehringer-eli-lilly--shows-reduced-adverse-effects-in-type-2-diabetes-patients/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2012/04/thrombogenics-resubmits-bla-for-ocriplasmin-with-the-fda/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-tafinlar---mekinist-for-adjuvant-treatment-of-adult-patients-with-stage-iii-melanoma-with-a-braf-v600-mutation--following-complete-resection--novartis-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2014/12/melphalan-captisol-filed-with-fda-for-multiple-myeloma-spectrum-pharma/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2013/11/surround-sound-renal-denervation-system--results-for-resistant-hypertension/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2013/01/european-commission-approves-amyvid--li-lilly--for-alzheimers-disease-investigations/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2018/08/results-of-camellia-timi-61-trial-of-belviq-showing-weight-loss-and-incidence-of-cv-events-was-presented-at-ecs-congress-and-published-in-nejm---eisai-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2013/02/study-of-pycnogenol--horpagh-research--shows-benefits-for-menopausal-women/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2017/12/new-phase-iii-data-for-zx-008-for-dravet-syndrome-shows-reduction-in-convulsive-seizures---zogenix-/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2019/11/cassiopea-announces-fda-acceptance-of-its-nda-for-clascoterone-cream-1---the-first-new-mechanism-of-action-for-acne-in-nearly-40-years-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2017/07/complete-response-letter-from-fda-for-evenity--romosozumab--as-a-treatment-for-postmenopausal-women-with-osteoporosis----amgen--ucb-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2012/12/tasimelteon---vanda-success-in-phase-iii-study-in-non-24-hour-disorder/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2019/05/additional-data-from-sophia-study-of-margetuximab--for-her2-positive-metastatic-breast-cancer/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-aptiom--sunovion--to-treat-epilepsy-/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2016/05/tecnis-symfony-iol-met-its-primary-endpoint-in-pivotal-trial-for-cataract--abbott/2021-09-24T07:09:33+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-secure-trial-on-cresemba--isavuconazonium-sulfate--in-invasive-aspergillosis-published-in-the-lancet--astellas/2024-02-19T11:01:57+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-removal-of-boxed-warning-regarding-serious-neuropsychiatric-events-for-chantix--varenicline--a-treatment-for-smoking-cessation---pfizer/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2019/11/studies-fx2014-04-and-fx2014-05-of-amzeeq-for-acne-published-in-journal-of-clinical-and-aesthetic-dermatology---foamix-pharma/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2013/08/long-term-study-finds-finasteride-safe/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2015/01/results-of-trial-of-lmtx-in-alzheimer-s-disease-published-taurx-therapeutics/2024-02-19T11:02:23+00:00weekly0.6https://www.medthority.com/news/2015/01/chmp-recommendations-for-kengrexal--cangrelor--orbactiv--oritavancin--and--raplixa--sealant--from-the-medicines-company/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-botox--onabotulinumtoxina--for-lower-limb-spasticity--allergan/2024-02-19T11:02:37+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-skyla--bayer-levonorgestrel-releasing-intrauterine-system-for-use-as-a-contraceptive-/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-trial-of-shp-621-meets-co-primary-endpoints-in-eosinophilic-esophagitis---takeda/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-grants-label-revision-for-simponi-aria--golimumab-for-infusion--in-rheumatoid-arthritis-janssen-biotech/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-recommends-approval-of-change-of-indication-for-yervoy-in-advanced--unresectable-or-metastatic--melanoma---bms-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2013/02/success-for-solitaire-fr--covidien--in-star-revasculization-study/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2013/10/eu-adds-new-approval-for-revolade-in-thrombocytopenia-/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2017/02/tivantinib-fails-to-meet-endpoint-in--metiv-hcc--phase-iii-trial-for-hepatocellular-carcinoma---arqule-inc----daiichi-sankyo/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2013/02/dalbavancin--durata-therapeutics--success-in-phase-iii-discover-2-trial-for-absssi/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-does-not-recommend-kisplyx--lenvatinib--from-eisa-and-fotivda--tivozanib--from-eusa-as-treatments-for-renal-cell-carcinoma-/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-extends-indication-for-urolift-system-a-treatment-for-benign-prostatic-hyperplasia---neotract-teleflex-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2011/12/eyebrain-tracker--eyebrain--used-in-parkinson-s-therapy-trial/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2018/06/results-of-phase-1-ii-northstar--hgb-204--study-and-ongoing--phase-iii-northstar-2--hgb-207-study-of-lentiglobin-gene-therapy--for-beta-thalassemia----bluebird-bio-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2017/07/latte-2-phase-iib-trial-of-injectable-cabotegravir-and-rilpivirine--as-a-two-drug-treatment-for-patients-with-hiv-1-infection-comparable-to-a-three-drug-oral-regimen--viiv-healthcare---janssen-therapeutics/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2016/03/amarin-pharma-and-fda-agree-settlement-permitting-off-label-promotion-of-vascepa---icosapent-ethyl-for-high--triglycerides-/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2019/08/eu-approves-tecentriq---abraxane-for-triple-negative-breast-cancer---genentech-roche/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2014/12/new-phase-iii-results-of-kyprolis-in-mm-amgen-onyx-pharma/2024-02-19T11:37:42+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-sonics-study-of-recorlev-for-cushing-s-syndrome-published-in-the-lancet-diabetes---endocrinology---strongbridge-biopharma/2024-10-21T14:44:57+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-memo-3d-rechord-for-mitral-valve-disease-sorin/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-change-in-marketing-authorisation-for--keytruda--pembrolizumab--in-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-give-510-k--approval-for-neuviz-64-ct-imaging-system--neusoft-medical-/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---button-batteries-can-rapidly-damage-stomach-lining-before-symptoms-appear/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2014/07/somatuline-autogel-submitted-to-ema-for-neuroendocrine-tumors-ipsen/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2012/07/ema-award-orphan-status-to-a-4250--albireo--for-the-treatment-of-primary-biliary-cirrhosis-/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2014/09/absorb-iv-trial-to-test-absorb-bioresorbable-vascular-scaffold-in-treatment-of-angina-abbott-vascular-/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2012/05/nucynta--j-j-janssen--provides-pain-management-for-patients-with-diabetic-peripheral-neuropathy/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2018/02/cosentyx-and-quality-of-life-for-psoriasis-patients---novartis-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2016/07/leo-pharma-to-market-brodalumab-in-europe-for-psoriasis-and-psoriatic-arthritis---valeant-pharma/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2012/03/sir-spheres-microspheres--sirtex--improves-survival-for-patients-with-inoperable-liver-tumours/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-data-in-trial-of-xarelto-to-reduce-stroke-risk-bayer-healthcare/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2012/01/glp-1r-agonists-lead-to-weight-loss-in-overweight-or-obese-patients-/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2016/10/keytruda--pembrolizumab--approved-by-fda-for-first-line-treatment-of-pd-l1-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2018/02/european-commission-approves-hemlibra-for-prophylaxis-of-bleeding-episodes-in-haemophilia-a--patients-with-factor-viii-inhibitors--roche-/2024-07-26T10:40:08+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-provides-complete-response-to-application-for-linhaliq-in-bronchiectasis---aradigm-corp-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-clonoseq-assay-for-all-and-multiple-myeloma---adaptive-biotechnologies-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-approves-bulkamid-device-for-the-treatment-of-stress-urinary-incontinence----contura/2021-09-24T07:12:02+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approves-ofev--nintedanib--to-treat-idiopathic-pulmonary-fibrosis-boehringer/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-gives-510-k--approval-for-scenergy-ct-ultrasound-fusion-and-image-guidance-system--clear-guide-medical/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2012/09/success-for-sng-001--synairgen--in-early-asthma-trial/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2019/12/positive-findings-from-real-world-use-of-yescarta-in-relapsed-or-refractory-large-b-cell-lymphoma--kite-pharma-gilead/2021-09-24T07:18:32+00:00weekly0.6https://www.medthority.com/news/2013/12/astrazeneca-buys-diabetes-business-from-bms/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-masters-hp--15mm-rotatable-mechanical-heart-valve-for-pediatric-heart-patients---abbott-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-cyclo-g6-laser-for-glaucoma-iridex-corp/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-credence-study-shows-invokana-cuts-cv-and-renal-risks-for-type-2-diabetes-patients---janssen-pharma/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-results-for-carillon-mitral-contour-system--cardiac-dimensions--for-heart-surgery/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2014/10/success-for-brincidofovir-in-phase-iii-trial-for-adenovirus-chimerix-inc-/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2012/05/study-shows-avandamet--glaxo-smith-kline--superior-to-metformin-alone-for-type-2-diabetes/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2012/07/chmp-recommends-adcetris---takeda--for-cd-30--hodgkin-lymphoma--/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2015/08/valeant-pharmaceuticals-acquires-sprout-pharmaceuticals-for--1-billion/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2015/08/pfizer-divests-assets-to-alvogen/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2012/04/nice-rejects-benlysta--gsk--for-sle-in-final-guidance/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-approves-adcetris---chemotherapy-to-treat-previously-untreated-stage-iii-or-iv-classical-hodgkin-lymphoma---seattle-genetics-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-gives-510-k--clearance-for--bd-phoenix-cpo-detect-test-to-identify-carbapenemase-producing-organisms--becton-dickinson/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-partosure-diagnostic-to-assess-risk-of-spontaneous-preterm-birth---qiagen-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-mekinist--glaxo-smith-kline--for-braf-v600e-k-metastatic-melanoma/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2018/03/study-suggests-possible-link-between-highly-processed-foods-and-cancer/2024-02-19T11:38:07+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-study-of-bmn-111-shows-positive-results-in-achondroplasia---biomarin-pharma/2021-09-24T07:18:29+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-grants-tentative-approval-to-xtampza-er--oxycodone-extended-release--to-treat-severe-pain--collegium-pharmaceutical/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2017/05/analyses-of-esbriet--pirfenidone--studies--ascend-and-capacity--in-idiopathic-pulmonary-fibrosis--ipf----roche--/2021-09-24T07:14:25+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-procysbi--raptor-pharmaceutical--for-nephropathic-cystinosis-/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2012/09/tc-5619--targacept--fails-phase-ii-trial-in-adhdi---------------/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2013/07/study-of-epoetin-alfa-in-breast-cancer-patients-published-in-journal-of-the-national-cancer-institute-/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-grants-510-k--approval-for-lineup-multi-extremity-weight-bearing-ct-system--curvebeam-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2013/05/four-year-follow-up-on-everest-ii-study-of-mitra-clip--abbott-/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2017/04/ritter-pharmaceuticals--inc-schedules-fda-meeting-to-plan-phase-iii-programme-for-rp-g28-for-the-treatment-of--lactose-intolerance-/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-for-four-week-dosing-schedule-of-opdivo-for-advanced-melanoma-and-renal-cell-carcinoma--bms-/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2015/09/dexcom-g5-continuous-glucose-monitor-receives-ce-mark--dexcom-inc-/2021-09-24T07:03:47+00:00weekly0.6https://www.medthority.com/news/2017/11/esgo-2017-starts-tomorrow-in-vienna/2024-02-19T11:38:36+00:00weekly0.6https://www.medthority.com/news/2011/10/hologic-presents-its-mammosite-ml-for-radiation-therapy/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2014/10/phase-iii-data-on-urocidin-in-bladder-cancer-published-bioniche-ls/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2018/11/b-20-study-of-oncotype-dx-breast-recurrence-score-test-shows-who-to-treat-for-breast-cancer---genomic-health-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends--strimvelis-gene-therapy-to-treat-ada-scid--severe-combined-immunodeficiency-due-to-adenosine-deaminase-deficiency---gsk/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-grants-accelerated-approval-for-opdivo--nivolumab--to-treat-locally-advanced-or-metastatic-urothelial-carcinoma----bms/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2013/06/transforms-study-of-gilenya--novartis--shows-sustained-improvements-in-patients-with-multiple-sclerosis/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2012/12/phase-ii-success-for-am-111--auris-medical--for-acute-sensorineural-hearing-loss/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2014/10/otezla-quality-of-life-data-for-psoriasis-patients-from-esteem--trials--celgene/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2012/10/positive-results-for-phase-iii-trial-of-bay-63-2521--bayer-healthcare--in-patients-with-cteph/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-results-for-sb5--adalimumab-biosimilar--demonstrate-equivalence-to-humira-in-rheumatoid-arthritis--samsung-bioepis/2021-09-24T07:04:24+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-tina-quant-hba1cdx-assay--roche--to-diagnose-diabetes/2021-09-24T07:16:21+00:00weekly0.6https://www.medthority.com/news/2013/12/update-on-dasision-trial-of-sprycel-for-ph-cp-cml--bms-otsuka/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2015/01/ce-mark-approval-for-lithoplasty-balloon-catheter-for-pad-shockwave-medical/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-trials-success-for-tofacitinib-in-plaque-psoriasis---pfizer/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2018/11/ce-mark-for--prismax-system-and-its-thermax-blood-warmer----baxter-international/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2012/04/mhra-recalls-mitch-trh-hip-replacements/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2015/03/phase-iii-trial-of-keytruda--pembrolizumab--meets-primary-endpoints-in-advanced-melanoma-and-stops-early-merck/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2013/02/new-data-shows-benefits-of-linx-reflux-system--torax-medical-inc--for-patients-with-gerd/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-invega-trinza--three-month-paliperidone-palmitate--to-treat-schizophrenia-janssen-pharma/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2014/05/shire-announced-planned-filing-at-fda-of-lifitegrast-for-dry-eye-disease-in-first-quarter-2015-/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-epoch-1-study-of-htx-011-in-bunionectomy-published-in-regional-anesthesia---pain-medicine/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-inform-her2-dual-ish-dna-probe-cocktail-assay--ventana-ms--as-breast-cancer-assay/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-drug-relief-neurostimulation-device-for-treating-symptoms-of-opioid-withdrawal---dyansys-inc-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2014/09/gilenya-data-links-brain-shrinkage-with-disability-risk-in-ms-patients--novartis/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-advisory-committee-to-review-drisapersen-for-the-treatment-of-patients-with-duchenne-muscular-dystrophy-amenable-to-exon-51-skipping--biomarin/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2015/10/ten-year-follow-up-of-freedom-study-of-prolia--denosumab--for-treatment-of-osteoporosis--amgen/2024-02-19T11:38:49+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-keveyis--dichlorphenamide--for-periodic-paralyses--taro-pharma/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-results-show-enstilar--calcipotriol-betamethasone--reduces-symptoms-of-itch-in-psoriasis-leo-pharma/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-imbrave150-study-of-tecentriq---avastin-meets-endpoints-in-liver-cancer---genentech-roche/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-pretomanid-for-drug-resistanttuberculosis---tb-alliance/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2016/01/post-hoc-analysis-of-mpact-trial-of-abraxane--paclitaxel-protein-bound-particles-for-injectable-suspension--albumin-bound--plus-gemcitabine-in-pancreatic-cancer--celgene/2024-02-19T11:39:01+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-grants-accelerated-approval-to-rubraca--rucaparib--for-ovarian-cancer--clovis-oncology/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2012/10/dulaglutide--eli-lilly--success-in-award-phase-iii-trials-for-type-2-diabetes/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-duo-study-data-of-copiktra-shows-effect-in-cll-sll---verastem/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2013/12/xiaflex-sbla-filed-with-fda-for-multiple-dupuytren-s-contracture-auxilium-pharma/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2019/01/theravance-biopharma---initiates-phase-iii-trial-of-td-9855-to-treat-symptomatic-neurogenic-orthostatic-hypotension-/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2018/06/european-commission-approves-prolia-for-the-treatment-of-bone-loss-associated-with-long-term-systemic-glucocorticoid-therapy-in-adult-patients-at-increased-risk-of-fracture---amgen-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2016/12/positive-data-from-gallium-study-presented-at-ash-for-obinutuzumab---chemotherapy-shows--improved-pfs-for-follicular-lymphoma---genentech---roche/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2012/04/first-three-phase-iii-studies-positive-for-qva-149--novartis-in-copd/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2017/06/ongoing-cvd-real-trial-of-farxiga--dapagliflozin--shows-no-new-safety-signals-in-type-2-diabetes--astrazeneca/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2017/08/world-breastfeeding-week-2017/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-symjepi--epinephrine-injection-pre-filled-single-dose-syringe--for-the-emergency-treatment-of-allergic-reactions--type-i--including-anaphylaxis--adamis-pharma/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2013/07/g-ba-finds-dificlir--astellas--provides-considerable-benefit-for-clostridium-infection/2024-10-21T14:48:32+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-agrees--form-of-cv-risk-trial-for-contrave/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-update-to-label-for-trintellix-in-depression---lundbeck-/2024-10-21T14:49:44+00:00weekly0.6https://www.medthority.com/news/2018/11/jazz-pharma-initiates-phase-iii-trial-of-jzp-258-to-treat-idiopathic-hypersomnia--/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2019/03/innovation-pharma-seeks-guidance-from-ema-for--brilacidin-oral-rinse-in-a-phase-iii-program-of-severe-oral-mucositis--/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2015/10/horizon-group-in-licenses-novel-kinase-inhibitors-from-servier/2021-09-24T07:03:19+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-neptune-trial-of-imfinzi-with-tremelimumab-for-stage-iv-nsclc-did-not-meet-the-primary-endpoint---astrazeneca/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-imfinzi-for-unresectable-stage-iii-non-small-cell-lung-cancer---astrazeneca---medimmune-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2019/06/chmp-recommends-approval-of-tecentriq---abraxane-in-triple-negative-breast-cancer/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-issues-complete-response-letter-to-invidior-for-its-naloxone-nasal-spray-to-treat-opioid-overdose-/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2019/11/scynexis-reports-positive-results-from-first-phase-iii--vanish-303--registration-study-of-oral-ibrexafungerp-in-vulvovaginal-candidiasis--/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-pivotal-study-of-pf-04965842-shows-efficacy-and-safety-in-atopic-dermatitis/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-study-of-tyverb-tykerb--glaxo-smith-kline--fails-to-meet-endpoint-for-gastric-cancer/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2012/06/semuloparin--sanofi--may-need-more-data-for-fda-approval-for-prophylaxis-of-vte/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trials-of-iglarlixi--insulin-glargine---lixisenatide--meet-primary-endpoints-in-type-2-diabetes--sanofi/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2015/09/hdm-slit--house-dust-mite-sublingual-allergy-immunotherapy-tablet--approved-in-the-eu-for-allergic-rhinitis-and-allergic-asthma--alk/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2013/09/mnk-795-success-in-phase-iii-study-for-acute-pain/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2017/08/fresenius-medical-to-acquire-nxstage-medical-inc---provider-of-home-stage-dialysis-devices/2021-09-24T07:14:55+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-data-on-cyramza-for-nsclc-published-in-the-lancet---eli-lilly/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2012/11/galns--biomarin--success-in-phase-iii-study-for-mps-iva/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/01/animas-vibe-insulin-pump-system-approved-by-fda-for-managing-diabetes-in-patients-2-17--animas-corporation/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-to-liso-cel-for-treatment-of-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma---bms/2021-09-24T07:12:03+00:00weekly0.6https://www.medthority.com/news/2016/08/ema-validates-application--maa--by-cempra-for-approval-of-solithromycin-for-the-treatment-of-community-acquired-bacterial-pneumonia--/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-halts-pediatric-trials-of-sensipar-amgen--for-hyperparathyroidism-/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-combination-of-letairis--ambrisentan--and-adcirca--tadalafil--in-pulmonary-arterial-hypertension--gilead-sciences/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2019/05/positive-interim-results-from-orion-3-study-of-inclisiran--twice-yearly-dosing-for-ldl-patients----the-medicines-company/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2019/01/eusa-pharma-acquires-world-rights-to-sylvant-to-treat-castleman-s-disease-/2024-10-21T14:46:30+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-accepts-supplemental-application-for-lucentis-to-treat-diabetic-retinopathy--genetech-roche/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2020/01/crysvita-submitted-to-fda-in-sbla-for-hypophosphatemia-associated-with-phosphaturic-mesenchymal-tumors---ultragenyx-pharmaceutical-and-kyowa-kirin/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-baqsimi-nasal-powder-3-mg--the-first-and-only-nasally-administered-glucagon-to-treat-severe-hypoglycemia-in-adults-and-children-with-diabetes/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2012/04/valeant-pharma-to-market-halaven-for-breast-cancer-in-eastern-europe/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-fulfil-study-of-triple-therapy--fluticasone-furoate-umeclidinium-vilanterol--meets-two-co-primary-endpoints-in-chronic-obstructive-pulmonary-disease--glaxosmithkline/2021-09-24T07:09:59+00:00weekly0.6https://www.medthority.com/news/2018/06/successful-phase-iii-optimismm-study--of-pomalyst---bortezomib---dexamethasone-for-multiple-myeloma---celgene-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2016/09/curemark-initiates-phase-iii-trial-to-evaluate-cm-at-as-a-treatment-for-children-with-autism-/2021-09-24T07:09:14+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-accepts-new-drug-application-from-pfizer-for-tafamidis-for-ttr-fap/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2015/10/positive-outcomes-from-phase-ii-trial-of-cirara--glibenclamide-for-injection--in-stroke-patients--remedy-pharmaceuticals/2024-02-19T11:39:15+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-trial-results-of-zydis-for-migraine-published-in-new-england-journal-of-medicine---biohaven-pharma/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-engage-af-timi-48-trial-shows-lixiana--edoxaban--provides-benefits-in-patients-with-different-stroke-risk--daiichi-sankyo-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-rejects-zykadia--ceritinib--to-treat-alk--metastatic-non-small-cell-lung-cancer--novartis/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-results-for-fycompa--perampanel--in-epilepsy-published-in-neurology--eisai/2024-02-19T12:13:28+00:00weekly0.6https://www.medthority.com/news/2011/10/merck-kgaa-returns-rights-to-safinamide-the-parkinsons-treatment-to-newron-pharma/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2015/05/bema-buprenorphine--belbuca--decreases-pain-scores-in-two-phase-iii-studies-in-patients-with-chronic-lower-back-pain--endo---biodelivery-sciences/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2018/08/enrollment-completed-in-phase-iii-trial-of-somatrogon-to-treat-growth-hormone-deficient-children---opko-health-inc-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2015/11/bms-acquires-cardioxyl-and-with-it-cxl-1427-treatment-for-heart-failure/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2014/07/three-studies-of-nepa-for-nausea-published-in-annals-of-oncology-eisai/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2012/06/idx-184--idenix--in-phase-ii-for-hepatitis-c/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-tagrisso--azd-9291--osimertinib--to-treat-egfr-t790m-mutation-positive-nsclc--astrazeneca/2024-02-19T12:20:01+00:00weekly0.6https://www.medthority.com/news/2017/01/maestro-study-of-opsumit--macitentan--in-patients-with-pulmonary-arterial-hypertension-fails-to-meet-primary-objective--actelion/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2019/01/allena-pharmaceuticals-agrees--with-fda-on-phase-iii-program-and-approval-pathway-of-reloxaliase-for-enteric-hyperoxaluria-/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2015/02/actavis-files-snda-with-fda-for-teflaro-in-absssi-actavis/2021-09-24T07:04:00+00:00weekly0.6https://www.medthority.com/news/2018/12/fmx-101-filed-with-fda-for-acne---foamix-pharma-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-grants-510-k--approval-for-aurora-xi-plasmapheresis-system----fresenius-kabi-/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2013/09/striverdi-respimat-efficacy-in-phase-iii-copd-trials/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-panther-fusion-gbs-assay-as-diagnostic-for-group-b-streptococcus-infection---hologic-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-natazia--bayer-healthcare--for-heavy-menstrual-bleeding/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2015/07/label-update-submitted-to-fda-for-simeprevir-and-sofosbuvir-in-hepatitis-c--janssen/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2017/06/aware-real-world-study-of-3-733-chronic-urticaria--cu--patients-shows-inadequate-care-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2018/09/janssen-pharma-files-nda-at-fda-for-esketamine-nasal-spray-to-treat-treatment-resistant-depression-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-to-investigate-saxagliptin-and-association-with-heart-failure--astrazeneca/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2012/07/lyrica--pfizer--success-in-gad-discontinuation-symptoms/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2014/10/biogen-files-maa-at-ema-for-elocta--rfviiifc---for-treatment-of-haemophilia-a-/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2012/04/up-446-botanical-extract--unigen--reduces-pain-scores-in-osteoarthritis/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2013/03/positive-results-from-phase-iii-trial-of-bi-201335--boehringer--for-hepatitis-c-patients/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2016/09/biogen-launches-flixabi--infliximab-biosimilar--in-the-uk---a-biosimilar-version-of-remicade-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2014/08/positive-results-in-study-of-lcz-696-for-heart-failure---novartis/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-juluca--for-hiv---viiv-healthcare-/2021-09-24T07:14:38+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-data-of-nexavar-for-thyroid-cancer-published-in-the-lancet---bayer-healthcare-onyx-pharma/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2011/12/buccolam-viro-pharma--is-launched-in-uk-for-prolonged--acute-convulsive-seizures-in-paediatric-patients-/2021-09-24T07:04:46+00:00weekly0.6https://www.medthority.com/news/2014/07/two-phase-iv-trials-report-data-on-vyvanse-for-adhd---shire/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2013/09/ly-3009806-fails-to-meet-endpoint-in-breast-cancer-study/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2012/06/an-nda-for-ta-2784--jansssen-pharmaceuticals-inc---is-submitted-to-the-fda-for-type-2-diabetes/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-oxtellar-xr--as-monotherapy-to-treat-partial-onset-seizures-in-adults-and-in-children-6-to-17-years-of-age---supernus-pharma/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2015/04/data-from-phase-iii-study-of-masican--masitinib--in-pancreatic-cancer-published-ab-science/2024-02-19T12:20:23+00:00weekly0.6https://www.medthority.com/news/2019/07/people-with-haemophilia-and-female-carriers-in-sweden-have-higher-risk-of-anxiety--depression-and-pain--based-on-treatment-patterns---sobi/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approval-for-attain-stability-quad-mri-surescan-left-heart-lead-designed-for-precise-lead-placement-and-stability---medtronic/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2013/11/biotronik-presents-results-of-4ever-study-of-pulsar-stent/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-approval-of-avastin-plus-chemo-in-cervical-cancer-roche/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2016/04/corevalve-demonstrates-superior-survival-to-surgery-in-aortic-stenosis-patients--medtronic/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2015/05/orkambi-phase-iii-trials-for-cystic-fibrosis-f508del-mutation-published-in-nejm--vertex/2024-02-19T12:20:41+00:00weekly0.6https://www.medthority.com/news/2016/10/sarepta-secures-rights-to-develop-and-market-in-eu--cis-and-turkey-to-summit-s-utrophin-modulator-pipeline--including-ezutromid-for-dmd-/2024-10-21T14:42:27+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-advisory-committe-recommends-vedolizumab-for-crohns-disease-and-ulcerative-colitis-takeda/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-trials-of-sipv-shows-vaccine-effective-in-polio---sinovac-biotec-/2021-09-24T07:05:21+00:00weekly0.6https://www.medthority.com/news/2013/07/statins-have-no-impact-on-cognition--according-to-new-meta-analysis/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-approves-zydelig-for-cll-gilead-sciences/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-trial-of-ads-5102--amantadine-hcl--shows-improvements-in-levodopa-induced-dyskinesia-in-parkinsons-disease--adamas-pharmaceuticals/2024-02-19T12:32:18+00:00weekly0.6https://www.medthority.com/news/2015/09/eighteen-months-data-for-opdivo--nivolumab--in-checkmate-057-trial-for-nsclc--bms/2024-02-19T12:33:30+00:00weekly0.6https://www.medthority.com/news/2013/01/nice-recommends-exogen--bioventus--for-treatment-of-long-bone-fractures/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2019/10/alexion-and-stealth-biotherapeutics-agree-option-for-alexion-to-participate-in--elamipretide-for-mitochondrial-diseases-/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2015/06/benefits-seen-in-phase-iii-results-of-ba-058--abaloparatide--in-osteoporosis-fracture--radius-health/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2011/10/fda-approves-ferriprox-for-iron-overload-in-thalassemia-patients/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-odomzo--sonidegib--formerly-lde225--to-treat-basal-cell-carcinoma---novartis/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2013/07/results-from-phase-iii-alsympca-trial-of-xofigo--bayer-healthcare--for-prostate-cancer-published-in-nejm/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-bio-rad-bioplex-2200-hiv-ag-ab-assay--bio-rad-laboratories-1/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2018/08/phase-iii-freedom-ev--study-shows-orenitram-delays-disease-progression-in-pulmonary-arterial-hypertension-patients--united-therapeutics/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2012/12/positive-results-in-phase-iii-trial-of-jakafi--incyte-corporation-novartis--for-patients-with-myelofibrosis/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2017/04/demcizumab--in-combination-with-abraxane--paclitaxel-protein-bound-particles-for-injectable-suspension---albumin-bound----gemcitabine-fails-phase-ii-trial-for-metastatic-pancreatic-cancer---oncomed-pharma/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2014/09/spiriva-respimat-approved-in-eu-for-asthma-treatment--boehringer/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-fulyzaq--salix-pharmaceuticals--for-diarrhoea-in-hiv-aids/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2015/09/rizaport--film-formulation-of-rizatriptan-is-approvable-in-europe-via-decentralised-procedure-to-treat-migraine--redhill-biopharma---intelgenx/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2012/03/tentative-fda-approval-for-generic-viagra/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2012/10/pt-003--pearl-therapeutics--success-in-phase-iib-study-for-copd/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2016/02/results-of-romana-phase-iii-trials-of-ono-7643--anamorelin--in-non-small-cell-lung-cancer-published-in-lancet-oncology--helsinn-/2024-02-19T12:33:56+00:00weekly0.6https://www.medthority.com/news/2016/10/rekovelle--follitropin-delta--is-recommended-by-ema-s-chmp-for-controlled-ovarian-stimulation-ferring-pharmaceuticals/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-flublok-vaccine-for-influenza-protein-sciences/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2015/11/phase-iii-results-with-onivyde--irinotecan-liposome-injection--in-pancreatic-cancer-published-in-the-lancet--merrimack-baxalta/2024-02-19T12:34:19+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-gives-supplemental-approval-for-latuda--lurasidone-hci--for-the-treatment-of-schizophrenia-in-adolescents-aged-13-to-17-years--sunovion-pharma/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-claria-mri-quad-cardiac-resynchronization-therapy-defibrillator-for-heart-failure--medtronic/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2015/03/pivotal-study-of-corevalve-shows-benefits-in-tavr-patients-medtronic/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2013/09/new-class-of-oral-treatment-for-overactive-bladder/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2018/10/jazz-pharmaceuticals-survey-highlights-significant-impact--of-excessive-daytime-sleepiness-related-to-sleep-apnea-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2018/02/study-shows-lma-gastro-airway-with-cuff-pilot-offers-high-airway-insertion-and-endoscopy-success-rates---teleflex-inc-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-exparel-snda-for-postsurgical-regional-analgesia---pacira-pharma-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2017/06/clovis-oncology-reports-data-from-phase-iii-ariel-3-trial-of-rucaparib-for-ovarian-cancer-and-plans-snda-for-second-line-and-maintenance-treatment-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2019/08/oasis-2-phase-iii-trial-of-nuzyra-in-skin-infection-published-in-the-lancet-infectious-diseases---paratek-pharma/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-results-from-absorb-ii-trial-of-absorb-vascular-scaffold-for-coronary-artery-disease--abbott-vascular/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2014/04/trial-results-of-abt-450-r--abt-267--abt-333-in-hcv-published-in-nejm---abbvie/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2020/01/conatus-pharma-to-merge-with-histogen-inc-and-trade-as-histogen-inc-/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2014/11/results-of-flint-trial-of-oca-for-nash-are-published-in-the-lancet--intercept-pharma/2024-02-19T12:34:40+00:00weekly0.6https://www.medthority.com/news/2015/08/pfizer-announces-results-of-two-phase-iii-trials-for-trumenba--meningococcal-group-b-vaccine-/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2018/04/chmp-recommends-approval-of-extension-to-indication-for-perjeta---herceptin-to-include-early-breast-cancer---roche-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2015/09/generic-version-of-rytary-for-parkinsons-filed-with-fda--allergan/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2013/06/star-study-of-inspire-uas-system--inspire-medical-systems--shows-benefits-for-obstructive-sleep-apnea/2021-09-24T07:16:06+00:00weekly0.6https://www.medthority.com/news/2017/12/two-phase-iii-trials-reported-in-nejm-for-trumenba-showing--a-protective-immune-response-against-diverse-meningococcal-group-b--menb--strains---pfizer-/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2012/11/epanova--omthera-pharma--successes-in-evolve-and-espirit-trials-for-dyslipidaemia---------------/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-results-of-checkmate-037-trial-for-opdivo--nivolumab--for-advanced-melanoma---bms/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-s-chmp-recommends-approval-of-ofev-for-pulmonary-fibrosis-boehringer/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2020/01/sorrento-therapeutics-rejects-takeover-offer-/2025-10-16T11:34:02+00:00weekly0.6https://www.medthority.com/news/2015/03/successful-phase-iii-trial-for-bax-817-for-haemophilia-inhibitor-treatment-baxter/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-advisory-committee-recommends-tazemetostat-as-a-treatment-for-metastatic-or-locally-advanced-epithelioid-sarcoma-not-eligible-for-curative-surgery---epizyme-inc-/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2017/01/eu-chmp-recommends-approval-of-daptomycin-hospira--daptomycin---a-generic-form-of-cubicin--for-infections--hospira/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-baqsimi--the-first-treatment-for-severe-hypoglycaemia--administered-without-an-injection-to-patients-with-diabetes-aged-four-years-and-older---eli-lilly/2021-09-24T07:17:19+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-clinical-trial-of-rbp-6000--buprenorphine-monthly-depot--meets-primary-endpoint-for-opioid-use-disorder--indivior-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-mylotarg--gemtuzumab-ozogamicin--for-adults-with-newly-diagnosed-acute-myeloid-leukemia-and-for-some-cases-of-relapse--pfizer-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-phase-iii-results-for-debio-8206-cpp--triptorelin-pamoate-slow-release--in-central-precocious-puberty--debiopharm/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2016/11/limflow-system-for-treatment-of-critical-limb-ischaemia-receives-ce-mark--limflow-s-a-/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2015/02/updated-results-for-study-of-thermodox-in-liver-cancer-celsion-corp/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2013/10/gsk-genmab-file-arzerra-for-cll-with-ema/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2017/11/european-commission-approves-zejula-to-treat-ovarian-cancer--tesaro-/2021-09-24T07:14:37+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-finds-adhd-drugs-have-no-link-to--cardiovascular-problems/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-cabometyx--cabozantinib---formerly-cometriq--to-treat-renal-cell-carcinoma---exelixis---ipsen/2024-02-19T12:35:12+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-phase-iii-trial-of-ibalizumab-for-treatment-of-resistant-hiv-1---theratechnologies-inc----taimed-biologics--inc/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-advisers-vote-in-favour-of-hematide--takeda-affymax--approval-for-anaemia/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2017/08/lasmiditan--met-its-primary-endpoint-in-spartan--a-second-phase-iii-study-for-the-acute-treatment-of-migraine---eli-lilly/2021-09-24T07:14:56+00:00weekly0.6https://www.medthority.com/news/2017/05/ionis-pharma-reports-phase-iii-neuro-ttr-study-of-inotersen--ionis-ttrrx--in-patients-with-familial-amyloid-polyneuropathy--fap--/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-keynote-024-study-of-keytruda--pembrolizumab--shows-positive-health-related-quality-of-life-in-non-small-cell-lung-cancer--merck-inc/2021-09-24T07:10:15+00:00weekly0.6https://www.medthority.com/news/2015/10/successful-phase-iii-trial-for-opioid-abuse-deterrent-eli-200-for-treatment-of-moderate-to-severe-pain--elite-pharma/2021-09-24T07:03:13+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-venclexta---rituxan-combination-to-treat-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma--with-or-without-17p-deletion--genentech-roche-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2017/10/siop-welcomes-paediatric-oncologists/2021-09-24T07:13:28+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-accepts-resubmission-of-exparel-for-prolonged-regional-analgesia---pacira-pharmaceuticals-/2021-09-24T07:13:23+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-abrilada--adalimumab-biosimilar---pfizer/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-study-of-gsk-1278863-meets-primary-endpoint-in-anaemia-from-chronic-kidney-disease---glaxosmithkline-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-ii-iii-starbeam-study-of-lenti-d-shows-efficacy-in-cerebral-adrenoleukodystrophy---bluebird-bio/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-lonsurf-for-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma---taiho-oncology/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2014/07/nice-recommends-selincro-for-alcholol-dependence--lundbeck-/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2016/12/bluebird-bio-initiates-treatment-in-northstar-2--the-phase-iii-study-of---lentiglobin-in-patients-with-transfusion-dependent-beta-thalassemia--/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approval-for-otezla--apremilast--for-psoriasis-and-psoriatic-arthritis--celgene/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-illumigene-hsv-1-2-diagnostics-for-herpes-simplex--meridian-bioscience/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2017/11/dawn-trial-of-trevo-retriever-in-stroke-is-published-in-nejm--stryker-/2024-11-15T08:43:45+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-subcutaneous-roactemra-for-ra-roche/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2017/08/kidney-transplantation--from-patients--quality-of-live-to-health-care-expenses-the-benefits-are-real/2024-11-14T16:09:23+00:00weekly0.6https://www.medthority.com/news/2016/01/mk-6072--bezlotoxumab--filed-with-fda-for-clostridium-difficile-infection--merck/2024-02-19T12:35:26+00:00weekly0.6https://www.medthority.com/news/2013/10/axona--accera--review-shows-benefits-for-alzheimer-s/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2012/08/study-shows-almost-no-difference-in-mortality-with-tnf-drugs-for-rheumatoid-arthritis/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-approves-rubraca-for-for-the-maintenance-treatment-of-recurrent-epithelial-ovarian--fallopian-tube--or-primary-peritoneal-cancer----clovis-oncology-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-commission-approves-reagila--cariprazine---for-the-treatment-of-schizophrenia---recordati---gedeon-richter-/2021-09-24T07:14:06+00:00weekly0.6https://www.medthority.com/news/2019/10/two-new-options-for-self-administration-of-nucala-now-approved-in-canada-for-patients-with-severe-eosinophilic-asthma-/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2016/09/ce-mark-granted-for--expanded-indication-for--sapien-3-transcatheter-heart-valves-to-cover-aortic-valve-stenosis-patients-at-intermediate-risk--edwards-lifesciences/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2016/12/allergan-acquires-life-cell-business-from-acelity-and-with-it-alloderm-regenerative-tissue-matrix-and-strattice-reconstructive-tissue-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-orencia--abatacept--for-active-psoriatic-arthritis--bms/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2012/10/sideguard-coronary-stent-success-in-coronary-bifurcation-disease/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2016/12/invendoscope-sc200--the-world-s-first-sterile--single-use-colonoscope--receives-ce-mark--invendo-medical-gmbh-/2024-10-21T14:40:46+00:00weekly0.6https://www.medthority.com/news/2012/08/-lcz-696-success--in-study-for-heart-failure-with-preserved-ejection-fraction----------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-illuminate-trial-of-imbruvica---gazyva-shows-prolonged-pfs-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma---abbvie-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-invokana-to-reduce-the-risk-of-major-adverse-cardiovascular--cv--events----janssen-pharma/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2017/06/seattle-genetics-will-discontinue-phase-iii-cascade-study-and-suspend-all-of-the-vadastuximab-talirine--sgn-cd33a--clinical-trials-/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2015/09/sayana-press-launched-in-uk-as-a-self-administered-injectable-contraceptive--pfizer/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-ravicti--hyperion-therapeutics---for-urea-cycle-disorders/2021-09-24T07:15:36+00:00weekly0.6https://www.medthority.com/news/2017/09/esmo-2017-press-release--alectinib--alex-and-alur-trials-show-cns-benefit-in-nsclc/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2016/12/oak-study-of-tecentriq--atezolimumab--reported-in-the-lancet-shows-improvement-of-overall-survival-versus-docetaxel-in-nsclc-patients--genetech---roche/2024-02-19T12:35:58+00:00weekly0.6https://www.medthority.com/news/2016/11/allergan-acquires-chase-pharmaceuticals-corporation-and-with-it-cpc-201-a-proposed-treatment-for-alzheimers-disease/2021-09-24T07:09:44+00:00weekly0.6https://www.medthority.com/news/2017/05/shire-plc-ends-development-of-shp-656-a-proposed-treatment-for-hemophilia-a-/2021-09-24T07:14:26+00:00weekly0.6https://www.medthority.com/news/2013/08/afrezza--non-inferior-to-insulin-aspart-in-type-1-diabetes/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2016/05/analysis-of-children-with-ada-scid-and-treated-with-autologous-cd34--cells-known-as-strimvelis-is-published-in-blood--gsk/2024-02-19T12:44:03+00:00weekly0.6https://www.medthority.com/news/2016/10/final-phase-iii-results-with-onivyde--irinotecan--in-combination-with-fluorouracil-and-leucovorin-shows-efficacy-is-maintained-in-pancreatic-ductal-adenocarcinoma---merrimack-pharma/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-iib-study-with-stx-209--seaside-therapeutics--reports-on-efficacy-in-autism-spectrum-disorder/2021-09-24T07:16:25+00:00weekly0.6https://www.medthority.com/news/2017/01/programme-cancelled-for-mg01ci--metadoxine-extended-release--in-treatment-of-attention-deficit-hyperactivity-disorder--alcobra-/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2017/10/ueg-week--artificial-intelligence--is-this-the-future-of-early-colorectal-cancer-detection-/2021-09-24T07:13:20+00:00weekly0.6https://www.medthority.com/news/2015/04/depomed-completes-purchase-of-nycunta--tapentadol--us-rights-for-the-treatment-of-pain-from-janssen-pharmaceuticals/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2019/01/abbott-acquires-cephea-valve-technologies-and-mitral-valve-technology/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2014/08/eisai-files-fycompa-at-ema-and-fda-for-uncontrolled-primary-generalized-tonic-clonic-seizures/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2014/07/tc-1734-fails-phase-iib-trial-for-alzheimers-disease---targacept-inc-/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2011/11/switching-from-tamoxifen-to-aromasin-improves-breast-cancer-survival-rate/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-approves-flixabi----infliximab-biosimilar--to-treat-indications-of-the-reference-product--remicade---biogen/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2017/11/nice-recommends-use-of-opdivo-in-squamous-non-small-cell-lung-cancer---bms-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iiib-expedition-8-study-of-mavyret-shows-sustained-response-in-hepatitis-c---abbvie-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-accepts-rolling-submission-of-v-920-in-ebola-zaire-disease---merck-inc-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2020/01/vibegron-filed-with-fda-for-overactive-bladder---urovant-sciences/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2013/12/b-long-study-of-alprolix-for-haemophilia-b-published-in-nejm-biogen-sobi/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2015/10/allergan-in-business-combination-discussions-with-pfizer/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2019/06/results-from-studies-of-dual-gip-and-glp-1-receptor-agonist--tirzepatide-reinforce-its-potential-in-lowering-a1c-and-body-weight-in-type-2-diabetes----eli-lilly/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2017/05/positive-results-for-imfinzi--durvalumab--from-phase-iii-pacific-trial-for-sequential-treatment-of-locally-advanced--unresectable--stage-iii--non-small-cell-lung-cancer--nsclc----astrazeneca/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-afinitor-for-her-2-negative-breast-cancer/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-advanced-brain-monitoring-s-sleep-profiler-to-be-used-in-the-diagnosis-of-sleep-apnea-/2024-10-21T14:42:35+00:00weekly0.6https://www.medthority.com/news/2014/02/phase-iii-trial-of-sc-version-of-berinert-begins-for-hae---csl-behring/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2017/12/millendo-therapeutics-acquires--aliz--pharma-sas-and-with-it-livoletide--a-drug--that-is-in-phase-ii-to-treat-prader-willi-syndrome-/2021-09-24T07:13:33+00:00weekly0.6https://www.medthority.com/news/2012/05/reprise-1-trial-reports-for-lotus-aortic-valve-system--boston-scientific-/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2015/11/cobas-cv-genotyping--gt--assay-for-the-hepatitis-c-virus-receives-ce-mark-approval-in-the-eu--roche/2021-09-24T07:04:24+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-results-for-esmya--ulipristal-acetate--demonstrates-management-of-uterine-fibroids--gedeon-richter/2024-02-19T12:44:18+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-positive-for-use-of-eylea--aflibercept--to-treat-macular-oedema-secondary-to-branch-retinal-vein-occlusion--brvo---bayer-healthcare/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2020/01/positive-top-line-results-from-the-breeze-ad5-phase-iii-study-of--baricitinib-for-moderate-to-severe-atopic-dermatitis--eli-lilly---incyte-corpn-/2021-09-24T07:11:43+00:00weekly0.6https://www.medthority.com/news/2019/03/pacira-pharma-acquires-myoscience-inc--and-with-it-iovera-system-a-non-opioid-treatment-for-pain-control/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-vaxelis-six-in-one-vaccine---sanofi-pasteur---msd-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2015/08/elad-system-fails-to-meet-primary-endpoint-of-phase-iii-trial-in-alcohol-induced-liver-decompensation--vital-therapies/2021-09-24T07:03:04+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-accepts-sbla-for-perjeta--pertuzumab----herceptin--trastuzumab--for-adjuvant--after-surgery--treatment-of-her2-positive-early-breast-cancer--genentech-roche/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp--recommends-against-approval-of-rlx-030--serelaxin--for-acute-heart-failure-novartis-/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-secuado--transdermal-patch-formulation-for-the-treatment-of-adults-with-schizophrenia--noven-pharma/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2016/03/scientific-approval-in-eu-given-to---enstilar--calcipotriol-betamethasone-dipropionate--to-treat-psoriasis-vulgaris--leo-pharma/2024-02-19T12:44:31+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-study-of-epidiolex-to-treat-lennox-gastaut-syndrome-is-published-in-the-lancet--gw-pharma/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2018/04/post-approval-study-of-mitra-clip-shows-improved-heart-performance-after-transcatheter-mitral-valve-repair---abbott-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2015/04/shire-agrees-regulatory-pathway-with-fda-for-shp-465--triple-bead-mixed-amphetamine-salts--for-adhd-in-adults-/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2019/12/bms-announces-fda-breakthrough-therapy-designation-for-orencia-to-help-prevent-acute-graft-versus-host-disease--a-potentially-life-threatening-complication-after-stem-cell-transplant---bms/2021-09-24T07:18:38+00:00weekly0.6https://www.medthority.com/news/2013/06/savor-timi-53-trial-of-onglyza-disappoints-bms-and-astrazeneca-in-diabetic-vascular-outcomes/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2012/07/brivanib--bms--fails-phase-iii-trial-for-hepatocellular-carcinoma/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2013/11/darapladib--gsk--fails-to-meet-endpoint-in-heart-disease/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-saxenda-for-obesity--novo-nordisk/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2014/12/eu-approves-duavive-for-oestrogen-deficiency-pfizer/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2016/06/results-of-phase-iii-ino-vate-all-study-of-pf-5208773--inotuzumab-ozogamicin--in-acute-lymphoblastic-leukemia-published-in-new-england-journal-of-medicine--pfizer/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2018/09/ce-mark-for--high-sensitive-troponin-i-blood-test-to-detect-cv-disease--abbott-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2017/11/biocartis-group-launches-ce-marked--idylla-ctkras-mutation-test-and-the-idylla-ctnras-braf-mutation-test-for-diagnosis-of-colorectal-cancer-/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2012/01/chmp-rejects-folotyn--allostherapeutics-and-mundipharma--for-t-cell-lymphoma/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2017/11/entyvio-is-first-drug-to-be-developed-with-needle-free-delivery-device---takeda---portal-instruments-/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-lower-dose-qnasl-for-allergic-rhinitis-teva-pharma/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-advisory-committee-recommends-raxibacumab--hgs---for-anthrax---------------/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2016/03/ema-reviews-zydelig--idelalisib--in-cll-and-follicular-lymphoma-due-to-serious-adverse-events--gilead-sciences/2021-09-24T07:10:23+00:00weekly0.6https://www.medthority.com/news/2018/03/sofia-lyme-fia-is-fda-510-k--approved-to-detect-human-borrelia-burgdorferi--lyme-disease---quidel-corporation-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2019/07/chmp-recommends-authorisation-for-forxiga-in-type-2-diabetes/2021-09-24T07:18:23+00:00weekly0.6https://www.medthority.com/news/2019/10/cosentyx-data-shows-treatment-results-in-rapid-and-sustained-resolution-of-signs-and-symptoms-of-psoriatic-arthritis-in-patients-with-and-without-enthesitis---novartis/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-of-mk-8228-for-cytomegalovirus---merck/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2016/12/new-analyses-of-phase-iii-data-for-tramiprosate-identifies-biological-phenotypes-in-alzheimer-s-disease---alzheon-inc-/2024-10-21T14:41:08+00:00weekly0.6https://www.medthority.com/news/2012/07/phase-iii-trial-for-odanacitib-merck-inc---in-osteoporosis-closes-early/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2012/04/gsk-announces-progress-in-harmony-syncria-programme-for-type-2-diabetes/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2019/07/mylan-will-combine-with-upjohn--pfizer-s-off-patent-branded-and-generic-established-medicines-business--creating-a-new-global-pharmaceutical-company-/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2014/04/sanofi-pasteur-success-in-phase-iii-efficacy-study-of-vaccine-for-dengue--disease/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2012/10/phase-iii-trial-of-bay-63-2521--bayer-healthcare--for-pah-meets-primary-endpoint/2021-09-24T07:02:03+00:00weekly0.6https://www.medthority.com/news/2019/04/bms-provides-long-term-survival-results-from-pooled-analyses-of-opdivo-in-previously-treated-nsclc-patients--/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-mavyret--glecaprevir-pibrentasvir---a-once-daily--ribavirin-free-treatment-for-adults-with-chronic-hepatitis-c-virus---abbvie/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-clears-the-way-for-amicus-therapeutics-to-submit-an-nda-to-the-agency-for-for-the-oral-precision-medicine-migalastat-for-fabry-disease-in-the-fourth-quarter-of-2017-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-verzenio--abemaciclib--to-treat-hormone-receptor--hr--positive---her2-negative-advanced-or-metastatic-breast-cancer---eli-lilly-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2019/03/first-line-eu-approval-for-nsclc-is-based-on-data-from-the-phase-iii-keynote-407-trial-of-keytruda-in-combination-with-chemotherapy---merck-inc-/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2016/04/real-world-phase-iii-data-on-viekirax--ombitasvir-paritaprevir-ritonavir--plus-exviera--dasabuvir--shows-efficacy-in-gt1-and-gt4-hepatitis-c-patients--abbvie-/2021-09-24T07:10:41+00:00weekly0.6https://www.medthority.com/news/2015/06/positive-phase-iii-results-for-itca-650-in-type-2-diabetes--intarcia-therapeutics/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2013/01/fda-approves-rebif-rebidose-emd-serono--for-treatment-of-multiple-sclerosis/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2020/01/ipsen-to-pause-dosing-patients-in-the-global-phase-iii--pvo-1a-301--study-to-evaluate-the-efficacy-and-safety-of-palovarotene-in-patients-with-fibrodysplasia-ossificans-progressiva-/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2017/11/a-look-back-at-paam-2017/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-and-ema-accept-supplemental-new-drug-application-for-bosulif--bosutinib--in-newly-diagnosed-chronic-phase-ph--chronic-myeloid-leukemia--pfizer-and-avillion-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2014/07/gsk-initiates-triple-therapy-phase-iii-trial-for-copd/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2012/07/vestiq-pharma-licenses-oravig-for-oropharyngeal-candidiasis-in-us-from-bioalliance-pharma/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2016/09/leader-cv-trial-shows-victoza--liraglutide--reduces-progression-of-kidney-damage-in-patients-with-type-2-diabetes-and-cv-risk--novo-nordisk/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2015/06/sb4--etanercept-biosimilar--phase-iii-results-for-rheumatoid-arthritis--biogen---samsung-bioepis/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-belbuca--buprenorphine-buccal-film--to-treat-chronic-pain--endo-pharma---biodelivery-sciences/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2019/11/imfinzi-granted-fda-priority-review-for-the-treatment-small-cell-lung-cancer-and-with-pdufa-date-in-q1-2020--astrazeneca/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2018/04/takeda-makes-fourth-proposal-for-takeover-of-shire-plc/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2016/12/novartis-enters-option-to-acquire-rights-to-emricasan-from-conatus-pharma-for-treatment-of-nash-cirrhosis-and-hcv-fibrosis-/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-vercise-deep-brain-stimulation--dbs--system-to-treat-parkinson-s-disease-symptoms---boston-scientific/2021-09-24T07:13:38+00:00weekly0.6https://www.medthority.com/news/2019/12/deciphera-pharma-files-ripretinib-at-fda-to-treat-patients-with-advanced--gastrointestinal-stromal-tumours--gist--/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2017/12/agios-pharmaceuticals-files-nda-at-fda-for-ivosidenib-to-treat-aml-patients-with-an-isocitrate-dehydrogenase-1--idh1--mutation-/2021-09-24T07:13:32+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-studies-of-daxi-in-glabellar-lines-published-in-jaad----revance-therapeutics/2021-09-24T07:18:37+00:00weekly0.6https://www.medthority.com/news/2012/05/acuson-sc-2000-ultrasound-system--siemens--is-launched/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-bio-t-gel--teva--for-male--hypogonadism/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2018/03/17th-world-conference-on-tobacco-or-health/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-analysis-of-erbitux-for-colorectal-cancer-confirms-earlier-studies-merck-kgaa/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-grants-priority-review-snda-for-fycompa-in-partial-onset-seizures-in-pediatric-patients---eisai-/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-snda-for-emend--fosaprepitant-dimeglumine--in-combination-with-other-antiemetic-medicines-for-prevention-of-delayed-nausea-and-vomiting--merck-inc/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2019/04/biotronik-launches-in-europe-carnelian-support-catheter-to-treat-tortuous-lesions-in-the--peripheral-vasculature-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2016/10/final-analysis-of-phase-iii-study-shows-opdivo--nivolumab--monotherapy-failed-to-meet-pfs-endpoint-in-non-small-cell-lung-cancer--bms/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-phoxillum-renal-replacement-therapy-in-acute-kidney-injury-patients--baxter/2021-09-24T07:03:26+00:00weekly0.6https://www.medthority.com/news/2017/04/positive-phase-iii-revive-1-study-of-iclaprim-in-patients-with-acute-bacterial-skin-and-skin-structure-infections--absssi----motif-bio-/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2018/12/vumerity-filed-at-fda-to-treat-relapsing-remitting-ms--biogen/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2017/09/interim-analysis-of-regain-study-of-soliris--eculizumab--for-the-treatment-of-patients-with-refractory-generalized-myasthenia-gravis----alexion-pharmaceuticals-/2021-09-24T07:13:54+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---first-ever-autonomously-controlled--capsule-robot--explores-colon/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2013/03/study-shows-metalyse-tnkase--boehringer--benefits-patients-with-pulmonary-embolism/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2019/03/interim-analysis-of-repair-study-of-opsumit-shows-improved-heart-function-in-pulmonary-arterial-hypertension---actelion-pharma-j-j/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2012/09/results-of-define-and-confirm-trials-of-bg-12-biogen-idec--in-multiple-sclerosis-published-in-nejm/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2016/04/ema-approves-coagadex--coagulation-factor-x-human--to-treat-hereditary-factor-x-deficiency---bio-products-ltd/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2013/01/the-lancet-reports-successful-phase-iii-study-of-bexsero-vaccine--novartis-against-menb/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2019/05/puldysa-is-filed-at-ema-to-treat-respiratory-dysfunction-in-patients-with-duchenne-muscular-dystrophy---santhera-pharma/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2014/06/viibryd-success-in-three-phase-iii-studies-for-generalised-anxiety-disorder--forest-labs/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-approves-stelara--ustekinumab--for-adults-with-moderately-to-severely-active-crohn-s-disease--janssen/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-results-for-victoza--liraglutide--in-type-1-diabetes--novo-nordisk/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2013/09/sonocare-s-x-porte-ultrasound-kiosk-is-ce-mark-approved/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2019/02/oral-pill-is-being-developed--for-delivery-of-insulin---novo-nordisk/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2014/04/aripiprazole-lauroxil-success-in-phase-iii-trial-for-monthly-treatment-of-schizophrenia---alkermes/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-approves-barostim-neo-system-for-heart-failure---cvrx/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-bla-for-ar-i0i-to--reduce-the-risk-of-anaphylaxis-following-accidental-exposure-to-peanut---aimmune-therapeutics/2021-09-24T07:18:53+00:00weekly0.6https://www.medthority.com/news/2017/06/prosper-trial-protocol-of-xtandi--enzalutamide--in-patients-with-non-metastatic-castration-resistant-prostate-cancer-is-amended---astellas-and-pfizer/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2016/02/abbott-acquires-alere-inc--diagnostics-maker-/2021-09-24T07:09:04+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-new-and-expanded-indication-for-vascepa-in-patients-with-elevated-triglyceride-levels-and-cv-risk---amarin/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2017/08/vitaros--alprostadil--refiled-with-the-fda-for-erectile-dysfunction--apricus-biosciences-/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2018/11/novo-nordisk-acquires-from-strongbridge-biopharma-us-and-canadian-rights-to-macrilen--an-oral-treatmant-for-adult-growth-hormone-deficiency--/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-venaseal-system-for-treatment-of-varicose-veins--covidien/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-eucrisa--crisaborole--ointment-2--for-the-treatment-of-mild-to-moderate-atopic-dermatitis---pfizer/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2014/04/study-shows-thermodox-improves-os-in-liver-cancer-patients---celsion/2021-09-24T07:07:21+00:00weekly0.6https://www.medthority.com/news/2012/05/lucassin--ikaria--is-approved-for-hepatorenal-syndrome-in-australia/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-grants-conditional-approval-of-polivy---mabthera---bendamustine-for-diffuse-large-b-cell-lymphoma---roche/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-eylea--regeneron--for-wet-amd/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-bosulif--pfizer--for-treatment-of-ph-cml/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-grants-expended-indication-for-vidaza--azacitidine-for-injection--for-older-patients-with-aml-not-eligible-for-stem-cell-transplantation--celgene/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-anthim--obiltoxaximab--for-anthrax--elusys-therapeutics/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2013/05/ce-mark-granted-for--architectt-hba1c-test-to-diagnose-diabetes/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-lotemax-sm-for-postoperative-pain-in-ocular-surgery---bausch---lomb/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2013/03/positive-phase-iii-results-for-tedizolid-phosphate--trius-therapeutics--for-absssi/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-study-of-alks-3831-meets-endpoints-in-schizophrenia---alkermes-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-recommends-lynparza--olaparib--to-treat-ovarian-cancer--astrazeneca/2021-09-24T07:04:30+00:00weekly0.6https://www.medthority.com/news/2017/11/8th-international-congress---psoriasis-from-gene-to-clinic/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2016/01/fda-approves-arzerra--ofatumumab--for-recurrent-or-progressive-chronic-lymphocytic-leukemia--novartis-genmab/2024-02-19T12:44:41+00:00weekly0.6https://www.medthority.com/news/2015/09/amgen-and-novartis-to-collaborate-in-neuroscience-field--specifically-cnp-520-and-migraine-drugs-amg-334-and-amg-331/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2012/06/nop-47-significant-impact-on-vascular-endothelial-function/2021-09-24T07:02:21+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-grants-de-novo-approval-of-nerivio-migra-for-migraine---theranica/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-sbla-for-ultomiris-to-treat-atypical-hemolytic-uremic-syndrome--ahus----alexion/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2014/06/study-shows-improved-os-with-proleukin-in-metastatic-renal-cell-carcinoma---prometheus-labs/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-alpivab-for-the-treatment-of-uncomplicated-influenza--biocryst---seqirus-/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-tremfya--guselkumab--to-treat-plaque-psoriasis---janssen-biotech-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2012/03/shire-withdraws-fda--application-for-replagal-for-fabry-disease-/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2013/10/amgen-acquires-roche-rights-to-neupogen-and-neulasta/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-phase-iii-results-for-vesneo-in-treatment-of-glaucoma-and-ocular-hypertension----bausch---lomb-nicox/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2013/04/ismp-analysis-highlights-link-between-pancreatic-cancer-and-pancreatitis-and-glp-1-class-of-anti-diabetic-medications/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2019/03/data-presented-at-aaos-meeting-for--exparel-results-in-high-rates-of-early-discharge-and-patient-satisfaction-for-total-knee-or-hip-arthroplasty---pacira-pharma/2021-09-24T07:18:55+00:00weekly0.6https://www.medthority.com/news/2013/03/european-commission-grants-conditional-marketing-approval-to-bosulif--pfizer--for-ph-cml-/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2019/07/livanova-launches-bi-flow-to-prevent-limb-ischemia-during-cardiac-surgery-/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2014/03/humira-enters-new-trial-for-fingernail-psoriasis---abbvie/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---experimental-drug-eases-effects-of-gluten-for-celiac-patients-on-gluten-free-diet/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2018/02/two-phase-iii-trials-show-positive-safety-and-efficacy-of-abbv-066-in--plaque-psoriasis---abbvie-/2021-09-24T07:05:54+00:00weekly0.6https://www.medthority.com/news/2015/11/intarcia-therapeutics-acquires-phoundry-pharmaceuticals/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-extends-the-indication-of-system-one-to-include-solo-home-hemodialysis-without-presence-of-a-care-partner--nxstage-medical-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2018/06/european-society-of-hypertension--esh--on--hypertension-and-cardiovascular-protection-/2022-02-08T07:44:52+00:00weekly0.6https://www.medthority.com/news/2013/11/mk-3745--merck-inc--moves-into-phase-iii-for-melanoma/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2014/08/allergan-acquires-liris-programme-from-taris-holdings-llc/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2016/06/post-hoc-analysis-of-phase-iiia-scale-study-of-saxenda--liraglutide--in-treatment-of-obesity--novo-nordisk/2024-02-19T12:44:50+00:00weekly0.6https://www.medthority.com/news/2019/11/myovant-sciences-announces-97--response-rate-in-positive-phase-iii-hero-study-of-once-daily--oral-relugolix-in-men-with-advanced-prostate-cancer-/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2011/11/jakafi--incyte-novartis--is-fda-approved-for-myelofibrosis-1/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2013/10/cubist-pharma-files-tedizolid-phosphate-at-fda-for-treatment-of-absssi/2021-09-24T07:16:12+00:00weekly0.6https://www.medthority.com/news/2019/05/stryker-secures-fda-pma-for-neuroform-atlas-brain-aneurysm-stent-system-/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-trials-of-zepatier--elbasvir-and-grazoprevir--in-hepatitis-c-shows-efficacy-in-different-patient-subgroups--merck/2024-02-19T12:45:10+00:00weekly0.6https://www.medthority.com/news/2018/12/positive-results-from-three-phase-iii-studies-of-roxadustat-for-anemia-in-patients-with-chronic-kidney-disease--fibrogen---astrazeneca/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-accepts-supplemental-application--snda--for-avycaz---ceftazidime-and-avibactam--to-treat-ciai-including-infections-due-to-ceftazidime-nonsusceptible--caz-ns--pathogens---allergan/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2016/08/ds-biopharma-announces-launch-of-spin-out-company-called-afimmune/2025-10-16T10:44:50+00:00weekly0.6https://www.medthority.com/news/2014/02/forest-files-combination-nebivolol--valsartan-at-fda-for-hypertension/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2016/02/successful-two-months-dosing-study-of-aristada--aripiprazole-lauroxil--extended-release-for-schizophrenia--alkermes/2024-02-19T12:45:24+00:00weekly0.6https://www.medthority.com/news/2017/10/impact-biomedicines-to-develop-fedratinib-to-treat-myelofibrosis--and-polycythemia-vera-/2021-09-24T07:13:25+00:00weekly0.6https://www.medthority.com/news/2011/11/xgeva-results-of--147--trial-prevention-of-bone-metastases-in-prostate-cancer-is-published-in-the-lancet/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/09/hansa-biopharma-to-meet-the-fda-relating-to-imlifidase-and-filing-requirements-for-the-prevention-of-antibody-mediated-organ-rejection-/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2018/05/uk-nice-approves-use-of-rydapt-in-acute-myeloid-leukaemia---novartis-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-advisory-committee-recommends-afrezza-for-type-1-and-type-2-diabetes---mannkind-corpn/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2018/02/eu-approves-expanded-indication-for-fluarix-tetra-for-adults-and-children-in-influenza---glaxosmithkline-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-adopts-a-negative-opinion-to--neratinib-for-the-extended-adjuvant-treatment-of-early-stage-her2-positive-breast-cancer---puma-pharma-/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2018/10/positive-results-from-phase-iii-solar-1-trial-for-byl-719---fulvestrant-in-postmenopausal-women-with-pik3ca-mutated-hormone-receptor-positive--hr--her2---metastatic-breast-cancer--novartis/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2017/01/glecaprevir--abt-493--pibrentasvir--abt-530---g-p--for-the-treatment-of-all-major-chronic-hepatitis-c-virus--hcv--genotypes-is-filed-at-ema--abbvie/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2016/03/phase-iii-castor-study-of-darzalex---velcade--daratumumab---bortezomib-and-dexamethasone--in-patients-with-relapsed-or-refractory-multiple-myeloma-meets-primary-endpoint--genmab/2024-02-19T12:45:38+00:00weekly0.6https://www.medthority.com/news/2018/02/eu-approval-for-crysvita-to-treat-x-linked-hypophosphatemia----kyowa-hakko-kirin---ultragenyx-/2021-09-24T07:05:49+00:00weekly0.6https://www.medthority.com/news/2018/02/anti-depressants--major-study-finds-they-work/2021-09-24T07:05:51+00:00weekly0.6https://www.medthority.com/news/2018/05/noveartis-initiates-arrow-study-to-assess-cosentyx-over-tremfya-in-psoriasis-patients-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2017/02/gemini-long-term-safety-study-of-entyvio--vedolizumab--shows-benefits-in-ulcerative-colitis-and-crohn-s-disease--takeda/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2018/05/american-journal-of-hematology-publishes-positive-results-of-phase-iii-trial-of-tavalisse-to-treat-chronic-immune-thrombocytopenia---rigel-pharma-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-dignicap-scalp-cooling-system-to-reduce-chemotherapy-induced-hair-loss--dignitana/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2013/10/acelrx-submits-zalviso-to-fda-for-pain-relief/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-trials-failure-for--locilex---pexiganan-cream-0-8----to-treat-diabetic-foot-ulcers---dipexium-pharmaceuticals-/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2014/07/european-commission-approves-plegridy-for-treatment-of-relapsing-remitting-ms---biogen-idec/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-advisory-committee-recommends-keytruda--for-the-treatment-of-certain-patients-with-high-risk--non-muscle-invasive-bladder-cancer--nmibc--/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2016/07/phase-iii-data-shows-improved-response-rate-of-xilonix--monoclonal-antibody--in-colorectal-cancer--xbiotech/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2017/06/forward-ide-trial-shows-benefits-of-nellix-evas-system-in-reduced-leakage-and-mortality-in-patients-with-abdominal-aortic-aneurysms--endologix-/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2018/12/draft-guidance-from-nice-rejects-the-use-of-tegsedi-in-hereditary-transthyretin-related-amyliodsis---akcea-therapeutics-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-awards-accelerated-approval-to-imfinzi--durvalumab--in-urothelial-carcinoma---astrazeneca-medimmune-/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-panorama-trial-of-eylea-shows-positive-results-in-diabetic-retinopathy---regeneron-pharma/2021-09-24T07:12:08+00:00weekly0.6https://www.medthority.com/news/2016/03/results-of-phase-iii-trial-of-otiprio--ciprofloxacin-otic-suspension--in-tympanostomy--published-in-jama-otolaryngology--otonomy/2024-02-09T16:26:11+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-accepts-sbla-for-sprycel-for-pediatric-patients-with-newly-diagnosed-philadelphia-chromosome-positive--ph---acute-lymphoblastic-leukemia--all----bms-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-filing-of-shp-555-for-chronic-idiopathic-constipation---shire-/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2015/11/chmp-recommends-benepali--etanercept-biosimilar---biosimilar-candidate-to-the-reference-product-enbrel--biogen---merck/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-kineret-for-caps-treatment/2021-09-24T07:15:57+00:00weekly0.6https://www.medthority.com/news/2018/08/alcon-withdraws-cypass-micro-stent-from-the-global-market-/2021-09-24T07:06:12+00:00weekly0.6https://www.medthority.com/news/2017/11/research-finds-possible-link-between-anabolic-androgenic-steroids-and-coronary-artery-disease/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2014/07/study-of-tozadenant-from-biotie-published-in-the-lancet-for-parkinsons-disease/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-otiprio--ciprofloxacin-otic-suspension--to-treat-otitis-media-paediatric-patients-undergoing-tympanostomy-tube-placement--otonomy/2021-09-24T07:04:30+00:00weekly0.6https://www.medthority.com/news/2012/09/legion-hk-hinge-knee-implant-launched-by-smith---nephew-in-us-and-canada---------------/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2016/05/nice-now-recommends-benlysta--belimumab--as-an-option-as-add-on-treatment-for-active-autoantibody-positive-systemic-lupus-erythematosus-in-adults--gsk/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2015/09/amgen-acquires-dezima-pharma-bv-and-ta-8995--a-cetp-inhibitor-for-dyslipidaemia/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2016/12/nn-9535--semaglutide-subcutaneous--filed-in-eu-and-us-for-type-2-diabetes--novo-nordisk/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2013/02/phase-iii-trial-of-naloxegol--astrazeneca--confirms-earlier-safety-studies-in-patients-with-opioid-induced-constipation/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/06/observational-study-finds-no-increased-risk-of-hospitalisation-for-heart-failure-with-onglyza--saxagliptin--compared-to-januvia--sitagliptin--in-type-2-diabetes--astrazeneca-/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2015/05/success-for-the-tyrx-absorbable-antibacterial-envelope-in-prevention-of-cardiac-device-site-infections--medtronic/2021-09-24T07:04:05+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-tafinlar--glaxo-smith-kline--for-braf-v600e-metastatic-melanoma/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2012/07/syncria--gsk--superior-to-januvia-in-harmony-8-study-in-renally-impaired-diabetes-patients/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-quadracel-vaccine-for-diptheria--tetanus--pertussis-and-polio--sanofi/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2015/02/biota-pharma-acquires-anaconda-pharma-including-lead-product-ap-611074-for-condyloma/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2019/05/data-for-aimovig-from-ole-trial-and-strive-trial-for-migraine-to-be-presented-at-american-academy-of-neurology-meeting---amgen/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2018/09/positive-phase-iii-results-for-soliris-to-treat-neuromyelitis-optica-spectrum-disorder--alexion-pharma/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2014/05/lemtrada-is-re-submitted-to-fda-for-multiple-sclerosis---genzyme-sanofi/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2014/12/merck-acquires-oncoethix/2025-10-16T11:09:42+00:00weekly0.6https://www.medthority.com/news/2019/05/positive-phase-iii-trial-of-epidiolex-to-treat-tuberous-sclerosis-complex---gw-pharma/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-trial-data-shows-improvement-due-to-cpx-351--cytarabine-daunorubicin--in-acute-myeloid-leukemia--celator-pharma/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-nda-for-fedratinib-to-treat-myelofibrosis---celgene/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2013/07/depomed-acquires-us-and-canadian-rights-to-lazanda-for-cancer-pain/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2013/03/stream-trial-shows-that-metalyse-tnkase--boehringer--offers-some-benefits-in-stemi-patients/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2015/03/success-for-saxenda--liraglutide-3-mg--in-scale-trial-showing-reduction-of-weight-and-comorbidities--novo-nordisk-/2021-09-24T07:04:15+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-juv-derm-voluma-xc--a-hyaluronic-acid-gel-dermal-filler--with-a-tsk-steriglide-cannula-for-cheek-augmentation--allergan-abbvie/2024-06-27T14:19:43+00:00weekly0.6https://www.medthority.com/news/2012/07/sanofi-pasteur-dengue-vaccine-success-in-clinical-trial/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2016/10/eu-chmp-recommend-change-to-authorisation-for-zebinix--eslicarbazepine--in-epilepsy--bial-portela/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2018/02/cold-open-water-plunge-provides-instant-pain-relief/2024-02-09T16:28:12+00:00weekly0.6https://www.medthority.com/news/2019/10/seattle-genetics-initiates-phase-iii-trial---her2climb-02---of-tucatinib---ado-trastuzumab-emtansine--to-treat-metastatic-her2-positive--her2---breast-cancer-/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2020/01/additional-indications-in-japan-for-fycompa-for-partial-onset-seizures--eisai/2021-09-24T07:11:48+00:00weekly0.6https://www.medthority.com/news/2017/06/previous-bacterial-infection-increases-risk-of-newly-diagnosed-sjogren-s-syndrome/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2018/05/abbv-066-filed-with-eu-for-moderate-to-severe-plaque-psoriasis---abbvie-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-sutent-to-treat-high-risk-patients-post-surgery-with-renal-cell-carcinoma---pfizer/2021-09-24T07:14:39+00:00weekly0.6https://www.medthority.com/news/2014/05/chmp-recommends-plegridy-as-a-treatment-for-multiple-sclerosis---biogen-idec/2021-09-24T07:08:05+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-cll14-study-of-venclexta---gazyva-meets-primary-endpoint-in-chronic-lymphocytic-leukemia---genentech-roche-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2016/12/sunovion-pharma-acquires-rights-in-us-to-utibron-neohaler--indacaterol---glycopyrrolate--seebri-neohaler--glycopyrrolate--and-arcapta-neohaler--indacaterol--from-novartis-/2021-09-24T07:10:08+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-updates-for-vipidia--vipdomet-and-incresync-for-t2d---takeda/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2017/01/filing-of-xgeva--denosumab--in-eu-to-treat-hypercalcaemia-of-malignancy-withdrawn-after-negative-review-by-chmp--amgen/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2012/09/assessment-finds-some-benefit-of--eliquis--bms-pfizer--in-patients-with-hip-replacements----------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2013/04/positive-trial-results-for-oms-302--omeros-corporation--in-cataract-surgery/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-krystexxa--savient-pharma--for-treatment-of-gout/2021-09-24T07:02:04+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-grants-full-approval-for-erivedge--vismodegib-to-treat-metastatic-basal-cell-carcinoma---genentech---roche/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2016/11/eptinezumab-in-new-phase-iii-trial-for-migraine--alder-biopharmaceuticals/2021-09-24T07:09:43+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-echelon-1-data-presented-at-ash-for-adcetris---chemo-to-treat-untreated-advanced-classical-hodgkin-lymphoma---takeda---seattle-genetics-/2024-02-09T16:28:37+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-octagram-10--for-itp---octapharma/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-study-309-results-for-halaven--eribulin--in-soft-tissue-sarcoma-published-in-the-lancet--eisai/2024-02-09T16:28:57+00:00weekly0.6https://www.medthority.com/news/2016/09/ema-s-chmp-recommends-approval-of-glyxambi--empagliflozin-and-linagliptin--for-type-2-diabetes--boehringer/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2011/09/fda-approves-abraxane-for-pancreatic-cancer/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-success-for-talimogene-laherparepvec--amgen--in-melanoma-/2021-09-24T07:15:42+00:00weekly0.6https://www.medthority.com/news/2016/04/sun-pharma-acquires-14-prescription-drugs-from-novartis-for-sale-in-japan/2021-09-24T07:10:50+00:00weekly0.6https://www.medthority.com/news/2014/04/eu-approves-vimizim-for-mps-iva---biomarin/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2016/10/uk-nice-rejects-imbruvica--ibrutinib--for-treating-waldenstrom-s-macroglobulinaemia--janssen/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-gives-expanded-approval-for-gammacore-for-preventive-treatment-of-cluster-headache---electrocore-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2012/08/phase-iii-development-of-bapineuzumab--janssen-alzheimer-immunotherapy--in-alzheimer-s-disease-discontinued/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2018/06/now-available--cardiovascular-metabolism-knowledge-centre/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2013/11/novartis-produces-mf-59-vaccine-against--h7n9-avian-influenza-virus/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-approves-harvoni--ledipasvir-and-sofosbuvir--to-treat-hepatitis-c-virus-in-children-ages-12-to-17--gilead-sciences/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2018/05/avxs-101-results-from-strive-trial-for-spinal-muscular-atrophy---avexis-inc-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-kalydeco-for-cystic-fibrosis-r117h-mutation--vertex/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-positive-for-kalydeco--to-treat-patients-with-cystic-fibrosis-aged-12-to-less-than-24-months-with-certain-mutations-in-the-cftr-gene---vertex-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/10/ce-mark-for-acumen-hypotension-probability-indicator--edwards-life-sciences/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2011/11/fda-approves-helifx-aortic-securement-system--actus-endosystems--for-treating-aortic-endografts/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2012/05/bg-12--biogen--is-filed-at-fda-and-ema-for-multiple-sclerosis/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2013/12/eu-regulator-approves-dexilant-for-gerd-takeda/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2015/06/tafinlar--dabrafenib----mekinist---trametinib--success-in-combi-d-trial-for-braf-v600e-k-mutation-positive-metastatic-melanoma--novartis/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2014/10/bms-to-discontinue-sunvepra--asunaprevir--fda-approval-process-in-us-for-hepatitis-c-/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2015/06/rapamune--sirolimus--is-fda-approved-for-lymphangioleiomyomatosis--pfizer/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2018/09/vertex-completes-enrollment-of-phase-iii-studies-of-vx-659-triple-combination-to-treat-cystic-fibrosis-in-people-with-f508del-mutations-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2020/01/dayvigo-is-approved-in-japan-to-treat-insomnia--eisai/2021-09-24T07:11:48+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-accepts-intercept-s-nda-for-oca-for-the-treatment-of-liver-fibrosis-due-to-nash-and-grants-priority-review-/2024-11-12T13:40:29+00:00weekly0.6https://www.medthority.com/news/2014/06/prevenar-13-approved-in-japan-for-older-adults-pfizer/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2015/02/five-year-safety-results-from-closure-fast-ablation-catheter-for-chronic-venous-insufficiency-published-in-brit--journal-of-surgery--medtronic-covidien/2024-02-09T16:29:21+00:00weekly0.6https://www.medthority.com/news/2019/08/anifrolumab-phase-iii-trial-tulip-2---meets-primary-endpoint-in-systemic-lupus-erythematosus--astrazeneca/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-endorses-new-pivotal-trial-of-am-111-for-patients-with-acute-profound-hearing-loss---auris-medical/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2016/09/european-commission-approves-orencia--abatacept---mtx-to-treat-ra-patients-not-previously-treated-with-mtx---bms/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2011/12/chmp-recommends-procoralan--servier-labs--for-chronic-heart-failure/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2016/09/astrazeneca-launches-programme-to-assess-the-potential-benefits-of-forxiga--dapagliflozin--for-kidney-disease-and-heart-failure-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2015/10/second-generation-overa-test-for-ovarian-cancer-receives-eu-ce-mark-approval-vermillion/2024-02-09T16:35:33+00:00weekly0.6https://www.medthority.com/news/2013/10/phase-iii-success-for-eylea--regeneron-bayer--for-brvo/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2016/08/jama-publishes-cost-effective-analysis-of-pcsk-9-drugs---amgen-regnereon-sanofi-/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-appproves-somatuline-depot-to-treat-gastroenteropancreatic-neuroendocrine-tumors--ipsen/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-nucala--mepolizumab--to-treat-severe-asthma--gsk/2024-02-09T16:35:46+00:00weekly0.6https://www.medthority.com/news/2019/05/pivotal-phase-iii-trial-of-yupelri-shows-additional-control-of-copd/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-xeomin-for-chronic-sialorrhea---merz-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-accepts-sbla-for-keytruda-to-treat-advanced-small-cell-lung-cancer----merck-inc--/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2016/04/merck-inc--will-not-seek-approval-for-marizev--omarigliptin--in-the-us-or-eu-for-type-2-diabetes-management/2021-09-24T07:10:41+00:00weekly0.6https://www.medthority.com/news/2013/05/phase-ii-study-of-ormd-0801--oramed-pharmaceuticals--successful-for-type-1-diabetes-treatment/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2018/10/journal-of-drugs-in-dermatology-has-published-results-of-two-phase-iii--trials-on-the-safety-and-efficacy-of-bryhali-to-treat--psoriasis--ortho-dermatologics/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2016/07/european-commission-approves-zinbryta--subcutaneous-daclizumab--to-treat-relapsing--multiple-sclerosis---biogen---abbvie/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-tiglutik-oral-suspension-for-amyotrophic-lateral-sclerosis---itf-pharma-/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2017/07/astrazeneca-and-merck-inc---to-collaborate-on-lynparza--olaparib--for-multiple-cancer-types-and-on-selumetinib-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-stendra--vivus-inc--for-erectile-dysfunction/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-natpara-for-hypoparathyroidism-nps-pharma-shire/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2019/11/advisory-committee-recommends-vascepa-to-reduce-the-risk-of-cardiovascular-events---amarin-corpn-/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-eu-label-expansion-of-synflorix-vaccine-for-pneumococcal-disease--glaxo-smith-kline/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-advisory-committee-to-review-repatha--evolocumab-for-treatment-of-high-cholesterol-on-10-june-2015-amgen/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2013/11/mitra-clip-therapy--abbott-vascular--data-published-in-jacc-/2021-09-24T07:16:37+00:00weekly0.6https://www.medthority.com/news/2019/07/fibrogen-announces-first-patient-dosed-in-zephyrus--a-phase-iii-clinical-trial-of-pamrevlumab-for-idiopathic-pulmonary-fibrosis-/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2018/01/eravacycline-filed-at-fda-to-treat-complicated-intra-abdominal-infections---tetraphase-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-expands-prescribing-information-for-fanapt--iloperidone--for-schizophrenia-in-adults--vanda-pharma/2024-02-09T16:35:57+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-zykadia-for-nsclc-novartis/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2012/05/phase-iii-trials-shows-vyvanse--shire--effective-in-children-and-adolescents-with-adhd/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2012/07/eisai-applies-to-ema-to-extend-use-of-zonegran-to-children-for-treatment-of-partial-seizures-/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2017/07/european-commission-approves-besponsa--inotuzumab-ozogamicin--as-monotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cd22-positive-b-cell-precursor-acute-lymphoblastic-leukemia--all---pfizer/2024-02-20T10:22:56+00:00weekly0.6https://www.medthority.com/news/2015/08/humira--adalimumab--is-eu-approved-to-treat-hidradenitis-suppurativa---abbvie/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2015/05/gsk-2696273-is-filed-at-ema-to-treat-adenosine-deaminase-severe-combined-immunodeficiency-syndrome--ada-scid---gsk/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2018/04/positive-data-indicate-that-patients-with-unilateral-knee-oa-pain-treated-with-zilretta-experienced-significant-and-sustained-improvements-in-pain--function--and-knee-related-quality-of-life-metrics---flexion-terpeutics-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-accepts-sbla-for-dupixent-as-an-add-on-maintenance-treatment-for-children-with-moderate-to-severe-atopic-dermatitis--sanofi---regeneron/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2019/12/mylan-and-biocon-launch-ogivri-in-the--us--being-the-first-biosimilar-trastuzumab-approved-by-the-fda-/2021-09-24T07:18:39+00:00weekly0.6https://www.medthority.com/news/2018/03/cabometyx-filed-with-fda-for-treating-previously-treated-advanced-hepatocellular-carcinoma---exelixis-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2019/01/safety-trial-of-in-pact-admiral-drug-coated-balloon-shows-no-link-to-mortality-in-peripheral-artery-disease---medtronic/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2011/11/komboglyze--bms-astrazeneca--is-eu-approved-as-a-combination-for-type-2-diabetes/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2017/08/nice-recommends-holoclar--ex-vivo-expanded-autologous-human-corneal-epithelial-cells-containing-stem-cells---to-treat-severe-limbal-stem-cell-deficiency--chiesi-farmaceutici-spa/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-grants-accelerated-approval-for--keytruda--pembrolizumab--in-combination-with-alimta--pemetrexed------carboplatin--for-the-first-line-treatment-of-metastatic-nonsquamous-nsclc----merck-inc----eli-lilly/2021-09-24T07:14:31+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-the-cobas-taqman-hiv-1-test--roche-/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2011/12/truvada-filed-at-fda-for-reduction-in-hiv-risk/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2018/09/successful-phase-iii-a16-study-of-flortaucipir-f-18---a-pet-agent-to-predict-alzheimers-disease-diagnosis----eli-lilly-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-mst-188--vepoloxamer--fails-to-meet-endpoint-in-sickle-cell-disease--mast-therapeutics/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2018/03/world-down-syndrome-day-2018-/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2014/01/phase-iii-results-of-alo-02-for-moderate-to-severe-low-back-pain-pfizer/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-nexobrid-for-treatment-of-burns---------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2012/03/phase-ii-success-of-sar236553-regn727-for-cholesterol-lowering--/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2015/03/results-of-study-with-total-artificial-heart-published-in-transplantation-procs-syncardia/2024-02-23T14:28:59+00:00weekly0.6https://www.medthority.com/news/2018/04/fda-510-k--approval-for-advantage-plus-pass-thru-automated-endoscope-reprocessor-for-infection-prevention--cantel-corpn-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-ii-iii-trial-of-rgn-259--thymosin-beta-4--for-the-treatment-of-dry-eye-fails-to-meet-endpoint-regenerx-biopharmaceuticals/2024-02-20T10:23:13+00:00weekly0.6https://www.medthority.com/news/2012/05/health-canada-approves-prochymal--osiris-therapeutics--for-graft-v-host-disease-in-children-/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2012/09/chmp-recommends-galvus-plus-insulin-and-eucras-triple-therapy-for-type--2-diabetes/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2017/10/va-106483--fedovapagon--meets-primary-endpoint-in-equinoc-phase-iii-trial-for-nocturia-in-men-with-benign-prostatic-hyperplasia---vantia-therapeutics-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2019/08/ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies--novartis/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2019/12/eu-approves-kadcyla-for-her2-positive-early-breast-cancer-with-residual-invasive-disease---roche/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2016/12/results-of-rapid-study-of-zemaira--alpha1-antitrypsin--in-patients-with-alpha-1-antitrypsin-deficiency-published-in-the-lancet-resp-medicine--csl-behring/2022-09-14T13:30:13+00:00weekly0.6https://www.medthority.com/news/2018/10/heartmate-3-heart-pump-is-now-fda-approved-for-advanced-heart-failure-patients-not-eligible-for-a-heart-transplant--abbott/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2013/10/eu-extends-approval-of-prevnar-13--pfizer--to-young-with-scd/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2016/01/trial-of-grazax--sublingual-allergy-immunotherapy-tablet--shows-benefits-in-allergy-prevention-alk-/2024-02-20T10:23:33+00:00weekly0.6https://www.medthority.com/news/2019/06/nucala-receives-positive-chmp-opinion-for-new-self-administration-options----gsk-/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2018/12/interim-analysis-of-long-term-study-shows-zydis-safe-for-migraine---biohaven-pharmaceutical-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-review-clears-testosterone-medicines-of-increased-risk-of-heart-problems-/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2012/03/chmp-recommends-extended-approval-for-menveo-novartis-for-meningococcal-disease/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-approves-snda-for-viekira-pak--ombitasvir--paritaprevir--and-ritonavir-tablets--dasabuvir-tablets--in-genotype-1b-chronic-hepatitis-c-virus-infection-and-compensated-cirrhosis--child-pugh-a---abbvie/2024-02-20T10:23:52+00:00weekly0.6https://www.medthority.com/news/2012/06/mdv-3100--astellas--for-prostate-cancer-submitted-to-ema-for-marketing-authorisation/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2019/07/wcd-2019---no-pain-more-gain--biophotonic-therapy-showing-great-results-1/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2019/07/ddw-2019---appendix-removal-associated-with-development-of-parkinson-s-disease/2021-09-24T07:18:14+00:00weekly0.6https://www.medthority.com/news/2016/02/incyte-announces-decision-to-discontinue-janus-studies-of-ruxolitinib--jakavi-jakafi--plus-capecitabine-in-patients-with-advanced-or-metastatic-pancreatic-cancer---incyte---novartis/2024-02-20T10:27:42+00:00weekly0.6https://www.medthority.com/news/2017/10/world-congress-on-controversies-in-breast-cancer/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-approves-change-to-authorisation-for-repatha--evolocumab--to-approve-single-dose-delivery-option-in-dyslipidaemia-treatment--amgen/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2018/04/canvas-program-studying-invokana-in-type-2-diabetes-shows-benefits---janssen-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2020/01/tecentriq-fails-in-phase-iii-imvigor010-study-as-an-adjuvant--after-surgery--monotherapy-compared-to-observation-in-people-with-muscle-invasive-urothelial-cancer---genentech-roche/2021-09-24T07:11:47+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-accepts-priority-review-for-xarelto--rivaroxaban--in-venous-thromboembolism--janssen/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-rejects-masican-for-gist--ab-science/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2018/07/new-data-on-the-impact-of-truvada-for-pre-exposure-prophylaxis--prep--on-the-number-of-hiv-diagnoses-in-the-united-states--gilead-sciences-/2021-09-24T07:06:57+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-velcade-for-treatment-of-mantle-cell-lymphoma--janssen-cilag-/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/06/ta-8995-success-in-phase-iib-tulip-study-for-dyslipidaemia--dezima-pharma/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2018/04/ce-mark-for-vagus-nerve-stimulation-therapy-from-liva-nova-to-treat-epilepsy-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2014/09/iqwig-finds-no-added-benefit-for-myrbetriq-in-overactive-bladder-astellas/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2011/03/merck-inc--returns-rights-to-betrixaban-to-portola-pharma/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2018/07/patent-appeal-positive-for-gilenya-extending-exclusivity-to-2027----novartis-/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/05/ce-mark-granted-for-rectiv8-neurostimulation-system-to-treat-disabling-chronic-low-back-pain--mainstay-medical/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2015/10/development-of-evacetrapib-to-treat-high-risk-atherosclerotic-cv-disease-is-stopped--eli-lilly/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-tresiba--insulin-degludec-injection--for-type-1-and-2-diabetes--novo-nordisk/2024-02-20T10:27:56+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-new-dosage-of-exelon--novartis--for-patients-with-alzheimers/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-from-study-of-pteropure--glanbia--in-patients-with-high-cholesterol/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2017/06/two-phase-iii-trials-of-tafenoquine-show-treatment-benefits-for-malaria---gsk-and-medicines-for-malaria-venture/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2012/01/combination-treatment-with-tekturna-rasilez--novartis--raises-risk-for-patients-with-hypertension/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2017/10/european-decentralised-procedure--dcp--approval-for-flutiform-k-haler-to-treat-asthma----mundipharma-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-secure-trial-of-twirla--contraceptive-patch--shows-positive-topline-results--agile-therapeutics/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-extending-use-of-tamiflu--oseltamivir--to-infants-with-influenza--roche/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2011/10/medimmune-and-pfizer-collaborate-on-anti-cancer-tremelimumab/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2019/12/ocaliva-filed-at-ema-to-treat-fibrosis-due-to-nash-and-fda-sets-advisory-committee-meeting-date---intercept-pharma-/2021-09-24T07:18:30+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-chmp-adopts-change-to-indication-for-revolade--eltrombopag--in-thrombocytopenic-purpura--novartis/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-gives-510-k--approval-for-leksell-gamma-knife-icon-radiosurgery-system--elekta/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2017/11/results-from-a-study-on-procysbi-delayed-release-capsules-in-treatment-na-ve-children-younger-than-6-years-of-age-with-nephropathic-cystinosis---horizon-pharma-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-approves-xcopri-to-treat-partial-onset-seizures-in-adults----sk-biopharma/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2016/12/chmp-positive-for-lifmior--etanercept-to-treat-same-conditions-as-enbrel---pfizer/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2016/12/interim-results-from-the-abound-clinical-trial-program-of-abraxane--paclitaxel-protein-bound-particles-for-injectable-suspension--for-advanced-nsclc----celgene/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2014/05/ultibro-breezhaler-non-inferior-to-tiotropium-plus-formoterol-in-quantify-study-of-copd---novartis/2021-09-24T07:08:08+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-approves-new-indication-for-xtandi-in-prostate-cancer-astellas-medivation/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2018/05/valeant-pharmaceuticals-inernational-to-be-renamed-bausch-health-companies-inc-/2021-09-24T07:07:11+00:00weekly0.6https://www.medthority.com/news/2019/02/opdivo---yervoy-30-month-results-from-checkmate-214-study-for-renal-cell-carcinoma---bms/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2020/01/morphosys-and-incyte-sign-global-collaboration-and-license-agreement-for-tafasitamab-/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-change-to-indication-for-novoseven-in-haemophilia---novo-nordisk-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/01/cangrelor--astrazeneca--the-medicines-company--maintains-platelet-inhibition-and-anti-clotting-levels-prior-to-cardiac-surgery/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2019/12/roche-acquires-non-us-rights-to-srp-9001-from-sarepta-therapeutics--a-treatment-for--duchenne-muscular-dystrophy-/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2015/05/positive-phase-iii-results-for-humira--adalimumab--in-uveitis--abbvie/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-of-kadcyla-for-adjuvant-treatment-of-her2-positive-early-breast-cancer---roche/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2011/09/study-finds-benefits-of-xolair-for-allergic-asthma-treatment-/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-trial-of-itca-650--continuous-subcutaneous-exenatide--in-type-2-diabetes-meets-all-endpoints--intarcia-therapeutics/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2015/08/esperion-therapeutics-update-on-phase-iii-programme-for-etc-1002--bempedoic-acid--to-treat-familial-hypercholesterolemia-and-atherosclerotic-cardiovascular-disease/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2016/06/dupilumab-success-in-liberty-ad-chronos-trial-for-treatment-of-atopic-dermatitis---sanofi---regeneron/2021-09-24T07:10:05+00:00weekly0.6https://www.medthority.com/news/2012/06/i-stent--glaukos-corporation--is-fda-approved-for-cataract-surgery/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2017/11/inveltys-is-filed-at-fda-to-treat-inflammation-and-pain-after-ocular-surgery---kala-pharmaceuticals-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2011/11/novottf-100a--novocure--therapy-achieves-encouraging-long-term-survival-time-for-glioblastoma-patients-/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2013/01/nice-recommends-eliquis--pfizer-bms--for-stroke-prevention/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2015/10/nice-recommends-daklinza--daclatasvir--to-treat-hepatitis-c-genotypes-1--3-and-4-in-combination-with-other-agents--bms/2021-09-24T07:03:12+00:00weekly0.6https://www.medthority.com/news/2015/03/topline-results-from-phase-iii-trial-of-nktr-102--etirinotecan-pegol--in-breast-cancer-nektar-therapeutics/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2011/08/nice-recommends-tasigna-for-ph-cml/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2014/05/astrazeneca-rejects-latest-pfizer-offer/2025-10-16T10:53:09+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-pomalidomide-celgene-as-a-treatment-for-multiple-myeloma-/2021-09-24T07:16:09+00:00weekly0.6https://www.medthority.com/news/2018/10/pureflow-system-receives-510-k--clearance-from-fda-for-chronic-stable-angina---xtreem-pulse-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2012/07/gilead-sciences-files-cobicistat-booster--for-aids-drugs/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2017/01/uk-s-nice-recommends-use-of-cimzia--certolizumab-pegol--in-active-psoriatic-arthritis--ucb/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-eylea--regeneron--for-macular-oedema-following-central-retinal-vein-occlusion-/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-epic-nitinol-stent--boston-scientific--for-iliac-artery-disease/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2018/01/mdt-2113-study-of-in-pact-admiral-drug-coated-balloon-shows-consistent-benefits-in-peripheral-artery-disease---medtronic-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-scenesse-for-the-rare-dermatology-disorder-of--erythropoietic-protoporphyria----clinuvel-pharmaceuticals/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2012/06/medtronic-files-pma-for-minimed-530g-system-for-diabetes-monitoring-and-treatment/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2016/06/shire-merger-with-baxalta-completed-/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2014/06/envarsus-xr-continues-to-perform-as-expected-in-phase-iii-trial-of-kidney-transplant-patients-veloxis-pharma/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2012/12/viiv-healthcare-files-dolutegravir-for-hiv-treatment-in-eu--us-and-canada/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2018/08/week-96-results-from-the-phase-iii-drive-forward-clinical-trial-of-doravirine-in-combination-with-other-antiretroviral-agents-for-treatment-of-hiv-1-infection-in-adult-patients-with-no-prior-antiretroviral-treatment-history---merck-inc-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2018/10/final-phase-iii-study-of-bempedoic-acid--to-treat-atherosclerotic-cardiovascular-disease----esperion/2021-09-24T07:05:38+00:00weekly0.6https://www.medthority.com/news/2018/07/genentech-roche-files-snda-at-the-fda--for-venclexta--in-combination-with-a-hypomethylating-agent-or-in-combination-with-low-dose-cytarabine--ldac--to-treat-people-with-previously-untreated-acute-myeloid-leukemia--aml--/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/09/eu-chmp-recommends-approval-of-ibrance--palbociclib--for-breast-cancer--pfizer/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2012/08/omnilink-elite-vascular-balloon-expandable-stent-system--abbott-vascular--for-iliac-artery-disease----------------/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2013/04/eu-extends-berinert--csl-behring--indication-for-pre-procedure-prevention-of-acute-hae-episodes/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2017/01/fda-approves-trulance--plecanatide---chronic-idiopathic-constipation--synergy-pharma/2021-09-24T07:13:05+00:00weekly0.6https://www.medthority.com/news/2017/12/phase-iii-haven-4-trial-of-hemlibra-positive-for-prophylaxis-of-hemophilia-a-patients-dosed-once-every-four-weeks--roche-genentech-/2024-07-26T10:24:24+00:00weekly0.6https://www.medthority.com/news/2012/04/eteplirsen--avi-biopharma--results-in-phase-iib-study-in-duchenne-muscular-dystrophy/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-investigation-into-essure-contraceptive-device-adverse-events-conceptus-bayerhealth-care/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2016/05/uk-nice-issues-positive-recommendation-for-zykadia--ceritinib--to-treat-alk--non-small-cell-lung-cancer--novartis/2021-09-24T07:09:28+00:00weekly0.6https://www.medthority.com/news/2016/01/amg-827--brodalumab--filed-with-fda-for-plaque-psoriasis--astrazeneca-valeant/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2018/07/european-commission-approves-hyrimoz--an-adalimunab-biosimilar--for-all-indications-of-the-reference-medicine----sandoz/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2017/09/optima-study-shows-urticaria-patients-respond-well-to-re--treatment-with-xolair--omalizumab---novartis-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2012/01/alcon-acquires-north-american-rights-to-finafloxacin-for-ear-infections-/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2017/08/european-commission-approves-maviret--glecaprevir-pibrentasvir---a-once-daily--ribavirin-free-treatment-for-adults-with-chronic-hepatitis-c-virus---abbvie/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2015/04/homechoice-claria-peritoneal-dialysis--apd--system-receives-ce-mark--baxter/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-range-trial-of-cyramza-shows-positive-trend-in-advanced-urothelial-carcinoma---eli-lilly-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2013/07/positive-phase-iii-results-with-eklira--almirall--published-in-copd-journal-/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-zorvolex-for-osteoarthritis-pain---iroko-pharma/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-lifts-partial-hold-on-trials-for-durvalumab-for-treatment-of-head-and-neck-cancer--astrazeneca/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-afx2-bifurcated-endograft-system-for-abdominal-aortic-aneurysms--endologix/2021-09-24T07:03:16+00:00weekly0.6https://www.medthority.com/news/2013/09/flutiform-enters-phase-iii-for-copd/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-accepts-nda-for-review-vesneo--latanoprostene-bunod-ophthalmic-solution--for-treatment-of-glaucoma-or-ocular-hypertension--bausch---lomb-and-nicox-sa/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2013/03/study-shows-picato--leo-pharma--provides-sustained-clearance-of-actinic-keratosis-at-12-months/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2013/07/chmp-recommends-ilaris--novartis--for-sjia/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-gives-accelerated-approval-for-alunbrig--brigatinib--in-anaplastic-lymphoma-kinase-positive--alk---metastatic-non-small-cell-lung-cancer--takeda/2021-09-24T07:14:09+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-accepts-sbla-for-keytruda--pembrolizumab--based-on-keynote-010-study-in-nsclc-confirmatory-for-full-approval--merck-inc-/2024-02-20T10:28:10+00:00weekly0.6https://www.medthority.com/news/2012/07/two-phase-iii-studies-of-oms-electrochemotherapy--oncosec-medical--show-qol-benefits/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2018/10/four-year-data-from-phase-iii-checkmate-067-trial-shows-durable-long-term-survival-results-with-opdivo---yervoy--bms/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2013/09/chmp-recommends-abilify-maintena-to-reduce-relapse-in-schizophrenia/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2019/11/positive-phase-iii-achieve-ii-trial-results-for-ubrogepant-published-in-the-journal-of-the-american-medical-association---allergan/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-approves-gazyvaro--obinutuzumab--for-follicular-lymphoma---roche/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2017/04/acorda-therapeutics-reports-two-long-term-safety-studies-for-cvt-301-for-treatment-of-parkinson-s-disease-/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-will-review-cabozantinib--exelixis-inc--as-a-treatment-for-thyroid-ccancer-on-29-november-2012/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2013/11/abbvie-reports-sapphire-1-study-3d-regimen-for-hepatitis-c/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2018/07/complete-response-for-buprenorphine-sublingual-spray-as-a-treatment-for-moderate-to-severe-acute-pain---insys-therapeutics-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2016/09/ace1rx-pharma-completes-final-phase-iii-trial-for-arx-04--sufentanil-sublingual-tablet-for-the-management-of-moderate-to-severe-acute-pain-/2021-09-24T07:09:18+00:00weekly0.6https://www.medthority.com/news/2012/05/bolero-2-study-update-for-afinitor--novartis--in-hr--breast-cancer--presented-at-asco/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2011/02/mistent--micell-technologies--enters-phase-iii-trial-for-cad/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2014/03/new-combination-of-sovaldi---gs-5816-success-in-hepatitis-c-study---gilead/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-for-phase-iii-study-of-enzalutamide--medivation--for-prostate-cancer-treatment/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-places-partial-hold-on-durvalumab-as-monotherapy-and-in-combination-with-tremelimumab-in-trials-for-head-and-neck-cancer--astrazeneca/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-aklief-cream-for-acne---galderma/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2019/05/european-commission-approves-waylivra-to-treat-patients-with-familial-chylomicronemia-syndrome-at-high-risk-for-pancreatitis---akcea-therapeutics-ionis-pharma/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2016/04/allergan-plc-acquires-rights-to-muscarinic-receptor-agonists-for-neurological-disorders-from-heptares-sosei-and-with-it-htl-9936-and-htl-18318-in-phase-i-development/2021-09-24T07:10:46+00:00weekly0.6https://www.medthority.com/news/2013/10/sancuso-launches-in--the-eu-for-nausea/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2018/01/complete-response-letter-for-twirla-contraceptive-patch---agile-therapeutics-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-advisory-committees--recommended-approval-of-abuse-deterrent--reformulation-of-roxicodone-by-the-nasal-route-to-manage-severe-pain---specgx---mallinckrodt-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-has-approved-actpen-162-mg-0-9-ml-autoinjector-for-actemra--genentech-roche-/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2013/03/nice-now-recommends-esbriet--intermune--for-idiopathic-pulmonary-fibrosis/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-magvita-tms-therapy-system-for-depression-magventure/2024-10-21T14:49:27+00:00weekly0.6https://www.medthority.com/news/2016/01/european-commission-approves-cyramza--ramucirumab-for-indications-in-nsclc-and-colorectal-cancer-eli-lilly-/2024-02-20T10:28:25+00:00weekly0.6https://www.medthority.com/news/2012/04/chmp-recommends-flutiform--skye-pharma-mundipharma--for-asthma/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2019/11/study-017-trial-of-safety-and-efficacy-of-ykp-3089-in-focal-seizures-published-in-the-lancet-neurology---sk-life-science/2021-09-24T07:17:57+00:00weekly0.6https://www.medthority.com/news/2018/07/new-data-further-supports-the-clinical-relevance-of-peak-expiratory-flow-as-a-predictor-of-disease-progression-in-duchenne-muscular-dystrophy---santhera-pharma-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iiib-assess-study-of-gilenya-meets-primary-endpoint-against-copaxone-in-ms---novartis-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-results-for-cosentyx--secukinumab--in-ankylosing-spondylitis-published-in-new-england-journal-of-medicine--novartis-/2024-02-20T10:28:48+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-gives-tentative-approval-for-admelog--insulin-lispro-injection--for-glycemic-control-in-adults-and-children-with-diabetes--sanofi-/2021-09-24T07:14:02+00:00weekly0.6https://www.medthority.com/news/2017/04/european-atherosclerosis-society--eas--host-85th-annual-congress/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-giotrif-for-nsclc-patients-with-egfr-mutations/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-extends-melanoma--indication-of-yervoy--bms-/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-gives-510-k--approval-to-ablatherm-integrated-imaging-hifu-for-prostate-cancer--edap-tms/2024-10-22T08:16:59+00:00weekly0.6https://www.medthority.com/news/2019/08/baxter-launches-in-the-eu-olimel-n12--a-new-addition-to-the-company-s-olive-oil-based-parenteral-nutrition-/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2017/03/nice-in-final-guidance-rejects-onivyde--nanoliposomal-encapsulated-irinotecan--in-combination-with-chemotherapy-as-a-cost-effective-treatment-for-metastatic-pancreatic-cancer---shire-plc-/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2012/09/lundbeck-files-vortioxetine-at-ema-for-major-depressive-episodes---------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2013/11/eu-approves-vitekta--gilead-sciences--for-hiv/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2014/11/astrazeneca-transfers-myalept-for-lipodystrophy-to-aegerion-pharma-/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-bevyxxa--betrixaban--to-treat--venous-thromboembolism--vte---portola-pharmaceuticals-inc-/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-advisory-committee-recommends-spiriva-respimat-for-treatment-of-copd---boehringer/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/10/nice-recommends-ezetrol--ezetimibe--in-primary--heterozygous-familial-and-non-familial--hypercholesterolaemia--merck-inc/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2011/06/insulin-degludec-success-in-types-1-and-2-diabetes/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2013/11/bms-files-daclatasvir---asunaprevir-in-japan-for-hepatitis-c/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2011/10/cialis--phase-iii-study-in-benign-prostatic-hyperplasia-is-reported-in-jo-sexual-medicine-/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2018/06/retrospective-review-of-patient-records--with-metastatic-adenocarcinoma-of-the-pancreas---shire-plc/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2018/06/motif-bio-plc-completes-rolling-submission-to-fda-for-iclaprim-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections--absssi--/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2015/12/janssen-files-at-fda-and-ema-seeking-approval-for-stelara--ustekinumab--to-treat-moderately-to-severely-active-crohn-s-disease-/2024-02-19T10:44:40+00:00weekly0.6https://www.medthority.com/news/2017/04/nice-now-recommends-mechanical-thrombectomy-procedures-to-remove-blockages-in-the-cerebral-arteries-/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2018/12/real-world-data-shows-revolade-improves-outcomes-for-itp-patients-compared-to-other-second-line-therapies---novartis/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2019/05/patient-enrollment-completed-in-phase-iii-reset-trial-of-rivipansel-for-the-acute-treatment-of-vaso-occlusive-crisis-in-sickle--cell-disease----glycomimetics---pfizer-/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2012/07/namenda--merz--positive-in-down-s-syndrome-trial/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-zerbaxa--ceftolozane---tazobactam-for-treatment-of-ciai--cuti-and-acute-pyelonephritis--merck-inc-/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2017/08/european-commission-approves-kisqali--ribociclib--in-combination-with-an-aromatase-inhibitor-for-treatment-hr--her2---locally-advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:14:53+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-approval-of-orkambi--lumacaftor-ivacaftor--to-treat-cystic-fibrosis-patients-with-two-copies-of-the-f508del-mutation--vertex/2021-09-24T07:03:43+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-darzalex--daratumumab--plus-pomalidomide-and-dexamethasone-for-multiple-myeloma--janssen-biotech/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends--cyramza---paclitaxel-for-advanced-gastric--stomach--or-gastroesophageal-junction--gej--adenocarcinoma---eli-lilly/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2018/05/interim-analysis-of-champ-hf-registry-shows-chronic-heart-failure-patients-on-entresto-demonstrate-improved-health---novartis-/2021-09-24T07:07:04+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-iperia-promri-hf-t-cardiac-resynchronization-defibrillator-for-heart-failure--biotronik/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-extending-indication-of-kuvan--sapropterin-dihydrochloride--to-children-with-phenylketonuria-below-4-years-of-age-merck-serono/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2011/12/patients-with-chronic-hepatitis-c-may-benefit-from-victrelis--merck--but-extent--unclear/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-trial-of-gimoti--metoclopramide-nasal--fails-to-meet-endpoint-but-shows-some-benefits-in-recurrent-diabetic-gastroparesis--evoke-pharma/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-switch1-trial-of-tresiba--insulin-degludec--meets-endpoint-in-type-1-diabetes--novo-nordisk/2024-02-19T10:44:51+00:00weekly0.6https://www.medthority.com/news/2018/09/array-biopharma-inc--announced-publication-in-the-lancet-oncology-of-the-columbus-trial-survival-results-for-melanoma-for-braftovi---mektovi-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2014/10/new-data-from-phase-iii-trial-of-entyvio-in-ulcerative-colitis-and-crohn-s---takeda/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2016/09/long-term-safety-findings-confirmed-in-phase-iii-trials-of-otezla--apremilast--in-plaque-psoriasis--and-psoriatic-arthritis--celgene/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-data-from-easie-trial-for-lantus--sanofi--in-patients-with-early-type-2-diabetes/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-advisory-panel-to-consider-expanding-the-label-of-jardiance--empagliflozin-to-include-reduction-of-cv-risk-in-type-2-diabetes--patients--eli-lily---boehringer/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2018/11/chmp-recommends-approval-of-macimorelin-as-diagnostic-for-growth-hormone-deficiency---aeterna-zentaris-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-senza-scs-system-for-chronic-pain--nevro-corp/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2019/08/mallinckrodt-announces-publication-of-results-of-phase-1b-clinical-trial-of-stratagraft-regenerative-tissue-in-burns/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2014/06/vertex-licenses-vx-787-for-influenza-to-janssen-pharma-/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-profound-trial-of-lynparza-shows-efficacy-in-prostate-cancer---astrazeneca---merck-inc/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-raplixa--fibrin-sealant--and-raplixa-spray-to-control-bleeding-the-medicines-company-/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2015/03/eu-expands-approval-of-prevenar-13-for-pneumonia-in-adults-pfizer/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-refuses-recommendation-for-winfuran-for-pruritus-toray-europe/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2015/02/actavis-launches-generic-pulmicort-respules-for-asthma-/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2013/02/adasuve---alexza-ferrer--is-eu-approved-to-control-agitation-in-schizophrenia-patients/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-laura-trial-full-results-support-potential-of-tagrisso--osimertinib-as-a-new-standard-of-care-for-egfr-mutated-nsclc--astrazeneca/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2019/10/european-commission-approves-nuceiva-to-treat-glabellar-lines--evolus-inc-/2021-09-24T07:17:26+00:00weekly0.6https://www.medthority.com/news/2018/05/american-society-of-clinical-oncology--asco--annual-meeting-2018/2024-07-26T10:42:03+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-bemfola-for-infertility--finox-bioscience/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2013/07/sobi-and-biogen-report-success-with-alprolix-as-a-treatment-for-haemophilia-b/2021-09-24T07:15:30+00:00weekly0.6https://www.medthority.com/news/2014/12/nice-does-not-recommend-entyvio-as-a-treatment-for-crohn-s-disease-takeda/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2013/09/ly-3009806-hits-endpoint-in-phase-iii-study-of-gastric-cancer/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/07/nice-recommends-lynparza-as-first-line-maintenance-therapy-for-ovarian-cancer-patients--astrazeneca/2021-09-24T07:18:03+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-map-us-study-of-rhb-104-meets-endpoint-in-crohn-s-disease--redhill-biopharma/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-authorisation-for-spherox-from-co-don-ag---to-treat-adult-patients-who-have-symptomatic-articular-cartilage-defects--/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2014/10/takeda-expands-market-coverage-of-amitiza--lubiprostone---sucampo---takeda/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2016/06/chmp-recommends-extension-of-marketing-authorisation-for-tysabri-natalizumab--for-relapsing-remitting-multiple-sclerosis---biogen/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2014/01/fda-approves-clinimacs-system-for-gvh-disease-miltenyi-biotec/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2016/03/resulta-of-lavolta-studies-of-lebrikizumab-for-treatment-of-severe-asthma--genentech/2024-02-19T10:48:06+00:00weekly0.6https://www.medthority.com/news/2016/05/successful-phase-ii-iii-trial-for-fasinumab-for-osteoarthritis-pain-of-hip-and-knee--regeneron/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2018/12/quantum-r-phase-iii-study-of-ac-220-consistent-with-overall-survival-data-in-acute-myeloid-leukemia---daiichi-sankyo-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-the-itrevia-dx-icd-for-arrhythmias-biotronik/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2012/12/nice-does-not-recommend-avastin--roche--as-a-treatment-for-ovarian-cancer/2021-09-24T07:02:38+00:00weekly0.6https://www.medthority.com/news/2015/06/keytruda-study--pembrolizumab--in-dna-mismatch-repair--mmr--deficiency-for-colorectal-cancer-merck-inc-/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2013/09/ema-accepts-filing-of-olaparib-for-ovarian-cancer/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2016/10/alnylam-pharmaceuticals--inc--discontinues-development-of-revusiran-for-the-treatment-of-hereditary-attr-amyloidosis-with-cardiomyopathy--/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2014/05/boston-scientific-acquires-interventional-division-of-bayer-ag-for--415-million/2025-10-16T11:16:13+00:00weekly0.6https://www.medthority.com/news/2019/12/abp-798-biosimilar-to-rituximab-has-bla-filed-at-the-fda-to-treat-the-conditions-of-the-originator-drug---amgen---allergan/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---kidney-transplant-patients-need-even-better-aftercare-/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2013/07/phase-iii-study-of-zonegran--eisai--in-younger-patients-with-epilepsy-shows-treatment-benefits/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2012/06/cranberry-juice-and-urinary-tract-infections-study/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2019/06/opdivo-in-checkmate-459-trial-versus-sorafenib-in-hepatocellular-carcinoma-fails-to-achieve-statistical-significance-for-overall-survival---bms/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-alpine-study-of-aristada---invega-sustenna-meets-endpoint-in-schizophrenia---alkermes/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2017/06/low-dose-ct-scanning-improves-assessment-of-ankylosing-spondylitis-patients/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2018/03/lundbeck-acquires-prexton-therapeutics-and-foliglurax--a-promising-treatment-for-parkinson-s-disease-/2021-09-24T07:06:29+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-advisory-committee-gives-restricted-recommendation-for-vibativ--theravance--for-nosocomial-pneumonia/2021-09-24T07:02:43+00:00weekly0.6https://www.medthority.com/news/2011/11/chmp-recommends-caprelsa--astrazeneca--for-thyroid-cancer/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2018/06/pf-04449913-filed-and-given-priority-review-by-fda-in-acute-myeloid-leukemia---pfizer-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2016/09/positive-interim-results-for-andexxa--andexanet-alfa-showed-reversal-of-anti-factor-xa-activity--portola-pharma/2021-09-24T07:09:24+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-gives-vent-os-sinus-dilation-system-ce-mark-approval-for-sinusitis--sinusys-corp/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2014/01/yttrium-90--90y--clivatuzumab-tetraxetan-enters-phase-iii-for-pancreatic-cancer--immunomedics--/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-phase-iii-data-for-krystexxa--savient-pharma--in-gout-patients-with-chronic-kidney-disease/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2013/11/trial-shows-efficacy--of-xeplion-in-schizophrenia--janssen-pharma/2021-09-24T07:16:26+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-study-of-lyrica-in-postherpetic-neuralgia-shows-benefits-pfizer/2021-09-24T07:08:31+00:00weekly0.6https://www.medthority.com/news/2018/10/integrated-safety-analysis-of-olumiant-over-six-years--eli-lilly---incyte/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2018/10/positive-phase-iii-pronto-t1d----pronto-t2d-studies-of-ultra-rapid-lispro-for-types-i---2-diabetes---eli-lilly/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2015/10/new-results-from-post-hoc-analysis-of-simponi--golimumab--in-ulcerative-colitis--msd/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2014/09/positive-phase-iii-data-for-invokana-in-t2d-janssen/2021-09-24T07:07:44+00:00weekly0.6https://www.medthority.com/news/2015/01/hospira-submits-bla-application-to-fda-for-retacrit--biosimilar-for-treatment-of-anaemia/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2017/06/pivotal-phase-iii-go-vibrant-study-of-simponi-aria--golimumab--shows-efficacy-in-psoriatic-arthritis--janssen-r-d/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2019/01/two-publications-that-support-remoxy-er-a-new-type-of-abuse-deterrent--twice-daily-capsule-gel-formulation-of-oxycodone---pain-therapeutics/2021-09-24T07:18:46+00:00weekly0.6https://www.medthority.com/news/2019/06/study-of-exparel-in-post-surgical-pain-shows-reduced-opioid-usage-after-dental-surgery---pacira-biosciences/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-keytruda-to-treat-small-cell-lung-cancer---merck-inc-/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2019/01/complete-response-letter-for-sacituzumab-govitecan-for-the-treatment-of-patients-with-metastatic-triple-negative-breast-cancer---immunomedics/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2015/06/study-shows-zebinix--eslicarbazepine-acetate--is-effective-and-well-tolerated-in-epilepsy-eisai/2021-09-24T07:03:32+00:00weekly0.6https://www.medthority.com/news/2013/08/afinitor-fails-phase-iii-trial-for-liver-cancer/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2017/03/results-of-phase-iii-einstein-choice-show-patients-with-venous-thromboembolism-taking-xarelto--rivaroxaban--have-reduced-bleeding-events--janssen-pharma/2024-11-15T08:45:24+00:00weekly0.6https://www.medthority.com/news/2015/12/sanofi-files-nda-at-fda-for-combination-of-insulin-glargine-and-lixisenatide--lixilan---to-treat-type-2-diabetes/2024-02-19T10:48:20+00:00weekly0.6https://www.medthority.com/news/2017/11/aibd-2017/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2018/02/american-college-of-legal-medicine-58th-annual-meeting-2018--aclm-2018-/2021-09-24T07:05:52+00:00weekly0.6https://www.medthority.com/news/2014/06/avp-825-meets-primary-endpoint-in-phase-iii-trial-for-migraine---avanir-pharma/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-breo-ellipta--fluticasone-furoate-vilanterol--ff-vi---for-asthma-in-adults-glaxo-smith-kline/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-keytruda-for-treatment-of-adult-and-pediatric-patients-with-refractory-primary-mediastinal-large-b-cell-lymphoma--pmbcl----merck-inc-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2012/06/sensipar--amgen--fails-endpoint-in-evolve-trial/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2016/11/st-jude-medical-notifies-physicians-to-halt-implants-of-the-nanostim-leadless-cardiac-pacemaker-/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2016/08/phase-iii-trials-show-repatha--evolocumab--reduces-ldl-c-levels-in-dyslipidaemia-with-cv-risks--amgen/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approve-coflex--paradigm-spinal--to-treat-moderate-to-severe-stenosis/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2016/11/results-of-aegis-i-study-of-csl-112-to-reduce-the-high-incidence-of-early-recurrent-cardiovascular-events-post-heart-attack---csl-behring/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2014/02/bay94-9027-effective-in-phase-iii-protect-viii-trial-for-haemophilia-a---bayer/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2018/04/regular-nut-intake-linked-to-lower-risk-of-heart-rhythm-irregularity--atrial-fibrillation-/2024-02-19T10:56:12+00:00weekly0.6https://www.medthority.com/news/2017/01/german-iqwig-concludes-additional-benefits-of-kisplyx--lenvatinib--plus-affinitor--everolimus--proven-in-advanced-renal-cell-carcinoma--eisai/2021-09-24T07:13:10+00:00weekly0.6https://www.medthority.com/news/2019/10/opdivo-demonstrates-statistically-significant-overall-survival-benefit-versus-chemotherapy-in-patients-with-advanced-esophageal-cancer---bms---ono-pharma/2021-09-24T07:17:30+00:00weekly0.6https://www.medthority.com/news/2017/09/esmo-2017-press-release--some-stroke-survivors-may-have-underlying-cancer/2021-09-24T07:13:58+00:00weekly0.6https://www.medthority.com/news/2014/11/success-in-phase-iii-trial-of-novottf-100a-for-brain-cancer---novocure/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2015/03/endo-offers--175-per-share-for-salix-/2025-10-16T11:00:46+00:00weekly0.6https://www.medthority.com/news/2014/02/covidien-buys-given-imaging-for--860-million-and-with-it-pill-cam/2025-10-16T10:57:19+00:00weekly0.6https://www.medthority.com/news/2019/08/urology-week-2019---learn-more/2021-09-24T07:17:44+00:00weekly0.6https://www.medthority.com/news/2017/10/revive-2--a-global-phase-iii-clinical-trial-has-success-in-evaluating-iclaprim-in-patients-with-acute-bacterial-skin-and-skin-structure-infections---motif-bio-/2021-09-24T07:13:30+00:00weekly0.6https://www.medthority.com/news/2017/06/besponsa--inotuzumab-ozogamicin--from-pfizer-is-found-not-cost-effective-by-nice--in-draft-guidance--to-treat-relapsed-or-refractory-cd22-positive-b-cell-precursor-acute-lymphoblastic-leukaemia----/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/10/study-shows-safety-and-efficacy-of-hizentra--csl-behring--for-treating-immunodeficiency/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2018/10/approved-and-investigational-multiple-sclerosis--ms--treatments-to-be-presented-at-ectrims-2018/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-accepts-filing-of-blu-285-for-exon-18-mutant-gastrointestinal-stromal-tumors---blueprint-medicines/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-premarket-approval-for-lutonix-035-drug-coated-balloon-pta-catheter-to-treat-end-stage-renal-disease---c-r-bard/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2014/03/nice-recommends-giotrif-for-egfr-positive-nsclc---boehringer-/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2019/10/positive-topline-results-from-the-moxie-registrational-trial-of-omaveloxolone-in-patients-with-friedreich-s-ataxia--/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-in-phase-iii-trials-of-naloxegol--astrazeneca--for-patients-with-opioid-induced-constipation/2021-09-24T07:01:30+00:00weekly0.6https://www.medthority.com/news/2016/04/dalcor-pharma-initiates-phase-iii-trial-of-dalcetrapib--focusing-on-patients-with-adcy9-gene-in-acute-coronary-syndrome-/2021-09-24T07:10:40+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-keytruda--pembrolizumab--for-advanced-melanoma--merck-inc/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2017/04/merck-inc-and-incyte-corpn--announce-extended-development-programme-for-combinations-of-keytruda--pembrolizumab--and-epacadostat-/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2017/06/edurant--dolutegravir----tivicay--rilpivirine--filed-with-eu-and-fda-for-hiv--janssen-viiv-healthcare-/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2014/09/ce-mark-for-freestyle-libre-flash-glucose-monitor--abbott-diabetes-care/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2016/03/cingal--sodium-hyaluronate--triamcinolone-hexacetonide--receives-ce-mark-to-treat-pain-associated-with-osteoarthritis-of-the-knee--anika-therapeutics/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2018/03/world-autism-awareness-day-2018/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2019/08/european-commission-approves--marketing-authorisation-for-forxiga-to-include-positive-cardiovascular--cv--outcomes-and-renal-data-from-the-phase-iii-declare-timi-58-trial-/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-cotellic--cobimetinib--plus-zelboraf--vemurafenib--for--unresectable-or-metastatic-melanoma-with-a-braf-v600-mutation--roche-/2024-02-19T12:45:50+00:00weekly0.6https://www.medthority.com/news/2019/12/illuminate-a-phase-iii-study-of-aln-go1-meets-primary-endpoint-in-primary-hyperoxaluria-type-1---alnylam-pharma/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-arakoda-for-malaria-prevention---60-degrees-pharma-/2021-09-24T07:06:19+00:00weekly0.6https://www.medthority.com/news/2011/12/pfizer-will-not-proceed-with-lyrica-for-restless-legs-syndrome/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2012/07/ecopipam--psyadon-pharmaceuticals--success-in-phase-ii-study-for-tourette-syndrome/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2017/09/new-analyses-of-empa-reg-outcome-trial-of-jardiance--empagliflozin--tablets-and-reduction-of-cv-risk-in-adults-with-type-2-diabetes---boehringer---eli-lilly/2024-07-26T10:39:36+00:00weekly0.6https://www.medthority.com/news/2016/06/uk-nice-recommends-use-of-opdivo---yervoy--nivolumab---ipilimumab--for-advanced--unresectable-or-metastatic--melanoma---bms/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-obizur-for-treatment-of-haemophilia-a-patients--baxter/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2014/11/novartis-reports-on-measure-1-and-measure-2-trials-of-ain-457-for-ankylosing-spondylitis/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-phase-iii-results-for-stratagraft-regenerative-tissue-for-burn-wounds--mallinckrodt-plc/2021-09-24T07:19:03+00:00weekly0.6https://www.medthority.com/news/2012/05/new-drug-application-filed-with-fda-for-bay-73-4506--bayer-healthcare--for-metastatic-colorectal-cancer/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2016/11/medivir-ab-acquires-two-clinical-programs-from-tetralogic-pharma--namely-remetinostat-and-birinapant-/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-study-of-tremfya-meets-endpoints-in-psoriatic-arthritis---janssen-pharma/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-extended-indication-of-ryzodeg--insulin-degludec-plus-insulin-aspart--for-diabetes-mellitus-in-adults--adolescents-and-children-from-the-age-of-2-years--novo-nordisk/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-qbrexza--for-the-topical-treatment-of-primary-axillary-hyperhidrosis---dermira-inc-/2021-09-24T07:07:02+00:00weekly0.6https://www.medthority.com/news/2013/10/boehringer-submits-an-maa-for-vargatef-in-nsclc/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-nustendi--bempedoic-acid---ezetimibe-fixed-dose-combination--for-the-treatment-of-hypercholesterolemia-and-mixed-dyslipidemia--esperion---daiichi-sankyo/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2017/12/toujeo-versus-insulin-degludec-in-bright-study-for-type-2-diabetes---sanofi/2021-09-24T07:13:44+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-data-on-ags-003-in-metastatic-renal-cell-carcinoma-shows-immune-response---argos-therapeutics-/2024-07-26T10:39:19+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-inroads-study-of-ads-5102-meets-primary-endpoint-in-multiple-sclerosis---adamas-pharma/2021-09-24T07:18:28+00:00weekly0.6https://www.medthority.com/news/2017/09/absorb-gt1-bioresorbable-vascular-scaffold-system--is-withdrawn-from-all-markets---abbott-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2017/07/phase-iii-trial-of-coagadex--coagulation-factor-x--human--shows-benefits-in-hereditary-factor-x-deficiency--bio-products-lab/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-earlens-contact-hearing-device-to-improve-hearing-impairment--earlens-corporation/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-leadership-301-trial-of-aqx-1125-fails-to-reach-primary-endpoint-in-interstitial-cystitis-bladder-pain-syndrome---aquinox-pharma-/2024-07-26T10:39:00+00:00weekly0.6https://www.medthority.com/news/2019/11/interim-results-from-emprise-phase-iii-trial-of-jardiance-show-reduced-risk-of-heart-failure-in-type-2-diabetes-with-cv-disease---boehringer---eli-lilly/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-issues-complete-response-letter-for-kxl-system-for-use-in-progressive-keratoconus--avedro-inc-/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2015/07/cabozantinib-success-vs-everolimus-in-phase-iii-study-for-renal-cell-carcinoma--exelixis/2024-02-19T12:46:07+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-issues-complete-response-letter-to--repros-therapeutics-in-respect-to---enclomiphene-for-the-treatment-of-secondary-hypogonadism-in-overweight-men-/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2013/04/nice-rejects-pixuvri--cell-therapeutics--for-the-treatment-of-non-hodgkin-s-lymphoma/2021-09-24T07:16:39+00:00weekly0.6https://www.medthority.com/news/2018/03/muscle-loss-in-old-age-linked-to-fewer-nerve-signals/2024-07-26T10:38:45+00:00weekly0.6https://www.medthority.com/news/2013/10/adempas--bayer--is-fda-approved-for-pulmonary-hypertension-and-cteph/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2015/10/data-and-safety-monitoring-board-recommends-continuation-of-phase-iii-trial-of-cpx-351--cytarabine-daunorubicin--liposome-for-injection--vyxeos--in-aml--celator-pharmaceuticals/2024-02-09T15:48:29+00:00weekly0.6https://www.medthority.com/news/2019/11/teva---celltrion-announce-the-availability-of-truxima-injection--the-first-biosimilar-to-rituxan-in-the-united-states-/2021-09-24T07:18:00+00:00weekly0.6https://www.medthority.com/news/2015/06/positive-results-from-phase-iii-trial-of-vokanamet-invokamet--canagliflozin--plus-metformin-in-type-2-diabetes-janssen/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-optic-trial-of-rg-1507-confirms-benefits-in-active-thyroid-eye-disease---horizon-therapeutics/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-ryzodeg--insulin-degludec-insulin-aspart-injection--for-treatment-of-diabetes-mellitus--novo-nordisk/2021-09-24T07:03:42+00:00weekly0.6https://www.medthority.com/news/2015/01/teva-launches-generic-zyvox-in-us-to-treat-severe-infections--pfizer/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-sivextro-for-treatment-of-acute-bacterial-skin-and-skin-structure-infections--cubist-pharma/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2018/03/uk-grants-patients-early-access-to-ionis-apoc-iiirx-for-familial-chylomicronaemia-syndrome---akcea-therapeutics-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2014/05/actavis-seeks-approval-for-generic-qsymia-for-treatment-of-obesity--vivus-inc-/2021-09-24T07:08:12+00:00weekly0.6https://www.medthority.com/news/2020/01/exparel-achieves-primary-and-key-secondary-endpoints-in-phase-iv-choice-study-in-cesarean-section-patients---pacira-biosciences-inc-/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-cassini-study-of-xarelto-failed-to-meet-endpoint-in-venous-thromboembolism---janssen-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-invega-sustenna-for-schizoaffective-disorder-janssen-pharma/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2012/06/elagolix-abbott--enters-phase-iii-trial-for-endometrosis/2021-09-24T07:02:26+00:00weekly0.6https://www.medthority.com/news/2012/06/prescribing-update-to-pradaxa--boehringer--for-stroke-prevention--af--patients/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2014/07/phase-iii-trial-of-maraviroc-combo-fails-to-meet-endpoint-for-hiv---viiv-healthcare/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2012/03/solabrgron--altherx--success-in-phase-ii-for-overactive-bladder/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2017/01/EU-CHMP-recommends-approval-of-Amgevita-adalimumab-biosimilar-for-rheumatoid-arthritis-juvenile-idiopathic-arthritis-axial-spondyloarthritis-psoriatic-arthritis-psoriasis-hidradenitis-suppurativa-Crohn-s-disease-ulcerative/2022-02-08T07:44:52+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-trials-of-movantik-for-oic-published-in-nejm-astrazeneca/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-label-extension-for-darzalex-rd-in--multiple-myeloma/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2019/04/european-commission-approves-zynquista-to-as-an-adjunct-to-improve-blood-sugar--glycemic--control-in-adults-with-type-1-diabetes---sanofi/2021-09-24T07:16:43+00:00weekly0.6https://www.medthority.com/news/2017/04/janssen-biotech--inc-will-not-proceed-with-phase-ii-trial-of-daratumumab-for-three-types-of--relapsed-or-refractory-non-hodgkin-s-lymphoma--nhl--/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-med-el-usa-s-cochlear-implants-for-single-sided-deafness-and-asymmetric-hearing-loss-/2024-10-21T14:47:17+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---the-kidneys--versatile-organs-with-multiple-functions/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2019/01/senhance-ultrasonic-system-receives-fda-510-k--clearance-for-laparoscopy-surgery---transenterix/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2015/03/impella-2-5-heart-pump-has-fda-approval-for--high-risk-pci-procedures--abiomed-inc-/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2011/06/affymax-and-takeda-submit-nda-for-hematide/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2016/04/biota-pharmaceuticals-changes-name-to-aviragen-therapeutics/2025-10-16T10:50:35+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-data-of-cimzia--certolizumab-pegol--in-chronic-plaque-psoriasis-shows-improvement-in-co-primary-endpoints--ucb-and-dermira/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-sahara-study-success-for-shp-616-liquid--subcutaneously-administered-c1-esterase-inhibitor--human--liquid-for-injection--to-treat-hereditary-angioedema--shire-plc-/2021-09-24T07:13:56+00:00weekly0.6https://www.medthority.com/news/2016/09/repros-therapeutics-files-maa-at-ema-for-enclomiphene-to-treat-hypogonadism-/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-extension-to-indication-for-trimbow-in-copd---chiesi-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2017/03/kitov-pharma-appoints-kuhnil-pharmaceutical-co--ltd-to-market-kt-302-in-south-korea-for-osteoarthritis--with-hypertension-reduction-/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2017/01/lucid-m1-transcranial-doppler-ultrasound-system-receives-ce-mark-for-monitoring-of-patients-with-brain-disorders--neural-analytics-inc-/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2014/04/nice-recommends-lemtrada-for-relapsing-remitting-multiple-sclerosis--genzyme---bayer/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2016/12/novartis-acquires-encore-vision-inc--and-with-it-ev-06-a-treatment-for-presbyopia-/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2014/06/mk-3475-success-in-updated-data-from-phase-1b-keynote-001-trial-for-advanced-melanoma---merck-inc--/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2019/12/sanofi-to-acquire-synthorx-and-with-it-thor-707/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2012/12/abilify-depot-is-filed-in-eu-for-maintenance-therapy-of-schizophrenia/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-vabomere--meropenem---vaborbactam---formerly-carbavance--to-treat-urinary-tract-infections--rempex-pharmaceuticals-the-medicines-company-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2014/01/eteplirsen-success-in-study-202-for-duchenne-muscular-dystrophy-sarepta-therapeutics/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2017/11/phenomapping--how-emerging-science-is-used-to-create-improved-personalised-treatment-/2024-07-26T10:38:03+00:00weekly0.6https://www.medthority.com/news/2014/05/ly-2605541-meets-endpoints-in-3-phase-iii-trials-for-t2d---eli-lilly/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2016/08/nice-rejects-imbruvica--ibrutinib--from-cancer-drugs-fund--as-a-treatment-for-mantle-cell-lymphoma--janssen-biotech/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-approves-corlanor--ivabradine--to-treat-heart-failure-amgen/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2017/02/eu-gives-ce-mark-approval-for-percepta-quad-crt-p-for-atrial-fibrillation--medtronic/2021-09-24T07:13:12+00:00weekly0.6https://www.medthority.com/news/2017/03/nice-rejects-cerdelga--eliglustat--as-a-cost-effective-treatment-for--type-1-gaucher-disease-in-its-draft-recommendation---sanofi-/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2012/07/odyssey-phase-iii-trials-enroll-for-sar-236553-treatment-of-ldl-cholesterol/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-declare-timi-58-results-for-farxiga-show-reduced-risk-of-hospitalisation-from-cv-events---astrazeneca-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2017/02/european-commission-approves-olumiant--baricitinib--to-treat-moderate-to-severe-active-rheumatoid-arthritis---eli-lilly-and-company-and-incyte-corporation-/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2019/09/nice-recommends-luxturna-to-treat-rpe65-mediated-inherited-retinal-dystrophies---novartis/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2011/10/ain-457-a-new-approach-to-psoriasis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2014/04/gsk-stops-magrit-trial-of-mage---a3-for-non-small-cell-lung-cancer/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2011/11/cobas-hpv-test--roche--offers-sensitive-primary-screening-strategy-for-cervical-cancer/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2013/07/nice-rejects-revlimid-celgene--for-myelodysplastic-syndromes-in-preliminary-appraisal/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2017/06/persistent-pain-shows-up-inefficiency-of-current-psoriatic-arthritis--psa--treatment/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2012/04/albireo-licences-asian-rights-for-elobixibat-to-ajimoto/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-extends-period-of-review-for--cariprazine-for-treatment-of-schizophrenia-and-bipolar--gedeon-richter---allergan/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2013/12/nice-questions-cost-benefit-of-lemtrada--genzyme-sanofi/2021-09-24T07:15:22+00:00weekly0.6https://www.medthority.com/news/2012/08/development-of-bms-986094--bms-inhibitex--for-hepatitis-c-halted/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2011/10/gantenerumab-reduces-amyloid-levels-in-patients-with-alzheimer-s-disease-1/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2019/03/nice-recommends-imfinzi-for-patients-with-locally-advanced-unresectable-nsclc-in-adults-whose-tumors-express-pd-l1--astrazeneca/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2018/12/real-world-data-supports-usage-of-oncotype-dx-breast-recurrence-score-test-in-breast-cancer---genomic-health-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-extends-berinert--csl-behring--indication-to-self-administration-in-hae-attacks/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2012/11/rts-s-anti-malaria-vaccine-further-results-in-african-study---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-approves-picosure-laser-system-for-skin-wrinkles---cynosure/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2018/04/successful-restore--imi-1-trial-of-imipenem-cilastatin-relebactam-in-patients-with-imipenem-non-susceptible-bacterial-infections--merck-inc-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2014/07/tc-5214-discontinued-for-overactive-bladder-targacept-/2021-09-24T07:08:45+00:00weekly0.6https://www.medthority.com/news/2016/06/jazz-pharma-to-buy-celator-pharma-for--1-5-billion-and-with-it-vyxeos/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2012/03/dccr--essentialis--shows-promise-in-phase-iib-trial-for-hypertriglyceridemia/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-caplyta-to-treat-schizophrenia--intra-cellular-therapies/2021-09-24T07:18:25+00:00weekly0.6https://www.medthority.com/news/2012/03/lorqess-is-filed-at-eu-by-arena-pharma-for-weight-loss/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2018/09/positive-phase-iii-data-for-yupelri-to-treat-copd-exacerbations---theravance---mylan/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2012/04/ce-mark-approval-for-advantio-ingenio-pacemakers-from-boston-scientific-for-bradycardia/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2014/03/ce-mark-for-prodigy-chronic-pain-system---st-jude-medical/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2015/10/positive-results-in-phase-iii-trial-of-ba-058--abaloparatide-subcutaneous--in-patients-with-postmenopausal-osteoporosis--radius-health/2024-02-09T15:48:43+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-for-filing-bla-for-rvt-802-to-treat-pediatric-congenital-athymia--a-condition-associated-with-digeorge-anomaly---enzyvant-riovant-/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-chmp-recommends-approval-of-tafinlar---mekinist--dabrafenib---trametinib--in-metastatic-melanoma-with-braf-v600--novartis/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-evotec---atazanavir---cobicistat--for-treatment-of-hiv-1--bms/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2015/07/alnylam-pharma-initiates-phase-iii-trial-of-patisiran-for-the-treatment-of-ttr-mediated-amyloidosis-in-familial-amyloidotic-polyneuropathy--ttr-fap--patients/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2013/07/anacor-files-tavaborole-at-fda-for-onychomycosis/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2015/02/phase-iii-trial-of-daxas-in-copd-published-in-the-lancet-takeda/2024-02-09T15:49:10+00:00weekly0.6https://www.medthority.com/news/2011/10/genes-predict-child-s-response-to-equasym-in-treatment-of-adhd/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2017/07/norgine-closes-acquisition-of-merus-labs-international-/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2014/08/successful-phase-iii-studies-of-caz-avi-for-intra-abdominal-infections---astrazeneca---forest/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2013/11/amg-145--amgen--success-in-lowering-ldl-in-osler-trial/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2019/04/eccmid-2019---find-out-more/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2017/06/eu-chmp-recommends-approval-of-four-dose-vial-of-synflorix-pneumococcal-vaccine--glaxosmithkline/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2015/06/sivextro--tedizolid-phosphate--launched-in-united-kingdom-to-treat-absssi---merck-inc-/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2018/08/inopulse-fails-phase-iii-trial-to-treat-pulmonary-arterial-hypertension---bellerophon-therapeutics-/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2019/07/uniqure-announces-long-term-follow-up-data-for-amt-060-in-patients-with-hemophilia-b-/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-extension-data-shows-reduction-in-decline-with-radicava--edaravone--in-amyotrophic-lateral-sclerosis---mt-pharma-america/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2014/03/olysio-meets-endpoint-for-hcv-in-phase-iii-trials---medivir/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2014/03/success-for-obeticholic-acid-in-phase-iii-poise-study-for-primary-biliary-cirrhosis---intercept-pharma/2021-09-24T07:08:24+00:00weekly0.6https://www.medthority.com/news/2016/07/fda-approves-raindrop-near-vision-inlay-implant-for-presbyopia--revision-optics/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-approval-of-dengvaxia-in-dengue-disease---sanofi-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2016/12/acetylon-pharma-spins-out-non-cancer-indications-of-ricolinostat-to-regenacy-pharma-and-celgene-will-acquire-acetylon--pharma-and-with-it-citarinostat--acy-241--and-ricolinostat--acy-1215-/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2019/11/advisory-committee-positive-for-twirla-a-combined-hormonal-contraceptive-patch---agile-therapeutics/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2014/10/pivotal-trial-data-on-appy1-test-for-appendicitis-venaxis/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2019/11/bms-acquisition-of-celgene-is-completed/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2016/06/trial-of-jzp-110-shows-abuse-potential-differs-from-traditional-stimulants-directed-to-narcolepsy---jazz-pharma/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-iii-trial-of-bi-201335--boehringer--succesful-for-hepatitis-c-patients/2021-09-24T07:16:38+00:00weekly0.6https://www.medthority.com/news/2015/01/merck-inc---to-withdraw-victrelis--boceprevir--from-us-as-a-treatment-for-hepatitis-c-/2021-09-24T07:03:25+00:00weekly0.6https://www.medthority.com/news/2013/12/phase-ii-data-on-prophage-vaccine-in-gbm-published-agenus/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2017/03/one-year-results-of-phase-iii-chronos-study-of-dupixent---dupilumab-for-treatment-of-atopic-dermatitis--sanofi---regeneron/2021-09-24T07:14:22+00:00weekly0.6https://www.medthority.com/news/2018/12/nice-recommends-use-of-lenvima-in-liver-cancer---eisai-and-merck-inc-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-imbruvica--pharmacyclics--for-mcl/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2018/03/brain-awareness-week--baw--2018/2024-02-20T11:12:36+00:00weekly0.6https://www.medthority.com/news/2013/12/eu-approval-for-airflusal-forspiro-generic-competitor-to-advair-seretide-for-asthma---copd-sandoz-/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2018/06/xultophy-provided-superior-blood-sugar-reduction--hba1c--compared-to-insulin-glargine-u-100-in-dual-ix-trial--novo-nordisk-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-transpyloric-shuttle-device-for-obesity/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2017/02/nice-confirms-positive-guidance-on-use-of-galafold--migalastat--to-treat-fabry-disease---amicus-therapeutics/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-study--sep360-301--evaluating-dasotraline-in-adults-with-attention-deficit-hyperactivity-disorder-fails-to-meet-primary-endpoint--sunovion-/2021-09-24T07:13:07+00:00weekly0.6https://www.medthority.com/news/2012/05/chmp-recommends-eu-approval-of-inlyta--pfizer--for-renal-cell-carcinoma/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2019/03/bd-statement-on-fda--relating-to--paclitaxel-coated-devices-and-long-term-mortality---becton--dickinson-and-company/2021-09-24T07:18:50+00:00weekly0.6https://www.medthority.com/news/2014/04/mepolizumab-in-phase-iii-trials-for-copd-gsk/2021-09-24T07:07:20+00:00weekly0.6https://www.medthority.com/news/2017/09/positive-data-from-first-part-of-phase-iii-switching-study-of-lumateperone-for-treatment-of-schizophrenia---intra-cellular-therapies-/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-approves-ion-and-taxus-liberte-drug-eluting-coronary-stents--boston-scientific---in-heart-attack-patients/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-advisory-committee-recommends-truvada-gilead--for-hiv-prophylaxis/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2014/06/positive-results-from-phase-iii-trial-of-itca-650-in-t2d---intarcia/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2012/07/chmp-recommends-dacogen--janssen-eisai--for-acute-myeloid-leukemia/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2016/03/endo-trial-of-endobarrier-therapy-in-obesity-and-type-2-diabetes-fails-to-meet-endpoint--gi-dynamics/2024-02-09T15:50:18+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-empliciti-----pomalidomide---dexamethasone-to-treat-multiple-myeloma----bms/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-now-recommends-perjeta--pertuzumab--to-treat-her-2-positive-early-stage-breast-cancer----roche/2021-09-24T07:09:47+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-abuse-deterrant-formulation-morphabond--morphine-sulfate-extended-release--for-pain-management--inspirion-delivery-technologies/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2013/07/in-draft-guidance-nice-does-not-recommend-bosulif--pfizer--for-cml/2021-09-24T07:15:28+00:00weekly0.6https://www.medthority.com/news/2019/08/phase-iii-dapa-hf-trial-of-farxiga-positive-for-treatment-of-heart-failure--astrazeneca/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2019/09/lundbeck-to-acquire-alder-biopharmaceuticals-and-with-it-eptinezumab-for-migraine-prevention/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2018/03/real-world-analysis-compares-effectiveness--safety-and-clinical-outcome-of-oral-anticoagulants-including-eliquis---bms---pfizer-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2017/06/bms-and-seattle-genetics-move-adcetris-brentuximab-vedotin---and-opdivo--nivolumab--combination-into-phase-iii-for-classical-hodgkin-lymphoma---/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-andexxa-as-antidote-for-patients-treated-with-rivaroxaban-and-apixaban---portola-pharma-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-issues-complete-response-letter-for-retacrit-biosimilar-version-of-epogen-procrit--hospira-pfizer/2021-11-26T14:43:20+00:00weekly0.6https://www.medthority.com/news/2016/04/results-of-eagles-trial-for-chantix-champix--varenicline--published-in-the-lancet-shows-no-significant-increase-in-serious-neuropsychiatric-events--pfizer/2024-02-09T15:50:40+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-ozempic-for-type-2-diabetes---cv-risks---novo-nordisk/2021-09-24T07:11:50+00:00weekly0.6https://www.medthority.com/news/2018/04/ema-approves-kineret-to-treat-still-s-disease---swedish-orphan-biovitrium-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2014/06/levemir-flextouch-for-type-1-2-diabetes-launched-in-us-novo-nordisk/2021-09-24T07:07:56+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-accepts-filing-of-nda-for-brexpiprazole-for-depression-and-schizophrenia-and-provides-pdufa-date---otsuka---lundbeck/2024-10-21T14:50:02+00:00weekly0.6https://www.medthority.com/news/2015/06/amicus-therapeutics-submits-maa-to-ema-for-galafold--migalastat-hcl--to-treat-genotype-of-fabry-disease-/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-lokwlma-to-treat-hyperkalaemia--astrazeneca-/2023-07-24T15:12:41+00:00weekly0.6https://www.medthority.com/news/2018/10/safety-data-for-rdx-5791-in-irritable-bowel-syndrome-with-constipation-shows-drug-well-tolerated---ardelyx-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2015/09/baxalta-files-at-fda-for-approval-of-gammagard-20--subcutaneous-treament-for-primary-immunodeficiencies/2021-09-24T07:03:45+00:00weekly0.6https://www.medthority.com/news/2016/05/aveo-oncology-initiates-phase-iii-trial-to-compare--tivozanib-to-sorafenib-in-treatment-of-refractory-renal-cell-carcinoma-/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2017/09/settlement-of-abbvie-and-amgen-litigation-concerning-amgevita-amjevita--adalimumab-biosimilar----amgen/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-farxiga-to-reduce-the-risk-of-hospitalisation-for-heart-failure-in-adults-with-type-2-diabetes-and-established-cardiovascular-disease---astrazeneca/2021-09-24T07:17:18+00:00weekly0.6https://www.medthority.com/news/2019/10/ucb-acquires-ra-pharmaceuticals-and-with-it-zilucoplan-a-proposed-treatment-for--generalised-myasthenia-gravis/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2011/12/tyverb--gsk--disappoints-in-her2-positive-breast-cancer/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-issues-guidance-to-help-bring-interchangeable-biosimilars-to-market-/2021-09-24T07:17:37+00:00weekly0.6https://www.medthority.com/news/2019/03/oral-semaglutide-7-mg-and-14-mg-demonstrated-superior-hba1c-and-body-weight-reductions-compared-to-januvia-in-patients-with-type-2-diabetes-/2021-09-24T07:18:50+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-recommends-alteration-to-indication-of-xultophy-in-type-2-diabetes---novo-nordisk-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2014/07/boehringer-files-nintedanib-at-fda-for-idiopathic-pulmonary-fibrosis/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2015/06/one-year-results-from-measure-2-study-for-secukinumab-in-treatment-of-ankylosing-spondylitis--novartis/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2011/09/zometa-reduces-risk-of-breast-cancer-recurrence-in-post-menopausal-patients/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2019/06/two-phase-iii-trials-of-xolair-meet-primary-endpoints-in-chronic-rhinosinusitis---novartis/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2019/04/post-hoc-analysis-of-kyntheum-data-shows-benefits-over-ustekinumab-in-psoriasis/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2012/09/janssen-responds-to-fda-complete-response-letter-for-xarelto-for-acute-coronary-syndrome/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-evolve-ms-2-study-demonstrates-improved-patient-assessed-gastrointestinal-tolerability-of-vumerity---a--treatment-for-relapsing-forms-of-multiple-sclerosis--compared-to-tecfidera----biogen/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2017/10/ueg-week-2017/2024-02-19T12:47:11+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-the-evera-mri-surescan-icd-system-for-arrhythmias-medtronic/2024-02-09T15:50:55+00:00weekly0.6https://www.medthority.com/news/2017/05/amg-334--erenumab--filed-with-fda-for-migraine--amgen/2021-09-24T07:14:28+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-lilly-s-new-fast-acting-mealtime-insulin--liumjev--to-improve-glycemic-control-in-adults-with-diabetes-/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2011/12/olaparib--astrazeneca-will-not-proceed-to-phase-iii-in-ovarian-cancer/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2014/07/astrazeneca-and-roche-collaborate-to-develop-diagnostic-test-for-azd-9291-/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-updated-surfaxin--discovery-labs--for-rds-/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2011/10/xigris-is-withdrawn-from-all-markets-for-septic-shock/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2013/01/cangrelor-the-medicines-company--success-in-phase-iii-trial-for-pci/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-gadavist--gadobutrol--contrast-medium-for-mri-use-in-paediatric-patients-bayerhealthcare/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2014/09/ultibro-breezhaler-superior-to-seretide-in-reduction-of-exacerbations-in-copd-in-lantern-study--novartis/2021-09-24T07:07:50+00:00weekly0.6https://www.medthority.com/news/2014/11/successful-phase-iiia-trial-for-saxenda-for-obesity-treatment--novo-nordisk/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2013/03/complete-response-letter-from-fda-for--q-pan-h5n1-influenza-vaccine/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-grants-tentative-approval-of-brixadi-for-severe-opioid-use-disorder---braeburn-pharma-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2015/10/decide-trial-shows-zinbryta--daclizumab-high-yield-process--hyp----superior-to-interferon-beta-1a-in-relapsing-remitting-ms--biogen---abbvie/2024-02-19T12:47:42+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-accepts-nda-for-entrectinib-for-ntrk-fusion-positive--locally-advanced-or-metastatic-solid-tumors---genentech-roche/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-hysingla-er-for-chronic-pain-purdue-pharma/2021-09-24T07:08:40+00:00weekly0.6https://www.medthority.com/news/2013/01/ec-approve-new-strength-prezista--j-j-janssen-cilag--for-aids-patients/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2019/08/ema-approves-giapreza-for-hypotension-in-adults-with-septic-shock---la-jolla-pharmaceutical/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2015/01/nice-recommends-jardiance--empagliflozin--for-t2d-boehringer-lilly/2021-09-24T07:03:25+00:00weekly0.6https://www.medthority.com/news/2017/05/atlantic-healthcare-plc-files-rolling-submission-at-fda-for-alicaforsen-to-treat-pouchitis-/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2015/09/eighteen-months-survival-data-for-opdivo--nivolumab--in-squamous-nsclc--bms/2024-02-19T12:48:19+00:00weekly0.6https://www.medthority.com/news/2014/10/teva-initiates-rolling-nda-at-fda-for-cep-33237-for-severe-pain-/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2019/04/luspatercept-is-filed-at-ema-for-myelodysplastic-syndromes-and-beta-thalassemia-associated-anemia---celgene---acceleron-pharma/2021-09-24T07:16:44+00:00weekly0.6https://www.medthority.com/news/2014/10/chmp-recommends-lynparza--olaparib--to-treat-ovarian-cancer-astrazeneca/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-healon-endocoat-ovd--abbott-medical-optics--for-use-in-cataract-extraction-/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2018/03/medimmune-creates-a-new-company-called-viela-bio-to-focus-on-severe-autoimmune-diseases-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2017/04/novartis-loses-patent-appeal-for-gilenya--fingolimod---opening-the-us-market-to-generic-competition-in-2019-/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2016/04/eu-s-chmp-recommends-approval-of--humira--adalimumab--for-crohns-disease-in-paediatric-patients--abbvie/2024-02-09T15:51:09+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-soolantra-cream-for-treatment-of-rosacea--galderma/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2017/06/cadazolid-meets-primary-endpoint-in-impact-1-study-and-but-not-in-impact-2-study-versus-vancomycin-in-the-treatment-of-clostridium-difficile-associated-diarrhea---actelion-j-j/2021-09-24T07:15:06+00:00weekly0.6https://www.medthority.com/news/2014/07/eliquis-enters-phase-iv-trial-for-nvaf-patients-undergoing-cardioversion---bms---pfizer/2021-09-24T07:08:50+00:00weekly0.6https://www.medthority.com/news/2018/03/higher-vitamin-d-levels-may-be-linked-to-lower-risk-of-cancer/2024-02-09T15:52:19+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-troxyca-er--oxycodone-hydrochloride-and-naltrexone-hydrochloride--extended-release-capsules--for-oral-use--for-the-management-of-severe-pain--pfizer/2021-09-24T07:09:36+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-data-shows-that-stelara--ustekinumab--offers-remission-benefits-in--moderate-to-severe-crohn-s-disease--janssen-/2024-02-09T15:52:34+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-approves-prosigna-assay-for-breast-cancer-risk/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2014/06/novoeight-reports-success-in-guardian-2-trial-for-haemophilia-a---novo-nordisk/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-extends-approval-of-tobramycin-as-a-hybrid-medicine-tobramycin-pari-for-infection-in-cystic-fibrosis---pari-pharma-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2020/01/lynparza-filed-sbla-at-fda-for-1st-line-maintenance-treatment-with-bevacizumab-in-advanced-ovarian-cancer--astrazeneca---merck-inc-/2021-09-24T07:11:52+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-viberzi--eluxadoline-for-treatment-of-irritable-bowel-syndrome-with-diarrhoea---actavis/2021-09-24T07:03:39+00:00weekly0.6https://www.medthority.com/news/2014/03/positive-results-in-3-phase-iii-studies-of-anoro-ellipta-for-copd-gsk-theravance/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-helios-trial-of-asp-0113-fails-to-meet-endpoints-in-cytomegalovirus---astellas-pharma---vical-/2021-09-24T07:05:09+00:00weekly0.6https://www.medthority.com/news/2012/10/fda-approves-quillivant-xr--next-wave--for-adhd/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2017/11/apsr-2017/2024-02-19T12:48:56+00:00weekly0.6https://www.medthority.com/news/2018/08/european-commission-approves-opdivo-for-the-adjuvant-treatment-of-adult-patients-with-melanoma-with-involvement-of-lymph-nodes-or-metastatic-disease-who-have-undergone-complete-resection----bms-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2020/02/phase-iii-studies-fx2016-11-and-fx2016-12-of-fmx-103-for-rosacea-published-in-journal-of-the-american-academy-of-dermatology---foamix-pharma/2021-09-24T07:12:08+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-ii-iii-act-in-sarc-trial-of-nbtxr-3-in-soft-tissue-sarcomas-published-in-lancet-oncology---nanobiotix/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2014/07/chmp-recommends-extended-indication-for-ozurdex-for-dme---allergan/2021-09-24T07:08:47+00:00weekly0.6https://www.medthority.com/news/2013/02/stjude-medical-expands-scope-of-enlightn--rds-system-in-uncontrolled-hypertension-with-enlightn-ii-trial/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2013/03/fda-awards--generally-recognized-as-safe--status-to-cardioviva--micropharma--to-help-reduce-bad-cholesterol/2021-09-24T07:15:47+00:00weekly0.6https://www.medthority.com/news/2013/03/hyqvia--baxter-halozyme--is-chmp-recommended-for-treatment-of-immunodeficiencies/2021-09-24T07:15:40+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-approves-sublocade-for-opioid-use-disorder----invidior-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2019/03/partner-3-trial-shows-sapien-3-valve-superior-to-surgery-in-severe-aortic-stenosis---edwards-lifesciences/2021-09-24T07:18:54+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-praxbind--idarucizumab--as-a-reversing-agent-for-pradaxa--dabigatran---boehringer-ingelheim/2024-02-09T15:53:11+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-advisory-committee-recommends-topas-system-to-treat-fecal-incontinence--astora-womens-health-endo-/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-ii-trial-of-intravenous--iv--meloxicam-for-the-treatment-of-pain-following-open-abdominal-hysterectomy--is-published-in-anesthesia---analgesia--recro-pharma-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2018/06/uk-nice-supports-use-of-keytruda-in-untreated-metastatic-nsclc---merck-inc-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-endorses-victrelis--merck-inc--for-hepatitis-c-genotype-1-infection/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-accepts-snda-for-brilinta--ticagrelor--for-prevention-of-artherothrombotic-events-astrazeneca/2021-09-24T07:04:09+00:00weekly0.6https://www.medthority.com/news/2012/05/iressa--astrazeneca--is-withdrawn-from-us-market-for-nsclc/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2019/05/six-year-data-from-phase-iii-trial-of-liletta-shows-cumulative-pregnancy-rates---medicines360/2021-09-24T07:17:41+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-adds-data-to-prescribing-information-of-tudorza-pressair-in-copd---circassia-pharma/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2016/12/positive-phase-iii-results-for-egalet-002-oxycodone-extended-release--in-the-management-of-pain--egalet-/2021-09-24T07:10:11+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-trial-of-rly-5016-for-hyperkalemia-meets-endpoints-relypsa/2021-09-24T07:07:45+00:00weekly0.6https://www.medthority.com/news/2014/05/sanofi-and-eli-lilly-combine-to-develop-and-market-otc-cialis---eli-lilly---sanofi/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2012/03/gastro-ad-soy-supplement-launched/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-filing-of-arikayce--liposomal-amikacin-for-inhalation--for-nontuberculous-mycobacteria-lung-disease-withdrawn-after-negative-response-from-chmp--insmed/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2016/10/elobixibat-meets-endpoint-in-phase-iii-trial-for-chronic-constipation--albireo-/2021-09-24T07:10:36+00:00weekly0.6https://www.medthority.com/news/2013/10/positive-final-data-for-everflex--covidien--in-pad/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-priority-review-and-ema-accelerated-assessment-for-kymriah-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--dlbcl----novartis-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2014/06/vartagef-filed-with-eu-for-pulmonary-fibrosis---boehringer/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2018/06/blueprint-medicines-initiates-phase-iii-trial-of-avapritinib-to-treat--patients-with--advanced-gist-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2019/05/data-from-release-1-and-release-2-phase-iii-studies-of-collagenase-clostridium-histolyticum/2021-09-24T07:17:35+00:00weekly0.6https://www.medthority.com/news/2015/11/iqwig-assessment-of-keytruda--pembrolizumab--finds-considerable-added-benefit-in-advanced-melanoma--merck-inc/2024-02-09T15:53:23+00:00weekly0.6https://www.medthority.com/news/2015/07/eu-commission-extends-indication-of-kuvan--sapropterin-dihydrochloride--to-include-children-with-phenylketonuria--pku--merck-kgaa/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-toujeo--insulin-glargine--rdna-origin---for-treatment-of-type-1-and-type-2-diabetes-sanofi/2021-09-24T07:04:17+00:00weekly0.6https://www.medthority.com/news/2017/05/chiesi-farmaceutici-s-p-a-acquires-rights-to-procysbi--cysteamine-bitartrate--and-quinsair--levofloxacin-inhalation-solution---in-eu--middle-east-and-africa-from-horizon-pharma-/2021-09-24T07:14:26+00:00weekly0.6https://www.medthority.com/news/2014/09/androxal-meets-primary-endpoints-in-study-of-secondary-hypogonadism---repros-therapeutics/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2019/10/european-commission-approves-bavencio---axitinib-combination-for-first-line-treatment-of-patients-with-advanced-renal-cell-carcinoma---merck-kgaa---pfizer-/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2018/09/alexion-to-acquire-syntimmune-and-with-it-synt-001-an-inhibitor-of-the-interaction-of-fcrn-with-immunoglobulin-g-/2021-09-24T07:06:39+00:00weekly0.6https://www.medthority.com/news/2017/11/global-af-awareness-week-2017/2024-02-19T12:49:48+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-addyi--flibanserin-100-mg--for-hypoactive-sexual-desire-disorder--sprout-pharma/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2011/11/syncria---gsk--is-inferior-to-victoza-in-type-2-diabetes-trial/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2013/01/ce-mark-granted-to-st-jude-medical-for-amplatzer-laa-occluder/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-issues-complete-response-letter-relating-to-brintellix--vortioxetine--for-treatment-of--cognitive-dysfunction-in-adults-with-major-depressive-disorder--mdd---takeda---lundbeck/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2018/06/euroheartcare-2018---tackling-the-complexity-of-cardiovascular-care/2024-02-19T12:50:03+00:00weekly0.6https://www.medthority.com/news/2016/09/fda-accepts-bla-for-dupilumab-to-treat-moderate-to-severe-atopic-dermatitis---sanofi---regeneron/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approves-truvada-gilead-sciences--for-hiv-prevention/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-grants-510-k--clearance-for-the-cintec-histology-test--to-determine-which-women-should-receive-treatment-for-cervical-pre-cancer--roche-/2021-09-24T07:14:15+00:00weekly0.6https://www.medthority.com/news/2015/06/trial-of-lyxumia--lixisenatide--meets-endpoints-in-type-2-diabetes--sanofi/2021-09-24T07:03:37+00:00weekly0.6https://www.medthority.com/news/2019/01/sufentanil-sublingual-tablets-pooled-analysis-for-short-term-pain-management-published-in-pain-management--acelrx-pharma/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-lymphoseek-for-radiopharmacutical-diagnosis---navidea-biopharmaceuticals/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2019/07/horizon-therapeutics-plc-submits-teprotumumab-bla-to-fda-for-the-treatment-of-active-thyroid-eye-disease-/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2018/09/first-patient-enrolled-in-phase-iii-charm-study-to-evaluate-biib-093--for-the-prevention-and-treatment-of-severe-cerebral-edema---biogen/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2014/04/impax-re-files-rytary-at-fda-for-parkinsons-disease/2021-09-24T07:07:24+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-use-of-arnuity-ellipta-for-maintenance-treatment-of-asthma-in-children-from-5-years---glaxosmithkline-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2016/12/supplemental-new-drug-application-for-oxaydo--oxycodone-hcl--usp--filed-with-fda-for-pain-treatment/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-accepts-bla-for-collagenase-clostridium-histolyticum-to-treat-patients-with-cellulite---endo-international/2021-09-24T07:17:55+00:00weekly0.6https://www.medthority.com/news/2012/01/afatinib-boehringer--enters-phase-iii-trials-for-head-and-neck-cancer/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-halo-study-of-tev-48125-in-episodic-migraine-published-in-journal-of-the-american-medical-association---teva-pharma-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2017/04/novo-nordisk-resubmits-the-new-drug-application--nda--for-fast-acting-insulin-aspart-at-fda-as-a-treatment-for-diabetes--/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-tolsura-for-fungal-infections---mayne-pharma-/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2016/05/itca-650-subcutaneous-exenatide-meets-primary-and-secondary-endpoints-in-phase-iii-trial-for-type-2-diabetes--intarcia-therapeutics/2024-02-09T15:53:37+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-next-generation-mitraclip-heart-valve-repair-device-to-repair-a-leaky-mitral-valve-without-open-heart-surgery---abbott--/2021-09-24T07:07:00+00:00weekly0.6https://www.medthority.com/news/2016/01/prosit-bio-study-supports-biosimilar-infliximab-in-crohns-disease-and-ulcerative-colitis--hospira-pfizer/2021-09-24T07:09:10+00:00weekly0.6https://www.medthority.com/news/2018/11/eu-approves-symveki---kalydeco-for-cystic-fibrosis-f508del-mutation---vertex-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2019/12/seattle-genetics---takeda-announce-additional-analyses-of-adcetris--echelon-1-phase-iii-clinical-trial-for-classical-hodgkin-lymphoma-/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2013/09/no-evidence-of-benefits-to-cognition-with-omega-3-fatty-acids/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2019/08/myovant-sciences-completes-ptient-recruitment-for-phase-iii-spirit-2-study-evaluating-relugolix-combination-therapy-in-women-with-endometriosis-/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2014/06/trials-show-safety-and-efficacy-of-rextoro-in-hypogonadism-clarus-therapeutics/2021-09-24T07:07:55+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-givlaari-to-treat-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2020/01/health-canada-approves-vascepa-to-reduce-the-risk-of-cv-events---hls-therapeutics-/2021-09-24T07:11:55+00:00weekly0.6https://www.medthority.com/news/2018/08/pivotal-phase-iii-trial-of-trogarzo-to-treat-hiv-is-published-in-nejm---theratechnologies-inc-/2021-09-24T07:06:14+00:00weekly0.6https://www.medthority.com/news/2019/04/study-shows-75-percent-of-female-patients-aged-70-years-and-older-at-increased-risk-of-fragility-fractures-were-not-treated-for-osteoporosis---amgen-/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2014/02/nice-rejects-yervoy-for-malignant-melanoma-first-line-treatment---bms/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2019/09/somapacitan-once-weekly-growth-hormone-derivative--showed-in-real-3--comparable-efficacy--safety-and-tolerability-to-once-daily-injections-of-norditropin--novo-nordisk/2021-09-24T07:19:04+00:00weekly0.6https://www.medthority.com/news/2013/05/trial-shows-vascazen--pivotal-therapeutics--effective-in-altering-cholesterol-levels-in-patients-with-cv-risk/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2013/09/gsk-terminates-traficet-en-programme/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2011/09/new-drug-eluting-stents-safer-for-pci-patients/2021-09-24T07:04:51+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-gives-510-k--clearance-for-abstats-system-for-gastro-intestinal-diagnostics--gi-logic/2021-09-24T07:04:27+00:00weekly0.6https://www.medthority.com/news/2012/02/chmp-recommends-nimenrix-vaccine--gsk--for-meningococcal-diseases-/2021-09-24T07:02:51+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-senscis-trial-of-ofev-shows-efficacy-in-interstitial-lung-disease/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-jardiance--empagliflozin--in-type-2-diabetes---cardiovascular-disease--boehringer/2021-09-24T07:10:17+00:00weekly0.6https://www.medthority.com/news/2014/03/brilinta-brilique-enters-phase-iii-trial-for-peripheral-artery-disease---astrazeneca/2021-09-24T07:08:22+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---benefits-beyond-fracture-risk-reduction--results-of-the-vitale-study/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2016/11/nice-recommends-taltz--ixekizumab-from-eli-lilly--to-treat-severe-plaque-psoriasis-/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2016/03/fispemifene-fails-proof-of-concept-trial-to-treat-secondary-hypogonadism-and-sexual-dysfunction--apricus-biosciences-/2024-02-09T15:53:51+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-filing-for-viaskin-peanut-allergy-treatment-voluntarily-withdrawn---dbv-technologies-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2012/04/eu-approves-signifor--novartis--for-cushing-s-disease/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-kymriah--tisagenlecleucel--for-b-cell-precursor-acute-lymphoblastic-leukemia--novartis-/2021-09-24T07:14:49+00:00weekly0.6https://www.medthority.com/news/2013/03/iqwig-finds-no-clear-benefit-of-using-pet-ct-for-patients-with-bone-or-soft-tissue-tumours/2021-09-24T07:15:45+00:00weekly0.6https://www.medthority.com/news/2019/02/democratic-republic-of-congo-approves-fexinidazole-to-treat-sleeping-sickness--sanofi/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-in-phase-iii-trial-of-oms-302--omeros-corporation--in-patients-undergoing-cataract-surgery/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2018/10/inovation-1-phase-iii-trial-of--inopulse-for-pulmonary-arterial-hypertension-confirms-action---bellerophon-therapeutics-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-jeuveau-to-treat-glabellar-lines---evolus-alphaeon/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2015/12/-the-ministry-of-food-and-drug-safety--mfds-in-south-korea-has-approved-renflexis--sb-2---infliximab-biosimilar--samsung-bioepis/2021-09-24T07:04:32+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-gives-510-k--approval-for-the-sekure-hba1c-assay-for-diabetes--sekisui-diagnostics-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2016/01/successful-trapid-ami-trial-for-cardiac-troponin-t-high-sensitivity-test-published-in-annals-of-emergency-medicine--roche/2024-02-19T14:54:58+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-chf-5993-for-maintenance-treatment-of-copd---chiesi-farmaceutici-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-select-study-data-shows-metastases-tumour-shrinkage-with-lenvima--lenvatinib--in-thyroid-cancer--eisai/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---more-sports--fewer-symptoms--how-ckd-patients-benefit-from-physical-exercise/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-topic-study-of-aubagio-shows-slowed-brain-atrophy-in--multiple-sclerosis---sanofi-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2012/09/aquilion-ct-scanner--toshiba--accurately-assess-coronary-blockages---------------/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2018/05/chmp-extends-kyprolis-label-to-include--overall-survival-data-from-aspire-trial-for-multiple-myeloma---amgen-/2021-09-24T07:07:14+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-results-show-drm-04-reduces-impact-and-improves-quality-of-life-in-pediatric-hyperhidrosis---dermira-/2021-09-24T07:05:54+00:00weekly0.6https://www.medthority.com/news/2018/06/oral-semaglutide-showed-significant-reduction-in-blood-sugar-vs-placebo-in-pioneer-1-trial-for-type-2-diabetes---novo-nordisk-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2019/09/eu-approves-lonsurf-for-gastric-cancer---servier-and-taiho-pharma/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2015/03/kanuma--sebelipase-alfa--is-filed-at-fda-for-lal-deficiency--synageva-biopharma--/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2016/11/positive-results-from-phase-iii-giacta-study-of-actemra--tocilizumab--for-giant-cell-arteritis---genentech---roche/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2013/11/engage-af-timi-48-results-for-edoxaban--daiichi-sankyo--in-stroke-prevention/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2012/05/alogliptin--takeda--filed-at-ema-for-type-2-diabetes/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-extends-sbla-for-keytruda-as-a-treatment-for-first-line-nsclc---merck-inc-/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-less-invasive-surgical-approach-for-abbott-s-heartmate-3-to-help-patients-avoid-open-heart-surgery---abbott/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2018/07/lentiglobin-for-the-treatment-of--transfusion-dependent-beta-thalassemia--and-a-non-beta0-beta0-genotype--was-granted-an-accelerated-assessment-by-the-chmp---bluebird-bio-inc-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2014/10/study-of-anoro-ellipta-in-copd-published-gsk/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2015/06/additional-results-from-phase-iii-trial-of-md-1003--biotin--support-benefits-in-multiple-sclerosis-medday/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2017/03/eu-commission-approves-amgevita--biosimilar-adalimumab--for-all-indications-of-the-originator-drug---amgen-/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2015/08/biogen---sobi-announce-interim-results-from-b-yond-study-of-alprolix-for-prophylaxis-of-haemophilia-b/2024-02-19T14:55:16+00:00weekly0.6https://www.medthority.com/news/2014/05/mallinckrodt-files-mnk-155-at-fda-for-moderate-to-severe-pain-/2021-09-24T07:08:05+00:00weekly0.6https://www.medthority.com/news/2019/02/brilinta---aspirin-in-phase-iii-themis-trial-showed-a-statistically-significant-reduction-in-major-adverse-cv-events-compared-to-aspirin--astrazeneca/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-ragwitek-for-treating-ragweed-induced-allergy---merck/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-new-labelling-for-stiolto-respimat-in-copd---boehringer-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2015/04/data-from-phase-iii-trial-of-mk-5172---mk-8742--grazoprevir-elbasvir--in-hcv-published-merck-inc/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2016/05/prenoxad-is-approved-in-five-european-countries-for-treatment-of-opioid-overdose-martindale-pharma-/2021-09-24T07:09:32+00:00weekly0.6https://www.medthority.com/news/2012/01/pradaxa-boehringer--risk-of-myocardial-infarction-and-acute-coronary-syndrome/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2015/04/shp-625-fails-phase-ii-imago-trial-to-treat-alagille-syndrome-shire/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2014/10/nice-does-not-recommend-imnovid-pomalyst-for-treatment-of-metastatic-melanoma--celgene/2021-09-24T07:07:17+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-grastek-for-grass-pollen-induced-allergic-rhinitis---merck-inc--/2021-09-24T07:07:23+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-accepts-for-review--sbla-for-doptelet-to-treat-chronic-immune-thrombocytopenia--itp--in-patients-who-had-an-insufficient-response-to-a-previous-treatment---dova-pharma---salix-pharma/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-recommends-gilenya--novartis--for-multiple-sclerosis/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-accepts-filing-of-adcetris---chemo-to-treat--advanced-classical-hodgkin-lymphoma---seattle-genetics-/2021-09-24T07:05:16+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-impower131-study-results-for-tecentriq-in-advanced-squamous-non-small-cell-lung-cancer---roche-/2021-09-24T07:06:27+00:00weekly0.6https://www.medthority.com/news/2013/11/revlimid--celgene--meets-endpoint-for-multiple-myeloma/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2017/07/chmp-approves-label-update-for--cosentyx--secukinumab--to-treat-moderate-to-severe-scalp-psoriasis-----novartis/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2015/01/cresemba--isavuconazole--has-advisory-committee-recommendation-for-invasive-aspergillosis--and-zygomycosis-astellas--basilea/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2012/04/aliskiren--novartis-availability-terms-agreed-with-fda/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-recommends-mabthera--roche--for-vasculitis/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2011/10/implanted-spr--micropulse-system-shows-benefit-for-patient-with-post-stroke-shoulder-pain/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-hyrimoz--adalimumab-biosimilar---sandoz-/2021-09-24T07:06:55+00:00weekly0.6https://www.medthority.com/news/2011/10/cialis-is-fda-approved-for-benign-prostatic-hyperplasia/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2016/02/ce-mark-for-mitralign-percutaneous-annuloplasty-system-to-treat-mitral-and-tricuspid-regurgitation--mitralign-inc-/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2013/11/stimuvax-fails-to-meet-primary-endpoint-in-nsclc-merck-serono/2021-09-24T07:16:34+00:00weekly0.6https://www.medthority.com/news/2015/11/pivotal-study-results-with-the-rezum-radiofrequency-system-in-benign-prostatic-hyperplasia-published-in-the-journal-of-urology--nxthera/2024-02-19T14:58:21+00:00weekly0.6https://www.medthority.com/news/2019/12/pooled-analysis-of-7-5-years-data-shows-imbruvica-improves-pfs-and-increases-chance-of-complete-response-in-mantle-cell-lymphoma---abbvie/2021-09-24T07:18:35+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-zohydro-with-beadtek-for-pain-zogenix/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2019/07/epilepsy-drugs-taken-by-pregnant-women-associated-with-higher-risk-of-language-impairment-in-their-children---but-folic-acid-is-protective/2021-09-24T07:18:21+00:00weekly0.6https://www.medthority.com/news/2016/03/3c-patch-system-gets-510-k--approval-for-wound-healing--reapplix/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2011/11/polarcath-pd-system--boston-scientific--decreases-risk-of-in-stent-restenosis-in-diabetic-patients/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2012/12/janssen-pharmaceuticals-submits-nda-to-fda-for-combined-ta-7284-and-metformin-treatment-for-type-2-diabetes/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-lenvima-in-combination-with-afinitor--lenvatinib---everolimus--for-patients-with-advanced-renal-cell-carcinoma--eisai/2024-02-09T15:54:40+00:00weekly0.6https://www.medthority.com/news/2018/03/platypus-milk--how-it-could-combat-super-bugs/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2016/10/phase-iii-positive-data-for-td-4208--revefenacin--to-treat-copd---theravance---mylan/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2015/06/glatopa-is-launched-in-us-as-generic-copaxone--glatiramer-acetate-injection--for-ms--sandoz---momenta/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2014/11/chmp-recommends-viekirax-and-exviera-for-hcv-abbvie/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-study-of-abp-710-confirms-non-inferiority-to-remicade-in-rheumatoid-arthritis---amgen-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2015/02/farydak--panobinostat--has-fda-accelerated-approval-to-treat-multiple-myeloma--novartis/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2013/10/stelara--j-j-janssen-cilag--reduces-damage-in-psoriatic-arthritis/2021-09-24T07:16:10+00:00weekly0.6https://www.medthority.com/news/2014/09/ce-mark-for-tyrx-absorbable-anti-bacterial-envelope-for-cardiac-procedures---medtronic/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2013/03/chmp-recommends-stribild--gilead-sciences--for-the-treatment-of-hiv/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2013/07/fda-approves-fetzima--forest-pierre-fabre--for-depression--/2021-09-24T07:15:25+00:00weekly0.6https://www.medthority.com/news/2016/07/astrazeneca-enters-agreement-with-leo-pharma-for-the-global-licence-to-tralokinumab-in-skin-diseases/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2016/10/nicepublishes-survey-of-evidence-of-truvada--emtricitabine-tenofovir-disoproxil--in-pre-exposure-prophylaxis--prep--against-hiv-in-adults-at-a-high-risk-of-infection--gilead-sciences/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2015/12/sandoz-announces-results-of-protect2-study-of-biosimilar-pegfilgrastim-with-the-reference-product--neulasta-/2024-02-09T15:54:50+00:00weekly0.6https://www.medthority.com/news/2020/01/eu-approves-expanded-indication-for-erleada-in-metastatic-hormone-sensitive-prostate-cancer---janssen-pharma/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2011/10/femara-offers-significant-advantages-over-tamoxifen-for-breast-cancer-patients/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-halts-alisporivir--novartis--phase-iii-trial/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-biktarvy-to-treat-hiv-infection---gilead-sciences/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2012/06/mk-4305--merck-inc---data-from-two-phase-iii-trials-for-sleep-disorder/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2013/02/successful-studies-for-rfviiifc-and-rfixfc--biogen-swedish-orphan--for-haemopilia/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2013/06/nice-does-not-recommend-zaltrap--sanofi--for-colorectal-cancer-in-draft-guidance/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-grants-priority-review-and-sets-pdufa-date-for-obeticholic-acid--oca--for-primary-biliary-cirrhosis--intercept-pharma/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2019/06/updated-results-from-studies-of-yervoy----opdivo-to-treat-metastatic-melanoma--bms/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-gilenya-to-treat-children-and-adolescents-with-relapsing-multiple-sclerosis--novartis-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2016/03/affymetrix-inc--rejects-offer-from-origin-technologies-and-recommends-offer-from-thermo-fisher/2021-09-24T07:10:19+00:00weekly0.6https://www.medthority.com/news/2018/12/b-yond-long-term-results-for-alprolix-confirms-safety-and-efficacy-in-haemophilia-b---orphan-biovitrum---bioverativ-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-approval-of-subcutaneous-herceptin--genentech-roche--for-her--breast-cancer/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2015/10/moventig-is-launched-in-uk-for-treatment-of-opioid-induced-constipation--astrazeneca/2024-02-19T14:58:36+00:00weekly0.6https://www.medthority.com/news/2012/08/ema-accepts-filing-for-heplisav--dynavax-technologies---a-vaccine-for-hepatitis-b--/2021-09-24T07:02:30+00:00weekly0.6https://www.medthority.com/news/2018/01/sanofi-to-acquire-ablynx-n-v--and-with-it-caplacizumab--/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2019/08/endologix-receives-ide-approval-for-a-pivotal-trial-for-the-nellix-chimney-endovascular-aneurysm-sealing-protocol-/2021-09-24T07:17:48+00:00weekly0.6https://www.medthority.com/news/2016/06/ocrevus--ocrelizumab--filed-with-fda-and-ema-for-relapsing-multiple-sclerosis-and-primary-progressive-multiple-sclerosis--genentech-roche/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-study-of-lucanix-fails-to-meet-endpoint-in-nsclc/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2018/09/complete-response-letter-for-ruconest-sbla-for-expanded-indication-in-hereditary-angioedema---pharming-/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2017/03/successful-phase-iii-approach-study-of-volanesorsen-for-treatment-of-familial-chylomicronemia-syndrome----akcea-therapeutics-ionis-pharma/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2013/12/oralair-for-grass-allergy-likely-to-get-fda-approval-stallergenes/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2018/02/post-marketing-study-of-aspireassist-system-in-obesity-published-in-obesity-surgery-journal---aspire-bariatrics-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2017/09/ariel-3-phase-iii-study-of-rucaparib-comprehensive-dataset-presented-at-esmo---clovis-oncology-/2021-09-24T07:13:56+00:00weekly0.6https://www.medthority.com/news/2019/07/new-frontiers-for-melanoma-early-diagnosis--less-removals-and-more-economic-saving--outcomes-from-the-use-of-confocal-laser-microscopy-were-presented-by-an-italian-research-team/2021-09-24T07:18:15+00:00weekly0.6https://www.medthority.com/news/2015/08/haemocloud-announced-by-haemonetics--a-sotware-device-to-connect-haemonetics-blood-management-devices-to-communicate-with-hospital-information-systems--/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2013/05/three-phase-iii-studies-of-brintellix--lundbeck-takeda--for-depression-meet-primary-endpoint/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2012/04/farletuzumab--morphotek--now-in-phase-iii-trial-for-ovarian-cancer/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2014/08/sanofi-to-market-afrezza-worldwide-for-types-1---2-diabetes---sanofi-mannkind-corporation/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-approves-mavenclad-to-treat-relapsing-remitting-multiple-sclerosis-disease--rrms--and-active-secondary-progressive-disease---merck-kgaa/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2017/07/endo-pharma-withdraws-opana-er--from-the-market-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-tobacco-products-scientific-advisory-committee-will-conduct-a-public-hearing-regarding-22nd-century-group-s-modified-risk-tobacco-product-application-for-its-vln-cigarettes-/2024-10-21T14:44:25+00:00weekly0.6https://www.medthority.com/news/2013/12/positive-phase-ii-data-for-gs-1101-in-inhl-gilead/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2013/12/cerena-transcranial-magnetic-stimulator-is-fda-approved-to-treat-migraine-eneura-therapeutics/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2016/12/arrowhead-pharma-discontinues--clinical-stage-drug-candidates-arc-520--arc-521--and-arc-aat-/2021-09-24T07:10:18+00:00weekly0.6https://www.medthority.com/news/2013/05/fda-approves-xofigo--bayer-healthcare--for-prostate-cancer/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-retacrit-for-anemia-caused-by-chronic-kidney-disease-or-chemotherapy---hospira-pfizer-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2014/10/impress-study-in-nsclc-shows-no-difference-in-continuation-of--iressa-after-disease-progression---astrazeneca/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2012/05/zogenix-files-nda-with-fda-for-zohydro-chronic-pain-treatment/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2019/10/alexion-to-acquire-achillion-pharma/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2019/06/new-analysis-shows-cardiorenal-risk-reductions-of-jardiance-are-consistent-in-adults-with-type-2-diabetes--cardiovascular-disease-and-kidney-disease-without-overt-proteinuria---eli-lilly/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-issues-warning-of-severe-joint-pain-relating-to-dpp-4-inhibitors/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-endurant-ii-aui-graft-stent--medtronic--for-abdominal-aortic-or-aorto-iliac-aneurysms/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2013/05/succesful-phase-iii-studies-with-fycompa--eisai--for-epilepsy-published-in-epilepsia-/2021-09-24T07:16:23+00:00weekly0.6https://www.medthority.com/news/2017/03/dc-bead-lumi--the-first-commercially-available-radiopaque-drug-eluting-bead-for-liver-cancers--has-received-ce-mark---btg-plc/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2015/06/preliminary-results-for-asp-2215-presented-at-eha-congress-for-aml--astellas/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2016/03/actavis-files-anda-at-fda-for-generic-abraxane--paclitaxel-protein-bound-particles-for-injectable-suspension---celgene/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2019/09/results-from-the-second-interim-analysis-of-the-phase-iii-spartan-study-featured-in-an-oral-presentation-at-esmo-2019--janssen-pharmaceuticals/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2018/12/boston-scientific-acquires-millipede-inc--and-with-it-iris-transcatheter-annuloplasty-ring-system/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2014/12/bema-buprenorphine-submitted-to-fda-for-pain-endo-pharma-biodelivery-sci/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-trial-of-elagolix-in--endometriosis-meets-primary-endpoint--abbvie-neurocrine-biosciences/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2014/09/cyramza-success-in-phase-iii-colorectal-cancer-trial-eli-lilly/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2018/11/updated-data-from-registration-enabling-navigator-trial-of-avapritinib-for-patients-with-pdgfralpha--d842v-driven-gist-and-in-second---third--and-fourth-line-for-other-gist-patients--blueprint-medicines/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-accepts-for-filing-the--bla-for-vaxchora--pxvx-0200--vaccine-for-cholera--paxvax/2024-02-09T15:55:03+00:00weekly0.6https://www.medthority.com/news/2016/04/post-hoc-analysis-of-paradigm-hf-data-with-entresto--sacubitril-valsartan--shows-benefits-in-heart-failure--novartis/2024-02-09T15:55:15+00:00weekly0.6https://www.medthority.com/news/2018/10/chmp-recommends-approval-of-ogivri-biosimilar-for-breast-cancer-and-gastric-cancer---mylan---biocon-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2012/04/cdp7851-amg-785--ucb-amgen--enters-phase-iii-for-osteoporosis/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2019/07/altimmune-inc--acquires-spitfire-pharma-and-with-it-nash-product-candidate-sp-1373/2021-09-24T07:18:17+00:00weekly0.6https://www.medthority.com/news/2019/09/immunogen-presents-full-data-and--exploratory-analyses-from-phase-iii-forward-i-study-of-mirvetuximab-soravtansine-in-ovarian-cancer-at-esmo-/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2012/09/baxter-acquires-eu-licence-to-rigosertib-from-oncanova/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-trulicity--dulaglutide--for-treatment-of-t2d---eli-lilly/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2012/06/trial-finds-that-brilinta---brilique--astrazeneca--is-cost-effective-for-acute-coronary-syndrome-patients/2021-09-24T07:02:19+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-accepts-nda-for-voxelotor--an-oral--once-daily-therapy-for-the-treatment-of-sickle-cell-disease---global-blood-therapeutics/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2015/11/eu-approves-orkambi--lumacaftor-ivacaftor--for-cystic-fibrosis-f508del-mutation--vertex-pharmaceuticals/2021-09-24T07:04:21+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-brainport-v100-device-to-orientate-blind-people--wicab-inc-/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2013/03/janssen-r-d-files-tmc-435-to-the-fda-for-hepatitis-c/2021-09-24T07:15:38+00:00weekly0.6https://www.medthority.com/news/2018/01/european-commission-approves-mvasi-the-first-biosimilar-bevacizumab-approved-by-the-ec-and-is-approved-for-the-treatment-of-certain-types-of-cancers---amgen---allergan-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2019/10/chmp-recommends-approval-of-tavalisse-in-chronic-immune-thrombocytopenia---rigel-pharma/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/05/bydureon--exenatide-extended-release--in-phase-iiib-iv-exscel-trial-showed-no-increase-in-cv-risk-in-adults-with-type-2-diabetes---astrazeneca/2021-09-24T07:14:27+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-gives-510-k--approval-for-acessa-provu-system-in-uterine-fibroids---acessa-health-/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2012/03/apg101--apogenix--meets-primary-endpoint-in-phase-ii-trial-for-glioblastoma-multiforme/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2014/01/covidien-withdraws-from-renal-denervation-programme/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2013/03/positive-results-in-phase-iii-trial-of-sufentanil-nanotab-pca--acelrx-pharmaceuticals--for-patients-with-post-operative-pain/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2018/12/positive-results-from-solo-3-trial-of-lynparza-for-brca-mutated-advanced-ovarian-cancer-patients--astrazeneca/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2019/01/fluzone-quadrivalent-is-fda-approved-to-treat-influenza-in-children-falling-within-the-six-to-35-month-age---sanofi-pasteur-/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-intone--incontrol-medical--for-female-urinary-incontinence/2021-09-24T07:01:43+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-rebel-platinum-chromium-coronary-stent-system---boston-scientific/2021-09-24T07:08:49+00:00weekly0.6https://www.medthority.com/news/2014/06/brintellix-success-treating-sexual-dysfunction-in-depression-patients-lundbeck/2024-10-21T14:50:11+00:00weekly0.6https://www.medthority.com/news/2015/05/cobimetinib---zelboraf--vemurafenib--cobrim-phase-iii-study-follow-up---genentech---roche/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2018/12/longer-term-analyses-of-eliana-study-of-kymriah-to-treat-all-_-novartis/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2013/07/eu-extends-approval-of-prevnar-13-vaccine--pfizer--to-adults-aged-18-49/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2017/06/results-of-fresco-trial-of--fruquintinib---a-proposed-treatment-for-colorectal-cancer--presented-by-chi-med-at-asco-/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2013/11/study-shows-scenesse--clinuvel-pharma--offers-benefits-for-epp/2021-09-24T07:16:33+00:00weekly0.6https://www.medthority.com/news/2019/07/post-hoc-analyses-of-phase-iii-pivotal-studies-of-emgality--show-improvements-in-daily-functioning-and-reductions-in-disability-in-patients-with-chronic-and-episodic-migraine----eli-lilly/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-extends-indication-of-gardasil-9--for-hpv-to-include-women-and-men-aged-27-through-45-years--merck-inc-/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2020/01/completion-of-patient-screening-in-phase-iii-trial-of-roluperidone-to-treat-negative-symptoms-in-schizophrenia---minerva-neurosciences/2021-09-24T07:11:54+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-accepts-nda-filing-for-nuplazid--pimavanserin--to-treat-parkinsons-disease-psychosis--acadia-pharma/2021-09-24T07:04:23+00:00weekly0.6https://www.medthority.com/news/2016/06/reports-for-vertis-mono-and-vertis-factorial-studies-of-ertugliflozin-and-ertugliflozin---sitagliptin-to-treat-type-2-diabetes-merck-inc--pfizer/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2012/10/lurasidone--takeda--filed-at-ema-for-schizophrenia/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-approves-xience-sierra--everolimus-eluting-coronary-stent-system---abbott-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2014/02/fda-approves-monovisc--for-osteoarthritis-of-the-knee---anika-dupuy-/2021-09-24T07:08:15+00:00weekly0.6https://www.medthority.com/news/2017/12/weekly-prophylactic-treatment-with-elocta--resulted-in-bleed-protection-and-target-joint-resolution-in-people-with-haemophilia-a--sobi----bioverativ-/2024-02-09T15:55:35+00:00weekly0.6https://www.medthority.com/news/2018/11/ema-grants-accelerated-assessment-for-elzonris-to-treat-blastic-plasmacytoid-dendritic-cell-neoplasm--stemline-therapeutics/2021-09-24T07:06:49+00:00weekly0.6https://www.medthority.com/news/2019/04/phase-iii-tappas-trial-of-trc-105---votrient-terminated-in-sarcoma---tracon-pharma/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-advisory-committee-recommends--premarket-approval--for-incraft-aaa-stent-graft-system-for-infrarenal-abdominal-aortic-aneurysms----cordis-cardinal-health-/2021-09-24T07:05:31+00:00weekly0.6https://www.medthority.com/news/2017/01/ema-approves-vemlidy--tenofovir-alafenamide--taf--to-treat-chronic-hepatitis-b---gilead-sciences-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-maia--mmy3008--study-of-darzalex---revlimid-in-multiple-myeloma-published-in-the-nejm---janssen-biotech/2021-09-24T07:17:31+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-accepts-label-expansion-application-for-proair-respiclick--albuterol-sulfate--inhalation-powder-in-bronchospasm-teva-pharmaceutical/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2016/09/allergan-acquires-tobira-therapeutics-for--1-695-billion-and-with-it-cenicriviroc-and-evogliptin/2021-09-24T07:09:16+00:00weekly0.6https://www.medthority.com/news/2018/01/eular-recommendations-for-the-use-of-imaging-in-large-vessel-vasculitis-in-clinical-practise-/2021-09-24T07:05:06+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-ruxience-a-biosimilar-to-mabthera--pfizer/2021-09-24T07:11:59+00:00weekly0.6https://www.medthority.com/news/2019/09/merck-kgaa-initiates-pivotal-phase-iii-programme-for-evobrutinib-in-relapsing-multiple-sclerosis-/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-da-vinci-xi-surgical-robot---intuitive-surgical/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2011/09/ema-concludes-revlimid-provides-positive-treatment-for-multiple-myeloma/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2016/09/study-of-oral-and-intranasal-arymo-er--morphine-sulfate--in-pain-relief-published-in-pain-medicine--egalet/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-study-on-efficacy-and-safety-of-exparel-in-post-surgical-pain-control-published-in-pain-medicine---pacira-biosciences/2021-09-24T07:17:04+00:00weekly0.6https://www.medthority.com/news/2015/01/nva-237-meets-endpoints-in-gem-studies-for-treatment-of-copd--novartis/2021-09-24T07:03:29+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-imfinzi-for-the-treatment-of-locally-advanced--unresectable-nsclc--astra-zeneca-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-grants-priority-review-to-ugn-101-for-upper-tract-urothelial-cancer---urogen-pharma/2021-09-24T07:18:27+00:00weekly0.6https://www.medthority.com/news/2012/12/new-assessment-of-evidence-for-the-effectiveness-of-tavi-rates-the-technique-s-benefits-as--moderate--/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2013/10/health-monitor-system-bodyguardian--preventice--ce-mark-approved/2021-09-24T07:16:16+00:00weekly0.6https://www.medthority.com/news/2012/12/aezs-108-to-commence-phase-iii-trial-for-endometrial-cancer/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-phase-iii-optic-study-reports-for-teprotumumab-for-the-treatment-of-active-thyroid-eye-disease---horizon-pharma/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-protect-study-of-sci-b-vac-meets-endpoints-in-hepatitis-b---vbi-vaccines/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2018/05/quality-cancer-care--not-just-a-matter-of-anti-cancer-medicines--esmo-press-statement-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii-reflections-b538-02-study-of-pf-06410293-adalimumab-biosimilar--met-its-primary-objective-in-rheumatoid-arthritis--pfizer/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2018/07/new-guidelines-label-millions-more-people-as-having-high-blood-pressure/2024-02-20T11:16:54+00:00weekly0.6https://www.medthority.com/news/2012/12/positive-results-in-phase-ii-study-of-bi-6727--boehringer--in-patients-with-aml/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2013/03/positive-topline-results-from-phase-iii-trial-of-enterovirus-71-vaccine--sinovac-biotech--against-hand--foot-and-mouth-disease/2021-09-24T07:15:43+00:00weekly0.6https://www.medthority.com/news/2016/06/positive-results-from-monarch--1-trial-of-abemaciclib-in-patients-with-hormone-receptor-positive--hr----human-epidermal-growth-factor-receptor-2-negative--her2---metastatic-breast-cancer--eli-lilly/2024-02-09T15:55:51+00:00weekly0.6https://www.medthority.com/news/2018/08/vernalis-plc-is-to-be-acquired-by-ligand-pharma/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2013/02/eu-approves-apifix-ais-system--apifix--for-adolescent-idiopathic-scoliosis/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2016/03/ipsen-acquires-rights-to-cometriq--cabozantinib--outside-the-us--canada-and-japan--exelixis/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-select-monotherapy-trial-data-of-abt-494-in-rheumatoid-arthritis-published-in-the-lancet---abbvie/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2015/08/five-year-data-for-fame-study-of-pressurewire-ffr-guided-stenting-in-pci-st-jude-medical/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2018/09/intra-cellular-therapies--completes-rolling-submission-of-lumateperone-to-treat-schizophrenia-/2021-09-24T07:06:38+00:00weekly0.6https://www.medthority.com/news/2016/09/tesaro-files-rolling-submission-at-fda-for-niraparib--to-treat-ovarian-cancer---/2021-09-24T07:09:19+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-approves-tymlos--abaloparatide--injection-for-the-treatment-of-postmenopausal-women-with-osteoporosis-and-high-fracture-risk---radius-health/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2014/12/xadago-refiled-with-fda-for-parkinsons-newron-pharma/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2015/05/epidiolex--cannabidiol--enters-phase-iii-trial-for-lennox-gastaut-syndrome--gw-pharma/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-grants-accelerated-approval-for-alecensa--alectinib--to-treat-alk-positive-nsclc--genentech/2021-09-24T07:04:30+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-approve-magnatom-spectra-3t-mri-imaging-system--siemens-/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-extension-of-approval-of-oralair-in-grass-allergy---stallergenes-greer-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2015/08/interim-phase-iii-trial-data-shows-rvsv-zebov-vaccine-100--effective-against-ebola--merck-inc-newlink-genetics/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2014/12/mln-9708-has-breakthrough-status-from-fda-and-starts-toumaline-ali-phase-iii-trial-for-amyloidosis--takeda---millennium/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2018/03/should-doctors-recommend-acupuncture-for-pain-/2024-02-09T15:56:31+00:00weekly0.6https://www.medthority.com/news/2015/03/clear-study-reported-at-aad-meeting-for-cosentyx--secukinumab--shown-superior-to-stelara--ustekinumab--in-psoriasis-novartis/2021-09-24T07:04:11+00:00weekly0.6https://www.medthority.com/news/2018/04/could-grilling-your-meat-raise-blood-pressure-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2016/06/bioequivalence-endpoints-met-in-study-of-biosimilar-etanercept---sandoz/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2013/06/pradaxa-boehringer--filed-at-ema-for-treatment-of-dvt-and-pulmonary-embolism/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2017/08/novartis-phase-iii-cantos-study-demonstrates-that-targeting-inflammation-with-acz-885---canakinumab---reduces-cardiovascular-risk-/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2012/01/chmp-recommends-remicade--janssen-biologic--for-paediatric-ulcerative-colitis/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2018/02/successful-phase-iii-trial-of-allogeneic-mesenchymal-stem-cell-product-msc-100-iv-to-treat-steroid-refractory-acute-graft-versus-host-disease----mesoblast-ltd-/2021-09-24T07:05:50+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-trial-of-iv-meloxicam-showing-safety-and-opioid-use-data-is-published-in-clinical-pharmacology-in-drug-development--recro-pharma/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2018/04/meningitis-b-vaccine-trial-for-teenagers-launched/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2015/08/phase-iii-trial-of-kynamro--mipomersen-sodium--meets-endpoint-in-severe-hefh--isis-pharmaceuticals/2021-09-24T07:03:08+00:00weekly0.6https://www.medthority.com/news/2012/04/regorafenib--onyx-bayer--in-phase-grid-study-for-gist/2021-09-24T07:01:55+00:00weekly0.6https://www.medthority.com/news/2015/04/new-eusa-emerges-from-jazz-pharma/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2013/10/four-year-study-of-humira--abbvie--shows-sustained-benefits-in-crohn-s/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2016/06/-the-us-centers-for-disease-control-and-prevention-recommends-flumist--quadrivalent-vaccine-should-not-be-used-for-the-2016-2017-influenza-season--astrazeneca/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/04/pellepharm--inc--doses-first-patient-in-phase-iii-trial-of-patidegib-topical-gel--2--to-treat-gorlin-syndrome-/2021-09-24T07:16:46+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-linzess--forest-ironwood--for--chronic-constipation-and-ibs/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2015/07/chmp-recommends-intuniv--guanfacine-hydrochloride-extended-release--for-adhd/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2013/02/positive-data-from-phase-iii-study-of-humira--abbvie--in-pediatric-patients-with-crohn-s-disease/2021-09-24T07:15:34+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-expanded-indication-for-prevenar-13-to-prevent-pneumonia-in-adults-pfizer/2021-09-24T07:04:16+00:00weekly0.6https://www.medthority.com/news/2018/03/takeda-considering-takeover-of-shire-plc/2021-09-24T07:06:22+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-grants-extended-approval-for-lynparza--olaparib--as-a-treatment-for-ovarian-cancer---astrazeneca---merck-inc-/2021-09-24T07:14:54+00:00weekly0.6https://www.medthority.com/news/2019/09/nice-recommends-takhzyro-for-hereditary-angioedema---takeda/2021-09-24T07:19:05+00:00weekly0.6https://www.medthority.com/news/2018/12/rolontis-filed-with-fda-for-chemotherapy-induced-neutropenia---spectrum-pharma-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2020/02/the-national-institute-of-allergy-and-infectious-diseases-stops-administration-of-vaccinations-in--hvtn-702-trial-of-an-investigational-hiv-vaccine-/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2016/10/eu-approves-kyleena--levonorgestrel-releasing-intrauterine-system--to-prevent-pregnancy--bayer-healthcare/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-somatropin-biopartners-for-growth-hormone-deficiency/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2013/08/first-implant-of-activa-pc-s-dbs-system/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2016/10/avycaz--ceftazidime-and-avibactam--snda-filed-for-patients-with-complicated-urinary-tract-infections-including-pyelonephritis--allergan/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2017/11/ctl-019-is-filed--at-ema-for-the-treatment-of--young-people-with-r-r-b-cell-acute-lymphoblastic-leukemia-and-for-adults-with-r-r-diffuse-large-b-cell-lymphoma---novartis/2021-09-24T07:14:45+00:00weekly0.6https://www.medthority.com/news/2017/09/monarch-3-study-positive-for-abemaciclib-in-combination-with-a-nonsteroidal-aromatase-inhibitor-as-treatment-of-postmenopausal-women-with-advanced-breast-cancer---eli-lilly-/2021-09-24T07:13:55+00:00weekly0.6https://www.medthority.com/news/2018/09/first-successful-implantation-of-the-vitaria-system-in-a-patient-in-the-anthem-hfref-pivotal-study-to-reduce-progression-of-heart-failure---livanova/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2014/11/success-for-brodalumab-in-comparison-with-stelara-in-amagine-2-trial-for-psoriasis---astrazeneca-amgen/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-chmp-recommends-approval-of-shingrix-for-herpes-zoster---glaxosmithkline-/2022-02-08T07:44:52+00:00weekly0.6https://www.medthority.com/news/2015/02/delay-for-basal-insulin-peglispro-in-filing-at-fda-for-types-1-and-2-diabetes--eli-lilly/2021-09-24T07:03:56+00:00weekly0.6https://www.medthority.com/news/2018/07/new-study-questions-use-of-talking-therapy--as-a-treatment-for-schizophrenia/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2011/09/genentech-files-vismodegib-at-fda-for-basal-cell-carcinoma/2021-09-24T07:04:52+00:00weekly0.6https://www.medthority.com/news/2016/12/abbott-seeks-to-terminate-acquisition-of-alere-inc-/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-approves-flexability-ablation-catheter--sensor-enabled-to-treat-atrial-flutter--abbott/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2014/07/bema-buprenorphine-meets-endpoints-in-phase-iii-pain-study-endo-pharma-biodelivery-sci/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2018/02/ema-review-of-esmya--a-treatment-for-uterine-fibroids-requires-no-new-patients-to-be-started-on-esmya--gedeon-richter---allergan/2021-09-24T07:05:58+00:00weekly0.6https://www.medthority.com/news/2011/11/lixiana-development-in-vte-for-usa-and-eu-is-discontinued/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2016/01/xtandi--enzalutamide--terrain-trial-results-published-in-the-lancet-oncology--astellas/2024-02-09T15:58:23+00:00weekly0.6https://www.medthority.com/news/2015/01/senza-spinal-cord-stimulation-system-has-approvable-letter-from-fda---nevro-corp-/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2012/12/the-medicines-company-and-bms-collaborate-in-marketing-recothrom-for-haemostasis-/2021-09-24T07:02:40+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-confirms-tkm-ebola-trial-now-on-partial-hold---tekmira-pharma/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2018/02/international-epilepsy-day-2018/2021-11-30T14:23:36+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-zalviso--sufentanil--to-manage-acute-moderate-to-severe-post-operative-pain--grunenthal/2021-09-24T07:03:44+00:00weekly0.6https://www.medthority.com/news/2015/08/jardiance--empagliflozin--meets-endpoint-in-trial-of-cv-outcomes-in-type-2-diabetes--boehringer-eli-lilly/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2014/01/chmp-recommends-approval-of-latuda-for-schizophrenia---takeda/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2015/10/novartis-broadens-immuno-oncology-pipeline-with-acquisition-of-admune-therapeutics-and-agreements-with-xoma-and-palobiofarma/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2019/07/complete-response-for-em-100-an-otc-eyedrop-to-treat-ocular-itching--eton-pharma---bausch-health-companies/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2019/08/royal-philips-launches-ce--approved-heartstart-intrepid-monitor-defibrillator-for-cardiac-arrest-/2021-09-24T07:17:47+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-requirements-presented-to-sarepta-therapeutics-for-eteplirsen-application-for-duchenne-muscular-dystrophy--/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-trial-is-initiated-for--pediatric-patients-for-ov-101-in-angelman-syndrome--ovid-therapeutics/2021-09-24T07:06:08+00:00weekly0.6https://www.medthority.com/news/2018/04/higher-cleansing-scores-correlate-with-increased-polyp-detection-in-patients-with-potential-colorectal-cancer--norgine-b-v-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-striverdi-respimat-for-treatment-of-copd---boehinger/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2016/04/results-of-structure-study-show-romosozumab-superior-to-teriparatide-in-change-of-bmd-inpostmenopausal-women-with-osteoporosis--amgen---ucb-/2024-02-09T15:59:37+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-approval-of-akynzeo--netupitant-palonosetron--for-cinv--helsinn/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2013/06/sanofi-terminates-development-of-iniparib-in-nsclc/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2012/06/chmp-recommends-subcutaneous-velcade--janssen--for-multiple-myeloma/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2019/08/us-district-court-rules-in-favour-of-amgen-on-patent-validity-of-enbrel-and-against-sandoz-biosimilar--erelzi-/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2017/09/launch-of-the-resonate-family-of-implantable-cardioverter-defibrillator--icd--and-cardiac-resynchronization-therapy-defibrillator--crt-d--systems-featuring-the-heartlogic-heart-failure-diagnostic-for-heart-failure--management---boston-scientific-/2024-07-26T10:56:07+00:00weekly0.6https://www.medthority.com/news/2011/11/injectafer-ferinject--vifor-luitpold--meets-endpoints-in-two-trials-for-iron-replacement/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-advisory-committee-votes-17-2-in-favour-of-zulresso-to-treat-postpartum-depression--sage-therapeutics/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-trial-of-respimat--tiotropium--shows-efficacy-in-asthma--boehringer/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2014/10/drisapersen-filed-at-fda-for-treatment-of-duchenne-muscular-dystrophy--prosena-n-v-/2021-09-24T07:07:18+00:00weekly0.6https://www.medthority.com/news/2016/06/nice-does-not-recommend-cotellic--cobimetinib--plus-zelboraf--vemurafenib--as-a-cost-effective-combination-for-metastatic-melanoma---roche/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2014/02/lcpn-1021-enters-phase-iii-trial-for-testosterone-deficiency-lipocine/2021-09-24T07:08:18+00:00weekly0.6https://www.medthority.com/news/2012/03/posiive-phase-iii-results-for-oms302--omeros-corp--in-cataract-surgery/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-grants-final-approval-for-trokendi-xr-for-epilepsy/2021-09-24T07:15:10+00:00weekly0.6https://www.medthority.com/news/2015/04/roadmap-results-for-heartmate-lvad-device-for-treatment-of-heart-failure-thoratec/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2016/02/eu-chmp-issues-positive-opinion-of-viekirax--ombitasvir-paritaprevir-ritonavir----exviera--dasabuvir--in-hepatitis-c-virus-infected-genotype-1b-patients-with-compensated-cirrhosis--abbvie/2024-02-09T15:59:52+00:00weekly0.6https://www.medthority.com/news/2017/06/boehringer-and-eli-lilly-to-conduct--large-trial-of-jardiance--empagliflozin--to-treat-chronic-kidney-disease-/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2011/10/nice-final-guidance-recommends-briique-in-acute-coronary-syndrome/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2017/05/-tackling-obesity-together--on-european-obesity-day---20th-may-2017/2021-09-24T07:14:29+00:00weekly0.6https://www.medthority.com/news/2018/03/trained-dogs-can-sniff-out-prostate-cancer/2024-02-19T14:59:29+00:00weekly0.6https://www.medthority.com/news/2019/11/analysis-of-phase-iii-twilight-trial-for-brilinta-showed-reduced-risk-of-bleeding-in-acute-coronary-syndromes---astrazeneca/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2019/02/genentech-completes-sbla-for-kadcyla-for-adjuvant-treatment-of--her2-positive-early-breast-cancer--ebc--with-residual-disease-/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-gives-ce-mark-approval-to-c-scan-imaging-system-for-colorectal-cancer-screening---check-cap-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2012/03/tmc-435--medivir--begins-two-new-phase-iii-trials-for-hepatitis-c-1/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2020/02/interim-data-from-phase-iiib-stardust-study-of-stelara-shows-clinical-response-in-crohns-disease---j-j-janssen-cilag/2021-09-24T07:12:05+00:00weekly0.6https://www.medthority.com/news/2017/02/successful-phase-iii-olympiad-trial-for-lynparza--olaparib--as-a-treatment-of-brca-mutated-metastatic-breast-cancer-----astra-zeneca/2021-09-24T07:13:14+00:00weekly0.6https://www.medthority.com/news/2016/10/study-shows-efficacy-of-resolute-integrity-drug-eluting-stent-in-coronary-artery-disease---medtronic/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-antimicrobial-drugs-advisory-committee-votes-in-favour-of-solitaire--solithromycin--in-community-acquired-bacterial-pneumonia--cempra/2021-09-24T07:09:53+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-gives-510-k--approval-to-aer-o-scope-colonoscopy-imaging-system-gi-imaging/2021-09-24T07:08:36+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-data-on-esbriet--intermune--in-patients-with-pulmonary-fibrosis/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2015/01/plum-360-infusion-system-receives-510--k--approval-at-fda--hospira/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2018/02/remote-regulators/2021-09-24T07:06:00+00:00weekly0.6https://www.medthority.com/news/2019/12/kite-gilead-submits-bla-to-fda-for-kte-x19-to-treat-relapsed-or-refractory-mantle-cell-lymphoma-/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-jakafi-for-the-treatment-of-steroid-refractory-acute-graft-versus-host-disease--incyte---novartis/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2015/11/successful-phase-iii-trial-of-daklinza--daclatasvir----sofosbuvir-in-treatment-of-hepatitis-c-patients-with-fibrosis-or-cirrhosis---bms/2024-02-19T15:24:52+00:00weekly0.6https://www.medthority.com/news/2017/12/fda-lifts-hold-on-fitusiran-trials-sanofi-alnylam/2021-09-24T07:13:37+00:00weekly0.6https://www.medthority.com/news/2015/06/phase-iii-trial-in-progress-for-sym-1219-for-bacterial-vaginosis---symbiomix-therapeutics-/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-xartemis-xr-for-management-of-acute-pain---mallinckrodt-/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2018/06/new-data-presented-at-eha-meeting-for-jakavi-for-treatment-of-myelofibrosis---novartis-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2019/11/fda-extends-pdufa-date-for-twirla--a-combined-hormonal-contraceptive-patch--to-16-february-2020---agile-therapeutics/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2018/03/ema-accepts-filing-of-forxiga-for-type-1-diabetes---astrazeneca-/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2015/03/new-study-demonstrates-value-of-mitra-clip-in-cardiac-surgery-abbott/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2018/12/draft-nice-guidance-does-not-recommend-onpattro-for-hereditary-transthyretin-related-amyliodsis---alnylam-pharmaceuticals-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-elevate-tn-trial-of-calquence-monotherapy-and-combined-with-gazyva-shows-improved-pfs-in-chronic-lymphocytic-leukaemia---astrazeneca/2021-09-24T07:18:36+00:00weekly0.6https://www.medthority.com/news/2018/06/new-analyses-from-empa-reg-outcome-trial-for-jardiance-on-renal-outcomes-in-patients-with-established-cv-disease-and-type-2-diabetes---boehringer---eli-lilly-/2024-07-26T10:35:05+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-trials-of-rolontis-show-consistent-efficacy-and-safety-in-neutropenia---spectrum-pharma/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-xpovio-to-treat-multiple-myeloma/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-foam-form-of-finacea--azelaic-acid--for-rosacea--bayer-healthcare/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-accepts-nda-for-arymo-er--morphine-sulfate--extended-release--egalet/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2016/07/bms-acquires-cormorant-pharma-and-with-it-humax-il8-/2021-09-24T07:08:56+00:00weekly0.6https://www.medthority.com/news/2011/09/optimer-pharma-agrees-a-licence-to-cubist-pharma-to-market-dificid-in-usa/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2013/09/siltuximab-filed-at-fda-and-eu-for-castleman-disease/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2014/06/ge-heathcare-has-fda-approval-and-launches-invenia-abus-imaging-technology-to-detect-breast-cancer-/2021-09-24T07:08:01+00:00weekly0.6https://www.medthority.com/news/2011/10/luveniq-is-withdrawn-from-ema-for-chronic-non-infectious-uveitis/2021-09-24T07:05:01+00:00weekly0.6https://www.medthority.com/news/2014/04/cubist-pharma-files-combination-ceftolozane---tazobactam-at-fda-for-urinary-tract-and-intra---abdominal-infections-/2021-09-24T07:07:22+00:00weekly0.6https://www.medthority.com/news/2013/01/european-commission-extends--zytiga-janssen-cilag--indication-in-prostate-cancer/2021-09-24T07:15:52+00:00weekly0.6https://www.medthority.com/news/2017/05/fda-grants-510-k--approval-for-endoflip-system-with-flip-topography-module--offering-a-new-way-for-clinicians-to-assess-patient-motility-disorders-during-endoscopy---crospon/2021-09-24T07:14:33+00:00weekly0.6https://www.medthority.com/news/2018/07/results-from-the-champion-trial-of-carbetocin-for-the-prevention-of-postpartum-haemorrhage-are-published-in-nejm---ferring-/2024-02-19T15:25:20+00:00weekly0.6https://www.medthority.com/news/2018/09/elad-system-for-acute-liver-failure-fails-phase-iii-trial---vital-therapeutics/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2013/01/aranesp--amgen--fails-heart-failure-trial/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2012/10/analysis-suggests-neurostar-tms-therapy--neuronetics--has-fewer-side-effects-than-drugs-in-treating-depression/2024-10-21T14:49:33+00:00weekly0.6https://www.medthority.com/news/2012/09/apremilast--celgene--success-in-palace-2---3-trials-for-psoriatic-arthritis/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/03/semglee--an-insulin-glargine-biosimilar--has-eu-and-australian-approval-to-treat-diabetes---mylan---biocon-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-accepts-bla-for-teprotumumab--for-the-treatment-of-active-thyroid-eye-disease---horizon-therapeutics-/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-iii-spartan-study-results-of-lasmiditan-for-migraine-presented-at-18th-congress-of-the-international-headache-society---eli-lilly-/2024-07-26T10:34:45+00:00weekly0.6https://www.medthority.com/news/2013/10/fda-approves-gonal-f--pen-injector--emd-serono--for-fertility-treatment/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-sbla-for-doptelet-to-treat-thrombocytopenia-in-adults/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-results-positive-for-cymraza---erlotinib-in-first-line-nsclc-egfr---eli-lilly/2021-09-24T07:18:56+00:00weekly0.6https://www.medthority.com/news/2016/06/further-data-from-alta-trial-for-brigatinib-in-treatment-of-alk---nsclc-that-is-resistant-to-crizotinib--ariad-pharma/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2018/09/chmp-positive-for-update-of-bydureon-label-to-refer-to-lowering-of-cv-risk--astrazeneca/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2018/02/12th-world-congress-on-copd-asthma-respiratory-allergy-2018-wipocis/2024-02-19T15:25:57+00:00weekly0.6https://www.medthority.com/news/2016/03/successful-phase-iii-study-for-fv-100-in-treatment-of-post-herpetic-neuralgia--contravirpharma/2024-02-19T15:26:15+00:00weekly0.6https://www.medthority.com/news/2018/12/longer-term-analyses-of-kymriah-juliet-study-for-dlbcl---novartis/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-sentinel-cerebral-protection-system-to-protect-against-risk-of-stroke-during-tavr-procedures---claret-medical/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-from-lux-lung-3-trial-of-tomtovok--boehringer--in-nsclc-patients/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2012/09/positive-results-for-edarbyclor--takeda--in-phase-iii-study-of-hypertension/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2017/05/phase-iii-trial-of-cam-2038--buprenorphine-depots--shows-positive-results-in-moderate-to-severe-opioid-use-disorder--camurus-and-braeburn-pharmaceuticals/2021-09-24T07:14:34+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-premarket-approval-for--relex--smile-expanding-myopia-treatment-to-patients-with-astigmatism--carl-zeiss-meditec/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-lenvima-in-liver-cancer---eisai-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2019/09/vp-102-filed-with-fda-for-molluscum-contagiosum---verrica-pharma/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-results-for-optina--ampio--in-patients-with-diabetic-macular-oedema/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2015/09/cynapsus-therapeutics-initiates-phase-iii-trial-of-apl-130277-for-treatment-of-parkinson-s-disease/2024-02-19T15:27:23+00:00weekly0.6https://www.medthority.com/news/2012/01/rebif-rebidose-approved-by-fda-for-self-administration-to-treat-multiple-sclerosis/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2017/03/phase-iii-trial-of-gsp-301--mometasone-furoate-and-olopatadine-hydrochloride--shows-significant-improvement-in-seasonal-allergic-rhinitis---glenmark-pharmaceuticals/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2017/08/american-journal-of-psychiatry-has-published-online-results-from-a-phase-iib-clinical-trial-of-min-101-a-proposed-treatment-for-schizophrenia---minerva-neurosciences-/2021-09-24T07:14:58+00:00weekly0.6https://www.medthority.com/news/2019/01/novel-mechanism-of-action--for-rapastinel-is-published-in-international-journal-of-neuropsychopharmacology---allergan/2021-09-24T07:18:47+00:00weekly0.6https://www.medthority.com/news/2018/06/interim-analysis-of--impower-133-study-positive-for-tecentriq-in-treatment-of-small-cell-lung-cancer---genentech-roche/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2016/09/hot-hmv-study-shows-increase-in-admission-free-survival-with-non-invasive-ventilation-devices-lumis--stellar-and-astral-in-chronic-obstructive-pulmonary-disease--resmed/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2013/06/fda-approves-revlimid-for-treatment-of-mantle-cell-lymphoma/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2013/11/corevalve-system--medtronic--success-in-continued-access-study/2021-09-24T07:16:36+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-recommends-tasigna--novartis--for-cml/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-approves-zydelig-for-follicular-lymphoma-gilead-sciences/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2018/03/successful-osmo-study-shows-nucala--improved-asthma-control-in-patients-uncontrolled-on-xolair----gsk-/2021-09-24T07:06:35+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-blincyto--blinatumomab--for-conditional-marketing-approval-to-treat-ph-relapsed-or-refractory-b-precursor-all--amgen/2024-02-19T15:27:37+00:00weekly0.6https://www.medthority.com/news/2018/04/ema-and-health-canada-accept-marketing-applications-for-shp-643-for-the-prevention-of-angioedema-attacks----shire-plc-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-cobas-hbv-and-cobas-hcv-viral-load-tests-for-hepatitis-b-and-hepatitis-c--roche/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2015/04/simplexa-group-a-strep-direct-kit-test-is-510-k--approved-by-the-fda-focus-diagnostics/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2014/12/prx-302-phase-iii-efficacy-threshold--for-bph-is-not-met--sophiris-bio/2021-09-24T07:08:32+00:00weekly0.6https://www.medthority.com/news/2012/12/bolero-2-18-month-follow-up-shows-benefits-with-afinitor-aromasin-combination--novartis-pfizer--in-breast-cancer-patients/2021-09-24T07:02:39+00:00weekly0.6https://www.medthority.com/news/2017/02/detailed-phase-iii-results-presented-for-edurant--dolutegravir--and-tivicay--rilpivirine--in-hiv-treatment--viiv-healthcare-and-janssen/2021-09-24T07:13:15+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-issues-complete-response-letter-to-portola-pharma-relating-to-andexxa--andexanet-alfa--antidote-for-factor-xa-inhibitors-/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-approves-extension-of-label-for-keytruda-for-the-first-line-treatment-of-patients-with-stage-iii-nsclc----merck-inc-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-updated-indication-for-velcade-in-multiple-myeloma---takeda/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-amplatzer-pfo-occluder-device-for-stroke-prevention--st-jude-medical/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2016/12/-kw-6002--istradefylline--did-not-meet-its-primary-endpoint-in-patients-with-parkinson-s-disease--kyowa-hakko-kirin-/2021-09-24T07:10:10+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-nayzilam-for-epilepsy/2021-09-24T07:17:34+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-cardio-ttr-study-of-ionis-ttrrx-in-ttr-amyloid-cardiomyopathy-no-longer-proceeding--gsk-ionis/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2012/06/sub-analysis-of-re-ly-trial-shows-pradaxa--boehringer--similar-to-warfarin-in-atrial-fibrillation-patients-undergoing-surgery/2021-09-24T07:02:22+00:00weekly0.6https://www.medthority.com/news/2013/10/viiv-healthcare-submits-trii-to-ema-for-hiv/2021-09-24T07:16:11+00:00weekly0.6https://www.medthority.com/news/2017/11/intellis-platform-for-spinal-cord-stimulation-and-peripheral-nerve-stimulation-receives-ce-mark--medtronic-/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2013/11/beloranib--zafgen--positive-in-phase-ii-trial-for-severe-obesity/2021-09-24T07:16:32+00:00weekly0.6https://www.medthority.com/news/2017/08/idhifa--enasidenib--was-granted--fda-approval-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-aml--r-r-aml--with-an-isocitrate-dehydrogenase-2--idh2--mutation----celgene---agios-pharma/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approves-lemtrada-for-treatment-for-multiple-sclerosis-genzyme-sanofi/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-praluent-to-reduce-risk-of-established-atherosclerotic-cardiovascular-disease--sanofi---regeneron/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2013/10/pfizer-to-continue-studies-for-remoxy-for-pain-control/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2016/03/-the-fda-has-rescheduled-its-advisory-committee-review-of-exondys--eteplirsen--to-treat-duchenne-muscular-dystrophy-to-25-april-2016--sarepta/2021-09-24T07:10:24+00:00weekly0.6https://www.medthority.com/news/2013/05/study-shows-multiple-sclerosis-patients-taking-gilenya--novartis--show-high-levels-of-satisfaction-with-the-drug/2021-09-24T07:16:19+00:00weekly0.6https://www.medthority.com/news/2016/05/luminex-corporation-acquires-nanosphere-inc---and-its-diagnostics-for--77-million-/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-tafinlar--dabrafenib----mekinist--trametinib--for-braf-v600e-k-metastatic-melanoma--novartis/2024-02-19T15:27:53+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-sakurasky-study-results-for-sa-237-shows-reduction-in-relapses-in-neuromyelitis-optica-spectrum-disorder---roche/2021-09-24T07:19:07+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-panel-rejects-avridi-opoid-pain-drug---purdue-pharma/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2017/12/chmp-recommends-approval-of-herzuma-biosimilar-in-breast-cancer/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-tegsedi-to-treat-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis--akcea-therapeutics---ionis-pharma/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2017/03/sigma-tau-pharmaceuticals-inc--changes-its-name-to-leadiant-biosciences-inc-/2021-09-24T07:14:23+00:00weekly0.6https://www.medthority.com/news/2018/02/pre-market-fda-approval-for-bd-onclarity-hpv-assay-to-detect-hpv-genotypes-16--18--and-45--associated-with-the-majority-of-cervical-cancers---bd-diagnostics-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-results-for-xarelto--bayer-janssen--in-pe-and-vte/2021-09-24T07:01:38+00:00weekly0.6https://www.medthority.com/news/2014/12/otsuka-acquires-avanir-for--3-5-billion/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2011/11/exparel-is-fda-approved-for-post-surgical-analgesia/2021-09-24T07:04:59+00:00weekly0.6https://www.medthority.com/news/2017/07/positive-results-from-phase-iii-flaura-trial-of-tagrisso--osimertinib--for-metastatic-epidermal-growth-factor-receptor-mutation-positive--egfrm--non-small-cell-lung-cancer--nsclc----astrazeneca/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2017/04/veliparib-does-not-meet-primary-endpoints-in-phase-iii-trials-for--non-small-cell-lung-cancer-or-triple-negative-breast-cancer---abbvie/2021-09-24T07:14:12+00:00weekly0.6https://www.medthority.com/news/2016/05/two-year-survival-data-from-checkmate-057-and-017-trials-for-opdivo--nivolumab--versus-docetaxel-in-nsclc--bms/2024-02-19T15:30:32+00:00weekly0.6https://www.medthority.com/news/2014/06/januvia-reduces-nocturnal-hypoglycemia-in-t2d---merck/2021-09-24T07:07:58+00:00weekly0.6https://www.medthority.com/news/2014/12/otsuka-to-market-iclusig-in-japan--s-korea--china-and-se-asia-/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2018/01/eu-approves-adnovi-for-prophylactic-use-of-patients-with-hemophilia-a---shire-/2021-09-24T07:05:12+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-grants-510-k--approval-to--omnipod-dash-insulin-management-system---insulet-corporation-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2015/05/us-development-of-gcs-100-discontinued-in-chronic-kidney-disease-la-jolla-pharma/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2016/02/three-phase-iii-trials-show-efficacy-of-bf-200-ala--5-aminolevulinic-acid--in-actinic-keratosis--biofrontera-/2021-09-24T07:09:00+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-brainsway-deep-tms-system-to-treat-obsessive-compulsive-disorder---brainsway-ltd-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2019/04/interim-data-from-its-phase-iii-str1ve-trial-of-zolgensma-in-spinal-muscular-atrophy--sma--type-1--avexis-novartis/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2016/08/positive-reslts-from-phase-iii-trial-of-baremsis--amisulpride-injection--in-post-operative-nausea---vomiting--acacia-pharma/2021-09-24T07:09:40+00:00weekly0.6https://www.medthority.com/news/2018/07/fda-approves-freestyle-libre-14-day-flash-glucose-monitoring-system----abbott-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2014/11/duaklir-genuair-is-eu-approved-for-treatment-of-copd-astrazeneca/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-approves-faslodex--fulvestrant--500mg-as-expanded-use--for-postmenopausal-women-with-hr--her2--advanced-breast-cancer--astrazeneca/2021-09-24T07:14:50+00:00weekly0.6https://www.medthority.com/news/2019/02/european-commission-approves-zirabec--bevacizumab-biosimilar-to-treat-the-same-indications-as-the-originator-product--avastin----pfizer/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2017/03/re-circuit-study-of-pradaxa--dabigatran-etexilate--shows-less-bleeding-and-fewer-serious-events-in-atrial-fibrillation-patients--boehringer/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2012/07/ema-approves-flutiform--mundipharma--for-asthma-treatment/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2015/10/heartmate-3-lvad-receives-ce-mark-approval-in-eu-for-heart-transplant-patients--st-jude-medical/2024-02-19T15:30:46+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-advisory-committee-recommends-triferic-for-chronic-kidney-disease--rockwell-medical/2021-09-24T07:08:43+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-keynote-426-trial-of-keytruda---inlyta-meets-primary-endpoints-in-renal-cell-carcinoma---merck-inc----pfizer-/2021-09-24T07:05:42+00:00weekly0.6https://www.medthority.com/news/2012/10/inlyta--pfizer--not-superior-to-nexavar-in-renal-cell-carcinoma-trial/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2018/01/alder-pharma-and-teva-enter-patent-settlement-relating-to-eptinezumab-treatment-for-migraine-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2017/04/valeant-pharmaceuticals-international-announces-marketing-information-for-siliq--brodalumab---a-new-treatment-for-psoriasis-/2021-09-24T07:14:11+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iv-study-of-exparel-shows-reduction-in-opioid-use-after-surgery---pacira-biosciences/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2014/05/complete-response-letter-from-fda-for-cangrelor-for-pci-and-coronary-artery-disease-the-medicines-company/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2012/09/fda-approves-prolia-amgen--for-treatment-of-male-osteoporosis---------------/2021-09-24T07:01:58+00:00weekly0.6https://www.medthority.com/news/2016/12/european-commission-approves-rekovelle--follitropin-delta-for-use-in-controlled-ovarian-stimulation---ferring-/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2016/06/findings-published-in-jama-cardiology-quantify-magnitude-of-potential-survival-benefits-if-entresto--sacubitril-valsartan--were-prescribed-to-all-eligible-us-hfref-patients--novartis-/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2019/02/sarepta-acquires-myonexus-therapeutics/2021-09-24T07:17:06+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-fycompa--perampanel--oral-suspension-for-epilepsy-as-alternative-to-tablet-form--eisai/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2014/12/ctl-019-studies-in-paediatric-all--novartis/2021-09-24T07:08:35+00:00weekly0.6https://www.medthority.com/news/2015/01/phase-iii-trials-of-praluent-for-hypercholesterolemia-meet-endpoints-regeneron-sanofi/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2019/09/novartis-announces-positive-results-from-phase-iii-palladium-study-of-inhaled-combination-qmf-149-in-patients-with-uncontrolled-asthma-/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-recommends-xgeva--amgen-gsk--for-sre-prevention-of-solid-tumors/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2018/05/in-final-guidance-nice-recommends-the-uk-use-of-tremfya-in-plaque-psoriasis---janssen-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2016/10/synergy-pharmaceuticals-presents-long-term-safety-data-for--plecanatide-for-the-treatment-of-chronic-idiopathic-constipation-/2021-09-24T07:10:30+00:00weekly0.6https://www.medthority.com/news/2015/07/mhra-review-supports-use-of--actilyse--alteplase--in-treatment-of-stroke-boehringer/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2018/07/catalent-inc--acquires-juniper-pharmaceuticals-inc-/2025-10-16T10:45:54+00:00weekly0.6https://www.medthority.com/news/2013/11/successful-light-study-of-contrave-for-obesity--orexigen/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2016/02/nice-does-not-recommend-3-molecular-tests-for-sepsis/2021-09-24T07:09:01+00:00weekly0.6https://www.medthority.com/news/2014/05/safinamide-is-filed-at-fda-as-add-on-therapy-for-parkinsons-disease---newron---zambon/2021-09-24T07:08:04+00:00weekly0.6https://www.medthority.com/news/2015/07/analyst-response-to-results-from-prime-study-of-aducanumab-for-mild-alzheimers-disease-biogen/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---the-forgotten-side-of-ckd--kidney-disease-triggers-cognitive-impairment-even-in-early-stages/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2019/04/esmo-breast-cancer-find-out-more/2024-02-23T11:51:55+00:00weekly0.6https://www.medthority.com/news/2013/10/g-ba-rules-jetrea--thrombogenics--offers-significant-benefit-in-vmt/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2020/01/european-commission-approval-for-mayzent-to-treat-secondary-progressive-multiple-sclerosis---novartis/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-eylea-to-treat-diabetic-retinopathy--regeneron/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2014/05/allergan-rejects-bid-from-valeant-pharmaceuticals/2025-10-16T10:52:36+00:00weekly0.6https://www.medthority.com/news/2019/04/fda-extends-review-of-nda-for-ac-220-in-acute-myeloid-leukemia---daiichi-sankyo/2021-09-24T07:16:48+00:00weekly0.6https://www.medthority.com/news/2011/07/no-sex-difference-in-hiv-patients-with-boosted-reyataz/2021-09-24T07:04:42+00:00weekly0.6https://www.medthority.com/news/2020/01/nejm-publishes-medalist-study-results-for-reblozyl-to-treat--anemia-in-myelodysplastic-syndromes---bms---acceleration-pharma/2021-09-24T07:11:53+00:00weekly0.6https://www.medthority.com/news/2012/11/positive-results-comparing-programming-of-s-icd-and-crt-d-defibrillators--boston-scientific--in-patients-at-risk-of-cardiac-arrest/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-accepts-sbla-of-botox-to-treat-pediatric-patients--2-years-of-age-and-older--with-upper-and-lower-limb-spasticity---allergan/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2016/08/fda-approves-expanded-indication-for-sapien-xt-and-sapien-3-transcatheter-heart-valves-to-cover-aortic-valve-stenosis-patients-at-intermediate-risk--edwards-lifesciences/2021-09-24T07:09:39+00:00weekly0.6https://www.medthority.com/news/2019/05/baxter-announces-new-research-on-3-in-1-oxiris-filter-set-for-continuous-renal-replacement-therapy-and-sepsis-management-/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2016/06/results-of-empa-reg-outcome-trial-for-jardiance--empagliflozin--show-risk-reductions-for-type-2-diabetes-consistent-across-age-groups--boehringer--eli-lilly-/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2015/10/tysabri-does-not-achieve-endpoints-in-secondary-progressive-ms-in-ascend-study--biogen/2024-02-19T15:31:16+00:00weekly0.6https://www.medthority.com/news/2015/10/mri-data-from-temso-study-shows-aubagio--teriflunomide--slows-brain-atrophy-in-ms-patients--sanofi/2024-02-19T15:31:35+00:00weekly0.6https://www.medthority.com/news/2018/07/apollo-phase-iii-trial-of-aln-ttr02-in-hattr-amyloidosis-published-in-nejm---alnylam-pharma-/2024-02-19T15:31:59+00:00weekly0.6https://www.medthority.com/news/2015/07/checkmate-025-phase-iii-trial-of-opdivo--nivolumab--from-bms---ono-for-renal-cell-carcinoma-is-stopped-early-after-showing-superior-overall-survival-compared-to-afinitor--everolimus-/2021-09-24T07:04:38+00:00weekly0.6https://www.medthority.com/news/2012/06/positive-phase-iii-data-for-t-dm1--genentech-roche--breast-cancer-patients-/2021-09-24T07:02:27+00:00weekly0.6https://www.medthority.com/news/2018/11/positive-trial-data-for-lutonix-014-drug-coated-balloon-to-treat-narrowed-or-obstructed-arteries-below-the-knee--becton-dickinson/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2012/08/torisel--pfizer--fails-in-combination--trial-with-avastin-in-renal-cell-carcinoma/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2017/03/rlx-030--serelaxin--fails-to-meet-endpoints-of-reduction-of-cardiovascular-death-or-worsening-heart-failure-in-relax-ahf-2---novartis/2021-09-24T07:14:19+00:00weekly0.6https://www.medthority.com/news/2015/08/maa-for-ibrance--palbociclib----endocrine-therapy-accepted-by-ema-for-treatment-of-hr--her2--metastatic-breast-cancer--pfizer/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2012/03/arcapta-neohaler--novartis--is-launched-in-usa-for-copd/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2015/11/japan-approves-elplat--oxaliplatin--for-postoperative-adjuvant-chemotherapy-in-gastric-cancer--yakult/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2012/10/canvas-study-of-canagliflozin-janssen-in-type-2-diabetes-sub-study/2024-02-19T15:32:12+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-clinical-trials-of-abt-494-shows-efficacy-and-safety-at-48-weeks-in-rheumatoid-arthritis---abbvie/2021-09-24T07:16:58+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-studies-of-dolutegravir-and-rilpivirine-met-endpoints-in-switching-hiv-patients-from-three-or-four-drug-regimens---viiv-healthcare---janssen-sciences-/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-epclusa--sofosbuvir-and-velpatasvir--to-treat-adult-patients-with-chronic-hepatitis-c-virus--gilead-sciences/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2016/04/-vevo-md---the--first-ultra-high-frequency--uhf--clinical-ultrasound-system--secures-510-k--clearance-from-fda-fujifilm-visualsonics-inc-/2021-09-24T07:10:39+00:00weekly0.6https://www.medthority.com/news/2019/12/real-world-trial-of-fluad-shows-benefits-in-reduced-hospitalisation-risk-for-influenza---seqirus/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2015/02/successful-interim-analysis-of-phase-iii-data-for-blisibimod-in-systemic-lupus-erythematosus-anthera-pharma/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2011/11/viread--gilead-sciences--dropped-from-hiv-prevention-trial/2021-09-24T07:04:53+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-hadlima-an-adalimumab-biosimilar/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-orkambi--lumacaftor---ivacaftor--to-treat-cystic-fibrosis-f508del-mutation--vertex-pharma/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approve-auvi-q--sanofi--for-anaphylaxis----------------/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2017/12/chmp-recommends-approval-of-herzuma-biosimilar-in-gastric-cancer/2021-09-24T07:13:36+00:00weekly0.6https://www.medthority.com/news/2017/07/rolling-submission-to-fda-started-for-cam-2038--buprenorphine-depots--in-opioid-use-disorder--braeburn-pharmaceuticals-and-camurus/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2013/10/nice-confirms-positive-recommendation-for-iluvien-for-dme/2021-09-24T07:16:18+00:00weekly0.6https://www.medthority.com/news/2014/09/cometriq-fails-to-meet-primary-endpoint-in-prostate-cancer-trial-exelixis/2021-09-24T07:07:51+00:00weekly0.6https://www.medthority.com/news/2013/12/chmp-recommends-neuraceq-for-pet-imaging-of-beta-amyloid-plaque-piramal-imaging/2021-09-24T07:15:15+00:00weekly0.6https://www.medthority.com/news/2013/04/elacyt--clavis-pharma--fails-phase-iii-trial-for-aml/2021-09-24T07:16:41+00:00weekly0.6https://www.medthority.com/news/2014/06/novo-nordisk-to-recruit-6000-more-staff-up-to-2022/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2014/08/us-government-closes-investigation-into-plato-trial-of-brilinta-and-will-take-no-further-action---astrazeneca/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2016/12/actimmune--interferon-gamma-1b--fails-to-meet-endpoints-in-phase-iii-trial-for-friedreich-s-ataxia---horizon-pharma/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2015/06/allergan-to-acquire-kythera-biopharma-for--2-1-billion-and-with-it-kybella-and-kyth-105--setipiprant-/2021-09-24T07:03:34+00:00weekly0.6https://www.medthority.com/news/2017/06/clarus-therapeutics-re-submits-nda-at-fda-for-jatenzo--formerly-rextor---the-company-s-oral--testosterone--t--replacement-product-/2021-09-24T07:14:59+00:00weekly0.6https://www.medthority.com/news/2015/01/eu-approves-cerdelga--eliglustat--for-treatment-of-gaucher-disease-type-1-sanofi-genzyme/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2018/09/jnj-42756493-filed-with-the-fda-for-metastatic-urothelial-cancer---janssen-r-d-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2016/10/insmed-incorporated-licenses-azd-7986-from-astrazeneca-for-the-treatment-of-non-cf-bronchiectasis-/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-advisory-committee-voted-8-8-on-the-overall-benefits-of-zynquista-to-treat-type-1-diabetes--sanofi---lexicon/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2019/09/sustain-8-and-10-phase-iii-trials-of-ozempic-show-ozempic-superior-in-type-2-diabetes---novo-nordisk/2021-09-24T07:19:06+00:00weekly0.6https://www.medthority.com/news/2015/05/sarepta-to-file-rolling-nda-submission-at-fda-for-eteplirsen-to-treat-duchenne-muscular-dystrophy--/2021-09-24T07:04:04+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-approves-toujeo--insulin-glargine--rdna-origin---for-treatment-of-type-1-and-type-2-diabetes-sanofi/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2018/09/ixora-r-trial-of-taltz-v-tremya-to-treat-psoriasis-is-initiated-eli-lilly/2021-09-24T07:06:46+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-the-corevalve-evolut-r-system-for-aortic-stenosis--medtronic/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2018/11/united-therapeutics-licenses-global-rights-from-arena-pharma-to-ralinepag-for-the-treatment-of-pulmonary-arterial-hypertension-/2021-09-24T07:06:52+00:00weekly0.6https://www.medthority.com/news/2014/06/eu-gives-ce-mark-approval-to-the-da-vinci-xi-surgical-system-intuitive-surgical/2021-09-24T07:07:54+00:00weekly0.6https://www.medthority.com/news/2012/02/viread-gilead-sciences--and-kidney-disease-risk/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2011/10/bax-111-starts-phase-iii-for-von-willebrand-disease/2021-09-24T07:05:02+00:00weekly0.6https://www.medthority.com/news/2016/04/tap-100-touch-activated-phlebotomy-device-enters-pivotal-trial-to-provide-painless-diagnostic-blood-collection---seventh-sense-biosystems/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2017/11/phase-iii-studies-of-vx-661--kalydeco-in-cystic-fibrosis-published-in-nejm---vertex-pharma-/2021-09-24T07:14:46+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-approves-unituxin-for-neuroblastoma-united-therapeutics-corp/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2017/05/twenty-four-months-data-of-long-term-safety-of-magmaris-resorbable-magnesium-scaffold---biotronik/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2019/05/gilead-sciences-to-donate-truvada-for-prep-in-support-of-national-efforts-to-help-prevent-hiv-and-end-the-epidemic-/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2012/01/pfizer-files-bosutinib-at-fda-for-ph-cml/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2018/03/world-kidney-day-2018/2021-09-24T07:06:36+00:00weekly0.6https://www.medthority.com/news/2013/02/gentium-unlikely-to-get-chmp-recommendation-for-defibrotide-use-in-hepatic-veno-occlusive-disease/2021-09-24T07:15:32+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-expands-indication-for-lumizyme-in-pompe-disease-genzyme-sanofi/2021-09-24T07:07:32+00:00weekly0.6https://www.medthority.com/news/2013/09/fda-guidance-on-generic-advair/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-metiv-hcc-trial-data-for-arq-197--tivantinib--in-hepatocellular-carcinoma-confirms-phase-ii-results--arqule/2024-02-19T15:32:28+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-rejects-keytruda-as-a-treatment-of-head-and-neck-cancer--merck-inc-/2021-09-24T07:11:51+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-expands-approval-of-corevalve-system-for-aortic-valve-in-valve-replacement-medtronic/2021-09-24T07:03:02+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-approves--xeljanz--pfizer--to-treat-rheumatoid-arthritis---------------/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2017/01/second-successful-phase-iii-trial-of-idp-118--halobetasol-propionate-and-tazarotene-lotion-to-treat-plaque-psoriasis---valeant-pharma-international-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-recommends-approval-for-cabometyx-as-first-line-treatment-for--advanced-renal-cell-carcinoma---ipsen-/2021-09-24T07:06:24+00:00weekly0.6https://www.medthority.com/news/2018/02/study-reveals-substantial-impact-of-chronic-diseases-on-cancer-risk/2024-02-19T15:32:51+00:00weekly0.6https://www.medthority.com/news/2016/09/ema-chmp-recommends-approval-of-somakit-toc--netspot--in-positron-emission-tomography-imaging-in-adult-patients-with-gastro-enteropancreatic-neuroendocrine-tumours---advanced-accelerator-applications/2021-09-24T07:09:17+00:00weekly0.6https://www.medthority.com/news/2018/04/researchers-discover-molecular-basis-for-increased-cardiovascular-disease-in-older-women--fcvb-2018-/2024-02-19T15:33:23+00:00weekly0.6https://www.medthority.com/news/2018/01/is-gluten-free-always-the-healthy-option-/2024-10-22T09:52:28+00:00weekly0.6https://www.medthority.com/news/2018/12/astellas-pharma-acquires-potenza-therapeutics-and-immuno-oncology-pipeline/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2018/06/additional-analyses-from-phase-iii-echelon-1-clinical-trial-of-adcetris-in-newly-diagnosed-advanced-hodgkin-lymphoma---seattle-genetics-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2018/08/ce-mark-for-im-refluxstop-device-to-treat-gastro-osophageal-reflux-disease--gerd----implantica-/2021-09-24T07:06:16+00:00weekly0.6https://www.medthority.com/news/2018/06/jama-article-shows-dramatic-increase-in-emergency-department-visits-by-gout-patients---horizon-pharma-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2018/04/alks-5461-filed-with-fda-for-major-depressive-disorder---alkermes-/2021-09-24T07:05:22+00:00weekly0.6https://www.medthority.com/news/2016/06/comparable-data-for-benepali--etanercept-biosimilar--and-flixabi--infliximab-biosimilar--and-sb-5---adalimumab-biosimilar--to-originator-drugs-presented-at-eular-congress----samsung-biologics---biogen/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2019/06/ascertain-phase-iii-study-of-astx-727-meets-primary-endpoint-in-myelodysplastic-syndromes-or-chronic-myelomonocytic-leukemia---astex-pharma/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-ii-blast-study-shows-median-overall-survival-of-36-5-months-in-patients-with---minimal-residual-disease-positive-acute-lymphoblastic-leukemia--amgen/2021-09-24T07:16:55+00:00weekly0.6https://www.medthority.com/news/2011/12/kalydeco-is-filed-at-fda-and-ema-for-cystic-fibrosis/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2014/05/european-commission-approves-hemangiol-for-treatment-of-hemangioma--pierre-fabre/2021-09-24T07:08:13+00:00weekly0.6https://www.medthority.com/news/2017/11/liberty-asthma-venture-study-shows-significant-reduction-of-corticosteroid-use-with-dupilumab-in-severe-asthma--sanofi---regeneron-/2024-07-26T10:34:13+00:00weekly0.6https://www.medthority.com/news/2016/03/bd-vacutainer-barricor-plasma-blood-collection-tube-receives-ce-mark--becton-dickinson-and-company/2021-09-24T07:10:26+00:00weekly0.6https://www.medthority.com/news/2017/02/realtime-zika-test-diagnostic-fda-approved-for-detection-of-zika-virus--abbott/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2017/09/phase-ii-iii-focus-study-is-terminated-for-ca4p--fosbretabulin--plus-avastin--bevacizumab--for-ovarian-cancer----mateon-therapeutics-/2021-09-24T07:13:47+00:00weekly0.6https://www.medthority.com/news/2019/04/espd-2019---discover-more/2021-12-01T14:09:52+00:00weekly0.6https://www.medthority.com/news/2015/09/european-commission-approves-praluent--alirocumab--to-treat-ldl-cholesterol-in-hypercholesterolemia-patients--sanofi---regeneron/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-sbla-for-rituxan--rituximab--as-a-treatment-for--pemphigus-vulgaris---genentech-roche/2021-09-24T07:06:28+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-xarelto-to-reduce-the-risk-of-cv-events---bayer-healthcare---janssen/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2018/07/two-phase-iii-studies-of-kx2-391-meet-primary-endpoint-in-actinic-keratosis---athenex-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2015/05/chmp-recommends-approval-of-imbruvica-ibrutinib-for-waldenstroms-macroglobulinemia-pharmacyclics/2021-09-24T07:04:03+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-approves-xultophy-for-treatment-of-type-2-diabetes--novo-nordisk/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2015/09/positive-results-in-dual-v-phase-iii-trial-of-xultophy--insulin-degludec-plus-liraglutide--in-type-2-diabetes--novo-nordisk/2024-02-19T15:33:37+00:00weekly0.6https://www.medthority.com/news/2016/06/analysis-of-aspire-trial-of-kyprolis--carfilzomib--plus-lenalidomide-and-dexamethasone-improved-pfs-and-orr-in-patients-with-multiple-myeloma--amgen/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2020/01/nice-does-not-recommend-stelara-to-treat-ulcerative-colitis---janssen/2024-02-20T13:47:58+00:00weekly0.6https://www.medthority.com/news/2019/11/chmp-recommends-approval-of-polivy---bendamustine---mabthera-for-diffuse-large-b-cell-lymphoma---roche/2021-09-24T07:17:56+00:00weekly0.6https://www.medthority.com/news/2019/05/post-hoc-analysis-of-radicava-in-amyotrophic-lateral-sclerosis-published-in-amyotrophic-lateral-sclerosis-and-frontotemporal-degeneration---mitsubishi-tanabe/2024-07-26T10:33:26+00:00weekly0.6https://www.medthority.com/news/2013/10/misodel--ferring--approved-in-eu-for-labour-induction/2021-09-24T07:16:13+00:00weekly0.6https://www.medthority.com/news/2018/05/europrevent-2018---a-fat-belly-is-bad-for-your-heart/2024-02-19T15:34:17+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-recommends-change-of-approval-of-ilaris--canakinumab--for-adult-onset-still-s-disease-and-systemic-juvenile-idiopathic-arthritis--novartis/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2012/06/stiefel-takes-world-rights-to-toctino-from-basilea-for-chronic-hand-eczema/2021-09-24T07:02:23+00:00weekly0.6https://www.medthority.com/news/2015/03/-fda-advisory-committee-recommends-atx-101-deoxycholic-acid--to-treat-submental-fat-in-adults---kytherabiopharmaceuticals-inc-/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2014/08/ixekizumab-superior-to-etanercept-in-phase-iii-trials-for-plaque-psoriasis--eli-lilly/2021-09-24T07:07:29+00:00weekly0.6https://www.medthority.com/news/2012/11/study-suggests-probiotic-cardioviva--micropharma--can-help-reduce-bad-cholesterol-in-blood---------------/2021-09-24T07:01:31+00:00weekly0.6https://www.medthority.com/news/2014/12/chmp-recommends-tasermity-from-genzyme-sanofi-for-treatment-of-hyperphosphataemia-/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/09/arx-04--sufentanil-sublingual-tablet--meets-endpoints-in-phase-iii-trial-for-acute-pain--acelrx-pharma/2024-02-19T15:34:29+00:00weekly0.6https://www.medthority.com/news/2018/05/phase-iii-sygma-trials-of-symbicort-turbohaler-for-asthma--as-needed--are-published-in-nejm---astrazeneca/2021-09-24T07:07:07+00:00weekly0.6https://www.medthority.com/news/2019/03/momentum-3-study-of-heartmate-3-lvad-meets-primary-endpoint-in-heart-failure---abbott/2024-02-19T15:35:49+00:00weekly0.6https://www.medthority.com/news/2019/07/medicinova-announces-phase-iii-clinical-trial-plan-for-mn-166--ibudilast--in-progressive-ms---medicinova-inc-/2021-09-24T07:18:18+00:00weekly0.6https://www.medthority.com/news/2018/07/international-congress-on-neuromuscular-diseases--icnmd-2018--6---10-july-2018-/2022-02-08T07:44:52+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-attain-trial-data-of-vibativ-in-hospital-acquired-pneumonia-published-in-infectious-diseases-and-therapy---cumberland-pharma/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2016/10/brilinta---ticagrelor--shows-no-benefit-over-clopidogrel-in-euclid-trial-for-peripheral-artery-disease---astrazeneca/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-grants-510--k--approval-for--omnipod-dash-insulin-management-system--omnipod-dash--tubeless-insulin-pump-technology---insulet-corporation-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2015/04/new-phase-iii-results-for-olysio-plus-sovaldi--simeprevir-plus-sofosbuvir--in-hcv-janssen/2021-09-24T07:02:55+00:00weekly0.6https://www.medthority.com/news/2014/03/trelagliptin--once-weekly-dpp-4-inhibitor-is-filed-in-japan-for-t2d---takeda/2021-09-24T07:08:26+00:00weekly0.6https://www.medthority.com/news/2016/03/fda-approves-mome-kardia--remote-monitor-to-diagnose-cardiac-arrhythmias--infobionics/2021-09-24T07:10:21+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-visible-1-trial-of-subcutaneous-entyvio-shows-remission-rates-in--ulcerative-colitis---takeda-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-places-hold-on-trial-of-bpx-501-in-graft-vs--host-disease---bellicum-pharma-/2021-09-24T07:06:03+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-approves-olysio-for-genotype-1-and-4-hepatitis-c-as-a-combination-treatment---janssen-cilag/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2013/09/sanofi-to-market-pozen-drugs-for-gastric-ulcer-in-us/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-supplemental-application-for-vectibix--panitumumab--in-wild-type-ras-metastatic-colorectal-cancer--amgen/2021-09-24T07:14:08+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-lumoxiti-to-treat-hairy-cell-leukaemia--astrazeneca/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-pivotal-trial-data-for-rdz-5792-for-hyperphosphatemia-published-in-journal-of-the-american-society-of-nephrology---ardelyx/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-expanded-dose-range-for-latuda--sunovion-pharma--in-treatment-of-adult-schizophrenia/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2012/03/phase-ii-study-underway-of-shok-pak--inflammagen-therapeutics--for-patients-with-shock/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2017/04/medtronic-initiates-stop-persistent-af-clinical-trial-using-the-arctic-front-advance-cardiac-cryoablation-catheter-to-treat-persistent-atrial-fibrillation-/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2015/03/faster-acting-insulin-aspart--fiasp--success-in-phase-iii-trials-compared-to-novorapid--insulin-aspart--in-diabetes-novo-nordisk/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2017/03/successful-phase-iii-genuine-trial-of--tg-1101--ublituximab--plus-imbruvica--ibrutinib--to-treat--high-risk-chronic-lymphocytic-leukemia---tg-therapeutics-/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2018/04/new-bladder-cancer-treatment--bca18-in-munich/2024-07-26T10:33:06+00:00weekly0.6https://www.medthority.com/news/2012/07/neupro--ucb-schwarz--re-inrroduced-in-us-for-rls-and-parkinsons-disease/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2011/12/flutiform--skye-mundipharma--european-application-referred-to-arbitration/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2012/10/eu-approves-subcutaneous-velcade--janssen--for-treatment-of-multiple-myeloma/2021-09-24T07:02:18+00:00weekly0.6https://www.medthority.com/news/2014/07/fda-approves-beleodaq-for-t-cell-lymphoma-bioalliance-pharma/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2016/06/rova-t--rovalpituzumab-tesirine--results-for-treatment-of-small-cell-lung-cancer--abbvie/2021-09-24T07:10:04+00:00weekly0.6https://www.medthority.com/news/2012/08/nupathe-re-files-transdermal-migraine-patch-at-fda/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2013/09/neutral-results-in-study-of-tekturna-for-hypertension-/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2012/09/lundbeck-otsuka-re-file-abilify-depot-with-the-fda-as-a-treatment-for-schizophrenia/2021-09-24T07:01:59+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-approves-avastin--bevacizumab--with-chemotherapy-for-platinum-sensitive-recurrent-epithelial-ovarian--fallopian-tube-or-primary-peritoneal-cancer--genentech/2021-09-24T07:10:16+00:00weekly0.6https://www.medthority.com/news/2019/11/cymabay-therapeutics-halts-clinical-development-of-seladelpar-/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2016/04/dynavax-re-files-bla-at-fda-for-heplisav-b-vaccine-against-hepatitis-b-/2021-09-24T07:10:49+00:00weekly0.6https://www.medthority.com/news/2014/03/positive-topline-results-for-appy1-test-for-appendicitis---venaxis/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2016/08/european-commission-approves-once-daily-truvada--emtricitabine-200-mg-tenofovir-disoproxil-245-mg--ftc-tdf--for-pre-exposure-prophylaxis-to-reduce-the-risk-of-sexually-acquired-hiv-1---gilead-sciences/2021-09-24T07:09:37+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-to-consider-scientific-data-of-essure-contraceptive-implant-bayer-healthcare/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trial-of-halaven--eisai--shows-qol-advantages-for-breast-cancer-patients/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2013/09/eu-approves-lemtrada-for-multiple-sclerosis/2021-09-24T07:15:59+00:00weekly0.6https://www.medthority.com/news/2018/02/phase-iii-results-of-zebinix-in-epilepsy-published-in-epilepsia---bial-and-eisai-/2021-09-24T07:06:02+00:00weekly0.6https://www.medthority.com/news/2013/05/teva-pharmaceutical-industries-will-market-adasuve-for--treatment-of-agitation-in-schizophrenia-in-the-united-states/2021-09-24T07:16:24+00:00weekly0.6https://www.medthority.com/news/2014/11/phase-iii-study-of-opdivo-in-advanced-melanoma-meets-primary-endpoint---bms/2021-09-24T07:08:41+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-biotronik-s-iperia-icd--implantable-cardioverter-defibrillator--systems-for-use-with-mri-imaging--biotronik/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2016/10/eisai-initiates-two-phase-iii-studies-of-fycompa--perampanel--for-lennox-gastaut-syndrome-/2021-09-24T07:10:28+00:00weekly0.6https://www.medthority.com/news/2012/05/omega-3-fatty-acids-cellular-processes-are-mapped-/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2015/07/study-results-with-senza-hf-spinal-cord-stimulation-system-in-pain-published-in-anesthesiology--nevro-corp/2024-02-19T15:36:07+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-duzallo-for-hyperuricaemia-in-gout---gruenenthal-/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-study-of-zilretta-in-osteoarthritis-of-the-knee-published-in-rheumatology-and-therapy---flexion-therapeutics/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2016/01/nice-recommends-docetaxel-for-treatment-of-hormone-sensitive-prostate-cancer-/2021-09-24T07:09:05+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-approves-zavicefta--ceftazidime-avibactam--for-treatment-of-serious-gram-negative-bacterial-infections-requiring-hospitalisation--astrazeneca/2021-09-24T07:09:56+00:00weekly0.6https://www.medthority.com/news/2016/03/two-phase-iii-trials-of-xeljanz--tofacitinib--in-ulcerative-colitis-meet-primary-endpoints--pfizer/2024-02-19T15:36:28+00:00weekly0.6https://www.medthority.com/news/2011/11/teva-will-not-file-laquinimod-at-the-fda-for-multiple-sclerosis-in-the-immediate-future-/2021-09-24T07:04:58+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-results-for-necitumumab-in-squamous-nsclc---eli-lilly/2021-09-24T07:08:10+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-approves-haegarda--subcutaneous-c1-esterase-inhibitor--for-subcutaneous-administration-to-prevent-hereditary-angioedema--hae--attacks-in-adolescent-and-adult-patients--csl-behring/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-trial-of-cresemba--isavuconazonium-sulfate--in-candida-fungal-infections-fails-to-meet-primary-endpoint--astellas/2024-02-20T13:49:24+00:00weekly0.6https://www.medthority.com/news/2012/09/phase-ii-success-for-bavituximab--peregrine-pharma--in-nsclc/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2018/09/otezla-studies-show-improvements-in-quality-of-life-for-psoriasis-patients-celgene/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2018/04/european-commission-approves-expanded-indication-for-xgeva-for-the-prevention-of-skeletal-related-events-in-adults-with-advanced-malignancies-involving--bone-metastases-from-solid-tumors-and-those-with-multiple-myeloma---amgen/2021-09-24T07:05:26+00:00weekly0.6https://www.medthority.com/news/2015/04/fda-accepts-filing-for-tresiba--insulin-degludec--and-ryzodeg--insulin-degludec-insulin-aspart--for-diabetes-novo-nordisk-/2021-09-24T07:03:00+00:00weekly0.6https://www.medthority.com/news/2019/01/stelara-filed-with-ema-for-ulcerative-colitis---janssen-/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2013/07/secukinumab-novartis--success-in-fixture-study-for-treatment-of-psoriasis-/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-grants-510-k--approval-for-ingenia-elition-3-0t-mr-solution---royal-philips-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2015/07/novartis-participates-in-new-mereo-biopharma-group-ltd-and-with-it-bps-804--bct-197-and-bgs-694/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2012/05/simponi--janssen-biotech--shows-positive-results-in-phase-iii-trial-for-ulcerative-colitis/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2017/05/positive-results-from-post-approval-clinical-trial-evaluating-bronchial-thermoplasty--pas2--of-alair-system-in-severe-persistent-asthma----boston-scientific-/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2014/07/new-study-shows-testosterone-therapy-in-older-men-does-not-increase-heart-attacks-/2021-09-24T07:08:53+00:00weekly0.6https://www.medthority.com/news/2017/06/biosimilar-concerns-of-rheumatology-patients-being-addressed-by-national-programme-in-denmark/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2012/08/serada--depomed--filed-at-fda-for-treatment-of-hot-flashes/2021-09-24T07:02:36+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-ii-registrational-trial-of-enhertu-to-treat-her2-positive-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-cancer---astrazeneca---daiichi-sankyo/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2014/11/harvoni--ledipasvir-sofosbuvir--shows-high-cure-rates-in-hepatitis-c-patients-who-failed-prior-treatment---gilead/2024-02-19T15:53:57+00:00weekly0.6https://www.medthority.com/news/2015/06/trial-shows-benefits-of-precision-spectra-spinal-cord-stimulator-system-in-low-back-pain-boston-scientific/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2019/06/three-year-overall-survival--os--results-from-the-phase-iii-pacific-trial-of-imfinzi-for-stage-iii-non-small-cell-lung-cancer--astrazeneca/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2015/03/chmp-recommends-approval-of-gardasil-9-for-nine-types-of-hpv--sanofi-pasteur-msd/2021-09-24T07:04:10+00:00weekly0.6https://www.medthority.com/news/2016/01/abp-501--adalimumab-biosimilar--bla-filing-accepted-at-fda-with-biosimilar-user-fee-act--bsufa--target-action-date-of-25-september-2016-amgen-/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2017/03/successful-phase-iii-ixora-s-study--finds-taltz--ixekizumab--superior-to-stelara--ustekinumab--in-treatment-of-psoriasis--eli-lilly/2021-09-24T07:14:21+00:00weekly0.6https://www.medthority.com/news/2019/07/phase-iii-ministone-2-study-reports-xofluza-reduces-flu-symptoms-in-children/2021-09-24T07:18:22+00:00weekly0.6https://www.medthority.com/news/2015/09/biogen-acquires-rights-to-mt-1303-from-mitsubushi-tanabe/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2018/04/a-liver-biopsy-based-substudy-from-the-poise-phase-iii-trial-suggests-that-long-term-obeticholic-acid--treatment-in-patients-with-primary-biliary-cholangitis-was-associated-with-reversal-or-stabilization-of-fibrosis-and-cirrhosis---intercept-pharma-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-approves-proair-digihaler-for-asthma---teva-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2013/01/preliminary-results-from-phase-iib-study-of-bi-201335-and-bi-207127--boehringer--show-positive-response-in-hepatitis-c-patients-/2021-09-24T07:15:51+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-requires-partial-hold-on-trials-for-venclexta-for-multiple-myeloma/2021-09-24T07:18:51+00:00weekly0.6https://www.medthority.com/news/2013/11/chmp-recommends-xigduo-for-type-2-diabetes-bms-astrazeneca/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2018/07/chmp-recommends-approval-of-ilumetri-in-plaque-psoriasis---almirall-/2021-09-24T07:06:56+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-sierra-trial-of-iomab-b-shows-positive-interim-results-in-acute-myeloid-leukemia---actinium-pharma/2021-09-24T07:17:16+00:00weekly0.6https://www.medthority.com/news/2018/06/nice-does-not-recommend-zytiga-plus-adt-and-prednisone-as-first-line-therapy-in-metastatic-prostate-cancer---janssen-/2024-07-26T10:32:43+00:00weekly0.6https://www.medthority.com/news/2019/07/mdna-life-sciences-with-aspire-pharma--launches-the-mitomic-prostate-test-to-identify-prostate-cancer-/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2019/03/fda-issues-complete-response-letter-to-recro-pharma-relating-to-iv-meloxicam-and-treatment-of-moderate-to-severe-pain-/2021-09-24T07:18:50+00:00weekly0.6https://www.medthority.com/news/2015/11/new-results-from-phase-iii-measure-1-trial-show-patient-response-to-cosentyx--secukinumab--in-ankylosing-spondylitis--novartis/2024-02-19T15:54:09+00:00weekly0.6https://www.medthority.com/news/2014/04/bms-filed-combination-daclatasvir---asunaprevir-for-genotype-1b-hepatitis-c/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2014/09/nice-rejects-abraxane-gemcitabine-combination-for-pancreatic-cancer--celgene/2021-09-24T07:07:48+00:00weekly0.6https://www.medthority.com/news/2017/06/phase-iii-latitude-clinical-trial--shows-zytiga--abiraterone-acetate--plus-prednisone-shows-impressive-improvement-in-survival-in-metastatic-prostate-cancer--janssen-r-d/2021-09-24T07:15:08+00:00weekly0.6https://www.medthority.com/news/2013/03/miravirsen--santaris-pharma--phase-ii-trial-for-hepatitis-c-is-reported-in-nejm/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2019/03/real-world-study-finds-tresiba-cuts-rate-of-hypoglycaemia-in-type-1---2-diabetes---novo-nordisk/2021-09-24T07:18:57+00:00weekly0.6https://www.medthority.com/news/2018/04/promise-1-phase-iii-trial-of-ald-403-show-bennfits-in-longer-treatment-for-episodic-migraine---alder-biopharma-/2021-09-24T07:05:18+00:00weekly0.6https://www.medthority.com/news/2018/10/avxs-101-filed-in-the-eu--us-and-japan-for-spinal-muscular-atrophy---avexis-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2016/09/phase-iii-data-shows-dose-adjustments-for-gilotrif--afatinib--in-non-small-cell-lung-cancer-reduces-adverse-events-but-not-efficacy--boehringer/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2014/08/medtronic-has-510--k--clearance-for-shilla-growth-guidance-system-to-treat-spinal-deformities-/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/02/mylan-acquires-womens-health-business-from-famy-care-limited/2021-09-24T07:04:01+00:00weekly0.6https://www.medthority.com/news/2018/01/mk-1439-filed-with-fda-for-hiv-infection-in-adults---merck-inc-/2021-09-24T07:05:15+00:00weekly0.6https://www.medthority.com/news/2013/02/nice-does-not-recommend-jakavi--novartis--for-myelofibrosis/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2015/11/astrazeneca-enters-agreement-with-perrigo/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2019/08/winlevi-filed-with-fda-for-acne---cassiopea/2021-09-24T07:17:46+00:00weekly0.6https://www.medthority.com/news/2016/01/osteocool-rf-ablation-system-approved-by-fda-to-treat-pain-from-spine-metastases--medtronic/2021-09-24T07:09:08+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-label-extension-of-use-of-promacta--eltrombopag--to-treat-infants--with-chronic-immune-thrombocytopenia--novartis/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-ii-study-of-vaccine-tol-3021--tolerion--demonstrates-potential-against-type-1-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2013/03/xarelto-bayer-janssen--initiates-trial-for-non-valvular-atrial-fibrillation/2021-09-24T07:15:44+00:00weekly0.6https://www.medthority.com/news/2018/03/fda-accepts-bla-for-calaspargase-pegol-a-proposed-treatment-for--all----shire-plc-/2021-09-24T07:06:37+00:00weekly0.6https://www.medthority.com/news/2013/12/mnk-155-positive-in-phase-iii-trial-for-moderate-to-severe-pain-mallinckrodt/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2012/01/biodelivery-sciences-intl-licenses-bema-buprenorphine-to-endo-pharma-for-mild-to-severe-chronic-pain/2021-09-24T07:01:36+00:00weekly0.6https://www.medthority.com/news/2019/02/pivotal-phase-iii-data-of-bavencio---inlyta-for-renal-cell-carcinoma-is-published-in-nejm---merck-kgaa---pfizer/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2019/06/eu-approves-talzenna-for-her2--breast-cancer---pfizer/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2019/02/successful-phase-iii-titian-trial-of-erleada-for-metastatic-castration-sensitive-prostate-cancer--janssen/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2016/12/phase-iii-trial-of-lx-4211--sotagliflozin--meets-primary-endpoint-in-type-1-diabetes--lexicon-pharma/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2017/05/ce-mark-granted-for-confirm-rx-insertable-cardiac-monitor--icm--to-monitor-cardiac-arrhythmias---abbott-/2021-09-24T07:14:32+00:00weekly0.6https://www.medthority.com/news/2019/05/elocta-and-alprolix-can-provide-perioperative-haemostatic-control-across-a-wide-spectrum-of-surgeries/2021-09-24T07:17:38+00:00weekly0.6https://www.medthority.com/news/2017/06/early-therapeutic-intervention-for-pre-rheumatoid-arthritis--pre-ra--patients-significantly-reduces-the-risk-of-ra/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-accepts-merck-s-bla-and-grants-priority-review-for-v-920--the--investigational-vaccine-for-ebola-zaire-virus-/2024-10-21T14:44:46+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves-sbla-for-dextenza-to-include-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery---ocular-therapeutix-/2021-09-24T07:16:53+00:00weekly0.6https://www.medthority.com/news/2017/05/supplemental-application-for-tresiba--insulin-degludec--in-hypoglycaemia-submitted-to-fda--novo-nordisk/2021-09-24T07:14:24+00:00weekly0.6https://www.medthority.com/news/2015/06/ce-mark-for-acrysof-iq-panoptix-trifocal-intraocular-lens-for-cataract-surgery---alcon-novartis/2021-09-24T07:03:33+00:00weekly0.6https://www.medthority.com/news/2019/05/positive-data-from-kalm-1-pivotal-phase-iii-trial-of-korsuva-in-hemodialysis-patients-with-moderate-to-severe-chronic-kidney-disease-associated-pruritus---cara-therapeutics/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-gives-emergency-approval-of-aptima-zika-virus-assay-for-zika-virus-diagnosis--hologic/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2012/11/phase-iii-trial-succes-for-perindopril-amlodipine-combination---xoma--for-hypertension/2021-09-24T07:01:29+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-absolute-pro-stent-system--abbott--for-pad/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2018/12/phase-iii-ampower-study-of-amphora-meets-primary-endpoint-in-contraception---evofem-biosciences-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-rejects-filing-for-neocart-for-osteoarthritis-of-the-knee-and-therapy-now-being-re-assessed---histogenics-/2021-09-24T07:06:04+00:00weekly0.6https://www.medthority.com/news/2018/09/copd-patients-suffer-fewer-respiratory-related-problems-when-treated-with-targeted-lung-denervation-/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2018/09/single-tablet-tivicay---epivir-for-hiv-filed-with-ema---viiv-healthcare-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2012/03/signifor-novartis--success-in-phase-iii-cushings-disease-trial/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2015/08/eu-approves-use-of-perjeta--pertuzumab--plus-herceptin-prior-to-surgery-in-early-stage-breast-cancer--roche/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-updates-label-of-trulicity--dulaglutide--for-use-in-type-2-diabetes--eli-lilly/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-federica-study-of-perjeta---herceptin-meets-secondary-endpoint-in-breast-cancer---genentech-roche---halozyme-therapeutics/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2019/11/boehringer-ingelheim-and-lilly-initiate-first-ever-study-to-assess-jardiance-in-people-hospitalized-for-acute-heart-failure-who-have-been-stabilized-/2021-09-24T07:17:58+00:00weekly0.6https://www.medthority.com/news/2016/09/successful-phase-iii-oak-trial-for-tecentriq--atezolizumab----docetaxel--for-metastatic-nsclc-patients-whose-disease-progressed-after-treatment-with-platinum-based-chemotherapy--genentech---roche/2024-07-26T10:32:29+00:00weekly0.6https://www.medthority.com/news/2015/12/astrazeneca-statement-on-results-of-atlantic-study-of-durvalumab-in-metastatic-nsclc/2024-02-19T15:54:45+00:00weekly0.6https://www.medthority.com/news/2017/03/phase-iii-study-evaluating-repatha--evolocumab--in-patients-with-excess-ldl-c-meets-primary-endpoint--amgen/2021-09-24T07:14:20+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-studies-of-nx-1207--fexapotide-triflutate--meet-endpoint-for-benign-prostatic-hyperplasia--nymox-pharma-/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-studies-of-fmx-103-show-improvement-in-rosacea---foamix-pharma-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2017/01/phase-iii--ab06006--study-of-masitinib-in-severe-indolent-systemic-mastocytosis-is-published-in-the-lancet--ab-science-sa/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-extension-of-approval-of-adcetris-in-cd30--stage-iv-hodgkin-lymphoma---takeda-/2021-09-24T07:06:07+00:00weekly0.6https://www.medthority.com/news/2015/02/iqwig-finds-benefits-of-latuda-in-schizophrenia-unproven-takeda/2021-09-24T07:03:59+00:00weekly0.6https://www.medthority.com/news/2017/05/eu-chmp-recommends-approval-of-oxervate-cenegermin-in-moderate-to-severe-neurotrophic-keratitis-dompe/2024-10-21T14:43:19+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-ii-iii-ascend-study-of-gz-402665-meets-first-endpoint-in-niemann-pick-disease---sanofi/2021-09-24T07:11:43+00:00weekly0.6https://www.medthority.com/news/2018/04/multiple-studies-of-vibativ-in-real-world-settings-for-infections-in-obese-or-elderly-patients---theravance-biopharma/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-advisory-committee-negative-for-oliceridine-to-treat-moderate-to-severe-acute-pain---trevena-inc-/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2012/03/glaucoma-drug-bol-303259-x--bausch---lomb--meets-endpoints-in-phase-iib-study/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2015/12/phase-iii-ratify-trial-of-pkc-412--midostaurin--success-for-flt3-mutated-acute-myeloid-leukemia--aml---novartis/2024-02-19T15:55:08+00:00weekly0.6https://www.medthority.com/news/2016/06/daiichi-sankyo-to-market-investigational-drug-therapy--onzeald--etirinotecan-pegol--nktr-102--in-europe--turkey-and-switzerland---nektar-therapeutics-/2021-09-24T07:10:06+00:00weekly0.6https://www.medthority.com/news/2013/06/vanda-pharma-files-vec-162-at-fda-for-treatment-of-non-24-hour-disorder/2021-09-24T07:16:08+00:00weekly0.6https://www.medthority.com/news/2013/11/pradaxa-antidote-reverses-anticoagulation-boehringer/2021-09-24T07:16:30+00:00weekly0.6https://www.medthority.com/news/2015/08/amgen-files-nda-at-fda-for-etelcalcetide--to-treat-secondary-hyperparathyroidism-in-patients-with-ckd/2021-09-24T07:03:03+00:00weekly0.6https://www.medthority.com/news/2014/08/fda-approves-belsomra-for-insomnia-merck-inc-/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/09/sun-pharma-to-acquire-insite-vision-and-its-ophthalmic-products/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2012/08/positive-results-from-study-of-pressurewire--st-jude-medical--in-pci-patients/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iii-titan-study-of-erleada-shows-improved-pfs-and-os-in-prostate-cancer---janssen-pharma/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2014/02/ramucirumab-success-in-phase-iii-revel-trial-for-nsclc---eli-lilly/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2016/09/gilead-sciences-terminates-phase-ii-iii-trial-of-gs-5745-as-a-treatment-for-ulcerative-colitis-/2021-09-24T07:09:15+00:00weekly0.6https://www.medthority.com/news/2017/09/complete-response-letter-for-itca-650--exenatide-implant--for-the-treatment-of-type-2-diabetes---intarcia-therapeutics-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2014/04/sobi-will-market-chrondocelect-in-eu--russia--middle-east-and-other-markets-for-cartilage-repair/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trials-of-ly-2189265--eli-lilly--show-safety-and-efficacy-benefits-in-type-2-diabetes/2021-09-24T07:16:03+00:00weekly0.6https://www.medthority.com/news/2016/06/shire-completes-decentralized-procedure--in-eu-to-support-approval-for-cuvitru--ig-20mg-ml-solution-for-subcutaneous-injection-to-treat-immunodeficiency/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2013/02/fda-approves-osphena--shionogi--for-dyspareunia-/2021-09-24T07:15:31+00:00weekly0.6https://www.medthority.com/news/2015/09/dextenza--sustained-release-dexamethasone--filed-with-fda-for-post-surgery-pain--ocular-therapeutix/2021-09-24T07:03:40+00:00weekly0.6https://www.medthority.com/news/2018/09/bora-trial-shows-long-term-safety-and-efficacy-of-fasenra-in-patients-with-eosinophilic-asthma--astrazeneca/2021-09-24T07:06:43+00:00weekly0.6https://www.medthority.com/news/2015/09/study-of-linx-reflux-management-system-demonstrates-benefits-in-gerd--torax-medical/2024-02-19T15:58:08+00:00weekly0.6https://www.medthority.com/news/2018/06/positive-results-from--monaleesa-3-trial-of-kisqali-plus-fulvestrant-in-advanced-or-metastatic-breast-cancer---novartis-/2024-02-19T15:58:55+00:00weekly0.6https://www.medthority.com/news/2015/04/eu-approves-use-of-humira--adalimumab-in-children-with-plaque-psoriasis-abbvie/2021-09-24T07:03:01+00:00weekly0.6https://www.medthority.com/news/2019/06/catalyst-pharmaceuticals-files-federal-lawsuit-against-fda-in-relation-to-approval-of-ruzurgi-/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2012/07/success-in-phase-iii-single-trial-of-dolutegravir/2021-09-24T07:01:48+00:00weekly0.6https://www.medthority.com/news/2012/05/ophena-is-filed-by-shionogi-inc-at-fda-for-vaginal-atrophy-/2021-09-24T07:02:47+00:00weekly0.6https://www.medthority.com/news/2012/01/fda-approves-kalydeco--vertex-pharma--for-cystic-fibrosis/2021-09-24T07:01:33+00:00weekly0.6https://www.medthority.com/news/2014/09/ono-7643-offers-improvements-in-phase-iii-cachexia-trials---helsinn/2021-09-24T07:07:39+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-advisory-committee-does-not-approve-nda-for-rociletinib-to-treat-nsclc-with-t790m-mutation--clovis-oncology-/2024-02-19T15:59:24+00:00weekly0.6https://www.medthority.com/news/2015/12/belviq--lorcaserin--filed-with-fda-for-an-extended-release-formulation-in-obesity--eisai-arena-pharma/2021-09-24T07:04:34+00:00weekly0.6https://www.medthority.com/news/2017/01/eradicate-hp-phase-iii-study-with-rhb-105-for-the-treatment-of-h--pylori-infection-meets-primary-endpoint--redhill-biopharma/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-committee-votes-in-support-of--saxenda-for-obesity-novo-nordisk/2021-09-24T07:07:47+00:00weekly0.6https://www.medthority.com/news/2012/08/pomaglumetad-methionil--eli-lilly--fails-phase-ii-studies-in-schizophrenia/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2017/08/gilead-sciences-to-acquire-kite-pharma/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2017/12/nice-rejects-scenesse-as-a-proposed-treatment-for--erythropoietic-protoporphyria----clinuvel-pharma-/2021-09-24T07:13:35+00:00weekly0.6https://www.medthority.com/news/2019/04/novartis-files-bla-at-fda-for-brolucizumab--to-treat-wet-age-related-macular-degeneration--/2021-09-24T07:16:45+00:00weekly0.6https://www.medthority.com/news/2019/01/genentech-roche-cancels-creed-1-and-d-creed-2-phase-iii-trials-of-crenezumab-for-alzheimer-s-disease/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2012/07/stryker-withdraws-rejuvenate-modular--and-abg-ii-neck-stem-hip-replacements/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2019/08/ventana-pd-l1--sp142--assay-given-ce-mark-approval-in-the-eu-as-diagnostic-for-triple-negative-breast-cancer---roche/2021-09-24T07:17:43+00:00weekly0.6https://www.medthority.com/news/2016/02/chmp-recommends-descovy--emtricitabine-and-tenofovir-alafenamide--to-treat-hiv-1-infection---gilead-sciences/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-approves-cardiomems-hf-system-to-monitor-heart-failure-patients---cardiomems-inc-/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-signifor-to-treat-acromegaly---novartis/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2012/03/cem-101--cempra--effective-in--phase-ii-study-against--n--gonorrhoeae/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2012/01/picato--leo-pharma--is-fda-approved-for-actinic-keratosis/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2015/07/phase-iii-results-significant-for-crisaborole-in-atopic-dermatitis--anacor-pharma-/2021-09-24T07:04:39+00:00weekly0.6https://www.medthority.com/news/2015/04/sorin-s-p-a-merges-with-cyberonics-inc-/2021-09-24T07:02:58+00:00weekly0.6https://www.medthority.com/news/2017/01/eu-approval-for-suliqua--insulin-glargine---lixisenatide-combination--to-treat-type-2-diabetes---sanofi/2021-09-24T07:13:06+00:00weekly0.6https://www.medthority.com/news/2016/03/merck-kgaa-initiates-phase-iii-trial-of-humira--adalimumab--biosimilar-msb-11022-to-treat-psoriasis/2024-02-19T15:59:35+00:00weekly0.6https://www.medthority.com/news/2014/12/phase-iii-data-shows-benefit-of-decapeptyl-in-breast-cancer-ipsen/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2013/12/phase-ii-data-on-gs-9973-in-b-cell-lymphoma-gilead/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2015/06/eu-approves-lixiana--edoxaban--for-stroke-prevention-in-patients-with-nvaf--and-for-dvt-and-pe--daiichi-sankyo/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-maestro-rechargeable-system-to-treat-obesity--enteromedics/2021-09-24T07:03:27+00:00weekly0.6https://www.medthority.com/news/2012/06/study-shows-positive-results-with-dabrafenib--glaxo-smith-kline--in-melanoma-patients/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2018/04/opdivo---yervoy-success-in-phase-iii-checkmate-227-study-for-nsclc-patients-with-high-tumor-mutational-burden---bms-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-approves--emgality-to-treat-episodic-cluster-headache----eli-lilly/2021-09-24T07:17:03+00:00weekly0.6https://www.medthority.com/news/2018/08/top-line-data-from-phase-iii-trial-of-mc2-01-cream-to-treat-psoriasis---mc2-therapeutics-a-s-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2011/09/decalth-php-brings-benefits-to-patients-with-liver-cancer-/2021-09-24T07:04:50+00:00weekly0.6https://www.medthority.com/news/2014/06/successful-zykadia-trial-for-alk--nsclc-patients---novartis/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2016/10/successful-phase-iii-trial--ca184-029--eortc-18071---five-year-analysis-of-yervoy--ipilimumab--for-stage-iii-melanoma---bms/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2012/10/bardoxolone--reata-abbott--phase-iii-trial-terminated-for-chronic-kidney-disease----------------/2021-09-24T07:02:16+00:00weekly0.6https://www.medthority.com/news/2018/06/phase-iii-select-early-trial-of-abt-494-meets-endpoint-in-rheumatoid-arthritis---abbvie-/2024-07-26T10:27:09+00:00weekly0.6https://www.medthority.com/news/2016/03/amgen-successful-in-patent-litigation-against-regeneron-and-sanofi-relating-to-praluent--alirocumab--/2021-09-24T07:10:20+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-gives-510-k--approval-for-elecsys-brahms-pct--procalcitonin--assay-in-sepsis-detection--roche/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-grants-priority-review-to-humax-cd38--daratumumab--in-multiple-myeloma--janssen-biotech/2021-09-24T07:03:51+00:00weekly0.6https://www.medthority.com/news/2016/10/fda--accepts-nda-and-ema-validates-maa-for-nusinersen-to-treat-spinal-muscular-atrophy----biogen/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2015/03/fda-accepts-re-submission-of-daclatasvir---sofosbuvir-combination-for-treatment-of-hepatitis-c-genotype-3--bms/2021-09-24T07:04:13+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-issues-emergency-authorisation-for-ncov-real-time-rt-pcr-diagnostic-panel-a-diagnostic-test-for--coronavirus-/2021-09-24T07:12:03+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-fiasp--insulin-aspart-injection--for-type-1-and-type-2-diabetes---novo-nordisk-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2015/07/vesneo--latanoprostene-bunod--filed-with-fda-for-glaucoma-or-ocular-hypertension--bausch---lomb/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2018/06/success-for-phase-ii-vision-trial-of-tepotinib-to-treat-nsclc-harboring-met-exon-14-skipping-mutations---merck-kgaa-/2021-09-24T07:05:34+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-data-shows-efficacy-and-safety-of-sd-809--deutetrabenazine--in-huntington-disease--teva-pharmaceutical/2024-02-19T15:59:47+00:00weekly0.6https://www.medthority.com/news/2020/02/final-overall-survival-data-for-phase-iii-prosper-trial-of-xtandi-shows-significant-improvement-in-prostate-cancer---astellas-pharma---pfizer/2021-09-24T07:12:04+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-portrazza--necitumumab--to-treat-metastatic-squamous-nsclc--eli-lilly/2024-02-19T16:00:52+00:00weekly0.6https://www.medthority.com/news/2018/04/real-world-study-of-invokana-shows-improved-glucose-control-in-type-2-diabetes--with-data-published-in-current-medical-research-and-opinion---janssen-pharma-/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2014/05/eu-commission-approves-entyvio-for-both-ulcerative-colitis-and-crohn-s-disease---takeda-pharmaceuticals/2021-09-24T07:08:06+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-results-presented-from-camp-1-and-camp-2-phase-iii-trials-of-vp-102--in-patients-with-molluscum-contagiosum----verrica-pharma/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2016/11/chiesi-farmaceutici-spa-acquires-atopix-therapeutics-for-some-euros-75-million-and-with-it-oc-459-in-phase-ii-development-to-treat-eosinophilic-asthma/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2018/03/biohaven-pharma-initiates-phase-iii-trial-for-zydis-to-treat-migraine-/2021-09-24T07:06:34+00:00weekly0.6https://www.medthority.com/news/2015/10/mulpleta--lusutrombopag--is-approved-in-japan-to-treat-thrombocytopenia-associated-with-chronic-liver-disease--shionogi/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2016/03/post-hoc-analysis-shows-efficacy-of-spiriva-respimat--tiotropium-bromide--in-asthma--boehringer/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2019/07/ean2019--new-research-links-statins-with-reduced-mortality-in-dementia-patients/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2019/05/phase-iii-quartz-study-of-inhaled-qmf-149-meets-endpoints-in-asthma---novartis/2021-09-24T07:17:32+00:00weekly0.6https://www.medthority.com/news/2014/09/final-phase-iii-data-shows-significant-improvements-with-zytiga-in-mcrpc---janssen/2021-09-24T07:07:38+00:00weekly0.6https://www.medthority.com/news/2016/05/phase-iii-data-on-vivlodex--meloxicam--shows-patients-on-this-therapy-use-less-medication-for-pain--osteoarthritis--iroko-pharma/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2013/08/albiglutide--fda-review-date-now-april-2014/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2017/02/fda-approves-airduo-respiclick--fluticasone-propionate-and-salmeterol-inhalation-powder--and-armonair-respiclick--fluticasone-propionate-inhalation-powder--to-treat-asthma--teva/2021-09-24T07:13:19+00:00weekly0.6https://www.medthority.com/news/2016/11/eu-chmp-recommends-approval-of-fiasp--rapid-acting-insulin-aspart--for-diabetes-in-adults--novo-nordisk/2021-09-24T07:09:51+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-advisory-committee-recommends-watchman-laa-device-to-prevent-clots-that-cause-stroke-boston-scientific/2021-09-24T07:15:19+00:00weekly0.6https://www.medthority.com/news/2019/12/seattle-genetics---takeda-announce-additional-analyses-of-results-of-adcetris-in--echelon-2-phase-iii-trial--for-peripheral-t-cell-lymphomas-/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2017/07/two-phase-iii-trials-of-mk-1439--doravirine--combination-meet-primary-endpoint-in-hiv-1--infection--merck-inc/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2017/01/u-s-district-court-grants-injunction-to-amgen-to-prevent-sanofi---regeneron-marketing-praluent-alirocumab--in-the-us-due-to-patent-infringement-/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2014/02/iqwig-finds-major-benefits-of-xtandi-for-prostate-cancer---astellas/2021-09-24T07:08:16+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-accepts-two-applications-for--dificid--to-treat-children-aged-six-months-up-to-18-years-with-clostridium-difficile-infections---merck-inc-/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2016/10/nice-recommends-forxiga--dapagliflozin--with-metformin-and-a-sulfonylurea-as-triple-therapy-fro-type-2-daibetes--astarzeneca-/2021-09-24T07:10:34+00:00weekly0.6https://www.medthority.com/news/2013/02/gsk-files--at-ema-trametinib---monotherapy--and-in-combination-with-dabrafenib-for-metastatic-melanoma/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2012/12/fda-approves-gattex--nps-pharma--for-adult-patients-with-short-bowel-syndrome-/2021-09-24T07:02:37+00:00weekly0.6https://www.medthority.com/news/2013/08/omeros-files-oms-302-at-fda-for-intraocular-lens-replacement-/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2018/09/coapt-study-of-mitra-clip-system-meets-endpoints-in-mitral-regurgitation---abbott-/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2012/12/stelara--j-j-janssen-cilag-janssen-biotech--filed-with-fda-and-ema-to-treat-adults-with-active-psoriatic-arthritis--/2021-09-24T07:02:41+00:00weekly0.6https://www.medthority.com/news/2019/01/trial-of-rezum-water-vapor-therapy-for-benign-prostatic-hyperplasia-is-published-in-urology---boston-scientific/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2016/11/acorda-therapeutics--inc--announced-that-the-milestone-clinical-study-did-not-show-sufficient-efficacy-to-support-further-development-of-dalfampridine-to-improve-post-stroke-walking-difficulties-/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-sbla-for-nplate-in-immune-thrombocytopenia---amgen/2021-09-24T07:17:20+00:00weekly0.6https://www.medthority.com/news/2017/05/prolaris-test-accurately-predicts-the-10-year-risk-of-metastases-in-men-treated-for-prostate-cancer---myriad-genetics-inc-/2021-09-24T07:14:30+00:00weekly0.6https://www.medthority.com/news/2015/09/eravacycline-fails-to-meet-endpoint-in-ignite-2-study-for-complicated-urinary-tract-infections--tetraphase/2021-09-24T07:03:49+00:00weekly0.6https://www.medthority.com/news/2014/07/results-from-cosmos-study-of-olysio---sovaldi-for-hcv-published-in-the-lancet-medivir/2021-09-24T07:08:46+00:00weekly0.6https://www.medthority.com/news/2012/03/patient-enrollment-complete-for-phase-iii-dry-eye-study-of-sar-1118--sarcode-/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2019/07/ce-mark-for-av-guardian-vascular-access-system/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2013/09/nice-requests-more-information-on-aubagio/2021-09-24T07:15:58+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-accepts-bla-for-zolgensma--a-gene-replacement-therapy-to-treat-spinal-muscular-atrophy--sma--type-1--novartis-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2017/06/european-commission-approves-opdivo--nivolumab--for-the-treatment-of-locally-advanced-unresectable-or-metastatic-urothelial-carcinoma----bms/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approval-for-tafinlar--dabrafenib----mekinist--trametinib--for-treatment-of-braf-v600-mutation-metastatic-melanoma--novartis/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-halts-trials-of-ib-1001--inspiration-pharmaceuticals--for-haemophilia-b/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2018/12/nice-now-allows-yescarta-in-specific-cases-for-large-b-cell-lymphoma---gilead-kite-/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2015/07/ema-validates-application-for-opdivo--nivolumab--to-treat-non-squamous-nsclc---bms/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2015/06/chmp-recommends-farydak--panobinostat--to-treat-multiple-myeloma---novartis/2024-02-19T16:01:04+00:00weekly0.6https://www.medthority.com/news/2019/03/positive-phase-iii-alleviate-trial-results-for-reproxalap-topical-ophthalmic-solution---aldeyra-therapeutics-/2021-09-24T07:18:49+00:00weekly0.6https://www.medthority.com/news/2015/08/aspire-bariatrics-files-pma-application-at-fda-for-aspireassist-as-alternative-to-weight-loss-surgery/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2013/02/-further-results-from-tivo-1-study-of-tivozanib--aveo-oncology--astellas--for-renal-cell-carcinoma-treatment-/2021-09-24T07:15:35+00:00weekly0.6https://www.medthority.com/news/2018/12/chmp-recommends-approval-of-lusutrombopag-shionogi-for-thrombocytopenia---shionogi-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2016/10/data-from-the-phase-iii-sunrise-trial-of-bavituximab-shows-overall-survival-benefit-in-non-small-cell-lug-cancer--peregrine-pharmaceuticals-/2021-09-24T07:10:33+00:00weekly0.6https://www.medthority.com/news/2018/04/european-commission--approves-mylotarg-to-treat-acute-myeloid-leukemia--pfizer-/2021-09-24T07:05:20+00:00weekly0.6https://www.medthority.com/news/2011/12/fda-approves--s-cervista--hta-system--hologic--for-cervical-cancer-screening/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2014/05/darapladib-mesylate-fails-to-meet-endpoint-in-acs-phase-iii-trial-gsk-/2021-09-24T07:08:11+00:00weekly0.6https://www.medthority.com/news/2019/03/phase-iii-flair-and-atlas-trials-of-edurant---gsk-1265744-meet-primary-endpoints-in-hiv---viiv-healthcare/2021-09-24T07:18:58+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-chmp-recommends-change-to-indication-for-xalkori--crizotinib--in-nsclc--pfizer/2021-09-24T07:03:11+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-approval-of-extension-to-indication-for-xeljanz-in-ulcerative-colitis---pfizer-/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2019/11/european-commission-approves-keytruda-for-the-first-line-treatment-of-metastatic-or-unresectable-recurrent-head-and-neck-squamous-cell-carcinoma---merck-inc-/2021-09-24T07:17:54+00:00weekly0.6https://www.medthority.com/news/2016/06/magmaris-bioresorbable-scaffold-receives-ce-mark--biotronik/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2019/06/declare-timi-58-phase-iii-trial-of--farxiga-forxiga-cut-the-progression-of-kidney-disease-in-type-2-diabetes-patients---astrazeneca/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2018/02/crash-diets-can-cause-transient-deterioration-in-heart-function/2024-02-19T16:01:29+00:00weekly0.6https://www.medthority.com/news/2012/04/kiva-vcf-treatment-system--benvenue-medical-zimmer--enters-kast-trial-/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2018/08/veniti-inc-is-acquired-by-boston-scientific-and-with-it-the-vici-venous-stent-system/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/10/the-fda-has-set-a-pdufa-goal-date-of-24-march-2019-for--intravenous--iv--meloxicam-to-manage--moderate-to-severe-pain---recro-pharma/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2013/08/fda-filing-of-aclidinium-bromide-formoterol-fumarate-delayed-/2021-09-24T07:15:11+00:00weekly0.6https://www.medthority.com/news/2016/12/viiv-healthcare-initiates-phase-iii-hptn-083-study-of-cabotegravir-versus-truvada-for-pre-exposure-prophylaxis--prep-to-prevent-hiv-infection-/2021-09-24T07:10:09+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-committee-votes-against-approving-linhaliq-for-bronchiectasis---aradigm-corp-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2019/01/pfizer-and-eli-lilly-report-results-of-phase-iii-study-of-tanezumab-for-moderate-to-severe-osteoarthritis--oa--pain-/2021-09-24T07:18:40+00:00weekly0.6https://www.medthority.com/news/2019/01/jewel-study-of-lurasidone-for-the-treatment-of-patients-with-schizophrenia-met-its-primary-endpoint---sumitomo-dainippon/2021-09-24T07:18:43+00:00weekly0.6https://www.medthority.com/news/2017/08/fda-accepts-nda-for-acalabrutinib-to-treat-relapsed-refractory-mantle-cell-lymphoma----astrazeneca/2021-09-24T07:14:57+00:00weekly0.6https://www.medthority.com/news/2018/03/re-act--congress---7-10-march-2018--bologna-/2022-02-08T07:44:53+00:00weekly0.6https://www.medthority.com/news/2014/11/fda-approve-license-addition-for-fluzone-high-dose-for-influenza-sanofi/2021-09-24T07:08:44+00:00weekly0.6https://www.medthority.com/news/2014/09/fda-review-panel-reports-on-low-testosterone-therapies-/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2018/09/new-data-from-phase-iii-trials-of-abbv-066-in-plaque-psoriasis---abbvie-/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2011/11/jakafi--incyte-novartis--is-fda-approved-for-myelofibrosis/2021-09-24T07:04:55+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-expands-approval-for-dysport--abobotulinumtoxina--for-spasticity-in-adults--ipsen-biopharmaceuticals/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-generic-bonviva--roche-/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2012/02/cimzia--ucb--phase-iii-success-in-psoriatic-arthritis/2021-09-24T07:02:52+00:00weekly0.6https://www.medthority.com/news/2016/01/nice-updates-guidance-on-7-dmards-for-rheumatoid-arthritis-/2021-09-24T07:09:06+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iib-trial-of-giotrif--afatinib--in-non-small-cell-lung-cancer-meets-endpoints--boehringer/2024-02-19T16:01:42+00:00weekly0.6https://www.medthority.com/news/2019/12/mgah-22-filed-with-fda-for-her2-positive-breast-cancer---macrogenics/2021-09-24T07:18:26+00:00weekly0.6https://www.medthority.com/news/2017/10/11th-men-s-health-world-congress--mhwc-2017-/2024-02-22T11:52:42+00:00weekly0.6https://www.medthority.com/news/2011/10/adventrx--pharma-discontinues-exelbine-for-non-small-cell-lung-cancer/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2015/09/empliciti-given-priority-review-at-fda-for-treatment-of-multiple-myeloma--bms/2024-02-19T16:01:58+00:00weekly0.6https://www.medthority.com/news/2020/01/phase-iii-mmpower-3-trial-of-ocuvia-fails-to-meet-endpoint-in-primary-mitochondrial-myopathy---stealth-biotherapeutics/2021-09-24T07:11:45+00:00weekly0.6https://www.medthority.com/news/2015/03/phase-iii-trial-of-kyprolis-in-multiple-myeloma-meets-primary-endpoint-amgen-onyx-pharma/2024-02-19T16:02:10+00:00weekly0.6https://www.medthority.com/news/2018/01/pf-05280586-biosimilar-versus-mabthera-rituxan-meets-endpoint-in--reflections-study----pfizer-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2015/04/astra-zeneca-reports-results-of-azd-9291-in-aura-trial-for-egfrm-nsclc-t790-mutation-/2021-09-24T07:02:57+00:00weekly0.6https://www.medthority.com/news/2019/01/fda-approves-ontruzant-biosimilar--for-all-indications-of-herceptin---samsung-bioepis---merck-inc-/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2011/11/phase-iii-trial-of-humira--abbott--shows-significant-benefits-for-axial-spondyloarthritis-treatment/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2018/02/eu-approves-herzuma-for-her2-early-breast-cancer-and-metastatic-breast-cancer---celltrion-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2018/09/fda-approves-denv-detect-ns1-elisa-kit-tp-detect-dengue-virus--inbios/2021-09-24T07:06:44+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-accepts-nda-for-givosiran-for-the-treatment-of-acute-hepatic-porphyria/2021-09-24T07:17:50+00:00weekly0.6https://www.medthority.com/news/2018/08/horizon-performance-tms--transcranial-magnetic-stimulation--therapy-system-receives-510-k--approval-from-the-fda-and-ce-mark--for-use-to-treat-depression---magstim/2021-09-24T07:06:18+00:00weekly0.6https://www.medthority.com/news/2018/04/roche-genentech-halts-recruiting-patients-in-phase-ii-modul-trial-for-tecentriq---cotellic-for-metastatic-colorectal-cancer-after-four-patient-deaths-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2011/12/cobas-egfr-mutation-test--roche--receives-ce-mark-for-nsclc-testing/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2012/10/nice-recommends-tobi---podhaler--novartis--for-treatment-of-cystic-fibrosis---------------/2021-09-24T07:02:02+00:00weekly0.6https://www.medthority.com/news/2013/11/fda-approves-varithena-for-varicose-vein-treatment-btg-plc/2021-09-24T07:16:27+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-globe-study-of-vb-111---avastin-fails-to-meet-endpoint-in-glioblastoma---vbl-therapeutics-/2021-09-24T07:06:33+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---air-pollution-can-cause-kidney-disease/2021-09-24T07:18:09+00:00weekly0.6https://www.medthority.com/news/2012/08/tofacitinib--pfizer--success-in-phase-ii-study-for-ulcerative-colitis/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2018/04/skin-cancer-awareness-month-2018/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2016/08/oasis-phase-iiib-study-with-jetrea--ocriplasmin--in-patients-with-symptomatic-vitreomacular-adhesion-published-in-opthalmology---thrombogenics/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2019/07/array-biopharma-announces-interim-results-of-braftovi---mektovi---cetuximab-for-treatment-of-brafv600e-mutant-metastatic-colorectal-cancer-at-the-esmo-congress-/2021-09-24T07:18:19+00:00weekly0.6https://www.medthority.com/news/2016/01/eu-chmp-recommends-approval-of-empliciti--elotuzumab--plus-lenalidomide-and-dexamethasone-for--multiple-myeloma--bms/2024-02-19T16:02:34+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-expands-approval-for-kalbitor-in-hereditory-angioedema---dyax/2021-09-24T07:07:26+00:00weekly0.6https://www.medthority.com/news/2016/04/study-showed-that-egalet-002--an-abuse-deterrent--extended-release-oxycodone-product-with-guardian--technology--required-more-effort-to-manipulate-than-oxycontin--oxycodone-hydrochloride---egalet-corporation-/2021-09-24T07:10:48+00:00weekly0.6https://www.medthority.com/news/2012/11/fda-approves-acessa-system--halt-medical--for-treating-uterine-fibroids/2021-09-24T07:01:32+00:00weekly0.6https://www.medthority.com/news/2017/07/amgen-submits-to-fda-and-ema--supplemental-applications-to-include-overall-survival-data-from-the-phase-iii-head-to-head-endeavor-trial-versus-velcade--bortezomib--in-relapsed-or-refractory-multiple-myeloma-patients-/2021-09-24T07:14:07+00:00weekly0.6https://www.medthority.com/news/2017/04/nice-does-not-recommend-opdivo---nivolumab--as-a-cost-effective-treatment-for-head-and-neck-cancer---bms/2021-09-24T07:14:14+00:00weekly0.6https://www.medthority.com/news/2013/06/chmp-recommends-tafinlar--gsk--for-treatment-of-braf-v600-metastatic-melanoma/2021-09-24T07:16:02+00:00weekly0.6https://www.medthority.com/news/2012/01/positive-results-for-4cmenb--novartis--vaccine-against-group-b-meningococcal-disease/2021-09-24T07:01:35+00:00weekly0.6https://www.medthority.com/news/2015/09/phase-ii-results-for-combination-odalasvir---sofosbuvir-for-hepatitis-c-achieves-100--svr12--janssen-pharma---achillion/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2013/07/neurosigma-starts-trial-for-monarch-etns-system-for-epilepsy/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2016/11/ce-mark-granted-for-er-reboa-emergency-occlusion-balloon-catheter-in-support-of-hemorrhage-control--prytime-medical-devices-/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-advisory-committee-supports-snda-for-brintellix--vortioxetine--in-major-depressive-disorder--takeda-lundbeck/2021-09-24T07:09:02+00:00weekly0.6https://www.medthority.com/news/2015/09/eu-approves-kanuma--sebelipase-alfa--an-enzyme-replacement-therapy-for-patients-with-lysosomal-acid-lipase-deficiency--alexion-pharmaceuticals/2021-09-24T07:03:53+00:00weekly0.6https://www.medthority.com/news/2015/06/complement-2-study-showed-that-treatment-with-arzerra--ofatumumab--plus-fludarabine-and-cyclophosphamide-significantly-improved-median-progression-free-survival-in-cll-patients--novartis/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2017/07/pacira-pharmaceuticals--inc--announces-publication-of-its-phase-iv-pillar-study-of-exparel--bupivacaine-liposome-injectable-suspension--in-total-knee-arthroplasty-/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2014/12/wirion-filter-system-for-stroke-prevention-filed-with-fda-allium-medical/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2018/01/cervical-cancer-prevention-week-2018-/2024-02-19T16:03:21+00:00weekly0.6https://www.medthority.com/news/2018/05/am-111-reviewed-in-hearing-research-as-an-investigational-treatment-for-acute-inner-ear-hearing-loss--auris-medical-holding-ag--journal/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2019/10/trelegy-ellipta-filed-with-fda-for-asthma-in-adults---gsk---innoviva/2021-09-24T07:17:29+00:00weekly0.6https://www.medthority.com/news/2015/02/fda-expands-indication-for-revlimid-in-multiple-myeloma-celgene/2021-09-24T07:03:57+00:00weekly0.6https://www.medthority.com/news/2019/04/eu-approves-vizimpro-for-egfr-non-small-cell-lung-cancer---pfizer/2021-09-24T07:16:49+00:00weekly0.6https://www.medthority.com/news/2016/08/chs-1701--pegfilgrastim-neulasta-biosimilar--filed-with-fda-for-neutropenia---coherus-biosciences/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2012/07/janssen-cilag-withdraws-application-at-ema-for-velcade-in-follicular-lymphoma/2021-09-24T07:01:49+00:00weekly0.6https://www.medthority.com/news/2015/07/teva-buys-allergan-generics-business/2021-09-24T07:04:35+00:00weekly0.6https://www.medthority.com/news/2018/09/positive-phase-iii-results-for-roxadustat-in-ckd-patients-with-anemia-and-not-on-dialysis--astellas/2021-09-24T07:06:42+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-approves-bridion--sugammadex--to-reverse-rocuronium-bromide-and-vecuronium-bromide-neuromuscular-blockade--merck/2021-09-24T07:04:28+00:00weekly0.6https://www.medthority.com/news/2018/05/re-kinect-and-kinect-4-studies-of-ingrezza-in-tardive-dyskinesia-show-sustained-improvements---neurocrine-biosciences-/2021-09-24T07:07:11+00:00weekly0.6https://www.medthority.com/news/2018/06/ema-warning-relating-to-use-of-keytruda-and-tecentriq-in-bladder-cancer--merck-inc--and-roche--/2021-09-24T07:05:36+00:00weekly0.6https://www.medthority.com/news/2015/09/new-data-from-phase-iii-trial-of-giotrif-gilotrif--afatinib--in-squamous-cell-carcinoma-of-the-lung--boehringer-ingelheim/2021-09-24T07:03:42+00:00weekly0.6https://www.medthority.com/news/2015/11/nice-recommends-brintellix--vortioxetine--as-a-third-line-treatment-for-major-depressive-episodes--takeda-lundbeck/2021-09-24T07:04:18+00:00weekly0.6https://www.medthority.com/news/2012/07/laquinomod--active-biotech-teva--is-filed-at-ema-for-multiple-sclerosis/2021-09-24T07:01:47+00:00weekly0.6https://www.medthority.com/news/2018/07/verkazia--is-eu-approved-to-treat-severe-vernal-keratoconjunctivitis----santen-pharma-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2013/05/idmc-halts-phase-iii-study-of-vargatef--boehringer--in-nsclc-/2021-09-24T07:16:22+00:00weekly0.6https://www.medthority.com/news/2018/02/trulicity---sglt-2-inhibitor-success-in-award-10-study-for-type-2-diabetes---eli-lilly/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2014/09/chmp-recommends-moventig-for-the-treatment-of-opioid-induced-constipation---astrazeneca-/2021-09-24T07:07:40+00:00weekly0.6https://www.medthority.com/news/2016/09/biomarin-provides-update-for-brineura--cerliponase-alfa--to-treat-children-with-cln2-disease---a-form-of-batten-disease--/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2014/05/fda-expands-approval-for-synribo-for-cml-teva/2021-09-24T07:08:14+00:00weekly0.6https://www.medthority.com/news/2017/01/takeda-acquires-ariad-pharma-and-with-it-rights-to-iclusig--ponatinib-/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2013/06/palace-1-study-reported-at-eular-for-apremilast-celgene--for-psoriatic-arthritis/2021-09-24T07:16:05+00:00weekly0.6https://www.medthority.com/news/2019/12/phase-iii-candor-study-of-darzalex---kyprolis---dexamethasone-shows-improved-pfs-in-multiple-myeloma---janssen-biotech/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2011/12/tc-5214-fails-second-phase-iii-trial-for-major-depressive-disorder/2021-09-24T07:04:43+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-expands-accelerated-approval-for-tecentriq--atezolizumab--for-the-treatment-of-people-with-locally-advanced-or-metastatic-urothelial-carcinoma--muc--who-are-not-eligible-for-cisplatin-chemotherapy---genentech-roche-/2021-09-24T07:14:13+00:00weekly0.6https://www.medthority.com/news/2019/10/trastuzumab-deruxtecan-granted-fda-priority-review-for-treatment-of-patients-with-her2-positive-metastatic-breast-cancer---daiichi-sankyo---astrazeneca/2021-09-24T07:17:21+00:00weekly0.6https://www.medthority.com/news/2013/12/fda-expands-indication-of-kcentra-csl-behring/2021-09-24T07:15:18+00:00weekly0.6https://www.medthority.com/news/2018/06/focal-one-focused-ultrasound--hifu--device-secures-fda-510-k--clearance-for-the-ablation-of-prostate-tissue---edap-tms-sa-/2021-09-24T07:05:32+00:00weekly0.6https://www.medthority.com/news/2014/12/alcon-secures-eu-approval-of-travatan-for-treatment-of-pediatric-glaucoma-/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2015/05/fda-approves-humalog-200-units-ml-kwikpen--u200--insulin-lispro--for-types-1---2-diabetes-eli-lilly/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-expands-label-of-erwinaze-for-all-jazz-pharma/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2015/05/early-success-of-lentiglobin-in-trial-for-sickle-cell-disease--bluebirdbio-inc--/2021-09-24T07:04:02+00:00weekly0.6https://www.medthority.com/news/2018/04/abbott-initiates-ilumien-iv-trial-to-test-oct-imaging-to-guide-stenting-for-cad-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2012/06/ven-309--vetrus-biosciences--fails-phase-iii-for-treatment-of-haemorrhoids/2021-09-24T07:02:20+00:00weekly0.6https://www.medthority.com/news/2012/07/takeda-re-submits-nesina-and-nesina-plus-actos-at-fda-for-type-2-diabetes/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-expands-approval-of-resolute-des-platforms-in-coronary-artery-disease---medtronic/2021-09-24T07:17:07+00:00weekly0.6https://www.medthority.com/news/2017/01/the-european-union-commission--grants-marketing-authorization-for---cystadrops-3-8mg-ml--for-treatment-of-corneal-cystine-crystal-deposits-in-adults-and-children-from-2-years-of-age-with-cystinosis---recordati/2021-09-24T07:13:03+00:00weekly0.6https://www.medthority.com/news/2018/05/plenvu-approved-by-fda-for-cleansing-of-the-colon---norgine-/2021-09-24T07:07:12+00:00weekly0.6https://www.medthority.com/news/2011/11/napo-pharma-terminates-agreement-wit-salix-pharma-for-crofelemer-for-chronic-diarrhoea-in-aids-patients/2021-09-24T07:04:56+00:00weekly0.6https://www.medthority.com/news/2019/06/trulicity-significantly-reduced-major-cardiovascular-events-in-rewind-trial-for-type-2-diabetes---eli-lilly/2021-09-24T07:17:01+00:00weekly0.6https://www.medthority.com/news/2019/12/gemini-phase-iii-trial-of-axs-05-meets-endpoint-in-major-depressive-disorder---axsome-therapeutics/2024-10-21T14:54:03+00:00weekly0.6https://www.medthority.com/news/2013/09/analysis-of-phase-iii-spiriva-trials-shows-benefits-in-asthma/2021-09-24T07:16:00+00:00weekly0.6https://www.medthority.com/news/2018/01/nice-rejects-xalkori-for-nhs-use-in-ros-1-positive-non-small-cell-lung-cancer---pfizer-/2021-09-24T07:05:11+00:00weekly0.6https://www.medthority.com/news/2018/03/keyzilen-fails-phase-iii-tactt3-trial-to-treat-tinnitus---auris-medical-/2021-09-24T07:06:30+00:00weekly0.6https://www.medthority.com/news/2012/06/prevail-trial-shows-positive-effects-of-livalo-kowa-hakko-kirin--over-pravastatin-in-ldl-c/2021-09-24T07:02:28+00:00weekly0.6https://www.medthority.com/news/2017/09/merck-inc--to-acquire-rigontec-gmbh-and-with-it--rgt-100-which--is-currently-in-phase-i-ii-in-advanced-solid-tumors--/2021-09-24T07:13:57+00:00weekly0.6https://www.medthority.com/news/2019/12/trastuzumab-deruxtecan-achieved-a-tumour-response-rate-of-60-9--in-pivotal-phase-ii-her2-positive-metastatic-breast-cancer-trial---destiny-breast01----daiichi-sankyo---astrazeneca/2021-09-24T07:18:31+00:00weekly0.6https://www.medthority.com/news/2013/12/evidence-of-tasgina-superiority-over-glivec-in-ph-cml-novartis/2021-09-24T07:15:21+00:00weekly0.6https://www.medthority.com/news/2013/10/-xolair--genentech--novartis--filed-at-fda-for-urticaria/2021-09-24T07:16:15+00:00weekly0.6https://www.medthority.com/news/2012/06/treatment-with-anti-tnfs-can-increase-the-risk-of-herpes-zoster-by-up-to-75-percent/2021-09-24T07:02:24+00:00weekly0.6https://www.medthority.com/news/2014/09/eu-grants-ce-mark-for-vizamyl-for-amyloid-pet-imaging--ge-healthcare/2021-09-24T07:07:46+00:00weekly0.6https://www.medthority.com/news/2014/06/new-data-for-kalydeco-for-g551d-mutation--r117h-mutation-and-non-g551d-mutation-of-cystic-fibrosis-announced-at-ecfs-meeting---vertex/2021-09-24T07:08:00+00:00weekly0.6https://www.medthority.com/news/2018/04/vx-445---tezacaftor---ivacaftor-combination-for-cystic-fibrosis-patients-with-a-f508del-mutation-enters-phase-iii-studies---vertex/2021-09-24T07:05:17+00:00weekly0.6https://www.medthority.com/news/2012/03/positive-update-from-phase-ii-trial-of-optina--ampio-pharma--for-diabetic-macular-oedema/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2016/10/eu-chmp-recommends-approval-of--venclyxto--venetoclax--for-chronic-lymphocytic-leukaemia--abbvie/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2017/12/falling-breast-cancer-deaths-in-the-netherlands-is-not-accredited-to-screening/2021-11-30T13:20:42+00:00weekly0.6https://www.medthority.com/news/2016/11/opdivo--nivolumab--success-in-ono-4538-12--a-phase-iii-study-for-unresectable-advanced-or-recurrent-gastric-cancer--bms---ono-pharma/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2016/05/brintellix--vortioxetine--to-be-renamed-trintellix---takeda-pharma---lundbeck/2021-09-24T07:09:31+00:00weekly0.6https://www.medthority.com/news/2019/08/clearside-biomedical-provides--update-for-xipere--a-treatment-of-macular-edema-associated-with-non-infectious-uveitis-/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2012/05/fda-approves-fabior--allergan--for-acne-vulgaris-in-12-year-olds-and-upwards/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2012/02/fda-advisory-committee--recommends-aclidium-bromide-forest-almirall--for-copd/2021-09-24T07:02:50+00:00weekly0.6https://www.medthority.com/news/2017/09/astra-transfers-residual-rights-to-anaesthetic-medicines-to-aspen-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2015/10/eu-awards-ce-mark-certification-to-aptima-hcv-quant-dx-assay-for-hepatitis-c-virus--hologic/2021-09-24T07:03:15+00:00weekly0.6https://www.medthority.com/news/2013/12/amg-145-meets-endpoint-in-phase-iii-trial-for-dyslipidaemia-amgen/2021-09-24T07:15:16+00:00weekly0.6https://www.medthority.com/news/2012/05/postive-results-from-phase-iii-analysis-of-amitiza--sucampo--for-ibs-c/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2019/10/phase-iii-relay-trial-of-cyramza-in-nsclc---egfr-published-in-the-lancet-oncology---eli-lilly/2021-09-24T07:17:27+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-approves-piqray---fulvestrant-to-treat-hormone-receptor-positive--human-epidermal-growth-factor-receptor-2-negative--hr--her2----pik3ca-mutated--advanced-or-metastatic-breast-cancer---novartis/2021-09-24T07:17:33+00:00weekly0.6https://www.medthority.com/news/2013/12/baxter-re-submits-hyqvia-at-fda-for-immunodeficiency/2021-09-24T07:15:23+00:00weekly0.6https://www.medthority.com/news/2013/08/nice-rejects-perjeta-for-breast-cancer/2021-09-24T07:15:13+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-voyage-1-trial-of-tremfya-shows-response-maintained-to-3-years-in-plaque-psoriasis---janssen-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2012/12/new-analysis-explains-competing-findings-in-studies-of-omega-3-fatty-acids-and-impact-on-cv-risk/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2014/08/avastin-is-fda-approved-to-treat-cervical-cancer---genentech-roche/2021-09-24T07:07:30+00:00weekly0.6https://www.medthority.com/news/2015/07/panther-biotechnology-acquires-alchemia-oncology-pty-limited-and-with-it-ha-irinotecan/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2020/02/chmp-recommends-approval-of-rybelsus-in-type-2-diabetes---novo-nordisk/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2015/07/fda-approves-technivie--ombitasvir---paritaprevir---ritonavir--with-ribavirin-for-hepatitis-c--abbvie/2021-09-24T07:04:36+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-removes-clinical-hold-from-phase-iii-trial-of-cr-845-in-postoperative-pain--cara-therapeutics/2024-02-19T16:03:33+00:00weekly0.6https://www.medthority.com/news/2019/11/biogen-to-expand-biosimilar-portfolio-through-new-transaction-with-samsung-bioepis-/2021-09-24T07:18:01+00:00weekly0.6https://www.medthority.com/news/2019/06/five-year-results-from-keynote-001-shows-keytruda-response-in-longest-follow-up-trial-for-nsclc---merck-inc/2021-09-24T07:17:05+00:00weekly0.6https://www.medthority.com/news/2014/02/ema-401-results-in-post-herpetic-neuralgia-are-published-in-the-lancet--spinifex-pharma/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2018/04/azeliragon-fails-phase-iii-steadfast-trial-in-patients-with-mild-alzheimers-disease---vtv-therapeutics-inc-/2021-09-24T07:05:24+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-agrees-to-filing-of-the-full-response-to-the-posimir-complete-response-letter-as-a-complete-class-2-resubmission--durect-corporation/2021-09-24T07:18:10+00:00weekly0.6https://www.medthority.com/news/2019/11/trevena-announces-publication-of-results-from-phase-iii--real-world--safety-study-for-oliceridine-in-the-journal-of-pain-research-/2021-09-24T07:17:53+00:00weekly0.6https://www.medthority.com/news/2017/05/may-10th-marks-world-lupus-day-in-support-of-5-million-sufferers-worldwide/2024-07-26T10:26:47+00:00weekly0.6https://www.medthority.com/news/2015/10/two-phase-iii-trials-show-genvoya--elvitegravir--cobicistat--emtricitabine-and-taf--is-non-inferior-to-stribild--elvitegravir--cobicistat--emtricitabine-and-tdf--in-hiv-gilead-sciences--/2024-02-19T16:03:49+00:00weekly0.6https://www.medthority.com/news/2014/02/andexanet-alfa-to-enter-phase-iii-trials-for-factor-xa-reversal-of-anticoagulation---portola-pharma-/2021-09-24T07:08:19+00:00weekly0.6https://www.medthority.com/news/2016/02/fda-approves-once-a-day-xeljanz-xr--tofacitinib-citrate-extended-release---to-treat-rheumatoid-arthritis--pfizer/2021-09-24T07:08:57+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-iii-results-for-invokana-in-t2d-janssen/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2015/06/trulicity--dulaglutide--superior-to-lantus--insulin-glargine--in-east-asia-study-for-type-2-diabetes--eli-lilly/2021-09-24T07:03:36+00:00weekly0.6https://www.medthority.com/news/2011/09/baxter-files-subcutaneous-hyq-at-ema-for-primary-immune-deficiency/2021-09-24T07:04:49+00:00weekly0.6https://www.medthority.com/news/2019/09/fda-approves-rituxan---glucocorticoids-to-treat-granulomatosis-with-polyangiitis--and-microscopic-polyangiitis-in-pediatric-patients---genentech-roche/2021-09-24T07:19:02+00:00weekly0.6https://www.medthority.com/news/2018/05/fda-accepts-for-review-cemiplimab-for-the-treatment-of-patients-with-metastatic-cutaneous-squamous-cell-carcinoma----regeneron---sanofi/2021-09-24T07:07:15+00:00weekly0.6https://www.medthority.com/news/2013/12/positive-results-for-imbruvica-in-extension-study-for-cll-janssen-biotech/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2015/09/abasaglar-biosimilar-to-lantus--insulin-glargine--is-launched-in-uk-and-germany-to-treat-diabetes--boehringer---eli-lilly/2021-09-24T07:03:48+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-banyan-bti--brain-trauma-indicator--diagnostic-to-detect-brain-trauma-injury---banyan-biomarkers-inc-/2021-09-24T07:05:56+00:00weekly0.6https://www.medthority.com/news/2013/01/european-commission-approves-bexsero-vaccine--novartis--for-meningococcal-disease/2021-09-24T07:15:50+00:00weekly0.6https://www.medthority.com/news/2014/06/chmp-recommends-stivarga-for-treatment-of-gist--bayer/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2013/10/latuda--takeda-sunovion--effective-for-schizophrenia/2021-09-24T07:16:14+00:00weekly0.6https://www.medthority.com/news/2019/12/fda-approves-lynparza-for-the-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-adenocarcinoma--astrazeneca---merck-inc-/2021-09-24T07:18:24+00:00weekly0.6https://www.medthority.com/news/2012/05/lancet-study-shows-raising-hdl-may-not-affect-heart-disease-risk/2021-09-24T07:02:45+00:00weekly0.6https://www.medthority.com/news/2013/01/phase-iii-study-of-lcp-tacro--veloxis-pharmaceuticals--shows-drug-is-non-inferior-to-current-treatment-in-kidney-transplant-patients/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2018/05/positive-advisory-committee--decision-for-plazomicin-for-treatment-of-adults-with-complicated-urinary-tract-infections--achaogen--inc-/2021-09-24T07:07:13+00:00weekly0.6https://www.medthority.com/news/2019/01/draft-nice-guidance-does-not-recommend-aimovig-in-migraine---novartis-/2021-09-24T07:18:45+00:00weekly0.6https://www.medthority.com/news/2012/07/eu-approves-jentadueto--boehringer--for-patients-with-type-2-diabetes/2021-09-24T07:01:45+00:00weekly0.6https://www.medthority.com/news/2016/11/phase-iii-trial-of-bremelanotide-in-hypoactive-sexual-desire-disorder-meets-primary-endpoints-palatin-technologies/2021-09-24T07:09:54+00:00weekly0.6https://www.medthority.com/news/2018/03/phase-iii-elaris-uf-ii-study-of-elagolix-meets-primary-endpoint-in-uterine-fibroids---abbvie-/2021-09-24T07:06:31+00:00weekly0.6https://www.medthority.com/news/2018/03/chmp-does-not-recommend-bevyxxa-for-prevention-of-venous-thromboembolism--in-adults---portola-pharma-/2021-09-24T07:06:23+00:00weekly0.6https://www.medthority.com/news/2018/12/imfinzi---tremelimumab-combination-does-not-meet-overall-survival-endpoint-in-phase-iii-eagle-trial-for-head---neck-cancer-astrazeneca/2021-09-24T07:06:09+00:00weekly0.6https://www.medthority.com/news/2018/01/fda-advisory-committee-rejects-nda-for-tlando--a-testosterone-replacement-therapy---lipocine-inc-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-approves-snda-for-alecensa-in-alk--metastatic-non-small-cell-lung-cancer---genentech-/2021-09-24T07:14:44+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-gives-accelerated-approval-to-opdivo--nivolumab--for-hodgkin-lymphoma--bms/2024-02-19T16:04:06+00:00weekly0.6https://www.medthority.com/news/2015/01/expanded-indication-for-prevenar-13-in-pneumonia-pfizer/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2016/06/new-drug-application-for-mci-186--edaravone--is-filed-at-fda-to-treat-als---mitsubishi-tanabe-/2021-09-24T07:09:58+00:00weekly0.6https://www.medthority.com/news/2014/01/chantix-champix-meets-endpoints-in-smoking-cessation-trial---pfizer/2021-09-24T07:07:34+00:00weekly0.6https://www.medthority.com/news/2015/06/nice-does-not-recommend-brintellix--vortioxetine--for-treatment-of-depression--lundbeck/2021-09-24T07:03:35+00:00weekly0.6https://www.medthority.com/news/2018/09/bavencio---inylta-positive-results-in-javelin-renal-101-study-for-renal-cell-carcinoma--merck-kgaa---pfizer/2021-09-24T07:06:45+00:00weekly0.6https://www.medthority.com/news/2015/08/shire-acquires-foresight-biotherapeutics-inc-for--300-million-and-with-it-fst-100/2021-09-24T07:03:09+00:00weekly0.6https://www.medthority.com/news/2016/03/abbvie-and-boehringer-ingelheim-to-collaborate-on-development-of-bi-655066-for-psoriasis-and-on-early-stage-bi-655064/2021-09-24T07:10:25+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-xerava-to-treat-complicated-intra-abdominal-infections----tetraphase-pharma-/2021-09-24T07:06:13+00:00weekly0.6https://www.medthority.com/news/2017/07/fda-approves-subcutaneous-formulation-of-benlysta--belimumab--for-systemic-lupus-erythematosus--glaxosmithkline/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2015/07/grazoprevir-elbasvir-single-tablet-combo-filed-in-eu-for-hepatitis-c-genotypes-1--3--4-or-6---merck-inc/2021-09-24T07:04:37+00:00weekly0.6https://www.medthority.com/news/2018/01/baxter-international-acquires-recothrom-and-preveleak-surgical-sealant-from-mallinckrodt-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2015/05/seven-year-follow-up-of-nulojix--belatacept-in-kidney-transplant-patients--bms/2021-09-24T07:04:08+00:00weekly0.6https://www.medthority.com/news/2014/06/teva-acquires-labrys-biologies-inc-and-with-it-lbr-101-anti-migraine-drug/2021-09-24T07:08:02+00:00weekly0.6https://www.medthority.com/news/2015/05/alectinib-success-in-advanced-alk-positive-nsclc-tumours--np28673-and-np28761-studies---genentech-roche/2021-09-24T07:04:06+00:00weekly0.6https://www.medthority.com/news/2014/12/brexpiprazole-phase-iii-results-for-adjunctive-therapy-in-major-depressive-disorder--otsuka---lundbeck/2021-09-24T07:08:34+00:00weekly0.6https://www.medthority.com/news/2013/03/voice-study-of-truvada-gel--gilead-sciences--unsuccessful-in-hiv-prevention/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-results-in-phase-iii-trial-of-bst-cargel--piramal-healthcare--for-tissue-repair/2021-09-24T07:02:46+00:00weekly0.6https://www.medthority.com/news/2019/03/hormonal-treatment-may-trigger-depression-in-men-with-prostate-cancer/2021-09-24T07:18:52+00:00weekly0.6https://www.medthority.com/news/2019/07/complete-response-for-nurtec-to-treat-amyotrophic-lateral-sclerosis/2021-09-24T07:18:07+00:00weekly0.6https://www.medthority.com/news/2015/11/shire-to-acquire-dyax--and-its-assets-in-hereditary-angioedema--for--5-9-billion/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-advises-review-date-for-hepislav-b--hepatitis-b-vaccine--recombinant--adjuvanted---treatment-for-hepatitis-b--dynavax-technologies/2021-09-24T07:14:16+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-lifts-partial-hold-on-canova-study-of-venclexta-to-treat-multiple-myeloma---abbvie/2021-09-24T07:16:52+00:00weekly0.6https://www.medthority.com/news/2011/12/zolinza-merck-inc---success-in-multiple-myeloma-trial/2021-09-24T07:04:45+00:00weekly0.6https://www.medthority.com/news/2017/04/gilead-sciences-announces-96-week-results-from-to-phase-iii-trials-evaluating--daily-vemlidy--tenofovir-alafenamide--taf-25mg--as-a-treatment-for-hepatitis-b-/2021-09-24T07:14:10+00:00weekly0.6https://www.medthority.com/news/2017/06/-the-european-commission-has-approved-brineura--cerliponase-alfa---the-first-treatment-approved-in-the-european-union-for-the-treatment-of-neuronal-ceroid-lipofuscinosis-type-2--cln2--disease---biomarin-pharmaceutical-inc-/2021-09-24T07:15:09+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-echelon-2-trial-of-adcetris-meets-primary-endpoint-in--t-cell-lymphoma---seattle-genetics---takeda/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2014/06/selexipag-success-in-phase-iii-griphon-study-for-pah---actelion/2021-09-24T07:07:57+00:00weekly0.6https://www.medthority.com/news/2016/01/chmp-recommendation-for-feraccru--ferric-maltol--to-treat-iron-deficiency-anaemia-in-patients-with-inflammatory-bowel-disease--shield-therapeutics/2024-02-19T16:11:18+00:00weekly0.6https://www.medthority.com/news/2012/08/watchman-laac-device--boston-scientific--receives-expanded-ce-indication---------------/2021-09-24T07:02:29+00:00weekly0.6https://www.medthority.com/news/2019/09/positive-results-for-selpercatinib-demonstrating-a-68-percent-objective-response-rate-in-heavily-non-small-cell-lung-cancer---eli-lilly/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2015/04/zinbryta--daclizumab--filed-with-fda-for-multiple-sclerosis-biogen-abbvie-/2021-09-24T07:02:53+00:00weekly0.6https://www.medthority.com/news/2013/10/results-of-ly-3009806-trial-for-gastric-cancer-in-the-lancet-/2021-09-24T07:16:17+00:00weekly0.6https://www.medthority.com/news/2012/08/fda-approves-marqibo--talon-therapeutics--for-ph-all------------------------------/2021-09-24T07:02:32+00:00weekly0.6https://www.medthority.com/news/2011/10/aubagio-from-genzyme-sanofi-is-filed-at-fda-for--relapsing-multiple-sclerosis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-a-label-variation-to-neulasta-to-include-the-neulasta-onpro-kit---amgen-/2021-09-24T07:05:47+00:00weekly0.6https://www.medthority.com/news/2017/07/mitsubishi-tanabe-will-acquire-neuroderm-ltd-and-with-it-nd-0612-a-proposed-treatment-for-parkinsons-disease/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2018/10/the-fda-has-agreed-to-a-rolling-submission-for-givosiran-for-acute-hepatic-porphyria---alnylam-pharma/2021-09-24T07:05:43+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-requires--longer-term-trials-for-hyqvia--halozyme-baxter--for-primary-immonodeficiency/2021-09-24T07:01:53+00:00weekly0.6https://www.medthority.com/news/2015/12/nice-recommendation-of-forxiga--dapagliflozin---invokana--canagliflozin--and-jardiance--empagliflozin--as-monotherapies-for-type-2-diabetes/2021-09-24T07:04:26+00:00weekly0.6https://www.medthority.com/news/2014/03/otezla-success-in-esteem-1-trial-for-psoriasis---celgene/2021-09-24T07:08:23+00:00weekly0.6https://www.medthority.com/news/2014/09/endo-pharma-proposes-to-acquire-auxilium-pharma-for--2-2-billion-including-xiaflex/2025-10-16T11:18:11+00:00weekly0.6https://www.medthority.com/news/2013/09/positive-results-in-phase-iii-trial-of-invokana-for-t2d/2021-09-24T07:15:56+00:00weekly0.6https://www.medthority.com/news/2019/06/future-5-trial-shows-cosentyx-provides-long-lasting-inhibition-of-radiographic-progression-in-psoriatic-arthritis--novartis/2021-09-24T07:17:00+00:00weekly0.6https://www.medthority.com/news/2014/01/tafinlar-mekinist-phase-iii-trial-meets-endpoint-in-melanoma-gsk/2021-09-24T07:07:33+00:00weekly0.6https://www.medthority.com/news/2019/08/ema-approves-extension-of-approval-for-invokana-and-vokanamet-for-chronic-kidney-disease-and-albuminuria-in-type-2-diabetes---mundipharma/2021-09-24T07:17:45+00:00weekly0.6https://www.medthority.com/news/2019/08/jazz-pharma-acquires-cavion-inc--and-with-it-cx-8998-a-potential-treatment-for-essential-tremor-/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2015/08/additional-requests-filed-with-fda-for-impella-family-of-heart-pumps-in-cardiac-surgery-patients--abiomed/2021-09-24T07:03:05+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-qnasl-for-allergic-rhinitis-in-children-teva/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---pcsk9-inhibitors--specific-studies-are-mandatory-to-prove-efficacy-and-safety-in-ckd/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2011/11/ucb-will-not-market-syn-118-for-parkinsons-disease/2021-09-24T07:04:54+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-advisory-committee-to-review--bla-for-abp-215--bevacizumab-biosimilar-on-13-july-2017---amgen---allergan/2021-09-24T07:15:07+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-advisory-committee-rejects-alks-5461-as-a-treatment-for-depression--alkermes/2024-10-21T14:51:33+00:00weekly0.6https://www.medthority.com/news/2018/03/pdos-and-personalised-medicine/2024-07-26T10:55:33+00:00weekly0.6https://www.medthority.com/news/2013/12/depomed-to-market-cambia-for-migraine-in-us/2021-09-24T07:15:17+00:00weekly0.6https://www.medthority.com/news/2014/07/alcon-licences-rights-for-google--glass-for-ocular-conditions---google---alcon/2021-09-24T07:08:51+00:00weekly0.6https://www.medthority.com/news/2015/08/fda-approves-extension-of-indication-for-zubsolv--buprenorphine-naloxone-ciii-sublingual-tablet--in-opioid-dependence--orexo/2021-09-24T07:03:06+00:00weekly0.6https://www.medthority.com/news/2011/12/lamictal--glaxo-smith-kline--one-of-superior-drug-combination-for-treating-epilepsy/2021-09-24T07:04:44+00:00weekly0.6https://www.medthority.com/news/2015/10/results-of-phase-iii-trial-of-mk-5172---mk-8742--grazoprevir---elbasvir--in-hepatitis-c-plus-ckd-published-in-the-lancet--merck/2024-02-19T16:11:36+00:00weekly0.6https://www.medthority.com/news/2020/02/genentech-roche-presents-one-year-data-from-part-2-of-sunfish-study-of-risdiplam-to-treat-spinal-muscular-atrophy-/2021-09-24T07:12:04+00:00weekly0.6https://www.medthority.com/news/2014/05/study-shows-enlighhtn-rds-safe-for-hypertension-patients---st-jude-medical/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-linx-reflux-management-system--torax-medical-inc---for-gerd/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2014/12/genentech-files-nda-for-cobimetinib---zelboraf-at-fda-for--braf-v600-mutation-positive-advanced-melanoma/2021-09-24T07:08:33+00:00weekly0.6https://www.medthority.com/news/2015/08/nice-recommends-lixiana--edoxaban--for-prevention-of-stroke-and-systemic-embolism--daiichi-sankyo/2021-09-24T07:03:07+00:00weekly0.6https://www.medthority.com/news/2014/09/nice-draft-guidance-recommends-olysio-for-hepatitis-c-genotype-1-janssen-cilag/2021-09-24T07:07:43+00:00weekly0.6https://www.medthority.com/news/2013/01/empagliflozin--boehringer-lilly--success-in-four-phase-iii-trials-for-type-2-diabetes/2021-09-24T07:15:53+00:00weekly0.6https://www.medthority.com/news/2015/12/cometriq--cabozantinib--filed-with-fda-in-rolling-submission-for-renal-cell-carcinoma--exelixis-/2024-02-19T14:03:02+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-approves-generic-lovaza-to-reduce-triglyceride--tg--levels--teva/2021-09-24T07:07:25+00:00weekly0.6https://www.medthority.com/news/2012/08/bosatria--gsk--study-in-severe-eosinophilic-asthma/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2015/04/ampion-fails-to-meet-endpoint-in-phase-iii-stride-study-for-osteoarthritis-knee--ampio-pharma/2021-09-24T07:02:56+00:00weekly0.6https://www.medthority.com/news/2016/12/european-commission-grants-conditional-approval-to-ocaliva--obeticholic-acid--for-the-treatment-of-primary-biliary-cholangitis---intercept-pharma--/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2017/08/novartis-announces-analysis-published-in-the-lancet-showing-acz-885--canakinumab--reduced-the-rate-of-lung-cancer-mortality-among-study-participants-by-77--/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2016/12/eu-approves-venclyxto--venetoclax--for-chronic-lymphocytic-leukaemia--abbvie/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-grants-510-k--approval-for--itotal-hip-replacement-system--conformis--inc-/2021-09-24T07:15:00+00:00weekly0.6https://www.medthority.com/news/2013/11/vimpat--ucb--filed-with-fda-as-monotherapy-for-epilepsy/2021-09-24T07:16:35+00:00weekly0.6https://www.medthority.com/news/2019/11/phase-iii-p301-trial-of-spn-810-in-patients-with-adhd--did-not-meet-its-primary-endpoint---supernus-pharma/2021-09-24T07:17:59+00:00weekly0.6https://www.medthority.com/news/2015/02/pfizer-submits-alo-02-abuse-deterrent-formulation-for-pain-pfizer/2021-09-24T07:03:58+00:00weekly0.6https://www.medthority.com/news/2016/04/european-commission-approves--descovy---emtricitabine-and-tenofovir-alafenamide-200-10-mg-and-200-25-mg--f-taf--to-treat-hiv-1-infection---gilead-sciences/2021-09-24T07:10:38+00:00weekly0.6https://www.medthority.com/news/2016/12/biologix-fzco-licenses-rights-in-middle-east-to-contrave--naltrexone-hcl---bupropion-hcl-monotherapy--from-orexigen-therapeutics-for-weight-management-/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2020/01/fda-approves-monoferric-for-iron-deficiency-anemia---pharmacosmos-therapeutics/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2015/11/bliss-sc-phase-iii-trial-of-benlysta--belimumab--shows-benefits-in-systemic-lupus-erythematosus--glaxosmithkline/2024-02-19T14:03:24+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-trial-shows-ilaris--novartis--allows-discontinuation-of-corticosterioids-in-sjia/2021-09-24T07:16:04+00:00weekly0.6https://www.medthority.com/news/2014/11/nice-recommends-entyvio-as-a-treatment-for-ulcerative-colitis--takeda/2021-09-24T07:08:38+00:00weekly0.6https://www.medthority.com/news/2019/07/the--new-skin--of-dermatology/2021-09-24T07:18:15+00:00weekly0.6https://www.medthority.com/news/2016/11/fda-approves-darzalex--daratumumab--in-combination-with-lenalidomide-and-dexamethasone--or-bortezomib-and-dexamethasone--for-the-treatment-of-patients-with-multiple-myeloma--genmab---janssen-biotech/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-indication-expanded-for-impella-cp-heart-pump-during-percutaneous-coronary-interventions--abiomed/2021-09-24T07:10:14+00:00weekly0.6https://www.medthority.com/news/2015/09/bms-has-option-to-acquire-promedior--inc--and-its-lead-asset-prm-151-in-phase-ii-development-for-the-treatment-of-idiopathic-pulmonary-fibrosis-and-myelofibrosis/2021-09-24T07:03:54+00:00weekly0.6https://www.medthority.com/news/2017/09/urology-week-2017/2021-11-30T11:25:22+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-issues-refusal-to-file-letter-for-trevyent--treprostinil----patchpump-technology--for-the-treatment-of-pulmonary-arterial-hypertension--steadymed-therapeutics-/2021-09-24T07:14:03+00:00weekly0.6https://www.medthority.com/news/2016/04/chmp-recommends-a-type-ii-variation-to-include-data-from-the-head-to-head-terrain-trial-of-enzalutamide-versus-bicalutamide-in-the-european-label-for-xtandi--enzalutamide--capsules---medivation---astellas/2024-02-19T14:03:56+00:00weekly0.6https://www.medthority.com/news/2015/09/secondary-analysis-of-phase-iii-data-for-ogx-011--custirsen--in-prostate-cancer-shows-some-benefit--oncogenex-pharmaceuticals/2024-02-19T14:04:11+00:00weekly0.6https://www.medthority.com/news/2016/02/positive-phase-iii-meteor-results-for-cometriq--cabozantinib--in-renal-cell-carcinoma--exelisis-/2024-02-20T13:49:34+00:00weekly0.6https://www.medthority.com/news/2015/05/disappointing-results-mean-mln-8237--alisertib--discontinued-in-t-cell-lymphoma-takeda/2021-09-24T07:04:07+00:00weekly0.6https://www.medthority.com/news/2015/10/new-results-for-biofreedom-biolimus-a9--umirolimus--drug-coated-stent-show-benefits-in-pci--biosensors-international/2024-02-19T14:04:37+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-zemdri-for-complicated-urinary-tract-infections---achaogen-/2021-09-24T07:05:28+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-opdivo-for-metastatic-melanoma-bms/2021-09-24T07:08:29+00:00weekly0.6https://www.medthority.com/news/2012/07/ec-approves-eklira-bretaris-genuair--almirall-menarini--for-treatment-of-copd/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2015/06/sorin-group-and-cyberonics-merged-company-to-be-known-as-livanova/2021-09-24T07:03:31+00:00weekly0.6https://www.medthority.com/news/2014/01/clarus-therapeutics-files-rextoro-at-fda-for--testosterone-deficiency/2021-09-24T07:07:35+00:00weekly0.6https://www.medthority.com/news/2018/06/once-weekly-kyprolis-shows-superior-pfs-and-os-response-rates-over-twice-weekly-kyprolis-treatment-of-multiple-myeloma-in-a-r-r-o-w-study--amgen-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2011/11/nomac-e2-is-rejected--by-fda-as-a-contraceptive/2021-09-24T07:04:57+00:00weekly0.6https://www.medthority.com/news/2012/08/nice-rejects-iluvien-alimera-sciences-for-dme-treatment/2021-09-24T07:02:34+00:00weekly0.6https://www.medthority.com/news/2018/02/chmp-recommends-extension-of-xgeva-indication-to-treat-giant-cell-tumour-of-the-bone---amgen-/2021-09-24T07:05:48+00:00weekly0.6https://www.medthority.com/news/2018/12/two-year-data-from-zuma-1-trial-for-yescarta-in-patients-with-refractory-large-b-cell-lymphoma---kite-gilead-/2021-09-24T07:06:11+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-rituxan-to-treat-severe-pemphigus-vulgaris---genentech-roche-/2021-09-24T07:05:33+00:00weekly0.6https://www.medthority.com/news/2018/01/create-1-trial-of-axs-02-in-complex-regional-pain-syndrome-is-stopped-for-futility--axsome-therapeutics-/2021-09-24T07:05:13+00:00weekly0.6https://www.medthority.com/news/2018/10/euro-esli-study-of-aptiom-confirms-effectiveness-in-focal-onset-epilepsy---bial---eisai-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2012/05/roche-halts-development-of-rg-1658-for-dyslipidaemia/2021-09-24T07:02:48+00:00weekly0.6https://www.medthority.com/news/2014/01/cell-therapeutics-regains-rights-to-pixuvri-and-opaxio-from-novartis/2021-09-24T07:07:36+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-trial-of-zgn-433--beloranib--in-prader-willi-syndrome-meets-endpoints--zafgen/2024-02-06T15:55:26+00:00weekly0.6https://www.medthority.com/news/2017/04/allergan-moves--botox--onabotulinumtoxin-a-into-phase-iii-as-a-potential-new-treatment-option-for-patients-with-depression-/2024-10-21T14:50:18+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-clinical-trial-of-gv-971-shows-promise-in-alzheimers-disease---green-valley-pharma-/2021-09-24T07:05:39+00:00weekly0.6https://www.medthority.com/news/2019/08/ultragenyx-pharmaceutical-inc---submits-nda-to-fda-for-ux-007-to-treat-long-chain-fatty-acid-oxidation-disorders--/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2018/05/corrective-action-required-for-heartmate-3--left-ventricular-assist-device---abbott-/2021-09-24T07:07:06+00:00weekly0.6https://www.medthority.com/news/2017/06/successful-phase-iii-hawk-and-harrier-studies-of-rth-258--brolucizumab--to-treat-neovascular-age-related-macular-degeneration---novartis/2021-09-24T07:15:02+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-issues-a-complete-response-for-farxiga-to-treat-type-1-diabetes--astrazeneca/2021-09-24T07:18:13+00:00weekly0.6https://www.medthority.com/news/2019/02/complete-response-letter-for-iclaprim-to-treat-acute-bacterial-skin-and-skin-structure-infections---motif-bio/2021-09-24T07:17:11+00:00weekly0.6https://www.medthority.com/news/2016/09/german-institute-for-quality-and-efficiency-in-health-care-suggests-no-additional-benefit-of-halaven--eribulin--in-liposarcomas--eisai/2021-09-24T07:09:22+00:00weekly0.6https://www.medthority.com/news/2018/10/teleflex-acquires-essential-medical-and-with-it-the-ce-marked--manta-vascular-closure-device/2021-09-24T07:05:45+00:00weekly0.6https://www.medthority.com/news/2013/11/leo-pharma-to-market-otrexup-in-us-for-psoriasis/2021-09-24T07:16:31+00:00weekly0.6https://www.medthority.com/news/2012/04/newron-pharma-licenses-us-and-eu-rights-to-safinamide--for-parkinsons-disease-to-zambon-spa/2021-09-24T07:01:54+00:00weekly0.6https://www.medthority.com/news/2014/05/boehringer-settles-pradaxa-claims-in-the-us-for--650-million-/2021-09-24T07:08:05+00:00weekly0.6https://www.medthority.com/news/2015/02/combination-of-daclatasvir---sofosbuvir-positive-in-ally-2-trial-for-co-infected-hiv-and-hepatitis-c-patients--bms/2021-09-24T07:03:55+00:00weekly0.6https://www.medthority.com/news/2020/02/trevena-resubmits-new-drug-application-for-oliceridine-for-the-management-of-moderate-to-severe-acute-pain-/2021-09-24T07:12:09+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-approves-first-generic-lexapro-for-depression-and-anxiety-disorder-/2021-09-24T07:01:41+00:00weekly0.6https://www.medthority.com/news/2012/01/tysabri-biogen-idec-elan--enters-phase-iii-ascend-trial-for-secondary-progressive-multiple-sclerosis/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2019/02/chmp-recommends-kromeya--adalimumab-biosimilar--for-the-treatment-of-certain-inflammatory-and-autoimmune-disorders---fresenius-kabi/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2017/11/new-societal-guidelines-recommend-subcutaneous-implantable-cardioverter-defibrillator-for-patients-with-ventricular-arrhythmias-at-risk-of-sudden-cardiac-death---boston-scientific/2021-09-24T07:14:43+00:00weekly0.6https://www.medthority.com/news/2016/06/impact-study-shows-freestyle-libre-system-met-its-primary-endpoint-of-a-reduction-in-time-spent-in-hypoglycemia-during-glucose-monitoring---abbott-diabetes/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2015/12/results-from-phase-iii-amplify-trial-of-eliquis--apixaban--in-venous-thromboembolism-published-online--bms-pfizer/2024-02-19T15:55:30+00:00weekly0.6https://www.medthority.com/news/2016/05/clovis-terminates-enrollment-for-clinical-trials-of-co-1686--rociletinib--in-non-small-cell-lung-cancer-and-withdraws-marketing-application-in-eu--clovis/2021-09-24T07:09:33+00:00weekly0.6https://www.medthority.com/news/2014/11/janssen-files-nda-at-fda-for-three-months-formulation-of-invega-sustenna-for-schizophrenia/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2016/03/neurostar-tms-therapy-reports-successful-study-for-treatment-of-depression--neuronetics-inc-/2024-02-19T15:56:12+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-grants-accelerated-approval-forocaliva--obeticholic-acid--for-the-treatment-of-primary-biliary-cholangitis--intercept-pharma-/2024-02-19T15:56:54+00:00weekly0.6https://www.medthority.com/news/2017/05/positive-new-health-economics-analysis-of-zilretta-for-the-treatment-of-knee-osteoarthritis--oa--pain---flexion-therapeutics--inc-/2021-09-24T07:14:26+00:00weekly0.6https://www.medthority.com/news/2017/01/capnia-inc--to-acquire-essentialis-and-with-it-dccr--diazoxide-choline-controlled-release-tablet--a-proposed-treatment-for-prader-willi-syndrome-/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-study-of-bydureon-meets-primary-endpoints-in-t2d-astrazeneca/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2014/10/fda-advisory-committee-recommends-kalydeco-to-treat-cystic-fibrosis-r117h-mutation--vertex/2021-09-24T07:07:16+00:00weekly0.6https://www.medthority.com/news/2017/12/positive-overall-survival-results-for-aspire-trial-of-kyprolis-for-multiple-myeloma--amgen-/2021-09-24T07:13:38+00:00weekly0.6https://www.medthority.com/news/2014/12/mln-9708-has-breakthrough-status-from-fda-and-starts-tourmaline-al1-phase-iii-trial-for-amyloidosis--takeda---millennium/2021-09-24T07:08:37+00:00weekly0.6https://www.medthority.com/news/2016/09/cytokinetics-advances-omecamtiv-mecarbil-into-phase-iii-as-a-potential-treatment-for-chronic-heart-failure-/2021-09-24T07:09:23+00:00weekly0.6https://www.medthority.com/news/2013/08/zerenex-filed-at-fda-for-hyperphosphataemia/2021-09-24T07:15:12+00:00weekly0.6https://www.medthority.com/news/2012/09/bayerhealthcare-filed-new-contraceptive-patch-in-european-union---------------/2021-09-24T07:01:57+00:00weekly0.6https://www.medthority.com/news/2019/07/positive-results-from-second-phase-iii--study-of-once-daily-relugolix-combination-therapy-in-women-with-uterine-fibroids-and-positive--bioequivalence-study/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2019/12/kymriah-demonstrates-consistent-efficacy-and-safety-outcomes-with-real-world-experience-in-children-and-young-adults-with-r-r-all---novartis/2021-09-24T07:18:34+00:00weekly0.6https://www.medthority.com/news/2019/06/urgent-action-needed-as-atrial-fibrillation-set-to-affect-millions-of-over-65-s-in-the-eu-by-2060/2024-02-19T14:20:49+00:00weekly0.6https://www.medthority.com/news/2014/04/novartis-announces-job-cuts/2025-10-16T11:10:37+00:00weekly0.6https://www.medthority.com/news/2019/01/three-post-approval-studies-of-sutureless-perceval-aortic-heart-valve--livanova-plc/2021-09-24T07:18:42+00:00weekly0.6https://www.medthority.com/news/2016/03/eu-gives-ce-mark-approval-to-next-generation-enroute-tns-for-artery-repair--silk-road-medical/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2011/04/fda-approves-roche-cobas-hpv-test/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2014/11/hemopurifier-succesful-in-treatment-of-ebola-patient-aethlon/2021-09-24T07:08:42+00:00weekly0.6https://www.medthority.com/news/2016/12/oxervate-eye-drops-filed-at-eu-by-dompe-to-treat-neurotrophic-keratitis-/2021-09-24T07:10:12+00:00weekly0.6https://www.medthority.com/news/2017/10/fda-gives-510-k--approval-of--optiscanner-5000-glucose-monitoring-system-for-critical-care---optiscan-biomedical-corp-/2021-09-24T07:13:24+00:00weekly0.6https://www.medthority.com/news/2013/07/completion-of-cll11---study-for-ga-101--genentech--for-treatment-of-cll/2021-09-24T07:15:26+00:00weekly0.6https://www.medthority.com/news/2018/01/phase-iii-trial-of-apl-130277-in-parkinsons-disease-met-primary-endpoint---sunovion-pharma-/2021-09-24T07:05:05+00:00weekly0.6https://www.medthority.com/news/2017/10/chmp-recommends-approval-of-change-in-indication-for-faslodex--fulvestrant--in-breast-cancer---astrazeneca-/2021-09-24T07:13:26+00:00weekly0.6https://www.medthority.com/news/2018/07/phase-iii-believe-study-of-luspatercept-achieved-primary-and-all-key-secondary-endpoints-for-patients-with-transfusion-dependent-beta-thalassemia---celgene---acceleron-pharma-/2024-07-26T10:55:08+00:00weekly0.6https://www.medthority.com/news/2020/01/true-ad2-pivotal-trial-of-ruxolitinib-cream-met-its-primary-endpoint-in-patients-with-atopic-dermatitis---incyte-corpn-/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2018/07/ema-approves-xeljanz-for-psoriatic-arthritis---pfizer-/2024-10-11T11:55:34+00:00weekly0.6https://www.medthority.com/news/2012/01/afinitor--novartis--fails-gastric-cancer-study/2021-09-24T07:01:34+00:00weekly0.6https://www.medthority.com/news/2018/11/european-commission-approves-jivi-for-the-treatment-and-prophylaxis-of-bleeding--in-patients-with-hemophilia-a--bayer-healthcare/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2018/10/sustain-study-shows-crizanlizumab-increased-the-number-of-patients-free-of-sickle-cell-pain-crises-vs-placebo---novartis/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2017/01/positive-two-year-data-for-pantheris-system-in-peripheral-artery-disease--avinger/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2019/09/in-pact-av-access-study-of-in-pact--drug-coated-balloon-meets-primary-endpoints-in-patients-with-end-stage-renal-disease---medtronic/2021-09-24T07:19:09+00:00weekly0.6https://www.medthority.com/news/2015/06/fda-approves-copiktra-to-treat-cll-sll-and-grants-accelerated-approval-for-follicular-lymphoma--verastem-inc-/2021-09-24T07:03:30+00:00weekly0.6https://www.medthority.com/news/2016/03/skyepharma-is-acquired-by-vectura-for-around--441-million-and-with-it-flutiform/2021-09-24T07:10:22+00:00weekly0.6https://www.medthority.com/news/2013/02/eu-approves-optisharp--dsm-nutritional-products--for-nutritional-use/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2011/06/first-patients--receive-ima-901-in-phase-iii-trial-for-renal-cell-carcinoma/2021-09-24T07:04:41+00:00weekly0.6https://www.medthority.com/news/2019/10/lantheus-holdings-to-acquire-progenics-pharmaceuticals/2021-09-24T07:17:24+00:00weekly0.6https://www.medthority.com/news/2015/07/novartis-faces--3-5-billion-us-lawsuit-for-false-claims-under-medicare-and-medicaid-/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2016/02/phase-iii-trial-of-hydros-ta--hyaluronic-acid-beads--meets-one-endpoint-in-pain-associated-with-osteoarthritis--carbylan-therapeutics/2024-02-19T14:21:01+00:00weekly0.6https://www.medthority.com/news/2012/02/mhra-issues-guidance-on-all-metal-hip-replacement/2021-09-24T07:02:49+00:00weekly0.6https://www.medthority.com/news/2018/11/positive-results-from-maia-study-of-darzalex---revlimid-and-dexamethasone-in-multiple-myeloma-patients-ineligible-for-transplant---genmab---janssen-biotech/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2013/07/nice-recommends--peginterferon-alfa-plus-ribavirin-for-hepatitis-c/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-trial-of-ocaliva--obeticholic-acid--shows-efficacy-in-primary-biliary-cholangitis--intercept-pharmaceuticals-/2024-02-19T14:21:14+00:00weekly0.6https://www.medthority.com/news/2017/01/uk-s-nice-recommends-use-of-cosentyx--secukinumab--in-active-psoriatic-arthritis--novartis/2021-09-24T07:13:09+00:00weekly0.6https://www.medthority.com/news/2018/11/pioneer-hf-trial-of-entresto-for-heart-failure-published-in-nejm---novartis-/2021-09-24T07:06:53+00:00weekly0.6https://www.medthority.com/news/2017/04/fda-grants-full-approval-for-tagrisso-osimertinib-80mg-for-the-treatment-of-patients-with-metastatic-epidermal-growth-factor-receptor-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-nsclc-astarzeneca/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2020/02/fda-grants-priority-review-for-tucatinib----trastuzumab---capecitabine-to-treat-locally-advanced-unresectable-or-metastatic-her2-positive-breast-cancer--including-patients-with-brain-metastases--seattle-genetics/2023-01-16T10:38:42+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-combi-ad-trial-of-tafinlar---mekinist-shows-benefits-for-relapse-free-survival-in-melanoma---novartis-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2011/10/takeda-discontinues-rozerem-for-insomnia--in-the-eu/2021-09-24T07:05:03+00:00weekly0.6https://www.medthority.com/news/2012/10/chmp-recommends-xarelto--bayer--for-the-treatment-of-pulmonary-embolism--and-the-prevention-of-recurrent-deep-vein-thrombosis--and-pulmonary-embolism-in-adults-/2024-10-15T08:02:47+00:00weekly0.6https://www.medthority.com/news/2013/07/nice--minded--not-to-recommend-mabthera-for-vasculitis/2021-09-24T07:15:24+00:00weekly0.6https://www.medthority.com/news/2017/09/teva-sells-paragard--an-intrauterine-copper-contraceptive-device-to-cooper-companies-for--1-1-billion-/2021-09-24T07:13:51+00:00weekly0.6https://www.medthority.com/news/2019/09/phase-iii-checkmate--548-trial-of-opdivo-in-glioblastoma-multiforme-fails-to-meet-primary-endpoint---bms/2021-09-24T07:19:10+00:00weekly0.6https://www.medthority.com/news/2020/02/cerecor-acquires-avei-genomic-medicine/2021-09-24T07:11:58+00:00weekly0.6https://www.medthority.com/news/2019/10/one-year-follow-up-results-with-lixiana-shows-low-rates-of-bleeding-in-non-valvular-atrial-fibrillation---daiichi-sankyo/2021-09-24T07:17:23+00:00weekly0.6https://www.medthority.com/news/2012/04/first-human-study-of-anatabloc--star-scientific--for-alzheimer-s-disease/2021-09-24T07:01:51+00:00weekly0.6https://www.medthority.com/news/2017/10/new-treatment-for-gastroparesis-preparing-for-fda-submission/2021-09-24T07:13:22+00:00weekly0.6https://www.medthority.com/news/2018/01/initial-data-from-repeat-prescription-phase-iiib-trial-for-zilretta-for-osteoarthritis-of-the-knee---flexion-therapeutics-/2021-09-24T07:05:14+00:00weekly0.6https://www.medthority.com/news/2018/02/ag-120-is-filed-at-fda-for-treatment-relapsed-or-refractory--r-r--acute-myeloid-leukemia--aml--with-an-isocitrate-dehydrogenase-1--idh1--mutation----agios-pharma-/2021-09-24T07:05:57+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approval-for--zenith-dissection-endovascular-system-for-the-endovascular-treatment-of-patients-with-type-b-aortic-dissection---cook-medical/2021-09-24T07:17:13+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-approves-odefsey--emtricitabine-200-mg-rilpivirine-25-mg-tenofovir-alafenamide-25-mg-or-r-f-taf--for-the-treatment-of-hiv-1-infection---gilead-sciences/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2013/04/byetta-and-bydureon-to-be-marketed-for-type-2-diabetes-by-bms-and-astra-zeneca-in-the-uk/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2016/02/data-from-trials-of-vargatef--nintedanib--in-idiopathic-pulmonary-fibrosis-published-in-respiratory-medicine--boehringer/2021-09-24T07:08:58+00:00weekly0.6https://www.medthority.com/news/2017/01/real-world-results-with-in-pact-admiral-drug-coated-balloon-show-benefits-in-peripheral-arterial-disease--medtronic/2021-09-24T07:13:04+00:00weekly0.6https://www.medthority.com/news/2011/10/confirm-trial-positive-for-bg-12-in-multiple-sclerosis/2021-09-24T07:05:00+00:00weekly0.6https://www.medthority.com/news/2014/04/fda-expands-approval-of-adacel-tdap-vaccine---sanofi-pasteur/2021-09-24T07:07:27+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-carolina-trial-of-tradjenta--meets-primary-endpoint-in-type-2-diabetes-and-cv-outcomes---boehringher---eli-lilly/2021-09-24T07:17:10+00:00weekly0.6https://www.medthority.com/news/2014/12/fda-approves-zerbaxa-for-treatment-of-cuti-and-ciai-infections--cubist-pharma-merck-inc-/2021-09-24T07:08:30+00:00weekly0.6https://www.medthority.com/news/2012/09/iqwig-finds-incivek-incivo--j-j-janssen-cilag--offers-some-advantages-for-hepatitis-c-patients/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2017/12/tx004hr--refiled-with-fda-for-vaginal-pain-due-to-menopause---therapeuticsmd-/2021-09-24T07:13:46+00:00weekly0.6https://www.medthority.com/news/2018/03/sipping-hot-fruit-teas-can-lead-to-tooth-erosion/2024-07-26T10:54:53+00:00weekly0.6https://www.medthority.com/news/2014/03/amgen-announces-three-phase-iii-studies--mendel-2--descartes-and-rutherford-2-of-evolocumab-for-high-cholesterol/2021-09-24T07:08:21+00:00weekly0.6https://www.medthority.com/news/2019/06/chmp-negative-for-evenity-for-the-treatment-of-severe-osteoporosis/2021-09-24T07:16:50+00:00weekly0.6https://www.medthority.com/news/2017/01/uk-nice-says-nexavar--sorafenib--is-not-value-for-money-in-liver-cancer-treatment--bayer-healthcare/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2016/07/fda-approves-absorb-gt1-bioresorbable-vascular-scaffold-system-for-coronary-artery-disease--abbott-vascular/2021-09-24T07:08:55+00:00weekly0.6https://www.medthority.com/news/2016/11/new-results-from-global-registry-for-endurant-ii-iis-stent-graft-system-in-abdominal-aortic-aneurysm--medtronic/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2016/11/blisibimod-fails-phase-iii-chablis-sc1-clinical-trial-to-treat-sle---anthera-pharma--/2021-09-24T07:09:49+00:00weekly0.6https://www.medthority.com/news/2017/07/eu-chmp-recommends-approval-of-actemra-roactemra--tocilizumab--for-the-treatment-of-giant-cell-arteritis--roche/2021-09-24T07:14:05+00:00weekly0.6https://www.medthority.com/news/2015/03/study-shows-benefits-of-sapien-tavr-device-in-aortic-valve-stenosis-edwards-lifesciences/2021-09-24T07:04:12+00:00weekly0.6https://www.medthority.com/news/2015/09/successful-phase-iii-studies-for-bezlotoxumab--in-treatment-of-prevention-of-c--difficile-recurrence--merck-inc-/2024-02-19T14:21:36+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-advisory-committee-recommends--zinplava--bezlotoxumab-injection--for-treatment-of-clostridium-difficile-infection-recurrence---merck-inc-/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2014/09/phase-iii-trial-of-zs-9-meets-endpoint-in-hyperkalemia-zs-pharma/2021-09-24T07:07:41+00:00weekly0.6https://www.medthority.com/news/2018/07/eusa--pharma-acquires-world-rights-to-sylvant-from-janssen-sciences---a-drug-approved-to-treat-idiopathic-multicentric-castleman-s-disease-/2021-09-24T07:06:58+00:00weekly0.6https://www.medthority.com/news/2012/03/alcon-acquires-non-usa-rights-to-ocriplasmin-for-vitreomacular-adhesion/2021-09-24T07:01:40+00:00weekly0.6https://www.medthority.com/news/2019/11/cosentyx-shows-encouraging-results-versus-humira-from-first-of-its-kind-head-to-head-trial-in-psoriatic-arthritis--novartis/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2011/12/pixuvri--celltherapeutics--is-refiled-at-the-fda-for-nhl/2021-09-24T07:04:47+00:00weekly0.6https://www.medthority.com/news/2012/07/chmp-refuses-recommendation-of-istodax--celgene--for-t-cell-lymphoma/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2019/09/lilly-announces-positive-registrational-data-for-selpercatinib--loxo-292--in-heavily-pretreated-ret-altered-thyroid-cancers-/2021-09-24T07:19:01+00:00weekly0.6https://www.medthority.com/news/2017/12/novel-compound-restores-immune-response-in-patients-with-melanoma-/2021-09-24T07:13:40+00:00weekly0.6https://www.medthority.com/news/2017/12/national-crossword-puzzle-day/2024-02-19T14:22:33+00:00weekly0.6https://www.medthority.com/news/2014/06/phase-ii-trial-of-olaparib-and-cediranib-show-pfs-benefits-in-ovarian-cancer---astrazeneca/2021-09-24T07:08:03+00:00weekly0.6https://www.medthority.com/news/2018/06/checkmate-214-trial-success-for-opdivo---yervoy--low-dose--v--sunitinib-for-renal-cell-carcinoma-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2019/09/apellis-initiates-phase-iii-prince-trial-of-apl-2-to-treat-paroxysmal-nocturnal-hemoglobinuria--/2021-09-24T07:19:08+00:00weekly0.6https://www.medthority.com/news/2017/01/arymo-er--morphine-sulfate--approved-by-fda-for-pain--egalet-corporation/2021-09-24T07:13:08+00:00weekly0.6https://www.medthority.com/news/2016/09/european-commission-approves-triberzi--eluxadoline--to-treat-irritable-bowel-syndrome-with-diarrhoea--allergan/2021-09-24T07:09:13+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-trial-of-shp-465--triple-bead-mixed-amphetamine-salts--in-adhd-demonstrates-efficacy-and-should-lead-to-resubmission-with-fda--shire/2024-02-19T14:22:46+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---clinical-trials-and-research-priorities-in-dialysis-patients--time-for-a-new-approach-/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2019/09/fremanezumab-data-in-the-lancet-demonstrate-clinically-meaningful-reduction-in-monthly-migraine-days-versus-placebo-for-difficult-to-treat-migraine--teva/2021-09-24T07:19:11+00:00weekly0.6https://www.medthority.com/news/2012/01/zytiga--j-j-janssen-cilag--offers-benefits-for-prostate-cancer-patients-who-are-not-eligible-for-docetaxel-therapy/2021-09-24T07:01:37+00:00weekly0.6https://www.medthority.com/news/2013/11/solo-smart-stentless-aotrtic-valve-gets-ce-mark--sorin/2021-09-24T07:16:29+00:00weekly0.6https://www.medthority.com/news/2019/03/new-data-from-bio-resort--meta-analysis-and-health-economic-evaluation-of-osiro--des-for-treatment-of-cad---biotronik/2021-09-24T07:18:59+00:00weekly0.6https://www.medthority.com/news/2018/05/tecentriq---avastin---chemotherapy-shows-survival-advantage-for-first-line-treatment-of-nsclc-patients---genentech-roche-/2021-09-24T07:07:08+00:00weekly0.6https://www.medthority.com/news/2014/02/chmp-recommends-anoro-ellipta-for-copd---gsk/2021-09-24T07:08:17+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iii-alesia-study-of-alecensa-meets-primary-endpoint-in-alk--nsclc---roche-/2021-09-24T07:05:40+00:00weekly0.6https://www.medthority.com/news/2016/04/eu-approves-giotrif--afatinib--for-advanced-squamous-cell-carcinoma--sqcc--of-the-lung--boehringer/2024-02-19T14:23:01+00:00weekly0.6https://www.medthority.com/news/2014/06/tecfidera-scores-high-for-safety-according-to-adverseevents-report--biogen/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2012/03/nice-does-not-recommend-sprycel--bms--for-cml/2021-09-24T07:01:39+00:00weekly0.6https://www.medthority.com/news/2014/10/positive-phase-iii-data-for-apd-421-in-nausea-acacia-pharma/2021-09-24T07:07:19+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-provides-complete-response-to-filing-of-kpi-121-0-25--in-dry-eye-disease---kala-pharma/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2013/12/updated-analyses-of-pomalyst-imnovid-for-multiple-myeloma--celgene/2021-09-24T07:15:20+00:00weekly0.6https://www.medthority.com/news/2015/04/preliminary-phase-iii-data-for-viekirax---exviera-in-hepatitis-c--abbvie/2021-09-24T07:02:54+00:00weekly0.6https://www.medthority.com/news/2016/01/akebia-therapeutics-initiates-phase-iii-pro2tec-programme-for-vadadustat-to-treat-anaemia-related-to-chronic-kidney-disease/2021-09-24T07:09:09+00:00weekly0.6https://www.medthority.com/news/2016/06/fda-approves-new-dosing-option-for-orfadin--nitisinone--in-hereditary-tyrosinemia-type-1--swedish-orphan-biovitrum/2021-09-24T07:10:00+00:00weekly0.6https://www.medthority.com/news/2018/12/lumateperone-fails-to-meet-endpoint-in-study-201-to-treat-agitation-in-alzheimer-s-patients--intra-cellular-therapies/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2012/09/ec-approves-inlyta--pfizer--for-real-cell-carcinoma/2021-09-24T07:02:01+00:00weekly0.6https://www.medthority.com/news/2012/09/new-data-for-suvorexant--merck-inc---for-treatment-of-insomnia------------------------------/2021-09-24T07:02:00+00:00weekly0.6https://www.medthority.com/news/2020/01/opdivo-did-not-improve-overall-survival-in-ono-4538-23-study-for-recurrent-ovarian-cancer---ono---bms/2021-09-24T07:11:44+00:00weekly0.6https://www.medthority.com/news/2018/02/feraccru-fails-aegis-ckd-pivotal-phase-iii-study-to-treat-iron-deficiency-anemia----shield-therapeutics-/2021-09-24T07:05:55+00:00weekly0.6https://www.medthority.com/news/2016/10/fda-approves-lucentis--ranibizumab-injection--prefilled-syringe-for-age-related-macular-degeneration-and-macular-edema-after-rvo---genentech-roche/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2016/10/allergan-enters-a-license-agreement-with-medimmune-for-the-global-rights-to-crohns-ulcerative-colitis-treatment-medi2070-/2021-09-24T07:10:35+00:00weekly0.6https://www.medthority.com/news/2016/05/eu-chmp-recommends-approval-of-zepatier--grazoprevir-elbasvir--against-chronic--long-term--hepatitis-c--merck/2021-09-24T07:09:25+00:00weekly0.6https://www.medthority.com/news/2016/08/abemaciclib---fulvestrant-has-failed-to-hit-interim-efficacy-targets-in-monarch-2-trial-for-women-with-hormone-receptor-positive--human-epidermal-growth-factor-receptor-2-negative-locally-advanced-or-metastatic-breast-cancer---eli-lilly/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2019/09/genentech-s-fixed-dose-subcutaneous-combination-of-perjeta----herceptin-showed-non-inferiority-when-compared-to-intravenous-formulations-for-her2-positive-breast-cancer-/2024-10-11T11:57:46+00:00weekly0.6https://www.medthority.com/news/2015/09/amg-416--etelcalcetide--filed-with-eu-for-secondary-hyperparathyroidism--amgen/2021-09-24T07:03:52+00:00weekly0.6https://www.medthority.com/news/2020/01/leo-pharma-withdraws-picato--a-treatmemt-for-actinic-keratosis--in-the-eu-/2021-09-24T07:11:49+00:00weekly0.6https://www.medthority.com/news/2015/12/fda-gives-510-k--approval-to-gmate-smart-blood-glucose-monitoring-system-for-diabetes--philosys/2021-09-24T07:04:33+00:00weekly0.6https://www.medthority.com/news/2014/11/eu-s-chmp-recommends-approval-of-cerdelga-for-gaucher-disease-genzyme/2021-09-24T07:08:39+00:00weekly0.6https://www.medthority.com/news/2016/03/new-results-from-study-of-oncotype-dx-diagnostics-system-in-breast-cancer-risk--genomic-health/2024-02-19T14:23:14+00:00weekly0.6https://www.medthority.com/news/2014/12/successful-trial-for--in-pact-admiral-drug-coated-balloon-in-pad-published-in-circulation--medtronic/2021-09-24T07:08:28+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-advisory-committee-recommends-approval-of-ct-p10-for-b-cell-lymphoma--nhl----celltrion---teva-/2021-09-24T07:05:44+00:00weekly0.6https://www.medthority.com/news/2014/07/eu-approve-arzerra-combination-treatment-for-cll-gsk-genmab/2021-09-24T07:08:54+00:00weekly0.6https://www.medthority.com/news/2016/11/-new-data-shows-heli-fx-endoanchor-system-enhances-outcomes-and-durability-in-complex-aortic-disease---medtronic-/2021-09-24T07:09:46+00:00weekly0.6https://www.medthority.com/news/2019/01/phase-i-phase-iii-trial-of-abp-798--rituximab-biosimilar--meets-primary-endpoint-in-rheumatoid-arthritis---amgen---allergan/2021-09-24T07:18:41+00:00weekly0.6https://www.medthority.com/news/2018/07/tecentriq---avastin-combination-in-phase-iii-trial-to-treat-liver-cancer---genentech---roche-/2021-09-24T07:06:59+00:00weekly0.6https://www.medthority.com/news/2013/01/nexavar--bayer--success-in-phase-iii-trial-for-thyroid-cancer/2021-09-24T07:15:54+00:00weekly0.6https://www.medthority.com/news/2016/08/ce-mark-for-avad-intraventricular-heart-pump-from-reliantheart-inc-/2021-09-24T07:09:42+00:00weekly0.6https://www.medthority.com/news/2019/03/biogen-acquires-nightstar-therapeutics-and-with-it-nsr-rep1-for-the-treatment-of-choroideremia/2021-09-24T07:19:00+00:00weekly0.6https://www.medthority.com/news/2017/08/phase-iii-alcyone-study--mmy3007--of-daratumumab-in-combination-with-bortezomib--melphalan-and-prednisone--vmp--versus-vmp-alone-as-front-line-treatment-for-newly-diagnosed-patients-in-front-line-multiple-myeloma--janssen-biotech/2021-09-24T07:14:52+00:00weekly0.6https://www.medthority.com/news/2011/10/nice-rejects-jevtana-for-prostate-cancer/2021-09-24T07:05:04+00:00weekly0.6https://www.medthority.com/news/2014/08/eylea-approved-by-european-commission-to-treat-diabetic-macular-edema---bayer-regeneron/2021-09-24T07:07:31+00:00weekly0.6https://www.medthority.com/news/2019/05/nejm-publishes-interim-results-from-phase-i-trial-of-bb-2121-for-multiple-myeloma--bluebird-bio---celgene-/2021-09-24T07:17:42+00:00weekly0.6https://www.medthority.com/news/2015/10/phase-iii-trial-of-stelara--ustekinumab--meets-endpoint-in-crohns-disease--janssen-r-d/2024-02-19T14:23:27+00:00weekly0.6https://www.medthority.com/news/2016/03/prostrakan-kyowa-hakko-kirin-to-market-moventig--naloxegol--to-treat-opioid-induced-constipation-in-the-eu--astrazeneca/2021-09-24T07:10:27+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-mulpleta-to-treat--thrombocytopenia-in-adult-patients-with-chronic-liver-disease---shionogi-/2021-09-24T07:06:20+00:00weekly0.6https://www.medthority.com/news/2019/11/pivotal-data-from-phase-iii-study-of-sutimlimab-in-cold-agglutinin-disease-to-be-presented-at-ash-2019-meeting---sanofi/2021-09-24T07:17:52+00:00weekly0.6https://www.medthority.com/news/2018/07/novartis-to-spinoff-alcon-as-a-separately-traded-standalone-company-/2021-09-24T07:07:03+00:00weekly0.6https://www.medthority.com/news/2012/03/aegerion-pharma-files-lomitapide-for-hofh-at-ema-and-fda/2021-09-24T07:01:42+00:00weekly0.6https://www.medthority.com/news/2016/05/two-phase-iii-trials-show-efficacy-of-s-297995--naldemedine--in-opioid-induced-constipation--shionogi-/2021-09-24T07:09:27+00:00weekly0.6https://www.medthority.com/news/2012/08/nexium-astrazeneca--to-be-otc-marketed-by-pfizer/2021-09-24T07:02:31+00:00weekly0.6https://www.medthority.com/news/2013/09/phase-iii-cruise-2-study-of-sfp-success-for-iron-deficiency-/2021-09-24T07:16:01+00:00weekly0.6https://www.medthority.com/news/2019/02/phase-iii-columba-study-of-darzalex-multiple-myeloma-met-both-co-primary-endpoints-in-multiple-myeloma---genmab/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2015/09/successful-12-months-follow-up-for-eccs-50-in-scleradec-i-trial-for-scleroderma--cytori-therapeutics/2024-02-19T14:23:45+00:00weekly0.6https://www.medthority.com/news/2016/09/acelity-inc--announces-global-launch-of-prevena-plus-incision-management-system-for-wound-closure-/2021-09-24T07:09:20+00:00weekly0.6https://www.medthority.com/news/2018/03/nice-draft-guidance-does-not-support-the-use-of-oxervate-cenegermin-for-neurotrophic-keratitis-dompe/2024-10-21T14:37:50+00:00weekly0.6https://www.medthority.com/news/2013/03/phase-iii-success-for-androxal--repros-therapeutics--for-hypogonadism-/2021-09-24T07:15:37+00:00weekly0.6https://www.medthority.com/news/2018/10/phase-iv-interim-data-on--h-p--acthar-gel-shows-reduced-disease-activity-in-rheumatoid-arthritis---mallinckrodt-/2021-09-24T07:05:41+00:00weekly0.6https://www.medthority.com/news/2015/11/-sar-153191--sarilumab--bla-is-filed-at-fda-to-treat-rheumatoid-arthritis--regeneron---sanofi/2021-09-24T07:04:25+00:00weekly0.6https://www.medthority.com/news/2017/11/fda-accepts-nda-for-idp-118---a-topical-treatment-for-plaque-psoriasis---ortho-dermatologics-valeant-/2021-09-24T07:14:47+00:00weekly0.6https://www.medthority.com/news/2013/01/sanofi-genzyme-files-lemtrada-at-fda-for-treatment-of-multiple-sclerosis/2021-09-24T07:15:48+00:00weekly0.6https://www.medthority.com/news/2012/04/emerge-study-of-lambda--bms--in-hepatitis-c-genotypes-2-and-3-presented-at-easl/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2017/11/world-aids-day-2017/2024-02-22T11:05:39+00:00weekly0.6https://www.medthority.com/news/2019/04/ema-approves-lynparza-to-treat-patients-with-germline-brca1-2-mutations--gbrcam--with--her2-negative-metastatic-breast-cancer--astrazeneca---merck-inc-/2021-09-24T07:16:47+00:00weekly0.6https://www.medthority.com/news/2018/06/chmp-recommends-myalepta-as-a-treatment-for-the-complications-of-leptin-deficiency-in-lipodystrophy---novelion-therapeutics-/2021-09-24T07:05:37+00:00weekly0.6https://www.medthority.com/news/2019/06/zogenix-will-resubmit-its-nda-for-fintepla-to-treat-seizures-associated-with-dravet-syndrome-in-q3-2019-/2021-09-24T07:16:51+00:00weekly0.6https://www.medthority.com/news/2019/10/fda-approves-xarelto-to-help-prevent-blood-clots-in-acutely-ill-medical-patients---bayerhealthcare---janssen-r-d/2021-09-24T07:17:22+00:00weekly0.6https://www.medthority.com/news/2016/04/phase-iii-c-edge-trial-with-zepatier--elbasvir-and-grazoprevir--shows-superiority-to-sofosbuvir-in-hepatitis-c-infection--merck/2021-09-24T07:10:42+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-approves-synergy-bioabsorbable-polymer-drug-eluting-stent-system-to-treat-coronary-artery-disease--boston-scientific/2021-09-24T07:03:20+00:00weekly0.6https://www.medthority.com/news/2014/04/phase-iii-trial-of-lcz-696-for-heart-failure-closes-early---novartis/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2019/08/fda-advisory-committee-s-recommendation-on-descovy-for-pre-exposure-prophylaxis---gilead-sciences/2021-09-24T07:17:49+00:00weekly0.6https://www.medthority.com/news/2016/10/bi-695501--adalumimab-biosimilar--meets-primary-endpoint-in-phase-iii-trial-for-rheumatoid-arthritis--boehringer-/2021-09-24T07:10:29+00:00weekly0.6https://www.medthority.com/news/2019/07/janssen-biotech-applied-to-ema-for-extension-of-the-darzalex-marketing-authorization-for-subcutaneous--formulation-in-multiple-myeloma-indications-/2021-09-24T07:18:08+00:00weekly0.6https://www.medthority.com/news/2016/11/triple-therapy--fluticasone-furoate-umeclidinium-vilanterol--filed-with-fda-for-chronic-obstructive-pulmonary-disease--glaxosmithkline-and-innoviva/2021-09-24T07:09:45+00:00weekly0.6https://www.medthority.com/news/2019/05/study-shows-reduced-incidence-of-post-operative-cystoid-macular-edema-with-omidria---omeros/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2015/10/fda-investigates-theranos-system-blood-testing-devices-and-procedures/2021-09-24T07:03:10+00:00weekly0.6https://www.medthority.com/news/2015/01/chmp-recommends-eylea--aflibercept--for-macular-edema-secondary-to-retinal-vein-occlusion--rvo--including-brvo--bayer-healthcare---regeneron/2021-09-24T07:03:23+00:00weekly0.6https://www.medthority.com/news/2017/12/long-term-data-from-zuma-1-study-of--yescarta-in-patients-with-refractory-large-b-cell-lymphoma--kite-gilead-/2021-09-24T07:13:38+00:00weekly0.6https://www.medthority.com/news/2017/01/sanofi-pasteur-and-merck-inc--terminate-their-joint-venture-in-vaccines-in-europe-/2021-09-24T07:13:11+00:00weekly0.6https://www.medthority.com/news/2017/09/fda-approves-supplemental-new-drug-application-for-briviact--brivaracetam--as-monotherapy-for-partial-onset-seizures-in-patients-16-years-and-older-with-epilepsy---ucb-/2021-09-24T07:13:53+00:00weekly0.6https://www.medthority.com/news/2012/12/study-shows-pet-scans-with-amyvid--cardinal-health--provides-significant-value-in-treating-patients-with-cognitive-impairment-/2021-09-24T07:02:42+00:00weekly0.6https://www.medthority.com/news/2018/12/eu-approves-keytruda-for-stage-iii-melanoma-and-lymph-node-involvement-after-resection---merck-inc-/2021-09-24T07:06:06+00:00weekly0.6https://www.medthority.com/news/2015/01/additional-benefit-of-halaven-in-breast-cancer-confirmed-by-g-ba---eisai/2021-09-24T07:03:24+00:00weekly0.6https://www.medthority.com/news/2015/11/zerbaxa--ceftolozane---tazobactam--is-launched-in-the-uk-merck-inc-/2021-09-24T07:04:19+00:00weekly0.6https://www.medthority.com/news/2014/04/topotarget-and-bioalliance-to-merge/2025-10-16T11:11:34+00:00weekly0.6https://www.medthority.com/news/2013/07/the-medicines-company-files-cangrelor-at-fda-to-treat-pci/2021-09-24T07:15:29+00:00weekly0.6https://www.medthority.com/news/2017/03/two-phase-iii-studies-reported-of--tezacaftor--vx-661----ivacaftor-combination-of-cystic-fibrosis-transmembrane-conductance-regulator--cftr--gene-affected-patients--vertex/2021-09-24T07:14:17+00:00weekly0.6https://www.medthority.com/news/2015/11/fda-approves-harvoni--ledipasvir---sofosbuvir--for-hepatitis-c---hiv--gilead-sciences/2024-02-19T14:23:57+00:00weekly0.6https://www.medthority.com/news/2016/05/crestor-us-patent-to-expire--astrazeneza/2021-09-24T07:09:35+00:00weekly0.6https://www.medthority.com/news/2016/04/fda-issues-complete-response-letter-to-otsuka-and-proteus-relating-to-their-digital-medicine-system-which-measures-adherence-to-treatment-for-schizophrenia--depression-and-bipolar-disorders/2021-09-24T07:10:37+00:00weekly0.6https://www.medthority.com/news/2019/02/baricitinib-success-in-two-phase-iii-breeze-ad1-and-breeze-ad2-trials-for-atopic-dermatitis--eli-lilly---incyte/2021-09-24T07:17:14+00:00weekly0.6https://www.medthority.com/news/2018/09/overall-survival-data-from-pacific-trial-of-imfinzi-for-nsclc-is-published-in-nejm--astrazeneca/2021-09-24T07:06:40+00:00weekly0.6https://www.medthority.com/news/2015/10/five-year-study-of-lap-band-device-for-obesity-published-in-international-journal-of-obesity--apollo-endosurgery/2024-02-19T14:24:20+00:00weekly0.6https://www.medthority.com/news/2019/07/omeros-corpn---announces-agreement-with--the-fda-on-primary-endpoint-for-narsoplimab-bla-in-stem-cell-transplant-associated-thrombotic-microangiopathy-/2021-09-24T07:18:16+00:00weekly0.6https://www.medthority.com/news/2017/06/new-imaging-technique-may-help-identify-joint-inflammation-in-children-earlier-with-greater-confidence/2021-09-24T07:15:05+00:00weekly0.6https://www.medthority.com/news/2018/02/fda-approves-dexycu-for-inflammation-associated-with-cataract-surgery---icon-bioscience-/2021-09-24T07:05:59+00:00weekly0.6https://www.medthority.com/news/2014/07/fixture-and-erasure-studies-of-secukinumab-for-plaque-psoriasis-reported-in-nejm--novartis/2021-09-24T07:08:52+00:00weekly0.6https://www.medthority.com/news/2020/02/ce-mark-for-orsiro-mission-drug-eluting-stent-system---biotronik/2021-09-24T07:11:57+00:00weekly0.6https://www.medthority.com/news/2019/02/european-commission-approves-sprycel-for-pediatric-patients-with--ph---acute-lymphoblastic-leukemia---bms/2021-09-24T07:17:12+00:00weekly0.6https://www.medthority.com/news/2018/05/world-lupus-day-/2021-09-24T07:07:09+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---nephrology-and-public-policy-committee--nppc--aims-to-intensify-research-activity/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2017/09/chmp-recommends-ontruzant---trastuzumab-biosimilar--to-treat-breast-cancer-and-gastric-cancer--sampsung-bioepis---merck-inc-/2021-09-24T07:13:52+00:00weekly0.6https://www.medthority.com/news/2017/06/cosentyx--secukinumab--shows-sustained-improvements-in-the-signs-and-symptoms-for-active-ankylosing-spondylitis--as--at-3-years--consistent-with-previous-findings-in-active-psoriatic-arthritis--psa--at-3-years---novartis/2021-09-24T07:15:03+00:00weekly0.6https://www.medthority.com/news/2012/06/relday-from-zogenix-is-filed-at-fda-for-schizophrenia/2021-09-24T07:02:25+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trial-of-ccd-1042--ganaxolone--in-focal-onset-seizures-fails-to-meet-endpoint--marinus-pharmaceuticals/2021-09-24T07:10:01+00:00weekly0.6https://www.medthority.com/news/2012/08/zetonna--sunovion--launched-in-us-for-allergic-rhinitis/2021-09-24T07:02:35+00:00weekly0.6https://www.medthority.com/news/2016/11/aptima-hsv-1---2-assay-receives-eu-ce-mark-approval-as-a-diagnostic-for-herpes-simplex-virus--hologic/2021-09-24T07:09:48+00:00weekly0.6https://www.medthority.com/news/2016/09/successful-phase-iii-arise-study-of-amg-334--erenumab--in-episodic-migraine-prevention-novartis/2021-09-24T07:09:12+00:00weekly0.6https://www.medthority.com/news/2017/09/eu-approves-rydapt--midostaurin--for-adults-with-newly-diagnosed-acute-myeloid-leukemia-who-are-flt3-mutation-positive-and-for-the-treatment-of-adults-with-aggressive-systemic-mastocytosis---novartis-/2021-09-24T07:13:49+00:00weekly0.6https://www.medthority.com/news/2013/03/study-shows-neupro--ucb--improves-gi-symptoms-in-parkinsons-patients/2021-09-24T07:15:39+00:00weekly0.6https://www.medthority.com/news/2018/01/nice-final-guidance-supports-zykadia-for-alk--non-small-cell-lung-cancer---novartis-/2021-09-24T07:05:08+00:00weekly0.6https://www.medthority.com/news/2019/07/fda-approves-myxredlin-for-use-as-a-short-acting-human-insulin-to-improve-glycemic-control-in--patients-with-diabetes-mellitus--baxter-/2021-09-24T07:18:06+00:00weekly0.6https://www.medthority.com/news/2018/10/fda-approves-kyprolis--once-weekly-dosing-option---dexamethasone-for-relapsed-or-refractory-multiple-myeloma--amgen/2021-09-24T07:05:46+00:00weekly0.6https://www.medthority.com/news/2015/12/advisory-committee-recommends-reslizumab-to-treat-asthma-in-patients-with-elevated-blood-eosinophils--teva/2021-09-24T07:04:30+00:00weekly0.6https://www.medthority.com/news/2015/10/sandoz-files-bla-at-fda-for-etanercept-biosimilar/2021-09-24T07:03:21+00:00weekly0.6https://www.medthority.com/news/2018/11/nice-reverses-earlier-ruling-and-recommends-use-of-stivarga-in-liver-cancer---bayer-healthcare-/2021-09-24T07:06:48+00:00weekly0.6https://www.medthority.com/news/2017/08/real-world-data-from-among-non-valvular-atrial-fibrillation--nvaf--patients-shows-eliquis--apixaban--reduces-risk-of-stroke--bms-pfizer-/2021-09-24T07:14:51+00:00weekly0.6https://www.medthority.com/news/2011/04/menactra--sanofi-pasteur--indication-is-expanded-by-fda/2021-09-24T07:04:48+00:00weekly0.6https://www.medthority.com/news/2014/03/fda-approves-iv-noxafil-for-fungal-infections---merck/2021-09-24T07:08:25+00:00weekly0.6https://www.medthority.com/news/2016/06/sle-patients-experienced-a-significantly-greater-response-to-treatment-with-benlysta--belimumab--200mg-administered-via-subcutaneous-injection-plus-standard-of-care--soc---compared-to-placebo-plus-soc---gsk/2021-09-24T07:10:03+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---still-an-unmet-need--new-therapeutic-targets-in-alport-syndrome/2021-09-24T07:18:12+00:00weekly0.6https://www.medthority.com/news/2016/06/eu-chmp-approves-change-to-authorisation-for-cervarix-vaccine-in-prevention-of-premalignant-ano-genital-lesions--cervical--vulvar--vaginal-and-anal--and-cervical-and-anal-cancers--glaxosmithkline/2021-09-24T07:09:57+00:00weekly0.6https://www.medthority.com/news/2017/12/adjuvant-trastuzumab-did-not-improve-outcomes-for-patients-with-her2-low-breast-cancer-/2024-10-22T08:21:55+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-jornay-pm-to-treat-adhd-symptoms---ironshore-pharma---development-inc-/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2018/05/valeant-pharmaceuticals-international-to-be-renamed-bausch-health-companies-inc-/2025-10-17T09:16:29+00:00weekly0.6https://www.medthority.com/news/2018/12/fda-extends-pdufa-date-for-solriamfetol-as-a-treatment-to-improve-wakefulness-and-reduce-excessive-daytime-sleepiness----jazz-pharma/2021-09-24T07:06:05+00:00weekly0.6https://www.medthority.com/news/2012/07/selzentry-celsentri-viiv--in-trial-for-hiv-prevention/2021-09-24T07:01:46+00:00weekly0.6https://www.medthority.com/news/2016/08/allergan-plc-acquires-forsight-vision5-and-with-it-a-peri-ocular-ring-designed-for-extended-drug-delivery-and-reducing-elevated-intraocular-pressure--iop--in-glaucoma-patients-/2021-09-24T07:09:41+00:00weekly0.6https://www.medthority.com/news/2018/11/fda-approves-gamifant--to-treat-patients-with-primary-haemophagocytic-lymphohistiocytosis----sobi/2021-09-24T07:06:50+00:00weekly0.6https://www.medthority.com/news/2012/07/fda-accepts-filing-of-hepislav---dynavax-technologies--vaccine-for-hepatitis-b/2021-09-24T07:01:50+00:00weekly0.6https://www.medthority.com/news/2018/11/theravance-biopharma-sells-vibativ-to-cumberland-pharma-/2021-09-24T07:06:54+00:00weekly0.6https://www.medthority.com/news/2019/06/oral-shift-phase-iiib-iv-study-of-xeljanz-xr-shows-efficacy-in-rheumatoid-arthritis---pfizer/2021-09-24T07:16:59+00:00weekly0.6https://www.medthority.com/news/2018/09/enrollment-completed-in-phase-iii-trial-of-teprotumumab-in-patients-living-with-moderate-to-severe-active-thyroid-eye-disease---horizon-pharma-/2021-09-24T07:06:47+00:00weekly0.6https://www.medthority.com/news/2015/09/chmp-recommends-cotellic--cobimetinib----zelboraf--vemurafenib--to-treat-braf-v600-mutation-positive-unresectable-or-metastatic-melanoma--roche/2024-02-19T14:24:34+00:00weekly0.6https://www.medthority.com/news/2015/03/phase-iii-trial-of-rescula-in-retinitis-pigmentosa-fails-to-meet-end-point-r-tech-ueno/2021-09-24T07:04:14+00:00weekly0.6https://www.medthority.com/news/2019/05/fda-expands-labeling-of-impella-5-0-and-ld-for-cardiogenic-shock/2021-09-24T07:17:36+00:00weekly0.6https://www.medthority.com/news/2018/08/fda-approves-azedra-for-pheochromocytoma---progenics-pharmaceuticals-/2021-09-24T07:06:21+00:00weekly0.6https://www.medthority.com/news/2018/02/anti-obesity-programmes-in-schools-unlikely-to-halt-child-obesity-epidemic/2024-02-19T14:25:43+00:00weekly0.6https://www.medthority.com/news/2014/08/medtronic-acquires-sapiens-steering-brain-stimulation-for--200-million/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2018/08/royal-philips-has-introduced-the-epiq-cvx-cardiovascular-ultrasound-system-/2021-09-24T07:06:15+00:00weekly0.6https://www.medthority.com/news/2019/02/fda-approves-esperoct-to-treat-haemophilia-a---novo-nordisk/2021-09-24T07:17:08+00:00weekly0.6https://www.medthority.com/news/2017/02/data-review-of-phase-iii-study-of-macrilen--macimorelin--for-the-evaluation-of-growth-hormone-deficiency-in-adults---aeterna-zentaris-inc--/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2019/06/fda-accepts-nda-for-combination-of-empagliflozin--linagliptin-and-metformin-extended-release-for-the-treatment-of-adults-with-type-2-diabetes---boehringer---eli-lilly-/2021-09-24T07:17:02+00:00weekly0.6https://www.medthority.com/news/2014/04/venaxis-files-appy1-test-for-appendicitis-with-fda---venaxis/2021-09-24T07:07:28+00:00weekly0.6https://www.medthority.com/news/2015/07/novo-nordisk-withdraws-tresiba--insulin-degludec--from-germany-due-to-price-negotiations/2021-09-24T07:04:40+00:00weekly0.6https://www.medthority.com/news/2013/03/lundbeck-and-otsuka-expand-collaboration-relating-to-abilify/2021-09-24T07:15:46+00:00weekly0.6https://www.medthority.com/news/2014/06/fda-approves-generic-cymbalta-for-dr-reddy/2021-09-24T07:07:53+00:00weekly0.6https://www.medthority.com/news/2016/05/fda-approves-sms--gobrain-neuro-mri-applications-to-reduce-time-for-mri-brain-scans--siemens/2021-09-24T07:09:34+00:00weekly0.6https://www.medthority.com/news/2019/05/results-of-flare-study-of-flowtriever-system-in-pulmonary-embolism-published-in-jacc---inari-medical/2021-09-24T07:17:40+00:00weekly0.6https://www.medthority.com/news/2014/09/two-new-papers-on-inspire-uas-for-osa-inspire-medical-systems/2021-09-24T07:07:42+00:00weekly0.6https://www.medthority.com/news/2017/03/fda-grants-accelerated--approval-for-bavencio--avelumab-to-treat-merkel-cell-carcinoma---merck-kgaa---pfizer/2021-09-24T07:14:18+00:00weekly0.6https://www.medthority.com/news/2015/10/shingrix-vaccine-succeeds-in-second-phase-iii-study-for-herpes-zoster--shingles--gsk/2024-02-19T14:33:37+00:00weekly0.6https://www.medthority.com/news/2018/07/overstitch-sx-endoscopic-suturing-system-receives-510-k--approval-for-endoscopic-suturing----apollo-endosurgery--inc-/2021-09-24T07:07:01+00:00weekly0.6https://www.medthority.com/news/2017/06/fda-grants-510-k--approval-for-bioplex-2200-syphilis-total---rpr-assay-to-diagnosis-syphilis-infection--bio-rad-laboratories/2021-09-24T07:15:04+00:00weekly0.6https://www.medthority.com/news/2016/10/ema-chmp-recommends-approval-of-ocaliva--obeticholic-acid--for-primary-biliary-cholangitis--intercept-pharmaceuticals/2021-09-24T07:10:32+00:00weekly0.6https://www.medthority.com/news/2017/11/male-pattern-baldness-and-premature-greying-associated-with-risk-of-early-heart-disease/2024-02-19T14:35:46+00:00weekly0.6https://www.medthority.com/news/2017/02/ablynx-n-v--has-submitted-a-marketing-authorisation-application-to-the-european-medicines-agency--for-approval-of-caplacizumab-for-the-treatment-of-acquired-thrombotic-thrombocytopenic-purpura-/2021-09-24T07:13:18+00:00weekly0.6https://www.medthority.com/news/2015/04/pabal--carbetocin--new-formulation-approved-through-eu-mutual-recognition-procedure-for-prevention-of-uterine-atony-and-postpartum-haemorrhage---ferring/2021-09-24T07:02:59+00:00weekly0.6https://www.medthority.com/news/2018/06/real-world-data-shows-treatment-advantages-of-trulicity-over-once-daily-liraglutide-and-once-weekly-exenatide-qw-for-type-2-diabetes--eli-lilly-/2021-09-24T07:05:29+00:00weekly0.6https://www.medthority.com/news/2016/01/phase-iii-program-initiated-fortrv-130--oliceridin--for-treatment-of-moderate-to-severe-pain--trevena-inc-/2024-02-19T14:35:58+00:00weekly0.6https://www.medthority.com/news/2019/10/galmed-pharmaceuticals-initiated-armor--a-phase-iii-iv-registrational-study-of-aramchol-in-subjects-with-nash-and-fibrosis-/2021-09-24T07:17:28+00:00weekly0.6https://www.medthority.com/news/2016/11/uk-s-nice-rejects-the-use-of-kyprolis--carfilzomib--based-combination-therapy-in-multiple-myeloma--amgen-/2021-09-24T07:09:52+00:00weekly0.6https://www.medthority.com/news/2018/04/four-years-of-continuous-treatment-benefits-were-sustained-by-ocrevus-for-relapsing-multiple-sclerosis-patients---genentech-roche-/2021-09-24T07:05:19+00:00weekly0.6https://www.medthority.com/news/2015/01/valeant-pharma-to-acquire-assets-from-dendreon-including-provenge--sipuleucel-t--for--296-million/2021-09-24T07:03:22+00:00weekly0.6https://www.medthority.com/news/2019/11/ema-validates-maa-for-vx-445--triple-combination-treatment-in-cystic-fibrosis--vertex/2021-09-24T07:18:02+00:00weekly0.6https://www.medthority.com/news/2012/10/phase-ii-success-for-odanacatib--merck-inc---for-post-menopausal-osteoporosis------------------------------/2021-09-24T07:02:17+00:00weekly0.6https://www.medthority.com/news/2019/07/era-edta-2019---linagliptin-improved-albuminuria-but-had-no-effect-on-egfr-and-cv-risk-in-patients-with-diabetes/2021-09-24T07:18:11+00:00weekly0.6https://www.medthority.com/news/2016/05/uk-nice-does-not-recommend-portrazza--necitumumab--for-treating-non-small-cell-lung-cancer--eli-lilly/2021-09-24T07:09:26+00:00weekly0.6https://www.medthority.com/news/2013/04/phase-ii-data-shows-pci-32765--pharmacyclics-inc---provides-sustained-control-in-cll-patients-/2021-09-24T07:16:40+00:00weekly0.6https://www.medthority.com/news/2018/12/new-data-from-phase-1-ii-hgb-206-study-of-lentiglobin-gene-therapy-in-patients-with-sickle-cell-disease--bluebird-bio-/2021-09-24T07:06:10+00:00weekly0.6https://www.medthority.com/news/2018/04/phase-iii-echo-301-keynote-252-study-of-epacadostat---keytruda-for-metastatic-melanoma-did-not-meet-endpoints--incyte---merck-inc-/2021-09-24T07:05:25+00:00weekly0.6https://www.medthority.com/news/2019/10/recordati-completes-acquisition-of-signifor--signifor-lar-and-osilodrostat-from-novartis-/2021-09-24T07:17:17+00:00weekly0.6https://www.medthority.com/news/2015/12/xalkori--crizotinib--filed-with-fda-for-ros-1-positive-non-small-cell-lung-cancer--pfizer-/2021-09-24T07:04:31+00:00weekly0.6https://www.medthority.com/news/2015/01/fda-approves-rytary-for-parkinsons-impax-pharma/2021-09-24T07:03:28+00:00weekly0.6https://www.medthority.com/news/2018/11/phase-iii-help-study-of-takhzyro-shows-reduction-in-attacks-of-hereditary-angioedema---shire-/2021-09-24T07:06:51+00:00weekly0.6https://www.medthority.com/news/2014/05/phase-iii-results-for-the-combo-dual-therapy-stent-for-cad---orbus-neich/2021-09-24T07:08:07+00:00weekly0.6https://www.medthority.com/news/2018/06/akebia-therapeutics-and-keryx-biopharmaceuticals-to-merge-and-combine-development-of-auryxia-and-vadadustat-for-ckd/2021-09-24T07:05:27+00:00weekly0.6https://www.medthority.com/news/2012/03/fda-rejects-prochieve-watson-pharma--for-risk-reduction-in-preterm-birth/2021-09-24T07:01:44+00:00weekly0.6https://www.medthority.com/news/2015/09/results-from-trial-of-vgx-3100-vaccine-published-in-the-lancet-inovio-pharma/2024-02-19T14:36:18+00:00weekly0.6https://www.medthority.com/news/2018/06/fda-approves-eversense--continuous-glucose-monitoring--cgm--system--senseonics-holdings-/2021-09-24T07:05:30+00:00weekly0.6https://www.medthority.com/news/2019/02/ce-mark-for-pascal-transcatheter-valve-repair-system-for-reduction-of-mitral-regurgitation----edwards-lifesciences/2021-09-24T07:17:09+00:00weekly0.6https://www.medthority.com/news/2018/08/medtronic-initiates-pilot-study-for-the--extravascular-implantable-cardioverter-defibrillator--/2021-09-24T07:06:17+00:00weekly0.6https://www.medthority.com/news/2015/09/fda-approves-vraylar--cariprazine---for-schizophrenia-and-bipolar-disorder-allergan/2021-09-24T07:03:46+00:00weekly0.6https://www.medthority.com/news/2017/02/metiv-hcc-phase-iii-study-of-arq-197--tivantinib--in-hepatocellular-carcinoma-fails-to-meet-endpoint--arqule-and-daiichi-sankyo/2021-09-24T07:13:13+00:00weekly0.6https://www.medthority.com/news/2013/07/study-on-cialis--eli-lilly--in-men-with-erectile-dysfunction-published-in-journal-of-sexual-medicine/2021-09-24T07:15:27+00:00weekly0.6https://www.medthority.com/news/2017/07/resubmission-of-olumiant--baricitinib--to-the-fda-for-the-treatment-of-rheumatoid-arthritis-will-be-delayed-beyond-2017--eli-lilly---incyte-corporation/2021-09-24T07:14:04+00:00weekly0.6https://www.medthority.com/news/2016/06/phase-iii-trials-of-invokana--canagliflozin--show-blood-glucose-control-and-other-improvements-in-type-2-diabetes--janssen-pharmaceuticals/2021-09-24T07:10:02+00:00weekly0.6https://www.medthority.com/news/2017/10/clareon--the-intraocular-lens--iol-is-to-be-launched-at-european-society-of-cataract---refractive-surgeons--escrs--congress--alcon-novartis-/2021-09-24T07:13:31+00:00weekly0.6https://www.medthority.com/news/2019/12/update-on-phase-iii-study-p301-of-spn-810-explains-variability-of-impulsive-aggression-control-in-adhd---supernus-pharma/2021-09-24T07:18:33+00:00weekly0.6https://www.medthority.com/news/2012/04/fda-approves-femtosecond--abbott-medical-optics--for-corneal-surgery/2021-09-24T07:01:52+00:00weekly0.6https://www.medthority.com/news/2016/09/valeant-pharmaceuticals-and-progenics-announce-the-us-launch-of-relistor--methylnaltrexone-bromide---tablets-to-treat-opioid-induced-constipation-in-adults-with-chronic-non-cancer-pain--/2021-09-24T07:09:21+00:00weekly0.6https://www.medthority.com/news/2016/04/bms-files-sbla-at-fda-for-opdivo--nivolumab--to-treat-classical-hodgkin-lymphoma-/2024-02-20T08:41:02+00:00weekly0.6https://www.medthority.com/news/2012/09/new-quality-of-life-data-presented-for-tomtovok--boehringer--treated-patients-with-nsclc/2021-09-24T07:01:56+00:00weekly0.6https://www.medthority.com/news/2019/06/phase-iiib-trial-of-linzess-meets-endpoints-in-irritable-bowel-syndrome-with-constipation---ironwood-pharma-allergan/2021-09-24T07:16:54+00:00weekly0.6https://www.medthority.com/news/2015/09/results-for-fx-006-in-osteoarthritis-of-the-knee-study--flexion-therapeutics/2021-09-24T07:03:50+00:00weekly0.6https://www.medthority.com/news/2010/12/elacyt--clavis-pharma--gets-fda-fast-track-status-for-aml/2021-09-24T07:01:28+00:00weekly0.6https://www.medthority.com/news/2012/05/positive-data-from-voyager-trial-of-crestor--astrazeneca--for-dyslipidemia-patients/2021-09-24T07:02:44+00:00weekly0.6https://www.medthority.com/news/2018/04/promethera-biosciences-sa-acquires-baliopharm-ag-/2021-09-24T07:05:23+00:00weekly0.6https://www.medthority.com/news/2013/09/dalbavancin-is-filed-at-fda-for-acute-bacterial-skin-and-skin-structure-infections-/2021-09-24T07:15:55+00:00weekly0.6https://www.medthority.com/news/2013/06/phase-iii-studies-of-vec-162--vanda-pharmaceuticals--meet-primary-endpoint-for-non-24-hour-disorder-/2021-09-24T07:16:07+00:00weekly0.6https://www.medthority.com/news/2016/12/fda-refuses-a-filing-application-for-xaracoll--bupivacaine-collagen-matrix--in-pain-treatment--innocoll-/2021-09-24T07:10:07+00:00weekly0.6https://www.medthority.com/news/2025/1/additional-phase-ii-data-and-phase-iii-program-design-for-lonigutamab-in-thyroid-eye-disease-announced-by-acelyrin-inc/2025-01-08T12:39:19+00:00weekly0.6https://www.medthority.com/news/2025/1/cassava-sciences-and-business-update/2025-01-08T12:42:45+00:00weekly0.6https://www.medthority.com/news/2025/1/-mhra-uk-has-granted-a-conditional-marketing-authorisation-to-imdylltra-tarlatamab-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-.--amgen2025-01-07T13:18:32+00:00weekly0.6https://www.medthority.com/news/2025/1/nmpa--china-approves-vyloyzolbetuximab---chemotherapy-to-treat-her2-negative-gastric-or-gej-adenocarcinoma-claudin-cldn-18.2-positive-tumours.--astellas-pharma2025-01-07T13:20:45+00:00weekly0.6https://www.medthority.com/news/2025/1/elucidation-of-part-of-the-mechanism-by-which-lecanemab-slows-the-progression-of-alzheimers-disease---eisai/2025-01-07T13:26:24+00:00weekly0.6https://www.medthority.com/news/2025/1/bayer-submits-application-in-china-for-third-indication-of-darolutamide/2025-01-23T13:52:54+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-nda--for--pyrukynd-mitapivat-for-the-treatment-of-adult-patients-with-non-transfusion-dependent-and-transfusion-dependent-alpha--or-beta-thalassemia.--agios-pharma2025-01-09T12:22:51+00:00weekly0.6https://www.medthority.com/news/2025/1/als-platform-trial-with-fosigotifator-did-not-meet-its-primary-endpoint---calico-life-sciences/2025-01-09T12:26:08+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-topline-results-announced-of-thephase-iii-study-oasis-4-of-elinzanetant-as-non-hormonal-treatment-for-vasomotor-symptoms-caused-by-adjuvant-endocrine-therapy-in-women-with-breast-cancer-.--bayer2025-02-03T15:11:47+00:00weekly0.6https://www.medthority.com/news/2025/1/galapagos-to-separate-into-two-entities/2025-01-09T12:35:04+00:00weekly0.6https://www.medthority.com/news/2025/1/boston-scientific-acquires-bolt-medicalthe-developer-of-an-intravascular-lithotripsy-laser-based-platform/2025-01-09T12:47:16+00:00weekly0.6https://www.medthority.com/news/2025/1/exceptional-launch-for-ohtuvayre-ensifentrine-for-the-maintenance-treatment-of-chronic-obstructive-pulmonary-disease.--verona-pharma2025-01-10T12:30:27+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-approves--extended-indication-for--palforzia--defatted-powder-ofarachis-hypogaeal.-semen-peanut-for--toddlers-with-a-confirmed-diagnosis-of-peanut-allergy..-stallergenes-greer2025-01-10T13:11:27+00:00weekly0.6https://www.medthority.com/news/2025/1/b7-h3-targeted-antibody-drug-conjugate-gsk5764227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma--gsk/2025-01-10T13:14:55+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-revised-appliction-of--izervay-avacincaptad-pegol-that-aims-to-add-positive-two-year-clinical-trial-data-to-the-drugs-label.---astellas2025-01-11T13:01:47+00:00weekly0.6https://www.medthority.com/news/2025/1/shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-us-fda---gsk/2025-01-11T12:52:41+00:00weekly0.6https://www.medthority.com/news/2025/1/lilly-and-rigel-enter-strategic-collaboration-to-develop-ripk1-inhibitors-for-the-treatment-of-immunological-and-neurodegenerative-diseases/2025-01-11T12:51:28+00:00weekly0.6https://www.medthority.com/news/2025/1/nice-uk-positive-for-kimmtrak-tebentafusp-for-treating-advanced-uveal-melanoma---immunocore-ltd/2025-01-11T13:00:11+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-topline-phase-iia-clinical-data-announced-for--ultra-long-acting-glp-1-receptor-agonist-met-097i-for-obesity--metsera-inc/2025-08-20T15:03:04+00:00weekly0.6https://www.medthority.com/news/2025/1/investigational-mri-contrast-agent-gadoquatrane-meets-primary-and-main-secondary-endpoints-in-pivotal-phase-iii-studies--bayer/2025-01-11T12:59:01+00:00weekly0.6https://www.medthority.com/news/2025/1/sasanlimab-in-combination-with-bcg-improves-event-free-survival-in-patients-with-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer---pfizer/2025-01-11T12:47:47+00:00weekly0.6https://www.medthority.com/news/2025/1/bayer-submits-application-to-the-fda-and-to-chinas-cde-for-new-indication-of-finerenone-for-patients-with-common-form-of-heart-failure-with-high-unmet-medical-need/2025-01-11T12:46:54+00:00weekly0.6https://www.medthority.com/news/2025/1/innate-pharma-announces-transformative-strategy-to-accelerate-growth/2025-01-11T12:45:51+00:00weekly0.6https://www.medthority.com/news/2025/1/european-ce-mark-approval-of-the-dual-energy-thermocool-smarttouch-sf-catheter-for-the-treatment-of-cardiac-arrhythmias--johnson--johnson-medtech/2025-05-22T10:45:07+00:00weekly0.6https://www.medthority.com/news/2025/1/-fda-has-required-and-approved-safety-labeling-changes-to-the-prescribing-information-for-abrysvo--and-arexvy---pfizer-gsk-/2025-01-12T19:16:59+00:00weekly0.6https://www.medthority.com/news/2025/1/leo-pharma-and-gilead-sciences-collaborate-to-accelerate-development-of-small-model-oral-stat6-programs/2025-01-12T19:15:22+00:00weekly0.6https://www.medthority.com/news/2025/1/leo-pharma-and-gilead-sciences-collaborate-to-accelerate-development-of-small-model-oral-stat6-prorams/2025-01-12T19:13:35+00:00weekly0.6https://www.medthority.com/news/2024/12/euroopean-commission-approves--vabysmo--faricimab-pre-filled-syringe-forneovascular-or-wet-age-related-macular-degeneration-diabetic-macular-edema--and-macular-edema-following-rvo.-roche2024-12-17T13:30:46+00:00weekly0.6https://www.medthority.com/news/2024/12/patient-enrollment--is-opened-for-the-confirmatory-phase-iii-study-evaluating-hybryte-synthetic-hypericin-in-the-treatment-of-cutaneous-t-cell-lymphoma-ctcl.--soligenix-inc..-2024-12-17T13:40:57+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-grants-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia---neurocrine-biosciences/2024-12-17T13:49:47+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-unloxcyt-cosibelimab-ipdl-for-the-treatment-of-adults-with-metastatic-cutaneous-squamous-cell-carcinoma--checkpoint-therapeutics/2024-12-17T13:52:38+00:00weekly0.6https://www.medthority.com/news/2024/12/discontinuation-is-announced-of-the-clinical-development-programs-for-vibostolimab-an-anti-tigit-antibody-and-favezelimab-an-anti-lag-3-antibody.--merck-inc2024-12-17T13:56:32+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-vtama-tapinarof-cream-1to-treat-atopic-dermatitis.--organon2024-12-17T13:59:59+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-nemluvio--nemolizumab-for-the-treatment-of-moderate-to-severe-atopic-dermatitis.--galderma2024-12-17T13:27:27+00:00weekly0.6https://www.medthority.com/news/2024/12/nmpa-china-approves-keytruda--pembrolizumab--chemotherapy-as-adjuvant-treatment-after-surgery-for-patients-with-resectable-stage-ii-iiia-or-iiib-non-small-cell-lung-cancer-nsclc.--merck-inc2025-02-03T15:41:15+00:00weekly0.6https://www.medthority.com/news/2025/1/chenodal-has-received-a-medical-necessity-determination-by-the-fda-for-the-treatment-of-cerebrotendinous-xanthomatosis.--mirum-therapeutics2025-01-02T10:55:10+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-approves-yselty-linzagolix-for-the-symptomatic-treatment-of-endometriosis.-theramex2025-01-02T11:21:20+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-nda-for-taletrectinib-to-treat-advanced-ros1-nsclc-line-agnostic.cancer-and-sets-pdufa-date-of-23-june-2025.--nuvation-bio-inc2025-01-02T11:45:27+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-nda-for-taletrectinib--for-the-treatment-of-advanced-ros1-nsclc-line-agnostic.and-sets-a-pdufa-date-for-june-23-2025.--2025-01-02T12:09:40+00:00weekly0.6https://www.medthority.com/news/2025/1/veru-announces-the-sale-of-the-fc2-female-condom-internal-condom-business-and-focus-on-enobosarm/2025-01-02T12:15:07+00:00weekly0.6https://www.medthority.com/news/2025/1/altamira-therapeutics-announces-successful-testing--of-its-nanoparticle-based-delivery-platform/2025-01-02T12:26:38+00:00weekly0.6https://www.medthority.com/news/2025/1/--results-from-phase-iii-koastal-1-study-of-navacaprant-for-major-depressive-disorder-did-not-demonstrate-a-statistically--significant-improvement.--neumora-therapeutics2025-01-03T11:28:27+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-nda-for--avutometinib--defactinib-to-treat--recurrent-low-grade-serous-ovarian-cancer-with-kras-mutation.--verastem-oncology2025-01-03T11:30:52+00:00weekly0.6https://www.medthority.com/news/2025/1/nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps--gsk/2025-01-06T07:31:28+00:00weekly0.6https://www.medthority.com/news/2025/1/santhera-pharma-and-clinigen-group-sign-supply-and-distribution-agreement-to-extend-access-to--agamree-vamorolone-to-patients-with-duchenne-muscular-dystrophy/2025-01-06T12:40:50+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-alyftrek-vanzacaftortezacaftordeutivacaftor-a-once-daily-next-in-class-cftr-modulator-for-the-treatment-of-cystic-fibrosis---vertex--/2024-12-24T12:07:34+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves--symvess-acellular-tissue-engineered-vessel-tyod-for-use-as-a-vascular-conduit-for-extremity-arterial-injury-when-urgent-revascularization-is-needed-to-avoid-imminent-limb-loss.-humacyte-inc2024-12-24T12:23:21+00:00weekly0.6https://www.medthority.com/news/2024/12/-first-trial-of-zejula-niraparib-and-jemperli-dostarlimab-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer--gsk/2024-12-24T12:28:05+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approval-for-trikafta-elexacaftortezacaftorivacaftor-and-ivacaftor-to-include-additional-non-f508del-trikafta-responsive-variants---vertex/2024-12-24T12:31:26+00:00weekly0.6https://www.medthority.com/news/2024/12/tagrisso-osimertinib-approved-in-the-eu-for-the-treatment-of-adult-patients-with-locally-advanced-unresectable-nsclc--with-tumours-having-exon-19-deletions-or-exon-21-mutations---astra-zeneca/2024-12-24T12:34:42+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-zepbound-tirzepatide-as-the-first-and-only-prescription-medicine-for-moderate-to-severe-obstructive-sleep-apnea-in-adults-with-obesity---eli-lilly/2024-12-24T12:39:15+00:00weekly0.6https://www.medthority.com/news/2024/12/results-from-phase-ii-study-of-suzetrigine-for-the-treatment-of-painful-lumbosacral-radiculopathy-show-that-it-met-its-primary-endpoint-with-statistically-significant-and-clinically-meaningful-reduction-in-pain---vertex/2024-12-24T12:44:19+00:00weekly0.6https://www.medthority.com/news/2024/12/-fda-approves-alhemo-concizumab-mtci-injection-as-a-once-daily-prophylaxis-to-prevent-or-reduce--bleeding-episodes--in-patients-with-hemophilia-a-or-b-with-inhibitors.--novo-nordisk2024-12-24T12:47:22+00:00weekly0.6https://www.medthority.com/news/2024/12/opdivo-nivolumab-plus-yervoy-ipilimumab-receives-european-commission-approval-for-the-first-line-treatment-of-adult-patients-with-microsatellite-instabilityhigh-or-mismatch-repair-deficient-metastatic-colorectal-cancer---bms/2024-12-27T11:08:16+00:00weekly0.6https://www.medthority.com/news/2024/12/-positive-topline-resultsannounced-from-two-pivotal-phase-iii-trials-evaluating-sotyktu-deucravacitinib-in-adults-with-psoriatic-arthritis.--bms2024-12-27T11:14:00+00:00weekly0.6https://www.medthority.com/news/2024/12/-fda-approves--imcivree--setmelanotide-for-children-with--obesity-due-to-bardet-biedl-syndrome--or-pro-opiomelanocortin--including-pcsk1-or-lepr-deficiency.--rhythm-pharma2024-12-27T11:20:31+00:00weekly0.6https://www.medthority.com/news/2024/12/johnson--johnson-enters-a-licence-agreement-for-a-stat6-program-from-kraken-pharma--for-autoimmune-and-allergic-diseases-including-kp-723-for-atopic-dermatitis/2024-12-27T11:25:05+00:00weekly0.6https://www.medthority.com/news/2024/12/sanofi-and-sk-bioscience-expand-agreement--to-develop-license-and-commercialize-next-generation-pcvs-/2024-12-27T11:29:34+00:00weekly0.6https://www.medthority.com/news/2024/12/cognition-therapeutics-announces-positive-results-in-phase-ii-study-of-ct-1812-in-dementia-with-lewy-bodies/2024-12-27T11:33:36+00:00weekly0.6https://www.medthority.com/news/2024/12/datopotamab-deruxtecan-application-in-the-eu-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-voluntarily-withdrawn--daiichi-sankyo----astrazeneca/2025-02-03T15:12:27+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-tevimbra-tislelizumab-jsgr--chemotherapy-to--treat--her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma--in-adults-whose-tumors-express-pd-l1-1--beigene/2024-12-30T08:56:57+00:00weekly0.6https://www.medthority.com/news/2024/12/datroway--datopotamab-deruxtecan--is-approved-in-japan-as-the-first-trop-2-directed-therapy-for-patients-with--hr-positive-her2-negative-breast-cancer---daiichi-sankyo/2024-12-30T09:01:56+00:00weekly0.6https://www.medthority.com/news/2024/12/mhlw-japan-approves-zepbound-tirzepatide-to-treat-obesity.--eli-lilly-kk---mitsubishi-tanabe2025-08-20T12:15:21+00:00weekly0.6https://www.medthority.com/news/2024/12/-supplemental-approval-of-opdivo----cisplatin--gemcitabine-for-treatment-of-unresectable-urothelial-carcinoma-in-japan.-ono-pharma2024-12-30T09:15:45+00:00weekly0.6https://www.medthority.com/news/2024/12/mhlw-japan-approves-uptravi-tablets-for-pediatric-pulmonary-arterial-hypertension-.--nippon-shinyaku2024-12-30T09:19:00+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approval-for-opdivo-qvantig-nivolumab-and-hyaluronidase-nvhy--for-subcutaneous-injection.-bms2024-12-30T09:22:27+00:00weekly0.6https://www.medthority.com/news/2024/12/interim-data-announced-from-two-clinical-studies-of-qrx-003-for-netherton-syndrome.--quoin-pharma2024-12-30T09:26:54+00:00weekly0.6https://www.medthority.com/news/2024/12/nice-uk-positive-for-zepbound-tirzepatide-for-managing-overweight-and-obesity---eli-lilly-/2025-08-20T12:14:30+00:00weekly0.6https://www.medthority.com/news/2024/12/mhlw-japan-approves-lunsumio-mosunetuzumab-to-treat-rr-follicular-lymphoma.--chugai-pharma2024-12-30T12:51:53+00:00weekly0.6https://www.medthority.com/news/2024/12/mhlw-japan-approves-hyqvia--immune-globulin-infusion-10-human-with-recombinant-human-hyaluronidase-for-agammaglobulinemia-or-hypogammaglobulinemia-disorders.--takeda2024-12-30T12:58:07+00:00weekly0.6https://www.medthority.com/news/2024/12/topline-results-announced--from-the-phase-iii-steer-study-of-intrathecal-onasemnogene-abeparvovec-oav101-it-in-treatment-naive-patients-with-spinal-muscular-atrophy-type-2--novartis/2024-12-31T12:10:33+00:00weekly0.6https://www.medthority.com/news/2024/12/-cagrisema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-redefine-1-trial--novo-nordisk-/2024-12-31T12:14:02+00:00weekly0.6https://www.medthority.com/news/2024/12/marinus-regains-commercial-rights-in-europe-for-ganaxolone.-from-orion-pharma2024-12-31T12:17:10+00:00weekly0.6https://www.medthority.com/news/2024/12/european-commission-approves-rybrevant--amivantamab--lazcluze--lazertinib-for-nsclcegfr-exon-19-deletions-or-exon-21-l858-mutations.-johnson--johnson2024-12-31T12:21:13+00:00weekly0.6https://www.medthority.com/news/2024/12/sangamo-therapeutics-inc.-announced-it-will-regain--rights-from-pfizer-to-giroctocogene-fitelparvovec-a-gene-therapy-candidate-for-moderately-severe-to-severe-hemophilia-a-2024-12-31T12:24:12+00:00weekly0.6https://www.medthority.com/news/2024/12/mhra-uk-approves-blincyto-blinatumomab-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia-.-amgen2024-12-18T12:50:23+00:00weekly0.6https://www.medthority.com/news/2024/12/phase-ii-study-success-of-quizartinib-astellasambit-bioscience-in-aml/2024-12-18T12:53:13+00:00weekly0.6https://www.medthority.com/news/2024/12/topline-data-from-thrive-2-phase-iii-trial-of-veligrotug-veli-in-patients-with-chronic-thyroid-eye-disease-.--viridian-therapeutics2024-12-18T12:57:06+00:00weekly0.6https://www.medthority.com/news/2024/12/new-and-updated-data-for-roches-fixed-duration-columvi-and-lunsumio-at-ash-2024-reinforce-their-potential-to-improve-outcomes-for-people-with-lymphoma--roche/2024-12-18T13:03:20+00:00weekly0.6https://www.medthority.com/news/2024/12/new-and-updated-data-for-roches-fixed-duration--lunsumio-at-ash-2024-reinforce-its--potential-to-improve-outcomes-for-people-with-lymphoma--roche/2024-12-18T13:07:36+00:00weekly0.6https://www.medthority.com/news/2024/12/arvinas-and-pfizer-announce-initial-phase-1b-data-from-the-tactive-u-sub-study-of-vepdegestrant-in-combination-with-abemaciclib-at-2024-san-antonio-breast-cancer-symposium---pfizer-/2024-12-18T13:11:12+00:00weekly0.6https://www.medthority.com/news/2024/12/datopotamab-deruxtecan-granted-breakthrough-therapy-designation-in-u.s.-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer---daiichi-sankyo2024-12-18T13:13:39+00:00weekly0.6https://www.medthority.com/news/2024/12/-quantum-wild-phase-iii-trial-of-vanflyta--quizartinib----consolidation--therapy-is-initiated-in-patients-with-newly-diagnosed-flt3-itd-negative-aml--daiichi-sankyo/2024-12-18T13:17:59+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-issues-a-complete-response-letter--for-a-fixed-combination-of-amivantamab-and-recombinant-human-hyaluronidase-for-subcutaneous-administration--in-nsclcegfr--johnson--johnson/2025-02-03T15:14:46+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-accepts-bla-for--clesrovimab-mk-1654-to-treat--infants-from-respiratory-syncytial-virus-rsv-disease---merck-inc/2024-12-18T13:25:39+00:00weekly0.6https://www.medthority.com/news/2024/12/complete-response-for--andexxa-andexanet-to-convert-accelerated-approval-to-full-approval-to-reverse-the-effects-of-direct-oral-anticoagulants-.--astrazeneca2025-08-20T14:57:21+00:00weekly0.6https://www.medthority.com/news/2024/12/nice-uk-positive-for-lytenava-bevacizumab-gamma-for-treating-wet-age-related-macular-degeneration-in-adults---outlook-theraputics/2024-12-19T12:08:06+00:00weekly0.6https://www.medthority.com/news/2024/12/ibrance-in-combination-with-standard-of-care-therapies-extends-pfs-survival-by-over-15-months-in-phase-iii-patina-study-in--hr-her2-metastatic-breast-cancer--pfizer-/2024-12-19T12:15:53+00:00weekly0.6https://www.medthority.com/news/2024/12/-fda-grants-breakthrough-therapy-designation-to-trodelvy-sacituzumab-govitecan-hziy-for-second-line-treatment-of-extensive-stage-small-cell-lung-cancer--gilead--sciences/2024-12-19T12:01:36+00:00weekly0.6https://www.medthority.com/news/2024/12/eton-pharmaceuticals-announces-final-readout-of-pku-golike-clinical-trial--eton-pharmaceuticals/2024-12-19T11:58:02+00:00weekly0.6https://www.medthority.com/news/2024/12/the-journal-brain-stimulation-has-published-two-pivotal-articles-chronicling-the-unipolar-cohort-data-set-for-the-recover-clinical-study-of-the.vns-therapy-system--livanova2024-12-19T11:54:35+00:00weekly0.6https://www.medthority.com/news/2024/12/topline-results-from-pivotal-phase-iii-trials-evaluating--once-daily-oral-two-drug-single-tablet-regimen-of-doravirineislatravir-for--virologically-suppressed-hiv-1---merck-inc/2024-12-21T16:22:15+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-ryoncil-remestemcel-l---for-steroid-refractory-acute-graft-versus-host-disease.--mesoblast-ltd2024-12-21T16:20:38+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approval-for-ensacove-ensartinib-for-adult-patients-with-anaplastic-lymphoma-kinase-alkpositive-locally-advanced-metastatic-nonsmall-cell-lung-cancer-nsclc.-xcovery-holdings-inc.-2024-12-21T16:18:59+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-adopts-positive-opinion-for-an-update-of-the-ozempic-once-weekly-subcutaneous-semaglutide-label-to-reflect-risk-reduction-of-kidney-disease-related-events--novo-nordisk/2024-12-21T16:16:56+00:00weekly0.6https://www.medthority.com/news/2024/12/topline-six-month-results-from-randomised-phase-iib-study-of-avicursen-in--duchenne-muscular-dystrophy-dmd--percheron-therapeutics-/2024-12-21T16:15:04+00:00weekly0.6https://www.medthority.com/news/2024/12/merck-inc.-to-licence-hs-10535-a-glp-1-agonist-from-hansoh-pharma2024-12-21T16:13:04+00:00weekly0.6https://www.medthority.com/news/2024/12/ultragenyx-submits-bla-to-the--fda-for-ux111-aav-gene-therapy-for-the-treatment-of-sanfilippo-syndrome-type-a-mps-iiia---ultragenyx-pharmaceutical/2024-12-21T16:11:07+00:00weekly0.6https://www.medthority.com/news/2024/12/astellas-to-licence-sangamos-novel-neurotropic-adeno-associated-virus-aavcapsid-stac-bbb/2024-12-21T16:09:15+00:00weekly0.6https://www.medthority.com/news/2024/12/abbvie-acquires-nimble-therapeutics-and-with-it-the-oral-peptide-il23r-inhibitor-a-potential-treatment-for-psoriasis-/2024-12-21T16:07:29+00:00weekly0.6https://www.medthority.com/news/2024/12/site-one-collaboration-with-vertex-for-non-opioid-treatments-in-pain-control/2024-12-21T16:05:47+00:00weekly0.6https://www.medthority.com/news/2024/12/a-type-ii-variation-application-to-ema-seeks-approval-for-imbruvica--ibrutinib-in-combination-with-r-chop-therapy-to-treat-mantle-cell-lymphoma--janssen-cilag-jj/2024-12-21T16:03:50+00:00weekly0.6https://www.medthority.com/news/2024/12/aflibercept-8-mg-met-primary-endpoint-in-phase-iii-study-and-demonstrates-vision-gains-with-extended-treatment-intervals-in-retinal-vein-occlusion--bayer/2024-12-21T16:02:31+00:00weekly0.6https://www.medthority.com/news/2024/12/-first-patient-dosed-in-pivotal-phase-iii-aspire-study-evaluating-gtx-102-in-angelman-syndrome--ultragenyx-pharmaceutical/2025-02-03T15:13:37+00:00weekly0.6https://www.medthority.com/news/2024/12/complete-response-letter-for--glepaglutide-for-the-treatment-of-adult-patients-with-short-bowel-syndrome-sbs-with-intestinal-failure.--zealand-pharma--as2024-12-21T15:58:04+00:00weekly0.6https://www.medthority.com/news/2024/12/results-from-the-phase-iib-padova-study-investigating-prasinezumab--for-early-stage-parkinsons-disease.--roche2024-12-21T15:55:56+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves--tryngolza-olezarsn-as-an-adjunct-to-diet-to-reduce-triglycerides-in-adults-with-familial-chylomicronemia-syndrome-.--ionis-pharma2025-02-03T15:14:15+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-ensacove-ensartinib-to-treat-alk-positive-non-small-cell-lung-cancer.--xcovery-holdings2024-12-21T15:53:50+00:00weekly0.6https://www.medthority.com/news/2024/12/complete-response-letter-for-zynquista-sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease-.--lexicon-pharma2025-02-03T15:13:16+00:00weekly0.6https://www.medthority.com/news/2024/12/relieve-uccd-phase-iib-study--of--duvakitug-met-its-primary-endpoints-in-patients-with-ulcerative-colitis-uc-and-crohns-disease-.--sanofi--teva2024-12-23T07:58:54+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-grants-accelerated-approval-for-braftovi--encorafenib--cetuximab-marketed-as-erbitux--and-mfolfox6-for--metastatic-colorectal-cancer-mcrc-with-a-braf-v600e-mutation.---pfizer2024-12-23T12:05:17+00:00weekly0.6https://www.medthority.com/news/2024/12/positive-updated-data-on-maat-013-in-the-early-access-program-at-ash-2024-annual-meeting-.--maat-pharma2024-12-12T11:57:03+00:00weekly0.6https://www.medthority.com/news/2024/12/nice-uk-managed-access-for-elrexfio-elranatamab-for-treating-relapsed-and-refractory-multiple-myeloma-after-3-or-more-treatments---pfizer/2024-12-12T12:04:53+00:00weekly0.6https://www.medthority.com/news/2024/12/five-year-results-confirm-roches-polivy-combination-therapy-as-new-standard-of-care-for-previously-untreated-aggressive-lymphoma--roche/2024-12-12T12:08:19+00:00weekly0.6https://www.medthority.com/news/2024/12/new-data-from-three-oral-presentations-showing-significant-clinical-benefit-with-sarclisa-based-quadruplets-in-newly-diagnosed-multiple-myeloma-ndmm-patients-presented-at-ash-meeting.-sanofi2025-02-03T15:35:19+00:00weekly0.6https://www.medthority.com/news/2024/12/-positive-results-from-the-pivotal-luna-3-phase-iii-study-of-rilzabrutinib-in-adults-with-persistent-or-chronic-immune-thrombocytopenia-.--sanofi2024-12-13T12:01:48+00:00weekly0.6https://www.medthority.com/news/2024/12/announcement-of-results-from-a-multicenter-phase-iii-clinical-trial-evaluating-can-2409-viral-immunotherapy--valacyclovir-in-localized-prostate-cancer-patients.--candel--therapeutics2025-01-23T13:43:06+00:00weekly0.6https://www.medthority.com/news/2024/12/-yescarta--axicabtagene-ciloleucel--only-car-t-cell-therapy-to-show-durable-response-and-long-term-survival-after-five-years-for-rr-non-hodgkin-lymphomas-at-ash-2024---kitegilead-sciences/2024-12-13T12:10:19+00:00weekly0.6https://www.medthority.com/news/2024/12/zilovertamab-vedotin--r-chp-demonstrates-complete-response-rate-of-100-at-1.75-mgkg-dose-in-phase-ii-trial-of-previously-untreated-patients-with-diffuse-large-b-cell-lymphoma---merck-inc2024-12-13T12:13:14+00:00weekly0.6https://www.medthority.com/news/2024/12/imlunestrant-phase-iii-results-demonstrate-a-significantly-improved-progression-free-survival-as-monotherapy-and-in-combination-with-verzenio-abemaciclib-in-patients-with-er-her2--advanced-breast-cancer---eli-lilly/2024-12-13T12:20:24+00:00weekly0.6https://www.medthority.com/news/2024/12/-new-data-is-presented-at-ash-underscoring-curative-potential-of-yescarta---axicabtagene-ciloleucel--in-rr-large-b-cell-lymphoma----kitegilead-sciences/2024-12-13T12:23:05+00:00weekly0.6https://www.medthority.com/news/2024/12/longest-follow-up-data-reported-for-tecartus--brexucabtagene-autoleucel-car-t-cell-therapy-at-ash-2024-reinforce-durable-efficacy-and-survival-benefits---kitegilead-sciences/2024-12-13T12:26:14+00:00weekly0.6https://www.medthority.com/news/2024/12/additional-data-presented-at-ash-from--two-ongoing-phase-ii-clinical-trials-of-elritercept-ker-050-in-patients-with-myelodysplastic-syndromes--and--myelofibrosis-.-keros-therapeutics2024-12-13T12:29:57+00:00weekly0.6https://www.medthority.com/news/2024/12/gilead-sciences-enters-option-agreement-with-tubulis-to-develop-an-antibody-drug-conjugate-adc-for-solid-tumours/2024-12-13T12:32:18+00:00weekly0.6https://www.medthority.com/news/2024/12/dreamm-7-phase-iii-trial-shows-blenrep-combination-nearly-tripled-median-progression-free-survival-versus-standard-of-care-combination-in-patients-with-relapsedrefractory-multiple-myeloma--gsk/2024-12-15T14:48:03+00:00weekly0.6https://www.medthority.com/news/2024/12/blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse--gsk/2024-12-15T14:46:23+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-omvoh-mirikizumab-to-treat-moderately-to-severely-active-crohns-disease-.-eli-lilly2025-02-03T15:31:41+00:00weekly0.6https://www.medthority.com/news/2024/12/lynparza-olaparib-showed-meaningful-improvements-in-overall-survival-os-at-six-years-for-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.--astrazeneca--merck-inc2025-02-03T15:33:10+00:00weekly0.6https://www.medthority.com/news/2024/12/us-fda-accepts-gsks-submission-for-the-use-of-nucala-mepolizumab-in-copd--gsk/2024-12-15T14:40:20+00:00weekly0.6https://www.medthority.com/news/2024/12/blenrep-belantamab-mafodotin-combination-accepted-for-priority-review-in-china-in-relapsedrefractory-multiple-myeloma--gsk/2024-12-15T14:38:19+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-kavigale-sipavibart-forthe-prevention-of-covid19-in-immunocompromised-people-aged-12-years-and-older.--astrazeneca2024-12-15T14:33:29+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-kostaive-vaccine-for-the-prevention-of-covid-19-in-adults.-.-csl-behring--arcurtus2024-12-15T14:31:22+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-andembry--garadacimab-as-a-once-monthly-prophylactic-treatment-for-hereditary-angioedema-hae-in-adult-and-adolescent-patients-aged-12-years-and-older..--csl-behring2025-02-03T15:34:12+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-beyonttra--acoramidis-for-the-treatment-of-wild-type-or-variant-transthyretin-amyloidosis-in-adult-patients-with-cardiomyopathy.--bridge-bio-and-bayer2024-12-15T14:26:41+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-rytelo-imetelstat-for-transfusion-dependent-td-anemia-due-to-very-low-low-or-intermediate-risk-myelodysplastic-syndromes-lr-mds.--geron-corporation2024-12-15T14:25:00+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-nemluvio-nemolizumab-for-the-treatment-of-both-atopic-dermatitis-and-prurigo-nodularis--galderma/2024-12-15T14:22:39+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for--seladelpar-for-the-treatment-of-primary-biliary-cholangitis-pbc-in-combination-with-ursodeoxycholic-acid.--gilead-sciences-2024-12-15T14:20:44+00:00weekly0.6https://www.medthority.com/news/2024/12/editas-advances-in-crispr-based-gene-editing-/2024-12-15T14:18:30+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-welireg--belzutifan-to-treat--von-hippel-lindau-disease-and-renal-cell-carcinoma-.--merck-inc2025-02-03T15:34:48+00:00weekly0.6https://www.medthority.com/news/2024/12/epkinly-epcoritamab-bysp-generated-deep-responses-in-patients-with-relapsedrefractory-chronic-lymphocytic-leukemia.-genmab-as--abbvie2024-12-15T14:12:01+00:00weekly0.6https://www.medthority.com/news/2024/12/beigene-licences-from-cspc-syh-2039---a-novel-methionine-adenosyltransferase-2a-mat2a-inhibitor-to-treat-solid-tumors/2024-12-15T14:08:57+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for--eydenzelt--aflibercept-biosimilar--celltrion/2024-12-16T11:48:25+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-avtozma--tocilizumab-biosimilar--celltrion/2024-12-16T11:54:40+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-stoboclo-denosumab-biosimilar--intended-for-the-treatment-ofosteoporosis-in-post-menopausal-women-bone-loss-in-men-and-treatment-of-systemic-glucocorticoid.---celltrion2024-12-16T12:04:23+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-yesintek-ustekinumab-biosimilar--for-the-treatment-of-adults-and-children-with-plaque-psoriasis-and-adults-with-psoriatic-arthritis-or-crohns-disease..--biocon2024-12-16T12:09:37+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-zefylti--filgrastim-biosimilar-for-the-treatment-of-neutropenia-and-the-mobilisation-of-peripheral-blood-progenitor-cells-pbpcs.---curateq-biologicsaurobindo2024-12-16T12:27:08+00:00weekly0.6https://www.medthority.com/news/2024/12/chmp-positive-for-osenvelt-denosumab-biosimilar-for-treatment-of-bone-diseases-.--celltrion2024-12-16T12:37:05+00:00weekly0.6https://www.medthority.com/news/2024/12/strides-phase-ii-study-of-azelaprag-as-monotherapy-and-in-combination-with-tirzepatide-to-be-discontinued-for-obesity.--bioage-labs2024-12-16T13:03:26+00:00weekly0.6https://www.medthority.com/news/2024/12/phase-iii-keylynk-001-trial--results-of-keytruda-pembrolizumab---chemotherapy-followed-by-lynparza-olaparib-with-or-without-bevacizumab-for-brca-epithelial-ovarian-cancer.-merck-inc.-2024-12-10T13:14:01+00:00weekly0.6https://www.medthority.com/news/2024/12/positive-topline-results-from-phase-iii-tempo--2-study-of--tavapadon-as-a-flexible-dose-monotherapy-in-early-parkinsons-disease.--abbvie2024-12-10T13:18:34+00:00weekly0.6https://www.medthority.com/news/2024/12/positive-results-from--phase-iii-energize-t-study-investigating-mitapivat-in-adults-with-transfusion-dependent-alpha--or-beta-thalassemia..--agios-pharmaceuticals2024-12-10T16:36:16+00:00weekly0.6https://www.medthority.com/news/2024/12/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all--amgen/2024-12-10T12:37:56+00:00weekly0.6https://www.medthority.com/news/2024/12/-phase-iii-cartitude-4-study--results--show-a-single-infusion-of-carvykti--ciltacabtagene-autoleucel-significantly-increased-minimal-residual-disease--negativity-rates-in-patients-with--multiple-myeloma--jj/2024-12-11T12:40:59+00:00weekly0.6https://www.medthority.com/news/2024/12/strides-phase-ii-study-of-azelaprag-as-monotherapy-and-in-combination-with-tirzepatide-for-obesity--is-discontinued.-bioage-labs2024-12-11T12:46:21+00:00weekly0.6https://www.medthority.com/news/2024/12/tonix-submits-nda-for-tnx-102-sl-tonmya-which-could-offer-new-hope-of-pain-relief-without-narcotics-for-fibromyalgia-sufferers/2024-12-11T12:53:13+00:00weekly0.6https://www.medthority.com/news/2024/12/the--nda-for-the-combination-oftyvyt-sintilimab-injectionand-elunate--fruquintinibhas-been-granted-conditional-approval-in-china-for-the-treatment-of-patients-with-advanced-endometrial-cancer-.--hutchmed--innovent-biologics2024-12-11T12:57:44+00:00weekly0.6https://www.medthority.com/news/2024/12/results-from-phase-iii-natalee-trial-of-kisqal--ribociclib--endocrine-therapy-show-sustained-reduction-of-recurrence-in-herher2--early-breast-cancer.--novartis2024-12-11T13:05:38+00:00weekly0.6https://www.medthority.com/news/2024/12/new-results--presented-at-ash-meeting-of-two-ongoing-clinical-trials-evaluating-epcoritamab-administered-subcutaneously-in-adult-patients-with-diffuse-large-b-cell-lymphoma.--abbvie--genmab-as2024-12-11T13:11:13+00:00weekly0.6https://www.medthority.com/news/2024/12/fixed-duration-calquence-acalabrutinib-plus-venetoclax-demonstrated-superior-progression-free-survival-vs.-standard-of-care-in-previously-untreated-chronic-lymphocytic-leukaemia---astra-zeneca2024-12-11T13:15:13+00:00weekly0.6https://www.medthority.com/news/2024/12/data-on-disease-burden--presented-at-ash-on-warm-autoimmune-hemolytic-anemia.--johnson--johnson2025-02-03T15:35:55+00:00weekly0.6https://www.medthority.com/news/2024/12/protara-announces-positive-results-from-the-ongoing-phase-ii-advanced-2-trial-of-tara-002-in-patients-with-nmibc/2024-12-11T13:30:03+00:00weekly0.6https://www.medthority.com/news/2024/12/longer-term-results-from-phase-iiiasc4first-trial-with-scemblix-asciminib-showing-superior-major-molecular-response-mmr-rates-at-week-96-.--novartis2024-12-09T12:17:15+00:00weekly0.6https://www.medthority.com/news/2024/12/-updated-phase-iii-data-of-an-exploratory-cohort-from-the-access-1-trial-investigating--pozelimab---cemdisiran-poze-cemdi-against-ravulizumab-in-paroxysmal-nocturnal-hemoglobinuria.--regeneron2024-12-09T16:32:37+00:00weekly0.6https://www.medthority.com/news/2024/12/submission-of-twos-blas-at-fda--for-tremfya--guselkumab-for--juvenile-patients-in-plaque-psoriasis-and-juvenile-psoriatic-arthritis.--johnson--johnson2024-12-04T12:28:43+00:00weekly0.6https://www.medthority.com/news/2024/12/novartis-acquires-ptc-518--an-htt-mrna-splice-modulator--for-huntingtons-disease-from-ptc-therapeutics-/2024-12-04T12:30:22+00:00weekly0.6https://www.medthority.com/news/2024/12/phase-ii-study-of-namilumab-an-investigational-anti-gm-csf-monoclonal-antibody-failed-to-show-a-treatment-benefit-for-chronic-active-pulmonary-sarcoidosis..---kinevant-riovant2024-12-04T12:32:40+00:00weekly0.6https://www.medthority.com/news/2024/12/supplemental-nda-submitted--to-fda-for-caplyta-lumateperone-for-the-treatment-of-major-depressive-disorder.-intra-cellulartherapies2024-12-04T12:34:31+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approves-yesintek-ustekinumab-kfce-a-biosimilar-to-the-reference-product-stelara-ustekinumab.--biocon-biologics2024-12-04T12:36:18+00:00weekly0.6https://www.medthority.com/news/2024/12/coherus-biosciences--sells-udenyca-pegfilgrastim-cbqv-franchise-to-intas-pharmaceuticals/2024-12-05T12:42:46+00:00weekly0.6https://www.medthority.com/news/2024/12/first-single-dose-medicine-for-p.-vivax-malaria-prequalified-by-who-and-included-in-who-guidelines--gsk2024-12-05T12:44:31+00:00weekly0.6https://www.medthority.com/news/2024/12/gsk--enters-an-option-agreement-to-acquire-rights-to--db-1324-from-duality-biologics/2024-12-05T12:46:05+00:00weekly0.6https://www.medthority.com/news/2024/12/imfinzi-durvalumab-approved-in-the-us-as-first-and-only-immunotherapy-regimen-for-patients-with-limited-stage-small-cell-lung-cancer---astrazeneca/2025-02-03T15:36:24+00:00weekly0.6https://www.medthority.com/news/2024/12/iinitiation-of-a-phase-iii-move-now-clinical-trial-to-evaluate-lagrvrio-molnupiravir-for-the-treatment-of-adults-with-covid-19-at-high-risk-for-disease-progression.-merck-inc2024-12-06T11:30:52+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-accepts-supplemental-bla-for-columvi--glofitamab--chemotherapy--combination-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--roche/2024-12-06T11:33:09+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-approval-of-bizengri--zenocutuzumab-zbco-for-nrg1-pancreatic-adenocarcinoma-and-nrg1-nonsmall-cell-lung-cancer-nsclc-.--merus-n.v2024-12-06T11:38:02+00:00weekly0.6https://www.medthority.com/news/2024/12/new-phase-iiib-data-shows--fabhalta--iptacopan-improved-hemoglobin-levels-in-adult-patients-with-paroxysmal-nocturnal-hemoglobinuria-who-switched-from-anti-c5-therapy-.--novartis2024-12-06T11:40:38+00:00weekly0.6https://www.medthority.com/news/2024/12/muna-therapeutics-to-collaborate-with-gsk-to-identify-new-drug-targets-for-alzheimers-disease/2024-12-06T11:43:46+00:00weekly0.6https://www.medthority.com/news/2024/12/mhra-uk-approves-anzupgo-delgocitinib-cream-for-the-treatment-of-adult-patients-with-moderate-to-severe-chronic-hand-eczema.--leo-pharma2024-12-09T09:45:05+00:00weekly0.6https://www.medthority.com/news/2024/12/partner-therapeutics-to-market-bizengri--zenocutuzumab-in-the-united-states--merus-n.v.-and-partner-therapeutics2024-12-09T09:44:15+00:00weekly0.6https://www.medthority.com/news/2024/12/datopotamab-deruxtecan-demonstrated-meaningful-clinical-activity-in-patients-with-previously-treated-advanced-egfr--mutated-non-small-cell-lung-cancer-in-tropion-lung05-and-tropion-lung01-pooled-analysis--daiichi-sankyo-/2024-12-09T09:43:03+00:00weekly0.6https://www.medthority.com/news/2024/12/results-from-phase-iii-pod1um-304-trial-of-zynyz--retifanlimab---chemotherapy-in-nsclc.--incyte-inc2024-12-09T09:42:05+00:00weekly0.6https://www.medthority.com/news/2024/12/long-term-data-from-ongoing-x-tole-open-label-extension-ole-study-of-azetukalner-in-patients-with-focal-onset-seizures.--xenon-pharmaceuticals2024-12-09T09:41:02+00:00weekly0.6https://www.medthority.com/news/2024/12/phase-iii--panova-3-trial--of-of-tumor-treating-fields-met-its-primary-endpoint-showing-a-statistically-significant-improvement-in-median-overall-survival-mos-versus-control-.-zai-lab--novocure2024-12-03T14:13:54+00:00weekly0.6https://www.medthority.com/news/2024/12/nice-uk-positive-for-wainzua-eplontersen-for-treating-hereditary-transthyretin-related-amyloidosis---astra-zeneca/2024-12-03T14:16:03+00:00weekly0.6https://www.medthority.com/news/2024/12/post-treatment-data-from-the-hpn-ctcl-04-study-comparing-hybryte-synthetic-hypericin-to-valchlor-mechlorethamine--demonstrated-continued-improvement-in-hybryte-treated-patients--soligenix/2024-12-03T14:18:22+00:00weekly0.6https://www.medthority.com/news/2024/12/ipsen--and-biomunex-pharmaceuticals-announced-an-exclusive-global-licensing-agreement-for-bmx-502/2024-12-03T14:21:15+00:00weekly0.6https://www.medthority.com/news/2024/12/fda-investigation-of-blood-cancer-risk-from-skysona-elivaldogene-autotemcel--bluebird-bio/2025-02-03T15:39:00+00:00weekly0.6https://www.medthority.com/news/2024/12/sarepta-therapeutics-to-acquire-global-rights-to-four-clinical-and-three-preclinical-programs-from-arrowhead-pharma/2024-12-03T14:28:44+00:00weekly0.6https://www.medthority.com/news/2024/12/medtronic-announces-strongly-positive-results-for-patients-from-procedural-and-design-innovation-of-evolut-tavr/2024-12-02T13:36:58+00:00weekly0.6https://www.medthority.com/news/2024/11/european-commission-approves-kisqali--ribociclib-with-an-aromatase-inhibitor-for-the-adjuvant-treatment-of-hr-positive-her2-negative-early-breast-cancer-.--novartis2024-11-28T11:22:26+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-premarket-approval-application-supplement-approved-for-the-oxford-cementless-partial-knee.--zimmer-biomet2024-11-28T11:38:59+00:00weekly0.6https://www.medthority.com/news/2024/11/regulatory-update-related-to-supplemental-nda--for-cabozantinib-cabometyx-for-the-treatment-of-previously-treated-advanced-neuroendocrine-tumors.--exelixis-inc2025-02-03T14:25:51+00:00weekly0.6https://www.medthority.com/news/2024/11/recursion-acquires-exscientia/2024-11-28T11:47:24+00:00weekly0.6https://www.medthority.com/news/2024/11/boston-scientific-acquires-intera-oncology-andintera-3000-hepatic-artery-infusion-pump/2024-11-28T11:50:05+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves-rapiblyk-landiolol--to-treat-supraventricular-tachycardia-atrial-fibrillation-and-atrial-flutter.--aop-orphan-pharmaceuticals-gmbh-2024-11-29T13:04:18+00:00weekly0.6https://www.medthority.com/news/2024/11/complete-response-letter-for-govorestat-for-the-treatment-of-classic-galactosemia.--applied-therapeutics2025-02-03T14:24:39+00:00weekly0.6https://www.medthority.com/news/2024/11/european-commission-approves-expanded-indications-for-tevimbra-tislelizumab-for-esophageal-squamous-cell-carcinoma--and--gastric-or-gastroesophageal-junction-adenocarcinoma.--beigene-ltd2024-11-29T13:21:08+00:00weekly0.6https://www.medthority.com/news/2024/11/amgen-announces-robust-weight-loss-with--maritide-in-people-living-with-obesity-at-52-weeks-in-a-phase-2-study--amgen/2024-11-29T13:26:10+00:00weekly0.6https://www.medthority.com/news/2024/11/gsks-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission--gsk-plc/2024-11-29T13:29:16+00:00weekly0.6https://www.medthority.com/news/2024/11/roche-reports-update-on-phase-iii-skyscraper-01-study-results--roche/2024-11-29T13:30:58+00:00weekly0.6https://www.medthority.com/news/2024/11/topline-results-from-phase-iii-rethink-alz-trial-of-simufilam-did-not-meet-biomarker-endpoints--for-alzheimers-disease.--cassava-sciences2024-11-29T13:33:01+00:00weekly0.6https://www.medthority.com/news/2024/11/roche-acquires-posieda-therapeutics/2024-11-29T12:27:09+00:00weekly0.6https://www.medthority.com/news/2024/11/-new-england-journal-of-medicine-publication-of-purpose-2-results--gilead--sciences/2025-02-03T15:06:50+00:00weekly0.6https://www.medthority.com/news/2024/11/eisai-signs-research-collaboration-agreement-with-the-national-center-of-neurology--psychiatry-to-initiate-apolipoprotein-e-genetic-testing-in-the-ad-dmt-registry-in-japan/2024-12-01T15:42:40+00:00weekly0.6https://www.medthority.com/news/2024/11/nice-uk-positive-for-iqirvo-elafibranor-for-previously-treated-primary-biliary-cholangitis-when-used-with-udca-or-alone-if-udca-cannot-be-tolerated---ipsen/2024-11-26T13:18:18+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-phase-iii-zenith-study-of-winrevair--sotatercept-csrk-in-adults-with-pulmonary-arterial-hypertension--merck-inc/2024-11-26T13:27:46+00:00weekly0.6https://www.medthority.com/news/2024/11/myval-octapro-thv-to-be-launched-at-gise-2024-and-london-valves-2024-conferences--meril-life-sciences/2024-11-26T13:29:25+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-accepts-sbla--for-vutrisiran--for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy.--alnylam-pharma2024-11-26T13:31:06+00:00weekly0.6https://www.medthority.com/news/2024/11/nmpa--approves-zorifer--zorifertinib-hydrochloride-tablets-for-nsclcegfr-brain-metastases.--alphabio-pharma--astrazeneca2024-11-26T13:33:30+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-accepts-for-review-bla-for-blenerep--belantamab-mafodotin-in-combinations-with-bortezomib--bordex-bvd-and-pomalidomide--pomdex-bpd-for-patients-with-multiple-myeloma.-gsk2024-11-26T13:35:14+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves-imkeldi-imatinib-oral-solution-to-treat-leukemiasmdsmpd-and-gist.-shorla-oncology--2024-11-27T12:17:19+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves-attruby--acoramidis-for-the-treatment-of-adults-with-attr-cm-to-reduce-cardiovascular-death-and-cardiovascular-related-hospitalization.--bridge-bio2024-11-27T12:20:05+00:00weekly0.6https://www.medthority.com/news/2024/11/eton-pharma-acquires-us-rights-to--amglidia-glyburide-oral-suspension-from-ammtek-for-the-treatment-of-neonatal-diabetes-mellitus-.-2024-11-27T12:22:20+00:00weekly0.6https://www.medthority.com/news/2024/11/-edwards-lifesciences--announced-one-year-data-highlighting-the-continued-outstanding-performance-of-its-sapien-3-ultra-resilia-valve/2025-02-03T14:26:50+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-capitello-281-phase-iii-trial--of-truqap-capivasertib--chemotherapy--for-pten-deficient-de-novo-metastatic-hormone-sensitive-prostate-cancer.--astrazeneca2025-01-23T13:57:05+00:00weekly0.6https://www.medthority.com/news/2024/11/nice-uk-positive-for-alecensa-alectinib-for-the-adjuvant-treatment-of-stage1b-tumours-4cm-or-larger-to-3a-alk-positive-non-small-cell-lung-cancer-nsclc-.--roche2024-11-22T13:34:37+00:00weekly0.6https://www.medthority.com/news/2024/11/update-on-progress-of-planned-resubmission-of-bla-of-narsoplimab-for--stem-cell-transplant-associated-thrombotic-microangiopathy-.--omeros-corpn2024-11-22T13:36:10+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-phase-ii-study-results--of-once-monthly-efimosfermin-alfa-in-participants-with-stage-f2f3-fibrosis-due-to-mash--boston-pharma/2024-11-22T13:37:40+00:00weekly0.6https://www.medthority.com/news/2024/11/fda--granted-accelerated-approval-of-ziiherazanidatamab-hrii-for-injection-to-treat-unresectable-or-metastatic-her2-positive-ihc-3-biliary-tract-cancer--jazz-pharma/2025-02-03T14:29:34+00:00weekly0.6https://www.medthority.com/news/2024/11/fda--510-k-approval-for-philips-spectral-ct-7500-rt-new-detector-based-spectral-computed-tomography-ct-radiotherapy-solution..--royal-philips2024-11-22T13:40:46+00:00weekly0.6https://www.medthority.com/news/2024/11/european-commission-approves-hympavza-marstacimab-for-the-routine-prophylaxis-of-bleeding-episodes-in-patients-12-years-of-age-with-severe-hemophilia-a---or-severe-hemophilia-b-.--pfizer2024-11-22T13:42:32+00:00weekly0.6https://www.medthority.com/news/2024/11/zai-lab-and-pfizer--announced--a-strategic-collaboration-for-xacduro-sulbactam-durlobactam-in-mainland-china.-.--zai-lab--pfizer2024-11-22T13:43:46+00:00weekly0.6https://www.medthority.com/news/2024/11/novartis-acquires-kate-therapeutics-focused-on-developing-adeno-associated-virus-based-gene-diseases/2024-11-22T13:45:09+00:00weekly0.6https://www.medthority.com/news/2024/11/nmpa-china-approves-welireg-belzutifan-for-the-treatment-of-adult-patients-with-von-hippel-lindau-vhl-disease-.--merck-inc2024-11-25T07:58:36+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-accepts-snda-for-nubeqa-darolutamide-plus-adt-to-treat-metastatic-hormone-sensitive-prostate-cancer.--bayer2025-01-23T13:57:12+00:00weekly0.6https://www.medthority.com/news/2024/11/royal-philips-launches--next-generation-1.5t-blueseal-mr-wide-bore-scanner-2024-11-25T07:56:12+00:00weekly0.6https://www.medthority.com/news/2024/11/trc-capital-and-offer-for-merck--inc.-shares2024-11-25T07:54:43+00:00weekly0.6https://www.medthority.com/news/2024/11/bla-is--filed-at-fda-for-accelerated-approval-for-vusolimogene-oderparepvec-rp1---nivolumab-opdivo--to-treat-advanced-melanoma--replimune/2024-11-25T07:54:00+00:00weekly0.6https://www.medthority.com/news/2024/11/omeros-coproration--provides-an-update-on-resubmission-of-bla-for-narsoplimab-to-treat-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy/2024-11-25T07:53:00+00:00weekly0.6https://www.medthority.com/news/2024/11/lexicon-re-structures/2024-11-25T07:51:55+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-aproves-revuforj-revumenib-as-the-first-and-only-menin-inhibitor-for-the-treatment-of-rr-acute-leukemia-with-a-lysine-methyltransferase-2a-gene-kmt2a-translocation.--syndax-pharma2024-11-19T12:25:58+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approval-for-danziten--nilotinib-to-treat-philadelphia-chromosome-positive-chronic-myeloid-leukemia-ph-cml--.-azurity-pharma2024-11-19T13:42:34+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-recommends-augtyro--repotrectinib-for-advanced-ros1--positive--nsclc-and-advanced-solid-tumors-expressing-a-ntrk-gene-fusion.--bms-2024-11-19T12:21:23+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-recommends-rybrevant-amivantamab--plus-lazcluze-lazertinib-for-the-first-line-treatment-of-egfr-mutated-advanced-non-small-cell-lung-cancer.--johnson--johnson2024-11-19T12:18:53+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-chmp-opinion-for-gohibic-vilobelimab-for-the-treatment-of-sars-cov-2-induced-acute-respiratory-distress-syndrome--inflarx-n.v2025-02-03T14:32:25+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-positive-for-keytruda--pembrolizumab--chemotherapy-for-unresectable-non-epithelioid-malignant-pleural-mesothelioma---merck-inc/2024-11-20T12:07:41+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-the-pivotal-phase-iii-mk-3475a-d77-trial-for-subcutaneous-pembrolizumab-in-nsclc.--merck-inc2024-11-20T12:11:21+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-positive-for-fyb-203-a-biosimilar-candidate--to-eylea--aflibercept.--formycon--klinge--bipharma-gmbh2024-11-20T12:16:04+00:00weekly0.6https://www.medthority.com/news/2024/11/european-commission-approves--opuviz--aflibercept-biosimilar--samsung-bioepis---biogen/2024-11-20T12:18:24+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-positive-for-obodence-denosumab-biosimilar-to-treat-osteoporosis.--samsung-bioepis2024-11-20T12:20:59+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-positive-for-xbryk--denosumab-biosimilar-for-for-the-prevention-of-skeletal-related-events-and-giant-tumour-of-the-bone.--samsung-bioepis2024-11-20T13:42:35+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-iconic-lead-phase-iii-trial-of--icotrokinra-jnj-2113--for-moderate-to-severe-plaque-psoriasis-.--johnson--johnson2024-11-20T13:44:51+00:00weekly0.6https://www.medthority.com/news/2024/11/european-commisson-approves--elahere-mirvetuximab-soravtansine-for-fr-positive-platinum-resistant-high-grade-serous-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer-.--abbvie2024-11-20T13:47:19+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves--bimzelx-bimekizumab-bkzx-for-the-treatment-of-adults-with-moderate-to-severe-hidradenitis-suppurativa-.--ucb2024-11-20T13:50:10+00:00weekly0.6https://www.medthority.com/news/2024/11/the-fda-clears-cero-theraputics-investigational-new-drug-application-ind-of-its-lead-compound-cer-1236-for-phase-1-clinical-trials-in-acute-myelogenous-leukemia-aml/2024-11-21T12:28:12+00:00weekly0.6https://www.medthority.com/news/2024/11/new-preliminary-data-is-announced--at-aasl--from-the-phase-iia-im-prove-ii-clinical-trial-ab-729202-of-people-with-chronic-hepatitis-b-virus.---arbutus-biopharma---barinthus-biotherapeutics-2024-11-21T12:30:46+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-positive-for-sarclisai-isatuximab-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-newly-diagnosed-multiple-myeloma-ineligible-for-autologous-stem-cell-transplant-.--sanofi2025-02-03T14:30:56+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-clearance-for--inpen-app-featuring-missed-meal-dose-detection-paving-the-way-for-the-launch-of-its-smart-mdi-system-with-the-simplera--continuous-glucose-monitor-cgm.--medtronic2024-11-21T12:40:50+00:00weekly0.6https://www.medthority.com/news/2024/11/phase-ii-dimension-trial-of-sage-718--dalzanemdor-for-cognitive-impairment--associated-with-huntingtons-disease-did-not-meet-its-primary-endpoint.--sage-therapeutics2024-11-21T12:43:48+00:00weekly0.6https://www.medthority.com/news/2024/11/nice-uk-recommends-teclistamab-as-an-option-for-treating-relapsed-and-refractory-multiple-myeloma-.--johnson--johnson2024-11-21T12:46:38+00:00weekly0.6https://www.medthority.com/news/2024/11/dapirolizumab-pegol-phase-iii-data-presented-at-the-american-college-of-rheumatology-meeting--shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity--biogen--ucb/2025-02-03T14:30:24+00:00weekly0.6https://www.medthority.com/news/2024/11/complete-response-letter-for-ocaliva-obeticholic-acid-oca-for--primary-biliary-cholangitis-.intercept-pharmaalfasigma-s.p.a2024-11-14T12:15:38+00:00weekly0.6https://www.medthority.com/news/2024/11/data-announced-from-phase-ii-ignyte-eso-trial-of-lete-cel-in-people-with-synovial-sarcoma-or-myxoidround-cell-liposarcoma--adaptimmune/2024-11-14T12:18:47+00:00weekly0.6https://www.medthority.com/news/2024/11/pfizer-explores-sale-of-its-hospital-drugs-unit/2024-11-14T12:21:45+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-grants-accelerated-approval-for-kebilidi--eladocagene-exuparvovec-tneq--for-the-treatment-of-aadc-deficiency.---ptc-therapeutics2024-11-15T13:06:36+00:00weekly0.6https://www.medthority.com/news/2024/11/beigene-to-change-its-name-to-beone-medicines-ltd/2024-11-15T13:11:53+00:00weekly0.6https://www.medthority.com/news/2024/11/treatment-with-tirzepatide-in-adults-with-pre-diabetes-and-obesity-or-overweight-resulted-in-sustained-weight-loss-and-nearly-99-remained-diabetes-free-at-176-weeks.--eli-lilly2024-11-15T13:14:53+00:00weekly0.6https://www.medthority.com/news/2024/11/chmp-eu-gives-positive-opinion-for-lecanemab-as-a-treatment-for-early-alzheimers-disease---eisai--biogen/2024-11-15T13:17:21+00:00weekly0.6https://www.medthority.com/news/2024/11/-biontech-se-acquires-biotheus-and-with-it-the-late-stage-clinical-asset-bnt327pm8002-an-investigational-bispecific-antibody-targeting-pd-l1-and-vegf-a/2024-11-15T13:19:51+00:00weekly0.6https://www.medthority.com/news/2024/11/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsedrefractory-multiple-myeloma.--gsk-plc2024-11-15T13:21:30+00:00weekly0.6https://www.medthority.com/news/2024/11/tonix-pharmaceuticals--announced--publication-of--recombinant-chimeric-horsepox-virus-tnx-801-is-attenuated-relative-to-vaccinia-virus-strains-in-both-in-vitro-and-in-vivo-models-in-msphere/2024-11-15T13:31:50+00:00weekly0.6https://www.medthority.com/news/2024/11/amgen--announced-the-presentation-of-new-data-across-its-rare-disease-portfolio--at-the-annual-american-college-of-rheumatology-acr-convergence-2024-conference.-2025-02-03T14:36:33+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-accepts-resubmission-of-sbla-for-dupixent-dupilumab-for-chronic-spontaneous-urticaria.--regeneron--sanofi2024-11-15T13:36:16+00:00weekly0.6https://www.medthority.com/news/2024/11/european-comimssion--approves-afqlir--a-biosimilar-to-reference-medicine-eylea-for-various-retinal-diseases---sandoz/2024-11-15T13:04:29+00:00weekly0.6https://www.medthority.com/news/2024/11/plumatrix-to-merge-with-cullgen-inc/2024-11-15T13:02:06+00:00weekly0.6https://www.medthority.com/news/2024/11/late-breaking-data-for-iqirvo-elafibranor-from-interim-analysis-of-phase-iii-elative-study-for-primary-biliary-cholangitis-at-aasld-meeting.--ipsen2024-11-17T14:46:46+00:00weekly0.6https://www.medthority.com/news/2024/11/--combination-of-low-dose-atropine-in-the-optejet-dispensing-platform--did-not-meet-primary-endpoint-for-progressive-myopia.--eyenovia2024-11-17T14:45:54+00:00weekly0.6https://www.medthority.com/news/2024/11/halozyme-offers-to-acquire-evotec/2024-11-17T14:45:11+00:00weekly0.6https://www.medthority.com/news/2024/11/results-from-phase-iii-summit-study-show-tirzepatide--significantly-reduced-the-risk-of-worsening-heart-failure-events-in-patients-with-heart-failure-and-obesity---eli-lilly/2025-02-03T14:34:30+00:00weekly0.6https://www.medthority.com/news/2024/11/cytokinetics-incorporated-announced-new-data-relating-to-aficamten-and-hypertrophic-cardiomyopathy-hcm-were-presented-at-the-american-heart-association-scientific-sessions-2024-in-chicago-il/2024-11-17T14:43:16+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-three-year-primary-endpoint-results-from-the-option-global-clinical-trial-of-the-watchman-flx-left-atrial-appendage-closure-laac-device.---boston-scientific2025-02-03T14:35:29+00:00weekly0.6https://www.medthority.com/news/2024/11/cytokinetics-incorporated--announced-new-data-at-aha-meeting-from-post-hoc-analyses-of-galactic-hf-phase-iii-trial-of-omecamtiv-mecarbil--for-cardiovascular-outcomes/2024-11-17T14:41:14+00:00weekly0.6https://www.medthority.com/news/2024/11/two-and-a-half-year-interim-analysis-from-the-ongoing-phase-iii-assure-study-showed-that-81--of-participants-with-primary-biliary-cholangitis--treated-with-livdelzi--seladelpar-achieved-a-composite-biochemical-response/2024-11-18T13:04:21+00:00weekly0.6https://www.medthority.com/news/2024/11/-ipsen-announced-data-at-the-aasld-meeting-assessing-the-long-term-efficacy-and-safety-of-patients-treated-with-bylvay-odevixibat-from-two-phase-iii-open-label-extension-studies/2024-11-18T13:10:22+00:00weekly0.6https://www.medthority.com/news/2024/11/tagrisso-osimertinib-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-unresectable-egfr-mutated-lung-cancer.--astrazeneca2025-05-13T08:51:38+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-removes-clinical-hold-on-covid-19-influenza-combination-cic-and-stand-alone-influenza-vaccine-candidates.---novavax2024-11-13T13:16:59+00:00weekly0.6https://www.medthority.com/news/2024/11/-an-nda-has-been-submitted-by-dizal-pharma-to-the-fda-for-approval-of-sunvozertinib-dzd9008-for--locally-advanced-or-metastatic-nonsmall-cell-lung-cancer-nsclc-harboring-egfr-exon-2/2024-11-13T13:19:25+00:00weekly0.6https://www.medthority.com/news/2024/11/stivarga--regorafenib-improved-overall-survival--in-rr-gastric-or-gastroesophageal-junction-gej-cancer.--bayer-2024-11-13T13:21:27+00:00weekly0.6https://www.medthority.com/news/2024/11/phase-iv-data-demonstrates--dovato--dtg3tc-is-highly-effective-in-treatment---naive-people-with-advanced-hiv--.--viiv-healthcare2024-11-13T13:23:33+00:00weekly0.6https://www.medthority.com/news/2024/11/phase-iii-maneuver-trial-of-pimicotinib-is-positive-for-tenosynovial-giant--tumor.--merck-gmbh--2024-11-13T13:25:47+00:00weekly0.6https://www.medthority.com/news/2024/11/new-bla-submitted-to-fda-for-accelerated-approval-for-datopotamab-deruxtecan-for-nsclcegfr.--daiichi-sankyo--astrazeneca2025-01-31T12:03:33+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-high-level-results-of-comet-phase-iii-trial-of--oral-koselugo--selumetinib--in-adults-with-neurofibromatosis-type-1--astrazeneca/2024-11-13T13:33:25+00:00weekly0.6https://www.medthority.com/news/2024/11/abbvie-announces-that-its-two-phase-ii-empower-trials-for-emraclidine-in-schizophrenia-did-not-meet-their-primary-endpoint/2024-11-13T13:36:10+00:00weekly0.6https://www.medthority.com/news/2024/11/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-iii-defi-trial-of-ogsiveo-nirogacestat-in-adults-with-desmoid-tumors-to-be-presented-at-the-connective-tissue-oncology-society-ctos-2024-annual-meeting/2024-11-13T13:38:04+00:00weekly0.6https://www.medthority.com/news/2024/11/fda--has-approved-the-ottava-robotic-surgical-system-investigational-device-exemption-ide-which-allows-the-clinical-trial-to-begin-at-u.s.-sites.--johnson--johnson-medtech2024-11-13T13:39:40+00:00weekly0.6https://www.medthority.com/news/2024/11/-altimmune-announced-the-successful-completion-of-its-end-of-phase-ii-meeting-with-the-fda-and-agreement-on-the-design-of-a-phase-iii-registrational-program-for-pemvidutide-to-treat-obesity/2025-01-31T12:04:25+00:00weekly0.6https://www.medthority.com/news/2024/11/submission-under-accelerated-approval-for-govorestat-for-the-treatment-of-sord-deficiency-anticipated-in-early-q1-2025-applied-therapeutics/2024-11-08T11:50:56+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approval-of-varipulse-platform-to-treat-refractory-paroxysmal-atrial-fibrillation-afib---jj-med-tech/2025-01-31T12:03:56+00:00weekly0.6https://www.medthority.com/news/2024/11/510k-clearance-from-the-fda-for-the-medrad--centargo-ct-injection-system--bayer/2024-11-08T11:53:59+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-high-level-results-from-the-phase-iii-waypoint-trial--of-tezspire-tezepelumab-in-patients-with-chronic-rhinosinusitis-with-nasal-polyps-.-amgen--astrazeneca2024-11-08T11:57:54+00:00weekly0.6https://www.medthority.com/news/2024/11/sarepta-discontinues-next-generation-of-exon-skipping-drugs-for-duchenne-muscular-dystrophy/2024-11-11T07:58:18+00:00weekly0.6https://www.medthority.com/news/2024/11/athira-pharma-pauses-development-of-fosgonimeton-in-patients-with-mild-to-moderate-alzheimers-disease/2024-11-11T07:57:39+00:00weekly0.6https://www.medthority.com/news/2024/11/kalaris-therapeutics-to-merge-with-allovir/2024-11-11T07:56:35+00:00weekly0.6https://www.medthority.com/news/2024/11/daiichi-sankyo-to-license-a-subcutaneous-version-of-enhertu-fam--trastuzumab-deruxtecan-from-alteogen/2024-11-11T07:55:57+00:00weekly0.6https://www.medthority.com/news/2024/11/servier-to-collaborate-with-aitia-using-gemini-twins-technology-to-focus-on-gliomas/2024-11-11T07:55:04+00:00weekly0.6https://www.medthority.com/news/2024/11/vk-2735-data-raise-best-in-class-expectations--viking-therapeutics/2024-11-11T07:54:17+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves-aucatzyl--obecabtagene-autoleucel-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia.--autolus-therapeutics2024-11-11T07:52:59+00:00weekly0.6https://www.medthority.com/news/2024/11/crown-laboratories-to-acquire-all-the-stock-of-revance-therapeutics-inc/2025-08-15T07:28:32+00:00weekly0.6https://www.medthority.com/news/2024/11/nice--uk-recommended-to-treat-systemic-mastocytosis-.--blueprint-medicines2024-11-11T12:23:13+00:00weekly0.6https://www.medthority.com/news/2024/11/applications-submitted--in-the-u.s.-and-eu-seeking-approval-of-darzalex-faspro--darzalex-as-subcutaneous-monotherapy-for-high-risk-smoldering-multiple-myeloma--johnson--johnson2024-11-11T12:33:40+00:00weekly0.6https://www.medthority.com/news/2024/10/alnylam-submits-regulatory-application-to-the-european-medicines-agency-for-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy/2024-10-30T15:23:52+00:00weekly0.6https://www.medthority.com/news/2024/10/fasenra-benralizumab-is-approved-in-the-european-union-eu-as-an-add-on-treatment-for-adult-patients-with-relapsing-or-refractory-eosinophilic-granulomatosis-with-polyangiitis-.--astrazeneca2024-11-15T11:19:33+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-feedback-from-end-of-phase-ii-meeting-with-the-fda-supporting-the-regulatory-path-forward-for-bitopertin-in-erythropoietic-protoporphyria--disc-medicine/2024-11-06T14:53:31+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approval-for--emrosi-minocycline-hydrochloride-extended-release-capsule-to-treat-rosacea-.--journey-medicine-corporation2024-11-06T14:52:17+00:00weekly0.6https://www.medthority.com/news/2024/11/validation-of-utility-of-intravascular-lithotripsy-in-lower-limb-lesions-in-late-breaking-presentation-at-viva-2024--shockwave-medicaljj-medtech/2024-11-06T14:50:40+00:00weekly0.6https://www.medthority.com/news/2024/11/first-clinical-outcomes-associated-with-the-shockwave-javelin-peripheral-ivl-catheter--shockwave-medicaljj-medtech/2024-11-06T14:36:36+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-study-304-for-lumateperone-for-prevention-of--relapse-in-patients-with-schizophrenia--intra-cellular-therapies/2024-11-07T11:55:37+00:00weekly0.6https://www.medthority.com/news/2024/11/pdufa-date-extended-for-zenocutuzumab-zeno-to-treat-ncslcngr1-positive-and-pancreatic-cancer--merus-nv/2024-11-07T12:04:04+00:00weekly0.6https://www.medthority.com/news/2024/11/the-european-medicines-agency-has-approved-dupixent-dupilumab-to-treat-eosinophilic-esophagitis-eoe-in-children-as-young-as-one-year-of-age.--sanofi2024-11-07T12:05:35+00:00weekly0.6https://www.medthority.com/news/2024/11/astrazeneca-china-president-is-currently-under-investigation/2025-10-16T11:05:32+00:00weekly0.6https://www.medthority.com/news/2024/10/mirikizumab-is-first-and-only-il23p19-antagonist-to-report-long-term-multi-year-sustained-efficacy-and-safety-data-for-both-ulcerative-colitis-and-crohns-disease--elililly/2024-10-30T15:22:02+00:00weekly0.6https://www.medthority.com/news/2024/10/initiation--of-interpath-009-a-pivotal-phase-iii-randomized-clinical-trial-evaluating-v940-mrna-4157-in-combination-with-keytruda--pembrolizumab--merck-inc.--moderna2024-10-30T15:21:09+00:00weekly0.6https://www.medthority.com/news/2024/10/new-sebetralstat-data--presented-at-the-2024-american-college-of-allergy-asthma-and-immunology-kalvista-pharmaceuticals/2024-10-30T15:20:11+00:00weekly0.6https://www.medthority.com/news/2024/10/spyral-htn-on-med-study-shows-significant-consistent-long-term-blood-pressure-lowering-effect-at-two-years.--medtronic2024-10-30T15:18:31+00:00weekly0.6https://www.medthority.com/news/2024/10/lillys-ebglyss-lebrikizumab-lbkz-demonstrated-meaningful-improvement-in-skin-clearance-and-itch-relief-in-the-majority-of-patients-with-moderate-to-severe-atopic-dermatitis-who-discontinued-dupilumab---eli-lilly/2024-10-30T15:17:35+00:00weekly0.6https://www.medthority.com/news/2024/10/european-commission-approves-expanded-use-of-hiv-1-therapy-edurant-rilpivirine-in-younger-pediatric-patients--johnson--johnson/2024-10-30T15:15:27+00:00weekly0.6https://www.medthority.com/news/2024/10/impella-ecp-pivotal-study-demonstrates-safetyefficacy-for-use-in-high-risk-pci---abiomed-jj-medtech/2024-10-30T15:14:30+00:00weekly0.6https://www.medthority.com/news/2024/10/abbvie-acquires-aliada-therapeutics-and-with-it-alia-1758/2024-10-30T15:13:41+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-results-from-phase-ii-trial-of-barzolvolimab-in-chronic-inducible-urticaria--cellldex-therapeutics/2024-10-30T15:12:37+00:00weekly0.6https://www.medthority.com/news/2024/10/-gsk-acquires-from-chimagen-biosciences-cmg-1a46--a-clinical-stage-dual-cd19-and-cd20-targeted-t-cell-engager-tce-/2024-10-30T15:08:44+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-results-from-trailblazer-alz-6-phase-iii-b-study-showing-a-reduction-in-amyloid-related-imaging-abnormalities-with-edemaeffusion-aria-e-at-the-24-week-primary-endpoint.--eli-lilly2024-10-30T15:07:46+00:00weekly0.6https://www.medthority.com/news/2024/10/glycomimetics-acquires-crescent-biopharma-and-with-it-cr-001/2024-10-30T15:06:57+00:00weekly0.6https://www.medthority.com/news/2024/10/triscend-ii-trial-demonstrates-superior-clinical-and-quality-of-life-benefits-with-edwards-evoque-system-for-severe-tricuspid-regurgitation/2024-11-15T11:20:24+00:00weekly0.6https://www.medthority.com/news/2024/10/orion--corporation-terminates-odm-111-development-programme/2024-10-31T11:00:01+00:00weekly0.6https://www.medthority.com/news/2024/10/sage-therapeutics-announces-a-strategic-reorganisation/2024-10-31T11:00:02+00:00weekly0.6https://www.medthority.com/news/2024/10/results-of-the-acurate-ide-clinical-trial-which-evaluated-theacurate-neo2-aortic-valve-system-in-the-treatment-of-patients-with-severe-symptomatic-aortic-stenosis.-boston-scientific2024-10-31T11:00:02+00:00weekly0.6https://www.medthority.com/news/2024/10/enrollment--is-complete-in-the-pilot-phase-of-the-omny-af-clinical-trialwhich-evaluates-the--omnypulse-platform-in-the-treatment-of-symptomatic-paroxysmal-atrial-fibrillation-afib.jj2024-10-31T11:00:02+00:00weekly0.6https://www.medthority.com/news/2024/10/new-england-journal-of-medicine-publishes-landmark-phase-iii-results-for--itovebi-showing-more-than-doubling-of-progression-free-survival-in-certain-type-of-hr-positive-advanced-breast-cancer--roche/2024-10-31T11:00:03+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-topline-one-year-results-from-the-open-label-single-arm-phase-iv-elevatum-study-evaluating-vabysmo--faricimab-for-the-treatment-of-dme-in-people-from-racial-and-ethnic-groups---roche/2024-10-31T11:00:03+00:00weekly0.6https://www.medthority.com/news/2024/10/new-analysis-of-phase-iii-scored-trial-of--sotagliflozin-in-patients-with-diabetic-kidney-disease.--lexicon-pharma2024-10-31T11:00:03+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-interim-results-from-the-phase-iii-trial-of-sibeprenlimab-for-the-treatment-of-immunoglobulin-a-nephropathy-in-adults--otsuka/2024-10-31T11:00:03+00:00weekly0.6https://www.medthority.com/news/2024/11/nice-uk-recommends-danicopan-as-add-on-to--ravulizumab-or-eculizumab-to-treat--residual-haemolytic-anaemia.--astrazeneca2024-11-01T13:39:17+00:00weekly0.6https://www.medthority.com/news/2024/11/new-data-for-emapalumab-in-the-treatment-of-macrophage-activation-syndrome-to-be-presented-at-the-acr-conference/2024-11-01T13:38:11+00:00weekly0.6https://www.medthority.com/news/2024/11/rolling-submission-to-fda-completed-for-subcutaneous-leqembi-lecanemab-irmb-for-treatment-of-alzheimers-disease--eisai--biogen/2024-11-01T13:37:18+00:00weekly0.6https://www.medthority.com/news/2024/11/two-phase-iii-trials-initiated-for-survodutide-for-the-treatment-of-adults-living-with-mash-and-fibrosis-scarring--boehringer/2024-11-01T13:36:30+00:00weekly0.6https://www.medthority.com/news/2024/11/wegovy--semaglutide-reduces-pain-from-obesity-related-knee-arthritis-.--novonordisk2024-11-15T11:21:25+00:00weekly0.6https://www.medthority.com/news/2024/11/lundbeck-announces-positive-results-from-phase-iii-pivotal-trial-sunrise-of-vyepti-eptinezumab-in-migraine-prevention/2024-11-01T13:34:06+00:00weekly0.6https://www.medthority.com/news/2024/11/positive-results-from-essence-trial-of-wegovy-semaglutide-2.4-mg-in-patients-with-metabolic-dysfunction-associated-steatohepatitis-mash--novo-nordisk2024-11-04T08:24:09+00:00weekly0.6https://www.medthority.com/news/2024/11/phase-ii-trial-of-masofaniten---enzalutamide-is-terminated--in-patients-with-metastatic-castration-resistant-prostate-cancer.--essa-pharma2025-01-23T13:57:22+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-drugs-advisory-committee-rejects-zynquista--sotagliflozin-as-an-adjunct-to-insulin-therapy-for-glycemic-control-in-adults-with-type-1-diabetes-and-chronic-kidney-disease.-lexicon-pharma2024-11-04T08:21:48+00:00weekly0.6https://www.medthority.com/news/2024/11/abbvie-to-collaborate-with-evolveimmune-therapeutics/2024-11-04T08:21:04+00:00weekly0.6https://www.medthority.com/news/2024/11/the-latest-findings-for-lecanemab-irmb-leqembi-for-early-alzheimers-disease-ad-were-presented-at-the-clinical-trials-for-alzheimers-disease-conference-.--eisai--biogen2024-11-04T08:20:15+00:00weekly0.6https://www.medthority.com/news/2024/11/supplemental-approval--from-the--fda-for-jylamvo-methotrexate-to-treat-all-and-polyarticular-juvenile-idiopathic-arthritis-.--shorla-oncology2024-11-04T08:19:02+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-grants-accelerated-approval-for-scemblix-asciminib-for-adult-patients-with-newly-diagnosed-philadelphia-chromosome-positive-chronic-myeloid-leukemia-in-chronic-phase.--novartis2024-11-04T11:59:54+00:00weekly0.6https://www.medthority.com/news/2024/11/fda-approves-roxybond--oxycodone-hydrochloride-immediate-release-for-the-management-of--severe-pain--protega-pharma/2024-11-05T13:09:39+00:00weekly0.6https://www.medthority.com/news/2024/11/shockwave-medical-completes-enrollment-in-all-female-coronary-intravascular-lithotripsy-study/2024-11-05T13:11:45+00:00weekly0.6https://www.medthority.com/news/2024/11/boston-scientific-acquires-cortex-and-with-it-the-optimap-system/2024-11-05T13:13:40+00:00weekly0.6https://www.medthority.com/news/2024/11/matinas-biopharma-holdings-reports-cessation-of-negotiations-for--rights-to--mat-2203-and-workforce-reduction/2024-11-05T13:15:42+00:00weekly0.6https://www.medthority.com/news/2024/10/transgene-announces-phase-ii-trial-of-therapeutic-cancer-vaccine-tg-4001-in-recurrent-or-metastatic-hpv16-positive-cervical-and-anogenital-cancers-did-not-meet-the-primary-objective-of-improvement-in-progression-free-survival/2024-10-18T12:17:08+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-phase-iii-data-for-uplizna--inebilizumab--cdon-in-generalised-myasthenia-gravis--presented-at-aanem-meeting--amgen/2024-10-18T12:19:42+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-vyalev-foscarbidopa--foslevodopa-subcutaneous-24-hour-infusion-of-levodopa-based-therapy-for--advanced-parkinsons-disease-.-abbvie2024-10-18T12:22:17+00:00weekly0.6https://www.medthority.com/news/2024/10/sanofi-and-orano-join-forces-to-develop-next-generation-radioligand-medicines/2024-10-18T12:29:41+00:00weekly0.6https://www.medthority.com/news/2024/10/new-drug-regimen-funded-by-cancer-care-uk-extends-survival-for-cervical-cancer-patients/2024-11-15T10:45:27+00:00weekly0.6https://www.medthority.com/news/2024/10/nice-uk-grants-managed-access-to-belzutifan-to-treat-von-hippel-lindau-vhl-disease/2024-10-19T15:16:59+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves--the-versius-surgical-system/2024-10-19T15:15:57+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-opinion-for-kisqali--ribociclib-to-help-reduce-risk-of-recurrence-in-people-with-hrher2--early-breast-cancer.--novartis2024-10-19T15:12:49+00:00weekly0.6https://www.medthority.com/news/2024/10/gilead-sciences-to-withdraw-trodelvy-sacituzumab-govitecan-hziy-for-bladder-cancer-in--the-us/2024-10-19T15:11:46+00:00weekly0.6https://www.medthority.com/news/2024/10/self-amplifying-mrna-covid-19-vaccine-demonstrates-superior-immune-response-compared-with-mrna-vaccine-at-12-months-post-vaccination--seqiruscsl/2024-10-20T14:22:40+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-vyloy-zolbetuximab-clzb---chemotherapy-to-treat-egfr--receptor-2-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma.--astellas2024-10-22T11:08:07+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-absimky-ustekinumab-biosimilar--from-accord-healthcareintas/2024-10-22T11:11:05+00:00weekly0.6https://www.medthority.com/news/2024/10/long-term-efficacy-and-safety-profile-of-eylea-8-mg-with-extended-dosing-intervals-in-diabetic-macular-edema-confirmed-at-three-years--bayer/2024-10-22T11:13:13+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-buprenorphine-neuraxpharm-buprenorphine--to-treat-opioid-dependence----neuraxpharm-pharmaceuticals/2024-10-22T11:15:45+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-flucelvax-vaccine-to-prevent-influenza/2024-10-22T11:21:22+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-botox-cosmetic-onabotulinumtoxina-for-temporary-improvement-in--platysma-bands-in-adults.--allerganabbvie2024-10-22T11:24:01+00:00weekly0.6https://www.medthority.com/news/2024/10/viatris-obtains-exclusive-licence-from-lexicon-for-sotaglifozin-outside-the-us-and-eu/2024-10-22T11:39:22+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-kevzara-sarilumab-to-treat-polymyalgia-rheumatica--sanofi/2024-10-22T11:49:06+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-tevimbra-tislelizumab-in-gastric-or-gastroesophageal-junction-ggej-adenocarcinoma-and-esophageal-squamous-cell-carcinoma-escc--beigene/2024-10-22T11:53:47+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-yeslty-linzagolix-to-treat-endometrosis.--theramax2024-10-22T11:56:31+00:00weekly0.6https://www.medthority.com/news/2024/10/complete-response-for-cam-2029-octreotide-to-treat-acromegaly--camurus/2024-10-23T11:29:48+00:00weekly0.6https://www.medthority.com/news/2024/10/headline-results--announced-from-the-soul-cardiovascular-outcomes-trial-of-oral-semaglutide.--novo-nordisk2024-10-23T11:31:41+00:00weekly0.6https://www.medthority.com/news/2024/10/-fda-approval-of-additional-presentation-of-selarsdi-ustekinumab-aekn-expanding-its-label-to-include-further-indications---teva-and-alvotech/2024-10-23T11:51:02+00:00weekly0.6https://www.medthority.com/news/2024/10/nda-resubmitted-to-fda-for-rivoceranib--camrelizumab--as-first-line-systemic-treatment-for-unresectable-or-metastatic-hepatocellular-carcinoma.--elevar-therapeutics-2025-01-31T12:05:23+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-siiltibcy-for-the-diagnosis-ofmycobacterium-tuberculosisinfection.-serum-life-science-europe-gmbh2024-10-21T11:28:51+00:00weekly0.6https://www.medthority.com/news/2024/10/-the--chmp-adopted-a-positive-opinion-for-wainzua-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-and-stage-1-or-2-polyneuropathy..-astrazeneca2024-10-21T12:35:49+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for--alhemo-concizumab-as-the-first-once-daily-subcutaneous-prophylactic-treatment-for-people-aged-12-years-or-older-living-with-haemophilia-a-or-b-with-inhibitors.--novonordisk2024-10-21T12:37:31+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-for-fluad-vaccine-for-the-prevention-of-influenza-disease-in-people-aged-50-years-and-older---seqiruscsl/2024-10-21T12:39:57+00:00weekly0.6https://www.medthority.com/news/2024/10/chmp-positive-fro-korjuny-catumaxomab-for-treatment-of-malignant-ascites--lindis-biotech-gmbh/2024-10-21T12:41:17+00:00weekly0.6https://www.medthority.com/news/2024/10/mhra-uk-approves-donanemab-to-treat-mild-cognitive-impairment-and-mild-dementia-in-the-uk.--eli-lilly2024-10-24T11:57:04+00:00weekly0.6https://www.medthority.com/news/2024/10/tersera-therapeutics-will-acquire-margenza-margetuximab-cmkb-from-macrogenics/2024-10-24T12:08:36+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval-for-farawave-nav-ablation-catheter-for-treatment-of-paroxysmal-atrial-fibrillation-and-for-new-faraview-software.--boston-scientific2024-10-24T12:12:08+00:00weekly0.6https://www.medthority.com/news/2024/10/fdas-decision-on-the-snda-of-sotorasib-and-panitumumab-in-kras-g12c-mutated-chemorefractory-metastatic-crc-has-been-delayed--amgen/2024-10-24T12:16:42+00:00weekly0.6https://www.medthority.com/news/2024/10/kisqali-ribociclib-recognized-as-category-1-preferred-breast-cancer-adjuvant-treatment-by-nccn-clinical-practice-guidelines-in-oncology---novartis/2024-10-24T12:20:35+00:00weekly0.6https://www.medthority.com/news/2024/10/nice-uk-recommends-vanflyta-quizartinib--to-treat-newly-diagnosed-flt3itdpositive-acute-myeloid-leukaemia-.-daiichi-sankyo2024-10-24T12:25:35+00:00weekly0.6https://www.medthority.com/news/2024/10/successful-outcome-of-interaction-with-fda-to-deterime-pathway-for-st-920-isaralgagene-civaparvovec-for-fabry-disease--sangamotherapeutics/2024-10-25T12:07:23+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval--for-abrysvo-respiratory-syncytial-virus-vaccine-for-prevention-of-lrtd-caused-by-rsv-in-individuals-18-to-59-years.--pfizer2024-10-25T12:09:26+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-keytruda--pembrolizumab--for-endometrial-carcinoma-and-figo-2014-stage-iii-iva-cervical-cancer.--merck-inc2024-10-25T12:13:51+00:00weekly0.6https://www.medthority.com/news/2024/10/team-hf-trial-to-measure-pulmonary-pressures-using-cardiomems-hf-system--abbott/2024-10-25T12:16:03+00:00weekly0.6https://www.medthority.com/news/2024/10/rigel-pharmaceuticals-issues-dear-health-care-provider-letter-relating-to-gavreto-pralsetinib/2024-10-25T12:19:58+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval-for-affera-mapping-and-ablation-system-with-sphere-9-catheter-for-treatment-of-persistent-atrial-fibrillation.--medtronic2024-10-25T12:22:09+00:00weekly0.6https://www.medthority.com/news/2024/10/bayer-to-licence--a-heart-disease-program-from-dewpoint-therapeutics-to-treat-dilated-cardiomyopathy/2024-10-25T12:55:01+00:00weekly0.6https://www.medthority.com/news/2024/10/merck-inc.-acquires-modifi-biosciences-inc2024-10-25T12:56:36+00:00weekly0.6https://www.medthority.com/news/2024/10/darzalex-daratumumab-sc-based-quadruplet-regimen-is-approved-by-the-european-commission-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible/2024-10-26T12:59:03+00:00weekly0.6https://www.medthority.com/news/2024/10/dupixent-late-breaking-positive-phase-iii-data-in-chronic-spontaneous-urticaria-to-be-presented-at-acaai--sanofi/2024-10-26T12:58:11+00:00weekly0.6https://www.medthority.com/news/2024/10/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-undertreated-plaque-psoriasis--johnson--johnson/2024-10-26T12:57:18+00:00weekly0.6https://www.medthority.com/news/2024/10/abbvie-and-gedeon-richter-to-collaborate--on--the-discovery-and-development-of-novel-targets-for-neuropsychiatric-conditions/2024-10-26T12:56:20+00:00weekly0.6https://www.medthority.com/news/2024/10/abbvie-and-gedeon-richter-tocollaborate-on-for-the-discovery-and-development-of-novel-targets-for-neuropsychiatric-cconditions/2024-10-26T12:55:35+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-orlynvah--sulopenem-etzadroxil-and-probenecid-for-the-treatment-of-uncomplicated-urinary-tract-infections--iterum-therapeutics/2024-10-27T18:40:14+00:00weekly0.6https://www.medthority.com/news/2024/10/oral-fabhalta-iptacopan-sustained-clinically-meaningful-results-at-one-year-in-phase-iii-c3-glomerulopathy-c3g-trial.--novartis-2024-10-27T18:39:25+00:00weekly0.6https://www.medthority.com/news/2024/10/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan-treatment-effect-in-patients-with-c3g--primary-ic-mpgn--sobi--apellis/2024-10-27T18:38:25+00:00weekly0.6https://www.medthority.com/news/2024/10/lyell-immunopharma-to-acquire-immpact-bio-usa-and-with-it-impt-314/2024-10-27T18:37:41+00:00weekly0.6https://www.medthority.com/news/2024/10/nipocalimab-demonstrates-sustained-disease-control-in-adolescents-living-with-generalized-myasthenia-gravis-in-phase-iiiii-study-johnson--johnson/2024-10-16T11:57:58+00:00weekly0.6https://www.medthority.com/news/2024/10/eu-marketing-authorization-application-is-submitted-for-elinzanetant-to-treat-moderate-to-severe-vasomotor-symptoms.--bayer2024-10-16T12:01:21+00:00weekly0.6https://www.medthority.com/news/2024/10/application-submitted-for-third-indication-of-darolutamide-in-the-eu--bayer/2025-01-23T13:57:29+00:00weekly0.6https://www.medthority.com/news/2024/10/gepotidacin-accepted-for-priority-review-by-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents--gsk/2024-10-17T11:00:00+00:00weekly0.6https://www.medthority.com/news/2024/10/capvaxive--pneumococcal-21-valent-conjugate-vaccine-demonstrates-positive-immune-rresponses-in-adults-with-increased-risk-for-pneumococcal-disease--merck-inc/2024-10-17T11:16:50+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-phase-iii-results-from-anchor-trials-for-depemokimab-in-chronic-rhinosinusitis-with-nasal-polyps--gsk/2024-11-15T10:43:19+00:00weekly0.6https://www.medthority.com/news/2024/10/johnson--johnson-extended-filing-at-ema-for-darzalex-daratumumab-subcutaneous--r-vdd-for-newly-diagnosed-multiple-myeloma/2024-10-11T11:33:14+00:00weekly0.6https://www.medthority.com/news/2024/10/talzenna-talazoparib----xtandi-enzalutamide-prolongs-overall-survival-in-phase-iii-talapro-2-trial-for-prostate-cancer/2025-01-23T13:57:46+00:00weekly0.6https://www.medthority.com/news/2024/10/tremfya--guselkumab-demonstrates-impressive-results-across-biologic-naive-and-biologic-refractory-patients-in-crohns-disease-and-ulcerative-colitis.-johnson--johnson2024-10-11T11:28:39+00:00weekly0.6https://www.medthority.com/news/2024/10/gritstone-bio-has-filed-a-voluntary-petition-under-chapter-11-of-the-united-states-bankruptcy-code-in-the-united-states-bankruptcy-court-for-the-district-of-delaware/2024-10-11T11:26:07+00:00weekly0.6https://www.medthority.com/news/2024/10/boehringer-to-access-the-mxmo-platform-of-circle-pharma-to-develop-a-first-in-class-cyclin-inhibitor-that-could-inhibit-cancer-cell-growth/2024-10-11T11:24:40+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-results-from-long-term-treatment-studies-and-updates-on-regulatory-progress-for-vatiquinone-for--friedreichs-ataxia-program-ptc-therapeutics/2024-10-12T14:29:23+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves--itovebi-inavolisib--a-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation--roche/2024-10-12T14:28:35+00:00weekly0.6https://www.medthority.com/news/2024/10/survey-commissioned-by-roche-of-womens-attitudes-to-screening-for-human-papillomavirus-hpv/2024-10-12T14:26:48+00:00weekly0.6https://www.medthority.com/news/2024/10/positive-vote-from-fda-advisory-committee-meeting-supporting-potential-approval-of-elamipretide-for-the-treatment-of-barth-syndrome--stealth-biotherapeutics/2024-10-14T11:00:57+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-perioperative-treatment-of-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-single-agent-opdivo-for-resectable-nsclc--/2024-10-14T10:58:36+00:00weekly0.6https://www.medthority.com/news/2024/10/majority-of-children-with-spinal-muscular-atrophy-sma-treated-with--evrysdi---risdiplam--are-able-to-sit-stand-and-walk-independently-two-year-data-demonstrate--genentechroche/2024-10-14T11:38:21+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval-for-320-mg-single-injection-device-presentations-of-bimzelxbimekizumab-bkzx--ucb/2024-10-14T11:40:31+00:00weekly0.6https://www.medthority.com/news/2024/10/bayer-submits-application-for-third-indication-of-darolutamide-in-the-eu-in-combination-with-androgen-deprivation-therapy-adt-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-/2025-01-23T13:57:36+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-accepts-nda--for-elinzanetant-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms--bayer/2024-12-30T15:12:22+00:00weekly0.6https://www.medthority.com/news/2024/10/astellas-and-aviadobio-announce-exclusive-option-and-license-agreement-for-gene-therapy-avb-101-targeting-frontotemporal-dementia-and-other-indications/2024-10-15T11:14:04+00:00weekly0.6https://www.medthority.com/news/2024/10/exeli-exelixis--and-merck--inc.sign-clinical-development-collaboration-to-evaluate--investigational-zanzalintinib---keytruda-pembrolizumab-in-head-and-neck-cancer-2024-10-15T11:19:53+00:00weekly0.6https://www.medthority.com/news/2024/10/updated-2024-2025-nuvaxovid-covid-19-vaccine-nvx-cov2705-receives-authorization-in-the-eu--novavax/2024-10-15T11:23:48+00:00weekly0.6https://www.medthority.com/news/2024/10/-one-year-histologic-outcomes-reported-in-phase-iii-study-of-mirikizumab-compared-to-ustekinumab-for-crohns-disease.--eli-lilly2024-10-15T11:26:26+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-hympavzi-marstacimab-hncq-for-the-treatment-of-adults-and-adolescents-with-hemophilia-a-or-b-without-inhibitors--pfizer/2024-10-15T11:40:38+00:00weekly0.6https://www.medthority.com/news/2024/10/lundbeck-to-acquire-longboard-pharma-and-with-it-bexicaserin-anti-seizure-product/2024-10-15T11:06:12+00:00weekly0.6https://www.medthority.com/news/2024/10/apitegromab-meets-primary-endpoint-in-phase-iii-sapphire-study-in-patients-with-spinal-muscular-atrophy-sma--scholar-rock/2024-10-08T11:21:58+00:00weekly0.6https://www.medthority.com/news/2024/10/gilead-sciences-inc.announced-additional-data-from-its-pivotal-phase-iii-purpose-2-trial-providing-an-overview-of-the-efficacy-and-safety-of-twice-yearly-lenacapavir2024-10-08T11:24:08+00:00weekly0.6https://www.medthority.com/news/2024/10/novaliq--laboratoires-thea-announce-partnership-and-eu-approval-for-vevizye-ciclosporin-0.1-eye-drops-solution-for-dry-eye-disease2024-10-08T11:26:13+00:00weekly0.6https://www.medthority.com/news/2024/10/cadonilimab-receives-second-indication-approval-from-nmpa-for-first-line-treatment-of-gastricgej-cancer-in-all-comers-population--akeso/2024-10-08T11:28:34+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-nda-for-ameluz-topical-gel-10-to-increase-maximum--dosage-for-actinic-keratosis---biofronetera/2024-10-08T11:30:32+00:00weekly0.6https://www.medthority.com/news/2024/10/-positive-data-for-arexvy-respiratory-syncytial-virus-rsv-vaccine-indicating-protection-over-three-rsv-seasons.--gsk2024-10-09T12:07:50+00:00weekly0.6https://www.medthority.com/news/2024/10/complete-response-from-fda-for--dasiglucagon--to-prevent-and-treat-congenital-hypoglycemia--novo-nordisk--zealand-pharma-/2024-10-09T12:13:53+00:00weekly0.6https://www.medthority.com/news/2024/10/keytruda-pembrolizumab-met-primary-endpoint-of-event-free-survival-efs-as-perioperative-treatment-regimen-in-patients-with-resected-locally-advanced-head-and-neck-squamous-cell-carcinoma/2024-10-09T12:25:34+00:00weekly0.6https://www.medthority.com/news/2024/10/bayer-and-moma-therapeutics-enter-collaboration-and-license-agreement-in-oncology/2024-10-09T12:33:36+00:00weekly0.6https://www.medthority.com/news/2024/10/supplemental-snda-to-the-fda--for-vutrisiran-for-the-treatment-of-transthyretin-amyloidosis-with-cardiomyopathy-alnylam/2024-10-10T11:50:59+00:00weekly0.6https://www.medthority.com/news/2024/10/dalzanemdor-sage-718-did-not-demonstrate-a-statistically-significant-difference-from-baseline-on-the-primary-endpoint-in-the-phase-ii-lightwave-study-for-the-treatment-of-mild-cognitive-impairment-and-mild-dementia-in-alzheimers-disease---sage/2024-10-10T11:54:36+00:00weekly0.6https://www.medthority.com/news/2024/10/concentra-biosciences-llc-submitted-a-non--binding-proposal-to-acquire-kezar-life-sciences-/2024-10-10T12:00:36+00:00weekly0.6https://www.medthority.com/news/2024/10/voluntary-recall-notifying-medtronic-insulin-pump-users-of-potential-risks-of-shortened-pump-battery-life/2024-10-07T11:41:11+00:00weekly0.6https://www.medthority.com/news/2024/10/johnson--johnson-discontinues-phase-ii-field-study-of-jnj-1802-for-dengue--virus/2024-10-07T11:36:07+00:00weekly0.6https://www.medthority.com/news/2024/10/airsupra-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-the-risk-of-severe-exacerbations-in-patients-with-intermittent-or-mild-persistent-asthma-in-batura-phase-iii-trial-/2024-11-15T10:41:25+00:00weekly0.6https://www.medthority.com/news/2024/10/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia/2024-10-02T11:47:12+00:00weekly0.6https://www.medthority.com/news/2024/10/enhertu-granted-priority-review-in-the-us-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-who-have-received-at-least-one-line-of-endocrine-therapy---astrazeneca--daiichi-sankyo-/2024-12-30T15:11:41+00:00weekly0.6https://www.medthority.com/news/2024/10/self-amplifying-mrna-covid-19-vaccine-demonstrates-superior-immune-response-compared-with-mrna-vaccine-at-12-months-post-vaccination---arcturus-theraputics-and-csl/2024-10-02T11:51:23+00:00weekly0.6https://www.medthority.com/news/2024/10/calquence-acalabrutinib--from--astrazeneca--granted-priority-review-in-the-us-for-patients-with-untreated-mantle-cell-lymphoma/2024-10-04T12:21:04+00:00weekly0.6https://www.medthority.com/news/2024/10/aldeyra-therapeutics-resubmits-reproxalap-new-drug-application-to-fda--for-the-treatment-of-dry-eye-disease/2024-10-04T12:24:24+00:00weekly0.6https://www.medthority.com/news/2024/10/eton-pharmaceuticals-to-acquire--increlex-mecasermin-injection-from-ipsen-s.a-to-treat-severe-igf-1-deficiency2024-10-04T12:26:29+00:00weekly0.6https://www.medthority.com/news/2024/10/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer/2025-05-06T15:01:04+00:00weekly0.6https://www.medthority.com/news/2024/10/gilead-sciences-signs-royalty-free-voluntary-licenses-with-six-generic-manufacturers-for-lenacapavir-for-hiv-prevention/2024-10-04T12:30:12+00:00weekly0.6https://www.medthority.com/news/2024/10/-filing-at-fda-for-darzalex-faspro-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients-for-whom-transplant-is-not-planned--johnson--johnson/2024-10-04T12:32:13+00:00weekly0.6https://www.medthority.com/news/2024/10/mithra-pharmaceuticals-enters-bankruptcy/2025-10-16T11:23:06+00:00weekly0.6https://www.medthority.com/news/2024/10/-fda-approves-flyrcado-flurpiridaz-f-18-radioactive-diagnostic-for-enhanced-diagnosis-of-coronary-artery-disease/2024-10-05T13:49:47+00:00weekly0.6https://www.medthority.com/news/2024/10/european-commission-approves-otulfi--ustekinumab-biosimilar-from-fresenius-kabi/2024-10-05T13:48:22+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval-for-otulfi--ustekinumab-biosimilar/2024-10-05T13:48:58+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approval-for-aqneursa--levacetylleucine-to-treat-niemann-pick-disease-type-c/2025-05-22T10:52:53+00:00weekly0.6https://www.medthority.com/news/2024/10/recordati-acquires--enjaymo--sutimlimab--from-sanofi/2024-10-05T13:47:33+00:00weekly0.6https://www.medthority.com/news/2024/10/nice-uk-positive-for-latanoprostnetarsudil-combination-to-treat-primary-open-angle-glaucoma-or-ocular-hypertension/2024-10-06T12:06:23+00:00weekly0.6https://www.medthority.com/news/2024/10/fda-approves-perioperative-treatment-of-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-surgery-and-adjuvant-single-agent-opdivo-for-resectable-nsclc/2024-10-06T12:04:44+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-phase-iii-results-show-xofluza-baloxavir-marboxil-significantly-reduces-the-transmission-of-influenza-viruses.-genentechroche2024-09-20T11:59:14+00:00weekly0.6https://www.medthority.com/news/2024/9/regulatory-update-on-govorestat-for-the-treatment-of-classic-galactosemia.--applied-therapeutics2024-09-20T11:57:28+00:00weekly0.6https://www.medthority.com/news/2024/9/an-fda-advisory-committee-recommended-against-full-approval-for-ocaliva--obeticholic-acid-for-primary-biliary-cholangitis-by-a-13-1-vote.--alfa-sigma--intercept2024-09-20T11:52:21+00:00weekly0.6https://www.medthority.com/news/2024/9/bavarian-nordic-receives-ema-approval-of-mpox-vaccine-for-adolescents.--bavarian-nordic2024-09-20T11:49:04+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-for-wegovy-semaglutide-2.4-mg-label-in-the-european-union-eu.--novo-nordisk2024-09-20T11:44:01+00:00weekly0.6https://www.medthority.com/news/2024/9/organon-acquires-dermavant-from-roivant-and-with-it-vtama-tapinarof-cream-for-plaque-psoriasis/2024-09-20T11:39:23+00:00weekly0.6https://www.medthority.com/news/2024/9/new-migraine-drugs-less-effective-than-previous-generation-of-triptan-meds-bmj-study/2024-09-21T12:38:53+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-opinion-for-omicron-kp.2-adapted-covid-19-vaccine-in-the-european-union.-pfizer--biontech-se2024-11-15T10:39:54+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-chmp-opinion-for-aflibercept-biosimilar-opuviz.--samsung-bioepis--biogen2024-09-21T12:42:57+00:00weekly0.6https://www.medthority.com/news/2024/9/dupixent-dupilumab-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-esophagitis-eoe-in-children-as-young-as-1-year-old.--regeneron--sanofi2024-09-21T12:44:14+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-for-the-treatment-of-certain-adult-ovarian-cancer--abbvie/2024-09-21T12:45:29+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-for-the-treatment-of-certain-adult-ovarian-cancer.--abbvie2024-09-21T12:47:33+00:00weekly0.6https://www.medthority.com/news/2024/9/flumist-nasal-spray-approved-for-self-administration-in-the-us--astra-zeneca/2024-09-21T12:48:39+00:00weekly0.6https://www.medthority.com/news/2024/9/complete-response-letter-for-tradipitant-to-treat-gastroparesis--vanda-pharma/2024-09-21T12:50:45+00:00weekly0.6https://www.medthority.com/news/2024/9/ipsen-announced--that-the-european-commission-has-conditionally-approved-iqirvo-elafibranor-80mg-tablets-for-the-treatment-of-primary-biliary-cholangitis-pbc-in-combination-with-ursodeoxycholic-acid-udca/2024-09-21T12:53:22+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-for-keytruda--pembrolizumab--chemotherapy-to-treat-first-line-advanced-or-recurrent-endometrial-cancer.--merck-inc2024-09-22T20:35:13+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-for-keytruda-pembrolizumab--chemotherapy-to-treat-figo-2024-stage-iii-iva-locally-advanced-cervical-cancer.--merck-inc2024-09-22T20:37:51+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-chmp-opinion-for-han-si-zhuang-as-first-line-treatment-for-extensive-stage-small-cell-lung-cancer.-shanghai-henlius-biotech-inc2024-09-22T20:41:50+00:00weekly0.6https://www.medthority.com/news/2024/9/darzalex-daratumumab-based-quadruplet-regimen-receives-positive-chmp-opinion-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma.--johnson--johnson2024-11-15T10:40:58+00:00weekly0.6https://www.medthority.com/news/2024/9/rybrevant-amivantamab-vmjw-plus-standard-of-care-approved-in-the-u.s.-as-first-and-only-targeted-regimen-to-cut-risk-of-disease-progression-by-more-than-half-in-second-line-egfr-mutated-advanced-lung-cancer.--johnson--johnson2024-09-22T21:02:05+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive--recommendation-for-afqlir-aflibercept-biosimilar.-sandoz.-2024-09-22T21:14:56+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-chmp-opinion-for-treatment-by-marstacimab-for-the-routine-prophylaxis-of-bleeding-episodes-in-adults-and-adolescents-12-years-and-older-with-severe-hemophilia-a-and-for-adults-and-adolescents-with-hemophilia-a-and-b.--pfizer2024-09-23T13:30:45+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-for-theralugand-lutetium-177lu-chloride-a-radiopharmaceutical.--eckert--ziegler2024-09-23T13:34:33+00:00weekly0.6https://www.medthority.com/news/2024/9/chmp-positive-for-fasenra--benralizumab-extension-of-indication-to-treat-eosinophilic-granulomatosis-with-polyangiitis-egpa.-astrazeneca2024-09-23T13:36:36+00:00weekly0.6https://www.medthority.com/news/2024/9/cidara-therapeutics--inc.-announced-the-first-subjects-dosed-in-the-phase-iib-navigate-trial-to-evaluate-the-efficacy-and-safety-of-cd-388-for-the-pre-exposure-prophylaxis-of-influenza.-2024-09-24T11:47:45+00:00weekly0.6https://www.medthority.com/news/2024/9/kayfanda--odevixibat-approved-in-european-union-for-cholestatic-pruritus-in-alagille-syndrome-a-rare-liver-disease.-ipsen2024-09-24T11:50:21+00:00weekly0.6https://www.medthority.com/news/2024/9/datopotamab-deruxtecan-final-overall-survival-results-reported-in-patients-with-metastatic-hr-positive-her2-low-or-negative-breast-cancer-in-tropion-breast01-phase-iii-trial-.astra-zeneca--daichi-sankyo2024-09-24T11:52:40+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approval-for-miplyffa-arimcolomol-to-treat-nieman-pick-disease--zevra-therapeutics/2024-09-24T11:54:03+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-recommends-rubraca-rucaparib-for-the-maintenance-treatment-of-relapsed-platinum-sensitive-high-grade-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-cancer.--pharma2024-09-24T11:55:56+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-recommends-crysvita-burosumab-to-treat-x-linked-hypophosphatemia-in-children.-kyowa-kirin2024-09-24T12:02:05+00:00weekly0.6https://www.medthority.com/news/2024/9/sarclisa-approved-in-the-us-as-the-first-anti-cd38-therapy-in-combination-with-standard-of-care-treatment-for-adult-patients-with-newly-diagnosed-multiple-myeloma-not-eligible-for-transplant.--sanofi2024-09-24T11:59:55+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-accepts-nda-for-delgocitinib-cream--20-mgg-2--to-treat-moderate-to-severe-hand-eczema.--leo-pharma2024-09-25T12:49:00+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves--tecentriq-hybreza-atezolizumab-and-hyaluronidase-tqjs-the-first-and-only-pd-l1-inhibitor-for-subcutaneous-sc-under-the-skin-injection-for-patients-in-the-united-states.---roche2024-09-25T12:51:34+00:00weekly0.6https://www.medthority.com/news/2024/9/tasfygo-tablets-35mg-tasurgratinib-succinate-approved-in-japan-for-biliary-tract-cancer-with-fgfr2-gene-fusions-or-rearrangements--eisai/2024-09-25T12:54:17+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-topline-results-from-phase-iii-study-of-dapirolizumab-pegol-in-systemic-lupus-erythematosus-and-initiation--of-second-phase-iii-study-in-2024.--biogen--ucb2024-09-26T11:30:39+00:00weekly0.6https://www.medthority.com/news/2024/9/ucb-announces-the-presentation-of-new-four-year-data-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-with-bimekizumab/2024-09-26T11:34:58+00:00weekly0.6https://www.medthority.com/news/2024/9/publication-of-data-highlighting-efficacy-of-lurmyz-sodium-oxybate-extended-release-oral-suspension-in-improving-narcolepsy-symptoms-regardless-of-concomitant-use-of-an-alerting-agent.avadel2024-09-26T11:42:28+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approval-of-the-prior-approval-supplement-application-for-zynrelef-bupivacaine--meloxicam-extended-release-vial-access-needle-van---heron-therapeutics/2024-09-26T11:45:09+00:00weekly0.6https://www.medthority.com/news/2024/9/update-on-karmma-9-trial-of-abecma-idecabtagene-vicleucel--with-lenalidomide-maintenance-in-patients-with-newly-diagnose-multiple-myeloma.--bms--2seventy-bio2024-09-26T11:47:56+00:00weekly0.6https://www.medthority.com/news/2024/9/tagrisso-osimertinib-approved-in-the-us-for-patients-with-unresectable-stage-iii-egfr-mutated-lung-cancer--astrazeneca-/2024-09-26T11:49:57+00:00weekly0.6https://www.medthority.com/news/2024/9/bluebird-bio-inc.-restructures2024-09-26T11:52:04+00:00weekly0.6https://www.medthority.com/news/2024/9/bayer-submits-application-to-fda-for-third-indication-of-darolutamide-for-the-use--in-combination-with-adt-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-mhspc.-2025-01-23T14:01:19+00:00weekly0.6https://www.medthority.com/news/2024/9/medtronic-expands-aible--spine-surgery-ecosystem-with-new-technologies.-2024-09-27T13:00:06+00:00weekly0.6https://www.medthority.com/news/2024/9/new-analysis-demonstrates-the-efficacy-of-rinvoq-upadacitinib-in-atopic-dermatitis-with-varying-degrees-of-severity-in-head-and-neck-involvement--abbvie/2024-09-27T13:02:42+00:00weekly0.6https://www.medthority.com/news/2024/9/veltassa-patiromer-approved-in-japan-to-treat-adult-patients-with-hyperkalemia.-zeria-pharma--csl-vifor2024-09-27T13:05:40+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-positive-for-lonsurf-tifluridinetipiracil--avastin--bevacizumab-to-treat-colorectal-cancer.--servier2024-09-27T13:07:31+00:00weekly0.6https://www.medthority.com/news/2024/9/biogen-terminates-rights-to-sage-314-program/2024-09-27T13:09:17+00:00weekly0.6https://www.medthority.com/news/2024/9/tepezza-teprotumumab-trbwreceives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-disease.-amgen-2024-09-27T13:11:11+00:00weekly0.6https://www.medthority.com/news/2024/9/pfizer-withdraws-all-lots-of-oxbrytavoxelotor-for-the-treatment-of-sickle-cell-disease/2024-09-27T12:54:13+00:00weekly0.6https://www.medthority.com/news/2024/9/late-breaking-data-for-bimzelx-bimekizumabfrom-two-year-phase-iii--studies-in-moderate-to-severe-hidradentis-suppurativa-presented-at-eadv.--ucb2024-10-29T14:13:48+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-cobenfy-xanomeline-and-trospium-chloride-a-first-in-class-muscarinic-agonist-for-the-treatment-of-schizophrenia-in-adults.--bms2024-09-27T12:49:58+00:00weekly0.6https://www.medthority.com/news/2024/9/european-commssion-approval-for--vyloy--zolbetuximab--chemotherapy-to-treat-egfr-2-her2-negative-gastric-or-gastroesophageal-junction-gej-adenocarcinoma-whose-tumors-are-claudin-cldn-18.2-positive.--astellas-pharma2024-09-27T12:46:51+00:00weekly0.6https://www.medthority.com/news/2024/9/dupixent--dupilumab-approved-in-china-as-the-first-ever-biologic-medicine-for-patients-with-copd.--regeneron--sanofi2024-09-28T14:59:04+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-dupixent-dupilumab-to-treat-chronic-obstructive-pulmonary-disease-with-an-eosinophilic-phenotype.--regeneron--sanofi2024-09-28T14:58:14+00:00weekly0.6https://www.medthority.com/news/2024/9/bluerock-therapeutics-investigational-cell-therapy-bemdaneprocel-for-parkinsons-disease-shows-positive-data-at-24-months/2024-09-28T14:57:28+00:00weekly0.6https://www.medthority.com/news/2024/9/roche-returns-rights-to-taspoglutide-to-ipsen/2024-09-28T14:55:55+00:00weekly0.6https://www.medthority.com/news/2024/9/update-of-phase-iii-keyform-007-trial-of-keytruda-pembrolizumab-favezelimab-in-positive-microsatellite-stable-mss-metastatic-colorectal-cancer-/2024-09-29T13:40:31+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-advisory-committee-votes-against-riskbenefit-profile-of-first-line-anti-pd-1-therapy-with-advanced-her2--negative-microsatellite-stable-gastricgastroesophageal-junction-gej-adenocarcinoma-with-a-pd-l1-expression-of-less-than-1.12024-09-30T11:32:48+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-advisory-committee-votes-against-riskbenefit-profile-of-first-line-anti-pd-1-therapy-with-advanced-her2--negative-microsatellite-stable-gastricgastroesophageal-junction-gej-adenocarcinoma-with-a-pd-l1-expression-of-less-than-12.12024-09-30T11:36:59+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-advisory-committee-votes-against-riskbenefit-profile-of-frontline-antipd-1-therapy-in-metastaticunresectable-escc-with-a-pd-l1-expression-under-1/2024-09-30T11:40:16+00:00weekly0.6https://www.medthority.com/news/2024/9/johnson--johnson-is-closing-down-its-pharma-divisions-cardiovascular-and-metabolic-unit/2025-10-16T11:23:24+00:00weekly0.6https://www.medthority.com/news/2024/10/genentech-acquires-a-portfolio-of-cdk-inhibitors/2024-10-01T12:28:10+00:00weekly0.6https://www.medthority.com/news/2024/9/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-european-society-of-cardiology-congress-2024/2024-09-03T11:37:50+00:00weekly0.6https://www.medthority.com/news/2024/9/bridgebio-shares-ddata-on-serum-ttr-increase-when-switching-participants-from-placebo-and-tafamidis-to-acoramidis-in-attribute-cm-and-its-open-label-extension.-bridgebio-pharma2024-09-03T11:29:21+00:00weekly0.6https://www.medthority.com/news/2024/9/tolebrutinib-meets-primary-endpoint-in-hercules-phase-iii-study-the-first-and-only-to-show-reduction-in-disability-accumulation-in-non-relapsing-secondary-progressive-multiple-sclerosis--sanofi/2024-09-03T11:23:18+00:00weekly0.6https://www.medthority.com/news/2024/9/finerenone-showed-statistically-significant-improvement-in-cardiovascular-outcomes-in-adults-with-common-form-of-heart-failure-with-high-unmet-medical-need.--bayer2024-09-03T11:13:17+00:00weekly0.6https://www.medthority.com/news/2024/9/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-usa.-novavax2024-09-01T13:12:34+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-clears--omnipod-5-automated-insulin-delivery-system-omnipod-5-for-use-by-people-with-type-2-diabetes--insulet-corporation/2024-09-01T13:11:37+00:00weekly0.6https://www.medthority.com/news/2024/9/new-data-related-to-the-safety-and-long-term-use-of-aficamten--is-presented-at-the-european-society-of-cardiology-congress-2024.--cytokinetics-inc2024-09-02T11:40:13+00:00weekly0.6https://www.medthority.com/news/2024/9/late-breaking-data-from-finerenone-pooled-analysis-on-cardiovascular-and-kidney-outcomes-and-mortality-in-high-risk-patient-populations-presented-at-esc-congress-2024/2024-09-02T11:46:20+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-grants-priority-review-to-nda-for-mirdametinib-for-the-treatment-of-adults-and-children-with-neurofibromatosis-type-1-associated-plexiform-neurofibromas.--springworks-therapeutics2024-09-02T11:49:54+00:00weekly0.6https://www.medthority.com/news/2024/9/an-nda-is-submitted-to-the-fda-for-tlx101-cdx-pixclara-18f-floretyrosine-or-18f-fet-an-investigational-pet-agent-for-the-characterisation-of-progressive-or-recurrent-gliomas.--telix2024-09-02T11:52:48+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-accepts-nda-for-sebetralstat-for-oral-on-demand-treatment-of-hereditary-angioedema.--kalvista-pharma2024-09-04T11:13:12+00:00weekly0.6https://www.medthority.com/news/2024/9/european-commission-approves-eur-neffy-epinephrine-nasal-spray--for-emergency-treatment-of-severe-allergic-reactions-in-adults-and-children.-ars-pharma2024-09-04T11:16:05+00:00weekly0.6https://www.medthority.com/news/2024/9/arrowhead-pharmaceuticals-presents-new-pivotal-phase-iii-data-at-esc-2024-from-palisade-study-of-plozasiran-in-patients-with-familial-chylomicronemia-syndrome---arrowhead-pharmaceuticals/2024-09-04T11:20:11+00:00weekly0.6https://www.medthority.com/news/2024/9/advanz-pharmas-response-to-european-commission-revocation-of-conditional-marketing-authorisation-for-ocaliva-obeticholic-acid-in-rare-disease-primary-biliary-cholangitis-/2024-09-05T11:48:12+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-topline-results-from-study-of-higher-dose-regimen-of-nusinersen-showing-significant-benefit-in-treatment-of-spinal-muscular-atrophy.--boogen2024-09-05T11:51:19+00:00weekly0.6https://www.medthority.com/news/2024/9/bayer-introduces-age-factor-ecosystem/2024-09-05T11:54:15+00:00weekly0.6https://www.medthority.com/news/2024/8/positive-topline-results-announced--from-phase-iii-valiant-study-of-pegcetacoplan-in-c3g-and-primary-ic-mpgn.-apellis-pharma--sobi2024-08-12T12:31:48+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-of-neffy--epinephrine-nasal-spray-the-first-and-only-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis.--ars-pharmaceuticals2024-08-12T12:33:13+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-of-neffy-epinephrine-nasal-spray-the-first-and-only-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis.--ars-pharmaceuticals2024-08-12T12:29:45+00:00weekly0.6https://www.medthority.com/news/2024/8/merck-inc.-acquires-cn-201-a-novel-cd3xcd19-targeting-t-cell-engager-bispecific-antibody-from-curon-biopharmaceutical2024-08-12T12:28:11+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-issues-a-complete-response-letter-for-midomafetamine-capsules-for-ptsd.--lykos-therapeutics2024-08-12T12:26:46+00:00weekly0.6https://www.medthority.com/news/2024/8/primary-endpoint-achieved-in-phase-iii-dry-eye-disease-clinical-trial-of-reproxalap.---aldeyra-therapeutics2024-08-12T12:24:34+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-for-inspire-v-therapy-system-to-treat-obstructive-sleep-disorder--inspire-medical-systems/2024-08-12T12:12:48+00:00weekly0.6https://www.medthority.com/news/2024/8/ucb-to-accelerate-innovation-and-strategic-partnerships-divesting-mature-product-portfolio-in-china-to-cbc-group/2024-08-28T13:22:04+00:00weekly0.6https://www.medthority.com/news/2024/8/ordspono-odronextamab-approved-in-the-european-union-for-the-treatment-of-relapsedrefractory-follicular-lymphoma-and-diffuse-large-b-cell-lymphoma.--regeneron-pharma2024-08-28T13:29:05+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approval-for-winrevair-sotatercept-in-combination--with-other-pulmonary-arterial-hypertension-pah-therapies-for-the-treatment-of-pah-in-adult-patients-with-functional-class-ii-iii.--merck-inc2024-08-28T13:36:23+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-balversa--erdafitinib-for-adult-patients-with-unresectable-or-metastatic-urothelial-carcinoma-bladder-cancer.-janssen-cilag-jj2024-08-28T11:40:25+00:00weekly0.6https://www.medthority.com/news/2024/8/alkermes-initiates-vibrance-2-study-of-alks-2680-for-narcolepsy/2024-08-28T11:38:35+00:00weekly0.6https://www.medthority.com/news/2024/8/ce-mark-for-acurate-prime-aortic-valve-system-transcatheter-aortic-valve-replacement-tavr-technology.-boston-scientific2024-08-28T11:37:13+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-after-failure-of-prior-therapy.--janssen-cilag-jj2024-08-28T11:00:24+00:00weekly0.6https://www.medthority.com/news/2024/8/phase-iii-clinical-study-of-fezolinetant--is-initiated-for-vms-in-women-with-breast-cancer-receiving-adjuvant-endocrine-therapy.--astellas2024-08-28T11:34:38+00:00weekly0.6https://www.medthority.com/news/2024/8/twice-yearly-leqvio--inclisiran-demonstrated-clinically-meaningful-statistically-significant-ldl-c-lowering-as-a-monotherapy-in-patients-at-low-or-moderate-ascvd-risk.--novartis2024-08-28T11:33:00+00:00weekly0.6https://www.medthority.com/news/2024/8/piasky-approved-in-the-eu-as-the-first-monthly-subcutaneous-treatment-for-people-with--paroxysmal-nocturnal-haemoglobinuria-pnh--roche/2024-08-29T11:36:48+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves--padcev-enfortumab-vedotin-in-combination-with-keytruda-pembrolizumab-for-first-line-treatment-of-advanced-urothelial-cancer-bladder-cancer--astellas/2024-08-29T11:39:08+00:00weekly0.6https://www.medthority.com/news/2024/8/nucala-mepolizumab-approved-in-japan-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps.--gsk2024-08-29T11:46:41+00:00weekly0.6https://www.medthority.com/news/2024/8/bayer-and-nextrna-collaboration/2025-10-16T11:03:55+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-confirms-acceptability-of-remaining-phase-iii-pivotal-clinical-trials-for-pl-9643-in-dry-eye-disease-ded--palatin-technologies-inc/2024-08-30T11:25:41+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-mresvia--mrna-1345-an-mrna-respiratory-syncytial-virus-rsv-vaccine-to-protect-adults-aged-60-years-and-older-from-lower-respiratory-tract-disease.--moderna-inc2024-08-30T11:31:05+00:00weekly0.6https://www.medthority.com/news/2024/8/merck-inc.-provides-update-on-phase-iii-keynote-867-trial-of-keytruda-pembrolizumab-in-combination-with-stereotactic-body-radiotherapy-for-nsclc2024-08-30T11:33:50+00:00weekly0.6https://www.medthority.com/news/2024/8/merck-discontinuesd-phase-iii-trial-of-keytruda-pembrolizumabfor-the-adjuvant-treatment-of-patients-with-high-risk-locally-advanced-cutaneous-squamous-cell-carcinoma.--2024-08-30T11:35:15+00:00weekly0.6https://www.medthority.com/news/2024/8/first-patient-dosed-in-phase-iii-study-of-oral-cladribine-in-generalized-myasthenia-gravis--merck-kgaa/2024-08-30T11:36:46+00:00weekly0.6https://www.medthority.com/news/2024/8/submission-of-nipocalimab-to-the-fda-to-treat-broadest-population-living-with-antibody-positive-generalized-myasthenia-gravis.-johnson--johnson2024-08-30T11:38:06+00:00weekly0.6https://www.medthority.com/news/2024/8/the-global-phase-iii-soho-02-trial-is-initiated-being-an-open-label-randomized-multicenter-clinical-trial-assessing-the-efficacy-and-safety-of-bay-2927088-as-first-line-therapy-in-patients-with-advanced-nsclc-with-her-2-mutations.--bayer2024-08-30T11:39:42+00:00weekly0.6https://www.medthority.com/news/2024/8/detailed-results-from-the-positive-helios-b-phase-iii-study-of-vutrisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy-presented-at-the-european-society-of-cardiology-congress.-alnylam-pharmaceuticals2024-08-31T13:55:20+00:00weekly0.6https://www.medthority.com/news/2024/8/researchers-disclosed-results-demonstrating-that-wegovy-semaglutide-once-weekly-injection--offers-addtional-benefits-to-patients-in-the-select-study-compared-to-placebo-it-cut-the-chances-of-dying-from-covid-19-by-roughly-a-third.--novo-nordisk2024-08-31T13:54:20+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-expanded-age-indication-for-arexvy-respiratory-syncytial-virus-vaccine-recombinant-adjuvanted-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk.--gsk2024-08-31T13:52:59+00:00weekly0.6https://www.medthority.com/news/2024/8/acam-2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-fda--approval-for-mpox-indication.--emergent-biosolutions2024-08-31T13:51:28+00:00weekly0.6https://www.medthority.com/news/2024/9/publication-of-restore-data-highlighting-challenges-with-twice-nightly-oxybates-and-strong-patient-preference-for-once-nightly-lumryz-dosing-sodium-oxybate-extended-release-oral-suspension.---avadel-pharma2024-09-09T11:40:26+00:00weekly0.6https://www.medthority.com/news/2024/9/novel-computational-pathology-based-trop2-biomarker-for-datopotamab-deruxtecan-was-predictive-of-clinical-outcomes-in-patients-with-non-small-cell-lung-cancer-in-tropion-lung01-phase-iii-trial/2024-11-15T09:26:53+00:00weekly0.6https://www.medthority.com/news/2024/9/summit-therapeutics-inc.-announced-data-from-the-primary-analysis-of-the-phase-iii-harmoni-2-trial-featuring-the-novel-potential-first-in-class-investigational-bispecific-antibody-ivonescimab2025-08-20T12:11:38+00:00weekly0.6https://www.medthority.com/news/2024/9/new-results-from-the-investigational-agent-bay-2927088-in-her2-mutant-non-small-cell-lung-cancer-nsclc-presented-at-wclc/2024-09-10T11:13:35+00:00weekly0.6https://www.medthority.com/news/2024/9/five-year-results-from-phase-iii-empower-1-trial-of-libtayo-cemiplimab-monotherapy-versus-chemotherapy-as-a-first-line-treatment-for-adults-with-advanced-nsclc.-regeneron2024-11-15T10:16:33+00:00weekly0.6https://www.medthority.com/news/2024/9/eylea-8-mg-pre-filled-syringe-approved-in-the-eu--bayer/2024-09-10T11:08:38+00:00weekly0.6https://www.medthority.com/news/2024/9/longer-follow-up-data-from-the-phase-iii-mariposa-study-which-showed--treatment-with-rybrevant-plus--lazcluze--provided-consistent-benefit-compared-to-osimertinib--in-adult-patients-with-advanced-nsclc.-2024-09-11T12:15:14+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-advisory-committee-review--for-sulopenem-etzadroxilprobenecid-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections.--iterum-therapeutics2024-09-11T12:12:31+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-top-line-results-from-phase-iii-trial-evaluating-efficacy-and-safety-of-gardasil-9-in-japanese-males.--merck-inc2024-09-12T12:37:18+00:00weekly0.6https://www.medthority.com/news/2024/9/urovant-sciences-announced-the-commercial-launch-of-gemtesa-vibegron-75-mg-tablets-for-the-treatment-of-overactive-bladder--with-symptoms-of-urge-urinary--incontinence-uui-urgency-and-urinary-frequency-in-adults/2024-09-12T12:34:07+00:00weekly0.6https://www.medthority.com/news/2024/9/dupiximab-confirmatory-phase-iii-trial-liberty-cupid-study-c-met-primary-and-secondary-endpoints-to-treat-chronic-spontaneous-urticaria.-regeneron--sanofi2024-09-12T12:27:45+00:00weekly0.6https://www.medthority.com/news/2024/9/dupixentdupikumab-is-the-first-and-only-biologic-to-achieve-significant-improvements-in-disease-remission-and-symptoms-in-bullous-pemphigoid-positive-pivotal-study.-sanofi--regeneron2024-09-12T12:25:57+00:00weekly0.6https://www.medthority.com/news/2024/9/jj-to-name-change--ethicon-depuy-synthes-biosense-webster-abiomed-and-cerenovus/2025-10-16T11:23:43+00:00weekly0.6https://www.medthority.com/news/2024/9/depemokimab-late-breaking-data-presented-at-ers-show-a-54-reduction-in-severe-asthma-exacerbations.--gsk2024-09-13T12:28:10+00:00weekly0.6https://www.medthority.com/news/2024/9/johnson--johnson--announced-that-the-fda-has-approved-tremfya-guselkumab-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-uc-a-chronic-disease-of-the-large-intestine-in-which-the-lining-of-the-colon-becomes-inflamed/2024-09-13T12:30:47+00:00weekly0.6https://www.medthority.com/news/2024/9/long-term-safety-and-efficacy-of-mavenclad-cladribine-in-multiple-measures-of-multiple-sclerosis-disease-activity.--merck-kgaa2024-09-13T12:32:10+00:00weekly0.6https://www.medthority.com/news/2024/9/twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and-demonstrated-superiority-to-daily-truvada-in-second-pivotal-phase-iii-trial--gilead-sciences/2024-09-13T12:35:12+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-positive-for-obgemsavibegron-to-treat-overactive-bladder.--pierre-fabre2024-09-13T12:36:35+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-positive-for-brukinsazanubrutinib-to-treat-marginal-zone-lymphoma.--beigene2024-09-13T12:38:17+00:00weekly0.6https://www.medthority.com/news/2024/9/johnson--johnson-announces-dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-small-cell-lung-cancer-treated-with-intravenous-rybrevant-amivantamab-vmjw/2024-09-13T12:40:04+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-positive-for-fabhalta-iptacopan-to-treat-paroxysmal-nocturnal-haemoglobinuria--novartis/2024-09-13T12:25:32+00:00weekly0.6https://www.medthority.com/news/2024/9/sanofi-licenses-alphamix-212pb-dotamtate-to-treat-somatostatin-receptor-expressing-neuroendocrine-tumors-nets-a-rare-cancer/2024-09-13T12:23:17+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-uk-positive-for-lytgobi-futibatinib-to-treat-metastatic-cholangiocarcinoma-with-an-fgfr2-fusion.--taihootsuka2024-09-15T20:08:48+00:00weekly0.6https://www.medthority.com/news/2024/9/enhertu-showed-substantial-clinical-activity-in-patients-with-her2-positive-metastatic-breast-cancer-and-brain-metastases-in-destiny-breast-12-trial.-daiichi-sankyo--astrazeneca2024-09-15T20:15:19+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-ocrevus-zunovo-ocrelizumab--hyaluronidase-ocsq-as-the-first-and-only-twice-a-year-10-minute-subcutaneous-injection-for-people-with-relapsing-and-progressive-multiple-sclerosis.--roche2024-09-15T20:31:00+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-positive-for-vabysmo--faricimabto-treat-retinal-vein-occlusion--roche/2024-09-15T20:47:09+00:00weekly0.6https://www.medthority.com/news/2024/9/nice-positive-for-exa-cel-exagamglogene-autotemcel-to-treat--transfusion-dependent-beta-thalassaemia-for-managed-access-but-not-routine-use--vertex--crispr-therapeutics-ag/2024-09-15T20:54:57+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-tecentriq-hybreza-atezolizumab-and-hyaluronidase-tqjs-the-first-and-only-pd-l1-inhibitor-for-subcutaneous-sc-under-the-skin-injection-for-patients-in-the-united-states.--roche2024-09-15T21:08:16+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approval-for-ebglyss-lebrikizumab-to-treat-atopic-dermatitis-eczema.--eli-lilly2024-09-15T21:15:28+00:00weekly0.6https://www.medthority.com/news/2024/9/keytruda-pembrolizumab--trastuzumab-and-chemotherapy-significantly-improved-overall-survival-versus-trastuzumab-and-chemotherapy-alone-in-first-line-treatment--of-her2-positive-advanced-gastric-or-gej-adenocarcinoma.--merck-inc2024-09-15T21:19:53+00:00weekly0.6https://www.medthority.com/news/2024/9/keytruda-pembrolizumab--chemoradiotherapy-crt-reduced-risk-of-death-by-33-versus-crt-alone-in-newly-diagnosed-high-risk-locally-advanced-cervical-cancer.--merck-inc2024-09-15T21:24:00+00:00weekly0.6https://www.medthority.com/news/2024/9/keytruda-pembrolizumab--lenvima-lenvatinib-in-combination-with-transarterial-chemoembolization-significantly-improved-progression-free-survival-compared-to-tace-alone-in-unresectable-non-metastatic-hepatocellular-carcinoma.--merck-inc.-eisai2024-09-16T11:14:39+00:00weekly0.6https://www.medthority.com/news/2024/9/imfinzi-durvalumab-perioperative-regimen-reduced-the-risk-of-recurrence-by-32-and-the-risk-of-death-by-25-vs.-neoadjuvant-chemotherapy-alone-in-muscle-invasive-bladder-cancer-in-the-niagara-phase-iii-trial.--astrazeneca2024-09-16T11:17:27+00:00weekly0.6https://www.medthority.com/news/2024/9/keytruda-pembrolizumab--chemotherapy-before-surgery-and-continued-as-single-agent-after-surgery-reduced-risk-of-death-by-more-than-one-third-34-versus-neoadjuvant-chemotherapy-in-high-risk-early-stage-triple-negative-breast-cancer.--merck-inc2024-09-16T11:20:31+00:00weekly0.6https://www.medthority.com/news/2024/9/in-a-first-of-its-kind-fixed-dose-study-once-weekly-insulin-efsitora-alfa-leads-to-a1c-reduction-similar-to-daily-insulin.--eli-lilly2024-09-06T12:24:24+00:00weekly0.6https://www.medthority.com/news/2024/9/presentation-at-european-society-of-cardiology-demonstrates-vivo-accuracy-in-complex-ventricular-tachycardia-patients.--catheter-precision-inc2024-09-30T10:52:07+00:00weekly0.6https://www.medthority.com/news/2024/9/roche-presents-new-48-week-data-for-the-brutons-tyrosine-kinase-btk-inhibitor-fenebrutinib-from-the-phase-ii-fenopta-open-label-extension-ole-study-at-the-ectrims-conference/2024-09-07T16:45:23+00:00weekly0.6https://www.medthority.com/news/2024/9/full-fda-approval-for-filspari-sparsentan-the-only-non-immunosuppressive-treatment-that-significantly-slows-kidney-function-decline-in-iga-nephropathy.-travere-therapeutics2024-09-07T16:43:56+00:00weekly0.6https://www.medthority.com/news/2024/9/positive-results-from-phase-iii-trial-of-nucala-mepolizumab-announced--in-copd.-gsk2024-09-07T16:42:02+00:00weekly0.6https://www.medthority.com/news/2024/9/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-to-manage-severe-depression/2024-09-07T16:43:00+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approval-of-dupixent-dupilumab-to-treat-rhinosinusitis-with-nasal-polyps.--regeneron--sanofi2024-09-17T11:11:22+00:00weekly0.6https://www.medthority.com/news/2024/9/ten-year-data-for-keytruda-pembrolizumab-demonstrates-sustained-overall-survival-benefit-versus-ipilimumab-in-advanced-melanoma.--merck-inc2024-09-17T11:16:12+00:00weekly0.6https://www.medthority.com/news/2024/9/imfinzi-durvalumab--imjudo-tremelimumab-demonstrated-unprecedented-overall-survival-in-advanced-liver-cancer-with-one-in-five-patients-surviving-five-years-in-himalaya-phase-iii-trial--astrazeneca-/2024-09-17T11:24:15+00:00weekly0.6https://www.medthority.com/news/2024/9/darolutamide-plus-adt-significantly-reduced-the-risk-of-radiological-progression-or-death-compared-to-placebo-plus-adt-in-patients-with-metastatic-hormone-sensitive-prostate-cancer.--bayer2025-01-23T14:03:51+00:00weekly0.6https://www.medthority.com/news/2024/9/patritumab-deruxtecan-demonstrates-a-statistically-significant-progression-free-survival-improvement-in-this-egfr-mutated-non-small-cell-lung-cancer-population-with-high-unmet-need-following-prior-egfr-tki-treatment.-merck-inc.--daiichi-sankyo2024-09-18T11:12:09+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-kisqali-ribociclib---an-aromatase-inhibitor-to-reduce-risk-of-recurrence-in-people-with-hrher2--early-breast-cancer.--novartis2024-09-18T11:14:16+00:00weekly0.6https://www.medthority.com/news/2024/9/final-overall-survival-results-from-phase-iii-contact-02-pivotal-study-evaluating-cabozantinib--with-an-immune-checkpoint-inhibitor-in-metastatic-castration-resistant-prostate-cancer-at-esmo-2024.-exelixis-inc2025-01-23T14:01:31+00:00weekly0.6https://www.medthority.com/news/2024/9/landmark-10-year-follow-up-data-from-checkmate--067-which-showed-continued-durable-long-term-survival-benefit-with-opdivo-nivolumab--yervoy-ipilimumab-in-advanced-melanoma--bms/2024-09-18T11:18:47+00:00weekly0.6https://www.medthority.com/news/2024/9/fasenra-benralizumab-approved-in-the-us-for-eosinophilic-granulomatosis-with-polyangiitis.-astrazeneca2024-09-20T12:08:19+00:00weekly0.6https://www.medthority.com/news/2024/9/fda-approves-keytrudapembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line-treatment-for-adult-patients-with-unresectable-advanced-or-metastatic-malignant-pleural-mesothelioma-.-merck-inc.-2024-09-20T12:06:37+00:00weekly0.6https://www.medthority.com/news/2024/9/new-long-term-zeposia-ozanimod-data-demonstrate-durable-efficacy-and-consistent-safety-in-relapsing-forms-of-multiple-sclerosis.--bms2024-09-20T12:04:06+00:00weekly0.6https://www.medthority.com/news/2024/9/new-data-in-relapsing-ms-reinforce-benefits-of-kesimpta-ofatumumab-for-first-line-and-switch-patients.--novartis2024-09-20T12:01:44+00:00weekly0.6https://www.medthority.com/news/2024/7/carvykti-ciltacabtagene-autoleucel-achieved-statistically-significant-and-clinically-meaningful-improvement-in-second-interim-analysis-of-the-phase-iii-cartitude-4-study.--johnson--johnson2024-07-04T11:16:24+00:00weekly0.6https://www.medthority.com/news/2024/7/dupixent--dupilumab-approved-in-the-eu-as-the-first-ever-targeted-therapy-for-patients-with-copd.-sanofi--regeneron2024-07-04T11:18:32+00:00weekly0.6https://www.medthority.com/news/2024/7/merck-inc.-announces-exercise-of-option-providing-merck-inc.-with-global-exclusive-rights-to-opevesostat--for-the-treatment-of-metastatic-castration-resistant-prostate-cancer2025-01-23T14:04:26+00:00weekly0.6https://www.medthority.com/news/2024/7/genentech-provides-update-on-phase-iiiii-skyscraper-06-study-in-metastatic-non-squamous-non-small-cell-lung-cancer.-2024-07-04T11:23:50+00:00weekly0.6https://www.medthority.com/news/2024/7/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/2024-07-04T11:30:46+00:00weekly0.6https://www.medthority.com/news/2024/7/cassava-sciences-issues-statement-on-former-science-advisor/2024-07-05T11:16:51+00:00weekly0.6https://www.medthority.com/news/2024/7/risk-of-nonarteritic-anterior-ischemic-optic-neuropathy-naionin-patients-prescribed-semaglutide.-novo-nordisk2024-07-05T11:23:22+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-approves-vabysmo-faricimab-svoa-prefilled-syringe-pfs-for-to-treat-wet-or-neovascular-age-related-macular-degeneration-amd-diabetic-macular-edema-dme-and-macular-edema-following-retinal-vein-occlusion-rvo.--genentechroche2024-07-05T11:26:25+00:00weekly0.6https://www.medthority.com/news/2024/7/rolling-bla-is-submitted-to-the-fda-for-sel-212-rapamycin--pegsiticase-for-the-potential-treatment-of-chronic-refractory-gout.--sobi2024-07-03T14:19:41+00:00weekly0.6https://www.medthority.com/news/2024/7/new-data-from-phase-iii--parkinsons-study-highlighting-improvements-in-unified-parkinsons-rating-scale-after-buntanetap-treatment-annovis-bio-/2024-07-03T14:22:36+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-accepts-nda-for-vanzacaftortezacaftordeutivacaftor-a-next-in-class-triple-combination-treatment-for-cystic-fibrosis.--vertex-pharma2024-07-03T14:32:26+00:00weekly0.6https://www.medthority.com/news/2024/7/positive-topline-results-announced-from-confirmatory-patient-study-for-avt-03-a-proposed-biosimilar-for-prolia-denosumab-and-xgeva-denosumab.---alvotech2024-07-03T14:35:28+00:00weekly0.6https://www.medthority.com/news/2024/7/kisunla-donanemab-azbt-approved-by-the-fda-for-the-treatment-of-early-symptomatic-alzheimers-disease.eli-lilly2024-07-03T14:40:30+00:00weekly0.6https://www.medthority.com/news/2024/7/approval-from-fda-and-european-commission-for-sirturo-bedaquiline-as-part-of-combination-therapy-in-adult-and-pediatric-patients-with-pulmonary-tuberculosis-tb-due-to-mycobacterium-tuberculosis-.--johnson--johnson2024-07-03T14:43:41+00:00weekly0.6https://www.medthority.com/news/2024/7/tagrisso-with-the-addition-of-chemotherapy-approved-in-the-eu-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.--astrazeneca2024-07-06T13:34:30+00:00weekly0.6https://www.medthority.com/news/2024/7/biologics-license-application-resubmission-to-fda-for-cosibelimab--checkpoint-therapeutics-inc/2024-07-08T11:31:05+00:00weekly0.6https://www.medthority.com/news/2024/7/durvalumab--chemo-maintains-os-benefit-in-advanced-biliary-tract-cancer.--astrazeneca2024-07-09T11:43:13+00:00weekly0.6https://www.medthority.com/news/2024/7/pari-pharma-gmbh-announces-termination-of-colifin-license-to-enbiotix-inc.spexis-ag2024-07-09T11:49:38+00:00weekly0.6https://www.medthority.com/news/2024/7/livmarli-approved-in-the-european-union-for-patients-with-progressive-familial-intrahepatic-cholestasis-.-mirum-therapeutics-inc2024-07-09T11:53:14+00:00weekly0.6https://www.medthority.com/news/2024/7/ce-mark-for-accu-chek-smartguide-an-ai-enabled-continuous-glucose-monitoring-solution--offering-critical-predictions-to-people-living-with-diabetes--roche/2024-07-09T11:55:40+00:00weekly0.6https://www.medthority.com/news/2024/7/eli-lilly-to-acquire-morphic-therapeutics-and-with-it-morf-057-a-potential-treatment-for-inflammatory-bowel-diseases/2024-07-09T11:58:27+00:00weekly0.6https://www.medthority.com/news/2024/7/moderna-and-mitsubishi-tanabe-pharma-corporation-enter-joint-agreement-to-promote-modernas-mrna-respiratory-vaccine-portfolio-in-japan-including-covid-19-vaccines/2024-07-10T11:39:43+00:00weekly0.6https://www.medthority.com/news/2024/7/update-on-snda-for-roflumilast-cream-0.15-for-atopic-dermatitis.--arcutis-biotherapeutics2024-07-10T11:41:45+00:00weekly0.6https://www.medthority.com/news/2024/7/jeraygo-aprocitentan-approved-in-europe-as-first-and-only-era-for-the-treatment-of-resistant-hypertension.--idorsia-ltd2024-07-10T11:43:36+00:00weekly0.6https://www.medthority.com/news/2024/7/health-data-analytics-company-truveta-found-that-lilly-s-tirzepatide-helped-patients-lose-more-weight-than-novos-semaglutide-with-the-effects-growing-over-time.-2024-07-10T11:45:34+00:00weekly0.6https://www.medthority.com/news/2024/7/expanded-hybryte-treatment-demonstrates-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma.--soligenix-inc2024-07-10T11:47:25+00:00weekly0.6https://www.medthority.com/news/2024/7/indivior-discontinues-sales-and-marketing-of-perseris-risperidone-subcutaneous-sustained-release-for-schizophrenia.--2025-08-20T14:45:14+00:00weekly0.6https://www.medthority.com/news/2024/7/genentech-to-reintroduce-susvimo--ranibizumab-injection-100-mgml-for-intravitreal-use-via-ocular-implant-for-people-wwith-wet-age-related-macular-degeneration/2024-07-11T12:05:41+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-advisory-committee-meeting-to-review-arimoclomol-for-the-treatment-of-niemann-pick-disease-type-c.--zevra-therapeutics2024-07-11T12:08:59+00:00weekly0.6https://www.medthority.com/news/2024/7/elevar-therapeutics-reports-plans-for-near-term-resubmission-of-nda-for-first-line-treatment-option-for-unresectable-hepatocellular-carcinoma-following-type-a-fda-meeting.-2024-07-11T12:12:14+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-approves-zoryve-roflumilast-cream-0.15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age.-arcutis-biotherapeutics-inc2024-07-11T12:14:45+00:00weekly0.6https://www.medthority.com/news/2024/7/ilumetri-tildrakizumab-demonstrates-high-rates-of-skin-clearance-and-sustained-wellbeing-restoration-in-adults-with-moderate-to-severe-plaque-psoriasis-to-general-population-levels-for-up-to-one-year.--almirall2024-07-11T12:17:17+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-issues-complete-response-letter-for-once-weekly-basal-insulin-icodec.-novo-nordisk2024-07-12T12:03:34+00:00weekly0.6https://www.medthority.com/news/2024/7/mhra-approves-imfinzi-durvalumab---chemotherapy-to-treat-resectable-non-small-cell-lung-cancer.-astrazeneca2024-07-13T12:55:03+00:00weekly0.6https://www.medthority.com/news/2024/7/regulatory-applications-submitted-to-fda-and-ema-for-upadacitinib-rinvoq-in-giant-cell-arteritis.--abbvie2024-07-13T12:53:58+00:00weekly0.6https://www.medthority.com/news/2024/7/ozempic-semaglutide-cuts-dementia-risk-compared-with--januvia--sitagliptin-oxford-study.-novo-nordisk2024-07-13T12:53:04+00:00weekly0.6https://www.medthority.com/news/2024/7/johnson--johnson-acquires-yellow-jersey-therapeutics-and-with-it-nm-26-for-skin-inflammation-and-skin-itch/2024-07-13T12:51:12+00:00weekly0.6https://www.medthority.com/news/2024/7/uk-mhra-grants-marketing-authorization-for-lytenava-bevacizumab-gamma-for-the-treatment-of-wet-amd--outlook-therapeutics/2024-07-14T12:54:16+00:00weekly0.6https://www.medthority.com/news/2024/7/biologic-licence-application-bla-re-submitted-to-fda-for-approval-of-ryoncil-remestemcel-l-to-treat-children-with-steroid-refractory-acute-graft-v.-host-disease.--mesoblast-ltd2024-07-15T11:52:51+00:00weekly0.6https://www.medthority.com/news/2024/7/lantheus-acquires-nav-4694-a-next-generation-beta-amyloid-pet-imaging-agent-for-alzheimers-disease/2024-07-16T12:02:32+00:00weekly0.6https://www.medthority.com/news/2024/7/mhrauk-has-approved-the--subcutaneous-version-of-ocrevus-ocrelizumab-subcutneous-to-treat-patients-with-relapsing-and-primary-progressive-multiple-sclerosis.---roche2024-07-16T12:00:36+00:00weekly0.6https://www.medthority.com/news/2024/7/approval-of-efgartigimod-alfa-injection-subcutaneous-injection-for-generalized-myasthenia-gravis-in-china.--zai-lab--argenx2024-07-16T11:53:47+00:00weekly0.6https://www.medthority.com/news/2024/7/initiation-of-phase-iii-program-for-barzolvolimab-in-patients-with-chronic-spontaneous-urticaria.--celldex-therapeutics2024-07-17T11:23:37+00:00weekly0.6https://www.medthority.com/news/2024/7/darolutamide-meets-primary-endpoint-in-phase-iii-aranote-trial-in-men-with-metastatic-hormone-sensitive-prostate-cancer.--bayer--orion2025-01-23T14:03:55+00:00weekly0.6https://www.medthority.com/news/2024/7/complete-response-letter-from-the--fda-regarding-the-nda-for-ox-124-a-high-dose-naloxone-rescue-medication-in-development-for-opioid-overdose.-orexo-ab2024-07-18T11:52:26+00:00weekly0.6https://www.medthority.com/news/2024/7/vabysmo-faricimab-showed-extended-durability-continued-efficacy-and-a-consistent-safety-profile-in-long-term-diabetic-macular-edema-dme-study.-roche2024-07-18T11:47:46+00:00weekly0.6https://www.medthority.com/news/2024/7/sobi-announced-the-publication-of-full-results-from-the-phase-iii-xtend-kids-study-in-children-younger-than-12-years-old-with-severe-haemophilia-a--in-the-new-england-journal-of-medicine/2024-07-18T11:39:03+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-approval-of-voquezna-vonoprazan-tablets-for-the-relief-of-heartburn-associated-with-non-erosive-gerd-in-adults.--phathom-pharmaceuticals-inc2024-07-20T17:33:24+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-grants-priority-review-to-tabelecleucel-for-adultpediatric-ebv-post-transplant-lymphoproliferative-disease.-pierre-fabre2024-07-22T12:32:51+00:00weekly0.6https://www.medthority.com/news/2024/7/nivolumab-tivozanib-fails-to-improve-pfs-in-advanced-renal-cell-carcinoma-after-prior-immune-checkpoint-inhibition.--aveo-oncology--bms2024-07-22T12:35:07+00:00weekly0.6https://www.medthority.com/news/2024/7/neoadjuvant-botensilimabbalstilimab-is-active-in-resectable-colon-cancer-despite-mmr-status.---agenus2024-07-22T12:36:23+00:00weekly0.6https://www.medthority.com/news/2024/7/positive-data-demonstrating--2-drug-regimen-shows-dovato--dolutegravirlamivudine-is-as-effective-as-3-drug-regimen-biktarvy-bictegraviremtricitabinetenofovir-alafenamide-fumarate-for-maintenance-therapy-of-hiv-1.-viiv-healthcare-2024-07-24T11:24:31+00:00weekly0.6https://www.medthority.com/news/2024/7/topline-results-from-phase-iibiii-trial-of-clesrovimab-mk-1654-an-investigational-respiratory-syncytial-virus-preventative-monoclonal-antibody-for-infants.---merck-inc2024-07-24T11:26:23+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-approves-epysqli-eculizumab-aagh-as-a-biosimilar-to-soliris-eculizumabfor-pnh-and-ahus.-samsung-bioepis-2024-07-24T11:32:14+00:00weekly0.6https://www.medthority.com/news/2024/7/phase-iii-ontarget-trial-results-announced-for-crofelemer-in-prophylaxis-of-diarrhea-for-cancer-supportive-care-.--jaguar-health2024-07-24T11:33:54+00:00weekly0.6https://www.medthority.com/news/2024/7/stada-and-alvotech-launch-uzpruvo-ustekinumab-biosimilar-the-first-approved-ustekinumab-biosimilar-to-stelara-across-europe/2024-07-23T11:36:23+00:00weekly0.6https://www.medthority.com/news/2024/7/spravato-esketamine-is-submitted-to-the-fda-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression.--johnson--johnson2024-07-23T11:38:20+00:00weekly0.6https://www.medthority.com/news/2024/7/second-phase-iii-trial-of-mazdutide-in-chinese-patients-with-type-2-diabetes-met-study-endpoints-and-innovent-biologics-plans-to-submit-nda-of-mazdutide-to-the-nmpa/2024-07-23T11:40:46+00:00weekly0.6https://www.medthority.com/news/2024/7/the-head-of-unaids-maintained-that-gilead-could-bring-the-aids-pandemic-toward-an-end-if-the-company-opens-up-access-to-lenacapavir.--gilead-sciences2024-07-23T11:42:38+00:00weekly0.6https://www.medthority.com/news/2024/7/sandoz-launches-biosimilar-pyzchiva-ustekinumab-across-europe-to-treat-chronic-inflammatory-diseases/2024-07-26T10:13:48+00:00weekly0.6https://www.medthority.com/news/2024/7/pfizer-advances-development-of-once-daily-formulation-of-oral-glp-1-receptor-agonist-danuglipron/2024-07-26T11:17:08+00:00weekly0.6https://www.medthority.com/news/2024/7/livmarli-maralixibat-now-approved-for-progressive-familial-intrahepatic-cholestasis-in-patients-12-months-and-older.--mirim-pharma2024-07-26T11:21:09+00:00weekly0.6https://www.medthority.com/news/2024/7/sage-therapeutics-and-biogen-announce-sage-324-biib124-did-not-demonstrate-a-statistically-significant-dose-response-relationship-on-the-primary-endpoint-in-participants-with-essential-tremor/2024-07-26T11:23:34+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-advisory-committee-reviewed-imfinzi-durvalumab-for-treatment-of-resectable-non-small-cell-lung-cancer-based-on-aegean-phase-iii-trial-results.-astrazeneca-2024-07-26T11:26:35+00:00weekly0.6https://www.medthority.com/news/2024/7/positive-topline-results-from-phase-iii-study-of-giroctocogene-fitelparvovec-a-hemophilia-a-gene-therapy-candidate.--pfizer2024-07-26T11:29:06+00:00weekly0.6https://www.medthority.com/news/2024/7/european-commission-approves-durveqtix-fidanacogene-elaparvovec-a-one-time-gene-therapy-for-adults-with-hemophilia-b.--pfizer2024-07-26T11:33:36+00:00weekly0.6https://www.medthority.com/news/2024/7/mhra-uk-approves-first-in-class-truqap-capivasertib-in-combination-with-fulvestrant-for-treating-the-most-common-type-of-advanced-breast-cancer.-astrazeneca2024-07-26T11:36:33+00:00weekly0.6https://www.medthority.com/news/2024/7/glycomimetics-announces-strategic-review-and-corporate-restructuring-plan/2024-07-26T11:39:23+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-accepts-bla-resubmission-of-cosibelimab-for-the-treatment-of-advanced-cutaneous-squamous-cell-carcinoma.--checkpoint-therapeutics2024-07-27T12:05:22+00:00weekly0.6https://www.medthority.com/news/2024/7/positive-chmp-opinion-for-including-mpox-real-world-effectiveness-data-in-european-marketing-authorization-for-smallpox-and-mpox-vaccine.--bavarian-nordic2024-07-27T12:04:31+00:00weekly0.6https://www.medthority.com/news/2024/7/positive-chmp-opinion-of-anzupgo-delgocitinib-cream-for-the-treatment-of-adults-with-moderate-to-severe-chronic-hand-eczema.---leo-pharma2024-07-27T12:03:45+00:00weekly0.6https://www.medthority.com/news/2024/7/ipsen-receives-chmp-positive-opinions-for-iqirvo-elafibranor-in-primary-biliary-cholangitis-and-kayfanda-odevixibat-in-alagille-syndrome-two-rare-cholestatic-liver-diseases/2024-07-27T12:02:59+00:00weekly0.6https://www.medthority.com/news/2024/7/-update-on-chmp-review-of-lecanemab--for-early-alzheimers-disease-in-the-european-union-.-eisai--biogen2024-07-27T12:00:31+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-approves-leqselvi-deuruxolitinib-to-treat--alopecia-areata--sun-pharma/2024-07-27T11:59:29+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-vevizye-cyclosporine-0.05-in-sfa-to-treat-dry-eye-disease.--novaliq-gmbh2024-07-28T13:28:49+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-vyloy-zolbetuximab-to-treat-gastric-or-gastro-oesophageal-junction-gej-adenocarcinoma.--astellas2024-07-28T13:29:41+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-loqtorzi-toripalimabfor-the-treatment-of-nasopharyngeal-carcinoma-and-oesophageal-squamous-cell-carcinoma.--tmc-pharma2024-07-28T13:33:58+00:00weekly0.6https://www.medthority.com/news/2024/7/vtv-therapeutics-announces-cadisegliatin-program-for-type-1-diabetes-placed-on-clinical-hold/2024-07-28T13:34:58+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-fymskina--fyb-202-a-biosimilar-candidate-to-stelara-ustekinumab-indicated-for-the-treatment-of-several-serious-inflammatory-diseases.fresenius-kabi.-2024-07-29T12:29:47+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-advisers-call-for-review-of-perioperative-lung-cancer-trials--astrazeneca/2024-07-29T12:31:30+00:00weekly0.6https://www.medthority.com/news/2024/7/european-commission-grants-full-approval-of-kinpeygo-budesonide-enteric-formulation-for-the-treatment-of-iga-nephropathy.-stada-arzneimittel-ag.-calliditas2024-07-29T12:38:42+00:00weekly0.6https://www.medthority.com/news/2024/7/fixed-duration-calquence-acalabrutinib--plus-venetoclax-with-or-without-obinutuzumab-significantly-improved-progression-free-survival-in-1st-line-chronic-lymphocytic-leukaemia-in-amplify-phase-iii-trial.--astrazeneca2024-07-29T12:48:36+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-yuvanci-macitentan---tadalafil-to-treat-pulmonary-arterial-hypertension-.--johnson--johnson2024-07-29T12:50:28+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-ituxredi-rituximab-biosimilar--dr-reddy/2024-07-29T12:58:50+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-otulfiustekinumab-biosimilar--for-the-treatment-of-adults-and-children-with-plaque-psoriasis-and-adults-with-psoriatic-arthritis-or-crohns-disease.--fresenius-kabi2024-07-30T10:44:43+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommendation-for-ranibizumab-midas-ranibizumab-biosimilar.--midas-pharma2024-07-30T11:26:39+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-tuznue-trastuzumab-biosimilar-intended-for-the-treatment-of-breast-and-gastric-cancer.-prestige-biopharma-belgium-bvba2024-07-30T11:31:43+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-braftovi-encorafenib---mektovi-binimetinibto-treat-adult-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-brafv600e-mutation.--pierre-fabre2024-07-30T11:34:52+00:00weekly0.6https://www.medthority.com/news/2024/7/chmp-recommends-a-change-to-the-existing-indication-for-slentyo-melatonin-prolonged-release-to-include-children-with-neurogenetic-disorders.--neurim-pharma2024-07-30T11:36:56+00:00weekly0.6https://www.medthority.com/news/2024/7/european-commission-approves-vabysmo-faricimab-for-treatment-of-retinal-vein-occlusion-rvo.--roche2024-07-30T11:39:47+00:00weekly0.6https://www.medthority.com/news/2024/7/new-data-for-susvimo-ranibizumab-injection-demonstrates-sustained-efficacy-in-diabetic-macular-edema-and-diabetic-retinopathy--.-genentechroche2024-07-19T11:22:51+00:00weekly0.6https://www.medthority.com/news/news-trends/asco-spotlight-transcripts/transcript-introduction-from-the-president-of-asco/2026-01-26T16:11:46+00:00weekly0.6https://www.medthority.com/news/news-trends/asco-spotlight-transcripts/transcript-the-emergence-of-generative-ai-for-biomedicine/2026-01-26T16:11:40+00:00weekly0.6https://www.medthority.com/news/news-trends/asco-spotlight-transcripts/transcript-transforming-clinical-research-with-the-nci-director/2026-01-26T16:11:24+00:00weekly0.6https://www.medthority.com/news/news-trends/asco-spotlight-transcripts/transcript-transforming-clinical-research-with-the-nci-director2/2026-01-26T16:09:22+00:00weekly0.6https://www.medthority.com/news/2024/7/cassava-sciences-announces-expansion-of-open-label-extension-trials/2024-07-31T11:39:34+00:00weekly0.6https://www.medthority.com/news/2024/7/topline-results-from-two-phase-iii-clinical-studies-evaluating-retifanlimab-zynyzin-squamous-cell-anal-carcinoma-scac-and-non-small-cell-lung-cancer-nsclc.--incyte-2024-07-31T11:41:54+00:00weekly0.6https://www.medthority.com/news/2024/7/health-canada-grants-full-approval-to-jemperli-dostarlimab-gxly-for-adult-patients-with-recurrent-or-advanced-mismatch-repairdeficient-dmmr-or-microsatellite-instabilityhigh-msi-h-endometrial-cancer.---gsk2024-07-31T13:27:58+00:00weekly0.6https://www.medthority.com/news/2024/7/new-clinical-data-demonstrates-three-years-of-continuous-treatment-with-dual-acting-leqembi-lecanemab-irmb-continues-to-significantly-benefit-early-alzheimers-disease-patients-presented-at-aaic-2024-.-eisai--biogen2024-07-31T11:50:27+00:00weekly0.6https://www.medthority.com/news/2024/7/fda-accepts-nda-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain--vertex/2024-07-31T11:51:44+00:00weekly0.6https://www.medthority.com/news/2024/7/vbi-vaccines-files-for-bankruptcy/2024-07-31T11:52:57+00:00weekly0.6https://www.medthority.com/news/2024/8/pamrevlumab-arm-of-the-precision-promise-study-in-metastatic-pancreatic-cancer-and-lapis-study-in-locally-advanced-unresectable-pancreatic-cancer-did-not-meet-the-primary-endpoints---fibrogen/2024-08-01T11:28:25+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-accepts-nda-for-suzetrigine--to-treat-moderate-to-severe-acute-pain.--vertex-pharma2024-08-01T11:31:42+00:00weekly0.6https://www.medthority.com/news/2024/8/windtree-therapeutics-provides-update-on-istaroxime-clinical-development-and-upcoming-clinical-trial-data/2024-08-01T11:39:31+00:00weekly0.6https://www.medthority.com/news/2024/8/new-drug-application-submitted-to---fda-for-elinzanetant-for-the-treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause.--bayer2024-08-01T11:41:38+00:00weekly0.6https://www.medthority.com/news/2024/8/tracon-pharmaceuticals-to-wind-down-operations/2024-08-01T11:43:26+00:00weekly0.6https://www.medthority.com/news/2024/8/vir-biotechnology-to-withdraw-from-infectious-diseases-research/2024-08-05T07:21:05+00:00weekly0.6https://www.medthority.com/news/2024/8/vir-biotechnology-expands-strategy-of-powering-the-immune-system-through-exclusive-worldwide-license-agreement-with-sanofi-for-multiple-potential-best-in-class-clinical-stage-t-cell-engagers/2024-08-05T07:22:45+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer-as-the-first-and-only-immuno-oncology-based-treatment-to-show-an-overall-survival-benefit.--gsk2024-08-05T07:33:06+00:00weekly0.6https://www.medthority.com/news/2024/8/depuy-synthes-launches-its-first-active-spine-robotics-and-navigation-platform/2024-08-05T07:20:37+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-advisory-committee-positive-forarimoclomol-as-effective-in-the-treatment-of-patients-with-niemann-pick-disease-type-c-npc.--zevra-therapeutics2024-08-05T07:19:21+00:00weekly0.6https://www.medthority.com/news/2024/8/boehringer-acquires-nerio-therapeutics-inc/2024-08-05T07:17:12+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-benzgalantamine-for-treatment-of-alzheimer-disease.-alpha-cognition2024-08-02T11:42:07+00:00weekly0.6https://www.medthority.com/news/2024/8/xspray-pharma-shares-new-information-on-dasynoc-dasatinib-formulationfor-chronic-myeloid-leukemia-cml-and-acute-lymphocytic-leukemia-all..-2024-08-02T11:45:00+00:00weekly0.6https://www.medthority.com/news/2024/8/ideate-lung02-phase-iii-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer.-daiichi-sankyo--merck-inc2024-08-02T11:47:55+00:00weekly0.6https://www.medthority.com/news/2024/8/tirzepatide-successful-in-phase-iii-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity.--eli-lilly2024-08-02T11:50:54+00:00weekly0.6https://www.medthority.com/news/2024/8/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u.s.-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible.--johnson--johnson2024-08-02T11:52:49+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-accelerated-approval-for--tecelra-afamitresgene-autoleucel-for-the-treatment-of-adults-with-unresectable-or-metastatic-synovial-sarcoma-who-have-received-prior-chemotherapy.--adaptimmune-therapeutics-plc2024-08-02T11:55:36+00:00weekly0.6https://www.medthority.com/news/2024/8/asciminib-receives-fda-priority-review-for-newly-diagnosed-ph-cp-cml.--novartis2024-08-05T11:42:48+00:00weekly0.6https://www.medthority.com/news/2024/8/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction--bayer/2024-08-05T11:30:28+00:00weekly0.6https://www.medthority.com/news/2024/8/otsuka-pharma-acquires-jnana-therapeutics/2024-08-05T11:27:28+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approval-for-320-mg-device-presentations-of-bimzelx-bimekizumab.--ucb2024-08-06T12:12:47+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-erzofri-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder.--luye-pharma2024-08-06T12:11:26+00:00weekly0.6https://www.medthority.com/news/2024/8/results-from-the-zoster-122-retrospective-observational-matched-cohort-study-in-adults-aged-50-years-and-over-examines-the-potential-association-between-shingrix-recombinant-zoster-vaccine-or-rzv-vaccination-and-reduced-risk-of-dementia.--gsk2024-08-06T12:09:00+00:00weekly0.6https://www.medthority.com/news/2024/8/cvc-capital-partners-fund-to-acquire-therakos-business-from-mallinckrodt/2024-08-06T12:06:59+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-expands-imcrivee--setmelanotide-marketing-authorization-to-include-children-as-young-as-2-years-old-living-with-bbs-or-pomc-pcsk1-or-lepr-deficiency.--rhythm-pharmaceuticals2024-08-07T12:40:25+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-ec-expanded-the-marketing-authorization-for-imcivree-setmelanotide-to-include-children-between-2-and-younger-than-6-years-old-with-obesity-due-to-bbs-or-pomc-pcsk1-or-lepr-deficiency.-rhythm-pharmaceuticals2024-08-07T12:56:14+00:00weekly0.6https://www.medthority.com/news/2024/8/-the-european-ccommission-approves-avzivi-a-biosimilar-referencing-bevacizumab-.--bio-thera-solutions2024-08-07T12:58:32+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-pediatric-indication-extension-for-palforzia-arachis-hypogaea-oral-immunotherapy-for-treatment-of-peanut-allergy.--stallergenes-greer2024-08-07T13:01:02+00:00weekly0.6https://www.medthority.com/news/2024/8/update-regarding-the-regulatory-status-of-leqembi--lecanemabsubcutaneous-formulation.--eisai2024-08-07T13:04:27+00:00weekly0.6https://www.medthority.com/news/2024/8/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/2024-08-07T13:09:23+00:00weekly0.6https://www.medthority.com/news/2024/8/seres-therapeutics-announces-signing-of-vowst-asset-purchase-agreement-with-nestle-health-science/2024-08-08T12:00:13+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-voranigo-vorasidenib-for-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation.--servier2024-08-08T12:03:46+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-adzynma-recombinant-adamts13-for-the-treatment-of-adamts13-deficiency-in--patients-with-congenital-thrombotic-thrombocytopenic-purpura.-takeda-2024-08-08T12:05:46+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-accepted-the-supplemental-new-drug-application-for--cabometyx-cabozantinib-for-patients-with-advanced-neuroendocrine-tumors.--exelixis-inc2024-08-08T12:10:44+00:00weekly0.6https://www.medthority.com/news/2024/8/wegovy-semaglutide-once-weekly-application-is-withdrawn-from-the-fda-for-heart-failure.--novo-nordisk2024-08-08T12:12:35+00:00weekly0.6https://www.medthority.com/news/2024/8/pharmacosmos-to-acquire-g1-therapeutics-and-with-it-cosela/2024-08-08T12:16:41+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-approves-eliquis-apixaban-for-the-treatment-of-deep-vein-thrombosis-dvt-and-pulmonary-embolism-pe-and-prevention-of-recurrent-dvt-and-pe.---bms--pfizer2024-09-30T12:09:00+00:00weekly0.6https://www.medthority.com/news/2024/8/sarclisa-isatuximab-induction-treatment-demonstrated-significantly-improved-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-eligible-for-transplant.-sanofi2024-08-09T11:21:21+00:00weekly0.6https://www.medthority.com/news/2024/8/-the-european-commission-approves--the--ge-68ga-68-radionuclide-generator-galliapharm.--eckert--ziegler-radiopharma-gmbh-2024-08-09T11:23:18+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-accelerated-approval-for-fabhalta-iptacopan-the-first-and-only-complement-inhibitor-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy-igan.--novartis2024-08-09T11:24:45+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-of-simplera--continuous-glucose-monitor-cgm-and-global-partnership-with-abbott.-medtronic2024-08-09T11:26:09+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma.--citius-pharmaceuticals2024-08-09T11:28:30+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-vorasidenib-for-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation.--servier-pharmaceuticals2024-08-27T10:43:07+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-for-enzeevu-aflibercept-biosimilar.--sandoz2024-08-12T12:07:37+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-requests-additional-demonstration-of-os-benefit-to-support-iomab-b-bla-in-rr-acute-myeloid-leukemia.-actinium-pharma2024-08-12T12:05:02+00:00weekly0.6https://www.medthority.com/news/2024/8/pacira-biosciences-comments-on-ruling-on-exparel-patent-litigation-from-u.s.-district-court-for-the-district-of-new-jersey2024-08-13T11:51:58+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-for-ipx-203-for-treatment-of-parkinsons-disease-to-be-launched-as-crexont-carbidopa-and-levodopa-extended-release-capsules.--amneal-pharma2025-08-20T13:07:08+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-zurnai-nalmefene-injection-auto-injector-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose-induced-by-natural-or-synthetic-opioids-in-adults-and-pediatric-patients-12-years-and-older.--purdue-pharma-lp2024-08-13T11:55:02+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-fibryga-for-acquired-fibrinogen-deficiency-potentially-ushering-in-a-new-standard-of-care.--octapharma2024-08-13T11:56:16+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-furosemide-injection-indication-in-heart-failure.--sc-pharmaceuticals2024-08-13T11:57:49+00:00weekly0.6https://www.medthority.com/news/2024/8/top-line-results-of-abrysvo-vaccine-for-rsv-in-immunocompromised-adults.--pfizer2024-08-13T11:59:50+00:00weekly0.6https://www.medthority.com/news/2024/8/enhertu-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer.--astrazeneca--daiichi-sankyo2024-08-16T12:04:09+00:00weekly0.6https://www.medthority.com/news/2024/8/enhertu-trastuzumab-deruxtecan-approved-in-china-for-patients-with-previously-treated-her2-positive-advanced-or-metastatic-gastric-cancer.--astrazeneca2024-08-16T12:03:08+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-yorvipath-palopegteriparatide-as-the-first-and-only-treatment-for-hypoparathyroidism-in-adults--ascendis-as/2024-08-16T12:02:13+00:00weekly0.6https://www.medthority.com/news/2024/8/launch-of-trileap-lower-extremity-anatomic-plating-system-designed-for-foot-and-ankle-surgeons.-depuy-synthes-jj2024-08-16T12:01:20+00:00weekly0.6https://www.medthority.com/news/2024/8/lynparza-and-imfinzi-combination-approved-in-the-eu-for-patients-with-mismatch-repair-proficient-advanced-or-recurrent-endometrial-cancer-.-astrazeneca2024-08-16T11:58:24+00:00weekly0.6https://www.medthority.com/news/2024/8/crown-laboratories-to-merge-with-revance-therapeutics/2024-08-16T11:55:34+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approves-for-nemluvio-nemolizumab-for-adult-patients-living-with-prurigo-nodularis--galderma/2024-08-16T11:54:44+00:00weekly0.6https://www.medthority.com/news/2024/8/livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-fda.--gilead-sciences2024-08-16T11:51:57+00:00weekly0.6https://www.medthority.com/news/2024/8/imfinzi-durvalumab-granted-priority-review-and-breakthrough-therapy-designation-for-patients-with-limited-stage-smallcell-lung-cancer-in-the-us.--astarzeneca2024-08-16T11:48:01+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-of-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd.--incyte--syndax-pharma2024-08-16T11:45:25+00:00weekly0.6https://www.medthority.com/news/2024/8/topline-results-from-palm-007-study-of-tecovirimat-in-treatment-of-mpox-released.--siga-technologies2024-08-16T11:44:05+00:00weekly0.6https://www.medthority.com/news/2024/8/who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern/2024-08-16T11:42:57+00:00weekly0.6https://www.medthority.com/news/2024/8/european-medicines-agency-confirms-acceptance-of-maa-for-avt-06-a-proposed-biosimilar-to-eylea-aflibercept.--alvotech--advanz-pharma2024-08-16T11:41:56+00:00weekly0.6https://www.medthority.com/news/2024/8/imfinzi--durvalumab-is-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery.--astrazeneca2024-08-16T11:38:58+00:00weekly0.6https://www.medthority.com/news/2024/8/bavarian-nordic-submits-data-to-ema-to-extend-mpoxsmallpox-vaccine-approval-to-adolescents/2024-08-16T11:35:52+00:00weekly0.6https://www.medthority.com/news/2024/8/galera-therapeutics-to-liquidate/2025-10-16T10:43:19+00:00weekly0.6https://www.medthority.com/news/2024/8/positive-topline-results-from-pivotal-study-of-tafasitamab-monjuvi-in-relapsed-or-refractory-follicular-lymphoma.--incyte2024-08-17T12:31:25+00:00weekly0.6https://www.medthority.com/news/2024/8/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influenza-and-covid-19-in-individuals-18-64-years-of-age/2024-08-19T14:00:31+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-grants-priority-review-to-durvalumab-for-limited-stage-small-cell-lung-cancer--ls-sclc-after-concurrent-chemoradiotherapy.--astrazeneca2024-08-19T13:58:18+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval-sought-for-ugn-102-in-low-grade-intermediate-risk--nonmuscle-invasive-bladder-cancer-nmibc--urogen-pharma/2024-08-19T13:56:36+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-grants-priority-review-to-vimseltinib-in-tenosynovial-giant-cell-tumor.--decipheraono2024-08-19T13:50:53+00:00weekly0.6https://www.medthority.com/news/2024/8/european-medicines-agency-validates-application-for-car-t-cell-therapy-breyanzi--lisocabtagene-maraleucel-liso-cel-for-relapsed-or-refractory-follicular-lymphoma.--bms2024-08-20T12:07:34+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-liquidia/2024-08-20T12:04:42+00:00weekly0.6https://www.medthority.com/news/2024/8/fasenra-benralizumab-approved-in-china-for-the-treatment-of-severe-eosinophilic-asthma.--astrazeneca2024-08-21T12:02:09+00:00weekly0.6https://www.medthority.com/news/2024/8/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-u.s.-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.-johnson--johnson2024-08-21T12:00:20+00:00weekly0.6https://www.medthority.com/news/2024/8/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight.--eli-lilly2024-08-21T11:58:43+00:00weekly0.6https://www.medthority.com/news/2024/8/european-commission-grants-second-indication-approval-for-tepkinly-epcoritamab-for-the-treatment-of-adults-with-rr-follicular-lymphoma.--abbvie2024-08-21T11:54:40+00:00weekly0.6https://www.medthority.com/news/2024/8/johnson--johnson--to-acquire-v-wave-ltd/2024-08-21T11:52:55+00:00weekly0.6https://www.medthority.com/news/2024/8/-fda-accepts-sbla-for-opdivo-nivolumab---yervoy--ipilimumab-as-first-line-treatment-of-unresectable-hepatocellular-carcinoma.--bms2024-08-22T11:24:44+00:00weekly0.6https://www.medthority.com/news/2024/8/regeneron-provides-update-on-bla--for-linvoseltamab-in-relapsedrefractory--multiple-myeloma/2024-08-22T11:22:15+00:00weekly0.6https://www.medthority.com/news/2024/8/abbott-advances-heart-failure-management-with-aspirin-free-regimen-for-patients-receiving-the-heartmate-3-heart-pump/2024-08-22T11:20:29+00:00weekly0.6https://www.medthority.com/news/2024/8/chinas-national-medical-products-administration-nmpa-approves-padcev-enfortumab-vedotin-for-treatment-of-locally-advanced-or-metastatic-urothelial-cancer.--astellas2024-08-22T11:17:12+00:00weekly0.6https://www.medthority.com/news/2024/8/leqembi-lecanemab-authorized-for-early-alzheimers-disease-in-great-britain.-eisai--biogen2024-08-23T11:40:44+00:00weekly0.6https://www.medthority.com/news/2024/8/ministry-of-health-labour-and-welfare-in-japan-approves-partial-change-application-for-modernas-covid-19-mrna-vaccine-targeting-sars-cov-2-variant-jn.12024-08-23T11:37:58+00:00weekly0.6https://www.medthority.com/news/2024/8/the-journal-of-american-medical-association-jama-publishes-elinzanetant-phase-iii-data.--bayer2024-08-23T11:35:30+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-to-convene-an-advisory-committee-meeting-to-review-use-of-bristol-myers-squibbs-opdivo-and-merck--co.s-keytruda-in-gastrointestinal-cancer2024-08-28T12:57:48+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-approval--authorization-for-omicron-kp.2-adapted-covid-19-vaccine.--biontech-se--pfizer2024-08-28T12:59:40+00:00weekly0.6https://www.medthority.com/news/2024/8/nice-does-not-recommend--leqembi-lecanemab-for-early-alzheimers-disease.--eisai--biogen2024-08-28T13:01:46+00:00weekly0.6https://www.medthority.com/news/2024/8/update-on-cannabidiol-oral-solution-phase-iii-trial-in-japan-in-treatment-resistant-epilepsies.--jazz-pharma2024-08-28T13:06:02+00:00weekly0.6https://www.medthority.com/news/2024/8/timber-pharmaceuticals-inc.-a-leo-pharma-company-provides-an-update-on-the-development-program-for-tmb-001-in-congenital-ichthyosis2024-08-28T13:08:07+00:00weekly0.6https://www.medthority.com/news/2024/8/fda-clearance-of-the-hydros-robotic-system-the-next-generation-ai-powered-platform-for-aquablation-therapy.--procept-biorobotics-corporation2024-08-28T13:09:45+00:00weekly0.6https://www.medthority.com/news/2024/8/first-real-world-analysis-of-ebola-vaccine-reveals-84-effectiveness-during-democratic-republic-congo-outbreak.--merck-inc2024-08-28T13:15:47+00:00weekly0.6https://www.medthority.com/news/2024/8/fulzerasib-approved-in-china-for-kras-g12cmutant-advanced-nsclc.--innovent-biologics2024-08-28T13:18:49+00:00weekly0.6https://www.medthority.com/news/2025/4/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma---gsk-plc/2025-04-22T11:47:28+00:00weekly0.6https://www.medthority.com/news/2025/4/dupixent-approved-in-the-us-as-the-first-new-targeted-therapy-in-over-a-decade-for-chronic-spontaneous-urticaria---sanofi--regeneron/2025-04-22T11:49:05+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-new-simplera-sync-sensor-for-the-minimed-780g-system-for-insulin-delivery---medtronic/2025-04-22T11:50:24+00:00weekly0.6https://www.medthority.com/news/2025/4/gsks-5-in-1-meningococcal-vaccine-penmenvy-receives-positive-recommendation-from-us-advisory-committee-on-immunization-practices/2025-04-22T11:16:30+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-accepts-application-for-bla-for-menabcwy-vaccine-for-meningococcal-disease.--pfizer2025-04-22T11:18:48+00:00weekly0.6https://www.medthority.com/news/2025/4/phase-iii-trial-of-menabcwy-pentavalent-meningococcal-vaccine-meets-primary-endpoints-and-is-set-for-bla.--pfizer2025-04-22T11:20:19+00:00weekly0.6https://www.medthority.com/news/2025/4/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices---gsk/2025-04-22T11:22:09+00:00weekly0.6https://www.medthority.com/news/2025/4/bluerock-therapeutics-announces-publication-in-nature-of-18-month-data-from-phase-i-clinical-trial-for-bemdaneprocel-an-investigational-cell-therapy-for-parkinsons-disease/2025-04-22T11:24:03+00:00weekly0.6https://www.medthority.com/news/2025/4/acip-votes-to-expand-recommendation-for-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-59-at-increased-risk-of-disease--pfizer/2025-04-22T11:26:49+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-penbraya-the-first-and-only-vaccine-for-the-prevention-of-the-five-most-common-serogroups-causing-meningococcal-disease-in-adolescents.--pfizer2025-04-22T11:28:50+00:00weekly0.6https://www.medthority.com/news/2025/4/orforglipron-an-oral-glp-1-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-iii-trial---eli-lilly/2025-04-22T11:30:36+00:00weekly0.6https://www.medthority.com/news/2025/4/camzyos-mavacamten-for-the-treatment-of-adult-patients-with-non-obstructive-hypertrophic-cardiomyopathy-nhcm-did-not-meet-its-primary-endpoints---bms2/2025-04-22T11:32:23+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-recommends-jakafi-ruxolitinib-for-treating-acute-graft-versus-host-disease-that-responds-inadequately-to-corticosteroids-in-people-12-years-and-over---novartis--incyte/2025-04-22T11:35:34+00:00weekly0.6https://www.medthority.com/news/2025/4/-eight-year-data-show-that-aortic-surgical-valves-treated-with-resilia-tissue-technology--significantly-improve-long-term-outcomes-compared-to--non-resilia-tissue-bioprosthetic-valves.-edwards-life-sciences2025-04-22T11:37:30+00:00weekly0.6https://www.medthority.com/news/2025/4/sbla-filed-at-fda-for-approval-of-nogapendekin-alfa-inbakicept-pmln-anktiva-to-treat-bacillus-calmetteguerin-bcgunresponsive-nonmuscle-invasive-bladder-cancer-with-papillary-disease.altor-bioscience2025-04-22T11:39:08+00:00weekly0.6https://www.medthority.com/news/2025/4/treatment-with-apalutamide-erleada-demonstrated-consistent-24-month-overall-survival-os-data-between-real-world-patients-with-metastatic-castration-sensitive-prostate-cancer.--johnson--johnson2025-05-27T12:53:51+00:00weekly0.6https://www.medthority.com/news/2025/4/-imdelltra-tarlatamab-dlle--demonstrated--superior-overall-survival--in--small-cell-lung-cancer--amgen-/2025-04-15T12:00:10+00:00weekly0.6https://www.medthority.com/news/2025/4/nejm-publishes-clinical-details-of-larotrectinib-a-treatment-for-trk-fusion--cancers.-loxo-oncology--bayer2025-04-15T12:04:43+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-new-tablet-formulation-of-livmarli--maralixibat-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome---progressive-intrahepatic-cholestasis.--mirum-pharma2025-04-15T12:07:06+00:00weekly0.6https://www.medthority.com/news/2025/4/pfizer-provides-update-on-oral-glp-1-receptor-agonist-danuglipron-/2025-04-15T12:09:15+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-columvi--glofitamab-as-the-first-bispecific-antibody-for-diffuse-large-b-cell-lymphoma-after-initial-therapy--roche/2025-04-15T12:14:08+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-grants-full-approval-of-vitrakvi--larotrectinib-for-adult-and-pediatric-patients-with-ntrk-gene-fusion--positive-solid-tumors--bayer/2025-04-15T12:16:22+00:00weekly0.6https://www.medthority.com/news/2025/4/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-by--the-european-commission---eisai/2025-04-15T12:18:23+00:00weekly0.6https://www.medthority.com/news/2025/4/-first-gastric-bypass-surgery-case-completed-with-with-ottava-robotic-surgical-system---johnson--johnson-medtech/2025-04-15T12:20:15+00:00weekly0.6https://www.medthority.com/news/2025/4/interim-results-announced--from--investigator-initiated-study-evaluating-extended-hybryte-synthetic-hypericin-in-early-stage-cutaneous-t-cell-lymphoma-.--soligenix-inc2025-04-15T12:23:02+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-requires-a-confirmatory-phase-iii-trial--to-progress--approval-of-apraglutide-for-patients-with-short-bowel-syndrome.--ironwood-pharma2025-04-16T12:18:18+00:00weekly0.6https://www.medthority.com/news/2025/4/camzyos-mavacamten-for-the-treatment-of-adult-patients-with-non-obstructive-hypertrophic-cardiomyopathy-nhcm-did-not-meet-its-primary-endpoints---bms/2025-04-16T12:15:53+00:00weekly0.6https://www.medthority.com/news/2025/4/efficacy-and-safety-of-axs-05-in-agitation-associated-with-alzheimers-disease-results-from-accord-a-phase-iii-relapse-prevention-trial--axsome-therapeutics/2025-05-13T09:01:43+00:00weekly0.6https://www.medthority.com/news/2025/4/preliminary-results-announced-from-the-shield-utah-study-of--covid-19-vaccine-adjuvanted-2024-2025-formula-targeting-the-jn.1-strain.--novavax2025-04-16T12:10:46+00:00weekly0.6https://www.medthority.com/news/2025/4/-preliminary-results-from-the-tide-asthma-phase-ii-study--demonstrates-amlitelimabs-compelling-efficacy-in-heterogeneous-inflammatory-asthma.--sanofi2025-04-16T12:07:30+00:00weekly0.6https://www.medthority.com/news/2025/4/sandoz-files-antitrust-litigation-against-amgen-regarding-patient-access-to-etanercept-biosimilar-in-the-us/2025-04-16T12:05:35+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-grants-interchangeable-designation-to-yuflyma-adalimumab-aaty-biosimilar-to-humira-adalimumab-celltrion-inc/2025-04-16T12:03:06+00:00weekly0.6https://www.medthority.com/news/2025/4/valneva-receives-first-marketing-authorization-for-ixchiq-vaccine-in-a-chikungunya-endemic-country/2025-04-16T12:01:17+00:00weekly0.6https://www.medthority.com/news/2025/4/leqembi--lecanemab-is-the-first-medicine-that-slows-progression-of-early-alzheimers-disease-to-be-authorized-in-the-european-union--eisai---biogen-/2025-04-17T11:27:48+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-grants-regenerative-medicine-advanced-therapy-rmat-designation-for-lyl-314-for-the-treatment-of-relapsed-andor-refractory-large-b-cell-lymphoma---lyell-immunopharma/2025-04-17T11:31:45+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-grants-isturisa-osilodrostat-expanded-indication-for-the-treatment-of-endogenous-hypercortisolemia-in-patients-with-cushings-syndrome--recordati-/2025-04-17T11:33:24+00:00weekly0.6https://www.medthority.com/news/2025/4/roche-receives-ce-mark-for-its-chest-pain-triage-algorithm-to-enhance-detection-of-acute-coronary-syndrome-acs/2025-04-28T07:25:53+00:00weekly0.6https://www.medthority.com/news/2025/4/late-breaking-elafibranor-iqirvo-primary-sclerosing-cholangitis-psc-data-demonstrates-favorable-safety-profile-and-significant-efficacy-in-second-potential-rare-liver-disease-indication--ipsen-/2025-04-28T07:28:11+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-submission-of-interoperable-insulin-pump-in-order-to-advance-medtronic-and-abbott-cgm-partnership---medtronic/2025-04-28T07:38:33+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-positive-for-lagevrio-molnupiravir-for-treating-covid-19---merck-inc/2025-04-28T07:58:12+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-terminated-appraisal-for-tevimbra-tislelizumab-in-combination-for-untreated-advanced-non-small-cell-lung-cancer---beigenebeone-medicines/2025-04-28T08:01:56+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approval-for-valtoco--diazepam-nasal-spray-for-short-term-treatment-of-seizure-clusters-also-known-as-acute-repetitive-seizures.--neurelis-inc2025-04-28T08:04:47+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-recommends-joenja-leniolisib-for-treating-activated-phosphoinositide-3-kinase-delta-syndrome-in-people-12-years-and-over---pharming/2025-04-28T08:07:20+00:00weekly0.6https://www.medthority.com/news/2025/4/-enhertu-trastuzumab-deruxtecan-supplemental-new-drug-application-submitted-in-japan-for-patients-with-her2-positive-metastatic-solid-tumors--daiichi-sankyo/2025-04-28T08:11:23+00:00weekly0.6https://www.medthority.com/news/2025/4/new-spatial-computing-injection-simulator-for-peyronies-disease-creates-immersive-learning-environment-for-urology-specialists--endo/2025-04-28T08:14:01+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-positive-for-rubraca-rucaparib-for-maintenance-treatment-of-advanced-ovarian-fallopian-tube-and-peritoneal-cancer-after-response-to-first-line-platinum-based-chemotherapy---pharma/2025-04-28T08:15:10+00:00weekly0.6https://www.medthority.com/news/2025/4/abbvie-submits-biologics-license-application-to--fda-for-trenibotulinumtoxine-trenibote-for-the-treatment-of-glabellar-lines/2025-04-28T08:19:32+00:00weekly0.6https://www.medthority.com/news/2025/4/second-phase-of-advantage-af-study-of-farapulse-pulsed-field-ablation-system-meets-primary-safety-and-efficacy-endpoints--boston-scientific/2025-04-28T08:21:52+00:00weekly0.6https://www.medthority.com/news/2025/4/new-england-journal-of-medicine-publishes-phase-iii-data-showing-single-dose-xofluza-baloxavirmarboxil.-significantly-reduces-influenza-virus-transmission--roche2025-04-28T13:52:09+00:00weekly0.6https://www.medthority.com/news/2025/4/highlights--presented--at-aua-meeting--from-the-phase-iib-cohort-2-sunrise-1-study-evaluating-tar--200for-bacillus-calmette-guerin-bcgunresponsive-high-risk-non-muscle-invasive-bladder-cancer--jj/2025-04-28T13:51:04+00:00weekly0.6https://www.medthority.com/news/2025/4/analysis-published-in-the-journal-of-clinical-psychiatry-showing-long-term-efficacy-and-a-consistent-safety-profile-of-ingrezza-valbenazine-capsules-in-older-adults-with-tardive-dyskinesia---neurocrine-biosciences/2025-04-28T13:49:53+00:00weekly0.6https://www.medthority.com/news/2025/4/astellas-and-japanese-foundation-for-cancer-research-announce-collaboration-to-accelerate-translational-and-clinical-oncology-research/2025-04-28T13:48:56+00:00weekly0.6https://www.medthority.com/news/2025/4/boehringer-ingelheim-and-cue-biopharma-partner-to-develop-next-generation-treatment-for-autoimmune-and-inflammatory-diseases/2025-04-28T13:48:03+00:00weekly0.6https://www.medthority.com/news/2025/4/boehringer-ingelheim-and-tessellate-bio-partner-to-develop-first-in-class-precision-treatments-for-people-with-hard-to-treat-cancers/2025-04-28T13:46:43+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approval-for-smallest-diameter-lumenless-defibrillation-lead-the-omniasecure-lead-and-announcement-of-investigational-clinical-study-results---medtronic/2025-04-28T13:45:43+00:00weekly0.6https://www.medthority.com/news/2025/4/biohaven-withdraws-application-for-dazluma-bhv-4157-to-treat-spinocerebellar-ataxia--from-ema/2025-04-28T13:43:59+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approval-for-penpulimab-kcqx--with-chemotherapy--and-as-monotherapy-for-the-first-line-treatment-of--non-keratinizing-nasopharyngeal-carcinoma-npc.--akeso-biophama2025-04-28T13:42:54+00:00weekly0.6https://www.medthority.com/news/2025/4/tavapadon-significantly-improved-motor-function-without-increasing-impulse-control-disorders-in-patients-with-early-parkinsons-disease-according-to-two-phase-iii-studies--abbvie/2025-08-20T14:19:15+00:00weekly0.6https://www.medthority.com/news/2025/4/mhra-uk-approves-acoramidis-beyonttra-to-treat-adult-patients-with-cardiomyopathy-damage-to-the-heart-muscle-caused-by-variant-or-wild-type-transthyretin-amyloidosis-attr-cm-bayer/2025-04-28T13:34:25+00:00weekly0.6https://www.medthority.com/news/2025/4/affera-pulsed-field-ablation-technologies-continue-to-demonstrate-promising-evidence-for-atrial-fibrillation-patients---medtronic/2025-04-28T13:33:25+00:00weekly0.6https://www.medthority.com/news/2025/4/expand-uro-u.s.-clinical-trial-meets-safety-and-effectiveness-primary-endpoints-for-hugo-robotic-assisted-surgery-system---medtronic2025-04-28T13:32:29+00:00weekly0.6https://www.medthority.com/news/2025/4/new-clinical-study-data-from-the-volt-ce-mark-study-showcase-long-term-sustained-benefits-of-volt-pfa-system-for-patients-with-afib---abbott/2025-04-28T13:31:05+00:00weekly0.6https://www.medthority.com/news/2025/4/best-in-disease-durability-data-from-phase-iii-bond-003-study-for-cretostimogene-grenadenorepvec-in-bladder-cancer-announced-at-the-aua-annual-meeting---cg-oncology/2025-04-28T13:30:05+00:00weekly0.6https://www.medthority.com/news/2025/4/3-month-data-from-omny-ire-clinical-trial-evaluating-the-omnypulse-platform-demonstrates-potential-for-high-acute-effectiveness-and-a-promising-safety-profile-for-paroxysmal-atrial-fibrillation---johnson--johnson-medtech-/2025-04-28T13:27:27+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-positive-for-attrogy--diflunisal-to-treat--hereditary-transthyretin-mediated-amyloidosis-attrv-in-adult-patients-with-stage-1-or-stage-2-polyneuropathy.--purpose-pharma2025-04-28T13:28:57+00:00weekly0.6https://www.medthority.com/news/2025/4/vertex-receives-chmp-positive-opinion-for-alyftrek-deutivacaftortezacaftorvanzacaftor-a-new-once-daily-cftr-modulator-for-the-treatment-of-cystic-fibrosis/2025-04-29T14:31:47+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-positive-recommendation-for--adcetris--brentuximab-vedotin--brecadd-chemotherapy-to-treat-stage-iib-with-risk-factorsiiiiv-hodgkin-lymphoma..-takeda--pfizer2025-04-29T14:30:17+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-adoptes-positive-opinion-for-tepezza-teprotumumab-for-treatment-of-adults-with-moderate-to-severe-thyroid-eye-disease--amgen/2025-04-29T14:28:29+00:00weekly0.6https://www.medthority.com/news/2025/4/curateq-biologics-receives-chmp-positive-opinion-for-dazublys--trastuzumab-biosimilar/2025-04-29T14:27:09+00:00weekly0.6https://www.medthority.com/news/2025/4/biocon-biologics-gains-favorable-chmp-opinions-for-denosumab-biosimilars-in-europe/2025-04-29T14:25:38+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-recommends-eu-approval-for-duvyzat-givinostat-to-treat-duchenne-muscular-dystrophy--italfarmaco/2025-04-29T14:24:37+00:00weekly0.6https://www.medthority.com/news/2025/4/ptc-therapeutics-receives-positive-chmp-opinion-for-sephience--sepiapterin-for-the-treatment-of-children-and-adults-living-with-phenylketonuria-pku/2025-08-14T09:28:15+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-adopts-a-positive-opinion-recommending--marketing-authorisation-for-izamby--mabxience-research/2025-04-29T14:21:30+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-adopts-a-positive-opinion-recommending-the-granting-of-a-marketing-authorisation-for-denbrayce-denosumab--biosimilar--mabxience-research/2025-04-29T14:20:07+00:00weekly0.6https://www.medthority.com/news/2025/4/biocon-biologics-gains-favorable-chmp-opinions-for-denosumab-biosimilars-in-europe2/2025-04-29T14:18:47+00:00weekly0.6https://www.medthority.com/news/2025/4/-chmp--adopts--positive-opinion-for-granting-of-a-marketing-authorisation-for-zadenvi--denosumab-biosimilar---zentiva-/2025-04-29T14:17:23+00:00weekly0.6https://www.medthority.com/news/2025/4/gedeon-richter-receives-positive-opinion-from-chmp-for-marketing-authorisation-for-junod-and-yaxwer-its-denosumab-biosimilars-for-bone-disease-and-osteoporosis/2025-04-29T14:16:12+00:00weekly0.6https://www.medthority.com/news/2025/4/jazz-pharmaceuticals-receives-chmp-positive-opinion-for-ziihera-zanidatamab-for-the-treatment-of-advanced-her2-positive-biliary-tract-cancer/2025-04-29T14:14:35+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-adoptes-a-positive-opinion-recommending-a-marketing-authorisation-for--enwylma-a-denosumab--biosimilar--zentiva/2025-04-29T14:13:13+00:00weekly0.6https://www.medthority.com/news/2025/4/ema-recommends-cystadrops-mercaptamine-for-infants-with-cystinosis-recordati-/2025-04-29T14:12:00+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-adopts-a-positive-opinion-recommending-a-change-to--marketing-authorisation-for-veklury-remdesivir/2025-04-29T14:10:10+00:00weekly0.6https://www.medthority.com/news/2025/4/argenx--announces-positive-chmp-opinion-for-vyvgart-efgartigimod-alfa-subcutaneous-injection-for-chronic-inflammatory-demyelinating-polyneuropathy-cidp/2025-04-29T14:08:33+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-recommends-approval-of-oczyesa-octreotide--for-treatment-of-acromegaly-in-the-eu--camurus/2025-04-29T14:05:25+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-positive-recommendation--for-amvuttra-vutrisiran-for-the-treatment-of-attr-amyloidosis-with-cardiomyopathy.-alnylam-pharma2025-04-29T14:03:22+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-positive-opinion-on-marketing-authorization-variation-for-calquence-acalabrutinib-in-previously-untreatedchronic-lymphocytic-leukaemia-in-combination-with-venetoclax.--astrazeneca2025-04-29T14:01:57+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp--positive-recommendation-for-a-change-to-the-marketing-authorisation-for-jivi-damoctocog-alfa-pegol-for-haemophiliaa----bayer/2025-04-29T13:54:48+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-the-conversion-of-the-conditional-marketing-approval--into-a-standard-marketing-authorization--for-filspari--for-adults-with-primary-iga-nephropathy--csl-vifor--travere/2025-04-29T13:51:57+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-the-conversion-of-the-conditional-marketing-approval-into-a-standard-marketing-authorization--for-filspari--for-the-treatment-of-primary-iga-nephropathy---cslvifor--travere/2025-04-29T11:48:46+00:00weekly0.6https://www.medthority.com/news/2025/4/perioperative-keytruda-pembrolizumab-poses-a-new-standard-of-care-option-in-resectable-locally-advanced-hnscc---merck-inc/2025-04-29T11:44:21+00:00weekly0.6https://www.medthority.com/news/2025/4/merck-kgaa-and-biopharmaceutical-company-springworks-therapeutics-have-entered-into-a-definitive-agreement-for-merck-to-acquire-springworks/2025-04-29T11:39:57+00:00weekly0.6https://www.medthority.com/news/2025/4/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-adults-with-giant-cell-arteritis/2025-04-09T11:18:04+00:00weekly0.6https://www.medthority.com/news/2025/4/bayer-files-for-approval-of-aflibercept-8-mg-for-treatment-of-retinal-vein-occlusion-in-eu/2025-04-09T11:20:15+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves--dyrupeg-a-peglyated-filgrastim-biosimilar.-curateq-biologics-aurobindo2025-04-09T11:22:25+00:00weekly0.6https://www.medthority.com/news/2025/4/new-data-showcases-the-strength-of-nipocalimab-demonstrating-long-term-sustained-disease-control-in-adults-living-with-generalized-myasthenia-gravis-gmg---johnson--johnson/2025-04-09T11:27:10+00:00weekly0.6https://www.medthority.com/news/2025/4/datroway-datopotamab-deruxtecan-approved--in-the-eu-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer---daiichi-sankyo--astrazeneca/2025-04-09T11:30:56+00:00weekly0.6https://www.medthority.com/news/2025/4/12-month-efficacy-and-safety-data--announced-from-the-phase-iib-trial-of-descartes-08-in-participants-with-generalized-myasthenia-gravis-mg.--cartesian-therapeutics-inc2025-04-10T12:46:11+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-palynziq-to-reduce-blood-phenylalanine-concentrations-in-adult-patients-with-phenylketonuria-pku--biomarin/2025-04-10T12:48:22+00:00weekly0.6https://www.medthority.com/news/2025/4/-fda-approves-an-updated-label-for-tryvio-aprocitentan-removing-the-rems-requirement--idorsia-/2025-04-10T12:50:48+00:00weekly0.6https://www.medthority.com/news/2025/4/biomarin-announces-positive-pivotal-data-for-palynziq-pegvaliase-pqpz-in-adolescents-with-phenylketonuria/2025-04-10T12:53:01+00:00weekly0.6https://www.medthority.com/news/2025/4/the-effect-of-aprocitentan-for-reducing-blood-pressure-and-proteinuria-in-black-patients-with-resistant-hypertension-published-in-hypertension---idorsia/2025-04-10T12:55:19+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-as-a-treatment-for-patients-with-previously-untreated-microsatellite-instability-high-or-mismatch-repair-deficient-unresectable-or-metastatic-colorectal-cancer---bms/2025-04-10T12:57:18+00:00weekly0.6https://www.medthority.com/news/2025/4/first-patient-enrolled-in-forward-cad-pivotal-study-of-novel-forward-intravascular-lithotripsy-platform---shockwave-medicaljohnson--johnson-medtech/2025-04-10T12:59:09+00:00weekly0.6https://www.medthority.com/news/2025/4/new-european-data-presented-from-prove--study-the--largest-real-world-evidence-study-of-fetrojafetcroja-cefiderocol-for-serious-gram-negative-gn-bacterial-infections.--shionogi2025-04-10T13:00:33+00:00weekly0.6https://www.medthority.com/news/2025/4/tonix-pharmaceuticals-and-makana-therapeutics-announce-collaboration-combining-tonixs-anti-cd40l-monoclonal-antibody-tnx-1500-with-makanas-genetically-engineered-organs-in-preclinical-and-clinical-xenotransplantation-studies/2025-04-11T11:59:07+00:00weekly0.6https://www.medthority.com/news/2025/4/-tivdak--tisotumab-vedotin-approved-by-european-commission-for-previously-treated-recurrent-or-metastatic-cervical-cancer--genmab/2025-04-11T12:02:17+00:00weekly0.6https://www.medthority.com/news/2025/4/teva-announces-fda-filling-acceptance-for-ajovy-fremanezumab-in-pediatric-episodic-migraine-prevention-/2025-04-11T12:05:40+00:00weekly0.6https://www.medthority.com/news/2025/4/teva-and-samsung-bioepis-announce-biosimilar-epysqli-eculizumab-aagh-injection-now-available-in-the-united-states/2025-04-11T12:08:38+00:00weekly0.6https://www.medthority.com/news/2025/4/pnew-icotrokinra-jnj-2113-data-from-a-subgroup-analysis-of-iconic-lead-a--phase-iii-registrational-study-in-moderate-to-severe-plaque-psoriasis.---protagonist2025-05-13T08:57:23+00:00weekly0.6https://www.medthority.com/news/2025/4/ema-approves--pavblu-aflibercept-ayyh--a-biosimilar-to-eylea-for-wet-age-related-macular-degeneration-amd-diabetic-macular-edema-and-retinal-vein-occlusions.--amgen2025-04-11T12:14:28+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-validates-extension-application-for-aspaveli-pegcetacoplan-for-the-treatment-of-c3-glomerulopathy-c3g--ic-mpgn.---sobi--apellis2025-04-14T09:55:00+00:00weekly0.6https://www.medthority.com/news/2025/4/ind-amendment-submitted-to-fda-for--nurown--autologous-mesenchymal-stem-cell-therapy-for-amyotrophic-lateral-sclerosis-als.--brainstorm-cell-therapeutics-inc2025-04-14T09:57:21+00:00weekly0.6https://www.medthority.com/news/2025/4/apellis-announces-fda-acceptance-and-priority-review-of-the-supplemental-new-drug-application-for-empaveli-pegcetacoplan-for-c3g-and-primary-ic-mpgn/2025-04-14T10:00:15+00:00weekly0.6https://www.medthority.com/news/2025/4/supplemental-fda-approval-for-vyvgart-hytrulo-with-a-prefilled-syringe-efgartigimod-alfa-and-hyaluronidase-qvfc-to-treat-myasthenia-gravis-and-cidp.---argenx-se2025-04-14T10:17:07+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-as-a-first-line-treatment-for-unresectable-or-metastatic-hepatocellular-carcinoma---bms/2025-04-14T11:08:02+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-update-for-crysvita-burosumab-for-treating-x-linked-hypophosphataemia-in-children-and-young-people---ultragenix--kyowa-kirin/2025-04-15T11:51:35+00:00weekly0.6https://www.medthority.com/news/2025/4/evolut-tavr-system-shows-durable-clinical-outcomes-and-outstanding-valve-performance-at-five-years-in-low-risk-aortic-stenosis-patients---medtronic/2025-04-01T11:53:25+00:00weekly0.6https://www.medthority.com/news/2025/4/positive-chmp-opinion-for---for-jubereq-a-denosumab-biosimilar-for-the-prevention-of-skeletal-related-events-in-adults-with-advanced-malignancies-involving-bone---accord-healthcare/2025-04-01T11:51:19+00:00weekly0.6https://www.medthority.com/news/2025/4/positive-chmp-opinion-for--for-osvyrti-a-denosumab-biosimilar-for-treatment-of-osteoporosis-and-bone-loss--accord-healthcare/2025-04-01T11:49:23+00:00weekly0.6https://www.medthority.com/news/2025/4/imfinzi-approved-in-the-us-as-first-and-only-perioperative-immunotherapy-for-patients-with-muscle-invasive-bladder-cancer---astrazeneca/2025-04-01T11:47:01+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-recommends-calquence-plus-chemoimmunotherapy-for-approval-in-the-eu-as-first-and-only-btk-inhibitor-for-1st-line-mantle-cell-lymphoma---astrazeneca/2025-04-01T11:45:06+00:00weekly0.6https://www.medthority.com/news/2025/4/positive-chmp-opinion-for-qoyvolma--ustekinumab-biosimilar-for-treatment-of-plaque-psoriasis---celltrion/2025-04-01T11:43:18+00:00weekly0.6https://www.medthority.com/news/2025/4/positive-chmp-opinion-for-bosulif--bosutinib--on-variation-to-marketing-authorisation-to-extend-the-use-of-bosulif-to-children-aged-6-years-and-older--pfizer/2025-04-01T11:41:36+00:00weekly0.6https://www.medthority.com/news/2025/4/triluminatepivotal-trial-shows-the-tricliptranscatheter-edge-to-edge-repair-system-for-tricuspid-regurgitation-offers-substantial-and-sustained-improvements-in-the-severity-of-tr-after-two-years--abbott/2025-04-01T11:39:44+00:00weekly0.6https://www.medthority.com/news/2025/4/ema-concludes-review-of-weight-management-medicine-mysimba-naltrexone--bupropion---currax-pharmaceuticals/2025-04-01T11:37:47+00:00weekly0.6https://www.medthority.com/news/2025/4/santen-receives-positive-chmp-opinion-in-europe-for-ryjunea-atropine-sulfate-hydrate-ophthalmic-formulation-for-slowing-the-progression-of-paediatric-myopia/2025-04-01T11:36:01+00:00weekly0.6https://www.medthority.com/news/2025/4/positive-chmp-opinion-for-the-subcutaneous-formulation-of-opdivo-nivolumab--opdivo-qvantig-across-multiple-solid-tumor-indications---bms/2025-04-01T11:33:31+00:00weekly0.6https://www.medthority.com/news/2025/4/tremfya--guselkumab-receives--positive-chmp-opinion--for-treatment-of-patients-with-moderately-to-severely-active-crohns-disease--jj/2025-04-01T11:31:30+00:00weekly0.6https://www.medthority.com/news/2025/4/lepodisiran-reduced-levels-of-genetically-inherited-heart-disease-risk-factor-lipoproteina-by-nearly-94-from-baseline-at-the-highest-tested-dose-in-adults-with-elevated-levels---eli-lilly/2025-04-01T11:29:43+00:00weekly0.6https://www.medthority.com/news/2025/4/beigene-receives-positive-chmp-opinion-for-tevimbra-tislelizumab-as-a-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-/2025-04-01T11:28:09+00:00weekly0.6https://www.medthority.com/news/2025/4/bluebird-bio-has-an-offer-from-ayrmid-ltd-to-acquire-the-company/2025-04-01T11:24:30+00:00weekly0.6https://www.medthority.com/news/2025/4/alnylam-presents-new-data-from-the-helios-b-phase-iii-study-of-vutrisiran-in-patients-with-attr-amyloidosis-with-cardiomyopathy-attr-cm-at-the-american-college-of-cardiologys-annual-scientific-session-2025/2025-04-02T11:46:27+00:00weekly0.6https://www.medthority.com/news/2025/4/winrevair-sotatercept-csrk-reduced-the-risk-of-a-composite-of-all-cause-death-lung-transplantation-and-hospitalization-for-pulmonary-arterial-hypertension-pah-by-76-compared-to-placebo-in-the-phase-iii-zenith-trial---merck-inc/2025-04-02T11:44:42+00:00weekly0.6https://www.medthority.com/news/2025/4/destiny-gastric05-phase-iii-trial-of-enhertu-trastuzumab-deruxtecan-initiated-in-patients-with-previously-untreated-her2-positive-advanced-gastric-cancer--daiichi-sankyo/2025-04-02T11:42:14+00:00weekly0.6https://www.medthority.com/news/2025/4/moderna-receives-australian-therapeutic-goods-administration-approval-for-rsv-vaccine-for-older-adults/2025-04-02T11:38:17+00:00weekly0.6https://www.medthority.com/news/2025/4/eton-pharmaceuticals-out-licenses-international-rights-to-increlex/2025-04-02T11:34:38+00:00weekly0.6https://www.medthority.com/news/2025/4/ozempic-once-weekly-semaglutide-1.0-mg-shown-to-improve-walking-distance-and-quality-of-life-in-adults-with-type-2-diabetes-and-peripheral-artery-disease-pad-at-acc-2025--novo-nordisk2025-04-03T11:13:16+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves--rsv-vaccine-abrysvo-to-help-protect-adults-aged-18-59-against-rsv-lower-respiratory-tract-disease---pfizer/2025-04-03T11:15:08+00:00weekly0.6https://www.medthority.com/news/2025/4/merck--kgaa-exercises-option-with-abbisko-for-worldwide-commercialization-rights-for-pimicotinib/2025-04-03T11:18:07+00:00weekly0.6https://www.medthority.com/news/2025/4/latest-advancements-in-heart-disease-treatment-with-impella-highlighted-at-acc.25---johnson--johnson-medtech2025-04-03T11:20:44+00:00weekly0.6https://www.medthority.com/news/2025/4/pivotal-12-month-effectiveness-and-safety-data-from-smartfire-study-presented-at-2025-ehra-congress---johnson--johnson-medtech/2025-04-03T11:23:55+00:00weekly0.6https://www.medthority.com/news/2025/4/fda--accelerated--approval-for--vanrafiaatrasentan--for-the-reduction-of-proteinuria-in-adults-with-primary-immunoglobulin-a-nephropathy-igan---novartis/2025-04-04T12:10:42+00:00weekly0.6https://www.medthority.com/news/2025/4/relovair-starts-phase-iii-trial-for-asthma/2025-04-04T12:06:10+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-positive-for-altuvoct-efanesoctocog-alfa-as-an-option-for-treating-and-preventing-bleeding-episodes-in-people-2years-and-over-with-haemophiliaa-congenital-factorviii-deficiency---sanofi/2025-04-04T12:03:54+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-terminated-appraisal-for-onivyde-pegylated-liposomal-irinotecan-in-combination-for-untreated-metastatic-pancreatic-cancer---servier/2025-04-04T12:01:26+00:00weekly0.6https://www.medthority.com/news/2025/4/nice-uk-xenpozyme-olipudase-alfa-for-treating-acid-sphingomyelinase-deficiency-niemannpick-disease-type-ab-and-type-b-is-not-recommended---sanofi/2025-04-04T11:59:11+00:00weekly0.6https://www.medthority.com/news/2025/4/rilzabrutinib-granted-orphan-drug-designation-in-the-us-for-warm-autoimmune-hemolytic-anemia-and--igg4-related-disease--two-rare-diseases--sanofi/2025-04-04T11:56:26+00:00weekly0.6https://www.medthority.com/news/2025/4/roche-provides-update-on-phase-iii--ocrevus-ocrelizumab-high-dose-study-in-people-with-relapsing-multiple-sclerosis/2025-04-04T11:52:59+00:00weekly0.6https://www.medthority.com/news/2025/4/complete-response-letter-for-resubmission-of-reproxalap--for-the-treatment-of-dry-eye-disease.--aldeyra-therapeutics2025-04-04T11:46:53+00:00weekly0.6https://www.medthority.com/news/2025/4/pacira-biosciences-announces-first-patient-dosed-in-phase-ii-study-evaluating-safety-and-efficacy-of-pcrx-201-enekinragene-inzadenovec-for-the-treatment-of-osteoarthritis-of-the-knee/2025-04-04T11:42:37+00:00weekly0.6https://www.medthority.com/news/2025/4/enhertu-trastuzumab-deruxtecan-approved-in-the-eu-as-first-her2-directed-therapy-for-patients-with-hr-positive-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy--daiichi-sankyo--astrazeneca/2025-04-07T11:54:50+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-pediatric-prolonged-release-melatonin-formulation-slenyto-for-insomnia-in-children-with-adhd.--neurim-pharmaceuticals2025-04-07T11:53:31+00:00weekly0.6https://www.medthority.com/news/2025/4/uplizna--inebilizumab-cdon-is-now-the-first-and-only--fda-approved--treatment-for-igg4-related-disease--amgen-/2025-04-07T11:51:23+00:00weekly0.6https://www.medthority.com/news/2025/4/imfinzi-based-perioperative-regimen-approved-in-the-eu-for-resectable-non-small-cell-lung-cancer---astrazeneca/2025-04-07T11:49:20+00:00weekly0.6https://www.medthority.com/news/2025/4/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-significantly-reduce-both-the-signs-symptoms-and-progression-of-structural-damage-in-adults-living-with-active-psoriatic-arthritis---johnson--johnson/2025-04-07T11:47:44+00:00weekly0.6https://www.medthority.com/news/2025/4/allakos-is-acquired-by-concentra-biosciences/2025-04-07T11:45:28+00:00weekly0.6https://www.medthority.com/news/2025/4/results-are-announced-from-the-phase-ii-advance-htn-trial-evaluating-lorundrostat-in-patients-with-confirmed-uncontrolled-hypertension-uhtn-or-resistant-hypertension-rhtn.-mineralys2025-04-07T11:43:35+00:00weekly0.6https://www.medthority.com/news/2025/4/rosella--trial-of-relacorilant-plus-nab-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-met-its-primary-endpoint.--corcept-therapeutics2025-05-13T08:55:01+00:00weekly0.6https://www.medthority.com/news/2025/4/ionis-pharmaceuticals-inc.-has-entered-into-a-license-agreement-under-which-sobi-has-exclusive-rights-in-countries-outside-the-u.s.-canada-and-china-to-commercialize-olezarsen-2025-04-08T11:48:51+00:00weekly0.6https://www.medthority.com/news/2025/4/data-and-analyses-of-tnx-102-sl-cyclobenzaprine-hcl-sublingual-tablets-treatment-effects-on-fibromyalgia-presented-at-the-american-academy-of-pain-medicine-aapm-2025-annual-meeting---tonix-pharmaceuticals/2025-04-08T11:51:22+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility---johnson--johnson/2025-04-08T11:55:59+00:00weekly0.6https://www.medthority.com/news/2025/4/european-commission-approves-label-expansion-of-kaftrio-ivacaftortezacaftorelexacaftor-in-a-combination-regimen-with-ivacaftor-for-the-treatment-of-people-with-cystic-fibrosis.--vertex2025-04-08T11:57:58+00:00weekly0.6https://www.medthority.com/news/2025/4/a-new-analysis-is-announced-of-the-pivotal-rise-pd-phase-iii-study-of-crexont-carbidopa-xr---levodopa-which-showed-significant-improvements-in-sleep-quality-for-parkinsons-disease-patients.--amneal2025-04-08T12:00:15+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-results-from-pivotal-phase-iii-precision-t-study-of-orca-t---in-patients-with--aml-all-high-risk-mds-and-mpal--orca-bio/2025-03-18T13:11:53+00:00weekly0.6https://www.medthority.com/news/2025/3/astrazeneca-to-acquire-esobiotec-to-advance-cell-therapy-ambition/2025-03-18T13:10:03+00:00weekly0.6https://www.medthority.com/news/2025/3/updated-data-from-cohort-b1-of-the-phase-1ii-rainfol-01-study-of-rinatabart-sesutecan--resulted-in-a-orr--of-55.6---in-heavily-pre-treated-ovarian-cancer-oc-patients--genmab-as2025-03-18T13:07:58+00:00weekly0.6https://www.medthority.com/news/2025/3/new-data-from-phase-ii-trial-with-stenoparib-monotherapy-in-advanced-ovarian-cancer-.--alarity-therapeutics2025-03-18T13:04:11+00:00weekly0.6https://www.medthority.com/news/2025/3/elahere--mirvetuximab-soravtansine-gynx-shows-consistent-survival-benefit-in-long-term-analysis-for-certain-ovarian-cancer-patients--abbvie/2025-03-18T13:01:45+00:00weekly0.6https://www.medthority.com/news/2025/3/fda--grants-priority-review-for-new-indication-of-finerenone-for-patients-with-heart-failure-and-with-a-left-ventricular-ejection-fraction-of-40--bayer/2025-03-18T12:59:33+00:00weekly0.6https://www.medthority.com/news/2025/3/eu-approves-imfinzi-durvalumab-as-first-and-only-immunotherapy-for-limited-stage-small-cell-lung-cancer---astrazeneca/2025-03-18T12:57:11+00:00weekly0.6https://www.medthority.com/news/2025/3/resulta-from-clinical-trial-evaluating-actimab-a---chemotherapy-clag-m-in-patients-with--rr--acute-myeloid-leukemia-were-published-in-the-peer-reviewed-journal-leukemia.--actinium-pharma2025-03-18T12:54:44+00:00weekly0.6https://www.medthority.com/news/2025/3/new-kinect-hd-data-shows-significant-reduction-in-chorea-across-body-regions-with-ingrezza-valbenazine-capsules--for-huntingtons-disease--neurocrine-biosciences/2025-03-18T12:52:11+00:00weekly0.6https://www.medthority.com/news/2025/3/opko-health-inc.--and-entera-bio-ltd.-to-collaborate-and-advance-the-first-oral-dual-agonist-glp-1glucagon-peptide-as-a-once-daily-tablet-treatment-for-patients-with-obesity2025-03-18T12:50:17+00:00weekly0.6https://www.medthority.com/news/2025/3/positive--topline-results-from-the-pivotal-phase-iii-stop-hs-clinical-trial-program-evaluating-povorcitinib-in-adult-patients-with-moderate-to-severe-hidradenitis-suppurativa.--incyte2025-03-18T12:46:01+00:00weekly0.6https://www.medthority.com/news/2025/3/eneboparatide-met-primary-endpoint-of-normalising-serum-calcium-in-adults-with-hypoparathyroidism-at-24-weeks-in-calypso-phase-iii-trial---astrazeneca/2025-03-18T12:44:05+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-rytelo--imetelstat-as-a-monotherapy-for--transfusion-dependent-td-anemia-due-to-very-low-low-or-intermediate-risk-myelodysplastic-syndromes-.--geron2025-03-19T11:47:45+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-accepts-a--351k-bla-submission-for-avt-03-a-proposed-biosimilar-of-prolia-denosumab-and-xgeva-denosumab.--alvotech--dr-reddys2025-03-19T11:45:08+00:00weekly0.6https://www.medthority.com/news/2025/3/a-clinical-program-is-announced--comprising--trials-studying-actimab-a--either-keytruda-pembrolizumab-or-opdivo-nivolumab--in-multiple-solid-tumor-indications.--actinium-pharma2025-03-19T11:42:37+00:00weekly0.6https://www.medthority.com/news/2025/3/nipocalimab-has-now-received-fast-track-designation-for-sjogrens-disease---johnson--johnson/2025-03-19T11:36:46+00:00weekly0.6https://www.medthority.com/news/2025/3/-phase-iib-clinical-trial--is-initiated--to-evaluate-oral--isomyosamine-as-a-treatment-for-chronic-inflammation-associated-with-muscle-loss-frailty-or-sarcopenia---tnf-pharma/2025-03-19T11:32:51+00:00weekly0.6https://www.medthority.com/news/2025/3/datroway-datopotamab-deruxtecan-is-launched-in-japan-as-the-first-trop-2-directed-therapy-for-patients-with-previously-treated-unresectable-or-recurrent-hr-positive-her2-negative-breast-cancer--daiichi-sankyo/2025-03-21T13:37:36+00:00weekly0.6https://www.medthority.com/news/2025/3/-topline-results-reported--from-phase-iii-study-of-batoclimab-in-myasthenia-gravis-and-initial-results-from-period-1-of-a-phase-ii-b-study-in-chronic-inflammatory-demyelinating-polyneuropathy.---immunovant-2025-03-21T13:35:16+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-safety-and-efficacy-results-announced--from-the-phase-iii-program-for-onasemnogene-abeparvovec-oav101-it-in--patients-aged-two-to-18-years-with-spinal-muscular-atrophy-sma.-novartis2025-03-21T13:38:05+00:00weekly0.6https://www.medthority.com/news/2025/3/servier-and-black-diamond-therapeutics-announce-global-licensing-agreement-for-bdtx-4933-a-therapy-with-best-in-class-potential-targeting-both-ras-mutations-and-raf-alterations-in-solid-tumors/2025-03-21T13:29:07+00:00weekly0.6https://www.medthority.com/news/2025/3/new-data-on-investigational-therapy-for-thymidine-kinase-2-deficiency-presented-at-muscular-dystrophy-association-mda-2025-conference---ucb/2025-03-21T13:27:14+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-grants-510k-clearance-for-the--monogram-mbos-tka--robotic-system-for-orthpedic-surgery-monogram-technologies/2025-03-21T13:25:06+00:00weekly0.6https://www.medthority.com/news/2025/3/alvotech-acquires-the-research-operations-of-xbrane-biopharma-ab-and-with-it-xb-003-referencing-cimzia-certolizumab-pegol/2025-03-21T13:21:22+00:00weekly0.6https://www.medthority.com/news/2025/3/new-48-week-remission-data-on-treatment-of-tardive-dyskinesia-with-ingrezza-valbenazine-capsules---neurocrine-biosciences/2025-03-21T13:19:27+00:00weekly0.6https://www.medthority.com/news/2025/3/as-mpox-cases-spread-around-the-world-tonix-pharmaceuticals-single-dose-vaccine-tnx-801-has-potential-to-slow-the-spread/2025-03-21T13:17:32+00:00weekly0.6https://www.medthority.com/news/2025/3/fabhalta-iptacopan-has-received-fda-approval-for-the-treatment-of-adults-with-c3-glomerulopathy-c3g-to-reduce-proteinuria-making-it-the-first-and-only-treatment-approved-for-this-condition.-novartis2025-03-21T13:15:17+00:00weekly0.6https://www.medthority.com/news/2025/3/enrollment-is-underway-for-the-phase-iii-program-evaluating-zaltenibart-in-paroxysmal-nocturnal-hemoglobinuria-pnh.--omeros-corportation2025-03-24T09:19:23+00:00weekly0.6https://www.medthority.com/news/2025/3/-fda-approval-announced-for-amvuttra--vutrisiran-in-attr-amyloidosis-with-cardiomyopathy-attr-cm.--alnylam2025-03-24T09:17:05+00:00weekly0.6https://www.medthority.com/news/2025/3/initial-results-announced-on-the-combination-of-the-allurion-balloon-with-low-dose-glp-1-therapy-to-optimize-muscle-mass-and-glp-1-adherence---allurion-technologies/2025-03-24T09:14:44+00:00weekly0.6https://www.medthority.com/news/2025/3/fdas-marketing-authorization-decision-for-prosense-in-early-stage-low-risk-breast-cancer-with-endocrine-therapy-to-be-reached-after-the-first-quarter-of-2025---icecure-medical/2025-03-24T09:12:44+00:00weekly0.6https://www.medthority.com/news/2025/3/parateck-to-acquire-optinose-and-with-it--xhance-fluticasone-propionate/2025-03-24T09:09:43+00:00weekly0.6https://www.medthority.com/news/2025/3/stryker-acquires-inari-medical-a-company-that-provides-solutions-for-venous--thromboembolism-clot-removal/2025-03-24T09:07:26+00:00weekly0.6https://www.medthority.com/news/2025/3/eyenovia-inc.and-betaliq-inc.to-merge-to-create-a-new-ophthalmic-company2025-03-24T09:05:34+00:00weekly0.6https://www.medthority.com/news/2025/3/earth-hcm-a-public-health-education-tool-for-the-hypertrophic-cardiomyopathy-community-is-launched---cytokinetics/2025-03-24T14:04:13+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with--crohns-disease---johnson--johnson/2025-03-24T14:07:21+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approval-for-tlx007-cdx-a-kit-for-the-preparation-of-gallium-68-68ga-gozetotide-injection-gozellix-for-use-in-pet-scanning-of-psma-positive-lesions-in-men-with-prostate-cancer-.--telix-2025-03-25T12:38:54+00:00weekly0.6https://www.medthority.com/news/2025/3/the-fda-has-approved-an-investigational-device-exemption-for-the--coronary-intravascular-lithotripsy--system-to-evaluate-the-treatment-of-severe-calcification-in-coronary-arteries-prior-to-stenting.--abbott2025-03-25T12:36:24+00:00weekly0.6https://www.medthority.com/news/2025/3/nmpa-china-appproves-penpulimab-formerly-ak105-an-antipd-1-monoclonal-antibody--chemotherapy-for-nasopharyngeal-carcinoma--akeso-sinobio/2025-03-25T12:34:22+00:00weekly0.6https://www.medthority.com/news/2025/3/the-fda-has-issued-a-second-complete-response-letter-for-camrelizumab--rivoceranib-as-a-treatment-for-unresectable-or-metastatic-hepatocellular-carcinoma--jiangsu-hengrui---elevar-therapeutics/2025-08-20T12:13:03+00:00weekly0.6https://www.medthority.com/news/2025/3/cretostimogene-grenadenorepvec-data-continues-to-demonstrate-best-in-class-durability-of-response-for-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer---cg-oncology/2025-03-25T12:30:26+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-keytruda-pembrolizumab--herceptin-trastuzumab--chemotherapy-for-her2-positive-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-expressing-pd-l1---merck-inc/2025-03-25T12:28:24+00:00weekly0.6https://www.medthority.com/news/2025/3/nmpa-china-approves-sycume-teprotumumab-n01-a-recombinant-anti-insulin-like-growth-factor-1-receptor--antibody-for-the-treatment-of-thyroid-eye-disease-ted--innovent-biologics/2025-03-25T12:26:10+00:00weekly0.6https://www.medthority.com/news/2025/3/eli-lilly-to-acquire-aurka-pharma-and-ak-01-an-aurora-kinase-a-inhibitor-in-early-trials-for-solid-tumours/2025-03-26T12:15:26+00:00weekly0.6https://www.medthority.com/news/2025/3/topline-data-indicate-that-refocus-alz-did-not-meet-each-of-the-prespecified-co-primary-secondary-and-exploratory-biomarker-endpoints--cassava-sciences/2025-03-26T12:16:19+00:00weekly0.6https://www.medthority.com/news/2025/3/novo-nordisk-has-entered-into-a-licence-agreement-with-the-united-bio-technology-hengqin-co.-ltd-for-ubt-251-for-the-treatment-of-obesity-type-2-diabetesand-other-diseases2025-03-26T12:11:27+00:00weekly0.6https://www.medthority.com/news/2025/3/new-findings-from-the-clear-study-showed-better-early-patient-satisfaction-and-sexual-function-with-the-urolift-system--compared-to-rezmwater-vapor-therapy--for-benign-prostatic-hyperplasia.--teleflex2025-03-26T12:08:06+00:00weekly0.6https://www.medthority.com/news/2025/3/new-study-results-reinforce-tagrisso-as-the-backbone-therapy-for-egfr-mutated-lung-cancer-across-stages-and-settings---astrazeneca/2025-03-26T12:00:43+00:00weekly0.6https://www.medthority.com/news/2025/3/tolebrutinib-regulatory-submission-accepted-for-priority-review-by-fda-for-patients-with-multiple-sclerosis---sanofi/2025-03-26T11:33:20+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-cabometyx--cabozantinib-to-treat--patients-12-years-of-age-and-older-with-previously-treated-unresectable-locally-advanced-or-metastatic--pancreatic-neuroendocrine-tumors.-exelixis2025-03-27T12:42:54+00:00weekly0.6https://www.medthority.com/news/2025/3/-positive-data-from-the-phase-ii-forward-53-trial-of-wve-n531--in-boys-with-duchenne-muscular-dystrophy-dmd-who-are-amenable-to-exon-53-skipping..--wave-life-sciences2025-03-27T12:40:55+00:00weekly0.6https://www.medthority.com/news/2025/3/merck-enters-exclusive-license-agreement-for-hrs-5346-an-investigational-oral-lipoproteina-inhibitor-for-cardiovascular-disease-from-jiangsu-hengrui-pharmaceuticals-co.-ltd2025-03-27T12:38:38+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-blujepa-gepotidacin-for-treatment-of-uncomplicated-urinary-tract-infections-uutis-in-female-adults-and-paediatric-patients-12-years-of-age-and-older---gsk/2025-03-27T12:37:04+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-prevention-of-invasive-pneumococcal-disease-and-pneumococcal-pneumonia-in-adults---merck-inc/2025-03-27T12:36:18+00:00weekly0.6https://www.medthority.com/news/2025/3/new-nipocalimab-data-and-real-world-research-highlight-positive-phase-iii-results-and-commitment-to-people-living-with-generalized-myasthenia-gravis-gmg---johnson--johnson/2025-03-27T12:31:33+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-positive-for-fintepla-fenfluramine-for-treating-seizures-associated-with-lennoxgastaut-syndrome-in-people-2-years-and-over---ucb/2025-03-28T14:56:55+00:00weekly0.6https://www.medthority.com/news/2025/3/application-to-expand-use-of-nucala-mepolizumab-for-the-treatment-of-copd-accepted-for-review-by-the-european-medicines-agency---gsk/2025-03-28T14:53:24+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-positive-for-breyanzi-isocabtagene-maraleucel-for-treating-relapsed-or-refractory-large-b-cell-lymphoma-after-first-line-chemoimmunotherapy-when-a-stem-cell-transplant-is-suitable---bms/2025-03-28T14:50:12+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-positive-for-blincyto-blinatumomab-with-chemotherapy-for-consolidation-treatment-of-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukaemia-in-adults---amgen/2025-03-28T13:24:32+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves--vykat-xr-diazoxide-choline-extended-release-tablets--for-the-treatment-of-hyperphagia-in-patients-with-prader-willi-syndrome-pws-.-soleno-therapeutics-2025-09-05T09:12:53+00:00weekly0.6https://www.medthority.com/news/2025/3/ce-mark-approved-in-europe-for-the-volt-pfa-system-to-treat-patients-with-atrial-fibrillation---abbott/2025-03-28T13:03:34+00:00weekly0.6https://www.medthority.com/news/2025/3/topline-data-announced-from-the-phase-iii-equator-study-evaluating-itolizumab-in-first-line-treatment-of-patients-with-acute-graft-versus-host-disease-agvhd.--equillium2025-03-28T13:00:26+00:00weekly0.6https://www.medthority.com/news/2025/3/merck-kgaa-collaboration-with-zebra-technologies/2025-03-28T12:58:07+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approval-for-pluvicto-lutetium-lu-177-vipivotide-tetraxetan-for-patients-with-psma-positive-metastatic-castration-resistant-prostate-cancer-considered-appropriate-to-delay-chemotherapy.-novartis2025-03-31T09:11:08+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-supplemental--bla--for-the-f8-formulation-of-tesamorelin--egrifta-wr-for--the-reduction-of-excess-abdominal-fat-in-adults-with-hiv-who-have-lipodystrophy.--theratechnologies-inc2025-03-31T09:05:24+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-isues-a-complete-response-letter-for-cardamyst-etripamil-nasal-spray-for-the-conversion-of-acute-episodes-of-psvt-to-sinus-rhythm-.--milestone-pharma2025-03-31T09:00:34+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-qfitlia-fitusiran--for-routine-prophylaxis-to-prevent-or-reduce-the-frequency-of-bleeding-episodes-in-adult-and-pediatric-patients-with-hemophilia-a-or-b---sanofi/2025-03-31T08:53:18+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-denosumab-biosimilars-conexxence--denosumab-bnht-and-bomyntra-denosumab-bnht.--fresenius-kabi2025-03-31T08:49:53+00:00weekly0.6https://www.medthority.com/news/2025/3/soul-cardiovascular-outcomes-trial-demonstates-that-rybelsus-oral-semaglutide-significantly-reduced-the-risk-of-major-adverse-cardiovascular-events-and-or-ckd.--novo-nordisk2025-03-31T11:25:00+00:00weekly0.6https://www.medthority.com/news/2025/3/first-generation-oral-pill-norovirus-vaccine-candidate--results-in-elderly-adults-55-80-years-have-been-published-in-science-translational-medicine-.-vaxart-2025-05-13T08:53:45+00:00weekly0.6https://www.medthority.com/news/2025/3/the-fda-has-approved-revakinagene-taroretcel-lwey-encelto-for-the-treatment-of-macular-telangiectasia-type-2-mactel--neurotech-pharma/2025-03-07T12:46:06+00:00weekly0.6https://www.medthority.com/news/2025/3/jazz-pharma-to-acquire-chimerix-ad-with-it-dordaviprone-for-h3-k27m-mutant-glioma/2025-03-07T12:50:27+00:00weekly0.6https://www.medthority.com/news/2025/3/roche-licenses-petrelintide-an-amylin-analog-from-zealand-pharma--to-treat-obesity-as-monotherapy-and-in-combination-with-ct-388/2025-03-14T12:43:26+00:00weekly0.6https://www.medthority.com/news/2025/3/-uplizna-inebilizumab-cdon-significantly-improves-generalized-myasthenia-gravis--symptoms-in-acetylcholine-receptor-autoantibody-positive-patients-over-52-weeks---amgen/2025-03-14T12:46:02+00:00weekly0.6https://www.medthority.com/news/2025/3/mallinckrodt-and-endo-to-merge-into-one-company/2025-03-14T12:49:57+00:00weekly0.6https://www.medthority.com/news/2025/3/eton-pharmaceuticals-announces-positive-pivotal-clinical-study-results-for-product-candidate-et-600/2025-03-17T12:38:53+00:00weekly0.6https://www.medthority.com/news/2025/3/complete-response-letter-for-si-6603--condoliase--a-treatment-that-reduces-leg-pain-associated-with-lumbar-disc-herniation.--seikagaku2025-03-17T12:51:58+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-rxulti-brexpiprazole-for-the-treatment-of-schizophrenia-in-adolescents-aged-13-years-and-older.-.--lundbeck--otsuka2025-03-17T12:54:40+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-breyanzi--liso-celfor-the-treatment-of-adult-patients-with-rr--follicular-lymphoma-fl-after-two-or-more-lines-of-systemic-therapy---bms/2025-03-17T12:57:04+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-an-expanded-label-for-iluvien-fluocinolone-acetonide-intravitreal-implant--for-the-treatment-of-chronic-non-infectious-uveitis-affecting-the-posterior-segment-of-the-eye----ani-pharma/2025-03-17T12:59:56+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-results-from-redefine-2-a-phase-iii-trial--of-once-weekly-subcutaneous-cagrisema-a-fixed-dose-combination-of-cagrilintide-2.4-mg---semaglutide-2.4-mg-compared-to-placebo--novo-nordisk2025-03-17T13:02:48+00:00weekly0.6https://www.medthority.com/news/2025/3/embrace-phase-iib-study.found-that-n6ls--given-every-four-months--monthly-cabotegravir-la--kept-viral-levels-suppressed-in-adults-living-with-hiv-who-were-already-stable-on-treatment.--viiv-healthcare2025-03-17T13:07:48+00:00weekly0.6https://www.medthority.com/news/2025/3/new-implementation-study-data-shows-zero-cases-of-hiv-with-apretude-cabotegravir-extended-release-the-only-long-acting-injectable-approved-for-hiv-prep---viiv-healthcare/2025-03-17T13:10:31+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-data-from-phase-iii-trials-that-show-the-investigational-once-daily-oral-two-drug-regimen-of-doravirineislatravir-dorisl-maintained-hiv-1-viral-suppression-at-week-48---merck-inc/2025-03-17T13:12:45+00:00weekly0.6https://www.medthority.com/news/2025/3/amgen-and-kyowa-kirin--provide-top-line-results--from--rocatinlimab-a---phase--iii-ignite--study-in-adults-with-moderate-to-severe-atopic-dermatitis-/2025-03-11T12:28:49+00:00weekly0.6https://www.medthority.com/news/2025/3/dupixent-late-breaking-positive-pivotal-data-in-bullous-pemphigoid-presented-at-aad---sanofi--regeneron/2025-03-11T12:20:58+00:00weekly0.6https://www.medthority.com/news/2025/3/icotrokinra-results-show-potential-to-set-a-new-standard-of-treatment-in-plaque-psoriasis---johnson--johnson/2025-03-11T12:13:26+00:00weekly0.6https://www.medthority.com/news/2025/3/grant-awarded-by-medical-cbrn-defense-consortium-mcdc-for-development-of-tnx-801-a-single-dose-mpox-and-smallpox-vaccine-candidate---tonix-pharmaceuticals/2025-03-11T12:00:00+00:00weekly0.6https://www.medthority.com/news/2025/3/icotrokinra-meets-primary-endpoint-of-clinical-response-in-ulcerative-colitis-study-and-shows-potential-to-transform-the-treatment-paradigm-for-patients---johnson--johnson/2025-03-12T11:59:54+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-stoboclo--ct-p41-denosumab-bmwo-and-osenvelt--ct-p41-denosumab-bmwo-biosimilars-referencing-prolia-denosumab-and-xgeva-denosumab-respectively.--celltrion2025-03-12T11:53:46+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-topline-results-announced-from-phase-iii-veritac-2-clinical-trial-of--vepdegestrant-.-arvinas--pfizer2025-03-12T11:55:35+00:00weekly0.6https://www.medthority.com/news/2025/3/-phase-iii-study-of-felzartamab-for-the-treatment-of-late-antibody-mediated-rejection-amr-in-kidney-transplant-patients---biogen/2025-05-13T08:49:37+00:00weekly0.6https://www.medthority.com/news/2025/3/bms-acquires-2seventy-bio-and-with-it-abecma-a-treatment-for-multiple-myeloma/2025-03-12T11:45:46+00:00weekly0.6https://www.medthority.com/news/2025/3/ionis-pharma-and-ono-pharma-enter-a-licence-agreeement-by-which-ono-gains-global-rights-to-sapablursen-arna-targeted-medicine-for-polycythemia-vera.--ono-pharma2025-03-13T12:26:09+00:00weekly0.6https://www.medthority.com/news/2025/3/fda--510k-regulatory-clearance-for-monarch-quest-for-enhanced-robotic-assisted-bronchoscopy---johnson--johnson-medtech/2025-03-13T12:15:20+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-wainzua-eplontersen-for-the-treatment-of-hereditary-transthyretin-mediated-amyloidosis-with-stage-1-or-stage-2-polyneuropathy.--astrazeneca--ionis-pharma2025-03-13T12:11:47+00:00weekly0.6https://www.medthority.com/news/2025/3/tnx-1500-shows-promise-in-preventing-organ-transplant-rejections-of-either-human-or-pig-organs-autoimmune-diseases-also-a-target---tonix-pharmaceuticals/2025-03-13T12:08:49+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-positive-for-acarizax-12-sq-hdm-slit-for-moderate-to-severe-house-dust-mite-allergic-rhinitis---alk/2025-03-13T11:55:56+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-negaive-for-vyloy-zolbetuximab--chemotherapy-for-untreated-claudin-18.2-positive-her2-negative-unresectable-advanced-gastric--gastro-oesophageal-junction-adenocarcinoma---astellas-pharma2025-03-13T11:51:39+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-terminated-appraisal-for-tecentriq-atezolizumab-for-untreated-advanced-or-recurrent-non-small-cell-lung-cancer-when-platinum-doublet-chemotherapy-is-unsuitable---roche/2025-03-13T11:49:05+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-accepts-sbla-for-gamifant-emapalumab-izsg-for-use-in-adult-and-paediatric-patients-with-macrophage-activation-syndrome.--sobi2025-02-28T12:05:57+00:00weekly0.6https://www.medthority.com/news/2025/2/the-european-medicines-agency-has-approved-an-additional-subcutaneous-administration-option-for-takhzyro--lanadelumab-for-recurrent-attacks-of-hereditary-angioedema----takeda-/2025-02-28T12:03:36+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-topline-results-announced--from-komet-001-the-phase-ii-registration-directed-trial-of-ziftomenib-in-patients-with--rr-npm1-mutant-npm1-m-acute-myeloid-leukemia-.--kyowa-kirin2025-02-28T12:00:43+00:00weekly0.6https://www.medthority.com/news/2025/2/teleflex-will-acquire-substantially-all-of-the-biotronik-vascular-intervention-business/2025-02-28T11:58:20+00:00weekly0.6https://www.medthority.com/news/2025/3/--positive-data-from--phase-ii-barzolvolimab-studies-in-patients-with-chronic-urticaria..--celldex2025-03-04T12:46:58+00:00weekly0.6https://www.medthority.com/news/2025/3/-fda-has-approved--odactra-tablet-for-use-in-young-children-with-house-dust-mite-hdm-allergy.--alk2025-03-04T12:44:51+00:00weekly0.6https://www.medthority.com/news/2025/3/phase-iii-study-shows-xolair-may-be-more-effective-with-fewer-side-effects-than-oral-immunotherapy-for-the-treatment-of-food-allergies--roche/2025-03-04T12:42:46+00:00weekly0.6https://www.medthority.com/news/2025/3/presentation-of-novel-data-related-to-long-term-prophylaxis-and-sebetralstat-for-hereditary-angioedema-at-the-wsaa-2025-annual-meeting.--kalvista-pharma2025-03-04T12:40:50+00:00weekly0.6https://www.medthority.com/news/2025/3/eisai-receives-regulatory-review-outcome-for-lecanemab-as-a-treatment-for-early-alzheimers-disease-in-australia--biogen--eisai/2025-03-04T12:37:38+00:00weekly0.6https://www.medthority.com/news/2025/3/eton-pharmaceuticals-announces-commercial-launch-of-galzin-zinc-acetate-capsules/2025-03-04T12:35:25+00:00weekly0.6https://www.medthority.com/news/2025/3/abbvie-to-acquire-rights-to-gub-014295-a-potential-best-in-class-long-acting-amylin-analog-for-the-treatment-of-obesity.--abbvie--gubra-as2025-03-04T12:32:58+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-results-from-phase-iii-verify-study-of-rusfertide--to-treat--phlebotomy-dependent-patients-with-polycythemia-vera.--protagonist-therapeutics--takeda2025-03-04T12:29:47+00:00weekly0.6https://www.medthority.com/news/2025/3/boston-scientific-corporation-to-acquire-sonivie-ltd-and-with-it-the-tivus--intravascular-ultrasound-system/2025-03-04T12:24:44+00:00weekly0.6https://www.medthority.com/news/2025/3/ibsrela-tenapanor-approved-in-china-to-control-serum-phosphorus-levels-in-dialysis-patients-with-chronic-kidney-disease-ckd-.--ardelyx-inc2025-03-05T11:58:25+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves--tnkase-tenecteplase-in-acute-ischemic-stroke-in-adults--genentech-roche/2025-03-05T11:56:32+00:00weekly0.6https://www.medthority.com/news/2025/3/positive-topline-results-showed-enhertu-trastuzumab-deruxtecan-demonstrated-an-improvement-in-overall-survival-in-patients-her2-positive-metastatic-gastric-cancer-at-interim-analysis-of-destiny-gastric04-phase-iii-trial---astrazeneca--daiichi-sankyo/2025-03-05T11:54:11+00:00weekly0.6https://www.medthority.com/news/2025/3/first-preschool-aged-child-receives-arpraziquantel-for-the-treatment-of-schistosomiasis--merck-kgaa/2025-03-05T11:49:37+00:00weekly0.6https://www.medthority.com/news/2025/3/nice-uk-positive-with-managed-access-for-casgevy-exagamglogene-autotemcel-for-treating-severe-sickle-cell-disease-in-people-12-years-and-over---vertex-pharmaceuticals--crispr-theraputics/2025-03-05T11:37:35+00:00weekly0.6https://www.medthority.com/news/2025/3/tnx-102-sl-demonstrated-statistically-significant-improvement-in-the-primary-endpoint-of-reduction-in-fibromyalgia-pain-in-two-double-blind-randomized-phase-iii-studies---tonix-pharmaceuticals/2025-08-14T11:27:33+00:00weekly0.6https://www.medthority.com/news/2025/3/novel-forward-intravascular-lithotripsy-platform-launched-in-u.s.-to-transform-treatment-of-difficult-to-cross-calcified-lesions---shockwave-medicaljohnson--johnson-medtech2025-03-05T11:30:15+00:00weekly0.6https://www.medthority.com/news/2025/3/depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp--gsk/2025-03-06T12:19:18+00:00weekly0.6https://www.medthority.com/news/2025/3/depemokimab-applications-accepted-for-review-by-the-us-fda-for-asthma-with-type-2-inflammation-and-for-chronic-rhinosinusitis-with-nasal-polyps-crswnp--gsk/2025-03-06T12:23:08+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-accepts-sbla-for--gazyvagazyvaro-obinutuzumab-for-the-treatment-of-lupus-nephritis--roche/2025-03-06T12:25:25+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-neffy-epinephrine-nasal-spray-for-the-emergency-treatment-of-allergic-reactions-type-i-including-those-that-are-life-threatening-anaphylaxis---ars-pharma/2025-03-06T12:27:45+00:00weekly0.6https://www.medthority.com/news/2025/3/-the-fda-has-accepted-for-review-a--bla--for-full-approval-for-deramiocel-as-a-treatment-for-patients-with-duchenne-muscular-dystrophy-dmd-cardiomyopathy.----capricor-therapeutics2025-03-06T12:29:52+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-expands-furoscix-indication-for-ckd-related-edema/2025-03-10T08:46:30+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-omlyclo-as-first-biosimilar-to-reference-xolair/2025-03-10T08:48:39+00:00weekly0.6https://www.medthority.com/news/2025/3/results-published-on-rhenium-186rnl-for-recurrent-glioma/2025-03-10T08:52:04+00:00weekly0.6https://www.medthority.com/news/2025/3/perioperative-treatment-with-imfinzi-durvalumab-in-combination-with-standard-of-care-flot-chemotherapy-demonstrated-a-superior-event-free-survival-over-standard-of-care---astrazeneca/2025-03-10T14:32:15+00:00weekly0.6https://www.medthority.com/news/2025/3/uk-mhra-has-accepted-the-marketing-authorisation-application-for-chikungunya-vaccine-in-the-uk-for-individuals-12-years-and-older---bavarian-nordic/2025-03-10T14:34:50+00:00weekly0.6https://www.medthority.com/news/2025/3/bimzelx-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis---ucb/2025-03-10T14:36:53+00:00weekly0.6https://www.medthority.com/news/2025/3/european-commission-approves-opdivo-nivolumab-plus-yervoy-ipilimumab-for-the-first-line-treatment-of-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma---bms/2025-03-10T14:38:10+00:00weekly0.6https://www.medthority.com/news/2025/3/bimzelx-bimekizumab-bkzx-two-year-data-at-aad-showed-potential-to-eliminate-draining-tunnels-in-hidradenitis-suppurativa-hs-and-reduction-in-disease-burden---ucb/2025-03-10T14:40:24+00:00weekly0.6https://www.medthority.com/news/2025/3/ebglyss-lebrikizumab-lbkz-single-monthly-maintenance-injection-achieved-completely-clear-skin-at-three-years-in-half-of-patients-with-moderate-to-severe-atopic-dermatitis---eli-lilly/2025-03-10T14:41:52+00:00weekly0.6https://www.medthority.com/news/2025/3/late-breaking-data-from-phase-iii-poetyk-psa-2-trial-demonstrates-superiority-of-sotyktu-deucravacitinib-compared-with-placebo-in-adults-with-psoriatic-arthritis---bristol-myers-squibb/2025-03-10T14:43:38+00:00weekly0.6https://www.medthority.com/news/2025/3/uk-mhra-approval-of-alyftrek-deutivacaftortezacaftorvanzacaftor-a-once-daily-next-in-class-cftr-modulator-for-the-treatment-of-cystic-fibrosis---vertex/2025-03-10T14:45:22+00:00weekly0.6https://www.medthority.com/news/2025/3/olumiant-baricitinib-delivered-high-rates-of-hair-regrowth-for-adolescents-with-severe-alopecia-areata-in-phase-iii-brave-aa-peds-study---eli-lilly/2025-03-10T14:47:51+00:00weekly0.6https://www.medthority.com/news/2025/3/two-year-data-from-smart-trial-continues-to-demonstrate-superior-valve-performance-for-evolut-tavr-system-compared-to-sapien-in-small-annulus-patients---medtronic/2025-03-10T14:49:51+00:00weekly0.6https://www.medthority.com/news/2025/2/nice-uk-positive-for-lynparza-olaparib-for-treating-brca-mutation-positive-her2-negative-advanced-breast-cancer-after-chemotherapy---astrazeneca--merck/2025-02-13T12:20:05+00:00weekly0.6https://www.medthority.com/news/2025/2/favorable-outcome-from-the-interim-analysis-of-alto-300-in-phase-iib-major-depressive-disorder-trial---alto-neuroscience/2025-02-13T12:13:55+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-gomekli-mirdametinib-for-the-treatment-of-adult-and-pediatric-patients-with-neurofibromatosis-type-1-nf1-who-have-symptomatic-plexiform-neurofibromas-pn---springworks-therapeutics-/2025-02-13T12:02:26+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-evrysdi-risdiplam-tablet-as-first-and-only-tablet-for-spinal-muscular-atrophy-sma---genentechroche/2025-02-13T12:00:14+00:00weekly0.6https://www.medthority.com/news/2025/2/bimzelx-bimekizumab-two-year-data-at-ehsf-2025-demonstrate-sustained-disease-control-in-hidradenitis-suppurativa-hs---ucb/2025-02-13T11:48:33+00:00weekly0.6https://www.medthority.com/news/2025/2/-fda-approves-adcetris-brentuximab-vedotin-combination-regimen-for-the-treatment-of-relapsedrefractory-diffuse-large-b-cell-lymphoma---pfizer/2025-02-14T12:33:56+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves-andembry-garadacimabto-prevent-attacks-of-hereditary-angioedema-hae-in-adult-and-adolescent-patients-aged-12-years-and-older---csl/2025-02-14T12:31:52+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-extends-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-without-a-limitation-on-duration-of-dosing-for-patients-with--geographic-atrophy--secondary-to-amd..--astellas2025-02-16T16:54:57+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves-kostaive--arct-154-a-self-amplifying-mrna-covid-19-vaccine.--csl--arcturus-therapeutics2025-02-16T16:54:06+00:00weekly0.6https://www.medthority.com/news/2025/2/bayer-files-for-approval-of-finerenone-in-heart-failure-in-japan/2025-02-16T16:53:01+00:00weekly0.6https://www.medthority.com/news/2025/2/-talzenna-talazoparib--in-combination-with-xtandi-enzalutamide-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer---pfizer/2025-05-06T15:07:33+00:00weekly0.6https://www.medthority.com/news/2025/2/ozempic-semaglutide-low-dose-in-phase-ii-trial-for-alcohol-use-disorder.--novo-nordisk2025-09-05T09:13:51+00:00weekly0.6https://www.medthority.com/news/2025/2/results-from-phase-iii-checkmate--9er-pivotal-trial-evaluating-cabometyx-cabozantinib--opdivo-nivolumab-versus-sunitinib-in-renal-cell-carcinoma.--exelixis-inc2025-02-16T16:50:52+00:00weekly0.6https://www.medthority.com/news/2025/2/new-five-year-sotyktu-deucravacitinib-data-show-consistent-safety-and-durable-response-rates-in-moderate-to-severe-plaque-psoriasis---bms/2025-02-17T11:52:40+00:00weekly0.6https://www.medthority.com/news/2025/2/update-on-phase-iii-relativity-098-trial-that-did-not-meet-its-primary-endpoint-of-recurrence-free-survival--for-the-adjuvant-treatment-stage-iii-iv-melanoma---bms/2025-02-17T11:46:42+00:00weekly0.6https://www.medthority.com/news/2025/2/imfinzi-reduced-the-risk-of-distant-metastases-and-death-from-bladder-cancer-vs.-neoadjuvant-chemotherapy-alone---astra-zeneca2025-02-17T11:43:25+00:00weekly0.6https://www.medthority.com/news/2025/2/immedica-completes-acquisition-of-marinus-pharmaceuticals-inc/2025-02-17T11:35:23+00:00weekly0.6https://www.medthority.com/news/2025/2/penmenvy--meningococcal-vaccine-approved-by-fda-to-help-protect-against-menabcwy--gsk/2025-02-18T12:12:07+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves--romvimza-vimseltinib-for-adult-patients-with-symptomatic-tenosynovial-giant-cell-tumor-tgct-.-decipheraono2025-02-18T12:08:16+00:00weekly0.6https://www.medthority.com/news/2025/2/first-participant-randomized-in-europe-in-phase-ii-gene-therapy-trial-of--ab-1002-for-congestive-heart-failure---askbio--bayer/2025-02-18T12:06:01+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves-emcitate-tiratricol-for-the-treatment-of-patients-with-monocarboxylate-transporter-8-mct8-deficiency.---egetis-therapeutics-ab2025-02-18T12:03:35+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-accepts-bla-for-avt-06-a-proposed-biosimilar-to-eylea-aflibercept-to-treat-eye-disorders-alvotech--teva-pharma/2025-02-19T15:01:18+00:00weekly0.6https://www.medthority.com/news/2025/2/ultragenyx-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-for-ux111-aav-gene-therapy-to-treat-sanfilippo-syndrome-type-a-mps-iiia---ultragenyx-pharmaceutical--/2025-02-19T14:57:46+00:00weekly0.6https://www.medthority.com/news/2025/2/new-data-for-darolutamide-confirm-safety-and-improved-efficacy-across-subgroups-of-patients-with-metastatic-hormone-sensitive-prostate-cancer---bayer/2025-02-19T11:33:26+00:00weekly0.6https://www.medthority.com/news/2025/2/novel-data-related-to-long-term-prophylaxis-and-sebetralstat--in-hereditary-angioedema-is-presented-at-the-wsaai-2025-annual-meeting--kalvista-pharma/2025-02-11T12:22:15+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-topline-results-for-breyanzi-lisocabtagene-maraleucel-in-adult-patients-with-relapsed-or-refractory-marginal-zone-lymphoma---bms/2025-02-11T12:26:41+00:00weekly0.6https://www.medthority.com/news/2025/2/eton-pharmaceuticals-announces-extension-of-pdufa-goal-date-for-et-400-for--adrenal-insufficiency/2025-02-11T12:29:49+00:00weekly0.6https://www.medthority.com/news/2025/2/once-weekly-mim8-is-well-tolerated-and-efficacious-in-children-living-with-haemophilia-a-with-and-without-inhibitors--novo-nordisk/2025-02-11T12:32:06+00:00weekly0.6https://www.medthority.com/news/2025/2/the-first-cohort-b-patient-in-the-achieve-phase-iib-uk-clinical-trial-evaluating-tcb-008-in-acute-myeloid-leukemia-has-completed-the-full-dosing-regiment-1000000000-cells.--tcb-biopham2025-02-11T12:35:10+00:00weekly0.6https://www.medthority.com/news/2025/2/long-term-efficacy-and-safety-of-eylea-8-mg--aflibercept-8-mg-with-extended-dosing-intervals-in-wet-age-related-macular-degeneration-confirmed-at-three-years--bayer/2025-02-11T12:37:21+00:00weekly0.6https://www.medthority.com/news/2025/2/novartis-acquires-anthos-therapeutics-and-with-it-abelacimab/2025-02-11T12:40:36+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-grants-approval-for-beyonttra--acoramidis--to--treat--wild-type-or-variant-transthyretin-amyloidosis-in-adult-patients-with-cardiomyopathy.--bridgebio-pharma2025-02-12T13:03:47+00:00weekly0.6https://www.medthority.com/news/2025/2/hansizhuang-serplulimab-hetronifly-in-europe---chemotherapy-is-approved-by-the-european-commission-as-a-first-line-treatment-of-adult-patients-with-small-cell-lung-cancer--shanghai-henlius-biotech/2025-05-06T13:41:58+00:00weekly0.6https://www.medthority.com/news/2025/2/padcev--enfortumab-vedotin-ejfv---keytruda--pembrolizumab-shows-long-term-efficacy-in-first-line-treatment-of-locally-advanced-or-metastatic-urothelial-cancer--pfizer--astellas-/2025-02-12T12:55:23+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-accepts-nda-for-troriluzole-for-the-treatment-of-adult-patients-with-spinocerebellar-ataxia-.--biohaven-ltd2025-02-12T12:43:05+00:00weekly0.6https://www.medthority.com/news/2025/2/zongertinib-bi-1810631-is-currently-being-evaluated-in-the-beamion-phase-ii-lung-2-trialfor-nsclcher2-tyrosine-kinase-domain-mutations/2025-02-12T12:35:15+00:00weekly0.6https://www.medthority.com/news/2025/2/nippon-boehringer-ingelheim--submits-in-japan--a-nda-for--zongertinib-for-the-treatment-of-her2-positive-unresectable-advanced-or-relapsed-non-small-cell-lung-cancer/2025-02-20T11:50:08+00:00weekly0.6https://www.medthority.com/news/2025/2/fda--accepts-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-under-priority-review---gilead-sciences/2025-02-20T11:54:47+00:00weekly0.6https://www.medthority.com/news/2025/2/askbio-receives-fda-regenerative-medicine-advanced-therapy-designation-for-parkinsons-disease-investigational-gene-therapy--bayer--askbio-/2025-02-20T11:58:12+00:00weekly0.6https://www.medthority.com/news/2025/2/final-analysis-of--overall-survival--from-the-phase-iii-checkmate---816-study-of-opdivo--nivolumab--chemotherapy-for-nsclcneoadjuvant--bms/2025-02-20T11:59:51+00:00weekly0.6https://www.medthority.com/news/2025/2/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications---merck/2025-02-20T12:03:53+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves--merilog-insulin-aspart-szjj-the-first-rapid-acting-insulin-biosimilar-product-for-treatment-of-diabetes---sanofi/2025-02-20T12:06:47+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-validates-extension-application-for-aspaveli-pegcetacoplan-for-the-treatmentof-c3-glomerulopathy-c3g--ic-mpgn.---sobi--apellis2025-02-20T12:13:52+00:00weekly0.6https://www.medthority.com/news/2025/2/the--fda-has-approved-the-blas-for-ospomyv--referencing-prolia-and-xbryk--referencing--xgeva--denosumab-biosimilars.--samsung-bioepis2025-02-21T13:11:52+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves-obodence-and-xbryk--denosumab-biosimilars--referencing-prolia-and-xgeva.--samsung-bioepis2025-02-21T13:09:24+00:00weekly0.6https://www.medthority.com/news/2025/2/nucala-mepolizumab-application-for-copd-accepted-for-review-in-china---gsk/2025-02-21T13:07:20+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-refusal-to-file-letter-for-pitolisant-for-the-treatment-of-excessive-daytime-sleepiness-eds-in-adult-patients-with-idiopathic-hypersomnia-ih.--harmony-biosciences2025-02-21T13:04:17+00:00weekly0.6https://www.medthority.com/news/2025/2/results-of-phase-i1b-arc-20-clinical-trial-of-casdatifan-in-patients-with-metastatic-ccrcc-after-two-or-more-prior-rounds-of-therapy-at-the-2025--asco-gu-cancers-symposium.--arcus2025-02-21T13:12:53+00:00weekly0.6https://www.medthority.com/news/2025/2/mhlw-ijapan-approves-andembrygaradacimabsubcutaneous-s.c.-injection-.-the-product-is-approved-for-the-prevention-of-acute-attacks-of-hereditary-angioedema.--csl-behring-k.k2025-02-21T12:58:11+00:00weekly0.6https://www.medthority.com/news/2025/2/astrazeneca-acquires-fibrogen-china/2025-02-21T12:55:14+00:00weekly0.6https://www.medthority.com/news/2025/2/sandoz-launches-biosimilar-pyzchiva-ustekinumab-ttwe-in-the-us-offering-new-treatment-for-around-12-million-patients/2025-02-25T13:37:14+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-ctexli-chenodiol-tablets-a-bile-acid-for-the-treatment-of-adults-with-cerebrotendinous-xanthomatosis.--mirum-pharma2025-02-25T13:42:28+00:00weekly0.6https://www.medthority.com/news/2025/2/european-medicines-agency-validates-maa--and-eu-medicines-for-all-application-for-twice-yearly-lenacapavir-for-hiv-prevention--gilead-sciences/2025-02-25T13:47:28+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-accepts-the-sbla-for-opdivo-nivolumab--yervoy-ipilimumab-for-patients-with-unresectable-or-metastatic-microsatellite-instability-high-or-mismatch-repair-deficient-colorectal-cancer---bms/2025-02-25T13:51:44+00:00weekly0.6https://www.medthority.com/news/2025/2/first-patient-dosed-in-emerald--phase-ii--study--of-ngm-120-a-gfral-antagonist-designed-to-block-gdf15-activity-for-the-treatment-of-hyperemesis-gravidarum-hg.--ngm-biopharma2025-02-25T13:54:27+00:00weekly0.6https://www.medthority.com/news/2025/2/lilly-launches-additional-zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients/2025-08-18T10:44:43+00:00weekly0.6https://www.medthority.com/news/2025/2/mhra-uk-and-swiss-medic-approve-nemolizumab-for-the-treatment-of-both-atopic-dermatitis-and-prurigo-nodularis-in-the-uk-and-switzerland-respectively.--galderma2025-02-26T12:52:05+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves-nemluvio-nemolizumab--to-treat--moderate-to-severe-atopic-dermatitis-and-prurigo-nodularis.--galderma2025-02-26T12:44:51+00:00weekly0.6https://www.medthority.com/news/2025/2/nmpa-china-approves--vibativ-telavancin-injection--for-patients-with-severe-bacterial-infections..-sciclone-phama--cumberland-pharma2025-02-26T12:42:03+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-has-granted-marketing-authorization-for-avtozma-ct-p47-a-biosimilar-referencing-roactemra-tocilizumab.--celltrion.-2025-02-26T12:38:50+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves--eydenzelt-ct-p42-aflibercept-and--stoboclo-and-osenvelt-ct-p41-denosumab-biosimilars-referencing-prolia----xgeva--.-celltrion2025-02-26T12:36:53+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-grants-priority-review-for-keytruda-pembrolizumab-plus-standard-of-care-as-perioperative-treatment-for-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma---merck/2025-02-26T12:35:10+00:00weekly0.6https://www.medthority.com/news/2025/2/fda--approval-of-vimkunya-vaccine-for-chikungunya-for-persons-aged-12-and-older---bavarian-nordic/2025-02-26T12:27:48+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-label-changes-for-sublocade--buprenorphine-extended-release-including-rapid-initiation-and-alternative-injection-sites.--indivior2025-02-26T12:25:25+00:00weekly0.6https://www.medthority.com/news/2025/2/mhlw-japan-approves-additional--dosage-of-canalia-combination-tablets-to-treat-type-2-diabetes.--mitsubishi-tanabe2025-02-26T12:22:07+00:00weekly0.6https://www.medthority.com/news/2025/2/nda-submitted-to-fda-for-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome---arrowhead-pharmaceuticals/2025-02-26T12:15:06+00:00weekly0.6https://www.medthority.com/news/2025/2/seladelpar-granted-european-approval-for-pbc/2025-02-23T14:16:59+00:00weekly0.6https://www.medthority.com/news/2025/2/selarsdi-ustekinumab-biosimilar-launched-in-usa/2025-02-23T14:17:10+00:00weekly0.6https://www.medthority.com/news/2025/2/tremfya-guselkumab-dual-induction-therapy-in-uc/2025-02-23T14:16:29+00:00weekly0.6https://www.medthority.com/news/2025/2/pfizer-withdraws--fidanacogene-elaparvovec-globally/2025-02-23T14:18:32+00:00weekly0.6https://www.medthority.com/news/2025/2/bluebird-bio-is-acquired-by-carlyle-group-and-sk-capital/2025-02-23T14:21:16+00:00weekly0.6https://www.medthority.com/news/2025/2/new-duvakitug-data-presented-at-ecco-reinforce-best-in-class-potential-in-ulcerative-colitis-and-crohns-disease---sanofi-and-teva-pharmaceuticals/2025-02-24T13:05:44+00:00weekly0.6https://www.medthority.com/news/2025/2/nice-uk-positive-for-retevmo-selpercatinib-for-previously-treated-ret-fusion-positive-advanced-non-small-cell-lung-cancer---eli-lilly/2025-02-24T13:00:43+00:00weekly0.6https://www.medthority.com/news/2025/2/nerandomilast-bi-1015550-meets-primary-endpoint-in-phase-iii-study-fibroneer-ild-in-progressive-pulmonary-fibrosis---boehringer/2025-02-24T12:57:54+00:00weekly0.6https://www.medthority.com/news/2025/2/zongertinib-receives-priority-review-from--fda-for-the-treatment-of-her2-erbb2-mutant-advanced-non-small-cell-lung-cancer---boehringer-ingelheim/2025-02-24T12:54:16+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-results-from-phase-iii-study-for-investigational-contrast-agent-gadoquatrane--bayer/2025-02-27T12:47:09+00:00weekly0.6https://www.medthority.com/news/2025/2/eli-lilly-acqures-fxr-314-program-from-organovo-holdings-inc/2025-02-27T12:44:10+00:00weekly0.6https://www.medthority.com/news/2025/2/publication-in-jama-of--results-for-triple-combination-of-versamune-hpv--pds01-adc-and-a-pd-l1-immune-checkpoint-inhibitor-for--hpv-associated-cancers-.pds-biotechnology2025-05-13T08:53:00+00:00weekly0.6https://www.medthority.com/news/2025/3/-chmp-opinion-for-upadacitinib-rinvoq-for-the-treatment-of-adults-with-giant-cell-arteritis--abbvie/2025-03-02T15:29:03+00:00weekly0.6https://www.medthority.com/news/2025/3/camizestrant-demonstrated-in-serena-6-trial-statistically-significant--improvement-in-progression-free-survival-in-1st-line-advanced-hr-positive-breast-cancer-with-an-emergent-esr1-tumour-mutation----astrazeneca/2025-03-02T15:28:12+00:00weekly0.6https://www.medthority.com/news/2025/3/bluerock-therapeutics-receives-fda-fast-track-designation-for-opct-001-for-the-treatment-of-primary-photoreceptor-diseases-/2025-03-02T15:27:28+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-recommends-eu-approval-of-columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma--roche/2025-03-02T15:26:47+00:00weekly0.6https://www.medthority.com/news/2025/3/fda-approves-leqembi-lecanemab--for-monthly-maintenance-dosing-for-early-alzheimers-disease-.-eisai2025-03-02T15:26:03+00:00weekly0.6https://www.medthority.com/news/2025/3/the-committee-for-medicinal-products-for-human-use-chmp-reaffirms-positive-opinion-for-lecanemab-in-early-alzheimers-disease---eisai--biogen-/2025-03-02T15:25:00+00:00weekly0.6https://www.medthority.com/news/2025/3/moderna-receives-medicines-and-healthcare-products-regulatory-agency-marketing-authorization-in-the-uk-for-rsv-vaccine/2025-03-02T15:25:15+00:00weekly0.6https://www.medthority.com/news/2025/3/enhertu-trastuzumab-deruxtecan--recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy--daiichi-sankyo---astrazeneca/2025-03-02T15:23:35+00:00weekly0.6https://www.medthority.com/news/2025/3/phase-iii-results-from-bruin-cll-321-show-pirtobrutinib-jaypirca-reduced-the-risk-of-disease-progression-or-death-by-46---eli-lilly/2025-03-02T15:22:41+00:00weekly0.6https://www.medthority.com/news/2025/3/jaypirca-pirtobrutinib-recommended-by-chmp-for-approval-in-the-european-union-for-adults-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-previously-treated-with-a-btk-inhibitor--eli-lilly-/2025-03-02T15:21:52+00:00weekly0.6https://www.medthority.com/news/2025/3/novartis-acquires-anthos-therapeutics/2025-03-02T15:21:00+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-postive-for--deqsiga-intended-for-replacement-therapy-in-people-with-primary-or-secondary-immunodeficiencies-and-immunomodulation.--takeda2025-03-02T15:20:10+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive-for-lynozyfic--linvoseltamab-to-treat-rr-multiple-myeloma.--regeneron-pharma2025-05-06T15:10:12+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-posiive-for-calquence-to-treat-mantle-cell-lymphoma--astrazeneca/2025-03-02T15:18:13+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive-for-imfinzi--durvalumab--chemotherapy--as-adjuvant-treatment-for-adults-with-resectable-nsclc-at-high-risk-of-recurrence-and-no-egfr-mutations-or-alk-rearrangements.--astrazeneca2025-03-02T15:17:09+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive-for-fabhalta--iptacopan--for-the-treatment-of-adults-with-c3-glomerulopathy-c3g.--novartis2025-03-02T15:16:11+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive-for-a-label-extension-for-ixchiq-a-single-dose-vaccine-for-the-prevention-of-disease-caused-by-the-chikungunya-virus--valneva-se/2025-03-02T15:15:03+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive-for-vyjuvek--beremagene-geperpavec-svdt--for-the-treatment-of-wounds-in-patients-with-dystrophic-epidermolysis-bullosa---krystal-biotech-inc/2025-03-02T15:14:08+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-positive--for-tremfya-guselkumab-to-include-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-who-have-had-an-inadequate-response.--johnson--johnson-2025-03-03T12:20:47+00:00weekly0.6https://www.medthority.com/news/2025/3/chmp-negative-opinion-for--kizfizo-temozolomide-oral-suspension-for-the-treatment-of-patients-with-relapsed-or-refractory-high-risk-neuroblastoma---orphelia-pharma/2025-03-03T12:24:00+00:00weekly0.6https://www.medthority.com/news/2025/1/--the-phase-iii-hyperion-study-evaluating-winrevair-sotatercept-csrk-versus-placebo-in-recently-diagnosed-adults-with-pulmonary-arterial-hypertension-will-be-stopped-early.---merck-inc2025-01-31T12:52:47+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-results-from-the-12-month-open-label-extension-of-the-phase-1biia-pacific-trial-evaluating-bexicaserin-in-participants-aged-12-65-with-developmental-and-epileptic-encephalopathies-dees..-lundbeck2025-01-31T12:58:39+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-approves--ahzantivebaiama-aflibercept-biosimilar--formyconklinge-biopharma--teva/2025-01-31T13:02:21+00:00weekly0.6https://www.medthority.com/news/2025/1/-s-337395-which-is-being-jointly-developed-with-ube-corporation-has-achieved-its-primary-endpoint-in-a-phase-ii--clinical-trial-.to-treat-respiratory-syncytial-virus.--shionogi2025-01-31T13:10:37+00:00weekly0.6https://www.medthority.com/news/2025/2/four-year-results-from-pivotal-hope-b-study-confirm-the-long-term-durability-and-safety-of-a-one-time-infusion-of-hemgenix--etranacogene-dezaparvovec-drlb-for-hemophilia-b.--cslbehring2025-02-10T08:41:18+00:00weekly0.6https://www.medthority.com/news/2025/2/omvoh-mirikizumab-mrkz-for-crohns-disease-achieved-sustained-clinical-remission-and-endoscopic-response-at-two-years-for-most-patients---eli-lilly/2025-02-10T08:40:26+00:00weekly0.6https://www.medthority.com/news/2025/2/nice-uk-positive-for-orserdu-elacestrant-for-treating-oestrogen-receptor-positive-her2-negative-advanced-breast-cancer-with-an-esr1-mutation-after-endocrine-treatment----menarini-/2025-02-10T08:39:31+00:00weekly0.6https://www.medthority.com/news/2025/2/alumis-inc.to-merge-with-acelyrin-inc2025-02-10T08:38:39+00:00weekly0.6https://www.medthority.com/news/2025/2/new-england-journal-of-medicine-publishes-new-data-for-gazyvagazyvaro-which-shows-superiority-over-standard-therapy-in-people-with-active-lupus-nephritis--roche/2025-02-10T08:37:47+00:00weekly0.6https://www.medthority.com/news/2025/2/-fda-accepts-revised-snda-for-izervay-avacincaptad-pegol-intravitreal-solution-to-treat-geographic-atrophy-ga-secondary-to-amd.--astellas2025-02-10T08:36:50+00:00weekly0.6https://www.medthority.com/news/2025/2/avacincaptad-pegol--is-submitted-to-mhlw-japan--for-the-treatment-of-geographic-atrophy-secondary-to-amd.--astellas2025-02-10T08:35:44+00:00weekly0.6https://www.medthority.com/news/2025/2/-the-fda-has-approved-emblaveoaztreonam-and-avibactamfor-the-treatment-of-complicated-intra-abdominal-infections-ciai--abbvie-/2025-02-10T08:34:32+00:00weekly0.6https://www.medthority.com/news/2025/2/globus-medical-to-acquire-nevro-corp.--a-global-medical-device-company-2025-10-16T10:43:45+00:00weekly0.6https://www.medthority.com/news/2025/2/aim-immunotech-inc.-commentary-on-journal-of-general-internal-medicine-article-linking-covid-19-to-myalgic-encephalomyelitischronic-fatigue-syndrome2025-02-10T11:37:39+00:00weekly0.6https://www.medthority.com/news/2025/2/updated-data-from-the-phase-iii-staar-study-continue-to-support-the-potential-of-isaralgagene-civaparvovec--st-920-as-a-treatment-for-fabry-disease--sangamo-therapeutics-/2025-02-10T11:34:18+00:00weekly0.6https://www.medthority.com/news/2025/2/the-addition-of-nab-paclitaxel-abraxane-to-gemcitabine--cisplatin-did-not-produce-a-statistically-significant-difference-in-overall-survival--and-progression-free-survival-in-patients-with-biliary-tract-cancer.--abraxisbms2025-02-04T12:51:45+00:00weekly0.6https://www.medthority.com/news/2025/2/roche-receives-fda-approval-for-the-first-companion-diagnostic-to-identify-patients-with-her2-ultralow-metastatic-breast-cancer-eligible-for-enhertu-trastuzumab-deruxtecan-/2025-02-04T12:54:17+00:00weekly0.6https://www.medthority.com/news/2025/2/braftovi--encorafenib--combination-regimen-significantly-improved-progression-free-survival-and-overall-survival-in-phase-iii-breakwater-trial---pfizer-/2025-02-04T12:58:18+00:00weekly0.6https://www.medthority.com/news/2025/2/bayer-files-for-approval-of-finerenone-in-heart-failure-in-the-eu/2025-02-04T13:01:18+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-approves--blincyto-blinatumomab-monotherapy-for--newly-diagnosed-philadelphia-chromosome-negative-cd19-positive-b-cell-precursor-acute-lymphoblastic-leukemia-.--amgen2025-02-04T13:06:01+00:00weekly0.6https://www.medthority.com/news/2025/2/chmp-positive-for-imfinzi-durvalumab-to-treat-limited-stage-small-cell-lung-cancer-ls-sclc--following-platinum-based-chemoradiation-therapy.--astrazeneca2025-02-04T13:08:19+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approval-for-onapgo--apomorphine-hydrochloride--injectionfor-the-treatment-of-motor-fluctuations-in-adults-with-advanced-parkinsons-disease-.--supernus-pharma2025-02-05T12:38:45+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-susvimo-ranibizumab-injection-100-mgml-for-the-treatment-of-diabetic-macular-edema.--roche2025-02-05T12:35:47+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-results-from-phase-ii-fight-dmd-trial-of-ifetroban.-a-novel-oral-therapy--for-duchenne-muscular-dystrophy-dmd-heart-disease-.--cumberland-pharma2025-02-07T08:08:29+00:00weekly0.6https://www.medthority.com/news/2025/2/new-data-demonstrates-positive-results--for-ux-111-in-patients-with-sanfilippo-syndrome-type-a-mps-iiia---ultragenyx-pharmaceutical-inc/2025-02-07T08:07:31+00:00weekly0.6https://www.medthority.com/news/2025/2/phase-iii-study-evaluating-buntanetap-is-initiated-in-early-alzheimers-disease.--annovis-bio-inc2025-02-07T08:06:42+00:00weekly0.6https://www.medthority.com/news/2025/2/mhra-uk-approves-ixchiq--chikungunya-vaccine.--valneva-se2025-02-07T08:05:48+00:00weekly0.6https://www.medthority.com/news/2025/2/immvention-therapeutix-and-novo-nordisk-to-collaborate-on-sickle-cell-disease-therapies/2025-02-07T08:04:55+00:00weekly0.6https://www.medthority.com/news/2025/2/12-month-data-from-the-phase-ii-study-sycamore-of-rec-994-the-first-industry-sponsored-phase-ii-trial-completed-in-cerebral-cavernous-malformations.-recursion2025-02-07T15:24:09+00:00weekly0.6https://www.medthority.com/news/2025/2/phase-iii-waveline-010-trial-initiated-evaluating-zilovertamab-vedotin-an-investigational-antibody-drug-conjugate-for-the-treatment-of-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma---merck/2025-02-07T15:23:19+00:00weekly0.6https://www.medthority.com/news/2025/1/braftovi-combination-regimen-demonstrates-improved-response-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer---pfizer/2025-01-28T12:17:18+00:00weekly0.6https://www.medthority.com/news/2025/1/initiation-of-a-phase-iii-clinical-trial-of--asp-1929-photoimmunotherapy-in-combination-with--keytruda-pembrolizumabfor-recurrent-head-and-neck-squamous-cell-carcinoma-..-rakuten-medical2025-01-28T12:14:40+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-bla-for-rp1-vusolimogene-oderparepvec--opdivo--nivolumab-to-treat-advanced-melanoma--replimune/2025-01-28T12:18:20+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-welireg--belzutifan-to-treat-advanced-unresectable-or-metastatic-pheochromocytoma-and-paraganglioma-.--merck-inc2025-05-06T14:34:43+00:00weekly0.6https://www.medthority.com/news/2025/1/veru-inc.--announced-positive-topline-results-from-the-phase-iib-quality-clinical-study2025-01-28T11:58:14+00:00weekly0.6https://www.medthority.com/news/2025/1/roche-announces-new-results-from-embark-demonstrating-significant-sustained-benefits-of-elevidys-in-ambulatory-individuals-with-duchenne-muscular-dystrophy-dmd/2025-05-06T14:59:02+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-leqembi--lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease--eisai---biogen/2025-01-28T11:41:27+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-topline-results-from-phase-iii-inavo120-study-investigating-itovebi-inavolisib--palbociclib-ibrance--fulvestrant--for-pik3ca-mutated-hr-her2---endocrine-resistant-breast-cancer--roche/2025-05-22T10:55:46+00:00weekly0.6https://www.medthority.com/news/2025/1/topline-results-from-symmetry-a-phase-iib-study-of-efruxifermin-efx-in-patients-with-biopsy-confirmed-compensated-cirrhosis-f4-child-pugh-class-a-due-to-mash.--alkero-therapeutics2025-01-29T12:27:16+00:00weekly0.6https://www.medthority.com/news/2025/1/enhertu-trastuzumab-deruxtecan--approved-in-the-u.s.-as-first-her2-directed-therapy-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-disease-progression-after-one-or-more-endocrine-therapies--daiichi-sankyo--astrazeneca2025-01-29T12:23:48+00:00weekly0.6https://www.medthority.com/news/2025/1/gsk-plc-and-oxford-university-enter-new-reseach-collaboration-for-cancer-prevention/2025-01-29T12:13:50+00:00weekly0.6https://www.medthority.com/news/2025/1/depemokimab-accepted-for-review-by-the-european-medicines-agency-for-use-in-asthma-with-type-2-inflammation-and-crswnp--gsk/2025-01-30T13:09:58+00:00weekly0.6https://www.medthority.com/news/2025/1/initiation-of-a-phase-iii-registrational-study-to-evaluate-osavampator-formerly-nbi-1065845-as-an-adjunctive-treatment-to-antidepressants-for-major-depressive-disorder-.-neurocrine-biosciences2025-01-30T13:07:39+00:00weekly0.6https://www.medthority.com/news/2025/1/shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency--gsk/2025-01-30T13:02:06+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-ozempic-semaglutide-injection-to-reduce-the-risk-of-kidney-disease-worsening-kidney-failure-and-death-due-to-cv--disease-in-adults-with-type-2-diabetes-and-ckd--novo-nordisk/2025-01-30T12:59:38+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approval--of-update-to-the-label-of--qelbree-viloxazine-extended-release-capsules-to-include-new-pharmacodynamic-data.--supernus-pharma2025-01-30T12:53:19+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-topline-results-rfrom--ath434-201-phase-ii-clinical-trial-in-patients-with-early-stage-multiple-system-atrophy-msa.--alterity-therapeutics2025-01-30T12:50:50+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-has-approved-journavx-suzetrigine-an-oral-non-opioid-highly-selective-nav1.8-pain-signal-inhibitor-for-the-treatment-of-adults-with-moderate-to-severe-acute-pain..--vertex2025-02-03T09:45:47+00:00weekly0.6https://www.medthority.com/news/2025/2/tropion-lung12-phase-iii-trial-initiated-evaluating-datroway-datopotamab-deruxtecan-as-part-of-adjuvant-regimen-for-patients-with-early-stage-non-small-cell-lung-cancer-at-high-risk-of-relapse--daiichi-sankyo/2025-02-03T09:44:37+00:00weekly0.6https://www.medthority.com/news/2025/2/chmp-recommends-vimkunya-chikv-vlp-vaccine-for-immunization-for-the-prevention-of-disease-caused-by-chikungunya-virus-in-individuals-12-years-and-older..--bavarian-nordic2025-02-03T09:43:20+00:00weekly0.6https://www.medthority.com/news/2025/2/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union---eisai--biogen-/2025-02-03T09:41:53+00:00weekly0.6https://www.medthority.com/news/2025/2/datopotamab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer--daiichi-sankyo/2025-05-22T10:52:24+00:00weekly0.6https://www.medthority.com/news/2025/2/chmp-recommends-pavblu--aflibercept-biosimilar-intended-for-amd-rvo-dme-and-myopic-cnv.--amgen2025-02-03T09:39:40+00:00weekly0.6https://www.medthority.com/news/2025/2/chmp-recommends-tivdak-tisotumab-vedotin-to-treat-recurrent-or-metastatic-cervical-cancer--pfizer/2025-02-03T09:38:31+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves--symbravo-meloxicam-and-rizatriptan-for-the-acute-treatment-of-migraine-with-or-without-aura-in-adults.--axsome-therapeutics2025-02-03T09:34:55+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-chmp-opinion-for-capvaxive-pneumococcal-21-valent-conjugate-vaccine-for-pneumococcal-vaccination-in-adults-.--merck-inc2025-02-03T09:33:33+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-chmp-opinion-for-car-t-cell-therapy-breyanzi-lisocabtagene-maraleucel-for-relapsed-or-refractory-follicular-lymphoma--bms/2025-02-03T09:33:47+00:00weekly0.6https://www.medthority.com/news/2025/2/positive-chmp-opinion-for-opdivo-nivolumab-plus-yervoy-ipilimumab-as-a-first-line-treatment-option-for-adult-patients-with-unresectable-or-advanced-hepatocellular-carcinoma--bms/2025-02-03T09:31:15+00:00weekly0.6https://www.medthority.com/news/2025/2/european-commission-has-authorisedvocabria-cabotegravir-long-acting-injections--rekambys-rilpivirine-long-acting-injections-for-the-treatment-of-hiv-1-infection-in-adolescents.--viiv-healthcare-2025-02-03T09:29:51+00:00weekly0.6https://www.medthority.com/news/2025/2/chmp-positive-for-rystiggo-rozanolixizumab--to-be-administered-via-an-infusion-syringe-pump-or-a-new-manual-push-syringe-method--ucb/2025-02-03T09:28:21+00:00weekly0.6https://www.medthority.com/news/2025/2/fda-approves-avtozma-tocilizumab-anoh-in-both-an-intravenous-iv-and-subcutaneous-sc-formulation-as-a-biosimilar-to-actemra..--celltrion2025-02-03T12:27:23+00:00weekly0.6https://www.medthority.com/news/2025/2/-nmpachina-approved-isatuximab-scarlisa--bortezomib-velcade--lenalidomide-revlimid--dexamethasone--for-the-treatment-of--patients-with-newly-diagnosed-multiple-myeloma--sanofi/2025-02-03T12:29:47+00:00weekly0.6https://www.medthority.com/news/2025/2/-177lu-edotreotide--extended-progression-free-survival-vs-everolimus-afinitor-in-patients-with--gastro-enteropancreatic-neuroendocrine-tumors-.itm-isotope-technologies2025-02-03T12:32:22+00:00weekly0.6https://www.medthority.com/news/2025/1/mhra-uk-approves-jeragyo-aprocitentan-to-treat-resistant-hypertension.--idorsia2025-01-21T14:18:08+00:00weekly0.6https://www.medthority.com/news/2025/1/nmpa-china-accepts-new-drug-application-for-karxt-xanomeline--trospium-for-the-treatment-of-schizophrenia.--zai-lab2025-01-21T14:16:21+00:00weekly0.6https://www.medthority.com/news/2025/1/-positive-topline-results-announced-for-tivdak--tisotumab-vedotin-in-the-china-subpopulation-of-the-phase-iii-innovatv-301-trial-in-patients-with-recurrent-or-metastatic-cervical-cancer.--zai-lab2025-01-21T14:14:16+00:00weekly0.6https://www.medthority.com/news/2025/1/junshi-biosciences-announces-commercialization-partnership-with-leo-pharma-for-toripalimab-in-europe/2025-01-21T14:12:31+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer--gsk/2025-01-22T13:05:24+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-places-hold-on-ebvallo--tabelecleucel-for-treatment-of--epstein-barr-virus--and-ata-3219--for-the-treatment-of-non-hodgkins-lymphoma.---atara-biotherapeutics-2025-01-22T13:00:56+00:00weekly0.6https://www.medthority.com/news/2025/1/simcere-zaiming-and-abbvie-announce-partnership-to-develop-a-novel-trispecific-antibody-candidate-in-multiple-myeloma/2025-01-22T12:56:35+00:00weekly0.6https://www.medthority.com/news/2025/1/cytokinetics-announces-start-of-amber-hfpef-a-phase-ii-clinical-trial-of-ck-586-in-patients-with-symptomatic-heart-failure-with-preserved-ejection-fraction/2025-01-22T12:49:17+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-provides-supplemental-approval--for-spravato-esketamine-ciii-nasal-spray-for-adults-living-with-major-depressive-disorder.--johnson--johnson2025-01-24T08:54:51+00:00weekly0.6https://www.medthority.com/news/2025/1/roche-receives-fda-clearance-with-clia-waiver-for-cobas-liat-molecular-tests-to-diagnose-sexually-transmitted-infections-at-the-point-of-care/2025-01-24T08:52:05+00:00weekly0.6https://www.medthority.com/news/2025/1/moderna-announces-updates-on-pandemic-influenza-program/2025-01-24T08:49:04+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approval-for-calquence-acalabrutinib-for-the-treatment-of--previously-untreated-mantle-cell-lymphoma-patients-who-are-ineligible-for-autologous-hematopoietic--stem-cell-transplantation.--astra-zeneca2025-05-13T08:59:37+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-approves-gohibic-vilobelimab-to-treat-patients-with-sars-cov-2-induced-acute-respiratory-distress-syndrome-who-are-receiving-systemic-corticosteroids--inflarxn.v2025-01-24T08:38:32+00:00weekly0.6https://www.medthority.com/news/2025/1/sarclisa-approved-in-the-eu-as-the-first-anti-cd38-therapy-in-combination-with-standard-of-care-vrd-to-treat-transplant-ineligible-newly-diagnosed-multiple-myeloma---sanofi/2025-01-24T08:35:39+00:00weekly0.6https://www.medthority.com/news/2025/1/european-commission-approves-lazcluze-lazertinib--rybrevant-amivantamab-for-the-first-line-treatment-of-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer---johnson--johnson/2025-01-24T08:32:01+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-grafapex--a-preparative-regimen-for-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-aml-or-mds-.--medexus2025-01-24T13:41:29+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma--biogen/2025-05-13T08:59:21+00:00weekly0.6https://www.medthority.com/news/2025/1/classic-congenital-adrenal-hyperplasia-supplement-published-in-the-journal-of-clinical-endocrinology--metabolism----neurocrine-biosciences/2025-01-24T13:35:46+00:00weekly0.6https://www.medthority.com/news/2025/1/findings-from-pivotal-nipocalimab-phase-iii-study-in-a-broad-antibody-positive-population-of-people-living-with-generalized-myasthenia-gravis-gmg-published-in-the-lancet-neurology---johnson--johnson/2025-01-24T13:32:16+00:00weekly0.6https://www.medthority.com/news/2025/1/nice-uk-positive-for-vafseo-vadadustat-for-treating-symptomatic-anaemia-in-adults-having-dialysis-for-chronic-kidney-disease---akebia-theraputics/2025-01-24T13:28:52+00:00weekly0.6https://www.medthority.com/news/2025/1/-valneva-se-reported-further-positive-phase-iii-data-in-adolescents-for-its-single-shot-chikungunya-virus-chikv-vaccine-ixchiq.-2025-01-25T15:27:54+00:00weekly0.6https://www.medthority.com/news/2025/1/phase-iii-leap-015-trial-results-of-keytruda-pembrolizumab--lenvima-lenvatinib-for-her2--negative-gastroesophageal-adenocarcinoma.--merck-inc.--eisai2025-01-25T15:29:21+00:00weekly0.6https://www.medthority.com/news/2025/1/aim-immunotech-inc.-offered-commentary-on-a-new-article-in-the-journal-of-general-internal-medicine-linking-covid-19-to-increased-risk-of-myalgic-encephalomyelitischronic-fatigue-syndrome-mecfs2025-01-26T15:49:45+00:00weekly0.6https://www.medthority.com/news/2025/1/enrollment-completed--of-patients-in-the-phase-iii-synchrony-real-world-study-of-efx-in-patients-with-mash--or-masld.--akero-therapeutics2025-01-26T15:48:56+00:00weekly0.6https://www.medthority.com/news/2025/1/-topline-results-reported-from-a-phase-1biia-clinical-trial-with-amycretin-a-unimolecular-glp-1-and-amylin-receptor-agonist-as-a-once-weekly-subcutaneous-administration-in-obese-patients--novo-nordisk.-2025-01-26T15:48:04+00:00weekly0.6https://www.medthority.com/news/2025/1/analysis-from--phase-iii-checkmate--8hw-trial-of-opdivo-nivolumab--yervoy-ipilimumab-versus-opdivo-monotherapy--for--msi-hdmmr-metastatic-colorectal--cancer.-bms2025-01-26T15:47:07+00:00weekly0.6https://www.medthority.com/news/2025/1/results-of-expansion-cohort-in-phase1ii-stellar-001-trial-of--zanzalintinib-alone-and-with-atezolizumab--for-colorectal-cancer-ras-wild-type.--exelisis-inc2025-01-26T15:46:21+00:00weekly0.6https://www.medthority.com/news/2025/1/results-from--phase-iii-leap-015-trial-of-keytruda--pembrolizumab--lenvima-lenvatinib-for-her2--negative-gastroesophageal-adenocarcinoma-.-merck-inc.---eisai2025-01-26T15:44:28+00:00weekly0.6https://www.medthority.com/news/2025/1/-positive-results-from-a-subgroup-analysis-of-the-phase-iii-cabinet-pivotal-study-of-patients-with-extra-pancreatic-neuroendocrine-tumors-arising-in-the-gastrointestinal-tract.--exelixis-inc2025-05-22T10:56:41+00:00weekly0.6https://www.medthority.com/news/2025/1/datroway-approved-in-the-u.s.-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer--daiichi-sankyo2025-01-19T13:12:32+00:00weekly0.6https://www.medthority.com/news/2025/1/top-line-results-from-the-phase-iii-connex-clinical-program-in-cognitive-impairment-in-adults-with-schizophrenia-show-primary-and-key-secondary-endpoints-were-not-met---boehringer-ingelheim/2025-01-19T13:11:28+00:00weekly0.6https://www.medthority.com/news/2025/1/nice-uk-update-to-technology-appraisal-guidance-697-on-ondexxya-andexanet-alfa-for-reversing-anticoagulation-from-apixaban-or-rivaroxaban---astra-zeneca/2025-01-19T13:10:32+00:00weekly0.6https://www.medthority.com/news/2025/1/datopotamab-deruxtecan-granted-priority-review-in-the-us-for-patients-with-previously-treated-advanced-egfr-mutated-non-small-cell-lung-cancer---astra-zeneca-and-daiichi-sankyo/2025-01-14T11:58:57+00:00weekly0.6https://www.medthority.com/news/2025/1/adaptimmune-announces-u.s.-fda-breakthrough-therapy-designation-granted-to-letetresgene-autoleucel-lete-cel-for-treatment-of-myxoidround-cell-liposarcoma-mrcls2025-01-14T12:06:05+00:00weekly0.6https://www.medthority.com/news/2025/1/bluerock-therapeutics-advances-investigational-cell-therapy-bemdaneprocel-for-treating-parkinsons-disease-to-registrational-phase-iii-clinical-trial/2025-01-14T12:11:20+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-accepts-bla-for-leqembi-sc-subcutaneous-autoinjector-for-weekly-dosing-to-treat-early-alzheimers-disease--eisai-biogen/2025-01-14T12:14:32+00:00weekly0.6https://www.medthority.com/news/2025/1/johnson--johnson-acquires-inter-celllular-therapies/2025-01-14T12:22:43+00:00weekly0.6https://www.medthority.com/news/2025/1/nmpa-china-approves-padcevenfortumab-vedotin---keytruda-pembrolizumab-for-adult-patients-with-locally-advanced-or-metastatic-urothelial-cancer.---astellas-pharma2025-01-15T12:50:58+00:00weekly0.6https://www.medthority.com/news/2025/1/first-participants-randomized-in-askbio-phase-ii-gene-therapy-trial-for-parkinsons-disease---bayer/2025-01-15T12:56:23+00:00weekly0.6https://www.medthority.com/news/2025/1/favorable-dsmb-review-of-sentinel-cohort-from-covid-19-phase-iib-clinical-trial-of-oral-vaccine-vxa-cov2-1---vaxart/2025-01-15T13:00:24+00:00weekly0.6https://www.medthority.com/news/2025/1/positive-results-from-the-phase-iii-c-post-trial--for-adjuvant-treatment-with--libtayo-cemiplimab--in-cutaneous-squamous-cell-carcinoma-after-surgery--regeneron/2025-01-15T13:05:10+00:00weekly0.6https://www.medthority.com/news/2025/1/gsk-acquires-idrx-inc.-and-with-it-idrx-42a-potential-treatment-for-first--and-second--line--gist2025-01-15T13:08:00+00:00weekly0.6https://www.medthority.com/news/2025/1/hybryte-synthetic-hypericin-expanded-treatment-continues-to-demonstrate-positive-outcomes-in-early-stage-cutaneous-t-cell-lymphoma---soligenix/2025-01-16T12:05:41+00:00weekly0.6https://www.medthority.com/news/2025/1/ce-mark-approval-in-eu-and-uk-for-brainsense-adaptive-deep-brain-stimulation--a-groundbreaking-advance-in-personalized-sensing-enabled-care-for-people-with-parkinsons----medtronic/2025-01-17T12:18:58+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-omvoh-mirikizumab-mrkz-for-crohns-disease-expanding-its-use-to-the-second-major-type-of-inflammatory-bowel-disease---eli-lilly/2025-01-17T12:21:30+00:00weekly0.6https://www.medthority.com/news/2025/1/voluntary-halt-to-all-dosing-in-the-tropos-trial-a-phase-ii-clinical-trial-of-cibotercept-ker-012---background-therapy-in-patients-with-pulmonary-arterial-hypertension---keros-therapeutics-inc/2025-01-17T12:28:40+00:00weekly0.6https://www.medthority.com/news/2025/1/complete-response-letter-for-ebvallo--tabelecleucel-to-treat-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld---atara--pierre-fabre/2025-01-18T12:07:29+00:00weekly0.6https://www.medthority.com/news/2025/1/submissions-to-ema-and-mhr-completed-for--anktiva-nogapendekin-alfa-inbakicept-plus-bcg-tor-treat--bcg-unresponsive-non-muscle-invasive-bladder-cancer.-immunity-bio2025-01-18T12:06:32+00:00weekly0.6https://www.medthority.com/news/2025/1/complete-analysis-of-norse-eight-trial-evaluating-ons-5010-in-wet-amd-patients---outlook-therapeutics/2025-01-18T12:05:41+00:00weekly0.6https://www.medthority.com/news/2025/1/mhra-uk-approves-seladelpar-livdelzi-to-treat--primary-biliary-cholangitis.-cymabay2025-01-23T14:37:56+00:00weekly0.6https://www.medthority.com/news/2025/1/nice-uk-positive-for-agamree-vamorolone-for-treating-duchenne-muscular-dystrophy-in-people-4-years-and-over---santhera-pharmaceuticals/2025-01-18T12:03:59+00:00weekly0.6https://www.medthority.com/news/2025/1/late-breaking-data-presented-at-af-symposium-2025-highlight-key-boston-scientific-therapies-for-management-of-patients-with-atrial-fibrillation/2025-01-18T12:02:45+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-calquence-acalabrutinib-plus-chemoimmunotherapy-for-patients-with-previously-untreated-mantle-cell-lymphoma---astra-zeneca/2025-01-18T12:01:51+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves-9mg-and-22mg--vial-sizes-of--niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease.--incyte--syndax2025-01-18T12:00:57+00:00weekly0.6https://www.medthority.com/news/2025/1/novo-nordisk--announced-headline-results-from-step-up-a-phase-iiib-trial-investigating-subcutaneous-semaglutide-7.2-mg-for-obesity2025-01-18T11:59:58+00:00weekly0.6https://www.medthority.com/news/2025/1/fda-approves--lumakras--sotorasib--in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer--amgen/2025-01-18T11:58:50+00:00weekly0.6https://www.medthority.com/news/2025/5/hansa-to-restructure/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/medtronic-to-separate--its-diabetes-business-into-a-new-company/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/the-fda-identified--a-potential-path-forward-for-elamipretide-to-treat--barth-syndrome-following-a-2024-cardiovascular-and-renal-drugs-advisory-committee-meeting-positive-decision.--stealth-therapeutics-2025-06-30T07:43:06+00:00weekly0.6https://www.medthority.com/news/2025/5/-topline-data-announced-from-the-tropos-trial-a-phase-ii-clinical-trial-of-cibotercept-ker-012-in-patients-with-pulmonary-arterial-hypertension.--keros-therapeutics2025-06-30T07:43:06+00:00weekly0.6https://www.medthority.com/news/2025/5/arecent-virology-study-showed-the-novel-broad-spectrum-influenza-pb2-inhibitor-cc-42344-exhibits-strong-antiviral-activity-against-the-highly-pathogenic-h5n1-avian-influenza-a-strain.--cocrystal-pharma2025-06-30T07:43:06+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-khindivi-hydrocortisone-oral-solution-for-adrenocortical-insufficiency-in-pediatric-patients-five-years-of-age-and-older---eton-pharmaceuticals/2025-06-30T07:43:06+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-menquadfi-meningococcal-vaccine-for-children-6-weeks-or-older---sanofi/2025-06-30T07:43:06+00:00weekly0.6https://www.medthority.com/news/2025/5/patritumab-deruxtecan-bla-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-is-voluntarily-withdrawn--daiichi-sankyo-and-merck-inc/2025-07-24T09:42:21+00:00weekly0.6https://www.medthority.com/news/2025/5/moderna-announces-update-on-investigational-pandemic-influenza-program-/2025-07-24T09:42:28+00:00weekly0.6https://www.medthority.com/news/2025/5/eisai-obtains-favorable-decision-in-patent-infringement-litigation-related-to-lenvatinib--in-the-u.s2025-07-24T09:36:22+00:00weekly0.6https://www.medthority.com/news/2025/5/chmp-adopts-positive-opinion-for-riulvy-tegomil-fumarate--neuraxpharm-pharmaceuticals/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/imfinzi-durvalumab-recommended-for-approval-in-the-eu-by-chmp-as-first-and-only-perioperative-immunotherapy-for-muscle-invasive-bladder-cancer--astrazeneca/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/-the-phase-iii-affirm-al-clinical-trial-evaluating-birtamimab-in-patients-with-al-amyloidosis-did-not-meet-its-primary-endpoint.---prothena-corporation2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/action-study-describes-inadequate-care-in-the-us-of-obesity.--the-obesity-society2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/resminostat-kinselby-received-a-negative-chmp-opinion-in-the-eu--4sc-ag/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild---liquidia/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/chmp-adopts-a-positive-opinion-for-rolcya-denosumab-biosimilar/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/chmp-positive-opinion-for-bomyntra-and--conexxence-biosimilars-for-the-treatment-of-osteoporosis-and-other-bone-related-conditions--fresenius-kabi/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/-positive-chmp-opinion-for-tevimbra-tislelizumab-as-a-first-line-treatment-for-nasopharyngeal-cancer--beigene-ltd/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-grants-approval-for-jivi--in-pediatric-patients-7-to-under-12-years-of-age-with-hemophilia-a-congenital-factor-viii-deficiency--bayer/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/nmpa-china--approves-minjuvi-tafasitamab---lenalidomide-followed-by-minjuvi-monotherapy-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-.-innocare2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/update-provided-on-phase-ii-clinical-trial-of-rp-a501-for-danon-disease---rocket-pharmaceuticals/2025-06-30T07:43:08+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-accepts-bla-for-sibeprenlimab-to-treat-patients-with-immunoglobulin-a-nephropathy-igan.--visterraotsuka2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/beone-medicines-ltd.formerly-known-as-beigene-ltd.--announced-its-new-name-and-redomiciliation-to-switzerland2025-08-20T12:15:37+00:00weekly0.6https://www.medthority.com/news/2025/5/novartis-announces-commencement-of-tender-offer-to-acquire-regulus-therapeutics/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/moderna-files-fda-application-for-the-lp.8.1-targeting-covid-19-vaccine2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee--gsk-and-spero-therapeutics/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/european-commission-approves-the-subcutaneous-formulation-of-opdivo-nivolumab-across-multiple-solid-tumor-indications---bms/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/pimicotinib-demonstrates-best-in-class-potential-with-significant-efficacy-and-clinically-meaningful-improvements-in-patients-with-tenosynovial-giant-cell-tumor--merck-kgaa/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/pfizer-and-biontech-submit-ema-application-for-covid-19-vaccine-targeting-lp.8.1-for-2025-2026-season-2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/new-clinical-data-for-the-monarch-platform-for-robotically-assisted-bronchoscopy---johnson--johnson-medtech/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-grants-approval-for-tendyne-first-of-its-kind-device-to-replace-the-mitral-valve-without-open-heart-surgery.--abbott2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/sanofi-completes-acquisition-of-dr-0201/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/eli-lilly-will-acquire-siteone-and-with-it-stc-004-a-pain-therapy-candidate/2025-06-30T07:43:07+00:00weekly0.6https://www.medthority.com/news/2025/5/people-with-cidp-reveal-treatment-priorities/2025-07-24T09:23:30+00:00weekly0.6https://www.medthority.com/news/2025/5/xbcm-test-halves-cystoscopy-use-in-bladder-cancer/2025-07-24T11:01:52+00:00weekly0.6https://www.medthority.com/news/2025/5/prompt-intervention-for-severe-aortic-stenosis-patients-demonstrates-lower-healthcare-costs-improved-clinical-outcomes--edwards-lifesciences/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/new-aurora-1-analysis-lupkynis-based-triple-immunosuppressive-therapy-yields-deep-proteinuria-reduction-in-lupus-nephritis--aurinia-pharma/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/eylea-aflibercept-8-mg-approved-in-china-for-wet-age-related-macular-degeneration---bayer/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-oncologic-drugs-advisory-committee-votes-in-favour-of-the-benefit-risk-profile-of-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma---johnson--johnson/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/shockwave-medical-study-confirms-benefit-of-ivl-first-strategy-in-real-world-female-patients-with-complex-calcified-lesions---johnson--johnson/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-susvimo-ranibizumab--injection-for-diabetic-retinopathy--roche/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/interim-clinical-data-from-the-ongoing-phase-ii-trial-of-petosemtamab-in-combination-with-pembrolizumab-/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/sanofi-to-acquire-vigil-neuroscience-inc.-adding-a-new-investigational-medicine-to-treat-alzheimers-disease-to-the-neurology-pipeline2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/ascent-03-trodelvy-demonstrates-highly-significant--clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-first-line-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-checkpoint-inhibitors--gilead-sciences/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/springworks-therapeutics-receives-positive-chmp-opinion-for-mirdametinib-ezmekly-for-the-treatment-of-adult-and-pediatric-patients-with-nf1-pn/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsedrefractory-multiple-myeloma--gsk/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/chmp-issues-positive-opinion-for-maple-syrup-urine-disease-drug---recordati/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/eylea-aflibercept-8-mg-with-extended-6-month-treatment-interval-recommended-for-approval-in-eu--bayer/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/-xtandi-enzalutamide-shows-long-term-overall-survival-in-metastatic-hormone-sensitive-prostate-cancer---astellas-and-pfizer/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/new-two-year-follow-up-of-columvi-glofitamab-extends-overall-survival-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-patients---roche/2025-06-30T07:43:10+00:00weekly0.6https://www.medthority.com/news/2025/5/nucala-mepolizumab-approved-by-us-fda-for-use-in-adults-with-chronic-obstructive-pulmonary-disease-copd--gsk/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/lautolus-therapeutics-announces-positive-chmp-opinion-for-obecabtagene-autoleucel-aucatzyl-for-adult-patients-age-26-and-older-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-rr-b-all/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/chmp-recommends-eu-approval-of-itovebi-for-pik3ca-mutated-er-positive-her2-negative-advanced-breast-cancer--roche/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/servier-to-acquire-a-potential-best-in-class-precision-therapy-for-acute-leukemias-from-bionova-pharmaceuticals/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-the-supplemental-nda--for-zoryve-roflumilasttopical-foam-0.3-for-the-treatment-of-plaque-psoriasis-of-the-scalp-and-body-in-adult-and-pediatric-patients.--arcutis-biotherapeutics2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/mhrauk-approves-akantior-polihexanide-to-treat-acanthamoeba-keratitis.-avanzanite-bioscience2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/servier-to-acquire-from-bionova--bn-104-a-potential-best-in-class-menin-inhibitor-currently-in-phase-iii-development-for-the-treatment-of-acute-leukemias.-2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/presentation-of-long-term-follow-up-data-from-the-phase-ii-tellomak-clinical-trial-evaluating-lacutamab-for-sezary-syndrome-ss-and-mycosis-fungoides-mf.--innate-pharma2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/--an-abstract-highlighting-the-full-data-analyses-from-the-komet-001-registration-directed-trial-of-ziftomenib-has-been-accepted-for-oral-presentation-at-the-upcoming-2025--asco-meeting.-kura-oncology2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/crescita-therapeutics-inc.--terminates-its-licence-to-croma-pharma-gmbh-to-to-market-pliaglis2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/regeneron-acquires-the-assets-of-23andme-holding-co/2025-06-30T07:43:09+00:00weekly0.6https://www.medthority.com/news/2025/5/once-weekly-sogroya-somapacitan-is-an-efficacious-and-well-tolerated-long-acting-growth-hormone-in-children-with-growth-disorders-results-from-real8-phase-iii-basket-study-presented-at-the-joint-congress-of-espe-and-ese---novo-nordisk/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/valneva-provides-update-on-recommended-use-of-ixchiq-by-elderly-individuals-in-the-united-states/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/biomarin-presents-new-data-for--voxzogo-vosoritide-in-children-with-achondroplasia-and-other-skeletal-conditions-at-two-international-endocrinology-meetings/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/blenrep-belantamab-mafodotin-combinations-approved-in-japan-for-treatment-of-relapsedrefractory-multiple-myeloma--gsk/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/amvuttra-vutrisiran-significantly-reduces-mortality-and-a-range-of-important-cardiovascular-events-in-patients-with-attr-amyloidosis-with-cardiomyopathy-additional-data-from-helios-b--alnylam-pharma/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-postpones-pdufa-date-to-q4-2025-for--troriluzole-nda--for-the-treatment-of-spinocerebellar-ataxia.--biohaven2025-08-20T13:34:01+00:00weekly0.6https://www.medthority.com/news/2025/5/-ideate-esophageal-01-phase-iii-trial-of-ifinatamab-deruxtecan-initiated-in-certain-patients-with-pretreated-advanced-or-metastatic-esophageal-squamous-cell-carcinoma--daiichi-sankyo-/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/u.s.-fda-approves-bla-for-novavaxs-covid-19-vaccine2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-bla-for-nuvaxoid-to-prevent-coronavirus-disease-2019-covid-19-caused-by-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2---novavax/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/global-phase-iii-trials-demonstrate-that-nerandomilast-slowed-lung-function-decline-in-ipf-and-ppf-with-similar-discontinuation-rates-to-placebo---boehringer-ingelheim/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/batura-phase-iii-trial-results-provide-new-evidence-for-airsupra-as-standard-of-care-for-as-needed-rescue-treatment-in-asthma---astrazeneca/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/early-and-sustained-increase-in-serum-ttr-levels-by-acoramidis-independently-predicted-improved-survival-in-the-attribute-cm-study---bridgebio/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/nice-uk-terminated-appraisal-for-skyclarys-omaveloxolone-for-treating-friedreichs-ataxia-in-people-16-years-and-over---biogen/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/nice-uk-recommends-adcetris-brentuximab-vedotin-in-combination-for-untreated-stage-3-or-4-cd30-positive-hodgkin-lymphoma---takeda/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/niceuk-recommends-tagrisso-osimertinib-with-pemetrexed-and-platinum-based-chemotherapy-for-untreated-egfr-mutation-positive-advanced-non-small-cell-lung-cancer---astrazeneca/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/niceuk-recommends-balversa-erdafitinib-for-treating-unresectable-or-metastatic-urothelial-cancer-with-fgfr3-alterations-after-a-pd-1-or-pd-l1-inhibitor---johnson--johnson/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/niceuk-recommends-ontozry-cenobamate-for-treating-focal-onset-seizures-in-epilepsy---arvelle-therapeutics/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/acoramidis-reduced-incidence-of-atrial-fibrillation-events-in-patients-with-attr-cm---bridgebio-pharma/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/pfizer-enters-into-exclusive-licensing-agreement-with-3sbio-/2025-08-20T12:13:48+00:00weekly0.6https://www.medthority.com/news/2025/5/connect-biopharma-presents-data-supporting-development-of-rademikibart-at-the-american-thoracic-society-ats-2025-international-conference/2025-06-30T07:43:12+00:00weekly0.6https://www.medthority.com/news/2025/5/early-and-sustained-increase-in-serum-ttr-levels-by-acoramidis-independently-predicted-improved-survival-in-the-attribute-cm-study---bridgebio-pharma/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/astrazenecas-acquisition-of-esobiotec-completes/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/roche-provides-update-on-fda-advisory-committee-meeting-on-columvi-combination-for-people-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/phase-ii-positive-data--from-willow-study-of-enpatoran-in-patients-with-cle-and-sle-lupus-rash.--merck-kgaa2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/oncologic-drugs-advisory-committee-voted-4-to-5-that-the-benefitrisk-of-ugn-102-mitomycin-for-intravesical-solution-was-favorable-for-the-treatment-of-recurrent-lg-ir-nmibc.--urogen-pharma2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/niceuk-recommends-truqap-capivasertib-with-fulvestrant-for-treating-hormone-receptor-positive-her2-negative-advanced-breast-cancer-after-endocrine-treatment---astrazeneca/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/soundstar-crystal-ultrasound-catheter-launched-in-the-us-redefining-image-clarity-in-2d-intracardiac-imaging---johnson--johnson-medtech/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/moderna-provides-update-on-bla-submission-for-combination-vaccine-against-influenza-and-covid-19/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-topline-results-announced-from-essence-study-of-olezarsen-tryngolza-in-people-with-moderately-elevated-triglycerides--ionis-pharmaceuticals-/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/sandoz-launches-pyzchiva-autoinjector-first-commercially-available-in-europe-for-ustekinumab-biosimilars/2025-06-30T07:43:11+00:00weekly0.6https://www.medthority.com/news/2025/5/zuma-12-axi-cel-shows-durable-response-in-lbcl/2025-07-24T11:00:46+00:00weekly0.6https://www.medthority.com/news/2025/5/new-data-from-studies-of--voxzogo--vosoritide-demonstrating-meaningful-impact-on-tibial-bowing-in-children-with-achondroplasia-and-investigational-early-efficacy-results-in-other-skeletal-conditions.--biomarin2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential---astrazeneca/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy-semaglutide-in-complete-surmount-5-results-published-in-the-new-england-journal-of-medicine---eli-lilly/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/ten-year-aphinity-data-show-perjeta-based-regimen-reduced-the-risk-of-death-by-17-in-people-with-her2-positive-early-stage-breast-cancer--roche/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/first-participant-dosed-with-acoramidis-in-act-early-the-first-ever-attr-primary-prevention-study---bridgebio-pharma/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/european-commission-approves-tremfya-guselkumab-the-first-dual-acting-il-23-inhibitor-offering-both-subcutaneous-and-intravenous-induction-options-for-adult-patients-with-moderately-to-severely-active-crohns-disease---johnson--johnson/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-topline-results-from-maple-hcm-in-a-phase-iii-clinical-trial-comparing-aficamten-as-monotherapy-to-metoprolol-as-monotherapy-in-patients-with-hcm---cytokinetics-incorporated/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/first-asymptomatic-participant-with-a-known-pathogenic-transthyretin-ttr-variant-has-been-dosed-in-act-early-with-acoramidis.-bridge-bio2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/iteos-and-gsk-have-made-the-decision-to-terminate-the-belrestotug-development-program-and-end-the-collaboration/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-acceptance-and-priority-review-of-the-bla-for-rgx-121-clemidsogene-lanparvovec-for-the-treatment-of-mucopolysaccharidosis-ii-mps-ii-also-known-as-hunter-syndrome---regenxbio-inc/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/roche-receives-fda-approval-for-the-ventana-mmet-sp44-rxdx-assay-as-the-first-companion-diagnostic-to-identify-non-squamous-non-small-cell-lung-cancer-patients-eligible-for-treatment-with-emrelis/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/alnylam-to-share-progress-across-its-transthyretin-amyloidosis-franchise-including-additional-analyses-of-the-helios-b-phase-iii-study-results-at-heart-failure-2025-congress/2025-06-30T07:43:15+00:00weekly0.6https://www.medthority.com/news/2025/5/phase-iii-keynote-b96-trial-of-keytruda--chemotherapy-meets-primary-endpoint-of-progression-free-survival-pfs-in-patients-with-platinum-resistant-recurrent-ovarian-cancer---merck-inc/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/reflect-studies-show-the-use-of-freestyle-libre-continuous-glucose-monitoring-cgm-technology-is-associated-with-reduced-hospitalization-for-heart-complications-in-people-with-diabetes---abbott/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-welireg-belzutifan-for-the-treatment-of-adults-and-pediatric-patients-with-locally-advanced-unresectable-or-metastatic-pheochromocytoma-or-paraganglioma-ppgl---merck-inc/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-emrelis-telisotuzumab-vedotin-tllv-for-adults-with-previously-treated-advanced-non-small-cell-lung-cancer-nsclc-with-high-c-met-protein-overexpression--abbvie-/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-grants-accelerated-approval-for-zynyz-retifanlimab-dlwr--chemotherapy-to-treat-inoperable-locally-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-anal-canal.--incyte2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/septerna-and-novo-nordisk-to-collaborate-on-oral-small-molecule-medicines-for-obesity-and-other-cardiometabolic-diseases/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/-tepezza--teprotumumab-granted-marketing-authorisation-as-the-first-targeted-treatment-specifically-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted-in-the-united-kingdom--amgen-/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/the-new-england-journal-of-medicine-publishes-data-from-phase-iib-trial-of-oral-orexin-receptor-2-agonist-oveporexton-tak-861-in-people-with-narcolepsy-type-1--takeda/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/mallinckrodt-presents-data-on-real-world-outcomes-with-acthar-gel-repository-corticotropin-injection-at-the-international-congress-on-systemic-lupus-erythematosus-lupus-2025/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/european-commission-approves-perioperative-regimen-of-neoadjuvant-opdivo-nivolumab-and-chemotherapy-followed-by-adjuvant-opdivo-for-resectable-high-risk-non-small-cell-lung-cancer-with-pd-l1-expression-1---bms/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/new-data-on-ingrezza-valbenazine-adds-to-the-growing-body-of-evidence-demonstrating-functional-and-quality-of-life-improvements-in-patients-with-tardive-dyskinesia---neurocrine-biosciences/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/data-shows-improvements-in-physiologic-glucocorticoid-dosing-and-select-reproductive-hormones-in-patients-with-classic-congenital-adrenal-hyperplasia-taking-crenessity-crinecerfont---neurocrine-biosciences/2025-06-30T07:43:14+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approval-for--lumipulse-g-ptau-217-amyloid-1-42-plasma-ratio-in-vitrodiagnostic-ivd-test-for-the-assessment-of-amyloid-pathology-in--alzheimers-disease.--fujirebio-diagnostics2025-08-20T13:59:41+00:00weekly0.6https://www.medthority.com/news/2025/5/jury-verdict-in-the-u.s.-district-court-for-the-district-of-delaware-finds-in-favour-of-regeneron-and-that-amgen-violated-anti-trust-and-tort-laws-in-promoting-repatha-evolocumab2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/biomarin-to-acquire-inozyme-pharma-and-with-it-inz-701-a-proposed-treatment-for-enpp1-deficiency/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-novavaxs-covid-19-vaccine-but-with-unusual-restrictions/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-results-from--phase-iii-trial-of-iontak-e7777-to-treat--cutaneous-t-cell-lymphoma--citiuspharma/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approval-for-brekiya-dihydroergotamine-mesylate-injection-for-the-acute-treatment-of-migraine-and-cluster-headaches-in-adults---amneal-pharmaceuticals/2025-06-30T07:43:13+00:00weekly0.6https://www.medthority.com/news/2025/4/enhertu-trastuzumab-deruxtecan--plus-perjeta-pertuzumab-demonstrated-highly-clinically-meaningful-improvement-in-progression-free-survival-versus-thp-as-first-line-therapy-for-her2-positive-metastatic-breast-cancer---daiichi-sankyo--astrazeneca-/2025-04-23T11:55:44+00:00weekly0.6https://www.medthority.com/news/2025/4/trodelvy-sacituzumab-govitecan-plus-keytruda-pembrolizumab-demonstrates-a-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-triple-negative-breast-cancer--gilead-sciences-/2025-04-23T11:28:04+00:00weekly0.6https://www.medthority.com/news/2025/4/update-on-eylea-hd-aflibercept-injection-8-mg-supplemental-biologics-license-application---regeneron--bayer/2025-04-23T11:23:45+00:00weekly0.6https://www.medthority.com/news/2025/4/diabetes-care-publishes-results-from-prevalence-phase-of-corcepts-catalyst-trial-in-people-with-difficult-to-control-type-2--diabetes--corcept--therapeutics/2025-04-23T11:20:54+00:00weekly0.6https://www.medthority.com/news/2025/4/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma---gsk-plc2/2025-04-28T06:56:38+00:00weekly0.6https://www.medthority.com/news/2025/4/results-announced-of-phase-iiib-trial-adstiladrin-nadofaragene-firadenovec--in-bcg-unresponsive-cis--high-grade-tat1-patients-n20-in-japan.--ferring2025-04-28T06:59:18+00:00weekly0.6https://www.medthority.com/news/2025/4/topline-results-announced-from-phase-iii-arise-trial-evaluating-cobenfy-xanomeline-and-trospium-chloride-as-an-adjunctive-treatment-to-atypical-antipsychotics-in-adults-with-schizophrenia---bms/2025-04-28T07:13:02+00:00weekly0.6https://www.medthority.com/news/2025/4/pharming-receives-positive-recommendation-from-nice-for-joenja-leniolisib-as-a-treatment-for-apds/2025-04-28T07:16:32+00:00weekly0.6https://www.medthority.com/news/2025/4/update-on-bla-seeking-fda-approval-for-covid-19-vaccine--novavax/2025-04-28T07:20:04+00:00weekly0.6https://www.medthority.com/news/2025/4/fda-510k-clearance-of-and-the-commercial-launch-of-phasix-st-umbilical-hernia-patch.-becton-dickinson-and-company2025-04-28T07:20:56+00:00weekly0.6https://www.medthority.com/news/2025/4/ivonescimab--chemotherapy--demonstrated-strongly-positive-results-in-the-phase-iii-clinical-trial-ak112-306harmoni-6-for-first-line-treatment-of-advanced-squamous-nsclc--akeso/2025-04-28T07:21:38+00:00weekly0.6https://www.medthority.com/news/2025/4/mhra-uk-approves-hympavzi-marstacimab-to-treat-haemophilia-a-or-b-in-adult-and-paediatric-patients.--pfizer2025-04-28T07:22:00+00:00weekly0.6https://www.medthority.com/news/2025/4/highlights--presented--at-aua-meeting--from-the-phase-iib-cohort-2-sunrise-1-study-evaluating-tar--200for-bacillus-calmette-guerin-bcgunresponsive-high-risk-non-muscle-invasive-bladder-cancer--jj2/2025-05-05T10:10:21+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp--adopts-a-positive-opinion--for-change-to-the-marketing-authorisation-for-zoonotic-influenza-vaccine-seqirus-aflunov--csl/2025-05-05T10:14:41+00:00weekly0.6https://www.medthority.com/news/2025/4/roche-granted-fda-breakthrough-device-designation-for-first-ai-driven-companion-diagnostic-for-non-small-cell-lung-cancer/2025-05-05T10:21:27+00:00weekly0.6https://www.medthority.com/news/2025/4/sasanlimab-combination-significantly-improves-event-free-survival-in-bcg-naive-high-risk-non-muscle-invasive-bladder-cancer--pfizer/2025-05-05T10:26:40+00:00weekly0.6https://www.medthority.com/news/2025/4/abbott-integrates-libres-data-with-epics-electronic-health-record-system-providing-healthcare-professionals-seamless-glucose-monitoring-information/2025-05-05T10:28:43+00:00weekly0.6https://www.medthority.com/news/2025/4/lynozyfic-linvoseltamab-approved-in-the-european-union-for-the-treatment-of-relapsedrefractory-multiple-myeloma---regeneron/2025-05-05T10:30:18+00:00weekly0.6https://www.medthority.com/news/2025/4/-chmp-positive-recommendation-for-xofluza-baloxavir-marboxil--for-infant-patients-in-the-eu-for-the-treatment-of-uncomplicated-influenza--roche/2025-05-05T10:33:21+00:00weekly0.6https://www.medthority.com/news/2025/4/chmp-positive-for-phesgo-a-subcutaneous--fixed-dose-combination-of-perjeta-pertuzumab-and-herceptin-trastuzumab-for--her2--positive-breast-cancer.-.-roche2025-05-05T10:34:20+00:00weekly0.6https://www.medthority.com/news/2025/4/-pcrx-201-enekinragene-inzadenovecshowed-sustained-improvements-in-knee-pain-stiffness-and-function-following-a-single-local-administration-for-mildmoderate-and-severe-osteoarthritis-of-the-knee-pacira-biosciences/2025-05-05T10:37:35+00:00weekly0.6https://www.medthority.com/news/2025/4/update-on-capitello-280-phase-iii-trial-of-truqapcapivasertib--in-metastatic-castration-resistant-prostate-cancer---astrazeneca/2025-05-27T12:53:33+00:00weekly0.6https://www.medthority.com/news/2025/4/eton-pharmaceuticals-announces-submission-of-nda-for-et-600-desmopressin-oral-solution/2025-05-05T10:45:14+00:00weekly0.6https://www.medthority.com/news/2025/4/european-approval-for-itulazax-tree-pollen-sublingual-allergy-immunotherapy-tablet-for-treatment-of-young-children-and-adolescents--.-alk2025-05-05T10:54:46+00:00weekly0.6https://www.medthority.com/news/2025/4/ngenla-somatrogon--withdrawal-of-application-for-variation-to-marketing-authorisation-for-growth-hormone-deficiency.---pfizer2025-05-05T10:56:27+00:00weekly0.6https://www.medthority.com/news/2025/5/-rinvoq-upadacitinib-receives-u.s.-fda-approval-for-giant-cell-arteritis-gca--abbvie2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/sandoz-enters-global-collaboration-license-agreement-with-henlius-to-commercialize-leading-oncology-therapy-ipilimumab-in-multiple-indications/2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/new-survey---provides-insights-into-diagnosis-and-treatment-journey-for-people-living-with-alcohol-use-disorder---alkermes/2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approval-for-zevaskyn--prademagene-zamikeracel-for-the-treatment-of-wounds-in-adult-and-pediatric-patients-with-recessive-dystrophic-epidermolysis-bullosa.--abeona-therapeutics2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approval-for-imaavy-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg---johnson--johnson/2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/initiation-of-phase-iii-registrational-program-for-nbi-1117568-as-potential-treatment-for-adults-with-schizophrenia---neurocrine-biosciences-/2025-06-30T07:43:21+00:00weekly0.6https://www.medthority.com/news/2025/5/fda--approval-for-atzumi--dihydroergotamine-dhe-nasal-powderfor-the-acute-treatment-of-migraine.--satsuma-pharma2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/updated-results-from-orca-3-phase-iii-trial-evaluating-cytisinicline-for-smoking-cessation.--achieve-life-sciences-inc2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/novartis-to-acquire-regulus-therapeutics-and-with-it-farabursen/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/nucala-mepolizumab-delivers-clinically-meaningful-and-statistically-significant-reduction-in-copd-exacerbations-with-positive-matinee-trial-results-published-in-new-england-journal-of-medicine--gsk/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/abivax-announces-completion-of-enrollment-for-the-phase-iii-abtect-trials-in-patients-with-moderately-to-severely-active-ulcerative-colitis/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/uk-mhra-grants-marketing-authorization-in-the-uk-for-vimkunya-vaccine-for-the-prevention-of-disease-caused-by-chikungunya-virus-in-individuals-12-years-and-older---bavarian-nordic/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy---cytokinetics/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/breztri--budesonideglycopyrroniumformoterol-fumarate--met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma---astrazeneca/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/nice-uk-update-for-paxlovid-nirmatrelvir-plus-ritonavir-sotrovimab-and-tocilizumab-for-treating-covid-19---pfizer/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/briacell-reports-late-breaker-phase-iii-data-at-aacr-2025-positive-tolerability-profile-and-potential-response-biomarkers-identified/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-data-from-phase-ii-calliper--trial-of--vidofludimus-calcium-imu-838-in-patients-with-progressive-multiple-sclerosis-pms.--immunic-inc2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approval-for-the-transcatheter-aortic-valve-replacement-therapy-the-sapien-3-platform-for-severe-aortic-stenosis-as-patients-without-symptoms.--edwards-life-sciences2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-grants-approval--for-100-mg10ml-multi-dose-vial-of-tepylute-a-ready-to-dilute-formulation-of-thiotepa-to-treat-breast-and-ovarian-cancer--shorla-oncology/2025-06-30T07:43:20+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-issues-complete-response-letter-for-tlx101-cdx-18f-floretyrosine-18f-fet-pixclara-for-use-in-the-imaging-of-glioma.-telix-pharma2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/tremfya-guselkumab-delivers-sustained-clinical-and-endoscopic-remission-in-ulcerative-colitis-through-two-years---johnson--johnson/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/tremfya-guselkumab-positioned-to-become-the-first-and-only-il-23-inhibitor-to-offer-subcutaneous-induction-in-ulcerative-colitis-as-demonstrated-in-new-data-through-24-weeks---johnson--johnson/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-lifts-clinical-hold-on-ind-applications-for--the-ebvallo-tabelecleucel-program--atara-biotherapeutics-pierre-fabre/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/ongoing-phase-ii-data-announced-of-barzolvolimab-in-eosinophilic-esophagitis-eoe..--celldex2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-selardsi-ustekinumab-aekn-injection-as-interchangeable-with-the-reference-biologic-stelara-ustekinumab.-teva-pharma--alvotech2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/updated-results-from-phase-1b11-epcore-nhl-2-trial-of-epcoritamab--lenalidomide--rituximab--for-rr-follicular-lymphoma.-abbvie2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/new-survey-reveals-need-for-routine-screening-and-earlier-diagnosis-for-people-living-with-tardive-dyskinesia---neurocrine-biosciences/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-proof-of-concept-for-tpm-502-nanoparticles-coupled-with-ced-disease-relevant-antigens-in-celiac-disease---topas-therapeutics/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/ptc-518--votoplam-pivot-hd-study-achieves-primary-endpoint--in-stage-2-and--stage-3-huntingtons-disease.---ptc-therapeutics2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/primary-endpoint-achieved-in-phase-iii-dry-eye-disease-chamber-trial-of-reproxalap-nda-resubmission-planned---aldeyra/2025-06-30T07:43:19+00:00weekly0.6https://www.medthority.com/news/2025/5/roche-introduces-innovative-elecsys-pro-c3-test-to-improve-precision-in-evaluating-liver-fibrosis-severity/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/calquence-plus-chemoimmunotherapy-approved-in-the-eu-as-first-and-only-btk-inhibitor-for-1st-line-mantle-cell-lymphoma---astrazeneca/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/italfarmaco-announces-u.s.-fda-grants-fast-track-designation-to-givinostat-duvyzat-in-treatment-of-polycythemia-vera-2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/sangamo-therapeutics-inc.-announced-important-derisking-events-in-the-pathway-to-a-planned-bla-submission-for-isaralgagene-civaparvovec--st-920-for-the-treatment-of-fabry-disease2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/genmab-to-submit-supplemental-biologics-license-application-to--fda--for-epcoritamab-plus-rituximab-and-lenalidomide-r2-in-patients-with-relapsedrefractory-follicular-lymphoma-fl-.----------------------2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-has-accepted-for-review-the-resubmission-of-the-bla-for-narsoplimab-for-the-treatment-of-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-ta-tma-pdufa-date-end-september-2025---omeros-corporation/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/presentation-at-easl-meeting--of--long-term-efficacy-and-safety-of--alxn-1840-tiomolybdate-choline--for-wilson-disease.--monopar-therapeutics2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/enhertu-trastuzumab-deruxtecan-followed-by-thp-before-surgery-showed-statistically-clinically-meaningful-improvement-in-response-in-patients-with-high-risk-her2-positive-early-stage-breast-cancer-in-destiny-breast11-trial--daiichi-sankyo--astrazeneca-/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/livdelzi-seladelpar-demonstrated-consistent-efficacy-and-safety-regardless-of-prior-treatment-history-in-new-data-for--primary-biliary-cholangitis-presented-at-easl---gilead-sciences/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/final-data-from-the-phase-iii-myr301-studyshowed--longer-treatment-with--hepcludex--bulevirtide-for-chronic-hepatitis-delta-virus--was-associated-with-sustaining-undetectability--gilead-sciences-/2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/phase-ii-results-announced-for-bemnifosbuvir--an-oral-nucleotide-ns5b-polymerase-inhibitor-and-ruzasvir--an-oral-ns5a-inhibitor-for-the-treatment-of-hepatitis-c-virus-hcv.---atea-pharma2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/top-line-data-announced-from-osprey-trial-of-aura-6000-system-for-the-treatment-of-moderate-to-severe-obstructive-sleep-apnea-.--livanova2025-06-30T07:43:18+00:00weekly0.6https://www.medthority.com/news/2025/5/api-cat-supports-extended-reduced-dose-apixaban/2025-07-24T10:59:48+00:00weekly0.6https://www.medthority.com/news/2025/5/real-world-data-clarify-ivig-safety-in-cidp/2025-07-24T10:48:25+00:00weekly0.6https://www.medthority.com/news/2025/5/tolebrutinib-potential-in-ms-phase-3-trials/2025-07-24T10:26:49+00:00weekly0.6https://www.medthority.com/news/2025/5/early-severity-of-hives-may-signal-chronicity/2025-07-24T10:47:33+00:00weekly0.6https://www.medthority.com/news/2025/5/mint-positive-outcomes-for-inebilizumab-in-gmg/2025-07-24T10:59:27+00:00weekly0.6https://www.medthority.com/news/2025/5/aquila-daratumumab-shows-promise-in-smm2/2025-07-24T11:02:41+00:00weekly0.6https://www.medthority.com/news/2025/5/late-breaking-exploratory-data-highlights-the-impact-of-iqirvo--elafibranor-on-fatigue-and-provides-mechanistic-insights-into-anti-inflammatory-and-symptom-related-effects-in-patients-with-primary-biliary-cholangitis--ipsen/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/positive-data-from-phase-iia-trial-of-mar-001-presented-at-eas-congress-for-treating-residual-cardiovascular-risk.--marea-therapeutics2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/valneva-provides-update-following-ema-announcement-on-use-of--ixchiq-for-in-elderly-people-for-chikungunya-fever/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/-subgroup-analyses-of-the-phase-iii-cahtalyst-pediatric-study-show-crenessity-crinecerfont-reduces-glucocorticoid-dosing-and-maintains-androstenedione-levels-in-congenital-adrenal-hyperplasia---neurocrine-biosciences/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/shionogi-to-acquire-japan-tobaccos-pharmaceutical-operations-including-listed-subsidiary-torii-pharmaceutical/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus-relentless-itch-in-primary-biliary-cholangitis-pbc---gsk/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/rystiggo-rozanolixizumab-receives-approval-in-japan-for-two-new-administration-methods-for-people-living-with-generalized-myasthenia-gravis-gmg---ucb/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/merit-medical-releases-12-month--efficacy-results-for-the-single-arm-arteriovenous-graft-avg-cohort-of-the-wrapsody--arteriovenous-efficacy-wave-trial/2025-06-30T07:43:17+00:00weekly0.6https://www.medthority.com/news/2025/5/aflibercept-8-mg-to-treat-macular-edema-following-retinal-vein-occlusion-submitted-for-approval-in-japan--bayer/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/fda-approves-avmapki-fakzynja-co-pack-avutometinib-capsules-defactinib-tablets--for-kras-mutated-recurrent-low-grade-serous-ovarian-cancer-lgsoc---verastem-oncology/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/imfinzi-regimen-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-disease-free-survival-for-high-risk-non-muscle-invasive-bladder-cancer-in-potomac-phase-iii-trial---astrazeneca/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/5/icotrokinra-results-show-significant-skin-clearance-in-patients-with-difficult-to-treat-scalp-and-genital-psoriasis---johnson--johnson/2025-06-30T07:43:16+00:00weekly0.6https://www.medthority.com/news/2025/7/severe-itch-linked-to-higher-burden-in-csu/2025-09-04T11:12:38+00:00weekly0.6https://www.medthority.com/news/2025/8/raainbow-supports-cinainu-for-pediatric-aa/2025-09-04T11:12:21+00:00weekly0.6https://www.medthority.com/news/2025/8/raise-data-support-early-zilucoplan-use-in-gmg/2025-09-04T11:11:12+00:00weekly0.6https://www.medthority.com/news/2025/5/high-persistent-psa-linked-to-worse-prognosis/2025-07-24T09:28:32+00:00weekly0.6https://www.medthority.com/news/2025/7/imaging-offers-clarity-in-people-with-cidp/2025-09-04T11:12:53+00:00weekly0.6https://www.medthority.com/news/2025/5/tacrolimus-shows-clinical-benefit-in-jmg/2025-07-24T09:35:42+00:00weekly0.6https://www.medthority.com/news/2025/8/ctdna-predicts-colorectal-cancer-survival/2025-09-04T11:10:44+00:00weekly0.6https://www.medthority.com/news/2025/8/black-men-face-gaps-in-prostate-cancer-care/2025-09-04T11:10:11+00:00weekly0.6https://www.medthority.com/news/2025/9/early-cystoscopy-improves-nmibc-survival/2025-10-17T07:21:44+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-inflammation-may-lead-to-serious-heart-issues-for-women-without-other-risk-factors/2026-01-05T11:07:09+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-a-mothers-breastmilk-supply-may-partly-depend-on-genetics/2026-01-05T11:09:42+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-nasal-spray-for-allergies-may-help-prevent-covid-common-cold-infections/2026-01-05T11:08:20+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-flu-drug-with-compound-found-in-chocolate-tops-tamiflu-in-early-study/2026-01-05T10:35:25+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-changes-in-dna-can-help-determine-heart-risks-of-type-2-diabetes-patients2/2026-01-05T10:36:35+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-weight-loss-before-ivf-may-improve-odds-of-pregnancy/2026-01-05T10:37:12+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-blood-test-finds-early-ovarian-cancer/2026-01-05T10:37:52+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-human-fetal-kidney-development-mimicked-in-test-tubes/2026-01-05T10:39:08+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-glp-1-drugs-linked-to-lower-cancer-risks/2026-01-05T10:39:56+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-experimental-jasper-drug-helps-stem-cell-transplant-patients-avoid-toxic-chemotherapy-in-tiny-trial/2026-01-05T10:51:53+00:00weekly0.6https://www.medthority.com/news/2025/8/health-rounds-shingles-vaccine-may-lower-the-risk-of-heart-attack-and-stroke/2026-01-05T10:53:58+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-clopidogrel-better-than-aspirin-for-preventing-heart-attacks-and-strokes/2026-01-05T11:06:23+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-ai-uses-sleep-study-data-to-accurately-predict-dozens-of-health-issues/2026-01-19T13:40:51+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-mrna-covid-vaccines-appear-to-make-immunotherapy-cancer-drugs-work-better/2026-01-05T11:24:08+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-combo-drugs-improve-on-chemo-alone-for-certain-breast-cancer-patients/2026-01-05T11:23:26+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-scientists-find-way-to-make-breast-cancer-drug-work-better-for-younger-women/2026-01-05T11:29:04+00:00weekly0.6https://www.medthority.com/news/2025/10/egfr-mutated-nsclc-osimertinib-data-updates/2025-10-20T10:26:24+00:00weekly0.6https://www.medthority.com/news/2025/10/alex-hits-os-milestone-in-alk-nsclc/2025-10-20T10:46:52+00:00weekly0.6https://www.medthority.com/news/2025/10/gdf-15-blocker-boosts-nivolumab-effect-in-mibc/2025-10-21T09:52:10+00:00weekly0.6https://www.medthority.com/news/2025/10/final-bladderpath-data-back-mri-mibc-staging/2025-10-21T09:44:40+00:00weekly0.6https://www.medthority.com/news/2025/10/harmoni-6-advances-squamous-nsclc-care/2025-10-21T09:47:50+00:00weekly0.6https://www.medthority.com/news/2025/10/early-cidp-misdiagnosis-remains-common/2025-11-04T11:01:13+00:00weekly0.6https://www.medthority.com/news/2025/10/dv-plus-toripalimab-scores-in-her2-uc/2025-10-21T11:08:52+00:00weekly0.6https://www.medthority.com/news/2025/10/optitrop-lung04-improves-egfrm-nsclc-outcomes/2025-10-20T17:31:26+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-scientists-change-kidney-blood-type-a-potential-advance-for-transplant-recipients/2026-01-05T11:28:33+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-genetics-play-a-role-in-higher-depression-risk-for-women/2026-01-05T11:27:07+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-increasing-sperm-mutations-in-older-fathers-may-affect-offspring/2026-01-05T11:27:48+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-cannabis-drug-superior-to-opioids-for-lower-back-pain/2026-01-05T11:25:54+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-low-dose-radiation-safely-eases-arthritis-pain/2026-01-05T11:25:13+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-raw-cat-food-poses-risks-for-pets-and-their-people/2026-01-05T10:56:07+00:00weekly0.6https://www.medthority.com/news/2025/9/transform-liso-cel-effective-in-2l-lbcl/2025-09-17T08:15:29+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-laser-surgery-safe-for-nearsighted-teens-study-shows/2026-01-05T11:05:39+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-new-menopause-pill-eases-hot-flashes-night-sweats/2026-01-05T11:00:32+00:00weekly0.6https://www.medthority.com/news/2025/9/health-rounds-researchers-find-key-to-preventing-common-liver-transplant-complication/2026-01-05T10:59:04+00:00weekly0.6https://www.medthority.com/news/2025/12/health-rounds-pfizer-drug-delays-progression-of-advanced-breast-cancer-in-trial/2026-01-05T10:22:33+00:00weekly0.6https://www.medthority.com/news/2025/12/health-rounds-carrying-babies-in-cloth-treated-with-insecticide-reduces-malaria-cases/2026-01-05T10:17:33+00:00weekly0.6https://www.medthority.com/news/2025/12/language-in-health-research-grants-is-changing-under-political-pressure/2026-01-05T10:14:03+00:00weekly0.6https://www.medthority.com/news/2026/1/mgspecific-biomarkers-validated-in-study/2026-03-06T12:09:40+00:00weekly0.6https://www.medthority.com/news/2025/12/ambramycin/2025-12-11T16:55:16+00:00weekly0.6https://www.medthority.com/news/2025/12/gabbroral/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/migristene/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/forapin-e/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/centramina/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/nebacetin/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/wisamt-n/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/ostochont/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/spasmo-nervogastrol/2025-12-11T16:55:15+00:00weekly0.6https://www.medthority.com/news/2025/12/health-rounds-shingles-vaccine-reduces-risk-of-death-from-dementia-study-finds/2026-01-05T10:27:45+00:00weekly0.6https://www.medthority.com/news/2025/12/health-rounds-experimental-drug-shows-promise-for-stroke-patients-who-miss-the-current-medical-treatment-window/2026-01-05T10:26:17+00:00weekly0.6https://www.medthority.com/news/2025/12/health-rounds-regeneron-drug-wipes-out-residual-multiple-myeloma-cells-in-small-trial/2026-01-05T10:31:05+00:00weekly0.6https://www.medthority.com/news/2025/12/yidixie-tests-aid-bladder-cancer-diagnosis/2025-12-18T09:41:59+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-thyroid-dysfunction-continued-during-pregnancy-linked-to-autism-risk/2026-01-05T10:09:38+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-researchers-find-clue-to-potentially-reversing-als-in-lab-studies/2026-01-05T10:09:05+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-viruses-may-hold-key-to-tackling-deadly-bacterial-infection/2026-01-05T11:10:30+00:00weekly0.6https://www.medthority.com/news/2025/11/platelet-activation-linked-to-inflammation-in-mg/2025-11-12T10:18:24+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-sound-waves-promote-healing-of-diabetic-foot-ulcers/2026-01-05T10:01:04+00:00weekly0.6https://www.medthority.com/news/2025/10/health-rounds-severe-colon-disorder-on-the-rise-in-younger-patients/2026-01-05T11:21:33+00:00weekly0.6https://www.medthority.com/news/2025/11/urine-test-detects-bladder-cancer-accurately/2026-02-05T12:06:58+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-mri-detects-heart-related-pain-missed-by-standard-testing/2026-01-05T10:05:54+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-lilly-blood-thinner-tops-astrazenecas-for-heart-procedure-patients-with-diabetes/2026-01-05T10:07:41+00:00weekly0.6https://www.medthority.com/news/2025/11/health-rounds-high-blood-pressure-among-children-doubles-obesity-may-be-driving-trend/2026-01-05T10:08:27+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-first-human-coronary-bypass-surgery-performed-without-chest-cracking/2026-01-19T13:40:50+00:00weekly0.6https://www.medthority.com/news/2026/1/study-confirms-ehrcat-score-for-vte-risk/2026-03-06T12:09:10+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-how-obesity-leads-to-uncontrolled-inflammation-discovered/2026-01-23T09:05:26+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-colon-cancer-becomes-leading-cause-of-us-cancer-deaths-for-those-under-50/2026-01-29T08:29:16+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-yoga-may-help-speed-recovery-from-opioid-withdrawal/2026-01-19T13:40:51+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-experimental-treatment-may-improve-odds-of-in-vitro-fertilization-success/2026-01-19T13:40:51+00:00weekly0.6https://www.medthority.com/news/2026/1/psa-suppression-predicts-prognosis-in-high-risk-mhspc/2026-01-29T11:55:01+00:00weekly0.6https://www.medthority.com/news/2026/1/mpmri-shows-higher-detection-than-psma-petct/2026-01-30T14:03:51+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-more-electric-vehicles-means-less-air-pollution-that-causes-health-risks/2026-01-30T08:35:38+00:00weekly0.6https://www.medthority.com/news/2026/1/health-rounds-apple-watches-help-patients-monitor-a-common-heart-disorder/2026-02-06T08:29:39+00:00weekly0.6https://www.medthority.com/news/2026/3/who-2025-guideline-update-hiv/2026-03-17T10:57:54+00:00weekly0.6https://www.medthority.com/news/2026/3/health-rounds-eliquis-proves-safer-than-xarelto-for-patients-with-deep-blood-clots/2026-03-17T08:13:55+00:00weekly0.6https://www.medthority.com/news/2026/3/health-rounds-blood-test-improves-detection-of-endometriosis/2026-03-19T11:00:23+00:00weekly0.6https://www.medthority.com/news/2026/3/aga-guideline-update-inpatient-ibd-management/2026-03-17T08:14:02+00:00weekly0.6https://www.medthority.com/news/2026/3/health-rounds-protein-related-to-parkinsons-linked-to-faster-alzheimers-progression-in-women/2026-03-17T08:14:02+00:00weekly0.6https://www.medthority.com/news/2026/3/health-rounds-death-from-dementia-on-the-rise-among-people-with-type-2-diabetes/2026-03-17T08:14:02+00:00weekly0.6https://www.medthority.com/news/2026/3/health-rounds-laser-treatment-before-immunotherapy-helps-brain-cancer-patients-live-longer/2026-03-17T08:14:03+00:00weekly0.6https://www.medthority.com/news/2026/3/earlier-enzyme-therapy-reshapes-pompe-outcomes/2026-03-17T08:14:03+00:00weekly0.6https://www.medthority.com/news/2026/3/worldsymposium-2026-fabry-disease-care-gaps/2026-03-17T08:14:03+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-scientists-develop-promising-antibodies-to-prevent-epstein-barr-infection/2026-03-02T11:08:35+00:00weekly0.6https://www.medthority.com/news/2026/2/no-added-benefit-from-cabazitaxel-in-vhr-pc/2026-02-27T14:41:10+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-researchers-find-cellular-clues-to-explain-faster-pain-recovery-in-men/2026-03-05T08:53:44+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-cancer-immunotherapies-may-be-more-effective-given-earlier-in-the-day/2026-02-27T14:12:02+00:00weekly0.6https://www.medthority.com/news/2026/2/lopd-care-from-screening-to-treatment/2026-02-27T14:12:01+00:00weekly0.6https://www.medthority.com/news/2026/2/mcrpc-targeting-resistance-pathways/2026-02-27T14:12:01+00:00weekly0.6https://www.medthority.com/news/2026/2/navigating-nmibc-treatment-complexity/2026-02-27T14:12:01+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-women-who-have-had-an-hpv-vaccine-need-fewer-cervical-cancer-screenings/2026-02-27T14:12:01+00:00weekly0.6https://www.medthority.com/news/2026/2/newborn-screening-guides-pompe-care/2026-03-06T12:10:25+00:00weekly0.6https://www.medthority.com/news/2026/2/prime-backs-biparametric-mri-diagnosis/2026-02-27T14:12:02+00:00weekly0.6https://www.medthority.com/news/2026/2/targeted-approaches-emerge-in-fabry-disease/2026-02-27T14:12:00+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-link-between-low-oxygen-and-reduced-blood-sugar-could-yield-new-diabetes-treatments/2026-02-27T14:11:59+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-moderna-combo-flucovid-vaccine-succeeds-in-mid-stage-trial/2026-02-27T14:11:59+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-experimental-drug-doubles-survival-of-ovarian-cancer-patients-in-trial/2026-02-27T14:12:00+00:00weekly0.6https://www.medthority.com/news/2026/2/st-920-gene-therapy-outcomes-in-fabry-disease/2026-02-27T14:12:00+00:00weekly0.6https://www.medthority.com/news/2026/2/emerging-targeted-therapies-in-lopd/2026-02-27T14:12:00+00:00weekly0.6https://www.medthority.com/news/2026/2/health-rounds-researchers-discover-how-severe-flu-damages-the-heart/2026-02-27T14:12:00+00:00weekly0.6https://www.medthority.com/news/news-trends/managing-opioid-prescribing-in-the-inherited-patient-with-pain/2024-11-15T11:34:25+00:00weekly0.7https://www.medthority.com/news/news-trends/psychedelics-in-psychiatry-a-world-first-in-australia/2024-08-19T15:04:44+00:00weekly0.7https://www.medthority.com/news/news-trends/challenges-in-the-management-of-painful-diabetic-peripheral-neuropathy/2024-11-15T11:35:30+00:00weekly0.7https://www.medthority.com/news/news-trends/the-future-of-vaccination-in-a-post-covid-19-world/2024-09-09T14:44:25+00:00weekly0.7https://www.medthority.com/news/news-trends/from-chickenpox-to-shingles/2024-08-19T14:52:02+00:00weekly0.7https://www.medthority.com/news/news-trends/why-do-we-not-have-vaccines-for-hiv-and-hepatitis-c/2024-09-09T14:44:54+00:00weekly0.7https://www.medthority.com/news/news-trends/racism-in-healthcare-systems/2024-11-15T10:12:26+00:00weekly0.7https://www.medthority.com/news/news-trends/pompe-disease-management-update/2024-09-09T14:43:09+00:00weekly0.7https://www.medthority.com/news/news-trends/opioid-analgesics-the-same-but-different/2024-09-19T12:30:28+00:00weekly0.7https://www.medthority.com/news/news-trends/can-telemedicine-palliate-patients-with-nsclc/2024-11-15T10:16:03+00:00weekly0.7https://www.medthority.com/news/news-trends/osimertinib-for-egfr-mutated-nsclc--laura-trial/2025-10-20T10:20:49+00:00weekly0.7https://www.medthority.com/news/news-trends/clinical-trial-update-on-treatments-for-mcrpc/2024-09-09T14:42:42+00:00weekly0.7https://www.medthority.com/news/news-trends/empty-shelves-drug-shortages-in-the-uk/2025-01-31T11:05:10+00:00weekly0.7https://www.medthority.com/news/news-trends/chronotherapy-introducing-the-circadian-rhythms-into-treatment-landscapes/2025-05-06T14:40:45+00:00weekly0.7https://www.medthority.com/news/news-trends/innovations-in-cancer-therapy-antibody-drug-conjugates/2024-08-21T15:34:18+00:00weekly0.7https://www.medthority.com/news/news-trends/a-gut-feeling-the-association-between-cancer-and-the-microbiome/2024-08-19T15:28:07+00:00weekly0.7https://www.medthority.com/news/news-trends/opioid-prescribing-for-chronic-noncancer-pain-in-general-practice/2024-10-08T14:47:36+00:00weekly0.7https://www.medthority.com/news/news-trends/abemaciclib-a-newcomer-in-the-treatment-of-hrher2-early-breast-cancer/2024-08-19T15:25:30+00:00weekly0.7https://www.medthority.com/news/news-trends/emergent-fungal-concerns-to-human-health-a-wake-up-call/2024-11-15T09:13:23+00:00weekly0.7https://www.medthority.com/news/news-trends/the-advantages-of-nourishing-the-clinician-patient-relationship-online-and-offline/2025-05-06T14:36:15+00:00weekly0.7https://www.medthority.com/news/news-trends/what-is-pneumonia-education-and-communication-between-physicians/2024-08-21T15:38:07+00:00weekly0.7https://www.medthority.com/news/news-trends/do-hcps-need-specific-lgbtq-training/2024-11-15T09:20:12+00:00weekly0.7https://www.medthority.com/news/news-trends/is-covid-19-associated-with-increased-risk-of-herpes-zoster/2024-08-21T15:34:54+00:00weekly0.7https://www.medthority.com/news/news-trends/responding-to-requests-for-opioid-analgesics-from-patients-with-chronic-pain/2024-08-21T15:35:57+00:00weekly0.7https://www.medthority.com/news/news-trends/its-all-in-your-head-what-long-covid-research-has-taught-us-about-chronic-fatigue-syndrome/2024-11-15T08:52:01+00:00weekly0.7https://www.medthority.com/news/news-trends/vision-for-a-better-future-lessons-from-the-lancet-global-health-commission-on-global-eye-health/2024-08-27T10:03:25+00:00weekly0.7https://www.medthority.com/news/news-trends/can-wearables-reliably-detect-signs-of-atrial-fibrillation-fda-says-yes-to-fitbit/2024-09-30T10:56:30+00:00weekly0.7https://www.medthority.com/news/news-trends/world-congress-of-dermatology-2019---a-new-era-for-global-dermatology/2024-09-09T09:41:17+00:00weekly0.7https://www.medthority.com/news/news-trends/over-the-horizon/2024-11-15T10:34:11+00:00weekly0.7https://www.medthority.com/news/news-trends/chronic-myelogenous-leukaemia--a-remarkable-success-story/2024-09-16T14:01:08+00:00weekly0.7https://www.medthority.com/news/news-trends/unravelling-the-microbiome-health-through-happy-communities/2024-11-15T09:12:37+00:00weekly0.7https://www.medthority.com/news/news-trends/inactivity-in-the-elderly-increases-their-cardiovascular-risk-by-14-/2024-09-16T14:57:24+00:00weekly0.7https://www.medthority.com/news/news-trends/retinal-diseases--progress-in-treatment/2024-09-09T11:47:32+00:00weekly0.7https://www.medthority.com/news/news-trends/obesity-new-treatment-hopes/2024-11-15T10:09:54+00:00weekly0.7https://www.medthority.com/news/news-trends/type-2-diabetes-risk-may-be-increased-by-statin-use-in-susceptible-individuals/2024-09-09T09:54:01+00:00weekly0.7https://www.medthority.com/news/news-trends/will-glucagon-like-peptide-1-agonists-dominate-the-type-2-diabetes-market--/2024-09-09T09:47:53+00:00weekly0.7https://www.medthority.com/news/news-trends/next-generation-obesity-therapies/2025-05-06T15:04:06+00:00weekly0.7https://www.medthority.com/news/news-trends/appetite-and-the-brain/2024-11-15T10:22:56+00:00weekly0.7https://www.medthority.com/news/news-trends/metastatic-melanoma--the-new-immunotherapies/2024-09-16T15:21:37+00:00weekly0.7https://www.medthority.com/news/news-trends/obesity--type-2-diabetes-and-cardiovascular-disease--finding-the-magic-bullet/2024-11-15T10:03:20+00:00weekly0.7https://www.medthority.com/news/news-trends/medical-cannabis-a-novel-approach-to-pain-control/2024-09-16T15:21:06+00:00weekly0.7https://www.medthority.com/news/news-trends/magnetic-nanoparticles-could-help-rejuvenate-damaged-hearts/2024-09-16T15:19:25+00:00weekly0.7https://www.medthority.com/news/news-trends/sglt2-inhibitors--good-news-for-diabetes/2024-11-15T09:29:10+00:00weekly0.7https://www.medthority.com/news/news-trends/targeted-therapies-in-triple-negative-breast-cancer/2024-11-15T11:23:04+00:00weekly0.7https://www.medthority.com/news/news-trends/senolytics--an-emerging-therapeutic-for-the-prevention-and-treatment-of-cardiovascular-disease/2024-11-15T09:44:00+00:00weekly0.7https://www.medthority.com/news/news-trends/acute-myeloid-leukaemia--hope-for-new-treatments/2024-09-16T13:37:09+00:00weekly0.7https://www.medthority.com/news/news-trends/new-findings-may-pave-the-way-for-novel-hiv-drugs/2024-09-16T15:30:10+00:00weekly0.7https://www.medthority.com/news/news-trends/obesity-links-to-diabetes-and-cardiovascular-disease/2024-11-15T10:05:41+00:00weekly0.7https://www.medthority.com/news/news-trends/from-acne-to-immunotherapy--new-applications-for-fmt--faecal-microbiota-transplantation-/2024-11-15T10:27:08+00:00weekly0.7https://www.medthority.com/news/news-trends/replacement-therapies-for-opioid-drugs-in-pain-treatment/2024-11-15T09:45:24+00:00weekly0.7https://www.medthority.com/news/news-trends/parkinson-s-disease--the-struggle-to-control-symptoms/2024-09-16T15:34:29+00:00weekly0.7https://www.medthority.com/news/news-trends/adoptive-t-cell-therapy/2024-09-16T13:37:23+00:00weekly0.7https://www.medthority.com/news/news-trends/an-independent-review-of-current-treatments-for-migraine/2024-11-15T10:19:31+00:00weekly0.7https://www.medthority.com/news/news-trends/senolytics-age-related-single-drug/2024-11-15T09:42:13+00:00weekly0.7https://www.medthority.com/news/news-trends/genetic-variation-drug-efficacy/2024-09-16T14:55:53+00:00weekly0.7https://www.medthority.com/news/news-trends/schizophrenia--challenges-in-a-crowded-market-/2024-09-09T11:47:15+00:00weekly0.7https://www.medthority.com/news/news-trends/targeted-therapies-in-her2-negative-breast-cancer/2025-02-03T15:03:56+00:00weekly0.7https://www.medthority.com/news/news-trends/vitamin-d-in-pregnancy/2024-09-09T09:51:38+00:00weekly0.7https://www.medthority.com/news/news-trends/migraine-treatments-on-the-horizon/2024-11-15T10:33:34+00:00weekly0.7https://www.medthority.com/news/news-trends/new-approaches-to-anticoagulant-therapy/2024-09-16T15:28:14+00:00weekly0.7https://www.medthority.com/news/news-trends/close-social-relationships-may-slow-cognitive-decline/2024-09-16T14:03:45+00:00weekly0.7https://www.medthority.com/news/news-trends/microbiomes-is-there-nothing-that-they-cant-do/2024-11-15T10:29:27+00:00weekly0.7https://www.medthority.com/news/news-trends/reformulation-of-postnatal-haemorrhage-prophylaxis/2024-09-09T11:48:13+00:00weekly0.7https://www.medthority.com/news/news-trends/exciting-developments-and-new-approaches-in-psoriasis/2024-09-16T14:37:00+00:00weekly0.7https://www.medthority.com/news/news-trends/opioids-the-future-and-challenging-the-epidemic/2024-11-15T10:34:57+00:00weekly0.7https://www.medthority.com/news/news-trends/opioids-the-war-on-drugs/2024-11-15T10:35:56+00:00weekly0.7https://www.medthority.com/news/news-trends/targeted-therapies-in-her2-positive-breast-cancer/2025-05-06T14:44:32+00:00weekly0.7https://www.medthority.com/news/news-trends/early-development/2024-11-15T09:22:04+00:00weekly0.7https://www.medthority.com/news/news-trends/obesity---the-big-epidemic/2024-09-16T15:31:13+00:00weekly0.7https://www.medthority.com/news/news-trends/breast-cancer-targeted-therapies/2024-11-15T10:32:15+00:00weekly0.7https://www.medthority.com/news/news-trends/nonalcoholic-steatohepatitis--the-next-global-epidemic-/2024-09-16T15:30:48+00:00weekly0.7https://www.medthority.com/news/news-trends/migraine-the-forgotten-epidemic/2024-09-16T15:24:52+00:00weekly0.7https://www.medthority.com/news/news-trends/copd--monotherapy--combination-therapy-and-triple-therapy---which-way-forward-/2024-09-16T14:18:47+00:00weekly0.7https://www.medthority.com/news/news-trends/the-way-ahead-for-cystic-fibrosis-/2024-08-21T15:19:45+00:00weekly0.7https://www.medthority.com/news/news-trends/japan-and-alzheimers/2025-05-06T15:04:39+00:00weekly0.7https://www.medthority.com/news/2026/2/2026-02-27T14:11:59+00:00weekly0.7https://www.medthority.com/news/2026/3/2026-03-18T15:04:09+00:00weekly0.7https://www.medthority.com/news/2025/11/2026-01-05T09:56:50+00:00weekly0.7https://www.medthority.com/news/2025/12/2026-01-05T09:51:41+00:00weekly0.7https://www.medthority.com/news/2026/1/2026-02-18T22:18:26+00:00weekly0.7https://www.medthority.com/news/2025/10/2026-01-05T09:56:58+00:00weekly0.7https://www.medthority.com/news/2025/9/2026-01-05T09:57:06+00:00weekly0.7https://www.medthority.com/news/2025/8/2026-01-05T09:58:52+00:00weekly0.7https://www.medthority.com/news/2025/7/2026-01-05T09:59:01+00:00weekly0.7https://www.medthority.com/news/2025/5/2026-01-05T09:59:12+00:00weekly0.7https://www.medthority.com/news/2025/2/2026-01-05T10:10:18+00:00weekly0.7https://www.medthority.com/news/2025/1/2026-01-05T10:10:28+00:00weekly0.7https://www.medthority.com/news/2025/3/2026-01-05T09:59:36+00:00weekly0.7https://www.medthority.com/news/2025/4/2026-01-05T09:59:19+00:00weekly0.7https://www.medthority.com/news/news-trends/exercise-for-parkinsons-disease/2024-10-25T11:51:16+00:00weekly0.7https://www.medthority.com/news/news-trends/real-world-bleeding-risk-after-doac-initiation/2024-09-19T12:29:46+00:00weekly0.7https://www.medthority.com/news/news-trends/asco-2024-a-high-level-overview/2024-10-25T08:22:55+00:00weekly0.7https://www.medthority.com/news/news-trends/apples-afib-history-fda-qualified-for-trials/2025-01-15T10:55:16+00:00weekly0.7https://www.medthority.com/news/news-trends/can-a-smartwatch-detect-sleep-apnea-earlier/2024-09-20T10:08:32+00:00weekly0.7https://www.medthority.com/news/news-trends/spotlight/2024-09-12T11:58:05+00:00weekly0.7https://www.medthority.com/news/news-trends/how-can-periodontitis-care-affect-chronic-disease/2024-11-15T11:18:06+00:00weekly0.7https://www.medthority.com/news/news-trends/can-early-ckd-detection-improve-outcomes/2025-09-05T07:25:37+00:00weekly0.7https://www.medthority.com/news/news-trends/managing-menstrual-migraine/2024-11-15T11:16:32+00:00weekly0.7https://www.medthority.com/news/2025/2026-01-05T09:51:26+00:00weekly0.8https://www.medthority.com/news/2026/2026-02-06T10:39:30+00:00weekly0.8https://www.medthority.com/news/2026-03-19T11:00:24+00:00weekly0.9